PT J
AU Kasler, M
AF Kasler, Miklos
TI Development of head and neck surgery at the end of the XXth century
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The development of the surgery of the head and neck tumors seemed to be completed for the end of the seventies by the widespread acceptance of the basic technologies. However, the discovery of two techniques, medical laser and PM-lobe initiated major developments in the surgical oncology of head and neck cancer. Based on our studies, the benefits of use of medical laser in oncology are its fine-tuned topological preciseness, tissue-protection and the lack of bleeding disorders. A special benefit of the medical laser is its ablasticity and the support of tissue repair. The wide-spread use of PM-lobe technique in head and neck surgery was made it possible by the development of various modifications such as the cutan-myocutan and the osteomyocutan ones. By the application of the developed variants we were able to correct the consequences of radical resections and achieved acceptable functional and esthetic status in cancer patients.
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 5
EP 10
PG 6
ER

PT J
AU Kasler, M
AF Kasler, Miklos
TI Protocols for comprehensive diagnosis and treatment of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 11
EP 35
PG 25
ER

PT J
AU Toth, J
   Szentkuti, A
AF Toth, Jozsef
   Szentkuti, Andras
TI Expression of HER2 in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In breast cancer the membrane expression of HER2 receptor protein encoded by the HER2 proto-oncogene seems to have an ever growing clinical significance. In tissue cultures and animal experiments it was shown that the HER2 gene amplification induces malignant transformation and intensifies the aggressiveness of the tumour cells. Correlating with the so called pheno-and genotypic prognostic markers, the overexpression of HER2 in breast cancer predicts also poor prognosis and indicates enhanced potential for metastatisation. In some of the so called precancerous proliferations and ''in situ ”carcinomas we demonstrated the enhanced membrane staining of the HER2 receptor protein. In these cases we frequently observed DNA aneuploidy,the presence of p53 mutational protein and CD44v6 glycoprotein. The immunohistochemical studies of HER2 protein in invasive carcinomas have revealed, an interrelationship between the grade of differentiation, histological type, aggressiveness and biological behaviour of the ''in situ'' and invasive carcinomas. In clinical studies trastuzumab, a humanized monoclonal antibody recognizing extracellular domain of HER2 receptor protein, has proved to be effective in HER2 overexpressing metastatic breast cancer either as monotherapy or in combination with chemotherapeutical agents. The DAKO ''HercepTest'' is a semiquantitative, standardised method for the determination of HER2 overexpression.
C1 [Toth, Jozsef] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Szentkuti, Andras] Roche (Magyarorszag) Kft.Budapest, Hungary.
RP Toth, J (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
EM joto@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 39
EP 51
PG 13
ER

PT J
AU Csuka, O
   Peley, G
   Dubecz, S
   Hargitai, �
   Toth, K
   Kamory, E
   Koves, I
   Doleschall, Z
   Peter, I
   Toth, J
AF Csuka, Orsolya
   Peley, Gabor
   Dubecz, Sandor
   Hargitai, Arpad
   Toth, Krisztina
   Kamory, Eniko
   Koves, Istvan
   Doleschall, Zoltan
   Peter, Ilona
   Toth, Jozsef
TI Prognostic factors of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: Characterization of breast cancers by various tumour markers which are appropriate for the identification of high risk groups. Markers related to the metastasis cascade and tumour recurrence have been investigated. MATERIALS AND METHODS: RT-PCR was used to determine the expression of cytokeratin 20 in the bone marrow and sentinel lymph node of breast cancer patients (n=45). The expression of HER2, Cadherin E, Cyclin D, Bcl2 and Bax has been evaluated by Western blot (n=744 invasive ductal carcinomas and 117 invasive lobular carcinomas, 124 recurrent breast cancers). Mutations of p53, APC and ß Catenin genes were detected by PCR-SSCP method. RESULTS: Expression of cytokeratin 20 was found in 30% of the bone marrow samples indicating the presence of micrometastasis. The level of Cyclin D, HER2 and Bcl2 is elevated four-fold in the recurrent breast cancers. The metastasis of invasive ductal carcinomas is accompained by high frequency of p53 mutations (24%) and APC mutations (18%). The invasive lobular carcinomas could be characterized with low frequency of p53 mutation (3%), low level of Cadherin E and high level of catenin ß. CONCLUSIONS: Identification of micrometastasis can promote the development of therapeutic strategy. Evaluation of HER2 level and determination of p53 mutations contribute to the identification of high risk patients. Our results suggest that the progression of invasive ductal carcinomas depends on the APC mutations, while metastasis of invasive lobular carcinomas depends on ß catenin mutations.
C1 [Csuka, Orsolya] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Dubecz, Sandor] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Hargitai, Arpad] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Toth, Krisztina] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Kamory, Eniko] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Doleschall, Zoltan] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Rath Gy.u.7-9., H1122 Budapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 53
EP 60
PG 8
ER

PT J
AU Tiboly, M
   Hafner, J
AF Tiboly, Marta
   Hafner, Janos
TI Clodronat therapy of hypercalcaemia associated with male breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB OBJECTIVES: The aim of this study is to survey the treatment of bone metastases and hypercalcaemia. MATERIALS AND METHODS: A case of male breast cancer is presented here by the authors. The applied clodronat therapy was beneficial. RESULTS: The diagnostic difficulties of such rare, unusually localised, metastasizing male breast cancer are discussed with the survey of Hungarian and world literature. CONCLUSION: The bisphosphonates - beside treating the hypercalcaemia caused by bone metastasis - provide a better quality of life.
C1 [Tiboly, Marta] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati Osztaly, Zrinyi ut 1., H8900 Zalaegerszeg, Hungary.
   [Hafner, Janos] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati Osztaly, Zrinyi ut 1., H8900 Zalaegerszeg, Hungary.
RP Tiboly, M (reprint author), Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati Osztaly, H8900 Zalaegerszeg, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 61
EP 63
PG 3
ER

PT J
AU Beczassy, E
   Szamel, I
   Sulyok, Z
   Otto, Sz
AF Beczassy, Eniko
   Szamel, Iren
   Sulyok, Zoltan
   Otto, Szabolcs
TI Tumour markers in human breast cyst fluid in gross cystic breast disease (GCBD)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: Parallel measurements of tumour markers in the serum and breast cyst fluid in a high risk group (GCBD) of breast cancer. The identification of individuals belonging to this group and their follow-up.  MATERIALS AND METHODS: In the breast cyst fluid of 108 patients with GCBD (mean age 47 years) we measured the levels of CA 15 –3, TPA, CEA and ß HCG completed by PCT determinations. Simultaneously, the serum CA 15 –3 and TPA concentrations were also measured using the Luminescent Immunoassay techniques. RESULTS: Strikingly high TPA values were found in 98% of the patients. The CA 15 –3 levels, however, were pathological only in 24%of them. The CEA and ß HCG levels showed hardly any rise and the PCT concentration remained normal. CONCLUSIONS: The lack of any rise in PCT concentration precludes the inflammatory origin of the cystic fluid and the normal serum arker levels exclude ultrafiltration. The increased TPA concentration in the breast cystic fluid and the occurrence of pathological CA 15 –3 level in the above percentage of the cases suggest that GCBD represents not only a high risk group but possibly a precancerous state, too.
C1 [Beczassy, Eniko] National Institute of Oncology, Central Clinical Laboratory, H1525 Budapest, Hungary.
   [Szamel, Iren] National Institute of Oncology, Central Clinical Laboratory, H1525 Budapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Central Clinical Laboratory, H1525 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical Laboratory, H1525 Budapest, Hungary.
RP Beczassy, E (reprint author), National Institute of Oncology, Central Clinical Laboratory, H1525 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 65
EP 67
PG 3
ER

PT J
AU Dank, M
   Padi, �
   Csepreghy, M
   Mako, E
AF Dank, Magdolna
   Padi, Eva
   Csepreghy, Magdolna
   Mako, Erno
TI Role of Iphosphamide in the treatment of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Breast cancer is the most frequent solid tumor in women. Predictive and prognostic factors play an important role in the treatment of this cancer. We focused on high risk and heavily pre-treated metastatic breast cancer patients, trying to find the best combination of cytotoxic drugs with high efficacy and low toxicity. Ifosfamide is chemically related to nitrogen mustard and is a synthetic analogue of cyclophosphamide. Ifosfamide has a wide range of antitumor activity. Since ifosfamide as monotherapy has introduced significant tumor reduction in 1st line chemotherapy for advanced breast cancer, some studies started with high-dose continuous infusion of ifosfamide,or combined with paclitaxel or vinorelbine. Patients with poor prognosis primary breast cancer treated with high-dose chemotherapy supported by peripheral blood progenitor cell (PBSC) transplantation have lower risk for local relapse and longer disease-free-survival. Ifosfamide working in the mobilization regimen has effective anti-tumor activity while mobilizing sufficient PBPCs in the majority of patients. In combination with other cytotoxics showed to be effective in high-dose protocols.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Padi, Eva] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Csepreghy, Magdolna] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mako, Erno] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a., H1082 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, H1082 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 69
EP 73
PG 5
ER

PT J
AU Pinter, T
   Prempeh, AK
   Szanto, J
   Szanto, J
AF Pinter, Tamas
   Prempeh, Agyemang Kofi
   Szanto, Janos
   Szanto, Janos
TI Taxotere phase III trial on the first-line treatment of metastatic breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: Doxorubicin and taxanes are the most effective agents in the treatment of advanced breast cancer. The aim of the study was to compare the efficacy of Doxorubicin (A) + Docetaxel (T) (AT) and standard Doxorubicin (A) + Cyclophosphamide (C) (AC) chemotherapy. MATERIALS AND METHODS: Results of first-line AT (50/75 mg/m2) and AC (60/600 mg/m2) D 1 q 3 wk, maximum of 8 cycles, were compared. Three Hungarian centers - Petz Aladar County Teaching Hospital, Gyor, St.Margit Hospital, Budapest, and BAZ County Hospital, Miskolc, with 33 patients participated the international, phase III randomized TAX 306 trial. Between June, 1996 and March, 1998, 429 metastatic breast cancer patients were enrolled in the study. Eligible patients were who had not received prior chemotherapy for advanced disease, and were anthracycline-naive. Objective response rate observed in the AT arm was significantly higher than in the AC arm (ORR: 60% vs. 47%, p=0.008). Time to progression was longer in the AT group (37.1 weeks vs. 31.9 weeks, p=0.0153). Except for higher incidence of neutropenia not requiring dose modification in the AT arm, there were no major differences concerning toxicity. T did not enhance cardiac toxicity induced by A. CONCLUSION: AT results in significantly higher response rate and longer time to progression than AC in advanced breast cancer, even in patients with unfavourable prognosis.
C1 [Pinter, Tamas] Petz Aladar Hospital, Department of Oncoradiology, H9002 Gyor, Hungary.
   [Prempeh, Agyemang Kofi] Petz Aladar Hospital, Department of Oncoradiology, H9002 Gyor, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szanto, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
RP Pinter, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, H9002 Gyor, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 75
EP 78
PG 4
ER

PT J
AU Nagykallai, T
AF Nagykallai, Tamas
TI Chemotherapy of breast cancer: focus on paclitaxel
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Paclitaxel is among the most effective agents in the treatment of breast cancer. Both as a single agent and in combinations, paclitaxel is effective as first-line therapy and as a salvage therapy in patients with locally advanced or metastatic disease. Paclitaxel also demonstrated efficacy in patients who received prior anthracyclin therapy and those with anthracyclin-resistant disease. In the adjuvant setting, data from randomized study have supported the sequential use of paclitaxel after therapy with doxorubicin / cyclophosphamide for patients with node-positive disease. The drug may be used in combination with other chemotherapeutical agents and immune stymulatory agents. Therapy on weekly and every-three-week schedules has been effective.
C1 [Nagykallai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29, H1145 Budapest, Hungary.
RP Nagykallai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H1145 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 79
EP 90
PG 12
ER

PT J
AU Dank, M
   Mako, E
AF Dank, Magdolna
   Mako, Erno
TI Aromatase inhibitors and inactivators in the treatment of advanced breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Advanced breast cancer remains incurable. For these patients, durable response and minimal toxicity are the main goals of current therapy. The antiestrogen tamoxifen has proved to be a significant advance in the treatment of breast cancer. Due to its partial estrogen activity, long term medication with tamoxifen has been found to cause endometrium proliferation wich can result in cancer in some patients. Reduction of estrogen production identified the aromatase inhibitors. Both steroidal substrate analog, type I inactivator, wich inactivate the enzyme and non-steroidal competitive reversible, type II inhibitors, are now avaiable. Two new 3rd generation aromatase inactivators have recently completed phase III evaluation (anastrozole and letrozole) and we have some results investigating one of the new 3rd generation aromatase inhibitors (exemestane). The 3rd generation aromatase inhibitors and inactivators are better tolerated and more effective than each of our current standard 2nd line endocrin therapies. These agents are being directly compared with standard adjuvant medication, tamoxifen, or are being evaluated in different sequences.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, H1082 Budapest, Hungary.
   [Mako, Erno] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, H1082 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, H1082 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2000
VL 44
IS 1
BP 91
EP 94
PG 4
ER

PT J
AU Timar, J
   Toth, J
   Dome, B
   Paku, S
AF Timar, Jozsef
   Toth, Jeanette
   Dome, Balazs
   Paku, Sandor
TI Tumoral sinuses or vascular channels in tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The re-discovery of the tumor cell-lined vascular channels and the possible pathomechanism (vasculogenic mimicry) earned major attention in the literature. This phenomenon is known for 60 years following B.Kellner, later supported by several groups, however its significance is still not known. The two new form of tumor blood supply, the incorporation/apoptotic remodeling of the preexisting vasculature and the latest discovery of endothelial gene expression in tumor cells suggest two alternative mechanisms for the development of tumor sinuses or vascular channels. The existence of these sinuses in malignant tumors and their possible function in the nutrient supply may limit the application of the new anti-angiogenic therapies.
C1 [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gy.u. 7-9.Budapest, Hungary.
   [Toth, Jeanette] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Dome, Balazs] National Institute of Oncology, Department of Tumor Progression, Rath Gy.u. 7-9.Budapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 105
EP 107
PG 3
ER

PT J
AU Major, T
   Polgar, Cs
   Mangel, L
   Takacsi Nagy, Z
   Somogyi, A
   Nemeth, Gy
AF Major, Tibor
   Polgar, Csaba
   Mangel, Laszlo
   Takacsi Nagy, Zoltan
   Somogyi, Andras
   Nemeth, Gyorgy
TI CT based conformal brachytherapy treatment planning
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To introduce the CT based three dimensional (3D) conformal brachytherapy treatment planning for interstitial implants, to compare the conventional X-ray film based planning with the 3D planning from the point of view of reconstruction and dosimetry, to discuss the differences and highlight the advantages. MATERIAL AND METHODS: On 10 patients with breast and 5 with head and neck tumor treated with HDR interstitial implants, following the catheter implantations, CT scans were taken at 5 mm spacing. The images were loaded into the PLATO BPS v14.0 3D planning system for brachytherapy. The contours of the target volume and critical structures were outlined on each slice, the catheter describing points were identified and the anatomical structures and catheter positions were reconstructed in 3D. Having taken into account the target volume, the active lengths were determined in each catheter, and dose optimization on dose points on target was performed. RESULTS: The 3D treatment planning was applied at interstitial breast treatments and head and neck implants. We investigated the dose distribution on axial, reconstructed coronal / sagittal planes and in 3D view with respect to anatomical structures. Dose volume histograms related to the target volume and critical structures were used for quantitative assessment of the plans. We found that the conformal dose distribution might result in increase of dose inhomogeneity within the target volume. CONCLUSIONS: The three dimensional brachytherapy treatment planning can be introduced into the clinical practice under proper technical conditions. A tradeoff between conformality and dose homogeneity results in an acceptable dose plan. The dose inhomogeneity can be decreased with the use of CT scans taken before the implantation. The guidelines and quantitative parameters describing the dose distribution, which can be used for determining the optimal dose distribution in clinical point of view, are still waiting to be established.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Mangel, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
EM major@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 109
EP 115
PG 7
ER

PT J
AU Takacsi Nagy, Z
   Oberna, F
   Somogyi, A
   Polgar, Cs
   Major, T
   Nemeth, Gy
AF Takacsi Nagy, Zoltan
   Oberna, Ferenc
   Somogyi, Andras
   Polgar, Csaba
   Major, Tibor
   Nemeth, Gyorgy
TI Experiences in the treatment of tumour of base of the tongue with high dose rate interstitial radiotherapy on the basis of a retrospective analysis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To describe the role, the execution and the importance of interstitial radiotherapy in the irradiation of the base of tongue cancer. MATERIAL AND METHODS: Between January, 1993 and December, 1998 nineteen patients with primary squamous cell cancer of the base of tongue (1 T1N0, 3 T2N0, 2 T3N0, 2 T3N2, 3 T4N0, 6 T4N1, 2 T4N2) were managed with brachytherapy partly with definitive intention combined with teletherapy (60-66 Gy) as a boost, partly as a single postoperative treatment. Irradiation was carried out by HDR after-loading (Ir-192) unit, using rigid needle or flexible plastic catheter. The treatment plan was made by PLATO 3D brachytherapy planning system. In case of boost the mean total dose of brachyherapy was 22 Gy (12-30 Gy), in postoperative treatment it was 27 Gy (24-30 Gy). RESULTS: 6-8 weeks after the definitive radiotherapy the CT/MR showed complete remission in 67% and partial remission in 33% of the patients. Of all treated patients during the mean follow-up period (30 months) the local tumour control was 42%. Five patients (26%) died in local failure. Six patients (32%) are alive with tumour. Osteoradionecrosis and fistula did not occur. CONCLUSIONS: In the oncological treatment of the advanced base of tongue tumour the combination of percutan and interstitial radiotherapy seems to be very advantageous,because it improves not only the curability, but the patients' quality of life as well.
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 117
EP 121
PG 5
ER

PT J
AU Mangel, L
   Kiss, T
   Skriba, Z
   Nemeth, Gy
AF Mangel, Laszlo
   Kiss, Tibor
   Skriba, Zoltan
   Nemeth, Gyorgy
TI The possible role of information technology in radiotherapy II.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: Developing a new medical software based on the utilisation of information technology required in 3-dimensional treatment planning and modern radiotherapy. METHODS: The physical dose distribution programs were converted into biological meaning with the insertion of biological equivalence equations based on LQ model. Biological dose distributions and biological dose-volume histograms were generated. The treatment plans of a brain tumour patient were investigated to determine the dose burdening of the normal central nervous system tissues. RESULTS: Employing 3D conformal method, the dose of the vital mid-line structures decreased significantly, which possesses a more meaningful biological importance. Different treatment plans and different fractionation regimens could be compared to each other by utilising this kind of biological model. CONCLUSION: By employing information technology we succeeded in establishing a theoretical biological dose distribution system that could be visualised. The advantages of 3D treatment planning proved unambiguous. In the future this method will probably be suitable to choose the best therapeutic regimens.
C1 [Mangel, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Kiss, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Skriba, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Mangel, L (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 123
EP 127
PG 5
ER

PT J
AU Kontra, G
   Horvath, �
   Bajcsay, A
   Nemeth, Gy
AF Kontra, Gabor
   Horvath, Akos
   Bajcsay, Andras
   Nemeth, Gyorgy
TI Dosimetry of total skin electron irradiation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Elaboration of such a simple technique for total skin electron irradiation which ensures good dose homogeneity and minimal x-ray background dose. MATERIALS AND METHODS: We started large electron field irradiations with the Neptun 10p linear accelerator in the National Institute of Oncology -Budapest in 1986. After the installation of the Siemens Mevatron KD linear accelerator it was possible to introduce the modified Stanford technique. This technique satisfies better the requirements given in the objective. The required field size of 200x75 cm is produced as a result of two fields with 30° angular separation (dual field) at a source skin distance of 465 cm. The patient's body is exposed to six dual electron fields. The electron energy is 6 MeV. Despite the long source skin distance the treatment time is relatively short due to the high dose rate (940 mu/min) capability of our Mevatron KD. The in air dose profiles were measured in miniphantom with semiconductor detector. Depth dose curves were measured in water and in polystyrene phantom with semiconductor detector and with films. RESULTS: The measured dose homogeneity of the 6 MeV energy dual field with 30° angular separation is within +/- 5%in a 200x75cm plane field. The depth of dose maximum of the resulting dose distribution of six dual field irradiation is between 2 mm and 5 mm, while the depth of 80% isodose curve is about 8 mm. The total body x-ray background dose is less than 1% of the skin dose. CONCLUSION: The modified Stanford technique adapted to our Mevatron KD linear accelerator is suitable for total skin electron beam therapy.
C1 [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Horvath, Akos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 129
EP 133
PG 5
ER

PT J
AU Polgar, Cs
   Orosz, Zs
   Szerdahelyi, A
   Fodor, J
   Magori, A
   Czeyda-Pommersheim, F
   Vamosi Nagy, I
   Szakolczai, I
   Fejos, Zs
   Nemeth, Gy
AF Polgar, Csaba
   Orosz, Zsolt
   Szerdahelyi, Andrea
   Fodor, Janos
   Magori, Aniko
   Czeyda-Pommersheim, Ferenc
   Vamosi Nagy, Istvan
   Szakolczai, Istvan
   Fejos, Zsuzsanna
   Nemeth, Gyorgy
TI Angiosarcomas of the chest wall and breast after radiotherapy: The questions of radiogenic origin, diagnosis and treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To present medical history of secondary chest wall and breast angiosarcomas (AS) developed after radiotherapy, and to discuss the questions of radiogenic origin, diagnosis and treatment by the review of the literature. METHODS: Report of two cases and MEDLINE search for relevant publications. RESULTS: Secondary AS occured in a previously irradiated field after a long (6 and 8 years) latency period in both cases. Detailed histopathological and immunohistochemical examinations from the biopsy and/or surgical specimens confirmed the diagnosis as AS. The first patient with moderately differentiated AS was treated successfully with radical surgery. The second patient with irresecable AS died of rapid local progression within 4 months. The incidence of chest wall and breast AS is increased after irradiation, however, controversial data exist in the literature. The incidence of chest wall and breast AS after radiotherapy was found to be 0.39 ‰ in our patient population, which means an estimated odds ratio of 2.4 for secondary AS. Stewart-Treves syndrome is not of radiogenic origin, since postoperative lymphoedema has been considered as primary etiological factor. CONCLUSIONS: Patients treated with surgery and/or radiotherapy for primary breast cancer are at higher risk for developing secondary AS, compared to the healthy population. An etiological relationship between radiotherapy and subsequent AS of chest wall and breast is likely, but still controversial. Initial radical surgery is the only effective treatment for achieving long term survival. Further adjuvant radiotherapy is no longer feasible, due to the previous irradiation. Chemotherapy has only palliative effect. These very rare cases deserve special attention due to the atypical clinical appearance, difficulties of differential diagnosis and poor prognosis.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szerdahelyi, Andrea] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Magori, Aniko] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Vamosi Nagy, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szakolczai, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 135
EP 139
PG 5
ER

PT J
AU Liszkay, G
   Farkas, E
   Peley, G
   Sinkovics, I
   Peter, I
   Banfalvi, T
   Fejos, Zs
   Gilde, K
AF Liszkay, Gabriella
   Farkas, Emil
   Peley, Gabor
   Sinkovics, Istvan
   Peter, Ilona
   Banfalvi, Teodora
   Fejos, Zsuzsanna
   Gilde, Katalin
TI Preoperative lymphoscintigraphy guided sentinel lymph node biopsy in malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors present preliminary experience with preoperative sentinel lymph node biopsy carried out with lymphoscintigraphy in patients with malignant melanoma. PATIENTS AND METHODS: In the present study patients operated for primary cutaneous malignant melanoma of moderate and high severity were included. On the day of surgery isotope labelled colloid was injected intradermally around the tumor to indicate the lymphatics and to obtain basic information about the localization of the sentinel lymph node(s).During surgery the lymph node(s) previously visualized by the injection of patent-blue staining were detected with the aid of a gamma probe. Simultaneously, the excision of the primary tumor was extended. Histologically verified metastasis in the surgically removed lymph node(s) necessitated block dissection possibly within two weeks. RESULTS: The distribution of patients (19) according to tumor localisation: 2 - upper extremities; 9 - lower extremities; 2 - sacral region; 6 - trunk. Tumor thickness ranged from <1.5 mm (6 patients) to 1.5-3 mm (5 patients) and to >3 mm (8 patients). In two cases the identification of the lymph node has failed. Positive sentinel ymph nodes were detected in two patients. It is noteworthy that with one patient the sentinel lymph node was not regional but intransit. This study was aimed at the development of a suitable method. Further on we wish to try it in prospective randomized studies.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, H1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 141
EP 143
PG 3
ER

PT J
AU Kardos, L
   Pacz, M
   Ermenyi, I
   Nemes, I
AF Kardos, Laszlo
   Pacz, Miklos
   Ermenyi, Imre
   Nemes, Istvan
TI Stomato-oncological screening test of volunteers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: Identification and relative incidence of precancerosis and malignancies of the head and neck region and in the oral cavity. MATERIAL AND METHODS: In three counties of the western region of Hungary we physically examined pathological abnormities of healthy volunteers. Computerised examination reports and anamnestic data have been registered on data sheets. RESULTS: During examination of 5054 persons we have found 5 malignant tumours and 3.7% precancerosis (mostly leukoplakia).  CONCLUSIONS: Orofacial tumours that are constantly increasing in our country account for the necessity of stomato-oncological screening test. Therefore, screening should be extended as far as possible to persons who live in poor social-economical circumstances. Persons with multiple risk factors are difficult to be reached by this screening test,therefore it is complicated to treat them at an early stage. We have found intense ignorance in connection with oral tumours and precancerosis. Oral hygiene and status are criticisable. Because of the deficiencies of methods in examination the morbidity rate of tumours in oral cavity is undoubtedly higher than the rate of the statistical data.
C1 [Kardos, Laszlo] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, H9700 Szombathely, Hungary.
   [Pacz, Miklos] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, H9700 Szombathely, Hungary.
   [Ermenyi, Imre] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, H9700 Szombathely, Hungary.
   [Nemes, Istvan] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, H9700 Szombathely, Hungary.
RP Kardos, L (reprint author), Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, H9700 Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 145
EP 147
PG 3
ER

PT J
AU Banhidy, F
   Melczer, Zs
   Lukacsi, L
   Gimes, G
   Paulin, F
   Siklos, P
AF Banhidy, Ferenc
   Melczer, Zsolt
   Lukacsi, Laszlo
   Gimes, Gabor
   Paulin, Ferenc
   Siklos, Pal
TI Changes of cell mediated immunity in malignant ovarian tumor patients after operation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: The authors discuss upon the changes in the two cell types involved in cell mediated immunity (Killer and Natural Killer) as a result of operation in malignant ovarian tumor atients. METHODS: They study the preoperative and postoperative cell mediated immunity of 28 malignant cystadenocarcinoma cases (FIGO stage I/a-III/c). To determine the maximum K and NK cell activity they used the kinetic model of cytotoxicity enzyme. RESULTS AND CONCLUSIONS: They conclude that operation of malignant ovarian tumors had no significant influence on K and NK cell activity. They hypothesize that unchanged cell mediated immunity seems to be independent of malignant tumors, especially in these conditions. We need further information about this change of cell mediated immunity.
C1 [Banhidy, Ferenc] Semmelweis University, 2nd Department of Obstetrics and Gynecology, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Melczer, Zsolt] Semmelweis University, 2nd Department of Obstetrics and Gynecology, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Lukacsi, Laszlo] Semmelweis University, 2nd Department of Obstetrics and Gynecology, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Gimes, Gabor] Semmelweis University, 2nd Department of Obstetrics and Gynecology, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Paulin, Ferenc] Semmelweis University, 2nd Department of Obstetrics and Gynecology, Ulloi ut 78/a., H1082 Budapest, Hungary.
   [Siklos, Pal] Szent Istvan Korhaz, Nogyogyaszati Onkologiai OsztalyBudapest, Hungary.
RP Banhidy, F (reprint author), Semmelweis University, 2nd Department of Obstetrics and Gynecology, H1082 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 149
EP 152
PG 4
ER

PT J
AU Peter, I
   Szentirmay, Z
   Schneider, T
   Rado, J
   Toth, J
AF Peter, Ilona
   Szentirmay, Zoltan
   Schneider, Tamas
   Rado, Judit
   Toth, Jozsef
TI Angiocentric T-cell lymphoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB SUMMARY: The CD20+ variant of angiocentric T-cell lymphoma is an unusual type of T-cell lymphomas that present cystic changes in organs because of ischaemic necroses. The purpose of this study was to describe a case of CD20+angiocentric T-cell lymphoma, discussing its clinical, histopathological and immunohistochemical features, to analyze its proliferation kinetics and to consider its possible relationship to the Epstein-Barr virus (EBV) to understand better the pathobiological nature of the disease. METHODS: The clinical, histopathological, immunohistochemical and single-cell DNA cytophotometric features of the case were analyzed. In addition in situ hybridization was performed to detect EBV. RESULTS: The 24 years old woman was admitted to our Institute because of pain in the abdominal region and weight loss. There were enlarged lymph nodes on the neck, and biopsy was done. Histological diagnosis: angiocentric T-cell lymphoma, CD20+ variant. CD3, CD43, CD45RA and CD45R0 antigens were positive in the atypic lymphoid cells of the tumour and in cells infiltrating the vascular wall. DNA index was 0.8589 (hypodiploid). Tumour cells in G1 phase: 47%, S phase: 45.4%, G2 phase: 7.6%. Combined chemotherapy was administered because of clinical stadium IV/B of malignant lymphoma (5 CHOP-Bleo, CEPP, CEP, CMVE treatment). The disease showed gradual progression and the patient died 14 months after the first symptoms had appeared. CONCLUSIONS: In the last 13 years there were 5 cases of angiocentric T-cell lymphoma at our Institute. The CD20+ variant is rare, its clinical symptoms are special, the prognosis is unfavourable. The cause why we demonstrate this case is to call attention to a new treatment for these patients by immunotherapy using monoclonal antibodies against CD20 antigen.
C1 [Peter, Ilona] National Institute of Oncology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Schneider, Tamas] National Institute of Oncology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Rado, Judit] National Institute of Oncology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Peter, I (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
EM helena@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2000
VL 44
IS 2
BP 155
EP 159
PG 5
ER

PT J
AU Kovacs, G
AF Kovacs, Gabor
TI Prevention: a real possibility to repress lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; prevention; screening; smoking
ID lung cancer; prevention; screening; smoking
AB In the lack of effective treatment, the role of prevention has increased in the repressing of lung cancer. Smoking being a pathogenetic factor in the development of lung cancer is an accepted fact. Because of this, primer prevention means first of all the reduction of smoking both with the help of preventing smoking and cessation. A bigger - historical - debate has developed around secunder prevention: the effective screening of lung cancer. Although it was observed that staging rate and resecability had been more advantageous in the screened group, the screening of lung cancer was declared ineffective, because mortality did not improve. The change of approach can be felt from the middle of the 90 ’s. Nowadays the creation of a multimodal lung cancer preventional strategy is in the center of researches. The screening of risk groups can mean the solution with the aid of biomarkers, chest X-ray and spiral CT. In Hungary, with the infrastructure of existing lung-screening network the up-to-date screening of risk groups seems to have reality in the near future.
C1 [Kovacs, Gabor] National Koranyi Institute of Pulmonology, Piheno ut 1., H1529 Budapest, Hungary.
RP Kovacs, G (reprint author), National Koranyi Institute of Pulmonology, H1529 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 183
EP 188
PG 6
ER

PT J
AU Strausz, J
AF Strausz, Janos
TI Diagnosis of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; diagnosis; staging
ID lung cancer; diagnosis; staging
AB Lung cancer is the most common malignant tumor among male and second among female. The most effective diagnostic tool would be the early detection of the lung cancer. The diagnosis of tumors has to be based on patho-morphological findings. The invasive diagnostic tools can be used if the proved lung process has any therapeutic consequence. Only an experienced team has the chance to examine quickly and effectively the patients.In Hungary there are pulmonological centers where these teams consisting of pneumonologist, radiologists and pathologists are working effectively.
C1 [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Strausz, J (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
EM str12196@ella.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 189
EP 193
PG 5
ER

PT J
AU Moldvay, J
AF Moldvay, Judit
TI Tumor markers and prognostic factors of the primary lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; tumor marker; prognostic factor; immunohistochemistry; molecular biology
ID lung cancer; tumor marker; prognostic factor; immunohistochemistry; molecular biology
AB Primary bronchial cancer is the most common cause of cancer death worldwide, and it shows a steadily increasing incidence. Beside classical histological typing and grading, immunohistochemical, cytometric, and molecular biological parameters are highly needed to assist light microscopy investigations to better characterize primary bronchial cancers. In this work the author summarizes the main tumor markers and prognostic factors in lung cancer studied intensively at present. Serum markers as well as different tissue markers, such as cell proliferation markers, oncogenes, growth factors, apoptosis markers and vascularisation markers, tumor suppressor genes and markers of drug resistance are discussed in details. The methods currently used in this field are also mentioned and the data of the literature is often completed with results of the author ’s own investigations. An overview is given about the role of tumor markers in the early detection of lung cancer, in the assessment of tumor aggressiveness, and in therapy of lung cancer. The aim of this work is to create a bridge between the research laboratory in which lung cancer is studied sometimes using very sophisticated techniques and the bedside with all its practical, difficult but very important questions. Getting closer the theory and the practice can be very promising in the establishment of a fruitful collaboration in order to be more effective in the fight against lung cancer.
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Department of Bronchology, Budapest, Hungary.
EM moldvay@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 195
EP 202
PG 8
ER

PT J
AU Csekeo, A
AF Csekeo, Attila
TI Changes in algorythm of surgical management for non-small cell lung cancer (NSCLC)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE lung cancer; indication; resection; results
ID lung cancer; indication; resection; results
AB In Hungary the incidence of lung cancer is growing further and the proportion of patients undergoing surgery is less than 30%. Some improvement is indicated by the rate of explorations decreasing to less than 10%. On the other hand the number of adenocarcinomas has grown to take over the position of the squamous cell carcinomas among the patients operated on. In the recent few decades only some minor changes have occurred in the surgical treatment. For this reason when operability has been established new perspectives have been reviewed before drawing conclusions on the number of cases qualifying for resection. Phrenic and recurrent nerve lesions and in some cases metastases in some other organs do not mean inoperability in the absolute sense any more. Based on the new TNM system the criteria of the qualification for and the date of resection are identified by staging implemented reliably and in details. Palliative surgery may also be possible in some selected cases. A complex approach to the treatment of lung cancer is clearly coming into the focus of our attention. Though a resection is the most important episode here an adjuvant (post-operative) therapy and most recently added that a neoadjuvant (pre-operative) therapy shall improve the patient’s chances for survival further, enhancing the favorable result caused by the resection itself. Both the limits and the options of he surgical treatment administered in the cases of metastases in the lung, the brain and the solitary suprarenal gland are discussed in details in the cases of NSCLC.
C1 [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Piheno u. 1., H1529 Budapest, Hungary.
RP Csekeo, A (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, H1529 Budapest, Hungary.
EM csekeo@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 203
EP 209
PG 7
ER

PT J
AU Horvath, �
AF Horvath, Akos
TI Radiotherapy in lung cancer. Mandatory or optional?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; radiotherapy; indications
ID lung cancer; radiotherapy; indications
AB The purpose of the paper is to outline the current treatment strategies in lung cancer focusing on the possibile role of radiotherapy. METHOD: It defines the place of radiotherapy at the main histological types and stadiums proposing indications according to evidence based medicine.  CONCLUSIONS: Radiotherapy is mandatory in non-operated NSCLC st. I-II in perioperative or palliative management of superior sulcus tumours; in the combined modality treatment of limited SCLC and in postoperative adjustment of resected single brain metastasis of lung cancer. It is optional after NSCLC segmentectomy; in palliation or postoperative adjuvation of NSCLC st. III Radiotherapy can be chosen as a part of best supportive care at NSCLC st. IV extensive SCLC and in case of multiple brain or localised lytic bone metastases.
C1 [Horvath, Akos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9, H1122 Budapest, Hungary.
RP Horvath, � (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 211
EP 214
PG 4
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI The big dilemma: the chemotherapy of non-small cell lung carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE non small cell lung cancer; chemotherapy; survival; quality of life
ID non small cell lung cancer; chemotherapy; survival; quality of life
AB The most problematic area in pulmonary oncology is the chemotherapy of non-small cell lung carcinoma and its place in the therapeutic strategy. Chemotherapy based on the earlier alkylating agents worsened survival of NSCLC patients. That was the reason for the nihilistic approach by many colleagues toward chemotherapy in NSCLC. Today this question has been resolved. Platinum based combined chemotherapy significantly prolongs survival and improves quality of life. Other possibilities are to incorporate the new chemotherapeutic agents (taxanes, Gemcitabine, Vinorelbine, Irinotecan) into the chemotherapeutic regimens. These agents improve the response rate and the quality of life and can be safely administered in outpatient bases, although in comparison to the earlier agents the survival gain is moderate. In early stages the role of adjuvant chemotherapy is questionable. Chemotherapy, surgery and postoperative irradiation may all have a role in the case of N2 disease.In locally advanced disease the use of radiochemotherapy is recommended. In advanced NSCLC chemotherapy is suggested in good performance status. The author summarises the role of chemotherapy in NSCLC, based on literature and on his own experience.
C1 [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, Piheno ut 1., H1529 Budapest, Hungary.
RP Ostoros, Gy (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, H1529 Budapest, Hungary.
EM ostoros@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 215
EP 220
PG 6
ER

PT J
AU Szondy, K
AF Szondy, Klara
TI Chemotherapy of small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE small cell lung cancer; chemotherapy; chemotherapeutic combinations; immunotherapy
ID small cell lung cancer; chemotherapy; chemotherapeutic combinations; immunotherapy
AB The author summarizes the most recent information on small cell lung cancer. Reviews the epidemiology, prognostic markers and stages of small cell lung cancer Details the more frequently used combined therapeutic modalities, the criteria of the optimal therapeutic approaches and the achieved remission rates. Based on the most recent data, summarizes the new chemotherapeutic agents and their most effective combinations, the second line treatment and immunotherapy. Finally tries to answer the most frequently asked questions.
C1 [Szondy, Klara] Semmelweis University, Department of Pulmonology, H1536 Budapest, Hungary.
RP Szondy, K (reprint author), Semmelweis University, Department of Pulmonology, H1536 Budapest, Hungary.
EM szondy@pulm.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 221
EP 225
PG 5
ER

PT J
AU Bogos, K
   Ostoros, Gy
AF Bogos, Krisztina
   Ostoros, Gyula
TI Supportive therapy of lung cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE supportive; palliative care; oncological side effects; quality of life
ID supportive; palliative care; oncological side effects; quality of life
AB The effectiveness of cancer treatment given to lung cancer patients is indicated by the asymptomatic and non-toxic survival time. The goal is not to prolong the patients’ suffering, but to lengthen the duration of the best quality of life lived (Time Without Symptoms and Toxicity –TWIST). Supportive care is the prevention and management of side effects which occur during therapy (chemotherapy, radiotherapy, surgery) given to patients suffering from cancer. Supportive care is the widespread activity of doctors, nurses and social workers, including psychosocial assistance and rehabilitation through the various stages of illness till death. Though palliative therapy is understood to be the high level and professional treatment of terminally ill patients in those cases where curative measures are not possible anymore, supportive and palliative treatment often overlap (e.g. pain control, cachexia, obstructive syndromes). Palliative care is part of supportive therapy. The goal of supportive care is to reduce the patients’ subjective symptoms to the minimum (''well being'') during therapy, follow up and consequently until death. The essence of supportive care is to keep the patients’ quality of life on the highest possible level. This article summarizes the pathophysiology, prevention and therapy of the most frequently occuring side effects observed during the management of lung cancer patients.
C1 [Bogos, Krisztina] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, Piheno u. 1., H1529 Budapest, Hungary.
   [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, Piheno u. 1., H1529 Budapest, Hungary.
RP Bogos, K (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, H1529 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 227
EP 233
PG 7
ER

PT J
AU Szabo, V
   Szucs, M
   Romics, I
AF Szabo, Vilmos
   Szucs, Miklos
   Romics, Imre
TI The role of repeated transurethral resection in the treatment of bladder tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Complete removal of the tumour or deep invasion can be proven by repeated transurethral resection of bladder wall at the previous tumour site. Six weeks after transurethral resection of bladder tumour (TURB), in all but TaG1 cases repeated resection were performed for the evaluation of radicality in 62 patients, 43 males and 19 females, suffering bladder cancer, from October 1998. In the case of positive histology another resection was performed for security reason. In the case of 38 superficial (Tis, Ta, T1) cancers, repeated resection revealed negative, identical or different T stage compared with previous histology in 28, 5 and 5 cases, respectively. In 7 cases repeated resection was applied as second intervention after the incomplete resection of large tumour mass. Indication of repeated resection was insufficient depth of resection and carcinoma in situ in 13 and 4 cases, respectively. Based on our data, we conclude that repeated resection should be performed when tumour-free status is not justified and biopsy according to Bressel was not taken.
C1 [Szabo, Vilmos] Semmelweis University, Department of Urology, Ulloi ut 78/b., H1082 Budapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of Urology, Ulloi ut 78/b., H1082 Budapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of Urology, Ulloi ut 78/b., H1082 Budapest, Hungary.
RP Szabo, V (reprint author), Semmelweis University, Department of Urology, H1082 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 236
EP 237
PG 2
ER

PT J
AU Lukits, J
   Dome, B
   Juhasz, A
   Paku, S
   Timar, J
   Repassy, G
AF Lukits, Julia
   Dome, Balazs
   Juhasz, Attila
   Paku, Sandor
   Timar, Jozsef
   Repassy, Gabor
TI Characterization of laryngopharyngeal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB A recent survey of head and neck cancer indicated a sharp difference in survival between cancer of the hypopharyx and cancers formed in other head and neck sites. We have analyzed tumor size relative to clinical stage and vascularization as possible causes for such a difference in a series of 21 patients with cancers of the laryngopharynx (11 glottic and 10 hypopharyngeal). We found that the volume of the smallest cancers of the larynx at stage 2 are significantly larger than the volume of the cancers of the hypopharynx at stage 4 (p<0.05). Next, we have determined by immunohistochemistry and morphometry the microvessel density (MVD), microvessel perimeter (MVP) and VEGF expression of laryngo-hypopharyngeal cancers. Analysis of these data indicates that there is no difference in vascularization and VEGF expression between these two tumor types. These data strongly suggest that the invasive-but not the angiogenic phenotype of hypopharyngeal cancer cells could be responsible for the more aggressive biological behavior of this head and neck cancer subtype.
C1 [Lukits, Julia] National Institute of Oncology, Rath Gy. u. 7-9., H1122 Budapest, Hungary.
   [Dome, Balazs] National Institute of Oncology, Rath Gy. u. 7-9., H1122 Budapest, Hungary.
   [Juhasz, Attila] Medical University, Department of Oto-Rhino-LaryngologyDebrecen, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Rath Gy. u. 7-9., H1122 Budapest, Hungary.
   [Repassy, Gabor] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, H1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2000
VL 44
IS 3
BP 239
EP 245
PG 7
ER

PT J
AU Magyarosy, E
AF Magyarosy, Edina
TI Hungarian experience in the treatment of childhood acute lymphoblastic leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The Hungarian Pediatric Oncology Study Group treated 362 acute lymphoblastic leukemia patients between 1990 and 1995 using the the ALL-BFM 90 protocol. The modified protocol, ALL-BFM 95, was used later to treat 257 patients. The two protocols were similarly successful to treat low and medium risk cases. However, the ALL-BFM 95 protocoll was more efficient to treat high risk patients and resulted in 10% increase in survival. The Western-European results are superior by 10-15% compared to the Hungarian data mainly due to the relatively high proportion of the early death in Hungary. Improvement of these data can only be expected from the development of the diagnostic potentials and from further improvement of treatment of the high isk patients.
C1 [Magyarosy, Edina] Heim Pal Children's Hospital, Ulloi ut 86., H1089 Budapest, Hungary.
RP Magyarosy, E (reprint author), Heim Pal Children's Hospital, H1089 Budapest, Hungary.
EM tapolcai@sztaki.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 255
EP 259
PG 5
ER

PT J
AU Babosa, M
   Garami, M
   Hauser, P
   Schuler, D
   Szendroi, M
AF Babosa, Maria
   Garami, Miklos
   Hauser, Peter
   Schuler, Dezso
   Szendroi, Miklos
TI Survival of Ewing’ s sarcoma patients in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Correlation between different prognostic factors and the overall survival of Ewing’s sarcoma patients has been investigted. In this study data have been selected from the databank of Hungarian Pediatric Oncologist Section (1988-1999) (n=65). Whenever it was possible statistical analysis has been performed. Results: In our patients time interval from the primary symptoms to the diagnosis was 2-16 months. The average event-free survival in patients suffering from Ewing’s sarcoma without metastasis is 0.39. Meanwhile, this value in patients with pulmonary or other metatasis is 0.24 (Kaplan-Meier analysis). Conclusion: Our results show a moderate difference between the Hungarian and the international event-free survival. Late detection is one of the answers of this discrepancy.
C1 [Babosa, Maria] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Babosa, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, H1094 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 261
EP 264
PG 4
ER

PT J
AU Kocsis, B
   Pap, L
   Szekely, G
   Takacsi Nagy, Z
   Nemeth, Gy
AF Kocsis, Bela
   Pap, Lilla
   Szekely, Gabor
   Takacsi Nagy, Zoltan
   Nemeth, Gyorgy
TI The role of radiotherapy in the prevention of recurrence and central nervous system metastases in childhood medulloblastoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To present the postoperative radiotherapy technique in children with medulloblastoma, and analyse the effectiveness of radiotherapy and the survival data. MATERIALS AND METHODS: 66 consecutive children (45 male and 21 female) received postoperative chemotherapy and radiotherapy between 1986 and 1998. The mean age was 8.3 years. The radiotherapy was performed with linear accelerator 9MV X-ray irradiation. The high risk patients received 36 Gy craniospinal irradiation, the low risk patients recived 30 Gy. The boost irradiation to the posterior fossa was 20 Gy in both patient groups. The patients received multi-drug chemotherapy immediately after the tumor resection. The radiotherapy started 6-8 weeks after the operation. RESULTS: All 66 patients were evaluated. The mean follow-up time was 45.4 months. The chance of cure is higher at age 8 or more, and less favorable under age 8. After 60 months 68.6% of children under age 8 and 75.9% older than 8 are alive. 20 children (64.5%) are alive after radical tumorectomy and 11 died. The 5 year overall survival was 71%. Recurrence was observed in 23/66 cases, it was the most frequent cause of death. Local failure was in posterior fossa in 15 patients (68.2%). CONCLUSION: The radicality of operation had no significant influence to the overall survival. The tumor stage, age of patients, risk group and metastases are important prognostic factors.
C1 [Kocsis, Bela] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Pap, Lilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
RP Kocsis, B (reprint author), National Institute of Oncology, Center of Radiotherapy, H1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 265
EP 269
PG 5
ER

PT J
AU Kemeny, V
   Meder, �
   Babosa, M
   Kontor, E
   Hajmassy, Zs
   Schaff, Zs
AF Kemeny, Viktoria
   Meder, Unoke
   Babosa, Maria
   Kontor, Elemer
   Hajmassy, Zsuzsa
   Schaff, Zsuzsa
TI Childhood liver tumor in Hungary: two interesting clinical cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Hepatic tumors account for 0.5-2% of all childhood tumors in Hungary, based of the data last ten years. More than half of the cases were histologically malignant. The worldwide incidence of malignant hepatic tumors is 1.6 / 1 million. Here we present two patients with hepatoblastoma. In the first case the size of the initially inoperable tumor diminished following the chemotherapy and total surgical resection became possible. No sign of relapse occurred so far. The second case included a congenital hepatic tumor which was remarkable because of its unusual clinical presentation and histology.
C1 [Kemeny, Viktoria] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Meder, Unoke] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Babosa, Maria] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Kontor, Elemer] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Hajmassy, Zsuzsa] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kemeny, V (reprint author), Semmelweis University, 2nd Department of Pediatrics, H1094 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 271
EP 274
PG 4
ER

PT J
AU Geczi, L
   Horvath, Zs
   Beczassy, E
   Kisbenedek, L
   Bak, M
   Bodrogi, I
AF Geczi, Lajos
   Horvath, Zsolt
   Beczassy, Eniko
   Kisbenedek, Laszlo
   Bak, Mihaly
   Bodrogi, Istvan
TI Early diagnosis of testicular cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: The authors analyze their 3-year results of the ''educational and early detection program for testicular cancer''. The goals of the program are to reduce the duration of symptoms and to improve early detection. METHODS: Advertisements were placed in the media describing the early signs of testicular cancer, the risks factors, the correct method of self-investigation and the importance of early detection. Between 1 April, 1995 and 1 April, 1998 5056 volunteers were examined. They underwent physical and ultrasound examination of the testicles, and in case of suspicious findings, tumor markers (alpha-fetoprotein, human choriogonadotropin) were checked. RESULTS: Testicular tumors were found in 1.28% of patients with symptoms (testicular enlargement or nodules). No tumor was found in the population that was symptom-free, or in patients with pain, sensitivity to palpation, or unrelated complaints. Of the patients with a palpable lump and swollen testicles, 4.5 and 3.9% were found to have tumors respectively. In total 32 testicular tumors were detected in 30 patients: 15 (2 bilateral) seminomas, 13 non-seminomas and 4 benign tumors. The occurrence of malignant testicular tumors was most frequent, 1.6% in the age group between 15 and 40 years. The stages were as follows: 9 I/A, 9 I/B, 1 I/S, 3 II/A, 1 II/B and 2 III/B. One patient was lost to follow-up after castration. All the other patients achieved complete remission. CONCLUSION: Despite the increasing incidence of testicular cancer screening of asymptomatic men does not lead to detection of tumors. The awareness of the early signs associated with cancer, self-examination, ultrasound examination of the testicle help in establishing an early diagnosis, nevertheless a widescale program for the early detection of testicular cancer is not justifiable. Effective early detection should be based on an educational program for the population at risk, the appropriate training of doctors and staff engaged in the health care of the young, and the initiation and facilitation of early ultrasound examination at the first symptoms. Serum markers play a limited role in early diagnosis.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. 7-9., H1122 Budapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. 7-9., H1122 Budapest, Hungary.
   [Beczassy, Eniko] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. 7-9., H1122 Budapest, Hungary.
   [Kisbenedek, Laszlo] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Bak, Mihaly] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. 7-9., H1122 Budapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. 7-9., H1122 Budapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, H1122 Budapest, Hungary.
EM horvathzs@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 275
EP 283
PG 9
ER

PT J
AU Hauser, P
   Slowik, F
   Babosa, M
   Bognar, L
   Fazekas, I
   Schuler, D
AF Hauser, Peter
   Slowik, Felicia
   Babosa, Maria
   Bognar, Laszlo
   Fazekas, Ilona
   Schuler, Dezso
TI A case of central nervous system atypical teratoid / rhabdoid tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The atypical teratoid / rhabdoid tumour is a rare type of tumours of central nervous system appearing usually under 2 years of age, bearing a rather bad prognosis and it may cause serious differential diagnostic problem. The tumour is characterized histologically by the presence of the rhabdoid cells, immunohistochemically by vimentin, SMA, EMA positivity, the frequent presence of cytokeratin, GFAP positivity, but germ cell markers: AFP, hCG negativity, cytogenetically by aberrations of chromosome 22. The case of a one and half month old female infant is presented, who died 8 months after the appearance of the first symptoms. The diagnostic possibilities and the unsolved problem of the therapy are discussed.
C1 [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Slowik, Felicia] National Institute of NeurosurgeryBudapest, Hungary.
   [Babosa, Maria] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Bognar, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
   [Fazekas, Ilona] National Institute of NeurosurgeryBudapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, H1094 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 285
EP 288
PG 4
ER

PT J
AU Muller, J
   Kovacs, G
   Schmidt, M
   Fekete, Gy
AF Muller, Judit
   Kovacs, Gabor
   Schmidt, Marianne
   Fekete, Gyorgy
TI Frequent infections of neutropenic pediatric patients and therapeutic modalities
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Neutropenia, resulting from intensive chemotherapy is a common problem. The appearance of fever in neutropenic patients should always raise the suspicion of infection and should be followed by an intensive diagnostic evaluation and start of antibacterial treatment. The authors analyzed the association between isolated bacteria from blood cultures and the clinical background of all febrile episodes that occurred in neutropenic children in a two-year long period. Comparable to the international trends, our results suggest an increased prevalence of the Gram-positive organisms causing bacteriaemia. The clear majority of the isolated bacteria was coagulase-negativ Staphylococcus (cnS), which is a multiresistant strain, and sensitive only to the glycopeptide antibiotics. This latter fact can be a consequence of the frequent use of central venous catheters. The empirical therapy, the therapy used in microbiologically and clinically proved infections, and the supplementary and prophylactic methods of treatment are presented.
C1 [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Schmidt, Marianne] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H1094 Budapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, H1094 Budapest, Hungary.
EM muller@gyer2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 289
EP 295
PG 7
ER

PT J
AU Raso, E
   Varga, N
   Timar, J
   Magyarosy, E
AF Raso, Erzsebet
   Varga, Norbert
   Timar, Jozsef
   Magyarosy, Edina
TI Nested PCR detection of WT1 expression in the peripheral blood in childhood acute leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Detection of minimal residual disease (MRD) in childhood leukemia is not possible by cytomorphology or Southern blotting due to their low sensitivity. On the other hand, the use of DNA markers and PCR amplification is helpful in a smaller proportion of leukemia cases (20-30%). Since childhood leukemia is characterized by WT1 gene expression in the majority of cases,monitoring of WT1 expression in the peripheral blood was suggested to be a method of choice to detect MRD. We have studied 22 newly diagnosed childhood acute leukemias and 17 cases in remission. As controls, 19 patients with non-leukemic diseases were included. The majority of our acute leukemia cases (80%) were proved to be WT1 expressors using a highly sensitive nested PCR technique. Ten WT1 + cases have been monitored for a year throughout the inicial therapy phase, using peripheral blood tests. We observed that in 20% of the follow-up cases MRD was suggested which was not detectable by any other methods. It is our intention to introduce this new molecular technique into the clinical management of childhood acute leukemia.
C1 [Raso, Erzsebet] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Varga, Norbert] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., H1122 Budapest, Hungary.
   [Magyarosy, Edina] Heim Pal Children's Hospital, Department of HematologyBudapest, Hungary.
RP Raso, E (reprint author), National Institute of Oncology, Department of Tumor Progression, H1122 Budapest, Hungary.
EM raso@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 297
EP 303
PG 7
ER

PT J
AU Grof, �
AF Grof, Agnes
TI Making Decisions on the Resources for Cancer Control
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB We aim at modelling the strategic decision making process in case of devoting resources to a governmental cancer control program. We use a model based on the theory of Analytic Hierarchy Process. In this article we describe the characteristic features of such a decision making process and reveal the complexity of the problem underlying the decisions. A second article will present and discuss the results from the application of the AHP model. Interventions which are capable of decreasing the burden of cancer in a society need strategic approach. Decisions on interventions seem inevitable to be based on and balance between the priorities and the available resources. There is not much doubt about it that the reason for setting the priorities arises on the one hand from the scarcity of resources. On the other hand, priorities evolve on other bases, and are supposed to ''guide'' health policy makers devoting the scarce resources. In general, a strategic mode of thought has been based on assumptions, which, in case of cancer control enhance the necessity to assess information on cancer and cancer patients, and to understand the factors contributing towards better health. The capabilities of the NCCP achieving its aims by preventing the development of cancer diseases (primary prevention), by making use of the means of early detection and appropriate therapy (secondary prevention), and by providing modern (comprehensive) tertiary prevention are inevitably affected by the priorities. Health policy should assume a responsibility for enforcing certain priorities and should be aware of the long-term interest of the population. To solve the problem we restrict the model to a simple three level one, representing the goals, the criteria, and the alternatives of the resource allocation. We determine ''decreasing the burden of cancer'' as the overall goal. ''Distributive justice'' ''cost-effectiveness'', ''human rights ”, ''evidences'', and ''standpoints of a community'' serve as criteria, while ''primary prevention'', ''early detection and therapy, both belonging to the secondary prevention'', ''tertiary prevention'', ''research'', and ''education'' form the alternatives.
C1 [Grof, Agnes] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Grof, � (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori Iskola, Pecs, Hungary.
EM grofa@matavnet.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2000
VL 44
IS 4
BP 305
EP 311
PG 7
ER

PT J
AU Otto, Sz
AF Otto, Szabolcs
TI Colorectal cancer screening: a new strategy for the demonstration of occult intestinal bleeding.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE colorectal cancer; screening; bleeding; immunochemistry
ID colorectal cancer; screening; bleeding; immunochemistry
AB The topic of colorectal cancer screening is discussed with special emphasis on its history and improvement of its methodology. The author’s own results are evaluated in terms of international data published in literature in order to put forward his proposals for a new strategy. The devastating power and endemic character of colorectal cancers is stressed and the development of screening activities is recommended to accomplish within the frame of the complex health service.
C1 [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, H-1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 3
EP 7
PG 5
ER

PT J
AU Gopcsa, L
   Barta, A
   Banyai, A
   Foldi, J
   Kalasz, L
   Pajor, L
   Gidali, J
   Paloczi, K
AF Gopcsa, Laszlo
   Barta, Aniko
   Banyai, Aniko
   Foldi, Janos
   Kalasz, Laszlo
   Pajor, Laszlo
   Gidali, Julia
   Paloczi, Katalin
TI Autologous hematopoietic stem cell transplantation in chronic myeloid leukaemia with different clinical stages.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE CML; hematopoietic stem-cells; autologous bone marrow transplantation
ID CML; hematopoietic stem-cells; autologous bone marrow transplantation
AB For most chronic myeloid leukaemia patients the option of a potentially curative allogeneic stem cell transplantation is not available because of age or lack of donor. Alternative therapy with interferon-alpha appears to prolong survival but is probably not curative. The aim of the study is to analyse the clinical results of the first Hungarian autologous transplantations in CML.  METHODS: Seven patients were treated with ICE-based regimen plus G-CSF with the aim of mobilising and collecting Ph-negative peripheral stem cells in the setting of autologous transplant program. Five patients had CML in first chronic phase and two in accelerated phase. All patients have been previously treated with interferon-alpha.  RESULTS: Median value and ranges for harvested mononuclear cells, CD34<sup>+</sup> cells and CFU-GM were: 5.65x10<sup>8</sup>/kg (2.61-11.38), 1.48x10<sup>6</sup>/kg (0.216-3.5) and 3.43x10<sup>4</sup>/kg (0.243-11.6), respectively. Four out of seven autologous grafts have been transplanted. Busulfan conditioning was used in one case and TBI/Cy conditioning in three patients. All patients are alive and well post-transplant being on interferon-alpha therapy.  CONCLUSIONS: Based on the clinical advantages of autologous transplantation including long-term chronic phase, achievement of second chronic phase and improved response to interferon-alpha therapy, the procedure can offer an alternative treatment in CML in lack of HLA-identical donor.
C1 [Gopcsa, Laszlo] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
   [Barta, Aniko] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
   [Banyai, Aniko] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
   [Foldi, Janos] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
   [Kalasz, Laszlo] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
   [Pajor, Laszlo] University of Pecs, Department of PathologyPecs, Hungary.
   [Gidali, Julia] National Institute of Haematology, Blood Transfusion and ImmunologyBudapest, Hungary.
   [Paloczi, Katalin] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
RP Gopcsa, L (reprint author), National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 9
EP 13
PG 5
ER

PT J
AU Barta, A
   Lengyel, L
   Sipos, A
   Torbagyi, �
   Foldi, J
   Paldi-Haris, P
   Tamaska, J
   Gyodi, �
   Rajczy, K
   Hoffer, I
   Jakab, J
   Kormos, L
   Petranyi, Gy
   Paloczi, K
AF Barta, Aniko
   Lengyel, Lilla
   Sipos, Andrea
   Torbagyi, Eva
   Foldi, Janos
   Paldi-Haris, Piroska
   Tamaska, Julia
   Gyodi, Eva
   Rajczy, Katalin
   Hoffer, Izabella
   Jakab, Judit
   Kormos, Luca
   Petranyi, Gyozo
   Paloczi, Katalin
TI Clinical and immunopathological significance of chimerism in bone marrow and organ transplantations
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE chimerism; transplantation; graft-versus-host disease; graft-versus-leukemia effect; CML
ID chimerism; transplantation; graft-versus-host disease; graft-versus-leukemia effect; CML
AB Chimerism is an exceptional immunogenetic state, characterized by the survival and collaboration of cell populations originated from two different individuals. The prerequisites to induce chimerism are immunosuppression, myeloablation or severe immunodeficiency of the recipients on one side and donor originated immuno-hematopoietic cells in the graft on the other. Special immunogenetic conditions to establish chimerism are combined with bone marrow transplantation, transfusion and various kinds of solid organ grafting. There are various methods to detect the type of chimera state depending on the immunogenetic differences between the donor and recipient. The chimera state seems to be one of the leading factors to influence the course of the post-transplant period, the frequency and severity of graft-versus-host disease (GVHD), and the rate of relapse. However, the most important contribution of the chimeric state is the development of graft versus leukemia (GVL) effect. A new conditioning protocol (DBM/Ara-C/Cy) for allogeneic BMT in CML patients and its consequence on chimera state and GVL effect is demonstrated.
C1 [Barta, Aniko] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Lengyel, Lilla] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Sipos, Andrea] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Torbagyi, Eva] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Foldi, Janos] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Paldi-Haris, Piroska] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Tamaska, Julia] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Gyodi, Eva] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Rajczy, Katalin] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Hoffer, Izabella] National Institute of Haematology, Blood Transfusion and ImmunologyBudapest, Hungary.
   [Jakab, Judit] National Institute of Haematology, Blood Transfusion and ImmunologyBudapest, Hungary.
   [Kormos, Luca] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Petranyi, Gyozo] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
   [Paloczi, Katalin] National Institute of Haematology, Blood Transfusion and Immunology, Daroczi ut 24., 1113 Budapest, Hungary.
RP Petranyi, Gy (reprint author), National Institute of Haematology, Blood Transfusion and Immunology, 1113 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 15
EP 21
PG 7
ER

PT J
AU Gado, K
   Gopcsa, L
   Paloczi, K
   Domjan, Gy
AF Gado, Klara
   Gopcsa, Laszlo
   Paloczi, Katalin
   Domjan, Gyula
TI Therapy of multiple myeloma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE myeloma multiplex; chemotherapy; sequential therapy
ID myeloma multiplex; chemotherapy; sequential therapy
AB Multiple myeloma (MM) is a haematological malignancy characterised by the clonal expansion of malignant plasma cells within the bone marrow. It accounts for 10% of all haematological malignant diseases and 1% of all malignancies. The median age of patients at the time of the diagnosis is 70 years. The characteristic clinical features of MM are bone marrow failure, susceptibility to infections, bone pain, pathological bone fractures, hypercalcaemia, and renal failure. Though MM is currently incurable, the important progress in chemotherapy has resulted in an improvement in survival from a median of 7 months in the 1950-ies to about 3 years today. Advances in the diagnosis and in supportive treatment of infections, hypercalcaemia, and renal failure also contributed to the prolongation of survival. For decades, the gold standard of treatment had been oral melphalan alone or in combination with prednisolone. Combination chemotherapy has not improved overall survival (OS), but these regimens have led to the prolongation of event-free survival (EFS) and also to a better quality of life. High-dose chemotherapy with haemopoietic stem cell rescue resulted in a great improvement in EFS as well as OS. For those very few who have an HLA-compatible donor and are under 55, allogeneic bone marrow transplantation offers the best hope of survival but comes at a greatly increased risk of toxicity. There are conflicting data in the literature concerning the role of interferon-alpha; it seems to be able to prolong the duration of the plateau phase. Current treatment is moving towards an approach using sequential therapy. This involves induction therapy proceeding to high-dose chemotherapy with some form of stem-cell rescue. Bisphosphonates reduce hypercalcaemia, bone pain and can inhibit bone destruction. They also possess a direct antitumor activity. The better understanding of the pathomechanism of the disease gives the opportunity of the application of new therapeutic modalities such as antagonising the effect of interleukin-6 (IL-6), or idiotypic vaccination.
C1 [Gado, Klara] National Institute of Haematology, Blood Transfusion and Immunology, 1389 Budapest, Hungary.
   [Gopcsa, Laszlo] National Institute of Haematology, Blood Transfusion and Immunology, 1389 Budapest, Hungary.
   [Paloczi, Katalin] National Institute of Haematology, Blood Transfusion and Immunology, 1389 Budapest, Hungary.
   [Domjan, Gyula] Semmelweis Egyetem, Geriatriai Tanszeki CsoportBudapest, Hungary.
RP Gado, K (reprint author), National Institute of Haematology, Blood Transfusion and Immunology, 1389 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 23
EP 30
PG 8
ER

PT J
AU Matolcsy, A
AF Matolcsy, Andras
TI The World Health Organization classification of lymphoid neoplasms
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hematological malignancy; classification; WHO; pathology; oncology
ID hematological malignancy; classification; WHO; pathology; oncology
AB The European Society of Pathology and the Society for Hematopathology have developed a new World Health Organization (WHO) classification of hematological malignancies. The classification is based on the principle that the classification is a list of entities defined by the combination of morphology, immunophenotype, genetic and clinical features. The WHO classification is a new basis of communications between pathologist and oncologist which will help to understand and treat hematological malignancies
C1 [Matolcsy, Andras] University of Pecs, Department of Pathology, Szigeti ut 12., H-7643 Pecs, Hungary.
RP Matolcsy, A (reprint author), University of Pecs, Department of Pathology, H-7643 Pecs, Hungary.
EM amatolc@pathology.pote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 31
EP 34
PG 4
ER

PT J
AU Varga, Gy
AF Varga, Gyula
TI Recommendation: high risk (aggressive) non-Hodgkin lymphoma (NHL)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE NHL
ID NHL
C1 [Varga, Gyula] University of Szeged, 2nd Department of Internal Medicine and Cardiology Centre, Dugovics ter 23., 6720 Szeged, Hungary.
RP Varga, Gy (reprint author), University of Szeged, 2nd Department of Internal Medicine and Cardiology Centre, 6720 Szeged, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 35
EP 37
PG 3
ER

PT J
AU Schneider, T
   Molnar, Zs
   Varady, E
   Deak, B
   Rosta, A
AF Schneider, Tamas
   Molnar, Zsuzsanna
   Varady, Erika
   Deak, Beata
   Rosta, Andras
TI Clinical features and guidelines of treatment of mucosa-associated lymphoid tissue lymphoma of stomach
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE MALT lymphoma; Helicobacter pylori; therapy
ID MALT lymphoma; Helicobacter pylori; therapy
AB The mucosa-associated lymphoid tissue (MALT) lymphoma is a very indolent disease. Its most common site is the stomach. The lymphoma begins as a reactive lymphocyte accumulation mostly due to an infection of Helicobacter pylori (HP). Through repeated mutations this tissue is transformed into the characteristic MALT lymphoma. At the time of the diagnosis the lymphoma is usually localised, but in one third of the patients the disease has already been disseminated. There are not any commonly accepted guidelines of therapy concerning this primary gastric MALT lymphoma, but certain general tendencies have already been defined. In the early disease the aim of the treatment is curative with the preservation of the stomach as much as possible. In a considerable number of cases, when the surface of the stomach is affected by HP, one can achieve histological and molecular biologic remission after eliminating the bacteria. However, there is no such therapeutic consequence to be expected in case of a deeply invasive tumour. The optimal treatment of patients of this group as well as those whose disease is resistant to HP eradication treatment together with those who are HP negative is radiotherapy or surgery with chemotherapy. In this latter case quality of life becomes worse. In an advanced case cure is impossible and chemotherapy is the most effective to ease the patient’s state.
C1 [Schneider, Tamas] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Molnar, Zsuzsanna] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Varady, Erika] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Deak, Beata] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Rosta, Andras] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Schneider, T (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, H-1122 Budapest, Hungary.
EM schneider@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 39
EP 44
PG 6
ER

PT J
AU Varga, F
   Demeter, J
AF Varga, Fatima
   Demeter, Judit
TI Progress in the treatment of non-Hodgkin’s lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE non-Hodgkin lymphoma; CLL; hairy cell leukemia; chemotherapy
ID non-Hodgkin lymphoma; CLL; hairy cell leukemia; chemotherapy
AB The authors analyze the progress achieved in the treatment of low-grade as well as of high-grade non-Hodgkin’s lymphomas. The challenging task in the treatment of low-grade or indolent lymphomas still is to decide whether watchful waiting is sufficient or whether chemotherapy is necessary and how aggressive this treatment should be. Among the new chemotherapeutic agents the role of purine analogues should be emphasized, fludarabin is especially important in the treatment of chronic lymphocytic leukemia and follicular lymphoma, while pentostatin and cladribine have revolutionized the treatment of hairy cell leukemia. Treatment with monoclonal antibodies, radioimmunoconjugates as well as autologous or allogeneic stem cell transplantation are potential new therapeutic options in the treatment of low-grade non-Hodgkin’s lymphomas. In the case of aggressive non-Hodgkin’s lymphomas risk-adapted strategies help the choice between standard or more intensive treatment options. In patients with relapsed high-grade lymphomas stem cell transplantation is indicated. In patients with marginal zone lymphoma the combination of hyperCVAD protocol + stem cell transplantation greatly improves prognosis.
C1 [Varga, Fatima] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor u. 2/a, H-1083 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor u. 2/a, H-1083 Budapest, Hungary.
RP Demeter, J (reprint author), Semmelweis University, 1st Department of Internal Medicine, H-1083 Budapest, Hungary.
EM demjud@bel1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 45
EP 50
PG 6
ER

PT J
AU Illes, �
   Molnar, Zs
   Udvardy, M
AF Illes, Arpad
   Molnar, Zsuzsa
   Udvardy, Miklos
TI Recommendation: Hodgkin disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE Hodgkin lymphoma
ID Hodgkin lymphoma
C1 [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Udvardy, Miklos] DEOEC, II.sz. Belgyogyaszati KlinikaDebrecen, Hungary.
RP Illes, � (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4004 Debrecen, Hungary.
EM illes@iiibel.dote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 53
EP 57
PG 5
ER

PT J
AU Uher, F
AF Uher, Ferenc
TI Impact of DNA chips on haematological oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE DNA microarray; leukemia; lymphoma diagnosis; prognosis
ID DNA microarray; leukemia; lymphoma diagnosis; prognosis
AB As the Human Genome Project hurtles towards completion, DNA microarray technology offers the potential to open wide new windows into the study of genome complexity. DNA chips can be used for many different purposes, most prominently to measure levels of gene expression (messenger RNA abundance) for tens of thousands of genes simultaneously. But how much of this data is useful and is some superfluous? Can array data be used to identify a handful of critical genes that will lead to a more detailed taxonomy of haematological malignancies and can this or similar array data be used to predict clinical outcome? It is still too early to predict what the ultimate impact of DNA chips will be on our understanding of cancer biology. There are many critically important questions about this new field that are yet unaddressed. By the publication of this article, it is hoped that the technology of DNA chips will be opened up and demystified, and that additional opportunities for creative exploration will be catalysed.
C1 [Uher, Ferenc] National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
RP Uher, F (reprint author), National Institute of Haematology, Blood Transfusion and Immunology, 1519 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 59
EP 66
PG 8
ER

PT J
AU Sebestyen, A
   Kopper, L
AF Sebestyen, Anna
   Kopper, Laszlo
TI The role of syndecans in lymphoid systems
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE syndecan-1; proteoglycan; B-CLL; B-non-Hodgkin lymphoma
ID syndecan-1; proteoglycan; B-CLL; B-non-Hodgkin lymphoma
AB Syndecans, transmembrane heparan sulfate proteoglycans, play an important role in cell-cell and cell-matrix interactions, as receptors/co-receptors of matrix elements, cytokines, growth factors. These functions are partly non-specific and due to the heparan sulfate chains attached to the ectodomain, and partly specific related to the transmembrane and cytoplasmic domains of the core protein. In hemopoietic cells syndecan-1 is expressed in certain B cells, in pre-B cells and plasma cells. In lymphoproliferative diseases this normal syndecan-1 expression of plasma cells is retained in myelomas/plasmocytomas, other lymphoplasmocytic NHL subtypes and primary effusional lymphomas. Syndecan-1 expression is probably gained in B-CLL, and lost in other NHLs of pre- or post-follicular origin. These results suggest that the expression of syndecan is essential for some NHLs, probably ensuring the required connections to the microenvironment. From a diagnostic point of view, syndecan-1 is a very useful phenotypic marker to identify cells with plasmocytic differentiation. The importance of syndecan expression in CLL and Hodgkin-lymphoma still requires further studies.
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26, H-1085 Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26, H-1085 Budapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, H-1085 Budapest, Hungary.
EM anna@korb1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 67
EP 74
PG 8
ER

PT J
AU Timar, J
   Sebestyen, A
   Magyarosy, E
AF Timar, Jozsef
   Sebestyen, Anna
   Magyarosy, Edina
TI Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE pediatric ALL; CD44v6; NM23-H1; progression; immuncytochemistry
ID pediatric ALL; CD44v6; NM23-H1; progression; immuncytochemistry
AB Two metastasis associated proteins, CD44v6 and NM23-H1, are expressed by normal lymphoid cells, the former serving as activation marker and the later as a constitutive protein. CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukemia (ALL). On the other hand, NM23-H1 is considered as a differentiation inhibitory factor in various hematological cancers and as a marker of poor prognosis. Therefore we have analyzed the expression of CD44v6 and NM23-H1 in bone marrow of sixteen pediatric ALL patients using immunocytochemistry. For the first time, we have demonstrated the expression of CD44v6 protein epitopes on leukemic cells in a proportion of ALL cases (6/16), primarily in the medium/high risk group (except one case), suggesting a possible association to an unfavorable outcome. On the other hand, NM23-H1 protein expression was maintained in leukemic cells in 50% of both low and medium/high risk ALL cases. The majority of the pediatric ALL cases expressed only one of the metastasis associated proteins (10/16). This feature is highly similar to the observations made in several adult solid cancers. The potential of CD44v6 expression in leukemic cells as prognosticator in pediatric ALL has to be evaluated in a larger clinical trial.
C1 [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Magyarosy, Edina] Heim Pal Children's HospitalBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Department of Tumor Progression, H-1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 75
EP 79
PG 5
ER

PT J
AU Borbenyi, E
   Dank, M
   Mako, E
AF Borbenyi, Erika
   Dank, Magdolna
   Mako, Erno
TI Management of cancer pain
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer pain; clinical management; NSAID; opioids; morphin sulfate; fentanyl
ID cancer pain; clinical management; NSAID; opioids; morphin sulfate; fentanyl
AB The morphin-analogue, Durogesic, has robust analgetic effect without repeated side-effects and is suitable for special applications providing it as the first choice for therapy of cancer pain and as an acceptable alternative for CR morphin. Clinical studies not only provided evidences for the pharmacological effectivity of Durogesic but suggested that the quality of life of cancer patients improved significantly as well.
C1 [Borbenyi, Erika] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1083 Budapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1083 Budapest, Hungary.
   [Mako, Erno] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1083 Budapest, Hungary.
RP Borbenyi, E (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, 1083 Budapest, Hungary.
EM borbi@radi.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 81
EP 88
PG 8
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI 23rd San Antonio Breast Cancer Symposium
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2001
VL 45
IS 1
BP 89
EP 93
PG 5
ER

PT J
AU Paldy, A
   Nador, G
   Vincze, I
   Bakacs, ZsM
   Rajcsanyi, �
   Pinter, A
AF Paldy, Anna
   Nador, Gizella
   Vincze, Istvan
   Bakacs, Zsambokine Marta
   Rajcsanyi, Agnes
   Pinter, Alan
TI Spatial differences in mortality and morbidity from cancer of the lip, oral cavity and pharynx in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE epidemiology; regional distribution; head and neck cancer; morbidity; statistics
ID epidemiology; regional distribution; head and neck cancer; morbidity; statistics
AB In evaluating the health state of the population one of the most reliable parameter is mortality. The development of statistical and spatial analytical methods gave a tool for evaluating mortality and morbidity in small areas. GIS mapping helps in the assessment of health state of small areas, to investigate causal relationship and create plans of intervention. Within the frames of the National Environmental Health Action Programme (NEHAP, 1996) a spatial statistical information system was elaborated. By the help of this system, mortality from cancer of the lip, oral cavity and pharynx (ICD-X.: C00-C14) was analysed for 1986-1997 and morbidity for 1997-1999 by computing standardised mortality and morbidity ratio. Regions with unfavourable mortality and morbidity were defined, statistical significance was tested. After age and gender stratification, a cluster analysis was also carried out. An international comparison of mortality was done as well. According to our data, mortality - most frequent in both sexes according to the international comparison - as well as morbidity showed a typical spatial distribution. An excess in mortality and morbidity is observable in the central part of the country, as well as in the Northern part and in traditional wine producing areas. The spatial accumulation of mortality is very similar to that of mortality from chronic liver diseases (ICD-X.: K70). In the primary prevention of oral cancer smoking cessation and the decrease of alcohol consumption is of great importance. Screening activity of GPs and dental doctors is of major importance in secondary prevention.
C1 [Paldy, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
   [Nador, Gizella] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
   [Vincze, Istvan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
   [Bakacs, Zsambokine Marta] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
   [Rajcsanyi, Agnes] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
   [Pinter, Alan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2-6., 1096 Budapest, Hungary.
RP Paldy, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, 1096 Budapest, Hungary.
EM paldy@mail.jobdei.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 106
EP 114
PG 9
ER

PT J
AU Johnson, WN
AF Johnson, W Newell
TI Aetiology and risk factors for oral cancer, with special reference to tobacco and alcohol use.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oral cancer; global statistics; Hungary; smoking; alcohol consumption
ID oral cancer; global statistics; Hungary; smoking; alcohol consumption
AB Animal experiments, in vitro studies of mechanisms, biological plausibility and massive epidemiological evidence prove that tobacco – smoked and unsmoked – is the major cause of oral cancer in the world. In Hungary today tobacco is mostly smoked in cigarettes, the smoking prevalence being amongst the highest in Europe: it is no surprise that Hungary has the highest rate of oral cancer in the world today. Tobacco use, however, synergises with heavy alcohol use in a dose dependent manner, the effect being supermultiplicative: most of the rising incidence of oral cancer in Europe is probably due to rising alcohol consumption in recent decades in the presence of continuing high levels of tobacco use. Smaller roles can be ascribed to inherited predisposition, environmental agents, poor diet, infections with viruses and fungi and poor oral hygiene/oral health care. The approach to primary prevention is thus clear, and must emphasise tobacco avoidance and sensible use of alcohol, together with good nutrition and dental care.
C1 [Johnson, W Newell] Guy's Kings and St Thomas's School of Medicine, St Thomas's Hospital, GKT Dental Institute, Caldecot Rd, SE5 9RW London, UK.
RP Johnson, WN (reprint author), Guy's Kings and St Thomas's School of Medicine, St Thomas's Hospital, SE5 9RW London, UK.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 115
EP 122
PG 8
ER

PT J
AU Squier, Ch
AF Squier, Christopher
TI The hierarchy of approaches to tobacco control.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tobacco control; oral cancer; education; legislation
ID tobacco control; oral cancer; education; legislation
AB Tobacco represents the single most preventable cause of disease and death in the world today. Of 260 million male deaths in the developed world between 1950 and 2000, it is estimated that 50 million will be due to smoking. In the oral and craniofacial region tobacco use has been associated with the occurrence of cleft palate, periodontal disease and tooth loss, and a variety of soft tissue lesions including oral cancer. For example, smoking is estimated to account for 92% of cancers of the lip, oral cavity and pharynx. Few studies have examined relative efficiency of the many different approaches to tobacco control but, in general, legislative approaches such as increasing tobacco taxes and prohibiting advertising are most effective and those based on printed educational materials and cessation groups, the least effective. In all cases, advice or intervention by health care professionals ranked among the most effective non-legislative approaches to control. A very wide range of professionally-based interventions have been described, including pharmacologic interventions, behavioral approaches and group counseling. The dental profession has a unique opportunity to influence tobacco use by their patients. Its use is almost always immediately evident to the dentist or dental assistant in terms of odor, staining, poor oral hygiene or obvious oral disease. There is also a tendency for the length of personal contact with the dentist to be greater than with a physician. Guidelines are now available that provide the dental professional with advice on the best approaches to tobacco control with their patients.
C1 [Squier, Christopher] University of Iowa, College of Dentistry, Office of the Provost, 234, Medicine Admin. Bldg, 52242-1101 Iowa City, USA.
RP Squier, Ch (reprint author), University of Iowa, College of Dentistry, 52242-1101 Iowa City, USA.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 123
EP 128
PG 6
ER

PT J
AU Lowe, BJ
AF Lowe, B John
TI Behavioral approaches in tobacco control
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE smoking; tobacco control; counseling; nicotine replacement therapy
ID smoking; tobacco control; counseling; nicotine replacement therapy
AB In most Western societies, there is an abundance of information on what needs to be done to control the use of tobacco. This paper presents different strategies for addressing tobacco control. Many of the strategies such as increasing taxes, increasing control over promotion of tobacco, and the restriction of smoking should be made a priority. However, there is still the need to provide help for the smoker to quit. The evidence with regards to effective ways of getting smokers to quit and the effectiveness of different modalities is reviewed. Programs found to be effective include self-help, individual counseling, and group counseling. Counseling programs appear to double the effect of success compared to no program. Nicotine replacement therapy has been demonstrated to be an important adjunct therapy to the behavioral programs. Issues regarding the cessation of tobacco by youth need to be addressed distinctively from adult cessation. Relapse prevention for both youth and adults needs to become a major focus of programs dealing with smokers who want to quit.
C1 [Lowe, B John] The University of Iowa - College of Publich Health, Department of Community & Behavioral Health, 52242-1008 Iowa City, IA, USA.
RP Lowe, BJ (reprint author), The University of Iowa - College of Publich Health, Department of Community & Behavioral Health, 52242-1008 Iowa City, USA.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 129
EP 132
PG 4
ER

PT J
AU Hovell, M
AF Hovell, Melbourne
TI Reducing children’s exposure to environmental tobacco smoke: Evidence from the U.S. and implications for Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE environment; tobacco smoke; children exposure
ID environment; tobacco smoke; children exposure
AB This review summarizes empirical evidence for clinical interventions designed to reduce children’s residentia environmental tobacco smoke (ETS) exposure. Legislation prohibiting ETS exposure in public buildings, especially work settings, may decrease ETS exposure in private residences. Media, policy/legal regulations, and brief clinical advice require more study to determine their effectiveness for decreasing ETS exposure in private residences. Three published and two in progress trials found that repeated counseling reduced ETS exposure in asthmatic and healthy children from lower through middle class families. Dentists, physicans, and other clinicians may be strategic supervisors for paraprofessional counseling designed to lower children’s ETS exposure in their home. Research is needed to determine the cultural tailoring needed to be effective in Hungary.
C1 [Hovell, Melbourne] University of Iowa, Department of Community & Behavioral Health, C-Beach, 9245 Sky Park Court, Suite 230., 92123 San Diego, CA, USA.
RP Hovell, M (reprint author), University of Iowa, Department of Community & Behavioral Health, 92123 San Diego, USA.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 133
EP 138
PG 6
ER

PT J
AU Kopp, M
   Csoboth, Cs
AF Kopp, Maria
   Csoboth, Csilla
TI Self-destructive behaviour in the Hungarian population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE Hungarian mortality; risk behavior; smoking incidence
ID Hungarian mortality; risk behavior; smoking incidence
AB In Hungary today the mortality rate of middle aged (55-64 years old) men is higher than it was in the 1930s. Within these statistics there are considerable socioeconomic differences, the mortality rate of lower secondary or lower educated middle aged men is 1.45 times higher than among those with higher education. About 40% of these socioeconomic mortality differences can be explained by higher prevalence of risk behaviour in lower socioeconomic groups. According to the results of our national representative survey conducted in the Hungarian population with 12640 persons in 1995, the prevalence of smoking was 45.5% among men and 26.6% among women. In the populaton younger than 45 years old the prevalence of smoking among men was 47.9%, among women 31.9%. Among men there is a clear socioeconomic gradient in smoking, in the number of daily cigarettes, the quantity of spirit consumption in one occasion, among women this socioeconomic gradient is not so obvious. The effectiveness of health promotion programmes depends on effective management of the motivational, psychological determinants of risk behaviour.
C1 [Kopp, Maria] Semmelweis University, Institute of Behavioural Sciences, Nagyvarad ter 4., H-1089 Budapest, Hungary.
   [Csoboth, Csilla] Semmelweis University, Institute of Behavioural Sciences, Nagyvarad ter 4., H-1089 Budapest, Hungary.
RP Kopp, M (reprint author), Semmelweis University, Institute of Behavioural Sciences, H-1089 Budapest, Hungary.
EM koppmar@net.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 139
EP 142
PG 4
ER

PT J
AU Banoczy, J
   Bako, A
   Dombi, Cs
   Ember, I
   Kosa, Zs
   Sandor, J
   Szabo, Gy
AF Banoczy, Jolan
   Bako, Attila
   Dombi, Csaba
   Ember, Istvan
   Kosa, Zsigmond
   Sandor, Janos
   Szabo, Gyorgy
TI Stomato-oncological screening examinations: possibilities for early diagnosis.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oral cancer screening; precancerosis; stomato-oncology
ID oral cancer screening; precancerosis; stomato-oncology
AB The dramatic increase in the mortality of lip- and oral cancers in Hungary in the last decades points to the importance of primary and secondary prevention. Stomato-oncological screening examinations belong to the latter category, and might represent useful tools in the early diagnosis and treatment of oral carcinomas and precancerous lesions. The aim of the paper is to review the methods, results and effectivity of stomato-oncological screening examinations in Hungary. Between 1962 and 2000 nine screening examinations were performed: one on a population sample, one in an industrial setting, four connected to X-ray lung-screening examinations (one with the help of a mobile unit), one on voluntary persons, one on high risk people (homeless), one in general medical practice. Among these, in the last five years, in the course of the stomato-oncological examination of 17325 individuals, oral carcinoma has been found in 0.12%, and oral precanceroses in 2.63%. Although the general dentist is obliged by law to perform a stomato-oncological examination on the patients appearing in the practice, unfortunately, about 50-to-90% of the population does not visit a dentist regularly. The regular examination of these - high risk - groups by the help of the above methods, including the help of general medical practitioners is highly recommended.
C1 [Banoczy, Jolan] Semmelweis University, Department of Oral Biology, Nagyvarad ter 4., H-1089 Budapest, Hungary.
   [Bako, Attila] Szabolcs- Szatmar-Bereg megyei ANTSZNyiregyhaza, Hungary.
   [Dombi, Csaba] Semmelweis University, Faculty of DentistryBudapest, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Kosa, Zsigmond] Szabolcs- Szatmar-Bereg megyei ANTSZNyiregyhaza, Hungary.
   [Sandor, Janos] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Szabo, Gyorgy] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
RP Banoczy, J (reprint author), Semmelweis University, Department of Oral Biology, H-1089 Budapest, Hungary.
EM banoczy@net.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 143
EP 148
PG 6
ER

PT J
AU Remenar, �
AF Remenar, Eva
TI Proposal for screening of oral and oropharyngeal cancer in the population at risk.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
DE head and neck cancer; screening; population; physician
ID head and neck cancer; screening; population; physician
AB The aim of our proposal is to suggest selected screening for people, who are the most likely candidates for the development of head and neck cancer. The screening organized by the family physicians on their own database in collaboration with the local dentists or ENT doctors involves examination and health education by effective communication and written information about risk of cancer and early signs and symptoms of the disease.
C1 [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM reva@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 149
EP 151
PG 3
ER

PT J
AU Szekely, G
   Remenar, �
   Kasler, M
   Gundy, S
AF Szekely, Gabor
   Remenar, Eva
   Kasler, Miklos
   Gundy, Sarolta
TI Exposure or cancer predisposition? Cytogenetic examination of head and neck squamous cancer patients.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; bleoycin test; chromatid breaks; lymphocyte
ID head and neck cancer; bleoycin test; chromatid breaks; lymphocyte
AB Search of different biomarkers is one of the most important demands of the national cancer prevention programme. We examined the usefulness of bleomycin sensitivity assay, whether it serves as a biomarker of individual sensitivity and risk for head and neck cancer under our environmental conditions. The test is based on the measurement of the means of chromatid breaks induced by bleomycin in vitro in a single lymphocyte (break/cell=b/c). 156 head and neck cancer patients were matched not only with 295 healthy controls (146 non-smokers and 149 smokers), but also with 51 strong alcoholic and smoking patients with liver disease whose lifestyle did not differ from that of the cancer patients. The aberrant cell frequency of cancer patients (2.85%), alcoholics (2.82%) and healthy smokers (2.81%) was similar and higher (p<0.03) than the values of non-smoker controls (2.25%). Thus, the results of conventional chromosome analysis indicate the effect of exposure to mutagens, derived mainly from smoking. Mutagen sensitivity measured by the bleomycin assay was significantly higher in both the cancer- (1.13 b/c) and the alcoholic patients (1.29 b/c) compared with smoker (1.04 b/c) and non-smoker controls (0.98 b/c). The bleomycin sensitivity assay, therefore, seems to be the biomarker not only for the cancer, but also for a disease of the same aetiology such as alcohol-related liver disease. However, the method is not suitable for the assessment of individual cancer risk due to overlapping of b/c values with those of controls. The proportion of mutagen sensitive persons in the group of Hungarian controls is 42-49%, which is two-fold of those in the US and Western Europe. When we estimate the cancer risk, the results of bleomycin sensitivity assay are equivocal under our experimental conditions, and they must be applied cautiously even in combination with the results of chromosome analysis.
C1 [Szekely, Gabor] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Gundy, Sarolta] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, H-1122 Budapest, Hungary.
EM gundy@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 152
EP 157
PG 6
ER

PT J
AU Csuka, O
   Olasz, J
   Juhasz, A
   Hargitai, �
   Remenar, �
   Kasler, M
AF Csuka, Orsolya
   Olasz, Judit
   Juhasz, Aliz
   Hargitai, Arpad
   Remenar, Eva
   Kasler, Miklos
TI Genetic marker analysis in head and neck cancer.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; p53; p16; cyclin D; E2F4; hMHL1; hMSH2
ID head and neck cancer; p53; p16; cyclin D; E2F4; hMHL1; hMSH2
AB Prognostication of head and neck cancer (HNCC) involves molecular identification of residual tumor cells, prediction of recurrence, distant metastases or secondary tumors and prediction of the sensitvity to therapy. Biomarkers of HNCC are mutations of p53, p16 and amplification of Cyclin D and E2F4. One hundred and fifty-two HNCC cases have been evaluated for p53, hMLH1, Cyclin D and p16 gene alterations using PCR-SSCP and Western blot analysis. P53 mutations of HNCC have been found in 37.5% of cases. However, 11% of the cases showed p53 mutations in the normal peritumoral mucosa suggesting ''field cancerization” process. Mismatch-repair gene mutations (MMR: hMHL1 and hMSH2) occurred with 17 and 8.6% frequency, respectively, while E2F4 mutations were even more frequent (21.4%) in HNCC. Our data suggest that E2F4 overexpression can be caused by the inactivation of the p16 gene in HNCC, while its mutations are most probably associated to the mutations of the MMR genes. These molecular informations can help to predict the biological potential of HNCC as well as the probability of the development of secondary HNCCs.
C1 [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Juhasz, Aliz] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Hargitai, Arpad] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, H-1122 Budapest, Hungary.
EM csuka@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 161
EP 167
PG 7
ER

PT J
AU Udvaros, I
   Szakall, Sz
   Oberna, F
   Polus, K
   Esik, O
   Tron, L
   Kasler, M
AF Udvaros, Istvan
   Szakall, Szabolcs
   Oberna, Ferenc
   Polus, Karoly
   Esik, Olga
   Tron, Lajos
   Kasler, Miklos
TI PET scanning in head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE positron emission tomography; head and neck cancer; staging
ID positron emission tomography; head and neck cancer; staging
AB INTRODUCTION: FDG (fluorine-labeled deoxy-glucose) and 11C-methionine positron emission tomography was evaluated in the diagnostics of head and neck cancer. PET scans were applied for identifying/staging relapse after oncotherapy or searching unknown primary tumor with metastatic lymph nodes of the neck.  METHODS: Retrospective analysis of 22 patients examined by 17 <sup>18</sup>FDG and 15 <sup>11</sup>C-methionine PET scan. In 9 cases indication was unknown primary tumor with positive neck, in 13 cases previously treated head and neck cancer patients were examined for recurrence/restaging.  RESULTS: In searching for unknown primary tumor not detectable with conventional methods, PET was effective in 22%, however, false positivity and uncertain results were found as well. In restaging PET proved to be very effective (85%) to discover recurrences and to differentiate them from post-treatment (mainly irradiation) effects. In two cases silent distant metastase were detected.  CONCLUSION: PET can provide valuable information about unknown primary tumors, recurrences after oncotherapy and distant metastases as well. Simultaneous use of FDG/methionine scans does not improve the results.
C1 [Udvaros, Istvan] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Szakall, Szabolcs] University of Debrecen, PET CenterDebrecen, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Esik, Olga] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Tron, Lajos] University of Debrecen, PET CenterDebrecen, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Udvaros, I (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM udwar@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 169
EP 172
PG 4
ER

PT J
AU Oberna, F
   Rethy, �
   Takacsi Nagy, Z
   Polus, K
   Kasler, M
AF Oberna, Ferenc
   Rethy, Agnes
   Takacsi Nagy, Zoltan
   Polus, Karoly
   Kasler, Miklos
TI Buccal flap reconstruction of oropharyngeal defects.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oral cancer; reconstruction surgery; buccal transposition flap
ID oral cancer; reconstruction surgery; buccal transposition flap
AB AIM: Introduction of a safe and reliable method for reconstruction of soft tissue defects after excision of T1-T2 and borderline carcinomas of the posterior part of the oral cavity and mesopharynx.  METHOD: Operation of two male patients suffering from tonsillolingual carcinoma, one with recurrent tumour after irradiation, the other with untreated primary and neck metastasis. After excision of the tumour with mandibular splitting method only a random buccal transposition flap was applied for reconstruction. The flap was adapted anatomically into the defect. It is a modification of previously described methods.  RESULTS: Both patients healed primarily with undisturbed blood circulation of the flap. The functional rehabilitation period was short, the flap tolerated the postoperative irradiation, a moderate trismus remained after completion of the treatment, but it was not attributable to the flap.  CONCLUSION: The use of the single buccal transposition flap for reconstruction of smaller defects of the posterior part of the oral cavity seems to be a simple, reliable and safe method even after irradiation. The key of the acceptable functional results is the correct adaptation of the flap
C1 [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Rethy, Agnes] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Oberna, F (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM obi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 173
EP 175
PG 3
ER

PT J
AU Fulop, M
   Remenar, �
   Oberna, F
   Boer, A
   Ivanyi, E
   Polus, K
   Kasler, M
AF Fulop, Miklos
   Remenar, Eva
   Oberna, Ferenc
   Boer, Andras
   Ivanyi, Emoke
   Polus, Karoly
   Kasler, Miklos
TI Radial forearm and fibula free flap reconstruction after radical resection of head and neck malignancies.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; reconstruction surgery; free flap transfer
ID head and neck cancer; reconstruction surgery; free flap transfer
AB The incidence of head and neck cancer has been rapidly increasing in Hungary during the last decade. Most of these tumors are discovered in advanced stage, consequently, surgical removal of the tumor results in large complex defects in the soft tisses and bone elements of the face and neck. For optimal anatomical and functional reconstruction we perform free flap transfer in increasing number of cases. Between December 1993 and March 2001 in the Head and Neck Surgery Department of the National Institute of Oncology the defects after resection of head and neck tumors were reconstructed with free flaps in 85 cases. Radial forearm flap in 64 cases, fibula osteoseptocutaneous flap in 14 cases were used. In 87% of the patients the postoperative period was uneventful, the surgical complications were not more numerous than following traditional reconstructions. The average duration of operations became shorter by 2.5 hours during the last two years than before. In most of the cases we achieved good functional and esthetic results. The quality of life of the patients was excellent in 14%, almost normal in 73% and bad with serious problems of social life in 13%. It is surprising that there was no significant difference between the survival of neck node positive and negative patients. In our practice the replacement of large defects in the head and neck region with free flaps is a reliable and useful method for reconstruction.
C1 [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Ivanyi, Emoke] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM fulop.m@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 177
EP 180
PG 4
ER

PT J
AU Petranyi, �
   Somogyi, A
   Glavak, Cs
   Takacsi Nagy, Z
   Antal, G
   Nemeth, Gy
AF Petranyi, Agota
   Somogyi, Andras
   Glavak, Csaba
   Takacsi Nagy, Zoltan
   Antal, Gergely
   Nemeth, Gyorgy
TI Importance of 3D conformal percutan and brachytherapy treatment planning based on CT and MRI examinations in treatment of oral cavity tumors.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oral cancer; CT; MRI; 3D planning; brachytherapy
ID oral cancer; CT; MRI; 3D planning; brachytherapy
AB AIM: The importance of 3D conformal percutan and brachytherapy treatment planning based on CT and MRI examinations in treatment of oral cavity tumors. Introducing of the planning procedure and the selection aspects.  METHOD: We present the treatment planning based on CT and MRI slices of an oral cavity tumor. The percutan or interstitial boost follow the percutan irradiation of the involved regions and lymph nodes, regarding to the target volume and the critical organs.  RESULT: Our ADAC 3D planning system gives us the possibility to add the first line and the boost treatment plans, to determine and compare the dose distribution within the planned target volume and the radiation load of the critical organs.  CONCLUSION: The comparative 3D radiation planning system allows higher local dose escalation required for the effective radiation treatment of oral cavity tumors with maximal protection of the surrounding healthy tissues.
C1 [Petranyi, Agota] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Glavak, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Antal, Gergely] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Petranyi, � (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM petrag@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 181
EP 185
PG 5
ER

PT J
AU Lengyel, E
   Forgacs, Gy
   Petranyi, �
   Baricza, K
   Somogyi, A
   Nemeth, Gy
AF Lengyel, Erzsebet
   Forgacs, Gyula
   Petranyi, Agota
   Baricza, Karoly
   Somogyi, Andras
   Nemeth, Gyorgy
TI Conformal radiotherapy of maxilla tumors.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE maxilla cancer; 3D planning; radiotherapy
ID maxilla cancer; 3D planning; radiotherapy
AB PURPOSE: To demonstrate a conventional and a new therapeutic method of 3D treatment planning in maxilla tumors, the process of 3D treatment planning and its significance and to compare these two methods.  METHOD: We performed 2D and 3D treatment plans. The ADAC planning system was used in the 3D treatment planning. CT and MRI scans were taken on the target volume and on each scan we demarcated the target volume and the critical organs. The irregular fields were obtained by 3D graphic reconstruction provided by the treatment planning programme.  RESULTS: Compared to the conventional treatment planning more favourable dose distribution was obtained within the target volume and the radiation burden of the critical organs was kept under their tolerance doses.  CONCLUSION: In conformal 3D treatment planning the shape and size of the irradiated volume are in good conformity with those of the target volume. In this way the radiation burden of the critical organs and adjacent intact tissues can be reduced.
C1 [Lengyel, Erzsebet] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Forgacs, Gyula] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Petranyi, Agota] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Lengyel, E (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM pepe@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 187
EP 191
PG 5
ER

PT J
AU Takacsi Nagy, Z
   Oberna, F
   Somogyi, A
   Major, T
   Nemeth, Gy
AF Takacsi Nagy, Zoltan
   Oberna, Ferenc
   Somogyi, Andras
   Major, Tibor
   Nemeth, Gyorgy
TI Modern radiotherapy techniques in the treatment of tumour of the base of tongue.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tongue cancer; 3D brachytherapy; percutan radiotherapy
ID tongue cancer; 3D brachytherapy; percutan radiotherapy
AB AIM: To demonstrate the role, the execution and the importance of the computed tomography (CT) based three-dimensional brachytherapy and conformal percutan radiotherapy in the treatment of the advanced tumour of the base of tongue.  METHODS: Between January 1993 and June 2000, 27 patients with stage III-IV squamous cell cancers of the base of tongue were treated after 60 Gy percutan irradiation with interstitial, high dose rate brachytherapy (23 patients) or conformal, multi-fields radiotherapy (4 patients) as a boost. The dose of the boost irradiation varied between 12 and 24 Gy.  RESULTS: Boost irradiation was well tolerated by the patients. The local tumour control at the mean follow-up period (39 months) was 52%. Using this two treatment methods in case of percutan conformal irradiation 6%, in case of brachytherapy 1.5% of the mandible received the prescribed boost dose. The spinal cord received a maximum of 15%, and 8% of the boost dose, respectively, depending on the two treatment types.  CONCLUSION: With the help of these two radiotherapeutic modalities locally higher cumulative dose and better tumour control can be achieved without the higher risk of radiation injury of the surrounding normal tissues and the two most critical organs (medulla, mandible).
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM takacsi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 193
EP 196
PG 4
ER

PT J
AU Koltai, P
   Remenar, �
   Boer, A
   Fulop, M
   Koltai, L
   Oberna, F
   Udvaros, I
   Polus, K
   Kasler, M
AF Koltai, Pal
   Remenar, Eva
   Boer, Andras
   Fulop, Miklos
   Koltai, Laszlo
   Oberna, Ferenc
   Udvaros, Istvan
   Polus, Karoly
   Kasler, Miklos
TI Neoadjuvant chemotherapy in head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; neoadjuvant chemotherapy; Cisplatin; 5-FU; quality of life
ID head and neck cancer; neoadjuvant chemotherapy; Cisplatin; 5-FU; quality of life
AB BACKGROUND: Neoadjuvant chemotherapy has an increasing role in multimodality treatment of advanced head and neck cancer. In this paper we summarize our first results with this treatment.  METHOD: Thirty-five, previously untreated, mostly inoperable head and neck cancer patients were given two cycles of Cisplatin and 5FU chemotherapy. We continued the therapy only in case of regression until four cycles, then the patients received surgical and/or radiotherapy according to their status. After the treatment patients’ status was regularly evaluated.  RESULTS: We detected 4 complete and 20 partial responses after the chemotherapy. Three patients became eligible for a radical operation. At this moment 10 patients are free of tumor, 8 patients died in consequence of the tumor, we have no data in 3 cases, 3 patients are given palliative therapy because of progression, 4 patients are receiving radiotherapy and 7 patients with partial response are candidates for further active oncotherapy.  CONCLUSIONS: Although the number of the patients we treated is too small for a statistical analysis, our results are similar to the conclusion of the large randomized studies: after neoadjuvant chemotherapy of advanced head and neck cancer partial response can improve the result of surgical or radiological treatment. Neoadjuvant chemotherapy does not improve survival in advanced head and neck cancer, but it is of great importance because of better quality of life of patients, especially those who had organ preserving therapy.
C1 [Koltai, Pal] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Koltai, Laszlo] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Udvaros, Istvan] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Koltai, P (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM koltaip@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 197
EP 199
PG 3
ER

PT J
AU Lovey, J
   Koronczay, K
   Remenar, �
   Csuka, O
   Nemeth, Gy
AF Lovey, Jozsef
   Koronczay, Krisztina
   Remenar, Eva
   Csuka, Orsolya
   Nemeth, Gyorgy
TI Low-dose Taxol radiosensitization in locally advanced head and neck cancers.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; chemo-radiotherapy; taxol; irradiation; response rate
ID head and neck cancer; chemo-radiotherapy; taxol; irradiation; response rate
AB INTRODUCTION: Combined modality treatment with chemotherapy and radiotherapy in locally advanced head and neck cancers is an effective and often the only treatment with a chance of cure. An alternative is to use chemotherapeutic agents at low doses as radiosensitizers. In this study we examined the radiosensitizing effect of low dose Taxol in locally advanced head and neck cancer. Patients and methods: 26 patients with locally advanced squamous cell carcinoma of the oral cavity and the oropharynx were treated with external beam radiotherapy up to doses of 66-70 Gy and received concomitantly 2 mg/m<sup>2</sup> Taxol intravenously three times a week. Response rates according to WHO criteria, side effects according to the National Cancer Institute Common Toxicity Criteria, overall and progression-free survival were evaluated.  RESULTS: All patients completed the therapy. Median radiation dose was 66 Gy, Taxol dose 40 mg/m<sup>2</sup> and treatment duration 54 days. 8 weeks after completion of therapy complete response was 30.8%, partial response 34.6%, stable disease 11.5% and progressive disease 23.1%. The median follow-up time was 25 months (9-36). At the cloes- out date 12 (46,1%) of the patients were alive, 9 without evidence of disease. The estimated median overall survival was 22 months (CI 14.2-34.6), the median progression-free survival 12 months (CI 5.2-18.8). We observed four grade 4, fourteen grade 3 and numerous grade 1-2 side effects. There was no treatment related death.  DISCUSSION: Our regimen resulted in a worse response rate than the aggressive chemoradiation protocols treating the same disease. However, the two-year survival was comparable with the results of other studies. The advantages of our schedule are that it is well tolerated, easy to perform on an outpatient basis, resource effective and does not deteriorate the general condition of the patients, therefore successive therapy can be carried out immediately if necessary. We intend to evaluate the effectivity of this treatment in a study comparing radiotherapy with Taxol sensitization versus radiotherapy alone.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Koronczay, Krisztina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 201
EP 206
PG 6
ER

PT J
AU Remenar, �
   Lovey, J
   Koronczay, K
   Csuka, O
   Nemeth, Gy
AF Remenar, Eva
   Lovey, Jozsef
   Koronczay, Krisztina
   Csuka, Orsolya
   Nemeth, Gyorgy
TI Combined modality treatment of locally advanced oral and oropharyngeal cancer following primary radiotherapy with and without taxol radiosenzitization.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oro-pharyngeal cancer; chemo-radiotherapy; low dose taxol
ID oro-pharyngeal cancer; chemo-radiotherapy; low dose taxol
AB AIM: To determine the effect of radiosensitization with Taxol and multimodality treatments on the survival of advanced oral and oropharyngeal cancer. Patients, methods: 56 patients with St. III-IV oral or oropharyngeal cancer were treated with external beam radiotherapy; 26 of them were sensitized by low-dose paxlitaxel and 30 were irradiated traditionally. The median follow up was 23 months (17-36). Endpoints of the study were: response to radiotherapy, progression-free and overall survival and the results of surgery and chemotherapy following radiation.  RESULTS: 73.3% (41/56) of treatments resulted in CR or PR with median 10 months (0-33) progression-free and 14 months (4-33) overall survival. There was no significant difference between the radiosensitized and traditional radiotherapy group (p=0.6). The survival was significantly influenced by the stage of tumor and the response to primary radiotherapy. Seven (38.9%) of 16 patients treated also by either surgery or chemotherapy for recurrent or residual disease are free of cancer, 6 (35%) alive with tumor and 5 (26.1%) died with median survivals of 21, 20.5 and 18 months, respectively. Those treated only with radiotherapy with or without sensitization are free of cancer in 31.6%, alive with cancer 5.3%, died 63.2%.  CONCLUSION: There were significant correlation between tumor stage, response to radiotherapy and combined modality treatment, and surival. The radiosensitizing effect of Taxol was not obvious so far, it may be apparent in the future by analyzing the long term survival data.
C1 [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Koronczay, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM reva@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2001
VL 45
IS 2
BP 207
EP 244
PG 38
ER

PT J
AU Naszaly, A
   Patonay, P
AF Naszaly, Attila
   Patonay, Peter
TI Biological basis of radiochemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tumor biology; radiobiology; chemo-radiotherapy
ID tumor biology; radiobiology; chemo-radiotherapy
AB The tumor biological and radiobiological aspects, the mechanism of actions and general considerations of clinical application of radiochemotherapy are discussed. The aims of radiochemotherapy are to prolong the patient's survival by improving local tumor control and decreasing distant metastases. The goal of radiochemotherapy is to enhance the therapeutic effect of radiation with tolerable and controllable local and systemic side effects. The mechanism of action of the most frequently used drugs are also discussed.
C1 [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Naszaly, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 323
EP 326
PG 4
ER

PT J
AU Patyanik, M
   Mayer, �
   Poti, Zs
AF Patyanik, Mihaly
   Mayer, Arpad
   Poti, Zsuzsa
TI Radio-chemotherapy of locally advanced head and neck cancer, providing tissue and organ protection
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; chemoradiotherapy; Amifostine; Carboplatine; irradiation
ID head and neck cancer; chemoradiotherapy; Amifostine; Carboplatine; irradiation
AB PURPOSE: the study of the effect of Amifostine in reducing acute mucositis, xerostomia and late xerostomia emerging in the course of locally advanced head and neck cancer radio-chemotherapy. METHODS: Starting in 1999 we have conducted radio-chemotherapy treatment on 7 patients with or without Amifostine protection, each receiving 60 Gy (2 Gy a day/5 fractions a week) loco-regional irradiation. From the first to the fifth day and from the twenty-first to the twenty-fifth day prior to irradiation they were given a 70 mg/m<sup>2</sup> Carboplatin treatment. In the Amifostine group, on days 1-5 and 21-25 300 mg/m<sup>2</sup> and on days 6-20 and 26-30 200 mg/m<sup>2</sup> Amifostine therapy was given prior to the radio- and chemotherapy.  RESULTS: In the course of the trial we did not find any haematologic side effects, or side effects directly connected to the Amifostine, which would have required suspension of the therapy. In the active phase, mucositis of Grade 1-2 was detected 1-2 weeks later than in the control group, in contrast to the mucositis of Grade 2-3 in the other arm. Global oral discomfort associated with acute xerostomia was of Grade 4-6 on a linear scale of ten, compared with Grade 7-8 on the active line. We had similar results when testing the symptoms directly connected with late xerostomia. Unstimulated and stimulated saliva production doubled following the Amifostine treatment.  CONCLUSION: Despite the small pool of patients we have the impression that Amifostine can effectively reduce the severity of acute mucositis, xerostomia and late xerostomia.
C1 [Patyanik, Mihaly] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Patyanik, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 327
EP 330
PG 4
ER

PT J
AU Takacsi Nagy, L
   Paczelt, F
   Patyanik, M
   Mayer, �
AF Takacsi Nagy, Laszlo
   Paczelt, Ferenc
   Patyanik, Mihaly
   Mayer, Arpad
TI Radiochemotherapy of bladder cancer with/without tissue-organ protection.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE bladder cancer; cisplatin; carboplatin; irradiation
ID bladder cancer; cisplatin; carboplatin; irradiation
AB The authors report the results of radiochemotherapy for bladder cancer, both advanced and early with a poor prognosis, on the basis of their own material as well as based on the literature. More than half of the patients received radioprotective madication at the same time. The short follow-up does not allow for far-reaching conclusions, but early results and limited complications appear hopeful. The authors emphasise that, if indicated, radiochemotherapy can serve as an alternative to cystectomy.
C1 [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Paczelt, Ferenc] Budapesti MAV Korhaz, Urologiai OsztalyBudapest, Hungary.
   [Patyanik, Mihaly] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Takacsi Nagy, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 331
EP 333
PG 3
ER

PT J
AU Pesznyak, Cs
   Lovey, K
   Weisz, Cs
   Polgar, I
   Mayer, �
AF Pesznyak, Csilla
   Lovey, Katalin
   Weisz, Csaba
   Polgar, Istvan
   Mayer, Arpad
TI Electronic portal imaging (EPI) on linear accelerator
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE electronic portal imaging; portal film; error correction
ID electronic portal imaging; portal film; error correction
AB The EPI has become available recently in the Oncoradiological Centre of Budapest. The purpose of this paper is to review the construction and operation of the electronic portal imaging devices (EPIDs). The different EPID systems as well the EPID technique vs. portal films are compared. The advantages in patient set-up and the detection of the set-up errors are discussed. The use of the EPID technique in the clinical everyday practice is detailed. Recommendations of the set-up error correction for the most often occurring failures is given.
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Lovey, Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Weisz, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Polgar, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 335
EP 341
PG 7
ER

PT J
AU Varga, Sz
   Takacsi Nagy, L
   Pesznyak, Cs
   Lovey, K
   Polgar, I
AF Varga, Szilvia
   Takacsi Nagy, Laszlo
   Pesznyak, Csilla
   Lovey, Katalin
   Polgar, Istvan
TI Field matching in breast irradiation.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast cancer; 3D planning; multi-leaf collimator; intensity modulated radiotherapy
ID breast cancer; 3D planning; multi-leaf collimator; intensity modulated radiotherapy
AB INTRODUCTION: In this paper the authors have combined different irradiation techniques for breast and adjacent supraclavicular lymph nodes. The aim was to reduce inhomogeneity in the match-line.  METHODS: The CadPlan 6.1.5 three-dimensional treatment planning system was applied in this study for CT based plan using a standard medial and lateral wedged tangential breast portals with the adjacent supraclavicular field. Isocenter is placed at depth on the match-line, where asymmetric jaws are used to produce non-divergent field edges. The tangential fields are shaped using multi-leaf collimator (MLC), by following the curvature of the thorax. In this way the cranial vertical match plane is maintaned without using the breast board. The prescribed dose was 50 Gy at the isocentre.  RESULTS: The calculated dose distributions were evaluated in three dimension in the match region of supraclavicular field and the two opposing tangential fields. This method produces a more uniform dose distribution in the target volume and in the match-line. Set-up is fast, this is done without the need for table rotation, or vertical cephalad blocks. The average dose to the ipsilateral lung is reduced using the IMRT (intensity modulated radiotherapy) technique by approximately 10% compared with the conventional technique. Furthermore, this new technique has the possibility to improve the field match between the tangential fields and the parasternal field, while maintaning the field match between the tangential fields and the axillary and supraclavicular fields.
C1 [Varga, Szilvia] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Lovey, Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Polgar, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Varga, Sz (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 343
EP 346
PG 4
ER

PT J
AU Mayer, �
   Patyanik, M
   Kegye, A
   Meszaros, E
AF Mayer, Arpad
   Patyanik, Mihaly
   Kegye, Adrienne
   Meszaros, Edina
TI Preoperative radiation therapy for rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE rectal cancer; preoperative and postoperative radiation; local failure; disease-free survival
ID rectal cancer; preoperative and postoperative radiation; local failure; disease-free survival
AB PURPOSE: Comparison of the effectiveness of preoperative and ''sandwich'' (preoperative and postoperative) radiation therapy in the treatment of midrectum and lower rectum carcinoma, based on a prospective clinical trial.  MATERIAL AND METHOD: Over the period between 1990 and 1997, we treated 115 patients suffering from mid-rectum and lower rectum carcinoma at the Budapest Oncoradiological Centre, using sandwich therapy (22.5 Gy preoperative-27.5 Gy postoperative) in the case of 36 patients and 36 Gy preoperative radiation therapy in the case of 79 patients with external-beam megavoltage therapy with mostly telecobalt radiation and to a smaller number of cases 6 MV energy. The external-beam radiation therapy was nearly always applied with a 4-field box technique, and radical surgery was performed within 10 days following the preoperative radiation treatment. Effectiveness was evaluated in terms of a Log-Rank and Peto-Wilcoxon tests and the Kaplan-Meier survival curve.  RESULTS: The effectiveness of the different therapies was compared in terms of the percentage of local failure and the rate of disease-free survival. The results show that when using the ''sandwich'' radiation therapy local failure is expected to occur in 13.8% of all cases, compared with 17.7%, when only preoperative radiation therapy is used. In terms of five-year disease-free survival, the sandwich therapy seems to be better, but for a higher number of years, namely 7.5, the preoperative radiation therapy yielded better results.  CONCLUSION: In terms of local failure, the effectiveness of the preoperative and the ''sandwich'' radiation therapies for the treatment of mid-rectum and lower rectum carcinoma was nearly identical, while preoperative radiation therapy provided longer disease-free survival. Further trials using multivariation analysis need to be performed to evaluate the two types of radiation treatments, taking into account other parameters, such as grading, age and lymphatic spread.
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Patyanik, Mihaly] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Kegye, Adrienne] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
EM mayera@elender.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 347
EP 351
PG 5
ER

PT J
AU Landherr, L
   Nagykalnai, T
   Klinko, T
AF Landherr, Laszlo
   Nagykalnai, Tamas
   Klinko, Timea
TI Radiotherapy of benign disorders
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bening tumors; radiation therapy; complications
ID bening tumors; radiation therapy; complications
AB The radiation oncologist's primary concern is treatment of patients with malignant tumors but sometimes faces on occasion rare, non malignant disorders. The scarcity of disease incidence is reflected by the paucity of references for these diseases in the literature. This minimal exchange of information may make research and analysis difficult, tedious and not easily directed. Even with recognition of the risks of late skin injury, carcinogenesis, leukemogenesis and genetic damage from all ionizing radiation, radiation therapy also continues to be accepted treatment for benign diseases that do not respond to other methods of therapy. The purpose of this paper is to provide a short overview of the radiotherapy of most frequent benign disorders.
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1145 Budapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1145 Budapest, Hungary.
EM landherr@axelero.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 353
EP 358
PG 6
ER

PT J
AU Polgar, Cs
   Fodor, J
   Nemeth, Gy
AF Polgar, Csaba
   Fodor, Janos
   Nemeth, Gyorgy
TI Radiotherapy of early breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE eary stage brest cancer; mastectomy; conservative surgery; radiotherapy
ID eary stage brest cancer; mastectomy; conservative surgery; radiotherapy
AB The authors review the value of radiotherapy in the multidisciplinary treatment of early (stage 0-II) breast cancer and describe past achievements, current scientific evidences and possible future prospects of clinical research. Results of randomized studies proved that conservative surgery with radiotherapy is equally effective to mastectomy for the treatment of in situ and invasive breast cancer, both in terms of local control and overall survival. In the nineties, findings of prospective clinical trials indicate that the use of irradiation in high-risk patients provides both a significant improvement in loco-regional control and survival rate. The magnitude of survival benefit with appropriate patient selection and radiotherapy technique is similar to that seen with adjuvant systemic therapy. Radiotherapy of early breast cancer is based on level I scientific evidences in the vast majority of cases. Remaining controversial issues are subjects of several ongoing international and Hungarian prospective randomized studies.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 4
BP 361
EP 371
PG 11
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI Chemoprevention of breast cancer - with special interest of tamoxifen
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tamoxifen; breast cancer; chemoprevention
ID tamoxifen; breast cancer; chemoprevention
AB The adjuvant use of tamoxifen confers a survival advantage for patients with node-positive and node-negative breast cancer and demonstrated benefit when used alone or in combination with chemotherapy to treat advanced breast cancer.Tamoxifen prevents induced mammary cancer in rats, decreases the contralateral breast cancer incidence in humans, and its safety record in clinical practice is excellent. This finding led to the concept that the drug might play role in breast cancer prevention. In 1986 at the Royal Marsden Hospital a small pilot study was started, which would serve as a feasibility assessment for a larger trial to determine if tamoxifen prevents breast cancer. The trial shows no effect, because the study is too small for accurate results. Similarly, in another tamoxifen prevention study performed in Italy, the incidence of breast cancer did not differ between groups of tamoxifen and placebo. The negative finding of the study is readily explained by the relatively low risk of breast cancer development in the study population, the high drop-out rate and the small number of women who completed 5 years of treatment. In the NSABP P-1 prevention trial tamoxifen reduced the risk of invasive breast cancer by 49% and of noninvasive breast cancer by 50% in the increased risk population of 13.388 healthy women. The article summarizes the recent theoretical and practical data of the chemoprevention of breast cancer.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., H-1122 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, H-1122 Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 377
EP 383
PG 7
ER

PT J
AU Polgar, Cs
   Fodor, J
   Orosz, Zs
   Major, T
   Mangel, L
   Takacsi-Nagy, Z
   Sulyok, Z
   Somogyi, A
   Toth, J
   Koves, I
   Kasler, M
   Nemeth, Gy
AF Polgar, Csaba
   Fodor, Janos
   Orosz, Zsolt
   Major, Tibor
   Mangel, Laszlo
   Takacsi-Nagy, Zoltan
   Sulyok, Zoltan
   Somogyi, Andras
   Toth, Jozsef
   Koves, Istvan
   Kasler, Miklos
   Nemeth, Gyorgy
TI The effect of tumour bed boost on local control after breast conserving surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast cancer; tumor bed; boost irradiation; local recurrence; clinical trial
ID breast cancer; tumor bed; boost irradiation; local recurrence; clinical trial
AB PURPOSE: To evaluate the effect of tumour bed boost on local tumour control (LTC) after breast conserving surgery in a prospective study.  METHODS: Between 1995 and 1998, 207 women with early invasive breast cancer who underwent conservative operation were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either no further radiotherapy (n=103) or a boost to the tumour bed (n=104) with either 16 Gy electron (n=52) or 12–14.25 Gy high dose rate brachytherapy (n=52).  RESULTS: At a median follow-up of 4.25 years the crude rate of local recurrence was 6.7% with and 13.6% without boost. The respective rates of tumour bed relapse were 3.8% vs. 10.7%. The 4 year probability of LTC, relapse-free survival and breast cancer-specific survival was 94.2% vs. 85.1% (p=0.1176), 82.3% vs. 67.2% (p=0.0438) and 84.8% vs. 90.9% (p=0.1111), respectively, in favour of the boost group. Systemic treatments had no significant impact on LTC (88.9% with and 89.6% without systemic treatment, p=0.8858).  CONCLUSION: Tumour bed boost decreased the incidence of local and tumor bed relapses with a reduction of 50% and 64%, respectively. Relapse-free survival was improved significantly with boost. However, the influence of boost treatment on breast cancer-specific survival should be tested in further studies. In spite of the higher incidence of late radiation side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. The final results of the EORTC trial and other ongoing studies will help to clarify the indication of boost dose according to prognostic subgroups.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Mangel, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kasler, Miklos] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 385
EP 391
PG 7
ER

PT J
AU Demeter, A
   Szirmai, K
   Sipos, N
   Balega, J
   Szantho, A
   Papp, Z
AF Demeter, Attila
   Szirmai, Katalin
   Sipos, Norbert
   Balega, Janos
   Szantho, Andras
   Papp, Zoltan
TI Ovarian carcinoma of low malignant potential treated at the 1st Department of Obstetrics and Gynecology Semmelweis University Faculty of Medicine, between 1990 and 2000
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE ovarian cancer; low malignant potential; therapy; follow up
ID ovarian cancer; low malignant potential; therapy; follow up
AB The authors analyzed the epidemiologic and histological characteristics and the management of ovarian carcinoma of low malignant potential (LMP) at a university hospital between 1990 and 2000. The authors carried out a retrospective study reviewing hospital charts. Based on the records experience with 29 such tumors is peresented. Of these 20 (74%) were of the serous variety, 7 (26%) were mucinous. LMP tumors accounted for 16% of proliferating epithelial ovarian tumors. They occured at a mean age of 45 years. The LMP tumors were bilateral in 12% of the cases. The majority of patients (87%) with LMP tumors presented with early stage disease. Tumor markers such as CA-125 were not always elevated as in invasive ovarian carcinoma. Laboratory investigations have not demonstrated that these tumors represent an intermediate step between benign ovarian tumors and carcinoma. The recommended therapy is surgical, consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and tumor debulking. Conservative surgery consisting of unilateral salpingo-oophorectomy is considered to be an appropriate treatment for young women with early stage LMP ovarian tumors who wish to retain their fertility potential. 50 percent of women who underwent conservative surgery subsequently conceived in this study. There were no recurrences in the study group, so the authors conclude that the long term outcome of LMP tumors is extremely favorable.
C1 [Demeter, Attila] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
   [Szirmai, Katalin] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
   [Sipos, Norbert] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
   [Balega, Janos] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
   [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
   [Papp, Zoltan] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., H-1088 Budapest, Hungary.
RP Demeter, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, H-1088 Budapest, Hungary.
EM demeter@noi1.sote.hu
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 393
EP 396
PG 4
ER

PT J
AU Kovacs, G
   Muller, J
   Borgulya, G
   Koos, R
   Magyar Gyermekonkologiai Halozat, 
AF Kovacs, Gabor
   Muller, Judit
   Borgulya, Gabor
   Koos, Rozalia
   Magyar Gyermekonkologiai Halozat, 
TI Treatment results of childhood Hodgkin’s lymphoma in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hodgkin disease; childhood; incidence; Hungary; chemotherapy
ID Hodgkin disease; childhood; incidence; Hungary; chemotherapy
AB Lymphomas are the third most frequent malignancies in childhood. The Hungarian Pediatric Oncology Group was founded in 1971, and since then the same chemotherapeutic protocols have been used in the whole country. In this study we analyzed the data of childhood Hodgkin’s lymphoma in Hungary in the last 11 years (1988-1998). We also compared our results with the international (German) data. The incidence of Hodgkin’s lymphoma (0-15 years) was 7.1/1,000,000 child/year (the same for non-Hodgkin’s lymphoma was 7.5/1,000,000/year); 5.5% of all pediatric malignancies in Hungary). The patients were treated according to the German DAL-HD-82 and 90 protocols. The therapy consisted of 2-6 cytostatic blocks, depending on the stage, followed by involved field irradiation. The overall survival was 94.7±2.0% at 5 years and 91.9±2.7% at 10 years. These results are very similar to the German data: 94% at 5 years and 93% at 10 years. The good results are due to the well organised network and the uniformed treatment. The results may be ameliorated by using autologous bone marrow transplantation.
C1 [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H-1094 Budapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H-1094 Budapest, Hungary.
   [Borgulya, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H-1094 Budapest, Hungary.
   [Koos, Rozalia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H-1094 Budapest, Hungary.
   [Magyar Gyermekonkologiai Halozat, ] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., H-1094 Budapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, H-1094 Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 397
EP 401
PG 5
ER

PT J
AU Marazi, L
   Szanto, J
   Szota, J
AF Marazi, Laszlo
   Szanto, Janos
   Szota, Judit
TI The role of irinotecan in the treatment of advanced colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE advanced colorectal cancer; irinotecan; side effects
ID advanced colorectal cancer; irinotecan; side effects
AB PURPOSE: The purpose of the study was the evaluation of efficacy and the side effects of irinotecan in treatment of advanced colorectal cancer.  METHODS: The authors presented their experiences with irinotecan in the treatment of 10 patients suffering from advanced colorectal cancer. The dose of irinotecan was 350 mg/m<sup>2</sup> every 21 days. Seven out of ten patients have taken oral fluoroquinolon to investigate its effect on the incidence of febrile episodes in case of febrile neutropenia. Three out of ten patients did not receive any antibiotic. The authors have examined the efficacy and safety of the treatment.  RESULTS: One complete remission was obtained. Authors describe the observed side effects and the administered supportive care against serious complications.  DISCUSSION: Serious diarrhoea has not been found in case of these 10 patients. The diarrhoea caused by irinotecan can be stopped by loperamide. The authors give accounts of early and following results.
C1 [Marazi, Laszlo] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Szentpeteri kapu 72-76., 3526 Miskolc, Hungary.
   [Szanto, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Szentpeteri kapu 72-76., 3526 Miskolc, Hungary.
   [Szota, Judit] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Szentpeteri kapu 72-76., 3526 Miskolc, Hungary.
RP Marazi, L (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, 3526 Miskolc, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 403
EP 405
PG 3
ER

PT J
AU Pap, L
   Kocsis, B
   Szekely, G
   Nemeth, Gy
AF Pap, Lilla
   Kocsis, Bela
   Szekely, Gabor
   Nemeth, Gyorgy
TI Radiotherapy of childhood brain stem tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE brain stem tumors; radiation therapy; 3D planning; hyperfractionation
ID brain stem tumors; radiation therapy; 3D planning; hyperfractionation
AB STUDY OBJECTIVE: Description and evaluation of radiotherapy of inoperable brain stem tumours. Possibilities of improving therapeutic results.  MATERIALS AND METHODS: Between 1987 and 2000 43 patients (23 boys and 20 girls, mean age 8.5±4.4 years) with brain stem tumours were treated with 6 MV and 9 MV X-ray. The doses administered ranged from 30 to 66 Gy; mean 50.41±7.67 Gy. Treatment in each case was performed according to CT- and /or MR-based radiotherapy plan. Since 2000 3D conformal radiotherapy plans have been prepared by using image fusion.  RESULTS: All patients were followed. The mean follow-up period was 19.4 months (range: 1 to 112 months). For survival statistics the 2 to 3-year overall and symptom-free survivals were taken into account, the former ones in the function of tumour localisations. The gender of children did not affect the survival (p>0.74). No significant difference was found as to survival in the function of tumour localisation either (p>0.87).  CONCLUSION: According to the literature data the results expected were not achieved by hyperfractionation and by delivering an overall focal dose of 72 to 78 Gy. Results can be improved by precise patient fixation and the routine application of 3D conformal radiotherapy plans prepared by CT- and MR-based image fusion. These together can result the correctly reproducible patient fixation, the homogenous radiation delivery in the target volume and the reduction of injury in the surrounding tissues. Irradiation should be performed also in histologically not verified tumours since a 24.6 month transitory improvement could be achieved in 60.5% of our patients.
C1 [Pap, Lilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Kocsis, Bela] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Pap, L (reprint author), National Institute of Oncology, Center of Radiotherapy, H-1122 Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 407
EP 410
PG 4
ER

PT J
AU Illes, �
   Gergely, L
   Andras, Cs
   Miltenyi, Zs
   Szegedi, Gy
AF Illes, Arpad
   Gergely, Lajos
   Andras, Csilla
   Miltenyi, Zsofia
   Szegedi, Gyula
TI Hypothyroidism in Hodgkin’s disease patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hodgkin lymphoma; therapy; hypothyreoidism
ID Hodgkin lymphoma; therapy; hypothyreoidism
AB PURPOSE: Study of thyroid function in Hodgkin’s disease patients in complete remission.  PATIENTS AND METHODS: We examined the thyroid function of 160 Hodgkin’s disease patients in complete remission for at least one year, and determined the values of supersensitive thyroid stimulating hormone (sTSH), free T4 (fT4), free T3 (fT3) hormones.  RESULTS: Normal values were observed in 117 patients, subclinical change (only elevated sTSH) in 28 patients, clinical hypothyroidism in 14 patients (also low fT4 and/or fT3), hyperthyroidism (Basedow’s disease) in one patient. Hypothyroidism was one and a half times more frequent in females than in males. The normal and low thyroid function group did not differ from each other in mean age, histological subtypes, disease stage, general symptoms, and whether lymphangiography was performed. Hypothyroidism was more frequent in patients who had undergone mantle or neck radiotherapy. The onset of thyroid gland underfunction was more pronounced from six years after neck radiotherapy. The thyroid disease could be controlled using a daily dose of 25–225 mg levothyroxin.  CONCLUSIONS: During the care of Hodgkin’s disease patients routine examination of the thyroid function is important for the early recognition and prevention of treatment related late complications. On the other hand in treatment planning phase more attention should be paid to thyroid gland protection when neck radiotherapy is used.
C1 [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., H-4004 Debrecen, Hungary.
   [Gergely, Lajos] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., H-4004 Debrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., H-4004 Debrecen, Hungary.
   [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., H-4004 Debrecen, Hungary.
   [Szegedi, Gyula] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., H-4004 Debrecen, Hungary.
RP Illes, � (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, H-4004 Debrecen, Hungary.
EM illes@iiibel.dote.hu
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 411
EP 415
PG 5
ER

PT J
AU Geczi, L
   Gomez, F
   Bak, M
   Bodrogi, I
AF Geczi, Lajos
   Gomez, Frederic
   Bak, Mihaly
   Bodrogi, Istvan
TI Bilateral germ cell testicular tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE germ cell testicular tumors; bilateral occurrence; synchronous and asynchronous testicular cancer
ID germ cell testicular tumors; bilateral occurrence; synchronous and asynchronous testicular cancer
AB PURPOSE: To study the clinical characteristics of bilateral testicular tumors in the cisplatin era.  PATIENTS AND METHODS: Between November 1988 and November 1998 2386 testicular cancer patients were treated in our Department and 72 bilateral germ cell testicular cancer patients were retrospectively explored (3%). The incidence, the clinical and histological characteristics and, in the case of asynchronous tumor, the interval between the two tumors were analyzed.  RESULTS: During the 10 years 19 synchronous (26.4%) and 53 asynchronous bilateral germ cell testicular cancers (73.6%) were treated. The incidence of bilateral synchronous seminoma was 68.4%. Among the asynchronous tumors 9 concordant seminomas and 9 concordant nonseminomas were detected. In the first, second and third 5-year follow-up period 39.6, 30.2, and 28.2% of asynchronous tumors were diagnosed. The incidence of seminoma after the first castration in the 5, 10 and 15 years was 19, 37.5, and 60%, respectively. The overall survival rates of synchronous and asynchronous testicular cancer were 84 and 93%. In cases of asynchronous tumor the prevalence of stage I cancer was significantly greater in a regularly controlled population (p=0.014) than in the not regularly followed population, but the survival rate was good in both groups. Nonseminoma showed up earlier as first and second tumor than seminoma (p=0.05, p=0.045). The interval between the two asynchronous tumors was shorter in the case of nonseminoma than in the case of seminoma (p=0.002).  CONCLUSION: The prognosis of bilateral germ cell testicular cancer is good because of the high incidence rate of seminoma and the effective treatment. With regular follow-up the early diagnosis of second testicular tumors is probable. The interval between the tumors depends on the patients’ age and the histology of the second tumor, in the case of seminoma it is longer. The effect of the previous treatment on the incidence of seminoma and the interval between the two asynchronous tumors requires further investigations.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Gomez, Frederic] Centre Regional Leon BerardLyon, France.
   [Bak, Mihaly] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., H-1122 Budapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, H-1122 Budapest, Hungary.
EM gelajos@oncol.hu
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 417
EP 423
PG 7
ER

PT J
AU Varkondi, E
   Gyori, F
   Nagy, A
   Kiss, I
   Ember, I
   Kozma, L
AF Varkondi, Edit
   Gyori, Ferenc
   Nagy, Andras
   Kiss, Istvan
   Ember, Istvan
   Kozma, Laszlo
TI Investigation of oncogene amplification or deletion, and oncoprotein expression in papillary thyroid cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE papillary thyroid cancer; p53; cyclin D1; p21; Ha-ras; dot-blot hybridization; prognosis
ID papillary thyroid cancer; p53; cyclin D1; p21; Ha-ras; dot-blot hybridization; prognosis
AB AIM: Assessment of occurrence and possible prognostic significance of c-myc and Ha-ras amplification, p53 deletion and overexpression of cyclin D1, p53 and p21 in papillary thyroid cancer.  MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded tumor tissue from 24 patients were investigated. Dot-blot DNA hybridization was used to detect oncogene amplification or deletion. The expression of oncoproteins was determined by immunohistochemical method.  RESULTS: In our samples neither Ha-ras amplification nor p53 deletion were found. Low c-myc amplification (mean: 2.55) occured in 4 cases (17%). p53 protein was detected in 16 samples (66.6%), with p21 expression (chi<sup>2</sup>=7.02, p<0.01) in 6 cases (25%). The p53 expression did not influence the tumor fenotype. Cyclin D1 overexpression was found in 12 cases (50%), it was often associated with p21 expression (chi2=10.1, p<0.001) and in inverse relation to the tumor lymphocytic infiltration (chi<sup>2</sup>=5.35, p<0.05). Increased expression of estrogen receptor was shown in 4 cyclin D1 positive samples (17%).  CONCLUSIONS: The p53 detected in our study is likely not to be mutant protein in all cases because its presence was associated with p21 expression that the mutant protein cannot induce and also it did not mean more aggressive tumor phenotype. The connection of cyclin D1 overexpression with the lymphocytic infiltration of the tumor suggests that the increased expression of cyclin D1 means poor prognosis. The coexpression of cyclin D1 and p21 raises the modulative character of the p21 protein, thought to be a tumor suppressor originally, but we find a CDK-independent, estrogen receptor mediated effect of cyclin D1 more likely, which has been described in breast cancer and is also proved by the coexpression of cyclin D1 and estrogen receptor detected here.
C1 [Varkondi, Edit] University of Debrecen, Faculty of Medicine, Department of Pathology, 4012 Debrecen, Hungary.
   [Gyori, Ferenc] University of Pecs, Department of SurgeryPecs, Hungary.
   [Nagy, Andras] University of Debrecen, Faculty of Medicine, Department of Pathology, 4012 Debrecen, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Kozma, Laszlo] University of Debrecen, Faculty of Medicine, Department of Pathology, 4012 Debrecen, Hungary.
RP Varkondi, E (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, 4012 Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 424
EP 429
PG 6
ER

PT J
AU Dank, M
AF Dank, Magdolna
TI Tumorus anorexia/cachexia syndrome
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cachexia; cancer; anorexia; molecular mechanism; treatment
ID cachexia; cancer; anorexia; molecular mechanism; treatment
AB The clinical importance of tumor-induced cachexia is indicated by the fact that two thirds of the cancer patients suffer from it and it plays an outstanding role in mortality of the disease. The onset of the tumorous anorexia/cachexia syndrome does not depend on tumor burden or the stage of the disease. The syndrome is very complex in nature and cannot be reversed by "over-feeding" of the patient. The appropriate supply of calories, carbohydrates, proteins and lipids is impossible, therefore administration of nutrients which do not cause volume-load for the patient is justified. Enteral feeding must be the primary aim in cancer patients till the gastrointestinal tract is functioning. To improve appetite and increase body weight specific pharmacological intervention may also be necessary. Understanding the molecular mechanisms of the development of tumorous anorexia/cachexia syndrome opens new ways of treatment.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, H-1082 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, H-1082 Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 431
EP 436
PG 6
ER

PT J
AU Borbenyi, Z
AF Borbenyi, Zita
TI Etiology and treatment of malignancy-associated anaemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer-associated anaemia; pathomechanism; erythropoetin treatment
ID cancer-associated anaemia; pathomechanism; erythropoetin treatment
AB Patients with cancer frequently develop anaemia. Various factors, including the type of malignancy and the intensity of chemotherapy influence the prevalence of anaemia and need of transfusions. Among the numerous causes of its development, the most frequent type is cancer anaemia, the so-called ''anaemia of chronic disorders”. Anaemia of chronic disorders is diagnosed when neoplastic disease is accompanied by an otherwise unexplained microcytic anaemia with compromised iron utilisation and decreased erythropoietin secretion. In 50-70% of patients with solid tumors or hematological malignancies, mainly with multiple myeloma and malignant lymphomas, transfusion can be avoided, or significantly decreased by the use of recombinant erythropoietin. This review provides tools to decide the best candidates for this treatment and a guideline to monitor its efficacy.
C1 [Borbenyi, Zita] University of Szeged, 2nd Department of Internal Medicine and Cardiology Centre, Koranyi fasor 6., H-6720 Szeged, Hungary.
RP Borbenyi, Z (reprint author), University of Szeged, 2nd Department of Internal Medicine and Cardiology Centre, H-6720 Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2001
VL 45
IS 5
BP 437
EP 441
PG 5
ER

PT J
AU Kopper, L
   Timar, J
AF Kopper, Laszlo
   Timar, Jozsef
TI Gene expression profiles in the diagnosis and prognosis of cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB DNA-microarray technology can be used to assess the expression of several thousands of genes at the same time.The identification of the gene expression profiles may help to better characterize human cancer.These studies may reveal subclasses of tumor types with similar histopathologic profile but different clinical courses.Furthermore,such studies could help to define therapeutic sensitivity and to estimate prognosis of various cancers.Identification of gene expression profiles of cancer can identify new therapeutic targets or cancer susceptibility genes.The DNA-microarray technology may write a new chapter in molecular oncology.
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., H1085 Budapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, H1085 Budapest, Hungary.
EM kopper@korb1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 3
EP 9
PG 7
ER

PT J
AU Bankfalvi, �
AF Bankfalvi, Agnes
TI HER-2 diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB HER-2 (c-erbB2, neu) receptor is the molecular marker of ductal breast cancer although it is verexpressed in other adenocarcinoma as well (e.g.endometrial, colorectal and lung cancers). The increased receptor expression is most frequently (90 –97%) due to gene amplification. Detection of the overexpression of HER-2 helps to determine prognosis, to predict chemoresistance and to select for Herceptin therapy. HER-2 overexpression can be estimated either by immunohistochemistry or by fluorescent in situ hybridisation (FISH). Standardization of the immunohistochemical HER-2 tests is the best in HercepTest DAKO), however, the frequent 2+level requires complementary FISH test to verify gene amplification. This combination is not necessary at low (0 –1+) or high (3+) level of immunohistochemical reactions, because the correlation with gene amplification status is acceptably high. Recently several new anti-HER-2 antibodies have been introduced into HER-2 diagnostics in various countries. According to our experiences we recommend to combine rationally the immunohistochemistry and FISH techniques to determine the HER-2 status in breast cancer.
C1 [Bankfalvi, Agnes] University of Munster, Department of PathologyMunster, Germany.
RP Bankfalvi, � (reprint author), University of Munster, Department of Pathology, Munster, Germany.
EM bankfal@uni-muenster.de
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 11
EP 15
PG 5
ER

PT J
AU Fule, T
   Kovalszky, I
AF Fule, Tibor
   Kovalszky, Ilona
TI The molecular diagnostics of viruses
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB For many years data of cancer research indicated that viruses can cause cancer. Virus infections induce cancer by different mechanisms. To predict the significance of a viral DNA fragment in human cells we have to be aware of the changes the particular virus is able to induce there.However, no matter which mechanisms of viral carcinogenesis are utilized, generally other factors (environmental, chemical, immunodeficiency, etc.) are also needed to induce invasive cancer in human. Before the introduction of nucleic acid based detection technique virus identification was a long and cumbersome process. This has been eliminated by the invention of recombinant gene technology and polymerase chain reaction. Virus nucleic acid can be detected without amplification using Southern, Northern and in situ hybridization. Techniques for target (polymerase chain reaction)or signal (hybrid capture, tyramine) amplification improved the sensitivity of detection.In the meantime, for the successful use of the arsenal of new methods we have to consider the characteristic feature of molecular virus research. A major achievement of molecular virus detection is that it proved the pathological significance of viruses in human cancers even in those where this was not expected. Hopefully these informations will increase the effort for elimination of oncogen virus infections.
C1 [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., H1085 Budapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., H1085 Budapest, Hungary.
RP Kovalszky, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, H1085 Budapest, Hungary.
EM koval@korb1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 17
EP 22
PG 6
ER

PT J
AU Sapi, Z
   Bodo, M
AF Sapi, Zoltan
   Bodo, Miklos
TI FISH diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB For over two decades banding has remained the ’gold standard’ of cytogenetic analysis, providing the first genome-wide screen for abnormalities. However, conventional cytogenetic banding techniques are limited to the detection of rearrangements involving more than 2 Mb of DNA. In addition,the identification of de novo unbalanced chromosome rearrangements provides a particular challenge for chromosome banding to decipher.In recent years a number of techniques based on FISH have evolved, all of which complement the conventional banding approaches and which have steadily increased the accuracy of cytogenetic diagnosis. FISH is now the method of choice because of the increased sensitivity, and speed with which it can be applied to a variety of cellular targets. In this article we try to highlight the technical aspects of FISH and the practical application of this technique on different tumors (soft tissue tumors, breast carcinomas, renal cell carcinomas, bladder tumors and germ cell tumors).
C1 [Sapi, Zoltan] St John's Hospital, Department of Pathology, Diosarok u.1., H1125 Budapest, Hungary.
   [Bodo, Miklos] Semmelweis Egyetem, Onkopathologiai es Citodiagnosztikai TanszekBudapest, Hungary.
RP Sapi, Z (reprint author), St John's Hospital, Department of Pathology, H1125 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 25
EP 32
PG 8
ER

PT J
AU Szentirmay, Z
   Szanto, I
   Balint, I
   Polus, K
   Remenar, �
   Tamas, L
   Szentkuti, G
   Melegh, Zs
   Nagy, P
   Kasler, M
AF Szentirmay, Zoltan
   Szanto, Imre
   Balint, Ildiko
   Polus, Karoly
   Remenar, Eva
   Tamas, Laszlo
   Szentkuti, Gabriella
   Melegh, Zsombor
   Nagy, Pal
   Kasler, Miklos
TI Causal association between human papilloma virus infection and head and neck and esophageal squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB HPVs commonly cause proliferative lesions of squamous epithelium, and infection with certain HPV types carries a high risk of malignant transformation. We used molecular techniques to detect and type HPV in papillomas and carcinomas in the oral cavity and esophagus. DNA was extracted from 150 fresh or paraffin embedded biopsy specimens, and analyzed for HPV by PCR with 15 sets of consensus primers directed to conserved regions of L1 gene, three sets of HPV16E6 primers (specific for the HPV 16 prototype and L83V variant), and sets of primers specific for the E6 gene of other mucosa type HPVs including HPV 6, 11, 16, 18, 52, 58, 66 and 73. Overall, HPV sequences were detected in 61 of 150 specimens. HPV DNA sequences were detected in 16/32 specimens in the oropharyngeal region, in 13/36 specimens in larynx and 32/82 specimens in esophagus. Papillomas contained only the episomal form of HPV 16.In the esophagus, the most common type was HPV 73. In all specimens examined, HPV 6/11 (4/150), HPV 16 (23/150), HPV 35 (1/150), HPV 45 (1/150), HPV 54 (1/150), HPV 58 (1/150), HPV 61 (1/150), HPV 66 (1/150), HPV 68 (2/150), HPV 70 (3/150), HPV 72 (1/150), HPV 73 (16/150), double HPV infection (2/150), and unidentified HPV type (4/150) was detected. Interestingly, HPV was found in all verrucous carcinomas and in 18/22 basaloid squamous cell carcinomas. HPV16E6 T350G mutant were observed only in two of eight carcinomas. Using correspondence analysis, a segregation of specific virus types in specific clinico-pathologic lesions (verrucous carcinoma and basaloid squamous cell carcinoma) was proved. It was shown that the relative rates of the HPV positive tumors were significantly higher in women than in men. The synergic action of mucosal irritation and HPV infection may be necessary for the development of the papillomas and the specific types of carcinomas in the oral cavity and in the esophagus.
C1 [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy utca 7-9., H1122 Budapest, Hungary.
   [Szanto, Imre] Semmelweis University, 3rd Department of SurgeryBudapest, Hungary.
   [Balint, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy utca 7-9., H1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Tamas, Laszlo] Jahn Ferenc South-Pest Hospital, Department of Oto-Rhino-LaryngologyBudapest, Hungary.
   [Szentkuti, Gabriella] Jahn Ferenc South-Pest Hospital, Department of Oto-Rhino-LaryngologyBudapest, Hungary.
   [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy utca 7-9., H1122 Budapest, Hungary.
   [Nagy, Pal] Orszagos Gyogyintezeti Kozpont, Patologiai osztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, H1122 Budapest, Hungary.
EM szentirmay@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 35
EP 41
PG 7
ER

PT J
AU Melegh, Zs
   Balint, I
   Nagy, K
   Magyarosy, E
   Galantai, I
   Szentirmay, Z
AF Melegh, Zsombor
   Balint, Ildiko
   Nagy, Kalman
   Magyarosy, Edina
   Galantai, Ilona
   Szentirmay, Zoltan
TI Detection of n-myc gene amplification in neuroblastoma using polymerase chain reaction based methods
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB We have used semiquantitative and real-time quantitative PCRs to detect n-myc gene-amplification in 21 frozen neuroblastoma biopsies and IMR 32 cell line in order to predict biological behaviour of the tumors. Two primer pairs were used in the semiquantitative method to co-amplify a 520-bp fragment of the beta -globin gene -used as a single copy reference standard -and a 258-bp fragment of the n-myc gene. After 30 cycles the PCR products were electrophoresed through an agarose gel and were compared to each other with use of a gel-densitometer. Real-time quantitative analysis was performed in a LightCycler instrument. A single primer pair was used to amplify a 120-bp fragment of the n-myc oncogene and a LC640-labelled fluorescent probe pair to detect the product. Calibration curve, which was set up from a serial dilution including samples with 1, 2, 10 , 13, 25-fold n-myc oncogene amplification, was employed for quantitative analysis. Semiquantitative method did not show distinct difference between tumor groups with no amplification and less than 10-fold amplification, while quantitative LightCycler analysis was able to detect even 2-fold amplification. In situ PCRs were performed in two cases of differentiated tumor samples which contained n-myc amplification. We used biotinylated ATP labelling and the same primer pair as for the LightCycler analysis.In both cases differentiated cell forms did not show n-myc gene amplification, while considerable amplification was detected in the neuroblasts.
C1 [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9, H1122 Budapest, Hungary.
   [Balint, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9, H1122 Budapest, Hungary.
   [Nagy, Kalman] Borsod-Abauj-Zemplen Megyei Korhaz, I. Gyermekhaematologiai-es Csontvelotranszplantacios OsztalyMiskolc, Hungary.
   [Magyarosy, Edina] Heim Pal Children's Hospital, Department of HematologyBudapest, Hungary.
   [Galantai, Ilona] Madarasz Utcai Gyermekkorhaz-Rendelointezet, Belgyogyaszati OsztalyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9, H1122 Budapest, Hungary.
RP Melegh, Zs (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, H1122 Budapest, Hungary.
EM melegh@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 43
EP 48
PG 6
ER

PT J
AU Esik, O
   Horvath, �
   Bajcsay, A
   Hideghety, K
   Agocs, L
   Piko, B
   Lengyel, Zs
   Petranyi, �
   Pisch, J
AF Esik, Olga
   Horvath, Akos
   Bajcsay, Andras
   Hideghety, Katalin
   Agocs, Laszlo
   Piko, Bela
   Lengyel, Zsolt
   Petranyi, Agota
   Pisch, Julianna
TI Principles of radiotherapy of non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The long-term survival probability for Hungarian lung cancer patients is 10% worse than the best results published in the most highly developed countries (the mean 5-year survival probability in Hungary is 5%, in contrast with the 15% survival probability in the USA). On the basis of the international recommendations and personal experience, an attempt was made to formulate the guidelines for radiotherapy as one of the fundamental non-small cell lung cancer (NSCLC) treatment modalities for national use. An expert panel was set up comprising physicians from 6 radiotherapeutic centers (the National Institute of Oncology / Semmelweis University, Budapest; the Beth Israel Medical Center, New York; the University of Kaposvar; the University of Essen; the University of Debrecen; and the County Hospital of Gyula). Experts in two important medical fields closely related to radiotherapy (surgery and diagnostic imaging) were also engaged in the elaboration of the manuscript. Discussion of the most important principles of the radiotherapy and an overview of the prognostic factors was followed by a critical analysis of the protocols applied in the radiotherapy of Hungarian NSCLC patients during recent decades. The new guidelines suggested for the radiotherapy of NSCLC are presented separately for the postoperative period, marginally resectable tumors, and the aggressive or non-aggressive radiotherapy of inoperable tumors. Detailed accounts are given of the techniques of external irradiation and brachytherapy, and of the acute and late radiation-induced damage of normal tissues. The authors believe that this document may be instrumental in improving the survival index of Hungarian NSCLC patients in the near future.
C1 [Esik, Olga] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9.Budapest, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9.Budapest, Hungary.
   [Hideghety, Katalin] University of Duisburg-Essen, University Hospital of EssenEssen, Germany.
   [Agocs, Laszlo] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Lengyel, Zsolt] University of Debrecen, PET CenterDebrecen, Hungary.
   [Petranyi, Agota] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9.Budapest, Hungary.
   [Pisch, Julianna] Beth Israel Medical Center, Department of Radiation OncologyNew York, USA.
RP Esik, O (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
EM esik@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2002
VL 46
IS 1
BP 51
EP 85
PG 35
ER

PT J
AU Otto, Sz
   Kasler, M
AF Otto, Szabolcs
   Kasler, Miklos
TI Cancer mortality and incidence in Hungary in relation to international data
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In Hungary mortality caused by malignant tumour diseases is very high. It is the second cause of death showing approximately 25% frequency. Statistics on disability has revealed that during the past 25 years the number of patients become invalid because of cancer has nearly doubled.In comparative international statistics cancer mortality and incidence of the Hungarian male population take the first and that of the female population the second place. The alarming public health problems caused by cancer in Hungary have prompted the authors to identify the causes and search for points of outbreak to stop and reverse these unfavourable tendencies. When analysing the current state of this country authors primarily rely on the studies of the European Cancer Centre, Lyon and those of the Hungarian Central Statistical Office (KSH) and National Cancer Registry. By years 2000-2001 the National Cancer Registry has become a reliable well functioning system. Its activities include the registration of all new cancer patients announced in the previous calendar year. Data processing requires information such as: year of diagnosis, tumour localisation and extension, morphological code and therapeutic interventions. It is a promising sign that the first time over the past 25 years cancer mortality decreased in year 2000. The unfavourable cancer mortality and incidence status in Hungary might be improved by the consistent accomplishment of the project ''For a Healthy Nation, A Public Health Project for years 2001-2010''.
C1 [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 111
EP 117
PG 7
ER

PT J
AU Muszbek, N
   Koncz, T
   V. Hajdu, P
   Adany, R
AF Muszbek, Noemi
   Koncz, Tamas
   V. Hajdu, Piroska
   Adany, Roza
TI Economic evaluation of population-based mass screening for the early detection of cancer: a systematic review
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB PURPOSE: The increasing premature mortality due to cancer has made population based screening programs for cervical,breast and colorectal cancers inevitable in Hungary. However, when confronted with limited resources, the aim is that, within the budget constrain, the greatest possible health gain should be ''produced''. METHODS: The authors made a systematic review of the international literature concerning the cost-effectiveness of screening programs for the above tumours. RESULTS: In case of cervical cancer the Papanicolaou test, in case of breast cancer the mammography meet the WHO criteria for population-based mass screening. The well-designed organised screening programs are more cost-effective than the opportunistic screening. Among sexually active women, according to structure the mobile screening buses, according to age group screening of the 30-39 years old women seems the most favourable. For breast cancer, screening the 60-70 years old population every second year is the reference strategy from a health economic perspective. The cost-effectiveness results of either increasing the frequency of screening, extending the program for other age groups, or selecting a high-risk population are contradictory. In case of colorectal cancer there is no screening method, which would meet the WHO criteria. The two-day FOBT seems the most favourable, followed by colonoscopy for positive results, in the 55-74 years old population every second year. CONCLUSION: In addition to fulfilling requirements for a population-based screening method, the cost-effectiveness perspective should be taken into account.
C1 [Muszbek, Noemi] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/B., 4028 Debrecen, Hungary.
   [Koncz, Tamas] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [V. Hajdu, Piroska] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/B., 4028 Debrecen, Hungary.
   [Adany, Roza] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/B., 4028 Debrecen, Hungary.
RP Muszbek, N (reprint author), Debreceni Egyetem, Nepegeszsegugyi Iskola, 4028 Debrecen, Hungary.
EM mnoemi@hotmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 119
EP 129
PG 11
ER

PT J
AU Paldy, A
   Nador, G
   Vincze, I
   Zsambokine, BM
   Rajcsanyi, �
   Pinter, A
AF Paldy, Anna
   Nador, Gizella
   Vincze, Istvan
   Zsambokine, Bakacs Marta
   Rajcsanyi, Agnes
   Pinter, Alan
TI Spatial accumulation of mortality and morbidity from cancer of the prostate (ICD-10:C61)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors examined the spatial accumulation of mortality and morbidity of cancer of the prostate of the total as well as age stratified male population of Hungary. Using GIS, a descriptive epidemiological study was carried out examining the spatial differences of mortality on settlement level with 2000 inhabitans by calculating standardized mortality and morbidity ratios. The significance of the difference of mortality and morbidity from the national mean was tested by chi square probe. On the basis of the results a significant excess in mortality was detected in 11 regions of the country. The unfavourable regions cover 11.6% of the territory of the country where 25.6% of the male population live. A significant excess morbidity can be observed in 8 counties. A significant correlation was found between the unfavourable regions of mortality and morbidity (r=0.443, p&lt;0.05). The age-specific analysis of morbidity revealed the highest excess in morbidity in the age group over 70 years accumulating in 3 counties of Transdanubia and in 6 counties of the Great Plain. On the basis of the results of mortality and morbidity analysis according to age and areas the unfavourable regions can be identified where mortality and morbidity from cancer of the prostate accumulates. These studies serve as a basis for intervention strategies.
C1 [Paldy, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
   [Nador, Gizella] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
   [Vincze, Istvan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
   [Zsambokine, Bakacs Marta] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
   [Rajcsanyi, Agnes] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
   [Pinter, Alan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Gyali ut 2 –6., 1097 Budapest, Hungary.
RP Paldy, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, 1097 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 131
EP 137
PG 7
ER

PT J
AU Sandor, J
   Havasi, V
   Kiss, I
   Szucs, M
   Brazay, L
   Sebestyen, A
   Ember, I
AF Sandor, Janos
   Havasi, Viktoria
   Kiss, Istvan
   Szucs, Maria
   Brazay, Laszlo
   Sebestyen, Andor
   Ember, Istvan
TI Small area inequalities in breast cancer mortality and screening
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Despite the unfavourable epidemiological status, the Hungarian breast cancer control is a non-appropriately developed system having considerable geographical inequalities. The study objective was to describe the small-area pattern of breast cancer mortality and of frequency of mammographical examination. The influence of socio-economical status on these patterns was also studied. The standardised mortality ratios and the standardised relative frequency of mammography was determined for settlements, zip code areas and small regions. Their correlations were analysed with education, unemployment ratio, ratio of Gypsy and German ethnic minorities, population size, smoking, distance to the nearest hospital. The South-Transdanubian Region (STR, consisting of three counties, 22 small regions, 444 zip code areas and 643 settlements) with 1 million inhabitants was the study area. All the studied parameters had significant spatial variability at all levels of aggregation. Beyond the relatively low average mortality risk in the STR, mortality clusters and increasing time trend were identified in certain areas. The mortality and the usage of mammography were inversely correlated with the indices of deprivation. These factors explain 64.5 and 17.5% of the whole variability of local mortality risks at the level of settlements and small regions. The explanatory role of these factors was similarly high for usage of mammography as well (40.2 and 52.6% for small regions and zip code areas). The factors having the strongest influence were the population size (in settlement level mortality model), ratio of gypsies (in small region level mortality and mammography usage models) and ratio of Germans (in mammography usage model for zip code areas). Inserting the counties' approaches for screening organisation into the model, it revealed that the population based screening organisation applied in Tolna county has the highest influence being 4.4 times stronger than the most important socio-economic factors.Altogether,it seems that the monitoring of spatial inequalities could improve the performance of breast cancer control identifying the populations with special needs, and there is a need to explore the pathways by which the socio-economic factors can exert their profound influence on the epidemiological status. Moreover, since the results clearly demonstrated that it is possible to achieve relatively high screening participation rates in Hungarian economical and legislative circumstances, the application of this successful method should be encouraged in other areas with low performance screening system.
C1 [Sandor, Janos] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti u. 12., 7643 Pecs, Hungary.
   [Havasi, Viktoria] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti u. 12., 7643 Pecs, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti u. 12., 7643 Pecs, Hungary.
   [Szucs, Maria] ANTSZ Regional Institute of State Public Health ServicePecs, Hungary.
   [Brazay, Laszlo] ANTSZ Regional Institute of State Public Health ServicePecs, Hungary.
   [Sebestyen, Andor] OEP, Baranya megyei Egeszsegbiztositasi PenztaraPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti u. 12., 7643 Pecs, Hungary.
RP Sandor, J (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, 7643 Pecs, Hungary.
EM janos@pubhealth.pote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 139
EP 145
PG 7
ER

PT J
AU Tompa, A
   Szende, B
AF Tompa, Anna
   Szende, Bela
TI Preventive medicine: biomonitoring and chemoprevention
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of chemoprevention is to delay or prevent the development of pathological conditions, or to correct abnormal regulatory mechanisms and in some cases even reverse the process. For this intervention to succeed, biomarkers must be found that characterize impaired health status in a phase when impairment is still reversible. Genotoxicological parameters may function as biomarkers of this kind, such as inhibition or delay of mitosis, inhibition of apoptosis, increase in the number of chromosomal aberrations, decrease in the capacity of DNA repairing enzymes, or parameters characterizing immunological status (eg. decreased NK activity). With the help of early signs, impending negative changes or illness (which could not be prevented without effective chemoprevention) can be predicted in apparently healthy individuals. Thus, the first and most important step in chemoprevention is risk characterization. Risk characterization is a complex concept, which includes risk analysis, risk assessment and risk management. Chemoprevention is a part of the latter process. Biomarkers, which can be studied mainly by up-to-date molecular biological methods, are used in discovering risk factors and also in the assessment of caused biological effects. Besides avoiding risk factors, it is very important to strengthen the protective mechanisms, to promote the metabolism of toxic substances, and to repair damage (ward off denaturation of macromolecules caused by free oxygen radicals with antioxidants for example). Chemopreventive agents are therefore diverse in their targets. Most of them have antioxidant properties, such as plant-derived substances, like glycosides, flavonoids, various vitamins, carotinoids, and some trace elements such as selenium. Another group of chemopreventive agents inhibit cell proliferation, or induce programmed cell death (apoptosis). Another group influence terminal differentiation, or inhibit angiogenesis. Some chemopreventive agents affect the metabolism or detoxification of xenobiotics, or boost the functions of the immune system. In many cases these effects are mediated by the rate of methylation of DNA molecules.
C1 [Tompa, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Nagyvarad t. 2., 1450 Budapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Tompa, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, 1450 Budapest, Hungary.
EM tompa.okbi@antsz.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 147
EP 153
PG 7
ER

PT J
AU Szentirmay, Z
   Cseh, L
   Otto, Sz
   Kasler, M
AF Szentirmay, Zoltan
   Cseh, Lujza
   Otto, Szabolcs
   Kasler, Miklos
TI Quality assurance in oncology: experiences of an ISO certification
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The ISO 9001 quality assurance of the National Institute of Oncology has been achieved successfully. We give an account of the brief history and the structure of the assurance system of the Institute, the process of setting our goals, and also the experience gained from drafting ISO 9001 handbook and flowcharts. Apart from the bureaucratic nature of quality assurance, it is a good opportunity for us to investigate our everyday work, put it into orderly manner and work more reliably. Experience has shown that the introduction of a quality assurance system increases the level of patient care, the documentation helps the Institute or some of its departments, or even individuals prevent law suits, and serves as a sound basis for proposing promotion, salary increases and bonuses, or even honors.
C1 [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Cseh, Lujza] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 155
EP 163
PG 9
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI Selective estrogen receptor modulators (SERMs) in the practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Selective estrogen receptor modulators (SERMs) represent a growing class of compounds that act as either estrogen receptor gonists or ntagonists in tissue-selective manner. SERMs with the appropriate selectivity profile offer the opportunity to dissociate the favorable bone and cardio-vascular effects of estrogen from its unfavorable stimulatory effects on the breast and uterus. The triphenylethylene drug tamoxifen proved to be invaluable to treat and protect against breast cancer and bone loss, probably reduces cardiovascular risk, but had side effects on uterus similar to natural estrogens. The tamoxifen derivate toremifene is also used to treat breast cancer, but has less effect on bone. The non-steroidal benzothiophene derivate, raloxifene, is the best SERM available thus far. It has the potential to prevent breast cancer (like tamoxifen), but has better profile in its actions on bone and cardiovascular system (produces a rapid reduction of serum cholesterol, decreases fibrinogen and lipoprotein, improves the vascular epithelial function, attenuates vascular intimal thickening, etc.). It does not increase the incidence of endometrial cancer. Compounds of this class are the first step in developing the perfect hormone replacement and other multitargeted therapy. This review summarizes the recent important knowledge about SERMs.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 165
EP 175
PG 11
ER

PT J
AU Marko, L
   Sarkany, J
   Toth, K
   Szucs, M
AF Marko, Laszlo
   Sarkany, Jeno
   Toth, Kalman
   Szucs, Miklos
TI The rare manifestation of soft tissue metastasis of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The authors report on a rare manifestation of soft tissue metastasis of operated colorectal cancer. Interestingly, two years after the resection a etastasis with extremely high tumor marker level (CEA, CA 19.9) was detected. Marker elevation preceded the manifestation of metastasis by nearly half a year. After the metastasectomy the disease progressed. The authors briefly refer to the epidemiology of colorectal cancer, the complex therapy and the follow up.
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri u. 38., 6001 Kecskemet, Hungary.
   [Sarkany, Jeno] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Ortopediai OsztalyKecskemet, Hungary.
   [Toth, Kalman] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Ortopediai OsztalyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri u. 38., 6001 Kecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, 6001 Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 177
EP 178
PG 2
ER

PT J
AU Dank, M
AF Dank, Magdolna
TI Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
AB Based on phase II and III trials Taxol administered in the form of three times/week 1 or 3 hr infusion as mono-or combined chemotherapy of breast cancer is an effective treatment option. These studies proved that this form of drug delivery is effective and well tolerated and the overall response rate is around 50%. The 1 hr weekly infusion of Taxol is an effective second-line treatment in metastatic breast cancer and is better than the 3-weekly infusion since the decreased toxicity increases the therapeutic index.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, 1082 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 189
EP 191
PG 3
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
AB Combined chemotherapy of breast cancer using antracyclins proved to be superior over classical drug combinations. Taxanes are considered even more effective agents against breast cancer than the previously used drugs. Based on these assumptions, multicentric phase III trial was initiated in Europe to compare the AT combination (doxorubicin and paclitaxel) with the classical FAC (5-fluorouracyl, doxorubicin and cyclophosphamid). AT combination proved to be more effective in the treatment of metastatic breast cancer than FAC as far as the overall response rate and the complete responses are concerned. Furthermore, the time to progression increased in the AT-arm too compared to the FAC-arm. Based on these data it is suggested to use AT combination for the first-line treatment of metastatic breast cancer.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 192
EP 193
PG 2
ER

PT J
AU Lang, I
AF Lang, Istvan
TI Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
AB Taxol (paclitaxel) and Herceptin (trastuzumab) are two milestones in the treatment of metastatic breast cancer. Accordingly it was feasible to study the combination of these two highly active drugs (with different toxicity profiles and mechanisms of action) in the treatment of metastatic breast cancer. In multicentric phase III trial performed in the US the combination of Herceptin with either taxane or anthracyclin was investigated. It was established that the combination of Herceptin with Taxol treatment significantly improves the overall response rate, increases the time to progression and the overall survival. These effects are more pronounced in patients characterized with HER/2 +++ overexpression. Based on these evidences the Herceptin-Taxol combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients.
C1 [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lang, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2002
VL 46
IS 2
BP 195
EP 196
PG 2
ER

PT J
AU Kalvin, B
   Fekeshazy, A
   Lengyel, Zs
   Szakall, Sz
   Agoston, P
   Lengyel, E
   Szekely, J
   Galuska, L
   Tron, L
   Esik, O
AF Kalvin, Beata
   Fekeshazy, Attila
   Lengyel, Zsolt
   Szakall, Szabolcs
   Agoston, Peter
   Lengyel, Erzsebet
   Szekely, Judit
   Galuska, Laszlo
   Tron, Lajos
   Esik, Olga
TI Cost-effective oncological PET investigations
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors have reviewed the financial considerations of oncological FDG PET examinations by the guidelines of the Health Care Financing Administration (USA). By critical assessment of large number of clinical investigations,the cost-effectiveness of FDG PET scans has been confirmed in the following cases: differential diagnosis of solitary pulmonary nodule, diagnosis,staging and restaging of non-small cell lung cancer, colorectal cancer, malignant lymphomas, melanoma malignum, esophageal neoplasms and cancers of the head and neck. The role of this method in breast cancer is currently under intensive investigation. Due to the correct staging, PET examinations in these indications enable the clinicians to choose the optimal treatment ensuring the maximum probability of recovery and being cost-effective as unnecessary medical interventions become avoidable.
C1 [Kalvin, Beata] University of Debrecen, PET Center, Bem ter 18/c, 4026 Debrecen, Hungary.
   [Fekeshazy, Attila] University of Debrecen, PET Center, Bem ter 18/c, 4026 Debrecen, Hungary.
   [Lengyel, Zsolt] University of Debrecen, PET Center, Bem ter 18/c, 4026 Debrecen, Hungary.
   [Szakall, Szabolcs] University of Debrecen, PET Center, Bem ter 18/c, 4026 Debrecen, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lengyel, Erzsebet] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Tron, Lajos] University of Debrecen, PET Center, Bem ter 18/c, 4026 Debrecen, Hungary.
   [Esik, Olga] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Kalvin, B (reprint author), University of Debrecen, PET Center, 4026 Debrecen, Hungary.
EM kalvin@pet.dote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 203
EP 223
PG 21
ER

PT J
AU Nagykalnai, T
   Landherr, L
   Zatkone Puskas, G
   Gyuricska, A
AF Nagykalnai, Tamas
   Landherr, Laszlo
   Zatkone Puskas, Gabriella
   Gyuricska, Annamaria
TI Pamidronate in the treatment of bone metastases from breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Bone metastases afflict over 70% of patients with advanced breast cancer, resulting in impaired quality of life and significant clinical problems. Until appearance of the bisphosphonates there was no specific therapeutic treatment available to manage the symptoms of osteolytic bone metastases. Bisphosphonates are stable chemical analogues of pyrophosphate, and inhibit osteoclast-mediated bone resorption, the treatment is effective in reducing skeletal morbidity in breast cancer with fewer skeletal related events, reduced pain and analgesic consumption, and improved quality of life. As a result, bisphosphonates should now be part of the routine management of metastatic bone disease and multiple myeloma. Promising data have resulted in considerable interest in the possible adjuvant use of bisphosphonates. Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status. Monthly pamidronate infusions for one or two years in addition to standard anticancer therapy reduce by more than one third the yearly frequency of skeletal-related events. The authors report their practice in which 119 breast cancer patients metastatic to bone received 90-120 mg pamidronate infusion/cycle in addition to standard breast cancer therapy every 3-4 weeks.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki 29., 1145 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki 29., 1145 Budapest, Hungary.
   [Zatkone Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki 29., 1145 Budapest, Hungary.
   [Gyuricska, Annamaria] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki 29., 1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 225
EP 233
PG 9
ER

PT J
AU Major, T
   Petranyi, �
   Varjas, G
   Nemeth, Gy
AF Major, Tibor
   Petranyi, Agota
   Varjas, Geza
   Nemeth, Gyorgy
TI The possibility of the use of MRI images in the three-dimensional external radiotherapy treatment planning
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To review the application of MRI images in the radiation treatment planning ,to discuss the advantages and disadvantages of MR imaging with respect to treatment planning, and to investigate the geometric distortion. METHODS: Humanoid therapy phantom was used for MRI and CT scanning, and distances between markers inside and on the surface of the phantom were measured in order to quantify the geometric distortion. The procedure of MRI/CT image fusion, which makes it possible to use the data of both imaging modalities for treatment planning, was described. RESULTS: At small volumes (head phantom) the geometric distortion was negligible (<2 mm), but at large volumes (eg. pelvis) remarkable geometric inaccuracies were observed. For example, the width of the pelvis measured in the MRI images was 7 mm less than the real distance, which corresponds to 2% inaccuracy. Geometric distortion was observed not only in the axial, but also in the sagittal and coronal planes. We have found that the geometric error increases with the distance measured from the magnetic isocenter. When the geometric distortion is not significant, the MRI/CT image fusion can be carried out reliably with the use of surface markers. CONCLUSIONS: At small volumes the MRI images can be used for treatment planning after their fusion with CT images. At larger volumes the geometric distortion without any correction may preclude the MRI images from using them in the treatment planning. A detailed assessment of geometric distortion must be carried out before the introduction of MRI images into the radiation treatment planning.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Petranyi, Agota] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM major@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 239
EP 245
PG 7
ER

PT J
AU Keresztes, K
   Miltenyi, Zs
   Andras, Cs
   Illes, �
AF Keresztes, Katalin
   Miltenyi, Zsofia
   Andras, Csilla
   Illes, Arpad
TI Second malignancies in managing Hodgkin's disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB THE AIM OF THE STUDY: to analyse the incidence of second malignant neoplasms (SMN) in patients treated for Hodgkin’s disease.  PATIENTS AND METHODS: Since 1st January 1967, 534 patients have received primary treatment for Hodgkin’s disease and 470 cases have proved to be adequate for data analysis as regards to the development of SMN. RESULTS: SMN developed in 34 cases (7.2%), solid neoplasms were diagnosed in 26 cases (5.5%), lung neoplasms had the greatest incidence (11/26), hematologic malignancies were detected in 8 cases (1.7%), and non-Hodgkin’s lymphoma was found in 5/8 cases. The mean age of patients with solid neoplasms was 38.1 years (18-59 years) at the diagnosis of Hodgkin’s disease and the length of time until the diagnosis of SMN was 13.5 years (1-33 years). The mean age of patients with hematologic malignancies was 45 years (17-64 years), the latency period was 3.2 years (9 months-12 years). The therapies employed prior to the development of solid neoplasms involve: irradiation in 6 cases, chemotherapy in 8 and combined therapy in 12 cases. Out of the 20 cases of chemotherapy, CV/O/PP and its variants were used in 17 cases. Prior to the development of hematologic malignancies, 5 patients had received chemotherapy, 3 combined therapy and 7 patients CV/O/PP and its variants. CONCLUSIONS: The incidence of SMN, especially as regards to hematologic malignancies, was found lower in our patients as compared to literary data. This can be explained by the less intensive therapeutic techniques employed earlier as well as by shorter survival periods. As a result of better therapeutic management, the chances of long term survivals have increased and we should make every effort to avoid late complications such as SMN when planning therapeutic strategies.
C1 [Keresztes, Katalin] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
RP Keresztes, K (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4004 Debrecen, Hungary.
EM katalin@iiibel.dote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 247
EP 251
PG 5
ER

PT J
AU Andras, Cs
   Ponyi, A
   Constantin, T
   Csiki, Z
   Illes, �
   Szegedi, Gy
   Danko, K
AF Andras, Csilla
   Ponyi, Andrea
   Constantin, Tamas
   Csiki, Zoltan
   Illes, Arpad
   Szegedi, Gyula
   Danko, Katalin
TI Association of myositis with tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIMS OF THE STUDY: In the 214 polymyositis / dermatomyositis patients in our department we studied the association of polymyositis / dermatomyositis with malignant tumors, the clinical specificities and therapeutic response changes in these cases. METHODS: Retrospective analysis of the data available since 1985 of the patients treated at the DEOEC 3rd Department of Internal Medicine. RESULTS: From 60 patients with dermatomyositis 9 were diagnosed with neoplasia. In 5 patients simultaneously with the dematomyositis diagnosis, in the other 4 patients 2-2-3-7 years after the onset of dermatomyositis. In the 154 patients with polymyositis we did not observe development of tumors. CONCLUSIONS: Neoplasm was observed in 15% of patients with dermatomyositis. The patients presented with serious skin involvement which did not respond well to the dermatomyositis treatment. The patients in whom tumors developed simultaneously with the dermatomyositis required more aggressive treatment. After the therapy of the tumor (surgery, radiotherapy), the skin and muscle symptomps responded better to the immunosuppresive therapy.
C1 [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Ponyi, Andrea] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Constantin, Tamas] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Csiki, Zoltan] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Szegedi, Gyula] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Danko, Katalin] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
RP Danko, K (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4004 Debrecen, Hungary.
EM danko@iiibel.dote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 253
EP 259
PG 7
ER

PT J
AU Bori, R
   Kiss, �Cs
   Huszka, E
   Szucs, M
   Tusa, M
   Cserni, G
AF Bori, Rita
   Kiss, Akos Csaba
   Huszka, Endre
   Szucs, Miklos
   Tusa, Magdolna
   Cserni, Gabor
TI A rare case of tumour-to-tumour metastasis: secondary deposits of pulmonary adenocarcinoma in a secretory meningioma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB OBJECTIVE: To report a rare case of tumour-to-tumour metastasis with differential diagnostic considerations. METHODS AND RESULTS: We report the operation of a Sylvian fissure secretory meningioma in a 48 year-old woman. The tumour was suspicious of a metastasis related to a pulmonary adenocarcinoma operated 4 months before. Histopathology confirmed metastatic adenocarcinoma in a secretory meningioma. CONCLUSIONS: Both secretory meningioma and tumour-to-tumour metastasis are rare, and to our knowledge this is the first report of such a rare coincidence. Secretory meningioma can simulate metastases both clinically (extensive oedema, space occupation, carcinoembryonic antigen secretion) and pathologically (secretory inclusions, positivity for cytokeratin 7 and carcinoembryonic antigen and negativity for vimentin), and therefore may cause a special differential diagnostic dilemma.
C1 [Bori, Rita] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Kiss, Akos Csaba] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Idegsebeszeti osztalyKecskemet, Hungary.
   [Huszka, Endre] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Idegsebeszeti osztalyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Tusa, Magdolna] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Radiologiai OsztalyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 261
EP 264
PG 4
ER

PT J
AU Kovacs, Zs
   Krutsay, M
AF Kovacs, Zsuzsanna
   Krutsay, Miklos
TI Lipid- and glycogen-rich carcinoma of the breast
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The authors observed a solid breast carcinoma in a patient aged 70 years. The tumor cells contained lipids, glycogen and neutral glycoproteins. Axillary lymph node metastasis had already existed at the operation.
C1 [Kovacs, Zsuzsanna] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
   [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai Osztaly, 8401 Ajka, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 265
EP 268
PG 4
ER

PT J
AU Jozsa, L
   Fothi, E
AF Jozsa, Laszlo
   Fothi, Erzsebet
TI Juxtacortical osteosarcoma of tibia from a medieval cemetery of Budapest
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Juxtacortical osteosarcoma occurred on the right tibia and fibula of a 20-22 years old man found in a medieval period cemetery of Budapest.  MACROSCOPIC DESCRIPTION: The tumor is located circumferentially on the midshaft of the tibia and fibula and appears cone-shaped. The lesion measured 160 mm in length and 3-5 mm in height. The surface of the tumor is irregular, rough, in some areas shows spicules. These spicules averaged 2-4 mm in length and 1-2 mm in diameter. The anterior and medial surface of the tibia is completely covered by osseous tumor. RADIOGRAPHY: The X-ray study demonstrates the medullary involvement, with mixed osteolytic and osteoblastic areas. Tumor infiltration of the cortex is also apparent as irregular rarefication and lytic lesions. In some areas a ''sunburst'' picture could be seen. The X-ray picture is characteristic for juxtacortical osteosarcoma. MICROSCOPIC EXAMINATION: stereomicroscopy of specimens shows a sponge-like structure of the surface. The cortical bone is completely destroyed and deep cavities are seen between spiculous and gyrificated neoplastic bone. The spiculae are varied in length and thickness. Irregular bulky bone trabeculae demonstrating uncontrolled neoplastic reaction could be detected. By light microscopic examination severe destruction, osteolytic lesions are seen both in the cortical bone and in the cancellous bone in the peripheral parts of the tumors. Within the neoplastic bone only few remnants of the primary (normal) bone structure could be demonstrated. No reparative reactions were seen next to the osteolysis, the collagen fibers and lamellas are destroyed. Beside the destruction of original bone larger structures composed of irregular newly built nepotistic bone trabeculae can be detected. The newly formed trabeculae (spiculae) contain a tumorous ground substance (probably osteoid tissue) with few collagen fibers, and these areas are covered with a thin bony lamella. In some areas the neoplastic structures are in intimate contact with the original cancellous bone remnants. IMMUNOHISTOCHEMISTRY: Both the osteosarcoma and chondrosarcoma show osteoid and bone neoformation while in the chondrosarcoma type II collagen could also detected. By immunohistochemical reactions no type II and III collagen, only type I collagen reaction was positive. This means that no cartilaginous tissues were present in the tumor. Scanning electron microscopy of these specimens shows sponge-like structures. The tumor reveals irregular trabecular and spicular texture,the spicules are various in diameter and in some spiculae rounded deposits attached to the surface.In our case we found typical radiological and histological picture of the juxtacortical osteosarcoma.
C1 [Jozsa, Laszlo] Orszagos Traumatologiai Intezet, Pathologiai es Szovetkonzervalo OsztalyaBudapest, Hungary.
   [Fothi, Erzsebet] Magyar Termeszettudomanyi Muzeum, Embertani Tara, Ludovika ter 2., 1083 Budapest, Hungary.
RP Fothi, E (reprint author), Magyar Termeszettudomanyi Muzeum, Embertani Tara, 1083 Budapest, Hungary.
EM fothi@ludovika.nhmus.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2002
VL 46
IS 3
BP 271
EP 276
PG 6
ER

PT J
AU Olah, E
AF Olah, Edit
TI Molecular oncogenetics, oncogenomics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
C1 [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Olah, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM e.olah@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 287
EP 290
PG 4
ER

PT J
AU Gaudi, I
   Kasler, M
AF Gaudi, Istvan
   Kasler, Miklos
TI The course of cancer mortality in Hungary between 1975 and 2001
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The course of cancer mortality in this country between 1975 and 2001 was analysed solely with mathematical methods using the mortality data provided by the Central Statistical Office. Mortality data were studied according to patient’s sex and tumour localisation and in relation to total cancer mortality. The increase and decrease in cancer mortality were found to differ by sex and tumour localisation: e.g. death rate caused by cancers of the oral cavity showed low deviation with an even increase just like the mortality caused by colorectal cancer, the latter, however, was steeper with men. In case of melanoma higher deviation was associated with increased mortality, again at a higher rate with men. Dying of testicular cancer and of gastric cancer in either sex showed decreasing tendencies. Lung cancer mortality assumed different patterns in the two genders: with men it kept increasing at an even pace until 1994 then the increase stopped. With women, however, the increase since 1985 was steeper than earlier. The breast cancer mortality rates can also be divided into two periods. There was an even rise until 1994 followed by stagnation. As to the total cancer mortality values, the authors state that the rhythm of increase during the first 20 years of the study period had changed, the steepness of trends in the last seven years can be expressed in a small positive number not differing from zero at significant level which means that the increase in cancer mortality has stopped.
C1 [Gaudi, Istvan] MTA, Szamitastechnikai es Automatizalasi Kutato Intezete, Lagymanyosi u. 11., 1111 Budapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Gaudi, I (reprint author), MTA, Szamitastechnikai es Automatizalasi Kutato Intezete, 1111 Budapest, Hungary.
EM gaudi@sztaki.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 291
EP 295
PG 5
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Report on the first year of the activity of the National Oncological R&D Consortium
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The project focuses on cancer types with outstanding publich health importance (breast-, colorectalhead and neck cancers and childhood tumors). Epidemiological studies revealed significant regional differences in the mobidity/mortality of these cancer types in Hungary. Molecular epidemiological studies revealed characteristic BRCA1 mutation patterns of familiar breast cancer and DNA repair enzyme polymorphism in head and neck cancer. New methods have been developed for the screening (lactoferrin), prognostication (c-met expression) or the prediction of therapeutic sensitivity (TS expression) of colorectal cancer. In the pediatric oncology program alternative way of MRD monitoring (WT1 expression) and a potential new therapeutic modality (IFN-alpha) of ALL was developed. Experimental studies demonstrated that the tumoral matrix significantly influences the effects of the classic chemotherapeutic agents. We have identified several genes the expression of which could serve efficiently as markers or targets for therapy of the progression of melanoma (alphaIIbbeta3 integrin, CD44v3 and decorin proteoglycans, AMF receptor).
C1 [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 297
EP 300
PG 4
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
AB The author summarizes the progress of adjuvant chemotherapy of breast cancer from the classical Bonadonna-type CMF over the anthracyclines to the taxanes. The CMF regimen represented the prototype of combination chemotherapy which significantly improved early and long term results. After 20 years the patients given adjuvant combination chemotherapy with CMF had significantly better rates of relapse-free survival (p<0.001) and overall survival (p=0.03) compared with no chemotherapy. 6 cycles of CMF was the gold standard of adjuvant chemotherapy in breast cancer for decades. The Milan research group decided in the early 1980s to challange this popular CMF combination by introducing doxorubicin within the adjuvant program. Compared with standard CMF, anthracyclin-containing regimens reduced the annual risk of recurrence by 12% and the annual risk of death by 11%, equating to a 3.2% absolute reduction in recurrence and a 2.7% absolute reduction in mortality at 5 years. This small but real difference seen with regimens containing three or more agents (e.g. CEF and CAF, FAC, FEC, etc.), whereas 4 cycles of 2-drug regimens (e.g. AC or EC) appears to be equivalent to 6 cycles of CMF. Among the novel chemotherapeutic drugs introduced in the 1990s the taxanes have emerged as the most powerful compounds in breast cancer. Several large, adjuvant clinical trials are currently ongoing or have recently completed accrual. The available results from innumerable clinical studies are still inconclusive and do not support the routine use of taxanes in the adjuvant setting - with the exception of the BCIRG 001 docetaxel trial, in which significant improvement was documented in disease free survival with 6 x TAC compared with 6 x FAC (82% vs 74%). Studies on the effect of the new trastuzumab (an antibody against the extracellular domain of the HER2) in adjuvant setting was initiated in early 2000. The Herceptin adjuvant trial programme is extensive, involving more than 12,000 patients worldwide. This trials will potentially offer many women with HER2-positive disease the chance of improved survival.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, 1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 307
EP 313
PG 7
ER

PT J
AU Tarjan, M
AF Tarjan, Miklos
TI Sentinel lymph node biopsy in Hungary. Hungarian results related to this revolutionary new method in surgical oncology.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB This review deals with results attained by Hungarian authors in the field of sentinel nodes and presents the current status of sentinel lymphadenectomy in Hungary. After a short historical overview, results with melanoma and breast cancer are summarized, and feasibility studies on other possible sites (gastrointestinal tract, thyroid gland) are also mentioned. Pathological aspects are also dealt with in a separate section. The summary of these results suggests that Hungarian authors have investigated several facets of sentinel node biopsy, their results are in keeping with international results. Despite the favourable results, the method still needs time to be more widely accepted and reflected in the literature.
C1 [Tarjan, Miklos] Bacs-Kiskun County Hospital, Department of Pathology, Nyiri ut 38., 6000 Kecskemet, Hungary.
RP Tarjan, M (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, 6000 Kecskemet, Hungary.
EM tarjanm@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 315
EP 321
PG 7
ER

PT J
AU Fodor, J
   Gulyas, G
   Polgar, Cs
   Major, T
   Szabo, �
   Koves, I
   Polus, K
   Nemeth, Gy
   Kasler, M
AF Fodor, Janos
   Gulyas, Gusztav
   Polgar, Csaba
   Major, Tibor
   Szabo, Eva
   Koves, Istvan
   Polus, Karoly
   Nemeth, Gyorgy
   Kasler, Miklos
TI Radiotherapy and delayed breast reconstruction with implant: examination of compatibility
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: Delayed breast reconstruction with implant is frequently used after mastectomy. However, given that many breast cancer patients receive adjuvant radiotherapy, the adaptation of this method raises questions concerning possible cumulative complications. In the present study the compatibility of post-mastectomy radiotherapy and delayed breast reconstruction with implant was examined.  PATIENTS AND METHODS: We evaluated a consecutive series of 66 invasive breast cancer patients who have received delayed breast reconstruction with implant after modified radical mastectomy between January 1997 and June 1999. The average time was 51 months from primary surgery to reconstruction. The median dose of loco-regional irradiation was 50 Gy. Grade III atrophic dermatitis was observed in none of the irradiated women. We identified two patient groups: 29 patients did not and 37 patients did receive post-mastectomy radiotherapy. The types and time of reconstruction related chronic complications (capsular contracture, defect of implant shell and skin necrosis) were recorded. Incidence of complications was estimated by the Kaplan-Meier method. Cancer related events were also studied. RESULTS: When expander was used, minor discomfort of the patients was common during the filling course. At four (11%) irradiated patients the expansion with expander was incomplete, due to severe pain. At a median follow up time of 53 months the incidence of capsular contracture was 24.1% without and 29.7% with radiotherapy (p=0.4121). The five-year estimated rate of late complications was 40% and 50%, respectively (relative risk: 1.29, 95% confidence interval: 0.58-2.89, p=0.5173). The position of implant had an impact on the incidence of capsular contracture: 46.2% with subcutaneous and 22.6% with submuscular position (p=0.0881). Four patients (6%) developed local relapse (three in the skin and one subcutaneous). All were treated with tumor excision without implant removal. CONCLUSION: Delayed breast reconstruction with implant after post-mastectomy radiotherapy can be offered to patients who are interested in breast reconstruction and had no severe late radiation skin toxicity. Post-mastectomy radiotherapy does not significantly increase the risk of complications. The use of skin expander is less tolerated by irradiated patients. Submuscular position of implants moderates the risk of capsular contracture.
C1 [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM fodor@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 323
EP 326
PG 4
ER

PT J
AU Remenar, �
   Szamel, I
   Budai, B
   Gaudi, I
   Kasler, M
   Gundy, S
AF Remenar, Eva
   Szamel, Iren
   Budai, Barna
   Gaudi, Istvan
   Kasler, Miklos
   Gundy, Sarolta
TI Serum sex steroid and hypophysis hormone levels of chronic alcoholics and head and neck cancer patients as compared to normal controls
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Head and neck squamous cell carcinoma (HNSCC) is diagnosed mainly in male patients (more than 80% of the cases) with a history of smoking and heavy alcohol consumption. However, only a few percent of all alcoholics develop head and neck cancer.  OBJECTIVE OF THE STUDY: to investigate the hormonal status in HNSCC patients as compared to healthy controls and alcoholic persons in order to find changes, if any, characteristic for cancer.  METHOD: The liver function expressed by gamma-GT levels, the hypophysis gonadotrop hormone (FSH, LH, prolactin) and sex steroid hormone serum levels were examined in 130 male HNSCC patients, in 54 men with alcoholic liver disease but without any known cancer and in 56 healthy men as controls. RESULTS: When compared to the healthy controls, both alcoholics and tumor patients had abnormal liver function, testosterone, sex hormone binding globuline and prolactin levels, reflecting the presence of alcoholic liver disease in tumor patients as well. However, abnormally elevated circulating FSH (p<0.005) and LH (p<0.0003) levels were present only in the tumor patients.  CONCLUSION: Sex steroid hormone abnormalities are common among head and neck cancer patients, mainly as results of the chronic alcoholic liver disease. Elevation of FSH and LH levels suggests a potential role of these hormones in the formation of head and neck cancer. The exact role of the hypothalamus-hypophysis-liver axis in the biology of head and neck cancer requires further investigations.
C1 [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Szamel, Iren] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Gundy, Sarolta] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM reva@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 329
EP 332
PG 4
ER

PT J
AU Kovesi, Gy
   Szende, B
AF Kovesi, Gyorgy
   Szende, Bela
TI Progression of the leukoplakia is associated to changes in apoptotic and mitotic index as well as in p53 and Ki-67 expression
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION: Leukoplakia is the most frequent preblastomatous alteration in the oral cavity. Its potential for malignant transformation is unpredictable. The aim of the present study was to provide data to the prognosis and molecular genetic background of this disease.  MATERIALS AND METHODS: Biopsy material from 15 leukoplakia patients and three oral squamous cell carcinoma patients treated at the Department of Periodontology, Semmelweis University were studied with histological and immunohistochemical methods. Hemotoxylin and eosin staining, Apop-Detect kit (for TUNEL reaction), immunohistochemical reactions for Ki-67 and p53 were applied. The severity of dysplasia, mitotic and apoptotic index and expression as well as distribution of Ki-67 and p53 were examined and related to the clinical appearance of leukoplakia.  RESULTS: Mitotic and apoptotic index, Ki-67 expression increased significantly in parallel with the severity of dysplasia and also with the clinical stage (homogenous, nodular erythroleukoplakia). Positivity and intracellular localisation of mutant p53 varied according to the clinical forms of leukoplakia. Homogenous and nodular forms showed cytoplasmic while erythroleukoplakia and carcinoma were characterized by nuclear positivity.  CONCLUSION: Increased mitotic, apoptotic and Ki-67 index may indicate unfavourable prognosis of leukoplakia. The expression of Ki-67 and p53 in various forms of leukoplakia varies in parallel with the severity of leukoplakia.
C1 [Kovesi, Gyorgy] Semmelweis Egyetem, Fogorvostudomanyi Kar, Parodontologiai KlinikaBudapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., H-1085 Budapest, Hungary.
RP Szende, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, H-1085 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 333
EP 338
PG 6
ER

PT J
AU Mandoky, L
   Geczi, L
   Doleschall, Z
   Csuka, O
   Bodrogi, I
   Bak, M
AF Mandoky, Laszlo
   Geczi, Lajos
   Doleschall, Zoltan
   Csuka, Orsolya
   Bodrogi, Istvan
   Bak, Mihaly
TI Lung Resistance Protein analysis in testicular cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Germ cell testicular cancers are well-curable neoplasms, because total remission can be achieved in about 80% of the cases. However, 15-20% of the patients die due to drug resistance (DR). A number of mechanisms of the multidrug resistance phenotype are known, including MDR/P-glycoprotein (P-gp) and the so-called multidrug resistance associated protein (MRP). Lung Resistance Protein (LRP) is an ATP dependent membrane transporter protein associated with MDR. In our present work we studied the expression of LRP in testicular cancers. LRP expression was determined by immunohistochemistry (IH), Western blot (WB) and RT-PCR techniques. Clinical resistance was defined in accordance with the clinical oncologic rules. In 29 (41%) of 70 primary testicular tumours and in 22 (63%) of 35 cases, elevated LRP levels were established by IH and WB, respectively. In the latter 63%, the LRP mRNA levels were elevated as well. Six cases of the 15 seminomas and 23 cases of the nonseminomatous germ cell tumours (NSGCT) proved to be positive. No relationship was demonstrated between LRP expression and the stage of the disease. Despite the LRP positivity of 6 tumour samples, all of the seminomas proved sensitive. Of the 39 sensitive NSGCT, 27 cases were LRP-negative, whereas 11 tumour samples of 16 patients belonging to the resistant group proved LRP-positive (p=0.04). The authors concluded that the expression of LRP is responsible for clinical drug resistance in non-seminomatous testicular cancer patients.
C1 [Mandoky, Laszlo] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gy. u. 7-9., H-1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Bak, Mihaly] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gy. u. 7-9., H-1122 Budapest, Hungary.
RP Bak, M (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, H-1122 Budapest, Hungary.
EM bak@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 339
EP 345
PG 7
ER

PT J
AU Boer, A
   Polus, K
AF Boer, Andras
   Polus, Karoly
TI Lingual thyroid: A rare disease resembling base of tongue cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The ectopic thyroid gland occurring in the midline of the base of tongue is a rare developmental anomaly. It may cause differential diagnostic problems with real malignant tumor. Symptoms, if where are any: foreign-body-feeling, swallowing difficulties, dyspnea, articulation disorders, bleeding and hypothyroidism, but in many cases the diagnosis is accidental. We describe two cases of lingual thyroid gland operated in our department, and discuss the present trends of the treatment of this disease. We agree with most of the authors that only cases presenting with symptoms should be operated, and if possible the normal thyroid tissue should be replaced into the body. However, all discovered cases have to be followed to avoid late hormonal disturbances.
C1 [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9, H-1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9, H-1122 Budapest, Hungary.
RP Boer, A (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, H-1122 Budapest, Hungary.
EM boer@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 347
EP 349
PG 3
ER

PT J
AU Miltenyi, Zs
   Keresztes, K
   Varoczy, L
   Illes, �
AF Miltenyi, Zsofia
   Keresztes, Katalin
   Varoczy, Laszlo
   Illes, Arpad
TI Renal and ureter complications from the treatment of Hodgkin's disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: The authors analysed renal and ureter complications in Hodgkin’s disease patients after treatment.  PATIENTS AND METHODS: We examined retrospectively 512 primary treated and followed up patients with Hodgkin’s disease.  RESULTS: We observed renal, ureter or bladder complications after irradiation in 16 cases (3.125%). Five patients had injured left kidney, out of them only two had pyuria or proteinuria and 4 received radiotherapy and chemotherapy as well. We observed complications of both kidneys in 7 patients. Four patients had pyelonephritis or cystitis. We did not find severe cystitis in patients treated wsith cyclophosphamide.  CONCLUSIONS: Acute and chronic irradiation nephropathy are rather anatomic than functional lesions. Planning, dose and period of the radiotherapy, irradiation volume play parts in the development of complications. Prior chemotherapy increases incidence of irradiation nephropathy. These rare complications of Hodgkin’s disease are usually avoided with the use of modern radiotherapy apparatus and the up to date treatment methods.
C1 [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Keresztes, Katalin] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Varoczy, Laszlo] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
RP Miltenyi, Zs (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, H-4004 Debrecen, Hungary.
EM mizso@iiibel.dote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 351
EP 355
PG 5
ER

PT J
AU Vegh, J
   Vadasz, Gy
   Miltenyi, Zs
   Soltesz, P
   Tizedes, F
   Illes, �
AF Vegh, Judit
   Vadasz, Gyorgyi
   Miltenyi, Zsofia
   Soltesz, Pal
   Tizedes, Franciska
   Illes, Arpad
TI The occurrence of valvulopathy in long term complete remission Hodgkin’s disease patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: To study the occurrence of valvulopathies after treatment in Hodgkin’s disease patients.  PATIENTS AND METHODS: 124 Hodgkin’s disease patients in complete remission for at least 1 year were echocardiographically examined.  RESULTS: Abnormal finding was observed in 48/124 (38.4%) of patients, all of them presented with regurgitation, no stenosis was observed. Regurgitation of grade I or II was recorded in most cases. We have found single valvulopathy in 25/48 (52.1%) of patients, and multiple valvulopathy in 23/48 (47.9%) of patients. In most cases (78.7%) the valvulopathy was detected in left heart. Among these 48 patients the ratio of females was significantly higher than those of males, and also the ratio of the patients in early phase compared with those in late phase. We could detect vitium mostly in those patients who had mediastinal irradiation. The combined treatment, including anthracycline therapy, did not increase the frequency of vitium.  CONCLUSION: The occurrence of valvulopathy is frequent in Hodgkin’s disease patients, particularly in patients treated by radiation. This is the reason why Hodgkin’s disease patients should be examined regularly with echocardiography. These patients with valvulopathy need treatment adjusted to their state of health, and where possible, the complications should be prevented. In the future, when planning of the radiotherapy - mediastinal irradiation of the Hodgkin’s disease patients their heart protection from radiation should be taken into account.
C1 [Vegh, Judit] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Vadasz, Gyorgyi] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Soltesz, Pal] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Tizedes, Franciska] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., H-4004 Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 357
EP 360
PG 4
ER

PT J
AU Horvath, Zs
AF Horvath, Zsolt
TI Role of adjuvant clodronat treatment in the prevention of bone metastasis in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Bisphosphonates are effective against increased bone resorption because they inhibit osteoclast activity. The use of these drugs is well established for the treatment of metastatic breast and other cancers; they reduce skeletal complications, hypercalcemia, bone pain, and metastatic progression and they can improve the overall survival and quality of life. Preclinical observations and early clinical data indicate that early bisphosphonate treatment reduces the incidence and the extent of newly developed metastases in breast cancer. There is considerable interest in determining whether bisphosphonate treatment is to prevent the incidence of bone metastases and associated complications. To date three randomized, controlled clinical trials have examined the effect of long-term use of clodronate (1600 mg/d po.) on the incidence of bone metastases, other metastases, the survival of patients, and the side effects of the study drug as well. All the trials have observed significant reduction of the occurrence of bone metastases, although this reduction was significant only during the medication period. One of the trials mentioned have shown an unexpected reduction in non-osseous metastases, and two of them have revealed significant improvements in the death rates. These promising results need further evaluation by large clinical trials with longer treatment periods to establish the clinical role of adjuvant bisphosphonate treatment of primary breast cancer.
C1 [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
EM horvathzs@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 361
EP 364
PG 4
ER

PT J
AU Lampek, K
   Torocsik, M
AF Lampek, Kinga
   Torocsik, Maria
TI The treatment of bone metastases with bisphosphonates - the patients’ view
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The Hungarian bisphosphonate market has been increasing for years; last year the number of patients was approximately 3200-3500. We decided to start a research among patients having malignant disease with bone metastases, in order to find out how patients evaluate the drugs, how they are informed and what is the role of doctors and nurses in compliance. Nearly 300 patients filled questionnaires and we have made 16 indepth interviews. The average age of patients was 57 years. More than 60% of patients were younger than 60 and the male-female ratio was 1:2. We found that more than one quarter of the patients arrived to their doctor from farther than 50 km and 70% of them meet their doctor at least once a month. The results showed that 95% of patients would prefer oral treatment (tablets or capsules), and 75% of the patients would choose tablets, if they were asked. Most of the patients wanted to be informed primarily by doctors. Nurses were the ''hostesses” of emotional problems. Doctor-patient relationship was characterised by paternalism. Female patients were more open to nurses, they talked over smaller problems emerging during the treatment and the same occured with some male patients, too. Only 5% of patients received the treatment of their choice. Patients want to be involved more actively in the planning of their treatment process than doctors think, they expect that doctors should prefer their interest. Cancer patients are frequently underinformed and they expect more help to solve their psychological problems.
C1 [Lampek, Kinga] Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Magatartastudomanyi IntezetPecs, Hungary.
   [Torocsik, Maria] Pecsi Tudomanyegyetem Kozgazdasagtudomanyi Kar, Marketing TanszekPecs, Hungary.
RP Lampek, K (reprint author), Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Magatartastudomanyi Intezet, Pecs, Hungary.
EM net300@axelero.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2002
VL 46
IS 4
BP 367
EP 371
PG 5
ER

PT J
AU Gilde, K
AF Gilde, Katalin
TI Milestones leading to new perspectives in melanoma therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The author stresses, out of the abundant literature of melanoma, those new pieces of information that have changed the conventional therapeutic approach to melanoma. Elements of melanoma progression leading to a rational transformation of the dogmatic radical surgery are described. In addition, the phenomenon of regression, still requiring further investigations, is also dealt with, as well as the hormonal dependence of melanoma, which has practical importance in the management of some problems, e.g. indication of pregnancy interruption, hormonal contraception, and hormon substitution therapy in postmenopausa. The limited effectiveness of conventional complex tumour killing mechanisms (chemotherapy and radiotherapy) necessitates new therapeutic strategies based on tumour biological knowledge. Finally, the fields of application of vaccination and antiangiogenic and gene manipulation techniques are touched upon.
C1 [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Gilde, K (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM gilde@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 3
EP 11
PG 9
ER

PT J
AU Gaudi, I
   Kasler, M
AF Gaudi, Istvan
   Kasler, Miklos
TI New cases of melanoma as documented in the National Cancer Registry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors briefly survey general aspects of crucial importance for the proper functioning of the National Cancer Registry, such as legislation, collected data, identification of patients, the completeness and validity of its content in relation to the results and conclusions of a comprehensive, national supervision performed after the Melanoma Consensus Conference. Compared to earlier national controlling attempts, the present supervision was highly successful: doctors of various hospitals did perform the detailed control of diagnosis in 95.81% of 1361 melanoma patients announced in 2001. They checked whether patients given the C43 BNO code had melanoma indeed, searched for those who received a different BNO code and identified those not announced for any reason to the Registry. After correction the Registry included 1117 new cases of melanoma in 2001. The authors state that the conclusions from this supervision may enhance the reliability not only of the data base of the Registry but that of the hospitals as well.
C1 [Gaudi, Istvan] MTA, Szamitastechnikai es Automatizalasi Kutato IntezeteBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Gaudi, I (reprint author), MTA, Szamitastechnikai es Automatizalasi Kutato Intezete, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 13
EP 17
PG 5
ER

PT J
AU Gilde, K
AF Gilde, Katalin
TI Naevus pigmentosus and melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Clinical observations and histological findings support the relationship between pigmented naevi and melanoma. The author describes the morphological characteristics of congenital, acquired and atypical naevi in relation to the appearance of melanoma. On the basis of clinical observations, in harmony with other investigators, the author advises patients to perform self examination and to undergo regular survey of numerous atypical naevi by a dermatologist. In fact, any of the atypical pigmented naevi present in high number may be a precursor lesion. Patients with such lesions are at higher risk of melanoma development.
C1 [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Gilde, K (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM gilde@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 19
EP 26
PG 8
ER

PT J
AU Orosz, Zs
AF Orosz, Zsolt
TI Pitfalls in the diagnosis of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The histological appearance of benign melanocytic naevi and malignant melanomas can be variable, causing in a significant number of cases severe differential diagnostic problems. The early, thin (less than 1 mm) melanomas have to be differentiated from naevi containing dominant junctional or lentiginous component or pagetoid melanocytosis and from some epithelial tumours, while in cases of thick lesion the diagnosis of thick melanoma, Spitz naevus, deep penetrating naevus or cellular blue naevus should be considered for example. The morphology of the so-called atypical Spitz naevus and atypical pigmented spindle cell naevus show overlapping with malignant melanoma and sometimes in these cases the biological behaviour cannot be assessed. The variable appearance of malignant melanoma is illustrated by the fact that different superficial soft tissue tumours with epithelioid and/or spindle cells or with pigment can mimic it. The rare balloon cell and signet ring cell melanoma is a mimicker of primary or metastatic carcinoma and the desmoplastic variant is often misdiagnosed as benign mesenchymal lesion. Lymph node metastasis of melanoma, when the primary tumour is not known, may raise the possibility of interdigitating reticulum cell tumour or anaplastic large cell lymphoma.
C1 [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Orosz, Zs (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, 1122 Budapest, Hungary.
EM zso@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 27
EP 39
PG 13
ER

PT J
AU Magori, A
AF Magori, Aniko
TI The role of fine needle aspiration biopsy in th diagnosis of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The role of fine needle aspiration biopsy (FNAB) is discussed in the follow up of patients with the diagnosis of malignant melanoma. The review is based on literary data and the author’s own material. The primary role of FNAB is to confirm metastatic or recurrent melanoma lesions. US or CT guided FNAB is valuable in the diagnosis of visceral metastases. FNAB has limited role in the diagnosis of primary melanomas except in cases with unusual clinical presentation (e.g. oral mucosa). In spite of the well-known cytology the diagnosis can be difficult due to the inherent histological variation of malignant melanomas, especially in cases with unusual localisation and amelanotic tumor presentation when immunocytochemistry is needed. The known clinical history of melanoma is very helpful.
C1 [Magori, Aniko] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Magori, A (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 41
EP 43
PG 3
ER

PT J
AU Szekeres, Gy
   Battyani, Z
AF Szekeres, Gyorgy
   Battyani, Zita
TI Immuno-diagnosis of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The diagnosis of malignant melanoma must be followed by treatment shown to be effective. Therefore a correct diagnosis, including staging, that will permit a meaningful prognosis and treatment, is essential. The usefulness and great specificity of immunological methods is based on the detection of antigens characteristic of neoplastic and reactive cells. In cases of malignant melanoma, immunohistochemistry has limited practical value in the routine diagnosis of melanocytic lesions. The method may be important, however, in the differential diagnosis of, for example, malignant melanoma vs. non-melanocytic anaplastic neoplasia, malignant vs. benign melanocytic lesions, etc. Recent advances in relating the immunostaining of antigens to the development of tumor cells, such as proliferation and apoptosis, metastatic potential, etc. have given considerable importance to the immunomorphological evaluation of malignant melanomas. Likewise, immunotherapy requires the immunophenotyping of the reactive cells of the immune system.
C1 [Szekeres, Gyorgy] Hisztopatologia KFT, 7608 Pecs, Hungary.
   [Battyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Szekeres, Gy (reprint author), Hisztopatologia KFT, 7608 Pecs, Hungary.
EM histopat@mail.datanet.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 45
EP 50
PG 6
ER

PT J
AU Cserni, G
AF Cserni, Gabor
TI Pathological work-up and assessment of sentinel lymph nodes in melanoma patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB This review summarizes data related to the pathological assessment and interpretation issues of sentinel lymph nodes in melanoma patients. After a short description of conventional nodal staging of melanoma, separate sections deal with detailed analysis of sentinel nodes, the use of immunohistochemistry, molecular analysis of occult metastases and the possibilities and limitations of intraoperative assessment. Possible pitfalls of each method are also discussed. Finally, research areas related to sentinel nodes are highlighted, too.
C1 [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of Pathology, Nyiri ut 38., 6000 Kecskemet, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, 6000 Kecskemet, Hungary.
EM cserni@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 51
EP 57
PG 7
ER

PT J
AU Olah, J
   Dobozy, A
AF Olah, Judit
   Dobozy, Attila
TI The new TNM classification of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The identification of increasingly powerful prognostic factors has led to sequential modifications of the cutaneous melanoma staging system. The American Joint Commitee on Cancer (AJCC) recently proposed major revision of tumor-nodemetastasis (TNM) categories and stage groupings for melanoma. The authors summarize the main characteristics of this new TNM classification of malignant melanoma. The importance of the novel technique - sentinel node biopsy - in the management of malignant melanoma is discussed.
C1 [Olah, Judit] University of Szeged, Department of Dermatology and Allergology, Koranyi fasor 6.Szeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and Allergology, Koranyi fasor 6.Szeged, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
EM oj@derma.szote.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 59
EP 61
PG 3
ER

PT J
AU Timar, J
   Csuka, O
AF Timar, Jozsef
   Csuka, Orsolya
TI Molecular diagnostics of malignant melanoma: molecular staging, minimal residual disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Nucleic acid based molecular techniques have been introduced into the diagnosis of malignant melanoma similarly to other cancers. They were applied for refinement of staging and to detect minimal residual disease. There are several good melanocyte-specific genetic markers such as tyrosinase, gp100, Melan-A/MART-1 and MIA. Unlike in the case of the lymph nodes, peripheral blood or bone marrow do not contain melanocytes excluding the possibility of fals positive reactions. Considering the pronounced heterogenity of melanoma cells the most reliable molecular marker is the expression of tyrosinase. Several studies indicate that the quantity of circulating melanoma cells correlates with tumor burden and disease progression and reflects the effect of therapy. On the other hand, molecular techniques detect circulating melanoma cells much more frequently than the clinical manifestation of the disease progression (molecular recurrence), questioning the clinical significance of the detection of a small number of melanoma cells in the circulation. Based on these data molecular diagnostics is not part of the melanoma protocols yet and further studies are necessary to define its diagnostic role.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 63
EP 66
PG 4
ER

PT J
AU Peley, G
   Farkas, E
   Matrai, Z
   Renyi-Vamos, F
   Kovacs, T
   Koves, I
AF Peley, Gabor
   Farkas, Emil
   Matrai, Zoltan
   Renyi-Vamos, Ferenc
   Kovacs, Tibor
   Koves, Istvan
TI The role of surgery in the treatment of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Surgical interventions have important role in the treatment of all stages of malignant melanoma. Surgery is the primary treatment of localized cutaneous melanoma. Excision of the primary tumor makes it possible to set up the histological diagnosis and to determine pathological prognostic factors. Appropriate surgical margin is important for local disease control. Sentinel lymph node biopsy with detailed histological examination has gained prominent importance for correct histological staging and for determining adjuvant oncological treatment. Surgery is the primary treatment of isolated regional metastases. Surgical methods also have a role in the palliative management of distant metastatic melanoma. In the present review the most important issues of the surgical treatment of malignant melanoma have been discussed in detail.
C1 [Peley, Gabor] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kovacs, Tibor] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Peley, G (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM peley@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 69
EP 77
PG 9
ER

PT J
AU Liszkay, G
   Peley, G
   Sinkovics, I
   Peter, I
   Fejos, Zs
   Horvath, B
   Banfalvi, T
   Gilde, K
   Koves, I
AF Liszkay, Gabriella
   Peley, Gabor
   Sinkovics, Istvan
   Peter, Ilona
   Fejos, Zsuzsanna
   Horvath, Bela
   Banfalvi, Teodora
   Gilde, Katalin
   Koves, Istvan
TI Report on clinical observations obtained with sentinel lymph node surgery in malignant melanoma and during their follow-up at the Department of Dermatology, National Institute of Oncology, Budapest
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: Report on clinical observations obtained with sentinel lymph node surgery for malignant melanoma and during follow-up at the Department of Dermatology, National Institute of Oncology, Budapest. PATIENTS AND METHOD: In the period from November, 1997 to September, 2002, the above surgical intervention was made with 179 patients having primary tumour, one to two months after primary tumour removal. Staining with patent blue was combined with isotope technique. The primary melanoma and the pertaining sentinel lymph node(s) were removed. Histological evaluation of the sentinel lymph nodes was performed in serial sections. Immunohistochemical detection of S100, HMB-45, or Melan-A was used in the case of suspected micrometastases. Demonstration of positive sentinel lymph nodes was followed, preferably within 2-3 weeks, by regional block dissection. Interferon in low doses or BCG immune therapy were applied as adjuvant therapy. Bimonthly follow-up of the patients included physical examination and the use of imaging techniques as specified in the melanoma protocol. RESULTS: Sentinel lymph node surgery was successful in 177/179 cases (98%). Positive sentinel lymph node was identified in 26/177 patients (14%). In node positive patients the thickness of the primary tumour was significantly greater than that of node negative ones (p<0.0000). Patients with micrometastases had significantly poorer symptom-free and overall survival by the Mantel-Cox test than those of the other group (p=0.0001 and p=0.0007, respectively). In the discriminance analysis of our data, the discriminant function established from tumour thickness yielded 81.7% and the positivity of sentinel lymph nodes 79.9% correct classification rates. CONCLUSION: In good harmony with literature data, positive sentinel lymph node(s) were found in the case of thicker tumours. The involvement of sentinel lymph node indicated a significantly poorer prognosis.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Bela] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Banfalvi, Teodora] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM liszkay@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 79
EP 83
PG 5
ER

PT J
AU Somlai, B
AF Somlai, Beata
TI Clinical characteristics of melanoma metastasis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Approximately one third of clinical Stage I melanoma patients will experience disease recurrence. The author reviews the main prognostic factors predicting the outcome of melanoma patients, the incidence, pattern and time of first metastases. Of all recurrences, two third will occur earlier by the lymphatic, and one third later by the hematogenous pathway. 75-80% of recurrences develop in the first 3 years, 3-4% of metastases occur after 10 years of disease-free interval. The data emphasize the value of lifelong follow-up.
C1 [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Maria u. 41., 1085 Budapest, Hungary.
RP Somlai, B (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, 1085 Budapest, Hungary.
EM sombea@bor.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 85
EP 88
PG 4
ER

PT J
AU Banfalvi, T
   Edesne, BM
   Gergye, M
   Udvarhelyi, N
   Orosz, Zs
   Gilde, K
   Kremmer, T
   Otto, Sz
   Timar, J
AF Banfalvi, Teodora
   Edesne, B Mariann
   Gergye, Maria
   Udvarhelyi, Nora
   Orosz, Zsolt
   Gilde, Katalin
   Kremmer, Tibor
   Otto, Szabolcs
   Timar, Jozsef
TI Laboratory markers of melanoma progression
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immunkomplex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropiate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.
C1 [Banfalvi, Teodora] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Edesne, B Mariann] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Gergye, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kremmer, Tibor] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Banfalvi, T (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 89
EP 104
PG 16
ER

PT J
AU Torok, L
AF Torok, Laszlo
TI Adjuvant interferon treatment of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Interferon is a pleiotropic antitumor biological agent that elicits its effect in a dose-dependent manner. Interferon has been tested in high, medium, and low doses; controlled studies, however, indicated that only high-dose therapy markedly prolonged the survival rate. Due to its high toxicity, the high-dose treatment modality has not been widely accepted. At present, neither the optimal dose, nor the duration of interferon adjuvant therapy are established. Furthermore, parameters that could predict responders to treatment are not yet identified. Before careful evaluation of the large-scale, controlled, multi-centric studies, the authors recommend strategy that combines intermedier and highdose therapy for adjuvant treatment of patients with melanoma.
C1 [Torok, Laszlo] Bacs-Kiskun Megyei Korhaz, Borgyogyaszat, Nagykorosi u. 15., 6000 Kecskemet, Hungary.
RP Torok, L (reprint author), Bacs-Kiskun Megyei Korhaz, Borgyogyaszat, 6000 Kecskemet, Hungary.
EM laszlo.a.torok@axelero.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 105
EP 107
PG 3
ER

PT J
AU Fedorcsak, I
   Sipos, L
AF Fedorcsak, Imre
   Sipos, Laszlo
TI Current treatment of melanoma metastases of the brain
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The appearence of brain metastases in patients with malignant melanoma predicts poor prognosis. During the last ten years important progress has been made in the treatment of brain metastases providing longer survival and better quality of life for these patients. In this review article the different treatment modalities, surgery, radiosurgery, radiation therapy and chemotherapy are described and the results published in the literature are briefly presented. Emphasis is made to show the effectiveness of a multimodality approach of this group of patients resulting in a better clinical outcome.
C1 [Fedorcsak, Imre] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Sipos, Laszlo] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
RP Fedorcsak, I (reprint author), National Institute of Neurosurgery, 1145 Budapest, Hungary.
EM fedoimr@mailer.oiti.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 109
EP 112
PG 4
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI Possibilities for the immunotherapy of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Despite their well-documented immunogenicity, malignant melanomas belong to the most aggressive tumor types. A potential explanation for this is the suboptimal activation of tumor infiltrating T cells. In order to boost immune responses against tumors, a variety of treatment modalities have been tested in animal models and in clinical setting. Antigen-nonspecific approaches (e.g., IFN-alpha and IL-2), as well as active specific immunotherapeutical modalities based on the use of autologous or allogeneic tumor cellsave been investigated in clinical trials of melanoma. The identification of melanoma-associated antigens has opened new avenues in antigen-specific immunotherapy. A promising alternative for the delivery of different forms of melanoma antigens is the application of dendritic cells, the most potent antigen presenting cells capable of eliciting efficient T-cell response. Beside active immunotherapy, immune response against melanoma antigens could be increased through the adoptive transfer of tumor infiltrating lymphocytes or antigenspecific T-cell clones. The most important conclusion that can be drawn from the results of published immunotherapy studies is that these modalities are able to induce durable complete tumor regressions,mostly with reasonable toxicity; however, generally only in a minority of patients. This points to the importance of appropriate patient selection, with regard to the expression of the targeted antigens and HLA molecules, as well as to the general immunocompetence of the patients. A crucial and still unsolved question is monitoring immune activation during treatment, although there are promising new tools that could prove useful in this respect. The presence of tumor-reactive CTL in the circulation or in the tumors does not guarantee an efficient immune response. It is important to assess if these T cells are in an activated and functional state. Finally, in several single target antigen-based clinical studies a therapy-induced immunoselection of antigen-negative clones, leading to disease progression, was observed. This could be overcome with the use of antigen cocktails or whole tumor approaches. A better understanding of the mechanisms of action of immunotherapeutical modalities may enhance the success rate of these strategies.
C1 [Ladanyi, Andrea] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
EM ladanyi@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2003
VL 47
IS 1
BP 113
EP 117
PG 5
ER

PT J
AU Kopper, L
AF Kopper, Laszlo
TI Apoptosis and tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM kopper@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 123
EP 131
PG 9
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI Perspectives for the hormonal therapy of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The role of estrogens, including its sources, tissue distribution, metabolism, and mechanism of action, is discussed in this review. The ER alpha and beta are functioning separately, and there is a physiological balance between their activity. Whenever this balance is overthrown due to endogenous or exogenous carcinogenic factors, malignancy develops. Risk factors of breast cancer are listed and evaluated individually. It should be stressed however, that their carcinogenic effect sums up. The knowledge of established risk factors rises the possibility of chemoprevention, which might be highly desirable in case of gene carriers. Special emphasis is attached to the SERM molecules which act as antiestrogens. Their antitumour effect is largely used in the treatment of hormone sensitive advanced breast cancer patients, and their efficacy has been proved in adjuvant therapy as well. Their preventive use might also be justified, especially in gene carriers. Aromatase inhibitors form a special class among the SERM molecules. In Hungary, anastrozole, letrozole and exemestane are widely applied for the therapy of breast cancer patients, while raloxifene has only been introduced recently, mainly in order to prevent osteoporosis. The therapeutic value of fulvestrant is unknown yet and its antitumour effect has to be explored. The therapeutic significance of these molecules lies in the fact that they might be effective after the development of tamoxifen resistance. There are several explanations for this phenomenon offering new targets for the further development of a succesful antitumour chemotherapy.
C1 [Eckhardt, Sandor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM eckhardt@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 133
EP 140
PG 8
ER

PT J
AU Boer, K
   Lang, I
   Juhos, �
   Pinter, T
   Szanto, J
AF Boer, Katalin
   Lang, Istvan
   Juhos, Eva
   Pinter, Tamas
   Szanto, Janos
TI Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: The authors present the Hungarian interim analysis and experience with the BCIRG 001 randomized, multicentric, phase III clinical trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients. The results are presented according to international data.  PATIENTS AND METHODS:  Three Hungarian centers - St. Margit Hospital, Budapest, National Institute of Oncology, Budapest, Petz Aladar Hospital, Gyor - participated in the international trial. Between June 1997 and June 1999, 61 patients with node positive breast cancer were enrolled in the study after the surgery. Thirty-four patients were randomized to TAC (75/50/500 mg/m2 6x q3wk) and 27 patients were randomized to FAC (500/50/500 mg/m2 6x q3wk) chemotherapy, with prospective stratification by node (1-3, 4+). In the case of patients with ER and/or PR positive tumours 5 years tamoxifen treatment was started. Radiotherapy was performed after the 6th cycle of chemotherapy.  RESULTS: 36 months of follow up was performed. In both arms the hematological toxicity was more frequent. The TAC group showed a higher incidence of neutropenia (76%) compared to the FAC (22%), as well as a higher incidence of febrile neutropenia (26%), without grade 3-4 infection and there were no cases of septic death. Regarding non-hematological toxicity more grade 3-4 nausea and vomiting was observed in the FAC group. At three years follow up, the international results show statistically significant improvement in disease-free survival (82% vs. 74%, p=0.0011) in favour of TAC, and similar tendency was observed in the case of overall survival (92% vs. 87%, p=0.11). This benefit with TAC was seen regardless of hormone receptor status. Due to the low number of Hungarian patients we cannot declare the same results.  CONCLUSIONS: Based on the international analysis TAC was superior to FAC chemotherapy. Additional follow up data will evaluate the role of TAC in the adjuvant setting of early breast cancer treatment. The results indicate that TAC has the potential to be incorporated in the new strategies of adjuvant breast cancer treatments.
C1 [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Becsi ut 132., 1032 Budapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Pinter, Tamas] Petz Aladar County HospitalGyor, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Boer, K (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, 1032 Budapest, Hungary.
EM kboer@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 141
EP 148
PG 8
ER

PT J
AU Boncz, I
   Sebestyen, A
   Gulacsi, L
   Pal, M
   Dozsa, Cs
AF Boncz, Imre
   Sebestyen, Andor
   Gulacsi, Laszlo
   Pal, Miklos
   Dozsa, Csaba
TI Health economics analysis of breast cancer screening
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION: The organized breast cancer screening programme has started in Hungary at the end of 2001.  AIM: To assess the screening rate, the cost of screening and treatment and to calculate the expected epidemiological and economic gain and cost-effectiveness of mass-screening programme. Methods: The data derive from the financial database of the National Health Insurance Fund of Hungary from 2001. To assess the screening rate the authors used the code ''No. 42400 mammography screening'' of outpatient care. The cost of treatment includes the cost of outpatient care, the acute and chronic inpatient care, the subsidies of the prices of medicines and the expenditure on disability to work (including sickness-pay). The expected benefits of the screening programme were modeled with changing mortality decrease for a 10 years interval. RESULTS: The screening rates of women aged 45-65 for 2001 and 2002 were 7% and 21.7%, respectively. The cost of treatment of breast cancer was around 8.6 billion Hungarian forints (29,939,868 USD, 33,426,321 EUR) in 2001. In the age-group 45-65 with 10% mortality decline 509 lives (net present value, NPV: 365), with 20% mortality decline 1.074 (NPV: 772) lives and with 30% mortality decline 1.582 (NPV: 1.139) lives can be saved during a 10 years screening programme. The cost of one life saved varies between 5.7 million forints (19,876 USD, 22,190 EUR)/life saved and 17.8 million forints (62,047 USD, 69,273 EUR)/life saved according to the mortality decline. The cost of one life year saved varies between 271,000 forints (946 USD, 1057 EUR)/life year saved and 847,000 forints (2955 USD, 3299 EUR)/life years saved. CONCLUSION: The implementation of organized breast cancer screening can lead to cost savings in Hungary. The cost-effectiveness of breast cancer screening seems to be acceptable for purchaser.
C1 [Boncz, Imre] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Sebestyen, Andor] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Gulacsi, Laszlo] Budapesti Kozgazdasagtudomanyi es Allamigazgatasi Egyetem, Kozszolgalati TanszekBudapest, Hungary.
   [Pal, Miklos] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Dozsa, Csaba] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
RP Boncz, I (reprint author), Orszagos Egeszsegbiztositasi Penztar, 1139 Budapest, Hungary.
EM boncz.i@oep.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 149
EP 154
PG 6
ER

PT J
AU Remenar, �
   Szamel, I
   Budai, B
   Orosz, Zs
   Gaudi, I
   Kasler, M
   Gundy, S
AF Remenar, Eva
   Szamel, Iren
   Budai, Barna
   Orosz, Zsolt
   Gaudi, Istvan
   Kasler, Miklos
   Gundy, Sarolta
TI Hormonal influence in head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE OF THE STUDY: to investigate the clinical outcome of HNSCC patients, and their hormonal status. METHOD: The liver function (GGT), hypophysis gonadotrop hormone (FSH, LH, prolactin) and sexsteroid hormone serum levels were examined in 130 male HNSCC patients. Clinical parameters for age, primary tumor site and clinical tumor stage were also recorded. RESULTS: The survival was disadvantageously influenced by the following parameters: age, the presence of lymph node metastasis, advanced tumor stage, the lower than normal testosterone and the higher than normal FSH serum levels. CONCLUSION: Elevated FSH and decreased testosterone serum levels showed significant correlation with the survival of head and neck cancer patients. The better understanding of their exact role in the biology of HNSCC requires further investigations.
C1 [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Szamel, Iren] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Gundy, Sarolta] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM reva@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 155
EP 159
PG 5
ER

PT J
AU Takacsi Nagy, Z
   Varga, J
   Poller, I
   Fodor, J
   Major, T
   Nemeth, Gy
AF Takacsi Nagy, Zoltan
   Varga, Janos
   Poller, Imre
   Fodor, Janos
   Major, Tibor
   Nemeth, Gyorgy
TI Successful treatment of a localised pancreatic cancer with radiotherapy alone: a case report
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB AIM: To present a unique case of an early (T1N0M0) adenocarcinoma of the head of the pancreas, which was successfully treated with radiotherapy alone. MATERIAL AND METHOD: After the computer tomography operated histological verification the combination of interstitial high dose rate after-loading brachytherapy (18 Gy, 6 Gy/die) and percutan irradiation (46 Gy) was applied. RESULT: Fifty-two months after completion of the treatment the patient is alive with no evidence of disease. CONCLUSION: The combination of these therapeutic modalities may be an effective tool to deliver curative dose without any significant sequelae in the treatment of operable pancreatic carcinoma, when the patient’s condition contraindicates surgery.
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Varga, Janos] Flor Ferenc Korhaz, Sebeszeti OsztalyKistarcsa, Hungary.
   [Poller, Imre] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM takacsi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 161
EP 163
PG 3
ER

PT J
AU Banfi, G
   Kiss, F
   Kadar, A
   Romics, I
AF Banfi, Gergely
   Kiss, Ferenc
   Kadar, Anna
   Romics, Imre
TI Summary of our clinical experiences with the determination of serum prostate-specific antigen level in the first 5-year period
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors determined serum PSA levels in combination with digital rectal examination (DRE) and evaluated their role in the differential diagnosis of prostate diseases with special reference to cancer. The possible causes of differences between the observed cut-off level of PSA and the standard level PSA were analyzed. In the last few years the PSA determination found its clinical role in the diagnosis of prostate cancer.
C1 [Banfi, Gergely] Semmelweis University, Department of Urology, Ulloi ut 78/b.Budapest, Hungary.
   [Kiss, Ferenc] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kadar, Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of Urology, Ulloi ut 78/b.Budapest, Hungary.
RP Banfi, G (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
EM banfigergely@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 165
EP 168
PG 4
ER

PT J
AU Kelecsenyi, Zs
   Szekely, G
   Gundy, S
AF Kelecsenyi, Zsolt
   Szekely, Gabor
   Gundy, Sarolta
TI Sporadic chromosomal aberrations in healthy individuals studied between 1986-2001
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In the second half of 2002, IARC for Central and Eastern European countries targeted studies on the relationship between chromosomal aberrations (CAs) and cancer risk. For these purposes we preliminarily investigated, under identical methodological circumstances, the base-line level of CAs in peripheral blood lymphocytes of 1414 healthy Hungarian persons between 1986 and 2001. The age and sex as biological, and smoking habit and residency (Budapest, industrial- and agricultural settlements) as environmental confounding factors were evaluated. Previously, people were not exposed to any known potential mutagens. The overall frequencies of aberrant cells (1.60±0.05%) were not influenced by sex, age and residency, but the smoking habits (1.84±0.09%) had significant impact on the elevation of aberrant cells. Aneuploidy, exchange-type dicentric chromosomes and the total of aberrations increased significantly with the age of the donors. The individual frequency of aberrant cells ranged between 0-12%. No aberrant cells were detected in 35% of individuals, and 1aberrant cell was found in 23% of the total population, while 42% of the examined persons were characterized with aberrant cell rates between 2-12%. The initial value of 0.85% of aberrant cells doubled by the end of the examined 16-year period, following 2-4-fold fluctuations. None of the investigated biological or environmental factors was responsible for the elevation of the CAs. The causes of the elevation of CA-level can be explained more precisely when these data will be compared to cancer registry database of these persons.
C1 [Kelecsenyi, Zsolt] National Institute of Oncology, Budapest, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Budapest, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Gundy, Sarolta] National Institute of Oncology, Budapest, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM gundy@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 169
EP 176
PG 8
ER

PT J
AU Sandor, J
   Szerencse, P
   Szucs, M
   Nemeth, �
   Kiss, I
   Ember, I
AF Sandor, Janos
   Szerencse, Peter
   Szucs, Maria
   Nemeth, Arpad
   Kiss, Istvan
   Ember, Istvan
TI Investigation of spatial cluster for environmental related cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB BACKGROUND: The environment is source of carcinogen effects, which cannot be monitored as precisely as it would be required. Due to this fact, it is worth to screen for areas with higher than expected number of cancers that is for clusters. The significance of cluster suspicion is highly variable and the investigations for clusters could need significant resources. Therefore step-wise protocols are recommended, which evaluate before proceedings the possibility of exclusion of cluster existence, or of requirement for further epidemiological investigations. Sometimes, the results establish actions to reorganise the environmental control. OBJECTIVES: The relationship between cancer incidence and dangerous waste disposal sites was investigated in Tolna county (Hungary) and the usefulness of cluster studies was demonstrated by the results. METHODS: The incidence data based on histological investigations and the location of 7 dangerous waste disposal sites were analysed by geographical information system. RESULTS: The incidences were not elevated around 6 sites. The cancer risk seemed to be high by site in settlement S., because of high standardised incidence ratio (SIH=1.41) and empirical Bayes adjusted SIH (SIHEB=1.38). The risk increase proved to be significant in z-test and mid-p test by 10% and 15% type I error. Since the risks showed nonhomogeneous spatial distribution in the county and the number of high-risk settlements was 2.3 to 6.6, the cluster in S. cannot be rejected as false positive observation. The chromium contaminated wastes have been stored in S. for several decades at river-side. Assuming that the exposure was spred by the river and the villages in the 5-km vicinity of the river were exposed, the SIHs were aggregated for every 15-km intervals. The distance from S. was inversely related to the aggregated SIHs. CONCLUSIONS: The sites proved to be noncarcinogenic sources apart from the site S. for which the results suggested the high-risk status. The environmental pollution by site in S. could explain the increased incidence. Consequently, additional studies are indicated in S. to improve the reliability of cluster evaluation. The study also demonstrated that the cluster investigation can be inserted into public health practise to improve the efficiency of cancer control.
C1 [Sandor, Janos] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti utca 12., 7643 Pecs, Hungary.
   [Szerencse, Peter] Allami Nepegeszsegugyi es Tisztiorvosi Szolgalat, Tolna Megyei IntezeteSzekszard, Hungary.
   [Szucs, Maria] Allami Nepegeszsegugyi es Tisztiorvosi Szolgalat, Tolna Megyei IntezeteSzekszard, Hungary.
   [Nemeth, Arpad] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti utca 12., 7643 Pecs, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti utca 12., 7643 Pecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti utca 12., 7643 Pecs, Hungary.
RP Sandor, J (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, 7643 Pecs, Hungary.
EM janos@pubhealth.pote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 177
EP 183
PG 7
ER

PT J
AU Ostoros, Gy
   Kovacs, G
   Gergely-Farnos, E
   Magyar, P
   Szondy, K
   Strausz, J
   Ferenczi, E
AF Ostoros, Gyula
   Kovacs, Gabor
   Gergely-Farnos, Erzsebet
   Magyar, Pal
   Szondy, Klara
   Strausz, Janos
   Ferenczi, Eniko
TI Efficacy of Gemzar-Cisplatine treatment in stage IIIA-N2, IIIB and IV non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB 120 chemotherapy naive patients were treated with gemcitabine 1250 mg/m2 iv. days 1 and 8 and cisplatin 70 mg/m2 iv. on day 1 between May 1999 and June 2001. The treatments were administered in 21 cycles. The median age of the patients was 53.1 years, the male/female ratio 65%-35%. Performance status was: WHO 0: 26%, WHO 1: 74%. The staging of patients were: IIIA-N2 23%, IIIB 37%, IV 40%. By histology the tumors were: 53.3% adenocarcinoma, 40% squamous cell carcinoma, 2.5% adenosquamous carcinoma, 0.8% macrocellular carcinoma and 3% non-small cell carcinoma (not categorised). We evaluated 413 cycles of chemotherapy. The median number of cycles was 3.44. The primary endpoint of the study was the median survival and time to progression, and the response rate. The results are the following: RR 40% (PR 37.5%, CR 2.5%), MR 13.3%, SD 25%, PD 22%. The time to progression (TTP) in the SD+MR group: 29.8 weeks, in the RR group: 34.1 weeks, mean of all patients: 28.1 weeks. The survival time was estimated by Kaplan-Meier curves. The median survival (MS) of all treated patients was: 54.9 weeks, in the PD group: 34.4 weeks, in the SD+MR group: 59.1 weeks, in the PR+CR group: 62.1 weeks. Conclusion: gemcitabine and cisplatin combination is a very well tolerated therapeutic regimen in the 1st line treatment of NSCLC. Furthermore, this treatment improves the RR and the survival of the patients as well.
C1 [Ostoros, Gyula] National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, Piheno u. 1., 1529 Budapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, Piheno u. 1., 1529 Budapest, Hungary.
   [Gergely-Farnos, Erzsebet] National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, Piheno u. 1., 1529 Budapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Szondy, Klara] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, 1529 Budapest, Hungary.
EM ostorosgyula@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 185
EP 188
PG 4
ER

PT J
AU Sarosi, V
   Lenart, T
AF Sarosi, Veronika
   Lenart, Timea
TI Gemcitabine-cisplatine combination in the first line treatment of non-small cell lung cancer. Analysis of the safety of the regime
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB In our Department we have studied the first line treatment of 90 stage IIIA-IV non-small cell lung cancer patients using gemcitabine/cisplatin combination. Thirteen cases have been unevaluable for various reasons. At the time of evaluation the planned 4 cycles have been delivered to 38% of patients (34/90). The PR was 39% (30/77), the CR was 2.6% (2/77) while the ORR was found to be 41% (32/77). 226 treatment cycles have been evaluated for side effects. There was no treatment-induced death in this series. CTC grade 3-4 neutropenia occurred in 5.7% of the cycles and only in 2 cases combined with fever. CTC grade 3-4 thrombocytopenia occurred in 4.4% of the cycles but only one patient required platelet suspension administration. Grade 3-4 anaemia developed in 3.5% of the cycles where 5 cases have been treated with RBC concentrate while 3 cases with erythropoetin. Complete alopecia occurred in 6 patients but 3 of them received brain irradiation as well. CTC grade 3-4 nausea and vomiting occurred in 4.4 and 3% of the cycles, respectively, but rehydration was only necessary in 3% of the cycles. Delay of the therapy due to hematological toxicity or vomiting occurred in 8% of the cycles but did not last longer than 2 weeks. Severe CTC grade 3-4 nephrotoxicity did not occur in this study while grade 1-2 elevation of serum creatinin level was found in 1.7% of the cycles. We have concluded that the gemcitabine/cisplatin combination is a safe outpatient modality for the first line treatment of advanced non-small cell lung cancer patients.
C1 [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Lenart, Timea] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
RP Sarosi, V (reprint author), Baranya County Hospital, Department of Respiratory Medicine, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 189
EP 193
PG 5
ER

PT J
AU Bodoky, Gy
AF Bodoky, Gyorgy
TI Experiences with the treatment of advanced pancreatic cancer in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB In the first phase of this study 34 patients with advanced pancreatic cancer have been treated either with gemcitabine/cisplatin or gemcitabine/5-fluorouracil (5FU)/leucovorin combination. (Gemzar: 900 mg/m2, Cisplatin: 20 mg/m2, 5-FU: 750 mg/m2). Treatments were continued till tumor progression. There was no difference observed between the two protocols in the clinical response rates (PR=65%). On the other hand, a significant difference was found between the two protocols regarding the side effects. In the case of gemcitabine/5-FU neutropenia, thrombocytopenia and anaemia (as well as nausea and vomiting) were much less frequent compared to gemcitabine/cisplatin combination. Based on these data the efficacy of gemcitabine/5-FU combination was evaluated in 99 stage III, T1-4, N1 and stage IV, T1-4, N0-1, M1 pancreatic cancer patients throughout 364 treatment cycles. OR was achieved in 10% while stable disease in 52% of the cases. The average survival period was 8.33 months while the time to progression was 5.75 months. Based on these data we recommend gemcitabine/5-FU/leucovorin combination for the treatment of advanced pancreatic cancer.
C1 [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Gyali ut 5-7., 1097 Budapest, Hungary.
RP Bodoky, Gy (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, 1097 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 194
EP 197
PG 4
ER

PT J
AU Bodrogi, I
AF Bodrogi, Istvan
TI Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB M-VAC combination chemotherapy was considered as the ''gold standard'' of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.
C1 [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Bodrogi, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM bodrogi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 198
EP 203
PG 6
ER

PT J
AU Tompa, A
AF Tompa, Anna
TI Short story of the primer preventive forum
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Tompa, Anna] Primer Prevencios ForumBudapest, Hungary.
RP Tompa, A (reprint author), Primer Prevencios Forum, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 205
EP 220
PG 16
ER

PT J
AU Demeter, J
AF Demeter, Judit
TI ''Actual questions of haemathology 2002'' course - overview and preview
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
C1 [Demeter, Judit] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Demeter, J (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2003
VL 47
IS 2
BP 221
EP 222
PG 2
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI Dr. Peter Zoltan
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Eckhardt, Sandor] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 230
EP 230
PG 1
ER

PT J
AU Nemeth, Gy
AF Nemeth, Gyorgy
TI In memoriam Professor Dr. Helmut Kuttig
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Nemeth, Gyorgy] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Nemeth, Gy (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 231
EP 231
PG 1
ER

PT J
TI 25th Congress of the Society of Hungarian Oncologists
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 233
EP 329
PG 97
ER

PT J
AU Adleff, V
   Szarvas, T
   Budai, B
   Gazdag, A
   Hitre, E
   Kovacs, T
   Kovalszky, I
   Kralovanszky, J
AF Adleff, Vilmos
   Szarvas, Tibor
   Budai, Barna
   Gazdag, Andrea
   Hitre, Erika
   Kovacs, Tibor
   Kovalszky, Ilona
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Szarvas, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Gazdag, Andrea] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Tibor] National Institute of OncologyBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Adleff, V (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 235
EP 235
PG 1
ER

PT J
AU Andras, Cs
   Szanto, J
AF Andras, Csilla
   Szanto, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Szanto, Janos] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Andras, Cs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 235
EP 235
PG 1
ER

PT J
AU Anna, L
   Gyorffy, E
   Gyori, Z
   Segesdi, J
   Minarovits, J
   Soltesz, I
   Kostic, Sz
   Csekeo, A
   Holmila, R
   Husgafvel-Pursiainen, K
   Schoket, B
AF Anna, Livia
   Gyorffy, Erika
   Gyori, Zoltan
   Segesdi, Judit
   Minarovits, Janos
   Soltesz, Ibolya
   Kostic, Szilard
   Csekeo, Attila
   Holmila, Reetta
   Husgafvel-Pursiainen, Kirsti
   Schoket, Bernadette
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Anna, Livia] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Gyorffy, Erika] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Gyori, Zoltan] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Segesdi, Judit] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Minarovits, Janos] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kostic, Szilard] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Holmila, Reetta] Finnish Institute of Occupational HealthHelsinki, Finland.
   [Husgafvel-Pursiainen, Kirsti] Finnish Institute of Occupational HealthHelsinki, Finland.
   [Schoket, Bernadette] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
RP Anna, L (reprint author), Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 235
EP 235
PG 1
ER

PT J
AU Antal, I
   Kiss, J
   Szendroi, M
AF Antal, Imre
   Kiss, Janos
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Antal, I (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 236
EP 236
PG 1
ER

PT J
AU Bahery, M
   Godeny, M
   Papai, Zs
   Horti, J
   Orosz, Zs
AF Bahery, Maria
   Godeny, Maria
   Papai, Zsuzsa
   Horti, Jozsef
   Orosz, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bahery, Maria] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Horti, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Bahery, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 236
EP 236
PG 1
ER

PT J
AU Bak, M
   Mandoky, L
   Geczi, L
   Toth, J
   Bodrogi, I
AF Bak, Mihaly
   Mandoky, Laszlo
   Geczi, Lajos
   Toth, Jozsef
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bak, Mihaly] National Institute of OncologyBudapest, Hungary.
   [Mandoky, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Toth, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Bak, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 236
EP 236
PG 1
ER

PT J
AU Baki, M
   Boer, K
   Lohinszky, J
   Zolnai, Zs
   Dobo, I
AF Baki, Marta
   Boer, Katalin
   Lohinszky, Julia
   Zolnai, Zsofia
   Dobo, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baki, Marta] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Lohinszky, Julia] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Zolnai, Zsofia] Szt. Margit Hospital, Department of PathologyBudapest, Hungary.
   [Dobo, Istvan] Szent Margit Korhaz, Sebeszeti OsztalyBudapest, Hungary.
RP Baki, M (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 237
EP 237
PG 1
ER

PT J
AU Balatoni, T
   Gilde, K
   Liszkay, G
   Fejos, Zs
   Borbola, K
AF Balatoni, Timea
   Gilde, Katalin
   Liszkay, Gabriella
   Fejos, Zsuzsanna
   Borbola, Kinga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 237
EP 237
PG 1
ER

PT J
AU Balatoni, Zs
   Bohak, �
   Godeny, M
AF Balatoni, Zsuzsa
   Bohak, Agnes
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Bohak, Agnes] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Balatoni, Zs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 237
EP 237
PG 1
ER

PT J
AU Balogh, Cs
   Elekne Kiss, B
   Piko, B
AF Balogh, Csaba
   Elekne Kiss, Barbara
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Csaba] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Balogh, Cs (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 238
EP 238
PG 1
ER

PT J
AU Barna, G
   Weischede, S
   Sebestyen, A
   Kopper, L
AF Barna, Gabor
   Weischede, Silke
   Sebestyen, Anna
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Weischede, Silke] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barna, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 238
EP 238
PG 1
ER

PT J
AU Bartfai, R
   Elo, J
   Horvath, E
   Balatoni, Zs
AF Bartfai, Reka
   Elo, Janos
   Horvath, Emilia
   Balatoni, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bartfai, Reka] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Elo, Janos] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Horvath, Emilia] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Balatoni, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Bartfai, R (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 238
EP 238
PG 1
ER

PT J
AU Battyani, Z
AF Battyani, Zita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Battyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Battyani, Z (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 238
EP 238
PG 1
ER

PT J
AU Becske, M
   Radvanszki, F
AF Becske, Miklos
   Radvanszki, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Becske, Miklos] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
   [Radvanszki, Ferenc] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
RP Becske, M (reprint author), Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti Osztaly, Kistarcsa, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 239
EP 239
PG 1
ER

PT J
AU Bereczky, B
   Tovari, J
   Timar, J
AF Bereczky, Biborka
   Tovari, Jozsef
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bereczky, Biborka] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Bereczky, B (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 239
EP 239
PG 1
ER

PT J
AU Bidlek, M
   Szabo, �
   Feher, I
   Magori, A
   Orosz, Zs
   Godeny, M
AF Bidlek, Maria
   Szabo, Eva
   Feher, Istvan
   Magori, Aniko
   Orosz, Zsolt
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Feher, Istvan] National Institute of OncologyBudapest, Hungary.
   [Magori, Aniko] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Bidlek, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 239
EP 239
PG 1
ER

PT J
AU Bodo, M
AF Bodo, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodo, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Bodo, M (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 239
EP 239
PG 1
ER

PT J
AU Bodoky, Gy
   Harisi, R
   Tamas, K
AF Bodoky, Gyorgy
   Harisi, Revekka
   Tamas, Karin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Harisi, Revekka] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Tamas, Karin] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Bodoky, Gy (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 240
EP 240
PG 1
ER

PT J
AU Bodrogi, I
   Romics, I
   Kisbenedek, L
   Hatar, A
   Kondas, J
   Mavrogenis, S
   Szamado, I
   Kiss, A
   Szamel, I
   Gaudi, I
   Vincze, B
   Geczi, L
AF Bodrogi, Istvan
   Romics, Imre
   Kisbenedek, Laszlo
   Hatar, Andras
   Kondas, Jozsef
   Mavrogenis, Stelios
   Szamado, Istvan
   Kiss, Attila
   Szamel, Iren
   Gaudi, Istvan
   Vincze, Borbala
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Kisbenedek, Laszlo] Saint Stephen Hospital, Department of UrologyBudapest, Hungary.
   [Hatar, Andras] Uzsoki Utcai Korhaz, Urologiai OsztalyBudapest, Hungary.
   [Kondas, Jozsef] Peterfy Hospital, Department of UrologyBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szamado, Istvan] Saint Stephen Hospital, Department of UrologyBudapest, Hungary.
   [Kiss, Attila] Peterfy Hospital, Department of UrologyBudapest, Hungary.
   [Szamel, Iren] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Bodrogi, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 240
EP 240
PG 1
ER

PT J
AU Bodrogi, I
AF Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Bodrogi, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 242
EP 242
PG 1
ER

PT J
AU Boer, K
   Lang, I
   Juhos, �
   Pinter, T
   Baki, M
   Szanto, J
AF Boer, Katalin
   Lang, Istvan
   Juhos, Eva
   Pinter, Tamas
   Baki, Marta
   Szanto, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Lang, Istvan] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Juhos, Eva] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Pinter, Tamas] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Baki, Marta] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Szanto, Janos] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
RP Boer, K (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 242
EP 242
PG 1
ER

PT J
AU Bogner, B
AF Bogner, Barna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bogner, Barna] County Hospital of Baranya, Department of PathologyPecs, Hungary.
RP Bogner, B (reprint author), County Hospital of Baranya, Department of Pathology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 242
EP 242
PG 1
ER

PT J
AU Bohacs, A
   Tamasi, L
   Wollak, A
   Bartfai, Z
AF Bohacs, Aniko
   Tamasi, Lilla
   Wollak, Andras
   Bartfai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Wollak, Andras] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartfai, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Bohacs, A (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 243
EP 243
PG 1
ER

PT J
AU Borbola, K
   Gilde, K
   Liszkay, G
   Fejos, Zs
   Hudacsek, K
AF Borbola, Kinga
   Gilde, Katalin
   Liszkay, Gabriella
   Fejos, Zsuzsanna
   Hudacsek, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Hudacsek, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Borbola, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 243
EP 243
PG 1
ER

PT J
AU Boross, G
   Cserni, G
   Rajtar, M
   Sinko, M
   Szucs, M
   Svebis, M
AF Boross, Gabor
   Cserni, Gabor
   Rajtar, Maria
   Sinko, Maria
   Szucs, Miklos
   Svebis, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Rajtar, Maria] Bacs-Kiskun Megyei Onk. Korhaza, Izotop laborKecskemet, Hungary.
   [Sinko, Maria] Bacs-Kiskun Megyei Onk. Korhaza, Izotop laborKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Boross, G (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 243
EP 243
PG 1
ER

PT J
AU Boyle, P
AF Boyle, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boyle, Peter] European Institute of Oncology, Division of Epidemiology and BiostatisticsMilan, Italy.
RP Boyle, P (reprint author), European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 245
EP 245
PG 1
ER

PT J
AU Budai, B
   Kralovanszky, J
   Jeney, A
   Literaty-Nagy, 
   Tory, K
AF Budai, Barna
   Kralovanszky, Judit
   Jeney, Andras
   Literaty-Nagy, P.
   Tory, Kalman
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Literaty-Nagy, P.] N-Gene Research and Development LtdBudapest, Hungary.
   [Tory, Kalman] N-Gene Research and Development LtdBudapest, Hungary.
RP Budai, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 245
EP 245
PG 1
ER

PT J
AU Burian, Zs
   Ladanyi, A
   Timar, J
AF Burian, Zsuzsanna
   Ladanyi, Andrea
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Burian, Zsuzsanna] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Burian, Zs (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 246
EP 246
PG 1
ER

PT J
AU Czigner, J
   Csanady, M
   Ivan, L
   Brzozka, M
   Jori, J
AF Czigner, Jeno
   Csanady, Miklos
   Ivan, Laszlo
   Brzozka, Marek
   Jori, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Brzozka, Marek] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Jori, Jozsef] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Czigner, J (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 246
EP 246
PG 1
ER

PT J
AU Csanady, M
   Ivan, L
   Czigner, J
   Jori, J
AF Csanady, Miklos
   Ivan, Laszlo
   Czigner, Jeno
   Jori, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Jori, Jozsef] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Csanady, M (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 246
EP 246
PG 1
ER

PT J
AU Csere, P
   Drechsler, D
   Blank, H
   Alheit, H
   Herrmann, Th
AF Csere, Peter
   Drechsler, Dietrich
   Blank, Hilbert
   Alheit, Horst
   Herrmann, Thomas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csere, Peter] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Drechsler, Dietrich] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Blank, Hilbert] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Alheit, Horst] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Herrmann, Thomas] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
RP Csere, P (reprint author), Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, Dresden, Germany.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 247
EP 247
PG 1
ER

PT J
AU Cserni, G
   Fejes, G
AF Cserni, Gabor
   Fejes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Fejes, Gabor] Bacs-Kiskun County Teaching Hospital, Department of InformaticsKecskemet, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 247
EP 247
PG 1
ER

PT J
AU Csonka, Cs
AF Csonka, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csonka, Csaba] Magyar Imre Korhaz, Sebeszeti OsztalyAjka, Hungary.
RP Csonka, Cs (reprint author), Magyar Imre Korhaz, Sebeszeti Osztaly, Ajka, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 247
EP 247
PG 1
ER

PT J
AU Csuka, O
   Juhasz, A
   Kolacsek, O
   Doleschall, Z
   Koves, I
   Otto, Sz
AF Csuka, Orsolya
   Juhasz, Aliz
   Kolacsek, Orsolya
   Doleschall, Zoltan
   Koves, Istvan
   Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Juhasz, Aliz] National Institute of OncologyBudapest, Hungary.
   [Kolacsek, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 248
EP 248
PG 1
ER

PT J
AU Csuka, O
   Juhasz, A
   Kolacsek, O
   Koves, I
   Otto, Sz
AF Csuka, Orsolya
   Juhasz, Aliz
   Kolacsek, Orsolya
   Koves, Istvan
   Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Juhasz, Aliz] National Institute of OncologyBudapest, Hungary.
   [Kolacsek, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 248
EP 248
PG 1
ER

PT J
AU Dani, �
   Varkonyi, �
   Nyiro, 
   Osvath, M
AF Dani, Arpad
   Varkonyi, Agnes
   Nyiro, I.
   Osvath, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dani, Arpad] St. Borbala University HospitalTatabanya, Hungary.
   [Varkonyi, Agnes] ONKOMED Kft.Tatabanya, Hungary.
   [Nyiro, I.] ONKOMED Kft.Tatabanya, Hungary.
   [Osvath, Marta] St. Borbala University HospitalTatabanya, Hungary.
RP Dani, � (reprint author), St. Borbala University Hospital, Tatabanya, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 248
EP 248
PG 1
ER

PT J
AU Dani, �
   Varkonyi, �
   Nyiro, 
   Osvath, M
AF Dani, Arpad
   Varkonyi, Agnes
   Nyiro, I.
   Osvath, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dani, Arpad] St. Borbala University HospitalTatabanya, Hungary.
   [Varkonyi, Agnes] ONKOMED Kft.Tatabanya, Hungary.
   [Nyiro, I.] ONKOMED Kft.Tatabanya, Hungary.
   [Osvath, Marta] St. Borbala University HospitalTatabanya, Hungary.
RP Dani, � (reprint author), St. Borbala University Hospital, Tatabanya, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 248
EP 248
PG 1
ER

PT J
AU Demeter, A
   Szirmai, K
   Szantho, A
   Timar, F
   Olah, L
   Jeney, A
AF Demeter, Attila
   Szirmai, Katalin
   Szantho, Andras
   Timar, Ferenc
   Olah, Laszlone
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Demeter, Attila] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Szirmai, Katalin] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Laszlone] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Demeter, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 249
EP 249
PG 1
ER

PT J
AU Dobos, J
   Ladanyi, A
   Bocsi, J
   Burian, Zs
   Timar, J
AF Dobos, Judit
   Ladanyi, Andrea
   Bocsi, Jozsef
   Burian, Zsuzsanna
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Bocsi, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Burian, Zsuzsanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Dobos, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 249
EP 249
PG 1
ER

PT J
AU Dobozy, A
   Kapitany, K
   Korom, I
   Olah, J
AF Dobozy, Attila
   Kapitany, Klara
   Korom, Irma
   Olah, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kapitany, Klara] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Dobozy, A (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 249
EP 249
PG 1
ER

PT J
AU Dubecz, S
   Peley, G
   Matrai, Z
   Feher, I
   Monostori, Zs
   Buza, N
   Beczasy, 
   Koves, I
AF Dubecz, Sandor
   Peley, Gabor
   Matrai, Zoltan
   Feher, Istvan
   Monostori, Zsuzsanna
   Buza, Natalia
   Beczasy, E.
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dubecz, Sandor] National Institute of OncologyBudapest, Hungary.
   [Peley, Gabor] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Feher, Istvan] National Institute of OncologyBudapest, Hungary.
   [Monostori, Zsuzsanna] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Buza, Natalia] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Beczasy, E.] Orszagos Onkologiai Intezet, Tumormarker Lab.Budapest, Hungary.
   [Koves, Istvan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Dubecz, S (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 250
EP 250
PG 1
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Eckhardt, Sandor] National Institute of OncologyBudapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 250
EP 250
PG 1
ER

PT J
AU Elekne Kiss, B
   Piko, B
AF Elekne Kiss, Barbara
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Elekne Kiss, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 250
EP 250
PG 1
ER

PT J
AU Elo, J
AF Elo, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Elo, Janos] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Elo, J (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 250
EP 250
PG 1
ER

PT J
AU Ember, I
   Pajor, L
   Varjas, T
   Varga, Cs
AF Ember, Istvan
   Pajor, Laszlo
   Varjas, Timea
   Varga, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ember, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Pajor, Laszlo] University of Pecs, Department of PathologyPecs, Hungary.
   [Varjas, Timea] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Varga, Csaba] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
RP Ember, I (reprint author), Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani Tanszek, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 251
EP 251
PG 1
ER

PT J
AU Erdos, S
   Szabo, L
AF Erdos, Sandor
   Szabo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Erdos, Sandor] Megyei Jogu Varosi Korhaz, OnkologiaNagykanizsa, Hungary.
   [Szabo, Laszlo] Crystal Institute Kft.Eger, Hungary.
RP Erdos, S (reprint author), Megyei Jogu Varosi Korhaz, Onkologia, Nagykanizsa, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 251
EP 251
PG 1
ER

PT J
AU Ernhardt, M
   Perger, L
   Strausz, J
AF Ernhardt, Maria
   Perger, Laszlo
   Strausz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ernhardt, Maria] County Hospital of PulmonologyTorokbalint, Hungary.
   [Perger, Laszlo] County Hospital of PulmonologyTorokbalint, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ernhardt, M (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 251
EP 251
PG 1
ER

PT J
AU Faluhelyi, Zs
AF Faluhelyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Faluhelyi, Zsolt] Baranya County Hospital, Department of OncologyPecs, Hungary.
RP Faluhelyi, Zs (reprint author), Baranya County Hospital, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 252
EP 252
PG 1
ER

PT J
AU Faluhelyi, Zs
   Varga, Zs
   Kover, E
AF Faluhelyi, Zsolt
   Varga, Zsuzsanna
   Kover, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Faluhelyi, Zsolt] Baranya County Hospital, Department of OncologyPecs, Hungary.
   [Varga, Zsuzsanna] Baranya County Hospital, Department of OncologyPecs, Hungary.
   [Kover, Erika] Baranya County Hospital, Department of OncologyPecs, Hungary.
RP Faluhelyi, Zs (reprint author), Baranya County Hospital, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 252
EP 252
PG 1
ER

PT J
AU Falus, A
   Darvas, Zs
   Lazar-Molnar, E
   Hegyesi, H
   Pos, Z
AF Falus, Andras
   Darvas, Zsuzsanna
   Lazar-Molnar, Eszter
   Hegyesi, Hargita
   Pos, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Darvas, Zsuzsanna] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Lazar-Molnar, Eszter] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Hegyesi, Hargita] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Pos, Zoltan] MTA-SE, Molekularis Immunologiai Kutato CsoportBudapest, Hungary.
RP Falus, A (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 252
EP 252
PG 1
ER

PT J
AU Farczadi, E
   Lohinszky, J
   Baki, M
AF Farczadi, Eniko
   Lohinszky, Julia
   Baki, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farczadi, Eniko] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lohinszky, Julia] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Baki, Marta] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
RP Farczadi, E (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 252
EP 252
PG 1
ER

PT J
AU Feher, K
   Merenyine Dombi, Zs
   Ettore, C
   Ember, I
AF Feher, Krisztina
   Merenyine Dombi, Zsuzsanna
   Ettore, M. S. Conti
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Feher, Krisztina] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Merenyine Dombi, Zsuzsanna] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Ettore, M. S. Conti] Istituto Regina ElenaRome, Italy.
   [Ember, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
RP Feher, K (reprint author), Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani Tanszek, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 254
EP 254
PG 1
ER

PT J
AU Fejos, Zs
   Gilde, K
   Battyani, Z
   Szavcsur, P
   Peter, I
   Somogyi, A
AF Fejos, Zsuzsanna
   Gilde, Katalin
   Battyani, Zita
   Szavcsur, Peter
   Peter, Ilona
   Somogyi, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Battyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Szavcsur, Peter] National Institute of OncologyBudapest, Hungary.
   [Peter, Ilona] National Institute of OncologyBudapest, Hungary.
   [Somogyi, Andras] National Institute of OncologyBudapest, Hungary.
RP Fejos, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 254
EP 254
PG 1
ER

PT J
AU Fejos, Zs
   Gaudi, I
   Gilde, K
AF Fejos, Zsuzsanna
   Gaudi, Istvan
   Gilde, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
RP Fejos, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 254
EP 254
PG 1
ER

PT J
AU Fekete, L
   Banfai, 
   Horvath, 
   Orgovan, Gy
AF Fekete, Laszlo
   Banfai, K.
   Horvath, L.
   Orgovan, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Laszlo] Honved KorhazBudapest, Hungary.
   [Banfai, K.] Honved KorhazBudapest, Hungary.
   [Horvath, L.] Honved KorhazBudapest, Hungary.
   [Orgovan, Gyorgy] Honved KorhazBudapest, Hungary.
RP Fekete, L (reprint author), Honved Korhaz, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 255
EP 255
PG 1
ER

PT J
AU Ferenczi, E
   Kiss, Cs
   Strausz, J
AF Ferenczi, Eniko
   Kiss, Csongor
   Strausz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Kiss, Csongor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ferenczi, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 255
EP 255
PG 1
ER

PT J
AU Forika, T
   Elekne Kiss, B
   Piko, B
   Csiffari, M
AF Forika, Tamas
   Elekne Kiss, Barbara
   Piko, Bela
   Csiffari, Margit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Forika, Tamas] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Forika, T (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 255
EP 255
PG 1
ER

PT J
AU Forster-Horvath, Cs
   Lukits, J
   Dome, B
   Ladanyi, A
   Remenar, �
   Kasler, M
   Bencsik, B
   Repassy, G
   Szabo, Gy
   Velich, N
   Suba, Zs
   Elo, J
   Balatoni, Zs
   Bajtai, A
   Talor, E
   Timar, J
AF Forster-Horvath, Csaba
   Lukits, Julia
   Dome, Balazs
   Ladanyi, Andrea
   Remenar, Eva
   Kasler, Miklos
   Bencsik, Beata
   Repassy, Gabor
   Szabo, Gyorgy
   Velich, Norbert
   Suba, Zsuzsanna
   Elo, Janos
   Balatoni, Zsuzsa
   Bajtai, Attila
   Talor, Eyal
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Forster-Horvath, Csaba] National Institute of OncologyBudapest, Hungary.
   [Lukits, Julia] National Institute of OncologyBudapest, Hungary.
   [Dome, Balazs] National Institute of OncologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Bencsik, Beata] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Repassy, Gabor] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Szabo, Gyorgy] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Velich, Norbert] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Suba, Zsuzsanna] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Elo, Janos] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Balatoni, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Bajtai, Attila] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Talor, Eyal] CEL-SCI CorporationVienna, VA, USA.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Forster-Horvath, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 257
EP 257
PG 1
ER

PT J
AU Foldesi, I
   Kahan, Zs
   Nyari, T
   Thurzo, L
   Pal, A
AF Foldesi, Imre
   Kahan, Zsuzsanna
   Nyari, Tibor
   Thurzo, Laszlo
   Pal, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldesi, Imre] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pal, Attila] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
RP Foldesi, I (reprint author), University of Szeged, Department of Obstetrics and Gynaecology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 257
EP 257
PG 1
ER

PT J
AU Franko, E
   Lengyelne Koczka, Sz
   Homor, Zs
AF Franko, Erzsebet
   Lengyelne Koczka, Szilvia
   Homor, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Franko, Erzsebet] ANTSZ Pest Megyei IntezeteBudapest, Hungary.
   [Lengyelne Koczka, Szilvia] ANTSZ Pest Megyei IntezeteBudapest, Hungary.
   [Homor, Zsuzsanna] ANTSZ Pest Megyei IntezeteBudapest, Hungary.
RP Franko, E (reprint author), ANTSZ Pest Megyei Intezete, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Furak, J
   Trojan, I
   Szoke, T
   Tiszlavicz, L
   Morvay, Z
   Balogh, �
AF Furak, Jozsef
   Trojan, Imre
   Szoke, Tamas
   Tiszlavicz, Laszlo
   Morvay, Zita
   Balogh, Adam
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of SurgerySzeged, Hungary.
   [Szoke, Tamas] University of Szeged, Department of SurgerySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Morvay, Zita] University of Szeged, Department of RadiologySzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of SurgerySzeged, Hungary.
RP Furak, J (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Fule, T
   Mathe, M
   Paku, S
   Csapo, Zs
   Papp, Z
   Suba, Zs
   Kovalszky, I
AF Fule, Tibor
   Mathe, Miklos
   Paku, Sandor
   Csapo, Zsolt
   Papp, Zoltan
   Suba, Zsuzsanna
   Kovalszky, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mathe, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csapo, Zsolt] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Papp, Zoltan] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Suba, Zsuzsanna] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Fule, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Fulop, A
   Zsiray, M
   Udud, K
   Badar, �
AF Fulop, Andrea
   Zsiray, Miklos
   Udud, Katalin
   Badar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulop, Andrea] Orszagos Koranyi TBC es Pulmonologiai Intezet, OKTPIBudapest, Hungary.
   [Zsiray, Miklos] Orszagos Koranyi TBC es Pulmonologiai Intezet, OKTPIBudapest, Hungary.
   [Udud, Katalin] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Badar, Eva] Orszagos Koranyi TBC es Pulmonologiai Intezet, CytologiaBudapest, Hungary.
RP Fulop, A (reprint author), Orszagos Koranyi TBC es Pulmonologiai Intezet, OKTPI, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Ganofszky, E
   Szakolczai, I
   Czegledi, F
   Juhos, �
   Horvath, Zs
   Hitre, E
   Szabo, E
   Papai, Zs
   Telekes, A
   Lang, I
AF Ganofszky, Erna
   Szakolczai, Istvan
   Czegledi, Ferenc
   Juhos, Eva
   Horvath, Zsolt
   Hitre, Erika
   Szabo, Eszter
   Papai, Zsuzsa
   Telekes, Andras
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Szakolczai, Istvan] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Telekes, Andras] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Ganofszky, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Garami, M
   Muller, J
   Hauser, P
   Schuler, D
AF Garami, Miklos
   Muller, Judit
   Hauser, Peter
   Schuler, Dezso
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Garami, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Garami, M
   Muller, J
   Hauser, P
   Schuler, D
   Szendroi, M
AF Garami, Miklos
   Muller, Judit
   Hauser, Peter
   Schuler, Dezso
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Garami, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Gazdag, N
   Hanesz, A
AF Gazdag, I.-Ne
   Hanesz, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gazdag, I.-Ne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hanesz, Andrea] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gazdag, N (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Gecse, A
AF Gecse, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gecse, Attila] Semmelweis Korhaz, Erzsebet Hospice OtthonMiskolc, Hungary.
RP Gecse, A (reprint author), Semmelweis Korhaz, Erzsebet Hospice Otthon, Miskolc, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Geczi, L
   Biro, K
   Rathonyi, E
   Nagyivanyi, K
   Fuszek, P
   Papp, J
   Farkas, L
   Bodrogi, I
AF Geczi, Lajos
   Biro, Krisztina
   Rathonyi, Emese
   Nagyivanyi, Krisztian
   Fuszek, Peter
   Papp, Janos
   Farkas, Laszlo
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Biro, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Rathonyi, Emese] National Institute of OncologyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Fuszek, Peter] National Institute of OncologyBudapest, Hungary.
   [Papp, Janos] University of Pecs, Faculty of MedicinePecs, Hungary.
   [Farkas, Laszlo] University of Pecs, Department of UrologyPecs, Hungary.
   [Bodrogi, Istvan] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Godeny, M
   Bocs, K
   Horvath, K
   Lengyel, E
   Koltai, L
   Remenar, �
   Polony, I
   Kasler, M
AF Godeny, Maria
   Bocs, Katalin
   Horvath, Katalin
   Lengyel, Erzsebet
   Koltai, Laszlo
   Remenar, Eva
   Polony, Istvan
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of OncologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Erzsebet] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Koltai, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Polony, Istvan] Peterfy HospitalBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Godeny, M
AF Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Gundy, S
   Babosa, M
   Baki, M
   Bodrogi, I
AF Gundy, Sarolta
   Babosa, Maria
   Baki, Marta
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] National Institute of OncologyBudapest, Hungary.
   [Babosa, Maria] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Baki, Marta] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Gyemant, N
   Vasas, A
   Hohmann, J
   Molnar, J
AF Gyemant, Nora
   Vasas, Anita
   Hohmann, Judit
   Molnar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyemant, Nora] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Vasas, Anita] SZTE, Farmakologiai es Farmakoterapiai IntezetSzeged, Hungary.
   [Hohmann, Judit] SZTE, Farmakologiai es Farmakoterapiai IntezetSzeged, Hungary.
   [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
RP Gyemant, N (reprint author), SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai Intezet, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Gyorffy, E
   Anna, L
   Gyori, Z
   Minarovits, J
   Soltesz, I
   Kostic, Sz
   Csekeo, A
   Schoket, B
AF Gyorffy, Erika
   Anna, Livia
   Gyori, Zoltan
   Minarovits, Janos
   Soltesz, Ibolya
   Kostic, Szilard
   Csekeo, Attila
   Schoket, Bernadette
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Erika] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Anna, Livia] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Gyori, Zoltan] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Minarovits, Janos] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kostic, Szilard] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Schoket, Bernadette] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
RP Gyorffy, E (reprint author), Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Gyorfi, Gy
AF Gyorfi, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorfi, Gyula] Borsod-Abauj-Zemplen megyei Korhaz, Szuleszet- Nogyogyaszati OsztalyMiskolc, Hungary.
RP Gyorfi, Gy (reprint author), Borsod-Abauj-Zemplen megyei Korhaz, Szuleszet- Nogyogyaszati Osztaly, Miskolc, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Hadlaczky, Gy
AF Hadlaczky, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hadlaczky, Gyula] Magyar Tudomanyos Akademia, Szegedi Biologiai Kutatokozpont, Genetikai IntezetSzeged, Hungary.
RP Hadlaczky, Gy (reprint author), Magyar Tudomanyos Akademia, Szegedi Biologiai Kutatokozpont, Genetikai Intezet, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Hajdu, M
   Kohut, E
   Uher, F
   Kopper, L
   Sebestyen, A
AF Hajdu, Melinda
   Kohut, Eszter
   Uher, Ferenc
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kohut, Eszter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Uher, Ferenc] National Medical CenterBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Hajdu, M (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Halasz, Gy
   Kisely, M
AF Halasz, Gyongyi
   Kisely, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halasz, Gyongyi] Vas Megye es Szombathely Megyei Jogu Varos Markusovszky Korhaza, Ful-Orr-Gegeszeti es Fej- Nyaksebeszeti OsztalySzombathely, Hungary.
   [Kisely, Mihaly] Vas Megye es Szombathely Megyei Jogu Varos Markusovszky Korhaza, Ful-Orr-Gegeszeti es Fej- Nyaksebeszeti OsztalySzombathely, Hungary.
RP Halasz, Gy (reprint author), Vas Megye es Szombathely Megyei Jogu Varos Markusovszky Korhaza, Ful-Orr-Gegeszeti es Fej- Nyaksebeszeti Osztaly, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Harsanyi, L
   Csapo, Zs
AF Harsanyi, Laszlo
   Csapo, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Csapo, Zsolt] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
RP Harsanyi, L (reprint author), Semmelweis University, 1st Department of Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Harsanyi, L
AF Harsanyi, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
RP Harsanyi, L (reprint author), Semmelweis University, 1st Department of Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Hegedus, Gy
   Bago, Zs
AF Hegedus, Gyne
   Bago, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Gyne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bago, Zsolt] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Hegedus, Gy (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Hegedus, K
AF Hegedus, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Katalin] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Hegedus, K (reprint author), Semmelweis University, Institute of Behavioural Sciences, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Hegyesi, H
   Safrany, G
   Pos, Z
   Toth, S
   Timar, J
   Falus, A
AF Hegyesi, Hargita
   Safrany, Geza
   Pos, Zoltan
   Toth, Sara
   Timar, Jozsef
   Falus, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyesi, Hargita] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Pos, Zoltan] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Toth, Sara] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Hegyesi, H (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Z., H
   Z., K
   S., H
   T., S
AF Z., Hernadi
   Z., Krasznai
   S., Huga
   T., Sapy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Z., Hernadi] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Z., Krasznai] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [S., Huga] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [T., Sapy] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Z., H (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Herrmann, Th
AF Herrmann, Thomas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herrmann, Thomas] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
RP Herrmann, Th (reprint author), Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, Dresden, Germany.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Herszenyi, L
AF Herszenyi, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herszenyi, Laszlo] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
RP Herszenyi, L (reprint author), Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Hitre, E
   Adleff, V
   Budai, B
   Ganofszky, E
   Horvath, Zs
   Juhos, �
   Szabo, E
   Lang, I
   Czegledi, F
   Orosz, Zs
   P. Gazdag, A
   Kralovanszky, J
AF Hitre, Erika
   Adleff, Vilmos
   Budai, Barna
   Ganofszky, Erna
   Horvath, Zsolt
   Juhos, Eva
   Szabo, Eszter
   Lang, Istvan
   Czegledi, Ferenc
   Orosz, Zsolt
   P. Gazdag, Anett
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [P. Gazdag, Anett] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Hitre, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Horti, J
   Bodrogi, I
AF Horti, Jozsef
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horti, Jozsef] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Horti, J (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Horvath, Zs
   Hitre, E
   Ganofszky, E
   Lang, I
AF Horvath, Zsolt
   Hitre, Erika
   Ganofszky, Erna
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Horvath, E
   Taller, A
   Bartfai, R
AF Horvath, Emilia
   Taller, Andras
   Bartfai, Reka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Emilia] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Taller, Andras] Uzsoki Municipal Hospital, 1st Department of Internal Medicine and CardiologyBudapest, Hungary.
   [Bartfai, Reka] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Horvath, E (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Hudacsek, K
   Gilde, K
   Liszkay, G
   Fejos, Zs
   Borbola, K
AF Hudacsek, Katalin
   Gilde, Katalin
   Liszkay, Gabriella
   Fejos, Zsuzsanna
   Borbola, Kinga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hudacsek, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Hudacsek, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Hunyadi, J
AF Hunyadi, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hunyadi, Janos] University of Debrecen, Department of DermatologyDebrecen, Hungary.
RP Hunyadi, J (reprint author), University of Debrecen, Department of Dermatology, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Iglodi, F
AF Iglodi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Iglodi, Ferenc] Szent Rokus Korhaz, OnkologiaBudapest, Hungary.
RP Iglodi, F (reprint author), Szent Rokus Korhaz, Onkologia, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Imre, G
   Paku, S
   Nagy, K
   Petak, I
   Kopper, L
   Szende, B
   Mihalik, R
AF Imre, Gergely
   Paku, Sandor
   Nagy, Katalin
   Petak, Istvan
   Kopper, Laszlo
   Szende, Bela
   Mihalik, Rudolf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Imre, Gergely] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Paku, Sandor] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
RP Imre, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Istvan, G
   Czegle, I
AF Istvan, Gabor
   Czegle, Ibolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Istvan, Gabor] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Czegle, Ibolya] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
RP Istvan, G (reprint author), Semmelweis University, 2nd Department of Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Ivan, L
   Czigner, J
   Jori, J
AF Ivan, Laszlo
   Czigner, Jeno
   Jori, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Jori, Jozsef] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Ivan, L (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Jakab, F
AF Jakab, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
RP Jakab, F (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Jeney, A
   Timar, F
   Harisi, R
   Olah, J
   Kenessey, I
   Babo, I
   Otvos, L
   Suline Vargha, H
AF Jeney, Andras
   Timar, Ferenc
   Harisi, Revekka
   Olah, Julia
   Kenessey, Istvan
   Babo, Istvan
   Otvos, Laszlo
   Suline Vargha, Helga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Babo, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Otvos, Laszlo] MTA Kemiai KutatokozpontBudapest, Hungary.
   [Suline Vargha, Helga] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Jeney, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Juhos, �
   Lang, I
AF Juhos, Eva
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Juhos, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Juhos, �
   Papai, Zs
   Hitre, E
   Szabo, E
   Horvath, Zs
   Lang, I
AF Juhos, Eva
   Papai, Zsuzsa
   Hitre, Erika
   Szabo, Eszter
   Horvath, Zsolt
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Juhos, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Kahan, Zs
   Gardi, J
   Foldesi, I
   Ormandi, K
   Hoffman, 
   Nyari, T
   Thurzo, L
AF Kahan, Zsuzsanna
   Gardi, Janos
   Foldesi, Imre
   Ormandi, Katalin
   Hoffman, Cs.
   Nyari, Tibor
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gardi, Janos] SZTE, Endokrin Onallo Osztaly es LaboratoriumSzeged, Hungary.
   [Foldesi, Imre] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Hoffman, Cs.] SZTE, Szeged Szakorvosi Ellatas Mamma CentrumSzeged, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Kahan, Zs
   Varga, Z
   Csenki, M
   Szil, E
   Gyulai, Zs
   Mandi, Y
   Thurzo, L
AF Kahan, Zsuzsanna
   Varga, Zoltan
   Csenki, Melinda
   Szil, Elemer
   Gyulai, Zsofia
   Mandi, Yvette
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gyulai, Zsofia] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Mandi, Yvette] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Kahan, Zs
AF Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Kalmar, K
   Cseke, L
   Varga, G
   Papp, A
   Illenyi, L
   Kelemen, D
   Kaposztas, Zs
   Stefanits, K
   Varga, E
   Horvath, PO
AF Kalmar, Katalin
   Cseke, Laszlo
   Varga, Gabor
   Papp, Andras
   Illenyi, Laszlo
   Kelemen, Dezso
   Kaposztas, Zsolt
   Stefanits, Klara
   Varga, Erika
   Horvath, Peter Ors
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalmar, Katalin] University of Pecs, Department of SurgeryPecs, Hungary.
   [Cseke, Laszlo] University of Pecs, Department of SurgeryPecs, Hungary.
   [Varga, Gabor] University of Pecs, Department of SurgeryPecs, Hungary.
   [Papp, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Illenyi, Laszlo] University of Pecs, Department of SurgeryPecs, Hungary.
   [Kelemen, Dezso] University of Pecs, Department of SurgeryPecs, Hungary.
   [Kaposztas, Zsolt] University of Pecs, Department of SurgeryPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Varga, Erika] Siofok Varosi KorhazSiofok, Hungary.
   [Horvath, Peter Ors] University of Pecs, Department of SurgeryPecs, Hungary.
RP Kalmar, K (reprint author), University of Pecs, Department of Surgery, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Kasler, M
AF Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Kelecsenyi, Zs
   Szekely, G
   Gundy, S
AF Kelecsenyi, Zsolt
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kelecsenyi, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of OncologyBudapest, Hungary.
   [Gundy, Sarolta] National Institute of OncologyBudapest, Hungary.
RP Kelecsenyi, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Keleti, Gy
   Molnar, 
   De Negri, N
   Szabo, Zs
AF Keleti, Gyorgy
   Molnar, P.
   De Negri, Nino
   Szabo, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Keleti, Gyorgy] Szent Istvan Hospital, Department of General SurgeryBudapest, Hungary.
   [Molnar, P.] Szent Istvan Hospital, Department of General SurgeryBudapest, Hungary.
   [De Negri, Nino] Szent Istvan Hospital, Department of General SurgeryBudapest, Hungary.
   [Szabo, Zsuzsanna] Municipal Hospital, Del-Pest, Department of PathologyBudapest, Hungary.
RP Keleti, Gy (reprint author), Szent Istvan Hospital, Department of General Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Kenessey, I
   Timar, F
   Harisi, R
   Polony, G
   Paku, S
   Olah, J
   Kovalszky, I
   Jeney, A
AF Kenessey, Istvan
   Timar, Ferenc
   Harisi, Revekka
   Polony, Gabor
   Paku, Sandor
   Olah, Julia
   Kovalszky, Ilona
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kenessey, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Polony, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Kenessey, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Kiss, Cs
   Ferenczy, �
   Strausz, J
AF Kiss, Csongor
   Ferenczy, Eva
   Strausz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Csongor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Ferenczy, Eva] County Hospital of PulmonologyTorokbalint, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Kiss, Cs (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Kiss, J
   Antal, I
   Nyiri, P
   Zahar, �
   Szendroi, M
AF Kiss, Janos
   Antal, Imre
   Nyiri, Peter
   Zahar, Akos
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Nyiri, Peter] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Zahar, Akos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Kiss, J (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Kocsis, Zs
   Marcsek, Z
   Jakab, M
   Hidvegi, M
   Szende, B
   Tompa, A
AF Kocsis, Zsuzsanna
   Marcsek, Zoltan
   Jakab, Matyas
   Hidvegi, Marta
   Szende, Bela
   Tompa, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Zsuzsanna] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
   [Marcsek, Zoltan] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
   [Jakab, Matyas] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
   [Hidvegi, Marta] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
   [Szende, Bela] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
   [Tompa, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi KozpontBudapest, Hungary.
RP Kocsis, Zs (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Kolacsek, O
   Csuka, O
   Koves, I
   Otto, Sz
AF Kolacsek, Orsolya
   Csuka, Orsolya
   Koves, Istvan
   Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kolacsek, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
RP Kolacsek, O (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Kondas, J
AF Kondas, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kondas, Jozsef] Peterfy Hospital, Department of UrologyBudapest, Hungary.
RP Kondas, J (reprint author), Peterfy Hospital, Department of Urology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Kopper, L
AF Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Korom, I
   Varga, E
   Olah, J
   Dobozy, A
AF Korom, Irma
   Varga, Erika
   Olah, Judit
   Dobozy, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Korom, I (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Kotai, Zs
   Elo, J
   Bartfai, R
   Balatoni, Zs
AF Kotai, Zsuzsa
   Elo, Janos
   Bartfai, Reka
   Balatoni, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Elo, Janos] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Bartfai, Reka] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Balatoni, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Kotai, Zs (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Kovacs, G
   Ostoros, Gy
AF Kovacs, Gabor
   Ostoros, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Kovacs, G (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Kovacs, G
   Erlaky, H
   Schlick, B
   Barany, O
   Koos, R
AF Kovacs, Gabor
   Erlaky, Hajna
   Schlick, Barbara
   Barany, Olga
   Koos, Rozalia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Erlaky, Hajna] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Schlick, Barbara] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Barany, Olga] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Koos, Rozalia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Kovacs, G
   Szendroi, M
   Antal, I
   Koos, R
AF Kovacs, Gabor
   Szendroi, Miklos
   Antal, Imre
   Koos, Rozalia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Koos, Rozalia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Kovalszky, I
   Hollosi, P
   Fule, T
   Szilak, L
AF Kovalszky, Ilona
   Hollosi, Peter
   Fule, Tibor
   Szilak, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hollosi, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szilak, Laszlo] Szilak Labor KftSzeged, Hungary.
RP Kovalszky, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Kokeny, Sz
   Orban, T
   Olah, E
AF Kokeny, Szabolcs
   Orban, Tamas
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kokeny, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Orban, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Kokeny, Sz (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Kover, E
   Faluhelyi, Zs
AF Kover, Erika
   Faluhelyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kover, Erika] Baranya County Hospital, Department of OncologyPecs, Hungary.
   [Faluhelyi, Zsolt] Baranya County Hospital, Department of OncologyPecs, Hungary.
RP Kover, E (reprint author), Baranya County Hospital, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Kralovanszky, J
   Pandi, E
   Adleff, V
   Katona, Cs
   Budai, B
   Hitre, E
   Kovacs, T
   Czegledi, F
   Gyergyay, F
   P. Gazdag, A
   Orosz, Zs
AF Kralovanszky, Judit
   Pandi, Erzsebet
   Adleff, Vilmos
   Katona, Csilla
   Budai, Barna
   Hitre, Erika
   Kovacs, Tibor
   Czegledi, Ferenc
   Gyergyay, Fruzsina
   P. Gazdag, Anett
   Orosz, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
   [Pandi, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Katona, Csilla] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Tibor] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of OncologyBudapest, Hungary.
   [P. Gazdag, Anett] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Kralovanszky, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Krascsenits, G
   Mangel, L
   Pulay, T
   Fodor, J
AF Krascsenits, Geza
   Mangel, Laszlo
   Pulay, Tamas
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Krascsenits, Geza] National Institute of OncologyBudapest, Hungary.
   [Mangel, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
RP Krascsenits, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 278
EP 278
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 279
EP 279
PG 1
ER

PT J
AU Ladanyi, A
   Somlai, B
   Gilde, K
   Fejos, Zs
   Kiss, J
   Gaudi, I
   Timar, J
AF Ladanyi, Andrea
   Somlai, Beata
   Gilde, Katalin
   Fejos, Zsuzsanna
   Kiss, Judit
   Gaudi, Istvan
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Kiss, Judit] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 279
EP 279
PG 1
ER

PT J
AU Baki, M
   Bercsenyi, L
   Bodoky, Gy
   Csejtei, A
   Erfan, J
   Faluhelyi, Zs
   Izso, J
   Kispal, M
   Kovacs, L
   Laszlo, Gy
   Mako, E
   Mayer, �
   Moskovits, K
   Pinter, T
   Romhanyi, �
   Szanto, J
   Szucs, M
   Tomoczky, J
   Thurzo, L
AF Baki, Marta
   Bercsenyi, Lajos
   Bodoky, Gyorgy
   Csejtei, Andras
   Erfan, Jozsef
   Faluhelyi, Zsolt
   Izso, Jozsef
   Kispal, Mihaly
   Kovacs, Laszlo
   Laszlo, Gyozo
   Mako, Erno
   Mayer, Arpad
   Moskovits, Katalin
   Pinter, Tamas
   Romhanyi, Eva
   Szanto, Janos
   Szucs, Miklos
   Tomoczky, Janos
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baki, Marta] St. Margit HospitalBudapest, Hungary.
   [Bercsenyi, Lajos] Szent Lazar Megyei KorhazSalgotarjan, Hungary.
   [Bodoky, Gyorgy] St. Laszlo HospitalBudapest, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Erfan, Jozsef] Josa Andras County HospitalNyiregyhaza, Hungary.
   [Faluhelyi, Zsolt] County Hospital of BaranyaPecs, Hungary.
   [Izso, Jozsef] BM Kozponti KorhazBudapest, Hungary.
   [Kispal, Mihaly] Csongrad Megyei Teruleti KorhazSzentes, Hungary.
   [Kovacs, Laszlo] Ferenc Markhot County HospitalEger, Hungary.
   [Laszlo, Gyozo] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Mako, Erno] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Moskovits, Katalin] St. Imre HospitalBudapest, Hungary.
   [Pinter, Tamas] Petz Aladar County HospitalGyor, Hungary.
   [Romhanyi, Eva] Kenezy Teaching HospitalDebrecen, Hungary.
   [Szanto, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Tomoczky, Janos] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Baki, M (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 279
EP 279
PG 1
ER

PT J
AU Lazar, Gy
   Ormandi, K
   Szentpali, K
   Paszt, A
   Lazar, M
   Hajnal Papp, R
   Pavics, L
   Kahan, Zs
AF Lazar, Gyorgy
   Ormandi, Katalin
   Szentpali, Karoly
   Paszt, Attila
   Lazar, Mate
   Hajnal Papp, Rozalia
   Pavics, Laszlo
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of SurgerySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Lazar, Mate] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Hajnal Papp, Rozalia] University of Szeged, Department of PathologySzeged, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Lengyel, E
   Dank, M
AF Lengyel, Erzsebet
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Erzsebet] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Lengyel, E (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Lippai, Zs
   Elekne Kiss, B
   Piko, B
   Bassam, A
AF Lippai, Zsuzsanna
   Elekne Kiss, Barbara
   Piko, Bela
   Bassam, Ali
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lippai, Zsuzsanna] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Lippai, Zs (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Liszkay, G
   Peley, G
   Sinkovics, I
   Peter, I
   Fejos, Zs
   Hudacsek, K
   Banfalvi, T
   Gilde, K
AF Liszkay, Gabriella
   Peley, Gabor
   Sinkovics, Istvan
   Peter, Ilona
   Fejos, Zsuzsanna
   Hudacsek, Katalin
   Banfalvi, Teodora
   Gilde, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sinkovics, Istvan] Orszagos Onkologiai Intezet, Izotopdiagnosztikai OsztalyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Hudacsek, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 281
EP 281
PG 1
ER

PT J
AU Lohinszky, J
   Levardi, F
   Zolnai, Zs
   Baki, M
AF Lohinszky, Julia
   Levardi, Ferenc
   Zolnai, Zsofia
   Baki, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lohinszky, Julia] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Levardi, Ferenc] Szent Margit Korhaz, NogyogyaszatBudapest, Hungary.
   [Zolnai, Zsofia] Szt. Margit Hospital, Department of PathologyBudapest, Hungary.
   [Baki, Marta] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
RP Lohinszky, J (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 281
EP 281
PG 1
ER

PT J
AU Lorincz, T
   Toth, J
   Szendroi, M
   Timar, J
AF Lorincz, Tamas
   Toth, Jozsef
   Szendroi, Miklos
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lorincz, Tamas] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szendroi, Miklos] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Lorincz, T (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 281
EP 281
PG 1
ER

PT J
AU Lovey, J
   Lukits, J
   Remenar, �
   Koronczay, K
   Kasler, M
   Nemeth, Gy
   Timar, J
AF Lovey, Jozsef
   Lukits, Julia
   Remenar, Eva
   Koronczay, Krisztina
   Kasler, Miklos
   Nemeth, Gyorgy
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lukits, Julia] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Koronczay, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 282
EP 282
PG 1
ER

PT J
AU Lovey, K
   Major, T
   Polgar, Cs
   Fodor, J
AF Lovey, Katalin
   Major, Tibor
   Polgar, Csaba
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 282
EP 282
PG 1
ER

PT J
AU Lumniczky, K
   Desaknai, Sz
   Hamada, H
   Safrany, G
AF Lumniczky, Katalin
   Desaknai, Szilvia
   Hamada, Hideo
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Desaknai, Szilvia] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Hamada, Hideo] Biomedical Research CenterSapporo, Japan.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Lumniczky, K (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 282
EP 282
PG 1
ER

PT J
AU Magyarosy, E
   Timar, J
   Francsovics, J
   Raso, E
AF Magyarosy, Edina
   Timar, Jozsef
   Francsovics, Judit
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyarosy, Edina] Heim Pal Children's Hospital, Department of HematologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Francsovics, Judit] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Magyarosy, E (reprint author), Heim Pal Children's Hospital, Department of Hematology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 283
EP 283
PG 1
ER

PT J
AU Mahr, K
   Kolonics, Zs
   Olah, K
   Ruzsa, �
AF Mahr, Karoly
   Kolonics, Zsuzsanna
   Olah, Katalin
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kolonics, Zsuzsanna] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Olah, Katalin] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Mahr, K (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 283
EP 283
PG 1
ER

PT J
AU Maraz, A
   Thurzo, L
AF Maraz, Aniko
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 283
EP 283
PG 1
ER

PT J
AU Maraz, R
   Boross, G
   Svebis, M
   Marko, L
   Hajnal, L
   Szucs, M
   Ambrozay, �
   Lorincz, M
   Cserni, G
AF Maraz, Robert
   Boross, Gabor
   Svebis, Mihaly
   Marko, Laszlo
   Hajnal, Lajos
   Szucs, Miklos
   Ambrozay, Eva
   Lorincz, Margit
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Lorincz, Margit] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 283
EP 283
PG 1
ER

PT J
AU Mark, Zs
   Bajzik, G
   Nagy, A
   Bogner, P
   Repa, I
   Strausz, J
AF Mark, Zsuzsa
   Bajzik, Gabor
   Nagy, Andrea
   Bogner, Peter
   Repa, Imre
   Strausz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mark, Zsuzsa] County Hospital of PulmonologyTorokbalint, Hungary.
   [Bajzik, Gabor] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Nagy, Andrea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Bogner, Peter] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Repa, Imre] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Mark, Zs (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 284
EP 284
PG 1
ER

PT J
AU Marko, L
   Boross, G
   Hajnal, L
   Maraz, R
   Cserni, G
   Szucs, M
   Svebis, M
AF Marko, Laszlo
   Boross, Gabor
   Hajnal, Lajos
   Maraz, Robert
   Cserni, Gabor
   Szucs, Miklos
   Svebis, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 284
EP 284
PG 1
ER

PT J
AU Marko, L
   Maraz, R
   Hajnal, L
   Boross, G
   Szucs, M
   Svebis, M
   Ambrozay, �
   Cserni, G
AF Marko, Laszlo
   Maraz, Robert
   Hajnal, Lajos
   Boross, Gabor
   Szucs, Miklos
   Svebis, Mihaly
   Ambrozay, Eva
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Radiologiai OsztalyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 284
EP 284
PG 1
ER

PT J
AU Mathe, Cs
   Nagyivanyi, K
   Orosz, Zs
   Vajda, E
   Bodrogi, I
AF Mathe, Csaba
   Nagyivanyi, Krisztian
   Orosz, Zsolt
   Vajda, Erika
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mathe, Csaba] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Vajda, Erika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Mathe, Cs (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 285
EP 285
PG 1
ER

PT J
AU Mathe, M
   Fule, T
   Suba, Zs
   Kovalszky, I
AF Mathe, Miklos
   Fule, Tibor
   Suba, Zsuzsanna
   Kovalszky, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mathe, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Suba, Zsuzsanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Mathe, M (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 285
EP 285
PG 1
ER

PT J
AU Matolcsy, A
AF Matolcsy, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Matolcsy, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 285
EP 285
PG 1
ER

PT J
AU Matrai, Z
   Peley, G
   Renyi-Vamos, F
   Szabo, �
   Bidlek, M
   Sinkovics, I
   Orosz, Zs
   Farkas, E
   Dubecz, S
   Koves, I
AF Matrai, Zoltan
   Peley, Gabor
   Renyi-Vamos, Ferenc
   Szabo, Eva
   Bidlek, Maria
   Sinkovics, Istvan
   Orosz, Zsolt
   Farkas, Emil
   Dubecz, Sandor
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Peley, Gabor] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Dubecz, Sandor] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 285
EP 285
PG 1
ER

PT J
AU Mayer, �
   Nemeskeri, Cs
   Naszaly, A
AF Mayer, Arpad
   Nemeskeri, Csaba
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 286
EP 286
PG 1
ER

PT J
AU Melegh, Zs
AF Melegh, Zsombor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Melegh, Zs (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 286
EP 286
PG 1
ER

PT J
AU Mezei, K
   Erfan, J
   Polya, Zs
AF Mezei, Klara
   Erfan, Jozsef
   Polya, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mezei, Klara] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Polya, Zsofia] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Mezei, K (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 286
EP 286
PG 1
ER

PT J
AU Moldvay, J
   Jackel, M
   Bogos, K
   Soltesz, I
   Agocs, L
   Kovacs, G
   Schaff, Zs
AF Moldvay, Judit
   Jackel, Marta
   Bogos, Krisztina
   Soltesz, Ibolya
   Agocs, Laszlo
   Kovacs, Gabor
   Schaff, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] County Hospital of PulmonologyTorokbalint, Hungary.
   [Jackel, Marta] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Agocs, Laszlo] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Moldvay, J (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 286
EP 286
PG 1
ER

PT J
AU Molnar, M
   Szucs, M
AF Molnar, Maria
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Molnar, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 287
EP 287
PG 1
ER

PT J
AU Molnar, J
   Mucsi, I
   Gyemant, N
   Ugocsai, K
   Hegyes, P
   Varga, A
AF Molnar, Jozsef
   Mucsi, Imre
   Gyemant, Nora
   Ugocsai, Katalin
   Hegyes, Peter
   Varga, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Mucsi, Imre] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Gyemant, Nora] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Ugocsai, Katalin] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Hegyes, Peter] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Varga, Andras] Humboldt Egyetem, Molekularis Parazitologiai IntezetBerlin, Germany.
RP Molnar, J (reprint author), SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai Intezet, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 287
EP 287
PG 1
ER

PT J
AU Monostori, Zs
   Godeny, M
   Schneider, F
AF Monostori, Zsuzsanna
   Godeny, Maria
   Schneider, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Monostori, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Schneider, Ferenc] National Institute of OncologyBudapest, Hungary.
RP Monostori, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 287
EP 287
PG 1
ER

PT J
AU Monos, Zs
   Fejos, Zs
   Begany, �
   Remenyik, �
AF Monos, Zsuzsa
   Fejos, Zsuzsanna
   Begany, Agnes
   Remenyik, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Monos, Zsuzsa] Fov. Szt. Istvan Korhaz, OnkodermatologiaBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Begany, Agnes] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Remenyik, Eva] University of Debrecen, Department of DermatologyDebrecen, Hungary.
RP Monos, Zs (reprint author), Fov. Szt. Istvan Korhaz, Onkodermatologia, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 287
EP 287
PG 1
ER

PT J
AU Moricz, I
AF Moricz, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moricz, Istvan] Fejer Megyei Szent Gyorgy Korhaz, Ful-orr-gegeszeti es Fej-nyaksebeszeti OsztalyaSzekesfehervar, Hungary.
RP Moricz, I (reprint author), Fejer Megyei Szent Gyorgy Korhaz, Ful-orr-gegeszeti es Fej-nyaksebeszeti Osztalya, Szekesfehervar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 288
EP 288
PG 1
ER

PT J
AU Morocz, �
   Strausz, J
AF Morocz, Eva
   Strausz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Morocz, Eva] County Hospital of PulmonologyTorokbalint, Hungary.
   [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Morocz, � (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 288
EP 288
PG 1
ER

PT J
AU Muszbek, K
AF Muszbek, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muszbek, Katalin] ESZSZK Szent Laszlo Korhaz, HospiceBudapest, Hungary.
RP Muszbek, K (reprint author), ESZSZK Szent Laszlo Korhaz, Hospice, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 288
EP 288
PG 1
ER

PT J
AU Muller, J
   Kovacs, G
   Garami, M
   Hauser, P
   Schmidt, M
   Fekete, Gy
AF Muller, Judit
   Kovacs, Gabor
   Garami, Miklos
   Hauser, Peter
   Schmidt, Marianne
   Fekete, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Schmidt, Marianne] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 288
EP 288
PG 1
ER

PT J
AU Muller, Z
   Bansaghi, Z
   Elo, J
   Balatoni, Zs
AF Muller, Zoltan
   Bansaghi, Zoltan
   Elo, Janos
   Balatoni, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Bansaghi, Zoltan] Peterfy Kh, RadiologiaBudapest, Hungary.
   [Elo, Janos] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Balatoni, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 289
EP 289
PG 1
ER

PT J
AU Nagy, B
   Thurzo, L
AF Nagy, Beatrix
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Beatrix] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nagy, B (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 289
EP 289
PG 1
ER

PT J
AU Nagy, E
   Beck, Z
   D. Toth, F
AF Nagy, Endre
   Beck, Zoltan
   D. Toth, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Endre] University of Debrecen, Faculty of Medicine, Department of Medical MicrobiologyDebrecen, Hungary.
   [Beck, Zoltan] University of Debrecen, Faculty of Medicine, Department of Medical MicrobiologyDebrecen, Hungary.
   [D. Toth, Ferenc] University of Debrecen, Faculty of Medicine, Department of Medical MicrobiologyDebrecen, Hungary.
RP Nagy, E (reprint author), University of Debrecen, Faculty of Medicine, Department of Medical Microbiology, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 289
EP 289
PG 1
ER

PT J
AU Nagy, K
   Izeradjene, K
   Petak, I
   Mihalik, R
   Szuts, K
   Douglas, L
   Kopper, L
   Houghton, AJ
AF Nagy, Katalin
   Izeradjene, Kamel
   Petak, Istvan
   Mihalik, Rudolf
   Szuts, Krisztina
   Douglas, Leslie
   Kopper, Laszlo
   Houghton, A Janet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Izeradjene, Kamel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szuts, Krisztina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Douglas, Leslie] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Houghton, A Janet] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Nagy, K (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 289
EP 289
PG 1
ER

PT J
AU Nagy, Zs
   Valtinyi, D
   Moskovits, K
AF Nagy, Zsuzsanna
   Valtinyi, Dorottya
   Moskovits, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Zsuzsanna] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Valtinyi, Dorottya] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Moskovits, Katalin] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
RP Nagy, Zs (reprint author), St. Imre Hospital, Department Clinical Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 290
EP 290
PG 1
ER

PT J
AU Nemes, I
   Pacz, M
   Kiss, Gy
AF Nemes, Istvan
   Pacz, Miklos
   Kiss, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemes, Istvan] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti OsztalySzombathely, Hungary.
   [Pacz, Miklos] Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti OsztalySzombathely, Hungary.
   [Kiss, Gyula] Vas Megyei Markusovszky Korhaz, Baleseti, Helyreallito- es Kezsebeszeti OsztalySzombathely, Hungary.
RP Nemes, I (reprint author), Megyei Markusovszky Korhaz, Arc-, Allcsont- es Szajsebeszeti Osztaly, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 290
EP 290
PG 1
ER

PT J
AU Nemeth, Gy
AF Nemeth, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Gyorgy] National Institute of OncologyBudapest, Hungary.
RP Nemeth, Gy (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 290
EP 290
PG 1
ER

PT J
AU Nyiro, 
AF Nyiro, I.
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nyiro, I.] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Nyiro,  (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 290
EP 290
PG 1
ER

PT J
AU Oberna, F
   Rethy, �
   Takacsi-Nagy, Z
   Polus, K
   Kasler, M
AF Oberna, Ferenc
   Rethy, Agnes
   Takacsi-Nagy, Zoltan
   Polus, Karoly
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Oberna, Ferenc] Pest Megyei Onkormanyzat Szent Rokus Korhaz, Arc-, Allcsont es Szajsebeszeti OsztalyBudapest, Hungary.
   [Rethy, Agnes] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Oberna, F (reprint author), Pest Megyei Onkormanyzat Szent Rokus Korhaz, Arc-, Allcsont es Szajsebeszeti Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 292
EP 292
PG 1
ER

PT J
AU Ocsai, H
   Haznagy, �
   Torok, L
AF Ocsai, Henriette
   Haznagy, Agnes
   Torok, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ocsai, Henriette] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Haznagy, Agnes] Bacs-Kiskun Megyei Onkormanyzat Korhaza, Kozponti LaboratoriumKecskemet, Hungary.
   [Torok, Laszlo] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
RP Ocsai, H (reprint author), Bacs-Kiskun Megyei Korhaz, Borgyogyaszat, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 292
EP 292
PG 1
ER

PT J
AU Olah, E
AF Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Olah, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 292
EP 292
PG 1
ER

PT J
AU Olah, J
   Gyulai, R
   Csoma, Zs
   Korom, I
   Varga, E
   Dobozy, A
AF Olah, Judit
   Gyulai, Rolland
   Csoma, Zsuzsanna
   Korom, Irma
   Varga, Erika
   Dobozy, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Gyulai, Rolland] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Csoma, Zsuzsanna] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 293
EP 293
PG 1
ER

PT J
AU Olasz, K
   Mari, B
   Kosztolanyi, Gy
   Gyarmati, Cs
   Kocsis, L
   Ocsai, H
   Torok, L
AF Olasz, Katinka
   Mari, Bela
   Kosztolanyi, Gyorgy
   Gyarmati, Csaba
   Kocsis, Lajos
   Ocsai, Henriette
   Torok, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Katinka] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Mari, Bela] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Kosztolanyi, Gyorgy] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Gyarmati, Csaba] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Kocsis, Lajos] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Ocsai, Henriette] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Torok, Laszlo] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
RP Olasz, K (reprint author), Bacs-Kiskun Megyei Korhaz, Borgyogyaszat, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 293
EP 293
PG 1
ER

PT J
AU Olasz, L
   Gelencser, G
   Nyarady, Z
   Ronai, A
   Elek, L
AF Olasz, Lajos
   Gelencser, Gabor
   Nyarady, Zoltan
   Ronai, Andras
   Elek, Laszlo
TI Applicability of the sternocleidomastoid myocutane lobe in oral pharyngeal reconstructions
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: To perform the reconstruction of tissue deficiencies in the course of resection surgery for oral and pharyngeal carcinomas as quickly as possible, but at the same time safely, with a relatively modest overload for the patient. Method: Swallowed and free lobes are used to compensate for tissue deficiencies following resection operations in the pharyngeal region. Among the swallowed myocutaneous lobes, the pectoralis maior and latissimus dorsi are the most commonly used, while among the free lobes, the forearm (Chinese) is the most commonly used. The sternocleidomastoid swallowed myocutane lobe is much less used than before. This lobe was examined to compensate for various oral-pharyngeal soft tissue deficiencies. Results: The ingested lobe of the sternocleidomastoid myocutan was used to compensate for mesopharyngeal, buccal, and fundus tissue deficiencies. The lobe can be dissected in a relatively short time (about 30 minutes) and could be used in the above-mentioned localizations, even to replace the bilateral fundus. The donor site could be closed with a primer in all cases. In the case of functional dissection of the neck, two of the three supply vessels can be preserved, which ensures unhindered healing at the recipient's site. Conclusion: The sternocleidomastoid myocutane lobe can be safely used to replace various pharyngeal defects. The lobe can be quickly retrieved from the vicinity of the resection surgical area, along with functional dissection. The donor site is aesthetic so that it does not require a second surgery. No special medication or treatment is required during the postoperative period. Not for use in radical cervical dissection. Compared to other lobes, there are many advantages, its use is more recommended!
C1 [Olasz, Lajos] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Gelencser, Gabor] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Nyarady, Zoltan] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Ronai, Andras] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Elek, Laszlo] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
RP Olasz, L (reprint author), University of Pecs, Department of Oral and Maxillofacial Surgery, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 293
EP 293
PG 1
ER

PT J
AU Orban, T
   Olah, E
AF Orban, Tamas
   Olah, Edit
TI BRCA1 “Breast Cancer Gene” Expression: Individual Variability and Tissue-Specific Alternative RNA Alignment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Intensive research is underway to elucidate the molecular mechanisms (e.g., gene expression disorder) involved in the development of sporadic tumors, which account for a significant proportion of breast tumors, in the absence of germ cell and somatic mutations. Our previous studies in cell lines have suggested that the tissue-specific distribution pattern and displacement of RNA isoforms formed from the gene by the alternative splicing mechanism may play a role in malignant transformation (TIG 17: 252, 2001; BBRC 280: 32, 2001). Our studies on tumor and leukocyte samples from breast cancer patients confirmed the tissue-specificity of the regulation, but we could not clearly correlate the change in expression levels with tumor formation. The distribution of BRCA1 RNA forms showed high variability, which in addition to inter-tumor variability may also result from variation in individual tissue gene expression (JCP-Mol Pathol, accepted for publication, 2003). Our further studies aim to understand the function of common BRCA1 isoforms. In this context, we plan to specifically remove the given variants by RNA interference in different cell lines, and to deduce the unique function of the variants from the resulting phenotypic differences. With these results, we may be closer to resolving the paradox of why an inherited defect in such a gene with general cytological functions leads to tissue-specific tumor formation, particularly in the breast and ovary.
C1 [Orban, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Orban, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 294
EP 294
PG 1
ER

PT J
AU Orosz, Zs
AF Orosz, Zsolt
TI Functional diagnostics of GIST
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In 1998, Kindblom et al. Demonstrated that a significant proportion of mesenchymal tumors in the gastrointestinal tract show c-kit (CD117) expression. The c-kit antigen with tyrosine kinase activity is present in Cajal interstitial cells with pacemaker function. Behind the abnormal c-kit protein expression of GISTs is a mutation in the c-kit gene, and this property distinguishes GISTs from tumors of the true leiomyogen and Schwann cell differentiation that rarely occur in the gastrointestinal tract. Accurate assessment of size and proliferative activity is crucial in assessing the expected biological behavior of GISTs. Instead of the usual "malignant" and "benign" grouping, it is recommended to use a prognostic risk group for recurrence and metastasis. In 2001, GIST came back into focus as a team of patients with multiple metastatic GIST successfully treated with the tyrosine kinase inhibitor ST1571. The importance of the procedure is given by the fact that no effective method for the treatment of metastatic GISTs was previously known. Since then, studies in larger groups of patients have shown that treatment is effective in 80% of cases, resulting in partial tumor regression or steady state. The author is a member of a Hungarian team working on the examination and treatment of patients with GIST. The author describes the pathological aspects, immunohistochemical results of the GISTs (90 cases) collected in the recent period, and the criteria used to determine the diagnosis and dignity.
C1 [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
RP Orosz, Zs (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 294
EP 294
PG 1
ER

PT J
AU Ostoros, Gy
   Kovacs, G
AF Ostoros, Gyula
   Kovacs, Gabor
TI Follow-up and care responsibilities in the care of lung cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB According to the joint resolution of the Professional Colleges of Lung Medicine and Oncology: "In Hungary, the majority of lung cancer patients are currently detected in lung care institutions by screening or complaints, and the examination, treatment, follow-up and care of patients is coordinated by the pulmonology network". The role of lung caregivers in the care of lung cancer patients is a complex task. Today, we can screen one-third of lung cancer patients in the asymptomatic and complaint-free stages by screen screening. During the investigation, the suspicion of cancerous lung disease is raised in the lung care network. The follow-up and care of patients with blast-operated lung cancer and those with curative lung cancer is also the responsibility of the lung care network. In blast-operated patients, recurrence of the disease can be expected mainly in the first four years. After five years, the likelihood of recurrence drops below ten percent. The development of a methacron lung tumor is also a realistic possibility. The aim of monitoring and caring for lung cancer patients is to detect the local recurrence of the disease and the development of possible metastases as soon as possible. International recommendations for follow-up and care are not uniform. It is recommended that patients be monitored every three months for the first two years, then every six months for three years, and annually thereafter. During the examination, an anamnesis should be taken, a physical examination, a chest X-ray (screening) should be performed, or a chest (baseline) CT examination after resection lung surgery may be considered. Of course, if there is any clinical suspicion of recurrence of the disease, a detailed inpatient examination is warranted. The development of a well-functioning surveillance system for specific lung diseases is also appropriate for lung cancer.
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 294
EP 294
PG 1
ER

PT J
TI Epidemiological rationale for the Public Health Screening Program
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The author analyzes the health status of the Hungarian population and the mortality and incidence of malignant neoplasms. It compares the domestic data with the large European and international data, on the basis of which it outlines the unfavorable indicators in Hungary, looking for their causes and possible breakout points. Among these, the greatest opportunity lies in the organized, continuous screening tests within the framework of the “Johan Bela National Program for the Decade of Health”. As cancer is a particularly serious public health problem in Hungary, the reduction of the exceptionally high cancer mortality by screening for the three planned localizations of cancer (cervical, breast, colon and rectal cancers) is absolutely justified.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 294
EP 294
PG 1
ER

PT J
AU Pajor, L
AF Pajor, Laszlo
TI Results of exenteral surgeries for pelvic tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To evaluate pelvic exenter surgery. Methods: Review of postoperative survival, quality of life, and surgical complications in 15 patients over the past 5 years. Results: Examination of two-year survival shows that half of the patients - 7 patients - live and their quality of life is acceptable. Six patients died of the tumor and one died as a result of the surgery. Conclusions: In a selected case, in a young patient, if the tumor is in the middle of the pelvis, surgery should be performed. Additional oncology treatment is required in all cases.
C1 [Pajor, Laszlo] University of Szeged, Department of UrologySzeged, Hungary.
RP Pajor, L (reprint author), University of Szeged, Department of Urology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 295
EP 295
PG 1
ER

PT J
AU P. Gazdag, A
   Adleff, V
   Budai, B
   Czegledi, F
   Hitre, E
   Orosz, Zs
   Kralovanszky, J
AF P. Gazdag, Anett
   Adleff, Vilmos
   Budai, Barna
   Czegledi, Ferenc
   Hitre, Erika
   Orosz, Zsolt
   Kralovanszky, Judit
TI Investigation of methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism in patients with colorectal cancer and healthy controls
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The homozygous form of the MTHFR C677T gene polymorphism is associated with a reduction in enzyme activity of approximately 90%, rearrangement of the “folate pool” toward unmethylated folates, which may affect the efficacy of fluoropyrimidine-type drugs. Objective: To compare the distribution of the MTHFR C677T gene polymorphism in 169 patients with colorectal cancer and 196 healthy blood donors and to find a correlation between the frequency of gene polymorphisms and clinical data in patients with colorectal cancer (gender, age, localization, Dukes stage and response to medication). ). Method: RFLP analysis of PCR amplitude of DNA fraction isolated from lymphocytes. Results: There was no significant difference in the genotype distribution between the control and patient groups (p = 0.77). The incidence of mutant (TT) genotype was 7.6% in the control group and 9.5% in cancer patients. No significant differences in the distribution of genotypes were found in patients when compared by gender, age, tumor localization, Dukes stage, metastasis, and location. However, in the group of patients with a median follow-up (18 ± 2), the genotype distribution of fluoropyrimidine-based adjuvant-treated and deceased patients differed significantly. Heterozygous (CT) and wild-type (CC) genotypes were significantly more common in tumor-free patients (p = 0.012). This difference was also reflected in the overall survival (OS) calculated by the Kaplan-Meier method.
C1 [P. Gazdag, Anett] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP P. Gazdag, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 295
EP 295
PG 1
ER

PT J
AU Pajkos, G
   Kiss, I
   Ember, I
   Stotz, Gy
   Rimanoczy, �
AF Pajkos, Gabor
   Kiss, Istvan
   Ember, Istvan
   Stotz, Gyula
   Rimanoczy, Eva
TI Detection of Kirsten ras oncogene change and prognostic value of serum preoperative carcinoembryonic antigen (CEA) in colorectal carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: The prognosis of colorectal carcinoma is very different despite the similarity of many clinical and pathological factors. Based on molecular biological research, we were the first Hungarian author to report the prognostic value of cross-mutation in colorectal carcinoma (Orv Hetilap 1999, Anticancer Res 2000). The subject of our present study is: 1. Is there an association between elevated preoperative CEA and the presence of Krasmutation? 2. Can their co-occurrence mean a worse prognosis? Methods: Of the eighty-eight surgical specimens, K-ras mutation was detected in 54 cases using “mutant allele specific amplification (MASA) polymerase chain recation (PCR)”. Preoperative CEA was high in 75 sera. Results: Oncogenic mutation and elevated CEA (Group I) 45, ras + and normal CEA (Group II) 9, abnormal CEA (Group III) 23, ras and normal CEA (Group IV) 11 patients was observed in the case of. Patient survival is significantly dependent on K-ras mutation and preoperative CEA. In their co-occurrence, progression-free survival (TTP) and median survival (OS) were significantly shorter than without - TTP: 18, 3 months (CI: 16, 2-19, 8 vs. 36, 1 (CI: 26, 4 -45, 9), OS: 29 months (CI: 25, 9-32) vs. 45 (CI: 33, 8-56, 2). Conclusions: In the process of carcinogenesis, the appearance of carcinoembryonic antigen is a later phenomenon and is independent of the development of the ras mutation. Their simultaneous appearance is basically a bad prognostic sign. Consideration of these factors may help to consider a wide range of modern therapeutic options (monoclonal antibody, tumor vaccine, aggressive chemotherapy protocols, radioimmunotherapy) based on the risk of disease progression.
C1 [Pajkos, Gabor] BM Kozponti KorhazBudapest, Hungary.
   [Kiss, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Ember, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Stotz, Gyula] BM Kozponti KorhazBudapest, Hungary.
   [Rimanoczy, Eva] Orszagos Gyogyintezeti Kozpont, Klinikai Kemiai LaboratoriumBudapest, Hungary.
RP Pajkos, G (reprint author), BM Kozponti Korhaz, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 295
EP 295
PG 1
ER

PT J
AU Pajor, L
AF Pajor, Laszlo
TI Screening or early detection in prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: To convince professional decision makers that prostate cancer mortality in Hungary can only be reduced by screening and stage migration. Method: Comparison of international epidemiological data with domestic mortality. Results: Opponents of screening argue that: - PSA-based screening does not detect some tumors - Advanced prostate cancer cannot be cured - Medium-risk tumors do not decide who should not be treated - Screened Some of the benefits of treatment - screening is costly Proponents of screening: - unnecessary treatments can be prevented by following exact protocols - curable localized prostate cancer can only be detected by screening - reduced mortality in the US after screening Conclusions: The introduction of screening in Hungary is recommended, early detection is not a viable method.
C1 [Pajor, Laszlo] University of Szeged, Department of UrologySzeged, Hungary.
RP Pajor, L (reprint author), University of Szeged, Department of Urology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 295
EP 295
PG 1
ER

PT J
AU Pal, 
   Boer, K
   Bosze, Sz
   Falus, A
   Darvas, Zs
AF Pal, Zs.
   Boer, Katalin
   Bosze, Szilvia
   Falus, Andras
   Darvas, Zsuzsanna
TI Investigation of histamine metabolism in human colon tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Our research group examines histamine metabolism in biopsy specimens of colon tumors and adenomas for comparison, which is an interesting area for tumor research due to the following observations: • that its levels are higher in rapidly proliferating tissues than in non-dividing tissues. Our methods: Detection of histidine decarboxylase (HDC; the only enzyme capable of producing histamine) by immunocytochemistry and Western blot, RP-HPLC to determine histamine, measurement of diaminooxidase (DAO; histamine degradation in the colon). Our results: HDC levels are elevated in adenocarcinomas compared to intact tissue and adenomas. Histamine levels are significantly higher in adenocarcinoma than in intact tissue, whereas in parallel, DAO activity is significantly lower. Our studies are important because by knowing the expression of histamine receptors, the development of specific inhibitors can provide valuable therapeutic tools in the treatment of colon adenocarcinomas.
C1 [Pal, Zs.] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Bosze, Szilvia] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Department of Organic ChemistryBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Darvas, Zsuzsanna] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Pal,  (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 296
EP 296
PG 1
ER

PT J
AU Paldy, A
   Nador, G
   Vincze, I
   Kishonti, K
AF Paldy, Anna
   Nador, Gizella
   Vincze, Istvan
   Kishonti, Krisztina
TI Spatial accumulation of mortality due to colorectal tumors (1986–2001) and morbidity (1997–2001) in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In our presentation, we want to contribute to the implementation of the strategic direction announced in the “Johan Bela National Program of the Decade of Health”: we present the epidemiological situation before the introduction of “colon and rectal cancer screening”. In our GIS analysis, we examine the method of cluster analysis between the ages of 25 and 100, broken down by 10-year age group, and between 25 and 54 years; 55–74; In the age group 75–100, between 1986–1993 and 1994–2001, the spatial distribution of deaths due to colorectal tumors among men and women (source: CSO) and between 1997 and 2001, the spatial distribution of diseases (source: MEDICINES) were aggregated and separately, according to localization. Results: The mortality of men due to colorectal tumors increases exponentially with age (y = e- 0.7X5.24 R2 = 0.9968. The clusters of the age groups older than 55 years occur in significantly the same places in space (Budapest, Heves, Jasz-Nagykun-Szolnok, Nograd, Komarom-Esztergom, Baranya counties). = 0.1664e0.1074x R2 = 0.9899) The location of the clusters is very similar to that of men, and the spatial distribution of the diseases is similar to that of mortality, but with a slightly larger extent.
C1 [Paldy, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
   [Nador, Gizella] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
   [Vincze, Istvan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
   [Kishonti, Krisztina] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
RP Paldy, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi Intezet, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 296
EP 296
PG 1
ER

PT J
AU Papai, Zs
   Bodoky, Gy
   Horti, J
   Tamas, K
   Nagy, T
   Orosz, Zs
   Sapi, Z
   Godeny, M
   Jakab, K
   Esik, O
   Tron, L
   Lang, I
   Bodrogi, I
   Besznyak, I
   Eckhardt, S
AF Papai, Zsuzsa
   Bodoky, Gyorgy
   Horti, Jozsef
   Tamas, Karin
   Nagy, Tunde
   Orosz, Zsolt
   Sapi, Zoltan
   Godeny, Maria
   Jakab, Katalin
   Esik, Olga
   Tron, Lajos
   Lang, Istvan
   Bodrogi, Istvan
   Besznyak, Istvan
   Eckhardt, Sandor
TI Efficacy of Glivec (imatinib) in gastrointestinal stromal tumors. Results of a clinical study in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction: Malignant gastrointestinal stromal tumors (GIST) are rapidly progressing tumors of the mesenchyme. A few years ago, literature data confirmed that most of GIST contains a c-kit antigen with tyrosine kinase activity. Glivec (imatinib) has been known in haematological practice for two years as a selective tyrosine kinase inhibitor. Of course, the question has arisen as to how effectively the formulation can be used in previously drug-resistant GIST. Patient Materials and Methods: Between October 1, 2001 and August 15, 2002, 38 metastatic, histologically verified, immunohistologically c-kit (CD117) positive GIST patients were included in our prospective study. The mean age of the patients was 54.2 (38-72) years. There were 14 women and 24 men in the study group. Imatinib 400 mg daily was administered orally during treatment. In case of insufficient response, the daily dose could be increased to 600 mg. Treatment was continued until progression. Laboratory tests were performed monthly to monitor the disease, and control imaging tests were performed every 2 months. Results: The aim of the study was to investigate the antitumor effect of Glivec (imatinib) and to analyze the side effects of the drug. Complete remission was observed in 1 (2.6%) patient. Partial remission (PR) was observed in 19 (50%) patients. In the study, 10 (26.3%) patients had stable conditions (SD) and 7 (18.4%) patients had advanced conditions (PD). The median time to response was 11 weeks. There was no fatal complication. Subcutaneous edema occurred in 8 (22%) cases. Abdominal pain occurred in 3 (8%) patients. Nausea and fatigue occurred in 2-2 (5% -5%) cases. Haematological adverse reactions occurred in 8 (22%) patients. The side effects occurred mainly at the beginning of treatment but were not severe. No interruption of treatment was required. Conclusion: Based on our results so far, it can be stated that Glivec (imatinib) is effective in the treatment of patients with gastrointestinal stromal tumors. Glivec (imatinib) treatment dramatically improved the survival and quality of life of patients with GIST. Further follow-up of the patient population and initiation of another prospective, randomized study appear necessary.
C1 [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Horti, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Tamas, Karin] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Sapi, Zoltan] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Jakab, Katalin] Szent Istvan Korhaz, Radiologiai OsztalyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Tron, Lajos] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Besznyak, Istvan] National Institute of OncologyBudapest, Hungary.
   [Eckhardt, Sandor] National Institute of OncologyBudapest, Hungary.
RP Papai, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 296
EP 296
PG 1
ER

PT J
AU Papai, Zs
AF Papai, Zsuzsa
TI Advanced treatment of malignant supporting tissue tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Malignant supporting tissue tumors make up only 2-3% of all malignant tumors. Although their occurrence is relatively rare, the specific diagnostic and treatment procedures, the high cost of treatment, and the average age of patients with osteosarcoma (20 years) make it appropriate to address this group of tumors. One group consists of soft-tissue tumors with a highly heterogeneous histological subtype and biological behavior, the determination of the degree of malignancy of which is a crucial point in the establishment of a treatment plan. A significant proportion of highly malignant tumors develop hematogenous variability within two years of diagnosis, with a five-year median survival of 40-60%. Significant changes have been observed in the diagnosis and treatment of soft tissue sarcomas over the past 10 years. Due to their heterogeneity, standard diagnostic and forms of treatment are quite difficult to design. While previously the treatment of these tumors was purely surgical, in addition to the primary removal of the tumor, the role of radiotherapy and chemotherapy has increased significantly in recent years. Despite differing opinions, neoadjuvant and adjuvant therapies have been introduced for tumors with high malignancy and poor prognosis. The expansion of molecular biological knowledge has made it possible to use a new, more effective drug in certain soft tissue sarcoma subtypes. Another group of supporting tissue tumors are bone tumors. There has also been a significant change in the diagnosis, treatment, and survival outcomes of both osteosarcoma and Ewing's sarcoma in recent decades. With the development of chemotherapy, neoadjuvant and adjuvant treatments, five-year survival increased to 60-85% from 15-20% previously achieved with surgery alone. The routine use of limb surgeries and the routine use of metastasectomy have also come to the fore. For Ewing's sarcoma, supplementation with medication with irradiation and the use of bone marrow transplantation in recent years has improved five-year survival to more than 50%. The study of prognostic factors is becoming increasingly important to further improve results. Successful treatment of sarcomas is possible with the joint work of a multidisciplinary team (surgeon, pathologist, radiologist, radiotherapist, clinical oncologist, physiotherapist or physiotherapist).
C1 [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
RP Papai, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 297
EP 297
PG 1
ER

PT J
AU Pap, �
   Hitre, E
   Pandi, E
   Budai, B
   Kralovanszky, J
AF Pap, Eva
   Hitre, Erika
   Pandi, Erzsebet
   Budai, Barna
   Kralovanszky, Judit
TI Pharmacokinetic monitoring of de Gramont in patients with colon cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: Plasma concentrations of 5-fluorouracil and its catabolite were determined during treatment with de Gramont in patients with colon cancer (8 men and 7 women, 55). We studied the effect of DPD activity and the pathological processes of patients (kidney, liver) on the drug level in plasma. Method: Plasma concentrations were measured by HPLC. Statistical analysis was performed with GraphPad Prism (ver. 2.0.). Results: The mean steady state (Css) plasma concentrations after treatment were 1.26 ± 0.29 μM for 5-FU and 4.37 ± 1.36 μM for FUH2. The clearance was 5-FU 361.5 ± 75.3 L / h and FUH2 112.9 ± 37.7 L / h. Significant differences from the mean were observed in the blood of a patient with renal impairment (5FU 75.99 μM and CL 195.0 L / h) and a kidney transplant patient (39.24 μM, CL 23.1 L / h). The FUH2 / FU ratio correlated with DPD activity (R: 0.73). Conclusions: In addition to DPD enzyme activity, the drug level resulting from the treatment is significantly affected by renal function.
C1 [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Pandi, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Pap, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 297
EP 297
PG 1
ER

PT J
AU Papp, I
   Elekne Kiss, B
   Kozma, Zs
   Piko, B
AF Papp, Ildiko
   Elekne Kiss, Barbara
   Kozma, Zsuzsanna
   Piko, Bela
TI Psychological leadership of cared for patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In their presentation, the authors address the psychological aspects of nursing activity. They emphasize the importance of a unity of body, soul and spirit, a holistic approach in patient care, especially for those suffering from chronic diseases, and in particular those suffering from malignant processes. It is emphasized that the nurse, as the health worker most directly associated with the patient, faces not only the somatic but also the psychological needs of the patients as an “emotional tank”, Creating a ‘healing atmosphere’. In addition to the “internal tasks” that require a change of attitude, the authors consider it important to provide external, qualified help and the regular involvement of a mental health professional in line with the objectives of the Hungarian National Cancer Control Program. Various interventions at the level of body, mind, and soul may be necessary in the lifestyle of a “client” with a disability that touches on issues such as healing and rehabilitation.
C1 [Papp, Ildiko] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Kozma, Zsuzsanna] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Papp, I (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 297
EP 297
PG 1
ER

PT J
AU Pasztor, E
   Zsary, A
   Szucs, 
   Keltai, K
   Schneider, T
   Rosta, A
   Sarman, P
   Janoskuti, L
   Fenyvesi, T
   Karadi, I
AF Pasztor, Emil
   Zsary, Andras
   Szucs, Sz.
   Keltai, Katalin
   Schneider, Tamas
   Rosta, Andras
   Sarman, Pal
   Janoskuti, Livia
   Fenyvesi, Tamas
   Karadi, Istvan
TI Effect of anthracycline on endothelin-1 levels and cardiac function, one-year follow-up
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The side effect of anthracycline on cardiomyopathy is known. Endothelial cells regulate cardiac function, in which endothelin-1 (ET-1) plays a central role. Twenty lymphoma (14 Hodgkin, 6 non- Hodgkin) patients (7 men, 20-68 years) were followed. ET-1 levels were determined by ELISA, ejection fraction (EF), E / A ratio, and deceleration time (DT) by echocardiography before, immediately after, and one year after treatment. ET-1 levels decreased (5.43 ± 3.34 vs.34 ± 0.69 pg / ml, p <0.02) and did not change after one year (3.43 ± 0.57 pg / ml p <0.008). EF (57.80 ± 4.73% vs. 48.05 ± 5.65%, p <0.0001), E / A ratio (135.05 ± 40.59 vs. 115.74 ± 40, 63 p <0.01) decreased, DT (177.00 ± 44.96ms vs. 209.50 ± 66.25ms p <0.04) increased after therapy. After 1 year, similar differences were observed (EF: 50.65 ± 8.87% p <0.0007, E / A: 110.15 ± 34.45 p <0.003, DT: 223.25 ± 46.85msec p <0.002 ). The direct effect of anthracycline may result in a decrease in ET-1 and lower ET-1 levels may play a role in cardiac dysfunction. The heart-damaging effects of anthracycline can be seen after treatment and can be demonstrated in the long term.
C1 [Pasztor, Emil] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Zsary, Andras] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Szucs, Sz.] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Keltai, Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
   [Sarman, Pal] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Janoskuti, Livia] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Fenyvesi, Tamas] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Karadi, Istvan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Pasztor, E (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 298
EP 298
PG 1
ER

PT J
AU Petak, I
   Nagy, K
   Juhasz, H
   Schwab, R
   Imre, G
   Mihalik, R
   Kopper, L
   Houghton, AJ
AF Petak, Istvan
   Nagy, Katalin
   Juhasz, Helga
   Schwab, Richard
   Imre, Gergely
   Mihalik, Rudolf
   Kopper, Laszlo
   Houghton, A Janet
TI The “use” of death receptors in the drug therapy of tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: The aim of our research is to identify new anti-tumor therapeutic options by studying Fas and TRAIL-R death receptors and their signaling mechanisms. Methods: In vitro functional studies were performed on colon carcinoma and rhabdomyosarcoma cell lines, immunohistochemistry in primary tumors, and immunocytochemistry in a phase I clinical trial. Results: We were able to increase Fas expression and sensitivity in colon carcinomas with interferon-gamma and this was associated with increased 5-fluorouracil sensitivity of tumor cells. Based on this, the maximum tolerated dose of interferon-gamma with standard 5-fluorouracil treatment was determined in a clinical study. We found that an increase in Fas expression at the achieved interferon-gamma dose could be detected in several peripheral white blood cell populations. Fas expression and sensitivity could also be enhanced by demethylated 5-aza-deoxycytidine treatment. The cytotoxicity of TRAIL was enhanced by proteasome inhibitors in both cell types and its molecular mechanisms were determined. Conclusions: Tumor-specific regulation of death receptor sensitivity offers important molecular target molecules for specific anti-tumor therapy.
C1 [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Imre, Gergely] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Houghton, A Janet] St. Jude Children's Research HospitalMemphis, USA.
RP Petak, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 298
EP 298
PG 1
ER

PT J
AU Peter, I
AF Peter, Ilona
TI Significance of ER / PR receptor expression in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Examination of the estrogen receptor (ER), progesterone receptor (PR), and other estrogen-induced proteins in breast cancer provides important information for the indication of hormone therapy and the assessment of the expected prognosis in some cases. Determining steroid hormone receptor status is now mandatory in the Department of Pathology. At our institute, we examine the tumors of about 700 breast cancer patients every year. In addition to the classical ligand-binding biochemical method, the immunohistochemical method has recently become widespread. The results of our literature and our own experience show that the two methods correlate well with each other. Using the in situ immunohistochemical method, receptor proteins present in the nucleus can be detected in a visible form by light microscopy within the tumor tissue. Simultaneous detection of ER isotypes (ERa and ERß) is absolutely warranted if PR is positive and ER is negative. Standardization of methods and participation in “quality control” provide an additional opportunity to modernize patient care. In connection with clinicopathological data (age, sex, histological type / grade, lymph node status), the status of steroid hormone receptors determined by immunohistochemistry in approximately 4,000 breast cancer patients from 1996 to the present is described.
C1 [Peter, Ilona] National Institute of OncologyBudapest, Hungary.
RP Peter, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 298
EP 298
PG 1
ER

PT J
AU Piko, B
   Szegedi, I
   Csiffari, M
   Medovarszki, T
   Kispal, M
AF Piko, Bela
   Szegedi, Istvan
   Csiffari, Margit
   Medovarszki, Tamas
   Kispal, Mihaly
TI Simultaneous radiochemotherapy of patients with rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB 147 patients were treated for malignant rectum tumors at the County Oncology Center of the Pandy Kalman Hospital of the Bekes County Council. Of these, 39 underwent simultaneous radiochemotherapy with daily oral administration of 3x15 mg calciumfolinate and 3x400 mg tegafur and conventionally fractionated pelvic telecobalt irradiation. Radiochemotherapy was also combined with local electrohyperthermia in the pelvis once a week in 8 cases. Treatment was for 14 irresectable tumors and 25 for local recurrence. In their presentation, the authors describe treatment outcomes and side effects, of which diarrhea predominated. In their opinion, the treatment is easy to perform, safe and effective, so its use is recommended for other centers to consider.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Szegedi, Istvan] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Medovarszki, Tamas] Kozponti Dozimetriai SzolgalatBudapest, Hungary.
   [Kispal, Mihaly] Csongrad Megyei Teruleti Korhaz, Onkologiai es Onkohaematologiai OsztalySzentes, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 299
EP 299
PG 1
ER

PT J
AU Piko, B
   Molnar, A
AF Piko, Bela
   Molnar, Anett
TI Informed consent
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The authors address one of the everyday issues of patients' rights, the proper exercise of the right to self-determination in health care. As a result of fundamental constitutional rights, the consent of the patient to the medical intervention is essential, with the exception of certain statutory exceptions, the form of which (implied conduct, oral, written consent) is regulated by Act CLIV of 1997. (the “Health Act”). The real content of consent is ensured if the patient makes his decision not only voluntarily but also in the light of his own real interests. This is made possible by the appropriate information received from the treating physician, the formal and substantive elements of which, in addition to the requirements set out in the Health Act, are contained in the Ethical Statute of the Hungarian Medical Chamber and the 1991 resolution of the Health Science Council. In their presentation, the authors also cover the most important errors and misunderstandings related to informed consent (eg form leaflets, 5% complication limit, waiver of rights).
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Molnar, Anett] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 299
EP 299
PG 1
ER

PT J
AU Pinter, T
AF Pinter, Tamas
TI Irinotecan - new combinations in the treatment of colorectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Irinotecan has become a key drug in the treatment of colorectal cancer over the past few years. In the second-line treatment of advanced colon cancer, monotherapy was shown to be more effective than the leucovorin-5-fluorouracil combinations leading to the best results. In advanced colon cancer, very good results can be obtained with different dosage combinations of capecitabine and irinotecan (CAPIRI). Treatment with capecitabine 900–1000 mg / m2 twice daily for 14 days and irinotecan 225–240 mg / m2 on day 1 or 100–125 mg / m2 on days 1 and 8 resulted in a response rate of 37-50% and progression-free survival for 10 months. CAPIRI treatment is well tolerated in the elderly. Outstanding randomized trials with irinotecan, leucovorin and 5-fluorouracil (IFL) in combination with an angiogenesis inhibitor (anti-VEGF) bevacizumab have shown outstanding results. Compared with the IFL + placebo control group, the IFL + bevacizumab group had a significantly higher response rate (45% vs. 35% p: 0.0029) and a duration of therapeutic response (10.4 vs. 7.1 months p: 0). 0014) and median survival time (20.3 vs. 15.6 months p: 0.00003). Bevacizumab treatment did not significantly increase the side effects of IFL, and combination therapy is well tolerated. The new combinations further improve the results of irinotecan treatment - resulting in a significant improvement not only in response rate but also in survival time.
C1 [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Pinter, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 299
EP 299
PG 1
ER

PT J
AU Pinter, O
   Toth, Cs
   Szabo, Z
   Liptak, J
   Fel, P
   Papp, Gy
   Holman, E
   Hazay, L
   Streit, B
   Kisbenedek, L
   Feher, M
   Kocsis, I
AF Pinter, Oliver
   Toth, Csaba
   Szabo, Zoltan
   Liptak, Jozsef
   Fel, Pal
   Papp, Gyorgy
   Holman, Endre
   Hazay, Lajos
   Streit, Bela
   Kisbenedek, Laszlo
   Feher, Miklos
   Kocsis, Iren
TI Treatment of advanced prostate cancer with Estracyt
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In the treatment of advanced prostate cancer, the primary treatment accepted today is surgical or chemical castration. During TAB treatment, androgen receptor inhibitors are added to the treatment. Hormone resistance may develop after 18 to 22 months. Then the medicine of choice is Estracy. The effectiveness of the treatment was measured from the data of 79 patients from 12 urology departments. The aim of the study was to determine the PSA value and the subjective complaints to be changed in the primary treatment. When do we start giving Estracy? We measure the effectiveness of the treatment according to the NPCP criteria. The effectiveness of the treatment is confirmed by PSA sampling. After machine data processing, the data of 79 patients were processed based on the above and additional data. We assessed side effects, quality of life according to the Karnovsky index, therapeutic response according to NPCP criteria, and change in pain according to the WHO-recommended stepwise pain scale. Treatment produced only temporary improvement in nearly two-thirds of cases. It can be concluded that TAB treatment is ineffective if the PSA value doubles to the start parameter. Above 100 μg / ml PSA, switching to Estracyt is less effective. Administration of Estracyt is recommended in case of deterioration and doubling of the basal PSA.
C1 [Pinter, Oliver] University of Szeged, Department of UrologySzeged, Hungary.
   [Toth, Csaba] Bacs-Kiskun County Teaching Hospital, Department of UrologyKecskemet, Hungary.
   [Szabo, Zoltan] Kanizsai Dorottya Korhaz, Urologiai OsztalyNagykanizsa, Hungary.
   [Liptak, Jozsef] Dombovari Kh, Urologiai OsztalyDombovar, Hungary.
   [Fel, Pal] Orszagos Gyogyintezeti Kp, Urologiai OsztalyBudapest, Hungary.
   [Papp, Gyorgy] Semmelweis Kh, Urologiai OsztalyMiskolc, Hungary.
   [Holman, Endre] Kiskunhalasi Kh, Urologiai OsztalyKiskunhalas, Hungary.
   [Hazay, Lajos] Dunaujvaros Kh, Urologiai OsztalyDunaujvaros, Hungary.
   [Streit, Bela] Tolna Megyei Balassa Janos Korhaz, Urologiai OsztalySzekszard, Hungary.
   [Kisbenedek, Laszlo] Jahn Ferenc Korhaz, UrologiaBudapest, Hungary.
   [Feher, Miklos] Miskolc Megyei Kh, Urologiai OsztalyMiskolc, Hungary.
   [Kocsis, Iren] Eger Kh, Urologiai OsztalyEger, Hungary.
RP Pinter, O (reprint author), University of Szeged, Department of Urology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 300
EP 300
PG 1
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI Unanswered Questions in Early Breast Cancer Radiation Management: A New Direction in Clinical Research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB With the adoption of organ-preserving breast surgery, the role of radiation therapy in the treatment of both in situ (St. 0) and early invasive (St. I-II) breast cancer has significantly increased in recent decades. Although radiotherapy for early breast cancer may in the vast majority of cases be based on first-level evidence, many questions remain unanswered. In in situ ductal breast cancer, 3 randomized studies (NSABP-B-17, B-24, EORTC 10853) demonstrated that radiation treatment after excision significantly reduced the rate of local recurrences. Based on the results of further randomized studies in progress (RTOG 98-04, OOI), we can identify low- and high-risk subgroups where radiotherapy can be safely omitted after breast retention or where mastectomy is still required. Based on the results of two studies now (Milan, NSABP-B-06), breast-conserving surgery and radiotherapy in early invasive breast cancer are now standard treatment. Three randomized studies (Lyon, EORTC 22881, OOI) demonstrated that irradiation of the tumor bed supplement (“boost”) significantly improved local tumor clearance. In patients at high risk for local recurrence, tumor bed “boost” treatment with both telotherapy and brachytherapy is standard treatment. EORTC plans to investigate the efficacy of further tumor bed dose escalation in another randomized study in young (<50 years) patients. A single accelerated partial breast brachytherapy with the same quality assurance and local survival as telotherapy for the whole breast. The exact group of patients suitable for brachytherapy will be determined on the basis of the results of ongoing and planned phase III studies (NSABP, GEC-ESTRO, OOI). Clinical trials of newer methods of accelerated partial breast irradiation (perioperative intracavital brachytherapy, 3D conformal and intensity-modulated teletherapy) are ongoing. The efficacy of single-dose, high-dose intraoperative radiotherapy (IORT) was evaluated in 2 randomized studies (ELIOTMilano, TARGIT-London). After mastectomy with ≥4 positive axillary lymph nodes, the survival-enhancing effect of locoregional radiotherapy has been demonstrated (ASCO consensus). A more accurate understanding of the survival-enhancing effect of irradiation will be possible with the results of additional randomized studies (RTOG 99-15, SUPREMO, OOI) with 1 to 3 positive lymph nodes. Another question is the extent to which the survival-enhancing effect of radiotherapy is due to irradiation of the chest wall and lymphatic regions. The value of radiation therapy for parasternal lymph nodes is also controversial and is under investigation (EORTC 22922). The encouraging results of surgical studios dealing with sentinel lymph node biopsy also raise new questions for radiotherapists as well. The effectiveness of axillary dissection versus radiotherapy in addition to a positive sentinel lymph node is currently being studied in 2 randomized studies (EORTC 10981- AMAROS, OOI).
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 300
EP 300
PG 1
ER

PT J
AU Polgar, Cs
   Fodor, J
   Nemeth, Gy
   Major, T
   Orosz, Zs
   Lovey, K
   Sulyok, Z
   Udvarhelyi, N
   Somogyi, A
   Kasler, M
AF Polgar, Csaba
   Fodor, Janos
   Nemeth, Gyorgy
   Major, Tibor
   Orosz, Zsolt
   Lovey, Katalin
   Sulyok, Zoltan
   Udvarhelyi, Nora
   Somogyi, Andras
   Kasler, Miklos
TI Single high-dose rate brachytherapy versus teletherapy after breast-conserving surgery: Results of a 6-year comparative study with matched controls
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: To compare the efficacy of single high-dose-rate brachytherapy (HDR-BT) and telotherapy (TT) after breast-conserving surgery. Methods: Between 1996 and 1998, a single HDR-BT of 7 x 4.3 Gy (n = 8) ill. At a dose of 7 x 5.2 Gy (n = 37). Patients (n = 83) treated with 50 Gy TT +/- 16 Gy “boost” irradiated during the same period based on clinicopathological prognostic factors were selected as control groups. After a median follow-up of 71 months (range 55–86), local tumor control (LTK), relapse-free survival (RMT), and breast cancer-specific survival (EST) were analyzed. Results: In the same-sided breast, the rate of local recurrence after HDR-BT and TT was 6.7% (3/45) and 8.4% (7/83), respectively. The 6-year LTK was 95.6% with HDR-BT and 90.3% with TT (p = 0.8). There was also no significant difference in the proportion of 6-year RMT (81.4% vs. 78.7%; p = 0.9) and EST (92.5% vs. 93.7%; p = 0.9). Conclusions: Accelerated single HDR-BT with adequate quality assurance in a selected group of patients provides similar local tumor control and survival as standard TT (Level 3 evidence). Higher levels of evidence can be obtained from ongoing randomized studies.
C1 [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lovey, Katalin] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Somogyi, Andras] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 302
EP 302
PG 1
ER

PT J
AU Popovits, J
   Rosta, I
AF Popovits, Jozsef
   Rosta, Ildiko
TI Endoscopic polypectomy is the best prevention of colon cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The health care government and the profession expect the stopping of the rise of colorectal cancer, which causes a significant number of diseases and high mortality in Hungary, from the beginning of the screening program for this purpose. In the hope of this, the authors give an overview of the precancerous conditions and changes of the colon, the focus of which is the adenomas of the colon. The pathology, symptomatology, diagnosis, therapy, care, and prevention of adenomas are described in detail. Between January 31, 1991 and December 31, 2001, 3419 complete colonoscopies were performed at the Endoscopic Laboratory of the Albert Schweitzer Hospital in Hatvan in patients with defecation complaints, abdominal pain, and bloody stools. In 628 patients, 941 colon polyps were diagnosed, 821 with endoscopic polypectomy, 11 with mucosectomy, 43 with piecemeal polypectomy, and 20 with surgical intervention. Endoscopic procedures revealed 38 in situ carcinomas and 94 severe dysplastic lesions. During therapeutic endoscopic interventions, 5 complications were observed and 1 patient was lost. They had no complications after the surgeries. Their patient material is analyzed according to the location, shape, number, histological structure of the lesion, the degree of dysplasia, and the type of interventions. It is confirmed that full colonoscopy is currently the most appropriate method for colon examination, and endoscopic polypectomy is the most effective colon cancer prevention, which can only be achieved with the successful interdisciplinary collaboration of a gastroenterologist, surgeon, pathologist, radiologist.
C1 [Popovits, Jozsef] Albert Schweitzer Korhaz, Endoszkopos LaboratoriumHatvan, Hungary.
   [Rosta, Ildiko] Albert Schweitzer Korhaz, Endoszkopos LaboratoriumHatvan, Hungary.
RP Popovits, J (reprint author), Albert Schweitzer Korhaz, Endoszkopos Laboratorium, Hatvan, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 302
EP 302
PG 1
ER

PT J
AU Pos, Z
   Hegyesi, H
   Falus, A
AF Pos, Zoltan
   Hegyesi, Hargita
   Falus, Andras
TI Effect of transgenic manipulation of histamine synthesis on the progression profile of melanoma in vivo in a mouse model
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Numerous experimental data now show that, like many other tumors, an increase in local histamine synthesis can be observed in the development of melanoma malignum, due in part to the autologous synthetic activity of the tumor and in part to the surrounding mast cell migrating mast cells. However, despite the large amount of data, the effect of increased activity of histamine decarboxylase (HDC), an enzyme that exclusively synthesizes histamine, on tumor progression is still rather vague. To further analyze the issue, three transgenic variants were generated from the B16-F10 mouse melanoma cell line by stable transfection as B16-F10 HDCs, HDCm, and HDCa (HDC sense, mock, and antisense). In each embodiment, under the control of a pTRiEX expression vector construct, the sequence corresponding to the whole mouse HDC mRNA, a meaningless control sequence (mock), and an antisense sequence interfering with a portion of the HDC mRNA are overexpressed. Due to this, the production of HDC enzyme, which performs histamine biosynthesis, takes place in the three groups at levels above, corresponding to or below normal, respectively, which demonstrably influences the intensity of histamine secretion in tumor cells. To characterize the effect of histamine, the progression profile of the three transgenic variants was analyzed in detail. To this end, we have set up a new RNase Protection Assay (RPA) system that can monitor 20 different melanoma and general tumor progression markers, some of which are already consensual in clinical research and some of which have recently emerged. We then performed studies with both classical size and metastasis number tracking and RPA in an in vivo C57Bl6 / J singlet mouse model suitable for modeling both primary skin tumors and metastases. Our primary results suggest that transgenic manipulation of histamine biosynthesis in vivo clearly influences the growth of primary skin tumors, insofar as higher histamine levels lead to significantly and reproducibly (p <0.001, p = 0.002) faster growth. In addition, histamine appears to have a very heterogeneous biological and molecular effect on the molecular malignancy profile of melanoma when transfection affects a number of markers (PCNA, MMP-2, VEGF), but not at all in a way that supports progression.
C1 [Pos, Zoltan] MTA-SE, Molekularis Immunologiai Kutato CsoportBudapest, Hungary.
   [Hegyesi, Hargita] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Falus, Andras] MTA-SE, Molekularis Immunologiai Kutato CsoportBudapest, Hungary.
RP Pos, Z (reprint author), MTA-SE, Molekularis Immunologiai Kutato Csoport, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 302
EP 302
PG 1
ER

PT J
AU Posztos, K
   Elekne Kiss, B
   Bassam, A
   Csiffari, M
   Piko, B
AF Posztos, Krisztina
   Elekne Kiss, Barbara
   Bassam, Ali
   Csiffari, Margit
   Piko, Bela
TI Care of patients with agranulocytosis in our department
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In addition to the usual tasks, two main aspects should be taken into account when treating patients with leukopenia or, in more severe cases, agranulocytosis as a result of anti-tumor treatment: any situation that may lead to infection in immunocompromised patients should be avoided. , which may further reduce the number of cells. When placing patients, ideally, isolation should be sought or, if this is not possible, placed in as small a ward as possible and with patients who are not a source of infection (febrile illness, exulcerated tumor, etc.). Appropriate work clothing (including the protection of the patient) during care is a requirement, but all invasive procedures (blood sampling, injection, catheterization, etc.) should also be performed with maximum antiseptic principles as far as possible. Temporarily implanted devices (venous cannula, catheter) should be closely monitored for the slightest sign of infection and the need for special therapy should be indicated to the treating physician. During washing, special care should be taken at the gates of infection (rhagads, immediate detection of incipient decubitus, careful mouthwash, prohibition of dentures, storage of prothesis in disinfectant solution, etc.). When planning the care process, it should also be clarified which medications the patient may receive in case of certain symptoms (eg fever) or what intervention is recommended instead (eg cooling bath, cold water compress) and this should be recorded to prevent further drug side effects further worsen the patient's condition. Careful monitoring by a nurse in the treatment of a patient with agranulocytosis, immediate communication of the observed phenomena to the doctor, provision of care appropriate to the special clinical situation are conditions without which even state-of-the-art treatment (broad-spectrum antibiotics, colony stimulating factor) may be ineffective. it can have an slow effect, worsening both the condition of the particular patient and the smooth functioning of the ward.
C1 [Posztos, Krisztina] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Posztos, K (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 303
EP 303
PG 1
ER

PT J
AU Radnoti, N
   Bujdoso, M
   Elekne Kiss, B
   Piko, B
AF Radnoti, A.-Ne
   Bujdoso, Maria
   Elekne Kiss, Barbara
   Piko, Bela
TI Duties and responsibilities of pharmacy assistants working in the oncology department in connection with the use of new cytostatics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB There is a large number of chemotherapies in the oncology department, which is the only one in Bekes county that also performs regional tasks. Therefore, in order to protect the health of workers, it is necessary to minimize the risk of cytostatic exposure, all the more so as the results of a previous cytogenetic study were not reassuring. To this end, a care protocol regulating the activity was developed, laminar boxing was put into operation and personal protective equipment was made mandatory. Under the new legislation, cytostatic mixture infusions are prepared by pharmacy assistants under the professional supervision of a hospital chief pharmacist. The control cytogenetic study no longer indicated abnormalities indicating chronic exposure, but based on the findings, the procedure was revised and an airtight packaging system was purchased for waste storage, which reduces the risk of air pollution until the hazardous waste containers are permanently sealed. They are confident that the controls will demonstrate a further improvement in the safety of dealing with cytostatics. More and more types of cytostatics have newer and newer rules of dissolution, which the authors explain specifically in their poster.
C1 [Radnoti, A.-Ne] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Bujdoso, Maria] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Radnoti, N (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 303
EP 303
PG 1
ER

PT J
AU Rahoty, P
   Antal, I
   Szendroi, M
   Kiss, J
AF Rahoty, Pal
   Antal, Imre
   Szendroi, Miklos
   Kiss, Janos
TI New possibilities for pelvic bone and soft tissue surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Our aim was to investigate the surgical outcomes, intra- and postoperative complications, and quality of life of 43 patients who underwent internal hemipelvectomy operated on in an interdisciplinary team between 1996 and 2002. From 2002, we introduced the femur – sacrum transposition as a new procedure in Hungary for the removal of the entire pelvis. The surgical results of five such patients are described. Material and method: Between 1986 and 2002, a total of 43 cases of partial pelvic resection were performed. internal hemipelvectomy with retention of the limb. We excluded from our material cases where only biopsy was performed. The mean age of the patients was 40 years (range, 18–78 years), and the gender distribution rates were 24 males and 19 females. The mean follow-up is 3 years (0.5-11 years). According to this, we determined surgical radicality and patients ’quality of life after surgery. Results: More than half of our patients have a propagation of the underlying disease or died of lung metastases within 5 years. The best functional results were obtained by resection of the I. and III. complications (hematoma, ischiadic lesion, infection) were more common. Conclusions: Internal hemipelvectomies may have the same radicality as external hemipelvectomies when properly indicated. More burdensome, time-consuming surgery than external hemipelvectomies. Complications are more common with removal of tumors affecting the periacetabular region or the entire pelvis. We have good initial experience with femursacrum transposition following complete pelvic removal.
C1 [Rahoty, Pal] BM.Kozponti Korhaz, Sebeszeti OsztalyaBudapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Rahoty, P (reprint author), BM.Kozponti Korhaz, Sebeszeti Osztalya, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 303
EP 303
PG 1
ER

PT J
AU Raso, E
   Puskas, GL
   Timar, J
AF Raso, Erzsebet
   Puskas, G Laszlo
   Timar, Jozsef
TI Identification of metastasis-associated genes in human melanomas using DNA chip technique
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To identify genes potentially involved in metastasis using a DNA chip technique in a human in vivo (+ versus in vitro) melanoma model in which the evaluation is not based on the mean change in expression pattern but on the behavior of the same tumor cell population under well-defined experimental conditions. between which allows the variable parameters to be kept to a minimum. Methods: In vitro culture human melanoma cell lines (WM983B, 1919high, 3.1pool, HT168M1) were implanted into neonatal and adult congenitally immunodeficient (scid) mice. Implantation was performed at the same time point, from the same suspension per line, and at the same localization. It is a long-standing experience that after this semiotope implantation, these cell lines never give rise to lung metastasis in an adult animal, whereas the frequency of metastasis in a newborn is practically 100%. Total mRNA was isolated from all initial cell populations and the same was done from subcutaneous (adult and “neonatal”) tumor tissue and lung metastases at the time of evaluation. Using a DNA chip, we compared the s.c. adult - s.c. “Neonate,” neonatal primary tumor and lung metastasis, and s.c. the gene expression pattern of tumors and in vitro growing cells. Results: Consistent up- (RxRγ, metallothionein III, β3endonexin, v-ral, GAPSH3) and down-regulation (TIMP3, UPAR, calpastatin, carboxypeptidase M) of several genes were detected in metastatic vs non-metastatic cell populations with Q-PCR. validation and verification on clinical specimens is ongoing. The greatest difference was found between the expression patterns of the in vitro and in vivo growing variants of the same cell line. Conclusions: The DNA chip technique has promised explosive advances in the detection of genes responsible for tumor behavior. However, it is now clear that some of the data, either because it is based on in vitro culture studies or because it targeted a less homogeneous starting tumor population (possibly using questionable control tissue), do not really provide a meaningful answer to the question posed. The model we have introduced promises a completely novel approach to this issue, which we hope will bring us closer to solving the problem of metastasis.
C1 [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Puskas, G Laszlo] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Raso, E (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 305
EP 305
PG 1
ER

PT J
AU Remenar, �
   Fulop, M
   Koltai, P
   Polus, K
   Kasler, M
AF Remenar, Eva
   Fulop, Miklos
   Koltai, Pal
   Polus, Karoly
   Kasler, Miklos
TI The need and problems of early detection of squamous cell carcinoma of the head and neck
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The incidence and mortality of head and neck squamous cell carcinoma in Hungary has increased exponentially in the last twenty years, and this process has continued in recent years. Among Hungarian men, the second most common cancer death after lung cancer is head and neck cancer. The disease cases occur in approx. 70% are recognized as advanced and consequently have a poor prognosis. Early detection of a more favorable course of the disease has not been solved in Hungary or abroad so far, although the tumor is expected to be in a well-defined population. The working group of our department developed a proposal for the targeted screening of the vulnerable population, the essence of which is to describe the danger situation caused by smoking and regular alcohol consumption and the early symptoms of squamous cell carcinoma in both the vulnerable population and primary care and other patients with potential head and neck cancer patients. with medical staff working in the professions. The proposed educational material and the results of our sample screening in a population of 42,500 are described on the poster.
C1 [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of OncologyBudapest, Hungary.
   [Polus, Karoly] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 305
EP 305
PG 1
ER

PT J
AU Renyi, I
   Kiss, Cs
   Kovacs, G
   Bartyik, K
   Kajtar, P
   Masat, P
   Nagy, K
   Fekete, F
AF Renyi, Imre
   Kiss, Csongor
   Kovacs, Gabor
   Bartyik, Katalin
   Kajtar, Pal
   Masat, Peter
   Nagy, Kalman
   Fekete, Ferenc
TI A New Opportunity in Supportive Therapy: Prevention and Treatment of Tumor Lysis Syndrome with FASTURTEC
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Destruction of a large tumor cell spontaneously or for cytostatic or irradiation therapy may lead to the development of tumor lysis syndrome. This severe metabolic disorder is a life-threatening complication: rapidly developing hyperphosphatemia, hyperchalemia, hypocalcaemia, and hyperuricaemia can lead to acute renal failure. It is expected to develop primarily in the treatment of acute lymphocytic leukemia and high-grade non-Hodgkin's lymphoma (Burkitt). It can also occur in the treatment of solid tumors with a high tumor mass and a high sensitivity to chemotherapy, such as breast, testicular and lung carcinoma. Allopurinol has been used to prevent tumor lysis syndrome to work in 24 to 48 hours and works by reducing uric acid production. The recombinant form of the enzyme urate oxidase breaks down uric acid very rapidly by enzymatic oxidation into allantoin, which is easily excreted by the kidneys in the urine. The pediatric oncology team successfully treated 36 children with recombinant urate oxidase (Fasturtec). Based on experience with the treatment of tumors with a high tumor mass, Fasturtec represents another option in supportive therapy for the treatment of complications from cytostatic and radiation therapy.
C1 [Renyi, Imre] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Kiss, Csongor] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Bartyik, Katalin] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Kajtar, Pal] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Masat, Peter] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Nagy, Kalman] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Fekete, Ferenc] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Renyi, I (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 305
EP 305
PG 1
ER

PT J
AU Rethy, �
   Oberna, F
   Orozs, Zs
   Polus, K
   Kasler, M
AF Rethy, Agnes
   Oberna, Ferenc
   Orozs, Zsolt
   Polus, Karoly
   Kasler, Miklos
TI Isolated vocal cord leiomyosarcoma (Case report)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Leiomyosarcoma is a very rare malignancy of the larynx. So far, only about 50 cases have been reported in the literature. After reviewing the literature, the authors describe the histopathological criteria for making a diagnosis and review treatment alternatives in their own case.
C1 [Rethy, Agnes] National Institute of OncologyBudapest, Hungary.
   [Oberna, Ferenc] Pest Megyei Onkormanyzat Szent Rokus KorhazBudapest, Hungary.
   [Orozs, Zsolt] Pest Megyei Onkormanyzat Szent Rokus KorhazBudapest, Hungary.
   [Polus, Karoly] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Rethy, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 306
EP 306
PG 1
ER

PT J
AU Rohanszky, M
   Bodoky, Gy
AF Rohanszky, Magda
   Bodoky, Gyorgy
TI "We have contracted for life." Experiences of the support group working in the Oncology Department of Szent Laszlo Hospital
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction: The effectiveness of support groups organized for cancer patients has been known for decades. The support group is a special communication opportunity in which an emotional processing process, self-knowledge work and problem solving take place. Our aim is to investigate the effect of the group option offered to patients receiving active treatment in the ward. Patient material and method: support group, continuous operation since January 2003. Patients receiving treatment in the ward organized appointments on an invitation basis, which were arranged by a psychologist. The group closed with 13 people after 1.5 months. The 2.5-hour weekly encounters were followed by a one-week residential stay in May. The intensive program was based on meditative, self-knowledge, and art therapy elements. Beck Depression Scale, Quality of Life Questionnaire, “Big Five” (Personality Meter). Results: The group grew into a strong, resilient team. The subjective perception of their quality of life changed in a positive direction. The group’s influence in accepting their illness and mastering more effective coping strategies is seen as cathartic. Beck's group average: January: 14 (39–4), May: 10 (30–2) Recipients' attitudes toward chemotherapy have become more acceptable, and side effects are better tolerated and treated. The presence of the treated group members during the treatment also has a positive effect on the other patients, and their behavior is patterned. Among the personality traits, courtesy and strong emotional control stand out in the majority of patients. Summary: The positive effects of the nondirective support group organized by the patients and kept in the bed by a psychologist are reflected in the patients' struggle with the disease, in the experience of a better quality of life, in cooperation with the treatments. The fate of the support group members is monitored.
C1 [Rohanszky, Magda] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Rohanszky, M (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 306
EP 306
PG 1
ER

PT J
AU Romics, I
AF Romics, Imre
TI Experiences Mainz II. with sigma pouch
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB One of the oldest ways to pass urinary deviation after cystectomy is to lead the ureters into sigma. The biggest flaw in the ureterosigmoideostomy described by Coffey and then modified by Goodwin was the high intraluminal pressure, consequent pyelonephritis, which often led to a septic, fatal outcome. We have been using low-pressure Mainz II for a decade in our clinic. type of urinary deviation, the essence of which is a urinary reservoir formed from sigma. Our position is that orthhotopic deviation is indicated if the patient can be ruled out with cystoprostatic lymphadenectomy. In a high-risk patient with palliative purpose, a Mainz type II deviation is performed. Good patient and bowel preparation is important. Continence test required before surgery. During surgery, short mesentery, especially in obese patients, can cause less difficulty. We recommend the a. ligature of iliaca interns. The ureters are implanted into the sigma without tension, with the urethral ends slit at least 5 mm apart and nailed according to Bominghaus. Both the back and front row of seams are sewn in one layer with knotted absorbent stitches. The mono J rails are routed next to the wind pipe. The wind pipe is removed on day 3-4 and the rails on day 8. At the time of removing the rails, begin alkalizing. The most common early complications are wound healing disorder, urinary incontinence, infection. Late complications are urethral anastomosis stenosis, tumor recurrence.
C1 [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Romics, I (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 306
EP 306
PG 1
ER

PT J
AU Rosta, A
AF Rosta, Andras
TI Effect of allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Years ago, the effect of allogeneic hematopoietic stem cell transplantation against solid tumors did not receive much attention because the morbidity and mortality associated with the procedure were very high. In recent years, however, the morbidity and mortality associated with the procedure have been significantly reduced using allogeneic bone marrow transplantation with non-myeloablative preparation. Considering the results of autologous adoptive cell therapy and the known immunological effect of allogeneic bone marrow transplants (graft versus leukemia effect), studies have been initiated to investigate the antitumor effect of allogeneic transplantation in solid tumors. The effect of clinical “graft versus tumor” (GVT) has been demonstrated early in allogeneic hematopoietic stem cell transplants with non-myeloablative conditioning, which is manifested against a number of solid tumors. The most significant effect was observed in renal tumors, where a clinical response of 10-50% was demonstrated. There are also sporadic data that the effect of GVT also works in breast, colon, and ovarian carcinomas. Initial test results should be evaluated with caution, but in view of the very poor prognosis of metastatic solid tumors, the use of allogeneic T cells as adoptive cell therapy in tumor types where GVT effects can be demonstrated should be carefully evaluated. Allogeneic hematopoietic stem cell transplantation alone is unlikely to be able to eradicate metastatic solid tumors, but it is possible that the method may enhance the efficacy of current immunotherapy and cytoreductive chemotherapy.
C1 [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Rosta, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 306
EP 306
PG 1
ER

PT J
AU Ruzsa, �
   Kolonics, Zs
   Szenes, M
AF Ruzsa, Agnes
   Kolonics, Zsuzsanna
   Szenes, Maria
TI Treatment of patients with advanced gastric cancer according to the Taxotere-Cisplatin protocol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction, material and method: We started the treatment of patients with advanced gastric carcinoma diagnosed in our hospital from June 2002 to June 1, 2003 according to the Taxotere-Cisplatin protocol. In the elapsed period, 10 patients were treated. A total of 40 cycles were given to patients. Results Two patients died, eight patients were alive, 6 patients had PR, and two patients had SD. Patients had a good quality of life (Kfy 70-80%). Anemia requiring transfusion was observed in 3 patients. One patient underwent emergency care for gastric bleeding. GII peripheral polyneuropathy and dyspnea were observed as side effects. Mean disease-free survival was 3 months and overall survival was 4 months, which cannot be assessed due to the short observation time. Conclusion The Taxotere Cisplatin treatment used was well tolerated by patients with an ORR of 80%, which cannot be assessed due to the small number of patients. The number of patients needs to be further increased and monitored.
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kolonics, Zsuzsanna] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szenes, Maria] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 307
EP 307
PG 1
ER

PT J
AU Ruzsa, �
AF Ruzsa, Agnes
TI Algorithm for analgesia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Depending on their training, painkillers may prefer certain painkillers. Where do oral painkillers have a place when using invasive interventions? After the primary examination and correct diagnosis of pain, which deals with the origin, extent and intensity of pain and daily fluctuations, we first start treatment with first- and second-degree drugs as defined by the WHO. At the same time, we also perform therapeutic activities in the form of surgery, radiation and chemotherapy. If the treatment is successful, even permanent improvement can be achieved and painkillers will no longer be needed. If pain persists, WHO second- and third-degree medications follow, followed by adjuvants. If the pain worsens, alternative opiates are used or the route of administration is changed. If the pain that appears to be unrestrained is regional or localized, nerve blockade, neurosurgical procedures, or chemical hypophysectomy for diffuse unrestrained pain can be attempted. In his presentation, the author describes in detail the new drugs and the changed dosing regimens.
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 307
EP 307
PG 1
ER

PT J
AU Safrany, G
   Kis, E
   Bognar, G
   Esik, O
AF Safrany, Geza
   Kis, Eniko
   Bognar, Gabor
   Esik, Olga
TI Investigation of individual radiation sensitivity in radiotherapy patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: Severe early and / or late radiological reactions occur in 5-10% of cases of radiation therapy in cancer patients. Our goal is to develop procedures that allow the screening of high-risk patients before the start of radiotherapy. Methods: Skin biopsies and blood samples were collected from radiotherapy patients. Primary fibroblast cell culture was initiated from the skin biopsy sample, and the radiosensitivity of fibroblast cells was studied by colony-forming assay and single-cell electrophoresis (comet) assay. The radiosensitivity of lymphocytes from a blood sample was studied by in vitro micronucleus, comet, and chromosome aberration assays. Results: By comparing the SF2 values ​​of the fibroblast samples (survival cell ratio after 2 Gy irradiation) and the toxic radiation reactions in the patients, we found that the SF2 values ​​of the samples from the control group of patients fell most often in the 26-35% survival range. SF2 values ​​in patients with late nervous system adverse events shifted toward low dose ranges (8-15 Gy). Shifting of SF2 values ​​to the left was also observed in cancer patients who developed epithelial side effects (dermatitis, mucositis, telangiectasia, fibrosis) after radiotherapy. Conclusions: Determining the in vitro radiation sensitivity of primary fibroblast cells from a skin biopsy specimen can be used to screen a group of patients at increased risk for toxic radiation reactions.
C1 [Safrany, Geza] OKK – OSSKI, Molekularis es Tumorsugarbiologiai OsztalyBudapest, Hungary.
   [Kis, Eniko] OKK – OSSKI, Molekularis es Tumorsugarbiologiai OsztalyBudapest, Hungary.
   [Bognar, Gabor] OKK – OSSKI, Molekularis es Tumorsugarbiologiai OsztalyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Safrany, G (reprint author), OKK – OSSKI, Molekularis es Tumorsugarbiologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 307
EP 307
PG 1
ER

PT J
AU Sandor, J
   Kiss, I
   Ember, I
AF Sandor, Janos
   Kiss, Istvan
   Ember, Istvan
TI Tumor death among gypsies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Everyday experience suggests that the situation of the Roma population is special from a health point of view, but the individual registration of the Roma population has not been resolved, so we have little and inaccurate data on the health status of this group. However, the problem can be examined with the help of maps containing the share of the Roma population by settlement, produced during the work of CIKOBI. We correlated the standardized and smoothed mortality risk measures per tumor and the participation rates in cervical and breast cancer screenings by the proportion of the Roma population in the given area. The study covered the 1990s and Southern Transdanubia. By the end of the decade, areas with the highest proportion of Roma had the highest rates of cancer deaths. This was mainly due to a similar pattern of lung cancer, laryngeal cancer, colorectal cancer and cervical cancer. Breast cancer, prostate cancer, and colon cancer, on the other hand, showed the lowest mortality in these areas. Cervical cancer screening and participation rates in mammography examinations were lowest in areas with the highest proportions of the Roma population. Although well-being-related cancer death rates were most favorable for Roma, this group had the worst cancer mortality rates during the 1990s. This is due to an increase in deaths from tumors associated with smoking and a lack of early detection.
C1 [Sandor, Janos] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Kiss, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
   [Ember, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
RP Sandor, J (reprint author), Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani Tanszek, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 307
EP 307
PG 1
ER

PT J
AU Sarvari, G
   Gaspar, Sz
AF Sarvari, Geza
   Gaspar, Szabolcs
TI Preventive osteosynthesis in cases of multiple bone metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The authors present an even less common surgical technique in Hungarian clinical practice for the prevention of pathological fractures in cases of multiple bone metastases. They compare the examination and care of injured people who have already suffered a pathological fracture in patients with a so-called “threatening fracture”. Attention is drawn to the obstacles that make it difficult to examine and care for injuries who have already suffered a pathological fracture. Diagnostic and therapeutic protocols are proposed for both patient groups. The authors emphasize the importance of performing these surgeries in musculoskeletal surgery departments where both orthopedic and traumatology professionals work.
C1 [Sarvari, Geza] Military Health Centre, Department of TraumatologyBudapest, Hungary.
   [Gaspar, Szabolcs] Military Health Centre, Department of TraumatologyBudapest, Hungary.
RP Sarvari, G (reprint author), Military Health Centre, Department of Traumatology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 308
EP 308
PG 1
ER

PT J
AU Schneider, T
   Toth, E
   Molnar, Zs
   Deak, B
   Varady, E
   Eid, H
   Rosta, A
AF Schneider, Tamas
   Toth, Erika
   Molnar, Zsuzsa
   Deak, Beata
   Varady, Erika
   Eid, Hanna
   Rosta, Andras
TI Treatment of rituximab-CHOP in B-cell diffuse large cell lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Since the mid-1970s, the standard treatment for B-cell diffuse large cell lymphoma (DLBCL) has been CHOP (cyclophosphamide, hydroxydaunorubicin, oncovine, prednisolone) combination chemotherapy. With this therapy, 65-70% of patients go into complete remission and the proportion of permanently cancer-free survivors (cured) is around 40%. The combination of B-cell binding anti-CD20 monoclonal antibody and CHOP treatment resulted in a significantly higher remission rate, lower relapse rate, and overall survival was more favorable in the rituximab arm. Between October 2002 and May 2003, 40 new untreated patients with DLBCL received the above R (ituximab) -CHOP treatment in their ward. The mean age of the 20 female and 20 male patients was 53 years. Combination immunochemotherapy was used in 20 patients with advanced clinical stage III-IV disease and 20 clinical stage I-II diseases with unfavorable prognostic features (“large” tumor, elevated LDH). The authors compare the results of the treatment with the data of the literature and the historical control group they had previously only treated with CHOP. The early results look convincing. The 65% overall remission rate achieved with CHOP treatment with R-CHOP is greater than 85%. The authors also analyze treatment outcomes by prognostic groups (IPI) and newer prognostic markers (bcl-2 status).
C1 [Schneider, Tamas] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Deak, Beata] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Varady, Erika] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Eid, Hanna] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Rosta, Andras] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Schneider, T (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 308
EP 308
PG 1
ER

PT J
AU Schoket, B
   Gyorffy, E
   Anna, L
   Gyori, Z
   Segesdi, J
   Minarovits, J
   Soltesz, I
   Kostic, Sz
   Csekeo, A
   Poirier, M
AF Schoket, Bernadette
   Gyorffy, Erika
   Anna, Livia
   Gyori, Zoltan
   Segesdi, Judit
   Minarovits, Janos
   Soltesz, Ibolya
   Kostic, Szilard
   Csekeo, Attila
   Poirier, C. Miriam
TI Effect of smoking-induced carcinogen-DNA adducts in the lung and genetic polymorphisms on the extent of DNA damage
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: To investigate the DNA-damaging ability of chemical carcinogens in the context of metabolism polymorphisms to elucidate cancer initiation mechanisms and genetic predisposing factors. Methods: 63 peripheral normal lung - lung tumor specimens and 200 normal bronchus specimens from lung resection due to lung cancer were tested. Carcinogen DNA adduct levels were determined by phosphorus isotope labeling and chemiluminescent immunoassay. Metabolic genotypes were determined by PCR-RFLP methods. Results: There was a close correlation between the DNA adducts measured by the two adduct methods in the tumor, but there was no correlation in intact lung tissue. There was a significant linear correlation between dose and bronchial DNA adduct levels at low exposures (≤15 cigarettes / day) in smokers with GSTM1 and GSTT1 homozygous deletion genotypes, respectively. Conclusions: The chemical composition of the carcinogenic DNA adduct pattern is different in tumor and intact tissue. GST polymorphisms may affect the extent of primary DNA damage caused by carcinogens.
C1 [Schoket, Bernadette] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Gyorffy, Erika] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Anna, Livia] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
   [Gyori, Zoltan] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Segesdi, Judit] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Minarovits, Janos] Bela Johan National Institute of Hygiene, Microbiological Research GroupBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kostic, Szilard] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Poirier, C. Miriam] National Institutes of Health, National Cancer InstituteBethesda, MD, USA.
RP Schoket, B (reprint author), Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 308
EP 308
PG 1
ER

PT J
AU Schoket, B
AF Schoket, Bernadette
TI The role of the interaction of genetic susceptibility factors and environmental factors in the development of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: Molecular epidemiological research on the developmental process of lung cancer primarily seeks to answer the question of how genetic susceptibility factors interact with environmental chemical and physical health agents to affect the risk of sporadic lung cancer. Genetic risk factors include genetic polymorphisms in Phase I and II enzyme systems that catalyze the metabolism of foreign compounds and in DNA repair enzyme systems. In this presentation, we present the latest research findings from international molecular epidemiological studies and our group. Results: International summaries of results from a comparison of lung cancer and control study populations show that certain combinations of CYP and GST gene polymorphisms increase the risk of lung cancer depending on exposure and age factors. In a Hungarian study, we found that CYP and GST gene polymorphisms individually have a small effect on the number of primary DNA lesions and carcinogenic DNA adducts in lung tissues caused by the carcinogenic components of tobacco smoke. However, significant DNA adduct level differences were detected in tightly determined CYP and GST genotype combinations. Conclusions: The gene polymorphisms studied so far have a small individual risk-modifying effect on the development of lung cancer. It is much more promising to understand the complex interactions of gene variants and the enzymes they encode in terms of their effect on genetic predisposition.
C1 [Schoket, Bernadette] Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai OsztalyBudapest, Hungary.
RP Schoket, B (reprint author), Fodor Jozsef OKK-OKI, Molekularis Kornyezetepidemiologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 310
EP 310
PG 1
ER

PT J
AU Schwab, R
   Petak, I
   Tejeda, M
   Schafer, E
   Gyokeres, T
   Keri, Gy
   Pap, �
AF Schwab, Richard
   Petak, Istvan
   Tejeda, Miguel
   Schafer, Eszter
   Gyokeres, Tibor
   Keri, Gyorgy
   Pap, Akos
TI The in vitro efficacy of TT-232 in P388 lymphoma overexpressing the MDR1 protein
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The aim was to test whether MDR1 (an ABC transporter mediating drug-transport related resistance) can confer resistance to TT-232 (a novel structure analogue of somatostatin) induced cell death in an in vitro functional assay. Methods: Wild type (P388wt) and MDR1 overexpressing lymphoma cells (P388-MDR1) were treated with increasing concentrations of TT-232. Cell proliferation was tested by MTT method. Drug resistance of P388-MDR1 was confirmed by calcein exclusion assay. Results: p388-MDR1 was confirmed to have strong MDR1 activity. P388wt and p388-MDR1 were found to be equally sensitive to TT-232. Conclusion: The efficacy of TT-232 is not altered by the MDR1 protein. TT-232 may be a candidate drug for the treatment of hematological malignancies including lymphomas expressing high level of MDR1 protein.
C1 [Schwab, Richard] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tejeda, Miguel] National Institute of OncologyBudapest, Hungary.
   [Schafer, Eszter] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Gyokeres, Tibor] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Keri, Gyorgy] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Pap, Akos] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
RP Schwab, R (reprint author), Semmelweis University, Cooperative Research Center, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 310
EP 310
PG 1
ER

PT J
AU Schwab, R
   Petak, I
   Schafer, E
   Diofalvi, K
   Tejeda, M
   Gyokeres, T
   Varga, Gy
   Pap, �
   Keri, Gy
AF Schwab, Richard
   Petak, Istvan
   Schafer, Eszter
   Diofalvi, Katalin
   Tejeda, Miguel
   Gyokeres, Tibor
   Varga, Gyula
   Pap, Akos
   Keri, Gyorgy
TI Multidrug-resistance in gastrointestinal neoplasms
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: was to investigate the role of MDR1 and MRP1 proteins in the multidrug-resistance of pancreatic and colon cancers in vitro. Methods: In vitro chemosensitivity of Ht-29 colon- and Panc-1 pancreatic cancer cell lines to methotrexate, 5FU, etoposide, doxorubicine and vincristin were compared in proliferation assays. MDR1 and MRP1 functional activities were measured by the MDQ assay (Solvo Biotechnologia Rt, www.solvobiotech.com). Results: There were significant differences in drug sensitivity between the two cell lines. MDR1 specific Multidrug-resistance Activity Factor (MAF) was much higher in Ht-29 cells than in chemotherapysensitive Panc-1 cells. Conclusion: MAF values reflecting MDR activity proved highly predictive for cytostatic sensitivity, in vitro. Measuring MDR activity can potentially improve personalized chemotherapy in the future.
C1 [Schwab, Richard] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schafer, Eszter] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Diofalvi, Katalin] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Tejeda, Miguel] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Gyokeres, Tibor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Varga, Gyula] Central Railway Hospital and PolyclinicBudapest, Hungary.
   [Pap, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Keri, Gyorgy] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
RP Schwab, R (reprint author), Semmelweis University, Cooperative Research Center, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 310
EP 310
PG 1
ER

PT J
AU Serenyi, P
AF Serenyi, Peter
TI Cervical screening in Northern Bacs-Kiskun county
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB It is a public health problem due to the prevalence of cervical cancer. The course of the disease is known, which can be favorably influenced by early detection and treatment. An effective, cost-effective method for cytological smear, supported by scientific evidence, supported by scientific evidence, is available for early detection. Therefore, it is necessary to involve as many women of vulnerable age as possible in cervical screening so that cervical cancer can be recognized in time as a cancer-preventing condition. Opportunistic screening is not enough to achieve the goal, so organized screening based on personal identification, invitation, recall is needed. The effectiveness of screening is indicated by the reduction in mortality from that disease. By operating a screening model developed with significant collaboration for two years, 46% of the female population aged 25-65 was included in the system. It is essential that the participants in the screening work closely together and that the cases that are screened are followed up. It is very important to win the affected age groups to participate in the screening. The method is different for each age group, as participation is also different for different age groups. The reasons for non-appearance should also be investigated. Exploring the causes can lead to a positive change in participation.
C1 [Serenyi, Peter] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Serenyi, P (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 311
EP 311
PG 1
ER

PT J
AU Simon, P
   Bahery, M
   Monostori, Zs
   Mandoky, L
   Godeny, M
AF Simon, Peter
   Bahery, Maria
   Monostori, Zsuzsanna
   Mandoky, Laszlo
   Godeny, Maria
TI Evaluation of our ultrasound and CT-guided liver biopsy cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: We analyzed the cases to be biopsy grouped according to the underlying diseases, we examined the accuracy of the biopsy sampling under ultrasound and CT control. Methods: Number of liver biopsies processed: 80 with ultrasound control, 40 with CT control. Both aspiration sampling was used for cytology and core biopsy for histology. On average, samples were taken by two punctures. For targeting, we always chose the imaging method that was able to identify and stab the lesion more safely. Under the same safety conditions, ultrasound was preferred. The following conditions were considered in addition to the appropriate coagulogram: availability of foci, provision of tamponing liver parenchyma, relationship to the surrounding vascular and biliary system, thoracic organs. Results: More than 90% of the biopsy samples gave technically evaluable results. The cause of the failure was parabiopsia and mechanical damage to the sample. No complications were observed in either case. Conclusions: Both ultrasound and CT-guided biopsy prove to be an accurate method for the pathological diagnosis of focal liver lesions. If the conditions are met, the procedure is safe.
C1 [Simon, Peter] National Institute of OncologyBudapest, Hungary.
   [Bahery, Maria] National Institute of OncologyBudapest, Hungary.
   [Monostori, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Mandoky, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Simon, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 311
EP 311
PG 1
ER

PT J
AU Sinko, J
AF Sinko, Janos
TI Fungal infections and their treatment in cancer patients - the place of new antifungal agents in therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Invasive mycoses are less common in patients treated for solid tumors than in haematological malignancies. Nevertheless, depending on the type of tumor and the therapy used, there may be an accumulation of risk factors for mycosis in some oncology patients. Risk factors include severe and persistent neutropenia, prolonged corticosteroid therapy, the use of cannulas, catheters and other plastic devices, and surgeries and mucositis that compromise the integrity of biological lines of defense, especially gastrointestinal barriers. Infections are most commonly caused by Candida spp., Less commonly by Aspergillus, Cryptococcus neoformans, and some other fungal species. The diagnosis of invasive mycoses is difficult to make in time, and their lethality is usually unacceptably high with the use of conventional antifungal agents. At the turn of the millennium, we witnessed the expansion of the antifungal arsenal: two new compounds, caspofungin and voriconazole, were registered in the United States and Europe. Caspofungin is an echinocandin molecule for parenteral administration that has a spectrum of activity against fluconazole-sensitive and resistant candidates, as well as Aspergillus spp. And Pneumocystis carinii. The drug is well tolerated and its toxicity is minimal. It can be used in invasive candidosis, for other therapies in refractory invasive aspergillosis. Voriconazole is an improved version of fluconazole that can be administered both parenterally and orally. In addition to aspergillus, fluconazole-sensitive and resistant candidiasis, it also affects some of the less common but severely infectious fungal species (Fusarium spp., Scedosporium spp.). Its effectiveness is outstanding in fungal infections of the central nervous system (brain abscess). Its toxicity profile is favorable and its use is more limited by drug interactions. First-line therapy for aspergillosis. In addition to the administration of antifungal agents, agents that affect the body's responsiveness, such as haematopoietic growth factors, may play a role in the treatment of invasive mycoses. An improvement in the prognosis of severe fungal infections can only be hoped for if the risk factors for the patient are properly assessed, the limitations of diagnostic methods are known, and the most effective antifungal therapy is chosen based on the available information.
C1 [Sinko, Janos] Del-Pesti CentrumkorhazBudapest, Hungary.
RP Sinko, J (reprint author), Del-Pesti Centrumkorhaz, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 311
EP 311
PG 1
ER

PT J
AU Somlai, B
AF Somlai, Beata
TI Dermatoscopic characteristics of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The dermatoscope is a hand-held instrument used to diagnose pigmented lesions of the skin at 10x magnification and is a useful adjunct to clinical examination. It provides information - in a horizontal plane - about the processes that take place in the upper part of the epithelium and dermis. Different types of melanoma show different histologically well-defined lesions within the epithelium. These features also appear during dermatoscopic examination. The author presents the dermatoscopic characteristics of different melanoma types (lentigo malignant melanoma, superficial spreading melanoma, nodular melanoma, acrolentiginosus melanoma). It highlights the prominent asymmetric nature of melanoma with a dermatoscope, the characteristics of the edges, and the richness of color in the tumor. It parallels the different structural elements (mesh, branched streaks, nuggets sitting at different depths, unstructured area, dots) with the morphological changes caused by the tumor process in the epithelium and upper part of the dermis. It also underlines the possibility of melanocyte origin in the absence of structural criteria for melanocyte origin. It presents the typical vascular changes observed in melanoma. The use of a dermatoscope increases diagnostic accuracy and improves the early detection of melanoma, thus significantly contributing to a more effective treatment of the tumor process.
C1 [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Somlai, B (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 312
EP 312
PG 1
ER

PT J
AU Staub, M
AF Staub, Maria
TI Sensitivity of cells to cytostatics can be enhanced by activation of general deoxynucleoside kinase: its role in DNA repair and apoptosis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Nucleoside analogs are one of the oldest and most important groups of chemotherapeutic treatments. The arabinosyl nucleoside, halogenated deoxyadenosine (Cladribine) and dideoxycytidine (Gemcitabine) derivatives are mainly used in hematological tumors. Dideoxycytidine and 5-F-uracil are also widely used in solid tumors. Many antiviral drugs also belong to this group of active substances. The importance of chemotherapeutic drugs is growing, with annual sales projected to reach $ 50 billion worldwide in 2005. The aim of our research was to clarify the molecular point of attack and to influence the sensitivity of cells and tumors to nucleoside analogues. Nucleoside analogs are converted to potent metabolites in cells and are phosphorylated by nucleoside kinases. This phosphorylation step determines in most cases the sensitivity of tissues to the nucleoside analog, which is catalyzed by nucleoside kinases. The so-called "General deoxynucleoside kinase", deoxycytidine kinase (dCK) is the most significant of these. Due to its wide substrate specificity, it is able to phosphorylate two purine deoxynucleosides (dA, dG) and their derivatives, such as Cladribine, Gemcitabine, Citarabine, etc., in addition to d-cytidine (dC). is also a major activator of analogues. Results: We found that dCK enzyme activity is enhanced when cells are pretreated for 1-2 hours with nucleoside analogs, other non-nucleoside DNA synthesis inhibitors (aphidicolin), and even gamma irradiation. 400% increase in activity. Of the natural nucleosides, dA also induces dCK activation by inhibiting its deamination. This increase in activity in all cases made the cells more sensitive to toxic nucleoside analogs. The enhancement of dCK activity is most pronounced in normal human G-phase lymphoid cells (PBMN), leukemia-derived cell cultures (HL60). The increase in dCK activity was not accompanied by an increase in either dCK mRNA or dCK protein, and post-translational protein modification was assumed. In parallel with the increase in dCK activity, gamma irradiation also increased the DNA repair activity of the cells and the activity of the Caspase-3 enzyme, which indicates apoptosis. The process of dCK activation can be prevented if the cells receive dC extracellularly during activation or if the intracellular Ca2 + concentration is reduced. “Activated dCK” can be inactivated by in vitro protein phosphatase treatment, suggesting protein phosphorylation. Conclusion: Increased dCK activity is a compensatory mechanism in the cell that seeks to prevent inhibition of nucleotide metabolism, inhibition of DNA synthesis, DNA strand breakage, and so on. DCK can provide all four deoxynucleotides to the cell for DNA repair, supporting its central role. If complete repair of the DNA fails, apoptosis occurs. Application: pretreatments with certain cytostatics, irradiation increase the sensitivity of tumors to other chemotherapeutic agents.
C1 [Staub, Maria] Semmelweis University, Department of Medical Chemistry, Molecular Biology and PathobiochemistryBudapest, Hungary.
RP Staub, M (reprint author), Semmelweis University, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 312
EP 312
PG 1
ER

PT J
AU Strausz, J
AF Strausz, Janos
TI Lung screening in Hungary. What do we filter and what should we filter?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In Hungary, lung screening is ordered annually by the National Health Insurance Fund, depending on the current epidemiological situation of tuberculosis. In a county where the incidence of tuberculosis exceeds 25% ooo, full population screening is mandatory, with 30-60% of those invited. Patients with lung cancer are highlighted in the above studies, with 30-40% of new clients being highlighted each year. There is no doubt that the chances of recovery (surgery) of patients discovered in a complaint-free state are significantly better than those highlighted with a complaint. The lung medicine profession has repeatedly stated that lung screening should be left for tuberculosis where the number of infections warrants. For lung cancer, full population screening is unjustified. However, screening the smoking population over the age of 40 is well-founded. The task of pulmonology is to explore and follow this risk group. Respiratory function testing linked to screening is also part of the complex screening because airway obstruction is also a risk factor for lung cancer.
C1 [Strausz, Janos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Strausz, J (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 312
EP 312
PG 1
ER

PT J
AU Sulyok, Z
   Kovacs, T
   Farkas, E
   Pommersheim, F
   Koves, I
AF Sulyok, Zoltan
   Kovacs, Tibor
   Farkas, Emil
   Pommersheim, Ferenc
   Koves, Istvan
TI sentinel lymph node examination for lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The condition of regional lymph nodes, namely lymph node metastases, plays a crucial role in the treatment and prognosis of solid tumors. Attempts are being made to detect lymph node (N1) and mediastinal (N2) non-small cell lung cancer in clear diagnostic lymph node metastasis cannot be demonstrated with diagnostic options. The authors describe the technique of double labeling, labeling with the isotulphan blue vital dye in addition to the isotope Technetium-99m. Conditions for patient selection: • Loco-regionally resectable • Preferably peripheral tumor • Non-small cell lung cancer • Optimal clinical ST I AB (T1-2, N0, M0) • Permissible clinical ST II AB (T1-2-3, N1-0, M0 ) A far-reaching conclusion on the usefulness of the method has not yet been drawn from some of the cases carried out so far. The sentinel lymph node examination in non-small cell lung cancer does not appear to be a method to reduce the extent of surgery or to avoid mediastinal lymph node block dissection, but rather to provide more accurate, patient-specific, adjuvant chemotherapy with more accurate pathological staging. - and radiotherapy planning.
C1 [Sulyok, Zoltan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Tibor] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Farkas, Emil] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Pommersheim, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Koves, Istvan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Sulyok, Z (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 313
EP 313
PG 1
ER

PT J
AU Sz. Nemeth, M
   Otto, Sz
AF Sz. Nemeth, Maria
   Otto, Szabolcs
TI Detection of two protein components (hemoglobin and albumin) in faeces in one step
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: The authors have developed an immunochemical method and immunization method for the simultaneous detection of fecal hemoglobin and albumin to increase the screening efficiency of colorectal cancers. Methods: In a human-specific blood test, bispecific immune sera recognizing two antigens were produced in goats by inoculation of a hemoglobin-albumin complex generated with glutaraldehyde. Purified dual antibody-containing immune serum was tested in a screening group of 1,196 people over the age of 40 using Fecatest cassettes. Results and Conclusions: The analytical sensitivity of the immune serum for both proteins was 0.5 μg / ml, which is very favorable for filtration. Furthermore, the intensity of immunochemical reactions increased, which increased the safety of detection without decreasing specificity. Because the number of immunochemical assays that can be performed per unit of time has doubled (at no additional cost), the method has increased the efficiency of screening in a cost-effective manner.
C1 [Sz. Nemeth, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
RP Sz. Nemeth, M (reprint author), National Institute of Oncology, Central Clinical Laboratory, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 313
EP 313
PG 1
ER

PT J
AU Szabo, �
   Bidlek, M
   Feher, I
   Godeny, M
AF Szabo, Eva
   Bidlek, Maria
   Feher, Istvan
   Godeny, Maria
TI Significance of MR mammography in population breast screening
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: One of the indicators of the cost-effectiveness of population-based breast screening is the proportion of benign-malignant surgeries, the percentage distribution of which is very good in our Institute based on the data of the previous year (PPV. 0, 87). The usefulness of breast MRI scans was investigated from the perspective of breast screening. Methods: In 2002, we conducted 13,017 studies as part of a population-based breast screening program launched under the Public Health Program. Of these, 728 recalled patients underwent additional examination (ultrasound, biopsy, MR). Breast MR examination was used in 42 cases when we could not form a definite opinion with the traditional diagnostic methods. Results: We were able to answer the following questions by MRI: in 13 cases we confirmed the benign process - the patients did not have surgery - in 5 cases we could prove the multifocality caused by a known foci - more radical surgery could be planned - in 8 cases the dens , in the fibrotic breast we were able to determine the exact extent of the known lesion. Conclusions: MR is a useful adjunct to traditional imaging procedures for the assessment of atypical processes that cause differential diagnostic difficulties during breast screening. It helps to separate malignant, benign processes, to assess polygamy, to evaluate dens breasts that are difficult to examine with the traditional method, to increase diagnostic accuracy, to reduce unnecessary surgeries and to make a more accurate surgical plan.
C1 [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Feher, Istvan] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Szabo, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 313
EP 313
PG 1
ER

PT J
AU Szarvas, T
   Majoros, A
   Szendroi, A
   Romics, I
   Bedi, K
   Kovalszky, I
AF Szarvas, Tibor
   Majoros, Attila
   Szendroi, Attila
   Romics, Imre
   Bedi, Katalin
   Kovalszky, Ilona
TI Microsatellite allele loss (LOH) assay for bladder cancer screening
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Some of the genetic disorders involved in carcinogenesis show tumor-specific characteristics. This provides an opportunity to develop selective screening methods. Aim: To establish a screening method based on microsatellite analysis using the literature to detect the presence of bladder tumors in urine in a non-invasive manner. Methods: Our studies were performed on blood, tumor and urine samples from patients with bladder tumors. Initially by conventional PCR followed by polyacrylamide gel electrophoresis and silver staining, later by capillary electrophoresis following fluorescent PCR. Results: Conventional PCR screened 11 patients with 5 markers. Of these, 6 showed at least one allele loss (54%). To date, 17 cases of bladder tumors have been studied using 12 markers using fluorescent PCR. Of these, at least one genetic abnormality was detected in 16 cases (94%). Most abnormalities were observed on chromosomes 9 and 17. Capillary electrophoresis studies are still ongoing. Conclusions: Our initial results suggest that genetic screening by allele loss testing provides an opportunity for non-invasive screening for bladder tumors.
C1 [Szarvas, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Bedi, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Szarvas, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 313
EP 313
PG 1
ER

PT J
AU Szasz, A
AF Szasz, Andras
TI Electro-hyperthermia as a new complementary oncology modality
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction: Hyperthermia, the overheating of tumor tissues, is a very dynamically developing form of cancer treatment. Classical hyperthermia can be traced back thousands of years, with the main technical and treatment parameters being the temperature reached and its distribution. The pitfalls and difficulties of its oncological applications are fundamentally related to the development of deep and targeted heat intake as well as heat tolerance. Electro-hyperthermia, also known as oncothermia, effectively focuses and avoids the massive appearance of heat shock proteins, thus avoiding resistance to treatments while preserving classical heat therapy effects. The current state of oncological hyperthermia is most similar to its use after the discovery of ionizing radiation: we know that it is well applicable, but the exact extent, limits of applicability, optimal treatment conditions, and especially its mechanism of action are not yet fully understood. Added to this is the current peculiarity of young therapies: the lack of sufficient treatment experience to produce long-term, multi-centered and comprehensive statistics. Aim: To present the possibilities and results of electro-hyperthermia. Method: Electro-hyperthermia is based on energy decoupling from the electric field and also takes advantage of the non-thermal effects provided by the biophysical effects of the electric field. The dielectric constant is significantly lower in disordered tissues than in disordered, tumor-specific scattered systems. Thus, the electric field decoupling is selective in terms of the differences between the dielectric constant and the disordered states. In addition to a strictly scientific theoretical description, the actual efficacy is shown by the results of clinical trials and its increasingly widespread successful application. Results: The results of the procedure are shown by a very large amount of clinical experience. Unfortunately, most of the experiences in the different localizations are mainly of a case description nature, but several very high quality publications have already reached the III. also into the investigation phase. (In general, evidence-based clinical manifestations of hyperthermia are now commonplace.) Applications of electro-hyperthermia consistently show that in almost all measurable success parameters (clinical response, asymptomatic survival, one-, three-, and five-year survivals, etc.) hyperthermia when used in combination with classical therapies has yielded very positive results. Its role in improving the quality of life is undeniable. Its stand-alone (monotherapy) applications are now also accepted in cases where the use of classical therapies is not possible for some reason. In Hungary, several controlled clinical trials (colorectal liver metastases, pancreas, primary hepatocellular carcinoma, mammary metastases (brain, lungs)) are being launched with the participation of leading oncology institutes. Electro-hyperthermia care is now available even in central locations (National Institute of Oncology, Uzsoki Street Hospital). Conclusions: Hyperthermia is an effective, increasingly widespread treatment modality in Hungarian oncology practice as well. The current state of technical and biophysical developments has created electrohyperthermia, which is the most advanced process in the field. Electro-hyperthermia is a painless, low-contraindicated, non-toxic, non-degrading, safe procedure that complements conventional therapies and increases their effectiveness when used in conjunction with conventional therapies.
C1 [Szasz, Andras] St. Istvan University, Faculty of Engineering, Department of BiotechnicsBudapest, Hungary.
RP Szasz, A (reprint author), St. Istvan University, Faculty of Engineering, Department of Biotechnics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 314
EP 314
PG 1
ER

PT J
AU Szekely, E
   Borka, K
AF Szekely, Eszter
   Borka, Katalin
TI Bladder tumors in the pathologist's eye
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Purpose: Bladder tumors are relatively common in both men and women. However, making a histological diagnosis can often be difficult. This may be due to a technical reason or a lack of communication between the urologist / pathologist. Method: In our institute, the approximately 14,000 biopsy materials examined annually, resp. about 15% of the cytological sample is from the Urology Clinic. These have approx. half come from the bladder. There are a number of problems that can arise when examining incoming materials. The accuracy and clinical / pathological evaluability of the findings of the 2002 bladder samples were examined. Result: In the vast majority of cases, the submission paper contains satisfactory clinical data so that an appropriate diagnosis can be made. However, if the sampling method is not ideal, information that is very important to the clinician / oncologist (tumor depth, vascular invasion, grade, etc.) should not be given. This presentation is intended to provide clinicians with some examples that clearly show when it would be risky to give a clear answer to some seemingly important clinical question that determines further treatment. In addition, the presentation aims to present some instructive cases, rare tumors. Conclusion: Ideal oncology treatment is still not possible without proper dialogue between the clinician and the pathologist. Although the statement is not recent, its truth is still valid today and cannot be overemphasized.
C1 [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szekely, E (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 315
EP 315
PG 1
ER

PT J
AU Szendroi, M
AF Szendroi, Miklos
TI Treatment of bone tumors at the Orthopedic Clinic of Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Epidemiology: Primary malignant bone tumors are rare, with all malignant tumors occurring at approx. They make up 0.5-1%. According to the data of the National Cancer Registry, approx. There are 52 new cases per year for the 3 most common primary malignant bone tumors (approximately 30 osteosarcoma; 17 chondrosarcoma; 5 Ewing's sarcoma). The small number of cases and the special nature of treatment require that bone tumor registries be established to collect experience and that patients be treated in centers by interdisciplinary teams. The SE Orthopedic Clinic has had a bone tumor registry since 1975, where we keep records of patients treated at the Clinic. The experience is significant, as we treat 50-70% of new malignant bone cancer patients in Hungary. In our registry, we record 1,642 primary benign, 763 primary malignant, 835 tumor-like bone lesions in 399 patients treated for bone metastases. Diagnosis: In addition to the traditional histological processing and intraoperative freezing histological examination, we use image intensification, ultrasound, CT-guided percutaneous needle biopsy, an immunohistochemical antibody panel specific for bone tumors is available (Dr. Gabriella Arato, National Medical Center) please (Dr. Zoltan Sapi, Szent Janos Hospital, Department of Pathology). Internationally, a chromosome translocation characteristic of each soft tissue sarcoma (eg synovial sc .: x; 18, myxoid liposarcoma: 12; 16) is detected on the smear by cytogenetic analysis using a modern method. The method requires a great deal of skill on the part of the pathologist, the advantage being that it can be performed on an outpatient basis, quickly, and to minimize tumor cell proliferation at biopsy. Within the SICOT and Arbeitsgemeinschaft fur Knochentumoren systems, it is possible to consult via the Internet in cases of diagnostic problems (telediagnostics). Within a few days after sending the clinical data, X-ray, CT, MR and histological images, there will be a response from pathologists, surgeons and radiologists from 10-20 telediagnostic centers. In recent years, we have used this option 2-4 times a year. Treatment: An average of 200-240 tumor surgeries are performed each year, with two-thirds of the cases being biopsy and curettage and spongiosa plastica. Since 1986, at the same time as the introduction of the COSS-86 protocol in osteosarcoma, we have been performing tendon-conserving surgery for osteosarcoma stage II / B, ie soft tissue fractures. In 2001, 82% of our patients underwent limb surgery and only 18% underwent amputation. In our material, five-year tumor-free survival is 72% and local recurrence is 4% (2% in the last 5 years), according to international statistics. We have developed a modular tumor endoprosthesis system, from which, since 1993, approx. 90 were implanted, 44 in knee tumors. Significant progress has been made in the introduction of so-called internal hemipelvectomies. Since 1986, we have performed 43 such surgeries in an interdisciplinary team. As a new surgical procedure, we introduced extraarticular tumor resection in joint-induced bone sarcomas, femoral and sacrum transposition with trevira mesh fixation in the removal of the entire pelvic half; replacement of the proximal end of the outer ankle and ulna with autologous fibula. We cooperate with international organizations, including the COSS (Combined Osteosarcoma Study) international working group as a regional surgical reference center. We established a soft tissue tumor working group four years ago, the aim of which is to unify the diagnostic steps and treatment of this also rare tumor type, and to evaluate the results multicenter. We can only perform our task at a high level together with other partner institutions, so we cooperate with the National Institute of Oncology, the Department of Oncoradiology on Uzsoki Street, the National Institute of Medical Rehabilitation, the Clinic of Radiology of the University, II. With its pediatric clinic, the Pediatric Oncology of the Miskolc Hospital.
C1 [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Szendroi, M (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 315
EP 315
PG 1
ER

PT J
AU Szekely, G
   Remenar, �
   Gundy, S
AF Szekely, Gabor
   Remenar, Eva
   Gundy, Sarolta
TI Investigation of the association between mutagenic susceptibility and the localization of squamous cell carcinoma of the head and neck
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The bleomycin (BLM) test reflects the degree of genetic susceptibility per cell on the basis of the increased number of chromatid fractures per cell resulting from in vitro BLM treatment of peripheral blood lymphocytes in tumors of environmental etiology. In our previous studies, we found that patients with head and neck cancer (FNyDB) had a higher rate of mutagenicity than controls. In our current study, we examined the relationship between FNyD localization and mutagenicity. BLM tests of 304 heavy smokers and drinkers FNyDB and 331 healthy controls (161 non-smokers and 170 smokers) were performed. Compared to controls, men with tumors of the tongue, mouth, pharynx, hypopharynx, and laryngeal cancers are significantly more susceptible to mutants than those with lip and mouth cancers, who have the same sensitivity as controls. Women differ from control only in the case of a language tumor. The correlation between tongue cancer and BLM sensitivity is most pronounced in men (OR = 2.08), and in women with tongue (OR = 12.55) and oral tumors (OR = 4.18). The proportion of mutants in all FNγDBs is 44%, including tongue, oral, and pharyngeal tumors, 56-67%, suggesting that squamous cell carcinoma is more likely to develop in these localizations.
C1 [Szekely, Gabor] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Gundy, Sarolta] National Institute of OncologyBudapest, Hungary.
RP Szekely, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 316
EP 316
PG 1
ER

PT J
AU Szende, B
   Szabo, J
   Lovasz, S
   Romics, I
AF Szende, Bela
   Szabo, Janos
   Lovasz, Sandor
   Romics, Imre
TI Possibility of increased apoptosis and its possible association with GnRH and androgen receptors in prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: The mode of action of GnRH analogues in the treatment of prostate cancer has previously been explained only by breaking the pituitary gonad axis. However, the direct effect of peptides on tumor cells has also been reported. We conducted our investigations to clarify this issue. Methods: The appearance and extent of apoptosis in tumor tissue were examined in biopsies taken from patients with prostate cancer after 1.7 and 30 days of treatment with Decapeptyl. The biopsy material of ten untreated prostate cancer patients was studied by immunohistochemistry for the appearance of GnRH and androgen receptors. Results: As early as 24 hours after injection of the GnRH analog, foci appeared in prostate cancer tissue in which 80-90% of the cells showed signs of apoptosis. Morphological signs of cell proliferation were observed in other foci. Essentially the same phenomenon was seen on day 7 of treatment. In the 30-day samples, the focal nature disappeared, cell proliferation was suppressed everywhere, and a moderately elevated apoptosis index was recorded in the tumor tissue. Based on hormone receptor detection, the tumor was androgen receptor-positive in seven of ten cases, while the LH-RH receptor was detectable in five cases. The androgen or No association was found between LH-RH receptor positivity. Conclusion: According to our results, GnRH analogue treatment has a direct apoptosis-inducing effect on certain cells of prostate cancer, respectively. cell groups. This effect is thought to be related to the presence of the GnRH receptor in the affected tumor cells. The change at day 30 suggests that by this time the effect of androgendepletion due to rupture of the pituitary-gonadal axis will come to the fore. All of these phenomena may explain the development of hormone resistance and possibly provide therapeutic support.
C1 [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szabo, Janos] Central Military Hospital, Department of UrologyBudapest, Hungary.
   [Lovasz, Sandor] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Szende, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 316
EP 316
PG 1
ER

PT J
AU Szentirmay, Z
AF Szentirmay, Zoltan
TI Molecular diagnosis of soft tissue tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Tissue imaging alone is not sufficient to properly differentiate soft tissue tumors. Histological diagnosis of soft tissue tumors is based on the tissue pattern, characteristic cell type, and stromal abnormalities present in each lesion. There is no sharp line between the tumor groups formed by the tissue structure, and the morphological picture within the group does not provide sufficient support for the further separation of the individual tumor types. Immunohistochemistry is often not specific enough for histogenetic diagnosis. Immunohistochemistry is an accepted method of diagnostic pathology. Usually, antigens are detected that normally occur in only one or two specific intact tissues. Aberrant expression of these antigens is common in soft tissue tumors. For example, the mesenchymal marker vimentin is found in epithelial tissue, while the epithelial marker cytokeratin may also be present in mesenchymal tumors. CD34 is present in intact tissues only in haematopoietic stem cells, endothelium, dermal and periadnexal dendritic reticulum cells, and endoneural dendritic cells, but in dermatofibrosarcoma in the peritoneal tract, in the gastrointestinal tract, also in sarcoma. It is further complicated by the fact that in routine histological sections, protein marker immunohistochemistry, which is otherwise characteristic of a tumor, can be detected in much smaller amounts than in intact tissue, and usually only with a frequency of 50% -80%. Detection of specific genetic abnormalities in soft tissue tumors helps in diagnosis and assessment of the expected course of the disease. Gene assays were performed on DNA and RNA samples obtained from unfixed, possibly formalin-fixed, and paraffin-embedded tumor tissue by a variety of PCR techniques. There are a number of gene alterations in soft tissue sarcomas that are not closely associated with a type of tumor, so their detection is of prognostic rather than diagnostic significance. Of these, the determination of the extent of N-myc oncogene amplification, which is essential for selecting the appropriate treatment in neuroblastoma, is described. Another type of chromosomal disorder occurs only in certain tumors. It is characteristic of this gene alteration that two otherwise non-tumorigenic genes are each broken down into a well-defined region and fused together to form a single new tumorigenic fusion gene. Different fusion genes are found in different tumors (Table), so their detection is diagnostic and in many cases prognostic. We illustrate this with examples.
C1 [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 318
EP 318
PG 1
ER

PT J
AU Szepesi, �
   Barna, G
   Matolcsy, A
AF Szepesi, Agota
   Barna, Gabor
   Matolcsy, Andras
TI Diagnostic issues in bone marrow manifestation of non-Hodgkin lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The key issue in the treatment of non-Hodgkin's lymphomas is the detection or exclusion of bone marrow involvement. Diagnosis can be based primarily on morphological, immunohistochemical, flow cytometric, and molecular studies. Morphological examination of a bone biopsy specimen containing lymphoid infiltrate may indicate a lymphoma-specific infiltration pattern, however, additional phenotypic and genotyping studies are usually required to make a definitive diagnosis and distinguish it from lymphoid infiltration associated with reactive conditions. By immunohistochemistry, antigenic expressions characteristic of a malignant cell clone can characterize a given lymphoma. However, the presence of reactive T cells accompanying B-cell lymphomas or, conversely, reactive B-cell infiltrates accompanying T-cell malignancies may make it difficult to determine the cell type of the process. If a bone marrow aspirate is also available, the pathological coexpression pattern detected by flow cytometry may clearly characterize the malignant cell clone. The diagnosis may be further refined by molecular test results. In addition to determining clonality, T cell receptor and immunoglobulin heavy chain gene rearrangement studies are also suitable for determining cell type. It is possible to clarify the diagnosis and follow the minimal residual disease by detecting specific translocations.
C1 [Szepesi, Agota] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Szepesi, � (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 318
EP 318
PG 1
ER

PT J
AU Szilagyi, �
   Bodi, F
   Perenyi, L
AF Szilagyi, Eva
   Bodi, Ferenc
   Perenyi, Laszlo
TI Our initial experience with new treatment methods in treating our patients with disseminated colorectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In our department, the range of chemotherapy treatments for our colorectal tumor patients has expanded over the past two years. In our work, we summarize our experience with Campto, Tomudex and Oxaliplatin and compare them with domestic and international results.
C1 [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bodi, Ferenc] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Perenyi, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Szilagyi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 319
EP 319
PG 1
ER

PT J
TI Secondary treatment of NSCLC with docetaxel monotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 319
EP 319
PG 1
ER

PT J
AU Szondy, K
   Lantos, �
   Murakozy, G
   Bohacs, A
AF Szondy, Klara
   Lantos, Akos
   Murakozy, Gabriella
   Bohacs, Aniko
TI Significance of Dynamic Magnetic Resonance Imaging (DMR) for Cervical Cancer in Clinical Practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The applicability of DMR was investigated in determining the target volume of radiotherapy, monitoring the effect of irradiation, and detecting tumor devitalization. In the last 5 years, we have treated 338 patients with cervical cancer at the University of Debrecen. 125 DMRs were performed in 61 patients and control DMRs in 32 cases. Of these, the measurements of 30 patients with squamous cell carcinoma and 2 patients with adenocarcinoma were compared with the clinical data. The mean age was 50.7 years. 1 In post-contrast T1-weighted studies with Tesla Shimadzu MR, we analyzed the change in tumor signal intensity. The effect of HDR treatments in neoadjuvant brachytherapy patients and the total radiation effect in those treated with primary combined irradiation were examined. The results of the change in contrast intensity were compared with the histological findings of Wertheim's surgeries. After effective radiotherapy, a significant reduction in contrast accumulation was observed with a decrease in tumor size. 5-year relapse-free survival correlated well with decreases in the intensity and rate of contrast accumulation measured, with changes in tumor devitalization and / or vascularization. DMR is a new opportunity for more accurate planning and dosing of radiochemotherapy, which is made possible by more accurate measurement of the tumor response. Further studies are needed to measure the relationship between demonstrated devitalization and tumor vascularization / oxygenation.
C1 [Szondy, Klara] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Lantos, Akos] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Murakozy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Szondy, K (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 319
EP 319
PG 1
ER

PT J
AU Szoke, T
   Trojan, I
   Furak, J
   Csada, E
   Szalontai, K
   Martyin, P
   Tiszlavicz, L
AF Szoke, Tamas
   Trojan, Imre
   Furak, Jozsef
   Csada, Edit
   Szalontai, Klara
   Martyin, Peter
   Tiszlavicz, Laszlo
TI Results of surgical treatment of small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To evaluate the results achieved in the surgical treatment of small cell lung cancer (SCLL). Method and patient material: Between 1990 and 1999, we operated on 38 patients for SCLL, which is 4.5% of all lung cancer cases. A diagnosis of SCLL was known in 28.9% of patients, and a further 7 patients had a diagnosis of other malignancies. In the case of known SCLL, preoperative staging based on I-II. stage, surgery was considered warranted after neoadjuvant chemotherapy. The following surgical procedures were performed: 12 pulmonectomies, 11 lobectomies, 6 machine wedge resections, and 9 exploratory thoracotomies. Based on the postoperative histological examination, the stage distribution was as follows: I / A 6, I / B 11, II / A 4, II / B 1, III / A 10, III / B 6. For statistical examinations, Kaplan-Meier and log -rank method was used Results: Five-year survival was 33.9% and median survival was 31 months. Among the subgroups, the survival of the intermediate cell type is significantly longer than that of the “oat-cell” form. Early or late complications were observed in 16 patients (42.7%) after surgery. There were 3 bronchial insufficiencies following all three pulmonectomies that had already developed during postoperative chemotherapy. We lost 3 patients in the perioperative period (7.8% mortality). Conclusion: Based on survival results, surgical treatment of SCLL may be warranted under more stringent indication conditions than for other tumors. However, due to multimodal treatment, the rate of complications and mortality is higher.
C1 [Szoke, Tamas] University of Szeged, Department of SurgerySzeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of SurgerySzeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Csada, Edit] SZTE, Pulmonologiai TanszekSzeged, Hungary.
   [Szalontai, Klara] SZTE, Pulmonologiai TanszekSzeged, Hungary.
   [Martyin, Peter] Bekes Megyei Onkormanyzat TudokorhazaGyula, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
RP Szoke, T (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 319
EP 319
PG 1
ER

PT J
AU Szoke, T
   Baumhakel, JD
   Kayser, K
   Trojan, I
   Furak, J
   Tiszlavicz, L
   Gabius, HJ
AF Szoke, Tamas
   Baumhakel, Jan-Dirk
   Kayser, Klaus
   Trojan, Imre
   Furak, Jozsef
   Tiszlavicz, Laszlo
   Gabius, Hans-Joachim
TI Prognostic significance of lectins and lectin-binding capacity in lung cancer cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To determine the prognostic role of lectins on primary malignant lung tumor cells by immunohistochemical and syntactic structural analysis. Patient material and method: We processed the histological material of 489 lung cancer patients who underwent radical surgery between 1990 and 1995. Ligand histochemical staining was performed with the following lectins resp. with anti-lectin antibodies: biotinylated galectin-1, galectin-3, CL-16, hyaluronic acid in Ca ++ -free (HA) and Ca ++ (HA-Ca ++) medium, and anti-galectin-1 and galectin-3 antibody, heparin-binding lectin anti-HBL antibody. Sections were processed using computer image analysis and the relationship between the following parameters and survival was examined: 1. Tumor cell staining or lack thereof. 2. Average distance of tumor cells from each other. 3. Mean distance between tumor cells with different staining. 4. Size of tumor cell clusters. The Cox regression model was used for statistical studies. Results: There was a significant correlation between survival and staining with galectin-3 (p = 0.022), anti-galectin-1 antibody (p = 0.015) and HA-Ca ++ (p = 0.046). We also found a strong correlation between the mean distance of intensely stained tumor cells when stained with galectin-1 and anti-HBL (p = 0.034 in both cases) and the mean distance between non-stained tumor cells after staining with galectin-3 (p = 0.049). Conclusion: Quantitative and qualitative immunohistochemical detection of lectins on the surface of tumor cells may be useful in determining the prognosis of radically operated lung cancer.
C1 [Szoke, Tamas] University of Szeged, Department of SurgerySzeged, Hungary.
   [Baumhakel, Jan-Dirk] University of Szeged, Department of PathologySzeged, Hungary.
   [Kayser, Klaus] University of Szeged, Department of PathologySzeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of SurgerySzeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Tiszlavicz, Laszlo] Vivantes Humboldt Klinikum, Department of PathologyBerlin, Germany.
   [Gabius, Hans-Joachim] Maximilan-Ludwig- Universitat, Inst. fur Physiologische ChemieMunchen, Germany.
RP Szoke, T (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 320
EP 320
PG 1
ER

PT J
AU Szoke, T
   Baumhakel, JD
   Kayser, K
   Trojan, I
   Furak, J
   Tiszlavicz, L
AF Szoke, Tamas
   Baumhakel, Jan-Dirk
   Kayser, Klaus
   Trojan, Imre
   Furak, Jozsef
   Tiszlavicz, Laszlo
TI Microvascularization and survival in operated lung tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To measure microvascularity in malignant lung tumors and their association with survival. Materials and Methods: Histological sections of 450 radically operated lung cancer patients were stained with anti-factor VIII antibody by immunohistochemistry. Sections were quantified using computer syntactic structure analysis. We measured the size of the vessel surface and vessel volume relative to the surrounding tissues, the mean vessel area, the mean vessel diameter, and the density of tumor cells near the vessel. Two-sample test, chi-square test, and Cox regression analysis were used for statistical analysis. Results: Based on the vascular parameters, no differences were found between the N0, N1, and N2 cases, but the more pronounced vascularization was associated with a significantly shorter survival in the N1-positive cases. The vascularity of T2 tumors is higher than that of T1 tumors, similarly, T4 tumors are more vascularized than T3 tumors, respectively. in both cases, the proportion of tumor cells in the immediate vicinity of the vessels was higher. No significant differences were found between the different histological types based on vascularity. Multivariate analysis confirmed that survival was most strongly associated with N status, histological type, and the proportion of tumor cells within 20 μm to the vessels. Conclusions: The degree of vascularization is not related to the development of lymph node metastases or with the histological type. Survival is negatively affected by a higher proportion of tumor cells in the vicinity of blood vessels.
C1 [Szoke, Tamas] University of Szeged, Department of SurgerySzeged, Hungary.
   [Baumhakel, Jan-Dirk] University of Szeged, Department of PathologySzeged, Hungary.
   [Kayser, Klaus] University of Szeged, Department of PathologySzeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of SurgerySzeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Tiszlavicz, Laszlo] Vivantes Humboldt Klinikum, Department of PathologyBerlin, Germany.
RP Szoke, T (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 320
EP 320
PG 1
ER

PT J
AU Szucs, M
   Mavrogenis, S
   Romics, I
AF Szucs, Miklos
   Mavrogenis, Stelios
   Romics, Imre
TI Systemic chemotherapy treatments in urological practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: Short-term evaluation of the indications, method and results of systemic chemotherapy in the urological surgery department. Method: Since 1999, our clinic has been regularly administering systemic chemotherapy for urological tumors under the guidance of a urologist with a clinical oncology examination. By the middle of this year, 1125 chemotherapy treatments had taken place, a separate department had been set up and the treatments were already supervised by two specialists. Results: Immunochemotherapy was performed in 54 patients with advanced or metastatic renal disease. Due to the side effects of the treatment, the dose was reduced by 18% and the treatment was forced to be temporarily stopped. No side effects requiring supportive treatment were observed. M-VAC treatment was performed in 14 patients with infiltrative urothelial tumors. The treatment according to the strict regimen had to be adjusted in 1/3 of the patients, the differences in the laboratory parameters and the general deterioration were mostly only temporary, it did not affect the amount of the planned total dose. In hormone-resistant prostate cancer, parenteral Estracyt was started in 24 patients, and if progression with subsequent oral administration, 24 patients Mitoxantrone therapy. If the above-mentioned tumors caused lytic or mixed bone metastases, 61 cases were supplemented with parenteral bisphosphonate. In metastatic penile tumors, 5 patients received Cisplatin + 5 FU, which resulted in transient regression that did not alter survival. Chemotherapy was not performed in patients with testicular tumors. The poster reports on treatment experiences, analyzes side effects, and provides insight into short-term results. Conclusions: In our opinion, routine systemic chemotherapy treatments with the appropriate indication have a place in the department of urological practice.
C1 [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 320
EP 320
PG 1
ER

PT J
AU Szucs, M
   Kammerer, K
   Molnar, M
   Rohanszky, M
   Varga, K
AF Szucs, Miklos
   Kammerer, Kinga
   Molnar, Maria
   Rohanszky, Magda
   Varga, Katalin
TI The contribution of psychooncology to the care of cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Psychooncology has become a dynamically evolving co-science of oncology in recent decades. His research results and clinical experience are an integral part of cancer research and the treatment of psychosocial disorders caused by the disease, and the need for them is no longer in question. In our view, the two professions can only work for the benefit of patients in close cooperation, knowing each other’s tools and capabilities. The aim of the participants of the round table is to show these connection points, the results achieved so far and to raise the difficulties that affect both areas. The lectures cover the following topics: - overview of the latest results and situation of psychooncology - psychooncology from the point of view of the oncologist - needs, expectations - possibilities of recognizing and treating the psychological symptoms that appear in the clinic - peculiarities of communication in the care of cancer patients it will allow for a constructive dialogue that facilitates cooperation.
C1 [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kammerer, Kinga] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Rohanszky, Magda] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Varga, Katalin] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Szucs, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 321
EP 321
PG 1
ER

PT J
AU Szucs, M
   Romics, I
AF Szucs, Miklos
   Romics, Imre
TI Local treatment of bladder tumors and their complications
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Surgical treatment of superficial bladder tumors is transurethral resection. Intravesical instillation is used to prevent frequent recurrence and progression in nearly 20% of cases. The choice of material delivered through the catheter should take into account the differentiation, multiplicity of the removed tumor and whether to treat primary or recurrent abnormalities. In addition to topically applied cystostatics, BCG, which elicits an immune response, should be used, with a superior rate of efficacy, but its more frequent and intense side effects partially limit its indication. The summary presentation reviews the indications, location and applicability of topical intravesical treatments with different ingredients. It also covers the causes of complications and their treatment.
C1 [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 321
EP 321
PG 1
ER

PT J
AU Szucs, 
   Vegh, �
   Tamas, K
   Bodoky, Gy
AF Szucs, Z.
   Vegh, Eva
   Tamas, Karin
   Bodoky, Gyorgy
TI Third-line treatment of Oxaliplatin in patients with advanced colon cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction: Oxaliplatin has been shown in the literature to improve efficacy in both chemotherapeutic and pretreated patients with colon cancer. Progressive patients pretreated with 5-fluorouracil / leucovorin according to the De Gramont regimen and secondarily with Camptode de Gramont were included in our study. Oxaliplatin according to the FOLFOX4 protocol was used as a third line agent. Patients and Methods: Between 18 April 2002 and 30 April 2003, 26 patients were treated with the Oxaliplatin index Gramont protocol. The mean age of the patients was 59 years (49–72), and 15 men and 11 women were studied. Treatment according to the FOLFOX4 protocol, i.e. 85 mg / m2 Oxaliplatin on day 1, 200 mg / m2 Leucovorin on day 1-2, 400 mg / m2 5-FU bolus plus 600 mg / m2 5-FU continuous 22 hour infusion was used. The treatment was repeated every 14 days. To monitor the disease, laboratory abdominal ultrasound or CT scans and a chest x-ray were performed every two weeks. Results: 9 patients had stabilized (SD), one had complete remission (CR), and two had had partial remission. The median time to progression was 3.9 months. The condition of 14 patients progressed (PD). The response rate (CR + PR + SD) was 46%. No fatal complication occurred. Drug-induced nausea was observed in 4 patients (15%). Febrile neutropenia occurred in 1 patient (3.9%). Anemia requiring transfusion was present in 4 patients (15.4%). Diarrhea occurred in 2 patients (7.7%). Paraesthesia was observed in 9 patients (34.6%). The side effects were not severe and discontinuation of treatment was not warranted. Conclusion: Oxaliplatin shows encouraging efficacy even in the third-line treatment of colon cancer. In addition, according to literature data and our own experience, we should strive to use the effective drug as soon as possible.
C1 [Szucs, Z.] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vegh, Eva] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Tamas, Karin] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Szucs,  (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 321
EP 321
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Oberna, F
   Polgar, Cs
   Somogyi, A
   Major, T
   Fodor, J
   Nemeth, Gy
AF Takacsi-Nagy, Zoltan
   Oberna, Ferenc
   Polgar, Csaba
   Somogyi, Andras
   Major, Tibor
   Fodor, Janos
   Nemeth, Gyorgy
TI Experiences gained during radiotherapy of tongue root tumors: significance of interstitial boost treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To report the results of patients with tongue root tumors using percutaneous or percutaneous and additional interstitial high-dose (HDR) radiation alone. Material and method: Between 1992 and 2000, 70 patients with histologically confirmed tongue root tumors (T1-4 N0-3) were treated with radiation therapy. The male / female ratio was 55/15. Forty patients (Group I) received combination radiotherapy alone (mean total dose 62 Gy), while thirty (Group II) received a combination of percutaneous (mean total dose 60 Gy) and boost, interstitial, HDR radiotherapy (mean total dose 18 Gy). No distant metastasis was detected at the start of treatment. The median follow-up was over 50 months in each group. Results: I. and II. group, the 5-year local, locoregional tumor clearance and survival rates were 44%, 40%, and 31%, and 60%, 52%, and 46%, respectively. Early radiogenic adverse reactions occurred in all cases grade 2-3 and 7 cases (4 patients in groups I and 3 in group II). Soft tissue necrosis occurred in 10–10% of patients. Osteoradionecrosis occurred in 1 case after boost treatment. Summary: The authors conclude that interstitial, HDR, boost treatment can improve both local control and survival without a significant increase in severe radiogenic side effects.
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 321
EP 321
PG 1
ER

PT J
AU Tanczos, I
AF Tanczos, Ildiko
TI Side effects and consequences of radiation therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Their place in everyday radiotherapy. The importance of their early detection and prevention. The role of consequences for patient quality of life.
C1 [Tanczos, Ildiko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Tanczos, I (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 322
EP 322
PG 1
ER

PT J
AU Tamas, K
   Vegh, �
   Szucs, 
   Bodoky, Gy
AF Tamas, Karin
   Vegh, Eva
   Szucs, Z.
   Bodoky, Gyorgy
TI Combination drug therapy for advanced gastric cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim of the study: The incidence of gastric cancer has been on a declining trend in recent years, yet its incidence and mortality remain high. The prognosis of advanced cases is markedly poor, with an average symptom survival of 3-4 months. Therefore, the study of drug treatment options for advanced gastric cancer is of particular importance. Materials and Methods: Between November 1, 2001 and April 30, 2003, a total of 64 patients with advanced gastric cancer were treated with medication in our ward. There were 25 women and 39 men in the study group. Cytostatics were administered in 6-week cycles until progression according to the following schedule: 5 fluorouracil 1500 mg / m2 / 22 hours continuous infusion weekly, Leucovorin 300 mg / m2 / 2 hour infusion weekly, Platinum 40 mg / m2 / infusion every two weeks. There was a 1 week break between cycles. During treatment, weekly clinical and laboratory examinations, monthly CEA and CA19-9 tests, abdominal ultrasound or CT and chest X-rays as cycles. examination, gastroscopy was performed after every third cycle. Results: According to our results, complete remission was not observed in the first 30 patients, partial remission was confirmed in 2 cases. More than 50% of the patients had a stable condition; 40% progressed. The median survival was 7.6 months. The entire patient population is being processed. The most common side effects during treatment were nausea, vomiting, superficial phlebitis, anemia, neutropenia, mucositis causing swallowing complaints. Conclusions: Based on our results, the combination of 5 Flurouracil, Leucovorin, Platinum represents an encouraging opportunity in the treatment of advanced gastric cancer. The side effects observed were predominant.
C1 [Tamas, Karin] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vegh, Eva] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szucs, Z.] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Tamas, K (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 322
EP 322
PG 1
ER

PT J
AU Tamasi, L
   Bohacs, A
   Wollak, A
   Meszaros, Zs
   Bartfai, Z
AF Tamasi, Lilla
   Bohacs, Aniko
   Wollak, Andras
   Meszaros, Zsolt
   Bartfai, Zoltan
TI Complex treatment of non-small cell lung cancer with remote metastasis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Until recently, lung cancer with distant metastases was considered unsuitable for surgical treatment. Recently, however, a number of cases have been reported in which, in combination with chemotherapy and / or radiotherapy, IV. In patients with non-small cell lung cancer with stage I, surgical removal of the primary tumor and distant metastasis was successful. In our case, a 47-year-old male patient underwent “complex” chemotherapy and surgery for non-small cell lung cancer. The patient was first examined at our clinic three years ago, at which time we found planocellular-type lung cancer that occupied almost the entire right upper lobe. The performed CT scan was performed on the right upper lung lung tumor, on the same side of the mediastinal and hilaris lymph node metastases as well as right adrenal metastases. The above lesion appeared to be inoperable at this stage, so combined cytostatic therapy (gemcitabine, cisplatin) was used. After four cycles of chemotherapy, the right upper lobe tumor showed a high degree of regression. It was then that we decided to surgically remove it. Lung tumor resp. after successful surgical removal of the laryngeal and mediastinal lymph nodes, the right adrenal region of the patient was subsequently explored and the formula proven to be lymph node metastasis by histological examination was removed. The patient then received two more cycles of gemcitabincisplatin chemotherapy. Regular follow-up examinations since then, including chest and abdominal CT scans, do not show tumor recurrence. The patient had no complaints and returned to his original occupation. The case described above demonstrates the potential for neo-adjuvant chemotherapy, surgical treatment, and adjuvant cytostasis complex in otherwise inoperable remote metastatic lung cancer.
C1 [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Wollak, Andras] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Meszaros, Zsolt] Bajcsi Zsilinszky Kh., Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bartfai, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 322
EP 322
PG 1
ER

PT J
AU Timar, F
   Paku, S
   Olah, J
   Jeney, A
AF Timar, Ferenc
   Paku, Sandor
   Olah, Julia
   Jeney, Andras
TI Three-dimensional culture of tumor cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: A significant portion of our knowledge of tumor biology comes from the study of monolayer cell cultures. As tumor cells in a living organism also grow in a multicellular organization, more and more laboratories are working to develop three-dimensional in vitro models that provide an opportunity to better understand the events involved in tumor progression, e.g. dormant status, heterogeneity, drug susceptibility. Methods: In our institute, we developed two models for the study of tumor cells in three dimensions: the penetration and migration of tumor cells into the ECM gel; formation of a three-dimensional, multicellular structure by whey extraction from a monolayer culture. Results: We found that HT1080 fibrosarcoma cells of human origin have a cell association corresponding to the desmosome pattern in the multicellular structure and accumulate significant amounts of fibronectin, and α6 integrin can be detected on their surface compared to HT1080 cells in the monolayer. When the multicellular structure is suspended (fetal calf serum is added), the ability of the cells to colonize is increased, while their ability to migrate is reduced. Of the cytostatic agents tested, methotrexate and fluorouracil are less effective on cells in the multicellular structure than on cells in the monolayer. Conclusion: In summary, the study of cultures in three-dimensional cultures provides a broader insight into the individual molecular events that determine tumor progression and the response of tumor cells to drugs.
C1 [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Timar, F (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 322
EP 322
PG 1
ER

PT J
AU Torok, L
   Kocsis, L
   Mari, B
   Gyarmati, Cs
   Olasz, K
   Ocsai, H
   Kosztolanyi, Gy
AF Torok, Laszlo
   Kocsis, Lajos
   Mari, Bela
   Gyarmati, Csaba
   Olasz, Katinka
   Ocsai, Henriette
   Kosztolanyi, Gyorgy
TI Investigation of sentinel and nonsentinel lymph node metastases in melanoma patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Sentinel node biopsy has opened up new possibilities in the surgical care of melanoma. The procedure is primarily important in correct staging and setting up the indication for adjuvant treatments. In the case of complete lymph node block dissection performed on histologically positive sentinel node biopsy, metastasis can be detected in an average of 20-30% in other non-sentinel lymph nodes. We aimed to study sentinel node metastasis to see if it can be inferred from sentinel nodemetastasis that other non-sentinel lymph nodes may or may not be metastasized.
C1 [Torok, Laszlo] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Kocsis, Lajos] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Mari, Bela] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Gyarmati, Csaba] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Olasz, Katinka] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Ocsai, Henriette] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
   [Kosztolanyi, Gyorgy] Bacs-Kiskun Megyei Korhaz, BorgyogyaszatKecskemet, Hungary.
RP Torok, L (reprint author), Bacs-Kiskun Megyei Korhaz, Borgyogyaszat, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 323
EP 323
PG 1
ER

PT J
AU Timar, J
   Ladanyi, A
   Raso, E
   Tovari, J
   Somlai, B
   Gilde, K
   Puskas, GL
AF Timar, Jozsef
   Ladanyi, Andrea
   Raso, Erzsebet
   Tovari, Jozsef
   Somlai, Beata
   Gilde, Katalin
   Puskas, G Laszlo
TI Determining the molecular profile of malignant melanoma is a way to identify more effective diagnostics / prognosis and new therapeutic targets
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The daily diagnosis of malignant melanoma is called consists of the use of melanocyte markers that are not suitable for nevus / melanoma isolation, but also for the purpose of predicting tumor prognosis or their suitability for cytokine therapy. In view of all this, the so-called global (genome-wide) molecular studies. Unfortunately, these have not yet revealed melanoma-specific genes. More recently, mutations in B-RAF have been identified in 60–70% of sporadic melanomas, but these are already present in similar proportions in nevus. Our own study considers one such melanoma-specific gene to be found in the proteoglycan of the extracellular matrix chondroitin sulfate, decorin. In addition to the success of cytokine therapy, the porognosis of melanomas is primarily influenced by the invasive / metastatic ability of the tumor, of which tumor thickness is not the most sensitive indicator. Our molecular and microarray studies have shown significant changes in the expression of many genes in melanoma that play a key role in the progression process: β3 integrin, CD44v3 and syndecan-4 proteoglycans, a new chemokine receptor called AMFR, MMP2 and uPA proteases, and oncogene. signaling pathway B-RAF-N-RAS-12-LOX-PKCα / β-MAPK. A significant prognostic role of some of these has been demonstrated in clinical material. Approximately half / third of melanoma patients receiving cytokine therapy (IFNα or IL-2) do not develop tumor recurrence or progression. However, the molecular characteristics of the tumor that may ensure the success of such treatments are not yet known. Therefore, genome-level studies that e.g. seek to determine the molecular conditions for the antitumor effect of IFNα. In addition to tumor antigens and HLA antigens, the so-called Expression of IFN-responsive genes appears to be significant. Chemotherapy for advanced malignant melanoma is one of the most difficult problems in oncology. Among the molecular basis of this is the fact that melanoma (and melanocyte) has a very significant resistance to apoptosis, without which even traditional cytostatics have no effect. A number of new drug targets have been identified through the determination of the molecular profile of melanoma: in 10% of tumors, mutated N-RAS or c-KIT predicts the use of farnesyltransferases and Gleevec, while the B-RAF mutation in most tumors alone is a kinase inhibitor. . Based on all this, it can be responsibly predicted that the molecular diagnosis of malignant melanoma will become increasingly important, which will change the protocols used today.
C1 [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Puskas, G Laszlo] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 323
EP 323
PG 1
ER

PT J
AU Toth, �K
   Kocsis, J
   Vatay, �
   Laki, J
   Fust, Gy
   Karadi, I
AF Toth, Eva Katalin
   Kocsis, Judit
   Vatay, Agnes
   Laki, Judit
   Fust, Gyorgy
   Karadi, Istvan
TI Investigation of TNF-alpha polymorphism in our tumor patient population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: TNF-alpha is known to play a significant role in the regulation of antitumor immunity. However, data on the association between TNF-alpha expression and tumor development and progression are conflicting. In our tumor population, we examined two TNF-alpha promoter polymorphisms that affect the rate of TNF-alpha expression. Methods: The polymorphism of TNF-alpha at positions -238 and -308 was examined in DNA samples from 84 healthy individuals with tumors and 138 controls. The mean age of the patients was 63.2 years (SD: 10.1). The distribution of tumors was as follows: 53 colorectal, 8 breast, 7 gastric, 4 bile ducts, and 12 others. Results: For the polymorphism at position –238, the occurrence of the variant A allele was significantly higher in individuals with cancer (7.1%) than in control healthy individuals (1.8%) (p = 0.0085). Examining the polymorphism at position –308, we found no significant difference between the two groups in terms of allele frequency. Conclusions: The wild-type allele (G) at position -238 has been shown to have higher TNF-alpha expression, while the presence of variant A allele leads to decreased TNF-alpha expression. Further studies are needed to elucidate how this genetic variation is associated with the development of individual cancers.
C1 [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Vatay, Agnes] MTA, Anyagcsere es Atherosclerosis Kutato KozpontBudapest, Hungary.
   [Laki, Judit] MTA, Anyagcsere es Atherosclerosis Kutato KozpontBudapest, Hungary.
   [Fust, Gyorgy] MTA, Anyagcsere es Atherosclerosis Kutato KozpontBudapest, Hungary.
   [Karadi, Istvan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Toth, �K (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 323
EP 323
PG 1
ER

PT J
AU Toth, J
AF Toth, Jozsef
TI Pathological aspects of early breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Early breast cancers include in situ carcinomas, microinvasive and so-called minimally invasive breast cancers are included, but lymph node-negative tumors less than 15 mm are also included clinically. Lesions that can be classified as early breast cancers: Intraductal in situ carcinoma DCIS and LCIS: 80% are not palpable, the lesion can be grouped according to the extent of the lesion and the number of affected ducts. In 20-40% of the cases, the process is multifocal or multicentric (the lesions are 4 mm apart and the localization on different quadrants is 2-4 cm apart). Microinvasive carcinoma: Tumor cell clusters (DCIS) or individual cells (LCIS) break through the basal membrane (reticular PAS immunohistochemistry for diagnosis), the lesion can be diagnosed in cases <1 mm in diameter. Occasionally (in lobular carcinoma), it is difficult to distinguish between in situ and invasive forms. In DCIS, axillary metastasis occurs in 2% and in microinvasion in 20%, mainly in comedo DCIS. Occult invasion is relatively common (24.5%). Minimally invasive breast cancers> 10 mm in diameter: The significance of the definition has decreased because 3% for tumors 0–5 mm, 10% for tumors 6–10 mm, 21% for tumors 11–15 mm, and 16–20 mm for tumors The rate of referrals is 30%. The most important prognostic markers are tissue grade, mitotic activity index, the presence of necrosis, and vascular invasion, which multiplies recurrence. Starting from the in situ forms, the differentiated differentiation, apocrine, mucinous, myoepithelial, neuroendocrine, etc., can be well followed. Vascular invasion is also important in early invasive forms.
C1 [Toth, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Toth, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 324
EP 324
PG 1
ER

PT J
AU Tovari, J
   Gilly, R
   Lovey, J
   Domotor, H
   Bereczky, B
   Timar, J
AF Tovari, Jozsef
   Gilly, Reka
   Lovey, Jozsef
   Domotor, Hargita
   Bereczky, Biborka
   Timar, Jozsef
TI Preclinical study of tumor biological effects of recombinant human erythropoietin (r-HuEPO)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB It has long been known that less oxygenated tumor tissues are less sensitive to radiotherapy and chemotherapy, and poorer oxygen supply increases the likelihood of metastasis. In the treatment of human cancer patients, erythropoietin is now routinely used to try to achieve normal hemoglobin levels in anemic patients. In our studies, we aimed to test the effect of recombinant human erythropoietin in vitro and in vivo on tumor cells themselves. The effect of r-HuEPO (epoetin alfa, 0.1-100 U / ml, 100-1000 U / kg) on ​​human squamous cell carcinoma (A431) was studied in vitro and in vivo. We examined the effect of different concentrations of erythropoietin on the proliferation of tumor cells and then on the proliferation and cloning ability of tumor cells after different doses of irradiation (0.5–8 Gy). The growth of subcutaneous tumors was measured in vivo and the vascular sensitivity of the tumors was determined. Our results suggest that r-HuEPO reduces tumor cell proliferation in vitro only at 10-fold the human dose and only under serum-free conditions. However, r-HuEPO at therapeutic concentrations significantly potentiated the inhibitory effect of irradiation on proliferation and cloning. R-HuEPO had no significant effect on subcutaneous tumor growth, but significantly increased the diameter of the edges of the tumor. However, r-HuEPO significantly enhanced the tumor growth inhibitory effect of irradiation.
C1 [Tovari, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Gilly, Reka] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Domotor, Hargita] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Bereczky, Biborka] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Tovari, J (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 324
EP 324
PG 1
ER

PT J
AU Udud, K
   Papai, Zs
   Zsiray, M
   Bajcsay, A
   Major, T
AF Udud, Katalin
   Papai, Zsuzsa
   Zsiray, Miklos
   Bajcsay, Andras
   Major, Tibor
TI Bronchus afterloading treatment based on 2- and 3-D irradiation design
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Introduction: Complete oncology treatment of tumors that break into the central airways includes afterloading therapy. Based on the patient material of the last 3 years, we examined the indication area, the therapeutic results, the expansion of endoscopic palliatio and the possibilities of radiation planning. Patients and methods: Between June 1999 and June 2003, the bronchology department of our institute performed brachytherapy in 78 cases in cooperation with the National Institute of Oncology. 33 times this treatment was given after stent implantation. 74% of patients have planocell. suffered from cc. In the remaining cases, the histological diagnosis was adenocc. Or other malignant tumors. Depending on the extent of the process, the treatment is It was also a “three-way” application from a “one-way”, “two-way” and esophagus approach. Accordingly, computer irradiation planning 2-. It was done using a 3-dimensional method. HDR-AL treatments were administered in the majority of cases at a single dose of 1x10 Gy / 0.5 cm tissue depth, respectively. several times in 2-3x5-7.5 Gy fractions. The procedure was followed by endoscopic control, adjunctive telotherapy, and chemotherapy. Results: In 90% of cases, PR was detected based on bronchoscopic control 14–28 days after irradiation. Conclusion: CT-based irradiation planning of brachytherapy for bronchial cancers is a new method in Hungary, which allows for individual dose prescribing, resp. accurate determination of the dose load on anatomical structures. In the case of centrally located tumors, endoscopic palliatio allows the initiation of oncology treatment and the application of the full toolbox.
C1 [Udud, Katalin] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Papai, Zsuzsa] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Zsiray, Miklos] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Bajcsay, Andras] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Udud, K (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 324
EP 324
PG 1
ER

PT J
AU Udvarhelyi, N
AF Udvarhelyi, Nora
TI Significance of determining HER2 status
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Due to advances in molecular biology, more and more molecular markers have been identified that may have prognostic and predictive value in malignant tumors. In breast cancer, HER2 is one of the best characterized such markers. It belongs to the HER2a tyrosine kinase receptor family, encoded by the HER2 / neu protooncogene at locus 17q21 on chromosome 17, and plays an important role in the regulation of cell proliferation, migration, and differentiation. Gene amplification / protein expression is detected in 20-30% of breast cancers. Anti-HER2 monoclonal antibody (Herceptin) immunotherapy is effective only in patients with high HER2 overexpression or HER2 gene amplification. Therefore, knowledge of the HER2 status of patients is essential when using Herceptin therapy. Accurate determination of HER2 status is necessary to ensure that all patients in whom it may be successful receive treatment, but unnecessary treatments are avoided. Methods for demonstrating receptor overexpression include immunohistochemistry (IHC) and ELISA, while FISH, CISH, Southern blot, and PCR techniques can be used to confirm gene amplification. The two most commonly used and internationally accepted and recommended methods in clinical diagnosis are IHC and FISH, but there are currently no tests that are generally accepted as the “gold standard”. Antibodies that react with different epitopes of HER2 are available in large numbers, but the specificity and sensitivity of monoclonal and polyclonal antibodies may differ. It is important to know that the methods used in the procedure may alter the specificity and sensitivity of a given antibody, so adherence to a standardized and tightly controlled protocol (Quality Control) is a primary consideration. Our international and our own experience shows that there is a significant “interobserver” difference in the evaluation of IH results, especially in the evaluation of + / ++ cases, so Quality Assurance is important: re-evaluation between different laboratories, re-testing and confirmation of the result by FISH test. Most national proposals recommend centralized testing, at least for the assessment of doubtful (2+) cases, as local testing usually only achieves accurate results similar to those of the centers if quality assurance and quality control work well in addition to the standard and validated protocol. Centralization is especially recommended for FISH testing, as this requires special practice in addition to expensive machines. According to the UK recommendation, a laboratory should perform at least 250 tests per year to ensure optimal results. According to the CAP proposal adopted in 2002, if the FISH / IHC concordance in 0/3 + cases in a laboratory is less than 90%, both tests should be performed in all cases. If the concordance is> 90%, results 0 and 3+ are acceptable to indicate Herceptin therapy. + / ++ cases should always be confirmed by FISH.
C1 [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
RP Udvarhelyi, N (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 325
EP 325
PG 1
ER

PT J
AU Ugocsai, K
   Molnar, J
   Varga, A
   Molnar, 
   Antus, S
AF Ugocsai, Katalin
   Molnar, Jozsef
   Varga, Andras
   Molnar, P.
   Antus, Sandor
TI Effect of flavonoids and carotenoids on drug accumulation and induction of apoptosis in tumor cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Cross-resistance between structurally and functionally different cytostatics is one of the major difficulties in drug therapy for cancer. A number of compounds have been shown to inhibit P-glycoprotein efflux activity and thus to modify resistance. Aim: The aim of our study was to investigate the inhibitory effects of several carotenoids and flavonoids on the activity of MDR1 and LRP proteins on human colon cancer cells (Colo 320) and their putative role in apoptosis induction. Methods: The effect of flavonoids and carotenoids on P-glycoprotein was investigated by measuring rhodamine accumulation on Colo 320 MDR1-LRP and Colo 205 sensitive cell lines. Results: Of the flavonoids, only Rotenone was shown to be effective in MDR reversal, while the other flavonoids had only a partial effect on drug accumulation and apoptosis induction. The carotenoids, β Cryptoxanthin, Luteoxanthine, Anteroxanthine, Violeoxanthine, Apple Peel Fetoxanthine, Luthein, Violaxanthin, Neoxanthine, were all able to increase rhodamine accumulation, which sensitively indicated inhibition of the efflux pump. In all cases, the degree of maximum fluorescence was concentration-dependent. Conclusion: The carotenoids tested were shown to be effective in modifying MDR1 resistance in vitro, while showing only a weak effect on apoptosis induction at a concentration of 10 μg / mL.
C1 [Ugocsai, Katalin] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Varga, Andras] Humboldt University, Institute of BiologyBerlin, Germany.
   [Molnar, P.] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Antus, Sandor] University of Debrecen, Faculty of Medicine, Department of Medical ChemistryDebrecen, Hungary.
RP Ugocsai, K (reprint author), SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai Intezet, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 325
EP 325
PG 1
ER

PT J
AU Uhercsak, G
   Kahan, Zs
   Hajnal Papp, R
   Boda, K
   Thurzo, L
AF Uhercsak, Gabriella
   Kahan, Zsuzsanna
   Hajnal Papp, Rozalia
   Boda, Krisztina
   Thurzo, Laszlo
TI Sequential Adriamycin-Taxol-Cytoxan Chemotherapy in High-Risk Early Breast Cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Dose-density sequential chemotherapy is an effective and less toxic treatment option than combination chemotherapy. Fifty-five high-risk early breast cancer patients were enrolled in our Phase II study of sequential Adriamycin (A) -Taxol (T) -Cytoxan (C) chemotherapy. The median age was 50 years, the median number of metastatic lymph nodes was 7, and the number of positive lymph nodes was 36% in 36% of patients. 60 mg / m2 A, 100 mg / m2 T, 800 mg / m2 C were administered sequentially every two weeks with hematopoietic cytokine if necessary. Grade 1-2 nausea and vomiting were observed primarily during A and C treatments, while grade 1-2 arthralgia, myalgia, and neurosensory impairment were generally observed during T treatments. Bone marrow toxicity was similar during all three cytostatic therapies: predominantly grade 1-2 neutropenia and grade 1 anemia. A total of 3 to 3 cases of febrile neutropenia occurred after A and T treatments. In four cases, we were forced to discontinue chemotherapy due to cardiac (A, n = 1), cutaneous (T, n = 1 and C, n = 1) and anaphylactic reactions (T, n = 1). Dose-density sequential A-T-C chemotherapy is a well-tolerated form of treatment. We plan to monitor patients and compare therapeutic outcomes with tumor characteristics.
C1 [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hajnal Papp, Rozalia] University of Szeged, Department of PathologySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Uhercsak, G (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 326
EP 326
PG 1
ER

PT J
AU Vajda, A
   Hollosi, M
AF Vajda, Adrienn
   Hollosi, Melinda
TI Clear cell sarcoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Clear cell sarcoma (melanoma of the soft tissues) is a rare disease with a poor prognosis. The 15-35 age group is mainly affected. Typical localization of the lower, less commonly the upper limbs, head or trunk almost never occurs. The 5-year survival is 67%. Tumor size is most important for prognosis. Local recurrence and lymph node metastasis are common, preventing disseminated disease. It can be distinguished from skin melanoma on the basis of clinical, light microscopic image, and immunohistochemical characteristics. Wide and deep surgical excision with adjuvant radiation therapy is essential in its treatment. Chemotherapy is justified only in the case of a disseminated disease, its effectiveness is questionable. Favorable results have been described with interferon treatment. The case of a 19-year-old female patient is described by the author. The skin of the leg was excised almost two years ago at another institute, according to a fingertip knot, and no histological examination was performed. Months later, a slowly growing nodule appeared in the scar, which was excised in our hospital. Histological examination of the excinate confirmed clear cell sarcoma. He has received adjuvant radiotherapy and is constantly receiving interferon. It is tumor-free almost three-quarters of a year after the second surgery.
C1 [Vajda, Adrienn] Allami Egeszsegugyi Kozpont – Honvedkorhaz, BorgyogyaszatBudapest, Hungary.
   [Hollosi, Melinda] Military Hospital, Department of PathologyBudapest, Hungary.
RP Vajda, A (reprint author), Allami Egeszsegugyi Kozpont – Honvedkorhaz, Borgyogyaszat, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 326
EP 326
PG 1
ER

PT J
AU Valicsek, E
   Maraz, A
   Kopniczky, Zs
   Thurzo, L
AF Valicsek, Erzsebet
   Maraz, Aniko
   Kopniczky, Zsolt
   Thurzo, Laszlo
TI Our first experience with the treatment of recurrent malignant glioblastomas and astrocytomas with temozolomide (TZ)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The aim of this presentation is to investigate the efficacy and toxicity of TZ, an promising new treatment option for the treatment of recurrent malignant glioblastomas and astrocytomas. Methods: 23 patients with recurrent glioblastoma (n = 17) and astrocytoma (n = 6) were treated at our clinic over a 26-month period. Patients received 200 mg / m2 TZ orally for 5 days every 4 weeks until progression. Therapeutic response and survival data were examined. The latter was compared with the survival of 23 patients who had previously received surgical and radiotherapy without TZ treatment. Results: The mean number of treatment cycles in the TZ-treated group was 5. Of the patients treated, partial remission was achieved in 8 cases (35%) and stagnation in 5 cases (22%). Progression occurred in 10 (43%) patients treated. The median time to progression was 6.2 months. Dose reduction was required in 4 cases due to grade 2 neutropenia and / or thrombocytopenia. In one case, severe grade 4 thrombocytopenia and neutropenia were observed concomitantly after the 1st treatment cycle. Patients should not be excluded from treatment due to myelotoxicity or allergic reactions. Conclusions: TZ has been shown to be effective in the treatment of recurrent malignant glioblastomas and astrocytomas. The time to progression was prolonged. Patients were well tolerated and had a positive effect on their quality of life.
C1 [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kopniczky, Zsolt] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Valicsek, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 326
EP 326
PG 1
ER

PT J
AU Vallyon, M
   Hideghety, K
   Hadzsiev, J
   Antalffy, Zs
   Benko, A
   Cselik, Zs
   Repa, I
AF Vallyon, Marta
   Hideghety, Katalin
   Hadzsiev, Janaki
   Antalffy, Zsolt
   Benko, Andras
   Cselik, Zsolt
   Repa, Imre
TI Efficacy of combination chemoradiotherapy in non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: To evaluate our first results with the introduction of sequential chemo-radiotherapy for non-small cell lung cancer. In the present work, we analyze the comparison of the results obtained with irradiation following induction polychemotherapy according to two different regimens and with the previous single radiation treatment (ES). Method: At the introduction of chemoradiotherapy, 2-3 cycles of cisplatin-Vepesid (VP) combination were followed by 3D planned conformal radiotherapy with a gradual field reduction to a total dose of 66 Gy, followed by irradiation with cisplatin-gemcitabine (GP) -based induction chemotherapy. Survival, local tumor control, tumor response, and adverse events were included in the endpoints of the study. Results: February 2001 to May 2003 132 IIIB-IV. Patients with stage I non-small cell lung tumors underwent conformal irradiation at the Institute of Diagnostics and Oncoradiology of the University of Kaposvar. The remission rate was significantly better in the chemotherapy groups, with complete remission detected in 5% occurring only in those treated with GP. The proportion of survivors over 1 year was 28% in the ES group, 38% in the VP group, and 42% in the GP group. Acute adverse reactions, anemia, granulocytopenia, radiogenic esophagitis, pneumonitis, and pulmonary fibrosis as complications were more common in those receiving chemotherapy, 75% / 52%. Conclusion: Our first results confirmed the data from international studies, which show an improvement in treatment results with the use of more aggressive combined treatment methods. However, the frequency and severity of side effects also increased, necessitating stronger supportive care.
C1 [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hideghety, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadzsiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antalffy, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Benko, Andras] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Vallyon, M (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 326
EP 326
PG 1
ER

PT J
AU Vamosi Nagy, I
   Koves, I
   Kovacs, T
   Peley, G
   Sinkovits, I
   Keresztes, S
AF Vamosi Nagy, Istvan
   Koves, Istvan
   Kovacs, Tibor
   Peley, Gabor
   Sinkovits, Imre
   Keresztes, Sandor
TI Determination of esophageal tumors sentinel lymph node
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The authors used two methods to determine sentinel lymph nodes in esophageal tumors. The isotope is injected under the mucosa endoscopically before surgery. The anatomical location of the sentinel lymph node is determined during preoperative isotope imaging. During surgery, patent blue is injected under the serosa with an open abdomen. With the help of gamma testing and blue staining, the sentinel lymph node (s) are searched for in two ways and subjected to separate pathological processing. The procedure was applied a total of 5 times.
C1 [Vamosi Nagy, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kovacs, Tibor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sinkovits, Imre] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Keresztes, Sandor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vamosi Nagy, I (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 327
EP 327
PG 1
ER

PT J
AU Varady, E
   Bodrogi, J
   Deak, B
   Eid, H
   Molnar, Zs
   Schneider, T
   Risko, �
   Rosta, A
AF Varady, Erika
   Bodrogi, Jozsef
   Deak, Beata
   Eid, Hanna
   Molnar, Zsuzsa
   Schneider, Tamas
   Risko, Agnes
   Rosta, Andras
TI Clinical features and economic implications of treatment of elderly patients with non-Hodgkin's lymphoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB One of the biggest public health problems of the century will be cancer in the elderly. The proportion of the elderly is rising, in Hungary the aging index (over 65 / under 14 x100) in 1970 was 54.4; In 2000, it was 85.5. The number of cancers is also on the rise, with more than half of patients over the age of 65. The sixth most common tumor is non-Hodgkin's lymphoma (NHL), a quarter of new patients are 70 years old. This disease is sensitive to chemotherapy and radiotherapy, potentially curable, the life expectancy of treated patients over 70 years of age can be several years, and survival of 5 years after therapy is a realistic goal. Problems with late-diagnosed, advanced disease, the presence of comorbidities, and the small number of protocols written for the elderly can be a problem. In addition to biological age and general condition, mental and social status should be taken into account when selecting appropriate, often individual, treatments. In addition to analyzing the clinical data of 183 (86 men and 97 women) NHL patients over 70 years of age treated between 1978 and 2001 at the Department of Chemotherapy, Department A of the National Institute of Oncology, the authors describe their quality of life (QoL) ) as well as the economic aspects and financing problems of the treatment. I would like to draw the attention of clinicians to elderly NHL, untreated or undertreated patients, the often unjustifiably poor therapeutic results, and the socio-economic importance of more intensive treatment.
C1 [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Bodrogi, Jozsef] Budapesti Kozgazdasagtudomanyi es Allamigazgatasi Egyetem, Szolgaltatas- menedzsment TanszekBudapest, Hungary.
   [Deak, Beata] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Eid, Hanna] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Risko, Agnes] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Varady, E (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 327
EP 327
PG 1
ER

PT J
AU Varga, E
   Korom, I
   Olah, J
   Dobozy, A
AF Varga, Erika
   Korom, Irma
   Olah, Judit
   Dobozy, Attila
TI Difficulty in the differential diagnosis of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The incidence of malignant melanoma is increasing worldwide, including Hungary, and its mortality is not decreasing. This justifies the need to place even more emphasis on early detection. Both clinical and histological diagnostic criteria are known, with the help of which diagnostic accuracy can be improved by introducing new tools and examination methods. In addition to the classic forms of the disease, the recognition of unusual melanoma types (amelanotic melanoma, desmoplastic melanoma, malignant blue naevus, subungual melanoma, naevoid melanoma) may also help to improve diagnostic accuracy. The authors provide a clinicopathological analysis of several cases in addition to the review of classical clinical and histological types in connection with the analysis of retrospective data of nearly 1,900 melanoma malignancies observed at the Department of Dermatology and Allergology of the University of Szeged over 30 years. Other skin lesions that are most commonly diagnosed in differential diagnosis (basal cell carcinoma, seborrheic keratosis, nausea) and the classical and modern methods used in isolation are presented.
C1 [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Varga, E (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 327
EP 327
PG 1
ER

PT J
AU Varga, N
   Puskas, GL
   Raso, E
   Timar, J
AF Varga, Norbert
   Puskas, G Laszlo
   Raso, Erzsebet
   Timar, Jozsef
TI Determination of melanoma-specific gene expression pattern using DNA chip technique, laser microdissection and Q-PCR
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The specific gene expression pattern for melanoma is unknown because the marker genes known today and used in diagnostics are melanocyte-specific. Therefore, the aim of our study was to determine marker genes whose expression separates melanoma from the benign tumor, also of melanocyte origin, naevus. The gene expression profiles of four metastatic and non-metastatic human melanoma cell lines with different biological behaviors were compared with the expression pattern of human naevus by DNA microarray analysis. In the first part of the study, 10-10 genes were selected, the expression of which in all cell lines was similar to naevus (increase> 2-fold, decrease> 50%). These genes included Cannabinoid receptor 1, glutamate receptor 6, glycocorticoid receptor 1, p107 (RB), sorcin, ryanodine receptor 2, LAMP2, cyclinE1, calnexin. In the next step, we verified the results of our microarray studies on melanoma cell lines for these genes using Real Time PCR assays. In order to check the relevance of the expression of the genes we have focused on in vivo, we also aimed to investigate the gene expression of melanoma cells in the tissue environment. For this purpose, stromal-free melanoma cells were isolated from surgically removed frozen human melanoma tissue samples by laser microdissection, as well as melanocytes from surgically removed naevus tissue samples. Gene expression of these dissected cells was compared at the mRNA level after complete RNA extraction followed by reverse transcription using Q-PCR assays. The gene expression profile of the stromal components was also examined. Our studies to date suggest that cyclin E1, for example, may be a promising marker for melanoma / nausea isolation.
C1 [Varga, Norbert] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Puskas, G Laszlo] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
   [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Varga, N (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 328
EP 328
PG 1
ER

PT J
AU Varga-Orvos, Z
   Olah, J
   Barzo, P
   Bodosi, M
   Dobozy, A
AF Varga-Orvos, Zoltan
   Olah, Judit
   Barzo, Pal
   Bodosi, Mihaly
   Dobozy, Attila
TI Investigation of prognostic factors in patients with cerebral metastatic melanoma malignum
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Objective: Melanoma malignum is one of the worst prognostic tumors. A common site of early hematogenous metastasis is the central nervous system. In our work, we examined the course of those with surgical cerebral metastases from the 2140 histologically confirmed melanoma patients treated and cared for at the Dermatology Clinic in Szeged as a regional center. Methods: The cases were retrieved from the histopathological descriptions of neurosurgical preparations from the records of the Institute of Pathology. Results: We were able to follow the course of 34 of the 43 patients thus found based on their medical records at the Dermatology Clinic. The detailed course of the remaining patients remained hidden from us, because these persons arrived at the Neurosurgery in Szeged only for the purpose of surgery to remove their brain metastases, and were undergoing treatment in another institution. In the above 34 patients, we searched for prognostic factors by examining several clinical aspects (e.g., histological type, tumor thickness, depth of invasion, regression). Conclusions: A retrospective study has shown that the survival time of patients after removal of both primary melanoma and cerebral metastasis is encouraging despite the hitherto extremely unfavorable prognosis of melanoma malignum. This shows the value of neurosurgery and adjunctive radiation and chemotherapy.
C1 [Varga-Orvos, Zoltan] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Bodosi, Mihaly] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Varga-Orvos, Z (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 328
EP 328
PG 1
ER

PT J
AU Vargane Tamas, R
   Elekne Kiss, B
   Piko, B
AF Vargane Tamas, Rozsa
   Elekne Kiss, Barbara
   Piko, Bela
TI Nursing implications for patients treated with Xeloda
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB There is no illness in which physical symptoms are not associated with a psychic, spiritual factor, there is no moment in a person's life where the body, soul and spirit, the "biological" and the "social" being, can be chosen separately. This is especially true for patients with malignancies, as these factors co-occur. The vast majority of our patients with colorectal cancer have colostomy, which - or the underlying malignancy - results in stigmatization, shame, despair of the disease, fear of treatment, reactive depression, and possibly a panic attack. There are few areas in medicine where the patient's faith, desire to heal, to live would be so important, and the “healing personality” of the doctor and nurse would have such an impact. The authors compare infusion cytostatic treatments that often require hospitalization and oral Xeloda (capecitabine) treatment from the perspective of the patient, nursing staff, and physician, and identify the benefits of effective oral medication.
C1 [Vargane Tamas, Rozsa] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Vargane Tamas, R (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 328
EP 328
PG 1
ER

PT J
AU Vass, L
AF Vass, Laszlo
TI Genetics, morality and society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The most significant scientific achievement of the last century was the understanding of the structure of DNA. The Nobel Prize-winning work on the molecule that explains the constancy of species and the diversity of individuals was published in the April 25, 1953 issue of Nature. The results of hereditary research have created an unpredictable future and opportunities in all fields of medicine. At the same time, they did not leave the thinking of the people of power untouched, and even awakened the hunger for power of some scientists. Ancient human desire is the possession of knowledge of the “future”. Genetics seems to be about this as well: the ever-increasing depth and amount of knowledge not only solves physiological, pathological and cancer biology issues, but also puts society at a crossroads: the individual, religious, social and political communities have to cope with hitherto unimaginable challenges. both. The “events” surrounding genetics and its achievements sometimes bring to life a struggle between good and evil that almost evokes the world of fairy tales. Can humanity handle the treasure it has found correctly? Do we have the power to know the future? My lecture is a tribute to the 50th anniversary of the great discovery, in mainstream genetics, to my Master, to all those I have encountered as a Master in my life. It is also a driving force for all researchers and thinkers whose group or personal decisions are meant to increase the wisdom, relationship to power, and humility of all of us in terms of both morality and humanity.
C1 [Vass, Laszlo] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
RP Vass, L (reprint author), Flor Ferenc University Hospital of Pest County, Kistarcsa, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 328
EP 328
PG 1
ER

PT J
AU Vincze, K
   Elekne Kiss, B
   Piko, B
AF Vincze, Krisztina
   Elekne Kiss, Barbara
   Piko, Bela
TI Rehabilitation opportunities in oncology departments
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Rehabilitation aims to minimize the limitations caused by illness and the treatments applied so that the individual can live the fullest and most meaningful life possible. The goal, then, is to restore normal or near-normal functions again. Rehabilitation should begin at the moment of diagnosis, accompanying the patient through the treatment phase, and the process lasts until the patient dies. Rehabilitation is a multidisciplinary task that includes a clinical oncologist, radiologist, plastic surgeon, oral surgeon, psychiatrist, psychologist, stomatologist, physiotherapist, prosthetist, nurse, pastor, social worker the activities of qualified volunteer helpers and health educators, the coordination of which is crucial. The authors analyze in detail the concept of a rehabilitation team, the most important areas of rehabilitation of cancer patients, and the issue of quality of life.
C1 [Vincze, Krisztina] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Elekne Kiss, Barbara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Vincze, K (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 329
EP 329
PG 1
ER

PT J
AU Wenczl, M
AF Wenczl, Miklos
TI Results obtained with Taxotere (TXT) treatment following Gemzar and Cisplatin (GC) IIIB-IV. stage NSCLC
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Aim: To determine the rate and value of second-line TXT treatment in GC-pretreated NSCLC. Methods: Between January 26, 2001 and December 10, 2002, 44 patients received first-line GC. Karnofsky> = 70%, no cerebral metastasis. N / F 27/73%. The average age is 60 (42-74) years. 9% do not smoke, the rest are heavy smokers since they were young. ARC. stage: 71%. Adenocarcinoma 50%, squamous cell carcinoma 39%, large cell anaplastic carcinoma 5%, atypical, bronchoalveolar carcinoma and carcinosc. 2-2%. Tumor size control by CT every two cycles. Progression: 25%> = increase, PR: size reduction greater than 50%. Staging by AJCC, weekly laboratory examination.Cisplatin 80mg / m2 d1, Gemzar 1250mg / m2 d1and d8, repetition 3x every 3 weeks, then non-progressives were randomized to Gemzar or symptomatic treatment. In case of progression, 75mg / m2 TXT every 3 weeks. Results: 18 (41%) received 1-6 maintenance Gemzar treatments after 4 GCs. By 6 July 2003, 11 patients (25%) had received TXT and 45% had received prior maintenance Gemzar therapy. The number of TXT cycles is 1-4, with an average of 3.5. PR achieved by TXT 9%, NC 73%, PD 18%. Of the 44 patients, 12 are alive. One died of coronary embolism caused by a tumor in the left atrium, two died of pulmonary embolism, and the others had exits due to tumor progression. Conclusions: TXT is recommended after NSCLC GC treatment.
C1 [Wenczl, Miklos] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Wenczl, M (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 329
EP 329
PG 1
ER

PT J
AU Zollei, I
   Csapo, J
   Schonfeld, J
   Gyori, A
   Varga, E
AF Zollei, Istvan
   Csapo, Jozsef
   Schonfeld, Janos
   Gyori, Attila
   Varga, Erika
TI Results of gastric cancer surgeries in geriatric patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The population of the elderly is constantly growing. Gastric cancer is a surgical indication for both young and elderly patients. The type of surgery is affected by the oncology status, the general condition of the patient, and comorbidities. We aimed to compare the data of patients over 70 years of age who underwent gastric cancer between 1997 and 1999 with those of those who underwent surgery between 2000 and 2002 when we tried to perform “radical” surgery. In the first study period, 41 and in the second, 50 elderly patients were treated for gastric cancer. The proportion of patients who underwent abdominal exploration only did not decrease. Among operable cases, the proportion of total gastrectomies increased from 11% to 19%, the proportion of distal gastric resections was 70% in both groups, while the proportion of palliative GEAs decreased to 20% in the second period. Perioperative mortality decreased from 20% to 14%. Significantly, respiratory complications decreased from 22.5% to 10.5% and cardiac problems improved from 7.5% to 2.2%. Direct surgical complications ranged in the same range. In the second period, surgeries for gastric cancer in elderly people, often with severe comorbidities, were more “radical” than before, with lower mortality and fewer cardiopulmonary complications.
C1 [Zollei, Istvan] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Csapo, Jozsef] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Schonfeld, Janos] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Gyori, Attila] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Varga, Erika] Tolna County Balassa Janos Hospital, IV. Department of Internal MedicineSzekszard, Hungary.
RP Zollei, I (reprint author), Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, Szekszard, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 329
EP 329
PG 1
ER

PT J
TI Summary of consultation meeting of the College of Radiotherapy and Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 330
EP 330
PG 1
ER

PT J
TI Summary of the consultation meeting of Colleges of Radiotherapy and Oncology and Chief Oncology Supervisors on Juny 6-7, 2003
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 331
EP 331
PG 1
ER

PT J
TI Society of Hungarian Molecular and Predictive Epidemiology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 333
EP 333
PG 1
ER

PT J
TI Suppletory Internet portal about tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2003
VL 47
IS 3
BP 336
EP 336
PG 1
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI Dr. Lehoczky Gyozo
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Eckhardt, Sandor] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 338
EP 338
PG 1
ER

PT J
AU Balogh, �
AF Balogh, Adam
TI Introduction
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Balogh, � (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 339
EP 339
PG 1
ER

PT J
AU Baradnay, G
   Varga, L
   Hohn, J
   Simonka, Zs
   Nagy, F
   Molnar, T
   Pajor, L
   Balogh, �
AF Baradnay, Gellert
   Varga, Laszlo
   Hohn, Jozsef
   Simonka, Zsolt
   Nagy, Ferenc
   Molnar, Tamas
   Pajor, Laszlo
   Balogh, Adam
TI Multiple organ resections for the surgical treatment of locally advanced colorectal cancer infiltrating the urinary tract
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors present data on 13 patients operated on for the treatment of locally advanced colorectal cancer infiltrating the adjacent parts of the urinary tract. Based on prior diagnostic evidences, every surgical intervention has been indicated as an expected curative resection. All patients of this study underwent a curative resection. The origin of the advanced cancer was in 9 cases the sigmoid colon, in 3 cases the rectum and in 1 case the ascending colon. Beside the resection of the tumorous colon or rectum, a resection of the urinary bladder has been performed in 9, a nephrectomy in 3 and the resection of the ureter in 2 cases. An additional gynecological resection was made in 4 cases for tumors infiltrating the female internal genitals. No mortality and no serious complication needing reoperation occurred in these series. Based on their experiences of a series of 13 radically operated cases, the authors suggest extended multiple organ resection for the treatment of advanced colorectal cancer infiltrating the urinary tract.
C1 [Baradnay, Gellert] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Varga, Laszlo] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Nagy, Ferenc] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Molnar, Tamas] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Pajor, Laszlo] University of Szeged, Department of UrologySzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Baradnay, G (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 341
EP 344
PG 4
ER

PT J
AU Farkas, Gy
AF Farkas, Gyula
TI Surgical treatment of neuroendocrine tumours of the pancreas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Gastro-entero-pancreatic (GEP) endocrine tumours can originate from various pancreatic islet cells, from endocrine cells of the gastric and duodenal mucosa, or from APUD cells of neuroectodermal origin in the gastrointestinal tract. They are benign when smaller than 2 cm, but larger tumours are generally malignant. Surgery is the only method for the curative treatment of GEP tumours. A diagnosed and localised tumour is an absolute indication for radical surgery. Conservative medical treatment may be indicated only in an inoperable condition, but in this case tumour reduction surgery is suggested. In the last 15 years 22 patients with pancreatic neuroendocrine tumours were treated without any mortality. Except for two of them, the surgical therapy was curative.
C1 [Farkas, Gyula] University of Szeged, Department of Surgery, Pecsi ut 4., 6720 Szeged, Hungary.
RP Farkas, Gy (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM fg@surg.szote.u-szeged.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 345
EP 347
PG 3
ER

PT J
AU Furak, J
   Trojan, I
   Szoke, T
   Tiszlavicz, L
   Morvay, Z
   Balogh, �
AF Furak, Jozsef
   Trojan, Imre
   Szoke, Tamas
   Tiszlavicz, Laszlo
   Morvay, Zita
   Balogh, Adam
TI The occurrence of bronchioloalveolar lung cancer among our patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION: One of the subtypes of pulmonary adenocarcinoma, bronchioloalveolar carcinoma (BAC), is mentioned as the lung cancer of non-smoking women. We have studied the clinical characteristics of BAC and its surgical teatment.  METHODS AND PATIENTS: Between 1992 and 2001, lung resections for BAC were performed on 101 patients: 55 men and 46 women, average age 59.7 years. Thirty-two of the patients were non-smokers, and 69 were active smokers. In 1992 the incidence of BAC was 17.5% of all adenocarcinomas, whereas in 2001 it had risen to 51.6%. The operations involved 76 lobectomies, 12 pulmonectomies, 11 wedge resections and 2 explorative thoracotomies.  RESULTS: The surgical mortality was 0.9%. The final histologic findings revealed that 82.1% of the tumours were in stages I or II, with 33.7% of the total in stage I/A. The average 5-year survival was 64.3%. Survival for women 75%, was significantly better than that for men, 51% (p=0.045). A significant difference was not found in the 5-year survival rate for multiple tumours or for BAC cases of different histological types.  CONCLUSIONS: The incidence of BAC, which occurs relatively frequently among women, and exhibits a relatively favourable course, has tended to increase in recent years. A majority of these tumours are removed in an early stage. The survival is not significantly poorer in the event of multiple tumours.
C1 [Furak, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Szoke, Tamas] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Morvay, Zita] University of Szeged, Department of RadiologySzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Furak, J (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 349
EP 353
PG 5
ER

PT J
AU Hohn, J
   Varga, L
   Baradnay, G
   Simonka, Zs
   Geczi, T
   Nagy, F
   Molnar, T
   Maraz, A
   Kahan, Zs
   Balogh, �
AF Hohn, Jozsef
   Varga, Laszlo
   Baradnay, Gellert
   Simonka, Zsolt
   Geczi, Tibor
   Nagy, Ferenc
   Molnar, Tamas
   Maraz, Aniko
   Kahan, Zsuzsanna
   Balogh, Adam
TI Causes of local recurrence after curative surgery of rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The rate of local recurrence (LR) has been 20-40% after resective surgery for rectal cancer by the traditional - Miles or Dixon - operative technics. The authors performed curative resection in 358 patients with rectal cancer in a 10 year period (01.01.1990 - 31.12.2000) in the Surgical Department of Szeged University. Since 01.01.1996 the authors changed this type of surgery for the Heald technics (total mesorectal excision - TME - with sharp dissection, using the UltraCision device) for the surgical treatment of middle or lower third rectal cancer. To compare the results of the two procedures, the authors analysed their material in two periods: Period I: 01.01.1991 - 31.12.1992: 62 patients operated on with the traditional operative technics; LR 15% within 2 years after surgery. Period II: 01.01.1997 - 31.12.1998: 78 patients operated on with the Heald technics (TME with sharp dissection); LR 6.4% within 2 years after surgery. Based on their results, the authors found that the modern operative technics by Heald, used in the second period of the study, was a relevant factor decreasing LR from 15% to 6.4%, while the gender, age of the patients, ratio of the abdominoperineal extirpation versus anterior resection (APRE/AR) and the free margin of more than 3 cm proved to be irrelevant.
C1 [Hohn, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Varga, Laszlo] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Baradnay, Gellert] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Geczi, Tibor] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Nagy, Ferenc] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Molnar, Tamas] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Hohn, J (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 355
EP 359
PG 5
ER

PT J
AU Marton, J
   Rigo, B
   Farkas, Gy
AF Marton, Janos
   Rigo, Balazs
   Farkas, Gyula
TI Results of surgical treatment of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of this study was to assess the results of the treatment of (255) patients with pancreatic cancer in the Department of Surgery, University of Szeged, during the time period 1997-2001.  METHODS: The age, male/female ratio, postoperative morbidity and mortality were discussed. RESULTS: The resecability rate was 17.3% (44/255 patients). The mortality rate was 2.3% (1/44 patients) after radical operations and 12.1% (15/124 patients) after the palliative procedures. Localization and UICC staging after pancreatic tumors were analyzed.  CONCLUSIONS: In spite of the improvement of the new diagnostic methods, the proportion of patients undergoing radical surgery has not been increased in this period. Palliative surgical procedures are indicated in the case of advanced tumor stage. Choledochojejunostomy with Roux-Y loop offers the best results for the treatment of biliary obstruction. The role of endoscopic stenting is very questionable and the increased rate of postoperative biliary infections indicates that this procedure should be avoided in the preoperative treatment of patients who are suitable for potentially curative operation.
C1 [Marton, Janos] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Rigo, Balazs] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Farkas, Gyula] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Marton, J (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM g.marton@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 361
EP 365
PG 5
ER

PT J
AU Marton, J
   Simonka, Zs
   Lenart, Zs
   Petri, A
   Balogh, �
AF Marton, Janos
   Simonka, Zsolt
   Lenart, Zsuzsanna
   Petri, Andras
   Balogh, Adam
TI Surgical treatment of gastric cancer: new methods and longstanding difficulties
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The incidence of gastric carcinoma has been declining and the same tendency is observed in Hungary. The five-year survival rate has been improved due to the fewer postoperative deaths and the more radical operations (e.g. extended lymphadenectomies). METHODS: The authors analyzed the clinical data of 183 patients with gastric carcinoma. Age, sex, histology reports, TNM staging and the surgical interventions are presented. RESULTS: Potentially curative resection could be performed in about half of the patients (92/182). A large proportion of the patients belonged to the locally advanced cancer group (112/182). The ratio of the different TNM stages remained the same year by year in the investigated period despite the improving endoscopic facilities. CONCLUSION: Early diagnosis of gastric cancer is crucial and continuous effort should be made by the surgeons, the gastroenterologist and the general practitioners to identify high risk patients with the use of new, sensitive screening methods.
C1 [Marton, Janos] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Lenart, Zsuzsanna] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Petri, Andras] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Marton, J (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM g.marton@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 367
EP 371
PG 5
ER

PT J
AU Marton, J
   Varga, L
   Geczi, T
   Farkas, Gy
   Balogh, �
AF Marton, Janos
   Varga, Laszlo
   Geczi, Tibor
   Farkas, Gyula
   Balogh, Adam
TI Surgical and endoscopic management of bile duct cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB There is still considerable controversy regarding the value of surgical versus nonsurgical treatment for bile duct cancer. Therapeutic modalities vary from total hepatectomy and liver transplantation to percutaneous or endoscopic stent insertion. The aim of this study was to assess the results of the treatment of 118 patients presented with bile duct cancer in the Department of Surgery, University of Szeged, during the time period 1990-2002. METHODS: The age, male/female ratio, postoperative morbidity and mortality were analyzed.  RESULTS: The resecability rate was 18% (21/118). The mortality rate was 23.8% (5/21) after radical operations and 7% or 12.5% after the palliative procedures. 67 patients had palliative surgery following unsuccessful or recurrent jaundice after non-surgical palliation. The previously applied palliative methods have been transpapillary stenting, endoscopic pig-tail drainage, percutaneous transhepatic drainage or dilatation.  CONCLUSIONS: Palliative surgery for jaundice caused by extrahepatic bile duct cancer is justified in cases with an unsuccessful attempt for endoscopic stenting or occlusion of endoscopically placed endoprothesis. Bilio-enteric bypass with a Roux-Y jejunal loop is superior than external drainage respecting desicterisation, postoperative recovery, mortality, complication rate and quality of life.
C1 [Marton, Janos] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Varga, Laszlo] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Geczi, Tibor] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Farkas, Gyula] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Marton, J (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM g.marton@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 373
EP 379
PG 7
ER

PT J
AU Olah, T
   Poor, T
   Somodi, K
   Baradnay, Gy
   Halasz, T
AF Olah, Tibor
   Poor, Tamas
   Somodi, Krisztian
   Baradnay, Gyula
   Halasz, Tamas
TI The role of laparoscopy in the surgical treatment of colorectal cancer. Initial results.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors have carried out laparoscopically assisted abdomino-perineal rectal resections on a selected group of 8 patients during the past two years. The laparoscopic technique was not accompanied by any complications, while the patients enjoyed the benefits of the procedure. The bowel function of the patients were restored on the 2nd to 3rd day, the mean length of the hospital stay was 8.3 days. On the basis of their own favourable initial experience and recent literature data, the authors discuss the benefits, disadvantages and pitfalls of the laparoscopically assisted technique for surgical treatment of colorectal cancer. The problematics of oncological radicality is analysed.
C1 [Olah, Tibor] Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, Kalvaria sgt. 57., 6725 Szeged, Hungary.
   [Poor, Tamas] Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, Kalvaria sgt. 57., 6725 Szeged, Hungary.
   [Somodi, Krisztian] Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, Kalvaria sgt. 57., 6725 Szeged, Hungary.
   [Baradnay, Gyula] Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, Kalvaria sgt. 57., 6725 Szeged, Hungary.
   [Halasz, Tamas] Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, Kalvaria sgt. 57., 6725 Szeged, Hungary.
RP Olah, T (reprint author), Szeged Megyei Jogu Varos Onkormanyzat Korhaza, Sebeszeti Osztaly, 6725 Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 381
EP 383
PG 3
ER

PT J
AU Palotas, A
   Szentpali, K
   Paszt, A
   Balogh, �
   Lazar, Gy
AF Palotas, Andras
   Szentpali, Karoly
   Paszt, Attila
   Balogh, Adam
   Lazar, Gyorgy
TI Palliation of inoperable esophageal tumor with endoscopic intubation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB RATIONALE: Access to expensive equipment and costly self-expanding metal endoprostheses is limited in some regions where unresectable esophageal cancer is not infrequent. The aim of this study was to review the long-term results of palliation of malignant esophageal obstruction using low-priced conventional plastic stents. PATIENTS AND METHODS: 103 patients with dysphagia due to inoperable esophageal cancer underwent esophageal intubation under endoscopic control alone, without general anesthesia, by the pulsion method. Stents mounted on their delivery device were inserted over an endoscopically placed guide wire.  RESULTS: Improvement in swallowing was seen in 100%. Dysphagia scores have improved from 3.64+/-0.21 to 1.08+/-0.17. Major early procedure-related morbidity was low (0.6%), with 1 intramural perforation and no transmural perforation at all. Minimal mucosal bleeding was seen with 48 cases (46.6%). Procedure-related mortality was 0%. Late procedure-related complications requiring further endoscopic procedures occurred in 13.5% (tube occlusion: 8.7%, tube dislocation: 4.8%). Our 7 day mortality was 0% and 5 patients had died within 30 days, usually from the disease itself. Those surviving the procedure (>7 days) had a mean survival of 209 days.  CONCLUSION: Esophageal plastic stents can be accurately and safely placed under direct endoscopic control with lower costs. Therefore, endoscopic intubation remains a useful palliative treatment for patients with unresectable carcinoma of the esophagus.
C1 [Palotas, Andras] University of Szeged, Department of Surgery, Pecsi u. 4., 6721 Szeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of Surgery, Pecsi u. 4., 6721 Szeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of Surgery, Pecsi u. 4., 6721 Szeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6721 Szeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of Surgery, Pecsi u. 4., 6721 Szeged, Hungary.
RP Palotas, A (reprint author), University of Szeged, Department of Surgery, 6721 Szeged, Hungary.
EM palotas@nepsy.szote.u-szeged.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 385
EP 389
PG 5
ER

PT J
AU Petri, A
   Hohn, J
   Wolfard, A
   Laszlo Kokai, E
   Kocsis Savanya, G
   Boros, M
   Balogh, �
AF Petri, Andras
   Hohn, Jozsef
   Wolfard, Antal
   Laszlo Kokai, Erzsebet
   Kocsis Savanya, Gabor
   Boros, Mihaly
   Balogh, Adam
TI Surgery of benign liver tumors: indications for treatment. Personal experience and review of the literature.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB BACKROUND AND AIMS: Our aim is to give an audit of our experience over the past two decades in the form of a retrospective study.  PATIENTS / METHODS: Between 1 January, 1982 and 15 December, 2001, 133 patients with benign liver tumor (adenoma: 22, focal nodular hyperplasia: 27, hemangioma: 83, lipoma: 1) were treated. A total of 113 patients underwent surgery, while 20 asymptomatic cases were merely observed. The mean age, the female/male ratio and the size of the tumor in the adenoma cases were 38.3±10.2 years, 20/2 and 7.7±2.4 cm, while for focal nodular hyperplasia they were 39.5±12.4, 24/3 and 6.3±2.7 cm, and for hemangioma 49.01±10.7, 62/21 and 6.5±3.6 cm. The results were compared and analyzed statistically. RESULTS: Enucleation was performed in 53.1% of the patients, nonanatomical resection in 24.8%, segmentectomy in 6.2%, lobectomy in 4.4%, extended lobectomy in 1.8%, stitching in 5.3%, exploration in 3.5% and liver transplantation in 0.9%. The overall 30-day postoperative mortality was 0.9% (1/113). Minor or major complications occurred in a total of 27.4%. CONCLUSIONS: Patients with asymptomatic focal nodular hyperplasia or hemangiomas must be excluded from surgery. Surgery is indicated only when growth or severe complaints are observed. Adenomas must be resected because of the precancerous behavior and the danger of bleeding from a rupture.
C1 [Petri, Andras] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Wolfard, Antal] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Laszlo Kokai, Erzsebet] University of Szeged, Faculty of Dentistry, Department of Oral SurgerySzeged, Hungary.
   [Kocsis Savanya, Gabor] University of Szeged, Faculty of Dentistry, Department of Oral SurgerySzeged, Hungary.
   [Boros, Mihaly] Szegedi Egyetem, Altalanos Orvostudomanyi Kar, Kiserletes Sebeszeti IntezetSzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Petri, A (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM pa@surg.szote.u-szeged.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 391
EP 395
PG 5
ER

PT J
AU Szoke, T
   Trojan, I
   Furak, J
   Tiszlavicz, L
   Balogh, �
AF Szoke, Tamas
   Trojan, Imre
   Furak, Jozsef
   Tiszlavicz, Laszlo
   Balogh, Adam
TI Prognostic significance of intrapulmonary metastases in operated lung cancer cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: The aim of this retrospective study was to establish the prognosis in lung tumour cases in which resection was followed by synchronous or metachronous intrapulmonary metastasis.  METHODS: Between 1990 and 1999, 857 patients were operated on for primary lung cancer. Intrapulmonary metastases were observed in 21 patients. 11 cases were in stage III/B (on the basis of T4), and 10 were in stage IV (on the basis of M1). The histologic distribution of the primary tumours was 7 squamous cell carcinomas, 11 adenocarcinomas, 2 large cell carcinomas and 1 carcinoid. In 8 patients, histology demonstrated N1 or N2 lymph node metastasis. In 4 cases, there were more than one metastases. RESULTS: The 5-year survival was 21%, and the mean survival time (MST) was 29.5 months. For both the 5-year survival rate and MST, there was significant difference between the lymph node negative (N0) and lymph node positive (N1/N2) patients (N-: 30.7%, N+: 0%, p=0.017, MST: N-: 38.3 months, N+: 10.5 months, p=0.014), according to the stage (III/B: 30%, IV: 11.1%, p=0.025, III/B: 40.1 months, IV: 17.8 months, p=0.04) and the number of metastases (1 metastasis: 26.6%, more than 1 metastasis: 0%, p=0.036, 1 metastasis: 35.2 months, more than 1 metastasis: 8.5 months, p=0.045). No significant difference was detected on the basis of histological type, pleural, vascular and lymphatic invasion. In patients where 1 metastasis was found within one lobe and there were no lymph node metastases, the 5-year survival rate was 42.8% and MST was 49 months. The complication rate was 28.5% and the 30-day mortality was 4.7% (1 patient). Reoperation was performed in 1 case, for thoracic wall haematoma. CONCLUSION: Primary lung tumours giving intrapulmonary metastases, under certain conditions (lymph node negativity, 1 metastasis in the same lobe), can be operated on with good survival possibilities.
C1 [Szoke, Tamas] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Trojan, Imre] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Szoke, T (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM szoketamas@emil.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 397
EP 401
PG 5
ER

PT J
AU Zollei, I
   Gyori, A
   Wener, G
AF Zollei, Istvan
   Gyori, Attila
   Wener, Gabor
TI Improving results of the surgical treatment of rectal cancer in the Surgical Department of County Hospital, Szekszard
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors present that 247 elective rectal operations were performed between 1January, 1996 and 31 December, 2001 in their surgical department. The examined 6 years were divided into a 4-year and a 2-year period. 148 operations were performed in the first and 99 in the second period. Beside personal changes, methodical and technical modifications were introduced in the second period. Distribution of age and sex was similar, and the groups were comparable. The early postoperative mortality rate decreased from 9% to 4% during the examined time. Due to the double stapling technique, the rate of anterior rectal resections has icreased from 40% to 69%, and the rate of abdomino-perineal rectal extirpation has decreased from 43% to 23%. Considerable difference was found in the rate of palliative stomacreation operations, since the 16% decreased to 8% in the second period, so the quality of life of patients has improved. The operative time, the hospital stay of the patients and the rate of operations with blood transfusion decreased. The different types of postoperative infections decreased due to the new methods.
C1 [Zollei, Istvan] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, Beri Balogh Adam u. 5-7., 7100 Szekszard, Hungary.
   [Gyori, Attila] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, Beri Balogh Adam u. 5-7., 7100 Szekszard, Hungary.
   [Wener, Gabor] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, Beri Balogh Adam u. 5-7., 7100 Szekszard, Hungary.
RP Zollei, I (reprint author), Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, 7100 Szekszard, Hungary.
EM zollei@tmkorhaz.terrasoft.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2003
VL 47
IS 4
BP 403
EP 408
PG 6
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular mechanism of tumor progression. From Krompecher to the DNA microarray
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Rate limiting steps of the metastatic cascade are proliferation-independent cellular events integrated into the common sequence of tumor cell-extracellular matrix interactions (adhesion, degradation, migration). The two common dissemination forms, lymphatic and hematogenous, are highly similar in respect of the individual steps, but fundamentally different in respect of tissue specificity. Although the scheme of the metastatic cascade is well known for some time, its tumor type-specific molecular characteristics are poorly understood. This is based on the diversity in the matrix receptors and their alterations during tumor progression, in the mechanism of locomotion of various cancer cell types, and on the diversity and cancer specific alterations in the tyrosine kinome. Application of the techniques of global gene expression- and proteome-analyses for the comparative studies of non-metastatic, locally invasive and metastatic cancer types suggests that we can identify reliable progression markers and specific targets of tumor dissemination.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 3
EP 11
PG 9
ER

PT J
AU Otto, Sz
   Ferencz, A
AF Otto, Szabolcs
   Ferencz, Antal
TI Tumour markers in malignant diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors define the concept of ''tumour markers'' that indicate the presence of malignant diseases and describe their various stages of development. In addition, they demonstrate the classification, selection and clinical application of these markers. The theoretical and practical aspects of their clinical use are also discussed in terms of national and international expectations. Shortcomings in the clinical use of tumour markers in Hungary are touched upon and recommendations are offered for tumour marker development in this country.
C1 [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Ferencz, Antal] Orszagos Laboratoriumi IntezetBudapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM sz.otto@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 13
EP 20
PG 8
ER

PT J
AU Szekeres, Gy
AF Szekeres, Gyorgy
TI Are there new possibilities in immunomorphology?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Immunomorphology, including immunohistochemistry and immunocytochemistry, forms a category of well known, reproducible, cost- and environmentsaving immunodiagnostic methods based on immunological specificity. Both the accurate diagnosis and a better knowledge of biological parameters of diseases, especially of malignant tumors, result from the continual development of technologies and applications concerning at least 60 years of history of immunostaining. This review attempts to summarize the most important steps of development of immunomorphology.
C1 [Szekeres, Gyorgy] Hisztopatologia KFT, 7608 Pecs, Hungary.
RP Szekeres, Gy (reprint author), Hisztopatologia KFT, 7608 Pecs, Hungary.
EM histopat@mail.datanet.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 21
EP 25
PG 5
ER

PT J
AU Vincze, B
   Sinkovics, I
   Keresztes, S
   Gergye, M
   Boer, A
   Remenar, �
   Peter, I
   Szentirmay, Z
   Kremmer, T
   Kasler, M
AF Vincze, Borbala
   Sinkovics, Istvan
   Keresztes, Sandor
   Gergye, Maria
   Boer, Andras
   Remenar, Eva
   Peter, Ilona
   Szentirmay, Zoltan
   Kremmer, Tibor
   Kasler, Miklos
TI Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Serum thyroglobulin (Tg) is a suitable marker for differentiated thyroid carcinoma following total thyroid ablation. Between 1998 and 2003, serum samples from 715 papillary and 179 follicular tumor patients treated with total/nearly total thyroidectomy and radioiodine ablation therapy were collected. According to the ''Guidelines for Oncotherapy in Hungary'', serum Tg, antithyroglobulin antibody (TgAb), TSH and FT4 levels were measured in periods of 3 months following the first treatment and of 6 months after 2 years. In the present work the prognostic value of Tg and TgAb data of cancer patients with hormone substitution therapy were evaluated individually and retrospectively. Serum Tg and TgAb concentrations were measured with a highly sensitive immunoradiometric (IRMA) method, and with a second generation, broad epitope specificity competitive radioimmunoassay, respectively. TSH levels determined by fourth generation LIAISON(R) kit were in a range of 0.05-0.10 mIU/L. Accuracy of measuring of Tg <1 ng/ml made it possible to select the low cut-off level (Tg <2 ng/ml) following total thyroidectomy. In the predominant part of TSH-suppressed patients (746/774, 96%) the serum Tg concentration was below the cut-off level of 2 ng/ml. The sensitivity of Tg determination in 59 TSH-suppressed thyroid cancer patients with lung and bone metastases was as high as 86 to 100%. On the contrary, the number of false negative data was high in cases with lymph node metastases of papillary cancer, and sensitivity did not exceed 62%. Specificity and sensitivity of Tg in TgAb negative patients were 91 to 100%. Based on our results it could be concluded that measuring of Tg and TgAb, using a current IRMA method and a second generation RIA kit, proved to be effective tools for the postoperative monitoring of differentiated thyroid tumours. It has to be noted that determination of TgAb is highly recommended for the adequate interpretation of serum Tg levels. Persistently high and/or increasing serum TgAb concentration with low Tg result had a diagnostic value during the follow-up and can be connected with the recurrence or persistence of the differentiated thyroid cancer.
C1 [Vincze, Borbala] National Institute of Oncology, Department of Biochemistry, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Keresztes, Sandor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gergye, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kremmer, Tibor] National Institute of Oncology, Department of Biochemistry, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Vincze, B (reprint author), National Institute of Oncology, Department of Biochemistry, 1122 Budapest, Hungary.
EM vincze@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 27
EP 34
PG 8
ER

PT J
AU Sipos, J
AF Sipos, Jozsef
TI The pathogenesis of ulcerative colitis-associated colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The fact that there is an increase in cases of ulcerative colitis-associated dysplasia and colitic cancer raises some problems for clinical practice and pathological diagnosis. How to detect ulcerative colitis-associated dysplasia and early cancer endoscopically? How to discriminate inflammatory regenerative epithelium from UC-associated dysplasia and aberrant crypt foci histologically? How to distinguish dysplasia-associated lesion or mass from sporadic adenoma pathologically? UCAC has established risk factors including, among others, long duration of disease, large extent and low activity of disease, and the lack of adequate surveillance and therapy. Colonoscopic and histological evidence of low grade and high grade dysplasia means the possible evidence of coexisting carcinoma. Carcinoma typically may occur in the entire colon, is often multiple and has undifferentiated histology. Important factor is the effectiveness of dysplasia surveillance as a population based strategy to decrease colorectal cancer mortality in inflammatory bowel disease patients. Colitis-related cancer may have distinct pathogenesis to sporadic colorectal cancer.
C1 [Sipos, Jozsef] County Hospital of Zala, Department of Pathology, 8901 Zalaegerszeg, Hungary.
RP Sipos, J (reprint author), County Hospital of Zala, Department of Pathology, 8901 Zalaegerszeg, Hungary.
EM siposj.pat@zmkorhaz.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 35
EP 43
PG 9
ER

PT J
AU Sz. Nemeth, M
   Otto, Sz
AF Sz. Nemeth, Maria
   Otto, Szabolcs
TI Production and examination of double antigen specific immunoserum for immunochemical detection of occult blood
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: The authors have developed an immunochemical procedure and an immunisation method for the simultaneous detection of fecal hemoglobin and albumin to increase the screening effectiveness of colorectal cancers.  METHODS: In the human specific blood testing, bispecific immunoserum recognising two antigens have been produced by glutardyaldehyde-hemoglobin-albumin makromolecule immunisation of goats. The purified and concentrated antiserum with double antibody specifity has been checked in a screening group of 1196 individuals aged over 40 years with Fecatest reservoirs.  RESULTS AND CONCLUSIONS: The analytical sensitivity was proved 0.5 µg/ml for both proteins, which was greatly favourable for the screening. Furthermore, the intensity of the immunochemical reactions has grown, and it has increased the safety of the detection without decreasing the specificity. Because the number of the immunochemical tests that could be completed at the same time has been doubled (without excess of cost), this method has increased the effectiveness of the screening with taking care of expense.
C1 [Sz. Nemeth, Maria] National Institute of Oncology, Central Clinical Laboratory, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical Laboratory, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, Central Clinical Laboratory, 1122 Budapest, Hungary.
EM sz.otto@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 45
EP 47
PG 3
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI Function and prognostic significance of immune cells infiltrating human tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The presence of a mononuclear infiltrate has prognostic importance in a variety of human cancers. The infiltration by different cell types, mainly T lymphocytes and dendritic cells has been correlated to tumor size, stage, metastatization, and patients’ survival. Their pathophysiological role is influenced by the cell types, their localization (intra- or peritumoral), and by tumor characteristics or patient subgroups. The prognostic significance of the different cell populations in the individual tumor types is frequently controversial, which is due, in part, to their multiple functions; for example, tumorassociated macrophages are involved in the regulation of angiogenesis beside their immunologic functions. Moreover, the presence of immune cells in the tumor does not guarantee the development of an efficient immune reaction, consequently, the degree of infiltration does not necessarily correlate with the intensity of the immune response. Therefore, recent studies emphasize the importance of the assessment of the functional and activation state of tumor infiltrating lymphocytes. Here we summarize results on the prognostic role of infiltrating mononuclear cells in human neoplasms, and present our data on studies performed on cutaneous malignant melanoma.
C1 [Ladanyi, Andrea] National Institute of Oncology, Department of Tumor Progression, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
EM ladanyi@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 49
EP 56
PG 8
ER

PT J
AU Beczassy, E
   Otto, Sz
   Vamosi Nagy, I
AF Beczassy, Eniko
   Otto, Szabolcs
   Vamosi Nagy, Istvan
TI Role of tumour markers in monitoring and follow-up of colorectal cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors describe the significance of colorectal cancers in public health in Hungary and at international level. This is followed by the discussion of the latest aspects of patients’ monitoring and continual follow-up with special emphasis on its clinical significance. In addition to CEA, the most important tumour marker in the present clinical practice, the authors review other tumour markers that might be used in controlling cancer treatment and patients’ status. The estimation of treatment effectiveness should be combined with tumour marker level determinations at regular intervals because they are capable of demonstrating the dynamics of malignant processes and, if applied in adequate combinations, indicate the presence of a recurrence or metastasis. The integration of a ''tumour marker panel'' into the practice of follow-up may help early cancer detection and reduce health care expenses.
C1 [Beczassy, Eniko] National Institute of Oncology, Central Clinical Laboratory, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical Laboratory, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vamosi Nagy, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Beczassy, E (reprint author), National Institute of Oncology, Central Clinical Laboratory, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 57
EP 61
PG 5
ER

PT J
AU Peter, I
   Szamel, I
   Peley, G
AF Peter, Ilona
   Szamel, Iren
   Peley, Gabor
TI Expression of oestrogen receptor beta in invasive breast tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Steroid hormone receptors are used routinely to predict endocrine responsiveness in patients with breast cancer. Two oestrogen receptors (ERs): ER alpha and ER beta have been identified. Although ER alpha and ER beta genes share a large degree of homology, it is generally thought that their distribution and function are substantially different in many tissues. Both of them may be expressed in normal and neoplastic tissues of the breast. While much is known about ER alpha, the role of ER beta is still undefined, especially at the protein level. Recent development of reliable antibodies to ER beta has provided opportunity to test immunohistochemical reactions detecting ER beta in archival breast tumours. The aim of our study was to learn more about the cellular mechanisms underlying the relationship of ER beta and progesterone receptor (PR) in breast cancer tissues, discriminating between hormone-dependent and hormone-independent tumours. ER alpha and PR content of tumour tissues of 154 patients with breast cancer were tested by in situ indirect immunohistochemical method parallel with ligand binding biochemical assay. ER beta was detected in 8 ER alpha-/PR+ breast carcinomas by immunohistochemical method too. Steroid hormone receptor content was analysed comparing to the histologic type and grading of the tumours. Conclusions: A considerable part of breast carcinomas belongs to the ER+/PR+ and ER-/PR- groups. About 1-2% of the tumours is expected to be ER alpha-/ER beta+/PR+ type. In such cases ER alpha negative reaction together with PR positivity can signal the necessity of the immunohistochemical detection of ER beta in routine histopathological practice, presenting the precise steroid hormone receptor status for the most effective endocrine therapy of the patients.
C1 [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gyorgy u. 7-9.Budapest, Hungary.
   [Szamel, Iren] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Peley, Gabor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Peter, I (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
EM helena@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 63
EP 69
PG 7
ER

PT J
AU Banfalvi, T
   Gergye, M
   Beczassy, E
   Gilde, K
   Otto, Sz
AF Banfalvi, Teodora
   Gergye, Maria
   Beczassy, Eniko
   Gilde, Katalin
   Otto, Szabolcs
TI Role of S100B protein in neoplasms and other diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The S100 protein family constitutes the largest subgroup of the Ca binding proteins. To date 20 members of the family were discovered. S100 proteins regulate intracellular processes such as cell growth and motility, cell cycle regulation, transcription and differentiation. S100B protein is expressed constitutively by brain astrocytes. Serum S100B protein concentration in Stage II-III-IV melanoma is a reliable prognostic marker. The serum level of S100B protein is significant independent prognostic marker in respect to disease specific survival, it is a relevant marker for therapy monitoring and patient follow-up. It is recommended to determine the S100B expression pattern and intensity of the primary tumour of melanoma before therapy monitoring. Elevated S100B levels were published after head trauma, subarachnoidal haemorrhage and stroke. Furthermore, it indicates blood-brain barrier dysfunction. S100B protein was used to determine the cerebral damage after cardiovascular surgery as well.
C1 [Banfalvi, Teodora] National Institute of Oncology, Department of Dermatology, Rath Gyogy 7-9., 1122 Budapest, Hungary.
   [Gergye, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Beczassy, Eniko] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of Dermatology, Rath Gyogy 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
RP Banfalvi, T (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM banfalvi@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 71
EP 74
PG 4
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Activity of the National Oncology R&D Consorcia in 2003
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Consorcial projects focused on 5 cancer types, breast-, colorectal-, head and neck- and pediatric cancers, and malignant melanoma. Breast cancer studies revealed unique splicing mechanisms concerning BRCA1. In sporadic breast cancers the involvement of DNA-repair genes was proved to be dependent on the histological type. Bone-metastatic tumors have been characterized by decreased NM23 and increased c-met and p53 expressions. C-erbB2 genotype of the primary tumor was not maintained frequently in bone metastases. Application of DNA-microarray and quantitative PCR technologies improved the prediction of therapeutic sensitivity of breast cancers. Colorectal cancer studies revealed regional inhomogenities (clusters) in various geographical regions of Hungary, which were distinct in the case of colonic and rectal cancers. To increase the sensitivity of fecal blood test of colorectal cancer screening, a new double-antibody test was developed and tested in a large cohort of patients. Genetic analysis revealed that hypermethylation is a significant factor in microsatellite instability which, and plays a role in silencing of APC and E-cadherin genes as well. The Hungarian pattern of TS polymorphism was also determined and was correlated not only with the efficacy of 5-FU treatment but with the progression of the disease as well. Population-based studies have been carried out in head and neck cancer patients (HNC) and smokers as well to reveal the genetic background of increasing tumor incidence. These studies revealed polymorphism in XRCC1/3 methylation enzime gene which has preventive role. Other studies found frequent local immunosuppression in HNC patients. Studies indicated that the success of irradiation in this cancer type is dependent on the anti-vascular effects. Pediatric cancer studies determined the parameters of neuroblastoma screening based on VMA measurements. New splice variants of the WT1 gene involved in the monitoring of MRD of ALL patients was also described this year. We also obtained positive experimental data for the retinoic acid therapy of ALL. Melanoma studies extensively used DNA-microarray technology which identified 4 melanoma-specific and 2 melanoma progression-specific genes. In experimental human melanoma xenograft models we have identified 3 anti-metastatic agents: low molecular weight heparin, 2-methoxyestradiol and erythropoietin-?, where the later was characterized by specific effects on tumor vasculature.
C1 [Timar, Jozsef] Nemzeti Onkologiai Kutatas-fejlesztesi KonzorciumBudapest, Hungary.
RP Timar, J (reprint author), Nemzeti Onkologiai Kutatas-fejlesztesi Konzorcium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 75
EP 79
PG 5
ER

PT J
AU Agoston, P
   Major, T
   Somogyi, A
   Szucs, M
   Danczig, �
   Lovey, J
   Polgar, Cs
   Fodor, J
   Nemeth, Gy
   Kasler, M
AF Agoston, Peter
   Major, Tibor
   Somogyi, Andras
   Szucs, Miklos
   Danczig, Agnes
   Lovey, Jozsef
   Polgar, Csaba
   Fodor, Janos
   Nemeth, Gyorgy
   Kasler, Miklos
TI Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To describe the technique and early results of ultrasound (US)-guided interstitial prostate brachytherapy (BT) introduced at our institute.  MATERIALS AND METHODS: Between December 2001 and July 2002, ten patients with clinically localised, high risk prostate cancer were treated with external beam irradiation and high dose rate (HDR) BT boost at the Radiotherapy Department of National Institute of Oncology, Budapest. Using CT based treatment planning, 46 Gy was delivered to the whole pelvis and then the prostate and vesicles were treated up to a total dose of 60 Gy by conformal external beams. BT boost was given in the first four weeks of external irradiation. Nine patients were under total androgen blockade. The interstitial BT was performed in spinal anaesthesia. Steel needles were implanted into the prostate using transrectal US guidance. The Ir-192 HDR isotope was loaded into the needles by remote control after-loading equipment. Treatment planning was based on transversal ultrasound images. The target volume was the whole prostate. The median number of inserted needles was 9 (range: 5-13). The prescribed dose to the surface of the prostate was 8 or 10 Gy, and the maximum reference dose of the urethra or rectum was less than 125% and 80% of the prescribed dose, respectively. PSA (prostate specific antigen) levels and acute side effects were monitored and documented regularly.  RESULTS: The prescribed treatment was completed on all patients. The median follow-up time from the completion of the radiotherapy was 6 months (range: 2-11 months). Perioperative side effects (haematuria caused by puncture of the bladder) occurred in two cases. Acute grade 2 toxicity was observed in four patients: genitourinal inflammation in 4, and proctitis in 2 cases. No PSA relapse occurred so far.  CONCLUSION: In our study we described our technique of interstitial BT boost as a part of prostate radiotherapy used for the first time in Hungary. The US based treatment planning resulted in adequate dose distribution in all cases. Incidence of perioperative and acute side effects were comparable to data known from the literature. Appropriate technical background and well organised team work are needed to ensure the good quality of the treatment.
C1 [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Danczig, Agnes] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM agostonp@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 81
EP 88
PG 8
ER

PT J
AU Arvai, K
   Toth, J
   Nemeth, T
   Kiss, Cs
   Molnar, P
   Olah, �
AF Arvai, Krisztina
   Toth, Judit
   Nemeth, Tamas
   Kiss, Csongor
   Molnar, Peter
   Olah, Eva
TI Cervical neuroblastoma in an infant
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The case of a one-month-old patient admitted to the Department of Pediatrics (Medical and Health Science Center, Debrecen University) because of respiratory distress caused by a cervical mass compressing the upper respiratory pathways is presented. The mass could only be partially removed, the histological diagnosis proved to be neuroblastoma (SBCT: ”small blue cell tumor”). Despite the fact that the DNA index of tumor cells (ploidy measurements) and the age of the patient suggested a favourable prognosis, the tumor continued to grow and metastases appeared. Because of symptoms of compression exerted on the respiratory system by the tumor, chemotherapy had to be applied. Since a standard OPEC/OJEC chemotherapeutic protocol proved to be not entirely effective and a residual tumor was still present, retinoic acid and interferon treatment was introduced. Presently, 4 years after the diagnosis, the patient is in complete remission and can be considered to be cured. The case presented here demonstrates that despite the favorable prognosis of the majority of infant neuroblastomas, in some cases the anatomic location of the tumor, leading to disturbance of vital functions, may serve as indication of chemotherapy. Our experience also proved the efficacy of retinoic acid and interferon treatment in relapsed neuroblastoma.
C1 [Arvai, Krisztina] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Toth, Judit] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Nemeth, Tamas] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Molnar, Peter] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Olah, Eva] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
RP Arvai, K (reprint author), Medical and Health Science Center, University of Debrecen, Department of Pediatrics, 4012 Debrecen, Hungary.
EM arvai.k@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 89
EP 95
PG 7
ER

PT J
AU Pulay, T
   Csomor, S
   Faluhelyi, Zs
   Hernadi, Z
   Krommer, K
   Mayer, �
   Szantho, A
   Szanto, I
   Thurzo, L
AF Pulay, Tamas
   Csomor, Sandor
   Faluhelyi, Zsolt
   Hernadi, Zoltan
   Krommer, Karoly
   Mayer, Arpad
   Szantho, Andras
   Szanto, Istvan
   Thurzo, Laszlo
TI Role of Caelyx in second line treatment of ovarian cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.2 years (35-80). The average time to progression was 3.8 months (1-8). The effects of the therapy were assessed on 36 patients and the results were 3 CR, 8 PR, 7 SD and 18 PD. Summarised the Caelyx therapy caused improvement in 30.55% of the patients and stabilisation in 19.44%. Supportive therapy was needed in 8 cases.
C1 [Pulay, Tamas] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Csomor, Sandor] Semmelweis University, 2nd Department of Obstetrics and GynecologyBudapest, Hungary.
   [Faluhelyi, Zsolt] Baranya County Hospital, Department of OncologyPecs, Hungary.
   [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Krommer, Karoly] University of Pecs, Department of OncologyPecs, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Szanto, Istvan] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Pulay, T (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2004
VL 48
IS 1
BP 97
EP 99
PG 3
ER

PT J
AU Boncz, I
   Sebestyen, A
   Dozsa, Cs
   Pal, M
   Sandor, J
   Palasti, J
   Betlehem, J
   Ember, I
AF Boncz, Imre
   Sebestyen, Andor
   Dozsa, Csaba
   Pal, Miklos
   Sandor, Janos
   Palasti, Judit
   Betlehem, Jozsef
   Ember, Istvan
TI Health economics analysis of colorectal screening
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: To assess the screening rate, the cost of screening and treatment, and to calculate the expected epidemiological and economic gain and cost-effectiveness of mass-screening programme.  METHODS: The data derive from the financial database of the National Health Insurance Fund of Hungary from 2001. The cost of treatment includes the cost of outpatient care, the acute and chronic inpatient care, the subsidies of medicines’ prices and the expenditure on disability to work (including sickness-pay). The expected benefits of the screening programme were modeled with different screening strategy and mortality decrease for a 10 years interval.  RESULTS: The cost of treatment of colorectal cancer was around 9.98 billion Hungarian forints (34 817 250 USD, 38 871 666 EUR) in 2001. In the age-group 45-65 with 10% mortality decline 718 lives (net present value, NPV: 515), with 20% mortality decline 1462 (NPV: 1050) lives can be saved during a 10 years screening programme. The cost of one life saved varies between 4.0 million Hungarian forints (13968 USD, 15595 EUR)/life saved and 16.3 million Hungarian forints (56.952 USD, 63.584 EURO)/life saved according to the mortality decline and screening strategy. The cost of one life year saved varies between 307 909 Hungarian forints (1074 USD, 1200 EUR)/life year saved and 1.25 million Hungarian forints (4381 USD, 4891 EUR)/life years saved.  CONCLUSION: The implementation of organized colorectal screening can lead to cost saving in Hungary. The cost-effectiveness of colorectal screening seems to be acceptable for purchaser, but many methodological and organizational issues should be discussed in details.
C1 [Boncz, Imre] Pecs University, Faculty of Health Sciences, Department of DiagnosticPecs, Hungary.
   [Sebestyen, Andor] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Dozsa, Csaba] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Pal, Miklos] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Sandor, Janos] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Palasti, Judit] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Betlehem, Jozsef] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Boncz, I (reprint author), Pecs University, Faculty of Health Sciences, Department of Diagnostic, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 111
EP 115
PG 5
ER

PT J
AU Tompa, A
AF Tompa, Anna
TI Predictive value of human genotoxicological biomarkers in the primary prevention of chronic non-infectious diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB The main goal of biomarker research in the frame of primary prevention of chronic diseases is the prevention of appearance of clinical symptoms by an early recognition of the process leading to the symptoms. By the use of well-established biomarkers one can detect such tendencies finally leading to the manifestation of the disease far before the progress turns irreversible. As several parameters play role in such processes, the estimation of biological changes with the help of biomarkers is a precise and relatively simple means of the prevention. Indications of intervention in order to prevent the manifestation of a disease are rather determined by the nature but not the number of alterations. The use of genetic screening and monitoring by adequate biomarkers provide us with a new opportunity to measure such qualitative changes rather than the quantitative ones, ensuring a great improvement to the previous methods. The use of qualitative parameters as a routine method instead of the classic quantitative measures might represent a challenge for current prevention policies in Europe to approach health problems and safety at work. When the biomarkers give positive results that means a high probability to be at risk but not yet the manifestation of a certain illness. This stage may be relevant to the early onset of certain pathological processes, but it does not necessarily turn to a performed disease. In consequence a so-called positive result might cause unnecessary disturbances for the probands leading to ethical issues of risk communication. The monitoring system, however, should find acceptable communication strategies for the high-risk conditions detected by the well-established biomarkers.
C1 [Tompa, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Nagyvarad ter 2., 1450 Budapest, Hungary.
RP Tompa, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, 1450 Budapest, Hungary.
EM tompa.okbi@okk.antsz.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 117
EP 120
PG 4
ER

PT J
AU Koteles, Gy
   Bognar, G
   Dam, A
   Kerekes, A
   Thuroczy, Gy
AF Koteles, Gyorgy
   Bognar, Gabriella
   Dam, Annamaria
   Kerekes, Andor
   Thuroczy, Gyorgy
TI Cellular biology and public health
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Within the framework of the National Research and Development Program No. 1/016 /2001 the authors determined the population levels of ionizing and nonionizing radiations, elaborated the system of assays for detection of biological effects including dose-effect relationships, studied the roles of protective and sensitizing factors in the effect modification. The radium content of building materials were determined as well as the indoor radon activity concentrations and the magnetic induction fields around household equipment operating with 50 Hz. Biological dosimetry techniques were categorized according to the indication time. In addition, radiation sensitivity of intracellular antioxidant enzymes and the antioxidant capacity of blood sera were measured.
C1 [Koteles, Gyorgy] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
   [Bognar, Gabriella] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
   [Dam, Annamaria] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
   [Kerekes, Andor] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
   [Thuroczy, Gyorgy] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
RP Koteles, Gy (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1775 Budapest, Hungary.
EM radbiol@hp.osski.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 121
EP 125
PG 5
ER

PT J
AU Major, J
   Jakab, M
   Biro, A
   Klupp, T
   Magyar, B
   Gal, K
   Olah, G
   Fodor, Z
   Tompa, A
AF Major, Jeno
   Jakab, Matyas
   Biro, Anna
   Klupp, Tibor
   Magyar, Balazs
   Gal, Katalin
   Olah, Gabor
   Fodor, Zoltan
   Tompa, Anna
TI Biomarker indicators of chemoprevention among subjects occupationally exposed to metals
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Chemoprevention with chelating agent Humetta® for three months was performed, due to anaemia and other haematologic disorders, immunotoxicological alterations and/or increased chromosome aberration rate among galvanisers and goldsmiths occupationally exposed to precious and heavy metals. Twenty-two of altogether 47 subjects took part voluntarily in the chemoprevention, and the rest of the subjects served as untreated controls. Complex clinical laboratory testing including detailed anamneses; genotoxicological and immunotoxicological monitoring were performed before and after administration of chemopreventive agent. After chemoprevention a significant improvement was observed in anaemia and serum glucose levels, while a less marked improvement was found in serum cholesterol levels and liver functions. Altered chromosome aberration and apoptotic cell fraction also tended to normalise after treatment. Immunological parameters were not affected by the treatment. The obtained results may suggest that chemoprevention with chelating agents as Humetta® can help in the prevention of harmful effects of occupational exposures to metals.
C1 [Major, Jeno] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Jakab, Matyas] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Biro, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Klupp, Tibor] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Magyar, Balazs] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Gal, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Olah, Gabor] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Fodor, Zoltan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Tompa, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
RP Major, J (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
EM majorj.okbi@okk.antsz.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 125
EP 129
PG 5
ER

PT J
AU Lugasi, A
   Hovari, J
   Biro, L
   Brandt, S
   Helyes, L
AF Lugasi, Andrea
   Hovari, Judit
   Biro, Lajos
   Brandt, Sara
   Helyes, Lajos
TI Factors influencing lycopene content of foods, and lycopene intake of Hungarian population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Lycopene is an acyclic, biologically active carotenoid that constitutes foods, its preventive role in several cancerous diseases have been proved by epidemiological and experimental data. Its beneficial role in maintenance of human health is related to its significant antioxidant properties. Data of dietary lycopene intake of the Hungarian population is not available. The aims of the present complex study were 1) to measure the lycopene content of foods frequently consumed in Hungary, 2) to investigate the effect of agrotechnological procedures and food processing on lycopene content of tomatoes, 3) to estimate the lycopene intake in two groups of the Hungarian population with the use of a three-day dietary record. The best lycopene sources are the raw (5.0-16.0 mg/100 g) and processed tomatoes and tomato products (3.0-80.0 mg/100 g), and also watermelon (3.6-6.2 mg/100 g). The variety of the plants, the growing circumstances, and the weather conditions significantly influence the lycopene content of freshly consumed and processed tomato fruits. Mild technological processes can preserve a considerable amount of the original lycopene content in tomato. The estimated average dietary intakes of the Hungarian children (n=521) and adults (n=205) were 2.98 +/- 4.71 mg/day/capita, and 4.24 +/- 8.47 mg/day/capita, respectively. Optimal climate conditions of Hungary makes possible to produce tomato fruits with high dietary value including significant amount of health protective lycopene. Increased consumption of tomato and tomato products with high concentration of lycopene may improve the antioxidant capacity of human body, and the risk of several cancerous diseases may be reduced.
C1 [Lugasi, Andrea] National Institute of Food and Nutrition Science, Gyali ut 3/a, 1097 Budapest, Hungary.
   [Hovari, Judit] National Institute of Food and Nutrition Science, Gyali ut 3/a, 1097 Budapest, Hungary.
   [Biro, Lajos] National Institute of Food and Nutrition Science, Gyali ut 3/a, 1097 Budapest, Hungary.
   [Brandt, Sara] Szt. Istvan University, Biotechnics DepartmentGodollo, Hungary.
   [Helyes, Lajos] Szt. Istvan University, Biotechnics DepartmentGodollo, Hungary.
RP Lugasi, A (reprint author), National Institute of Food and Nutrition Science, 1097 Budapest, Hungary.
EM h4550tot@ella.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 131
EP 136
PG 7
ER

PT J
AU Biro, A
   Pallinger, �
   Falus, A
   Tompa, A
AF Biro, Anna
   Pallinger, Eva
   Falus, Andras
   Tompa, Anna
TI Characterization of chemically exposed groups by immunotoxicological methods
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB At the National Institute of Chemical Safety we have surveyed the immunological status of donors from the oil industry, health services, and metallurgy exposed to different immunotoxic compounds. Their data were compared to those of healthy, non-exposed controls. Our aim was to study the relationship between immunotoxic exposure and immune function, and to establish a system of immunological parameters by which chemical exposure can be specifically monitored. Subpopulations and activation of lymphocytes was measured by flow cytometry, using immunephenotyping of peripheral blood lymphocytes. In the groups exposed to immunotoxic compounds we found an increase in helper, and a decrease in cytotoxic T lymphocytes, leading to a shift in Th/Tc ratios. These phenomena are not substance specific, but relate to chemical exposure. The lymphocytes of exposed groups showed a higher proportion of activated cells, but there was a difference in the expressed activation markers. Our results suggest that characterizing lymphocyte subpopulations and activation markers on PBL of donors is a useful tool in tracking environmental immunotoxic effects.
C1 [Biro, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Pallinger, Eva] MTA-SE, Molekularis Immunologiai Kutato CsoportBudapest, Hungary.
   [Falus, Andras] MTA-SE, Molekularis Immunologiai Kutato CsoportBudapest, Hungary.
   [Tompa, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
RP Biro, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
EM biro.okbi@okk.antsz.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 137
EP 139
PG 3
ER

PT J
AU Mayer, �
   Nemeskeri, Cs
   Poti, Zs
AF Mayer, Arpad
   Nemeskeri, Csaba
   Poti, Zsuzsa
TI Evaluation of high-dose-rate brachytherapy of the preoperative treatment of stage IB (FIGO) cervical carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: Examination of stage IB (FIGO) cervical cancer patients treated with preoperative high dose rate brachytherapy (HDR BT) on the basis of specimen histology, local control and disease-free survival. MATERIAL AND METHOD: Patients with stage IB cervical cancer were treated between 01/01/1993 and 31/1/1997 as part of complex treatment with HDR BT, the dose calculated for point A 2x5.5 Gy, with one week interval in the Municipal Centre of Oncoradiology, Uzsoki Hospital, Budapest. Different types of surgery were carried out in general within two weeks after preoperative HDR BT. Depending on the specimen histology, postoperative radiation treatment varied. In case of residual tumor vaginal BT 2x5.5 Gy was applied within a week; the dose was relevant to a tissue depth of 5 mm and to the upper third of vagina. This was followed by percutan irradiation (telecobalt, linear accelerator) at a dose of 50 Gy, box technique. In certain cases the paraaortal region was simultanously irradiated. In case of negative specimen no postoperative vaginal HDR BT was applied in the majority of patients. Retrospective analysis helped to determine the effectiveness of regularly followed patients, as for local control and metastasis on the basis of the time of development of dissemination, respectively.  RESULT: 33.4% of 153 preoperatively treated patients had tumor-free specimen. Regular follow-up (at least 5 years) showed local relapse in 17 patients (11%), dissemination in 13 patients (8.4%), and 4 among them (2.6%) had simultaneous local relapse.  CONCLUSION: On the basis of our data it can be stated that preoperative HDR BT in stage IB cervical carcinoma decreased local relapse. In spite of negative specimen histology, vaginal HDR BT can be suggested, but if there is residual tumor, both HDR BT and percutan irradiation is suggested on the basis of our data.
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM mayera@elender.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 141
EP 144
PG 4
ER

PT J
AU Nagy, B
   Molnar, J
   Rovo, L
   Paczona, R
   Thurzo, L
AF Nagy, Beatrix
   Molnar, Jozsef
   Rovo, Laszlo
   Paczona, Robert
   Thurzo, Laszlo
TI Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB A previous preclinical study revealed that the maximal additive effect between chemotherapy (CT) and irradiation (RT) occurred at a low level of CT. Therapy was therefore designed with an oral drug daily given in combination with RT in order to determine the efficacy and toxicity. Locoregionally advanced head and neck tumor patients were treated with simultaneous RT and CT. RT was administered 5 times per week at 2 Gy per fraction in a total dose of 70 Gy. Throughout the treatment 30 mg/kg Tegafur was given daily orally. In the period between 2000 and 2002, 50 patients were enrolled. Complete remission was attained in 60%, with an overall response rate of 94%. Acute mucositis of grade 2 or 3 was observed in 56% (28 patients), and gastrointestinal and hematologic toxicity of grade 2 or 3 occurred in 8% (4 patients). Because of side-effects, the duration of treatment was at most 2 weeks longer. Toxicity was eliminated quickly by careful supportive therapy. In conclusion, it is considered that oral low-dose CT in combination with RT is an efficient and simple mode of treatment for locally advanced head and neck tumor patients with a poor prognosis.
C1 [Nagy, Beatrix] University of Szeged, Department of Oncotherapy, Megyei Jogu Varosi Onkormanyzat Korhaza, Kalvaria sugarut 57., 6725 Szeged, Hungary.
   [Molnar, Jozsef] University of Szeged, Albert Szent-Gyorgyi Clinical Centre, Institute of Clinical MicrobiologySzeged, Hungary.
   [Rovo, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Paczona, Robert] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of Oncotherapy, Megyei Jogu Varosi Onkormanyzat Korhaza, Kalvaria sugarut 57., 6725 Szeged, Hungary.
RP Nagy, B (reprint author), University of Szeged, Department of Oncotherapy, 6725 Szeged, Hungary.
EM nbeatrix@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 145
EP 149
PG 5
ER

PT J
AU Patonay, P
   Naszaly, A
   Mayer, �
AF Patonay, Peter
   Naszaly, Attila
   Mayer, Arpad
TI The radiochemotherapy of the oesophageal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: To prove the efficacy of the simultaneous radio-chemotherapy of the inoperable or irresectable esophageal cancer.  METHODS: Twenty-nine patients with inoperable or irresectable oesophageal cancer were treated betwen January 1995 and December 2002. The therapy was started with intraluminal HDR AL irradiation for the recanalisation of the esophagus (8 Gy at 0.5 cm depth, repeated two-three times, with one-week interval), followed by percutan megavolt irradiation one week after the last HDR AL session (50 Gy total dose, 5x2 Gy/week fractions for 5 weeks). The chemotherapy was started simultanously with the percutan megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, with four-week intervals).  RESULTS: The swallow function has been improved in 16/29 patients, it remained unchanged in 10/29 and got worse in 3/29 patients (1 and 3 Units), respectively. Remission: complete 9/29 patients, partial 17/29 patients. Side effects: Esophagitis of different degree occurred in all patients, consecutive transitory dysphagia developed in 8/29 patients, leucopenia after the chemotherapy in 2/29 patients, tracheo-esophageal fistula in 3/29 patients. Follow-up time: average 12.2 months (3-55 months). The duration of the swallow function improvement: average 10.7 months (2-55 months).  CONCLUSION: The initial results refer to the favourable effect of the palliative radio-chemotherapy of the inoperable esophageal cancer.
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29., 1145 Budapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29., 1145 Budapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29., 1145 Budapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 151
EP 156
PG 6
ER

PT J
AU Illes, �
AF Illes, Arpad
TI Treating Hodgkin's disease: for whom the more means better?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB During the last half century, our knowledge and expertise increased, and Hodgkin's disease became one of the most curable malignant diseases. However, our results are still not satisfactory in the case of advanced stage. Apart from standard chemotherapy regimens, several other, so-called intensive first line therapy schedules have been tried, whose common characteristic is that more antineoplastic drugs within a reasonably shorter period and sometimes with increased dose had been administered. Out of these regimens, escalated dose BEACOPP (bleomycin, etoposid, adriamycin, cyclophosphamid, vincristin, procarbazin, prednisolon), the therapy yielding the best results and inciting hot debates in the literature is discussed here in detail. Though many questions related to BEACOPP scheme are still unanswered and at present it is not recommended for use in first line therapy except for trials, it seems that patients under 60 years of age, with advanced stage disease having poor prognosis, may benefit from this treatment.
C1 [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
RP Illes, � (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4004 Debrecen, Hungary.
EM illes@iiibel.dote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 157
EP 161
PG 5
ER

PT J
AU Lehoczky, O
AF Lehoczky, Otto
TI Pure red-cell anemia due to recombinant human erythropoietin and its status in the oncological practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB A special form of anemia was observed during the treatment with recombinant human erythropoietin having been applied for more than 15 years. The pure red-cell anemia due to antibodies against erythropoietin was described in chronic renal failure patients. Since oncological patients are also treated with rhuEPO it is interesting to know whether this side effect could be observed in the patients with solid tumors as well. It should be considered in tumorous patients when coexistence of antibodies against rhuEPO with pure red-cell aplasia is demonstrated, and its other causes as immunological disease, thymoma, viral infections (eg. Parvovirus B12, Hepatitis B or C) are exluded. The author collected literature data and found the absence of reports on this side effect in cases of treatment with rhuEPO in cancer patients. The rhuEPO treatment is a safe method for the cure of cancer anemia as antibodies against rhuEPO have not been shown together with PRCA among cancer patients. The possible explanation could be the shorter application time in cancer compared to the chronic renal failure patients. The side effect observed in chronic renal failure patients calls the attention to the precise compliance with the instructions of the manufacturers.
C1 [Lehoczky, Otto] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Lehoczky, O (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 163
EP 166
PG 4
ER

PT J
AU Godeny, M
   Kasler, M
AF Godeny, Maria
   Kasler, Miklos
TI Diagnostic imaging of cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
AB Rapid development of imaging techniques provided much more precise methodology of diagnosis, staging and dynamics of cancer. Nowadays the onco-radiodiagnostic units are able to select the optimal imaging technique based on established international protocols. These protocols provide the basis of cancer diagnosis, therapy control and clinical research. The onco-radiodiagnostic unit is essential part of the oncoteam managing the cancer patients. Follow-up protocols are now equally important compared to those of the diagnosis and staging, requiring a continuous interaction between radiologists and physicians. The comprehensive cancer centers with all the necessary imaging techniques are the optimal organizations where professional and economic priorities both can be considered for the benefit of cancer patients.
C1 [Godeny, Maria] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM godeny.maria@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 167
EP 190
PG 24
ER

PT J
AU Kocsis, J
AF Kocsis, Judit
TI European School of Oncology Spring Masterclass in Clinical Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 191
EP 191
PG 1
ER

PT J
AU Sugarterapias es Onkologiai, SzK
   Anaesthesiologiai es, ISzK
   Sebeszeti, SzK
AF Sugarterapias es Onkologiai, Szakmai Kollegium
   Anaesthesiologiai es, Intenzivterapias Szakmai Kollegium
   Sebeszeti, Szakmai Kollegium
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
C1 [Sugarterapias es Onkologiai, Szakmai Kollegium] National Institute of Oncology, Rath Gyorgy u. 7-9., 1022 Budapest, Hungary.
   [Anaesthesiologiai es, Intenzivterapias Szakmai Kollegium] National Institute of Oncology, Rath Gyorgy u. 7-9., 1022 Budapest, Hungary.
   [Sebeszeti, Szakmai Kollegium] National Institute of Oncology, Rath Gyorgy u. 7-9., 1022 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD AUG
PY 2004
VL 48
IS 2
BP 193
EP 196
PG 4
ER

PT J
AU Schoket, B
AF Schoket, Bernadette
TI The role of DNA adducts in smoking-related carcinogenesis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Epidemiological studies indicate a close association between smoking and cancer. Biological activity of many chemical carcinogens and of their metabolites is induced by covalent binding of their reactive derivatives to DNA, which consequently causes mutations in critical genes. Carcinogen-DNA adducts formed by exposure to tobacco smoke have a key role in the initiation of various types of cancer including lung cancer. Presence of tobacco smoke-related carcinogen-DNA adducts in various tissues of smokers proves the DNA damaging effect of smoking. DNA adducts are important biomarkers for the biomonitoring of human genotoxic exposures to tobacco smoke. The paper gives a short overview on the role of smoking-related DNA adducts in carcinogenesis.
C1 [Schoket, Bernadette] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Gyali ut 2-6., 1097 Budapest, Hungary.
RP Schoket, B (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, 1097 Budapest, Hungary.
EM schoketb@okk.antsz.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 201
EP 205
PG 5
ER

PT J
AU Kovalszky, I
   Dudas, J
   Gallai, M
   Hollosi, P
   Tatrai, P
   Tatrai, E
   Schaff, Zs
AF Kovalszky, Ilona
   Dudas, Jozsef
   Gallai, Monika
   Hollosi, Peter
   Tatrai, Peter
   Tatrai, Eniko
   Schaff, Zsuzsa
TI Proteoglycans in the liver
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Proteoglycans are macromolecules formed by a protein core to which sugar chains are covalently attached. They are present on the cell surface and in the ECM of living things. In normal liver syndecan-1 is the dominant transmembrane proteoglycan, trace amounts of ECM proteoglycans are in the stromal components. The amounts of proteoglycans we studied increase in liver cirrhosis. In liver cancer abnormal localization of syndecan-1 and stroma rich in agrin was characteristic. The core proteins as well as the sugar chains of proteoglycans interact with and modulate the effect of regulatory factors. This implies that structural alterations of proteoglycans contribute to the development of malignant phenotype. Heparan sulfate chains of liver cancer are undersulfated with decreased or altered biological activity. Their binding capacity for transcription factor decreases, and they do not inhibit topoisomerase I enzyme. Truncated form of syndecan-1 lacking the extracellular domain of the molecule induces differentiation of hepatoma cell line and inhibits the shedding of syndecan-1. This phenomenon calls attention to the importance of syndecan-1 shedding in the regulation of cell behavior.
C1 [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Dudas, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Gallai, Monika] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Hollosi, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Tatrai, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Tatrai, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kovalszky, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM koval@korb1.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 207
EP 213
PG 7
ER

PT J
AU Szende, B
AF Szende, Bela
TI The occurrence and significance of apoptosis in tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Decreased apoptotic activity in precancerous lesions and in malignant tumors has largely been prejudiced. Results of studies performed in the last years showed that this suggestion is correct only in certain types of tumors. Data have been revealed on higher apoptotic activity in poorly differentiated tumors, whereas in well-differentiated neoplasms this activity is relatively low. At the same time, cytostatic or hormonal treatment of well-differentiated tumors result in a considerable elevation of the apoptotic index. The author considers the inducibility of apoptosis as a predictive factor regarding the efficacy of therapy in case of prostate carcinoma, colon carcinoma and acute lymphoid leukemia. This statement is less applicable to breast cancer or mesopharyngeal carcinoma. Very low apoptotic activity was observed in neuroblastomas, follicular adenomas, as well as follicular and papillary carcinomas of the thyroid gland, and adenomas of the parathyroid gland. Expression of genes influencing apoptosis, such as bcl2, p53, and bax, may rather be of importance from the point of view of histological differential diagnosis.
C1 [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulooi ut 26., 1085 Budapest, Hungary.
RP Szende, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bszende@korb1.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 215
EP 219
PG 5
ER

PT J
AU Otvos, L
   Sagi, Gy
AF Otvos, Laszlo
   Sagi, Gyula
TI Antisense oligonucleotides with antitumor activity
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Antisense oligonucleotides (AONs) provide an efficient approach for developing target-selective anticancer drugs, because they can inhibit gene expression sequence specifically. To improve the therapeutic effenciency of AONs, two new types of the compounds have been developed. The first group of antisense oligodeoxynucleotides investigated contains base modified nucleotide units. Incorporation of 5-substituted pyrimidines into AONs increases cell membrane permeability (a), duplex stability (b), and nuclease resistance (c). These properties were studied using a large number of model oligonucleotides. The application of 5-(1-hexynyl)dU has been found to be the best modification. Application of MMP-9 collagenase inhibitor oligonucleotides (potential metastasis inhibitors) containing these nucleotide units instead of thymidines increased the collagenase inhibition potency by one order of magnitude compared to that of parental oligonucleotide including thymine bases. The second group of the compounds investigated represents a new type of antisense oligonucleotide synthesized by the antisense directed prodrug therapy (ADPT) conception. According to this principle, a telomerase inhibitor AON was conjugated with 5-fluoro-2'-deoxyuridine (FdU) and oligo-FdUs by phosphodiester bond at the 3’-terminus. The antitumor activities of conjugates in comparison with that of FdU were tested in HT1080 human fibrosarcoma and HT29 human colon adenocarcinoma cell lines. In HT29 cell culture the antiproliferative activity of prodrugs significantly increased with increasing length of the 3’-(FdU)n tail. The conjugate with one FdU unit was about 5 times, while the AON-(FdU)3 analogue was almost 19 times more active than FdU. Antitumor activity of the prodrug containing six FdU units was extremely high (relative efficiency = 26.6), therefore, in vivo testing of this analogue seems to be reasonable and promising. Antiproliferative activity of (FdU)n conjugated with a telomerase inhibitor increased by 5-13 times in HT1080 cells as compared to FdU administered in nucleoside form.
C1 [Otvos, Laszlo] MTA Kemiai Kutatokozpont, Pusztaszeri ut 59-67., 1025 Budapest, Hungary.
   [Sagi, Gyula] MTA Kemiai Kutatokozpont, Pusztaszeri ut 59-67., 1025 Budapest, Hungary.
RP Otvos, L (reprint author), MTA Kemiai Kutatokozpont, 1025 Budapest, Hungary.
EM otvos@chemres.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 221
EP 227
PG 7
ER

PT J
AU Staub, M
AF Staub, Maria
TI The special function of deoxycytidine kinase (dCK) in the activation of chemotherapeutic nucloside analogs and in inhibition of cell proliferation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Deoxycytidine kinase (dCK) plays a central role in the deoxynucleoside salvage processes, phosphorylating dC, dA, and dG to their monophosphates. In mammalian cells, the major source of dTTP comes also from dC via dCMP deaminase. Moreover, based on its broad substrate specificity, this enzyme is responsible for the activation of several nucleoside analogues of therapeutical importance, influencing the sensitivity of malignant tissues towards chemotherapy. The expression of dCK is highest in different lymphoid cells/tissues, in embryonic cells and in most malignant cells (2, 7, 13-15, 18). The activity of dCK is not cell cycle-regulated. In contrast to this, dCK activity was found to be elevated several fold upon short-term treatments of normal human lymphocytes with therapeutic nucleoside anlogues, and other genotoxic agents as well as by DNA damaging agents including the DNA polymerase inhibitor aphidicolin, the topoisomerase II inhibitor etoposide and ?-irradiation, which might be a potentially important phenomenon with respect to the clinical practice, too. These findings indicated that the main trigger of activation could be the damaged DNA itself, and the biological relevance might be to supply the dNTPs for the enhanced DNA repair. Activation of dCK was paralleled by elevated levels of intracellular dATP, raising the possibility that dCK activation is linked to the induction of apoptosis. With regard to the mechanism of enzyme activation, no changes were found in the protein and mRNA levels of dCK upon stimulation, while the activation process was calcium dependent and comprised a protein phosphorylation step. A positive correlation was found between the enzymatic activity and the native immunoreactivity of dCK, strongly arguing that dCK undergoes a conformational change during activation, which results in the formation of a catalytically more active steric structure (8-11, 22, 26, 32-34, 35, 36).
C1 [Staub, Maria] Semmelweis University, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Puskin u. 9., 1088 Budapest, Hungary.
RP Staub, M (reprint author), Semmelweis University, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, 1088 Budapest, Hungary.
EM Staub@puskin.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 229
EP 234
PG 6
ER

PT J
AU Tovari, J
   Bereczky, B
   Gilly, R
   Skopal, J
   Vago, �
   Timar, J
AF Tovari, Jozsef
   Bereczky, Biborka
   Gilly, Reka
   Skopal, Judit
   Vago, Agnes
   Timar, Jozsef
TI Heparin inhibits metastatization of experimental melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Heparin treatment, at human equivalent doses, modulates coagulation parameters in mice similarly to the human situation. Heparins were tested in various melanoma metastasis models for their antimetastatic acitvity. Heparins were active against melanoma metastasis without influencing the primary tumor. Tumor cell-induced platelet aggregation was not the primary target of heparins, since melanoma cells were not active in this respect. Our results support the notion that heparins have antimetastatic acitivity.
C1 [Tovari, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bereczky, Biborka] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gilly, Reka] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Skopal, Judit] Nemzeti Stroke Kozpont, Hemostasis laboratoriumBudapest, Hungary.
   [Vago, Agnes] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 235
EP 241
PG 7
ER

PT J
AU Katona, Cs
   Timar, F
   Olah, J
   Bocsi, J
   Budai, B
   Otvos, L
   Kralovanszky, J
AF Katona, Csilla
   Timar, Ferenc
   Olah, Julia
   Bocsi, Jozsef
   Budai, Barna
   Otvos, Laszlo
   Kralovanszky, Judit
TI Potentiation of 5-fluorouracil efficacy. Molecular mechanisms playing a role in the cytotoxic action of 5-fluorouracil and 5-ethyl-2'-deoxyuridine (EUdR) combination.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Pharmacologic modulation of 5-fluorouracil (5-FU) metabolism provides a possibility for the enhancement of its clinical efficacy. AIM: The purpose of the present work was to study the effect of 5-ethyl-2’-deoxyuridine (EUdR), a potent 5-FU modulator, on different molecular mechanisms, influenced by 5-FU itself, and to obtain further data about the mode of action of the combination. MATERIALS AND METHODS: SW620 cell line was used for the experiments. Cytotoxicity was studied by MTT test, cell kinetic changes by FACStar flow cytometer, apoptosis by fluorescent microscope after staining the cells with acridine orange and ethydium bromide, DNA fragmentation by PAGE electrophoresis after RNase and proteinase-K digestion, thymidine incorporation with 3H-thymidine, p53 and PCNA protein expression by Western blotting. RESULTS: The cytotoxicity of 5-FU was potentiated dose dependently by EUdR. One hundred µM concentration of EUdR resulted in a 40% decrease of the IC50 value of 5-FU. Cell cycle arrest in the G2/M transition phase was most pronounced after combined treatment with 5-FU+EUdR. EUdR potentiated the incorporation of 3Hthymidine into DNA. In addition to the increase of apoptosis rate, the expression of p53 protein, caused by 5-FU was further potentiated by UdR. CONCLUSION: This study demonstrated a potential novel approach to increase the efficacy of 5-FU by EUdR, which incorporated two complementary molecular actions, the selective modulation of TS inhibition and potentiation of the p53 protein expression, consequently leading to an increase in the apoptotic rate.
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bocsi, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otvos, Laszlo] MTA Kemiai KutatokozpontBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kralovanszky, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM kralo@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 243
EP 251
PG 9
ER

PT J
AU Budai, B
   Hitre, E
   Adleff, V
   Czegledi, F
   Gyergyay, F
   Lang, I
   Kralovanszky, J
AF Budai, Barna
   Hitre, Erika
   Adleff, Vilmos
   Czegledi, Ferenc
   Gyergyay, Fruzsina
   Lang, Istvan
   Kralovanszky, Judit
TI The clinical importance of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the 5-fluoropyrimidine-based therapy of metastatic colorectal tumours.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.
C1 [Budai, Barna] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Adleff, Vilmos] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Czegledi, Ferenc] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kralovanszky, Judit] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Budai, B (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM budai@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 253
EP 257
PG 5
ER

PT J
AU Demeter, A
   Varkonyi, T
   Csapo, Zs
   Szantho, A
   Olah, J
   Papp, Z
AF Demeter, Attila
   Varkonyi, Tibor
   Csapo, Zsolt
   Szantho, Andras
   Olah, Julianna
   Papp, Zoltan
TI Analysing prognostic factors of common epithelial ovarian tumours.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: The outcome and prognosis of apparently similar cases of epithelial ovarian cancers with the same histology and stage is highly variable. The objective was to compare survival and prognostic factors of patients treated at the 1st Department of Obstetrics and Gynecology of Semmelweis University between 1993-2003 with the similar data of the 25th Annual Report on the Results of Treatment in Gynecological Cancer of FIGO. In addition, the aim was to assess the prognostic value of MMP activities and fibronectin concentration in ovarian tumour patients. METHODS: The 25th Annual Report of FIGO included 5694 patients with ovarian tumours from 32 countries diagnosed and treated between 1995 and 1998. Hungary did not participate in this report. Between 1993 and 2003, 180 patients with common epithelial ovarian tumours had been treated at the 1st Department of Obstetrics and Gynecology of Semmelweis University. Treatment and survival data derived from medical record review and from the Population Register Office. In order to compare different prognostic factors, a multivariate Cox proportional regression analysis was performed. The authors measured MMP activities in 33 surgically removed ovarian tumours, serum and ascites by applying zymographic technique. Fibronectin content was determined by Western blot analysis and quantitated by densitometry. RESULTS: The 5-year survival was 90.0% and 30.9% in the case of ovarian tumours with low malignant potential and of epithelial ovarian cancers, respectively. Multivariate analysis identified adverse prognostic factors including advanced age (>60 years) and stage, high grade and suboptimal operation with residual macroscopic disease and the presence of ascites. However, the histological type was not identified to be an adverse prognostic factor in this study. No correlation could be seen between the histology of the ovarian tumours and the elevation of MMP-2/9 activity. More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease. CONCLUSION: A great deal of effort should be devoted to identification of further prognostic factors to improve treatment of ovarian cancer. These prognostic factors might help to identify those ovarian cancer patients at the time of diagnosis whose disease will have unfavourable outcome. Our data support the notion that high expression of MMP-9 and fibronectin indicates poor prognosis of ovarian cancer patients.
C1 [Demeter, Attila] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., 1088 Budapest, Hungary.
   [Varkonyi, Tibor] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., 1088 Budapest, Hungary.
   [Csapo, Zsolt] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., 1088 Budapest, Hungary.
   [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., 1088 Budapest, Hungary.
   [Olah, Julianna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papp, Zoltan] Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Baross u. 27., 1088 Budapest, Hungary.
RP Demeter, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, 1088 Budapest, Hungary.
EM demeter@noi1.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 259
EP 265
PG 7
ER

PT J
AU Kahan, Zs
AF Kahan, Zsuzsanna
TI Torekvesek az emlorak adjuvans szisztemas kezelesenek individualizalasara - ASCO, 2004
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2004
VL 48
IS 3
BP 268
EP 269
PG 2
ER

PT J
AU Pulay, T
   Baki, M
   Bodoky, Gy
   Dank, M
   Cseh, J
   Csejtei, A
   Csomor, S
   Erfan, J
   Faluhelyi, Zs
   Izso, J
   Hernadi, Z
   Kammerer, K
   Krommer, K
   Magyar, T
   Mayer, �
   Megyery, �
   Moskovits, K
   Pecsi, L
   Piko, B
   Pinter, T
   Ruzsa, �
   Szantho, A
   Szanto, I
   Szanto, J
   Szucs, M
   Talos, Zs
   Thurzo, L
   Kasler, M
AF Pulay, Tamas
   Baki, Marta
   Bodoky, Gyorgy
   Dank, Magdolna
   Cseh, Jozsef
   Csejtei, Andras
   Csomor, Sandor
   Erfan, Jozsef
   Faluhelyi, Zsolt
   Izso, Jozsef
   Hernadi, Zoltan
   Kammerer, Kinga
   Krommer, Karoly
   Magyar, Tamas
   Mayer, Arpad
   Megyery, Eva
   Moskovits, Katalin
   Pecsi, Lajos
   Piko, Bela
   Pinter, Tamas
   Ruzsa, Agnes
   Szantho, Andras
   Szanto, Istvan
   Szanto, Janos
   Szucs, Miklos
   Talos, Zsuzsanna
   Thurzo, Laszlo
   Kasler, Miklos
TI Status report on the chemotherapy of ovarian cancer in Hungary (2002-2003)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Data on the first-line treatment of ovarian cancer in special centers of Hungary 2002 and 2003 are presented, involving 283 and 416 patients, respectively. Patients’ age, clinical stage and histological type of the tumor were highly similar to literature data, while grades were different. Surgical effectivity in case of IIIc staged tumors with >1 cm residual mass was 37%. The ratio of intervallaparotomy was about 15%. Overall response rates of the first-line treatment of ovarian cancer was 82%, while the rate of complete remissions was 60%. The authors provide detailed analysis of factors that can improve the chemotherapy of ovarian cancer in Hungary.
C1 [Pulay, Tamas] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Baki, Marta] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bodoky, Gyorgy] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Dank, Magdolna] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Cseh, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Csejtei, Andras] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Csomor, Sandor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Erfan, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Faluhelyi, Zsolt] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Izso, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Hernadi, Zoltan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kammerer, Kinga] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Krommer, Karoly] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Magyar, Tamas] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Mayer, Arpad] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Megyery, Eva] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Moskovits, Katalin] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pecsi, Lajos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Piko, Bela] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pinter, Tamas] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Ruzsa, Agnes] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szantho, Andras] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szanto, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szanto, Janos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szucs, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Talos, Zsuzsanna] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Thurzo, Laszlo] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Pulay, T (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM pulay@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 275
EP 280
PG 6
ER

PT J
AU Lang, I
   Hitre, E
AF Lang, Istvan
   Hitre, Erika
TI Novel data on the irinotecan treatment of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC). Irinotecan - just like oxaliplatin - given as neoadjuvant therapy with 5-FU - folinic acid (FUFA) can render originally unresectable liver or lung metastases of CRC resectable, giving the hope of long-term survival for a proportion of patients. Irinotecan combined with 5-FU is an essential part of the most successful palliative sequetial chemotherapy of stage IV CRC. Sequential FOLFIRI before or after FOLFOX combination ensures the longest possible progression-free and overall survival for metastatic CRC patients in the palliatic setting. In order to achieve the longest survival time, sequential use of both 5-FU, irinotecan and oxaliplatin is necessary. The French GERCOR Group achieved 26 months median overall survival with the sequential use of continuous infusional FUFA, oxaliplatin and irinotecan combinations in stage IV CRC. The analysis of large phase III trials using 5-FU, irinotecan and oxaliplatin revealed that the higher proportion of patients was treated with all three drugs, the longer overall survival was achieved. If applied with caution, toxicity and efficacy of irinotecan in elderly patients is not significantly different from that seen in younger population. The anti-VEGF bevacizumab increases the efficacy of first-line irinotecan therapy, while the addition of cetuximab restores irinotecan sensitivity in second line treatment of stage IV CRC. The combination of irinotecan with oral capecitabine is safe and effective in advanced CRC.
C1 [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lang, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM lang@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 281
EP 288
PG 8
ER

PT J
AU Muller, J
   Koos, R
   Garami, M
   Hauser, P
   Borgulya, G
   Schuler, D
   Benyo, G
   Magyarosy, E
   Galantai, I
   Milei, K
   Torok, K
   Bardi, E
   Hunyadi, K
   Gabor, K
   Masath, P
   Bodnar, L
   Kovacs, G
AF Muller, Judit
   Koos, Rozalia
   Garami, Miklos
   Hauser, Peter
   Borgulya, Gabor
   Schuler, Dezso
   Benyo, Gabor
   Magyarosy, Edina
   Galantai, Ilona
   Milei, Krisztina
   Torok, Katalin
   Bardi, Edit
   Hunyadi, Katalin
   Gabor, Krisztina
   Masath, Peter
   Bodnar, Laszlo
   Kovacs, Gabor
TI Experiences with Langerhans' cell histiocytosis in children in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB BACKGROUND: Langerhans cell histiocytosis (LCH) in children is relatively rare, and the long-term analysis of therapy results has not been done yet in Hungary.  PURPOSE: In this review we summarise the incidence, clinical features, prognostic risk factors and treatment results of children’s LCH in Hungary, using data from the National Childhood Cancer Registry in Hungary in a 20-year period between 1981 and 2000. RESULTS: From January 1981 to December 2000, 111 children under 18 years of age were newly diagnosed with LCH in Hungary. The male-female ratio was 1.36:1, the mean age: 4 years 11 months. The minimal and median follow-up time was 3.48 years and 10.98 years respectively. 38 children had singlesystem disease, while in 73 cases we found systemic dissemination already at the time of diagnosis. Twenty-two patients were treated only by local surgery, 7 by surgery with local irradiation and 5 children received only local irradiation. In two cases remission was obtained with local steroid administration. 75 patient received chemotherapy. During the twenty years 14 children died, 9 due to the progression of the disease. Sixteen of the 111 patients had relapse with a mean of 2.16±1.29 years after the first diagnosis. Three patients with relapse got chemotherapy generally used in lymphoma and remission was achieved. The overall survival of all patients (n=111) was 88.3±3.1% at 5 years and 87.3±3.2% at 10 and 20 years. CONCLUSION: Childhood LCH is a well treatable disease and the survival rate is high. Even disseminated diseases have a quite good prognosis in childhood.
C1 [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Koos, Rozalia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Borgulya, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Benyo, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Magyarosy, Edina] Heim Pal Children's HospitalBudapest, Hungary.
   [Galantai, Ilona] Madarasz Street Pediatric HospitalBudapest, Hungary.
   [Milei, Krisztina] Bethesda Children's Hospital of the Hungarian Reformed ChurchBudapest, Hungary.
   [Torok, Katalin] University of Pecs, Department of PediatricsPecs, Hungary.
   [Bardi, Edit] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Hunyadi, Katalin] BAZ Megyei Korhaz, GyermekosztalyMiskolc, Hungary.
   [Gabor, Krisztina] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Masath, Peter] Markusovszky Vas Country Hospital, Department of PediatricsSzombathely, Hungary.
   [Bodnar, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM muller@gyer2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 289
EP 295
PG 7
ER

PT J
AU Takacsi Nagy, Z
   Oberna, F
   Somogyi, A
   Polgar, Cs
   Major, T
   Polus, K
   Fodor, J
   Nemeth, Gy
AF Takacsi Nagy, Zoltan
   Oberna, Ferenc
   Somogyi, Andras
   Polgar, Csaba
   Major, Tibor
   Polus, Karoly
   Fodor, Janos
   Nemeth, Gyorgy
TI Teletherapy versus teletherapy and ''boost'' brachytherapy in the treatment of base of tongue tumors: 5-year results
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: To study the importance of high-dose-rate (HDR) boost brachytherapy (BT) after percutaneous irradiation of base of tongue tumors. METHODS: Between 1992 and 2000 seventy patients with biopsy proven carcinoma of the base of tongue were treated with primary radiation therapy. Fourty patients received a mean dose of 61 Gy (range, 50-72 Gy) external beam irradiation, and afterwards 30 patients were treated with a mean dose of 18 Gy (range, 12-30 Gy) boost HDR BT. Prognostic factors were analyzed in uni- and multivariate model. RESULTS: At a median follow-up of 56 (16-108) months, boost BT increased the incidence of local tumor control (LTC) from 38% to 67% (p=0.0145). The 5-year probability of LTC was 60% vs. 36% (p=0.0188), the locoregional tumor control 52% vs. 34% (p=0.0753) and the overall survival (OS) 46% vs. 26% (p=0.0545), respectively, in favor of the boost group. Serious, grade 4 radiation toxicity occurred in 5% (2/40) and 13% (4/30) without or with boost treatment, respectively (p=0.2110). In multivariate analyses for LTC, tumor size (p=0.0042) and boost (p=0.0444), and for OS tumor size (p=0.0047) and nodal status (p=0.0163) had a significant effect. CONCLUSION: Boost BT after teletherapy improves LTC significantly without considerable increase in the risk of side-effects.
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polus, Karoly] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM takacsi@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 297
EP 301
PG 5
ER

PT J
AU Patonay, P
   Naszaly, A
   Mayer, �
   Pocza, K
   Kovacs, L
AF Patonay, Peter
   Naszaly, Attila
   Mayer, Arpad
   Pocza, Karoly
   Kovacs, Lajos
TI Radio-chemotherapy of irresectable primary esophageal malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: to demonstrate the simultaneous radio-chemotherapy of primary esophageal malignant melanoma on the basis of one case. PATIENT AND METHODS: 68-years-old male patient with malignant melanoma in middle part of the esophagus. The therapy was started with intraluminal high-dose-rate afterloading brachytherapy for the recanalisation of the esophagus (8 Gy in 0.5 cm deep), followed by percutaneous megavolt therapy two weeks after the last HDR AL session (50 Gy total dose, 5x2 Gy/week fractions for 5 week, 3D conformal planning). The chemotherapy was started simultaneously with the percutaneous megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, repeated in four-week intervals). After the radio-chemotherapy a supraclavicular metastasis was verified, so the radio-chemotherapy was followed with megavolt therapy of the metastasis at 30 Gy dose (5x2 Gy/week fractions), and chemotherapy (Cisplatin-Dacarbazine combination in 6-session, four-week intervals) and after them immunotherapy was started. RESULTS: The swallow function has been improved, the supraclavicular metastasis was in partial remission. After the beginning of the radio-chemotherapy the swallow function was good for 16 months, and 18 months after the beginning of radio-chemotherapy the patient died due to pulmonary and hepatic dissemination. CONCLUSION: Radio-chemotherapy of esophageal malignant melanoma has favorable palliative effect with acceptable quality of life.
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Pocza, Karoly] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Kovacs, Lajos] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 303
EP 308
PG 6
ER

PT J
AU Kovesi, Gy
   Szende, B
AF Kovesi, Gyorgy
   Szende, Bela
TI Prognotic significance of cyclin D1, p27 and p63 expression in oral leukoplakia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Studies on the expression of genes regulating cell proliferation and apoptosis is of importance in relation to understanding the severity of the process and the possibility of malignant transformation. In the present study immunohistochemical demonstration of cyclin D1, p27 and p63 has been added to our previous investigations on Ki-67, p53 and apoptosis index. Clinical and pathologicalimmunohistochemical studies on oral leukoplakias of 18 patients were performed. Clinically homogenous, non-homogenous or nodular, and erythroleukoplakia were distinguished. Pathologically the grading was made according to the degree of dysplasia. Immunoperoxidase reactions for cyclin D1, p27 and p63 were carried out, and the positivity was expressed in per cent, considering 1000 epithelial cells. Expression of cyclin D1 increased in paralel with the severity of leukoplakia. p27 expression was 14-16% in homogenous and nodular leukoplakias, whereas in erythroleukoplakia it decreased to 1-2%. p63 expression was 10% in average in homogenous, and 5% in nodular leukoplakias. While in erythroleukoplakias it increased to 20 per cent. The characteristic cyclin D1, p27 and p63 phenotype in various forms of leukoplakia may be considered as prognostic factors.
C1 [Kovesi, Gyorgy] Semmelweis Egyetem, Fogorvostudomanyi Kar, Parodontologiai KlinikaBudapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Szende, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bszende@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 309
EP 313
PG 5
ER

PT J
AU Kover, E
   Faluhelyi, Zs
   Bogner, B
   Kalmar, K
   Horvath, G
   Tornoczky, T
AF Kover, Erika
   Faluhelyi, Zsolt
   Bogner, Barna
   Kalmar, Katalin
   Horvath, Gabor
   Tornoczky, Tamas
TI Dual tumours in the GI tract: Synchronous and metachronous stromal (GIST) and epithelial/neuroendocrine neoplasms
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Gastrointestinal stromal tumours (GIST) constitute the most frequent group of mesenchymal tumours in the gastrointestinal tract (GI). During the last several decades major advances have been taken in the diagnostics, treatment, and understanding of its pathogenesis. However, much less is known about the either metachronous or synchronous concurrence of GIST and other tumours of different histogenesis. In the present study clinicopathological data of 43 patients with histologically proved gastrointestinal stromal tumour were studied mainly in regard of the occurrence of a secondary neoplasm. Among the 43, 7 cases were found with secondary tumour mainly of epithelial origin. In three cases (cases 3, 5, and 7) GIST concurred with colorectal adenocarcinoma, in one case (case 1) GIST occurred in a patient with a 3-years-history of chronic lymphocytic leukaemia (CLL), in other two (cases 2 and 4) the stromal tumour was combined with in situ adenocarcinoma of the stomach and carcinoid of the pancreas, respectively. In case 6, GIST concurred with a duodenal Brunner gland adenoma. In five cases the stromal tumour and the other neoplasm occurred synchronously, and in four of them, being the stromal tumour clinically silent, GISTs were intraoperative findings. This confirms the importance of surgical intraabdominal control before closure. In one hand the repeated concurrence of GIST and colorectal adenocarcinoma in our series, and on the other hand, that of GIST and adenocarcinoma of the stomach in the literature, may indicate an at least partly common factor, which may be involved in the pathogenesis of these neoplasms.
C1 [Kover, Erika] Baranya County Hospital, Department of Oncology, Rakoczi ut 2., 7623 Pecs, Hungary.
   [Faluhelyi, Zsolt] Baranya County Hospital, Department of Oncology, Rakoczi ut 2., 7623 Pecs, Hungary.
   [Bogner, Barna] County Hospital of Baranya, Department of PathologyPecs, Hungary.
   [Kalmar, Katalin] University of Pecs, Department of SurgeryPecs, Hungary.
   [Horvath, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Tornoczky, Tamas] University of Pecs, Department of PathologyPecs, Hungary.
RP Kover, E (reprint author), Baranya County Hospital, Department of Oncology, 7623 Pecs, Hungary.
EM yst@pathology.pote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 315
EP 321
PG 7
ER

PT J
AU Drahos, �
   Dam, A
   Oreg, Zs
AF Drahos, Agnes
   Dam, Annamaria
   Oreg, Zsolt
TI Radiosensitizing effect of hyperfractionated radiation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB To determine whether hyperfractionated treatment has benefits in the radiation therapy, two melanoma cell lines were irradiated with eight 0.5 Gy fractions as well as one single 4 Gy in vitro. The radiation was performed in air and in hypoxia as well. Cells were also irradiated in the presence of dibromodulcitol, a bifunctional alkylating agent with a weak radiosensitizer effect. The aim of the study was to examine whether hyperfractionation can influence the radiosensitizing effect of the bioreductive agent. Survival of the cells was determined immediately and 24 hours after various treatments by cell counting in hemocytometer and clonogenic assay. The number of the apoptotic cells was determined by the TUNEL assay and was followed up to 72 hours after treatment. Hypoxic cells had higher sensitivity than normoxic cells after 0.5 Gy irradiation. Radiosensitizing enhancement of DBD was higher with fractionated irradiation. The number of the apoptotic cells was significantly higher after hyperfractionated treatments than after single dose treatment combinations. Our results showed the significance of the hyperfractionated irradiation with 0.5 Gy per fraction in vitro.
C1 [Drahos, Agnes] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna u. 5., 1221 Budapest, Hungary.
   [Dam, Annamaria] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna u. 5., 1221 Budapest, Hungary.
   [Oreg, Zsolt] Semmelweis Egyetem, Egeszsegugyi Foiskolai KarBudapest, Hungary.
RP Drahos, � (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1221 Budapest, Hungary.
EM drahos@hp.osski.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 323
EP 331
PG 9
ER

PT J
AU Janosi, J
   Sebestyen, A
   Bocsi, J
   Barna, G
   Nagy, K
   Valyi-Nagy, I
   Kopper, L
AF Janosi, Judit
   Sebestyen, Anna
   Bocsi, Jozsef
   Barna, Gabor
   Nagy, Katalin
   Valyi-Nagy, Istvan
   Kopper, Laszlo
TI Mevastatin induced apoptosis in U266 human myeloma cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Statins have been used succesfully in the treatment of hypercholesterinaemia. Moreover, in vitro studies have shown that statins can trigger apoptosis in a variety of tumor cell lines. In the present study we analysed the effect of mevastatin - a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway - on U266 human myeloma cells. Apoptosis induced by mevastatin was associated with increased caspase activity and depolarisation of mitochondrial membrane. Expression of BCL-2 mRNA and protein was downregulated, with no change in BAX or BCLxL protein production. The mitochondrial program was supported by caspase-8 and cleaved BID activity. None of the antibodies neutralising death-ligand/death-receptor pathway - TRAIL-R2Fc, anti-TNF-a, anti FASL (NOK-1) - influenced the mevastatin-induced apoptosis. Mevastatin also stimulated shedding of syndecan-1 from the surface of myeloma cells.
C1 [Janosi, Judit] National Medical Center, Department of Hematology and Stem Cell Transplantation, Szabolcs u. 33-35., 1135 Budapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bocsi, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Valyi-Nagy, Istvan] National Medical Center, Department of Hematology and Stem Cell Transplantation, Szabolcs u. 33-35., 1135 Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Janosi, J (reprint author), National Medical Center, Department of Hematology and Stem Cell Transplantation, 1135 Budapest, Hungary.
EM janosijudit@hotmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 333
EP 337
PG 5
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 339
EP 347
PG 9
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 349
EP 349
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2004
VL 48
IS 4
BP 351
EP 356
PG 6
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Activity of the National Oncology R&D Consorcia in 2004.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB We have prepared the map of regional distribution of cervical cancer in Hungary. Serial HPV genotyping of sexual partners provided evidence for the sexually transmitted infections. Molecular epidemiology studies revealed activating c-kit mutation in bilateral testicular cancers. A cost-effective molecular staging method was introduced to the management of breast cancer patients. Genomic profiling identified the gene signature of Herceptin and taxane sensitivity of breast cancer. In colon cancer patients we have determined the mutational spectrum of hMLH1 and hMSH2 genes in Hungary. The prognostic power of SHMT and MTHFR polymorphism was determined in colorectal cancer patients. In head and neck cancer the gene signature of cisplatin sensitivity and the EGFR polymorphism was determined. We have introduced a cost-effective in vitro assay to determine the drug resistance of pediatric leukemias. The prognostic power of N-myc genotyping was determined in neuroblastoma patients. A phase I trial for gene therapy of brain cancer was started by using a GM-CSF adenoviral vector system. Using global genomic approaches the gene signature of malignant melanoma and its metastatic disease was determined. We have found that Ca-channel blockers and EGFR tyrosine kinase inhibitors are effective in preclinical human melanoma models in breaking the apoptosis resistance of this tumor.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9.,, 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 3
EP 7
PG 5
ER

PT J
AU Suveges, I
AF Suveges, Ildiko
TI Intraocular tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Intraocular tumours may be benign or malignant. The latter are more numerous, and endanger not only vision but life as well. Two of them deserve special attention: melanoma malignum oculi in adults and retinoblastoma in children. Melanoma malignum may arise from all three areas of the uvea: the iris, the ciliary body and the choroid. The more malignant growths are those which are situated closer to the posterior pole. Histologically the epitheloid cell-type of melanoma is more malignant than those containing only spindle cells. Their treatment depends on the size: in the case of large tumours enucleation is required, while for the smaller ones, radiation therapy can be applied. Retinoblastoma is most common in children of 1-2 years of age. It has familial and sporadic forms. Sixty-seven percent of the inherited-type cases are bilateral. An early symptom in small children is strabismus. A white tissue mass growing into the vitreous is seen on the fundus. A diagnostic feature that can be detected by ultrasound examination is calcification. The tumour may also present intracranially, therefore CT of the skull should be performed in each case. Histologically the tumour contains malignant neuroepithelial cells, which may form a rosette. In the case of large tumours the treatment is enucleation; in bilateral processes the bulbus with the larger mass is removed and the other eye is treated with radiation therapy. In both cases chemotherapy is used according to a prescribed schedule. Metastases to the eye occur most frequently from carcinomas of the breast, lungs or gastrointestinal tract. These are treated with radiotherapy, chemotherapy and hormone therapy. Primary intraocular lymphoma often occurs bilaterally, and may be accompanied by primary lymphoma of the central nervous system (CNS). Some benign tumours are found by chance on routine eye examinations, others due to subjective and objective symptoms.
C1 [Suveges, Ildiko] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29., 1083 Budapest, Hungary.
RP Suveges, I (reprint author), Semmelweis University, Department of Ophthalmology, 1083 Budapest, Hungary.
EM si@szem1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 9
EP 13
PG 5
ER

PT J
AU Hammer, H
   Toth-Molnar, E
   Olah, J
   Dobozy, A
AF Hammer, Helga
   Toth-Molnar, Edit
   Olah, Judit
   Dobozy, Attila
TI Connection between uveal melanoma and dysplastic naevus syndrome.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The dysplastic naevus syndrome increases the risk of cutaneous (RR: 4.36; CI: 1.84-10.36) as well as uveal melanoma (RR: 4.22; CI: 1.81-9.84). A significantly higher occurrence rate of conjunctival naevi (3.2% vs. 0%; p=0.029), choroidal naevi (5.2% vs. 0.7%; p=0.023) and iris freckles (17.1% vs. 5.6%; p=0.002) could be detected in the dysplastic naevus syndrome patients compared to subjects in the control group. The presence of cutaneous dysplastic naevi in uveal melanoma patients increases the risk of the prognostically worse - epitheloid or mixed - forms of uveal melanoma (RR: 5.97%; CI: 1.61-22.14), compared to patients without cutaneous atypical naevi.
C1 [Hammer, Helga] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-12., 6720 Szeged, Hungary.
   [Toth-Molnar, Edit] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-12., 6720 Szeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Hammer, H (reprint author), Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, 6720 Szeged, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 15
EP 18
PG 4
ER

PT J
AU Toth, J
AF Toth, Jeannette
TI Retrospective study on uveal melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Purpose: To report the results of a retrospective study carried out at the 1st Department of Ophthalmology of Semmelweis University, Budapest, among patients treated for ocular melanoma. Clinical data of the patients, histopathological characteristics of the tumours and follow-up results are reported. Patients and Methods: Retrospective review of patients’ charts, histopathological data and statistical analysis of collected data. Results: From 120 patients treated by enucleation or exenteration for uveal melanoma, 22 had died by the end of the study. The medium survival after operation was 34.0±25.4 months, the majority of deaths occurred within three years following surgery. Statistically significant relationship was demonstrated between extraocular extension of the tumour and death, and between epithelioid cell tumours and death. Most large tumours involved the ciliary body, the prognosis of these tumours tended to be worse than for those infiltrating only the choroid, but the difference was not statistically significant. Uveal melanoma almost exclusively gives haematogeneous metastases, liver metastases being the most frequent; rarely lung metastases are also reported. Since extraocular extension and epithelioid tumours carry a very poor prognosis, the possibility of providing adjuvant chemo-immunotherapy for patients harbouring these tumours should be entertained, even if liver metastases are not demonstrated at the time of diagnosis.
C1 [Toth, Jeannette] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29., 1085 Budapest, Hungary.
RP Toth, J (reprint author), Semmelweis University, Department of Ophthalmology, 1085 Budapest, Hungary.
EM tj@szem1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 19
EP 25
PG 7
ER

PT J
AU Toth-Molnar, E
   Hammer, H
AF Toth-Molnar, Edit
   Hammer, Helga
TI Second primary malignant tumors among ocular melanoma patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Multiple primary malignant tumors have been documented with increased frequency over the last two decades. Continuously increasing success of modern oncotherapy has led to long-term remissions in many cases, but this success rate poses a growing risk for the development of second primary malignancies. The incidence of those involving an intraocular tumor is relatively rare. In the present study we report five ocular melanoma patients with second primary malignant tumors diagnosed during a fourteen-year period in our department. We wish to emphasize that an intraocular mass lesion in a patient with a history of a previous malignancy should not be dismissed as a metastatic lesion. The diagnosis of an intraocular lesion as a separate primary tumor drastically changes the prognosis and the therapeutic approach.
C1 [Toth-Molnar, Edit] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-11., 6725 Szeged, Hungary.
   [Hammer, Helga] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-11., 6725 Szeged, Hungary.
RP Toth-Molnar, E (reprint author), Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, 6725 Szeged, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 27
EP 30
PG 4
ER

PT J
AU Degi, R
   Szabo, �
   Janaky, M
AF Degi, Rozsa
   Szabo, Agnes
   Janaky, Marta
TI Experience on 13-year follow-up of melanocytoma of the optic nerve head.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Thirteen years ago, a 35-year-old woman was found on routine ocular examination to have a pigmented tumor in her right eye, adjacent to the optic nerve head. The appearance of her fundus was suggestive of a melanocytoma. Her visual acuities were RE: 1.0 and LE: 1.0. Ultrasound examination revealed that the tumor diameter was 4.4 mm on the base and the maximal thickness was 2.7 mm. Fluorescein angiography showed a persistent hypofluorescence of the lesion. There were several additional examinations (e.g. determination of the visual field, measurement of the intraocular pressure, detection of visually evoked potentials, CT scan and MRI examination) to exclude a benign tumor of similar appearance, The patient underwent ocular examination every year. During the observation period a minor tumor enlargement occurred but there were no changes in the visual acuities. In the last two years minor signs of malignant transformation were found. The findings documented and illustrated here suggest that our methods were useful to differentiate the melanocytoma from a malignant melanoma, and no surgical interventions were needed to characterize or to remove the tumor. In addition, our patient has had a good vision during the past 13 years.
C1 [Degi, Rozsa] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-12., 6720 Szeged, Hungary.
   [Szabo, Agnes] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-12., 6720 Szeged, Hungary.
   [Janaky, Marta] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-12., 6720 Szeged, Hungary.
RP Degi, R (reprint author), Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, 6720 Szeged, Hungary.
EM degi@ophth.szote.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 31
EP 34
PG 4
ER

PT J
AU Nemeth, J
   Tapaszto, B
   Toth, J
   Harkanyi, Z
AF Nemeth, Janos
   Tapaszto, Beata
   Toth, Jeannette
   Harkanyi, Zoltan
TI Evaluation of color Doppler imaging of ophthalmic tumors in the framework of the histopathological findings
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Purpose: To examine retrospectively the diagnostic and differential diagnostic value of color Doppler imaging (CDI) in cases of suspected intraocular and orbital tumors. Patients and Methods: Color Doppler examination (using Acuson 128, Philips-ATL UM-9, HDI 3000, 5000, Siemens Elegra, GE Logiq9) was performed in a total of 194 patients (177 intraocular, 17 orbital tumors). The results were compared to the clinical findings (routine examination, conventional ultrasound examination) and the results of angiography (FLAG, ICG). Furthermore, in 73 cases histopathology records were obtained for comparison. Results: Signs of blood flow could be detected in 137 cases (71%); the Doppler spectrum was low resistance in the large majority (130) of these cases. In cases where histopathology records were available, 60 of the 73 (82%) showed good concordance between the CDI diagnosis and the pathological results. CDI gave false positive results in 3, and false negative findings in 10 cases; the latter occurred mainly in small iris or ciliary body tumors. Conclusions: Using CDI, blood flow is demonstrable in the majority of intraocular and orbital tumors, especially if the tumor diameter is larger than 3 mm. CDI flow detection, however, is less reliable for iris or ciliary body tumors.
C1 [Nemeth, Janos] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29.Budapest, Hungary.
   [Tapaszto, Beata] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29.Budapest, Hungary.
   [Toth, Jeannette] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29.Budapest, Hungary.
   [Harkanyi, Zoltan] Heim Pal Gyermekkorhaz, Radiologiai OsztalyBudapest, Hungary.
RP Nemeth, J (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
EM nj@szem1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 35
EP 41
PG 7
ER

PT J
AU Gyetvai, T
   Kolozsvari, L
AF Gyetvai, Tamas
   Kolozsvari, Lajos
TI Ultrasound biomicroscopical examination of the tumours of the iris and ciliary body
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The ultrasound biomicroscope (UBM) has a major role in detecting and following different types of intra-ocular masses in the anterior part of the eye. This equipment may provide the possibility to detect the inner structure of the masses, to differentiate between cysts and solid tumours, and to follow their progression and spreading into the surrounding tissue. In the last six years 30 patients with iris and ciliary body tumour were found in our laboratory. The examination were performed by Zeiss Humphrey Ultrasound Biomicroscope, Model 840, 50 MHz probe. We followed closely 22 patients. Surgical removal and histological examination were performed in 3 cases. Melanocytoma, retinoblastoma and ring melanoma were revealed. Although the symptoms of the anterior uveal tumours are uncommon, and these tumours show very slow progression, early detection and regular follow-up is needed. In the case of tumour progression the UBM has an important role in planning and timing of surgery or radiotherapy, which can have a favourable effect on the outcome of the disease.
C1 [Gyetvai, Tamas] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-11., 6720 Szeged, Hungary.
   [Kolozsvari, Lajos] Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, Koranyi fasor 10-11., 6720 Szeged, Hungary.
RP Gyetvai, T (reprint author), Szegedi Tudomanyegyetem, AOK, Szemeszeti Klinika, 6720 Szeged, Hungary.
EM gyetvai@opht.szote.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 43
EP 46
PG 4
ER

PT J
AU Lukats, O
AF Lukats, Olga
TI Oncological principles of surgery in the periorbital region
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of this study is to describe the most common malignant periorbital tumours and principles of their surgical treatment. The most common malignant tumours of the eyelids are: basocellular carcinoma, squamocellular carcinoma, sebaceous carcinoma and malignant melanoma. The primary treatment of periorbital tumours is surgery, other methods are cryotherapy or radiotherapy. Malignant tumours of the eyelids are fairly rare. Diagnosis in some of the cases is difficult, since the first signs of the tumours are small changes on the eyelid margin or eyelid skin. Focal loss of the eyelashes could be the first sign of a malignant tumour. General oncological principles are valid also in the surgery of periorbital region. Eyelids have special anatomical structure and their main role is protection of the eyeball. Therefore, early diagnosis and total tumour removal - regardless of the anatomical borders - as well as immediate reconstruction are important in the treatment of eyelid tumours.
C1 [Lukats, Olga] Semmelweis University, Department of Ophthalmology, Tomo u. 25-29., 1083 Budapest, Hungary.
RP Lukats, O (reprint author), Semmelweis University, Department of Ophthalmology, 1083 Budapest, Hungary.
EM lo@szem1.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 47
EP 52
PG 6
ER

PT J
AU Berta, A
AF Berta, Andras
TI Radiotherapy of intraocular tumors with Ruthenium-106-containing, beta-emitting ophthalmic applicators. Experiences with treatments performed between 1986 and 1999 in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Aim: Till October 15, 2004, 312 patients were irrradiated with Ruthenium-106-containing ophthalmic applicators at the Department of Ophthalmology, Medical Faculity, University of Debrecen. In this paper we report on experience gained with the irradiation of 187 patients, treated between 1986 and 1999, whose follow-up time interval was at least 5 years. Patients and methods: The distribution according to diagnosis of the patients irradiated between 1986 and 1999 were: choroidal melanoma 148, retinoblastoma 15, retinal angioma 9, carcinoma metastasis 4, subretinal neovascularization 11. The instruments purchased from the German Bebig firm were sutured under surgical circumstances onto the sclera, and were removed from the eye with another operation. The applied dose calculated to the inner surface of the tumors was 100 Gy in the case of choroidal melanomas, and 50 Gy in the case of retinoblastomas. Results: From the patients irradiated because of malignant intraocular tumors 154 (95.7%) were evaluated. From the evaluated patients 148 (96.1%) are alive. Among the living patients 4 (2.7%) is suffering from distant metastasis. From the irradiated eyes 148 (96.1%) could be saved. Six eyes had to be enucleated, 1 eye because of phthisis bulbi, 2 because of hemorrhagic glaucoma, and 3 because of uncontrollable tumor growth. Discussion: With the help of radioactive isotope-containing applicators the intraocular malignant tumors can be distroyed, so that the eyes can be saved with useful vision, without risking the patients’ life.
C1 [Berta, Andras] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti Klinika, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
RP Berta, A (reprint author), Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti Klinika, 4012 Debrecen, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 53
EP 57
PG 5
ER

PT J
AU Pamer, Zs
   Kovacs, B
AF Pamer, Zsuzsanna
   Kovacs, Balint
TI Transpupillary thermotherapy for choroidal metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Purpose: To present three cases with choroidal metastases treated with transpupillary thermotherapy (TTT). Patients and methods: Five choroidal metastases of three patients were treated with infrared laser thermotherapy (TTT). In all cases the distorted vision, caused by serous retinal detachment joining the posterior pole metastasis, led the patients to an ophthalmologist. In our first case an intraductal breast carcinoma led to bilateral multifocal choroidal metastases. In the second case a squamous cell carcinoma of the hypopharynx caused a rapidly growing choroidal metastasis. The primary tumor of the third patient was urothelial carcinoma. The efficacy of treatment and systemic (general health) outcomes are discussed. Results: Three of the tumors regressed to a flat scar, and led to improved vision after one session of treatment, one tumor needed two sessions of treatment to regress. The metastasis from the squamous cell carcinoma grew very fast and caused an early death not allowing follow-up. Conclusions: TTT can be a safe therapeutic option for small choroidal metastases. This one-session treatment leads to tumor regression, improves vision and positively affects quality of life of the patient suffering from metastatic cancer.
C1 [Pamer, Zsuzsanna] University of Pecs, Department of Ophthalmology, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Kovacs, Balint] University of Pecs, Department of Ophthalmology, Ifjusag utja 13., 7624 Pecs, Hungary.
RP Pamer, Zs (reprint author), University of Pecs, Department of Ophthalmology, 7624 Pecs, Hungary.
EM zsuzsanna.pamer@aok.pte.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 59
EP 64
PG 6
ER

PT J
AU Hajda, M
   Koranyi, K
   Salomvary, B
   Bajcsay, A
AF Hajda, Marta
   Koranyi, Katalin
   Salomvary, Bernadett
   Bajcsay, Andras
TI Clinical presentation, differential diagnosis and treatment of lacrimal gland tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Purpose: We describe the tumours occuring in the lacrimal gland fossa region, the important symptoms and the principles of the therapy. Methods: We surveyed the patients observed and operated at the National Institute of Neurosurgery, Budapest, Hungary. Results: Space-occupying lesions of lacrimal gland fossa are: 1. Epithelial lacrimal gland tumours, which may be benign or malignant (benign pleomorphic adenoma, malignant pleomorphic adenocarcinoma, adenoid cystic carcinoma, other carcinomas). 2. Lymphoproliferative tumours (lymphoma, leukaemia, Hodgkin’s disease, lymphosarcoma, plasmocytoma). 3. Pseudotumours (chronic inflammation, granuloma, sarcoidosis, reactive lymphoid hyperplasia). 4. Other tumours (dermoid cyst, haemangioma, neurinoma, haemangiopericytoma, metastatic tumour). In our Institute, 42% of the tumours of the lacrimal fossa was epithelial, 50% was lymphoid or pseudotumour, and 8% other tumours. Of the 59 primary epithelial tumours 62.7% was benign and 37.3% was malignant. The differential diagnosis and management are based on the clinical presentations, imaging studies and histological examination. Conclusions: Pleomorphic adenomas of the lacrimal gland should be diagnosed on radiological and clinical evidence, and biopsy avoided to prevent the recurrences and malignant transformation. The prognosis of pleomorphic adenomas depends on the early diagnosis and radical surgical excision of the lesion. In cases of suspected malignant epithelial tumours, lymphomas and pseudotumours, biopsy is indicated for the choice of appropriate treatment.
C1 [Hajda, Marta] National Institute of Neurosurgery, Amerikai u. 57., 1145 Budapest, Hungary.
   [Koranyi, Katalin] National Institute of Neurosurgery, Amerikai u. 57., 1145 Budapest, Hungary.
   [Salomvary, Bernadett] National Institute of Neurosurgery, Amerikai u. 57., 1145 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
RP Hajda, M (reprint author), National Institute of Neurosurgery, 1145 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 65
EP 70
PG 6
ER

PT J
AU Lehoczky, O
   Thurzo, L
   Bagameri, A
   Sarosi, Zs
   Udvary, J
   Pulay, T
AF Lehoczky, Otto
   Thurzo, Laszlo
   Bagameri, Andrea
   Sarosi, Zsuzsanna
   Udvary, Janos
   Pulay, Tamas
TI Results of treatment with docetaxel in patients with relapsed ovarian cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers. Material and methods: Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15). Results: CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50% 5 months after the beginning of treatment. Conclusion: Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.
C1 [Lehoczky, Otto] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bagameri, Andrea] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Sarosi, Zsuzsanna] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Udvary, Janos] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lehoczky, O (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM lehoczky@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 71
EP 75
PG 5
ER

PT J
AU Szucs, M
   Moskovits, K
AF Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2004. december 17-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Szucs, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 77
EP 79
PG 3
ER

PT J
AU Jakab, F
   Szucs, M
AF Jakab, Ferenc
   Szucs, Miklos
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium kepviseloinek 2004. december 16-i szakmai egyezteteserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Jakab, Ferenc] Sebeszeti Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Jakab, F (reprint author), Sebeszeti Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2005
VL 49
IS 1
BP 81
EP 89
PG 9
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Editorial opinion
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gy.u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 98
EP 98
PG 1
ER

PT J
AU Otto, Sz
   Kasler, M
AF Otto, Szabolcs
   Kasler, Miklos
TI Trends in cancer mortality and morbidity in Hungarian and international statistics. Characteristics and potential outcome of public health screening programmes.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB This work is a comparative analysis of Hungarian and international cancer mortality and morbidity data with special attention to the epidemiological background of these indices. The authors also discuss the epidemiological reasons for a national public health screening program, its major objectives and the strategy of choice in relation to similar international programs. The recent cancer mortality and morbidity data including their trends are also provided.
C1 [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9.Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9.Budapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, Budapest, Hungary.
EM sz.otto@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 99
EP 107
PG 9
ER

PT J
AU Boncz, I
   Hoffer, G
   Sebestyen, A
   Dozsa, Cs
   Ember, I
AF Boncz, Imre
   Hoffer, Gabor
   Sebestyen, Andor
   Dozsa, Csaba
   Ember, Istvan
TI The results of the monitoring of the first year (2002) of the Hungarian nationwide organised breast cancer screening programme.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: The aim of the study is to analyse the regional and time range characteristics of the breast cancer screening programme and the utilization of health services related to the programme. METHODS: The data derive from the database of the National Health Insurance Fund Administration containing routinely collected financial data. The patients include all the women having mammography screening in the year of 2002 (N=314,395). In the time range analysis the starting point (T0) was the time of the mammography screening identified with the outpatient code ''42400 mammography screening”. We calculated the average delay between the time of mammography screening (time=T0), further diagnostic (time=T1) and therapeutic (time=T2) procedures. For the calculation of the average period spent from the time of mammography screening we used the median value instead of arithmetic mean. RESULTS: According to our data 17,303 women had ultrasound examination in axilla (T1 median value: 20 days) and 23,249 women had ultrasound examination in breast (T1 median value: 26 days). Among the women having mammography examination in 2002, 906 had chemotherapy (T2 median value: 83 days), while 1364 patients had radiotherapy (T2 median value: 136 days). The T2 median value of subtotal and total mastectomy was 43-47 days and 50-53 days respectively, while the T2 median value of breast operations because of non-malignant causes was 57 days after mammography screening. The total annual cost of organised breast cancer screening programme, including the cost of mammography examination, the cost of further diagnostic examination and surgical, radio- and chemotherapy treatment of recalled women, was 2,242 billion Hungarian forints (8,968 million euros) in 2002. CONCLUSION: We observed significant regional differences, which result in large discrepancies in the equity. We can assume that these differences can be reduced by better organisation and the more consistent application of professional guidelines.
C1 [Boncz, Imre] Pecs University, Faculty of Health Sciences, Department of DiagnosticPecs, Hungary.
   [Hoffer, Gabor] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Sebestyen, Andor] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Dozsa, Csaba] Orszagos Egeszsegbiztositasi Penztar, Vaci ut 73/a., 1139 Budapest, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Boncz, I (reprint author), Pecs University, Faculty of Health Sciences, Department of Diagnostic, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 109
EP 115
PG 7
ER

PT J
AU Kardos, L
   Papp, Z
   Vargane Hajdu, P
   Ferencz, P
   Adany, R
AF Kardos, Laszlo
   Papp, Zoltan
   Vargane Hajdu, Piroska
   Ferencz, Peter
   Adany, Roza
TI Spatial analysis of cancer mortality, using empirical Bayes estimates in Fejer County, Hungary.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB General practitioners in the vicinity of Lake Velencei in Fejer County, Hungary, have reported an unusual pattern of recent cancer mortality. Our aim was to clarify whether the presumed mortality cluster is epidemiologically justified; whether it is restricted to the locations in question or also appears elsewhere in the county; and if it is associated with some particular disease group. County mortality from malignancies of the digestive system, other malignancies, and all other causes for the period 1994 to 1999 was analyzed in 15- to 64-year-old men and women, using conventional standardized mortality ratios and empirical Bayes estimates. A continuous surface was interpolated from settlement level data for mortality maps. A mortality cluster from men’s digestive cancers is apparent north and east of Lake Velencei and also elsewhere in the county. Differences from the country average in the frequency of males’ deaths from other malignancies are fairly limited. A number of problematic areas in men’s mortality from other causes are identifiable, including some of the settlements under the primary focus. Women’s digestive tract cancer mortality in the area of the men’s cluster near Lake Velencei is below the national average. There are almost no differences from the country level in women’s deaths from other malignancies. Female mortality from all other causes shows remarkable elevations in the south of the county. Our results suggest the possible role of geographically localized exposures. Men’s high mortality from digestive tract cancers is a problem affecting a considerable area of the county, necessitating further investigation. Continued search for causes is also warranted by some estimates of exceptionally high death rates in women from causes other than malignancies.
C1 [Kardos, Laszlo] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/b, 4028 Debrecen, Hungary.
   [Papp, Zoltan] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/b, 4028 Debrecen, Hungary.
   [Vargane Hajdu, Piroska] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/b, 4028 Debrecen, Hungary.
   [Ferencz, Peter] ANTSz Fejer megyei IntezeteSzekesfehervar, Hungary.
   [Adany, Roza] Debreceni Egyetem, Nepegeszsegugyi Iskola, Kassai ut 26/b, 4028 Debrecen, Hungary.
RP Adany, R (reprint author), Debreceni Egyetem, Nepegeszsegugyi Iskola, 4028 Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 117
EP 124
PG 8
ER

PT J
AU Sipos, G
   Krutsay, M
AF Sipos, Gabor
   Krutsay, Miklos
TI Primary lymphoma of the heart.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The authors describe the case of a 59-year-old woman, treated for breast cancer by mastectomy and chemotherapy 13 years before her death. Eleven years later she was treated successfully by gastic resection and chemotherapy for gastric cancer. In the last five months, the patient presented dyspnoe, leucopenia, hydropericardium and thoracic fluid both sides. In vivo the origin of these symptoms has not been discovered, neither by cytology nor by pleural biopsy.
C1 [Sipos, Gabor] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
   [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
RP Sipos, G (reprint author), Magyar Imre Korhaz, Patologiai Osztaly, 8401 Ajka, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 125
EP 128
PG 4
ER

PT J
AU Horvath, �
   Gaspar, A
   Bajcsay, A
   Szluha, K
   Adamecz, Zs
   Lengyel, L
AF Horvath, Akos
   Gaspar, Alicia
   Bajcsay, Andras
   Szluha, Kornelia
   Adamecz, Zsolt
   Lengyel, Laszlo
TI Brain metastasis treatment based on RPA classification.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB RPA classification of patients suffering from brain metastases is not widely used in Hungary. The authors reviewed the RPA disposition-based therapeutic recommendations in the literature. Retrospective analysis of their 123 brain metastatic cases showed 3.8 months median, 34.1% 1-year and 7.9% 2-year overall survival. Patient number and median survival in subgroups: RPA 1: 42/14 months, RPA 2: 38/6,2 months, RPA 3a: 6/3.1 months, 3b: 13/2 months, 3c: 10/0.7 months. Median survival of patients with brain meastases from cancer of unknown primary (CUP) was 3 months. In RPA class 1 and 2, 10% undertreatment has been found for soliter brain metastases, and all of the 3c patients were overtreated according to literature recommendations. The authors strongly recommend the use of RPA classification in the management of brain metastases and in contemplation of the capacity of radiotherapy/neurosurgery and oncology.
C1 [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Gaspar, Alicia] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Lengyel, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
RP Horvath, � (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4012 Debrecen, Hungary.
EM horvakos@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 129
EP 134
PG 6
ER

PT J
AU Toth, E
   Schneider, T
   Melegh, Zs
   Csernak, E
   Udvarhelyi, N
   Rosta, A
   Szentirmay, Z
AF Toth, Erika
   Schneider, Tamas
   Melegh, Zsombor
   Csernak, Erzsebet
   Udvarhelyi, Nora
   Rosta, Andras
   Szentirmay, Zoltan
TI Complex diagnosis of follicular lymphomas.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION: In the Western world the second most common type of non-Hodgkin’s lymphomas is follicular lymphoma (FL) comprising 30–35% of all cases. According to the data of the National Cancer Registry and our institute, this ratio is lower in Hungary and is about 15–20%, but the occurrence shows an increasing tendency. AIMS: Our aim was to survey and revise FLs that had been diagnosed at the National Institute of Oncology between 1990–1995. We studied the diagnostic relevance of histology, immunohistochemistry and the detection of immunoglobulin heavy chain (IgH) and bcl-2 gene rearrangements. MATERIALS AND METHODS: We surveyed 53 cases that were previously diagnosed as follicular or centrocytic, centroblastic lymphoma. Following histological re-examination, immunohistochemistry (CD20, CD3, bcl-2, CD10, bcl-6, CD5, p53, cyclin D1 and Ki-67) was performed on each case. We also studied the IgH and bcl-2 (major breakpoint region=MBR) gene rearrangement on paraffin embedded samples with conventional PCR methods. The classification was made according to the new WHO classification. RESULTS: After the revision of the 53 cases we found 37 follicular, 11 diffuse large Bcell, 1 mantle cell and 1 marginal zone lymphomas, 1 nodular lymphocyte predominant Hodgkin’s lymphoma and 2 follicular hyperplasias. The grade of the FLs correlated with the expression of different antigens. CD10, bcl-2 expression and the proliferation index with Ki-67 showed good correlation with the grade of FLs. We could detect bcl-2 gene rearrangement in 55% of the FLs. CONCLUSION: Considering the diagnostic relevance of the different methods we can conclude that histology alone is not sufficient to make a correct diagnosis. Ninety percent of our cases were solvable with the help of immunohistochemistry and in 10% of the cases the diagnosis was partly based on the molecular pathological results.
C1 [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Schneider, Tamas] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Rosta, Andras] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM terika@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 135
EP 140
PG 6
ER

PT J
AU Haltrich, I
   Kost-Alimova, M
   Kovacs, G
   Krivan, G
   Dobos, M
   Imreh, S
   Fekete, Gy
AF Haltrich, Iren
   Kost-Alimova, Maria
   Kovacs, Gabor
   Krivan, Gergely
   Dobos, Matild
   Imreh, Stefan
   Fekete, Gyorgy
TI Identification of 3q21q26 syndrome by ''multipoint'' interphase FISH analyses in childhood myeloid leukemia.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Cytogenetic syndrome involving bands 3q21 and 3q26, known as ''3q21q26 syndrome” has been observed in adult patients with acute myelogenous leukemia (0,5-2%), chronic myelogenous leukemia in blast crisis (20%), myelodysplastic syndromes and myeloproliferative disorders. In the present study bone marrow samples from two boys (12 and 16 years), diagnosed with CML and AML respectively, were investigated using conventional cytogenetic methods, interphase ''multipoint” fluorescence in situ hybridization (FISH), dual color-FISH and multiplex FISH. The ''multipoint” FISH analysis identified in de novo childhood AML case an inv(3)(q21q26) and a complex 3q rearrangement including inversion and duplication in the CML case. The ''3q21q26 syndrome” is associated with normal or elevated platelet counts with marked abnormalities of megakaryocytopoiesis, involvement of multiple hematopoietic lineages. The affected patients were resistant to conventional chemotherapy and had a short survival. This syndrome is very rare in de novo childhood AML, and simultaneous presence of 3q inversion and duplication, to our knowledge, has not yet been identified in hematological malignancies. The results of our study underline the importance of classical and modern cytogenetic analysis in the diagnosis of hematological malignancies, because in the majority of cases they can provide additional diagnostic information for the clinicians in deciding the best therapeutic approach, precise classification and prognosis of the disease.
C1 [Haltrich, Iren] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 5-7., 1094 Budapest, Hungary.
   [Kost-Alimova, Maria] Karolinska Institutet, Microbiology and Tumor Biology Center (MTC)Stockholm, Sweden.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 5-7., 1094 Budapest, Hungary.
   [Krivan, Gergely] Del-Pesti CentrumkorhazBudapest, Hungary.
   [Dobos, Matild] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 5-7., 1094 Budapest, Hungary.
   [Imreh, Stefan] Karolinska Institutet, Microbiology and Tumor Biology Center (MTC)Stockholm, Sweden.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 5-7., 1094 Budapest, Hungary.
RP Haltrich, I (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM Haltrich@gyer2.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 141
EP 147
PG 7
ER

PT J
AU Forgacs, Zs
   Kubinyi, Gy
   Sinay, G
   Bakos, J
   Hudak, A
   Surjan, A
   Revesz, Cs
   Thuroczy, Gy
AF Forgacs, Zsolt
   Kubinyi, Gyorgyi
   Sinay, Gaborne
   Bakos, Jozsef
   Hudak, Aranka
   Surjan, Andras
   Revesz, Csaba
   Thuroczy, Gyorgy
TI Effects of 1800 MHz GSM-like exposure on the gonadal function and hematological parameters of male mice.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of this study was to evaluate the possible effects of in vivo 1800 MHz GSM-like exposure on male reproduction. In five separate experiments, male NMRI mice (35–41 g) were exposed (11–12 mice each) to 1800 MHz GSM-like radiation. The average power density was 100 µW/cm2, the estimated SAR was 0.018–0.023 W/kg. The animals were exposed ten times (over two weeks on workdays) and the duration of exposure was 2 h/day. On the day of the last treatment, mice were anesthetized with i.p. pentobarbital, and blood samples were taken for hematology, serum chemistry and serum testosterone (T) determinations (ELISA). Testicles, epididymes, adrenals, prostates and pituitary glands were removed for histology. One testicle of each animal was used for culture of Leydig cells. The cells were cultured for 48 h in the presence or absence of human chorionic gonadotropin (hCG) to evaluate the in vitro steroidogenic response of Leydig cells. In the exposed animals red blood cell count (RBC: 8.59±0.10 T/l, n=37) and volume of packed red cells (VPRC: 42.29±0.43%, n=37) were significantly higher (p<0.01) compared with the controls (RBC: 8.12±0.08 T/l, n=36; VPRC: 39.76±0.36%, n=36). The serum testosterone level of the exposed animals (7.85±1.08 ng/ml, n=56) was also significantly elevated (p<0.05) compared to the controls (5.12±0.79, n=52), while the in vitro steroidogenic capacity of the Leydig cells was unaltered. No significant differences in the other investigated variables were found between controls and exposed mice. Our results indicate that the applied GSM-like microwave exposure may induce slight, but statistically significant alterations in some hematological and endocrine parameters of male mice within the physiological range. Further investigations are required to establish the biological significance of these phenomena.
C1 [Forgacs, Zsolt] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Kubinyi, Gyorgyi] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Sinay, Gaborne] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Bakos, Jozsef] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Hudak, Aranka] Orszagos Munkahigienes es Foglalkozas-egeszsegugyi IntezetBudapest, Hungary.
   [Surjan, Andras] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Revesz, Csaba] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
   [Thuroczy, Gyorgy] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Forgacs, Zs (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, 1450 Budapest, Hungary.
EM forgacs@bigfoot.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 149
EP 151
PG 3
ER

PT J
AU Toth, J
AF Toth, Jeno
TI Clinical signs and differential diagnosis of iris melanoma.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Iris melanoma is the rarest type of uveal melanomas. Only 4-5% of uveal melanomas occur on the iris. Although the iris can be easily examined due to its location, differentiation of melanocytic malformations such as naevi or melanomas is difficult for the examiner. According to publications by Rones and Zimmermann, histological examinations showed 22% of tumors to be malignant and 78% to be benignant. This lead to iridectomy and iridocyclectomy as therapeutic solutions to gain ground over enucleation. Follow-up of the clinical signs, transillumination, ultrasonic biomicroscopy, iris fluorescein angiography and photo-documentation of the clinical signs can be of great help in diagnosis of pigmented iris tumours. Growth of the tumour, secondary glaucoma, hyphaema, significant vascularisation of the tumour and increasing extent of pigmentation can be signs of malignant behaviour.
C1 [Toth, Jeno] Fejer Megyei Szent Gyorgy Korhaz, Szemeszeti Osztaly, Seregelyesi ut 3., 8000 Szekesfehervar, Hungary.
RP Toth, J (reprint author), Fejer Megyei Szent Gyorgy Korhaz, Szemeszeti Osztaly, 8000 Szekesfehervar, Hungary.
EM szemeszet@fmkorhaz.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 153
EP 159
PG 7
ER

PT J
AU Baliko, Z
   Sarosi, V
AF Baliko, Zoltan
   Sarosi, Veronika
TI The role of neoadjuvant therapy in the treatment of locally advanced, stage III non-small-cell lung cancer.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: to review the progress achieved in the neoadjuvant treatment of patients with locally advanced NSCLC by evaluating the articles published during the last 10 years. METHOD: altogether 51 articles (including prospective and retrospective studies, and reviews) were analysed with the intention to evaluate the efficacy of the different neoadjuvant modalities. RESULTS: different types of neoadjuvant treatments were reported. The articles were heterogenous not only in the aspect of the patient populations but also in regard to the treament modalities and schedules, the mode and timing of combination of chemotherapy with radiotherapy. Most studies support the advantage of chemoradiotherapy. The chemotherapy should be platinum based, and combination with modern drugs as gemcitabine is recommended. Surgery provides the best local control of the disease. Lobectomy, and in special circumstances sleeve resection, are preferred. The best prognostic factors are the R0 resection and the downstaging of the mediastinal lymph nodes. The cause of death is usually progressive disease, often brain metastases. Because of frequent occurrence of brain metastases, preventive cranial irradiation is recommended by many authors. CONCLUSION: to be able to compare different treatment modalities with consistent patient groups, patients should be classified into well-defined subgroups. T4 tumours (except pleuritis carcinomatosa) behave as locoregional disease, N2/N3 tumours, however, resemble more to systemic diseases. With two- or three-modality treatment, 3-7% improvement can be achieved in the 5-year survival time of patients. Evaluating the results, the heterogenity of stage III NSCLC should always be kept in mind. It is still unkown to which patients should surgery be offered after neoadjuvant therapy, and who will benefit more from chemoradiotherapy alone. Considering the downstaging effect of the therapy, the tumour and nodal state should be evaluated separately. To answer these questions, it is time to start large randomised studies.
C1 [Baliko, Zoltan] Baranya County Hospital, Department of Respiratory Medicine, Angyan Janos u.2., 7635 Pecs, Hungary.
   [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory Medicine, Angyan Janos u.2., 7635 Pecs, Hungary.
RP Baliko, Z (reprint author), Baranya County Hospital, Department of Respiratory Medicine, 7635 Pecs, Hungary.
EM bmktudo@enternet.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 161
EP 168
PG 8
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. januar 28-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 169
EP 171
PG 3
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. marcius 17-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 173
EP 177
PG 5
ER

PT J
TI XII. Primer Prevencios Forum osszefoglaloi
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2005
VL 49
IS 2
BP 179
EP 196
PG 18
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI Eletrajzi meltatas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Dr. Gyenes Gyorgy Budapesten szuletett 1925-ben.
C1 [Eckhardt, Sandor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 199
EP 199
PG 1
ER

PT J
AU Gyenes, G
AF Gyenes, Gabor
TI A besugarzas okozta szivbetegsegnek a korai emlorakos betegek tulelesere gyakorolt hatasa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
C1 [Gyenes, Gabor] University of Alberta, Walter Mackenzie Health Sciences Centre, T6G 2B7 Edmonton, Alberta, Canada.
RP Gyenes, G (reprint author), University of Alberta, Walter Mackenzie Health Sciences Centre, T6G 2B7 Edmonton, Canada.
EM ggyenes@cha.ab.ca
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 201
EP 202
PG 2
ER

PT J
AU Fodor, J
   Mozsa, E
   Zaka, Z
   Polgar, Cs
   Major, T
AF Fodor, Janos
   Mozsa, Emoke
   Zaka, Zoltan
   Polgar, Csaba
   Major, Tibor
TI Local relapse in young (≤40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: Data from various sources indicate that after breast conserving surgery (BCS), younger patients have a high risk of local relapse, but there is insufficient evidence about the risk of post-mastectomy local recurrence. This study investigates the risk of local recurrence for young (&#8804;40 years) patients treated with either conservative or radical surgery, with or without radiotherapy (RT). METHODS: 148 young (&#8804;40 years) women with early invasive breast cancer underwent axillary dissection and mastectomy (n=92) or BCS (n=56) between January 1983 and December 1997. When adjuvant RT was given, the median dose was 50 Gy. The risk factors of local recurrence were estimated by uni- and multivariate analysis. RESULTS: At a median follow-up time of 199 months 60 (40.5%) women died of breast cancer. The type of surgery (mastectomy vs. wide tumour excision) had no significant impact on breast cancer-specific survival. The crude rate of local relapse for nonirradiated mastectomy and BCS patients was 24% and 75% (p=0.0041), and for irradiated patients 4% and 23%, respectively (p=0.0091). After mastectomy in univariate analysis nodal status (negative vs. positive) and RT (no vs. yes) were significant predictors of local control, but tumour size (T1 vs. T2) and histological grade (1-2 vs. 3) were not. In multivariate analysis both nodal involvement and omission of RT remained independent significant negative predictors of local control. After BCS in univariate analysis extensive intraductal component (EIC, negative vs. positive) and RT (no vs. yes) were significant predictors of local control, but tumour size (T1 vs. T2), nodal status (N0 vs. N1) and histological grade (1-2 vs. 3) were not. In multivariate analysis omission of RT and presence of EIC remained independent significant negative predictors of local control. The 15-year actuarial rate of local relapse was 29% for irradiated, and 75% for nonirradiated BCS patients (RR, 0.21; 95% CI, 0.07-0.55; p=0.0052). The 15-year actuarial rate of local recurrence was 6% for irradiated, and 46% for nonirradiated node-positive mastectomy patients (RR, 0.12; 95% CI, 0.06-0.96; p=0.0095). CONCLUSION: The incidence of local recurrence is high for young patients treated either with BCS or mastectomy, and RT significantly reduces the risk. The use of postmastectomy RT in node-positive patients gives a good local control. The efficacy of BCS and RT as a treatment modality for young patients needs further investigations.
C1 [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM fodor@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 203
EP 208
PG 6
ER

PT J
AU Horvath, �
   Bajcsay, A
AF Horvath, Akos
   Bajcsay, Andras
TI Lung cancer radiotherapy: survey and latest evidences
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Based on their experience, the authors survey Hungarian and international literature for changes of indications, techniques and results in lung cancer radiotherapy. At the end of historical review, the latest evidence-based levels of different indications, the up-to-date techniques and the expected results are discussed.
C1 [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Horvath, � (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4012 Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 209
EP 213
PG 5
ER

PT J
AU Bajcsay, A
   Kontra, G
   Forgacs, Gy
   Fodor, J
AF Bajcsay, Andras
   Kontra, Gabor
   Forgacs, Gyula
   Fodor, Janos
TI Lens-sparing external beam radiotherapy of periocular lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: The presentation of techniques and results of lens-sparing external beam radiotherapy of patients with ophthalmologic lymphomas. MATERIAL AND METHODS: From 1991 to 2001, at the Department of Radiotherapy of the National Institute of Oncology, Budapest, 92 patients with periocular lymphomas were treated by photon and/or electron beam irradiation depending on the localization. Mean age was 63 years (range: 26-89 years) and the male/female ratio was 1.3. According to the Ann Arbor classification, 72% were in stage I.E. Histologically 85 patients (92.4%) were Grade I while 7 patients (7.6%) presented with higher grade disease. In case of low-grade lymphoma, a dose of 24-32 Gy was delivered, and for higher grade of malignacy we applied 34-40 Gy total dose, using 1.8-2 Gy daily fractions. RESULTS: The local remission rate was 94.4% (CR: 78.8% and PR: 15.6%). There was no change in 2.3%, and 3.3% showed progression. Mild and intermediate acute side effects occurred in 28%, and the incidence of chronic late complications was 3%. CONCLUSION: External beam radiotherapy applying lenssparing methods is safe and effective in the treatment of periocular lymphomas.
C1 [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Forgacs, Gyula] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM bajcsay@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 215
EP 219
PG 5
ER

PT J
AU Kocsis, B
   Pap, L
   Szekely, G
   Garami, M
AF Kocsis, Bela
   Pap, Lilla
   Szekely, Gabor
   Garami, Miklos
TI Radiotherapy of childhood brainstem tumours.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB STUDY OBJECTIVE: Description and evaluation of radiotherapy of inoperable tumours of central nervous system. New possibilities in radiotherapy planning. MATERIALS AND METHODS: Between 1987 and 2004, 58 patients (30 boys and 28 girls, mean age 8.5±4.3 years) with brain stem tumours were treated with 6 MV or 9 MV photons of the linear accelerator, or with telecobalt. The doses administered ranged from 30 to 71.2 Gy; mean 51.7±8.4 Gy. Treatment in each case was performed according to CT- and/or MR-based radiotherapy plan. As of 2000, in case of 16 patients a 3D conformal irradiation plan has been prepared. RESULTS: All patients were followed. The mean follow-up period was 21.8 months (range: 7 to 158 months). The mean duration of symptoms prior to diagnosis was 6.6±8.1 weeks (range: 1-52 weeks). Overall survival (OS) and progression-free survival (PFS) rates for all 58 patients were 39.9% and 21.2% at 1 years, 19.1% and 14.7% at 2 years, and 14.8% and 14.7% at 3 years respectively. The following factors were of prognostic influence on the OS in univariate analysis: duration of symptoms (&#8804;2 months vs. >2 months, p=0.0081), radiological response (p<0.0001) and clinical improvement (p=0.0003). Prognostic factors for PFS were similar to those predicting for OS. Multivariate analysis revealed that the radiological (OS, p=0.0034, PFS, p=0.024) and clinical (OS, p=0.026, PFS, p=0.044) improvement 6 weeks after completion of radiotherapy were of prognostic significance. CONCLUSION: Accurate field arrangement, precise patient fixation, and CT- and MR-based 3D conformal radiotherapy planning may result in better outcome of disease as well as minimal effect on surrounding normal tissues. Radiotherapy should be provided also for histologically not verified tumours. Sixty-eight percent of these patients had a transitory 20.6-month improvement, and 12.1% of them completely recovered.
C1 [Kocsis, Bela] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pap, Lilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Kocsis, B (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM szekelyg@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 221
EP 228
PG 8
ER

PT J
AU Kontra, G
   Fedorcsak, I
   Bajcsay, A
AF Kontra, Gabor
   Fedorcsak, Imre
   Bajcsay, Andras
TI Improvement of the first cerebral stereotactic radiosurgery system of Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: The first cerebral stereotactic radiosurgery system in Hungary was built in 1991. This system was based on a Leksell stereotactic head frame and a Neptun 10p linear accelerator. We performed 624 radiosurgery treatments with this system between 1991 and 2000. Our objective was to increase the reliability of operation and to extend the applicability of our radiosurgery system. METHODS AND MATERIALS: We modified our stereotactic floor stand with specially designed adapter plates to make it compatible with the Mevatron KD and Neptun 10p linear accelerators and other stereotactic head frames (Riechert-Mundiger, CRW and BrainLab). We made a new tertiary collimator holder attachable to the Mevatron KD linac. The range of treatable cerebral lesion was increased from 10-30 mm to 5-42.5 mm with additional collimator inserts. With the above modifications our radiosurgery system is compatible simultaneously with the Neptun 10p and the Mevatron KD linear accelerators. This way we were able to increase the reliability of operation of the system, as the treatment can be performed with the Neptun 10p linac in case of breakdown of the Mevatron KD linac after fixation of the head frame to a patient’s skull. RESULTS: The measured diameter of the radiation isocenter defined by the new radiosurgery collimator was less than 1 mm with the Mevatron KD linac. According to the Lutz-test the distance between the radiosurgery isocenter and the rotation axis of ZIV treatment table was less than 0.5 mm. Results of phantom test showed that the overall spatial precision of our modified radiosurgery system was better than 1.3 mm with Leksell head frame. CONCLUSIONS: On the basis of experiences with 662 patients' radiosurgery treatments, the extension of our first cerebral radiosurgery system to Mevatron KD linear accelerator resulted in a more reliable operation. In accordance with our phantom tests the extension of the original system did not worsen its overall spatial precision.
C1 [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fedorcsak, Imre] National Institute of NeurosurgeryBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM kontra@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 229
EP 233
PG 5
ER

PT J
AU Major, T
   Skriba, Z
   Varjas, G
   Fodor, J
AF Major, Tibor
   Skriba, Zoltan
   Varjas, Geza
   Fodor, Janos
TI Dosimetric assessment of external treatment plans for breast cancer: the significance of dose prescription selection.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To analyze the treatment plans of breast irradiation performed with two tangential beams, to discuss the importance of dose prescription, and to estimate the differences in delivered dose due to various dose prescription methods. MATERIAL AND METHODS: A survey was performed between the Hungarian radiotherapy centers in order to compare the dose prescription methods. Then, treatment plans of 125 breast cancer patients treated in our department were evaluated. The irradiations were performed with cobalt unit, and with 6 and 9 MV photon beams of linear accelerators. The dose distributions were normalized to izocenter, then dose values in five points in central plane; local medial, lateral and central maximums (D<sub>med</sub>, D<sub>lat</sub> and D<sub>cent</sub>); volumetric maximum and its location were determined. To characterize the dose to lung and to heart at left-sided tumors the central lung distance (CLD) and maximum heart distance (MHD) were used. Based on the results, estimation was made to assess the differences between delivered dose due to various dose prescriptions applied at the institutions. RESULTS: Four types of dose prescription are currently used in our country, and most frequently the isocenter is selected as a reference point. In the central plane the calculated dose in all but one points differed only a little from the dose to isocenter. The mean D<sub>med</sub>, D<sub>lat</sub> and D<sub>cent</sub> were 107%, 107% and 101%, respectively. The volumetric maximum was on average 13% higher than the dose to isocenter. Regarding the beam qualities, this value was 16%, 13% and 11% for cobalt unit, 6 MV and 9 MV photon beams, respectively. The mean CLD and MHD were 1.9 and 0.8 cm, respectively. The difference between delivered doses at the institutions was 6% on average, but in extreme cases it can be as high as 20%. CONCLUSIONS: Three-dimensional treatment planning and plan evaluation are recommended at breast irradiation, especially for large breasts. Since the various dose prescriptions may result in significant differences in the delivered doses, use of a standard dose prescription protocol is recommended.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Skriba, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM major@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 235
EP 243
PG 9
ER

PT J
AU Varjas, G
   Pazonyi, B
   Forgacs, Gy
AF Varjas, Geza
   Pazonyi, Bela
   Forgacs, Gyula
TI Computerized treatment planning: from the beginning to modern methods.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: To present the development of treatment planning methods at the National Institute of Oncology (NIO) from 1969 till 2005. METHODS: The methods and devices of treatment planning is described chronologically. RESULTS: First we did the treatment planning with in-house made devices: body contour drawing instrument, simplified anatomical cross sections, treatment planning table for the cross section projection, archives of isodose curves adjusted to body contours, etc. It was a significant improvement when the graphical addition of isodose curves was followed by computerized dose calculation. In 1978 the work of the Computerized National Treatment Planning Network was started. The Network was organized by IAEA, Ministry of Health Hungary and NIO. The modern treatment planning started at NIO in 1981. From this year, the treatment planning was based on CT, using the CT apparatus of the Medical Postgraduate University. In 1991 a Siemens MEVAPLAN treatment planning system was installed at NIO. The CT data were transferred to the system via floppy disk. The 3D treatment planning program (Pinnacle software of ADAC) started in 2000. The CT, the treatment planning system and newer linear accelerators are connected through the computerized radiotherapy network. Patient positioning, fixing and control devices (mask, EPID etc.) increased the efficacy of the treatment. In-house made devices help this aim too: mirrors at the linear accelerators, special skin marks for CT, block verification unit, multileaf collimator for x-ray treatment simulator. In this year the intensity-modulated radiotherapy (IMRT) will be started at NIO. CONCLUSIONS: The treatment planning at NIO developed to high degree during the investigated time, and it had a considerable effect on the efficacy of radiotherapy.
C1 [Varjas, Geza] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Pazonyi, Bela] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Forgacs, Gyula] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
RP Varjas, G (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM varjas@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 245
EP 249
PG 5
ER

PT J
AU Lang, I
AF Lang, Istvan
TI New clinical data on the erythropoetin treatment of anemic patients with malignancy. Summary of the major presentations at the Annual Meeting of ASCO in Orlando, 2005.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients’ quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.
C1 [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
RP Lang, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 251
EP 254
PG 4
ER

PT J
TI Congress of the Hungarian Radiotherapeutic Society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB October 13-15, 2005 Pannon University, Kaposvar, Hungary
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 255
EP 278
PG 24
ER

PT J
AU Abdulfatahr, B
   Dankovics, Zs
   Csejtei, A
AF Abdulfatahr, Bishr
   Dankovics, Zsofia
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Abdulfatahr, Bishr] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Abdulfatahr, B (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 256
EP 256
PG 1
ER

PT J
AU Agoston, P
   Major, T
   Somogyi, A
   Baricza, K
   Szasz, K
   Lovey, J
   Nemeth, Gy
   Kasler, M
   Fodor, J
AF Agoston, Peter
   Major, Tibor
   Somogyi, Andras
   Baricza, Karoly
   Szasz, Kornelia
   Lovey, Jozsef
   Nemeth, Gyorgy
   Kasler, Miklos
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szasz, Kornelia] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, Onko-rekonstrukcios SebeszetBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 256
EP 256
PG 1
ER

PT J
AU Antalffy, Zs
   Hadjiev, J
   Cselik, Zs
   Faour, A
   Benko, A
   Gyorfy, K
   Vincze, K
   Schmidt, L
   Repa, I
AF Antalffy, Zsolt
   Hadjiev, Janaki
   Cselik, Zsolt
   Faour, Amer
   Benko, Andras
   Gyorfy, Karoly
   Vincze, Krisztina
   Schmidt, Laszlo
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Antalffy, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Faour, Amer] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Benko, Andras] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Gyorfy, Karoly] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Vincze, Krisztina] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Schmidt, Laszlo] Szent Lukacs Egeszsegugyi KHT, Sebeszeti OsztalyDombovar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Antalffy, Zs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 256
EP 256
PG 1
ER

PT J
AU Al-Farhat, Y
   Kovacs, P
   Gulyban, �
   Bellyei, Sz
   Csere, T
   Stefanits, K
   Esik, O
   Hideghety, K
AF Al-Farhat, Yousuf
   Kovacs, Peter
   Gulyban, Akos
   Bellyei, Szabolcs
   Csere, Tibor
   Stefanits, Klara
   Esik, Olga
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
RP Al-Farhat, Y (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 257
EP 257
PG 1
ER

PT J
AU Beganyi, N
AF Beganyi, Nora
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Beganyi, Nora] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Beganyi, N (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 257
EP 257
PG 1
ER

PT J
AU Bellyei, Sz
   Kovacs, P
   Gulyban, �
   Farkas, R
   Hideghety, K
   Esik, O
AF Bellyei, Szabolcs
   Kovacs, Peter
   Gulyban, Akos
   Farkas, Robert
   Hideghety, Katalin
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 257
EP 257
PG 1
ER

PT J
AU Bellyei, Sz
   Szigeti, A
   Farkas, R
   Boronkai, �
   Berki, T
   Bodis, J
   Esik, O
   Sumegi, B
AF Bellyei, Szabolcs
   Szigeti, Andras
   Farkas, Robert
   Boronkai, Arpad
   Berki, Timea
   Bodis, Jozsef
   Esik, Olga
   Sumegi, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Berki, Timea] University of Pecs, Faculty of Medicine, Department of Immunology and BiotechnologyPecs, Hungary.
   [Bodis, Jozsef] Baranya Megyei Korhaz, Szuleszeti es Nogyogyaszati OsztalyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Sumegi, Balazs] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Benko, A
   Hadjiev, J
   Vallyon, M
   Lakosi, F
   Kovacs, �
   Antalffy, Zs
   Faour, A
   Glavak, Cs
   Kotek, Gy
   Repa, I
AF Benko, Andras
   Hadjiev, Janaki
   Vallyon, Marta
   Lakosi, Ferenc
   Kovacs, Arpad
   Antalffy, Zsolt
   Faour, Amer
   Glavak, Csaba
   Kotek, Gyula
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benko, Andras] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vallyon, Marta] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antalffy, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Faour, Amer] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kotek, Gyula] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Benko, A (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Bodacs, I
   Baricza, K
   Varjas, G
AF Bodacs, Istvan
   Baricza, Karoly
   Varjas, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodacs, Istvan] National Institute of OncologyBudapest, Hungary.
   [Baricza, Karoly] National Institute of OncologyBudapest, Hungary.
   [Varjas, Geza] National Institute of OncologyBudapest, Hungary.
RP Bodacs, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Borbely, �
   Gyanone Halasz, I
   Peterfaine Gimesi, V
   Solymos, E
AF Borbely, Agnes
   Gyanone Halasz, Ibolya
   Peterfaine Gimesi, Vera
   Solymos, Endre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Agnes] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Gyanone Halasz, Ibolya] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Peterfaine Gimesi, Vera] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Solymos, Endre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Borbely, � (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Borsfai, G
   Fenyvesi, J
   Rubintne Hidasi, V
   Nagy, K
AF Borsfai, Gezane
   Fenyvesi, Jozsefne
   Rubintne Hidasi, Valeria
   Nagy, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borsfai, Gezane] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Fenyvesi, Jozsefne] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Rubintne Hidasi, Valeria] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Nagy, Karoly] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Borsfai, G (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Csenki, M
   Hideghety, K
   Varga, Z
   Jakab, G
   Szabo, J
   Kahan, Zs
   Thurzo, L
AF Csenki, Melinda
   Hideghety, Katalin
   Varga, Zoltan
   Jakab, Gabriella
   Szabo, Judit
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Jakab, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Csenki, M (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 259
EP 259
PG 1
ER

PT J
AU Braz, K
   Korodi, L
   Erfan, J
   Jenei, P
   Fulop, I
   Olajos, J
AF Braz, Katalin
   Korodi, Laszlo
   Erfan, Jozsef
   Jenei, Peter
   Fulop, Imre
   Olajos, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Braz, Katalin] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Korodi, Laszlo] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Jenei, Peter] Josa Andras Megyei Korhaz, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti OsztalyNyiregyhaza, Hungary.
   [Fulop, Imre] Josa Andras Megyei Korhaz, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti OsztalyNyiregyhaza, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Braz, K (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Cselik, Zs
   Glavak, Cs
   Antal, G
   Kotek, Gy
   Hadzsiev, J
   Repa, I
AF Cselik, Zsolt
   Glavak, Csaba
   Antal, Gergely
   Kotek, Gyula
   Hadzsiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kotek, Gyula] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadzsiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Cselik, Zs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Csere, T
   Holcz, T
   Al-Farhat, Y
   Bellyei, Sz
   Farkas, R
   Kott, I
   Miszlai, Zs
   Sinko, E
   Stefanits, K
   Strassz, A
   Hideghety, K
   Esik, O
AF Csere, Tibor
   Holcz, Tibor
   Al-Farhat, Yousuf
   Bellyei, Szabolcs
   Farkas, Robert
   Kott, Ilona
   Miszlai, Zsuzsa
   Sinko, Eszter
   Stefanits, Klara
   Strassz, Andras
   Hideghety, Katalin
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Holcz, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Al-Farhat, Yousuf] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Kott, Ilona] University of Pecs, Department of OncologyPecs, Hungary.
   [Miszlai, Zsuzsa] University of Pecs, Department of OncologyPecs, Hungary.
   [Sinko, Eszter] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Strassz, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Csere, T (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Cselik, Zs
   Lakosi, F
   Antal, G
   Glavak, Cs
   Kotek, Gy
   Hadjiev, J
   Repa, I
AF Cselik, Zsolt
   Lakosi, Ferenc
   Antal, Gergely
   Glavak, Csaba
   Kotek, Gyula
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kotek, Gyula] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Cselik, Zs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Cselik, Zs
   Szabo, Sz
   Hadjiev, J
   Antal, G
   Glavak, Cs
   Lakosi, F
   Kovacs, �
   Seffer, I
   Repa, I
AF Cselik, Zsolt
   Szabo, Szilard
   Hadjiev, Janaki
   Antal, Gergely
   Glavak, Csaba
   Lakosi, Ferenc
   Kovacs, Arpad
   Seffer, Istvan
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Szabo, Szilard] Seffer-Renner MaganklinikaKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Seffer, Istvan] Seffer-Renner MaganklinikaKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Cselik, Zs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Dankovics, Zs
   Kecskes, L
   Szima, B
   Csejtei, A
AF Dankovics, Zsofia
   Kecskes, Laszlo
   Szima, Barna
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Kecskes, Laszlo] Markusovszky Korhaz, Mellkassebeszeti OsztalySzombathely, Hungary.
   [Szima, Barna] Markusovszky Korhaz, Pulmonologiai OsztalySzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Faour, A
   Hadjiev, J
   Antal, G
   Kotek, Gy
   Benko, A
   Vallyon, M
   Kovacs, �
   Lakosi, F
   Repa, I
AF Faour, Amer
   Hadjiev, Janaki
   Antal, Gergely
   Kotek, Gyula
   Benko, Andras
   Vallyon, Marta
   Kovacs, Arpad
   Lakosi, Ferenc
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Faour, Amer] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kotek, Gyula] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Benko, Andras] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vallyon, Marta] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Faour, A (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 261
EP 261
PG 1
ER

PT J
AU Esik, O
   Lumniczky, K
   Kis, E
   Mayer, �
   Nemeskeri, Cs
   Poti, Zs
   Csere, T
   Stefanits, K
   Hideghety, K
   Lengyel, E
   Dank, M
   Illes, �
   Safrany, G
AF Esik, Olga
   Lumniczky, Katalin
   Kis, Eniko
   Mayer, Arpad
   Nemeskeri, Csaba
   Poti, Zsuzsa
   Csere, Tibor
   Stefanits, Klara
   Hideghety, Katalin
   Lengyel, Erzsebet
   Dank, Magdolna
   Illes, Arpad
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Kis, Eniko] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Lengyel, Erzsebet] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Illes, Arpad] University of Debrecen, Faculty of Medicine, Department of Internal MedicineDebrecen, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Esik, O (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Farkas, R
   Al-Farhat, Y
   Gulyban, �
   Kovacs, P
   Bellyei, Sz
   Csere, T
   Stefanits, K
   Derczy, K
   Horvath, �P
   Sule, N
   Hideghety, K
   Esik, O
AF Farkas, Robert
   Al-Farhat, Yousuf
   Gulyban, Akos
   Kovacs, Peter
   Bellyei, Szabolcs
   Csere, Tibor
   Stefanits, Klara
   Derczy, Katalin
   Horvath, Ors Peter
   Sule, Norbert
   Hideghety, Katalin
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Al-Farhat, Yousuf] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Derczy, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Ors Peter] University of Pecs, Department of SurgeryPecs, Hungary.
   [Sule, Norbert] University of Pecs, Department of PathologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Farkas, R (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Farkas, R
   Bellyei, Sz
   Gulyban, �
   Kovacs, P
   Csere, T
   Sinko, E
   Hideghety, K
   Esik, O
AF Farkas, Robert
   Bellyei, Szabolcs
   Gulyban, Akos
   Kovacs, Peter
   Csere, Tibor
   Sinko, Eszter
   Hideghety, Katalin
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Sinko, Eszter] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Farkas, R (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Fazekas, O
   Uhercsak, G
   Kahan, Zs
   Varga, Z
   Heim, A
   Nagy, Z
   Fekete, G
   Szil, E
   Thurzo, L
AF Fazekas, Olga
   Uhercsak, Gabriella
   Kahan, Zsuzsanna
   Varga, Zoltan
   Heim, Andras
   Nagy, Zoltan
   Fekete, Gabor
   Szil, Elemer
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fekete, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fazekas, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Horvath, �
   Bajcsay, A
   Adamecz, Zs
   Szluha, K
AF Horvath, Akos
   Bajcsay, Andras
   Adamecz, Zsolt
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Akos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Adamecz, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Horvath, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 263
EP 263
PG 1
ER

PT J
AU Fodor, J
   Orosz, Zs
   Szabo, �
   Sulyok, Z
   Polgar, Cs
   Zaka, Z
   Major, T
AF Fodor, Janos
   Orosz, Zsolt
   Szabo, Eva
   Sulyok, Zoltan
   Polgar, Csaba
   Zaka, Zoltan
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Gaal, Sz
   Hideghety, K
   Fazekas, O
   Szabo, J
   Muhammad, S
   Varga, Z
   Heim, A
   Szil, E
   Kahan, Zs
   Thurzo, L
AF Gaal, Szilvia
   Hideghety, Katalin
   Fazekas, Olga
   Szabo, Judit
   Muhammad, Saqqa
   Varga, Zoltan
   Heim, Andras
   Szil, Elemer
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Muhammad, Saqqa] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gaal, Sz (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Gallaine Foldvari, D
   Arany, M
   Banhegyi, Gy
   Brauner, T
   Futo, A
   Hortobagyi, E
   Pora, K
   Tihanyi, �
   Neumann, 
   Derczy, K
   Esik, O
   Hideghety, K
AF Gallaine Foldvari, Dora
   Arany, Magdolna
   Banhegyi, Gyorgy
   Brauner, Tiborne
   Futo, Andrea
   Hortobagyi, Erzsebet
   Pora, Krisztina
   Tihanyi, Eva
   Neumann, J.
   Derczy, Katalin
   Esik, Olga
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gallaine Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Arany, Magdolna] University of Pecs, Department of OncologyPecs, Hungary.
   [Banhegyi, Gyorgy] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Futo, Andrea] University of Pecs, Department of OncologyPecs, Hungary.
   [Hortobagyi, Erzsebet] University of Pecs, Department of OncologyPecs, Hungary.
   [Pora, Krisztina] University of Pecs, Department of OncologyPecs, Hungary.
   [Tihanyi, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Neumann, J.] University of Pecs, Department of OncologyPecs, Hungary.
   [Derczy, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
RP Gallaine Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Gabor, G
   Jakab, G
   Szucs, M
AF Gabor, Gabriella
   Jakab, Gabriella
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Jakab, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gabor, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Glavak, Cs
   Antal, G
   Kotek, Gy
   Hadjiev, J
   Cselik, Zs
   Repa, I
AF Glavak, Csaba
   Antal, Gergely
   Kotek, Gyula
   Hadjiev, Janaki
   Cselik, Zsolt
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kotek, Gyula] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Glavak, Cs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Gulyban, �
   Bellyei, Sz
   Farkas, R
   Strassz, A
   Kovacs, P
   Gallaine Foldvari, D
   Derczy, K
   Hideghety, K
   Esik, O
AF Gulyban, Akos
   Bellyei, Szabolcs
   Farkas, Robert
   Strassz, Andras
   Kovacs, Peter
   Gallaine Foldvari, Dora
   Derczy, Katalin
   Hideghety, Katalin
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Strassz, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Gallaine Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Derczy, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Gulyban, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 265
EP 265
PG 1
ER

PT J
AU Hadjiev, J
   Lakosi, F
   Kovacs, �
   Antalffy, Zs
   Bajzik, G
   Prievara, F
   Csok, I
   Battyanyi, Z
   Antal, G
   Bogner, P
   Repa, I
AF Hadjiev, Janaki
   Lakosi, Ferenc
   Kovacs, Arpad
   Antalffy, Zsolt
   Bajzik, Gabor
   Prievara, Ferenc
   Csok, Imre
   Battyanyi, Zita
   Antal, Gergely
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antalffy, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bajzik, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Prievara, Ferenc] Kaposi Mor Oktato Korhaz, Szuleszet- Nogyogyaszati OsztalyKaposvar, Hungary.
   [Csok, Imre] Kaposi Mor Oktato Korhaz, Ful- Orr- Gegeszeti OsztalyKaposvar, Hungary.
   [Battyanyi, Zita] Kaposi Mor Teaching Hospital, Department of DermatologyKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Hadjiev, J (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Horvath, Zs
   Szavai, J
   Horvath, G
   Strassz, A
   Kobor, J
   Hideghety, K
   Doczi, T
   Esik, O
AF Horvath, Zsolt
   Szavai, Jozsef
   Horvath, Gabor
   Strassz, Andras
   Kobor, Jozsef
   Hideghety, Katalin
   Doczi, Tamas
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Szavai, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Strassz, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Kobor, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Hideghety, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Doczi, Tamas] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Horvath, Zs (reprint author), Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Kara, L
   Varga, E
   Fekete, G
   Gabor, G
   Szucs, M
AF Kara, Laszlo
   Varga, Edit
   Fekete, Gabor
   Gabor, Gabriella
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kara, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Varga, Edit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Fekete, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Kara, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Janvary, ZsL
   Zaka, Z
   Lovey, K
   Polgar, Cs
   Major, T
   Fodor, J
AF Janvary, Zsolt Levente
   Zaka, Zoltan
   Lovey, Katalin
   Polgar, Csaba
   Major, Tibor
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Kahan, Zs
   Csenki, M
   Varga, Z
   Szil, E
   Boda, K
   Thurzo, L
AF Kahan, Zsuzsanna
   Csenki, Melinda
   Varga, Zoltan
   Szil, Elemer
   Boda, Krisztina
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Kis, E
   Lumniczky, K
   Esik, O
   Safrany, G
AF Kis, Eniko
   Lumniczky, Katalin
   Esik, Olga
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kis, Eniko] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Kis, E (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Pesznyak, Cs
   Poti, Zs
AF Pesznyak, Csilla
   Poti, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 267
EP 267
PG 1
ER

PT J
AU Kobor, J
   Gulyban, �
   Kovacs, P
   Holcz, T
   Esik, O
AF Kobor, Jozsef
   Gulyban, Akos
   Kovacs, Peter
   Holcz, Tibor
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kobor, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Holcz, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Kobor, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Kovacs, �
   Hadjiev, J
   Lakosi, F
   Vallyon, M
   Antal, G
   Bajzik, G
   Bogner, P
   Repa, I
AF Kovacs, Arpad
   Hadjiev, Janaki
   Lakosi, Ferenc
   Vallyon, Marta
   Antal, Gergely
   Bajzik, Gabor
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vallyon, Marta] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bajzik, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Kovacs, � (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Kocsis, B
   Pap, L
   Szekely, G
   Varjas, G
AF Kocsis, Bela
   Pap, Lilla
   Szekely, Gabor
   Varjas, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Bela] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pap, Lilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kocsis, B (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 269
EP 269
PG 1
ER

PT J
AU Lakosi, F
   Hadjiev, J
   Kovacs, �
   Antal, G
   Bajzik, G
   Bogner, P
   Repa, I
AF Lakosi, Ferenc
   Hadjiev, Janaki
   Kovacs, Arpad
   Antal, Gergely
   Bajzik, Gabor
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bajzik, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 269
EP 269
PG 1
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 269
EP 269
PG 1
ER

PT J
AU Lovey, K
   Sulyok, Z
   Szabo, �
   Takacsi-Nagy, Z
   Major, T
   Fodor, J
   Polgar, Cs
AF Lovey, Katalin
   Sulyok, Zoltan
   Szabo, Eva
   Takacsi-Nagy, Zoltan
   Major, Tibor
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Nemes, J
   Papp, J
   Pintye, �
   Horvath, �
AF Nemes, Judit
   Papp, Judit
   Pintye, Eva
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemes, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Papp, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Nemes, J (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Szemzone Kerekes, 
   Bakos, B
   Ambrus, N
   Takacs, A
AF Szemzone Kerekes, K.
   Bakos, Bernadett
   Ambrus, Nelli
   Takacs, Aliz
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szemzone Kerekes, K.] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bakos, Bernadett] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Ambrus, Nelli] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Takacs, Aliz] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Szemzone Kerekes,  (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Nemeth, Gy
AF Nemeth, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Gyorgy] National Institute of OncologyBudapest, Hungary.
RP Nemeth, Gy (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Major, T
   Skriba, Z
   Varjas, G
   Fodor, J
AF Major, Tibor
   Skriba, Zoltan
   Varjas, Geza
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Skriba, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Papp, J
   Pintye, �
   Bagyi, P
   Benkone Szabo, K
   Horvath, �
AF Papp, Judit
   Pintye, Eva
   Bagyi, Peter
   Benkone Szabo, Krisztina
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Bagyi, Peter] Radikon KftDebrecen, Hungary.
   [Benkone Szabo, Krisztina] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Akos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Papp, J (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 271
EP 271
PG 1
ER

PT J
AU Nagy, V
   Vargane Elischer, �
   Korodine Karaszi, K
   Erfan, J
   Olajos, J
AF Nagy, Veronika
   Vargane Elischer, Eva
   Korodine Karaszi, Katalin
   Erfan, Jozsef
   Olajos, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Veronika] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Vargane Elischer, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Korodine Karaszi, Katalin] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Nagy, V (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 272
EP 272
PG 1
ER

PT J
AU Pesznyak, Cs
AF Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 272
EP 272
PG 1
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 272
EP 272
PG 1
ER

PT J
AU Safrany, G
   Kis, E
   Keszei, M
   Esik, O
   Lumniczky, K
AF Safrany, Geza
   Kis, Eniko
   Keszei, Marton
   Esik, Olga
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Kis, Eniko] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Keszei, Marton] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Safrany, G (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Muhammad, S
   Hideghety, K
   Gaal, Sz
   Varga, Z
   Heim, A
   Fazekas, O
   Kahan, Zs
   Szil, E
   Thurzo, L
AF Muhammad, Saqqa
   Hideghety, Katalin
   Gaal, Szilvia
   Varga, Zoltan
   Heim, Andras
   Fazekas, Olga
   Kahan, Zsuzsanna
   Szil, Elemer
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muhammad, Saqqa] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Muhammad, S (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Vallyon, M
   Hadjiev, J
   Antal, G
   Glavak, Cs
   Repa, I
AF Vallyon, Marta
   Hadjiev, Janaki
   Antal, Gergely
   Glavak, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vallyon, Marta] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Vallyon, M (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 273
EP 273
PG 1
ER

PT J
AU Sinko, E
   Sarosi, V
   Horvath, G
   Kovacs, P
   Kobor, J
   Kott, I
   Szigeti, A
   Baliko, Z
   Esik, O
AF Sinko, Eszter
   Sarosi, Veronika
   Horvath, Gabor
   Kovacs, Peter
   Kobor, Jozsef
   Kott, Ilona
   Szigeti, Andras
   Baliko, Zoltan
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sinko, Eszter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Horvath, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Kobor, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Kott, Ilona] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Baliko, Zoltan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Sinko, E (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Strassz, A
   Emri, M
   Gulyban, �
   Kovacs, P
   Horvath, Zs
   Doczi, T
   Tron, L
   Esik, O
AF Strassz, Andras
   Emri, Miklos
   Gulyban, Akos
   Kovacs, Peter
   Horvath, Zsolt
   Doczi, Tamas
   Tron, Lajos
   Esik, Olga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Strassz, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Emri, Miklos] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Doczi, Tamas] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Tron, Lajos] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
RP Strassz, A (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Szabo, J
   Gaal, Sz
   Cserhati, A
   Csenki, M
   Heim, A
   Kahan, Zs
   Hideghety, K
   Thurzo, L
AF Szabo, Judit
   Gaal, Szilvia
   Cserhati, Adrienn
   Csenki, Melinda
   Heim, Andras
   Kahan, Zsuzsanna
   Hideghety, Katalin
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Szabo, J (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Szakacs, M
   Toth, 
   Vargane Elischer, �
   Korodine Karaszi, K
   Erfan, J
   Olajos, J
AF Szakacs, Mihalyne
   Toth, M.
   Vargane Elischer, Eva
   Korodine Karaszi, Katalin
   Erfan, Jozsef
   Olajos, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakacs, Mihalyne] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Toth, M.] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Vargane Elischer, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Korodine Karaszi, Katalin] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Szakacs, M (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Zsidai, 
   Vizkeleti, J
AF Zsidai, Gy.
   Vizkeleti, Julia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zsidai, Gy.] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Zsidai,  (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 275
EP 275
PG 1
ER

PT J
AU Szlavik, K
   Major, T
AF Szlavik, Katalin
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szlavik, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szlavik, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Szluha, K
   Opauszki, A
   Borbely, T
   Pintye, �
   Varga, I
   Fulop, B
   Garami, Z
   Devenyi, K
   Andras, Cs
   Dezso, B
   Adamecz, Zs
   Urbancsek, H
   Der, �
   Horvath, �
AF Szluha, Kornelia
   Opauszki, Adrienn
   Borbely, Tibor
   Pintye, Eva
   Varga, Imre
   Fulop, Balazs
   Garami, Zoltan
   Devenyi, Katalin
   Andras, Csilla
   Dezso, Balazs
   Adamecz, Zsolt
   Urbancsek, Hilda
   Der, Adam
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Opauszki, Adrienn] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Borbely, Tibor] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Varga, Imre] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Fulop, Balazs] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Garami, Zoltan] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Devenyi, Katalin] Debreceni Egyetem, AOK, Orvosi Kepalkoto Intezet, Radiologia nem onallo TanszekDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Urbancsek, Hilda] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Der, Adam] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Oberna, F
   Polgar, Cs
   Somogyi, A
   Major, T
   Fodor, J
   Nemeth, Gy
AF Takacsi-Nagy, Zoltan
   Oberna, Ferenc
   Polgar, Csaba
   Somogyi, Andras
   Major, Tibor
   Fodor, Janos
   Nemeth, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Varga, Z
   Kahan, Zs
   Csenki, M
   Szabo, J
   Nikolenyi, A
   Boda, K
   Thurzo, L
AF Varga, Zoltan
   Kahan, Zsuzsanna
   Csenki, Melinda
   Szabo, Judit
   Nikolenyi, Aliz
   Boda, Krisztina
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Thurzo, L
   Bago, Zs
   Fekete, G
   Heim, A
   Nagy, Z
   Varga, Z
   Szil, E
   Fodor, E
AF Thurzo, Laszlo
   Bago, Zsolt
   Fekete, Gabor
   Heim, Andras
   Nagy, Zoltan
   Varga, Zoltan
   Szil, Elemer
   Fodor, Emese
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bago, Zsolt] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fekete, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Thurzo, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Zaka, Z
   Janvary, ZsL
   Ladanyi, K
   Lovey, K
   Major, T
   Polgar, Cs
   Fodor, J
AF Zaka, Zoltan
   Janvary, Zsolt Levente
   Ladanyi, Katalin
   Lovey, Katalin
   Major, Tibor
   Polgar, Csaba
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ladanyi, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Zaka, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Varga, Z
   Hideghety, K
   Fodor, E
   Heim, A
   Nagy, Z
   Thurzo, L
AF Varga, Zoltan
   Hideghety, Katalin
   Fodor, Emese
   Heim, Andras
   Nagy, Zoltan
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Varjas, G
   Pazonyi, B
   Forgacs, Gy
AF Varjas, Geza
   Pazonyi, Bela
   Forgacs, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pazonyi, Bela] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Forgacs, Gyula] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varjas, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 277
EP 277
PG 1
ER

PT J
AU Vigh, 
   Farkas, A
   Biro, E
   Tokai, R
AF Vigh, T.
   Farkas, Andrea
   Biro, Edit
   Tokai, Richard
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vigh, T.] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Biro, Edit] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Tokai, Richard] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Vigh,  (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Voit, E
   Varjas, G
   Pazonyi, B
   Kontra, G
   Weber, A
   Polgar, Cs
   Fodor, J
AF Voit, Erikne
   Varjas, Geza
   Pazonyi, Bela
   Kontra, Gabor
   Weber, Andras
   Polgar, Csaba
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Voit, Erikne] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pazonyi, Bela] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Weber, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Voit, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Thurzo, L
   Bago, Zs
   Fekete, G
   Heim, A
   Nagy, Z
   Varga, Z
   Szil, E
   Fodor, E
AF Thurzo, Laszlo
   Bago, Zsolt
   Fekete, Gabor
   Heim, Andras
   Nagy, Zoltan
   Varga, Zoltan
   Szil, Elemer
   Fodor, Emese
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bago, Zsolt] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fekete, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Heim, Andras] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Thurzo, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovics, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovics, Katalin
TI Note about the Meeting of the Hungarian Radiotherapeutic and Oncology Scientific Commettee (April 29, 2005)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Helyszin: Tolna Megyei Balassa Janos Korhaz-Rendelintezet Kulturterme, Szekszard Jelen vannak: 18 kollegiumi tag es a meghivottak
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovics, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 279
EP 282
PG 4
ER

PT J
AU Kasler, M
   Szucs, M
   Piko, B
AF Kasler, Miklos
   Szucs, Miklos
   Piko, Bela
TI Note about the Meeting of the Radiotherapetutic and Oncology Scientific Committee (June 10, 2005)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem, Budapest Jelen vannak: 18 kollegiumi tag es a meghivottak
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Piko, Bela] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 283
EP 287
PG 5
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI J.G. Sinkovics, J.C. Horvath (eds): Viral Therapy of Human Cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB A rakkutatas szamos megoldatlan problemaja kozott is elokelo helyet foglal el az onkolitikus virusok terapias alkalmazasa. Joggal kerdezhetjuk: lehetseges-e egyaltalan a daganatgyogyitas virusokkal, hiszen az elmult evtizedekben egyre tobb olyan virust ismerhettunk meg, melyeknek emberi patogenitasa bizonyitottnak tekintheto.
C1 [Eckhardt, Sandor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 289
EP 289
PG 1
ER

PT J
AU Agoston, P
AF Agoston, Peter
TI Congress of GEC-ESTRO
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Az Europai Sugarterapias Tarsasag Brachyterapias Csoportjanak (GEC-ESTRO) kongresszusat iden majus 5-7. kozott Budapest rendezhette meg.
C1 [Agoston, Peter] Organizing Committee of the GEC-ESTRO CongressBudapest, Hungary.
RP Agoston, P (reprint author), Organizing Committee of the GEC-ESTRO Congress, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 291
EP 291
PG 1
ER

PT J
TI News
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB A Magyar Onkologusok Tarsasaga XXVI. Kongresszusat rendezi Budapesten 2005. november 10-13. kozott A Magyar Tudogyogyasz Tarsasag Onkopulmonologiai Szekcioja 2005. december 2-3-an tartja ez evi tudomanyos rendezvenyet
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2005
VL 49
IS 3
BP 292
EP 292
PG 1
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Salutation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Nemeth Gyorgy professzor 2005-ben toltotte be 70. eletevet.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 295
EP 295
PG 1
ER

PT J
AU Agoston, P
   Somogyi, A
   Major, T
AF Agoston, Peter
   Somogyi, Andras
   Major, Tibor
TI Nagy dozisteljesitmenyu brachyterapias ''boost'' besugarzas a lokalizalt prosztatarak sugarkezeleseben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 297
EP 297
PG 1
ER

PT J
AU Fodor, J
AF Fodor, Janos
TI Klinikai gyakorlat es kutatas az Orszagos Onkologiai Intezet Sugarterapias Osztalyan
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 298
EP 298
PG 1
ER

PT J
AU Mayer, �
AF Mayer, Arpad
TI Hagyomanyok es fejlesztesek a Fovarosi Onkoradiologiai Kozpont sugarterapiajaban
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 299
EP 299
PG 1
ER

PT J
AU Naszaly, A
   Patonay, P
   Nemeskeri, Cs
AF Naszaly, Attila
   Patonay, Peter
   Nemeskeri, Csaba
TI Radiokemoterapia a Fovarosi Onkoradiologiai Kozpontban
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Naszaly, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 302
EP 302
PG 1
ER

PT J
AU Polgar, Cs
   Lovey, K
   Major, T
AF Polgar, Csaba
   Lovey, Katalin
   Major, Tibor
TI A brachyterapia szerepe a korai emlorak sugarkezeleseben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 303
EP 303
PG 1
ER

PT J
AU Takacsi Nagy, Z
   Vizkeleti, J
   Major, T
AF Takacsi Nagy, Zoltan
   Vizkeleti, Julia
   Major, Tibor
TI A nyelvgyokrak sugarkezelese: korszeru technikak es besugarzastervezes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 304
EP 304
PG 1
ER

PT J
AU Takacsi Nagy, L
   Patyanik, M
   Katona, Cs
AF Takacsi Nagy, Laszlo
   Patyanik, Mihaly
   Katona, Csilla
TI Mezoillesztesi technikak, doziseszkalacio a fej-nyaki daganatok sugarkezeleseben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Patyanik, Mihaly] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Takacsi Nagy, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 305
EP 305
PG 1
ER

PT J
AU Lovey, J
   Lukits, J
   Remenar, �
   Koronczay, K
   Kasler, M
   Nemeth, Gy
   Timar, J
AF Lovey, Jozsef
   Lukits, Julia
   Remenar, Eva
   Koronczay, Krisztina
   Kasler, Miklos
   Nemeth, Gyorgy
   Timar, Jozsef
TI Radiation-induced alterations in microvessel density as predictor of treatment efficiency in oropharyngeal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In this prospective study we have evaluated the predictive role of intratumoral microvessel density (MVD) for the therapeutic response and progression of inoperable oropharyngeal cancer (OPCC) treated with radiotherapy. Thirty-five OPCC patients were enrolled in this study. Biopsies from the primary tumor were taken before and after 20 Gy irradiation. Pathological factors such as histological grade, mitotic activity index and MVD were determined in both samples. Correlations of these factors with response to therapy, progression-free and overall survival were analyzed after a follow-up period of a minimum of 50 months. Objective response and survival was independent of the pretreatment MVD of OPCC. On the other hand, objective response was significantly affected by stage and low posttreatment MVD. Response to irradiation, and therapy-induced low postirradiation MVD were significant indicators of better overall and progression-free survival. We have shown in this small exploratory study that the anti-angiogenic effect of irradiation has a predictive value of the success of radiotherapy in locally advanced OPCC and can be used to select a radioresistant patient population which might require a more aggressive protocol.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lukits, Julia] National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
   [Koronczay, Krisztina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 307
EP 313
PG 7
ER

PT J
AU Lehoczky, O
   Pulay, T
AF Lehoczky, Otto
   Pulay, Tamas
TI Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Combination therapy with paclitaxel is widely proposed for first-line adjuvant treatment in ovarian cancer patients in Hungary as well as worldwide. The authors summarize the results of paclitaxelcarboplatin therapy of the years from 2000 to 2002, and compare them to the results observed in 2002. MATERIAL AND METHODS: 86 patients with ovarian cancer of stage I-IV were treated with the combination with paclitaxel (175 mg/m2, 3 hours) and carboplatin (AUC 5) at the Gynecological Department, National Institute of Oncology, Budapest. Average age of the patients was found 54+/-9.8 years. Optimal surgery (hysterectomy with bilateral adnexectomy and omentectomy with a maximal residual tumor burden of 1 cm) was done in 43 of the 86 patients. RESULTS: Tumor-free status was found in 60% and 31% of the patients in 2002 and 2005 respectively. Tumor-free status was observed in the groups of optimally operated and non-optimally operated patients in 79% and 42% in 2002 and in 44% and 19% in 2005. Median progression-free interval was higher in the optimally than in the nonoptimally operated patients (25 and 11 months), and was resulted in 16.5 months of all patients. CONCLUSION: Our paclitaxel-carboplatin treatment resulted in a similar progression-free interval as that was found in the literature, however, the ratio of tumor-free patients decreased to 31% during the follow-up time (median: 41 months).
C1 [Lehoczky, Otto] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Lehoczky, O (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 315
EP 318
PG 4
ER

PT J
AU Egyed, Zs
   Pentek, Z
   Magyar, Z
AF Egyed, Zsofia
   Pentek, Zoltan
   Magyar, Zoltan
TI The effect of hormone replacement therapy on mammographic density in female breast
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB BACKGROUND: Mammographic parenchymal patterns are of particular interest because the denser patterns reduce sensitivity and they have been shown to be affected by exogenous oestrogens. PURPOSE: To evaluate the possible effects of peri- and postmenopausal hormone replacement therapy (HRT) on the mammographic density in the different types of parenchymal patterns. Patients and methods: During a period of 7 years (average: 3.44), 1158 women with combined or monophasic HRT were checked with mammography yearly. Their base-line mammograms were compared with those of 1433 screening participants of the same age (average 56 years). Mammograms were evaluated according to the Tabar classification. We studied the changes in density between two examinations in the HRT group, especially in the subgroup with benign lesion. RESULTS: In comparison of the HRT and screening group, the distribution of their parenchymal patterns were similar. Pattern I (glandular) and II (adipose) eventually dominated, 38.9% and 47.9% in the HRT group, and 34.0% and 42.2% in the screening group. Pattern IV (adenotic) and V (fibrotic) types have been found in 8.9% of the HRT group, and 13.1% of the screening group. During HRT, an increase of breast density has developed after a few months, then it remained unchanged. Density increased in 30.8% of the whole HRT group, and in 38.0% of women who had benign lesions as well. Although there was a significant increase in breast density in case of pattern I-II and III (p=0.0013), pattern IV and V remained totally unchanged. The distribution of the patterns has changed significantly (p=0.0000) during HRT: the proportion of pattern I (glandular) type increased from 38.9% to 51.3%, pattern II (adipose) decreased from 47.9% to 30.6%, while the IV (adenotic) and V (fibrotic) types together showed no change. CONCLUSION: Careful clinical and mammographical follow-up might be appropriate in women undergoing HRT, especially in those with benign lesion, because the HRT-induced increase in breast density proved significant.
C1 [Egyed, Zsofia] MaMMa Egeszsegugyi Rt, Kapas u. 22., 1027 Budapest, Hungary.
   [Pentek, Zoltan] MaMMa Egeszsegugyi Rt, Kapas u. 22., 1027 Budapest, Hungary.
   [Magyar, Zoltan] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
RP Egyed, Zs (reprint author), MaMMa Egeszsegugyi Rt, 1027 Budapest, Hungary.
EM egyed.zsofia@axelero.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 319
EP 325
PG 7
ER

PT J
AU Szepesi, �
AF Szepesi, Agota
TI Molecular biology of CLL
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Recently, major advances have occurred in our understanding of the biology of chronic lymphocytic leukemia (CLL). CD5-positive CLL cells were once assumed to originate from immature, immunologically incompetent B lymphocytes, and to passively accumulate due to increased life time. In 1999, two research groups demonstrated that CLL, which is a morphologically uniform but clinically heterogenous disease, can be classified into two major subgroups on the basis of the mutational status of the immunglobulin heavy chain (IgH) genes. It was also suggested that these two groups both originate from mature cells that have passed the antigen selection process. This hypothesis was confirmed by gene expression studies indicating a uniform pattern characteristic to memory cells, as well as specific B-cell receptor (BCR) structures supporting the existence of a functional antigen selection. The differences in the BCR signal transduction mechanisms may underlie the different clinical behavior in which zeta-associated tirosine kinase (ZAP-70) may play a pivotal role, since elevated ZAP-70 expression is likely to be an unfavorable prognostic factor in CLL. The diagnostic testing for ZAP-70 expression plays an important role in the therapeutic decisions.
C1 [Szepesi, Agota] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Szepesi, � (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM agota@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 327
EP 330
PG 4
ER

PT J
AU Lampe, L
AF Lampe, Laszlo
TI The possibilities of retaining fertility in malignant gynecological tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The protection of reproductive organs and retaining fertility have always been of paramount importance in gynecology. Development of gynecological oncology and reproductive medicine over the last few decades have achieved and, indeed, made it compulsory to insist on retaining fertility when treatment of malignant disease leaves an opportunity for future pregnancies. The basic rule of gynecological cancer surgery is clarified further that radicality should not be more extensive than necessary and, at the same time, as intensive as the least necessary. One of the new challenges of current demographic trends, mostly in developed countries, is that the first child by the average family is planned nearly 10 years later than some decades ago. As a result, more and more women experience the development of malignant disease before they complete their family planning intentions. Beside the improved cancer treatment methods, deep frozen conservation of eggs and ovarian tissue together with chemotherapy and GnRH agonist treatment will provide further opportunity to enhance reproductive potential of women who are successfully treated of their gynecological cancer.
C1 [Lampe, Laszlo] University Medical School of Debrecen, Department of Gynecology and Obstetrics, Nagyerdei krt. 98.Debrecen, Hungary.
RP Lampe, L (reprint author), University Medical School of Debrecen, Department of Gynecology and Obstetrics, Debrecen, Hungary.
EM lampe@jaguar.dote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 331
EP 335
PG 5
ER

PT J
AU Sipocz, I
   Kulka, J
   Pinter, T
AF Sipocz, Istvan
   Kulka, Janina
   Pinter, Tamas
TI The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.
C1 [Sipocz, Istvan] Petz Aladar Hospital, Department of Oncoradiology, Vasvari Pal u. 2-4.Gyor, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of Oncoradiology, Vasvari Pal u. 2-4.Gyor, Hungary.
RP Sipocz, I (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
EM drsipocz@axelero.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 337
EP 342
PG 6
ER

PT J
AU Miltenyi, Zs
   Szekely, Gy
   Simon, Zs
   Keresztes, K
   Illes, �
AF Miltenyi, Zsofia
   Szekely, Gyorgy
   Simon, Zsofia
   Keresztes, Katalin
   Illes, Arpad
TI Differencies of arteria carotis in patients with Hodgkin's lymphoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Radiotherapy increases the risk of cardiovascular morbidity. We examined arteria carotis atherosclerosis and stenosis in Hodgkin’s lymphoma patients. We examined arteria carotis of 120 Hodgkin’s lymphoma patients who have been in complete remission for at least 5 years. 70 patients received neck irradiation (mean age at the time of the examination was 44. 6 years). Twenty-four (34.3%) of them had carotis sclerosis or stenosis, and it was significantly more than in the control group [8 out of 60 patients 13.3%)]. Twelve patients of the 50 who did not receive radiotherapy had carotis lesions, and there was no significant difference compared to the control group. Significant stenosis (>50%) was detected in only 3 patients (in the irradiated group). TIA, stroke or amaurosis fugax did not occur. Carotis stenosis does not seem to play a role in late mortality in Hodgkin’s lymphoma, but if the patient has an increased risk for atherosclerotic changes, then regular examinations are necessary, and other risk factors (smoking, hypertension, diabetes mellitus, hypothyreoidism, early menopausa) need to be treated.
C1 [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Szekely, Gyorgy] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Simon, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Keresztes, Katalin] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zs. krt. 22., 4004 Debrecen, Hungary.
RP Miltenyi, Zs (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4004 Debrecen, Hungary.
EM miltenyi@iiibel.dote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 343
EP 347
PG 5
ER

PT J
TI Beszamolo az I. Euro-Med rontgenasszisztensi kongresszusrol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 349
EP 349
PG 1
ER

PT J
AU Olah, E
AF Olah, Edit
TI The Best of European Cancer Research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Edit] Magyar Onkologusok TarsasagaBudapest, Hungary.
RP Olah, E (reprint author), Magyar Onkologusok Tarsasaga, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 352
EP 352
PG 1
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. oktober 3-i rendkivuli uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2005
VL 49
IS 4
BP 353
EP 356
PG 4
ER

PT J
TI Koszonto: Gyarmathy Laszlo foorvos 85 eves
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 3
EP 3
PG 1
ER

PT J
AU Gundy, S
AF Gundy, Sarolta
TI The role of chemical and physical factors in cancer development
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The author deals with the effects of environmental chemical-, and physical carcinogens playing predominant role in nearly 90% of the cancer development. Different steps of chemical carcinogenesis, classification and evaluation of carcinogens according to the criteria of International Agency for Research on Cancer, and the most important biological markers of genotoxic exposures are presented. Among physical agents the carcinogenic effects of ionizing and nonionizing radiations are demonstrated, including limited, inadequate or proved carcinogenic action of UV, microwave, static and low-frequency electric and magnetic fields.
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, 1122 Budapest, Hungary.
EM gundy@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 5
EP 18
PG 14
ER

PT J
AU Peley, G
   Torok, K
   Farkas, E
   Matrai, Z
   Horvath, Zs
   Sinkovics, I
   Hitre, E
   Renyi-Vamos, F
   Orosz, Zs
   Koves, I
AF Peley, Gabor
   Torok, Klara
   Farkas, Emil
   Matrai, Zoltan
   Horvath, Zsolt
   Sinkovics, Istvan
   Hitre, Erika
   Renyi-Vamos, Ferenc
   Orosz, Zsolt
   Koves, Istvan
TI The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION AND AIMS: The feasibility, accuracy and clinical significance of sentinel lymph node biopsy for patients with breast cancer after neoadjuvant chemotherapy has not yet been determined. The aim of this study was to investigate these questions. Patients and method: Dual agent-guided sentinel lymph node biopsy with preoperative lymphoscintigraphy was performed on 17 breast cancer patients after neoadjuvant chemotherapy at the Department of General and Thoracic Surgery, National Institute of Oncology, Budapest, from April 2004 to August 2005. Patients with clinically lymph node-negative breast cancer less than 3 cm in size after neoadjuvant chemotherapy were enrolled in the study.  RESULTS: Lymphoscintigraphy showed no axillary lymphatic drainage in 7 patients (41%), and no sentinel lymph node could be identified during surgery in these patients. Axillary lymph nodes were histologically positive in 6 (86%) out of these 7 patients. Sentinel lymph node biopsy was successful in 10 patients (59%), and in 8 (80%) of them the sentinel lymph node proved to be positive pathologically. False negative sentinel lymph node biopsy did not occur. Axillary lymph node status was histologically positive in 14 (82%) out of the 17 patients. The predicitive value of the clinical examination of the axilla after neoadjuvant chemotherapy, for the histological nodal status, was very low.  DISCUSSION AND CONCLUSIONS: Our sentinel lymph node identification rate is lower than the published average in the literature. This difference can be explained by the differences in the indication for neoadjuvant chemotherapy. Our false negative rate (0%) is, however, significantly better than that of others. On the basis of international experiences sentinel lymph node biopsy after neoadjuvant chemotherapy is technically feasible, but its accuracy is not satisfactory and its clinical significance has not yet been determined. Our success rate is specifically low, which cannot be explained by the lack of practice. Taking the histologically very high axillary positive rate into consideration, sentinel lymph node biopsy has no clinical role in our practice after neoadjuvant chemotherapy.
C1 [Peley, Gabor] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Torok, Klara] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Peley, G (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM peley@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 19
EP 23
PG 5
ER

PT J
AU Erlaky, H
   Toth, K
   Szabolcs, J
   Horvath, E
   Kemeny, V
   Muller, J
   Csoka, M
   Jokuti, L
   Erdelyi, D
   Kovacs, G
AF Erlaky, Hajna
   Toth, Kornelia
   Szabolcs, Judit
   Horvath, Erzsebet
   Kemeny, Viktoria
   Muller, Judit
   Csoka, Monika
   Jokuti, Laszlo
   Erdelyi, Daniel
   Kovacs, Gabor
TI Subacute cardiotoxicity caused by anthracycline therapy in children: Can dexrazoxane prevent this effect?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVES: The use of anthracyclines are limited by their cardiotoxic side effects (first of all congestive cardiomyopathy). In this study we analyzed the anthracycline-induced cardiotoxicity and the possible preventive role of dexrazoxane in children. PATIENTS: 158 anthracycline-treated long-term survivors could be analyzed. Sixty-one children received dexrazoxane (group D) and 97 patients received anthracyclines only (group C). METHODS: Cardiac ultrasound examinations (ECHO) and electrocardiograms (ECG) were performed regularly from the beginning of chemotherapy and yearly thereafter. Shortening fraction (FS) was used as indicator of the ventricular function. RESULTS: The incidence of reduced left ventricular function (FS) was 13.4% in C, and 8.2% in D (p=ns). Two years after completion of the chemotherapy FS was reduced in 13.7% in C and 0% in D, respectively (p=0.056), and 5 years after therapy in 11.0% in C and 2.4% in D, respectively (P=0.034). Left chamber wall diameter was abnormal in systole in 6% in C and 2% in D, in diastole in 11% in C and 7% in D (p=ns) after 3 years of follow-up. CONCLUSION: Anthracycline-induced subacute cardiotoxicity can be significantly diminished by the concomitant use of dexrazoxane. For the final conclusions longer follow-up is necessary.
C1 [Erlaky, Hajna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Toth, Kornelia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Szabolcs, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Horvath, Erzsebet] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Kemeny, Viktoria] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Jokuti, Laszlo] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM kovi@gyer2.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 25
EP 32
PG 8
ER

PT J
AU Kiss-Laszlo, Zs
   Nagy, B
   Thurzo, L
   Szabo, J
AF Kiss-Laszlo, Zsuzsanna
   Nagy, Beatrix
   Thurzo, Laszlo
   Szabo, Janos
TI Thymidylate synthase gene promoter polymorphism in advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: Thymidylate synthase (TS) is a rate-limiting enzyme in the DNA synthetic pathway, and represents a cellular target of antimetabolite drug 5-fluorouracil. It catalyzes the reductive methylation of deoxyuridine-5’-monophosphate to deoxythymidine-5’-monophosphate. Inhibition of TS will result in depletion of both dTMP and, subsequently, dTTP. As a consequence, dUTP is misincorporated into DNA, resulting in DNA breakage and cell death. Developing resistance against 5-fluorouracil (FURA) based drugs might be due to the failure of inhibition of thymidylate synthase enzyme function. In the promoter region of the TS gene there is a tandem repeat sequence (2R or 3R), which was found to be polymorphic and influences the gene expression. Effectiveness and tolerability of Tegafur treatment might be influenced by expression of the TS gene. Our purpose was to determine the effectiveness and tolerability of concomitant radiotherapy and low-dose chemotherapy using Tegafur in respect of promoter polymorphism of thymidilate synthase gene. MATERIAL AND METHODS: TS promoter polymorphism (2R/2R, 2R/3R, 3R/3R) was determined by polymerase chain reaction using genomic DNA, in 47 patients with advanced head and neck cancer. RESULTS: Thirty patients out of 47 showed complete response, and genotyping of these patients revealed 2R/2R in 22 (73.3%), 2R/3R in 2 (6.7%) and 3R/3R in 6 (20%). Seventeen out of 47 patients reacted with partial response, and 2R/2R or 2R/3R were revealed in 5 (29.4%) and 3 (17.6%) patients, respectively, and 3R/3R genotype was identified in 9 patients (53%). CONCLUSION: We did not find any correlation between patient’s data and response to therapy, but strong correlation was found between the latter and the patient’s genotype. This facts indicate that the analysis of promoter polymorphism of thymidylate synthase gene might be a useful target to examine before FURA-based chemotherapy, and might allow to go into the direction of individualized treatment of head and neck cancer. We suppose that tumor response depends on genomic features of the patients.
C1 [Kiss-Laszlo, Zsuzsanna] University of Szeged, Department of Medical Genetics, Somogyi B. u. 4., 6720 Szeged, Hungary.
   [Nagy, Beatrix] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Janos] University of Szeged, Department of Medical Genetics, Somogyi B. u. 4., 6720 Szeged, Hungary.
RP Szabo, J (reprint author), University of Szeged, Department of Medical Genetics, 6720 Szeged, Hungary.
EM szabo@comser.szote.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 33
EP 37
PG 5
ER

PT J
AU Szanto, I
   Banai, J
   Vamosi-Nagy, I
   Nagy, P
   Bajtai, A
AF Szanto, Imre
   Banai, Janos
   Vamosi-Nagy, Istvan
   Nagy, Pal
   Bajtai, Attila
TI Importance of endoscopic biopsy and cytology in the diagnosis of esophageal squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB We have tested the role and significance of histology combined with cytology in the diagnosis of esophageal squamous cell carcinomas. Biopsy specimens and samples for cytological smear were taken by a fiberoptic flexible endoscope. In order to minimise the loss of biological sample, the residue from the brush was removed with rinsing fluid. From 1973 to 2005 we examined 820 patients with squamous cell carcinoma of the esophagus. Endoscopic biopsy yielded positive result in 97.2%. Cytology performed in 724 patients turned out to be positive in 90.3%. Both examinations were conducted in 648 patients (79%), and yielded positive result in 572 patients (88.3%). Negative biopsy result was obtained in 22 patients, however, 14 of them had positive cytological diagnosis. Both biopsy and cytology were negative in 8 cancer patients (1%). No complication was observed with either diagnostic technique. In our material cancer was diagnosed in 776 patients by histology. However, in a further 14 of 22 patients with negative histology, cancer was detected by cytology. This means that the presence of cancer was also confirmed on the basis of morphological features in 790 cases, i.e. in 96.3% of the patients. Our results show that the combined use of biopsy and cytology in malignant tumours yields high diagnostic accuracy. Since abrasion exfoliate cytology is a quick and useful diagnostic measure it should be a routine examination in the evaluation of abnormal changes in the esophageal mucosa. The examination of the rinsing fluid of the sampling brush, introduced by us, yielded additional diagnostic information.
C1 [Szanto, Imre] Orszagos Gyogyintezeti Kozpont, Sebeszeti Osztaly, Szabolcs u. 33-35., 1135 Budapest, Hungary.
   [Banai, Janos] National Medical Center, 1st Department of Internal MedicineBudapest, Hungary.
   [Vamosi-Nagy, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Nagy, Pal] Orszagos Gyogyintezeti Kozpont, Patologiai osztalyBudapest, Hungary.
   [Bajtai, Attila] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
RP Szanto, I (reprint author), Orszagos Gyogyintezeti Kozpont, Sebeszeti Osztaly, 1135 Budapest, Hungary.
EM szantoimre@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 39
EP 41
PG 3
ER

PT J
AU Lehoczky, O
   Pulay, T
AF Lehoczky, Otto
   Pulay, Tamas
TI First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Weekly docetaxel therapy is a new therapeutical form of relapsed ovarian cancer. Phase I and II trials of this administration form are rare in the literature of this tumor type. The authors report on a retrospective study of this treatment. MATERIALS AND METHODS: Ten patients with recurrent epithelial ovarian carcinoma were treated by dose-dense weekly docetaxel in 57 courses. The patients received a median of 6 courses of docetaxel on day 1, 8 and 15 together with a one-week pause, in 4-week courses. The average age of the patients was 61±9 years. Eight patients received a docetaxel monotherapy at a dose of 40 mg/m2, in weekly administration, and two patients weekly docetaxel combination therapy with carboplatin of AUC 3, on the same days as above. The premedication used before docetaxel was the same as the one given in the 3-week protocols: the patients received treatments of 100 mg methyl-prednisolone 12 hours and half an hour before docetaxel infusion. No G4 hematological toxicities were observed. G3 and G2 leucopenia was found in 6/57=11% and 4/57=8% of treatments. No granulocyte colony stimulating factor was given. Progression-free interval (PFI) was calculated by GraphPad Prism (version 2.0) program. RESULTS: Complete response was found in two patients (2/10=20%), and the patients are tumor-free 2 and 3 months after treatment. All the other patients showed tumor progression after some time of stabilization. The median progression-free interval was calculated as 2 months. CONCLUSION: Weekly docetaxel is found to be a tolerable treatment form of relapsed ovarian cancer patients. For the evaluation of the treatment more studies are warranted.
C1 [Lehoczky, Otto] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lehoczky, O (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 43
EP 46
PG 4
ER

PT J
AU Szoke, T
   Kayser, K
   Baumhakel, JD
   Trojan, I
   Furak, J
   Tiszlavicz, L
   Szluha, K
   Horvath, �
AF Szoke, Tamas
   Kayser, Klaus
   Baumhakel, Jan-Dirk
   Trojan, Imre
   Furak, Jozsef
   Tiszlavicz, Laszlo
   Szluha, Kornelia
   Horvath, Akos
TI Prognostic role of microvascularization in operated lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB OBJECTIVE: The aim of our study was the determination of microvascularization and its prognostic significance in lung cancer patients. METHODS: Histological sections were prepared from paraffinembedded tissues removed from the peripheral part of the tumor of 450 radically operated non-small cell and small cell lung cancer patients. Immunohistochemical staining was performed with antibody against factor VIII-associated antigen. During computer imaging, the absolute and relative parameters of vascularization were determined, as was the density of tumor cells situated to the nearest neighboring vessels. The results were compared with TNM status, the cell type and survival. RESULTS: T2 and T4 tumors demonstrated an enhanced vascularization, however, except for the surface fraction, statistically significant difference was not found. The microvascularization parameters did not differ significantly between tumors with different N status. In small cell lung cancer cases, the vascularization was stronger than in non-small cell lung cancer cases, while cell density was lower, however, these differences did not prove statistically significant. The survival rate decreased significantly with the increasing tumor cell density in the interval of 0-20 &#181;m. CONCLUSIONS: A clear connection could not be demonstrated between vascularization and the appearance of lymph node metastases. The density of tumor cells measured in the direct vicinity of vessels proved an important prognostic factor.
C1 [Szoke, Tamas] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Kayser, Klaus] Vivantes Humboldt Klinikum, Department of PathologyBerlin, Germany.
   [Baumhakel, Jan-Dirk] Vivantes Humboldt Klinikum, Department of PathologyBerlin, Germany.
   [Trojan, Imre] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szoke, T (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM szoketama@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 47
EP 53
PG 7
ER

PT J
AU Krutsay, M
   Sipos, G
AF Krutsay, Miklos
   Sipos, Gabor
TI Gliomatosis cerebri
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB A 64 years old woman presented with weakness, vertigo, paresthesia, dementia, which progressed to coma in a three-month-long period. The autopsy revealed pulmonary thrombosis and infarction, gastric erosions, peptic ulcer in the duodenum, leiomyoma in the esophagus, fibrosis of the pancreas and mild atherosclerosis. On macroscopic examination, the 1440 g brain did not show any bleeding, infarction or tumor. The histologic examination revealed gliomatosis cerebri of the white matter of the cerebral hemispheres.
C1 [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi Frigyes u. 1., 8400 Ajka, Hungary.
   [Sipos, Gabor] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi Frigyes u. 1., 8400 Ajka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai Osztaly, 8400 Ajka, Hungary.
EM miklos.krutsay@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 55
EP 58
PG 4
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. szeptember 16-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: SzE AOK Szemeszeti Klinika, Csaladorvosi Tanszek, Konyvtar Jelen van: 15 kollegiumi tag, meghivottak jelenleti iv szerint
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 59
EP 65
PG 7
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. november 4-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Szent Lazar Megyei Korhaz, Salgotarjan Jelen van: 17 kollegiumi tag, meghivottak jelenleti iv szerint
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 67
EP 78
PG 12
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2005. december 2-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 19 kollegiumi tag, meghivottak jelenleti iv szerint
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2006
VL 50
IS 1
BP 79
EP 83
PG 5
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Lapis Karoly akademikus 80 eves
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 91
EP 91
PG 1
ER

PT J
AU Jeney, A
   Kenessey, I
   Timar, F
   Olah, J
   Pogany, G
   Babo, I
   Harisi, R
AF Jeney, Andras
   Kenessey, Istvan
   Timar, Ferenc
   Olah, Julia
   Pogany, Gabor
   Babo, Istvan
   Harisi, Reveka
TI Inhibition of cell migration for the development of antimetastatic agents
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Further progress in the therapy of malignant diseases is expected from the introduction of potent antimetastatic drugs. Surveying of the complex and multi-step behavior of the metastatic process, compounds showing inhibitory action against tumor cell migration may be ranked among the promising antimetastatic agents. Our present study indicate, however, that the antimigratory actions of certain antitumor drugs (doxorubicin, taxol), and inhibitors of signal transduction (PD-98059, LY-294002, SB-203580) are highly dependent on the assay applied (Boyden-chamber, 3D ECM cell culture). It has been proposed that agents interrupting cell-extracellular matrix contacts (hexyldeoxyuridine, borrelidin) and others interfering with the regulatory mechanism of gene translation (rapamycin, ribavirin) could be regarded as leading compounds in the antimetastatic drug development process. Nevertheless, for introducing diagnostically based targeted therapy the forthcoming tasks must include the further elucidation of the molecular mechanisms implicated in the amoeboid and cluster type of cell migration.
C1 [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26.Budapest, Hungary.
   [Kenessey, Istvan] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Timar, Ferenc] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Olah, Julia] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Pogany, Gabor] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Babo, Istvan] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Harisi, Reveka] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
RP Jeney, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
EM ajeney@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 93
EP 100
PG 8
ER

PT J
AU Kopper, L
   Hajdu, M
AF Kopper, Laszlo
   Hajdu, Melinda
TI Tumor stem cells - a possible scenario
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB More and more evidence support that tumors arise from somatic stem cells or from cells, either progenitors or differentiated ones, with the properties of stemness. It is a question whether all tumor cells have the capacity for selfrenewal and unlimited growth or only a fraction of them, i.e. the tumor stem cells. The concept is challenging, since the existence of tumor stem cells has an important practical consequence: only stem cells should be removed or stopped in order to control the tumor, while the other cells have temporary proliferative capacity.
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM kopper@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 101
EP 106
PG 6
ER

PT J
AU Nagy, P
   Laszlo, V
   Schaff, Zs
AF Nagy, Peter
   Laszlo, Viktoria
   Schaff, Zsuzsa
TI Hepatocarcinogenesis in human liver
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Due to the development of the imaging techniques and liver surgery, pathologists are encountered more frequently with preneoplastic liver lesions. Well-defined stages of human hepatocarcinogenesis have been distinguished recently. Dysplastic foci represent the earliest stage of this process. Small-cell dysplastic foci are tumor precursors, but the large-cell form of this lesion does not progress further. The next stage is the dysplastic nodule, this larger lesion can be recognized by imaging techniques and gross examination of the specimen. Low- and high-risk forms are distinguished based on the level of cytological and structural atypia. The small hepatocellular carcinomas have a diameter of less than 2 cm by definition. The small HCC of indistinctly nodular type is equivalent of in situ carcinomas in other organs and designated sometimes as early HCC. The small HCC of the distinctly nodular type can be interpreted as advanced cancer despite its small size. The distinction between these lesions can be facilitated by ancillary techniques. The so-called capillarization of the liver sinusoids during the progression is characterized by the increased expression of endothelial markers as CD31 and CD34. Immunostaining for CD44, beta-catenin and p53 has prognostic value. Molecular biological techniques reveal gradual epigenetic and DNA changes during the process of hepatocarcinogenesis. Global gene expression profiling of hepatocellular carcinomas may result in a new classification of this tumor and can reveal new potential therapeutic targets.
C1 [Nagy, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26, 1085 Budapest, Hungary.
   [Laszlo, Viktoria] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26, 1085 Budapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Nagy, P (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM nagy@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 107
EP 113
PG 7
ER

PT J
AU Peterfia, B
   Hollosi, P
   Szilak, L
   Timar, F
   Paku, S
   Jeney, A
   Kovalszky, I
AF Peterfia, Balint
   Hollosi, Peter
   Szilak, Laszlo
   Timar, Ferenc
   Paku, Sandor
   Jeney, Andras
   Kovalszky, Ilona
TI Role of syndecan-1 proteoglycan in the invasiveness of HT-1080 fibrosarcoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Syndecan-1 is a transmembrane heparan sulfate proteoglycan which plays pivotal role in cell-cell and cell-extracellular matrix interactions. However, its implication in the establishment of malignant phenotype is still controversial. Its expression indicates differentiated phenotype in certain tumors, while it confers invasive nature for others. For the better understanding of the role of syndecan-1 in cancer we transfected HT-1080 fibrosarcoma cell line with the full and a truncated construct of syndecan-1 and established stable cell lines with them. We studied the in vitro and in vivo growth capacity and metastatic potential of the transfectants in comparison with the cell line bearing only the EGFP expression vector. Our results showed that the growth rate of syndecan transfectants increased and they developed more lung metastases than the control cells. As local growth of the full transfectant was faster than that of the 78sig we presume that the full protein and maybe the shedding is needed for the local development of the tumor, but the intracellular and transmembrane domain is sufficient to promote metastasis formation.
C1 [Peterfia, Balint] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Hollosi, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Szilak, Laszlo] Szilak Labor KftSzeged, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Kovalszky, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM koval@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 115
EP 120
PG 6
ER

PT J
AU Strausz, J
AF Strausz, Janos
TI Imaging technics in bronchology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Bronchoscopic imaging and diagnostics are tightly connected with radiological and pathological techniques. While computer tomography (virtual bronchoscopy) makes possible to mimic a realistic endobronchial situation, autofluorescent bronchoscopy holds significant potential to discover precancerous lesions not identifiable by standard bronchoscopy. Endoscopic ultrasound and fluoroscopy can be applied in order to obtain images and tissue samples from the extrabronchial areas. Electromagnetic navigation during flexible bronchoscopy, a novel technology that facilitates approaching peripheral lung lesions, involves creating an electromagnetic field around the thorax and localizing an endoscopic tool using a microsensor overlaid upon previously acquired CT images. In conclusion, parallel use of invasive and non-invasive imaging has the potential for considerable improvements in the diagnostic possibilities of routine bronchoscopic procedures.
C1 [Strausz, Janos] National Koranyi Institute of Pulmonology, Piheno u. 1., 1529 Budapest, Hungary.
RP Strausz, J (reprint author), National Koranyi Institute of Pulmonology, 1529 Budapest, Hungary.
EM strausz@koranyi.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 121
EP 125
PG 5
ER

PT J
AU Suba, Zs
   Ujpal, M
AF Suba, Zsuzsanna
   Ujpal, Marta
TI Correlations of the insulin resistance and tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Insulin resistance is a worldwide risk factor for the two most dangerous human disease groups; namely, for cardiovascular lesions and malignancies. The insulin resistance syndrome have five basic criteria: hyperglycemia, visceral obesity, elevated serum triglyceride level, low HDL-cholesterol level (dyslipidemia) and hypertension. Each of these criteria alone are risk factors for cancer, and they mean together a multiple risk. Insulin resistance of the liver, skeletal muscles, and fatty tissue leads to a reactive hyperinsulinemia by the increased secretory activity of the beta-cells. Insulin has diverse metabolic effects, and at the same time is a growth factor. It enhances the production and mitogenic activity of other, insulin-like growth factors, and leads to pathological cell proliferation. In the uncompensated phase of insulin resistance hyperglycemia appears, which promotes tumor genesis by several pathways. The elevated serum glucose level is advantageous for the increased DNA synthesis of the tumor cells. It provokes deliberation of free radicals, which will cause derangement of both the DNA and the enzymes having a role in the repair mechanisms. Hyperglycemia leads to a nonenzymatic glycation of protein structures, and the glycated products enhance the deliberation of free radicals, cytokines and growth factors. Insulin resistance means an enhanced risk for breast, pancreas, liver, colon, bladder, prostate and oral cavity cancers. The moderately increased fasting glucose level is also a risk factor for breast, stomach and colon cancers, even without manifestation of type 2 diabetes. Insulin resistance promotes tumor progression as well. In cancer patients with hyperglycemia or type 2 diabetes, the rate of tumor recurrence, metastatic spread and fatal outcome is higher as compared with the tumor patients without metabolic disease. The correlation between insulin resistance and tumor promotion reveals new possibilities in the prevention and treatment of cancer. The healthy diet, physical activity and weight loss increase insulin sensitivity, and decrease the risk for both cardiovascular diseases and malignancies.
C1 [Suba, Zsuzsanna] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
   [Ujpal, Marta] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
RP Suba, Zs (reprint author), Semmelweis University, Department of Oral and Maxillofacial Surgery, 1085 Budapest, Hungary.
EM suba@szajseb.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 127
EP 135
PG 9
ER

PT J
AU Szende, B
   Arvai, K
   Petak, I
   Nagy, K
   Vegso, Gy
   Perner, F
AF Szende, Bela
   Arvai, Kristof
   Petak, Istvan
   Nagy, Katalin
   Vegso, Gyula
   Perner, Ferenc
TI Changes in gene expression during the proliferative processes of parathyroid gland
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of this study was to investigate the changes in expression pattern of the most important genes connected with apoptosis in proliferative apoptotic lesions (hyperplasia, adenoma), applying cDNA microarray technique, in order to promote the possible diagnostic or therapeutic utilisation of any difference in gene expression compared to the healthy (normal) parathyroid gland. Samples were taken from surgically removed 2 hyperplasias, 2 adenomas and 2 normal parathyroid glands. The Apoptosis Gene Array (Superarray) was used. This contains 112 genes, in tetraspot arrangement. The probes measured 250-600 base pairs. Streptavidin was bound to the array. CDP Star TM chemiluminescent substrate was used for detection. The samples deriving from hyperplasia or adenoma were compared to samples from normal parathyroid glands. The following genes were overexpressed in both hyperplasia and adenoma: CHEK1, ATM, BCL-XL, FAS, TNF, cIAP1, TRAIL, FADD, CASP 4,5,6,8, CD120b, CD137, LTA, TANK, TARF2, CAD, LIGHTR, DR3LG. CASP1,10, BFAR, BOD, BCL2L2, TRANCE were underexpressed in both hyperplasia and adenoma. Genes overexpressed only in hyperplasia were: MDM2, MCL1, BCL2A1, BLK, RIPK2, CD40LG, TRAF5, HUS1, BNIP3. Underexpressed only in hyperplasia: BOK, CIDEA, TRAF1, TRIP. Overexpressed only in adenoma: APOLLON, RIPK1, LTB, LTBR, CASP2,13, cIAP2, CIDEB. Underexpressed only in adenoma: TRAF4 and FASLG. Overexpresion or underexpression meant 1.5-fold difference from normal average values. As a result of this study, both pro-apoptotic and antiapoptotic genes were identified in hyperplasia and adenoma of the parathyroid gland. It seems that increased proliferation is connected also with increased apoptotic activity, but tumor cell candidates are able to survive, by activation of signal pathways resulting in overexpresion of anti-apoptotic genes.
C1 [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Arvai, Kristof] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Perner, Ferenc] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Szende, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bszende@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 137
EP 140
PG 4
ER

PT J
AU Timar, J
   Paku, S
   Tovari, J
   Dome, B
AF Timar, Jozsef
   Paku, Sandor
   Tovari, Jozsef
   Dome, Balazs
TI Rationale of the antivascular therapies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Vascularization of cancer is a complex and heterogenous process where neoangiogenesis by sprouting is only one of the possible mechanisms that also include postnatal vasculogenesis, vessel incorporation, intussusceptive microvascular growth, glomeruloid angiogenesis and vascular mimicry. Furthermore, the mechanism of vascularization may also depend on the cancer type and the host tissue as well. Antivascular agents can be divided into angiosuppressive ones (endothelial cell proliferation inhibitors), vascular-targeted agents (microvessel disrupting agents) and anti-hypoxia agents (targeting the molecular pathways responsible for the development of the angiogenic phenotype). Since antivascular therapy is a special form of targeted therapy, it is necessary to apply it in a rational manner to consider the type of vascularization, the molecular background of the angiogenic phenotype, the stage of the disease and the standard anticancer therapy. Whithout such a fine-tuning, antivascular therapies cannot be integrated more successfully into the management of cancer patients.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 141
EP 151
PG 11
ER

PT J
AU Tompa, A
   Magyar, B
   Toth, F
   Biro, A
   Fodor, Z
   Jakab, M
   Major, J
AF Tompa, Anna
   Magyar, Balazs
   Toth, Ferenc
   Biro, Anna
   Fodor, Zoltan
   Jakab, Matyas
   Major, Jeno
TI Characterization of the health state of oncology unit nurses by geno- and immunotoxicological biomarkers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Statistical data indicate a chronic shortage of work-force due to overwork, ill health state and increased risk of chronic noninfectious diseases in Hungarian health care personnel, which needs investigations in order to decrease the risk. Nurses of oncology units, often exposed to carcinogens when preparing and handling cytostatic drugs, are especially at high risk. In the present publication we report a complex clinical, geno- and immunotoxicology risk assessment of altogether 500 nurses, performed during the last 10 years at various oncology units in Hungary. The obtained results indicate that the health status of nurses at oncology units is better than the Hungarian average, especially of hypertonia and type II diabetes. However, the prevalence of iron deficiency anemia and different thyroid gland diseases is significantly higher than those of the controls matched for sex and age. The results suggest that iron deficiency can potentiate the resistance to insulin, i.e. the persistance of iron deficiency may increase the serum glucose levels and thus the risk of diabetes. Among the studied geno- and immunotoxicology biomarkers, the frequency of chromosome aberrations, sister chromatide exchange and B lymphocytes was significantly increased compared to the matched controls. The obtained alterations demonstrate the occupational exposure of the nurses to cytostatic drugs, thus the introduction of more strict hygienic controls and compliance with the European Union chemical safety regulations is necessary.
C1 [Tompa, Anna] Semmelweis University, Department of Public Health, Nagyvarad ter 4., 1445 Budapest, Hungary.
   [Magyar, Balazs] Semmelweis University, Department of Public Health, Nagyvarad ter 4., 1445 Budapest, Hungary.
   [Toth, Ferenc] Semmelweis University, Department of Public Health, Nagyvarad ter 4., 1445 Budapest, Hungary.
   [Biro, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi IntezetBudapest, Hungary.
   [Fodor, Zoltan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi IntezetBudapest, Hungary.
   [Jakab, Matyas] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi IntezetBudapest, Hungary.
   [Major, Jeno] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi IntezetBudapest, Hungary.
RP Tompa, A (reprint author), Semmelweis University, Department of Public Health, 1445 Budapest, Hungary.
EM tomann@net.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 153
EP 161
PG 9
ER

PT J
AU Zalatnai, A
AF Zalatnai, Attila
TI Familial pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Familial clustering is estimated in 5-10% of pancreatic cancers. In different countries Familial Pancreatic Cancer Registries have been established to investigate the epidemiology, and genetic background in these families and, to organize the screening programs for high-risk relatives and for follow-up. The largest such registry is found at Johns Hopkins University Hospital. Evaluating the available date revealed that familial pancreatic cancer is heterogeneous: it may occur in kindreds of pancreatic cancer patients, but it may also be associated with various familial cancer syndromes. Such syndromes include FAMMM-syndrome, hereditary breast cancer, Peutz-Jeghers syndrome, but other associations can also be taken into account. The germline mutations are also heterogeneous, and although they are not absolutely decisive, they significantly increase the risk of the affected persons, making the organ more susceptible for environmental carcinogens. High-risk family members should be screened for gene mutations (especially for BRCA2, STK11/LKB1, CDKN2A/p16, PRSS1 genes), and by using endoscopic ultrasound. These methods are useful for identifying the preneoplastic conditions, but of equal importance is the cessation of smoking. In Hungary there are no relevant data about the epidemiology of familial pancreatic cancer, but their number is estimated to be about 80-150 annually. Considering the very high (and continuously increasing) incidence, it seems to be necessary to register and screen these families. This review emphasizes the importance of these goals.
C1 [Zalatnai, Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Zalatnai, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM zalatnai@korb1.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 163
EP 168
PG 6
ER

PT J
TI XIII. Primer Prevencios Forum osszefoglaloi
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 169
EP 192
PG 24
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. januar 13-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 19 kollegiumi tag
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 193
EP 198
PG 6
ER

PT J
AU Szucs, M
   Moskovits, K
AF Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. marcius 24-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 13 kollegiumi tag, es meghivottak
C1 [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Szucs, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2006
VL 50
IS 2
BP 199
EP 204
PG 6
ER

PT J
AU Kovacs, G
   Gaudi, I
   Kovi, R
AF Kovacs, Gabor
   Gaudi, Istvan
   Kovi, Rita
TI An interdisciplinary malignancy, the lung cancer in Hungary in 2006: epidemiology, prevention and access to therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The most frequent malignant tumor is lung cancer all around the world. Mortality rate is highest in Hungary. The frequency accumulates in the Southern part of the country. Early radical resection is the really effective treatment of the disease, which can bring the chance of longer survival. The methods of prevention, such as restrain of smoking and early detection with targeted examinations of the risk groups need more attention. There are unacceptable differences among regions in Hungary on the field of the accessibility to the adequate therapies. There are three-fold differences in the rate of operation and radiotherapy between certain counties. The frequency of the chemotherapy is acceptable, but there are some centers which do not use the recommended modern protocols. Professional supervisors and inspectors must give marked attention to the quality control of lung cancer therapies to provide equal chances to patients, independently of their residence.
C1 [Kovacs, Gabor] National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, Piheno ut 1., 1529 Budapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kovi, Rita] Orszagos Egeszsegbiztositasi PenztarBudapest, Hungary.
RP Kovacs, G (reprint author), National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, 1529 Budapest, Hungary.
EM kovac@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 207
EP 215
PG 9
ER

PT J
AU Palko, A
AF Palko, Andras
TI Imaging diagnosis of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Lung cancer is one of the major causes of death as one of the most frequent malignant diseases in Hungary. Imaging examinations, especially computed tomography (CT), magnetic resonance imaging (MRI) and positron emission computed tomography (PET-CT) play eminent role in the detection, differential diagnosis, staging and follow-up of the disease. The purpose of this article is to review the role and efficacy of the available modalities and to define the diagnostic algorithm appropriate in different periods of the disease.
C1 [Palko, Andras] University of Szeged, Department of Radiology, 6720 Szeged, Hungary.
RP Palko, A (reprint author), University of Szeged, Department of Radiology, 6720 Szeged, Hungary.
EM palko@radio.szote.u-szeged.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 217
EP 221
PG 5
ER

PT J
AU Csekeo, A
AF Csekeo, Attila
TI The possibility of surgery for smallcell lung cancer (state of art)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The author provides information about epidemiology as well as surgical practice for small cell lung cancer (SCLC) in Hungary. It is emphasized that, based on the author’s experience and on international consensus, TNM system is the basis of accurate oncological treatment. The oncological management of SCLC is summarized, which is based on surgery. SCLC, especially cases undergoing surgery, are often detected as a peripheral nodule which should be examined preoperatively by special algorithm. Despite the published favorable results, surgical treatment alone is not accepted nowadays as a correct oncological point of view. The aim of adjuvant therapy is to improve survival and to decrease local recurrence. The 5-year survival of SCLC according to stages is between 4 and 60%. After the late 80’s, the complex multimodality oncotherapy has started, with neoadjuvant treatment. SCLC is chemosensitive, even at N2 stage after down-staging surgery might be available. The late results show 20-46% cumulative 5-year survival rate. However, in the case of N2 disease, only 15-30% 5-year survival is achieved. This is a critical question for surgery of SCLC, because the dominant opinion is that for N2 disease and especially residual N2 surgery does not prolong survival. SCLC often occurs in combination with NSCLC. Therefore, salvage operation is a possible choice to remove the residual chemo/radiation resistant SCLC and NSCLC components. In conclusion, surgery has an advantage for SCLC therapy especially in patients with stage I-II disease. Value of surgery for stage III/a disease is under discussion and it is not recommended in Hungarian practice. To use a complex neoadjuvant protocol is advised which provides from 20 up to 40% five-year survival rate.
C1 [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Piheno u. 1., 1529 Budapest, Hungary.
RP Csekeo, A (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, 1529 Budapest, Hungary.
EM csekeo@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 223
EP 227
PG 5
ER

PT J
AU Szondy, K
   Egri, G
AF Szondy, Klara
   Egri, Gabor
TI The role of adjuvant chemotherapy in the treatment of non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Postoperative treatments for lung cancer have been evaluated for more than two decades, but in the majority of the studies (especially until 1990) no significant effect on survival has been shown. In 1995, a meta-analysis of eight cisplatin-based adjuvant chemotherapy trials with NSCLC showed a 13% reduction in the risk of death (P=0.08) and 5% benefit in 5-year survival. Among four positive trials (IALT, JBR10, ANITA and CALGB study) the absolute increase in the 5-year survival rates by adjuvant chemotherapy ranged from 4% to 15%, and the hazard ratios for death ranged from 0.6 to 0.86. The author analyzes the most important studies. Conclusion: adjuvant chemotherapy after complete resection of NSCLC can be considered as a new standard of care in patients with good performance status. Patients should receive 4 cycles of platina-based chemotherapy beginning 4-8 weeks after surgery. Future perspectives: optimization of chemotherapy regimens including targeted therapy (such as EGFR inhibitors, angiogenesis inhibitors, anti-EGFR monoclonal antibodies). Further progress is anticipated through the integration of chemopreventive agents into the adjuvant treatment.
C1 [Szondy, Klara] Semmelweis University, Department of Pulmonology, Diosarok 1/C, 1125 Budapest, Hungary.
   [Egri, Gabor] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Szondy, K (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM szondy1@citromail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 229
EP 232
PG 4
ER

PT J
AU Szilasi, M
   Horvath, �
   Dolinay, T
   Szanto, J
   Brugos, L
   Lengyel, L
   Sz. Kiss, S
   Kiss, M
   Adamecz, Zs
AF Szilasi, Maria
   Horvath, Akos
   Dolinay, Tamas
   Szanto, Janos
   Brugos, Laszlo
   Lengyel, Laszlo
   Sz. Kiss, Sandor
   Kiss, Magdolna
   Adamecz, Zsolt
TI Results on 42 irresectable NSCLC IIA-B patients with initial concurrent Taxotere-Cisplatin chemoradiotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB GOALS: A prospective multicenter study to treat non-small cell lung cancer (NSCLC) with inductive chemoradiotherapy for improving chances of operability. If used as first-line therapy, combined treatment improves survival and it is well tolerated with a low rate of side effects. PATIENTS: 42 patiens with stage IIIA-B NSCLC from which 36 could be followed. METHODS: A full dose Taxotere-Cisplatin chemotherapy was given to patients with concurrent radiotherapy in 2 Gy fractions up to 60 Gy via conformal irradiation. RESULTS: Local response was very high and 40.47% of patients became operable while in inoperable cases consolidation chemotherapy showed similar results as other protocols. We also found a low rate of side effects. The high rate of brain metastasis suggests that prophylactic cranial irradiation (PCI) should be considered.
C1 [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Dolinay, Tamas] University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Brugos, Laszlo] University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Lengyel, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Sz. Kiss, Sandor] Medical Faculty, University of Debrecen, 2 nd Department of SurgeryDebrecen, Hungary.
   [Kiss, Magdolna] University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szilasi, M (reprint author), University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, 4012 Debrecen, Hungary.
EM mszilasi@jaguar.unideb.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 233
EP 236
PG 4
ER

PT J
AU Ostoros, Gy
   Dome, B
AF Ostoros, Gyula
   Dome, Balazs
TI Erlotinib in the treatment of non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.
C1 [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Piheno ut 1., 1529 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Piheno ut 1., 1529 Budapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, 1529 Budapest, Hungary.
EM ostorosgyula@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 237
EP 241
PG 5
ER

PT J
AU Tamasi, L
   Bohacs, A
   Wollak, A
   Magyar, P
AF Tamasi, Lilla
   Bohacs, Aniko
   Wollak, Andras
   Magyar, Pal
TI Erythropoietin is a novel therapeutic option in the treatment of anemia caused by small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Anemia is very common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases the patient’s quality of life. Erythropoietin therapy is accessible in Hungary for the treatment of chemotherapy-induced anemia in patients suffering from small cell lung cancer. In our case report we present the case of a 62-year-old female small cell lung cancer patient with severe anemia, treated by erythropoietin-beta. The erythropoietin treatment provided the possibility of effective chemo- and radiotherapy. The patient's quality of life greatly improved due to the lack of the symptoms of anemia. The adequate use of erythropoietin is of great help to the physician in the management of small cell lung cancer patients, by improving the quality of life.
C1 [Tamasi, Lilla] Semmelweis University, Department of Pulmonology, Dios arok 1c., 1125 Budapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of Pulmonology, Dios arok 1c., 1125 Budapest, Hungary.
   [Wollak, Andras] Semmelweis University, Department of Pulmonology, Dios arok 1c., 1125 Budapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of Pulmonology, Dios arok 1c., 1125 Budapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM engi.tamasi@freestart.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 243
EP 246
PG 4
ER

PT J
AU Takacs, T
   Szentpali, K
   Paszt, A
   Ormandi, K
   Lazar, M
   Palka, I
   Kahan, Zs
   Lazar, Gy
AF Takacs, Tibor
   Szentpali, Karoly
   Paszt, Attila
   Ormandi, Katalin
   Lazar, Mate
   Palka, Istvan
   Kahan, Zsuzsanna
   Lazar, Gyorgy
TI Importance of sentinel lymph node biopsy in surgical therapy of in situ breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB INTRODUCTION AND AIMS: The aim of this retrospective study was to determine the rate of sentinel lymph node (SLN) positivity in patients with a final diagnosis of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: Between October 2002 and January 2006, 47 patients with DCIS underwent wide excision after radio-guided lesion localisation; 44 of them (93.6%) had simultaneous SLN mapping. SLNs were analysed by 250 micron step-sectioning by H&amp;E and immunohistochemical evaluation. RESULTS: The histological investigation verified pure breast DCIS in 36 cases (76.6%), DCIS with microinvasion in 7 cases (14.9%) and lobular in situ breast cancer in 4 cases (8.5%). SLNs were identified in 40 cases (91%) and removed in 39 cases: an average of 1.5 SLNs per patient. In 4 patients (9%) SLN biopsy was unsuccessful because of the lack of migration of radiocolloid substance. In these cases, axillary sampling was performed. In 1 case (2.3%), only a parasternal SLN was detected; this was not removed. Histological analysis of SLNs and axillary lymph nodes with haematoxylin and eosin or cytokeratin immunohistochemistry did not prove metastases. DISCUSSION AND CONCLUSION: On the basis of international data and our present results, routine SLN biopsy is not recommended in pure DCIS cases. If the final histology verifies an invasive or microinvasive tumour, or if mastectomy is to be performed, SLN mapping is suggested.
C1 [Takacs, Tibor] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Lazar, Mate] University of Szeged, Department of RadiologySzeged, Hungary.
   [Palka, Istvan] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of Surgery, Pecsi u. 4., 6720 Szeged, Hungary.
RP Takacs, T (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM takiti@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 247
EP 251
PG 5
ER

PT J
AU Muller, J
   Csoka, M
   Jakab, Zs
   Ponyi, A
   Erlaky, H
   Kovacs, G
AF Muller, Judit
   Csoka, Monika
   Jakab, Zsuzsanna
   Ponyi, Andrea
   Erlaky, Hajna
   Kovacs, Gabor
TI Hungarian experience with non-Hodgkin's lymphoma in childhood
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Between 1990 and 2004, 230 children with non-Hodgkin’s lymphoma (NHL) were treated according to the Berlin-Frankfurt-Munster (BFM) protocols (NHL-BFM-90 and -95) in Hungary. The aim of the present study was to summarize our experience with these protocols, to assess the survival rates and to compare the Hungarian data with the international results. The male-to-female ratio was 2.59:1, the mean age at the time of diagnosis was 10 years and 1 month. Ninety-one children had lymphoblastic/T-NHL (LB/T-NHL), 108 B-NHL and 31 anaplastic large cell lymphoma (ALCL). Twenty-eight patients had relapse after a mean time of 13 months from the time of the initial diagnosis. In the above mentioned period, 16 children underwent autologous stem-cell transplantation. Nine patients with B-NHL got anti-CD20 immunotherapy. The five-year overall survival (OS) of our patients is 77.8%±3%, the event-free survival (EFS) is 75.1%±3%. The 5-year OS and EFS rates were not statistically different in the three histology groups (OS: 71.6%±5%, 82.7%±4% and 80.3%±7%; EFS: 68.7%±5%, 81.1%±4% and 73.9%±8% in LB/T-NHL, B-NHL and ALCL, respectively). We can conclude that non-Hodgkin’s lymphoma has a quite good prognosis among the malignant pediatric diseases. The cure rate is over 75%. The Hungarian results are comparable with other international data. In the last five years the mortality during induction was reduced from 10% to 2% and the OS is about 10% better than it was before. In case of relapse or residual disease, therapeutic results can be improved with stem-cell transplantation with or without immunotherapy.
C1 [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Ponyi, Andrea] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Erlaky, Hajna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM muller@gyer2.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 253
EP 259
PG 7
ER

PT J
AU Lehoczky, O
   Pulay, T
AF Lehoczky, Otto
   Pulay, Tamas
TI Effectivity of pegylated liposomal doxorubicin in relapsed ovarian cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIMS: Pegylated liposomal doxorubicin is considered as one of the treatment options proposed nowadays for recurrent ovarian cancer patients. The aim of this study was to evaluate toxicity profile and effectivity of this treatment in patients with recurrent ovarian cancer. MATERIALS AND METHODS: Thirteen patients with recurrent epithelial ovarian carcinoma were treated by pegylated liposomal doxorubicin of 50 mg/m2 dose in 4-week courses. No serious hematological toxicity was observed. Only one patient showed grade 2 hand-foot syndrome at the 5-7th course, and she had to switch to another therapy. Progression-free interval (PFI) was calculated by GraphPad Prism (version 2.0) program. RESULTS: Two of the 13 patients (15%) showed complete response for 6 months, and 2 patients had partial response (15%). Median PFI was calculated as 2 months in all patients. CONCLUSION: Pegylated liposomal doxorubicin therapy can be administered with little toxicity in this subset of patients. The PFI is similar to data in the literature (an average of 4 months) in case of excluding data of the incurable patients with very advanced disease who could recieve only 1-2 courses of chemotherapy.
C1 [Lehoczky, Otto] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Lehoczky, O (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 261
EP 264
PG 4
ER

PT J
AU Szucs, M
   Moskovits, K
AF Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. majus 19-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 16 kollegiumi tag, es meghivottak
C1 [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Szucs, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 265
EP 271
PG 7
ER

PT J
AU Kasler, M
   Szucs, M
   Piko, B
AF Kasler, Miklos
   Szucs, Miklos
   Piko, Bela
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. junius 23-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 16 kollegiumi tag
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Piko, Bela] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2006
VL 50
IS 3
BP 273
EP 283
PG 11
ER

PT J
AU Orosz, Zs
   Dezso, B
   Sapi, Z
   Tiszlavicz, L
   Tornoczky, T
AF Orosz, Zsolt
   Dezso, Balazs
   Sapi, Zoltan
   Tiszlavicz, Laszlo
   Tornoczky, Tamas
TI Reclassification of gastrointestinal mesenchymal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB A retrospective (1985-2005) multicentric evaluation of the pathological diagnoses of GIST (gastrointestinal stromal tumor) in Hungary was performed. A large cohort of 463 patients with abdominal mesenchymal tumors was reevaluated with the help of immunohistochemistry for CD117, CD34, desmin and S100. Prognostic groups have been established based on international criteria. Two hundred fiftyfive GISTs have been found in 245 patients during the evaluated period. Beside GIST, 81 leiomyogenic and 25 neurogenic tumors were the primary pathological diagnosis and in 74/255 cases the primary diagnosis was a benign tumor. In our cohort high-risk GIST cases were found to be the predominant. Based on our experience, in case of abdominal tumors of uncertain localization, immunohistochemical markers of CD117, CD34, S100 and desmin provide a proper tool for precise identification of the tumor entity including GIST.
C1 [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic Pathology, Budapest, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Tornoczky, Tamas] University of Pecs, Department of PathologyPecs, Hungary.
RP Orosz, Zs (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
EM zso@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 287
EP 292
PG 6
ER

PT J
AU Lang, I
   Hitre, E
AF Lang, Istvan
   Hitre, Erika
TI Trastuzumab (Herceptin) in the adjuvant teatment of HER-2-positive early breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The prognosis of HER-2-positive breast cancer (characterized by amplification of the HER-2 oncogen and/or overexpression of HER-2 receptor) is unfavourable. Trastuzumab (Herceptin), a monoclonal antibody against HER-2 receptor can improve the outcome of HER-2-positive breast cancer. Up to now this was proven only in advanced disease. Recently five large multicentric phase III adjuvant trials gave level one evidence on the benefit of adjuvant treatment with Herceptin, concerning disease-free survival (DFS) and overall survival (OS). Herceptin has decreased the relative risk of recurrence with about 50% and that of death with nearly 30% in HER-2-positive early breast cancer. Based on these results Herceptin, together with chemotherapy, has been recently approved for the adjuvant treatment of HER-2-positive breast cancer.
C1 [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lang, I (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM lang@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 293
EP 302
PG 10
ER

PT J
AU Szanto, J
   Toth, J
AF Szanto, Janos
   Toth, Judit
TI Complex treatment of inflammatory breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Inflammatory beast cancer represents 2-5% of all malignant breast lesions. Its rapid progression, the rather short medical history of the disease is unique and seems to be very typical. The combined modality treatment of inflammatory breast cancer is a special challange for the medical oncologists. Preoperative chemotherapy is of great importance. After getting fair remission, surgery and radiotherapy should be delivered. With combined modality therapy the 5-year overall survival is about 50%. Knowing more pharmacogenomical details on the disease and delivering new medicaments the effectiveness of the treatment will be further enhanced.
C1 [Szanto, Janos] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
RP Szanto, J (reprint author), University of Debrecen, Department of Oncology, 4012 Debrecen, Hungary.
EM szanto@axelero.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 303
EP 307
PG 5
ER

PT J
AU Timar, J
   Kopper, L
   Bodrogi, I
AF Timar, Jozsef
   Kopper, Laszlo
   Bodrogi, Istvan
TI Molecular pathology and targeted therapy of clear cell renal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 309
EP 314
PG 6
ER

PT J
AU Tegze, B
   Tulassay, Zs
   Gyorffy, B
AF Tegze, Balint
   Tulassay, Zsolt
   Gyorffy, Balazs
TI Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Colorectal carcinoma is one of the most common cancers in Hungary, responsibe for about 5000 deaths each year. In the first line treatment the most commonly used drugs are 5-fluorouracil, oxaliplatin and irinotecan. The most frequently used drug is 5-fluorouracil, which has no effect in 90% of the cases. In combination with leukovorin or with 5-ethyl-2&#65533;-deoxyuridin fluorouracil has an increased effect. The main mechanisms of the resistance against 5-fluorouracil are due to the overexpression of dihydropyrimidine dehydrogenase, MRP8, thymidylate synthase, and NF?B p65. Oxaliplatin forms reactive platinum complexes, which are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. The oxaliplatin-5-fluorouracil-leucovorin combination was the first to reach more than 20 months median survival. The main mechanisms of resistance are decreased accumulation, increased detoxification and increased DNA repair. Irinotecan inhibits the topoisomerase I enzyme, resulting in the inhibition of the repair of DNA breaks occurring during DNA synthesis. With sequential 5-fluorouracil, oxaliplatin, irinotecan combination 26 months median survival was reached. Mechanisms resulting in resistance are decreased accumulation, increased enzymatic detoxification, alterations of ABC transporters, DNA repair system, apoptotic pathways and topoisomerase I. Survival can be elongated using biological therapy (cetuximab, bevacizumab). In the near future biologial therapy is expected to spread.
C1 [Tegze, Balint] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Tulassay, Zsolt] Hungarian Academy of Science, Clinical Gastroenterology Research UnitBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Szentagothai Janos Tudaskozpont, Bokay u. 53/54, 1085 Budapest, Hungary.
RP Gyorffy, B (reprint author), Semmelweis Egyetem, Szentagothai Janos Tudaskozpont, 1085 Budapest, Hungary.
EM gyorffy@szjt.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 315
EP 323
PG 9
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI The role of ibandronate in the daily oncological practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB Intravenous ibandronate at a dose of 6 mg every 3-4 weeks in patients with breast cancer and bone metastases produced a significant, 40% reduction in the relative risk of skeletal-related events. Oral ibandronate at a dose of 50 mg once daily for 96 weeks similarly reduced the overall skeletal morbidity, equating to a reduction in the relative risk of skeletal-related events of 38% relative to placebo. Ibandronate was generally well tolerated in clinical trials and their long-term extensions. Both type of administration significantly improve patients&#65533; healthrelated quality of life. There was no evidence of renal toxicity with iv. or oral ibandronate.
C1 [Nagykalnai, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM nagykalnai@uzsoki.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 325
EP 327
PG 3
ER

PT J
AU Biro, K
   Noszek, L
   Prekopp, P
   Nagyivanyi, K
   Geczi, L
   Gaudi, I
   Bodrogi, I
AF Biro, Krisztina
   Noszek, Laszlo
   Prekopp, Peter
   Nagyivanyi, Krisztian
   Geczi, Lajos
   Gaudi, Istvan
   Bodrogi, Istvan
TI Detection of late ototoxic side effect of cisplatin by distorsion product otoacustic emission (DPOAE)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Cisplatin-based chemotherapy results in high cure rate in testicular cancer. The issue of toxicity is of special concern in young men with a probability of cure of at least 70-80% even in disseminated disease. As the literature shows, the ototoxic side effects of cisplatin have been studied mostly by conventional method. The authors used distorsion product otoacustic emission to detect the long-term ototoxic effect of cisplatin in 223 patients with a median follow-up time of 4.27 years (range 0.5-20 years) and a median age of 37 years (range 18-55 years). Cisplatin (20 mg/m2 body surface) was administered for five days per cycle, in combination with other antitumor drugs. The control group consisted of 40 testicular cancer patients who did not receive chemotherapy, with a median age of 35 years (range 16-54 years). A detailed medical history based on a standardized questionnaire evaluated hearing complaints and audiological risk factors, such as head injuries, chronic otitis media, previous noise exposure and familial hearing loss. DPOAE was measured at 8 frequencies from 750 to 8000 Hz. No amplitude changes were detected in patients receiving =300 mg/m2 cisplatin. At higher doses, contrary to the literature, not only high frequencies were affected: our method could detect significant hearing impairment at lower frequencies important for speech perception in patients receiving at least 400 mg/m2 cisplatin. The lower frequencies where significant amplitude changes were detected were 3000 Hz at 400 mg/m2, and 1500, 2000 and 3000 Hz at 500-600 mg/m2. We detected the worst hearing in the case of patients who had symptomatic ototoxicity. Age and the cumulative dose of cisplatin proved statistically significant risk factors, while smoking or noise exposure did not have predictive value. As a conclusion, DPOAE is a fast, noninvasive and reliable method for the detection of late ototoxicity in testicular cancer patients. In our study hearing loss correlated with the cumulative dose of cisplatin. Hearing impairment contributes to the already compromised situation of cancer patients.
C1 [Biro, Krisztina] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Noszek, Laszlo] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Prekopp, Peter] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Biro, K (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM birok@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 329
EP 335
PG 7
ER

PT J
AU Varga, Cs
   Szendi, K
AF Varga, Csaba
   Szendi, Katalin
TI In vivo mutagenicity of the carcinogenic 1-nitropyrene. A model of a potential asbestos exposure
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The environmental carcinogen 1-nitropyrene was orally and intraperitoneally administered to rats in a single dose of 30 mmol/kg. Mutagenicity of excreted urine was tested in Salmonella typhimurium TA 98 and 100 strains. The mutagenic pattern of urine in case of oral exposure proved to be completely different as compared to the intraperitoneal administration. Frame-shift mutagen(s) was/were detected only after enzymatic deconjugation of sulphate or glucuronide metabolites within the first 24 h. Base-pair substitution-type mutagenicity was only detected in the urine samples collected after intraperitoneal treatment. Since environmental asbestos exposure involves carcinogenic effects of adsorbed polycyclic aromatic hydrocarbons, this animal model provides a useful tool for testing fiber-associated nitroarenes, in both mechanistic and risk assessment studies.
C1 [Varga, Csaba] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti ut 12., 7643 Pecs, Hungary.
   [Szendi, Katalin] University of Pecs, Faculty of Medicine, Department of Public Health, Szigeti ut 12., 7643 Pecs, Hungary.
RP Varga, Cs (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, 7643 Pecs, Hungary.
EM chemsafety@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 337
EP 340
PG 4
ER

PT J
AU Pesznyak, Cs
   Poti, Zs
AF Pesznyak, Csilla
   Poti, Zsuzsa
TI New radiotherapeutic technique for application of craniospinal target volume
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB AIM: To work out a craniospinal target volume definition and radiotherapy which can be used in clinical practice. METHOD: This technique has been applied in the Municipal Center of Oncoradiology since 2004 for total cerebral and spinal (neuroaxis) radiation. The individual radiation treatment plans were carried out using the CadPlan (Varian) 3D planning system with linear accelerator, in 3D on the basis of CT. The CT slices were prepared at 1 cm distance. The target volume and the organs at risk (OAR) were marked in slices. To delineate the field asymmetrical blending and multileaf collimator (MLC) were applied. Depending on the shape and size of the target, two or more field matching were made with the new technique. RESULTS: The dose distribution in the target volume and the OAR were controlled in the coronary, sagittal and horizontal views and with dose volume histograms (DVH). CONCLUSIONS: The condition for applying this technique is the accurate adjustment of digital simulator picture, field-control picture and DRR (digital reconstructed radiogram).
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Poti, Zs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM drpoti.zs@uzsoki.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 341
EP 344
PG 4
ER

PT J
AU Krutsay, M
   Chanis, W
AF Krutsay, Miklos
   Chanis, William
TI Primary gastrointestinal stromal tumor of the mesentery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB Primary solid tumors of the mesentery are very rare. The authors found a bulky gastrointestinal stromal tumor (GIST) in the mesentery. The stomach and the intestines were tumor-free.
C1 [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, Koranyi Frigyes u. 1., 8401 Ajka, Hungary.
   [Chanis, William] Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, Koranyi Frigyes u. 1., 8401 Ajka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, 8401 Ajka, Hungary.
EM miklos.krutsay@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 345
EP 348
PG 4
ER

PT J
AU Timar, J
   Kasler, M
   Katai, J
   Soos, M
   Mathiasz, D
   Romany, A
   Patthy, L
   Kovacs, G
   Jozsa, A
   Szilak, L
   Forrai, T
AF Timar, Jozsef
   Kasler, Miklos
   Katai, Jozsef
   Soos, Miklos
   Mathiasz, Dora
   Romany, Anna
   Patthy, Laszlo
   Kovacs, Gabor
   Jozsa, Adrienn
   Szilak, Laszlo
   Forrai, Tamas
TI Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB Research on developing molecular diagnostics for hereditary cancers resulted in establishing diagnostic services for familiar polyposis and non-polyposis patients (mutation determination of APC, MYH, STK11, SMAD4, MLH1, MSH2). In familiar testicular cancers the role of gr/gr gene on Y chromosome was identified. Molecular diagnostic tool was established to monitor the progression of follicular lymphoma using Bcl-2/IgH fusion sequences. Molecular diagnostic tools were developed to monitor circulating endothelial precursor cells (CEP) as well and the technique was tested in lung cancer patients. In malignant melanoma we have tested several potential novel markers among which ryanodine receptor seems to be a promising one, while the functional P2X7 receptor may serve as a therapeutic target. We have determined the tirosine kinase ''kinome'' profile of HER-2-amplified breast cancers. Furthermore, the ''kinome&#65533; profile was found to be characteristic for head and neck cancers of various anatomical location. Based on previous studies on the antimigratory and antimetastatic potential of low-molecular-weight heparins, we have identified short heparin-derived oligosaccharides with maintained antimetastatic- but non-anticoagulant potentials. Pharmacogenomic studies on the role of polymorphysm of the serine-hydroxymethyl-transferase (SHMT) gene in the efficacy of 5-FU and FOLFIRI protocols of colorectal cancer patients revealed a significant effect resulting in altered overall survival as well.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Katai, Jozsef] AstraZeneca KftTorokbalint, Hungary.
   [Soos, Miklos] Auro-Science Kft.Budapest, Hungary.
   [Mathiasz, Dora] GlaxoSmithKline KftBudapest, Hungary.
   [Romany, Anna] Janssen-Cilag KftTorokbalint, Hungary.
   [Patthy, Laszlo] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Jozsa, Adrienn] Roche Hungary LtdBudaors, Hungary.
   [Szilak, Laszlo] Szilak Labor KftSzeged, Hungary.
   [Forrai, Tamas] Zenon Bio KftSzeged, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 349
EP 359
PG 11
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. szeptember 22-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Kaposvari Egyetem Egeszsegtudomanyi Centrum, Kaposvar Jelen van: 19 kollegiumi tag es meghivottak
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 361
EP 368
PG 8
ER

PT J
AU Garamine Kokuti, K
AF Garamine Kokuti, Katalin
TI Akkreditalt tanfolyamok, 2007
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB Daganatok diagnosztikaja es komplex terapiaja Korszeru onkodermatologia Az emlorakos megbetegedes es halalozas csokkentese (epidemiologiai, MGR-UHMRI, citologiai es pathologiai aspektusok) A mehnyakrakos megbetegedes es halalozas csokkentese (epidemiologiai, citodiagnosztikai es klinikai aspektusok) A nogyogyaszati daganatok korai diagnosztikaja es komplex kezelese. Kolposzkopos tanfolyam Paradigma valtas a fej-nyak daganatok kezeleseben. Megvaltozott diagnosztikus feladatok, uj diagnosztikus modszerek JELENTKEZESI LAP TOVABBKEPZESRE A Magyar Onkologusok Tarsasaganak kozlemenye
C1 [Garamine Kokuti, Katalin] National Institute of Oncology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Garamine Kokuti, K (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM garami@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2006
VL 50
IS 4
BP 369
EP 379
PG 11
ER

PT J
AU Olah, E
AF Olah, Edit
TI President's greetings
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB XXVII. jubileumi kongresszus Budapest, 2007. november 8-10. 50 eve a rak ellen
C1 [Olah, Edit] Magyar Onkologusok Tarsasaga, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Olah, E (reprint author), Magyar Onkologusok Tarsasaga, 1122 Budapest, Hungary.
EM garami@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 3
EP 5
PG 1
ER

PT J
AU Tompa, A
AF Tompa, Anna
TI Theory and practice of primary cancer prevention
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB The primary aim of cancer prevention is to stop carcinogens from entering the body. Since the low doses involved in carcinogenesis do not cause true toxicological effects, usual toxicological analytic methods do not allow the detection of the early effects of carcinogens. Exposure to chemical carcinogens causes damage to nuclear chromatin, the most vulnerable part of the cell, by inducing DNA damage, chromosomal abnormalities and mutations, which foreshadow the danger of cancer development. In such cases intervention is possible in two ways. On the one hand, we attempt to remove the causative agent from the environment, while on the other we aid the elimination of somatic mutations. The latter is called active prevention; the introduction of substances into the body that can help the elimination of defective cells (apoptosis induction) or stop processes responsible for elongation errors (i.e. with antioxidants). Concerning our own studies, we present the results of 25 years of research on the genotoxicological characteristics of workers exposed to various chemicals, which show that active prevention can in fact be effective in conjunction with information on specific biomarkers. We present in detail the genotoxic changes found in hospital nurses who routinely administer intravenous cytostatic therapy, and the relationship of these changes to their immunotoxic and clinical laboratory parameters. Genotoxic substances decrease the oxidative burst and natural killer (NK) cell activity, which may explain the immunosuppressive effects of occupational exposures. We also present the detailed results of a follow-up study involving two groups of industrial workers. We monitored the status of workers involved in benzene production for 15 years and of asphalt industry workers for 8 years. In both studies we concluded that genotoxic effects can be decreased by ensuring appropriate working conditions, while a temporary lapse in these conditions or accidental changes lead to increases in genotoxic parameters. Since genotoxic effects develop over an extended period (4-5 months), they are independent of hygienic conditions at any single inspection and, thus, their detection also offers a way to ascertain true exposure levels. Our studies also show a connection between genotoxic effects and immune function, which is adversely affected not only by occupational exposures, but also by medications and smoking. From our results with workers in the oil and asphalt industries, we concluded that the levels of chromosomal aberrations (CAs) and sister chromatid exchange (SCE) increase in proportion to exposure levels and decrease with a certain delay following the attenuation of the exposure. We could not detect an increased frequency of any chronic disease in industrial workers. The increased numbers of iron deficiency anemia and thyroid disease in nurses providing cytostatic therapy was, however, related to their occupational exposure.
C1 [Tompa, Anna] Semmelweis University, Department of Public Health, Nagyvarad ter 4., 1445 Budapest, Hungary.
RP Tompa, A (reprint author), Semmelweis University, Department of Public Health, 1445 Budapest, Hungary.
EM tomann@net.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 7
EP 21
PG 15
ER

PT J
AU Cserni, G
   Kalman, E
   Kulka, J
   Orosz, Zs
   Udvarhelyi, N
   Krenacs, T
AF Cserni, Gabor
   Kalman, Ede
   Kulka, Janina
   Orosz, Zsolt
   Udvarhelyi, Nora
   Krenacs, Tibor
TI Quality control of HER2 immunohistochemitry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Whether a breast carcinoma is HER2-positive or -negative has a significant impact on its treatment. The most common method of evaluating the HER2 status of breast tumors is immunohistochemistry. Preliminary data suggest that the proportion of HER2-positive tumors in Hungary shows a wide range from laboratory to laboratory, and overall it just reaches the bottom levels of the incidence reported in the literature (12% 3+ and 11% 2+ cases). A 3-round quality-control test was implemented on a voluntary and anonymous basis. Participating laboratories had to immunostain and evaluate 4 tumor samples per circulation, according to their daily routine. The authors of the present article gave an expert opinion in all cases, and this was compared with the individual laboratories’ evaluation and the real FISH-controlled HER2 status of the samples. On the basis of the participants’ and experts’ evaluation 22/218 and 21/218 HER2 3+ cases were underscored, corresponding to an underevaluation rate of 10%. As most samples were from HER2-positive tumors, overscoring was less common (1%), but reached 5% (individual laboratories’ evaluation) or 7% (expert evaluation) when the 2+ scoring of negative cases was also considered. Each case was discussed interactively with the participants and technical advise was also given when deemed necessary. The evaluation of the HER2 status of breast cancers gives reliable results only if adequate quality control measures are implemented, and this study was an important step in this respect.
C1 [Cserni, Gabor] Bacs-Kiskun County Hospital, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Kalman, Ede] University of Pecs, Department of PathologyPecs, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, 6000 Kecskemet, Hungary.
EM cserni@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 23
EP 29
PG 7
ER

PT J
AU Frohlich, G
   Agoston, P
   Lovey, J
   Somogyi, A
   Fodor, J
   Major, T
AF Frohlich, Georgina
   Agoston, Peter
   Lovey, Jozsef
   Somogyi, Andras
   Fodor, Janos
   Major, Tibor
TI Dosimetric evaluation of interstitial high-dose-rate implants for localised prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: Quantitative evaluation of dose distributions of high-dose-rate prostate implants in order to make a later comparison with clinical outcome. MATERIAL AND METHODS: Treatment plans of 169 implants for 161 patients were evaluated using dose-volume histograms. The planning was based on transrectal US imaging and 10 Gy (100%) dose was prescribed to the surface of the prostate. The tolerance dose to urethra and rectum was 125% and 80%, respectively. The volume of the prostate was measured, and its fraction receiving 90%, 100%, 150% and 200% of the prescribed dose was calculated (V90, V100, V150, V200). The dose delivered to 90% of the prostate volume (D90) and the minimum dose in the prostate (Dmin) were determined. The dose nonuniformity ratio (DNR) and the dose homogeneity index (DHI) were calculated to quantify the dose homogeneity. The coverage index (CI) was determined, and the dose conformality to the target volume was assessed with the use of the conformal index (COIN). Maximal dose to rectum (Dr) and urethra (Du) reference points, dose to volume of 2 cm3 of the rectum (D2) and 0.1 cm3 and 1% of the urethra (D0.1, D1) were determined, too. Correlation analysis was performed between point and volume doses. In most patients in-vivo dose measurement was performed in the rectum with semiconductor detectors. RESULTS: The median number of needles was 16, the mean prostate volume was 25.5 cm3. The mean V90, V100, V150 and V200 were 98%, 94%, 41% and 14%, respectively. The mean D90 was 107%, and the Dmin was 82%. The mean dose to rectum and urethra reference points was 75% and 120%, respectively. The mean volume doses were D2=49% for the rectum, D0.1=128% and D1=143% for the urethra. The correlation coefficients were: R(Dr,D2)=0.69, R(Du,D0.1)=0.55, R(Du,D1)=0.23. The mean DNR was 0.39, while the DHI was 0.57. On average, 94% of the target volume received at least the prescribed dose (CI=0.94) and the mean COIN was 0.64. The mean maximal measured dose in the rectum was 2.67 Gy. CONCLUSIONS: Our US-based treatment plans based on the real positions of catheters provided acceptable dose distributions. In the majority of our cases the dose to urethra and rectum was kept below the defined tolerance level. The dose of rectal reference points correlated well with rectal dose-volume parameters but for urethra dose determination the use of the D1 volumetric parameter is recommended. Finding correlations between dose-volume parameters and clinical side effects requires further analysis.
C1 [Frohlich, Georgina] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Frohlich, G (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 31
EP 38
PG 8
ER

PT J
AU Plotar, V
   Orosz, Zs
   Toth, E
   Szentirmay, Z
AF Plotar, Vanda
   Orosz, Zsolt
   Toth, Erika
   Szentirmay, Zoltan
TI Histopathological prognostic factors of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The incidence of melanocytic skin lesions, including malignant melanoma has increased in the past few years; histopathologists and dermatopathologists have to face them more often. The correct treatment of melanoma patients by the oncodermatologist and oncologist is based on the histopathological report containing the most important histological prognostic factors. However, the accurate interpretation of these factors may be difficult in the everyday practice, especially in reporting tumor thickness, the level of invasion, the type of exulceration and regression. It is important to standardize the content of the histopathological reports in a reproducible way.
C1 [Plotar, Vanda] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Plotar, V (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
EM plotar.vanda@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 39
EP 46
PG 8
ER

PT J
AU Szluha, K
   Lazanyi, K
   Molnar, P
AF Szluha, Kornelia
   Lazanyi, Kornelia
   Molnar, Peter
TI The role of emotional labour in oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Oncologists and related health care professionals (HCPs) do not only have to follow professional protocols in their everyday work, but also have to communicate proper attitudes towards patients suffering from malignant diseases. This task is often a heavier load than the implementation of professional activities themselves. The present article is based on a survey on HCP work motivation, employment parameters and correlations with emotional labour. Fifty oncology HCPs at Debrecen University Medical Health Sciences Centre volunteered to participate in this survey containing 20 simple-choice questions. More than 90 percent of HCPs make an effort to hide their emotional state, giving way to possible negative side effects. The survey showed significant differences between the level of emotional labour of those working in the field of oncology longer or shorter than ten years. Surface and deep emotional labour is more frequent among professionals already working in oncology for a longer period of time. This can serve us with explanation to the burn-out syndrome so frequent in this profession. To diminish the load of emotional labour, healthcare institutes have to aim at hiring employees that spontaneously fit the emotional and behavioural norms facing them, and do not need officially prescribed behavioural norms for everyday work. Their constant need for respect and appreciation of their values must be kept in mind, because the capability of genuine emotional labour diminishes parallel to the number of years spent in work.
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Lazanyi, Kornelia] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
   [Molnar, Peter] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4012 Debrecen, Hungary.
EM szluha@dote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 47
EP 51
PG 5
ER

PT J
AU Lovey, J
   Kenessey, I
   Raso, E
   Dobos, J
   Vago, �
   Kasler, M
   Futosi, K
   Dome, B
   Timar, J
   Tovari, J
AF Lovey, Jozsef
   Kenessey, Istvan
   Raso, Erzsebet
   Dobos, Judit
   Vago, Agnes
   Kasler, Miklos
   Futosi, Krisztina
   Dome, Balazs
   Timar, Jozsef
   Tovari, Jozsef
TI Human recombinant erythropoietin-alpha increases the efficacy of irradiation in preclinical model
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB According to recent data erythropoietin receptor (EPOR) is expressed not only by bone marrow erythroid progenitors but by endothelial- and cancer cells and it was suggested that erythropoietin (EPO) may affect their functions as well. We have analyzed the effects of recombinant human erythropoietin-alpha (rHuEPOalpha) on radiation sensitivity of EPOR+ human epidermoid carcinoma (A431) xenograft model. In vivo rHuEPOalpha treatment was started after tumor cell inoculation into SCID mice. 5 Gy irradiation was performed on day 14, the effect of which was measured on day 22. Hemoglobin level, tumor-associated microvessels and HIF-1alpha expression of the xenograft were monitored during the experiment. rHuEPOalpha administration prevented the development of tumorinduced anemia of SCID mice and reduced the level of HIF-1alpha expression of the xenograft tumor without affecting tumor growth. We have found that rHuEPOalpha treatment significantly increased the efficacy of antitumor effect of irradiation which was partly mediated by complex effects on tumorassociated microvessels. In vitro rHuEPOalpha did not affect proliferation of A431 cells but enhanced the antiproliferative and proapoptotic effects of irradiation. We concluded that rHuEPOalpha administration positively modulated the antitumoral effects of irradiation at least by two pathways, decreasing systemic hypoxia resulting in decreased tumoral HIF-1alpha expression and enhancing direct effects on tumor-associated microvessels.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Raso, Erzsebet] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Dobos, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Vago, Agnes] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Futosi, Krisztina] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Tovari, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Tovari, J (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 53
EP 61
PG 9
ER

PT J
AU Krutsay, M
   Chanis, W
AF Krutsay, Miklos
   Chanis, William
TI Retroperitoneal adenoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
AB The authors describe a tumor localized next to the left adrenal gland. On histological examination the lipid-rich tumor was found to be partly a solid adrenocortical adenoma and partly a tubular oncocytoma.
C1 [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
   [Chanis, William] Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai es Sebeszeti Osztaly, 8401 Ajka, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 63
EP 65
PG 3
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2006. november 10-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 19 kollegiumi tag es meghivottak
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 67
EP 70
PG 4
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2007. januar 12-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet, Tanacsterem Jelen van: 19 kollegiumi tag
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2007
VL 51
IS 1
BP 71
EP 79
PG 9
ER

PT J
AU Timar, J
   Kasler, M
AF Timar, Jozsef
   Kasler, Miklos
TI Eckhardt Sandor akademikus 80 eves
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Nemregen unnepelte 80. szuletesnapjat Eckhardt Sandor, az Orszagos Onkologiai Intezet 1971-1992 kozotti foigazgato foorvosa.
C1 [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 87
EP 87
PG 1
ER

PT J
AU Olah, E
AF Olah, Edit
TI The first 20 years of the Department of Molecular Genetics at the National Institute of Oncology (NIO)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Molecular cancer genetics has developed during the last three decades as an independent discipline. Recent technological advances and discoveries in genomic and molecular research, including genome-wide analyses, provided unprecedented amount of knowledge on the aetiology of human cancer, and offered a framework for applying the novel results to clinical studies and the rapidly evolving field of molecular oncology. The Department of Molecular Genetics at NIO was established in 1986. Our group has played a pioneering role in molecular cancer research in Hungary and the region. This article overviews the achievements of our Department generated over the last two decades with a focus on cancer (susceptibility) genes.
C1 [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Olah, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM e.olah@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 89
EP 94
PG 6
ER

PT J
AU Csepe, P
   Banoczy, J
   Dombi, Cs
   Forrai, J
   Gyenes, M
   Dobrossy, L
AF Csepe, Peter
   Banoczy, Jolan
   Dombi, Csaba
   Forrai, Judit
   Gyenes, Monika
   Dobrossy, Lajos
TI Model program for screening oral cancers in the Roma population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Oral cancer has been identified as a significant public health threat. It is reported that about 3,800 new cases of oral cancer are diagnosed in Hungary each year with approximately 1,700 associated deaths. Oral cancer is the 6th most common cancer in men. Most oral cancers are preventable; 75% of oral cancers are related to tobacco use, alcohol use, or use of both substances together. While there is insufficient evidence to support or refute the use of visual examination as a method of screening for oral cancer in the general population, screening in high-risk populations is highly recommended. It was presumed that high-risk behavior including tobacco and alcohol use is one of the characteristics of Roma people. The main aim of the study was to elaborate a screening model program for the Roma population to determine risk factors of oral cancer and establish early diagnosis hence to reduce morbidity and mortality. In the program we planned to survey the risk factors in the target population, establish the diagnosis of oral cancer and/or pre-cancer and direct the patients to health care facilities. First we determined the target population in four Hungarian towns with the help of Roma social workers and local public health officers. We assembled a questionnaire on risk factors. Training for Roma social workers and screening personnel was also accomplished. Screening for oral precancerous lesions and cancer and survey the risk factors in the target population were performed at the same time. Patients screened to be positive were referred to specialists. Altogether 1,146 persons, 656 male and 490 female (age 20-77 years, mean 40 years), participated in the screening; 84% of them reported on some kind of complaints. We have got valid data on risk factors in connection with oral cancer. More than fifty percent of participants did not clean their teeth regularly, 75% were smokers, while 45% drunk alcohol regularly. 1,6% of screened participants had oral lesions that did not require referral to a specialist, while 2.3% of the screened subjects had referable oral mucosal lesions including leukoplakia. The overwhelming majority (93%) of participants screened to be positive did not see dentist regularly. As a conclusion, we elaborated a screening model program, which is applicable for disadvantaged (e.g. Roma) population to determine risk factors of oral cancer and establish early diagnosis hence to reduce morbidity and mortality. We surveyed the risk factors in the target population, established the diagnosis of oral cancer and/or pre-cancer lesions and directed the patients to care facilities. We also assisted them to get appropriate long-term care and follow-up. The importance of screening activities targeted on high-risk population was underlined.
C1 [Csepe, Peter] Semmelweis University, Department of Public Health, 1445 Budapest, Hungary.
   [Banoczy, Jolan] Semmelweis University, Department of Oral BiologyBudapest, Hungary.
   [Dombi, Csaba] Semmelweis University, Faculty of DentistryBudapest, Hungary.
   [Forrai, Judit] Semmelweis University, Department of Public Health, 1445 Budapest, Hungary.
   [Gyenes, Monika] Semmelweis University, Department of Public HealthBudapest, Hungary.
   [Dobrossy, Lajos] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
RP Csepe, P (reprint author), Semmelweis University, Department of Public Health, 1445 Budapest, Hungary.
EM csepet@net.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 95
EP 101
PG 7
ER

PT J
AU Orosz, Zs
   Sapi, Z
   Szentirmay, Z
   Timar, J
   Toth, J
AF Orosz, Zsolt
   Sapi, Zoltan
   Szentirmay, Zoltan
   Timar, Jozsef
   Toth, Jozsef
TI Paradigm shift in surgical pathology of cancer: molecular diagnostics, prognosticators and predictive pathology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Classical methodology of surgical pathology extended first with ultrastructural methods, then with immunohistochemistry and more recently with molecular/ genomic techniques. These changes added new dimensions to the classical tissueand cellular levels of diagnostics: the molecular level. This change is the primary motor of the development of the diagnostic as well as the prognostic and predictive pathology. It is now possible to identify an ethiological factor (HPV) or reclassify an entire entity (soft tissue tumors). Prognosis of cancer relies more and more on molecular/genetic parameters such as microsatellite instability, gene amplifications etc. Targeted therapy of cancer develops parallel with the molecular predictive pathology such as the anti-HER2 or anti-EGFR therapies. In conclusion, it is fair to say that molecular pathology contributes significantly to the development of clinical oncology.
C1 [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor Progression, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Department of Tumor Progression, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 103
EP 112
PG 10
ER

PT J
AU Kralovanszky, J
   Adleff, V
   Hitre, E
   Pap, �
   Reti, A
   Komlosi, V
   Budai, B
AF Kralovanszky, Judit
   Adleff, Vilmos
   Hitre, Erika
   Pap, Eva
   Reti, Andrea
   Komlosi, Viktor
   Budai, Barna
TI Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The cytoxic effect of 5-fluorouracil (5-FU) is mediated by the inhibition of thymidylate synthase (TS), however, at the same time 5-FU is catabolized by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5-FU may therefore depend on the TS and DPD activity and on pharmacogenetic factors influencing these enzymes. Our aims were 1) to determine the distribution of DPD activity, the frequency of DPD deficiency and the DPD (IVS14+1G>A) mutation in the peripheral blood mononuclear cells of colorectal cancer (CRC) patients, and study the relationship between DPD deficiency and toxicity of 5-FU; 2) to investigate the influence of TS polymorphisms and DPD activity on the survival of CRC patients receiving 5-FU-based adjuvant therapy. The frequency of DPD deficiency was determined by radiochemical methods in the peripheral blood mononuclear cells (PBMCs) of 764 CRC patients treated with 5-FU. The relationship between the TS polymorphisms, DPD activity and the diseasefree- and overall survival was studied in 166 CRC patients receiving 5-FU-based adjuvant therapy. TS polymorphisms were determined in the DNA samples separated from the PBMCs, by PCR-PAGE and PCR-RFLP-PAGE (restriction fragment length polymorphism) methods. Low DPD values (<10 pmol/min/106 PBMCs) were demonstrated in 160/764 patients (20.9%), and of those DPD deficiency (<5 pmol/min/106 PBMCs) was verified in 38 patients (4.9%). In the latter group severe (>Gr 3) toxicity was found in 87%. The prevalence of the DPD IVS14+1G>A mutation among the 38 DPDdeficient patients was 7.8% (3/38) and was accompanied by severe Gr 4 toxic symptoms (neutropenia, mucositis, diarrhea). TS polymorphisms showed a relationship with the survival of CRC patients. It is important to mention that by combining the 3-3 genotypes of 5’-TSER and 3’-TSUTR polymorphisms the obtained 8 genotype combinations showed significantly different Kaplan-Meier survival curves. The evaluation of these curves with Cox regression analysis resulted in two prognostically different groups: ''A'' good prognosis (RR<1) and ''B'' bad prognosis (RR>1). The disease-free- and overall survival of these two groups were significantly different. DPD activity also showed correlation with the survival; patients with DPD activity <10 pmol/min/106 PBMCs showed significantly longer disease-free- and overall survival. The determination of DPD activity proved to be a more valuable parameter in the evaluation of serious 5-FU-related toxicity compared to the IVS14+1G>A mutation analysis. According to the Cox multivariate analysis the combination of germline TS polymorphisms and DPD activity is/an independent prognostic marker of survival in CRC patients treated with adjuvant 5-FU therapy.
C1 [Kralovanszky, Judit] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Adleff, Vilmos] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Pap, Eva] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Reti, Andrea] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Komlosi, Viktor] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Rath Gyorgy u 7-9., 1122 Budapest, Hungary.
RP Kralovanszky, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM kralo@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 113
EP 125
PG 13
ER

PT J
AU Fodor, J
AF Fodor, Janos
TI Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of the study was to investigate prognosis of patients who develop an isolated local recurrence (ILR) after conservative surgery (CS) for early-stage invasive breast cancer. Between 1983 and 1987, 415 patients with stage I-II breast cancer were treated with CS. Of these patients, 68 developed an ILR. The mean follow-up time after ILR was 167 months. Cox models taking potential prognostic factors into account were used to estimate the risk of death. On univariate analysis, age (&#8804;40 vs. >40 years) at first treatment, time to ILR (&#8804;24 vs. >24 months), type of recurrence (true vs. new primary tumor, NP), and extent of recurrence (operable vs. inoperable) were, but initial tumor stage (pT1 vs. pT2), initial lymph node stage (pN-negative vs. -positive), adjuvant radiotherapy (yes vs. no), type of salvage surgery (wide excision vs. mastectomy), and recurrent tumor grade (1-2 vs. 3) were not significant predictors of post-recurrence survival. On multivariate analysis only time to ILR proved independent predictor of survival (relative risk: 3.2; 95% confidence interval: 1.4-7.3; p=0.0051), and the age of the patients showed borderline significance (p=0.0659). The 15-year actuarial rate of cause-specific survival after ILR was 58% for all patients, 60% and 0% for patients with operable or inoperable recurrence, 30% and 71% for patients with age &#8804;40 or >40 years, 25% and 72% for patients with time to ILR &#8804;24 or >24 months, 54% and 88% for patients with true recurrence or NP, and 92% for patients with age >40 years with NP, respectively. The rate of second local recurrence after salvage mastectomy or repeated wide excision was 16% and 28%, respectively (p=0.2265). As a conclusion, many patients with ILR have good prognosis, particularly those with operable recurrence with prolonged time to ILR, or with NP. Salvage mastectomy is not mandatory for all CS patients.
C1 [Fodor, Janos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM fodor@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 127
EP 131
PG 5
ER

PT J
AU Geczi, L
AF Geczi, Lajos
TI Modern chemotherapy of invasive bladder cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB PURPOSE: to identify the place and role of modern chemotherapy in invasive bladder cancer. METHODS: overview of the important data of papers presented in the last three years. RESULTS: Cisplatin-based chemotherapy with methotrexatevinblastine-doxorubicin-cisplatin (M-VAC) or gemcitabine-cisplatin (GC) is the standard treatment and prolongs survival in metastatic disease. The paclitaxelgemcitabine-cisplatin (TGC) protocol did not change standard therapy. Neoadjuvant chemotherapy before cystectomy for T2-3 disease provides a survival benefit compared with surgery alone. Adjuvant chemotherapy is less compelling, however, it is used in case of locally advanced, extravesical and/or lymph nodepositive disease. The identification of patient's risk factors helps the decision of individual treatment strategy. CONCLUSION: Better understanding of molecular mechanisms and carcinogenetic pathways of bladder cancer and combination of old and new drugs with targeted therapy may increase the effectiveness of treatment in bladder cancer.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM gelajos@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 133
EP 138
PG 6
ER

PT J
AU Bodoky, Gy
AF Bodoky, Gyorgy
TI Role of angiogenesis inhibitors in the treatment of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.
C1 [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Nagyvarad ter 1., 1096 Budapest, Hungary.
RP Bodoky, Gy (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, 1096 Budapest, Hungary.
EM bodokygy@hungarnet.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 139
EP 144
PG 6
ER

PT J
AU Bodrogi, I
AF Bodrogi, Istvan
TI Effect of angiosuppressive agents on renal cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Sporadic renal cell carcinomas are characterized by EGFR (HER-1) and EGFR-2 (HER-2) expression, however, signal transduction inhibitors of this pathway were clinically ineffective. Clear cell renal cell cancer is hormone-, irradiation- and chemotherapy resistant with moderate sensitivity to immunotherapy. The only clinically effective class of agents in case of this tumor type was proved to be the angiosuppressive agents. In 2005 FDA approved sorafenib for the first line treatment while in 2006 sunitinib for second line treatment in the cytokine resistant medium-risk renal cell carcinoma. This was followed by the European approval of both agents for second line treatment of renal cell cancer. Sunitinib was approved for first line treatment of renal cell cancer in Europe based on a phase III trial comparing it to interferon. Temsirolimus obtained its approval for the treatment of high risk renal cell cancer patients in 2007. Last but not least, FDA approval is on the way in case of bevacizumab as well to treat renal cell cancer. Based on the data demonstrated on the ASCO’2007, various modalities have to be developed for various stages of progression of clear cell renal cell cancer.
C1 [Bodrogi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Bodrogi, I (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM bodrogi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 145
EP 153
PG 9
ER

PT J
AU Gyergyay, F
AF Gyergyay, Fruzsina
TI Role of targeted therapy in the treatment of squamous cell head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Epidermal growth factor receptor (EGFR) is highly expressed in head and neck cancer (HNC). Since EGFR has a large extracellular ligand binding as well as an intracellular tyrosine kinase domain, anti-EGFR therapy may involve anti-ligand binding domain antibody- or tyrosine kinase inhibitor therapies. Phase II-III studies confirmed the efficacy of anti-EGFR antibody therapy in case of squamous cell HNC. In combination with irradiation, anti-EGFR antibody therapy improved survival of locally advanced HNC patients. In case of recurrent or metastatic HNC, anti-EGFR antibody therapy in combination with chemotherapy significantly increased remission rate without increasing toxicity. Although studies on EGFR kinase inhibitors in HNC are in early phase, preliminary data are encouraging.
C1 [Gyergyay, Fruzsina] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Gyergyay, F (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM gyergyai@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 155
EP 157
PG 3
ER

PT J
TI XIV. Primer Prevencios Forum osszefoglaloi
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
AB 2007. majus 23.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 159
EP 174
PG 16
ER

PT J
AU Olah, E
AF Olah, Edit
TI Elnoki koszonto
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Nagy oromomre szolgal, hogy hirdethetem a MOT fennallasanak 50. evfordulojat, es az evfordulohoz kapcsolodo jubileumi kongresszust, amelyet Budapesten tartunk 2007. november 8-10. kozott.
C1 [Olah, Edit] Magyar Onkologusok TarsasagaBudapest, Hungary.
RP Olah, E (reprint author), Magyar Onkologusok Tarsasaga, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 175
EP 180
PG 6
ER

PT J
AU Szucs, M
   Piko, B
AF Szucs, Miklos
   Piko, Bela
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2007. marcius 23-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: DEOEC Centrumelnoki Hivatal, Nagy tanacsterem, Debrecen Jelen voltak: 15 kollegiumi tag, valamint meghivottak
C1 [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Piko, Bela] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Szucs, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 181
EP 186
PG 6
ER

PT J
AU Kasler, M
   Strausz, J
AF Kasler, Miklos
   Strausz, Janos
TI Egyuttmukodesi megallapodas az Orszagos Onkologiai Intezet es az Orszagos Koranyi TBC es Pulmonologiai Intezet kozott a tudorakos betegek optimalis ellatasa erdekeben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Egyuttmukodesi megallapodas az Orszagos Onkologiai Intezet es az Orszagos Koranyi TBC es Pulmonologiai Intezet kozott a tudorakos betegek optimalis ellatasa erdekeben
C1 [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Strausz, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2007
VL 51
IS 2
BP 187
EP 187
PG 1
ER

PT J
AU Moldvay, J
AF Moldvay, Judit
TI Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Lung cancer is the leading cause of cancer death worldwide, and it is responsible for 20-25% of all cancer deaths. In Hungary, more than 4,000 lung cancer patients receive chemotherapy every year, and of them 3,000 suffer from non-small cell lung cancer. Despite the rapid development in antitumor treatment options, the response rates of chemotherapies in non-small cell lung cancer still remain between 15-35%. Recently, EGFR tyrosine kinase inhibitor therapy has been introduced with a response rate of 15% when used in unselected patients. However, this ratio may increase up to 70% when only patients with tumors containing EGFR mutation are treated. Therefore, results of translational research that could help pulmonologists and oncologists to apply tailored therapy in lung cancer patients are of great importance. The purpose of our work was to establish a model in order to study the relevance of immunohistochemical and molecular biological analyses of tumor specimens in treatment and patient selection, and to investigate their cost-sparing effects. We concluded that the most cost-effective type of patient selection could be achieved with EGFR mutation status analysis of the tumor tissue. Our results may help to determine the most cost-effective way of patient selection in case of non-small cell lung cancer patients requiring second line therapy; moreover, they might serve as a basis for further economic analyses.
C1 [Moldvay, Judit] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c, 1125 Budapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 191
EP 196
PG 6
ER

PT J
AU Grof, �
AF Grof, Agnes
TI Allocating resources for cancer control - resolving multicriteria decision-making using the analytic hierarchy process
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB When competing programs ought to be financed simultaneously for the same purpose, an allocation problem occurs due to scarce resources, and different perspectives and preferences. Facing the problem needs determining criteria which the decision might be based on. Those criteria form the objectives (the scope) of the different participants, and are relevant for the achievement of the goal, providing a comprehensive resource allocation that bridges and integrates the different perspectives. In case of cancer control primary prevention, secondary prevention, therapy and tertiary prevention, education, basic sciences, and clinical trials form the alternatives. An analytic hierarchy process (AHP) is used for supporting decision-making in the resource allocation problem. AHP is a method for setting priorities, but can only work out the implications of what was declared through the pairwise-ranking process, namely the relative preferences, weighing the criteria and rating the alternatives two by two. In the first analysis the relative weights to criteria were 0.099 for ’distributive justice’; 0.120 for constitutional and human rights; 0.251 for lay opinion; 0.393 for EBM; 0.137 for cost-effectiveness. Ranking the alternatives using ’judgements’ resulted in relative preference of 0.238 for therapy, 0.204 for primary prevention, 0.201 for secondary prevention, 0.135 for clinical trials, 0.111 for tertiary prevention, 0.066 for basic sciences and 0.045 for education. In the second analysis the relative importance of ''cost-effectiveness'' was doubled, thus resulting in 0.234 for therapy, 0.216 for secondary prevention, 0.183 for primary prevention, 0.145 for clinical trials, 0.113 for tertiary prevention, 0.063 for basic sciences and 0.046 for education. Sensitivity analysis has shown that increasing the relative weight of cost-effectiveness up to approximately 0.4 changes the rank of alternatives, and above 0.4 this criterion gives secondary prevention preferences. According to the relative rates computed in both of the models all criteria vote for therapy, but these preferences change at the high level of weights, in case of EBM, ’rights’, and cost-effectiveness. Costeffectivness prefers secondary prevention to therapy; the criterion of constitutional and human rights and the criterion of evidence-based medicine vote for primary prevention.
C1 [Grof, Agnes] StratMed Kft., Barbakan ter 1., 7624 Pecs, Hungary.
RP Grof, � (reprint author), StratMed Kft., 7624 Pecs, Hungary.
EM agnes.grof@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 197
EP 208
PG 12
ER

PT J
AU Dank, M
   Torgyik, L
   Szentmartoni, Gy
AF Dank, Magdolna
   Torgyik, Laszlo
   Szentmartoni, Gyongyver
TI Chemotherapy for advanced gastric cancer - our possibilities in 2007
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Gastric cancer is the fourth most common malignancy in Hungary. Surgery remains the mainstay of any curative treatment, however, approximately two-thirds of patients diagnosed with gastric cancer have unresectable (locally advanced and/or metastatic) disease. In that stage, palliative chemotherapy is of crucial importance. Gastric cancer is heterogeneous regarding location, etiology, histology and natural course. This diversity is reflected in the results of randomized controlled trials as well. Patient selection, location of primary, stage and pretreatment of the tumor, as well as the reference treatment, patient stratification and endpoints have varied among trials. Based on the results of the clinical trials of the past decades, gastric cancer is chemosensitive, however, patient prognosis remains very poor, with a median survival of less than one year, and therapy-associated toxicity remains an issue. Based on the afore-mentioned, no standard regimens have yet been established worldwide. New compounds and targeted biological treatment make the development of more effective, less toxic, individualized treatment modalities possible.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/aBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/aBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/aBudapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
EM dank@radi.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 209
EP 217
PG 9
ER

PT J
AU Kovacs, �
   Hadjiev, J
   Lakosi, F
   Antal, G
   Horvath, �
   Bogner, P
   Repa, I
AF Kovacs, Arpad
   Hadjiev, Janaki
   Lakosi, Ferenc
   Antal, Gergely
   Horvath, Akos
   Bogner, Peter
   Repa, Imre
TI Tumor movements detected by multi-slice CT-based image fusion in the radiotherapy of lung cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB The aim of our study was to detect the possible uncertainties arising from tumor movements in the daily routine treatment planning, in extreme breathing conditions. Ten patients with lung cancer were enrolled into the study. According to tumor location, five patients had periferial and five had central tumor. After the normal planning CT scan, two more scans were made with the same CT parameters in maximal exhalation and in maximal inhalation. For planning, the normal breathing scans were used with the fusion of the maximal inhalation and maximal exhalation scans. After the fusion in all breathing phases the gross tumor volumes were contoured (GTV1, GTV2, GTV3). Around the GTV1 (normal breathing phase GTV) 3 planning target volumes (PTV) were generated with the margin of 0.5 cm, 1.5 cm and 2.5 cm (PTV1, PTV2, PTV3). Individual plans were generated to all PTVs. All GTV volumes were registered. In all cases volume deviations were registered in different breathing phases (min: 1.5%, max: 35.6%). For GTV coverage comparison the coverage index (CI) was used. In case of extreme breathing conditions, using 0.5 cm margin was sufficient to reach good coverage for central tumors. For periferal tumors 1.5 cm margin had to be used for the acceptable coverage (CI: 0.85-1.00). In our study, extreme breathing conditions were analyzed. According to our results, CT scans used in the daily routine do not exactly represent the tumor midposition and the true tumor volume. Due to breathing synchron tumor movements, 0.5 cm margin must be used for planning in central location. In periferal tumors wider margin should be used.
C1 [Kovacs, Arpad] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching Hospital, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
RP Kovacs, � (reprint author), Kaposi Mor Teaching Hospital, 7400 Kaposvar, Hungary.
EM kovacs.arpad@sic.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 219
EP 223
PG 5
ER

PT J
AU Csiszer, E
   Antus, B
   Himber, G
   Hertel, K
   Fillinger, J
AF Csiszer, Eszter
   Antus, Balazs
   Himber, Gabriella
   Hertel, Katalin
   Fillinger, Janos
TI New diagnostic method in pulmonary carcinoid
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB In clinical oncology tumor markers could be helpful in diagnostics, and may play a complementary role beside the imaging systems in the follow up of patients with malignant disease. Chromogranin A can be considered as a marker in neuroendocrine malignancies such as pulmonary carcinoids. Based on recommendations adopted from the literature, the authors measured chromogranin A levels in sera of patients with carcinoid tumors of different stages. Although the patient number is low, our data suggest that in cases where carcinoid metastasis can be detected, chromogranin A levels are elevated.
C1 [Csiszer, Eszter] National Koranyi Institute of Pulmonology, Piheno u.1., 1529 Budapest, Hungary.
   [Antus, Balazs] National Koranyi Institute of Pulmonology, Piheno u.1., 1529 Budapest, Hungary.
   [Himber, Gabriella] National Koranyi Institute of Pulmonology, Piheno u.1., 1529 Budapest, Hungary.
   [Hertel, Katalin] National Koranyi Institute of Pulmonology, Piheno u.1., 1529 Budapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of Pulmonology, Piheno u.1., 1529 Budapest, Hungary.
RP Csiszer, E (reprint author), National Koranyi Institute of Pulmonology, 1529 Budapest, Hungary.
EM csiszer@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 225
EP 228
PG 4
ER

PT J
AU Dabasi, G
   Hauser, P
   Kertesz, PG
   Balazs, Gy
   Karadi, Z
   Constantin, T
   Bognar, L
   Klekner, �
   Schuler, D
   Garami, M
AF Dabasi, Gabriella
   Hauser, Peter
   Kertesz, P Gabriella
   Balazs, Gyorgy
   Karadi, Zoltan
   Constantin, Tamas
   Bognar, Laszlo
   Klekner, Almos
   Schuler, Dezso
   Garami, Miklos
TI Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB Malignant solid tumors and leukemias are the second most common causes of death in childhood. The most frequent pediatric solid tumors are brain tumors. Brain tumors, especially medulloblastoma should be treated by surgery, irradiation and chemotherapy. However, chemotherapy has only moderate effect. Pediatric brain tumors, especially medulloblastomas, express somatostatin receptors. The aim of this study was the investigation of the expression of somatostatin receptors in pediatric brain tumors for diagnostic and therapeutic purpose. Fifty-six scintigraphic imagings (111In-DTPA-D-Phe1-octreotide) made in 45 children treated with brain tumor at the Unit of Oncology of the 2nd Department of Pediatrics, Semmelweis University. The diagnosis was medulloblastoma in 21 cases (46.7%). MRI scans have been performed parallel with the Octreoscan images. Octreoscan images were positive in 27 of 56 (48.2%) cases. The 27 positive Octreoscan images consisted of 16 medulloblastomas, 4 ependymomas, 4 astrocytomas and 3 glioblastomas. In 37 (66.1%) cases the results of Octreoscans were the same as those of the MRI scans. However, in 19 scans (33.9%) the outcome was different. Octreoscan imaging is not suitable for differential diagnosis in pediatric brain tumors, including medulloblastomas. Isotopes specifically binding to the somatostatin receptors (111In-DTPA-D-Phe1-octreotide) can be applied in medulloblastomas for diagnosis and follow-up treatment. In Octreoscan-positive tumors the Octreoscan images establish the opportunity to somatostatin analogue and/or specifically targeted radiation therapies.
C1 [Dabasi, Gabriella] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23-25., 1082 Budapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kertesz, P Gabriella] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Balazs, Gyorgy] Semmelweis University, Department of Cardiovascular SurgeryBudapest, Hungary.
   [Karadi, Zoltan] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Constantin, Tamas] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Bognar, Laszlo] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Dabasi, G (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM dabasi@trans.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 229
EP 234
PG 6
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2007. majus 18-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
AB Helyszin: Orszagos Onkologiai Intezet Tanacsterme, Budapest Jelen voltak: 18 kollegiumi tag es a meghivottak
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 235
EP 239
PG 5
ER

PT J
TI MBFT-Magyar Orvosfizikai Tarsasag (MOFT) XIV. Konferenciaja
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB Kecskemet 2007. szeptember 20-22.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 241
EP 249
PG 9
ER

PT J
TI A Magyar Sugarterapias Tarsasag VIII. Kongresszusa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB Debrecen 2007. oktober 25-27.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 251
EP 282
PG 32
ER

PT J
AU Adamecz, Zs
   Szekanecz, �
   Horvath, �
   Urbancsek, H
   Kiss, M
   Szilasi, M
   Opauszki, A
AF Adamecz, Zsolt
   Szekanecz, Eva
   Horvath, Akos
   Urbancsek, Hilda
   Kiss, Magdolna
   Szilasi, Maria
   Opauszki, Adrienn
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Urbancsek, Hilda] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kiss, Magdolna] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Opauszki, Adrienn] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Adamecz, Zs (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 253
EP 253
PG 1
ER

PT J
AU Al-Farhat, Y
   Kovacs, P
   Gulyban, �
   Farkas, R
   Liposits, G
   Kelemen, D
   Horvath, �P
   Esik, O
   Mangel, L
AF Al-Farhat, Yousuf
   Kovacs, Peter
   Gulyban, Akos
   Farkas, Robert
   Liposits, Gabor
   Kelemen, Dezso
   Horvath, Ors Peter
   Esik, Olga
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Liposits, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Kelemen, Dezso] University of Pecs, Department of SurgeryPecs, Hungary.
   [Horvath, Ors Peter] University of Pecs, Department of SurgeryPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Al-Farhat, Y (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 253
EP 253
PG 1
ER

PT J
AU Beganyi, N
AF Beganyi, Nora
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Beganyi, Nora] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Beganyi, N (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 253
EP 253
PG 1
ER

PT J
AU Bellyei, Sz
   Farkas, R
   Szigeti, A
   Miszlai, Zs
   Kovacs, P
   Esik, O
   Bodis, J
   Mangel, L
AF Bellyei, Szabolcs
   Farkas, Robert
   Szigeti, Andras
   Miszlai, Zsuzsa
   Kovacs, Peter
   Esik, Olga
   Bodis, Jozsef
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Miszlai, Zsuzsa] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Bodis, Jozsef] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 254
EP 254
PG 1
ER

PT J
AU Biro, E
   Farkas, A
   Vandulek, Cs
   Lakosi, F
   Antal, G
   Battyani, Z
   Hadjiev, J
   Bogner, P
   Repa, I
AF Biro, Edit
   Farkas, Andrea
   Vandulek, Csaba
   Lakosi, Ferenc
   Antal, Gergely
   Battyani, Zita
   Hadjiev, Janaki
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Edit] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Battyani, Zita] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Biro, E (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 254
EP 254
PG 1
ER

PT J
AU Birone Riz, T
   Fabry, L
   Baricza, K
AF Birone Riz, Tunde
   Fabry, Laszlo
   Baricza, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Birone Riz, Tunde] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fabry, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Birone Riz, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 254
EP 255
PG 2
ER

PT J
AU Czovek, I
   Kiss, B
   Lorencz, P
   Heim, A
   Csejtei, A
AF Czovek, Imre
   Kiss, Balazs
   Lorencz, Peter
   Heim, Andras
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czovek, Imre] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Kiss, Balazs] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Lorencz, Peter] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Heim, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
RP Czovek, I (reprint author), Vas County Markusovszky Hospital, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 256
EP 256
PG 1
ER

PT J
AU Dankovics, Zs
   Kiraly, I
   Csejtei, A
AF Dankovics, Zsofia
   Kiraly, Istvan
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Kiraly, Istvan] Markusovszky Korhaz, Kardiovaszkularis es Intervencios Radiologiai OsztalySzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 256
EP 256
PG 1
ER

PT J
AU Der, �
   Szluha, K
   Simon, M
   Kovacs, AB
   Horvath, �
AF Der, Adam
   Szluha, Kornelia
   Simon, Mihaly
   Kovacs, Attila Barna
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Der, Adam] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Attila Barna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Akos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Der, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 256
EP 258
PG 3
ER

PT J
AU Fazekas, O
   Uhercsak, G
   Varga, Z
   Nagy, Z
   Fodor, E
   Kahan, Zs
   Thurzo, L
AF Fazekas, Olga
   Uhercsak, Gabriella
   Varga, Zoltan
   Nagy, Zoltan
   Fodor, Emese
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fazekas, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Fazekas, O
   Hideghety, K
   Varga, Z
   Nagy, Z
   Maraz, A
   Thurzo, L
AF Fazekas, Olga
   Hideghety, Katalin
   Varga, Zoltan
   Nagy, Zoltan
   Maraz, Aniko
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fazekas, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Fekete, G
   Varga, Z
   Szil, E
   Kahan, Zs
AF Fekete, Gabor
   Varga, Zoltan
   Szil, Elemer
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szil, Elemer] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fekete, G (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 258
EP 258
PG 1
ER

PT J
AU Gaal, Sz
   Hideghety, K
   Maraz, A
   Fazekas, O
   Vereb, B
   Torday, L
   Uhercsak, G
   Bontovics, J
   Fodor, E
   Tiszlavicz, L
   Szentpali, K
   Simonka, Zs
   Varga, L
   Hohn, J
   Lazar, Gy
   Thurzo, L
AF Gaal, Szilvia
   Hideghety, Katalin
   Maraz, Aniko
   Fazekas, Olga
   Vereb, Blanka
   Torday, Laszlo
   Uhercsak, Gabriella
   Bontovics, Julianna
   Fodor, Emese
   Tiszlavicz, Laszlo
   Szentpali, Karoly
   Simonka, Zsolt
   Varga, Laszlo
   Hohn, Jozsef
   Lazar, Gyorgy
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vereb, Blanka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bontovics, Julianna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of SurgerySzeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of SurgerySzeged, Hungary.
   [Varga, Laszlo] University of Szeged, Department of SurgerySzeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gaal, Sz (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Gallaine Foldvari, D
   Farkas, R
   Gulyban, �
   Kovacs, P
   Olaszne Halasz, J
   Esik, O
   Mangel, L
   Sebestyen, Zs
AF Gallaine Foldvari, Dora
   Farkas, Robert
   Gulyban, Akos
   Kovacs, Peter
   Olaszne Halasz, Judit
   Esik, Olga
   Mangel, Laszlo
   Sebestyen, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gallaine Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Olaszne Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
RP Gallaine Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 260
EP 260
PG 1
ER

PT J
AU Horvath, �
   Adamecz, Zs
   Opauszki, A
   Szekanec, �
   Varga, I
   Szilasi, M
AF Horvath, Akos
   Adamecz, Zsolt
   Opauszki, Adrienn
   Szekanec, Eva
   Varga, Imre
   Szilasi, Maris
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Akos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Adamecz, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Opauszki, Adrienn] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szekanec, Eva] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Varga, Imre] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Szilasi, Maris] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Horvath, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Huga, S
   Papp, J
   Hernadi, Z
   Horvath, �
AF Huga, Sandor
   Papp, Judit
   Hernadi, Zoltan
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Huga, Sandor] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Papp, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Huga, S (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Janvary, ZsL
   Fodor, J
   Major, T
   Orosz, Zs
   Sulyok, Z
   Lovey, K
   Polgar, Cs
AF Janvary, Zsolt Levente
   Fodor, Janos
   Major, Tibor
   Orosz, Zsolt
   Sulyok, Zoltan
   Lovey, Katalin
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Lovey, Katalin] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 262
EP 262
PG 1
ER

PT J
AU Kahan, Zs
AF Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 264
EP 264
PG 1
ER

PT J
AU Kobor, J
   Treer, T
   Pora, K
   Arany, M
AF Kobor, Jozsef
   Treer, Tivadar
   Pora, Krisztina
   Arany, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kobor, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Treer, Tivadar] University of Pecs, Department of OncologyPecs, Hungary.
   [Pora, Krisztina] University of Pecs, Department of OncologyPecs, Hungary.
   [Arany, Magdolna] University of Pecs, Department of OncologyPecs, Hungary.
RP Kobor, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 264
EP 266
PG 3
ER

PT J
AU Lakosi, F
   Antal, G
   Vandulek, Cs
   Kovacs, �
   Garamvolgyi, R
   Petnehazy, O
   Hadjiev, J
   Bogner, P
   Repa, I
AF Lakosi, Ferenc
   Antal, Gergely
   Vandulek, Csaba
   Kovacs, Arpad
   Garamvolgyi, Rita
   Petnehazy, Ors
   Hadjiev, Janaki
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Garamvolgyi, Rita] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Petnehazy, Ors] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Bogner, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Lengyel, Zs
   Szakall, Sz
   Molnar, P
   Kajary, K
AF Lengyel, Zsolt
   Szakall, Szabolcs
   Molnar, Peter
   Kajary, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Molnar, Peter] Pozitron Diagnosztika KftBudapest, Hungary.
   [Kajary, Kornelia] Pozitron Diagnosztika KftBudapest, Hungary.
RP Lengyel, Zs (reprint author), Pozitron Diagnosztika Kft, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Lovey, J
   Agoston, P
   Czigner, K
   Major, T
   Lengyel, Zs
   Polgar, Cs
   Fodor, J
   Godeny, M
   Kasler, M
   Borbely, K
AF Lovey, Jozsef
   Agoston, Peter
   Czigner, Krisztina
   Major, Tibor
   Lengyel, Zsolt
   Polgar, Csaba
   Fodor, Janos
   Godeny, Maria
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Czigner, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 266
EP 266
PG 1
ER

PT J
AU Mangel, L
   Molnar, K
   Lovey, J
   Bajcsay, A
   Poller, I
   Fodor, J
AF Mangel, Laszlo
   Molnar, Katalin
   Lovey, Jozsef
   Bajcsay, Andras
   Poller, Imre
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Molnar, Katalin] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Poller, Imre] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Maraz, A
   Cserhati, A
   Turcsanyi, V
   Fodor, E
   Fazekas, O
   Nagy, Z
   Thurzo, L
   Hideghety, K
AF Maraz, Aniko
   Cserhati, Adrienn
   Turcsanyi, Veronika
   Fodor, Emese
   Fazekas, Olga
   Nagy, Zoltan
   Thurzo, Laszlo
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Turcsanyi, Veronika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 268
EP 268
PG 1
ER

PT J
AU Miltenyi, L
   Adamec, Zs
   Urbancsek, H
   Szluha, K
   Miltenyi, Zs
   Horvath, �
AF Miltenyi, Laszlo
   Adamec, Zsolt
   Urbancsek, Hilda
   Szluha, Kornelia
   Miltenyi, Zsofia
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Miltenyi, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Adamec, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Urbancsek, Hilda] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Miltenyi, Zsofia] University of Debrecen, Medical and Health Center, 3rd Department of MedicineDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Miltenyi, L (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Mrazik, B
   Mangel, L
AF Mrazik, Bernadett
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mrazik, Bernadett] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Mrazik, B (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 270
EP 270
PG 1
ER

PT J
AU Nikolenyi, A
   Varga, Z
   Mezo, T
   Hideghety, K
   Kahan, Zs
   Thurzo, L
AF Nikolenyi, Aliz
   Varga, Zoltan
   Mezo, Tamas
   Hideghety, Katalin
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mezo, Tamas] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nikolenyi, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 272
EP 272
PG 1
ER

PT J
AU Padanyi, G
   Dankovics, Zs
   Toth, M
   Czovek, I
   Heim, A
   Kiss, B
   Lorentz, P
   Csejtei, A
AF Padanyi, Gergo
   Dankovics, Zsofia
   Toth, Monika
   Czovek, Imre
   Heim, Andras
   Kiss, Balazs
   Lorentz, Peter
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Padanyi, Gergo] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Dankovics, Zsofia] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Toth, Monika] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Czovek, Imre] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Heim, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Kiss, Balazs] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Lorentz, Peter] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
RP Padanyi, G (reprint author), Vas County Markusovszky Hospital, Szombathely, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 272
EP 272
PG 1
ER

PT J
AU Rusu, P
   Ciuleanu, TE
   Cernea, D
   Pelau, D
   Gaal, V
   Cebotaru, C
   Iancu, D
   Guttman, T
   Todor, N
   Ghilezan, N
AF Rusu, Petronela
   Ciuleanu, Tudor-Eliade
   Cernea, Dana
   Pelau, Doris
   Gaal, Viola
   Cebotaru, Cristina
   Iancu, Dana
   Guttman, Tiberiu
   Todor, Nicolae
   Ghilezan, Nicolae
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rusu, Petronela] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Ciuleanu, Tudor-Eliade] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Cernea, Dana] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Pelau, Doris] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Gaal, Viola] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Cebotaru, Cristina] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Iancu, Dana] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Guttman, Tiberiu] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Todor, Nicolae] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
   [Ghilezan, Nicolae] I. Chiricuta Onkologiai IntezetCluj-Napoca, Romania.
RP Rusu, P (reprint author), I. Chiricuta Onkologiai Intezet, Cluj-Napoca, Romania.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 274
EP 274
PG 1
ER

PT J
AU Stefanits, K
   Mangel, L
   Perjes, �
   Csere, T
AF Stefanits, Klara
   Mangel, Laszlo
   Perjes, Abel
   Csere, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Perjes, Abel] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
RP Stefanits, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 274
EP 276
PG 3
ER

PT J
AU Szanto, J
   Agoston, L
AF Szanto, Janos
   Agoston, Lorant
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szanto, Janos] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Agoston, Lorant] Megyei Korhaz, Bel, GastroenterologiaNyiregyhaza, Hungary.
RP Szanto, J (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 276
EP 276
PG 1
ER

PT J
AU Szluha, K
   Der, �
   Opauszki, A
   Andras, Cs
   Toth, J
   Szanto, J
   Pintye, �
   Horvath, �
AF Szluha, Kornelia
   Der, Adam
   Opauszki, Adrienn
   Andras, Csilla
   Toth, Judit
   Szanto, Janos
   Pintye, Eva
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Der, Adam] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Opauszki, Adrienn] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Toth, Judit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Szanto, Janos] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Takacs, I
   Bodis, S
AF Takacs, Istvan
   Bodis, Stephan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacs, Istvan] Kantonsspital, Institut fur Radio-OnkologieAarau, Switzerland.
   [Bodis, Stephan] Kantonsspital, Institut fur Radio-OnkologieAarau, Switzerland.
RP Takacs, I (reprint author), Kantonsspital, Institut fur Radio-Onkologie, Aarau, Switzerland.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Takacsi Nagy, L
AF Takacsi Nagy, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Takacsi Nagy, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Takacsi Nagy, Z
AF Takacsi Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 278
EP 278
PG 1
ER

PT J
AU Varga, Sz
   Pesznyak, Cs
AF Varga, Szilvia
   Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Varga, Sz (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Varga, Z
   Hideghety, K
   Csenki, M
   Szabo, J
   Mezo, T
   Thurzo, L
   Kahan, Zs
AF Varga, Zoltan
   Hideghety, Katalin
   Csenki, Melinda
   Szabo, Julianna
   Mezo, Tamas
   Thurzo, Laszlo
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Julianna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mezo, Tamas] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Vargane Elischer, �
   Erfan, J
   Korodine Karaszi, K
   Dioszeghy, P
   Olajos, J
AF Vargane Elischer, Eva
   Erfan, Jozsef
   Korodine Karaszi, Katalin
   Dioszeghy, Peter
   Olajos, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vargane Elischer, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Korodine Karaszi, Katalin] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Dioszeghy, Peter] Josa Andras Oktato Korhaz, Neurologiai OsztalyNyiregyhaza, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Vargane Elischer, � (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 280
EP 280
PG 1
ER

PT J
AU Viola, �
   Major, T
   Kolumban, Zs
   Tron, L
   Emri, M
   Bajzik, G
   Borbely, K
   Julow, J
AF Viola, Arpad
   Major, Tibor
   Kolumban, Zsuzsa
   Tron, Lajos
   Emri, Miklos
   Bajzik, Gabor
   Borbely, Katalin
   Julow, Jeno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Viola, Arpad] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
   [Major, Tibor] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
   [Kolumban, Zsuzsa] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
   [Tron, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Bajzik, Gabor] Somogy Megyei Kaposi Mor Oktato Korhaz, Radiologiai OsztalyKaposvar, Hungary.
   [Borbely, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Julow, Jeno] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
RP Viola, � (reprint author), Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 282
EP 282
PG 1
ER

PT J
AU Viola, �
   Major, T
   Julow, J
AF Viola, Arpad
   Major, Tibor
   Julow, Jeno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Viola, Arpad] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Julow, Jeno] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
RP Viola, � (reprint author), Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti Osztaly, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 282
EP 282
PG 1
ER

PT J
AU Gaspardy, G
AF Gaspardy, Geza
TI Bertok L. &amp; Chow D. (eds.): Natural Immunity, Elsevier, Amsterdam-Boston-London-New York-Oxford-Paris-San Diego-San Francisco-Singapore-Sidney-Tokyo, 2005
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Konyvismertetes
C1 [Gaspardy, Geza] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
RP Gaspardy, G (reprint author), Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2007
VL 51
IS 3
BP 283
EP 283
PG 1
ER

PT J
AU Besznyak, I
   Eckhardt, S
   Lapis, K
   Kasler, M
   Szucs, M
   Olah, E
   Landherr, L
   Faluhelyi, Zs
   Horvath, Zs
   Rahoty, P
AF Besznyak, Istvan
   Eckhardt, Sandor
   Lapis, Karoly
   Kasler, Miklos
   Szucs, Miklos
   Olah, Edit
   Landherr, Laszlo
   Faluhelyi, Zsolt
   Horvath, Zsolt
   Rahoty, Pal
TI A Magyar Onkologusok Tarsasaganak XXVII. Jubileumi Kongresszusa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
AB A Magyar Onkologusok Tarsasaganak XXVII. Jubileumi Kongresszusa, Osszefoglalok A KONGRESSZUS TUDOMANYOS PROGRAMJA  Fo temak: Daganatepidemiologia, prevencio, rakellenes programok, Molekularisan celzott terapiak az onkologiaban, Multidiszciplinaris megkozelitesek emlorakban, tudorakban, colorectalis es fej-nyaki daganatokban  Forumok: Gyermekkori es fiatalkori daganatok Mozgasszervi daganatok Uro-onkologia Aktualis bioetikai es jogi kerdesek az onkologiaban Pszichoszocialis tenyezok es daganatos megbetegedesek  A kongresszus fovednokei: Besznyak Istvan, akademikus Eckhardt Sandor, akademikus Lapis Karoly, akademikus  A kongresszus vednokei: Egeszsegugyi Miniszterium Orszagos Onkologiai Intezet: Kasler Miklos, foigazgato foorvos Sugarterapias es Onkologiai Szakmai Kollegium: Szucs Miklos, elnok  A kongresszus elnoke: Olah Edit, a MOT elnoke  Szervezo bizottsag: Elnok Landherr Laszlo, a MOT fotitkara Tagok Faluhelyi Zsolt, Horvath Zsolt, Nagykalnai Tamas, Rahoty Pal
C1 [Besznyak, Istvan] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Eckhardt, Sandor] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Lapis, Karoly] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Szucs, Miklos] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Olah, Edit] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Landherr, Laszlo] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Faluhelyi, Zsolt] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Zsolt] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Rahoty, Pal] Magyar Onkologusok Tarsasaga, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Besznyak, I (reprint author), Magyar Onkologusok Tarsasaga, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 285
EP 420
PG 136
ER

PT J
AU Adleff, V
   Komlosi, V
   Budai, B
   Reti, A
   Hitre, E
   Hajnal, 
   Kralovanszky, J
AF Adleff, Vilmos
   Komlosi, Viktor
   Budai, Barna
   Reti, Andrea
   Hitre, Erika
   Hajnal, A.
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Komlosi, Viktor] Semmelweis UniversityBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Reti, Andrea] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Hajnal, A.] National Institute of Haematology, Blood Transfusion and ImmunologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Adleff, V (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 287
EP 287
PG 1
ER

PT J
AU Anna, L
   Gyorffy, E
   Kovacs, K
   Gyori, Z
   Segesdi, J
   Minarovits, J
   Soltesz, I
   Kostic, Sz
   Csekeo, A
   Holmila, R
   Husgafvel-Pursiainen, K
AF Anna, Livia
   Gyorffy, Erika
   Kovacs, Katalin
   Gyori, Zoltan
   Segesdi, Judit
   Minarovits, Janos
   Soltesz, Ibolya
   Kostic, Szilard
   Csekeo, Attila
   Holmila, Reetta
   Husgafvel-Pursiainen, Kirsti
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Anna, Livia] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Gyorffy, Erika] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Kovacs, Katalin] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Gyori, Zoltan] National Center for EpidemiologyBudapest, Hungary.
   [Segesdi, Judit] National Center for EpidemiologyBudapest, Hungary.
   [Minarovits, Janos] National Center for EpidemiologyBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kostic, Szilard] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Holmila, Reetta] Finnish Institute of Occupational HealthHelsinki, Finland.
   [Husgafvel-Pursiainen, Kirsti] Finnish Institute of Occupational HealthHelsinki, Finland.
RP Anna, L (reprint author), Orszagos Kornyezetegeszsegugyi Intezet, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 287
EP 287
PG 1
ER

PT J
AU Apostol, K
AF Apostol, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Apostol, Katalin] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Apostol, K (reprint author), University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 287
EP 287
PG 1
ER

PT J
AU Avramucz, Cs
AF Avramucz, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Avramucz, Csaba] Semmelweis University, Faculty of MedicineBudapest, Hungary.
RP Avramucz, Cs (reprint author), Semmelweis University, Faculty of Medicine, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 288
EP 288
PG 1
ER

PT J
AU Arvai, K
   Szende, B
   Petak, I
   Nagy, K
   Vegso, Gy
   Perner, F
AF Arvai, Kristof
   Szende, Bela
   Petak, Istvan
   Nagy, Katalin
   Vegso, Gyula
   Perner, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arvai, Kristof] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Szende, Bela] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Petak, Istvan] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Nagy, Katalin] Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular PathologyBudapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Perner, Ferenc] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Arvai, K (reprint author), Hungarian Academy of Sciences and Semmelweis University, Research Group of Molecular Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 288
EP 288
PG 1
ER

PT J
AU Bagameri, A
   Pulay, T
AF Bagameri, Andrea
   Pulay, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bagameri, Andrea] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Bagameri, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 288
EP 288
PG 1
ER

PT J
AU Bajcsay, A
AF Bajcsay, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 289
EP 289
PG 1
ER

PT J
AU Bak, M
   Nyari, T
   Olasz, J
   Geczi, L
   Csuka, O
   Szende, B
   Bodrogi, I
AF Bak, Mihaly
   Nyari, Tibor
   Olasz, Judit
   Geczi, Lajos
   Csuka, Orsolya
   Szende, Bela
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bak, Mihaly] National Institute of OncologyBudapest, Hungary.
   [Nyari, Tibor] University of SzegedSzeged, Hungary.
   [Olasz, Judit] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Szende, Bela] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Bak, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 289
EP 289
PG 1
ER

PT J
AU Balazs, K
AF Balazs, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Katalin] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balazs, K (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 289
EP 290
PG 2
ER

PT J
AU Balkay, L
   Kis, SA
   Tron, L
   Galuska, L
   Bukki, T
   Muller, I
   Molnar, J
   Valastyan, I
   Hegyesi, Gy
   Szlavecz, �
   Lorincz, E
AF Balkay, Laszlo
   Kis, Sandor Attila
   Tron, Lajos
   Galuska, Laszlo
   Bukki, Tamas
   Muller, Illes
   Molnar, Jozsef
   Valastyan, Ivan
   Hegyesi, Gyula
   Szlavecz, Akos
   Lorincz, Emoke
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kis, Sandor Attila] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Tron, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Bukki, Tamas] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
   [Muller, Illes] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
   [Molnar, Jozsef] ATOMKIDebrecen, Hungary.
   [Valastyan, Ivan] ATOMKIDebrecen, Hungary.
   [Hegyesi, Gyula] ATOMKIDebrecen, Hungary.
   [Szlavecz, Akos] BME, Iranyitastechnika es Informatikai TanszekBudapest, Hungary.
   [Lorincz, Emoke] BME, Atomfizika TanszekBudapest, Hungary.
RP Balkay, L (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 290
EP 290
PG 1
ER

PT J
AU Balogh, I
   Nagy, Zs
   Gal, P
   Bakos, M
   Hajdu, Zs
   Pasztor, T
   Kopcsanyi, Zs
   Zilahy, 
   Landherr, L
AF Balogh, Ildiko
   Nagy, Zsuzsanna
   Gal, Peter
   Bakos, Magdolna
   Hajdu, Zsuzsanna
   Pasztor, Tamas
   Kopcsanyi, Zsuzsanna
   Zilahy, L.
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Nagy, Zsuzsanna] Josa Andras County HospitalNyiregyhaza, Hungary.
   [Gal, Peter] Javorszky Odon KorhazVac, Hungary.
   [Bakos, Magdolna] Bekes County Pandy Kalman HospitalGyula, Hungary.
   [Hajdu, Zsuzsanna] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Pasztor, Tamas] Kenezy Teaching HospitalDebrecen, Hungary.
   [Kopcsanyi, Zsuzsanna] Peterfy HospitalBudapest, Hungary.
   [Zilahy, L.] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balogh, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 290
EP 290
PG 1
ER

PT J
AU Balogh, I
   Fekeshazy, A
   Varga, Zs
   Balatoni, Zs
   Pocza, K
AF Balogh, Ildiko
   Fekeshazy, Attila
   Varga, Zsolt
   Balatoni, Zsuzsa
   Pocza, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Fekeshazy, Attila] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Varga, Zsolt] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Balatoni, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Pocza, Karoly] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balogh, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 291
EP 291
PG 1
ER

PT J
AU Bardi, E
   Kiss, Cs
AF Bardi, Edit
   Kiss, Csongor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bardi, Edit] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
RP Bardi, E (reprint author), Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 291
EP 291
PG 1
ER

PT J
AU Barko, Zs
   Nagy, Zs
AF Barko, Zsuzsanna
   Nagy, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barko, Zsuzsanna] St. Imre HospitalBudapest, Hungary.
   [Nagy, Zsuzsanna] St. Imre HospitalBudapest, Hungary.
RP Barko, Zs (reprint author), St. Imre Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 291
EP 292
PG 2
ER

PT J
AU Barna, G
   Sebestyen, A
   Dunai, Zs
   Kopper, L
   Mihalik, R
AF Barna, Gabor
   Sebestyen, Anna
   Dunai, Zsuzsanna
   Kopper, Laszlo
   Mihalik, Rudolf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dunai, Zsuzsanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barna, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 292
EP 292
PG 1
ER

PT J
AU Bartfai, R
   Josa, V
   Fodor, I
AF Bartfai, Reka
   Josa, Valeria
   Fodor, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bartfai, Reka] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Josa, Valeria] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Fodor, Istvan] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Bartfai, R (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 292
EP 292
PG 1
ER

PT J
AU Barti-Juhasz, H
   Nagy, K
   Kanya, M
   Mihalik, R
   Petak, I
AF Barti-Juhasz, Helga
   Nagy, Katalin
   Kanya, Melinda
   Mihalik, Rudolf
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kanya, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barti-Juhasz, H (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 292
EP 293
PG 2
ER

PT J
AU Bata, P
   Szendroi, A
   Magyar, P
   Romics, I
   Karlinger, K
AF Bata, Pal
   Szendroi, Attila
   Magyar, Peter
   Romics, Imre
   Karlinger, Kinga
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bata, Pal] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Magyar, Peter] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Karlinger, Kinga] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Bata, P (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 293
EP 293
PG 1
ER

PT J
AU Bata, P
   Toth, G
   Lovasz, S
   Hamvas, A
   Romics, I
AF Bata, Pal
   Toth, Geza
   Lovasz, Sandor
   Hamvas, Antal
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bata, Pal] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Toth, Geza] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Lovasz, Sandor] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Hamvas, Antal] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Bata, P (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 293
EP 293
PG 1
ER

PT J
AU Batar, P
   Telek, B
   Rejto, L
   Remenyi, Gy
   Kiss, A
   Udvardy, M
AF Batar, Peter
   Telek, Bela
   Rejto, Laszlo
   Remenyi, Gyula
   Kiss, Attila
   Udvardy, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Batar, Peter] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Telek, Bela] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Rejto, Laszlo] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Remenyi, Gyula] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Kiss, Attila] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Udvardy, Miklos] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
RP Batar, P (reprint author), DE OEC, II. Belgyogyaszati Klinika, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 293
EP 293
PG 1
ER

PT J
AU Batmunkh, E
   Tatrai, P
   Szabo, E
   Lodi, Cs
   Holczbauer, �
   Paska, Cs
   Kupcsulik, P
   Kiss, A
   Schaff, Zs
   Kovalszky, I
AF Batmunkh, Enkhjargal
   Tatrai, Peter
   Szabo, Eszter
   Lodi, Csaba
   Holczbauer, Agnes
   Paska, Csilla
   Kupcsulik, Peter
   Kiss, Andras
   Schaff, Zsuzsa
   Kovalszky, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Batmunkh, Enkhjargal] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tatrai, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szabo, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lodi, Csaba] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Holczbauer, Agnes] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Paska, Csilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kupcsulik, Peter] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Batmunkh, E (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 294
EP 294
PG 1
ER

PT J
AU Bene, I
   Szegedi, Gy
   Radvanyi, G
AF Bene, Ibolya
   Szegedi, Gyula
   Radvanyi, Gaspar
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bene, Ibolya] Semmelweis Hospital, Department of HematologyMiskolc, Hungary.
   [Szegedi, Gyula] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Radvanyi, Gaspar] Semmelweis Hospital, Department of HematologyMiskolc, Hungary.
RP Bene, I (reprint author), Semmelweis Hospital, Department of Hematology, Miskolc, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 294
EP 294
PG 1
ER

PT J
AU Benedek, A
   Safrany, G
AF Benedek, Anett
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benedek, Anett] OSSKIBudapest, Hungary.
   [Safrany, Geza] OSSKIBudapest, Hungary.
RP Benedek, A (reprint author), OSSKI, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 294
EP 295
PG 2
ER

PT J
AU Benyo, G
   Galantai, I
   Jakab, Zs
   Hauser, P
   Karadi, Z
   Halasz, J
   Renyi, I
   Garami, M
AF Benyo, Gabor
   Galantai, Ilona
   Jakab, Zsuzsanna
   Hauser, Peter
   Karadi, Zoltan
   Halasz, Judit
   Renyi, Imre
   Garami, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benyo, Gabor] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Galantai, Ilona] Heim Pal Children's HospitalBudapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Karadi, Zoltan] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Halasz, Judit] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Renyi, Imre] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Benyo, G (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 295
EP 295
PG 1
ER

PT J
AU Benyo, G
   Jakab, Zs
   Hauser, P
   Renyi, I
   Szentirmay, Z
   Garami, M
AF Benyo, Gabor
   Jakab, Zsuzsanna
   Hauser, Peter
   Renyi, Imre
   Szentirmay, Zoltan
   Garami, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benyo, Gabor] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Renyi, Imre] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Benyo, G (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 295
EP 295
PG 1
ER

PT J
AU Bereczky, B
   Nakao, Sh
   Kono, R
   Bognar, G
   Kimura, Y
   Nakano, T
   Ono, M
   Kuwano, M
AF Bereczky, Biborka
   Nakao, Shintaro
   Kono, Riichiro
   Bognar, Gabor
   Kimura, N. Yoshikuni
   Nakano, Toshiaki
   Ono, Mayumi
   Kuwano, Michihiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bereczky, Biborka] Kyushu University, Graduate School of Medical Sciences, Department of Medical BiochemistryFukuoka, Japan.
   [Nakao, Shintaro] Kyushu University, Graduate School of Medical Sciences, Department of Medical BiochemistryFukuoka, Japan.
   [Kono, Riichiro] Kyushu University, Department of Pathology, Division of Pathophysiological and Experimental PathologyFukuoka, Japan.
   [Bognar, Gabor] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Kimura, N. Yoshikuni] Kyushu University, Station for Collaborative Research IIFukuoka, Japan.
   [Nakano, Toshiaki] Kyushu University, Department of Pathology, Division of Pathophysiological and Experimental PathologyFukuoka, Japan.
   [Ono, Mayumi] Kyushu University, Graduate School of Medical Sciences, Department of Medical BiochemistryFukuoka, Japan.
   [Kuwano, Michihiko] Kyushu University, Station for Collaborative Research IIFukuoka, Japan.
RP Bereczky, B (reprint author), Kyushu University, Graduate School of Medical Sciences, Department of Medical Biochemistry, Fukuoka, Japan.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 296
EP 296
PG 1
ER

PT J
AU Berkes, E
   Kotai, Zs
AF Berkes, Eniko
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Berkes, Eniko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Berkes, E (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 296
EP 296
PG 1
ER

PT J
AU Bidlek, M
   Szabo, �
   Matrai, Z
   Udvarhelyi, N
   Godeny, M
AF Bidlek, Maria
   Szabo, Eva
   Matrai, Zoltan
   Udvarhelyi, Nora
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Bidlek, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 296
EP 296
PG 1
ER

PT J
AU Biro, K
   Noszek, L
   Prekopp, P
   Nagyivanyi, K
   Geczi, L
   Gaudi, I
   Bodrogi, I
AF Biro, Krisztina
   Noszek, Laszlo
   Prekopp, Peter
   Nagyivanyi, Krisztian
   Geczi, Lajos
   Gaudi, Istvan
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Noszek, Laszlo] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Prekopp, Peter] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Biro, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 297
EP 297
PG 1
ER

PT J
AU Bittner, N
   Angi, E
   Dombi, P
   Szucs, I
   Pajor, P
AF Bittner, Nora
   Angi, Edit
   Dombi, Peter
   Szucs, Ivan
   Pajor, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Angi, Edit] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Dombi, Peter] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Szucs, Ivan] St. Borbala University Hospital, Department of PathologyTatabanya, Hungary.
   [Pajor, Peter] Szent Borbala Korhaz, Radiologia OsztalyTatabanya, Hungary.
RP Bittner, N (reprint author), Szent Borbala Korhaz, Onkologia, Tatabanya, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 297
EP 297
PG 1
ER

PT J
AU Bittner, N
   Szentmartoni, Gy
AF Bittner, Nora
   Szentmartoni, Gyongyver
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Bittner, N (reprint author), Szent Borbala Korhaz, Onkologia, Tatabanya, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 298
EP 298
PG 1
ER

PT J
AU Bodrogi, I
AF Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Bodrogi, I (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 298
EP 298
PG 1
ER

PT J
AU Boer, A
   Remenar, �
   Ivanyi, E
   Patko, T
AF Boer, Andras
   Remenar, Eva
   Ivanyi, Emoke
   Patko, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Ivanyi, Emoke] National Institute of OncologyBudapest, Hungary.
   [Patko, Tamas] National Institute of OncologyBudapest, Hungary.
RP Boer, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 299
EP 299
PG 1
ER

PT J
AU Boer, K
   Farczadi, E
AF Boer, Katalin
   Farczadi, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Farczadi, Eniko] St. Margit HospitalBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 299
EP 299
PG 1
ER

PT J
AU Boer, K
   Rumszauer, �
   Toth, K
   Muszbek, K
AF Boer, Katalin
   Rumszauer, Agnes
   Toth, Karoly
   Muszbek, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Rumszauer, Agnes] St. Margit HospitalBudapest, Hungary.
   [Toth, Karoly] St. Margit HospitalBudapest, Hungary.
   [Muszbek, Katalin] ESZSZK Szent Laszlo Korhaz, HospiceBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 299
EP 299
PG 1
ER

PT J
AU Bogos, K
   Noel, N
   Claudot, F
   Grosdidier, G
   Siat, J
   Vignaud, J
   Martinet, Y
   Martinet, N
AF Bogos, Krisztina
   Noel, Nicolas
   Claudot, Frederique
   Grosdidier, Gilles
   Siat, Joelle
   Vignaud, Jean‐Michel
   Martinet, Yves
   Martinet, Nadine
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Noel, Nicolas] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Claudot, Frederique] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Grosdidier, Gilles] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Siat, Joelle] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Vignaud, Jean‐Michel] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Martinet, Yves] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
   [Martinet, Nadine] Faculte de Medecine de Nancy, Centre de Resources Biologiques „Oncogenese Thoracique”Nancy, France.
RP Bogos, K (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 300
EP 300
PG 1
ER

PT J
AU Bohacs, A
   Tamasi, L
   Wollak, A
   Meszaros, Zs
   Kovacs, RB
   Sapi, Z
   Bartfai, Z
AF Bohacs, Aniko
   Tamasi, Lilla
   Wollak, Andras
   Meszaros, Zsolt
   Kovacs, Rita Beata
   Sapi, Zoltan
   Bartfai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Wollak, Andras] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Meszaros, Zsolt] Bajcsy Hospital, Department of SurgeryBudapest, Hungary.
   [Kovacs, Rita Beata] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Sapi, Zoltan] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Bartfai, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Bohacs, A (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 300
EP 300
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 300
EP 301
PG 2
ER

PT J
AU Borosne Gerner, A
AF Borosne Gerner, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borosne Gerner, Aniko] Kaposi Mor Oktato Korhaz, VI. Pulmonologiai OsztalyMosdos, Hungary.
RP Borosne Gerner, A (reprint author), Kaposi Mor Oktato Korhaz, VI. Pulmonologiai Osztaly, Mosdos, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 303
EP 303
PG 1
ER

PT J
AU Boross, G
   Maraz, R
   Marko, L
   Ambrozay, �
   Tekle, E
   Sinko, M
   Bori, R
   Svebis, M
   Cserni, G
AF Boross, Gabor
   Maraz, Robert
   Marko, Laszlo
   Ambrozay, Eva
   Tekle, W. Eliza
   Sinko, Maria
   Bori, Rita
   Svebis, Mihaly
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boross, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Tekle, W. Eliza] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Sinko, Maria] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Bori, Rita] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Boross, G (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 303
EP 303
PG 1
ER

PT J
AU Boszormenyi-Nagy, G
   Fritz, F
   Siller, Gy
   Fazakas, Zs
AF Boszormenyi-Nagy, Geza
   Fritz, Ferenc
   Siller, Gyorgy
   Fazakas, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boszormenyi-Nagy, Geza] Bajcsy-Zsilinszky Korhaz, UrologiaBudapest, Hungary.
   [Fritz, Ferenc] Budapest, XV. ker. Onkormanyzat Egeszsegugyi IntezmenyeBudapest, Hungary.
   [Siller, Gyorgy] Peterfy HospitalBudapest, Hungary.
   [Fazakas, Zsolt] Bajcsy-Zsilinszky Korhaz, UrologiaBudapest, Hungary.
RP Boszormenyi-Nagy, G (reprint author), Bajcsy-Zsilinszky Korhaz, Urologia, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 303
EP 303
PG 1
ER

PT J
AU Budai, B
   Hitre, E
   Komlosi, V
   Adleff, V
   Pap, �
   Reti, A
   Orosz, Zs
   Lang, I
   Kralovanszky, J
AF Budai, Barna
   Hitre, Erika
   Komlosi, Viktor
   Adleff, Vilmos
   Pap, Eva
   Reti, Andrea
   Orosz, Zsolt
   Lang, Istvan
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Komlosi, Viktor] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Reti, Andrea] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Budai, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 304
EP 304
PG 1
ER

PT J
AU Burian, Zs
   Orosz, Zs
   Szollar, A
   Lovey, J
AF Burian, Zsuzsanna
   Orosz, Zsolt
   Szollar, Andras
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Burian, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Szollar, Andras] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Burian, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 304
EP 304
PG 1
ER

PT J
AU Bursics, A
   Porneczi, B
   Koveskuti, �
   Csonka, S
   Mikes, Cs
   Varga, Gy
   Gyokeres, T
   Pap, �
   Rahoty, P
AF Bursics, Attila
   Porneczi, Balazs
   Koveskuti, Agnes
   Csonka, Sandor
   Mikes, Csaba
   Varga, Gyula
   Gyokeres, Tibor
   Pap, Akos
   Rahoty, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bursics, Attila] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Porneczi, Balazs] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Koveskuti, Agnes] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Csonka, Sandor] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Mikes, Csaba] AEK (MAV Kh), I.sz. Sebeszeti OsztalyBudapest, Hungary.
   [Varga, Gyula] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Gyokeres, Tibor] AEK, Gastroenterologiai OsztalyBudapest, Hungary.
   [Pap, Akos] AEK, Gastroenterologiai OsztalyBudapest, Hungary.
   [Rahoty, Pal] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
RP Bursics, A (reprint author), AEK, II. Sebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 305
EP 305
PG 1
ER

PT J
AU Csada, E
   Palfoldi, R
   Ugocsai, K
   Szalontai, K
AF Csada, Edit
   Palfoldi, Regina
   Ugocsai, Katalin
   Szalontai, Klara
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csada, Edit] SZTE AOK, Mellkasi Betegsegek SzakkorhazaDeszk, Hungary.
   [Palfoldi, Regina] SZTE AOK, Mellkasi Betegsegek SzakkorhazaDeszk, Hungary.
   [Ugocsai, Katalin] SZTE AOK, Mellkasi Betegsegek SzakkorhazaDeszk, Hungary.
   [Szalontai, Klara] SZTE AOK, Mellkasi Betegsegek SzakkorhazaDeszk, Hungary.
RP Csada, E (reprint author), SZTE AOK, Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 305
EP 305
PG 1
ER

PT J
AU Csaki, G
   Boer, A
   Somogyi, A
   Takacsi-Nagy, Z
   Lovey, J
   Godeny, M
   Kasler, M
AF Csaki, Gabor
   Boer, Andras
   Somogyi, Andras
   Takacsi-Nagy, Zoltan
   Lovey, Jozsef
   Godeny, Maria
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csaki, Gabor] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Somogyi, Andras] National Institute of OncologyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Csaki, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 305
EP 305
PG 1
ER

PT J
AU Csanady, M
   Czigner, J
   Jori, J
AF Csanady, Miklos
   Czigner, Jeno
   Jori, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Jori, Jozsef] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Csanady, M (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 306
EP 306
PG 1
ER

PT J
AU Cseh, J
AF Cseh, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseh, Jozsef] Fejer County Szent Gyorgy HospitalSzekesfehervar, Hungary.
RP Cseh, J (reprint author), Fejer County Szent Gyorgy Hospital, Szekesfehervar, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 306
EP 306
PG 1
ER

PT J
AU Csekeo, A
AF Csekeo, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
RP Csekeo, A (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 306
EP 306
PG 1
ER

PT J
AU Csere, P
   Alheit, H
   Lehmann, D
   Baumann, M
   Herrmann, Th
AF Csere, Peter
   Alheit, Horst
   Lehmann, Dietmar
   Baumann, Michael
   Herrmann, Thomas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csere, Peter] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Alheit, Horst] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Lehmann, Dietmar] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Baumann, Michael] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Herrmann, Thomas] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
RP Csere, P (reprint author), Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, Dresden, Germany.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 307
EP 307
PG 1
ER

PT J
AU Csere, P
   Blank, H
   Alheit, H
   Baumann, M
   Herrmann, Th
AF Csere, Peter
   Blank, Hilbert
   Alheit, Horst
   Baumann, Michael
   Herrmann, Thomas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csere, Peter] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Blank, Hilbert] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Alheit, Horst] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Baumann, Michael] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Herrmann, Thomas] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
RP Csere, P (reprint author), Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, Dresden, Germany.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 307
EP 307
PG 1
ER

PT J
AU Csoka, M
   Krivan, G
   Benyo, G
   Magyarosy, E
   Bartyik, K
   Kajtar, P
   Kiss, Cs
   Kovacs, G
AF Csoka, Monika
   Krivan, Gergely
   Benyo, Gabor
   Magyarosy, Edina
   Bartyik, Katalin
   Kajtar, Pal
   Kiss, Csongor
   Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Krivan, Gergely] St. Laszlo HospitalBudapest, Hungary.
   [Benyo, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Magyarosy, Edina] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Bartyik, Katalin] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Kajtar, Pal] University of Pecs, Department of PediatricsPecs, Hungary.
   [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Csoka, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 308
EP 308
PG 1
ER

PT J
AU Csoka, M
   Szathmary, B
   Muller, J
   Kovacs, G
AF Csoka, Monika
   Szathmary, Boglarka
   Muller, Judit
   Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Szathmary, Boglarka] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Csoka, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 308
EP 308
PG 1
ER

PT J
AU Csuka, O
   Olasz, J
   Juhasz, A
   Remenar, �
   Kasler, M
AF Csuka, Orsolya
   Olasz, Judit
   Juhasz, Aliz
   Remenar, Eva
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Olasz, Judit] National Institute of OncologyBudapest, Hungary.
   [Juhasz, Aliz] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 308
EP 309
PG 2
ER

PT J
AU Czigner, J
   Paczona, R
   Csanady, M
   Jori, J
AF Czigner, Jeno
   Paczona, Robert
   Csanady, Miklos
   Jori, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Paczona, Robert] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Jori, Jozsef] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Czigner, J (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 309
EP 309
PG 1
ER

PT J
AU Dani, �
   Nagy, P
AF Dani, Arpad
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dani, Arpad] Vaszary Kolos Korhaz, Hospice/Rehabilitacios OsztalyEsztergom, Hungary.
   [Nagy, Peter] Vaszary Kolos Korhaz, Hospice/Rehabilitacios OsztalyEsztergom, Hungary.
RP Dani, � (reprint author), Vaszary Kolos Korhaz, Hospice/Rehabilitacios Osztaly, Esztergom, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 310
EP 310
PG 1
ER

PT J
AU Demeter, A
   Varga, Sz
   Nagy, B
AF Demeter, Attila
   Varga, Szilvia
   Nagy, Balint
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Demeter, Attila] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Varga, Szilvia] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nagy, Balint] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
RP Demeter, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 310
EP 310
PG 1
ER

PT J
AU Derkacsne Titz, I
AF Derkacsne Titz, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Derkacsne Titz, Ildiko] University of Pecs, Faculty of MedicinePecs, Hungary.
RP Derkacsne Titz, I (reprint author), University of Pecs, Faculty of Medicine, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 310
EP 310
PG 1
ER

PT J
AU Dombi, P
   Bittner, N
   Osvath, M
   Valasinyoszki, E
   Eros, M
   Angi, E
   Meszaros, R
AF Dombi, Peter
   Bittner, Nora
   Osvath, Marta
   Valasinyoszki, Erika
   Eros, Monika
   Angi, Edit
   Meszaros, Rozsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dombi, Peter] St. Borbala University HospitalTatabanya, Hungary.
   [Bittner, Nora] St. Borbala University HospitalTatabanya, Hungary.
   [Osvath, Marta] St. Borbala University HospitalTatabanya, Hungary.
   [Valasinyoszki, Erika] St. Borbala University HospitalTatabanya, Hungary.
   [Eros, Monika] St. Borbala University HospitalTatabanya, Hungary.
   [Angi, Edit] St. Borbala University HospitalTatabanya, Hungary.
   [Meszaros, Rozsa] St. Borbala University HospitalTatabanya, Hungary.
RP Dombi, P (reprint author), St. Borbala University Hospital, Tatabanya, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 310
EP 310
PG 1
ER

PT J
AU Dome, B
AF Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Dome, B (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 311
EP 311
PG 1
ER

PT J
AU Elekne Kiss, B
AF Elekne Kiss, Barbara
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Elekne Kiss, Barbara] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 311
EP 311
PG 1
ER

PT J
AU Engert, ZV
   Varga, L
   Markus, B
AF Engert, Zoltan Vendel
   Varga, Laszlo
   Markus, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Engert, Zoltan Vendel] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Varga, Laszlo] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Markus, Bela] Vas County Markusovszky HospitalSzombathely, Hungary.
RP Engert, ZV (reprint author), Vas County Markusovszky Hospital, Szombathely, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 311
EP 311
PG 1
ER

PT J
AU Engert, ZV
   Nadasi, G
AF Engert, Zoltan Vendel
   Nadasi, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Engert, Zoltan Vendel] Vas M-i Markusovszky L. Oktatokorhaz, Urologiai Sebeszeti OsztalySzombathely, Hungary.
   [Nadasi, Geza] Markusovszky Egyetemi Oktatokorhaz, Altalanos Sebeszeti OsztalySzombathely, Hungary.
RP Engert, ZV (reprint author), Vas M-i Markusovszky L. Oktatokorhaz, Urologiai Sebeszeti Osztaly, Szombathely, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 312
EP 312
PG 1
ER

PT J
AU Engi, H
   Hohmann, J
   Geng, G
   Pusztai, R
   Molnar, J
   Csuka, O
AF Engi, Helga
   Hohmann, Judit
   Geng, Gang
   Pusztai, Rozalia
   Molnar, Jozsef
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Engi, Helga] National Institute of OncologyBudapest, Hungary.
   [Hohmann, Judit] Szegedi Tudomanyegyetem, Farmakognoziai IntezetSzeged, Hungary.
   [Geng, Gang] The Hospital of Traditional Chinese Medicine of Inner MongoliaHohhot, China.
   [Pusztai, Rozalia] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
RP Engi, H (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 312
EP 312
PG 1
ER

PT J
AU Fabianne Kiss, Sz
AF Fabianne Kiss, Szilvia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabianne Kiss, Szilvia] National Institute of OncologyBudapest, Hungary.
RP Fabianne Kiss, Sz (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 312
EP 312
PG 1
ER

PT J
AU Faluhelyi, Zs
   Kiss, I
   Orsos, Zs
   Varga, Zs
   Ember, I
AF Faluhelyi, Zsolt
   Kiss, Istvan
   Orsos, Zsuzsanna
   Varga, Zsuzsanna
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Faluhelyi, Zsolt] County Hospital of BaranyaPecs, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Orsos, Zsuzsanna] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Varga, Zsuzsanna] County Hospital of BaranyaPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Faluhelyi, Zs (reprint author), County Hospital of Baranya, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 313
EP 313
PG 1
ER

PT J
AU Farczadi, E
   Boer, K
   Nemeth, Zs
AF Farczadi, Eniko
   Boer, Katalin
   Nemeth, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farczadi, Eniko] St. Margit HospitalBudapest, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Nemeth, Zsuzsanna] St. Margit HospitalBudapest, Hungary.
RP Farczadi, E (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 313
EP 313
PG 1
ER

PT J
AU Farkas, E
   Matrai, Z
   Renyi-Vamos, F
   Hitre, E
   Orosz, Zs
   Agoston, P
   Koves, I
AF Farkas, Emil
   Matrai, Zoltan
   Renyi-Vamos, Ferenc
   Hitre, Erika
   Orosz, Zsolt
   Agoston, Peter
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
RP Farkas, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 313
EP 313
PG 1
ER

PT J
AU Farkas, Gy
   Kiss, K
   Frigyesi, M
   Vass, N
   Szekely, G
   Gundy, S
AF Farkas, Gyongyi
   Kiss, Krisztina
   Frigyesi, Maria
   Vass, Nagyezsda
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] National Institute of OncologyBudapest, Hungary.
   [Kiss, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Frigyesi, Maria] National Institute of OncologyBudapest, Hungary.
   [Vass, Nagyezsda] National Institute of OncologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of OncologyBudapest, Hungary.
   [Gundy, Sarolta] National Institute of OncologyBudapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 313
EP 313
PG 1
ER

PT J
AU Fazekas, O
   Uhercsak, G
   Varga, Z
   Nagy, Z
   Fodor, E
   Hideghety, K
   Kahan, Zs
   Thurzo, L
AF Fazekas, Olga
   Uhercsak, Gabriella
   Varga, Zoltan
   Nagy, Zoltan
   Fodor, Emese
   Hideghety, Katalin
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fazekas, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 313
EP 313
PG 1
ER

PT J
AU Fejos, Zs
   Papp, A
   Banfalvi, T
   Borbola, K
   Gilde, K
   Liszkay, G
   Fedorcsak, I
   Sipos, L
   Mangel, L
   Bajcsay, A
   Horvath, �
AF Fejos, Zsuzsanna
   Papp, Andrea
   Banfalvi, Teodora
   Borbola, Kinga
   Gilde, Katalin
   Liszkay, Gabriella
   Fedorcsak, Imre
   Sipos, Laszlo
   Mangel, Laszlo
   Bajcsay, Andras
   Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Papp, Andrea] National Institute of OncologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of NeurosurgeryBudapest, Hungary.
   [Sipos, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
   [Mangel, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Horvath, Akos] University of DebrecenDebrecen, Hungary.
RP Fejos, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 317
EP 317
PG 1
ER

PT J
AU Ferenczi, E
   Borbely, T
   Lantos, �
   Palinkasi, Sz
   Varga, I
   Tolnay, E
AF Ferenczi, Eniko
   Borbely, Tibor
   Lantos, Akos
   Palinkasi, Szvetlana
   Varga, Ilona
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Borbely, Tibor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Palinkasi, Szvetlana] County Hospital of PulmonologyTorokbalint, Hungary.
   [Varga, Ilona] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ferenczi, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 317
EP 317
PG 1
ER

PT J
AU Fodor, I
AF Fodor, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Istvan] Loma L. UniversityLoma, USA.
RP Fodor, I (reprint author), Loma L. University, Loma, USA.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 317
EP 318
PG 2
ER

PT J
AU Fodor, J
   Major, T
   Polgar, Cs
   Orosz, Zs
   Sulyok, Z
AF Fodor, Janos
   Major, Tibor
   Polgar, Csaba
   Orosz, Zsolt
   Sulyok, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 318
EP 318
PG 1
ER

PT J
AU Fodor, Z
   Armos, N
   Balkay, L
   Tron, L
   Potari, N
   Galuska, L
   Marian, T
AF Fodor, Zoltan
   Armos, Nelly
   Balkay, Laszlo
   Tron, Lajos
   Potari, Norbert
   Galuska, Laszlo
   Marian, Terez
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Zoltan] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Armos, Nelly] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Tron, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Potari, Norbert] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Marian, Terez] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Fodor, Z (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 318
EP 318
PG 1
ER

PT J
AU Frohlich, G
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 319
EP 319
PG 1
ER

PT J
AU Fule, T
   Diczhazi, Cs
   Kovacs, A
   Krenacs, T
   Kovalszky, I
AF Fule, Tibor
   Diczhazi, Csaba
   Kovacs, Attila
   Krenacs, Tibor
   Kovalszky, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Diczhazi, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovacs, Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Fule, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 319
EP 319
PG 1
ER

PT J
AU Fulop, M
   Remenar, �
   Csaki, G
   Korenyi, 
   Patko, T
AF Fulop, Miklos
   Remenar, Eva
   Csaki, Gabor
   Korenyi, K.
   Patko, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Csaki, Gabor] National Institute of OncologyBudapest, Hungary.
   [Korenyi, K.] National Institute of OncologyBudapest, Hungary.
   [Patko, Tamas] National Institute of OncologyBudapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 319
EP 319
PG 1
ER

PT J
AU Gaal, D
   Kulcsar, Gy
AF Gaal, Dezso
   Kulcsar, Gyozo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gaal, Dezso] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Kulcsar, Gyozo] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
RP Gaal, D (reprint author), National Institute of Oncology, Department of Clinical Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 320
EP 320
PG 1
ER

PT J
AU Gaal, Sz
   Hideghety, K
   Maraz, A
   Fazekas, O
   Vereb, B
   Torday, L
   Uhercsak, G
   Kahan, Zs
   Bontovics, J
   Fodor, E
   Tiszlavicz, L
   Szentpali, K
   Simonka, Zs
   Varga, L
   Hohn, J
   Lazar, Gy
   Thurzo, L
AF Gaal, Szilvia
   Hideghety, Katalin
   Maraz, Aniko
   Fazekas, Olga
   Vereb, Blanka
   Torday, Laszlo
   Uhercsak, Gabriella
   Kahan, Zsuzsanna
   Bontovics, Julianna
   Fodor, Emese
   Tiszlavicz, Laszlo
   Szentpali, Karoly
   Simonka, Zsolt
   Varga, Laszlo
   Hohn, Jozsef
   Lazar, Gyorgy
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vereb, Blanka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bontovics, Julianna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of SurgerySzeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of SurgerySzeged, Hungary.
   [Varga, Laszlo] University of Szeged, Department of SurgerySzeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gaal, Sz (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 320
EP 320
PG 1
ER

PT J
AU Gabor, M
   Bartyik, K
   Karg, E
AF Gabor, K. Mita
   Bartyik, Katalin
   Karg, Eszter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gabor, K. Mita] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Bartyik, Katalin] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Karg, Eszter] University of Szeged, Department of PediatricsSzeged, Hungary.
RP Gabor, M (reprint author), University of Szeged, Department of Pediatrics, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 321
EP 321
PG 1
ER

PT J
AU Galffy, G
   Egri, G
   Tamasi, L
   Bartusek, D
   Losonczy, Gy
AF Galffy, Gabriella
   Egri, Gabor
   Tamasi, Lilla
   Bartusek, Dora
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Egri, Gabor] Bajcsi Zsilinszky Kh., Mellkassebeszeti OsztalyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartusek, Dora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 321
EP 321
PG 1
ER

PT J
AU Galffy, G
   Bartusek, D
   Losonczy, Gy
AF Galffy, Gabriella
   Bartusek, Dora
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartusek, Dora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 321
EP 322
PG 2
ER

PT J
AU Galffy, G
   Bartusek, D
AF Galffy, Gabriella
   Bartusek, Dora
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartusek, Dora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 322
EP 322
PG 1
ER

PT J
AU Ganofszky, E
   Horvath, Zs
   Hitre, E
   Juhos, �
   Gaudi, I
   Lang, I
AF Ganofszky, Erna
   Horvath, Zsolt
   Hitre, Erika
   Juhos, Eva
   Gaudi, Istvan
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Ganofszky, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 322
EP 322
PG 1
ER

PT J
AU Gerencser, Zs
   Jozsa, G
AF Gerencser, Zsolt
   Jozsa, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gerencser, Zsolt] St. Margit HospitalBudapest, Hungary.
   [Jozsa, Gabor] Roche Hungary LtdBudaors, Hungary.
RP Gerencser, Zs (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 323
EP 323
PG 1
ER

PT J
AU Gergely-Farnos, E
   Bogos, K
   Gyokeres, Gy
   Mihaly, 
   Kovacs, G
   Ostoros, Gy
AF Gergely-Farnos, Erzsebet
   Bogos, Krisztina
   Gyokeres, Gyongyi
   Mihaly, E.
   Kovacs, Gabor
   Ostoros, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gergely-Farnos, Erzsebet] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Gyokeres, Gyongyi] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Mihaly, E.] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Gergely-Farnos, E (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 323
EP 323
PG 1
ER

PT J
AU Gilde, K
   Banfalvi, T
   Borbola, K
   Fejos, Zs
   Liszkay, G
   Papp, A
   Abraham, K
   Borbely, K
AF Gilde, Katalin
   Banfalvi, Teodora
   Borbola, Kinga
   Fejos, Zsuzsanna
   Liszkay, Gabriella
   Papp, Andrea
   Abraham, Katalin
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Papp, Andrea] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Abraham, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Gilde, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 324
EP 324
PG 1
ER

PT J
AU Gilde, K
   Boldizsar, M
   Vincze, B
   Kapuvari, B
   Banfalvi, T
   Papp, A
   Fejos, Zs
   Otto, Sz
AF Gilde, Katalin
   Boldizsar, Mariann
   Vincze, Borbala
   Kapuvari, Bence
   Banfalvi, Teodora
   Papp, Andrea
   Fejos, Zsuzsanna
   Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Boldizsar, Mariann] National Institute of OncologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of OncologyBudapest, Hungary.
   [Papp, Andrea] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
RP Gilde, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 324
EP 324
PG 1
ER

PT J
AU Gombos, K
   Szele, E
   Varjas, T
   Puskas, GL
   Kozma, L
   Juhasz, F
   Ember, I
AF Gombos, Katalin
   Szele, Eszter
   Varjas, Timea
   Puskas, G Laszlo
   Kozma, Laszlo
   Juhasz, Ferenc
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Szele, Eszter] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Varjas, Timea] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Puskas, G Laszlo] MTA SZBK, Funkcionalis Genomikai LaboratoriumSzeged, Hungary.
   [Kozma, Laszlo] Orszagos Verellato SzolgalatDebrecen, Hungary.
   [Juhasz, Ferenc] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Gombos, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 325
EP 325
PG 1
ER

PT J
AU Godeny, M
   Horvath, K
   Bocs, K
   Petri, K
   Andi, J
   Manninger, S
   Remenar, �
   Boer, A
   Lovey, J
   Orosz, Zs
   Hitre, E
AF Godeny, Maria
   Horvath, Katalin
   Bocs, Katalin
   Petri, Klara
   Andi, Judit
   Manninger, Sandor
   Remenar, Eva
   Boer, Andras
   Lovey, Jozsef
   Orosz, Zsolt
   Hitre, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Manninger, Sandor] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, Klinikai Onkologiai OsztalyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 325
EP 325
PG 1
ER

PT J
AU Godeny, M
AF Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 325
EP 326
PG 2
ER

PT J
AU Gulya, E
   Gombas, P
   Kristo, K
   Pajkos, G
   Rahoty, P
   Stotz, Gy
   Matolcsy, A
   Bodoki, Gy
AF Gulya, Erno
   Gombas, Peter
   Kristo, Katalin
   Pajkos, Gabor
   Rahoty, Pal
   Stotz, Gyula
   Matolcsy, Andras
   Bodoki, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gulya, Erno] Honved KorhazBudapest, Hungary.
   [Gombas, Peter] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Kristo, Katalin] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Pajkos, Gabor] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Rahoty, Pal] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Stotz, Gyula] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodoki, Gyorgy] St. Laszlo HospitalBudapest, Hungary.
RP Gulya, E (reprint author), Honved Korhaz, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 326
EP 326
PG 1
ER

PT J
AU Gundy, S
   Farkas, Gy
   Szekely, G
   Susanszky, �
AF Gundy, Sarolta
   Farkas, Gyongyi
   Szekely, Gabor
   Susanszky, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Susanszky, Eva] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 326
EP 326
PG 1
ER

PT J
AU Gyergyay, F
   Agoston, P
   Lovey, J
   Vizkeleti, J
   Bodrogi, I
AF Gyergyay, Fruzsina
   Agoston, Peter
   Lovey, Jozsef
   Vizkeleti, Julia
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyergyay, Fruzsina] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Gyergyay, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 326
EP 327
PG 2
ER

PT J
AU Gyongyosine Joga, M
   Jakab, BN
AF Gyongyosine Joga, Marianna
   Jakab, B-Ne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyongyosine Joga, Marianna] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Jakab, B-Ne] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Gyongyosine Joga, M (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 327
EP 327
PG 1
ER

PT J
AU Gyorffy, B
   Schaefer, R
   Surowiak, P
   Abdul-Ghani, R
   Dietel, M
AF Gyorffy, Balazs
   Schaefer, Reinhold
   Surowiak, Pawel
   Abdul-Ghani, Rula
   Dietel, Manfred
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Schaefer, Reinhold] Charite University HospitalBerlin, Germany.
   [Surowiak, Pawel] Wroclaw Medical UniversityWroclaw, Poland.
   [Abdul-Ghani, Rula] University of JerusalemJerusalem, Israel.
   [Dietel, Manfred] Charite University HospitalBerlin, Germany.
RP Gyorffy, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 327
EP 327
PG 1
ER

PT J
AU Gyuranecz, M
AF Gyuranecz, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyuranecz, Miklos] Fejer County Szent Gyorgy HospitalSzekesfehervar, Hungary.
RP Gyuranecz, M (reprint author), Fejer County Szent Gyorgy Hospital, Szekesfehervar, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 327
EP 327
PG 1
ER

PT J
AU Halmos, G
   Schally, A
AF Halmos, Gabor
   Schally, V. Andrew
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Schally, V. Andrew] University of Miami, Miller School of MedicineMiami, FL, USA.
RP Halmos, G (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 328
EP 328
PG 1
ER

PT J
AU Haltrich, I
   Kovacs, G
   Csoka, M
   Fekete, Gy
AF Haltrich, Iren
   Kovacs, Gabor
   Csoka, Monika
   Fekete, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Haltrich, Iren] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Haltrich, I (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 328
EP 328
PG 1
ER

PT J
AU Harisi, R
   Dudas, J
   Nagy-Olah, J
   Szendroi, M
   Jeney, A
AF Harisi, Revekka
   Dudas, Jozsef
   Nagy-Olah, Julia
   Szendroi, Miklos
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dudas, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy-Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 329
EP 329
PG 1
ER

PT J
AU Hauser, P
   Csorba, Gn
   Timar, F
   Hanzely, Z
   Mathe, D
   Szabo, E
   Jeney, A
   Schuler, D
   Garami, M
AF Hauser, Peter
   Csorba, G-ne
   Timar, Ferenc
   Hanzely, Zoltan
   Mathe, Domokos
   Szabo, Edit
   Jeney, Andras
   Schuler, Dezso
   Garami, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Csorba, G-ne] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hanzely, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Mathe, Domokos] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Szabo, Edit] Debreceni Egyetem, Bolcsesztudomanyi KarDebrecen, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 329
EP 329
PG 1
ER

PT J
AU Hauser, P
   Bognar, L
   Hanzely, Z
   Kocsis, B
   Vizkeleti, J
   Schuler, D
   Garami, M
AF Hauser, Peter
   Bognar, Laszlo
   Hanzely, Zoltan
   Kocsis, Bela
   Vizkeleti, Julia
   Schuler, Dezso
   Garami, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Bognar, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
   [Hanzely, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Kocsis, Bela] National Institute of OncologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of OncologyBudapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 329
EP 329
PG 1
ER

PT J
AU Hitre, E
   Budai, B
   Horvath, Zs
   Lang, I
   Czegledi, F
   Kralovanszky, J
AF Hitre, Erika
   Budai, Barna
   Horvath, Zsolt
   Lang, Istvan
   Czegledi, Ferenc
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Hitre, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 330
EP 330
PG 1
ER

PT J
AU Horti, J
   Geczi, L
   Biro, K
   Rathonyi, E
   Nagyivanyi, K
   Bodrogi, I
AF Horti, Jozsef
   Geczi, Lajos
   Biro, Krisztina
   Rathonyi, Emese
   Nagyivanyi, Krisztian
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horti, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Biro, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Rathonyi, Emese] National Institute of OncologyBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Horti, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 330
EP 330
PG 1
ER

PT J
AU Horti, J
   Bodrogi, I
AF Horti, Jozsef
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horti, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
RP Horti, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 330
EP 330
PG 1
ER

PT J
AU Horvath, �
   Szluha, K
   Adamecz, Zs
   Der, �
   Szanto, J
   Sz. Kiss, S
   Szilasi, M
AF Horvath, Akos
   Szluha, Kornelia
   Adamecz, Zsolt
   Der, Adam
   Szanto, Janos
   Sz. Kiss, Sandor
   Szilasi, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Der, Adam] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Sz. Kiss, Sandor] Medical Faculty, University of Debrecen, 2 nd Department of SurgeryDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Horvath, � (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 331
EP 331
PG 1
ER

PT J
AU Horvath, A
   Palik, �
   Toth, �K
   Nebenfuhrer, Zs
   Czegle, I
   Kocsis, J
AF Horvath, Anna
   Palik, Eva
   Toth, Eva Katalin
   Nebenfuhrer, Zsuzsanna
   Czegle, Ibolya
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Anna] Semmelweis UniversityBudapest, Hungary.
   [Palik, Eva] Semmelweis UniversityBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis UniversityBudapest, Hungary.
   [Nebenfuhrer, Zsuzsanna] Semmelweis UniversityBudapest, Hungary.
   [Czegle, Ibolya] Semmelweis UniversityBudapest, Hungary.
   [Kocsis, Judit] Semmelweis UniversityBudapest, Hungary.
RP Horvath, A (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 331
EP 331
PG 1
ER

PT J
AU Horvath, K
   Galambos, K
   Lovey, J
   Pete, I
   Godeny, M
AF Horvath, Katalin
   Galambos, Klaudia
   Lovey, Jozsef
   Pete, Imre
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Galambos, Klaudia] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 331
EP 331
PG 1
ER

PT J
AU Horvath, Zs
   Lang, I
   Hitre, E
   Simo, E
   Talos, Zs
   Vizhanyo, R
   Andras, Cs
   Padi, �
   Dank, M
   Ganofszky, E
   Juhos, �
   Esik, O
   Faluhelyi, Zs
   Szucs, M
   Szanto, J
   Cseh, J
   Mako, E
AF Horvath, Zsolt
   Lang, Istvan
   Hitre, Erika
   Simo, Erzsebet
   Talos, Zsuzsanna
   Vizhanyo, Rita
   Andras, Csilla
   Padi, Eva
   Dank, Magdolna
   Ganofszky, Erna
   Juhos, Eva
   Esik, Olga
   Faluhelyi, Zsolt
   Szucs, Miklos
   Szanto, Janos
   Cseh, Jozsef
   Mako, Erno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Simo, Erzsebet] University of Pecs, Department of OncologyPecs, Hungary.
   [Talos, Zsuzsanna] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Padi, Eva] Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Onkologiai OsztalySzekesfehervar, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Faluhelyi, Zsolt] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szanto, Janos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Cseh, Jozsef] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Mako, Erno] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 332
EP 332
PG 1
ER

PT J
AU Hullan, L
   Jaszay, Zs
   Csiba, A
   Trezl, L
   Szarvas, T
   Petnehazy, I
   Tajeda, 
   Sarkadi, L
   Soos, G
   Toke, L
AF Hullan, Lehel
   Jaszay, Zsuzsa
   Csiba, Andras
   Trezl, Lajos
   Szarvas, Tibor
   Petnehazy, Imre
   Tajeda, M.
   Sarkadi, Laszlo
   Soos, Gergely
   Toke, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hullan, Lehel] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Jaszay, Zsuzsa] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Csiba, Andras] Fovarosi Allategeszsegugyi es Elelmiszer Ellenorzo IntezetBudapest, Hungary.
   [Trezl, Lajos] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Szarvas, Tibor] Izotop Intezet Kft.Budapest, Hungary.
   [Petnehazy, Imre] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Tajeda, M.] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Sarkadi, Laszlo] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Soos, Gergely] Semmelweis UniversityBudapest, Hungary.
   [Toke, Laszlo] Budapest University of Technology and EconomicsBudapest, Hungary.
RP Hullan, L (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 332
EP 332
PG 1
ER

PT J
AU Imreh, I
AF Imreh, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Imreh, Istvan] Karolinska Institutet, Microbiology and Tumor Biology Center (MTC)Stockholm, Sweden.
RP Imreh, I (reprint author), Karolinska Institutet, Microbiology and Tumor Biology Center (MTC), Stockholm, Sweden.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 335
EP 335
PG 1
ER

PT J
AU Ivan, L
   Sztano, B
   Czigner, J
AF Ivan, Laszlo
   Sztano, Balazs
   Czigner, Jeno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Sztano, Balazs] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Ivan, L (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 335
EP 335
PG 1
ER

PT J
AU Jakab, M
AF Jakab, G. Matyas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jakab, G. Matyas] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi IntezetBudapest, Hungary.
RP Jakab, M (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 335
EP 336
PG 2
ER

PT J
AU Janvary, ZsL
   Major, T
   Fodor, J
   Polgar, Cs
AF Janvary, Zsolt Levente
   Major, Tibor
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 336
EP 336
PG 1
ER

PT J
AU Jardanhazy, A
   Jardanhazy, T
   Molnar, J
AF Jardanhazy, Anett
   Jardanhazy, Tamas
   Molnar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jardanhazy, Anett] University of Szeged, Albert Szent-Gyorgyi Clinical Centre, Medical Faculty, Department of NeurologySzeged, Hungary.
   [Jardanhazy, Tamas] University of Szeged, Albert Szent-Gyorgyi Clinical Centre, Medical Faculty, Department of NeurologySzeged, Hungary.
   [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
RP Jardanhazy, A (reprint author), University of Szeged, Albert Szent-Gyorgyi Clinical Centre, Medical Faculty, Department of Neurology, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 337
EP 337
PG 1
ER

PT J
AU Jederan, �
   Godeny, M
   Farkas, E
   Matrai, Z
   Orosz, Zs
   Szentirmay, Z
   Lovey, J
   Lang, I
   Koves, I
AF Jederan, Eva
   Godeny, Maria
   Farkas, Emil
   Matrai, Zoltan
   Orosz, Zsolt
   Szentirmay, Zoltan
   Lovey, Jozsef
   Lang, Istvan
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, Klinikai Onkologiai OsztalyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 337
EP 337
PG 1
ER

PT J
AU Josa, V
   Bartfai, R
AF Josa, Valeria
   Bartfai, Reka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Josa, Valeria] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Bartfai, Reka] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Josa, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 337
EP 337
PG 1
ER

PT J
AU Juhasz, A
   Huga, S
   Mile, M
   Dezso, B
   Hernadi, Z
   Halmos, G
AF Juhasz, Aliz
   Huga, Sandor
   Mile, Melinda
   Dezso, Balazs
   Hernadi, Zoltan
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Aliz] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Huga, Sandor] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Mile, Melinda] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Hernadi, Zoltan] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Juhasz, A (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 338
EP 338
PG 1
ER

PT J
AU Juhasz, A
   Nagy, Cs
   Paldy, A
AF Juhasz, Attila
   Nagy, Csilla
   Paldy, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Attila] ANTSz, Kozep-magyarorszagi Regionalis IntezeteBudapest, Hungary.
   [Nagy, Csilla] ANTSz, Kozep-magyarorszagi Regionalis IntezeteBudapest, Hungary.
   [Paldy, Anna] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
RP Juhasz, A (reprint author), ANTSz, Kozep-magyarorszagi Regionalis Intezete, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 338
EP 338
PG 1
ER

PT J
AU Juhasz, E
   Temesi, G
   Soter, Sz
   Peter, 
   Jonas, J
AF Juhasz, Erzsebet
   Temesi, Gabriella
   Soter, Szabolcs
   Peter, T.
   Jonas, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Erzsebet] Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. TudoosztalyBudapest, Hungary.
   [Temesi, Gabriella] Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. TudoosztalyBudapest, Hungary.
   [Soter, Szabolcs] Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. TudoosztalyBudapest, Hungary.
   [Peter, T.] Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. TudoosztalyBudapest, Hungary.
   [Jonas, Jozsef] Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. TudoosztalyBudapest, Hungary.
RP Juhasz, E (reprint author), Orszagos Koranyi TBC es Pulmonologiai Intezet, XIV. Tudoosztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 339
EP 339
PG 1
ER

PT J
AU Juhasz, K
AF Juhasz, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Krisztina] Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia OsztalyBudapest, Hungary.
RP Juhasz, K (reprint author), Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 339
EP 339
PG 1
ER

PT J
AU Juhasz, K
AF Juhasz, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Krisztina] Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia OsztalyBudapest, Hungary.
RP Juhasz, K (reprint author), Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 340
EP 340
PG 1
ER

PT J
AU Juhos, �
   Szabo, E
   Hitre, E
   Papai, Zs
   Ganovszki, E
   Horvath, Zs
   Lang, I
AF Juhos, Eva
   Szabo, Eszter
   Hitre, Erika
   Papai, Zsuzsa
   Ganovszki, Erna
   Horvath, Zsolt
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Papai, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Ganovszki, Erna] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Juhos, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 340
EP 340
PG 1
ER

PT J
AU Kajary, K
   Lengyel, Zs
   Szakall, Sz
   Petranyi, �
   Bodoky, Gy
AF Kajary, Kornelia
   Lengyel, Zsolt
   Szakall, Szabolcs
   Petranyi, Agota
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kajary, Kornelia] Pozitron Diagnosztika KftBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kajary, K (reprint author), Pozitron Diagnosztika Kft, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 341
EP 341
PG 1
ER

PT J
AU Kapuvari, B
   Szabo, I
   Vincze, B
   Kovacs, M
   Boldizsar, M
   Csuka, O
   Bosze, Sz
   Gaal, D
   Szabo, ER
   Toth, G
   Mezo, G
AF Kapuvari, Bence
   Szabo, Ildiko
   Vincze, Borbala
   Kovacs, Magdolna
   Boldizsar, Mariann
   Csuka, Orsolya
   Bosze, Szilvia
   Gaal, Dezso
   Szabo, Emilia Rita
   Toth, Gabor
   Mezo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Szabo, Ildiko] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Magdolna] Pecsi Tudomanyegyetem AOK, Anatomiai IntezetPecs, Hungary.
   [Boldizsar, Mariann] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Bosze, Szilvia] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Gaal, Dezso] National Institute of OncologyBudapest, Hungary.
   [Szabo, Emilia Rita] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Toth, Gabor] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 341
EP 341
PG 1
ER

PT J
AU Kenessey, I
   Tovari, J
   Raso, E
   Adam, 
   Meszaros, L
   Kramer, Zs
   Timar, J
AF Kenessey, Istvan
   Tovari, Jozsef
   Raso, Erzsebet
   Adam, A.
   Meszaros, Laszlo
   Kramer, Zsofia
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kenessey, Istvan] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Raso, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Adam, A.] National Institute of OncologyBudapest, Hungary.
   [Meszaros, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Kramer, Zsofia] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Kenessey, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 341
EP 341
PG 1
ER

PT J
AU Kerpel-Fronius, S
AF Kerpel-Fronius, Sandor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kerpel-Fronius, Sandor] Semmelweis University, Department of Pharmacology and PharmacotherapyBudapest, Hungary.
RP Kerpel-Fronius, S (reprint author), Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 342
EP 342
PG 1
ER

PT J
AU Kertesz, I
   Gardi, J
   Tron, L
   Galuska, L
   Halmos, G
AF Kertesz, Istvan
   Gardi, Janos
   Tron, Lajos
   Galuska, Laszlo
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kertesz, Istvan] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Gardi, Janos] SZTE, Endokrin Onallo Osztaly es LaboratoriumSzeged, Hungary.
   [Tron, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Kertesz, I (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 342
EP 342
PG 1
ER

PT J
AU Kertesz, I
   Galuska, L
   Tron, L
   Kovacs, Z
AF Kertesz, Istvan
   Galuska, Laszlo
   Tron, Lajos
   Kovacs, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kertesz, Istvan] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Tron, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kovacs, Zoltan] ATOMKIDebrecen, Hungary.
RP Kertesz, I (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 343
EP 343
PG 1
ER

PT J
AU Kiss, A
   Holczbauer, �
   Batmunkh, E
   Szijarto, A
   Kupcsulik, P
   Schaff, Zs
AF Kiss, Andras
   Holczbauer, Agnes
   Batmunkh, Enkhjargal
   Szijarto, Attila
   Kupcsulik, Peter
   Schaff, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Holczbauer, Agnes] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Batmunkh, Enkhjargal] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szijarto, Attila] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Kupcsulik, Peter] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kiss, A (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 343
EP 343
PG 1
ER

PT J
AU Kiss, A
   Fodor, Z
   Remenyi, Gy
   Batar, P
   Szasz, R
   Radvanyi, G
   Udvardy, M
   Galuska, L
AF Kiss, Attila
   Fodor, Zoltan
   Remenyi, Gyula
   Batar, Peter
   Szasz, Robert
   Radvanyi, Gaspar
   Udvardy, Miklos
   Galuska, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Attila] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Fodor, Zoltan] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Remenyi, Gyula] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Batar, Peter] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Szasz, Robert] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Radvanyi, Gaspar] Semmelweis HospitalMiskolc, Hungary.
   [Udvardy, Miklos] DE OEC, II. Belgyogyaszati KlinikaDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Kiss, A (reprint author), DE OEC, II. Belgyogyaszati Klinika, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 344
EP 344
PG 1
ER

PT J
AU Kiss, Cs
   Bardi, E
AF Kiss, Csongor
   Bardi, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Bardi, Edit] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
RP Kiss, Cs (reprint author), Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 344
EP 344
PG 1
ER

PT J
AU Kiss, J
   Szendroi, M
   Antal, I
AF Kiss, Janos
   Szendroi, Miklos
   Antal, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Janos] Semmelweis UniversityBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Antal, Imre] Semmelweis UniversityBudapest, Hungary.
RP Kiss, J (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 344
EP 344
PG 1
ER

PT J
AU Kocsis, J
   Toth, �K
   Madaras, B
   Biro, A
   Pocsai, Zs
   Fust, Gy
   Blasko, B
   Adany, R
   Laki, J
AF Kocsis, Judit
   Toth, Eva Katalin
   Madaras, Balazs
   Biro, Adrienne
   Pocsai, Zsuzsa
   Fust, Gyorgy
   Blasko, Bernadette
   Adany, Roza
   Laki, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Madaras, Balazs] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Biro, Adrienne] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Pocsai, Zsuzsa] University of DebrecenDebrecen, Hungary.
   [Fust, Gyorgy] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Blasko, Bernadette] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Adany, Roza] University of DebrecenDebrecen, Hungary.
   [Laki, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 345
EP 345
PG 1
ER

PT J
AU Kocsis, Zs
   Marcsek, Z
   Szende, B
   Jakab, M
   Molnar, K
   Szilvasine Horvath, K
   Tompa, A
AF Kocsis, Zsuzsanna
   Marcsek, Zoltan
   Szende, Bela
   Jakab, Matyas
   Molnar, Kornelia
   Szilvasine Horvath, Kata
   Tompa, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Zsuzsanna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Marcsek, Zoltan] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Szende, Bela] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Jakab, Matyas] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Molnar, Kornelia] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Szilvasine Horvath, Kata] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai OsztalyBudapest, Hungary.
   [Tompa, Anna] Semmelweis University, Department of Public HealthBudapest, Hungary.
RP Kocsis, Zs (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kemiai Biztonsagi Intezet, Citogenetikai es Molekularis Toxikologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 345
EP 345
PG 1
ER

PT J
AU Koltai, L
   Keresztes, S
   Sinkovics, I
   Boer, A
   Remenar, �
   Keresztes, K
AF Koltai, Laszlo
   Keresztes, Sandor
   Sinkovics, Istvan
   Boer, Andras
   Remenar, Eva
   Keresztes, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Keresztes, Sandor] National Institute of OncologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Keresztes, Katalin] National Institute of OncologyBudapest, Hungary.
RP Koltai, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 346
EP 346
PG 1
ER

PT J
AU Koltai, P
   Hegyesi, H
   Molnar, V
   Peter, I
   Falus, A
AF Koltai, Pal
   Hegyesi, Hargita
   Molnar, Viktoria
   Peter, Ilona
   Falus, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Pal] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Hegyesi, Hargita] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Molnar, Viktoria] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Koltai, P (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 346
EP 346
PG 1
ER

PT J
AU Komlodi-Pasztor, E
   Trostel, Sh
   Murphy, 
   Fojo, T
AF Komlodi-Pasztor, Edina
   Trostel, Shana
   Murphy, B.
   Fojo, Tito
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Komlodi-Pasztor, Edina] Semmelweis UniversityBudapest, Hungary.
   [Trostel, Shana] National Institutes of Health, National Cancer InstituteBethesda, USA.
   [Murphy, B.] National Institutes of Health, National Cancer InstituteBethesda, USA.
   [Fojo, Tito] National Institutes of Health, National Cancer InstituteBethesda, USA.
RP Komlodi-Pasztor, E (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 346
EP 347
PG 2
ER

PT J
AU Kopp, M
AF Kopp, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kopp, Maria] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Kopp, M (reprint author), Semmelweis University, Institute of Behavioural Sciences, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 347
EP 347
PG 1
ER

PT J
AU Kotai, Zs
   Balatoni, Zs
AF Kotai, Zsuzsa
   Balatoni, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Balatoni, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Kotai, Zs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 347
EP 347
PG 1
ER

PT J
AU Koti, Cs
   Fecso, A
   Toth, E
   Salah, S
   Nabradi, Z
AF Koti, Csaba
   Fecso, Andras
   Toth, Eniko
   Salah, Suleiman
   Nabradi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koti, Csaba] Teruleti KorhazBerettyoujfalu, Hungary.
   [Fecso, Andras] Teruleti KorhazBerettyoujfalu, Hungary.
   [Toth, Eniko] Teruleti KorhazBerettyoujfalu, Hungary.
   [Salah, Suleiman] Teruleti KorhazBerettyoujfalu, Hungary.
   [Nabradi, Zoltan] Teruleti KorhazBerettyoujfalu, Hungary.
RP Koti, Cs (reprint author), Teruleti Korhaz, Berettyoujfalu, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 348
EP 348
PG 1
ER

PT J
AU Kovacs, �
   Hadjiev, J
   Lakosi, F
   Antal, G
   Glavak, Cs
   Kotek, Gy
   Bogner, P
   Repa, I
AF Kovacs, Arpad
   Hadjiev, Janaki
   Lakosi, Ferenc
   Antal, Gergely
   Glavak, Csaba
   Kotek, Gyula
   Bogner, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Arpad] University of KaposvarKaposvar, Hungary.
   [Hadjiev, Janaki] University of KaposvarKaposvar, Hungary.
   [Lakosi, Ferenc] University of KaposvarKaposvar, Hungary.
   [Antal, Gergely] University of KaposvarKaposvar, Hungary.
   [Glavak, Csaba] University of KaposvarKaposvar, Hungary.
   [Kotek, Gyula] University of KaposvarKaposvar, Hungary.
   [Bogner, Peter] University of KaposvarKaposvar, Hungary.
   [Repa, Imre] University of KaposvarKaposvar, Hungary.
RP Kovacs, � (reprint author), University of Kaposvar, Kaposvar, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 348
EP 348
PG 1
ER

PT J
AU Kovacs, G
   Muller, J
   Hegyi, M
   Csoka, M
   Semsei, �
   Tordai, A
   Szalai, Cs
   Falus, A
   Erdelyi, D
   Fekete, Gy
AF Kovacs, Gabor
   Muller, Judit
   Hegyi, Marta
   Csoka, Monika
   Semsei, Agnes
   Tordai, Attila
   Szalai, Csaba
   Falus, Andras
   Erdelyi, Daniel
   Fekete, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hegyi, Marta] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Semsei, Agnes] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Tordai, Attila] National Medical CenterBudapest, Hungary.
   [Szalai, Csaba] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 348
EP 348
PG 1
ER

PT J
AU Kovacs, G
   Nemes, K
   Hegyi, M
   Erdelyi, D
   Csoka, M
   Semsei, �
   Szendroi, M
   Fekete, Gy
   Falus, A
   Szalai, Cs
AF Kovacs, Gabor
   Nemes, Karolina
   Hegyi, Marta
   Erdelyi, Daniel
   Csoka, Monika
   Semsei, Agnes
   Szendroi, Miklos
   Fekete, Gyorgy
   Falus, Andras
   Szalai, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Nemes, Karolina] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Hegyi, Marta] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Semsei, Agnes] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Szalai, Csaba] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 349
EP 349
PG 1
ER

PT J
AU Kovacs, M�
   Papp, J
   Otto, Sz
   Szentirmay, Z
   Olah, E
AF Kovacs, Marietta Eva
   Papp, Janos
   Otto, Szabolcs
   Szentirmay, Zoltan
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Marietta Eva] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Kovacs, M� (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 349
EP 349
PG 1
ER

PT J
AU Kovacs, Sz
   Kotai, Zs
AF Kovacs, Szilvia
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Szilvia] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Kovacs, Sz (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 349
EP 350
PG 2
ER

PT J
AU Kovalszky, I
   Dobos, K
   Hollosi, P
   Tatrai, E
   Szilak, L
AF Kovalszky, Ilona
   Dobos, Katalin
   Hollosi, Peter
   Tatrai, Eniko
   Szilak, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dobos, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hollosi, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tatrai, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szilak, Laszlo] Szilak Labor KftSzeged, Hungary.
RP Kovalszky, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 350
EP 350
PG 1
ER

PT J
AU Kovats, Zs
   Csekeo, A
   Fillinger, J
   Magyar, P
   Muller, V
AF Kovats, Zsuzsanna
   Csekeo, Attila
   Fillinger, Janos
   Magyar, Pal
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovats, Zsuzsanna] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Fillinger, Janos] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Kovats, Zs (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 350
EP 350
PG 1
ER

PT J
AU Kokeny, Sz
AF Kokeny, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kokeny, Szabolcs] Applera Mo KftBudapest, Hungary.
RP Kokeny, Sz (reprint author), Applera Mo Kft, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 350
EP 351
PG 2
ER

PT J
AU Koveskuti, �
   Bursics, A
   Villango, B
   Gyokeres, T
   Bodoky, Gy
   Papai, Zs
   Rahoty, P
AF Koveskuti, Agnes
   Bursics, Attila
   Villango, Balazs
   Gyokeres, Tibor
   Bodoky, Gyorgy
   Papai, Zsuzsa
   Rahoty, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koveskuti, Agnes] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Villango, Balazs] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Gyokeres, Tibor] AEK, Gastroenterologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Rahoty, Pal] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
RP Koveskuti, � (reprint author), AEK, II. Sebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 351
EP 351
PG 1
ER

PT J
AU Krascsenits, G
   Polgar, Cs
   Pulay, T
   Fodor, J
AF Krascsenits, Geza
   Polgar, Csaba
   Pulay, Tamas
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Krascsenits, Geza] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
RP Krascsenits, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 351
EP 351
PG 1
ER

PT J
AU Kristo, K
   Csomor, J
   Matolcsy, A
   Pajkos, G
   Papai, Zs
AF Kristo, Katalin
   Csomor, Judit
   Matolcsy, Andras
   Pajkos, Gabor
   Papai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kristo, Katalin] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Pajkos, Gabor] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Kristo, K (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 352
EP 352
PG 1
ER

PT J
AU Kristo, K
   Vachaja, J
   Kokai, T
   Farkas, M
   Papai, Zs
AF Kristo, Katalin
   Vachaja, Jozsef
   Kokai, Tunde
   Farkas, Marianne
   Papai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kristo, Katalin] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Farkas, Marianne] Del-Pesti CentrumkorhazBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Kristo, K (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 352
EP 352
PG 1
ER

PT J
AU Kulcsar, Gy
   Toth, Z
   Kulcsar, I
   Berente, Z
   Osz, E
   Halasz, H
AF Kulcsar, Gyozo
   Toth, Zoltan
   Kulcsar, Istvan
   Berente, Zoltan
   Osz, Erzsebet
   Halasz, Helena
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kulcsar, Gyozo] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Toth, Zoltan] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Kulcsar, Istvan] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Berente, Zoltan] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Osz, Erzsebet] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Halasz, Helena] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
RP Kulcsar, Gy (reprint author), University of Pecs, Institute of Biochemistry and Medical Chemistry, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 352
EP 353
PG 2
ER

PT J
AU Ladanyi, A
   Raso, E
   Dobos, J
   Lorincz, T
   Tovari, J
   Timar, J
AF Ladanyi, Andrea
   Raso, Erzsebet
   Dobos, Judit
   Lorincz, Tamas
   Tovari, Jozsef
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Raso, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Lorincz, Tamas] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 353
EP 353
PG 1
ER

PT J
AU Lahm, E
   Sikter, M
   Uhlyarik, A
   Agoston, P
   Szekely, J
   Somogyi, A
   Voros, A
   Papai, Zs
AF Lahm, Erika
   Sikter, Marta
   Uhlyarik, Andrea
   Agoston, Peter
   Szekely, Judit
   Somogyi, Andras
   Voros, Attila
   Papai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Szekely, Judit] National Institute of OncologyBudapest, Hungary.
   [Somogyi, Andras] National Institute of OncologyBudapest, Hungary.
   [Voros, Attila] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Lahm, E (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 353
EP 353
PG 1
ER

PT J
AU Landherr, L
AF Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 353
EP 353
PG 1
ER

PT J
AU Lang, I
AF Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Lang, I (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 354
EP 354
PG 1
ER

PT J
AU Lazar, Gy
   Takacs, T
   Paszt, A
   Szentpali, K
   Ormandi, K
   Lazar, M
   Palka, I
   Kahan, Zs
AF Lazar, Gyorgy
   Takacs, Tibor
   Paszt, Attila
   Szentpali, Karoly
   Ormandi, Katalin
   Lazar, Mate
   Palka, Istvan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Takacs, Tibor] University of Szeged, Department of SurgerySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Szentpali, Karoly] University of Szeged, Department of SurgerySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Lazar, Mate] SZTE AOK, Nemzetkozi Egeszsegugyi KozpontSzeged, Hungary.
   [Palka, Istvan] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 354
EP 354
PG 1
ER

PT J
AU Lengyel, Zs
   Toth, Gy
   Szakall, Sz
   Molnar, P
   Kajary, K
   Pavics, L
AF Lengyel, Zsolt
   Toth, Gyula
   Szakall, Szabolcs
   Molnar, Peter
   Kajary, Kornelia
   Pavics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Toth, Gyula] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Molnar, Peter] Pozitron Diagnosztika KftBudapest, Hungary.
   [Kajary, Kornelia] Pozitron Diagnosztika KftBudapest, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
RP Lengyel, Zs (reprint author), Pozitron Diagnosztika Kft, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 354
EP 354
PG 1
ER

PT J
AU Lichtenberger, Gy
AF Lichtenberger, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lichtenberger, Gyorgy] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Lichtenberger, Gy (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 355
EP 355
PG 1
ER

PT J
AU Liszkay, G
   Orosz, Zs
   Plotar, V
   Sinkovics, I
   Koves, I
   Renyi-Vamos, F
   Gilde, K
   Fejos, Zs
   Banfalvi, T
   Kasler, M
AF Liszkay, Gabriella
   Orosz, Zsolt
   Plotar, Vanda
   Sinkovics, Istvan
   Koves, Istvan
   Renyi-Vamos, Ferenc
   Gilde, Katalin
   Fejos, Zsuzsanna
   Banfalvi, Teodora
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of OncologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 355
EP 355
PG 1
ER

PT J
AU Liszkay, G
   Sinkovics, I
   Orosz, Zs
   Koves, I
   Renyi-Vamos, F
   Gilde, K
   Borbola, K
   Papp, A
   Kasler, M
AF Liszkay, Gabriella
   Sinkovics, Istvan
   Orosz, Zsolt
   Koves, Istvan
   Renyi-Vamos, Ferenc
   Gilde, Katalin
   Borbola, Kinga
   Papp, Andrea
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Papp, Andrea] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 356
EP 356
PG 1
ER

PT J
AU Losonczy, Gy
   Mathe, Cs
   Bohacs, A
   Magyar, P
AF Losonczy, Gyorgy
   Mathe, Csaba
   Bohacs, Aniko
   Magyar, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Mathe, Csaba] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Losonczy, Gy (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 356
EP 356
PG 1
ER

PT J
AU Lovey, J
   Agoston, P
   Czigner, K
   Major, T
   Lengyel, Zs
   Polgar, Cs
   Fodor, J
   Godeny, M
   Remenar, �
   Kasler, M
   Borbely, K
AF Lovey, Jozsef
   Agoston, Peter
   Czigner, Krisztina
   Major, Tibor
   Lengyel, Zsolt
   Polgar, Csaba
   Fodor, Janos
   Godeny, Maria
   Remenar, Eva
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Czigner, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 357
EP 357
PG 1
ER

PT J
AU Lukacs, G
   Juhasz, F
   Gyory, F
   Szabados, L
   Galuska, L
AF Lukacs, Geza
   Juhasz, Ferenc
   Gyory, Ferenc
   Szabados, Lajos
   Galuska, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Geza] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Juhasz, Ferenc] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Gyory, Ferenc] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Szabados, Lajos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Lukacs, G (reprint author), University of Debrecen, Medical and Health Science Centre, 1st Department of Surgery, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 357
EP 357
PG 1
ER

PT J
AU Lukats, O
   Imre, L
   Tapaszto, B
   Toth, J
AF Lukats, Olga
   Imre, Laszlo
   Tapaszto, Beata
   Toth, Jeannette
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Imre, Laszlo] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Tapaszto, Beata] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
RP Lukats, O (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 357
EP 357
PG 1
ER

PT J
AU Lumniczky, K
   Szatmari, T
   Huszty, G
   Desaknai, Sz
   Spasokoukotskaja, T
   Sasvari-Szekely, M
   Staub, M
   Safrany, G
AF Lumniczky, Katalin
   Szatmari, Tunde
   Huszty, Gergely
   Desaknai, Szilvia
   Spasokoukotskaja, Tatjana
   Sasvari-Szekely, Maria
   Staub, Maria
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] OSSKIBudapest, Hungary.
   [Szatmari, Tunde] OSSKIBudapest, Hungary.
   [Huszty, Gergely] OSSKIBudapest, Hungary.
   [Desaknai, Szilvia] OSSKIBudapest, Hungary.
   [Spasokoukotskaja, Tatjana] OSSKIBudapest, Hungary.
   [Sasvari-Szekely, Maria] Semmelweis UniversityBudapest, Hungary.
   [Staub, Maria] Semmelweis UniversityBudapest, Hungary.
   [Safrany, Geza] OSSKIBudapest, Hungary.
RP Lumniczky, K (reprint author), OSSKI, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 358
EP 358
PG 1
ER

PT J
AU Magyar, M
   Ostoros, Gy
   Dome, B
   Kovacs, G
AF Magyar, Melinda
   Ostoros, Gyula
   Dome, Balazs
   Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyar, Melinda] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Magyar, M (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 358
EP 358
PG 1
ER

PT J
AU Magyarosy, E
   Domonkos, B
   Muller, J
   Jakab, Zs
AF Magyarosy, Edina
   Domonkos, Brigitta
   Muller, Judit
   Jakab, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyarosy, Edina] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Domonkos, Brigitta] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Magyarosy, E (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 358
EP 358
PG 1
ER

PT J
AU Mahr, K
   Ruzsa, �
AF Mahr, Karoly
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mahr, Karoly] County Hospital of ZalaZalaegerszeg, Hungary.
   [Ruzsa, Agnes] County Hospital of ZalaZalaegerszeg, Hungary.
RP Mahr, K (reprint author), County Hospital of Zala, Zalaegerszeg, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 359
EP 359
PG 1
ER

PT J
AU Majoros, A
   Bach, D
   Keszthelyi, A
   Hamvas, A
   Romics, I
AF Majoros, Attila
   Bach, Dietmar
   Keszthelyi, Attila
   Hamvas, Antal
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Bach, Dietmar] St Agnes HospitalBocholt, Germany.
   [Keszthelyi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Hamvas, Antal] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Majoros, A (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 359
EP 359
PG 1
ER

PT J
AU Maka, E
   Toth, J
   Lukats, O
   Senyi, K
   Csakany, B
AF Maka, Erika
   Toth, Jeannette
   Lukats, Olga
   Senyi, Katalin
   Csakany, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maka, Erika] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Senyi, Katalin] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Csakany, Bela] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
RP Maka, E (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 359
EP 359
PG 1
ER

PT J
AU Maraz, R
   Boross, G
   Svebis, M
   Szucs, M
   Ambrozay, �
   Lorincz, M
   Sinko, M
   Cserni, G
AF Maraz, Robert
   Boross, Gabor
   Svebis, Mihaly
   Szucs, Miklos
   Ambrozay, Eva
   Lorincz, Margit
   Sinko, Maria
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Lorincz, Margit] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Sinko, Maria] Bacs-Kiskun Megyei Onk. Korhaza, Izotop laborKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 360
EP 360
PG 1
ER

PT J
AU Maraz, R
   Boross, G
   Fustos, L
   Svebis, M
   Ambrozay, �
   Lorincz, M
   Cserni, G
AF Maraz, Robert
   Boross, Gabor
   Fustos, Laszlo
   Svebis, Mihaly
   Ambrozay, Eva
   Lorincz, Margit
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Fustos, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Lorincz, Margit] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 360
EP 360
PG 1
ER

PT J
AU Marko, L
   Boross, G
   Maraz, R
   Svebis, M
   Cserni, G
   Ambrozay, �
   Szucs, M
AF Marko, Laszlo
   Boross, Gabor
   Maraz, Robert
   Svebis, Mihaly
   Cserni, Gabor
   Ambrozay, Eva
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 360
EP 360
PG 1
ER

PT J
AU Marko, L
   Gabor, G
   Hajnal, L
   Jakab, G
   Maraz, R
   Svebis, M
   Szucs, M
AF Marko, Laszlo
   Gabor, Gabriella
   Hajnal, Lajos
   Jakab, Gabriella
   Maraz, Robert
   Svebis, Mihaly
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Jakab, Gabriella] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Szucs, Miklos] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 360
EP 360
PG 1
ER

PT J
AU Matrai, Z
   Polgar, Cs
   Orosz, Zs
   Nagy, T
   Feher, I
   Simon, P
   Ringwald, G
   Renyi-Vamos, F
   Farkas, E
   Savolt, �
   Szollar, A
AF Matrai, Zoltan
   Polgar, Csaba
   Orosz, Zsolt
   Nagy, Tunde
   Feher, Istvan
   Simon, Peter
   Ringwald, Gabor
   Renyi-Vamos, Ferenc
   Farkas, Emil
   Savolt, Akos
   Szollar, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Nagy, Tunde] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Feher, Istvan] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Simon, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Ringwald, Gabor] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 361
EP 361
PG 1
ER

PT J
AU Matrai, Z
   Papp, J
   Peter, I
   Szendroi, M
   Rahoty, P
   Papai, Zs
   Sapi, Z
   Koves, I
   Olah, E
AF Matrai, Zoltan
   Papp, Janos
   Peter, Ilona
   Szendroi, Miklos
   Rahoty, Pal
   Papai, Zsuzsa
   Sapi, Zoltan
   Koves, Istvan
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Rahoty, Pal] BM Kozponti KorhazBudapest, Hungary.
   [Papai, Zsuzsa] National Medical CenterBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 361
EP 361
PG 1
ER

PT J
AU Mayer, �
   Patyanik, M
AF Mayer, Arpad
   Patyanik, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Patyanik, Mihaly] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 361
EP 362
PG 2
ER

PT J
AU Meszaros, K
   Remenar, �
   Kovacs, E
   Godeny, M
   Kasler, M
   Hacki, T
   Varga, Zs
AF Meszaros, Krisztina
   Remenar, Eva
   Kovacs, Eszter
   Godeny, Maria
   Kasler, Miklos
   Hacki, Tamas
   Varga, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Krisztina] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Hacki, Tamas] Regensburgi Egyetem, FOG KlinikaRegensburg, Germany.
   [Varga, Zsuzsa] Semmelweis Egyetem, Egeszsegugyi Foiskolai KarBudapest, Hungary.
RP Meszaros, K (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 362
EP 362
PG 1
ER

PT J
AU Michna, K
AF Michna, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Michna, Krisztina] Kaposi Mor Oktato Korhaz, Tudo- es SzivkorhazaMosdos, Hungary.
RP Michna, K (reprint author), Kaposi Mor Oktato Korhaz, Tudo- es Szivkorhaza, Mosdos, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 362
EP 362
PG 1
ER

PT J
AU Micsik, T
   Mersich, T
   Besznyak, I
   Dede, K
   Zarand, A
   Jakab, F
   Karaszi, �
   Lorincz, A
   Schwab, R
   Keri, Gy
   Petak, I
AF Micsik, Tamas
   Mersich, Tamas
   Besznyak, Istvan
   Dede, Kristof
   Zarand, Attila
   Jakab, Ferenc
   Karaszi, Eva
   Lorincz, Andras
   Schwab, Richard
   Keri, Gyorgy
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Micsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Zarand, Attila] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Karaszi, Eva] National Medical CenterBudapest, Hungary.
   [Lorincz, Andras] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Schwab, Richard] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Keri, Gyorgy] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
RP Micsik, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 363
EP 363
PG 1
ER

PT J
AU Mikecz, P
   Niedzielska, D
   Schulze, 
   Buchert, R
   Brenner, W
   Mester, J
   Schumacher, U
AF Mikecz, Pal
   Niedzielska, Dagmara
   Schulze, O. R.
   Buchert, Ralph
   Brenner, Winfried
   Mester, Janos
   Schumacher, Udo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mikecz, Pal] Debreceni Egyetem OEC, NMIDebrecen, Hungary.
   [Niedzielska, Dagmara] Universitatsklinikum Hamburg-Eppendorf, Klinik f-r Nuklear MedizinHamburg-Eppendorf, Germany.
   [Schulze, O. R.] Universitatsklinikum Hamburg-Eppendorf, Klinik f-r Nuklear MedizinHamburg-Eppendorf, Germany.
   [Buchert, Ralph] Universitatsklinikum Hamburg-Eppendorf, Klinik f-r Nuklear MedizinHamburg-Eppendorf, Germany.
   [Brenner, Winfried] Universitatsklinikum Hamburg-Eppendorf, Klinik f-r Nuklear MedizinHamburg-Eppendorf, Germany.
   [Mester, Janos] Universitatsklinikum Hamburg-Eppendorf, Klinik f-r Nuklear MedizinHamburg-Eppendorf, Germany.
   [Schumacher, Udo] Universitatsklinikum Hamburg-Eppendorf, Institut fur Anatomie IIHamburg-Eppendorf, Germany.
RP Mikecz, P (reprint author), Debreceni Egyetem OEC, NMI, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 363
EP 363
PG 1
ER

PT J
AU Miklovicz, T
   P. Szabo, J
   Mikecz, P
   Kovacs, Z
   Galuska, L
   Marian, T
AF Miklovicz, Tunde
   P. Szabo, Judit
   Mikecz, Pal
   Kovacs, Zoltan
   Galuska, Laszlo
   Marian, Terez
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Miklovicz, Tunde] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [P. Szabo, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Mikecz, Pal] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kovacs, Zoltan] ATOMKIDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Marian, Terez] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Miklovicz, T (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 364
EP 364
PG 1
ER

PT J
AU Mile, M
   Huga, S
   Juhasz, A
   Treszl, A
   Hernadi, Z
   Halmos, G
AF Mile, Melinda
   Huga, Sandor
   Juhasz, Aliz
   Treszl, Andrea
   Hernadi, Zoltan
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mile, Melinda] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Huga, Sandor] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Juhasz, Aliz] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Hernadi, Zoltan] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Mile, M (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 364
EP 364
PG 1
ER

PT J
AU Moldvay, J
   Jackel, M
   Kiss, A
   Paska, Cs
   Soltesz, I
   Schaff, Zs
AF Moldvay, Judit
   Jackel, Marta
   Kiss, Andras
   Paska, Csilla
   Soltesz, Ibolya
   Schaff, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Jackel, Marta] AEK, PathologiaBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Paska, Csilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 364
EP 364
PG 1
ER

PT J
AU Molnar, J
   Engi, H
   Thornton, BB
   Luo, L
AF Molnar, Jozsef
   Engi, Helga
   Thornton, Bob Billy
   Luo, Lan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Jozsef] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Engi, Helga] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Thornton, Bob Billy] SZTE, Fizika KarSzeged, Hungary.
   [Luo, Lan] University of SydneySydney, Australia.
RP Molnar, J (reprint author), SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai Intezet, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 367
EP 367
PG 1
ER

PT J
AU Molnar, V
   Hegyesi, H
   Toth, S
   Falus, A
AF Molnar, Viktoria
   Hegyesi, Hargita
   Toth, Sara
   Falus, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Viktoria] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Hegyesi, Hargita] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Toth, Sara] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Molnar, V (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 367
EP 368
PG 2
ER

PT J
AU Molnar, Zs
   Deak, B
   Lengyel, Zs
   Molnar, P
   Rosta, A
   Schneider, T
   Sendlovski-Lakos, 
   Varady, E
   Borbely, K
AF Molnar, Zsuzsa
   Deak, Beata
   Lengyel, Zsolt
   Molnar, Peter
   Rosta, Andras
   Schneider, Tamas
   Sendlovski-Lakos, M.
   Varady, Erika
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Deak, Beata] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Molnar, Peter] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Sendlovski-Lakos, M.] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Molnar, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 368
EP 368
PG 1
ER

PT J
AU Monostori, Zs
AF Monostori, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Monostori, Zsuzsanna] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Monostori, Zs (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 368
EP 368
PG 1
ER

PT J
AU Moravszki, M
   Szakall, Sz
   Lengyel, Zs
   Szilvasi, I
AF Moravszki, Monika
   Szakall, Szabolcs
   Lengyel, Zsolt
   Szilvasi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moravszki, Monika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szilvasi, Istvan] SE, Nuklearis Medicina Tanszeki CsoportBudapest, Hungary.
RP Moravszki, M (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 368
EP 368
PG 1
ER

PT J
AU Muller, I
AF Muller, Illes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Illes] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
RP Muller, I (reprint author), Mediso Medical Imaging Systems Kft., Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 369
EP 369
PG 1
ER

PT J
AU Muller, J
   Kovacs, G
   Adleff, V
   Komlosi, V
   Pap, �
   Erdelyi, DJ
   Hegyi, M
   Kralovanszky, J
AF Muller, Judit
   Kovacs, Gabor
   Adleff, Vilmos
   Komlosi, Viktor
   Pap, Eva
   Erdelyi, Daniel Janos
   Hegyi, Marta
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Judit] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Komlosi, Viktor] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Erdelyi, Daniel Janos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hegyi, Marta] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 369
EP 369
PG 1
ER

PT J
AU Muller, V
   Tamasi, L
   Magyar, P
   Losonczy, Gy
AF Muller, Veronika
   Tamasi, Lilla
   Magyar, Pal
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Muller, V (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 369
EP 369
PG 1
ER

PT J
AU Muller, Z
   Vityi, T
   Kotai, Zs
AF Muller, Zoltan
   Vityi, Tamas
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 370
EP 370
PG 1
ER

PT J
AU Nagy, E
AF Nagy, Endre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Endre] Szegedi Egyetem, Egeszsegtudomanyi es Szocialis Kepzesi KarSzeged, Hungary.
RP Nagy, E (reprint author), Szegedi Egyetem, Egeszsegtudomanyi es Szocialis Kepzesi Kar, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 370
EP 370
PG 1
ER

PT J
AU Nagy, K
   Barti-Juhasz, H
   Arvai, K
   Petak, I
   Kopper, L
AF Nagy, Katalin
   Barti-Juhasz, Helga
   Arvai, Kristof
   Petak, Istvan
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Katalin] Semmelweis Egyetem, Szentagothai Janos TudaskozpontBudapest, Hungary.
   [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Arvai, Kristof] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Nagy, K (reprint author), Semmelweis Egyetem, Szentagothai Janos Tudaskozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 371
EP 371
PG 1
ER

PT J
AU Nagy, T
   Dabasi, G
   Lang, I
AF Nagy, Tunde
   Dabasi, Gabriella
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Dabasi, Gabriella] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Nagy, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 371
EP 371
PG 1
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagykalnai, Tamas] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Nagykalnai, T (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 371
EP 371
PG 1
ER

PT J
AU Nagyne Losonczi, �
AF Nagyne Losonczi, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagyne Losonczi, Eva] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Nagyne Losonczi, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 372
EP 372
PG 1
ER

PT J
AU Nemeth, 
   Muller, I
   Nagy, L
   Hoppin, J
   Lackas, Ch
   Schram, 
AF Nemeth, G.
   Muller, Illes
   Nagy, Laszlo
   Hoppin, W. Jack
   Lackas, Christian
   Schram, N. U.
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, G.] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
   [Muller, Illes] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
   [Nagy, Laszlo] Mediso Medical Imaging Systems Kft.Budapest, Hungary.
   [Hoppin, W. Jack] Bioscan IncWashington, USA.
   [Lackas, Christian] Bioscan IncWashington, USA.
   [Schram, N. U.] Research CenterJulich, Germany.
RP Nemeth,  (reprint author), Mediso Medical Imaging Systems Kft., Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 372
EP 372
PG 1
ER

PT J
AU Nemeth, K
   Tiringer, I
   Karamanne Pakai, A
   Der, A
AF Nemeth, Katalin
   Tiringer, Istvan
   Karamanne Pakai, Annamaria
   Der, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Katalin] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Tiringer, Istvan] Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Magatartastudomanyi IntezetPecs, Hungary.
   [Karamanne Pakai, Annamaria] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Der, Aniko] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
RP Nemeth, K (reprint author), Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi Intezet, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 372
EP 372
PG 1
ER

PT J
AU Nemeth, Zs
   Boer, K
   Farczadi, E
AF Nemeth, Zsuzsanna
   Boer, Katalin
   Farczadi, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] St. Margit HospitalBudapest, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Farczadi, Eniko] St. Margit HospitalBudapest, Hungary.
RP Nemeth, Zs (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 373
EP 373
PG 1
ER

PT J
AU Nyirady, P
   Kelemen, Zs
   Szucs, M
   Romics, I
AF Nyirady, Peter
   Kelemen, Zsolt
   Szucs, Miklos
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Kelemen, Zsolt] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Nyirady, P (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 373
EP 373
PG 1
ER

PT J
AU Ocsai, H
   Varga, E
   Gyulai, R
   Korom, I
   Olah, J
AF Ocsai, Henriette
   Varga, Erika
   Gyulai, Rolland
   Korom, Irma
   Olah, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ocsai, Henriette] Bekes County Pandy Kalman HospitalGyula, Hungary.
   [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Gyulai, Rolland] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Ocsai, H (reprint author), Bekes County Pandy Kalman Hospital, Gyula, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 373
EP 373
PG 1
ER

PT J
AU Olah, J
   Csoma, Zs
   Gyulai, R
   Orvos, H
   Hencz, P
   Dobozy, A
   Kemeny, L
AF Olah, Judit
   Csoma, Zsuzsanna
   Gyulai, Rolland
   Orvos, Hajnalka
   Hencz, Peter
   Dobozy, Attila
   Kemeny, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Csoma, Zsuzsanna] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Gyulai, Rolland] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Orvos, Hajnalka] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
   [Hencz, Peter] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Dobozy, Attila] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kemeny, Lajos] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 374
EP 374
PG 1
ER

PT J
AU Olasz, J
   Juhasz, A
   Remenar, �
   Engi, H
   Bak, M
   Csuka, O
   Kasler, M
AF Olasz, Judit
   Juhasz, Aliz
   Remenar, Eva
   Engi, Helga
   Bak, Mihaly
   Csuka, Orsolya
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Judit] National Institute of OncologyBudapest, Hungary.
   [Juhasz, Aliz] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Engi, Helga] National Institute of OncologyBudapest, Hungary.
   [Bak, Mihaly] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Olasz, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 374
EP 374
PG 1
ER

PT J
AU Olasz, L
   Nyarady, Z
   Kinczel, G
   Orsi, E
   Tornoczky, T
AF Olasz, Lajos
   Nyarady, Zoltan
   Kinczel, Gabor
   Orsi, Eniko
   Tornoczky, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Lajos] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Nyarady, Zoltan] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Kinczel, Gabor] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Orsi, Eniko] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Tornoczky, Tamas] University of Pecs, Department of PathologyPecs, Hungary.
RP Olasz, L (reprint author), University of Pecs, Department of Oral and Maxillofacial Surgery, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 374
EP 374
PG 1
ER

PT J
AU Olasz, L
   Nyarady, Z
   Kinczel, G
   Orsi, E
AF Olasz, Lajos
   Nyarady, Zoltan
   Kinczel, Gabor
   Orsi, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Lajos] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Nyarady, Zoltan] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Kinczel, Gabor] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Orsi, Eniko] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
RP Olasz, L (reprint author), University of Pecs, Department of Oral and Maxillofacial Surgery, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 375
EP 375
PG 1
ER

PT J
AU Orban, E
   Miklan, Zs
   Hudecz, F
AF Orban, Erika
   Miklan, Zsanett
   Hudecz, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Miklan, Zsanett] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Hudecz, Ferenc] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Department of Organic ChemistryBudapest, Hungary.
RP Orban, E (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 375
EP 375
PG 1
ER

PT J
AU Orosz, M
   Kunos, L
   Gyulai, N
AF Orosz, Monika
   Kunos, Laszlo
   Gyulai, Nora
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Monika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kunos, Laszlo] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Gyulai, Nora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Orosz, M (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 375
EP 376
PG 2
ER

PT J
AU Orosz, Zs
   Jani, N
   Kahan, Zs
   Gabor, G
   Hadjiev, J
   Cserni, G
   Kulka, J
   Sulyok, Z
   Lazar, Gy
   Diczhazi, Cs
   Fodor, J
AF Orosz, Zsolt
   Jani, Nora
   Kahan, Zsuzsanna
   Gabor, Gabriella
   Hadjiev, Janaki
   Cserni, Gabor
   Kulka, Janina
   Sulyok, Zoltan
   Lazar, Gyorgy
   Diczhazi, Csaba
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Jani, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Diczhazi, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Orosz, Zs (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 376
EP 376
PG 1
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 376
EP 376
PG 1
ER

PT J
AU Otto, Sz
AF Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 377
EP 377
PG 1
ER

PT J
AU Papai, Zs
   Lahm, E
   Uhlyarik, A
   Sikter, M
   Ray-Coquard, I
   Le Cesne, A
   Schoffski, P
   Marreaud, S
   De Brauwer, A
   Blay, JY
AF Papai, Zsuzsa
   Lahm, Erika
   Uhlyarik, Andrea
   Sikter, Marta
   Ray-Coquard, Isabelle
   Le Cesne, Axel
   Schoffski, Patrick
   Marreaud, Sandrine
   De Brauwer, Annelies
   Blay, Jean-Yves
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Ray-Coquard, Isabelle] Centre Regional Leon BerardLyon, France.
   [Le Cesne, Axel] Institute Gustave RoussyVillejuif, France.
   [Schoffski, Patrick] Catholic University of LeuvenLeuven, Belgium.
   [Marreaud, Sandrine] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [De Brauwer, Annelies] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [Blay, Jean-Yves] Centre Regional Leon BerardLyon, France.
RP Papai, Zs (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 377
EP 377
PG 1
ER

PT J
AU Papp, J
   Kovacs, M�
   Solyom, 
   Koves, I
   Olah, E
AF Papp, Janos
   Kovacs, Marietta Eva
   Solyom, Sz.
   Koves, Istvan
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kovacs, Marietta Eva] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Solyom, Sz.] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Papp, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 377
EP 378
PG 2
ER

PT J
AU Patocs, B
   Garami, M
   Kovalszky, I
   Szendroi, M
   Fekete, Gy
AF Patocs, Barbara
   Garami, Miklos
   Kovalszky, Ilona
   Szendroi, Miklos
   Fekete, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patocs, Barbara] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Patocs, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 378
EP 378
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 378
EP 378
PG 1
ER

PT J
AU Petak, I
   Schwab, R
   Pinter, F
   Nagy, K
   Juhasz, H
   Jori, B
   Mihalik, R
   Keri, Gy
   Kopper, L
AF Petak, Istvan
   Schwab, Richard
   Pinter, Ferenc
   Nagy, Katalin
   Juhasz, Helga
   Jori, Balazs
   Mihalik, Rudolf
   Keri, Gyorgy
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Nagy, Katalin] Semmelweis Egyetem, Szentagothai Janos TudaskozpontBudapest, Hungary.
   [Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jori, Balazs] KPS Kft.Budapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Keri, Gyorgy] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Petak, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 381
EP 381
PG 1
ER

PT J
AU Petak, I
AF Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petak, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Petak, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 381
EP 381
PG 1
ER

PT J
AU Peter, I
   Czeida-Pommersheim, F
   Koves, I
   Orosz, Zs
AF Peter, Ilona
   Czeida-Pommersheim, Ferenc
   Koves, Istvan
   Orosz, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Peter, Ilona] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Czeida-Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Peter, I (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 381
EP 381
PG 1
ER

PT J
AU Petri, K
   Horvath, �
   Schneider, T
   Godeny, M
   Rosta, A
AF Petri, Klara
   Horvath, Akos
   Schneider, Tamas
   Godeny, Maria
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Akos] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 382
EP 382
PG 1
ER

PT J
AU Pinter, F
   Papay, J
   Sapi, Z
   Kanya, M
   Szabo, E
   Jori, B
   Moldvay, J
   Kopper, L
   Petak, I
AF Pinter, Ferenc
   Papay, Judit
   Sapi, Zoltan
   Kanya, Melinda
   Szabo, Edit
   Jori, Balazs
   Moldvay, Judit
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kanya, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szabo, Edit] Semmelweis University, Cooperative Research CenterBudapest, Hungary.
   [Jori, Balazs] KPS Kft.Budapest, Hungary.
   [Moldvay, Judit] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Pinter, F (reprint author), KPS Kft., Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 382
EP 382
PG 1
ER

PT J
AU Pinter, T
AF Pinter, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Pinter, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 382
EP 383
PG 2
ER

PT J
AU Pocza, P
   Kerekes, 
   Veres, D
   Pocza, K
   Darvas, Zs
   Falus, A
AF Pocza, Peter
   Kerekes, M.
   Veres, Daniel
   Pocza, Karoly
   Darvas, Zsuzsanna
   Falus, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Peter] Semmelweis UniversityBudapest, Hungary.
   [Kerekes, M.] Semmelweis UniversityBudapest, Hungary.
   [Veres, Daniel] Semmelweis UniversityBudapest, Hungary.
   [Pocza, Karoly] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Darvas, Zsuzsanna] Semmelweis UniversityBudapest, Hungary.
   [Falus, Andras] Semmelweis UniversityBudapest, Hungary.
RP Pocza, P (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 383
EP 383
PG 1
ER

PT J
AU Pocza, P
   Wiener, Z
   Pos, Z
   Pocza, K
   Dede, K
   Mersich, T
   Baranyai, Zs
   Jakab, F
   Darvas, Zs
   Falus, A
AF Pocza, Peter
   Wiener, Zoltan
   Pos, Zoltan
   Pocza, Karoly
   Dede, Kristof
   Mersich, Tamas
   Baranyai, Zsolt
   Jakab, Ferenc
   Darvas, Zsuzsanna
   Falus, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Peter] Semmelweis UniversityBudapest, Hungary.
   [Wiener, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Pos, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Pocza, Karoly] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Baranyai, Zsolt] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Darvas, Zsuzsanna] Semmelweis UniversityBudapest, Hungary.
   [Falus, Andras] Semmelweis UniversityBudapest, Hungary.
RP Pocza, P (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 383
EP 383
PG 1
ER

PT J
AU Podmaniczky, E
   Varga, J
   Barta, P
   Losonczy, Gy
   Magyar, P
   Gyorffy, B
AF Podmaniczky, Eszter
   Varga, Janos
   Barta, Peter
   Losonczy, Gyorgy
   Magyar, Pal
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Podmaniczky, Eszter] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Varga, Janos] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Barta, Peter] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Gyorffy, Balazs] Hungarian Academy of Sciences - Semmelweis University, 1st Dept. of Pediatrics, Research Laboratory for Pediatrics and NephrologyBudapest, Hungary.
RP Podmaniczky, E (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 384
EP 384
PG 1
ER

PT J
AU Polgar, Cs
   Orosz, Zs
   Kahan, Zs
   Jani, N
   Gabor, G
   Hadjiev, J
   Cserni, G
   Kulka, J
   Sulyok, Z
   Lazar, Gy
   Diczhazi, Cs
AF Polgar, Csaba
   Orosz, Zsolt
   Kahan, Zsuzsanna
   Jani, Nora
   Gabor, Gabriella
   Hadjiev, Janaki
   Cserni, Gabor
   Kulka, Janina
   Sulyok, Zoltan
   Lazar, Gyorgy
   Diczhazi, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Jani, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Kulka, Janina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Diczhazi, Csaba] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 384
EP 384
PG 1
ER

PT J
AU Rahoty, P
   Gondos, M
   Bursics, A
   Hentes, T
   Szabo, T
   Villango, B
   Szendroi, M
   Karner, T
   Gombas, P
   Forrai, G
   Papay, Zs
AF Rahoty, Pal
   Gondos, Miklos
   Bursics, Attila
   Hentes, Tibor
   Szabo, Tamas
   Villango, Balazs
   Szendroi, Miklos
   Karner, Tamas
   Gombas, Peter
   Forrai, Gabor
   Papay, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rahoty, Pal] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Gondos, Miklos] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Hentes, Tibor] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Szabo, Tamas] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Villango, Balazs] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Karner, Tamas] Governmental Health Center, Department Anaesthesiology and Intensive CareBudapest, Hungary.
   [Gombas, Peter] AEK, PathologiaBudapest, Hungary.
   [Forrai, Gabor] AEK, RadiodiagnosztikaBudapest, Hungary.
   [Papay, Zsuzsa] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Rahoty, P (reprint author), AEK, II. Sebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 385
EP 385
PG 1
ER

PT J
AU Raso, E
   Barbai, T
   Magyar, M
   Badar, �
   Dome, B
   Strausz, J
   Dobos, J
   Timar, J
AF Raso, Erzsebet
   Barbai, Tamas
   Magyar, Melinda
   Badar, Eva
   Dome, Balazs
   Strausz, Janos
   Dobos, Judit
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Barbai, Tamas] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Magyar, Melinda] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Badar, Eva] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Strausz, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dobos, Judit] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
RP Raso, E (reprint author), National Institute of Oncology, Department of Tumor Progression, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 385
EP 385
PG 1
ER

PT J
AU Rathonyi, E
   Geczi, L
   Bodrogi, I
   Biro, K
AF Rathonyi, Emese
   Geczi, Lajos
   Bodrogi, Istvan
   Biro, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rathonyi, Emese] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Rathonyi, E (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 385
EP 385
PG 1
ER

PT J
AU Rathonyi, E
   Bodrogi, I
   Geczi, L
   Gyergyay, F
   Borbely, K
AF Rathonyi, Emese
   Bodrogi, Istvan
   Geczi, Lajos
   Gyergyay, Fruzsina
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rathonyi, Emese] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Rathonyi, E (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 386
EP 386
PG 1
ER

PT J
AU Renyi-Vamos, F
   Farkas, E
   Savolt, �
   Gobor, L
   Szollar, A
   Matrai, Z
   Koves, I
   Tovari, J
   Timar, J
   Fillinger, J
   Paku, S
   Dome, B
AF Renyi-Vamos, Ferenc
   Farkas, Emil
   Savolt, Akos
   Gobor, Laszlo
   Szollar, Andras
   Matrai, Zoltan
   Koves, Istvan
   Tovari, Jozsef
   Timar, Jozsef
   Fillinger, Janos
   Paku, Sandor
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Gobor, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Szollar, Andras] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Renyi-Vamos, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 386
EP 386
PG 1
ER

PT J
AU Reti, A
   Budai, B
   Barna, G
   Zalatnay, A
   Komlosi, V
   Adleff, V
   Jeney, A
   Kralovanszky, J
AF Reti, Andrea
   Budai, Barna
   Barna, Gabor
   Zalatnay, Attila
   Komlosi, Viktor
   Adleff, Vilmos
   Jeney, Andras
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Reti, Andrea] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Zalatnay, Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Komlosi, Viktor] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Reti, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 387
EP 387
PG 1
ER

PT J
AU Riesz, P
   Kiss, A
   Paska, Cs
   Torzsok, P
   Lotz, G
   Majoros, A
   Schaff, Zs
   Romics, I
AF Riesz, Peter
   Kiss, Andras
   Paska, Csilla
   Torzsok, Peter
   Lotz, Gabor
   Majoros, Attila
   Schaff, Zsuzsa
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Paska, Csilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Torzsok, Peter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Riesz, P (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 387
EP 387
PG 1
ER

PT J
AU Risko, �
   Molnar, Zs
   Rosta, A
   Schneider, T
   Varady, E
   Deak, B
AF Risko, Agnes
   Molnar, Zsuzsa
   Rosta, Andras
   Schneider, Tamas
   Varady, Erika
   Deak, Beata
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Risko, Agnes] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
RP Risko, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 387
EP 388
PG 2
ER

PT J
AU Romics, I
   Majoros, A
   Panovics, J
   Riesz, P
   Keszthelyi, A
AF Romics, Imre
   Majoros, Attila
   Panovics, Jozsef
   Riesz, Peter
   Keszthelyi, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Panovics, Jozsef] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Keszthelyi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Romics, I (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 388
EP 388
PG 1
ER

PT J
AU Rosta, A
AF Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Rosta, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 388
EP 388
PG 1
ER

PT J
AU Rozsa, B
   Toth, Gy
   Toth, Cs
   Flasko, T
   Dezso, B
   Halmos, G
AF Rozsa, Bernadett
   Toth, Gyorgy
   Toth, Csaba
   Flasko, Tibor
   Dezso, Balazs
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rozsa, Bernadett] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Toth, Gyorgy] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Toth, Csaba] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Rozsa, B (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 389
EP 389
PG 1
ER

PT J
AU Rubovszky, G
   Horvath, Zs
   Hitre, E
   Ganofszky, E
   Nagy, T
   Szabo, E
   Lang, I
AF Rubovszky, Gabor
   Horvath, Zsolt
   Hitre, Erika
   Ganofszky, Erna
   Nagy, Tunde
   Szabo, Eszter
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 389
EP 389
PG 1
ER

PT J
AU Rudnai, P
   Sarkany, E
   Csanady, M
   Varro, MJ
   Borsanyi, M
   Mucsi, Gy
   Varosi, Zs
   Kovacs, F
   Debreczeni, S
   Gurzau, E
   Leonardi, G
AF Rudnai, Peter
   Sarkany, Endre
   Csanady, Miklos
   Varro, Mihaly Janos
   Borsanyi, Matyas
   Mucsi, Gyula
   Varosi, Zsuzsanna
   Kovacs, Ferenc
   Debreczeni, Sara
   Gurzau, Eugen
   Leonardi, Giovanni
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rudnai, Peter] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Sarkany, Endre] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Csanady, Miklos] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Varro, Mihaly Janos] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Borsanyi, Matyas] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Mucsi, Gyula] ANTSZ, Delalfoldi Regionalis IntezeteBekescsaba, Hungary.
   [Varosi, Zsuzsanna] ANTSZ, Kalocsai, Kiskorosi Kistersegi IntezeteKalocsa, Hungary.
   [Kovacs, Ferenc] ANTSZ, Szeged, Morahalomi Kistersegi IntezeteSzeged, Hungary.
   [Debreczeni, Sara] ANTSZ, Eszak-alfoldi Regionalis IntezeteSzolnok, Hungary.
   [Gurzau, Eugen] Kornyezetegeszsegugyi KozpontCluj-Napoca, Romania.
   [Leonardi, Giovanni] London School of Hygiene and Tropical MedicineLondon, UK.
RP Rudnai, P (reprint author), Orszagos Kornyezetegeszsegugyi Intezet, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 390
EP 390
PG 1
ER

PT J
AU Ruzsa, �
   Fekete, I
   Locsei, Z
AF Ruzsa, Agnes
   Fekete, Ilona
   Locsei, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Fekete, Ilona] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Locsei, Zoltan] University of Pecs, Faculty of MedicinePecs, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 390
EP 390
PG 1
ER

PT J
AU Ruzsa, �
   Kolonics, Zs
   Locsei, Z
AF Ruzsa, Agnes
   Kolonics, Zsuzsanna
   Locsei, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kolonics, Zsuzsanna] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Locsei, Zoltan] University of Pecs, Faculty of MedicinePecs, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 391
EP 391
PG 1
ER

PT J
AU Safrany, G
   Kis, E
   Benedek, A
   Szatmari, T
   Keszei, M
   Falus, A
   Esik, O
   Lumniczky, K
AF Safrany, Geza
   Kis, Eniko
   Benedek, Anett
   Szatmari, Tunde
   Keszei, Marton
   Falus, Andras
   Esik, Olga
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Safrany, Geza] OSSKIBudapest, Hungary.
   [Kis, Eniko] OSSKIBudapest, Hungary.
   [Benedek, Anett] OSSKIBudapest, Hungary.
   [Szatmari, Tunde] OSSKIBudapest, Hungary.
   [Keszei, Marton] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Lumniczky, Katalin] OSSKIBudapest, Hungary.
RP Safrany, G (reprint author), OSSKI, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 391
EP 391
PG 1
ER

PT J
AU Sapi, Z
   Szendroi, M
   Moskovszky, L
AF Sapi, Zoltan
   Szendroi, Miklos
   Moskovszky, Linda
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Moskovszky, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sapi, Z (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 391
EP 392
PG 2
ER

PT J
AU Savolt, �
   Renyi-Vamos, F
   Matrai, Z
   Polgar, Cs
   Horvath, Zs
   Orosz, Zs
   Koves, I
AF Savolt, Akos
   Renyi-Vamos, Ferenc
   Matrai, Zoltan
   Polgar, Csaba
   Horvath, Zsolt
   Orosz, Zsolt
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Koves, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Savolt, � (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 392
EP 392
PG 1
ER

PT J
AU Schneider, F
   Balint, K
   Hanzely, Z
   Orosz, Zs
   Mangel, L
   Major, O
   Vajda, J
   Perenyi, J
AF Schneider, Ferenc
   Balint, Katalin
   Hanzely, Zoltan
   Orosz, Zsolt
   Mangel, Laszlo
   Major, Otto
   Vajda, Janos
   Perenyi, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Balint, Katalin] National Institute of NeurosurgeryBudapest, Hungary.
   [Hanzely, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Mangel, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Major, Otto] National Institute of NeurosurgeryBudapest, Hungary.
   [Vajda, Janos] National Institute of NeurosurgeryBudapest, Hungary.
   [Perenyi, Jozsef] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
RP Schneider, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 392
EP 392
PG 1
ER

PT J
AU Schneider, T
   Molnar, Zs
   Deak, B
   Varady, E
   Lakos, 
   Szaleczky, E
   Rosta, A
AF Schneider, Tamas
   Molnar, Zsuzsa
   Deak, Beata
   Varady, Erika
   Lakos, M.
   Szaleczky, Erika
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Lakos, M.] National Institute of OncologyBudapest, Hungary.
   [Szaleczky, Erika] National Institute of OncologyBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Schneider, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 393
EP 393
PG 1
ER

PT J
AU Seber, J
AF Seber, Jozsefne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Seber, Jozsefne] National Institute of OncologyBudapest, Hungary.
RP Seber, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 393
EP 393
PG 1
ER

PT J
AU Sebestyen, A
   Hajdu, M
   Berczi, L
   Krenacs, T
   Timar, B
   Kopper, L
AF Sebestyen, Anna
   Hajdu, Melinda
   Berczi, Lajos
   Krenacs, Tibor
   Timar, Botond
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Berczi, Lajos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 393
EP 394
PG 2
ER

PT J
AU Semjeni, M
   Treszl, A
   Huga, S
   Juhasz, A
   Hernadi, Z
   Halmos, G
AF Semjeni, Mariann
   Treszl, Andrea
   Huga, Sandor
   Juhasz, Aliz
   Hernadi, Zoltan
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Semjeni, Mariann] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Huga, Sandor] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Juhasz, Aliz] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Hernadi, Zoltan] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Semjeni, M (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 394
EP 394
PG 1
ER

PT J
AU Shipitsin, M
   Campbell, 
   Bloushtain-Qimron, N
   Yao, 
   Hu, 
   Argani, P
   Weremowicz, S
   Sukumar, S
   Richardson, A
   Nikolsky, Y
   Polyak, K
AF Shipitsin, Michail
   Campbell, L. I.
   Bloushtain-Qimron, Noga
   Yao, J.
   Hu, M.
   Argani, Pedram
   Weremowicz, Stanislawa
   Sukumar, Sudarkodi
   Richardson, I. Andrea
   Nikolsky, Yuri
   Polyak, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Shipitsin, Michail] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
   [Campbell, L. I.] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
   [Bloushtain-Qimron, Noga] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
   [Yao, J.] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
   [Hu, M.] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
   [Argani, Pedram] Harvard Medical School, Program in Biological and Biomedical SciencesBoston, USA.
   [Weremowicz, Stanislawa] Johns Hopkins University, School of MedicineBaltimore, USA.
   [Sukumar, Sudarkodi] Harvard Medical School, Program in Biological and Biomedical SciencesBoston, USA.
   [Richardson, I. Andrea] GeneGo, Inc.St. Joseph, USA.
   [Nikolsky, Yuri] Brigham and Women’s Hospital, Department of PathologyBoston, USA.
   [Polyak, Kornelia] Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical OncologyBoston, USA.
RP Shipitsin, M (reprint author), Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 395
EP 395
PG 1
ER

PT J
AU Sikter, M
   Lahm, E
   Uhlyarik, A
   Papai, Zs
AF Sikter, Marta
   Lahm, Erika
   Uhlyarik, Andrea
   Papai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Sikter, M (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 395
EP 395
PG 1
ER

PT J
AU Simon, P
   Jederan, �
   Bahery, M
   Godeny, M
AF Simon, Peter
   Jederan, Eva
   Bahery, Maria
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simon, Peter] National Institute of OncologyBudapest, Hungary.
   [Jederan, Eva] National Institute of OncologyBudapest, Hungary.
   [Bahery, Maria] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Simon, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 396
EP 396
PG 1
ER

PT J
AU Sinko, D
   Nemeskeri, Cs
   Mayer, �
AF Sinko, Daniel
   Nemeskeri, Csaba
   Mayer, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Sinko, D (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 396
EP 396
PG 1
ER

PT J
AU Sulyok, Z
   Vamosi Nagy, I
   Czeyda-Pommersheim, F
   Matrai, Z
   Savolt, �
   Koves, I
AF Sulyok, Zoltan
   Vamosi Nagy, Istvan
   Czeyda-Pommersheim, Ferenc
   Matrai, Zoltan
   Savolt, Akos
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Vamosi Nagy, Istvan] National Institute of OncologyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
RP Sulyok, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 396
EP 396
PG 1
ER

PT J
AU Szabo, E
   Risko, �
AF Szabo, Eszter
   Risko, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Risko, Agnes] National Institute of OncologyBudapest, Hungary.
RP Szabo, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 396
EP 397
PG 2
ER

PT J
AU Szabo, �
   Olah, E
   Bidlek, M
   Toth, E
   Godeny, M
AF Szabo, Eva
   Olah, Edit
   Bidlek, Maria
   Toth, Erika
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Olah, Edit] National Institute of OncologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Toth, Erika] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Szabo, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 397
EP 397
PG 1
ER

PT J
AU Szabo, E
   Korpos, �
   Batmunkh, E
   Lotz, G
   Holczbauer, �
   Kovalszky, I
   Deak, F
   Kiss, I
   Schaff, Zs
   Kiss, A
AF Szabo, Erzsebet
   Korpos, Eva
   Batmunkh, Enkhjargal
   Lotz, Gabor
   Holczbauer, Agnes
   Kovalszky, Ilona
   Deak, Ferenc
   Kiss, Ibolya
   Schaff, Zsuzsa
   Kiss, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Korpos, Eva] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Batmunkh, Enkhjargal] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Holczbauer, Agnes] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Deak, Ferenc] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Kiss, Ibolya] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szabo, E (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 397
EP 398
PG 2
ER

PT J
AU Szakaly, 
AF Szakaly, G.
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakaly, G.] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
RP Szakaly,  (reprint author), Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 398
EP 398
PG 1
ER

PT J
AU Szakall, Sz
   Molnar, P
   Toth, Gy
   Lengyel, Zs
AF Szakall, Szabolcs
   Molnar, Peter
   Toth, Gyula
   Lengyel, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Molnar, Peter] Pozitron Diagnosztika KftBudapest, Hungary.
   [Toth, Gyula] Pozitron Diagnosztika KftBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
RP Szakall, Sz (reprint author), Pozitron Diagnosztika Kft, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 398
EP 398
PG 1
ER

PT J
AU Szalai, T
AF Szalai, Tamasne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Tamasne] National Institute of OncologyBudapest, Hungary.
RP Szalai, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 398
EP 398
PG 1
ER

PT J
AU Szatmari, T
   Lumniczky, K
   Safrany, G
AF Szatmari, Tunde
   Lumniczky, Katalin
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szatmari, Tunde] OSSKIBudapest, Hungary.
   [Lumniczky, Katalin] OSSKIBudapest, Hungary.
   [Safrany, Geza] OSSKIBudapest, Hungary.
RP Szatmari, T (reprint author), OSSKI, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 398
EP 399
PG 2
ER

PT J
AU Szekely, B
   Dank, M
AF Szekely, Borbala
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Borbala] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Szekely, B (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 399
EP 399
PG 1
ER

PT J
AU Szekely, G
   Farkas, Gy
   Pulay, A
   Remenar, �
   Gundy, S
AF Szekely, Gabor
   Farkas, Gyongyi
   Pulay, Attila
   Remenar, Eva
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gabor] National Institute of OncologyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of OncologyBudapest, Hungary.
   [Pulay, Attila] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Gundy, Sarolta] National Institute of OncologyBudapest, Hungary.
RP Szekely, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 399
EP 400
PG 2
ER

PT J
AU Szendroi, A
   Majoros, A
   Szekely, E
   Kiss, A
   Szucs, M
AF Szendroi, Attila
   Majoros, Attila
   Szekely, Eszter
   Kiss, Andras
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Szendroi, A (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 400
EP 400
PG 1
ER

PT J
AU Szendroi, A
   Tabak, �
AF Szendroi, Attila
   Tabak, Adam
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Tabak, Adam] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Szendroi, A (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 400
EP 400
PG 1
ER

PT J
AU Szendroi, M
   Entz, L
   Gulyas, G
   Revesz, Zs
   Antal, I
   Kiss, J
   Rahoty, P
AF Szendroi, Miklos
   Entz, Laszlo
   Gulyas, Gusztav
   Revesz, Zsolt
   Antal, Imre
   Kiss, Judit
   Rahoty, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Entz, Laszlo] Semmelweis University, Department of Cardiovascular SurgeryBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of OncologyBudapest, Hungary.
   [Revesz, Zsolt] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Judit] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Rahoty, Pal] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Szendroi, M (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 400
EP 400
PG 1
ER

PT J
AU Szenes, M
   Bali, O
   Ruzsa, �
   Nagy, Gy
   Vattay, P
   Volgyi, Z
   Gasztonyi, B
AF Szenes, Maria
   Bali, Ottilia
   Ruzsa, Agnes
   Nagy, Gyongyi
   Vattay, Peter
   Volgyi, Zoltan
   Gasztonyi, Beata
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szenes, Maria] County Hospital of ZalaZalaegerszeg, Hungary.
   [Bali, Ottilia] County Hospital of ZalaZalaegerszeg, Hungary.
   [Ruzsa, Agnes] County Hospital of ZalaZalaegerszeg, Hungary.
   [Nagy, Gyongyi] County Hospital of ZalaZalaegerszeg, Hungary.
   [Vattay, Peter] County Hospital of ZalaZalaegerszeg, Hungary.
   [Volgyi, Zoltan] County Hospital of ZalaZalaegerszeg, Hungary.
   [Gasztonyi, Beata] County Hospital of ZalaZalaegerszeg, Hungary.
RP Szenes, M (reprint author), County Hospital of Zala, Zalaegerszeg, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 401
EP 401
PG 1
ER

PT J
AU Szentmartoni, Gy
   Torgyik, L
   Zergenyi, �
   Borbenyi, E
   Dank, M
AF Szentmartoni, Gyongyver
   Torgyik, Laszlo
   Zergenyi, Eva
   Borbenyi, Erika
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentmartoni, Gyongyver] Semmelweis UniversityBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis UniversityBudapest, Hungary.
   [Zergenyi, Eva] Semmelweis UniversityBudapest, Hungary.
   [Borbenyi, Erika] Semmelweis UniversityBudapest, Hungary.
   [Dank, Magdolna] Semmelweis UniversityBudapest, Hungary.
RP Szentmartoni, Gy (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 401
EP 401
PG 1
ER

PT J
AU Szentpetery, F
   Atkari, B
   Jakab, F
AF Szentpetery, Felix
   Atkari, Bence
   Jakab, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentpetery, Felix] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Atkari, Bence] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
RP Szentpetery, F (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 401
EP 401
PG 1
ER

PT J
AU Szigeti, A
AF Szigeti, Annamaria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Annamaria] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Szigeti, A (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 402
EP 402
PG 1
ER

PT J
AU Szilagyi, �
   Nemeth, I
   Tiszlavicz, L
AF Szilagyi, Eva
   Nemeth, Istvan
   Tiszlavicz, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nemeth, Istvan] University of Szeged, Department of PathologySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
RP Szilagyi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 402
EP 402
PG 1
ER

PT J
AU Szluha, K
   Lazanyi, K
   Molnar, P
AF Szluha, Kornelia
   Lazanyi, Kornelia
   Molnar, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Lazanyi, Kornelia] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
   [Molnar, Peter] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 402
EP 402
PG 1
ER

PT J
AU Szluha, K
   Pintye, �
   Kovacs, �
   Simon, M
   Opauszki, A
   Emri, M
   Opposits, G
   Balkay, L
   Garai, I
   Horvath, �
   Galuska, L
AF Szluha, Kornelia
   Pintye, Eva
   Kovacs, Arpad
   Simon, Mihaly
   Opauszki, Adrienn
   Emri, Miklos
   Opposits, Gabor
   Balkay, Laszlo
   Garai, Ildiko
   Horvath, Akos
   Galuska, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kovacs, Arpad] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Simon, Mihaly] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Opauszki, Adrienn] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Opposits, Gabor] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Garai, Ildiko] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 402
EP 402
PG 1
ER

PT J
AU Szollar, A
   Matrai, Z
   Lovey, J
   Hitre, E
   Orosz, Zs
   Godeny, M
   Sulyok, Z
   Renyi-Vamos, F
   Farkas, E
   Koves, I
AF Szollar, Andras
   Matrai, Zoltan
   Lovey, Jozsef
   Hitre, Erika
   Orosz, Zsolt
   Godeny, Maria
   Sulyok, Zoltan
   Renyi-Vamos, Ferenc
   Farkas, Emil
   Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szollar, Andras] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
RP Szollar, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 403
EP 403
PG 1
ER

PT J
AU Szondi, 
   Boer, K
AF Szondi, Zs.
   Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szondi, Zs.] St. Margit HospitalBudapest, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
RP Szondi,  (reprint author), St. Margit Hospital, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 403
EP 403
PG 1
ER

PT J
AU Szoke, J
   Csernak, E
   Szakacs, O
   Szentirmay, Z
AF Szoke, Janos
   Csernak, Erzsebet
   Szakacs, Orsolya
   Szentirmay, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szoke, Janos] National Institute of OncologyBudapest, Hungary.
   [Csernak, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Szakacs, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Szoke, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 403
EP 403
PG 1
ER

PT J
AU Sztano, B
   Czigner, J
AF Sztano, Balazs
   Czigner, Jeno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sztano, Balazs] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Sztano, B (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 404
EP 404
PG 1
ER

PT J
AU Szucs, M
   Gaal, D
   Bak, M
   Doleschall, Z
   Molnar, J
   Pusztai, R
   Bak, M
   Kasler, M
AF Szucs, Miklos
   Gaal, Dezso
   Bak, Mihaly
   Doleschall, Zoltan
   Molnar, Jozsef
   Pusztai, Rozalia
   Bak, Mihaly
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szucs, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gaal, Dezso] National Institute of OncologyBudapest, Hungary.
   [Bak, Mihaly] Peterfy HospitalBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Molnar, Jozsef] University of SzegedSzeged, Hungary.
   [Pusztai, Rozalia] University of SzegedSzeged, Hungary.
   [Bak, Mihaly] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Szucs, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 404
EP 404
PG 1
ER

PT J
AU Szucs, M
   Mavrogenis, S
   Szekely, E
   Szendroi, A
   Romics, I
AF Szucs, Miklos
   Mavrogenis, Stelios
   Szekely, Eszter
   Szendroi, Attila
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szucs, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis UniversityBudapest, Hungary.
   [Szekely, Eszter] Semmelweis UniversityBudapest, Hungary.
   [Szendroi, Attila] Semmelweis UniversityBudapest, Hungary.
   [Romics, Imre] Semmelweis UniversityBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 405
EP 405
PG 1
ER

PT J
AU Szucs, M
   Mavrogenis, S
   Romics, I
AF Szucs, Miklos
   Mavrogenis, Stelios
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szucs, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis UniversityBudapest, Hungary.
   [Romics, Imre] Semmelweis UniversityBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 405
EP 405
PG 1
ER

PT J
AU Szucs, M
   Mavrogenis, S
   Romics, I
AF Szucs, Miklos
   Mavrogenis, Stelios
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szucs, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis UniversityBudapest, Hungary.
   [Romics, Imre] Semmelweis UniversityBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 405
EP 405
PG 1
ER

PT J
AU Takacs, I
   Somogyi, 
   Radvanyi, G
AF Takacs, Istvan
   Somogyi, M.
   Radvanyi, Gaspar
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacs, Istvan] Semmelweis HospitalMiskolc, Hungary.
   [Somogyi, M.] Semmelweis HospitalMiskolc, Hungary.
   [Radvanyi, Gaspar] Semmelweis HospitalMiskolc, Hungary.
RP Takacs, I (reprint author), Semmelweis Hospital, Miskolc, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 405
EP 405
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Oberna, F
   Fulop, M
   Polgar, Cs
   Somogyi, A
   Major, T
   Nemeth, Gy
   Fodor, J
AF Takacsi-Nagy, Zoltan
   Oberna, Ferenc
   Fulop, Miklos
   Polgar, Csaba
   Somogyi, Andras
   Major, Tibor
   Nemeth, Gyorgy
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Somogyi, Andras] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 406
EP 406
PG 1
ER

PT J
AU Tamas, K
   Vincze, B
   Kapuvari, B
   Czeyda-Pommersheim, F
   Udvarhelyi, N
   Horvath, Zs
   Lang, I
AF Tamas, Karin
   Vincze, Borbala
   Kapuvari, Bence
   Czeyda-Pommersheim, Ferenc
   Udvarhelyi, Nora
   Horvath, Zsolt
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamas, Karin] National Institute of OncologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Tamas, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 406
EP 406
PG 1
ER

PT J
AU Tamasi, L
   Muller, V
   Magyar, P
   Losonczy, Gy
AF Tamasi, Lilla
   Muller, Veronika
   Magyar, Pal
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 406
EP 407
PG 2
ER

PT J
AU Tamasi, L
   Muller, V
AF Tamasi, Lilla
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 407
EP 407
PG 1
ER

PT J
AU Tatrai, P
   Somoracz, �
   Kovalszky, I
   Nagy, P
AF Tatrai, Peter
   Somoracz, Aron
   Kovalszky, Ilona
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tatrai, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Somoracz, Aron] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Tatrai, P (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 407
EP 407
PG 1
ER

PT J
AU Tejeda, M
   Gaal, D
   Hullan, L
   Telekes, A
AF Tejeda, Miguel
   Gaal, Dezso
   Hullan, Lehel
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tejeda, Miguel] National Institute of OncologyBudapest, Hungary.
   [Gaal, Dezso] National Institute of OncologyBudapest, Hungary.
   [Hullan, Lehel] National Institute of OncologyBudapest, Hungary.
   [Telekes, Andras] National Institute of OncologyBudapest, Hungary.
RP Tejeda, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 408
EP 408
PG 1
ER

PT J
AU Telekes, A
   Puskas, GL
   Raso, E
AF Telekes, Andras
   Puskas, G Laszlo
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Telekes, Andras] National Institute of OncologyBudapest, Hungary.
   [Puskas, G Laszlo] AVIDIN Kutato Fejleszto es Kereskedelmi Kft.Szeged, Hungary.
   [Raso, Erzsebet] National Institute of OncologyBudapest, Hungary.
RP Telekes, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 408
EP 409
PG 2
ER

PT J
AU Tim, A
   Kissne Kovasznai, Cs
AF Tim, Aniko
   Kissne Kovasznai, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tim, Aniko] BM Kozponti KorhazBudapest, Hungary.
   [Kissne Kovasznai, Csilla] BM Kozponti KorhazBudapest, Hungary.
RP Tim, A (reprint author), BM Kozponti Korhaz, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 409
EP 409
PG 1
ER

PT J
AU Tolnay, E
   Ferenczi, E
   Varga, I
   Kiss, Cs
   Mark, Zs
   Dulka, E
   Papay, J
   Lantos, �
AF Tolnay, Edina
   Ferenczi, Eniko
   Varga, Ilona
   Kiss, Csongor
   Mark, Zsuzsa
   Dulka, Edit
   Papay, Judit
   Lantos, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
   [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Varga, Ilona] County Hospital of PulmonologyTorokbalint, Hungary.
   [Kiss, Csongor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Mark, Zsuzsa] County Hospital of PulmonologyTorokbalint, Hungary.
   [Dulka, Edit] County Hospital of PulmonologyTorokbalint, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Tolnay, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 409
EP 409
PG 1
ER

PT J
AU Tolnay, E
   Ferenczi, E
   Varga, I
   Palinkasi, Sz
   Borbely, T
   Lantos, �
AF Tolnay, Edina
   Ferenczi, Eniko
   Varga, Ilona
   Palinkasi, Szvetlana
   Borbely, Tibor
   Lantos, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
   [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Varga, Ilona] County Hospital of PulmonologyTorokbalint, Hungary.
   [Palinkasi, Szvetlana] County Hospital of PulmonologyTorokbalint, Hungary.
   [Borbely, Tibor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
RP Tolnay, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 409
EP 409
PG 1
ER

PT J
AU Torday, L
   Uhercsak, G
   Vereb, B
   Maraz, A
   Gaal, Sz
   Nikolenyi, A
   Szabo, J
   Kahan, Zs
   Thurzo, L
AF Torday, Laszlo
   Uhercsak, Gabriella
   Vereb, Blanka
   Maraz, Aniko
   Gaal, Szilvia
   Nikolenyi, Aliz
   Szabo, Judit
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vereb, Blanka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 410
EP 410
PG 1
ER

PT J
AU Torday, L
   Fodor, E
   Kahan, Zs
   Thurzo, L
AF Torday, Laszlo
   Fodor, Emese
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 410
EP 410
PG 1
ER

PT J
AU Toth, EJ
   Kovacs, E
   Liptak, Zs
   Godeny, M
AF Toth, Eszter Judit
   Kovacs, Eszter
   Liptak, Zsuzsanna
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Eszter Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Liptak, Zsuzsanna] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Toth, EJ (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 410
EP 410
PG 1
ER

PT J
AU Toth, T
   Gargyan, K
AF Toth, Tomas
   Gargyan, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Tomas] National Health Institute, Department of OncologyBudapest, Hungary.
   [Gargyan, Katalin] National Health Institute, Department of OncologyBudapest, Hungary.
RP Toth, T (reprint author), National Health Institute, Department of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 411
EP 411
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 411
EP 411
PG 1
ER

PT J
AU Tovari, J
   Timar, J
   Dobos, J
   Raso, E
   Dome, B
AF Tovari, Jozsef
   Timar, Jozsef
   Dobos, Judit
   Raso, Erzsebet
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tovari, Jozsef] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Timar, Jozsef] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Dobos, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Raso, Erzsebet] National Institute of Oncology, Department of Tumor ProgressionBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
RP Tovari, J (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 412
EP 412
PG 1
ER

PT J
AU Udvarhelyi, N
   Cserni, G
   Kalman, E
   Kulka, J
   Orosz, Zs
   Krenacs, T
AF Udvarhelyi, Nora
   Cserni, Gabor
   Kalman, Endre
   Kulka, Janina
   Orosz, Zsolt
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Udvarhelyi, N (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 412
EP 412
PG 1
ER

PT J
AU Udvary, J
   Pulay, T
AF Udvary, Janos
   Pulay, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Udvary, Janos] National Institute of OncologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of OncologyBudapest, Hungary.
RP Udvary, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 413
EP 413
PG 1
ER

PT J
AU Uhlyarik, A
   Lahm, E
   Sikter, M
   Papai, Zs
AF Uhlyarik, Andrea
   Lahm, Erika
   Sikter, Marta
   Papai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsa] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Uhlyarik, A (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 413
EP 413
PG 1
ER

PT J
AU Valicsek, E
   Voros, A
   Kahan, Zs
   Thurzo, L
AF Valicsek, Erzsebet
   Voros, Andras
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Valicsek, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 413
EP 413
PG 1
ER

PT J
AU Varga, Gy
   Bursics, A
   Ivanyi, A
   Fekete, A
   Csonka, S
   Harmos, F
   Gyokeres, T
   Pap, �
   Rahoty, P
AF Varga, Gyula
   Bursics, Attila
   Ivanyi, Andras
   Fekete, Aniko
   Csonka, Sandor
   Harmos, Florian
   Gyokeres, Tibor
   Pap, Akos
   Rahoty, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Gyula] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Ivanyi, Andras] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Fekete, Aniko] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Csonka, Sandor] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Harmos, Florian] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Gyokeres, Tibor] AEK, Gastroenterologiai OsztalyBudapest, Hungary.
   [Pap, Akos] AEK, Gastroenterologiai OsztalyBudapest, Hungary.
   [Rahoty, Pal] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
RP Varga, Gy (reprint author), AEK, II. Sebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 414
EP 414
PG 1
ER

PT J
AU Varga, M
   Lovey, J
   Major, T
   Nagy, T
   Orosz, Zs
   Sulyok, Z
   Fodor, J
AF Varga, Maria
   Lovey, Jozsef
   Major, Tibor
   Nagy, Tunde
   Orosz, Zsolt
   Sulyok, Zoltan
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Maria] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
RP Varga, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 414
EP 414
PG 1
ER

PT J
AU Vaszilko, M
   Cseplo, K
   Barabas, J
   Bogdan, S
   Szabo, Gy
   Ujpal, M
AF Vaszilko, Mihaly
   Cseplo, Krisztina
   Barabas, Jozsef
   Bogdan, Sandor
   Szabo, Gyorgy
   Ujpal, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszilko, Mihaly] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Cseplo, Krisztina] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Barabas, Jozsef] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Bogdan, Sandor] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Szabo, Gyorgy] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Ujpal, Marta] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
RP Vaszilko, M (reprint author), Semmelweis University, Department of Oral and Maxillofacial Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 414
EP 414
PG 1
ER

PT J
AU Vaszko, T
   Papp, J
   Geczi, L
   Bodrogi, I
   Horti, J
   Olah, E
AF Vaszko, Tibor
   Papp, Janos
   Geczi, Lajos
   Bodrogi, Istvan
   Horti, Jozsef
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszko, Tibor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Horti, Jozsef] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Vaszko, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 415
EP 415
PG 1
ER

PT J
AU Veleczki, Zs
   Szentirmay, Z
AF Veleczki, Zsuzsa
   Szentirmay, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Veleczki, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Veleczki, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 415
EP 415
PG 1
ER

PT J
AU Villango, B
   Szabo, T
   Hentes, T
   Gondos, M
   Karaffa, I
   Kokai, T
   Szilasi, Zs
   Racz, G
   Bursics, A
   Rahoty, P
AF Villango, Balazs
   Szabo, Tamas
   Hentes, Tibor
   Gondos, Miklos
   Karaffa, Ivan
   Kokai, Tunde
   Szilasi, Zsuzsanna
   Racz, Gergely
   Bursics, Attila
   Rahoty, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Villango, Balazs] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Szabo, Tamas] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Hentes, Tibor] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Gondos, Miklos] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Karaffa, Ivan] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Szilasi, Zsuzsanna] Semmelweis UniversityBudapest, Hungary.
   [Racz, Gergely] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bursics, Attila] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
   [Rahoty, Pal] AEK, II. Sebeszeti OsztalyBudapest, Hungary.
RP Villango, B (reprint author), AEK, II. Sebeszeti Osztaly, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 416
EP 416
PG 1
ER

PT J
AU Vincze, B
   Czeyda-Pommersheim, F
   Udvarhelyi, N
   Kapuvari, B
   Tamas, K
   Horvath, Zs
   Boldizsar, M
   Orosz, Zs
   Koves, I
   Lang, I
   Kasler, M
AF Vincze, Borbala
   Czeyda-Pommersheim, Ferenc
   Udvarhelyi, Nora
   Kapuvari, Bence
   Tamas, Karin
   Horvath, Zsolt
   Boldizsar, Mariann
   Orosz, Zsolt
   Koves, Istvan
   Lang, Istvan
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Tamas, Karin] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Boldizsar, Mariann] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Vincze, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 416
EP 416
PG 1
ER

PT J
AU Vityi, T
   Muller, Z
   Balatoni, Zs
   Kotai, Zs
AF Vityi, Tamas
   Muller, Zoltan
   Balatoni, Zsuzsa
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Muller, Zoltan] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Balatoni, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Vityi, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 417
EP 417
PG 1
ER

PT J
AU Wikonkal, N
   Kaszab, Cs
   Paragh, Gy
   Blazsek, A
   Karpati, S
AF Wikonkal, Norbert
   Kaszab, Csilla
   Paragh, Gyorgy
   Blazsek, Antal
   Karpati, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wikonkal, Norbert] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Kaszab, Csilla] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Paragh, Gyorgy] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Blazsek, Antal] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Karpati, Sarolta] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Wikonkal, N (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 417
EP 417
PG 1
ER

PT J
AU Zambo, K
   Schmidt, E
AF Zambo, Katalin
   Schmidt, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Schmidt, Erzsebet] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Zambo, K (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 417
EP 418
PG 2
ER

PT J
AU Zambo, O
   Kotai, Zs
AF Zambo, Orsolya
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Orsolya] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Zambo, O (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 418
EP 418
PG 1
ER

PT J
AU Zatkone Puskas, G
AF Zatkone Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zatkone Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Zatkone Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 418
EP 418
PG 1
ER

PT J
AU Zatkone Puskas, G
AF Zatkone Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zatkone Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Zatkone Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 418
EP 418
PG 1
ER

PT J
AU Zollei, I
   Orosz, Zs
   Toth, J
   Intzedy, K
AF Zollei, Istvan
   Orosz, Zsolt
   Toth, Jozsef
   Intzedy, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zollei, Istvan] Oroshazi KorhazOroshaza, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Toth, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Intzedy, Katalin] Oroshazi KorhazOroshaza, Hungary.
RP Zollei, I (reprint author), Oroshazi Korhaz, Oroshaza, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 419
EP 419
PG 1
ER

PT J
AU Zsilak, J
   Bassam, A
   Piko, B
AF Zsilak, Janos
   Bassam, Ali
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zsilak, Janos] Bekescsaba Varosi Onkormanyzat Rethy Pal Korhaza, Sebeszeti OsztalyBekescsaba, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Zsilak, J (reprint author), Bekescsaba Varosi Onkormanyzat Rethy Pal Korhaza, Sebeszeti Osztaly, Bekescsaba, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 419
EP 419
PG 1
ER

PT J
AU Zsiray, M
   Markoczy, Zs
   Borbely, K
   Szabo, Zs
   Lengyel, Zs
   Fekeshazy, A
AF Zsiray, Miklos
   Markoczy, Zsolt
   Borbely, Katalin
   Szabo, Zsuzsanna
   Lengyel, Zsolt
   Fekeshazy, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zsiray, Miklos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Szabo, Zsuzsanna] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Fekeshazy, Attila] PET-CT Medical Diagnostic LtdBudapest, Hungary.
RP Zsiray, M (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2007
VL 51
IS 4
BP 419
EP 419
PG 1
ER

PT J
TI Editor's page
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 5
EP 5
PG 1
ER

PT J
TI Prof. Dr. Mayer Arpad 65 eves
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 7
EP 7
PG 1
ER

PT J
AU Kralovanszky, J
AF Kralovanszky, Judit
TI Efforts to enhance the efficiency of tumor chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE kemoterapia; hatekonysagfokozas; toxicitascsokkentes; prediktiv faktorok; farmakogenetika
ID kemoterapia; hatekonysagfokozas; toxicitascsokkentes; prediktiv faktorok; farmakogenetika
AB Antiproliferative cytotoxic agents, of which several are still in clinical practice nowadays, could be characterized by low selectivity, narrow therapeutic index, medium or serious side effects and rapid formation of resistance. In the limited efficacy of these drugs several factors are playing a role such as the age, gender and pharmacogenetics of the patients, the morphological and biological feature of the tumor, moreover, pharmacokinetics and pharmacodynamics of the drugs. The question could be justified if there are methods which, by influencing the above parameters, are helpful in enhancing the efficacy and decreasing the toxic side effects of these drugs. Since a long time we have been interested in evaluating methods of preclinical and clinical level for increasing drug efficacy. The aim of this minireview is to give a short summary about our previous and present projects aiming: 1.) to characterize and mitigate toxic side effects of several cytotoxic agents; 2.) to decrease the toxic side effects and improve the antitumor effect of 5-fluorouracil by biochemical modulation and 3.) to study the possibility of individualized drug selection, based on the pharmacobiochemical and pharmacogenetic characteristics of the patients. Kralovanszky J. Efforts to enhance the efficiency of tumor chemotherapy.
C1 [Kralovanszky, Judit] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kralovanszky, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM kralo@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 9
EP 18
PG 10
ER

PT J
AU Kasler, M
   Otto, Sz
AF Kasler, Miklos
   Otto, Szabolcs
TI European and national tasks of oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE rakmortalitas es rakhalalozas; Nemzeti Rakkontroll Program
ID rakmortalitas es rakhalalozas; Nemzeti Rakkontroll Program
AB It is well known that cancer incidence and mortality figures are very poor in Hungary. By providing the latest figures the authors analyze the epidemiological background and the risk factors responsible for this situation. Furthermore, based on international recommendations and national specificities, the authors define areas of action to solve this significant health issue. The main conclusion of their analysis is that it is inevitable to improve oncology care by adjusting it to European standards. The decade-old National Cancer Control Program (NCCP) is improved by incorporating legislatory actions, educational issues, research and development priorities. The program now provides the definition of regional centers, recommend improvements of the function of oncology teams and rehabilitation. Based on successful European models, this program must be coordinated by the National Cancer Institute. Kasler M, Otto S. European and national tasks of oncology.
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM sz.otto@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 21
EP 33
PG 13
ER

PT J
AU Francz, M
AF Francz, Monika
TI The premalignant disease of the endometrium: endometrial intraepithelial neoplasia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE endometrialis hyperplasia; endometrialis intraepithelialis neoplasia; rakmegelozo allapot; klasszifikacio; PTEN-protein; D-score
ID endometrialis hyperplasia; endometrialis intraepithelialis neoplasia; rakmegelozo allapot; klasszifikacio; PTEN-protein; D-score
AB The WHO 1994 classification for endometrial hyperplasias is based on the morphologic features of the lesions. This system characterizes the nuclear cytologic morphology as typical or atypical and describes the glandular architectural pattern as simple or complex. The main problem of this classification is the poor reproducibility. Although the predictive value of the atypical category is high, there are many typical hyperplasia cases with cancer progression. Modern molecular data related to endometrial tumorigenesis and precise computerized morphometric analysis have identified the lesion that may be considered as a precursor of endometrioid adenocarcinoma. By definition, this endometrial intraepithelial neoplasia (EIN) is a clonal proliferation of architecturally and cytologically altered endometrial glands which are prone to malignant transformation to endometrioid (type I) endometrial adenocarcinoma. The morphometric basis of EIN diagnosis is the D-score (DS), which is a logical combination of three morphometric features that represent the glandular complexity, glandular volume and cytological alterations. PTEN inactivation and K-ras mutation are the earliest genetic changes that can be revealed in these lesions. Hyperplasia cases that do not fit into the EIN categories are considered as benign or hormonal endometrial hyperplasia. This is the theoretical basis of a new classification system in premalignant endometrial diseases. Retrospective clinical data proved the high predictive value of the EIN scheme, so the decision on therapy can be more established. The reproducibility is excellent with application of precise definitions and PTEN immunohistochemistry. In the "Blue book" published in 2003 the WHO introduces the new morphometric- and molecular-based EIN system, and recommends it as an alternative classification method.
C1 [Francz, Monika] Josa Andras Teaching Hospital, Department of Pathology, Szent Istvan u. 68., 4400 Nyiregyhaza, Hungary.
RP Francz, M (reprint author), Josa Andras Teaching Hospital, Department of Pathology, 4400 Nyiregyhaza, Hungary.
EM mfrancz@josa.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 35
EP 40
PG 6
ER

PT J
AU Tamasi, L
   Muller, V
   Magyar, P
   Losonczy, Gy
AF Tamasi, Lilla
   Muller, Veronika
   Magyar, Pal
   Losonczy, Gyorgy
TI Erythropoietic protein supportive treatment in small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kissejtes tudodaganat; anaemia; kemoterapia; dozisintenzitas; transzfuzio; eritropoetin
ID kissejtes tudodaganat; anaemia; kemoterapia; dozisintenzitas; transzfuzio; eritropoetin
AB Anemia is common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases patient's quality of life, and worsens the dose intensity of chemotherapy. The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-erythropoietin, due to anemia observed after the first cycle of chemotherapy. The mean pre-treatment hemoglobin oncentration of the patients was 116.67±8.17 g/L (mean±SD). The mean pre-erythropoietin hemoglobin concentration at baseline was 103.11±7.52 g/L. Six cycles of platina-toposid were used. The post-treatment hemoglobin concentration of patients was 110.11±5.37 g/L (p=0,028 vs. baseline). During these 54 chemotherapeutic cycles, only 2 patients needed transfusion, each of them once. According to our experience, the use of beta-erythropoietin in 9 anemic small cell lung cancer patients resulted in a low rate of transfusions and maintenance of cytotoxic treatment dose intensity. The adequate use of beta-erythropoietin is of great help to the physician in the management of small cell lung cancer patients.
C1 [Tamasi, Lilla] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM tamasi@pulm.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 43
EP 46
PG 4
ER

PT J
AU Horvath, Zs
   Farkas, P
   Ganofszky, E
   Hitre, E
   Juhos, �
   Nagy, T
   Rubovszky, G
   Szabo, E
   Lang, I
AF Horvath, Zsolt
   Farkas, Peter
   Ganofszky, Erna
   Hitre, Erika
   Juhos, Eva
   Nagy, Tunde
   Rubovszky, Gabor
   Szabo, Eszter
   Lang, Istvan
TI Changes in renal function during bisphosphonate treatment of breast cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE biszfoszfonat; vesetoxicitas; kreatinin-clearence; emlorak; kemoterapia
ID biszfoszfonat; vesetoxicitas; kreatinin-clearence; emlorak; kemoterapia
AB Renal function aberrations during bisphosphonate treatment is a well-known fenomenon. In our retrospective study we examined renal functions of 97 breast cancer patients with bone metastasis during their first year of bisphosphonate treatment i.e. (1) frequency of initial renal function alterations; (2) frequency of decreasing renal function during bisphosphonate treatment; (3) the connection between the laboratory findings and the renal function parameters measured at the beginning of bisphosphonate treatment. At the beginning of bisphosphonate treatment we found a surprisingly high rate (26.80%) of decreased creatinine clearence calculated by the Cockcroft-Gault formule. Decreased creatinine clearence at least once during bisphosphonate treatment has been found in 32.99% of the patients, and in 13.4% of the patients with decreased renal function parameters before bisphosphonates it remained decreased during the one-year period. Expected normal renal function is prognosticated by the renal function parameters and serum calcium level measured before starting bisphosphonate treatment. However, we could not demonstrate any connection between decreasing renal function and either the route of administration or the generation or type of bisphosphonates or the previous use of platina compounds. Our analysis confirms the necessity of monitoring renal function before and during bisphosphonate treatment, and it is advisable to calculate the creatinine clearence in the upper quater of the normal range of creatinine levels. In case of decreased renal function, change to a less nephrotoxic bisphosphonate or disruption of the treatment is suggested. Whilst our results are out of key with the published literature, the above-mentioned questions should be examined in a prospective trial.
C1 [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Farkas, Peter] Semmelweis University, Department of Pharmacology and PharmacotherapyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Juhos, Eva] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nagy, Tunde] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Rubovszky, Gabor] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szabo, Eszter] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM hor.zsolt@vnet.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 49
EP 55
PG 7
ER

PT J
AU Szentpetery, F
   Atkari, B
   Jakab, F
AF Szentpetery, Felix
   Atkari, Bence
   Jakab, Ferenc
TI Our results coming from a long-term follow-up of the patients operated on for rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE rectumcarcinoma; hosszu tavu kovetes; helyi daganatkiujulas; metasztazis; tobb szervi progresszio; masodik daganat
ID rectumcarcinoma; hosszu tavu kovetes; helyi daganatkiujulas; metasztazis; tobb szervi progresszio; masodik daganat
AB In developed societies colorectal cancer (CRC) is the second most frequent malignant tumor which causes more than 5000 deaths yearly in Hungary. We have attempted to answer the question how to improve the above mentioned data by the long-term follow-up of patients operated upon for rectal cancer at our department. Of the patients operated on for rectal cancer at our department between March 1990 and April 2006, we have conducted regular follow-up of 297 patients according to a protocol developed by us. We have examined the length of time between the rectum operation and the diagnosis and the number of local recurrences, distant metastases, tumor progression in more than one organ as well as second tumors (independent of the rectal cancer). During this period we found 24 local recurrences, 32 distant metastases, 43 tumor progressions in more than one organ, and 21 second tumors. In two patients, in addition to distant metastases, we found a second CRC independent of the original rectal cancer, and in one patient with tumor progression in more than one organ we also detected breast cancer. In one patient we found 3 second tumors (CR, lung and urinary bladder) independent of the original rectal cancer. Altogether we found tumors in 117 out of 297 patients. During the same period, we performed 69/117 operations and 31/117 patients were alive at the end of our study with a median survival of 60.4 (3-184) months. In summary, we can state that this work is beneficial for curing the recurrence of rectal cancer, making the patients' life longer or making the quality of life better for the patients operated on for rectal cancer.
C1 [Szentpetery, Felix] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Uzsoki utca 29., 1145 Budapest, Hungary.
   [Atkari, Bence] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Uzsoki utca 29., 1145 Budapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Uzsoki utca 29., 1145 Budapest, Hungary.
RP Szentpetery, F (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, 1145 Budapest, Hungary.
EM szentpetery@uzsoki.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 57
EP 63
PG 7
ER

PT J
AU Szluha, K
   Lazanyi, K
   Horvath, �
   Szanto, J
   Toth, J
   Hernadi, Z
   Poka, R
   Damjanovich, L
   Garami, Z
   Fulop, B
   Molnar, B
AF Szluha, Kornelia
   Lazanyi, Kornelia
   Horvath, Akos
   Szanto, Janos
   Toth, Judit
   Hernadi, Zoltan
   Poka, Robert
   Damjanovich, Laszlo
   Garami, Zoltan
   Fulop, Balazs
   Molnar, Bela
TI Research on carreer motivators affecting the emotional labour of oncology health care professionals
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE erzelmi munka; mellekhatasok; segito foglalkozasuak; onkologiai szakdolgozok
ID erzelmi munka; mellekhatasok; segito foglalkozasuak; onkologiai szakdolgozok
AB In the course of their everyday work health care professionals (HCPs) often have to change their true feelings. The literature labels this performance as emotional labor. This article is presenting data on the characteristics of HCPs' most endangered by the negative consequences of emotional labor. Our simple choice question survey was conducted at Debrecen University Medical Healthcare Center with the help of 50 oncology HCPs volunteers. Nearly 90% of the HCPs examined change their true feelings in the course of work. It is very difficult to classify the assemblage of those threatened by the negative upshots of the emotional labor. Due to our research we found appalling differences of work motivation that were tightly interconnected with the respondents' emotional labor and their perceived role/emotional expectations. We succeeded in establishing three clusters and defining each cluster's characteristics. Figures suggest that only somewhat more than the half of the HCPs is authentic professional helper, and 45% of them does not or only slightly perceive the patients' demands concerning their work. Therefore, it is important that the work environment does not only assist the work of HCPs by professional means, but along emotional dimensions as well.
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 2012 Debrecen, Hungary.
   [Lazanyi, Kornelia] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
   [Horvath, Akos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 2012 Debrecen, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Poka, Robert] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Damjanovich, Laszlo] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Garami, Zoltan] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Fulop, Balazs] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Molnar, Bela] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 2012 Debrecen, Hungary.
EM lazanyi@uni-corvinus.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 65
EP 69
PG 5
ER

PT J
AU Krutsay, M
AF Krutsay, Miklos
TI Lipoma of the fallopian tube
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lipoma; zsirszovet; mehkurt; choristoma
ID lipoma; zsirszovet; mehkurt; choristoma
AB A swollen fallopian tube was found in a 34 years old woman operated for acute abdominal pain. During this operation the fallopian tube together with the appendix were removed. The histological examination identified appendicitis and a lipoma of the fallopian tube.
C1 [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi F. u. 1., 8401 Ajka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai Osztaly, 8401 Ajka, Hungary.
EM krutsaym@korhazajka.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2008
VL 52
IS 1
BP 71
EP 73
PG 3
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: To lead, to switch or to extend?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE aromatazgatlok; adjuvans endokrin kezeles; hormonerzekeny emlorak; posztmenopauzalis emlorak
ID aromatazgatlok; adjuvans endokrin kezeles; hormonerzekeny emlorak; posztmenopauzalis emlorak
AB From the big randomized clinical trials there are evidences that adjuvant endocrine therapy for hormone-sensitive early breast cancer in postmenopausal women should include an aromatase inhibitor (AI). Anastrozole or letrozole should be used upfront for 5 years (ATAC and BIG 1-98), the sequential approach of tamoxifen for 2-3 years, followed by anastrozole or exemestane for 2-3 years is a reasonable alternative (ABCSG8, ARNO 95, IES, ITA), and mostly in patients with node-positive disease completing 5 years of tamoxifen should be offered letrozole up to 4-5 years (MA-17). In each of these trials incorporation of an AI resulted in significant improvement in study endpoints. Further results will be needed to establish the optimal beneficial effect, use, duration and safety of adjuvant AI therapies.
C1 [Nagykalnai, Tamas] Bajcsy-Zsilinszky Korhaz Rendelointezet, Maglodi u. 89-91., 1106 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, 1106 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 133
EP 143
PG 11
ER

PT J
AU Takacsi Nagy, Z
   Kasler, M
AF Takacsi Nagy, Zoltan
   Kasler, Miklos
TI Brachytherapy of head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE fej-nyaki daganatok; brachyterapia; low-dose-rate; high-dose-rate; pulsed-doserate
ID fej-nyaki daganatok; brachyterapia; low-dose-rate; high-dose-rate; pulsed-doserate
AB In the non-surgical treatment of head and neck tumours, the "organ preserving" modalities have become more and more important. At present radiotherapy is the most important means of this kind of treatment. In the radiotherapy of head and neck cancer local dose escalation is an important factor in increasing local tumour control. However, with sole external beam irradiation it is difficult to spare adjacent normal tissues. Interstitial brachytherapy (BT) is ideally suited to deliver a high dose limited to the volume of the primary tumour, thus maximizing tumour control while minimizing complications. Low-dose-rate (LDR) BT, which has been applied for a long time in the treatment of these tumours, is now challenged by high-dose-rate (HDR) and pulsed-dose-rate (PDR) BT. The purpose of this work is to show the role and the indications of BT in tumours of the head and neck region and to offer general and site-specific recommendations based upon the available information from the literature.
C1 [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Takacsi Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM takacsi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 145
EP 150
PG 6
ER

PT J
AU Gundy, S
   Szekely, G
   Farkas, Gy
   Pulay, A
   Remenar, �
AF Gundy, Sarolta
   Szekely, Gabor
   Farkas, Gyongyi
   Pulay, Attila
   Remenar, Eva
TI Problems occurring in the application of cytogenetic biomarkers for alcoholics with and without malignant diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE alkohol; dohanyzas; onbevallas; rakriziko; gyulladas; kromoszoma
ID alkohol; dohanyzas; onbevallas; rakriziko; gyulladas; kromoszoma
AB Applicability of alcohol- and smoking-related cancer-risk biomarkers might be modified by several factors. Among those, reality of self-reports on alcohol consumption of alcoholic patients with different diseases and extreme high mutagen hypersensitivity of Hungarians, as well as the immunologic role of peripheral lymphocytes as experimental objects of cytogenetic biomarkers seem to be new viewpoints of interest. To clarify these problems, 432 head and neck cancer patients (HNCP), 62 alcoholics with alcoholic hepatitis (ALCL), and 101 disease-free chronic alcoholics (ALC) were examined. Despite clinically confirmed alcohol-related diagnoses (and GGT and MCV values) only about half of HNCPs and ALCLs reported about any alcohol consumption, in contrast to the realistic self-reports of ALCs. In cytogenetic case control investigations no difference between the spontaneous rate of chromosomal aberrations (CAs) of healthy controls and ALCs was found, however, genetic instability expressed as a 40-50% elevation rate of CAs in HNCPs and ALCLs might be associated with systemic inflammatory reaction of lymphocytes. Bleomycin sensitivity assay showed the highest break/cell (b/c) values not in HNCPs (1.06 b/c) as it was reported earlier, but in "healthy" ALCs (1.52 b/c). This phenomenon can be related to the local effect of genotoxins (alcohol, smoking, and in particular the diet), which probably reflects merely a reaction of mucosal immune system. Nearly 50% of mutagen-hypersensitive Hungarian controls, in contrary to the expected 10-20% ones, might also be explained by this. Similarly, HNCPs with oral cancer, where the local mutagen effect was the most intensive, had the highest b/c values. In conclusion, when cytogenetic biomarkers of alcoholism are examined, the subjective character of self-reports at epidemiologic level and immunologic role of lymphocyte subpopulations as genetic confounders must also be taken into consideration.
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Attila] Orszagos Pszichiatriai es Neurologiai Intezet, Alkohologiai OsztalyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM gundy@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 153
EP 161
PG 9
ER

PT J
AU Balazs, �
   Kupcsulik, KP
   Galambos, Z
AF Balazs, Akos
   Kupcsulik, K Peter
   Galambos, Zoltan
TI Pathological caracteristics of esophago-respiratory fistulas of esophageal tumor origin
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oesophago-respiratoricus fistula; nyelocsotumor; kortani jellemzok; endoprothesisbeultetes; tuleles
ID oesophago-respiratoricus fistula; nyelocsotumor; kortani jellemzok; endoprothesisbeultetes; tuleles
AB Esophago-respiratory fistulas, evolving as a result of esophageal tumors, are serious and lethal complications on account of the constant respiratory contamination and the inability to swallow. They can develop either as the complication of the end stage disease or sometimes even in the first stage of the malignancy. The objective was to reveal the caracteristics of the disease. In a prospective single-center study in the period between 1984 and 2004, 243 fistulas were diagnosed. Their data were analyzed using multivariant analysis. The mean age of patients with fistula was 56.9 years, the male-to-female ratio was 4.3:1. The average time of the complaints was 5.2 months, while the time of manifestation of the fistula was 7.5 months. Dysphagia was diagnosed in 97.5% of the patients, fever in 36.9%, and cachexia in 59.5%, respectively. The average loss of weight was 10.4 kg and the average size of the tumor was 7.7 cm. Endoscopic intubation was performed in 176 cases. The average survival was 3.4 months. Patients with fistula were divided into two groups, where the caracteristics of the disease were significantly different. Only in 66.3% was the fistula a late complication. In the other 33.7% of the cases the fistula was diagnosed in younger patients at the early stage of the disease, with a more agressive, less differentiated histology. In these patients the weight loss, the grade of dysphagia and the size of the tumor were smaller, the possibilities of treatment were fewer, and survival were shorter.
C1 [Balazs, Akos] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Kupcsulik, K Peter] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Galambos, Zoltan] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
RP Balazs, � (reprint author), Semmelweis University, 1st Department of Surgery, 1082 Budapest, Hungary.
EM balazsdr@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 163
EP 170
PG 8
ER

PT J
AU Kasler, M
   Remenar, �
   Lengyel, CsGy
   Boer, A
AF Kasler, Miklos
   Remenar, Eva
   Lengyel, Csongor Gyorgy
   Boer, Andras
TI Laser surgery of head and neck lesions at the National Institute of Oncology, Budapest
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE fej-nyaksebeszet; lezersebeszet; CO2-lezer; Nd:YA G-lezer; laryngotrachealis stenosis
ID fej-nyaksebeszet; lezersebeszet; CO2-lezer; Nd:YA G-lezer; laryngotrachealis stenosis
AB In spite of the continued expansion of non-surgical therapeutic modalities surgery still plays an important role in the treatment of head and neck cancer. Parallel with the use of conventional approaches, more sophisticated surgical approaches, like the use of laser in oncologic surgery, appeared with a more favorable outcome. Laser is a precise surgical tool, particularly when coupled to an operating microscope (with a variable spot size micromanipulator), allowing microprecision and hemostatic ability. The benefits of the use of laser are: bloodless operation field, high hit probability, "no touch" technique, ablasticity, support of tissue repair, and the lack of edema and scar formation. Between 1981 and 2008, 7934 surgical procedures were performed at the Department of Head and Neck Surgery, National Institute of Oncology, Budapest, Hungary. The aim is to present our results and experience with laser surgery of cutaneous lesions of the head and neck, oral, pharyngeal and laryngeal pathologies including cases of laryngotracheal stenosis.
C1 [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lengyel, Csongor Gyorgy] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM m.kasler@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 171
EP 176
PG 6
ER

PT J
AU Tamasi, L
   Muller, V
   Magyar, P
AF Tamasi, Lilla
   Muller, Veronika
   Magyar, Pal
TI Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE magasan emetogen kemoterapia; antiemetikus kezeles; ondansetron; aprepitant; nem kissejtes tudorak
ID magasan emetogen kemoterapia; antiemetikus kezeles; ondansetron; aprepitant; nem kissejtes tudorak
AB Approximately one half of cancer patients experience nausea or vomiting during chemotherapy containing high-dose cisplatin, despite the use of a corticosteroid and 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonists. The addition of aprepitant, a neurokinin 1 receptor antagonist, improves control of emesis by a further 15-20%, and improves late phase symptoms (>24 h after chemotherapy). The cornerstone of standard first line lung cancer chemotherapy is high-dose cisplatin. Our experience with aprepitant in the chemotherapy of 10 lung cancer patients is described, who reported more than one episode of vomiting caused by chemotherapy despite the use of ondansetron previously. Aprepitant prevented acute and late phase oncoming vomiting in all 10 patients and acute and late phase nausea in 9 of the 10 patients. According to our experience on a limited number of patients, aprepitant may be of clinical benefit in the supportive treatment of lung cancer, in achieving better quality of life during chemotherapeutic cycles in these patients.
C1 [Tamasi, Lilla] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
   [Magyar, Pal] Semmelweis University, Department of Pulmonology, Dios arok 1c, 1125 Budapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM engi.tamasi@freestart.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 179
EP 183
PG 5
ER

PT J
AU Timar, J
   Lang, I
AF Timar, Jozsef
   Lang, Istvan
TI The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE EGFR; K-RAS onkogen; antitest-terapia; vastagbelrak
ID EGFR; K-RAS onkogen; antitest-terapia; vastagbelrak
AB During the carcinogenesis of colorectal cancer in about half of the cases K-RAS, while much less frequently B-RAF mutation occur in early adenomas. While K-RAS mutant tumors are more likely present in male patients, B-RAF mutant tumors develop more frequently in females and are independent of the microsatellite status. Colorectal cancers are characterized by EGFR expression; the gene is not mutated, rarely amplified and increased copy number is due to chromosomal polysomy. This pheno-/genotype of colorectal cancer lent support to the introduction of anti-EGFR antibody therapies. For a while positive EGFR expression status of the tumor was the basis of patient selection for these targeted therapies in colorectal cancer. Monotherapies with the two available anti-EGFR antibodies of chemoresistant colorectal cancers resulted in appr. 10% objective response rate, which was independent of the level of EGFR expression. In case of panitumumab it was discovered that the efficacy of this targeted therapy depends on the K-RAS mutant status of the tumors. Furthermore, preliminary data suggest that cetuximab combined with chemotherapy is effective also exclusively in K-RAS wild-type tumors. Based on these data it is safe to say that K-RAS mutant status of colorectal cancer is a negative predictor for EGFR-targeted therapies of colorectal cancer. Accordingly, it is necessary to determine the K-RAS status of colorectal cancer before making therapeutic decisions.
C1 [Timar, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 185
EP 191
PG 7
ER

PT J
AU Blasko, Gy
AF Blasko, Gyorgy
TI The necessity of anticoagulant profilaxis during chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE trombozis; rak-prokoagulans; szoveti faktor; daganatok; kemoterapeutikumok
ID trombozis; rak-prokoagulans; szoveti faktor; daganatok; kemoterapeutikumok
AB The modern pathobiochemical explanation of the old clinical finding, i.e. that the occurrence of the thromboembolic complications in cancer patients is significantly higher, starts to be clarified on the basis of recent knowledge regarding the role of cancer procoagulant, the expressed tissue factor and the changes in the clotting and fibrinolytic systems. Furthermore, the presently used chemotherapeutic agents have activating effects of the coagulation system as well. The details of these phenomena, the frequently used drugs and their pathobiochemical effects are detailed in this publication. Finally, it gives an outlook regarding the new adjuvant, beneficial effects of the direct anticoagulants in malignancies.
C1 [Blasko, Gyorgy] Debreceni Egyetem OEC, Gyogyszerugyi Management es Szervezes, Tolgy u. 7., 2083 Solymar, Hungary.
RP Blasko, Gy (reprint author), Debreceni Egyetem OEC, Gyogyszerugyi Management es Szervezes, 2083 Solymar, Hungary.
EM blaskogy@mail.externet.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 193
EP 199
PG 7
ER

PT J
TI XV. primer prevencios forum "Kornyezeti artalmak es a szaporodas osszefuggesei" cimu eloadasainak osszefoglaloi
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE kornyezeti artalmak; szaporodas
ID kornyezeti artalmak; szaporodas
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 201
EP 218
PG 19
ER

PT J
AU Avramucz, Cs
   Horvath, A
   Kocsis, J
AF Avramucz, Csaba
   Horvath, Anna
   Kocsis, Judit
TI European School of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Avramucz, Csaba] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Horvath, Anna] Semmelweis University, 3rd Department of Internal Medicine, Kutvolgyi ut 4., 1125 Budapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal Medicine, Kutvolgyi ut 4., 1125 Budapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, 1125 Budapest, Hungary.
EM kocsisjuci@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2008
VL 52
IS 2
BP 221
EP 223
PG 3
ER

PT J
AU Mayer, �
AF Mayer, Arpad
TI In memoriam Prof. Dr. Med. Friedrich Kamprad (1939. januar 23 - 2008. julius 25.)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29.Budapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 245
EP 245
PG 1
ER

PT J
AU Dome, B
   Magyar, M
AF Dome, Balazs
   Magyar, Melinda
TI Tumor vasculature as a therapeutic target in non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE angiogenezis; tudorak
ID angiogenezis; tudorak
AB Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.
C1 [Dome, Balazs] National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, Piheno u. 1., 1529 Budapest, Hungary.
   [Magyar, Melinda] National Koranyi Institute for TB and Pulmonology, Department of PulmonologyBudapest, Hungary.
RP Dome, B (reprint author), National Koranyi Institute for TB and Pulmonology, Department of Pulmonology, 1529 Budapest, Hungary.
EM domeb@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 247
EP 259
PG 13
ER

PT J
AU Fulop, M
   Boer, A
   Remenar, �
   Lengyel, Cs
   Kasler, M
AF Fulop, Miklos
   Boer, Andras
   Remenar, Eva
   Lengyel, Csongor
   Kasler, Miklos
TI Applicable methods of reconstruction for the replacement of soft tissue after the radical resection of oral tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE szajuregi daganatok; rekonstrukcio; nasolabialis lebeny; pectoralis major lebeny; alkarlebeny
ID szajuregi daganatok; rekonstrukcio; nasolabialis lebeny; pectoralis major lebeny; alkarlebeny
AB In Hungary the number of oral and pharyngeal cancers is alarmingly high. While the mortality rate in 1955 was 282, by 2005 it rose to 1567. However, in the last 1-2 years stagnation can be observed. Nevertheless, even now significant proportions of men and women are involved. Alcohol consumption and smoking are invariably the leading causes, but one cannot disregard the shortcomings of oral cancer screenings, either. Unfortunately, drastic changes in this field are not likely to occur in the near future. Numerous solutions have been developed for the replacement of soft tissue. In our article, we describe and evaluate four of them. When using these techniques, we were oft en successful in replacing soft tissue deficiencies.
C1 [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lengyel, Csongor] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM fulop.m@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 261
EP 267
PG 7
ER

PT J
AU Polgar, Cs
   Orosz, Zs
   Kahan, Zs
   Gabor, G
   Jani, N
   Cserni, G
   Hadijev, J
   Kulka, J
   Sulyok, Z
   Boross, G
   Lazar, Gy
   Laszlo, Zs
   Diczhazi, Cs
   Udvarhelyi, N
   Szabo, �
   Pentek, Z
   Major, T
   Fodor, J
AF Polgar, Csaba
   Orosz, Zsolt
   Kahan, Zsuzsanna
   Gabor, Gabriella
   Jani, Nora
   Cserni, Gabor
   Hadijev, Janaki
   Kulka, Janina
   Sulyok, Zoltan
   Boross, Gabor
   Lazar, Gyorgy
   Laszlo, Zsolt
   Diczhazi, Csaba
   Udvarhelyi, Nora
   Szabo, Eva
   Pentek, Zoltan
   Major, Tibor
   Fodor, Janos
TI Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: Preliminary results of the Hungarian multicentric prospective randomised study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE duktalis in situ emlorak; emlomegtarto mutet; sugarkezeles; helyi daganatkiujulas; randomizalt klinikai vizsgalat; molekularis prognosztikai markerek
ID duktalis in situ emlorak; emlomegtarto mutet; sugarkezeles; helyi daganatkiujulas; randomizalt klinikai vizsgalat; molekularis prognosztikai markerek
AB The aim of this work is to report the preliminary results of the Hungarian multicentric randomised DCIS study. Between 2000 and 2007, 278 patients with ductal carcinoma in situ (DCIS) treated by breast-conserving surgery were randomised according to predetermined risk groups. Low/intermediate-risk patients (n=29) were randomised to 50 Gy whole-breast irradiation (WBI) or observation. High-risk cases (n=235) were allocated to receive 50 Gy WBI vs. 50 Gy WBI plus 16 Gy tumour bed boost. Very high-risk patients (patients with involved surgical margins; n=14) were randomised to 50 Gy WBI plus 16 Gy tumour bed boost or reoperation (reexcision plus radiotherapy or mastectomy alone). Immunohistochemistry (IHC) was performed to detect the expression of potential molecular prognostic markers (ER, PR, Her2, p53, Bcl-2 and Ki-67). At a median follow-up of 36 months no recurrence was observed in the low/intermediate- and very high-risk patient groups. In the high-risk group, 4 (1.7%) local recurrences and 1 (0.4%) distant metastasis occurred. No patient died of breast cancer. In the high-risk group of patients, the 3- and 5-year probability of local recurrence was 1.1% and 3.1%, respectively. The positive immunostaining for Her2 (38%), p53 (37%) and Ki-67 (44%) correlated with a high nuclear grade. Significant inverse correlation was found between the expression of ER (77%), PR (67%), Bcl-2 (64%) and grade. Preliminary results suggest that breast-conserving surgery followed by radiotherapy yields an annual local recurrence rate of less than 1% in patients with DCIS. IHC  of molecular prognostic markers can assist to gain insight into the biologic heterogeneity of DCIS.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Jani, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Hadijev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Laszlo, Zsolt] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Diczhazi, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Pentek, Zoltan] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 269
EP 277
PG 9
ER

PT J
AU Kasler, M
   Remenar, �
   Boer, A
   Ivanyi, E
   Fulop, M
AF Kasler, Miklos
   Remenar, Eva
   Boer, Andras
   Ivanyi, Emoke
   Fulop, Miklos
TI Our clinical experience with fibula free flap
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE szajuregi daganatok; mandibulareszekcio; fibula-szabadlebeny
ID szajuregi daganatok; mandibulareszekcio; fibula-szabadlebeny
AB Oral cancer incidence in Hungary is strikingly high, even by international standards. In most cases the tumours are to be treated in advanced stage. Hence it follows that we are often forced to remove a part of the mandible, too. We usually use a fibula free flap to reconstruct the bone deficiency. In this paper we report on our clinical experience with fibula free flap.
C1 [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Ivanyi, Emoke] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM m.kasler@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 279
EP 281
PG 3
ER

PT J
AU Haltrich, I
   Csoka, M
   Kovacs, G
   Fekete, Gy
AF Haltrich, Iren
   Csoka, Monika
   Kovacs, Gabor
   Fekete, Gyorgy
TI Cytogenetic and FISH findings are complementary in childhood ALL
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE akut limfoid leukemia; citogenetika; I-FISH
ID akut limfoid leukemia; citogenetika; I-FISH
AB Primary genetic abnormalities of leukemia cells have important prognostic significance in childhood acute leukemia. In the last two years 30 newly diagnosed or recurrent childhood ALL bone marrow samples were analyzed for chromosomal abnormalities with conventional G-banding and interphase-fluorescence in situ hybridization (I-FISH) using probes to detect BCR/ABL fusions, cryptic TEL/AML1 and MLL rearrangements and p16(9p21) tumor suppressor gene deletions. G-banded karyotype analysis found clonal chromosomal aberrations in 50% of cases. With the use of complementary I-FISH techniques, ALL-specific structural and numerical changes could be identified in 70% of the patients. Nine cases (30%) had subtle chromosomal aberrations with prognostic importance that had not been detected in G-banded analysis. Conventional G-banding yielded additional information (rare and complex structural aberrations) in 19% of patients. The most common aberration (30%) was AML1 copy number increase present in G-banded hyperdiploid karyotype as a chromosome 21 tetrasomy in the majority of cases; one case displayed 5-6 copies and in another case amplification of AML1 gene on der(21) was combined with TEL/AML1 fusion of the homologue AML1 gene and deletion of the remaining TEL allele. High hiperdiploidy was detected in 6 cases, in one patient with normal G-banding karyotype. TEL/AML1 fusion signals were identified in four patients. Deletion of p16 locus was found in eight cases (23%), of which only two had cytogenetically visible rearrangements. G-banding in combination with I-FISH has produced major improvements in the sensitivity and accuracy of cytogenetic analysis of ALL patients and this method helps to achieve a more precise identification of different risk categories in order to choose the optimal treatment.
C1 [Haltrich, Iren] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
RP Haltrich, I (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM haltrich@gyer2.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 283
EP 291
PG 9
ER

PT J
AU Meszaros, K
   Remenar, �
   Kasler, M
AF Meszaros, Krisztina
   Remenar, Eva
   Kasler, Miklos
TI Swallowing and speech treatment in rehabilitation for head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE artikulacios gyakorlatok; eletminoseg; foniatria; nyelesterapia; rehabilitacio
ID artikulacios gyakorlatok; eletminoseg; foniatria; nyelesterapia; rehabilitacio
AB The aim of treating head and neck cancer is to eliminate the tumor and save functions as much as possible. Despite all eff orts the vital (swallowing) and communicative (phonation, articulation) functions can be injured. The treatment of dysphagia is the most important in the rehabilitation, because it can lead to fatal complications: aspiration pneumonia (for example aspiration of saliva), dehydration, malnutrition. According to the localization of the lesion we distinguish oropharyngeal and esophageal dysphagia. The aspiration may be pre-, intra- and postdeglutitory. The aspiration without coughing is called silent aspiration which is mainly seen in neurogenic dysphagia, but can also happen in head and neck cancer patients. There are different possibilities to compensate the failing functions in the phoniatric rehabilitation. The swallowing therapy includes causal, compensatory and dietary strategies. In addition to the swallowing therapy the treatment of communicative dysfunctions with articulation exercises will also improve the quality of life of the patients.
C1 [Meszaros, Krisztina] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Meszaros, K (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM kmesz@hotmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 293
EP 297
PG 5
ER

PT J
AU Gyarmathy, L
   Varjas, G
   Major, T
   Fodor, J
   Kasler, M
AF Gyarmathy, Laszlo
   Varjas, Geza
   Major, Tibor
   Fodor, Janos
   Kasler, Miklos
TI Fifty-year-old history of cobalt radiotherapy in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kobaltagyu; Co-60; kobaltterapia hazai tortenete
ID kobaltagyu; Co-60; kobaltterapia hazai tortenete
AB The first patient in Hungary was treated by cobalt therapy fifty years ago at the National Institute of Oncology with a Gravicert type equipment. On the occasion of this anniversary, the 50-year history of the Hungarian cobalt therapy is reviewed, and its present role is discussed. The first cobalt unit (Gravicert) was designed by Laszlo Bozoky seven years after the first cobalt unit installation in the world in Canada. The megavoltage energy of the Co-60 source (average: 1.25 MeV) resulted in more successful treatments of deep-seated tumors compared to the X-ray therapy. In the next two-three decades, until the widespread use of the high-energy linear accelerators, the Co-60 teletherapy meant the modern radiation treatment throughout the world. Improvements of quality in radiation techniques necessitated exact localization of the tumors and developments of treatment planning methods. At the beginning, the localization was performed with X-ray machines, while the treatment planning was done manually. In 1965 a Rotacert type cobalt unit was installed at our institute. This machine was already capable of making irradiation in multiple directions and it worked in rotating mode, too. In Hungary, more cobalt units - first the Gravicert type, then foreign made machines - were gradually installed in other radiotherapy centers too. The quality of treatments was significantly improved by the introduction of the computerized treatment planning, and the foundation of the IAEA-supported National Treatment Planning Network in 1978 was an important step in this process. The next important development was the commencement of the CT image based treatment planning in 1981. With the spread of modern linear accelerators the role of the cobalt units has greatly decreased by now, however, nearly 2,500 cobalt units are still in use worldwide. Their usage could be further increased with technical developments. At present, radiation treatments are performed with cobalt units in eight out of twelve radiotherapy centers in Hungary.
C1 [Gyarmathy, Laszlo] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 299
EP 304
PG 6
ER

PT J
TI Dr. Olah Edit professzor az EACR tiszteletbeli tagja
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 305
EP 305
PG 1
ER

PT J
AU Avramucz, Cs
   Foubert, J
AF Avramucz, Csaba
   Foubert, Jan
TI Az Europai Onkologiai Apolok Tarsasaga - European Oncology Nursing Society (EONS): Tarsunk a rak elleni kuzdelemben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Avramucz, Csaba] Semmelweis University, Faculty of Medicine, Vas u. 17., 1088 Budapest, Hungary.
   [Foubert, Jan] Free University of Brussels (ULB), Erasme HospitalBrussels, Belgium.
RP Avramucz, Cs (reprint author), Semmelweis University, Faculty of Medicine, 1088 Budapest, Hungary.
EM csabaavramucz@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2008
VL 52
IS 3
BP 307
EP 309
PG 3
ER

PT J
TI Editor's page
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 337
EP 337
PG 1
ER

PT J
AU Tusnady, G
   Gaudi, I
   Rejto, L
   Kasler, M
   Szentirmay, Z
AF Tusnady, Gabor
   Gaudi, Istvan
   Rejto, Lidia
   Kasler, Miklos
   Szentirmay, Zoltan
TI Survival chances of Hungarian cancer patients in the National Cancer Registry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE daganatos betegek tulelese; periodusanalizis; Gompertz-eloszlas; halalozasi rata; rakregiszter
ID daganatos betegek tulelese; periodusanalizis; Gompertz-eloszlas; halalozasi rata; rakregiszter
AB The Hungarian National Cancer Registry (HNCR) was launched in August, 1999 by the National Cancer Institute. The main goal of HNCR is to determine the prevalence of different types of malignant cancers. A new method, period analysis was invented to determine survival chances of patients with malignant tumor. Based on period analysis we developed a new method by approximating survivals of Hungarian cancer patients with the help of Gompertz distribution. Our survival analysis was based on HNCR data of patients with cancer recognized between January 1, 2002 and December 31, 2005. These data are far enough from the time when HNCR started, thus they do not contain the initial errors, but also far enough from the present so their correction could be considered completed. In case of 21 malignant tumor locations for males and 23 ones for females we determined the parameters of the Gompertz distribution and based on the estimated parameters we estimated the expected survival probabilities for each specific tumor type and gender. In this study we have not used the TNM-based clinical stage or any other data of the patients contained by HNCR. Using the Gompertz model, the complete recovery of a cancer patient is always possible and the probability of recovery has a reliable estimate based on a short follow-up period only. We compared our results with five-year survival data of Canada, Italy, Norway and Finland and we did not find substantial differences. For both men and women, considering any specific location, the differences in survival among countries are much smaller than the difference between locations.
C1 [Tusnady, Gabor] Hungarian Academy of Sciences, Renyi Alfred Mathematical InstituteBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Rejto, Lidia] University of DelawareNewark, DE, USA.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM szentirmay@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 339
EP 349
PG 11
ER

PT J
AU Kaszper, �
   Hanzely, Z
   Szende, B
   Dabasi, G
   Garami, M
   Schuler, D
   Hauser, P
AF Kaszper, Eva
   Hanzely, Zoltan
   Szende, Bela
   Dabasi, Gabriella
   Garami, Miklos
   Schuler, Dezso
   Hauser, Peter
TI Examination of somatostatin receptor expression in recurrent childhood medulloblastomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE medulloblastoma; szomatosztatinreceptor; Octreoscan; medulloblastoma recidiva; SSTR; immunhisztokemia; gyermekkori agytumor
ID medulloblastoma; szomatosztatinreceptor; Octreoscan; medulloblastoma recidiva; SSTR; immunhisztokemia; gyermekkori agytumor
AB Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2- positive tumor cells was 30-90%. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.
C1 [Kaszper, Eva] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Hanzely, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dabasi, Gabriella] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM haupet@gyer2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 351
EP 355
PG 5
ER

PT J
AU Bence, Zs
   Kovacs, G
   Jakab, Zs
   Csoka, M
   Muller, J
AF Bence, Zsofia
   Kovacs, Gabor
   Jakab, Zsuzsanna
   Csoka, Monika
   Muller, Judit
TI Lymphomas in adolescents: Are childhood lymphoma therapy protocols suitable for this patient group?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hodgkin-lymphoma; non-Hodgkin-lymphoma; adoleszcens; tuleles; protokoll
ID Hodgkin-lymphoma; non-Hodgkin-lymphoma; adoleszcens; tuleles; protokoll
AB The centres of the Hungarian Paediatric Oncology Network annually take care of 250-300 new patients with childhood cancer, every tenth of them suffering from lymphoma. The aim of our work was to analyse the data of the adolescents (14-19 years) with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), comparing their survival rates with younger patients under fourteen and with the international data. From January 1990 to December 2004 there were 281 children diagnosed with HL and 230 with NHL. Among the HL patients 107, while among the NHL patients 51 were older than 14 years old. In the group of HL the distribution of patients according to the stage was similar in younger and older patients. In the NHL group 55% of the children younger than 14, and 72% of the patients older than 14 years old had advanced stage disease (stage III or IV). In both groups the patients received chemotherapy according to the current paediatric protocols. The overall survival (OS) of the HL patients younger than 14 was 92.5±2% at 5 years and 90.3±2% at 10 years, and for the adolescents 93.4±2% and 90.7±3% at 5 and 10 years (n.s.). The OS of the younger children in the NHL group was 78.2±3% at 5 and 10 years, and 77.9±6% for the adolescents (n.s.). As a conclusion, survival rates of the adolescents do not diff er significantly from the parameters of the patients under fourteen, so the therapy protocols used for childhood lymphomas are suitable for the treatment of the lymphomas appearing at the age of 14-19 years.
C1 [Bence, Zsofia] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7&#65533;9., 1094 Budapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7&#65533;9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7&#65533;9., 1094 Budapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7&#65533;9., 1094 Budapest, Hungary.
RP Muller, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM muller@gyer2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 357
EP 362
PG 6
ER

PT J
AU Plotar, V
   Szentirmay, Z
   Orosz, Zs
AF Plotar, Vanda
   Szentirmay, Zoltan
   Orosz, Zsolt
TI Reactivity of five different antibodies with benign and malignant melanocytic lesions
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
AB At the histological examination of an increasing number of melanocytic tumors there is a need to use various immunohistochemical methods. Nowadays we are supplied by several antibodies working well on formalin-fixed, paraffin-embedded samples. We have tested fi ve antibodies (S-100, HMB-45, Melan-A, MITF, PNL-2) on 34 benign and 34 malignant melanocytic tumors. We examined the specificity and sensitivity in the junctional and dermal component separately, with special consideration to features disturbing the evaluation (regression, halo-like inflammation, etc.). We have concluded that the histological diagnosis of melanocytic tumors is based on the detailed examination of traditional HE slides and the immunohistochemical methods only confirm or weaken our opinion.
C1 [Plotar, Vanda] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Plotar, V (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
EM plotar.vanda@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 363
EP 373
PG 11
ER

PT J
AU Hajdu, M
   Krutsay, M
   Chanis, W
AF Hajdu, Maria
   Krutsay, Miklos
   Chanis, William
TI Gastrointestinal manifestation of Recklinghausen's disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Recklinghausen-kor; neurofibromatosis; neurofibroma; neurinoma
ID Recklinghausen-kor; neurofibromatosis; neurofibroma; neurinoma
AB In a 52-year-old women suffering in Recklinghausen's disease, operated for acute abdomen, subserous neurinomas and neurofibroma were found on the jejunum and in the mesentery. Gastrointestinal tumors (neurofibroma, GIST, carcinoid etc.) should be considered in patients with Recklinghausen's disease and gastrointestinal symptoms.
C1 [Hajdu, Maria] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi Frigyes u. 1., 8401 Ajka, Hungary.
   [Krutsay, Miklos] Magyar Imre Korhaz, Patologiai Osztaly, Koranyi Frigyes u. 1., 8401 Ajka, Hungary.
   [Chanis, William] Magyar Imre Korhaz, Sebeszeti OsztalyAjka, Hungary.
RP Krutsay, M (reprint author), Magyar Imre Korhaz, Patologiai Osztaly, 8401 Ajka, Hungary.
EM krutsaym@korhazajka.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 375
EP 377
PG 3
ER

PT J
AU Tatrai, P
AF Tatrai, Peter
TI Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE agrin; hepatocellularis carcinoma; bazalis membran; tumor-angiogenezis; differencialdiagnosztika
ID agrin; hepatocellularis carcinoma; bazalis membran; tumor-angiogenezis; differencialdiagnosztika
AB Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and is the fifth most common malignancy worldwide. HCC typically develops in the cirrhotic liver. Our preliminary results indicated that agrin, a heparan sulfate proteoglycan (HSPG) detected by us for the first time in the liver, accumulates in the basement membranes (BMs) of the cirrhotic liver and HCC. This novel finding prompted us to investigate the role of agrin in the pathogenesis and diff erential diagnosis of HCC. First, the previously unspecified monoclonal antibody anti-HSPG clone 7E12 was verifi ed as anti-agrin, using mass spectrometry. Our subsequent experiments were carried out on specimens from 131 patients with chronic liver disease and 18 individuals with healthy liver, from 4 rats subjected to cirrhosis/HCC induction and 1 untreated control rat, as well as from cultured cells. In both human and rats, significantly increased expression of agrin in cirrhosis and HCC was demonstrated by immunohistochemistry (IHC), Western blot, and quantitative RT-PCR. By double immunofluorescen studies, agrin was localized to the muscular layer of blood vessel walls, the BM of bile ducts and ductular reaction, the microvessel walls of HCC, and occasionally the BM of hepatocellular tumor cells. Colocalization, gene expression, and mRNA in situ hybridization experiments suggested that the sources of agrin include vascular smooth muscle cells, epithelial cells of bile ducts and ductules, activated mesenchymal cells in the stroma of hepatocellular tumors, and occasionally tumor hepatocytes. Agrin in the BMs of bile ducts and blood vessels is thought to play an important role in the survival of bile duct epithelium and vascular endothelium, respectively. Thus, agrin may contribute to the formation of ductular reaction and HCC neovessels. As opposed to HCC neovessels that were consistently found agrin-positive, normal and cirrhotic sinusoids were always devoid of agrin, raising the possibility that agrin IHC might be useful in the differential diagnosis of benign versus malignant hepatocellular lesions. Agrin IHC was performed on 68 benign lesions (8 large regenerative nodules, 23 low-grade and 7 high-grade dysplastic nodules, 30 liver adenomas) and 29 malignant lesions (8 small HCC, 21 HCC), and was evaluated semi-quantitatively. Based on the results of IHC for agrin as well as CD34, a decision algorithm was devised that differentiated benign and malignant parenchymal lesions with a sensitivity of 93.1% and a specificity of 92.6%. Hence, we propose that agrin IHC might help distinguish between malignant hepatocellular lesions and their benign mimickers.
C1 [Tatrai, Peter] Semmelweis University, School of PhD Studies, Ulloi ut 93., 1091 Budapest, Hungary.
RP Tatrai, P (reprint author), Semmelweis University, School of PhD Studies, 1091 Budapest, Hungary.
EM tatpeter@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 379
EP 383
PG 5
ER

PT J
AU Kiss, J
AF Kiss, Judit
TI Examination of different factors influencing the vascularization of human cutaneous melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE melanoma malignum; vaszkularizacio; immunsejtek; hyperforin; tumorellenes szer
ID melanoma malignum; vaszkularizacio; immunsejtek; hyperforin; tumorellenes szer
AB We analyzed the relationship among microvessel density (MVD) and tumor infiltrating cells in cutaneous malignant melanoma. We also studied the effect of hyperforin on tumor- and endothelial cell growth in vitro and in vivo. The density of lymphocyte subpopulations, macrophages, dendritic cells and CD34+ microvessels was determined by immunohistochemistry in primary tumor samples from 52 patients with melanoma thicker than 1 mm. The antiproliferative effect of hyperforin was studied on 16 human- and 7 rat cell lines and on human dermal microvascular endothelial cells (HDMEC). Intratumoral MVD did not show significant association with infiltration for any of these cell types. In the case of peritumoral reactive cell densities analyzed in the whole patient population, significant correlation was found with CD3+ T-cell density. This association was stronger in melanomas >4.0 mm and in visceral metastatic tumors. In these subgroups similar phenomenon was observed for CD8+ cells. We found significant correlation of MVD with CD68+ macrophage density only in the highest thickness category, and weak associations with Bcell and dendritic cell infiltration in visceral metastatic cases. MVD did not vary significantly in tumors categorized according to thickness, location, ulceration or histological type. However, both intratumoral MVD and macrophage infiltration were significantly higher in male patients compared to females. Hyperforin inhibited tumor cell proliferation and induced apoptosis. In vitro, it blocked capillary formation of HDMEC on a complex extracellular matrix. Furthermore, hyperforin reduced proliferation of HDMEC, without displaying toxic effects or inducing apoptosis. In Wistar rats hyperforin inhibited tumor growth and reduced tumor vascularization. Since the net outcome of the enrichment in tumor-infiltrating host cells and in tumor vascularization cannot be easily predicted, further clinicopathological studies are needed on human skin melanoma patients. Hyperforin holds the promise of being an interesting antineoplastic and antiangiogenic agent with low toxicity.
C1 [Kiss, Judit] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Kiss, J (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM kisjudit@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 385
EP 389
PG 5
ER

PT J
AU Toth, J
   Szanto, J
AF Toth, Judit
   Szanto, Janos
TI Prophylaxis of chemotherapy-induced vomiting and nausea
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE kemoterapia kivaltotta hanyinger es hanyas; 5-HT3-receptor blokkolok
ID kemoterapia kivaltotta hanyinger es hanyas; 5-HT3-receptor blokkolok
AB Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.
C1 [Toth, Judit] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Szanto, Janos] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Toth, J (reprint author), University of Debrecen, Department of Oncology, 4032 Debrecen, Hungary.
EM szantoj@dote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 391
EP 394
PG 4
ER

PT J
AU Baki, M
AF Baki, Marta
TI Beszamolo az Amerikai Klinikai Onkologiai Tarsasag 44. Kongresszusarol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Baki, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2008
VL 52
IS 4
BP 397
EP 398
PG 2
ER

PT J
TI Editor's pages
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 5
EP 6
PG 2
ER

PT J
AU Fodor, J
AF Fodor, Janos
TI Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional risk factors and biomarkers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE invaziv emlorak; adjuvans sugarkezeles; prognosztikai faktorok
ID invaziv emlorak; adjuvans sugarkezeles; prognosztikai faktorok
AB Adjuvant radiotherapy after modified radical mastectomy and breast-conserving surgery for early-stage invasive breast cancer substantially reduces the risk of locoregional failure and is evidence-based. Using traditional clinical and pathological factors, patients can be classified into subgroups by the risk of locoregional recurrence. In the high-risk groups the absolute benefit of irradiation is larger. However, the patients are over-treated in every subgroup. Substantial proportion of the patients remains free of locoregional recurrence even in the absence of irradiation, and some patients develop locoregional recurrence despite postoperative irradiation. Molecular markers may provide sufficient information to allow accurate individual risk assessment to identify patients who might benefit from irradiation. Despite of hundreds of reports on tumor markers, results are controversial and the number of validated markers for clinical practice is small. Prognostic and predictive factors commonly used in radiotherapy practice are ER, PgR and HER-2. Adjuvant radiotherapy not only reduces locoregional recurrence rates but also improves cancer-specific survival in patients receiving systemic therapy. The highest mortality reduction is observed in mastectomy patients with good prognostic factors (<4 positive nodes, tumor size <2 cm, Grade 1 malignancy, ER- and PgR-positive, HER-2-negative). After mastectomy the chest wall, and after breast conserving surgery the ipsilateral breast are the sites at greatest risk of recurrence. The risk of axillary recurrence is low in patients undergoing axillary dissection. Axillary and supraclavicular recurrences generally forecast a grim prognosis, and they are indicators of distant dissemination. Improvement in survival resulting from the use of irradiation is more related to the prevention of local recurrences. Post-irradiation local recurrence increases the risk of mortality, but with good prognostic factors the 10-year survival is 80&#8211;90%. Patients with &#8804;2 cm ipsilateral breast recurrence might receive a second conservative surgery. The radiation dose to the lung and heart can be significantly reduced by individualized CT-based treatment planning. The rate of Grade 3 atrophic dermatitis and fibrosis is 3&#8211;4%. The estimated incidence of ipsilateral breast angiosarcoma is less than 0.2%, but the mortality rate is high.
C1 [Fodor, Janos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM fodor@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 7
EP 14
PG 8
ER

PT J
AU Zsiray, M
   Markoczy, Zs
   Magyar, M
   Lengyel, Zs
   Fekeshazy, A
   Borbely, K
AF Zsiray, Miklos
   Markoczy, Zsolt
   Magyar, Melinda
   Lengyel, Zsolt
   Fekeshazy, Attila
   Borbely, Katalin
TI The advantage of Positron Emission Tomography combined with Computer Tomography (PET-CT) in the diagnosis of lung cancer, our own experience with 408 patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE PET-CT; nem kissejtes tudorak; stadiumba sorolas; onkologia
ID PET-CT; nem kissejtes tudorak; stadiumba sorolas; onkologia
AB The authors analyzed the results of PET-CT scans made with oncological indications among 408 patients. One hundred and fifty-four PET-CTs were done to characterize pulmonary foci, after which in 59 cases lung surgery was performed. The method&#8217;s sensitivity in respect to malignancy was 100%, specificity was 56%. Staging of affected lymph nodes resulted in 17 mediastinoscopies and 54 thoracotomies. In the former indications PET-CT-positive lymph nodes always need cytologic/histologic verification. M-staging done with PET-CT was performed in 141 cases, mediastinal restaging of patients having received neoadjuvant chemotherapy was done in 24 cases. The latter indications we consider superfluous because of the diagnostic inaccuracy of PET-CT. In 175 cases we analyzed the frequently determining factor of the PET-CT scan in the indication of lung surgery. The authors wish to share their experience for the better use of this method and to accelerate the inclusion of PET-CT into the diagnostic protocol.
C1 [Zsiray, Miklos] National Koranyi Institute of Pulmonology, Piheno ut 1., 1525 Budapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of Pulmonology, Piheno ut 1., 1525 Budapest, Hungary.
   [Magyar, Melinda] National Koranyi Institute of Pulmonology, Piheno ut 1., 1525 Budapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Fekeshazy, Attila] National Institute of NeurosurgeryBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Zsiray, M (reprint author), National Koranyi Institute of Pulmonology, 1525 Budapest, Hungary.
EM zsiray@koranyi.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 17
EP 21
PG 5
ER

PT J
AU Vereczkey, I
   Toth, E
   Orosz, Zs
AF Vereczkey, Ildiko
   Toth, Erika
   Orosz, Zsolt
TI Diagnostic difficulties of serous borderline tumors of the ovary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE petefeszek; serosus; borderline; tumor
ID petefeszek; serosus; borderline; tumor
AB About 15-20% of all ovarian neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential). They represent a common diagnostic and treatment problem both for the pathologist and for clinicians. The borderline tumors occur most commonly in childbearing age, show an indolent course and have good prognosis but are resistant to the traditional chemotherapies. The serous borderline tumors are the most common types of borderline ovarian tumors and they can cause differential diagnostic problems even for the experienced pathologist. We studied 30 cases which were diagnosed in our institute from 2000 to 2008. Thirteen were typical serous borderline tumors, in 7 cases the pattern was micropapillary, in 2 cases with microinvasion and in the remaining 8 cases the borderline tumors were associated with low-grade serous carcinomas. Seventeen of the 22 borderline cases were stage I tumors. There were noninvasive implants in the remaining 5 cases and in the cases of the low-grade carcinomas we could find, besides the noninvasive implants (in 3 cases), invasive implants or metastasis too. The main diagnostic problems in serous ovarian borderline tumors are the presence of micropapillary pattern, to detect microinvasion, or to differentiate the pseudo-borderline pattern of the low-grade serous tumors from a real borderline tumor and especially to diagnose the extraovarian diseases (types of implants). We discuss these diagnostic problems and criteria according to recent literature and our experience.
C1 [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Vereczkey, I (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM vereczkey.ildiko@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 23
EP 31
PG 9
ER

PT J
AU Molnar, P
   Mehes, G
AF Molnar, Peter
   Mehes, Gabor
TI Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE astrocytoma; oligodendroglioma; prediktiv markerek; MGMT-metilacio; EGFRgenetika; 1p19q-delecio
ID astrocytoma; oligodendroglioma; prediktiv markerek; MGMT-metilacio; EGFRgenetika; 1p19q-delecio
AB The authors review the current literature on the major biological advances in the molecular testing of brain tumors. The incorporation of several new aspects required for proper disease management into the classical pathology service is in the focus of the review. One of the important achievements of the last years in neuro-oncology is the observation that the promoter methylation status of the MGMT (O6-methylguanine DNA methyltransferase) gene determines the treatment efficacy of temozolomide (Temodal) in glioblastomas. This can best be evaluated by methylation-specific PCR (MSP) using tumor tissue obtained for histological evaluation. Further to this, up-regulation of EGFR signaling through gene amplification has been recognized and targeted by anti-EGFR approaches in high-grade gliomas. The EGFRvIII mutant receptor is practically unique to glioma cells hence analysis of EGFR seems to be justifiably demanded either by oncologists or patients. Immunohistochemistry (IHC) can easily be included in routine laboratory workflow. In addition to this FISH analysis can be performed for the assessment of EGFR gene copy numbers at cellular level. Studying the EGFR status at a genetic and simultaneously at the protein expression level seems to be a valid approach for making treatment decision. Similarly complex and even less clear biological background characterizes the behavior of tumors with oligodendroglial differentiation. The deletion of the chromosomal regions 1p and 19q was found to be associated with favorable outcome and good response to the PCV treatment protocol. Therapeutic decisions are therefore also enabled on the basis of the 1p/19q status. Concurrent temozolomide/radiation therapy is often indicated on the basis of 1p/19q testing. The 1p/19q status can be assessed by FISH or, less frequently, by aCGH or LOH assay. Based on the in-depth overview of the literature the authors highly recommend the adaptation of molecular glioma testing that most efficiently could be done in centralized neuropathology laboratories. This approach would comply with the increasing need for personalized ("tailored") therapy while best satisfying cost/benefit issues.
C1 [Molnar, Peter] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Molnar, P (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, 4032 Debrecen, Hungary.
EM molnarp@dote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 33
EP 38
PG 6
ER

PT J
AU Piko, B
   Bassam, A
AF Piko, Bela
   Bassam, Ali
TI Treatment of tumor therapy-induced nausea and vomiting
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE hanyascsillapitas; kemoterapia; sugarterapia; neurokininreceptor-antagonista; ajanlasok
ID hanyascsillapitas; kemoterapia; sugarterapia; neurokininreceptor-antagonista; ajanlasok
AB Even today, nausea and vomiting are two of the most distressing adverse effects associated with tumor therapy. The authors give an overview of the mechanism and the trigger factors (emetogenic potential of the chemotherapies, the patient risk factors, and the used antiemetic drugs) of nausea and vomiting. A short summary will describe the antiemetic drugs focusing on metoclopramid, steroid and the currently widely used setron therapy which is effective only during the acute phase of chemotherapy-induced nausea and vomiting (CINV). In the treatment of CINV the latest improvement was the introduction of the neurokinin (NK1) receptor antagonist class. Currently the only available agent is aprepitant which is indicated to treat CINV in case of highly and moderately emetogenic chemotherapies. The pivotal phase III trials defi ned that aprepitant is the first drug that is able to protect against the delayed phase of CINV plus can improve the antiemetic therapy during the acute phase. Currently aprepitant is reimbursed in Hungary only after the failure of setron therapy in case of high dose (>50 mg/m2) cisplatin protocols. The authors give a recommendation how to treat CINV based on the latest international antiemetic guidelines. The mechanism and the trigger factors of radiotherapy-induced nausea and vomiting (RINV) are different from CINV. For treatment of RINV metoclopramid (due to reimbursement regulation) and ondansetron can be used. In case of radio-chemotherapy the antiemetic treatment should follow the CINV guidelines.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM piko_b@pandy.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 39
EP 45
PG 7
ER

PT J
AU Dobos, J
AF Dobos, Judit
TI Endocrine factors influencing melanoma progression
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; nemi hormonok; 2-metoxi-osztradiol; apoptozis
ID melanoma; nemi hormonok; 2-metoxi-osztradiol; apoptozis
AB According to recent findings that beside cancers traditionally considered as hormone-dependent, several other tumor types show different behavior in the two sexes, indicating the possible role of endocrine factors in the course of these diseases. The possibility that endocrine factors may influence the clinical course of human malignant melanoma is suggested by the higher survival rate in premenopausal vs. postmenopausal women or men of any ages. However, investigations on the sex hormone receptor status of human cutaneous melanomas and experiments attempting to support the epidemiological results yielded conflicting results. In our human melanoma cell lines we failed to detect steroid receptors at protein level, while quantitative PCR demonstrated that their mRNA expression level was orders of magnitude lower compared to the positive control cell lines. Sex hormones did not influence the in vitro features of the human melanoma cells considerably. On the other hand, glucocorticoid receptor was present both at mRNA and protein level, although dexamethasone was effective in vitro only at high doses. Our previous experiments showed that intrasplenic injection of human melanoma cells resulted in a significantly higher number of liver colonies in male than in female SCID mice. We now show that this difference evolves during the first day. After injection into the tail vein we did not observe gender-dependent difference in the efficiency of pulmonary colonization. Examining the pattern of metastasis formation after intracardiac injection, we have found differences between the two sexes in the incidence or number of colonies only in the case of the liver but not in other organs. We concluded that the observed phenomenon is specific to the liver; therefore we investigated the effects of 2-methoxyestradiol, an endogenous metabolite of estradiol produced mainly in the liver, with an estrogen receptor-independent antitumor activity. 2ME2 effectively inhibited melanoma cell proliferation by inducing apoptosis and an arrest in the G2/M phase. The mechanism of action involved microtubules, mitochondrial damage and caspase activation as well. In SCID mice, 2ME2 was effective in reducing primary tumor weight and the number of liver colonies after intrasplenic injection of human melanoma cells, and causing significantly higher rate of apoptotic cells in the colonies.
C1 [Dobos, Judit] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Dobos, J (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 47
EP 50
PG 4
ER

PT J
AU Lukits, J
AF Lukits, Julia
TI The effect of the microenvironment of head and neck cancers on tumor progression
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE fej-nyaki laphamrak; mikrovaszkularis denzitas; progresszio; hormonreceptorok; immunterapia
ID fej-nyaki laphamrak; mikrovaszkularis denzitas; progresszio; hormonreceptorok; immunterapia
AB In the last 20 years the incidence and mortality of head and neck squamous cell carcinomas showed an increasing rate in Hungary. In our work we examined the microenvironment of head and neck cancers localized in different anatomical regions. Clinical evidence shows that the prognosis of hypopharyngeal tumors is poorer than that of head and neck cancers in other anatomical locations. We investigated if tumor size or vascularity correlates with the biological behavior of these tumors. The results showed that the tumor size of laryngeal cancers in T2 stage were significantly larger than that of hypopharyngeal cancers in T4 stage. Regarding the vascularity or VEGF expression we did not find any difference between these two tumor types, suggesting that the more aggressive behavior of hypopharyngeal cancers is probably due to the invasive phenotype of this tumor, an assumption supported by genomic examination. In a prospective study we examined the relation between the microvascular density and treatment outcome in irradiated head and neck cancer patients. We demonstrated that the decreased vascularity induced by radiotherapy is a predictive marker of treatment success. We have investigated the role of the endocrine environment in tumor progression, determining the hormone receptor status of head and neck cancers using immunohistochemical and molecular methods. Results showed that ER and PGR are expressed in almost half of the examined tumors, and the presence of functional ER was also frequent in these cases (40.3%), while the solitaire hormone receptor expression was a rare phenomenon. Expression of hormone receptors in all the examined cases did not show any correlation with patient survival but in the laryngeal/hypopharyngeal group ER positivity was associated with a shortened survival (p=0.0636). In a multicenter phase I/II clinical trial we examined the tumoral and stromal effects of a natural leukocyte interleukin (LI) in oral squamous cell cancers. LI was administered locally in four different doses. The proportion of tumor cell nests and tumor stroma decreased significantly after LI treatment (induction of fibrosis), which was associated with the induction of necrosis. Morphometric determination of Ki-67+ cells showed a tendency of cycling stromal cells to decrease in response to treatment by the different doses of LI, while lower doses of LI produced a temporary increase in cycling tumor cells. Density of intraepithelial neutrophils was higher after LI treatment, and the stromal density of neutrophils was higher in the responder subgroup. In the tumor stroma macrophage density was similar in the treated and control cases, while a significant decrease of these cells was observed intraepithelially. Finally, we were not able to detect CD34+ immunosuppressive mononuclear cells in these tumors. Our examinations supported the theory that the tumor stroma and its components play an important role in tumor progression, and therapeutic modulation of these components can influence the progression.
C1 [Lukits, Julia] Semmelweis University, School of PhD Studies, Kuruclesi ut 11/c., 1021 Budapest, Hungary.
RP Lukits, J (reprint author), Semmelweis University, School of PhD Studies, 1021 Budapest, Hungary.
EM jlukits@t-online.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 51
EP 59
PG 9
ER

PT J
AU Kaposi-Novak, P
AF Kaposi-Novak, Pal
TI Comparative genomic classification of human hepatocellular carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE maj; hepatocellularis karcinoma; transzgen eger; genexpresszio; genomikai klasszifikacio
ID maj; hepatocellularis karcinoma; transzgen eger; genexpresszio; genomikai klasszifikacio
AB Global transcriptome analysis has been successfully applied to characterize various human tumors, including hepatocellular carcinomas. This novel technology can facilitate early discovery as well as prognostic and therapeutic diversification of cancer patients. To enhance access to the genomic information buried in archived pathology samples, we assessed RT-PCR amplification rates in paraffin-embedded tissues preserved in three different fixatives. Reliable amplification could be achieved from all paraffin-embedded specimens, when the amplicon size did not exceed 225 bp. A longer amplicon size resulted in rapid decrease of yield and reproducibility. In addition, formalin provided superior morphology and better reactivity with claudin-4 and -7 immunohistochemistry. Amplification of the initial sample is often required before transcriptome analysis of clinical specimens could be performed. We introduced a random nonamer primed T3 polymerase reaction into the conventional linear RNA amplification protocol. The modified T3T7 method generated a sense strand product ideal for synthesizing indirectly labeled cDNA templates. Microarray analysis of amplified frozen and laser-microdissected Myc and Myc/TGF&#945; mouse liver tumors confirmed good reproducibility (r=0.9) of the reaction and conservation of original transcriptional patterns (r=0.78). Finally, we tested the utility of expression profiling for the classification of human HCC samples. By comparing expression data from HGF-treated c-Met conditional knock-out and control primary mouse hepatocytes, we identified 690 HGF/c-Met target genes. Functional analysis of the significant gene set implicated c-Met as key regulator of hepatocyte motility and oxidative homeostasis. Cross comparison of the c-Met-induced transcription signature with human HCC expression profiles revealed a group of tumors (27%) with potentially activated c-Met signaling (MET+). These tumors were characterized by higher vascular invasion rate, increased microvessel density, and shortened survival. A prediction model based on 111 cross-species conserved c-Met signature genes was able to diversify HCC patients into good and bad prognostic groups with 83-95% accuracy. Our results therefore demonstrate that careful experimental design and state-of-the-art laboratory methods could open the way for global expression profiling of archived and limited availability pathologic samples. Comparative functional genomics based analysis of the cancer transcriptome could lead to novel molecular classification systems which are essential for the introduction of individualized cancer therapeutics.
C1 [Kaposi-Novak, Pal] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Kaposi-Novak, P (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 61
EP 67
PG 7
ER

PT J
AU Kasler, M
   Moskovits, K
   Szucs, M
AF Kasler, Miklos
   Moskovits, Katalin
   Szucs, Miklos
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2008. szeptember 26-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2009
VL 53
IS 1
BP 69
EP 76
PG 8
ER

PT J
AU Landherr, L
   Nagykalnai, T
AF Landherr, Laszlo
   Nagykalnai, Tamas
TI Chemotherapy of elderly patients with colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kolorektalis rak; idos beteg; szisztemas kezeles; kemoterapia; celzott terapia
ID kolorektalis rak; idos beteg; szisztemas kezeles; kemoterapia; celzott terapia
AB Elderly patients will be the largest group of oncology patients in the future. Because of minimal participation of older patients in randomized clinical trials there is a lack of evidence-based data to make correct decisions with regard to chemotherapy and/or targeted therapy in this age group. Elderly patients have similar benefits from systemic therapies as younger counterparts, but many elders have substantial co-morbidities, which may limit the life expectancy and the effectiveness of systemic therapy. Close collaboration between oncologists and geriatrists will help make decisions on the management of elderly patients suffering from cancer.
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Nagykalnai, Tamas] Bajcsy-Zsilinszky Korhaz Rendelointezet, Onkologiai GondozoBudapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM landherr@uzsoki.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 97
EP 105
PG 9
ER

PT J
AU Bogner, B
   Hegedus, G
AF Bogner, Barna
   Hegedus, Geza
TI The importance of elastic staining in detecting vascular invasion in colorectal carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE colorectalis carcinoma; elasztikus festes; erinvazio
ID colorectalis carcinoma; elasztikus festes; erinvazio
AB Venous invasion (VI) is one of the most important prognostic factors in colorectal carcinomas (CRC). The interobserver variation of this feature varies between 10% and 89.5%, mainly due to the specimen processing and staining. VI was assessed using haematoxylin and eosin (H+E) alone in 611 cases and with elastic stain (orcein-haematoxylin) in 243 CRCs. The stage, the pattern of invasion and the presence of intramural and extramural VI were determined. VI was identified in 27.45% of the H+E stained sections and in 67.1% using elastic stain counterstained with haematoxylin. The incidence of VI proved stage dependent as it has been noted in 13% of Dukes A, 36% of Dukes B, 80% of Dukes C and in 83% of CRCs with distant metastasis. The pattern of invasion is strongly connected to the VI, accordingly, VI could be identified in 82% of CRCs with invasive and only in 44% with expansive margin. The use of elastic stain did not help in differentiation of extramural tumour deposits due to the damage of elastic membranes in the vascular walls and the presence of elastic fibres in the lymph node capsule. As a conclusion, the routine use of elastic stains in our practice doubled the identification of VI. The frequency of VI depends on the stage and pattern of invasion in CRCs. As it is more likely to occur in the advanced CRCs, the use of elastic stain is even more suggested in Dukes B carcinomas with invasive margin.
C1 [Bogner, Barna] Balassa Janos County Hospital, Department of Pathology, Beri Balogh Adam u. 5-7., 7100 Szekszard, Hungary.
   [Hegedus, Geza] County Hospital of Baranya, Department of PathologyPecs, Hungary.
RP Bogner, B (reprint author), Balassa Janos County Hospital, Department of Pathology, 7100 Szekszard, Hungary.
EM bogner.barna@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 107
EP 113
PG 7
ER

PT J
AU Berhidi, A
   Szluka, P
   Vasas, L
AF Berhidi, Anna
   Szluka, Peter
   Vasas, Livia
TI New bibliometric indicators. Is this the end of the impact factor era?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tudomanymetria; teljesitmenymutatok; idezettseg; onkologia; folyoiratok
ID tudomanymetria; teljesitmenymutatok; idezettseg; onkologia; folyoiratok
AB More and more bibliometric indicators emerge beside the impact factor, and a few of them are promising performance indicators. The aim of the study is to show briefly, but clearly the newest bibliometric measure numbers - like the recent enhancements of Journal Citation Report Web, Hirsch-index, Eigenfactor and SCImago Journal & Country Rank algorithms - focusing on the ranking of oncological journals, and to demonstrate the similarities and differences of the results with some examples. There are unified and well-structured web pages behind the newly appeared indicators, and some of the new numbers are presented in the well-known databases (Web of Science, Scopus) as scientific measures. The ranking of the compared oncological journals based on the different indicators show more similarities than differences, but more in-depth studies are required to find out how the results converge on any scientific area. There are some other methods, such as usage factor of the journals, beyond the indicators based on the citations. But the main point is that any ranking system should be a valid and correct representation of the scientific quality.
C1 [Berhidi, Anna] Semmelweis Egyetem, Kozponti Konyvtar, Mikszath ter 5., 1088 Budapest, Hungary.
   [Szluka, Peter] Semmelweis Egyetem, Kozponti Konyvtar, Mikszath ter 5., 1088 Budapest, Hungary.
   [Vasas, Livia] Semmelweis Egyetem, Kozponti Konyvtar, Mikszath ter 5., 1088 Budapest, Hungary.
RP Berhidi, A (reprint author), Semmelweis Egyetem, Kozponti Konyvtar, 1088 Budapest, Hungary.
EM aberhidi@lib.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 115
EP 125
PG 11
ER

PT J
AU Vereczkey, I
   Toth, E
   Orosz, Zs
AF Vereczkey, Ildiko
   Toth, Erika
   Orosz, Zsolt
TI Diagnostic problems of ovarian mucinous borderline tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE petefeszek; borderline; mucinosus
ID petefeszek; borderline; mucinosus
AB About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors. The borderline tumor is a serious diagnostic and treatment problem both for the pathologists and for clinicians. These tumors appeared to be intermediate in their histologic and prognostic features between the benign cystadenomas and clearly malignant carcinomas. The borderline tumors occur most commonly in childbearing age, and show an indolent course. Their prognosis is good, but they are resistant to the traditional chemotherapies. To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases. Eleven cases diagnosed as mucinous borderline ovarian tumor in our institute from 2000 to 2008 were reviewed. Eight out of 11 were intestinal type while three were cervical (mullerian) type. In 5 cases our diagnosis was intraepithelial carcinoma and in 5 cases we found microinvasion. We discuss all of these problems according to the latest literature and our experience, mentioning the problems of the peritoneal and ovarian pseudomyxomas.
C1 [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Zsolt] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Vereczkey, I (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM vereczkey.ildiko@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 127
EP 133
PG 7
ER

PT J
AU Piko, B
AF Piko, Bela
TI Panitumumab-treatment of metastatic colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE panitumumab; EGFR; K-ras; human monoklonalis antitest; citosztatikus kezeles utani monoterapia
ID panitumumab; EGFR; K-ras; human monoklonalis antitest; citosztatikus kezeles utani monoterapia
AB In the molecular target treatment strategy of metastatic colorectal cancer patients panitumumab represents a new class of drugs due to its fully human nature, and no need for premedication and loading dose. Panitumumab binds to epidermal growth factor receptor (EGFR) selectively. In registration pivotal studies the analysis of patient subgroups for KRAS status gives strong evidence for the important role of RAS oncogene: median progression-free survival was 16 weeks on panitumumab arm in KRAS wildtype patients (8 weeks in best supportive care), while in KRAS mutant patients panitumumab showed no efficacy, however adverse events were more frequent and severe. According to SmPC, panitumumab is indicated as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- , and irinotecan-containing chemotherapy regimens. Adverse events are similar as with other EGFR inhibitors: skin symptoms (rash), lung infiltrates, diarrhoea, ion abnormalities of renal origin. The drug was formerly available via named patient reimbursement, and now is financed by diagnosis-related group (DRG) system.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM piko_bhome@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 135
EP 142
PG 8
ER

PT J
AU Zatkone Puskas, G
AF Zatkone Puskas, Gabriella
TI The role of oncology nurses in the treatment with zoledronic acid / what can we do for our patient's compliance?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE zoledronsav; biszfoszfonat-terapia; az apolok szerepe; terapias huseg; betegcompliance
ID zoledronsav; biszfoszfonat-terapia; az apolok szerepe; terapias huseg; betegcompliance
AB Patients with cancer and bone metastasis usually need to be treated with bisphosphonates to reduce or delay skeletal complications (pathologic fracture, hypercalcemia, surgery or radiotherapy). The nurses can provide important education to patients, support and encourage use of bisphosphonates throughout therapy. Literatures, trainings, congress reports provide useful information about bisphosphonate therapy, side effects, adverse events etc. However, patients need more information to support them during courses. To optimize the care, nurses can monitor pain scores, changes in mobility, adverse events, creatinin clearance levels. A useful tool for recording these parameters is a patients-diary. The nurse should fill out the diary at each patients visit and compare it to the baseline information before treatment. At the same time they can get some information from the patient's performance (adequate hydration, dental hygiene). Nurses play an important role in the care of patients during bisphosphonate therapy and in supporting patients to continue treatment to preserve their functional independence.
C1 [Zatkone Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29-41., 1145 Budapest, Hungary.
RP Zatkone Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM zatko.gabi@uzsoki.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 145
EP 148
PG 4
ER

PT J
AU Vegso, Gy
AF Vegso, Gyula
TI Posttransplantation malignant tumors and the challenges of immunosuppressive therapy in transplantanted patients developing lymphoma. Mycophenolic acid - a possibility
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE szervatultetes; immunszuppresszio; rosszindulatu daganat; lymphoma; mycophenolsav
ID szervatultetes; immunszuppresszio; rosszindulatu daganat; lymphoma; mycophenolsav
AB The increasing frequency of malignant tumors developing during chronic immunosuppression is an important determinant of the long-term survival of organ transplanted patients. This problem can be solved only if we are aware of the special characteristics concerning our patients. The incidence and frequency of tumors occurring in kidney transplant recipients differ from those of the Hungarian population. The increased tumor risk resulting from chronic renal failure, increasing age of prospective kidney recipients and, in addition, the increasing frequency of tumors diagnosed in the early post-transplantation period emphasize the importance of regular oncological screening of patients on the waiting list. Early diagnosis and treatment of tumors and precancerous conditions are equally important in transplanted patients as well, and the tumor risk could be decreased by applying low dose immunosuppression and the preferential usage of immunosuppressive drugs with an oncologically favorable effect. The prognosis of post-transplantation tumors is poor, as they respond poorly to therapy. Lymphomas are of great importance because of their frequency. Different immunosuppressive regimens represent varying degrees of risk in lymphoma development. This risk is lower in the case of mycophenolic acid. The composition of immunosuppression is a major factor in treatment; an oncologically ideal compound would prevent organ rejection and, at the same time, would not counteract oncological therapy. We have shown that mycophenolic acid inhibits the proliferation of human B-cell non-Hodgkin lymphomas and induces apoptosis by activating the intrinsic pathway, both in vitro and in vivo. The favorable properties of mycophenolic acid suggest that it can provide the necessary immunoprotection for the transplanted organ and, given its anti-lymphoma effects, it may also prove useful in the therapy of lymphoma patients. It may also be helpful in the treatment of "traditional" lymphomas of the non-transplanted population, where the major cause of therapeutical failure is the development of apoptosis resistance. Mycophenolic acid, combined with other chemotherapeutical drugs, may enhance apoptosis in lymphoma cells. Our promising experimental results provide a basis for further, clinical studies.
C1 [Vegso, Gyula] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Vegso, Gy (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 149
EP 156
PG 8
ER

PT J
AU Remenar, �
AF Remenar, Eva
TI Cytogenetic and hormonal changes in head and neck squamous cell cancer patients: potential biomarkers for functional approaches in surgical oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE fej-nyaki rak epidemiologiaja; prognozis; biomarkerek; kromoszomaaberraciok; mutagenerzekenyseg; hypophysishormonok; szexszteroidhormonok
ID fej-nyaki rak epidemiologiaja; prognozis; biomarkerek; kromoszomaaberraciok; mutagenerzekenyseg; hypophysishormonok; szexszteroidhormonok
AB Squamous cell cancer of the head and neck (SCCHN) is the third most common cause of death from cancer among Hungarian males. This cancer is caused in most of the cases by chronic toxic effects of the environment, especially by tobacco smoking and regular alcohol consumption. SCCHNs similar for the first sight, might have different clinical course, mainly because of their different responses to anticancer therapies. In this study, potential biomarkers were examined that were thought to develop as biologic responses to the known environmental toxicities, therefore, their testing is supposed to help answer the most important questions of clinical oncology: understanding tumor development, early detection of cancer and individually tailored therapy planning based on the biological nature of a particular cancer. Elevated rate of spontaneous chromosome aberrations proved to be a reliable marker of the SCCHN phenotype. However, increased mutagen sensitivity by the bleomycin-test, unlike in the US or in Western Europe, was not suitable to detect the individual cancer risk in this country, because of the high mutagen sensitivity of more than half of the healthy Hungarian population examined. In the light of the high cancer incidence and mortality statistics of Hungary, the frequency of elevated mutagen sensitivity even among healthy people is a meaningful finding, and requires further clarification. Our studies on the hormonal status of male SCCHN patients revealed some pathological changes in the sex steroid and pituitary hormone serum levels, which most probably accompanied chronic alcoholic liver disease. The elevated prolactin and decreased total and free testosterone levels predicted poor prognosis of the disease. The importance of the potential relationship between hormones and SCCHN is underscored by our further finding of functioning estrogen and progesterone receptors in SCCHN tissue of our patients.
C1 [Remenar, Eva] Szegedi Tudomanyegyem, Doktori IskolaSzeged, Hungary.
RP Remenar, � (reprint author), Szegedi Tudomanyegyem, Doktori Iskola, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 157
EP 164
PG 8
ER

PT J
AU Kasler, M
   Moskovits, K
   Szucs, M
AF Kasler, Miklos
   Moskovits, Katalin
   Szucs, Miklos
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2008. november 21-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 167
EP 173
PG 7
ER

PT J
TI A Sugarterapias es Onkologiai Szakmai Kollegium allasfoglalasa a Vectibix(R) (Panitumumab) tarsadalombiztositasi befogadasaval kapcsolatban
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2009
VL 53
IS 2
BP 175
EP 176
PG 2
ER

PT J
AU Landherr, L
   Nagykalnai, T
AF Landherr, Laszlo
   Nagykalnai, Tamas
TI Development of the first line treatment of mCRC
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kolorektalis rak; celzott biologiai kezeles; elso valasztasu kemoterapia
ID kolorektalis rak; celzott biologiai kezeles; elso valasztasu kemoterapia
AB Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years. Besides of the standard fluorouracil/folinic acid treatment some new active agents (oxaliplatin and irinotecan) have been introduced, and more recently the "targeted" biologicals (bevacizumab, cetuximab, panitumumab) have demonstrated their high effectiveness. This review summarizes the development of the first line treatment of mCRC.
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Nagykalnai, Tamas] Bajcsy-Zsilinszky Korhaz Rendelointezet, Onkologiai GondozoBudapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM landherr@uzsoki.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 237
EP 246
PG 10
ER

PT J
AU Pesznyak, Cs
   Weisz, Cs
   Kiraly, R
   Kiss, B
   Zelic, S
   Polgar, I
   Zarand, P
AF Pesznyak, Csilla
   Weisz, Csaba
   Kiraly, Reka
   Kiss, Balazs
   Zelic, Stipan
   Polgar, Istvan
   Zarand, Pal
TI Quality control of computed tomography scanners from the aspect of radiotherapy treatment planning (Hungarian review)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE CT-szam; CT-fantom; minosegellenorzes; minosegbiztositas
ID CT-szam; CT-fantom; minosegellenorzes; minosegbiztositas
AB The aim of this publication is to review the requirements necessary for using computed tomography (CT) for radiotherapy treatment planning. The equipments were tested with different CT phantoms. The authors made several measurements for checking the CT number, the quality and the mechanical parameters of CT tables. The CT numbers measured on the equipments of different manufacturers were in quite good agreement with the IAEA requirements. The geometric distortions of CT images are negligible, while the mechanical parameters of CT tables show considerable variety. A quality assurance - quality control protocol is recommended to implement in a safe workflow.
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Weisz, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Kiraly, Reka] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Kiss, Balazs] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Zelic, Stipan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Polgar, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Zarand, Pal] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29., 1145 Budapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM csilla.pesznyak@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 247
EP 251
PG 5
ER

PT J
AU Petras, M
   Hutoczki, G
   Varga, I
   Vereb, Gy
   Szollosi, J
   Bognar, L
   Ruszthi, P
   Kenyeres, A
   Toth, J
   Hanzely, Z
   Scholtz, B
   Klekner, �
AF Petras, Miklos
   Hutoczki, Gabor
   Varga, Imre
   Vereb, Gyorgy
   Szollosi, Janos
   Bognar, Laszlo
   Ruszthi, Peter
   Kenyeres, Annamaria
   Toth, Judit
   Hanzely, Zoltan
   Scholtz, Beata
   Klekner, Almos
TI Expression pattern of invasion-related molecules in cerebral tumors of different origin
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE glioblasztoma; atteti daganat; invazio; EGFR; integrin
ID glioblasztoma; atteti daganat; invazio; EGFR; integrin
AB Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of radical surgical resection and successful treatment, with tumor recurrence as microdisseminated disease. Epidermal growth factor receptors (EGFRs), integrins and their ligands in the extracellular matrix (ECM) predominantly participate in the invasion process, including the cell adhesion to the surrounding microenvironment and cell migration. The extent of infiltration of the surrounding brain tissue by malignant tumors strongly depends on the tumor cell type. Malignant gliomas show much more intensive peritumoral invasion than do metastatic tumors. In this study, the mRNA expression of 29 invasionrelated molecules (18 cell membrane receptors or receptor subunits (EGFRs and integrins) and 11 ECM components: collagens, laminins and fibronectin) was investigated by quantitative reverse transcriptasepolymerase chain reaction. Fresh frozen human tissue samples from glioblastoma (GBM) and intracerebral bronchial adenocarcinoma metastases (five pieces from each) were evaluated. Significant differences were established in six of the 29 molecules (ErbB1, 2, 3, integrins alpha3, 7 and beta1). To confirm our results at the protein level, immunohistochemical analysis of nine molecules was performed. The staining intensity differed definitely in the case of ErbB1, 2 and integrins alpha3 and beta1. Determining the differences in invasion-related molecules in tumors of different origin can help identify the exact molecular mechanisms that facilitate peritumoral infiltration by glioblastoma cells. These results should allow the selection of target molecules for potential chemotherapeutic agents directed against highly invasive malignant gliomas.
C1 [Petras, Miklos] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Hutoczki, Gabor] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Varga, Imre] Kenezy Gyula Hospital, Department of PulmonologyDebrecen, Hungary.
   [Vereb, Gyorgy] University Medical School of Debrecen, Department of Biophysics and Cell BiologyDebrecen, Hungary.
   [Szollosi, Janos] University Medical School of Debrecen, Department of Biophysics and Cell BiologyDebrecen, Hungary.
   [Bognar, Laszlo] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Ruszthi, Peter] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Kenyeres, Annamaria] University of Medicine, The Institute of Anatomy, Histology and EmbryologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Hanzely, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Scholtz, Beata] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
RP Klekner, � (reprint author), University of Debrecen, Clinical Center, Department of Neurosurgery, 4032 Debrecen, Hungary.
EM aklekner@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 253
EP 258
PG 6
ER

PT J
AU Fulop, M
   Branzaniuc, K
   Kasler, M
AF Fulop, Miklos
   Branzaniuc, Klara
   Kasler, Miklos
TI Role of fibula in replacement of mandible
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE mandibulapotlas; fibula; fej-nyaki daganatok; mikrovaszkularis technika
ID mandibulapotlas; fibula; fej-nyaki daganatok; mikrovaszkularis technika
AB The mandible and the fibula are two totally different bones of the human skeleton. The fibula is a long straight bone of the lower leg playing secondary role compared with the tibia. The mandible, or jaw bone, is the only facial bone that moves and has complex spatial structure. The blood supply of the mandible is mainly endosteal, the inferior mandibular artery, which is one of the more important branch of the maxillary artery is responsible for its arterial supply. The fibula shows the uniform pattern of periosteal blood supply receiving many small branches from the peroneal artery, and having only weak endosteal supply. The mandible articulates with the two temporal bone, and the fibula articulates with the tibia at the tibio-fibular syndesmosis and distally has a role in the formation of the lateral talocrural joint. The demand for mandibular replacement was approved simultaneously with the appearance of ablative surgery for head and neck cancer. As knowledge of physiology and pharmacology expanded in the twentieth century, major developments in the field of anesthesiology and surgery opened new windows of ablative cancer surgery that were previously unimaginable. Soldiers were badly wounded with extensive soft - tissue defects during World Wars and in certain countries, high gun ownership rates show substantial correlations with gun-related injuries. Health care development and the invention and wide-spread use of antibiotics revolutionized medical treatment and improved recovery rates and reduced mortality following trauma. Total or partial loss of the mandible without reconstruction incurs serious functional and psychological morbidity for patients. Prior to the development of advanced reconstruction options for mandibular defects, they were left with terrible cosmetic deformities. Throughout the second half of the twentieth century, various attempts were made to replace the mandible but the major breakthrough was the appearance of the microvascular technique at the end of the seventies and the beginning of the eighties.
C1 [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Branzaniuc, Klara] Marosvasarhelyi Orvosi es Gyogyszereszeti Egyetem, Anatomia, Szovetes Fejlodestani TanszekMarosvasarhely, Romania.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1145 Budapest, Hungary.
EM fulop.m@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 259
EP 262
PG 4
ER

PT J
AU Kuronya, Zs
   Bodrogi, I
   Lovey, J
   Plotar, V
   Manninger, S
   Papai, Zs
AF Kuronya, Zsofia
   Bodrogi, Istvan
   Lovey, Jozsef
   Plotar, Vanda
   Manninger, Sandor
   Papai, Zsuzsanna
TI Metachronous metastasis to the penis from carcinoma of the rectum
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE rectum; adenocarcinoma; penis; metastasis
ID rectum; adenocarcinoma; penis; metastasis
AB Despite of its rich vascularization and extensive circulatory communication with neighboring organs, penile metastases are rare. Even more infrequent is a penile metastasis of rectum tumors. Since the first report of rectal carcinoma with metastasis to the penis (Ehbert 1870), approximately 50 cases have been reported, most of them from the USA, the remaining from Western Europe, the Middle East and Japan. The first Hungarian case is reported now of penile metastasis of a rectal carcinoma. The case of a 65-year-old man is presented: isolated penile metastasis discovered 4.5 years after the primary rectal cancer resection. IHC tissue diagnosis and detailed clinical investigations confirmed metastatic rectal adenocarcinoma. As our patient refused penectomy and KRAS mutation was proven, FOLFIRI chemotherapy was initiated without cetuximab. This was followed by chemoradiotherapy that resulted only in transient regression. Currently the patient receives the FOLFOX regimen. At present the patient is in good performance status, without pain. The size and the number of penile metastases have not shown significant changes. According to the literature the average survival of patients with penile metastases treated with radiochemotherapy is 8 months. New chemotherapeutic modalities may improve the survival.
C1 [Kuronya, Zsofia] National Institute of Oncology, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Manninger, Sandor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1145 Budapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, 1145 Budapest, Hungary.
EM kuronyazsofia@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 263
EP 266
PG 4
ER

PT J
AU Tamasi, L
AF Tamasi, Lilla
TI Antitumor activity of zoledronic acid
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE zoledronsav; daganatellenes aktivitas; tudorak; human adatok
ID zoledronsav; daganatellenes aktivitas; tudorak; human adatok
AB Bisphosphonates are used for supportive treatment in bone metastases of malignant diseases. Advance in various therapeutic options, molecular targeted therapies of malignant diseases result in longer survival, and may bring a higher number of patients surviving until development of secondary lesions, e.g. bone metastases. This review summarizes the antitumor activity of the amino-bisphosphonate zoledronate, describing results of in vitro and animal model studies. Zoledronic acid treatment in patients with malignant solid tumors causing bone metastases prolongs their survival. According to the emerging, until now not too large amount of data, zoledronic acid may have a clinically significant and important direct antitumor activity which is resulted by many pathomechanical pathways summarized in this report. Randomized clinical trials are needed for evaluating real life antitumor activity of amino-bisphosphonates.
C1 [Tamasi, Lilla] Semmelweis University, Department of Pulmonology, Dios arok u. 1/C., 1125 Budapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM tamasi@sterlingconsulting.org
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 269
EP 271
PG 3
ER

PT J
AU Borka, K
AF Borka, Katalin
TI Claudin expression in different pancreatic cancers and its significance in differential diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE tight junction; claudin; pancreasdaganatok; differencialdiagnozis; terapia
ID tight junction; claudin; pancreasdaganatok; differencialdiagnozis; terapia
AB Claudins (CLDNs) are essential proteins of tight junctions. Changes in their expression pattern have been demonstrated in a number of tumors. CLDNs-3 and -4 are receptors of the Clostridium perfringens enterotoxin, cytolytic effects of the toxin are well known. The aim of our studies was to compare the different CLDN expression patterns in normal pancreas cells, pancreatic endocrine tumors, adenocarcinomas, mucinous cystic tumors and acinar cell carcinomas. Expressions of CLDN-1, -2, -3, -4 and -7 proteins were examined using immunohistochemical as well as RT-PCR techniques and the following observations were made: 1.) In addition to the well-known CLDN-1 and -4 expression CLDN-2, -3 and -7 proteins were demonstrated in ductal cells, while CLDN-3 and -7 proteins showed expression in acinar cells. Expression of CLDNs-3 and -7 was manifest in endocrine cells. 2.) CLDN-3 and -7 proteins showed high expression in endocrine tumors, CLDN-1, -2, and -4 proteins in exocrine tumors. This is the first description of CLDN protein expression in endocrine tumors. 3.) The level of CLDN-1, -4 and -7 protein expression in borderline cystic tumors is in between that of benign and malignant tumors. This supports the sequential development theory regarding mucinous cystic tumors. 4.) This is a first review on childhood acinar cell carcinoma causing Cushing syndrome. According to our results the following conclusions are made. 1.) The presence of CLDN-3 refers to endocrinediff erentiation. The adenocarcinomas and cystic mucinous tumors of exocrine origin denoted CLDN-1, -2, -4 and -7 positivity, whereas acinar cell carcinomas expressed only CLDN-1 and -2. Considering the CLDN expression observed in normal pancreas cells, it can be established that CLDN-1, -2 and -4 proteins are definitely markers of ductal differentiation, CLDN-1 protein of acinar and CLDN-3 of endocrine differentiation. 2). The increased CLDN-4 expression in adenocarcinomas and mucinous cystic tumors, as well as the high CLDN-3 expression in endocrine tumors may open up new prospects in the targeted therapy of these tumors. 3). The claudin expression pattern of pancreas tumors may be employed in the differential diagnosis of these tumors and may be of help in deciding dignity.
C1 [Borka, Katalin] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Borka, K (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 273
EP 278
PG 6
ER

PT J
AU Biro, K
AF Biro, Krisztina
TI Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE hallaskarosodas; cisplatin; otoakusztikus emisszio; heredaganat
ID hallaskarosodas; cisplatin; otoakusztikus emisszio; heredaganat
AB The aim of the research was to detect the acute and long-term ototoxic effect of cisplatin in testicular cancer patients, using OAE (otoacoustic emission), a highly sensitive new objective method, for detecting medication-related hearing loss. Secondary objective was to evaluate the risk factors that contribute to hearing loss. In the study for acute hearing loss ten males with different histological types of testicular germ cell tumor were examined with TOAE (transiently evoked otoacoustic emission), before the 1st and after the 5th day of their 1st cycle of cytostatic therapy. Patients received 100 mg/m2 cisplatin per cycle (20 mg/m2 for five days). Ten age-matched healthy volunteers of good hearing and without treatment were also examined with the same method. Wilcoxon and paired t-tests were used for statistical evaluation. In this acute phase study no differences were found either in otological physiological examination, in conventional audiometry, or in tympanometry. There were no statistically significant differences in amplitude either before and after therapy, or between patient and control group. No patient complained of hearing loss or tinnitus. In the long-term hearing loss study 223 cured patients were assessed by DPOAE (distorsion product otoacoustic emission). Patients received 100 mg/m2 cisplatin per cycle, in EP, BEP, VeIP, VIP or VPB regimens. The control group consisted of 40 testicular cancer patients without chemotherapy. A detailed medical history of the patient and his family evaluated audiological risk factors and hearing complaints. Before DPOAE, otoscopic examination and tympanometry tests were used to exclude any conductive component. DPOAE was measured in eight frequencies from 750 to 8,000 Hz. Paired t-test, Mann-Whitney test and stepwise discriminant analysis were used for statistical evaluation. Symptomatic ototoxicity was observed in 20% of the patients. In patients receiving &#8804;300 mg/m2 cisplatin, no amplitude changes were detected. Beyond this dose, hearing impairment proved to be dosedependent. Contrary to the literature, not only high frequencies were affected. In patients receiving &#8805;400 mg/m2, our method could also detect significant hearing impairment at lower frequencies that are important for speech perception (1000-3000 Hz). The lowest amplitudes were detected in those patients who had symptomatic ototoxicity. The only statistically significant risk factors were the cumulative dose of cisplatin and age; neither smoking nor previous noise exposure proved to be risk factors. As the life expectancy of testicular cancer patients matches in most cases the life expectancy of healthy males, studying long-term side effects is of great importance. OAE is a fast, noninvasive and reliable method in detecting ototoxicity in testicular cancer patients. Cisplatin dose regimens should be reduced to the minimum required for cure, based on a risk-adapted treatment.
C1 [Biro, Krisztina] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Biro, K (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 279
EP 283
PG 5
ER

PT J
AU Mayer, �
AF Mayer, Arpad
TI Visszatekintes a Magyar Sugarterapias Tarsasag IX. Pecsi Kongresszusara
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 285
EP 286
PG 2
ER

PT J
AU Kasler, M
   Szucs, M
   Moskovits, K
AF Kasler, Miklos
   Szucs, Miklos
   Moskovits, Katalin
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2009. marcius 6-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Szucs, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Moskovits, Katalin] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Kasler, M (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2009
VL 53
IS 3
BP 289
EP 297
PG 9
ER

PT J
AU Timar, J
   Kasler, M
   Heringh, A
   Soos, M
   Mathiasz, D
   Romany, A
   Jozsa, A
   Szilak, L
   Forrai, T
   Patthy, L
   Kovacs, G
AF Timar, Jozsef
   Kasler, Miklos
   Heringh, Alexandra
   Soos, Miklos
   Mathiasz, Dora
   Romany, Anna
   Jozsa, Adrienn
   Szilak, Laszlo
   Forrai, Tamas
   Patthy, Laszlo
   Kovacs, Gabor
TI Developments in cancer management by innovative genomics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE genomika; gendiagnosztika; celzott terapia; kutatas-fejlesztes; onkologia
ID genomika; gendiagnosztika; celzott terapia; kutatas-fejlesztes; onkologia
AB In the 3rd year of the program 8 new molecular diagnostic services have been introduced to clinic in the management of breast-, lung-, colorectal cancers as well as in GIST and melanoma. Two patents have been filed for innovative modulation of mito/motogenic signaling pathways in cancer cells. In preclinical models of human cancer a functional imaging technique was developed to detect vascular effects of erythropoietin. Using a genomic approach, the sequential changes in human melanoma during systemic dissemination were determined revealing several novel potential prognostic factors and some interesting novel targets for therapy.
C1 [Timar, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Heringh, Alexandra] AstraZeneca KftTorokbalint, Hungary.
   [Soos, Miklos] Auro-Science Kft.Budapest, Hungary.
   [Mathiasz, Dora] GlaxoSmithKline KftBudapest, Hungary.
   [Romany, Anna] Janssen-Cilag KftTorokbalint, Hungary.
   [Jozsa, Adrienn] Roche Hungary LtdBudaors, Hungary.
   [Szilak, Laszlo] Szilak Labor KftSzeged, Hungary.
   [Forrai, Tamas] Zenon Bio KftSzeged, Hungary.
   [Patthy, Laszlo] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Timar, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 321
EP 334
PG 14
ER

PT J
AU Kulka, J
   Tokes, AM
   Toth, AI
   Szasz, AM
   Farkas, A
   Borka, K
   Jaray, B
   Szekely, E
   Istok, R
   Lotz, G
   Madaras, L
   Korompay, A
   Harsanyi, L
   Laszlo, Zs
   Rusz, Z
   Molnar, B�
   Molnar, IA
   Kenessey, I
   Szentmartoni, Gy
   Szekely, B
   Dank, M
AF Kulka, Janina
   Tokes, Anna-Maria
   Toth, Adrienn Ildiko
   Szasz, Attila Marcell
   Farkas, Andrea
   Borka, Katalin
   Jaray, Balazs
   Szekely, Eszter
   Istok, Roland
   Lotz, Gabor
   Madaras, Lilla
   Korompay, Anna
   Harsanyi, Laszlo
   Laszlo, Zsolt
   Rusz, Zoltan
   Molnar, Bela Akos
   Molnar, Istvan Arthur
   Kenessey, Istvan
   Szentmartoni, Gyongyver
   Szekely, Borbala
   Dank, Magdolna
TI Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE neoadjuvans terapia; primer szisztemas terapia; emlorak; fenotipus
ID neoadjuvans terapia; primer szisztemas terapia; emlorak; fenotipus
AB The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors. Pathological response rates were assessed following surgical removal of tumors by using the Chevallier classification. DFS and OS was measured in 88 cases from the date of definitive surgery to the date of last follow-up or death. Pathological complete or near-complete remission (pCR = Chevallier I and II) was observed in 13 of 92 cases (14.1%). According to the preoperative characteristics of the 13 tumors achieving pCR, 9 of the cases were triple negative, one of 13 was ER-/HER2+ and three of 13 ER+/HER2+. Twenty-four of 92 patients received taxane based neoadjuvant chemotherapy, 30 of 92 anthracyclin based neoadjuvant chemotherapy, 33 of 92 taxane + anthracyclin regimen and 2 of 92 CMF regimen. In the taxane treated group of patients the pCR rate was 29.1%, in the anthracyclin group 6.6% and in the taxane + anthracyclin treated group 12.1%. Concerning DFS, significant difference was observed between the Chevallier III and IV groups (p=0.006), and less events were observed in the pCR group (not significant). pCR was associated with significantly better OS (p=0.050). It seems that even limited, routinely used immunohistochemical profiling of tumors is able to predict the likelihood of pCR to neoadjuvant chemotherapy. Patients with triple negative and HER2-positive cancers are likely to achieve pCR after neoadjuvant chemotherapy.
C1 [Kulka, Janina] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Toth, Adrienn Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Farkas, Andrea] St. Imre HospitalBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Istok, Roland] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Korompay, Anna] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Laszlo, Zsolt] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Rusz, Zoltan] Schopf-Merei Korhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Molnar, Bela Akos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Molnar, Istvan Arthur] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szekely, Borbala] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM kj@korb2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 335
EP 343
PG 9
ER

PT J
AU Rapolti, E
   Szigeti, A
   Farkas, R
   Bellyei, Sz
   Boronkai, �
   Papp, A
   Gomori, �
   Horvath, �P
   Mangel, L
AF Rapolti, Edit
   Szigeti, Andras
   Farkas, Robert
   Bellyei, Szabolcs
   Boronkai, Arpad
   Papp, Andras
   Gomori, Eva
   Horvath, Ors Peter
   Mangel, Laszlo
TI Neoadjuvant radiochemotherapy in the treatment of locally advanced rectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE neoadjuvans radiokemoterapia; rectumtumor; belly-board; Mandard-score; mellekhatas
ID neoadjuvans radiokemoterapia; rectumtumor; belly-board; Mandard-score; mellekhatas
AB We investigated the response rate and side effects of simultaneous, neoadjuvant radiochemotherapy (RCT) in locally advanced rectal cancer. Between 2005 and 2007, we treated 112 patients in stage II-III rectal carcinoma at the Institute of Oncotherapy, University of Pecs. For staging abdomino-pelvic CT (112) and transrectal US (49) or pelvic MR (10), or PET-CT (1) was performed. Radiation therapy was delivered with 3D CRT-based technique using belly-board with 18 MV photon energy, while patients in prone position. A total dose of 45 Gy (single dose 1.8 Gy) was delivered to the tumor and the pelvic lymph nodes. 5-FU and Ca-folinate was administered concomitantly in the 1st and 5th week of radiotherapy. Four weeks after delivering neoadjuvant RCT the patients' control CT was evaluated according to RECIST criteria. RCT was followed by surgery in 6-9 weeks. We graded the histology using the Mandard regression score system. Side effects were registered using CTCAE v 3.0. Grade 1, 2 or 3 acute gastrointestinal toxicity occurred in 12%, grade 3 hematological toxicity in 9.5% of the patients. The response rate determined by using control CT was 64.85%. According to the Mandard regression score, TRG1 occurred in 15%, TRG2 in 30.4%, TRG3 in 28%, TRG4 in 24% and TRG5 in 2.6% of the cases. Radical surgery was performed in 89 cases, 72 with R0 resection. By assessing the histological samples we found downstaging in 46% of the T and 34.5% of the N stage. We have no information on increased postoperative complications. We followed 86 patients after neoadjuvant therapy. Until March 2009 there was no progression in 48 of our patients. In 13 cases local relapse occurred, and in 25 cases the disease progressed because of distant metastasis, although local control was maintained. 10 patients had local relapse and distant metastases. 17 patients passed away. As a conclusion, neoadjuvant RCT of Stage II-III patients is an effective and well tolerated treatment, allowing for high R0 resection rate and bearing no higher risk for postoperative morbidity.
C1 [Rapolti, Edit] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
   [Papp, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Gomori, Eva] University of Pecs, Department of PathologyPecs, Hungary.
   [Horvath, Ors Peter] University of Pecs, Department of SurgeryPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Ifjusag ut 13., 7623 Pecs, Hungary.
RP Szigeti, A (reprint author), University of Pecs, Department of Oncology, 7623 Pecs, Hungary.
EM andras.szigeti@aok.pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 345
EP 349
PG 5
ER

PT J
AU Penzvalto, Zs
   Mihaly, Zs
   Gyorffy, B
AF Penzvalto, Zsofia
   Mihaly, Zsuzsanna
   Gyorffy, Balazs
TI Gene expression based multigene prognostic and predictive tests in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE microarray; emlotumor; prognozis; predikcio; multigenes tesztek
ID microarray; emlotumor; prognozis; predikcio; multigenes tesztek
AB Patient tailored therapy will serve the fundamentals of future cancer treatment. For this it will be imperative to characterize the tumor and to acquire precise predictive and prognostic information. We can achieve this by using not only monogenic (like ER, PR, HER-2, Ki-67) but also multigene assays, which can provide answers to several diagnostic questions simultaneously. We present a summary of currently available RT-PCR and microarray based multigene tests including MammaPrint, Oncotype DX, BLN Assay, Theros Breast Cancer Index SM, MapQuant DX, ARUP Breast Bioclassifier, Celera Metastatic Score, eXagen BCtm, Invasive Gene Signature, Wound Response Indicator and Mammostrat. Two of these (Oncotype DX and MammaPrint) are already incorporated in several diagnostic protocols. However, multiple unsolved issues deteriorate the value of these tests: generally the validation is poor, the gene sets do not confirm each other, the associated costs are high and the necessary bioinformatics is highly complex.
C1 [Penzvalto, Zsofia] Semmelweis University, 1st Department of Pediatrics, Bokay u. 53/54., 1083 Budapest, Hungary.
   [Mihaly, Zsuzsanna] Semmelweis University, 1st Department of Pediatrics, Bokay u. 53/54., 1083 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 1st Department of Pediatrics, Bokay u. 53/54., 1083 Budapest, Hungary.
RP Penzvalto, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, 1083 Budapest, Hungary.
EM penzvaltozsofi@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 351
EP 359
PG 9
ER

PT J
AU Kopper, L
   Timar, J
AF Kopper, Laszlo
   Timar, Jozsef
TI Validation study of KRAS mutation in colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE KRAS; vastagbelrak; molekularis diagnosztika; validalas
ID KRAS; vastagbelrak; molekularis diagnosztika; validalas
AB There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the molecular targets can help in the prediction of the antitumoral effect as well as in the positive or negative selection of patients. Such a marker is KRAS, since its mutation inhibits the effectiveness of anti-EGFR monoclonal antibodies in the treatment of advanced and/or metastatic colorectal cancer. To identify KRAS mutations different methods and techniques are available. A voluntarily performed study served to control the validity of our methods. As a result the 7 partcipating laboratories approached but not fulfilled (except one) the criteria set by EPS. A joint discussion helped to call the attention to some technical and financial problems. The key conditions to recognize mutational status of KRAS or other similar markers are the accredited laboratory for molecular diagnostics and the validated method. The improvement of the quality of such techniques is supported by the fact that more and more drugs can be used only after the obligatory measurement of relevant molecular target(s).
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM kopper@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 361
EP 366
PG 6
ER

PT J
AU Piko, B
AF Piko, Bela
TI Lapatinib-treatment-option in trastuzumab-resistant breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE tirozinkinaz-gatlas; emlorak; HER2-pozitivitas; trastuzumab-rezisztencia
ID tirozinkinaz-gatlas; emlorak; HER2-pozitivitas; trastuzumab-rezisztencia
AB HER2 is overexpressed in 20-25% of breast cancers and is associated with an aggressive phenotype and poor prognosis. Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2. Having more targets, probably its antitumor activity could be more efficient. Preclinical data reveal that lapatinib has activity in trastuzumab-resistant cell lines as well as synergistic activity with trastuzumab. Phase I clinical trials have also shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common toxic effects and low incidence of cardiotoxicity. Lapatinib can cross the blood-brain barrier and might therefore have a role in preventing central-nervous-system progression. In a pivotal phase III trial, a combination of lapatinib and capecitabine almost doubled time to disease progression when compared to capecitabine alone (8.4 vs. 4.1 months) in women with HER2/ErbB2-positive advanced or metastatic breast cancer previously treated with anthracyclin, taxanes and trastuzumab. The overall survival was 15.6 vs. 15.4 months. Several clinical trials that explore the efficacy of lapatinib in combination with conventional chemotherapeutic agents, hormone therapy and other target therapies are ongoing in advanced breast cancer or in neoadjuvant and adjuvant settings.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM piko_bhome@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 369
EP 375
PG 7
ER

PT J
AU Gyorffy, H
AF Gyorffy, Hajnalka
TI Studies on claudins and prognostic factors in gastrointestinal diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE claudin; Barrett -metaplasia; coeliakia; GIST; immunhisztokemia
ID claudin; Barrett -metaplasia; coeliakia; GIST; immunhisztokemia
AB Gastrointestinal tumors are highly ranked regarding tumoral mortality worldwide. The development and progression of gastrointestinal (GI) diseases go hand in hand with the changes of tight junctions (TJ). Claudins (CLDN) are the main TJ proteins, showing different expression by the different tissues, with the expressed CLDN profile being representative. I. We explored the changes of CLDN expression in Barrett's esophagus and related adenocarcinoma. CLDN2 and -3 expression in Barrett's esophagus was higher than in normal foveolar epithelium. Adenocarcinoma showed higher CLDN2 and -3 expression compared with normal and Barrett's epithelia. The similar CLDN expression profile of Barrett's esophagus and adenocarcinoma supports their sequential development. II. Gastric intestinal metaplasia showed higher expression of CLDN2, -3 and -4 as compared with normal antral foveolar mucosa. Tumors of small and large bowels exhibited higher CLDN2 expression when compared with normal epithelia. Colorectal adenoma and adenocarcinoma could not be differentiated according to their CLDN profile. Intestinal metaplasias of Barrett's esophagus and stomach show similar CLDN profile to small bowel epithelium. III. Studies on duodenal mucosa in celiac disease in childhood demonstrated CLDN2 and -3 expression to be higher than in normal mucosa. The expression was significantly higher in the distal part of the duodenum samples. This and the serious histological findings suggest that the distal duodenum is more adequate for biopsy testing. IV. Beside the epithelial cells, mesenchymal tumors express intercellular junctional proteins. Expression of claudins in gastrointestinal stromal tumors (GIST) and other mesenchymal neoplasia was also studied. The CLDN profile was found to be representative to the individual tumor. GIST, angiosarcoma, hemangioma, leiomyosarcoma and leiomyoma showed expression of various CLDNs. CLDN2 was detected in all entities. CLDN1, however, was found positive in leiomyosarcoma only. Leiomyoma, on the other hand, expressed only CLDN2. GISTs and leiomyosarcomas showed CLDN2, -3, -4, -5 and -7-expression. The angiogenic tumors revealed CLDN2 and -5 expression. The similar CLDN profile observable in GIST and leiomyosarcoma is suggestive of a histogenetic relationship. Smooth muscle and vessel tumors of different dignity could also be separated from each other based on CLDN profile.
C1 [Gyorffy, Hajnalka] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Gyorffy, H (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 377
EP 383
PG 7
ER

PT J
AU Szarvas, T
AF Szarvas, Tibor
TI The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hugyholyagrak; mikroszatellita-analizis; angiogenezis; prognozis
ID hugyholyagrak; mikroszatellita-analizis; angiogenezis; prognozis
AB Bladder cancer is the second most common malignancy affecting the urinary system. Currently, histology is the only tool that determines therapy and patients' prognosis. As the treatment of non-invasive (Ta/T1) and muscle invasive (T2-T4) bladder tumors are completely different, correct staging is important, although it is often hampered by disturbing factors. Molecular methods offer new prospects for early disease detection, confirmation of unclear histological findings and prognostication. Applying molecular biological methods, the present study is searching for answers to current diagnostic and prognostic problems in bladder carcinoma. We analyzed tumor, blood and/or urine samples of 334 bladder cancer patients and 117 control individuals. Genetic alterations were analyzed in urine samples of patients and controls, both by PCR-based microsatellite loss of heterozigosity (LOH) analysis using 12 fluorescently labeled primers and by DNA hybridization based UroVysion FISH technique using 4 probes, to assess the diagnostic values of these methods. Whole genome microsatellite analysis (with 400 markers) was performed in tumor and blood specimens of bladder cancer patients to find chromosomal regions, the loss of which may be associated with tumor stage. Furthermore, we assessed the prognostic value of Tie2, VEGF, Angiopoietin-1 and -2. We concluded that DNA analysis of voided urine samples by microsatellite analysis and FISH are sensitive and non-invasive methods to detect bladder cancer. Furthermore, we established a panel of microsatellite markers that could differentiate between non-invasive and invasive bladder cancer. However, further analyses in a larger cohort of patients are needed to assess their specificity and sensitivity. Finally, we identified high Ang-2 and low Tie2 gene expression as significant and independent risk factors of tumor recurrence and cancer related survival.
C1 [Szarvas, Tibor] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Szarvas, T (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 385
EP 389
PG 5
ER

PT J
TI Az Orszagos Koranyi TBC es Pulmonologiai Intezet ESMO-akkreditacioja
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 391
EP 392
PG 2
ER

PT J
AU Thurzo, L
   Kasler, M
   Tolnay, E
AF Thurzo, Laszlo
   Kasler, Miklos
   Tolnay, Edina
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2009. junius 12-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Thurzo, Laszlo] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Tolnay, Edina] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Thurzo, L (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 4
BP 393
EP 399
PG 7
ER

PT J
TI A Magyar Onkologusok Tarsasaganak XXVIII. Kongresszusa a Magyar Gerincgyogyaszati Tarsasag reszvetelevel
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 5
EP 143
PG 134
ER

PT J
AU Andocs, G
   Galfi, P
   Helmut, R
   Balogh, L
   Fonyad, L
   Jakab, Cs
   Szasz, A
AF Andocs, Gabor
   Galfi, Peter
   Helmut, Renner
   Balogh, Lajos
   Fonyad, Laszlo
   Jakab, Csaba
   Szasz, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andocs, Gabor] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Galfi, Peter] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Helmut, Renner] Klinikum Nuernberg, Clinic of RadiooncologyNuernberg, Germany.
   [Balogh, Lajos] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Fonyad, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jakab, Csaba] Szent Istvan University, Faculty of Veterinary Medicine, Department of Pathology and Forensic Veterinary MedicineBudapest, Hungary.
   [Szasz, Andras] Szt. Istvan University, Biotechnics DepartmentGodollo, Hungary.
RP Andocs, G (reprint author), Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Andocs, G
   Galfi, P
   Szasz, O
   Szasz, A
AF Andocs, Gabor
   Galfi, Peter
   Szasz, Oliver
   Szasz, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andocs, Gabor] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Galfi, Peter] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Szasz, Oliver] SzIE, Mernoki Kar, Gyogyszertani TanszekGodollo, Hungary.
   [Szasz, Andras] SzIE, Mernoki Kar, Gyogyszertani TanszekGodollo, Hungary.
RP Andocs, G (reprint author), Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 5
EP 6
PG 2
ER

PT J
AU Anna, L
   Holmila, R
   Kovacs, K
   Gyorffy, E
   Gyori, Z
   Segesdi, J
   Minarovits, J
   Soltesz, I
   Kostic, Sz
   Csekeo, A
   Husgafvel-Pursiainen, K
AF Anna, Livia
   Holmila, Reetta
   Kovacs, Katalin
   Gyorffy, Erika
   Gyori, Zoltan
   Segesdi, Judit
   Minarovits, Janos
   Soltesz, Ibolya
   Kostic, Szilard
   Csekeo, Attila
   Husgafvel-Pursiainen, Kirsti
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Anna, Livia] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Holmila, Reetta] Finnish Institute of Occupational HealthHelsinki, Finland.
   [Kovacs, Katalin] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Gyorffy, Erika] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Gyori, Zoltan] National Center for EpidemiologyBudapest, Hungary.
   [Segesdi, Judit] National Center for EpidemiologyBudapest, Hungary.
   [Minarovits, Janos] National Center for EpidemiologyBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kostic, Szilard] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Husgafvel-Pursiainen, Kirsti] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
RP Anna, L (reprint author), Orszagos Kornyezetegeszsegugyi Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 6
EP 7
PG 2
ER

PT J
AU Apathy, �
AF Apathy, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Apathy, Agnes] National Institute for Rheumatology and PhysiotherapyBudapest, Hungary.
RP Apathy, � (reprint author), National Institute for Rheumatology and Physiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Aranyosi, G
AF Aranyosi, Gaborne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Aranyosi, Gaborne] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Aranyosi, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 7
EP 8
PG 2
ER

PT J
AU Arvay, TI
   Telekes, A
AF Arvay, Tunde Ilona
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arvay, Tunde Ilona] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
   [Telekes, Andras] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Arvay, TI (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Balatoni, T
   Borbola, K
   Fejos, Zs
   Gaudi, I
   Hunyadi, J
   Major, E
   Schmith, E
   Gurgolne Marcsa, K
   Miklos, Z
   Pinterne Monori, I
   Liszkay, G
AF Balatoni, Timea
   Borbola, Kinga
   Fejos, Zsuzsanna
   Gaudi, Istvan
   Hunyadi, Janos
   Major, Edina
   Schmith, Emese
   Gurgolne Marcsa, Krisztina
   Miklos, Zoltanne
   Pinterne Monori, Ilona
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Hunyadi, Janos] National Institute of OncologyBudapest, Hungary.
   [Major, Edina] National Institute of OncologyBudapest, Hungary.
   [Schmith, Emese] National Institute of OncologyBudapest, Hungary.
   [Gurgolne Marcsa, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Miklos, Zoltanne] National Institute of OncologyBudapest, Hungary.
   [Pinterne Monori, Ilona] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 8
EP 9
PG 2
ER

PT J
AU Balazs, M
   Ecsedi, Sz
   Vizkeleti, L
   Lazar, V
   Rakosy, Zs
   Szollosi, AG
   Begany, �
   Emri, G
   Adany, R
AF Balazs, Margit
   Ecsedi, Szilvia
   Vizkeleti, Laura
   Lazar, Viktoria
   Rakosy, Zsuzsa
   Szollosi, AttIla Gabor
   Begany, Agnes
   Emri, Gabriella
   Adany, Roza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Margit] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Ecsedi, Szilvia] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Vizkeleti, Laura] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Lazar, Viktoria] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Rakosy, Zsuzsa] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Szollosi, AttIla Gabor] University of Debrecen, Faculty of Medicine, Department of PhysiologyDebrecen, Hungary.
   [Begany, Agnes] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Emri, Gabriella] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Adany, Roza] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
RP Balazs, M (reprint author), Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani Intezet, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balogh, I
   Paczelt, A
   Varga, J
   Medveczki, A
   Pocza, K
AF Balogh, Ildiko
   Paczelt, Andras
   Varga, Jozsef
   Medveczki, Andrea
   Pocza, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Paczelt, Andras] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Varga, Jozsef] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Medveczki, Andrea] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Pocza, Karoly] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balogh, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 9
EP 10
PG 2
ER

PT J
AU Balogh, I
   Kovacs, Gy
   Medveczki, A
   Landherr, L
AF Balogh, Ildiko
   Kovacs, Gyorgyi
   Medveczki, Andrea
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kovacs, Gyorgyi] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Medveczki, Andrea] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balogh, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Balogh, I
   Toth, V
   Galler, Z
   Kovacs, F
AF Balogh, Ildiko
   Toth, Viktoria
   Galler, Zoltan
   Kovacs, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Toth, Viktoria] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Galler, Zoltan] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kovacs, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Balogh, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Banky, B
   Barbai, T
   Timar, J
   Raso, E
AF Banky, Balazs
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banky, Balazs] St. Borbala University HospitalTatabanya, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Banky, B (reprint author), St. Borbala University Hospital, Tatabanya, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 11
EP 12
PG 2
ER

PT J
AU Barbai, T
   Timar, J
   Raso, E
AF Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Barbai, T (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Barna, G
   Mihalik, R
   Timar, B
   Tombol, J
   Csende, Zs
   Sebestyen, A
   Bodor, Cs
   Csernus, B
   Reiniger, L
   Matolcsy, A
AF Barna, Gabor
   Mihalik, Rudolf
   Timar, Botond
   Tombol, Judit
   Csende, Zsolt
   Sebestyen, Anna
   Bodor, Csaba
   Csernus, Balazs
   Reiniger, Lilla
   Matolcsy, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tombol, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csende, Zsolt] Semmelweis Egyetem, Biomechanikai IntezetBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csernus, Balazs] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barna, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Barti-Juhasz, H
   Imre, G
   Nagy, K
   Kopper, L
   Schwab, R
   Petak, I
   Mihalik, R
AF Barti-Juhasz, Helga
   Imre, Gergely
   Nagy, Katalin
   Kopper, Laszlo
   Schwab, Richard
   Petak, Istvan
   Mihalik, Rudolf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Imre, Gergely] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barti-Juhasz, H (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Bely, M
AF Bely, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bely, Miklos] Budai Irgalmasrendi Korhaz, Patologiai OsztalyBudapest, Hungary.
RP Bely, M (reprint author), Budai Irgalmasrendi Korhaz, Patologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Benyo, G
   Vertesi, G
   Kallay, K
   Simon, R
   Goda, V
   Marton, G
   Toth, �
   Jakab, Zs
   Bence, Zs
   Jakab, E
   Nagy, K
AF Benyo, Gabor
   Vertesi, Gabriella
   Kallay, Krisztian
   Simon, Reka
   Goda, Vera
   Marton, Gabriella
   Toth, Agnes
   Jakab, Zsuzsanna
   Bence, Zsofia
   Jakab, Eszter
   Nagy, Kalman
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benyo, Gabor] St. Laszlo HospitalBudapest, Hungary.
   [Vertesi, Gabriella] Borsod-Abauj-Zemplen Megyei Korhaz, I. Gyermekhaematologiai-es Csontvelotranszplantacios OsztalyMiskolc, Hungary.
   [Kallay, Krisztian] St. Laszlo HospitalBudapest, Hungary.
   [Simon, Reka] Borsod-Abauj-Zemplen Megyei Korhaz, I. Gyermekhaematologiai-es Csontvelotranszplantacios OsztalyMiskolc, Hungary.
   [Goda, Vera] St. Laszlo HospitalBudapest, Hungary.
   [Marton, Gabriella] Borsod-Abauj-Zemplen Megyei Korhaz, I. Gyermekhaematologiai-es Csontvelotranszplantacios OsztalyMiskolc, Hungary.
   [Toth, Agnes] St. Laszlo HospitalBudapest, Hungary.
   [Jakab, Zsuzsanna] Gyermekonkologia Munkacsoport, Gyermekrak RegiszterBudapest, Hungary.
   [Bence, Zsofia] Semmelweis UniversityBudapest, Hungary.
   [Jakab, Eszter] Semmelweis UniversityBudapest, Hungary.
   [Nagy, Kalman] Borsod-Abauj-Zemplen Megyei Korhaz, I. Gyermekhaematologiai-es Csontvelotranszplantacios OsztalyMiskolc, Hungary.
RP Benyo, G (reprint author), St. Laszlo Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 14
EP 15
PG 2
ER

PT J
AU Berta, J
   Kenessey, I
   Dobos, J
   Tovari, J
   Keszthelyi, M
   Dome, B
AF Berta, Judit
   Kenessey, Istvan
   Dobos, Judit
   Tovari, Jozsef
   Keszthelyi, Magdolna
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Berta, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Keszthelyi, Magdolna] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Berta, J (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Bezsenyine Bobis, M
AF Bezsenyine Bobis, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bezsenyine Bobis, Marta] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Bezsenyine Bobis, M (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Bittner, N
   Szentirmay, Z
   Bidlek, M
AF Bittner, Nora
   Szentirmay, Zoltan
   Bidlek, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] National Institute of OncologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
RP Bittner, N (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Bittner, N
   Toth, E
   Bocs, K
AF Bittner, Nora
   Toth, Erika
   Bocs, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] National Institute of OncologyBudapest, Hungary.
   [Toth, Erika] National Institute of OncologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of OncologyBudapest, Hungary.
RP Bittner, N (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Bodizs, A
AF Bodizs, Andrasne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodizs, Andrasne] Markhot Ferenc Korhaz-Rendelointezet, Onko-terapias OsztalyEger, Hungary.
RP Bodizs, A (reprint author), Markhot Ferenc Korhaz-Rendelointezet, Onko-terapias Osztaly, Eger, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Bogos, K
   Renyi-Vamos, F
   Dobos, J
   Kenessey, I
   Tovari, J
   Timar, J
   Strausz, J
   Ostoros, Gy
   Klepetko, W
   Ankersmit, HJ
   Lang, Gy
AF Bogos, Krisztina
   Renyi-Vamos, Ferenc
   Dobos, Judit
   Kenessey, Istvan
   Tovari, Jozsef
   Timar, Jozsef
   Strausz, Janos
   Ostoros, Gyula
   Klepetko, Walter
   Ankersmit, Hendrik Jan
   Lang, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Dobos, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tovari, Jozsef] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Strausz, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Klepetko, Walter] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Ankersmit, Hendrik Jan] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Lang, Gyorgy] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Bogos, K (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Boncz, I
   Donkane Verebes, �
   Oberfrank, F
AF Boncz, Imre
   Donkane Verebes, Eva
   Oberfrank, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boncz, Imre] University of PecsPecs, Hungary.
   [Donkane Verebes, Eva] Integra Consulting ZrtBudapest, Hungary.
   [Oberfrank, Ferenc] MTA, Kiserleti Orvostudomanyi KutatointezetBudapest, Hungary.
RP Boncz, I (reprint author), University of Pecs, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Boncz, I
   Kasler, M
AF Boncz, Imre
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boncz, Imre] University of PecsPecs, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Boncz, I (reprint author), University of Pecs, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 19
EP 20
PG 2
ER

PT J
AU Borbola, K
   Plotar, V
   Fejos, Zs
   Schmidt, E
   Major, E
   Gilde, K
   Eles, K
   Liszkay, G
AF Borbola, Kinga
   Plotar, Vanda
   Fejos, Zsuzsanna
   Schmidt, Emese
   Major, Edina
   Gilde, Katalin
   Eles, Klara
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Schmidt, Emese] National Institute of OncologyBudapest, Hungary.
   [Major, Edina] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Eles, Klara] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Borbola, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Boriani, S
AF Boriani, Stefano
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boriani, Stefano] AOSpineRome, Italy.
RP Boriani, S (reprint author), AOSpine, Rome, Italy.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Borka, K
   Korompay, A
   Zalatnai, A
AF Borka, Katalin
   Korompay, Anna
   Zalatnai, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Korompay, Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Zalatnai, Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Borka, K (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 20
EP 21
PG 2
ER

PT J
AU Boross, G
   Pajkos, G
   Marko, L
   Maraz, R
   Svebis, M
   Ambrozay, �
   Cserni, G
AF Boross, Gabor
   Pajkos, Gabor
   Marko, Laszlo
   Maraz, Robert
   Svebis, Mihaly
   Ambrozay, Eva
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boross, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Boross, G (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Bocs, K
   Kovacs, E
   Remenar, �
   Hitre, E
   Takacsi Nagy, Z
   Godeny, M
AF Bocs, Katalin
   Kovacs, Eszter
   Remenar, Eva
   Hitre, Erika
   Takacsi Nagy, Zoltan
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bocs, Katalin] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Bocs, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Budai, B
   Hitre, E
   Adleff, V
   Komlosi, V
   Czegledi, F
   Pap, �
   Rubovszky, G
   Horvath, Zs
   Lang, I
   Kralovanszky, J
AF Budai, Barna
   Hitre, Erika
   Adleff, Vilmos
   Komlosi, Viktor
   Czegledi, Ferenc
   Pap, Eva
   Rubovszky, Gabor
   Horvath, Zsolt
   Lang, Istvan
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Komlosi, Viktor] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Budai, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Buglyo, �
   Treszl, A
   Huga, S
   Juhasz, A
   Halmos, G
AF Buglyo, Armin
   Treszl, Andrea
   Huga, Sandor
   Juhasz, Aliz
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Buglyo, Armin] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Treszl, Andrea] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Huga, Sandor] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Juhasz, Aliz] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Halmos, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
RP Buglyo, � (reprint author), University of Debrecen, Department of Pharmacology and Pharmacotherapy, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Czegle, IA
   Toth, �K
   Szabo, Sz
   Vamos, M
   Sugar, I
   Graf, L
   Horvath, A
   Kocsis, J
   Karadi, I
AF Czegle, Ibolya Anett
   Toth, Eva Katalin
   Szabo, Szilard
   Vamos, Marta
   Sugar, Istvan
   Graf, Laszlo
   Horvath, Anna
   Kocsis, Judit
   Karadi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czegle, Ibolya Anett] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Szabo, Szilard] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Vamos, Marta] Semmelweis Egyetem, KKT, RadiologiaBudapest, Hungary.
   [Sugar, Istvan] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Graf, Laszlo] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Horvath, Anna] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Karadi, Istvan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Czegle, IA (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Czigner, J
   Csanady, M
AF Czigner, Jeno
   Csanady, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Czigner, J (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Czigner, K
   Agoston, P
   Pap, �
   Bajcsay, A
   Fodor, J
   Lengyel, Zs
   Polgar, Cs
   Kasler, M
   Borbely, K
   Lovey, J
AF Czigner, Krisztina
   Agoston, Peter
   Pap, Eva
   Bajcsay, Andras
   Fodor, Janos
   Lengyel, Zsolt
   Polgar, Csaba
   Kasler, Miklos
   Borbely, Katalin
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czigner, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
RP Czigner, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Csanady, M
   Czigner, J
AF Csanady, Miklos
   Czigner, Jeno
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Csanady, M (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Cserhati, R
   Palotai, A
   Kiraly, Zs
   Hoffmann, F
AF Cserhati, Rita
   Palotai, Andrea
   Kiraly, Zsolt
   Hoffmann, Ferencne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cserhati, Rita] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
   [Palotai, Andrea] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
   [Kiraly, Zsolt] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
   [Hoffmann, Ferencne] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
RP Cserhati, R (reprint author), Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Cseri, Zs
   Javor, L
AF Cseri, Zsolt
   Javor, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseri, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Javor, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Cseri, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Csoszi, T
AF Csoszi, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csoszi, Tibor] Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Klinikai OnkologiaSzolnok, Hungary.
RP Csoszi, T (reprint author), Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Klinikai Onkologia, Szolnok, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Csuka, O
AF Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
RP Csuka, O (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Deme, D
AF Deme, Daniel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei KorhazSalgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Deme, D
   Bishr, MA
   Orosz, I
   Szollosi, Zs
AF Deme, Daniel
   Bishr, Mohamed Abdulfatah
   Orosz, Ivan
   Szollosi, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Belgyogyaszati OsztalySalgotarjan, Hungary.
   [Bishr, Mohamed Abdulfatah] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Orosz, Ivan] Szent Lazar Megyei Korhaz, Szajsebeszeti AmbulanciaSalgotarjan, Hungary.
   [Szollosi, Zsuzsanna] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Belgyogyaszati Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 26
EP 27
PG 2
ER

PT J
AU Dobos, J
   Horvath, Z
   Szokol, B
   Orfi, L
   Keri, Gy
AF Dobos, Judit
   Horvath, Zoltan
   Szokol, Balint
   Orfi, Laszlo
   Keri, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zoltan] Vichem Kft.Budapest, Hungary.
   [Szokol, Balint] Vichem Kft.Budapest, Hungary.
   [Orfi, Laszlo] Vichem Kft.Budapest, Hungary.
   [Keri, Gyorgy] Vichem Kft.Budapest, Hungary.
RP Dobos, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Doleviczenyi, Z
   Boer, A
AF Doleviczenyi, Zoltan
   Boer, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doleviczenyi, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
RP Doleviczenyi, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Doros, A
   Hartmann, E
   Nemeth, A
   Juharosi, Gy
   Gorog, D
   Mathe, Z
   Nemes, B
   Fehervari, I
   Nagy, P
   Kobori, L
AF Doros, Attila
   Hartmann, Erika
   Nemeth, Andrea
   Juharosi, Gyongyi
   Gorog, Denes
   Mathe, Zoltan
   Nemes, Balazs
   Fehervari, Imre
   Nagy, Peter
   Kobori, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doros, Attila] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Hartmann, Erika] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Nemeth, Andrea] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Juharosi, Gyongyi] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Gorog, Denes] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Mathe, Zoltan] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Nemes, Balazs] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Fehervari, Imre] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Nagy, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kobori, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Doros, A (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Dobrossy, L
AF Dobrossy, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobrossy, Lajos] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
RP Dobrossy, L (reprint author), Orszagos Tisztifoorvosi Hivatal, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Dome, B
AF Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Dome, B (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Edesne Boldizsar, M
   Gilde, K
   Fejos, Zs
   Kapuvari, B
   Vincze, B
   Liszkay, G
AF Edesne Boldizsar, Marianna
   Gilde, Katalin
   Fejos, Zsuzsanna
   Kapuvari, Bence
   Vincze, Borbala
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Edesne Boldizsar, Marianna] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Edesne Boldizsar, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Engi, H
   Doleschall, Z
   Ashaber, M
   Csuka, O
AF Engi, Helga
   Doleschall, Zoltan
   Ashaber, Maria
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Engi, Helga] National Institute of OncologyBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Ashaber, Maria] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
RP Engi, H (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 29
EP 31
PG 3
ER

PT J
AU Fabianne Kiss, Sz
   Kmetty, L
AF Fabianne Kiss, Szilvia
   Kmetty, Laszlone
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabianne Kiss, Szilvia] National Institute of OncologyBudapest, Hungary.
   [Kmetty, Laszlone] National Institute of OncologyBudapest, Hungary.
RP Fabianne Kiss, Sz (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Fejos, Zs
   Barbai, T
   Timar, J
   Raso, E
AF Fejos, Zsuzsanna
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Fejos, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 31
EP 32
PG 2
ER

PT J
AU Fekete, T
   Munkacsy, Gy
   Pete, I
   Raso, E
   Tegze, B
   Gyorffy, B
AF Fekete, Tibor
   Munkacsy, Gyongyi
   Pete, Imre
   Raso, Erzsebet
   Tegze, Balint
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Tibor] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Munkacsy, Gyongyi] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Pete, Imre] National Institute of OncologyBudapest, Hungary.
   [Raso, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Tegze, Balint] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Hungarian Academy of Sciences - Semmelweis University, 1st Dept. of Pediatrics, Research Laboratory for Pediatrics and NephrologyBudapest, Hungary.
RP Fekete, T (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Ferenczi, E
   Nagy, A
   Varga, I
   Lantos, �
   Borbely, T
   Palinkasi, Sz
   Morocz, �
   Tolnay, E
AF Ferenczi, Eniko
   Nagy, Andrea
   Varga, Ilona
   Lantos, Akos
   Borbely, Tibor
   Palinkasi, Szvetlana
   Morocz, Eva
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Nagy, Andrea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Varga, Ilona] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Borbely, Tibor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Palinkasi, Szvetlana] County Hospital of PulmonologyTorokbalint, Hungary.
   [Morocz, Eva] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ferenczi, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Fodor, I
   Boer, A
AF Fodor, Istvan
   Boer, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Istvan] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
RP Fodor, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Fonyad, L
   Moskovszky, L
   Szemlaky, Zs
   Szendroi, M
   Sapi, Z
AF Fonyad, Laszlo
   Moskovszky, Linda
   Szemlaky, Zsuzsanna
   Szendroi, Miklos
   Sapi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fonyad, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moskovszky, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szemlaky, Zsuzsanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Fonyad, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Frohlich, G
   Major, T
   Agoston, P
   Polgar, Cs
AF Frohlich, Georgina
   Major, Tibor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 33
EP 34
PG 2
ER

PT J
AU Fulop, M
   Remenar, �
AF Fulop, Miklos
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Galffy, G
   Bartusek, D
   Srenyer, T
   Tamasi, L
AF Galffy, Gabriella
   Bartusek, Dora
   Srenyer, Tunde
   Tamasi, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartusek, Dora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Srenyer, Tunde] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 34
EP 35
PG 2
ER

PT J
AU Garai, I
   Barna, S
   Szabados, L
AF Garai, Ildiko
   Barna, Sandor
   Szabados, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garai, Ildiko] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Barna, Sandor] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Szabados, Lajos] PET-CT Medical Diagnostic LtdBudapest, Hungary.
RP Garai, I (reprint author), PET-CT Medical Diagnostic Ltd, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Gergely, I
   Nagy, �
AF Gergely, Istvan
   Nagy, Ors
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gergely, Istvan] Marosvasarhelyi EgyetemTargu Mureș, Romania.
   [Nagy, Ors] Marosvasarhelyi EgyetemTargu Mureș, Romania.
RP Gergely, I (reprint author), Marosvasarhelyi Egyetem, Targu Mureș, Romania.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Gilde, K
   Edesne Boldizsar, M
   Kapuvari, B
   Banfalvi, T
   Fejos, Zs
   Papp, A
   Liszkay, G
   Otto, Sz
   Vincze, B
AF Gilde, Katalin
   Edesne Boldizsar, Marianna
   Kapuvari, Bence
   Banfalvi, Teodora
   Fejos, Zsuzsanna
   Papp, Andrea
   Liszkay, Gabriella
   Otto, Szabolcs
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Edesne Boldizsar, Marianna] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Banfalvi, Teodora] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Papp, Andrea] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
RP Gilde, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Gobor, L
   Matrai, Z
   Feher, I
   Renyi Vamos, F
   Farkas, E
   Savolt, �
   Szollar, A
   Koves, I
   Toth, L
AF Gobor, Laszlo
   Matrai, Zoltan
   Feher, Istvan
   Renyi Vamos, Ferenc
   Farkas, Emil
   Savolt, Akos
   Szollar, Andras
   Koves, Istvan
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gobor, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Feher, Istvan] National Institute of OncologyBudapest, Hungary.
   [Renyi Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Szollar, Andras] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Gobor, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Gombos, K
   Gobel, Gy
   Szanyi, I
   Ember, I
AF Gombos, Katalin
   Gobel, Gyula
   Szanyi, Istvan
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Gobel, Gyula] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Szanyi, Istvan] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Gombos, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Gorog, D
   Gerlei, Zs
   Fehervari, I
   Nemes, B
   Kobori, L
AF Gorog, Denes
   Gerlei, Zsuzsa
   Fehervari, Imre
   Nemes, Balazs
   Kobori, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gorog, Denes] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Gerlei, Zsuzsa] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Fehervari, Imre] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Nemes, Balazs] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Kobori, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Gorog, D (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Godeny, M
AF Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Gyorffy, B
   Lanckzy, A
   Eklund, A
   Qiyuan, L
   Szallasi, Z
AF Gyorffy, Balazs
   Lanckzy, Andras
   Eklund, Aron
   Qiyuan, Li
   Szallasi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Lanckzy, Andras] Pazmany Peter Catholic UniversityBudapest, Hungary.
   [Eklund, Aron] Dan Muszaki EgyetemLingby, Denmark.
   [Qiyuan, Li] Dan Muszaki EgyetemLingby, Denmark.
   [Szallasi, Zoltan] Dan Muszaki EgyetemLingby, Denmark.
RP Gyorffy, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 38
EP 39
PG 2
ER

PT J
AU Gyorgy, ZM
   Lazary, �
   Varga, PP
AF Gyorgy, Zoltan Magor
   Lazary, Aron
   Varga, Peter Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorgy, Zoltan Magor] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
   [Lazary, Aron] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
   [Varga, Peter Pal] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
RP Gyorgy, ZM (reprint author), Orszagos Gerincgyogyaszati Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Halmos, G
   Schally, A
AF Halmos, Gabor
   Schally, V. Andrew
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Schally, V. Andrew] University of MiamiMiami, FL, USA.
RP Halmos, G (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 39
EP 40
PG 2
ER

PT J
AU Haltrich, I
   Kovacs, G
   Csoka, M
   Fekete, Gy
AF Haltrich, Iren
   Kovacs, Gabor
   Csoka, Monika
   Fekete, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Haltrich, Iren] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Fekete, Gyorgy] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Haltrich, I (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Harisi, R
   Szendroi, M
   Olah Nagy, J
   Pogany, G
   Dudas, J
   Kovalszky, I
   Timar, F
   Krenacs, T
   Jeney, A
AF Harisi, Revekka
   Szendroi, Miklos
   Olah Nagy, Julia
   Pogany, Gabor
   Dudas, Jozsef
   Kovalszky, Ilona
   Timar, Ferenc
   Krenacs, Tibor
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Olah Nagy, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Pogany, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dudas, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Ferenc] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Harisi, R
   Weltner, J
   Szekely, Gy
   Jaray, B
   Kupcsulik, P
   Harsanyi, L
   Flautner, L
   Friedman, G
   Winternitz, T
   Jeney, A
AF Harisi, Revekka
   Weltner, Janos
   Szekely, Gyorgy
   Jaray, Balazs
   Kupcsulik, Peter
   Harsanyi, Laszlo
   Flautner, Lajos
   Friedman, Gabor
   Winternitz, Tamas
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Weltner, Janos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Szekely, Gyorgy] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kupcsulik, Peter] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Flautner, Lajos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Friedman, Gabor] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Winternitz, Tamas] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 41
EP 42
PG 2
ER

PT J
AU Hartmann, E
   Bonyarne Muller, K
   Figler, M
   Lelovics, Zs
AF Hartmann, Eszter
   Bonyarne Muller, Katalin
   Figler, Maria
   Lelovics, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hartmann, Eszter] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Bonyarne Muller, Katalin] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Figler, Maria] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Lelovics, Zsuzsanna] University of Pecs, Faculty of Health SciencesPecs, Hungary.
RP Hartmann, E (reprint author), University of Pecs, Faculty of Health Sciences, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Hascsi, Zs
   Garami, Z
   Fedinecz, N
   Szabados, L
   Garai, I
AF Hascsi, Zsolt
   Garami, Zoltan
   Fedinecz, Nikol
   Szabados, Lajos
   Garai, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hascsi, Zsolt] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Garami, Zoltan] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Fedinecz, Nikol] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Szabados, Lajos] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Garai, Ildiko] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
RP Hascsi, Zs (reprint author), Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai Kft, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 42
EP 43
PG 2
ER

PT J
AU Haska, Gy
   Farkasne Nagy, �
AF Haska, Gyorgyne
   Farkasne Nagy, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Haska, Gyorgyne] Municipal Hospital, HodmezovasarhelyHodmezovasarhely, Hungary.
   [Farkasne Nagy, Eva] Municipal Hospital, HodmezovasarhelyHodmezovasarhely, Hungary.
RP Haska, Gy (reprint author), Municipal Hospital, Hodmezovasarhely, Hodmezovasarhely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Hegedus, B
   Timar, J
   Gutmann, D
AF Hegedus, Balazs
   Timar, Jozsef
   Gutmann, H. David
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Gutmann, H. David] Washington University School of MedicineSt. Louis, USA.
RP Hegedus, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Hegedus, M
   Barbai, T
   Timar, J
   Raso, E
AF Hegedus, Marta
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Marta] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Hegedus, M (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Hegyesi, H
   Sandor, N
   Schilling, B
   Safrany, G
AF Hegyesi, Hargita
   Sandor, Nikolett
   Schilling, Boglarka
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyesi, Hargita] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Sandor, Nikolett] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Schilling, Boglarka] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Hegyesi, H (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Hegyi, M
   F. Semsei, �
   Csagoly, E
   Bacsi, K
   Erdelyi, D
   Szalai, Cs
   Kovacs, G
AF Hegyi, Marta
   F. Semsei, Agnes
   Csagoly, Edit
   Bacsi, Krisztian
   Erdelyi, Daniel
   Szalai, Csaba
   Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyi, Marta] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [F. Semsei, Agnes] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Csagoly, Edit] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Bacsi, Krisztian] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Szalai, Csaba] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Hegyi, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 45
EP 46
PG 2
ER

PT J
AU Herczeg, A
   Doleviczenyi, Z
AF Herczeg, Adrienn
   Doleviczenyi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herczeg, Adrienn] National Institute of OncologyBudapest, Hungary.
   [Doleviczenyi, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Herczeg, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Hernadi, Z
   Krasznai, Z
AF Hernadi, Zoltan
   Krasznai, Zoard
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Krasznai, Zoard] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Hernadi, Z (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Hitre, E
   Budai, B
   Adleff, V
   Komlosi, V
   Czegledi, F
   Pap, �
   Rubovszky, G
   Horvath, Zs
   Kralovanszky, J
   Lang, I
AF Hitre, Erika
   Budai, Barna
   Adleff, Vilmos
   Komlosi, Viktor
   Czegledi, Ferenc
   Pap, Eva
   Rubovszky, Gabor
   Horvath, Zsolt
   Kralovanszky, Judit
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Komlosi, Viktor] National Institute of OncologyBudapest, Hungary.
   [Czegledi, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
RP Hitre, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Homonnay, E
   Gerendai, T
AF Homonnay, Erzsebet
   Gerendai, Tamasne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Homonnay, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Gerendai, Tamasne] National Institute of OncologyBudapest, Hungary.
RP Homonnay, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Horvath, �
AF Horvath, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Akos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Horvath, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Horvath, A
   Czegle, IA
   Graf, L
   Madaras, B
   Bereczky, B
   Toth, K
   Kocsis, J
AF Horvath, Anna
   Czegle, Ibolya Anett
   Graf, Laszlo
   Madaras, Balazs
   Bereczky, Biborka
   Toth, E. Katalin
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Anna] Semmelweis UniversityBudapest, Hungary.
   [Czegle, Ibolya Anett] Semmelweis UniversityBudapest, Hungary.
   [Graf, Laszlo] Semmelweis UniversityBudapest, Hungary.
   [Madaras, Balazs] Semmelweis UniversityBudapest, Hungary.
   [Bereczky, Biborka] Semmelweis UniversityBudapest, Hungary.
   [Toth, E. Katalin] Semmelweis UniversityBudapest, Hungary.
   [Kocsis, Judit] Semmelweis UniversityBudapest, Hungary.
RP Horvath, A (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Horvath, K
   Pete, I
   Lovey, J
   Godeny, M
AF Horvath, Katalin
   Pete, Imre
   Lovey, Jozsef
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of OncologyBudapest, Hungary.
   [Pete, Imre] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Horvathne Kives, Zs
   Batthyani, Z
   Bajor, K
   Sandor, J
AF Horvathne Kives, Zsuzsanna
   Batthyani, Zita
   Bajor, Klara
   Sandor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvathne Kives, Zsuzsanna] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Batthyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Bajor, Klara] Tolna Megyei Onkormanyzat Balassa Janos Korhaz, Borgyogyaszati OsztalySzekszard, Hungary.
   [Sandor, Janos] Debreceni Egyetem, Nepegeszsegugyi Kar, Biostatisztikai es Epidemiologiai TanszekDebrecen, Hungary.
RP Horvathne Kives, Zs (reprint author), University of Pecs, Faculty of Health Sciences, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Horvath, I
   Gyulai, N
   Szatmari, B
   Hernadi, M
   Lazar, Zs
   Losonczy, Gy
AF Horvath, Ildiko
   Gyulai, Nora
   Szatmari, Balazs
   Hernadi, Marton
   Lazar, Zsofia
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Ildiko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Gyulai, Nora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Szatmari, Balazs] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Hernadi, Marton] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Lazar, Zsofia] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Horvath, I (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Horvath, Zs
   Ganofszky, E
   Hitre, E
   Juhos, �
   Nagy, T
   Rubovszky, G
   Szabo, E
   Lang, I
   Kasler, M
AF Horvath, Zsolt
   Ganofszky, Erna
   Hitre, Erika
   Juhos, Eva
   Nagy, Tunde
   Rubovszky, Gabor
   Szabo, Eszter
   Lang, Istvan
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Ganofszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Juhos, Eva] National Institute of OncologyBudapest, Hungary.
   [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Horvath, Zs
   Lang, I
   Kasler, M
   Borbely, K
AF Horvath, Zsolt
   Lang, Istvan
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 50
EP 51
PG 2
ER

PT J
AU Hullan, L
   Jaszay, Zs
   Tejeda, M
   Soos, G
   Szarvas, T
   Csiba, A
AF Hullan, Lehel
   Jaszay, Zsuzsa
   Tejeda, Miguel
   Soos, Gergely
   Szarvas, Tibor
   Csiba, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hullan, Lehel] National Institute of OncologyBudapest, Hungary.
   [Jaszay, Zsuzsa] MTA Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Szerves Kemiai Technologiai KutatocsoportBudapest, Hungary.
   [Tejeda, Miguel] National Institute of OncologyBudapest, Hungary.
   [Soos, Gergely] National Institute of OncologyBudapest, Hungary.
   [Szarvas, Tibor] Izotop Intezet Kft.Budapest, Hungary.
   [Csiba, Andras] Fovarosi Allategeszsegugyi es Elelmiszer Ellenorzo IntezetBudapest, Hungary.
RP Hullan, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Illes, MB
   Sarosi, V
   Ruzsics, I
   Juhasz, E
   Baliko, Z
AF Illes, Miklos Balazs
   Sarosi, Veronika
   Ruzsics, Istvan
   Juhasz, Erzsebet
   Baliko, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Illes, Miklos Balazs] County Hospital of BaranyaPecs, Hungary.
   [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Ruzsics, Istvan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Juhasz, Erzsebet] Pecs University, Faculty of Health Sciences, Department of DiagnosticPecs, Hungary.
   [Baliko, Zoltan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
RP Illes, MB (reprint author), County Hospital of Baranya, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Jakab, G
   Gabor, G
   Hodi, Zs
   Hajnal, L
   Vizhanyo, R
   Megyesi, Cs
   Pajkos, G
AF Jakab, Gabriella
   Gabor, Gabriella
   Hodi, Zsuzsanna
   Hajnal, Lajos
   Vizhanyo, Rita
   Megyesi, Csaba
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jakab, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hodi, Zsuzsanna] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Megyesi, Csaba] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Jakab, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Javor, L
   Cseri, Zs
AF Javor, Laszlo
   Cseri, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Javor, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Cseri, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Javor, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Jederan, �
   Lovey, J
   Toth, L
   Matrai, Z
   Szabo, E
   Godeny, M
AF Jederan, Eva
   Lovey, Jozsef
   Toth, Laszlo
   Matrai, Zoltan
   Szabo, Eszter
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Jori, B
   Arvai, K
   Varkondi, E
   Pinter, F
   Nagy, K
   Micsik, T
   Schwab, R
   Kopper, L
   Petak, I
AF Jori, Balazs
   Arvai, Kristof
   Varkondi, Edit
   Pinter, Ferenc
   Nagy, Katalin
   Micsik, Tamas
   Schwab, Richard
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jori, Balazs] KPS Kft.Budapest, Hungary.
   [Arvai, Kristof] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Varkondi, Edit] KPS Kft.Budapest, Hungary.
   [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Micsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Jori, B (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 53
EP 54
PG 2
ER

PT J
AU Josa, V
   Monos, M
   Becske, M
AF Josa, Valeria
   Monos, Monika
   Becske, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Josa, Valeria] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
   [Monos, Monika] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
   [Becske, Miklos] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
RP Josa, V (reprint author), Flor Ferenc University Hospital of Pest County, Kistarcsa, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Jung, J
AF Jung, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jung, Janos] Marosvasarhelyi EgyetemTargu Mureș, Romania.
RP Jung, J (reprint author), Marosvasarhelyi Egyetem, Targu Mureș, Romania.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Kapuvari, B
   Vincze, B
   Tejeda, M
   Gaal, D
   Schultz, �
   Manea, M
   Orban, E
   Szabo, I
   Csuka, O
   Mezo, G
AF Kapuvari, Bence
   Vincze, Borbala
   Tejeda, Miguel
   Gaal, Dezso
   Schultz, Akos
   Manea, Marilena
   Orban, Erika
   Szabo, Ildiko
   Csuka, Orsolya
   Mezo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Tejeda, Miguel] National Institute of OncologyBudapest, Hungary.
   [Gaal, Dezso] National Institute of OncologyBudapest, Hungary.
   [Schultz, Akos] National Institute of OncologyBudapest, Hungary.
   [Manea, Marilena] University of Konstanz, Zukunftskolleg, Department of ChemistryKonstanz, Germany.
   [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Szabo, Ildiko] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Kas, J
   Papai, Zs
   Agocs, L
   Csekeo, A
   Heiler, Z
   Kocsis, �
   Soltesz, I
AF Kas, Jozsef
   Papai, Zsuzsanna
   Agocs, Laszlo
   Csekeo, Attila
   Heiler, Zoltan
   Kocsis, Akos
   Soltesz, Ibolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kas, Jozsef] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Agocs, Laszlo] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Heiler, Zoltan] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kocsis, Akos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Soltesz, Ibolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Kas, J (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Kasler, M
AF Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Kenessey, I
   Koi, K
   Horvath, O
   Dobos, J
   Tovari, J
   Timar, J
AF Kenessey, Istvan
   Koi, Krisztina
   Horvath, Orsolya
   Dobos, Judit
   Tovari, Jozsef
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Koi, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Horvath, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kenessey, I (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Kiss, Cs
   Jakab, Zs
   Magyarosy, E
   Kappelmayer, J
   Kovacs, G
   Sholtz, B
AF Kiss, Csongor
   Jakab, Zsuzsa
   Magyarosy, Edina
   Kappelmayer, Janos
   Kovacs, Gabor
   Sholtz, Bea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Jakab, Zsuzsa] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Magyarosy, Edina] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kappelmayer, Janos] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Sholtz, Bea] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
RP Kiss, Cs (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Klinko, T
   Sinko, D
AF Klinko, Timea
   Sinko, Daniel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Klinko, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Kobori, L
   Vegso, Gy
   Benko, T
   Fehervari, I
   Nemes, B
   Piros, L
   Gorog, D
   Doros, A
   Fazakas, J
   Jaray, J
   Langer, R
AF Kobori, Laszlo
   Vegso, Gyula
   Benko, Tamas
   Fehervari, Imre
   Nemes, Balazs
   Piros, Laszlo
   Gorog, Denes
   Doros, Attila
   Fazakas, Janos
   Jaray, Jeno
   Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kobori, Laszlo] Semmelweis UniversityBudapest, Hungary.
   [Vegso, Gyula] Semmelweis UniversityBudapest, Hungary.
   [Benko, Tamas] Semmelweis UniversityBudapest, Hungary.
   [Fehervari, Imre] Semmelweis UniversityBudapest, Hungary.
   [Nemes, Balazs] Semmelweis UniversityBudapest, Hungary.
   [Piros, Laszlo] Semmelweis UniversityBudapest, Hungary.
   [Gorog, Denes] Semmelweis UniversityBudapest, Hungary.
   [Doros, Attila] Semmelweis UniversityBudapest, Hungary.
   [Fazakas, Janos] Semmelweis UniversityBudapest, Hungary.
   [Jaray, Jeno] Semmelweis UniversityBudapest, Hungary.
   [Langer, Robert] Semmelweis UniversityBudapest, Hungary.
RP Kobori, L (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 57
EP 58
PG 2
ER

PT J
AU Kocsis, J
   Madaras, B
   Toth, �K
   Fust, Gy
   Prohaszka, Z
   Karadi, I
AF Kocsis, Judit
   Madaras, Balazs
   Toth, E Katalin
   Fust, Gyorgy
   Prohaszka, Zoltan
   Karadi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Madaras, Balazs] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, E Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Fust, Gyorgy] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Prohaszka, Zoltan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Karadi, Istvan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Kokai, T
   Fulop, V
   Szigetvari, I
   Vachaja, J
   Lahm, E
   Uhlyarik, A
   Papai, Zs
AF Kokai, Tunde
   Fulop, Vilmos
   Szigetvari, Ivan
   Vachaja, Jozsef
   Lahm, Erika
   Uhlyarik, Andrea
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Fulop, Vilmos] Allami Egeszsegugyi Kozpont – Honvedkorhaz, NogyogyaszatBudapest, Hungary.
   [Szigetvari, Ivan] Allami Egeszsegugyi Kozpont – Honvedkorhaz, NogyogyaszatBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Kokai, T (reprint author), Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephely, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 58
EP 59
PG 2
ER

PT J
AU Koltai, L
   Gulyas, G
   Bago, A
   Godeny, M
AF Koltai, Laszlo
   Gulyas, Gusztav
   Bago, Attila
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of OncologyBudapest, Hungary.
   [Bago, Attila] National Institute of NeurosurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Koltai, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Koltai, P
AF Koltai, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Pal] National Institute of OncologyBudapest, Hungary.
RP Koltai, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 59
EP 60
PG 2
ER

PT J
AU Korompay, R
   Czebe, K
   Szucs, Zs
   Tolnay, E
AF Korompay, Reka
   Czebe, Krisztina
   Szucs, Zsuzsanna
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Korompay, Reka] County Hospital of PulmonologyTorokbalint, Hungary.
   [Czebe, Krisztina] County Hospital of PulmonologyTorokbalint, Hungary.
   [Szucs, Zsuzsanna] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Korompay, R (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Kosa, J
   Bajcsay, A
AF Kosa, Judit
   Bajcsay, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kosa, Judit] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
RP Kosa, J (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Kotai, Zs
   Varga, E
   Bartfai, R
AF Kotai, Zsuzsa
   Varga, Edit
   Bartfai, Reka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Varga, Edit] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Bartfai, Reka] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Kotai, Zs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Kotlan, B
   Ravindranath, HM
   Dobos, J
   Szentirmay, Z
   Glassy, CM
AF Kotlan, Beatrix
   Ravindranath, H Mepur
   Dobos, Judit
   Szentirmay, Zoltan
   Glassy, C Mark
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] National Institute of OncologyBudapest, Hungary.
   [Ravindranath, H Mepur] Terasaki Alapitvany LaboratoriumaLos Angeles, USA.
   [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Glassy, C Mark] Egyesitett Orvosbiologiai Kutatasi SzervezetSan Diego, USA.
RP Kotlan, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Kovacs, A
AF Kovacs, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Attila] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
RP Kovacs, A (reprint author), Orszagos Tisztifoorvosi Hivatal, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Kovacs, Sz
   Kotai, Zs
AF Kovacs, Szilvia
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Szilvia] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Kovacs, Sz (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 62
EP 63
PG 2
ER

PT J
AU Kollo, K
AF Kollo, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kollo, Katalin] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Kollo, K (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Koves, I
AF Koves, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
RP Koves, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Kriszbacher, I
AF Kriszbacher, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kriszbacher, Ildiko] University of Pecs, Faculty of Health SciencesPecs, Hungary.
RP Kriszbacher, I (reprint author), University of Pecs, Faculty of Health Sciences, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Kulka, J
   Tokes, AM
   Toth, A
   Szasz, AM
   Szekely, B
   Madaras, L
   Harsanyi, L
   Molnar, B
   Laszlo, Zs
   Dank, M
AF Kulka, Janina
   Tokes, Anna-Maria
   Toth, Adrienn
   Szasz, Attila Marcell
   Szekely, Borbala
   Madaras, Lilla
   Harsanyi, Laszlo
   Molnar, Bela
   Laszlo, Zsolt
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Toth, Adrienn] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Borbala] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Molnar, Bela] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Laszlo, Zsolt] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Kurucz, T
   Mukics, E
   Gaspar, �
   Hatvani, G
   Nagy, A
AF Kurucz, Timea
   Mukics, Emilia
   Gaspar, Eva
   Hatvani, Gaborne
   Nagy, Anita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kurucz, Timea] National Institute of OncologyBudapest, Hungary.
   [Mukics, Emilia] National Institute of OncologyBudapest, Hungary.
   [Gaspar, Eva] National Institute of OncologyBudapest, Hungary.
   [Hatvani, Gaborne] National Institute of OncologyBudapest, Hungary.
   [Nagy, Anita] National Institute of OncologyBudapest, Hungary.
RP Kurucz, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Kuronya, Zs
   Bodrogi, I
   Lovey, J
   Plotar, V
   Manninger, S
   Papai, Zs
AF Kuronya, Zsofia
   Bodrogi, Istvan
   Lovey, Jozsef
   Plotar, Vanda
   Manninger, Sandor
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kuronya, Zsofia] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of OncologyBudapest, Hungary.
   [Manninger, Sandor] National Institute of OncologyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Ladanyi, A
   Mohos, A
   Somlai, B
   Liszkay, G
   Gilde, K
   Fejos, Zs
   Gaudi, I
   Timar, J
AF Ladanyi, Andrea
   Mohos, Anita
   Somlai, Beata
   Liszkay, Gabriella
   Gilde, Katalin
   Fejos, Zsuzsanna
   Gaudi, Istvan
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Mohos, Anita] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Lahm, E
   Sikter, M
   Uhlyarik, A
   Vachaja, J
   Kokai, T
   Papai, Zs
AF Lahm, Erika
   Sikter, Marta
   Uhlyarik, Andrea
   Vachaja, Jozsef
   Kokai, Tunde
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
RP Lahm, E (reprint author), Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephely, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Langer, R
AF Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Langer, R (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Lantos, �
   Korompay, R
   Nagy, A
   Tolnay, E
AF Lantos, Akos
   Korompay, Reka
   Nagy, Andrea
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Korompay, Reka] County Hospital of PulmonologyTorokbalint, Hungary.
   [Nagy, Andrea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Lantos, � (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Lazary, �
   Varga, PP
AF Lazary, Aron
   Varga, Peter Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lazary, Aron] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
   [Varga, Peter Pal] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
RP Lazary, � (reprint author), Orszagos Gerincgyogyaszati Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Lehoczkyne Hanyecz, K
AF Lehoczkyne Hanyecz, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lehoczkyne Hanyecz, Katalin] National Institute of OncologyBudapest, Hungary.
RP Lehoczkyne Hanyecz, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 67
EP 68
PG 2
ER

PT J
AU Lengyel, CsGy
   Dabasi, G
   Doros, A
   Langer, R
   Fulop, I
   Ivanyi, E
   Boer, A
   Remenar, �
AF Lengyel, Csongor Gyorgy
   Dabasi, Gabriella
   Doros, Attila
   Langer, Robert
   Fulop, Imre
   Ivanyi, Emoke
   Boer, Andras
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Csongor Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Dabasi, Gabriella] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Doros, Attila] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Fulop, Imre] Josa Andras Megyei Korhaz, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti OsztalyNyiregyhaza, Hungary.
   [Ivanyi, Emoke] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
RP Lengyel, CsGy (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Liptak, Zs
   Bajcsay, A
   Molnar, Zs
   Kuronya, Zs
   Nagy, T
   Ganovszky, E
   Monostori, Zs
AF Liptak, Zsuzsanna
   Bajcsay, Andras
   Molnar, Zsuzsa
   Kuronya, Zsofia
   Nagy, Tunde
   Ganovszky, Erna
   Monostori, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liptak, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of OncologyBudapest, Hungary.
   [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
   [Ganovszky, Erna] National Institute of OncologyBudapest, Hungary.
   [Monostori, Zsuzsa] National Koranyi Institute of PulmonologyBudapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 68
EP 69
PG 2
ER

PT J
AU Liszkay, G
   Csuka, O
   Plotar, V
   Matrai, Z
   Toth, L
   Borbola, K
   Schmidt, E
   Fejos, Zs
   Balatoni, T
   Otto, Sz
   Kasler, M
AF Liszkay, Gabriella
   Csuka, Orsolya
   Plotar, Vanda
   Matrai, Zoltan
   Toth, Laszlo
   Borbola, Kinga
   Schmidt, Emese
   Fejos, Zsuzsanna
   Balatoni, Timea
   Otto, Szabolcs
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Schmidt, Emese] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Losonczy, Gy
   Bartusek, D
   Cseh, �
   Nagy, A
   Komlosi, Zs
   Szarvas, Zs
   Horvath, R
   Vasarhelyi, B
   Galffy, G
AF Losonczy, Gyorgy
   Bartusek, Dora
   Cseh, Aron
   Nagy, Andrea
   Komlosi, Zsolt
   Szarvas, Zsuzsanna
   Horvath, Rita
   Vasarhelyi, Barna
   Galffy, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bartusek, Dora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Cseh, Aron] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Nagy, Andrea] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Komlosi, Zsolt] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Szarvas, Zsuzsanna] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Horvath, Rita] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Vasarhelyi, Barna] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Losonczy, Gy (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Lovey, J
   Czigner, K
   Major, T
   Lengyel, Zs
   Pap, �
   Agoston, P
   Polgar, Cs
   Kasler, M
   Borbely, K
AF Lovey, Jozsef
   Czigner, Krisztina
   Major, Tibor
   Lengyel, Zsolt
   Pap, Eva
   Agoston, Peter
   Polgar, Csaba
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Czigner, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Lukats, O
   Tapaszto, B
   Toth, J
   Barabas, J
AF Lukats, Olga
   Tapaszto, Beata
   Toth, Jeannette
   Barabas, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Tapaszto, Beata] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Barabas, Jozsef] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
RP Lukats, O (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Lumniczky, K
   Persa, E
   Felgyinszky, N
   Bogdandi, EN
   Szatmari, T
   Safrany, G
AF Lumniczky, Katalin
   Persa, Eszter
   Felgyinszky, Nikolett
   Bogdandi, Eniko Noemi
   Szatmari, Tunde
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Persa, Eszter] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Felgyinszky, Nikolett] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Bogdandi, Eniko Noemi] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Szatmari, Tunde] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Lumniczky, K (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Magyar, T
AF Magyar, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyar, Tamas] Peterfy HospitalBudapest, Hungary.
RP Magyar, T (reprint author), Peterfy Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 71
EP 73
PG 3
ER

PT J
AU Magyar, T
   Bansaghi, Z
AF Magyar, Tamas
   Bansaghi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyar, Tamas] Peterfy HospitalBudapest, Hungary.
   [Bansaghi, Zoltan] Szent Imre Hospital, Department of Diagnostic ImagingBudapest, Hungary.
RP Magyar, T (reprint author), Peterfy Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 73
EP 74
PG 2
ER

PT J
AU Mahr, K
   Fekete, I
   Kolonics, Zs
   Olah, K
   Ruzsa, �
AF Mahr, Karoly
   Fekete, Ilona
   Kolonics, Zsuzsanna
   Olah, Katalin
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Fekete, Ilona] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kolonics, Zsuzsanna] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Olah, Katalin] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Mahr, K (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Major, E
   Balatoni, T
   Borbola, K
   Fejos, Zs
   Schmidt, E
   Liszkay, G
AF Major, Edina
   Balatoni, Timea
   Borbola, Kinga
   Fejos, Zsuzsanna
   Schmidt, Emese
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Major, Edina] National Institute of OncologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Schmidt, Emese] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Major, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Manninger, S
   Varallyay, Gy
   Deak, B
   Bajcsay, A
   Vonoczky, K
AF Manninger, Sandor
   Varallyay, Gyorgy
   Deak, Beata
   Bajcsay, Andras
   Vonoczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Manninger, Sandor] National Institute of OncologyBudapest, Hungary.
   [Varallyay, Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Vonoczky, Katalin] National Institute of OncologyBudapest, Hungary.
RP Manninger, S (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Maraz, R
   Boross, G
   Svebis, M
   Pajkos, G
   Vizhanyo, R
   Hajnal, L
   Marko, L
   Ambrozay, �
AF Maraz, Robert
   Boross, Gabor
   Svebis, Mihaly
   Pajkos, Gabor
   Vizhanyo, Rita
   Hajnal, Lajos
   Marko, Laszlo
   Ambrozay, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Mark, �
   Nemes, K
   Hajdu, M
   Varga, V
   Csorba, G
   Kopper, L
   Sebestyen, A
AF Mark, Agnes
   Nemes, Karolina
   Hajdu, Melinda
   Varga, Viktoria
   Csorba, Gezane
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nemes, Karolina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Varga, Viktoria] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csorba, Gezane] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Mark, � (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Marko, L
   Pajkos, G
   Svebis, M
   Cserni, G
AF Marko, Laszlo
   Pajkos, Gabor
   Svebis, Mihaly
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Matrai, Z
   Orosz, Zs
   Papp, J
   Vadasz, P
   Szendroi, M
   Rahoty, P
   Papai, Zs
   Toth, L
AF Matrai, Zoltan
   Orosz, Zsolt
   Papp, Janos
   Vadasz, Pal
   Szendroi, Miklos
   Rahoty, Pal
   Papai, Zsuzsanna
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Papp, Janos] National Institute of OncologyBudapest, Hungary.
   [Vadasz, Pal] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Rahoty, Pal] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Matrai, Z
   Plotar, V
   Liszkay, G
   Orosz, Zs
   Szekely, J
   Hitre, E
   Bartal, A
   Bocs, K
   Farkas, E
   Savolt, �
   Toth, L
AF Matrai, Zoltan
   Plotar, Vanda
   Liszkay, Gabriella
   Orosz, Zsolt
   Szekely, Judit
   Hitre, Erika
   Bartal, Alexandra
   Bocs, Katalin
   Farkas, Emil
   Savolt, Akos
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Szekely, Judit] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Bartal, Alexandra] National Institute of OncologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Meszaros, K
   Remenar, �
   Boer, A
   Doleviczenyi, Z
   Fulop, M
   Koltai, L
   Koltai, P
   Lengyel, Cs
   Takacsi Nagy, Z
AF Meszaros, Krisztina
   Remenar, Eva
   Boer, Andras
   Doleviczenyi, Zoltan
   Fulop, Miklos
   Koltai, Laszlo
   Koltai, Pal
   Lengyel, Csongor
   Takacsi Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Doleviczenyi, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Koltai, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Csongor] National Institute of OncologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Meszaros, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Mezei, K
   Erfan, J
   Korodine Karaszi, K
AF Mezei, Klara
   Erfan, Jozsef
   Korodine Karaszi, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mezei, Klara] Josa Andras County HospitalNyiregyhaza, Hungary.
   [Erfan, Jozsef] Josa Andras County HospitalNyiregyhaza, Hungary.
   [Korodine Karaszi, Katalin] Josa Andras County HospitalNyiregyhaza, Hungary.
RP Mezei, K (reprint author), Josa Andras County Hospital, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 78
EP 79
PG 2
ER

PT J
AU Mile, M
   Farczadi, E
   Szanto, J
   Juhasz, A
   Halmos, G
AF Mile, Melinda
   Farczadi, Eniko
   Szanto, Janos
   Juhasz, Aliz
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mile, Melinda] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Farczadi, Eniko] St John's HospitalBudapest, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Juhasz, Aliz] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Mile, M (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Moldvay, J
   Sapi, Z
   Egri, G
   Gyulai, M
   Szende, B
   Losonczy, Gy
   Timar, J
   Papay, J
AF Moldvay, Judit
   Sapi, Zoltan
   Egri, Gabor
   Gyulai, Marton
   Szende, Bela
   Losonczy, Gyorgy
   Timar, Jozsef
   Papay, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Egri, Gabor] Bajcsi Zsilinszky Kh., Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gyulai, Marton] County Hospital of PulmonologyTorokbalint, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 79
EP 80
PG 2
ER

PT J
AU Molnar, A�
   Rozsa, B
   Szegedi, I
   Kiss, Cs
   Halmos, G
AF Molnar, Anna Eva
   Rozsa, Bernadett
   Szegedi, Istvan
   Kiss, Csongor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Anna Eva] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Rozsa, Bernadett] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Szegedi, Istvan] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Halmos, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
RP Molnar, A� (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 80
EP 80
PG 1
ER

PT J
AU Moravszki, M
   Lengyel, Zs
   Szakall, Sz
   Szendroi, M
   Papai, Zs
   Szilvasi, I
AF Moravszki, Monika
   Lengyel, Zsolt
   Szakall, Szabolcs
   Szendroi, Miklos
   Papai, Zsuzsanna
   Szilvasi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moravszki, Monika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Szilvasi, Istvan] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Moravszki, M (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 81
EP 81
PG 1
ER

PT J
AU Moskovszky, L
   Kopper, L
   Szendroi, M
   Sapi, Z
AF Moskovszky, Linda
   Kopper, Laszlo
   Szendroi, Miklos
   Sapi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moskovszky, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Moskovszky, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 81
EP 81
PG 1
ER

PT J
AU Muha, E
AF Muha, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muha, Eniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Muha, E (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 81
EP 81
PG 1
ER

PT J
AU Munkacsy, Gy
   Schafer, R
   Abdul-Ghani, R
   Mihaly, Zs
   Gyorffy, B
AF Munkacsy, Gyongyi
   Schafer, Reinhold
   Abdul-Ghani, Rula
   Mihaly, Zsuzsa
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Munkacsy, Gyongyi] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Schafer, Reinhold] Charite University HospitalBerlin, Germany.
   [Abdul-Ghani, Rula] Al-Quds UniversityJerusalem, Israel.
   [Mihaly, Zsuzsa] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Gyorffy, Balazs] Hungarian Academy of Sciences - Semmelweis University, 1st Dept. of Pediatrics, Research Laboratory for Pediatrics and NephrologyBudapest, Hungary.
RP Munkacsy, Gy (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 82
EP 82
PG 1
ER

PT J
AU Muller, Z
   Vityi, T
   Kotai, Zs
AF Muller, Zoltan
   Vityi, Tamas
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 82
EP 83
PG 2
ER

PT J
AU Nagy, A
   Fajt, E
   Tolnay, E
AF Nagy, Andrea
   Fajt, Erzsebet
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Andrea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Fajt, Erzsebet] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Nagy, A (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 83
EP 83
PG 1
ER

PT J
AU Nagy, K
   Barti-Juhasz, H
   Arvai, K
   Mihalik, R
   Kopper, L
   Petak, I
AF Nagy, Katalin
   Barti-Juhasz, Helga
   Arvai, Kristof
   Mihalik, Rudolf
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Arvai, Kristof] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Nagy, K (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 83
EP 84
PG 2
ER

PT J
AU Nagy, P
   Lahm, E
   Szendroi, M
   Papai, Zs
AF Nagy, Peter
   Lahm, Erika
   Szendroi, Miklos
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Nagy, P (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 84
EP 84
PG 1
ER

PT J
AU Nagy, P
   Szentmartoni, Gy
   Szekely, B
   Szekely, E
   Jaray, B
   Nagy, P
   Sreter, L
   Dank, M
AF Nagy, Peter
   Szentmartoni, Gyongyver
   Szekely, Borbala
   Szekely, Eszter
   Jaray, Balazs
   Nagy, Peter
   Sreter, Lidia
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szekely, Borbala] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Nagy, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sreter, Lidia] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Nagy, P (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 84
EP 85
PG 2
ER

PT J
AU Nagy, T
AF Nagy, Tunde
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Tunde] National Institute of OncologyBudapest, Hungary.
RP Nagy, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 85
EP 85
PG 1
ER

PT J
AU Nemes, K
   Mark, �
   Hajdu, M
   Csorba, G
   Kopper, L
   Csoka, M
   Sebestyen, A
AF Nemes, Karolina
   Mark, Agnes
   Hajdu, Melinda
   Csorba, Gezane
   Kopper, Laszlo
   Csoka, Monika
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemes, Karolina] Semmelweis UniversityBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csorba, Gezane] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Nemes, K (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 85
EP 86
PG 2
ER

PT J
AU Nemeth, H
   Kupcsulik, P
   Petranyi, �
   Tamas, K
   Farkas, M
   Babics, J
   Bodoky, Gy
AF Nemeth, Hajnalka
   Kupcsulik, Peter
   Petranyi, Agota
   Tamas, Karin
   Farkas, Marianne
   Babics, Julia
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Hajnalka] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kupcsulik, Peter] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Tamas, Karin] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Farkas, Marianne] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Babics, Julia] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Nemeth, H (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 86
EP 86
PG 1
ER

PT J
AU Nemeth, K
   Szalai, T
   Karamanne Pakai, A
   Der, A
   Kornya, L
   Farkas, Sz
   Kriszbacher, I
AF Nemeth, Katalin
   Szalai, Tamasne
   Karamanne Pakai, Annamaria
   Der, Aniko
   Kornya, Laszlo
   Farkas, Szimonetta
   Kriszbacher, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Katalin] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Szalai, Tamasne] National Institute of OncologyBudapest, Hungary.
   [Karamanne Pakai, Annamaria] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Der, Aniko] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Kornya, Laszlo] Peterfy HospitalBudapest, Hungary.
   [Farkas, Szimonetta] University of Pecs, Faculty of Health SciencesPecs, Hungary.
   [Kriszbacher, Ildiko] University of Pecs, Faculty of Health SciencesPecs, Hungary.
RP Nemeth, K (reprint author), University of Pecs, Faculty of Health Sciences, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 87
EP 87
PG 1
ER

PT J
AU Nemeth, K
   Szalai, T
   Karamanne Pakai, A
   Der, A
   Matyus, A
   Gazdag, L
   Kriszbacher, I
AF Nemeth, Katalin
   Szalai, Tamasne
   Karamanne Pakai, Annamaria
   Der, Aniko
   Matyus, Anita
   Gazdag, Levente
   Kriszbacher, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Katalin] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Szalai, Tamasne] National Institute of OncologyBudapest, Hungary.
   [Karamanne Pakai, Annamaria] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Der, Aniko] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
   [Matyus, Anita] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Gazdag, Levente] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Kriszbacher, Ildiko] Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi IntezetPecs, Hungary.
RP Nemeth, K (reprint author), Pecsi Tudomanyegyetem, Egeszsegugyi Foiskolai Kar, Klinikai es Apolastudomanyi Intezet, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 87
EP 87
PG 1
ER

PT J
AU Oberna, F
   Santha, B
   Major, T
   Takacsi Nagy, Z
AF Oberna, Ferenc
   Santha, Beata
   Major, Tibor
   Takacsi Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Oberna, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Santha, Beata] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Oberna, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 88
EP 88
PG 1
ER

PT J
AU Ohgaki, H
AF Ohgaki, Hiroko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ohgaki, Hiroko] IARCParis, France.
RP Ohgaki, H (reprint author), IARC, Paris, France.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 88
EP 88
PG 1
ER

PT J
AU Olasz, J
   Doleschall, Z
   Orosz, Zs
   Csuka, O
AF Olasz, Judit
   Doleschall, Zoltan
   Orosz, Zsolt
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Judit] National Institute of OncologyBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
RP Olasz, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 88
EP 89
PG 2
ER

PT J
AU Orban, E
   Miklan, Zs
   Banoczi, Z
   Hudecz, F
AF Orban, Erika
   Miklan, Zsanett
   Banoczi, Zoltan
   Hudecz, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Miklan, Zsanett] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Banoczi, Zoltan] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Hudecz, Ferenc] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Department of Organic ChemistryBudapest, Hungary.
RP Orban, E (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 89
EP 89
PG 1
ER

PT J
AU Orosz, MZs
   Garai, G
AF Orosz, Maria Zsuzsa
   Garai, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Maria Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Garai, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Orosz, MZs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 89
EP 89
PG 1
ER

PT J
AU Ostoros, Gy
   Sarosi, V
   Losonczy, Gy
   Tolnay, E
   Molnar, L
AF Ostoros, Gyula
   Sarosi, Veronika
   Losonczy, Gyorgy
   Tolnay, Edina
   Molnar, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Sarosi, Veronika] County Hospital of BaranyaPecs, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
   [Molnar, Lajos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 90
EP 90
PG 1
ER

PT J
AU Orfi, Z
   Nagy, K
   Jori, B
   Wiesner, T
   Penzes, K
   Kurko, I
   Barti-Juhasz, H
   Mihalik, R
   Kopper, L
   Schwab, R
   Keri, Gy
AF Orfi, Zoltan
   Nagy, Katalin
   Jori, Balazs
   Wiesner, Teresa
   Penzes, Kinga
   Kurko, Ibolya
   Barti-Juhasz, Helga
   Mihalik, Rudolf
   Kopper, Laszlo
   Schwab, Richard
   Keri, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orfi, Zoltan] Vichem Kft.Budapest, Hungary.
   [Nagy, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jori, Balazs] KPS Kft.Budapest, Hungary.
   [Wiesner, Teresa] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Penzes, Kinga] Vichem Kft.Budapest, Hungary.
   [Kurko, Ibolya] Vichem Kft.Budapest, Hungary.
   [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Keri, Gyorgy] Vichem Kft.Budapest, Hungary.
RP Orfi, Z (reprint author), Vichem Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 90
EP 91
PG 2
ER

PT J
AU Pap, �
AF Pap, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pap, Eva] National Institute of OncologyBudapest, Hungary.
RP Pap, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 91
EP 91
PG 1
ER

PT J
AU Papai, Zs
   Lahm, E
   Uhlyarik, A
   Sikter, M
   Ray-Coquard, 
   Le Cesne, A
   Schoffski, P
   Marreaud, S
   De Brauwer, A
   Blay, JY
AF Papai, Zsuzsanna
   Lahm, Erika
   Uhlyarik, Andrea
   Sikter, Marta
   Ray-Coquard, 
   Le Cesne, Axel
   Schoffski, Patrick
   Marreaud, Sandrine
   De Brauwer, Annelies
   Blay, Jean-Yves
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Ray-Coquard, ] Centre Regional Leon BerardLyon, France.
   [Le Cesne, Axel] Institute Gustave RoussyVillejuif, France.
   [Schoffski, Patrick] Catholic University of LeuvenLeuven, Belgium.
   [Marreaud, Sandrine] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [De Brauwer, Annelies] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [Blay, Jean-Yves] Centre Regional Leon BerardLyon, France.
RP Papai, Zs (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 91
EP 92
PG 2
ER

PT J
AU Papp, J
   Kovacs, M�
   Szentirmay, Z
   Otto, Sz
   Olah, E
   Ray-Coquard, 
   Le Cesne, A
   Schoffski, P
   Marreaud, S
   De Brauwer, A
   Blay, JY
AF Papp, Janos
   Kovacs, Marietta Eva
   Szentirmay, Zoltan
   Otto, Szabolcs
   Olah, Edit
   Ray-Coquard, 
   Le Cesne, Axel
   Schoffski, Patrick
   Marreaud, Sandrine
   De Brauwer, Annelies
   Blay, Jean-Yves
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Marietta Eva] National Institute of OncologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
   [Olah, Edit] National Institute of OncologyBudapest, Hungary.
   [Ray-Coquard, ] Centre Regional Leon BerardLyon, France.
   [Le Cesne, Axel] Institute Gustave RoussyVillejuif, France.
   [Schoffski, Patrick] Catholic University of LeuvenLeuven, Belgium.
   [Marreaud, Sandrine] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [De Brauwer, Annelies] GlaxoSmithKline, ResearchTriangle Park, NC, USA.
   [Blay, Jean-Yves] Centre Regional Leon BerardLyon, France.
RP Papp, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 92
EP 92
PG 1
ER

PT J
AU Papp, Z
   Vajda, J
   Veres, R
   Banczerowski, P
AF Papp, Zoltan
   Vajda, Janos
   Veres, Robert
   Banczerowski, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Zoltan] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Vajda, Janos] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Veres, Robert] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Banczerowski, Peter] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
RP Papp, Z (reprint author), Orszagos Pszichiatriai es Neurologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 92
EP 93
PG 3
ER

PT J
AU Paraczki, �
   Szucs, Zs
   Lantos, �
   Papay, J
   Tolnay, E
AF Paraczki, Agnes
   Szucs, Zsuzsanna
   Lantos, Akos
   Papay, Judit
   Tolnay, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Paraczki, Agnes] County Hospital of PulmonologyTorokbalint, Hungary.
   [Szucs, Zsuzsanna] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Paraczki, � (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 93
EP 93
PG 1
ER

PT J
AU Patko, T
   Koltai, P
   Remenar, �
   Boer, A
AF Patko, Tamas
   Koltai, Pal
   Remenar, Eva
   Boer, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patko, Tamas] National Institute of OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
RP Patko, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 93
EP 94
PG 2
ER

PT J
AU Patonay, P
   Naszaly, A
   Mayer, �
AF Patonay, Peter
   Naszaly, Attila
   Mayer, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 94
EP 94
PG 1
ER

PT J
AU Pazsitka, A
   Barti-Juhasz, H
   Schwab, R
   Kopper, L
   Petak, I
   Mihalik, R
AF Pazsitka, Andras
   Barti-Juhasz, Helga
   Schwab, Richard
   Kopper, Laszlo
   Petak, Istvan
   Mihalik, Rudolf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pazsitka, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barti-Juhasz, Helga] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
   [Mihalik, Rudolf] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Pazsitka, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 94
EP 95
PG 2
ER

PT J
AU Perlaky, T
   Kiss, J
   Tarjan, Zs
   Mester, �
   Szendroi, M
AF Perlaky, Tamas
   Kiss, Janos
   Tarjan, Zsolt
   Mester, Adam
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Perlaky, Tamas] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Tarjan, Zsolt] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Mester, Adam] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Perlaky, T (reprint author), Semmelweis University, Department of Orthopedics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 95
EP 95
PG 1
ER

PT J
AU Petak, I
   Schwab, R
   Keri, Gy
   Kopper, L
AF Petak, Istvan
   Schwab, Richard
   Keri, Gyorgy
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petak, Istvan] KPS Kft.Budapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Keri, Gyorgy] Vichem Kft.Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Petak, I (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 95
EP 96
PG 2
ER

PT J
AU Pete, I
   Udvary, J
   Pulay, T
AF Pete, Imre
   Udvary, Janos
   Pulay, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of OncologyBudapest, Hungary.
   [Udvary, Janos] National Institute of OncologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of OncologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 96
EP 96
PG 1
ER

PT J
AU Petri, K
   Toth, E
   Schneider, T
   Molnar, Zs
   Varady, E
AF Petri, Klara
   Toth, Eszter
   Schneider, Tamas
   Molnar, Zsuzsa
   Varady, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of OncologyBudapest, Hungary.
   [Toth, Eszter] National Institute of OncologyBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 96
EP 97
PG 2
ER

PT J
AU Pinter, F
   Varkondi, E
   Kovesdi, A
   Szabo, E
   Schwab, R
   Kopper, L
   Petak, I
AF Pinter, Ferenc
   Varkondi, Edit
   Kovesdi, Andrea
   Szabo, Edit
   Schwab, Richard
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Varkondi, Edit] KPS Kft.Budapest, Hungary.
   [Kovesdi, Andrea] KPS Kft.Budapest, Hungary.
   [Szabo, Edit] KPS Kft.Budapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Pinter, F (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 97
EP 97
PG 1
ER

PT J
AU Pintye, �
   Dobos, E
   Kovacs, AB
   Simon, M
   Szluha, K
   Hascsi, Zs
   Opposits, G
   Emri, M
AF Pintye, Eva
   Dobos, Erik
   Kovacs, Attila Barna
   Simon, Mihaly
   Szluha, Kornelia
   Hascsi, Zsolt
   Opposits, Gabor
   Emri, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Dobos, Erik] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kovacs, Attila Barna] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Simon, Mihaly] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Hascsi, Zsolt] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
   [Opposits, Gabor] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Pintye, � (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 97
EP 98
PG 2
ER

PT J
AU Posafalvi, A
   Juhasz, A
   Gyetvai, A
   Toth, K
   Halmos, G
AF Posafalvi, Anna
   Juhasz, Aliz
   Gyetvai, Andras
   Toth, Kalman
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Posafalvi, Anna] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Juhasz, Aliz] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Gyetvai, Andras] Szegedi Tudomanyegyetem, Ortopediai KlinikaSzeged, Hungary.
   [Toth, Kalman] Szegedi Tudomanyegyetem, Ortopediai KlinikaSzeged, Hungary.
   [Halmos, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
RP Posafalvi, A (reprint author), University of Debrecen, Department of Pharmacology and Pharmacotherapy, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 98
EP 98
PG 1
ER

PT J
AU Puskas, �
AF Puskas, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Eva] ESZSZK Szent Laszlo Korhaz, HospiceBudapest, Hungary.
RP Puskas, � (reprint author), ESZSZK Szent Laszlo Korhaz, Hospice, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 98
EP 98
PG 1
ER

PT J
AU Racz, G
AF Racz, Gizella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Racz, Gizella] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Racz, G (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 99
EP 99
PG 1
ER

PT J
AU Racz, L
   Novak, M
AF Racz, Laszlone
   Novak, Melinda
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Racz, Laszlone] National Institute of OncologyBudapest, Hungary.
   [Novak, Melinda] National Institute of OncologyBudapest, Hungary.
RP Racz, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 99
EP 99
PG 1
ER

PT J
AU Radacsi, A
   Takacs, E
   Kocsis, J
   Toth, �K
   Szilvasi, I
AF Radacsi, Andrea
   Takacs, Edit
   Kocsis, Judit
   Toth, Eva Katalin
   Szilvasi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Radacsi, Andrea] Semmelweis Egyetem, KUT, Izotop OsztalyBudapest, Hungary.
   [Takacs, Edit] Semmelweis Egyetem, KUT, Izotop OsztalyBudapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Szilvasi, Istvan] Magyar Honvedseg Egeszsegugyi Kozpont, Nuklearis MedicinaBudapest, Hungary.
RP Radacsi, A (reprint author), Semmelweis Egyetem, KUT, Izotop Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 99
EP 100
PG 2
ER

PT J
AU Rektorovics, K
AF Rektorovics, Kitti
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rektorovics, Kitti] National Institute of OncologyBudapest, Hungary.
RP Rektorovics, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 100
EP 100
PG 1
ER

PT J
AU Remenar, �
   Borbely, K
   Lengyel, Zs
   Godeny, M
   Kasler, M
AF Remenar, Eva
   Borbely, Katalin
   Lengyel, Zsolt
   Godeny, Maria
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 100
EP 100
PG 1
ER

PT J
AU Remenar, �
   Lovey, J
   Boer, A
   Fulop, M
   Koltai, P
   Patko, T
   Andi, J
   Bocs, K
   Horvath, K
   Godeny, M
   Kasler, M
AF Remenar, Eva
   Lovey, Jozsef
   Boer, Andras
   Fulop, Miklos
   Koltai, Pal
   Patko, Tamas
   Andi, Judit
   Bocs, Katalin
   Horvath, Katalin
   Godeny, Maria
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Remenar, Eva] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of OncologyBudapest, Hungary.
   [Fulop, Miklos] National Institute of OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of OncologyBudapest, Hungary.
   [Patko, Tamas] National Institute of OncologyBudapest, Hungary.
   [Andi, Judit] National Institute of OncologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of OncologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 101
EP 101
PG 1
ER

PT J
AU Renyi, I
   Jakab, Zs
AF Renyi, Imre
   Jakab, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Renyi, Imre] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Jakab, Zsuzsa] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Renyi, I (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 101
EP 101
PG 1
ER

PT J
AU Renyi-Vamos, F
   Hoda, MA
   Jaksch, P
   Taghavi, Sh
   Lang, Gy
   Aigner, C
   Scheed, A
   Toth, L
   Kasler, M
   Klepetko, W
AF Renyi-Vamos, Ferenc
   Hoda, Mir Alireza
   Jaksch, Peter
   Taghavi, Shahrokh
   Lang, Gyorgy
   Aigner, Clemens
   Scheed, Axel
   Toth, Laszlo
   Kasler, Miklos
   Klepetko, Walter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Hoda, Mir Alireza] National Institute of OncologyBudapest, Hungary.
   [Jaksch, Peter] National Institute of OncologyBudapest, Hungary.
   [Taghavi, Shahrokh] National Institute of OncologyBudapest, Hungary.
   [Lang, Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Aigner, Clemens] National Institute of OncologyBudapest, Hungary.
   [Scheed, Axel] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Klepetko, Walter] National Institute of OncologyBudapest, Hungary.
RP Renyi-Vamos, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 102
EP 102
PG 1
ER

PT J
AU Reti, A
   Pap, �
   Budai, B
   Adleff, V
   Zalatnai, A
   Jeney, A
   Kralovanszky, J
AF Reti, Andrea
   Pap, Eva
   Budai, Barna
   Adleff, Vilmos
   Zalatnai, Attila
   Jeney, Andras
   Kralovanszky, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Reti, Andrea] National Institute of OncologyBudapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Adleff, Vilmos] National Institute of OncologyBudapest, Hungary.
   [Zalatnai, Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
RP Reti, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 102
EP 102
PG 1
ER

PT J
AU Risko, �
   Rosta, A
   Molnar, Zs
   Schneider, T
   Varady, E
   Deak, B
   Varga, F
   Szaleczky, E
AF Risko, Agnes
   Rosta, Andras
   Molnar, Zsuzsanna
   Schneider, Tamas
   Varady, Erika
   Deak, Beata
   Varga, Fatima
   Szaleczky, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Risko, Agnes] National Institute of OncologyBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Varga, Fatima] National Institute of OncologyBudapest, Hungary.
   [Szaleczky, Erika] National Institute of OncologyBudapest, Hungary.
RP Risko, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 103
EP 103
PG 1
ER

PT J
AU Romics, I
   Szasz, M
   Szekely, E
   Nyirady, P
   Riesz, P
   Majoros, A
AF Romics, Imre
   Szasz, Marcell
   Szekely, Eszter
   Nyirady, Peter
   Riesz, Peter
   Majoros, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szasz, Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Romics, I (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 103
EP 104
PG 1
ER

PT J
AU Rosta, A
AF Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Rosta, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 104
EP 104
PG 1
ER

PT J
AU Rozsa, B
   Juhasz, A
   Dezso, B
   Toth, Gy
   Flasko, T
   Klekner, �
   Mezey, G
   Bognar, L
   Molnar, A
   Kiss, Cs
   Gyetvai, A
AF Rozsa, Bernadett
   Juhasz, Aliz
   Dezso, Balazs
   Toth, Gyorgy
   Flasko, Tibor
   Klekner, Almos
   Mezey, Geza
   Bognar, Laszlo
   Molnar, Anna
   Kiss, Csongor
   Gyetvai, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rozsa, Bernadett] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Juhasz, Aliz] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Toth, Gyorgy] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Mezey, Geza] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Bognar, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Molnar, Anna] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Gyetvai, Andras] Szegedi Tudomanyegyetem, Ortopediai KlinikaSzeged, Hungary.
RP Rozsa, B (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 104
EP 105
PG 2
ER

PT J
AU Rubovszky, G
   Lang, I
   Koves, I
   Farkas, E
   Horvath, Zs
   Kasler, M
AF Rubovszky, Gabor
   Lang, Istvan
   Koves, Istvan
   Farkas, Emil
   Horvath, Zsolt
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Koves, Istvan] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 105
EP 105
PG 1
ER

PT J
AU Ruzsa, �
   Fekete, I
AF Ruzsa, Agnes
   Fekete, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Fekete, Ilona] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 105
EP 107
PG 3
ER

PT J
AU Ruzsa, �
   Olah, K
AF Ruzsa, Agnes
   Olah, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Olah, Katalin] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Ruzsa, � (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 107
EP 107
PG 1
ER

PT J
AU Ruzsics, I
   Litter, I
   Sarosi, V
   Baliko, Z
AF Ruzsics, Istvan
   Litter, Ilona
   Sarosi, Veronika
   Baliko, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsics, Istvan] Baranya Megyei Korhaz, Kozponti LaboratoriumPecs, Hungary.
   [Litter, Ilona] Baranya Megyei Korhaz, Kozponti LaboratoriumPecs, Hungary.
   [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Baliko, Zoltan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
RP Ruzsics, I (reprint author), Baranya Megyei Korhaz, Kozponti Laboratorium, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 107
EP 107
PG 1
ER

PT J
AU Safrany, G
   Lumniczky, K
   Bogdandi, EN
   Balogh, A
   Felgyinszki, N
   Szatmari, T
AF Safrany, Geza
   Lumniczky, Katalin
   Bogdandi, Eniko Noemi
   Balogh, Andrea
   Felgyinszki, Nikolett
   Szatmari, Tunde
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Bogdandi, Eniko Noemi] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Felgyinszki, Nikolett] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Szatmari, Tunde] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Safrany, G (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 108
EP 108
PG 1
ER

PT J
AU Sapi, Z
AF Sapi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sapi, Z (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 108
EP 108
PG 1
ER

PT J
AU Sapi, Z
   Moskovszky, L
   Szendroi, M
AF Sapi, Zoltan
   Moskovszky, Linda
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moskovszky, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sapi, Z (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 108
EP 108
PG 1
ER

PT J
AU Sarosi, V
   Ruzsics, I
   Grexa, E
   Sinkovicz, A
   Baliko, Z
AF Sarosi, Veronika
   Ruzsics, Istvan
   Grexa, Erzsebet
   Sinkovicz, Andras
   Baliko, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sarosi, Veronika] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Ruzsics, Istvan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Grexa, Erzsebet] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Sinkovicz, Andras] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
   [Baliko, Zoltan] Baranya County Hospital, Department of Respiratory MedicinePecs, Hungary.
RP Sarosi, V (reprint author), Baranya County Hospital, Department of Respiratory Medicine, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 108
EP 110
PG 1
ER

PT J
AU Schmidt, E
   Balatoni, T
   Hitre, E
   Liszkay, G
AF Schmidt, Emese
   Balatoni, Timea
   Hitre, Erika
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schmidt, Emese] National Institute of OncologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Schmidt, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 110
EP 110
PG 1
ER

PT J
AU Schmidt, E
   Szabo, Zs
   Derczy, K
   Weninger, Cs
   Szekeres, S
   Sarkadi, M
   Zambo, K
AF Schmidt, Erzsebet
   Szabo, Zsuzsanna
   Derczy, Katalin
   Weninger, Csaba
   Szekeres, Sarolta
   Sarkadi, Margit
   Zambo, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schmidt, Erzsebet] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szabo, Zsuzsanna] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Derczy, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Weninger, Csaba] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szekeres, Sarolta] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Sarkadi, Margit] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Schmidt, E (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 110
EP 111
PG 2
ER

PT J
AU Schneider, T
   Toth, E
   Lovey, J
   Molnar, Zs
   Varady, E
   Deak, B
   Szaleczky, E
   Varga, F
   Petri, K
   Lengyel, Zs
   Rosta, A
AF Schneider, Tamas
   Toth, Erika
   Lovey, Jozsef
   Molnar, Zsuzsa
   Varady, Erika
   Deak, Beata
   Szaleczky, Erika
   Varga, Fatima
   Petri, Klara
   Lengyel, Zsolt
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Toth, Erika] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Szaleczky, Erika] National Institute of OncologyBudapest, Hungary.
   [Varga, Fatima] National Institute of OncologyBudapest, Hungary.
   [Petri, Klara] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Schneider, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 111
EP 111
PG 1
ER

PT J
AU Schonleber, J
   Olah, J
   Baranyai, L
   Kornyei, J
   Pap, �
   Kralovanszky, J
   Jeney, A
AF Schonleber, Julianna
   Olah, Julia
   Baranyai, Lajos
   Kornyei, Jozsef
   Pap, Eva
   Kralovanszky, Judit
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schonleber, Julianna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Baranyai, Lajos] Magyar Tudomanyos Akademia, Izotop Zrt.Budapest, Hungary.
   [Kornyei, Jozsef] Magyar Tudomanyos Akademia, Izotop Zrt.Budapest, Hungary.
   [Pap, Eva] National Institute of OncologyBudapest, Hungary.
   [Kralovanszky, Judit] National Institute of OncologyBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Schonleber, J (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 112
EP 112
PG 1
ER

PT J
AU Schulcz, �
   Vincze, Z
   Gaal, D
   Csuka, O
AF Schulcz, Akos
   Vincze, Zoltan
   Gaal, Dezso
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schulcz, Akos] National Institute of OncologyBudapest, Hungary.
   [Vincze, Zoltan] Szent Istvan University, Faculty of Veterinary MedicineBudapest, Hungary.
   [Gaal, Dezso] National Institute of OncologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
RP Schulcz, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 112
EP 112
PG 1
ER

PT J
AU Schwab, R
   Kovesd, Zs
   Fodor, Gy
   Gelley, A
   Szokoloczi, O
   Petak, I
AF Schwab, Richard
   Kovesd, Zsuzsa
   Fodor, Gyorgy
   Gelley, Andras
   Szokoloczi, Orsolya
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schwab, Richard] Kelen Korhaz Kft.Budapest, Hungary.
   [Kovesd, Zsuzsa] Kelen Korhaz Kft.Budapest, Hungary.
   [Fodor, Gyorgy] Kelen Korhaz Kft.Budapest, Hungary.
   [Gelley, Andras] Kelen Korhaz Kft.Budapest, Hungary.
   [Szokoloczi, Orsolya] KPS Kft.Budapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Schwab, R (reprint author), Kelen Korhaz Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 113
EP 113
PG 1
ER

PT J
AU Seber, J
AF Seber, Jozsefne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Seber, Jozsefne] National Institute of OncologyBudapest, Hungary.
RP Seber, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 113
EP 113
PG 1
ER

PT J
AU Sikter, M
   Kokai, T
   Lahm, E
   Uhlyarik, A
   Vachaja, J
   Papai, Zs
AF Sikter, Marta
   Kokai, Tunde
   Lahm, Erika
   Uhlyarik, Andrea
   Vachaja, Jozsef
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Sikter, M (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 114
EP 114
PG 1
ER

PT J
AU Simon, P
   Bahery, M
   Feher, I
   Horvath, Zs
   Toth, L
   Godeny, M
AF Simon, Peter
   Bahery, Maria
   Feher, Istvan
   Horvath, Zsolt
   Toth, Laszlo
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simon, Peter] National Institute of OncologyBudapest, Hungary.
   [Bahery, Maria] National Institute of OncologyBudapest, Hungary.
   [Feher, Istvan] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Simon, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 114
EP 114
PG 1
ER

PT J
AU Somlai, B
   Harsing, J
   Bottlik, Gy
   Remport, �
   Torok, Sz
   Foldes, K
   Perner, F
   Karpati, S
AF Somlai, Beata
   Harsing, Judit
   Bottlik, Gyula
   Remport, Adam
   Torok, Szilard
   Foldes, Katalin
   Perner, Ferenc
   Karpati, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Harsing, Judit] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Bottlik, Gyula] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Remport, Adam] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Torok, Szilard] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Foldes, Katalin] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Perner, Ferenc] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Karpati, Sarolta] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Somlai, B (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 115
EP 115
PG 1
ER

PT J
AU Somlyai, G
   Krempels, K
   Somlyai, I
   Molnar, M
   Gyongyi, Z
AF Somlyai, Gabor
   Krempels, Krisztina
   Somlyai, Ildiko
   Molnar, Miklos
   Gyongyi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somlyai, Gabor] HYD Rakkutato es Gyogyszerfejleszto KftPecs, Hungary.
   [Krempels, Krisztina] HYD Rakkutato es Gyogyszerfejleszto KftPecs, Hungary.
   [Somlyai, Ildiko] HYD Rakkutato es Gyogyszerfejleszto KftPecs, Hungary.
   [Molnar, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Gyongyi, Zoltan] University of PecsPecs, Hungary.
RP Somlyai, G (reprint author), HYD Rakkutato es Gyogyszerfejleszto Kft, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 115
EP 115
PG 1
ER

PT J
AU Somoracz, �
   Holzbauer, �
   Lotz, G
   Torzsok, P
   Szijarto, A
   Kupcsulik, P
   Schaff, Zs
   Kiss, A
AF Somoracz, Aron
   Holzbauer, Agnes
   Lotz, Gabor
   Torzsok, Peter
   Szijarto, Attila
   Kupcsulik, Peter
   Schaff, Zsuzsa
   Kiss, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somoracz, Aron] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Holzbauer, Agnes] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Torzsok, Peter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szijarto, Attila] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Kupcsulik, Peter] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Somoracz, � (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 116
EP 116
PG 1
ER

PT J
AU Strausz, J
   Udud, K
   Markoczy, Zs
   Fulop, A
   Rojko, L
   Dome, B
   Timar, J
AF Strausz, Janos
   Udud, Katalin
   Markoczy, Zsolt
   Fulop, Andrea
   Rojko, Livia
   Dome, Balazs
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Strausz, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Udud, Katalin] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Fulop, Andrea] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Rojko, Livia] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Strausz, J (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 116
EP 116
PG 1
ER

PT J
AU Szabados, L
   Hascsi, Zs
   Garai, I
AF Szabados, Lajos
   Hascsi, Zsolt
   Garai, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabados, Lajos] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Hascsi, Zsolt] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Garai, Ildiko] PET-CT Medical Diagnostic LtdBudapest, Hungary.
RP Szabados, L (reprint author), PET-CT Medical Diagnostic Ltd, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 116
EP 117
PG 2
ER

PT J
AU Szabo, A
   Nagy, A
AF Szabo, Attila
   Nagy, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Attila] National Institute of OncologyBudapest, Hungary.
   [Nagy, Attila] National Institute of OncologyBudapest, Hungary.
RP Szabo, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 117
EP 117
PG 1
ER

PT J
AU Szabo, E
AF Szabo, Eszter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eszter] National Institute of OncologyBudapest, Hungary.
RP Szabo, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 117
EP 117
PG 1
ER

PT J
AU Szabo, �
   Bidlek, M
   Schneider, F
   Horvath, Zs
   Toth, L
   Farkas, E
   Gulyas, G
   Polgar, Cs
   Godeny, M
AF Szabo, Eva
   Bidlek, Maria
   Schneider, Ferenc
   Horvath, Zsolt
   Toth, Laszlo
   Farkas, Emil
   Gulyas, Gusztav
   Polgar, Csaba
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Schneider, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Farkas, Emil] National Institute of OncologyBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Szabo, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 118
EP 118
PG 1
ER

PT J
AU Szabo, P
   Szilasi, M
AF Szabo, Peter
   Szilasi, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Peter] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Szabo, P (reprint author), University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 118
EP 118
PG 1
ER

PT J
AU Szalai, M
AF Szalai, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Marta] Szazszorszep Hastanc KlubBudapest, Hungary.
RP Szalai, M (reprint author), Szazszorszep Hastanc Klub, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 118
EP 118
PG 1
ER

PT J
AU Szaleczky, E
   Schneider, T
   Deak, B
   Molnar, Zs
   Varady, E
   Varga, F
   Lovey, J
   Toth, E
   Csomor, J
   Matolcsy, A
   Rosta, A
AF Szaleczky, Erika
   Schneider, Tamas
   Deak, Beata
   Molnar, Zsuzsa
   Varady, Erika
   Varga, Fatima
   Lovey, Jozsef
   Toth, Erika
   Csomor, Judit
   Matolcsy, Andras
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szaleczky, Erika] National Institute of OncologyBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Varga, Fatima] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Toth, Erika] National Institute of OncologyBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
RP Szaleczky, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 119
EP 119
PG 1
ER

PT J
AU Szasz, AM
   Micsinai, M
   Tokes, AM
   Madaras, L
   Baranyai, Zs
   Dede, K
   Mersich, T
   Salamon, F
   Kulka, J
AF Szasz, Attila Marcell
   Micsinai, Mariann
   Tokes, Anna-Maria
   Madaras, Lilla
   Baranyai, Zsolt
   Dede, Kristof
   Mersich, Tamas
   Salamon, Ferenc
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Micsinai, Mariann] New York University School of Medicine, Sackler InstituteNew York, USA.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Baranyai, Zsolt] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szasz, AM (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 119
EP 120
PG 2
ER

PT J
AU Szasz, O
   Andocs, G
   Szasz, A
AF Szasz, Oliver
   Andocs, Gabor
   Szasz, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szasz, Oliver] Oncotherm Kft.Budapest, Hungary.
   [Andocs, Gabor] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Szasz, Andras] St. Istvan University, Faculty of Engineering, Department of BiotechnicsBudapest, Hungary.
RP Szasz, O (reprint author), Oncotherm Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 120
EP 120
PG 1
ER

PT J
AU Szegedi, I
   Kovacs, G
   Krivan, G
   Kiss, Cs
AF Szegedi, Istvan
   Kovacs, Gabor
   Krivan, Gergely
   Kiss, Csongor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szegedi, Istvan] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Krivan, Gergely] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
RP Szegedi, I (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 120
EP 121
PG 1
ER

PT J
AU Szekely, Gy
   Vajda, K
   Harisi, R
   Szilvas, �
   Farkas, J
AF Szekely, Gyorgy
   Vajda, Katalin
   Harisi, Revekka
   Szilvas, Agnes
   Farkas, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gyorgy] St John's HospitalBudapest, Hungary.
   [Vajda, Katalin] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Harisi, Revekka] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Szilvas, Agnes] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Farkas, Janos] Saint John’s Hospital, Department of Traumatology and Hand surgeryBudapest, Hungary.
RP Szekely, Gy (reprint author), St John's Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 121
EP 121
PG 1
ER

PT J
AU Szendroi, A
   Dinya, E
   Szasz, AM
   Kardos, M
   Nemeth, Zs
   Romics, I
   Szendroi, M
AF Szendroi, Attila
   Dinya, Elek
   Szasz, Attila Marcell
   Kardos, Magdolna
   Nemeth, Zsuzsanna
   Romics, Imre
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Dinya, Elek] EGIS Pharmaceuticals PLCBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kardos, Magdolna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Nemeth, Zsuzsanna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Szendroi, A (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 121
EP 122
PG 2
ER

PT J
AU Szentmartoni, Gy
   Zergenyi, �
   Torgyik, L
   Toth, A
   Szita, A
   Dank, M
AF Szentmartoni, Gyongyver
   Zergenyi, Eva
   Torgyik, Laszlo
   Toth, Andrea
   Szita, Anita
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Zergenyi, Eva] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Toth, Andrea] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szita, Anita] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Szentmartoni, Gy (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 122
EP 122
PG 1
ER

PT J
AU Szigeti, A
AF Szigeti, Annamaria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Annamaria] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Szigeti, A (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 122
EP 122
PG 1
ER

PT J
AU Szigeti, A
AF Szigeti, Annamaria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Annamaria] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Szigeti, A (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 123
EP 123
PG 1
ER

PT J
AU Szluha, K
   Lazanyi, K
   Papp, J
   Simon, M
   Abramyuk, A
   Tokalov, S
   Wolf, G
   Csere, P
   Abolmaali, N
   Appold, S
   Garai, I
AF Szluha, Kornelia
   Lazanyi, Kornelia
   Papp, Judit
   Simon, Mihaly
   Abramyuk, Andrij
   Tokalov, Sergey
   Wolf, Gunter
   Csere, Peter
   Abolmaali, Nasreddin
   Appold, Steffen
   Garai, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Lazanyi, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Papp, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Simon, Mihaly] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Abramyuk, Andrij] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Tokalov, Sergey] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Wolf, Gunter] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Csere, Peter] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Abolmaali, Nasreddin] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und Radioonkologie, OncoRay ZIK der TU DresdenDresden, Germany.
   [Appold, Steffen] Carl Gustav Carus der TU Dresden, Medizinische Fakultat, Strahlentherapie und RadioonkologieDresden, Germany.
   [Garai, Ildiko] Debreceni Egyetem OEC, PET/CT Orvosi Diagnosztikai KftDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 123
EP 123
PG 1
ER

PT J
AU Szokoloczi, O
   Schwab, R
   Gelley, A
   Kovesd, Zs
   Petak, I
AF Szokoloczi, Orsolya
   Schwab, Richard
   Gelley, Andras
   Kovesd, Zsuzsa
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szokoloczi, Orsolya] KPS Kft.Budapest, Hungary.
   [Schwab, Richard] Kelen Korhaz Kft.Budapest, Hungary.
   [Gelley, Andras] Kelen Korhaz Kft.Budapest, Hungary.
   [Kovesd, Zsuzsa] Kelen Korhaz Kft.Budapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Szokoloczi, O (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 125
EP 125
PG 1
ER

PT J
AU Szucs, M
   Mavrogenis, S
   Riesz, P
   Szendroi, A
   Nyirady, P
   Romics, I
AF Szucs, Miklos
   Mavrogenis, Stelios
   Riesz, Peter
   Szendroi, Attila
   Nyirady, Peter
   Romics, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szucs, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Mavrogenis, Stelios] Semmelweis UniversityBudapest, Hungary.
   [Riesz, Peter] Semmelweis UniversityBudapest, Hungary.
   [Szendroi, Attila] Semmelweis UniversityBudapest, Hungary.
   [Nyirady, Peter] Semmelweis UniversityBudapest, Hungary.
   [Romics, Imre] Semmelweis UniversityBudapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 125
EP 125
PG 1
ER

PT J
AU Szy, K
AF Szy, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szy, Katalin] Peterfy HospitalBudapest, Hungary.
RP Szy, K (reprint author), Peterfy Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 126
EP 126
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Fodor, J
   Oberna, F
   Major, T
   Polgar, Cs
   Kasler, M
AF Takacsi-Nagy, Zoltan
   Fodor, Janos
   Oberna, Ferenc
   Major, Tibor
   Polgar, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 126
EP 126
PG 1
ER

PT J
AU Tamas, K
   Sapi, Z
   Fule, T
   Bodoky, Gy
AF Tamas, Karin
   Sapi, Zoltan
   Fule, Tibor
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamas, Karin] Del-Pesti CentrumkorhazBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fule, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodoky, Gyorgy] Del-Pesti CentrumkorhazBudapest, Hungary.
RP Tamas, K (reprint author), Del-Pesti Centrumkorhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 127
EP 127
PG 1
ER

PT J
AU Tamasi, L
   Muller, V
   Bajcsay, A
   Meszaros, Zs
AF Tamasi, Lilla
   Muller, Veronika
   Bajcsay, Andras
   Meszaros, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Meszaros, Zsolt] Bajcsi Zsilinszky Kh., Mellkassebeszeti OsztalyBudapest, Hungary.
RP Tamasi, L (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 127
EP 128
PG 2
ER

PT J
AU Tamassy, K
   Paldy, A
   Nador, G
AF Tamassy, Klara
   Paldy, Anna
   Nador, Gizella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamassy, Klara] Semmelweis University, Kutvolgyi Clinical CentreBudapest, Hungary.
   [Paldy, Anna] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
   [Nador, Gizella] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Kornyezet-egeszsegugyi IntezetBudapest, Hungary.
RP Tamassy, K (reprint author), Semmelweis University, Kutvolgyi Clinical Centre, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 128
EP 128
PG 1
ER

PT J
AU Tarpay, �
   Otto, Sz
   Szabadosne Nemeth, M
   Burai, M
   Pap, �
AF Tarpay, Adam
   Otto, Szabolcs
   Szabadosne Nemeth, Maria
   Burai, Maria
   Pap, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tarpay, Adam] National Institute of OncologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of OncologyBudapest, Hungary.
   [Szabadosne Nemeth, Maria] National Institute of OncologyBudapest, Hungary.
   [Burai, Maria] National Institute of OncologyBudapest, Hungary.
   [Pap, Akos] National Institute of OncologyBudapest, Hungary.
RP Tarpay, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 128
EP 129
PG 2
ER

PT J
AU Tegze, B
   Munkacsy, Gy
   Penzvalto, Zs
   Gyorffy, B
AF Tegze, Balint
   Munkacsy, Gyongyi
   Penzvalto, Zsofia
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tegze, Balint] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Munkacsy, Gyongyi] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Penzvalto, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Tegze, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 129
EP 129
PG 1
ER

PT J
AU Timar, J
   Hegedus, B
   Raso, E
AF Timar, Jozsef
   Hegedus, Balazs
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 130
EP 130
PG 1
ER

PT J
AU Tolnay, E
   Nagy, A
   Ferenczi, E
   Varga, I
   Lantos, �
   Borbely, T
   Palinkasi, Sz
   Morocz, �
AF Tolnay, Edina
   Nagy, Andrea
   Ferenczi, Eniko
   Varga, Ilona
   Lantos, Akos
   Borbely, Tibor
   Palinkasi, Szvetlana
   Morocz, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
   [Nagy, Andrea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Ferenczi, Eniko] County Hospital of PulmonologyTorokbalint, Hungary.
   [Varga, Ilona] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lantos, Akos] County Hospital of PulmonologyTorokbalint, Hungary.
   [Borbely, Tibor] County Hospital of PulmonologyTorokbalint, Hungary.
   [Palinkasi, Szvetlana] County Hospital of PulmonologyTorokbalint, Hungary.
   [Morocz, Eva] County Hospital of PulmonologyTorokbalint, Hungary.
RP Tolnay, E (reprint author), County Hospital of Pulmonology, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 130
EP 130
PG 1
ER

PT J
AU Toronyi, �
   Chmel, R
   Foldes, K
   Torok, Sz
   Varga, M
   Mathe, Zs
   Sarvary, E
   Vegso, Gy
   Langer, R
AF Toronyi, Eva
   Chmel, Rita
   Foldes, Katalin
   Torok, Szilard
   Varga, Marina
   Mathe, Zsolt
   Sarvary, Eniko
   Vegso, Gyula
   Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toronyi, Eva] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Chmel, Rita] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Foldes, Katalin] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Torok, Szilard] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Varga, Marina] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Mathe, Zsolt] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Sarvary, Eniko] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Toronyi, � (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 131
EP 131
PG 1
ER

PT J
AU Toth, EP
   Hallbauer, I
AF Toth, Erika Piroska
   Hallbauer, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Erika Piroska] National Institute of OncologyBudapest, Hungary.
   [Hallbauer, Ildiko] National Institute of OncologyBudapest, Hungary.
RP Toth, EP (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 132
EP 132
PG 1
ER

PT J
AU Toth, L
AF Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Toth, L (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 132
EP 132
PG 1
ER

PT J
AU Toth, L
   Hitre, E
   Kasler, M
   Borbely, K
AF Toth, Laszlo
   Hitre, Erika
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Hitre, Erika] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Toth, L (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 132
EP 132
PG 1
ER

PT J
AU Toth, V
   Balogh, I
   Toth, Z
AF Toth, Viktoria
   Balogh, Ildiko
   Toth, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Viktoria] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Balogh, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Toth, Zoltan] PET-CT Medical Diagnostic LtdBudapest, Hungary.
RP Toth, V (reprint author), PET-CT Medical Diagnostic Ltd, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 133
EP 133
PG 1
ER

PT J
AU Torzsok, P
   Lotz, G
   Riesz, P
   Szekely, E
   Somoracz, �
   Romics, I
   Schaff, Zs
   Kiss, A
AF Torzsok, Peter
   Lotz, Gabor
   Riesz, Peter
   Szekely, Eszter
   Somoracz, Aron
   Romics, Imre
   Schaff, Zsuzsa
   Kiss, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torzsok, Peter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Somoracz, Aron] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Romics, Imre] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Torzsok, P (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 133
EP 133
PG 1
ER

PT J
AU Udvary, J
   Pete, I
   Pulay, T
AF Udvary, Janos
   Pete, Imre
   Pulay, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Udvary, Janos] National Institute of OncologyBudapest, Hungary.
   [Pete, Imre] National Institute of OncologyBudapest, Hungary.
   [Pulay, Tamas] National Institute of OncologyBudapest, Hungary.
RP Udvary, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 134
EP 134
PG 1
ER

PT J
AU Uhlyarik, A
   Kokai, T
   Lahm, E
   Nagy, P
   Sikter, M
   Vachaja, J
   Papai, Zs
AF Uhlyarik, Andrea
   Kokai, Tunde
   Lahm, Erika
   Nagy, Peter
   Sikter, Marta
   Vachaja, Jozsef
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Uhlyarik, A (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 134
EP 134
PG 1
ER

PT J
AU Vachaja, J
   Vajda, A
   Kiss, E
   Kokai, T
   Uhlyarik, A
   Sikter, M
   Lahm, E
   Nagy, P
   Atol, �
   Szentkereszti, B
   Papai, Zs
AF Vachaja, Jozsef
   Vajda, Adrienn
   Kiss, Edina
   Kokai, Tunde
   Uhlyarik, Andrea
   Sikter, Marta
   Lahm, Erika
   Nagy, Peter
   Atol, Eva
   Szentkereszti, Balazs
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Vajda, Adrienn] Allami Egeszsegugyi Kozpont – Honvedkorhaz, BorgyogyaszatBudapest, Hungary.
   [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephelyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Atol, Eva] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Szentkereszti, Balazs] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
RP Vachaja, J (reprint author), Allami Egeszsegugyi Kozpont, Podmaniczky utcai telephely, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 135
EP 135
PG 1
ER

PT J
AU Varga, E
AF Varga, Eszter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Eszter] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Varga, E (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 135
EP 136
PG 2
ER

PT J
AU Varga, PP
AF Varga, Peter Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Peter Pal] Orszagos Gerincgyogyaszati KozpontBudapest, Hungary.
RP Varga, PP (reprint author), Orszagos Gerincgyogyaszati Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 136
EP 136
PG 1
ER

PT J
AU Varjas, G
   Frohlich, G
   Fodor, J
   Agoston, P
AF Varjas, Geza
   Frohlich, Georgina
   Fodor, Janos
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varjas, Geza] National Institute of OncologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
RP Varjas, G (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 136
EP 136
PG 1
ER

PT J
AU Varkondi, E
   Pinter, F
   Szabo, E
   Kovesdi, A
   Micsik, T
   Papay, J
   Sapi, Z
   Schwab, R
   Kopper, L
   Petak, I
AF Varkondi, Edit
   Pinter, Ferenc
   Szabo, Edit
   Kovesdi, Andrea
   Micsik, Tamas
   Papay, Judit
   Sapi, Zoltan
   Schwab, Richard
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varkondi, Edit] KPS Kft.Budapest, Hungary.
   [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Szabo, Edit] KPS Kft.Budapest, Hungary.
   [Kovesdi, Andrea] KPS Kft.Budapest, Hungary.
   [Micsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Varkondi, E (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 136
EP 137
PG 1
ER

PT J
AU Vaszko, T
   Papp, J
   Geczi, L
   Bodrogi, I
   Olah, E
AF Vaszko, Tibor
   Papp, Janos
   Geczi, Lajos
   Bodrogi, Istvan
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszko, Tibor] National Institute of OncologyBudapest, Hungary.
   [Papp, Janos] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
   [Bodrogi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Olah, Edit] National Institute of OncologyBudapest, Hungary.
RP Vaszko, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 137
EP 137
PG 1
ER

PT J
AU Vegso, Gy
   Gorog, D
   Kobori, L
   Fehervari, I
   Nemes, B
   Langer, R
AF Vegso, Gyula
   Gorog, Denes
   Kobori, Laszlo
   Fehervari, Imre
   Nemes, Balazs
   Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Gorog, Denes] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Kobori, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Fehervari, Imre] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Nemes, Balazs] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Vegso, Gy (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 137
EP 138
PG 2
ER

PT J
AU Vegso, Gy
   Piros, L
   Toronyi, �
   Chmel, R
   Torok, Sz
   Foldes, K
   Molnar, M
   Langer, R
AF Vegso, Gyula
   Piros, Laszlo
   Toronyi, Eva
   Chmel, Rita
   Torok, Szilard
   Foldes, Katalin
   Molnar, Miklos
   Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Piros, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Toronyi, Eva] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Chmel, Rita] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Torok, Szilard] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Foldes, Katalin] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Molnar, Miklos] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Vegso, Gy (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 138
EP 139
PG 2
ER

PT J
AU Veleczki, Zs
AF Veleczki, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Veleczki, Zsuzsa] National Institute of OncologyBudapest, Hungary.
RP Veleczki, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 139
EP 139
PG 1
ER

PT J
AU Vincze, B
   Czeyda-Pommersheim, F
   Udvarhelyi, N
   Horvath, Zs
   Kapuvari, B
   Kovacs, J
   Sulyok, Z
   Toth, L
   Lang, I
   Kasler, M
AF Vincze, Borbala
   Czeyda-Pommersheim, Ferenc
   Udvarhelyi, Nora
   Horvath, Zsolt
   Kapuvari, Bence
   Kovacs, Judit
   Sulyok, Zoltan
   Toth, Laszlo
   Lang, Istvan
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Judit] National Institute of OncologyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Vincze, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 139
EP 140
PG 2
ER

PT J
AU Vincze, B
   Kovacs, J
   Deak, B
   Rosta, A
   Schneider, T
   Szaleczky, E
   Varga, F
   Varady, E
   Kapuvari, B
   Molnar, Zs
AF Vincze, Borbala
   Kovacs, Judit
   Deak, Beata
   Rosta, Andras
   Schneider, Tamas
   Szaleczky, Erika
   Varga, Fatima
   Varady, Erika
   Kapuvari, Bence
   Molnar, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Borbala] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Judit] National Institute of OncologyBudapest, Hungary.
   [Deak, Beata] National Institute of OncologyBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
   [Schneider, Tamas] National Institute of OncologyBudapest, Hungary.
   [Szaleczky, Erika] National Institute of OncologyBudapest, Hungary.
   [Varga, Fatima] National Institute of OncologyBudapest, Hungary.
   [Varady, Erika] National Institute of OncologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of OncologyBudapest, Hungary.
   [Molnar, Zsuzsa] National Institute of OncologyBudapest, Hungary.
RP Vincze, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 140
EP 140
PG 1
ER

PT J
AU Virag, J
   Baksa, G
   Kiss, A
   Timar, J
   Schaff, Zs
   Garami, M
   Hegedus, B
AF Virag, Jozsef
   Baksa, Gabor
   Kiss, Andras
   Timar, Jozsef
   Schaff, Zsuzsa
   Garami, Miklos
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Virag, Jozsef] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Baksa, Gabor] Faculty of Medicine, Semmelweis University, Institute of Human Morphology and Developmental BiologyBudapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Virag, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 141
EP 141
PG 1
ER

PT J
AU Vitalis, E
   Olajos, J
AF Vitalis, Eleonora
   Olajos, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vitalis, Eleonora] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Vitalis, E (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 141
EP 141
PG 1
ER

PT J
AU Vityi, T
   Muller, Z
   Elo, J
   Kotai, Zs
AF Vityi, Tamas
   Muller, Zoltan
   Elo, Janos
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Muller, Zoltan] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Elo, Janos] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Kotai, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Vityi, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 141
EP 142
PG 1
ER

PT J
AU Zambo, K
   Sarkadi, M
   Mezosi, E
   Bajnok, L
   Szabo, Zs
   Szekeres, S
   Schmidt, E
AF Zambo, Katalin
   Sarkadi, Margit
   Mezosi, Emese
   Bajnok, Laszlo
   Szabo, Zsuzsanna
   Szekeres, Sarolta
   Schmidt, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Sarkadi, Margit] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Mezosi, Emese] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Bajnok, Laszlo] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Szabo, Zsuzsanna] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szekeres, Sarolta] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Schmidt, Erzsebet] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Zambo, K (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 142
EP 142
PG 1
ER

PT J
AU Zatkone Puskas, G
AF Zatkone Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zatkone Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Zatkone Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 142
EP 143
PG 2
ER

PT J
AU Zsiray, M
   Markoczy, Zs
   Lengyel, Zs
   Fekeshazy, A
   Borbely, K
AF Zsiray, Miklos
   Markoczy, Zsolt
   Lengyel, Zsolt
   Fekeshazy, Attila
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zsiray, Miklos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Fekeshazy, Attila] PET-CT Medical Diagnostic LtdBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Zsiray, M (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2009
VL 53
IS 5
BP 143
EP 143
PG 1
ER

PT J
TI Bucsuzunk Sugar Janos professzortol (1922-2010); 100 eve szuletett Rode Ivan; Emlekezes Rode Ivanra (1910-1989)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 5
EP 8
PG 4
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; rezisztencia; attetes emlorak; anthracyclin/taxanrezisztens emlorak; palliativ kezeles
ID emlorak; rezisztencia; attetes emlorak; anthracyclin/taxanrezisztens emlorak; palliativ kezeles
AB The treatment of recurrent, progressing, metastatic breast cancer, which has previously been exposed to anthracyclines and/or taxanes is not only a major clinical challenge, but has a significant social impact too. In the absence of formal guidelines, this review aimed to summarize the published evidences that are needed to guide clinical decision-making. Four new agents are approved for use in this setting: capecitabine, gemcitabine, ixabepilone, and nanoparticle albumin-bound paclitaxel. Nevertheless this review summarizes the results of studies with other active agents, as liposomal doxorubicin, rotation of taxanes, larotaxel, vinorelbine, and biologic agents.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Vorosmarty utca 31., 1064 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1064 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 9
EP 16
PG 8
ER

PT J
AU Szekely, B
   Madaras, L
   Szentmartoni, Gy
   Szasz, AM
   Baranyak, Zs
   Szittya, L
   Torgyik, L
   Zergenyi, �
   Borbenyi, E
   Kenessey, I
   Korompay, A
   Langmar, Z
   Banhidy, F
   Kulka, J
   Dank, M
AF Szekely, Borbala
   Madaras, Lilla
   Szentmartoni, Gyongyver
   Szasz, Attila Marcell
   Baranyak, Zsuzsanna
   Szittya, Liliana
   Torgyik, Laszlo
   Zergenyi, Eva
   Borbenyi, Erika
   Kenessey, Istvan
   Korompay, Anna
   Langmar, Zoltan
   Banhidy, Ferenc
   Kulka, Janina
   Dank, Magdolna
TI Comparison of breast cancer in young and old women based on clinicopathological features
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; fiatal; idos; prognozis; tuleles
ID emlorak; fiatal; idos; prognozis; tuleles
AB The two far ends of the age at the diagnosis of breast cancer are the age of younger than 35, and that of older than 70. Most probably, these two groups of patients differ in many ways. The aim of our present study was to underline the fact that age at the diagnosis of breast cancer is indeed a prognostic factor. Between October 1995 and March 2009, 80 old and 51 young breast cancer patients were treated at the Department of Diagnostic Radiology and Oncotherapy, Semmelweis University, Budapest. The prognostic and predictive factors of the tumors were analysed together with the disease-free and overall survival data. There were statistically significant differences between the two groups concerning the menstrual and reproductive factors, histological characteristics and immunophenotype of the tumors. Tumor size, nodal status and the Nottingham Prognostic Index did not show statistically significant differences. A trend to a shorter disease-free survival, higher rate of distant metastases and disease-specific death was seen in the group of young patients, but it was not significant. Overall survival was significantly shorter in the group of young patients. Therefore, we can state that young patients have a more aggressive disease and worse outcome. There is an increased importance of self examination in these groups, since both age groups are beyond the age limits of the screening population in Hungary. The media and primary school education as well should be involved in educating women concerning this aspect. The individual follow-up of young patients with positive family history should also be established.
C1 [Szekely, Borbala] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Baranyak, Zsuzsanna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szittya, Liliana] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
   [Zergenyi, Eva] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
   [Borbenyi, Erika] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Korompay, Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Langmar, Zoltan] Semmelweis University, 2nd Department of Obstetrics and GynecologyBudapest, Hungary.
   [Banhidy, Ferenc] Semmelweis University, 2nd Department of Obstetrics and GynecologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a, 1082 Budapest, Hungary.
RP Szekely, B (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, 1082 Budapest, Hungary.
EM szekely@radi.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 19
EP 26
PG 8
ER

PT J
AU Boncz, I
   Donkane Verebes, �
   Oberfrank, F
   Kasler, M
AF Boncz, Imre
   Donkane Verebes, Eva
   Oberfrank, Ferenc
   Kasler, Miklos
TI Health-economics of oncology care: changes in hospital bed capacity
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE egeszsegbiztositas; korhazi agykapacitas; egeszsegpolitika; onkologia
ID egeszsegbiztositas; korhazi agykapacitas; egeszsegpolitika; onkologia
AB The aim of our study was to analyze the effect of hospital bed reforms on April 1, 2007 in Hungary, with special respect to the changes of acute care cancer beds. Data were derived from the database of the National Health Insurance Fund Administration (OEP). We identified cancer care hospital capacities (beds) with the following financial codes: code nr. 12 (oncology), code nr. 24 (radiotherapy) and code nr. 28 (hematology). We analyzed the changes of these beds before and after the reform. The total number of acute care hospital beds decreased by 25.7%, while in the field of cancer care beds we found different trends. The number of hospital beds for oncology care and hematology care decreased by 11.4% and 11.1%, respectively. The number of hospital beds for radiotherapy departments even increased by 16.3%. We did not find any changes in regional inequalities. We can conclude that during the hospital bed reform in 2007, the number of oncology and hematology care beds decreased less than the total number of acute care hospital beds, and the number of beds for radiotherapy even increased, without significantly aff ecting the regional inequalities.
C1 [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, Vorosmarty u. 4., 7621 Pecs, Hungary.
   [Donkane Verebes, Eva] Integra Consulting ZrtBudapest, Hungary.
   [Oberfrank, Ferenc] MTA, Kiserleti Orvostudomanyi KutatointezetBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, 7621 Pecs, Hungary.
EM imre.boncz@etk.pte.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 29
EP 33
PG 5
ER

PT J
AU Boncz, I
   Donkane Verebes, �
   Oberfrank, F
   Kasler, M
AF Boncz, Imre
   Donkane Verebes, Eva
   Oberfrank, Ferenc
   Kasler, Miklos
TI Health economics of oncology care: financial effect of performance volume limit (PVL)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE egeszsegbiztositas; finanszirozas; egeszsegpolitika; onkologia
ID egeszsegbiztositas; finanszirozas; egeszsegpolitika; onkologia
AB The aim of our study is to analyze the effect of performance volume limit (PVL) on the performance indicators of acute oncology care, with special respect to the health insurance reimbursement not paid to health care providers. Data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP) covering the period of 2006-2008. We analyzed the effect of PVL according to medical specialities. We calculated the average annual reimbursement rate of DRG cost-weight with and without the application of PVL. The loss due to PVL was calculated both by monetary terms and as the % of annual revenue. The loss of medical specialities measured by monetary units (Hungarian forint, HUF) and as a percent of their revenues was the following in 2008: oncology 1327 million HUF (4.7%), cardiology 791 million HUF (3.0%), gynecology and obstetrics 772 million HUF (3.0%), internal medicine 708 million HUF (3.3%), intensive care 661 million HUF (2.5%), surgery 637 million HUF (3.2%), pediatrics 614 million HUF (3.9%), traumatology 545 million HUF (2.5%), radiotherapy 438 million HUF (3.1%). The application of performance volume limit had significantly different effect on the different medical specialities. Oncology care can be considered as one of the largest losers of the application of performance volume limit.
C1 [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, Vorosmarty u. 4., 7621 Pecs, Hungary.
   [Donkane Verebes, Eva] Integra Consulting ZrtBudapest, Hungary.
   [Oberfrank, Ferenc] MTA, Kiserleti Orvostudomanyi KutatointezetBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, 7621 Pecs, Hungary.
EM imre.boncz@etk.pte.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 35
EP 39
PG 5
ER

PT J
AU Maroti-Nagy, �
   Paulik, E
   Thurzo, L
AF Maroti-Nagy, Agnes
   Paulik, Edit
   Thurzo, Laszlo
TI Medical staff's advice and changes in dietary behavior in Hungarian women with cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; nogyogyaszati tumor; tanacsadas; taplalkozasvaltoztatas
ID emlorak; nogyogyaszati tumor; tanacsadas; taplalkozasvaltoztatas
AB The aim of this study was to investigate the changes in dietary habits in women with gynecological or breast cancer, and to analyze the role of some demographic factors, type of the malignant tumor, and the role of medical staff's advice in dietary behavior change of these women, after the diagnosis of cancer. A self-administered questionnaire-based retrospective study was performed, and 155 randomly selected patients, treated for gynecological or breast cancer, were involved. A self-developed questionnaire was used to measure the socio-demographic characteristics, the circumstances of visiting the physician, therapy, present health status and lifestyle before and after the diagnosis of neoplasm. More than three-fourths of the women reported changes in nutrition after the diagnosis of cancer. The consumption of fruits and vegetables increased in the highest proportion (70.3%). Women with higher education changed their diet in higher proportion (p=0.031) compared to women with lower education. Women who were advised to change their lifestyle by their therapists were about four times more likely (OR: 3.87; CI: 1.40-10.69 ) to change their nutrition. Patients with breast cancer changed three times more likely (OR: 3.21; CI: 1.05-9.84) their dietary habits than patients with gynecological cancer. The most influential proven factor to make cancer patients alter their diet was being advised for this by physicians. Thus, our study proved that physicians and nurses have a very important role in changing their cancer patients' nutritional habits into a healthier one.
C1 [Maroti-Nagy, Agnes] Szegedi Tudomanyegyetem, AOK, Nepegeszsegtani Intezet, Dom ter 10., 6720 Szeged, Hungary.
   [Paulik, Edit] Szegedi Tudomanyegyetem, AOK, Nepegeszsegtani Intezet, Dom ter 10., 6720 Szeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maroti-Nagy, � (reprint author), Szegedi Tudomanyegyetem, AOK, Nepegeszsegtani Intezet, 6720 Szeged, Hungary.
EM nagya@puhe.szote.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 41
EP 45
PG 5
ER

PT J
AU Lapis, K
AF Lapis, Karoly
TI Host defense peptides and peptidomimetics as new weapons for cancer treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE rakellenes peptidek; antimikrobialis peptidek; gazdavedo peptidek
ID rakellenes peptidek; antimikrobialis peptidek; gazdavedo peptidek
AB Host defence peptides (HDP) produced by almost all species of living organisms and widely recognized as antimicrobial antibiotics have also proved to be capable of killing a wide variety of cancer cells. In this respect they have many advantages over conventional cytotoxic chemotherapeutic agents. They seem to kill cancer cells by effects on plasma membranes and/or the membranes of mitochondria. They are often effective against multidrug-resistant cells. They have a broad spectrum of activity in that their killing effects are not restricted to particular kinds of cancer. Above all they commonly have few side effects in that they do not have the same detrimental effects on normal cells as they do on cancer cells. It has been demonstrated that HDP can be used as effective adjuvants to conventional chemotherapeutic agents. In addition they have effects on neo-angiogenesis which is important in relation to tumour growth. HDP have been shown to be powerful immunomodulators in a number of circumstances and in this respect they are believed to be instrumental in strengthening immunological host defence against cancer cells. Importantly it has also been shown that certain HDP have the capability to alter the capacity of cells to import Ca ions by aff ecting the location and thus function of calreticulin. Such changes it has been argued are significant in facilitating the killing of tumour cells by immunogical means. HDP constitute a novel class of anticancer agents for which, as we develop better knowledge of their pharmacokinetic profiles and learn better how to tailor their administration, hold high promise to augment or even replace the currently available cytotoxic anticancer chemotherapeutic agents most of which owe their efficacy to their capacity to bind to and damage target cell DNA.
C1 [Lapis, Karoly] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Lapis, K (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM lapkar@t-online.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 47
EP 58
PG 12
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular basis of bone metastasis formation and its targeted therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE csontatt etkepzes; molekularis mechanizmus; celzott terapia
ID csontatt etkepzes; molekularis mechanizmus; celzott terapia
AB Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF receptor family member RANK and its ligand RANKL. The feasibility of using this system to control bone resorption or cancer-induced skeletal events was proven clinically in trials using an anti-RANKL antibody. The clinical success of anti-RANKL antibody therapy provide further evidence that only precise identification of molecular pathways operational in cancers can lead to discovery of more effective (targeted) therapies.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@korb2.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 59
EP 64
PG 6
ER

PT J
AU Thurzo, L
   Kasler, M
   Tolnay, E
AF Thurzo, Laszlo
   Kasler, Miklos
   Tolnay, Edina
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2009. november 11-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Thurzo, Laszlo] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Kasler, Miklos] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Tolnay, Edina] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Thurzo, L (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 65
EP 69
PG 5
ER

PT J
TI Elnoki beszamolo; Fotitkari beszamolo; Kincstarnoki beszamolo (2007. november-2009. november)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2010
VL 54
IS 1
BP 71
EP 78
PG 8
ER

PT J
AU Horvath, �
AF Horvath, Akos
TI Stereotaxic brain radiosurgery in Hungary 1991-2009
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE sztereotaxia; agyi sugarsebeszet; indikaciok; modszerek; eredmenyek
ID sztereotaxia; agyi sugarsebeszet; indikaciok; modszerek; eredmenyek
AB Stereotaxic brain radiosurgery as a non-invasive type of local treatment appeared as a therapeutic approach of intracranial lesions in the middle of the last century. Originally it was developed for treating functional disorders but with the evolution of their medication the clinical need increasingly turned to treating pathomorphological intracerebral target volumes. A review of the indication's historical changes and the installation, methods, results and perspectives of Hungarian brain radiosurgery are presented. During the above mentioned period 2565 patient have been treated in five institutes of Hungary: 52% for brain metastases, 29.5% for benignomas, 12% for arteriovenous malformations, 6% for primary malignant brain tumors and 0.5% for functional disorders. Local tumor control of 86% and median survivals among patients with metastasis of 24 months in RPA class 1, 8.5 months in RPA 2 and 3.4 months in RPA 3 were reported. These results are comparable with those in the literature. Hopefully with a change in the therapeutic approach and better organization of patients' management, stereotaxic brain radiosurgery will be integrated into everyday routine in Hungary.
C1 [Horvath, Akos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Horvath, � (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM akoshorvath.horvathdr8@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 93
EP 98
PG 6
ER

PT J
TI Eloszo
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 100
EP 100
PG 1
ER

PT J
AU Balogh, �
AF Balogh, Adam
TI The stage of cancer surgery at the beginning of the third millenium
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE daganatsebeszet; colorectalis rak; subtotalis colectomia; teljes mesorectalis excisio; multivisceralis resectio
ID daganatsebeszet; colorectalis rak; subtotalis colectomia; teljes mesorectalis excisio; multivisceralis resectio
AB The author presents a historical overview of cancer surgery of the last century. At the last quarter of the century the main characteristic of this process has been the significant extension of surgical radicality. Three new surgical methods appeared and have been routinly used at the Surgical Clinic of the Szeged University School, to increase surgical radicality, to improve survival rate without impairing the postoperative quality of life. 1.) Subtotal colectomy (STC) involves an extended resection of the colon over the splenic flexure. In a period of 8 years a total of 72 STCs were performed for the treatment of large bowel obstructions or symptomatic stenosis caused by cancer of the left colon. STC offers: a) one stage treatment for colonic obstruction in emergency surgery, b.) removal of the tumor with sufficient oncological radicality, c.) primary reconstruction of the digestive tract, with a safe ileocolic anastomosis even in emergency cases. Based on a study about postoperative quality of life of STC operated patients, it proved to be normal. 2.) The author reports a total of 108 middle and low third rectal cancer cases operated on by total mesorectal excision (TME) by the method of Heald. The oncological basis of this procedure is the horizontal regional metastatization of rectal cancer. The author succeeded in 60% of cases to perform an anterior resection with preservation of the anal sphincter, and to decrease the early (within two years after surgery) local recurrence rate from 14.5% to 6.4%, compared to the group of patients operated on by traditional technic. 3.) A total of 154 patients with locally advanced - stage IV - colorectal cancer underwent extended surgery of multivisceral resections as a treatment of cancer process involving adjecent abdominal organs. Surgery was performed to treat advanced cancer of the colon in 112 cases and the one of the rectum in 42 cases. The mortality rate was 7% in the colon cancer group, and 12% in the group of rectal cancer patients. In their tumor-free postoperative period 90% of colon cancer patients and 95% of rectal cancer patients had an improved quality of life. The 5 years survival rate was 40% in the colon group and 22% in the rectal cancer group. In the group of patients having more than 3 simultanously tumorous organs, in spite of the multiple organ resections, no 5 years survival has been recorded.
C1 [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
RP Balogh, � (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM dr.balogh.adam.sandor@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 101
EP 115
PG 15
ER

PT J
TI Dr. Balogh Adam 70 eves
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 116
EP 116
PG 1
ER

PT J
AU Lazar, Gy
   Paszt, A
   Simonka, Zs
   Rokszin, R
   Abraham, Sz
AF Lazar, Gyorgy
   Paszt, Attila
   Simonka, Zsolt
   Rokszin, Richard
   Abraham, Szabolcs
TI Laparoscopic surgery in colorectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE laparoscopos/laparoscoposan asszisztalt belresectio; colorectalis tumor; in testinalis resectio; colorectalis laesio; minimalisan invaziv sebeszet
ID laparoscopos/laparoscoposan asszisztalt belresectio; colorectalis tumor; in testinalis resectio; colorectalis laesio; minimalisan invaziv sebeszet
AB The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases. Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors. The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors. Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008. The surgical indication was neoplastic colorectal lesion in 40 cases. The average age of them was 64 years (from 36 to 89 years). Four patients belonged to the risk group of ASA I, 11 patients to ASA II, 24 to ASA III, and one to ASA IV. Twenty-six patients underwent rectosigmoideal resection, 2 had rectal exstirpation, 9 had right hemicolectomy and one had left hemicolectomy. There were no surgical or postoperative complications. Four conversions and in one case a reoperation occurred due to adhesion ileus. The startup of the passage (2.4 days, on average) and the possibility of nourishing per os were significantly shortened. The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases. Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery. There are a number of benefits for the patients mainly in the early postoperative period (faster recovery, shorter hospitalization) and their long-term survival results are good as well.
C1 [Lazar, Gyorgy] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Rokszin, Richard] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Abraham, Szabolcs] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM lg@surg.szote.u-szeged.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 117
EP 122
PG 5
ER

PT J
AU Petri, A
   Hohn, J
   Balogh, �
   Kovach, K
   Andrasi, L
   Lazar, Gy
AF Petri, Andras
   Hohn, Jozsef
   Balogh, Adam
   Kovach, Kornel
   Andrasi, Laszlo
   Lazar, Gyorgy
TI Surgical treatment of liver metastasis of colorectal cancer: the impact of simultaneous liver and colorectal resection for synchronous colorectal metastasis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE vastagbelrak; attet; maj; indikacio; mutet
ID vastagbelrak; attet; maj; indikacio; mutet
AB Metastatic liver disease is a challenging and life-threatening situation often with dismal prognosis. Nearly half of the patients with colorectal cancer develop liver metastasis during the course of their diseases. Hepatic resection is the treatment of choice in patients with colorectal liver metastasis. This study was conducted to compare the results of patients undergoing simultaneous liver and colorectal resection for synchronous liver metastasis and of those for whom a colorectal and liver resection was made separately. A retrospective analysis was performed on 1597 patients who underwent surgery because of colorectal cancer between January 1999 and December 2008. The results of the treatment were separately evaluated in case of the 152 patients who had liver metastasis. The proportion of the liver metastasis was 9.52%. The metastases arose in 40.8% from the rectum and in 31.8% from the sigmoid colon. It proved to be inoperable in 109 (71.7%) of the 152 patients who had liver metastasis. Simultaneous liver resection was performed because of synchronous metastasis in 14 (32.6%) cases (Group 1) and two step resection in 29 (67.4%) cases (Group 2). In case of synchronous operations only minor liver surgery was done. The mean size of the metastasis was 2.6 cm in diameter in Group 1 and 4.6 cm in Group 2 (p<0.005). The transfused blood volume was 0.3 U/patient. Only minor complications could be observed in Group 1. The hospitalization was 13.1 days in Group 1 and 11.7 days in Group 2. The mean survival time was 37.3 and 47.9 months (p<0.005). Simultaneous liver resection seems to be a safe procedure on those patients who develop small metastases with a limited number. However, the optimal timing of the liver resection and the identification of patients who will have the greatest benefit in survival still remain obscure.
C1 [Petri, Andras] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Balogh, Adam] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Kovach, Kornel] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Andrasi, Laszlo] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
RP Petri, A (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM pa@surg.szote.u-szeged.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 125
EP 128
PG 4
ER

PT J
AU Varga, L
   Baradnay, G
   Hohn, J
   Simonka, Zs
   Hideghethy, K
   Maraz, A
   Nikolenyi, A
   Vereb, B
   Tiszlavicz, L
   Nemeth, I
   Man, E
   Lazar, Gy
AF Varga, Laszlo
   Baradnay, Gellert
   Hohn, Jozsef
   Simonka, Zsolt
   Hideghethy, Katalin
   Maraz, Aniko
   Nikolenyi, Aliz
   Vereb, Blanka
   Tiszlavicz, Laszlo
   Nemeth, Istvan
   Man, Eszter
   Lazar, Gyorgy
TI Clinical and histopathological results aft er the neo-adjuvant treatment of advanced rectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE rectumcarcinoma; neoadjuvans radio-kemoterapia
ID rectumcarcinoma; neoadjuvans radio-kemoterapia
AB The role of the surgical intervention is decisive in treating colorectal tumors. The neo-adjuvant radiochemotherapy has improved the efficacy of the treatment of advanced rectum tumors. In order to decrease the size and stage of advanced rectal carcinoma and to increase the rate of resecability, we introduced neoadjuvant radio-chemotherapy. We carried out neo-adjuvant and surgical treatment in case of 67 patients with rectal adenocarcinoma (T2-4N1-2M0) between June 1, 2005 and July 31, 2008. The average age of the patients was 61.2 years, the division according to sex was 44 males/23 females. Regarding the local stage of the rectal process or the proximity to the sphincter, we applied radio-chemotherapy (radiotherapy 25 times altogether 45 Gy and on the first and last week for 5-5 days they received 350 mg/m2/ day 5-FU and 20 mg/m2/day leucovorin chemotherapy, recently complemented with 3x1.8 Gy advanced boost radiation aiming at the macroscopic tumor site with security zone). Patients underwent surgery 8 weeks on average after restaging examinations. Thirty-eight patients underwent anterior rectal resection with double stapler procedure; there were 18 abdominoperineal rectal extirpations, 7 Hartmann operations and 4 per anum excisions. Compared to the preoperative staging, the histological evaluation of the resected specimens showed total remission (pT0N0) in 11% and partial remission in 43%. The morbidity necessitating reoperation was 5.9%, without mortality and suture insufficiency. The long-term neoadjuvant oncological treatment led to down-staging of rectal tumors in most cases and increased the resecability and rate of resection operations.
C1 [Varga, Laszlo] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Baradnay, Gellert] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Hohn, Jozsef] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Hideghethy, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vereb, Blanka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Nemeth, Istvan] University of Szeged, Department of PathologySzeged, Hungary.
   [Man, Eszter] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of Surgery, Pecsi u. 6., 6720 Szeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM va@surg.szote.u-szeged.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 129
EP 135
PG 7
ER

PT J
AU Ostoros, Gy
   Dome, B
   Strausz, J
   Timar, J
AF Ostoros, Gyula
   Dome, Balazs
   Strausz, Janos
   Timar, Jozsef
TI Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE nem-kissejtes tudorak; kemoterapia; celzott terapia; molekularis diagnosztika
ID nem-kissejtes tudorak; kemoterapia; celzott terapia; molekularis diagnosztika
AB Major advancements have been made in the clinical management of non-small cell lung cancer (NSCLC) in the past decade. This development involved the introduction of pemetrexed and several targeted therapies (bevacizumab, erlotinib, gefitinib) in the first and second line treatments of NSCLC. Novel maintenance therapeutic strategies for NSCLC (erlotinib) and for non-squamous-NSCLC (pemetrexed, bevacizumab+erlotinib) have also been developed resulting in a significant improvement in patient's survival. These changes have modified registrations of various drugs and require continuous update of guidelines and reimbursement schemes as well. These advantages are based on refinement of differential diagnosis of NSCLC and on the development of molecular predictive markers. Our aim is to summarize the changes in the diagnosis and therapy of NSCLC and to present the altered therapeutic scheme.
C1 [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Piheno utca 1., 1525 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Piheno utca 1., 1525 Budapest, Hungary.
   [Strausz, Janos] National Koranyi Institute of Pulmonology, Piheno utca 1., 1525 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, 1525 Budapest, Hungary.
EM ostorosgyula@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 137
EP 143
PG 7
ER

PT J
AU Schuler, D
AF Schuler, Dezso
TI The chemotherapy of pediatric medulloblastoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE medulloblastoma; kemoterapia; molekularis genetika
ID medulloblastoma; kemoterapia; molekularis genetika
AB Medulloblastoma is one of the most frequent brain tumors in childhood. The mortality of medulloblastoma decreased significantly during the last few decades, which was the result of the better surgical and radiotherapy and to the development of chemotherapy. The aim of this publication is the critical review of the present chemotherapeutic treatment. The new therapeutic trials based on the molecular genetic mechanism of these tumors are also mentioned.
C1 [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
RP Schuler, D (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM schdez@gyer2.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 145
EP 152
PG 8
ER

PT J
AU Jakubovits, E
AF Jakubovits, Edit
TI Role of hypnosis and hypno-suggestions methods in the complex therapy of tumor patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE daganat; stressz; hipnozis; spontan transz; hipnoszuggesztiv kommunikacio; poszttraumas novekedes
ID daganat; stressz; hipnozis; spontan transz; hipnoszuggesztiv kommunikacio; poszttraumas novekedes
AB Besides more conventional tumor risks, depression and negative life events are significant risk factors in cancer here in Hungary, therefore oncopsychology is increasingly important. We discuss traumatizing effects of the diagnosis and invasive diagnostic and therapeutic procedures from the viewpoint of altered state of consciousness. During stress and hypnosis brain functioning is altered in a similar way, which can be seen both in the patient's symptoms and his/her physiological and neuroimaging findings. In trance state patients part from reality, they no longer communicate conventionally or maturely. Hypnosis is characterized not only by physical and mental changes, but important unique social interactions as well. These interactions affect the endocrine and immune system and the mental state of the patient, they strengthen and synchronize resources and help posttraumatic growth. Since in the stress induced spontaneous altered state of consciousness the susceptibility to suggestions is increased, suggestive communication can be used effectively and it can even result in formal hypnosis induction. Under the strong time and mental pressure characterizing the work of the oncologic departments, it might help the staff to improve the cooperation with the patient if staff members, physicians and nurses as well, are aware of the nature and the neurophysiologic background of the spontaneous trance state induced by the life-threatening diagnosis of cancer.
C1 [Jakubovits, Edit] Semmelweis University, Institute of Morphology and Physiology, Vas. u. 17., 1088 Budapest, Hungary.
RP Jakubovits, E (reprint author), Semmelweis University, Institute of Morphology and Physiology, 1088 Budapest, Hungary.
EM jakedit@se-etk.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2010
VL 54
IS 2
BP 153
EP 160
PG 8
ER

PT J
AU Kasler, M
AF Kasler, Miklos
TI A 2. Emlorak Konszenzus Konferencia szakmai ajanlasai (2009. november 8-9., Kecskemet) - Eloszo
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 209
EP 209
PG 1
ER

PT J
AU Forrai, G
   Szabo, �
   Ormandi, K
   Ambrozay, �
   Pentek, Z
   Milics, M
   Rajtar, M
   Sinkovics, I
AF Forrai, Gabor
   Szabo, Eva
   Ormandi, Katalin
   Ambrozay, Eva
   Pentek, Zoltan
   Milics, Margit
   Rajtar, Maria
   Sinkovics, Istvan
TI A kepalkoto vizsgalomodszerek alkalmazasa az emlodaganatok korszeru diagnosztikajaban es szureseben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Forrai, Gabor] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Ormandi, Katalin] University of SzegedSzeged, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Pentek, Zoltan] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Milics, Margit] County Hospital of ZalaZalaegerszeg, Hungary.
   [Rajtar, Maria] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Sinkovics, Istvan] National Institute of OncologyBudapest, Hungary.
RP Forrai, G (reprint author), Allami Egeszsegugyi Kozpont, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 211
EP 216
PG 6
ER

PT J
AU Cserni, G
   Francz, M
   Jaray, B
   Kalman, E
   Kovacs, I
   Kulka, J
   Orosz, Zs
   Udvarhelyi, N
   Vass, L
AF Cserni, Gabor
   Francz, Monika
   Jaray, Balazs
   Kalman, Endre
   Kovacs, Ilona
   Kulka, Janina
   Orosz, Zsolt
   Udvarhelyi, Nora
   Vass, Laszlo
TI Az emlorak patologiai diagnosztikaja, feldolgozasa es korszovettani leletezese
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Francz, Monika] Josa Andras County HospitalNyiregyhaza, Hungary.
   [Jaray, Balazs] Semmelweis UniversityBudapest, Hungary.
   [Kalman, Endre] University of PecsPecs, Hungary.
   [Kovacs, Ilona] Kenezy Teaching HospitalDebrecen, Hungary.
   [Kulka, Janina] Semmelweis UniversityBudapest, Hungary.
   [Orosz, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Vass, Laszlo] Flor Ferenc University Hospital of Pest CountyKistarcsa, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 217
EP 226
PG 10
ER

PT J
AU Lazar, Gy
   Besznyak, I
   Boross, G
   Farsang, Z
   Gulyas, G
   Jakab, F
   Maraz, R
   Markus, B
   Toth, L
AF Lazar, Gyorgy
   Besznyak, Istvan
   Boross, Gabor
   Farsang, Zoltan
   Gulyas, Gusztav
   Jakab, Ferenc
   Maraz, Robert
   Markus, Bela
   Toth, Laszlo
TI Az emlorak korszeru sebeszi kezelese
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Lazar, Gyorgy] University of SzegedSzeged, Hungary.
   [Besznyak, Istvan] National Institute of OncologyBudapest, Hungary.
   [Boross, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Farsang, Zoltan] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of OncologyBudapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Markus, Bela] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Toth, Laszlo] National Institute of OncologyBudapest, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 227
EP 234
PG 8
ER

PT J
AU Lang, I
   Kahan, Zs
   Pinter, T
   Dank, M
   Boer, K
   Pajkos, G
   Faluhelyi, Zs
   Piko, B
   Eckhardt, S
   Horvath, Zs
AF Lang, Istvan
   Kahan, Zsuzsanna
   Pinter, Tamas
   Dank, Magdolna
   Boer, Katalin
   Pajkos, Gabor
   Faluhelyi, Zsolt
   Piko, Bela
   Eckhardt, Sandor
   Horvath, Zsolt
TI Az emlorak belgyogyaszati onkologiai (gyogyszeres) kezelese
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of SzegedSzeged, Hungary.
   [Pinter, Tamas] Petz Aladar County HospitalGyor, Hungary.
   [Dank, Magdolna] Semmelweis UniversityBudapest, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Faluhelyi, Zsolt] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Piko, Bela] Bekes County Pandy Kalman HospitalGyula, Hungary.
   [Eckhardt, Sandor] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Lang, I (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 237
EP 254
PG 18
ER

PT J
AU Polgar, Cs
   Csejtei, A
   Gabor, G
   Landherr, L
   Mangel, L
   Mayer, �
   Nemeth, Gy
   Fodor, J
AF Polgar, Csaba
   Csejtei, Andras
   Gabor, Gabriella
   Landherr, Laszlo
   Mangel, Laszlo
   Mayer, Arpad
   Nemeth, Gyorgy
   Fodor, Janos
TI Sugarterapias iranyelvek
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Mangel, Laszlo] University of PecsPecs, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 257
EP 265
PG 9
ER

PT J
AU Dank, M
AF Dank, Magdolna
TI Terhesseg es emlorak
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 267
EP 268
PG 2
ER

PT J
TI Genetikai szures lehetosegei az Orszagos Onkologiai Intezetben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 269
EP 269
PG 1
ER

PT J
TI Tesztkerdesek kreditpontokert
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2010
VL 54
IS 3
BP 270
EP 272
PG 1
ER

PT J
AU Eckhardt, S
AF Eckhardt, Sandor
TI Bucsuzunk Horti Jozseftol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Eckhardt, Sandor] National Institute of OncologyBudapest, Hungary.
RP Eckhardt, S (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 281
EP 282
PG 2
ER

PT J
AU Boncz, I
   Donkane Verebes, �
   Oberfrank, F
   Kasler, M
AF Boncz, Imre
   Donkane Verebes, Eva
   Oberfrank, Ferenc
   Kasler, Miklos
TI Assessment of annual health insurance reimbursement of oncology drugs in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE egeszsegbiztositas; gyogyszerkiadas; egeszsegpolitika; onkologia
ID egeszsegbiztositas; gyogyszerkiadas; egeszsegpolitika; onkologia
AB The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group "L" and ICD codes C00-C99 and D00-D48. Within "L" ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP).
C1 [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, Vorosmarty u. 4., 7621 Pecs, Hungary.
   [Donkane Verebes, Eva] Integra Consulting ZrtBudapest, Hungary.
   [Oberfrank, Ferenc] MTA, Kiserleti Orvostudomanyi KutatointezetBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszseg-gazdasagtani, Egeszsegpolitikai es Egeszsegugyi Menedzsment Tanszek, 7621 Pecs, Hungary.
EM boncz@etk.pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 283
EP 288
PG 6
ER

PT J
AU Losonczy, Gy
   Mathe, Cs
   Muller, V
   Szondy, K
   Moldvay, J
AF Losonczy, Gyorgy
   Mathe, Csaba
   Muller, Veronika
   Szondy, Klara
   Moldvay, Judit
TI Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tudorak; cisplatin; nefrotoxicitas; sodiurezis; kreatininclearance
ID tudorak; cisplatin; nefrotoxicitas; sodiurezis; kreatininclearance
AB High-dose (75 mg/m2) cisplatin is baseline chemotherapy in lung cancer. To prevent nephrotoxicity, patients generally receive saline infusion on the day of chemotherapy prior to and following cisplatin (total of 3.5-4.0 liters during 3-4 hours). Despite these measures nephrotoxicity has remained frequent, especially among patients also suffering from cardiovascular disease or diabetes mellitus. Since 2005 several international recommendations have been formed about prevention of cisplatin nephrotoxicity. According to these recommendations: 1) renal function should not be evaluated by serum creatinine concentration; 2) evaluation of renal function should be based on calculated creatinine clearance (e.g. by the Cockcroft-Gault equation); 3) patients to be treated by high-dose cisplatin should be euvolemic and should have saline diuresis (urine NaCl concentration ~1%) of at least 100 ml/hour prior to, during and several days following the administration of cisplatin. Keeping these recommendations ensures prolonged cisplatin treatability of lung cancer patients. Moreover, decreased renal function will not limit the full dose administration of several other cytotoxic agents.
C1 [Losonczy, Gyorgy] Semmelweis University, Dios arok ut 1/c., 1125 Budapest, Hungary.
   [Mathe, Csaba] Semmelweis University, Dios arok ut 1/c., 1125 Budapest, Hungary.
   [Muller, Veronika] Semmelweis University, Dios arok ut 1/c., 1125 Budapest, Hungary.
   [Szondy, Klara] Semmelweis University, Dios arok ut 1/c., 1125 Budapest, Hungary.
   [Moldvay, Judit] Semmelweis University, Dios arok ut 1/c., 1125 Budapest, Hungary.
RP Losonczy, Gy (reprint author), Semmelweis University, 1125 Budapest, Hungary.
EM losonczy@pulm.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 289
EP 296
PG 8
ER

PT J
AU Strausz, J
   Timar, J
AF Strausz, Janos
   Timar, Jozsef
TI Non-surgical biopsy in lung cancer: a paradigm shift
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tudorak; biopszia; citologia; szovettan; celzott terapia
ID tudorak; biopszia; citologia; szovettan; celzott terapia
AB Histological subgroups of non-small cell lung cancer have different prognosis and they require different therapeutic approaches. Accordingly, there is a clinical need in this field to supplement conventional pathological diagnostics with protein and genetic biomarkers that can help to recognize patients responsive to these therapies. Methods for subgroup classification and target identification were developed using surgical samples (surgical lung tumor specimens are available only in 20% of all lung cancer cases). The majority of lung cancer patients, however, have tumors that are irresectable at the time of diagnosis. Therefore, their diagnosis is usually based on bronchoscopically removed tissue or needle biopsy samples analyzed mainly by cytology. Because of the growing need for immunohistochemistry and molecular pathology in lung cancer diagnosis, emphasis should be given to diagnostic bronchoscopic procedures providing tissue samples. Combination of the different biopsy techniques (histology, cytology, bronchial brush, BAL, TBNA etc.), embedding the cells (preparing cell blocks) and, moreover, the availability of immunohistochemical and molecular pathological facilities are all required to set up the proper diagnosis and therapeutic strategy in human lung cancer.
C1 [Strausz, Janos] National Koranyi Institute of Pulmonology, Piheno u. 1., 1121 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Strausz, J (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
EM strausz@koranyi.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 297
EP 301
PG 5
ER

PT J
AU Speer, G
AF Speer, Gabor
TI The role of vitamin D in the prevention and the additional therapy of cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE D-vitamin; tumor genezis; CYP24A1; vastagbelrak
ID D-vitamin; tumor genezis; CYP24A1; vastagbelrak
AB The active metabolite of vitamin D apart from a crucial role in maintaining mineral homeostasis and skeletal functions, has antiproliferative, apoptosis and differentiation inducing as well as immunomodulatory effects in cancer. It is well known that with increasing sunshine exposure the incidence of breast, prostate and colorectal cancer is decreasing. A number of in vitro and in vivo experiments documented the effects of vitamin D in the inhibition of the tumorigenesis. In studying the role of vitamin D in cancer, it is imperative to examine the potential pathways that control local tissue levels of vitamin D. The enzyme 24-hydroxylase converts the active vitamin D to inactive metabolite. Extra-renal production of this enzyme is observed and has been increasingly recognized as present in cancer cells. This enzyme is rate limiting for the amount of local vitamin D in cancer tissues and elevated expression is associated with an adverse prognosis. 24-hydroxylase may be a predictive marker of vitamin D efficacy in patients with cancer as an adjunctive therapy. There are many vitamin D analogs with no pronounced hypercalcemizing effects. Some analogs are in phase 1 and 2 clinical test, and they might have a role in the therapy of several types of cancer. At present our main task is to make an effort to decrease the vitamin D deficiency in Hungary.
C1 [Speer, Gabor] Semmelweis University, 1st Department of Internal Medicine, Szilagyi Erzsebet fasor 38., 1125 Budapest, Hungary.
RP Speer, G (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1125 Budapest, Hungary.
EM kempermaja@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 303
EP 314
PG 12
ER

PT J
AU Banhegyi, RJ
   Rus-Gal, PO
   Nagy, �K
   Martyin, T
   Wagner, R
   Varga, R
   Piko, B
AF Banhegyi, Robert Janos
   Rus-Gal, Paul Ovidiu
   Nagy, Agnes Krisztina
   Martyin, Tibor
   Wagner, Robert
   Varga, Richard
   Piko, Bela
TI Correlation between type 2 diabetes and malignant tumors - new possibilities in the complex therapy of cancers?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE 2-es tipusu diabetesz; inzulinrezisztencia; metformin; IGFR elleni monoklonalis antitestek; komplex anyagcsere kontroll
ID 2-es tipusu diabetesz; inzulinrezisztencia; metformin; IGFR elleni monoklonalis antitestek; komplex anyagcsere kontroll
AB Nowadays the lack of exercise and improper feeding are the main characteristics of modern life style. This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors. Today there are many epidemiologic trials that demonstrate the connection between type 2 diabetes and formation of several malignomas. Its cause should be searched in common paths of pathologic processes. One of this is the birth of hyperinsulinsulinemia, which accompanies insulin resistance. Hyperinsulinemia of the host leads to increased glucose uptake in the highly insuline sensitive tumor cells which supports tumor growth. This makes type 2 diabetes a metabolic state favoring tumor formation, suggesting a potential application of oral insulin sensitizers in cancer therapy. Currently several international trials are testing the anti-tumor activity of metformin and thiazolidinedions (TZD). Besides this, encouraging results were obtained with the use of anti-IGFR antibodies in the treatment of tumors. A common therapy of diabetes and tumor may lead to new possibilities in the treatment of malignant tumor diseases. By doing this we could be able to weaken the tumor and strengthen the body, enabling it to fight against cancer.
C1 [Banhegyi, Robert Janos] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Rus-Gal, Paul Ovidiu] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Nagy, Agnes Krisztina] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Martyin, Tibor] Pandy Kalman Korhaz, Infektologiai (Hepatologia es Immunologia) OsztalyGyula, Hungary.
   [Wagner, Robert] Kreiskrankenhaus Sigmaringen, Innere AbteilungSigmaringen, Germany.
   [Varga, Richard] Bekes County Pandy Kalman Hospital, Department of Internal MedicineGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Banhegyi, RJ (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM dr.banhegyi.robert@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 315
EP 323
PG 9
ER

PT J
AU Rubovszky, G
   Udvarhelyi, N
   Horvath, Zs
   Lang, I
   Kasler, M
AF Rubovszky, Gabor
   Udvarhelyi, Nora
   Horvath, Zsolt
   Lang, Istvan
   Kasler, Miklos
TI Triple negative breast carcinoma - rewiev of current literature
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tripla-negativ; emlokarcinoma; epidemiologia; prognozis; terapia
ID tripla-negativ; emlokarcinoma; epidemiologia; prognozis; terapia
AB Breast cancer is one of the most common malignancies in women. Approximately 15% of cases belong to the triple-negative breast cancer (TNBC) group, in which no estrogen/progesterone receptors, or HER2 expression is detected. The unfavorable prognosis of this group of patients, as well as the lack of effective targeted therapy makes TNBC the subject of intensive research. In the present study, we searched PubMed for publications from January 2007 to June 2009 with the following key-words in addition to "breast cancer" and "triple negative": "epidemiology" or "gene-profile" or "predictive" or "prognostic" or "therapy" or "review". A total of 513 publications were identified. Relevant references were also reviewed. Beyond the well-known facts that TNBC affects younger patients, and is more common among Afro- or Hispano-Americans with lower socioeconomic status, hormonal environment and obesity emerged as potential etiologic factors. TNBC is not a homogenous disease. It can be further subclassified based on histomorphologic features and immunohistochemistry. Hereditary BRCA1 mutations as well as acquired BRCA1 disfunction are described to be common in TNBC. Previously, many investigators considered TNBC to be identical to a subgroup called basal-like breast cancer defined by gene expression micro-array technology, but in the light of more recent findings, this view is no longer accepted by most investigators. Several large studies provide evidence that triple negativity, per se, is an independent adverse prognostic factor, in spite of the fact that approximately 10% of TNBC patients have a good prognosis. The therapy of choice for TNBC is systemic chemotherapy. Promising novel targeted chemotherapeutic agents include PARP1 inhibitors, a new group of compounds exploiting the defective DNA repair machinery.
C1 [Rubovszky, Gabor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM garub@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 325
EP 335
PG 11
ER

PT J
AU Dank, M
AF Dank, Magdolna
TI Recent advances in the treatment of gastric cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE gyomorrak; gyogyszeres kezeles; celzott terapia; biologiai markerek
ID gyomorrak; gyogyszeres kezeles; celzott terapia; biologiai markerek
AB Gastric cancer is the 9th most common malignancy in Hungary, being the 4th most frequent cause of death among all cancers. The traditional treatment approaches did not turn out to be effective against advanced gastric cancer. On the other hand, due to better understanding of the underlying molecular biology of tumors, targeted therapeutics emerge resulting in longer survival times.
C1 [Dank, Magdolna] Semmelweis University, Department of Radiology and Oncotherapy, Ulloi ut 78/a., 1082 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, 1082 Budapest, Hungary.
EM magdolna.dank@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 337
EP 341
PG 5
ER

PT J
AU Kulka, J
   Szirtes, I
   Szasz, AM
   Kupcsulik, P
   Kenessey, I
   Lotz, G
   Timar, J
AF Kulka, Janina
   Szirtes, Ildiko
   Szasz, Attila Marcell
   Kupcsulik, Peter
   Kenessey, Istvan
   Lotz, Gabor
   Timar, Jozsef
TI Pathology background of targeted therapy; quality control in pathology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE gyomorrak; celzott terapia; HER2; minosegbiztositas
ID gyomorrak; celzott terapia; HER2; minosegbiztositas
AB The administration of targeted therapy of gastric carcinoma is a very important recent improvement of its treatment and prognosis. The basis of the successful treatment is the excellent quality of pathology, now including HER2 testing: the use of validated methods and strict criteria. This is especially important if we consider that many gastric cancers are diagnosed in small biopsy material, in which HER2 testing is challenging. This requires standardized, validated methods and experienced pathologists. Being of diagnostic and predictive significance, high quality of both the technique and the interpretation of the test is mandatory. In order to achieve general high quality in this field, technical and interpretation external quality control of HER2 testing is necessary. Hungarian pathologists with the help of Roche Hungary Ltd. completed an external quality control round which showed that most of the participating laboratories are able.
C1 [Kulka, Janina] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szirtes, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kupcsulik, Peter] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM kj@korb2.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 343
EP 350
PG 8
ER

PT J
AU Deme, D
   Ragan, M
   Kalmar, K
   Kovacs, L
   Varga, E
   Varga, T
   Rakonczai, E
AF Deme, Daniel
   Ragan, Marton
   Kalmar, Katalin
   Kovacs, Lajos
   Varga, Erzsebet
   Varga, Tunde
   Rakonczai, Ervin
TI Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE kronikus DIC; TTP-HUS; metasztatikus prosztatarak; heveny veseelegtelenseg; LMWH; antiandrogen kezeles; ketokonazol
ID kronikus DIC; TTP-HUS; metasztatikus prosztatarak; heveny veseelegtelenseg; LMWH; antiandrogen kezeles; ketokonazol
AB Disseminated intravascular coagulopathy (DIC) is characterized as activation of the clotting system resulting in fibrin thrombi, gradually diminishing levels of clotting factors with increased risk of bleeding. Basically two types of DIC are distinguished: (1) chronic (compensated) - with alteration of laboratory values and (2) acute (non-compensated) - with severe clinical manifestations: bleeding, shock, acute renal failure (ARF), transient focal neurologic deficit, delirium or coma. Chronic DIC related to metastatic neoplasia is caused by pancreatic, gastric or prostatic carcinoma in most of the cases. Incidence rate of DIC is 13-30% in prostate cancer, among those only 0.4-1.65% of patients had clinical signs and symptoms of DIC. In other words, chronic DIC is developed in one of eight patients with prostate cancer. DIC is considered as a poor prognostic factor in prostatic carcinoma. The similar clinical and laboratory findings of TTP-HUS (thrombotic thrombocytopenic purpura - hemolytic uremic syndrome) and DIC makes it difficult to differentiate between them. A 71 years old male patient with known chronic obstructive pulmonary disease, benign prostatic hyperplasia, significant carotid artery stenosis, gastric ulcer and alcoholic liver disease was admitted to another hospital with melena. Gastroscopy revealed intact gastric mucosa and actually non-bleeding duodenal ulcer covered by clots. Laboratory results showed hyperkalemia, elevated kidney function tests, indirect hyperbilirubinemia, increased liver function tests, leukocytosis, anemia, thrombocytopenia and elevated international normalized ratio (INR). He was treated with saline infusions, four units of red blood cells and one unit of fresh frozen plasma transfusions. Four days later he was transported to our Institution with ARF. Physical examination revealed dyspnoe, petechiae, hemoptoe, oliguria, chest-wall pain and aggressive behavior. Thrombocytopenia, signs of MAHA (fragmentocytes and helmet cells in the peripheral blood), normal INR, elevated lactate dehydrogenase (LDH) and ARF suggested TTP-HUS. Hemodialysis and six plasmaferesis (PF) were carried out. After the fifth PF, skin manifestations of thrombotic microangiopathy occurred on the feet. Clotting analysis revealed elevated D-dimer (>5 ng/mL), normal fibrinogen (3.2 g/L), a slightly raised INR (1.36) and activated partial prothrombin time (APTT) (45.8 sec), normal reticulocyte (57 G/L) and a slightly low platelet count (123 G/L), which proved to be chronic DIC. Therapeutic dose of low-molecular-weight heparin (LMWH) was started. Elevated prostate-specific antigen (PSA) (109.6 ng/mL) suggested prostatic carcinoma. Prostate biopsy revealed adenocarcinoma (Gleason: 4+4 for left lobe and 3+3 for right lobe). Elevated alkaline phosphatase suggested metastases in the bone, which were confirmed by bone scintigraphy. Combined androgen blockade (CAB) was started. After three months follow-up our patient's status is satisfactory. PSA is in the normal range (4.6 ng/mL). Thrombocytopenia of uncertain origin with normal or raised INR, APTT, elevated D-dimer, normal fibrinogen and reticulocyte count prove the diagnosis of chronic DIC. This process warrants searching for metastatic neoplasia. Due to the relatively low serum levels of circulating procoagulant factors (e.g. tissue factor), therapeutic dose of LMWH can be used with good efficiency in chronic DIC with low risk of bleeding. Severe DIC as a complication of metastatic prostate cancer can be treated by androgen deprivation therapy (ADT) or CAB in combination with ketokonazole and concomitant use of supportive treatment.
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Belgyogyaszati Osztaly, Fuleki ut 54-56., 3100 Salgotarjan, Hungary.
   [Ragan, Marton] Szent Lazar Megyei Korhaz, Urologiai OsztalySalgotarjan, Hungary.
   [Kalmar, Katalin] Szent Lazar Megyei Korhaz, Integramed Kozponti LaboratoriumSalgotarjan, Hungary.
   [Kovacs, Lajos] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
   [Varga, Erzsebet] Szent Lazar Megyei Korhaz, Intenziv OsztalySalgotarjan, Hungary.
   [Varga, Tunde] Szent Lazar Megyei Korhaz, Fresenius MC Dializis KozpontSalgotarjan, Hungary.
   [Rakonczai, Ervin] Szent Lazar Megyei Korhaz, Belgyogyaszati Osztaly, Fuleki ut 54-56., 3100 Salgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Belgyogyaszati Osztaly, 3100 Salgotarjan, Hungary.
EM danieldeme@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2010
VL 54
IS 4
BP 351
EP 357
PG 7
ER

PT J
AU Kasler, M
AF Kasler, Miklos
TI Bucsuzunk Dr. Szucs Miklostol 1944-2011
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 3
EP 3
PG 1
ER

PT J
AU Piko, B
   Puskasne Szatmari, K
   Bassam, A
   Csiffari, M
   Dimak, S
   Szabo, Zs
   Ocsai, H
   Csotye, J
AF Piko, Bela
   Puskasne Szatmari, Klara
   Bassam, Ali
   Csiffari, Margit
   Dimak, Sandor
   Szabo, Zsolt
   Ocsai, Henriette
   Csotye, Janos
TI Paravasation of cytostatic drugs
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE citosztatikum; paravazacio; kezeles; dokumentacio; egyuttmukodes
ID citosztatikum; paravazacio; kezeles; dokumentacio; egyuttmukodes
AB Paravasation of cytostatic drugs during peripheral intravenous administration is a well known complication. In the United States of America it occurs in seven percent of cases with different severity and consequences. Although methods to completely avoid this complication are still unavailable, we are able to decrease the risks by identifying the patient- and procedure-related factors. The educated patient is a good indicator of paravasation in case he or she can cooperate and call the nurse. When the patient is unable to cooperate, the risks of extravasation is higher and closer nursing surveillance is indicated. The extent of injury depends mainly on the chemical structure of the extravasant substance (vesicant, irritant or non-vesicant) which may be modified by other factors. There is no strong evidence-based guidance for the management of complication. Abrupt cessation of the infusion and drawing back on the inserted venous catheter as well as elevating and resting the affected limb are necessary measures. In the available literature cooling or warming of the affected area is controversial. Similarly there are still open questions regarding the value of using antidotes as dexrazoxane, dimethylsulfoxide, thiosulfate and hyaluronidase (which is not registered as medicament in Hungary). In the event of extravasation early multidisciplinary dermatological and surgical assessment is essential for definitive diagnosis and setting the optimal management.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Puskasne Szatmari, Klara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Dimak, Sandor] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Szabo, Zsolt] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Ocsai, Henriette] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Dermatoonkologiai Szakrendeles, 5700 Gyula, Hungary.
   [Csotye, Janos] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Baleseti Sebeszeti Osztaly, 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM dr.piko.bela@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 4
EP 13
PG 10
ER

PT J
AU Bartal, A
   Matrai, Z
   Rosta, A
   Szucs, A
AF Bartal, Alexandra
   Matrai, Zoltan
   Rosta, Andras
   Szucs, Attila
TI Implementation of an extravasation protocol at the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE citosztatikum; extravazacio; protokoll
ID citosztatikum; extravazacio; protokoll
AB Extravasation of cytostatics occurs when an infusion containing a cytotoxic drug leaks into the surrounding perivascular and subcutaneous tissues. Incidence of cytostatic extravasation is found to be 0.1-6% according to the literature. Depending on the severity of complications, pain, loss of function in the extremities, or in extreme cases tissue necrosis necessitating an amputation may develop, drawing consequences like delay or interruption of the chemotherapy. Extent of complications is greatly influenced by the type of medication administered, general condition of the patient, and professional preparedness of staff providing the oncological health service. The protocol recently implemented in the National Institute of Oncology is a short, compact guidance for physicians and nurses providing oncological care, so by quick and adequate management of extravasation cases, severe complications could be prevented. More complex practical guidelines including algorithms could be created as a result of a wider collaboration, with the help of which oncological health professionals could easily cope with this rare problem. The authors describe in their review the implementation of the use of dry warm and cold packs, dymethylsulfoxide and hyaluronidase and their function within the algorithm of extravasation treatment.
C1 [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Rosta, Andras] National Institute of OncologyBudapest, Hungary.
   [Szucs, Attila] Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Bartal, A (reprint author), Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, 1122 Budapest, Hungary.
EM alexandra.bartal@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 14
EP 20
PG 7
ER

PT J
AU Jakubovits, E
AF Jakubovits, Edit
TI Possibilities of hypnosis and hypno-suggestions methods in oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE daganat; hipnozis; szorongas; fajdalom; hanyas; eletminoseg; hangulat; immunrendszer; hot flush
ID daganat; hipnozis; szorongas; fajdalom; hanyas; eletminoseg; hangulat; immunrendszer; hot flush
AB Fear of death, pain, or the recurrence of the illness of tumor patients can narrow their attention to a point where a spontaneous altered state of consciousness occurs. In these cases hypnosis either in formal psychotherapy or embedded into the everyday communication with the physician can effectively complement other already known medical and psychological techniques. Although numerous studies have reported the beneficial physical and mental changes induced by hypnosis, for a long time there were not enough research to affect evidence-based medicine. New studies meeting the most rigorous methodological standards, new reviews and the characteristics of hypnosis shown by neuroimaging techniques support the acceptance of this method. Hypnosis is used and studied with adult and child tumor patients alike mostly in the areas of anxiety, pain, nausea, vomiting, quality of life, mood amelioration, immune system and hot flushes. Most of the assays describe hypnosis as an empirically validated treatment technique that in most cases surpass attention diversion, coping trainings, cognitive behavior and relaxation techniques and other regular treatments. In this paper we review these observations.
C1 [Jakubovits, Edit] Semmelweis University, Institute of Morphology and Physiology, Vas u. 17., 1088 Budapest, Hungary.
RP Jakubovits, E (reprint author), Semmelweis University, Institute of Morphology and Physiology, 1088 Budapest, Hungary.
EM jakedit@se-etk.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 22
EP 31
PG 10
ER

PT J
AU Nagykalnai, T
   Landherr, L
   Meszaros, E
AF Nagykalnai, Tamas
   Landherr, Laszlo
   Meszaros, Edina
TI Aromatase inhibitors and arthralgia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hormonerzekeny emlorak; aromatazgatlok; AI mellekhatasok; AI-kkel osszefuggo; artralgia
ID hormonerzekeny emlorak; aromatazgatlok; AI mellekhatasok; AI-kkel osszefuggo; artralgia
AB In several large adjuvant clinical trials it has been demonstrated that substitution (eventually addition) of aromatase inhibitors (AIs) provides an improved outcome of endocrine-sensitive breast cancer over tamoxifen alone. Nevertheless, arthralgia induced by the AIs is one of the most frequent side effects in hormonal therapy. It is characterized by tenosynovial changes and is more frequent in patients in clinical practice than previously appreciated in adjuvant clinical trials. AI-related arthralgia may be related to estrogen deprivation, but estrogen replacement is not an option for these women. Therefore standard painkillers, NSAIDs (COX2 inhibitors), week opioids and other interventions (vitamin D, calcium, bisphosphonates, exercise, acupuncture, complementary and alternative approaches, eventually switch to another endocrine drug) are used for managing this treatment-related side effect, and improve adherence and quality of life among breast cancer survivors.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Vorosmarty utca 31., 1064 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1064 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 32
EP 39
PG 8
ER

PT J
AU Matrai, Z
   Gulyas, G
   Toth, L
   Polgar, Cs
   Bidlek, M
   Szabo, �
   Lang, I
   Horvath, Zs
   Udvarhelyi, N
   Kunos, Cs
   Savolt, �
   Pesthy, P
   Kasler, M
AF Matrai, Zoltan
   Gulyas, Gusztav
   Toth, Laszlo
   Polgar, Csaba
   Bidlek, Maria
   Szabo, Eva
   Lang, Istvan
   Horvath, Zsolt
   Udvarhelyi, Nora
   Kunos, Csaba
   Savolt, Akos
   Pesthy, Pal
   Kasler, Miklos
TI Oncoplastic challenges in modern breast surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE onkologiai emlosebeszet; emlorekonstrukcio; onkoplasztikai sebeszet
ID onkologiai emlosebeszet; emlorekonstrukcio; onkoplasztikai sebeszet
AB Breast screening programs along with advances in diagnostic methods and oncologic treatment have resulted in full recovery for a decisive number of patients diagnosed with early-stage breast cancer. The results of the ultra-radical-, followed by the breast conserving era pose new opportunities and challenges for the oncologic breast surgeon. The focus of oncoplastic surgery is not only on the tumor, but also on the female patient, allowing for individualized immediate breast reconstruction with acceptable esthetic result following radical tumor exstirpation. Modern procedures differ both in concept and technique from that of traditional breast surgery. This paper provides a comprehensive and detailed overview of reconstructive and oncoplastic breast surgery.
C1 [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pesthy, Pal] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM matraidok@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 40
EP 52
PG 13
ER

PT J
TI A Patologiai Szakmai Kollegium ajanlasa a gastrointestinalis neuroendokrin tumorok leleteinek minimalis tartalmara
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 53
EP 54
PG 2
ER

PT J
AU Kenessey, I
AF Kenessey, Istvan
TI Investigation of the motogenic signal in human melanoma cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE tirozinkinaz-gatlok; heparin-oligoszacharidok; attetkepzes; xenograft; human malignus melanoma
ID tirozinkinaz-gatlok; heparin-oligoszacharidok; attetkepzes; xenograft; human malignus melanoma
AB The components of the extracellular matrix (ECM) are more than just adhesion sites for migrating tumor cells: following enzymatic degradation of the ECM, the release of sequestrated growth factors increases, thus they become available for tumor cells. In a number of cancers dysfunction of epidermal growth factor receptor (EGFR) or hepatocyte growth factor receptor (c-Met) contribute to the malignant transformation that directly regulates cell proliferation, survival and motility. Furthermore, intracellular calcium level plays an important role in the regulation of the tyrosine kinase pathway. In our preclinical experiments, by administering heparin-derived oligosaccharides we influenced the interaction between human melanoma cells and ECM. In vitro cell migration was inhibited by heparin fragments. Moreover, two of the effective oligosaccharides reduced the number of lung colonies formed in SCID mice. In human melanoma cells an important element of Ca2+ homeostasis, the purinergic Ca2+ channel P2X7 proved to be an anti-apoptotic protein. EGFR and c-Met showed constitutive activity in human melanoma cells, and their inhibition in vitro caused decreased proliferation, migration and elevated apoptosis. Administration of a selective c-Met-TKI significantly decreased primary tumor growth in vivo as well as the capacity for liver colony formation in SCID mice. Selective EGFR-TKI had less inhibitory effect on metastasis formation, and had no effect on the primary tumor. Our results suggest the necessity of a rational dual-specific drug design for the purpose in the therapy of malignant melanoma.
C1 [Kenessey, Istvan] Semmelweis University, School of PhD Studies, Ulloi ut 92., 1091 Budapest, Hungary.
RP Kenessey, I (reprint author), Semmelweis University, School of PhD Studies, 1091 Budapest, Hungary.
EM steveken12@yahoo.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 55
EP 58
PG 4
ER

PT J
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2010. szeptember 17-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 59
EP 62
PG 4
ER

PT J
TI Beszamolo a Magyar Uroonkologiai Tarsasag I. Kongresszusarol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 63
EP 64
PG 2
ER

PT J
TI A Magyar Onkologia 2010. evi (54. evfolyam) Tartalomjegyzeke
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2011
VL 55
IS 1
BP 65
EP 67
PG 3
ER

PT J
TI Dr. Polgar Istvan 1947-2011
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 71
EP 71
PG 1
ER

PT J
AU Matrai, Z
   Toth, L
   Polgar, Cs
   Lang, I
   Godeny, M
   Sinkovics, I
   Horvath, Zs
   Bidlek, M
   Udvarhelyi, N
   Bartal, A
   Savolt, �
   Ujhelyi, M
   Kasler, M
AF Matrai, Zoltan
   Toth, Laszlo
   Polgar, Csaba
   Lang, Istvan
   Godeny, Maria
   Sinkovics, Istvan
   Horvath, Zsolt
   Bidlek, Maria
   Udvarhelyi, Nora
   Bartal, Alexandra
   Savolt, Akos
   Ujhelyi, Mihaly
   Kasler, Miklos
TI Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neoadjuvans kemoterapia; orszemnyirokcsomo-biopszia; axillaris staging; axillaris nyirokcsomo-disszekcio
ID neoadjuvans kemoterapia; orszemnyirokcsomo-biopszia; axillaris staging; axillaris nyirokcsomo-disszekcio
AB The indication of neoadjuvant chemotherapy has been recently extended; it is now applied not only in locally advanced breast cancer but in primarily resecable tumours as well, in order to promote breast conservation. Based on recent clinical results, the reconsideration of traditional lymph node dissection in axillary staging is timely in patients receiving neoadjuvant chemotherapy. Precise axillary staging needs surgical removal of lymph nodes. Based on prospective randomised trials, sentinel lymph node biopsy appears to be appropriate for axillary staging even in tumours requiring neoadjuvant treatment. The extended indication of sentinel lymph node biopsy raises several questions and problems. In the present paper the authors review the results and possible limitations of sentinel lymph node biopsy in relation to neoadjuvant chemotherapy.
C1 [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Ujhelyi, Mihaly] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM matraidok@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 73
EP 84
PG 12
ER

PT J
AU Kovacs, P
   Sebestyen, Zs
   Farkas, R
   Bellyei, Sz
   Szigeti, A
   Gulyban, �
   Horvath, Zs
   Doczi, T
   Mangel, L
AF Kovacs, Peter
   Sebestyen, Zsolt
   Farkas, Robert
   Bellyei, Szabolcs
   Szigeti, Andras
   Gulyban, Akos
   Horvath, Zsolt
   Doczi, Tamas
   Mangel, Laszlo
TI Conformal stereotactic radiosurgery treatment: plan evaluation methods and results
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE sugarsebeszet; mikro-multileaf kollimator; allo mezo; sztereotaxia; dozimetria
ID sugarsebeszet; mikro-multileaf kollimator; allo mezo; sztereotaxia; dozimetria
AB The purpose of our study was the objective evaluation of micro-multileaf collimator (mMLC)-based stereotactic radiosurgery treatment plans. Forty-seven patients, 71 lesions received static beam conformal stereotactic radiosurgery treatment in our institute between November 2005 and June 2008. Target volume and organs at risk were outlined on a MRI-CT image fusion basis. BrainSCAN 5.31 system (BrainLAB AG, Heimstetten, Germany) was used for treatment planning, Elekta Presice TS linear accelerator (Elekta Oncology Systems Ltd, Crawley, UK) and BrainLAB m3 mMLC were used for treatment delivery. An invasive head frame, mounted to the treatment table, was used with four screws for patient head fixation. Treatment plans were analysed with objective parameters, such as conformal index (COIN), homogeneity index (HI), coverage index (CI) and healthy tissue relative overdose factor (HTOF) tools. x2 tests were performed between COIN, HI and the geometrical parameters of the target volume (lesion volume - LV, lesion-organ distance - LOD, lesion deformity index - LDI). Mean value of COIN, HI, HTOF and CI was 0.52 (SD 0.13), 1.16 (SD 0.1), 0.88 (SD 0.53), and 0.94 (SD 0.11), respectively. COIN significantly correlated with (p<0.001 in all three cases), while HI was independent of LV, LOD, LDI (p=0.94; 0.14 and 0.72). COIN is similar, HTOF is less than data from the literature. According to our results geometrical parameters of the target volume (size, location, deformation) significantly influence the COIN, but they have no effect on HI.
C1 [Kovacs, Peter] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Doczi, Tamas] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Kovacs, P (reprint author), University of Pecs, Department of Oncology, 7624 Pecs, Hungary.
EM peter.kovacs@aok.pte.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 85
EP 90
PG 6
ER

PT J
AU Bartal, A
   Matrai, Z
   Szucs, A
   Liszkay, G
AF Bartal, Alexandra
   Matrai, Zoltan
   Szucs, Attila
   Liszkay, Gabriella
TI Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kez-lab szindroma; dermatologiai mellekhatas; oralis kemoterapia; szupportiv terapia
ID kez-lab szindroma; dermatologiai mellekhatas; oralis kemoterapia; szupportiv terapia
AB Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil. It affects the skin of the palms and soles manifesting characteristic symptoms like erythema, inflammation, dysesthesia, pain, thickening, desquamation and cracking of the skin that may progress to cause wounds and ulceration, negatively influencing quality of life, psychological state and belief in recovery, which often result in the need of permanent or temporary interruption of the oncologic treatment and are potential sources of danger to the completion of the therapy. Adequate provision of the syndrome is of particular importance since a decline in adherence due to adverse events endangers precise maintenance of the self-sufficient oral treatment at home. Early recognition of symptoms, regular oncologic checkups and patient education on how to prevent or soothe the unpleasant skin toxicities could ensure a more successful treatment.
C1 [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szucs, Attila] Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Bartal, A (reprint author), Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, 1122 Budapest, Hungary.
EM alexandra.bartal@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 91
EP 98
PG 8
ER

PT J
AU Hegedus, Z
   Barbai, T
   Tatrai, P
   Hegedus, B
   Kiss, A
   Raso, E
   Bodoky, Gy
AF Hegedus, Zita
   Barbai, Tamas
   Tatrai, Peter
   Hegedus, Balazs
   Kiss, Andras
   Raso, Erzsebet
   Bodoky, Gyorgy
TI Effect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kolorektalis rak; KRAS; Avastin
ID kolorektalis rak; KRAS; Avastin
AB Anti-angiogenic therapy became a standard care of advanced colorectal cancer. Since the most frequent genetic alteration of colorectal cancer is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment. Since 2008 we have determined the KRAS status of 575 patients with colorectal carcinoma using a sensitive screening method and sequencing. In our database the frequency of KRAS mutation in colorectal cancer is 37% (codon 12: 31% followed by codon 13: 6%). We have examined the effect of KRAS status on the efficacy of Avastin treatment in 35 patients. Progression-free survival of KRAS mutant patients was highly similar to that of wild-type patients using log-rank test (9.2+/-5.5 months versus 8.7+/-5.7 months, respectively). Our data support those observations that KRAS status of colorectal cancer does not interfere with the efficacy of Avastin treatment.
C1 [Hegedus, Zita] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Tatrai, Peter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Hegedus, Z (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM hz@korb2.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 99
EP 104
PG 6
ER

PT J
AU Moldvay, J
   Papay, J
   Puskas, R
   Furak, J
   Losonczy, Gy
   Matolcsy, A
AF Moldvay, Judit
   Papay, Judit
   Puskas, Rita
   Furak, Jozsef
   Losonczy, Gyorgy
   Matolcsy, Andras
TI Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE ERCC1-proteinexpresszio; immunhisztokemia; prediktiv faktorok; neoadjuvans terapia; nem-kissejtes tudorak
ID ERCC1-proteinexpresszio; immunhisztokemia; prediktiv faktorok; neoadjuvans terapia; nem-kissejtes tudorak
AB Platinum-based chemotherapies are widely used in the treatment of lung cancer. However, little is known about their effect in the expression of certain tissue biomarkers. We have studied the ERCC1 (excision repair cross-complementation group 1) expression in tissue samples of patients treated with neoadjuvant chemotherapy. Fifty lung cancer tissue blocks of 25 patients (15 males, 10 females) were studied. They included 25 bronchoscopic biopsies (14 squamous cell carcinomas and 11 adenocarcinomas) together with their corresponding surgical biopsies after neoadjuvant chemotherapy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues to study the expression of ERCC1. Staining scores (0-300) were calculated by multiplying the percentage of positive tumor cells (0-100) by the staining intensity (0-3). All but one bronchosopic squamous cell carcinoma tissues (13/14) expressed ERCC1. Four of these cases became negative after neoadjuvant therapy, and in 8 cases the level of expression decreased. In the adenocarcinoma group all but one bronchosopic tissues (10/11) expressed ERCC1. Six of these cases became negative after neoadjuvant therapy, and in 4 cases the level of expression decreased. Comparison of staining scores before and after chemotherapy revealed more pronounced decrease in adenocarcinomas and in female patients. There was no newly expressed ERCC1-positive case in the surgical biopsy group. The results of the present study suggest that platinum-based chemotherapy affects the expression of tissue biomarker (ERCC1) which may have predictive value, and probably induces a selection of tumor cells with more aggressive phenotype. This knowledge might be of importance when designing treatment protocols for non-small cell lung cancer patients.
C1 [Moldvay, Judit] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Puskas, Rita] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Furak, Jozsef] Szegedi Tudomanyegyetem, AOK, Mellkassebeszeti TanszekSzeged, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 105
EP 109
PG 5
ER

PT J
AU Bardi, E
   Jenei, Z
   Horvath, �
   Bodo, T
   Bende, M
   Sandor, L
   Riz, �
   Kappelmayer, J
   Kiss, Cs
AF Bardi, Edit
   Jenei, Zoltan
   Horvath, Agnes
   Bodo, Timea
   Bende, Marianna
   Sandor, Laura
   Riz, Adam
   Kappelmayer, Janos
   Kiss, Csongor
TI Complex assessment of late side effects affecting quality of life - the "Debrecen model"
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kesoi tulelok; nefrotoxicitas; oszteoporozis; kardiovaszkularis riziko
ID kesoi tulelok; nefrotoxicitas; oszteoporozis; kardiovaszkularis riziko
AB As the outcome of childhood cancer improved substantially during the last 3 decades, the attitude of pediatric oncology has changed from "cure at any cost" to "cure at least cost". We investigated factors affecting quality of life in long-term survivors of childhood cancer in the in- and outpatient clinics of the Department of Pediatric Hematology-oncology, Institute of Pediatrics, Medical and Health Science Center, Debrecen. As a part of a comprehensive follow-up care program, we focused our attention on nephrotoxicity, osteoporosis and on cardiovascular morbidity. For long-term survivors of childhood cancer sensitive and cost-effective diagnostic algorithms were developed that can help in guiding secondary and tertiary prevention programs, in addition to assessing accurately the condition of patients. We found that anti-cancer treatments, including some of the supportive interventions, have adverse effects on glomerular (10%) and tubular functions (37%), impair the balance of bone resorption and formation (69%) and increase the frequency of cardiovascular risk factors (62%) in a significant proportion of patients. Our data confirm and extend the findings of other investigators and cooperative groups. In conclusion, we consider it important that the treatment plans of high-risk patients with cancer should be aimed at preserving the anticancer potential of therapy, without enhancing the frequency and severity of complications. The presented "Debrecen model" may help in achieving this goal and in increasing quality of life of long-term survivors of childhood cancer.
C1 [Bardi, Edit] Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, Markusovszky utca 5., 9700 Szombathely, Hungary.
   [Jenei, Zoltan] University of Debrecen, Faculty of Medicine, Department of Internal MedicineDebrecen, Hungary.
   [Horvath, Agnes] University of Debrecen, Faculty of Medicine, Department of Internal MedicineDebrecen, Hungary.
   [Bodo, Timea] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Bende, Marianna] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Sandor, Laura] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Riz, Adam] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Kappelmayer, Janos] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
RP Bardi, E (reprint author), Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, 9700 Szombathely, Hungary.
EM editbardi@hotmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 110
EP 116
PG 7
ER

PT J
AU Borbely, K
   Szilagyi, I
   Kasler, M
AF Borbely, Katalin
   Szilagyi, Istvan
   Kasler, Miklos
TI IV. PET/CT Multidiszciplinaris Nemzeti Konszenzus Konferencia Allasfoglalasa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Borbely, Katalin] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szilagyi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 117
EP 127
PG 11
ER

PT J
TI A Magyar Sugarterapias Tarsasag X. Kongresszusa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 146
PG 18
ER

PT J
AU Arnoczkine Orban, H
   Dargai, ME
   Fekri, K
AF Arnoczkine Orban, Helga
   Dargai, Marta Edit
   Fekri, Kathrin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arnoczkine Orban, Helga] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Dargai, Marta Edit] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Fekri, Kathrin] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Arnoczkine Orban, H (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Bekesi, B
   Csendes, V
   Toller, G
   Farkas, A
   Glavak, Cs
   Vandulek, Cs
   Hadjiev, J
   Repa, I
AF Bekesi, Barbara
   Csendes, Viktoria
   Toller, Gabor
   Farkas, Andrea
   Glavak, Csaba
   Vandulek, Csaba
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bekesi, Barbara] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Csendes, Viktoria] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Bekesi, B (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Birone Riz, T
   Mozsa, E
   Major, T
   Fabry, L
   Polgar, Cs
AF Birone Riz, Tunde
   Mozsa, Emoke
   Major, Tibor
   Fabry, Laszlo
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Birone Riz, Tunde] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fabry, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Birone Riz, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Dovalovszkine Drencsenyi, R
   Hegedus, Gy
   Varga, Z
   Hideghety, K
   Nikolanyi, A
   Kahan, Zs
   Thurzo, L
AF Dovalovszkine Drencsenyi, Rita
   Hegedus, Gyne
   Varga, Zoltan
   Hideghety, Katalin
   Nikolanyi, A
   Kahan, Zsuzsanna
   Thurzo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dovalovszkine Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hegedus, Gyne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolanyi, A] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dovalovszkine Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Gehlne Kaulak, �
   Tar, A
   Pintye, �
   Szluha, K
AF Gehlne Kaulak, Agota
   Tar, Anna
   Pintye, Eva
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gehlne Kaulak, Agota] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Tar, Anna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Gehlne Kaulak, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 129
EP 130
PG 2
ER

PT J
AU Kullerne V, Cs
   Horvathne Kovacs, Zs
   Pinter, T
   Barla, F
AF Kullerne V, Cs
   Horvathne Kovacs, Zsuzsanna
   Pinter, Tamas
   Barla, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullerne V, Cs] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Horvathne Kovacs, Zsuzsanna] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Barla, Ferenc] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullerne V, Cs (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Jaromi, M
   Halasz, Z
   Margitne V, A
   Frohlich, M
   Laczko, EZ
   Gabor, G
   Pajkos, G
AF Jaromi, Mihalyne I.
   Halasz, Zita
   Margitne V, A
   Frohlich, Monika
   Laczko, E Z
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jaromi, Mihalyne I.] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Halasz, Zita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Margitne V, A] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Frohlich, Monika] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Laczko, E Z] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Jaromi, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Olaszne Halasz, J
   Simonne Revesz, J
   Farkas, R
   Sebestyen, K
   Sebestyen, Zs
   Kovacs, P
   Mangel, L
AF Olaszne Halasz, Judit
   Simonne Revesz, Judit
   Farkas, Robert
   Sebestyen, Klara
   Sebestyen, Zsolt
   Kovacs, Peter
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olaszne Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Simonne Revesz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Olaszne Halasz, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Pall, J
   Kovacs, �
   Hadjiev, J
   Liposits, G
   Antal, G
   Glavak, Cs
   Farkas, A
   Vandulek, Cs
   Repa, I
AF Pall, Janos
   Kovacs, Arpad
   Hadjiev, Janaki
   Liposits, Gabor
   Antal, Gergely
   Glavak, Csaba
   Farkas, Andrea
   Vandulek, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pall, Janos] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Liposits, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Pall, J (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Pasztine Gal, L
   Racz, A
   Abrahamne Laczi, E
   Varga, T
   Hideghety, K
AF Pasztine Gal, Laura
   Racz, Attila
   Abrahamne Laczi, Edina
   Varga, Tne
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pasztine Gal, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Racz, Attila] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Abrahamne Laczi, Edina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Tne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Pasztine Gal, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Somodi, M
   Branyiczkine Fehervari, R
AF Somodi, Mne
   Branyiczkine Fehervari, Renata
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somodi, Mne] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Branyiczkine Fehervari, Renata] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
RP Somodi, M (reprint author), County Hospital of Borsod-Abauj-Zemplen, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 130
EP 131
PG 1
ER

PT J
AU Tar, A
   Gehlne Kaulak, �
   Beregszaszi, Gy
   Pintye, �
   Simon, M
   Szluha, K
AF Tar, Anna
   Gehlne Kaulak, Agota
   Beregszaszi, Gyula
   Pintye, Eva
   Simon, Mihaly
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tar, Anna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Gehlne Kaulak, Agota] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Beregszaszi, Gyula] Medirex Zrt.Debrecen, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Tar, A (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Tothne Mako, 
   Pinter, T
   Barla, F
AF Tothne Mako, M.
   Pinter, Tamas
   Barla, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tothne Mako, M.] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Barla, Ferenc] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Tothne Mako,  (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Vandulek, Cs
   Pall, J
   Lakosi, F
   Antal, G
   Farkas, A
   Kovacs, �
   Hadjiev, J
   Repa, I
AF Vandulek, Csaba
   Pall, Janos
   Lakosi, Ferenc
   Antal, Gergely
   Farkas, Andrea
   Kovacs, Arpad
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Pall, Janos] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Vandulek, Cs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Varga, Sz
   Major, T
   Agoston, P
AF Varga, Szilvia
   Major, Tibor
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varga, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Agoston, P
   Major, T
   Szabo, Z
   Varjas, G
   Frohlich, G
   Lovey, J
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Szabo, Zoltan
   Varjas, Geza
   Frohlich, Georgina
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 131
EP 132
PG 2
ER

PT J
AU Frohlich, G
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Janvary, ZsL
   Jansen, N
   Devillers, M
   Baart, V
   Mievis, C
   Cucchiaro, S
   Lenaerts, E
   Coucke, P
AF Janvary, Zsolt Levente
   Jansen, Nicolas
   Devillers, Magali
   Baart, Veronique
   Mievis, Carole
   Cucchiaro, Severine
   Lenaerts, Eric
   Coucke, Philippe
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Jansen, Nicolas] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Devillers, Magali] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Baart, Veronique] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Mievis, Carole] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Cucchiaro, Severine] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Lenaerts, Eric] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Coucke, Philippe] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
RP Janvary, ZsL (reprint author), University Hospital of Liege, Department of Radiation Oncology, Liege, Belgium.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Jorgo, K
   Agoston, P
   Major, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 132
EP 133
PG 2
ER

PT J
AU Kovacs, Gy
   Meyer, J
AF Kovacs, Gyorgy
   Meyer, E. Jens
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gyorgy] Universitat zu Lubeck, Interdiszciplinaris Brachyterapia Kozpont, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
   [Meyer, E. Jens] Universitat zu Lubeck, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaLubeck, Germany.
RP Kovacs, Gy (reprint author), Universitat zu Lubeck, Interdiszciplinaris Brachyterapia Kozpont, D-23538 Lubeck, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 133
EP 133
PG 1
ER

PT J
AU Locsei, Z
   Aradi, M
   Orsi, G
   Perlaki, G
   Derczy, K
   Kovacs, P
   Mangel, L
AF Locsei, Zoltan
   Aradi, Mihaly
   Orsi, Gergely
   Perlaki, Gabor
   Derczy, Katalin
   Kovacs, Peter
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Aradi, Mihaly] Pecsi Diagnosztikai Kozpont Kft.Pecs, Hungary.
   [Orsi, Gergely] Pecsi Diagnosztikai Kozpont Kft.Pecs, Hungary.
   [Perlaki, Gabor] Pecsi Diagnosztikai Kozpont Kft.Pecs, Hungary.
   [Derczy, Katalin] Pecsi Diagnosztikai Kozpont Kft.Pecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 133
EP 133
PG 1
ER

PT J
AU Lovey, J
   Major, T
   Belak, B
   Mozsa, E
   Polgar, Cs
AF Lovey, Jozsef
   Major, Tibor
   Belak, Barbara
   Mozsa, Emoke
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Belak, Barbara] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 133
EP 134
PG 2
ER

PT J
AU Polgar, Cs
   Major, T
   Fodor, J
   Sulyok, Z
   Takacsi-Nagy, Z
   Somogyi, A
   Nemeth, Gy
AF Polgar, Csaba
   Major, Tibor
   Fodor, Janos
   Sulyok, Zoltan
   Takacsi-Nagy, Zoltan
   Somogyi, Andras
   Nemeth, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Szabo, Z
   Agoston, P
   Major, T
   Polgar, Cs
AF Szabo, Zoltan
   Agoston, Peter
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szabo, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Szluha, K
   Lazanyi, K
   Szabo, I
   Pintye, �
   Besenyoi, M
   Abramyuk, A
AF Szluha, Kornelia
   Lazanyi, Kornelia
   Szabo, Imre
   Pintye, Eva
   Besenyoi, Maria
   Abramyuk, Andrij
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Lazanyi, Kornelia] DE OEC, Magatartastudomanyi Intezet, Biologiai es Molekularis Kepalkoto Kozpont (ONCO-Ray)Debrecen, Hungary.
   [Szabo, Imre] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Besenyoi, Maria] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Abramyuk, Andrij] Technische Universitat DresdenDresden, Germany.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Belak, B
   Agocs, L
   Szekely, J
   Horvath, �
   Bajcsay, A
AF Belak, Barbara
   Agocs, Laszlo
   Szekely, Judit
   Horvath, Akos
   Bajcsay, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Belak, Barbara] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agocs, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Akos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Belak, B (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Bellyei, Sz
   Cseh, �
   Hocsak, E
   Pozsgai, E
AF Bellyei, Szabolcs
   Cseh, Aron
   Hocsak, Eniko
   Pozsgai, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Cseh, Aron] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Hocsak, Eniko] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Pozsgai, Eva] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 134
EP 135
PG 2
ER

PT J
AU Boronkai, �
   Sarosi, V
   Ruzsics, I
   Kalincsak, J
   Mangel, L
AF Boronkai, Arpad
   Sarosi, Veronika
   Ruzsics, Istvan
   Kalincsak, Judit
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Ruzsics, Istvan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Boronkai, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Dubinsky, P
   Barilikova, G
   Matula, P
   Tolvajova, E
AF Dubinsky, Pavol
   Barilikova, Gabriela
   Matula, Pavol
   Tolvajova, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dubinsky, Pavol] East Slovakia Institute of Oncology, Department of RadiotherapyKosice, Slovakia.
   [Barilikova, Gabriela] East Slovakia Institute of Oncology, Department of RadiotherapyKosice, Slovakia.
   [Matula, Pavol] East Slovakia Institute of Oncology, Department of RadiotherapyKosice, Slovakia.
   [Tolvajova, Eniko] East Slovakia Institute of Oncology, Department of RadiotherapyKosice, Slovakia.
RP Dubinsky, P (reprint author), East Slovakia Institute of Oncology, Department of Radiotherapy, Kosice, Slovakia.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Farkas, R
   Pozsgai, E
   Bellyei, Sz
   Laszlo, Z
   Szigeti, A
   Sebestyen, K
   Rapolti, E
   Gomori, �
   Papp, A
   Mangel, L
AF Farkas, Robert
   Pozsgai, Eva
   Bellyei, Szabolcs
   Laszlo, Zoltan
   Szigeti, Andras
   Sebestyen, Klara
   Rapolti, Edit
   Gomori, Eva
   Papp, Andras
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Pozsgai, Eva] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Rapolti, Edit] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Gomori, Eva] University of Pecs, Department of PathologyPecs, Hungary.
   [Papp, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Farkas, R (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Jakab, G
   Gabor, G
   Hodi, Zs
   Pajkos, G
AF Jakab, Gabriella
   Gabor, Gabriella
   Hodi, Zsuzsanna
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jakab, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hodi, Zsuzsanna] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Jakab, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 135
EP 136
PG 2
ER

PT J
AU Kara, L
   Vizhanyo, R
   Gabor, G
   Pajkos, G
AF Kara, Laszlo
   Vizhanyo, Rita
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kara, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Kara, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 136
EP 136
PG 1
ER

PT J
AU Laszlo, Z
   Farkas, R
   Kalincsak, J
   Mangel, L
AF Laszlo, Zoltan
   Farkas, Robert
   Kalincsak, Judit
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Laszlo, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 136
EP 136
PG 1
ER

PT J
AU Liposits, G
   Hadjiev, J
   Kovacs, �
   Lakosi, F
   Antal, G
   Glavak, Cs
   Repa, I
AF Liposits, Gabor
   Hadjiev, Janaki
   Kovacs, Arpad
   Lakosi, Ferenc
   Antal, Gergely
   Glavak, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liposits, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Liposits, G (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 136
EP 136
PG 1
ER

PT J
AU Mangel, L
   Lovey, J
   Farkas, R
   Bellyei, Sz
   Bajcsay, A
   Nemeth, Gy
   Fodor, J
   Polgar, Cs
AF Mangel, Laszlo
   Lovey, Jozsef
   Farkas, Robert
   Bellyei, Szabolcs
   Bajcsay, Andras
   Nemeth, Gyorgy
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bellyei, Szabolcs] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Nemeth, Gyorgy] University of Pecs, Department of OncologyPecs, Hungary.
   [Fodor, Janos] University of Pecs, Department of OncologyPecs, Hungary.
   [Polgar, Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 136
EP 137
PG 2
ER

PT J
AU Nagy, Zs
   Bercesi, �
   Csere, T
   Mangel, L
AF Nagy, Zsuzsanna
   Bercesi, Eva
   Csere, Tibor
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Bercesi, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Nagy, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Pap, �
   Lovey, J
   Lengyel, Zs
   Major, T
   Borbely, K
   Polgar, Cs
AF Pap, Eva
   Lovey, Jozsef
   Lengyel, Zsolt
   Major, Tibor
   Borbely, Katalin
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pap, Eva] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pap, � (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Szanto, E
   Vegvary, Z
   Valicsek, E
   Tiszlavicz, L
   Nemeth, I
   Dosa, S
   Szakal, G
   Barzo, P
   Cserhati, A
   Fodor, E
   Varga, Z
   Hideghety, K
AF Szanto, Erika
   Vegvary, Zoltan
   Valicsek, Erzsebet
   Tiszlavicz, Laszlo
   Nemeth, Istvan
   Dosa, Sandor
   Szakal, Gergo
   Barzo, Pal
   Cserhati, Adrienne
   Fodor, Emese
   Varga, Zoltan
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Nemeth, Istvan] University of Szeged, Department of PathologySzeged, Hungary.
   [Dosa, Sandor] University of Szeged, Department of PathologySzeged, Hungary.
   [Szakal, Gergo] University of Szeged, Department of PathologySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Szanto, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 137
EP 138
PG 2
ER

PT J
AU Takacsi-Nagy, Z
   Hitre, E
   Remenar, �
   Oberna, F
   Fodor, J
   Polgar, Cs
   Kasler, M
AF Takacsi-Nagy, Zoltan
   Hitre, Erika
   Remenar, Eva
   Oberna, Ferenc
   Fodor, Janos
   Polgar, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Kelemen, Gy
   Varga, Z
   Lazar, Gy
   Thurzo, L
   Kahan, Zs
AF Kelemen, Gyongyi
   Varga, Zoltan
   Lazar, Gyorgy
   Thurzo, Laszlo
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kelemen, Gy (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Pesti, L
   Dankovics, Zs
   Lorencz, P
   Csejtei, A
AF Pesti, Lajos
   Dankovics, Zsofia
   Lorencz, Peter
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesti, Lajos] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Lorencz, Peter] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Pesti, L (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Major, T
   Frohlich, G
   Janvary, ZsL
   Lovey, K
   Mozsa, E
   Polgar, Cs
AF Major, Tibor
   Frohlich, Georgina
   Janvary, Zsolt Levente
   Lovey, Katalin
   Mozsa, Emoke
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of OncologyBudapest, Hungary.
   [Janvary, Zsolt Levente] University Hospital of LiegeLiege, Belgium.
   [Lovey, Katalin] State Hospital KremsKrems an der Donau, Austria.
   [Mozsa, Emoke] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 138
EP 139
PG 2
ER

PT J
AU Mozsa, E
   Polgar, Cs
   Frohlich, G
   Major, T
   Janvary, ZsL
   Lovey, K
   Sulyok, Z
   Fodor, J
   Kasler, M
AF Mozsa, Emoke
   Polgar, Csaba
   Frohlich, Georgina
   Major, Tibor
   Janvary, Zsolt Levente
   Lovey, Katalin
   Sulyok, Zoltan
   Fodor, Janos
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mozsa, Emoke] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Janvary, Zsolt Levente] University Hospital of LiegeLiege, Belgium.
   [Lovey, Katalin] State Hospital KremsKrems an der Donau, Austria.
   [Sulyok, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Mozsa, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Szabo, I
   Schultes, HN
   Szluha, K
AF Szabo, Imre
   Schultes, Henriette Noemi
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Imre] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Schultes, Henriette Noemi] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Szabo, I (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Szappanos, Sz
   Nagy, Zs
   Mangel, L
AF Szappanos, Szabolcs
   Nagy, Zsuzsanna
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Szappanos, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Tamaskovics, B
   Gossler, B
   Karzei, Z
   Lux, S
   Budach, W
AF Tamaskovics, Balint
   Gossler, Birte
   Karzei, Zaid
   Lux, Sebastian
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Gossler, Birte] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Karzei, Zaid] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Lux, Sebastian] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine Universitat, Klinik fur Strahlentherapie und Radioonkologie, Dusseldorf, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 139
EP 140
PG 2
ER

PT J
AU Varga, Sz
   Krascsenits, G
   Frohlich, G
   Vizkeleti, J
   Pete, I
   Polgar, Cs
AF Varga, Szilvia
   Krascsenits, Geza
   Frohlich, Georgina
   Vizkeleti, Julia
   Pete, Imre
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Krascsenits, Geza] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varga, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Varga, Z
   Cserhati, A
   Hideghety, K
   Boda, K
   Thurzo, L
   Kahan, Zs
AF Varga, Zoltan
   Cserhati, Adrienne
   Hideghety, Katalin
   Boda, Krisztina
   Thurzo, Laszlo
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Vizkeleti, J
   Vereczkey, I
   Pete, I
   Frohlich, G
   Varga, Sz
   Pulay, T
   Kasler, M
   Polgar, Cs
AF Vizkeleti, Julia
   Vereczkey, Ildiko
   Pete, Imre
   Frohlich, Georgina
   Varga, Szilvia
   Pulay, Tamas
   Kasler, Miklos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Zaka, Z
   Szabo, �
   Mozsa, E
   Renyi-Vamos, F
   Horvath, Zs
   Frohlich, G
   Major, T
   Polgar, Cs
   Fodor, J
AF Zaka, Zoltan
   Szabo, Eva
   Mozsa, Emoke
   Renyi-Vamos, Ferenc
   Horvath, Zsolt
   Frohlich, Georgina
   Major, Tibor
   Polgar, Csaba
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Zaka, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 140
EP 141
PG 2
ER

PT J
AU Adamecz, Zs
   Furka, A
   Szabados, �A
   Durunda, O
   Klekner, �
AF Adamecz, Zsolt
   Furka, Andrea
   Szabados, Eva Anna
   Durunda, Okszana
   Klekner, Almos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Furka, Andrea] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szabados, Eva Anna] DE OEC, Orvosi Rehabilitacio es Fizikalis Medicina TanszekDebrecen, Hungary.
   [Durunda, Okszana] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
RP Adamecz, Zs (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Cselik, Zs
   Glavak, Cs
   Antal, G
   Benko, A
   Kovacs, �
   Vallyon, M
   Liposits, G
   Toller, G
   Antalffy, Zs
   Hadjiev, J
   Repa, I
AF Cselik, Zsolt
   Glavak, Csaba
   Antal, Gergely
   Benko, Andras
   Kovacs, Arpad
   Vallyon, Marta
   Liposits, Gabor
   Toller, Gabor
   Antalffy, Zsolt
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Benko, Andras] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Liposits, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antalffy, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Cselik, Zs (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Dankovics, Zs
   Padanyi, G
   Heim, A
   Csejtei, A
AF Dankovics, Zsofia
   Padanyi, Gergely
   Heim, Andras
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Padanyi, Gergely] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Dobi, �
   Groh, F
   Cserhati, A
   Gaal, Sz
   Szanto, E
   Egyud, Zs
   Fodor, E
   Hideghety, K
AF Dobi, Agnes
   Groh, Fruzsina
   Cserhati, Adrienne
   Gaal, Szilvia
   Szanto, Erika
   Egyud, Zsofia
   Fodor, Emese
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Groh, Fruzsina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dobi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Egyud, Zs
   Szabo, J
   Cserhati, A
   Szanto, E
   Nagy, Z
   Fodor, E
   Varga, Z
   Fazekas, O
   Nikolenyi, A
   Csenki, M
   Maraz, A
   Hideghety, K
AF Egyud, Zsofia
   Szabo, Judit
   Cserhati, Adrienne
   Szanto, Erika
   Nagy, Zoltan
   Fodor, Emese
   Varga, Zoltan
   Fazekas, Olga
   Nikolenyi, Aliz
   Csenki, Melinda
   Maraz, Aniko
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fazekas, Olga] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Egyud, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 141
EP 142
PG 2
ER

PT J
AU Hideghety, K
   Szanto, E
   Cserhati, A
   Valicsek, E
   Fodor, E
   Nagy, Z
   Tiszlavicz, L
   Dosa, S
   Mencser, Z
   Kopniczki, Zs
   Deak, Gy
   Kis, D
   Barzo, P
AF Hideghety, Katalin
   Szanto, Erika
   Cserhati, Adrienne
   Valicsek, Erzsebet
   Fodor, Emese
   Nagy, Zoltan
   Tiszlavicz, Laszlo
   Dosa, Sandor
   Mencser, Zoltan
   Kopniczki, Zsolt
   Deak, Gyorgy
   Kis, David
   Barzo, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Dosa, Sandor] University of Szeged, Department of PathologySzeged, Hungary.
   [Mencser, Zoltan] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Kopniczki, Zsolt] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Deak, Gyorgy] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Kis, David] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Kalincsak, J
   Kovacs, P
   Sebestyen, Zs
   Horvath, Zs
   Farkas, R
   Bellyei, Sz
   Szigeti, A
   Mangel, L
AF Kalincsak, Judit
   Kovacs, Peter
   Sebestyen, Zsolt
   Horvath, Zsolt
   Farkas, Robert
   Bellyei, Szabolcs
   Szigeti, Andras
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Kalincsak, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Kovacs, �
   Hadjiev, J
   Liposits, G
   Antal, G
   Glavak, Cs
   Repa, I
AF Kovacs, Arpad
   Hadjiev, Janaki
   Liposits, Gabor
   Antal, Gergely
   Glavak, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Liposits, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kovacs, � (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Padanyi, G
   Dankovics, Zs
   Heim, A
   Csejtei, A
AF Padanyi, Gergely
   Dankovics, Zsofia
   Heim, Andras
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Padanyi, Gergely] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Padanyi, G (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 142
EP 143
PG 2
ER

PT J
AU Sebestyen, K
   Kovacs, P
   Sebestyen, Zs
   Farkas, R
   Bellyei, Sz
   Olaszne Halasz, J
   Kalincsak, J
   Percsi, P
   Hideghety, K
   Mangel, L
AF Sebestyen, Klara
   Kovacs, Peter
   Sebestyen, Zsolt
   Farkas, Robert
   Bellyei, Szabolcs
   Olaszne Halasz, Judit
   Kalincsak, Judit
   Percsi, Petra
   Hideghety, Katalin
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Olaszne Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Percsi, Petra] University of Pecs, Faculty of MedicinePecs, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 143
EP 143
PG 1
ER

PT J
AU Sebestyen, Zs
   Kovacs, P
   Farkas, R
   Bellyei, Sz
   Szigeti, A
   Sebestyen, K
   Olaszne Halasz, J
   Mangel, L
AF Sebestyen, Zsolt
   Kovacs, Peter
   Farkas, Robert
   Bellyei, Szabolcs
   Szigeti, Andras
   Sebestyen, Klara
   Olaszne Halasz, Judit
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Olaszne Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 143
EP 143
PG 1
ER

PT J
AU Szigeti, A
   Farkas, R
   Bellyei, Sz
   Kovacs, P
   Sebestyen, Zs
   Gallaine Foldvari, D
   Mangel, L
   Horvath, Zs
AF Szigeti, Andras
   Farkas, Robert
   Bellyei, Szabolcs
   Kovacs, Peter
   Sebestyen, Zsolt
   Gallaine Foldvari, Dora
   Mangel, Laszlo
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Gallaine Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
RP Szigeti, A (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 143
EP 144
PG 2
ER

PT J
AU Varga, K
   Magyary, I
   Farkas, R
   Hideghety, K
AF Varga, Katalin
   Magyary, Istvan
   Farkas, Robert
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Magyary, Istvan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Farkas, Robert] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Glavak, Cs
   Perlaki, G
   Hadjiev, J
   Repa, I
AF Glavak, Csaba
   Perlaki, Gabor
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Perlaki, Gabor] Pecs University, Faculty of Health Sciences, Department of DiagnosticPecs, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Glavak, Cs (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Heim, A
   Farkas, B
   Lorencz, P
   Horvath, L
   Csejtei, A
AF Heim, Andras
   Farkas, Bela
   Lorencz, Peter
   Horvath, Lilla
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Farkas, Bela] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Lorencz, Peter] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Horvath, Lilla] Siemens ZrtSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Heim, A (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Heim, A
   Kiss, B
AF Heim, Andras
   Kiss, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Kiss, Balazs] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Heim, A (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Kontra, G
   Bago, A
   Bajcsay, A
   Fedorcsak, I
   Julow, J
   Horvath, �
   Major, T
AF Kontra, Gabor
   Bago, Attila
   Bajcsay, Andras
   Fedorcsak, Imre
   Julow, Jeno
   Horvath, Akos
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bago, Attila] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Julow, Jeno] Fovarosi Onkormanyzat, Szent Janos Korhaz es Rendelo Intezet, Idegsebeszeti OsztalyBudapest, Hungary.
   [Horvath, Akos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 144
EP 145
PG 2
ER

PT J
AU Kovacs, P
   Sebestyen, Zs
   Mangel, L
AF Kovacs, Peter
   Sebestyen, Zsolt
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Kovacs, P (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 145
EP 145
PG 1
ER

PT J
AU Oroszlany, E
   Major, T
AF Oroszlany, E
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Oroszlany, E] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
RP Oroszlany, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 145
EP 145
PG 1
ER

PT J
AU Pesznyak, Cs
   Pocza, T
   Sinko, D
   Zarand, P
AF Pesznyak, Csilla
   Pocza, Tamas
   Sinko, Daniel
   Zarand, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Pocza, Tamas] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Zarand, Pal] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 145
EP 145
PG 1
ER

PT J
AU Pesznyak, Cs
   Hajdu, Cs
   Bojtos, P
   Elek, R
   Legrady, D
AF Pesznyak, Csilla
   Hajdu, Csaba
   Bojtos, Peter
   Elek, Richard
   Legrady, David
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hajdu, Csaba] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Bojtos, Peter] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Elek, Richard] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Legrady, David] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 145
EP 146
PG 2
ER

PT J
AU Pesznyak, Cs
   Polgar, I
   Zarand, P
AF Pesznyak, Csilla
   Polgar, Istvan
   Zarand, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Polgar, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Zarand, Pal] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Pesznyak, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Pintye, �
   Csepura, Gy
   Dobos, E
   Kovacs, �
   Simon, M
   Balogh, I
   Schultes, HN
   Szluha, K
AF Pintye, Eva
   Csepura, Gyorgy
   Dobos, Erik
   Kovacs, Arpad
   Simon, Mihaly
   Balogh, Istvan
   Schultes, Henriette Noemi
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Csepura, Gyorgy] ANTSZDebrecen, Hungary.
   [Dobos, Erik] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Schultes, Henriette Noemi] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Pintye, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Rusko, L
   Szanto, E
   Kovacs, F
   Hideghety, K
AF Rusko, Laszlo
   Szanto, Erika
   Kovacs, Ferenc
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rusko, Laszlo] GE Healthcare MagyarorszagSzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kovacs, Ferenc] GE Healthcare MagyarorszagSzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Rusko, L (reprint author), GE Healthcare Magyarorszag, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Varjas, G
   Agoston, P
   Major, T
   Fodor, J
   Baricza, K
   Polgar, Cs
AF Varjas, Geza
   Agoston, Peter
   Major, Tibor
   Fodor, Janos
   Baricza, Karoly
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varjas, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Thurzo, L
   Tolnai, E
AF Thurzo, Laszlo
   Tolnai, Edina
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2010. november 19-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Thurzo, Laszlo] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
   [Tolnai, Edina] Sugarterapias es Onkologiai Szakmai KollegiumBudapest, Hungary.
RP Thurzo, L (reprint author), Sugarterapias es Onkologiai Szakmai Kollegium, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2011
VL 55
IS 2
BP 148
EP 151
PG 4
ER

PT J
AU Sinko, J
AF Sinko, Janos
TI Treatment and prevention of infections in cancer patients with neutropenia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lazas neutropenia; szolid tumor; empirikus antibiotikum-terapia; granulocyta-koloniastimulalo faktor; infekciokontroll
ID lazas neutropenia; szolid tumor; empirikus antibiotikum-terapia; granulocyta-koloniastimulalo faktor; infekciokontroll
AB Prognosis of malignant diseases is significantly influenced by infectious morbidity and mortality. Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections. In order to improve outcome, patients developing febrile neutropenia following antitumour treatment should be adequately informed regarding the risk of infections. At the same time, centres responsible for cancer patient care should set up written protocols for basic workup and empirical antibiotic therapy. Here general characteristics of neutropenic infections developing in solid tumour patients are outlined and key points for risk assessment are highlighted. In addition, options and limits of anti-infective therapy as well as prophylaxis of infections are reviewed. Importance of a fully functional institutional infection control system and multidisciplinary patient management is also emphasised.
C1 [Sinko, Janos] Del-Pesti Centrumkorhaz, Gyali u 5-7., 1097 Budapest, Hungary.
RP Sinko, J (reprint author), Del-Pesti Centrumkorhaz, 1097 Budapest, Hungary.
EM janos.sinko@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 155
EP 163
PG 9
ER

PT J
AU Piko, B
   Bassam, A
   Dimak, S
   Kis, A
   Csiffari, M
   Rus-Gal, P
   Szabo, Zs
   Vereb, B
AF Piko, Bela
   Bassam, Ali
   Dimak, Sandor
   Kis, Anita
   Csiffari, Margit
   Rus-Gal, Paul
   Szabo, Zsolt
   Vereb, Blanka
TI Thoughts about thromboembolic events prophylaxis in cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE daganatos betegseg; venas tromboembolias esemeny; kockazati tenyezok; profilaxis; alacsony molekulatomegu heparin
ID daganatos betegseg; venas tromboembolias esemeny; kockazati tenyezok; profilaxis; alacsony molekulatomegu heparin
AB The risk of venous thromboembolic events (VTE) in cancer patients is higher than in the general population. Treatment may also increase this risk in these patients. Based on the appropriate criteria (of which the most important are the current ministerial guidelines) thrombosis prophylaxis should be started (given that there is no contraindication) on these patients and be continued while they are at risk. In the event of permanent risk thrombosis prophylaxis should be given lifelong. The drug of choice is low-molecular-weight heparin (LMWH) which is safer and more effective than the oral vitamin K antagonists. Platelet aggregation inhibitors have proved unsuccessful in this patient group. The evidence so far suggests that LMWH (during VTE prophylaxis) can have a positive impact on the course of cancer and perhaps it will be registered under the indication section for cancer patients in the future.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Dimak, Sandor] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Kis, Anita] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Rus-Gal, Paul] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Szabo, Zsolt] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Vereb, Blanka] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM dr.piko.bela@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 164
EP 169
PG 6
ER

PT J
AU Agoston, P
   Major, T
   Frohlich, G
   Baricza, K
   Szabo, Z
   Lovey, J
   Varjas, G
   Kasler, M
   Fodor, J
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Frohlich, Georgina
   Baricza, Karoly
   Szabo, Zoltan
   Lovey, Jozsef
   Varjas, Geza
   Kasler, Miklos
   Fodor, Janos
   Polgar, Csaba
TI Permanent implant brachytherapy for early, organ confined prostate cancer. Implementation and initial experience in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE permanens implantacio; prosztata-brachyterapia; I-125
ID permanens implantacio; prosztata-brachyterapia; I-125
AB Purpose: Implementation of permanent prostate implant (PPI) brachytherapy in Hungary and presentation of initial experience. Patients and methods: Between December 2008 and 2010, thirty-nine patients with low (n=26) and intermediate (n=13) risk prostate cancer were treated with PPI. Their mean age and initial PSA were 66 year (51-80 year) and 9 ng/ml (3,2-15 ng/ml). Iodine-125 loose seeds were implanted under spinal anaesthesia using the FIRST system (Nucletron, The Netherlands). Needles were inserted into the prostate through the perineum according to the preplan based on transrectal ultrasound images. The treatment plan was modified according to updated positions of the needles on live US images. The prescribed dose to the prostate was 145 Gy. Seed loading was performed under real-time US assistance. Implanted sources were checked by X-ray and CT images. Patients were discharged one day after the implantation. On follow-up visits PSA and toxicity were registered. Results: The mean follow-up was 10 months (3-27 months), the median number of seeds was 53 (30-78), their mean activity was 0.48 mCi (0.41-0.52 mCi). The mean coverage of the prostate by the prescribed dose was 96% (92-98%). The mean percent dose of the prescribed dose that covered the 90% of the prostate (D90), 2 cm3 of the rectum (Dr2cm3) and 10% of the urethra (Du10) were 113% (104-121%), 85% (48-121%) and 124% (98-146%) respectively. Deviation from the requested dose-volume constraints never exceeded 3%. Acute >grade 2 proctitis, grade 2 and 3 cysto-prostatitis were observed in 0 (0%), 13 (33.3%) and 1 (2.6%) cases. Biochemical relapse occurred in one patient (2.6%). Conclusion: This is a report of the first application of PPI in Hungary. The observed rate of acute proctitis was negligible, the rate and severity of acute cysto-prostatitis was tolerable. With the use of intraoperative planning, dose distributions met the dose-volume constraints in most of the cases. The biochemical control is excellent but the follow-up time is still short.
C1 [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM agoston.p@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 170
EP 177
PG 8
ER

PT J
AU Garai, I
   Borbely, K
   Barna, S
   Szucs, B
   Hascsi, Zs
   Toth, Z
   Illes, �
AF Garai, Ildiko
   Borbely, Katalin
   Barna, Sandor
   Szucs, Bernadett
   Hascsi, Zsolt
   Toth, Zoltan
   Illes, Arpad
TI 18F-FDG PET/CT in lymphomas: difficulties in the evaluation of metabolism due to illness characteristics, and review of literature data
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hodgkin-lymphoma; PET/CT; FDG; extranodalis lokalizacio
ID Hodgkin-lymphoma; PET/CT; FDG; extranodalis lokalizacio
AB Fluor-18-deoxy-glucose (18F-FDG or FDG) positron emission tomography - computer tomography (PET/CT) has recently become integrated into the clinical routine of patients with lymphoma in Hungary. The basic condition of risk-adapted treatment of these patients is the exact staging and early objective evaluation of the effectiveness of therapy. Between 1 May 2007 and 31 October 2010, 1862 18F-FDG PET/CT examinations were conducted for lymphoma patients at the PET/CT Center in Debrecen. This is more than 15% of the total examined patient population, and this rate shows a slight increase with each year. Based on the experience obtained from lymphoma patients by routine metabolic PET/CT scans we analyzed the difficulties of the evaluation in different time frames of patients' management. It is well known that FDG uptake of lymphomas depends on multiple factors. Although most histological subtypes are associated with uptake of FDG, the intensity of the tracer uptake is different. Different intensity of FDG uptake of the same type of lymphoma following therapeutic procedures might cause difficulties in the evaluation of the scans ensuring that primary staging by PET/CT is highly required for precise measurement and reliable comparison of data. Extranodal involvement was detected in ~40% of the patients with variable rate of prevalence. Extranodal involvement is associated with great diversity and in most cases it is not characteristic of the illness and might appear in different forms and in any organs. Additionally, because accompanying disease may produce false positive results, detailed clinical data and precise case history is highly required.
C1 [Garai, Ildiko] Scanomed Kft., Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Barna, Sandor] Scanomed Kft., Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Szucs, Bernadett] Scanomed Kft., Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Hascsi, Zsolt] Scanomed Kft., Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Toth, Zoltan] Scanomed Kft., Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Illes, Arpad] University of Debrecen, Medical and Health Center, 3rd Department of MedicineDebrecen, Hungary.
RP Garai, I (reprint author), Scanomed Kft., 4032 Debrecen, Hungary.
EM garai@belklinika.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 178
EP 186
PG 9
ER

PT J
AU Sebestyen, Zs
   Kovacs, P
   Gulyban, �
   Farkas, R
   Bellyei, Sz
   Szigeti, A
   Gallaine Foldvari, D
   Mangel, L
AF Sebestyen, Zsolt
   Kovacs, Peter
   Gulyban, Akos
   Farkas, Robert
   Bellyei, Szabolcs
   Szigeti, Andras
   Gallaine Foldvari, Dora
   Mangel, Laszlo
TI Modern 3D conformal craniospinal radiotherapy planning method
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE CNS besugarzas; 3D konformalis tervezesi technika; mezoillesztes (illeszteseltolas); frakcion beluli illeszteseltolas; mezoszegmensek
ID CNS besugarzas; 3D konformalis tervezesi technika; mezoillesztes (illeszteseltolas); frakcion beluli illeszteseltolas; mezoszegmensek
AB The main problem of craniospinal irradiation (CSI) is the matching of the fields. The use of a suitable technique is very important because matching of the fields is necessary to use for the optimal cancer irradiation of the long planning target volume (PTV). Since 2007, 8 patients have received CT-based, 3D-planned conformal CSI in our Institute. Patient immobilization was made in prone position in a vacuum bed, using skull and pelvis masks. Organ-at-risk (OAR) contours were made by radiographers. PTV was contoured by radiation oncologists. The prescribed dose to the PTV was 36 Gy with 1.8 Gy dose per fraction. In the planning process the following aspects were taken under consideration: all points of the PTV had to receive at least 95% of the prescribed dose (according to ICRU 50, 62); at junction field edges the overlapping parts were eliminated using a multisegmental technique, where the adjacent segment ends of the neighbouring fields were shifted two times 2 cm, so that the three equally weighted segments used in one field had 2-2 cm distance from each other. In the CSI planning the shape of the patient and so the length of the PTV has made a big emphasis on determining the number of field matching. Thus in some cases instead of two, only one field matching was sufficient - this could be achieved by increasing the source-to-skin distance (SSD) of the fields. The verification made with a solid-water phantom justified the precision of the field matching. The offset used at junction field edges in between one treatment facilitates the verification of field matching - and so the patient positioning. Thus the possibility of having overdosed regions could be reduced, which was very important from a radiation biological point of view.
C1 [Sebestyen, Zsolt] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Gulyban, Akos] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Gallaine Foldvari, Dora] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, 7624 Pecs, Hungary.
EM zsolt.sebestyen@aok.pte.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 187
EP 192
PG 6
ER

PT J
AU Rohanszky, M
   Konkoly Thege, B
   Bodoky, Gy
AF Rohanszky, Magda
   Konkoly Thege, Barna
   Bodoky, Gyorgy
TI Those who have survived the illness - Quality of life of Hungarian cancer patients. A retrospective study.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE daganatos betegek; eletminoseg; szorongas; depresszio; elet ertelme; retrospektiv vizsgalat
ID daganatos betegek; eletminoseg; szorongas; depresszio; elet ertelme; retrospektiv vizsgalat
AB Goal: To follow up Hungarian gastrointestinal cancer patients who were treated at St. Laszlo Hospital (Budapest) between the years of 2001-2006. We focused on the impact of the illness, quality of life, emotional health, and factors contributing to meaning in life. Methods: Out of the 240 questionnaires that were sent out in 2010, altogether 64 were returned (refusal rate: 72.3%) of which 40 filled-in questionnaires were interpretable. Mean age of the respondents (33% males) was 66.9+/-8.3 years. The following measure instruments were used: 1.) Ad hoc questions referring to the illness experience; 2.) Hospital Anxiety and Depression Scale (during the illness in a retrospective way and at present); 3.) WHO Well-being Index (WBI-5); 4.) general evaluation of quality of life on a 7-point Likert-scale (during the illness in a retrospective way and at present); 5.) Personal Meaning Profile (PMP). Results: Our respondents reported significantly better quality of life at present when compared to the time of illness (p<0.001). Level of depression and anxiety were also significantly lower at the time of participation (p<0.001 and p=0.009, respectively). Self-acceptance, good interpersonal relationships, and sense of achievement proved to be the most important factors contributing to a sense of meaning in life. As a result of their illness, our respondents considered themselves as more patient, opener persons with elevated health consciousness. Conclusions: Quality of life of the respondents 4-9 years after treatment seemed to be adequate as perceived by the participants who showed low level of depression and anxiety. The illness itself has brought positive changes for the participants in their attitudes towards life and their surroundings. In spite of this fact, the perceived threat of the recurrence of cancer remains constant in their everyday life.
C1 [Rohanszky, Magda] Tuzmadar AlapitvanyBudapest, Hungary.
   [Konkoly Thege, Barna] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Perenyi ut 28., 1037 Budapest, Hungary.
RP Rohanszky, M (reprint author), Tuzmadar Alapitvany, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 193
EP 198
PG 6
ER

PT J
AU Telekes, A
   Raso, E
   Vekey, K
AF Telekes, Andras
   Raso, Erzsebet
   Vekey, Karoly
TI Investigation of fatty acid profile for diagnostic purposes in mouse melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tomegspektrometria; melanoma; zsirsavprofil; diagnosztikus marker
ID tomegspektrometria; melanoma; zsirsavprofil; diagnosztikus marker
AB The aim of this study was to investigate whether fatty acid profile is a suitable marker for diagnostic purposes in mouse melanoma. Twelve C57Bl/6 male mice were implanted with B16 mouse melanoma cells (106 cells/animal) orthotopically (subcutaneously). After the implantation 4-4 animals were bled by cardiac puncture following narcosis, at days 7, 14, and 21. In order to investigate fatty acid profiles a method based on extraction and HPLC-MS was developed. Signal intensities of 14 fatty acids were determined by mass spectrometry in tumor-free animals as well as tumor bearing animals at the three time points. Mathematical analysis showed non-significant profile changes when control (tumor-free) animals were compared to tumor-implanted ones as well as during tumor progression on week 1, 2 and 3. In case of three fatty acids (myristic acid, palmitoleic acid and eicosadienoic acid) a trend was observed during tumor progression but its statistical significance cannot be evaluated without further investigations. The fatty acid profile cannot be used for early diagnoses in mouse melanoma.
C1 [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Maglodi ut 89-91., 1106 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Vekey, Karoly] MTA Kemiai KutatokozpontBudapest, Hungary.
RP Telekes, A (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, 1106 Budapest, Hungary.
EM andras.telekes@bajcsy.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 199
EP 204
PG 6
ER

PT J
AU Lazanyi, K
   Molnar, P
   Bugan, A
   Kiss, Cs
   Szanto, J
   Gonda, A
   Toth, Z
   Hernadi, Z
   Hadijev, J
   Remenyik, �
   Damjanovich, L
   Dinya, T
   Flasko, T
   Bagyi, P
   Szluha, K
AF Lazanyi, Kornelia
   Molnar, Peter
   Bugan, Antal
   Kiss, Csongor
   Szanto, Janos
   Gonda, Andrea
   Toth, Zoltan
   Hernadi, Zoltan
   Hadijev, Janaki
   Remenyik, Eva
   Damjanovich, Laszlo
   Dinya, Tamas
   Flasko, Tibor
   Bagyi, Peter
   Szluha, Kornelia
TI The emotions of oncologists
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE erzelem; erzelmi terkep; erzelmi beallitottsag; onkologia
ID erzelem; erzelmi terkep; erzelmi beallitottsag; onkologia
AB Emotions are parts of organizational reality to an ever increasing extent. Importantly, they are not just tools in the hand of healthcare workers to achieve better physician / healthcare professional-to-patient interactions but intrinsic processes and characteristics with psychic, cognitive and somatic actions. For a thorough investigation of the issue, a PANAS-X questionnaire was used to examine the emotions of 187 physicians and other healthcare professionals, all engaged in oncology, in 2009. The research succeeded in exploring the overall emotional state oncology professionals had assumed in relation with their job as well as enabled the authors of this study to draw the respondents' emotional map and assess their fundamental emotional attitudes. Furthermore, the authors managed to identify groups of respondents that had felt more intense positive, and/or less intense negative emotions that are socially accepted than others. They included those of senior experienced oncologists, males, individuals with families, childless individuals, ward workers, and skilled professionals. According to the findings, the range of emotions an oncologist experiences / feels intently during his everyday work is dependent upon a great number of factors.
C1 [Lazanyi, Kornelia] Debreceni Egyetem, Pszichologiai Intezet, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Molnar, Peter] Debreceni Egyetem, Pszichologiai Intezet, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Bugan, Antal] Debreceni Egyetem, Pszichologiai Intezet, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Szanto, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Gonda, Andrea] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Zoltan] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Hadijev, Janaki] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Remenyik, Eva] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Damjanovich, Laszlo] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Dinya, Tamas] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Bagyi, Peter] Kenezy Korhaz Nonprofit Kft.,, Kozponti Radiologiai DiagnosztikaDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Lazanyi, K (reprint author), Debreceni Egyetem, Pszichologiai Intezet, 4012 Debrecen, Hungary.
EM kornelia.lazanyi@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 205
EP 212
PG 8
ER

PT J
TI XVIII. Primary Prevention Forum
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 213
EP 223
PG 11
ER

PT J
AU Thurzo, L
   Tolnay, E
AF Thurzo, Laszlo
   Tolnay, Edina
TI Emlekezteto a Sugarterapias es Onkologiai Szakmai Kollegium 2011. februar 4-i uleserol
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Thurzo, Laszlo] National Institute of Oncology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Tolnay, Edina] National Institute of Oncology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Thurzo, L (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2011
VL 55
IS 3
BP 225
EP 229
PG 5
ER

PT J
AU Takacsi Nagy, L
   Polgar, Cs
AF Takacsi Nagy, Laszlo
   Polgar, Csaba
TI Dr. Somogyi Andras 1947-2011
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Takacsi Nagy, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 233
EP 233
PG 1
ER

PT J
AU Rubovszky, G
   Horvath, Zs
AF Rubovszky, Gabor
   Horvath, Zsolt
TI Menopausal symptoms and their treatment emerging during hormonal therapy of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE endokrin terapia; menopauzalis tunetek; emlodaganat
ID endokrin terapia; menopauzalis tunetek; emlodaganat
AB Hormonal compounds play an important role in the treatment of breast cancer. Their side effects may lead to suspension of therapy and consequently to the failure of the expected effect. Common and the same way most prevalent side effects of hormonal compounds are the menopausal complaints which can alter quality of life significantly. The early recognition and treatment of menopausal complaints and symptoms help to reach therapeutic success. In general, of menopausal related complaints the role of hot flash, atrophic vaginitis and sexual dysfunction is emphasized. Within the topic, it is possible to mention some musculo-skeletal complaints according to their similar etiology, the failure of estrogen effect. In the treatment of hot flash non-pharmacologic and pharmacologic methods can be distinguished. Based on meta-analyses anti-depressants, some anti-convulsants and clonidine proved to be effective. Musculo-skeletal complaints explained by the lack of estrogen effect do not cause permanent impairment but may indicate greater efficacy of endocrine treatment. In the context of osteoporosis it is important to emphasize prevention. The main goal of endocrine therapies is to ameliorate remission rate or survival, but we should not forget to treat side effects which can influence quality of life.
C1 [Rubovszky, Gabor] National Institute of Oncology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM garub@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 235
EP 242
PG 8
ER

PT J
AU Piko, B
   Rahoty, P
   Kremer, I
   Zsilak, J
   Torok, E
   Bassam, A
   Csiffari, M
   Dimak, S
   Kis, A
   Rus-Gal, P
   Szabo, Zs
   Vereb, B
   Puskasne Szatmari, K
AF Piko, Bela
   Rahoty, Pal
   Kremer, Ildiko
   Zsilak, Janos
   Torok, Eniko
   Bassam, Ali
   Csiffari, Margit
   Dimak, Sandor
   Kis, Anita
   Rus-Gal, Paul
   Szabo, Zsolt
   Vereb, Blanka
   Puskasne Szatmari, Klara
TI Detection of multiple colon and rectal tumors during diagnostic treatment and follow-up
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kolorektalis karcinoma; multiplex beltumorok; kolonoszkopia; elsodleges kivizsgalas; gondozas
ID kolorektalis karcinoma; multiplex beltumorok; kolonoszkopia; elsodleges kivizsgalas; gondozas
AB Recognition of the commonly encountered colorectal cancer (CRC) generally begins and takes place because of and based on symptoms and signs, due to the unsettled screening of this type of cancer. Sometimes, because of advanced stage cancer urgent surgical intervention could become necessary and, if this is the case, there is no time and possibility for searching for an eventual second tumor and perhaps the patient’s status does not permit performing intraoperative investigations either. The incidence of multiple colon cancer is considered to be between 2.5 and 30% according to the literature. That is why one should exclude them even in the absence of pre- and intraoperative investigations and complaints. On the other hand, colonoscopy and perhaps irrigoscopy of seemingly healthy followed-up patients is mandatory. In the case of the presence of complaints/symptoms denoting impaired intestinal passage seen in a followed-up patient or during the adjuvant setting or metastatic/recurrent disease, treatment and even during hospice care we should evaluate the possibility of a second metachronous tumor. Moreover, if there is no urgency, the multidisciplinary team (oncoteam) should recommend the adequate treatment by balancing gain/utility and risk.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Rahoty, Pal] MH Honvedkorhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Kremer, Ildiko] Pest Megyei Flor Ferenc Korhaz, Aneszteziologiai es Intenziv Terapias OsztalyKistarcsa, Hungary.
   [Zsilak, Janos] Bekescsaba Varosi Onkormanyzat Rethy Pal Korhaza, Sebeszeti OsztalyBekescsaba, Hungary.
   [Torok, Eniko] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Dimak, Sandor] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Kis, Anita] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Rus-Gal, Paul] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Szabo, Zsolt] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Vereb, Blanka] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Puskasne Szatmari, Klara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM dr.piko.bela@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 244
EP 249
PG 6
ER

PT J
AU Matrai, Z
   Gulyas, G
   Toth, L
   Savolt, �
   Kunos, Cs
   Pesthy, P
   Bartal, A
   Kasler, M
AF Matrai, Zoltan
   Gulyas, Gusztav
   Toth, Laszlo
   Savolt, Akos
   Kunos, Csaba
   Pesthy, Pal
   Bartal, Alexandra
   Kasler, Miklos
TI The place of skin-sparing mastectomy in oncoplastic breast surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bortakarekos mastectomia; emlorak; azonnali emlorekonstrukcio
ID bortakarekos mastectomia; emlorak; azonnali emlorekonstrukcio
AB Despite its ever increasing popularity, there is no evidence-based confirmation so far on the results of skin-sparing mastectomy, introduced 20 years ago. However, the results of countless published retrospective, long-term trials seem to underpin the ability of the precisely implemeted procedure in early stage invasive and in situ breast cancers to yield the oncological results of modified radical mastectomy. As a result of the procedure involving special surgical techniques, the skin not affected by cancer can be preserved, which facilitates immediate reconstruction and improves cosmetic outcome. The effect of postmastectomy radiotherapy on the reconstruction needs to be considered at the time of the multidisciplinary design of the surgical procedure. The authors give a detailed description of the surgical techniques, and provide a wide review of the literature, for the first time in Hungarian language.
C1 [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Pesthy, Pal] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM matraidok@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 252
EP 267
PG 16
ER

PT J
AU Tarpay, �
   Szabadosne Nemeth, M
   Orosz, E
   Kasler, M
   Burai, M
   Pap, �
   Otto, Sz
AF Tarpay, Adam
   Szabadosne Nemeth, Maria
   Orosz, Eniko
   Kasler, Miklos
   Burai, Maria
   Pap, Akos
   Otto, Szabolcs
TI A double immunochemical method for the detection of faecal haemoglobin rectal screening: sensitivity and specificity
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE vastagbelrak; szures; szekletver; immunkemiai teszt; kolonoszkopia
ID vastagbelrak; szures; szekletver; immunkemiai teszt; kolonoszkopia
AB Undoubtedly, colonoscopy is the “gold standard” in the diagnosis of colorectal cancers. Sophisticated bowel preparation and risk of bowel perforation and bleeding, as well as the patient’s discomfort during examination lead to low compliance in screening. Therefore, alternative non-invasive screening methods tend to come into the fore. In this study we compared the sensitivity and specificity of the double immunochemical FECA test for the haemoglobin + albumin content of the faeces with those of control colonoscopy in the detection of colorectal neoplasms. In a 3-year period 154 patients (69 males and 85 females) were scheduled for colonoscopy with previously collected stool samples. The sensitivity and specificity of the double immunochemical test for faecal haemoglobin + albumin content were determined in colorectal neoplasms of different severity. Colonoscopy served as a control examination. Colonoscopy identified in 77 cases benign lesions, and in 10 cases malignant tumours. The double immunochemical test for faecal blood and protein successfully used in model screening population showed in our present study 52.7% sensitivity and 92.3% specificity for significant neoplastic lesions (high-risk polyps and tumours). When the evaluation was limited to the high-risk polyps, the sensitivity was modified to 45.5% and the specificity to 92.3% and in case of invasive tumours to 90% and 100%, respectively. If only faecal haemoglobin content was measured, the overall sensitivity for polyps of any size and sort was 15.7% which, however, increased to 27.63% if faecal albumin was also measured. Based on relevant literature, the sensitivity of the FECA test for colorectal polyp and cancer is more favourable than that of other FITs. However, the increased sensitivity of the double faecal protein test falls short of the standard colonoscopy. Therefore, in certain cases the latter might be considered as a primary screening method.
C1 [Tarpay, Adam] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szabadosne Nemeth, Maria] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Orosz, Eniko] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Burai, Maria] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pap, Akos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Tarpay, � (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM tarpay@kkk.org.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 268
EP 273
PG 6
ER

PT J
AU Locsei, Z
   Hideghety, K
   Farkas, R
   Bellyei, Sz
   Sarosi, V
   Sebestyen, K
   Sebestyen, Zs
   Kovacs, P
   Mangel, L
AF Locsei, Zoltan
   Hideghety, Katalin
   Farkas, Robert
   Bellyei, Szabolcs
   Sarosi, Veronika
   Sebestyen, Klara
   Sebestyen, Zsolt
   Kovacs, Peter
   Mangel, Laszlo
TI Application of PET/CT in the radiotherapy of patients with non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE PET/CT; nem-kissejtes tudodaganat; celterfogat; rizikoszervek; sugarterapias dontes
ID PET/CT; nem-kissejtes tudodaganat; celterfogat; rizikoszervek; sugarterapias dontes
AB The goal of this paper was to investigate the influence of FDG-PET/CT scan on the modification of staging and irradiation planning in patients suffering from non-small cell lung cancer (NSCLC). Fifteen patients suffering from NSCLC were analyzed by the authors from January, 2008 to July, 2009. The aim of the analysis was to examine the influence of FDG-PET/CT on irradiation planning and on decision-making of the complex oncologic therapy. The FDG-PET/CT scan was carried out in the position of irradiation performed later. For irradiation planning, planning target volumes (PTV) and the organs of risk were contoured on the patients’ topometric CT slides as well as on the fused FDG-PET/CT slides. We evaluated how the application of PET/CT modified the stage of the illness, the complex oncologic therapeutic plan, the volume and the localization of the PTV, and the irradiation doses of the organs at risk. The mean and maximum dose of the spinal cord, the mean and V20 dose load of the lungs and the mean dose loads of the heart as well as of the left ventricle were measured. In 8 of 15 cases the stage of the disease and the treatment strategy was modified, since distant metastases were detected by the PET/CT. We evaluated the modification of the PTV and dose load of the organs at risk in 7 cases. According to the PET/CT the PTV was reduced in 5 cases (mean: 393.6 cm3) and was increased in 2 cases (mean: 250.8 cm3). Concerning the risk organs we found that the average (8.8 Gy/9.5 Gy) and maximum (33.4 Gy/36.4 Gy) dose load of the spinal cord increased, while the average (24.5 Gy/13.8 Gy) and V20 (33.7%/22.1%) dose load of the lungs decreased. We likewise found a decrease in the mean dose load of the heart (17.3 Gy/16.8 Gy) and left ventricle (12.9 Gy/9.6 Gy). In the majority of the cases the FDG-PET/CT scan modified the therapeutic decision, the size of the irradiated volume, and the dose load of the lung, the organ at risk causing the most difficulties at irradiation planning, was also reduced. The PET/CT scan plays an essential role in the complex oncologic treatment and irradiation therapy of NSCLC.
C1 [Locsei, Zoltan] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Farkas, Robert] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Sarosi, Veronika] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, 7624 Pecs, Hungary.
EM zoltan.locsei@kk.pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 274
EP 280
PG 7
ER

PT J
AU Czigner, K
   Agoston, P
   Forgacs, Gy
   Kasler, M
AF Czigner, Krisztina
   Agoston, Peter
   Forgacs, Gyula
   Kasler, Miklos
TI The effect of different patient positions on overlapping volumes at the radiotherapy of high-risk prostate cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE nagy kockazatu prosztatarak; vedendo szervek atfedese; ep szovetek vedelme; betegrogzites
ID nagy kockazatu prosztatarak; vedendo szervek atfedese; ep szovetek vedelme; betegrogzites
AB The purpose of the study was to evaluate the relationship among planning target volumes (PTVs) and organs at risk (OARs) based on four different radiotherapy treatment plans for high-risk prostate cancer patients. CT scans were obtained in supine position with knee and ankle support (KAS) and in prone position with belly-board (BB) both with full bladder (FB) and empty bladder (EB). Overlapping volumes of the delineated PTVs and OARs on four different setup combinations (KAS-FB; BB-FB; KAS-EB; BB-EB) were analyzed according to the patient position, bladder filling and circumference of abdomen (CA). Overlapping (∩) was significantly smaller with FB than with EB at the bowels and bladder: PTVpel∩bladder: p=0.0069, PTVpvs∩bladder: p<0.001, PTVp∩bladder: p<0.001, PTVpel∩bowels: p=0.0055. Comparison according to small and large CA resulted in significantly smaller overlapping of PTVs and OARs for large CA patients at: KAS-FB: PTVpel∩rectum: p=0.0255, PTVpvs∩rectum: p=0.0179, PTVp∩rectum: p=0.0386, PTVpel∩bladder: p=0.0355. KAS-EB: PTVpvs∩bladder: p=0.0184, PTVp∩bladder: p=0.0107. BB-EB: PTVpvs∩bladder: p=0.0464, PTVp∩bladder: p=0.0077. The exception was PTVpel∩rectum at KAS-FB where the overlapping were smaller for small CA (p=0.0255). According to our results we recommend to deliver radiotherapy treatment for high-risk prostate cancer patients in supine position with KAS immobilization and full bladder. The overlapping volumes of PTVs and OARs were smaller practically at all patients with larger circumference of abdomen.
C1 [Czigner, Krisztina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Forgacs, Gyula] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Czigner, K (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM kczigner7@yahoo.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 281
EP 285
PG 5
ER

PT J
AU Kopper, L
   Timar, J
AF Kopper, Laszlo
   Timar, Jozsef
TI mTOR complexes – molecular spiders in molecular networks
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE celzott terapia; mTOR-gatlok; hatasmechanizmus; celzott terapia
ID celzott terapia; mTOR-gatlok; hatasmechanizmus; celzott terapia
AB PI3K route is one of the most outstanding signal transduction pathways, which has a key role in the decision-making processes and functions of a cell. In this network mTOR (mammalian target of rapamycin) is a well-known integrator. mTOR forms two complexes, and their increased activity is present in many human tumors. Therefore, mTOR inhibitors became more and more important in the targeted therapy, first of all in the treatment of renal cancer, neuroendocrine pancreatic cancer and certain astrocytomas, and many trials are going on in other tumor types. The therapeutic results are obvious, but problems also occur, which stimulate application of new strategies and development of new drugs in order to approach the more individual cancer therapy.
C1 [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kopper, L (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM kopper@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 287
EP 294
PG 8
ER

PT J
AU Bardi, J
   Kovacs, �
   Rurik, I
AF Bardi, Judit
   Kovacs, Eva
   Rurik, Imre
TI Awareness of family physicians in the oncology care. Screening and diagnosis in the primary care
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE daganat; haziorvos; keslekedes; onkologia; prevencio; szures
ID daganat; haziorvos; keslekedes; onkologia; prevencio; szures
AB Delay time between the first experienced symptoms, visiting doctor and setting diagnosis up may depend on several factors. One hundred and ten cancer patients were compared regarding gender, age, social status, qualifications, economic status, participation in organized screening programs, regular attendance by family physicians and delay in the diagnostic procedures. According to the results, 67% of the patients visited the doctor only in case of symptoms occurring. After recognizing the first symptoms, 44% of the men and 53% of the women turned to doctor within one month. The longest delay time was observed in the case of patients over 60 and some patients with university degree, while usually shorter periods were reported in the case of the secondary school and most of the university graduated patients. Low income persons were over-represented in all delay categories. Twenty-five percent of female and 33% of male patients with lung cancer were diagnosed with routine x-ray screening. In the age cohort recommended for participation in organized screening programs, 66% of women took part on mammography and 69% on pap-screen. This ratio was the highest (88%) in the case of secondary school and the lowest (50%) in the case of university graduated women. The awareness of cancer has a high importance in primary care, and family physicians should motivate their patients to participate in organized screening programs as well.
C1 [Bardi, Judit] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Nepegeszsegugyi Kar, Csaladorvosi es Foglalkozas-egeszsegugyi Tanszek, Moricz Zs. krt. 22., 4032 Debrecen, Hungary.
   [Kovacs, Eva] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Nepegeszsegugyi Kar, Csaladorvosi es Foglalkozas-egeszsegugyi Tanszek, Moricz Zs. krt. 22., 4032 Debrecen, Hungary.
   [Rurik, Imre] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Nepegeszsegugyi Kar, Csaladorvosi es Foglalkozas-egeszsegugyi Tanszek, Moricz Zs. krt. 22., 4032 Debrecen, Hungary.
RP Bardi, J (reprint author), Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Nepegeszsegugyi Kar, Csaladorvosi es Foglalkozas-egeszsegugyi Tanszek, 4032 Debrecen, Hungary.
EM csotanszek@sph.unideb.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 4
BP 295
EP 301
PG 7
ER

PT J
TI 29th Congress of the Hungarian Cancer Society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB 2011. november 10–12. Abstracts
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 1
EP 84
PG 84
ER

PT J
AU Adamecz, Zs
   Furka, A
   Durunda, O
   Szalayne Konya, Zs
   Fodor, A
   Szilasi, M
AF Adamecz, Zsolt
   Furka, Andrea
   Durunda, Okszana
   Szalayne Konya, Zsuzsa
   Fodor, Andrea
   Szilasi, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Furka, Andrea] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Durunda, Okszana] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szalayne Konya, Zsuzsa] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Dietetikai SzolgalatDebrecen, Hungary.
   [Fodor, Andrea] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Adamecz, Zs (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Agoston, P
   Major, T
   Szabo, Z
   Varjas, G
   Frohlich, G
   Baricza, K
   Lovey, J
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Szabo, Zoltan
   Varjas, Geza
   Frohlich, Georgina
   Baricza, Karoly
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Alzubi, A
   Zollei, I
   Intzedi, K
   Krenacs, L
AF Alzubi, Ali
   Zollei, Istvan
   Intzedi, Katalin
   Krenacs, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Alzubi, Ali] Oroshazi Korhaz, Sebeszeti-onkologiai OsztalyOroshaza, Hungary.
   [Zollei, Istvan] Oroshazi Korhaz, Sebeszeti-onkologiai OsztalyOroshaza, Hungary.
   [Intzedi, Katalin] Oroshazi Korhaz, Patologiai OsztalyOroshaza, Hungary.
   [Krenacs, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
RP Alzubi, A (reprint author), Oroshazi Korhaz, Sebeszeti-onkologiai Osztaly, Oroshaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 5
EP 6
PG 2
ER

PT J
AU Andi, J
   Lorand, �
   Szentirmay, Z
   Pap, �
   Toth, L
   Lovey, J
   Godeny, M
AF Andi, Judit
   Lorand, Agnes
   Szentirmay, Zoltan
   Pap, Akos
   Toth, Laszlo
   Lovey, Jozsef
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lorand, Agnes] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pap, Akos] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Andi, J (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Arvay, T
AF Arvay, Tunde
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arvay, Tunde] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Arvay, T (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Bahery, M
   Simon, P
   Szentirmay, Z
   Juhos, �
   Godeny, M
AF Bahery, Maria
   Simon, Peter
   Szentirmay, Zoltan
   Juhos, Eva
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bahery, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Simon, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Juhos, Eva] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Bahery, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 6
EP 7
PG 2
ER

PT J
AU Baki, M
   Katona, Cs
   Szentgyorgyi, E
   Szule, E
   Varga, J
AF Baki, Marta
   Katona, Csilla
   Szentgyorgyi, Ervin
   Szule, Endre
   Varga, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szentgyorgyi, Ervin] Javorszky Odon Korhaz, Urologiai OsztalyVac, Hungary.
   [Szule, Endre] Flor Ferenc Korhaz, Urologiai OszalyKistarcsa, Hungary.
   [Varga, Jozsef] Uzsoki Utcai Korhaz, Urologiai OsztalyBudapest, Hungary.
RP Baki, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Balatoni, T
   Borbola, K
   Plotar, V
   Liszkay, G
AF Balatoni, Timea
   Borbola, Kinga
   Plotar, Vanda
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Balizs, T
   Vreca, I
   Marton, B
AF Balizs, Tibor
   Vreca, Istvan
   Marton, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balizs, Tibor] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vreca, Istvan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Marton, Balazs] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Balizs, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Balla, P
   Moskovszky, L
   Maros, M
   Krenacs, T
AF Balla, Peter
   Moskovszky, Linda
   Maros, Mate
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balla, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moskovszky, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Maros, Mate] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Balla, P (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Banhegyi, RJ
   Csiffari, M
   Varga, I
   Piko, B
AF Banhegyi, Robert Janos
   Csiffari, Margit
   Varga, Istvan
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banhegyi, Robert Janos] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Varga, Istvan] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Banhegyi, RJ (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Barbai, T
   Fejos, Zs
   Timar, J
   Raso, E
AF Barbai, Tamas
   Fejos, Zsuzsanna
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Fejos, Zsuzsanna] Allami Egeszsegugyi KozpontBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Barbai, T (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 8
EP 9
PG 2
ER

PT J
AU Bardi, E
   Hjorth, L
   Garwicz, S
   Skinner, R
   Haupt, R
   Grabow, D
   Byrne, J
   Frey, E
   Kremer, L
AF Bardi, Edit
   Hjorth, Lars
   Garwicz, Stanislaw
   Skinner, Roderick
   Haupt, Riccardo
   Grabow, Desiree
   Byrne, Julianne
   Frey, Eva
   Kremer, Leontien
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bardi, Edit] Vas County Markusovszky Hospital, Department of HematologySzombathely, Hungary.
   [Hjorth, Lars] Lund UniversityLund, Sweden.
   [Garwicz, Stanislaw] Lund UniversityLund, Sweden.
   [Skinner, Roderick] Newcastle UniversityNewcastle, UK.
   [Haupt, Riccardo] Istituto Giannina GasliniGenova, Italy.
   [Grabow, Desiree] University Medical Center Hamburg EppendorfHamburg, Germany.
   [Byrne, Julianne] Boyne Research InstituteDrogheda, Ireland.
   [Frey, Eva] St. Anna KinderkrebsforschungVienna, Austria.
   [Kremer, Leontien] Academic Medical CenterAmsterdam, The Netherlands.
RP Bardi, E (reprint author), Vas County Markusovszky Hospital, Department of Hematology, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Batka, G
AF Batka, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Batka, Gabor] Zala Megyei Korhaz, Intezeti GyogyszertarZalaegerszeg, Hungary.
RP Batka, G (reprint author), Zala Megyei Korhaz, Intezeti Gyogyszertar, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Becsagh, P
   Barbai, T
   Timar, J
   Raso, E
AF Becsagh, Peter
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Becsagh, Peter] Roche (Magyarorszag) Kft.Budapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Becsagh, P (reprint author), Roche (Magyarorszag) Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Bellyei, Sz
   Pozsgai, E
   Schally, VA
AF Bellyei, Szabolcs
   Pozsgai, Eva
   Schally, V Andrew
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Pozsgai, Eva] University of Pecs, Institute of Biochemistry and Medical ChemistryPecs, Hungary.
   [Schally, V Andrew] Miller School of Medicine, Department of Pathology, Department of MedicineMiami, USA.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Benedek, A
   Balogh, A
   Safrany, G
   Lumniczky, K
AF Benedek, Anett
   Balogh, Andrea
   Safrany, Geza
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benedek, Anett] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Benedek, A (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 10
EP 11
PG 2
ER

PT J
AU Bertha, A
AF Bertha, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bertha, Andras] Bermedpharm Kft.Budapest, Hungary.
RP Bertha, A (reprint author), Bermedpharm Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Bezsenyine Bobis, M
AF Bezsenyine Bobis, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bezsenyine Bobis, Marta] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Bezsenyine Bobis, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 11
EP 12
PG 2
ER

PT J
AU Bocs, K
   Liszkay, G
   Borbola, K
   Plotar, V
   Godeny, M
AF Bocs, Katalin
   Liszkay, Gabriella
   Borbola, Kinga
   Plotar, Vanda
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Bocs, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Bodoky, Gy
   Marrero, J
   Lencioni, R
   Kudo, M
   Ye, ShL
   Nakajima, K
   Cihon, F
   Venook, A
AF Bodoky, Gyorgy
   Marrero, Jorge
   Lencioni, Riccardo
   Kudo, Masatoshi
   Ye, Sheng-Long
   Nakajima, Keiko
   Cihon, Frank
   Venook, Alan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Marrero, Jorge] University of Michigan, Multidisciplinary Liver Tumor ClinicMichigan, USA.
   [Lencioni, Riccardo] University of Pisa, Department of Liver Transplantation, Division of Diagnostic Imaging and InterventionPisa, Italy.
   [Kudo, Masatoshi] Kinki University School of Medicine, Department of Gastroenterology and HepatologyOsaka-Sayama, Japan.
   [Ye, Sheng-Long] Fudan University, Zhongshan Hospital, Liver Cancer InstituteShanghai, China.
   [Nakajima, Keiko] Bayer HealthCare Pharmaceuticals, Global Medical AffairsWhippany, NJ, USA.
   [Cihon, Frank] Bayer HealthCare Pharmaceuticals, Global StatisticsWhippany, NJ, USA.
   [Venook, Alan] University of CaliforniaOakland, USA.
RP Bodoky, Gy (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
   Conti, P
AF Borbely, Katalin
   Kasler, Miklos
   Conti, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Conti, Peter] University of Southern California, Biomedical Engineering & Pharmacy, PET Imaging Sc.Los Angeles, USA.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Bozsik, A
AF Bozsik, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bozsik, Aniko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Bozsik, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Buglyo, �
   Treszl, A
   Kiss, L
   Szilasi, M
   Halmos, G
AF Buglyo, Armin
   Treszl, Andrea
   Kiss, Lili
   Szilasi, Maria
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Buglyo, Armin] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Kiss, Lili] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Buglyo, � (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Csanady, M
   Vass, G
   Majoros, V
   Czigner, J
   Bartyik, K
AF Csanady, Miklos
   Vass, Gabor
   Majoros, Valeria
   Czigner, Jeno
   Bartyik, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csanady, Miklos] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Vass, Gabor] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Majoros, Valeria] Szegedi Tudomanyegyetem, Aneszteziologiai es Intenziv Terapias IntezetSzeged, Hungary.
   [Czigner, Jeno] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Bartyik, Katalin] University of Szeged, Department of PediatricsSzeged, Hungary.
RP Csanady, M (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Csatarine Varga, Zs
AF Csatarine Varga, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csatarine Varga, Zsuzsa] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Csatarine Varga, Zs (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Cseh, J
   Pazsit, E
   Orsos, Zs
   Kiss, I
   Ember, I
AF Cseh, Jozsef
   Pazsit, Emese
   Orsos, Zsuzsanna
   Kiss, Istvan
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseh, Jozsef] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Pazsit, Emese] Borsod-Abauj-Zemplen megyei Korhaz, Szuleszet- Nogyogyaszati OsztalyMiskolc, Hungary.
   [Orsos, Zsuzsanna] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Ember, Istvan] Pecsi Tudomanyegyetem, Kozegeszsegtani es Jarvanytani TanszekPecs, Hungary.
RP Cseh, J (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 14
EP 15
PG 2
ER

PT J
AU Csiha, S
   Treszl, A
   Kiss, L
   Pataki, L
   Szilasi, M
   Halmos, G
AF Csiha, Sara
   Treszl, Andrea
   Kiss, Lili
   Pataki, Lajos
   Szilasi, Maria
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csiha, Sara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Kiss, Lili] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Pataki, Lajos] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Csiha, S (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Czegle, IA
   Graf, L
   Toth, �K
   Istvan, G
   Kovacs, B
   Magyar, P
   Fonyad, L
   Nemes, B
   Kocsis, J
AF Czegle, Ibolya Anett
   Graf, Laszlo
   Toth, Eva Katalin
   Istvan, Gabor
   Kovacs, Balazs
   Magyar, Peter
   Fonyad, Laszlo
   Nemes, Balazs
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czegle, Ibolya Anett] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Graf, Laszlo] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Istvan, Gabor] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Kovacs, Balazs] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Magyar, Peter] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Fonyad, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nemes, Balazs] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Czegle, IA (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Deme, D
   Kiss, Zs
AF Deme, Daniel
   Kiss, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Kiss, Zsofia] Semmelweis University, Faculty of MedicineBudapest, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Dobi, �
   Groh, F
   Cserhati, A
   Kahan, Zs
   Gaal, Sz
   Szanto, E
   Egyud, Zs
   Fodor, E
   Hideghety, K
AF Dobi, Agnes
   Groh, Fruzsina
   Cserhati, Adrienne
   Kahan, Zsuzsanna
   Gaal, Szilvia
   Szanto, Erika
   Egyud, Zsofia
   Fodor, Emese
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Groh, Fruzsina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dobi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Dohan, O
AF Dohan, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dohan, Orsolya] Allami Egeszsegugyi Kozpont – Honvedkorhaz, DiabetologiaBudapest, Hungary.
RP Dohan, O (reprint author), Allami Egeszsegugyi Kozpont – Honvedkorhaz, Diabetologia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Dombi, P
   Angi, E
   Meszaros, R
   Osvath, M
   Padi, �
AF Dombi, J. Peter
   Angi, Edit
   Meszaros, Rozsa
   Osvath, Marta
   Padi, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dombi, J. Peter] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Angi, Edit] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Meszaros, Rozsa] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Osvath, Marta] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Padi, Eva] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
RP Dombi, P (reprint author), Szent Borbala Korhaz, Onkologia, Tatabanya, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Ember, �
AF Ember, Agoston
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ember, Agoston] University of Pecs, Department of SurgeryPecs, Hungary.
RP Ember, � (reprint author), University of Pecs, Department of Surgery, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Ember, I
AF Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Ember, I (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Farkas, Gy
   Szekely, G
   Vass, N
   Kiss, K
AF Farkas, Gyongyi
   Szekely, Gabor
   Vass, Nagyezsda
   Kiss, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Vass, Nagyezsda] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Kiss, Krisztina] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Fazekas, K
AF Fazekas, Klara
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Klara] Pest Megyei Onkormanyzat Szent Rokus KorhazBudapest, Hungary.
RP Fazekas, K (reprint author), Pest Megyei Onkormanyzat Szent Rokus Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Fejos, Zs
   Barbai, T
   Timar, J
   Raso, E
AF Fejos, Zsuzsanna
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fejos, Zsuzsanna] Allami Egeszsegugyi Kozpont – Honvedkorhaz, BorgyogyaszatBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Fejos, Zs (reprint author), Allami Egeszsegugyi Kozpont – Honvedkorhaz, Borgyogyaszat, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Ferencz, V
   Landherr, L
AF Ferencz, Valeria
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferencz, Valeria] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Ferencz, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Fodor, A
   Kulcsar, EL
   Szilasi, M
AF Fodor, Andrea
   Kulcsar, Edina Linda
   Szilasi, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Andrea] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Kulcsar, Edina Linda] University of DebrecenDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Fodor, A (reprint author), University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Fulop, M
   Remenar, �
   Lengyel, Zs
   Kasler, M
AF Fulop, Miklos
   Remenar, Eva
   Lengyel, Zsolt
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulop, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Fulop, M (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 20
EP 21
PG 2
ER

PT J
AU Galffy, G
   Gyulai, N
   Kollar, A
   Istok, R
   Raso, E
AF Galffy, Gabriella
   Gyulai, Nora
   Kollar, Attila
   Istok, Roland
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Gyulai, Nora] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kollar, Attila] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Istok, Roland] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Garay, TM
   Juhasz, �
   Dobos, J
   Laszlo, V
   Schelch, K
   Grusch, M
   Berger, W
   Timar, J
   Hegedus, B
AF Garay, Tamas Marton
   Juhasz, Eva
   Dobos, Judit
   Laszlo, Viktoria
   Schelch, Karin
   Grusch, Michael
   Berger, Walter
   Timar, Jozsef
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garay, Tamas Marton] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Juhasz, Eva] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dobos, Judit] National Institute of OncologyBudapest, Hungary.
   [Laszlo, Viktoria] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Schelch, Karin] Medical University, Comprehensive Cancer Centre ViennaVienna, Austria.
   [Grusch, Michael] Medical University, Comprehensive Cancer Centre ViennaVienna, Austria.
   [Berger, Walter] Medical University, Comprehensive Cancer Centre ViennaVienna, Austria.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Garay, TM (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 21
EP 22
PG 2
ER

PT J
AU Gehlne Kaulak, �
   Tar, A
   Pintye, �
AF Gehlne Kaulak, Agota
   Tar, Anna
   Pintye, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gehlne Kaulak, Agota] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Tar, Anna] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Gehlne Kaulak, � (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Gobor, L
   Matrai, Z
   Savolt, �
   Sulyok, Z
   Toth, L
AF Gobor, Laszlo
   Matrai, Zoltan
   Savolt, Akos
   Sulyok, Zoltan
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gobor, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Gobor, L (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Gocze, K
   Kovacs, K
   Benczik, M
   Gocze, P
   Ember, I
AF Gocze, Katalin
   Kovacs, Krisztina
   Benczik, Marta
   Gocze, Peter
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gocze, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Kovacs, Krisztina] University of Pecs, Department of PathologyPecs, Hungary.
   [Benczik, Marta] Genoid Kft.Pecs, Hungary.
   [Gocze, Peter] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Gocze, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 22
EP 24
PG 3
ER

PT J
AU Godeny, M
AF Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Gombos, K
   Juhasz, F
   Ember, I
AF Gombos, Katalin
   Juhasz, Ferenc
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Juhasz, Ferenc] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Gombos, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Graf, L
   Pozsonyi, Z
   Kocsis, J
AF Graf, Laszlo
   Pozsonyi, Zoltan
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Graf, Laszlo] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Pozsonyi, Zoltan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Graf, L (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Gulya, E
   Gombas, P
   Gorombey, Z
   Istok, RZ
   Karpati, �
   Szephalmi, L
   Voros, A
   Pajkos, G
AF Gulya, Erno
   Gombas, Peter
   Gorombey, Zoltan
   Istok, Roland Zoltan
   Karpati, Agnes
   Szephalmi, Laszlo
   Voros, Attila
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gulya, Erno] Honved KorhazBudapest, Hungary.
   [Gombas, Peter] St. Borbala University HospitalTatabanya, Hungary.
   [Gorombey, Zoltan] Honved KorhazBudapest, Hungary.
   [Istok, Roland Zoltan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Karpati, Agnes] St. Imre HospitalBudapest, Hungary.
   [Szephalmi, Laszlo] BM Kozponti KorhazBudapest, Hungary.
   [Voros, Attila] Honved KorhazBudapest, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gulya, E (reprint author), Honved Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Gundy, S
   Farkas, Gy
   Szekely, G
   Kasler, M
AF Gundy, Sarolta
   Farkas, Gyongyi
   Szekely, Gabor
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Gundy, S
   Szekely, G
   Gaudi, I
   Farkas, Gy
AF Gundy, Sarolta
   Szekely, Gabor
   Gaudi, Istvan
   Farkas, Gyongyi
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Gyergyay, F
   Geczi, L
   Nagyivanyi, K
   Kuronya, Zs
   Bodrogi, I
AF Gyergyay, Fruzsina
   Geczi, Lajos
   Nagyivanyi, Krisztian
   Kuronya, Zsofia
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Gyergyay, F (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Gyorffy, B
   Benke, Zs
   Lanczky, A
   Balazs, B
   Timar, J
   Szallasi, Z
   Schafer, R
AF Gyorffy, Balazs
   Benke, Zsombor
   Lanczky, Andras
   Balazs, Balint
   Timar, Jozsef
   Szallasi, Zoltan
   Schafer, Reinhold
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Benke, Zsombor] Pazmany Peter Catholic UniversityBudapest, Hungary.
   [Lanczky, Andras] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Balazs, Balint] Pazmany Peter Catholic UniversityBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical SchoolBoston, USA.
   [Schafer, Reinhold] Charite University HospitalBerlin, Germany.
RP Gyorffy, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Harisi, R
   Szekely, Gy
   Olah, J
   Baranyai, L
   Kornyei, J
   Jeney, A
AF Harisi, Revekka
   Szekely, Gyorgy
   Olah, Julia
   Baranyai, Lajos
   Kornyei, Jozsef
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Szekely, Gyorgy] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Baranyai, Lajos] Izotop Intezet Kft.Budapest, Hungary.
   [Kornyei, Jozsef] Izotop Intezet Kft.Budapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 26
EP 27
PG 2
ER

PT J
AU Harisi, R
   Kenessey, I
   Olah, J
   Jeney, A
AF Harisi, Revekka
   Kenessey, Istvan
   Olah, Julia
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai OsztalyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Fovarosi Onkormanyzat Szent Janos Korhaza, I. Belgyogyaszati es Gastroenterologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Hegedus, M
   Barbai, T
   Timar, J
   Raso, E
AF Hegedus, Marta
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Marta] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Hegedus, M (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 27
EP 28
PG 2
ER

PT J
AU Hegedus, R
AF Hegedus, Rozsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegedus, Rozsa] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Hegedus, R (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Hegyesi, H
   Sandor, N
   Kis, E
   Safrany, G
AF Hegyesi, Hargita
   Sandor, Nikolett
   Kis, Eniko
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyesi, Hargita] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Sandor, Nikolett] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Kis, Eniko] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Hegyesi, H (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 28
EP 29
PG 2
ER

PT J
AU Hegyi, K
   Egervari, K
   Sandor, Zs
   Mehes, G
AF Hegyi, Katalin
   Egervari, Kristof
   Sandor, Zsuzsa
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyi, Katalin] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Egervari, Kristof] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Sandor, Zsuzsa] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Hegyi, K (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Hernadi, Z
AF Hernadi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Hernadi, Z (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Herodek, G
   Barla, F
   Gerdan, M
   Pinter, T
   Molnar, S
   Jenei, T
   Cebo-Polik, E
   Urban, L
AF Herodek, Gabriella
   Barla, Ferenc
   Gerdan, Mercedesz
   Pinter, Tamas
   Molnar, Sandor
   Jenei, Timea
   Cebo-Polik, Elzbieta
   Urban, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herodek, Gabriella] Petz A. Egyetemi Oktatokorhaz, Onkologiai OsztalyGyor, Hungary.
   [Barla, Ferenc] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Gerdan, Mercedesz] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Molnar, Sandor] Petz Aladar Megyei Oktato Korhaz, PulmonologiaGyor, Hungary.
   [Jenei, Timea] Petz Aladar Megyei Oktato Korhaz, PulmonologiaGyor, Hungary.
   [Cebo-Polik, Elzbieta] Petz Aladar Megyei Oktato Korhaz, PulmonologiaGyor, Hungary.
   [Urban, Laszlo] Petz Aladar Megyei Oktato Korhaz, PulmonologiaGyor, Hungary.
RP Herodek, G (reprint author), Petz A. Egyetemi Oktatokorhaz, Onkologiai Osztaly, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Horvath, K
   Vereczkey, I
   Vizkeleti, J
   Pete, I
   Godeny, M
AF Horvath, Katalin
   Vereczkey, Ildiko
   Vizkeleti, Julia
   Pete, Imre
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Horvath, Zs
   Madaras, B
   Hitre, E
   Rubovszky, G
   Nagy, Z
   Rozsa, P
   Lang, I
AF Horvath, Zsolt
   Madaras, Balazs
   Hitre, Erika
   Rubovszky, Gabor
   Nagy, Zoltan
   Rozsa, Peter
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Madaras, Balazs] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Nagy, Zoltan] Med Gen-Sol KftBudapest, Hungary.
   [Rozsa, Peter] MediConcept Kft.Budapest, Hungary.
   [Lang, Istvan] MediConcept Kft.Budapest, Hungary.
RP Horvath, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 30
EP 31
PG 2
ER

PT J
AU Janoki, M
   Pinter, T
   Vincze, A
   B.-ne Czizmadia, R
   Zamolyi, G
AF Janoki, Marta
   Pinter, Tamas
   Vincze, Anita
   B.-ne Czizmadia, Rita
   Zamolyi, Gezane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janoki, Marta] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Vincze, Anita] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [B.-ne Czizmadia, Rita] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Zamolyi, Gezane] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Janoki, M (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Janvary, ZsL
AF Janvary, Zsolt Levente
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] University Hospital of LiegeLiege, Belgium.
RP Janvary, ZsL (reprint author), University Hospital of Liege, Liege, Belgium.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Jederan, �
   Toth, L
   Szentirmay, Z
   Hitre, E
   Nagy, T
   Godeny, M
AF Jederan, Eva
   Toth, Laszlo
   Szentirmay, Zoltan
   Hitre, Erika
   Nagy, Tunde
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Josa, V
   El Khoffash, A
   Csaszar, J
   Becske, M
AF Josa, Valeria
   El Khoffash, Amina
   Csaszar, Julia
   Becske, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Josa, Valeria] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
   [El Khoffash, Amina] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
   [Csaszar, Julia] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
   [Becske, Miklos] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti OsztalyKistarcsa, Hungary.
RP Josa, V (reprint author), Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti Osztaly, Kistarcsa, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Juhasz, A
   Nagy, Cs
   Paldy, A
   Kasler, M
AF Juhasz, Attila
   Nagy, Csilla
   Paldy, Anna
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Attila] Budapest Fovaros Kormanyhivatala, Nepegeszsegugyi Szakigazgatasi Szerve, Egeszsegfejlesztesi OsztalyBudapest, Hungary.
   [Nagy, Csilla] Budapest Fovaros Kormanyhivatala, Nepegeszsegugyi Szakigazgatasi SzerveBudapest, Hungary.
   [Paldy, Anna] Orszagos Kornyezetegeszsegugyi IntezetBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Juhasz, A (reprint author), Budapest Fovaros Kormanyhivatala, Nepegeszsegugyi Szakigazgatasi Szerve, Egeszsegfejlesztesi Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Juhasz, K
   Stanitz, �
   Ember, I
AF Juhasz, Krisztina
   Stanitz, Eva
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Krisztina] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Stanitz, Eva] Vas Megyei Kormanyhivatal, Nepegeszsegugyi Szakigazgatasi SzerveSzombathely, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Juhasz, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Kapuvari, B
   Vincze, B
   Manea, M
   Schulcz, �
   Tejeda, M
   Tovari, J
   Orban, E
   Mezo, G
AF Kapuvari, Bence
   Vincze, Borbala
   Manea, Marilena
   Schulcz, Akos
   Tejeda, Miguel
   Tovari, Jozsef
   Orban, Erika
   Mezo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Manea, Marilena] University of Konstanz, Zukunftskolleg, Department of ChemistryKonstanz, Germany.
   [Schulcz, Akos] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tejeda, Miguel] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Katona, Cs
AF Katona, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Katona, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Kiss, E
AF Kiss, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kiss, L
   Szabo, Zs
   Semjeni, M
   Treszl, A
   Toth, Gy
   Flasko, T
   Buglyo, �
   Halmos, G
AF Kiss, Lili
   Szabo, Zsuzsanna
   Semjeni, Mariann
   Treszl, Andrea
   Toth, Gyorgy
   Flasko, Tibor
   Buglyo, Armin
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Lili] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Semjeni, Mariann] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Toth, Gyorgy] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Buglyo, Armin] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Kiss, L (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kiss, N
   Nagy, P
   Foldesi, J
   Papai, Zs
AF Kiss, Nora
   Nagy, Peter
   Foldesi, Janos
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Nora] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Foldesi, Janos] Allami Egeszsegugyi Kozpont – Honvedkorhaz, UrologiaBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, N (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 34
EP 35
PG 2
ER

PT J
AU Kiszner, G
   Balla, P
   Barbai, T
   Varga, E
   Nemeth, I
   Plotar, V
   Raso, E
   Krenacs, T
   Stelkovics, �
AF Kiszner, Gergo
   Balla, Peter
   Barbai, Tamas
   Varga, Erika
   Nemeth, Istvan
   Plotar, Vanda
   Raso, Erzsebet
   Krenacs, Tibor
   Stelkovics, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiszner, Gergo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Balla, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Nemeth, Istvan] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Stelkovics, Eva] Bay Zoltan Alkalmazott Kutatasi KozalapitvanyBudapest, Hungary.
RP Kiszner, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Kiszner, G
   Nemeth, I
   Varga, E
   Korom, I
   Krenacs, T
AF Kiszner, Gergo
   Nemeth, Istvan
   Varga, Erika
   Korom, Irma
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiszner, Gergo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nemeth, Istvan] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Korom, Irma] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Kiszner, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 35
EP 36
PG 2
ER

PT J
AU Kocsis, J
   Toth, �K
   Nahm, K
   Czegle, I
AF Kocsis, Judit
   Toth, Eva Katalin
   Nahm, Krisztina
   Czegle, Ibolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Nahm, Krisztina] Semmelweis Egyetem, KKT, RadiologiaBudapest, Hungary.
   [Czegle, Ibolya] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Kocsis, J
   Palik, �
   Karadi, I
AF Kocsis, Judit
   Palik, Eva
   Karadi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Palik, Eva] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Karadi, Istvan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Kocsis, J (reprint author), Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Komaromi, �
AF Komaromi, Edua
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Komaromi, Edua] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Komaromi, � (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Korompay, A
   Szasz, AM
   Borka, K
   Kulka, J
   Torgyik, L
   Szentmartoni, Gy
AF Korompay, Anna
   Szasz, Attila Marcell
   Borka, Katalin
   Kulka, Janina
   Torgyik, Laszlo
   Szentmartoni, Gyongyver
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Korompay, Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Korompay, A (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Kosa, J
AF Kosa, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kosa, Judit] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Kosa, J (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Kotai, Zs
   Varga, E
   Bartfai, R
AF Kotai, Zsuzsa
   Varga, Edit
   Bartfai, Reka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Varga, Edit] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Bartfai, Reka] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Kotai, Zs (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Kotlan, B
   Liszkay, G
   Plotar, V
   Gobor, L
   Szollar, A
   Eles, K
   Toth, E
   Ladanyi, A
   Toth, L
AF Kotlan, Beatrix
   Liszkay, Gabriella
   Plotar, Vanda
   Gobor, Laszlo
   Szollar, Andras
   Eles, Klara
   Toth, Erika
   Ladanyi, Andrea
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Gobor, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Kotlan, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Kovac, B
   Barbai, T
   Timar, J
   Raso, E
AF Kovac, Barnabas
   Barbai, Tamas
   Timar, Jozsef
   Raso, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovac, Barnabas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kovac, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Kovacs, E
   Szoke, J
   Monostori, Zs
AF Kovacs, Eszter
   Szoke, Janos
   Monostori, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Monostori, Zsuzsa] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Kovacs, E (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Kovacs, G
AF Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Gabor] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
RP Kovacs, G (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. Tudobelosztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 39
EP 40
PG 2
ER

PT J
AU Kovacs, J
   Vincze, B
   Czeyda-Pommersheim, F
   Udvarhelyi, N
   Horvath, Zs
   Kapuvari, B
   Doleschall, Z
   Csuka, O
   Toth, L
AF Kovacs, Judit
   Vincze, Borbala
   Czeyda-Pommersheim, Ferenc
   Udvarhelyi, Nora
   Horvath, Zsolt
   Kapuvari, Bence
   Doleschall, Zoltan
   Csuka, Orsolya
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Kovacs, J (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kovacs, P
   Panczel, G
   Borbola, K
   Vonoczky, K
   Liszkay, G
AF Kovacs, Peter
   Panczel, Gitta
   Borbola, Kinga
   Vonoczky, Katalin
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] National Institute of OncologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of OncologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of OncologyBudapest, Hungary.
   [Vonoczky, Katalin] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Kovacs, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 40
EP 41
PG 2
ER

PT J
AU Kovacs, Zs
   Pignitckine Rigo, A
   Szabo, �
   Godeny, M
   Bidlek, M
AF Kovacs, Zsuzsanna
   Pignitckine Rigo, Adrien
   Szabo, Eva
   Godeny, Maria
   Bidlek, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Zsuzsanna] Semmelweis Egyetem, Alkalmazott Pszichologia TanszekBudapest, Hungary.
   [Pignitckine Rigo, Adrien] ELTE PPK, Pszichologiai IntezetBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Kovacs, Zs (reprint author), Semmelweis Egyetem, Alkalmazott Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Kuronya, Zs
   Bodrogi, I
AF Kuronya, Zsofia
   Bodrogi, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Kuronya, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 41
EP 42
PG 2
ER

PT J
AU Ladanyi, A
   Kiss, J
   Mohos, A
   Somlai, B
   Liszkay, G
   Gilde, K
   Fejos, Zs
   Gaudi, I
   Timar, J
AF Ladanyi, Andrea
   Kiss, Judit
   Mohos, Anita
   Somlai, Beata
   Liszkay, Gabriella
   Gilde, Katalin
   Fejos, Zsuzsanna
   Gaudi, Istvan
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kiss, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Mohos, Anita] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Lahm, E
   Vachaja, J
   Nagy, P
   Papai, Zs
   Kiss, E
   Uhlyarik, A
   Sikter, M
AF Lahm, Erika
   Vachaja, Jozsef
   Nagy, Peter
   Papai, Zsuzsanna
   Kiss, Edina
   Uhlyarik, Andrea
   Sikter, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Lanczky, A
   Gyorffy, B
AF Lanczky, Andras
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lanczky, Andras] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Hungarian Academy of Sciences - Semmelweis University, 1st Dept. of Pediatrics, Research Laboratory for Pediatrics and NephrologyBudapest, Hungary.
RP Lanczky, A (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 42
EP 43
PG 2
ER

PT J
AU Landherr, L
   Sinko, D
AF Landherr, Laszlo
   Sinko, Daniel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Lazanyi, K
AF Lazanyi, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lazanyi, Kornelia] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
RP Lazanyi, K (reprint author), Debreceni Egyetem, Pszichologiai Intezet, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Levai, A
   Lerant, G
   Toth, E
   Remenar, �
   Boer, A
   Takacsi Nagy, Z
   Godeny, M
AF Levai, Andrea
   Lerant, Gergely
   Toth, Erika
   Remenar, Eva
   Boer, Andras
   Takacsi Nagy, Zoltan
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Levai, Andrea] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lerant, Gergely] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Levai, A (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Lovey, J
   Horvath, Zs
   Bago, A
   Fedorcsak, I
   Manninger, S
   Lang, I
   Polgar, Cs
   Kasler, M
AF Lovey, Jozsef
   Horvath, Zsolt
   Bago, Attila
   Fedorcsak, Imre
   Manninger, Sandor
   Lang, Istvan
   Polgar, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Bago, Attila] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Manninger, Sandor] National Institute of OncologyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Lukasz, P
   Selley, Cs
   Szabo, HZ
   Kesseru, B
   Ecsedy, G
   Glasz, T
   Ender, F
AF Lukasz, Peter
   Selley, Csaba
   Szabo, Huba Zoltan
   Kesseru, Balazs
   Ecsedy, Gabor
   Glasz, Tibor
   Ender, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukasz, Peter] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Selley, Csaba] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Szabo, Huba Zoltan] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Kesseru, Balazs] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Ecsedy, Gabor] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Glasz, Tibor] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
   [Ender, Ferenc] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
RP Lukasz, P (reprint author), Jahn Ferenc South-Pest Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Lukats, O
   Remenar, �
   Toth, J
AF Lukats, Olga
   Remenar, Eva
   Toth, Jeannette
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
RP Lukats, O (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Lumniczky, K
   Persa, E
   Balogh, A
   Szatmari, T
   Safrany, G
AF Lumniczky, Katalin
   Persa, Eszter
   Balogh, Andrea
   Szatmari, Tunde
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Persa, Eszter] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Szatmari, Tunde] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Lumniczky, K (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Madaras, B
   Horvath, Zs
   Lengyel, Zs
   Lang, I
   Kasler, M
   Borbely, K
AF Madaras, Balazs
   Horvath, Zsolt
   Lengyel, Zsolt
   Lang, Istvan
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Madaras, Balazs] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Madaras, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Madaras, B
   Rozsa, P
   Radovics, T
   Lang, I
   Nagy, Z
   Horvath, Zs
AF Madaras, Balazs
   Rozsa, Peter
   Radovics, Tibor
   Lang, Istvan
   Nagy, Zoltan
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Madaras, Balazs] National Institute of OncologyBudapest, Hungary.
   [Rozsa, Peter] MediConcept Kft.Budapest, Hungary.
   [Radovics, Tibor] Semmelweis UniversityBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Nagy, Zoltan] Med Gen-Sol KftBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Madaras, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Mangel, L
   Lovey, J
   Farkas, R
   Bellyei, Sz
   Bajcsay, A
   Nemeth, Gy
   Fodor, J
   Polgar, Cs
AF Mangel, Laszlo
   Lovey, Jozsef
   Farkas, Robert
   Bellyei, Szabolcs
   Bajcsay, Andras
   Nemeth, Gyorgy
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nemeth, Gyorgy] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Maraz, A
   Uhercsak, G
   Szilagyi, �
AF Maraz, Aniko
   Uhercsak, Gabriella
   Szilagyi, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 46
EP 47
PG 2
ER

PT J
AU Maraz, A
   Bodoky, Gy
   Bodrogi, I
   Csejtei, A
   Dank, M
   Geczi, L
   Kuronya, Zs
   Mangel, L
   Petranyi, �
   Szucs, M
   Zsalek, J
AF Maraz, Aniko
   Bodoky, Gyorgy
   Bodrogi, Istvan
   Csejtei, Andras
   Dank, Magdolna
   Geczi, Lajos
   Kuronya, Zsofia
   Mangel, Laszlo
   Petranyi, Agota
   Szucs, Miklos
   Zsalek, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Zsalek, Judit] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Mark, �
   Nagy, N
   Paku, S
   Kopper, L
   Sebestyen, A
AF Mark, Agnes
   Nagy, Noemi
   Paku, Sandor
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Eotvos Lorand University, Institute of Biology, Department of ImmunologyBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Mark, � (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Marko, L
   Pajkos, G
   Svebis, M
AF Marko, Laszlo
   Pajkos, Gabor
   Svebis, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 47
EP 48
PG 2
ER

PT J
AU Matrai, Z
   Gulyas, G
   Toth, L
   Savolt, �
   Pesthy, P
   Kunos, Cs
   Kasler, M
AF Matrai, Zoltan
   Gulyas, Gusztav
   Toth, Laszlo
   Savolt, Akos
   Pesthy, Pal
   Kunos, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Pesthy, Pal] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Mayer, �
AF Mayer, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Meggyeshazi, N
   Andocs, G
   Krenacs, T
AF Meggyeshazi, Nora
   Andocs, Gabor
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meggyeshazi, Nora] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Andocs, Gabor] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Meggyeshazi, N (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 48
EP 49
PG 2
ER

PT J
AU Mihaly, Zs
   Munkacsy, Gy
   Schafer, R
   Gyorffy, B
AF Mihaly, Zsuzsanna
   Munkacsy, Gyongyi
   Schafer, Reinhold
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mihaly, Zsuzsanna] Semmelweis UniversityBudapest, Hungary.
   [Munkacsy, Gyongyi] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Schafer, Reinhold] Charite University HospitalBerlin, Germany.
   [Gyorffy, Balazs] Hungarian Academy of Sciences - Semmelweis University, 1st Dept. of Pediatrics, Research Laboratory for Pediatrics and NephrologyBudapest, Hungary.
RP Mihaly, Zs (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Mohos, A
   Somlai, B
   Liszkay, G
   Gilde, K
   Fejos, Zs
   Gaudi, I
   Plotar, V
   Ladanyi, A
AF Mohos, Anita
   Somlai, Beata
   Liszkay, Gabriella
   Gilde, Katalin
   Fejos, Zsuzsanna
   Gaudi, Istvan
   Plotar, Vanda
   Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mohos, Anita] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gilde, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fejos, Zsuzsanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gaudi, Istvan] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Mohos, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Molnar, Zs
   Deak, B
   Kapuvari, B
   Kovacs, J
   Rosta, A
   Szaleczky, E
   Varga, F
   Vincze, B
AF Molnar, Zsuzsanna
   Deak, Beata
   Kapuvari, Bence
   Kovacs, Judit
   Rosta, Andras
   Szaleczky, Erika
   Varga, Fatima
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Zsuzsanna] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Deak, Beata] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Rosta, Andras] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Szaleczky, Erika] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Varga, Fatima] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Molnar, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Monos, Zs
   Fejos, Zs
   Plotar, V
AF Monos, Zsuzsa
   Fejos, Zsuzsanna
   Plotar, Vanda
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Monos, Zsuzsa] MaganrendeloBudapest, Hungary.
   [Fejos, Zsuzsanna] Allami Egeszsegugyi Kozpont – Honvedkorhaz, BorgyogyaszatBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Monos, Zs (reprint author), Maganrendelo, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 50
EP 51
PG 2
ER

PT J
AU Muller, V
   Tamasi, L
   Szondy, K
   Galffy, G
AF Muller, Veronika
   Tamasi, Lilla
   Szondy, Klara
   Galffy, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Szondy, Klara] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Muller, V (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Muller, Z
   Vityi, T
AF Muller, Zoltan
   Vityi, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Nagy, B
AF Nagy, Belane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Belane] Orszagos Onkologiai Intezet, Foglalkozas-Egeszsegugyi SzolgalatBudapest, Hungary.
RP Nagy, B (reprint author), Orszagos Onkologiai Intezet, Foglalkozas-Egeszsegugyi Szolgalat, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 51
EP 52
PG 2
ER

PT J
AU Nagy, P
   Budai, B
   Ballago, K
   Szucs, J
   Makacsne Polenyi, Cs
   Nagy, A
   Csuka, O
   Otto, Sz
   Kasler, M
AF Nagy, Peter
   Budai, Barna
   Ballago, Krisztina
   Szucs, Judit
   Makacsne Polenyi, Csilla
   Nagy, Attila
   Csuka, Orsolya
   Otto, Szabolcs
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ballago, Krisztina] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Szucs, Judit] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Makacsne Polenyi, Csilla] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Nagy, Attila] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
RP Nagy, P (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Nagy, P
   Lahm, E
   Papai, Zs
AF Nagy, Peter
   Lahm, Erika
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Nagy, P (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 52
EP 53
PG 2
ER

PT J
AU Nagy, T
   Godeny, M
   Toth, L
AF Nagy, Tunde
   Godeny, Maria
   Toth, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Nagy, T (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Nagy, T
   Godeny, M
AF Nagy, Tunde
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Nagy, T (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Nagy, Zs
AF Nagy, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
RP Nagy, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 53
EP 54
PG 2
ER

PT J
AU Nagy, Zs
AF Nagy, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
RP Nagy, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Nagykalnai, T
AF Nagykalnai, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia SzakrendelesBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Naszados, Gy
   Simon, P
   Peter, I
   Lang, I
   Rubovszky, G
   Godeny, M
AF Naszados, Gyorgy
   Simon, Peter
   Peter, Ilona
   Lang, Istvan
   Rubovszky, Gabor
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Naszados, Gyorgy] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Simon, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Naszados, Gy (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 54
EP 55
PG 2
ER

PT J
AU Nemeth, Zs
   Boer, K
AF Nemeth, Zsuzsanna
   Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai OsztalyBudapest, Hungary.
   [Boer, Katalin] Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai OsztalyBudapest, Hungary.
RP Nemeth, Zs (reprint author), Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Olah, E
   Papp, J
   Vaszko, T
   Bozsik, A
   Szabo, �
   Otto, Sz
   Orosz, E
   Toth, L
   Antoniou, A
AF Olah, Edit
   Papp, Janos
   Vaszko, Tibor
   Bozsik, Aniko
   Szabo, Eva
   Otto, Szabolcs
   Orosz, Eniko
   Toth, Laszlo
   Antoniou, Antonis
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vaszko, Tibor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bozsik, Aniko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Orosz, Eniko] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Antoniou, Antonis] CIMBA, Consortium of Investigators of Modifiers of BRCA1/2Cambridge, UK.
RP Olah, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Olasz, J
   Dunai, Zs
   Pazsitka, A
   Csuka, O
AF Olasz, Judit
   Dunai, Zsuzsanna
   Pazsitka, Andras
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Dunai, Zsuzsanna] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pazsitka, Andras] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Olasz, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Orban, E
   Bosze, Sz
   Manea, M
   Marquardt, A
   Hudecz, F
AF Orban, Erika
   Bosze, Szilvia
   Manea, Marilena
   Marquardt, Andreas
   Hudecz, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Bosze, Szilvia] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Manea, Marilena] University of KonstanzKonstanz, Germany.
   [Marquardt, Andreas] University of KonstanzKonstanz, Germany.
   [Hudecz, Ferenc] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Orban, E (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 56
EP 57
PG 2
ER

PT J
AU Orosz, K
AF Orosz, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Krisztina] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Orosz, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Palfine Kegye, A
   Padi, �
   Kis, S
   Dombi, P
AF Palfine Kegye, Adrienne
   Padi, Eva
   Kis, Sandor
   Dombi, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Palfine Kegye, Adrienne] Vaszary Kolos Korhaz, Hospice/Rehabilitacios OsztalyEsztergom, Hungary.
   [Padi, Eva] Vaszary Kolos Korhaz, Hospice/Rehabilitacios OsztalyEsztergom, Hungary.
   [Kis, Sandor] Vaszary Kolos Korhaz, Hospice/Rehabilitacios OsztalyEsztergom, Hungary.
   [Dombi, Peter] Szent Borbala Hospital, Department of HematologyTatabanya, Hungary.
RP Palfine Kegye, A (reprint author), Vaszary Kolos Korhaz, Hospice/Rehabilitacios Osztaly, Esztergom, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Panczel, G
   Hidvegi, J
   Bak, M
   Hunyadi, J
   Liszkay, G
AF Panczel, Gitta
   Hidvegi, Judit
   Bak, Mihaly
   Hunyadi, Janos
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Hidvegi, Judit] National Institute of OncologyBudapest, Hungary.
   [Bak, Mihaly] National Institute of OncologyBudapest, Hungary.
   [Hunyadi, Janos] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Papai, Zs
   Kokai, T
   Vachaja, J
   Lahm, E
   Uhlyarik, A
   Szigetvari, I
   Fulop, V
AF Papai, Zsuzsanna
   Kokai, Tunde
   Vachaja, Jozsef
   Lahm, Erika
   Uhlyarik, Andrea
   Szigetvari, Istvan
   Fulop, Vilmos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kokai, Tunde] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Szigetvari, Istvan] Allami Egeszsegugyi Kozpont – Honvedkorhaz, NogyogyaszatBudapest, Hungary.
   [Fulop, Vilmos] Allami Egeszsegugyi Kozpont – Honvedkorhaz, NogyogyaszatBudapest, Hungary.
RP Papai, Zs (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Papp, J
   Orosz, E
   Otto, Sz
   Matrai, Z
   Olah, E
AF Papp, Janos
   Orosz, Eniko
   Otto, Szabolcs
   Matrai, Zoltan
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Orosz, Eniko] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Papp, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Penzvalto, Zs
   Tegze, B
   Sztupinszki, Zs
   Szasz, AM
   Liko, I
   Szendroi, A
   Gyorffy, B
AF Penzvalto, Zsofia
   Tegze, Balint
   Sztupinszki, Zsofia
   Szasz, Attila Marcell
   Liko, Istvan
   Szendroi, Attila
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Penzvalto, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Tegze, Balint] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Sztupinszki, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Liko, Istvan] Richter Gedeon NyrtBudapest, Hungary.
   [Szendroi, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Penzvalto, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 58
EP 59
PG 2
ER

PT J
AU Petak, I
AF Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petak, Istvan] Oncompass Medicine Kft.Budapest, Hungary.
RP Petak, I (reprint author), Oncompass Medicine Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Pete, I
AF Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 59
EP 60
PG 2
ER

PT J
AU Peter, I
   Sarosi, Zs
   Toth, E
   Lehoczky, O
   Pete, I
AF Peter, Ilona
   Sarosi, Zsuzsa
   Toth, Erika
   Lehoczky, Otto
   Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Peter, Ilona] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Sarosi, Zsuzsa] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Lehoczky, Otto] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Peter, I (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Petranyi, �E
   Igaz, P
   Racz, K
   Bodoky, Gy
AF Petranyi, Agota Eszter
   Igaz, Peter
   Racz, Karoly
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petranyi, Agota Eszter] St. Laszlo HospitalBudapest, Hungary.
   [Igaz, Peter] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Racz, Karoly] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Bodoky, Gyorgy] St. Laszlo HospitalBudapest, Hungary.
RP Petranyi, �E (reprint author), St. Laszlo Hospital, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Petri, K
   Sandor, Zs
   Agoston, P
   Geczi, L
   Godeny, M
AF Petri, Klara
   Sandor, Zsuzsa
   Agoston, Peter
   Geczi, Lajos
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sandor, Zsuzsa] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Pinter, F
   Kovesdi, A
   Varkondi, E
   Szabo, E
   Schwab, R
   Jaray, B
   Kopper, L
   Petak, I
AF Pinter, Ferenc
   Kovesdi, Andrea
   Varkondi, Edit
   Szabo, Edit
   Schwab, Richard
   Jaray, Balazs
   Kopper, Laszlo
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Ferenc] KPS Kft.Budapest, Hungary.
   [Kovesdi, Andrea] KPS Kft.Budapest, Hungary.
   [Varkondi, Edit] KPS Kft.Budapest, Hungary.
   [Szabo, Edit] KPS Kft.Budapest, Hungary.
   [Schwab, Richard] KPS Kft.Budapest, Hungary.
   [Jaray, Balazs] Medserv KftBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petak, Istvan] KPS Kft.Budapest, Hungary.
RP Pinter, F (reprint author), KPS Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Pinter, T
   Herodek, G
   Laszip, I
   Mak, M
   Belagyi, T
   Issekutz, �
   Kocsis, K
   Prempeh, AK
   Sipocz, I
   Olah, A
AF Pinter, Tamas
   Herodek, Gabriella
   Laszip, Ilona
   Mak, Maria
   Belagyi, Tibor
   Issekutz, Akos
   Kocsis, Karoly
   Prempeh, Agyemang Kofi
   Sipocz, Istvan
   Olah, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Herodek, Gabriella] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Laszip, Ilona] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Mak, Maria] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Belagyi, Tibor] Petz Aladar Megyei Oktato Korhaz, SebeszetGyor, Hungary.
   [Issekutz, Akos] Petz Aladar Megyei Oktato Korhaz, SebeszetGyor, Hungary.
   [Kocsis, Karoly] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Prempeh, Agyemang Kofi] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Sipocz, Istvan] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Olah, Attila] Petz Aladar Megyei Oktato Korhaz, SebeszetGyor, Hungary.
RP Pinter, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 61
EP 62
PG 2
ER

PT J
AU Pos, Z
   Selleri, S
   Spivey, LT
   Wang, KJ
   Liu, H
   Falus, A
   Wang, E
   Alter, JH
   Marincola, MF
AF Pos, Zoltan
   Selleri, Silvia
   Spivey, L Tara
   Wang, K Jeanne
   Liu, Hui
   Falus, Andras
   Wang, Ena
   Alter, J Harvey
   Marincola, M Francesco
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pos, Zoltan] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Selleri, Silvia] Scientific Institute H. S. Raffaele, San Raffaele Telethon Institute for Gene TherapyMilan, Italy.
   [Spivey, L Tara] CC, NIH, Department of Transfusion MedicineBethesda, USA.
   [Wang, K Jeanne] CDER, FDA, Office of Oncology Drug Products, Division of Medical Imaging and Hematology ProductsSilver Spring, MD, USA.
   [Liu, Hui] CC, NIH, Department of Transfusion MedicineBethesda, USA.
   [Falus, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Wang, Ena] CC, NIH, Department of Transfusion MedicineBethesda, USA.
   [Alter, J Harvey] CC, NIH, Department of Transfusion MedicineBethesda, USA.
   [Marincola, M Francesco] CC, NIH, Department of Transfusion MedicineBethesda, USA.
RP Pos, Z (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Puskas, G
   Feherne Kosa, I
AF Puskas, Gabriella
   Feherne Kosa, Iren
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Feherne Kosa, Iren] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Renyi-Vamos, F
   Lang, Gy
   Taghavi, Sh
   Aigner, C
   Kasler, M
   Klepetko, W
AF Renyi-Vamos, Ferenc
   Lang, Gyorgy
   Taghavi, Shahrokh
   Aigner, Clemens
   Kasler, Miklos
   Klepetko, Walter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lang, Gyorgy] Medical University of Vienna, Department of SurgeryVienna, Austria.
   [Taghavi, Shahrokh] Medical University of Vienna, Department of SurgeryVienna, Austria.
   [Aigner, Clemens] Medical University of Vienna, Department of SurgeryVienna, Austria.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Klepetko, Walter] Medical University of Vienna, Department of SurgeryVienna, Austria.
RP Renyi-Vamos, F (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Risko, �
AF Risko, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Risko, Agnes] National Institute of OncologyBudapest, Hungary.
RP Risko, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Rosta, A
AF Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Rosta, A (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 63
EP 64
PG 2
ER

PT J
AU Rumszauer, �
   Boer, K
AF Rumszauer, Agnes
   Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rumszauer, Agnes] Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai OsztalyBudapest, Hungary.
   [Boer, Katalin] Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai OsztalyBudapest, Hungary.
RP Rumszauer, � (reprint author), Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Ruszkai, K
AF Ruszkai, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruszkai, Katalin] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Ruszkai, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Savolt, �
   Peley, G
   Toth, L
   Matrai, Z
   Polgar, Cs
   Horvath, Zs
   Szabo, �
   Borbely, K
AF Savolt, Akos
   Peley, Gabor
   Toth, Laszlo
   Matrai, Zoltan
   Polgar, Csaba
   Horvath, Zsolt
   Szabo, Eva
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Peley, Gabor] Norfolk and Norwich University HospitalNorfolk, UK.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Horvath, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Szabo, Eva] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Savolt, � (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 64
EP 65
PG 2
ER

PT J
AU Schlittne Csernok, �
   Szucs, R
AF Schlittne Csernok, Agnes
   Szucs, Rozalia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schlittne Csernok, Agnes] Tolosi Peter Alapitvany, Rehabilitacios KozpontPecs, Hungary.
   [Szucs, Rozalia] Egyesitett Egeszsegugyi Intezmenyek, Gyermekonkologiai GondozoPecs, Hungary.
RP Schlittne Csernok, � (reprint author), Tolosi Peter Alapitvany, Rehabilitacios Kozpont, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Schneider, A
AF Schneider, Attilane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Attilane] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Schneider, A (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Sebestyen, A
   Mark, �
   Nemes, K
   Varadi, Zs
   Nagy, N
   Sticz, T
   Csoka, M
   Kopper, L
AF Sebestyen, Anna
   Mark, Agnes
   Nemes, Karolina
   Varadi, Zsofia
   Nagy, Noemi
   Sticz, Tamas
   Csoka, Monika
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nemes, Karolina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Varadi, Zsofia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sticz, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Serester, OK
   Gallai, M
   Csernak, E
   Szentirmay, Z
   Toth, E
AF Serester, Orsolya Katalin
   Gallai, Monika
   Csernak, Erzsebet
   Szentirmay, Zoltan
   Toth, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Serester, Orsolya Katalin] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Gallai, Monika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Serester, OK (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Sikter, M
   Kiss, E
   Lahm, E
   Nagy, P
   Uhlyarik, A
   Vachaja, J
   Papai, Zs
AF Sikter, Marta
   Kiss, Edina
   Lahm, Erika
   Nagy, Peter
   Uhlyarik, Andrea
   Vachaja, Jozsef
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Sikter, M (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Szabados, M
AF Szabados, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabados, Marta] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Szabados, M (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 66
EP 67
PG 2
ER

PT J
AU Szabo, �
   Bidlek, M
   Nagy, T
   Feher, K
   Udvarhelyi, N
   Sinkovics, I
   Polgar, Cs
   Horvath, Zs
   Matrai, Z
   Godeny, M
AF Szabo, Eva
   Bidlek, Maria
   Nagy, Timea
   Feher, Krisztina
   Udvarhelyi, Nora
   Sinkovics, Istvan
   Polgar, Csaba
   Horvath, Zsolt
   Matrai, Zoltan
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Nagy, Timea] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Feher, Krisztina] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Sinkovics, Istvan] Orszagos Onkologiai Intezet, Izotopdiagnosztikai OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Szabo, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Szabo, I
   Orban, E
   Bosze, Sz
   Mezo, G
AF Szabo, Ildiko
   Orban, Erika
   Bosze, Szilvia
   Mezo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Ildiko] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Orban, Erika] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Bosze, Szilvia] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Szabo, I (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Szalai, M
   Nemeth, K
   Szirmai, A
   Vajda, R
   Kriszbacher, I
AF Szalai, Marta
   Nemeth, Katalin
   Szirmai, Anna
   Vajda, Reka
   Kriszbacher, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Marta] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Nemeth, Katalin] University of PecsPecs, Hungary.
   [Szirmai, Anna] ELTE PPK, Pszichologiai Doktori IskolaBudapest, Hungary.
   [Vajda, Reka] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Kriszbacher, Ildiko] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Szalai, M (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori Iskola, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 67
EP 68
PG 2
ER

PT J
AU Szenes, M
   Volgyi, Z
   Ruzsa, �
   Nagy, Gy
   Bali, O
   Vattay, P
   Gasztonyi, B
AF Szenes, Maria
   Volgyi, Zoltan
   Ruzsa, Agnes
   Nagy, Gyongyi
   Bali, Ottilia
   Vattay, Peter
   Gasztonyi, Beata
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szenes, Maria] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
   [Volgyi, Zoltan] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
   [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Nagy, Gyongyi] Zala Megyei Korhaz, RadiologiaZalaegerszeg, Hungary.
   [Bali, Ottilia] County Hospital of Zala, Department of PathologyZalaegerszeg, Hungary.
   [Vattay, Peter] Zala Megyei Szent Rafael Korhaz, Altalanos SebeszetZalaegerszeg, Hungary.
   [Gasztonyi, Beata] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
RP Szenes, M (reprint author), Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati Osztaly, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Szirmai, M
AF Szirmai, Monika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szirmai, Monika] Bermedpharm Kft.Budapest, Hungary.
RP Szirmai, M (reprint author), Bermedpharm Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Szluha, K
   Opauszki, A
   Szabo, I
AF Szluha, Kornelia
   Opauszki, Adrienn
   Szabo, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Opauszki, Adrienn] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Szluha, K (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 68
EP 69
PG 2
ER

PT J
AU Tanyi, Zs
   Bugan, A
   Szluha, K
AF Tanyi, Zsuzsanna
   Bugan, Antal
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tanyi, Zsuzsanna] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
   [Bugan, Antal] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
   [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Tanyi, Zs (reprint author), DE OEC, Magatartastudomanyi Intezet, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Tar, A
   Gehlne Kaulak, �
   Pintye, �
AF Tar, Anna
   Gehlne Kaulak, Agota
   Pintye, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tar, Anna] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Gehlne Kaulak, Agota] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Tar, A (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Tegze, B
AF Tegze, Balint
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tegze, Balint] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Tegze, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Telekes, A
AF Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Telekes, A (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Tokes, T
   Somlai, K
   Szekely, B
   Kulka, J
   Szentmartoni, Gy
   Galgoczy, H
   Lengyel, Zs
   Gyorke, T
   Dank, M
AF Tokes, Timea
   Somlai, Krisztian
   Szekely, Borbala
   Kulka, Janina
   Szentmartoni, Gyongyver
   Galgoczy, Hajna
   Lengyel, Zsolt
   Gyorke, Tamas
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Timea] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Somlai, Krisztian] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szekely, Borbala] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Galgoczy, Hajna] Scanomed Orvosi Diagnosztikai Kutato es Oktato Kft.Budapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Gyorke, Tamas] Scanomed Orvosi Diagnosztikai Kutato es Oktato Kft.Budapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Tokes, T (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Toth, L
   Duboczky, Zs
   Matrai, Z
   Lovey, J
   Jederan, �
   Szentirmay, Z
AF Toth, Laszlo
   Duboczky, Zsolt
   Matrai, Zoltan
   Lovey, Jozsef
   Jederan, Eva
   Szentirmay, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Duboczky, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Toth, L (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Toth, T
   Janoki, M
AF Toth, Tomas
   Janoki, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Tomas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Janoki, Marta] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Toth, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Uhercsak, G
   Valicsek, E
   Maraz, A
   Torday, L
   Hideghety, K
   Kelemen, Gy
   Kahan, Zs
AF Uhercsak, Gabriella
   Valicsek, Erzsebet
   Maraz, Aniko
   Torday, Laszlo
   Hideghety, Katalin
   Kelemen, Gyongyi
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Uhercsak, G (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 71
EP 72
PG 2
ER

PT J
AU Uhlyarik, A
   Vachaja, J
   Lahm, E
   Sikter, M
   Nagy, P
   Kiss, E
   Kiss, N
   Papai, Zs
AF Uhlyarik, Andrea
   Vachaja, Jozsef
   Lahm, Erika
   Sikter, Marta
   Nagy, Peter
   Kiss, Edina
   Kiss, Nora
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Nora] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Uhlyarik, A (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Vachaja, J
   Vajda, A
   Uhlyarik, A
   Sikter, M
   Lahm, E
   Kiss, E
   Nagy, P
   Papai, Zs
AF Vachaja, Jozsef
   Vajda, Adrienn
   Uhlyarik, Andrea
   Sikter, Marta
   Lahm, Erika
   Kiss, Edina
   Nagy, Peter
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vachaja, Jozsef] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Vajda, Adrienn] Allami Egeszsegugyi Kozpont – Honvedkorhaz, BorgyogyaszatBudapest, Hungary.
   [Uhlyarik, Andrea] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
RP Vachaja, J (reprint author), Allami Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 72
EP 74
PG 2
ER

PT J
AU Vajda, R
   Bogner, B
   Szalai, M
   Fusch, N
   Radnai, Z
   Kornya, L
   Kriszbacher, I
AF Vajda, Reka
   Bogner, Barna
   Szalai, Marta
   Fusch, Nikolett
   Radnai, Zoltan
   Kornya, Laszlo
   Kriszbacher, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vajda, Reka] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Bogner, Barna] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Szalai, Marta] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Fusch, Nikolett] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Radnai, Zoltan] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Kornya, Laszlo] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Kriszbacher, Ildiko] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Vajda, R (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori Iskola, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Varga, E
   Vincze, A
   Janoki, M
AF Varga, Edit
   Vincze, Anita
   Janoki, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Edit] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Vincze, Anita] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Janoki, Marta] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Varga, E (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Varga, E
AF Varga, Eszter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Eszter] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Varga, E (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Varga, Sz
   Krascsenits, G
   Frochlich, G
   Major, T
   Vizkeleti, J
   Pete, I
   Polgar, Cs
AF Varga, Szilvia
   Krascsenits, Geza
   Frochlich, Georgina
   Major, Tibor
   Vizkeleti, Julia
   Pete, Imre
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Krascsenits, Geza] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Frochlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varga, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 74
EP 75
PG 2
ER

PT J
AU Vaszko, T
   Papp, J
   Geczi, L
   Bodrogi, I
   Krausz, Cs
   Olah, E
AF Vaszko, Tibor
   Papp, Janos
   Geczi, Lajos
   Bodrogi, Istvan
   Krausz, Csilla
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszko, Tibor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Krausz, Csilla] University of Florence, Department of Clinical Physiopathology, Andrology UnitFlorence, Italy.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Vaszko, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Vegh, �
   Demeter, Gy
   Petranyi, �
   Lakatos, G
   Bodoky, Gy
AF Vegh, Eva
   Demeter, Gyula
   Petranyi, Agota
   Lakatos, Gabor
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegh, Eva] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Demeter, Gyula] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lakatos, Gabor] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Vegh, � (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 75
EP 76
PG 2
ER

PT J
AU Vincze, A
   Janoki, M
   Bakodine Geber, J
AF Vincze, Anita
   Janoki, Marta
   Bakodine Geber, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Anita] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Janoki, Marta] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Bakodine Geber, Judit] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Vincze, A (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Virag, J
   Timar, J
   Hegedus, B
   Garami, M
AF Virag, Jozsef
   Timar, Jozsef
   Hegedus, Balazs
   Garami, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Virag, Jozsef] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Virag, J (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Vityi, T
   Muller, Z
   Takacsi Nagy, L
   Kotai, Zs
AF Vityi, Tamas
   Muller, Zoltan
   Takacsi Nagy, Laszlo
   Kotai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Takacsi Nagy, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Kotai, Zsuzsanna] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Vityi, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 76
EP 77
PG 2
ER

PT J
AU Wagner, I
AF Wagner, Ida
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wagner, Ida] Tolosi Peter Alapitvany, OnkologiaPecs, Hungary.
RP Wagner, I (reprint author), Tolosi Peter Alapitvany, Onkologia, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Yadamsuren, EA
   Hegedus, I
   Cifra, J
   Pajor, L
   Bogner, B
AF Yadamsuren, Enkh-Amar
   Hegedus, Ivett
   Cifra, Janos
   Pajor, Laszlo
   Bogner, Barna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Yadamsuren, Enkh-Amar] University of Pecs, Department of PathologyPecs, Hungary.
   [Hegedus, Ivett] University of Pecs, Department of PathologyPecs, Hungary.
   [Cifra, Janos] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Pajor, Laszlo] University of Pecs, Department of PathologyPecs, Hungary.
   [Bogner, Barna] University of Pecs, Department of PathologyPecs, Hungary.
RP Yadamsuren, EA (reprint author), University of Pecs, Department of Pathology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 77
EP 78
PG 2
ER

PT J
AU Zambo, K
   Mezosi, E
   Szabo, Zs
   Szekeres, S
   Derczy, K
   Weninger, Cs
   Schmidt, E
AF Zambo, Katalin
   Mezosi, Emese
   Szabo, Zsuzsanna
   Szekeres, Sarolta
   Derczy, Katalin
   Weninger, Csaba
   Schmidt, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Mezosi, Emese] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Szabo, Zsuzsanna] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szekeres, Sarolta] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Derczy, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Weninger, Csaba] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Schmidt, Erzsebet] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Zambo, K (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Zsakovics, I
   Szasz, AM
   Balla, P
   Kulka, J
   Krenacs, T
AF Zsakovics, Ivett
   Szasz, Attila Marcell
   Balla, Peter
   Kulka, Janina
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zsakovics, Ivett] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Balla, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Zsakovics, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Pirker, R
AF Pirker, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pirker, Robert] Medical University of ViennaVienna, Austria.
RP Pirker, R (reprint author), Medical University of Vienna, Vienna, Austria.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2011
VL 55
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Torok, Sz
   Dome, B
AF Torok, Szilvia
   Dome, Balazs
TI Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE angiogenezis; receptor-tirozinkinaz-inhibitorok; VEGFR-; PDGFR-; FGFR-szignalizacio; ernormalizacio; antiangiogen terapia biomarkerei
ID angiogenezis; receptor-tirozinkinaz-inhibitorok; VEGFR-; PDGFR-; FGFR-szignalizacio; ernormalizacio; antiangiogen terapia biomarkerei
AB Functional blood vasculature is essential for tumor progression. The main signalization pathways that play a key role in the survival and growth of tumor vessels originate from the VEGF-, PDGF- and FGF tyrosine kinase receptors. In the past decade, significant results have been published on receptor tyrosine kinase inhibitors (RTKIs). In this paper, the mechanisms of action and the results so far available of experimental and clinical studies on multi-target antiangiogenic TKIs are discussed. On the one hand, notable achievements have been made recently and these drugs are already used in clinical practice in some patient populations. On the other hand, the optimal combination and dosage of these drugs, selection of the apropriate biomarker and better understanding of the conflicting role of PDGFR and FGFR signaling in angiogenesis remain future challenges.
C1 [Torok, Szilvia] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
RP Torok, Sz (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, 1121 Budapest, Hungary.
EM szilvia.torok@koranyi.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 3
EP 15
PG 13
ER

PT J
AU Kiss-Toth, �
   Juhaszne Szalai, A
   Koska, P
   Szebeni, J
   Kiss-Toth, E
   Barkai, L
   Fodor, B
AF Kiss-Toth, Eva
   Juhaszne Szalai, Adrienn
   Koska, Peter
   Szebeni, Janos
   Kiss-Toth, Emoke
   Barkai, Laszlo
   Fodor, Bertalan
TI New perspective in the treatment of chronic myeloid leukemia? Gene silencing therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kronikus mieloid leukemia; fuzios onkogen; tirozinkinaz-gatlok; siRNS; gencsendesites
ID kronikus mieloid leukemia; fuzios onkogen; tirozinkinaz-gatlok; siRNS; gencsendesites
AB Chronic myeloid leukemia is an incurable white blood cell disease with slow progression which affects myeloid stem cells. In the course of chromosome 22 shortening a fusion oncogene arises whose product, a Bcr-Abl oncoprotein, is a continuously expressed tyrosine kinase protein. Beside the opportunity of chemotherapy, stem cell therapy and interferon-a therapy, the application of tyrosine kinase inhibitors also became widespread in the treatment of the disease. Patients bearing the T315I point mutation, however, show resistance against all tyrosine kinase inhibitors, which can be managed by dose escalation or the combination of therapies. The discovery of RNA interference or gene silencing put the therapeutic opportunity of CML in new light. The in vitro application of anti-bcr-abl siRNA showed promising results in the causal treatment of the disease, feasible for identification of new genes associated to the disease, but we do not have sufficient evidence for the safety and efficacy of this method in human therapy.
C1 [Kiss-Toth, Eva] Miskolci Egyetem Egeszsegugyi Kar, Nanobiotechnologiai es Regenerativ Medicina Tanszek, B3/B4 ep., II. em., 3515 Miskolc-Egyetemvaros, Hungary.
   [Juhaszne Szalai, Adrienn] Miskolci Egyetem Egeszsegugyi Kar, Nanobiotechnologiai es Regenerativ Medicina Tanszek, B3/B4 ep., II. em., 3515 Miskolc-Egyetemvaros, Hungary.
   [Koska, Peter] Miskolci Egyetem Egeszsegugyi Kar, Nanobiotechnologiai es Regenerativ Medicina Tanszek, B3/B4 ep., II. em., 3515 Miskolc-Egyetemvaros, Hungary.
   [Szebeni, Janos] Semmelweis Egyetem, Nanomedicina Kutato es Oktato KozpontBudapest, Hungary.
   [Kiss-Toth, Emoke] Miskolci Egyetem Egeszsegugyi Kar, Vedonoi TanszekMiskolc-Egyetemvaros, Hungary.
   [Barkai, Laszlo] Miskolci Egyetem Egeszsegugyi Kar, Elmeleti Egeszsegtudomanyi TanszekMiskolc-Egyetemvaros, Hungary.
   [Fodor, Bertalan] Miskolci Egyetem Egeszsegugyi Kar, Nanobiotechnologiai es Regenerativ Medicina Tanszek, B3/B4 ep., II. em., 3515 Miskolc-Egyetemvaros, Hungary.
RP Kiss-Toth, � (reprint author), Miskolci Egyetem Egeszsegugyi Kar, Nanobiotechnologiai es Regenerativ Medicina Tanszek, 3515 Miskolc-Egyetemvaros, Hungary.
EM evakisstoth@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 16
EP 22
PG 7
ER

PT J
AU Madaras, B
   Horvath, Zs
   Lang, I
   Kasler, M
   Borbely, K
AF Madaras, Balazs
   Horvath, Zsolt
   Lang, Istvan
   Kasler, Miklos
   Borbely, Katalin
TI Role of PET/CT in diagnosis and treatment of breast cancer – Review on present knowledge and current research trends
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PET/CT; emlorak; kepalkotas; kemoterapia; radiofarmakon
ID PET/CT; emlorak; kepalkotas; kemoterapia; radiofarmakon
AB Positron emission tomography (PET) has revolutionized the diagnostic opportunities of malignances, however, it has still a controversial role at some conditions in the management of breast cancer. The article compares PET alone and PET/CT. We review the latest trends of using PET or PET/CT for diagnosis, staging, evaluation of the primary tumor and regional lymph node status, as well as early detection of recurrence and distant lesions. PET/CT provides new methods of assessment of early chemo/endocrine therapy response of locally advanced breast cancer. We discuss the development of new radiotracers and their value in predicting treatment response, identifying tumor subtypes and finding new therapeutic targets by them.
C1 [Madaras, Balazs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1121 Budapest, Hungary.
   [Horvath, Zsolt] National Institute of Oncology, Rath Gyorgy u. 7-9., 1121 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1121 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1121 Budapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, Rath Gyorgy u. 7-9., 1121 Budapest, Hungary.
RP Madaras, B (reprint author), National Institute of Oncology, 1121 Budapest, Hungary.
EM madarasb@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 23
EP 29
PG 7
ER

PT J
AU Hegyi, M
   Felne Semsei, �
   Jakab, Zs
   Antal, I
   Kiss, J
   Szendroi, M
   Csoka, M
   Kovacs, G
AF Hegyi, Marta
   Felne Semsei, Agnes
   Jakab, Zsuzsanna
   Antal, Imre
   Kiss, Janos
   Szendroi, Miklos
   Csoka, Monika
   Kovacs, Gabor
TI Results of the treatment of pediatric osteosarcoma in the Hungarian population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE osteosarcoma; gyermekonkologia; kemoterapia; prognozis; tuleles
ID osteosarcoma; gyermekonkologia; kemoterapia; prognozis; tuleles
AB The objective of this report was to estimate long-term outcome and prognostic factors in children and adolescents with osteosarcoma. To evaluate the efficacy of surgery and multiagent chemotherapy for treating osteosarcoma, we reviewed 122 cases (65 males, 57 females, mean age 13.8±3.6 years) treated at the Second Department of Pediatrics in Budapest between 1988 and 2006. Demographic parameters, tumor-related and treatment-related variables, response, overall survival (OS) and event-free survival (EFS) were analyzed. The 5-year OS and EFS were 68% and 61.5%, respectively. OS of patients without metastasis was 79%, while OS with early metastasis was 17%. Survival of patients with amputation (n=30) was not significantly different from that of patients with limb-salvage surgery (n=82), but all patients without radical surgery died. Gender and histological classification had no prognostic significance. Patients with localized tumors in extremities had increased survival compared to those with axial skeleton tumors (p=0.013). Poor histological response to neoadjuvant chemotherapy (rate of survivor tumor cells >10%) was associated with decreased survival (p=0.018). Patients under 14 years had better EFS than patients over 14 years (p=0.008). Our results demonstrate that younger patients with localized osteosarcoma of the extremities who receive limb-salvage surgery and chemotherapy have an excellent survival.
C1 [Hegyi, Marta] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7–9., 1094 Budapest, Hungary.
   [Felne Semsei, Agnes] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7–9., 1094 Budapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7–9., 1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7–9., 1094 Budapest, Hungary.
RP Kovacs, G (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM kovi@gyer2.sote.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 30
EP 37
PG 8
ER

PT J
AU Moldvay, J
   Petak, I
AF Moldvay, Judit
   Petak, Istvan
TI EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE tudorak; molekularis celzott terapia; EGFR-TKI; EGFR aktivalo mutacio; EGFR rezisztenciamutacio
ID tudorak; molekularis celzott terapia; EGFR-TKI; EGFR aktivalo mutacio; EGFR rezisztenciamutacio
AB Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.
C1 [Moldvay, Judit] Semmelweis University, Department of Pulmonology, Dios arok 1/cBudapest, Hungary.
   [Petak, Istvan] Semmelweis University, Department of Medical Chemistry, Molecular Biology and PathobiochemistryBudapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 38
EP 49
PG 12
ER

PT J
AU Szabolcsi, O
   Nagy-Toldi, A
   Zeher, M
   Vegh, J
AF Szabolcsi, Orsolya
   Nagy-Toldi, Annamaria
   Zeher, Margit
   Vegh, Judit
TI Systemic sclerosis in a patient suffering from breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE scleroderma; emlotumor
ID scleroderma; emlotumor
AB Scleroderma is the general disease of the connective tissue, which can be characterized by the proliferation of the connective tissue and fibrosis. According to the results of international studies scleroderma is frequently accompanied by neoplastic diseases, among which the most often occurring is the neoplastic pathology of the breast and the lungs. In May 2007, in the case of our 40-year-old woman patient the histological examination of the tumor we noticed in the left breast verified invasive carcinoma. In December 2007, after neoadjuvant chemotherapy she had a left mastectomy and then she was given postoperative irradiation, hormone therapy and trastuzumab (Herceptin) treatment, which was suspended in December 2008 due to oedema and fibrosis all over the body. In May 2009 she first visited the immunology outpatient department of our clinic, where we started her examination because of our suspicion of scleroderma and her cutaneous fibrosis symptoms, which was established on the basis of the examinations (immunoserology, body plethysmography, diffusing capacity of the lung for carbon monoxide, capillary microscopy, barium swallow) and her symptoms. She was given a conservative therapy (pentoxyphylline, amlodipine, nitroglycerin). Scleroderma arising after the neoplastic process of the breast is usually much more progressive than the primary disease. International reports also show a close correlation between breast cancer and the development of scleroderma, but its exact mechanism is not yet clear.
C1 [Szabolcsi, Orsolya] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Nagy-Toldi, Annamaria] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Zeher, Margit] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Vegh, Judit] University of Debrecen, Medical and Health Center, 3rd Department of Medicine, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
RP Szabolcsi, O (reprint author), University of Debrecen, Medical and Health Center, 3rd Department of Medicine, 4032 Debrecen, Hungary.
EM orsi0618@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 50
EP 54
PG 5
ER

PT J
AU Dudnyikova, A
   Vereczkey, I
   Pete, I
AF Dudnyikova, Anna
   Vereczkey, Ildiko
   Pete, Imre
TI Synchronous tumors of the female genital tract: triple malignant and one benign tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE szinkron tumorok; nogyogyaszati daganatok; esetismertetes
ID szinkron tumorok; nogyogyaszati daganatok; esetismertetes
AB Synchronous tumors of the female genital tract are rare, accounting for 0.7–1.8% of all cases. Double synchronous tumors are most often mentioned in the literature. Reviewing the English literature on this topic, we have found only one case report of a triple synchronous tumor. The 55-year-old patient mentioned in our case has had advanced diabetes mellitus, and has been treated with corticosteroid therapy for a long time because of chronic obstructive pulmonary disease (COPD). She was examined because of her vulvar tumor. During the diagnostic procedure, cervical and endometrial malignant tumors and a benign ovarian cyst have also been found. This event brings to our attention the fact that we should be prepared to manage synchronous even triple malignant gynecological tumors.
C1 [Dudnyikova, Anna] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Dudnyikova, A (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM mariefolders@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2012
VL 56
IS 1
BP 55
EP 59
PG 5
ER

PT J
AU Polgar, Cs
   Major, T
   Sulyok, Z
   Frohlich, G
   Szabo, �
   Savolt, �
   Matrai, Z
   Toth, L
   Fodor, J
AF Polgar, Csaba
   Major, Tibor
   Sulyok, Zoltan
   Frohlich, Georgina
   Szabo, Eva
   Savolt, Akos
   Matrai, Zoltan
   Toth, Laszlo
   Fodor, Janos
TI Second breast-conserving surgery and reirradiation with interstitial high-dose-rate brachytherapy for the management of intra-breast recurrences – 5-year results
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; helyi daganatkiujulas; masodik emlomegtarto mutet; sugarkezeles; brachyterapia
ID emlorak; helyi daganatkiujulas; masodik emlomegtarto mutet; sugarkezeles; brachyterapia
AB The purpose of our work was to evaluate the efficacy of second breast-conserving surgery (BCS) and reirradiation with interstitial high-dose-rate (HDR) brachytherapy (BT) for the management of local recurrences. Between 1999 and 2010, fifteen patients initially treated for breast carcinoma by BCS and radiation therapy who had isolated intra-breast recurrence underwent second BCS and perioperative HDR multicatheter BT. Breast cancer related events, late side effects, and cosmetic results were assessed. At a median follow-up of 62 months (range: 11–127) second local recurrence has not occurred, yielding a 100% mastectomy-free survival. Four patients (27%) developed subsequent distant metastasis and died of breast cancer. The 5-year actuarial rate of disease-free and overall survival was 69% and 85%, respectively. Cosmetic results were rated excellent, good, fair, poor, and unknown in 1 (7%), 10 (66%), 2 (13%), 1 (7%), and 1 (7%) patients, respectively. Grade 2 fibrosis and skin toxicity occurred in 1 (7%) and 1 (7%) patients. Asymptomatic fat necrosis was detected in 9 (60%) women. No patient developed grade 3-4 late side effects. Second BCS followed by partial breast reirradiation is a safe and effective option for the management of selected patients developing intra-breast recurrence after previous breast-conserving therapy. Perioperative HDR BT may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 68
EP 74
PG 7
ER

PT J
AU Madaras, L
   Szasz, AM
   Baranyak, Zs
   Tokes, AM
   Szittya, L
   Lotz, G
   Szekely, B
   Szentmartoni, Gy
   Dank, M
   Baranyai, Zs
   Kulka, J
AF Madaras, Lilla
   Szasz, Attila Marcell
   Baranyak, Zsuzsanna
   Tokes, Anna-Maria
   Szittya, Liliana
   Lotz, Gabor
   Szekely, Borbala
   Szentmartoni, Gyongyver
   Dank, Magdolna
   Baranyai, Zsolt
   Kulka, Janina
TI Morphological and immunophenotypical heterogeneity in breast cancers of young and elderly women
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; heterogenitas; immunhisztokemia; morfologia
ID emlorak; heterogenitas; immunhisztokemia; morfologia
AB There is a reasonable heterogeneity in the morphological appearance and the immunohistochemical properties of distinct breast tumors. Furthermore, it is also known that cancer arising in young women have different prognosis than the ones developing in the elderly. We analyzed breast tumors of 41 young (<35 years) and 33 older women (>65 years) regarding histopathological properties and immunohistochemical reactions for ER, PgR, HER2 and Ki-67, as well as HER2 FISH. The longest diameters, thus largest available surface areas of the tumors were included in the evaluation. Different regions were marked for morphology and in all immunohistochemical reactions. The regions in the distinct tumors showing different pathological and immunohistochemical appearance were identical (p<0.001). The number of morphologically different tumor regions were more frequent in tumors developing in the young (1.82 vs. 1.48 regions/tumor), and 53.6% of tumors with heterogeneous architecture were in young vs. 39.4% in the elderly. However, regarding HER2 staining, cancers in the young patients have shown greater variability among the different tumor areas (p=0.007). The origin of tumor cells predicting prognosis remains undetermined. Whether the analysis of the expression pattern of the whole tumor is conducted or the minute regions are separately examined and averaged, the same results can be achieved. With the development of molecular techniques and accurate prognostic and treatment information rendered to samples the question may be soon answered.
C1 [Madaras, Lilla] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Baranyak, Zsuzsanna] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szittya, Liliana] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szekely, Borbala] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Baranyai, Zsolt] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM kj@korb2.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 75
EP 78
PG 4
ER

PT J
AU Feher, K
   Nagy, T
   Szabo, �
   Bidlek, M
   Bak, M
   Savolt, �
   Godeny, M
AF Feher, Krisztina
   Nagy, Timea
   Szabo, Eva
   Bidlek, Maria
   Bak, Mihaly
   Savolt, Akos
   Godeny, Maria
TI Diagnostic imaging and histologic background of nipple discharge – according to our experience in relation to 40 patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlovaladekozas; emlodaganat; ductus; galaktografia; mammografia
ID emlovaladekozas; emlodaganat; ductus; galaktografia; mammografia
AB The authors present the diverse etiology of nipple discharge, which background may be a tumor. They discuss the checkup ways of nipple discharge and review in detail the galactographic technique and evaluation. The examination of pathologic nipple discharge is essentially based on contact cytology, x-ray-, and ultrasound mammography. Consequently, galactography is applied by filling the ducts with contrast material. The final diagnosis is rendered by histologic examination, following the operation. The authors demonstrate the application and role of galactography through various cases.
C1 [Feher, Krisztina] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nagy, Timea] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bak, Mihaly] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] Marosvasarhelyi Orvosi es Gyogyszereszeti EgyetemMarosvasarhely, Romania.
RP Feher, K (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM feherkriszta77@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 79
EP 83
PG 5
ER

PT J
AU Fulop, M
   Kasler, M
   Remenar, �
   Lengyel, Zs
   Borbely, K
AF Fulop, Miklos
   Kasler, Miklos
   Remenar, Eva
   Lengyel, Zsolt
   Borbely, Katalin
TI The Role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE PET-CT; SUVmax szerepe; ismeretlen primer tumor; fej-nyaki regio; nyaki attet
ID PET-CT; SUVmax szerepe; ismeretlen primer tumor; fej-nyaki regio; nyaki attet
AB PET-CT examination was conducted with 440 patients treated at the Department of Head and Neck Surgery, National Institute of Oncology, Budapest, between January 1, 2006 and December 31, 2010. Out of them 77 patients were selected with whom no examination of any sort (physical, pan-endoscopy, or any of the conventional imaging techniques) succeeded in identifying the primary tumour. In each case the primary examination (aspiration cytology and histology) verified cervical metastases, most of them being squamous cell carcinoma. The significance of PET-CT was retrospectively evaluated in cases of unknown primary tumour with verified cervical metastases. We tested the sensitivity of PET-CT in detection of the primary malignant tumour, and possible distant metastases or a second primary in order to plan an optimal treatment schedule for the patient. Patients with whom the examinations specified in the treatment protocol (physical examination, pan-endoscopy, conventional imaging, biopsy) had failed to diagnose the primary tumour were referred to PET-CT. In each case 18F-FDG tracer was used. In 21/77 patients (27%), the PET-CT yielded unequivocal evidence for the primary tumour confirmed by histology, as well. With 10 others (13%), the precarious diagnoses by various imaging techniques were confirmed by the PET-CT. False positive findings with PET-CT that were not verified either by histology or control examination tests occurred but in 10 patients (13%). Concerning the primary tumour, false negative result was obtained only with 3 patients (4%). It should be noted that their retrospective evaluation proved diagnostic errors, the primary tumours were visible in all the scans. With 33 patients (43%) PET-CT furnished no additional information compared to the previous examinations. In 10 patients, asymptomatic distant metastases and in 3 patients synchronous tumours were diagnosed. We also acknowledge that the significance of PET-CT using 18F-FDG is unquestionable in the detection of unknown primary tumours. It is strongly recommended to re-include the detection of unknown primaries in the approved national indication list of PET-CT. (Note, until January 1, 2008 it had been included!) PET-CT is capable of detecting a primary tumour, after all unsuccessful diagnostic examinations till then, in 25–40% of the cases. One cannot disregard the role and significance of PET-CT in the detection of asymptomatic synchronous tumours, or distant metastases. These benefits make PET-CT a suitable tool for the refinement of individually tailored treatment strategies leading to better therapeutic results and more favourable cost-benefit ratio.
C1 [Fulop, Miklos] Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti Osztaly, Semmelweis ter 1., 2143 Kistarcsa, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Fulop, M (reprint author), Pest Megyei Flor Ferenc Korhaz, Ful-orr-gege es Fej-nyaksebeszeti Osztaly, 2143 Kistarcsa, Hungary.
EM fulopmiklos@yahoo.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 84
EP 92
PG 9
ER

PT J
AU Orosz, E
   Ember, I
   Gombos, K
   Toth, L
   Vamosi Nagy, I
   Tarpay, �
   Pap, �
   Otto, Sz
AF Orosz, Eniko
   Ember, Istvan
   Gombos, Katalin
   Toth, Laszlo
   Vamosi Nagy, Istvan
   Tarpay, Adam
   Pap, Akos
   Otto, Szabolcs
TI Need for developing a new strategy in the follow-up of colorectal cancer patients; the micro RNAs (miRNAs), as potential new biomarkers of early detection
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE vastag- es vegbelrakok; betegkovetes; uj biomarkerek
ID vastag- es vegbelrakok; betegkovetes; uj biomarkerek
AB In the mortality statistics of European countries colorectal cancers are known to assume the 2nd place after lung cancer. The mortality indices are particularly unfavourable in Hungary. Early detection is therefore of vital importance to the patient either the detection of the primary or recurrence after successful surgery is concerned. The latter is only feasible within a proper follow-up strategy. The present review focuses on follow-up due after surgical removal of the tumour with special emphasis on the efficacy of a new biomarker group (miRNAs) and their potential combination with the traditional markers. It is a model in the follow-up strategy that considers the results of risk assessment, as well. Since the methodology and strategy of follow-up are still controversial matters it is obvious that the development of a new follow-up strategy is imperative.
C1 [Orosz, Eniko] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vamosi Nagy, Istvan] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Tarpay, Adam] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pap, Akos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Orosz, E (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM oroszeniko@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 93
EP 102
PG 10
ER

PT J
AU Kerpel-Fronius, S
AF Kerpel-Fronius, Sandor
TI Clinical pharmacological aspects of development and application of follow-on biosimilar antibodies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE biohasonlo; monoklonalis ellenanyag; IgG; immunogenitas; forgalombahozatali engedely
ID biohasonlo; monoklonalis ellenanyag; IgG; immunogenitas; forgalombahozatali engedely
AB Due to the microheterogeneity of the macromolecules produced in biological systems, only the high degree of similarity but not the structural identity of the follow-on biological active agents can be proven. In case of monoclonal antibodies (mAbs) the proof of similarity is much more difficult due to the large molecular weight, complicated structure and complex biological effects of the IgG molecule. The identity of the amino acid sequence is the basic requirement of biosimilarity. Smaller changes in the carbohydrate side chains attached to the protein molecule can be accepted if they do not cause significant functional changes. On the other hand, the alteration of some carbohydrate side chain(s) located at strategically important sites might significantly influence the biological properties of the mAbs. Besides the antigen binding the pharmacological effects of the antibodies depend on several other effector functions related to the Fc fragment such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and phagocytosis. Hence several biological functions must be measured and evaluated in their totality for stating the degree of biosimilarity. According to the concordant strict requirements of the European Medicines Agency (EMA) and the American Food and Drug Administration (FDA), the proof of similar efficacy and safety must be based on the results obtained in the most sensitive and suitable in vitro and in vivo experimental designs. The fundamental proofs are provided by the comparison of the pharmacokinetic and pharmacodynamic measurements, as well as the similarity of the dose-effect relationships. These observations are complemented by the comparative clinical therapeutic trials which eventually support the similar therapeutic use of the follow-on medicinal products in the clinical practice. The final judgement of biosimilarity is a case-by-case decision based on the joint evaluation of all the data available.
C1 [Kerpel-Fronius, Sandor] Semmelweis University, Department of Pharmacology and Pharmacotherapy, Nagyvarad ter 4., 1089 Budapest, Hungary.
RP Kerpel-Fronius, S (reprint author), Semmelweis University, Department of Pharmacology and Pharmacotherapy, 1089 Budapest, Hungary.
EM kerfro@net.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 104
EP 112
PG 9
ER

PT J
AU Ostoros, Gy
   Bajcsay, A
   Baliko, Z
   Borbely, K
   Csekeo, A
   Fillinger, J
   Godeny, M
   Horvath, �
   Kecskes, L
   Kopper, L
   Kovacs, G
   Losonczy, Gy
   Moldvay, J
   Molnar, FT
   Monostori, Zs
   Rahoty, P
   Orosz, Zs
   Strausz, J
   Szentirmay, Z
   Szilagyi, I
   Szondy, K
   Timar, J
   Tolnay, E
AF Ostoros, Gyula
   Bajcsay, Andras
   Baliko, Zoltan
   Borbely, Katalin
   Csekeo, Attila
   Fillinger, Janos
   Godeny, Maria
   Horvath, Akos
   Kecskes, Laszlo
   Kopper, Laszlo
   Kovacs, Gabor
   Losonczy, Gyorgy
   Moldvay, Judit
   Molnar, F Tamas
   Monostori, Zsuzsa
   Rahoty, Pal
   Orosz, Zsolt
   Strausz, Janos
   Szentirmay, Zoltan
   Szilagyi, Istvan
   Szondy, Klara
   Timar, Jozsef
   Tolnay, Edina
TI A tudorak megelozesenek, diagnosztikajanak es kezelesenek alapelvei
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
DE tudorak; megelozes; diagnosztika; kezeles
ID tudorak; megelozes; diagnosztika; kezeles
C1 [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Baliko, Zoltan] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Csekeo, Attila] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
   [Horvath, Akos] National Institute of OncologyBudapest, Hungary.
   [Kecskes, Laszlo] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Moldvay, Judit] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Molnar, F Tamas] University of Pecs, Department of SurgeryPecs, Hungary.
   [Monostori, Zsuzsa] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Rahoty, Pal] MH Honvedkorhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Orosz, Zsolt] University College Hospital GalwayGalway, Ireland.
   [Strausz, Janos] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Szentirmay, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Szilagyi, Istvan] National Institute of OncologyBudapest, Hungary.
   [Szondy, Klara] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tolnay, Edina] County Hospital of PulmonologyTorokbalint, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
EM ostorosgyula@freemail.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 114
EP 132
PG 19
ER

PT J
TI Mindennapi sugarzasok
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE program
ID program
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 136
EP 136
PG 1
ER

PT J
TI Abstracts
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAY
PY 2012
VL 56
IS 2
BP 137
EP 147
PG 11
ER

PT J
AU Fodor, J
   Varjas, G
AF Fodor, Janos
   Varjas, Geza
TI In memoriam Dr. Kiss Bela
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Fodor, Janos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 151
EP 151
PG 1
ER

PT J
AU Matrai, Z
   Toth, L
   Savolt, �
   Peley, G
   Tinusz, A
   Palla, �
   Bartal, A
   Horti, I
   Kasler, M
AF Matrai, Zoltan
   Toth, Laszlo
   Savolt, Akos
   Peley, Gabor
   Tinusz, Aniko
   Palla, Eva
   Bartal, Alexandra
   Horti, Ildiko
   Kasler, Miklos
TI Breast care nurse. A new specialist in the multidisciplinary care of breast cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE emlorak; emlorak-kozpont; emlorak-terapas nover; mulitiszciplinaris ellatas; breast cancer; breast unit; breast care nurse; mutlidisciplinary care
ID emlorak; emlorak-kozpont; emlorak-terapas nover; mulitiszciplinaris ellatas; breast cancer; breast unit; breast care nurse; mutlidisciplinary care
AB The uniform European structure and professional standards for high quality breast cancer care were established in conjunction with the European Organisation for Research and Treatment, the European Society of Mastology and the European Breast Cancer Coalition with the support of the European Parliament. Well-prepared professional teams including a new member called the breast care nurse serve as ground for special breast cancer centers with international accreditation that provide modern, evidence based, patient centered multidisciplinary oncological care. The responsibilities of the new qualified professional staff member include the psycho-social support of the patient and carers from the moment of diagnosis throughout the whole oncological treatment, the fostering of delivering information and communication between patients and specialists. As a result of the curriculum founded by the European Oncology Nursing Society, breast care nurses have become key members of the practice of holistic breast cancer care in countries where the European recommendations have already been implemented. Considering the expected rearrangement of national oncological care, the new sub-speciality is outlined for the first time in the light of the experiences gained at the National Institute of Oncology, Budapest, a comprehensive cancer center.
C1 [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Peley, Gabor] Norfolk and Norwich University Hospital, Breast Unit, Department of General SurgeryNorfolk, UK.
   [Tinusz, Aniko] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Palla, Eva] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Horti, Ildiko] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM matraidok@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 152
EP 157
PG 6
ER

PT J
AU Muller, V
   Tamasi, L
   Galffy, G
   Losonczy, Gy
AF Muller, Veronika
   Tamasi, Lilla
   Galffy, Gabriella
   Losonczy, Gyorgy
TI Practice of supportive care during lung cancer chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tudorak; kemoterapia; szupportacio; megelozes; lung cancer; chemotherapy; supportive therapy; prevention
ID tudorak; kemoterapia; szupportacio; megelozes; lung cancer; chemotherapy; supportive therapy; prevention
AB Active oncotherapy, combination chemotherapy of lung cancer is accompanied with many side effects which may impair patients’ quality of life and compromise the effectiveness of chemotherapy. Most side effects of chemotherapy are preventable or treatable with optimal supportive care which enhances success in patient care and treatment. The aim of this review is to summarize the most important conditions that may be associated with combined chemotherapy of lung cancer from the practical point of view.
C1 [Muller, Veronika] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of Pulmonology, Diosarok u. 1/c., 1125 Budapest, Hungary.
RP Muller, V (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM mulver@pulm.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 159
EP 165
PG 7
ER

PT J
AU Piko, B
   Bassam, A
   Nagy, �K
   Torok, E
   Vaghy, R
   Vargane Tamas, R
   Puskasne Szatmari, K
AF Piko, Bela
   Bassam, Ali
   Nagy, Agnes Krisztina
   Torok, Eniko
   Vaghy, Rita
   Vargane Tamas, Rozsa
   Puskasne Szatmari, Klara
TI Administration of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive gliobastoma multiforme
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE glioblastoma; bevacizumab; VEGF-gatlas; temozolomid; irinotekan; VEGF inhibition; temozolomide; irinotecan
ID glioblastoma; bevacizumab; VEGF-gatlas; temozolomid; irinotekan; VEGF inhibition; temozolomide; irinotecan
AB Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances. Administration of temozolomide is also recommended in relapse if the patient is naive to this treatment. In recurrent or progressive glioblastoma following the above therapy, several biological therapeutic agents were tested, out of which the angiogenesis inhibitor bevacizumab has been approved by FDA (and similar authority of several other countries). Bevacizumab monotherapy resulted in objective tumor response in 28.2%, the median of progression-free survival was 4.2 (2.9–5.8) months, the median of overall survival was 9.2 (8.2–10.7) months. When combined with irinotecan, these results were 37.8%, 5.6 (4.4–6.2) and 8.7 (7.8–10.9) months, respectively. Adverse events were known from the use of bevacizumab in other indications, symptoms affecting the central nervous system were mild, i.e. the therapy proved to be not only effective but safe as well. Reduction of edema provided further advantage. In Hungary the product is available for “off-label” use only through a fairness request process.
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Nagy, Agnes Krisztina] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Torok, Eniko] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Vaghy, Rita] Varosi Onkormanyzat Rethy Pal Korhaza, Radiologiai OsztalyBekescsaba, Hungary.
   [Vargane Tamas, Rozsa] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Puskasne Szatmari, Klara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, 5700 Gyula, Hungary.
EM dr.piko.bela@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 166
EP 170
PG 5
ER

PT J
AU Vizkeleti, J
   Pete, I
   Vereczkey, I
   Frohlich, G
   Horvath, K
   Varga, Sz
   Pulay, T
   Kasler, M
   Polgar, Cs
AF Vizkeleti, Julia
   Pete, Imre
   Vereczkey, Ildiko
   Frohlich, Georgina
   Horvath, Katalin
   Varga, Szilvia
   Pulay, Tamas
   Kasler, Miklos
   Polgar, Csaba
TI Pathological complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE mehnyakrak; preoperativ; brachyterapia; patologiai komplett remisszio; cervical cancer; preoperative; brachytherapy; pathologic complete remission
ID mehnyakrak; preoperativ; brachyterapia; patologiai komplett remisszio; cervical cancer; preoperative; brachytherapy; pathologic complete remission
AB The purpose of the study was a preliminary evaluation of the efficacy of preoperative intracavitary high-dose-rate brachytherapy (HDR BT) in sterilization of the specimen of operable cervical cancer patients enrolled into a prospective, randomized study. Between 2005 and 2010, 100 operable cervical cancer patients of FIGO stage I/A2 (n=4), I/B1 (n=51), I/B2 (n=19), IIA (n=17), and proximal II/B (n=9) were randomized in two arms: in arm "A" (n=50) allocated treatment was 2x8 Gy preoperative intracavitary HDR BT followed by radical surgery, in arm "B" (n= 50) no preoperative treatment was given before the planned radical Wertheim hysterectomy. The rates of pathologic complete remission (pCR) were compared using the Fisher-exact test. In arm "A" 41 patients (82%), in arm "B" 42 patients (84%) underwent radical hysterectomy. The rate of pCR after preoperative BT was 26.8% (11/41), while in the control group the specimen was free of tumor in 7.1% (3/42; p=0.0204). Preoperative HDR BT for cervical cancer patients significantly increases the rate of pathologically tumor-free specimens. Longer follow-up is needed to evaluate the impact of pCR on local tumor control and survival. Our preliminary results support further enrollment of patients into our randomized clinical trial.
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] Marosvasarhelyi Orvosi es Gyogyszereszeti EgyetemMarosvasarhely, Romania.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM j.keleti@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 171
EP 177
PG 7
ER

PT J
AU Jederan, �
   Matrai, Z
   Toth, L
   Lovey, J
   Lang, I
   Hitre, E
   Naszados, Gy
   Godeny, M
AF Jederan, Eva
   Matrai, Zoltan
   Toth, Laszlo
   Lovey, Jozsef
   Lang, Istvan
   Hitre, Erika
   Naszados, Gyorgy
   Godeny, Maria
TI Role of MRI in determining the therapy of rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE rectumcarcinoma; MRI; TNM; kepalkoto prognosztikus faktor; rectal cancer; imaging prognostic factors
ID rectumcarcinoma; MRI; TNM; kepalkoto prognosztikus faktor; rectal cancer; imaging prognostic factors
AB Over the past decade, significant progress has been made in the management of rectal cancer. Advances in surgical technique and adjuvant therapies have led to significant improvements in outcome for some patients. The advances in preoperative therapies have led to the need for an accurate preoperative staging technique to select those patients who are expected to benefit from these interventions without subjecting others to unnecessary treatment. Performing neoadjuvant therapy knowledge of the relationship of the tumor to the circumferential resection margin is of importance. In Hungary, respecting European guideleines, the high resolution magnetic resonance imaging is mandatory in the staging of rectal cancer, and in early rectal cancer transrectal endosonography has a complementary role. The current role of multidetector computer tomography is for detecting distant metastasis and in local tumor staging of advaced cancers.
C1 [Jederan, Eva] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lang, Istvan] National Institute of OncologyBudapest, Hungary.
   [Hitre, Erika] National Institute of OncologyBudapest, Hungary.
   [Naszados, Gyorgy] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM jederan@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 179
EP 186
PG 8
ER

PT J
AU Kovacs, G
   Barsai, A
   Szilasi, M
AF Kovacs, Gabor
   Barsai, Andrea
   Szilasi, Maria
TI Smoking: a prognostic factor of lung cancer survival
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE dohanyzas; tudorak; prognosztikai faktorok; tuleles; smoking; lung cancer; prognostic factors; survival
ID dohanyzas; tudorak; prognosztikai faktorok; tuleles; smoking; lung cancer; prognostic factors; survival
AB Eighty % of lung cancer cases are attributable to smoking. There have been several publications concerning the prognostic factor role of smoking in lung cancer survival. Our research proposed four aims: 1) to gather more concise data about the smoking habits of lung cancer patients; 2) to demonstrate the relationship between the quantitative indicator pack year index (PYI) of smoking history and survival; 3) to test the hypothesis that smoking is not only a risk factor, but also a prognostic factor in lung cancer survival; and 4) to assess the survival advantage of smoking cessation at the time of diagnosis among lung cancer patients. We employed a questionnaire based prospective cohort design of lung cancer patients diagnosed in Budapest, 2009. We collected data on the method of cancer detection, cell types, stage, treatment, comorbidities and smoking habits at baseline. Follow-up questionnaires were completed to document changes (survival, smoking habits) every six months. Our sample included 929 patients (521 males and 408 females). The majority had a history of smoking (79%), including 68% current and 32% former smokers. The average PYI was 33. Fifty-seven % of current smokers quit at the time of lung cancer diagnosis (3% relapsed) and 43% continued smoking. The 30-month survival probabilities were found to be as follows: smokers who had PYI≤39: 44%; PYI≥40: 35%. PYI ≤39 vs. ≥40 [HR=1.26, 95% CI 1.02 1.64; p=0.045]. The 30-month survival proved to be significantly better for those patients who quit at the time of diagnosis (quitters: 54% vs. continuous smokers: 42% [HR=1.29, 95% CI 1.12 1.78; p<0.001]). The benefit of quitting smoking was observed both in the surgically resected and the not resected group. Our results demonstrate that smoking is not only a risk factor for lung cancer, but also a strong prognostic factor of survival at 30 months after diagnosis. Survival is also significantly influenced by the smoking history (PYI). It is markedly important for smoking patients to quit smoking at the time of diagnosis.
C1 [Kovacs, Gabor] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Barsai, Andrea] Fovarosi Uzsoki utcai Korhaz XIV. keruleti TudogondozoBudapest, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
RP Kovacs, G (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
EM kovac@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 187
EP 191
PG 5
ER

PT J
AU Jorgo, K
   Agoston, P
   Major, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Major, Tibor
   Polgar, Csaba
TI Evaluation of patient positioning using in-room kV CT for image-guided radiotherapy (IGRT) of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kepvezerelt sugarkezeles; prosztatarak; kilovoltos CT; image-guided radiotherapy; prostate cancer; kVCT
ID kepvezerelt sugarkezeles; prosztatarak; kilovoltos CT; image-guided radiotherapy; prostate cancer; kVCT
AB The purpose of the study was to evaluate accuracy of patients’ set up verified by kV CT-on-rails system and compare automatic and manual image registration of planning and verification kVCT-s. Between January 2001 and March 2011, at ten patients with prostate cancer the clinical target volumes (CTVs) for prostate (CTV-PROS), and prostate plus caudal 1 cm of seminal vesicles (CTV-PVS) with or without pelvic lymph node region were contoured on the treatment planning CT, according to risk category of the patient. Planning target volumes (PTVs) were created with 1 cm margin extended around the CTVs in each direction. The isocentre was marked on the skin with three radiopaque markers. After the set up, treatment couch with the patient was turned by 180 degree and images were acquired of the region of the isocentre with a kV helical CT-on-rails system (treatment CT). An image registration software was used to co-register planning and treatment CT images. Automatic CT image co-registration was followed by manual co-registration taking into account the CTV-PROS contour and soft tissue informations. Deviations of the isocentres in lateral (LAT), longitudinal (LONG) and vertical (VERT) directions were recorded after each image co-registration. Corresponding data were compared using the t-probe. Systematic (S) and random (s) errors of the set up were calculated. Adequate PTV to CTV margins were calculated by van Herk’s formula (2.5xS + 0,7xs). Overall 252 deviations were analysed on fourty-two CT series of 10 patients. The mean errors of the set up with automatic and manual image co-registrations were 0.19 cm and 0.07 cm (p=0.001) in LAT, 0.05 cm and 0.03 cm (p=0.07) in LONG and 0.16 cm and 0.22 cm (p=0.16) in VERT directions, respectively. The systematic errors of the set up for automatic and manual image registrations were 0.22 cm and 0.26 cm in LAT, 0.17 cm and 0.18 cm in LONG, 0.25 cm and 0.26 cm in VERT directions, respectively. The random errors of the set up for automatic and manual image registrations were 0.31 cm and 0.26 cm in LAT, 0.27 cm and 0.27 cm in LONG and 0.24 cm and 0.33 cm in VERT directions, respectively. In case of manual image co-registration, the required PTV to CTV margins to cover at least 95% of the CTVs with at least 95% percent of the prescribed dose were calculated to 0.93 cm in LAT, 0.65 cm in LONG, and 0.89 cm in VERT directions. Patients set up can be verified with manual image co-registration based on soft tissues around the prostate using a kV CT-on-rails system installed in the treatment room. The difference between automatic and manual image co-registration was significant in LAT direction. A PTV to CTV margin <1 cm seems to be appropriate to cover the CTVs in image-guided prostate radiotherapy. These findings support our recent clinical protocol.
C1 [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM jorgokliton@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 193
EP 198
PG 6
ER

PT J
AU Torok, Sz
   Cserepes T., M
   Renyi-Vamos, F
   Dome, B
AF Torok, Szilvia
   Cserepes T., Mihaly
   Renyi-Vamos, Ferenc
   Dome, Balazs
TI Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE angiogenezis; tirozinkinaz-inhibitorok; BIBF 1120; szolid daganatok; angiogenesis; receptor tyrosine kinase inhibitors; solid tumors
ID angiogenezis; tirozinkinaz-inhibitorok; BIBF 1120; szolid daganatok; angiogenesis; receptor tyrosine kinase inhibitors; solid tumors
AB Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.
C1 [Torok, Szilvia] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
   [Cserepes T., Mihaly] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
RP Torok, Sz (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, 1121 Budapest, Hungary.
EM szilvia.torok@koranyi.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 199
EP 208
PG 10
ER

PT J
AU Szasz, AM
AF Szasz, Attila Marcell
TI Claudins as prognostic factors of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE emlorak; claudin; cadherin; prognozis; breast cancer; prognosis
ID emlorak; claudin; cadherin; prognozis; breast cancer; prognosis
AB Different expression of claudins and E-cadherin has been described in the pathogenesis and progression of breast cancer. Changes in the expression of these junctional molecules have also been described as being of prominent importance in other cancers as well. Thus, we aimed at exploring the potential prognostic relevance of these cell junctional molecules in breast carcinoma cases. Expression of claudin-1, -3, -4, -5, -7, -8, -10, -15, -18 and E-cadherin at mRNA level was evaluated in correlation with survival in publicly available datasets containing expression measurements of 1809 breast cancer patients. Breast cancer tissues of 636 patients were evaluated with tissue microarray technique and immunohistochemical method for claudin-1, -2, -3, -4, -5, -7 and E-cadherin protein expression. In 96 cases lymph node metastases were also subjects of the study. Claudin expression bears prognostic information in itself. Based on bioinformatic data analysis, the meta-gene of claudin-3, -4, -7 and E-cadherin has proved the most powerful in predicting survival. An immunohistochemical protein profile consisting of claudin-2, -4 and E-cadherin was able to predict outcome in the most effective manner in the training set. Combining the overlapping members of the distinct methods resulted in the CC index (consisting of claudin-4 and E-cadherin, a.k.a. CURIO), which was able to accurately predict relapse-free survival in the validation cohort (p=0.029) in a more efficient way than its components. Cox regression analysis including clinicopathological variables and the average CC score showed that in univariate analysis most of them were prognostic but most of them lost independent prognostic value in multivariate analysis except for the CC index, the subtypes defined by immunoprofiling and vascular invasion. On the other hand, the CC index was able to further refine prognosis splitting good vs. poor prognosis patients into two clusters in these subgroups. Evaluation of lymph node metastases has shown that decreased expression of claudin-1 and elevated expression of claudin-4 can predict worse prognosis in breast cancers spreading to the regional lymph nodes. The defined claudin-cadherin index provides additional prognostic information besides the routinely utilized diagnostic approaches and factors. The level of expression of certain claudins can be of prognostic significance in regional lymph node metastases.
C1 [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Szasz, AM (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM cac@korb2.sote.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 209
EP 212
PG 4
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI A LUX-Lung 3 vizsgalat ismertetese
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE LUX-Lung 3
ID LUX-Lung 3
AB The description of the LUX-Lung 3 trial is based on the following article: Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30(suppl): LBA7500), 2012
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2012
VL 56
IS 3
BP 214
EP 215
PG 2
ER

PT J
AU Petranyi, �
AF Petranyi, Agota
TI The treatment of castration-resistant prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kasztraciorezisztens prosztatadaganat; kemoterapia; celzott terapia; csontattet; molekularis celpontu terapia; immunterapia
ID kasztraciorezisztens prosztatadaganat; kemoterapia; celzott terapia; csontattet; molekularis celpontu terapia; immunterapia
AB The last several years have seen extraordinary progress in the management of patients with castration resistant prostate cancer (CRPC). Although metastatic prostate cancer remains an incurable disease, substantial advances have been made in therapeutic options. Development of novel agents that modulate the androgen receptor pathway, growth factor signalling pathways, and immune function and bone targeting pathways has been the focus of therapeutic strategies because of its significance in the biology of prostate cancer progression. In 2004, docetaxel/prednisone was the first therapy shown to prolong survival. For the next 6 years, no substantial progress was made in prolonging survival, but the latest 2 years have marked the beginning of a new and exciting era for the treatment of mCRPC. Based on phase III clinical trials cabazitaxel, abiraterone acetate, sipuleucel-T and denosumab represent available therapeutic options in this setting, radium-223 chloride and MDV3100 demonstrated a survival advantage in phase III trials and the road for their introduction in clinical practice is rapidly ongoing. Results are also awaited for phase III studies currently underway or planned with new drugs given as monotherapy (TAK-700, cabozantinib, tasquinimod, PROSTVAC-VF, ipilimumab) or in combination with docetaxel (custirsen, aflibercept, dasatinib, zibotentan), while other emerging molecules have shown hopeful results. The aim of this review is to summarize the most important new findings for metastatic CRPC (mCRPC) according to the different molecular pathways and to discuss their potential influence on future management of this disease.
C1 [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Gyali ut 5-7., 1097 Budapest, Hungary.
RP Petranyi, � (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, 1097 Budapest, Hungary.
EM apetranyi@laszlokorhaz.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 219
EP 228
PG 10
ER

PT J
AU Sinko, D
   Landherr, L
AF Sinko, Daniel
   Landherr, Laszlo
TI The role of PET/CT in decision-making during cancer treatment. Clinical experience
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE PET/CT; terapias dontes; sugarterapia
ID PET/CT; terapias dontes; sugarterapia
AB Nowadays PET/CT examinations have got more and more important role during cancer treatment. It has importance not only in diagnostic examination and staging but also in the radiation planning process and measuring the therapeutic effect. From November 2006 to November 2010 there were 153 PET/CT examinations requested by the Oncology Outpatient Clinic, Uzsoki Hospital. Nine patients were excluded from the examination. In the clinical trial we have aimed to measure what the correlation between the oncologists’ questions and the PET/CT results was, in how many cases the PET/CT had influence on therapeutic decision-making. In the case of the patients waiting for the operation we compared the results of the pathological examinations to the results of the PET/CT. The oncologists got the expected answers in 79 cases, while in 45 cases the answers were negative. In 10 cases there were no definite answers. Ten cases proved to be false negative or false positive based on the later pathological examination. As a result of the PET/CT findings the originally planned therapeutic decisions or the therapies in process have been modified in 77 cases. To sum up, the PET/CT gave the expected answers to the oncologists’ questions in more than half of the cases (54.9%) and modified the originally prescribed therapy in 53.5% of the cases.
C1 [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
RP Sinko, D (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM sinko.daniel@uzsoki.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 230
EP 234
PG 5
ER

PT J
AU Mozsa, E
   Polgar, Cs
   Frohlich, G
   Major, T
   Janvary, ZsL
   Lovey, K
   Sulyok, Z
   Takacsi Nagy, L
   Fodor, J
   Kasler, M
AF Mozsa, Emoke
   Polgar, Csaba
   Frohlich, Georgina
   Major, Tibor
   Janvary, Zsolt Levente
   Lovey, Katalin
   Sulyok, Zoltan
   Takacsi Nagy, Laszlo
   Fodor, Janos
   Kasler, Miklos
TI Accelerated partial breast irradiation with three-dimensional conformal external beam radiotherapy following breast-conserving surgery - Preliminary results of a phase II clinical study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE akceleralt parcialis emlobesugarzas; haromdimenzios konformalis kulso sugarkezeles; korai emlorak; emlomegtarto mutet
ID akceleralt parcialis emlobesugarzas; haromdimenzios konformalis kulso sugarkezeles; korai emlorak; emlomegtarto mutet
AB The aim of the study was to implement accelerated partial breast irradiation (APBI) by means of three-dimensional conformal radiotherapy (3D-CRT) following breast-conserving surgery (BCS) for early-stage breast cancer. Between December 2006 and February 2011, in 45 cases of low-risk, stage I–II breast cancer the tumour bed was marked with titanium clips during BCS. Postoperative APBI was given by means of 3D-CRT using 3 to 5 non-coplanar fields. The total dose of APBI was 36.9 Gy (9 x 4.1 Gy) using a twice-a-day fractionation over 5 consecutive days. Early and late radiation side effects and cosmetic results were analysed for the first 30 patients with a minimum follow-up of 1 year. At a mean follow-up of 25.2 months neither loco-regional nor distant failure was observed. Excellent, good, fair, and poor cosmetic outcome was detected in 10 (33.3%), 16 (53.4%), 4 (13.3%), and 0 (0%) patients, respectively. Grade 2 or worse acute side effect was not observed. Grade 1 fibrosis, grade 2 teleangiectasia and asymptomatic fat necrosis occurred in 4 (13.3%), 1 (3.3%) and 5 (16.7%) patients, respectively. No grade 3–4 late side effects were detected. 3D-CRT is a reproducible and feasible technique for the delivery of APBI following conservative surgery for the treatment of low-risk, early-stage invasive breast carcinoma. The preliminary results are promising, early- and mid-term radiation side effects are rare, and cosmetic results are excellent.
C1 [Mozsa, Emoke] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Janvary, Zsolt Levente] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Lovey, Katalin] State Hospital Krems, Department of RadiooncologyKrems an der Donau, Austria.
   [Sulyok, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Takacsi Nagy, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Mozsa, E (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM emozsa@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 235
EP 241
PG 7
ER

PT J
AU Horvath, Zs
AF Horvath, Zsolt
TI Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE emlorak; posztmenopauza; anasztrozol; eletminoseg; fizikai allapot; SF RAND-36
ID emlorak; posztmenopauza; anasztrozol; eletminoseg; fizikai allapot; SF RAND-36
AB Due to the recognition and diagnosis of breast cancer in increasingly early stages, quality of life becomes an important part of treatment beyond the efficacy indicators. In the scientific literature quality of life data related to adjuvant treament of early breast cancer is poorly represented. Our aim was collecting data to capture the changes in quality of life of postmenopausal, early breast cancer patients. This multicenter, prospective, observational, non-interventional study enrolled 1502 postmenopausal, early stage breast cancer patients. The answers to the QoL questionnaire were rated on a scale from 0 to 100. Overall the patients judged their working ability fairly negative at the start however, this parameter improved by the end of the survey. According to earlier studies the physical parameters deteriorated more significantly among patients belonging to the elderly (≥65 years) age group compared to younger patients. This correlation was confirmed by our study as well. Our results however are somewhat conflicting with the observations by Fehlauer et al (14) that younger patients show greater absolute and relative functional deterioration in their physical status compared to middle-aged or elderly patients. Fatigue appeared in the same rate among different age groups, while deterioration in vitality and daily functionality levels could persist for several years. Based on our findings the elderly patient’s care needs special attention from treating personnel.
C1 [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Horvath, Zs (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
EM horvathzsolt@med.unideb.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 242
EP 246
PG 5
ER

PT J
AU Kovacs, Zs
   Rigo, A
   Kokonyei, Gy
   Szabo, �
   Kovacs, D
   Sebestyen, �
   Balogh, B
   Prezenszki, Zs
   Nagy, M
AF Kovacs, Zsuzsanna
   Rigo, Adrien
   Kokonyei, Gyongyi
   Szabo, Eva
   Kovacs, Dorottya
   Sebestyen, Arpad
   Balogh, Bela
   Prezenszki, Zsuzsanna
   Nagy, Melania
TI Complex psycho-social intervention program complementing conventional antitumor therapy - promising results
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlodaganat; eletminoseg; megkuzdes; komplex pszichoszocialis intervencio; poszttraumas novekedes
ID emlodaganat; eletminoseg; megkuzdes; komplex pszichoszocialis intervencio; poszttraumas novekedes
AB The aim of the research was to assess the effectiveness of a comprehensive, complex psycho-social intervention program, operating on different levels of spiritual plane, life management and behavioural health, among women with breast cancer. The general objective of the study was to help in coping, promote cognitive and emotional processing, encourage psychological and spiritual growth, improve the quality of life, and reduce the chances of remission. The research has been carried out in Budapest at the Radiology Diagnostic Department of the National Oncology Institute, involving 173 women treated for malignant breast tumour (C50) (experimental group: n=86, control group: n=87). Thirty-four women from the experimental group participated in the complex intervention program. We carried out two tests: one before the start and one after the end of the program. Research tools: Shortened Beck Depression Inventory, Quality of Life Questionnaire (EORTC QLQ-C30, QLQ-BR23), Spielberger’s State-Trait Anxiety Inventory (STAI-T), the Revised Illness Perception Questionnaire (IPQ-R), the Posttraumatic Growth Inventory, and the Benefit Finding Questionnaire. The women participating the experimental program showed a significant positive change in comparison to the control group: in anxiety F (1, 65)=6.021, p=0.017; in depression: F(1, 72)=4.347, p=0.041; in experience of personal control: F(1, 69)=7.346, p=0.008; in EORTC General Health/Quality of Life Subscale F(1, 78)=7.531, p=0.008; in EORTC physical functioning F(1, 78)=4.874, p=0.014; in EORTC fatigue F(1, 78)=15.060, p=0.000; in BR23 body-image F(1, 79)=8.828, p=0.004; in BR23 arm symptoms F(1, 78)=7.229, p=0.009; in benefit finding F(1, 80)=21.171, p=0.000, and in posttraumatic growth F(1, 31)=24.186, p=0.000). The program has proven effective, its widespread use in practice is recommended.
C1 [Kovacs, Zsuzsanna] Semmelweis University, Institute of Behavioural Sciences, Vas utca 17., 1088 Budapest, Hungary.
   [Rigo, Adrien] Eotvos Lorand Tudomanyegyetem PPK, Klinikai Pszichologia es Addiktologia TanszekBudapest, Hungary.
   [Kokonyei, Gyongyi] Eotvos Lorand Tudomanyegyetem PPK, Klinikai Pszichologia es Addiktologia TanszekBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Dorottya] A rak ellen, az emberert, a holnapert! Tarsadalmi AlapitvanyBudapest, Hungary.
   [Sebestyen, Arpad] Egeszsegforras AlapitvanyBudapest, Hungary.
   [Balogh, Bela] Egeszsegforras AlapitvanyBudapest, Hungary.
   [Prezenszki, Zsuzsanna] A rak ellen, az emberert, a holnapert! Tarsadalmi AlapitvanyBudapest, Hungary.
   [Nagy, Melania] Egeszsegforras AlapitvanyBudapest, Hungary.
RP Kovacs, Zs (reprint author), Semmelweis University, Institute of Behavioural Sciences, 1088 Budapest, Hungary.
EM kovacszs@se-etk.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 247
EP 257
PG 11
ER

PT J
AU Major, T
   Agoston, P
   Jorgo, K
   Polgar, Cs
AF Major, Tibor
   Agoston, Peter
   Jorgo, Kliton
   Polgar, Csaba
TI Application of image-guided radiotherapy in external beam radiation of cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kepvezerelt sugarterapia; IGRT; megavoltos cone beam CT; betegbeallitas
ID kepvezerelt sugarterapia; IGRT; megavoltos cone beam CT; betegbeallitas
AB The aim of the study was to present the clinical application of megavoltage cone beam CT (MV-CBCT) for image-guided radiotherapy at different tumour sites in our department. Altogether 2772 CT examinations were performed to verify the accuracy of patient setup before irradiation of 462 patients with pelvic (n=281), thoracic (n=107), head and neck (n=33) and cranial (n=41) tumours. A MV-CBCT with 6 MV photon beam integrated into a linear accelerator was used for imaging. The verification CT images were registered to planning CTs using bony structures, and in the three main directions (lateral, longitudinal, vertical) deviation between treatment and planning isocentres was determined in order to characterise the accuracy of patient setup. The verifications were performed before the first four fractions, and weekly-biweekly thereafter. From data obtained during the first three measurements systematic error of patient setup was calculated „off line”, and the setup was corrected with the calculated value. At errors larger than 5 mm „on line” table correction was applied. The measured data were grouped and analysed according to location, and systematic and random errors were determined. From the data safety zone around clinical target volume (CTV) was calculated to create planning target volume (PTV). Following isocentre correction after the first three fractions the patient setup became more accurate at all site locations. At pelvic irradiation the mean error in all the three directions was below 1 mm, and the range of standard deviation was 0.32–0.38. At pelvic and thoracic irradiation the CTV-PTV safety zone calculated without any correction was 9–13 mm depending on direction, while at head and neck and cranial irradiation it was 6–9 mm. After correction of systematic error these data were 7–9 mm and 3–6 mm. After on line correction of setup errors larger than 5 mm the safety zone was 5–6 mm at pelvic and thoracic irradiation, 5 mm at head and neck, and 3–5 mm at cranial irradiation. Verification of patient setup with MV-CBCT at different locations can be easily performed. The initial systematic error can be corrected with a simple verification protocol which results in a few millimeter decrease of the CTV-PTV safety zone. Use of smaller safety zone is possible only with more frequent verifications and on line corrections.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM major@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 258
EP 265
PG 8
ER

PT J
AU Szabo, Z
   Agoston, P
   Major, T
   Horvath, K
   Jederan, �
   Polgar, Cs
AF Szabo, Zoltan
   Agoston, Peter
   Major, Tibor
   Horvath, Katalin
   Jederan, Eva
   Polgar, Csaba
TI Comparison of CT- and MRI-based clinical target volumes for 3 dimensional conformal external-beam radiotherapy of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prosztatarak; besugarzastervezes; MRI-alapu tervezes; kepfuzio; celterfogat
ID prosztatarak; besugarzastervezes; MRI-alapu tervezes; kepfuzio; celterfogat
AB The aim of the study was to compare clinical target volumes defined by CT and MRI for 3 dimensional conformal external beam radiotherapy of prostate cancer. CT and T2-weighed MRI images with 3 mm slice thickness were acquired for 13 patients with clinically organ-confined prostate cancer. Target volumes were contoured by two clinicians (“AP” and “SZ”) experienced in prostate radiotherapy. Two clinical target volumes were defined: prostate (CTVpros) and prostate with a margin including the proximal 1 cm of the seminal vesicles (CTVpvs). Eight clinical target volumes were outlined for all patients: CTVprosAPCT, CTVprosAPMR, CTVpvsAPCT, CTVpvsAPMR, CTVprosSZCT, CTVprosSZMR, CTVpvsSZCT, CTVpvsSZMR. Volumes were measured in cm3. The volumes of different PTVs were compared using the Student’s t-test. Mean CTVpros and CTVpvs using CT vs. MRI were 36.9 (range:13.8–121) vs. 32.0 (9.7–120.1) (p=0.0002), and 77.2 (30.5–209.5) vs. 67.6 (29.8–191.1) (p=0.0001), respectively. Mean CTVprosAPCT vs. CTVprosAPMR were 39.2 vs. 32.0 (p<0.00005), respectively. Mean CTVprosSZCT vs. CTVprosSZMR were 34.6 vs. 31.9 (p=0.15). Mean CTVpvsAPCT vs. CTVpvsAPMR were 85.8 vs. 70.9 (p<0.00006). Mean CTVpvsSZCT vs. CTVpvsSZMR were 68.6 vs. 64.4 (p=0.14). Interobserver difference for CTVpros defined by CT images was significant (39.2 vs. 34.6; p=0,0058). However, the difference was not significant using MRI images (32.0 vs. 31.9; p=0.93). Interobserver differences for CTVpvs were significant using either CT (85.8 vs. 68.6; p=0.0001) or MRI (70.9 vs. 64.4; p=0.004). Ratio of mean volumes contoured by the two observers were 1,12 (CT) vs. 1 (MRI) for CTVpros and 1,2 (CT) vs. 1,09 (MRI) for CTVpvs. Clinical target volumes defined for prostate cancer external beam radiotherapy by MRI images are significantly smaller compared to CT image based contouring. The magnitudes of differences are observer dependent. The use of MRI decreases the interobserver difference of mean volumes with 11% and 12% for CTVpvs and CTVpros.
C1 [Szabo, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Szabo, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM szaboz74@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 267
EP 273
PG 7
ER

PT J
AU Zapf, I
   Fekecs, T
   Moezzi, M
   Tizedes, Gy
   Pavlovics, G
   Kalman, E
   Horvath, �P
   Ferencz, A
AF Zapf, Istvan
   Fekecs, Tamas
   Moezzi, Medhi
   Tizedes, Gyorgy
   Pavlovics, Gabor
   Kalman, Endre
   Horvath, Ors Peter
   Ferencz, Andrea
TI DSC data of blood plasma in breast cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlodaganat; verplazma; DSC technika
ID emlodaganat; verplazma; DSC technika
AB Breast cancer is the commonest cause of cancer death in women worldwide. Its incidence has been increasing for many years in economically developed countries. Differential scanning calorimetry (DSC) is a thermoanalytical technique which monitors small heat changes between sample and reference materials. This examination is a validly efficient method for the demonstration of structural changes not only in the physical sciences, but in numerous human oncological diseases. The goal of this study was to measure DSC thermogram of blood plasma in breast cancer patients with different stages. Nineteen women with different tumor diameter (0.5–7.5 mm) and with or without regional lymph node metastases were involved in the study. Preoperatively peripheral blood samples were collected from the patients and from healthy controls, and plasma components were analysed by SETARAM micro DSC-II calorimeter. The diameter of the tumor tissue and the number of metastatic lymph nodes were evaluated on the basis of postoperative histological results. In the current study we found difference in changes of the thermal parameters (transition temperature, calorimetric enthalpy) of breast cancer patients’ plasma components. Moreover, a tendency has been found for association of these results with tumor size and with the degree of regional lymph node involvement. Preliminary study of the clinical utility of DSC technology arises, even though there is no data in the literature. In cases of breast cancer the blood plasma may be suitable for DSC analysis for diagnosis or staging as well. In order to clarify the relationships we are planning further studies.
C1 [Zapf, Istvan] University of Pecs, Department of Surgery, Ifjusag ut 13., 7624 Pecs, Hungary.
   [Fekecs, Tamas] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Moezzi, Medhi] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Tizedes, Gyorgy] University of Pecs, Department of Surgery, Ifjusag ut 13., 7624 Pecs, Hungary.
   [Pavlovics, Gabor] University of Pecs, Department of Surgery, Ifjusag ut 13., 7624 Pecs, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Horvath, Ors Peter] University of Pecs, Department of Surgery, Ifjusag ut 13., 7624 Pecs, Hungary.
   [Ferencz, Andrea] Semmelweis University, 3rd Department of SurgeryBudapest, Hungary.
RP Zapf, I (reprint author), University of Pecs, Department of Surgery, 7624 Pecs, Hungary.
EM zapfistvan@googlemail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 274
EP 279
PG 6
ER

PT J
AU Dudnyikova, A
   Toth, E
   Deak, B
   Pete, I
AF Dudnyikova, Anna
   Toth, Erika
   Deak, Beata
   Pete, Imre
TI Burkitt’s lymphoma presenting as ovarian tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE Burkitt-lymphoma; petefeszektumor
ID Burkitt-lymphoma; petefeszektumor
AB Burkitt’s lymphoma is a rapidly progressing tumor, which could be cured in 60–80% of cases. Its infiltration of the ileo-cecal region often spreads to the ovaries, though primary ovarian manifestation is also common. By presenting our case of a 27-year-old nulliparous patient with primary ovarian Burkitt’s lymphoma, we would like to draw attention to its diagnostic and therapeutic difficulties.
C1 [Dudnyikova, Anna] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Deak, Beata] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Dudnyikova, A (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM dudnyik@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2012
VL 56
IS 4
BP 282
EP 286
PG 5
ER

PT J
AU Nemeth, Gy
   Jelinek, I
AF Nemeth, Gyorgy
   Jelinek, Ivett
TI New directions in drug development, biomarker research and personalized medicine
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE biomarker; szemelyre szabott terapia
ID biomarker; szemelyre szabott terapia
AB In the recent years, medicine has taken some first important steps toward a major paradigm shift that could result in a landslide for personalized therapies. Indeed, evidence-based medicine seems to yield to personalized medicine in multiple areas, including both the thinking patterns of healthcare workers and everyday medical practice. Nevertheless, although a steadily increasing number of personalized treatment modalities have recently become available for patients, so far, no breakthrough can be seen in the paradigm shift from evidence-based medicine to personalized therapy. We believe that a more efficient identification and utilisation of future and already known biomarkers, respectively, might be the key to speed up this progress. In line with this, biomarkers are becoming increasingly important tools in late stage research, drug development and in clinical practice, as well. Correct classification of biomarkers becomes especially important, as different types of biomarkers provide markedly different information to drug developers and health care professionals.
C1 [Nemeth, Gyorgy] Magyar Szemelyre Szabott Medicina TarsasagBudapest, Hungary.
   [Jelinek, Ivett] Richter Gedeon Nyrt, Gyomroi ut 19-21., 1103 Budapest, Hungary.
RP Jelinek, I (reprint author), Richter Gedeon Nyrt, 1103 Budapest, Hungary.
EM gy.nemeth@richter.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 5
EP 10
PG 6
ER

PT J
AU Pogany, G
AF Pogany, Gabor
TI Personalized medicine in the eye of patients and their relatives
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE szemelyre szabott orvoslas; betegszervezetek; ritka betegsegek; nemzeti strategia
ID szemelyre szabott orvoslas; betegszervezetek; ritka betegsegek; nemzeti strategia
AB Our goal was to overview the situation of personalized medicine, especially to characterize the role of patient organizations. We embedded this process into the on-going procedures of the transformation of health care system, outlining the Hungarian and international tendencies. We introduce the exceptional role of rare diseases, among others the rare cancers, thanks to their special status. Some results of the recent Hungarian and international surveys are also demonstrated. The presented global tendencies give the frame for the necessary alteration of the Hungarian health care system. Beside the solution of the country-specific problems of our health care system, the main principles of the new paradigm of 21st century medicine are also influencing: personalized, participatory, preventive, predictive and proactive. The new medicine is continuously associated with the patients, instead of separated interventions. The changing of attitude is necessary for spreading these principles and also gives the basis of future medical service of society. The role of patient organizations is vital during this progress. The development is possible to the direction of patient-centred health care model by changing the structure of residential expenditure, even during the time of global financial crisis. However, a stronger community involvement is required. Good examples of this patient organization involvement are presented in the case of rare diseases, which can be, together with orphan drugs, the precursors to personalized medicine, paving the path to this direction. A closer participation of patients and their organizations is essential to transform the present health care system to the route of personalized medicine and to alter the public outlook.
C1 [Pogany, Gabor] Ritka es Veleszuletett Rendellenesseggel Elok Orszagos Szovetsege, Ulloi ut 82., 1082 Budapest, Hungary.
RP Pogany, G (reprint author), Ritka es Veleszuletett Rendellenesseggel Elok Orszagos Szovetsege, 1082 Budapest, Hungary.
EM pogany@rirosz.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 11
EP 15
PG 5
ER

PT J
AU Molnar, MJ
   Magyarosi, Sz
   Nemeth, Gy
AF Molnar, Maria Judit
   Magyarosi, Szilvia
   Nemeth, Gyorgy
TI Significance of genetic tests in the era of personalized medicine
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prevencios orvoslas; predikcio; genetikai teszt; monogenes betegseg; poligenes komplex betegseg; kozvetlenul a fogyasztoknak
ID prevencios orvoslas; predikcio; genetikai teszt; monogenes betegseg; poligenes komplex betegseg; kozvetlenul a fogyasztoknak
AB Due to the rapid development in genomics, genetic markers gain importance in all areas of medicine including prevention, management and therapy of patients. As a result, medicine started to shift away from evidence based procedures to a more personalized one. However, the later one requires high quality validated genetic tests. These new tests appeared as preconceptional, preimplantational, prenatal, presymptomatic, diagnostic and direct to consumer forms. Before approval such tests must be analytically and clinically validated. Broader use of these genetic tests is dependent on their price and reimbursement schemes.
C1 [Molnar, Maria Judit] Semmelweis Egyetem, Genomikai Medicina es Ritka Betegsegek Intezete, Tomo u. 25-29., 1083 Budapest, Hungary.
   [Magyarosi, Szilvia] Richter Gedeon NyrtBudapest, Hungary.
   [Nemeth, Gyorgy] Magyar Szemelyre Szabott Medicina TarsasagBudapest, Hungary.
RP Molnar, MJ (reprint author), Semmelweis Egyetem, Genomikai Medicina es Ritka Betegsegek Intezete, 1083 Budapest, Hungary.
EM molnarmj@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 16
EP 20
PG 5
ER

PT J
AU Balint, LB
   Nagy, L
AF Balint, Laszlo Balint
   Nagy, Laszlo
TI The place of functional genomics in oncological research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE genomika; exomszekvenalas; funkcionalis genomika; epigenetika; onkogenomika
ID genomika; exomszekvenalas; funkcionalis genomika; epigenetika; onkogenomika
AB The 1000 genomes project changed the way how we see the human genome. The rapid development of the deep sequencing technologies is raising several practical questions, and the way how we answer these questions will affect deeply the future of the oncological reseach in Hungary. In our manuscript we give a short overview of the results of the 1000 genomes project and we present the place of the functional genomic investigations between other genomic tools. Based on the recent development in the field we summarize the challenges that have to be addressed in the next couple of years.
C1 [Balint, Laszlo Balint] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular Biology, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Nagy, Laszlo] University of Debrecen, Faculty of Medicine, Division of Clinical ImmunologyDebrecen, Hungary.
RP Balint, LB (reprint author), University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular Biology, 4012 Debrecen, Hungary.
EM lbalint@med.unideb.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 21
EP 25
PG 5
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Role of contemporary pathological diagnostics in the personalized treatment of cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE daganatpatologia; molekularis klasszifikacio; szemelyre szabott terapia
ID daganatpatologia; molekularis klasszifikacio; szemelyre szabott terapia
AB Due to the developments of pathology in the past decades (immunohistochemistry and molecular pathology) classification of cancers changed fundamentally, laying a ground for personalized management of cancer patients. Our picture of cancer is more complex today, identifying the genetic basis of the morphological variants. On the other hand, this picture has a much higher resolution enabling us to subclassify similar histological cancer types based on molecular markers. This redefined classification of cancers helps us to better predict the possible biological behavior of the disease and/or the therapeutic sensitivity, opening the way toward a more personalized treatment of this disease. The redefined molecular classification of cancer may affect the universal application of treatment protocols. To achieve this goal molecular diagnostics must be an integral and reimbursed part of the routine pathological diagnostics. On the other hand, it is time to extend the multidisciplinary team with molecular pathologist to improve the decision making process of the management of cancer patients.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 26
EP 32
PG 7
ER

PT J
AU Moldvay, J
   Rokszin, Gy
   Abonyi-Toth, Zs
   Katona, L
   Kovacs, G
AF Moldvay, Judit
   Rokszin, Gyorgy
   Abonyi-Toth, Zsolt
   Katona, Lajos
   Kovacs, Gabor
TI Analysis of drug therapy of lung cancer in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tudorak; kemoterapia; molekularis celzott terapia; hazai gyakorlat
ID tudorak; kemoterapia; molekularis celzott terapia; hazai gyakorlat
AB Hungary is a world leader in the field of lung cancer deaths, so it is particularly important that patients could have access to modern treatments. The aim of our analysis was to find how drug treatments are used in Hungary and how they are compatible with international practice. The in-patient and prescription database of the National Health Insurance Fund for three years (2008–2010) was used to study the frequency of certain chemotherapy protocols, the duration of therapies, and the changes in the individual protocols and drugs used for lung cancer treatment (ICD: C33H0–C34) during the reviewed period. We did not differentiate between neoadjuvant and adjuvant treatment and therapy after progression. During the study period 12326 lung cancer patients received first-line chemotherapy, one third of those (n=3791) received second-line, and one third of those (n=1174) third-line treatment. The average treatment duration was between 3 and 4 months. The first-line treatment of NSCLC mainly consisted of platinum treatment in combination with third generation cytotoxic agents. A downward trend of gemcitabine, still the most common combination compound, was observed, in parallel with the increased use of paclitaxel, and as a consequence carboplatin replaced cisplatin. Among new agents the use of pemetrexed and bevacizumab has increased. Pemetrexed appeared mainly in second-line treatment, while erlotinib also in second, but mostly in third line. The first-line treatment of SCLC consisted of a platinum-etoposide combination, and in second-line setting topotecan was the most commonly used drug. According to our results the chemotherapeutic combinations and sequencing are in accordance with international and national recommendations. Further detailed analysis of the available data may help to obtain more accurate picture of the efficacy of lung cancer treatments as well.
C1 [Moldvay, Judit] Semmelweis University, Department of Pulmonology, Dios arok 1/C., 1125 Budapest, Hungary.
   [Rokszin, Gyorgy] RxTarget Kft.Budapest, Hungary.
   [Abonyi-Toth, Zsolt] RxTarget Kft.Budapest, Hungary.
   [Katona, Lajos] Orszagos Egeszsegbiztositasi PenztarBudapest, Hungary.
   [Kovacs, Gabor] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 33
EP 38
PG 6
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI The treatment of chemotherapy induced anemia in lung cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tudodaganat; kemoterapia okozta anemia; transzfuzio; eletminoseg; eritropoetin
ID tudodaganat; kemoterapia okozta anemia; transzfuzio; eletminoseg; eritropoetin
AB Anemia is common among patients with malignant tumors, due to the disease and chemotherapy. Active oncotherapy, combination chemotherapy of lung cancer is accompanied with many side effects which may impair the patient’s quality of life and compromise the effectiveness of chemotherapy, the most frequent one of them being chemotherapy induced anemia. Anemia decreases not only the patient’s quality of life, but also worsens the dose- intensity of chemotherapy. One of the potential treatments of chemotherapy-induced anemia is erythropoietin-stimulating agents (ESAs) using the appropriate indications. Several national and international studies have shown that ESA therapy effectively increases hemoglobin level. However, in recent times, contradictory results were published on ESA treatment in terms of survival and progression of the tumor. The background of this may be that the tumor cells and endothelial cells as well may express erythropoietin receptor, the role of which has not yet been fully elucidated in tumor progression.
C1 [Galffy, Gabriella] Semmelweis University, Department of Pulmonology, Dios arok 1/C., 1125 Budapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM ggalffy@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 39
EP 49
PG 11
ER

PT J
AU Nagy, Zs
AF Nagy, Zsolt
TI Assessment of Hungarian ESA and G-CSF treatments to national and international guidelines and protocols
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kemoterapia indukalta neutropenia; lazas neutropenia; kemoterapia indukalta anemia; szupportacio; megelozes
ID kemoterapia indukalta neutropenia; lazas neutropenia; kemoterapia indukalta anemia; szupportacio; megelozes
AB Chemotherapy induced neutropenia (CIN), febrile neutropenia (FN), chemotherapy induced anemia (CIA) frequently occur following myelosuppressive chemotherapy and are associated with morbidity, mortality, costs, and relative dose intensity (RDI), hence influencing overall survival (OS). Given prophylactically, granulocyte colony-stimulating factors (G-CSFs) can stimulate neutrophil production and depletion, they may thus reduce FN incidence when following chemotherapy. Erythropoietins are widely used to treat chemotherapy induced anemia. Several guidelines have been published to help onco-hematologists design their supportive therapy. The aim of our study was to assess the guidelines concerning everyday routine in supportive care. The final conclusion is that the Hungarian therapy support guidelines are up to date, are highly compliant with international standards [ASCO (1), EORTC (2), ESMO (3, 4), NCCN (5-7)], and that the clinicians have a deep understanding and comprehensive usage in their everyday practice.
C1 [Nagy, Zsolt] MISEK Kft., Csabai kapu 9-11., 3529 Miskolc, Hungary.
RP Nagy, Zs (reprint author), MISEK Kft., 3529 Miskolc, Hungary.
EM drzsoltnagy@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 50
EP 55
PG 6
ER

PT J
AU Nagy, Zs
AF Nagy, Zsuzsanna
TI Biomarkers in solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE KRAS-mutacio; vastagbelrak; szoveti mikroarray; D-dimer
ID KRAS-mutacio; vastagbelrak; szoveti mikroarray; D-dimer
AB In the past decade the revolutionary development of molecular technology contributed a lot to the increase of our knowledge on cancer. These informations led to the discovery and understanding of those key regulatory changes in the genesis and progression of malignancies that can serve as targets in tumor diagnostics and therapy. One of the main challenges in the research field is to identify the most important molecular networks, the molecular targets, the markers (biomarkers) which can predict therapeutic responsiveness in order to select the appropriate patients, as well as markers to judge the prognosis of the disease. The aims of our study approached some details of the biomarker area and reached certain conclusions: (1) The anti-EGFR therapy, used in the second line or even further, proved to be effective, providing clinical advantage (operability, regression) in 36% of patients carrying wild-type KRAS. G13D mutations were the most frequent among the KRAS-mutants, which, according to current data, could react to anti-EGFR therapy. (2) Extended immunohistochemical (IHC) analysis on colorectal cancer samples (using tissue microarray) found rather few correlations between the IHC estimation and the clinical characteristics related mainly to survival. According to the results with anti-EGFR antibodies in the diagnostic histological samples, the regulatory pathway which rules the proliferation of normal colonic mucosa is also present in colonic cancer cells. This finding is supported by the increased ativity of the downstream members (as RAS, RAF, ERK) of the EGFR signalling. (3) The level of D-dimer increased at least as much as the level of classical tumor markers in the early stages of tumor growth. D-dimer can be considered as a prognostic factor in tumor types studied (breast-, colorectal-, ovarian cancers) and its measurement is advised besides the classical markers. We hope that these results may contribute to the design of a more individual-based and more effective antitumor strategy.
C1 [Nagy, Zsuzsanna] Semmelweis University, School of PhD Studies, 1085 Budapest, Hungary.
RP Nagy, Zs (reprint author), Semmelweis University, School of PhD Studies, 1085 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2013
VL 57
IS 1
BP 56
EP 62
PG 7
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Introduction
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE melanoma; DTIC; BRAF; ASCO
ID melanoma; DTIC; BRAF; ASCO
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 67
EP 67
PG 1
ER

PT J
AU Plotar, V
   Liszkay, G
   Ladanyi, A
   Toth, E
AF Plotar, Vanda
   Liszkay, Gabriella
   Ladanyi, Andrea
   Toth, Erika
TI New TNM classification (AJCC 2009) and the pathological significance of sentinel lymph node biopsy in malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; TNM; orszemnyirokcsomo
ID melanoma; TNM; orszemnyirokcsomo
AB The novel TNM staging system (AJCC, 2009) has some new aspects on pathological microstaging of malignant melanoma. It highlights and reflects the importance of vertical growth phase of these tumors. Furthermore, the morphometrical evaluation of sentinel lymph nodes (SLNs) is more important than ever since, according to the new classification, even the presence of isolated tumor cells means more advanced stage.
C1 [Plotar, Vanda] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Plotar, V (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, 1122 Budapest, Hungary.
EM plotar.vanda@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 68
EP 72
PG 5
ER

PT J
AU Timar, J
   Harsing, J
   Somlai, B
AF Timar, Jozsef
   Harsing, Judit
   Somlai, Beata
TI Molecular classification and markers of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; molekularis klasszifikacio; markerek
ID melanoma; molekularis klasszifikacio; markerek
AB Pathological classification of malignant melanoma did not change in the past decade, it was just completed with UV-induced skin alterations. A new feature, however, is the establishment of molecular classification of melanoma indicating that beside the most frequent genetic alterations (BRAF, NRAS, CKIT mutations) there is a wide variety of rare molecular subclasses. Unfortunately, none of these genetic alterations can be used to discriminate benign lesions from malignant ones. The frequently used "melanoma" markers are mostly melanosomal markers, therefore they are not helpful for this diagnostic purpose either. More recently, novel FISH kits have been developed analyzing characteristic copy number alterations specific for malignant melanoma. Though melanosomal markers are helpful in differencial diagnostics, the presence of normal melanocytes in various tissues (lymph nodes, intestine or brain) requires application of molecular techniques when melanoma metastasis is in question.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Harsing, Judit] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 73
EP 78
PG 6
ER

PT J
AU Raso, E
   Barbai, T
   Gyorffy, B
   Timar, J
AF Raso, Erzsebet
   Barbai, Tamas
   Gyorffy, Balazs
   Timar, Jozsef
TI Prognostic and predictive markers of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; prognozis; terapiarezisztencia; genetikai markerek
ID melanoma; prognozis; terapiarezisztencia; genetikai markerek
AB Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.
C1 [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 79
EP 83
PG 5
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI Prognostic value of tumor-infiltrating immune cells in melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; tumorinfiltralo immunsejtek; limfocitak; dendritikus sejtek; prognozis
ID melanoma; tumorinfiltralo immunsejtek; limfocitak; dendritikus sejtek; prognozis
AB Host cells representing an integral component of solid tumors, among them cells contributing to the development of native and adaptive immune responses, can exert both positive and negative effects on the outcome of the disease. Infiltration of T lymphocyte subsets and antigen presenting dendritic cells, crucial in mounting an efficient antitumor immune response, is generally associated with favorable prognosis. On the contrary, accumulation of tumor-associated macrophages, mast cells and neutrophils, playing important roles in chronic inflammatory processes promoting tumor progression, predicts unfavorable disease outcome in most cases. In melanoma, studies on the prognostic impact of the lymphoid infiltrate in general, and that of T cells, yielded controversial results. In our studies, density of activated T lymphocytes correlated with patients’ survival, and we obtained similar results in the case of B cells and mature dendritic cells. The amount of both B cells and dendritic cells showed correlation with that of activated T lymphocytes, and their combined analysis identified patient subgroups with different prognosis. According to data from the literature, intense infiltration by neutrophil granulocytes could be associated with shorter survival, while no unambiguous conclusions can be drawn from studies on the prognostic value of tumor-associated macrophages and other immune cell types. Our results indicate that a prominent infiltration of dendritic cells, B cells and activated T lymphocytes can be considered as a favorable prognostic factor in malignant melanoma.
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM ladanyi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 85
EP 95
PG 11
ER

PT J
AU Lazar, V
AF Lazar, Viktoria
TI Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE primer melanoma; komparativ genomialis hibridizacio; BRAF-mutacio; NRAS-mutacio; 11q13 kromoszomaregio; CCND1-amplifikacio; jelatviteli utvonalak
ID primer melanoma; komparativ genomialis hibridizacio; BRAF-mutacio; NRAS-mutacio; 11q13 kromoszomaregio; CCND1-amplifikacio; jelatviteli utvonalak
AB Human malignant melanoma is one of the most aggressive forms of skin cancer with an exceptionally bad prognosis. Melanoma often displays constitutively activated MAPK pathway through BRAF or NRAS mutations. It is also known that these mutations are almost never simultaneously present and that they appear at early stages and preserved throughout tumor progression, although it is proved that these alterations alone are insufficient to cause tumor progression. Therefore the first aim of our study was to evaluate those distinct genetic alterations which can properly differentiate the three important molecular subtypes of primary melanomas with a) BRAF, b) NRAS mutation and c) WT (wild type for both loci). High-resolution array comparative genomic hybridization (array CGH) was used to assess genome-wide analysis of DNA copy number alterations. Primary melanomas with BRAF mutation more frequently exhibited losses on 10q23-10q26 and gains on chromosome 7 and 1q23-1q25 compared to melanomas with NRAS mutation. Loss on the 11q23-11q25 sequence was found mainly in conjunction with NRAS mutation. Based on these results, we proved the existence of marked differences in the genetic pattern of the BRAF and NRAS mutated melanoma subgroups, which might suggest that these mutations contribute to the development of malignant melanoma in conjunction with distinct cooperating oncogenic events. In general, it is an interesting phenomenon suggesting that these mutations provide probably the "guiding force" for these tumors and it also suggests that there are alternative genetic pathways to melanoma. These additional oncogenic events which are associated with BRAF or NRAS mutations can provide rational additional targets for a combination therapy with kinase inhibitors. In this study we also investigated the specific dynamic activities among different signalling pathways highlighting the frequent alterations of genes involved in the signalling interactions between the MAPK-JAK pathways in BRAF mutated melanomas. Using a data mining algorithm we also found a gene alteration signature in the MAPK pathway that was commonly related to the presence of BRAF mutation in our melanoma cohorts. The second aim of this study was to develop an accurate Q-PCR method for determining the co-amplification pattern of six candidate genes that reside in the 11q13 amplicon core. We found that co-amplification of these candidate genes or the CCND1 amplification along with either BRAF or NRAS mutations might be more important for prognosis than the presence of these alterations alone.
C1 [Lazar, Viktoria] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani Intezet, Kassai ut 26., 4028 Debrecen, Hungary.
RP Lazar, V (reprint author), Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani Intezet, 4028 Debrecen, Hungary.
EM vlazar@brc.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 96
EP 99
PG 4
ER

PT J
AU Ladanyi, A
   Balatoni, T
AF Ladanyi, Andrea
   Balatoni, Timea
TI Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; immunterapia; CTLA-4; PD-1
ID melanoma; immunterapia; CTLA-4; PD-1
AB Recent advances in tumor immunology, a better understanding of mechanisms regulating the immune response has led to experimental and clinical testing of a novel type of immunotherapeutics: antibodies blocking negative regulatory mechanisms of T-cell activation. The application of the CTLA-4 antagonist ipilimumab, the prototype of this new class of immune stimulating agents, represents the first treatment that resulted in significant prolongation of the survival of metastatic melanoma patients in randomized, controlled trial, leading to the approval of its use for the therapy of these patients in 2011. Together with the BRAF inhibitor vemurafenib, which was also approved in 2011, ipilimumab has changed the standard therapy of metastatic melanoma, and also paved the way for other agents aiming at influencing immune regulating molecules, of which antibodies blocking the PD-1 pathway also showed promising clinical activity. According to clinical experience collected so far, these agents induce objective tumor response in a relatively small proportion of patients, with a characteristic response kinetics frequently showing delayed activity, but resulting in durable remission in a considerable proportion of the responding patients. On the other hand, antitumor activity is frequently accompanied by significant toxicity. The spectrum of side effects is different from that of conventional therapies, and a large part of them is caused by the enhanced systemic immune activity. In order to spare non-responding patients of the severe side effects and to increase response rate, the search for biomarkers that could help in identifying patients likely to react to the treatment represents an important focus of studies. Furthermore, development of combinations with other immunotherapeutic modalities, chemo- or targeted therapies may further increase the efficiency of immunomodulatory antibodies.
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9Budapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
EM ladanyi@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 100
EP 107
PG 8
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI Vemurafenib (Zelboraf) in the therapy of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE melanoma; celzott terapia; vemurafenib; BRAF
ID melanoma; celzott terapia; vemurafenib; BRAF
AB The incidence of malignant melanoma is continuously rising, but the therapy of advanced melanoma remains insufficient. Advances in the understanding of the immunological and genetical background resulted in the development of a new target therapeutic agent, vemurafenib (Zelboraf) accepted by the FDA in 2011 and by the EMA in 2012. Vemurafenib improved the overall and progression-free survival of untreated melanoma with the mutation BRAF V600E. In a phase III study vemurafenib was associated with a 63% reduction in the risk of deaths compared with dacarbazine and of 74% in the risk of either death or disease progression. Objective response was 48% in the vemurafenib and 5% in the dacarbazine arm. Vemurafenib has special side effects, surprisingly even secondary skin tumors. Additional research is needed to understand the mechanism of drug resistance and to find new targeted therapeutic agents and combinations.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM liszkay@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 110
EP 113
PG 4
ER

PT J
TI 11th CONGRESS OF THE HUNGARIAN RADIOTHERAPEUTICAL SOCIETY
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE sugarterapia; kongresszus
ID sugarterapia; kongresszus
AB Tihany, 23-25 May 2013
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 114
EP 135
PG 22
ER

PT J
AU Adamecz, Zs
   Smanyko, V
   Durunda, O
   Furka, A
AF Adamecz, Zsolt
   Smanyko, Viktor
   Durunda, Okszana
   Furka, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Durunda, Okszana] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Furka, Andrea] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Adamecz, Zs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 114
EP 114
PG 1
ER

PT J
AU Agoston, P
   Major, T
   Baricza, K
   Varjas, G
   Jorgo, K
   Szabo, Z
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Baricza, Karoly
   Varjas, Geza
   Jorgo, Kliton
   Szabo, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 114
EP 114
PG 1
ER

PT J
AU Arkocsevics, E
   Petre, I
   Agoston, P
   Major, T
   Baricza, K
   Meszaros, N
   Polgar, Cs
AF Arkocsevics, Edina
   Petre, Ildiko
   Agoston, Peter
   Major, Tibor
   Baricza, Karoly
   Meszaros, Norbert
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arkocsevics, Edina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Petre, Ildiko] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Arkocsevics, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 114
EP 115
PG 2
ER

PT J
AU Bagdi, Z
   Sebestyen, Zs
   Bellyei, Sz
   Boronkai, �
   Szappanos, Sz
   Nagy, Zs
   Moricz, P
   Kott, I
   Mangel, L
AF Bagdi, Zita
   Sebestyen, Zsolt
   Bellyei, Szabolcs
   Boronkai, Arpad
   Szappanos, Szabolcs
   Nagy, Zsuzsanna
   Moricz, Peter
   Kott, Ilona
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bagdi, Zita] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Moricz, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Kott, Ilona] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bagdi, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 115
EP 115
PG 1
ER

PT J
AU Baricza, K
   Agoston, P
   Varjas, G
AF Baricza, Karoly
   Agoston, Peter
   Varjas, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Baricza, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 115
EP 115
PG 1
ER

PT J
AU Beganyi, N
   Klinko, T
AF Beganyi, Nora
   Klinko, Timea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Beganyi, Nora] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Beganyi, N (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 115
EP 116
PG 2
ER

PT J
AU Bekesi, B
   Vandulek, Cs
   Farkas, A
   Hadjiev, J
   Repa, I
   Kovacs, �
AF Bekesi, Barbara
   Vandulek, Csaba
   Farkas, Andrea
   Hadjiev, Janaki
   Repa, Imre
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bekesi, Barbara] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Bekesi, B (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 116
EP 116
PG 1
ER

PT J
AU Bellyei, Sz
   Sebestyen, Zs
   Sebestyen, K
   Csapo, L
   Farkas, R
   Locsi, Z
   Mangel, L
AF Bellyei, Szabolcs
   Sebestyen, Zsolt
   Sebestyen, Klara
   Csapo, Laszlo
   Farkas, Robert
   Locsi, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsi, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 116
EP 116
PG 1
ER

PT J
AU Bencsik, B
   Stelczer, G
   Major, T
   Takacsi-Nagy, Z
   Pesznyak, Cs
   Polgar, Cs
AF Bencsik, Barbara
   Stelczer, Gabor
   Major, Tibor
   Takacsi-Nagy, Zoltan
   Pesznyak, Csilla
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bencsik, Barbara] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Stelczer, Gabor] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bencsik, B (reprint author), Budapest University of Technology and Economy, Institute of Nuclear Technique, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 116
EP 116
PG 1
ER

PT J
AU Boronkai, �
   Kalincsak, J
   Sarosi, V
   Baliko, Z
   Ruzsics, I
   Molnar, P
   Kajary, K
   Szakall, Sz
   Brichter, N
   Csapo, L
   Sebestyen, Zs
   Sebestyen, K
   Schipp, I
   Al-Farhat, Y
   Mangel, L
AF Boronkai, Arpad
   Kalincsak, Judit
   Sarosi, Veronika
   Baliko, Zoltan
   Ruzsics, Istvan
   Molnar, Peter
   Kajary, Kornelia
   Szakall, Szabolcs
   Brichter, Nora
   Csapo, Laszlo
   Sebestyen, Zsolt
   Sebestyen, Klara
   Schipp, Ildiko
   Al-Farhat, Yousuf
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Ruzsics, Istvan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Molnar, Peter] Pozitron Diagnosztika KftBudapest, Hungary.
   [Kajary, Kornelia] Pozitron Diagnosztika KftBudapest, Hungary.
   [Szakall, Szabolcs] Pozitron Diagnosztika KftBudapest, Hungary.
   [Brichter, Nora] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Schipp, Ildiko] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Boronkai, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 116
EP 117
PG 1
ER

PT J
AU Borzasi, E
   Varga, Z
   Fodor, E
   Egyud, Zs
   Kahan, Zs
   Hideghety, K
   Furak, J
   Palfoldi, R
   Maraz, A
AF Borzasi, Emoke
   Varga, Zoltan
   Fodor, Emese
   Egyud, Zsofia
   Kahan, Zsuzsanna
   Hideghety, Katalin
   Furak, Jozsef
   Palfoldi, Regina
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Palfoldi, Regina] SZTE, Pulmonologiai TanszekSzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Borzasi, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 117
EP 117
PG 1
ER

PT J
AU Czifra, Gy
   Halasz, J
   Varady, Gy
   Mangel, L
AF Czifra, Gyozo
   Halasz, Judit
   Varady, Gyongyi
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czifra, Gyozo] University of Pecs, Department of OncologyPecs, Hungary.
   [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Czifra, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 117
EP 117
PG 1
ER

PT J
AU Csenki, M
   Varga, Z
   Cserhati, A
   Ujhidy, D
   Kahan, Zs
AF Csenki, Melinda
   Varga, Zoltan
   Cserhati, Adrienn
   Ujhidy, Dora
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Ujhidy, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Csenki, M (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 117
EP 117
PG 1
ER

PT J
AU Dovalovszkine Drencsenyi, R
   Berenyi, �
   Nagy, Z
   Mozes, P
   Hideghety, K
AF Dovalovszkine Drencsenyi, Rita
   Berenyi, Eva
   Nagy, Zoltan
   Mozes, Petra
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dovalovszkine Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Berenyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dovalovszkine Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 117
EP 117
PG 1
ER

PT J
AU Egyud, Zs
   Mozes, P
   Rusko, L
   Nagy, Z
   Fodor, E
   Hideghety, K
AF Egyud, Zsofia
   Mozes, Petra
   Rusko, Laszlo
   Nagy, Zoltan
   Fodor, Emese
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusko, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Egyud, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 117
EP 118
PG 2
ER

PT J
AU Feher, Zs
   Vizkeleti, J
AF Feher, Zsuzsanna
   Vizkeleti, Julia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Feher, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Feher, Zs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 118
EP 118
PG 1
ER

PT J
AU Fekete, V
   Haranyi, G
   Szekely, J
   Lovey, J
   Polgar, Cs
AF Fekete, Viktoria
   Haranyi, Gabriella
   Szekely, Judit
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Viktoria] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Haranyi, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Fekete, V (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 118
EP 118
PG 1
ER

PT J
AU Fodor, J
AF Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Fodor, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 118
EP 118
PG 1
ER

PT J
AU Foldvari, D
   Bellyei, Sz
   Farkas, R
   Horvath, Zs
   Sebestyen, Zs
   Szigeti, A
   Mangel, L
AF Foldvari, Dora
   Bellyei, Szabolcs
   Farkas, Robert
   Horvath, Zsolt
   Sebestyen, Zsolt
   Szigeti, Andras
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Szigeti, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 118
EP 119
PG 2
ER

PT J
AU Glavak, Cs
   Antal, G
   Cselik, Zs
   Kovacs, �
   Toller, G
   Hadzsiev, J
   Repa, I
AF Glavak, Csaba
   Antal, Gergely
   Cselik, Zsolt
   Kovacs, Arpad
   Toller, Gabor
   Hadzsiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadzsiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Glavak, Cs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 119
EP 119
PG 1
ER

PT J
AU Godeny, A
   Agoston, P
   Frohlich, G
   Polgar, Cs
AF Godeny, Anna
   Agoston, Peter
   Frohlich, Georgina
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Godeny, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 119
EP 119
PG 1
ER

PT J
AU Hadjiev, J
   Toller, G
   Antal, G
   Repa, I
AF Hadjiev, Janaki
   Toller, Gabor
   Antal, Gergely
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Hadjiev, J (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 119
EP 119
PG 1
ER

PT J
AU Halasz, J
   Brauner, T
   Czifra, Gy
   Simonne Revesz, J
   Vereckei, E
   Vitari, I
   Weiczl, H
   Mangel, L
AF Halasz, Judit
   Brauner, Tiborne
   Czifra, Gyozo
   Simonne Revesz, Judit
   Vereckei, Erika
   Vitari, Ildiko
   Weiczl, Hajnalka
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Czifra, Gyozo] University of Pecs, Department of OncologyPecs, Hungary.
   [Simonne Revesz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Vereckei, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Vitari, Ildiko] University of Pecs, Department of OncologyPecs, Hungary.
   [Weiczl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Halasz, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 119
EP 120
PG 2
ER

PT J
AU Herein, A
   Major, T
   Agoston, P
   Polgar, Cs
AF Herein, Andras
   Major, Tibor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Herein, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 120
EP 120
PG 1
ER

PT J
AU Herrmann, Th
   Schorcht, J
AF Herrmann, Thomas
   Schorcht, Johannes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herrmann, Thomas] Sachsische LandesarztekammerDresden, Germany.
   [Schorcht, Johannes] Sachsische LandesarztekammerDresden, Germany.
RP Herrmann, Th (reprint author), Sachsische Landesarztekammer, Dresden, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 120
EP 120
PG 1
ER

PT J
AU Hideghety, K
   Cserhati, A
   Groh, F
   Fodor, E
   Mozes, P
   Borzasi, E
   Varga, L
   Maraz, A
   Egyud, Zs
   Kahan, Zs
AF Hideghety, Katalin
   Cserhati, Adrienn
   Groh, Fruzsina
   Fodor, Emese
   Mozes, Petra
   Borzasi, Emoke
   Varga, Linda
   Maraz, Aniko
   Egyud, Zsofia
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Groh, Fruzsina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 120
EP 120
PG 1
ER

PT J
AU Janvary, ZsL
   Jansen, N
   Lenaerts, E
   Devillers, M
   Baart, V
   Ernst, Ch
   Cucchiaro, S
   Coucke, P
AF Janvary, Zsolt Levente
   Jansen, Nicolas
   Lenaerts, Eric
   Devillers, Magali
   Baart, Veronique
   Ernst, Christelle
   Cucchiaro, Severine
   Coucke, Philippe
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Jansen, Nicolas] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Lenaerts, Eric] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Devillers, Magali] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Baart, Veronique] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Ernst, Christelle] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Cucchiaro, Severine] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Coucke, Philippe] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
RP Janvary, ZsL (reprint author), University Hospital of Liege, Department of Radiation Oncology, Liege, Belgium.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 120
EP 121
PG 2
ER

PT J
AU Jorgo, K
   Agoston, P
   Major, T
   Szabo, Z
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Major, Tibor
   Szabo, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 121
EP 121
PG 1
ER

PT J
AU Kahan, Zs
   Csenki, M
   Egyud, Zs
   Cserhati, A
   Rarosi, F
   Boda, K
   Varga, Z
AF Kahan, Zsuzsanna
   Csenki, Melinda
   Egyud, Zsofia
   Cserhati, Adrienn
   Rarosi, Ferenc
   Boda, Krisztina
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rarosi, Ferenc] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 121
EP 121
PG 1
ER

PT J
AU Kalincsak, J
   Horvath, Zs
   Sebestyen, Zs
   Kovacs, P
   Farkas, R
   Bellyei, Sz
   Laszlo, Z
   Kovacs, 
   Doczi, T
   Mangel, L
AF Kalincsak, Judit
   Horvath, Zsolt
   Sebestyen, Zsolt
   Kovacs, Peter
   Farkas, Robert
   Bellyei, Szabolcs
   Laszlo, Zoltan
   Kovacs, B.
   Doczi, Tamas
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, B.] University of Pecs, Department of OncologyPecs, Hungary.
   [Doczi, Tamas] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Kalincsak, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 121
EP 122
PG 2
ER

PT J
AU Katona, Cs
   Plavecz, �
   Klinko, T
   Meszaros, E
   Kner, E
AF Katona, Csilla
   Plavecz, Eva
   Klinko, Timea
   Meszaros, Edina
   Kner, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Kner, Erika] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Katona, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 122
EP 122
PG 1
ER

PT J
AU Kiscsatari, L
   Varga, Z
   Gorbe, A
   Morvay, N
   Kovari, B
   Ferdinandy, P
   Lepran, I
   Kahan, Zs
AF Kiscsatari, Laura
   Varga, Zoltan
   Gorbe, Aniko
   Morvay, Nikolett
   Kovari, Bence
   Ferdinandy, Peter
   Lepran, Istvan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiscsatari, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gorbe, Aniko] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Morvay, Nikolett] SZTE, Farmakologiai es Farmakoterapiai IntezetSzeged, Hungary.
   [Kovari, Bence] University of Szeged, Department of PathologySzeged, Hungary.
   [Ferdinandy, Peter] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Lepran, Istvan] SZTE, Farmakologiai es Farmakoterapiai IntezetSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kiscsatari, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 122
EP 122
PG 1
ER

PT J
AU Kontra, G
AF Kontra, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 122
EP 122
PG 1
ER

PT J
AU Kovacs, �
   Toth, L
   Bajzik, G
   Glavak, Cs
   Hadjiev, J
   Antal, G
   Emri, M
   Vandulek, Cs
   Repa, I
AF Kovacs, Arpad
   Toth, Lilla
   Bajzik, Gabor
   Glavak, Csaba
   Hadjiev, Janaki
   Antal, Gergely
   Emri, Miklos
   Vandulek, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toth, Lilla] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Bajzik, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Emri, Miklos] University of DebrecenDebrecen, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kovacs, � (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 122
EP 123
PG 1
ER

PT J
AU Kovacs, P
   Chis, 
   Mandea, Y
   Papiu, 
AF Kovacs, Peter
   Chis, A.
   Mandea, Yvette
   Papiu, M.
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Diagnosztikai es Onkoterapias CentrumBrasov, Romania.
   [Chis, A.] Diagnosztikai es Onkoterapias CentrumBrasov, Romania.
   [Mandea, Yvette] Diagnosztikai es Onkoterapias CentrumBrasov, Romania.
   [Papiu, M.] Diagnosztikai es Onkoterapias CentrumBrasov, Romania.
RP Kovacs, P (reprint author), Diagnosztikai es Onkoterapias Centrum, Brasov, Romania.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 123
EP 123
PG 1
ER

PT J
AU Lakosi, F
   Hermesse, J
   Warlimont, B
   Ruyange, W
   Kridelka, F
   Gennigens, Ch
   Coucke, P
AF Lakosi, Ferenc
   Hermesse, Johanne
   Warlimont, Bernard
   Ruyange, Willy
   Kridelka, Frederic
   Gennigens, Christine
   Coucke, Philippe
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Hermesse, Johanne] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Warlimont, Bernard] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Ruyange, Willy] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Kridelka, Frederic] University Hospital of Liege, Department of GynecologyLiege, Belgium.
   [Gennigens, Christine] University Hospital of Liege, Department of OncologyLiege, Belgium.
   [Coucke, Philippe] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
RP Lakosi, F (reprint author), University Hospital of Liege, Department of Radiation Oncology, Liege, Belgium.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 123
EP 123
PG 1
ER

PT J
AU Laszlo, Z
   Csapo, L
   Musch, Z
   Sebestyen, Zs
   Farkas, R
   Kalincsak, J
   Karadi, O
   Mangel, L
AF Laszlo, Zoltan
   Csapo, Laszlo
   Musch, Zoltan
   Sebestyen, Zsolt
   Farkas, Robert
   Kalincsak, Judit
   Karadi, Oszkar
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Karadi, Oszkar] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Laszlo, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 123
EP 123
PG 1
ER

PT J
AU Locsei, Z
   Bellyei, Sz
   Csapo, L
   Sebestyen, Zs
   Mangel, L
AF Locsei, Zoltan
   Bellyei, Szabolcs
   Csapo, Laszlo
   Sebestyen, Zsolt
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 124
EP 124
PG 1
ER

PT J
AU Lorincz, 
   Antal, G
   Farkas, A
   Vandulek, Cs
   Hadjiev, J
   Repa, I
   Kovacs, �
AF Lorincz, G.
   Antal, Gergely
   Farkas, Andrea
   Vandulek, Csaba
   Hadjiev, Janaki
   Repa, Imre
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lorincz, G.] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Lorincz,  (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 124
EP 124
PG 1
ER

PT J
AU Major, T
   Agoston, P
   Szabo, Z
   Jorgo, K
   Baricza, K
   Frohlich, G
   Polgar, Cs
AF Major, Tibor
   Agoston, Peter
   Szabo, Zoltan
   Jorgo, Kliton
   Baricza, Karoly
   Frohlich, Georgina
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 124
EP 124
PG 1
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 124
EP 125
PG 2
ER

PT J
AU Maraz, A
   Furak, J
   Palfoldi, R
   Tiszlavicz, L
   Kahan, Zs
   Hideghety, K
AF Maraz, Aniko
   Furak, Jozsef
   Palfoldi, Regina
   Tiszlavicz, Laszlo
   Kahan, Zsuzsanna
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Palfoldi, Regina] SZTE, Pulmonologiai TanszekSzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 125
EP 125
PG 1
ER

PT J
AU Mayer, �
   Sinko, D
   Szarvas, V
   Szalai, T
AF Mayer, Arpad
   Sinko, Daniel
   Szarvas, Viktor
   Szalai, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szarvas, Viktor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Mayer, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 125
EP 125
PG 1
ER

PT J
AU Meszaros, N
   Major, T
   Stelczer, G
   Zaka, Z
   Mozsa, E
   Fodor, J
   Polgar, Cs
AF Meszaros, Norbert
   Major, Tibor
   Stelczer, Gabor
   Zaka, Zoltan
   Mozsa, Emoke
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 125
EP 125
PG 1
ER

PT J
AU Mozes, P
   Barzo, P
   Mencser, Z
   Kiss, D
   Tiszlavicz, L
   Valicsek, E
   Bartyik, K
   Cserhati, A
   Fodor, E
   Nagy, Z
   Egyud, Zs
   Borzasi, E
   Varga, L
   Hideghety, K
AF Mozes, Petra
   Barzo, Pal
   Mencser, Zoltan
   Kiss, Doloresz
   Tiszlavicz, Laszlo
   Valicsek, Erzsebet
   Bartyik, Katalin
   Cserhati, Adrienn
   Fodor, Emese
   Nagy, Zoltan
   Egyud, Zsofia
   Borzasi, Emoke
   Varga, Linda
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Mencser, Zoltan] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Kiss, Doloresz] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bartyik, Katalin] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Mozes, P (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 125
EP 126
PG 2
ER

PT J
AU Mozsa, E
   Meszaros, N
   Major, T
   Frohlich, G
   Sulyok, Z
   Fodor, J
   Polgar, Cs
AF Mozsa, Emoke
   Meszaros, Norbert
   Major, Tibor
   Frohlich, Georgina
   Sulyok, Zoltan
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sulyok, Zoltan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Mozsa, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 126
EP 126
PG 1
ER

PT J
AU Pasztine Gal, L
   Varga, T
   Kahan, Zs
   Varga, Z
AF Pasztine Gal, Laura
   Varga, Tne
   Kahan, Zsuzsanna
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pasztine Gal, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Tne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Pasztine Gal, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 126
EP 126
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 126
EP 126
PG 1
ER

PT J
AU Pesznyak, Cs
   Major, T
   Agoston, P
   Pocza, T
   Jorgo, K
   Szabo, Z
   Polgar, Cs
AF Pesznyak, Csilla
   Major, Tibor
   Agoston, Peter
   Pocza, Tamas
   Jorgo, Kliton
   Szabo, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pesznyak, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 126
EP 127
PG 2
ER

PT J
AU Petera, J
   Paulikova, S
   Sirak, I
   Vosmik, M
   Drastikova, M
   Dusek, L
   Cvanova, M
   Soumarova, R
   Spacek, J
   Beranek, M
AF Petera, Jiri
   Paulikova, Simona
   Sirak, Igor
   Vosmik, Milan
   Drastikova, Monika
   Dusek, Ladislav
   Cvanova, Michaela
   Soumarova, Renata
   Spacek, Jiri
   Beranek, Martin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petera, Jiri] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Paulikova, Simona] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Sirak, Igor] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Vosmik, Milan] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Drastikova, Monika] Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Institute for Clinical Biochemistry and DiagnosticsHradec Kralove, Czech Republic.
   [Dusek, Ladislav] Masaryk University, Institute of Biostatistics and AnalysesBrno, Czech Republic.
   [Cvanova, Michaela] Masaryk University, Institute of Biostatistics and AnalysesBrno, Czech Republic.
   [Soumarova, Renata] Cancer Centre Novy JicinNovy Jicin, Czech Republic.
   [Spacek, Jiri] Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Department of Obstetrics and GynecologyHradec Kralove, Czech Republic.
   [Beranek, Martin] Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Institute for Clinical Biochemistry and DiagnosticsHradec Kralove, Czech Republic.
RP Petera, J (reprint author), Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and Radiotherapy, Hradec Kralove, Czech Republic.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 127
EP 127
PG 1
ER

PT J
AU Pintye, �
   Balogh, I
   Dobos, E
   Hocza, G
   Kovacs, �
   Valastyanne Nagy, J
AF Pintye, Eva
   Balogh, Istvan
   Dobos, Erik
   Hocza, Gergely
   Kovacs, Arpad
   Valastyanne Nagy, Julianna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Dobos, Erik] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Hocza, Gergely] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Valastyanne Nagy, Julianna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Pintye, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 127
EP 127
PG 1
ER

PT J
AU Pocza, T
   Szilagyi, A
   Lovey, J
   Pesznyak, Cs
   Kontra, G
   Major, T
   Polgar, Cs
AF Pocza, Tamas
   Szilagyi, Andras
   Lovey, Jozsef
   Pesznyak, Csilla
   Kontra, Gabor
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pocza, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 127
EP 127
PG 1
ER

PT J
AU Polgar, Cs
   Major, T
   Sulyok, Z
   Fodor, J
AF Polgar, Csaba
   Major, Tibor
   Sulyok, Zoltan
   Fodor, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sulyok, Zoltan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 127
EP 127
PG 1
ER

PT J
AU Radics, E
   Agoston, P
   Meszaros, N
   Major, T
   Frohlich, G
   Jorgo, K
   Baricza, K
   Polgar, Cs
AF Radics, A. Erika
   Agoston, Peter
   Meszaros, Norbert
   Major, Tibor
   Frohlich, Georgina
   Jorgo, Kliton
   Baricza, Karoly
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Radics, A. Erika] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Radics, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 127
EP 128
PG 2
ER

PT J
AU Sebestyen, Zs
   Kovacs, P
   Farkas, R
   Bellyei, Sz
   Mangel, L
AF Sebestyen, Zsolt
   Kovacs, Peter
   Farkas, Robert
   Bellyei, Szabolcs
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 128
EP 128
PG 1
ER

PT J
AU Sebestyen, K
   Sebestyen, Zs
   Csapo, L
   Mangel, L
AF Sebestyen, Klara
   Sebestyen, Zsolt
   Csapo, Laszlo
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 128
EP 128
PG 1
ER

PT J
AU Simonne Revesz, J
   Halasz, J
   Laszlo, Z
   Mangel, L
AF Simonne Revesz, Judit
   Halasz, Judit
   Laszlo, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simonne Revesz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Simonne Revesz, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 128
EP 128
PG 1
ER

PT J
AU Sirak, I
   Petera, J
   Tucek, L
   Paluska, P
   Kasaova, L
   Paulikova, S
   Laco, J
AF Sirak, Igor
   Petera, Jiri
   Tucek, Lubos
   Paluska, Petr
   Kasaova, Linda
   Paulikova, Simona
   Laco, Jan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sirak, Igor] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Petera, Jiri] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Tucek, Lubos] University Hospital Hradec Kralove, Dept. of StomatologyHradec Kralove, Czech Republic.
   [Paluska, Petr] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Kasaova, Linda] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Paulikova, Simona] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and RadiotherapyHradec Kralove, Czech Republic.
   [Laco, Jan] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, The Fingerland Department of PathologyHradec Kralove, Czech Republic.
RP Sirak, I (reprint author), Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Department of Oncology and Radiotherapy, Hradec Kralove, Czech Republic.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 128
EP 129
PG 2
ER

PT J
AU Stefan, A
   Erdos, R
   Pocza, T
   Szekely, J
   Bajcsay, A
   Polgar, Cs
AF Stefan, Anita
   Erdos, Reka
   Pocza, Tamas
   Szekely, Judit
   Bajcsay, Andras
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stefan, Anita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Erdos, Reka] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stefan, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Stelczer, G
   Meszaros, N
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Stelczer, Gabor
   Meszaros, Norbert
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stelczer, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Szabo, H
   Szabo, Zs
   Vereb, B
   Laczo, I
   Banhegyi, R
   Groska, E
   Thurzo, L
   Piko, B
AF Szabo, Helga
   Szabo, Zsolt
   Vereb, Blanka
   Laczo, Ibolya
   Banhegyi, Robert
   Groska, Erika
   Thurzo, Laszlo
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Helga] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szabo, Zsolt] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Vereb, Blanka] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Banhegyi, Robert] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Groska, Erika] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Thurzo, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Szabo, H (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 129
EP 129
PG 1
ER

PT J
AU Szabo, I
   Opauszki, A
   Banyasz, T
AF Szabo, Imre
   Opauszki, Adrienn
   Banyasz, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Opauszki, Adrienn] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Banyasz, Tamas] University of Debrecen, Faculty of Medicine, Department of PhysiologyDebrecen, Hungary.
RP Szabo, I (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 129
EP 130
PG 2
ER

PT J
AU Szabo, Zs
   Vereb, B
   Szabo, H
   Groska, E
   Piko, B
AF Szabo, Zsolt
   Vereb, Blanka
   Szabo, Helga
   Groska, Erika
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsolt] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Vereb, Blanka] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szabo, Helga] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Groska, Erika] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Szabo, Zs (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Szantai, P
AF Szantai, Peterne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szantai, Peterne] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szantai, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Szappanos, Sz
   Locsei, Z
   Kalincsak, J
   Musch, Z
   Csapo, L
   Sebestyen, K
   Sebestyen, Zs
   Mangel, L
AF Szappanos, Szabolcs
   Locsei, Zoltan
   Kalincsak, Judit
   Musch, Zoltan
   Csapo, Laszlo
   Sebestyen, Klara
   Sebestyen, Zsolt
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Szappanos, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 130
EP 130
PG 1
ER

PT J
AU Szarvas, V
   Szalai, T
   Meszaros, E
   Landherr, L
AF Szarvas, L. Viktor
   Szalai, Tibor
   Meszaros, Edina
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szarvas, L. Viktor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Szarvas, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 130
EP 131
PG 2
ER

PT J
AU Szerdahelyi, T
   Fabian, N
   Lengyel, Zs
   Somogyine Ezer, �
   Hadjiev, J
   Repa, I
   Kovacs, �
AF Szerdahelyi, Tamasne
   Fabian, Nora
   Lengyel, Zsolt
   Somogyine Ezer, Eva
   Hadjiev, Janaki
   Repa, Imre
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szerdahelyi, Tamasne] Pozitron Diagnosztika KftBudapest, Hungary.
   [Fabian, Nora] Pozitron Diagnosztika KftBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Somogyine Ezer, Eva] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Szerdahelyi, T (reprint author), Pozitron Diagnosztika Kft, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Szilagyi, A
   Pocza, T
   Bajcsay, A
   Major, T
   Polgar, Cs
   Lovey, J
AF Szilagyi, Andras
   Pocza, Tamas
   Bajcsay, Andras
   Major, Tibor
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szilagyi, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 131
EP 131
PG 1
ER

PT J
AU Szilagyi, Cs
   Nemes, J
   Papp, J
   Pintye, �
   Horvath, Zs
AF Szilagyi, Csaba
   Nemes, Judit
   Papp, Judit
   Pintye, Eva
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Csaba] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Nemes, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Szilagyi, Cs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 131
EP 132
PG 2
ER

PT J
AU Szluha, K
   Furka, A
   Szabo, I
   Miko, I
   Kiss, F
   Pintye, �
   Nemeth, N
AF Szluha, Kornelia
   Furka, Andrea
   Szabo, Imre
   Miko, Iren
   Kiss, Ferenc
   Pintye, Eva
   Nemeth, Norbert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Furka, Andrea] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Miko, Iren] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Kiss, Ferenc] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Nemeth, Norbert] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
RP Szluha, K (reprint author), Semmelweis University, Department of Radiology and Oncotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Oberna, F
   Koltai, P
   Hitre, E
   Major, T
   Fodor, J
   Polgar, Cs
AF Takacsi-Nagy, Zoltan
   Oberna, Ferenc
   Koltai, Pal
   Hitre, Erika
   Major, Tibor
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Koltai, Pal] National Institute of Oncology, Department of Head and Neck SurgeryBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Toller, G
   Farkas, A
   Rajczi, P
   Battyani, Z
   Lakosi, F
   Vandulek, Cs
   Hadjiev, J
   Repa, I
AF Toller, Gabor
   Farkas, Andrea
   Rajczi, Petra
   Battyani, Zita
   Lakosi, Ferenc
   Vandulek, Csaba
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Rajczi, Petra] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Battyani, Zita] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Toller, G (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Urbancsek, H
   Opauszki, A
   Szabo, I
   Adamecz, Zs
   Horvath, Zs
AF Urbancsek, Hilda
   Opauszki, Adrienn
   Szabo, Imre
   Adamecz, Zsolt
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Urbancsek, Hilda] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Opauszki, Adrienn] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Adamecz, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Urbancsek, H (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 132
EP 132
PG 1
ER

PT J
AU Varady, Gy
   Vereckei, E
   Arany, M
   Racsko, G
   Mangel, L
AF Varady, Gyongyi
   Vereckei, Erika
   Arany, Magdolna
   Racsko, Gaborne
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Vereckei, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Arany, Magdolna] University of Pecs, Department of OncologyPecs, Hungary.
   [Racsko, Gaborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Varady, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 132
EP 133
PG 2
ER

PT J
AU Varga, L
   Hideghety, K
   Kahan, Zs
   Bartyik, K
   Kaiser, L
AF Varga, Linda
   Hideghety, Katalin
   Kahan, Zsuzsanna
   Bartyik, Katalin
   Kaiser, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bartyik, Katalin] University of Szeged, Department of PediatricsSzeged, Hungary.
   [Kaiser, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 133
EP 133
PG 1
ER

PT J
AU Varga, Sz
   Agoston, P
   Major, T
AF Varga, Szilvia
   Agoston, Peter
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varga, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 133
EP 133
PG 1
ER

PT J
AU Varga, Z
   Kiscsatari, L
   Borzasi, E
   Varga, L
   Kelemen, Gy
   Kahan, Zs
AF Varga, Zoltan
   Kiscsatari, Laura
   Borzasi, Emoke
   Varga, Linda
   Kelemen, Gyongyi
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kiscsatari, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 133
EP 133
PG 1
ER

PT J
AU Varjas, G
   Major, T
   Pesznyak, Cs
   Polgar, Cs
AF Varjas, Geza
   Major, Tibor
   Pesznyak, Csilla
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varjas, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 133
EP 134
PG 2
ER

PT J
AU Vegvary, Z
   Cserhati, A
   Mozes, P
   Egyud, Zs
   Varga, L
   Borzasi, E
   Szanto, E
   Fodor, E
   Hideghety, K
   Kahan, Zs
AF Vegvary, Zoltan
   Cserhati, Adrienn
   Mozes, Petra
   Egyud, Zsofia
   Varga, Linda
   Borzasi, Emoke
   Szanto, Erika
   Fodor, Emese
   Hideghety, Katalin
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Vereb, B
   Szabo, H
   Szabo, Zs
   Rus-Gal, PO
   Laczo, I
   Torok, E
   Hideghety, K
   Piko, B
AF Vereb, Blanka
   Szabo, Helga
   Szabo, Zsolt
   Rus-Gal, Paul Ovidiu
   Laczo, Ibolya
   Torok, Eniko
   Hideghety, Katalin
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vereb, Blanka] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szabo, Helga] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szabo, Zsolt] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Rus-Gal, Paul Ovidiu] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Torok, Eniko] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Vereb, B (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Vereckei, E
   Weiczl, H
   Csapo, L
   Schipp, I
   Al-Farhat, Y
   Mangel, L
   Boronkai, �
AF Vereckei, Erika
   Weiczl, Hajnalka
   Csapo, Laszlo
   Schipp, Ildiko
   Al-Farhat, Yousuf
   Mangel, Laszlo
   Boronkai, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vereckei, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Weiczl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
RP Vereckei, E (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 134
EP 134
PG 1
ER

PT J
AU Vicini, F
AF Vicini, A. Frank
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vicini, A. Frank] William Beaumont Hospital, The Beaumont Cancer CentreRoyal Oak, MI, USA.
RP Vicini, F (reprint author), William Beaumont Hospital, The Beaumont Cancer Centre, Royal Oak, USA.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 134
EP 135
PG 2
ER

PT J
AU Vizkeleti, J
   Vereczkey, I
   Pete, I
   Mayer, �
   Nemeskeri, Cs
   Frohlich, G
   Varga, Sz
   Pulay, T
   Sipos, N
   Kasler, M
   Polgar, Cs
AF Vizkeleti, Julia
   Vereczkey, Ildiko
   Pete, Imre
   Mayer, Arpad
   Nemeskeri, Csaba
   Frohlich, Georgina
   Varga, Szilvia
   Pulay, Tamas
   Sipos, Norbert
   Kasler, Miklos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Sipos, Norbert] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2013
VL 57
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Boncz, I
   Dobrossy, L
   Pentek, Z
   Kovacs, A
   Budai, A
   Vajda, R
   Sebestyen, A
AF Boncz, Imre
   Dobrossy, Lajos
   Pentek, Zoltan
   Kovacs, Attila
   Budai, Andras
   Vajda, Reka
   Sebestyen, Andor
TI The attendance of the third (2006–2007) screening round of the Hungarian organised breast cancer screening programme
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emlorak; emloszures; lakossagi szures; atszurtseg; Magyarorszag
ID emlorak; emloszures; lakossagi szures; atszurtseg; Magyarorszag
AB Organised, nationwide screening for breast cancer with mammography in the age group of 45–65 years with 2 years screening interval started in Hungary in January 2002. The aim of this study is to analyse the attendance rate of breast screening programme for the 2006/2007 years, including the analysis of the ratio of screening and diagnostic mammography examinations. The data derive from the financial database of the National Health Insurance Fund Administration (NHIFA) covering the 8 years period between 2000 and 2007. The ratio of women in the age group of 45–65 years was calculated having either a screening mammography or a diagnostic mammography. The analysis was carried out for the years 2000–2001 before and 2006–2007 after the implementation of nationwide organised programme. In the years 2000–2001 7.26% of the women aged 45–65 years had an opportunistic screening mammography while in 2006–2007 29.4% of the target population had screening mammography within the organised programme. During the same periods 19.8% (2000–2001) and 21.8% (2006–2007) of women aged 45–65 years had a diagnostic mammography. Thus the total (screening and diagnostic) coverage of mammography increased from 26.2% (2000–2001) to 49.7% (2006–2007). The attendance of the Hungarian organised breast cancer screening programme slightly declined in 2006–2007 compared to 2002–2003/2004–2005, and to achieve the expected results in mortality decrease a further improvement of the uptake is necessary.
C1 [Boncz, Imre] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
   [Dobrossy, Lajos] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Pentek, Zoltan] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Kovacs, Attila] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Budai, Andras] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Vajda, Reka] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
   [Sebestyen, Andor] Orszagos Egeszsegbiztositasi Penztar, Del-Dunantuli Teruleti HivatalPecs, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, 7621 Pecs, Hungary.
EM imre.boncz@etk.pte.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 140
EP 146
PG 7
ER

PT J
AU Mihaly, Zs
   Gyorffy, B
AF Mihaly, Zsuzsanna
   Gyorffy, Balazs
TI HER2-positive breast cancer: available targeted agents and biomarkers of therapy response
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE HER2; emlorak; biomarkerek; trastuzumab; celzott terapia
ID HER2; emlorak; biomarkerek; trastuzumab; celzott terapia
AB In the last decade, the targeted therapy of breast cancer became part of routine clinical protocols all over the globe. Options in today’s targeted therapy include hormonal therapy and the modulation of the EGFR/HER-pathway. Of the four HER receptors, HER2 is the target of currently used treatment strategies. HER2 activates multiple intracellular pathways via RAS, RAF and PI3K. We give a comprehensive summary of approved monoclonal antibodies and tyrosine kinase inhibitors acting over HER2, including trastuzumab, lapatinib and pertuzumab. We elaborate on their mechanism of action and on clinical trials behind their approval. Agents in third phase clinical studies (neratinib, afatinib) are also described. We give a brief overview of agents currently in phase I and phase II studies; these are acting over the PI3K pathway, over IGFR1 and over HSP90. Furthermore, currently validated negative biomarkers (markers predicting lack of response) in clinical use are also summarized. Finally, the major bottlenecks of clinical application including tumor heterogeneity and the high diversity of clinical studies are discussed. For a breakthrough we will need to identify new positive biomarkers of therapy response.
C1 [Mihaly, Zsuzsanna] Semmelweis University, 1st Department of Pediatrics, Bokay u. 53-54., 1083 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 1st Department of Pediatrics, Bokay u. 53-54., 1083 Budapest, Hungary.
RP Mihaly, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, 1083 Budapest, Hungary.
EM zsuzsannamihaly@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 147
EP 156
PG 10
ER

PT J
AU Dank, M
   Tokes, T
AF Dank, Magdolna
   Tokes, Timea
TI Monoclonal antibody therapy in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE emlorak; monoklonalis antitest; molekularis celzott terapia; szemelyre szabott terapia
ID emlorak; monoklonalis antitest; molekularis celzott terapia; szemelyre szabott terapia
AB A new tendency occurred in the daily oncological practice in the past twenty years: we are progressively moving forward to the individualized and personalized treatments. The treatment of breast cancer is one of the best examples to underline the outstanding efficiency of the individualized approach. The modern molecular pathological features are capable of the exact mapping of the biological behavior of the tumors which gives a new basis for our therapeutic choices, both for neoadjuvant and adjuvant settings, as well as for metastatic disease. In our paper we would like to review the currently used monoclonal antibodies in the treatment of breast cancer and overview the new researches and future directions in this field.
C1 [Dank, Magdolna] Semmelweis University, 1st Department of Internal Medicine, Tomo utca 25-29., 1083 Budapest, Hungary.
   [Tokes, Timea] Semmelweis University, 1st Department of Internal Medicine, Tomo utca 25-29., 1083 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1083 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 157
EP 165
PG 9
ER

PT J
AU Nemeth, Zs
   Turi, K
   Lehner, Gy
   Veres, DS
   Csurgay, K
AF Nemeth, Zsolt
   Turi, Katalin
   Lehner, Gyorgy
   Veres, Daniel Sandor
   Csurgay, Katalin
TI The prognostic role of age in oral cancer. A clinical study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE szajuregi daganat; eletkor; nem; prognozis; daganatspecifikus tuleles
ID szajuregi daganat; eletkor; nem; prognozis; daganatspecifikus tuleles
AB The problem of malignant tumors developing in a young age is a topic of special importance and subject of intensive research. The occurrence of oral cavity tumors shows a decreasing trend worldwide, while the incidences of oral squamous cell carcinoma diagnosed at young adulthood is increasing. The etiology of tumors developing in young age is not yet fully understood, however, it can be stated that the usual high-risk behavioral patterns (i.e. smoking and alcohol abuse) play only a minor role in this patient group, if any. Our own observations indicate a higher regional and locoregional relapse for these patients and, although they turn for help early, at an early stage of the disease, a lower chance of survival. The target of our research was to analyze the differences in certain etiological, pathological and clinical parameters of our own patient group consisting of both young and older patients. The data of 105 young (<50 years) and, as a control group, 105 older (>50 years) patients were analyzed. The patients have undergone surgery and, if necessary, radiotherapy and/or chemotherapy. The tumor-specific survival was determined at 36 months. Our study aimed at understanding the relationship between the clinical prognostic factors (stage, localization, anamnestic time), smoking habits, gender and age of the patients. Relationship between cancer occurrence (local, locoregional relapse) and survival rate, as well as age and survival rate were analyzed. We found that young patients report themselves for treatment at an early stage. Smoking and alcohol abuse were considerably less. When a relapse occurs, it occurs more frequently and earlier than at older patients. The most decisive correlation was observed between age and anamnestic time, age and number of cigarettes smoked, age and time elapsed until relapse, as well as age and cancer-specific survival. Moreover, cancer-specific survival of patients younger than 50 years of age was found significantly shorter than in the control group.
C1 [Nemeth, Zsolt] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
   [Turi, Katalin] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
   [Lehner, Gyorgy] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
   [Veres, Daniel Sandor] Semmelweis University, Department of Biophysics and Radiation BiologyBudapest, Hungary.
   [Csurgay, Katalin] Semmelweis University, Department of Oral and Maxillofacial Surgery, Maria u. 52., 1085 Budapest, Hungary.
RP Nemeth, Zs (reprint author), Semmelweis University, Department of Oral and Maxillofacial Surgery, 1085 Budapest, Hungary.
EM nemeth.zsolt@dent.semmelweis-univ.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 166
EP 172
PG 7
ER

PT J
AU Maraz, A
   Bodrogi, I
   Csejtei, A
   Dank, M
   Geczi, L
   Kuronya, Zs
   Mangel, L
   Petranyi, �
   Szucs, M
   Bodoky, Gy
AF Maraz, Aniko
   Bodrogi, Istvan
   Csejtei, Andras
   Dank, Magdolna
   Geczi, Lajos
   Kuronya, Zsofia
   Mangel, Laszlo
   Petranyi, Agota
   Szucs, Miklos
   Bodoky, Gyorgy
TI First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE attetes veserak; VEGFR-gatlo; pazopanib; TKI; mellekhatas
ID attetes veserak; VEGFR-gatlo; pazopanib; TKI; mellekhatas
AB Pazopanib, a tyrosine kinase inhibitor, is one of the new registered first-line therapeutic options in the treatment of metastatic clear cell renal carcinoma. Our aim was to evaluate the efficiency and toxicity of first-line pazopanib therapy administered for patients with metastatic clear cell renal carcinoma with good- and medium prognosis according to MSKCC criteria. Between January and May, 2011, 24 patients have been treated with pazopanib in 8 oncology centers in Hungary, out of them 21 patients’ data were analyzed. The mean age was 65.3 (49–81) years, 10 males and 11 females. According to MSKCC the prognosis was good and medium in 3 and 18 cases, respectively. Daily dose of pazopanib was 800 mg administered continuously in 28 day cycles. Dose reduction was performed according to the instructions of the registration study. Tumor response was evaluated according to RECIST 1.0. Currently 6 (28.6%) patients are on treatment. Dose reduction was necessary in 6 (28.6%) cases with an average duration of 14.55 (7–150) days. Mean±SE daily dose was 692.97±13.67 (400–800) mg. Median PFS was 12.41 months (95% CI 11.52–12.94 months). Complete remission (CR), as the best tumor response occurred in 2 (9.5%) cases. Partial remission (PR), stable disease (SD) and progression was observed in 6 (28.6%), 10 (47.6%) and 3 (14.3%) cases, respectively. Objective tumor response was observed in 8 pts (38%). Median survival could not be statistically analyzed yet due to the insignificant number of fatal outcomes. Median follow-up was 25.22 months (95% CI 2.47–28.1 months). As common side-effect fatigue, weakness and diarrhea occurred in 11 (52.4%), 9 (42.9%) and 8 (38%) cases, respectively. Besides these, worsening of high blood pressure and ALT/AST elevation was observed in 5 (23.8%) and 6 (28.6%) cases, respectively. Based on the initial Hungarian experiences, pazopanib is a well tolerable product and can be administered safely. According to our results its efficiency in terms of tumor response and progression-free survival is comparable to the results of the registration study.
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bodrogi, Istvan] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 173
EP 176
PG 4
ER

PT J
AU Lengyel, Z
   Boer, K
   Halaszlaki, Cs
   Nemeth, Zs
AF Lengyel, Zoltan
   Boer, Katalin
   Halaszlaki, Csaba
   Nemeth, Zsuzsanna
TI Diabetes in patients with malignant tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE diabetes; malignus tumor; inzulin; hypoglykaemia; dieta
ID diabetes; malignus tumor; inzulin; hypoglykaemia; dieta
AB Disturbances of the carbohydrate metabolism are fairly common is patients with malignancy. On the other hand, diabetes appears to have an effect on the development and progression of various tumors. Malignant diseases and the therapies used in their treatment often have an impact on carbohydrate metabolism, while diabetes may hinder specific oncotherapy or influence oncological therapeutic decisions. Several complications of malignant diseases and some of the medications used in their treatment, such as steroids or parenteral nutrition, may raise blood glucose levels. The various obstacles of oral nutrition frequently seen in patients with malignancy can lead to hypoglycaemia in patients with diabetes. Our article endeavours to review the pathophysiological and clinical connection between diabetes and malignant diseases and the use of insulin, oral antidiabetic drugs and diet in patients with malignant disease.
C1 [Lengyel, Zoltan] Szent Margit Korhaz, Altalanos Belgyogyaszati Osztaly, Becsi ut 132., 1032 Budapest, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Halaszlaki, Csaba] Szent Margit Korhaz, Altalanos Belgyogyaszati Osztaly, Becsi ut 132., 1032 Budapest, Hungary.
   [Nemeth, Zsuzsanna] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
RP Lengyel, Z (reprint author), Szent Margit Korhaz, Altalanos Belgyogyaszati Osztaly, 1032 Budapest, Hungary.
EM lengyeldr@sztmargit.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 177
EP 181
PG 5
ER

PT J
AU Godeny, M
AF Godeny, Maria
TI Role and responsibility of multimodal imaging in head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE rak; fej-nyaki daganat; MRI; CT; PET/CT
ID rak; fej-nyaki daganat; MRI; CT; PET/CT
AB Hungary is first in head and neck cancer mortality in Europe in men and also in women. Head and neck (HN) is a difficult region, its anatomy and also pathology is very complex, various connection points exist between the sites which determine the extension of the disease. Diagnostic algorithms as well as imaging techniques have to be optimized to examine in standard manner. Like most other cancers, prognosis depends largely on the stage of the tumor. Accuracy of tumor detection and evaluation is very important because it affects treatment planning. As non-surgical organ-preserving therapeutic modalities (chemotherapy, chemoradiotherapy, targeted biological therapy) gain general acceptance, the importance of noninvasive diagnostic accuracy as well as radiologic evaluation of the extent of the tumor has increased. Clinical examinations including endoscopy should be combined with radiologic imaging to assess the precise local (T), regional nodal (N), and distant (M) extent of the tumor. Computed tomography (CT) and magnetic resonance imaging (MRI) have become basic tools in the diagnosis of head and neck tumors. They are both useful for assessing deep tumor extensions, able to detect changes missed by endoscopy. It has been shown that the primary determined tumor stage increases in up to 90% of patients after the results of cross sectional imaging. MRI is being increasingly used and has become the gold standard in head and neck cancer for staging, assessing tumor response, finding recurrent tumor and also for treatment planning in radiotherapy. The field strength of MRI scanners has been increasing to 1.5 T and now 3 T with better signal-to-noise ratio, higher resolution images and better tissue diagnosis. Functional MR techniques such as dynamic contrast enhanced MRI (DCE-MRI) and diffusion weighted MRI (DW-MRI) may provide further characterization. PET/CT is beneficial in detecting unsuspected metastatic nodes, distant disease and second primary tumor. PET/CT and MRI both appeared almost similarly accurate in the detection of an occult primary tumor. The effective management of patients depends highly on the competece of radiologists and requires close collaboration between clinical and surgical oncologists, diagnostic and therapeutic radiologists as well as pathologists.
C1 [Godeny, Maria] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM godeny.maria@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 182
EP 202
PG 21
ER

PT J
AU Dudnyikova, A
   Horvath, K
   Pete, I
AF Dudnyikova, Anna
   Horvath, Katalin
   Pete, Imre
TI Endometrial cancer in young patients: report of 17 cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE endometriumcarcinoma; fiatal eletkor; PCO-szindroma
ID endometriumcarcinoma; fiatal eletkor; PCO-szindroma
AB Endometrial cancer of young (less then 40 years old) patients comprises 4-5% of all endometrial cancers in Hungary. The majority of patients did not give birth yet, so fertility sparing is very important. Fertility sparing treatment is possible if the tumor’s histology is endometrial type and Grade 1 (well differentiated). The tumor localizes only to the endometrium and there is no myometrium infiltration. The authors present 17 cases of patients treated at the Department of Gynecology of National Institute of Oncology (Budapest, Hungary). In 3 cases conservative therapy (progesterone treatment) was possible, and 14 patients had to undergo surgery, because conservative treatment did fail. Of 17 patients 14 were never pregnant. The average patient’s age was 32.35 ± 4.27 years. The mean body weight was 93.13 ± 30.79 kg (from 58 kg up to 147 kg); in 7 cases BMI (body mass index) was more than 30. After surgery histological examination had revealed 2 cases with normal ovaries, 1 case of simple cyst and 1 case of malignant ovarian tumor (serous adenocarcinoma, Grade 2), and 10 cases of polycystic ovaries associated with endometrial cancer. Of 3 cases that had only curettage, the endometrial cancer was Grade 1, and in 1 case radiological imaging showed simplex ovarian cyst. The authors’ findings concerning young endometrial cancer patients confirm the results published in the literature. In cases suitable for fertility sparing treatment it is not sufficient to concentrate only on endometrial findings, but is very important to focus on the therapy of cystic ovaries (80% of which is PCO), obesity and diabetes mellitus as well.
C1 [Dudnyikova, Anna] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Dudnyikova, A (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM dudnyik@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 203
EP 206
PG 4
ER

PT J
AU Szaloki, AE
   Vereczkey, I
   Pete, I
AF Szaloki, Aliz Eszter
   Vereczkey, Ildiko
   Pete, Imre
TI Appendiceal mucocele as differential diagnostic problem of palpable mass in the right lower abdominal region
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE feregnyulvany-mucocele; petefeszektumor; esetismertetes
ID feregnyulvany-mucocele; petefeszektumor; esetismertetes
AB Appendiceal mucocele is a rare disease (0.2-0.3% of all appendectomies) and it is defined as abnormal accumulation of mucoid material in the appendiceal lumen. Almost half of the patients are asymptomatic. The most common clinical manifestation is pain and palpable mass in the right iliac fossa, which is difficult to differentiate from the malignant or benign adnexal masses. By presenting our three cases, we would like to draw attention to the diagnostic difficulties of the pain and palpable mass in the right lower abdominal region.
C1 [Szaloki, Aliz Eszter] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Szaloki, AE (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM szaloki.aliz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2013
VL 57
IS 3
BP 207
EP 210
PG 4
ER

PT J
AU Turanyi, E
   Hanzely, Z
   Balint, K
   Reiniger, L
AF Turanyi, Eszter
   Hanzely, Zoltan
   Balint, Katalin
   Reiniger, Lilla
TI The role of the pathologist in the diagnosis and therapy planning of central nervous system tumors. Prognostic and predictive markers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kozponti idegrendszeri daganatok; patologiai diagnozis; prognosztikus marker; prediktiv marker; neuropatologia
ID kozponti idegrendszeri daganatok; patologiai diagnozis; prognosztikus marker; prediktiv marker; neuropatologia
AB Despite advances in imaging methods, the standard of diagnosis and treatment of the tumours of the nervous system remains the histological report issued by a neuropathologist. For reliable, definitive diagnosis, close collaboration with other medical professions is essential, correlation of histological findings with clinical and imaging results is necessary. Neuropathology became a subspecialty because of the specific knowledge and experience it requires. In more complex cases consultation with neuropathologists is important to ensure adequate diagnosis and subsequent treatment. In both establishing the diagnosis and treatment planning, the molecular testing of brain tumors becomes more and more important. These tests are reliably available only in larger centers. Out of the molecular markers, in current practice the investigation of codeletion at 1p/19q, IDH mutations, β-katenin nuclear positivity and MGMT methylation gained acceptance. Besides these tests already in practice, a vast array of potential diagnostic and prognostic markers are being investigated, which in the future may assist in delivering better and more individualized therapy.
C1 [Turanyi, Eszter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26.Budapest, Hungary.
   [Hanzely, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26.Budapest, Hungary.
   [Balint, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26.Budapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26.Budapest, Hungary.
RP Turanyi, E (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
EM turanyi@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 215
EP 221
PG 7
ER

PT J
AU Klekner, �
   Virga, J
   Toth, J
   Hortobagyi, T
   Der, �
   Szemcsak, Cs
   Bognar, L
AF Klekner, Almos
   Virga, Jozsef
   Toth, Judit
   Hortobagyi, Tibor
   Der, Adam
   Szemcsak, Csaba
   Bognar, Laszlo
TI The role of extracellular matrix components in the invasion of intracranial malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE agydaganat; glioma; invazio; extracellularis matrix; onkoterapia
ID agydaganat; glioma; invazio; extracellularis matrix; onkoterapia
AB The usual local recurrence of primary brain tumors is mainly due to the infiltration of adjacent brain parenchyma by the glioma cells. This invasive feature of the tumors makes total surgical excision impossible and also decreases the efficacy of focal radiotherapy. Interestingly, intracerebral metastases originating from many anaplastic tumors of other organs perform very moderate peritumoral infiltration, therefore radical resection can be routinely achieved and focal irradiation, even stereotactic radiotherapy, provides good tumor control. Differences in the effectiveness of treatment between the two tumor types derive from the remarkably different extent of peritumoral infiltration. Thus significant molecular biological research has been dealing with the infiltrative activity of various brain tumors and many attempts were made to develop anti-invasive drugs for oncotherapy. This review summarizes the results of these studies, describing cellular and molecular events of brain tumor invasion and according potential oncotherapeutic possibilities.
C1 [Klekner, Almos] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei krt.98., 4032 Debrecen, Hungary.
   [Virga, Jozsef] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei krt.98., 4032 Debrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Hortobagyi, Tibor] Debreceni Egyetem OEC, Neuropatologiai TanszekDebrecen, Hungary.
   [Der, Adam] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szemcsak, Csaba] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei krt.98., 4032 Debrecen, Hungary.
   [Bognar, Laszlo] University of Debrecen, Clinical Center, Department of Neurosurgery, Nagyerdei krt.98., 4032 Debrecen, Hungary.
RP Klekner, � (reprint author), University of Debrecen, Clinical Center, Department of Neurosurgery, 4032 Debrecen, Hungary.
EM aklekner@yahoo.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 222
EP 231
PG 10
ER

PT J
AU Lovey, J
   Fedorcsak, I
   Bajcsay, A
   Sipos, L
   Mangel, L
   Kasler, M
   Bago, A
AF Lovey, Jozsef
   Fedorcsak, Imre
   Bajcsay, Andras
   Sipos, Laszlo
   Mangel, Laszlo
   Kasler, Miklos
   Bago, Attila
TI Results of postoperative radiochemotherapy of glioblastoma multiforme
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE glioblastoma; sugarkezeles; temozolomid; adjuvans
ID glioblastoma; sugarkezeles; temozolomid; adjuvans
AB Glioblastoma multiforme has one of the worst prognoses of all cancers. A substantial progression in its treatment has been achieved only eight years ago when a new adjuvant radiochemotherapy regimen containing temozolomid has been introduced to the clinical practice. In this paper we evaluate the treatment results in adjuvant radiochemotherapy of glioblastoma carried out by two neurosurgery and oncology centers in Budapest, Hungary and we compared our results to the data of the reference phase III registration trial of the EORTC/NCIC. We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013. The primary endpoints of our study were overall survival and side effects. We studied and statistically analyzed the influence of multiple factors on survival. We compared our results with the data of the reference study and other results published in the literature. The median follow-up for the surviving patients in our study was 52 months. The median age of our patients was 58 (18-79) years. Seventy-two women and 138 men have been treated. The median overall survival was 17 (3-96) months, the progression-free survival 11 (3-96) months. The radiochemotherapy phase was completed in 95.2% and the monotherapy phase in 68% of all cases.Univariate analysis showed that age, ECOG status and RPA class had significant influence on survival. In multivariate analysis only RPA class remained statistically significant (RR 1.86, 95% CI 1.14-3.05). The proportion of grade III and worse side effects during the chemoradiation phase was 3.8% and in the monotherapy phase 1.9%. These were hematological side effects only. Serious hematological sequelae occurred nearly exclusively in women. Comparing to the reference study the demographic distribution of the patients was similar in our study but among our patients there were less patients with unfavorable prognosis (ECOG 2 or RPA V), and it resulted in a longer median survival than in the original trial (17 vs. 14.6 months). With this analysis of our patients treated according to the Stupp-protocol for glioblastoma multiforme we validated the results of the original EORTC/NCIC study in a Hungarian patient population. Moreover, this comparison proves that the comprehensive Hungarian neuro-oncology service is not at all inferior when compared to any of the developed countries in Europe.
C1 [Lovey, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Fedorcsak, Imre] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Sipos, Laszlo] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bago, Attila] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 232
EP 239
PG 8
ER

PT J
AU Bago, AGy
   Osztie, �
   Varallyay, P
   Fedorcsak, I
AF Bago, Attila Gyorgy
   Osztie, Eva
   Varallyay, Peter
   Fedorcsak, Imre
TI Treatment-induced tumor-like lesions in the course of neurooncological therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE agydaganat; radio-kemoterapia; pszeudoprogresszio; sugarnekrozis; sztereotaxias sugarsebeszet
ID agydaganat; radio-kemoterapia; pszeudoprogresszio; sugarnekrozis; sztereotaxias sugarsebeszet
AB The proper interpretation of imaging changes in the course of multimodal neurooncological therapy (neurosurgery, radiotherapy, chemotherapy, stereotactic radiosurgery) is crucial. The appearance of abnormal or new contrast-enhancing lesions does not indicate obvious tumor progression, in the contrary they are frequently induced by the oncological therapy itself. The differentiation of real tumor progression from therapy-induced lesions is essential, since the diagnosis of progressive disease results in the termination of the current regimen and initiation of second or third line therapy, if possible. The most common frequent therapy-induced tumor-like lesions include the followings: pseudoprogression seen at 1-3 months after the completion of concomittant radiochemotherapy of high-grade gliomas, real radiation necrosis which can develop even years after the completion of fractionated external beam radiotherapy of gliomas, and radiation necrosis seen after stereotactic radiosurgery delivered to metastatic brain tumors. The absorbable hemostatic materials applied to the wall of resection cavity during brain tumor surgery might cause delayed disturbancies in the blood brain barrier, inducing abnormal signal changes and contrast enhancement mimicking residual or recurrent tumor. Cerebrovascular ischemic lesions might cause cortical enhancement in the subacute stage, which may be misinterpreted as leptomeningeal tumor spread. The correct assessment of imaging findings requires special knowledge and multidisciplinary consultation, therefore the treatment and follow-up of brain tumor patients should be linked to brain tumor centers staffed by experts in the field of neurosurgery, neurooncology and brain tumor imaging.
C1 [Bago, Attila Gyorgy] National Institute of Clinical Neurosciences, Amerikai ut 57., 1145 Budapest, Hungary.
   [Osztie, Eva] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Varallyay, Peter] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical Neurosciences, Amerikai ut 57., 1145 Budapest, Hungary.
RP Bago, AGy (reprint author), National Institute of Clinical Neurosciences, 1145 Budapest, Hungary.
EM bagoatt@hotmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 240
EP 250
PG 11
ER

PT J
AU Horvath, Zs
   Bellyei, Sz
   Farkas, R
   Mangel, L
   Kovacs, P
   Sebestyen, Zs
   Doczi, T
AF Horvath, Zsolt
   Bellyei, Szabolcs
   Farkas, Robert
   Mangel, Laszlo
   Kovacs, Peter
   Sebestyen, Zsolt
   Doczi, Tamas
TI Fractionated stereotactic irradiation of skull-base related tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE agydaganat; frakcionalt sugarterapia; koponyaalapi tumorok; sugarsebeszet; sztereotaxias besugarzas
ID agydaganat; frakcionalt sugarterapia; koponyaalapi tumorok; sugarsebeszet; sztereotaxias besugarzas
AB The prognosis of the treatment of brain tumours depends on two main factors: biological nature and localisation of the neoplasm. Requirements of oncologic surgery can be met only partially if at all in neurological surgery of brain tumours. Resectability depends primarily on localisation of the neoplasms. The leading principle is preservation of fine neural structures, minimising morbidity from tissue resection with the goal of maximal tumour resection. As nervous structures and the target volume do not move in the intracranial space, large radiation doses unusual in traditional radiotherapy can be given either in one or in fractionated sessions to small targets (point-radiation) and a well-controlled radiation necrosis of the pathological tissue can be achieved. Management principles of treatment of skull-base related tumours are very similar due to high risks of functional morbidity evoked by surgical injury to the cranial nerves, brainstem structures, vessels of the Willis circle and those of the substantia perforata anterior and posterior, etc. Such tumours are neoplasms arising from the skull base, those infiltrating the cavernous sinuses, invasive pituitary tumours, those arising from the glomus jugulare, or located within the cerebello-pontine angle, etc. This manuscript intends to illustrate and prove the hypothesis by means of 4 cases that fractionated stereotactic radiotherapy (fSRT) is an important part of treatment armamentarium in the latter cases, as it is capable of exploiting both the advantages of traditional fractionated irradiation and that of the high conformality and selectivity of radiosurgery. It is capable of administering appropriate quantity of total target dose with a lower than limit dose on surrounding structures. The presentation proves that fSRT can be planned already in the phase of surgical indication as a „microsurgery-assisted radiotherapy”.
C1 [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Doczi, Tamas] University of Pecs, Department of NeurologyPecs, Hungary.
RP Doczi, T (reprint author), University of Pecs, Department of Neurology, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 251
EP 258
PG 8
ER

PT J
AU Hauser, P
   Vancso, I
   Pocza, T
   Schuler, D
   Garami, M
AF Hauser, Peter
   Vancso, Ildiko
   Pocza, Timea
   Schuler, Dezso
   Garami, Miklos
TI Antiangiogenic treatment of pediatric CNS tumors in Hungary with Kieran schedule
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE angiogenezis-gatlas; recidiva; gyermekkor; kozponti idegrendszeri daganat; daganatellenes terapia
ID angiogenezis-gatlas; recidiva; gyermekkor; kozponti idegrendszeri daganat; daganatellenes terapia
AB In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at Semmelweis University on individual decisions a daily combined per oral treatment was introduced in pediatric patients with recurrent or progressive CNS tumor (Kieran schedule: thalidomid, celecoxib, etoposid and cyclophosphamid). Efficacy of therapy was analyzed in terms of demographic data, histology, side effects and tolerability in a retrospective manner. From 2010 through 2013, twenty patients were treated with Kieran schedule (medulloblastoma: 3, ependymoma: 5, anaplastic astrocytoma: 2, GBM: 4, plexus choroideus carcinoma: 1, central primitive neuroectodermal tumor: 1, optic glioma: 2, brainstem tumor: 2). Median treatment time and median progression-free survival were 0.60 and 0.61 years, respectively. Based on the preliminary analysis of a limited cohort of patients, the therapy was efficient in those cases of medulloblastoma, ependymoma, high-grade and optic gliomas, where the expected survival time was more than 3 months at start of treatment. Side effects were slight myelosuppresion in terms of previous therapy, 16% transient ischemic attack (TIA)-like episodes. During therapy patients could live their everyday life. Kieran schedule was well-tolerable and efficient with good quality of life in certain cases of pediatric CNS tumors.
C1 [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Vancso, Ildiko] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Pocza, Timea] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Schuler, Dezso] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM hauserpeti@yahoo.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 259
EP 263
PG 5
ER

PT J
AU Kiss, E
   Lahm, E
   Vachaja, J
   Nagy, P
   Bazso, P
   Fekete, Zs
   Takacsi-Nagy, Z
   Papai, Zs
AF Kiss, Edina
   Lahm, Erika
   Vachaja, Jozsef
   Nagy, Peter
   Bazso, Peter
   Fekete, Zsolt
   Takacsi-Nagy, Zoltan
   Papai, Zsuzsanna
TI Our experience with targeted therapy in glioblastoma multiforme
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE glioblastoma multiforme; temozolomid; bevacizumab; AVAglio
ID glioblastoma multiforme; temozolomid; bevacizumab; AVAglio
AB Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.
C1 [Kiss, Edina] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111. 3. emelet, 1062 Budapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111. 3. emelet, 1062 Budapest, Hungary.
   [Vachaja, Jozsef] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111. 3. emelet, 1062 Budapest, Hungary.
   [Nagy, Peter] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111. 3. emelet, 1062 Budapest, Hungary.
   [Bazso, Peter] MH Egeszsegugyi Kozpont, Idegsebeszeti OsztalyBudapest, Hungary.
   [Fekete, Zsolt] MH Egeszsegugyi Kozpont, Idegsebeszeti OsztalyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111. 3. emelet, 1062 Budapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, 1062 Budapest, Hungary.
EM edina.kiss.dobos@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 264
EP 268
PG 5
ER

PT J
AU Horvath, Zs
   Szavai, J
   Bellyei, Sz
   Farkas, R
   Mangel, L
   Kovacs, P
   Sebestyen, Zs
   Kaso, G
   Gomori, �
   Horvath, G
   Esik, O
   Doczi, T
AF Horvath, Zsolt
   Szavai, Jozsef
   Bellyei, Szabolcs
   Farkas, Robert
   Mangel, Laszlo
   Kovacs, Peter
   Sebestyen, Zsolt
   Kaso, Gabor
   Gomori, Eva
   Horvath, Gabor
   Esik, Olga
   Doczi, Tamas
TI Fractionated conformal stereotactic irradiation of recurrent sacral tumour. Case report and first description of the method in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE chordoma; konformalis sugarterapia; frakcionalt sztereotaxias pontbesugarzas; sacrumdaganat
ID chordoma; konformalis sugarterapia; frakcionalt sztereotaxias pontbesugarzas; sacrumdaganat
AB Non-invasive procedures completing traditional surgical treatment play an increasing role in the management of central nervous system malignancies. Conformal stereotactic irradiation (radiosurgery) has become a routine method in intracranial malignancies. However, application of this modality in tumours of the spinal cord and spinal column is much more difficult to perform. It is because extracranial organs can be only inaccurately fixed, and radio-sensitivity of the spinal cord and risks of radionecrosis with ensuing paraplegia are high. A recurrent sacrum chordoma treated by means of this modality - first reported in Hungary - has been chosen for case presentation as the criteria for radiotherapy such as high dose to target volume, minimal dose to neighbouring structures highly sensitive to radiation are best met in these tumours by means of conformal stereotactic radiotherapy. On the basis of further 13 extracranial cases treated with this method one can conclude that high precision stereotactic conformal radiotherapy offers up-grade to traditional radiotherapy despite the fact that it is a time-consuming procedure. The oncological efficiency, the reduced risks of side effects and the improved quality of life due to this treatment modality compensate duly for the increased labour input.
C1 [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Szavai, Jozsef] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kaso, Gabor] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Gomori, Eva] University of Pecs, Department of PathologyPecs, Hungary.
   [Horvath, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Esik, Olga] University of Pecs, Department of OncologyPecs, Hungary.
   [Doczi, Tamas] University of Pecs, Department of NeurologyPecs, Hungary.
RP Doczi, T (reprint author), University of Pecs, Department of Neurology, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 269
EP 274
PG 6
ER

PT J
AU Hudak, I
   Stefanits, J
   Kaso, G
   Botz, L
   Doczi, T
AF Hudak, Istvan
   Stefanits, Janos
   Kaso, Gabor
   Botz, Lajos
   Doczi, Tamas
TI Preoperative embolisation of spinal metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE DSA; spinalis metasztazis; tumorembolizacio
ID DSA; spinalis metasztazis; tumorembolizacio
AB In the management of spinal metastases bringing about neurological symptoms and signs, palliative surgical treatment plays an important role. The goals of surgery are preservation of neurological function especially that of the mobility, pain relief and local tumor control. Many of spinal metastases are hypervascularised, accordingly, preoperative embolisation offers logically improvement in technical realisation of surgery by means of reduction of intraoperative profuse bleeding. To prove this working hypothesis a retrospective analysis was performed. Results of preoperative transarterial embolisation of hypervascularised spinal tumours were worked up from 2000 to 2012. By means of 2 case presentations - to our knowledge, first in the Hungarian literature - the techniques of transarterial spinal embolisation of spinal metastases are described. Indications, complications and effect on intraoperative bleeding events of the embolisation procedure in these oncological cases are presented on the basis of literature search and of our own experience. The case analyses, based mainly on qualitative retrospective data, support the notion that histologically known spinal hypervascularised metastases or those found to be hypervascularised by MRI can be treated effectively by means of preoperative superselective embolisation without major risks of morbidity or mortality.
C1 [Hudak, Istvan] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Stefanits, Janos] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Kaso, Gabor] Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Ret u. 2., 7623 Pecs, Hungary.
   [Botz, Lajos] Pecsi Tudomanyegyetem, Gyogyszereszeti IntezetPecs, Hungary.
   [Doczi, Tamas] University of Pecs, Department of NeurologyPecs, Hungary.
RP Doczi, T (reprint author), University of Pecs, Department of Neurology, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 275
EP 281
PG 7
ER

PT J
AU Borbely, K
   Geczi, L
   Kasler, M
AF Borbely, Katalin
   Geczi, Lajos
   Kasler, Miklos
TI Why is PET/CT essential in urooncology?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE uroonkologiai megbetegedesek; PET/CT; PET/MR; tracerek
ID uroonkologiai megbetegedesek; PET/CT; PET/MR; tracerek
AB The wide use of molecular positron emission tomography/computed tomography (PET/CT) imaging in the tumor diagnostics has been playing an important role recently. The clinical role of hybrid imaging (PET/CT, single photon ECT/CT (SPECT/CT)) is growing continuously due to the simultaneous imaging of anatomy and function. Regarding oncology the role of 18F-fluorodeoxyglucose (18F-FDG) PET is proved in several clinical questions, including urooncology. Urologic cancers are associated with low or slightly significant uptake of FDG, due to their more benign behaviour. However, alternative PET tracers have been developed which show promising clinical results and hopefully, in the near future the combination of different tracers are awaited. Additionally, in the future the use of multiparametric measurements, multitracer techniques, and the multimodal PET/magnetic resonance imaging (PET/MRI) technology is going to have a crucial clinical role.
C1 [Borbely, Katalin] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 282
EP 296
PG 15
ER

PT J
TI XX. Forum for Primary Prevention
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE primer prevencio; forum; kongresszusi osszefoglalo
ID primer prevencio; forum; kongresszusi osszefoglalo
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2013
VL 57
IS 4
BP 297
EP 311
PG 15
ER

PT J
TI 30th Congress of the Hungarian Cancer Society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
AB 2013. november 14–16. Abstracts
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 1
EP 104
PG 104
ER

PT J
AU Bishr, MA
   Deme, D
   Szollosi, Zs
   Jamool, N
   Telekes, A
AF Bishr, Mohamed Abdulfatah
   Deme, Daniel
   Szollosi, Zsuzsanna
   Jamool, Nizar
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bishr, Mohamed Abdulfatah] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Szollosi, Zsuzsanna] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Jamool, Nizar] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Bishr, MA (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Al-Farhat, Y
   Auth, P
   Cifra, J
   Vajda, K
   Bogner, B
AF Al-Farhat, Yousuf
   Auth, Peter
   Cifra, Janos
   Vajda, Kornel
   Bogner, Barna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Cifra, Janos] Balassa Janos County Hospital, Department of PathologySzekszard, Hungary.
   [Vajda, Kornel] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Bogner, Barna] AMEDES Med. Dienstleistung GmbH, Patologiai OsztalyGottingen, Germany.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Al-Farhat, Y
   Auth, P
   Cifra, J
   Szemes, L
   Schipp, I
   Nemerei, Zs
AF Al-Farhat, Yousuf
   Auth, Peter
   Cifra, Janos
   Szemes, Laszlo
   Schipp, Ildiko
   Nemerei, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Cifra, Janos] Balassa Janos County Hospital, Department of PathologySzekszard, Hungary.
   [Szemes, Laszlo] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Nemerei, Zsuzsa] Mamma Klinika, Mammografias LaborSzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Albert Toth, J
AF Albert Toth, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Albert Toth, Judit] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Albert Toth, J (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Bassam, A
   Dimak, S
   Torok, E
   Piko, B
AF Bassam, Ali
   Dimak, Sandor
   Torok, Eniko
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bassam, Ali] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Dimak, Sandor] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Torok, Eniko] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Bassam, A (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Andras, Cs
   Antal-Szalmas, P
   Horvath, Zs
AF Andras, Csilla
   Antal-Szalmas, Peter
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Antal-Szalmas, Peter] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Andras, Cs (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Andras, Cs
AF Andras, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Andras, Cs (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 6
EP 7
PG 2
ER

PT J
AU Acs, B
   Szekely, NA
   Szasz, AM
   Lotz, G
   Kulka, J
   Szekely, T
   Istok, R
   Szekely, E
   Jaray, B
AF Acs, Balazs
   Szekely, Nora Anna
   Szasz, Attila Marcell
   Lotz, Gabor
   Kulka, Janina
   Szekely, Tamas
   Istok, Roland
   Szekely, Eszter
   Jaray, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Acs, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Nora Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Istok, Roland] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Acs, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Acs, B
   Szekely, NA
   Szasz, AM
   Tokes, AM
   Tokes, T
   Dank, M
   Kulka, J
AF Acs, Balazs
   Szekely, Nora Anna
   Szasz, Attila Marcell
   Tokes, Anna-Maria
   Tokes, Timea
   Dank, Magdolna
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Acs, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Nora Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Timea] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Acs, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Agoston, P
   Major, T
   Baricza, K
   Varjas, G
   Jorgo, K
   Szabo, Z
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Baricza, Karoly
   Varjas, Geza
   Jorgo, Kliton
   Szabo, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varjas, Geza] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 7
EP 8
PG 2
ER

PT J
AU Bagameri, A
   Pete, I
   Vereczkey, I
AF Bagameri, Andrea
   Pete, Imre
   Vereczkey, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bagameri, Andrea] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Bagameri, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Bagameri, A
   Pete, I
AF Bagameri, Andrea
   Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bagameri, Andrea] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Bagameri, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Bagameri, A
AF Bagameri, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bagameri, Andrea] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Bagameri, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 8
EP 9
PG 2
ER

PT J
AU Bak, M
   Seberne Ell, M
   Boka, M
   Veleczki, Zs
   Nyari, T
   Pete, I
   Szentirmay, Z
AF Bak, Mihaly
   Seberne Ell, Maria
   Boka, Melinda
   Veleczki, Zsuzsanna
   Nyari, Tibor
   Pete, Imre
   Szentirmay, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Seberne Ell, Maria] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Boka, Melinda] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Veleczki, Zsuzsanna] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Bak, M (reprint author), Orszagos Onkologiai Intezet, Citopatologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Baki, M
   Egyed, Zs
   Knerr, E
   Lobl, T
   Landherr, L
AF Baki, Marta
   Egyed, Zsofia
   Knerr, Erika
   Lobl, Tibor
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Egyed, Zsofia] Uzsoki Utcai Korhaz, Rontgen DiagnosztikaBudapest, Hungary.
   [Knerr, Erika] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Lobl, Tibor] Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Baki, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balatoni, T
   Borbola, K
   Liszkay, G
AF Balatoni, Timea
   Borbola, Kinga
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 9
EP 10
PG 2
ER

PT J
AU Balizs, T
   Vreca, I
AF Balizs, Tibor
   Vreca, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balizs, Tibor] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vreca, Istvan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Balizs, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Ballago, K
   Budai, B
   Palinkas, Z
   Barancsine Szucs, J
   Nagy, A
   Kasler, M
   Nagy, P
AF Ballago, Krisztina
   Budai, Barna
   Palinkas, Zoltan
   Barancsine Szucs, Judit
   Nagy, Attila
   Kasler, Miklos
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ballago, Krisztina] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Palinkas, Zoltan] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Barancsine Szucs, Judit] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Nagy, Attila] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Ballago, K (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Balogh, AJ
AF Balogh, Andrea Johanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Andrea Johanna] Pro Karmine Kft., KommunikacioBudapest, Hungary.
RP Balogh, AJ (reprint author), Pro Karmine Kft., Kommunikacio, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Bartal, A
   Savolt, �
   Szucs, A
   Matrai, Z
AF Bartal, Alexandra
   Savolt, Akos
   Szucs, Attila
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szucs, Attila] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Bartal, A (reprint author), Orszagos Onkologiai Intezet, Intezeti Gyogyszertar, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Battyany, I
   Harmat, Z
   Rostas, T
   Horvath, L
AF Battyany, Istvan
   Harmat, Zoltan
   Rostas, Tamas
   Horvath, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Battyany, Istvan] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Harmat, Zoltan] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Rostas, Tamas] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Horvath, Laszlo] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Battyany, I (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Besznyak, I
   Dede, K
   Szentpetery, F
   Mersich, T
   Svastics, I
   Egyed, T
   Bursics, A
AF Besznyak, Istvan
   Dede, Kristof
   Szentpetery, Felix
   Mersich, Tamas
   Svastics, Imre
   Egyed, Tamas
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Szentpetery, Felix] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Svastics, Imre] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Egyed, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
RP Besznyak, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Biro, K
   Geczi, L
   Gyergyay, F
   Nagyivanyi, K
   Kuronya, Zs
   Nemeth, H
AF Biro, Krisztina
   Geczi, Lajos
   Gyergyay, Fruzsina
   Nagyivanyi, Krisztian
   Kuronya, Zsofia
   Nemeth, Hajnalka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Biro, K (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 11
EP 12
PG 2
ER

PT J
AU Bittner, N
   Toth, E
   Geczi, L
   Sarosi, V
   Laszlo, T
AF Bittner, Nora
   Toth, Erika
   Geczi, Lajos
   Sarosi, Veronika
   Laszlo, Terezia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] Orszagos Onkologiai Intezet, III. Sz. Kemoterapias Belgyogyaszati AmbulanciaBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Laszlo, Terezia] University of Pecs, Department of PathologyPecs, Hungary.
RP Bittner, N (reprint author), Orszagos Onkologiai Intezet, III. Sz. Kemoterapias Belgyogyaszati Ambulancia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Boda, �
   Pajkos, G
AF Boda, Eva
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boda, Eva] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Boda, � (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Boer, A
   Remenar, �
   Herczeg, A
   Hegedus, S
   Levay, B
AF Boer, Andras
   Remenar, Eva
   Herczeg, Adrienn
   Hegedus, Sabina
   Levay, Bernadett
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Hegedus, Sabina] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Levay, Bernadett] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Boer, A (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Boer, K
AF Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Borbely, K
   Garai, I
   Lengyel, Zs
AF Borbely, Katalin
   Garai, Ildiko
   Lengyel, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Garai, Ildiko] Nuklearis Medicina TanacsBudapest, Hungary.
   [Lengyel, Zsolt] Nuklearis Medicina TanacsBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Boross, G
   Fekete, L
   Maraz, R
   Marko, L
   Pajkos, G
   Pap Szekeres, J
   Svebis, M
AF Boross, Gabor
   Fekete, Laszlo
   Maraz, Robert
   Marko, Laszlo
   Pajkos, Gabor
   Pap Szekeres, Jozsef
   Svebis, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Fekete, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pap Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Boross, G (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Brauswetter, D
   Varga, A
   Keri, Gy
   Petak, I
AF Brauswetter, Diana
   Varga, Attila
   Keri, Gyorgy
   Petak, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Brauswetter, Diana] Semmelweis University, Department of Medical Chemistry, Molecular Biology and PathobiochemistryBudapest, Hungary.
   [Varga, Attila] Hungarian Academy of Sciences and Semmelweis University, Pathobiochemistry Research GroupBudapest, Hungary.
   [Keri, Gyorgy] Hungarian Academy of Sciences and Semmelweis University, Pathobiochemistry Research GroupBudapest, Hungary.
   [Petak, Istvan] Hungarian Academy of Sciences and Semmelweis University, Pathobiochemistry Research GroupBudapest, Hungary.
RP Brauswetter, D (reprint author), Semmelweis University, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 14
EP 15
PG 2
ER

PT J
AU Buchinger, R
AF Buchinger, Rita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Buchinger, Rita] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Buchinger, R (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Bursics, A
   Dede, K
   Mersich, T
   Besznyak, I
   Porneczi, B
   Jakab, F
   Landherr, L
AF Bursics, Attila
   Dede, Kristof
   Mersich, Tamas
   Besznyak, Istvan
   Porneczi, Balazs
   Jakab, Ferenc
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Porneczi, Balazs] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Jakab, Ferenc] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Bursics, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Cseri, Zs
   Jederan, �
   Kaszonyi, B
   Lieber, T
   Geczi, Cs
AF Cseri, Zsolt
   Jederan, Eva
   Kaszonyi, Botond
   Lieber, Tamas
   Geczi, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseri, Zsolt] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kaszonyi, Botond] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lieber, Tamas] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Geczi, Csaba] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Cseri, Zs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Csernakne Risko, �
   Molnar, Zs
   Varady, E
   Rosta, A
AF Csernakne Risko, Agnes
   Molnar, Zsuzsa
   Varady, Erika
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csernakne Risko, Agnes] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Csernakne Risko, � (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Csiha, S
   Treszl, A
   Szilasi, M
   Szollosine Erdei, E
   Halmos, G
AF Csiha, Sara
   Treszl, Andrea
   Szilasi, Maria
   Szollosine Erdei, Edit
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csiha, Sara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szilasi, Maria] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Szollosine Erdei, Edit] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Csiha, S (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Csikos, �
   Busa, Cs
   Lukacs, M
AF Csikos, Agnes
   Busa, Csilla
   Lukacs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csikos, Agnes] University of Pecs, Department of OncologyPecs, Hungary.
   [Busa, Csilla] University of Pecs, Department of OncologyPecs, Hungary.
   [Lukacs, Miklos] University of Pecs, Department of OncologyPecs, Hungary.
RP Csikos, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Csiszer, E
   Sutto, Z
   Bajcsay, A
   Soltesz, I
   Fillinger, J
   Penzes, I
   Csekeo, A
AF Csiszer, Eszter
   Sutto, Zoltan
   Bajcsay, Andras
   Soltesz, Ibolya
   Fillinger, Janos
   Penzes, Istvan
   Csekeo, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csiszer, Eszter] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Sutto, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Soltesz, Ibolya] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Fillinger, Janos] Orszagos Koranyi Pulmonologiai Intezet, XI. TudobelosztalyBudapest, Hungary.
   [Penzes, Istvan] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Intenziv Terapias OsztalyBudapest, Hungary.
   [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
RP Csiszer, E (reprint author), National Koranyi Institute of Pulmonology, Department of Bronchology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 16
EP 17
PG 2
ER

PT J
AU Czirbesz, K
   Gorka, E
   Kovacs, F
   Borbola, K
   Peter, A
   Liszkay, G
AF Czirbesz, Kata
   Gorka, Eszter
   Kovacs, Fruzsina
   Borbola, Kinga
   Peter, Antal
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kovacs, Fruzsina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Peter, Antal] Budapesti Muszaki Egyetem, BiostatisztikaBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Czirbesz, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Dank, M
   Budi, L
   Landherr, L
   Piko, B
   Mangel, L
   Erfan, J
   Cseh, J
   Ruzsa, �
   Nagy, A
AF Dank, Magdolna
   Budi, Laszlo
   Landherr, Laszlo
   Piko, Bela
   Mangel, Laszlo
   Erfan, Jozsef
   Cseh, Jozsef
   Ruzsa, Agnes
   Nagy, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Budi, Laszlo] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Cseh, Jozsef] Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Onkologiai OsztalySzekesfehervar, Hungary.
   [Ruzsa, Agnes] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Nagy, Andras] Roche (Magyarorszag) Kft., Orvosi OsztalyBudaors, Hungary.
RP Dank, M (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Dankovics, Zs
   Vegh, G
   Padanyi, G
   Csejtei, A
AF Dankovics, Zsofia
   Vegh, Gabriella
   Padanyi, Gergo
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Vegh, Gabriella] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Padanyi, Gergo] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Dankovics, Zs
   Bokor, A
   Kiraly, I
   Csejtei, A
AF Dankovics, Zsofia
   Bokor, Anita
   Kiraly, Istvan
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Bokor, Anita] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Kiraly, Istvan] Markusovszky University Teaching Hospital, Department of RadiologySzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Dede, K
   Mersich, T
   Besznyak, I
   Landherr, L
   Bursics, A
AF Dede, Kristof
   Mersich, Tamas
   Besznyak, Istvan
   Landherr, Laszlo
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Dede, K (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Deme, D
   Bishr, MA
   Szollosi, Zs
   Jamool, N
   Telekes, A
AF Deme, Daniel
   Bishr, Mohamed Abdulfatah
   Szollosi, Zsuzsanna
   Jamool, Nizar
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Bishr, Mohamed Abdulfatah] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Szollosi, Zsuzsanna] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Jamool, Nizar] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Demeter, A
   Pete, I
AF Demeter, Attila
   Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Demeter, Attila] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Demeter, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Dimak, S
   Rus-Gal, PO
   Bassam, A
   Csiffari, M
   Piko, B
AF Dimak, Sandor
   Rus-Gal, Paul Ovidiu
   Bassam, Ali
   Csiffari, Margit
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dimak, Sandor] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Rus-Gal, Paul Ovidiu] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Dimak, S (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 19
EP 20
PG 2
ER

PT J
AU Dobos, K
   Benedek, A
   Takacs, Sz
   Safrany, G
   Lumniczky, K
AF Dobos, Katalin
   Benedek, Anett
   Takacs, Szabolcs
   Safrany, Geza
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobos, Katalin] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Benedek, Anett] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Takacs, Szabolcs] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Dobos, K (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Docs, O
   Fazakas, F
   Horvathne Lugosi, N
   Mehes, G
AF Docs, Otto
   Fazakas, Ferenc
   Horvathne Lugosi, Nora
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Docs, Otto] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Fazakas, Ferenc] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Horvathne Lugosi, Nora] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Docs, O (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Docs, O
   Gyongyosi, A
   Andras, Cs
   Horvath, Zs
   Balint, BL
   Mehes, G
AF Docs, Otto
   Gyongyosi, Adrienn
   Andras, Csilla
   Horvath, Zsolt
   Balint, Balint Laszlo
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Docs, Otto] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Gyongyosi, Adrienn] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Docs, O (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 20
EP 21
PG 2
ER

PT J
AU Dohan, O
AF Dohan, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dohan, Orsolya] Semmelweis Egyetem, Egeszsegtudomanyi KarBudapest, Hungary.
RP Dohan, O (reprint author), Semmelweis Egyetem, Egeszsegtudomanyi Kar, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Doleschall, Z
   Olasz, J
   Remenar, �
   Csuka, O
AF Doleschall, Zoltan
   Olasz, Judit
   Remenar, Eva
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doleschall, Zoltan] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Olasz, Judit] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Doleschall, Z (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Dolgosne Farkas, E
   Csomor, Z
AF Dolgosne Farkas, Edina
   Csomor, Zita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dolgosne Farkas, Edina] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Csomor, Zita] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Dolgosne Farkas, E (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 21
EP 22
PG 2
ER

PT J
AU Dorogi, B
   Savolt, �
   Teglas, M
   Udvarhelyi, N
   Bidlek, M
   Kovacs, E
   Kasler, M
   Matrai, Z
AF Dorogi, Bence
   Savolt, Akos
   Teglas, Melinda
   Udvarhelyi, Nora
   Bidlek, Maria
   Kovacs, Eszter
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dorogi, Bence] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Teglas, Melinda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Dorogi, B (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Doros, A
   Deak, P�
   Langer, R
AF Doros, Attila
   Deak, Pal Akos
   Langer, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doros, Attila] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Deak, Pal Akos] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Langer, Robert] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
RP Doros, A (reprint author), Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Dudnyikova, A
   Pete, I
   Vereczkey, I
AF Dudnyikova, Anna
   Pete, Imre
   Vereczkey, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dudnyikova, Anna] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Dudnyikova, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Erb, A
   Galambos, Cs
   Torok, M
   Simonne Vincze, M
   Al-Farhat, Y
AF Erb, Attilane
   Galambos, Csilla
   Torok, Marta
   Simonne Vincze, Maria
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Erb, Attilane] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Galambos, Csilla] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Torok, Marta] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Simonne Vincze, Maria] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Erb, A (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Fabian, K
   Papay, J
   Fillinger, J
   Bogos, K
   Losonczy, Gy
   Krenacs, T
   Timar, J
   Moldvay, J
AF Fabian, Katalin
   Papay, Judit
   Fillinger, Janos
   Bogos, Krisztina
   Losonczy, Gyorgy
   Krenacs, Tibor
   Timar, Jozsef
   Moldvay, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabian, Katalin] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fillinger, Janos] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Bogos, Krisztina] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Moldvay, Judit] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Fabian, K (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Fabosne Netling, I
   Peley, B
   Kiss, E
AF Fabosne Netling, Ibolya
   Peley, Bernadette
   Kiss, Eniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabosne Netling, Ibolya] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Peley, Bernadette] Pecsi Tudomanyegyetem, BTK Pszichologia Intezet, Fejlodes es Klinikai Pszichologia TanszekPecs, Hungary.
   [Kiss, Eniko] Pecsi Tudomanyegyetem, BTK Pszichologia Intezet, Szemelyiseg- es Egeszsegpszichologiai TanszekPecs, Hungary.
RP Fabosne Netling, I (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 23
EP 24
PG 2
ER

PT J
AU Farkas, E
   Ujhelyi, M
   Gulyas, G
   Kunos, Cs
   Kenessey, I
   Savolt, �
   Kasler, M
   Matrai, Z
AF Farkas, Emil
   Ujhelyi, Mihaly
   Gulyas, Gusztav
   Kunos, Csaba
   Kenessey, Istvan
   Savolt, Akos
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Ujhelyi, Mihaly] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Farkas, E (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Farkas, Gy
   Szekely, G
   Gundy, S
AF Farkas, Gyongyi
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Farkas, Gy (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Feher, I
AF Feher, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Feher, Istvan] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Feher, I (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Feherne Kosa, I
AF Feherne Kosa, Iren
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Feherne Kosa, Iren] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Feherne Kosa, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Fulopne Farkas, N
   Major, G
   Kunos, Cs
   Savolt, �
   Pukancsik, D
   Gulyas, G
   Matrai, Z
AF Fulopne Farkas, Nikolett
   Major, Gaborne
   Kunos, Csaba
   Savolt, Akos
   Pukancsik, David
   Gulyas, Gusztav
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulopne Farkas, Nikolett] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Major, Gaborne] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kunos, Csaba] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Gulyas, Gusztav] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Fulopne Farkas, N (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Gal, L
AF Gal, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gal, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Gal, L (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Gargyan, K
AF Gargyan, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gargyan, Katalin] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Gargyan, K (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Geczi, Cs
   Janiga, I
AF Geczi, Csaba
   Janiga, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geczi, Csaba] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Janiga, Ildiko] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Geczi, Cs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Geczi, L
   Biro, K
   Kuronya, Zs
   Nemeth, H
   Nagyivanyi, K
   Vajdics, T
   Gyergyai, F
AF Geczi, Lajos
   Biro, Krisztina
   Kuronya, Zsofia
   Nemeth, Hajnalka
   Nagyivanyi, Krisztian
   Vajdics, Timea
   Gyergyai, Fruzsina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Vajdics, Timea] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyai, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Geczi, L (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 26
EP 27
PG 2
ER

PT J
AU Gerlinger, L
AF Gerlinger, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Gerlinger, L (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Gerlinger, L
   Peti, J
AF Gerlinger, Lilla
   Peti, Julianna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Peti, Julianna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Gerlinger, L (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Gieszer, B
   Czeyda Pommersheim, F
   Toth, L
   Godeny, M
   Hitre, E
   Lovey, J
   Matrai, Z
AF Gieszer, Balazs
   Czeyda Pommersheim, Ferenc
   Toth, Laszlo
   Godeny, Maria
   Hitre, Erika
   Lovey, Jozsef
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gieszer, Balazs] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Czeyda Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Gieszer, B (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Gobor, L
   Savolt, �
   Kovacs, E
   Bidlek, M
   Toth, E
   Udvarhelyi, N
   Teglas, M
   Toth, L
   Matrai, Z
AF Gobor, Laszlo
   Savolt, Akos
   Kovacs, Eszter
   Bidlek, Maria
   Toth, Erika
   Udvarhelyi, Nora
   Teglas, Melinda
   Toth, Laszlo
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gobor, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Teglas, Melinda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Gobor, L (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 27
EP 28
PG 2
ER

PT J
AU Godeny, A
   Agoston, P
   Frohlich, G
   Polgar, Cs
AF Godeny, Anna
   Agoston, Peter
   Frohlich, Georgina
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Godeny, A (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Gombos, K
   Olasz, L
   Ember, I
AF Gombos, Katalin
   Olasz, Lajos
   Ember, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Olasz, Lajos] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Gombos, K (reprint author), University of Pecs, Faculty of Medicine, Department of Public Health, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Gorka, E
   Czirbesz, K
   Kovacs, FA
   Fabo, D
   Borbola, K
   Deak, T
   Liszkay, G
AF Gorka, Eszter
   Czirbesz, Kata
   Kovacs, Fruzsina Anna
   Fabo, Daniel
   Borbola, Kinga
   Deak, Tibor
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kovacs, Fruzsina Anna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fabo, Daniel] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Deak, Tibor] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Gorka, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 28
EP 29
PG 2
ER

PT J
AU Godeny, M
   Remenar, �
AF Godeny, Maria
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Gundy, S
AF Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Gundy, S (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Gurgolne Marcsa, K
AF Gurgolne Marcsa, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gurgolne Marcsa, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Gurgolne Marcsa, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Gyapjas, T
   Molnar, M
   Pajkos, G
AF Gyapjas, Tunde
   Molnar, Maria
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gyapjas, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Gyenesne Vago, �
   Schneider, T
   Szabadosne Nemeth, M
   Zsigmondne Borisza, M
   Palfalvi, G
AF Gyenesne Vago, Agnes
   Schneider, Tamas
   Szabadosne Nemeth, Maria
   Zsigmondne Borisza, Maria
   Palfalvi, Gaborne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyenesne Vago, Agnes] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Schneider, Tamas] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Szabadosne Nemeth, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Zsigmondne Borisza, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Palfalvi, Gaborne] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
RP Gyenesne Vago, � (reprint author), National Institute of Oncology, Central Clinical Laboratory, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Gyenesne Vago, �
   Schneider, T
   Zsigmondne Borisza, M
   Nemethne Szabados, M
AF Gyenesne Vago, Agnes
   Schneider, Tamas
   Zsigmondne Borisza, Maria
   Nemethne Szabados, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyenesne Vago, Agnes] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Schneider, Tamas] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Zsigmondne Borisza, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Nemethne Szabados, Maria] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
RP Gyenesne Vago, � (reprint author), National Institute of Oncology, Central Clinical Laboratory, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 30
EP 31
PG 2
ER

PT J
AU Gyorffy, B
   Karn, Th
   Sztupinszki, Zs
   Weltz, B
   Muller, V
   Pusztai, L
AF Gyorffy, Balazs
   Karn, Thomar
   Sztupinszki, Zsofia
   Weltz, Boglarka
   Muller, Volkmar
   Pusztai, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Karn, Thomar] Goethe University Frankfurt, Department of Obstetrics and GynecologyFrankfurt, Germany.
   [Sztupinszki, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Weltz, Boglarka] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Muller, Volkmar] University Medical Center, Department of GynecologyHamburg, Germany.
   [Pusztai, Lajos] Yale Cancer Center, Genomics ProgramNew Haven, USA.
RP Gyorffy, B (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Gyorffy, ME
AF Gyorffy, Monika Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Monika Erzsebet] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Gyorffy, ME (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Gyori, J
   Gulyas, G
   Kunos, Cs
   Bidlek, M
   Kovacs, E
   Kasler, M
   Matrai, Z
AF Gyori, Julia
   Gulyas, Gusztav
   Kunos, Csaba
   Bidlek, Maria
   Kovacs, Eszter
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyori, Julia] National Institute of OncologyBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Gyori, J (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 31
EP 32
PG 2
ER

PT J
AU Gyulai, R
   Paluska, M
   Baltas, E
   Gaal, M
   Ocsai, H
   Kemeny, L
   Olah, J
AF Gyulai, Rolland
   Paluska, Marta
   Baltas, Eszter
   Gaal, Magdolna
   Ocsai, Henriette
   Kemeny, Lajos
   Olah, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyulai, Rolland] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Paluska, Marta] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Baltas, Eszter] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Gaal, Magdolna] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Ocsai, Henriette] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kemeny, Lajos] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Gyulai, R (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Hadijev, J
   Toller, G
   Antal, G
   Lakosi, F
   Glavak, Cs
   Repa, I
AF Hadijev, Janaki
   Toller, Gabor
   Antal, Gergely
   Lakosi, Ferenc
   Glavak, Csaba
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hadijev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Hadijev, J (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Halasz, J
   Sebestyen, K
   Sebestyen, Zs
   Szappanos, Sz
   Locsei, Z
   Laszlo, Z
   Kalincsak, J
   Mangel, LCs
AF Halasz, Judit
   Sebestyen, Klara
   Sebestyen, Zsolt
   Szappanos, Szabolcs
   Locsei, Zoltan
   Laszlo, Zoltan
   Kalincsak, Judit
   Mangel, Laszlo Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Halasz, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Hallbauer, I
AF Hallbauer, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hallbauer, Ildiko] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Hallbauer, I (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Harisi, R
   Kenessey, I
   Olah, J
   Jeney, A
AF Harisi, Revekka
   Kenessey, Istvan
   Olah, N. Julia
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Olah, N. Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Hartmann, E
   Ruzsa, �
   Kiss, A
   Lelovics, Zs
   Kiss, I
AF Hartmann, Eszter
   Ruzsa, Agnes
   Kiss, Anna
   Lelovics, Zsuzsanna
   Kiss, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hartmann, Eszter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Kiss, Anna] Semmelweis Egyetem, Egeszsegtudomanyi KarBudapest, Hungary.
   [Lelovics, Zsuzsanna] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kiss, Istvan] University of Pecs, Faculty of MedicinePecs, Hungary.
RP Hartmann, E (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 33
EP 34
PG 2
ER

PT J
AU Hegyesi, H
   Schilling-Toth, B
   Walter, F
   Sandor, N
   Deli, M
   Safrany, G
AF Hegyesi, Hargita
   Schilling-Toth, Boglarka
   Walter, Fruzsina
   Sandor, Nikolett
   Deli, Maria
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyesi, Hargita] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Schilling-Toth, Boglarka] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Walter, Fruzsina] Hungarian Academy of Sciences, Biological Research Centre, Institute of BiophysicsSzeged, Hungary.
   [Sandor, Nikolett] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Deli, Maria] Hungarian Academy of Sciences, Biological Research Centre, Institute of BiophysicsSzeged, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Hegyesi, H (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Hegyi, K
   Bedekovics, J
   Mehes, G
AF Hegyi, Katalin
   Bedekovics, Judit
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyi, Katalin] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Bedekovics, Judit] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Hegyi, K (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 34
EP 35
PG 2
ER

PT J
AU Herczeg, A
   Fodor, I
   Zambo, O
   Koltai, P
   Koltai, L
   Doleviczenyi, Z
   Boer, A
   Remenar, �
AF Herczeg, Adrienn
   Fodor, Istvan
   Zambo, Orsolya
   Koltai, Pal
   Koltai, Laszlo
   Doleviczenyi, Zoltan
   Boer, Andras
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Fodor, Istvan] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Zambo, Orsolya] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Koltai, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Doleviczenyi, Zoltan] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Herczeg, A (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Herczeg, A
   Zambo, O
   Remenar, �
AF Herczeg, Adrienn
   Zambo, Orsolya
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Zambo, Orsolya] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Herczeg, A (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Hernadi, Z
AF Hernadi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Hernadi, Z (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Hideghety, K
   Mozes, P
   Valicsek, E
   Szanto, E
   Tiszlavicz, L
   Szakal, G
   Barzo, P
   Cserhati, A
   Fodor, E
AF Hideghety, Katalin
   Mozes, Petra
   Valicsek, Erzsebet
   Szanto, Erika
   Tiszlavicz, Laszlo
   Szakal, Gergo
   Barzo, Pal
   Cserhati, Adrienne
   Fodor, Emese
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szanto, Erika] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Szakal, Gergo] University of Szeged, Department of PathologySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Homor, K
   Bercesi, �
   Kover, E
   Varga, Zs
   Mangel, L
   Stefanits, K
AF Homor, Katinka
   Bercesi, Eva
   Kover, Erika
   Varga, Zsuzsanna
   Mangel, Laszlo
   Stefanits, Klara
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Homor, Katinka] University of PecsPecs, Hungary.
   [Bercesi, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
RP Homor, K (reprint author), University of Pecs, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Hornyak, L
   Talos, Zs
   Ligeti, E
   Kocsis, R
AF Hornyak, Lajos
   Talos, Zsuzsanna
   Ligeti, Erika
   Kocsis, Roland
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hornyak, Lajos] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Talos, Zsuzsanna] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Ligeti, Erika] County Hospital, Department of PathologyVeszprem, Hungary.
   [Kocsis, Roland] Csolnoky Ferenc Korhaz, KontrollingVeszprem, Hungary.
RP Hornyak, L (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Horvath, KB
   Pankovics, P
   Kalman, E
   Reuter, G
AF Horvath, Katalin Barbara
   Pankovics, Peter
   Kalman, Endre
   Reuter, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin Barbara] ANTSZ Regional Institute of State Public Health Service, Regional Laboratory of VirologyPecs, Hungary.
   [Pankovics, Peter] ANTSZ Regional Institute of State Public Health Service, Regional Laboratory of VirologyPecs, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Reuter, Gabor] ANTSZ Regional Institute of State Public Health Service, Regional Laboratory of VirologyPecs, Hungary.
RP Horvath, KB (reprint author), ANTSZ Regional Institute of State Public Health Service, Regional Laboratory of Virology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Horvath, G
AF Horvath, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Gabor] Klinikum Rhon AG, FrankenwaldklinikKronach, Germany.
RP Horvath, G (reprint author), Klinikum Rhon AG, Frankenwaldklinik, Kronach, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Horvath, I
   Somogyine Ezer, �
   Kovacs, �
   Ruzsa, �
AF Horvath, Istvanne
   Somogyine Ezer, Eva
   Kovacs, Arpad
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Istvanne] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Somogyine Ezer, Eva] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Horvath, I (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Horvath, K
   Godeny, M
AF Horvath, Katalin
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Horvath, Zs
   Vincze, B
   Kapuvari, B
   Kohalmy, K
   Rubovszky, G
   Hitre, E
   Szabo, E
   Ganofszky, E
   Nagy, T
   Madaras, B
   Nagy, J
   Matrai, Z
   Udvarhelyi, N
   Lang, I
AF Horvath, Zsolt
   Vincze, Borbala
   Kapuvari, Bence
   Kohalmy, Krisztina
   Rubovszky, Gabor
   Hitre, Erika
   Szabo, Eszter
   Ganofszky, Erna
   Nagy, Tunde
   Madaras, Balazs
   Nagy, Janos
   Matrai, Zoltan
   Udvarhelyi, Nora
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Szabo, Eszter] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Ganofszky, Erna] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Madaras, Balazs] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagy, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Horvath, Zs (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Hunyadi, J
   Kotlan, B
   Ladanyi, A
AF Hunyadi, Janos
   Kotlan, Beatrix
   Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hunyadi, Janos] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kotlan, Beatrix] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Hunyadi, J (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 38
EP 39
PG 2
ER

PT J
AU Jakab, G
   Gabor, G
   Hodi, Zs
   Kosa, M
   Pajkos, G
AF Jakab, Gabriella
   Gabor, Gabriella
   Hodi, Zsuzsanna
   Kosa, Miklos
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jakab, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hodi, Zsuzsanna] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kosa, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Jakab, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Javor, L
AF Javor, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Javor, Laszlo] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Javor, L (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Jeney, A
   Szoboszlai, N
   Olah, J
   Fullar, A
   Pap, �
   Kralovanszky, J
   Kovalszky, I
   Baranyai, L
   Kornyei, J
   Hujber, Z
   Vekey, K
AF Jeney, Andras
   Szoboszlai, Norbert
   Olah, Julia
   Fullar, Alexandra
   Pap, Eva
   Kralovanszky, Judit
   Kovalszky, Ilona
   Baranyai, Lajos
   Kornyei, Jozsef
   Hujber, Zoltan
   Vekey, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szoboszlai, Norbert] Eotvos Lorand Tudomanyegyetem, Kemiai Intezet, Analitikai Kemiai TanszekBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fullar, Alexandra] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Pap, Eva] Orszagos Onkologiai Intezet, KKLOBudapest, Hungary.
   [Kralovanszky, Judit] Orszagos Onkologiai Intezet, KKLOBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Baranyai, Lajos] Izotop Intezet Kft.Budapest, Hungary.
   [Kornyei, Jozsef] Izotop Intezet Kft.Budapest, Hungary.
   [Hujber, Zoltan] Eotvos Lorand Tudomanyegyetem, Kemiai Intezet, Analitikai Kemiai TanszekBudapest, Hungary.
   [Vekey, Karoly] MTA Kemiai Kutatokozpont, Tomegspektroszkopiai LaboratoriumBudapest, Hungary.
RP Jeney, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Juharos, �
   Borsos, A
   Gyapjas, T
AF Juharos, Agota
   Borsos, Andrea
   Gyapjas, Tunde
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juharos, Agota] Magyar Honvedseg Egeszsegugyi Kozpont, Kozponti Radiologiai Diagnosztika OsztalyBudapest, Hungary.
   [Borsos, Andrea] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Juharos, � (reprint author), Magyar Honvedseg Egeszsegugyi Kozpont, Kozponti Radiologiai Diagnosztika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kalincsak, J
   Sarosi, V
   Al-Farhat, Y
   Auth, P
   Schipp, I
   Laszlo, Z
   Mangel, L
   Boronkai, �
AF Kalincsak, Judit
   Sarosi, Veronika
   Al-Farhat, Yousuf
   Auth, Peter
   Schipp, Ildiko
   Laszlo, Zoltan
   Mangel, Laszlo
   Boronkai, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
RP Kalincsak, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kanizsaine Minorics, R
   Bozsity, N
   Mernyak, E
   Schneider, Gy
   Wolfling, J
   Zupko, I
AF Kanizsaine Minorics, Renata
   Bozsity, Noemi
   Mernyak, Erzsebet
   Schneider, Gyula
   Wolfling, Janos
   Zupko, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kanizsaine Minorics, Renata] Szegedi Tudomanyegyetem, Gyogyszeresztudomanyi Kar, Gyogyszerhatastani es Biofarmaciai IntezetSzeged, Hungary.
   [Bozsity, Noemi] Szegedi Tudomanyegyetem, Gyogyszeresztudomanyi Kar, Gyogyszerhatastani es Biofarmaciai IntezetSzeged, Hungary.
   [Mernyak, Erzsebet] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Schneider, Gyula] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Wolfling, Janos] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Zupko, Istvan] Szegedi Tudomanyegyetem, Gyogyszeresztudomanyi Kar, Gyogyszerhatastani es Biofarmaciai IntezetSzeged, Hungary.
RP Kanizsaine Minorics, R (reprint author), Szegedi Tudomanyegyetem, Gyogyszeresztudomanyi Kar, Gyogyszerhatastani es Biofarmaciai Intezet, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 40
EP 41
PG 2
ER

PT J
AU Kapuvari, B
   Schulcz, �
   Hegedus, R
   Vincze, B
   Kohalmy, K
   Tovari, J
   Manea, M
   Csuka, O
   Mezo, G
AF Kapuvari, Bence
   Schulcz, Akos
   Hegedus, Rozsa
   Vincze, Borbala
   Kohalmy, Krisztina
   Tovari, Jozsef
   Manea, Marilena
   Csuka, Orsolya
   Mezo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Schulcz, Akos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Hegedus, Rozsa] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Manea, Marilena] University of Konstanz, Zukunftskolleg, Department of ChemistryKonstanz, Germany.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Karadi, O
   Bercesi, �
   Kover, E
   Miszlay, Zs
   Nagy, Zs
   Stefanits, K
   Varga, Zs
   Mangel, L
AF Karadi, Oszkar
   Bercesi, Eva
   Kover, Erika
   Miszlay, Zsuzsanna
   Nagy, Zsuzsanna
   Stefanits, Klara
   Varga, Zsuzsanna
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karadi, Oszkar] University of Pecs, Department of OncologyPecs, Hungary.
   [Bercesi, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Miszlay, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Nagy, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Stefanits, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Karadi, O (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Karczub, P
AF Karczub, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karczub, Peter] Havasi es Karczub Ugyvedi IrodaBudapest, Hungary.
RP Karczub, P (reprint author), Havasi es Karczub Ugyvedi Iroda, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 41
EP 42
PG 2
ER

PT J
AU Karoly, B
   Fabianne Kiss, Sz
AF Karoly, Beatrix
   Fabianne Kiss, Szilvia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karoly, Beatrix] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Fabianne Kiss, Szilvia] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Karoly, B (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Karpati, I
AF Karpati, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karpati, Ilona] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Karpati, I (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Kartnik, K
AF Kartnik, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kartnik, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Kartnik, K (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Kas, J
   Dulka, E
   Soltesz, I
AF Kas, Jozsef
   Dulka, Edit
   Soltesz, Ibolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kas, Jozsef] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Dulka, Edit] Pest County Hospital, III.PulmonologyTorokbalint, Hungary.
   [Soltesz, Ibolya] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
RP Kas, J (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 42
EP 43
PG 2
ER

PT J
AU Kas, J
   Agocs, L
   Csekeo, A
   Heiler, Z
   Kocsis, �
   Vadasz, P
AF Kas, Jozsef
   Agocs, Laszlo
   Csekeo, Attila
   Heiler, Zoltan
   Kocsis, Akos
   Vadasz, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kas, Jozsef] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Agocs, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Heiler, Zoltan] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Kocsis, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Vadasz, Pal] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
RP Kas, J (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Kaszas, B
   Gombos, K
   Papp, R
   Kelemen, D
AF Kaszas, Balint
   Gombos, Katalin
   Papp, Robert
   Kelemen, Dezso
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kaszas, Balint] University of Pecs, Faculty of MedicinePecs, Hungary.
   [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Papp, Robert] University of Pecs, Department of SurgeryPecs, Hungary.
   [Kelemen, Dezso] University of Pecs, Department of SurgeryPecs, Hungary.
RP Kaszas, B (reprint author), University of Pecs, Faculty of Medicine, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Katona, Cs
   Plavecz, �
   Klinko, T
   Meszaros, E
   Kner, E
AF Katona, Csilla
   Plavecz, Eva
   Klinko, Timea
   Meszaros, Edina
   Kner, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Kner, Erika] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Katona, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Kecskes, LI
   Gerencser, J
   Toth, Cs
   Herodek, G
AF Kecskes, Laszlo Istvan
   Gerencser, Jozsef
   Toth, Csaba
   Herodek, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kecskes, Laszlo Istvan] Markusovszky Korhaz, Mellkassebeszeti OsztalySzombathely, Hungary.
   [Gerencser, Jozsef] Markusovszky Egyetemi Oktatokorhaz, Altalanos Sebeszeti OsztalySzombathely, Hungary.
   [Toth, Csaba] Markusovszky Hospital, Department of PathologySzombathely, Hungary.
   [Herodek, Gabriella] Petz A. Egyetemi Oktatokorhaz, Onkologiai OsztalyGyor, Hungary.
RP Kecskes, LI (reprint author), Markusovszky Korhaz, Mellkassebeszeti Osztaly, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Keszthelyi, O
AF Keszthelyi, Oszkar
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Keszthelyi, Oszkar] Dr. Keszthelyi Oszkar Ugyvedi IrodaBudapest, Hungary.
RP Keszthelyi, O (reprint author), Dr. Keszthelyi Oszkar Ugyvedi Iroda, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Kiss, D
   Lukats, O
   Hajnal, K
   Kotai, Zs
AF Kiss, Doloresz
   Lukats, Olga
   Hajnal, Klara
   Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Doloresz] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Hajnal, Klara] Uzsoki Utcai Korhaz, Rontgen DiagnosztikaBudapest, Hungary.
   [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Kiss, D (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Kiss, E
   Lahm, E
   Vachaja, J
   Nagy, P
   Bazso, P
   Fekete, Zs
   Takacsi-Nagy, Z
   Papai, Zs
AF Kiss, Edina
   Lahm, Erika
   Vachaja, Jozsef
   Nagy, Peter
   Bazso, Peter
   Fekete, Zsolt
   Takacsi-Nagy, Zoltan
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bazso, Peter] MH Egeszsegugyi Kozpont, Idegsebeszeti OsztalyBudapest, Hungary.
   [Fekete, Zsolt] MH Egeszsegugyi Kozpont, Idegsebeszeti OsztalyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Kiss, L
   Szabo, Zs
   Semjeni, M
   Dezso, B
   Flasko, T
   Toth, Gy
   Halmos, G
AF Kiss, Lili
   Szabo, Zsuzsanna
   Semjeni, Mariann
   Dezso, Balazs
   Flasko, Tibor
   Toth, Gyorgy
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Lili] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Semjeni, Mariann] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Toth, Gyorgy] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Kiss, L (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Kiss, N
   Bursics, A
   Papai, Zs
AF Kiss, Nora
   Bursics, Attila
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Nora] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, N (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 45
EP 46
PG 2
ER

PT J
AU Kiss, O
   Tokes, AM
   Szasz, AM
   Kulka, J
AF Kiss, Orsolya
   Tokes, Anna-Maria
   Szasz, Attila Marcell
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Orsolya] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Hungarian Academy of Sciences, MTA-SE Tumor Progression Research GroupBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kiss, O (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Kocsis, J
   Andras, Cs
   Gonda, A
   Juhasz, B
   Szekanecz, �
   Toth, J
   Talladi, Z
   Szilagyi, �
   Horvath, Zs
AF Kocsis, Judit
   Andras, Csilla
   Gonda, Andrea
   Juhasz, Balazs
   Szekanecz, Eva
   Toth, Judit
   Talladi, Zoltanne
   Szilagyi, Eva
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Gonda, Andrea] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Juhasz, Balazs] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Talladi, Zoltanne] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szilagyi, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Kocsis, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Kocsis, J
AF Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Kocsis, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 46
EP 47
PG 2
ER

PT J
AU Koltai, L
AF Koltai, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Koltai, L (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Koltai, P
   Bocs, K
   Plotar, V
   Liszkay, G
AF Koltai, Pal
   Bocs, Katalin
   Plotar, Vanda
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Koltai, P (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Koncz, Zs
   Kovacs, P
   Godeny, A
   Gerlinger, L
   Peti, J
   Risko, �
AF Koncz, Zsuzsa
   Kovacs, Peter
   Godeny, Anna
   Gerlinger, Lilla
   Peti, Julianna
   Risko, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koncz, Zsuzsa] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Peti, Julianna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Risko, Agnes] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Koncz, Zs (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 47
EP 48
PG 2
ER

PT J
AU Koreinne Szanto, A
AF Koreinne Szanto, Adrienn
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koreinne Szanto, Adrienn] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Koreinne Szanto, A (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Kotai, Zs
AF Kotai, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotai, Zsuzsa] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Kotai, Zs (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Kotlan, B
   Naszados, Gy
   Godeny, M
   Toth, L
   Gobor, L
   Plotar, V
   Horvath, Sz
   Eles, K
   Toth, E
   Kasler, M
   Liszkay, G
   Marincola, F
AF Kotlan, Beatrix
   Naszados, Gyorgy
   Godeny, Maria
   Toth, Laszlo
   Gobor, Laszlo
   Plotar, Vanda
   Horvath, Szabolcs
   Eles, Klara
   Toth, Erika
   Kasler, Miklos
   Liszkay, Gabriella
   Marincola, Francesco
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Naszados, Gyorgy] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Gobor, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Marincola, Francesco] SIDRA Klinikai Kutatasi CentrumDoha, Qatar.
RP Kotlan, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Kotlan, B
   Liszkay, G
   Borbola, K
   Balatoni, T
   Csuka, O
   Olasz, J
   Toth, L
   Plotar, V
   Horvath, Sz
   Blank, M
   Shoenfeld, Y
   Kasler, M
AF Kotlan, Beatrix
   Liszkay, Gabriella
   Borbola, Kinga
   Balatoni, Timea
   Csuka, Orsolya
   Olasz, Judit
   Toth, Laszlo
   Plotar, Vanda
   Horvath, Szabolcs
   Blank, Miri
   Shoenfeld, Yehuda
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Blank, Miri] Sheba Medical Center, Zablukowitz Center of Autoimmune DiseasesTel Aviv, Israel.
   [Shoenfeld, Yehuda] Sheba Medical Center, Zablukowitz Center of Autoimmune DiseasesTel Aviv, Israel.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Kotlan, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Kovacs, E
   Bidlek, M
AF Kovacs, Eszter
   Bidlek, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Kovacs, E (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Kovacs, J
   Edesne Boldizsar, M
   Kapuvari, B
   Udvarhelyi, N
   Horvath, Zs
   Czeyda-Pommersheim, F
   Lang, I
   Matrai, Z
   Vincze, B
AF Kovacs, Judit
   Edesne Boldizsar, Marianna
   Kapuvari, Bence
   Udvarhelyi, Nora
   Horvath, Zsolt
   Czeyda-Pommersheim, Ferenc
   Lang, Istvan
   Matrai, Zoltan
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Edesne Boldizsar, Marianna] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Kovacs, J (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Kovacs, P
   Panczel, G
   Borbola, K
   Juhasz, G
   Liszkay, G
AF Kovacs, Peter
   Panczel, Gitta
   Borbola, Kinga
   Juhasz, Gabriella
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Borbola, Kinga] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Juhasz, Gabriella] Semmelweis University, Department of Pharmacology and PharmacotherapyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Kohalmy, K
   Kovacs, J
   Kapuvari, B
   Boldizsar, M
   Czeyda-Pommersheim, F
   Udvarhelyi, N
   Horvath, Zs
   Lang, I
   Matrai, Z
   Csuka, O
   Vincze, B
AF Kohalmy, Krisztina
   Kovacs, Judit
   Kapuvari, Bence
   Boldizsar, Mariann
   Czeyda-Pommersheim, Ferenc
   Udvarhelyi, Nora
   Horvath, Zsolt
   Lang, Istvan
   Matrai, Zoltan
   Csuka, Orsolya
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Boldizsar, Mariann] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Kohalmy, K (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Krascsenits, G
   Pete, I
   Orosz, E
   Otto, Sz
AF Krascsenits, Geza
   Pete, Imre
   Orosz, Eniko
   Otto, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Krascsenits, Geza] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Orosz, Eniko] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Otto, Szabolcs] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
RP Krascsenits, G (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Kruchio, �
AF Kruchio, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kruchio, Eva] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Kruchio, � (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Kullmann, T
AF Kullmann, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Kunos, Cs
   Gulyas, G
   Palvolgyi, K
   Toth, E
   Kovacs, E
   Pukancsik, D
   Matrai, Z
AF Kunos, Csaba
   Gulyas, Gusztav
   Palvolgyi, Klara
   Toth, Erika
   Kovacs, Eszter
   Pukancsik, David
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kunos, Csaba] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Palvolgyi, Klara] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Pukancsik, David] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Kunos, Cs (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 51
EP 52
PG 2
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Lahm, E
AF Lahm, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Lang, I
AF Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Lang, I (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 52
EP 53
PG 2
ER

PT J
AU Lantos, L
AF Lantos, Lenke
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lantos, Lenke] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Lantos, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Laszlo, Z
   Farkas, R
   Kalincsak, J
   Mangel, L
AF Laszlo, Zoltan
   Farkas, Robert
   Kalincsak, Judit
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Laszlo, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Lengyel, M
   Radovicsne Bakos, B
AF Lengyel, Monika
   Radovicsne Bakos, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Radovicsne Bakos, Borbala] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Lengyel, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 53
EP 54
PG 2
ER

PT J
AU Lengyel, Zs
   Battyani, Z
   Szekeres, Gy
   Csernus, V
   Gyulai, R
   Nagy, A
AF Lengyel, Zsuzsanna
   Battyani, Zita
   Szekeres, Gyorgy
   Csernus, Valer
   Gyulai, Rolland
   Nagy, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Battyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Szekeres, Gyorgy] Hisztopatologia KFTPecs, Hungary.
   [Csernus, Valer] Pecsi Tudomanyegyetem AOK, Anatomiai IntezetPecs, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Nagy, Andras] Pecsi Tudomanyegyetem AOK, Anatomiai IntezetPecs, Hungary.
RP Lengyel, Zs (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Locsei, Z
   Szappanos, Sz
   Sebestyen, K
   Sebestyen, Zs
   Csapo, L
   Mangel, LCs
AF Locsei, Zoltan
   Szappanos, Szabolcs
   Sebestyen, Klara
   Sebestyen, Zsolt
   Csapo, Laszlo
   Mangel, Laszlo Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Lovey, J
   Horvath, Zs
   Bago, A
   Fedorcsak, I
   Manninger, S
   Lang, I
   Polgar, Cs
   Kasler, M
AF Lovey, Jozsef
   Horvath, Zsolt
   Bago, Attila
   Fedorcsak, Imre
   Manninger, Sandor
   Lang, Istvan
   Polgar, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Bago, Attila] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
   [Fedorcsak, Imre] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
   [Manninger, Sandor] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Lukacs, G
   Volgyi, Z
   Ruzsa, �
AF Lukacs, Gabor
   Volgyi, Zoltan
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Volgyi, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Ruzsa, Agnes] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Lukacs, G (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Lukats, O
   Fodor, E
   Veres, A
   Jaray, B
   Toth, J
AF Lukats, Olga
   Fodor, Eszter
   Veres, Amarilla
   Jaray, Balazs
   Toth, Jeannette
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukats, Olga] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Fodor, Eszter] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Veres, Amarilla] Semmelweis University, Department of OphthalmologyBudapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Lukats, O (reprint author), Semmelweis University, Department of Ophthalmology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Madaras, L
   Kovacs, KA
   Szasz, AM
   Tokes, AM
   Szekely, B
   Kenessey, I
   Kiss, O
   Dank, M
   Kulka, J
AF Madaras, Lilla
   Kovacs, Kristof Attila
   Szasz, Attila Marcell
   Tokes, Anna-Maria
   Szekely, Borbala
   Kenessey, Istvan
   Kiss, Orsolya
   Dank, Magdolna
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kovacs, Kristof Attila] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szekely, Borbala] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Orsolya] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Madaras, L (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Majer, R
   Mailath, M
   Horvath, Zs
AF Majer, Reka
   Mailath, Monika
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Majer, Reka] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Mailath, Monika] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Majer, R (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Mansell, J
   Weiler-Mithoff, E
   Stallard, Sh
   Romics, L
AF Mansell, James
   Weiler-Mithoff, Eva
   Stallard, Sheila
   Romics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mansell, James] NHS Victoria Infirmary, SebeszetGlasgow, UK.
   [Weiler-Mithoff, Eva] Glasgow Royal Infirmary, SebeszetGlasgow, UK.
   [Stallard, Sheila] Western Infirmary Glasgow, SebeszetGlasgow, UK.
   [Romics, Laszlo] NHS Victoria Infirmary, SebeszetGlasgow, UK.
RP Mansell, J (reprint author), NHS Victoria Infirmary, Sebeszet, Glasgow, UK.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 57
EP 58
PG 2
ER

PT J
AU Mansell, J
   Weiler-Mithoff, E
   Stallard, Sh
   Romics, L
AF Mansell, James
   Weiler-Mithoff, Eva
   Stallard, Sheila
   Romics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mansell, James] NHS Victoria Infirmary, SebeszetGlasgow, UK.
   [Weiler-Mithoff, Eva] Glasgow Royal Infirmary, SebeszetGlasgow, UK.
   [Stallard, Sheila] Western Infirmary Glasgow, SebeszetGlasgow, UK.
   [Romics, Laszlo] NHS Victoria Infirmary, SebeszetGlasgow, UK.
RP Mansell, J (reprint author), NHS Victoria Infirmary, Sebeszet, Glasgow, UK.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Mansell, J
   Weiler-Mithoff, E
   Stallard, Sh
   Romics, L
AF Mansell, James
   Weiler-Mithoff, Eva
   Stallard, Sheila
   Romics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mansell, James] NHS Victoria Infirmary, SebeszetGlasgow, UK.
   [Weiler-Mithoff, Eva] Glasgow Royal Infirmary, SebeszetGlasgow, UK.
   [Stallard, Sheila] Western Infirmary Glasgow, SebeszetGlasgow, UK.
   [Romics, Laszlo] NHS Victoria Infirmary, SebeszetGlasgow, UK.
RP Mansell, J (reprint author), NHS Victoria Infirmary, Sebeszet, Glasgow, UK.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Maraz, A
   Bodoky, Gy
   Dank, M
   Geczi, L
   Kahan, Zs
   Mangel, L
   Revesz, J
   Szucs, M
AF Maraz, Aniko
   Bodoky, Gyorgy
   Dank, Magdolna
   Geczi, Lajos
   Kahan, Zsuzsanna
   Mangel, Laszlo
   Revesz, Janos
   Szucs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Revesz, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Maraz, R
   Boross, G
   Pap-Szekeres, J
   Marko, L
   Cserni, G
AF Maraz, Robert
   Boross, Gabor
   Pap-Szekeres, Jozsef
   Marko, Laszlo
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pap-Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Marko, L
   Pajkos, G
   Hajnal, L
   Vizhanyo, R
   Pap-Szekeres, J
   Svebis, M
   Cserni, G
AF Marko, Laszlo
   Pajkos, Gabor
   Hajnal, Lajos
   Vizhanyo, Rita
   Pap-Szekeres, Jozsef
   Svebis, Mihaly
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pap-Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Marosfoi, M
   Szikora, I
AF Marosfoi, Miklos
   Szikora, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marosfoi, Miklos] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Szikora, Istvan] National Institute of Clinical NeurosciencesBudapest, Hungary.
RP Marosfoi, M (reprint author), National Institute of Clinical Neurosciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Mate, Sz
   Szathmari, E
AF Mate, Szabolcs
   Szathmari, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mate, Szabolcs] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Szathmari, Erzsebet] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
RP Mate, Sz (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Matrai, Z
AF Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Matrai, Z
   Kunos, Cs
   Udvarhelyi, N
   Bidlek, M
   Rubovszky, G
   Zaka, Z
   Savolt, �
   Kasler, M
AF Matrai, Zoltan
   Kunos, Csaba
   Udvarhelyi, Nora
   Bidlek, Maria
   Rubovszky, Gabor
   Zaka, Zoltan
   Savolt, Akos
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Meilinger-Dobra, M
   Remenar, �
AF Meilinger-Dobra, Monika
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meilinger-Dobra, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Meilinger-Dobra, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Mersich, T
   Dede, K
   Besznyak, I
   Landherr, L
   Egyed, Zs
   Salamon, F
   Bursics, A
AF Mersich, Tamas
   Dede, Kristof
   Besznyak, Istvan
   Landherr, Laszlo
   Egyed, Zsofia
   Salamon, Ferenc
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Egyed, Zsofia] Uzsoki Utcai Korhaz, Rontgen DiagnosztikaBudapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Mersich, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Meszaros, E
   Landherr, L
AF Meszaros, Edina
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Meszaros, E (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 61
EP 62
PG 2
ER

PT J
AU Meszaros, G
AF Meszaros, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Gabriella] Orszagos Orvosi Rehabilitacios Intezet, Baleseti Mozgasszervi Rehabilitacios OsztalyBudapest, Hungary.
RP Meszaros, G (reprint author), Orszagos Orvosi Rehabilitacios Intezet, Baleseti Mozgasszervi Rehabilitacios Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Mihaly, Zs
   Lanczky, A
   Dank, M
   Szasz, AM
   Kormos, M
   Gyorffy, B
AF Mihaly, Zsuzsanna
   Lanczky, Andras
   Dank, Magdolna
   Szasz, Attila Marcell
   Kormos, Mate
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mihaly, Zsuzsanna] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Lanczky, Andras] Pazmany Peter Catholic UniversityBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kormos, Mate] Pazmany Peter Catholic UniversityBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
RP Mihaly, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Mihaly, Zs
   Szucs, M
   Riesz, P
   Nyirady, P
AF Mihaly, Zsuzsanna
   Szucs, Miklos
   Riesz, Peter
   Nyirady, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mihaly, Zsuzsanna] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Mihaly, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 62
EP 63
PG 2
ER

PT J
AU Molnar, Zs
   Kapuvari, B
   Kovacs, J
   Rosta, A
   Vincze, B
AF Molnar, Zsuzsanna
   Kapuvari, Bence
   Kovacs, Judit
   Rosta, Andras
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Zsuzsanna] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Molnar, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Nagy, ACs
   Gulacsi-Bardos, PP
   Landherr, L
   Nagykalnai, T
AF Nagy, Andras Csaba
   Gulacsi-Bardos, Petra Panna
   Landherr, Laszlo
   Nagykalnai, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Andras Csaba] Uzsoki Utcai Korhaz, I-es Belgyogyaszat – KardiologiaVeresegyhaz, Hungary.
   [Gulacsi-Bardos, Petra Panna] Uzsoki Utcai Korhaz, I-es Belgyogyaszat – KardiologiaVeresegyhaz, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nagykalnai, Tamas] Gyula Nyiro HospitalBudapest, Hungary.
RP Nagy, ACs (reprint author), Uzsoki Utcai Korhaz, I-es Belgyogyaszat – Kardiologia, Veresegyhaz, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Nagy, A
   Szabo, T
AF Nagy, Attila
   Szabo, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Attila] Orszagos Onkologiai Intezet, Kuraszeru Ellato ReszlegBudapest, Hungary.
   [Szabo, Tamas] Orszagos Onkologiai Intezet, Kuraszeru Ellato ReszlegBudapest, Hungary.
RP Nagy, A (reprint author), Orszagos Onkologiai Intezet, Kuraszeru Ellato Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Nagy, B
   Antal, A
AF Nagy, Balazs
   Antal, Anita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Balazs] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Antal, Anita] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Nagy, B (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Nagy, B
AF Nagy, Belane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Belane] Orszagos Onkologiai Intezet, Foglalkozas-Egeszsegugyi SzolgalatBudapest, Hungary.
RP Nagy, B (reprint author), Orszagos Onkologiai Intezet, Foglalkozas-Egeszsegugyi Szolgalat, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Nagy, J
   Horvath, Zs
AF Nagy, Janos
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Nagy, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 64
EP 65
PG 2
ER

PT J
AU Nagy, N
   Mark, �
   Molnar, A
   Sticz, T
   Buthi, N
   Hajdu, M
   Paku, S
   Kopper, L
   Sebestyen, A
AF Nagy, Noemi
   Mark, Agnes
   Molnar, Anna
   Sticz, Tamas
   Buthi, Nora
   Hajdu, Melinda
   Paku, Sandor
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Molnar, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sticz, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Buthi, Nora] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Nagy, N (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Nagy, P
   Kiss, E
   Oberna, F
   Barabas, J
   Papai, Zs
AF Nagy, Peter
   Kiss, Edina
   Oberna, Ferenc
   Barabas, Jozsef
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Barabas, Jozsef] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Nagy, P (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Nagy, P
   Liszkay, G
AF Nagy, Peter
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Nagy, P (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Nagy, Zs
AF Nagy, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Zsolt] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Nagy, Zs (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Nagyivanyi, K
   Biro, K
   Bodrogi, I
   Gyergyay, F
   Kuronya, Zs
   Nemeth, H
   Geczi, L
AF Nagyivanyi, Krisztian
   Biro, Krisztina
   Bodrogi, Istvan
   Gyergyay, Fruzsina
   Kuronya, Zsofia
   Nemeth, Hajnalka
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Nagyivanyi, K (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Nagykalnai, T
   Nagy, ACs
   Landherr, L
AF Nagykalnai, Tamas
   Nagy, Andras Csaba
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia SzakrendelesBudapest, Hungary.
   [Nagy, Andras Csaba] Uzsoki Municipal Hospital, 1st Department of Internal Medicine and CardiologyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Naszados, Gy
   Kotlan, B
   Plotar, V
   Eles, K
   Toth, E
   Godeny, M
AF Naszados, Gyorgy
   Kotlan, Beatrix
   Plotar, Vanda
   Eles, Klara
   Toth, Erika
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Naszados, Gyorgy] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kotlan, Beatrix] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Naszados, Gy (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Nemeth, H
   Kuronya, Zs
   Biro, K
   Toth, K
   Horvath, Sz
   Geczi, L
AF Nemeth, Hajnalka
   Kuronya, Zsofia
   Biro, Krisztina
   Toth, Krisztina
   Horvath, Szabolcs
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Toth, Krisztina] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Nemeth, H (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Nemeth, Zs
   Boer, K
   Kasler, M
   Borbely, K
AF Nemeth, Zsuzsanna
   Boer, Katalin
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Nemeth, Zs (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 67
EP 68
PG 2
ER

PT J
AU Novak, M
   Antal, A
AF Novak, Melinda
   Antal, Anita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Novak, Melinda] Orszagos Onkologiai Intezet, MammographiaBudapest, Hungary.
   [Antal, Anita] Orszagos Onkologiai Intezet, MammographiaBudapest, Hungary.
RP Novak, M (reprint author), Orszagos Onkologiai Intezet, Mammographia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Ocsai, H
   Battyani, Z
   Emri, G
   Liszkay, G
   Somlai, B
   Olah, J
AF Ocsai, Henriette
   Battyani, Zita
   Emri, Gabriella
   Liszkay, Gabriella
   Somlai, Beata
   Olah, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ocsai, Henriette] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Battyani, Zita] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Emri, Gabriella] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Ocsai, H (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Olasz, J
   Doleschall, Z
AF Olasz, Judit
   Doleschall, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Doleschall, Zoltan] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Olasz, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Orosz, �
   Revesz, P
   Szanyi, I
   Pajkos, G
   Gombos, K
AF Orosz, Eva
   Revesz, Peter
   Szanyi, Istvan
   Pajkos, Gabor
   Gombos, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Eva] University of Pecs, Faculty of MedicinePecs, Hungary.
   [Revesz, Peter] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Szanyi, Istvan] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
RP Orosz, � (reprint author), University of Pecs, Faculty of Medicine, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Orosz, K
   Szabados, M
AF Orosz, Krisztina
   Szabados, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orosz, Krisztina] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Szabados, Marta] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Orosz, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Otto, Sz
   Pete, I
AF Otto, Szabolcs
   Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Otto, Szabolcs] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Otto, Sz (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Pajkos, G
   Boda, �
   Hajnal, L
   Kosa, M
   Radetzky, �
   Szasz, �
   Vizhanyo, R
AF Pajkos, Gabor
   Boda, Eva
   Hajnal, Lajos
   Kosa, Miklos
   Radetzky, Agota
   Szasz, Arpad
   Vizhanyo, Rita
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Boda, Eva] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kosa, Miklos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Radetzky, Agota] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szasz, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Pajkos, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 69
EP 70
PG 2
ER

PT J
AU Pajkos, G
   Frohlich, M
   Pecznik, �
   Somodi, Zs
   Szabo, A
AF Pajkos, Gabor
   Frohlich, Monika
   Pecznik, Eva
   Somodi, Zsolt
   Szabo, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Frohlich, Monika] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pecznik, Eva] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Somodi, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szabo, Aniko] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Pajkos, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Panczel, G
   Szucs, M
   Szoke, J
   Liszkay, G
AF Panczel, Gitta
   Szucs, Miklos
   Szoke, Janos
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Papai, Zs
   Sapi, Z
   Perlaky, Z
   Kiss, J
   Szalai, K
   Szendroi, M
AF Papai, Zsuzsanna
   Sapi, Zoltan
   Perlaky, Zoltan
   Kiss, Janos
   Szalai, Krisztian
   Szendroi, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papai, Zsuzsanna] Honved KorhazBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Perlaky, Zoltan] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szalai, Krisztian] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
RP Papai, Zs (reprint author), Honved Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Papp, J
   Vaszko, T
   Gyuris, T
   Balint, BL
   Horvath, A
   Nagy, L
   Gezsi, A
   Sarkozy, P
   Peter, A
   Olah, E
AF Papp, Janos
   Vaszko, Tibor
   Gyuris, Tibor
   Balint, Balint Laszlo
   Horvath, Attila
   Nagy, Laszlo
   Gezsi, Andras
   Sarkozy, Peter
   Peter, Antal
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vaszko, Tibor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Gyuris, Tibor] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Horvath, Attila] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Nagy, Laszlo] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Gezsi, Andras] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai KarBudapest, Hungary.
   [Sarkozy, Peter] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai KarBudapest, Hungary.
   [Peter, Antal] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai KarBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Papp, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Paszternakne Bakos, M
AF Paszternakne Bakos, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Paszternakne Bakos, Maria] Orszagos Onkologiai Intezet, Kuraszeru Ellato ReszlegBudapest, Hungary.
RP Paszternakne Bakos, M (reprint author), Orszagos Onkologiai Intezet, Kuraszeru Ellato Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 71
EP 72
PG 2
ER

PT J
AU Pete, I
AF Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Pete, I
AF Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Peti, J
AF Peti, Julianna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Peti, Julianna] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
RP Peti, J (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 72
EP 73
PG 2
ER

PT J
AU Piko, B
   Bassam, A
   Banhegyi, RJ
   Zsilak, J
   Puskasne Szatmari, K
   Csikosne Macsok, E
   Csiffari, M
AF Piko, Bela
   Bassam, Ali
   Banhegyi, Robert Janos
   Zsilak, Janos
   Puskasne Szatmari, Klara
   Csikosne Macsok, Erzsebet
   Csiffari, Margit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Banhegyi, Robert Janos] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Zsilak, Janos] Bekescsaba Varosi Onkormanyzat Rethy Pal Korhaza, Sebeszeti OsztalyBekescsaba, Hungary.
   [Puskasne Szatmari, Klara] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csikosne Macsok, Erzsebet] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Pinter, Zs
AF Pinter, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Zsuzsanna] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Pinter, Zs (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 73
EP 74
PG 2
ER

PT J
AU Polgar, Cs
   Resch, A
   Gal, J
   Kauer-dorner, D
   Strnad, V
   Niehoff, P
   Loessl, K
   Kovacs, Gy
   Van Limbergen, E
   Hannoun-Levi, JM
AF Polgar, Csaba
   Resch, Alexandra
   Gal, Jocelyn
   Kauer-dorner, Daniela
   Strnad, Vratislav
   Niehoff, Peter
   Loessl, Kristina
   Kovacs, Gyorgy
   Van Limbergen, Erik
   Hannoun-Levi, Jean-Michel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Resch, Alexandra] Medical University of Vienna, Department of RadiologyVienna, Austria.
   [Gal, Jocelyn] Antoine Lacassagne Cancer Center, Biostatistic UnitNizza, France.
   [Kauer-dorner, Daniela] Medical University of Vienna, Department of RadiologyVienna, Austria.
   [Strnad, Vratislav] University of Erlangen, Department of Radiation OncologyErlangen, Germany.
   [Niehoff, Peter] City Hospital Cologne, Department of RadiotherapyKoln, Germany.
   [Loessl, Kristina] Hospital Bernes, Department of Radiation OncologyBern, Switzerland.
   [Kovacs, Gyorgy] Universitat zu Lubeck, Interdiszciplinaris Brachyterapia KozpontLubeck, Germany.
   [Van Limbergen, Erik] University Hospital Gasthuisberg, Department of Radiation OncologyLeuven, Belgium.
   [Hannoun-Levi, Jean-Michel] Antoine Lacassagne Cancer Center, Biostatistic UnitNizza, France.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 74
EP 75
PG 2
ER

PT J
AU Porneczy, E
   Pete, I
   Vizkeleti, J
   Fabry, L
   Liszkay, G
AF Porneczy, Edit
   Pete, Imre
   Vizkeleti, Julia
   Fabry, Laszlo
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fabry, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Porneczy, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Pukancsik, D
   Savolt, �
   Kunos, Cs
   Gulyas, G
   Godeny, M
   Kovacs, E
   Udvarhelyi, N
   Zaka, Z
   Kasler, M
   Matrai, Z
AF Pukancsik, David
   Savolt, Akos
   Kunos, Csaba
   Gulyas, Gusztav
   Godeny, Maria
   Kovacs, Eszter
   Udvarhelyi, Nora
   Zaka, Zoltan
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pukancsik, David] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kunos, Csaba] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Pukancsik, D (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Puskas, G
AF Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Revesz, Cs
   Palosi, E
AF Revesz, Csilla
   Palosi, Edina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Revesz, Csilla] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Palosi, Edina] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Revesz, Cs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Rozsa, D
   Olah, G
   Kertesz, I
   Trencsenyi, Gy
   Marian, T
   Treszl, A
   Mezo, G
   Halmos, G
AF Rozsa, David
   Olah, Gabor
   Kertesz, Istvan
   Trencsenyi, Gyorgy
   Marian, Terez
   Treszl, Andrea
   Mezo, Gabor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rozsa, David] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Olah, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Kertesz, Istvan] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Trencsenyi, Gyorgy] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Marian, Terez] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Treszl, Andrea] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Halmos, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
RP Rozsa, D (reprint author), University of Debrecen, Department of Pharmacology and Pharmacotherapy, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Rus-Gal, PO
   Bassam, A
   Csiffari, M
   Dimak, S
   Piko, B
AF Rus-Gal, Paul Ovidiu
   Bassam, Ali
   Csiffari, Margit
   Dimak, Sandor
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rus-Gal, Paul Ovidiu] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Dimak, Sandor] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Rus-Gal, PO (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Rusz, O
   Kelemen, Gy
   Voros, A
   Ormandi, K
   Paszt, A
   Kahan, Zs
AF Rusz, Orsolya
   Kelemen, Gyongyi
   Voros, Andras
   Ormandi, Katalin
   Paszt, Attila
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Rusz, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Rusz, O
   Pal, M
   Kovacs, L
   Tomisa, B
   Tosoki, R
   Meszaros, N
   Nagy, O
   Szilagyi, �
   Rovo, L
   Mozes, P
   Deak, P
   Kahan, Zs
AF Rusz, Orsolya
   Pal, Margo
   Kovacs, Levente
   Tomisa, Bettina
   Tosoki, Renata
   Meszaros, Noemi
   Nagy, Olga
   Szilagyi, Eva
   Rovo, Laszlo
   Mozes, Petra
   Deak, Peter
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pal, Margo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Kovacs, Levente] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Tomisa, Bettina] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Tosoki, Renata] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Meszaros, Noemi] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Nagy, Olga] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rovo, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Mozes, Petra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Deak, Peter] Szegedi Biologiai Kozpont, Biokemiai IntezetSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Rusz, O (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Ruszkai, K
AF Ruszkai, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruszkai, Katalin] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Ruszkai, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Ruzsa, �
AF Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Ruzsa, � (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Ruzsics, I
   Semjen, D
   Derczy, K
   Baliko, Z
   Sarosi, V
AF Ruzsics, Istvan
   Semjen, David
   Derczy, Katalin
   Baliko, Zoltan
   Sarosi, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsics, Istvan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Semjen, David] University of Pecs, Department of PathologyPecs, Hungary.
   [Derczy, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
RP Ruzsics, I (reprint author), University of Pecs, Faculty of Medicine, Department of Pulmonology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Sarosi, V
   Baliko, Z
   Albert, B
AF Sarosi, Veronika
   Baliko, Zoltan
   Albert, Brigitta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Albert, Brigitta] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
RP Sarosi, V (reprint author), University of Pecs, Faculty of Medicine, Department of Pulmonology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Savolt, �
   Polgar, Cs
   Sinkovics, I
   Udvarhelyi, N
   Bidlek, M
   Kovacs, E
   Farkas, E
   Matrai, Z
AF Savolt, Akos
   Polgar, Csaba
   Sinkovics, Istvan
   Udvarhelyi, Nora
   Bidlek, Maria
   Kovacs, Eszter
   Farkas, Emil
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Savolt, � (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 78
EP 79
PG 2
ER

PT J
AU Schipp, I
   Auth, P
   Al-Farhat, Y
AF Schipp, Ildiko
   Auth, Peter
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schipp, Ildiko] Tolnai Megyei Balassa Janos Korhaz, Tudogyogyaszati OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Schipp, I (reprint author), Tolnai Megyei Balassa Janos Korhaz, Tudogyogyaszati Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Schneider, B
   Kotai, Zs
AF Schneider, Brigitta
   Kotai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Brigitta] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Kotai, Zsuzsanna] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Schneider, B (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Schneider, T
   Rottek, J
AF Schneider, Tamas
   Rottek, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rottek, Janos] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Schneider, T (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Seber, J
AF Seber, Jozsefne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Seber, Jozsefne] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
RP Seber, J (reprint author), Orszagos Onkologiai Intezet, Citopatologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 80
EP 80
PG 1
ER

PT J
AU Sebestyen, A
   Mark, �
   Nagy, N
   Hajdu, M
   Csoka, M
   Sticz, T
   Barna, G
   Varadi, Zs
   Kopper, L
AF Sebestyen, Anna
   Mark, Agnes
   Nagy, Noemi
   Hajdu, Melinda
   Csoka, Monika
   Sticz, Tamas
   Barna, Gabor
   Varadi, Zsofia
   Kopper, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Sticz, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Varadi, Zsofia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 80
EP 80
PG 1
ER

PT J
AU Sikter, M
   Lahm, E
   Papai, Zs
AF Sikter, Marta
   Lahm, Erika
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Sikter, M (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 80
EP 80
PG 1
ER

PT J
AU Simon, T
AF Simon, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simon, Tamas] Magyar Rakellenes LigaBudapest, Hungary.
RP Simon, T (reprint author), Magyar Rakellenes Liga, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 80
EP 81
PG 2
ER

PT J
AU Sipos, �
   Treszl, A
   Steiber, Z
   Berta, A
   Halmos, G
AF Sipos, Eva
   Treszl, Andrea
   Steiber, Zita
   Berta, Andras
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sipos, Eva] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Steiber, Zita] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti KlinikaDebrecen, Hungary.
   [Berta, Andras] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti KlinikaDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Sipos, � (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 81
EP 81
PG 1
ER

PT J
AU Somogyine Ezer, �
   Kovacs, �
   Liposits, G
   Antal, G
   Gilincsek, L
   Zadori, P
   Repa, I
AF Somogyine Ezer, Eva
   Kovacs, Arpad
   Liposits, Gabor
   Antal, Gergely
   Gilincsek, Lajos
   Zadori, Peter
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somogyine Ezer, Eva] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Liposits, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gilincsek, Lajos] Kaposi Mor Oktato Korhaz, Ful- Orr- Gegeszeti OsztalyKaposvar, Hungary.
   [Zadori, Peter] Somogy Megyei Kaposi Mor Oktato Korhaz, Diagnosztikai KozpontKaposvar, Hungary.
   [Repa, Imre] Somogy Megyei Kaposi Mor Oktato Korhaz, Diagnosztikai KozpontKaposvar, Hungary.
RP Somogyine Ezer, � (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 81
EP 81
PG 1
ER

PT J
AU Steuer, R
   Papai, Zs
AF Steuer, Robert
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Steuer, Robert] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Steuer, R (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 82
EP 82
PG 1
ER

PT J
AU Szabo, BG
   Kis, I
   Marton, A
   Vizler, Cs
   Timar, J
   Tatrai, E
   Tovari, J
   Szilak, L
AF Szabo, Balint Gergely
   Kis, Ibolya
   Marton, Annamaria
   Vizler, Csaba
   Timar, Jozsef
   Tatrai, Eniko
   Tovari, Jozsef
   Szilak, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Balint Gergely] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Kis, Ibolya] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Marton, Annamaria] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
   [Vizler, Csaba] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tatrai, Eniko] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Szilak, Laszlo] Nyugat-magyarorszagi Egyetem, TTK Biologiai IntezetSzombathely, Hungary.
RP Szabo, BG (reprint author), Semmelweis University, Faculty of Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 82
EP 82
PG 1
ER

PT J
AU Szabo, I
   Opauszki, A
   Banyasz, T
   Horvath, Zs
AF Szabo, Imre
   Opauszki, Adrienn
   Banyasz, Tamas
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Imre] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Opauszki, Adrienn] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Banyasz, Tamas] University of Debrecen, Faculty of Medicine, Department of PhysiologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Szabo, I (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 82
EP 83
PG 2
ER

PT J
AU Szabo, T
AF Szabo, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Tamas] National Institute of OncologyBudapest, Hungary.
RP Szabo, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 83
EP 83
PG 1
ER

PT J
AU Szabo, Zs
   Kiss, L
   Dezso, B
   Flasko, T
   Gombos, K
   Juhasz, K
   Ember, I
   Mehes, G
   Hever, Zs
   Mogyorosi, R
   Halmos, G
AF Szabo, Zsuzsanna
   Kiss, Lili
   Dezso, Balazs
   Flasko, Tibor
   Gombos, Katalin
   Juhasz, Krisztina
   Ember, Istvan
   Mehes, Gabor
   Hever, Zsofia
   Mogyorosi, Rita
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Kiss, Lili] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Juhasz, Krisztina] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Ember, Istvan] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Hever, Zsofia] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Mogyorosi, Rita] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Szabo, Zs (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 83
EP 83
PG 1
ER

PT J
AU Szalai, M
   Lasztoczi, E
AF Szalai, Marta
   Lasztoczi, Emil
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Marta] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Lasztoczi, Emil] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szalai, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 83
EP 83
PG 1
ER

PT J
AU Szalai, M
AF Szalai, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Marta] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Szalai, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 83
EP 84
PG 2
ER

PT J
AU Szaleczky, E
AF Szaleczky, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Szaleczky, E (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 84
EP 84
PG 1
ER

PT J
AU Szantho, A
AF Szantho, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
RP Szantho, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 84
EP 84
PG 1
ER

PT J
AU Szappanos, Sz
   Locsei, Z
   Kalincsak, J
   Laszlo, Z
   Musch, Z
   Csapo, L
   Sebestyen, K
   Sebestyen, Zs
   Farkas, R
   Mangel, L
AF Szappanos, Szabolcs
   Locsei, Zoltan
   Kalincsak, Judit
   Laszlo, Zoltan
   Musch, Zoltan
   Csapo, Laszlo
   Sebestyen, Klara
   Sebestyen, Zsolt
   Farkas, Robert
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Szappanos, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 84
EP 85
PG 2
ER

PT J
AU Szasz, AM
   Tokes, AM
   Madaras, L
   Lukacs, L
   Meggyeshazi, N
   Turanyi, E
   Kas, J
   Harsanyi, L
   Baranyai, Zs
   Fillinger, J
   Soltesz, I
   Hanzely, Z
   Balint, K
   Arato, G
   Szendroi, M
   Kulka, J
AF Szasz, Attila Marcell
   Tokes, Anna-Maria
   Madaras, Lilla
   Lukacs, Lilla
   Meggyeshazi, Nora
   Turanyi, Eszter
   Kas, Jozsef
   Harsanyi, Laszlo
   Baranyai, Zsolt
   Fillinger, Janos
   Soltesz, Ibolya
   Hanzely, Zoltan
   Balint, Katalin
   Arato, Gabriella
   Szendroi, Miklos
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lukacs, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Meggyeshazi, Nora] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Turanyi, Eszter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kas, Jozsef] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Baranyai, Zsolt] Tumorgenetika Human Biospecimen Collection and ResearchBudapest, Hungary.
   [Fillinger, Janos] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Soltesz, Ibolya] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Hanzely, Zoltan] Orszagos Idegtudomanyi Intezet, Patologiai OsztalyBudapest, Hungary.
   [Balint, Katalin] Orszagos Idegtudomanyi Intezet, Patologiai OsztalyBudapest, Hungary.
   [Arato, Gabriella] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szasz, AM (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 85
EP 85
PG 1
ER

PT J
AU Szekely, G
   Farkas, Gy
   Kasler, M
   Gundy, S
AF Szekely, Gabor
   Farkas, Gyongyi
   Kasler, Miklos
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Szekely, G (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 85
EP 86
PG 2
ER

PT J
AU Szekely, B
   Szasz, AM
   Tokes, AM
   Lotz, G
   Kiss, O
   Nagy, ZsI
   Farago, Zs
   Dank, M
   Kulka, J
AF Szekely, Borbala
   Szasz, Attila Marcell
   Tokes, Anna-Maria
   Lotz, Gabor
   Kiss, Orsolya
   Nagy, Zsofia Ilona
   Farago, Zsofia
   Dank, Magdolna
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Borbala] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kiss, Orsolya] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Nagy, Zsofia Ilona] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Farago, Zsofia] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szekely, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 86
EP 86
PG 1
ER

PT J
AU Szekely, NA
   Acs, B
   Szasz, AM
   Nyirady, P
   Kulka, J
AF Szekely, Nora Anna
   Acs, Balazs
   Szasz, Attila Marcell
   Nyirady, Peter
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Nora Anna] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Acs, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Szekely, NA (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 86
EP 87
PG 2
ER

PT J
AU Szell, M
AF Szell, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szell, Marta] University of Szeged, Department of Medical GeneticsSzeged, Hungary.
RP Szell, M (reprint author), University of Szeged, Department of Medical Genetics, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 87
EP 87
PG 1
ER

PT J
AU Szenes, M
   Gasztonyi, B
AF Szenes, Maria
   Gasztonyi, Beata
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szenes, Maria] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
   [Gasztonyi, Beata] Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati OsztalyZalaegerszeg, Hungary.
RP Szenes, M (reprint author), Zala Megyei Korhaz-Rendelointezet, I. Belgyogyaszati Osztaly, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 87
EP 87
PG 1
ER

PT J
AU Szentirmay, Z
   Csernak, E
   Toth, E
   Molnar, J
   Marx, P
   Tusnady, G
   Tusnady, G
AF Szentirmay, Zoltan
   Csernak, Erzsebet
   Toth, Erika
   Molnar, Janos
   Marx, Peter
   Tusnady, E. Gabor
   Tusnady, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentirmay, Zoltan] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Molnar, Janos] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Marx, Peter] Abbiomics Europe Kft., BioinformatikaBudapest, Hungary.
   [Tusnady, E. Gabor] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Tusnady, Gabor] Hungarian Academy of Sciences, Renyi Alfred Mathematical InstituteBudapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 87
EP 88
PG 2
ER

PT J
AU Szentpetery, F
AF Szentpetery, Felix
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentpetery, Felix] Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti OsztalyBudapest, Hungary.
RP Szentpetery, F (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Oktato Korhaz, Sebeszeti-Ersebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 88
EP 88
PG 1
ER

PT J
AU Szigeti, A
AF Szigeti, Annamaria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Annamaria] Szigeti Gyula Janos Egeszsegugyi Szakkepzo IskolaKaposvar, Hungary.
RP Szigeti, A (reprint author), Szigeti Gyula Janos Egeszsegugyi Szakkepzo Iskola, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 88
EP 88
PG 1
ER

PT J
AU Szigeti, A
AF Szigeti, Annamaria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Annamaria] Szigeti Gyula Janos Egeszsegugyi Szakkepzo IskolaKaposvar, Hungary.
RP Szigeti, A (reprint author), Szigeti Gyula Janos Egeszsegugyi Szakkepzo Iskola, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 88
EP 88
PG 1
ER

PT J
AU Sziklavari, Zs
   Ried, M
   Christian, G
   Szoke, T
   Neu, R
   Hans-Stefan, H
AF Sziklavari, Zsolt
   Ried, Michael
   Christian, Grosser
   Szoke, Tamas
   Neu, Reiner
   Hans-Stefan, Hofmann
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sziklavari, Zsolt] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
   [Ried, Michael] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
   [Christian, Grosser] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
   [Szoke, Tamas] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
   [Neu, Reiner] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
   [Hans-Stefan, Hofmann] Krankenhaus Barmherzige Bruder, MellkassebeszetPettendorf, Germany.
RP Sziklavari, Zs (reprint author), Krankenhaus Barmherzige Bruder, Mellkassebeszet, Pettendorf, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 88
EP 89
PG 2
ER

PT J
AU Szilagyi, A
   Pocza, T
   Bajcsay, A
   Major, T
   Polgar, Cs
   Lovey, J
AF Szilagyi, Andras
   Pocza, Tamas
   Bajcsay, Andras
   Major, Tibor
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szilagyi, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 89
EP 89
PG 1
ER

PT J
AU Szluha, K
   Furka, A
   Szabo, I
   Pintye, �
   Miko, I
   Kiss, F
   Nemeth, N
AF Szluha, Kornelia
   Furka, Andrea
   Szabo, Imre
   Pintye, Eva
   Miko, Iren
   Kiss, Ferenc
   Nemeth, Norbert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szluha, Kornelia] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Furka, Andrea] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Szabo, Imre] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Pintye, Eva] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Miko, Iren] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Kiss, Ferenc] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Nemeth, Norbert] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
RP Szluha, K (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 89
EP 90
PG 2
ER

PT J
AU Szollar, A
   Udvarhelyi, N
   Bidlek, M
   Rubovszky, G
   Zaka, Z
   Savolt, �
   Kasler, M
   Olah, E
   Matrai, Z
AF Szollar, Andras
   Udvarhelyi, Nora
   Bidlek, Maria
   Rubovszky, Gabor
   Zaka, Zoltan
   Savolt, Akos
   Kasler, Miklos
   Olah, Edit
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Szollar, A (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 90
EP 90
PG 1
ER

PT J
AU Tamaskovics, B
   Santacroce, A
   Budach, W
AF Tamaskovics, Balint
   Santacroce, Antonio
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Santacroce, Antonio] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine Universitat, Klinik fur Strahlentherapie und RadioonkologieDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine Universitat, Klinik fur Strahlentherapie und Radioonkologie, Dusseldorf, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 90
EP 90
PG 1
ER

PT J
AU Tannock, I
AF Tannock, F. Ian
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tannock, F. Ian] Princess Margaret Cancer CentreToronto, Canada.
RP Tannock, I (reprint author), Princess Margaret Cancer Centre, Toronto, Canada.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 90
EP 90
PG 1
ER

PT J
AU Tanyi, Zs
   Bugan, A
   Szluha, K
AF Tanyi, Zsuzsanna
   Bugan, Antal
   Szluha, Kornelia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tanyi, Zsuzsanna] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
   [Bugan, Antal] DE OEC, Magatartastudomanyi IntezetDebrecen, Hungary.
   [Szluha, Kornelia] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Tanyi, Zs (reprint author), DE OEC, Magatartastudomanyi Intezet, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 90
EP 91
PG 1
ER

PT J
AU Tatrai, E
   Bartal, A
   Feher, Zs
   Paku, S
   Kenessey, I
   Garay, T
   Tovari, J
AF Tatrai, Eniko
   Bartal, Alexandra
   Feher, Zsuzsanna
   Paku, Sandor
   Kenessey, Istvan
   Garay, Tamas
   Tovari, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tatrai, Eniko] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Feher, Zsuzsanna] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
RP Tatrai, E (reprint author), National Institute of Oncology, Department of Clinical Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 91
EP 91
PG 1
ER

PT J
AU Telekes, A
   Kosa, J
AF Telekes, Andras
   Kosa, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kosa, Judit] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Telekes, A (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 91
EP 91
PG 1
ER

PT J
AU Telekes, A
AF Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Telekes, A (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 91
EP 92
PG 2
ER

PT J
AU Tokes, T
   Torgyik, L
   Toth, A
   Kulka, J
   Lengyel, Zs
   Galgoczy, H
   Gyorke, T
   Dank, M
AF Tokes, Timea
   Torgyik, Laszlo
   Toth, Andrea
   Kulka, Janina
   Lengyel, Zsolt
   Galgoczy, Hajna
   Gyorke, Tamas
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Timea] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Toth, Andrea] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Galgoczy, Hajna] Scanomed Orvosi Diagnosztikai Kutato es Oktato Kft.Budapest, Hungary.
   [Gyorke, Tamas] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Tokes, T (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 92
EP 92
PG 1
ER

PT J
AU Tokes, T
   Kajary, K
   Torgyik, L
   Lengyel, Zs
   Gyorke, T
   Dank, M
AF Tokes, Timea
   Kajary, Kornelia
   Torgyik, Laszlo
   Lengyel, Zsolt
   Gyorke, Tamas
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Timea] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Kajary, Kornelia] Pozitron Diagnosztika KftBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Gyorke, Tamas] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Tokes, T (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 92
EP 92
PG 1
ER

PT J
AU Torday, L
   Kahan, Zs
AF Torday, Laszlo
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 92
EP 93
PG 2
ER

PT J
AU Toth, A
   Utassy, R
AF Toth, Anett
   Utassy, Regina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Anett] Orszagos Onkologiai Intezet, AngiographiaBudapest, Hungary.
   [Utassy, Regina] Orszagos Onkologiai Intezet, AngiographiaBudapest, Hungary.
RP Toth, A (reprint author), Orszagos Onkologiai Intezet, Angiographia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 93
EP 93
PG 1
ER

PT J
AU Toth, LB
   Szigligeti, G
   Bogdan Rajcs, S
   Antek, Cs
AF Toth, Lajos Barna
   Szigligeti, Gabor
   Bogdan Rajcs, Sandor
   Antek, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Lajos Barna] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos SebeszetNyiregyhaza, Hungary.
   [Szigligeti, Gabor] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, AneszteziologiaNyiregyhaza, Hungary.
   [Bogdan Rajcs, Sandor] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos SebeszetNyiregyhaza, Hungary.
   [Antek, Csaba] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, AneszteziologiaNyiregyhaza, Hungary.
RP Toth, LB (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos Sebeszet, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 93
EP 93
PG 1
ER

PT J
AU Toth, LB
AF Toth, Lajos Barna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Lajos Barna] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos SebeszetNyiregyhaza, Hungary.
RP Toth, LB (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos Sebeszet, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 93
EP 94
PG 2
ER

PT J
AU Toth, L
   Duboczki, Zs
   Meszaros, P
   Lang, I
   Hitre, E
   Rubovszky, G
   Kaposztas, Zs
AF Toth, Laszlo
   Duboczki, Zsolt
   Meszaros, Peter
   Lang, Istvan
   Hitre, Erika
   Rubovszky, Gabor
   Kaposztas, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Meszaros, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kaposztas, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Toth, L (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 94
EP 94
PG 1
ER

PT J
AU Tothne Nagy, M
   Balla, L
   Fischerne Berzsan, V
   Kulcsar, J
   Veghne Weber, K
AF Tothne Nagy, Mariann
   Balla, Laszlone
   Fischerne Berzsan, Valeria
   Kulcsar, Jozsefne
   Veghne Weber, Klara
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tothne Nagy, Mariann] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Balla, Laszlone] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Fischerne Berzsan, Valeria] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Kulcsar, Jozsefne] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Veghne Weber, Klara] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
RP Tothne Nagy, M (reprint author), Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 94
EP 94
PG 1
ER

PT J
AU Torok, M
   Galambos, Cs
   Erb, A
   Simonne Vincze, M
   Al-Farhat, Y
AF Torok, Marta
   Galambos, Csilla
   Erb, Attilane
   Simonne Vincze, Maria
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torok, Marta] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Galambos, Csilla] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Erb, Attilane] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Simonne Vincze, Maria] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Torok, M (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 94
EP 95
PG 2
ER

PT J
AU Torok, Sz
   Vegvari, �
   Marko-Varga, Gy
   Paku, S
   Tovari, J
   Hegedus, B
   Dome, B
AF Torok, Szilvia
   Vegvari, Akos
   Marko-Varga, Gyorgy
   Paku, Sandor
   Tovari, Jozsef
   Hegedus, Balazs
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torok, Szilvia] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Vegvari, Akos] Lund University, Department of Measurement Technology and Industrial Electrical EngineeringLund, Sweden.
   [Marko-Varga, Gyorgy] Lund University, Department of Measurement Technology and Industrial Electrical EngineeringLund, Sweden.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Torok, Sz (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 95
EP 95
PG 1
ER

PT J
AU Uhlyarik, A
   Szilvasi, I
   Gyokeres, T
   Torday, L
   Wild, D
   Papai, Zs
AF Uhlyarik, Andrea
   Szilvasi, Istvan
   Gyokeres, Tibor
   Torday, Laszlo
   Wild, Damian
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szilvasi, Istvan] Magyar Honvedseg Egeszsegugyi Kozpont, Nuklearis MedicinaBudapest, Hungary.
   [Gyokeres, Tibor] Magyar Honvedseg Egeszsegugyi Kozpont, GasztroenterologiaBudapest, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Wild, Damian] University Hospital Basel, Radiology and Nuclear Medicine DepartmentBasel, Switzerland.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Uhlyarik, A (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 95
EP 96
PG 2
ER

PT J
AU Ujhelyi, M
   Savolt, �
   Bidlek, M
   Kovacs, E
   Rubovszky, G
   Nyari, T
   Udvarhelyi, N
   Bak, M
   Matrai, Z
AF Ujhelyi, Mihaly
   Savolt, Akos
   Bidlek, Maria
   Kovacs, Eszter
   Rubovszky, Gabor
   Nyari, Tibor
   Udvarhelyi, Nora
   Bak, Mihaly
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujhelyi, Mihaly] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Ujhelyi, M (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 96
EP 96
PG 1
ER

PT J
AU Urbancsek, H
   Opauszki, A
   Szabo, I
   Adamecz, Zs
   Horvath, Zs
AF Urbancsek, Hilda
   Opauszki, Adrienn
   Szabo, Imre
   Adamecz, Zsolt
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Urbancsek, Hilda] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Opauszki, Adrienn] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Adamecz, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Urbancsek, H (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 96
EP 96
PG 1
ER

PT J
AU Varady, E
   Deak, B
   Molnar, Zs
   Schneider, T
   Szaleczky, E
   Varga, F
   Rosta, A
AF Varady, Erika
   Deak, Beata
   Molnar, Zsuzsa
   Schneider, Tamas
   Szaleczky, Erika
   Varga, Fatima
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Deak, Beata] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varga, Fatima] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Varady, E (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 96
EP 96
PG 1
ER

PT J
AU Varga, Sz
   Csejtey, A
   Hideghety, K
   Mangel, L
   Polgar, Cs
AF Varga, Szilvia
   Csejtey, Andras
   Hideghety, Katalin
   Mangel, Laszlo
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Csejtey, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Varga, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 97
EP 97
PG 1
ER

PT J
AU Varga, Zs
   Peterfi, Z
   Kumanovics, G
AF Varga, Zsuzsanna
   Peterfi, Zoltan
   Kumanovics, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Peterfi, Zoltan] Pecsi Tudomanyegyetem KK, InfektologiaPecs, Hungary.
   [Kumanovics, Gabor] Pecsi Tudomanyegyetem KK, Reumatologiai es Immunologiai KlinikaPecs, Hungary.
RP Varga, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 97
EP 97
PG 1
ER

PT J
AU Vass, G
   Mohos, G
   Varga, J
   Ivan, L
   Rovo, L
AF Vass, Gabor
   Mohos, Gabor
   Varga, Janos
   Ivan, Laszlo
   Rovo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vass, Gabor] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Mohos, Gabor] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Janos] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Rovo, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Vass, G (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 97
EP 97
PG 1
ER

PT J
AU Vaszko, T
   Papp, J
   Gezsi, A
   Hajos, G
   Olah, E
AF Vaszko, Tibor
   Papp, Janos
   Gezsi, Andras
   Hajos, Gergely
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszko, Tibor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Gezsi, Andras] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai KarBudapest, Hungary.
   [Hajos, Gergely] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai KarBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Vaszko, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 98
EP 98
PG 1
ER

PT J
AU Verheijen, R
AF Verheijen, H.M. Rene
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Verheijen, H.M. Rene] University Medical Center Utrecht, Gynaecological OncologyUtrecht, The Netherlands.
RP Verheijen, R (reprint author), University Medical Center Utrecht, Gynaecological Oncology, Utrecht, The Netherlands.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 98
EP 98
PG 1
ER

PT J
AU Vincze, B
   Kapuvari, B
   Udvarhelyi, N
   Horvath, Zs
   Czeyda-Pommersheim, F
   Kohalmy, K
   Kovacs, J
   Edesne Boldizsar, M
   Matrai, Z
   Lang, I
AF Vincze, Borbala
   Kapuvari, Bence
   Udvarhelyi, Nora
   Horvath, Zsolt
   Czeyda-Pommersheim, Ferenc
   Kohalmy, Krisztina
   Kovacs, Judit
   Edesne Boldizsar, Mariann
   Matrai, Zoltan
   Lang, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Czeyda-Pommersheim, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Edesne Boldizsar, Mariann] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Vincze, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 98
EP 99
PG 2
ER

PT J
AU Zoltanne Csorba, �
AF Zoltanne Csorba, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zoltanne Csorba, Eva] Orszagos Onkologiai Intezet, Kozponti SterilizaloBudapest, Hungary.
RP Zoltanne Csorba, � (reprint author), Orszagos Onkologiai Intezet, Kozponti Sterilizalo, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2013
VL 57
IS 5
BP 99
EP 99
PG 1
ER

PT J
AU Maraz, A
   Bodoky, Gy
   Dank, M
   Geczi, L
   Kahan, Zs
   Mangel, L
   Revesz, J
   Szucs, M
AF Maraz, Aniko
   Bodoky, Gyorgy
   Dank, Magdolna
   Geczi, Lajos
   Kahan, Zsuzsanna
   Mangel, Laszlo
   Revesz, Janos
   Szucs, Miklos
TI Experience with everolimus therapy for patients with metastatic renal cancer in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE metastatic kidney cancer; mTOR inhibitor; everolimus; anemia; ECOG
ID metastatic kidney cancer; mTOR inhibitor; everolimus; anemia; ECOG
AB Everolimus is indicated for the therapy of adults with advanced renal cell carcinoma after failure of treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The aim of the study was a multicenter evaluation of efficiency and toxicity of everolimus in patients with metastatic renal carcinoma who received one line of VEGFR-TKI therapy. Data of one hundred and one patients were analyzed retrospectively. Patients received everolimus therapy between January 2010 and July 2013. Data were collected in 7 different oncology institutes in Hungary. Starting daily dose of everolimus was 10 mg in 28-day cycles. Physical and laboratory examinations were done monthly. Imaging tests were performed every 3 months. Tumor response and toxicity were evaluated according to RECIST 1.0 and NCI CTCAE 3.0, respectively. Statistical analysis was performed with SPPS version 20.0 for Windows. Currently 26 (27%) patients are being treated, 52 (54.1%) patients are alive. Median progression-free survival (PFS) was 5.7 months (95% CI 4.07–7.33). Partial remission, stable disease and progression occurred in 6 (6%), 71 (74%) and 19 (20%) patients, respectively. Median overall survival (OS) was 14.3 months (95% CI 6.99–19.81). PFS and OS results were more favorable in patients with ECOG 0-1. Survival was poorer in case of anemia, while better if PFS was longer than 12 months. In anemic patients with ECOG 0-1 and ECOG 2-3 OS was 30.9 and 7.7 months, respectively (p=0.031). Dose reduction and treatment delay happened in 8 (7.9%) and 12 (11.9%) cases, respectively. The most common side effects were the following: exanthema, edema, stomatitis, pneumonitis, anemia and abnormal kidney-, liver functions, blood sugar and cholesterol levels. According to the Hungarian experience, everolimus can safely be administered. PFS and OS results representing the centers’ everyday practice, are similar to the results of the respective subgroups in the registration study.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 4
EP 9
PG 6
ER

PT J
AU Sapi, Z
AF Sapi, Zoltan
TI Pathology of soft tissue sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE soft tissue sarcoma; grade; translocation
ID soft tissue sarcoma; grade; translocation
AB Soft tissue sarcomas encompass around 1% of all malignant tumors, but they are relatively more frequent in childhood and adolescent age. This latter fact even more underlines that the proper diagnosis should be done in time for the optimal treatment. The very recent WHO classification (2013) lays down the following main categories: adipocytic tumors, fibroblastic/myofibroblastic tumors, so-called fibrohistiocytic tumors, smooth-muscle tumors, pericytic tumors, skeletal-muscle tumors, vascular tumors, chondro-osseous tumors, gastrointestinal stromal tumors, nerve sheath tumors, tumors of uncertain differentiation and undifferentiated/unclassified sarcomas (including the former malignant fibrous histiocytoma). Beside the proper diagnosis it is also important to give the grade which basically determines the therapy. We use the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system. The choice of preoperative diagnosis can be both fine needle and core biopsy and together with radiological image analysis they define the type of surgical intervention. The modern pathological diagnosis of soft tissue sarcomas is still based on the examination of H&E slides but it is also necessary to have a wide immunohistochemical panel and to use molecular methods for the sake of precise diagnosis and the broadening possibilities of targeted therapy.
C1 [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Sapi, Z (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM sapi.zoltan.dr@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 11
EP 23
PG 13
ER

PT J
AU Borbely, K
   Nemeth, Zs
   Kasler, M
AF Borbely, Katalin
   Nemeth, Zsuzsanna
   Kasler, Miklos
TI Clinical application of 18F-FDG PET/CT in the treatment of sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE 18F-FDG PET/CT; sarcoma; RECIST; PERCIST; metabolic response
ID 18F-FDG PET/CT; sarcoma; RECIST; PERCIST; metabolic response
AB [18F]-Fluoro-deoxyglucose positron emission tomography / computer tomography (18F-FDG PET/CT) is able to detect and assess the abnormal metabolism, enabling visualization and quantification in vivo with integration into CT anatomic information. The clinical usefulness of FDG PET/CT in the management of patients with sarcomas has been assessed by numerous investigators. Sarcomas are solid malignant tumors with distinct clinical and pathological features. Effective management of patients with sarcoma requires accurate diagnosis and staging. The authors discuss the major indications of PET/CT on the basis of literature data for diagnosis, staging, guidance of biopsy and monitoring response to therapy in both primary bone and soft tissue tumors. The consistent use of PET molecular imaging methods is of high importance in characterizing and understanding sarcoma behavior in clinical practice.
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Zsuzsanna] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 24
EP 31
PG 8
ER

PT J
AU Antal, I
   Kiss, J
   Perlaky, T
   Szalay, K
   Vancso, P
   Olah, Z
   Sapi, Z
   Papai, Zs
   Szendroi, M
AF Antal, Imre
   Kiss, Janos
   Perlaky, Tamas
   Szalay, Krisztian
   Vancso, Peter
   Olah, Zoltan
   Sapi, Zoltan
   Papai, Zsuzsanna
   Szendroi, Miklos
TI Resection and reconstruction in cases of musculosceletal soft tissue sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE soft tissue sarcoma; reconstruction; surgery; limb salvage
ID soft tissue sarcoma; reconstruction; surgery; limb salvage
AB Soft tissue sarcomas are rare, reaching some 1.5% of all malignant tumors. While formerly the surgical management of sarcomas almost exclusively consisted of amputation, in the recent years limb saving surgery has become the first choice of therapy. Negative factors affecting the survival rate are: histologically high-grade tumor, size and localization of the tumor, vascular invasion, extensive tumor necrosis, certain subgroups, local recurrence and oncologically positive surgical margin at the resection. Many modern reconstruction possibilities are essential for the safe limb saving surgery with wide surgical margins, such as bone allograft implantation, tumor endoprostheses reconstruction, vascular grafting and plastic surgery. There should always be an attempt to perform limb saving surgery, however life quality, life expectancy and survival are more important considerations influencing essentially the surgical method of choice. In our follow-up study no significant difference in recurrence rate was found between the group of patients with sarcomas requiring a complex reconstruction procedure and the group of those treated by only resection methods (32% versus 47%).
C1 [Antal, Imre] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Perlaky, Tamas] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Szalay, Krisztian] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Vancso, Peter] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Olah, Zoltan] Semmelweis University, Department of Cardiovascular SurgeryBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
RP Perlaky, T (reprint author), Semmelweis University, Department of Orthopedics, 1113 Budapest, Hungary.
EM pertamas@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 32
EP 36
PG 5
ER

PT J
AU Kiss, J
   Antal, I
   Perlaky, T
   Szalay, K
   Olah, Z
   Vancso, P
   Revesz, Zs
   Rahoty, P
   Lestar, B
   Entz, L
   Szendroi, M
AF Kiss, Janos
   Antal, Imre
   Perlaky, Tamas
   Szalay, Krisztian
   Olah, Zoltan
   Vancso, Peter
   Revesz, Zsolt
   Rahoty, Pal
   Lestar, Bela
   Entz, Laszlo
   Szendroi, Miklos
TI Limb saving surgery in cases of bone sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bone tumors; limb saving surgery; reconstructive limb surgery
ID bone tumors; limb saving surgery; reconstructive limb surgery
AB At the Orthopedic Department of Semmelweis University we operate an internationally recognized bone and soft tissue tumor center. Our specialty is the treatment of benign and malignant bone tumors, tumor-like lesions and surgery of soft tissue tumors. Our main aim, taking into account the appropriate oncologic radicality, is to create the conditions for the development of limb saving surgery. Limb saving surgery is an interdisciplinary activity both in diagnosis and in treatment. We have proper pathology, radiology and interventional radiology background for the fast and advanced pathomorphological and radiomorphological diagnosis of different tumors. Using modern chemotherapy, radiotherapy and other advanced cancer treatment protocols rapid access to oncology background is provided for children and adults as well, both primary and secondary bone tumors and soft tissue sarcoma cases of the extremities. The limb saving surgery after removal of the tumor is essentially a reconstructive surgery. Reconstructive surgery in childhood and younger ages mean mainly the biological solutions (vascularized autologus bone grafts and/or homologous bone graft), otherwise in elderly ages implantation of tumor endoprostheses has a greater significance. Furthermore, the final tumor surgery requires experienced abdominal surgeon, vascular surgeon and plastic surgeon to ensure the background as well. The professional background of our clinical practice is based on participating in international conferences and spending several months abroad in different big tumor centers. Over the past 15 years, several international cancer congresses were organized in Hungary by our Department.
C1 [Kiss, Janos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Perlaky, Tamas] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Szalay, Krisztian] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Olah, Zoltan] Semmelweis University, Department of Cardiovascular SurgeryBudapest, Hungary.
   [Vancso, Peter] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Revesz, Zsolt] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Rahoty, Pal] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Lestar, Bela] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Entz, Laszlo] Semmelweis University, Department of Cardiovascular SurgeryBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
RP Kiss, J (reprint author), Semmelweis University, Department of Orthopedics, 1113 Budapest, Hungary.
EM dysplasia.drkiss61@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 37
EP 46
PG 10
ER

PT J
AU Bursics, A
   Besznyak, I
   Mersich, T
   Porneczi, B
   Dede, K
   Papp, G
   Agoston, P
   Papai, Zs
AF Bursics, Attila
   Besznyak, Istvan
   Mersich, Tamas
   Porneczi, Balazs
   Dede, Kristof
   Papp, Geza
   Agoston, Peter
   Papai, Zsuzsanna
TI Surgical treatment of retroperitoneal sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE soft tissue sarcoma; retroperitoneal sarcoma; R0 resection
ID soft tissue sarcoma; retroperitoneal sarcoma; R0 resection
AB Retroperitoneal sarcomas make up 0.15% of all solid tumors. The mainstay of their treatment is surgical resection, though the removal of the often sizable tumors may pose serious challenge to surgeons. There is no clear-cut recommendation for neoadjuvant, nor for adjuvant treatment so far. We collected the data and recommendations concerning the attributes and the treatment options for retroperitoneal sarcomas. Mainly we focused on the possibilities and the recent change in tactics of surgery. There is no prospective randomized study dealing with surgical treatment of retroperitoneal sarcomas. According to data in the literature the en-block R0 resection along with all the possibly involved neighboring organs offers the best chance for cure. The greatest problem is to define the required resection margin which is needed for R0 resection. Radio- and/or chemotherapy can be used for diminishing the possibility of tumor recurrence. The greatest risk factors for recurrence are incomplete resection, high grade tumor, and non-liposarcoma type histology. Survival depends on local recurrence rather than on distant metastases. Retroperitoneal sarcomas are ideally treated in sarcoma centers, where multidisciplinary consultation is available and complex treatment plans can be set. Complete recovery can be achieved with radical surgical excision. The chance for R0 resection is enhanced by chemo- and radiotherapy.
C1 [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Besznyak, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Mersich, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Porneczi, Balazs] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Papp, Geza] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Uzsoki u. 29., 1145 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Bursics, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, 1145 Budapest, Hungary.
EM bursics@uzsoki.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 47
EP 51
PG 5
ER

PT J
AU Papai, Zs
AF Papai, Zsuzsanna
TI Medical treatment of soft tissue sarcomas based on the histological subtype
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE adult soft tissue sarcomas; chemotherapy; target therapy
ID adult soft tissue sarcomas; chemotherapy; target therapy
AB The medical treatment of adult soft tissue sarcomas is more and more dictated by the histological subtype, this applies to both cytotoxics and target therapies. Doxorubicin and ifosfamid are the two drugs used either in monotherapy or combination with the best established response rates in adult soft tissue sarcomas for several years. In addition to these compounds there is evidence of efficacy of new drugs such as taxanes in angiosarcoma, gemcitabine+taxanes combination in leiomyosarcomas, trabectedin in leiomyosarcomas and liposarcomas with an extremely high activity in myxoid liposarcoma. With regard to target therapy pazopanib seems especially active in leiomyosarcomas and synoviosarcomas, but totally inactive in liposarcomas, sunitinib and cediranib in alveolar soft part sarcomas, sunitinib and bevacizumab+temozolamide combination in solitary fibrous tumors, and sorafenib in angiosarcomas. mTOR inhibitors are active in PEComas (perivascular epitheloid cell tumors) and crizotinib in ALK rearranged inflammatory myofibroblastic tumors. The efficacy of imatinib and sunitinib in GIST tumors are established, and that of imatinib in dermatofibrosarcoma as well.
C1 [Papai, Zsuzsanna] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
RP Papai, Zs (reprint author), Honved Korhaz, Onkologiai Osztaly, 1062 Budapest, Hungary.
EM zspapai@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 53
EP 58
PG 6
ER

PT J
AU Banusz, R
   Varadi, Zs
   Varga, E
   Jakab, Zs
   Garami, M
   Csoka, M
AF Banusz, Rita
   Varadi, Zsofia
   Varga, Edit
   Jakab, Zsuzsa
   Garami, Miklos
   Csoka, Monika
TI Diagnosis and treatment of childhood soft tissue sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pediatric oncology; rhabdomyosarcoma (RMS); alveolar RMS; embryonal RMS; undifferentiated RMS; chemotherapy; surgery; irradiation
ID pediatric oncology; rhabdomyosarcoma (RMS); alveolar RMS; embryonal RMS; undifferentiated RMS; chemotherapy; surgery; irradiation
AB Malignant tumors of mesenchymal origin are called sarcomas. Mesenchymal cells normally mature into skeletal muscle, smooth muscle, fat, fibrous tissue, bone and cartilage. Rhabdomyosarcoma (RMS) arises from immature mesenchymal cells that are committed to skeletal muscle lineage. However, it can also arise in tissues in which striated muscle is normally not found (such as the urinary tract). Undifferentiated sarcomas cannot be ascribed to any specific lineage. Treatment results improved significantly in the last decade by combined treatment (chemotherapy, surgery, irradiation, in some cases targeted therapy). Good treatment results can be achieved in pediatric oncology centers by early diagnosis and adequate treatment according to international treatment protocols.
C1 [Banusz, Rita] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Varadi, Zsofia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Varga, Edit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Jakab, Zsuzsa] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Csoka, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM csoka.monika@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 59
EP 64
PG 6
ER

PT J
AU Agoston, P
   Jorgo, K
   Matrai, Z
   Polgar, Cs
AF Agoston, Peter
   Jorgo, Kliton
   Matrai, Zoltan
   Polgar, Csaba
TI Radiotherapy of soft tissue sarcomas of the extremities and superficial trunk
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE extremity; trunk; soft tissue sarcoma; radiotherapy
ID extremity; trunk; soft tissue sarcoma; radiotherapy
AB Soft tissue sarcomas represent a histopathologically and clinically heterogeneous group of tumors that make up around 1% of malignancies, in which soft tissue sarcomas of the extremities and superficial trunk (STSET) are treated with more or less the same strategy. Over the past 30 years, there has been a migration away from amputation and radical ablative surgical procedures for localized STSET toward more conservative, function-preserving surgery combined with radiotherapy +/- chemotherapy. The latter complex treatment ensures equal local control to radical surgery. This multidisciplinary management includes organ sparing surgery as the main procedure but also radiotherapy of different types applied before, during or after the surgery, chemotherapy depending of the stadium of the tumor and plastic, reconstructive surgery, and last but not least rehabilitation of the patient after treatment. In this publication we overview the practical guidelines for the treatment of STSET based on the available literature from the last decades. Indication and timing of radiotherapy of STSET as well as available external beam and brachytherapy techniques are summarized. The prescribed radiation dose, the role of alternative fractionations, the combination of radiotherapy and systemic chemotherapy, hyperthermia or limb perfusion regards to STSET are also discussed. Practical considerations of radiotherapy, the target volumes and the role of newer radiotherapy technology in STSET treatment are overviewed.
C1 [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM agoston.p@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 65
EP 76
PG 12
ER

PT J
AU Agoston, P
   Jorgo, K
   Matrai, Z
   Polgar, Cs
AF Agoston, Peter
   Jorgo, Kliton
   Matrai, Zoltan
   Polgar, Csaba
TI Role of radiotherapy in the treatment of retroperitoneal soft tissue sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE retroperitoneal; soft-tissue; sarcoma; radiotherapy
ID retroperitoneal; soft-tissue; sarcoma; radiotherapy
AB Soft tissue sarcomas are rare tumors, composing 1% of all malignancies. Fifteen percent of them are situated in the retroperitoneal region. The primary curative treatment for this group of patients is complete surgical resection. In most cases, due to their large size and localization at diagnoses, complete resection (R0) is not feasible. The main cause of disease-specific death is local recurrence. Therefore, improved local control by radiotherapy (RT) may contribute to better survival results. Based on international studies, despite the frequent positive surgical margins, only 25% of the patients with retroperitoneal sarcoma (RPS) receive perioperative RT. We performed a literature review based on the available data on the role of RT in the management of RPS. The 5-year local recurrence-free survival after surgery alone, and surgery + RT has been reported in the range of 23–54% and 40–62%, respectively. The respective 5-year rate of overall survival was of 33–49% and 48–64%. There are no available results from prospective randomized studies comparing surgery to surgery + RT. The majority of studies were retrospective and the treatments were performed over a time span of several decades. The total dose, technique and timing of RT were not standardized. Gastrointestinal and genitourinary side effects of RT are common, but their incidence and severity can be significantly reduced by using modern techniques. Based on the currently available studies, RT improves local control and it may play a role in the prolongation of overall survival as well. However, prospective randomized studies are needed to clarify the role of RT in the multidisciplinary management of RPS.
C1 [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM agoston.p@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2014
VL 58
IS 1
BP 77
EP 82
PG 6
ER

PT J
AU Szendroi, M
   Antal, I
   Kiss, J
   Perlaky, T
   Szalay, K
AF Szendroi, Miklos
   Antal, Imre
   Kiss, Janos
   Perlaky, Tamas
   Szalay, Krisztian
TI Contemporary management of bone tumors at Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE bone tumor registry; complex management of bone tumors; bone biobanking
ID bone tumor registry; complex management of bone tumors; bone biobanking
AB The incidence of bone tumors is low therefore it is highly recommended to treat patients in specialized centers. In the late 70ies a bone tumor registry was initiated at the Department of Orthopedics of the Semmelweis University followed by the development of a specialized diagnostic unit and a bone cancer center. Several novel surgical procedures have been introduced, including the extremity-sparing surgery, leading to a significant improvement of the patients survival. This is fully supported by a specialized bone cancer oncoteam of experts. The 6000-sized registry and biobank now allows the development of translational research in this orphan tumor type.
C1 [Szendroi, Miklos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Perlaky, Tamas] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
   [Szalay, Krisztian] Semmelweis University, Department of Orthopedics, Karolina ut 27., 1113 Budapest, Hungary.
RP Szendroi, M (reprint author), Semmelweis University, Department of Orthopedics, 1113 Budapest, Hungary.
EM szenmik@orto.sote.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 88
EP 93
PG 6
ER

PT J
AU Nagy, P
   Lahm, E
   Papai, Zs
AF Nagy, Peter
   Lahm, Erika
   Papai, Zsuzsanna
TI Rare hereditary tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE hereditary; Recklinghausen; Li-Fraumeni; Rothmund-Thomson
ID hereditary; Recklinghausen; Li-Fraumeni; Rothmund-Thomson
AB Almost 5-10% of all tumours are hereditary, which manifest in tumour syndrome or neoplasmic complication of a genetic disease. We present a short introduction of some of these rare diseases through our patients with the aspect of the clinical signs, diversities and challenges. These cases indicate that the incidency of malignancies are increased at genetic diseases, it means even multiple neoplasms in the same patient. The therapy does not differ from the ordinary tumour’s therapy and the results are nearly the same as in cases without genetic diseases.
C1 [Nagy, Peter] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
RP Nagy, P (reprint author), Honved Korhaz, Onkologiai Osztaly, 1062 Budapest, Hungary.
EM n.peter4@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 94
EP 97
PG 4
ER

PT J
AU Gaal, Zs
   Olah, �
AF Gaal, Zsuzsanna
   Olah, Eva
TI Epigenetic regulatory mechanisms and their disorders in leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE epigenetics; leukemia; DNA methylation; histone modification; prognosis
ID epigenetics; leukemia; DNA methylation; histone modification; prognosis
AB The term epigenetics includes regulatory mechanisms that influence gene expression without any changes in the sequence of the DNA, namely DNA methylation, histone modification and small, non-coding RNAs. Methylation of the DNA leads to the repression of gene expression, while histone modification can result in both activation and inhibition of the transcription depending on the type and site of modification. These mechanisms are confirmed to have important pathogenetic role during the process of leukemogenesis. In distinct subtypes of leukemia specific alterations of the DNA methylation profile, histone code and typical changes of the microRNA expression levels have been observed. The importance of them is inhered in their promising potential clinical applications. In order to achieve further improvement in the therapeutic results of leukemia, prognostic classification has to be further improved. With the help of the epigenetic alterations, subgroups could be differentiated within the known prognostic groups. Changes in the DNA methylation pattern, histone code and microRNA expression levels correlate with the success of the treatment in many cases, moreover they could provide help to predict chemoresistance or detect the minimal residual disease following chemotherapy. Enzymes influencing the structure of chromatin form a wide variety of new potential therapeutic targets. Based on preliminary results, sorts of epigenetic therapy may be combined successfully either with each other or with conventional chemotherapeutic drugs in the treatment of leukemia.
C1 [Gaal, Zsuzsanna] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Olah, Eva] Medical and Health Science Center, University of Debrecen, Department of Pediatrics, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Olah, � (reprint author), Medical and Health Science Center, University of Debrecen, Department of Pediatrics, 4032 Debrecen, Hungary.
EM eolah@med.unideb.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 99
EP 107
PG 9
ER

PT J
AU Bodacs, I
   Polgar, Cs
   Major, T
AF Bodacs, Istvan
   Polgar, Csaba
   Major, Tibor
TI Dosimetric comparison of external partial breast irradiation with whole breast irradiation and partial breast brachytherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE partial and whole breast irradiation; breast brachytherapy; treatment planning; dosimetry
ID partial and whole breast irradiation; breast brachytherapy; treatment planning; dosimetry
AB Different techniques exist for the delivery of radiotherapy after breast conserving surgery. The conventional method is whole breast irradiation. However, in selected patients partial breast irradiation can be performed, either with external beams or brachytherapy. In the current study three irradiation techniques are compared regarding dosimetric aspects. Treatment plans of thirty women treated with external beam conformal partial breast irradiation (CONF) were evaluated using dose-volume histograms. For the same patients whole breast irradiation plans (WBI) were made and compared with the CONF ones. Breast and lung of both sides, and heart at left sided lesions were contoured as organs at risk. After this, dose plans of another thirty patients treated with interstitial brachytherapy (IBT) were analyzed and compared with the CONF plans. According to our results the 90% isodose curve covered at least 97% of the target volume at all three techniques, and this value was 100% for CONF. The maximal dose within target volume was 106% in CONF and 115% in WBI plans. Volume of ipsilateral breast receiving the prescribed dose was 66%, 15% and 13% in the WBI, CONF and IBT plans, respectively. The dose to the contralateral breast was less for CONF compared to WBI. Volume of the ipsilateral lung receiving 30% of the prescribed dose was 15%, 8% and 1%, the maximal dose was 105%, 94% and 47% in the WBI, CONF and IBT plans, respectively. In the same order the maximal dose to the heart was 82%, 49% and 25%, while the dose irradiated to 5% of the heart volume was 27%, 19% and 14% at left sided lesions. Regarding target coverage, the conformal technique was the best, and the dose was more homogeneous than at WBI. With respect to dose to organs at risk the partial breast irradiation techniques were much more favorable than WBI, and the lowest doses occurred in the IBT treatment plans.
C1 [Bodacs, Istvan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9.Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9.Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9.Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
EM major@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 108
EP 115
PG 8
ER

PT J
AU Matrai, Z
   Gulyas, G
   Kovacs, E
   Sandor, Zs
   Polgar, Cs
   Bartal, A
   Kasler, M
AF Matrai, Zoltan
   Gulyas, Gusztav
   Kovacs, Eszter
   Sandor, Zsuzsanna
   Polgar, Csaba
   Bartal, Alexandra
   Kasler, Miklos
TI Oncoplastic versus conventional breast conserving surgery. A comparison of clinicopathological findings, cosmetic results and quality of life of 60 cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oncoplastic surgery; breast-conserving surgery; breast cancer
ID oncoplastic surgery; breast-conserving surgery; breast cancer
AB Oncoplastic surgical techniques seem to be suitable for realizing the goal of retaining cosmesis following radical removal of breast tumors. The purpose of the present study is to provide a clinical and pathological comparison of conventional (BCS) and oncoplastic (OPS) breast-conserving surgeries, supplemented by a subjective assessment of cosmesis and quality of life of patients, the first time on a Hungarian sample. The authors performed a retrospective assessment of clinicopathological data of 60 advanced oncoplastic and 60 conventional breast-conserving surgery cases, and following adjuvant radiotherapy, the authors also surveyed patients for cosmetic results and quality of life (EORTC BR23). Comparison of the results was performed by statistical methods. The two groups did not differ substantially in age, tumor location, breast size, type of axillary surgery (sentinel node biopsy vs. axillary lymphadenectomy), tumor grade and receptor status. Tumor size was significantly greater (p=0.0009), the rate of quadranectomies was higher (p=0.0032), metastases in the regional lymph nodes (p=0.0043) and the administration of adjuvant chemotherapy (p=0.0122) were more frequent in the OPS group. The duration of surgeries was longer (p<0.001), the weight of the specimens was greater (p=0.0308), the rate of completion surgeries due to microscopically positive surgical margins was significantly smaller (p=0.0306) in the OPS than in the BCS group. There was no difference between the two groups in the rate of complications and the time elapsed to the start of adjuvant treatment. The cosmetic outcome was clearly superior in the OPS group (p<0.001), and OPS patients had fewer arm, shoulder (p=0.0399), and chest pain (of the affected side) (p=0.0304), upper limb movements of the operated side were also better (p=0.006). The short follow-up period of the OPS group (mean 32.2 vs. 8.7 months in BCS and OPS, respectively) did not allow a meaningful assessment of oncologic endpoints. When compared to conventional breastconserving surgery, oncoplastic surgery is suitable for microscopically radical tumor removal even in case of larger lesions and true quadranectomy with longer surgical time but lower rate of complications without delaying the adjuvant treatments and thus not increasing the cancer risk. OPS yields better cosmetic results and higher patient satisfaction compared to BCS. More experience and longer follow-up is needed for the assessment of local tumor control achieved by OPS.
C1 [Matrai, Zoltan] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gulyas, Gusztav] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sandor, Zsuzsanna] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bartal, Alexandra] Orszagos Onkologiai Intezet, Intezeti GyogyszertarBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Department of Surgery, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Matrai, Z (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM matraidoc@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 116
EP 127
PG 12
ER

PT J
AU Rubovszky, G
   Lang, I
AF Rubovszky, Gabor
   Lang, Istvan
TI BOLERO - another remarkable step in treatment of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; targeted therapy; everolimus
ID breast cancer; targeted therapy; everolimus
AB The expansion of molecular genetic knowledge leads to targeted therapy which is a common part of cancer treatment. Targeted agents also exist in breast cancer treatment. However, new efficient molecules are pressingly needed. On one hand there are cancer subgroups where we do not have efficient targeted drugs, on the other hand the results of established cancer therapies can be improved by interfering with another signal transduction pathway. Everolimus is a targeted agent which was effective in several clinical trials and became registered for treatment of hormone receptor positive breast cancer. This article summarizes the results of published breast cancer everolimus trials. The results of two phase 3 trials are available. In the BOLERO-2 trial exemestane was compared with the combination of exemestane and everolimus, while in BOLERO-3 trial trastuzumab and vinorelbine were investigated with or without everolimus. In both trials the progression-free survival was significantly longer in the experimental arm. The overall survival data of BOLERO-2 trial, a secondary end point, are also available. The 4.4 month benefit in the experimental arm is clinically important but it has not reached the level of statistical significance. We have not had biomarkers so far that could help us to identify a subgroup of cancers sensitive to everolimus.
C1 [Rubovszky, Gabor] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lang, Istvan] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM garub@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 128
EP 132
PG 5
ER

PT J
AU Moldvay, J
   Papay, J
   Kovalszky, I
   Balazs, Gy
   Puskas, R
   Losonczy, Gy
AF Moldvay, Judit
   Papay, Judit
   Kovalszky, Ilona
   Balazs, Gyorgy
   Puskas, Rita
   Losonczy, Gyorgy
TI Gefitinib treatment in lung cancer - Rebiopsy, retreatment, remission
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE lung adenocarcinoma; EGFR-TKI therapy; gefitinib; rebiopsy; retreatment
ID lung adenocarcinoma; EGFR-TKI therapy; gefitinib; rebiopsy; retreatment
AB The authors present a case of a 81-year-old non-smoker woman who was diagnosed with extended, bilateral bronchial adenocarcinoma in 2008. Two years later the tumor showed marked progression. EGFR sensitizing mutation (exon 19 deletion) was detected and gefitinib treatment was started in March 2010. After 12 months of spectacular and complete remission and 8 months of slow progression docetaxel therapy was applied and yielded partial remission. When progression redeveloped rebiopsy was performed and revealed EGFR exon 19 deletion again. Gefitinib retreatment was introduced in February 2013 and resulted in partial remission with excellent clinical status. In March, 2014 the patient is still on gefitinib treatment without any signs or symptoms of lung cancer but with very slow radiological progression. The authors overview the most important theoretical and practical questions regarding rebiopsy and retreatment in lung cancer with EGFR-TKI therapy.
C1 [Moldvay, Judit] Semmelweis University, Department of Pulmonology, Dios arok 1/C., 1125 Budapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Balazs, Gyorgy] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Puskas, Rita] Semmelweis University, Department of Pulmonology, Dios arok 1/C., 1125 Budapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of Pulmonology, Dios arok 1/C., 1125 Budapest, Hungary.
RP Moldvay, J (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 133
EP 137
PG 5
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Criteria of the molecular pathology testing of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; molecular diagnostics; sampling problems
ID lung cancer; molecular diagnostics; sampling problems
AB From the aspect of the contemporary pathologic diagnostics of lung cancer the tissue obtained is a key issue since small biopsies and cytology still play a major role. In the non-small cell lung cancer era cytology is considered equal to biopsy however, in recent years it is unable to provide quality diagnosis and must be replaced by biopsy. Various molecular techniques can handle various different tissue samples which must be considered during molecular pathology diagnosis. Moreover, tumor cell-normal cell ratio in the obtained tissue, as well as the absolute tumor cell number have great significance, which information must be provided in the primary lung cancer diagnosis. Last but not least, for continuous sustainable molecular diagnostics of lung cancer rational algorithms, affordable technology and appropriate reimbursement are equally necessary.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 139
EP 142
PG 4
ER

PT J
AU Mark, �
AF Mark, Agnes
TI Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE lymphoma; Hodgkin lymphoma; diffuse large B-cell lymphoma; mTOR kinase activity; prognosis; regulatory T-cell; galectin-1
ID lymphoma; Hodgkin lymphoma; diffuse large B-cell lymphoma; mTOR kinase activity; prognosis; regulatory T-cell; galectin-1
AB Neoplastic processes, tumor growth, and tumor cell proliferation and survival are often due to the altered activation of different signaling pathways. The increased activity of PI3K/AKT/mTOR signaling has been shown to be an important regulator of tumor growth in several solid tumors and in mantle cell lymphomas. The active form of mTOR kinase (mammalian target of rapamycin) is a key signaling molecule, and it exists in two different complexes, mTORC1 and mTORC2. In the present work, mTOR activity was investigated in different lymphoma types, in parallel with clinical data. We also examined in Hodgkin lymphomas (HL) the role of mTOR activity in survival mechanisms such as antiapoptotic protein expression and alterations in the microenvironment. We determined which lymphoma types display characteristic high mTOR activity in our TMA (tissue microarray) study. We observed that mTOR activity is increased in mitotic lymphoid cells compared to interphasic cells. The number of diffuse large B cell lymphoma (DLBCL) and HL cases was extended in a further set of TMA. We observed significantly higher mTOR activity in the non-centrum germinativum derived subtype of DLBCL than in the centrum germinativum derived subtype, which was a prognostic marker; 63% of mTOR active cases showed Rictor overexpression, indicating mTORC2 activity. High mTOR activity was also established in 92% of HL cases, which was linked to mTORC1. This finding was not a prognostic marker, however, it can be useful in targeted therapy. We observed the overexpression of the antiapoptotic protein BCL-xL and NFκB-p50 in the majority of mTOR active HLs. HLs showed high numbers of regulatory T cells in the microenvironment and high expression of galectin-1 in tumor cells and in the extracellular matrix, when compared to reactive lymph nodes. We confirmed that mTOR inhibition had significant antiproliferative and antiapoptotic effects in lymphoma cell lines and in lymphoma xenografts (HL, DLBCL, Burkitt lymphoma). We also showed that rapamycin was able to augment the effect of chemotherapeutic agents and TGF-β. Taken together, mTOR activity may be a potential therapeutic target in different lymphoma types. However, patient and inhibitor selection criteria must be carefully considered. The combination of mTOR inhibitors with other agents will probably offer the highest efficiency for achieving the best clinical response, and may also allow dose reduction in order to decrease late treatment toxicity in these cases.
C1 [Mark, Agnes] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Mark, � (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2014
VL 58
IS 2
BP 143
EP 148
PG 6
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular classification of urogenital cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE urogenital tumors; histological classification; molecular classification
ID urogenital tumors; histological classification; molecular classification
AB The molecular genetic dogma is valid that the histological variants of a given cancer represent genetic variants. Basis of this subclassification is known in clear cell renal cancer but still a mistery in prostate or bladder cancers. Meanwhile another genetic dogma developed recently that a given histological variant of a cancer can further be subdivided based on molecular characteristics. Best examples are clear cell renal cancer, adenocarcinoma of the prostate or transitional cell carcinoma of the bladder. This new knowledge helps in the differential diagnostics of cancer, and in determining prognosis, but also provides an opportunity to better tailor existing therapies even to consider novel target agents. Discovery of the molecular subtypes of cancers (such as leukemia or lung adenocarcinoma) contributed significantly to the extension of the progression-free or overall survival of cancer patients, and it is expected that it could lead to similar effects in case of urogenital cancers.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 157
EP 160
PG 4
ER

PT J
AU Kuronya, Zs
   Kovacs, E
   Lahm, E
   Geczi, L
AF Kuronya, Zsofia
   Kovacs, Eszter
   Lahm, Erika
   Geczi, Lajos
TI Successful sunitinib treatment of a patient with Stauffer‘s syndrome
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE Stauffer’s syndrome; sunitinib; complete remission
ID Stauffer’s syndrome; sunitinib; complete remission
AB Several potential biomarkers of response to targeted therapies are being evaluated in metastatic renal cell carcinoma (RCC) to improve drug development and to determine which patient may benefit the most from the different treatment options. Stauffer’s syndrome is a paraneoplastic syndrome that presents with the elevation of hepatic enzymes without hepatic metastases in patients with renal cell carcinoma. Hereby we report the case of our patient who suffered from multiple peritoneal metastases of renal cell cancer accompanied by Stauffer’s syndrome. During his course of disease, the change in the serum gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) levels correlated well with the extent of metastatic spread. Hypertension, grade 2 hand-foot syndrome and hypothyreosis also developed in relation to the successful sunitinib treatment. These side effects are predictive biomarkers in patients responding well to sunitinib. As other potential causes of increased GGT and ALP were excluded, the elevation of these enzymes were attributed to Stauffer‘s syndrome. During treatment, magnetic resonance imaging (MRI) follow-up showed complete regression, while the serum GGT and ALP levels halved. In this case, besides the known biomarkers, changes in serum GGT and ALP levels correlated well with the regression of metastatic renal cell carcinoma. To our knowledge, this is the first case published in the medical literature to show GGT and ALP levels in Stauffer’s syndrome as potential biomarkers.
C1 [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lahm, Erika] Allami Egeszsegugyi Kozpont, Onkologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM kuronyaz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 162
EP 165
PG 4
ER

PT J
AU Maraz, A
   Cserhati, A
   Uhercsak, G
   Szilagyi, �
   Varga, Z
   Kahan, Zs
AF Maraz, Aniko
   Cserhati, Adrienn
   Uhercsak, Gabriella
   Szilagyi, Eva
   Varga, Zoltan
   Kahan, Zsuzsanna
TI Therapeutic significance of sunitinib-induced “off-target” side effects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE metastatic renal carcinoma; sunitinib; side effect; potential biomarker; predictive marker
ID metastatic renal carcinoma; sunitinib; side effect; potential biomarker; predictive marker
AB Sunitinib is a basic medicine in the therapy of metastatic clear cell renal carcinoma. Our aim was to retrospectively evaluate the efficacy of sunitinib in the everyday clinical practice taking the most common side effects and clinical features into consideration. Data of ninety-four patients with metastatic, clear cell renal carcinoma, receiving sunitinib therapy were analyzed retrospectively, regarding efficacy and toxicity. Factors potentially influencing progression-free survival (PFS) and overall survival (OS) [age, nephrectomy, “off-target” side effects that are not connected to vascular endothelial growth factor receptor (VEGFR)] were studied. Complete remission, partial remission and stable disease occurred in 8 (8.5%), 30 (31.9%) and 50 (53.1%) patients, respectively. Objective tumor response developed in 38 (40.4%) cases. Median PFS and OS were 18.3 (95% CI 14.45–22.14) and 27.9 (95% CI 20.95–34.85) months, respectively. PFS and OS were more favorable in case of hypothyreosis (pPFS=0.005, pOS=0.043), hand-foot syndrome (pPFS=0.006, pOS=0.008), grade ≥2 neutropenia (pPFS=0.003, pOS=0.008) and thrombocytopenia (pPFS=0.01, pOS=0.011). Effective therapy of manageable side effects (most of which have potential predictive effect) is important for favorable survival results. Maintenance of dose intensity is also essential in order to compare the daily routine with the efficacy and safety results of clinical trials.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 167
EP 172
PG 6
ER

PT J
AU Szabo, JF
   de la Taille, A
AF Szabo, Janos Ferenc
   de la Taille, Alexander
TI Prostate cancer treatment by da Vinci surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE da Vinci robot-assisted surgery; prostate cancer; radical prostatectomy
ID da Vinci robot-assisted surgery; prostate cancer; radical prostatectomy
AB Minimally invasive laparoscopic surgery replaces many open surgery procedures in urology due to its advantages concerning post-operative morbidity. However, the technical challenges and need of learning have limited the application of this method to the work of highly qualified surgeons. The introduction of da Vinci surgical system has offered important technical advantages compared to the laparoscopic surgical procedure. Robot-assisted radical prostatectomy became a largely accepted procedure. It has paved the way for urologists to start other, more complex operations, decreasing this way the operative morbidity. The purpose of this article is to overview the history of robotic surgery, its current and future states in the treatment of the cancer. We present our robot-assisted radical prostatectomy and the results.
C1 [Szabo, Janos Ferenc] National Institute of Oncology, Department of Surgery, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [de la Taille, Alexander] C. H. U. Henri Mondor, Service d’UrologieCreteil-Paris, France.
RP Szabo, JF (reprint author), National Institute of Oncology, Department of Surgery, 1122 Budapest, Hungary.
EM drjszabo@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 173
EP 181
PG 9
ER

PT J
AU Jorgo, K
   Agoston, P
   Szabo, Z
   Major, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Szabo, Zoltan
   Major, Tibor
   Polgar, Csaba
TI The use of the gold radiopaque markers implanted into the prostate for image guided radiotherapy of prostate cancer patients. The presentation of side effects caused by the marker implantation.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE image-guided radiotherapy; gold marker; transperineal implantation
ID image-guided radiotherapy; gold marker; transperineal implantation
AB The purpose of the study was to introduce the use of the gold radiopaque markers implanted into the prostate for image-guided radiotherapy of prostate cancer patients and to present the side effects caused by the marker implantation. Between November 2011 and November 2013, three radiopaque, gold-plated markers (Best Medical International, Springfield, VA, USA, 1.0 mm x 3.0 mm) were implanted transperineally into the prostate of 60 patients under transrectal ultrasound guidance. Local anaesthesia was performed in all patients. A week after the procedure the patients filled in a questionnaire regarding the pain, dysuria, urinary frequency, nycturia, rectal bleeding, haematuria, haematospermia or fever symptoms caused by the implantation. The pain caused by the intervention was scored on a 1-10 scale, where 1 was a very weak and 10 was an unbearable pain. Ten days after the implantation a treatment planning CT was performed and subsequently patients started intensity-modulated radiation therapy (IMRT) within one week. During the treatments markers were used for daily verification and correction of patient’s setup. No patients experienced fever or infection. Based on the questionnaires nobody experienced dysuria or rectal bleeding after implantation. Among the 60 patients studied, five (8 %) had haematospermia, nine (15 %) haematuria, which lasted in average of 3.4 and 1.8 days, respectively. The average pain score on 1-10 scale was 4.2 (range: 0-9). After the marker implantation 18 patients (30%) reported less, 10 patients (17%) more, and 27 patients (45%) equal amount of pain compared to biopsy. Five patients, who had a biopsy performed under general anaesthesia, did not answer this question. None of the patients needed analgesics after implantation. The gold marker implantation implemented for image-guided radiotherapy was well tolerated under a local anaesthesia. The complications were limited, rate and frequency of perioperative pain was comparable to the pain caused by biopsy. After implantation, the patients did not require analgesics. The method can be performed safely in clinical practice.
C1 [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM jorgokliton@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 182
EP 187
PG 6
ER

PT J
AU Brodszky, V
   Pentek, M
   Baji, P
   Rencz, F
   Geczi, L
   Szucs, M
   Berczi, Cs
   Gulacsi, L
AF Brodszky, Valentin
   Pentek, Marta
   Baji, Petra
   Rencz, Fanni
   Geczi, Lajos
   Szucs, Miklos
   Berczi, Csaba
   Gulacsi, Laszlo
TI Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE castration-resistant prostate cancer; enzalutamide; abiraterone; cabazitaxel; meta-analysis
ID castration-resistant prostate cancer; enzalutamide; abiraterone; cabazitaxel; meta-analysis
AB Enzalutamide, abiraterone-acetate, and cabazitaxel are licensed post-docetaxel treatments of metastatic castration-resistant prostate cancer (mCRPC) in Hungary. The objectives of the study were to assess the efficacy and safety of post-docetaxel enzalutamide treatment and to compare it with abiraterone and with cabazitaxel, using Medline-based systematic literature search, and meta-analysis of randomised controlled trials (RCT). Overall 3 RCTs were included, one for each substance. Compared to placebo, enzalutamide proved significant efficacy in each primary and secondary endpoint. Enzalutamide extended median overall survival by 4.8 months. Due to lack of a common comparator in the cabazitaxel trial, only enzalutamide and abiraterone were involved in an indirect comparison. No significant difference was identified either in the primary endpoint (overall survival) (HR: 0.97, 95% CI: 0.75–1.25) or in frequencies of adverse events between these two treatments. However, enzalutamide was significantly more efficacious than abiraterone in 3 secondary endpoints: time to prostate-specific antigen (PSA) progression (HR: 0.43, 95% CI: 0.31–0.59), radiographic progression-free survival (HR: 0.6, 95% CI: 0.5-0.72), and PSA response rate (RR: 7.48, 95% CI: 2.83–19.72). Enzalutamide therapy proved clinical efficacy and safety in patients with post-docetaxel mCRPC. In the indirect comparison, efficacy and safety of abiraterone and enzalutamide were found to be similar.
C1 [Brodszky, Valentin] Corvinus University of Budapest, Department of Health Economics, Fovam ter 8., 1093 Budapest, Hungary.
   [Pentek, Marta] Corvinus University of Budapest, Department of Health Economics, Fovam ter 8., 1093 Budapest, Hungary.
   [Baji, Petra] Corvinus University of Budapest, Department of Health Economics, Fovam ter 8., 1093 Budapest, Hungary.
   [Rencz, Fanni] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Berczi, Csaba] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Gulacsi, Laszlo] Corvinus University of Budapest, Department of Health Economics, Fovam ter 8., 1093 Budapest, Hungary.
RP Brodszky, V (reprint author), Corvinus University of Budapest, Department of Health Economics, 1093 Budapest, Hungary.
EM valentin.brodszky@uni-corvinus.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 189
EP 197
PG 9
ER

PT J
AU Geczi, L
   Sinkovics, I
AF Geczi, Lajos
   Sinkovics, Istvan
TI Bone targeted treatment in prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE prostate cancer; bone metastases; targeted therapy; radioisotope treatment
ID prostate cancer; bone metastases; targeted therapy; radioisotope treatment
AB Prostate cancer is one of the most common cancers in men. In case of metastatic disease, bone manifestation is presented in 85-90% of the patients. The new targeted treatments are the denosumab RANK-ligand monoclonal antibody and Ra-223-chloride radioisotope therapy. This paper summarizes the treatment possibilities of bone metastasis and presents the results of phase III trials of denosumab and Ra-223-chloride. The upcoming change in financial support underlines the actuality of this paper.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM gelajos@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 199
EP 203
PG 5
ER

PT J
AU Madaras, L
   Szirtes, I
   Bata, P
   Riesz, P
   Somoracz, �
   Szekely, E
   Romics, M
   Majoros, A
   Borka, K
   Szasz, AM
   Nyirady, P
AF Madaras, Lilla
   Szirtes, Ildiko
   Bata, Pal
   Riesz, Peter
   Somoracz, Aron
   Szekely, Eszter
   Romics, Miklos
   Majoros, Attila
   Borka, Katalin
   Szasz, Attila Marcell
   Nyirady, Peter
TI Significance of positive surgical margin in radical prostatectomy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE radical prostatectomy; positive surgical margin; relapse
ID radical prostatectomy; positive surgical margin; relapse
AB The optimal oncological result of radical prostatectomy (RP) is complete removal of the prostate gland and seminal vesicles with negative surgical margins. Preoperative diagnostic biopsies are examined and reported by the pathologist according to standardized rules. Staging of the disease is based on modern preoperative image analysis, most commonly multiparametric MRI. Pathological assessment and reporting of RP specimens is based on the International Society of Uropathology guidelines issued by the 2009 Consensus Conference. Positive surgical margin (PSM) is reported by the pathologist in approximately 1/3rd of RP cases. PSM increases the risk of biochemical, local and systemic progression. Pseudo-whole mount assessment of these specimens is the basis for radio-pathological correlation, thus providing quality control for preoperative MRI as well as assisting preoperative image analysis, sampling and diagnostic workup.
C1 [Madaras, Lilla] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szirtes, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Bata, Pal] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Riesz, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Somoracz, Aron] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Romics, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Majoros, Attila] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Madaras, L (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM madaras.lilla@med.semmelweis-univ.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 204
EP 210
PG 7
ER

PT J
AU Lovey, J
   Nie, D
   Tovari, J
   Kenessey, I
   Kandouz, M
   Timar, J
   Kasler, M
   Honn, VK
AF Lovey, Jozsef
   Nie, Daotai
   Tovari, Jozsef
   Kenessey, Istvan
   Kandouz, Mahmout
   Timar, Jozsef
   Kasler, Miklos
   Honn, V Kenneth
TI Selective 12-lipoxygenase inhibition potentiates the effect of radiation on human prostate cancer cells in vitro and in vivo
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prostate cancer; radiotherapy; 12-lipoxygenase; radiosensitivity
ID prostate cancer; radiotherapy; 12-lipoxygenase; radiosensitivity
AB Prostate cancer is one of the leading cancer types in males in the developed world. Radiotherapy is a major method in the curative treatment of prostate cancer however, up to 30% of the patients experience local relapse. Arachidonic acid metabolites have been shown to have important role in cancer. 12-lipoxygenase (12-LOX) has been proven to significantly influence prostate cancer progression, by apoptosis regulation and by promoting cancer cell survival. In this study we examined whether 12-LOX inhibition may increase radiation sensitivity of prostate cancer cells in vitro and in vivo. Prostate cancer cell lines were treated with 12-LOX inhibitors, different doses of radiation and the combination of 12-LOX inhibitors and radiation. We measured the effect of these treatments through clonogenic survival and apoptosis in vitro and tumor growth in vivo in a tumor xenograft model. 12-LOX inhibition and radiation both increased apoptosis and decreased clonogenic survival of prostate cancer cell lines in vitro. Combined treatment resulted in a supra-additive effect in vitro. In vivo both 12-LOX inhibition and radiotherapy caused delay in growth of the xenograft tumors but the combined treatment resulted in the strongest growth inhibition. The presented data prove that 12-LOX and its metabolite 12(S)-HETE have a major role in prostate cancer cell progression and radiosensitivity. We have shown by different methods in vitro and in vivo that inhibition of 12-LOX activity significantly sensitizes prostate cancer cells to radiation. Therefore we can state that 12-LOX inhibitors are promising compounds to be developed to become a new class of clinical radiation sensitizers in prostate cancer.
C1 [Lovey, Jozsef] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Nie, Daotai] Southern Illinois University School of Medicine, Department of Medical Microbiology, Immunology, and Cell BiologySpringfield, IL, USA.
   [Tovari, Jozsef] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kandouz, Mahmout] Wayne State University, Department of PathologyDetroit, MI, USA.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Honn, V Kenneth] Detroit Medical Center, Barbara Ann Karmanos Cancer InstituteDetroit, MI, USA.
RP Lovey, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 211
EP 218
PG 8
ER

PT J
AU Gesztesi, L
   Agoston, P
   Major, T
   Godeny, M
   Andi, J
   Lengyel, Zs
   Polgar, Cs
AF Gesztesi, Laszlo
   Agoston, Peter
   Major, Tibor
   Godeny, Maria
   Andi, Judit
   Lengyel, Zsolt
   Polgar, Csaba
TI Salvage 125I brachytherapy of locally recurrent prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE prostate cancer; local recurrence; salvage; brachytherapy
ID prostate cancer; local recurrence; salvage; brachytherapy
AB The purpose of the study is to report a case of salvage low dose rate (LDR) prostate brachytherapy in a patient with locally recurrent prostate cancer, four years after his first treatment with combined external beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy. A 61-year-old man was treated with 1x10 Gy HDR brachytherapy and a total of 60 Gy EBRT for an organ confined intermediate risk carcinoma of the prostate in 2009. The patient’s tumor had been in regression with the lowest PSA level of 0.09 ng/ml, till the end of 2013. After slow but continuous elevation, his PSA level had reached 1.46 ng/ml by February 2014. Pelvis MRI and whole body acetate PET/CT showed recurrent tumor in the dorsal-right region of the prostate. Bone scan was negative. After discussing the possible salvage treatment options with the patient, he chose LDR brachytherapy. In 2014, in spinal anesthesia 21 125I „seeds” were implanted with transrectal ultrasound guidance into the prostate. The prescribed dose to the whole prostate was 100 Gy, to the volume of the recurrent tumor was 140 Gy. The patient tolerated the salvage brachytherapy well. The postimplant dosimetry was evaluated using magnetic resonance imaging-computed tomography (MR-CT) fusion and appeared satisfactory. PSA level decreased from the pre-salvage value of 1.46 ng/ml to 0.42 ng/ml by one month and 0.18 ng/ml by two months after the brachytherapy. No gastrointestinal side effects appeared, the patient’s urination became slightly more frequent. In selected patients, salvage LDR brachytherapy can be a good choice for curative treatment of locally recurrent prostate cancer, after primary radiation therapy. Multiparametric MRI is fundamental, acetate PET/CT can play an important role when defining the localization of the recurrent tumor.
C1 [Gesztesi, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Gesztesi, L (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM laszlogesztesi@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 219
EP 224
PG 6
ER

PT J
AU Kuronya, Zs
   Nemeth, H
   Geczi, L
AF Kuronya, Zsofia
   Nemeth, Hajnalka
   Geczi, Lajos
TI Successful treatment of metastatic testicular cancer of extreme size
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE testicular cancer; advanced; incurable; complete remission
ID testicular cancer; advanced; incurable; complete remission
AB Testicular cancer is the most common cancer in young males. Testicular cancer has one of the highest cure rates of all cancers: with modern chemotherapy treatment five-year survival rate exceeds 90 percent overall, and reaches almost 100 percent in early stages. However, these favorable results can only be achieved if these patients are transferred to a reference center, because better outcome was reported for patients who had been treated in a high volume center. Strict adherence to therapeutic protocol is vital for good results. We present a case of a testicular cancer patient with very advanced disease and poor performance status, who was deemed incurable by another oncological center. We achieved complete remission by strictly adhering to the protocol, and using all the available supportive measures. We would like to demonstrate the difficulties we were facing while treating this poor prognostic patient.
C1 [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Hajnalka] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM kuronyaz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2014
VL 58
IS 3
BP 225
EP 228
PG 4
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI Dear Reader
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 231
EP 231
PG 1
ER

PT J
AU Borbely, K
AF Borbely, Katalin
TI New challenges and perspectives in nuclear medicine imaging
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE SPECT/CT; PET/CT; PET/MRI
ID SPECT/CT; PET/CT; PET/MRI
AB Hybrid positron emission tomography/computer tomography (PET/CT) and single photon emission computer tomography/computer tomography (SPECT/CT) have resulted in significant advances both in medical research and routine clinical use. The most recent multimodality system that combines PET and magnetic resonance imaging (MRI) offers new potentials unthinkable before. The hybrid techniques allow obtaining simultaneous morphologic, functional, and molecular information of a living system. The proper use of multimodality imaging is of high importance as they facilitate both basic medical research and clinical practice.
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 232
EP 238
PG 7
ER

PT J
AU Balogh, L
   Polyak, A
   Postenyi, Z
   Haasz, V
   Dabasi, G
   Joba, R
   Bus, K
   Janoki, G
   Thuroczy, J
   Zambo, K
   Garai, I
   Kornyei, J
   Janoki, Gy
AF Balogh, Lajos
   Polyak, Andras
   Postenyi, Zita
   Haasz, Veronika
   Dabasi, Gabriella
   Joba, Robert
   Bus, Katalin
   Janoki, Gergely
   Thuroczy, Julianna
   Zambo, Katalin
   Garai, Ildiko
   Kornyei, Jozsef
   Janoki, Gyozo
TI SPECT radiopharmaceuticals - novelties and new possibilities
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE single photon emission computer tomography (SPECT); gamma emitting isotope (radionuclide); carrier molecule; in vivo radioactive diagnostics; nanomedicine
ID single photon emission computer tomography (SPECT); gamma emitting isotope (radionuclide); carrier molecule; in vivo radioactive diagnostics; nanomedicine
AB Actual state of affairs and future perspectives of SPECT radiopharmaceuticals regarding local and international data were summarized. Beyond conventional gamma-emitting radioisotopes, localization studies with beta emitting therapeutic radiopharmaceuticals hold increasing importance. Extension of hybrid (SPECT/CT) equipments has modified conventional scintigraphic and SPECT methods as well but more important changes come into the world through novel ligands for specific diagnoses and therapy.
C1 [Balogh, Lajos] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna utca 5., 1221 Budapest, Hungary.
   [Polyak, Andras] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna utca 5., 1221 Budapest, Hungary.
   [Postenyi, Zita] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna utca 5., 1221 Budapest, Hungary.
   [Haasz, Veronika] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna utca 5., 1221 Budapest, Hungary.
   [Dabasi, Gabriella] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Joba, Robert] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Bus, Katalin] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Janoki, Gergely] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Thuroczy, Julianna] Szent Istvan Egyetem, Allatorvos-tudomanyi Kar, Szuleszeti es Szaporodasbiologiai Tanszek es KlinikaBudapest, Hungary.
   [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Garai, Ildiko] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kornyei, Jozsef] Izotop Intezet Kft.Budapest, Hungary.
   [Janoki, Gyozo] Medi-Radiopharma Kft.Erd, Hungary.
RP Balogh, L (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1221 Budapest, Hungary.
EM balogh.lajos@osski.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 239
EP 244
PG 6
ER

PT J
AU Kornyei, J
   Mikecz, P
   Toth, Gy
AF Kornyei, Jozsef
   Mikecz, Pal
   Toth, Gyula
TI PET radiopharmaceuticals: Novelties and new possibilities
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE 18F- and 11C-compounds; positron emitter metal isotopes; oncological diagnostics
ID 18F- and 11C-compounds; positron emitter metal isotopes; oncological diagnostics
AB 18F-fluoro-deoxyglucose (FDG) can be considered as the „work-horse” of PET/CT and PET/MR imaging modalities. FDG provides insight in the pathophysiology of tumors and metastases from the point of view of sugar consumption. On the other hand, amino acid metabolism, expression of various receptors in the cells or on the surface of the cells, angiogenesis, appearance of hypoxic cells/tissues and apoptosis also participate in the pathophysiological processes and may have importance in determining the treatment strategy for patients or in monitoring the chosen therapy. Many molecules involved can be labeled by 18F radionuclide but certain metabolisms require 11C-labelled agents. Molecular imaging is of key importance in cancer research and various metal complexes containing 44Sc, 64Cu, 68Ga, 86Y, 89Zr positron emitters can be very useful in this activity.
C1 [Kornyei, Jozsef] Izotop Intezet Kft., Konkoly Thege Miklos ut 29–33., 1121 Budapest, Hungary.
   [Mikecz, Pal] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Toth, Gyula] Pozitron Diagnosztika KftBudapest, Hungary.
RP Kornyei, J (reprint author), Izotop Intezet Kft., 1121 Budapest, Hungary.
EM kornyei@izotop.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 245
EP 250
PG 6
ER

PT J
AU Balkay, L
   Emri, M
   Galuska, L
   Garai, I
   Kis, SA
   Szucs, B
   Varga, J
AF Balkay, Laszlo
   Emri, Miklos
   Galuska, Laszlo
   Garai, Ildiko
   Kis, Sandor Attila
   Szucs, Bernadett
   Varga, Jozsef
TI New trends in the functional medical imaging: Quantitative methods
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE SPECT/CT; PET/CT; PET/MRI; MRI; CT; oncology; kinetics
ID SPECT/CT; PET/CT; PET/MRI; MRI; CT; oncology; kinetics
AB Deriving quantitative measures from the medical imaging methods is a key issue for the optimal oncologic therapy, when the anatomical abnormalities and changes of the metabolic state of the tissues need to be characterized. In order to improve the effectiveness of the therapy, the results of medical imaging procedures should be comparable after two or more consecutive scans. There are several tomographic imaging applications (CT, MRI, SPECT and PET), but in this work we will focus on the quantitative capability of PET, because this method provides the most versatile possibilities for quantifying the resulting images.
C1 [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Garai, Ildiko] Scanomed Kft.Debrecen, Hungary.
   [Kis, Sandor Attila] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Szucs, Bernadett] Scanomed Kft.Debrecen, Hungary.
   [Varga, Jozsef] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Balkay, L (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4032 Debrecen, Hungary.
EM balkay.laszlo@med.unideb.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 251
EP 260
PG 10
ER

PT J
AU Varallyay, P
AF Varallyay, Peter
TI Novelties and new possibilities in radiological diagnostics of brain tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE biomarker; diffusion-weighted MR; diffusion tensor MR; perfusion-weighted MR; spectroscopy
ID biomarker; diffusion-weighted MR; diffusion tensor MR; perfusion-weighted MR; spectroscopy
AB Modern MR imaging with advanced techniques such as diffusion, perfusion and functional imaging as well as spectroscopy have improved the characterization of brain tumors. Unlike conventional imaging providing mainly anatomical or structural information, these advanced applications give insight into the microstructure and physiology of brain tumors. Several biomarkers are available which correlate with tumor cellularity, microstructure, vascularity and metabolism. These techniques not only aid in the imaging diagnosis and treatment planning of brain tumors, but they also play a role in clinical management and monitoring treatment effect.
C1 [Varallyay, Peter] National Institute of Clinical Neurosciences, Amerikai ut 57., 1145 Budapest, Hungary.
RP Varallyay, P (reprint author), National Institute of Clinical Neurosciences, 1145 Budapest, Hungary.
EM pvarallyay@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 261
EP 268
PG 8
ER

PT J
AU Godeny, M
   Lerant, G
AF Godeny, Maria
   Lerant, Gergely
TI New opportunities, MRI biomarkers in the evaluation of head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE functional MRI; diffusion-weighted MRI; dynamic contrast MRI; MR spectroscopy; MR biomarker
ID functional MRI; diffusion-weighted MRI; dynamic contrast MRI; MR spectroscopy; MR biomarker
AB Magnetic resonance imaging (MRI) has developed rapidly during the past few years and, according to the needs of therapy, has opened new perspectives in oncologic imaging with better and better realization of the latest technological advances. After the introduction of „organ preservation” protocols the role of imaging has become more important. New therapeutic methods (improvement in radiation therapy and chemotherapy) need better tumor characterization and prognostic information along with the most accurate anatomical information. Multiparametric anatomical and functional MR imaging (MM-MRI) using high magnetic field strength (3 Tesla) are useful in determining tumor-specific MRI biomarkers and in evaluating the changes in these parameters during therapy to provide early assessment of the therapeutic response. Diffusion-weighted MRI (DW-MRI) provides information at the cellular level about cell density and the integrity of the plasma membrane. DW-MRI shows potential in improving the detection of cancer due to its high specificity and high negative predictive value. Quantification is performed using an apparent diffusion coefficient (ADC), the values are independent of the magnetic field strength. In the latest publications the accuracy of DW-MRI has been reported around 90% for the differentiation between malignant versus benign tumor using an ADC cut-off mean value of 0.700–1.200 10–3 mm2/s units, but no common threshold ADC value exists in clinical routine for the differentiation of malignant and benign tissues. Dynamic contrast-enhanced MRI (DCE-MRI), as a marker of angiogenesis, provides information about vascularization at the tissue level. Angiogenetic alterations cause changes in the parameters of vascular physiology (perfusion, blood volume, capillary permeability) and thus alter the contrast enhancement observed on contrast MRI. High-grade and/or advanced stage tumors are associated with increased blood volume, increased permeability and increased perfusion; the data can be evaluated using semiquantitative or quantitative methods. Magnetic resonance spectroscopic imaging (MRSI) provides biochemical analysis at the molecular level. The results are promising, although further studies are required to determine whether MRSI can be used to identify or exclude cancer within regions where the cancer is not evident on conventional MRI or with the other functional imaging methods. Some of the studies demonstrated the usefulness of these functional MRI methods also in the head and neck region to differentiate benign from malignant tumors, to quantify the response to radiation therapy and chemotherapy, to identify residual or recurrent tumor and to correlate the perfusion or diffusion data with prognosis. There are still some overlaps between benign and malignant changes, and the use of these functional MR measurements in routine diagnostics are still not fully validated today. Functional MR measurements are useful parts of the high quality multiparametric MRI, they offer important supportive biological and molecular information with the aid of high resolution morphological imaging.
C1 [Godeny, Maria] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Lerant, Gergely] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM godeny.maria@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 269
EP 280
PG 12
ER

PT J
AU Baranyai, T
AF Baranyai, Tibor
TI Novelties and new possibilities in radiological diagnostics of kidney and urethral tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE renal cell carcinoma; transitional cell carcinoma; dynamic imaging; contrast agent wash-out; dignity
ID renal cell carcinoma; transitional cell carcinoma; dynamic imaging; contrast agent wash-out; dignity
AB The author analyses the opportunities granted by diagnostic imaging for the early perception of kidney and urethral tumors and exact tumor staging. The wide-scale application of non-invasive ultrasound scans has lead to an increase in incidentalomas. Volumetric (multidetector or dual source) CT scans, the various MR techniques and, more recently, PET/CT scans have largely contributed to the exact preoperative staging of tumorous diseases, and help characterize the tumors found. In the case of small kidney tumors, attempts are made to decide which masses require operation and which do not, based on the tumor’s absorption of the contrast agent and its wash-out intensity as observed by dynamic contrast-enhanced scans. The author points out that despite the achieved development, especially in terms of small tumors, image-guided biopsies still play a significant role. Medical imaging techniques are also indispensable for post-therapy follow-up of patients (PET/CT, CT and MR perfusion imaging).
C1 [Baranyai, Tibor] Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Rontgen- es Izotopdiagnosztikai Osztaly, Gyori ut 15., 9400 Sopron, Hungary.
RP Baranyai, T (reprint author), Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Rontgen- es Izotopdiagnosztikai Osztaly, 9400 Sopron, Hungary.
EM baranyai.tibor@sopronigyogykozpont.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 281
EP 289
PG 9
ER

PT J
AU Baranyai, T
AF Baranyai, Tibor
TI Novelties and new possibilities in radiological diagnostics of tumors of the prostate, seminal vesicle, testicle and penis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE transitional cell carcinoma; lymph node metastasis; prostate cancer; testicular cancer; penis tumor
ID transitional cell carcinoma; lymph node metastasis; prostate cancer; testicular cancer; penis tumor
AB This review analyses the opportunities granted by diagnostic imaging of cancers of the urinary bladder, prostate gland, seminal vesicle, testicle and penis. The author discusses in details the value and role of the various procedures in early detection, characterization of tumors and in determination of the exact tumor staging. All these support the selection of the optimal patient-specific treatment, then the assessment of the efficacy of therapy.
C1 [Baranyai, Tibor] Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Rontgen- es Izotopdiagnosztikai Osztaly, Gyori ut 15., 9400 Sopron, Hungary.
RP Baranyai, T (reprint author), Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Rontgen- es Izotopdiagnosztikai Osztaly, 9400 Sopron, Hungary.
EM baranyai.tibor@sopronigyogykozpont.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 290
EP 300
PG 11
ER

PT J
AU Kovacs, LG
AF Kovacs, L Gabor
TI New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prostate cancer; PSA; new laboratory markers; screening; routine diagnosis; research
ID prostate cancer; PSA; new laboratory markers; screening; routine diagnosis; research
AB Prostate cancer is usually a disease of elderly men, however, over 40 years of age the tumor can appear at any times. PSA is a protein molecule synthesized by prostate cells. Measurement of serum PSA has revolutionized the diagnosis and treatment of prostate cancer. However, PSA is not sufficiently specific for the detection of prostate cancer, since serum PSA might also be elevated in benign prostate diseases, as well as following physical stimulation of the gland (digital rectal examination, biopsy, catheterization, or even ejaculation). To increase the specificity of PSA, different derivative parameters have been developed i.e. PSA density (ratio of PSA to prostate volume), PSA velocity (change of PSA over a time period) or age-specific reference ranges. 65-95% of circulating PSA is bound to different proteins, while the rest of PSA circulates in a non-bound form (free PSA, fPSA). In addition to fPSA, the prostate health index [phi; (-2)proPSA/fPSA×√PSA] is increasingly used to differentiate between carcinoma-induced and non-carcinoma-induced increase in PSA. PCA3 is a non-coding messenger RNA, which is 60-70-fold overexpressed by cancer cells in the prostate. Measurement of urine PCA3 appears to be more sensitive than %tPSA, and is independent of prostate volume, age or tPSA. The author reviews laboratory biomarkers related to prostate cancer, used either in the routine clinical practice, or in research. Laboratory biomarkers seem to be useful tools to reduce the incidence of advanced stage, or metastatic prostate cancer, and the cancer-related death rate. A promising perspective for the future is the detection of circulating prostate cancer cells and the profiling of microRNAs, especially on the field of tumor prognosis.
C1 [Kovacs, L Gabor] University of Pecs, Department of Laboratory Medicine, Ifjusag utca 13., 7624 Pecs, Hungary.
RP Kovacs, LG (reprint author), University of Pecs, Department of Laboratory Medicine, 7624 Pecs, Hungary.
EM kovacs.l.gabor@pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 301
EP 309
PG 9
ER

PT J
AU Szekely, E
   Istok, R
   Szekely, T
   Kovacs, I
   Somoracz, �
   Jaray, B
AF Szekely, Eszter
   Istok, Roland
   Szekely, Tamas
   Kovacs, Istvan
   Somoracz, Aron
   Jaray, Balazs
TI The role of aspiration cytology in tumor diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE US-guided FNAB
ID US-guided FNAB
AB Fine needle aspiration biopsy (FNAB) of focal lesions is a quick, relatively simple and cost-effective diagnostic method. However, performing aspirations and interpreting smears require skill and experience. Before initiating an aspiration the doctor needs to be aware of the limits of cytology as it is vital to know what kind of diagnostic issues can be answered upon a smear and what kind of questions cannot. Traditionally FNAB was performed without radiologic guidance, and therefore almost only palpable lesions were aspirated. Since ultrasound (US) has become widely used in medicine, it is axiomatical that FNAB is ideally performed with US guidance not only for the protection of the patients but also for targeting the lesion more safely. Several cytologists find US guidance unnecessary as a routinely used examination, which may lead to unsatisfactory smears and false negative results. This means not only a loss for the patient, but leads to a negative judgement of this diagnostic method. Our interventional cytology diagnostic team developed a working method resulting in excellent statistical results. In the followings we would like to share our experience refined the past two decades to restore the reputation of this diagnostic method.
C1 [Szekely, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Istok, Roland] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szekely, Tamas] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kovacs, Istvan] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Somoracz, Aron] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Szekely, E (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM szeszter@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 311
EP 323
PG 13
ER

PT J
AU Sarosi, V
   Baliko, Z
AF Sarosi, Veronika
   Baliko, Zoltan
TI Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE NSCLC; EGFR mutation; afatinib; LUX-Lung 3; LUX-Lung 6
ID NSCLC; EGFR mutation; afatinib; LUX-Lung 3; LUX-Lung 6
AB Therapy of patients with advanced NSCLC has lately changed due to the algorithm based on the presence or absence of oncogenic mutations. There is an agreement nowadays that in the presence of activating EGFR mutations, the administration of EGFR TKI (gefitinib, erlotinib, afatinib) is the most efficacious initial treatment. Unlike the first-generation TKIs, afatinib is a new, irreversible ErbB blocker, selectively and effectively blocking signals from the ErbB family receptors. Afatinib’s marketing authorization is based on a large, randomized, phase III clinical trial, LUX-Lung 3, where patients in the control arm were treated with the best available chemotherapy (pemetrexed/cisplatin combination). Primary endpoint was progression-free survival (PFS). Patients with common EGFR mutations showed a PFS of 13.6 months when treated with afatinib, while treatment in the control arm resulted in a PFS of 6.9 months. Overall survival (OS) was 31.6 and 28.2 months, respectively. LUX-Lung 3 has been followed by the LUX-Lung 6 trial, comparing afatinib treatment to traditional chemotherapy (gemcitabine/cisplatin) in Asian patients with NSCLC harboring EGFR mutations. This clinical trial has also proved benefit of afatinib: PFS was 11.0 months in the afatinib arm and 5.6 months in the control arm by independent reviewer, while OS was 23.6 months and 23.5 months, respectively. Similarity of the OS values in both trials is explained by the cross-over treatment. When further analyzing OS data, a statistically significant difference between the afatinib and the control arm was seen in the EGFR exon 19 del subgroup (LUX-Lung 3: 33.3 vs. 21.1 months, LUX-Lung 6: 31.4 vs. 18.4 months, respectively).
C1 [Sarosi, Veronika] University of Pecs, I. Department of Internal Medicine, Rakozi ut 2., 7623 Pecs, Hungary.
   [Baliko, Zoltan] University of Pecs, I. Department of Internal Medicine, Rakozi ut 2., 7623 Pecs, Hungary.
RP Sarosi, V (reprint author), University of Pecs, I. Department of Internal Medicine, 7623 Pecs, Hungary.
EM sarosi.veronika@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2014
VL 58
IS 4
BP 325
EP 329
PG 5
ER

PT J
AU Balkay, L
   Emri, M
   Krizsan, �K
   Opposits, G
   Varga, J
AF Balkay, Laszlo
   Emri, Miklos
   Krizsan, Aron Krisztian
   Opposits, Gabor
   Varga, Jozsef
TI New trends in functional medical imaging: Imaging methods
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE emission tomography; SPECT/CT; PET/CT; PET/MRI; MRI; CT; oncology
ID emission tomography; SPECT/CT; PET/CT; PET/MRI; MRI; CT; oncology
AB The aim of the study is to review the new tomographic imaging technologies which enable to investigate the metabolic activity of the human body. Accordingly, we overview the current promising methodology in the field of PET and SPECT, but we will also mention interesting applications at the area of MRI and CT.
C1 [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Krizsan, Aron Krisztian] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Opposits, Gabor] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Varga, Jozsef] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Balkay, L (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4032 Debrecen, Hungary.
EM balkay.laszlo@med.unideb.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 4
EP 9
PG 6
ER

PT J
AU Borbely, K
AF Borbely, Katalin
TI New challenges and new potentials in the management of patients in oncology: PET/MRI clinical applications
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PET/MRI; PET/CT; hybrid imaging
ID PET/MRI; PET/CT; hybrid imaging
AB The most recent multimodality technique, the hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) combines two very different technologies, which is a great result of human creativity. The combined PET/MRI has significant potentials in clinical oncology providing new perspectives of functional and anatomical information. PET/MRI offers simultaneous measurements of multifunctional data such as PET mapping by different specific tracers or MRI morphologic, MR molecular (MR spectroscopy, MRS), or MR functional (fMR) information of a living system.
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 10
EP 16
PG 7
ER

PT J
AU Zambo, K
   Schmidt, E
   Szabo, Zs
   Sarkadi, M
   Derczy, K
   Szekeres, S
AF Zambo, Katalin
   Schmidt, Erzsebet
   Szabo, Zsuzsanna
   Sarkadi, Margit
   Derczy, Katalin
   Szekeres, Sarolta
TI Novelties and new facilities in the clinical application of SPECT/CT imaging
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE SPECT/CT; fused imaging; molecular diagnostics; specific radiotherapy
ID SPECT/CT; fused imaging; molecular diagnostics; specific radiotherapy
AB The application of hybrid equipments and fused techniques has increasing importance in the field of imaging diagnostics. The biggest advantage of these methods is the simultaneous use of several modalities which can give data about the morphological, functional as well as molecular changes of the different diseases at the same time. The facilities, advantages and the applicability of the SPECT/CT (single photon emission computer tomograph/computer tomograph) are summarized in this paper mainly in oncologic diseases, but also in other disorders. The multimodality equipments showing the function and morphology together increase the specificity and diagnostic accuracy of the nuclear medicine methods and were found to be more efficient in the therapy effectiveness, too.
C1 [Zambo, Katalin] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Schmidt, Erzsebet] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Szabo, Zsuzsanna] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Sarkadi, Margit] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Derczy, Katalin] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
   [Szekeres, Sarolta] PTE KK, Radiologiai Klinika, Ifjusag utja 13., 7624 Pecs, Hungary.
RP Zambo, K (reprint author), PTE KK, Radiologiai Klinika, 7624 Pecs, Hungary.
EM zambo.katalin@pte.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 17
EP 24
PG 8
ER

PT J
AU Garai, I
   Farkas, B
   Oszlanszki, A
   Berczi, Cs
   Flasko, T
   Galuska, L
AF Garai, Ildiko
   Farkas, Bence
   Oszlanszki, Attila
   Berczi, Csaba
   Flasko, Tibor
   Galuska, Laszlo
TI 11C-choline PET/CT in the diagnosis of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kolin; PET/CT; prosztatarak
ID kolin; PET/CT; prosztatarak
AB 11C-choline has been used in the diagnosis and follow-up of patients with prostate cancer for years. Choline PET/CT has been available in human care since March, 2014 in our country. Unfortunately this examination has not been reimbursed by the National Health Insurance so far. We retrospectively analysed and assessed the results of 40 patients who underwent 11C-choline PET/CT on the basis of previous literature. As our study group was heterogeneous statistical analysis was not performed.
C1 [Garai, Ildiko] Scanomed Kft., Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Farkas, Bence] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Oszlanszki, Attila] Scanomed Kft., Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Berczi, Csaba] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Galuska, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Garai, I (reprint author), Scanomed Kft., 4032 Debrecen, Hungary.
EM garai.ildiko@scanomed.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 25
EP 29
PG 5
ER

PT J
AU Mateka, I
   Bikhazi, Z
   Bartha, �
   Palko, A
AF Mateka, Ilona
   Bikhazi, Ziad
   Bartha, Eva
   Palko, Andras
TI Modern imaging of liver and pancreatic neoplasms
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE liver; pancreas; neoplasm; imaging diagnostics
ID liver; pancreas; neoplasm; imaging diagnostics
AB Modern imaging modalities play an outstanding role in the detection, characterization, staging, therapy planning, treatment outcome evaluation and follow-up of patients with liver and pancreatic neoplasms. Diagnostic performance and accuracy of the available modalities are continuously improving therefore, it is necessary to overview from time to time the diagnostic protocols and algorithms.
C1 [Mateka, Ilona] Diagnoscan Hungary LtdSzeged, Hungary.
   [Bikhazi, Ziad] Diagnoscan Hungary LtdSzeged, Hungary.
   [Bartha, Eva] Diagnoscan Hungary LtdSzeged, Hungary.
   [Palko, Andras] University of Szeged, Department of Radiology, Semmelweis u. 6., 6725 Szeged, Hungary.
RP Palko, A (reprint author), University of Szeged, Department of Radiology, 6725 Szeged, Hungary.
EM palko.andras@med.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 30
EP 36
PG 7
ER

PT J
AU Monostori, Zs
AF Monostori, Zsuzsanna
TI Novelties and new possibilities in radiological diagnostics of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; staging; imaging modality; molecular diagnostics
ID lung cancer; staging; imaging modality; molecular diagnostics
AB In recent years there have been significant changes in the management of lung cancer. In 2009 a new staging system became effective while in 2011 a new adenocarcinoma classification was introduced. Molecular biology, genetics with hybrid multimodal imaging progressed greatly. New biopsy needles were developed for the histological analysis in molecular pathology. Role of LDCT screening in early diagnosis of lung cancer became evident and working groups put it into practice. Integrated and multiparametric devices facilitate more accurate patient follow-up with new biomarkers and newly developed contrast materials. The future of radiology is in the combined use of anatomical, functional and molecular medical imaging.
C1 [Monostori, Zsuzsanna] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Radiologiai OsztalyBudapest, Hungary.
RP Monostori, Zs (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Radiologiai Osztaly, Budapest, Hungary.
EM monostori@koranyi.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 37
EP 43
PG 7
ER

PT J
AU Bidlek, M
   Kovacs, E
   Feher, K
   Godeny, M
AF Bidlek, Maria
   Kovacs, Eszter
   Feher, Krisztina
   Godeny, Maria
TI New opportunities in imaging of breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; MR mammography; diffusion-weighted MRI; dynamic-contrast enhanced MRI; tomosynthesis
ID breast cancer; MR mammography; diffusion-weighted MRI; dynamic-contrast enhanced MRI; tomosynthesis
AB Complex tumor therapy development and new opportunities in surgery, which take into account both oncological principles as well as esthetic aspects, have set the requirements far higher for diagnostic imaging of the breast and for radiologists. Despite these new opportunities, X-ray mammography remains the basic examination. However, part of the cancers is hidden on the mammogram, which is partly a consequence of the dense glandular tissue and may also be influenced by the histological type of cancer. Besides reducing radiation dose, digital X-ray mammography improves the examination sensitivity of the dense breast. State of the art digital examination methods, such as tomosynthesis and contrast-enhanced mammography, increase the accuracy of examination. Ultrasound mammography is the most important supplementary method of X-ray mammography. Among the new applications of ultrasound mammography, US elastography, which is based on different tissue elasticity, as well as automatic 3D ultrasound, can be highlighted. Furthermore, among imaging methods that provide functional or metabolic data, MR mammography is the most appropriate non-invasive, non-ionising method for the detection of malignancy and for structure examination. MR mammography is the most sensitive method for the detection of breast cancer and in 20-30% of cases, results in changes of the therapy, and it is also effective in the examination of the dense breast. High level of evidence proves that MR mammography is very useful in the screening of women at risk of breast cancer. Promising results prove that MR mammography will play more considerable role in the evaluation of the effectiveness of the therapy. Diffusion-weighted MR imaging is based on the different diffusion of tissue water, qualitative analysis and quantitative evaluation can be performed. DCE-MR examines that contrast enhancement over time, which can mainly be useful for the qualitative and quantitative evaluation of perfusion changes which may indicate the biological response to tumor therapy. The MR spectroscopic (MRSI) biochemical analysis increases the characterization of the lesions. Multimodal imaging techniques provide more accurate analysis, which is confirmed by more and more evidence, but none of the imaging methods are sufficiently specific to provide histological diagnosis. However, imagingguided biopsies enable precise histological or cytological confirmation. Technical development, new imaging methods, experienced radiologists and multi-disciplinary cooperation increase the accuracy of the diagnosis and the effectiveness of personalized therapy.
C1 [Bidlek, Maria] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Feher, Krisztina] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Godeny, Maria] University of Medicine and Pharmacy, Department of Postgraduate Education and Scientific ResearchTargu-Mures, Romania.
RP Bidlek, M (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM bidlekm@freemail.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 44
EP 55
PG 12
ER

PT J
AU Rosztoczy, A
AF Rosztoczy, Andras
TI New tools and actual possibilities in the diagnosis of esophageal malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE esophageal cancer; Barrett’s esophagus
ID esophageal cancer; Barrett’s esophagus
AB The diagnosis of esophageal malignancies remains to be a significant challenge. The lack of symptoms and widely applicable, predictive screening tests make their early recognition difficult, however this would be essential for the successful treatment, costeffective management and the improvement of survival. In this manuscript the author discusses the diagnostic tools available at present and in the near future.
C1 [Rosztoczy, Andras] University of Szeged, 1st Department of Medicine, Koranyi fasor 8-10.Szeged, Hungary.
RP Rosztoczy, A (reprint author), University of Szeged, 1st Department of Medicine, Szeged, Hungary.
EM rosztoczy.andras@med.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 56
EP 59
PG 4
ER

PT J
AU Gyokeres, T
AF Gyokeres, Tibor
TI Novelties and new possibilities in endoscopic diagnostics of gastrointestinal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE virtual chromoendoscopy; optical biopsy; small bowel enteroscopy; Barrett’s esophagus
ID virtual chromoendoscopy; optical biopsy; small bowel enteroscopy; Barrett’s esophagus
AB This publication shortly reviews the attributes of cornerstones of the latest technical developments in the field of endoscopy (virtual chromoendoscopy, optical biopsy, etc.), as well as some technical details of novel endoscopic methods (deep enteroscopy, capsule endoscopy). It evaluates the clinical consequences of the technical progress concerning several diseases that are important from the point of view of oncology. Some novel endoscopic innovations till now with uncertain clinical relevance are also mentioned. We can face the fact what a huge gap exists between our everyday possibilities at almost all our workplaces and the up-to-date endoscopic diagnostic modalities of the developed world.
C1 [Gyokeres, Tibor] Magyar Honvedseg Egeszsegugyi Kozpont, Gasztroenterologia, Podmaniczky u. 111., 1062 Budapest, Hungary.
RP Gyokeres, T (reprint author), Magyar Honvedseg Egeszsegugyi Kozpont, Gasztroenterologia, 1062 Budapest, Hungary.
EM tiborgyokeres65@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 62
EP 67
PG 6
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI The developments in melanoma diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; diagnosis; dermoscopy; sentinel lymph node biopsy; molecular diagnostics; PET/CT
ID melanoma; diagnosis; dermoscopy; sentinel lymph node biopsy; molecular diagnostics; PET/CT
AB The continuously increasing incidence of melanoma and new developments in the therapy of metastatic disease require accurate diagnosis in all stages of melanoma. This study overviews the development of diagnostics tools in recent years/decades that are used in everyday medical practice such as optical diagnostic tools utilized for diagnosing primary tumors, sentinel lymph node biopsy, developments in molecular diagnostics, as well as the role of PET/CT in imaging techniques.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM liszkay@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 68
EP 72
PG 5
ER

PT J
AU Illes, �
   Simon, Zs
AF Illes, Arpad
   Simon, Zsofia
TI Novel findings and new possibilities in the diagnosis of lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lymphoma; molecular pathology; genetics; PET/CT; targeted therapy
ID lymphoma; molecular pathology; genetics; PET/CT; targeted therapy
AB Successful treatment of lymphomas requires classical morphological diagnosis and also immunophenotyping as well as cytogenetics and molecular genetic examinations. The expansion of pathogenetic knowledge resulted in new classifications, new disease entities, and subtypes that are identified with distinct genetic aberrations bearing prognostic value as well and also serving as potential targets for new targeted therapies. The more detailed molecular background is explored the more precise personalized treatment options can be utilized nowadays and in the near future. Thus new up-to-date hematopathology is the key to successful oncohematological treatment. The imaging diagnosis has also evolved during the last decade in the diagnosis of lymphomas. This can also help us to monitor response to therapy by using positron emission tomography. This enables us to monitor therapy and make decisions based on efficiency of the therapeutic regimen. Survival data of lymphoma patients can further be improved by avoiding under- and overtreatment, which is achieved by using PET/CT as a “biomarker” or response indicator besides conventional biologic and clinical prognostic markers.
C1 [Illes, Arpad] University of Debrecen, Faculty of Medicine, Department of Hematology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Simon, Zsofia] University of Debrecen, Faculty of Medicine, Department of Hematology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Illes, � (reprint author), University of Debrecen, Faculty of Medicine, Department of Hematology, 4032 Debrecen, Hungary.
EM illesarpaddr@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2015
VL 59
IS 1
BP 73
EP 78
PG 6
ER

PT J
AU Polgar, Cs
   Major, T
   Kiraly, R
   Fodor, J
   Kasler, M
AF Polgar, Csaba
   Major, Tibor
   Kiraly, Reka
   Fodor, Janos
   Kasler, Miklos
TI Status report of Hungarian radiotherapy based on treatment data, available infrastucture, and human resources
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hungarian radiotherapy; infrastructure; human resources
ID Hungarian radiotherapy; infrastructure; human resources
AB The purpose of the study is to report the status of Hungarian radiotherapy (RT) based on the assessment of treatment data in years 2012 to 2014, available infrastructure, and RT staffing. Between December 2014 and January 2015, a RT questionnaire including 3 parts (1. treatment data; 2. infrastructure; 3. staffing) was sent out to all Hungarian RT centers (n=12). All RT centers responded to all questions of the survey. 1. Treatment data: In 2014, 33,162 patients were treated with RT: 31,678 (95.5%) with teletherapy, and 1484 (4.5%) with brachytherapy (BT). Between 2012 and 2014, the number of patients treated with radiotherapy increased with 6.6%, but the number of BT patients decreased by 11%. Forty-two percent of all patients were treated in the two centers of the capital: 9235 patients (28%) at the National Institute of Oncology (NIO), and 4812 (14%) at the Municipial Oncoradiology Center (MOC). Out of the patients treated on megavoltage RT units (n=22,239), only 901 (4%) were treated with intensity-modulated RT (IMRT), and 2018 (9%) with image-guided RT (IGRT). In 2014, 52% of all BT treatments were performed in Budapest: NIO – 539 patients (36%); MOC – 239 patients (16%); and BT was not available in 3 RT centers. Prostate I-125 seed implants and interstitial breast BT was utilized in one, prostate HDR BT in two, and head&neck implants in three centers. 2. Infrastructure: Including ongoing development projects funded by the European Union, by the end of year 2015, 39 megavoltage teletherapy units, and 12 HDR BT units will be in use in 13 available Hungarian RT centers. 3. Staffing: Actually, 92 radiation oncologists (RO), 29 RT residents, 61 medical physicists, and 229 radiation therapy technologists are working in 12 RT centers. There are 23 vacant positions (including 11 RO positions) available at the Hungarian RT centers. According to the professional minimal requirements and WHO guidelines, the implementation of 11 new linear accelerators, and 1 BT units are needed in Hungary. Further resources for the development and upgrade of RT infrastructure and capacity should be allocated to RT centers in Budapest. Brachytherapy and modern teletherapy (e.g. IMRT and IGRT) are underutilized in Hungary compared to other European countries. Implementation of continuous education and practical training programs in leading Hungarian and international RT centers are suggested in an effort to a wider implementation of modern RT techniques in Hungarian RT centers.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 85
EP 94
PG 10
ER

PT J
AU Pesznyak, Cs
   Bela, D
   Takacsi-Nagy, Z
   Major, T
   Polgar, Cs
AF Pesznyak, Csilla
   Bela, Dalma
   Takacsi-Nagy, Zoltan
   Major, Tibor
   Polgar, Csaba
TI Dosimetry analysis of intensity-modulated and conformal radiation therapy for head and neck tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE intensity-modulated; head and neck tumor; conformal therapy
ID intensity-modulated; head and neck tumor; conformal therapy
AB The aim of the study was to compare different treatment plans – intensity-modulated and conformal – for head and neck cancer patients. Treatment plans were developed for ten head and neck cancer patients by applying four different techniques: two conventional 3D conformal plans (forward treatment planning, with two opposing fields 90o–270o and one asymmetric anterior field, matching in isocenter /Conv/, conformal parotis sparing plans /ConPas/), 3D conformal plans with inverse treatment planning techniques /INVCRT/ and intensity-modulated radiation therapy plans /IMRT/. The plans were made for the same target volumes PTV50 (elective) and PTV66 (boost-16 Gy). The cumulative dose was 66 Gy, and the Philips Pinnacle3 v8.0m TPS was used for treatment planning. The organs at risk (OAR) were as follows: spinal cord, brain stem, left and right parotis and oral cavity. The dose constrains and conditions for optimization were determined for IMRT techniques with 7 fields. During the optimization we applied two different protocols: in one case the plans were made by 40 segments for “step and shoot” IMRT techniques and by 14 segments for INVCRT, which were converted into static fields. The homogeneity (HI) and conformity (COIN) indices were calculated for planning target volumes and the comparisons were assessed on several dosimetric parameters for OARs. The IMRT, INVCRT, Conv and ConPas techniques for PTV50 planning target volume gave the following values for homogeneity index: 0.13, 0.18, 0.22, 0.19, and for conformity index: 0.76, 0.68, 0.13, 0.09. The spinal cord received a maximum of 38 Gy, 42 Gy, 45 Gy and 44 Gy for the PTV66. Mean doses of the oral cavity outside the target volume were 33 Gy, 36 Gy, 30 Gy and 48 Gy. When the 16 Gy boost treatment was applied on one side only, the mean dose for the parotis on the contralateral side was 28 Gy, 31 Gy, 49 Gy and 43 Gy, while 39 Gy, 41 Gy, 59 Gy and 53 Gy on the same side. The objectives of adequate target coverage and sparing of critical structures were fulfilled only with IMRT technique. Although the sparing of the oral cavity was the most effectively provided by the traditional technique – due to the arrangement of the fields – it gave the worst results regarding the parotis and the target volume. The highest dose for the oral cavity was given by the ConPas technique, which can cause serious early and late side effects. By increasing the number of segments for IMRT at a reasonable level, the dose for OARs can be reduced.
C1 [Pesznyak, Csilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Pesznyak, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM pesznyak@reak.bme.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 95
EP 101
PG 7
ER

PT J
AU Hideghety, K
   Cserhati, A
   Besenyi, Zs
   Zag, L
   Gaal, Sz
   Egyud, Zs
   Mozes, P
   Szanto, E
   Csenki, M
   Rusz, O
   Varga, Z
   Dobi, �
   Maraz, A
   Pavics, L
   Lengyel, Zs
AF Hideghety, Katalin
   Cserhati, Adrienne
   Besenyi, Zsuzsanna
   Zag, Levente
   Gaal, Szilvia
   Egyud, Zsofia
   Mozes, Petra
   Szanto, Erika
   Csenki, Melinda
   Rusz, Orsolya
   Varga, Zoltan
   Dobi, Agnes
   Maraz, Aniko
   Pavics, Laszlo
   Lengyel, Zsolt
TI Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE 18FDG-PETCT; locally advanced head and neck squamous cell cancer; GTV; radiotherapy
ID 18FDG-PETCT; locally advanced head and neck squamous cell cancer; GTV; radiotherapy
AB celThe purpose of our work is evaluation of the impact of 18FDG-PET/CT on the complex management of locoregionally advanced (T3-4N1-3) head and neck squamous cell cancer (LAHNSC), and on the target definiton for 3D conformal (3DCRT) and intensity-modulated radiotherapy (IMRT). 18FDG-PET/CT were performed on 185 patients with LAHNSC prior to radiotherapy/chemoradiation in the treatment position between 2006 and 2011. Prior to it 91 patients recieved induction chemotherapy (in 20 cases of these, baseline PET/CT was also available). The independently delineated CT-based gross tumor volume (GTVct) and PET/CT based ones (GTVpet) were compared. Impact of PET/CT on the treatment strategy, on tumor response evaluation to ICT, on GTV definition furthermore on overall and disease-specific survival (OS, DSS) was analysed. PET/CT revealed 10 head and neck, 2 lung cancers for 15 patients with carcinoma of unknown primary (CUP) while 3 remained unknown. Second tumors were detected in 8 (4.4%), distant metastasis in 15 (8.2%) cases. The difference between GTVct and GTVpet was significant (p=0.001). In 16 patients (14%) the GTVpet were larger than GTVct due to multifocal manifestations in the laryngo-pharyngeal regions (4 cases) or lymph node metastases (12 cases). In the majority of the cases (82 pts, 72%) PET/CT-based conturing resulted in remarkable decrease in the volume (15-20%: 4 cases, 20–50%: 46 cases, >50%: 32 cases). On the basis of the initial and post-ICT PET/CT comparison in 15/20 patients more than 50% volume reduction and in 6/20 cases complete response were achieved. After an average of 6.4 years of follow-up the OS (median: 18.3±2.6 months) and DSS (median: 25.0±4.0 months) exhibited close correlation (p=0.0001) to the GTVpet. In cases with GTVpet <10 cm3 prior to RT, DSS did not reach the median, the mean is 82.1±6.1 months, while in cases with GTVpet 10–40 cm3 the median of the DSS was 28.8±4.9 months (HR = 3.57; 95% CI: 1.5–8.3), and in those with GTVpet >40 cm3 the median DSS was 8.4±0.96 months (HR= 11.48; 95% CI: 5.3–24.9). Our results suggest that 18FDG-PET/CT plays an important role for patient with LAHNSC, by modifying the treatment concept and improving the target definition for selective RT modalities. Volumetric PET/CT-based assessment of the tumor response after ICT gives valuable contribution to further therapy planning.
C1 [Hideghety, Katalin] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Zag, Levente] Bacs-Kiskun Megyei Korhaz, Surgossegi Betegellato OsztalyKecskemet, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Mozes, Petra] Technische Universitat Munchen, Klinikum rechts der Isar, Department of Radiation OncologyMunich, Germany.
   [Szanto, Erika] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Csenki, Melinda] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM katalin.hideghety@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 103
EP 110
PG 8
ER

PT J
AU Meszaros, N
   Major, T
   Stelczer, G
   Zaka, Z
   Mozsa, E
   Fodor, J
   Polgar, Cs
AF Meszaros, Norbert
   Major, Tibor
   Stelczer, Gabor
   Zaka, Zoltan
   Mozsa, Emoke
   Fodor, Janos
   Polgar, Csaba
TI Accelerated partial breast irradiation with image-guided intensity-modulated radiotherapy following breast-conserving surgery – preliminary results of a phase II clinical study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE image-guided; accelerated; intensity-modulated; partial breast irradiation
ID image-guided; accelerated; intensity-modulated; partial breast irradiation
AB The purpose of the study was to implement accelerated partial breast irradiation (APBI) by means of image-guided intensity-modulated radiotherapy (IG-IMRT) following breast-conserving surgery (BCS) for low-risk early invasive breast cancer. Between July 2011 and March 2014, 60 patients with low-risk early invasive (St I-II) breast cancer who underwent BCS were enrolled in our phase II prospective study. Postoperative APBI was given by means of step and shoot IG-IMRT using 4 to 5 fields to a total dose of 36.9 Gy (9×4.1 Gy) using a twice-a-day fractionation. Before each fraction, series of CT images were taken from the region of the target volume using a kV CT on-rail mounted in the treatment room. An image fusion software was used for automatic image registration of the planning and verification CT images. Patient set-up errors were detected in three directions (LAT, LONG, VERT), and inaccuracies were adjusted by automatic movements of the treatment table. Breast cancer related events, acute and late toxicities, and cosmetic results were registered and analysed. At a median follow-up of 24 months (range 12–44) neither locoregional nor distant failure was observed. Grade 1 (G1), G2 erythema, G1 oedema, and G1 and G2 pain occurred in 21 (35%), 2 (3.3%), 23 (38.3%), 6 (10%) and 2 (3.3%) patients, respectively. No G3–4 acute side effects were detected. Among late radiation side effects G1 pigmentation, G1 fibrosis, and G1 fat necrosis occurred in 5 (8.3%), 7 (11.7%), and 2 (3.3%) patients, respectively. No ≥G2 late toxicity was detected. Excellent and good cosmetic outcome was detected in 45 (75%) and 15 (25%) patients. IG-IMRT is a reproducible and feasible technique for the delivery of APBI following conservative surgery for the treatment of low-risk, early-stage invasive breast carcinoma. Preliminary results are promising, early radiation side effects are minimal, and cosmetic results are excellent.
C1 [Meszaros, Norbert] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM meszarosnorbert@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 111
EP 118
PG 8
ER

PT J
AU Kontra, G
   Major, T
   Polgar, Cs
AF Kontra, Gabor
   Major, Tibor
   Polgar, Csaba
TI Measurement of peak correction factor of Farmer chamber for calibration of flattening filter free (FFF) clinical photon beams
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE dosimetry; FFF beams; Farmer chamber; peak correction
ID dosimetry; FFF beams; Farmer chamber; peak correction
AB Farmer-type ionization chambers are considered the most reliable detectors and for this reason they are most frequently used for the calibration of photon beams of medical linear accelerators. Flattening filter free (FFF) photon beams of linear accelerators have recently started to be used in radiotherapy. The dose profile of FFF beams is peaked in the center of the field and the dose distribution will be inhomogeneous along the axis of the 2.3 cm long measuring volume of the Farmer chamber. The peaked radiation field will result in volume averaging effects in the large Farmer chamber, therefore this chamber will underestimate the true central axis dose. Our objective was to determine the value of the peak correction factor (Kp) of Farmer-type chamber with measurements to avoid the underestimation of the central axis dose during the calibration of FFF radiation fields. Measurements were made with 6 MV and 10 MV flattened (6X and 10X) and FFF beams (6XFFF and 10XFFF) of a Varian TrueBeam medical linear accelerator in a solid water phantom at 10 cm depth. The source surface distance (SSD) was 100 cm, the field size was 10×10 cm and the dose rate was always 400 MU/min during the measurements. We delivered 100 MU in each measurement and the absorbed dose to water was calculated according to the IAEA TRS-398 dosimetry protocol. The measured signals of the ionization chambers were always corrected for the ion recombination loss. The ion recombination correction factors (Kr) were determined with the two-voltage method separately for the used ion chambers and for flattened and unflattened beams. First, we measured the dose to water with PTW TM30012 Farmer chamber in 6XFFF and 6X beams, then calculated the ratio of doses of 6XFFF and 6X beams (R6,Farmer). Immediately after this we repeated the above measurements with PTW TM31010 Semiflex chamber and determined the ratio of doses of 6XFFF and 6X beams again (R6,Semiflex). The length of the sensitive volume of the Semiflex chamber is only 6.5 mm. According to our dose profile measurements the peak correction factor of this chamber equals to unity for both photon energies. As a consequence R6,Semiflex is larger than R6,Farmer and Kp6XFFF = R6,Semiflex / R6,Farmer, where Kp6XFFF is the peak correction factor of the Farmer chamber in 6XFFF beam. The advantage of this method is that we have to calculate ratio of doses, so it is not necessary to know the calibration factors of the chambers. Repeating the above measurements with 10X and 10XFFF beams we determined the peak correction factor of Farmer chamber for 10XFFF beam, too (Kp10XFFF). According to our measurements Kp6XFFF = 1.0025 and Kp10XFFF = 1.009. The bigger peak correction factor for 10XFFF beam is in accordance with the fact that the peak of dose profile is steeper for higher photon energy. The above described method for the determination of Kp can be used for other photon energies and other large volume ionization chambers.
C1 [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM kontra@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 119
EP 123
PG 5
ER

PT J
AU Valastyanne, NJ
   Janvary, ZsL
   Balogh, I
   Horvath, Zs
AF Valastyanne, Nagy Julianna
   Janvary, Zsolt Levente
   Balogh, Istvan
   Horvath, Zsolt
TI Implementation of cone beam CT-guided volumetric modulated arc therapy and establishment of related institutional quality assurance protocols
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE image-guided radiotherapy; volumetric modulated arc therapy; kilovoltage cone-beam CT; quality assurance
ID image-guided radiotherapy; volumetric modulated arc therapy; kilovoltage cone-beam CT; quality assurance
AB We intend to present the process of implementation of kilovoltage CT-guided volumetric modulated arc therapy (VMAT), and related quality assurance (QA). An Elekta Synergy™ linear accelerator has been installed recently in our institution, equipped with Agility© head, kilovoltage cone-beam CT image guidance and ability of arc therapy. The major steps of the implementation of these techniques and the background of physics QA will be described. Specific dynamic tests have been performed to verify intensity-modulated radiation delivery and the accuracy of on board imaging. Systematic daily, weekly and monthly physics QA protocols have been worked out and applied in the clinical practice. As a result, cone beam CT based image-guided radiotherapy (IGRT) and volumetric modulated arc therapy was introduced in our institution.
C1 [Valastyanne, Nagy Julianna] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Janvary, Zsolt Levente] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Balogh, Istvan] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Valastyanne, NJ (reprint author), University of Debrecen, Department of Oncology, 4032 Debrecen, Hungary.
EM nagy.julianna@med.unideb.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 125
EP 132
PG 8
ER

PT J
AU Pocza, T
   Pesznyak, Cs
   Lovey, J
   Bajcsay, A
   Szilagyi, A
   Almady, B
   Major, T
   Polgar, Cs
AF Pocza, Tamas
   Pesznyak, Csilla
   Lovey, Jozsef
   Bajcsay, Andras
   Szilagyi, Andras
   Almady, Balazs
   Major, Tibor
   Polgar, Csaba
TI Imaging protocols for the management of respiratory motions in the treatment planning of early stage lung cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breathing management; respiratory gating; lung tumour; 4D CT
ID breathing management; respiratory gating; lung tumour; 4D CT
AB The aim of our work is to present the imaging techniques used at the National Institute of Oncology for taking into consideration the breathing motion at radiation therapy treatment planning. Internationally recommended imaging techniques, such as 4D CT, respiratory gating and ITV (Internal Target Volume) definition were examined. The different imaging techniques were analysed regarding the delivered dose during imaging, the required time to adapt the technique, and the necessary equipment. The differences in size of PTVs (Planning Target Volume) due to diverse volume defining methods were compared in 5 cases. For 4D CT breath monitoring is crucial, which requires special equipment. To decrease the relatively high exposure of 4D CT it is possible to scan only a few predefined breathing phases. The possible positions of the tumour can be well approximated with CT scans taken in the inhale maximum, the exhale maximum and in intermediate phase. The intermediate phase can be exchanged with an ordinary CT image set, and the extreme phase CT images can be ensured by given verbal instructions for the patient. This way special gating equipment is not required. Based on these 3 breathing phases an ITV can be defined. Using this ITV definition method the margin between the CTV (Clinical Target Volume) and the PTV can be reduced by 1 cm. Using this imaging protocol PTV can be reduced by 30%. A further 10% PTV reduction can be achieved with respiratory gating. In the routine clinical practice respiratory motion management with a 3-phase CT-imaging protocol the PTV for early-stage lung cancer can be significantly reduced without the use of 4D CT and/or respiratory gating. For special, high precision treatment techniques 4D CT is recommended.
C1 [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szilagyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Almady, Balazs] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Pocza, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM poczatamas87@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 133
EP 138
PG 6
ER

PT J
AU Sinko, D
   Nemeskeri, Cs
   Pallinger, �
   Weisz, Cs
   Naszaly, A
   Landherr, L
AF Sinko, Daniel
   Nemeskeri, Csaba
   Pallinger, Agnes
   Weisz, Csaba
   Naszaly, Attila
   Landherr, Laszlo
TI Historical overview and the current practice of intracavitary treatment of cervical and endometrial cancer in the Oncoradiology Center of Budapest
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE brachytherapy; cervical cancer; endometrial cancer; 3D planning
ID brachytherapy; cervical cancer; endometrial cancer; 3D planning
AB The aims of our study were to describe the history and development of intracavitary brachytherapy in the treatment of gynecological tumors, to introduce our current practice for intracavitary brachytherapy treatments based on CT planning. Gynecological intracavitary brachytherapy has been applied in our department since the early 1930s. After a long development it has been completely renewed by 2014. In our center definitive and/or preoperative gynecological HDR-AL brachytherapy treatments were given to 25 patients (13 corpus uterine cancer patients and 12 cervical cancer patients) during the period of 01. 01. 2014–31. 01. 2015. In each case, target volumes were planned by CT images, DVH (dose volume histogram) analysis was performed in order to calculate the radiation tolerance dose of rectum and urinary bladder. Evaluation was performed by the EclipseTM 11.0.47. brachytherapy treatment planning system. During the definitive treatments of the 13 uterine cancer patients the D2cc value related to rectum tolerance was 66.3 GyEQD2 (46–91 Gy). The average D2cc value of urinary bladder tolerance was 76.5 GyEQD2 (30–112 Gy). CI was 0.72 (0.6–0.95). Average value of COIN was 0.57 (0.35–0.78). Compared to the prescribed dose D100 and D90 values were given in ratios. Compared to the volume which receives 100% of reference dose V150 and V200 values were also given in ratios. D100 and D90 were calculated to be 0.66 (0.47–0.97) and 0.91 (0.8–1.25). V150 and V200 volumes were 0.11 (0.04–0.18) and 0.06 (0.02–0.1). During the definitive treatments of 12 cervical cancer patients the D2cc value related to rectum tolerance calculated by DVH was 75.2 GyEQD2 (60–82 Gy). The average D2cc value of urinary bladder tolerance was 85 GyEQD2 based on DVH. CI was 0.66 (0.42–0.76). Average value of COIN was 0.52 (0.32–0.78). Mean value of DHI was 0.46 (0.27–0.54). D100 and D90 were calculated to be 0.72 (0.57–0.89) and 0.91 (0.84–1.11). V150 and V200 volumes were 0.057 (0.02–0.13) and 0.02 (0.002–0.06). During treatments no severe side effects were found. During gynecological intracavitary HDR therapies the calculated dose of the target volume can be given safely using the EclipseTM 11.0.47. brachytherapy planning system and CT-based planning. CT-based treatment planning provides optimal safety for organs at risk, acceptable doses for rectum and urinary bladder while the target volume receives the proper prescribed dose.
C1 [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Pallinger, Agnes] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Weisz, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki u. 29-41., 1145 Budapest, Hungary.
RP Sinko, D (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM sinkodaniel@yahoo.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 140
EP 147
PG 8
ER

PT J
AU Herein, A
   Agoston, P
   Szabo, Z
   Jorgo, K
   Markgruber, B
   Pesznyak, Cs
   Polgar, Cs
   Major, T
AF Herein, Andras
   Agoston, Peter
   Szabo, Zoltan
   Jorgo, Kliton
   Markgruber, Balazs
   Pesznyak, Csilla
   Polgar, Csaba
   Major, Tibor
TI Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prostate; PIPB; brachytherapy; MRI-based post-implant dosimetry; I-125
ID prostate; PIPB; brachytherapy; MRI-based post-implant dosimetry; I-125
AB The purpose of our work was to compare intraoperative and four-week post-implant dosimetry for loose and stranded seed implants for permanent prostate implant brachytherapy. In our institute low-dose-rate (LDR) prostate brachytherapy is performed with encapsulated I-125 isotopes (seeds) using transrectal ultrasound guidance and metal needles. The SPOT PRO 3.1 (Elekta, Sweden) system is used for treatment planning. In this study the first 79 patients were treated with loose seed (LS) technique, the consecutive patients were treated with stranded seed (SS) technique. During intraoperative planning the dose constraints were the same for both techniques. All LSs were placed inside the prostate capsule, while with SS a 2 mm margin around the prostate was allowed for seed positioning. The prescribed dose for the prostate was 145 Gy. This study investigated prostate dose coverage in 30-30 randomly selected patients with LS and SS. Four weeks after the implantation native CT and MRI were done and CT/MRI image fusion was performed. The target was contoured on MRI and the plan was prepared on CT data. To assess the treatment plan dose-volume histograms were used. For the target coverage V100, V90, D90, D100, for the dose inhomogeneity V150, V200, and the dose-homogeneity index (DHI), for dose conformality the conformal index (COIN) were calculated. Intraoperative and postimplant plans were compared. The mean V100 values decreased at four-week plan for SS (97% vs. 84%) and for LS (96% vs. 80%) technique, as well. Decrease was observed for all parameters except for the DHI value. The DHI increased for SS (0.38 vs. 0.41) and for LS (0.38 vs. 0.47) technique, as well. The COIN decreased for both techniques at four-week plan (SS: 0.63 vs. 0.57; LS: 0.67 vs. 0.50). All differences were significant except for the DHI value at SS technique. The percentage changes were not significant, except the COIN value. The dose coverage of the target decreased significantly at four-week plans for both techniques. The decrease was larger for LS technique, but the difference between techniques was not significant at this patient number. The dose distribution was more homogenous, but the conformality was worse at four-week plans.
C1 [Herein, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Markgruber, Balazs] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Herein, A (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM hereina@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 148
EP 153
PG 6
ER

PT J
AU Laszlo, Z
   Boronkai, �
   Locsei, Z
   Kalincsak, J
   Szappanos, Sz
   Farkas, R
   Al Farhat, Y
   Sebestyen, Zs
   Sebestyen, K
   Kovacs, P
   Csapo, L
   Mangel, L
AF Laszlo, Zoltan
   Boronkai, Arpad
   Locsei, Zoltan
   Kalincsak, Judit
   Szappanos, Szabolcs
   Farkas, Robert
   Al Farhat, Yousuf
   Sebestyen, Zsolt
   Sebestyen, Klara
   Kovacs, Peter
   Csapo, Laszlo
   Mangel, Laszlo
TI Clinical experience in image-guided ultra-conformal hypofractionated radiotherapy in case of metastatic diseases at the University of Pecs
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE hypofractionated radiotherapy; metastases; image-guided radiotherapy; intensity-modulated arc therapy
ID hypofractionated radiotherapy; metastases; image-guided radiotherapy; intensity-modulated arc therapy
AB With the development of radiation therapy technology, the utilization of more accurate patient fixation, inclusion of PET/CT image fusion into treatment planning, 3D image-guided radiotherapy, and intensity-modulated dynamic arc irradiation, the application of hypofractionated stereotactic radiotherapy can be extended to specified extracranial target volumes, and so even to the treatment of various metastases. Between October 2012 and August 2014 in our institute we performed extracranial, hypofractionated, image-tobbguided radiotherapy with RapidArc system for six cases, and 3D conformal multifield technique for one patient with Novalis TX system in case of different few-numbered and slow-growing metastases. For the precise definition of the target volumes we employed PET/CT during the treatment planning procedure. Octreotid scan was applied in one carcinoid tumour patient. Considering the localisation of the metastases and the predictable motion of the organs, we applied 5 to 20 mm safety margin during the contouring procedure. The average treatment volume was 312 cm3. With 2.5–3 Gy fraction doses we delivered 39–45 Gy total dose, and the treatment duration was 2.5 to 3 weeks. The image guidance was carried out via ExacTrac, and kV-Cone Beam CT equipment based on an online protocol, therefore localisation differences were corrected before every single treatment. The patients tolerated the treatments well without major (Gr>2) side effects. Total or near total regression of the metastases was observed at subsequent control examinations in all cases (the median follow-up time was 5 months). According to our first experience, extracranial, imageguided hypofractionated radiotherapy is well-tolerated by patients and can be effectively applied in the treatment of slow-growing and few-numbered metastases.
C1 [Laszlo, Zoltan] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Al Farhat, Yousuf] Tolna County Balassa Janos HospitalSzekszard, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Laszlo, Z (reprint author), University of Pecs, Department of Oncology, 7624 Pecs, Hungary.
EM laszlo.zoltan@pte.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 154
EP 159
PG 6
ER

PT J
TI A Magyar Sugarterapias Tarsasag XII. Kongresszusa
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE Kongresszusi osszefoglalo
ID Kongresszusi osszefoglalo
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 162
EP 179
PG 18
ER

PT J
AU Agoston, P
   Major, T
   Baricza, K
   Szabo, Z
   Jorgo, K
   Polgar, Cs
AF Agoston, Peter
   Major, Tibor
   Baricza, Karoly
   Szabo, Zoltan
   Jorgo, Kliton
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 162
EP 162
PG 1
ER

PT J
AU Arkocsevics, E
   Petre, I
   Agoston, P
   Major, T
   Baricza, K
   Polgar, Cs
AF Arkocsevics, Edina
   Petre, Ildiko
   Agoston, Peter
   Major, Tibor
   Baricza, Karoly
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arkocsevics, Edina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Petre, Ildiko] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Arkocsevics, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 162
EP 162
PG 1
ER

PT J
AU Bajcsay, A
   Pocza, T
   Lovey, J
   Szilagyi, A
   Zongor, Zs
   Major, T
   Agoston, P
   Polgar, Cs
AF Bajcsay, Andras
   Pocza, Tamas
   Lovey, Jozsef
   Szilagyi, Andras
   Zongor, Zsuzsanna
   Major, Tibor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 162
EP 163
PG 2
ER

PT J
AU Balogh, I
   Janvary, ZsL
   Valastyanne Nagy, J
   Horvath, Zs
AF Balogh, Istvan
   Janvary, Zsolt Levente
   Valastyanne Nagy, Julianna
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Valastyanne Nagy, Julianna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Balogh, I (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 163
EP 163
PG 1
ER

PT J
AU Baricza, K
   Heissler, 
   Fabry, L
   Lengyel, L
AF Baricza, Karoly
   Heissler, D.
   Fabry, Laszlo
   Lengyel, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Heissler, D.] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fabry, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lengyel, Lilla] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
RP Baricza, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 163
EP 163
PG 1
ER

PT J
AU Beganyi, N
   Farkas, R
   Klinko, T
   Katona, Cs
   Meszaros, E
   Szarvas, V
   Landherr, L
AF Beganyi, Nora
   Farkas, Robert
   Klinko, Timea
   Katona, Csilla
   Meszaros, Edina
   Szarvas, Viktor
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Beganyi, Nora] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szarvas, Viktor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Beganyi, N (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 163
EP 163
PG 1
ER

PT J
AU Bela, D
   Kiraly, R
   Stelczer, G
   Pocza, T
   Herein, A
   Gyokos, R
   Major, T
   Pesznyak, Cs
AF Bela, Dalma
   Kiraly, Reka
   Stelczer, Gabor
   Pocza, Tamas
   Herein, Andras
   Gyokos, Reka
   Major, Tibor
   Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gyokos, Reka] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bela, D (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 163
EP 164
PG 2
ER

PT J
AU Bellyei, Sz
   Szappanos, Sz
   Boronkai, �
   Sebestyen, Zs
   Locsi, Z
   Kott, I
   Mangel, L
AF Bellyei, Szabolcs
   Szappanos, Szabolcs
   Boronkai, Arpad
   Sebestyen, Zsolt
   Locsi, Zoltan
   Kott, Ilona
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsi, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kott, Ilona] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 164
EP 164
PG 1
ER

PT J
AU Bencsik, B
   Grochowska, P
   Izewska, J
AF Bencsik, Barbara
   Grochowska, Paulina
   Izewska, Joanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bencsik, Barbara] International Atomic Energy AgencyVienna, Austria.
   [Grochowska, Paulina] International Atomic Energy AgencyVienna, Austria.
   [Izewska, Joanna] International Atomic Energy AgencyVienna, Austria.
RP Bencsik, B (reprint author), International Atomic Energy Agency, Vienna, Austria.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 164
EP 164
PG 1
ER

PT J
AU Boronkai, �
   Sebestyen, Zs
   Sebestyen, K
   Kovacs, P
   Csapo, L
   Godi, Sz
   Mangel, L
AF Boronkai, Arpad
   Sebestyen, Zsolt
   Sebestyen, Klara
   Kovacs, Peter
   Csapo, Laszlo
   Godi, Szilard
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Godi, Szilard] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Boronkai, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 164
EP 165
PG 2
ER

PT J
AU Czifra, Gy
   Varady, Gy
   Mangel, L
AF Czifra, Gyozo
   Varady, Gyongyi
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czifra, Gyozo] University of Pecs, Department of OncologyPecs, Hungary.
   [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Czifra, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 165
EP 165
PG 1
ER

PT J
AU Cselik, Zs
   Farkas, A
   Biro, E
   Kovacs, �
   Toller, G
   Vallyon, M
   Faour, A
   Hadjiev, J
AF Cselik, Zsolt
   Farkas, Andrea
   Biro, Edit
   Kovacs, Arpad
   Toller, Gabor
   Vallyon, Marta
   Faour, Amer
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Biro, Edit] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Faour, Amer] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Cselik, Zs (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 165
EP 165
PG 1
ER

PT J
AU Dobi, �
   Cserhati, A
   Egyud, Zs
   Fodor, E
   Kahan, Zs
   Koszo, R
   Maraz, A
   Szabo, Cs
   Varga, L
   Varga, Z
   Hideghety, K
AF Dobi, Agnes
   Cserhati, Adrienn
   Egyud, Zsofia
   Fodor, Emese
   Kahan, Zsuzsanna
   Koszo, Renata
   Maraz, Aniko
   Szabo, Csilla
   Varga, Linda
   Varga, Zoltan
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Csilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dobi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 165
EP 165
PG 1
ER

PT J
AU Drajko, V
   Katona, Cs
   Landherr, L
AF Drajko, Veronika
   Katona, Csilla
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Drajko, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 165
EP 165
PG 1
ER

PT J
AU Drencsenyi, R
   Boda, N
   Pasztine Gal, L
   Cserhati, A
   Fodor, E
   Kahan, Zs
   Maraz, A
AF Drencsenyi, Rita
   Boda, Gy.-Ne
   Pasztine Gal, Laura
   Cserhati, Adrienn
   Fodor, Emese
   Kahan, Zsuzsanna
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Gy.-Ne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pasztine Gal, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 165
EP 166
PG 2
ER

PT J
AU Dubinsky, P
   Belanova, K
   Janickova, N
   Matula, P
   Hostova, 
AF Dubinsky, Pavol
   Belanova, Katarina
   Janickova, Natalia
   Matula, Pavol
   Hostova, B.
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dubinsky, Pavol] VOU a. s.Kosice, Slovakia.
   [Belanova, Katarina] VOU a. s.Kosice, Slovakia.
   [Janickova, Natalia] VOU a. s.Kosice, Slovakia.
   [Matula, Pavol] VOU a. s.Kosice, Slovakia.
   [Hostova, B.] VOU a. s.Kosice, Slovakia.
RP Dubinsky, P (reprint author), VOU a. s., Kosice, Slovakia.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 166
EP 166
PG 1
ER

PT J
AU Egyud, Zs
   Cserhati, A
   Dobi, �
   Szabo, Cs
   Koszo, R
   Vegvary, Z
   Paszt, A
   Tiszlavicz, L
   Torday, L
   Maraz, A
   Hideghety, K
AF Egyud, Zsofia
   Cserhati, Adrienn
   Dobi, Agnes
   Szabo, Csilla
   Koszo, Renata
   Vegvary, Zoltan
   Paszt, Attila
   Tiszlavicz, Laszlo
   Torday, Laszlo
   Maraz, Aniko
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Csilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Egyud, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 166
EP 166
PG 1
ER

PT J
AU Farkas, Gy
   Szekely, G
   Gundy, S
AF Farkas, Gyongyi
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Farkas, Gy (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 166
EP 166
PG 1
ER

PT J
AU Fekete, V
   Mayr, M
   Haranyi, G
   Agoston, P
   Polgar, Cs
AF Fekete, Viktoria
   Mayr, Matthias
   Haranyi, Gabriella
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Viktoria] University of Applied SciencesWiener Neustadt, Austria.
   [Mayr, Matthias] University of Applied SciencesWiener Neustadt, Austria.
   [Haranyi, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Fekete, V (reprint author), University of Applied Sciences, Wiener Neustadt, Austria.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 166
EP 167
PG 2
ER

PT J
AU Foldi, G
   Polgar, Cs
   Nagy, T
   Lovey, J
AF Foldi, Gerda
   Polgar, Csaba
   Nagy, Tunde
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Foldi, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 167
EP 167
PG 1
ER

PT J
AU Gabor, G
   Acs, F
   Boda, �
   Pajkos, G
AF Gabor, Gabriella
   Acs, Ferenc
   Boda, Eva
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Boda, Eva] Nagykorosi Rehabilitacios Szakkorhaz es Rendelointezet, Belgyogyaszati OsztalyNagykoros, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gabor, G (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 167
EP 167
PG 1
ER

PT J
AU Gesztesi, L
   Agoston, P
   Godeny, M
   Andi, J
   Lengyel, Zs
   Baricza, K
   Major, T
   Polgar, Cs
AF Gesztesi, Laszlo
   Agoston, Peter
   Godeny, Maria
   Andi, Judit
   Lengyel, Zsolt
   Baricza, Karoly
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Gesztesi, L (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 167
EP 167
PG 1
ER

PT J
AU Gundy, S
AF Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Gundy, S (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 167
EP 168
PG 2
ER

PT J
AU Halasz, J
   Vitari, I
   Simonne Revesz, J
   Weiczl, H
   Brauner, T
   Locsei, Z
   Szappanos, Sz
   Farkas, R
   Jorgo, K
   Agoston, P
   Polgar, Cs
   Mangel, L
AF Halasz, Judit
   Vitari, Ildiko
   Simonne Revesz, Judit
   Weiczl, Hajnalka
   Brauner, Tiborne
   Locsei, Zoltan
   Szappanos, Szabolcs
   Farkas, Robert
   Jorgo, Kliton
   Agoston, Peter
   Polgar, Csaba
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Vitari, Ildiko] University of Pecs, Department of OncologyPecs, Hungary.
   [Simonne Revesz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Weiczl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Jorgo, Kliton] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Halasz, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 168
EP 168
PG 1
ER

PT J
AU Herein, A
   Agoston, P
   Szabo, Z
   Jorgo, K
   Pesznyak, Cs
   Polgar, Cs
   Major, T
AF Herein, Andras
   Agoston, Peter
   Szabo, Zoltan
   Jorgo, Kliton
   Pesznyak, Csilla
   Polgar, Csaba
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Herein, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 168
EP 168
PG 1
ER

PT J
AU Jambori, A
   Major, T
   Pesznyak, Cs
   Takacsi-Nagy, Z
   Polgar, Cs
AF Jambori, Attila
   Major, Tibor
   Pesznyak, Csilla
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jambori, Attila] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jambori, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 168
EP 168
PG 1
ER

PT J
AU Jorgo, K
   Agoston, P
   Szabo, Z
   Major, T
   Pocza, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Szabo, Zoltan
   Major, Tibor
   Pocza, Tamas
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 169
EP 169
PG 1
ER

PT J
AU Kalincsak, J
   Molnar, K
   Kovacs, P
   Boronkai, �
   Bellyei, Sz
   Sebestyen, Zs
   Sebestyen, K
   Mangel, L
AF Kalincsak, Judit
   Molnar, Krisztian
   Kovacs, Peter
   Boronkai, Arpad
   Bellyei, Szabolcs
   Sebestyen, Zsolt
   Sebestyen, Klara
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Molnar, Krisztian] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Kalincsak, J (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 169
EP 169
PG 1
ER

PT J
AU Kalmar, A
   Vasko, G
   Takacsi-Nagy, Z
   Haranyi, G
   Stelczer, G
   Polgar, Cs
AF Kalmar, Anna
   Vasko, Gergely
   Takacsi-Nagy, Zoltan
   Haranyi, Gabriella
   Stelczer, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalmar, Anna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vasko, Gergely] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Haranyi, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kalmar, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 169
EP 169
PG 1
ER

PT J
AU Karancsine Heffler, F
   Miklos, N
   Jakab, G
   Pajkos, G
AF Karancsine Heffler, Fatime
   Miklos, J.-Ne
   Jakab, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karancsine Heffler, Fatime] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Miklos, J.-Ne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Jakab, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Karancsine Heffler, F (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 169
EP 169
PG 1
ER

PT J
AU Kiscsatari, L
   Varga, Z
   Gaspar, R
   Gorbe, A
   Ferdinandy, P
   Gardi, J
   Kahan, Zs
AF Kiscsatari, Laura
   Varga, Zoltan
   Gaspar, Renata
   Gorbe, Aniko
   Ferdinandy, Peter
   Gardi, Janos
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiscsatari, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaspar, Renata] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Gorbe, Aniko] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Ferdinandy, Peter] University of Szeged, Department of Medical ChemistrySzeged, Hungary.
   [Gardi, Janos] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kiscsatari, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 169
EP 170
PG 2
ER

PT J
AU Kisivan, K
   Farkas, A
   Vandulek, Cs
   Vallyon, M
   Hadjiev, J
   Repa, I
AF Kisivan, Katalin
   Farkas, Andrea
   Vandulek, Csaba
   Vallyon, Marta
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kisivan, Katalin] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Vallyon, Marta] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Kisivan, K (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 170
EP 170
PG 1
ER

PT J
AU Klausz, M
   Legrady, D
   Major, T
AF Klausz, Milan
   Legrady, David
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Klausz, Milan] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Legrady, David] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Klausz, M (reprint author), Budapest University of Technology and Economy, Institute of Nuclear Technique, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 170
EP 170
PG 1
ER

PT J
AU Kollak, E
   Hocza, G
   Besenyoi, M
   Hevesi, E
   Csiki, E
   Nagy, J
   Horvath, Zs
AF Kollak, Erzsebet
   Hocza, Gergely
   Besenyoi, Maria
   Hevesi, Erika
   Csiki, Emese
   Nagy, Janos
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kollak, Erzsebet] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Hocza, Gergely] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Besenyoi, Maria] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Hevesi, Erika] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Csiki, Emese] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Nagy, Janos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Kollak, E (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 170
EP 170
PG 1
ER

PT J
AU Koszo, R
   Kahan, Zs
   Cserhati, A
   Hideghety, K
   Egyud, Zs
   Szabo, Cs
   Varga, Z
   Fodor, E
   Maraz, A
AF Koszo, Renata
   Kahan, Zsuzsanna
   Cserhati, Adrienn
   Hideghety, Katalin
   Egyud, Zsofia
   Szabo, Csilla
   Varga, Zoltan
   Fodor, Emese
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Csilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 170
EP 170
PG 1
ER

PT J
AU Lakosi, F
   Nguyen, VP
   Hermesse, J
   Ben Mustapha, S
   Martin, 
   Nicolas, S
   Coucke, P
   Gulyban, �
AF Lakosi, Ferenc
   Nguyen, Viet Paul
   Hermesse, Johanne
   Ben Mustapha, Selma
   Martin, N.
   Nicolas, Sophie
   Coucke, Philippe
   Gulyban, Akos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Nguyen, Viet Paul] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Hermesse, Johanne] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Ben Mustapha, Selma] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Martin, N.] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Nicolas, Sophie] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Coucke, Philippe] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Gulyban, Akos] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
RP Lakosi, F (reprint author), University Hospital of Liege, Department of Radiation Oncology, Liege, Belgium.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 171
EP 171
PG 1
ER

PT J
AU Locsei, Z
   Farkas, R
   Szappanos, Sz
   Laszlo, Z
   Kalincsak, J
   Bellyei, Sz
   Boronkai, �
   Vojcek, �
   Ottoffy, G
   Mangel, L
AF Locsei, Zoltan
   Farkas, Robert
   Szappanos, Szabolcs
   Laszlo, Zoltan
   Kalincsak, Judit
   Bellyei, Szabolcs
   Boronkai, Arpad
   Vojcek, Agnes
   Ottoffy, Gabor
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Vojcek, Agnes] PTE KK, Gyermekgyogyaszati Klinika, Onkologiai OsztalyPecs, Hungary.
   [Ottoffy, Gabor] PTE KK, Gyermekgyogyaszati Klinika, Onkologiai OsztalyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 171
EP 171
PG 1
ER

PT J
AU Lovey, J
   Agoston, P
   Olajos, J
   Pintye, �
   Cselik, Zs
   Janvary, ZsL
   Polgar, Cs
AF Lovey, Jozsef
   Agoston, Peter
   Olajos, Judit
   Pintye, Eva
   Cselik, Zsolt
   Janvary, Zsolt Levente
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Olajos, Judit] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Cselik, Zsolt] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 171
EP 171
PG 1
ER

PT J
AU Mangel, L
   Laszlo, Z
   Sebestyen, Zs
AF Mangel, Laszlo
   Laszlo, Zoltan
   Sebestyen, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 171
EP 172
PG 2
ER

PT J
AU Maraz, A
   Cserhati, A
   Egyud, Zs
   Kahan, Zs
   Koszo, R
   Szabo, Cs
   Varga, L
   Varga, Z
   Hideghety, K
AF Maraz, Aniko
   Cserhati, Adrienn
   Egyud, Zsofia
   Kahan, Zsuzsanna
   Koszo, Renata
   Szabo, Csilla
   Varga, Linda
   Varga, Zoltan
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Csilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 172
EP 172
PG 1
ER

PT J
AU Markgruber, B
   Meszaros, N
   Major, T
   Matrai, Z
   Polgar, Cs
AF Markgruber, Balazs
   Meszaros, Norbert
   Major, Tibor
   Matrai, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Markgruber, Balazs] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Markgruber, B (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 172
EP 172
PG 1
ER

PT J
AU Marki, I
   Mokanszki, B
   Pajkos, G
AF Marki, Istvan
   Mokanszki, Bela
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marki, Istvan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Mokanszki, Bela] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Marki, I (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 172
EP 172
PG 1
ER

PT J
AU Meszaros, N
   Major, T
   Stelczer, G
   Zaka, Z
   Mozsa, E
   Fodor, J
   Polgar, Cs
AF Meszaros, Norbert
   Major, Tibor
   Stelczer, Gabor
   Zaka, Zoltan
   Mozsa, Emoke
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 172
EP 172
PG 1
ER

PT J
AU Miovecz, �
   Glavak, Cs
   Perlaki, G
   Farkas, A
   Vandulek, Cs
   Kovacs, �
   Hadjiev, J
   Repa, I
AF Miovecz, Adam
   Glavak, Csaba
   Perlaki, Gabor
   Farkas, Andrea
   Vandulek, Csaba
   Kovacs, Arpad
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Perlaki, Gabor] Pecs University, Faculty of Health Sciences, Department of DiagnosticPecs, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Miovecz, � (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 172
EP 173
PG 2
ER

PT J
AU Oberna, F
   Tizedes, Gy
   Santha, B
   Sass, T
   Toth, I
AF Oberna, Ferenc
   Tizedes, Gyorgy
   Santha, Beata
   Sass, Tamas
   Toth, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Tizedes, Gyorgy] University of Pecs, Department of SurgeryPecs, Hungary.
   [Santha, Beata] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Sass, Tamas] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Toth, Ildiko] University of Pecs, Medical Faculty, Department of Anesthesia and Intensive TherapyPecs, Hungary.
RP Oberna, F (reprint author), Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti Osztaly, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 173
EP 173
PG 1
ER

PT J
AU Ortutay, R
   Lovey, J
AF Ortutay, Rita
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ortutay, Rita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Ortutay, R (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 173
EP 173
PG 1
ER

PT J
AU Padanyi, G
   Oberna, F
   Heim, A
   Csejtei, A
AF Padanyi, Gergely
   Oberna, Ferenc
   Heim, Andras
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Padanyi, Gergely] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Padanyi, G (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 173
EP 173
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 173
EP 174
PG 2
ER

PT J
AU Pesznyak, Cs
   Bela, D
   Takacsi-Nagy, Z
   Major, T
   Polgar, Cs
AF Pesznyak, Csilla
   Bela, Dalma
   Takacsi-Nagy, Zoltan
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pesznyak, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 174
EP 174
PG 1
ER

PT J
AU Petre, I
   Arkocsevics, E
   Bajcsay, A
   Major, T
   Baricza, K
   Agoston, P
AF Petre, Ildiko
   Arkocsevics, Edina
   Bajcsay, Andras
   Major, Tibor
   Baricza, Karoly
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petre, Ildiko] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Arkocsevics, Edina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baricza, Karoly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Petre, I (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 174
EP 174
PG 1
ER

PT J
AU Pintye, �
   Galdi, �
   Hollo, T
   Dobos, E
   Kovacs, �
   Szabo, I
   Gulyas, L
   Furka, A
AF Pintye, Eva
   Galdi, Adam
   Hollo, Tamas
   Dobos, Erik
   Kovacs, Arpad
   Szabo, Imre
   Gulyas, Laszlo
   Furka, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pintye, Eva] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Galdi, Adam] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Hollo, Tamas] Gamma Sugarsebeszeti Kozpont (Brain-X Kft)Debrecen, Hungary.
   [Dobos, Erik] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szabo, Imre] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Gulyas, Laszlo] Gamma Sugarsebeszeti Kozpont (Brain-X Kft)Debrecen, Hungary.
   [Furka, Andrea] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Pintye, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 174
EP 174
PG 1
ER

PT J
AU Pocza, T
   Agoston, P
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Pocza, Tamas
   Agoston, Peter
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pocza, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 174
EP 175
PG 2
ER

PT J
AU Polgar, Cs
   Major, T
   Kiraly, R
   Fodor, J
   Kasler, M
AF Polgar, Csaba
   Major, Tibor
   Kiraly, Reka
   Fodor, Janos
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 175
EP 175
PG 1
ER

PT J
AU Sebestyen, Zs
   Kovacs, P
   Sebestyen, K
   Szappanos, Sz
   Locsei, Z
   Kalincsak, J
   Laszlo, Z
   Boronkai, �
   Bellyei, Sz
   Farkas, R
   Mangel, L
AF Sebestyen, Zsolt
   Kovacs, Peter
   Sebestyen, Klara
   Szappanos, Szabolcs
   Locsei, Zoltan
   Kalincsak, Judit
   Laszlo, Zoltan
   Boronkai, Arpad
   Bellyei, Szabolcs
   Farkas, Robert
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 175
EP 175
PG 1
ER

PT J
AU Sebestyen, Zs
   Kovacs, P
   Sebestyen, K
   Locsei, Z
   Kalincsak, J
   Laszlo, Z
   Szappanos, Sz
   Boronkai, �
   Bellyei, Sz
   Mangel, L
AF Sebestyen, Zsolt
   Kovacs, Peter
   Sebestyen, Klara
   Locsei, Zoltan
   Kalincsak, Judit
   Laszlo, Zoltan
   Szappanos, Szabolcs
   Boronkai, Arpad
   Bellyei, Szabolcs
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 175
EP 176
PG 2
ER

PT J
AU Smanyko, V
   Bela, D
   Pesznyak, Cs
   Takacsi-Nagy, Z
   Polgar, Cs
AF Smanyko, Viktor
   Bela, Dalma
   Pesznyak, Csilla
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Smanyko, V (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 176
EP 176
PG 1
ER

PT J
AU Somogyi, E
   Stefan, A
   Herein, A
   Bajcsay, A
AF Somogyi, Erzsebet
   Stefan, Anita
   Herein, Andras
   Bajcsay, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somogyi, Erzsebet] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stefan, Anita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Somogyi, E (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 176
EP 176
PG 1
ER

PT J
AU Stefan, A
   Somogyi, E
   Herein, A
   Agoston, P
   Szekely, J
   Bajcsay, A
AF Stefan, Anita
   Somogyi, Erzsebet
   Herein, Andras
   Agoston, Peter
   Szekely, Judit
   Bajcsay, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stefan, Anita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Somogyi, Erzsebet] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stefan, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 176
EP 176
PG 1
ER

PT J
AU Stelczer, G
   Meszaros, N
   Major, T
   Polgar, Cs
   Pesznyak, Cs
AF Stelczer, Gabor
   Meszaros, Norbert
   Major, Tibor
   Polgar, Csaba
   Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stelczer, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 176
EP 177
PG 2
ER

PT J
AU Szappanos, Sz
   Halasz, J
   Locsei, Z
   Laszlo, Z
   Kalincsak, J
   Sebestyen, Zs
   Sebestyen, K
   Csapo, L
   Kovacs, P
   Mangel, L
   Farkas, R
   Jorgo, K
   Agoston, P
   Polgar, Cs
AF Szappanos, Szabolcs
   Halasz, Judit
   Locsei, Zoltan
   Laszlo, Zoltan
   Kalincsak, Judit
   Sebestyen, Zsolt
   Sebestyen, Klara
   Csapo, Laszlo
   Kovacs, Peter
   Mangel, Laszlo
   Farkas, Robert
   Jorgo, Kliton
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Kovacs, Peter] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Jorgo, Kliton] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Szappanos, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 177
EP 177
PG 1
ER

PT J
AU Szekely, G
   Gundy, S
AF Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Szekely, G (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 177
EP 177
PG 1
ER

PT J
AU Szilagyi, A
   Bajcsay, A
   Pocza, T
   Major, T
   Polgar, Cs
   Lovey, J
AF Szilagyi, Andras
   Bajcsay, Andras
   Pocza, Tamas
   Major, Tibor
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szilagyi, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 177
EP 178
PG 2
ER

PT J
AU Tamaskovics, B
   Doll, Th
   Budach, W
AF Tamaskovics, Balint
   Doll, Thorsten
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Doll, Thorsten] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 178
EP 178
PG 1
ER

PT J
AU Vandulek, Cs
   Szalai, 
   Biro, G
   Fenyvesi, N
   Farkas, A
   Hadjiev, J
   Kovacs, �
   Repa, I
AF Vandulek, Csaba
   Szalai, Z.
   Biro, Gergely
   Fenyvesi, J.-Ne
   Farkas, Andrea
   Hadjiev, Janaki
   Kovacs, Arpad
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vandulek, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Szalai, Z.] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Biro, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Fenyvesi, J.-Ne] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Farkas, Andrea] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Vandulek, Cs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 178
EP 178
PG 1
ER

PT J
AU Vekas, M
   Vandulek, Cs
   Farkas, A
   Emri, M
   Opposits, G
   Hadjiev, J
   Kovacs, �
   Repa, I
AF Vekas, Marton
   Vandulek, Csaba
   Farkas, Andrea
   Emri, Miklos
   Opposits, Gabor
   Hadjiev, Janaki
   Kovacs, Arpad
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vekas, Marton] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vandulek, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Emri, Miklos] Debreceni Egyetem, AOK, Orvosi Kepalkoto Intezet, Radiologia nem onallo TanszekDebrecen, Hungary.
   [Opposits, Gabor] Debreceni Egyetem, AOK, Orvosi Kepalkoto Intezet, Radiologia nem onallo TanszekDebrecen, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Vekas, M (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 178
EP 178
PG 1
ER

PT J
AU Vereckei, E
   Racsko, T
   Varady, Gy
   Mangel, L
AF Vereckei, Erika
   Racsko, Tibor
   Varady, Gyongyi
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vereckei, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Racsko, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
   [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Vereckei, E (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 178
EP 178
PG 1
ER

PT J
AU Weizl, H
   Halasz, J
   Simonne Revesz, J
   Vitari, I
   Brauner, T
   Locsei, Z
   Farkas, R
   Szappanos, Sz
   Laszlo, Z
   Kalincsak, J
   Bellyei, Sz
   Boronkai, �
   Mangel, L
AF Weizl, Hajnalka
   Halasz, Judit
   Simonne Revesz, Judit
   Vitari, Ildiko
   Brauner, Tiborne
   Locsei, Zoltan
   Farkas, Robert
   Szappanos, Szabolcs
   Laszlo, Zoltan
   Kalincsak, Judit
   Bellyei, Szabolcs
   Boronkai, Arpad
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Weizl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Halasz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Simonne Revesz, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Vitari, Ildiko] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szappanos, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Weizl, H (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 178
EP 179
PG 2
ER

PT J
AU Zongor, Zs
   Major, T
   Pesznyak, Cs
AF Zongor, Zsuzsanna
   Major, Tibor
   Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Zongor, Zs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2015
VL 59
IS 2
BP 179
EP 179
PG 1
ER

PT J
AU Jederan, �
   Godeny, M
AF Jederan, Eva
   Godeny, Maria
TI Technical novelties, latest diagnostic options in the MRI and CT diagnostics of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE colorectal cancer; functional MRI; diffusion-weighted MRI; perfusion dynamic contrast-enhanced MRI; computed tomographic colonography
ID colorectal cancer; functional MRI; diffusion-weighted MRI; perfusion dynamic contrast-enhanced MRI; computed tomographic colonography
AB Diagnostic and therapeutic options of colorectal cancer (CRC) have changed over the past decade. Imaging plays a major role, thus the use of scanning methods is recommended by guidelines. Accurate staging, evaluation of treatment efficacy and identification of residual and recurrent tumors are required for the modern management of colorectal cancer. If adequate technical background is provided, magnetic resonance imaging (MRI) gives the information upon which therapeutic options may be determined. High-resolution MRI scans can be interpreted as maps providing functional and molecular information. Diffusion-weighted MRI (DW-MRI) has shown promising results regarding the determination of tumor volume and evaluation of treatment efficacy. Perfusion dynamic contrast-enhanced MRI (P-DCE-MRI) is the subject of research in the early assessment of treatment efficacy. Magnetic resonance spectroscopic imaging (MRSI) is a procedure utilizing biochemical analysis. Its application in CRC is under investigation. Clinical effectiveness of PET-MRI (hardware-based combination of MRI and positron emission tomography) is also being studied. Diagnostic value of computed tomographic colonography (CTC) has been proven in the detection of CRC as well as of polyps.
C1 [Jederan, Eva] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Godeny, Maria] University of Medicine and Pharmacy, Department of Postgraduate Education and Scientific ResearchTargu-Mures, Romania.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM jederan@t-online.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 184
EP 192
PG 9
ER

PT J
AU Pavics, L
AF Pavics, Laszlo
TI Nuclear medicine in oncotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE nuclear medicine; radiotherapy; oncology; review
ID nuclear medicine; radiotherapy; oncology; review
AB After a brief historical overview, the basic concept of therapy with radionuclides is summarised. This is followed by a review of the physical and biological features of the different radiopharmaceuticals that are available. A clinical application of the different techniques commences with the treatment of differentiated thyroid cancer using radio-iodine. From the various bone-seeking radiopharmceuticals, we opted for the alpha-emitting 223-RaCl2 for treatment purposes. Due to the increasing prevalence of neuroendocrine tumors nowadays, somatostatin receptor and adrenerg analog radiotherapy are discussed. Next, one of the most promising new techniques is presented along with some radioimmunological applications. Lastly, the importance of multidisciplinary cooperation is analysed from the viewpoint of successful individual oncotherapy and safe radionuclide treatment for the benefit of patients.
C1 [Pavics, Laszlo] University of Szeged, Department of Nuclear Medicine, Koranyi fasor 8., 6720 Szeged, Hungary.
RP Pavics, L (reprint author), University of Szeged, Department of Nuclear Medicine, 6720 Szeged, Hungary.
EM pavics.laszlo@med.u-szeged.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 193
EP 197
PG 5
ER

PT J
AU Farkas, Gy
   Szekely, G
   Vass, N
   Kiss, K
   Gundy, S
AF Farkas, Gyongyi
   Szekely, Gabor
   Vass, Nagyezsda
   Kiss, Krisztina
   Gundy, Sarolta
TI Rate of spontaneous numerical chromosome aberrations in Hungarian healthy population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE spontaneous aneuploidy; chromosomal instability; risk of cancer; biomarker
ID spontaneous aneuploidy; chromosomal instability; risk of cancer; biomarker
AB Aneuploidy plays very important role in tumor development as the consequence of either congenital or acquired mutations. In order to evaluate the adverse effects of various aneugens, the knowledge of the spontaneous frequency of numerical chromosome abnormalities in healthy population is fundamental. In our study we analyzed the spontaneous rate of numerical and structural chromosome aberrations in peripheral blood lymphocytes of 2145 healthy individuals, with special attention to the influence of biological (gender, age) and life-style factors (smoking, different occupational exposure). Correlation between aneuploidy and risk of cancer development were investigated according to National Cancer Registry data followed for 1–23 years. In the whole population the average frequency of aneuploid cells was 1.77±0.06% . This value increased by age linearly (r2 =0.81) regardless of occupational exposures. Gender (biological factor) or smoking (life style factor) did not influence the values, however, the occupation of individuals modified the frequency of numerical aberrations. Individuals who worked at workplaces with radiation hazard had the lowest (1.44±0.10%), and those working in the chemical industry had the highest (1.89±0.05%) values of aneuploidy, respectively. We could not find any correlation between numerical and structural chromosome aberrations. In our population studied 97 individuals developed cancer and only those who had ≤2% aneuploidy survived more than 12 years in good health conditions. To our knowledge, this study has the highest case number investigated up to now. Our results support that aneuploidy, similarly to structural chromosomal aberrations, might be an additional cytogenetic biomarker of the genetic instability.
C1 [Farkas, Gyongyi] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vass, Nagyezsda] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kiss, Krisztina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gundy, Sarolta] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM farkas.gyongyi@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 198
EP 204
PG 7
ER

PT J
AU Tamas, J
   Vereczkey, I
   Toth, E
AF Tamas, Judit
   Vereczkey, Ildiko
   Toth, Erika
TI Metastatic tumors of the ovary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE ovary; metastasis
ID ovary; metastasis
AB The ovary is a common site of metastases. Secondary tumors account for 3–40% of all ovarian malignancies. Most ovarian metastases arise from the colon, although tumors of the breast, stomach and endometrium are also common places of origin. Clinical and histological features of metastatic tumors frequently mimic primary ovarian malignancies, causing serious diagnostic problems for the surgical pathologist. However, differentiation between primary ovarian cancer and ovarian metastasis is important in order to prevent inappropriate management and suboptimal treatment. The distinction between primary and secondary ovarian malignancies is especially difficult in cases when the metastasis is diagnosed before the primary tumor. Frozen section is widely used in the intra-operative assessment of patients with ovarian tumors but it can be very difficult to distinguish certain types of primary ovarian tumors and metastases from other sites. We examined 152 cases of secondary ovarian neoplasm diagnosed at the National Institute of Oncology, Hungary from 2000 to 2014. Colorectal cancer was the most common primary tumor (58 cases), followed by breast (33 cases), endometrium (30 cases) and stomach cancer (13 cases). The differential diagnosis proved the most difficult in cases when endometrioid and mucinous tumors were presented in the ovaries. Metastases of colorectal and gastric adenocarcinomas may simulate benign or borderline cystadenomas too. In these cases the knowledge of the patient’s history and immunohistochemical stains were helpful. In our study we discuss the diagnostic challenge of distinguishing these secondary ovarian tumors from primary ovarian neoplasms and the limits of the intraoperative frozen sections.
C1 [Tamas, Judit] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Tamas, J (reprint author), National Institute of Oncology, Center of Diagnostic and Experimental Tumorpathology, 1122 Budapest, Hungary.
EM tamas.judit86@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 205
EP 213
PG 9
ER

PT J
AU Horvath, K
   Godeny, M
AF Horvath, Katalin
   Godeny, Maria
TI New opportunities, MRI biomarkers in the evaluation of gynaecological cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE gynaecological cancer; imaging biomarkers; diffusion-weighted MRI (DW-MRI); dynamic contrast-enhanced MRI (DCEMRI); multiparametric MRI
ID gynaecological cancer; imaging biomarkers; diffusion-weighted MRI (DW-MRI); dynamic contrast-enhanced MRI (DCEMRI); multiparametric MRI
AB The determination and classification of gynaecological tumour stage which is based on clinical and pathological examinations became more precise due to the development of imaging techniques. Recently new MRI methods are being introduced which serve functional, tissue-specific, molecular information; beyond the excellent anatomical and contrast resolution with the aid of high resolution morphological measurements as well as quantification can also be performed. Diffusion-weighted MRI (DW-MRI) is based on the mobility of water molecules and provides information about the cell density of a given tissue and the integrity of cell membranes. Quantification can also be performed using an apparent diffusion coefficient (ADC). DW-MRI is a useful tool in determining myometrium invasion in endometrium carcinomas especially if a tumour has the same signal intensity as the makromomyometrium on the T2-weighted images and the use of contrast agents are contraindicated. The extra-uterine tumour invasion, the peritoneal metastatic foci can be determined by DW-MRI as well. Lymph node status is the most important predictive factor regarding survival. Both CT and MRI have low sensitivity (70-80%) in revealing metastatic lymph nodes. DW-MRI is a promising method with a sensitivity of 87% and specificity of 80% in distinguishing benign and malignant lymph nodes. Dynamic contrastenhanced MRI (DCE-MRI), as a marker of angiogenesis, provides information about vascularisation at the tissue level. In endometrial carcinoma with application of T2-weighted sequence together with DCE-MRI in determining the stage MRI has the accuracy about 90%. DCE-MRI has proven to be useful for distinguishing benign from malignant ovarian tumours, for detecting tumour extension; it can help predict peritoneal carcinomatosis. It is proven by high-level evidence that multiparametric MRI (MP-MRI) is the most precise diagnostic tool in determining the status of cervical carcinoma, its accuracy being above 90%. In the case of parametrial tumour invasion the accuracy of the clinical examination is 78%, while that of CT and MRI are 70% and 92%, respectively. DCE-MRI and DWMRI are promising imaging biomarkers in the early assessment of the effectiveness of the therapy and also in detecting residual as well as recurrent tumours.
C1 [Horvath, Katalin] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of Radiology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM vakhor2@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 216
EP 227
PG 12
ER

PT J
AU Kuronya, Zs
   Biro, K
   Geczi, L
   Nemeth, H
AF Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
   Nemeth, Hajnalka
TI Treatment strategies for advanced prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE androgen-deprivation therapy; castration-resistant prostate cancer; abiraterone actetate; enzalutamide; radium 223; treatment algorithm
ID androgen-deprivation therapy; castration-resistant prostate cancer; abiraterone actetate; enzalutamide; radium 223; treatment algorithm
AB There has been dramatic improvement in the diagnosis and treatment of prostate cancer recently. The treatment of localized disease became more successful with the application of new, sophisticated techniques available for urologic surgeons and radiotherapists. Nevertheless a significant proportion of patients relapses after the initial local treatment or is diagnosed with metastatic disease at the beginning. In the past five years, six new drugs became registered for the treatment of metastatic, castration-resistant prostate cancer, such as sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, the α-emitting radionuclide alpharadin and the receptor activator of nuclear factor kappa-B (RANK) ligand inhibitor denosumab. The availability of these new treatment options raises numerous questions. In this review we present the standard of care of metastatic prostate cancer by disease stage (hormone naive/ hormone sensitive metastatic prostate cancer, non-metastatic castration-resistant prostate cancer, oligometastatic/multimetastatic castration-resistant prostate cancer) and the emerging treatment modalities presently assessed in clinical trials. We would also like to give advice on debatable aspects of the management of metastatic prostate cancer.
C1 [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nemeth, Hajnalka] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 229
EP 240
PG 12
ER

PT J
AU Risko, �
AF Risko, Agnes
TI The first 25 years of oncopsychology at National Institute of Oncology: antecedents and events (1988–2013)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oncology; oncopsychology; psychosocial problems; oncopsychological interventions; multidisciplinary cooperation
ID oncology; oncopsychology; psychosocial problems; oncopsychological interventions; multidisciplinary cooperation
AB The first oncopsychological department was established in National Institute of Oncology by Sandor Eckhardt in 1988. At an early stage the specialists who were interested in mental hygiene made a united effort with Katalin Muszbek’s oncopsychologic group. Agnes Risko was the first specialist who seceded from this group, and she became a permanent member of the onco-hematology group in 1992. Due to the universalized approach, the psyhcologist would become a permanent member of onco-team. The overhand and increasing multidisciplinary cooperation enable to use this accepted method in the daily medical treatment. When necessary, patients’ relatives may come in for treatment and this method can help for medical stuff to avoid burnout. As a result of oncopsychology techniques and cooperation of oncologic teamwork the integration of psychosocial intervention into a complex oncologic treatment has already begun. The attendance of supervised onco-psychological specialists is being increased. Our activity contributes to improve our patients’ psychosocial standard of living, their cooperation with the medical staff and the atmosphere of oncologic departments. The integration of the approach and methods of psychosocial rehabilitation into the new oncologic professional guideline has also begun.
C1 [Risko, Agnes] National Institute of Oncology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Risko, � (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM csernakrisko@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 241
EP 250
PG 10
ER

PT J
AU Nagykalnai, T
   Landherr, L
   Laczo, I
   Piko, B
AF Nagykalnai, Tamas
   Landherr, Laszlo
   Laczo, Ibolya
   Piko, Bela
TI Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hormone sensitive breast cancer; antiestrogen; aromatase inhibitors; fulvestrant; estrogen receptor down-regulator
ID hormone sensitive breast cancer; antiestrogen; aromatase inhibitors; fulvestrant; estrogen receptor down-regulator
AB Endocrine agents are well established standards of care in hormone-sensitive postmenopausal breast cancer. The pure estrogen receptor antagonist (down-regulator) fulvestrant after binding to the ER induces its conformational change which disrupts ER signal and accelerates ER degradation. Fulvestrant is devoid of partial agonist activity. In unselected patients there was no difference in TTP between „standard dose” fulvestrant and aromatase inhibitors, but in first-line treatment of advanced breast cancer the elevated dose of fulvestrant may delay progression and may extend the overall survival compared with aromatase inhibitors.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Rakos ut 77/A., 1152 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1152 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 251
EP 257
PG 7
ER

PT J
AU Ryska, A
   Dziadziuszko, R
   Olszewski, W
   Berzinec, P
   Oz, B
   Gottfried, M
   Cufer, T
   Samarzija, M
   Plank, L
   Ostoros, Gy
   Timar, J
AF Ryska, Ales
   Dziadziuszko, Rafal
   Olszewski, Wojciech
   Berzinec, Peter
   Oz, Buge
   Gottfried, Maya
   Cufer, Tanja
   Samarzija, Miroslav
   Plank, Lukas
   Ostoros, Gyula
   Timar, Jozsef
TI Molecular diagnostics of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE non-small cell lung cancer; molecular diagnostics
ID non-small cell lung cancer; molecular diagnostics
AB Development of the target therapies of lung cancer was a rapid process which fundamentally changed the pathological diagnosis as well. Furthermore, molecular pathology became essential part of the routine diagnostics of lung cancer. These changes generated several practical problems and in underdeveloped countries or in those with reimbursement problems have been combined with further challenges. The central and eastern region of Europe are characterized by similar problems in this respect which promoted the foundation of NSCLC Working Group to provide up to date protocols or guidelines. This present paper is a summary of the molecular pathology and target therapy guidelines written with the notion that it has to be upgraded continuously according to the development of the field.
C1 [Ryska, Ales] Charles University, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, The Fingerland Department of PathologyHradec Kralove, Czech Republic.
   [Dziadziuszko, Rafal] Medical University of Gdansk, Department of Oncology and RadiotherapyGdansk, Poland.
   [Olszewski, Wojciech] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Berzinec, Peter] Spec. Hospital St Zoerardus ZoborNitra, Slovakia.
   [Oz, Buge] Istambul UniversityIstanbul, Turkey.
   [Gottfried, Maya] Meir Hospital, Department of Lung CancerTel Aviv, Israel.
   [Cufer, Tanja] University of Ljubjana, University Clinic GolnicLjubljana, Slovenia.
   [Samarzija, Miroslav] Poliklinika ApneaZagreb, Croatia.
   [Plank, Lukas] Comenius University, Jessenius Faculty of Medicine, Department of PathologyMartin, Slovakia.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 259
EP 266
PG 8
ER

PT J
AU Vizkeleti, L
AF Vizkeleti, Laura
TI Biological role and prognostic significance of genetic alterations in human malignant melanomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE malignant melanoma; fluorescence in situ hybridization; tissue microarray; CCND1 alterations; 7q31 amplification; CAV1 and TES expressions; BRAF and NRAS mutations
ID malignant melanoma; fluorescence in situ hybridization; tissue microarray; CCND1 alterations; 7q31 amplification; CAV1 and TES expressions; BRAF and NRAS mutations
AB Metastatic process accounts for the vast majority of melanoma associated mortality, and also results in difficulties in the effective treatment. Therefore, identification of novel biomarkers could contribute to melanoma prognosis, and may also provide new opportunities for efficient cancer treatment. Several signaling pathways have been identified as key regulators in melanoma progression, including the frequent activation of Ras/MAPK signaling pathway through the mutant BRAF or NRAS genes. Besides, alterations of CCND1 may also be of great importance. The oncogene plays a significant role in the G1/S phase transition of the cell cycle, and its transcriptional activation is primarily carried out by the Ras/MAPK cascade. One of our aims was to determine the genetic and gene expression alterations of CCND1 during melanoma progression, considering the mutation status of BRAF and NRAS genes. Analysis of CCND1 copy number alterations revealed significant association with poor clinical outcome in primary melanomas, which was influenced by the mutation status of BRAF or NRAS in the term of sun exposure. Regarding gene expression, CCND1 mRNA level decreased in lesions with multiple metastases and were correlated with both the mRNA levels and mutation status of BRAF and NRAS. CCND1 protein expression was associated with Breslow thickness, metastasis formation and shorter survival time. However, the proportion of cells expressing the protein showed a heterogeneous distribution, influencing the association with clinical-pathological parameters. Therefore melanoma cell lines with different biological behavior were also analyzed for protein expression. These experiments revealed an increasing CCND1 protein level throughout primary cancer progression, which then decreased in the metastasis. The other purpose of our study was to determine the role of 7q31 region in melanoma progression, which was found frequently altered using array comparative genomic hybridization (aCGH). 7q31 is a gene dense locus, including the FRA7G fragile site, which serves as a mutation hot spot. In its close vicinity TES (focal adhesions) and CAV1 (lipid rafts) genes are located. Using interphase FISH, significant associations were found between 7q31 copy number alterations and poor clinical outcome. Both mRNA and protein levels of CAV1 decreased in thick lesions whereas primary melanomas forming multiple metastases were featured by decreased TES mRNA level.
C1 [Vizkeleti, Laura] Debreceni Egyetem, Egeszsegtudomanyok Doktori Iskola, Kassai ut 26., 4028 Debrecen, Hungary.
RP Vizkeleti, L (reprint author), Debreceni Egyetem, Egeszsegtudomanyok Doktori Iskola, 4028 Debrecen, Hungary.
EM laura.vizkeleti@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2015
VL 59
IS 3
BP 268
EP 272
PG 5
ER

PT J
AU Balazs, M
   Vizkeleti, L
   Ecsedi, Sz
   Adany, R
   Raso, E
   Hegedus, B
   Ladanyi, A
   Tovari, J
   Timar, J
AF Balazs, Margit
   Vizkeleti, Laura
   Ecsedi, Szilvia
   Adany, Roza
   Raso, Erzsebet
   Hegedus, Balazs
   Ladanyi, Andrea
   Tovari, Jozsef
   Timar, Jozsef
TI Melanoma research in Hungary: promising results in a previously orphan tumor
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; progression; molecular markers; tumor microenvironment
ID melanoma; progression; molecular markers; tumor microenvironment
AB Melanoma research has a two decade history in Hungary and is based on three groups located at the National Institute of Oncology (NIO), the University of Debrecen (DU) and Semmelweis University (SU). Previously we have summarized the achievements of the NIO group in this Journal, now this paper summarizes the recent results of their collaborations. The research group of DU revealed several novel genetic alterations in the melanoma genome which might have clinical relevance as prognosticators or predictors in light of the novel target therapies. Data indicating unique, perhaps melanoma-specific epigenetic changes during progression might be even more important, identifying novel genes otherwise not detected as genetically altered ones. The research group in Budapest extensively used experimental human melanoma models and demonstrated the host sex as a key factor in progression due to the specific function of NK cells. Identification of functional glucocorticoid receptor in human melanoma might lead to therapeutic exploitation similar to certain leukemias. Studies on extracellular matrix revealed collagen XVII and CD44 splice variants as progression associated factors of melanoma. Since the double wild type genotype of melanoma is lacking effective therapy, data on the use of FGFR2, c-met or cannabinoid receptor as target can be important. On the other hand, experimental data on the antitumoral effects of heparin derivatives or bisphosphonate in melanoma models can also be encouraging.
C1 [Balazs, Margit] Debreceni Egyetem, Nepegeszsegugyi IskolaDebrecen, Hungary.
   [Vizkeleti, Laura] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Ecsedi, Szilvia] Debreceni Egyetem, Nepegeszsegugyi IskolaDebrecen, Hungary.
   [Adany, Roza] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Hegedus, Balazs] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 275
EP 281
PG 6
ER

PT J
AU Hegedus, B
   Moldvay, J
   Berta, J
   Lohinai, Z
   Rozsas, A
   Cserepes, TM
   Fabian, K
   Ostoros, Gy
   Tovari, J
   Renyi-Vamos, F
   Timar, J
   Dome, B
AF Hegedus, Balazs
   Moldvay, Judit
   Berta, Judit
   Lohinai, Zoltan
   Rozsas, Anita
   Cserepes, T Mihaly
   Fabian, Katalin
   Ostoros, Gyula
   Tovari, Jozsef
   Renyi-Vamos, Ferenc
   Timar, Jozsef
   Dome, Balazs
TI Excerpts from the collaborative lung cancer research program of Semmelweis University, the National Institute of Oncology and Koranyi Institute of TB and Pulmonology (2010–2015)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; angiogenesis; KRAS; EGFR; targeted therapy
ID lung cancer; angiogenesis; KRAS; EGFR; targeted therapy
AB Lung cancer places a significant socio-economic burden on the Hungarian population. This overview summarizes the findings of collaborative translational lung cancer research efforts of three Hungarian flagship academic institutions, the Semmelweis University, the National Institute of Oncology and the National Koranyi Institute of TB and Pulmonology. With regards to the molecular factors regulating tumor angiogenesis, we identified the prognostic significance of apelin and erythropoietin receptor (EPOR) expression in non-small cell lung cancer (NSCLC). Furthermore, the impact of KRAS mutation subtypes and ERCC1 (excision repair cross-complementation group 1) expression on the response to platinum-based chemotherapy have been studied. We also described the epidemiology and predictive power of rare EGFR (epidermal growth factor receptor) mutations in a large Hungarian patient cohort. Lastly, the expression of molecular factors associated with NSCLC progression was studied specifically in brain metastatic matched cases series. These preclinical and clinical studies provide clinically relevant information that hopefully will contribute to the improvement of lung cancer patient care.
C1 [Hegedus, Balazs] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Berta, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lohinai, Zoltan] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Rozsas, Anita] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Cserepes, T Mihaly] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Fabian, Katalin] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Dome, B (reprint author), Medical University of Vienna, Department of Thoracic Surgery, Vienna, Austria.
EM domeb@yahoo.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 282
EP 285
PG 4
ER

PT J
AU Kulka, J
   Tokes, AM
   Madaras, L
   Kovacs, A
   Acs, B
   Illyes, I
   Kiss, O
   Szekely, B
   Lotz, G
   Szasz, AM
AF Kulka, Janina
   Tokes, Anna-Maria
   Madaras, Lilla
   Kovacs, Attila
   Acs, Balazs
   Illyes, Ildiko
   Kiss, Orsolya
   Szekely, Borbala
   Lotz, Gabor
   Szasz, Attila Marcell
TI Clinico-pathologically focused breast cancer research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast carcinoma; predictive/prognostic markers; neoadjuvant and adjuvant treatment; metastatic breast cancer
ID breast carcinoma; predictive/prognostic markers; neoadjuvant and adjuvant treatment; metastatic breast cancer
AB In the second half of the 20th century research focusing to breast carcinomas at the Semmelweis University had been mostly linked to the 2nd Department of Pathology. Nowadays, following the rapidly improving treatment modalities in breast cancer there is an increasing need for defining new predictive and prognostic markers. The modern molecular pathological approach helps tremendously in mapping the biological behavior of individual cases of breast cancers and meanwhile, it is one of the prerequisites of a more efficient treatment both in neoadjuvant and adjuvant settings, as well as in metastatic disease. We provide a brief review of the relevant results we have obtained in breast cancer research between 2000 and 2015.
C1 [Kulka, Janina] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kovacs, Attila] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Acs, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Illyes, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kiss, Orsolya] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szekely, Borbala] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM kulka.janina@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 286
EP 291
PG 6
ER

PT J
AU Hujber, Z
   Jeney, A
   Olah, J
   Szoboszlai, N
   Baranyai, L
   Kornyei, J
   Petovari, G
   Sebestyen, A
AF Hujber, Zoltan
   Jeney, Andras
   Olah, Julia
   Szoboszlai, Norbert
   Baranyai, Lajos
   Kornyei, Jozsef
   Petovari, Gabor
   Sebestyen, Anna
TI Measuring 14C-glucose and 14C-acetate oxidation in tumour cells and tumorous host organism
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE metabolic profile; 14C-labelled energy substrate; glucose oxidation; acetate oxidation; oncometabolite
ID metabolic profile; 14C-labelled energy substrate; glucose oxidation; acetate oxidation; oncometabolite
AB Tumour cell metabolism can be influenced by alterations of the extracellular microenvironment and the tumour-promoting genetically changed mechanisms. There is increasing interest to introduce appropriate bioenergetic assays to describe the therapeutic effect and metabolic subtypes of tumours in clinical oncology. The analysis of 14C-glucose and 14C-acetate oxidation could be a suitable method to examine the metabolic/bioenergetic profiles of tumour cells and tumorous host organisms. The metabolic activity of tumour cells (in vitro cell lines, primary human lymphocytes and leukaemia cells) and the tumourous host organism were examined in vitro and in vivo by detecting the released CO2 levels derived from the radioactive carbon atom labelled energy substrates. We have found that the most cancer cells of solid tumours oxidised glucose more intensively than acetate. It was interesting that AML, CML and CLL cells isolated from blood preferred acetate as an energy substrate in vitro. Furthermore, based on our observations, tumours affected the glucose or acetate oxidation of the organism when applying bioenergetic substrates per os or iv. We provided the first data about the alterations in metabolic profiles of the tumour bearing organism in xenograft models. In summary, according to our results, comparison of the energy substrate oxidation can be an indicative method related to the metabolic profile analysis of tumour cells in vitro and tumorous host organism in vivo.
C1 [Hujber, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Szoboszlai, Norbert] Eotvos Lorand Tudomanyegyetem, Kemiai Intezet, Analitikai Kemiai TanszekBudapest, Hungary.
   [Baranyai, Lajos] Magyar Tudomanyos Akademia, Izotop Zrt.Budapest, Hungary.
   [Kornyei, Jozsef] Magyar Tudomanyos Akademia, Izotop Zrt.Budapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Sebestyen, Anna] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
RP Sebestyen, A (reprint author), Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research Group, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 292
EP 301
PG 10
ER

PT J
AU Alfoldi, R
   Szebeni, GJ
   Puskas, GL
AF Alfoldi, Robert
   Szebeni, Gabor Janos
   Puskas, G Laszlo
TI The potential of three-dimensional tumor models and cell culturing in cancer research and diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE A549 non-small cell lung cancer; in vitro three-dimensional tumor models; RAFT(TM); viability; tumor microenvironment
ID A549 non-small cell lung cancer; in vitro three-dimensional tumor models; RAFT(TM); viability; tumor microenvironment
AB In vitro testing of antitumor agents on human cancer cell lines has become essential in pharmaceutical research and in clinical practice. Although the most widely used technique is the two-dimensional cell growing protocol (in tissue culture plates), the new three-dimensional methods are becoming more and more popular as their structure and complexity is more similar to the microenvironment of the real tumor. The aim of the present study is to describe the most widely used in vitro three-dimensional tumor models and to compare a RAFT(TM) three dimensional in vitro tumor model with the traditional two-dimensional tumor cell cultures. In the study, the viability and the enzyme activity of cultured A549 non-small cell lung cancer (NSCLC) cells under different conditions were compared. The results show that while the number of necrotic cells increased significantly (20-fold; 2D/A549 T75 conventional tissue culture flask 1.6%; 2D/A549-collagen coated T75 tissue culture flask 1.45%, RAFT(TM) 22.11%) during long culturing period in the RAFT(TM) three-dimensional in vitro tumor model, there was no significant difference during the conventional antitumor screening period (3-5 day) compared to the traditional two-dimensional cell cultures. The structure of the tumor cell islets grown with RAFT(TM) is much more complex than that of the traditional two-dimensional cultures. Thus, similarly to the in vivo tumor microenvironment, there is also a collagen matrix in the extracellular space which can have significant effect on the diffusion of the antitumor agents to cells. In conclusion, it can be stated that testing of antitumor agents on tumor cells cultured in three-dimensional systems can be an important complementary method to the traditional two-dimensional in vitro analyses. The results of the new three-dimensional method can be more easily applied in the in vivo analysis and translated into clinical practice.
C1 [Alfoldi, Robert] AVIDIN Kutato Fejleszto es Kereskedelmi Kft., Also kikoto sor 11., 6726 Szeged, Hungary.
   [Szebeni, Gabor Janos] AVIDIN Kutato Fejleszto es Kereskedelmi Kft., Also kikoto sor 11., 6726 Szeged, Hungary.
   [Puskas, G Laszlo] AVIDIN Kutato Fejleszto es Kereskedelmi Kft., Also kikoto sor 11., 6726 Szeged, Hungary.
RP Alfoldi, R (reprint author), AVIDIN Kutato Fejleszto es Kereskedelmi Kft., 6726 Szeged, Hungary.
EM r.alfoldi@avidinbiotech.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 303
EP 309
PG 7
ER

PT J
AU Kapuvari, B
   Schulcz, �
   Hegedus, R
   Szabo, I
   Manea, M
   Vincze, B
   Tovari, J
   Gacs, A
   Tejeda, M
   Gaal, D
   Mezo, G
AF Kapuvari, Bence
   Schulcz, Akos
   Hegedus, Rozsa
   Szabo, Ildiko
   Manea, Marilena
   Vincze, Borbala
   Tovari, Jozsef
   Gacs, Alexandra
   Tejeda, Miguel
   Gaal, Dezso
   Mezo, Gabor
TI Studying the tumor growth inhibitory effect of modified GnRH-III-anthracycline bioconjugates in subcutaneous vs. orthotopic models in vivo
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE targeted tumor therapy; orthotopical; GnRH; daunorubicin; colon cancer
ID targeted tumor therapy; orthotopical; GnRH; daunorubicin; colon cancer
AB Targeted tumor therapy is a perspective procedure to specifically destroy the cancer tissues with eliminating or at least decreasing the side effects of anticancer drugs. For this purpose the drug molecule is attached to a targeting moiety (e.g. peptide hormones) that recognizes tumor specific or overexpressed receptors on cancer cells. The in vitro cytostatic or cytotoxic assays do not give proper information whether the tumor growth inhibitory effect of the conjugate is better than the activity of the free drug. Only in vivo studies are adequate to answer this question. However, the selection of the appropriate tumor model is important to eliminate the false positive results. In our studies a gonadotropin-releasing hormone analog (GnRH-III) was applied as targeting moiety in drug conjugates. The in vivo antitumor activity of these conjugates was investigated on mice bearing subcutaneously or orthotopically szigdeveloped tumors. The subcutaneously implanted tumor model which is isolated from its surroundings may provide false results in tumor growth inhibition. In contrast, the orthotopically developed tumor is a better model representing appropriate anatomical and clinical status of cancer. Therefore, the orthotopical colon cancer developed in our laboratory is a suitable model for the study of the antitumor activity of the conjugates prepared for targeted tumor therapy.
C1 [Kapuvari, Bence] National Institute of Oncology, Department of Biochemistry, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Schulcz, Akos] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Hegedus, Rozsa] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Szabo, Ildiko] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
   [Manea, Marilena] University of Konstanz, Zukunftskolleg, Department of ChemistryKonstanz, Germany.
   [Vincze, Borbala] National Institute of Oncology, Department of Biochemistry, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Gacs, Alexandra] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tejeda, Miguel] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Gaal, Dezso] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide ChemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Department of Biochemistry, 1122 Budapest, Hungary.
EM kapuvari.bence@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 310
EP 318
PG 9
ER

PT J
AU Szabo, V
   Bugyik, E
   Dezso, K
   Tovari, J
   Dome, B
   Paku, S
AF Szabo, Vanessza
   Bugyik, Edina
   Dezso, Katalin
   Tovari, Jozsef
   Dome, Balazs
   Paku, Sandor
TI Role of tumour cell invasion/migration in the vascularisation of experimental lung metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung metastasis; vascularization; vessel co-option; tumour cell migration
ID lung metastasis; vascularization; vessel co-option; tumour cell migration
AB Treatment of patients with lung metastases remains a major challenge. A possible target for therapies is the inhibition of vascularization of metastases. Our study aimed to determine the possible mechanisms of the experimental lung metastasis vascularisation for tumours of various origins. We created lung metastases by intravenous injection of five tumour cell lines (HT1080, HT25, B16, C26 and MATB). Each cell line showed the same vascularisation type. Tumours gained vasculature by advancing through the alveolar spaces thereby incorporating the pre-existing alveolar capillaries (i.e. vessel co-option). From the alveolar spaces tumours entered into the alveolar walls. The tumour cells during the invasion/migration separated the pneumocytes from the capillaries. During this process the basement membrane was split into an epithelial and an endothelial layer. The heavily compressed pneumocytes inside the tumour became fragmented but the incorporated and stripped vessels remained functional, so they were able to provide blood supply for the metastases.
C1 [Szabo, Vanessza] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Bugyik, Edina] National Institute of OncologyBudapest, Hungary.
   [Dezso, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Tovari, Jozsef] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Paku, Sandor] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
RP Szabo, V (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM nesszy20@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 319
EP 323
PG 5
ER

PT J
AU Tovari, J
AF Tovari, Jozsef
TI Potential role of patient-derived tumor xenografts (PDTXs) in the selection of optimal therapeutic strategy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE patient-derived tumor xenograft (PDTX); personalized therapy; immune deficient mice
ID patient-derived tumor xenograft (PDTX); personalized therapy; immune deficient mice
AB The rapid selection of the efficient anticancer therapy may decrease the unwanted burden to patients and has financial consequences. Tumor models including xenografts in mice were used previously mostly in the development of new anticancer drugs. Nowadays xenografts from direct patient-derived tumor tissues (PDTT) in immune deficient mice yield better models than experimental tumors originating from cell cultures. The new method enables researchers to observe heterogeneous tumor cells with their surrounding tissue elements and matrices representing the clinical situation in humans much better. The cells in PDTT tumors are alive and functionally active through several generations after serial transplantation. Therefore using these models we may investigate tumor response to different therapies, the selection of resistant cell populations and the formation of metastasis predicting the outcomes in the personalized therapy.
C1 [Tovari, Jozsef] National Institute of Oncology, Department of Clinical Research, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Tovari, J (reprint author), National Institute of Oncology, Department of Clinical Research, 1122 Budapest, Hungary.
EM tozsi@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 324
EP 328
PG 5
ER

PT J
AU Gundy, S
AF Gundy, Sarolta
TI Serving biological dosimetry for 4 decades
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE biological dosimetry; chromosome aberrations; radiation therapy
ID biological dosimetry; chromosome aberrations; radiation therapy
AB The author provides a comprehensive picture on introduction and application of chromosome biodosimetry in Hungary for measuring and estimation of biological doses of ionizing radiation. She describes different mathematical equations existing between the frequencies of dicentric and ring chromosome aberrations, and the different radiation doses of various radiation sources which form the basis of the method. She presents examples for estimation of biological doses received at radiation accidents, or cumulated during residential and occupational exposures in Hungary. The method of chromosome dosimetry is also offered to be used in radiotherapy because it allows the calculation of whole-body equivalent biological doses, and the determination of individual radiosensitivity as well, which cannot be fully informative by sole physical dose measurements. Dose-effect relationship in partial body irradiation might be affected by not only therapeutic doses, but also the localization and the volume of irradiated area of the body. In case of the same radiation therapy protocols and clinical features of the patients up to 2.5-fold differences in individual radiosensitivity may occur. Finally, the author analyzes the future state of biological dosimetry, the advantages and disadvantages of the methods to ensure determination of individual radiosensitivity, thereby administration of individualized radiotherapy.
C1 [Gundy, Sarolta] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Gundy, S (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM gundy@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 329
EP 337
PG 9
ER

PT J
AU Furedi, A
   Toth, Sz
   Hamori, L
   Nagy, V
   Tovari, J
   Szakacs, G
AF Furedi, Andras
   Toth, Szilard
   Hamori, Lilla
   Nagy, Veronika
   Tovari, Jozsef
   Szakacs, Gergely
TI Relevance of animal models in the development of compounds targeting multidrug resistant cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE multidrug resistance; animal models; chemotherapy; drug development
ID multidrug resistance; animal models; chemotherapy; drug development
AB Anticancer compounds are typically identified in in vitro screens. Unfortunately, the in vitro drug sensitivity of cell lines does not reflect treatment efficiency in animal models, and neither show acceptable correlation to clinical results. While cell lines and laboratory animals can be readily “cured”, the treatment of malignancies remains hampered by the multidrug resistance (MDR) of tumors. Genetically engineered mouse models (GEMMs) giving rise to spontaneous tumors offer a new possibility to characterize the evolution of drug resistance mechanisms and to target multidrug resistant cancer.
C1 [Furedi, Andras] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
   [Toth, Szilard] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
   [Hamori, Lilla] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
   [Nagy, Veronika] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Szakacs, Gergely] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
RP Szakacs, G (reprint author), Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, 1117 Budapest, Hungary.
EM szakacs.gergely@ttk.mta.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 338
EP 345
PG 8
ER

PT J
AU Olasz, J
   Doleschall, Z
   Dunai, Zs
   Pazsitka, A
   Csuka, O
AF Olasz, Judit
   Doleschall, Zoltan
   Dunai, Zsuzsanna
   Pazsitka, Andras
   Csuka, Orsolya
TI PI3K/AKT pathway activation and therapeutic consequences in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE PI3K/AKT pathway; PTEN; therapy resistance; targeted therapy; FGFR1
ID PI3K/AKT pathway; PTEN; therapy resistance; targeted therapy; FGFR1
AB The phosphatidylinositol-3-kinase/AKT (PI3K/AKT) pathway is commonly deregulated in breast cancer through several mechanisms, including PI3K catalytic subunit alpha (PIK3CA) mutations and loss of phosphatase and tensin homolog (PTEN). The hiperactivated PI3K/AKT signaling can be associated with endocrine or trastuzumab therapy resistance and underscore the impact of targeting the pathway. Our aim was to identify PIK3CA mutations and the mechanisms of PTEN loss and assess their therapeutic consequences in breast cancer patients. In addition, we aimed to identify further possible therapeutic targets associated with PTEN loss. Sixty-nine primary breast cancer samples (24 ER+/PR+/HER2-, 20 HER2+ (ER-/PR-/HER2+) and 25 triple-negative (TN) samples) were studied. We determined the PTEN mRNA levels, PTEN and PIK3CA mutations, PTEN allelic loss and promoter hypermethylation. mRNA expression patterns of PTEN knocked out and wild type MCF10A cell lines were compared using oligonucleotide microarray and their sensitivity to FGFR1 inhibitor PD166866 was tested. Elevated PI3K/AKT pathway activity was found in 68% of TN and about 45% of ER+/PR+ and HER2+ tumors. PTEN loss was dominant in TN and HER2+ tumors, while PTEN loss and PI3K activation were equally represented in ER+/PR+ cancers. The coexistence of PTEN loss and PI3K activation was typical of a portion of HER2+ tumors. The PTEN-deficient MCF10A cell line showed increased expression of certain members of the fibroblast growth factor 2 (FGF2)/FGFR1 pathway. We suppose that loss of PTEN enhances the autocrine FGF signaling promoting cell proliferation. FGF-2 and FGFR1 can be potential targets in PTEN deficient breast cancers.
C1 [Olasz, Judit] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Doleschall, Zoltan] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Dunai, Zsuzsanna] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Pazsitka, Andras] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Olasz, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM olasz@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 346
EP 351
PG 6
ER

PT J
AU Vankos, BJ
   Piurko, V
   Suba, Zs
   Nemeth, Zs
   Timar, J
   Kenessey, I
AF Vankos, Borbala Judit
   Piurko, Violetta
   Suba, Zsuzsanna
   Nemeth, Zsolt
   Timar, Jozsef
   Kenessey, Istvan
TI The prognostic role of expression of p16 tumor suppressor gene in Hungarian patients with oral squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oral tumor; squamous cell carcinoma; HPV; p16; prognosis
ID oral tumor; squamous cell carcinoma; HPV; p16; prognosis
AB Beside smoking and alcohol consumption, human papillomavirus (HPV) infection is the most common risk factor of squamous cell carcinoma in the head and neck region (HNSCC). The latter group of patients associates with better prognosis. During HPV infection, the level of p16 tumor suppressor elevates, which could give an additional opportunity for diagnosis: instead of molecular diagnostic tools, the application of immunohistochemistry is acceptable. However, the majority of the published studies focused on the whole head and neck region and did not separately handled cancers of the oral cavity. Our recent work analyzed the expression of p16 in 67 oral squamous cancers, and compared to routine clinicopathologic parameters. From surgical samples tissue microarray blocks were prepared and expression of p16 as well as other molecular markers (p53, Ki67, EGFR) were studied. In contrast to previous studies on HNSCC, with the exception of recurrence, the expression of p16 was not found associated to clinicopathologic parameters. Nuclear stabilization of p53 appeared mainly in younger patients. The expression of p53 and EGFR significantly correlated to each other. We concluded that traditional molecular categorization of HNSCC could not be completely adaptable to Hungarian samples. Potential coexposition of common etiological factors (e.g. HPV, smoking, alcohol) could blur borders between distinct categories.
C1 [Vankos, Borbala Judit] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Piurko, Violetta] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Suba, Zsuzsanna] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Nemeth, Zsolt] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
RP Kenessey, I (reprint author), National Institute of Oncology, National Cancer Registry, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 352
EP 359
PG 8
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI Dabrafenib (Tafinlar) therapy – effect and side effects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE melanoma; side effects; cerebral metastasis; dabrafenib; survival
ID melanoma; side effects; cerebral metastasis; dabrafenib; survival
AB Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the „still water” moves, now with multiple medications the patient survival can be improved. Dabrafenib is the second registered BRAF kinase inhibitor. In clinical trials it resulted in 5–9 month progression-free survival (PFS). It proved to be effective in BRAF V600K mutation and also in the case of cerebral metastases. Side effects are well tolerated. The most frequent side effects are fever, skin symptoms, benign skin tumors, keratoacanthoma/squamous cell carcinoma, hyperkeratosis, weakness and joint pain.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM liszkay@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 361
EP 364
PG 4
ER

PT J
AU Hegyi, K
AF Hegyi, Katalin
TI Biologic mechanisms of mitotic abnormalities and chromosome number changes in malignant tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE mitotic failures; malignant transformation; Aurora kinase B; kinase overexpression; invasive breast cancer; lymphoma
ID mitotic failures; malignant transformation; Aurora kinase B; kinase overexpression; invasive breast cancer; lymphoma
AB The main goal of this work was to study the effect of Aurora kinase expression on cell ploidy and tumorigenesis. Fifty invasive breast cancer, 50 diffuse large B-cell lymphoma and 10 reactive lymph node samples were recruited in the study. Because of the significant correlation with the overall cell proliferation rate, the overexpression of Aurora B could not be stated on the basis of kinase expressing tumor cell fractions alone. The relative expression of Aurora B kinase is better reflected by the AMI index which represents the Aurora B expression in relation to the whole proliferative fraction of the tumor. A higher relative Aurora B expression was associated with higher mitotic activity in B-cell lymphoma. FISH analysis of the AURKB locus did not show any gains or amplifications in the samples analyzed. On the other hand, we have observed the loss of the gene in breast carcinoma and lymphoma samples as well. A strong correlation was shown between AURKB and TP53 copy numbers: AURKB loss was associated with TP53 deletion in all samples. According to our results on breast carcinoma, losses at 17p13.1 and chromosome 17 aneusomy determined by FISH showed a statistically significant correlation. Our study presents the frequent occurrence of chromosome 17 aneusomy in breast carcinoma and B-cell lymphoma samples. Chromosome 17 aneusomy evaluated by FISH correlated with aneuploidy determined by flow cytometry. Direct correlation between kinase expression and ploidy could not be shown. The highest AMI values were seen in B-ALCL samples, and it was associated with high chromosome 17 copy numbers and mitotic activity. The damaged Aurora B kinase function results in regulatory deficiencies in the CPC complex leading to mitotic errors, while p53 deficiency helps malignant cells to survive due to insufficient activation of the intrinsic apoptotic pathways. The upregulation of Aurora kinase B function may cause error in an important mitotic checkpoint, thus resulting in induction of aneuploid cell populations. These parallel effects finally increase the complexity of mitotic abnormalities and generate aneuploid cell populations.
C1 [Hegyi, Katalin] Debreceni Egyetem, Egeszsegtudomanyok Doktori Iskola, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Hegyi, K (reprint author), Debreceni Egyetem, Egeszsegtudomanyok Doktori Iskola, 4032 Debrecen, Hungary.
EM dull.kata@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2015
VL 59
IS 4
BP 365
EP 371
PG 7
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 1
EP 79
PG 79
ER

PT J
AU Acs, B
   Bodor, Zs
   Micsik, T
   Kiszler, G
   Madaras, L
   Kovacs, A
   Tokes, AM
   Kulka, J
   Szasz, AM
AF Acs, Balazs
   Bodor, Zsuzsanna
   Micsik, Tamas
   Kiszler, Gabor
   Madaras, Lilla
   Kovacs, Attila
   Tokes, Anna-Maria
   Kulka, Janina
   Szasz, Attila Marcell
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Acs, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bodor, Zsuzsanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Micsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kiszler, Gabor] 3D HISTECH KftBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kovacs, Attila] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Acs, B (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 3
EP 3
PG 1
ER

PT J
AU Agoston, EI
   Baranyai, Zs
   Dede, K
   Bodoky, Gy
   Kulka, J
   Bursics, A
   Harsanyi, L
   Szasz, AM
AF Agoston, Emese Irma
   Baranyai, Zsolt
   Dede, Kristof
   Bodoky, Gyorgy
   Kulka, Janina
   Bursics, Attila
   Harsanyi, Laszlo
   Szasz, Attila Marcell
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Emese Irma] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Baranyai, Zsolt] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Agoston, EI (reprint author), Semmelweis University, 1st Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 3
EP 3
PG 1
ER

PT J
AU Agoston, G
AF Agoston, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Gabriella] Forras MaganrendelesSolymar, Hungary.
RP Agoston, G (reprint author), Forras Maganrendeles, Solymar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 3
EP 3
PG 1
ER

PT J
AU Al-Farhat, Y
   Auth, P
AF Al-Farhat, Yousuf
   Auth, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 3
EP 4
PG 2
ER

PT J
AU Al-Farhat, Y
   Auth, P
AF Al-Farhat, Yousuf
   Auth, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 4
EP 4
PG 1
ER

PT J
AU Andi, J
   Bahery, M
   Simon, P
   Renyi-Vamos, F
   Szoke, J
   Fillinger, J
AF Andi, Judit
   Bahery, Maria
   Simon, Peter
   Renyi-Vamos, Ferenc
   Szoke, Janos
   Fillinger, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bahery, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Simon, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Fillinger, Janos] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Andi, J (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 4
EP 4
PG 1
ER

PT J
AU Andras, Cs
   Talladi, Z
   Kocsis, J
   Szekanecz, �A
   Juhasz, B
   Toth, J
   Balogh, I
   Horvath, Zs
AF Andras, Csilla
   Talladi, Zoltanne
   Kocsis, Judit
   Szekanecz, Eva Andrea
   Juhasz, Balazs
   Toth, Judit
   Balogh, Ingrid
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Talladi, Zoltanne] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szekanecz, Eva Andrea] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Juhasz, Balazs] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Balogh, Ingrid] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Andras, Cs (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 4
EP 5
PG 2
ER

PT J
AU Babuskov, A
   Popovic, L
   Vajs, O
AF Babuskov, Angelika
   Popovic, Lazar
   Vajs, Oliver
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Babuskov, Angelika] Kinicki Centar VojvodineVojvodine, Serbia.
   [Popovic, Lazar] Institut za Onkologiju VojvodineVojvodine, Serbia.
   [Vajs, Oliver] Kinicki Centar VojvodineVojvodine, Serbia.
RP Babuskov, A (reprint author), Kinicki Centar Vojvodine, Vojvodine, Serbia.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 5
EP 5
PG 1
ER

PT J
AU Bajcsay, A
   Pocza, T
   Lovey, J
   Szilagyi, A
   Zongor, Zs
   Major, T
   Agoston, P
AF Bajcsay, Andras
   Pocza, Tamas
   Lovey, Jozsef
   Szilagyi, Andras
   Zongor, Zsuzsanna
   Major, Tibor
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 5
EP 6
PG 2
ER

PT J
AU Balatoni, T
AF Balatoni, Timea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Banhegyi, RJ
   Laczo, I
   Kis, A
   Szabo, HE
   Csiffari, M
   Fulop, F
   Piko, B
AF Banhegyi, Robert Janos
   Laczo, Ibolya
   Kis, Anita
   Szabo, Helga Erzsebet
   Csiffari, Margit
   Fulop, Ferenc
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banhegyi, Robert Janos] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Kis, Anita] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szabo, Helga Erzsebet] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Csiffari, Margit] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Fulop, Ferenc] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Radiologiai OsztalyGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Banhegyi, RJ (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 6
EP 6
PG 1
ER

PT J
AU Barna, G
   Mark, �
   Kriston, Cs
   Csomor, J
   Szabo, O
   Gyurcso-Deak, L
   Matolcsy, A
AF Barna, Gabor
   Mark, Agnes
   Kriston, Csilla
   Csomor, Judit
   Szabo, Orsolya
   Gyurcso-Deak, Linda
   Matolcsy, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kriston, Csilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szabo, Orsolya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Gyurcso-Deak, Linda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Barna, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 6
EP 7
PG 2
ER

PT J
AU Bata, OS
   Csernus, R
   Torok, K
   Agocs, L
   Petri, K
   Godeny, M
AF Bata, Orsolya Sara
   Csernus, Reka
   Torok, Klara
   Agocs, Laszlo
   Petri, Klara
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bata, Orsolya Sara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Csernus, Reka] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Torok, Klara] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Agocs, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Bata, OS (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Bences, I
AF Bences, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bences, Ilona] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Bences, I (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Bere, Zs
   Vass, GZs
   Tobias, Z
   Ivan, L
   Rovo, L
AF Bere, Zsofia
   Vass, Gabor Zsolt
   Tobias, Zoltan
   Ivan, Laszlo
   Rovo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bere, Zsofia] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Vass, Gabor Zsolt] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Tobias, Zoltan] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Rovo, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Bere, Zs (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Besenyi, Zs
   Urban, Sz
   Hideghety, K
   Lengyel, Zs
   Pavics, L
AF Besenyi, Zsuzsanna
   Urban, Szabolcs
   Hideghety, Katalin
   Lengyel, Zsolt
   Pavics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Urban, Szabolcs] Szegedi Tudomanyegyetem, Kepfeldolgozas es Szamitogepes Grafika TanszekSzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
RP Besenyi, Zs (reprint author), University of Szeged, Department of Nuclear Medicine, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 7
EP 8
PG 2
ER

PT J
AU Besznyak, IE
   Dede, K
   Szentpetery, F
   Porneczi, B
   Svastics, I
   Faludi, S
   Lang, I
   Mester, G
   Papp, G
   Bursics, A
AF Besznyak, Istvan Endre
   Dede, Kristof
   Szentpetery, Felix
   Porneczi, Balazs
   Svastics, Imre
   Faludi, Sandor
   Lang, Istvan
   Mester, Gabor
   Papp, Geza
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Besznyak, Istvan Endre] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Szentpetery, Felix] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Porneczi, Balazs] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Svastics, Imre] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Faludi, Sandor] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Lang, Istvan] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Mester, Gabor] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Papp, Geza] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Besznyak, IE (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Bezsenyi, I
AF Bezsenyi, Istvanne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bezsenyi, Istvanne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Bezsenyi, I (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Biro, A
   Ballago, K
   Palinkas, Z
   Barancsine Szucs, J
   Garai, D
   Nagy, P
AF Biro, Adrienn
   Ballago, Krisztina
   Palinkas, Zoltan
   Barancsine Szucs, Judit
   Garai, Dorottya
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Adrienn] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ballago, Krisztina] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Palinkas, Zoltan] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Barancsine Szucs, Judit] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Garai, Dorottya] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Biro, A (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 8
EP 9
PG 2
ER

PT J
AU Biro, E
   Kelemen, Gy
   Dudas, R
   Irinyi, T
   Pakaski, M
   Drotos, G
   Rusz, O
   Kahan, Zs
   Kalman, J
   Hamvai, Cs
AF Biro, Edit
   Kelemen, Gyongyi
   Dudas, Rita
   Irinyi, Tamas
   Pakaski, Magdolna
   Drotos, Gergely
   Rusz, Orsolya
   Kahan, Zsuzsanna
   Kalman, Janos
   Hamvai, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Edit] Szegedi Tudomanyegyetem, Pszichiatriai KlinikaSzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dudas, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Irinyi, Tamas] Szegedi Tudomanyegyetem, Pszichiatriai KlinikaSzeged, Hungary.
   [Pakaski, Magdolna] Szegedi Tudomanyegyetem, Pszichiatriai KlinikaSzeged, Hungary.
   [Drotos, Gergely] Szegedi Tudomanyegyetem, Pszichiatriai KlinikaSzeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kalman, Janos] Szegedi Tudomanyegyetem, Pszichiatriai KlinikaSzeged, Hungary.
   [Hamvai, Csaba] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Biro, E (reprint author), Szegedi Tudomanyegyetem, Pszichiatriai Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Biro, K
   Szonyi, M
   Gyergyay, F
   Nagyivanyi, K
   Kuronya, Zs
   Nemeth, H
   Geczi, L
AF Biro, Krisztina
   Szonyi, Marta
   Gyergyay, Fruzsina
   Nagyivanyi, Krisztian
   Kuronya, Zsofia
   Nemeth, Hajnalka
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Szonyi, Marta] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Biro, K (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Borka, K
   Kramer, Zs
   Shechtmann, L
   Timar, J
AF Borka, Katalin
   Kramer, Zsofia
   Shechtmann, Lea
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kramer, Zsofia] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Shechtmann, Lea] Haemek Hospital, Department of PathologyAfula, Israel.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Borka, K (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Bozsik, A
   Papp, J
   Vaszko, T
   Gyuris, T
   Balint, BL
   Olah, E
AF Bozsik, Aniko
   Papp, Janos
   Vaszko, Tibor
   Gyuris, Tibor
   Balint, Balint Laszlo
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Gyuris, Tibor] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Bozsik, A (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 10
EP 11
PG 2
ER

PT J
AU Bursics, A
   Mester, G
   Tolgyes, T
   Papp, G
AF Bursics, Attila
   Mester, Gabor
   Tolgyes, Tamas
   Papp, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Mester, Gabor] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Tolgyes, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Papp, Geza] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Bursics, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Cserepes, M
   Turk, D
   Kenessey, I
   Tovari, J
   Szakacs, G
AF Cserepes, Mihaly
   Turk, Dora
   Kenessey, Istvan
   Tovari, Jozsef
   Szakacs, Gergely
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cserepes, Mihaly] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Turk, Dora] National Academy of Sciences, Research Group for Membrane Biology and ImmunopathologyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tovari, Jozsef] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Szakacs, Gergely] National Academy of Sciences, Research Group for Membrane Biology and ImmunopathologyBudapest, Hungary.
RP Cserepes, M (reprint author), Orszagos Onkologiai Intezet, Kiserletes Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Czirbesz, K
   Gorka, E
   Melegh, K
   Porneczy, E
   Horvathy-Kovacs, A
   Peter, A
   Gezsi, A
   Liszkay, G
AF Czirbesz, Kata
   Gorka, Eszter
   Melegh, Krisztina
   Porneczy, Edit
   Horvathy-Kovacs, Aniko
   Peter, Antal
   Gezsi, Andras
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Melegh, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Horvathy-Kovacs, Aniko] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Peter, Antal] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai Kar, Merestechnika es Informacios Rendszerek TanszekBudapest, Hungary.
   [Gezsi, Andras] BME, Villamosmernoki es Informatikai Kar, BioinformatikaBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Czirbesz, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 11
EP 12
PG 2
ER

PT J
AU Darazs, B
   Varga, Z
   Koszo, R
   Borzasi, E
   Varga, L
   Kahan, Zs
AF Darazs, Barbara
   Varga, Zoltan
   Koszo, Renata
   Borzasi, Emoke
   Varga, Linda
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Darazs, B (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Dede, K
   Korom, N
   Landherr, L
AF Dede, Kristof
   Korom, Nikoletta
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Korom, Nikoletta] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Dede, K (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Deme, D
   Papai, I
   Bishr, MA
   Jamool, N
   Telekes, A
AF Deme, Daniel
   Papai, Iren
   Bishr, Mohamed Abdulfatah
   Jamool, Nizar
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Papai, Iren] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Bishr, Mohamed Abdulfatah] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Jamool, Nizar] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
   [Telekes, Andras] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Demeter, A
   Pete, I
AF Demeter, Attila
   Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Demeter, Attila] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Demeter, A (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Doleschall, Z
   Kohalmy, K
   Matrai, Z
   Boldizsar, M
   Vincze, B
   Csuka, O
AF Doleschall, Zoltan
   Kohalmy, Krisztina
   Matrai, Zoltan
   Boldizsar, Mariann
   Vincze, Borbala
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doleschall, Zoltan] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Boldizsar, Mariann] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Doleschall, Z (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 13
EP 14
PG 2
ER

PT J
AU Fabian, K
   Gyulai, M
   Furak, J
   Varallyay, P
   Jackel, M
   Bogos, K
   Dome, B
   Papay, J
   Timar, J
   Szallasi, Z
   Moldvay, J
AF Fabian, Katalin
   Gyulai, Marton
   Furak, Jozsef
   Varallyay, Peter
   Jackel, Marta
   Bogos, Krisztina
   Dome, Balazs
   Papay, Judit
   Timar, Jozsef
   Szallasi, Zoltan
   Moldvay, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabian, Katalin] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Gyulai, Marton] Pest County Institute of Pulmonology, 2nd DepartmentTorokbalint, Hungary.
   [Furak, Jozsef] University of Szeged, Department of SurgerySzeged, Hungary.
   [Varallyay, Peter] Orszagos Idegtudomanyi Intezet, Radiologiai OsztalyBudapest, Hungary.
   [Jackel, Marta] Military Hospital, Department of PathologyBudapest, Hungary.
   [Bogos, Krisztina] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical School, Children’s Hospital, Informatics ProgramBoston, USA.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
RP Fabian, K (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Farkas, A
   Radeczky, P
   Gieszer, B
   Ghimessy, �
   Bogyo, L
   Meszaros, L
   Torok, K
   Kocsis, �
   Lang, Gy
   Renyi-Vamos, F
   Agocs, L
AF Farkas, Attila
   Radeczky, Peter
   Gieszer, Balazs
   Ghimessy, Aron
   Bogyo, Levente
   Meszaros, Laszlo
   Torok, Klara
   Kocsis, Akos
   Lang, Gyorgy
   Renyi-Vamos, Ferenc
   Agocs, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Attila] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lang, Gyorgy] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Farkas, A (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Farkas, Gy
   Szekely, G
   Gundy, S
AF Farkas, Gyongyi
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Farkas, Gy (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Farkas, R
   Klinko, T
   Landherr, L
AF Farkas, Robert
   Klinko, Timea
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Farkas, R (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Fenyvesi, IM
   Szucs, R
AF Fenyvesi, Ilona Maria
   Szucs, Rozalia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fenyvesi, Ilona Maria] Tolosi Peter Alapitvany a leukemias es tumoros megbetegedesu gyermekek gyogyitasaert, Ambulans rendelesPecs, Hungary.
   [Szucs, Rozalia] Tolosi Peter Alapitvany a leukemias es tumoros megbetegedesu gyermekek gyogyitasaert, GondozasPecs, Hungary.
RP Fenyvesi, IM (reprint author), Tolosi Peter Alapitvany a leukemias es tumoros megbetegedesu gyermekek gyogyitasaert, Ambulans rendeles, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Fodor, K
   Treszl, A
   Steiber, Z
   Halmos, G
AF Fodor, Klara
   Treszl, Andrea
   Steiber, Zita
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Klara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Steiber, Zita] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti KlinikaDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Fodor, K (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Foldi, G
   Nagy, T
   Lovey, J
   Polgar, Cs
AF Foldi, Gerda
   Nagy, Tunde
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Foldi, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Futo, I
AF Futo, Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Futo, Ildiko] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Futo, I (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Garay, TM
   Laszlo, V
   Molnar, E
   Hoda, MA
   Pirker, Ch
   Kenessey, I
   Szirtes, I
   Grusch, M
   Jakopovic, M
   Kern, I
   Klepetko, W
   Berger, W
   Dome, B
   Hegedus, B
AF Garay, Tamas Marton
   Laszlo, Viktoria
   Molnar, Eszter
   Hoda, Mir Alireza
   Pirker, Christine
   Kenessey, Istvan
   Szirtes, Ildiko
   Grusch, Michael
   Jakopovic, Marko
   Kern, Izidor
   Klepetko, Walter
   Berger, Walter
   Dome, Balazs
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garay, Tamas Marton] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Laszlo, Viktoria] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Molnar, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hoda, Mir Alireza] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Pirker, Christine] Medical University of Vienna, Department of Internal MedicineVienna, Austria.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szirtes, Ildiko] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Grusch, Michael] Medical University of Vienna, Department of Internal MedicineVienna, Austria.
   [Jakopovic, Marko] University of Zagreb, School of Medicine, University Hospital Center, Department for Respiratory Diseases JordanovacZagreb, Croatia.
   [Kern, Izidor] University Clinic of Respiratory and Allergic DiseasesGolnik, Slovenia.
   [Klepetko, Walter] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Berger, Walter] Medical University of Vienna, Department of Internal MedicineVienna, Austria.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Hegedus, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Garay, TM (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 17
EP 18
PG 2
ER

PT J
AU Geczi, L
   Vajdics, T
   Nagyivanyi, K
   Gyergyay, F
   Nemeth, H
   Kuronya, Zs
   Biro, K
AF Geczi, Lajos
   Vajdics, Timea
   Nagyivanyi, Krisztian
   Gyergyay, Fruzsina
   Nemeth, Hajnalka
   Kuronya, Zsofia
   Biro, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Vajdics, Timea] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Geczi, L (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Gerlinger, L
   Meszaros, K
AF Gerlinger, Lilla
   Meszaros, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Meszaros, Krisztina] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Gerlinger, L (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Ghimessy, �K
   Agnes, K
   Gieszer, B
   Farkas, A
   Radeczky, P
   Torok, K
   Meszaros, L
   Bogyo, L
   Gyugos, M
   Fillinger, J
   Toth, E
   Glasz, T
   Vadasz, P
   Moser, B
   Kocsis, �
   Agocs, L
   Renyi-Vamos, F
   Lang, Gy
   Dome, B
AF Ghimessy, Aron Kristof
   Agnes, Kelemen
   Gieszer, Balazs
   Farkas, Attila
   Radeczky, Peter
   Torok, Klara
   Meszaros, Laszlo
   Bogyo, Levente
   Gyugos, Monika
   Fillinger, Janos
   Toth, Erika
   Glasz, Tibor
   Vadasz, Pal
   Moser, Bernhard
   Kocsis, Akos
   Agocs, Laszlo
   Renyi-Vamos, Ferenc
   Lang, Gyorgy
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ghimessy, Aron Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agnes, Kelemen] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Farkas, Attila] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gyugos, Monika] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Fillinger, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Glasz, Tibor] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Vadasz, Pal] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Moser, Bernhard] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lang, Gyorgy] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Ghimessy, �K (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Gieszer, B
   Farkas, A
   Onody, P
   Hartyanszky, I
   Radeczky, P
   Ghimessy, �
   Torok, K
   Meszaros, L
   Bogyo, L
   Kocsis, �
   Dome, B
   Lang, Gy
   Agocs, L
   Renyi-Vamos, F
AF Gieszer, Balazs
   Farkas, Attila
   Onody, Peter
   Hartyanszky, Istvan
   Radeczky, Peter
   Ghimessy, Aron
   Torok, Klara
   Meszaros, Laszlo
   Bogyo, Levente
   Kocsis, Akos
   Dome, Balazs
   Lang, Gyorgy
   Agocs, Laszlo
   Renyi-Vamos, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Farkas, Attila] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Onody, Peter] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Hartyanszky, Istvan] Semmelweis Egyetem, Varosmajori Sziv- es Ergyogyaszati KlinikaBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lang, Gyorgy] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Gieszer, B (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Godeny, A
   Sparrow, J
   Baxter, J
AF Godeny, Anna
   Sparrow, Jo
   Baxter, Judith
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] National Institute of OncologyBudapest, Hungary.
   [Sparrow, Jo] The Shakespeare Hospice, Day HospiceStratford-Upon-Avon, UK.
   [Baxter, Judith] The Shakespeare Hospice, Day HospiceStratford-Upon-Avon, UK.
RP Godeny, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Godeny, M
   Lengyel, Zs
   Takacsi Nagy, Z
   Remenar, �
AF Godeny, Maria
   Lengyel, Zsolt
   Takacsi Nagy, Zoltan
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lengyel, Zsolt] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Gorka, E
   Czirbesz, K
   Danyi, T
   Gezsi, A
AF Gorka, Eszter
   Czirbesz, Kata
   Danyi, Timea
   Gezsi, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gezsi, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Gorka, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 19
EP 20
PG 2
ER

PT J
AU Gundy, S
AF Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Gundy, S (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 20
EP 20
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Gulacsi-Bardos, P
AF Gulacsi-Bardos, Petra
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gulacsi-Bardos, Petra] Uzsoki Municipal Hospital, 1st Department of Internal Medicine and CardiologyBudapest, Hungary.
RP Gulacsi-Bardos, P (reprint author), Uzsoki Municipal Hospital, 1st Department of Internal Medicine and Cardiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Gyergyay, F
   Budai, B
   Nagyivanyi, K
   Biro, K
   Kuronya, Zs
   Geczi, L
AF Gyergyay, Fruzsina
   Budai, Barna
   Nagyivanyi, Krisztian
   Biro, Krisztina
   Kuronya, Zsofia
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyergyay, Fruzsina] National Institute of OncologyBudapest, Hungary.
   [Budai, Barna] National Institute of OncologyBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of OncologyBudapest, Hungary.
   [Biro, Krisztina] National Institute of OncologyBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of OncologyBudapest, Hungary.
   [Geczi, Lajos] National Institute of OncologyBudapest, Hungary.
RP Gyergyay, F (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Gyorffy, B
   Ponger, L
   Nagy, �
   Sztupinszki, Zs
AF Gyorffy, Balazs
   Ponger, Lorinc
   Nagy, Adam
   Sztupinszki, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Ponger, Lorinc] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Nagy, Adam] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Sztupinszki, Zsofia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Gyorffy, B (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Hajdu, E
   Gyapjas, T
   Pajkos, G
AF Hajdu, Edit
   Gyapjas, Tunde
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hajdu, Edit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Hajdu, E (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 21
EP 22
PG 2
ER

PT J
AU Hajdu, M
   Harasztdombi, J
   Mark, �
   Nagy, N
   Timar, B
   Szepesi, �
   Kopper, L
   Sebestyen, A
AF Hajdu, Melinda
   Harasztdombi, Jozsef
   Mark, Agnes
   Nagy, Noemi
   Timar, Botond
   Szepesi, Agota
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Harasztdombi, Jozsef] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szepesi, Agota] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Hajdu, M (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Harami-Papp, H
   Hauser, P
   Ambrus, A
   Tretter, L
   Gyorffy, B
AF Harami-Papp, Hajnalka
   Hauser, Peter
   Ambrus, Attila
   Tretter, Laszlo
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harami-Papp, Hajnalka] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Ambrus, Attila] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Tretter, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Harami-Papp, H (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 22
EP 23
PG 2
ER

PT J
AU Harisi, R
   Szekely, Gy
   Jeney, A
AF Harisi, Revekka
   Szekely, Gyorgy
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia OsztalyBudapest, Hungary.
   [Szekely, Gyorgy] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Hegyesi, H
   Zambo, B
   Sandor, N
   Schilling-Toth, B
   Safrany, G
AF Hegyesi, Hargita
   Zambo, Barbara
   Sandor, Nikolett
   Schilling-Toth, Boglarka
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hegyesi, Hargita] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Zambo, Barbara] Semmelweis Egyetem, Egeszsegtudomanyi KarBudapest, Hungary.
   [Sandor, Nikolett] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Schilling-Toth, Boglarka] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Hegyesi, H (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Hernadi, Z
AF Hernadi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Hernadi, Z (reprint author), Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai Tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 23
EP 24
PG 2
ER

PT J
AU Hollosi, V
   Csoma, Zs
   Gajdocsi, R
   Kelemen, Zs
   Bogos, K
AF Hollosi, Virag
   Csoma, Zsuzsanna
   Gajdocsi, Reka
   Kelemen, Zsuzsanna
   Bogos, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hollosi, Virag] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Csoma, Zsuzsanna] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Gajdocsi, Reka] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Kelemen, Zsuzsanna] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
   [Bogos, Krisztina] Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. TudobelosztalyBudapest, Hungary.
RP Hollosi, V (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, IV. Tudobelosztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Hornyak, L
   Kocsis, R
   Fogarassyne Vathy, �
AF Hornyak, Lajos
   Kocsis, Roland
   Fogarassyne Vathy, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hornyak, Lajos] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Kocsis, Roland] Csolnoky Ferenc Korhaz, KontrollingVeszprem, Hungary.
   [Fogarassyne Vathy, Agnes] Pannon Egyetem, Informatikai KarVeszprem, Hungary.
RP Hornyak, L (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Horvath, D
   Agoston, P
   Godeny, A
   Kovacs, P
   Polgar, Cs
AF Horvath, Dora
   Agoston, Peter
   Godeny, Anna
   Kovacs, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dora] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Horvath, D (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Horvath, DK
   Futo, I
   Telekes, A
AF Horvath, Dorottya Katalin
   Futo, Ildiko
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dorottya Katalin] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Futo, Ildiko] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Horvath, DK (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Horvath, K
   Godeny, M
AF Horvath, Katalin
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Horvathy-Kovacs, A
   Balatoni, T
   Porneczy, E
   Melegh, K
   Czirbesz, K
   Gorka, E
   Lorincz, L
   Lengyel, Zs
   Borbely, K
   Liszkay, G
AF Horvathy-Kovacs, Aniko
   Balatoni, Timea
   Porneczy, Edit
   Melegh, Krisztina
   Czirbesz, Kata
   Gorka, Eszter
   Lorincz, Lenke
   Lengyel, Zsolt
   Borbely, Katalin
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvathy-Kovacs, Aniko] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Melegh, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Lorincz, Lenke] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Horvathy-Kovacs, A (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Hosszu, A
AF Hosszu, Attilane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hosszu, Attilane] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Hosszu, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Hujber, Z
   Jeney, A
   Szoboszlai, N
   Olah, J
   Mark, �
   Nagy, N
   Petovari, G
   Danko, T
   Sebestyen, A
AF Hujber, Zoltan
   Jeney, Andras
   Szoboszlai, Norbert
   Olah, Julia
   Mark, Agnes
   Nagy, Noemi
   Petovari, Gabor
   Danko, Titanilla
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hujber, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szoboszlai, Norbert] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Hujber, Z (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 26
EP 27
PG 2
ER

PT J
AU Ivan, L
   Vass, G
   Bere, Zs
   Rovo, L
AF Ivan, Laszlo
   Vass, Gabor
   Bere, Zsofia
   Rovo, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ivan, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Vass, Gabor] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Bere, Zsofia] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Rovo, Laszlo] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
RP Ivan, L (reprint author), Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti Klinika, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Janosi, Sz
AF Janosi, Szilvia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janosi, Szilvia] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Janosi, Sz (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Jederan, �
   Lovey, J
   Szentirmay, Z
   Hitre, E
AF Jederan, Eva
   Lovey, Jozsef
   Szentirmay, Zoltan
   Hitre, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Jorgo, K
   Agoston, P
   Szabo, Z
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Szabo, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szabo, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 27
EP 28
PG 2
ER

PT J
AU Juhasz, B
   Szekanecz, �
   Andras, Cs
   Horvath, Zs
AF Juhasz, Balazs
   Szekanecz, Eva
   Andras, Csilla
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Balazs] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Juhasz, B (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Juranyi, Zs
   Farkas, Gy
   Kocsis, Zs
   Szekely, G
   Gundy, S
AF Juranyi, Zsolt
   Farkas, Gyongyi
   Kocsis, Zsuzsa
   Szekely, Gabor
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kocsis, Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Juranyi, Zs (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 28
EP 29
PG 2
ER

PT J
AU Kapuvari, B
   Molnar, Zs
   Kovacs, J
   Deak, B
   Rosta, A
   Schneider, T
   Varady, E
   Szaleczky, E
   Varga, F
   Vincze, B
AF Kapuvari, Bence
   Molnar, Zsuzsa
   Kovacs, Judit
   Deak, Beata
   Rosta, Andras
   Schneider, Tamas
   Varady, Erika
   Szaleczky, Erika
   Varga, Fatima
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Deak, Beata] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varga, Fatima] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Kas, J
   Csekeo, A
   Feher, Cs
   Heiler, Z
   Kecskes, L
   Kostic, Sz
   Molnar, M
   Vagvolgyi, A
   Vadasz, P
AF Kas, Jozsef
   Csekeo, Attila
   Feher, Csaba
   Heiler, Zoltan
   Kecskes, Lorant
   Kostic, Szilard
   Molnar, Miklos
   Vagvolgyi, Attila
   Vadasz, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kas, Jozsef] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Feher, Csaba] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Heiler, Zoltan] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Kecskes, Lorant] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Kostic, Szilard] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Molnar, Miklos] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Vagvolgyi, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Vadasz, Pal] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
RP Kas, J (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Katona, Cs
AF Katona, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Katona, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Kenessey, I
   Vankos, BJ
   Piurko, V
   Suba, Zs
   Nemeth, Zs
   Timar, J
AF Kenessey, Istvan
   Vankos, Borbala Judit
   Piurko, Violetta
   Suba, Zsuzsanna
   Nemeth, Zsolt
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Vankos, Borbala Judit] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Piurko, Violetta] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Suba, Zsuzsanna] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Nemeth, Zsolt] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kenessey, I (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 29
EP 30
PG 2
ER

PT J
AU Kiss, E
   Bago, A
   Csokay, A
   Lovey, J
   Gesztesi, L
   Vizkelety, J
   Papai, Zs
AF Kiss, Edina
   Bago, Attila
   Csokay, Andras
   Lovey, Jozsef
   Gesztesi, Laszlo
   Vizkelety, Julia
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bago, Attila] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
   [Csokay, Andras] MH Egeszsegugyi Kozpont, Idegsebeszeti OsztalyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkelety, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Kiss, N
   Farsang, Z
   Varadi, A
   Agoston, P
   Jorgo, K
   Papai, Zs
AF Kiss, Nora
   Farsang, Zoltan
   Varadi, Andras
   Agoston, Peter
   Jorgo, Kliton
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Nora] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Farsang, Zoltan] MH Honvedkorhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Varadi, Andras] Magyar Honvedseg Egeszsegugyi Kozpont, Kozponti Anaesthesiologia es Intenziv TerapiaBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, N (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Kocsis, J
   Madaras, B
   Graf, L
   Garam, N
   Malati, �
   Bartfai, Z
   Galffy, G
   Tamasi, L
   Dome, B
   Ostoros, Gy
   Prohaszka, Z
   Horvath, Zs
AF Kocsis, Judit
   Madaras, Balazs
   Graf, Laszlo
   Garam, Nora
   Malati, Eva
   Bartfai, Zoltan
   Galffy, Gabriella
   Tamasi, Lilla
   Dome, Balazs
   Ostoros, Gyula
   Prohaszka, Zoltan
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Madaras, Balazs] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Graf, Laszlo] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Garam, Nora] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Malati, Eva] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Bartfai, Zoltan] Soproni Gyogykozpont, PulmonologiaSopron, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, TudobelosztalyBudapest, Hungary.
   [Prohaszka, Zoltan] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Kocsis, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 30
EP 31
PG 2
ER

PT J
AU Kocsis, Zs
   Juranyi, Zs
   Farkas, Gy
   Szekely, G
   Polgar, Cs
AF Kocsis, Zsuzsa
   Juranyi, Zsolt
   Farkas, Gyongyi
   Szekely, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kocsis, Zs (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Koiss, R
   Jaray, B
   Hernadi, Z
   Szentirmay, Z
AF Koiss, Robert
   Jaray, Balazs
   Hernadi, Zoltan
   Szentirmay, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koiss, Robert] Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Szuleszeti-Nogyogyaszati OsztalyBudapest, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hernadi, Zoltan] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
   [Szentirmay, Zoltan] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
RP Koiss, R (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Szuleszeti-Nogyogyaszati Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 31
EP 32
PG 2
ER

PT J
AU Koltai, L
   Gerlinger, L
AF Koltai, Laszlo
   Gerlinger, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
RP Koltai, L (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Koncz, Zs
   Kovacs, P
   Matrai, Z
AF Koncz, Zsuzsa
   Kovacs, Peter
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koncz, Zsuzsa] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Koncz, Zs (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Koszo, R
   Rusz, O
   Kelemen, Gy
   Lazar, Gy
   Voros, A
   Kovari, B
   Ormandi, K
   Kahan, Zs
AF Koszo, Renata
   Rusz, Orsolya
   Kelemen, Gyongyi
   Lazar, Gyorgy
   Voros, Andras
   Kovari, Bence
   Ormandi, Katalin
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Kovari, Bence] University of Szeged, Department of PathologySzeged, Hungary.
   [Ormandi, Katalin] Diagnoscan Hungary LtdSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Kotlan, B
   Liszkay, G
   Plotar, V
   Csuka, O
   Godeny, M
   Farkas, E
   Toth, L
   Szollar, A
   Savolt, �
   Horvath, Sz
   Balatoni, T
   Olasz, J
   Marincola, F
   Kasler, M
AF Kotlan, Beatrix
   Liszkay, Gabriella
   Plotar, Vanda
   Csuka, Orsolya
   Godeny, Maria
   Farkas, Emil
   Toth, Laszlo
   Szollar, Andras
   Savolt, Akos
   Horvath, Szabolcs
   Balatoni, Timea
   Olasz, Judit
   Marincola, Francesco
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Olasz, Judit] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Marincola, Francesco] SIDRA Klinikai Kutatasi Centrum, Kutatasi ReszlegDoha, Qatar.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
RP Kotlan, B (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Kovacs, E
   Bidlek, M
   Godeny, M
   Kelemen, PB
   Matrai, Z
AF Kovacs, Eszter
   Bidlek, Maria
   Godeny, Maria
   Kelemen, Peter Bertalan
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kelemen, Peter Bertalan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Kovacs, E (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Kovacs, E
   Bidlek, M
   Godeny, M
AF Kovacs, Eszter
   Bidlek, Maria
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Kovacs, E (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 33
EP 34
PG 2
ER

PT J
AU Kovacs, P
   Panczel, G
   Melegh, K
   Gorka, E
   Czirbesz, K
   Lorincz, LCs
   Porneczy, E
   Balatoni, T
   Liszkay, G
AF Kovacs, Peter
   Panczel, Gitta
   Melegh, Krisztina
   Gorka, Eszter
   Czirbesz, Kata
   Lorincz, Lenke Csilla
   Porneczy, Edit
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Melegh, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Lorincz, Lenke Csilla] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kovacs, Zs
   Monok, K
   Kokonyei, Gy
   Urban, R
   Rigo, A
AF Kovacs, Zsuzsa
   Monok, Kata
   Kokonyei, Gyongyi
   Urban, Robert
   Rigo, Adrien
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Zsuzsa] Semmelweis Egyetem, ETK, Alkalmazott Pszichologia TanszekBudapest, Hungary.
   [Monok, Kata] ELTE PPK, Pszichologiai Doktori IskolaBudapest, Hungary.
   [Kokonyei, Gyongyi] ELTE PPK, Pszichologiai IntezetBudapest, Hungary.
   [Urban, Robert] ELTE PPK, Pszichologiai IntezetBudapest, Hungary.
   [Rigo, Adrien] ELTE PPK, Pszichologiai IntezetBudapest, Hungary.
RP Kovacs, Zs (reprint author), Semmelweis Egyetem, ETK, Alkalmazott Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Krausz, Cs
AF Krausz, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Krausz, Csilla] University of Florence, Department of Clinical and Experimental MedicineFlorence, Italy.
RP Krausz, Cs (reprint author), University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Krencz, I
   Sebestyen, A
   Mark, �
   Fabian, K
   Moldvay, J
   Papay, J
AF Krencz, Ildiko
   Sebestyen, Anna
   Mark, Agnes
   Fabian, Katalin
   Moldvay, Judit
   Papay, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fabian, Katalin] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Krencz, I (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Kriston, Cs
   Plander, M
   Mark, �
   Szabo, O
   Matolcsy, A
   Barna, G
AF Kriston, Csilla
   Plander, Mark
   Mark, Agnes
   Szabo, Orsolya
   Matolcsy, Andras
   Barna, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kriston, Csilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Plander, Mark] Vas County Markusovszky Hospital, Department of HematologySzombathely, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szabo, Orsolya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Barna, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Kriston, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 35
EP 36
PG 2
ER

PT J
AU Kulka, J
AF Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Kulka, J (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Kullmann, T
   Kocsis, K
   Torzsok, F
   Olah, A
   Pinter, T
AF Kullmann, Tamas
   Kocsis, Karoly
   Torzsok, Ferenc
   Olah, Attila
   Pinter, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kocsis, Karoly] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Torzsok, Ferenc] Petz Aladar Hospital, Department of UrologyGyor, Hungary.
   [Olah, Attila] Petz Aladar Megyei Oktato Korhaz, SebeszetGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Kullmann, T
   Sipocz, I
   Pinter, T
AF Kullmann, Tamas
   Sipocz, Istvan
   Pinter, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Sipocz, Istvan] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Kuronya, Zs
AF Kuronya, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Kuronya, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Lacsan, K
AF Lacsan, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lacsan, Katalin] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Lacsan, K (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Ladanyi, A
   Toth, E
   Kapuvari, B
   Koltai, P
   Lovey, J
   Horvath, K
   Godeny, M
   Remenar, �
AF Ladanyi, Andrea
   Toth, Erika
   Kapuvari, Bence
   Koltai, Pal
   Lovey, Jozsef
   Horvath, Katalin
   Godeny, Maria
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Lahm, E
   Szilvasi, I
   Papai, Zs
AF Lahm, Erika
   Szilvasi, Istvan
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szilvasi, Istvan] Magyar Honvedseg Egeszsegugyi Kozpont, Nuklearis MedicinaBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Lahm, E
   Fulop, V
   Riedl, E
   Papai, Zs
AF Lahm, Erika
   Fulop, Vilmos
   Riedl, Erika
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Fulop, Vilmos] Magyar Honvedseg Egeszsegugyi Kozpont, Honvedkorhaz, Szuleszet-nogyogyaszati OsztalyBudapest, Hungary.
   [Riedl, Erika] Magyar Honvedseg Egeszsegugyi Kozpont, Kozponti Radiologiai Diagnosztika OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 38
EP 39
PG 2
ER

PT J
AU Lang, Gy
   Renyi-Vamos, F
   Torok, K
   Agocs, L
   Taghavi, Sh
   Aigner, C
   Klepetko, W
AF Lang, Gyorgy
   Renyi-Vamos, Ferenc
   Torok, Klara
   Agocs, Laszlo
   Taghavi, Shahrokh
   Aigner, Clemens
   Klepetko, Walter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lang, Gyorgy] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Torok, Klara] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Agocs, Laszlo] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Taghavi, Shahrokh] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Aigner, Clemens] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Klepetko, Walter] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Lang, Gy (reprint author), Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Laszlo, V
   Ozsvar, J
   Hoda, MA
   Klikovits, Th
   Lakatos, D
   Garay, T
   Klepetko, W
   Hilberg, F
   Dome, B
   Hegedus, B
AF Laszlo, Viktoria
   Ozsvar, Judit
   Hoda, Mir Alireza
   Klikovits, Thomas
   Lakatos, Dora
   Garay, Tamas
   Klepetko, Walter
   Hilberg, Frank
   Dome, Balazs
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Viktoria] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Ozsvar, Judit] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Hoda, Mir Alireza] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Klikovits, Thomas] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Lakatos, Dora] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Klepetko, Walter] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Hilberg, Frank] Boehringer Ingelheim Research and DevelopmentVienna, Austria.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Hegedus, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Laszlo, V (reprint author), Medical University of Vienna, Department of Thoracic Surgery, Vienna, Austria.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Lener, V
   Sandor, N
   Harsanyi, I
   Hegyesi, H
   Safrany, G
AF Lener, Violetta
   Sandor, Nikolett
   Harsanyi, Izabella
   Hegyesi, Hargita
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lener, Violetta] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Sandor, Nikolett] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Harsanyi, Izabella] Semmelweis University, Institute of Morphology and PhysiologyBudapest, Hungary.
   [Hegyesi, Hargita] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
RP Lener, V (reprint author), Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Lengyel, Zs
   Gyulai, R
AF Lengyel, Zsuzsanna
   Gyulai, Rolland
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Lengyel, Zs (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Lerant, G
   Sarkozy, P
   Takacsi Nagy, Z
   Polony, G
   Tamas, L
   Toth, E
   Boer, A
   Javor, L
   Godeny, M
AF Lerant, Gergely
   Sarkozy, Peter
   Takacsi Nagy, Zoltan
   Polony, Gabor
   Tamas, Laszlo
   Toth, Erika
   Boer, Andras
   Javor, Laszlo
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lerant, Gergely] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sarkozy, Peter] Budapest University of Technology, Department of Measurement and Information systemsBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polony, Gabor] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Tamas, Laszlo] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Javor, Laszlo] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Lerant, G (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Lohinai, Z
   Moldvay, J
   Fabian, K
   Ostoros, Gy
   Cserepes, M
   Kovalszky, I
   Timar, J
   Dome, B
   Hegedus, B
AF Lohinai, Zoltan
   Moldvay, Judit
   Fabian, Katalin
   Ostoros, Gyula
   Cserepes, Mihaly
   Kovalszky, Ilona
   Timar, Jozsef
   Dome, Balazs
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lohinai, Zoltan] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Fabian, Katalin] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, TudobelosztalyBudapest, Hungary.
   [Cserepes, Mihaly] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Hegedus, Balazs] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
RP Lohinai, Z (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Lorincz, P
   Telekes, A
AF Lorincz, Peter
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lorincz, Peter] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lorincz, P (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Lukacs, M
AF Lukacs, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Miklos] University of Pecs, Department of OncologyPecs, Hungary.
RP Lukacs, M (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Lumniczky, K
   Bogdandi, EN
   Virag, P
   Fekete, Zs
   Brie, I
   Barbos, O
   Fodor-Fischer, �
   Safrany, G
AF Lumniczky, Katalin
   Bogdandi, Eniko Noemi
   Virag, Piroska
   Fekete, Zsolt
   Brie, Ioana
   Barbos, Otilia
   Fodor-Fischer, Eva
   Safrany, Geza
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Bogdandi, Eniko Noemi] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Virag, Piroska] I. Chiricuta Onkologiai Intezet, Sugarbiologiai OsztalyCluj-Napoca, Romania.
   [Fekete, Zsolt] I. Chiricuta Onkologiai Intezet, Sugarbiologiai OsztalyCluj-Napoca, Romania.
   [Brie, Ioana] I. Chiricuta Onkologiai Intezet, Sugarbiologiai OsztalyCluj-Napoca, Romania.
   [Barbos, Otilia] I. Chiricuta Onkologiai Intezet, Sugarbiologiai OsztalyCluj-Napoca, Romania.
   [Fodor-Fischer, Eva] I. Chiricuta Onkologiai Intezet, Sugarbiologiai OsztalyCluj-Napoca, Romania.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Lumniczky, K (reprint author), Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 42
EP 43
PG 2
ER

PT J
AU Mahr, K
AF Mahr, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Mahr, K (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Manninger, SP
   Lovey, J
   Godeny, M
AF Manninger, Sandor Peter
   Lovey, Jozsef
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Manninger, Sandor Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Manninger, SP (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Maraz, A
   Cserhati, A
   Dobi, �
   Egyud, Zs
   Hideghety, K
   Koszo, R
   Szabo, Cs
   Varga, L
   Varga, Z
AF Maraz, Aniko
   Cserhati, Adrienne
   Dobi, Agnes
   Egyud, Zsofia
   Hideghety, Katalin
   Koszo, Renata
   Szabo, Csilla
   Varga, Linda
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Csilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Maraz, R
   Pap-Szekeres, J
   Marko, L
   Pajkos, G
   Cserni, G
AF Maraz, Robert
   Pap-Szekeres, Jozsef
   Marko, Laszlo
   Pajkos, Gabor
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pap-Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Surgery, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Marko, L
   Pajkos, G
   Gabor, G
   Hajnal, L
   Maraz, R
   Svebis, M
   Pap-Szekeres, J
AF Marko, Laszlo
   Pajkos, Gabor
   Gabor, Gabriella
   Hajnal, Lajos
   Maraz, Robert
   Svebis, Mihaly
   Pap-Szekeres, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Hajnal, Lajos] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pap-Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Meilinger-Dobra, M
   Karoly, B
   Gerlinger, L
   Meszaros, K
AF Meilinger-Dobra, Monika
   Karoly, Boroka
   Gerlinger, Lilla
   Meszaros, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meilinger-Dobra, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Karoly, Boroka] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Gerlinger, Lilla] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Meszaros, Krisztina] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Meilinger-Dobra, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Melegh, K
   Petranyi, �
   Szlavik, J
   Liszkay, G
AF Melegh, Krisztina
   Petranyi, Agota
   Szlavik, Janos
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Melegh, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szlavik, Janos] Del-pesti Centrumkohaz, Orszagos Hematologiai es Infektologiai Intezet (DPC-OHII)Budapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Melegh, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Mersich, T
   Meszaros, P
   Sztipits, T
   Duboczki, Zs
AF Mersich, Tamas
   Meszaros, Peter
   Sztipits, Tamas
   Duboczki, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Meszaros, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sztipits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Mersich, T (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Meszaros, L
   Agocs, L
   Kocsis, �
   Torok, K
   Bogyo, L
   Farkas, A
   Gieszer, B
   Radeczky, P
   Ghimessy, �
   Dome, B
   Renyi-Vamos, F
   Lang, Gy
AF Meszaros, Laszlo
   Agocs, Laszlo
   Kocsis, Akos
   Torok, Klara
   Bogyo, Levente
   Farkas, Attila
   Gieszer, Balazs
   Radeczky, Peter
   Ghimessy, Aron
   Dome, Balazs
   Renyi-Vamos, Ferenc
   Lang, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Farkas, Attila] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lang, Gyorgy] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Meszaros, L (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 45
EP 46
PG 2
ER

PT J
AU Meszaros, N
   Major, T
   Stelczer, G
   Mozsa, E
   Zaka, Z
   Fodor, J
   Polgar, Cs
AF Meszaros, Norbert
   Major, Tibor
   Stelczer, Gabor
   Mozsa, Emoke
   Zaka, Zoltan
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Meszaros, P
   Duboczki, Zs
   Sztipits, T
   Mersich, T
   Lovey, J
   Strausz, T
   Jederan, �
AF Meszaros, Peter
   Duboczki, Zsolt
   Sztipits, Tamas
   Mersich, Tamas
   Lovey, Jozsef
   Strausz, Tamas
   Jederan, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sztipits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Strausz, Tamas] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Meszaros, P (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Meszaros, R
AF Meszaros, Rozsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Rozsa] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
RP Meszaros, R (reprint author), Szent Borbala Korhaz, Onkologia, Tatabanya, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Molnar, Zs
   Borbely, K
   Rosta, A
AF Molnar, Zsuzsanna
   Borbely, Katalin
   Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Zsuzsanna] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Molnar, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Muller, Z
   Gorgey, Cs
AF Muller, Zoltan
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Gorgey, Csaba] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Nagy, �
   Gyorffy, B
AF Nagy, Adam
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Adam] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Nagy, � (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 47
EP 48
PG 2
ER

PT J
AU Nagy, ACs
AF Nagy, Andras Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Andras Csaba] Uzsoki Municipal Hospital, 1st Department of Internal Medicine and CardiologyBudapest, Hungary.
RP Nagy, ACs (reprint author), Uzsoki Municipal Hospital, 1st Department of Internal Medicine and Cardiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Nagy, J
   Sipka, S
   Kocsis, J
   Horvath, Zs
AF Nagy, Janos
   Sipka, Sandor
   Kocsis, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Sipka, Sandor] University of Debrecen, Faculty of Medicine, Department of Internal MedicineDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Nagy, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 48
EP 49
PG 2
ER

PT J
AU Nagy, N
   Mark, �
   Hujber, Z
   Molnar, A
   Toth, M
   Danko, T
   Petovari, G
   Kiraly, PA
   Hajdu, M
   Kopper, L
   Sebestyen, A
AF Nagy, Noemi
   Mark, Agnes
   Hujber, Zoltan
   Molnar, Anna
   Toth, Monika
   Danko, Titanilla
   Petovari, Gabor
   Kiraly, Peter Attila
   Hajdu, Melinda
   Kopper, Laszlo
   Sebestyen, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Mark, Agnes] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hujber, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Molnar, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Toth, Monika] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kiraly, Peter Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Nagy, N (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Nagy, P
   Biro, A
   Doka, �
   Ballago, K
   Palinkas, Z
   Garai, D
   Budai, B
   Nagy, A
   Barancsine Szucs, J
   Vasas, A
   Rosta, A
   Kasler, M
AF Nagy, Peter
   Biro, Adrienn
   Doka, Eva
   Ballago, Krisztina
   Palinkas, Zoltan
   Garai, Dorottya
   Budai, Barna
   Nagy, Attila
   Barancsine Szucs, Judit
   Vasas, Anita
   Rosta, Andras
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Biro, Adrienn] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Doka, Eva] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ballago, Krisztina] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Palinkas, Zoltan] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Garai, Dorottya] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Nagy, Attila] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Barancsine Szucs, Judit] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Vasas, Anita] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Nagy, P (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Nemeth, H
AF Nemeth, Hajnalka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Nemeth, H (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Nemeth, Zs
   Boer, K
   Lengyel, Zs
   Hitre, E
   Borbely, K
AF Nemeth, Zsuzsanna
   Boer, Katalin
   Lengyel, Zsolt
   Hitre, Erika
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Nemeth, Zs (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Nemeth, Zs
   Lengyel, Zs
   Boer, K
   Hitre, E
   Borbely, K
AF Nemeth, Zsuzsanna
   Lengyel, Zsolt
   Boer, Katalin
   Hitre, Erika
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Nemeth, Zs (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 50
EP 51
PG 2
ER

PT J
AU Nikolenyi, A
   Horgas, N
   Uhercsak, G
   Koszo, R
   Rusz, O
   Ormandi, K
   Voros, A
   Lazar, Gy
   Kahan, Zs
AF Nikolenyi, Aliz
   Horgas, Norbert
   Uhercsak, Gabriella
   Koszo, Renata
   Rusz, Orsolya
   Ormandi, Katalin
   Voros, Andras
   Lazar, Gyorgy
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Horgas, Norbert] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nikolenyi, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Olah, E
AF Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Olah, E (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 51
EP 52
PG 2
ER

PT J
AU Ozvald, G
AF Ozvald, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ozvald, Gabriella] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Ozvald, G (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Panczel, G
   Danyi, T
   Plotar, V
   Bocs, K
   Liszkay, G
AF Panczel, Gitta
   Danyi, Timea
   Plotar, Vanda
   Bocs, Katalin
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Papp, A
   Horvath, �P
   Cseke, L
   Vereczkei, A
AF Papp, Andras
   Horvath, Ors Peter
   Cseke, Laszlo
   Vereczkei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Horvath, Ors Peter] University of Pecs, Department of SurgeryPecs, Hungary.
   [Cseke, Laszlo] University of Pecs, Department of SurgeryPecs, Hungary.
   [Vereczkei, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
RP Papp, A (reprint author), University of Pecs, Department of Surgery, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Papp, J
   Vaszko, T
   Bozsik, A
   Pocza, T
   Gyuris, T
   Balint, BL
   Gezsi, A
   Peter, A
   Olah, E
AF Papp, Janos
   Vaszko, Tibor
   Bozsik, Aniko
   Pocza, Timea
   Gyuris, Tibor
   Balint, Balint Laszlo
   Gezsi, Andras
   Peter, Antal
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Gyuris, Tibor] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Gezsi, Andras] Budapest University of Technology, Department of Measurement and Information systemsBudapest, Hungary.
   [Peter, Antal] Budapest University of Technology, Department of Measurement and Information systemsBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Papp, J (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Papp, J
   Vaszko, T
   Pocza, T
   Bozsik, A
   Olah, E
AF Papp, Janos
   Vaszko, Tibor
   Pocza, Timea
   Bozsik, Aniko
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Papp, J (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Patonay, P
   Naszaly, A
AF Patonay, Peter
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 53
EP 54
PG 2
ER

PT J
AU Pete, I
AF Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Pete, I
AF Pete, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Pete, I (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Petri, K
   Agoston, P
   Godeny, M
AF Petri, Klara
   Agoston, Peter
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Plavecz, �
   Klinko, T
   Egyed, Zs
   Baki, M
AF Plavecz, Eva
   Klinko, Timea
   Egyed, Zsofia
   Baki, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Egyed, Zsofia] Uzsoki Utcai Korhaz, Rontgen DiagnosztikaBudapest, Hungary.
   [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Plavecz, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Pocza, T
   Bozsik, A
   Papp, J
   Vaszko, T
   Olah, E
AF Pocza, Timea
   Bozsik, Aniko
   Papp, Janos
   Vaszko, Tibor
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Pocza, T (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Polgar, Cs
   Ott, O
   Hildebrandt, G
   Kauer-dorner, D
   Major, T
   Strand, V
AF Polgar, Csaba
   Ott, Oliver
   Hildebrandt, Guido
   Kauer-dorner, Daniela
   Major, Tibor
   Strand, Vratislav
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ott, Oliver] University of Erlangen, Department of Radiation OncologyErlangen, Germany.
   [Hildebrandt, Guido] University Hospital Leipzig, Department of Radiation OncologyLeipzig, Germany.
   [Kauer-dorner, Daniela] University Hospital AKH, Department of Radiotherapy and RadiobiologyVienna, Austria.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Strand, Vratislav] University of Erlangen, Department of Radiation OncologyErlangen, Germany.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Pongor, L
   Sztupinszki, Zs
   Gyorffy, B
AF Pongor, Lorinc
   Sztupinszki, Zsofia
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pongor, Lorinc] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Sztupinszki, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Pongor, L (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Porneczy, E
   Danyi, T
   Czirbesz, K
   Gorka, E
   Liszkay, G
AF Porneczy, Edit
   Danyi, Timea
   Czirbesz, Kata
   Gorka, Eszter
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Porneczy, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 56
EP 57
PG 2
ER

PT J
AU Pukancsik, D
   Ujhelyi, M
   Kovacs, E
   Jani, N
   Matrai, Z
AF Pukancsik, David
   Ujhelyi, Mihaly
   Kovacs, Eszter
   Jani, Nora
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Jani, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Pukancsik, D (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Pukancsik, D
   Ujhelyi, M
   Godeny, M
   Kovacs, E
   Udvarhelyi, N
   Zaka, Z
   Kasler, M
   Matrai, Z
AF Pukancsik, David
   Ujhelyi, Mihaly
   Godeny, Maria
   Kovacs, Eszter
   Udvarhelyi, Nora
   Zaka, Zoltan
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Pukancsik, D (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 57
EP 58
PG 2
ER

PT J
AU Puskas, G
AF Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai KorhazaBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Pusztai, L
AF Pusztai, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pusztai, Lajos] Yale School of Medicine, Yale Cancer Center, Breast Medical OncologyNew Haven, CT, USA.
RP Pusztai, L (reprint author), Yale School of Medicine, Yale Cancer Center, Breast Medical Oncology, New Haven, USA.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Radovics, T
   Rubovszky, G
   Ganofszky, E
   Hitre, E
   Juhos, �
   Madaras, B
   Nagy, T
   Szabo, E
   Lang, I
   Geczi, L
   Horvath, Zs
AF Radovics, Tibor
   Rubovszky, Gabor
   Ganofszky, Erna
   Hitre, Erika
   Juhos, Eva
   Madaras, Balazs
   Nagy, Tunde
   Szabo, Eszter
   Lang, Istvan
   Geczi, Lajos
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Radovics, Tibor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Ganofszky, Erna] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Juhos, Eva] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Madaras, Balazs] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Szabo, Eszter] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lang, Istvan] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Radovics, T (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 58
EP 59
PG 2
ER

PT J
AU Revesz, J
AF Revesz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Revesz, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Revesz, J (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Risko, �
AF Risko, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Risko, Agnes] Boldeazy Bt.Budapest, Hungary.
RP Risko, � (reprint author), Boldeazy Bt., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Rosta, A
AF Rosta, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Rosta, A (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Roza, Zs
AF Roza, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Roza, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
RP Roza, Zs (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Rubovszky, G
   Lengyel, Zs
   Markoczy, Zs
   Kasler, M
   Borbely, K
AF Rubovszky, Gabor
   Lengyel, Zsolt
   Markoczy, Zsolt
   Kasler, Miklos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Rubovszky, G (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Ruszkai, K
AF Ruszkai, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruszkai, Katalin] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Ruszkai, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Ruzsa, �
AF Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Ruzsa, � (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Sarosi, V
   Sztrikovics, Sz
   Ruzsics, I
   Baliko, Z
AF Sarosi, Veronika
   Sztrikovics, Szilard
   Ruzsics, Istvan
   Baliko, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Sztrikovics, Szilard] Pecsi Tudomanyegyetem AOK, V. evfolyamPecs, Hungary.
   [Ruzsics, Istvan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
RP Sarosi, V (reprint author), University of Pecs, Faculty of Medicine, Department of Pulmonology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Savolt, �
   Szollar, A
   Kelemen, P
   Ujhelyi, M
   Pukancsik, D
AF Savolt, Akos
   Szollar, Andras
   Kelemen, Peter
   Ujhelyi, Miklos
   Pukancsik, David
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szollar, Andras] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Miklos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Savolt, � (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 61
EP 62
PG 2
ER

PT J
AU Schaig, K
   Kadar, Zs
   Lengyel, Zs
   Durkot, P
   Gyomorei, Cs
   Gyulai, R
AF Schaig, Krisztian
   Kadar, Zsolt
   Lengyel, Zsuzsanna
   Durkot, Patricia
   Gyomorei, Csaba
   Gyulai, Rolland
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schaig, Krisztian] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Kadar, Zsolt] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Durkot, Patricia] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Gyomorei, Csaba] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Schaig, K (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Sebestyen, A
   Hujber, Z
   Szoboszlai, N
   Olah, J
   Nemeth, A
   Danko, T
   Petovari, G
   Nagy, N
   Kopper, L
   Jeney, A
AF Sebestyen, Anna
   Hujber, Zoltan
   Szoboszlai, Norbert
   Olah, Julia
   Nemeth, Andrea
   Danko, Titanilla
   Petovari, Gabor
   Nagy, Noemi
   Kopper, Laszlo
   Jeney, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Hujber, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szoboszlai, Norbert] Eotvos Lorand Tudomanyegyetem, Kemiai Intezet, Analitikai Kemiai TanszekBudapest, Hungary.
   [Olah, Julia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nemeth, Andrea] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kopper, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Sebestyen, T
   Mohos, A
   Kiss, J
   Liszkay, G
   Somlai, B
   Ladanyi, A
AF Sebestyen, Timea
   Mohos, Anita
   Kiss, Judit
   Liszkay, Gabriella
   Somlai, Beata
   Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Timea] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Mohos, Anita] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kiss, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Somlai, Beata] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Sebestyen, T (reprint author), St John's Hospital, Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 62
EP 63
PG 2
ER

PT J
AU Sikter, M
   Kiss, E
   Kiss, N
   Lahm, E
   Nagy, P
   Nagy, Zs
   Szentesi, A
   Uhlyarik, A
   Vachaja, J
   Lestar, B
   Bursics, A
   Dede, K
   Papai, Zs
AF Sikter, Marta
   Kiss, Edina
   Kiss, Nora
   Lahm, Erika
   Nagy, Peter
   Nagy, Zsofia
   Szentesi, Aniko
   Uhlyarik, Andrea
   Vachaja, Jozsef
   Lestar, Bela
   Bursics, Attila
   Dede, Kristof
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Nora] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Zsofia] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szentesi, Aniko] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lestar, Bela] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Sikter, M (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Simo, E
   Hornyak, L
   Kovago, L
AF Simo, Erzsebet
   Hornyak, Lajos
   Kovago, Levente
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simo, Erzsebet] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Hornyak, Lajos] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Kovago, Levente] Cholnoky Ferenc Korhaz, Borgyogyaszati OsztalyVeszprem, Hungary.
RP Simo, E (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Sipka, G
   Besenyi, Zs
   Lengyel, Zs
   Pavics, L
AF Sipka, Gabor
   Besenyi, Zsuzsanna
   Lengyel, Zsolt
   Pavics, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sipka, Gabor] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
RP Sipka, G (reprint author), University of Szeged, Department of Nuclear Medicine, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 63
EP 64
PG 2
ER

PT J
AU Sipos, �
   Docs, O
   Steiber, Z
   Mehes, G
   Treszl, A
   Halmos, G
AF Sipos, Eva
   Docs, Otto
   Steiber, Zita
   Mehes, Gabor
   Treszl, Andrea
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sipos, Eva] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Docs, Otto] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Steiber, Zita] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti KlinikaDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Sipos, � (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Sipos, L
   Fedorcsak, I
AF Sipos, Laszlo
   Fedorcsak, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sipos, Laszlo] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Fedorcsak, Imre] Orszagos Idegtudomanyi Intezet, Neuroonkologiai OsztalyBudapest, Hungary.
RP Sipos, L (reprint author), National Institute of Clinical Neurosciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 64
EP 65
PG 2
ER

PT J
AU Somlai, K
   Torgyik, L
   Pfeiffer, Cs
   Sulcz, R
   Tokes, T
   Szentmartoni, Gy
   Kulka, J
   Riedl, E
   Imreh, D
   Szijarto, A
   Sinko, D
   Kovacs, A
   Dank, M
AF Somlai, Krisztian
   Torgyik, Laszlo
   Pfeiffer, Csaba
   Sulcz, Roland
   Tokes, Timea
   Szentmartoni, Gyongyver
   Kulka, Janina
   Riedl, Erika
   Imreh, Domonkos
   Szijarto, Attila
   Sinko, Daniel
   Kovacs, Attila
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Somlai, Krisztian] Szent Margit Korhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Torgyik, Laszlo] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Pfeiffer, Csaba] Medsom Kft.Budapest, Hungary.
   [Sulcz, Roland] Appon Line Kft.Budapest, Hungary.
   [Tokes, Timea] Szent Margit Korhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Szent Margit Korhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Riedl, Erika] Magyar Honvedseg Egeszsegugyi Kozpont, Kozponti Radiologiai Diagnosztika OsztalyBudapest, Hungary.
   [Imreh, Domonkos] Szent Margit Korhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Szijarto, Attila] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Kovacs, Attila] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Somlai, K (reprint author), Szent Margit Korhaz, Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Szabo, V
   Bugyik, E
   Dezso, K
   Reynolds, A
   Paku, S
   Dome, B
AF Szabo, Vanessza
   Bugyik, Edina
   Dezso, Katalin
   Reynolds, Andrew
   Paku, Sandor
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Vanessza] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bugyik, Edina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dezso, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Reynolds, Andrew] The Institute of Cancer Research, Breakthrough Breast Cancer Research Centre, Tumour Biology TeamLondon, UK.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dome, Balazs] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
RP Szabo, V (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Szabo, Zs
   Szegedi, K
   Flasko, T
   Gombos, K
   Kovacs, N
   Harda, K
   Olah, G
   Halmos, G
AF Szabo, Zsuzsanna
   Szegedi, Krisztian
   Flasko, Tibor
   Gombos, Katalin
   Kovacs, Nikoletta
   Harda, Kristof
   Olah, Gabor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szegedi, Krisztian] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Gombos, Katalin] University of Pecs, Faculty of Medicine, Department of Public HealthPecs, Hungary.
   [Kovacs, Nikoletta] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Harda, Kristof] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Olah, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Szabo, Zs (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Szakacs, O
   Rubovszky, G
   Madaras, B
   Csuka, O
AF Szakacs, Orsolya
   Rubovszky, Gabor
   Madaras, Balazs
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakacs, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Madaras, Balazs] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Szakacs, O (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Szantho, A
AF Szantho, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szantho, Andras] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
RP Szantho, A (reprint author), Semmelweis Medical University, Ist Department of Gynaecology and Obstetrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Szanyi, Sz
   Le, N
   Nagy, Zs
   Feher, B
   Burai, M
   Tarpay, �
   Pozsar, J
   Pap, �
   Molnar, B
   Tulassay, Zs
   Bak, M
   Szmola, R
AF Szanyi, Szilard
   Le, Nha
   Nagy, Zsofia
   Feher, Boglarka
   Burai, Maria
   Tarpay, Adam
   Pozsar, Jozsef
   Pap, Akos
   Molnar, Bela
   Tulassay, Zsolt
   Bak, Mihaly
   Szmola, Richard
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szanyi, Szilard] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Le, Nha] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Nagy, Zsofia] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Feher, Boglarka] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Burai, Maria] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Tarpay, Adam] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Pozsar, Jozsef] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Pap, Akos] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Molnar, Bela] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Tulassay, Zsolt] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Szmola, Richard] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
RP Szanyi, Sz (reprint author), Orszagos Onkologiai Inezet, Gasztroenterologia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Szekanecz, �
   Kocsis, J
   Andras, Cs
   Toth, J
   Juhasz, B
   Horvath, Zs
AF Szekanecz, Eva
   Kocsis, Judit
   Andras, Csilla
   Toth, Judit
   Juhasz, Balazs
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Juhasz, Balazs] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Szekanecz, � (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Szekely, B
   Rubovszky, G
   Bajko, �
   Gerlinger, L
   Geczi, L
AF Szekely, Borbala
   Rubovszky, Gabor
   Bajko, Eva
   Gerlinger, Lilla
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Borbala] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bajko, Eva] Orszagos Onkologiai Intezet, Kardiologiai AmbulanciaBudapest, Hungary.
   [Gerlinger, Lilla] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Szekely, B (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 67
EP 68
PG 2
ER

PT J
AU Szekely, G
   Farkas, Gy
   Gundy, S
AF Szekely, Gabor
   Farkas, Gyongyi
   Gundy, Sarolta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Gundy, Sarolta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Szekely, G (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Szentkereszty, M
   Komlosi, Zs
   Vannay, �
   Vasarhelyi, B
   Losonczy, Gy
   Galffy, G
AF Szentkereszty, Marton
   Komlosi, Zsolt
   Vannay, Adam
   Vasarhelyi, Barna
   Losonczy, Gyorgy
   Galffy, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentkereszty, Marton] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Komlosi, Zsolt] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Vannay, Adam] Semmelweis University, Department of Laboratory MedicineBudapest, Hungary.
   [Vasarhelyi, Barna] Semmelweis University, Department of Laboratory MedicineBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Szentkereszty, M (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Szigeti, B
   Lukasz, P
   Kari, D
   Ecsedy, G
   Kovacs, JB
AF Szigeti, Balint
   Lukasz, Peter
   Kari, Daniel
   Ecsedy, Gabor
   Kovacs, Janos Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szigeti, Balint] Jahn Ferenc Del-pesti Korhaz es Rendelointezet, SebeszetBudapest, Hungary.
   [Lukasz, Peter] Jahn Ferenc Del-pesti Korhaz es Rendelointezet, SebeszetBudapest, Hungary.
   [Kari, Daniel] Jahn Ferenc Del-pesti Korhaz es Rendelointezet, SebeszetBudapest, Hungary.
   [Ecsedy, Gabor] Jahn Ferenc Del-pesti Korhaz es Rendelointezet, SebeszetBudapest, Hungary.
   [Kovacs, Janos Balazs] Jahn Ferenc Del-pesti Korhaz es Rendelointezet, SebeszetBudapest, Hungary.
RP Szigeti, B (reprint author), Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Sebeszet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 68
EP 69
PG 2
ER

PT J
AU Szilagyi, A
   Bajcsay, A
   Pocza, T
   Major, T
   Polgar, Cs
   Lovey, J
AF Szilagyi, Andras
   Bajcsay, Andras
   Pocza, Tamas
   Major, Tibor
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szilagyi, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Szoke, I
   Foldi, G
   Agoston, P
AF Szoke, Ilona
   Foldi, Gerda
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szoke, Ilona] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szoke, I (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Szollar, A
   Udvarhelyi, N
   Bidlek, M
   Rubovszky, G
   Zaka, Z
   Savolt, �
   Olah, E
AF Szollar, Andras
   Udvarhelyi, Nora
   Bidlek, Maria
   Rubovszky, Gabor
   Zaka, Zoltan
   Savolt, Akos
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szollar, Andras] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Szollar, A (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Szollar, A
   Savolt, �
   Borbely, K
AF Szollar, Andras
   Savolt, Akos
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szollar, Andras] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Szollar, A (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Sztupinszki, Zs
   Gyorffy, B
AF Sztupinszki, Zsofia
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sztupinszki, Zsofia] Semmelweis University, 1st Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Sztupinszki, Zs (reprint author), Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Takacsi-Nagy, Z
   Hitre, E
   Remenar, �
   Oberna, F
   Polgar, Cs
   Major, T
   Godeny, M
   Fodor, J
   Kasler, M
AF Takacsi-Nagy, Zoltan
   Hitre, Erika
   Remenar, Eva
   Oberna, Ferenc
   Polgar, Csaba
   Major, Tibor
   Godeny, Maria
   Fodor, Janos
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Tamaskovics, B
   Bolke, E
   Gossler, B
   Karzei, Z
   Santacroce, A
   Budach, W
AF Tamaskovics, Balint
   Bolke, Edwin
   Gossler, Birte
   Karzei, Zaid
   Santacroce, Antonio
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Bolke, Edwin] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Gossler, Birte] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Karzei, Zaid] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Santacroce, Antonio] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Tarpay, �
   Burai, M
   Pozsar, J
AF Tarpay, Adam
   Burai, Maria
   Pozsar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tarpay, Adam] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Burai, Maria] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Pozsar, Jozsef] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
RP Tarpay, � (reprint author), Orszagos Onkologiai Inezet, Gasztroenterologia, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Tatrai, E
   Gacs, A
   Cserepes T., M
   Garay, T
   Tovari, J
AF Tatrai, Eniko
   Gacs, Alexandra
   Cserepes T., Mihaly
   Garay, Tamas
   Tovari, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tatrai, Eniko] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Gacs, Alexandra] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Cserepes T., Mihaly] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tovari, Jozsef] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
RP Tatrai, E (reprint author), Orszagos Onkologiai Intezet, Kiserletes Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Telekes, A
   Kiss, I
AF Telekes, Andras
   Kiss, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Istvan] Semmelweis Egyetem, Geriatriai Tanszeki CsoportBudapest, Hungary.
RP Telekes, A (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Tokes, T
   Tokes, AM
   Szentmartoni, Gy
   Kiszner, G
   Madaras, L
   Kulka, J
   Krenacs, T
   Dank, M
AF Tokes, Timea
   Tokes, Anna-Maria
   Szentmartoni, Gyongyver
   Kiszner, Gergo
   Madaras, Lilla
   Kulka, Janina
   Krenacs, Tibor
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Timea] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Tokes, Anna-Maria] Hungarian Academy of Sciences, MTA-SE Tumor Progression Research GroupBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Kiszner, Gergo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Tokes, T (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 72
EP 73
PG 2
ER

PT J
AU Torok, K
   Agocs, L
   Kocsis, �
   Lang, Gy
   Meszaros, L
   Bogyo, L
   Farkas, A
   Gieszer, B
   Radeczky, P
   Ghimessy, �
   Renyi-Vamos, F
AF Torok, Klara
   Agocs, Laszlo
   Kocsis, Akos
   Lang, Gyorgy
   Meszaros, Laszlo
   Bogyo, Levente
   Farkas, Attila
   Gieszer, Balazs
   Radeczky, Peter
   Ghimessy, Aron
   Renyi-Vamos, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lang, Gyorgy] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Farkas, Attila] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Torok, K (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Toth, D
   Varga, Zs
   Kathy, S
   Kincses, Zs
   Bokor, L
AF Toth, Dezso
   Varga, Zsolt
   Kathy, Sandor
   Kincses, Zsolt
   Bokor, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Dezso] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
   [Varga, Zsolt] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
   [Kathy, Sandor] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
   [Kincses, Zsolt] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
   [Bokor, Laszlo] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
RP Toth, D (reprint author), Kenezy Teaching Hospital, Department of General Surgery, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Uhlyarik, A
   Lahm, E
   Papai, Zs
AF Uhlyarik, Andrea
   Lahm, Erika
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Uhlyarik, A (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 73
EP 74
PG 2
ER

PT J
AU Uhlyarik, A
   Kiss, E
   Kiss, N
   Lahm, E
   Nagy, Zs
   Nagy, P
   Sikter, M
   Szentesi, A
   Papai, Zs
AF Uhlyarik, Andrea
   Kiss, Edina
   Kiss, Nora
   Lahm, Erika
   Nagy, Zsofia
   Nagy, Peter
   Sikter, Marta
   Szentesi, Aniko
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Nora] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Zsofia] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Peter] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szentesi, Aniko] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Uhlyarik, A (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Ujhelyi, M
   Kelemen, P
   Pukancsik, D
   Savolt, �
   Matrai, Z
AF Ujhelyi, Mihaly
   Kelemen, Peter
   Pukancsik, David
   Savolt, Akos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Ujhelyi, M (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Ujhelyi, M
   Savolt, �
   Bidlek, M
   Kovacs, E
   Rubovszky, G
   Nyari, T
   Kenessey, I
   Udvarhelyi, N
   Bak, M
   Matrai, Z
AF Ujhelyi, Mihaly
   Savolt, Akos
   Bidlek, Maria
   Kovacs, Eszter
   Rubovszky, Gabor
   Nyari, Tibor
   Kenessey, Istvan
   Udvarhelyi, Nora
   Bak, Mihaly
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Ujhelyi, M (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 74
EP 75
PG 2
ER

PT J
AU Ujlaki, M
   Harkanyi, Z
   Bahery, M
   Godeny, M
AF Ujlaki, Matyas
   Harkanyi, Zoltan
   Bahery, Maria
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujlaki, Matyas] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Harkanyi, Zoltan] Heim Pal Gyermekkorhaz, Radiologiai OsztalyBudapest, Hungary.
   [Bahery, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Ujlaki, M (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Vajdics, T
   Biro, K
   Gyergyai, F
   Kuronya, Zs
   Nemeth, H
   Nagyivanyi, K
   Pozsar, J
   Tarpay, �
   Szmola, R
   Geczi, L
AF Vajdics, Timea
   Biro, Krisztina
   Gyergyai, Fruzsina
   Kuronya, Zsofia
   Nemeth, Hajnalka
   Nagyivanyi, Krisztian
   Pozsar, Jozsef
   Tarpay, Adam
   Szmola, Richard
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vajdics, Timea] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyai, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Hajnalka] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Pozsar, Jozsef] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Tarpay, Adam] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Szmola, Richard] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Vajdics, T (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 75
EP 76
PG 2
ER

PT J
AU Vass, N
   Kiss, K
AF Vass, Nagyezsda
   Kiss, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vass, Nagyezsda] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kiss, Krisztina] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Vass, N (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Vaszko, T
   Papp, J
   Gyuris, T
   Balint, BL
   Pocza, T
   Bozsik, A
   Olah, E
AF Vaszko, Tibor
   Papp, Janos
   Gyuris, Tibor
   Balint, Balint Laszlo
   Pocza, Timea
   Bozsik, Aniko
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Gyuris, Tibor] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Vaszko, T (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Vig, Zs
   Nagy, H
AF Vig, Zsuzsanna
   Nagy, Henriett
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vig, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Nagy, Henriett] ELTE PPK, Pszichologiai IntezetBudapest, Hungary.
RP Vig, Zs (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 76
EP 77
PG 2
ER

PT J
AU Vincze, E
   Plotar, V
   Toth, E
AF Vincze, Eszter
   Plotar, Vanda
   Toth, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vincze, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Vincze, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Virag, L
   Szabo, �
   Hegedus, Cs
   Kovacs, K
   Lakatos, P
AF Virag, Laszlo
   Szabo, Eva
   Hegedus, Csaba
   Kovacs, Katalin
   Lakatos, Petra
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Virag, Laszlo] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Szabo, Eva] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Hegedus, Csaba] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Kovacs, Katalin] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Lakatos, Petra] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
RP Virag, L (reprint author), University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular Biology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Vityi, T
   Koltai, L
   Muller, Z
   Elo, J
   Gorgey, Cs
AF Vityi, Tamas
   Koltai, Laszlo
   Muller, Zoltan
   Elo, Janos
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Koltai, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Elo, Janos] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Gorgey, Csaba] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Vityi, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 77
EP 78
PG 2
ER

PT J
AU Wind, A
   Nagy, P
   Marosi, E
   Lovey, J
   Podmaniczky, E
   Szabo, A
   Presti, P
   Kasler, M
   Van Harten, W
AF Wind, Anke
   Nagy, Peter
   Marosi, Edit
   Lovey, Jozsef
   Podmaniczky, Erzsebet
   Szabo, Annamaria
   Presti, Pietro
   Kasler, Miklos
   Van Harten, Wim
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wind, Anke] Netherlands Cancer Institute, Psychosocial Research and EpidemiologyAmsterdam, The Netherlands.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Marosi, Edit] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Podmaniczky, Erzsebet] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Szabo, Annamaria] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Presti, Pietro] European Cancer Patient CoalitionBrussels, Belgium.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Van Harten, Wim] Netherlands Cancer Institute, Psychosocial Research and EpidemiologyAmsterdam, The Netherlands.
RP Wind, A (reprint author), Netherlands Cancer Institute, Psychosocial Research and Epidemiology, Amsterdam, The Netherlands.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Zambo, K
   Szabo, Zs
   Szekeres, S
   Ban, Zs
   Schmidt, E
AF Zambo, Katalin
   Szabo, Zsuzsanna
   Szekeres, Sarolta
   Ban, Zsuzsanna
   Schmidt, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Katalin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szabo, Zsuzsanna] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szekeres, Sarolta] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Ban, Zsuzsanna] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Schmidt, Erzsebet] PTE KK, Radiologiai KlinikaPecs, Hungary.
RP Zambo, K (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 78
EP 78
PG 1
ER

PT J
AU Zarand, A
AF Zarand, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zarand, Attila] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
RP Zarand, A (reprint author), Semmelweis University, 1st Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 78
EP 79
PG 2
ER

PT J
AU Zidan, J
   Mzalbat, R
   Sharabi, A
   Mermerstein, W
AF Zidan, Jamal
   Mzalbat, Raneen
   Sharabi, Adi
   Mermerstein, Wilmosh
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zidan, Jamal] Ziv Medical Center, Oncology InstituteSafed, Israel.
   [Mzalbat, Raneen] Ziv Medical Center, Central LaboratorySafed, Israel.
   [Sharabi, Adi] Ziv Medical Center, Oncology InstituteSafed, Israel.
   [Mermerstein, Wilmosh] Soroka Medical Center, Department of OncologyBeer-Sheva, Israel.
RP Zidan, J (reprint author), Ziv Medical Center, Oncology Institute, Safed, Israel.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 79
EP 79
PG 1
ER

PT J
AU Zilahi, L
   Borbely, K
   Ferenczy, �
   Mendly, J
   Repa, I
AF Zilahi, Livia
   Borbely, Katalin
   Ferenczy, Eva
   Mendly, Jozsef
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zilahi, Livia] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Ferenczy, Eva] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Mendly, Jozsef] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
   [Repa, Imre] Kaposvari Egyetem, PET/MR DiagnosztikaKaposvar, Hungary.
RP Zilahi, L (reprint author), Kaposvari Egyetem, PET/MR Diagnosztika, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2015
VL 59
IS 5
BP 79
EP 79
PG 1
ER

PT J
TI In memoriam Dr. Petranyi Julia 1943–2015
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 3
EP 3
PG 1
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI Immunologic biomarkers in predicting the efficacy of cancer therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer therapy; immunotherapy; immune checkpoint inhibitors; biomarker; predictive marker
ID cancer therapy; immunotherapy; immune checkpoint inhibitors; biomarker; predictive marker
AB Immune checkpoint agents, representing a new class of immunotherapeutic modalities, have proven their beneficial effect inducing durable clinical response in a widening spectrum of tumor types. To enhance their efficacy it is of primary importance to search for biomarkers that could help predict the likelihood of therapeutic effect. Results of studies on potential predictive immunological parameters suggest that the existing antitumor immune activity detectable in the patients, although not sufficient to control tumor progression in itself, could increase the efficacy of different immunotherapies. Moreover, the contribution of immune reactions to the effect of other antitumor treatment modalities as chemo-, radio-, and targeted therapy has also been demonstrated. Combinations of immunotherapies with these and with each other will probably represent treatment approaches resulting in the highest therapeutic effect, which may necessitate the development of biomarker panels with multiple components characterizing the immune status of the patient and the tumor as well.
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM ladanyi@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 4
EP 10
PG 7
ER

PT J
AU Liszkay, G
AF Liszkay, Gabriella
TI Clinical studies and accepted therapies of advanced melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; immunotherapy; ipilimumab; pembrolizumab; nivolumab
ID melanoma; immunotherapy; ipilimumab; pembrolizumab; nivolumab
AB The objective of the work is presentation of the available therapeutic results of the clinical trials with anti CTLA-4 and anti PD-1 treatment, which are operating on the immune checkpoints registered in advanced melanoma, and the results of T-VEC vaccination (NCT00094653, NCT00324155, KEYNOTE-001, -002, -006, CheckMate-066, -037, -067, NCT00769704). With ipilimumab therapy, long-term survival can be achieved in the case of 20% of patients, with low (10%) therapeutic response, and grade 3-4 treatment related, predominantly autoimmune adverse events occurring in 10-15% of patients. Anti-PD-1 therapy proved more effective compared to ipilimumab, resulting in 21-40% therapeutic response, with 60-74% one-year survival rate and significantly less severe and frequent side effects. Progression-free survival achieved with ipilimumab/nivolumab combination was 11.5 months with grade 3-4 side effects occurring in 55% of patients. T-VEC therapy resulted in 26.4% objective response rate without a significant survival advantage. In the possession of the new immunotherapeutic possibilities, knowledge of the results of clinical studies is essential for the optimal complex therapy of melanoma.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM liszkay@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 11
EP 15
PG 5
ER

PT J
AU Olah, J
   Gyulai, R
AF Olah, Judit
   Gyulai, Rolland
TI How to choose the optimal therapy? New issues in the treatment of metastatic melanoma.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; targeted therapy; immunooncology; BRAF inhibitor; MEK inhibitor
ID melanoma; targeted therapy; immunooncology; BRAF inhibitor; MEK inhibitor
AB The last few years brought about a complete paradigm-shift in the field of melanoma therapy: eight new drugs, including three immunooncologic, four targeted and one oncolytic virus, became available in the daily practice. These new treatments provide a significantly increased overall survival potential for patients with metastatic melanoma. Choosing the optimal treatment for the individual patient, however, requires the careful evaluation of several patient- and drug-related factors, and poses a great challenge for the oncologists. This review summarizes the practical aspects of the selection of the optimal melanoma treatment.
C1 [Olah, Judit] University of Szeged, Department of Dermatology and Allergology, Koranyi fasor 6., 6720 Szeged, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, 6720 Szeged, Hungary.
EM lazarne.olah.judit@med.u-szeged.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 17
EP 21
PG 5
ER

PT J
AU Kovacs, P
   Panczel, G
   Melegh, K
   Balatoni, T
   Porneczy, E
   Lorincz, L
   Czirbesz, K
   Gorka, E
   Liszkay, G
AF Kovacs, Peter
   Panczel, Gitta
   Melegh, Krisztina
   Balatoni, Timea
   Porneczy, Edit
   Lorincz, Lenke
   Czirbesz, Kata
   Gorka, Eszter
   Liszkay, Gabriella
TI Psychological aspects of immunotherapies in the treatment of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE malignant melanoma; immunotherapy; depression; anxiety; psychoneuroimmunology
ID malignant melanoma; immunotherapy; depression; anxiety; psychoneuroimmunology
AB Psychological problems may arise in connection with oncomedical treatments in three ways: 1. acute and/or 2. chronic ways, as well as 3. co-morbid psychiatric diseases that already exist must also be taken into account. Immunotherapies have the most common and also clinically relevant psychological side effects. Fatigue, anhedonia, social isolation, psychomotor slowness is reported during treatment. Anti-CTLA-4 antibody (ipilimumab) immunotherapy can present one of the most modern opportunities for adequate treatment for patients having distant metastasis or unresectable tumour. In relation to immunotherapies, acute psychological side effects (acute stress) emerging during treatments develop in a way that can mostly be linked to environmental factors, e.g. notification of diagnosis, hospitalisation, progression, deterioration in quality of life, imminent dates of control. Crisis is a temporary and threatening condition that endangers psychological balance. In such conditions, enhanced psychological vulnerability must be taken into account and doctors play a key role in the rapid recognition of the condition. Chronic psychological problems, which may arise from the depressogenic effect of the applied treatment or originated from a pre-melanoma psychiatric condition, may exceed the diagnostic and psychotherapeutic competences of a clinical psychologist. Even in case of a well-defined depressogenic biological mechanism such as the activation of the pro-inflammatory cytokine pathway, positive environmental effects can reduce symptoms and thus increase compliance. Side effects can be treated successfully using psychotherapeutic methods and/or psychiatric medicines. The application of routinely used complex psychosocial screening packages can provide the easiest method to identify worsening psychological condition during immunotherapy and give rapid feedback to the oncologist and the patient. Team work is of particular importance in a situation like this as it requires complex, interdisciplinary and high-level professional collaboration. Multidisciplinarity is the basic framework for modern tumour therapy where, under the guidance of oncologists, the work of specialist nurses, social workers, physiotherapists, dieticians and last but not least psychiatrists/psychologists are indispensable and play a significant role.
C1 [Kovacs, Peter] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Melegh, Krisztina] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lorincz, Lenke] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kovacs, P (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 22
EP 27
PG 6
ER

PT J
AU Moldvay, J
   Ostoros, Gy
AF Moldvay, Judit
   Ostoros, Gyula
TI Self defense instead of offense – Immunotherapy in lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; immunotherapy; PD-1-; PD-L1-; CTLA-4 inhibition
ID lung cancer; immunotherapy; PD-1-; PD-L1-; CTLA-4 inhibition
AB Lung cancer is the leading cause of cancer death worldwide and also in Hungary, therefore new therapeutic strategies are of great importance. Among immunotherapeutic approaches immune checkpoint inhibition appears to be the most promising. Recent studies have shown efficacy of immunotherapy, especially in squamous cell lung cancer, which is a big step forward in the treatment of this histological subtype. Unlike in the molecularly targeted therapies, the patient selection method has not yet been developed, although some studies indicate the predictive value of tumor cell PD-L1 immunopositivity, especially in lung adenocarcinoma. Introduction of immunotherapy carries challenge for clinicians regarding the radiological assessment of therapeutic efficiency as well as the management of side effects of new profile. The favorable results of recent studies, however, provide hope in this malignancy still presenting a major therapeutic challenge.
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor Biology, Piheno u. 1., 1121 Budapest, Hungary.
   [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, TudobelosztalyBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, 1121 Budapest, Hungary.
EM drmoldvay@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 28
EP 33
PG 6
ER

PT J
AU Pusztai, L
   Ladanyi, A
   Szekely, B
   Dank, M
AF Pusztai, Lajos
   Ladanyi, Andrea
   Szekely, Borbala
   Dank, Magdolna
TI Immunotherapy opportunities in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; immunotherapy; immune checkpoints; immune markers; immune surveillance
ID breast cancer; immunotherapy; immune checkpoints; immune markers; immune surveillance
AB The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20% tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.
C1 [Pusztai, Lajos] Yale School of Medicine, Yale Cancer Center, Breast Medical Oncology, 333 Cedar Street, 06520-8032 New Haven, CT, USA.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szekely, Borbala] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
RP Pusztai, L (reprint author), Yale School of Medicine, Yale Cancer Center, Breast Medical Oncology, 06520-8032 New Haven, USA.
EM lajos.pusztai@yale.edu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 34
EP 40
PG 7
ER

PT J
AU Geczi, L
   Ladanyi, A
   Vajdics, T
   Kuronya, Zs
   Biro, K
   Gyergyay, F
   Martin, T
   Nagyivanyi, K
AF Geczi, Lajos
   Ladanyi, Andrea
   Vajdics, Timea
   Kuronya, Zsofia
   Biro, Krisztina
   Gyergyay, Fruzsina
   Martin, Tamas
   Nagyivanyi, Krisztian
TI Immunotherapy in the treatment of genitourinary cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immunotherapy; ipilimumab; nivolumab; CTLA-4; PD-1; PD-L1
ID immunotherapy; ipilimumab; nivolumab; CTLA-4; PD-1; PD-L1
AB In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vajdics, Timea] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Martin, Tamas] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM gelajos@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 41
EP 45
PG 5
ER

PT J
AU Lumniczky, K
   Safrany, G
AF Lumniczky, Katalin
   Safrany, Geza
TI The effect of radiotherapy on the antitumor immune response. Possibilities to combine radiotherapy with immunotherapy.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE malignant tumors; combined therapy; radiotherapy; immunotherapy; antitumor immunity
ID malignant tumors; combined therapy; radiotherapy; immunotherapy; antitumor immunity
AB The past three decades of immunology research led to a drastic increase in the knowledge of antitumor immune response mechanisms and in parallel to a rapid development in various antitumor immune therapy strategies. This will most probably result in the implementation of immunotherapeutic protocols within the standard anticancer regimens in a very near future. Though, it is obvious that combination of immunotherapy with traditional anticancer treatment modalities will only be legitimate if the combination has at least an additive, or perhaps a synergistic effect. The similarly dynamic progress in the radiobiological knowledge proved that ionizing radiation does not have a general immune suppressing effect, as it has been thought for decades, but might possess certain immune stimulatory effects, as well. It is also known by now that local irradiation due to its out-of-field effects has systemic immune modulatory capacity, too. In the light of all these novel findings the optimal combination between antitumor immunotherapy and radiotherapy has become an increasing option. The first part of the present review summarizes the main antitumor mechanisms that can be influenced by ionizing radiation, and the second part attempts to provide a comprehensive overview of those antitumor immunotherapeutic modalities that are currently being used in combination with radiotherapy in preclinical and/or clinical trials for the treatment of various tumors.
C1 [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna u. 5., 1221 Budapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Anna u. 5., 1221 Budapest, Hungary.
RP Lumniczky, K (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, 1221 Budapest, Hungary.
EM lumniczky.katalin@osski.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 46
EP 54
PG 9
ER

PT J
AU Muzes, Gy
   Sipos, F
AF Muzes, Gyorgyi
   Sipos, Ferenc
TI Tumorigenesis: interplay of pattern recognition receptors and autophagy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE autophagy; Toll-like receptor; tumorigenesis; inflammation; immune response
ID autophagy; Toll-like receptor; tumorigenesis; inflammation; immune response
AB According to recent data, the involvement of autophagy in tumor development is unquestionable. Nevertheless, cell-derived pathogen/danger-associated molecular pattern (PAMP/DAMP)-sensing Toll-like receptors (TLRs) are also able to contribute to tumorigenesis and immune escape of malignantly transformed cells. Besides immunocompetent cells, several types of tumors also exhibit TLRs. TLR- and autophagy-related signaling pathways, on the other hand, may evolve anti-tumor effects in a context dependent cell- and microenvironment-specific mode. Nowadays, the autophagy machinery has been considered as a crucial homeostatic process of eukaryotic cells, and as essential constituent of the immune system influencing antimicrobial and inflammation-related immune responses. Accumulating evidence indicates that TLRs and autophagy are interdependent in response to PAMPs and DAMPs, in addition there is a bi-directional controling cross-modulation between them. Regarding personalized medicine, theoretically, it is reasonable that manipulation of the TLR-autophagy regulatory loop might be adaptable for anti-cancer therapy.
C1 [Muzes, Gyorgyi] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
   [Sipos, Ferenc] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
RP Muzes, Gy (reprint author), Semmelweis University, 2nd Department of Internal Medicine, 1088 Budapest, Hungary.
EM muzes.gyorgyi@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 55
EP 63
PG 9
ER

PT J
AU Kotlan, B
   Csuka, O
   Toth, L
   Farkas, E
   Plotar, V
   Horvath, Sz
   Eles, K
   Olasz, J
   Toth, J
   Kasler, M
   Liszkay, G
AF Kotlan, Beatrix
   Csuka, Orsolya
   Toth, Laszlo
   Farkas, Emil
   Plotar, Vanda
   Horvath, Szabolcs
   Eles, Klara
   Olasz, Judit
   Toth, Jozsef
   Kasler, Miklos
   Liszkay, Gabriella
TI Genetic information from tumor-infiltrating B lymphocytes as a driver tool (“GPS”) for anti-tumor T cell CARs
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE tumor-infiltrating B lymphocytes; chimeric antigen receptor; disialylated glycosphingolipids
ID tumor-infiltrating B lymphocytes; chimeric antigen receptor; disialylated glycosphingolipids
AB The rapidly growing field of gene therapy techniques to modify T cells with chimeric antigen receptors (CARs) for cancer care solutions, reached considerable achievements. However, there is an urgent need of reliable, well tolerable tumor-associated antigen specific antibodies. Tumor-infiltrating B (TIL-B) cell originated single chain Fv (scFv) gene regions could be selected with tumor specificity. DNA sequences of these antibody variable regions were subjects to get engineered into new CAR constructs. Our novel strategy harnesses tumor-infiltrating B cells’ unique capacity to reveal highly tumor-associated disialylated glycosphingolipids (GD3 gangliosides). We used these human antibody fragments for generating GD3 ganglioside specific CAR gene constructs for potential usage in solid tumors.
C1 [Kotlan, Beatrix] National Institute of Oncology, Department of Biochemistry, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Jozsef] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kotlan, B (reprint author), National Institute of Oncology, Department of Biochemistry, 1122 Budapest, Hungary.
EM kotlanb@netscape.net
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 64
EP 71
PG 8
ER

PT J
AU Tarjan, M
AF Tarjan, Miklos
TI Diagnostic problems and prognostic factors in prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE ductal adenocarcinoma; immunohistochemistry; large section histopathology; 3D pathology; radical prostatectomy; extracapsular extension
ID ductal adenocarcinoma; immunohistochemistry; large section histopathology; 3D pathology; radical prostatectomy; extracapsular extension
AB We aimed to refine the methodology for discriminating ductal (DAP) and acinar adenocarcinomas (AAP) of the prostate preoperatively with a high degree of accuracy, and confirm that prostate carcinoma of ductal origin is a more aggressive subtype. Moreover, we intended to evaluate the clinical utility of transrectal ultrasound-guided systematic sextant or octant biopsies in prediction of extracapsular extension (ECE) at radical prostatectomy. A blinded retrospective analysis of 3-dimensional histology specimens from 110 consecutive radical prostatectomy (RP) cases operated between 2000 and 2006 was carried out (average follow-up: 5.1 years). The samples were also analyzed for 9 different biomarkers. We performed a retrospective analysis of 84 cases of patients who underwent transrectal ultrasound-guided systematic sextant (in 60 cases) or octant (in 24 cases) biopsy. The presence of ECE was correlated to the number of positive biopsies on each side of the prostate by chi-square analysis. Sensitivity, specificity, positive and negative predictive values were calculated for both positive (two or three positive biopsies per side) and negative (no or only one positive biopsy per side) test results. The number of positive cores was thereafter combined with two other parameters: prostate-specific antigen (PSA) and Gleason score. 3-dimensional and conventional histology classified 97 cases of AAP and 13 cases of DAP. DAP cases had a significantly greater frequency of pT3a and more advanced cancers (p<0.0001), >20 mm tumor focus (p=0.0020), highgrade PIN (p=0.0079), Gleason score ≥7 (p<0.0001), positive surgical margin (p=0.0219), ECE (p<0.0001), vascular invasion (p=0.0033), seminal vesicle infiltration (p=0.0213), biochemical/local recurrence (p=0.0015), regional lymph node metastases and distant metastases (p<0.0001). Three biomarkers in combination (chromogranine A, EGFR, p53) distinguished DAP from AAP with an accuracy of 94% (AUC 0.94; 95% CI: 0.88–0.99). ECE was evidenced at RP in 24% (20/84) of the patients. Chi-square analysis demonstrated a significant correlation between the number of positive biopsies and presence of ECE. Analysis of the 168 prostate sides and dominant sides revealed that systematic needle biopsies had a positive predictive value of 46.7% and 37% and a negative predictive value of 89%, and 94%, respectively. Combination of parameters (biopsy Gleason score ≥7 vs. <7, PSA >10 ng/ml vs. ≤10 ng/ml and more than one positive cores vs. 0 or 1 positives) identified patients at high or low risk of ECE, respectively. On the extremes, with only lowrisk parameters none of the 10 patients, while 77% of those with high-risk group had ECE at RP. Both 3-dimensional histology and the three selected biomarkers can accurately distinguish DAP from AAP. This discriminatory ability offers AAP cases less radical treatment regimens and emphasizes the need to develop more effective treatment regimens for DAP cases. The probability of ECE at radical prostatectomy can be accurately predicted based on the number of positive sextant and octant biopsies, solely or in combination with other parameters.
C1 [Tarjan, Miklos] Szegedi Tudomanyegyem, Doktori IskolaSzeged, Hungary.
RP Tarjan, M (reprint author), Szegedi Tudomanyegyem, Doktori Iskola, Szeged, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 72
EP 77
PG 6
ER

PT J
AU Toth, V
AF Toth, Veronika
TI Necessity of the development of a melanoma prevention program in Hungary - in the light of epidemiological data
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE melanoma; stage; screening; atomic power plant; second primary tumor
ID melanoma; stage; screening; atomic power plant; second primary tumor
AB The prevention and the early diagnosis of melanoma malignum are essential because of the aggressive spreading and poor therapeutic response of the tumor. Since survival mainly depends on the tumor stage, in the first part of the Ph.D. thesis the stage distribution of melanomas was assessed in the melanoma patients treated at the Department of Dermatology, Dermatooncology and Venerology, Semmelweis University. This work filled a gap, because the Hungarian National Cancer Registry, similarly to other cancer registries, does not include the tumor stages. The results of the assessment showed that most of the patients (43.8%) belonged to stage IA, while only 0.4% of them were in stage IV. In comparison with international studies from Western Europe, Australia and the United States, the distribution of our patients was highly favorable concerning stages IA and IV. To assess the risk of melanoma among special work circumstances (Nuclear Power Plant of Paks) the Department of Dermatology, Dermatooncology and Venerology organized an oncodermatological screening. The results of the screening confirmed that melanoma incidence was not elevated among the nuclear industry workers compared to the general Hungarian population. Among the 556 examined workers we found one melanoma in situ, and the medical history of this patient suggested that UV exposure rather than ionizing radiation could have been the cause of this tumor. Our results also underline the necessity of analyzing skin effects of UV light to avoid false positive correlations. The risk of second primary cancers among melanoma survivors was also assessed in our Department. The findings suggest that the risk of all second primary tumors significantly, 11-15-times increased after having a former melanoma, compared to the general population. The higher risk was mostly caused by the elevated incidence of second primary melanoma and non-melanoma skin cancers. Besides skin tumors, the risk of some internal malignancies was also significantly higher. Our results emphasize that the regular oncologic control is crucial after having melanoma in order to diagnose a second skin or internal malignancy early. Melanoma awareness, primary and secondary prevention programs would be highly necessary to decrease the number of new melanomas, to increase the rate of the early diagnosed tumors and to improve survival.
C1 [Toth, Veronika] Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Maria utca 41., 1085 Budapest, Hungary.
RP Toth, V (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, 1085 Budapest, Hungary.
EM toveroka@yahoo.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2016
VL 60
IS 1
BP 78
EP 83
PG 6
ER

PT J
AU Kiraly, PA
   Alpar, D
   Fesus, V
   Marosvari, D
   Matolcsy, A
   Bodor, Cs
AF Kiraly, Peter Attila
   Alpar, Donat
   Fesus, Viktoria
   Marosvari, Dora
   Matolcsy, Andras
   Bodor, Csaba
TI Introduction to the molecular diagnostic methods of oncohematology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oncohematology; molecular diagnostics; MRD monitoring; targeted therapy
ID oncohematology; molecular diagnostics; MRD monitoring; targeted therapy
AB Owing to our rapidly expanding knowledge on the genetic background of various oncohematologic diseases and the introduction of novel targeted therapies, molecular genetic techniques have been playing an increasingly important role in the diagnostics and follow-up of hematological malignancies. The various DNA- and RNA-based in situ hybridization, polymerase chain reaction and sequencing technologies are of key significance in diagnostics, classification and prognostic assessment of these diseases, as well as in the monitoring of minimal residual disease and selection of the most appropriate targeted therapy. This review provides an overview on the background and applications of the molecular methods most commonly used in oncohematological diagnostics.
C1 [Kiraly, Peter Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Alpar, Donat] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Fesus, Viktoria] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Marosvari, Dora] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Matolcsy, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Bodor, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bodor.csaba1@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 88
EP 98
PG 11
ER

PT J
AU Szepesi, �
AF Szepesi, Agota
TI Molecular and histological features of diffuse large B-cell lymphoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE diffuse large B-cell lymphoma; germinal center B cell; activated B cell; prognostic factor; biomarker
ID diffuse large B-cell lymphoma; germinal center B cell; activated B cell; prognostic factor; biomarker
AB Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoproliferative disease of mature B cells, representing the most common lymphoid malignancy of adulthood. There are multiple distinct subgroups of DLBCL in the 2008 WHO classification, organ specific forms, DLBCL associated with immunodeficiency and viral infections and rare CD20 negative and intermediate forms. However, most of the cases are still classified under the DLBCL not otherwise specified (NOS) category. This group of disease shows remarkable heterogeneity with respect to clinical presentation, biology and response to treatment, reflecting several molecular subgroups: the origin of B cells at various developmental stages, the oncogenic pathways that drive tumor development and also epigenetic changes and mutations involving the escape of immune surveillance. Contemporary chemo-immunotherapy does not result in durable remissions in as many as 30% of the cases. To achieve longer survival, the definition of new biomarkers are needed for targeted therapy based on better subgrouping of tumors according to the molecular pathways involved in lymphomagenesis. This paper summarizes the most important features influencing the outcome of this broad disease at the level of morphology, phenotype and genotype and gives a guideline for the routine pathological practice at present for the diagnostics of DLBCL treated by chemo-immunotherapy.
C1 [Szepesi, Agota] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Szepesi, � (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM szepesi.agota@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 99
EP 107
PG 9
ER

PT J
AU Paksi, M
   Demeter, J
   Szabo, P
AF Paksi, Melinda
   Demeter, Judit
   Szabo, Peter
TI The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE diffuse large B-cell lymphoma; PET/CT; staging; response; prognosis
ID diffuse large B-cell lymphoma; PET/CT; staging; response; prognosis
AB Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). Although this lymphoma is curable, 40% of patients with DLBCL will die of relapsed or refractory disease. 18F-Fluoro-deoxyglucose positron emission tomography (FDG-PET) is a noninvasive, 3-dimensional, functional imaging modality. When combined with the anatomical imaging tool computed tomography (CT), PET/CT can differentiate among others necrotic masses and viable tumors. PET scan has become a basic clinical tool for staging and response assessment in aggressive lymphomas, such as DLBCL. It has been evaluated in pretreatment staging, restaging, monitoring during therapy, post-therapy surveillance and assessment of transformation. Based on the preliminary results of several studies FDG-PET scans play an important role in the early assessment of treatment response, in planning of the treatment including radiation therapy and in the estimation of prognosis.
C1 [Paksi, Melinda] Semmelweis University, 1st Department of Internal Medicine, Ulloi ut 26., 1085 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Ulloi ut 26., 1085 Budapest, Hungary.
   [Szabo, Peter] Scanomed Orvosi Diagnosztikai Kutato es Oktato Kft.Budapest, Hungary.
RP Paksi, M (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1085 Budapest, Hungary.
EM drpakmel@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 108
EP 117
PG 10
ER

PT J
AU Marosvari, D
   Alpar, D
   Kiraly, PA
   Rajnai, H
   Reiniger, L
   Bodor, Cs
AF Marosvari, Dora
   Alpar, Donat
   Kiraly, Peter Attila
   Rajnai, Hajnalka
   Reiniger, Lilla
   Bodor, Csaba
TI The genetic landscape of chronic lymphocytic leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE chronic lymphocytic leukemia; next-generation sequencing; driver mutations; clonal evolution
ID chronic lymphocytic leukemia; next-generation sequencing; driver mutations; clonal evolution
AB Chronic lymphocytic leukemia (CLL) is the most frequent mature B-cell non-Hodgkin’s lymphoma in the Western countries. The recent next-generation sequencing (NGS) studies lead to an exponential increase in our knowledge of the pathogenesis and progression of CLL. Whole genome and exome sequencing studies revealed a remarkable inter- and intra-patient genetic heterogeneity with a significant therapy-induced clonal evolution in the majority of the patients. Driver mutations were identified in components of various signalling pathways and cellular processes with notable prognostic and therapeutic relevance. Interestingly, these studies revealed only a few genes mutated in at least 15-20% of the patients with a larger number of genes mutated in a smaller proportion of patients. This improved understanding of the genomic landscape of CLL has opened new avenues for a more precise patient stratification and rational application of novel, more effective targeted therapies.
C1 [Marosvari, Dora] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Alpar, Donat] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kiraly, Peter Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Rajnai, Hajnalka] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Bodor, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bodor.csaba1@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 118
EP 125
PG 8
ER

PT J
AU Mucsi, O
AF Mucsi, Orsolya
TI Treatment of patients with chronic lymphocytic leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE treatment; chronic lymphocytic leukemia; immunochemotherapy; ibrutinib
ID treatment; chronic lymphocytic leukemia; immunochemotherapy; ibrutinib
AB Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western countries. The abnormal B lymphocytes progress into the blood and infiltrate the bone marrow, liver, spleen and lymph nodes. CLL is a disease of the adults and older individuals who often have coexisting conditions. It usually progresses slowly, but in patients who need treatment, CLL eventually returns. For relapsed, refractory patients treatment options are limited. The only curative treatment is bone marrow transplantation. However, the new, alternative therapeutics show superior efficacy in CLL than standard regimens. The aim of this review is to summarize the most important therapeutic aspects of CLL and to give an insight into the novel treatment options.
C1 [Mucsi, Orsolya] Semmelweis University, 1st Department of Internal Medicine, Ulloi ut 26., 1085 Budapest, Hungary.
RP Mucsi, O (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1085 Budapest, Hungary.
EM orsolya.mucsi@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 127
EP 136
PG 10
ER

PT J
AU Sari, E
   Rajnai, H
   Denes, K
   Bodor, Cs
   Csomor, J
   Korosmezey, G
   Tarkanyi, I
   Eid, H
   Nagy, Zs
   Demeter, J
AF Sari, Eszter
   Rajnai, Hajnalka
   Denes, Kitti
   Bodor, Csaba
   Csomor, Judit
   Korosmezey, Gabor
   Tarkanyi, Ilona
   Eid, Hanna
   Nagy, Zsolt
   Demeter, Judit
TI Novelties in the diagnostics and therapy of hairy cell leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE hairy cell leukemia; cladribine; vemurafenib; BRAF
ID hairy cell leukemia; cladribine; vemurafenib; BRAF
AB Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.
C1 [Sari, Eszter] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Rajnai, Hajnalka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Denes, Kitti] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Korosmezey, Gabor] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Tarkanyi, Ilona] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Eid, Hanna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
RP Demeter, J (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1078 Budapest, Hungary.
EM demeter.judit@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 137
EP 144
PG 8
ER

PT J
AU Timar, B
AF Timar, Botond
TI The pathology and genetic background of myeloma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE plasma cell; myeloma; genetics; subclonality
ID plasma cell; myeloma; genetics; subclonality
AB Plasma cell myeloma is a heterogeneous hematologic malignancy of plasma cells, occurring dominantly in the elderly population. It is now accepted that all myeloma cases are preceded by a clinically silent expansion of clonal plasma cells, known as monoclonal gammopathy of undetermined significance. Our knowledge on the genetics of myeloma is still limited and lags behind other well-characterized hematological malignancies. One of the reasons of this fact is the difficulty to induce metaphases within the malignant plasma cell population. With the development of new molecular techniques (microarrays and next generation sequencing), our understanding of the pathogenesis and progression of myeloma has been highly improved in the past years. This review offers an insight into this newly gained knowledge.
C1 [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Timar, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM timar.botond@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 145
EP 153
PG 9
ER

PT J
AU Nagy, Zs
AF Nagy, Zsolt
TI Multiple myeloma and other plasma cell dyscrasias
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE MGUS; SMM; MM; diagnosis; treatment
ID MGUS; SMM; MM; diagnosis; treatment
AB Multiple myeloma is the most common primary malignant disease of bone marrow. It mainly occurs among elderly people and, according to international databases, it is twice as frequent in men, however in our country this fact cannot be observed because of the high male mortality rate. The presence of this disease increased by more than one and the half times during the last 60 years. The five year survival for multiple myeloma has increased from 25% to 40% since the seventies due to high-dose chemotherapy followed by autologous stem cell transplantation and the new anti-myeloma drugs which were introduced in the last decade, such as immunomodulators (IMiD) like thalidomide, lenalidomide, pomalidomide and proteasome inhibitors (PI) like bortezomib, carfilzomib, ixazomib. The number of treatment options are growing fast, and not only because of using new combinations of medications, but also due to the development of investigational products which are available for the patients by participating in a clinical trial.
C1 [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Ulloi ut 26., 1085 Budapest, Hungary.
RP Nagy, Zs (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1085 Budapest, Hungary.
EM nagy.zsolt@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 154
EP 163
PG 10
ER

PT J
AU Istenes, I
   Nagy, Zs
   Demeter, J
AF Istenes, Ildiko
   Nagy, Zsolt
   Demeter, Judit
TI Chemotherapy-induced peripheral neuropathy: characteristics, diagnosis and treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE chemotherapy-induced peripheral neuropathy; sensory neuropathy; proteasome inhibitors; platinum compounds; vinca alkaloids; taxanes; brentuximab vedotin; angiogenesis inhibitors
ID chemotherapy-induced peripheral neuropathy; sensory neuropathy; proteasome inhibitors; platinum compounds; vinca alkaloids; taxanes; brentuximab vedotin; angiogenesis inhibitors
AB Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients’ quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.
C1 [Istenes, Ildiko] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Koranyi S. u. 2/A, 1078 Budapest, Hungary.
RP Istenes, I (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1078 Budapest, Hungary.
EM istildi78@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2016
VL 60
IS 2
BP 165
EP 175
PG 11
ER

PT J
AU Forrai, G
   Ambrozay, �
   Bidlek, M
   Borbely, K
   Kovacs, E
   Lengyel, Zs
   Ormandi, K
   Pentek, Z
   Riedl, E
   Sebo, �
   Szabo, �
AF Forrai, Gabor
   Ambrozay, Eva
   Bidlek, Maria
   Borbely, Katalin
   Kovacs, Eszter
   Lengyel, Zsolt
   Ormandi, Katalin
   Pentek, Zoltan
   Riedl, Erika
   Sebo, Eva
   Szabo, Eva
TI Use of imaging methods in the current screening, diagnostics and treatment of breast cancer – Professional guidelines. 3rd Breast Cancer Consensus Meeting.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE mammography; breast ultrasound; breast screening; breast MRI; biopsy; PET/CT
ID mammography; breast ultrasound; breast screening; breast MRI; biopsy; PET/CT
AB Breast radiologists and nuclear medical specialists have refreshed their previous statement text during the 3rd Hungarian Breast Cancer Consensus Meeting. They suggest taking into consideration this actual protocol for the screening, diagnostics and treatment of breast tumors, from now on. This recommendation includes the description of the newest technologies, the recent results of scientific research, as well as the role of imaging methods in the therapeutic processes and the follow-up. Suggestions for improvement of the Hungarian current practice and other related issues as forensic medicine, media connections, regulations, and reimbursement are also detailed. The statement text has been cross-checked with the related medical disciplines.
C1 [Forrai, Gabor] Duna Medical Center, Lechner Odon fasor 7., 1095 Budapest, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Bidlek, Maria] National Institute of OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Ormandi, Katalin] University of SzegedSzeged, Hungary.
   [Pentek, Zoltan] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Riedl, Erika] Honved KorhazBudapest, Hungary.
   [Sebo, Eva] Kenezy Teaching HospitalDebrecen, Hungary.
   [Szabo, Eva] Perla Kft.Erd, Hungary.
RP Forrai, G (reprint author), Duna Medical Center, 1095 Budapest, Hungary.
EM forrai.gabor@t-online.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 181
EP 193
PG 13
ER

PT J
AU Lazar, Gy
   Bursics, A
   Farsang, Z
   Harsanyi, L
   Kosa, Cs
   Maraz, R
   Matrai, Z
   Paszt, A
   Pavlovics, G
   Tamas, R
AF Lazar, Gyorgy
   Bursics, Attila
   Farsang, Zoltan
   Harsanyi, Laszlo
   Kosa, Csaba
   Maraz, Robert
   Matrai, Zoltan
   Paszt, Attila
   Pavlovics, Gabor
   Tamas, Robert
TI 3rd Hungarian Breast Cancer Consensus Conference – Surgery Guidelines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE surgical therapy; breast cancer; sentinel lymph node; oncoplastic principles
ID surgical therapy; breast cancer; sentinel lymph node; oncoplastic principles
AB Therapy for breast cancer today is characterised by ever more precise diagnostic methods and ever more effective oncological treatments, a trend which will certainly continue in the future. Breast preservation and the application of oncoplastic principles are increasingly popular. A sentinel lymph node biopsy in the surgical treatment of the axilla is primary, with the indication for axillary block dissection (ABD) narrowing and radiation therapy becoming an alternative to ABD in certain cases. This publication summarises our recommendations on the surgical treatment of breast cancer based on the content of the 2nd Breast Cancer Consensus Conference and considering the latest international studies and professional recommendations.
C1 [Lazar, Gyorgy] University of Szeged, Department of Surgery, Szokefalvi-Nagy u. 6., 6720 Szeged, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Farsang, Zoltan] Allami Egeszsegugyi Kozpont, SebeszetBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Kosa, Csaba] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Paszt, Attila] University of Szeged, Department of Surgery, Szokefalvi-Nagy u. 6., 6720 Szeged, Hungary.
   [Pavlovics, Gabor] University of Pecs, Department of SurgeryPecs, Hungary.
   [Tamas, Robert] Honved KorhazBudapest, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Department of Surgery, 6720 Szeged, Hungary.
EM gylazar@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 194
EP 207
PG 14
ER

PT J
AU Cserni, G
   Kulka, J
   Francz, M
   Jaray, B
   Kalman, E
   Kovacs, I
   Krenacs, T
   Udvarhelyi, N
   Vass, L
AF Cserni, Gabor
   Kulka, Janina
   Francz, Monika
   Jaray, Balazs
   Kalman, Endre
   Kovacs, Ilona
   Krenacs, Tibor
   Udvarhelyi, Nora
   Vass, Laszlo
TI Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; consensus conference; pathology; recommendations; diagnostics
ID breast cancer; consensus conference; pathology; recommendations; diagnostics
AB There have been relevant changes in the diagnosis and treatment of breast cancer to implement the updating of the 2010 recommendations made during the 2nd national consensus conference on the disease. Following a wide interdisciplinary consultation, the present recommendations have been finalized after their public discussion at the 3rd Hungarian Consensus Conference on Breast Cancer. The recommendations cover non-operative and intraoperative diagnostics, the work-up of operative specimens, the determination of prognostic and predictive markers and the content of the cytology and histology reports. Furthermore, it touches some special issues such as the current status of multigene molecular markers, the role of pathologists in clinical trials and prerequisites for their involvement, some relevant points about the future.
C1 [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of Pathology, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Francz, Monika] Josa Andras Teaching Hospital, Department of PathologyNyiregyhaza, Hungary.
   [Jaray, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Kovacs, Ilona] Kenezy Teaching Hospital, Department of PathologyDebrecen, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Vass, Laszlo] Flor Ferenc University Hospital of Pest County, Department. of Pathology/CytopathologyKistarcsa, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, 6000 Kecskemet, Hungary.
EM cserni@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 209
EP 228
PG 20
ER

PT J
AU Polgar, Cs
   Kahan, Zs
   Csejtei, A
   Gabor, G
   Landherr, L
   Mangel, L
   Mayer, �
   Fodor, J
AF Polgar, Csaba
   Kahan, Zsuzsanna
   Csejtei, Andras
   Gabor, Gabriella
   Landherr, Laszlo
   Mangel, Laszlo
   Mayer, Arpad
   Fodor, Janos
TI 3rd Hungarian Breast Cancer Consensus Conference – Radiotherapy Guidelines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; radiotherapy; guidelines
ID breast cancer; radiotherapy; guidelines
AB The radiotherapy expert panel revised and updated the radiotherapy (RT) guidelines accepted in 2009 at the 2nd Hungarian Breast Cancer Consensus Conference based on new scientific evidence. Radiotherapy of the conserved breast is indicated in ductal carcinoma in situ (St. 0), as RT decreases the risk of local recurrence by 60%. In early stage (St. I-II) invasive breast cancer RT remains a standard treatment following breast conserving surgery. However, in elderly (≥70 years) patients with stage I, hormone receptor positive tumour hormonal therapy without RT can be considered. Hypofractionated (15×2.67 Gy) whole breast irradiation and for selected cases accelerated partial breast irradiation are validated treatment alternatives of conventional (25×2 Gy) whole breast irradiation. Following mastectomy RT significantly decreases the risk of locoregional recurrence and improves overall survival of patients having 1 to 3 (pN1a) or ≥4 (pN2a, pN3a) positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be omitted and substituted with axillary RT. After neoadjuvant chemotherapy (NAC) followed by breast conserving surgery whole breast irradiation is mandatory, while after NAC followed by mastectomy locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM polgar@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 229
EP 239
PG 11
ER

PT J
AU Horvath, Zs
   Boer, K
   Dank, M
   Kahan, Zs
   Kocsis, J
   Kover, E
   Pajkos, G
   Piko, B
   Rubovszky, G
   Eckhardt, S
AF Horvath, Zsolt
   Boer, Katalin
   Dank, Magdolna
   Kahan, Zsuzsanna
   Kocsis, Judit
   Kover, Erika
   Pajkos, Gabor
   Piko, Bela
   Rubovszky, Gabor
   Eckhardt, Sandor
TI Systemic therapy of breast cancer: practice guideline.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE early breast cancer; locally advanced breast cancer; adjuvant treatment; neoadjuvant treatment; metastatic breast cancer; inflammatory breast cancer; breast cancer during pregnancy; male breast cancer; guideline
ID early breast cancer; locally advanced breast cancer; adjuvant treatment; neoadjuvant treatment; metastatic breast cancer; inflammatory breast cancer; breast cancer during pregnancy; male breast cancer; guideline
AB The article presents the practice guideline of systemic treatment of breast cancer and recommendations of the 3rd Hungarian Breast Cancer Consensus Conference. It reflects the recent international guidelines (ESMO, NCCN, ABC2, St Gallen’s) irrespectively of the current financial opportunities. Here we follow the early – locally advanced – locally relapsed – metastatic breast cancer line for didactic considerations and we discuss the different subgroups of breast cancer based on hormone receptor and HER2 receptor status. Diagnosis and treatment options of rare clinical entities are summarised at the end of the paper.
C1 [Horvath, Zsolt] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Rubovszky, Gabor] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Eckhardt, Sandor] National Institute of OncologyBudapest, Hungary.
RP Horvath, Zs (reprint author), University of Debrecen, Department of Oncology, 4032 Debrecen, Hungary.
EM horvathzsolt@med.unideb.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 241
EP 257
PG 17
ER

PT J
AU Kahan, Zs
   Szanto, I
   Molnar, M
   Rohanszky, M
   Koncz, Zs
   Mailath, M
   Kapitany, Zs
   Dudas, R
AF Kahan, Zsuzsanna
   Szanto, Istvan
   Molnar, Maria
   Rohanszky, Magda
   Koncz, Zsuzsa
   Mailath, Monika
   Kapitany, Zsuzsanna
   Dudas, Rita
TI Breast cancer: patient care, rehabilitation, psychooncology.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; follow-up; social rehabilitation; physical rehabilitation; psychological rehabilitation
ID breast cancer; follow-up; social rehabilitation; physical rehabilitation; psychological rehabilitation
AB The development of a recommendation was intended for the follow-up of breast cancer patients treated with curative intent in Hungary. Follow-up includes the permanent contact with and health education of the patient, the surveillance and control of the adverse effects of oncological therapies or radiotherapy, the screening of metachron cancers, and the comprehensive (physical, psychological and social) rehabilitation of the patient. The early detection of local/regional tumor relapse is essential with careful follow-up, but there is no need for screening of distant metastases by means of imaging studies or tumor marker tests. If adjuvant endocrine therapy is needed, optimal adherence should be ensured with supportive therapy. In rare cases, special issues such as breast cancer risk/genetic mutation, pregnancy are raised, which should be thoughtfully discussed in view of recent advances in oncology. Follow-up is generally practised by the oncologist, however, in some cases the social worker, the physiotherapist, the psychooncologist, or in special cases, the lymphoedema expert is to be involved. The follow-up approach should be comprehensive and holistic.
C1 [Kahan, Zsuzsanna] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Szanto, Istvan] Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Onkologiai OsztalySzekesfehervar, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Rohanszky, Magda] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Koncz, Zsuzsa] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Mailath, Monika] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kapitany, Zsuzsanna] Semmelweis Egyetem ETK, Fizioterapia TanszekBudapest, Hungary.
   [Dudas, Rita] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM kahan.zsuzsanna@med.u-szeged.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2016
VL 60
IS 3
BP 258
EP 268
PG 11
ER

PT J
AU Olah, E
   Kasler, M
AF Olah, Edit
   Kasler, Miklos
TI In memoriam professor Sandor ECKHARDT (1927–2016)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Olah, Edit] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Olah, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 271
EP 272
PG 2
ER

PT J
AU Nagy, �
   Gyorffy, B
AF Nagy, Adam
   Gyorffy, Balazs
TI Internet-based opportunities in breast cancer diagnostics and research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; biomarker; prognosis; gene expression; mutation
ID breast cancer; biomarker; prognosis; gene expression; mutation
AB A new generation of internet-based diagnostic and research tools have arrived in the last decade. The most extensive group of these includes programs predicting the expected survival mainly by utilizing clinical data of the patient. This includes Adjuvant! Online, the MSKCC and MD Anderson nomograms and the UK-based PREDICT algorithm. A common feature of all these is the comparison of the given patient to previously treated breast cancer samples, and evaluating the clinical outcome of these previous patients. New diagnostic biomarkers can be gene expression or mutation based. Of these, large transcriptomic databases lay the basis for the KMplot.com analysis platform which is capable to assess the prognostic value of a selected gene or gene set. The link between a given mutation and survival is the focus of the cBioportal and the G-2-O software. Diagnosis is based on a transcriptome-level data derived using gene chips in the RecurrenceOnline algorithm. A risk of breast cancer development is assessed by a polygenic model in BOADICEA. In our review we target oncologists, pathologists and breast cancer researchers and provide a comprehensive summary of these and other analysis platforms.
C1 [Nagy, Adam] MTA TTK, Lendulet Cancer Biomarker Research Group, Magyar Tudosok korutja 2., 1117 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Nagy, � (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, 1117 Budapest, Hungary.
EM nagy.adam@ttk.mta.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 273
EP 280
PG 8
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI Cachexia in cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE anorexia; cachexia; loss of body mass; systemic inflammation; cytokines
ID anorexia; cachexia; loss of body mass; systemic inflammation; cytokines
AB About 50% of all patients with cancer eventually develop anorexia/cachexia syndrome, which represents a complex clinical syndrome occurring in several illnesses, including cancer. The syndrome is characterized by systemic inflammation and primarily loss of body fat and body mass. In this review we shortly summarize the pathomechanism of anorexia/cachexia syndrome and list the current pharmacological approaches.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Rakos ut 77/A, 1152 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, 1152 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 281
EP 287
PG 7
ER

PT J
AU Nagy, T
   Rubovszky, G
AF Nagy, Tunde
   Rubovszky, Gabor
TI Review of medical or combined treatment of local or locally advanced oesophageal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oesophageal cancer; chemoradiotherapy; neoadjuvant treatment; survival
ID oesophageal cancer; chemoradiotherapy; neoadjuvant treatment; survival
AB More than 800 oesophageal tumours are diagnosed each year in Hungary. The disease is characterized by high mortality. The curative treatment traditionally surgical, although the study results of recent decades pointed out that patient outcome can be improved with the proper application of radio- and chemotherapy. The diverse study designs, the low number of recruited patients and the sometimes conflicting results make the determination of optimal treatment difficult. The aim of this work is to facilitate the choice of treatment modality with the best outcome, especially with the view of medical oncologists. The treatment remains surgery for very early tumours (up to pT1b) and palliative therapy for tumours with metastasis. In other cases additional therapy, such as chemotherapy, radiotherapy, or their combinations, and targeted therapies, may result in improved survival. There are data mostly for neoadjuvant therapy because patients after surgery are rarely candidates for adjuvant therapy. Neoadjuvant chemotherapy may improve survival over surgery alone, but this improvement is more pronounced and supported by more evidence for neoadjuvant chemoradiotherapy (CRT). Certain results suggest that in selected cases after neoadjuvant CRT omission of surgery might not compromise survival, but the routine omission of surgery is not advised. However, the agent given concomitantly to radiotherapy may have importance. Besides cisplatin and fluorouracil other platinum derivatives (carboplatin, oxaliplatin) and taxanes (docetaxel, paclitaxel) can be used without compromising survival but with more favourable toxicity profile.
C1 [Nagy, Tunde] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Rubovszky, Gabor] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Nagy, T (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM drnt@freemail.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 288
EP 298
PG 11
ER

PT J
AU Zongor, Zs
   Bela, D
   Kiraly, R
   Stelczer, G
   Major, T
   Pesznyak, Cs
AF Zongor, Zsuzsanna
   Bela, Dalma
   Kiraly, Reka
   Stelczer, Gabor
   Major, Tibor
   Pesznyak, Csilla
TI Investigating the clinical applicability of EBT2 self-developing films
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE EBT2 film; intensity-modulated; gamma analysis; radiochromic
ID EBT2 film; intensity-modulated; gamma analysis; radiochromic
AB The purpose of the study was to investigate the physical properties of the EBT2 radiochromic films and define the conditions of its clinical applicability. We irradiated the films with different treatment techniques 3D conformal (3DCRT), intensity-modulated (IMRT) and stereotactic body radiotherapy with arc therapy (SBRT), and then compared the data with the dose distribution exported from the treatment planning system (Eclipse). Two film analysis softwares were investigated for the comparison: PTW Mephysto and FilmQA Pro. The comparisons of dose distributions were performed with gamma analysis, and the gamma criterion was 3%, 3mm, and 2%, 2mm. The gamma analysis results by the two programs were the following, (PTW/FilmQA Pro) with 3%, 3mm gamma criterion: 3DCRT (95,5/100%), IMRT (97/99,9%), SBRT (99,7/100%). In case of 2%, 2mm the results were: 3DCRT (87,1/98,9%), IMRT (92/98,5%), SBRT (96,7/97,9%). Based on the results it can be stated that during proper use, the features of the scanner do not affect the results. Both evaluation softwares are suitable for calibrating and evaluating films, moreover, performing the gamma analysis. The EBT2 film is suitable for the two-dimensional controlling of radiation therapy plans.
C1 [Zongor, Zsuzsanna] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
RP Zongor, Zs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM zongorzs@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 299
EP 304
PG 6
ER

PT J
AU Stelczer, G
   Major, T
   Meszaros, N
   Polgar, Cs
   Pesznyak, Cs
AF Stelczer, Gabor
   Major, Tibor
   Meszaros, Norbert
   Polgar, Csaba
   Pesznyak, Csilla
TI Dosimetric comparison of different techniques for external beam accelerated partial breast irradiation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE APBI; IMRT; IMAT; RapidArc; dosimetric evaluation
ID APBI; IMRT; IMAT; RapidArc; dosimetric evaluation
AB The aim of this article is to evaluate and compare four different radiotherapy techniques of accelerated partial breast irradiation (APBI) considering planning quality, dosimetric and practical aspects. The investigated techniques are three dimensional conformal radiotherapy (3D-CRT), „step and shoot” (SS) and „sliding window” (SW) intensity-modulated radiotherapy, intensity-modulated arc therapy (RA). CT scans of 10 patients previously treated with APBI were selected for the study. Surgical clips were placed on the borders of the tumour bed during breast conserving surgery. Target volume (PTV) was defined as enlarged CTV, which was created from the tumour bed through volume expansion using individual margins. Planning objectives were set up according to the international recommendations. Non-coplanar fields were used only for the 3D-CRT plans. For each plan homogeneity, conformity and plan quality indices were calculated from volumetric and dosimetric parameters of target volumes and organs at risk. The total monitor units and feasibility were also investigated. There was no significant difference in the coverage of the target volume by the prescribed dose between the techniques. SW plans were significantly more homogeneous (HI=0.033) than the 3D-CRT (HI=0.057) and the RA (HI=0.073) plans. The homogeneity of the SS technique (HI=0.053) did not differ significantly compared to others. The conformity of the 3D-CRT technique was significantly worse (CN=0.62) than that of SS (CN=0.85), SW (CN=0.85) and RA (CN=0.86) plans. There was a significant difference between RA (29.4%) and 3D-CRT (44.1%) and SW (35.6%) plans in the V50% of the ipsilateral breast. Mean V10% of the ipsilateral lung in 3D-CRT (10.1%) plans was significantly lower than in SS (34.3%), SW (34.3%) and RA (35.3%) plans. 3D-CRT technique provided the best heart protection. The shortest treatment times were achieved with RA technique. Good target volume coverage and tolerable dose to the organs at risk are achievable with all four techniques. Taking into account all the aspects, we recommend the sliding window IMRT technique for accelerated partial breast irradiation.
C1 [Stelczer, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
RP Stelczer, G (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM gabor.stelczer@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 305
EP 311
PG 7
ER

PT J
AU Szilagyi, A
   Pocza, T
   Polgar, Cs
   Major, T
   Bajcsay, A
   Lovey, J
AF Szilagyi, Andras
   Pocza, Tamas
   Polgar, Csaba
   Major, Tibor
   Bajcsay, Andras
   Lovey, Jozsef
TI Curative radiotherapy of early-stage lung cancer using respiratory motion compensation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; three-dimensional conformal radiotherapy; respiratory motion management
ID lung cancer; three-dimensional conformal radiotherapy; respiratory motion management
AB In this paper we present our early experience with a method for the management of respiratory motion in radiotherapy for early-stage lung cancer. Forty-six patients were irradiated with a total dose of 60 Gy. Tumor response on control CT, survival, local and distant progression as well as early and late side effects were registered. Complete and partial remission, stable and progressive disease was 17 (37.0%), 15 (32.6%), 11 (23.9%) and 3 (6.5%). Isolated local recurrence and distant metastasis appeared in 4 (8.7%) and 2 (4.3%) cases, while simultaneous local and distant progression was diagnosed in 3 (6.5%) patients. The probability of 2-year local recurrence-free, progression-free, and overall survival was 76.8%, 64.0%, and 83.2%. Grade 1 (G1) and G2 early side effects occurred at 15 (32.6%) and 3 (6.5%) patients without ≥G3 side effects. G1 and G2 late side effects were observed in 10 (21.7%) and 7 (15.2%) cases. G1-2 post-irradiation fibrosis occurred in 11 (23.9%) cases. Twenty months after the irradiation, G5 respiration failure was developed in one patient. The implemented technique of respiratory motion management for the radiotherapy of early-stage lung cancer resulted in promising local freedom from relapse and survival with favorable side effect profile. Further follow-up is needed to assess longterm side effects and survival results.
C1 [Szilagyi, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 314
EP 319
PG 6
ER

PT J
AU Krascsenits, G
   Balazs, B
   Dudnyikova, A
   Purcsi, K
   Orosz, E
   Pete, I
AF Krascsenits, Geza
   Balazs, Boglarka
   Dudnyikova, Anna
   Purcsi, Katalin
   Orosz, Eniko
   Pete, Imre
TI Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE adnexal masses; ovarian cancer; risk evaluation; RMI; ROMA
ID adnexal masses; ovarian cancer; risk evaluation; RMI; ROMA
AB We were investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity, in order to determine whether these methods are suitable for the early detection of ovarian malignancy. Our study included 162 patients treated at the Gynecological Department of the National Institute of Oncology (Budapest, Hungary). These patients were diagnosed with ovarian tumor of uncertain dignity, and were admitted to our Department with the purpose of gynecological surgery. Each of them had CA-125, HE4 blood tests and ultrasound scan in order to calculate RMI and ROMA indices and to study their effectiveness. In every case, the final type of surgery was determined by intraoperative frozen section examination results. Efficacy of RMI and ROMA indices was detected by the final histological examination taken from the same material that was sent for intraoperative frozen section. The sensitivity and specificity of RMI index was 82.0% and 85.1%, respectively, while ROMA index sensitivity and specificity was 88.5% and 72.3%. The results were better in postmenopausal women: RMI sensitivity had increased to 90.9% and specificity to 82.8%. ROMA index sensitivity reached 95.5% with a specificity of 60.7%. Thus premenopausal RMI sensitivity significantly decreased (58.8%), and specificity had surged (88.4%). In case of premenopausal ROMA results sensitivity had declined, though the results are much better than for RMI (70.6% vs. 58.8%), while specificity was 14% less than that of RMI (74.4% vs. 88.4%). According to our study, RMI and ROMA indices are good methods for identifying the dignity of malignant ovarian tumors. The sensitivity and specificity results are in accordance with international literature. Even though the premenopausal and postmenopausal values are different, RMI and ROMA tests complement each other and are excellent for predicting the dignity of a tumor. With the help of these indices 61 cases of malignancy were detected, which means that we have to operate only 3 patients in order to detect 1 case of malignancy
C1 [Krascsenits, Geza] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Balazs, Boglarka] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Dudnyikova, Anna] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Purcsi, Katalin] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Orosz, Eniko] National Institute of Oncology, Central Clinical LaboratoryBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Krascsenits, G (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM krascsenits.geza@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 320
EP 327
PG 8
ER

PT J
AU Muzes, Gy
   Csomor, J
   Sipos, F
AF Muzes, Gyorgyi
   Csomor, Judit
   Sipos, Ferenc
TI Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman’s disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE multicentric Castleman’s disease; HHV8; IL-6; rituximab; tocilizumab
ID multicentric Castleman’s disease; HHV8; IL-6; rituximab; tocilizumab
AB This is a case presentation of a HHV8-positive multicentric Castleman’s disease (MCD) of plasma cell type. The patient failed to respond to combined immunosuppressive therapy and monoclonal anti-CD20 therapy. Interestingly, administration of anti-IL-6R antibody stabilized the disease and resulted in clearance of HHV8 from the involved lymph nodes.
C1 [Muzes, Gyorgyi] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sipos, Ferenc] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
RP Muzes, Gy (reprint author), Semmelweis University, 2nd Department of Internal Medicine, 1088 Budapest, Hungary.
EM muzes.gyorgyi@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 328
EP 332
PG 5
ER

PT J
AU Forrai, G
   Lazar, Gy
   Cserni, G
   Polgar, Cs
   Horvath, Zs
   Kahan, Zs
   Kasler, M
   Svebis, M
AF Forrai, Gabor
   Lazar, Gyorgy
   Cserni, Gabor
   Polgar, Csaba
   Horvath, Zsolt
   Kahan, Zsuzsanna
   Kasler, Miklos
   Svebis, Mihaly
TI Level az emlorak felismeresetol az emlorakos betegek rehabilitaciojaig tarto folyamat javitasanak erdekeben
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE emlorak
ID emlorak
C1 [Forrai, Gabor] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Lazar, Gyorgy] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Cserni, Gabor] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Polgar, Csaba] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Horvath, Zsolt] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Kahan, Zsuzsanna] III. Emlorak Konszenzus Konferencia, MunkacsoportokBudapest, Hungary.
   [Kasler, Miklos] III. Emlorak Konszenzus Konferencia, Szervezo BizottsagBudapest, Hungary.
   [Svebis, Mihaly] III. Emlorak Konszenzus Konferencia, Szervezo BizottsagBudapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 333
EP 337
PG 5
ER

PT J
AU Garay, MT
AF Garay, M Tamas
TI Oncogen dependent regulation of the migration and proliferation of human tumor cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE proliferation; migration; growth factor receptor signaling; "go or grow" hypothesis
ID proliferation; migration; growth factor receptor signaling; "go or grow" hypothesis
AB The high mortality of solid tumors can be attributed to their invasive and metastatic potential that is based on their migration and proliferation. Importantly, growth factor receptor (GF) signaling pathways regulating proliferation and migration are often affected by oncogenic mutations and are important targets for antitumor therapy. We found positive correlation between migration and proliferation in melanoma and lung cancer cells using videomicroscopy, not supporting the “go or grow” hypothesis. Furthermore, the invasion into collagen I matrices from brain tumor spheroids was not impaired upon the inhibition of proliferation. Sensitivity of human melanoma cells towards EGF and FGF2 treatment but not against GF receptor tyrosine kinase inhibitors was oncogenic BRAF or NRAS mutation status dependent. Prenylation inhibition failed to decrease clonogenic growth in BRAF mutant but PTEN wild-type melanoma lines but increased migration in BRAF-mutant cells. In certain mesothelioma cells, activin signaling showed a pro-tumorigenic effect suggesting activin as a valuable candidate for therapeutic interference. In summary, our findings demonstrate that proliferation is neither an obstacle nor a prerequisite for tumor cell invasion. Furthermore, the specific oncogenic mutations may differentially regulate migration and proliferation of tumor cells. Therefore, they are not only therapeutic targets but can also profoundly influence the efficacy of various therapies.
C1 [Garay, M Tamas] Semmelweis University, School of PhD Studies, II. Sz. Patologiai Intezet, Ulloi ut 93., 1091 Budapest, Hungary.
RP Garay, MT (reprint author), Semmelweis University, School of PhD Studies, 1091 Budapest, Hungary.
EM garay.tamas@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2016
VL 60
IS 4
BP 339
EP 342
PG 4
ER

PT J
AU Lehoczky, D
AF Lehoczky, Dezso
TI Looking back, review
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Lehoczky, Dezso] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
RP Lehoczky, D (reprint author), Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 3
EP 5
PG 3
ER

PT J
AU Timar, B
AF Timar, Botond
TI The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lymphoplasmacytic lymphoma; Waldenstrom; genetic background; MYD88; pathology
ID lymphoplasmacytic lymphoma; Waldenstrom; genetic background; MYD88; pathology
AB Lymphoplasmacytic lymphoma is a rare low-grade B-cell lymphoma, which is composed of a mixture of small lymphocytes, plasmacytoid cells and plasma cells that typically infiltrate the bone marrow, but lymph nodes and rarely other organs can be involved as well. Waldenstrom macroglobulinaemia is a lymphoplasmacytic lymphoma with typical bone marrow involvement and is associated with detectable IgM paraproteins. The diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia (LPL/WM) can be challenging, due to similarities to other small B-cell lymphomas with plasmacytic differentiation and/or with IgM paraproteins. The recently discovered MYD88 mutation may help in the diagnosis, as it is present in over 90% of LPL/WMs. This short review covers the pathology of LPL/WM and offers some insight into the new molecular findings that may help in the diagnostic procedure and in the new therapeutic choices.
C1 [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Timar, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM timar.botond@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 6
EP 11
PG 6
ER

PT J
AU Mucsi, OA
   Nagy, Zs
AF Mucsi, Orsolya Anna
   Nagy, Zsolt
TI How can we treat Waldenstrom’s macroglobulinemia?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE MGUS; smoldering WM; WM; diagnosis; treatment
ID MGUS; smoldering WM; WM; diagnosis; treatment
AB Waldenstrom’s macroglobulinemia is a rare, low-grade non-Hodgkin lymphoma of B cell origin, most common in elderly male patients with a median age of 64 years at diagnosis. It accounts for approximately 2% of hematologic malignancies. The disease is incurable now with a median overall survival of 6.2 years. In the past decade growing evidence suggests the role of the complex signaling pathways and microenvironment as a potential target of the therapy in the lymphoproliferative disorders as well as Waldenstrom’s macroglobulinemia. In this review we try to highlight the importance of these novel targets and their possible role in the therapeutic strategies. We further summarize our knowledge about the pathophysiology, diagnostics and therapeutics standards of the disease.
C1 [Mucsi, Orsolya Anna] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor u. 2/A., 1083 Budapest, Hungary.
   [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor u. 2/A., 1083 Budapest, Hungary.
RP Nagy, Zs (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1083 Budapest, Hungary.
EM nagy.zsolt@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 12
EP 20
PG 9
ER

PT J
AU Rajnai, H
   Kiraly, PA
AF Rajnai, Hajnalka
   Kiraly, Peter Attila
TI Pathogenesis and genetic landscape of acute myeloid leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE acute myeloid leukemia; genetic background; clonal heterogeneity
ID acute myeloid leukemia; genetic background; clonal heterogeneity
AB The recent advances in the field of molecular biology have enabled a more comprehensive genomic analysis in myeloid malignancies. The studies have unveiled recurrent somatic mutations in several genes illuminating the clinical heterogeneity of these diseases. In this review, we discuss the pathogenesis of de novo and secondary acute myeloid leukemia (AML) in view of recent findings. Mutational analysis of several genes are already included in the everyday diagnostic procedure of AML. The identification of these mutations enables improvements in risk-stratification strategies and provides new potential targets for treatment of AML.
C1 [Rajnai, Hajnalka] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kiraly, Peter Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Rajnai, H (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM rajnai.hajnalka@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 21
EP 28
PG 8
ER

PT J
AU Tarkanyi, I
AF Tarkanyi, Ilona
TI Acute myeloid leukaemia in adults: therapeutic possibilities today and new agents in the future
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE acute myeloid leukaemia; treatment; new therapeutic agents
ID acute myeloid leukaemia; treatment; new therapeutic agents
AB Advances in the treatment of acute myeloid leukaemia are still modest. Through emerging knowledge in molecular genetics we gain new insights into the pathogenesis of the disease. The first targeted therapies have emerged, but failed to show a breakthrough effect. The outcome of standard chemotherapy has improved due to improvements in supportive care and slight modifications in the protocols, but we still hope to augment the results of intensive chemotherapy applied in our young and fit patients, by adding targeted therapeutic agents. Possibilities of old and frail patients were even less: they could only receive cytotoxic agents with low efficacy but severe side effects. This group of patients can already benefit from new therapies, like hypomethylating agents. The review summarizes current approved therapies and gives insight into ongoing development of new agents, which will hopefully enrich our therapeutic possibilities in the near future.
C1 [Tarkanyi, Ilona] Semmelweis University, 1st Department of Internal Medicine, 1428 Budapest, Hungary.
RP Tarkanyi, I (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1428 Budapest, Hungary.
EM ilona_tarkanyi@yahoo.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 29
EP 35
PG 7
ER

PT J
AU Mozes, R
   Gango, A
   Boha, Zs
   Csomor, J
   Bodor, Cs
AF Mozes, Reka
   Gango, Ambrus
   Boha, Zsofia
   Csomor, Judit
   Bodor, Csaba
TI The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE primary myelofibrosis; high molecular risk; CALR-/ASXL1+ genotype; driver mutations; subclonal mutations
ID primary myelofibrosis; high molecular risk; CALR-/ASXL1+ genotype; driver mutations; subclonal mutations
AB Primary myelofibrosis (PMF) is a Philadelphia chromosome negative, clonal myeloproliferative neoplasm characterised by a progressive nature. Morphologically, the bone marrow biopsy shows features of abnormal proliferation of terminally differentiated megakaryocytes and subsequent bone marrow fibrosis. The molecular landscape of PMF includes phenotypic driver mutations (JAK2 V617F, CALR and MPL) which represent major diagnostic criteria, and subclonal mutations that also occur in several other myeloid diseases, but have a prognostic value in disease progression of MF. The most important subclonal mutations affect the genes ASXL1, TET2, IDH1/2, EZH2 and TP53. Triple negative genotype and the high molecular risk genotype and CALR-/ASXL1+ are associated with adverse survival with the latest indicating stem cell transplantation independently of the DIPSS-plus score.
C1 [Mozes, Reka] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Gango, Ambrus] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Boha, Zsofia] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Mozes, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM mozesreka@yahoo.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 36
EP 45
PG 10
ER

PT J
AU Korosmezey, G
   Gyori, G
   Rudas, G
   Eid, H
   Nagy, Zs
   Demeter, J
AF Korosmezey, Gabor
   Gyori, Gabriella
   Rudas, Gabor
   Eid, Hanna
   Nagy, Zsolt
   Demeter, Judit
TI Treatment options and limitations in the management of myelofibrosis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE myelofibrosis; myeloproliferative neoplasm; JAK2; ruxolitinib; hydroxyurea
ID myelofibrosis; myeloproliferative neoplasm; JAK2; ruxolitinib; hydroxyurea
AB Primary myelofibrosis has the worst outcome among classical chronic myeloproliferative neoplasms. The past decade has brought numerous discoveries elucidating the role of proliferative mutations in disease pathogenesis. Mutations of the genes JAK2, MPL and CALR are present in about 90 percent of all primary myelofibrosis cases. The prognosis of myelofibrosis is considered heterogeneous, the expected survival of patients may range from one year to more than a decade based on several prognostic factors. Estimated survival can be assessed based on clinical prognostic scores. The aim of treatment is to reduce mortality and to alleviate the main aspects of disease-associated morbidity, e.g. anemia, splenomegalia and systemic symptoms. The effect of conventionally used cytoreductive agent hydroxyurea is usually transient. Use of allogeneic hematopoietic stem cell transplantation is limited by significant procedure-associated mortality. JAK2 tyrosine kinase inhibitors are the first treatment modality with evidence of improved overall survival, however, even these molecularly targeted therapies have failed to bring complete and permanent remission for the majority of myelofibrosis patients. Further improvement in overall survival for myelofibrosis can be expected from better understanding of the underlying molecular pathology and novel molecular therapeutic targets.
C1 [Korosmezey, Gabor] Semmelweis University, 1st Department of Internal Medicine, Ulloi u. 26., 1085 Budapest, Hungary.
   [Gyori, Gabriella] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Rudas, Gabor] Semmelweis Egyetem, MR KutatokozpontBudapest, Hungary.
   [Eid, Hanna] Semmelweis University, 1st Department of Internal Medicine, Ulloi u. 26., 1085 Budapest, Hungary.
   [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Ulloi u. 26., 1085 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Ulloi u. 26., 1085 Budapest, Hungary.
RP Korosmezey, G (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1085 Budapest, Hungary.
EM kgabor88@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 47
EP 55
PG 9
ER

PT J
AU Kiss, R
   Kiraly, PA
   Gaal-Weisinger, J
   Marosvari, D
   Gango, AP
   Demeter, J
   Bodor, Cs
AF Kiss, Richard
   Kiraly, Peter Attila
   Gaal-Weisinger, Julia
   Marosvari, Dora
   Gango, Ambrus Peter
   Demeter, Judit
   Bodor, Csaba
TI Molecular monitoring of myeloid leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE chronic myeloid leukemia; BCR-ABL1; TKI therapy; molecular monitoring
ID chronic myeloid leukemia; BCR-ABL1; TKI therapy; molecular monitoring
AB The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modification. With the development of the international scale and inter-laboratory standardization the residual tumor mass can be measured accurately and the results are comparable between the different laboratories. By the growing experience in the field of molecular responses we can now accurately predict treatment outcome early on with the so called early molecular response and BCR-ABL1 kinetics, allowing the selection of the best TKI with the treatment-free remission representing real option of the near future. Nevertheless, further advancements can be expected, including the workflow automatization and detection of even deeper molecular responses.
C1 [Kiss, Richard] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kiraly, Peter Attila] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Gaal-Weisinger, Julia] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Marosvari, Dora] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Gango, Ambrus Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Bodor, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bodor.csaba1@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 57
EP 66
PG 10
ER

PT J
AU Gaal-Weisinger, J
   Mucsi, O
   Korosmezey, G
   Szili, B
   Eid, H
   Kiss, R
   Bodor, Cs
   Tarkanyi, I
   Nagy, Zs
   Demeter, J
AF Gaal-Weisinger, Julia
   Mucsi, Orsolya
   Korosmezey, Gabor
   Szili, Balazs
   Eid, Hanna
   Kiss, Richard
   Bodor, Csaba
   Tarkanyi, Ilona
   Nagy, Zsolt
   Demeter, Judit
TI Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE chronic myeloid leukemia; tyrosine kinase inhibitors; diagnostics; treatment
ID chronic myeloid leukemia; tyrosine kinase inhibitors; diagnostics; treatment
AB The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.
C1 [Gaal-Weisinger, Julia] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Mucsi, Orsolya] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Korosmezey, Gabor] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Szili, Balazs] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Eid, Hanna] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Kiss, Richard] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Tarkanyi, Ilona] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Nagy, Zsolt] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
   [Demeter, Judit] Semmelweis University, 1st Department of Internal Medicine, Koranyi Sandor utca 2/A, 1083 Budapest, Hungary.
RP Demeter, J (reprint author), Semmelweis University, 1st Department of Internal Medicine, 1083 Budapest, Hungary.
EM demeter.judit@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 67
EP 74
PG 8
ER

PT J
AU Sinko, J
AF Sinko, Janos
TI Invasive fungal infections in patients with haematological malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE invasive mycosis; aspergillosis; candidiasis; leukaemia; antifungal therapy
ID invasive mycosis; aspergillosis; candidiasis; leukaemia; antifungal therapy
AB Invasive fungal diseases represent an ever changing field within infectology, profoundly affecting daily clinical activities of specialists in haematology. The dynamic development seen in oncohaematology creates novel risk groups of patients, consequently necessitating a re-evaluation of principles in antifungal therapy from time to time. Not even in 2017 may achievements of fungal diagnostics and therapy become a substitute for clinical thinking and adaptation of general guidelines according to local experience. For antifungal management all centres should elaborate appropriate strategies. By creating and operating a multidisciplinary team, decision making can effectively be supported.
C1 [Sinko, Janos] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, Albert Florian ut 5-7., 1097 Budapest, Hungary.
RP Sinko, J (reprint author), Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, 1097 Budapest, Hungary.
EM janos.sinko@istvankorhaz.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 75
EP 80
PG 6
ER

PT J
AU Mehes, G
AF Mehes, Gabor
TI Primary central nervous system lymphoma: pathogenesis and histomorphology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE aggressive lymphoma; nervous system; antigen; B-cell; immunity
ID aggressive lymphoma; nervous system; antigen; B-cell; immunity
AB Lymphoproliferative diseases of the central nervous system are rare, diagnostics and treatment are accordingly challenging. Since the introduction of the 2008 WHO lymphoma classification, primary CNS DLBCL – also covering the associated primary ocular (vitreoretinal) lymphoma – is a separate entity. The special localization is related with a series of newly recognized genetic, genomic and immunologic features directing to the strong interaction between transformed lymphoma cells, neural tissue components and the local immune response. Histological differentiation is frequently disabled by the limited sampling opportunities and requires the application of all available hematopathologic technologies including immunohistochemistry, cytology, liquor serology, flow cytometry, fluorescence in situ hybridization and polymerase chain reaction with sequencing.
C1 [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Mehes, G (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, 4032 Debrecen, Hungary.
EM gabor.mehes@med.unideb.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 81
EP 87
PG 7
ER

PT J
AU Gergely, L
AF Gergely, Lajos
TI Drug therapy of lymphomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lymphoma; proteasome; immunomodulatory; antibody; histone deacetylase
ID lymphoma; proteasome; immunomodulatory; antibody; histone deacetylase
AB The therapy of lymphomas has undergone a major expansion during the last decade. Novel therapeutic targets have appeared beyond classical chemotherapeutic combinations. These novel drugs have very pronounced action across lymphoma types, and their toxicity profile is usually better tolerable compared to standard chemotherapies. These new therapies are enabling us to offer treatment to those patients who have refractory disease, and we had no option to treat them before these drugs. The author describes several new therapeutic options. New chemotherapeutic drugs are pixantrone and bendamustin. Monoclonal antibodies, like rituximab, ofatumumab, obinotuzumab are described, and conjugated antibodies like brentuximab vedotin and inotuzumab ozogamicin are also discussed. The bispecific antibody blinatumomab can modulate the immune response, and the new class of immune checkpoint inhibitors (pembrolizumab, nivolumab) is also discussed. Therapies targeting the epigenetic regulatory network are also important. Several studies reported promising results of abexinostat, vorinostat, belinostat and panobinostat. The new class of immunomodulatory drugs (imids) is also growing, results with thalidomid and lenalidomid are discussed. The proteasome inhibitors are offering new combinations, with the use of bortezomid, carfilzomib, ixazomib. All these new drugs described above offer to the physician several therapeutic options to better treat patients with lymphoma.
C1 [Gergely, Lajos] University of Debrecen, Faculty of Medicine, Department of Hematology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Gergely, L (reprint author), University of Debrecen, Faculty of Medicine, Department of Hematology, 4032 Debrecen, Hungary.
EM lgergely.work@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 89
EP 96
PG 8
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI Current questions in the radiotherapy of lymphoproliferative tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lymphoma; radiotherapy; involved node; PET-CT
ID lymphoma; radiotherapy; involved node; PET-CT
AB Radiation therapy traditionally plays a major role in the treatment of lymphoproliferative diseases. Diagnostics and treatment of these tumors improved tremendously in the recent decades. Molecular diagnostics is able to discriminate its subtypes more precisely than ever and opens the possibility of the introduction of targeted medicines. Imaging, especially functional imaging now has an established role in forming treatment strategy. Radiation therapy showed substantial technical development too. As a consequence of these, the role, dose and technique of radiotherapy changes instantly. In this short review we discuss situations which clinicians, both hemato-oncologists and radiation oncologist may face day by day. These are: the changing role of radiation therapy in early Hodgkin’s disease, including dose and filed size reduction and PET-driven radiation therapy; the use of radiation in advanced Hodgkin’s disease; the role of radiation therapy of diffuse large B-cell lymphoma in the light of the use of rituximab; and finally the use of modern radiation therapy techniques like intensity-modulated radiation therapy or particle therapy.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 97
EP 104
PG 8
ER

PT J
AU Galffy, G
   Puskas, R
AF Galffy, Gabriella
   Puskas, Rita
TI Role of pembrolizumab in the treatment of non-small cell lung cancer (NSCLC)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
DE lung cancer; immunotherapy; PD-1 inhibitors; PD-L1 inhibitors; CTLA-4 inhibition; overall survival; pembrolizumab
ID lung cancer; immunotherapy; PD-1 inhibitors; PD-L1 inhibitors; CTLA-4 inhibition; overall survival; pembrolizumab
AB Lung cancer is the leading cause of cancer-related death, not only in our country but also worldwide. It is particularly the incidence and mortality regarding females that have increased significantly in recent years. For many years chemotherapeutic treatments of lung cancer were the only way forward in the treatment of patients. In 2015 immunotherapy proved to be a great breakthrough in the treatment of non-small cell lung cancer (NSCLC), resulting from a new treatment strategy, described as immune checkpoint inhibition. Recent studies have shown the best efficacy of immunotherapy, especially in squamous cell lung cancer and the smoking-related non-squamous cell lung cancer which is explained by research regarding the high occurrence of increased mutation rate caused by smoking. The introduction of immunotherapy carries a great challenge for clinicians regarding the best therapeutic efficacy, longer survival, better quality of life as well as the management of the different profile of side effects. Pembrolizumab was the first PD-1 inhibitor, which was registered for first-line, second-line or greater treatment of non-small cell lung cancer.
C1 [Galffy, Gabriella] Semmelweis University, Department of Pulmonology, Dios arok 1/C, 1125 Budapest, Hungary.
   [Puskas, Rita] Semmelweis University, Department of Pulmonology, Dios arok 1/C, 1125 Budapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, 1125 Budapest, Hungary.
EM ggalffy@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 107
EP 110
PG 4
ER

PT J
TI AbbVie PRESS RELEASE
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE AbbVie; VENCLYXTO; venetoklax
ID AbbVie; VENCLYXTO; venetoklax
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2017
VL 61
IS 1
BP 111
EP 112
PG 2
ER

PT J
AU Fesus, V
AF Fesus, Viktoria
TI Recent advances of immunooncology in the treatment of solid tumours and haematological malignancies: the immune checkpoint inhibitors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immunotherapy; immune checkpoint blockade; ipilimumab; nivolumab; pembrolizumab
ID immunotherapy; immune checkpoint blockade; ipilimumab; nivolumab; pembrolizumab
AB Cancer immunotherapy is coming of age, as outstanding results can be achieved in the therapy of cancer with poor prognosis by altering the patients’ immune system and by promoting the immune response against tumours. Amongst immunotherapies, the immune checkpoint inhibitors (ICI) proved to be the most effective, primarily in the treatment of solid tumours, including melanoma, non-small cell lung carcinoma, and classical Hodgkin’s lymphoma. The reason for this efficacy is the immunosuppressive microenvironment typical for many cancer types, directly and indirectly inhibiting effector T-cell responses. To date, three cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1) checkpoint inhibitors have been approved in Europe, and six in the USA. Furthermore, an increasing number of these drugs is available in the setting of clinical trials. For the optimal use of the numerous different ICIs there is an ever increasing need to identify reliable predictive biomarkers and to explore therapy-associated resistance mechanisms, which will represent the main challenge of the next years.
C1 [Fesus, Viktoria] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Fesus, V (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM fesus.viktoria@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 116
EP 125
PG 10
ER

PT J
AU Geczi, L
   Nagyivanyi, K
   Maraz, A
AF Geczi, Lajos
   Nagyivanyi, Krisztian
   Maraz, Aniko
TI Immunotherapy of renal cell cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE renal cell cancer; PD-1/PD-L1 inhibitors; atezolizumab; nivolumab; pembrolizumab
ID renal cell cancer; PD-1/PD-L1 inhibitors; atezolizumab; nivolumab; pembrolizumab
AB The authors briefly highlight the results of targeted therapy and present new solutions in kidney cancer immunotherapy. The important checkpoint inhibitors (anti-CTLA-4, -PD-1 and -PD-L1/2) and their combinations, together with the combinations of targeted drugs and immunotherapy are discussed. The newest checkpoint agents, vaccination and pegylated interleukin-2 are also presented. The most promising clinical trials (CheckMate-025, AGS-003, IMA 901) and the on-going first line phase III trials are shown in metastatic clear cell renal carcinoma.
C1 [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM gelajos@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 126
EP 131
PG 6
ER

PT J
AU Olah, J
AF Olah, Judit
TI Advances in immunotherapy for metastatic melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE ipilimumab; nivolumab; pembrolizumab; combined immunotherapy
ID ipilimumab; nivolumab; pembrolizumab; combined immunotherapy
AB Improved understanding of melanoma genetics and immune regulatory pathways have culminated in the development of targeted and immunotherapies of the patients with metastatic melanoma. Recent advances in these oncological modalities have dramatically shifted this landscape with highly increased survival rates. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 based treatments (ipilimumab, nivolumab and pembrolizumab) have been an integral part of this therapeutic success. Nowadays the combined immune checkpoint inhibitor therapies have demonstrated a significant improvement in overall survival of patients with advanced melanoma. This review summarizes briefly the most important updated principals of this field in dermato-oncology.
C1 [Olah, Judit] University of Szeged, Department of Dermatology and Allergology, Koranyi fasor 6., 6720 Szeged, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, 6720 Szeged, Hungary.
EM lazarne.olah.judit@med.u-szeged.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 132
EP 136
PG 5
ER

PT J
AU Maraz, A
   Geczi, L
AF Maraz, Aniko
   Geczi, Lajos
TI The role of immunotherapy in the modern treatment of urothelial carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE urothelial bladder cancer; PD-1/PD-L1 inhibitors; atezolizumab; nivolumab; pembrolizumab
ID urothelial bladder cancer; PD-1/PD-L1 inhibitors; atezolizumab; nivolumab; pembrolizumab
AB By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. According to the recent publications, they have been effective in case of progression after platinum therapy, in or after second-line and in firstline therapies for cisplatin ineligible patients, respectively. Patient survival and tumor response data are very promising; in particular stages, they seem to be more effective than the previously administered chemotherapies. Their toxicity profiles also appear to be more favorable. Immunological side effects are rare; their identification and management require preparedness and multidisciplinary thinking. Current and ongoing trials are investigating the combinations of new remedies with other immunotherapeutic agents (e.g., CTLA-4 inhibitor ipilimumab, tremelimumab) or chemotherapies as well as trying to identify biomarkers in order to further increase effectiveness. In our review, we summarize the recently published data about urothelial carcinoma therapy and give a brief overview of the ongoing clinical trials.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 139
EP 146
PG 8
ER

PT J
AU Bodoky, Gy
AF Bodoky, Gyorgy
TI Role of immunotherapy in the management of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE colorectal cancer; immunotherapy; PD-1; microsatellite instability
ID colorectal cancer; immunotherapy; PD-1; microsatellite instability
AB Immunotherapy proved to be effective in various forms of cancer but it is in its infancy in colorectal cancer, although the Immunoscore was developed to classify this tumor immunologically. Various forms of immunotherapy were tested in early clinical trials but anti-PD-1 antibodies seem the most promising so far. These studies also revealed that one particular molecular subgroup of colorectal cancer, the microsatellite instable variant, is extremely sensitive for such modality.
C1 [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Nagyvarad ter 1., 1097 Budapest, Hungary.
RP Bodoky, Gy (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, 1097 Budapest, Hungary.
EM bodokygy@hungarnet.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 147
EP 151
PG 5
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI Immunotherapy for lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immune checkpoint inhibitors; lung cancer; PD-1 axis inhibitors; CTLA-4 inhibitors
ID immune checkpoint inhibitors; lung cancer; PD-1 axis inhibitors; CTLA-4 inhibitors
AB Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate and immunogenicity. The PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab is a labelled indication in second line setting in advanced nonsmall cell lung cancer (NSCLC). Avelumab and durvalumab have promising activity as well. Based on the data of KEYNOTE 024 trial, pembrolizumab is approved in first line setting for cases with ≥50% PD-L1 expression. In this selected patient population, progression-free survival has doubled, and overall survival was significantly better in pembrolizumab-treated patients compared to those receiving standard of care. Pembrolizumab treatment became a new first line standard of care in advanced NSCLC. There are numerous ongoing clinical trials in lung cancer with immune checkpoint inhibitors in combination with cytotoxic chemotherapy, targeted agents, or in adjuvant setting.
C1 [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, Piheno u. 1., 1121 Budapest, Hungary.
RP Ostoros, Gy (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Tudobelosztaly, 1121 Budapest, Hungary.
EM drostorosgyula@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 153
EP 157
PG 5
ER

PT J
AU Timar, J
   Ladanyi, A
AF Timar, Jozsef
   Ladanyi, Andrea
TI Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immunotherapy; predictive marker; prognostic marker; PD-L1
ID immunotherapy; predictive marker; prognostic marker; PD-L1
AB Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promotes the development of clinically valid prognostic and predictive immunological makers. The most advanced immunological markers are the Immunoscore (density of T-cell subpopulations), and PD-L1 protein expression on tumor or immune cells. PD-L1 testing of cancers raises new issues since almost all novel therapies developed its own in vitro diagnostics. Due to the incompatibility of these assays it is suggested to use the companion diagnostic of the given immunotherapeutic drug defined in its label.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 158
EP 166
PG 9
ER

PT J
AU Boer, K
AF Boer, Katalin
TI Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2– advanced breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE breast cancer; endocrine therapy; CDK4/6 inhibitor; palbociclib
ID breast cancer; endocrine therapy; CDK4/6 inhibitor; palbociclib
AB Until recently, the only endocrine agents used to treat HR+/HER2– advanced breast cancers were tamoxifen, aromatase inhibitors and fulvestrant, although a substantial proportion of patients relapse on these standard therapies. Intensive research has been conducted to develop new strategies to overcome endocrine resistance and to enhance the efficacy of endocrine treatments by combining hormone therapy with other targeted treatment approaches. The development of selective CDK4/6 inhibitors and the introduction of palbociclib, the first molecule in this class in clinical practice, represent an important step in the treatment of HR+ advanced breast cancer. High level evidence supports the use of palbociclib plus letrozole in the treatment of endocrine sensitive breast cancers, or palbociclib plus fulvestrant in tumors that develop acquired resistance to endocrine therapy. These combinations are effective and well tolerated therapeutic modalities. The new combination regimens with palbociclib represent an important addition to the therapeutic armamentarium in locally advanced and metastatic ER+/HER2– breast cancer. The article reviews the current role of palbociclib in combination with endocrine therapy in the therapy of HR+/HER2– advanced breast cancer.
C1 [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - Oncology, Becsi ut 132., 1032 Budapest, Hungary.
RP Boer, K (reprint author), Szent Margit Hospital, V. Department of Internal Medicine - Oncology, 1032 Budapest, Hungary.
EM katalin.boer@t-online.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 167
EP 173
PG 7
ER

PT J
AU Landherr, L
   Nagykalnai, T
AF Landherr, Laszlo
   Nagykalnai, Tamas
TI Treatment of bone metastases: bisphosphonates and denosumab
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE skeletal metastases; bisphosphonates; zoledronic acid; ibandronate; denosumab; SREs; RANK ligand
ID skeletal metastases; bisphosphonates; zoledronic acid; ibandronate; denosumab; SREs; RANK ligand
AB Some disseminated tumor cells (as „seeds”) feel well in the skeletal tissue, as a „soil”, but the humoral crosstalk between tumor cells and bone cells disrupts the normal bone homeostasis (remodeling), which leads to a vicious circle, the multiple bone metastatic disease. The tumor cells could stimulate bone resorption, bone neo-formation or both, characteristic of the primary tumor. This usually incurable condition involves serious consequences, as fractures, pain, surgeries, irradiations, plegias, hypercalcemia, etc. (skeletal-related events, SREs), which destroy the quality of life. Targeting bone resorption with bisphosphonates or RANK ligand dependent mechanism could improve the rate of serious SREs and disease-free survival.
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Rakos ut 77/A., 1152 Budapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1152 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 175
EP 180
PG 6
ER

PT J
AU Magyar Sugarterapias, T
AF Magyar Sugarterapias, Tarsasag
TI XIII. Congress of the Hungarian Radiotherapy Society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
AB Magyar Sugarterapias Tarsasag Kongresszusa (Gyor, 2017.05.18-20.) Helyszin: Gyor, Eto Park Hotel Business & Stadium**** (Gyor, Nagysandor Jozsef u. 31.)   Fo temak:  Szetereotaxias sugarkezelesek  Nogyogyaszati sugarterapia  QC/QA a sugarterapiaban  Szabadon valasztott temak   Kedvezmenyes jelentkezesi hatarido: 2017. marcius 17.  Absztrakt bekuldesi hatarido: 2017. marcius 23-ig meghosszabbitva.
C1 [Magyar Sugarterapias, Tarsasag] Magyar Sugarterapias Tarsasag, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Magyar Sugarterapias, T (reprint author), Magyar Sugarterapias Tarsasag, 1122 Budapest, Hungary.
EM sugarterapia@doki.net
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 183
EP 211
PG 29
ER

PT J
AU Darazs, B
   Vegvary, Z
   Rusko, L
   Ferenczi, L
   Varga, Z
   Fodor, E
   Hideghety, K
AF Darazs, Barbara
   Vegvary, Zoltan
   Rusko, Laszlo
   Ferenczi, Lehel
   Varga, Zoltan
   Fodor, Emese
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusko, Laszlo] GE Healthcare MagyarorszagSzeged, Hungary.
   [Ferenczi, Lehel] GE Healthcare MagyarorszagSzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Darazs, B (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 183
EP 183
PG 1
ER

PT J
AU Pesznyak, Cs
AF Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pesznyak, Csilla] National Institute of OncologyBudapest, Hungary.
RP Pesznyak, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 183
EP 183
PG 1
ER

PT J
AU Frohlich, G
   Vizkeleti, J
   Nguyen, AN
   Meszaros, N
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Vizkeleti, Julia
   Nguyen, Anhhong Nhung
   Meszaros, Norbert
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 183
EP 184
PG 2
ER

PT J
AU Farkas, Gy
   Kocsis, Zs
   Szekely, G
   Bela, D
   Pesznyak, Cs
   Major, T
   Juranyi, Zs
   Polgar, Cs
AF Farkas, Gyongyi
   Kocsis, S. Zsuzsa
   Szekely, Gabor
   Bela, Dalma
   Pesznyak, Csilla
   Major, Tibor
   Juranyi, Zsolt
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 184
EP 184
PG 1
ER

PT J
AU Juranyi, Zs
   Bajcsay, A
   Ostoros, Gy
   Markoczy, Zs
   Farkas, Gy
   Kocsis, Zs
   Szekely, G
   Bela, D
   Lovey, J
   Polgar, Cs
AF Juranyi, Zsolt
   Bajcsay, Andras
   Ostoros, Gyula
   Markoczy, Zsolt
   Farkas, Gyongyi
   Kocsis, S. Zsuzsa
   Szekely, Gabor
   Bela, Dalma
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juranyi, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of OncologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of OncologyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Szekely, Gabor] National Institute of OncologyBudapest, Hungary.
   [Bela, Dalma] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Juranyi, Zs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 184
EP 184
PG 1
ER

PT J
AU Zaka, Z
   Meszaros, N
   Varga, Sz
   Takacsi-Nagy, Z
   Frohlich, G
   Polgar, Cs
AF Zaka, Zoltan
   Meszaros, Norbert
   Varga, Szilvia
   Takacsi-Nagy, Zoltan
   Frohlich, Georgina
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Zaka, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 184
EP 185
PG 2
ER

PT J
AU Szekely, G
   Farkas, Gy
   Kocsis, Zs
   Varadi, M
   Bela, D
   Juranyi, Zs
   Polgar, Cs
AF Szekely, Gabor
   Farkas, Gyongyi
   Kocsis, S. Zsuzsa
   Varadi, Melinda
   Bela, Dalma
   Juranyi, Zsolt
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varadi, Melinda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szekely, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 185
EP 185
PG 1
ER

PT J
AU Kahan, Zs
   Rarosi, F
   Gaal, Sz
   Cserhati, A
   Boda, K
   Darazs, B
   Varga, Z
AF Kahan, Zsuzsanna
   Rarosi, Ferenc
   Gaal, Szilvia
   Cserhati, Adrienn
   Boda, Krisztina
   Darazs, Barbara
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rarosi, Ferenc] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Boda, Krisztina] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 185
EP 185
PG 1
ER

PT J
AU Pintye, �
   Korodi, L
   Csiriban, M
   Balogh, �
AF Pintye, Eva
   Korodi, Laszlo
   Csiriban, Mihaly
   Balogh, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pintye, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Korodi, Laszlo] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Csiriban, Mihaly] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
   [Balogh, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Pintye, � (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 185
EP 186
PG 2
ER

PT J
AU Kolumban, B
   Sebestyen, Zs
   Doczi, T
   Buki, A
   Locsey, Z
   Bellyei, Sz
   Boronkai, �
   Sebestyen, K
   Mangel, L
   Horvath, Zs
AF Kolumban, Balint
   Sebestyen, Zsolt
   Doczi, Tamas
   Buki, Andras
   Locsey, Zoltan
   Bellyei, Szabolcs
   Boronkai, Arpad
   Sebestyen, Klara
   Mangel, Laszlo
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kolumban, Balint] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Doczi, Tamas] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Buki, Andras] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Locsey, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
RP Kolumban, B (reprint author), Pecsi Tudomanyegyetem, Idegsebeszeti Klinika, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 186
EP 186
PG 1
ER

PT J
AU Foldi, G
   Zongor, Zs
   Polgar, Cs
   Lovey, J
AF Foldi, Gerda
   Zongor, Zsuzsanna
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Foldi, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 186
EP 186
PG 1
ER

PT J
AU Cselik, Zs
   Szabo, Z
   Fekete, V
   Pocza, T
   Galdi, �
   Antal, G
AF Cselik, Zsolt
   Szabo, Zoltan
   Fekete, Viktoria
   Pocza, Tamas
   Galdi, Adam
   Antal, Gergely
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Szabo, Zoltan] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Fekete, Viktoria] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Pocza, Tamas] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Galdi, Adam] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Antal, Gergely] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Cselik, Zs (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 186
EP 186
PG 1
ER

PT J
AU Tatai-Szabo, D
   Stelczer, G
   Palvolgyi, J
   Major, T
   Pesznyak, Cs
   Polgar, Cs
AF Tatai-Szabo, Dora
   Stelczer, Gabor
   Palvolgyi, Jeno
   Major, Tibor
   Pesznyak, Csilla
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tatai-Szabo, Dora] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Palvolgyi, Jeno] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Tatai-Szabo, D (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 186
EP 187
PG 2
ER

PT J
AU Mokanszki, B
   Puskas, �
   Acs, F
   Marki, I
   Pajkos, G
AF Mokanszki, Bela
   Puskas, Arpad
   Acs, Ferenc
   Marki, Istvan
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mokanszki, Bela] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Puskas, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Marki, Istvan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Mokanszki, B (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 187
EP 187
PG 1
ER

PT J
AU Varady, Gy
   Vereckei, E
   Derczi, K
   Mangel, L
AF Varady, Gyongyi
   Vereckei, Erika
   Derczi, Katalin
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Vereckei, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Derczi, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Varady, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 187
EP 187
PG 1
ER

PT J
AU Gyapjas, T
   Molnar, M
   Gabor, G
   Pajkos, G
AF Gyapjas, Tunde
   Molnar, Maria
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gyapjas, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 187
EP 187
PG 1
ER

PT J
AU Vegvary, Z
   Koszo, R
   Egyud, Zs
   Varga, L
   Gal, V
   Cserhati, A
   Banyai, �
   Nagy, Z
   Darazs, B
   Varga, Z
   Kahan, Zs
AF Vegvary, Zoltan
   Koszo, Renata
   Egyud, Zsofia
   Varga, Linda
   Gal, Viorica
   Cserhati, Adrienn
   Banyai, Eva
   Nagy, Zoltan
   Darazs, Barbara
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 187
EP 188
PG 2
ER

PT J
AU Smanyko, V
   Meszaros, N
   Ujhelyi, M
   Stelczer, G
   Major, T
   Matrai, Z
   Polgar, Cs
AF Smanyko, Viktor
   Meszaros, Norbert
   Ujhelyi, Mihaly
   Stelczer, Gabor
   Major, Tibor
   Matrai, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ujhelyi, Mihaly] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Smanyko, V (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 188
EP 188
PG 1
ER

PT J
AU Vizkeleti, J
   Frohlich, G
   Horvath, K
   Nguyen, AN
   Meszaros, N
   Major, T
   Polgar, Cs
AF Vizkeleti, Julia
   Frohlich, Georgina
   Horvath, Katalin
   Nguyen, Anhhong Nhung
   Meszaros, Norbert
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 188
EP 188
PG 1
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 188
EP 189
PG 2
ER

PT J
AU Karancsine Heffler, F
   Kovecses, M
   Acs, F
   Gabor, G
   Pajkos, G
AF Karancsine Heffler, Fatime
   Kovecses, Maria
   Acs, Ferenc
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karancsine Heffler, Fatime] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kovecses, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Karancsine Heffler, F (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 189
EP 189
PG 1
ER

PT J
AU Orban, P
   Szollosi, A
   Mokanszki, B
   Gabor, G
   Pajkos, G
AF Orban, Petra
   Szollosi, Anett
   Mokanszki, Bela
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orban, Petra] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szollosi, Anett] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Mokanszki, Bela] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Orban, P (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 189
EP 189
PG 1
ER

PT J
AU Banyai, �
   Pigniczki, T
   Darazs, B
   Nagy, Z
   Vegvary, Z
   Kahan, Zs
AF Banyai, Eva
   Pigniczki, Terezia
   Darazs, Barbara
   Nagy, Zoltan
   Vegvary, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pigniczki, Terezia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Banyai, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 189
EP 189
PG 1
ER

PT J
AU Foldvari, D
   Futo, A
   Brauner, T
   Pora, K
   Horvath, Zs
   Sebestyen, Zs
   Sebestyen, K
   Mangel, L
AF Foldvari, Dora
   Futo, Andrea
   Brauner, Tiborne
   Pora, Krisztina
   Horvath, Zsolt
   Sebestyen, Zsolt
   Sebestyen, Klara
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Futo, Andrea] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Pora, Krisztina] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 189
EP 189
PG 1
ER

PT J
AU Fodor, E
   Koszo, R
   Varga, Z
   Kahan, Zs
AF Fodor, Emese
   Koszo, Renata
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fodor, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 190
EP 190
PG 1
ER

PT J
AU Drencsenyi, R
   Kiscsatari, L
   Nagy, G
   Varga, Z
   Kahan, Zs
AF Drencsenyi, Rita
   Kiscsatari, Laura
   Nagy, Gabor
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kiscsatari, Laura] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Gabor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 190
EP 190
PG 1
ER

PT J
AU Varga, Z
   Koszo, R
   Gaal, Sz
   Darazs, B
   Kahan, Zs
AF Varga, Zoltan
   Koszo, Renata
   Gaal, Szilvia
   Darazs, Barbara
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 190
EP 190
PG 1
ER

PT J
AU Nagy, P
   Antal, G
   Glavak, Cs
   Kovacs, P
   Lakosi, F
   Walter, N
   Cselik, Zs
   Hadjiev, J
AF Nagy, Peter
   Antal, Gergely
   Glavak, Csaba
   Kovacs, Peter
   Lakosi, Ferenc
   Walter, Norbert
   Cselik, Zsolt
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Walter, Norbert] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Nagy, P (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 190
EP 191
PG 2
ER

PT J
AU Glavak, Cs
   Nagy, P
   Antal, G
   Kovacs, P
   Walter, N
   Hadjiev, J
AF Glavak, Csaba
   Nagy, Peter
   Antal, Gergely
   Kovacs, Peter
   Walter, Norbert
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Nagy, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Walter, Norbert] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Glavak, Cs (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 191
EP 191
PG 1
ER

PT J
AU Miovecz, �
   Kisivan, K
   Csendes, V
   Toller, G
   Laszlo, Z
   Vallyon, M
   Glavak, Cs
   Kovacs, P
   Farkas, A
   Cselik, Zs
   Repa, I
   Lakosi, F
   Hadjiev, J
AF Miovecz, Adam
   Kisivan, Katalin
   Csendes, Viktoria
   Toller, Gabor
   Laszlo, Zoltan
   Vallyon, Marta
   Glavak, Csaba
   Kovacs, Peter
   Farkas, Andrea
   Cselik, Zsolt
   Repa, Imre
   Lakosi, Ferenc
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Csendes, Viktoria] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Miovecz, � (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 191
EP 191
PG 1
ER

PT J
AU Balogh, I
   Csiki, E
   Simon, M
   Horvath, Zs
AF Balogh, Istvan
   Csiki, Emese
   Simon, Mihaly
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Csiki, Emese] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Balogh, I (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 191
EP 192
PG 2
ER

PT J
AU Kisivan, K
   Miovecz, �
   Erdelyesi, D
   Csendes, V
   Farkas, A
   Vallyon, M
   Nagy, P
   Kovacs, P
   Glavak, Cs
   Gugyeras, D
   Laszlo, Z
   Toller, G
   Cselik, Zs
   Repa, I
   Lakosi, F
   Hadjiev, J
AF Kisivan, Katalin
   Miovecz, Adam
   Erdelyesi, Dora
   Csendes, Viktoria
   Farkas, Andrea
   Vallyon, Marta
   Nagy, Peter
   Kovacs, Peter
   Glavak, Csaba
   Gugyeras, Daniel
   Laszlo, Zoltan
   Toller, Gabor
   Cselik, Zsolt
   Repa, Imre
   Lakosi, Ferenc
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Erdelyesi, Dora] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Csendes, Viktoria] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Nagy, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gugyeras, Daniel] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kisivan, K (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 192
EP 192
PG 1
ER

PT J
AU Locsei, Z
   Szappanos, Sz
   Laszlo, Z
   Bellyei, Sz
   Sebestyen, Zs
   Sebestyen, K
   Musch, Z
   Csapo, L
   Mangel, LCs
AF Locsei, Zoltan
   Szappanos, Szabolcs
   Laszlo, Zoltan
   Bellyei, Szabolcs
   Sebestyen, Zsolt
   Sebestyen, Klara
   Musch, Zoltan
   Csapo, Laszlo
   Mangel, Laszlo Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Szappanos, Szabolcs] Strahlentherapie Tauber-FrankenBad Mergentheim, Germany.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Csapo, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 192
EP 192
PG 1
ER

PT J
AU Szilagyi, Cs
   Mihaly, E
   Papp, J
   Janvary, ZsL
   Simon, M
AF Szilagyi, Csaba
   Mihaly, Edit
   Papp, Judit
   Janvary, Zsolt Levente
   Simon, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Csaba] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Mihaly, Edit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Szilagyi, Cs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 192
EP 192
PG 1
ER

PT J
AU Kamu, Sz
   Kovacs, P
   Antal, G
   Glavak, Cs
   Nagy, P
   Walter, N
   Kovacs, �
   Repa, I
   Hadjiev, J
AF Kamu, Szabolcs
   Kovacs, Peter
   Antal, Gergely
   Glavak, Csaba
   Nagy, Peter
   Walter, Norbert
   Kovacs, Arpad
   Repa, Imre
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kamu, Szabolcs] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Kovacs, Peter] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Nagy, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Walter, Norbert] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kamu, Sz (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 193
EP 193
PG 1
ER

PT J
AU Balogh, Z
   Gehlne Kaulak, �
   Derjan, B
   Papp, J
   Janvary, ZsL
   Simon, M
AF Balogh, Zoltan
   Gehlne Kaulak, Agota
   Derjan, Brigitta
   Papp, Judit
   Janvary, Zsolt Levente
   Simon, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Zoltan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Gehlne Kaulak, Agota] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Derjan, Brigitta] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Balogh, Z (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 193
EP 193
PG 1
ER

PT J
AU Lakosi, F
   Toller, G
   Laszlo, Z
   Kalincsak, J
   Vallyon, M
   Somogyine Ezer, �
   Glavak, Cs
   Kovacs, P
   Nagy, P
   Walter, N
   Gugyeras, D
   Kisivan, K
   Miovecz, �
   Repa, I
   Cselik, Zs
   Hadjiev, J
AF Lakosi, Ferenc
   Toller, Gabor
   Laszlo, Zoltan
   Kalincsak, Judit
   Vallyon, Marta
   Somogyine Ezer, Eva
   Glavak, Csaba
   Kovacs, Peter
   Nagy, Peter
   Walter, Norbert
   Gugyeras, Daniel
   Kisivan, Katalin
   Miovecz, Adam
   Repa, Imre
   Cselik, Zsolt
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kalincsak, Judit] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Somogyine Ezer, Eva] Kaposi Mor Oktato Korhaz, OnkopulmonologiaKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Nagy, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Walter, Norbert] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gugyeras, Daniel] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 193
EP 193
PG 1
ER

PT J
AU Csoban, E
   Molnar, A
   Janvary, ZsL
   Papp, J
   Simon, M
AF Csoban, Eszter
   Molnar, Anett
   Janvary, Zsolt Levente
   Papp, Judit
   Simon, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csoban, Eszter] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Molnar, Anett] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Csoban, E (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 193
EP 194
PG 2
ER

PT J
AU Janvary, ZsL
   Simon, M
   Der, �
   Mihaly, E
   Szanto, E
   Horvath, Zs
AF Janvary, Zsolt Levente
   Simon, Mihaly
   Der, Adam
   Mihaly, Edit
   Szanto, Erika
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Der, Adam] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Mihaly, Edit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Szanto, Erika] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Janvary, ZsL (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 194
EP 194
PG 1
ER

PT J
AU Tamaskovics, B
   Haussmann, J
   Budach, W
AF Tamaskovics, Balint
   Haussmann, Jan
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Haussmann, Jan] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 194
EP 194
PG 1
ER

PT J
AU Tamaskovics, B
   Haussmann, J
   Budach, W
AF Tamaskovics, Balint
   Haussmann, Jan
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Haussmann, Jan] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 194
EP 195
PG 2
ER

PT J
AU Simon, M
AF Simon, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Simon, M (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 195
EP 195
PG 1
ER

PT J
AU Simon, M
   Balogh, I
   Dobos, E
   Hocza, G
   Kovacs, A
   Janvary, ZsL
   Papp, J
   Horvath, Zs
AF Simon, Mihaly
   Balogh, Istvan
   Dobos, Erik
   Hocza, Gergely
   Kovacs, Attila
   Janvary, Zsolt Levente
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Dobos, Erik] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Hocza, Gergely] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Attila] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Simon, M (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 195
EP 195
PG 1
ER

PT J
AU Jorgo, K
   Agoston, P
   Major, T
   Tenke, P
   Kovacs, G
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Major, Tibor
   Tenke, Peter
   Kovacs, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Tenke, Peter] Jahn Ferenc Korhaz, UrologiaBudapest, Hungary.
   [Kovacs, Gabor] Central Military Hospital, Department of UrologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 195
EP 195
PG 1
ER

PT J
AU Varga, L
   Mullner, K
   Szabo, D
   Koszo, R
   Darazs, B
   Fodor, E
   Varga, Z
   Nikolenyi, A
   Hideghety, K
   Kahan, Zs
   Maraz, A
AF Varga, Linda
   Mullner, Kitti
   Szabo, Dorottya
   Koszo, Renata
   Darazs, Barbara
   Fodor, Emese
   Varga, Zoltan
   Nikolenyi, Aliz
   Hideghety, Katalin
   Kahan, Zsuzsanna
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mullner, Kitti] University of SzegedSzeged, Hungary.
   [Szabo, Dorottya] University of SzegedSzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 195
EP 196
PG 2
ER

PT J
AU Kocsis, Zs
   Agoston, P
   Farkas, Gy
   Szekely, G
   Jorgo, K
   Polgar, Cs
   Juranyi, Zs
AF Kocsis, S. Zsuzsa
   Agoston, Peter
   Farkas, Gyongyi
   Szekely, Gabor
   Jorgo, Kliton
   Polgar, Csaba
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kocsis, Zs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 196
EP 196
PG 1
ER

PT J
AU Bodakos, D
   Suli, K
   Fekete, V
   Santa, M
   Magyarodi, B
   Bohos, B
   Galdi, �
   Antal, G
   Szabo, Z
   Cselik, Zs
AF Bodakos, Dalma
   Suli, Kitti
   Fekete, Viktoria
   Santa, Melinda
   Magyarodi, Beatrix
   Bohos, Bianka
   Galdi, Adam
   Antal, Gergely
   Szabo, Zoltan
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodakos, Dalma] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Suli, Kitti] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Fekete, Viktoria] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Santa, Melinda] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Magyarodi, Beatrix] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Bohos, Bianka] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Galdi, Adam] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Antal, Gergely] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Szabo, Zoltan] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Bodakos, D (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 196
EP 196
PG 1
ER

PT J
AU Suli, K
   Bodakos, D
   Bohos, B
   Fekete, V
   Magyarodi, B
   Pall, J
   Santa, M
   Pocza, T
   Szabo, Z
AF Suli, Kitti
   Bodakos, Dalma
   Bohos, Bianka
   Fekete, Viktoria
   Magyarodi, Beatrix
   Pall, Janos
   Santa, Melinda
   Pocza, Tamas
   Szabo, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Suli, Kitti] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Bodakos, Dalma] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Bohos, Bianka] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Fekete, Viktoria] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Magyarodi, Beatrix] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Pall, Janos] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Santa, Melinda] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Pocza, Tamas] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Szabo, Zoltan] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Suli, K (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 196
EP 196
PG 1
ER

PT J
AU Galdi, �
   Bodakos, D
   Antal, G
   Cselik, Zs
AF Galdi, Adam
   Bodakos, Dalma
   Antal, Gergely
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galdi, Adam] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Bodakos, Dalma] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Antal, Gergely] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Galdi, � (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 196
EP 197
PG 2
ER

PT J
AU Pocza, T
   Szabo, Z
   Cselik, Zs
AF Pocza, Tamas
   Szabo, Zoltan
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Tamas] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Szabo, Zoltan] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Pocza, T (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 197
EP 197
PG 1
ER

PT J
AU Pall, J
   Fekete, V
   Pocza, T
   Szabo, Z
   Toller, G
   Antal, G
   Cselik, Zs
AF Pall, Janos
   Fekete, Viktoria
   Pocza, Tamas
   Szabo, Zoltan
   Toller, Gabor
   Antal, Gergo
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pall, Janos] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Fekete, Viktoria] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Pocza, Tamas] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Szabo, Zoltan] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Toller, Gabor] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Antal, Gergo] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
RP Pall, J (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 197
EP 197
PG 1
ER

PT J
AU Foldi, G
   Polgar, Cs
   Zongor, Zs
   Stelczer, G
   Lovey, J
AF Foldi, Gerda
   Polgar, Csaba
   Zongor, Zsuzsanna
   Stelczer, Gabor
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Foldi, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 197
EP 197
PG 1
ER

PT J
AU Koszo, RL
   Kahan, Zs
   Dobi, �
   Rusz, O
   Kelemen, Gy
   Varga, Z
   Hideghety, K
AF Koszo, Renata Lilla
   Kahan, Zsuzsanna
   Dobi, Agnes
   Rusz, Orsolya
   Kelemen, Gyongyi
   Varga, Zoltan
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 197
EP 198
PG 2
ER

PT J
AU Kalmar, A
   Meszaros, N
   Stelczer, G
   Todor, Sz
   Major, T
   Polgar, Cs
AF Kalmar, Anna
   Meszaros, Norbert
   Stelczer, Gabor
   Todor, Szabolcs
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalmar, Anna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Todor, Szabolcs] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kalmar, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 198
EP 198
PG 1
ER

PT J
AU Bajcsay, A
   Lovey, J
   Zongor, Zs
   Bela, D
   Stelczer, G
   Major, T
   Agoston, P
   Polgar, Cs
AF Bajcsay, Andras
   Lovey, Jozsef
   Zongor, Zsuzsanna
   Bela, Dalma
   Stelczer, Gabor
   Major, Tibor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 198
EP 198
PG 1
ER

PT J
AU Cselik, Zs
   Antal, G
   Hadjiev, J
   Repa, I
AF Cselik, Zsolt
   Antal, Gergely
   Hadjiev, Janaki
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Antal, Gergely] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Cselik, Zs (reprint author), Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias Osztaly, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 198
EP 198
PG 1
ER

PT J
AU Huszar, A
   Heim, A
   Farkas, B
   Dankovics, Zs
   Csejtei, A
AF Huszar, Attila
   Heim, Andras
   Farkas, Bela
   Dankovics, Zsofia
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Huszar, Attila] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Heim, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Farkas, Bela] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Huszar, A (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 199
EP 199
PG 1
ER

PT J
AU Gaal, Sz
   Cserhati, A
   Fodor, E
   Varga, Z
   Egyud, Zs
   Borzasi, E
   Varga, L
   Vegvary, Z
   Banyai, K
   Dobi, �
   Csenki, M
   Torday, L
   Nikolenyi, A
   Maraz, A
   Reisz, Z
   Tiszlavicz, L
   Lazar, Gy
   Kahan, Zs
   Hideghety, K
AF Gaal, Szilvia
   Cserhati, Adrienne
   Fodor, Emese
   Varga, Zoltan
   Egyud, Zsofia
   Borzasi, Emoke
   Varga, Linda
   Vegvary, Zoltan
   Banyai, Klara
   Dobi, Agnes
   Csenki, Melinda
   Torday, Laszlo
   Nikolenyi, Aliz
   Maraz, Aniko
   Reisz, Zita
   Tiszlavicz, Laszlo
   Lazar, Gyorgy
   Kahan, Zsuzsanna
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Banyai, Klara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Reisz, Zita] University of Szeged, Department of PathologySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gaal, Sz (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 199
EP 199
PG 1
ER

PT J
AU Sebestyen, Zs
   Horvath, Zs
   Sebestyen, K
   Locsei, Z
   Boronkai, �
   Bellyei, Sz
   Kolumban, B
   Musch, Z
   Mangel, L
AF Sebestyen, Zsolt
   Horvath, Zsolt
   Sebestyen, Klara
   Locsei, Zoltan
   Boronkai, Arpad
   Bellyei, Szabolcs
   Kolumban, Balint
   Musch, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Horvath, Zsolt] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Kolumban, Balint] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 199
EP 200
PG 2
ER

PT J
AU Vekas, M
   Stelczer, G
   Bajcsay, A
   Agoston, P
   Rausch, G
   Polgar, Cs
AF Vekas, Marton
   Stelczer, Gabor
   Bajcsay, Andras
   Agoston, Peter
   Rausch, Gabriella
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vekas, Marton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Rausch, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vekas, M (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 200
EP 200
PG 1
ER

PT J
AU Patonay, P
   Drajko, V
   Naszaly, A
AF Patonay, Peter
   Drajko, Veronika
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 200
EP 200
PG 1
ER

PT J
AU Szalai, T
   Hegedus, L
   Katona, Cs
   Poti, Zs
   Landherr, L
AF Szalai, Tibor
   Hegedus, Laszlo
   Katona, Csilla
   Poti, Zsuzsa
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hegedus, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Szalai, T (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 200
EP 200
PG 1
ER

PT J
AU Katona, Cs
   Valikovics, A
   Hegedus, L
   Szalai, T
   Landherr, L
AF Katona, Csilla
   Valikovics, Aniko
   Hegedus, Laszlo
   Szalai, Tibor
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Valikovics, Aniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hegedus, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Katona, Cs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 201
EP 201
PG 1
ER

PT J
AU Antal, G
   Cselik, Zs
   Gulyban, �
   Glavak, Cs
   Nagy, P
   Walter, N
   Lakosi, F
   Hadjiev, J
AF Antal, Gergely
   Cselik, Zsolt
   Gulyban, Akos
   Glavak, Csaba
   Nagy, Peter
   Walter, Norbert
   Lakosi, Ferenc
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Antal, Gergely] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cselik, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Gulyban, Akos] University Hospital of Liege, Department of Radiation OncologyLiege, Belgium.
   [Glavak, Csaba] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Nagy, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Walter, Norbert] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposi Mor Teaching HospitalKaposvar, Hungary.
RP Antal, G (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 201
EP 201
PG 1
ER

PT J
AU Akiyama, H
   Major, T
   Polgar, Cs
   Takacsi-Nagy, Z
AF Akiyama, Hironori
   Major, Tibor
   Polgar, Csaba
   Takacsi-Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Akiyama, Hironori] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Akiyama, H (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 201
EP 201
PG 1
ER

PT J
AU Bianco-Molnar, Zs
   Agoston, P
   Jorgo, K
   Major, T
AF Bianco-Molnar, Zsanett
   Agoston, Peter
   Jorgo, Kliton
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bianco-Molnar, Zsanett] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
RP Bianco-Molnar, Zs (reprint author), Budapest University of Technology and Economics, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 202
EP 202
PG 1
ER

PT J
AU Bukovszky, B
   Polgar, Cs
   Fodor, J
   Major, T
AF Bukovszky, Bence
   Polgar, Csaba
   Fodor, Janos
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bukovszky, Bence] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Fodor, Janos] National Institute of OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
RP Bukovszky, B (reprint author), Semmelweis University, Faculty of Medicine, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 202
EP 202
PG 1
ER

PT J
AU Kovacs, P
   Szita, E
   Schvarcz, K
   Csendes, V
   Kisivan, K
   Miovecz, �
   Kalincsak, J
   Antal, G
   Glavak, Cs
   Nagy, P
   Walter, N
   Gugyeras, D
   Kovacs, �
   Repa, I
   Hadjiev, J
AF Kovacs, Peter
   Szita, Evelin
   Schvarcz, Kitti
   Csendes, Viktoria
   Kisivan, Katalin
   Miovecz, Adam
   Kalincsak, Judit
   Antal, Gergely
   Glavak, Csaba
   Nagy, Peter
   Walter, Norbert
   Gugyeras, Daniel
   Kovacs, Arpad
   Repa, Imre
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szita, Evelin] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Schvarcz, Kitti] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Csendes, Viktoria] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kalincsak, Judit] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Nagy, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Walter, Norbert] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gugyeras, Daniel] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kovacs, P (reprint author), PTE KK, Radiologiai Klinika, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 202
EP 202
PG 1
ER

PT J
AU Fodor, D
   Bellyei, Sz
   Laszlo, Z
   Mangel, L
AF Fodor, David
   Bellyei, Szabolcs
   Laszlo, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, David] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Fodor, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 202
EP 203
PG 2
ER

PT J
AU Mangel, L
   Boronkai, �
   Csere, T
AF Mangel, Laszlo
   Boronkai, Arpad
   Csere, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Csere, Tibor] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 203
EP 203
PG 1
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 203
EP 203
PG 1
ER

PT J
AU Dargai, ME
   Czegledi, J
   Pavlikovics, A
   Molnar, K
   Revesz, J
AF Dargai, Marta Edit
   Czegledi, Judit
   Pavlikovics, Annamaria
   Molnar, Katalin
   Revesz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dargai, Marta Edit] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Czegledi, Judit] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Pavlikovics, Annamaria] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Molnar, Katalin] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Revesz, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Dargai, ME (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 203
EP 203
PG 1
ER

PT J
AU Branyiczkine Fehervari, R
   Fekri, K
   Kalman, G
   Molnar, K
AF Branyiczkine Fehervari, Renata
   Fekri, Kathrin
   Kalman, Gabriella
   Molnar, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Branyiczkine Fehervari, Renata] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Fekri, Kathrin] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Kalman, Gabriella] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Molnar, Katalin] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Branyiczkine Fehervari, R (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 203
EP 204
PG 2
ER

PT J
AU Adamecz, Zs
   Varga, E
   Revesz, J
AF Adamecz, Zsolt
   Varga, Emese
   Revesz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Varga, Emese] DE KK, Fogaszati Intezet, RadiologiaDebrecen, Hungary.
   [Revesz, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Adamecz, Zs (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 204
EP 204
PG 1
ER

PT J
AU Palvolgyi, J
   Kofi, AP
AF Palvolgyi, Jeno
   Kofi, Agemang-Prempeh
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Palvolgyi, Jeno] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kofi, Agemang-Prempeh] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Palvolgyi, J (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 204
EP 204
PG 1
ER

PT J
AU Koszo, R
   Vegvary, Z
   Egyud, Zs
   Varga, L
   Nagy, Z
   Darazs, B
   Varga, Z
   Kahan, Zs
AF Koszo, Renata
   Vegvary, Zoltan
   Egyud, Zsofia
   Varga, Linda
   Nagy, Zoltan
   Darazs, Barbara
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 204
EP 204
PG 1
ER

PT J
AU Polgar, Cs
   Strnad, V
   Ott, JO
   Major, T
   Hildebrandt, G
   Kauer-dorner, D
   Knauerhase, H
   Lyczek, J
   Guinot, JL
   Gutierrez, MC
   Slampa, P
   Allgauer, M
   Lossl, K
   Polat, B
   Kovacs, Gy
   Fischedick, AR
   Niehoff, P
   Potter, R
   Gall, Ch
   Uter, W
AF Polgar, Csaba
   Strnad, Vratislav
   Ott, J Oliver
   Major, Tibor
   Hildebrandt, Guido
   Kauer-dorner, Daniela
   Knauerhase, Hellen
   Lyczek, Jaroslaw
   Guinot, Jose Luis
   Gutierrez, Miguelez Cristina
   Slampa, Pavel
   Allgauer, Michael
   Lossl, Kristina
   Polat, Bulent
   Kovacs, Gyorgy
   Fischedick, Arnt-Rene
   Niehoff, Peter
   Potter, Richard
   Gall, Christine
   Uter, Wolfgang
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Strnad, Vratislav] University of ErlangenErlangen, Germany.
   [Ott, J Oliver] University of ErlangenErlangen, Germany.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Hildebrandt, Guido] University Hospital LeipzigLeipzig, Germany.
   [Kauer-dorner, Daniela] University Hospital AKHVienna, Austria.
   [Knauerhase, Hellen] University Hospital RostockRostock, Germany.
   [Lyczek, Jaroslaw] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Guinot, Jose Luis] Fundacion Instituto Valenciano de OncologiaValencia, Spain.
   [Gutierrez, Miguelez Cristina] Catalan Institute of OncologyBarcelona, Spain.
   [Slampa, Pavel] Masaryk Memorial HospitalBrno, Czech Republic.
   [Allgauer, Michael] Hospital Barmherzige BruderRegensburg, Germany.
   [Lossl, Kristina] University Hospital BernBern, Switzerland.
   [Polat, Bulent] University Hospital WurzburgWurzburg, Germany.
   [Kovacs, Gyorgy] University of Luebeck, University-Hospital Schleswig- HolsteinLubeck, Germany.
   [Fischedick, Arnt-Rene] Clemens Hospital MunsterMunster, Germany.
   [Niehoff, Peter] University Medical Center Schleswig-HolsteinKiel, Germany.
   [Potter, Richard] Clemens Hospital MunsterMunster, Germany.
   [Gall, Christine] University of ErlangenErlangen, Germany.
   [Uter, Wolfgang] University of ErlangenErlangen, Germany.
RP Polgar, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 204
EP 205
PG 2
ER

PT J
AU Arnoczkine Orban, H
   Stefan, A
   Toth, J
   Bela, D
   Stelczer, G
   Foldi, G
   Polgar, Cs
   Lovey, J
AF Arnoczkine Orban, Helga
   Stefan, Anita
   Toth, Judit
   Bela, Dalma
   Stelczer, Gabor
   Foldi, Gerda
   Polgar, Csaba
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arnoczkine Orban, Helga] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stefan, Anita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Toth, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Arnoczkine Orban, H (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 205
EP 205
PG 1
ER

PT J
AU Bela, D
   Zongor, Zs
   Stelczer, G
   Pesznyak, Cs
   Bajcsay, A
   Lovey, J
   Major, T
   Polgar, Cs
AF Bela, Dalma
   Zongor, Zsuzsanna
   Stelczer, Gabor
   Pesznyak, Csilla
   Bajcsay, Andras
   Lovey, Jozsef
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bela, D (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 205
EP 205
PG 1
ER

PT J
AU Todor, ISz
   Stelczer, G
   Jorgo, K
   Agoston, P
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Todor, Istvan Szabolcs
   Stelczer, Gabor
   Jorgo, Kliton
   Agoston, Peter
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Todor, Istvan Szabolcs] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Todor, ISz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 205
EP 206
PG 21
ER

PT J
AU Ferenczi, �
   Oberna, F
   Somogyi, A
   Major, T
   Polgar, Cs
   Takacsi-Nagy, Z
AF Ferenczi, Ors
   Oberna, Ferenc
   Somogyi, Andras
   Major, Tibor
   Polgar, Csaba
   Takacsi-Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Ors] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti OsztalyKecskemet, Hungary.
   [Somogyi, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Ferenczi, � (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 206
EP 206
PG 1
ER

PT J
AU Szabo, I
   Esik, O
   Revesz, J
AF Szabo, Imre
   Esik, Olga
   Revesz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Imre] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Esik, Olga] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
RP Szabo, I (reprint author), County Hospital of Borsod-Abauj-Zemplen, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 206
EP 206
PG 1
ER

PT J
AU Gesztesi, L
   Jorgo, K
   Stelczer, G
   Agoston, P
   Polgar, Cs
AF Gesztesi, Laszlo
   Jorgo, Kliton
   Stelczer, Gabor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Gesztesi, L (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 206
EP 206
PG 1
ER

PT J
AU Toller, G
   Lakosi, F
   Miovecz, �
   Antal, G
   Pall, J
   Farkas, A
   Nagy, D
   Jenei, T
   Repa, I
   Hadjiev, J
AF Toller, Gabor
   Lakosi, Ferenc
   Miovecz, Adam
   Antal, Gergely
   Pall, Janos
   Farkas, Andrea
   Nagy, Denes
   Jenei, Tibor
   Repa, Imre
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Pall, Janos] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Nagy, Denes] Kaposi Mor Teaching Hospital, Department of UrologyKaposvar, Hungary.
   [Jenei, Tibor] Kaposi Mor Teaching Hospital, Department of UrologyKaposvar, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Toller, G (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 206
EP 207
PG 2
ER

PT J
AU Bellyei, Sz
   Laszlo, Z
   Papp, A
   Gomori, �
   Mangel, L
   Farkas, R
AF Bellyei, Szabolcs
   Laszlo, Zoltan
   Papp, Andras
   Gomori, Eva
   Mangel, Laszlo
   Farkas, Robert
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Papp, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Gomori, Eva] University of Pecs, Department of PathologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 207
EP 207
PG 1
ER

PT J
AU Molnar, A
   Boronkai, �
   Mangel, L
   Locsei, Z
   Kalincsak, J
   Sarosi, V
   Baliko, Z
   Al-Farhat, Y
AF Molnar, Andras
   Boronkai, Arpad
   Mangel, Laszlo
   Locsei, Zoltan
   Kalincsak, Judit
   Sarosi, Veronika
   Baliko, Zoltan
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalincsak, Judit] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Molnar, A (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 207
EP 207
PG 1
ER

PT J
AU Nikolenyi, A
   Dobi, �
   Varga, L
   Gal, V
   Varga, Z
   Fodor, E
   Mencser, Z
   Varga, �
   Balazsfi, M
   Kahan, Zs
   Hideghety, K
AF Nikolenyi, Aliz
   Dobi, Agnes
   Varga, Linda
   Gal, Viorica
   Varga, Zoltan
   Fodor, Emese
   Mencser, Zoltan
   Varga, Adam
   Balazsfi, Marton
   Kahan, Zsuzsanna
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mencser, Zoltan] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Varga, Adam] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Balazsfi, Marton] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nikolenyi, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 207
EP 208
PG 2
ER

PT J
AU Maraz, A
   Varga, L
   Mullner, K
   Szabo, D
   Cserhati, A
   Fodor, E
   Varga, Z
   Hideghety, K
   Kahan, Zs
AF Maraz, Aniko
   Varga, Linda
   Mullner, Kitti
   Szabo, Dorottya
   Cserhati, Adrienn
   Fodor, Emese
   Varga, Zoltan
   Hideghety, Katalin
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mullner, Kitti] University of SzegedSzeged, Hungary.
   [Szabo, Dorottya] University of SzegedSzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 208
EP 208
PG 1
ER

PT J
AU Meszaros, N
   Major, T
   Stelczer, G
   Zaka, Z
   Takacsi-Nagy, Z
   Mozsa, E
   Fodor, J
   Polgar, Cs
AF Meszaros, Norbert
   Major, Tibor
   Stelczer, Gabor
   Zaka, Zoltan
   Takacsi-Nagy, Zoltan
   Mozsa, Emoke
   Fodor, Janos
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mozsa, Emoke] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 208
EP 208
PG 1
ER

PT J
AU Plavecz, �
   Klinko, T
   Jobahazi, J
   Nagy, Zs
   Landherr, L
AF Plavecz, Eva
   Klinko, Timea
   Jobahazi, Jeno
   Nagy, Zsolt
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Jobahazi, Jeno] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Nagy, Zsolt] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Plavecz, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 208
EP 209
PG 2
ER

PT J
AU Bencsik, B
   Stelczer, G
   Papp, I
   Elek, R
   Major, T
   Polgar, Cs
   Pesznyak, Cs
AF Bencsik, Barbara
   Stelczer, Gabor
   Papp, Ildiko
   Elek, Richard
   Major, Tibor
   Polgar, Csaba
   Pesznyak, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bencsik, Barbara] National Institute of OncologyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of OncologyBudapest, Hungary.
   [Papp, Ildiko] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Elek, Richard] Orszagos Kozegeszsegugyi Kozpont, Orszagos Sugarbiologiai es Sugaregeszsegugyi Kutato Igazgatosag, Molekularis Sugarbiologia es Biodozimetria OsztalyBudapest, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of OncologyBudapest, Hungary.
RP Bencsik, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 209
EP 209
PG 1
ER

PT J
AU Bodacs, I
   Polgar, Cs
   Meszaros, N
   Major, T
AF Bodacs, Istvan
   Polgar, Csaba
   Meszaros, Norbert
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bodacs, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bodacs, I (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 209
EP 209
PG 1
ER

PT J
AU Czifra, Gy
   Csongradi, T
   Mangel, L
AF Czifra, Gyozo
   Csongradi, Timea
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czifra, Gyozo] University of Pecs, Department of OncologyPecs, Hungary.
   [Csongradi, Timea] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Czifra, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 209
EP 210
PG 2
ER

PT J
AU Marki, I
   Mokanszki, B
   Acs, F
   Puskas, �
AF Marki, Istvan
   Mokanszki, Bela
   Acs, Ferenc
   Puskas, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marki, Istvan] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Mokanszki, Bela] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Puskas, Arpad] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Marki, I (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 210
EP 210
PG 1
ER

PT J
AU Moricz, DA
   Folyovich, �
   Kontra, G
   Bencsik, B
   Bajcsay, A
   Major, T
AF Moricz, Diana Alexandra
   Folyovich, Eva
   Kontra, Gabor
   Bencsik, Barbara
   Bajcsay, Andras
   Major, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moricz, Diana Alexandra] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Folyovich, Eva] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bencsik, Barbara] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Moricz, DA (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 210
EP 210
PG 1
ER

PT J
AU Nguyen, AN
   Varga, Sz
   Kiraly, R
   Major, T
   Polgar, Cs
AF Nguyen, Anhhong Nhung
   Varga, Szilvia
   Kiraly, Reka
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Nguyen, AN (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 210
EP 210
PG 1
ER

PT J
AU Kontra, G
   Major, T
   Polgar, Cs
AF Kontra, Gabor
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kontra, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2017
VL 61
IS 2
BP 210
EP 211
PG 2
ER

PT J
AU Nagy, ACs
   Lodi, M
   Balogh, I
   Czuriga, D
   Kocsis, J
AF Nagy, Andras Csaba
   Lodi, Maria
   Balogh, Ingrid
   Czuriga, Daniel
   Kocsis, Judit
TI New recommendations in oncocardiology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cardiotoxicity; cancer; cardiology
ID cardiotoxicity; cancer; cardiology
AB It is well-known that modern oncotherapy significantly reduced the mortality of malignant diseases. However, serious side effects of the applied cancer therapies have evolved, which may adversely affect the cardiovascular system. Early side effects often limit therapeutic success of oncotherapy and may require treatment interruption, while late-onset side effects can adversely influence the long-term survival of patients recovering from cancer. Oncocardiology is a new medical field gaining more and more attention. It aims at the optimisation of the efficacy of cancer therapy and clinical outcome of patients. In the current review we present such important recommendations that may help the management of cardiovascular toxicity of cancer therapy in the everyday clinical practice.
C1 [Nagy, Andras Csaba] Uzsoki Municipal Hospital, 1st Department of Internal Medicine and Cardiology, Uzsoki u. 29-41., 1145 Budapest, Hungary.
   [Lodi, Maria] University of Debrecen, Faculty of Medicine, Department of PhysiologyDebrecen, Hungary.
   [Balogh, Ingrid] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Czuriga, Daniel] Debreceni Egyetem, Klinikai Kozpont, Kardiologiai IntezetDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Nagy, ACs (reprint author), Uzsoki Municipal Hospital, 1st Department of Internal Medicine and Cardiology, 1145 Budapest, Hungary.
EM nagycsaba@uzsoki.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 219
EP 227
PG 9
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI Nutrition therapy of cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer; nutrition therapy; malnutrition; cachexia; sarcopenia
ID cancer; nutrition therapy; malnutrition; cachexia; sarcopenia
AB The majority of cancer patients becomes malnourished during the course of their disease. Malnutrition deteriorates the efficiency of all kinds of oncologic interventions. As a consequence of it, treatment-related toxicity increases, hospital stay is lengthened, chances of cure and survival as well as the quality of life of the patients worsen. Nutritional status therefore influences all aspects of outcome of oncology care. In spite of this the use of nutritional therapy varies across health care providers but its application is far from being sufficient during active oncology interventions as well as rehabilitation and supportive care. It threatens not only the outcome and quality of life of cancer patients but also the success of oncologic treatments which often demand high input of human and financial resources. Meanwhile application of nutritional therapy is legally regulated in Hungary and a very recent update of the European guideline on cancer patient nutrition published in 2017 is available. Moreover, cost effectiveness of nutritional therapy has been proven in a number of studies. In this review we present the basics of nutritional therapy including nutritional screening and evaluation, nutritional plan, the role of nutrition support teams, oral, enteral and parenteral nutrition, the use of different drugs and special nutrients and the follow-up of the patients.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 229
EP 237
PG 9
ER

PT J
AU Telekes, A
AF Telekes, Andras
TI Approaching new pharmacotherapy options in pain treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pain treatment; genetic/epigenetic targets; RNA therapy; pain receptors
ID pain treatment; genetic/epigenetic targets; RNA therapy; pain receptors
AB The evolution of medicine is noticeable in most therapeutic areas, the worse the current therapeutic result, the more quick the improvement. This is especially true in such areas that require substantial social resources, namely oncology, diabetology and CNS diseases. Pain is not a disease, it is a symptom. Pain is one of the most important components of human suffering thus it deserves special attention. In recent years new formulations of old medicines were introduced rather than new medicines. Maybe ziconitide is the last pain killer with new mechanism of action which was approved by FDA in 2004. However, the new information and techniques are also appearing in the field of analgesia. Nowadays one can talk about genetic/epigenetic targets, RNA therapies, voltage-gated calcium channels, new pain receptors (TRPV1, TRPV4, NMDA, Nav receptors) regarding pain treatment, indicating that the practice of the pharmacotherapy of pain will change fundamentally in the immediate future. This paper is intended to give a short summary of these new options.
C1 [Telekes, Andras] Semmelweis University, 2nd Department of Internal Medicine, Halmi utca 20-22., 1115 Budapest, Hungary.
RP Telekes, A (reprint author), Semmelweis University, 2nd Department of Internal Medicine, 1115 Budapest, Hungary.
EM prof.andras.telekes@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 238
EP 245
PG 8
ER

PT J
AU Simko, Cs
AF Simko, Csaba
TI Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer; palliative care; nausea; vomiting; antiemetics
ID cancer; palliative care; nausea; vomiting; antiemetics
AB Nausea and vomiting are frequent and fearful issues both of cancer itself and its treatment, resulting in reduced quality of life, hospitalization and unnecessary medical investigations. Unconventionally, the author discusses the treatment-related and non-treatment-related complaints together, so as to give an integrated approach to this problem. Different types of nausea/vomiting and important causes are explained by discussion of the pathophysiology and clinical symptoms. Different classes of antiemetics are detailed, emphasizing the evolving role of olanzapine in the treatment of both the acute and delayed type of chemotherapy-induced nausea/vomiting. It was no aim of this review to detail all aspects of MASCC and ESMO antiemetic guideline issued in 2016, but the main topics are presented together with other antiemetic strategies.
C1 [Simko, Csaba] Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz, Erzsebet Hospice OtthonMiskolc, Hungary.
RP Simko, Cs (reprint author), Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz, Erzsebet Hospice Otthon, Miskolc, Hungary.
EM simkocsa@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 247
EP 257
PG 11
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI Treatment of chemotherapy-induced febrile neutropenia in solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE febrile neutropenia; solid tumor; antibiotics; granulocyte colony-stimulating factor
ID febrile neutropenia; solid tumor; antibiotics; granulocyte colony-stimulating factor
AB One of the most dangerous complications of bone marrow suppression due to chemotherapy is febrile neutropenia. The treatment of the affected patients is a multidisciplinary task. In addition to chemotherapy, adequate G-CSF therapy as a primary and secondary prophylaxis can be used to prevent a large part of febrile neutropenic events. Before each chemotherapy cycle, the risk of febrile neutropenia should be evaluated, taking into account the chemotherapeutic combination and patient-specific parameters. Appropriate antibiotic and G-CSF therapy initiated in the course of febrile neutropenia is essential for the success of the therapy. The oncologists can reach treatment success in the patient’s therapy if he or she provides the patient the adequate supportive medications at the appropriate time.
C1 [Galffy, Gabriella] Semmelweis University, Department of Pulmonology, Dios arok 1/CBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
EM ggalffy@hotmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 261
EP 266
PG 6
ER

PT J
AU Pfliegler, Gy
AF Pfliegler, Gyorgy
TI Venous thromboembolism (VTE) – current diagnosis and therapy, with special attention towards oncologic patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE venous thromboembolia; diagnosis; therapy; oncology
ID venous thromboembolia; diagnosis; therapy; oncology
AB Deep vein thrombosis (DVT), pulmonary embolism (PE), or with the common name venous thromboembolism (VTE) are frequent manifestations of pathologic hemostasis in malignancies, thereby contributing to the large number of patients despite recent developments in thrombosis prevention. In the present paper up-to-date practice of diagnosis and therapy will be discussed partly based on the author’s previous publications on epidemiology and prophylaxis of VTE in oncological patients.
C1 [Pfliegler, Gyorgy] Debreceni Egyetem Klinikai Kozpont, Ritka Betegsegek Szakertoi Kozpont es Belgyogyaszati Intezet, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Pfliegler, Gy (reprint author), Debreceni Egyetem Klinikai Kozpont, Ritka Betegsegek Szakertoi Kozpont es Belgyogyaszati Intezet, 4032 Debrecen, Hungary.
EM g.pfliegler@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 267
EP 274
PG 8
ER

PT J
AU Mailath, M
   Laczkone Majer, R
   Horvath, Zs
   Szabo, GS
AF Mailath, Monika
   Laczkone Majer, Reka
   Horvath, Zsolt
   Szabo, Gergely Sandor
TI The early recognition of mental morbidities during psycho-oncologic treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE psycho-oncology; distress; screening; problem list; distress thermometer
ID psycho-oncology; distress; screening; problem list; distress thermometer
AB Unfortunately there have been no positive changes in the main indicators of cancer incidence in Hungarian population since the turn of the millennium. The main goal of psycho-oncologic treatment is to provide the highest possible quality of life to the patient. The prevalence of mental disorders in cancer patients is high and it is accompanied by a rather small number of qualified staff. Thus, the remedy might be the identification of high-risk patients, i.e. the systematic psycho-oncologic screening. Hungary is still lacking a unified screening method that involves all oncologic treatment-providing units. Compiling the Hungarian standards for the Distress Thermometer and the Problem List is the first step of a complex program for creating a general psycho-oncologic screening. Such a comprehensive program might improve oncologic patient-care and, eventually, the quality and prospect of the lives of patients.
C1 [Mailath, Monika] University of Debrecen, Department of Oncology, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Laczkone Majer, Reka] University of Debrecen, Department of Oncology, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of Oncology, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
   [Szabo, Gergely Sandor] Karoli Gaspar Reformatus Egyetem, Pszichologia Intezet, Klinikai Pszichologia TanszekBudapest, Hungary.
RP Mailath, M (reprint author), University of Debrecen, Department of Oncology, 4032 Debrecen, Hungary.
EM mailathmoni@freemail.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 276
EP 283
PG 8
ER

PT J
AU Kovacs, P
   Koncz, Zs
   Peti, J
   Godeny, A
   Horvath, D
   Gerlinger, Cs
   Lacsan, K
   Molnar, P
   Risko, �
AF Kovacs, Peter
   Koncz, Zsuzsa
   Peti, Julianna
   Godeny, Anna
   Horvath, Dora
   Gerlinger, Csilla
   Lacsan, Katalin
   Molnar, Petra
   Risko, Agnes
TI Areas and challenges of oncopsychological rehabilitation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oncopsychosocial; rehabilitation; cancer patients; education; psychotherapy
ID oncopsychosocial; rehabilitation; cancer patients; education; psychotherapy
AB Patients with cancer present a number of different difficulties that adversely affect their health care and recovery (e.g. poor communication with physicians, lack of knowledge about their illness and its management, financial problems). Furthermore, mental health problems, such as distress, depression and anxiety, are common amongst patients with cancer. These mental health problems are additional contributors to functional impairment in carrying out family, work, and other social roles, poor adherence to medical treatments, and adverse medical outcomes. Oncopsychosocial rehabilitation aims to optimize the possibilities of medical health care through psychological interventions by helping cancer patients and their families and/or health care workers with the management of the psychological and social aspects of the illness. Oncopsychosocial rehabilitation includes all psychosocial interventions that are designed to positively influence patient psychosocial adaptation and adjustment to diagnosis, treatment, and survivorship. Oncopsychological rehabilitation could also manage cancer related distress and other psychosocial problems with specific types of treatments or interventions including prevention, relaxation techniques, structured psychoeducational interventions including sexual information and/or preparation for surgery, and various methods of psychotherapy.
C1 [Kovacs, Peter] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Koncz, Zsuzsa] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Peti, Julianna] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Godeny, Anna] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Dora] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gerlinger, Csilla] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lacsan, Katalin] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Molnar, Petra] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Risko, Agnes] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kovacs, P (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM kope.kope@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 284
EP 291
PG 8
ER

PT J
AU Benyo, G
   Lukacs, M
   Busa, Cs
   Mangel, L
   Csikos, �
AF Benyo, Gabor
   Lukacs, Miklos
   Busa, Csilla
   Mangel, Laszlo
   Csikos, Agnes
TI Current situation of palliative care in Hungary. Integrated palliative care model as a breakout possibility
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE palliative-hospice care; integrated; early palliative care; multidisciplinary teams; quality of life; communication
ID palliative-hospice care; integrated; early palliative care; multidisciplinary teams; quality of life; communication
AB Modern palliative-hospice care has gained space in Europe for more than 50 years. Since the initial empirical work of Cicely Saunders, palliative medicine has gained its place in evidence-based medicine in more and more countries. However, development, as in many other medical fields, is not uniform, there are big differences between countries in the world. There are also significant differences in development of care and the level of services within the European Union amongst Western and Eastern European countries. These differences affect the professional approach, legislative mechanisms and social acceptance. Hungarian palliative-hospice care has developed significantly over the past 15 years. For further development thoughtful strategic steps and service development is needed. The integration of palliative care into standard oncology is an international requirement, which also appears in the form of professional guidelines. Hungary has also played a role in the development of the European model of integrated palliative care of which Hungarian implementation, the “Pecs model”, is discussed in detail in our paper.
C1 [Benyo, Gabor] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, Bartok B. u. 21., 2045 Torokbalint, Hungary.
   [Lukacs, Miklos] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Busa, Csilla] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Csikos, Agnes] PTE AOK, Alapellatasi IntezetPecs, Hungary.
RP Benyo, G (reprint author), Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, 2045 Torokbalint, Hungary.
EM drbenyo@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 292
EP 299
PG 8
ER

PT J
AU Timar, J
   Lotz, G
   Raso, E
   Moldvay, J
AF Timar, Jozsef
   Lotz, Gabor
   Raso, Erzsebet
   Moldvay, Judit
TI Molecular diagnostics of ALK-positive lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE ALK gene rearrangement; lung cancer; diagnostics; therapy
ID ALK gene rearrangement; lung cancer; diagnostics; therapy
AB ALK translocation is the 3rd most frequent genetic aberration in lung adenocarcinoma, and several inhibitors are now clinically available in first and second line settings. Accordingly, molecular diagnostics of ALK-positive lung cancer is very important and can be done with the rational combination of several methods. All international recommendations suggest that, except for cytological samples, screening technology for ALK-positive tumors is immunohistochemistry using a validated test. It is highly recommended that in case of ALK protein positive samples gene translocation must be confirmed by fluorescent in situ hybridization (FISH). In case of cytological samples FISH technique must be used as ALK diagnostics. In equivocal cases the genetic alteration of ALK can be confirmed by alternative molecular techniques such as next generation sequencing or RNAbased PCR methods. Upon administration of ALK inhibitors, acquired resistance is frequent which is mostly due to ALK amplification and/or mutation. It is evident that the diagnostics of these secondary ALK gene alterations must be done from recurrent tumors or circulating nucleic acids.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2017
VL 61
IS 3
BP 301
EP 311
PG 11
ER

PT J
AU Matrai, Z
   Mangel, L
   Kasler, M
   Nagy, P
   Szende, B
   Harsanyi, L
AF Matrai, Zoltan
   Mangel, Laszlo
   Kasler, Miklos
   Nagy, Peter
   Szende, Bela
   Harsanyi, Laszlo
TI In memoriam Prof. Dr. Besznyak Istvan
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Matrai, Zoltan] Magyar Onkologusok Tarsasaga, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Mangel, Laszlo] Magyar Onkologusok Tarsasaga, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Nagy, Peter] Magyar Onkologusok Tarsasaga, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Szende, Bela] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Harsanyi, Laszlo] Magyar Sebesz TarsasagBudapest, Hungary.
RP Matrai, Z (reprint author), Magyar Onkologusok Tarsasaga, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 316
EP 317
PG 2
ER

PT J
AU Deme, D
   Telekes, A
AF Deme, Daniel
   Telekes, Andras
TI Prognostic importance of cross-linked fibrin degradation products (D-dimer) in oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE D-dimer; malignancy; prognosis
ID D-dimer; malignancy; prognosis
AB Cross-linked fibrin degradation products (D-dimer) are formed in two ways: on the one hand through coagulation cascade and on the other hand through fibrinolytic cascade. In the former case, plasmin cleaves the soluble cross-linked fibrin, and in the latter it cleaves the non-soluble cross-linked fibrin. In patients with malignant diseases, several factors influence the clinical evaluation of the result of D-dimer assay. First, D-dimer level can be elevated in cancer patients without thrombosis, which can be explained by procoagulant factors produced by malignant cells. Second, none of the algorithms used for diagnosing venous thromboembolism have been validated on patients with malignant diseases. Furthermore, the negative predictive value of D-dimer on thrombosis or thromboembolism is lower in cancer patients comparing to those who are not suffering from malignant disease. In patients with malignant disease, where venous thrombosis has not been proven, higher D-dimer level correlates with shorter survival. Based on the available data of the literature, the authors summarize some important studies which revealed the relationship between baseline D-dimer level and prognosis in cancer patients.
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Fuleki ut 54., 3100 Salgotarjan, Hungary.
   [Telekes, Andras] Semmelweis Egyetem, Geriatriai Tanszeki CsoportBudapest, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, 3100 Salgotarjan, Hungary.
EM danieldeme_md@ymail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 319
EP 326
PG 8
ER

PT J
AU Nagy, �
   Garzuly, F
   Kalman, B
AF Nagy, Adam
   Garzuly, Ferenc
   Kalman, Bernadette
TI Pathogenic alterations within the neurofibromin gene in various cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE NF1; neurofibromin; tumor suppressor gene; mutations; tumorigenesis
ID NF1; neurofibromin; tumor suppressor gene; mutations; tumorigenesis
AB The product of the neurofibromin gene (NF1) belongs to the family of tumor suppressor proteins. Neurofibromin plays important roles in the negative regulation of signaling pathways where the Ras oncogen is involved. The protein and gene names were derived from the disease, neurofibromatosis type 1 that is caused by germline mutations in NF1 and inherited by an autosomal dominant manner. Besides germline mutations, acquired, somatic mutations are also observed in NF1 in several malignant and benign tumors. NF1 mutations have been identified in a great number of solid tumors, leukemias and malignant skin lesions (e.g. melanoma). Such mutations define certain subsets of gliomas. More specifically, a molecular subset of glioblastomas, termed the mesenchymal subtype, is most frequently associated with somatic NF1 deletions and mutations. The aim of this survey is to provide an overview of the most frequent alterations in the NF1 gene with their effects on the function of the protein and the biology of the cell, as well as of the resultant diseases. Simultaneously, we give some insight into ongoing research studies investigating abnormalities of NF1.
C1 [Nagy, Adam] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Garzuly, Ferenc] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Kalman, Bernadette] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Kalman, B (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori Iskola, Pecs, Hungary.
EM bernadett.kalman@etk.pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 327
EP 336
PG 10
ER

PT J
AU Kupcsulik, P
   Onody, P
AF Kupcsulik, Peter
   Onody, Peter
TI Laparoscopic resection of giant hepatocellular carcinoma and the Barcelona staging
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE hepatocellular carcinoma; laparoscopic liver resection; pedunculated liver tumor; Barcelona (BCLC) staging
ID hepatocellular carcinoma; laparoscopic liver resection; pedunculated liver tumor; Barcelona (BCLC) staging
AB Liver resection is the most effective treatment for hepatocellular carcinoma, however, decision for surgery remained confusing. In Europe the most accepted Barcelona staging system sets minimal value on surgical interventions. Long lasting diagnostic steps and uncertainty for indication of resection are possible consequences of this approach. The reported case is an example for the fact that exceptionally large tumor having been grown during time-consuming diagnostic attempts might be removed by laparoscopic surgery. The case hopefully could lead to widespread acceptance of up-to-date surgical treatment of hepatocellular carcinoma.
C1 [Kupcsulik, Peter] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Onody, Peter] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
RP Kupcsulik, P (reprint author), Semmelweis University, 1st Department of Surgery, 1082 Budapest, Hungary.
EM sibas@t-online.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 339
EP 342
PG 4
ER

PT J
AU Kovacs, Zs
   Rigo, A
   Szabo, �
   Sebestyen, �
   Fulop, E
   Szabo, Cs
AF Kovacs, Zsuzsa
   Rigo, Adrien
   Szabo, Eva
   Sebestyen, Arpad
   Fulop, Emoke
   Szabo, Csaba
TI Health-related quality of life from a new perspective – The role of illness representations in patients with breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast cancer; predictors of quality of life; negative affectivity; illness perception
ID breast cancer; predictors of quality of life; negative affectivity; illness perception
AB In the modern oncology care the subject of quality of life has an emphasized importance. In our research we assessed aspects which may predict the quality of life. We hypothesized that after controlling the demographical and some medical factors, psychological distress and illness representations would have significant roles as predictors. The research has been carried out in Budapest at the Radiology Diagnostic Department of the National Institute of Oncology; participants were women (N=221) treated for malignant breast tumour (C50). The research tools included the Shortened Beck Depression Inventory, Quality of Life Questionnaire (EORTC QLQ-C30, QLQBR23), Spielberger’s State-Trait Anxiety Inventory (STAI-T), and the Revised Illness Perception Questionnaire (IPQ-R). In terms of functional (β=-0.705, p=0.000; β=0.493, p=0.003), and symptom quality of life (β=0.517, p=0.000) negative affectivity has an outstanding role as predictor. Among the illness representations, the functional quality of life is influenced by cognitions concerning the illness consequences (β=0.243, p=0.008) and by emotional representations (β=0.220, p=0.034). Cognitive representations influencing the symptom quality of life are serious consequences (β=0.240, p=0.016) and illness perception (β=0.212, p=0.011). In the improvement of quality of life, treating negative affectivity has determining and the modification of dysfunctional illness cognitions play important roles.
C1 [Kovacs, Zsuzsa] Semmelweis University, Institute of Behavioural Sciences, Vas utca 17., 1088 Budapest, Hungary.
   [Rigo, Adrien] Eotvos Lorand Tudomanyegyetem PPK, Klinikai Pszichologia es Addiktologia TanszekBudapest, Hungary.
   [Szabo, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sebestyen, Arpad] Egeszsegforras AlapitvanyBudapest, Hungary.
   [Fulop, Emoke] Semmelweis University, Institute of Behavioural Sciences, Vas utca 17., 1088 Budapest, Hungary.
   [Szabo, Csaba] Debreceni Egyetem, Pszichologiai IntezetDebrecen, Hungary.
RP Kovacs, Zs (reprint author), Semmelweis University, Institute of Behavioural Sciences, 1088 Budapest, Hungary.
EM kovacszs@se-etk.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 343
EP 348
PG 6
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI The post-treatment cognitive impairment („chemobrain”) in breast cancer patients. Short review.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; chemotherapy; cognitive impairment; chemobrain
ID breast cancer; chemotherapy; cognitive impairment; chemobrain
AB With the continually growing number of cancer survivors in the past decades there is an increased interest in understanding and treating the adverse events of cancer therapy, which damage the survivor’s quality of life. Post-treatment cognitive impairment (chemobrain) is well known in women with breast cancer and other patients with malignancy. The goal of the current short review is to arouse the caregivers’ attention to the not severe, but real problem.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Vorosmarty utca 31., 1064 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1064 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 349
EP 351
PG 3
ER

PT J
AU Maraz, A
   Boer, K
   Dankovics, Zs
   Dank, M
   Lahm, E
   Petranyi, �
   Revesz, J
   Ruzsa, �
   Szucs, M
   Valikovics, A
   Vas, M
   Kuronya, Zs
AF Maraz, Aniko
   Boer, Katalin
   Dankovics, Zsofia
   Dank, Magdolna
   Lahm, Erika
   Petranyi, Agota
   Revesz, Janos
   Ruzsa, Agnes
   Szucs, Miklos
   Valikovics, Aniko
   Vas, Maria
   Kuronya, Zsofia
TI Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE metastatic prostate cancer; cabazitaxel; castration resistance; chemotherapy; docetaxel
ID metastatic prostate cancer; cabazitaxel; castration resistance; chemotherapy; docetaxel
AB Our aim was to assess the efficacy and adverse effects of cabazitaxel (CBZ), a chemotherapeutic agent that can be administered to patients with metastatic castrate resistant prostate cancer (mCRPC) after docetaxel (DOC) therapy. We retrospectively analyzed data of CBZ received by mCRPC patients in 12 Hungarian oncological centers between 01/2016 and 06/2017. CBZ (25 or 20 mg/m2 q3w) was administered after DOC. Physical and laboratory examinations were performed in every cycle, tumor response was evaluated in every third cycle based on PCWG2 criteria. Adverse effects were evaluated based on CTCAE 4.0. Data of 60 patients were analyzed. CBZ was administered in 2nd and 3rd lines in 31.6% and 46.6%, while in 4th and 5th lines in 15% and 6.6% patients, respectively. Its starting dose was 25 mg/m2 and 20 mg/m2 in 65% and 35% of cases, respectively. The median number of cycles was 5. Progression-free survival and overall survival were 5.52 and 15.77 months, respectively. Survival results were similar in case of DOC-CBZ-ART/alfaradin and DOC-ART/alfaradin-CBZ sequences. Adverse effects were detected in 63,3% of patients. The most common adverse effects were neutropenia, anemia, and diarrhea. Our observations suggest that CBZ, with the appropriate support and chemotherapeutic experience, is well-tolerated and effective therapy of mCRPC after DOC.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Petranyi, Agota] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Ruzsa, Agnes] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Valikovics, Aniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Vas, Maria] Peterfy Sandor Utcai Korhaz, Onkologia-Hematologia OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 353
EP 360
PG 11
ER

PT J
AU Vajda, R
   Arvane Egri, Cs
   Kovacs, A
   Budai, A
   Dobrossy, L
   Koiss, R
   Kives, Zs
   Boncz, I
AF Vajda, Reka
   Arvane Egri, Csilla
   Kovacs, Attila
   Budai, Andras
   Dobrossy, Lajos
   Koiss, Robert
   Kives, Zsuzsanna
   Boncz, Imre
TI Quality and performance indicators of the pilot program for cervical cancer screening by health visitors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE health visitor; cervical cancer screening; cervical cancer; HPV prevalence; participation rate
ID health visitor; cervical cancer screening; cervical cancer; HPV prevalence; participation rate
AB The aim of our analysis was the assessment of the qualitative and performance indicators of a pilot program for health visitors’ cervical cancer screening. The analysis involved the data from the Communication module of the Office of the National Chief Medical Officer. In the examined period (October, 2013 – September, 2015) the participation indicators of women aged 25–65, the prevalence rates of human papillomavirus and the cervical intraepithelial neoplasia were determined. In the screening period, the call-in rate was 32.45% nationally, with the compliance of 8.26%. The occurrence of a positive result was 1.85% nationally, with the highest rate in Hajdu-Bihar county (7.24%). HPV infection was detected in 113 cases (0.45%) nationally, HPV prevalence was 37.44/100,000 persons. The willingness for participation among women was low concerning the indicators. Their raising should be an emphasized task for public health in favor of reducing mortality from morbidities.
C1 [Vajda, Reka] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Vorosmarty M. u. 4., 7621 Pecs, Hungary.
   [Arvane Egri, Csilla] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Kovacs, Attila] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Budai, Andras] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Dobrossy, Lajos] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Koiss, Robert] Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Szuleszeti-Nogyogyaszati OsztalyBudapest, Hungary.
   [Kives, Zsuzsanna] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Vorosmarty M. u. 4., 7621 Pecs, Hungary.
   [Boncz, Imre] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Vorosmarty M. u. 4., 7621 Pecs, Hungary.
RP Vajda, R (reprint author), Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, 7621 Pecs, Hungary.
EM reka.vajda@etk.pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 361
EP 367
PG 7
ER

PT J
AU Moghaddam, AM
   Perlaky, T
   Kovacs, K
   Kiss, J
   Szalay, K
   Antal, I
   Sapi, Z
   Szendroi, M
AF Moghaddam, Amin Maysam
   Perlaky, Tamas
   Kovacs, Krisztian
   Kiss, Janos
   Szalay, Krisztian
   Antal, Imre
   Sapi, Zoltan
   Szendroi, Miklos
TI Epidemiology of soft tissue sarcomas in a university center in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE soft tissue sarcoma; epidemiology; diagnostic delay; prognostic factors
ID soft tissue sarcoma; epidemiology; diagnostic delay; prognostic factors
AB Our aim was to investigate the rare malignant soft tissue sarcomas responsible for 1.5% of all malignant tumors, to compare our epidemiological data from the patient population of the Department of Orthopaedics, Semmelweis University, to data described in the international literature for soft tissue tumors. We reviewed 595 cases of primary soft tissue sarcomas treated between 1994 and 2014 and compared results to international data from the literature. Our results were similar to those found in the international literature: mean age, mild male predominance, the most common sarcoma subgroups, the superficial and deep sarcoma ratio, low and high grade sarcoma ratio, the ratio of patients with a primary lung metastasis. Compared to other European data we found significantly longer patient referral to centers (3.6 months in case of superficial sarcomas, 8 months in case of deep localization) which surprisingly had no substantial effect on average tumor size (superficial: 5 cm, deep: 10.5 cm). This corresponds with data from the literature. The long delay period in patients’ request of medical service draws attention to difficulties in differential diagnosis in this rare type of tumor, delays in referring patients to a center, and the lack of consultation. We recommend that the required investigations be performed in a musculoskeletal oncology center where this type of cancer is treated.
C1 [Moghaddam, Amin Maysam] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Perlaky, Tamas] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Kovacs, Krisztian] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Szalay, Krisztian] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Antal, Imre] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of Orthopedics, Ulloi ut 78/B, 1082 Budapest, Hungary.
RP Moghaddam, AM (reprint author), Semmelweis University, Department of Orthopedics, 1082 Budapest, Hungary.
EM dr.ma.maysam@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 368
EP 373
PG 6
ER

PT J
AU Jeney, A
   Kralovanszky, J
   Lapis, K
AF Jeney, Andras
   Kralovanszky, Judit
   Lapis, Karoly
TI Anticancer drug research in Hungary, 1950−2000
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE drug design; mode of action; pharmacokinetics; metastasis; clinical application
ID drug design; mode of action; pharmacokinetics; metastasis; clinical application
AB The present review about the history of anticancer drug research in Hungary intends to call attention to the importance of studies on their mode of action. Several lines of evidence suggest that clinically usable oncopharmacological properties could be revealed by this way. Among the numerous compounds certain alkylating sugar alcohols and 2’-deoxyuridine derivatives were submitted to detailed investigations concerning their mode of action. Myelobromol with selective action on the myeloid elements of bone marrow has been justified for its application in chronic myeloid leukemia therapy and also in bone marrow ablation before transplantation. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors. 5-etil-2’-deoxyuridine by reducing dihydropyrimidine dehydrogenase activity is able to increase 5-fluorouracil concentration in the blood, resulting in improved antitumor effect. In contrast, 5-hexil-2’-deoxyuridine, as an inhibitor of glycoconjugate pathway by reducing heparan sulfate production, has the ability to prevent metastasis. Noteworthy, the remarkable effects of vinca alkaloids, antiestrogens, and GNRH analogues were also presented in this review.
C1 [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kralovanszky, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Lapis, Karoly] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Jeney, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM ajeney@korb1.sote.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 375
EP 382
PG 8
ER

PT J
AU Foldi, G
   Zongor, Zs
   Polgar, Cs
   Stelczer, G
   Madaras, B
   Andi, J
   Lovey, J
AF Foldi, Gerda
   Zongor, Zsuzsanna
   Polgar, Csaba
   Stelczer, Gabor
   Madaras, Balazs
   Andi, Judit
   Lovey, Jozsef
TI Stereotactic ablative body radiotherapy (SABRT) for locally advanced pancreatic cancer. Case report and review of literature
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE pancreatic cancer; stereotactic ablative body radiotherapy; SABRT
ID pancreatic cancer; stereotactic ablative body radiotherapy; SABRT
AB Pancreatic cancer has one of the worst outcomes among malignant tumors. At the time of diagnosis only 20% of the cases are resectable and 30-50% are locally advanced, when curative intervention cannot be performed. After resection local relapse occurs in 20-60%, and in 30% it is the reason of death. This latter highlights the importance of local control. However, there have been no convincing results with conformal radiation therapy and radiochemotherapy yet. Adjuvant radiochemotherapy has been settled into the routine in the US, but not in Europe and Asia and only sporadic data are available about neoadjuvant radiotherapy. Based on the result of recent studies, conformal radiation therapy does not seem to become part of the standard treatment of locally advanced disease. Radiation resistance, long treatment time and incompatibility with the most advanced chemotherapy regimens may make conformal radiotherapy ineffective. Stereotactic ablative body radiotherapy (SABRT) when a limited target volume is irradiated in few fractions, with high precision and high biological effective dose, is ablative for the tumor and could be a possible solution for this issue. In our report, we describe to our knowledge the first SABRT for locally advanced pancreatic cancer in Hungary and give a short literature review.
C1 [Foldi, Gerda] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Madaras, Balazs] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Andi, Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 4
BP 387
EP 392
PG 6
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
AB Tisztelt Kollegak! Az iden 60 eves Magyar Onkologusok Tarsasaga® 2017 novembereben Debrecenben tartja orszagos kongresszusat. Hatvan ev egy orvosi tarsasag eleteben komoly ido, ezert szeretnenk sokak szamara erdekes, emlekezetes es szakmailag tanulsagos, tartalmas rendezvenyt szervezni. A Magyar Onkologusok Tarsasaga® multidiszciplinaris tarsasag, ezert termeszetesen minden rakbetegseggel foglalkozo szakma kepviseloit szivesen latjuk. Az egyes kongresszusi szekciokat is e szemlelet alapjan allitjuk ossze, azaz egy-egy betegsegcsoport kivizsgalasanak es kezelesenek kozos megbeszeleset tervezzuk patologus, radiologus, sebesz, sugarterapias es klinikai onkologus kollegak kozott. Termeszetesen varjuk a rakkutatassal foglalkozo szakembereket is, hiszen szamukra ez a legkomolyabb hazai megmerettetes. Az elmult evek szakmai fejlodesenek megfeleloen a molekularis onkologia mellett kiemelt kongresszusi temaink az immunonkologia es az innovativ sugarterapia. A szubdiszciplinakkal torteno egyuttmukodes kereteben pedig a MOT®-kongresszus reszekent tartja konferenciajat a Magyar Neuroonkologiai Tarsasag es a Magyar Mesterseges Taplalasi Tarsasag is, tovabba lehetoseget biztositunk a legfiatalabb szakmai diszciplina, a kardioonkologia megmutatkozasara is. Termeszetes, hogy a Magyar Onkologusok Tarsasaga® szekcioinak – a Szakdolgozoi, Pszichoonkologiai es Rehabilitacios, valamint a Fiatal Onkologusok Szekcioja – tagjai is tartanak tudomanyos eloadasokat. Beszelgeteseket tervezunk a szakmapolitikai helyzetrol is. A szakvizsgara keszuloknek, de remenyeink szerint a szakorvosoknak is hasznos lesz a legujabb TNM-et bemutato eloadas-sorozat. Az elmult 2-3 ev jelentos hazai sugarterapias fejleszteseinek ismertetesere is sor kerul majd. Atadjuk a 2016. evi Krompecher-dijat, valamint a Magyar Onkologia 2016. evi legjobb kozlemenyeiert jaro dijakat is. A szervezobizottsag neveben remeljuk, hogy hasznos es erdekes szakmai rendezveny elott allunk, melyet a kulturalis programokkal es a szakmai baratsagok elmelyitesere is lehetoseget nyujto tarsasagi esemenyekkel is igyekszunk emlekezetesse tenni. Minden erdeklodo, rakkutatassal vagy rakgyogyitassal foglalkozo kollegat szeretettel varunk Debrecenbe!
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 1
EP 84
PG 84
ER

PT J
AU Al-Farhat, Y
   Schipp, I
   Auth, P
AF Al-Farhat, Yousuf
   Schipp, Ildiko
   Auth, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Albert Toth, J
AF Albert Toth, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Albert Toth, Judit] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Albert Toth, J (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Bajcsay, A
   Lovey, J
   Mihaly, D
   Bencsik, B
   Stelczer, G
   Major, T
   Agoston, P
   Polgar, Cs
AF Bajcsay, Andras
   Lovey, Jozsef
   Mihaly, Dalma
   Bencsik, Barbara
   Stelczer, Gabor
   Major, Tibor
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bencsik, Barbara] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Balatoni, T
   Ladanyi, A
   Frohlich, G
   Panczel, G
   Czirbesz, K
   Plotar, V
   Liszkay, G
AF Balatoni, Timea
   Ladanyi, Andrea
   Frohlich, Georgina
   Panczel, Gitta
   Czirbesz, Kata
   Plotar, Vanda
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Balogh, Z
   Gehlne Kaulak, �
   Derjan, B
   Papp, J
   Simon, M
   Horvath, Zs
AF Balogh, Zoltan
   Gehlne Kaulak, Agota
   Derjan, Brigitta
   Papp, Judit
   Simon, Mihaly
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Zoltan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Gehlne Kaulak, Agota] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Derjan, Brigitta] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Balogh, Z (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Barbocz, Z
   Drajko, V
   Landherr, L
AF Barbocz, Zoltan
   Drajko, Veronika
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barbocz, Zoltan] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Barbocz, Z (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Bedekovics, J
   Mehes, G
AF Bedekovics, Judit
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bedekovics, Judit] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Bedekovics, J (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 8
EP 9
PG 2
ER

PT J
AU Bences, I
AF Bences, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bences, Ilona] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Bences, I (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Bercesi, �
   Olah, E
   Miszlai, Zs
   Faluhelyi, Zs
   Klaics, T
   Szalai, G
   Molnar, K
   Szigeti, N
   Fabian, Gy
   Mangel, L
AF Bercesi, Eva
   Olah, Edit
   Miszlai, Zsuzsanna
   Faluhelyi, Zsolt
   Klaics, Tunde
   Szalai, Gabor
   Molnar, Krisztian
   Szigeti, Nora
   Fabian, Gyorgy
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bercesi, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Miszlai, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Faluhelyi, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Klaics, Tunde] University of Pecs, Department of OncologyPecs, Hungary.
   [Szalai, Gabor] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Molnar, Krisztian] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Szigeti, Nora] University of Pecs, 2nd Department of Medicine and Nephrological CenterPecs, Hungary.
   [Fabian, Gyorgy] University of Pecs, 2nd Department of Medicine and Nephrological CenterPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bercesi, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Betenbuk, J
   Biro, K
   Vajdics, T
   Kuronya, Zs
   Nagyivanyi, K
   Gyergyai, F
   Geczi, L
AF Betenbuk, Judit
   Biro, Krisztina
   Vajdics, Timea
   Kuronya, Zsofia
   Nagyivanyi, Krisztian
   Gyergyai, Fruzsina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Betenbuk, Judit] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Vajdics, Timea] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyai, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Betenbuk, J (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Bezsenyi, I
AF Bezsenyi, Istvanne
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bezsenyi, Istvanne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Bezsenyi, I (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 9
EP 10
PG 2
ER

PT J
AU Bittner, N
   Toth, E
   Geczi, L
   Sarosi, V
   Laszlo, T
   Kasler, M
AF Bittner, Nora
   Toth, Erika
   Geczi, Lajos
   Sarosi, Veronika
   Laszlo, Terezia
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bittner, Nora] Orszagos Onkologiai Intezet, III. Amb., Ritka Daganatos Betegsegek Klinikai EgysegBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Sarosi, Veronika] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Laszlo, Terezia] University of Pecs, Department of PathologyPecs, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
RP Bittner, N (reprint author), Orszagos Onkologiai Intezet, III. Amb., Ritka Daganatos Betegsegek Klinikai Egyseg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Boer, K
AF Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Boer, K
   Kahan, Zs
   Landherr, L
   Csoszi, T
   Mahr, K
   Ruzsa, �
   Rubovszky, G
AF Boer, Katalin
   Kahan, Zsuzsanna
   Landherr, Laszlo
   Csoszi, Tibor
   Mahr, Karoly
   Ruzsa, Agnes
   Rubovszky, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Csoszi, Tibor] Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Klinikai OnkologiaSzolnok, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 10
EP 11
PG 2
ER

PT J
AU Boer, K
   Nemeth, Zs
   Lengyel, Zs
   Borbely, K
AF Boer, Katalin
   Nemeth, Zsuzsanna
   Lengyel, Zsolt
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Nemeth, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Boer, K (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Bohacs, A
   Sutto, Z
   Eszes, N
   Kovats, Zs
   Lazar, Zs
   Csiszer, E
   Lang, Gy
   Renyi-Vamos, F
   Papay, J
   Kovalszky, I
   Torok, Sz
   Sax, B
   Muller, V
AF Bohacs, Aniko
   Sutto, Zoltan
   Eszes, Noemi
   Kovats, Zsuzsanna
   Lazar, Zsofia
   Csiszer, Eszter
   Lang, Gyorgy
   Renyi-Vamos, Ferenc
   Papay, Judit
   Kovalszky, Ilona
   Torok, Szilard
   Sax, Balazs
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Sutto, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Eszes, Noemi] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kovats, Zsuzsanna] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Lazar, Zsofia] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Csiszer, Eszter] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Lang, Gyorgy] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Torok, Szilard] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Sax, Balazs] Semmelweis Egyetem, Varosmajori Sziv- es Ergyogyaszati KlinikaBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Bohacs, A (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Borbely, K
   Kasler, M
AF Borbely, Katalin
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] University of PecsPecs, Hungary.
   [Kasler, Miklos] Marosvasarhelyi Orvosi es Gyogyszereszeti EgyetemMarosvasarhely, Romania.
RP Borbely, K (reprint author), University of Pecs, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Bozsik, A
   Pocza, T
   Papp, J
   Vaszko, T
   Gyuris, T
   Balint, BL
   Olah, E
AF Bozsik, Aniko
   Pocza, Timea
   Papp, Janos
   Vaszko, Tibor
   Gyuris, Tibor
   Balint, Balint Laszlo
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Gyuris, Tibor] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Balint, Balint Laszlo] University of Debrecen, Faculty of MedicineDebrecen, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Bozsik, A (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Czigleczki, G
   Sinko, D
   Reiniger, L
   Fedorcsak, I
   Bago, A
   Nemeskeri, Cs
   Landherr, L
   Sipos, L
AF Czigleczki, Gabor
   Sinko, Daniel
   Reiniger, Lilla
   Fedorcsak, Imre
   Bago, Attila
   Nemeskeri, Csaba
   Landherr, Laszlo
   Sipos, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czigleczki, Gabor] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Sinko, Daniel] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Bago, Attila] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Sipos, Laszlo] National Institute of Clinical NeurosciencesBudapest, Hungary.
RP Czigleczki, G (reprint author), National Institute of Clinical Neurosciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Czirbesz, K
   Gorka, E
   Panczel, G
   Liszkay, G
AF Czirbesz, Kata
   Gorka, Eszter
   Panczel, Gitta
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Czirbesz, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Csemez, I
   Godeny, M
AF Csemez, Imre
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csemez, Imre] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Csemez, I (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Cseri, Zs
AF Cseri, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseri, Zsolt] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Cseri, Zs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Csikos, �
   Radvanyi, I
   Frank, N
   Lukacs, M
   Mangel, L
AF Csikos, Agnes
   Radvanyi, Ildiko
   Frank, Nora
   Lukacs, Miklos
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csikos, Agnes] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Radvanyi, Ildiko] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Frank, Nora] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Lukacs, Miklos] PTE AOK, Alapellatasi IntezetPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Csikos, � (reprint author), PTE AOK, Alapellatasi Intezet, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 13
EP 14
PG 2
ER

PT J
AU Csoban, E
   Molnar, A
   Simon, M
   Papp, J
   Janvary, ZsL
   Horvath, Zs
AF Csoban, Eszter
   Molnar, Anett
   Simon, Mihaly
   Papp, Judit
   Janvary, Zsolt Levente
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csoban, Eszter] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Molnar, Anett] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Csoban, E (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Danos, K
   Birtalan, E
   Brauswetter, D
   Kocsis, A
   Tamas, L
AF Danos, Kornel
   Birtalan, Ede
   Brauswetter, Diana
   Kocsis, Adrienn
   Tamas, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Danos, Kornel] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Birtalan, Ede] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Brauswetter, Diana] Semmelweis University, Department of Medical Chemistry, Molecular Biology and PathobiochemistryBudapest, Hungary.
   [Kocsis, Adrienn] NEUMANN Diagnostics Kft.Pecs, Hungary.
   [Tamas, Laszlo] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
RP Danos, K (reprint author), Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Dede, K
   Egyed, T
   Nedermann, A
   Bursics, A
AF Dede, Kristof
   Egyed, Tamas
   Nedermann, Attila
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Egyed, Tamas] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Nedermann, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Dede, K (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 14
EP 15
PG 2
ER

PT J
AU Drajko, V
   Katona, Cs
   Landherr, L
AF Drajko, Veronika
   Katona, Csilla
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Drajko, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Drencsenyi, R
   Varga, Z
   Kahan, Zs
AF Drencsenyi, Rita
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Fabian, G
   Szilagyi, �
   Hegedus, Cs
   Petak, I
   Kahan, Zs
AF Fabian, Gabriella
   Szilagyi, Eva
   Hegedus, Csilla
   Petak, Istvan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fabian, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hegedus, Csilla] Oncompass Medicine Kft.Budapest, Hungary.
   [Petak, Istvan] Oncompass Medicine Kft.Budapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fabian, G (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Foldi, G
   Polgar, Cs
   Lovey, J
   Stelczer, G
   Zongor, Zs
   Bela, D
AF Foldi, Gerda
   Polgar, Csaba
   Lovey, Jozsef
   Stelczer, Gabor
   Zongor, Zsuzsanna
   Bela, Dalma
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldi, Gerda] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Foldi, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Foldvari, D
   Czifra, Gy
   Mangel, L
AF Foldvari, Dora
   Czifra, Gyozo
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Czifra, Gyozo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Franko, J
AF Franko, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Franko, Judit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Franko, J (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Frohlich, G
   Vizkeleti, J
   Nguyen, AN
   Meszaros, N
   Horvath, K
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Vizkeleti, Julia
   Nguyen, Anhhong Nhung
   Meszaros, Norbert
   Horvath, Katalin
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 16
EP 17
PG 2
ER

PT J
AU Galffy, G
   Szentkereszty, M
   Komlosi, Zs
   Losonczy, Gy
AF Galffy, Gabriella
   Szentkereszty, Marton
   Komlosi, Zsolt
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Szentkereszty, Marton] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Komlosi, Zsolt] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Galffy, G (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Geczi, L
   Torday, L
   Rokszin, Gy
   Fabian, I
   Bodoky, Gy
AF Geczi, Lajos
   Torday, Laszlo
   Rokszin, Gyorgy
   Fabian, Ibolya
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rokszin, Gyorgy] RxTarget LtdSzolnok, Hungary.
   [Fabian, Ibolya] RxTarget LtdSzolnok, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Geczi, L (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Geszti, F
   Czirbesz, K
   Panczel, G
   Lorincz, L
   Gorka, E
   Balatoni, T
   Kenessey, I
   Liszkay, G
AF Geszti, Franciska
   Czirbesz, Kata
   Panczel, Gitta
   Lorincz, Lenke
   Gorka, Eszter
   Balatoni, Timea
   Kenessey, Istvan
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Geszti, Franciska] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Lorincz, Lenke] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Geszti, F (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Gorka, E
   Czirbesz, K
   Gezsi, A
   Liszkay, G
   Fabo, D
AF Gorka, Eszter
   Czirbesz, Kata
   Gezsi, Andras
   Liszkay, Gabriella
   Fabo, Daniel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gezsi, Andras] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fabo, Daniel] Orszagos Klinikai es Idegtudomanyi Intezet, Neurologia OsztalyBudapest, Hungary.
RP Gorka, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Gocze, K
   Kovacs, K
   Stefanovits, �
AF Gocze, Katalin
   Kovacs, Krisztina
   Stefanovits, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gocze, Katalin] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Sportmedicina TanszekPecs, Hungary.
   [Kovacs, Krisztina] University of Pecs, Department of PathologyPecs, Hungary.
   [Stefanovits, Agnes] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
RP Gocze, K (reprint author), Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Sportmedicina Tanszek, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Godeny, A
   Mersich, T
AF Godeny, Anna
   Mersich, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
RP Godeny, A (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Gyapjas, T
   Molnar, M
   Gabor, G
   Pajkos, G
AF Gyapjas, Tunde
   Molnar, Maria
   Gabor, Gabriella
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gyapjas, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Hajdune Kovacs, E
   Lengyel, I
   Papp, J
   Horvath, Zs
AF Hajdune Kovacs, Erzsebet
   Lengyel, Ildiko
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hajdune Kovacs, Erzsebet] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Lengyel, Ildiko] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Hajdune Kovacs, E (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Hamar, P
   Le Minh, TN
   Lieberman, J
AF Hamar, Peter
   Le Minh, Tam Nina
   Lieberman, Judy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hamar, Peter] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Le Minh, Tam Nina] Harvard Medical School, Boston Children’s Hospital, Program in Cellular and Molecular MedicineBoston, MA, USA.
   [Lieberman, Judy] Harvard Medical School, Boston Children’s Hospital, Program in Cellular and Molecular MedicineBoston, MA, USA.
RP Hamar, P (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Harisi, R
   Bodoky, Gy
AF Harisi, Revekka
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harisi, Revekka] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Harisi, R (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Horvath, K
   Vizkeleti, J
   Godeny, M
AF Horvath, Katalin
   Vizkeleti, Julia
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Horvath, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Huszar, A
   Dankovics, Zs
   Csejtei, A
AF Huszar, Attila
   Dankovics, Zsofia
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Huszar, Attila] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Huszar, A (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Illyesne Kovacs, I
   Papp, J
   Horvath, Zs
AF Illyesne Kovacs, Ildiko
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Illyesne Kovacs, Ildiko] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Illyesne Kovacs, I (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Imredi, E
   Timar, J
   Plotar, V
   Gorka, E
   Godeny, M
   Fedorcsak, I
   Liszkay, G
AF Imredi, Eleonora
   Timar, Jozsef
   Plotar, Vanda
   Gorka, Eszter
   Godeny, Maria
   Fedorcsak, Imre
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Gorka, Eszter] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Imredi, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 20
EP 21
PG 2
ER

PT J
AU Ivady, G
   Kovacs, E
   Matrai, Z
   Fillinger, J
   Bak, M
AF Ivady, Gabriella
   Kovacs, Eszter
   Matrai, Zoltan
   Fillinger, Janos
   Bak, Mihaly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ivady, Gabriella] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Fillinger, Janos] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
RP Ivady, G (reprint author), Orszagos Onkologiai Intezet, Citopatologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Janvary, ZsL
   Simon, M
   Horvath, Zs
AF Janvary, Zsolt Levente
   Simon, Mihaly
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Janvary, ZsL (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Jederan, �
   Duboczki, Zs
   Mersits, T
   Godeny, M
AF Jederan, Eva
   Duboczki, Zsolt
   Mersits, Tamas
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Mersits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 21
EP 22
PG 2
ER

PT J
AU Jeglne Illes, Zs
   Bonczok, A
AF Jeglne Illes, Zsuzsanna
   Bonczok, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jeglne Illes, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Bonczok, Andrea] University of Pecs, Department of OncologyPecs, Hungary.
RP Jeglne Illes, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Jorgo, K
   Polgar, Cs
   Tenke, P
   Kovacs, G
   Major, T
   Stelczer, G
   Agoston, P
AF Jorgo, Kliton
   Polgar, Csaba
   Tenke, Peter
   Kovacs, Gabor
   Major, Tibor
   Stelczer, Gabor
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Tenke, Peter] Jahn Ferenc Korhaz, UrologiaBudapest, Hungary.
   [Kovacs, Gabor] Central Military Hospital, Department of UrologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Kapitany, Zs
   Pollner, P
   Erdei, A
   Schlakker, I
   Mihallfy, V
   Horvath, A
AF Kapitany, Zsuzsanna
   Pollner, Peter
   Erdei, Anett
   Schlakker, Imrene
   Mihallfy, Veronika
   Horvath, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapitany, Zsuzsanna] Semmelweis Egyetem ETK, Fizioterapia TanszekBudapest, Hungary.
   [Pollner, Peter] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Erdei, Anett] Semmelweis University, Kutvolgyi Clinical CentreBudapest, Hungary.
   [Schlakker, Imrene] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Mihallfy, Veronika] Semmelweis Egyetem ETK, Fizioterapia TanszekBudapest, Hungary.
   [Horvath, Anna] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Kapitany, Zs (reprint author), Semmelweis Egyetem ETK, Fizioterapia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Kaposztas, Zs
   Pap, �
   Szatmari, G
   Lote, S
   Lukacs, G
   Horvath, Gy
   Hunyady, B
   Ruzsa, �
   Olah, T
   Repa, I
AF Kaposztas, Zsolt
   Pap, Akos
   Szatmari, Gergely
   Lote, Sandor
   Lukacs, Gabor
   Horvath, Gyula
   Hunyady, Bela
   Ruzsa, Agnes
   Olah, Tibor
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kaposztas, Zsolt] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Pap, Akos] Somogy Megyei Kaposi Mor Oktato Korhaz, Gasztroenterologiai OsztalyKaposvar, Hungary.
   [Szatmari, Gergely] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Lote, Sandor] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Lukacs, Gabor] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Horvath, Gyula] Somogy Megyei Kaposi Mor Oktato Korhaz, Radiologiai OsztalyKaposvar, Hungary.
   [Hunyady, Bela] Somogy Megyei Kaposi Mor Oktato Korhaz, Gasztroenterologiai OsztalyKaposvar, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Olah, Tibor] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Repa, Imre] Somogy Megyei Kaposi Mor Oktato Korhaz, strategiai igazgatoKaposvar, Hungary.
RP Kaposztas, Zs (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti Osztaly, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 22
EP 23
PG 2
ER

PT J
AU Kapuvari, B
   Molnar, Zs
   Kovacs, J
   Kohalmy, K
   Boldizsar, Sz
   Rosta, A
   Schneider, T
   Vincze, B
AF Kapuvari, Bence
   Molnar, Zsuzsa
   Kovacs, Judit
   Kohalmy, Krisztina
   Boldizsar, Szandra
   Rosta, Andras
   Schneider, Tamas
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kapuvari, Bence] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Boldizsar, Szandra] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Kas, J
   Csekeo, A
   Feher, Cs
   Heiler, Z
   Kostic, Sz
   Molnar, M
   Vagvolgyi, A
   Vadasz, P
AF Kas, Jozsef
   Csekeo, Attila
   Feher, Csaba
   Heiler, Zoltan
   Kostic, Szilard
   Molnar, Miklos
   Vagvolgyi, Attila
   Vadasz, Pal
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kas, Jozsef] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Csekeo, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Feher, Csaba] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Heiler, Zoltan] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Kostic, Szilard] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Molnar, Miklos] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Vagvolgyi, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Vadasz, Pal] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
RP Kas, J (reprint author), Orszagos Koranyi Tbc es Pulmonologiai Intezet, Mellkassebeszet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Kaucsar, T
   Danics, L
   Sarkozy, H
   Schvarz, Cs
   Bellovits, K
   Balogh, A
   Vancsik, T
   Krenacs, T
   Benyo, Z
   Hamar, P
AF Kaucsar, Tamas
   Danics, Lea
   Sarkozy, Henrietta
   Schvarz, Csaba
   Bellovits, Klara
   Balogh, Andrea
   Vancsik, Tamas
   Krenacs, Tibor
   Benyo, Zoltan
   Hamar, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kaucsar, Tamas] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Danics, Lea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Sarkozy, Henrietta] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Schvarz, Csaba] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Bellovits, Klara] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Hamar, Peter] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Kaucsar, T (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 23
EP 24
PG 2
ER

PT J
AU Kegye, A
   Prezenszki, Zs
AF Kegye, Adrienne
   Prezenszki, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kegye, Adrienne] Urpion Kft.Budapest, Hungary.
   [Prezenszki, Zsuzsa] Gyula Nyiro Hospital, National Institute of Psychiatry and AddictionsBudapest, Hungary.
RP Kegye, A (reprint author), Urpion Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Kegye, A
   Czegledi, E
   Zana, �
   Hegedus, K
AF Kegye, Adrienne
   Czegledi, Edit
   Zana, Agnes
   Hegedus, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kegye, Adrienne] Urpion Kft.Budapest, Hungary.
   [Czegledi, Edit] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Zana, Agnes] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Hegedus, Katalin] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Kegye, A (reprint author), Urpion Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Kelemen, PB
   Pukancsik, D
   Ujhelyi, M
   Kovacs, E
   Kenessey, I
   Matrai, Z
AF Kelemen, Peter Bertalan
   Pukancsik, David
   Ujhelyi, Mihaly
   Kovacs, Eszter
   Kenessey, Istvan
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kelemen, Peter Bertalan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Kelemen, PB (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Kis, K
   Bonczok, A
AF Kis, Katalin
   Bonczok, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kis, Katalin] University of Pecs, Department of OncologyPecs, Hungary.
   [Bonczok, Andrea] University of Pecs, Department of OncologyPecs, Hungary.
RP Kis, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Kiss, Cs
   Kovacs, G
AF Kiss, Csongor
   Kovacs, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Kiss, Cs (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Kiss, E
   Uhlyarik, A
   Gondos, M
   Takacsi-Nagy, Z
   Papai, Zs
AF Kiss, Edina
   Uhlyarik, Andrea
   Gondos, Miklos
   Takacsi-Nagy, Zoltan
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Gondos, Miklos] MH Honvedkorhaz, Sebeszeti OsztalyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Klarik, Z
   Herczeg, A
   Fodor, I
   Zambo, O
   Bartfai, R
   Koltai, P
   Koltai, L
   Kiss, D
   Levay, B
   Boer, A
   Remenar, �
AF Klarik, Zoltan
   Herczeg, Adrienn
   Fodor, Istvan
   Zambo, Orsolya
   Bartfai, Reka
   Koltai, Pal
   Koltai, Laszlo
   Kiss, Doloresz
   Levay, Bernadett
   Boer, Andras
   Remenar, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Klarik, Zoltan] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Fodor, Istvan] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Zambo, Orsolya] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Bartfai, Reka] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Koltai, Laszlo] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Kiss, Doloresz] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Levay, Bernadett] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Klarik, Z (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Koszo, RL
   Kahan, Zs
   Dobi, �
   Rusz, O
   Kelemen, Gy
   Varga, Z
   Hideghety, K
AF Koszo, Renata Lilla
   Kahan, Zsuzsanna
   Dobi, Agnes
   Rusz, Orsolya
   Kelemen, Gyongyi
   Varga, Zoltan
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusz, Orsolya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Koszo, RL
   Varga, Z
   Darazs, B
   Kahan, Zs
AF Koszo, Renata Lilla
   Varga, Zoltan
   Darazs, Barbara
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 26
EP 27
PG 2
ER

PT J
AU Kotlan, B
   Csuka, O
   Plotar, V
   Horvath, Sz
   Eles, K
   Doleschall, Z
   Farkas, E
   Vamosi Nagy, I
   Szollar, A
   Savolt, �
   Naszados, Gy
   Godeny, M
   Kasler, M
   Liszkay, G
AF Kotlan, Beatrix
   Csuka, Orsolya
   Plotar, Vanda
   Horvath, Szabolcs
   Eles, Klara
   Doleschall, Zoltan
   Farkas, Emil
   Vamosi Nagy, Istvan
   Szollar, Andras
   Savolt, Akos
   Naszados, Gyorgy
   Godeny, Maria
   Kasler, Miklos
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Plotar, Vanda] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Doleschall, Zoltan] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Vamosi Nagy, Istvan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Naszados, Gyorgy] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kotlan, B (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Kovacs, P
   Liszkay, G
AF Kovacs, Peter
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Kovacs, Zs
   Rigo, A
AF Kovacs, Zsuzsa
   Rigo, Adrien
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Zsuzsa] Semmelweis Egyetem, ETK, Alkalmazott Pszichologia TanszekBudapest, Hungary.
   [Rigo, Adrien] ELTE, PPKBudapest, Hungary.
RP Kovacs, Zs (reprint author), Semmelweis Egyetem, ETK, Alkalmazott Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 27
EP 28
PG 2
ER

PT J
AU Kullmann, T
   Culine, S
AF Kullmann, Tamas
   Culine, Stephane
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Culine, Stephane] Hopital Saint Louis, Department of Medical OncologyParis, France.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Kuronya, Zs
   Biro, K
   Gyergyay, F
   Geczi, L
AF Kuronya, Zsofia
   Biro, Krisztina
   Gyergyay, Fruzsina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Kuronya, Zs (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Lahm, E
   Gorombey, Z
   Voros, A
AF Lahm, Erika
   Gorombey, Zoltan
   Voros, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved KorhazBudapest, Hungary.
   [Gorombey, Zoltan] Honved KorhazBudapest, Hungary.
   [Voros, Attila] Honved KorhazBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Lengyel, Zs
   Kadar, Zs
   Gyomorei, Cs
   Kalman, E
   Mangel, L
   Gyulai, R
AF Lengyel, Zsuzsanna
   Kadar, Zsolt
   Gyomorei, Csaba
   Kalman, Endre
   Mangel, Laszlo
   Gyulai, Rolland
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Kadar, Zsolt] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Gyomorei, Csaba] University of Pecs, Department of PathologyPecs, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
RP Lengyel, Zs (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 28
EP 29
PG 2
ER

PT J
AU Levai, D
   Szaleczky, E
   Elek, J
   Sinko, J
   Strausz, T
   Schneider, T
AF Levai, Dora
   Szaleczky, Erika
   Elek, Jeno
   Sinko, Janos
   Strausz, Tamas
   Schneider, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Levai, Dora] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Elek, Jeno] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Sinko, Janos] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Strausz, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Levai, D (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Locsei, Z
   Fodor, D
   Bellyei, Sz
   Vereczkei, A
   Mangel, L
AF Locsei, Zoltan
   Fodor, David
   Bellyei, Szabolcs
   Vereczkei, Andras
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Fodor, David] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Vereczkei, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Lukacs, G
   Toth, Z
   Cselik, Zs
   Bajzik, G
   Toller, G
   Volgyi, Z
   Szigeti, A
   Ruzsa, �
   Moizs, M
   Repa, I
   Kovacs, �
AF Lukacs, Gabor
   Toth, Zoltan
   Cselik, Zsolt
   Bajzik, Gabor
   Toller, Gabor
   Volgyi, Zoltan
   Szigeti, Annamaria
   Ruzsa, Agnes
   Moizs, Mariann
   Repa, Imre
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toth, Zoltan] MEDICOPUS Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.Kaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Bajzik, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toller, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Volgyi, Zoltan] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Szigeti, Annamaria] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Ruzsa, Agnes] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Moizs, Mariann] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Repa, Imre] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Kovacs, Arpad] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Lukacs, G (reprint author), Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Lupak, �
AF Lupak, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lupak, Eva] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Lupak, � (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Mangel, L
   Miszlai, Zs
   Kover, E
   Boronkai, �
AF Mangel, Laszlo
   Miszlai, Zsuzsa
   Kover, Erika
   Boronkai, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Miszlai, Zsuzsa] University of Pecs, Department of OncologyPecs, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Mangel, L
   Tornoczky, T
AF Mangel, Laszlo
   Tornoczky, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Tornoczky, Tamas] University of Pecs, Department of PathologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 30
EP 31
PG 2
ER

PT J
AU Maraz, A
   Boer, K
   Csejtei, A
   Dank, M
   Lahm, E
   Petranyi, �
   Revesz, J
   Ruzsa, �
   Szucs, M
   Valikovics, A
   Vas, M
   Kuronya, Zs
AF Maraz, Aniko
   Boer, Katalin
   Csejtei, Andras
   Dank, Magdolna
   Lahm, Erika
   Petranyi, Agota
   Revesz, Janos
   Ruzsa, Agnes
   Szucs, Miklos
   Valikovics, Aniko
   Vas, Maria
   Kuronya, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of SzegedSzeged, Hungary.
   [Boer, Katalin] St. Margit HospitalBudapest, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Dank, Magdolna] Semmelweis UniversityBudapest, Hungary.
   [Lahm, Erika] Honved KorhazBudapest, Hungary.
   [Petranyi, Agota] Del-Pesti CentrumkorhazBudapest, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Ruzsa, Agnes] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Szucs, Miklos] Semmelweis UniversityBudapest, Hungary.
   [Valikovics, Aniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Vas, Maria] Peterfy HospitalBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of OncologyBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Maraz, R
   Ambrozay, �
   Sikorszki, L
   Zombori, T
   Cserni, G
AF Maraz, Robert
   Ambrozay, Eva
   Sikorszki, Laszlo
   Zombori, Tamas
   Cserni, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Zombori, Tamas] University of Szeged, Department of PathologySzeged, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Matrai, T
   Dorogi, B
   Savolt, �
   Ujhelyi, M
   Pukancsik, D
   Kelemen, P
   Szollar, A
   Kovacs, T
   Polgar, Cs
   Matrai, Z
AF Matrai, Tamas
   Dorogi, Bence
   Savolt, Akos
   Ujhelyi, Mihaly
   Pukancsik, David
   Kelemen, Peter
   Szollar, Andras
   Kovacs, Tibor
   Polgar, Csaba
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Tamas] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Dorogi, Bence] Budai Irgalmasrendi Korhaz, SebeszetBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szollar, Andras] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Tibor] Guy’s and St Thomas’s Hospitals NHS Foundation Trust, Department of Breast SurgeryLondon, UK.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Matrai, T (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Mehes, G
   Monus, A
   Horvath, Zs
   Andras, Cs
   Bihari, Z
   Mokanszki, A
AF Mehes, Gabor
   Monus, Aniko
   Horvath, Zsolt
   Andras, Csilla
   Bihari, Zoltan
   Mokanszki, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Monus, Aniko] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Bihari, Zoltan] Xenovea Kft.Szeged, Hungary.
   [Mokanszki, Attila] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Mehes, G (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Meilinger-Dobra, M
   Boer, A
AF Meilinger-Dobra, Monika
   Boer, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meilinger-Dobra, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Meilinger-Dobra, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Menyhart, O
   Fekete, J
   Gyorffy, B
AF Menyhart, Otilia
   Fekete, Janos
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Menyhart, Otilia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Fekete, Janos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Menyhart, O (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Mersich, T
   Sztipits, T
   Duboczki, Zs
   Meszaros, P
   Olah, G
AF Mersich, Tamas
   Sztipits, Tamas
   Duboczki, Zsolt
   Meszaros, Peter
   Olah, Gergely
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Sztipits, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Duboczki, Zsolt] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Peter] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Olah, Gergely] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
RP Mersich, T (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Meszaros, P
   Duboczki, Zs
   Sztipits, T
   Olah, G
   Mersich, T
AF Meszaros, Peter
   Duboczki, Zsolt
   Sztipits, Tamas
   Olah, Gergely
   Mersich, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Peter] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Duboczki, Zsolt] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Sztipits, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Olah, Gergely] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
RP Meszaros, P (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Mezei, T
   Pollner, P
   Czigleczki, G
   Bancserovszki, P
   Horvath, A
AF Mezei, Tamas
   Pollner, Peter
   Czigleczki, Gabor
   Bancserovszki, Peter
   Horvath, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mezei, Tamas] Semmelweis UniversityBudapest, Hungary.
   [Pollner, Peter] ELTE-MTABudapest, Hungary.
   [Czigleczki, Gabor] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Bancserovszki, Peter] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Horvath, Anna] Semmelweis UniversityBudapest, Hungary.
RP Mezei, T (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Moldvay, J
   Rojko, L
   Teglasi, V
   Fabian, K
   Pipek, O
   Vagvolgyi, A
   Agocs, L
   Fillinger, J
   Kajdacsi, Z
   Timar, J
   Dome, B
   Szallasi, Z
   Reiniger, L
AF Moldvay, Judit
   Rojko, Livia
   Teglasi, Vanda
   Fabian, Katalin
   Pipek, Orsolya
   Vagvolgyi, Attila
   Agocs, Laszlo
   Fillinger, Janos
   Kajdacsi, Zita
   Timar, Jozsef
   Dome, Balazs
   Szallasi, Zoltan
   Reiniger, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Rojko, Livia] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Teglasi, Vanda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Fabian, Katalin] St Imre Hospital, Department of PathologyBudapest, Hungary.
   [Pipek, Orsolya] Eotvos Lorand University, Department of Physics of Complex SystemsBudapest, Hungary.
   [Vagvolgyi, Attila] Orszagos Koranyi Tbc es Pulmonologiai Intezet, MellkassebeszetBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Fillinger, Janos] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Kajdacsi, Zita] Orszagos Koranyi Pulmonologiai Intezet, Patologiai OsztalyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical School, Children’s Hospital, Informatics ProgramBoston, MA, USA.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Moldvay, J
   Fabian, K
   Puskas, R
   Kakuk, T
   Pres, L
   Fejes, D
   Szegedi, Zs
   Rojko, L
   Pipek, O
   Dome, B
   Szallasi, Z
AF Moldvay, Judit
   Fabian, Katalin
   Puskas, Rita
   Kakuk, Timea
   Pres, Laszlo
   Fejes, Dorottya
   Szegedi, Zsolt
   Rojko, Livia
   Pipek, Orsolya
   Dome, Balazs
   Szallasi, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Fabian, Katalin] St Imre Hospital, Department of PathologyBudapest, Hungary.
   [Puskas, Rita] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kakuk, Timea] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Pres, Laszlo] Pest Megyei Flor Ferenc Korhaz, Aneszteziologiai es Intenziv Terapias OsztalyKistarcsa, Hungary.
   [Fejes, Dorottya] Orszagos Koranyi Pulmonologiai Intezet, XI. TudobelosztalyBudapest, Hungary.
   [Szegedi, Zsolt] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Rojko, Livia] National Koranyi Institute of Pulmonology, Department of BronchologyBudapest, Hungary.
   [Pipek, Orsolya] Eotvos Lorand University, Department of Physics of Complex SystemsBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical School, Children’s Hospital, Informatics ProgramBoston, MA, USA.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 34
EP 35
PG 2
ER

PT J
AU Molnar, A
   Boronkai, �
   Mangel, L
   Locsei, Z
   Sarosi, V
   Baliko, Z
   Al-Farhat, Y
AF Molnar, Andras
   Boronkai, Arpad
   Mangel, Laszlo
   Locsei, Zoltan
   Sarosi, Veronika
   Baliko, Zoltan
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnar, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Baliko, Zoltan] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Molnar, A (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Muhl, D
   Kleiner, D
   Dohan, O
   Dank, M
AF Muhl, Dorottya
   Kleiner, Denes
   Dohan, Orsolya
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muhl, Dorottya] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kleiner, Denes] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Dohan, Orsolya] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Muhl, D (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 35
EP 35
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 35
EP 36
PG 2
ER

PT J
AU Muller, V
   Vincze, K
   Eszes, N
   Lazar, Zs
   Bohacs, A
   Losonczy, Gy
AF Muller, Veronika
   Vincze, Krisztina
   Eszes, Noemi
   Lazar, Zsofia
   Bohacs, Aniko
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Vincze, Krisztina] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Eszes, Noemi] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Lazar, Zsofia] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Muller, V (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Nagy, P
   Podmaniczky, E
   Marosi, E
   Szabo, A
   Ferbert, Zs
   Porneczy, E
   Bittner, N
   Kasler, M
AF Nagy, Peter
   Podmaniczky, Erzsebet
   Marosi, Edit
   Szabo, Annamaria
   Ferbert, Zsuzsanna
   Porneczy, Edit
   Bittner, Nora
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Podmaniczky, Erzsebet] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Marosi, Edit] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Szabo, Annamaria] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Ferbert, Zsuzsanna] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Bittner, Nora] Orszagos Onkologiai Intezet, III. Sz. Kemoterapias Belgyogyaszati AmbulanciaBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
RP Nagy, P (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Nagyivanyi, K
   Geczi, L
AF Nagyivanyi, Krisztian
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Nagyivanyi, K (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Nemes, J
   Farkas, Gy
   Balogh, I
   Papp, J
   Simon, M
   Horvath, Zs
AF Nemes, Judit
   Farkas, Gyongyver
   Balogh, Istvan
   Papp, Judit
   Simon, Mihaly
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemes, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Farkas, Gyongyver] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Balogh, Istvan] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Nemes, J (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Nemeth, Zs
   Lengyel, Zs
   Boer, K
   Borbely, K
AF Nemeth, Zsuzsanna
   Lengyel, Zsolt
   Boer, Katalin
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
RP Nemeth, Zs (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Olah, E
AF Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Olah, E (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Ozvald, G
AF Ozvald, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ozvald, Gabriella] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Ozvald, G (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Panczel, G
   Balatoni, T
   Szavcsur, P
   Liszkay, G
AF Panczel, Gitta
   Balatoni, Timea
   Szavcsur, Peter
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Szavcsur, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Papp, J
   Olah, E
AF Papp, Janos
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Papp, J (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Peto, Zs
   Papp, J
   Horvath, Zs
AF Peto, Zsuzsanna
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Peto, Zsuzsanna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Peto, Zs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Petri, K
   Biro, K
AF Petri, Klara
   Biro, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 38
EP 39
PG 2
ER

PT J
AU Piko, B
   Torok, E
   Laczo, I
AF Piko, Bela
   Torok, Eniko
   Laczo, Ibolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Torok, Eniko] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Polgar, Cs
   Strnad, V
   Ott, JO
   Major, T
   Hildebrandt, G
   Kauer-dorner, D
   Knauerhase, H
   Lyczek, J
   Guinot, JL
   Gutierrez, MC
   Slampa, P
   Allgauer, M
   Lossl, K
   Polat, B
   Kovacs, Gy
   Fishedick, Ar
   Niehoff, P
   Potter, R
   Gall, Ch
   Uter, W
AF Polgar, Csaba
   Strnad, Vratislav
   Ott, J Oliver
   Major, Tibor
   Hildebrandt, Guido
   Kauer-dorner, Daniela
   Knauerhase, Hellen
   Lyczek, Jaroslaw
   Guinot, Jose Luis
   Gutierrez, Miguelez Cristina
   Slampa, Pavel
   Allgauer, Michael
   Lossl, Kristina
   Polat, Bulent
   Kovacs, Gyorgy
   Fishedick, Arnt-rene
   Niehoff, Peter
   Potter, Richard
   Gall, Christine
   Uter, Wolfgang
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Strnad, Vratislav] Friedrich-Alexander-Universitat Erlangen-Nurnberg, University Hospital ErlangenErlangen, Germany.
   [Ott, J Oliver] Friedrich-Alexander-Universitat Erlangen-Nurnberg, University Hospital ErlangenErlangen, Germany.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Hildebrandt, Guido] University Hospital LeipzigLeipzig, Germany.
   [Kauer-dorner, Daniela] St. Anna KinderkrebsforschungVienna, Austria.
   [Knauerhase, Hellen] University Hospital RostockRostock, Germany.
   [Lyczek, Jaroslaw] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Guinot, Jose Luis] Fundacion Instituto Valenciano de OncologiaValencia, Spain.
   [Gutierrez, Miguelez Cristina] Catalan Institute of OncologyBarcelona, Spain.
   [Slampa, Pavel] Masaryk Memorial HospitalBrno, Czech Republic.
   [Allgauer, Michael] Hospital Barmherzige BruderRegensburg, Germany.
   [Lossl, Kristina] University Hospital BernBern, Switzerland.
   [Polat, Bulent] University Hospital WurzburgWurzburg, Germany.
   [Kovacs, Gyorgy] University of Luebeck, University-Hospital Schleswig- HolsteinLubeck, Germany.
   [Fishedick, Arnt-rene] Clemens Hospital MunsterMunster, Germany.
   [Niehoff, Peter] University Medical Center Schleswig-HolsteinKiel, Germany.
   [Potter, Richard] St. Anna KinderkrebsforschungVienna, Austria.
   [Gall, Christine] Friedrich-Alexander-Universitat Erlangen-Nurnberg, University Hospital ErlangenErlangen, Germany.
   [Uter, Wolfgang] Friedrich-Alexander-Universitat Erlangen-Nurnberg, University Hospital ErlangenErlangen, Germany.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Poti, Zs
   Katona, Cs
   Szalai, T
   Hegedus, L
   Landherr, L
AF Poti, Zsuzsa
   Katona, Csilla
   Szalai, Tibor
   Hegedus, Laszlo
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Poti, Zsuzsa] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hegedus, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Poti, Zs (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 39
EP 40
PG 2
ER

PT J
AU Porneczy, E
   Geczi, L
AF Porneczy, Edit
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Porneczy, Edit] Orszagos Onkologiai Intezet, III. Amb., Ritka Daganatos Betegsegek Klinikai EgysegBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Porneczy, E (reprint author), Orszagos Onkologiai Intezet, III. Amb., Ritka Daganatos Betegsegek Klinikai Egyseg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Prem, E
   Papp, J
   Horvath, Zs
AF Prem, Edit
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Prem, Edit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Prem, E (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Pukancsik, D
   Kelemen, P
   Savolt, �
   Ujhelyi, M
   Kovacs, E
   Matrai, Z
AF Pukancsik, David
   Kelemen, Peter
   Savolt, Akos
   Ujhelyi, Mihaly
   Kovacs, Eszter
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Pukancsik, D (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 40
EP 41
PG 2
ER

PT J
AU Puskas, G
AF Puskas, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Remenar, �
   Boer, A
   Koranyi, K
   Godeny, M
   Horvath, K
   Sandor, Zs
   Kasler, M
AF Remenar, Eva
   Boer, Andras
   Koranyi, Katalin
   Godeny, Maria
   Horvath, Katalin
   Sandor, Zsuzsa
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Koranyi, Katalin] Orszagos Onkologiai Intezet, SzemeszetBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sandor, Zsuzsa] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
RP Remenar, � (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Revesz, Cs
AF Revesz, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Revesz, Csilla] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Revesz, Cs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Rigo, �
   Talladi, Z
   Szekanecz, �
   Papp, J
   Horvath, Zs
AF Rigo, Eva
   Talladi, Zoltanne
   Szekanecz, Eva
   Papp, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rigo, Eva] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Talladi, Zoltanne] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Szekanecz, Eva] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Rigo, � (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 41
EP 42
PG 2
ER

PT J
AU Rittler, D
   Baranyi, M
   Molnar, E
   Tovari, J
   Timar, J
   Hegedus, B
   Garay, T
AF Rittler, Dominika
   Baranyi, Marcell
   Molnar, Eszter
   Tovari, Jozsef
   Timar, Jozsef
   Hegedus, Balazs
   Garay, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rittler, Dominika] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Baranyi, Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Molnar, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Rittler, D (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Rohanszky, M
   Fedor, M
   Pusztafalvi, H
AF Rohanszky, Magdolna
   Fedor, Mariann
   Pusztafalvi, Henrietta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rohanszky, Magdolna] Tuzmadar AlapitvanyBudapest, Hungary.
   [Fedor, Mariann] Tuzmadar AlapitvanyBudapest, Hungary.
   [Pusztafalvi, Henrietta] Tuzmadar AlapitvanyBudapest, Hungary.
RP Rohanszky, M (reprint author), Tuzmadar Alapitvany, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Rumszauer, �
   Merth, G
   Mokrai, D
   Rozsa, P
   Gerencser, Zs
AF Rumszauer, Agnes
   Merth, Gabriella
   Mokrai, David
   Rozsa, Peter
   Gerencser, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rumszauer, Agnes] MediConcept Kft.Budapest, Hungary.
   [Merth, Gabriella] MediConcept Kft.Budapest, Hungary.
   [Mokrai, David] MediConcept Kft.Budapest, Hungary.
   [Rozsa, Peter] MediConcept Kft.Budapest, Hungary.
   [Gerencser, Zsolt] MediConcept Kft.Budapest, Hungary.
RP Rumszauer, � (reprint author), MediConcept Kft., Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Salamon, A
   Gaal, L
AF Salamon, Andrea
   Gaal, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Salamon, Andrea] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Gaal, Laszlo] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Salamon, A (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Sarosi, V
AF Sarosi, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
RP Sarosi, V (reprint author), University of Pecs, Faculty of Medicine, Department of Pulmonology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Savolt, �
   Peley, G
   Polgar, Cs
   Udvarhelyi, N
   Rubovszky, G
   Kovacs, E
   Renyi-Vamos, F
   Gyorffy, B
   Matrai, Z
AF Savolt, Akos
   Peley, Gabor
   Polgar, Csaba
   Udvarhelyi, Nora
   Rubovszky, Gabor
   Kovacs, Eszter
   Renyi-Vamos, Ferenc
   Gyorffy, Balazs
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Peley, Gabor] Norfolk and Norwich University Hospital, Breast Unit, Department of General SurgeryNorfolk, UK.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Rubovszky, Gabor] National Institute of OncologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of OncologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Savolt, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Schipp, I
   Auth, P
   Cifra, J
   Hegedus, I
   Lacza, �
   Tornoczky, T
   Al-Farhat, Y
AF Schipp, Ildiko
   Auth, Peter
   Cifra, Janos
   Hegedus, Ivett
   Lacza, Agnes
   Tornoczky, Tamas
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Cifra, Janos] Balassa Janos County Hospital, Department of PathologySzekszard, Hungary.
   [Hegedus, Ivett] University of Pecs, Department of PathologyPecs, Hungary.
   [Lacza, Agnes] University of Pecs, Department of PathologyPecs, Hungary.
   [Tornoczky, Tamas] University of Pecs, Department of PathologyPecs, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Schipp, I (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Smanyko, V
   Meszaros, N
   Ujhelyi, M
   Frohlich, G
   Stelczer, G
   Major, T
   Matrai, Z
   Polgar, Cs
AF Smanyko, Viktor
   Meszaros, Norbert
   Ujhelyi, Mihaly
   Frohlich, Georgina
   Stelczer, Gabor
   Major, Tibor
   Matrai, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ujhelyi, Mihaly] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Smanyko, V (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Stefan, A
   Arnoczkine Orban, H
   Toth, J
   Stelczer, G
   Polgar, Cs
   Agoston, P
AF Stefan, Anita
   Arnoczkine Orban, Helga
   Toth, Judit
   Stelczer, Gabor
   Polgar, Csaba
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stefan, Anita] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Arnoczkine Orban, Helga] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Toth, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stefan, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Molnarne Szabados, M
   Orosz, K
AF Molnarne Szabados, Marta
   Orosz, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Molnarne Szabados, Marta] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Orosz, Krisztina] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Molnarne Szabados, M (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Szakonyi, J
AF Szakonyi, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakonyi, Jozsef] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Szakonyi, J (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Szaszne, SzAJ
   Garami, M
   Sapi, Z
   Papai, Zs
AF Szaszne, Szentesi Aniko Judit
   Garami, Miklos
   Sapi, Zoltan
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szaszne, Szentesi Aniko Judit] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Szaszne, SzAJ (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Szentkereszty, M
   Galffy, G
   Komlosi, Zs
   Losonczy, Gy
AF Szentkereszty, Marton
   Galffy, Gabriella
   Komlosi, Zsolt
   Losonczy, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szentkereszty, Marton] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Galffy, Gabriella] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Komlosi, Zsolt] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Losonczy, Gyorgy] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Szentkereszty, M (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Szilagyi, Cs
   Janvary, ZsL
   Papp, J
   Simon, M
   Horvath, Zs
AF Szilagyi, Csaba
   Janvary, Zsolt Levente
   Papp, Judit
   Simon, Mihaly
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Csaba] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Janvary, Zsolt Levente] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Papp, Judit] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Szilagyi, Cs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Sugarterapia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 45
EP 46
PG 2
ER

PT J
AU Szilagyi-Mezei, �
AF Szilagyi-Mezei, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi-Mezei, Agnes] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Szilagyi-Mezei, � (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Szy, �
AF Szy, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szy, Agnes] ESZSZK Szent Laszlo Korhaz, HospiceBudapest, Hungary.
RP Szy, � (reprint author), ESZSZK Szent Laszlo Korhaz, Hospice, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Szy, �
AF Szy, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szy, Agnes] ESZSZK Szent Laszlo Korhaz, HospiceBudapest, Hungary.
RP Szy, � (reprint author), ESZSZK Szent Laszlo Korhaz, Hospice, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 46
EP 47
PG 2
ER

PT J
AU Takacsi-Nagy, Z
AF Takacsi-Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Tokes, T
   Tokes, AM
   Szentmartoni, Gy
   Kiszner, G
   Molnar, B�
   Kulka, J
   Krenacs, T
   Dank, M
AF Tokes, Timea
   Tokes, Anna-Maria
   Szentmartoni, Gyongyver
   Kiszner, Gergo
   Molnar, Bela Akos
   Kulka, Janina
   Krenacs, Tibor
   Dank, Magdolna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Timea] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Tokes, Anna-Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szentmartoni, Gyongyver] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kiszner, Gergo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Molnar, Bela Akos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Tokes, T (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Ujhelyi, M
   Pukancsik, D
   Kelemen, P
   Savolt, �
   Godeny, M
   Kenessey, I
   Matrai, T
   Bak, M
   Kasler, M
   Matrai, Z
AF Ujhelyi, Mihaly
   Pukancsik, David
   Kelemen, Peter
   Savolt, Akos
   Godeny, Maria
   Kenessey, Istvan
   Matrai, Tamas
   Bak, Mihaly
   Kasler, Miklos
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Matrai, Tamas] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, IgazgatosagBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Ujhelyi, M (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 47
EP 48
PG 2
ER

PT J
AU Uray, I
   Zsolczai, D
   Peiying, Y
   Horvath, Zs
AF Uray, Ivan
   Zsolczai, David
   Peiying, Yang
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Uray, Ivan] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Zsolczai, David] UT MD Anderson Cancer Center, Clinical Cancer PreventionHouston, TX, USA.
   [Peiying, Yang] UT MD Anderson Cancer Center, Clinical Cancer PreventionHouston, TX, USA.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Uray, I (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Vancsik, T
   Kovago, Cs
   Kiss, �
   Forika, G
   Meggyeshazi, N
   Benyo, Z
   Krenacs, T
AF Vancsik, Tamas
   Kovago, Csaba
   Kiss, Eva
   Forika, Gertrud
   Meggyeshazi, Nora
   Benyo, Zoltan
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kovago, Csaba] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Kiss, Eva] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Meggyeshazi, Nora] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Vancsik, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Varga, L
   Mullner, K
   Szabo, D
   Koszo, R
   Darazs, B
   Fodor, E
   Varga, Z
   Nikolenyi, A
   Hideghety, K
   Kahan, Zs
   Maraz, A
AF Varga, Linda
   Mullner, Kitti
   Szabo, Dorottya
   Koszo, Renata
   Darazs, Barbara
   Fodor, Emese
   Varga, Zoltan
   Nikolenyi, Aliz
   Hideghety, Katalin
   Kahan, Zsuzsanna
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mullner, Kitti] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Dorottya] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 48
EP 49
PG 2
ER

PT J
AU Vegvary, Z
   Koszo, R
   Gal, V
   Egyud, Zs
   Varga, L
   Nagy, Z
   Darazs, B
   Varga, Z
   Kahan, Zs
AF Vegvary, Zoltan
   Koszo, Renata
   Gal, Viorica
   Egyud, Zsofia
   Varga, Linda
   Nagy, Zoltan
   Darazs, Barbara
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Vekas, M
   Stelczer, G
   Bajcsay, A
   Agoston, P
   Rausch, G
   Polgar, Cs
AF Vekas, Marton
   Stelczer, Gabor
   Bajcsay, Andras
   Agoston, Peter
   Rausch, Gabriella
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vekas, Marton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Rausch, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vekas, M (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Veleczki, Zs
AF Veleczki, Zsuzsa
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Veleczki, Zsuzsa] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Veleczki, Zs (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Virga, J
   Bognar, L
   Hortobagyi, T
   Zahuczky, G
   Felsberg, J
   Toth, J
   Szivos, L
   Remenyi-Puskar, J
   Klekner, �
AF Virga, Jozsef
   Bognar, Laszlo
   Hortobagyi, Tibor
   Zahuczky, Gabor
   Felsberg, Jorg
   Toth, Judit
   Szivos, Laszlo
   Remenyi-Puskar, Judit
   Klekner, Almos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Virga, Jozsef] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Bognar, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Hortobagyi, Tibor] Debreceni Egyetem OEC, Neuropatologiai TanszekDebrecen, Hungary.
   [Zahuczky, Gabor] UD-GenoMed Medical Genomic Technologies LtdDebrecen, Hungary.
   [Felsberg, Jorg] Heinrich Heine Universitat, Universitatsklinikum Dusseldorf, Institut fur NeuropathologieDusseldorf, Germany.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szivos, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Remenyi-Puskar, Judit] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
RP Virga, J (reprint author), University of Debrecen, Clinical Center, Department of Neurosurgery, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Vizkeleti, J
   Frohlich, G
   Horvath, K
   Nguyen, AN
   Meszaros, N
   Major, T
   Polgar, Cs
AF Vizkeleti, Julia
   Frohlich, Georgina
   Horvath, Katalin
   Nguyen, Anhhong Nhung
   Meszaros, Norbert
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Zambo, O
AF Zambo, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zambo, Orsolya] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Zambo, O (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Zana, �
   Kegye, A
   Hegedus, K
AF Zana, Agnes
   Kegye, Adrienne
   Hegedus, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zana, Agnes] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Kegye, Adrienne] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Hegedus, Katalin] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Zana, � (reprint author), Semmelweis University, Institute of Behavioural Sciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 50
EP 51
PG 2
ER

PT J
AU Al-Farhat, Y
   Schipp, I
   Auth, P
AF Al-Farhat, Yousuf
   Schipp, Ildiko
   Auth, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Auth, Peter] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Alzubi, A
   Zollei, I
   Gyori, A
   Sahin-Toth, G
   Farkas, N
   Intzedi, K
   Krenacs, L
AF Alzubi, Ali
   Zollei, Istvan
   Gyori, Attila
   Sahin-Toth, Gabor
   Farkas, Norbert
   Intzedi, Katalin
   Krenacs, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Alzubi, Ali] Oroshazi Korhaz, Klinikai OnkologiaOroshaza, Hungary.
   [Zollei, Istvan] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Gyori, Attila] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Sahin-Toth, Gabor] Oroshazi Korhaz, Klinikai OnkologiaOroshaza, Hungary.
   [Farkas, Norbert] Oroshazi Korhaz, Klinikai OnkologiaOroshaza, Hungary.
   [Intzedi, Katalin] Oroshazi Korhaz, Patologiai OsztalyOroshaza, Hungary.
   [Krenacs, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
RP Alzubi, A (reprint author), Oroshazi Korhaz, Klinikai Onkologia, Oroshaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Andras, Cs
   Kocsis, J
   Szekanecz, �
   Juhasz, B
   Horvath, Zs
AF Andras, Csilla
   Kocsis, Judit
   Szekanecz, Eva
   Juhasz, Balazs
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Kocsis, Judit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Szekanecz, Eva] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Juhasz, Balazs] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Andras, Cs (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Arokszallasi, A
   Balogh, I
   Varga, E
   Andras, Cs
   Juhasz, B
   Szekanecz, �
   Toth, J
   Beres, E
   Horvath, Zs
   Kocsis, J
AF Arokszallasi, Anita
   Balogh, Ingrid
   Varga, Eniko
   Andras, Csilla
   Juhasz, Balazs
   Szekanecz, Eva
   Toth, Judit
   Beres, Edit
   Horvath, Zsolt
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arokszallasi, Anita] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Balogh, Ingrid] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Varga, Eniko] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Juhasz, Balazs] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Szekanecz, Eva] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Toth, Judit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Beres, Edit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Horvath, Zsolt] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Kocsis, Judit] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Arokszallasi, A (reprint author), Debreceni Egyetem, Onkologiai Klinika, Onkologia Osztaly, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Baki, M
   Valikovics, A
   Szucs, M
   Landherr, L
AF Baki, Marta
   Valikovics, Aniko
   Szucs, Miklos
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Valikovics, Aniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Baki, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Balazs, K
   Bogdandi, N
   Widlak, P
   Safrany, G
   Lumniczky, K
AF Balazs, Katalin
   Bogdandi, E. Noemi
   Widlak, Piotr
   Safrany, Geza
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Bogdandi, E. Noemi] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Widlak, Piotr] Maria Sklodowska- Curie Memorial Cancer Center and Institute of Oncology, Gliwice BranchGliwice, Poland.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Balazs, K (reprint author), Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Balogh, A
   Besztercei, B
   Benyo, Z
   Tigyi, G
AF Balogh, Andrea
   Besztercei, Balazs
   Benyo, Zoltan
   Tigyi, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balogh, Andrea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Besztercei, Balazs] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Tigyi, Gabor] University of Tennessee, Health Science Center, Department of PhysiologyMemphis, USA.
RP Balogh, A (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Bellyei, Sz
   Boronkai, �
   Mangel, L
AF Bellyei, Szabolcs
   Boronkai, Arpad
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Beres, E
   Andras, Cs
   Juhasz, B
   Horvath, Zs
   Kocsis, J
AF Beres, Edit
   Andras, Csilla
   Juhasz, Balazs
   Horvath, Zsolt
   Kocsis, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Beres, Edit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Juhasz, Balazs] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Beres, E (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Besztercei, B
   Balogh, A
   Vancsik, T
   Major, E
   Krenacs, T
   Benyo, Z
AF Besztercei, Balazs
   Balogh, Andrea
   Vancsik, Tamas
   Major, Eniko
   Krenacs, Tibor
   Benyo, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Besztercei, Balazs] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Major, Eniko] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Besztercei, B (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 57
EP 58
PG 2
ER

PT J
AU Csenge, M
   Drajko, V
   Landherr, L
AF Csenge, Melinda
   Drajko, Veronika
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csenge, Melinda] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Csenge, M (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Dankovics, Zs
   Huszar, A
   Csejtei, A
AF Dankovics, Zsofia
   Huszar, Attila
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Huszar, Attila] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Dankovics, Zs (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Deme, D
   Telekes, A
AF Deme, Daniel
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Telekes, Andras] Semmelweis Egyetem, Geriatriai Tanszeki CsoportBudapest, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Drajko, V
   Katona, Cs
   Landherr, L
AF Drajko, Veronika
   Katona, Csilla
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Drajko, V (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Fodor, K
   Sipos, �
   Nagy, J
   Mehes, G
   Treszl, A
   Okos, A
   Halmos, G
AF Fodor, Klara
   Sipos, Eva
   Nagy, Janos
   Mehes, Gabor
   Treszl, Andrea
   Okos, Andrea
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Klara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Sipos, Eva] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Nagy, Janos] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Okos, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Fodor, K (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Forika, G
   Kiss, �
   Vancsik, T
   Benyo, Z
   Krenacs, T
AF Forika, Gertrud
   Kiss, Eva
   Vancsik, Tamas
   Benyo, Zoltan
   Krenacs, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kiss, Eva] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Forika, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Futo, I
   Telekes, A
AF Futo, Ildiko
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Futo, Ildiko] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Futo, I (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 59
EP 60
PG 2
ER

PT J
AU Gocze, K
   Kovacs, K
   Stefanovits, �
AF Gocze, Katalin
   Kovacs, Krisztina
   Stefanovits, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gocze, Katalin] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Sportmedicina TanszekPecs, Hungary.
   [Kovacs, Krisztina] University of Pecs, Department of PathologyPecs, Hungary.
   [Stefanovits, Agnes] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
RP Gocze, K (reprint author), Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Sportmedicina Tanszek, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Gyergyay, F
   Budai, B
   Biro, K
   Kuronya, Zs
   Nagyivanyi, K
   Geczi, L
AF Gyergyay, Fruzsina
   Budai, Barna
   Biro, Krisztina
   Kuronya, Zsofia
   Nagyivanyi, Krisztian
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Gyergyay, F (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Harda, K
   Szabo, Zs
   Treszl, A
   Steiber, Z
   Olah, G
   Szasz, Cs
   Beke, L
   Mehes, G
   Halmos, G
AF Harda, Kristof
   Szabo, Zsuzsanna
   Treszl, Andrea
   Steiber, Zita
   Olah, Gabor
   Szasz, Csaba
   Beke, Livia
   Mehes, Gabor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harda, Kristof] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Steiber, Zita] Debreceni Egyetem, Orvos- es Egeszsegtudomanyi Centrum, Altalanos Orvostudomanyi Kar, Szemeszeti KlinikaDebrecen, Hungary.
   [Olah, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szasz, Csaba] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Beke, Livia] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
RP Harda, K (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Horvath, A
   Pozsonyi, Z
   Bokros, J
   Varga, A
   Katona, G
   Balazs, Gy
AF Horvath, Anna
   Pozsonyi, Zoltan
   Bokros, Judit
   Varga, Andrea
   Katona, Gabor
   Balazs, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Anna] Semmelweis UniversityBudapest, Hungary.
   [Pozsonyi, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Bokros, Judit] Semmelweis UniversityBudapest, Hungary.
   [Varga, Andrea] Semmelweis UniversityBudapest, Hungary.
   [Katona, Gabor] Semmelweis UniversityBudapest, Hungary.
   [Balazs, Gyorgy] Semmelweis UniversityBudapest, Hungary.
RP Horvath, A (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Horvath, D
   Kosa, J
   Futo, I
   Telekes, A
AF Horvath, Dorottya
   Kosa, Judit
   Futo, Ildiko
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dorottya] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kosa, Judit] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Futo, Ildiko] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Telekes, Andras] Bajcsy -Zsilinszky Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Horvath, D (reprint author), Bajcsy -Zsilinszky Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Horvath, O
AF Horvath, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Orsolya] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Horvath, O (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Huszar, A
   Dankovics, Zs
   Csejtei, A
AF Huszar, Attila
   Dankovics, Zsofia
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Huszar, Attila] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Dankovics, Zsofia] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Huszar, A (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 61
EP 62
PG 2
ER

PT J
AU Ifju, V
   Biro, K
   Nagyivanyi, K
   Gyergyay, F
   Kuronya, Zs
   Bodrogi, I
   Bak, M
   Toth, L
   Geczi, L
AF Ifju, Vivien
   Biro, Krisztina
   Nagyivanyi, Krisztian
   Gyergyay, Fruzsina
   Kuronya, Zsofia
   Bodrogi, Istvan
   Bak, Mihaly
   Toth, Laszlo
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ifju, Vivien] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nagyivanyi, Krisztian] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Gyergyay, Fruzsina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bodrogi, Istvan] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Bak, Mihaly] Orszagos Onkologiai Intezet, Citopatologiai OsztalyBudapest, Hungary.
   [Toth, Laszlo] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Ifju, V (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Janosi, D
   Hegedus, G
   Kander, K
   Olah, T
   Bajzik, G
   Ruzsa, �
AF Janosi, Dalma
   Hegedus, Geza
   Kander, Klara
   Olah, Tibor
   Bajzik, Gabor
   Ruzsa, Agnes
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janosi, Dalma] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Hegedus, Geza] Kaposi Mor Hospital, Department of PathologyKaposvar, Hungary.
   [Kander, Klara] Somogy Megyei Kaposi Mor Oktato Korhaz, Radiologiai OsztalyKaposvar, Hungary.
   [Olah, Tibor] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Bajzik, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
RP Janosi, D (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Kalman, P
   Pap, J
   Horvath, Zs
   Uray, I
AF Kalman, Patricia
   Pap, Julia
   Horvath, Zsolt
   Uray, Ivan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kalman, Patricia] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Pap, Julia] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Uray, Ivan] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Kalman, P (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Kis, E
   Safrany, G
   Widlak, P
   Lumniczky, K
AF Kis, Eniko
   Safrany, Geza
   Widlak, Piotr
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kis, Eniko] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Widlak, Piotr] Maria Sklodowska- Curie Memorial Cancer Center and Institute of Oncology, Gliwice BranchGliwice, Poland.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Kis, E (reprint author), Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Kocsis, Zs
   Agoston, P
   Farkas, Gy
   Szekely, G
   Jorgo, K
   Polgar, Cs
   Juranyi, Zs
AF Kocsis, Zsuzsa
   Agoston, Peter
   Farkas, Gyongyi
   Szekely, Gabor
   Jorgo, Kliton
   Polgar, Csaba
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Koltai, P
   Bartfai, R
AF Koltai, Pal
   Bartfai, Reka
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Bartfai, Reka] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Koltai, P (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Kovacs, P
   Melegh, K
   Czirbesz, K
   Panczel, G
   Balatoni, T
   Liszkay, G
AF Kovacs, Peter
   Melegh, Krisztina
   Czirbesz, Kata
   Panczel, Gitta
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Melegh, Krisztina] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 63
EP 64
PG 2
ER

PT J
AU Kohalmy, K
   Balazs, B
   Kovacs, J
   Pulay, T
   Pete, I
   Demeter, A
   Vincze, B
AF Kohalmy, Krisztina
   Balazs, Boglarka
   Kovacs, Judit
   Pulay, Tamas
   Pete, Imre
   Demeter, Attila
   Vincze, Borbala
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Balazs, Boglarka] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Pulay, Tamas] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Demeter, Attila] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Kohalmy, K (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Kullmann, T
   Sipocz, I
   Pinter, T
AF Kullmann, Tamas
   Sipocz, Istvan
   Pinter, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Sipocz, Istvan] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Lahm, E
   Joba, R
   Szilvasi, I
   Papai, Zs
AF Lahm, Erika
   Joba, Robert
   Szilvasi, Istvan
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Joba, Robert] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szilvasi, Istvan] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 64
EP 65
PG 2
ER

PT J
AU Laszlo, Z
   Papp, A
   Gomori, �
   Farkas, R
   Mangel, L
   Bellyei, Sz
AF Laszlo, Zoltan
   Papp, Andras
   Gomori, Eva
   Farkas, Robert
   Mangel, Laszlo
   Bellyei, Szabolcs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Papp, Andras] University of Pecs, Department of OncologyPecs, Hungary.
   [Gomori, Eva] University of Pecs, Department of PathologyPecs, Hungary.
   [Farkas, Robert] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
RP Laszlo, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Lukacs, G
   Kaposztas, Zs
   Ruzsa, �
   Bajzik, G
   Toth, Z
   Repa, I
   Kovacs, �
AF Lukacs, Gabor
   Kaposztas, Zsolt
   Ruzsa, Agnes
   Bajzik, Gabor
   Toth, Zoltan
   Repa, Imre
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Gabor] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Kaposztas, Zsolt] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Ruzsa, Agnes] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Bajzik, Gabor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Toth, Zoltan] MEDICOPUS Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.Kaposvar, Hungary.
   [Repa, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Kovacs, Arpad] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
RP Lukacs, G (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologia, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Marko, L
   Maraz, R
   Boross, G
   Svebis, M
   Pap-Szekeres, J
   Sikorszki, L
   Ambrozay, �
   Cserni, G
   Pajkos, G
AF Marko, Laszlo
   Maraz, Robert
   Boross, Gabor
   Svebis, Mihaly
   Pap-Szekeres, Jozsef
   Sikorszki, Laszlo
   Ambrozay, Eva
   Cserni, Gabor
   Pajkos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Boross, Gabor] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Svebis, Mihaly] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Pap-Szekeres, Jozsef] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Pajkos, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Martin, T
   Biro, K
   Geczi, L
AF Martin, Tamas
   Biro, Krisztina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Martin, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Martin, T (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Mezei, T
   Pollner, P
   Czigleczki, G
   Horvath, A
   Banczerowski, P
AF Mezei, Tamas
   Pollner, Peter
   Czigleczki, Gabor
   Horvath, Anna
   Banczerowski, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mezei, Tamas] Semmelweis UniversityBudapest, Hungary.
   [Pollner, Peter] MTA-ELTE, Statisztikus es Biologiai Fizika KutatocsoportBudapest, Hungary.
   [Czigleczki, Gabor] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Horvath, Anna] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Banczerowski, Peter] National Institute of Clinical NeurosciencesBudapest, Hungary.
RP Mezei, T (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Misik, F
   Sipos, L
   Reiniger, L
   Czirjak, S
AF Misik, Ferenc
   Sipos, Laszlo
   Reiniger, Lilla
   Czirjak, Sandor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Misik, Ferenc] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
   [Sipos, Laszlo] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Czirjak, Sandor] Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztalyBudapest, Hungary.
RP Misik, F (reprint author), Orszagos Klinikai Idegtudomanyi Intezet, Vascularis es Koponyaalapi Idegsebeszeti osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 66
EP 67
PG 2
ER

PT J
AU Munkacsy, Gy
   Herman, P
   Gyorffy, B
AF Munkacsy, Gyongyi
   Herman, Peter
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Munkacsy, Gyongyi] Semmelweis UniversityBudapest, Hungary.
   [Herman, Peter] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis UniversityBudapest, Hungary.
RP Munkacsy, Gy (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Muller, Z
   Vityi, T
   Szucs, M
   Gorgey, Cs
AF Muller, Zoltan
   Vityi, Tamas
   Szucs, Milan
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki Utcai Korhaz, Zugloi Egeszsegugyi Szolgalat, Ful-orr-gege OsztalyBudapest, Hungary.
   [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Szucs, Milan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Gorgey, Csaba] Uzsoki Utcai Korhaz, Zugloi Egeszsegugyi Szolgalat, Ful-orr-gege OsztalyBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki Utcai Korhaz, Zugloi Egeszsegugyi Szolgalat, Ful-orr-gege Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Nagy, �
   Lanczky, A
   Gyorffy, B
AF Nagy, Adam
   Lanczky, Andras
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Adam] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Lanczky, Andras] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Gyorffy, Balazs] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
RP Nagy, � (reprint author), Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 67
EP 68
PG 2
ER

PT J
AU Nagy, �K
   Piko, B
   Vereb, B
   Vargane Tamas, R
   Szucs, B
   Fulop, F
AF Nagy, Agnes Krisztina
   Piko, Bela
   Vereb, Blanka
   Vargane Tamas, Rozsa
   Szucs, Bernadett
   Fulop, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Agnes Krisztina] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Vereb, Blanka] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Vargane Tamas, Rozsa] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Szucs, Bernadett] Scanomed Kft.Debrecen, Hungary.
   [Fulop, Ferenc] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Nagy, �K (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Nagy, J
   Sipka, S
   Kocsis, J
   Horvath, Zs
AF Nagy, Janos
   Sipka, Sandor
   Kocsis, Judit
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Janos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Sipka, Sandor] University of Debrecen, Faculty of Medicine, Department of Internal MedicineDebrecen, Hungary.
   [Kocsis, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Horvath, Zsolt] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Nagy, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Nemeth, Zs
   Lengyel, Zs
   Csemez, I
   Boer, K
   Borbely, K
AF Nemeth, Zsuzsanna
   Lengyel, Zsolt
   Csemez, Imre
   Boer, Katalin
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nemeth, Zsuzsanna] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Csemez, Imre] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Nemeth, Zs (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Osz, �
   Pongor, LS
   Szirmai, D
   Gyorffy, B
AF Osz, Agnes
   Pongor, Lorinc Sandor
   Szirmai, Danuta
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Osz, Agnes] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Pongor, Lorinc Sandor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Szirmai, Danuta] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Osz, � (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 68
EP 69
PG 2
ER

PT J
AU Papp, O
   Vizkeleti, L
   Doma, V
   Reiniger, L
   Piurko, V
   Timar, J
AF Papp, Orsolya
   Vizkeleti, Laura
   Doma, Viktoria
   Reiniger, Lilla
   Piurko, Violetta
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Orsolya] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Vizkeleti, Laura] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Doma, Viktoria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Piurko, Violetta] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Papp, O (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Patonay, P
   Drajko, V
   Naszaly, A
AF Patonay, Peter
   Drajko, Veronika
   Naszaly, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Patonay, Peter] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Drajko, Veronika] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Patonay, P (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Pinter, T
   Bely, M
   Sipocz, I
AF Pinter, Tamas
   Bely, Maria
   Sipocz, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Bely, Maria] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Sipocz, Istvan] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Pinter, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Plavecz, �
   Baki, M
   Fuder, E
   Salamon, F
   Toth, Z
   Landherr, L
AF Plavecz, Eva
   Baki, Marta
   Fuder, Eniko
   Salamon, Ferenc
   Toth, Zoltan
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Baki, Marta] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Fuder, Eniko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Toth, Zoltan] Uzsoki Utcai Korhaz, Urologiai OsztalyBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Plavecz, � (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Pongor, LS
   Harami-Papp, H
   Mehes, E
   Czirok, A
   Gyorffy, B
AF Pongor, Lorinc Sandor
   Harami-Papp, Hajnalka
   Mehes, Elod
   Czirok, Andras
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pongor, Lorinc Sandor] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Harami-Papp, Hajnalka] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Mehes, Elod] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Czirok, Andras] University of Kansas, Medical Center, Department of Anatomy and Cell BiologyKansas, USA.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Pongor, LS (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Prekopp, P
   Szabo, B
   Molnar, V
   Dank, M
   Tamas, L
AF Prekopp, Peter
   Szabo, Balazs
   Molnar, Viktoria
   Dank, Magdolna
   Tamas, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Prekopp, Peter] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Szabo, Balazs] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Molnar, Viktoria] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Tamas, Laszlo] Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck SurgeryBudapest, Hungary.
RP Prekopp, P (reprint author), Semmelweis University, Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Rottek, J
   Szaleczky, E
   Benis, G
   Barta, Zs
   Mersich, T
   Strausz, T
   Szmola, R
   Schneider, T
AF Rottek, Janos
   Szaleczky, Erika
   Benis, Greta
   Barta, Zsofia
   Mersich, Tamas
   Strausz, Tamas
   Szmola, Richard
   Schneider, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rottek, Janos] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Benis, Greta] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Barta, Zsofia] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Strausz, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Szmola, Richard] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Rottek, J (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Rubovszky, G
   Madaras, B
   Pinter, T
   Hitre, E
AF Rubovszky, Gabor
   Madaras, Balazs
   Pinter, Tamas
   Hitre, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Madaras, Balazs] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Pinter, Tamas] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Rubovszky, G (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Salamon, A
   Jordanne Pupak, Sz
AF Salamon, Andrea
   Jordanne Pupak, Szilvia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Salamon, Andrea] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Jordanne Pupak, Szilvia] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Salamon, A (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 71
EP 72
PG 2
ER

PT J
AU Sikter, M
AF Sikter, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Sikter, M (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Sipos, �
   Fodor, K
   Rozsa, D
   Treszl, A
   Schally, A
   Halmos, G
AF Sipos, Eva
   Fodor, Klara
   Rozsa, David
   Treszl, Andrea
   Schally, Andrew
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sipos, Eva] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Fodor, Klara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Rozsa, David] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Treszl, Andrea] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Schally, Andrew] University of Miami, Miller School of MedicineMiami, USA.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Sipos, � (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 72
EP 72
PG 1
ER

PT J
AU Szabo, E
   Rubovszky, G
AF Szabo, Eszter
   Rubovszky, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Eszter] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Szabo, E (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 72
EP 73
PG 2
ER

PT J
AU Szabo, HE
   Szabo, Zs
   Mahr, K
AF Szabo, Helga Erzsebet
   Szabo, Zsolt
   Mahr, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Helga Erzsebet] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Zsolt] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Szabo, HE (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Szabo, Zs
   Kaposztas, Zs
   Lakosi, F
   Szabo, H
   Mahr, K
AF Szabo, Zsolt
   Kaposztas, Zsolt
   Lakosi, Ferenc
   Szabo, Helga
   Mahr, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsolt] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kaposztas, Zsolt] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Szabo, Helga] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Szabo, Zs (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Szabo, Zs
   Szegedi, K
   Kallai, J
   Sipos, �
   Olah, G
   Bereczky, Zs
   Harda, K
   Szasz, Cs
   Szabo, Zs
   Flasko, T
   Halmos, G
AF Szabo, Zsuzsanna
   Szegedi, Krisztian
   Kallai, Judit
   Sipos, Eva
   Olah, Gabor
   Bereczky, Zsuzsanna
   Harda, Kristof
   Szasz, Csaba
   Szabo, Zsuzsanna
   Flasko, Tibor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szegedi, Krisztian] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Kallai, Judit] University of Debrecen, Faculty of Medicine, Department of Laboratory MedicineDebrecen, Hungary.
   [Sipos, Eva] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Olah, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Bereczky, Zsuzsanna] University of Debrecen, Faculty of Medicine, Department of Laboratory MedicineDebrecen, Hungary.
   [Harda, Kristof] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szasz, Csaba] Kenezy Teaching Hospital, Department of PathologyDebrecen, Hungary.
   [Szabo, Zsuzsanna] University of Debrecen, Faculty of Medicine, Department of Laboratory MedicineDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Szabo, Zs (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 73
EP 73
PG 1
ER

PT J
AU Szasz, AM
   Pongor, L
   Doma, V
   Szakonyi, J
   Huszty, G
   Fonyad, L
   Karpati, S
   Timar, J
   Marko-Varga, Gy
   Gyorffy, B
AF Szasz, Attila Marcell
   Pongor, S. Lorinc
   Doma, Viktoria
   Szakonyi, Jozsef
   Huszty, Gergely
   Fonyad, Laszlo
   Karpati, Sarolta
   Timar, Jozsef
   Marko-Varga, Gyorgy
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szasz, Attila Marcell] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Pongor, S. Lorinc] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Doma, Viktoria] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Szakonyi, Jozsef] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Huszty, Gergely] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Fonyad, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Karpati, Sarolta] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Marko-Varga, Gyorgy] Lund University, Department of Biomedical Engineering, Division of Clinical Protein Science and ImagingLund, Sweden.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Szasz, AM (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Szaszne, SzAJ
   Dede, K
   Bursics, A
AF Szaszne, Szentesi Aniko Judit
   Dede, Kristof
   Bursics, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szaszne, Szentesi Aniko Judit] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Dede, Kristof] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
RP Szaszne, SzAJ (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 74
EP 74
PG 1
ER

PT J
AU Szilagyi, D
   Horvath, A
   Toth, �K
   Graf, L
   Bokros, J
   Kapitany, Zs
   Mihalffy, V
   Pollner, P
   Tegze, B
AF Szilagyi, Dalma
   Horvath, Anna
   Toth, Eva Katalin
   Graf, Laszlo
   Bokros, Judit
   Kapitany, Zsuzsa
   Mihalffy, Veronika
   Pollner, Peter
   Tegze, Balint
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szilagyi, Dalma] Semmelweis UniversityBudapest, Hungary.
   [Horvath, Anna] Semmelweis UniversityBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis UniversityBudapest, Hungary.
   [Graf, Laszlo] Semmelweis UniversityBudapest, Hungary.
   [Bokros, Judit] Semmelweis UniversityBudapest, Hungary.
   [Kapitany, Zsuzsa] Semmelweis UniversityBudapest, Hungary.
   [Mihalffy, Veronika] Semmelweis UniversityBudapest, Hungary.
   [Pollner, Peter] Semmelweis UniversityBudapest, Hungary.
   [Tegze, Balint] Semmelweis UniversityBudapest, Hungary.
RP Szilagyi, D (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 74
EP 75
PG 2
ER

PT J
AU Szkukalek, J
   Valtinyi, D
   Borbely, K
AF Szkukalek, Judita
   Valtinyi, Dorottya
   Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szkukalek, Judita] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Valtinyi, Dorottya] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Szkukalek, J (reprint author), St. Imre Hospital, Department Clinical Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Szkukalek, J
   Valtinyi, D
   Borbely, K
   Nagy, Zs
AF Szkukalek, Judita
   Valtinyi, Dorottya
   Borbely, Katalin
   Nagy, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szkukalek, Judita] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Valtinyi, Dorottya] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
   [Nagy, Zsuzsanna] St. Imre Hospital, Department Clinical OncologyBudapest, Hungary.
RP Szkukalek, J (reprint author), St. Imre Hospital, Department Clinical Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 75
EP 75
PG 1
ER

PT J
AU Tamaskovics, B
   Haussmann, J
   Budach, W
AF Tamaskovics, Balint
   Haussmann, Jan
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Haussmann, Jan] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 75
EP 76
PG 2
ER

PT J
AU Vancsik, T
   Major, E
   Kiss, �
   Forika, G
   Krenacs, T
   Benyo, Z
   Balogh, A
AF Vancsik, Tamas
   Major, Eniko
   Kiss, Eva
   Forika, Gertrud
   Krenacs, Tibor
   Benyo, Zoltan
   Balogh, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Major, Eniko] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Kiss, Eva] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Balogh, Andrea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Vancsik, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Varga, Zs
   Mangel, L
AF Varga, Zsuzsanna
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Varga, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 76
EP 76
PG 1
ER

PT J
AU Varga, Zs
   Kalmar, NK
   Vereczkei, A
   Mangel, L
AF Varga, Zsuzsanna
   Kalmar, Nagy Karoly
   Vereczkei, Andras
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Kalmar, Nagy Karoly] University of Pecs, Department of SurgeryPecs, Hungary.
   [Vereczkei, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Varga, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 76
EP 77
PG 2
ER

PT J
AU Vityi, T
   Szucs, M
   Muller, Z
   Klinko, T
   Gorgey, Cs
AF Vityi, Tamas
   Szucs, Milan
   Muller, Zoltan
   Klinko, Timea
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Szucs, Milan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Gorgey, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Vityi, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Vizkeleti, L
   Papp, O
   Doma, V
   Reiniger, L
   Piurko, V
   Timar, J
AF Vizkeleti, Laura
   Papp, Orsolya
   Doma, Viktoria
   Reiniger, Lilla
   Piurko, Violetta
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Laura] Hungarian Academy of Sciences - Semmelweis University, MTA-SE NAP, Brain Metastasis Research GroupBudapest, Hungary.
   [Papp, Orsolya] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Doma, Viktoria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Reiniger, Lilla] Hungarian Academy of Sciences - Semmelweis University, MTA-SE NAP, Brain Metastasis Research GroupBudapest, Hungary.
   [Piurko, Violetta] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Hungarian Academy of Sciences - Semmelweis University, Molecular Oncology Research GroupBudapest, Hungary.
RP Vizkeleti, L (reprint author), Hungarian Academy of Sciences - Semmelweis University, MTA-SE NAP, Brain Metastasis Research Group, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 77
EP 77
PG 1
ER

PT J
AU Wenczl, M
AF Wenczl, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wenczl, Miklos] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Wenczl, M (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2017
VL 61
IS 5
BP 77
EP 78
PG 2
ER

PT J
AU Nagy, G
   Dezso, K
   Kiss, G
   Gerlei, Zs
   Nagy, P
   Kobori, L
AF Nagy, Gergely
   Dezso, Katalin
   Kiss, Gergely
   Gerlei, Zsuzsanna
   Nagy, Peter
   Kobori, Laszlo
TI Benign liver tumours – current diagnostics and therapeutic modalities
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE benign liver tumours; contrast-enhanced MRI; malignant transformation; resection
ID benign liver tumours; contrast-enhanced MRI; malignant transformation; resection
AB The most common benign liver tumours are haemangiomas, focal nodular hyperplasia and hepatocellular adenoma. We perform a review of the literature and show the current diagnostic and therapeutic modalities based on the EASL Clinical Practice Guideline. With the widespread use of ultrasound, the detection of liver lesions is increased. They are usually found in women of childbearing age with atypical abdominal pain or incidentally. Contrast-enhanced US, CT or MRI are usually necessary for differential diagnosis. In atypical appearance or in malignancy suspect cases biopsy could be performed. For symptomatic patients conservative therapy can be sufficient. In haemorrhagic cases transarterial embolisation can be useful, also for tumour size decreasing before surgery. In patients with persisting symptoms, with vessel or soft tissue compression effect or in malignancy suspect cases definitive surgical treatment is advised. In men with hepatocellular adenoma primary resection is appropriate because of the higher risk for malignant transformation. As alternative treatment options radiofrequency ablation, irradiation, chemotherapy, monoclonal antibody therapy or liver transplantation are published.
C1 [Nagy, Gergely] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Dezso, Katalin] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kiss, Gergely] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Gerlei, Zsuzsanna] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Nagy, Peter] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kobori, Laszlo] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
RP Nagy, G (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM gergelynagymd@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 5
EP 13
PG 9
ER

PT J
AU Szijarto, A
   Fulop, A
AF Szijarto, Attila
   Fulop, Andras
TI Surgical treatment of primary liver malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hepatocellular carcinoma; cholangiocellular carcinoma; surgical treatment
ID hepatocellular carcinoma; cholangiocellular carcinoma; surgical treatment
AB The incidence of primary malignant liver tumours is globally rising. Hepatocellular carcinoma constitutes 75-85% of primary liver malignancies. Owing to advancements of oncological therapies, several methods are available to combat the tumour. Upon the complexity of the disease and the wide spectrum of therapeutical regimens, therapy of HCC is debated, with several undecided issues. Noteworthy, however, is that in early tumour stages, as a de facto curative approach, surgical therapy remains the most effective, allowing long-term survival. Intrahepatic cholangiocellular carcinoma (iCCC) is the second most frequent primary malignant liver tumour. Despite technical developments, prognosis of iCCC patients remains dismal. Unfortunately, as the sole curative approach, surgery (nearing 40% 5-year survival) is mostly contraindicated because of a late diagnosis. In these cases, median survival remains below 7-12 months despite parallel palliative therapies. The present review focuses on the surgical management of primary malignant liver tumours.
C1 [Szijarto, Attila] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Fulop, Andras] Semmelweis University, 1st Department of Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
RP Szijarto, A (reprint author), Semmelweis University, 1st Department of Surgery, 1082 Budapest, Hungary.
EM szijartoattila@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 14
EP 25
PG 12
ER

PT J
AU Fehervari, I
   Piros, L
   Vegso, Gy
   Mathe, Z
AF Fehervari, Imre
   Piros, Laszlo
   Vegso, Gyula
   Mathe, Zoltan
TI Liver transplantation in the treatment of hepatic tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE transplantation; liver; oncologic; contraindication; metastases
ID transplantation; liver; oncologic; contraindication; metastases
AB The indications for liver transplantation have become generally accepted over the last decades. However, in the last ten years, this indication area changes, it seems to be enlarged. Increasingly, previously classified as contraindications have become indications like cholangiocarcinoma or colorectal cancer liver metastases in selected cases. We have reviewed the old and new oncologic indications, whose survival rates do not differ from liver transplants due to other indications.
C1 [Fehervari, Imre] Semmelweis University, Department of Transplantation and Surgery, Baross utca 23-25., 1082 Budapest, Hungary.
   [Piros, Laszlo] Semmelweis University, Department of Transplantation and Surgery, Baross utca 23-25., 1082 Budapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and Surgery, Baross utca 23-25., 1082 Budapest, Hungary.
   [Mathe, Zoltan] Semmelweis University, Department of Transplantation and Surgery, Baross utca 23-25., 1082 Budapest, Hungary.
RP Fehervari, I (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM fehervari.imre@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 26
EP 28
PG 3
ER

PT J
AU Vegso, Gy
   Fekete, L
   Fehervari, I
   Mathe, Z
AF Vegso, Gyula
   Fekete, Laura
   Fehervari, Imre
   Mathe, Zoltan
TI Surgical treatment of secondary liver malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE liver metastases; liver resection; colorectal cancer; neuroendocrine tumors; non-colorectal non-neuroendocrine tumors
ID liver metastases; liver resection; colorectal cancer; neuroendocrine tumors; non-colorectal non-neuroendocrine tumors
AB Surgical treatment of liver metastases, under certain conditions, can be a step of a multidisciplinary treatment strategy for advanced malignant disease. Nevertheless, it is not the same if metachronous or synchronous metastases are planned to be treated. Indications for surgery are the most clearly defined and accepted in cases of colorectal and neuroendocrine liver metastases. At the same time, the steps of the traditional oncotherapy has changed in the management of synchronous colorectal metastases: the novel concept of the treatment strategy is removing the liver metastases before the colorectal primary. The role of surgery is less clear and defined in the management of metastases from other, non-colorectal and non-neuroendocrine primaries. The main purpose is to evaluate which kind of criteria should be fulfilled to indicate the resection of liver metastases, which are the conditions that, when present, may provide a benefit to a patient from surgery, improving survival. These criteria have not been clarified precisely yet; randomized prospective trials are needed. Consensus recommendations in such cases could be determined based on the results of the mentioned trials.
C1 [Vegso, Gyula] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Fekete, Laura] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Fehervari, Imre] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Mathe, Zoltan] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
RP Vegso, Gy (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM vegso.gyula@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 29
EP 36
PG 8
ER

PT J
AU Piros, L
   Mathe, Z
AF Piros, Laszlo
   Mathe, Zoltan
TI Laparoscopy in liver surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE laparoscopy; liver resection; hepatocellular carcinoma; colorectal cancer liver metastasis
ID laparoscopy; liver resection; hepatocellular carcinoma; colorectal cancer liver metastasis
AB More than 9000 laparoscopic liver resections (LLR) are performed worldwide for benign lesions, malignancy (mainly for hepatocellular carcinoma and colorectal cancer liver metastasis), and living donor hepatectomy. Although there is no absolute size criterion, smaller, peripheral lesions (<5 cm) of the anteriolateral segments, that lie far from major vessels and anticipated transection planes are most amenable to LLR, but nowadays lesions of the less ideal posterosuperior segments are feasible for LLR too. Centers with extensive experience in hepatobiliary surgery and laparoscopy have performed laparoscopic major hepatic resections with satisfactory outcomes. Patient benefits from LLR include less intraoperative blood loss, less postoperative pain and painkiller requirement, early mobilization and shorter length of hospital stay, with comparable postoperative morbidity and mortality to open liver resection. Comparison studies between open resection and LLR have revealed no differences in width of resection margins or overall survival after resection for hepatocellular cancer or colorectal cancer liver metastases. Other advantages of LLR for HCC are avoidance of collateral vessel ligation, decreased postoperative hepatic insufficiency and fewer postoperative adhesions, all of them facilitates a possible subsequent liver transplantation.
C1 [Piros, Laszlo] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Mathe, Zoltan] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
RP Piros, L (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM pirosl666@hotmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 37
EP 44
PG 8
ER

PT J
AU Bibok, A
   Doros, A
AF Bibok, Andras
   Doros, Attila
TI Role of interventional radiological procedures in the treatment of liver cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE liver neoplasms; interventional radiology; ablation techniques; chemoembolization
ID liver neoplasms; interventional radiology; ablation techniques; chemoembolization
AB Invasive radiological procedures provide more and more therapeutic options for patients with liver cancer. The treatment options previously used as a 2nd/3rd line treatment are making their way to 1st line treatment in selected cases. In this review, the authors take an overview of the interventional radiological procedures used in the most frequent liver neoplasms. There is a rapid development in ablational therapy, especially in the volumetric planning and stereotactic navigation. Using those new devices, the reliability of the ablation can improve a lot. At the field of embolization, new randomized studies were published recently, which can help to choose the right patient group who gains the most from the treatment. Interventional radiology has now an established place in the team of specialists treating malignant liver diseases.
C1 [Bibok, Andras] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
   [Doros, Attila] Semmelweis University, Department of Transplantation and Surgery, Baross u. 23., 1082 Budapest, Hungary.
RP Bibok, A (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM bibok.andras@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 45
EP 52
PG 8
ER

PT J
AU Dank, M
   Padanyi, P
AF Dank, Magdolna
   Padanyi, Peter
TI Systemic treatment options of primary hepatocellular carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hepatocellular carcinoma; systemic therapy; targeted therapy; immunotherapy
ID hepatocellular carcinoma; systemic therapy; targeted therapy; immunotherapy
AB Hepatocellular carcinoma is the most common primary malignancy of the liver, with increasing incidence worldwide. Chronic liver diseases, especially liver cirrhosis, are the primary risk factors in the pathogenesis. Curative therapy is usually possible only in early disease, however, most cases are diagnosed at advanced stage. Until recently sorafenib was the only viable option for systemic treatment, however, over the past years many new targeted and immunotherapy drugs proved to be efficient in first and second line as well.
C1 [Dank, Magdolna] Semmelweis University, Department of Oncology, Tomo utca 25-29., 1083 Budapest, Hungary.
   [Padanyi, Peter] Semmelweis University, Department of Oncology, Tomo utca 25-29., 1083 Budapest, Hungary.
RP Dank, M (reprint author), Semmelweis University, Department of Oncology, 1083 Budapest, Hungary.
EM dank.magdolna@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 53
EP 61
PG 9
ER

PT J
AU Foldi, G
   Polgar, Cs
   Zongor, Zs
   Melles-Bencsik, B
   Stelczer, G
   Madaras, B
   Pinter, T
   Jederan, �
   Lovey, J
AF Foldi, Gerda
   Polgar, Csaba
   Zongor, Zsuzsanna
   Melles-Bencsik, Barbara
   Stelczer, Gabor
   Madaras, Balazs
   Pinter, Tamas
   Jederan, Eva
   Lovey, Jozsef
TI Stereotactic body radiotherapy of liver metastasis: early experience
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE hepatic metastasis; oligometastasis; stereotactic ablative body radiotherapy; SABRT
ID hepatic metastasis; oligometastasis; stereotactic ablative body radiotherapy; SABRT
AB Recently the prevalence of oligometastatic patients is increasing. A common site of distant spread is the liver. The standard of care is curative surgical resection, however, the resecability rate is only 10-20%. Alternatively, radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) may be used. Stereotactic ablative body radiotherapy (SABRT) makes it possible to deliver curative radiation dose without radiation injury to the healthy liver tissue. We delivered SABRT to three patients with inoperable hepatic metastases. The primary tumors were rectal (2) and lung (1). The dose was 3x20 Gy every other day. We observed one grade 1 side effect. All the metastases showed complete remission and no local recurrence or late side effect occurred during the one year of follow-up. One patient is tumor-free, one has stable disease, in one patient two new hepatic metastases appeared and receives chemo-biological therapy. SABRT of liver metastases is safe and highly effective. It can be expected that in the near future it will become one of the standard treatments of hepatic tumors.
C1 [Foldi, Gerda] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Melles-Bencsik, Barbara] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Madaras, Balazs] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Pinter, Tamas] National Institute of Oncology, Department of Chemotherapy and ClinicopharmacologyBudapest, Hungary.
   [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 62
EP 67
PG 6
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI Alcohol and breast cancer. A short survey
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE alcohol; acetaldehyde; carcinogen; breast cancer
ID alcohol; acetaldehyde; carcinogen; breast cancer
AB Regular consumption of alcohol increases the risk of developing (one or more of) several malignant conditions: the frequency of tumours in the aerodigestive tract, in the liver, in the colorectal region and in the breast is increased. The principal carcinogen component of alcoholic drinks is ethanol itself; the effect is unmistakably proportional to the daily/weekly dosage. Under the influence of alcohol-dehydrogenase, ethanol will metabolise to acetaldehyde, which is a known carcinogen. Among other things chronic alcohol consumption promotes the production of endogen hormones, affects the insulin-like growth factor-1, alters several biological pathways, raises oxidative stress, and damages the genes. Even modest daily alcohol intake will increase the risk of breast cancer.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Vorosmarty u. 31., 1064 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1064 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2018
VL 62
IS 1
BP 68
EP 71
PG 4
ER

PT J
AU Timar, J
   Patocs, A
AF Timar, Jozsef
   Patocs, Attila
TI Genomics of neuroendocrine tumors of the lung and gastrointestinal tract: similarities and differences
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung; GI; neuroendocrine tumor; genetics
ID lung; GI; neuroendocrine tumor; genetics
AB The incidence of neuroendocrine tumors sharply increased in the past years. It is also important that beside the relatively benign, slow growing tumors, prevalence of aggressive neuroendocrine carcinomas is also increasing. It is now evident that the carcinoids are genetically heterogeneous entities, localized to lung, pancreas or to the small intestines. A significant proportion of these neuroendocrine tumors are associated with hereditary syndromes but the etiology of the sporadic versions is still unknown, although in case of the lung, neuroendocrine carcinomas have a similar etiology than the non-endocrine carcinomas. This review summarizes the results of recent complex genomic analyses. Based on these data it is evident that the neuroendocrine tumors of the lung are different as compared to gastrointestinal ones. These genetic differences may fundamentally affect their biology, prognosis and therapy which must be considered.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Patocs, Attila] Hungarian Academy of Sciences and Semmelweis University, Hereditary Endocrine Tumors Research GroupBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 77
EP 82
PG 6
ER

PT J
AU Fillinger, J
AF Fillinger, Janos
TI Pathology of lung neuroendocrine tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuroendocrine tumors; lung; core biopsy; bronchoscopy; cytology
ID neuroendocrine tumors; lung; core biopsy; bronchoscopy; cytology
AB The heterogeneous group of lung neuroendocrine tumors are divided into four main types: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCLC). Classification is based on the analysis of surgical resection specimens, which, in addition to basic morphological features, takes into account the mitotic count in 2 mm², the presence or absence of necrosis. According to prognosis, TC is low grade, AC is intermediate grade, while SCLC and LCNEC are high grade carcinomas with very poor prognosis. The morphological diagnosis can be refined by the use of neuroendocrine immunohistochemical markers. Based on the histological diagnosis, clinical prognosis is not always clear. Application of Ki-67 labeling can get closer to real biological behavior. Recently, more than 2/3 of the cases are small samples (core biopsy, bronchoscopic biopsy, cytological smears). Diagnostic algorithms developed for resection specimens has limited usage for these samples. In a single case, a wide range of histological techniques should be used in the processing of the sample, and still only an unsatisfactory result is obtained. Knowing the potential information content of the samples can help the clinician to set up a diagnostic and therapeutic plan.
C1 [Fillinger, Janos] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Fillinger, J (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
EM fillinger@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 83
EP 89
PG 7
ER

PT J
AU Borka, K
AF Borka, Katalin
TI Clinicopathological characterization of gastro-entero- pancreatic neuroendocrine tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE gastro-entero-pancreatic tumors; neuroendocrine tumor; neuroendocrine carcinoma; classification; grade
ID gastro-entero-pancreatic tumors; neuroendocrine tumor; neuroendocrine carcinoma; classification; grade
AB Tumors arising from the diffuse neuroendocrine (NE) system are mostly located in gastro-entero-pancreatic (GEP) tract and in the lung, and show increasing incidence and wide spectrum appearance. Different therapeutic possibilities need accurate diagnosis, classification and prognosis prediction, which determination for pathological diagnostics is a great challenge. All of these are based on the WHO classification, TNM classification of tumors of different location, and clinicopathological characterization. This review provides a comprehensive overview of the general characteristics of NE tumors, in particular the clinical-pathological properties of gastro-entero-pancreatic tumors and the requirements of correct pathological diagnosis for treatment.
C1 [Borka, Katalin] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Borka, K (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM borka.katalin@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 90
EP 97
PG 8
ER

PT J
AU Toth, M
AF Toth, Miklos
TI The treatment of gastroenteropancreatic neuroendocrine tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuroendocrine tumor; therapeutic guidelines; somatostatin analogues; peptide receptor radiotherapy
ID neuroendocrine tumor; therapeutic guidelines; somatostatin analogues; peptide receptor radiotherapy
AB Gastroenteropancreatic neuroendocrine tumors have been increasing in frequency over the past decades. The goal of this paper is to provide a concise overview of various treatment options based mainly on consensus guidelines. The only curative therapy for these tumors is timely surgical intervention including endoscopic removal of early stage neuroendocrine tumors. Since at initial diagnosis about half of these patients present with advanced disease, systemic drug and non-drug treatments are discussed in details. Therapeutic approaches of advanced stages include surgical, medical, interventional radiological and nuclear medicine strategies. The aims of treatment are to provide an appropriate antisecretory and antiproliferative effect. Optimization of diverse treatment strategies is best achieved by multidisciplinary approaches.
C1 [Toth, Miklos] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
RP Toth, M (reprint author), Semmelweis University, 2nd Department of Internal Medicine, 1088 Budapest, Hungary.
EM toth.miklos@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 99
EP 106
PG 8
ER

PT J
AU Kappelmayer, J
   Bhattoa Harjit, P
AF Kappelmayer, Janos
   Bhattoa Harjit, Pal
TI Laboratory diagnostics of lung neuroendocrine tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE small cell lung cancer; carcinoid; tumor markers
ID small cell lung cancer; carcinoid; tumor markers
AB Perhaps innovations in protein and peptide analysis utilizing immunochemistry methodology have been the most demarcating in the field of routine laboratory diagnostics in the past few decades. Presently, the state of art immunochemistry (e.g., immunofluorimetry, electrochemiluminescence) and separation techniques (e.g., high pressure liquid chromatography) facilitate achievement of detection limits well below the nmol/L range. These techniques have allowed reproducible and high throughput analysis with a short turnaround time of tumor markers, among others, in the routine diagnostic laboratory setting. Tumor marker determination is an integral part of the diagnostic work-up of tumors, and is indispensable in therapeutic monitoring and clinical decision-making. This article presents the utility of tumor markers in the diagnostics of lung neuroendocrine tumors (NET). Furthermore, since the majority of the tests used in lung NET diagnostics are infrequently requested, quite a few practical issues are also discussed. The generally applicable rule pertaining to tumor markers is also valid for NET diagnostics, i.e., improved sensitivity and specificity is widely achieved with a combination of tumor markers, as such, promoting diagnosis, efficient therapeutic monitoring and defining the prognosis.
C1 [Kappelmayer, Janos] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Bhattoa Harjit, Pal] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Kappelmayer, J (reprint author), University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, 4032 Debrecen, Hungary.
EM kappelmayer@med.unideb.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 108
EP 112
PG 5
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI Diagnosis and treatment of the neuroendocrine tumors of the lung
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuroendocrine tumor; lung carcinoid; small cell carcinoma; large cell carcinoma
ID neuroendocrine tumor; lung carcinoid; small cell carcinoma; large cell carcinoma
AB Lung neuroendocrine tumors comprise 20% of all pulmonary tumors. Their appearance and behavior are very heterogeneous. Histologically they are divided into four groups, well-differentiated and low-malignant typical carcinoid, poorly differentiated and worse prognosis atypical carcinoid, and highly malignant small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma. Of these, the most common is small cell lung cancer with an incidence of 15%, while those of large cell neuroendocrine tumors and lung carcinoids are 3% and 2%, respectively. The treatment and prognosis of carcinoids are very different from those of highly malignant small cell and large cell neuroendocrine carcinomas. The paper summarizes the characteristics of lung neuroendocrine tumors.
C1 [Galffy, Gabriella] County Hospital of Pulmonology, Munkacsy Mihaly u. 70., 2045 Torokbalint, Hungary.
RP Galffy, G (reprint author), County Hospital of Pulmonology, 2045 Torokbalint, Hungary.
EM ggalffy@hotmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 113
EP 118
PG 6
ER

PT J
AU Hudacsek, V
   Gyorffy, B
AF Hudacsek, Viktoria
   Gyorffy, Balazs
TI Genome engineering using the CRISPR-Cas9 system and applications in cancer research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE mutations; gene knock-in; gene knock-out; genome editing; transfection; in vitro models
ID mutations; gene knock-in; gene knock-out; genome editing; transfection; in vitro models
AB Today, we have to investigate the effects of selected mutations and molecular alterations – this is made possible by the new genome editing technologies. In these, either a section of the DNA is deleted or moved, or a targeted mutation is introduced into the cell. Here, we describe in detail the CRISPR-Cas9 genome editing method. The technology is based on a feature used by bacteria to combat recurrent viral infections. At present, commencing a set of modifications, the method is functional and can be applied in eukaryotic cells as well. The method has three major steps: first, the system has to be carefully designed and constructed, then the construct has to be introduced into the target cells by transfection, and finally, the achieved effect has to be functionally validated. The reliability of the method enables multiple applications in oncology, including the detailed and efficient investigation of oncogenes, tumor suppressor genes, chromosomal translocations and other molecular changes. At the moment, available CRISPR-Cas9 protocols enable both in vitro and in vivo application. All these already made CRISPR-Cas9 one of the basic methods required for future-proof oncology research.
C1 [Hudacsek, Viktoria] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research Group, Magyar Tudosok korutja 2, 1117 Budapest, Hungary.
RP Gyorffy, B (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, 1117 Budapest, Hungary.
EM gyorffy.balazs@ttk.mta.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 119
EP 127
PG 9
ER

PT J
AU Ozvald, G
AF Ozvald, Gabriella
TI The effect of early psychotrauma on the behavior of patients undergoing active oncologic therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE sexual abuse; cancer; psycho-oncology; compliance
ID sexual abuse; cancer; psycho-oncology; compliance
AB Physical and sexual trauma during childhood is a matter of public health problem. The consequences of cumulative childhood trauma follows on one’s journey through life and are decisive for nerve development, social, emotional and cognitive functioning, and leads to the development of other health risk behaviors as well as to early death. 22-44% of patients in health care suffered from childhood trauma. This ratio is even higher in case of cancer patients. Traumatised oncological patients are particularly characterised by delaying tests or rejecting treatment even in the case of noticeable complaints. According to the recommendations of international literature, questions regarding childhood sexual abuse should be added to the routine exploration, however, screening is difficult because of the sensitivity of the subject. The aim of my study is to explore the frequent problems of traumatised cancer patients through presenting specific cases, in order to bring the specifically vulnerable group of patients closer to help, and mainly to deeper understanding.
C1 [Ozvald, Gabriella] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Szent Istvan u. 68., 4400 Nyiregyhaza, Hungary.
RP Ozvald, G (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, 4400 Nyiregyhaza, Hungary.
EM gabriellaozvald@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2018
VL 62
IS 2
BP 129
EP 132
PG 4
ER

PT J
AU Kriszta, E
   Csik, P
AF Kriszta, Edina
   Csik, Peter
TI Dr. Antal Genersich's 100th Anniversary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE Genersich
ID Genersich
C1 [Kriszta, Edina] Dr. Genersich Antal Alapitvany, Tuske u. 7., 1026 Budapest, Hungary.
   [Csik, Peter] Dr. Genersich Antal Alapitvany, Tuske u. 7., 1026 Budapest, Hungary.
RP Kriszta, E (reprint author), Dr. Genersich Antal Alapitvany, 1026 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 136
EP 137
PG 2
ER

PT J
AU Toth, E
AF Toth, Erika
TI Pathology of HPV-associated oropharyngeal squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oropharynx; HPV16; squamous cell carcinoma; p16 immunohistochemistry
ID oropharynx; HPV16; squamous cell carcinoma; p16 immunohistochemistry
AB Over the past decade, human papillomavirus-related oropharyngeal squamous cell carcinoma has become a distinct entity that differs from conventional head and neck cancer in many ways including its epidemiology, genetics, tumor behavior, and prognosis. Human papillomavirus-related oropharyngeal squamous cell carcinomas also exhibit characteristic histologic features. This review will cover the histomorphologic appearances of human papillomavirus-related oropharyngeal carcinoma, with an emphasis on their differences from conventional, human papillomavirus-unrelated cancer. Besides these we summarize the mechanism of carcinogenesis and the last guidelines for diagnosing this type of cancers.
C1 [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM erika66toth@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 139
EP 144
PG 6
ER

PT J
AU Takacsi-Nagy, Z
AF Takacsi-Nagy, Zoltan
TI Changing trends in the management of the human papillomavirus induced oropharyngeal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oropharynx; human papillomavirus; radiotherapy; dose reduction
ID oropharynx; human papillomavirus; radiotherapy; dose reduction
AB The incidence of oropharyngeal cancers caused by human papillomavirus rises sharply. They are characterized by very good therapeutic response, including radiosensitivity, as is demonstrated by the results of several retrospective analyses. In the following review publications related to this topic are introduced, (radio)biological causes of radiosensitivity are explored and the role of surgical, chemo- and biological therapeutic methods of these types of tumors are discussed with the aim to better understand their different behavior. Taking into account the younger age and better general condition of patients as well as the tumor radiosensitivity it is recommended to override the current therapeutic guidelines in respect of the doses and treatment methods primarily in order to reduce therapeutic complications. Currently several randomized trials on this subject are in progress.
C1 [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM takacsi@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 145
EP 152
PG 8
ER

PT J
AU Meilinger-Dobra, M
   Remenar, �
   Frohlich, G
   Sinkovics, I
   Peter, I
   Boer, A
AF Meilinger-Dobra, Monika
   Remenar, Eva
   Frohlich, Georgina
   Sinkovics, Istvan
   Peter, Ilona
   Boer, Andras
TI Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE thyroid carcinoma; papillary carcinoma; thyroidectomy; active surveillance
ID thyroid carcinoma; papillary carcinoma; thyroidectomy; active surveillance
AB The standard treatment of papillary microcarcinomas (mPTC; ≤1 cm) regardless of their size, was similar to the advanced ones till the recent past: immediate surgery ± radioactive iodine (RAI) therapy. However, the American Thyroid Association (ATA) 2015 guidelines accept the active surveillance in selected cases. We performed a retrospective analysis on the clinical data of 103 patients with PTmC in a single (62.1%) or multiple nodes (37.9%), treated with immediate surgery followed in most cases by postoperative RAI between 2001 and 2010. N stage of the neck was pN0 in 81, and pN+ in 22 patients. Survival probability was significantly related to age (p<0.001), TSH level (p=0.0347), N stage (p=0.0402) and need for neck dissection (p=0.0045). Overall survival at 5, 10, and 15 years was 95%, 89%, and 86%, while disease-specific mortality at 5 and 10 years was 3% and 5%, respectively. Our data show that immediate radical surgery with or without postoperative RAI yielded long-term survival similar to those published. Nevertheless, progression affecting mostly older men was not prevented by immediate surgery. Our findings do not contradict the acceptability of active surveillance recommended by the 2015 ATA Guidelines.
C1 [Meilinger-Dobra, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Boer, Andras] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gy. u. 7-9, 1122 Budapest, Hungary.
RP Meilinger-Dobra, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, 1122 Budapest, Hungary.
EM moni.dobra@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 153
EP 158
PG 6
ER

PT J
AU Godeny, M
   Remenar, �
   Takacsi-Nagy, Z
   Petri, K
   Horvath, K
   Bocs, K
   Manninger, S
   Andi, J
   Lerant, G
   Kasler, M
AF Godeny, Maria
   Remenar, Eva
   Takacsi-Nagy, Zoltan
   Petri, Klara
   Horvath, Katalin
   Bocs, Katalin
   Manninger, Sandor
   Andi, Judit
   Lerant, Gergely
   Kasler, Miklos
TI Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE head and neck cancer; CT; MRI; postirradiation status; complication
ID head and neck cancer; CT; MRI; postirradiation status; complication
AB Most head and neck cancer patients are treated with combined modalities such as surgery, radiotherapy (RT), chemotherapy (ChT). Concurrent chemo-radiation has improved treatment outcomes with increased toxic effects. Reactions after RT are divided into early and late changes. Early reactions are seen during the course of therapy or within 3 months; these are reversible in most cases. Late complications are observed 3 months to years after RT and they are generally irreversible. As typical late reaction radiation induced necrosis may occur in soft tissues, cartilage, bones and brain. Tumor recurrence and post-radiation necrosis typically appear at the same time, within 2-3 years after RT; the differentiation may be difficult. Computed tomography (CT) and magnetic resonance imaging (MRI) have become the gold standards not only for staging and assessing tumor response, but also to evaluate posttreatment status, to distinguish residual or recurrent tumor and RT complications. Using baseline CT or MRI between 2-3 months after treatment and performing standard follow-up imaging with strict clinical follow-up are required to establish early salvage treatment.
C1 [Godeny, Maria] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Petri, Klara] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Manninger, Sandor] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Andi, Judit] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Lerant, Gergely] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Godeny, M (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM godeny.maria@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 159
EP 173
PG 15
ER

PT J
AU Oberna, F
   Czuczor, M
   Fuzes, A
AF Oberna, Ferenc
   Czuczor, Marcell
   Fuzes, Attila
TI Mandibular angle and head reconstruction with fibular free flap
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE fibula free flap; reconstruction; free flap; temporomandibular joint; axial splitting
ID fibula free flap; reconstruction; free flap; temporomandibular joint; axial splitting
AB Extended mandibular defects can be safely managed by applying microvascular free bone transfer. The flap of choice for this procedure is a fibula free flap due to its anatomical structure, proper length and good plasticity. The body of the mandible can be formed by removing wedge bone segments. However the gonial angle can be formed on a different, safer and easier way by performing axial osteotomy as it is done in the orthognathic surgery. The special advantage of this method is that by setting the exact angle of the ascending mandibular part, the ramus replacer fibula segment is perfectly suitable for the replacement of the head of the mandible. While recalling the anatomy of this region our clinical case demonstrates the functional reconstruction of these two delicate mandibular parts.
C1 [Oberna, Ferenc] Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti Osztaly, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Czuczor, Marcell] Semmelweis University, 1st Department of AnatomyBudapest, Hungary.
   [Fuzes, Attila] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Oberna, F (reprint author), Bacs-Kiskun Megyei Korhaz, Arc-, Allcsont Szajsebeszeti es Ful-orr Gegeszeti Osztaly, 6000 Kecskemet, Hungary.
EM obernaf@kmk.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 169
EP 174
PG 6
ER

PT J
AU Bellyei, Sz
   Bako, P
   Orosz, �
   Molnar, K
   Remenar, �
   Mangel, L
AF Bellyei, Szabolcs
   Bako, Peter
   Orosz, Eva
   Molnar, Krisztian
   Remenar, Eva
   Mangel, Laszlo
TI First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE recurrent/metastatic head and neck cancer; immunotherapy; immune checkpoint inhibitor; nivolumab
ID recurrent/metastatic head and neck cancer; immunotherapy; immune checkpoint inhibitor; nivolumab
AB The prognosis for recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) remains dismal and its treatment poses a challenge for oncologists. Nivolumab belongs to the class of immune checkpoint inhibitors (ICI) and is an antibody developed to target the programmed cell death protein 1 (PD-1) receptor. The CheckMate 141 randomized phase 3 trial proved the efficacy of nivolumab in the treatment of R/M HNSCC as it was shown to significantly increase overall survival and quality of life. We present the case of a 53-year-old woman with R/M HNSCC who was given nivolumab monotherapy, as third-line treatment due the progression of her tumor. After treatment with nivolumab, the size of her tumor decreased, then was stable, while she did not experience any adverse events or notable side effects. Our case report is the first to demonstrate the application of nivolumab in R/M HNSCC in Hungary.
C1 [Bellyei, Szabolcs] University of Pecs, Department of Oncology, Edesanyak utja 17., 7635 Pecs, Hungary.
   [Bako, Peter] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Orosz, Eva] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti KlinikaPecs, Hungary.
   [Molnar, Krisztian] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7635 Pecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, 7635 Pecs, Hungary.
EM bellyeisz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 175
EP 178
PG 4
ER

PT J
AU Janvary, ZsL
   Ferenczi, �
   Takacsi-Nagy, Z
   Bajcsay, A
   Polgar, Cs
AF Janvary, Zsolt Levente
   Ferenczi, Ors
   Takacsi-Nagy, Zoltan
   Bajcsay, Andras
   Polgar, Csaba
TI Application of CyberKnife stereotactic radiosurgery in the treatment of head and neck cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE head and neck cancer; CyberKnife; robotic radiosurgery; stereotactic radiotherapy; SBRT; highly conformal radiotherapy
ID head and neck cancer; CyberKnife; robotic radiosurgery; stereotactic radiotherapy; SBRT; highly conformal radiotherapy
AB The treatment of squamous cell carcinoma of the head and neck is multimodal, including surgery, chemotherapy, and radiotherapy, or the combination of those. Though aggressive treatment results in complete tumor remission in many patients even in locally advanced stages, unfortunately local relapse is not uncommon. For patients not candidate for salvage surgery, chemotherapy and conventional fractionated external beam irradiation can be applied. However, for patients previously treated with full-dose radiotherapy, the deliverable reirradiation dose is limited, considering the elevated risk of toxicity caused by cumulative doses. CyberKnife is a highly conformal radiosurgical technology which can successfully treat this subset of patients. In addition, it can be applied for hardly resectable rare tumors of the skull base and the head and neck region like chordoma, chondrosarcoma and paragangliomas. The CyberKnife stereotacic radiosurgery technology is now available in Hungary, in the National Institute of Oncology.
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Ferenczi, Ors] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM janvarylevente@yahoo.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 180
EP 185
PG 6
ER

PT J
AU Levay, B
AF Levay, Bernadett
TI Report about the 3rd International Thyroid NOTES Conference
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Levay, Bernadett] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gyorgy u. 7-9, 1122 Budapest, Hungary.
RP Levay, B (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 186
EP 186
PG 1
ER

PT J
AU Zambo, O
AF Zambo, Orsolya
TI International Head-Neck Surgical Training and Examination (2015-2017)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
C1 [Zambo, Orsolya] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Zambo, O (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, 1122 Budapest, Hungary.
EM orsolya.zambo@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 187
EP 190
PG 4
ER

PT J
TI Treatment of metastatic colorectal tumors beyond the second line
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 191
EP 192
PG 2
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI Lipegfilgrastim – long acting G-CSF in prevention of chemotherapy-induced neutropenia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Lecture
DE febrile neutropenia; solid tumor; antibiotics; granulocyte colony-stimulating factor; lipegfilgrastim
ID febrile neutropenia; solid tumor; antibiotics; granulocyte colony-stimulating factor; lipegfilgrastim
AB One of the most dangerous complications of bone marrow suppression due to chemotherapy is febrile neutropenia. The treatment of the affected patients is a multidisciplinary task. In addition to chemotherapy, adequate G-CSF therapy as a primary or secondary prophylaxis can be used to prevent a large part of febrile neutropenic events. Before each chemotherapy cycle, the risk of febrile neutropenia should be evaluated, taking into account the chemotherapeutic combination and patient-specific parameters. Appropriate antibiotic and G-CSF therapy initiated in the course of febrile neutropenia is essential for the success of the therapy. Long-acting G-CSF therapy for secondary prevention, lipegfilgrastim is effective, safe and simple dosing for the patient. The oncologists can reach treatment success in the patient’s therapy if he or she provides the patient the adequate supportive medications at the appropriate time. Lipegfilgrastim is not a biosimilar, but a new molecule created by a two-step empiric glycopegylation process.
C1 [Galffy, Gabriella] Tudogyogyintezet Torokbalint, Onkologiai es Jarobeteg Centrum, Munkacsy Mihaly u. 70., 2045 Torokbalint, Hungary.
RP Galffy, G (reprint author), Tudogyogyintezet Torokbalint, Onkologiai es Jarobeteg Centrum, 2045 Torokbalint, Hungary.
EM ggalffy@hotmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2018
VL 62
IS 3
BP 195
EP 200
PG 6
ER

PT J
AU Szegedi, I
   Gaspar, I
   Gyurina, K
   Zele, Zs
   Kiss, Cs
AF Szegedi, Istvan
   Gaspar, Imre
   Gyurina, Katalin
   Zele, Zsuzsa
   Kiss, Csongor
TI Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE non-Hodgkin lymphoma; childhood and adolescence; rituximab; obinutuzumab; siltuximab
ID non-Hodgkin lymphoma; childhood and adolescence; rituximab; obinutuzumab; siltuximab
AB Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. The small number of patients hinders introduction of targeted therapies. Here we summarize principles and perspectives of pediatric NHL supported by results of a retrospective clinical survey. Twenty-five patients (21 boys, 4 girls; mean age: 11.9 years) were registered between 2009 and 2018: 11 Burkitt lymphomas, 4 diffuse large B-cell lymphomas, 5 T-cell lymphoblastic lymphomas, and 1-1 grey-zone lymphoma, anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, and Castleman disease. Remission rate was 22/25, 20/25 patients survived (mean follow-up time: 3.9 years). Chemotherapies according to NHL-BFM 95, CHOP, FAB/LMB96, Inter-B-NHL Ritux 2010, Euro-LB02, and ALCL99 were applied. Adjuvant immunotherapy was applied in patients with mature B-cell NHL (rituximab in 7 cases, obinutuzumab in 2 relapsed cases). In Castleman disease siltuximab was applied.
C1 [Szegedi, Istvan] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Gaspar, Imre] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Gyurina, Katalin] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Zele, Zsuzsa] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Kiss, Cs (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, 4032 Debrecen, Hungary.
EM kisscs@med.unideb.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 204
EP 213
PG 10
ER

PT J
AU Vojcek, �
   Pajor, L
AF Vojcek, Agnes
   Pajor, Laszlo
TI High hyperdiploid acute lymphoblastic leukemia is a highly curable subtype of childhood leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE acute lymphoblastic leukemia; high hyperdiploid
ID acute lymphoblastic leukemia; high hyperdiploid
AB Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. In Hungary 60-70 new cases are diagnosed annually. The survival rate is 85-90% in developed countries with current treatment protocols. The most common genetic category of childhood ALL is the high hyperdiploid subtype (HHD) with chromosome numbers of 51 to 67. It accounts for approximately 25% of all cases. The prognosis is very good, though relapse occurs in ~15% of cases and there are data on the heterogeneity of this subgroup as well. In this paper we give an overview of the cytogenetic, clinical, epidemiological and prognostic features of this subgroup. We also demonstrate our interphase fluorescent in situ hybridization (iFISH) analysis performed retrospectively on 168 untreated bone marrow samples of precursor B pediatric ALL patients to reveal the numerical aberrations of chromosomes 4, 6, 10, 14, 17, 18, 21 and X, which are most frequently affected by gain in HHD ALL. Data from 48 high hyperdiploid patients indicated that high modal number (>55 chromosomes) and specific chromosomal gains (+4, +4/+6, +4/+17, +4/+18) exhibited significance in terms of beneficial overall survival.
C1 [Vojcek, Agnes] University of Pecs, Department of Pediatrics, Jozsef Attila u. 7., 7623 Pecs, Hungary.
   [Pajor, Laszlo] University of Pecs, Department of PathologyPecs, Hungary.
RP Vojcek, � (reprint author), University of Pecs, Department of Pediatrics, 7623 Pecs, Hungary.
EM vojcek.agnes@pte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 214
EP 221
PG 8
ER

PT J
AU Bots, B
   Eipel, O
   Terkovics, L
   Felkai, L
   Csoka, M
AF Bots, Bianka
   Eipel, Oliver
   Terkovics, Lotte
   Felkai, Luca
   Csoka, Monika
TI Treatment results of pediatric soft tissue sarcomas at the 2nd Department of Pediatrics, Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE pediatric oncology; soft tissue sarcomas; rhabdomyosarcoma; surgery; chemotherapy; radiotherapy; survival
ID pediatric oncology; soft tissue sarcomas; rhabdomyosarcoma; surgery; chemotherapy; radiotherapy; survival
AB Malignant tumors found in children are different from the ones that occur in adults. Compared to the malignancies in adults, the histological entities in pediatric patients are different and survival rates are higher among the children. Though pediatric soft tissue sarcomas are less common than leukemia and central nervous system malignancies, recognition of them is necessary to start the therapy as soon as possible. The delay of an appropriate treatment – chemotherapy, radiotherapy, surgery, in some cases targeted therapy – is unfavorable because somatic damages and functional loss can occur. In our study at the oncology department of the 2nd Department of Pediatrics of Semmelweis University, we collected and analyzed the data of 90 children who were diagnosed with soft tissue sarcomas between January of 2000 and November of 2016. Our results correlate with the data collected worldwide.
C1 [Bots, Bianka] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Eipel, Oliver] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Terkovics, Lotte] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Felkai, Luca] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Csoka, M (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM csoka.monika@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 222
EP 229
PG 8
ER

PT J
AU Geiszl, Zs
   Kiss, J
   Szendroi, M
   Vizkeleti, J
   Arato, G
   Sapi, Z
   Krivan, G
   Mohas, A
   Renyi, I
   Garami, M
   Hauser, P
AF Geiszl, Zsofia
   Kiss, Janos
   Szendroi, Miklos
   Vizkeleti, Julia
   Arato, Gabriella
   Sapi, Zoltan
   Krivan, Gergely
   Mohas, Anna
   Renyi, Imre
   Garami, Miklos
   Hauser, Peter
TI Survival of pediatric patients with Ewing sarcoma treated at Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Ewing sarcoma; bone tumor; child; survival; prognostic factor
ID Ewing sarcoma; bone tumor; child; survival; prognostic factor
AB The survival of children treated with Ewing sarcoma at Semmelweis University were investigated. Pediatric patients with Ewing sarcoma treated at Semmelweis University from 2001 through 2013 were analyzed in terms of overall survival and clinical factors (age, primary localization and extent of the tumor, time interval from primary complaints to diagnosis). For statistical analysis Kaplan-Meier estimated survival and log rank test were applied. Mean age and follow-up time of the 78 patients were 11.16 and 6.29 years, respectively. In 57% of patients time interval from primary symptoms to diagnosis was less than half year. In 53.8% of the patients the disease was metastatic at primary diagnosis (pulmonary only: 29.5%, any other: 24.3%). 5- and 10-year overall survival of patients were 68.1% and 60.4%, respectively. Among the analyzed factors, the presence of metastasis impaired 5-year overall survival significantly (88.5% for localized disease, 63.5% for pulmonary only and 40.9% for any other metastasis). The survival rate of pediatric patients with Ewing sarcoma treated at Semmelweis University is similar to the result in Western European countries.
C1 [Geiszl, Zsofia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Kiss, Janos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of OncologyBudapest, Hungary.
   [Arato, Gabriella] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krivan, Gergely] Del-Pesti CentrumkorhazBudapest, Hungary.
   [Mohas, Anna] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Renyi, Imre] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7-9., 1094 Budapest, Hungary.
RP Hauser, P (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM hauserpeti@yahoo.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 230
EP 236
PG 7
ER

PT J
AU Gyorke, E
   Vargane Nemeth, A
   Balogh, M
   Masat, P
   Benyo, G
   Reiniger, L
   Nagy, G
   Hauser, P
AF Gyorke, Eszter
   Vargane Nemeth, Anita
   Balogh, Marta
   Masat, Peter
   Benyo, Gabor
   Reiniger, Lilla
   Nagy, Gabor
   Hauser, Peter
TI Aspects of nutrition therapy of an infant with central nervous system tumour
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE atypical teratoid/rhabdoid tumour; chemotherapy; nutrition therapy; malnutrition; sarcopenia
ID atypical teratoid/rhabdoid tumour; chemotherapy; nutrition therapy; malnutrition; sarcopenia
AB The atypical teratoid/rhabdoid tumour (ATRT) is a rare type of central nervous system tumour appearing usually under 2 years of age. The survival of patients is insufficient despite the combined treatment (neurosurgical removal, intensive chemo- and radiotherapy). ATRT recurs one year after completion of treatment in 60% of cases. Maintaining appropriate nutritional status during treatment is of great importance in this young age group. Nutritional treatment of patients with ATRT is especially difficult due to young age and possible neurological sequelae. A successful case of a three-month-old female infant is presented, with special emphasis on the importance of feeding therapy.
C1 [Gyorke, Eszter] Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, Markusovszky L. u. 3-5., 9700 Szombathely, Hungary.
   [Vargane Nemeth, Anita] Markusovszky Vas Country Hospital, Department of PediatricsSzombathely, Hungary.
   [Balogh, Marta] Markusovszky Vas Country Hospital, Department of PediatricsSzombathely, Hungary.
   [Masat, Peter] Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, Markusovszky L. u. 3-5., 9700 Szombathely, Hungary.
   [Benyo, Gabor] Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, Markusovszky L. u. 3-5., 9700 Szombathely, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Gabor] Semmelweis University of Medicine, Department of NeurologyBudapest, Hungary.
   [Hauser, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Gyorke, E (reprint author), Markusovszky Teaching Hospital, Department of Pediatric Hematology and Oncology, 9700 Szombathely, Hungary.
EM gyorke.eszter@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 237
EP 241
PG 5
ER

PT J
AU Frohlich, G
   Vizkeleti, J
   Nguyen, NA
   Horvath, K
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Vizkeleti, Julia
   Nguyen, Nhung Anhhong
   Horvath, Katalin
   Major, Tibor
   Polgar, Csaba
TI Dosimetric evaluation of intracavitary-interstitial image-guided adaptive brachytherapy of cervical cancer and comparison with conventional treatment techniques
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cervical cancer; brachytherapy; interstitial; image- guided; inverse optimization
ID cervical cancer; brachytherapy; interstitial; image- guided; inverse optimization
AB Our aim was the dosimetric evaluation of intracavitary-interstitial high-dose-rate image-guided adaptive cervix brachytherapy, implemented in Hungary. Between 2016 and 2018, 21 patients with cervical cancer were treated with overall 72 fractions. Graphical optimized treatment plans were compared to inverse optimized plans, 3D optimized plans (without needles) and conventional intracavitary 2D plans. Significant difference was found in almost all dose-volume parameters. The most advantageous values came from interstitial plans, inverse optimized plans did not differ dosimetrically from the treatment plans, while intracavitary optimized plans disposed of less appropriate dose-volume parameters, the least of all were intracavitary 2D plans. Needle number showed correlation with conformality, but inverse correlation with Dose Nonuniformity Ratio and D2cm3 of rectum. Volume of High Risk CTV correlated with D2cm3 of bladder, rectum and sigmoid. Although 3D optimization improved the quality of conventional 2D plans, interstitial plans resulted in even more homogeneous dose distribution and significantly lower doses to organs at risks.
C1 [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nguyen, Nhung Anhhong] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM frohlich.georgina@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 242
EP 248
PG 7
ER

PT J
AU Vizkeleti, J
   Frohlich, G
   Nguyen, NA
   Horvath, K
   Major, T
   Polgar, Cs
AF Vizkeleti, Julia
   Frohlich, Georgina
   Nguyen, Nhung Anhhong
   Horvath, Katalin
   Major, Tibor
   Polgar, Csaba
TI Clinical results of combined intracavitary-interstitial image-guided adaptive brachytherapy in locally advanced cervical cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cervical cancer; brachytherapy; image-guided; interstitial; adaptive
ID cervical cancer; brachytherapy; image-guided; interstitial; adaptive
AB We present the early clinical results achieved with image-guided adaptive brachytherapy (IGABT) with combined intracavitary-interstitial (IC-IS) technique recently implemented in Hungary in the treatment of locally advanced cervical cancer (LACC). Twenty-one patients were treated with radio-chemotherapy (RCT) followed by combined IC-IS BT. At the end of the RCT we assessed the residual tumour with pelvic MRI. On CT images registered with the applicator in place we contoured the organs at risk and the high-risk clinical target volume, which included the whole cervix and the eventual residual tumour in the parametria. No grade 4 toxicity was noticed. At 11 months follow-up the local control rate was 92.3%, the pelvic control rate 86.5%, the distant metastasis free survival and the disease-free survival were 74%. The combined IC-IS treatment was well tolerated. Our clinical results are similar to those reported in the literature.
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nguyen, Nhung Anhhong] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Vizkeleti, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM j.keleti@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 249
EP 257
PG 9
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI Oral contraception and the risk of breast cancer. Review of the literature
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oral contraception; breast cancer; relative risk
ID oral contraception; breast cancer; relative risk
AB At present an estimated hundred millions of women worldwide use oral contraception, but the influence of hormonal contraception on carcinogenesis of breast is not fully understood. Previous studies of breast cancer risk show inconsistent findings – from zero elevation to approximately 30%-40% increase in risk. The beneficial effect on ovarian and endometrial cancer risk is apparent. In this literature review we attempt to determine effects of oral contraception in relation to the risk of breast cancer. The risk increased with longer duration of use, but absolute increase is very small. „Beneficial effects of OCs on the gynecological cancers thus outweighed adverse effects.” (Vessey)
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, Vorosmarty u. 31., 1064 Budapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Nagykalnai, T (reprint author), Budapest, XV. ker. Onkormanyzat Egeszsegugyi Intezmenye, Onkologia Szakrendeles, 1064 Budapest, Hungary.
EM nagykalnai.tamas@t-online.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 258
EP 263
PG 6
ER

PT J
AU Szentirmay, Z
AF Szentirmay, Zoltan
TI Influence of HPV infection on cell cycle regulation in epithelial cell alterations of cervix uteri: Immunohistochemical and in situ hybridization observations
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE CIN3; HPV16 copy number; p16; p21; p27 immunohistochemistry; cell cycle
ID CIN3; HPV16 copy number; p16; p21; p27 immunohistochemistry; cell cycle
AB The HPV16 E6 DNA incorporation into the cervical epithelial cell genome was determined. In addition, using p16, p21 and p27 protein immunohistochemistry, we intended to present how the normal cell cycle machinery was disturbed in cervical epithelial cells. In CIN1 the epithelial cells are transformed into koilocytes, p16 is not expressed. p21 is only visible over the parabasal cell layers, while p27 manifests in koilocytes and lymphocytes. In CIN2/3, one copy of HPV16 DNA is integrated in the epithelial cell genome. In CIN3, p16 is expressed in great quantities, while p21 can be seen in the upper 2/3 segment of cervical epithelium causing minimal cell differentiation. p27 is highly expressed in the basal cells of stratified epithelium blocking the autonomous proliferation phases of the cell cycle.
C1 [Szentirmay, Zoltan] National Institute of Oncology, Department of Diagnostic Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Szentirmay, Z (reprint author), National Institute of Oncology, Department of Diagnostic Pathology, 1122 Budapest, Hungary.
EM szentirmay@oncol.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 264
EP 271
PG 8
ER

PT J
TI Accurate diagnosis with the right tools
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 272
EP 272
PG 1
ER

PT J
AU Lendvai, G
AF Lendvai, Gabor
TI What can a cell do?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Lendvai, Gabor] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Lendvai, G (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 273
EP 273
PG 1
ER

PT J
AU Locsei, Z
AF Locsei, Zoltan
TI Sanofi Genzyme Symposium ESMO 2018 Munich
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2018
VL 62
IS 4
BP 275
EP 276
PG 2
ER

PT J
AU Geczi, L
   Nyirady, P
AF Geczi, Lajos
   Nyirady, Peter
TI Introduction to "What's New in Prostate Cancer Diagnosis and Treatment"?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 4
EP 4
PG 1
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular pathology of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostate cancer; molecular classification; inheritance; prognostication; prediction
ID prostate cancer; molecular classification; inheritance; prognostication; prediction
AB Prostate cancer seems to be two diseases: a localized early cancer and a castration-resistant metastatic cancer. While in the localized form the most prevalent genetic alterations are the translocations of the ETS genes, in the castration-resistant form the most prevalent genetic alteration affects androgen receptor and oncosuppressors TP53 and PTEN. The main drivers of the genetic progression of prostate cancer are defects of the DNA-repair systems which are also responsible for the familiar disease. Several prognostic genomic classifiers have been developed and validated clinically which are able to guide management of the early diseases. Today the most useful predictive genetic testing is that of the androgen receptor but others are becoming equally important which can predict taxane resistance.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 5
EP 9
PG 5
ER

PT J
AU Toth, E
   Salamon, F
AF Toth, Erika
   Salamon, Ferenc
TI Prostate cancer reporting: needle biopsy and radical prostatectomy specimen
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostatic adenocarcinoma; needle biopsy; prostatectomy; prognostic pathology report
ID prostatic adenocarcinoma; needle biopsy; prostatectomy; prognostic pathology report
AB Prostatic adenocarcinoma is the most common cancer affecting men. A substantial majority of patients have the diagnosis made on fine needle biopsies. Treatment choices ranging from surveillance to radical prostatectomy or radiation therapy are largely driven by the pathologic findings in the biopsy specimen. Our review focuses on important morphologic parameters in needle biopsy and radical prostatectomy specimens. This includes Gleason score, Gleason grade, tumor quantification as well as other parameters such as extraprostatic extension, seminal vesicle invasion, perineural invasion, lymphovascular invasion. Surgical margin status and lymph node status are also discussed. Our aim was to present the most recent international guidelines of reporting of prostate adenocarcinoma.
C1 [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Ráth György u. 7-9., 1122 Budapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 10
EP 15
PG 6
ER

PT J
AU Nagy, B
   Bhattoa Harjit, P
   Kappelmayer, J
AF Nagy, Bela
   Bhattoa Harjit, Pal
   Kappelmayer, Janos
TI Routine laboratory diagnostics of prostate cancer: Past, present and the future
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostate cancer; tumor markers; PSA; Prostate Health Index
ID prostate cancer; tumor markers; PSA; Prostate Health Index
AB Prostate cancer is one of the most frequently occurring malignancies in men. It is increasingly recognized in patients above 40 years of age. The discovery of prostate-specific antigen (PSA) nearly 50 years ago and the subsequent capability to measure it on automated immunoassay platforms have led to a widespread use in laboratory diagnostics. However, the plethora of the elevated PSA values resulted in premature invasive treatments in several cases, so the term ’overdiagnosis of prostate cancer’ has been created. Beside the classical total PSA test, several new methods have emerged in the past years that considerably enhanced the specificity of PSA-based diagnostics and this paved the way for more adequate clinical decisions. Some of these new and complex laboratory tests are not yet financed in Hungary, but the techniques are already available. In addition to the measurement of various proteins by immunoassays, large attention is devoted to molecular tests that not only help to establish the underlying pathophysiological process, but may also aid in determining the proper prognostic subgroup.
C1 [Nagy, Bela] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Bhattoa Harjit, Pal] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Kappelmayer, Janos] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Kappelmayer, J (reprint author), University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, 4032 Debrecen, Hungary.
EM kappelmayer@med.unideb.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 16
EP 25
PG 10
ER

PT J
AU Nyirady, P
AF Nyirady, Peter
TI Surgical treatment of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostate cancer; radical prostatectomy
ID prostate cancer; radical prostatectomy
AB Prostate cancer is one of the most commonly diagnosed malignant neoplasms. In Hungary, 4000-4500 men are diagnosed annually, which is below the European incidence. In contrast, the Hungarian prostate cancer mortality clearly exceeds the EU average. This is probably due to the lack of awareness and early recognition of prostate cancer. At an early stage, prostate cancer can be cured, 5-year survival is almost 100%, while in metastatic form it is only 28%. There are several treatment options available for prostate cancer. Since it is multiplex within the organ and the cancer foci are histopathologically heterogeneous, only the treatment of the whole prostate is curative. Radical prostatectomy is the only curative treatment that can provide a complete healing and increased life expectancy in men with prostate cancer. It is recommended to be performed in men with a life expectancy of at least 10 years. During surgery, the prostate is removed, along with its capsule, seminal vesicles on both sides and pelvic lymph nodes. During surgery, the urinary continence and, if possible, erectile function should be preserved.
C1 [Nyirady, Peter] Semmelweis University, Department of Urology, Ulloi ut 78/B, 1082 Budapest, Hungary.
RP Nyirady, P (reprint author), Semmelweis University, Department of Urology, 1082 Budapest, Hungary.
EM nyirady.peter@med.semmelweis-univ.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 26
EP 31
PG 6
ER

PT J
AU Maraz, A
   Geczi, L
   Kuronya, Zs
AF Maraz, Aniko
   Geczi, Lajos
   Kuronya, Zsofia
TI New therapeutic options for hormone sensitive prostate cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hormone sensitive prostate cancer; androgen deprivation therapy; abiraterone and androgen deprivation in hormone-naive prostate cancer; early administration of docetaxel in hormone sensitive prostate cancer; radiotherapy in low volume metastatic prostate 
ID hormone sensitive prostate cancer; androgen deprivation therapy; abiraterone and androgen deprivation in hormone-naive prostate cancer; early administration of docetaxel in hormone sensitive prostate cancer; radiotherapy in low volume metastatic prostate 
AB During the last decades androgen deprivation therapy (ADT) was the standard treatment of prostate cancers. Survival of metastatic patients is 4 years if they receive ADT, but in case of poor prognosis survival rate is under 3 years. Since 2014 two prospective phase III studies have proven the survival advantage of early docetaxel therapy, administered together with ADT, for metastatic hormone-sensitive prostate cancer patients. Its advantage was even more considerable in case of high-volume metastatic cases. In two other studies the benefit of abiraterone-prednisone therapy combined with ADT was proven in comparison with ADT itself in case of newly diagnosed, metastatic, high-risk, hormone-naive patients. One prospective study has proven the survival benefit of ADT administered together with radiotherapy of the prostate in case of low volume metastatic diseases. In our analysis we demonstrate these clinical studies and try to answer the contradictory questions about the occasionally overlapping therapeutic options.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 33
EP 39
PG 7
ER

PT J
AU Kuronya, Zs
   Biro, K
   Maraz, A
   Geczi, L
AF Kuronya, Zsofia
   Biro, Krisztina
   Maraz, Aniko
   Geczi, Lajos
TI The modern treatment of metastatic castration-resistant prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE castration-resistant prostate cancer; apalutamide; enzalutamide; abiraterone; Radium-223
ID castration-resistant prostate cancer; apalutamide; enzalutamide; abiraterone; Radium-223
AB The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, isotope treatment and RANK-ligand inhibition. The year 2018 was a major success in the treatment of nonmetastatic castration-resistant prostate carcinoma, with the FDA authorizing both apalutamide and enzalutamide at this stage. The aim of this review is to present the standard of care of metastatic castration-resistant prostate cancer by disease stage, and to introduce the emerging treatment modalities presently assessed in clinical trials and discuss the open questions.
C1 [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM kuronyaz@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 41
EP 50
PG 10
ER

PT J
AU Jorgo, K
   Agoston, P
   Janvary, ZsL
   Gesztesi, L
   Stelczer, G
   Kontra, G
   Major, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Janvary, Zsolt Levente
   Gesztesi, Laszlo
   Stelczer, Gabor
   Kontra, Gabor
   Major, Tibor
   Polgar, Csaba
TI Stereotactic body radiation therapy with CyberKnife accelerator for low- and intermediate risk prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prostate cancer; stereotactic radiotherapy; CyberKnife; hypofractionation; image guidance
ID prostate cancer; stereotactic radiotherapy; CyberKnife; hypofractionation; image guidance
AB We report implementation of stereotactic body radiotherapy (SBRT) for the treatment of early, localized prostate cancer patients, and acute side effects caused by radiation therapy. Between February 2018 and July 2018, 36 prostate cancer patients were treated with SBRT. Treatments were performed with „CyberKnife M6” linear accelerator. In low-risk patients 8 Gy was delivered to the prostate in each fraction. For intermediate risk, 8 Gy to the prostate and 6.5 Gy to the seminal vesicles were delivered by each fraction with a simultaneous integrated boost technique. A total of 5 fractions (total dose 40 Gy) were given every second working days. Acute radiogenic genitourinary (GU) and gastrointestinal (GI) side effects were assessed using the Radiation Therapy Oncology Group (RTOG) score. The duration of radiotherapy was 1 week and 3 days. The frequency of acute radiogenic side effects was as follows: GU grade 0: 13.9%, grade I: 30.6%, grade II: 52.8%, grade III: 2.7%. GI grade 0: 55.5%, grade I: 30.6%, grade II: 13.9%, grade III: 0%. Grade IV-V side effects were not observed. SBRT appears to be a safe and well tolerated treatment in patients with early stage, localized prostate cancer.
C1 [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Agoston, Peter] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Stelczer, Gabor] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM jorgokliton@gmail.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 52
EP 59
PG 8
ER

PT J
AU Biro, K
   Geczi, L
AF Biro, Krisztina
   Geczi, Lajos
TI The role of exercise in prostate cancer prevention and treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer of the prostate; physical activity; androgen deprivation therapy; toxicity; multidisciplinary team
ID cancer of the prostate; physical activity; androgen deprivation therapy; toxicity; multidisciplinary team
AB As a result of the growing incidence of cancer as well as increased survival of patients, an increasing number of people are living longer with cancer. In recent years, research has shown that physical activity not only protects against a number of cancer types, but is also valuable for patients undergoing cancer treatment and during the rehabilitation phase, as well as for improving function and quality of life. Regular physical activity is an effective way to reduce the side effects of cancer, resulting in part from physical inactivity and in part from the disease itself. Too much rest can lead to a decrease in aerobic fitness, strength, mobility and unwanted weight gain in the patient. In prostate cancer patients, hormonal treatment especially accelerates this process. In this paper we summarize the available evidence concerning the role of exercise in prostate cancer prevention, treatment and rehabilitation.
C1 [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Ráth György u. 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Ráth György u. 7-9., 1122 Budapest, Hungary.
RP Biro, K (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM birok@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2019
VL 63
IS 1
BP 60
EP 64
PG 5
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Pathological diagnostics of CUP (Cancer of Unknown Primary)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE CUP; pathological differential diagnostics; biology
ID CUP; pathological differential diagnostics; biology
AB CUP (Cancer of Unknown Primary) is a relatively frequent cancer type causing incomparable difficulties in pathological diagnosis as compared to other tumor types. The primary may even remain unknown at authopsy due to microscopic size or previous regression. By applying the biological, epidemiological cancer information it is possible to compose rational pathological differential diagnostic algorithms to define with high probability the primary site of the cancer. The new molecular tests developed for CUP are very helpful especially if they are used in combination with pathological data.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 67
EP 74
PG 9
ER

PT J
AU Kocsmar, �
   Kocsmar, I
   Karczub, J
   Istok, R
   Kiss, A
   Schaff, Zs
   Lotz, G
AF Kocsmar, Eva
   Kocsmar, Ildiko
   Karczub, Janos
   Istok, Roland
   Kiss, Andras
   Schaff, Zsuzsa
   Lotz, Gabor
TI Clinicopathological characterization and autopsybased classification of the Cancer of Unknown Primary origin (CUP) syndrome
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE autopsy; unknown primary tumors
ID autopsy; unknown primary tumors
AB Cancer of Unknown Primary origin (CUP) is characterized by metastatic tumor spread without identifiable primary tumor. CUP cohort was selected from 6966 autopsy cases (2001–2014). Type-1 (“clinical”) CUPs: primary site was not found clinically but identified by autopsy. Type-2 (“clinicopathological”) CUPs: no primary site either clinically or by autopsy. Type-3 (“pathological”) CUPs: no tumor was suspected clinically whereas autopsy revealed metastatic spread from unidentifiable source. 2160 malignant tumors were found including 80 CUPs (type-1/2/3: 42/29/9). Cumulative incidence declined with time (3.70%; 2001–2007: 4.51%; 2008–2014: 3.19%) due to decreasing incidence of type-1 and -3 CUPs. CUPs were mostly adenocarcinomas and type-1 CUPs usually originate from the lung or pancreas. As a conclusion, type-2 and -3 CUPs may originate from microscopic-sized metastasizing primary tumors. Based on the above classification, improvement of clinical diagnostics may contribute to decreased incidence of type-1 CUPs and transfer of type-3 CUPs into type-2 category.
C1 [Kocsmar, Eva] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kocsmar, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Karczub, Janos] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Istok, Roland] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Lotz, G (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM lotz.gabor@med.semmelweis-univ.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 75
EP 84
PG 10
ER

PT J
AU Horvath, Zs
   Kocsis, J
AF Horvath, Zsolt
   Kocsis, Judit
TI Treatment of patients with cancer of unknown primary – possibilities and problems
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer of unknown primary; favorable; unfavorable; clinical trial
ID cancer of unknown primary; favorable; unfavorable; clinical trial
AB Cancer of unknown primary is a relatively common clinical entity that accounts for 3-5% of all invasive cancers. Clinical entities of this heterogeneous group of diseases can originate from different tissues of the body and be manifested as metastases in different organs. Clinical behavior can be favorable or more often unfavorable. Clinical work-up should be practical and effective while excessive delay can turn clinically treatable disease to untreatable state. Favorable clinicopathologic entities should be treated similarly to known equivalent tumors. Unfavorable clinicopathologic entities should receive doublet chemotherapy if possible. Currently there is no clear evidence for usefulness of routine molecular testing. Patients are recommended to be selected in clinical trials if available.
C1 [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri u. 38., 6000 Kecskemet, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri u. 38., 6000 Kecskemet, Hungary.
RP Horvath, Zs (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, 6000 Kecskemet, Hungary.
EM horvathzso@kmk.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 85
EP 92
PG 8
ER

PT J
AU Major, T
   Kiraly, R
   Polgar, Cs
AF Major, Tibor
   Kiraly, Reka
   Polgar, Csaba
TI Report on current status of Hungarian radiotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE Hungarian radiotherapy; human resources; infrastructure; treatment data
ID Hungarian radiotherapy; human resources; infrastructure; treatment data
AB The purpose of the study is to report the status of Hungarian radiotherapy (RT). In the 13 centers 84 radiation oncologists, 19 residents, 66 physicists and 231 radiotherapy technologists work, and 40 megavoltage units (38 linear accelerators, 2 cobalt units) are in use. HDR afterloader is available in all and CT-simulator in all but one centers. In 2017 33,024 patients received RT, 22,236 were irradiated with MV beams, 1,406 with BT and 9,382 with orthovoltage X-ray. Main indications for BT were gynecological tumors (75%), HDR prostate implants were performed in 3 centers. Due to the recent infrastructural developments the number of patients receiving modern RT increased, but in order to fulfil the international recommendations additional linear accelerators have to be installed along with the replacement of the out of date equipment. From professional point of view further developments are warranted in Budapest.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Kiraly, Reka] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM major@oncol.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 93
EP 101
PG 10
ER

PT J
AU Bukovszky, B
   Fodor, J
   Zongor, Zs
   Mihaly, D
   Matrai, Z
   Polgar, Cs
   Major, T
AF Bukovszky, Bence
   Fodor, Janos
   Zongor, Zsuzsanna
   Mihaly, Dalma
   Matrai, Zoltan
   Polgar, Csaba
   Major, Tibor
TI Dose coverage of axillary target volumes using different field arrangements following breast conserving surgery for invasive breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE whole breast irradiation; axillary lymph nodes; dose coverage
ID whole breast irradiation; axillary lymph nodes; dose coverage
AB The purpose of this study was to investigate the dose coverage of sentinel lymph node (SLN) site, level I, II and III axillary target volumes using different field arrangements (standard or high tangent fields: STgF, HTgF and STgF + axillary-supraclavicular field: ASF) in N0 invasive breast cancer patients treated with breast conserving surgery. In 30 patients the SLN site was marked with titanium clip. They were treated with 3D-conformal radiotherapy. Retrospectively, for the purpose of this study, the SLN site and axillary target volumes were contoured, and three plans were generated for each patient using the original CT data. The prescribed dose was 50 Gy (2 Gy/fraction). The mean dose with STgF or HTgF was 33.1 and 49.1 Gy (p=0.0001) in the SLN site, 25.7 and 45.1 Gy (p<0.0001) in level I, 7.2 and 28.9 Gy (p<0.0001) in level II and 3.5 and 12.7 Gy (p=0.0003) in level III. The mean dose with STgF+ASF in level II or III was 45 and 46 Gy. The dose coverage is inadequate to all axillary levels with STgM. The target volumes should be delineated to give accurate dose estimation.
C1 [Bukovszky, Bence] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Zongor, Zsuzsanna] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Major, Tibor] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Bukovszky, B (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM bence.bukovszky@gmail.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 102
EP 109
PG 8
ER

PT J
AU Kiraly, R
   Pesznyak, Cs
   Varga, Sz
   Nguyen, NA
   Major, T
   Polgar, Cs
AF Kiraly, Reka
   Pesznyak, Csilla
   Varga, Szilvia
   Nguyen, Nhung Anhhong
   Major, Tibor
   Polgar, Csaba
TI Initial experience with image-guided and intensity-modulated postoperative radiotherapy of gynecological cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE image-guided radiotherapy; intensity-modulated radiotherapy; conformal radiotherapy; gynecological cancer
ID image-guided radiotherapy; intensity-modulated radiotherapy; conformal radiotherapy; gynecological cancer
AB Our goal was to determine the extent of the CTV-PTV margin. Accuracy of patient setup was checked with daily CBCT. Two radiation oncologists performed the image matching independently. The CTV-PTV margin was calculated with the van Herk formula. The treatment plans were created with the Varian Eclipse v11 planning system, and the treatments were carried out with a Varian TrueBeam accelerator by using RapidArc technique with two full arcs. Dose constraints on the target volume and organs at risk recommended by international bodies were applied. Conformity number (CN) for PTV, V45 and V50 for organs at risk were used to assess and compare the treatment plans of RapidArc and 3D-KRT (conformal radiotherapy) techniques. The average CTV-PTV margins with or without IGRT were 0.67 cm vs. 1.53 cm, 0.66 cm vs. 1.25 cm and 0.34 cm vs. 0.98 cm in vertical, longitudinal and lateral directions, respectively. In case of daily on-line CBCT verification 0.5 cm margin can be used.
C1 [Kiraly, Reka] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] Budapest University of Technology and Economy, Institute of Nuclear TechniqueBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nguyen, Nhung Anhhong] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Kiraly, R (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM kiraly.reka@gmx.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 110
EP 115
PG 6
ER

PT J
AU Kisivan, K
   Miovecz, �
   Gugyeras, D
   Takacs, A
   Farkas, A
   Glavak, Cs
   Kovacs, P
   Antal, G
   Laszlo, Z
   Vallyon, M
   Cselik, Zs
   Petone Csima, M
   Gulyban, �
   Hadjiev, J
   Lakosi, F
AF Kisivan, Katalin
   Miovecz, Adam
   Gugyeras, Daniel
   Takacs, Aliz
   Farkas, Andrea
   Glavak, Csaba
   Kovacs, Peter
   Antal, Gergely
   Laszlo, Zoltan
   Vallyon, Marta
   Cselik, Zsolt
   Petone Csima, Melinda
   Gulyban, Akos
   Hadjiev, Janaki
   Lakosi, Ferenc
TI Multimodal imaging during lung and abdominal stereotactic ablative radiotherapy: from cine MRI through 3D/4D CBCT to intrafractional kV verification
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE image-guided radiation therapy; stereotactic ablative radiation therapy; cine MRI; cone-beam CT
ID image-guided radiation therapy; stereotactic ablative radiation therapy; cine MRI; cone-beam CT
AB Our aim was to present our treatment and verification protocols of linear accelerator-based lung and abdominal stereotactic ablative radiotherapy (SABR). During our treatments both the volumetric imaging (3D/4D CBCT/CT) and triggered kV intrafractional tumor motion control could be combined allowing a full control on the whole workflow. The most optimal kV directions from which the tumor is well detectable were defined. Tumor movements measured on cine MRI in treatment position correlated well with the ones on 4D CBCT, thus cine MRI is considered an excellent device to pre-select the appropriate image/treatment verification SABR protocol. In abdominal targets implanted markers and cine MRI are preferred due to limited image quality of CBCT with the current version. In selected lung SABR cases (≥8mm motion) the dose delivery of organs at risk (lungs – GTV, chest wall) could be reduced compared to free breathing conditions, however, the treatment time is at least two-folds higher.
C1 [Kisivan, Katalin] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Gugyeras, Daniel] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Takacs, Aliz] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Vallyon, Marta] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Petone Csima, Melinda] Kaposvari Egyetem, Pedagogiai KarKaposvar, Hungary.
   [Gulyban, Akos] Europe Hospitals, Department of Radiation OncologyBrussels, Belgium.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposvar University, Department of Radiation Oncology, 7400 Kaposvar, Hungary.
EM lakosiferenc@yahoo.com
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 116
EP 124
PG 10
ER

PT J
AU Kives, Zs
   Kovacs, A
   Budai, A
   Dobrossy, L
   Vajda, R
   Endrei, D
   Boncz, I
AF Kives, Zsuzsanna
   Kovacs, Attila
   Budai, Andras
   Dobrossy, Lajos
   Vajda, Reka
   Endrei, Dora
   Boncz, Imre
TI Quality and performance indicators of colorectal cancer screening pilot program in Csongrad County, Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE colorectal cancer; cancer screening; patient participation rate; pilot
ID colorectal cancer; cancer screening; patient participation rate; pilot
AB Colorectal cancer is a major social and economic burden for developed countries. Our analysis aimed to evaluate the quality and performance indicators of colorectal cancer screening pilot program. The colon cancer screening pilot program was carried out in 2015 involving an average-risk population aged 50-69 in Csongrad county, Hungary. The analysis involved data from the Communication module of the Office of the National Chief Medical Officer. We recorded 21.1% invitation rate (22,130 persons), 51.2% attendance and 47.3% participation rates, with a higher female participation rate (p<0.001). Participation rate was far lower than the expected 65%. The rate of non-negative results (13.1%) exceeds the international reference rate. Participation rate on the colonoscopy screening (90.1%) reached the expected value. Compared to the number of actual colonoscopies performed, adenomas were found in 2.5% and malignant lesions in 0.3% of the cases. Our results highlight the deficiencies regarding the follow-up and data recording of screening results in the IT system as well as the lack of communication between the GP and the diagnostic laboratories.
C1 [Kives, Zsuzsanna] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
   [Kovacs, Attila] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Budai, Andras] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Dobrossy, Lajos] Orszagos Tisztifoorvosi HivatalBudapest, Hungary.
   [Vajda, Reka] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
   [Endrei, Dora] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
   [Boncz, Imre] Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Maria u. 5-7., 7621 Pecs, Hungary.
RP Kives, Zs (reprint author), Pecsi Tudomanyegyetem Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, 7621 Pecs, Hungary.
EM zsuzsa.kives@etk.pte.hu
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 125
EP 132
PG 8
ER

PT J
TI XIV. Congress of the Hungarian Radiotherapy Society
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 135
EP 161
PG 27
ER

PT J
AU Herein, A
   Stelczer, G
   Meszaros, N
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Herein, Andras
   Stelczer, Gabor
   Meszaros, Norbert
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Herein, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Koszo, RL
   Kahan, Zs
   Darazs, B
   Rarosi, F
   Varga, Z
AF Koszo, Renata Lilla
   Kahan, Zsuzsanna
   Darazs, Barbara
   Rarosi, Ferenc
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rarosi, Ferenc] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 135
EP 135
PG 1
ER

PT J
AU Meszaros, N
   Janvary, ZsL
   Stelczer, G
   Smanyko, V
   Major, T
   Zaka, Z
   Polgar, Cs
AF Meszaros, Norbert
   Janvary, Zsolt Levente
   Stelczer, Gabor
   Smanyko, Viktor
   Major, Tibor
   Zaka, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 135
EP 136
PG 2
ER

PT J
AU Polgar, Cs
   Rebekka, Sch
   Strnad, V
   Uter, W
   Hildebrandt, G
   Ott, JO
   Kauer-dorner, D
   Knauerhase, H
   Major, T
   Lyczek, J
   Jose, LG
   Cristina, GM
   Slampa, P
   Allgauer, M
   Lossl, K
   Kovacs, Gy
   Fischedick, AR
   Resch, A
   Anna, K
   Niehoff, P
   Polat, B
AF Polgar, Csaba
   Rebekka, Schafer
   Strnad, Vratislav
   Uter, Wolfgang
   Hildebrandt, Guido
   Ott, J Oliver
   Kauer-dorner, Daniela
   Knauerhase, Hellen
   Major, Tibor
   Lyczek, Jaroslaw
   Jose, Luis Guinot
   Cristina, Gutierrez Miguelez
   Slampa, Pavel
   Allgauer, Michael
   Lossl, Kristina
   Kovacs, Gyorgy
   Fischedick, Arnt-Rene
   Resch, Alexandra
   Anna, Kulik
   Niehoff, Peter
   Polat, Bulent
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Rebekka, Schafer] University Hospital WurzburgWurzburg, Germany.
   [Strnad, Vratislav] University of ErlangenErlangen, Germany.
   [Uter, Wolfgang] University of ErlangenErlangen, Germany.
   [Hildebrandt, Guido] University Hospital LeipzigLeipzig, Germany.
   [Ott, J Oliver] University of ErlangenErlangen, Germany.
   [Kauer-dorner, Daniela] University Hospital AKHVienna, Austria.
   [Knauerhase, Hellen] University Hospital RostockRostock, Germany.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Lyczek, Jaroslaw] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Jose, Luis Guinot] Fundacion Instituto Valenciano de OncologiaValencia, Spain.
   [Cristina, Gutierrez Miguelez] Catalan Institute of OncologyBarcelona, Spain.
   [Slampa, Pavel] Masaryk Memorial HospitalBrno, Czech Republic.
   [Allgauer, Michael] Hospital Barmherzige BruderRegensburg, Germany.
   [Lossl, Kristina] University Hospital BernBern, Switzerland.
   [Kovacs, Gyorgy] University of Luebeck, University-Hospital Schleswig- HolsteinLubeck, Germany.
   [Fischedick, Arnt-Rene] Clemens Hospital MunsterMunster, Germany.
   [Resch, Alexandra] University Hospital AKHVienna, Austria.
   [Anna, Kulik] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Niehoff, Peter] Sana Hospital OffenbachOffenbach, Germany.
   [Polat, Bulent] University Hospital WurzburgWurzburg, Germany.
RP Polgar, Cs (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 136
EP 136
PG 1
ER

PT J
AU Varga, Z
   Koszo, R
   Paczona, V
   Kahan, Zs
AF Varga, Zoltan
   Koszo, Renata
   Paczona, Viktor
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paczona, Viktor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 136
EP 136
PG 1
ER

PT J
AU Takacsi-Nagy, Z
   Janvary, ZsL
   Ferenczi, �
   Todor, ISz
   Stelczer, G
   Kontra, G
   Polgar, Cs
AF Takacsi-Nagy, Zoltan
   Janvary, Zsolt Levente
   Ferenczi, Ors
   Todor, Istvan Szabolcs
   Stelczer, Gabor
   Kontra, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacsi-Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of OncologyBudapest, Hungary.
   [Ferenczi, Ors] National Institute of OncologyBudapest, Hungary.
   [Todor, Istvan Szabolcs] National Institute of OncologyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of OncologyBudapest, Hungary.
   [Kontra, Gabor] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Takacsi-Nagy, Z (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 136
EP 137
PG 2
ER

PT J
AU Zolcsak, Z
   Katona, Cs
   Klinko, T
   Plavecz, �
   Hegedus, L
   Szalai, T
   Landherr, L
AF Zolcsak, Zita
   Katona, Csilla
   Klinko, Timea
   Plavecz, Eva
   Hegedus, Laszlo
   Szalai, Tibor
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zolcsak, Zita] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Plavecz, Eva] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hegedus, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Zolcsak, Z (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Szarvas, T
AF Szarvas, Tibor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szarvas, Tibor] Semmelweis University, Department of UrologyBudapest, Hungary.
RP Szarvas, T (reprint author), Semmelweis University, Department of Urology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Tenke, P
AF Tenke, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tenke, Peter] Jahn Ferenc South-Pest HospitalBudapest, Hungary.
RP Tenke, P (reprint author), Jahn Ferenc South-Pest Hospital, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 137
EP 137
PG 1
ER

PT J
AU Farkas, Gy
   Bajcsay, A
   Ostoros, Gy
   Markoczy, Zs
   Kocsis, Zs
   Kun-gazda, M
   Budai, M
   Szekely, G
   Mihaly, D
   Lovey, J
   Polgar, Cs
AF Farkas, Gyongyi
   Bajcsay, Andras
   Ostoros, Gyula
   Markoczy, Zsolt
   Kocsis, S. Zsuzsa
   Kun-gazda, Marta
   Budai, Mariann
   Szekely, Gabor
   Mihaly, Dalma
   Lovey, Jozsef
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Budai, Mariann] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Farkas, Gy (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Hideghety, K
AF Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Juranyi, Zs
   Kocsis, Zs
   Lumniczky, K
   Balazs, K
   Farkas, Gy
   Kun-gazda, M
   Szekely, G
   Polgar, Cs
AF Juranyi, Zsolt
   Kocsis, S. Zsuzsa
   Lumniczky, Katalin
   Balazs, Katalin
   Farkas, Gyongyi
   Kun-gazda, Marta
   Szekely, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Balazs, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Juranyi, Zs (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 138
EP 138
PG 1
ER

PT J
AU Kocsis, Zs
   Agoston, P
   Farkas, Gy
   Kun-gazda, M
   Szekely, G
   Major, T
   Mihaly, D
   Pesznyak, Cs
   Stelczer, G
   Jorgo, K
   Gesztesi, L
   Polgar, Cs
   Juranyi, Zs
AF Kocsis, S. Zsuzsa
   Agoston, Peter
   Farkas, Gyongyi
   Kun-gazda, Marta
   Szekely, Gabor
   Major, Tibor
   Mihaly, Dalma
   Pesznyak, Csilla
   Stelczer, Gabor
   Jorgo, Kliton
   Gesztesi, Laszlo
   Polgar, Csaba
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Kocsis, Zs (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Lumniczky, K
AF Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lumniczky, Katalin] Nemzeti Nepegeszsegugyi KozpontBudapest, Hungary.
RP Lumniczky, K (reprint author), Nemzeti Nepegeszsegugyi Kozpont, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Drencsenyi, R
   Varga, L
   Fodor, E
   Varga, Z
   Besenyi, Zs
   Farkas, I
   Pavics, L
   Cserhati, A
   Vegvary, Z
   Koszo, R
   Maraz, A
AF Drencsenyi, Rita
   Varga, Linda
   Fodor, Emese
   Varga, Zoltan
   Besenyi, Zsuzsanna
   Farkas, Istvan
   Pavics, Laszlo
   Cserhati, Adrienn
   Vegvary, Zoltan
   Koszo, Renata
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Farkas, Istvan] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 139
EP 139
PG 1
ER

PT J
AU Gugyeras, D
   Farkas, A
   Petone Csima, M
   Hadjiev, J
   Gulyban, �
   Lakosi, F
AF Gugyeras, Daniel
   Farkas, Andrea
   Petone Csima, Melinda
   Hadjiev, Janaki
   Gulyban, Akos
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gugyeras, Daniel] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Petone Csima, Melinda] Kaposvari Egyetem, Pedagogiai KarKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gulyban, Akos] Europe HospitalsBrussels, Belgium.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Gugyeras, D (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Karancsine Heffler, F
   Ivanics, A
   Puskas, �
   Gabor, G
   Horvath, Zs
AF Karancsine Heffler, Fatime
   Ivanics, Anna
   Puskas, Arpad
   Gabor, Gabriella
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karancsine Heffler, Fatime] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ivanics, Anna] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Puskas, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Karancsine Heffler, F (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Kisivan, K
   Farkas, A
   Antal, G
   Pethone Csima, M
   Cselik, Zs
   Hadjiev, J
   Gulyban, �
   Lakosi, F
AF Kisivan, Katalin
   Farkas, Andrea
   Antal, Gergely
   Pethone Csima, Melinda
   Cselik, Zsolt
   Hadjiev, Janaki
   Gulyban, Akos
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Pethone Csima, Melinda] Kaposvari Egyetem, Pedagogiai KarKaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gulyban, Akos] Europe Hospitals, Department of Radiation OncologyBrussels, Belgium.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kisivan, K (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 140
EP 140
PG 1
ER

PT J
AU Miovecz, �
   Kisivan, K
   Takacs, A
   Farkas, A
   Cselik, Zs
   Hadjiev, J
   Lakosi, F
AF Miovecz, Adam
   Kisivan, Katalin
   Takacs, Aliz
   Farkas, Andrea
   Cselik, Zsolt
   Hadjiev, Janaki
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Takacs, Aliz] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Miovecz, � (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 140
EP 141
PG 2
ER

PT J
AU Orban, H
   Folyovich, �
   Herein, A
   Tolvaj, E
   Szekely, J
   Vizkeleti, J
   Polgar, Cs
AF Orban, Helga
   Folyovich, Eva
   Herein, Andras
   Tolvaj, Eniko
   Szekely, Judit
   Vizkeleti, Julia
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Orban, Helga] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Folyovich, Eva] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Tolvaj, Eniko] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Judit] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Orban, H (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Piszer, N
   Vekas, M
   Stelczer, G
   Major, T
   Janvary, ZsL
   Polgar, Cs
AF Piszer, Nikolett
   Vekas, Marton
   Stelczer, Gabor
   Major, Tibor
   Janvary, Zsolt Levente
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Piszer, Nikolett] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vekas, Marton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Piszer, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Pall, J
   Suli, K
   Santa, M
   Csapo, L
   Antal, G
   Dezso, �
   Cselik, Zs
AF Pall, Janos
   Suli, Kitti
   Santa, Melinda
   Csapo, Laszlo
   Antal, Gergely
   Dezso, Arpad
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pall, Janos] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Suli, Kitti] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Santa, Melinda] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Pall, J (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 141
EP 141
PG 1
ER

PT J
AU Vekas, M
   Piszer, N
   Miovecz, �
   Stelczer, G
   Haranyi, G
   Major, T
   Polgar, Cs
AF Vekas, Marton
   Piszer, Nikolett
   Miovecz, Adam
   Stelczer, Gabor
   Haranyi, Gabriella
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vekas, Marton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Piszer, Nikolett] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Miovecz, Adam] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Haranyi, Gabriella] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Vekas, M (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Bajcsay, A
   Janvary, ZsL
   Lovey, J
   Stelczer, G
   Pocza, T
   Kontra, G
   Polgar, Cs
AF Bajcsay, Andras
   Janvary, Zsolt Levente
   Lovey, Jozsef
   Stelczer, Gabor
   Pocza, Tamas
   Kontra, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Galdi, �
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Galdi, Adam
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galdi, Adam] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Galdi, � (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 142
EP 142
PG 1
ER

PT J
AU Nguyen, AN
   Varga, Sz
   Galdi, �
   Frohlich, G
   Major, T
   Polgar, Cs
AF Nguyen, Anhhong Nhung
   Varga, Szilvia
   Galdi, Adam
   Frohlich, Georgina
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nguyen, Anhhong Nhung] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Galdi, Adam] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Nguyen, AN (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 142
EP 143
PG 1
ER

PT J
AU Pocza, T
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Pocza, Tamas
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Pocza, T (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 143
EP 143
PG 1
ER

PT J
AU Vegvary, Z
   Koszo, R
   Egyud, Zs
   Varga, L
   Nagy, Z
   Darazs, B
   Varga, Z
   Banyai, �
   Kahan, Zs
AF Vegvary, Zoltan
   Koszo, Renata
   Egyud, Zsofia
   Varga, Linda
   Nagy, Zoltan
   Darazs, Barbara
   Varga, Zoltan
   Banyai, Eva
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 143
EP 143
PG 1
ER

PT J
AU Vizkeleti, J
   Vereczkey, I
   Frohlich, G
   Horvath, K
   Pete, I
   Sipos, N
   Nemeskeri, Cs
   Mayer, �
   Nagy, B
   Mangel, L
   Major, T
   Polgar, Cs
AF Vizkeleti, Julia
   Vereczkey, Ildiko
   Frohlich, Georgina
   Horvath, Katalin
   Pete, Imre
   Sipos, Norbert
   Nemeskeri, Csaba
   Mayer, Arpad
   Nagy, Bettina
   Mangel, Laszlo
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Diagnostic and Experimental TumorpathologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Sipos, Norbert] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Nemeskeri, Csaba] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Nagy, Bettina] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 143
EP 144
PG 2
ER

PT J
AU Antal, G
   Kisivan, K
   Gulyban, �
   Farkas, A
   Hadjiev, J
   Lakosi, F
AF Antal, Gergely
   Kisivan, Katalin
   Gulyban, Akos
   Farkas, Andrea
   Hadjiev, Janaki
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Gulyban, Akos] Europe Hospitals, Department of Radiation OncologyBrussels, Belgium.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Antal, G (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Frohlich, G
   Agoston, P
   Jorgo, K
   Major, T
   Polgar, Cs
AF Frohlich, Georgina
   Agoston, Peter
   Jorgo, Kliton
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Frohlich, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 144
EP 144
PG 1
ER

PT J
AU Jorgo, K
   Polgar, Cs
   Major, T
   Stelczer, G
   Herein, A
   Pocza, T
   Gesztesi, L
   Agoston, P
AF Jorgo, Kliton
   Polgar, Csaba
   Major, Tibor
   Stelczer, Gabor
   Herein, Andras
   Pocza, Tamas
   Gesztesi, Laszlo
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Herein, Andras] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Pocza, Tamas] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Gesztesi, Laszlo] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 144
EP 145
PG 2
ER

PT J
AU Jorgo, K
   Agoston, P
   Janvary, ZsL
   Gesztesi, L
   Stelczer, G
   Kontra, G
   Major, T
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Janvary, Zsolt Levente
   Gesztesi, Laszlo
   Stelczer, Gabor
   Kontra, Gabor
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 145
EP 145
PG 1
ER

PT J
AU Lakosi, F
   Antal, G
   Glavak, Cs
   Laszlo, Z
   Kisivan, K
   Farkas, A
   Cselik, Zs
   Jenei, T
   Liptak, J
   Hadjiev, J
AF Lakosi, Ferenc
   Antal, Gergely
   Glavak, Csaba
   Laszlo, Zoltan
   Kisivan, Katalin
   Farkas, Andrea
   Cselik, Zsolt
   Jenei, Tibor
   Liptak, Jozsef
   Hadjiev, Janaki
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Jenei, Tibor] Kaposi Mor Teaching Hospital, Department of UrologyKaposvar, Hungary.
   [Liptak, Jozsef] Kanizsai Dorottya Korhaz, Urologiai OsztalyNagykanizsa, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 145
EP 145
PG 1
ER

PT J
AU Maraz, A
   Varga, L
   Fodor, E
   Varga, Z
   Farkas, I
   Pavics, L
   Cserhati, A
   Vegvary, Z
   Kerpel, F
   Koszo, R
   Besenyi, Zs
AF Maraz, Aniko
   Varga, Linda
   Fodor, Emese
   Varga, Zoltan
   Farkas, Istvan
   Pavics, Laszlo
   Cserhati, Adrienne
   Vegvary, Zoltan
   Kerpel, Fanni
   Koszo, Renata
   Besenyi, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Farkas, Istvan] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kerpel, Fanni] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear MedicineSzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 145
EP 146
PG 2
ER

PT J
AU Szabo, D
   Garai, I
   Agoston, P
   Polgar, Cs
AF Szabo, Diana
   Garai, Ildiko
   Agoston, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Diana] Semmelweis UniversityBudapest, Hungary.
   [Garai, Ildiko] Scanomed Kft.Debrecen, Hungary.
   [Agoston, Peter] Semmelweis UniversityBudapest, Hungary.
   [Polgar, Csaba] Semmelweis UniversityBudapest, Hungary.
RP Szabo, D (reprint author), Semmelweis University, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Varga, L
   Koszo, R
   Vegvary, Z
   Varga, Z
   Nagy, Z
   Maraz, A
   Agoston, P
AF Varga, Linda
   Koszo, Renata
   Vegvary, Zoltan
   Varga, Zoltan
   Nagy, Zoltan
   Maraz, Aniko
   Agoston, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Agoston, Peter] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 146
EP 146
PG 1
ER

PT J
AU Agoston, P
   Frohlich, G
   Jorgo, K
   Gesztesi, L
   Major, T
   Polgar, Cs
AF Agoston, Peter
   Frohlich, Georgina
   Jorgo, Kliton
   Gesztesi, Laszlo
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 146
EP 147
PG 2
ER

PT J
AU Boronkai, �
   Godi, Sz
   Nagy, B
   Sebestyen, Zs
   Sebestyen, K
   Locsei, Z
   Mangel, L
AF Boronkai, Arpad
   Godi, Szilard
   Nagy, Bettina
   Sebestyen, Zsolt
   Sebestyen, Klara
   Locsei, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Godi, Szilard] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Nagy, Bettina] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Boronkai, � (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 147
EP 147
PG 1
ER

PT J
AU Dobi, �
   Fodor, E
   Darazs, B
   Laszlo, Sz
   Dodd, L
   Cserhati, A
   Hideghety, K
AF Dobi, Agnes
   Fodor, Emese
   Darazs, Barbara
   Laszlo, Szilvia
   Dodd, Leopold
   Cserhati, Adrienne
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Laszlo, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dodd, Leopold] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dobi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 147
EP 147
PG 1
ER

PT J
AU Ferenczi, �
   Janvary, ZsL
   Bajcsay, A
   Bago, A
   Sipos, L
   Fedorcsak, I
   Stelczer, G
   Kontra, G
   Polgar, Cs
AF Ferenczi, Ors
   Janvary, Zsolt Levente
   Bajcsay, Andras
   Bago, Attila
   Sipos, Laszlo
   Fedorcsak, Imre
   Stelczer, Gabor
   Kontra, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Ors] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bago, Attila] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Sipos, Laszlo] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Ferenczi, � (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 147
EP 147
PG 1
ER

PT J
AU Godeny, A
   Horvath, D
   Kovacs, P
   Polgar, Cs
AF Godeny, Anna
   Horvath, Dora
   Kovacs, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Horvath, Dora] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Godeny, A (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 148
EP 148
PG 1
ER

PT J
AU Horvath, D
   Godeny, A
   Kovacs, P
   Polgar, Cs
AF Horvath, Dora
   Godeny, Anna
   Kovacs, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dora] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Godeny, Anna] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Horvath, D (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 148
EP 148
PG 1
ER

PT J
AU Locsei, Z
   Farkas, R
   Bellyei, Sz
   Boronkai, �
   Vojcek, �
   Benedek, N
   Ottoffy, G
   Borbasne Farkas, K
   Mangel, L
AF Locsei, Zoltan
   Farkas, Robert
   Bellyei, Szabolcs
   Boronkai, Arpad
   Vojcek, Agnes
   Benedek, Noemi
   Ottoffy, Gabor
   Borbasne Farkas, Kornelia
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Farkas, Robert] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Vojcek, Agnes] PTE KK, Gyermekgyogyaszati Klinika, Onkologiai OsztalyPecs, Hungary.
   [Benedek, Noemi] PTE KK, Gyermekgyogyaszati Klinika, Onkologiai OsztalyPecs, Hungary.
   [Ottoffy, Gabor] PTE KK, Gyermekgyogyaszati Klinika, Onkologiai OsztalyPecs, Hungary.
   [Borbasne Farkas, Kornelia] PTE KK, Bioanalitikai IntezetPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Locsei, Z (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 148
EP 148
PG 1
ER

PT J
AU Sebestyen, Zs
   Kotrusz, B
   Musch, Z
   Sebestyen, K
   Locsei, Z
   Bellyei, Sz
   Boronkai, �
   Mangel, L
AF Sebestyen, Zsolt
   Kotrusz, Barnabas
   Musch, Zoltan
   Sebestyen, Klara
   Locsei, Zoltan
   Bellyei, Szabolcs
   Boronkai, Arpad
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Kotrusz, Barnabas] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, Zs (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 148
EP 148
PG 1
ER

PT J
AU Adamecz, Zs
   Paszternak, E
   Czegledi, J
   Oross, E
   Csanky, E
   Slarku, I
   Geszti, I
AF Adamecz, Zsolt
   Paszternak, Emoke
   Czegledi, Judit
   Oross, Endre
   Csanky, Eszter
   Slarku, Ilona
   Geszti, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamecz, Zsolt] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Paszternak, Emoke] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Czegledi, Judit] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Oross, Endre] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Csanky, Eszter] Borsod-Abauj-Zemplen Megyei Kozponti Korhaz, TudogyogyaszatMiskolc, Hungary.
   [Slarku, Ilona] Robert Koch Hospital, Department of PulmonologyEdeleny, Hungary.
   [Geszti, Imre] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Adamecz, Zs (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 149
EP 149
PG 1
ER

PT J
AU Balazs, K
   Kis, E
   Szatmari, T
   Widlak, P
   Safrany, G
   Lumniczky, K
AF Balazs, Katalin
   Kis, Eniko
   Szatmari, Tunde
   Widlak, Piotr
   Safrany, Geza
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Katalin] Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Kis, Eniko] Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Szatmari, Tunde] Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Widlak, Piotr] Maria-Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsaw, Poland.
   [Safrany, Geza] Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Balazs, K (reprint author), Nemzeti Nepegeszsegugyi Kozpont, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 149
EP 149
PG 1
ER

PT J
AU Bellyei, Sz
   Papp, A
   Hegedus, I
   Bogner, B
   Vincze, �
   Solt, J
   Rosztoczy, A
   Vass, T
   Tinusz, B
   Eross, B
AF Bellyei, Szabolcs
   Papp, Andras
   Hegedus, Ivett
   Bogner, Barna
   Vincze, Aron
   Solt, Jeno
   Rosztoczy, Andras
   Vass, Tamas
   Tinusz, Benedek
   Eross, Balint
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Papp, Andras] University of Pecs, Department of SurgeryPecs, Hungary.
   [Hegedus, Ivett] University of Pecs, Department of PathologyPecs, Hungary.
   [Bogner, Barna] University of Pecs, Department of PathologyPecs, Hungary.
   [Vincze, Aron] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Solt, Jeno] University of Pecs, I. Department of Internal MedicinePecs, Hungary.
   [Rosztoczy, Andras] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Vass, Tamas] Semmelweis Medical University, Ist Department of Gynaecology and ObstetricsBudapest, Hungary.
   [Tinusz, Benedek] University of Pecs, Institute for Translational MedicinePecs, Hungary.
   [Eross, Balint] University of Pecs, Institute for Translational MedicinePecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 149
EP 149
PG 1
ER

PT J
AU Bianco-Molnar, Zs
   Antal, G
   Csapo, L
   Zahenszky, P
   Dezso, �
   Cselik, Zs
AF Bianco-Molnar, Zsanett
   Antal, Gergely
   Csapo, Laszlo
   Zahenszky, Peter
   Dezso, Arpad
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bianco-Molnar, Zsanett] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Zahenszky, Peter] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Bianco-Molnar, Zs (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 149
EP 150
PG 2
ER

PT J
AU Borzasi, E
   Becze, DR
   Varga, L
   Dobi, �
   Nikolenyi, A
   Varga, Z
   Hideghety, K
   Maraz, A
AF Borzasi, Emoke
   Becze, Dominika Reka
   Varga, Linda
   Dobi, Agnes
   Nikolenyi, Aliz
   Varga, Zoltan
   Hideghety, Katalin
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Becze, Dominika Reka] University of SzegedSzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Borzasi, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 150
EP 150
PG 1
ER

PT J
AU Banyai, �
   Garamvolgyi, S
   Pigniczki, T
   Koszo, R
   Vegvary, Z
   Nagy, Z
   Varga, Z
   Kahan, Zs
AF Banyai, Eva
   Garamvolgyi, Sandor
   Pigniczki, Terezia
   Koszo, Renata
   Vegvary, Zoltan
   Nagy, Zoltan
   Varga, Zoltan
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Garamvolgyi, Sandor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pigniczki, Terezia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Banyai, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 150
EP 150
PG 1
ER

PT J
AU Csapo, L
   Antal, G
   Bianco-Molnar, Zs
   Zahenszky, P
   Dezso, �
   Cselik, Zs
AF Csapo, Laszlo
   Antal, Gergely
   Bianco-Molnar, Zsanett
   Zahenszky, Peter
   Dezso, Arpad
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Bianco-Molnar, Zsanett] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Zahenszky, Peter] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Csapo, L (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 150
EP 151
PG 2
ER

PT J
AU Csapo, L
   Antal, G
   Bianco-Molnar, Zs
   Zahenszky, P
   Dezso, �
   Cselik, Zs
AF Csapo, Laszlo
   Antal, Gergely
   Bianco-Molnar, Zsanett
   Zahenszky, Peter
   Dezso, Arpad
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Bianco-Molnar, Zsanett] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Zahenszky, Peter] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Csapo, L (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 151
EP 151
PG 1
ER

PT J
AU Cselik, Zs
   Dezso, �
   Csapo, L
   Bianco-Molnar, Zs
   Zahenszky, P
   Antal, G
AF Cselik, Zsolt
   Dezso, Arpad
   Csapo, Laszlo
   Bianco-Molnar, Zsanett
   Zahenszky, Peter
   Antal, Gergely
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Bianco-Molnar, Zsanett] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Zahenszky, Peter] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Cselik, Zs (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 151
EP 151
PG 1
ER

PT J
AU Czegledi, J
   Dargai, ME
   Gyongyosine Hubai, H
   Pavlikovics, A
   Molnar, K
AF Czegledi, Judit
   Dargai, Marta Edit
   Gyongyosine Hubai, Henriette
   Pavlikovics, Annamaria
   Molnar, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czegledi, Judit] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Dargai, Marta Edit] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Gyongyosine Hubai, Henriette] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Pavlikovics, Annamaria] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Molnar, Katalin] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
RP Czegledi, J (reprint author), County Hospital of Borsod-Abauj-Zemplen, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 151
EP 151
PG 1
ER

PT J
AU Drencsenyi, R
   Fodor, E
   Koszo, R
   Paczona, V
   Varga, Z
   Hideghety, K
   Kahan, Zs
AF Drencsenyi, Rita
   Fodor, Emese
   Koszo, Renata
   Paczona, Viktor
   Varga, Zoltan
   Hideghety, Katalin
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paczona, Viktor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Drencsenyi, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 151
EP 152
PG 2
ER

PT J
AU Fodor, E
   Gal, V
   Molnar, D
   Vegvary, Z
   Koszo, RL
   Egyud, Zs
   Nagy, Z
   Rarosi, F
   Kahan, Zs
   Varga, Z
AF Fodor, Emese
   Gal, Viorica
   Molnar, Dora
   Vegvary, Zoltan
   Koszo, Renata Lilla
   Egyud, Zsofia
   Nagy, Zoltan
   Rarosi, Ferenc
   Kahan, Zsuzsanna
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Molnar, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rarosi, Ferenc] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Fodor, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 152
EP 152
PG 1
ER

PT J
AU Foldvari, D
   Kopacsi, T
   Szitkay, �
   Karacsonyi, G
   Varady, Gy
   Arany, M
   Schvarcz, K
   Locsei, Z
   Mangel, L
AF Foldvari, Dora
   Kopacsi, Timea
   Szitkay, Eva
   Karacsonyi, Gabor
   Varady, Gyongyi
   Arany, Magdolna
   Schvarcz, Kitti
   Locsei, Zoltan
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Kopacsi, Timea] University of Pecs, Department of OncologyPecs, Hungary.
   [Szitkay, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Karacsonyi, Gabor] University of Pecs, Department of OncologyPecs, Hungary.
   [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Arany, Magdolna] University of Pecs, Department of OncologyPecs, Hungary.
   [Schvarcz, Kitti] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Foldvari, D (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 152
EP 152
PG 1
ER

PT J
AU Gal, V
   Vegvary, Z
   Koszo, R
   Banyai, �
   Fodor, E
   Nagy, Z
   Varga, Z
   Nagy, B
   Terhes, G
   Kahan, Zs
AF Gal, Viorica
   Vegvary, Zoltan
   Koszo, Renata
   Banyai, Eva
   Fodor, Emese
   Nagy, Zoltan
   Varga, Zoltan
   Nagy, Bence
   Terhes, Gabriella
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Bence] University of Szeged, Department of PathologySzeged, Hungary.
   [Terhes, Gabriella] SZTE AOK, Klinikai Mikrobiologiai Diagnosztikai IntezetSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gal, V (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 152
EP 152
PG 1
ER

PT J
AU Glavak, Cs
   Simon, M
   Kovacs, P
   Antal, G
   Kovacs, �
   Cselik, Zs
   Hadjiev, J
   Lakosi, F
AF Glavak, Csaba
   Simon, Mihaly
   Kovacs, Peter
   Antal, Gergely
   Kovacs, Arpad
   Cselik, Zsolt
   Hadjiev, Janaki
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Kovacs, Peter] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Hadjiev, Janaki] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Glavak, Cs (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 153
EP 153
PG 1
ER

PT J
AU Kelemen, Gy
   Nikolenyi, A
   Dobi, �
   Varga, L
   Gal, V
   Varga, Z
   Fodor, E
   Mencser, Z
   Varga, �
   Balazsfi, M
   Kahan, Zs
   Hideghety, K
AF Kelemen, Gyongyi
   Nikolenyi, Aliz
   Dobi, Agnes
   Varga, Linda
   Gal, Viorica
   Varga, Zoltan
   Fodor, Emese
   Mencser, Zoltan
   Varga, Adam
   Balazsfi, Marton
   Kahan, Zsuzsanna
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Mencser, Zoltan] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Varga, Adam] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Balazsfi, Marton] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kelemen, Gy (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 153
EP 153
PG 1
ER

PT J
AU Kerpel, F
   Varga, L
   Koszo, R
   Vegvary, Z
   Fodor, E
   Cserhati, A
   Varga, Z
   Hideghety, K
   Maraz, A
AF Kerpel, Fanni
   Varga, Linda
   Koszo, Renata
   Vegvary, Zoltan
   Fodor, Emese
   Cserhati, Adrienne
   Varga, Zoltan
   Hideghety, Katalin
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kerpel, Fanni] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kerpel, F (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 153
EP 153
PG 1
ER

PT J
AU Kun-gazda, M
   Kocsis, Zs
   Herein, A
   Polgar, Cs
   Nagy, P
   Juranyi, Zs
AF Kun-gazda, Marta
   Kocsis, S. Zsuzsa
   Herein, Andras
   Polgar, Csaba
   Nagy, Peter
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Kun-gazda, M (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 154
EP 154
PG 1
ER

PT J
AU Koszo, RL
   Uhercsak, G
   Csenki, M
   Nemeth, G
   Sztano, B
   Kahan, Zs
AF Koszo, Renata Lilla
   Uhercsak, Gabriella
   Csenki, Melinda
   Nemeth, Gabor
   Sztano, Balazs
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nemeth, Gabor] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
   [Sztano, Balazs] Szegedi Tudomanyegyetem, Ful-Orr-Gegeszeti KlinikaSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 154
EP 154
PG 1
ER

PT J
AU Mokanszki, B
   Szabo, Z
   Kara, L
   Puskas, �
   Acs, F
   Marki, I
   Gabor, G
   Horvath, Zs
AF Mokanszki, Bela
   Szabo, Zoltan
   Kara, Laszlo
   Puskas, Arpad
   Acs, Ferenc
   Marki, Istvan
   Gabor, Gabriella
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mokanszki, Bela] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szabo, Zoltan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kara, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Puskas, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Marki, Istvan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Mokanszki, B (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 154
EP 154
PG 1
ER

PT J
AU Meszaros, N
   Dobi, �
   Vegvary, Z
   Torday, L
   Fodor, E
   Hideghety, K
   Stelczer, G
   Janvary, ZsL
   Polgar, Cs
AF Meszaros, Norbert
   Dobi, Agnes
   Vegvary, Zoltan
   Torday, Laszlo
   Fodor, Emese
   Hideghety, Katalin
   Stelczer, Gabor
   Janvary, Zsolt Levente
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 154
EP 155
PG 2
ER

PT J
AU Nagy, B
   Locsei, Z
   Mangel, LCs
   Ottoffy, G
   Buki, A
AF Nagy, Bettina
   Locsei, Zoltan
   Mangel, Laszlo Csaba
   Ottoffy, Gabor
   Buki, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Bettina] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
   [Ottoffy, Gabor] University of Pecs, Department of PediatricsPecs, Hungary.
   [Buki, Andras] Pecsi Tudomanyegyetem, Idegsebeszeti KlinikaPecs, Hungary.
RP Nagy, B (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 155
EP 155
PG 1
ER

PT J
AU Paczona, VR
   Koszo, R
   Szabo, J
   Drencsenyi, R
   Kahan, Zs
   Varga, Z
AF Paczona, Viktor Robert
   Koszo, Renata
   Szabo, Judit
   Drencsenyi, Rita
   Kahan, Zsuzsanna
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Paczona, Viktor Robert] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Drencsenyi, Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Paczona, VR (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 155
EP 155
PG 1
ER

PT J
AU Puskas, �
   Mokanszki, B
   Marki, I
   Belak, B
   Horvath, Zs
AF Puskas, Arpad
   Mokanszki, Bela
   Marki, Istvan
   Belak, Barbara
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Mokanszki, Bela] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Marki, Istvan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Belak, Barbara] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Puskas, � (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 155
EP 156
PG 2
ER

PT J
AU Schvarcz, K
   Foldvari, D
   Szitkay, �
   Pora, K
   Locsei, Z
   Mangel, LCs
AF Schvarcz, Kitti
   Foldvari, Dora
   Szitkay, Eva
   Pora, Krisztina
   Locsei, Zoltan
   Mangel, Laszlo Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schvarcz, Kitti] University of Pecs, Department of OncologyPecs, Hungary.
   [Foldvari, Dora] University of Pecs, Department of OncologyPecs, Hungary.
   [Szitkay, Eva] University of Pecs, Department of OncologyPecs, Hungary.
   [Pora, Krisztina] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Schvarcz, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 156
EP 156
PG 1
ER

PT J
AU Smanyko, V
   Bela, D
   Bartfai, R
   Takacsi Nagy, Z
   Polgar, Cs
AF Smanyko, Viktor
   Bela, Dalma
   Bartfai, Reka
   Takacsi Nagy, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bela, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bartfai, Reka] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Smanyko, V (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 156
EP 156
PG 1
ER

PT J
AU Szabo, D
   Kiss, B
   Farkas, B
   Heim, A
   Ungvari, T
   Csejtei, A
AF Szabo, Dome
   Kiss, Balazs
   Farkas, Bela
   Heim, Andras
   Ungvari, Tamas
   Csejtei, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Dome] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Kiss, Balazs] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Farkas, Bela] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Heim, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Ungvari, Tamas] Vas County Markusovszky HospitalSzombathely, Hungary.
   [Csejtei, Andras] Vas County Markusovszky HospitalSzombathely, Hungary.
RP Szabo, D (reprint author), Vas County Markusovszky Hospital, Szombathely, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 156
EP 156
PG 1
ER

PT J
AU Szabo, I
   Esik, O
   Revesz, J
AF Szabo, Imre
   Esik, Olga
   Revesz, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Imre] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Esik, Olga] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Revesz, Janos] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Szabo, I (reprint author), Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical Oncology, Miskolc, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 157
EP 157
PG 1
ER

PT J
AU Szabo, Z
   Acs, F
   Puskas, �
   Gabor, G
   Horvath, Zs
AF Szabo, Zoltan
   Acs, Ferenc
   Puskas, Arpad
   Gabor, Gabriella
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zoltan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Acs, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Puskas, Arpad] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Szabo, Z (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 157
EP 157
PG 1
ER

PT J
AU Szegedi, D
   Stelczer, G
   Kontra, G
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Szegedi, Domonkos
   Stelczer, Gabor
   Kontra, Gabor
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szegedi, Domonkos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Szegedi, D (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 157
EP 157
PG 1
ER

PT J
AU Tamaskovics, B
   Haussmann, J
   Freddy-Joel, D
   Bolke, E
   Christiane, M
AF Tamaskovics, Balint
   Haussmann, Jan
   Freddy-Joel, Djiepmo
   Bolke, Edwin
   Christiane, Matuschek
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Haussmann, Jan] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Freddy-Joel, Djiepmo] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Bolke, Edwin] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Christiane, Matuschek] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 158
EP 158
PG 1
ER

PT J
AU Todor, ISz
   Stelczer, G
   Jorgo, K
   Agoston, P
   Pesznyak, Cs
   Major, T
   Polgar, Cs
AF Todor, Istvan Szabolcs
   Stelczer, Gabor
   Jorgo, Kliton
   Agoston, Peter
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Todor, Istvan Szabolcs] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Todor, ISz (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 158
EP 158
PG 1
ER

PT J
AU Varady, Gy
   Csongradi, T
   Arany, M
   Vitari, I
   Weiczl, H
   Locsei, Z
   Sebestyen, K
   Sebestyen, Zs
   Mangel, L
AF Varady, Gyongyi
   Csongradi, Timea
   Arany, Magdolna
   Vitari, Ildiko
   Weiczl, Hajnalka
   Locsei, Zoltan
   Sebestyen, Klara
   Sebestyen, Zsolt
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varady, Gyongyi] University of Pecs, Department of OncologyPecs, Hungary.
   [Csongradi, Timea] University of Pecs, Department of OncologyPecs, Hungary.
   [Arany, Magdolna] University of Pecs, Department of OncologyPecs, Hungary.
   [Vitari, Ildiko] University of Pecs, Department of OncologyPecs, Hungary.
   [Weiczl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Varady, Gy (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 158
EP 158
PG 1
ER

PT J
AU Vegvary, Z
   Darazs, B
   Rusko, L
   Ferenczi, L
   Varga, Z
   Fodor, E
   Dobi, �
   Paczona, VR
   Kis, D
   Barzo, P
   Hideghety, K
AF Vegvary, Zoltan
   Darazs, Barbara
   Rusko, Laszlo
   Ferenczi, Lehel
   Varga, Zoltan
   Fodor, Emese
   Dobi, Agnes
   Paczona, Viktor Robert
   Kis, David
   Barzo, Pal
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rusko, Laszlo] GE Healthcare, MagyarorszagBudapest, Hungary.
   [Ferenczi, Lehel] GE Healthcare, MagyarorszagBudapest, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paczona, Viktor Robert] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kis, David] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of NeurosurgerySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 158
EP 159
PG 2
ER

PT J
AU Weiczl, H
   Vitari, I
   Brauner, T
   Sebestyen, K
   Sebestyen, Zs
   Musch, Z
   Kotrusz, B
   Locsei, Z
   Mangel, LCs
AF Weiczl, Hajnalka
   Vitari, Ildiko
   Brauner, Tiborne
   Sebestyen, Klara
   Sebestyen, Zsolt
   Musch, Zoltan
   Kotrusz, Barnabas
   Locsei, Zoltan
   Mangel, Laszlo Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Weiczl, Hajnalka] University of Pecs, Department of OncologyPecs, Hungary.
   [Vitari, Ildiko] University of Pecs, Department of OncologyPecs, Hungary.
   [Brauner, Tiborne] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Musch, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kotrusz, Barnabas] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo Csaba] University of Pecs, Department of OncologyPecs, Hungary.
RP Weiczl, H (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 159
EP 159
PG 1
ER

PT J
AU Zahenszky, P
   Antal, G
   Csapo, L
   Bianco-Molnar, Zs
   Dezso, �
   Cselik, Zs
AF Zahenszky, Peter
   Antal, Gergely
   Csapo, Laszlo
   Bianco-Molnar, Zsanett
   Dezso, Arpad
   Cselik, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zahenszky, Peter] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Antal, Gergely] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Csapo, Laszlo] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Bianco-Molnar, Zsanett] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Dezso, Arpad] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
RP Zahenszky, P (reprint author), Ferenc Csolnoky Hospital, Oncological Center, Veszprem, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 159
EP 159
PG 1
ER

PT J
AU Janvary, ZsL
   Bajcsay, A
   Stelczer, G
   Kontra, G
   Csonka, �
   Agoston, P
   Jorgo, K
   Lovey, J
   Meszaros, N
   Takacsi-Nagy, Z
   Major, T
   Polgar, Cs
AF Janvary, Zsolt Levente
   Bajcsay, Andras
   Stelczer, Gabor
   Kontra, Gabor
   Csonka, Agnes
   Agoston, Peter
   Jorgo, Kliton
   Lovey, Jozsef
   Meszaros, Norbert
   Takacsi-Nagy, Zoltan
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Csonka, Agnes] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 159
EP 160
PG 2
ER

PT J
AU Major, T
   Kiraly, R
   Polgar, Cs
AF Major, Tibor
   Kiraly, Reka
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Kiraly, Reka] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 160
EP 160
PG 1
ER

PT J
AU Mangel, L
   Sarkany, H
   Locsei, Z
   Bellyei, Sz
   Kover, E
AF Mangel, Laszlo
   Sarkany, Henrik
   Locsei, Zoltan
   Bellyei, Szabolcs
   Kover, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Sarkany, Henrik] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 160
EP 160
PG 1
ER

PT J
AU Sebestyen, K
   Major, T
   Hideghety, K
   Lakosi, F
   Nagy, P
   Gabor, G
   Marki, I
   Sebestyen, Zs
   Mangel, L
AF Sebestyen, Klara
   Major, Tibor
   Hideghety, Katalin
   Lakosi, Ferenc
   Nagy, Peter
   Gabor, Gabriella
   Marki, Istvan
   Sebestyen, Zsolt
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sebestyen, Klara] University of Pecs, Department of OncologyPecs, Hungary.
   [Major, Tibor] National Institute of OncologyBudapest, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lakosi, Ferenc] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Nagy, Peter] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Marki, Istvan] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Sebestyen, Zsolt] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Sebestyen, K (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 160
EP 160
PG 1
ER

PT J
AU Stelczer, G
   Kontra, G
   Janvary, ZsL
   Major, T
   Pesznyak, Cs
   Polgar, Cs
AF Stelczer, Gabor
   Kontra, Gabor
   Janvary, Zsolt Levente
   Major, Tibor
   Pesznyak, Csilla
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Stelczer, G (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2019
VL 63
IS 2
BP 160
EP 161
PG 2
ER

PT J
AU Ladanyi, A
AF Ladanyi, Andrea
TI Role of T cells in tumor immunology and immunotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE T cells; tumor immunology; immunotherapy; immune checkpoint inhibitors; combination therapy
ID T cells; tumor immunology; immunotherapy; immune checkpoint inhibitors; combination therapy
AB In the immune defense against cancer, cell-mediated adaptive immune response is considered of primary importance, in which T lymphocytes play a key role. Activation, expansion and function of antigen-specific T cells is a multistep process and its outcome depends on the balance of positive and negative regulatory mechanisms controlling each step. Many factors can hamper the development of an efficient antitumor immune response, such as insufficient expression of tumor antigens or of molecules necessary for their processing, inhibitory molecular interactions (e.g. immune checkpoints), immune suppressive factors or suppressor cells. Various therapeutic strategies have been developed in order to increase the efficiency of antitumor immune defense, of which the application of immune checkpoint inhibitors, antibodies blocking the brakes of immune response, is the most widespread. These immunomodulatory antibodies had more favorable effect than traditional treatment modalities on a widening spectrum of tumor types, still the majority of patients do not or only transiently respond. Therefore, great efforts are made to develop rational combinations of immune and other therapies, and to identify resistance mechanisms and biomarkers predicting therapy outcome.
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM ladanyi@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 165
EP 171
PG 7
ER

PT J
AU Timar, J
   Ladanyi, A
AF Timar, Jozsef
   Ladanyi, Andrea
TI Immunogenomic aspects of tumor progression
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immune microenvironment; immunogenomics; tumor progression; metastasis
ID immune microenvironment; immunogenomics; tumor progression; metastasis
AB Genomic instability is a hallmark of cancer therefore of the metastatic disease as well. High tumor mutation burden is due to deficiencies of the DNA repair systems and leads to immunosensitivity due to generation of neoantigens. However, APOBEC activation of that system, though increases mutation rate, but causes immunoresistance. Deficient antigen presentation due to HLA class I defects is another major cause of immunoresistance. The contemporary immunotherapies may exploit gene amplification of PD-L1 but if the affected chromosome is damaged IFN activation can be lost, again causing immunoresistance. Since these genetic changes can be generated continuously during tumor progression (the entire metastatic process), it would be necessary to monitor them continuously. On the other hand, since tumors are genetically and phenotypically heterogeneous, multiple sampling would be necessary to obtain a more realistic picture of biomarker expressions.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 173
EP 182
PG 10
ER

PT J
AU Lotz, G
   Smuk, G
   Kocsmar, �
   Kocsmar, I
   Timar, J
AF Lotz, Gabor
   Smuk, Gabor
   Kocsmar, Eva
   Kocsmar, Ildiko
   Timar, Jozsef
TI Predictive diagnostics of the programmed cell death receptor 1 (PD-1) – programmed cell death ligand 1 (PD-L1) inhibitory therapies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PD-1; PD-L1; biomarker; predictive diagnostics
ID PD-1; PD-L1; biomarker; predictive diagnostics
AB In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro diagnostic test with its own evaluation protocol. These tests have different diagnostic sensitivity for PD-L1 protein and the evaluation protocols differ in many respects, as cancer and immune cell positivities are considered variously in the immunotherapy-specific evaluation schemes. Accordingly, in the routine PD-L1 diagnostics, it is crucial to follow the individual therapy-specific technical and evaluation protocols since these are not interchangeable and non-adherence may affect therapeutic efficacy.
C1 [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Smuk, Gabor] University of Pecs, Department of PathologyPecs, Hungary.
   [Kocsmar, Eva] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kocsmar, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Lotz, G (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM lotz.gabor@med.semmelweis-univ.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 183
EP 191
PG 9
ER

PT J
AU Bogner, B
AF Bogner, Barna
TI Predictive markers of immunotherapy of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE Immunoscore; mismatch repair; PD-1/PD-L1; colorectal cancer
ID Immunoscore; mismatch repair; PD-1/PD-L1; colorectal cancer
AB Colorectal carcinomas are heterogeneous in their morphologic, immunologic and molecular aspects. The smooth and sharply demarcated medullary carcinomas present with an expansive border and high tumor stroma ratio. The high load of cancer neoantigens as a consequence of microsatellite instability results in numerous reactive regional lymph nodes. In contrast, the low grade, MSS type carcinomas are spiculated, desmoplastic and hard, frequently with smaller and sometimes also desmoplastic lymph node metastases. This macroscopic and histological heterogeneity is mirrored on the immunohistochemical and molecular level and is decisive from prognostic and predictive point of view. As immunotherapy opened a new front in the therapy of colorectal cancer, the pathology report has to quantify and qualify the characteristics of the tumor microenvironment, the peritumoral and intratumoral lymphoid infiltration and tumor stroma ratio in order to improve patient selection.
C1 [Bogner, Barna] University of Pecs, Department of Pathology, 7643 Pecs, Hungary.
RP Bogner, B (reprint author), University of Pecs, Department of Pathology, 7643 Pecs, Hungary.
EM bogner.barna@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 192
EP 195
PG 4
ER

PT J
AU Lovey, J
   Polgar, Cs
AF Lovey, Jozsef
   Polgar, Csaba
TI Combination of radiation and immunotherapy in cancer treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE radiation; immunotherapy; abscopal effect
ID radiation; immunotherapy; abscopal effect
AB It is known since the beginning of the 20th century that ionizing radiation has an effect on the immune system. The abscopal effect was well known but extremely rare. However, many study groups performed intensive preclinical research in the field. One of the most prominent recent developments of medical science is the introduction of modern immunotherapy to the treatment of cancer. The widespread use of immunotherapy drew again the attention to the possible role of radiation in conjunction with immunotherapy. There is growing evidence that ionizing radiation may potentiate the effect of immunotherapy. Prospective trials have been launched and the results are very much awaited. But research is booming and new targets of immunotherapy are identified, while we have insufficient knowledge about the underlying biological mechanisms. Therefore, it is highly important that intensive basic and translation research be done and its results should provide sound knowledge to design new clinical trials which, we believe, will lead to better treatment of our patients. In this short review we try to give a snapshot about the current state of the combined clinical use of radiation and immunotherapy.
C1 [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM lovey@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 196
EP 201
PG 6
ER

PT J
AU Kocsis, J
AF Kocsis, Judit
TI Benefits of combining chemotherapy with immuno- oncology therapies or „Is it true that chemotherapy destroys the immune system?”
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE chemotherapy; immune system; immune modulator; immune checkpoint inhibitor; metronomic chemotherapy
ID chemotherapy; immune system; immune modulator; immune checkpoint inhibitor; metronomic chemotherapy
AB In recent years widespread use of immuno-oncology drugs are in the focus of modern systemic anticancer therapies. Parallel to the evolving role of immune checkpoint inhibitors many people believe that using chemotherapy is coming to an end. Moreover laymen opinions are being communicated about the detrimental role of chemotherapy. The aim of this article is to dissolve this misbelief. The manuscript details the immunomodulatory effects of chemotherapy. Having the ability to stop division of cancer cells and kill them together with immunomodulatory effects, chemotherapy is an ideal partner for combination with immune checkpoint inhibitors. There is increasing number of evidence for synergistic effect between chemotherapy and immuno-oncology drugs. Ongoing and future clinical trials will determine the optimal combinations.
C1 [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri ut 38., 6000 Kecskemet, Hungary.
RP Kocsis, J (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, 6000 Kecskemet, Hungary.
EM kocsisj@kmk.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 202
EP 207
PG 6
ER

PT J
AU Maraz, A
   Varga, L
   Kuronya, Zs
AF Maraz, Aniko
   Varga, Linda
   Kuronya, Zsofia
TI Opportunities that improve the effectivity of immunotherapy, bringing targeted therapies into focus
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE combined immunotherapy; cold tumors; immune avoidance mechanisms; immune-phenotypes; inflammatory tumors
ID combined immunotherapy; cold tumors; immune avoidance mechanisms; immune-phenotypes; inflammatory tumors
AB Immunotherapy is getting more and more successful therapeutic option in case of many cancer types. Despite the clinical effectiveness of checkpoint inhibitor antibodies, long-lasting advantages can only be seen in a part of the patients, which makes necessary to examine immunotherapy more thoroughly. Immunity is influenced by the tumor, its microenvironment, and patient’s characteristic and environmental factors. These elements control the strength and duration of antitumor response. Immunotherapeutic response may be more significant and may even last for years in case of hot tumors, while in most of the cases immunotherapy is not so effective in poorly immunogenic cold tumors. Combined therapies potentially increase efficiency. In our article T-cell activation phases of antitumor immune response, possible defects, their consequences and the potentially effective therapeutic opportunities are summarized shortly. Combined immunotherapy is a novel, promising possibility for modern oncology.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Varga, Linda] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 209
EP 216
PG 8
ER

PT J
AU Mangel, L
   Najbauer, J
   Kajtar, B
   Pongracz, JE
AF Mangel, Laszlo
   Najbauer, Jozsef
   Kajtar, Bela
   Pongracz, Judit Erzsebet
TI Difficulties and prospects in the immunotherapy of gliomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE glioma; immunotherapy; immunosuppression; microenvironment
ID glioma; immunotherapy; immunosuppression; microenvironment
AB Despite the spectacular development of clinical immunotherapy (IT) in the last decade, the regular treatment approaches for the most common central nervous system (CNS) tumors, the malignant gliomas (MGs) has not changed yet. The most important pitfalls of the routine application of immunotherapy can be imputed to the special and originally immunosuppressed microenvironment and the extreme heterogeneity of MGs, however the defensive role of the blood-brain barrier, the general usage of steroids and the difficulties in the evaluation of brain images can also play a role in these types of difficulties. Additionally, in the case of MGs, well-accepted IT biomarker assays (PDL1 positivity, mismatch repair deficiencies, tumor mutation burden, etc.) generally reveal only minimal levels of immunogen activities. Nevertheless, there are some promising results with the utilization of checkpoint inhibitors and other IT modalities (such as virus-based therapies, tumor vaccines, adoptive T cell therapies) and with the combination of conventional oncotherapy methods in case of CNS malignancies, as well. In conclusion, although the CNS is not any more considered as an “immunological sanctuary” and despite some encouraging experimental and clinical results in CNS oncotherapy, the routine application of IT in case of MGs is still awaited.
C1 [Mangel, Laszlo] University of Pecs, Department of Oncology, Edesanyak utja 17., 7624 Pecs, Hungary.
   [Najbauer, Jozsef] University of Pecs, Faculty of Medicine, Department of Immunology and BiotechnologyPecs, Hungary.
   [Kajtar, Bela] University of Pecs, Department of PathologyPecs, Hungary.
   [Pongracz, Judit Erzsebet] Pecsi Tudomanyegyetem, Gyogyszereszeti IntezetPecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Department of Oncology, 7624 Pecs, Hungary.
EM mangel.laszlo@pte.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 217
EP 223
PG 7
ER

PT J
AU Rubovszky, G
   Muzes, Gy
AF Rubovszky, Gabor
   Muzes, Gyorgyi
TI Immunotherapy possibilities and results in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast neoplasms; immunogenicity; immune checkpoint inhibitors; adaptive immunity
ID breast neoplasms; immunogenicity; immune checkpoint inhibitors; adaptive immunity
AB In recent years, a number of tumor types have shown significant therapeutic benefit with immunotherapy. Breast cancer has not been regarded traditionally as a typical immunogenic tumor, however, based on results so far, immunotherapy may play a role in the therapy. The most important change in attitude is that the target of therapy is not the disease but the host. A better understanding of the host’s immune system and the process between the tumor and host provides an opportunity for therapeutic intervention, in this case (re-)activating anti-tumor immune processes. The purpose of this summary is to briefly summarize for clinicians the basics of anti-tumor immunity process, the available clinical results and the major therapeutic options in this field.
C1 [Rubovszky, Gabor] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Muzes, Gyorgyi] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
RP Rubovszky, G (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM garub@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 225
EP 231
PG 7
ER

PT J
AU Teglasi, V
   Moldvay, J
   Szallasi, Z
   Reiniger, L
AF Teglasi, Vanda
   Moldvay, Judit
   Szallasi, Zoltan
   Reiniger, Lilla
TI Possibilities of immune checkpoint inhibitor therapy for patients with metastatic non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE non-small cell lung cancer; lung adenocarcinoma; brain metastasis; immunotherapy; PD-L1
ID non-small cell lung cancer; lung adenocarcinoma; brain metastasis; immunotherapy; PD-L1
AB Survival of patients with lung cancer is unfavorable. Distant metastasis is detected in more than half of the patients at diagnosis. In advanced stages, platinum-based chemotherapy has been the main therapeutic approach for a long time, however, in 2004 targeted therapies emerged. Recently, PDL1/ PD-1 inhibitors have been introduced in the treatment of metastatic lung cancers, for which the therapeutic criteria are increasingly outlined. Based on international and Hungarian data, it is likely that determination of PD-L1 expression in the primary tumor samples may be sufficient for the establishment of therapeutic indication, if PD-L1 expression of tumor cells remains the sole criterion. However, if the combined positive score, which takes into account PD-L1 expression of both tumor and immune cells, will be introduced as a therapeutic criterion, testing of all the actual tumor samples may be required to initiate treatment, as conventional oncotherapies may affect the PD-L1 expression of immune cells.
C1 [Teglasi, Vanda] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical School, Children’s Hospital, Informatics ProgramBoston, USA.
   [Reiniger, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Reiniger, L (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 233
EP 238
PG 6
ER

PT J
AU Lengyel, Zs
   Gyulai, R
AF Lengyel, Zsuzsanna
   Gyulai, Rolland
TI Possible immunotherapies of skin cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE melanoma; non-melanoma skin cancer; immune checkpoint; PD-1 inhibitor
ID melanoma; non-melanoma skin cancer; immune checkpoint; PD-1 inhibitor
AB Skin cancers represent the most common type of malignancy. The incidence rate of melanoma and non-melanoma skin cancer depicts a continuous rise worldwide, which is attributed mainly (but not exclusively) to the growing incidence of non-melanoma skin cancer in the elderly population. Most skin cancer types are sensitive to immunotherapy. Melanoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma showed response rates of at least 40% for PD-1 inhibitor therapy as reported in recent articles. In this article we review the current and future immunotherapy agents and procedures for skin cancers.
C1 [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Akac u. 1., 7632 Pecs, Hungary.
   [Gyulai, Rolland] University of Pecs, Department of Dermatology, Venereology and Oncodermatology, Akac u. 1., 7632 Pecs, Hungary.
RP Gyulai, R (reprint author), University of Pecs, Department of Dermatology, Venereology and Oncodermatology, 7632 Pecs, Hungary.
EM gyulai.rolland@pte.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 239
EP 245
PG 7
ER

PT J
AU Dienes, T
   Horvath, O
   Geczi, L
AF Dienes, Tamas
   Horvath, Orsolya
   Geczi, Lajos
TI Adverse events of immune checkpoint inhibitors and their treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer; immunotherapy; adverse effects; immunosuppression
ID cancer; immunotherapy; adverse effects; immunosuppression
AB Therapy with immune checkpoint inhibitors (ICPis) has become widespread in medical oncology, becoming part of the routine treatment for various malignancies. These antibodies induce an anti-cancer immune activation by blocking the natural immunosuppression, which is supposed to protect the human body’s healthy cells from destruction by the immune system, caused also by cancers, and as a result, allow the immune system to take part in destroying malignant cells. However, the immune activation created by these molecules is not selective against cancer tissues, therefore adverse events associated to these therapies are similar to the signs and symptoms of autoimmune diseases. Common adverse events affect the skin, liver, lungs, gastrointestinal and endocrine systems, less frequently the heart and the nervous system, occasionally causing life-threatening complications. Therapy of these adverse events requires rapid diagnosis and adequate treatment in the form of various immunosuppressants.
C1 [Dienes, Tamas] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Horvath, Orsolya] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Dienes, T (reprint author), National Institute of Oncology, Department of Chemotherapy and Clinicopharmacology, 1122 Budapest, Hungary.
EM thomas.dienes.md@gmail.com
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 246
EP 255
PG 10
ER

PT J
AU Suto, G
AF Suto, Gabor
TI Possibilities of immunotherapy in cancer patients with autoimmune disease
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neoplasms; autoimmune disease; immunotherapy; immune checkpoint inhibitors; adverse effects
ID neoplasms; autoimmune disease; immunotherapy; immune checkpoint inhibitors; adverse effects
AB The immune checkpoint inhibitors (ICI) opened a new era in anticancer treatment. This type of treatment is beneficial for a subset of patients who had a restricted success in the past. However, manipulation of the immune system may lead to the flare up of preexisting autoimmune diseases, requiring intervention. Furthermore, immune suppression strongly influences the outcome of ICI treatment. The ICI treatment of cancer patients with autoimmune disease is a complex task: pre-treatment assessment of the patients, early management of flare ups, and introduction of effective immune suppression is required to achieve the best outcome.
C1 [Suto, Gabor] University of Pecs, 2nd Department of Medicine and Nephrological Center, Pacsirta u 1., 7624 Pecs, Hungary.
RP Suto, G (reprint author), University of Pecs, 2nd Department of Medicine and Nephrological Center, 7624 Pecs, Hungary.
EM gabor.suto@immunologus.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 257
EP 260
PG 4
ER

PT J
AU Hayden, Zs
   Borocz, K
   Csizmadia, Zs
   Kellermayer, Z
   Balogh, P
   Berki, T
AF Hayden, Zsofia
   Borocz, Katalin
   Csizmadia, Zsuzsanna
   Kellermayer, Zoltan
   Balogh, Peter
   Berki, Timea
TI Paraneoplastic neurologic syndromes: laboratory diagnostics and immunological aspects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE paraneoplastic neurologic syndromes; autoimmune encephalitis; autoantibody; laboratory diagnostics
ID paraneoplastic neurologic syndromes; autoimmune encephalitis; autoantibody; laboratory diagnostics
AB Paraneoplastic neurologic syndromes (PNS) and autoimmune encephalitis (AE) are rare neurological disorders, which have similar symptoms, but vary in outcome and treatment strategy. In our retrospective statistical study we evaluated the autoantibody test results of serum and CSF from 2362 patients with suspected PNS and 1034 patients with suspected AE. For autoantibody testing, immunoblot assay (PNS) and cell-based indirect immunofluorescence assay (AE) were used. Autoantibodies were present in 8% of patients with suspected PNS: anti-Yo > anti-Hu > anti-Ma2 > anti-CV2 > anti-titin > anti-Zic4 > anti-amphiphysin > anti-Ri > anti-GAD65 > anti-Sox1 > anti-recoverin. Mostly elderly women were affected. Autoantibodies were present in 5.8% of patients with suspected AE: anti-NMDAR (young women) > anti-LGI1 (middle-aged men) > anti-GABABR (elderly men) > anti-Caspr2 (adult men). Our results correspond to the data described in the literature. The number of patients with suspected PNS and AE shows an increasing tendency, where the autoantibody testing with modern laboratory diagnostic methods helps in the early introduction of the appropriate therapy.
C1 [Hayden, Zsofia] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Borocz, Katalin] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Csizmadia, Zsuzsanna] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Kellermayer, Zoltan] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Balogh, Peter] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Berki, Timea] University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, Szigeti ut 12., 7624 Pecs, Hungary.
RP Berki, T (reprint author), University of Pecs, Faculty of Medicine, Department of Immunology and Biotechnology, 7624 Pecs, Hungary.
EM berki.timea@pte.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2019
VL 63
IS 3
BP 261
EP 267
PG 7
ER

PT J
AU Valyi-Nagy, I
   Petak, I
AF Valyi-Nagy, Istvan
   Petak, Istvan
TI Development and national rollout of electronic decision support systems using artificial intelligence in the field of onco-hematology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE electronic medical decision support systems; national dynamic disease registries
ID electronic medical decision support systems; national dynamic disease registries
AB Systematic, structured and longitudinal collection of realtime Big Patient Data and the analysis of aggregated diagnostic, therapeutic and therapy response data of onco-hematologic patients leads to the development of nationwide dynamic disease registries providing a platform for medical, health industrial and data science research, hospital and health insurance cost analysis, measurement of innovative diagnostics and therapeutics performance, evaluation of compassion-based treatments and general support for insurance and health policy decisions. First in Hungary, we developed a complex computerized case management, data collection, processing, and analysis program (OncoGenomic) and a self-learning artificial intelligence (AI) precision medicine decision support application (Oncompass Calculator) that organize basic research (R), applied research and development (R and D) and innovation (I) under a common umbrella. These progams support the national dynamic hematologic disease registry. Exchange of data through the Electronic Health Service Space (EESZT) supports equal opportunity access of patients to innovative diagnostics and therapy.
C1 [Valyi-Nagy, Istvan] Del-pesti Centrumkohaz, Orszagos Hematologiai es Infektologiai Intezet (DPC-OHII), Nagyvarad ter 1., 1097 Budapest, Hungary.
   [Petak, Istvan] Oncompass Medicine Kft.Budapest, Hungary.
RP Valyi-Nagy, I (reprint author), Del-pesti Centrumkohaz, Orszagos Hematologiai es Infektologiai Intezet (DPC-OHII), 1097 Budapest, Hungary.
EM drvnistvan@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 275
EP 280
PG 6
ER

PT J
AU Andrikovics, H
   Kovy, P
   Bors, A
   Csaban, D
   Meggyesi, N
   Orfi, Z
   Borsy, A
   Kozma, A
   Dolgos, J
   Harasztdombi, J
   Mikala, G
   Remenyi, P
   Valyi-Nagy, I
AF Andrikovics, Hajnalka
   Kovy, Petra
   Bors, Andras
   Csaban, Dora
   Meggyesi, Nora
   Orfi, Zoltan
   Borsy, Adrienn
   Kozma, Andras
   Dolgos, Janos
   Harasztdombi, Jozsef
   Mikala, Gabor
   Remenyi, Peter
   Valyi-Nagy, Istvan
TI Importance of next generation sequencing in precision oncology approach of acute myeloid leukemia
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE acute myeloid leukemia; cytogenetics; molecular genetics; next generation sequencing; prognosis
ID acute myeloid leukemia; cytogenetics; molecular genetics; next generation sequencing; prognosis
AB In contrast to solid tumours, the genetic background of acute myeloid leukemia (AML) is characterized by a relatively low number of alterations per sample (average 3-5 mutations similarly to paediatric malignancies). Although the mutational background is rather heterogeneous, the detection of genetic alterations has diagnostic, prognostic and therapeutic relevance. We investigated cytogenetic and most commonly occurring molecular genetic alterations, and their co-occurrence in 830 AML patients diagnosed and treated in our institute between 2001 and 2019. Results from the recently introduced next generation sequencing for seven AML patients are also presented. Both methods (previously performed standard PCR-based tests and NGS) achieved the same results for commonly occurring mutations, but NGS technique was capable to identify further, rarely occurring mutations which bear diagnostic and prognostic importance according to the recent European LeukemiaNet recommendations. The introduction of NGS techniques to routine laboratory diagnostic applications is a required step following international expertise.
C1 [Andrikovics, Hajnalka] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Kovy, Petra] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Bors, Andras] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Csaban, Dora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Meggyesi, Nora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Orfi, Zoltan] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Borsy, Adrienn] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Kozma, Andras] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5-7., 1097 Budapest, Hungary.
   [Dolgos, Janos] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Harasztdombi, Jozsef] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Mikala, Gabor] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Remenyi, Peter] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Valyi-Nagy, Istvan] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
RP Andrikovics, H (reprint author), Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, 1097 Budapest, Hungary.
EM andrikovics.hajnalka@dpckorhaz.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 282
EP 287
PG 6
ER

PT J
AU Mezo, G
   Biri-Kovacs, B
   Petho, L
   Schuster, S
   Kiss, K
   Olahne Szabo, R
   Randelovic, I
   Tovari, J
AF Mezo, Gabor
   Biri-Kovacs, Beata
   Petho, Lilla
   Schuster, Sabine
   Kiss, Krisztina
   Olahne Szabo, Rita
   Randelovic, Ivan
   Tovari, Jozsef
TI Optimization of peptide-drug conjugates for targeted tumor therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE drug delivery systems; molecular targeted therapy; peptide library; colonic neoplasms; glioblastoma
ID drug delivery systems; molecular targeted therapy; peptide library; colonic neoplasms; glioblastoma
AB In case of cancers with high mortality rate and lacking efficient medication there is a huge need of new, innovative treatments. Targeted tumor therapy, a real breakthrough in this field, is based on the concept that the antitumor agent is linked to a targeting molecule (e.g. peptide) specifically recognizing receptors or antigens that are tumor specific or overexpressed by tumor cells. The efficiency of this conjugate can be influenced by several factors. Among these, the structure of the targeting device, the type and number of the antitumor drug, its position in the conjugate and the chemical bonding of the drug to the targeting molecule are all important features that can determine receptor affinity and cellular uptake, and also the release and the cellular localization of the free drug or its active metabolite. Our goal in the framework of the grant NVKP_16-1-2016-0036 was to generate conjugates against cancers with high mortality rate. Through the below described studies, we introduce the course of the research process through which conjugates are optimized in order to develop more efficient drug candidates.
C1 [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Biri-Kovacs, Beata] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Petho, Lilla] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Schuster, Sabine] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Kiss, Krisztina] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Olahne Szabo, Rita] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Randelovic, Ivan] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
RP Mezo, G (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary.
EM gmezo@caesar.elte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 290
EP 300
PG 11
ER

PT J
AU Mezo, G
   Dokus, L
   Schlosser, G
   Lajko, E
   Szasz, Zs
   Randelovic, I
   Biri-Kovacs, B
   Tovari, J
   Kohidai, L
AF Mezo, Gabor
   Dokus, Levente
   Schlosser, Gitta
   Lajko, Eszter
   Szasz, Zsofia
   Randelovic, Ivan
   Biri-Kovacs, Beata
   Tovari, Jozsef
   Kohidai, Laszlo
TI Comparison of therapeutic peptides targeting pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE drug delivery systems; molecular targeted therapy; peptide library; pancreatic neoplasms; daunorubicin
ID drug delivery systems; molecular targeted therapy; peptide library; pancreatic neoplasms; daunorubicin
AB Despite the small number of cases, pancreatic cancer is one of the biggest challenges in tumor therapy as its treatment is not yet resolved and the expected 5-year survival rate is only 5%. Therefore, innovative solutions for pancreatic cancer are of great importance. Targeted tumor therapy might provide new possibilities in this field. In our research, we focused on finding peptide-based homing molecules and modified their structure to achieve better targeting properties. We compared several peptides that efficiently recognize receptors that are specific for or overexpressed by pancreatic cancer cells. Their structure-effect relationship was determined that can be useful during drug designing in the future. The antitumor effect of Dau=Aoa-GFLG-K(Dau=Aoa) SKAAKN-OH conjugate, which turned out to be the most efficient one during in vitro studies, were analyzed in vivo in female SCID mice. The obtained 30% inhibition, beside the low toxic side effects, might be a good starting point to develop further, more powerful conjugates.
C1 [Mezo, Gabor] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Dokus, Levente] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Schlosser, Gitta] Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Lajko, Eszter] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Szasz, Zsofia] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Randelovic, Ivan] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Biri-Kovacs, Beata] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Kohidai, Laszlo] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Mezo, G (reprint author), Eotvos Lorand University, Hungarian Academy of Sciences, MTA-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary.
EM gmezo@caesar.elte.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 301
EP 308
PG 8
ER

PT J
AU Nyiri, K
   Koppany, G
   Palfy, Gy
   Vida, I
   Toth, Sz
   Orgovan, Z
   Randelovic, I
   Baranyi, M
   Molnar, E
   Keseru, GyM
   Tovari, J
   Perczel, A
   Vertessy, GB
   Timar, J
AF Nyiri, Kinga
   Koppany, Gergely
   Palfy, Gyula
   Vida, Istvan
   Toth, Szilard
   Orgovan, Zoltan
   Randelovic, Ivan
   Baranyi, Marcell
   Molnar, Eszter
   Keseru, Gyorgy Miklos
   Tovari, Jozsef
   Perczel, Andras
   Vertessy, G Beata
   Timar, Jozsef
TI Allele-specific inhibitors of mutant KRAS are in the focus of RASopathy consortium
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE KRAS; G12C mutation; allele-specific inhibitor; in vitro; in vivo testing
ID KRAS; G12C mutation; allele-specific inhibitor; in vitro; in vivo testing
AB The RASopathy consortium was built from research groups of the Budapest University of Technology and Economics, Eotvos Lorand University, Semmelweis University and two startups: KINETO Lab Ltd. and Fototronic Ltd. The goal was to design and test novel covalent and allele-specific KRAS small molecular inhibitors. KRAS is the most frequently mutated human oncogene which was unsuccessfully targeted until recently. The consortium established G12C-expressing bacterial and human cancer cell models (homo- and heterozygous variants) of lung, colorectal and pancreatic tumors. Using covalent fragment and acrylamide warhead libraries we were able to select novel candidates of small molecular G12C-specific inhibitors which were compared to published best-in-class drug candidates.
C1 [Nyiri, Kinga] Budapest University of Technology and Economics, Department of Applied Biotechnology and Food ScienceBudapest, Hungary.
   [Koppany, Gergely] Budapest University of Technology and Economics, Department of Applied Biotechnology and Food ScienceBudapest, Hungary.
   [Palfy, Gyula] Szerkezeti Kemia es Biologia LaboratoriumBudapest, Hungary.
   [Vida, Istvan] Szerkezeti Kemia es Biologia LaboratoriumBudapest, Hungary.
   [Toth, Szilard] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Orgovan, Zoltan] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Randelovic, Ivan] KINETO Lab Kft.Budapest, Hungary.
   [Baranyi, Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Molnar, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Keseru, Gyorgy Miklos] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Tovari, Jozsef] KINETO Lab Kft.Budapest, Hungary.
   [Perczel, Andras] MTA-ELTE Feherjemodellezo KutatocsoportBudapest, Hungary.
   [Vertessy, G Beata] Hungarian Academy of Sciences, Research Centre for Natural Sciences, Institute of EnzymologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 310
EP 323
PG 14
ER

PT J
AU Baranyi, M
   Molnar, E
   Rittler, D
   Hegedus, B
   Timar, J
AF Baranyi, Marcell
   Molnar, Eszter
   Rittler, Dominika
   Hegedus, Balazs
   Timar, Jozsef
TI Impact of prenylation inhibition on RAS mutant tumors in preclinical studies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE RAS mutation; prenylation-inhibition; bisphosphonate
ID RAS mutation; prenylation-inhibition; bisphosphonate
AB Oncogenic mutation of RAS occurs in 20-25% of all malignancies. Our research group have examined inhibition of RAS prenylation on RAS wild type and RAS mutated melanoma, colorectal cancer and lung adenocarcinoma cell lines. Effects of clinically approved bisphosphonate (zoledronic acid) and its lipophilic derivate (BPH1222) on cell viability and cell signaling were determined. In models of melanoma and colorectal cancer we found no relevant difference in sensitivity to the drugs in light of RAS mutation presence. In case of lung adenocarcinoma bisphosphonate treatment inhibited both wild-type and mutated K-RAS, although tumor cells carrying mutated K-RAS seemed to be more sensitive to the bisphosphonate treatment. In summary, further investigations are warranted to identify tumor subgroups where bisphosphonates could have an effective therapeutic potential.
C1 [Baranyi, Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Molnar, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Rittler, Dominika] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 320
EP 329
PG 10
ER

PT J
AU Menyhart, O
   Szabo, A
   Garami, M
   Gyorffy, B
AF Menyhart, Otilia
   Szabo, Andras
   Garami, Miklos
   Gyorffy, Balazs
TI Subgroup-specific genomic alterations and potential prognostic biomarkers in childhood medulloblastomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE medulloblastoma; prognostic biomarker; WNTactivated MB; SHH-activated MB; Group 3 MB; Group 4 MB
ID medulloblastoma; prognostic biomarker; WNTactivated MB; SHH-activated MB; Group 3 MB; Group 4 MB
AB Despite continuing advances in therapeutic strategies, survival of childhood medulloblastoma (MB) patients has reached a plateau in the past decade. Current clinical approaches divide patients into average- and high-risk treatment categories, although this categorization does not take patient heterogeneity into account. Advanced genomics has initiated an exciting transition that lead to a consensus of four distinct molecular entities within MBs (WNT-activated, SHH-activated, Group 3 MB, and Group 4 MB), each with distinct origins, demographics, molecular alterations and clinical outcomes. Within each of the four primary subgroups additional subtypes started to emerge with distinct biological backgrounds and clinical outcomes. Here we summarize subgroup-specific genomic alterations, affected signaling pathways and potential prognostic biomarkers. The poor prognosis associated with recurrent disease is responsible for the stagnant survival rates. Nevertheless, the mortality is unlikely to change without new biomarkers linked to different mechanisms of pathway activation.
C1 [Menyhart, Otilia] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Szabo, Andras] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Menyhart, O (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 331
EP 345
PG 15
ER

PT J
AU Osz, �
   Aszodi, B
   Vajda, R
   Keseru, GyM
   Moll, PH
   Casanova, E
   Gyorffy, B
AF Osz, Agnes
   Aszodi, Boglarka
   Vajda, Reka
   Keseru, Gyorgy Miklos
   Moll, P Herwig
   Casanova, Emilio
   Gyorffy, Balazs
TI CHEK1 expression and inhibitors in TP53 mutant cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE TP53 mutation; CHEK1; tyrosine kinase; lung cancer; personalized therapy
ID TP53 mutation; CHEK1; tyrosine kinase; lung cancer; personalized therapy
AB The most frequently mutated gene in human tumors is TP53 and its mutation significantly deteriorates patients’ survival. However, to date no targeted therapy is established for TP53 mutated tumors. Here, our aim was to identify druggable kinases with higher expression in TP53 mutated tumors, as well as relate these to altered prognosis. We also aimed to validate a target gene in TP53 wild type and mutant isogenic cell lines using a specific kinase inhibitor. Gene expression and mutation data were collected from 994 lung tumor samples. Samples were separated based on TP53 mutation status, and differential gene expression was compared using Mann–Whitney test between patient cohorts. Prognostic value of identified genes was validated in an array-based lung cancer dataset (n=1926). Survival analysis was performed using Cox proportional hazards regression and Kaplan-Meier survival plots. Effect of TP53 mutations on CHEK1 expression was validated in the A549 isogenic lung cancer cell line. The cell line was also treated using Chk1 protein specific kinase inhibitor to monitor cell functions. Expression of CHEK1 was elevated significantly among targetable kinases and higher expression of CHEK1 related to worse prognosis. Our results confirm the higher expression of CHEK1 kinase associated to TP53 mutations and to shorter survival.
C1 [Osz, Agnes] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
   [Aszodi, Boglarka] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Vajda, Reka] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Keseru, Gyorgy Miklos] TTK, SZKI, Gyogyszerkemiai KutatocsoportBudapest, Hungary.
   [Moll, P Herwig] Medical University of Vienna, Department of PhysiologyVienna, Austria.
   [Casanova, Emilio] Ludwig Boltzmann Institute for Cancer Research (LBI-CR)Vienna, Austria.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of Pediatrics, Tuzolto utca 7-9., 1094 Budapest, Hungary.
RP Gyorffy, B (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
EM gyorffy.balazs@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 345
EP 352
PG 8
ER

PT J
AU Dank, M
   Balogh, A
   Benedek, A
   Besztercei, B
   Danics, L
   Forika, G
   Garay, T
   Hamar, P
   Karaszi, �
   Kaucsar, T
   Kiss, �
   Krenacs, T
   Major, E
   Mohacsi, R
   Portoro, I
   Ruisanchez, �
   Schvarcz, Cs
   Szasz, AM
   Mbuotidem, JTh
   Vancsik, T
   Zolcsak, Z
   Benyo, Z
AF Dank, Magdolna
   Balogh, Andrea
   Benedek, Anett
   Besztercei, Balazs
   Danics, Lea
   Forika, Gertrud
   Garay, Tamas
   Hamar, Peter
   Karaszi, Adam
   Kaucsar, Tamas
   Kiss, Eva
   Krenacs, Tibor
   Major, Eniko
   Mohacsi, Reka
   Portoro, Istvan
   Ruisanchez, Eva
   Schvarcz, Csaba
   Szasz, Attila Marcell
   Mbuotidem, J Thomas
   Vancsik, Tamas
   Zolcsak, Zita
   Benyo, Zoltan
TI Preclinical and clinical investigation and development of electromagnetic oncological device – experience with solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE modulated electro-hyperthermia (mEHT); solid tumors; cell culture; animal model; treatment
ID modulated electro-hyperthermia (mEHT); solid tumors; cell culture; animal model; treatment
AB Our objective was to develop an electromagnetic tumor therapy device in a consortial cooperation between Semmelweis University and Oncotherm Ltd., to provide data and contribute to the development of the next generation of devices through preclinical, clinical and developmental modules via in vivo, in vitro studies, and patient treatments. Our numerous preclinical studies support the efficacy of mEHT. Clinical treatments were performed in 181 patients with inoperable and/or oligometastatic solid tumors. The protocols were developed, an international guideline was completed, and the planned steps of device development were realized. By optimizing previous selective RF techniques based on recent research findings, we can provide the most modern evidence-based treatment in the future.
C1 [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Balogh, Andrea] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Benedek, Anett] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Besztercei, Balazs] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Danics, Lea] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Garay, Tamas] Pazmany Peter Catholic University, Faculty of Information Technology and BionicsBudapest, Hungary.
   [Hamar, Peter] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Karaszi, Adam] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kaucsar, Tamas] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Kiss, Eva] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Major, Eniko] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Mohacsi, Reka] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Portoro, Istvan] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Ruisanchez, Eva] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Schvarcz, Csaba] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Mbuotidem, J Thomas] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Zolcsak, Zita] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37-47., 1094 Budapest, Hungary.
RP Benyo, Z (reprint author), Semmelweis University, Department of Immunology-Haematology-Transfusiology, 1094 Budapest, Hungary.
EM benyo.zoltan@med.semmelweis-univ.hu
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 354
EP 358
PG 5
ER

PT J
AU Krenacs, T
   Meggyeshazi, N
   Kovago, Cs
   Kiss, �
   Forika, G
   Balogh, A
   Vancsik, T
AF Krenacs, Tibor
   Meggyeshazi, Nora
   Kovago, Csaba
   Kiss, Eva
   Forika, Gertrud
   Balogh, Andrea
   Vancsik, Tamas
TI Mechanism of action of modulated electro- hyperthermia (mEHT) induced tumor damage in colorectal adenocarcinoma models
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE modulated electro-hyperthermia; C26 colorectal adenocarcinoma; apoptosis; damage associated molecular pattern (DAMP) signaling; immunogenic cell death; systemic abscopal effect
ID modulated electro-hyperthermia; C26 colorectal adenocarcinoma; apoptosis; damage associated molecular pattern (DAMP) signaling; immunogenic cell death; systemic abscopal effect
AB Modulated electro-hyperthermia (mEHT) is a non-invasive treatment modality of cancer where electric field generated by 13.56 MHz radiofrequency can selectively accumulate in malignant tumors compared to adjacent normal tissues. This effect is based on the metabolic shift in cancer cells which upregulates glycolysis even under oxygenated conditions (Warburg effect), resulting in elevated lactate and ion concentration. The concomitant increased permittivity can induce dielectric polarization and rotational friction of dipole molecules resulting in elevated core temperature, which can be controlled at 42 °C with the treating instrument. Complementary application of loco-regional mEHT can improve the efficiency of chemo-, radio- and recently molecular targeted therapies based on increasing local perfusion and xenobiotic concentration, resolving tumor hypoxia and improved immune surveillance supported by high-fever range hyperthermia. We earlier showed that mEHT has its own tumor inhibiting/destructing effect, however, its mechanism had not been clarified. In this project we have investigated the molecular mechanism of action of mEHT treatment using in vitro and in vivo models of colorectal adenocarcinoma.
C1 [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Meggyeshazi, Nora] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kovago, Csaba] Szent Istvan Egyetem, Allatorvostudomanyi Kar,, Farmakologiai es Toxikologiai IntezetBudapest, Hungary.
   [Kiss, Eva] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Balogh, Andrea] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Krenacs, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM krenacst@gmail.com
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 4
BP 359
EP 364
PG 6
ER

PT J
TI Hungarian Society of Oncologists XXXIII. Congress
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE congress
ID congress
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 1
EP 74
PG 74
ER

PT J
AU Adamcsikne Forgo, A
   Papai, Zs
AF Adamcsikne Forgo, Anita
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamcsikne Forgo, Anita] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Adamcsikne Forgo, A (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Adamik, I
   Biro, K
   Geczi, L
AF Adamik, Imola
   Biro, Krisztina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Adamik, Imola] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Adamik, I (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Al-Farhat, Y
   Schipp, I
   Cifra, J
AF Al-Farhat, Yousuf
   Schipp, Ildiko
   Cifra, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Cifra, Janos] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Al-Farhat, Y
   Schipp, I
   Szabo, A
AF Al-Farhat, Yousuf
   Schipp, Ildiko
   Szabo, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Szabo, Attila] Tolna Megyei Balassa Janos Korhaz, Urologiai OsztalySzekszard, Hungary.
RP Al-Farhat, Y (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Aranyi, M
   Kiss, N
   Bursics, A
   Uhlyarik, A
   Sikter, M
   Lahm, E
   Szentesi, A
   Ecker, N
   Takacs, K
   Laczko-David, Zs
   Szabo, �
   Papai, Zs
AF Aranyi, Marietta
   Kiss, Nora
   Bursics, Attila
   Uhlyarik, Andrea
   Sikter, Marta
   Lahm, Erika
   Szentesi, Aniko
   Ecker, Nora
   Takacs, Klara
   Laczko-David, Zsofia
   Szabo, Adam
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Aranyi, Marietta] Honved KorhazBudapest, Hungary.
   [Kiss, Nora] Honved KorhazBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Sikter, Marta] Honved KorhazBudapest, Hungary.
   [Lahm, Erika] Honved KorhazBudapest, Hungary.
   [Szentesi, Aniko] Honved KorhazBudapest, Hungary.
   [Ecker, Nora] Honved KorhazBudapest, Hungary.
   [Takacs, Klara] Honved KorhazBudapest, Hungary.
   [Laczko-David, Zsofia] Honved KorhazBudapest, Hungary.
   [Szabo, Adam] Honved KorhazBudapest, Hungary.
   [Papai, Zsuzsanna] Honved KorhazBudapest, Hungary.
RP Aranyi, M (reprint author), Honved Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Arokszallasi, A
   Toth, L
   Wild, D
   Nicolas, G
   Barna, S
   Varga, E
   Arkosy, P
   Andras, Cs
AF Arokszallasi, Anita
   Toth, Laszlo
   Wild, Damian
   Nicolas, Guillaume
   Barna, Sandor
   Varga, Eniko
   Arkosy, Peter
   Andras, Csilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Arokszallasi, Anita] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Laszlo] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Wild, Damian] University Hospital Basel, Radiology and Nuclear Medicine DepartmentBasel, Switzerland.
   [Nicolas, Guillaume] University Hospital Basel, Radiology and Nuclear Medicine DepartmentBasel, Switzerland.
   [Barna, Sandor] Debreceni Egyetem, AOK, Orvosi Kepalkoto Intezet, Radiologia nem onallo TanszekDebrecen, Hungary.
   [Varga, Eniko] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Arkosy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Arokszallasi, A (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 8
EP 8
PG 1
ER

PT J
AU Badon, ES
   Beke, L
   Andras, Cs
   Matolay, O
   Mehes, G
AF Badon, Emese Sarolta
   Beke, Livia
   Andras, Csilla
   Matolay, Orsolya
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Badon, Emese Sarolta] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Beke, Livia] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Matolay, Orsolya] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Badon, ES (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Badon, ES
   Mokanszki, A
   Monus, A
   Molnar, Cs
   Mehes, G
AF Badon, Emese Sarolta
   Mokanszki, Attila
   Monus, Aniko
   Molnar, Csaba
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Badon, Emese Sarolta] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mokanszki, Attila] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Monus, Aniko] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Molnar, Csaba] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Badon, ES (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balatoni, T
   Frohlich, G
   Herczeg, A
   Liszkay, G
AF Balatoni, Timea
   Frohlich, Georgina
   Herczeg, Adrienn
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balatoni, T
   Mohos, A
   Papp, E
   Sebestyen, T
   Liszkay, G
   Olah, J
   Varga, A
   Lengyel, Zs
   Emri, G
   Ferrone, S
   Ladanyi, A
AF Balatoni, Timea
   Mohos, Anita
   Papp, Eszter
   Sebestyen, Timea
   Liszkay, Gabriella
   Olah, Judit
   Varga, Anita
   Lengyel, Zsuzsanna
   Emri, Gabriella
   Ferrone, Soldano
   Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Mohos, Anita] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papp, Eszter] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Sebestyen, Timea] St John's Hospital, Department of PathologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Anita] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Lengyel, Zsuzsanna] University of Pecs, Department of Dermatology, Venereology and OncodermatologyPecs, Hungary.
   [Emri, Gabriella] University of Debrecen, Department of DermatologyDebrecen, Hungary.
   [Ferrone, Soldano] Massachusetts General Hospital, Harvard Medical School, Department of SurgeryBoston, USA.
   [Ladanyi, Andrea] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Balazs, BH
   Kohalmy, K
   Vincze, B
   Kovacs, J
   Pete, I
   Novak, Z
AF Balazs, Boglarka Hajnalka
   Kohalmy, Krisztina
   Vincze, Borbala
   Kovacs, Judit
   Pete, Imre
   Novak, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Boglarka Hajnalka] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kovacs, Judit] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Balazs, BH (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Balazs, K
   Juranyi, Zs
   Kocsis, Zs
   Agoston, P
   Jorgo, K
   Safrany, G
   Lumniczky, K
AF Balazs, Katalin
   Juranyi, Zsolt
   Kocsis, S. Zsuzsa
   Agoston, Peter
   Jorgo, Kliton
   Safrany, Geza
   Lumniczky, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Balazs, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of OncologyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of OncologyBudapest, Hungary.
   [Agoston, Peter] National Institute of OncologyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of OncologyBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Balazs, K (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 10
EP 11
PG 2
ER

PT J
AU Banky, B
   Almasi, K
   Abraham, Sz
   Baracs, J
   Bursics, A
   Jano, Z
   Sztipits, T
   Szuts, �
   Toth, D
   Zarand, A
AF Banky, Balazs
   Almasi, Kalman
   Abraham, Szabolcs
   Baracs, Jozsef
   Bursics, Attila
   Jano, Zoltan
   Sztipits, Tamas
   Szuts, Aron
   Toth, Dezso
   Zarand, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Banky, Balazs] Szent Borbala Korhaz, Sebeszeti OsztalyTatabanya, Hungary.
   [Almasi, Kalman] Szent Borbala Korhaz, Sebeszeti OsztalyTatabanya, Hungary.
   [Abraham, Szabolcs] University of Szeged, Department of SurgerySzeged, Hungary.
   [Baracs, Jozsef] University of Pecs, Department of SurgeryPecs, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Jano, Zoltan] Csolnoky Ferenc Korhaz, Sebeszeti OsztalyVeszprem, Hungary.
   [Sztipits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szuts, Aron] Csolnoky Ferenc Korhaz, Sebeszeti OsztalyVeszprem, Hungary.
   [Toth, Dezso] Kenezy Teaching Hospital, Department of General SurgeryDebrecen, Hungary.
   [Zarand, Attila] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
RP Banky, B (reprint author), Szent Borbala Korhaz, Sebeszeti Osztaly, Tatabanya, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Baranyai, F
   Farkas, E
   Czirbesz, K
   Kispal, M
   Panczel, G
   Imredi, E
   Danyi, T
   Balatoni, T
   Liszkay, G
AF Baranyai, Fanni
   Farkas, Emil
   Czirbesz, Kata
   Kispal, Mihaly
   Panczel, Gitta
   Imredi, Eleonora
   Danyi, Timea
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Baranyai, F (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Barczi, E
   Nagy, T
   Vincze, K
   Eszes, N
   Bohacs, A
   Muller, V
AF Barczi, Eniko
   Nagy, Tamas
   Vincze, Krisztina
   Eszes, Noemi
   Bohacs, Aniko
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Barczi, Eniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Nagy, Tamas] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Vincze, Krisztina] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Eszes, Noemi] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Bohacs, Aniko] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Barczi, E (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 11
EP 12
PG 2
ER

PT J
AU Bartha, �
   Gyorffy, B
AF Bartha, Aron
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bartha, Aron] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Bartha, � (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Bassam, A
   Tordai, L
   Piko, B
AF Bassam, Ali
   Tordai, Laszlo
   Piko, Bela
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Tordai, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
RP Bassam, A (reprint author), Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias Osztaly, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 12
EP 12
PG 1
ER

PT J
AU Bellyei, Sz
   Boronkai, �
   Fodor, D
   Mangel, L
AF Bellyei, Szabolcs
   Boronkai, Arpad
   Fodor, David
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Boronkai, Arpad] University of Pecs, Department of OncologyPecs, Hungary.
   [Fodor, David] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 12
EP 13
PG 2
ER

PT J
AU Benyo, G
   Benko, H
   Hegedus, J
   Kovacs, �A
AF Benyo, Gabor
   Benko, Henrietta
   Hegedus, Judit
   Kovacs, Agnes Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benyo, Gabor] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benko, Henrietta] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Hegedus, Judit] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Kovacs, Agnes Anna] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
RP Benyo, G (reprint author), Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Benyo, G
   Hegedus, J
   Benko, H
   Kovacs, �A
AF Benyo, Gabor
   Hegedus, Judit
   Benko, Henrietta
   Kovacs, Agnes Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Benyo, Gabor] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Hegedus, Judit] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benko, Henrietta] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Kovacs, Agnes Anna] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
RP Benyo, G (reprint author), Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Betenbuk, J
   Biro, K
   Geczi, L
AF Betenbuk, Judit
   Biro, Krisztina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Betenbuk, Judit] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Betenbuk, J (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Bezsenyi Istvanne, M
AF Bezsenyi Istvanne, Marta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bezsenyi Istvanne, Marta] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Bezsenyi Istvanne, M (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 13
EP 14
PG 2
ER

PT J
AU Biro, K
   Geczi, L
   Gyergyay, F
   Horvath, O
   Kiszner, G
   Lenart, E
   Nagyivanyi, K
   Martin, T
   Dienes, T
   Kovacs, �
   Toth, A
   Fazekas, F
   Kuronya, Zs
AF Biro, Krisztina
   Geczi, Lajos
   Gyergyay, Fruzsina
   Horvath, Orsolya
   Kiszner, Gergo
   Lenart, Eniko
   Nagyivanyi, Krisztian
   Martin, Tamas
   Dienes, Tamas
   Kovacs, Agnes
   Toth, Attila
   Fazekas, Fruzsina
   Kuronya, Zsofia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Horvath, Orsolya] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kiszner, Gergo] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Lenart, Eniko] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Martin, Tamas] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Dienes, Tamas] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kovacs, Agnes] Boehringer Ingelheim RCV GmbH & Co. KGBudapest, Hungary.
   [Toth, Attila] Adherencia.net LtdBudapest, Hungary.
   [Fazekas, Fruzsina] Peterfy Hospital, Department of UrologyBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Biro, K (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Bitai, Zs
   Perjesi, E
   Manninger, S
   Agocs, L
   Godeny, M
AF Bitai, Zsuzsanna
   Perjesi, Eszter
   Manninger, Sandor
   Agocs, Laszlo
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bitai, Zsuzsanna] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Perjesi, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Manninger, Sandor] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Bitai, Zs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Bogdan, P
   Kovacs, V
   Horvath, Zs
AF Bogdan, Peter
   Kovacs, Viktorne
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bogdan, Peter] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kovacs, Viktorne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Bogdan, P (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 14
EP 15
PG 2
ER

PT J
AU Boldizsar, Sz
   Varga, F
   Rotek, J
   Schneider, T
   Szaleczky, E
AF Boldizsar, Szandra
   Varga, Fatima
   Rotek, Janos
   Schneider, Tamas
   Szaleczky, Erika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Boldizsar, Szandra] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varga, Fatima] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rotek, Janos] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Boldizsar, Sz (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Borbely, K
AF Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 15
EP 16
PG 2
ER

PT J
AU Borbely, K
AF Borbely, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Borzasi, E
   Becze, DR
   Varga, L
   Dobi, �
   Nikolenyi, A
   Varga, Z
   Hideghety, K
   Maraz, A
AF Borzasi, Emoke
   Becze, Dominika Reka
   Varga, Linda
   Dobi, Agnes
   Nikolenyi, Aliz
   Varga, Zoltan
   Hideghety, Katalin
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Becze, Dominika Reka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Borzasi, E (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 16
EP 16
PG 1
ER

PT J
AU Bozsik, A
   Papp, J
   Pocza, T
   Patocs, A
   Olah, E
AF Bozsik, Aniko
   Papp, Janos
   Pocza, Timea
   Patocs, Attila
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Bozsik, A (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 16
EP 17
PG 2
ER

PT J
AU Bocskei, RM
AF Bocskei, Renata Marietta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Bocskei, Renata Marietta] Szent Borbala Korhaz, Pulmonologiai osztalyTatabanya, Hungary.
RP Bocskei, RM (reprint author), Szent Borbala Korhaz, Pulmonologiai osztaly, Tatabanya, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Butz, H
   Papp, J
   Bozsik, A
   Budai, B
   Pocza, T
   Patocs, A
AF Butz, Henriett
   Papp, Janos
   Bozsik, Aniko
   Budai, Barna
   Pocza, Timea
   Patocs, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Butz, Henriett] Semmelweis University, Department of Laboratory MedicineBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Patocs, Attila] Semmelweis University, Department of Laboratory MedicineBudapest, Hungary.
RP Butz, H (reprint author), Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Czibula, E
   Bogos, K
AF Czibula, Eszter
   Bogos, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czibula, Eszter] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
RP Czibula, E (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Czirbesz, K
   Baranyai, F
   Imredi, E
   Kispal, M
   Panczel, G
   Danyi, T
   Vizkeleti, J
   Frohlich, G
   Balatoni, T
   Liszkay, G
AF Czirbesz, Kata
   Baranyai, Fanni
   Imredi, Eleonora
   Kispal, Mihaly
   Panczel, Gitta
   Danyi, Timea
   Vizkeleti, Julia
   Frohlich, Georgina
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Czirbesz, K (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Csemez, I
   Mersich, T
   Godeny, M
AF Csemez, Imre
   Mersich, Tamas
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csemez, Imre] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Csemez, I (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Cserepes, M
   Turk, D
   Hegedus, Z
   Randelovic, I
   Kenessey, I
   Ladanyi, A
   Csiko, KGy
   Tovari, J
AF Cserepes, Mihaly
   Turk, Dora
   Hegedus, Zita
   Randelovic, Ivan
   Kenessey, Istvan
   Ladanyi, Andrea
   Csiko, Kristof Gyorgy
   Tovari, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cserepes, Mihaly] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Turk, Dora] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Hegedus, Zita] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Randelovic, Ivan] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Csiko, Kristof Gyorgy] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Tovari, Jozsef] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai OsztalyBudapest, Hungary.
RP Cserepes, M (reprint author), Orszagos Onkologiai Intezet, Kiserletes Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 18
EP 19
PG 2
ER

PT J
AU Cseri, Zs
   Volgyesi, T
   Biro, V
AF Cseri, Zsolt
   Volgyesi, Tilda
   Biro, Virag
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Cseri, Zsolt] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Volgyesi, Tilda] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Biro, Virag] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Cseri, Zs (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Csiki, E
   Simon, M
   Papp, J
   Kovacs, �
AF Csiki, Emese
   Simon, Mihaly
   Papp, Judit
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csiki, Emese] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Simon, Mihaly] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Papp, Judit] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Kovacs, Arpad] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
RP Csiki, E (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Csuka, O
   Doleschall, Z
   Engi, H
   Szakacs, O
   Vaszko, T
   Olasz, J
AF Csuka, Orsolya
   Doleschall, Zoltan
   Engi, Helga
   Szakacs, Orsolya
   Vaszko, Tibor
   Olasz, Judit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Doleschall, Zoltan] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Engi, Helga] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Szakacs, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Olasz, Judit] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Csuka, O (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 19
EP 20
PG 2
ER

PT J
AU Danics, L
   Schvarcz, Cs
   Vancsik, T
   Forika, G
   Kaucsar, T
   Zolcsak, Z
   Krenacs, T
   Agrawal, S
   Benyo, Z
   Hamar, P
AF Danics, Lea
   Schvarcz, Csaba
   Vancsik, Tamas
   Forika, Gertrud
   Kaucsar, Tamas
   Zolcsak, Zita
   Krenacs, Tibor
   Agrawal, Siddarth
   Benyo, Zoltan
   Hamar, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Danics, Lea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Schvarcz, Csaba] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Forika, Gertrud] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kaucsar, Tamas] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Zolcsak, Zita] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Agrawal, Siddarth] Wroclaw Medical University, Department of PathologyWroclaw, Poland.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Hamar, Peter] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Danics, L (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Danics, L
   Schvarcz, Cs
   Zolcsak, Z
   Benyo, Z
   Kaucsar, T
   Hamar, P
AF Danics, Lea
   Schvarcz, Csaba
   Zolcsak, Zita
   Benyo, Zoltan
   Kaucsar, Tamas
   Hamar, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Danics, Lea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Schvarcz, Csaba] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Zolcsak, Zita] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Kaucsar, Tamas] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Hamar, Peter] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Danics, L (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 20
EP 20
PG 1
ER

PT J
AU Danyi, T
   Balatoni, T
   Panczel, G
   Czirbesz, K
   Imredi, E
   Baranyai, F
   Kispal, M
   Beke, D
   Gal, A
   Bocs, K
   Toth, E
   Frohlich, G
   Liszkay, G
AF Danyi, Timea
   Balatoni, Timea
   Panczel, Gitta
   Czirbesz, Kata
   Imredi, Eleonora
   Baranyai, Fanni
   Kispal, Mihaly
   Beke, Dora
   Gal, Andrea
   Bocs, Katalin
   Toth, Erika
   Frohlich, Georgina
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Beke, Dora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Gal, Andrea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Danyi, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 20
EP 21
PG 2
ER

PT J
AU Danyi, T
   Balatoni, T
   Panczel, G
   Czirbesz, K
   Kispal, M
   Imredi, E
   Baranyai, F
   Liszkay, G
AF Danyi, Timea
   Balatoni, Timea
   Panczel, Gitta
   Czirbesz, Kata
   Kispal, Mihaly
   Imredi, Eleonora
   Baranyai, Fanni
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Danyi, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Deak-Karancsi, B
   Polgar, Cs
   Bago, A
   Lovey, J
AF Deak-Karancsi, Borbala
   Polgar, Csaba
   Bago, Attila
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deak-Karancsi, Borbala] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Polgar, Csaba] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Bago, Attila] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Lovey, Jozsef] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Deak-Karancsi, B (reprint author), Semmelweis University, Faculty of Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Deme, D
   Jamool, N
   El-Khalid, O
   Telekes, A
AF Deme, Daniel
   Jamool, Nizar
   El-Khalid, Osama
   Telekes, Andras
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Jamool, Nizar] Szent Lazar Megyei Korhaz, Patologiai OsztalySalgotarjan, Hungary.
   [El-Khalid, Osama] Szent Lazar Megyei Korhaz, Belgyogyaszati OsztalySalgotarjan, Hungary.
   [Telekes, Andras] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 21
EP 22
PG 2
ER

PT J
AU Dobi, �
   Cserhati, A
   Varga, L
   Hideghety, K
AF Dobi, Agnes
   Cserhati, Adrienne
   Varga, Linda
   Hideghety, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienne] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Dobi, � (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Doka, �
   Yumi, A
   Markus, D
   Tomoaki, I
   Balog, N
   Belen, E
   Akira, N
   Yosuke, F
   Hiroaki, M
   Jon, F
   Prigge, J
   Schmidt, E
   Arner, E
   Yoshito, K
   Takaaki, A
   Nagy, P
AF Doka, Eva
   Yumi, Abiko
   Markus, Dagnell
   Tomoaki, Ida
   Balog, Noemi
   Belen, Espinosa
   Akira, Nishimura
   Yosuke, Funato
   Hiroaki, Miki
   Jon, Fukuto
   Prigge, R. Justin
   Schmidt, E. Edward
   Arner, S. J. Elias
   Yoshito, Kumagai
   Takaaki, Akaike
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Doka, Eva] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Yumi, Abiko] University of Tsukuba, Environmental Biology SectionTsukuba, Japan.
   [Markus, Dagnell] Karolinska Institute, Department of Medical Biochemistry and Biophysics, Division of BiochemistryStockholm, Sweden.
   [Tomoaki, Ida] Tohoku University, Graduate School of Medicine, Department of Environmental Medicine and Molecular ToxicologySendai, Japan.
   [Balog, Noemi] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Belen, Espinosa] Karolinska Institute, Department of Medical Biochemistry and Biophysics, Division of BiochemistryStockholm, Sweden.
   [Akira, Nishimura] Tohoku University, Graduate School of Medicine, Department of Environmental Medicine and Molecular ToxicologySendai, Japan.
   [Yosuke, Funato] Osaka University, Department of Cellular Regulation, Research Institute for Microbial DiseasesOsaka, Japan.
   [Hiroaki, Miki] Osaka University, Department of Cellular Regulation, Research Institute for Microbial DiseasesOsaka, Japan.
   [Jon, Fukuto] Sonoma State University, Department of ChemistrySonoma, CA, USA.
   [Prigge, R. Justin] Montana State University, Department of Microbiology and ImmunologyBozeman, MT, USA.
   [Schmidt, E. Edward] Montana State University, Department of Microbiology and ImmunologyBozeman, MT, USA.
   [Arner, S. J. Elias] Karolinska Institute, Department of Medical Biochemistry and Biophysics, Division of BiochemistryStockholm, Sweden.
   [Yoshito, Kumagai] University of Tsukuba, Environmental Biology SectionTsukuba, Japan.
   [Takaaki, Akaike] Tohoku University, Graduate School of Medicine, Department of Environmental Medicine and Molecular ToxicologySendai, Japan.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Doka, � (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Duboczki, Zs
   Meszaros, P
   Sztipits, T
   Olah, G
   Wettstein, D
   Mersich, T
   Hitre, E
   Rubovszky, G
AF Duboczki, Zsolt
   Meszaros, Peter
   Sztipits, Tamas
   Olah, Gergely
   Wettstein, Daniel
   Mersich, Tamas
   Hitre, Erika
   Rubovszky, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Meszaros, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Sztipits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Olah, Gergely] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Wettstein, Daniel] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Duboczki, Zs (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 22
EP 23
PG 2
ER

PT J
AU Ecker, N
   Uhlyarik, A
   Harsanyi, L
   Bursics, A
   Papai, Zs
AF Ecker, Nora
   Uhlyarik, Andrea
   Harsanyi, Laszlo
   Bursics, Attila
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ecker, Nora] Magyar Honvedseg Egeszsegugyi Kozpont, Honvedkorhaz, II. Sz. BelgyogyaszatBudapest, Hungary.
   [Uhlyarik, Andrea] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Harsanyi, Laszlo] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Ecker, N (reprint author), Magyar Honvedseg Egeszsegugyi Kozpont, Honvedkorhaz, II. Sz. Belgyogyaszat, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Egyud, Zs
   Santha, D
   Nikolenyi, A
   Lovey, J
AF Egyud, Zsofia
   Santha, Dora
   Nikolenyi, Aliz
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Lovey, Jozsef] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Egyud, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Engi, H
   Szakacs, O
   Szmola, R
   Mavrogenis, S
   Szabo, JF
   Geczi, L
   Csuka, O
AF Engi, Helga
   Szakacs, Orsolya
   Szmola, Richard
   Mavrogenis, Stelios
   Szabo, Janos Ferenc
   Geczi, Lajos
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Engi, Helga] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Szakacs, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Szmola, Richard] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Mavrogenis, Stelios] Orszagos Onkologiai Inezet, UrologiaBudapest, Hungary.
   [Szabo, Janos Ferenc] Orszagos Onkologiai Inezet, UrologiaBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Engi, H (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 23
EP 24
PG 2
ER

PT J
AU Erdelyi, T
   Nagy, A
   Tamasi, L
   Muller, V
AF Erdelyi, Tamas
   Nagy, Attila
   Tamasi, Lilla
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Erdelyi, Tamas] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Nagy, Attila] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Erdelyi, T (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Facsar, L
AF Facsar, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Facsar, Lilla] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai OsztalyNyiregyhaza, Hungary.
RP Facsar, L (reprint author), Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Onkoradiologiai Osztaly, Nyiregyhaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 24
EP 24
PG 1
ER

PT J
AU Farkas, F
   Bauer, A
   Szabados, E
AF Farkas, Flora
   Bauer, Andrea
   Szabados, Eszter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Flora] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bauer, Andrea] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szabados, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Farkas, F (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 24
EP 25
PG 2
ER

PT J
AU Farkas, Gy
   Bajcsay, A
   Ostoros, Gy
   Markoczy, Zs
   Kocsis, Zs
   Kun-gazda, M
   Budai, M
   Szekely, G
   Mihaly, D
   Lovey, J
   Polgar, Cs
   Juranyi, Zs
AF Farkas, Gyongyi
   Bajcsay, Andras
   Ostoros, Gyula
   Markoczy, Zsolt
   Kocsis, S. Zsuzsa
   Kun-gazda, Marta
   Budai, Mariann
   Szekely, Gabor
   Mihaly, Dalma
   Lovey, Jozsef
   Polgar, Csaba
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Markoczy, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kun-gazda, Marta] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Budai, Mariann] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Fazekas, F
   Buzogany, I
   Beothe, T
AF Fazekas, Fruzsina
   Buzogany, Istvan
   Beothe, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fazekas, Fruzsina] Peterfy Hospital, Department of UrologyBudapest, Hungary.
   [Buzogany, Istvan] Peterfy Hospital, Department of UrologyBudapest, Hungary.
   [Beothe, Tamas] Peterfy Hospital, Department of UrologyBudapest, Hungary.
RP Fazekas, F (reprint author), Peterfy Hospital, Department of Urology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Fekete, JT
   Osz, �
   Pete, I
   Vereczkey, I
   Gyorffy, B
AF Fekete, Janos Tibor
   Osz, Agnes
   Pete, Imre
   Vereczkey, Ildiko
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fekete, Janos Tibor] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Osz, Agnes] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Pete, Imre] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Fekete, JT (reprint author), MTA TTK, Lendulet Cancer Biomarker Research Group, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 25
EP 26
PG 2
ER

PT J
AU Ferenczi, �
   Janvary, ZsL
   Bajcsay, A
   Sipos, L
   Bago, A
   Fedorcsak, I
   Stelczer, G
   Kontra, G
   Polgar, Cs
AF Ferenczi, Ors
   Janvary, Zsolt Levente
   Bajcsay, Andras
   Sipos, Laszlo
   Bago, Attila
   Fedorcsak, Imre
   Stelczer, Gabor
   Kontra, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ferenczi, Ors] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sipos, Laszlo] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Bago, Attila] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Fedorcsak, Imre] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Ferenczi, � (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Futo, I
   Horvath, DK
   Meszaros, E
   Landherr, L
   Klinko, T
AF Futo, Ildiko
   Horvath, Dorottya Katalin
   Meszaros, Edina
   Landherr, Laszlo
   Klinko, Timea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Futo, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Horvath, Dorottya Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Futo, I (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Fulop, M
AF Fulop, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Fulop, Miklos] Egyetemi Korhaz, Orebro, Ful-orr-gegeszeti OsztalyOrebro, Sweden.
RP Fulop, M (reprint author), Egyetemi Korhaz, Orebro, Ful-orr-gegeszeti Osztaly, Orebro, Sweden.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Galambos, K
   Erdelyi, K
   Balog, N
   Nagy, P
AF Galambos, Klaudia
   Erdelyi, Katalin
   Balog, Noemi
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Galambos, Klaudia] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Erdelyi, Katalin] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Balog, Noemi] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Galambos, K (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Garai, G
   Fabianne Kiss, Sz
   Falta, E
AF Garai, Gabriella
   Fabianne Kiss, Szilvia
   Falta, Emese
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Garai, Gabriella] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Fabianne Kiss, Szilvia] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Falta, Emese] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Garai, G (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Gellert, �
   Ghimessy, �K
   Schlegl, E
   Hegedus, B
   Raso, E
   Barbai, T
   Timar, J
   Ostoros, Gy
   Megyesfalvi, Zs
   Gieszer, B
   Moldvay, J
   Renyi-Vamos, F
   Lohinai, Z
   Mir, AH
   Klikovits, Th
   Klepetko, W
   Laszlo, V
   Dome, B
AF Gellert, Aron
   Ghimessy, Aron Kristof
   Schlegl, Erzsebet
   Hegedus, Balazs
   Raso, Erzsebet
   Barbai, Tamas
   Timar, Jozsef
   Ostoros, Gyula
   Megyesfalvi, Zsolt
   Gieszer, Balazs
   Moldvay, Judit
   Renyi-Vamos, Ferenc
   Lohinai, Zoltan
   Mir, Alireza Hoda
   Klikovits, Thomas
   Klepetko, Walter
   Laszlo, Viktoria
   Dome, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gellert, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Schlegl, Erzsebet] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Ostoros, Gyula] Orszagos Koranyi Tbc es Pulmonologiai Intezet, TudobelosztalyBudapest, Hungary.
   [Megyesfalvi, Zsolt] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Lohinai, Zoltan] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Mir, Alireza Hoda] Medical University, Comprehensive Cancer Centre Vienna, Sebeszeti OsztalyVienna, Austria.
   [Klikovits, Thomas] Medical University, Comprehensive Cancer Centre Vienna, Sebeszeti OsztalyVienna, Austria.
   [Klepetko, Walter] Medical University, Comprehensive Cancer Centre Vienna, Sebeszeti OsztalyVienna, Austria.
   [Laszlo, Viktoria] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Gellert, � (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 27
EP 28
PG 2
ER

PT J
AU Godeny, A
   Horvath, D
   Kovacs, P
   Polgar, Cs
AF Godeny, Anna
   Horvath, Dora
   Kovacs, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Horvath, Dora] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Godeny, A (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Gurgolne Marcsa, K
AF Gurgolne Marcsa, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gurgolne Marcsa, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Gurgolne Marcsa, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Gyapjas, T
   Molnar, M
   Horvath, Zs
AF Gyapjas, Tunde
   Molnar, Maria
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Gyapjas, Tunde] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Gyapjas, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 28
EP 28
PG 1
ER

PT J
AU Harda, K
   Szabo, Zs
   Szabo, E
   Szegedi, K
   Flasko, T
   Halmos, G
AF Harda, Kristof
   Szabo, Zsuzsanna
   Szabo, Erzsebet
   Szegedi, Krisztian
   Flasko, Tibor
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Harda, Kristof] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szabo, Erzsebet] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szegedi, Krisztian] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Flasko, Tibor] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
RP Harda, K (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 28
EP 29
PG 2
ER

PT J
AU Heintz, �T
   Horvath, K
   Kohalmy, K
   Balazs, B
   Godeny, M
AF Heintz, Adam Tamas
   Horvath, Katalin
   Kohalmy, Krisztina
   Balazs, Boglarka
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Heintz, Adam Tamas] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Balazs, Boglarka] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Heintz, �T (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Herczeg, A
   Rona, �
   Remenar, �
   Toth, E
   Hitre, E
   Oberna, F
   Ladanyi, A
AF Herczeg, Adrienn
   Rona, Agnes
   Remenar, Eva
   Toth, Erika
   Hitre, Erika
   Oberna, Ferenc
   Ladanyi, Andrea
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Rona, Agnes] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
RP Herczeg, A (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Hideghety, K
   Dobi, �
   Szabo, ER
   Brunner, Sz
   Polanek, R
   Tokes, T
AF Hideghety, Katalin
   Dobi, Agnes
   Szabo, Emilia Rita
   Brunner, Szilvia
   Polanek, Robert
   Tokes, Tunde
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szabo, Emilia Rita] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Brunner, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Polanek, Robert] ELI-HU Nonprofit Kft.Szeged, Hungary.
   [Tokes, Tunde] ELI-HU Nonprofit Kft.Szeged, Hungary.
RP Hideghety, K (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 29
EP 30
PG 2
ER

PT J
AU Horvath, B
   Godeny, M
AF Horvath, Barnabas
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Barnabas] National Institute of OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of OncologyBudapest, Hungary.
RP Horvath, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Horvath, D
   Godeny, A
   Kovacs, P
   Polgar, Cs
AF Horvath, Dora
   Godeny, Anna
   Kovacs, Peter
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dora] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Horvath, D (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Horvath, DK
   Futo, I
   Zolcsak, Z
   Meszaros, E
   Landherr, L
   Salamon, F
AF Horvath, Dorottya Katalin
   Futo, Ildiko
   Zolcsak, Zita
   Meszaros, Edina
   Landherr, Laszlo
   Salamon, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Dorottya Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Futo, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Zolcsak, Zita] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Meszaros, Edina] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
RP Horvath, DK (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 30
EP 31
PG 2
ER

PT J
AU Horvath, O
   Jakus, N
AF Horvath, Orsolya
   Jakus, Nikoletta
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Orsolya] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Jakus, Nikoletta] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Horvath, O (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Horvath, O
   Szakal, Sz
   Biro, K
   Gyergyai, F
   Nagyivanyi, K
   Kuronya, Zs
   Porneczy, E
   Geczi, L
AF Horvath, Orsolya
   Szakal, Szabina
   Biro, Krisztina
   Gyergyai, Fruzsina
   Nagyivanyi, Krisztian
   Kuronya, Zsofia
   Porneczy, Edit
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Horvath, Orsolya] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Szakal, Szabina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyai, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Porneczy, Edit] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Horvath, O (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Imredi, E
   Liszkay, G
   Fedorcsak, I
   Godeny, M
   Timar, J
AF Imredi, Eleonora
   Liszkay, Gabriella
   Fedorcsak, Imre
   Godeny, Maria
   Timar, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of Clinical NeurosciencesBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Imredi, E (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Janvary, ZsL
   Bajcsay, A
   Stelczer, G
   Kontra, G
   Csonka, �
   Agoston, P
   Jorgo, K
   Lovey, J
   Meszaros, N
   Takacsi-Nagy, Z
   Major, T
   Polgar, Cs
AF Janvary, Zsolt Levente
   Bajcsay, Andras
   Stelczer, Gabor
   Kontra, Gabor
   Csonka, Agnes
   Agoston, Peter
   Jorgo, Kliton
   Lovey, Jozsef
   Meszaros, Norbert
   Takacsi-Nagy, Zoltan
   Major, Tibor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Csonka, Agnes] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 31
EP 32
PG 2
ER

PT J
AU Jederan, �
   Godeny, M
AF Jederan, Eva
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jederan, Eva] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Jeszenszky, K
   Farkas, P
   Balogh, A
   Benedek, Sz
   Horvath, L
   Illes, S
   Masszi, A
   Szombath, G
   Varga, G
   Varkonyi, J
   Masszi, T
AF Jeszenszky, Krisztina
   Farkas, Peter
   Balogh, Alexandra
   Benedek, Szabolcs
   Horvath, Laura
   Illes, Sarolta
   Masszi, Andras
   Szombath, Gergely
   Varga, Gergely
   Varkonyi, Judit
   Masszi, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jeszenszky, Krisztina] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Farkas, Peter] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Balogh, Alexandra] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Benedek, Szabolcs] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Horvath, Laura] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Illes, Sarolta] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Masszi, Andras] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Szombath, Gergely] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Varga, Gergely] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Varkonyi, Judit] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
   [Masszi, Tamas] Semmelweis University, 3rd Department of Internal MedicineBudapest, Hungary.
RP Jeszenszky, K (reprint author), Semmelweis University, Faculty of Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 32
EP 32
PG 1
ER

PT J
AU Jorgo, K
   Agoston, P
   Gesztesi, L
   Stelczer, G
   Polgar, Cs
AF Jorgo, Kliton
   Agoston, Peter
   Gesztesi, Laszlo
   Stelczer, Gabor
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 32
EP 33
PG 2
ER

PT J
AU Juhasz, P
   Mokanszki, A
   Yi-che, ChCh
   Monus, A
   Andras, Cs
   Mehes, G
AF Juhasz, Peter
   Mokanszki, Attila
   Yi-che, Chien Chang
   Monus, Aniko
   Andras, Csilla
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Juhasz, Peter] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mokanszki, Attila] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Yi-che, Chien Chang] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Monus, Aniko] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Juhasz, P (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Karadi, O
   Bellyei, Sz
   Varga, Zs
   Mangel, L
AF Karadi, Oszkar
   Bellyei, Szabolcs
   Varga, Zsuzsanna
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Karadi, Oszkar] University of Pecs, Department of OncologyPecs, Hungary.
   [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Varga, Zsuzsanna] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Karadi, O (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Kelemen, Gy
   Toth, R
   Koszo, R
   Nikolenyi, A
   Uhercsak, G
   Santha, D
   Valicsek, E
   Szilagyi, �
   Torday, L
   Pepo, J
   Dobi, �
   Priskin, K
   Pinter, L
   Polya, S
   Haracska, L
   Sukosd, F
   Kahan, Zs
AF Kelemen, Gyongyi
   Toth, Rozalia
   Koszo, Renata
   Nikolenyi, Aliz
   Uhercsak, Gabriella
   Santha, Dora
   Valicsek, Erzsebet
   Szilagyi, Eva
   Torday, Laszlo
   Pepo, Judit
   Dobi, Agnes
   Priskin, Katalin
   Pinter, Lajos
   Polya, Sara
   Haracska, Lajos
   Sukosd, Farkas
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Toth, Rozalia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Priskin, Katalin] Delta Bio 2000 KftSzeged, Hungary.
   [Pinter, Lajos] Delta Bio 2000 KftSzeged, Hungary.
   [Polya, Sara] Magyar Tudomanyos Akademia, Szegedi Biologiai Kutatokozpont, Genetikai IntezetSzeged, Hungary.
   [Haracska, Lajos] Delta Bio 2000 KftSzeged, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kelemen, Gy (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Kenessey, I
   Polgar, Cs
AF Kenessey, Istvan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kenessey, I (reprint author), National Institute of Oncology, National Cancer Registry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Keresztes, T
   Kocsis, J
   Szocs, A
   Kuti, F
   Horvath, Zs
AF Keresztes, Tamas
   Kocsis, Judit
   Szocs, Aniko
   Kuti, Ferenc
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Keresztes, Tamas] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szocs, Aniko] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kuti, Ferenc] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Keresztes, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kertes, I
   Rubovszky, G
AF Kertes, Istvan
   Rubovszky, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kertes, Istvan] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Kertes, I (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kispal, M
   Baranyai, F
   Czirbesz, K
   Panczel, G
   Imredi, E
   Danyi, T
   Balatoni, T
   Liszkay, G
AF Kispal, Mihaly
   Baranyai, Fanni
   Czirbesz, Kata
   Panczel, Gitta
   Imredi, Eleonora
   Danyi, Timea
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kispal, M (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 34
EP 35
PG 2
ER

PT J
AU Kispal, M
   Janvary, ZsL
   Baranyai, F
   Czirbesz, K
   Panczel, G
   Imredi, E
   Danyi, T
   Balatoni, T
   Liszkay, G
AF Kispal, Mihaly
   Janvary, Zsolt Levente
   Baranyai, Fanni
   Czirbesz, Kata
   Panczel, Gitta
   Imredi, Eleonora
   Danyi, Timea
   Balatoni, Timea
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kispal, M (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Kiss, Cs
   Horvath, J
   Labiscsak, P
   Markus, B
   Dezso, B
   Szabo, A
   Tar, I
   Piffko, J
   Jakus, P
   Barabas, J
   Barabas, P
   Olasz, L
   Kover, Zs
   Tozser, J
   Sandor, J
   Csosz, �
   Scholtz, B
   Marton, I
AF Kiss, Csongor
   Horvath, Jozsef
   Labiscsak, Peter
   Markus, Bernadett
   Dezso, Balazs
   Szabo, Adrienn
   Tar, Ildiko
   Piffko, Jozsef
   Jakus, Petra
   Barabas, Jozsef
   Barabas, Peter
   Olasz, Lajos
   Kover, Zsanett
   Tozser, Jozsef
   Sandor, Janos
   Csosz, Eva
   Scholtz, Beata
   Marton, J. Ildiko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Csongor] University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-OncologyDebrecen, Hungary.
   [Horvath, Jozsef] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Labiscsak, Peter] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Markus, Bernadett] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Dezso, Balazs] University of Debrecen, Faculty of Dentistry, Department of Oral PathologyDebrecen, Hungary.
   [Szabo, Adrienn] University of Debrecen, Faculty of Dentistry, Department of Oral and Maxillofacial SurgeryDebrecen, Hungary.
   [Tar, Ildiko] Debreceni Egyetem, Oralis Medicina TanszekDebrecen, Hungary.
   [Piffko, Jozsef] University of Szeged, Faculty of Dentistry, Department of Oral SurgerySzeged, Hungary.
   [Jakus, Petra] University of Szeged, Faculty of Dentistry, Department of Oral SurgerySzeged, Hungary.
   [Barabas, Jozsef] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Barabas, Peter] Semmelweis University, Department of Oral and Maxillofacial SurgeryBudapest, Hungary.
   [Olasz, Lajos] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Kover, Zsanett] University of Pecs, Department of Oral and Maxillofacial SurgeryPecs, Hungary.
   [Tozser, Jozsef] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Sandor, Janos] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Csosz, Eva] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Scholtz, Beata] University of Debrecen, Faculty of Medicine, Department of Biochemistry and Molecular BiologyDebrecen, Hungary.
   [Marton, J. Ildiko] University of Debrecen, Faculty of Dentistry, Department of Restorative DentistryDebrecen, Hungary.
RP Kiss, Cs (reprint author), University of Debrecen, Medical and Health Science Center, Department of Pediatric Hematology-Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Kiss, E
   Szabo, �
   Szendroi, M
   Agoston, P
   Papai, Zs
AF Kiss, Edina
   Szabo, Adam
   Szendroi, Miklos
   Agoston, Peter
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szabo, Adam] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 35
EP 36
PG 2
ER

PT J
AU Kiszner, G
   Kuronya, Zs
   Biro, K
   Geczi, L
AF Kiszner, Gergo
   Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kiszner, Gergo] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Kiszner, G (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Kocsis, J
   Radeczky, �
   Fajth, B
   Maraz, R
   Cserni, G
   Horvath, Zs
AF Kocsis, Judit
   Radeczky, Agota
   Fajth, Bence
   Maraz, Robert
   Cserni, Gabor
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Radeczky, Agota] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Fajth, Bence] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Kocsis, J (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 36
EP 36
PG 1
ER

PT J
AU Kocsis, Zs
   Agoston, P
   Farkas, Gy
   Kun-gazda, M
   Szekely, G
   Major, T
   Mihaly, D
   Pesznyak, Cs
   Stelzer, G
   Jorgo, K
   Gesztesi, L
   Polgar, Cs
   Juranyi, Zs
AF Kocsis, S. Zsuzsa
   Agoston, Peter
   Farkas, Gyongyi
   Kun-gazda, Marta
   Szekely, Gabor
   Major, Tibor
   Mihaly, Dalma
   Pesznyak, Csilla
   Stelzer, Gabor
   Jorgo, Kliton
   Gesztesi, Laszlo
   Polgar, Csaba
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kun-gazda, Marta] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelzer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Kocsis, Zs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 36
EP 37
PG 2
ER

PT J
AU Koncz, Zs
   Kovacs, P
   Gyorffy, Zs
   Matrai, Z
AF Koncz, Zsuzsa
   Kovacs, Peter
   Gyorffy, Zsuzsanna
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koncz, Zsuzsa] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Gyorffy, Zsuzsanna] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Koncz, Zs (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Koszo, RL
   Kahan, Zs
   Darazs, B
   Rarosi, F
   Varga, Z
AF Koszo, Renata Lilla
   Kahan, Zsuzsanna
   Darazs, Barbara
   Rarosi, Ferenc
   Varga, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Koszo, Renata Lilla] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Darazs, Barbara] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Rarosi, Ferenc] TTIK, Orvosi Fizikai es Orvosi Informatikai IntezetSzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Koszo, RL (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Kotlan, B
   Czirbesz, K
   Naszados, Gy
   Horvath, Sz
   Eles, K
   Csuka, O
   Ujhelyi, M
   Szollar, A
   Savolt, �
   Farkas, E
   Godeny, M
   Kasler, M
   Liszkay, G
AF Kotlan, Beatrix
   Czirbesz, Katalin
   Naszados, Gyorgy
   Horvath, Szabolcs
   Eles, Klara
   Csuka, Orsolya
   Ujhelyi, Mihaly
   Szollar, Andras
   Savolt, Akos
   Farkas, Emil
   Godeny, Maria
   Kasler, Miklos
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kotlan, Beatrix] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Czirbesz, Katalin] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Naszados, Gyorgy] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Szabolcs] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Szollar, Andras] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Savolt, Akos] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Farkas, Emil] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kasler, Miklos] Emberi Eroforrasok MiniszteriumaBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kotlan, B (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 37
EP 38
PG 2
ER

PT J
AU Kovacs, �A
   Benko, H
   Hegedus, J
   Benyo, G
AF Kovacs, Agnes Anna
   Benko, Henrietta
   Hegedus, Judit
   Benyo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Agnes Anna] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benko, Henrietta] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Hegedus, Judit] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benyo, Gabor] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
RP Kovacs, �A (reprint author), Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Kovacs, �A
   Benko, H
   Hegedus, J
   Benyo, G
AF Kovacs, Agnes Anna
   Benko, Henrietta
   Hegedus, Judit
   Benyo, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Agnes Anna] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benko, Henrietta] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Hegedus, Judit] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
   [Benyo, Gabor] Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha GyermekhospiceTorokbalint, Hungary.
RP Kovacs, �A (reprint author), Hospice es Palliativ Ellatas Szakmai Kollegiumi Tagozat Elnok, Tabitha Gyermekhospice, Torokbalint, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Kovacs, AR
   Pal, L
   Szucs, S
   Lukacs, L
   Lampe, R
AF Kovacs, Anna Rebeka
   Pal, Laszlo
   Szucs, Sandor
   Lukacs, Luca
   Lampe, Rudolf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Anna Rebeka] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Pal, Laszlo] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Szucs, Sandor] Debreceni Egyetem Nepegeszsegugyi Kar, Megelozo Orvostani IntezetDebrecen, Hungary.
   [Lukacs, Luca] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
   [Lampe, Rudolf] University Medical School of Debrecen, Department of Gynecology and ObstetricsDebrecen, Hungary.
RP Kovacs, AR (reprint author), University Medical School of Debrecen, Department of Gynecology and Obstetrics, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 38
EP 39
PG 2
ER

PT J
AU Kovacs, �
   Sipos, D
   Toth, Z
   Lukacs, G
   Bajzik, G
   Moizs, M
   Cselik, Zs
   Repa, I
AF Kovacs, Arpad
   Sipos, David
   Toth, Zoltan
   Lukacs, Gabor
   Bajzik, Gabor
   Moizs, Mariann
   Cselik, Zsolt
   Repa, Imre
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Arpad] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Sipos, David] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Toth, Zoltan] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Lukacs, Gabor] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori IskolaPecs, Hungary.
   [Bajzik, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Moizs, Mariann] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Repa, Imre] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Kovacs, � (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Doktori Iskola, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Kovacs, P
   Godeny, A
AF Kovacs, Peter
   Godeny, Anna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Godeny, Anna] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Kovacs, V
   Bogdan, P
   Horvath, Zs
AF Kovacs, Viktorne
   Bogdan, Peter
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kovacs, Viktorne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Bogdan, Peter] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Kovacs, V (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Kohalmy, K
   Vincze, B
   Kuronya, Zs
   Horvath, O
   Geczi, L
AF Kohalmy, Krisztina
   Vincze, Borbala
   Kuronya, Zsofia
   Horvath, Orsolya
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Horvath, Orsolya] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Kohalmy, K (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kullmann, T
   Kocsis, K
   Kranitz, N
   Szepesvary, Zs
AF Kullmann, Tamas
   Kocsis, Karoly
   Kranitz, Noemi
   Szepesvary, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kocsis, Karoly] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kranitz, Noemi] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Szepesvary, Zsolt] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kullmann, T
   Ambrus, A
   Pinter, T
AF Kullmann, Tamas
   Ambrus, Adel
   Pinter, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Ambrus, Adel] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Pinter, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Kun-gazda, M
   Kocsis, Zs
   Herein, A
   Polgar, Cs
   Nagy, P
   Juranyi, Zs
AF Kun-gazda, Marta
   Kocsis, S. Zsuzsa
   Herein, Andras
   Polgar, Csaba
   Nagy, Peter
   Juranyi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Herein, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Kun-gazda, M (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 40
EP 41
PG 2
ER

PT J
AU Kuronya, Zs
   Biro, K
   Geczi, L
   Gyergyay, F
   Nagyivanyi, K
   Varga, L
   Varga, Z
   Sukosd, F
   Maraz, A
AF Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
   Gyergyay, Fruzsina
   Nagyivanyi, Krisztian
   Varga, Linda
   Varga, Zoltan
   Sukosd, Farkas
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Laczko-David, Zs
   Uhlyarik, A
   Ecker, N
   Papai, Zs
AF Laczko-David, Zsofia
   Uhlyarik, Andrea
   Ecker, Nora
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laczko-David, Zsofia] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Uhlyarik, Andrea] Szent Borbala Korhaz, OnkologiaTatabanya, Hungary.
   [Ecker, Nora] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Laczko-David, Zs (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Lahm, E
   Fulop, V
   Bassam, A
   Szepesi, G
   Papai, Zs
AF Lahm, Erika
   Fulop, Vilmos
   Bassam, Ali
   Szepesi, Gabor
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Fulop, Vilmos] Magyar Honvedseg Egeszsegugyi Kozpont, Honvedkorhaz, Szuleszet-nogyogyaszati OsztalyBudapest, Hungary.
   [Bassam, Ali] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Szepesi, Gabor] Affidea Magyarorszag, Dozsa Gyorgy uti Diagnosztikai kozpontBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Lahm, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 41
EP 42
PG 2
ER

PT J
AU Lakosi, F
   Toller, G
   Glavak, Cs
   Lukacs, G
   Somogyine Ezer, �
   Cselik, Zs
   Mahr, K
   Szabo, Zs
   Szabo, H
   Kaposztas, Zs
AF Lakosi, Ferenc
   Toller, Gabor
   Glavak, Csaba
   Lukacs, Gabor
   Somogyine Ezer, Eva
   Cselik, Zsolt
   Mahr, Karoly
   Szabo, Zsolt
   Szabo, Helga
   Kaposztas, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Toller, Gabor] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Lukacs, Gabor] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Somogyine Ezer, Eva] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Zsolt] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Helga] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Kaposztas, Zsolt] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Laszlo, Z
   Antal, G
   Glavak, Cs
   Kisivan, K
   Farkas, A
   Jenei, T
   Cselik, Zs
   Lakosi, F
AF Laszlo, Zoltan
   Antal, Gergely
   Glavak, Csaba
   Kisivan, Katalin
   Farkas, Andrea
   Jenei, Tibor
   Cselik, Zsolt
   Lakosi, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Laszlo, Zoltan] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Antal, Gergely] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Kisivan, Katalin] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
   [Jenei, Tibor] Kaposi Mor Teaching Hospital, Department of UrologyKaposvar, Hungary.
   [Cselik, Zsolt] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation OncologyKaposvar, Hungary.
RP Laszlo, Z (reprint author), Kaposvar University, Department of Radiation Oncology, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Lenart, E
   Biro, K
   Gyergyai, F
   Horvath, O
   Kuronya, Zs
   Nagyivanyi, K
   Porneczi, E
   Geczi, L
AF Lenart, Eniko
   Biro, Krisztina
   Gyergyai, Fruzsina
   Horvath, Orsolya
   Kuronya, Zsofia
   Nagyivanyi, Krisztian
   Porneczi, Edit
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lenart, Eniko] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyai, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Horvath, Orsolya] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Porneczi, Edit] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Lenart, E (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 42
EP 43
PG 2
ER

PT J
AU Lengyel, D
   Horvath, K
   Szavcsur, P
   Vereczkey, I
   Novak, Z
AF Lengyel, Daniel
   Horvath, Katalin
   Szavcsur, Peter
   Vereczkey, Ildiko
   Novak, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lengyel, Daniel] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Horvath, Katalin] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Szavcsur, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Lengyel, D (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Lerant, G
   Rona, �
   Szavcsur, P
   Sarkozy, P
   Godeny, M
AF Lerant, Gergely
   Rona, Agnes
   Szavcsur, Peter
   Sarkozy, Peter
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lerant, Gergely] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Rona, Agnes] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szavcsur, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Sarkozy, Peter] Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Villamosmernoki es Informatikai Kar, Merestechnika es Informacios Rendszerek TanszekBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Lerant, G (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Levai, D
   Csomor, J
   Timar, B
   Schneider, T
AF Levai, Dora
   Csomor, Judit
   Timar, Botond
   Schneider, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Levai, Dora] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Timar, Botond] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Levai, D (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 43
EP 44
PG 2
ER

PT J
AU Levai, D
   Deak, B
   Molnar, Zs
   Szaleczky, E
   Varady, E
   Varga, F
   Rottek, J
   Rosta, A
   Toth, E
   Lovey, J
   Csomor, J
   Lengyel, Zs
   Schneider, T
AF Levai, Dora
   Deak, Beata
   Molnar, Zsuzsa
   Szaleczky, Erika
   Varady, Erika
   Varga, Fatima
   Rottek, Janos
   Rosta, Andras
   Toth, Erika
   Lovey, Jozsef
   Csomor, Judit
   Lengyel, Zsolt
   Schneider, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Levai, Dora] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Deak, Beata] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Molnar, Zsuzsa] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Szaleczky, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varady, Erika] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Varga, Fatima] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rottek, Janos] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Rosta, Andras] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Csomor, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnosztika KftBudapest, Hungary.
   [Schneider, Tamas] Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai OsztalyBudapest, Hungary.
RP Levai, D (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „A” Belgyogyaszati- Onkologiai es Hematologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Lukacs, E
   Biro, K
   Geczi, L
   Gyergyay, F
   Bagameri, A
   Novak, Z
AF Lukacs, Edina
   Biro, Krisztina
   Geczi, Lajos
   Gyergyay, Fruzsina
   Bagameri, Andrea
   Novak, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Lukacs, Edina] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Bagameri, Andrea] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Lukacs, E (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Magyar, T
   Geczi, L
   Kovacs, P
AF Magyar, Ticia
   Geczi, Lajos
   Kovacs, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Magyar, Ticia] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Magyar, T (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 44
EP 45
PG 2
ER

PT J
AU Makai, A
   Kortvely, M
   Balogh, I
   Arkossy, P
   Kovacs, �
   Bittner, N
   Mehes, K
AF Makai, Attila
   Kortvely, Magdolna
   Balogh, Ingrid
   Arkossy, Peter
   Kovacs, Arpad
   Bittner, Nora
   Mehes, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Makai, Attila] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Kortvely, Magdolna] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Balogh, Ingrid] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Arkossy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kovacs, Arpad] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Bittner, Nora] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Mehes, Karoly] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Makai, A (reprint author), University of Debrecen Medical and Health Science Center, Department of Pulmonary Medicine, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Maraz, A
   Varga, L
   Pajor, L
   Bajory, Z
   Takacs, P
   Revesz, J
   Sukosd, F
AF Maraz, Aniko
   Varga, Linda
   Pajor, Laszlo
   Bajory, Zoltan
   Takacs, Peter
   Revesz, Janos
   Sukosd, Farkas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pajor, Laszlo] University of Szeged, Department of UrologySzeged, Hungary.
   [Bajory, Zoltan] University of Szeged, Department of UrologySzeged, Hungary.
   [Takacs, Peter] Janssen-Cilag Kft.Budapest, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Maraz, R
   Sikorszki, L
   Ambrozay, �
   Cserni, G
   Horvath, Zs
AF Maraz, Robert
   Sikorszki, Laszlo
   Ambrozay, Eva
   Cserni, Gabor
   Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Maraz, Robert] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Maraz, R (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Marko, L
   Maraz, R
   Ambrozay, �
   Cserni, G
   Horvath, Zs
   Sikorszki, L
AF Marko, Laszlo
   Maraz, Robert
   Ambrozay, Eva
   Cserni, Gabor
   Horvath, Zsolt
   Sikorszki, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun Megyei Korhaz, MaMMa Zrt.Kecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Marosi, E
   Podmaniczky, E
   Ferbert, Zs
   Van Dale, D
   Hendriksen, M
   Lemmens, L
   Papartyte, L
   Savolainen, N
   Polgar, Cs
   Nagy, P
AF Marosi, Edit
   Podmaniczky, Erzsebet
   Ferbert, Zsuzsanna
   Van Dale, Djoeke
   Hendriksen, Marieke
   Lemmens, Lidwien
   Papartyte, Lina
   Savolainen, Nella
   Polgar, Csaba
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marosi, Edit] National Institute of OncologyBudapest, Hungary.
   [Podmaniczky, Erzsebet] National Institute of OncologyBudapest, Hungary.
   [Ferbert, Zsuzsanna] National Institute of OncologyBudapest, Hungary.
   [Van Dale, Djoeke] National Institute for Public Health and the EnvironmentBilthoven, The Netherlands.
   [Hendriksen, Marieke] National Institute for Public Health and the EnvironmentBilthoven, The Netherlands.
   [Lemmens, Lidwien] National Institute for Public Health and the EnvironmentBilthoven, The Netherlands.
   [Papartyte, Lina] European Partnership for Health Equity and Wellbeing (EuroHealthNet)Brussels, Belgium.
   [Savolainen, Nella] National Institute for Wealth and WelfareHelsinki, Finland.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
RP Marosi, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 46
EP 46
PG 1
ER

PT J
AU Marosi, E
   Podmaniczky, E
   Ferbert, Zs
   Felho, R
   Csuka, O
   Lovey, J
   Polgar, Cs
   Nagy, P
AF Marosi, Edit
   Podmaniczky, Erzsebet
   Ferbert, Zsuzsanna
   Felho, Reka
   Csuka, Orsolya
   Lovey, Jozsef
   Polgar, Csaba
   Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Marosi, Edit] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Podmaniczky, Erzsebet] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Ferbert, Zsuzsanna] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Felho, Reka] Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok OsztalyaBudapest, Hungary.
   [Csuka, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
RP Marosi, E (reprint author), Orszagos Onkologiai Intezet, Nemzetkozi Kapcsolatok Osztalya, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 46
EP 47
PG 2
ER

PT J
AU Martin, T
   Biro, K
   Geczi, L
AF Martin, Tamas
   Biro, Krisztina
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Martin, Tamas] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Martin, T (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Masszi, L
   Kenessey, I
   Polgar, Cs
   Liszkay, G
AF Masszi, Laura
   Kenessey, Istvan
   Polgar, Csaba
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Masszi, Laura] Semmelweis UniversityBudapest, Hungary.
   [Kenessey, Istvan] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of OncologyBudapest, Hungary.
RP Masszi, L (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Matolay, O
   Beke, L
   Gyurkovics, A
   Francz, M
   Varjasi, G
   Rejto, L
   Illes, �
   Bedekovics, J
   Mehes, G
AF Matolay, Orsolya
   Beke, Livia
   Gyurkovics, Andrea
   Francz, Monika
   Varjasi, Gabriella
   Rejto, Laszlo
   Illes, Arpad
   Bedekovics, Judit
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matolay, Orsolya] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Beke, Livia] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Gyurkovics, Andrea] Josa Andras Teaching Hospital, Department of PathologyNyiregyhaza, Hungary.
   [Francz, Monika] Josa Andras Teaching Hospital, Department of PathologyNyiregyhaza, Hungary.
   [Varjasi, Gabriella] Szabolcs-Szatmar-Bereg County Josa Andras Hospital, Department of HaematologyNyiregyhaza, Hungary.
   [Rejto, Laszlo] Szabolcs-Szatmar-Bereg County Josa Andras Hospital, Department of HaematologyNyiregyhaza, Hungary.
   [Illes, Arpad] University of Debrecen, Faculty of Medicine, Department of HematologyDebrecen, Hungary.
   [Bedekovics, Judit] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Matolay, O (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 47
EP 48
PG 2
ER

PT J
AU Matolay, O
   Tarkanyi, N
   Beke, L
   Szegedi, I
   Kiss, Cs
   Mehes, G
AF Matolay, Orsolya
   Tarkanyi, Nora
   Beke, Livia
   Szegedi, Istvan
   Kiss, Csongor
   Mehes, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matolay, Orsolya] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Tarkanyi, Nora] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Beke, Livia] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Szegedi, Istvan] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Kiss, Csongor] Medical and Health Science Center, University of Debrecen, Department of PediatricsDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Matolay, O (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Matrai, T
   Ujhelyi, M
   Kovacs, T
   Kelemen, P
   Savolt, �
   Kovacs, E
   Eles, K
   Meszaros, N
   Kenessey, I
   Stamatiou, A
   Pukancsik, D
   Matrai, Z
AF Matrai, Tamas
   Ujhelyi, Mihaly
   Kovacs, Tibor
   Kelemen, Peter
   Savolt, Akos
   Kovacs, Eszter
   Eles, Klara
   Meszaros, Norbert
   Kenessey, Istvan
   Stamatiou, Alexia
   Pukancsik, David
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Matrai, Tamas] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Tibor] Guy’s and St Thomas’s Hospitals NHS Foundation Trust, Department of Breast SurgeryLondon, UK.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Eles, Klara] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Stamatiou, Alexia] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Matrai, T (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Menyhart, O
   Herman, P
   Munkacsy, Gy
   Gyorffy, B
AF Menyhart, Otilia
   Herman, Peter
   Munkacsy, Gyongyi
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Menyhart, Otilia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Herman, Peter] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Munkacsy, Gyongyi] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Menyhart, O (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 48
EP 49
PG 2
ER

PT J
AU Menyhart, O
   Kakisaka, T
   Pongor, L
   Uetake, H
   Ajay, G
   Gyorffy, B
AF Menyhart, Otilia
   Kakisaka, Tatsuhiko
   Pongor, Lorinc
   Uetake, Hiroyuki
   Ajay, Goel
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Menyhart, Otilia] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kakisaka, Tatsuhiko] Baylor Scott&White Research Institute and Charles A. Sammons Cancer Center, Center for Gastrointestinal Research & Center for Translational Genomics and OncologyDallas, USA.
   [Pongor, Lorinc] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Uetake, Hiroyuki] Tokyo Medical and Dental University, Graduate School of Medicine, Department of Specialized SurgeryTokyo, Japan.
   [Ajay, Goel] Baylor Scott&White Research Institute and Charles A. Sammons Cancer Center, Center for Gastrointestinal Research & Center for Translational Genomics and OncologyDallas, USA.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Menyhart, O (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Mersich, T
   Sztipits, T
   Duboczki, Zs
   Olah, G
   Meszaros, P
   Wettstein, D
   Strausz, T
   Nagy, T
   Csemez, I
   Schlachter, K
   Pap, �
AF Mersich, Tamas
   Sztipits, Tamas
   Duboczki, Zsolt
   Olah, Gergely
   Meszaros, Peter
   Wettstein, Daniel
   Strausz, Tamas
   Nagy, Tunde
   Csemez, Imre
   Schlachter, Krisztina
   Pap, Eva
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Sztipits, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Duboczki, Zsolt] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Olah, Gergely] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Peter] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Wettstein, Daniel] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Strausz, Tamas] Orszagos Onkologiai Intezet, HPB-teamBudapest, Hungary.
   [Nagy, Tunde] Orszagos Onkologiai Intezet, HPB-teamBudapest, Hungary.
   [Csemez, Imre] Orszagos Onkologiai Intezet, HPB-teamBudapest, Hungary.
   [Schlachter, Krisztina] Orszagos Onkologiai Intezet, HPB-teamBudapest, Hungary.
   [Pap, Eva] Orszagos Onkologiai Intezet, HPB-teamBudapest, Hungary.
RP Mersich, T (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Meszaros, N
   Janvary, ZsL
   Stelczer, G
   Smanyko, V
   Major, T
   Zaka, Z
   Polgar, Cs
AF Meszaros, Norbert
   Janvary, Zsolt Levente
   Stelczer, Gabor
   Smanyko, Viktor
   Major, Tibor
   Zaka, Zoltan
   Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Smanyko, Viktor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Zaka, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Meszaros, N (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 49
EP 50
PG 2
ER

PT J
AU Moldvay, J
   Teglasi, V
   Pipek, O
   Rojko, L
   Glasz, T
   Vagvolgyi, A
   Kovalszky, I
   Gyulai, M
   Lohinai, Z
   Raso, E
   Timar, J
   Dome, B
   Szallasi, Z
   Reiniger, L
AF Moldvay, Judit
   Teglasi, Vanda
   Pipek, Orsolya
   Rojko, Livia
   Glasz, Tibor
   Vagvolgyi, Attila
   Kovalszky, Ilona
   Gyulai, Marton
   Lohinai, Zoltan
   Raso, Erzsebet
   Timar, Jozsef
   Dome, Balazs
   Szallasi, Zoltan
   Reiniger, Lilla
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Teglasi, Vanda] Semmelweis UniversityBudapest, Hungary.
   [Pipek, Orsolya] Eotvos Lorand UniversityBudapest, Hungary.
   [Rojko, Livia] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Glasz, Tibor] Semmelweis UniversityBudapest, Hungary.
   [Vagvolgyi, Attila] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis UniversityBudapest, Hungary.
   [Gyulai, Marton] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lohinai, Zoltan] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis UniversityBudapest, Hungary.
   [Timar, Jozsef] Semmelweis UniversityBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Szallasi, Zoltan] Harvard Medical SchoolBoston, USA.
   [Reiniger, Lilla] Semmelweis UniversityBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Muhl, D
   Nagy, �
   Bodor, Cs
   Dank, M
   Szasz, AM
AF Muhl, Dorottya
   Nagy, Akos
   Bodor, Csaba
   Dank, Magdolna
   Szasz, Attila Marcell
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muhl, Dorottya] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Nagy, Akos] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Muhl, D (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 50
EP 50
PG 1
ER

PT J
AU Muller, Z
   Vityi, T
   Szucs, M
   Gorgey, Cs
AF Muller, Zoltan
   Vityi, Tamas
   Szucs, Milan
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Szucs, Milan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Gorgey, Csaba] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Muller, Z (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 50
EP 51
PG 2
ER

PT J
AU Nagy, �
   Gyorffy, B
AF Nagy, Adam
   Gyorffy, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Adam] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
RP Nagy, � (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Nagy, A
   Kolonics-Farkas, A
   Eszes, N
   Vincze, K
   Horvath, G
   Muller, V
AF Nagy, Attila
   Kolonics-Farkas, Abigel
   Eszes, Noemi
   Vincze, Krisztina
   Horvath, Gabor
   Muller, Veronika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Attila] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Kolonics-Farkas, Abigel] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Eszes, Noemi] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Vincze, Krisztina] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Horvath, Gabor] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Nagy, A (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Nagy, B
   Locsei, Z
   Kelemen, D
   Mangel, L
AF Nagy, Bettina
   Locsei, Zoltan
   Kelemen, Dezso
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Bettina] University of Pecs, Department of OncologyPecs, Hungary.
   [Locsei, Zoltan] University of Pecs, Department of OncologyPecs, Hungary.
   [Kelemen, Dezso] University of Pecs, Department of SurgeryPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Nagy, B (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 51
EP 52
PG 2
ER

PT J
AU Nagy, P
AF Nagy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
RP Nagy, P (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Nagy-Laszlo, R
   Torday, L
AF Nagy-Laszlo, Roland
   Torday, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nagy-Laszlo, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Nagy-Laszlo, R
   Uhercsak, G
   Pepo, J
   Csenki, M
   Torday, L
AF Nagy-Laszlo, Roland
   Uhercsak, Gabriella
   Pepo, Judit
   Csenki, Melinda
   Torday, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nagy-Laszlo, R (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 52
EP 53
PG 2
ER

PT J
AU Nagyne, RJ
   Schipp, I
   Al-Farhat, Y
AF Nagyne, Racz Judit
   Schipp, Ildiko
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nagyne, Racz Judit] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Nagyne, RJ (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Nikolenyi, A
   Uhercsak, G
   Valicsek, E
   Dobi, �
   Torday, L
   Santha, D
   Horvath, E
   Egyedi, M
   Haracska, L
   Kahan, Zs
AF Nikolenyi, Aliz
   Uhercsak, Gabriella
   Valicsek, Erzsebet
   Dobi, Agnes
   Torday, Laszlo
   Santha, Dora
   Horvath, Emese
   Egyedi, Marton
   Haracska, Lajos
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Horvath, Emese] University of Szeged, Department of Medical GeneticsSzeged, Hungary.
   [Egyedi, Marton] Delta Bio 2000 KftSzeged, Hungary.
   [Haracska, Lajos] Delta Bio 2000 KftSzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Nikolenyi, A (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Novak, Z
   Mersich, T
AF Novak, Zoltan
   Mersich, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Novak, Z (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Olasz, J
   Vaszko, T
   Doleschall, Z
   Matrai, Z
   Szoke, J
AF Olasz, Judit
   Vaszko, Tibor
   Doleschall, Zoltan
   Matrai, Zoltan
   Szoke, Janos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Olasz, Judit] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Vaszko, Tibor] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Doleschall, Zoltan] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
RP Olasz, J (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 53
EP 54
PG 2
ER

PT J
AU Panczel, G
   Balatoni, T
   Imredi, E
   Liszkay, G
AF Panczel, Gitta
   Balatoni, Timea
   Imredi, Eleonora
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Imredi, Eleonora] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Papdan, T
   Torday, L
AF Papdan, Timea
   Torday, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papdan, Timea] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Papdan, T (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Papp, J
   Bozsik, A
   Pocza, T
   Patocs, A
   Olah, E
AF Papp, Janos
   Bozsik, Aniko
   Pocza, Timea
   Patocs, Attila
   Olah, Edit
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Papp, J (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Paszkan, EK
   Megyesfalvi, Zs
   Ghimessy, �K
   Ganofszky, E
   Dome, B
   Rubovszky, G
   Renyi-Vamos, F
AF Paszkan, Evelyn Katalin
   Megyesfalvi, Zsolt
   Ghimessy, Aron Kristof
   Ganofszky, Erna
   Dome, Balazs
   Rubovszky, Gabor
   Renyi-Vamos, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Paszkan, Evelyn Katalin] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Megyesfalvi, Zsolt] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Ghimessy, Aron Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ganofszky, Erna] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Paszkan, EK (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Pecsi, B
   Mangel, L
AF Pecsi, Balazs
   Mangel, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Pecsi, Balazs] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Pecsi, B (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Petri, K
   Agoston, P
   Godeny, M
AF Petri, Klara
   Agoston, Peter
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Petri, Klara] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Petri, K (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 55
EP 56
PG 2
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Polk, N
   Biro, K
   Nagyivanyi, K
   Kuronya, Zs
   Gyergyay, F
   Budai, B
   Geczi, L
AF Polk, Nandor
   Biro, Krisztina
   Nagyivanyi, Krisztian
   Kuronya, Zsofia
   Gyergyay, Fruzsina
   Budai, Barna
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Polk, Nandor] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Polk, N (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 56
EP 56
PG 1
ER

PT J
AU Posfai, B
   Szalay, I
   Tiszlavicz, L
   Maraz, A
AF Posfai, Boglarka
   Szalay, Istvan
   Tiszlavicz, Laszlo
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Posfai, Boglarka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szalay, Istvan] University of Szeged, Department of UrologySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Posfai, B (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 56
EP 57
PG 2
ER

PT J
AU Priskin, K
   Polya, S
   Pinter, L
   Jaksa, G
   Kelemen, Gy
   Sukosd, F
   Kahan, Zs
   Haracska, L
AF Priskin, Katalin
   Polya, Sari
   Pinter, Lajos
   Jaksa, Gabor
   Kelemen, Gyongyi
   Sukosd, Farkas
   Kahan, Zsuzsanna
   Haracska, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Priskin, Katalin] Delta Bio 2000 Kft, Deltagene molekularis diagnosztikai laborSzeged, Hungary.
   [Polya, Sari] Delta Bio 2000 Kft, Deltagene molekularis diagnosztikai laborSzeged, Hungary.
   [Pinter, Lajos] Delta Bio 2000 Kft, Deltagene molekularis diagnosztikai laborSzeged, Hungary.
   [Jaksa, Gabor] Delta Bio 2000 Kft, Deltagene molekularis diagnosztikai laborSzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Haracska, Lajos] Hungarian Academy of Sciences, Biological Research CenterSzeged, Hungary.
RP Priskin, K (reprint author), Delta Bio 2000 Kft, Deltagene molekularis diagnosztikai labor, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Puskas, G
   Feherne Kosa, I
AF Puskas, Gabriella
   Feherne Kosa, Iren
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Feherne Kosa, Iren] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Puskas, G
   Benczes, I
AF Puskas, Gabriella
   Benczes, Ilona
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Benczes, Ilona] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Puskas, G
   Gurgolne Marcsa, K
AF Puskas, Gabriella
   Gurgolne Marcsa, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Gurgolne Marcsa, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Radovics, T
   Horvath, L
   Haller, I
   Farczadi, E
   Boer, K
AF Radovics, Tibor
   Horvath, Lilla
   Haller, Istvan
   Farczadi, Eniko
   Boer, Katalin
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Radovics, Tibor] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Horvath, Lilla] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Haller, Istvan] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Farczadi, Eniko] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
   [Boer, Katalin] St. Margit Hospital, Clinical Oncology DepartmentBudapest, Hungary.
RP Radovics, T (reprint author), St. Margit Hospital, Clinical Oncology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 58
EP 59
PG 2
ER

PT J
AU Revesz, M
   Oberna, F
   Takacsi Nagy, Z
AF Revesz, Monika
   Oberna, Ferenc
   Takacsi Nagy, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Revesz, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Revesz, M (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Rittler, D
   Baranyi, M
   Molnar, E
   Garay, T
   Hegedus, L
   Jalsovszky, I
   Timar, J
   Hegedus, B
AF Rittler, Dominika
   Baranyi, Marcell
   Molnar, Eszter
   Garay, Tamas
   Hegedus, Luca
   Jalsovszky, Istvan
   Timar, Jozsef
   Hegedus, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rittler, Dominika] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Baranyi, Marcell] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Molnar, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Hegedus, Luca] University Duisburg-Essen, Ruhrlandklinik, Department of Thoracic SurgeryEssen, Germany.
   [Jalsovszky, Istvan] Lorand Eotvos University, Institute of Organic ChemistryBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Rittler, D (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Rona, �
   Herczeg, A
   Remenar, �
   Godeny, M
AF Rona, Agnes
   Herczeg, Adrienn
   Remenar, Eva
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rona, Agnes] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Herczeg, Adrienn] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Rona, � (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 59
EP 60
PG 2
ER

PT J
AU Rubovszky, G
   Matrai, Z
   Szoke, J
   Budai, B
AF Rubovszky, Gabor
   Matrai, Zoltan
   Szoke, Janos
   Budai, Barna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Rubovszky, G (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Rzepiel, A
   Kutszegi, N
   Gezsi, A
   Cs. Sagi, J
   Egyed, B
   Horvath, A
   Zombori, M
   F. Semsei, �
   Erdelyi, D
AF Rzepiel, Andrea
   Kutszegi, Nora
   Gezsi, Andras
   Cs. Sagi, Judit
   Egyed, Balint
   Horvath, Anna
   Zombori, Mariann
   F. Semsei, Agnes
   Erdelyi, Daniel
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Rzepiel, Andrea] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Kutszegi, Nora] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Gezsi, Andras] Magyar Tudomanyos Akademia- Semmelweis Egyetem, Immun-Proteogenomikai Extracellularis Vezikula KutatocsoportBudapest, Hungary.
   [Cs. Sagi, Judit] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Egyed, Balint] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Horvath, Anna] Budapest University of Technology and EconomicsBudapest, Hungary.
   [Zombori, Mariann] Heim Pal Children's HospitalBudapest, Hungary.
   [F. Semsei, Agnes] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Rzepiel, A (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 60
EP 60
PG 1
ER

PT J
AU Savolt, �
   Cserni, G
   Lazar, Gy
   Maraz, R
   Kelemen, P
   Gyorffy, B
   Matrai, Z
AF Savolt, Akos
   Cserni, Gabor
   Lazar, Gyorgy
   Maraz, Robert
   Kelemen, Peter
   Gyorffy, Balazs
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Kelemen, Peter] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Gyorffy, Balazs] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Savolt, � (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 60
EP 61
PG 2
ER

PT J
AU Schipp, I
   Parajsz, G
   Al-Farhat, Y
AF Schipp, Ildiko
   Parajsz, Gabor
   Al-Farhat, Yousuf
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schipp, Ildiko] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
   [Parajsz, Gabor] Tolnai Megyei Balassa Janos Korhaz, Tudogyogyaszati OsztalySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Schipp, I (reprint author), Tolna Megyei Balassa Janos Korhaz, Onkologiai Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Schvarcz, Cs
   Danics, L
   Kaucsar, T
   Vancsik, T
   Krenacs, T
   Benyo, Z
AF Schvarcz, Csaba
   Danics, Lea
   Kaucsar, Tamas
   Vancsik, Tamas
   Krenacs, Tibor
   Benyo, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Schvarcz, Csaba] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Danics, Lea] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Kaucsar, Tamas] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Klinikai Kiserleti Kutato IntezetBudapest, Hungary.
RP Schvarcz, Cs (reprint author), Semmelweis Egyetem, Klinikai Kiserleti Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Stefanovits, N
   Kovacs, P
   Geczi, L
AF Stefanovits, Nora
   Kovacs, Peter
   Geczi, Lajos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Stefanovits, Nora] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Stefanovits, N (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 61
EP 62
PG 2
ER

PT J
AU Susztrik, B
   Vincze, B
   Sinkovics, I
   Kohalmy, K
AF Susztrik, Beatrix
   Vincze, Borbala
   Sinkovics, Istvan
   Kohalmy, Krisztina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Susztrik, Beatrix] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Vincze, Borbala] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
   [Sinkovics, Istvan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kohalmy, Krisztina] National Institute of Oncology, Department of BiochemistryBudapest, Hungary.
RP Susztrik, B (reprint author), National Institute of Oncology, Department of Biochemistry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Szabo, �
   Lahm, E
   Papai, Zs
AF Szabo, Adam
   Lahm, Erika
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Adam] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Szabo, � (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Szabo, E
   Szabo, Zs
   Fejes, Zs
   Nagy, B
   Harda, K
   Szegedi, K
   Halmos, G
AF Szabo, Erzsebet
   Szabo, Zsuzsanna
   Fejes, Zsolt
   Nagy, Bela
   Harda, Kristof
   Szegedi, Krisztian
   Halmos, Gabor
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Erzsebet] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Szabo, Zsuzsanna] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Fejes, Zsolt] University of Debrecen, Faculty of Medicine, Department of Laboratory MedicineDebrecen, Hungary.
   [Nagy, Bela] University of Debrecen, Faculty of Medicine, Department of Laboratory MedicineDebrecen, Hungary.
   [Harda, Kristof] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
   [Szegedi, Krisztian] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Halmos, Gabor] University of Debrecen, Department of Pharmacology and PharmacotherapyDebrecen, Hungary.
RP Szabo, E (reprint author), University of Debrecen, Department of Pharmacology and Pharmacotherapy, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Szabo, Zs
   Csordas, J
   Olah, K
   Szabo, H
   Mahr, K
AF Szabo, Zsolt
   Csordas, Jozsef
   Olah, Katalin
   Szabo, Helga
   Mahr, Karoly
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szabo, Zsolt] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Csordas, Jozsef] Zala Megyei Szent Rafael Korhaz, Altalanos SebeszetZalaegerszeg, Hungary.
   [Olah, Katalin] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Helga] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Szabo, Zs (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Szakacs, O
   Engi, H
   Szmola, R
   Mavrogenis, S
   Szabo, JF
   Geczi, L
   Csuka, O
AF Szakacs, Orsolya
   Engi, Helga
   Szmola, Richard
   Mavrogenis, Stelios
   Szabo, Janos Ferenc
   Geczi, Lajos
   Csuka, Orsolya
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szakacs, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Engi, Helga] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
   [Szmola, Richard] Orszagos Onkologiai Inezet, GasztroenterologiaBudapest, Hungary.
   [Mavrogenis, Stelios] Orszagos Onkologiai Inezet, UrologiaBudapest, Hungary.
   [Szabo, Janos Ferenc] Orszagos Onkologiai Inezet, UrologiaBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Csuka, Orsolya] Orszagos Onkologiai Inezet, Pathogenetikai OsztalyBudapest, Hungary.
RP Szakacs, O (reprint author), Orszagos Onkologiai Inezet, Pathogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 63
EP 64
PG 2
ER

PT J
AU Szalontai, L
   Szavcsur, P
   Simon, P
   Godeny, M
AF Szalontai, Laszlo
   Szavcsur, Peter
   Simon, Peter
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szalontai, Laszlo] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szavcsur, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Simon, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Szalontai, L (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Szanto, E
   Der, �
   Balogh, I
   Simon, M
   Andras, Cs
   Bajusz, �
   Arkosy, P
   Kovacs, �
AF Szanto, Erika
   Der, Adam
   Balogh, Istvan
   Simon, Mihaly
   Andras, Csilla
   Bajusz, Eva
   Arkosy, Peter
   Kovacs, Arpad
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szanto, Erika] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Der, Adam] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Balogh, Istvan] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Simon, Mihaly] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Bajusz, Eva] Kenezy Gyula Egyetemi Korhaz, Onkologia OsztalyDebrecen, Hungary.
   [Arkosy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kovacs, Arpad] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Szanto, E (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Szavcsur, P
   Szalontai, L
   Horvath, B
   Godeny, M
AF Szavcsur, Peter
   Szalontai, Laszlo
   Horvath, Barnabas
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szavcsur, Peter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szalontai, Laszlo] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Horvath, Barnabas] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Szavcsur, P (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Szollosi, R
   Lakatos, G
   Vegh, �
   Tokodi, Zs
   Vajdics, T
   Harisi, R
   Farkas, M
   Demeter, Gy
   Lorincz, P
   Bodoky, Gy
AF Szollosi, Rego
   Lakatos, Gabor
   Vegh, Eva
   Tokodi, Zsofia
   Vajdics, Timea
   Harisi, Revekka
   Farkas, Marianne
   Demeter, Gyula
   Lorincz, Peter
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szollosi, Rego] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lakatos, Gabor] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vegh, Eva] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Tokodi, Zsofia] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vajdics, Timea] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Harisi, Revekka] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Farkas, Marianne] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Demeter, Gyula] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Lorincz, Peter] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Bodoky, Gyorgy] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Szollosi, R (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 64
EP 65
PG 2
ER

PT J
AU Szonyi, M
   Lengyel, E
AF Szonyi, Marta
   Lengyel, Erzsebet
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Szonyi, Marta] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
   [Lengyel, Erzsebet] Bajcsy-Zsilinszky Korhaz RendelointezetBudapest, Hungary.
RP Szonyi, M (reprint author), Bajcsy-Zsilinszky Korhaz Rendelointezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 65
EP 65
PG 1
ER

PT J
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 65
EP 65
PG 1
ER

PT J
AU Sztipits, T
   Meszaros, P
   Duboczki, Zs
   Olah, G
   Wett-Stein, D
   Mersich, T
AF Sztipits, Tamas
   Meszaros, Peter
   Duboczki, Zsolt
   Olah, Gergely
   Wett-Stein, Daniel
   Mersich, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Sztipits, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Meszaros, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Duboczki, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Olah, Gergely] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Wett-Stein, Daniel] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Mersich, Tamas] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Sztipits, T (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 65
EP 66
PG 2
ER

PT J
AU Takacs, K
   Sikter, M
   Papai, Zs
AF Takacs, Klara
   Sikter, Marta
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Takacs, Klara] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Takacs, K (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Tamaskovics, B
   Haussmann, J
   Plettenberg, Ch
   Scheckenbach, K
   Rana, M
   Jaschinski, S
   Budach, W
AF Tamaskovics, Balint
   Haussmann, Jan
   Plettenberg, Christian
   Scheckenbach, Kathrin
   Rana, Majeed
   Jaschinski, Sandra
   Budach, Wilfried
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tamaskovics, Balint] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Haussmann, Jan] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
   [Plettenberg, Christian] Heinrich Heine Egyetem, Ful-Orr-Gegeszeti KlinikaDusseldorf, Germany.
   [Scheckenbach, Kathrin] Heinrich Heine Egyetem, Ful-Orr-Gegeszeti KlinikaDusseldorf, Germany.
   [Rana, Majeed] Heinrich Heine Egyetem, Maxillofacialis es Szajsebeszeti KlinikaDusseldorf, Germany.
   [Jaschinski, Sandra] Heinrich Heine University, Institute of PathologyDusseldorf, Germany.
   [Budach, Wilfried] Heinrich Heine University, Department of Nuclear MedicineDusseldorf, Germany.
RP Tamaskovics, B (reprint author), Heinrich Heine University, Department of Nuclear Medicine, Dusseldorf, Germany.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 66
EP 66
PG 1
ER

PT J
AU Toth, EJ
   Kovacs, E
   Bidlek, M
   Szalontai, L
   Godeny, M
AF Toth, Eszter Judit
   Kovacs, Eszter
   Bidlek, Maria
   Szalontai, Laszlo
   Godeny, Maria
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toth, Eszter Judit] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kovacs, Eszter] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Bidlek, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Szalontai, Laszlo] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Godeny, Maria] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Toth, EJ (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 66
EP 67
PG 2
ER

PT J
AU Toke, J
   Reismann, P
   Jakab, Zs
   Micsik, T
   Doros, A
   Kiss, R
   Szucs, N
   Sarman, B
   Pusztai, P
   Nagy, G
   Horanyi, J
   Szlavik, R
   Huszty, G
   Piros, L
   Lohinszky, J
   Borka, K
   Laki, A
   Varga, Zs
   Sapi, Z
   Igaz, P
   Toth, M
AF Toke, Judit
   Reismann, Peter
   Jakab, Zsuzsa
   Micsik, Tamas
   Doros, Attila
   Kiss, Robert
   Szucs, Nikolette
   Sarman, Beatrix
   Pusztai, Peter
   Nagy, Geza
   Horanyi, Janos
   Szlavik, Rezso
   Huszty, Gergely
   Piros, Laszlo
   Lohinszky, Julia
   Borka, Katalin
   Laki, Andras
   Varga, Zsolt
   Sapi, Zoltan
   Igaz, Peter
   Toth, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Toke, Judit] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Reismann, Peter] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Jakab, Zsuzsa] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Micsik, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Doros, Attila] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Kiss, Robert] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Szucs, Nikolette] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Sarman, Beatrix] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Pusztai, Peter] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Nagy, Geza] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Horanyi, Janos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Szlavik, Rezso] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Huszty, Gergely] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Piros, Laszlo] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Lohinszky, Julia] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Laki, Andras] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Varga, Zsolt] Semmelweis University, Department of Radiology and OncotherapyBudapest, Hungary.
   [Sapi, Zoltan] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Igaz, Peter] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
   [Toth, Miklos] Semmelweis University, 2nd Department of Internal MedicineBudapest, Hungary.
RP Toke, J (reprint author), Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Tokes, AM
   Pollner-Szundi, Cs
   Sztupinszky, Zs
   Vari-Kakas, I�
   Molnar, B�
   Madaras, L
   Kovacs, A
   Kulka, J
AF Tokes, Anna Maria
   Pollner-Szundi, Csilla
   Sztupinszky, Zsofia
   Vari-Kakas, Istvan Akos
   Molnar, Bela Akos
   Madaras, Lilla
   Kovacs, Attila
   Kulka, Janina
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Tokes, Anna Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Pollner-Szundi, Csilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Sztupinszky, Zsofia] Danish Cancer Society Research Center, Translational Cancer GenomicsCopenhagen, Denmark.
   [Vari-Kakas, Istvan Akos] Universitatea Oradea, Faculty of Electrical Engineering and Information TechnologyOradea, Romania.
   [Molnar, Bela Akos] Semmelweis University, 1st Department of SurgeryBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kovacs, Attila] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Tokes, AM (reprint author), Semmelweis University, 2nd Department of Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 67
EP 67
PG 1
ER

PT J
AU Ujhelyi, M
   Szollar, A
   Polgar, Cs
   Olah, E
   Pukancsik, D
   Rubovszky, G
   Udvarhelyi, N
   Kovacs, T
   Savolt, �
   Kenessey, I
   Matrai, Z
AF Ujhelyi, Mihaly
   Szollar, Andras
   Polgar, Csaba
   Olah, Edit
   Pukancsik, David
   Rubovszky, Gabor
   Udvarhelyi, Nora
   Kovacs, Tibor
   Savolt, Akos
   Kenessey, Istvan
   Matrai, Zoltan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Szollar, Andras] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Pukancsik, David] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Kovacs, Tibor] Guy’s and St Thomas’s Hospitals NHS Foundation Trust, Department of Breast SurgeryLondon, UK.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Ujhelyi, M (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Valikovics, AK
   Landherr, L
AF Valikovics, Aniko Katalin
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Valikovics, Aniko Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Valikovics, AK (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Varga, A
   Alzubi, A
   Mehes, M
AF Varga, Antonia
   Alzubi, Ali
   Mehes, Monika
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Antonia] Oroshazi Korhaz, Klinikai OnkologiaOroshaza, Hungary.
   [Alzubi, Ali] Oroshazi Korhaz, Klinikai OnkologiaOroshaza, Hungary.
   [Mehes, Monika] Oroshazi Korhaz, Transzfuzios OsztalyOroshaza, Hungary.
RP Varga, A (reprint author), Oroshazi Korhaz, Klinikai Onkologia, Oroshaza, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 68
EP 68
PG 1
ER

PT J
AU Varga, E
   Andras, Cs
   Arokszallasi, A
   Kanyari, Zs
   Toth, J
   Bocskai, P
   Arkosy, P
AF Varga, Eniko
   Andras, Csilla
   Arokszallasi, Anita
   Kanyari, Zsolt
   Toth, Judit
   Bocskai, Pal
   Arkosy, Peter
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Eniko] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Andras, Csilla] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Arokszallasi, Anita] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Kanyari, Zsolt] University of Debrecen, Medical and Health Science Centre, 1st Department of SurgeryDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Bocskai, Pal] Kenezy Teaching Hospital, Department of PathologyDebrecen, Hungary.
   [Arkosy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Varga, E (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 68
EP 69
PG 2
ER

PT J
AU Varga, L
   Maraz, A
AF Varga, Linda
   Maraz, Aniko
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Vegvary, Z
   Gal, V
   Koszo, R
   Banyai, �
   Fodor, E
   Nagy, Z
   Varga, Z
   Kalmar, L
   Nagy, B
   Terhes, G
   Kahan, Zs
AF Vegvary, Zoltan
   Gal, Viorica
   Koszo, Renata
   Banyai, Eva
   Fodor, Emese
   Nagy, Zoltan
   Varga, Zoltan
   Kalmar, Laszlo
   Nagy, Bence
   Terhes, Gabriella
   Kahan, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gal, Viorica] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Banyai, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Fodor, Emese] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kalmar, Laszlo] University of Szeged, Department of Obstetrics and GynaecologySzeged, Hungary.
   [Nagy, Bence] University of Szeged, Department of PathologySzeged, Hungary.
   [Terhes, Gabriella] University of Szeged, Albert Szent-Gyorgyi Clinical Centre, Institute of Clinical MicrobiologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Vegvary, Z (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 69
EP 69
PG 1
ER

PT J
AU Virga, J
   Szivos, L
   Toth, P
   Toth, J
   Bognar, L
   Arkosy, P
   Klekner, �
AF Virga, Jozsef
   Szivos, Laszlo
   Toth, Peter
   Toth, Judit
   Bognar, Laszlo
   Arkosy, Peter
   Klekner, Almos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Virga, Jozsef] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szivos, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Toth, Peter] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Bognar, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Arkosy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
RP Virga, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 69
EP 70
PG 2
ER

PT J
AU Vityi, T
   Muller, Z
   Szucs, M
   Salamon, F
   Beganyi, N
   Gorgey, Cs
AF Vityi, Tamas
   Muller, Zoltan
   Szucs, Milan
   Salamon, Ferenc
   Beganyi, Nora
   Gorgey, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Vityi, Tamas] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Muller, Zoltan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Szucs, Milan] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Beganyi, Nora] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Gorgey, Csaba] Uzsoki University Teaching Hospital, Department of ENT and Head-Neck SurgeryBudapest, Hungary.
RP Vityi, T (reprint author), Uzsoki University Teaching Hospital, Department of ENT and Head-Neck Surgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Volgyesi, T
   Fabianne Kiss, Sz
AF Volgyesi, Tilda
   Fabianne Kiss, Szilvia
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Volgyesi, Tilda] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Fabianne Kiss, Szilvia] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
RP Volgyesi, T (reprint author), National Institute of Oncology, Center of Radiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 70
EP 70
PG 1
ER

PT J
AU Wenczl, M
AF Wenczl, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wenczl, Miklos] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
RP Wenczl, M (reprint author), Vas Megyei Markusovszky Korhaz, Onkoradiologia, Szombathely, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 70
EP 71
PG 2
ER

PT J
AU Wettstein, D
   Olah, G
   Sztipits, T
   Duboczki, Zs
   Meszaros, P
   Mersich, T
AF Wettstein, Daniel
   Olah, Gergely
   Sztipits, Tamas
   Duboczki, Zsolt
   Meszaros, Peter
   Mersich, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Wettstein, Daniel] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Olah, Gergely] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Sztipits, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Duboczki, Zsolt] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Peter] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
RP Wettstein, D (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Zolcsak, Z
   Katona, Cs
   Horvath, DK
   Futo, I
   Klinko, T
   Hegedus, L
   Szalai, T
   Landherr, L
AF Zolcsak, Zita
   Katona, Csilla
   Horvath, Dorottya Katalin
   Futo, Ildiko
   Klinko, Timea
   Hegedus, Laszlo
   Szalai, Tibor
   Landherr, Laszlo
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
C1 [Zolcsak, Zita] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Katona, Csilla] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Horvath, Dorottya Katalin] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Futo, Ildiko] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Klinko, Timea] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Hegedus, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Szalai, Tibor] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Zolcsak, Z (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2019
VL 63
IS 5
BP 71
EP 71
PG 1
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular basis of hereditary cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer susceptibility; inheritance; oncosuppressor gene; oncogene
ID cancer susceptibility; inheritance; oncosuppressor gene; oncogene
AB Cancer susceptibility but not specific cancer types can be inherited. This susceptibility(ies) is due to inherited germline mutations of key genes of the controllers of genome integrity, translational control, the cell cycle regulation or even the tumor vascularization. Cancer susceptibility can be manifested in various forms of specific syndromes, each associated with different alterations of genes. Most of these genes are tumor suppressors, and the mutations affect one or both alleles. Interestingly, inherited mutations of oncogenes resulting in cancer susceptibility are much rarer, typically affect only one allele, and the inheritance is dominant. However, cancer susceptibility is influenced not only by high penetrance gene defects but also by inherited low penetrance gene mutations, complicating the effective identification of affected individuals and their families.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Muller C, Matthews L, Kupfer SS, Weiss JM. Effective identification of Lynch syndrome in gastroenterology. Curr Treat Opt Gastroenterol 17:666−680, 2019
   Ma H, Brosens LAAA, Offenhaus GJA, et al. Pathology and genetics of hereditary colorectal cancer. Pathology 50:49−59, 2018
   Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 16:110−120, 2016
   Correa H. Li-Fraumeni syndrome. J Pediatr Genet 5:84−86, 2016
   Ferri D, Oriolo D, Botta E. Heterogeneity and overlaps in nucleotide excision repair disorders. Clin Genet 97:12−24, 2020
   Tian P, Cheng X, Zhao Z, et al. Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing. Pathol Oncol Res, 2019,, DOI  10.1007/s12253-019-00771-5
   Velez-Cruz R, Johnson DG. The retinoblastoma tumor suppressor: pushing back against genome instability on multiple fronts. Int J Mol Sci 18:E1776, 2017
   Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations. Ann Rev Med, 2019,, DOI  10.1146/annurev-med-052218-125823
   Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am 103:1035−1054, 2019
   Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing and management of hereditary melanoma. Cancer Metastasis Rev 36:77−90, 2017
   Timar J, Patocs A. A tudo es a gesztrointesztinum neuroendokrin daganatainak genetikaja: hasonlosagok es kulonbsegek. Magy Onkol 62:77−82, 2018
   Kim E, Zschiedrich S. Renal cell carcinoma in von Hippel-Lindau disease. From tumor genetics to novel therapeutic strategies. Front Pediatr 6:16, 2018
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 7
EP 11
PG 5
ER

PT J
AU Kahan, Zs
AF Kahan, Zsuzsanna
TI Medical treatment options in BRCA-associated cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE BRCA; targeted therapy; inherited cancer syndrome; PARP inhibitors; platinum-based chemotherapy
ID BRCA; targeted therapy; inherited cancer syndrome; PARP inhibitors; platinum-based chemotherapy
AB Germinal or somatic mutations of the BRCA genes may serve as therapeutic targets. Deficient functioning of the BRCA genes render the cancer vulnerable to such therapeutic interventions as chemotherapy with DNA-targeted agents and PARP inhibitors targeting DNA repair capacity. Although BRCA mutations may be detected in a large variety of cancers, the mentioned specific therapies are efficient in the so called BRCA-associated cancers only including ovarian, breast, pancreatic, prostate cancers and the rare uterine sarcomas. While in ovarian and prostate carcinomas both germinal and somatic, in breast and pancreatic cancers exclusively germinal, and in uterine sarcomas mostly somatic mutations specify the tumor as BRCA-dependent; platinum-sensitivity in ovarian cancer may replace BRCA testing by indicating the presence of frequent DNA repair deficiency. Platinum-based chemotherapy is frequently efficient in BRCA-dependent cancers, while PARP inhibitors yet registered for ovarian, breast and pancreatic cancers bring paradigm change in the treatment of ovarian cancer and provide an additional treatment option of the others.
C1 [Kahan, Zsuzsanna] University of Szeged, Department of Oncotherapy, Koranyi fasor 12.Szeged, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
EM kahan.zsuzsanna@med.u-szeged.hu
CR Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792, 1995
   Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71, 1994
   Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68–78, 2011
   Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 158:119–125, 2005
   Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408, 1997
   Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271, 1995
   Kuchenbaecker KB, Hopper JL, Barnes DR. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc 317:2402–2416, 2017
   Jonsson P, Bandlamudi C, Cheng ML, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature 571:576–579, 2019
   Manickam K, Buchanan AH, Schwartz MLB, et al. Exome sequencing- based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Network Open 1:e182140, 2018
   Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 355:1152–1158, 2017
   Taylor KN, Eskander RN. PARP inhibitors in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov 13:145–158, 2018
   Gourley C, Balmana J, Ledermann JA, et al. Moving from poly, ADP-ribose, polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol 37:2257−2269, 2019
   Nicolas E, Bertucci F, Sabatier R, Goncalves A. Targeting BRCA deficiency in breast cancer: What are the clinical evidences and the next perspectives? Cancers, Basel, 10:12, 2018
   Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:3764–3777, 2009
   Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019,, DOI  10.1001/jamaoncol.2019.1048
   Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019,, DOI  10.1001/jamaoncol. 2019.1029
   Adashek JJ, Jain RK, Zhang J. Clinical development of PARP inhibitors in treating metastatic castration-resistant prostate cancer. Cells 8:8, 2019
   George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 14:284−296, 2017
   Staropoli N, Ciliberto D, Del Giudice T, et al. The Era of PARP inhibitors in ovarian cancer: „Class Action” or not? A systematic review and meta-analysis. Crit Rev Oncol Hematol 131:83−89, 2018
   Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget 8:285−302, 2017
   Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 6:CD007414, 2013
   Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose, polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245−251, 2010
   Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose, polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372−379, 2012
   Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 12:852−861, 2011
   Tomai F, Bardhi E, Di Pinto A. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev 80:101909, 2019
   Jorge S, Swisher EM, Norquist BM, et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep 29:113−117, 2019
   Labidi-Galy SI, de La Motte Rouge T, Derbel O, et al. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol 155:262−269, 2019
   Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381:2403−2415, 2019
   Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416−2428, 2019
   Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391−2402, 2019
   Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495−2505, 2018
   Coleman RL, Fleming GF, Brady MF et al. VELIA/GOG-3005: Integration of veliparib, V, with front-line chemotherapy and maintanence in women with high-grade serous carcinoma of ovarian, Fallopian tube, or primar peritoneal origin, HGSC). Ann Oncol 30(suppl_5):v851−v934, 2019
   Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154−2164, 2016
   Garutti M, Pelizzari G, Bartoletti M, et al. Platinum salts in patients with breast cancer: A focus on predictive factors. Int J Mol Sci 20:3390, 2019
   Telli ML, Hellyer J, Audeh W, et al. Homologous recombination deficiency, HRD, status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat 168:625−630, 2018
   Paluch-Shimon S, Friedman E, Berger R, et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Res Treat 157:157−165, 2016
   Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33:1902−1909, 2018
   Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24:628−637, 2018
   Kahan Zs, Tari G, Enyedi M, Haracska L. Hogyan befolyasolja a BRCA-statusz az emlorak ellatasat 2019-ben? Klin Onkol 6:13−22, 2019
   Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498−2506, 2018
   Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose, polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235−244, 2010
   Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther 12:5177−5187, 2019
   Turner NC, Telli ML, Rugo HS, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations, ABRAZO). Clin Cancer Res 25:2717−2724, 2019
   Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523−533, 2017
   Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753−763, 2018
   Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 29:1939−1947, 2018
   Poggio F, Bruzzone M, Ceppi M, et al. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open 3:e000361, 2018
   Dieras VC, Han HS, Kaufman B, et al. Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Ann Oncol 30, suppl_5):v851−v934, 2019
   Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38:388−394, 2020
   Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124−3129, 2015
   Salo-Mullen EE, O’Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 121:4382−4388, 2015
   Lowery MA, Wong W, Jordan EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst 110:1067−1074, 2018
   Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 122:333−339, 2020
   Rebelatto TF, Falavigna M, Pozzari M, et al. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes, BRCA, 1 and 2-mutated pancreatic ductal adenocarcinoma, PDAC, patients? A systematic review and meta-analysis. Cancer Treat Rev 80:101895, 2019
   Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16:1397−1402, 2011
   Lowery MA, Kelsen DP, Capanu M, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 89:19−26, 2018
   O’Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 124:1374−1382, 2018
   O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020,, DOI  10.1200/JCO.19.02931
   Ohmoto A, Yachida S, Morizane C. Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci 20:pii: E561, 2019
   Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017,, DOI  10.1200/PO.17.00029
   Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697−1708, 2015
   Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations, TOPARP- B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21:162−174, 2020
   Abida W, Bryce AH, Vogelzang NJ, et al. Results from TRITON2: Phase 2 study of rucaparib in patients, pts, with metastatic castration-resistant prostate cancer, mCRPC, associated with homologous recombination repair, HRR, gene alteration. Ann Oncol 29(suppl_8): viii271-viii302, 2018
   Seligson ND, Kautto EA, Passen EN, et al. BRCA1/2 functional loss defines a targetable subset in leiomyosarcoma. Oncologist 24:973−979, 2019
   Laitman Y, Michaelson-Cohen R, Levi E, et al. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer 125:698–703, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 13
EP 24
PG 12
ER

PT J
AU Patocs, A
AF Patocs, Attila
TI Molecular genetic methods used in diagnosis of hereditary cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hereditary cancer syndromes; targeted genetic test; next generation sequencing
ID hereditary cancer syndromes; targeted genetic test; next generation sequencing
AB The technical developments lead to revolution and speed-up of molecular genetic diagnostics of hereditary cancer syndromes. In those apparently sporadic, solid tumors where the chance of inheritance is higher than 10%, the molecular genetic analysis is indicated. Nowadays these tests are performed using next generation sequencing technologies which allow parallel testing of multiple genes. However, in well-defined cancer syndromes where the clinical presentation clearly suggests the diagnosis and the disease is monogenic, targeted testing is still recommended. Clinical indication of molecular genetic testing and its interpretation is a complex procedure; all steps are regulated. Beside ethical and legal aspects both the laboratory, bioinformatic steps and the interpretation of the results require strong supervision and control. The current review summarizes the genetic alterations responsible for hereditary cancer syndromes and molecular genetic methods which are used during diagnostics in everyday practice.
C1 [Patocs, Attila] Hungarian Academy of Sciences and Semmelweis University, Hereditary Endocrine Tumors Research GroupBudapest, Hungary.
RP Patocs, A (reprint author), Hungarian Academy of Sciences and Semmelweis University, Hereditary Endocrine Tumors Research Group, Budapest, Hungary.
EM patocs.attila@med.semmelweis-univ.hu
CR Butz H, Patocs A. Brief summary of the most important molecular genetic methods, PCR, qPCR, microarray, next-generation sequencing, etc.). Exp Suppl 111:33–52, 2019
   Buermans HPT, den Dunnen JT. Next generation sequencing technology: Advances and application. Biochim Biophys Acta 1842:1932–1941, 2014
   Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 475:348–352, 2011
   Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53–59, 2008
   Merriman B, Rothberg JM. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis 3333:3397–3417, 2012
   Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 106:19096−19101, 2009
   van El CG, Cornel MC, Borry P, et al. ESHG Public and Professional Policy Committee. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 21:580−584, 2013
   Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424, 2015
   Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 17:552−555, 2019
   Singer CF, Balmana J, Burki N, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer – an European consensus statement and expert recommendations. Eur J Cancer 106:54–60, 2019
   Bonache S, Esteban I, Moles-Fernandez A, et al. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. J Cancer Res Clin Oncol 144:2495−2513, 2018
   Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497−506, 2014
   Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 20:1515– 1521, 2018
   Friez MJ. Attention: Direct-To-Consumer patrons: Proceed with caution. Genet Med 20:1508−1509, 2018
   Gulland A. All patients with colorectal cancer should be tested for genetic condition, NICE advises. BMJ 356:j998, 2017
   Sarkadi B, Grolmusz VK, Butz H, et al. Molekularis genetikai vizsgalatok az orokletes endokrinologiai tumor szindromak klinikai diagnosztikajaban. Orv Hetil 159:285–292, 2018
   Sarkadi B, Patocs A. Hereditary diseases predisposing to pheochromocytoma, VHL, NF-1, paraganglioma syndromes, and novel genes). Exp Suppl 111:129–147, 2019
   https://www.agilent.com/cs/library/datasheets/public/Performance% 20characteristics%20BRCA%20MASTR%20Plus%20Dx%205991- 8423ENN.pdf
   Rattenberry E, Vialard L, Yeung A, et al. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98:E1248−1256, 2013
   Welander J, Andreasson A, Juhlin CC, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 99:E1352−1360, 2014
   Vrijenhoek T, Kraaijeveld K, Elferink M, et al. Next-generation sequencing- based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet 23:1142–1150, 2015
   Gergics P, Toke J, Szilagyi A, et al. A nagy gendeletiok kimutatasanak modszerei es alkalmazasuk egyes orokletes betegsegekben. Orv Hetil 150:2258−2264, 2009
   https://www.mrcholland.com/product/P002/491
   Patocs A. Multiplex endokrin neoplasiak es egyeb orokletes endokrin tumor szindromak. In: Az endokrin es anyagcsere-betegsegek gyakorlati kezikonyve. Szerk. Leovey A, Nagy VE, Paragh G, Racz K, Medicina Konyvkiado, Budapest 2011, pp. 447−464
   Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99:1915−1942, 2014
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 25
EP 31
PG 7
ER

PT J
AU Uhlyarik, A
AF Uhlyarik, Andrea
TI Therapeutic aspects of inherited colorectal cancer syndromes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE colorectal carcinoma; inherited syndrome; screening; MSI/MMR; immunotherapy
ID colorectal carcinoma; inherited syndrome; screening; MSI/MMR; immunotherapy
AB Inherited colorectal cancer syndromes account for 6–10% of all cases. The diagnosis of the polypoid forms is easier due to their phenotypes, compared to the non-polypoid cases. The evaluation of the MSI/MMR status of the already developed colorectal cancer cases could help in the recognition and screening of the latter forms. This screening method is much more sensitive than that solely based on family anamnestic data. The MSI/MMR status of the tumor also could help in adjuvant or palliative treatment planning, therefore it is recommended in all colorectal cancer cases. Here we review the available information regarding the inherited colorectal cancer syndromes, and the role of MSI/MMR status in the management of colorectal cancers.
C1 [Uhlyarik, Andrea] Semmelweis University, 2nd Department of Internal Medicine, Szentkiralyi u. 46., 1088 Budapest, Hungary.
RP Uhlyarik, A (reprint author), Semmelweis University, 2nd Department of Internal Medicine, 1088 Budapest, Hungary.
EM uhlyarik.andrea@med.semmelweis-univ.hu
CR Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 247:574−588, 2019
   Halvarsson B, Anderson H, Domanska K, et al. Clinicopathologic factors identify sporadic mismatch repair–defective colon cancers. Am J Clin Pathol 129:238−244, 2008
   Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 138:2044–2058, 2010
   Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127:444–451, 2004
   Win AK, Dowty JG, Cleary SP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208–1211, 2014
   Campos FG, Figueiredo MN, Martinez CA. Colorectal cancer risk in hamartomatous polyposis syndromes. World J Gastrointest Surg 7:25–32, 2015
   Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 5:751−756, 1998
   Stjepanovic N, Moreira L, Carneiro F, et al. On behalf of the ESMO Guidelines Committee. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1558–1571, 2019
   Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 348:919– 932, 2003
   Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–1985, 2005
   Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087, 2011
   NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 3.2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
   Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054–1059, 2002
   Samadder NJ, Neklason DW, Boucher KM, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 315:1266–1275, 2016
   NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
   Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol 28:466−474, 2010
   Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266–273, 2009
   Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797−1806, 2004
   Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257, 2003
   Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226, 2010
   Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261−1270, 2011
   NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version1.2020. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
   Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability high colorectal cancer, CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–1191, 2017
   Overman MJ, Lonardi S, Wong KYM, Lenz HJ. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability- high metastatic colorectal cancer. J Clin Oncol 36:773–779, 2018
   Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab, NIVO, + low-dose ipilimumab, IPI, as first-line, 1L, therapy in microsatellite instability-high/DNA mismatch repair deficient, MSI-H/dMMR, metastatic colorectal cancer, mCRC): Clinical update. J Clin Oncol 37(15_suppl):3521−3521, 2019
   https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/ 125554s070lbl. pdf
   https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/ 125514s040lbl.pdf
   Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520, 2015
   Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 38:11−19, 2020
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 32
EP 37
PG 6
ER

PT J
AU Ripszam, R
   Melegh, B
   Hadzsiev, K
AF Ripszam, Reka
   Melegh, Bela
   Hadzsiev, Kinga
TI When is it necessary to refer a child with cancer to genetic counseling?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Guideline
DE oncogenetic counseling; childhood cancer; professional recommendation
ID oncogenetic counseling; childhood cancer; professional recommendation
AB In the past few years there is an emerging need for clinical genetics counseling in the case of malignant diseases as well. For these reasons a novel professional recommendation has been developed for oncogenetic counseling, whose publication is in progress. In nearly 10% of childhood cancers there is an underlying tumor predisposition syndrome, but this value is thought to be underestimated. Due to the treatment of these cancers and the risk of a possible new developing tumor, genetic counseling is strongly recommended in these children, to establish a correct diagnosis and to evaluate the tumor risk of family members. In this article we summarize the indication for genetic counseling referral in the case of childhood cancers, in which we especially have to pay attention to family anamnesis, the pathology of the tumor, multiple primary tumors, congenital anomalies and dysmorphic features, as well as excessive treatment toxicity.
C1 [Ripszam, Reka] University of Pecs, Department of Medical Genetics and Child Development, Jozsef Attila u. 7., 7623 Pecs, Hungary.
   [Melegh, Bela] University of Pecs, Department of Medical Genetics and Child Development, Jozsef Attila u. 7., 7623 Pecs, Hungary.
   [Hadzsiev, Kinga] University of Pecs, Department of Medical Genetics and Child Development, Jozsef Attila u. 7., 7623 Pecs, Hungary.
RP Hadzsiev, K (reprint author), University of Pecs, Department of Medical Genetics and Child Development, 7623 Pecs, Hungary.
EM hadzsiev.kinga@pte.hu
CR Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33:3660−3667, 2015
   Kuhlen M, Taeubner J, Brozou T et al. A. Family-based germline sequencing in children with cancer. Oncogene 38:1367−1380, 2019
   Brozou T, Taeubner J, Velleuer E, et al. Genetic predisposition in children with cancer – affected families’ acceptance of Trio-WES. Eur J Pediatr 177:53−60, 2018
   Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 17:70−87, 2015
   Emberi Eroforrasok Miniszteriuma − Egeszsegugyert Felelos Allamtitkarsag Egeszsegugyi Szakmai Kollegium Egeszsegugyi szakmai iranyelv – A genetikai tanacsadasrol. https://kollegium.aeek.hu/Iranyelvek/Index, megjelenes alatt)
   McCarthy P, LeRoy BS. Facilitating the Genetic Counseling Process: A Practice Manual. Springer International Publishing AG, 2003
   Pakakasama S, Tomlinson GE. Genetic predisposition and screening in pediatric cancer. Pediatr Clin North Am 49:1393−1413, 2002
   Jongmans MC, Loeffen JL, Waanders, E et al. Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. Eur J Med Genet 59:116−125, 2016
   Ripperger T, Bielack SS, Borkhardt A, et al. Childhood cancer predisposition syndromes – A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A 173:1017−1037, 2017
   Postema FAM, Hopman SMJ, Aalfs CM, et al. Childhood tumours with a high probability of being part of a tumour predisposition syndrome; reason for referral for genetic consultation. Eur J Cancer 80:48−54, 2017
   Perrino M, Cooke-Barber J, Dasgupta R, et al. Genetic predisposition to cancer: Surveillance and intervention. Semin Pediatr Surg 28:150858, 2019
   Rao A, Rothman J, Nichols KE. Genetic testing and tumor surveillance for children with cancer predisposition syndromes. Curr Opin Pediatr 20:1−7, 2008
   Villani A, Greer MC, Kalish JM, et al. Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk. Clin Cancer Res 23:e83−e90, 2017
   Postema FAM, Hopman SMJ, Hennekam RC, et al. Consequences of diagnosing a tumor predisposition syndrome in children with cancer: A literature review. Pediatr Blood Cancer 65,, DOI  10.1002/pbc.26718, 2018
   Samuel N, Villani A, Fernandez CV, et al. Management of familial cancer: sequencing, surveillance and society. Nat Rev Clin Oncol 11:723−731, 2014
   McGill BC, Wakefield CE, Vetsch J, et al. „I remember how I felt, but I don’t remember the gene”: Families’ experiences of cancer-related genetic testing in childhood. Pediatr Blood Cancer 66:e27762, 2019
   Kuhlen M, Wieczorek D, Siebert R, et al. How I approach hereditary cancer predisposition in a child with cancer. Pediatr Blood Cancer 66:e27916, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 38
EP 42
PG 38
ER

PT J
AU Kotmayer, L
   Kallay, K
   Bodor, Cs
AF Kotmayer, Lili
   Kallay, Krisztian
   Bodor, Csaba
TI Hereditary haematological malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hereditary genetic alteration; genetic susceptibility; molecular oncohaematology; next-generation sequencing
ID hereditary genetic alteration; genetic susceptibility; molecular oncohaematology; next-generation sequencing
AB The majority of haematological malignancies represent sporadic diseases, but hereditary entities with predisposing genetic alterations have also been described. Diseases of the myeloid and lymphoid cell lineages with genetic predispositions are associated with heterogeneous clinical manifestations, with many symptoms being specific for certain cytogenetic and molecular aberrations. Apart from the myeloid predisposition syndromes with clear Mendelian inheritance patterns, cases with ambiguous predisposing factors are also known, but their role in hereditary leukemogenesis is still poorly understood. The presence of these genetic lesions is usually associated with an increased risk of familial malignancies and often leads to familial disease aggregation. Lymphoid malignancies often lack the disease-associated germline pathogenic variants, with their propensity to familial aggregation being most likely explained by their complex genotype serving as a hereditary base to many sporadic diseases. The heterogeneous clinical features and the large number of potentially affected genes tend to make the diagnosis of hereditary haematological malignancies difficult, however the elevated familial risk caused by predisposing genetic alterations underlines the importance of testing for individuals and families with genetic susceptibility.
C1 [Kotmayer, Lili] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kallay, Krisztian] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Bodor, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM bodor.csaba1@med.semmelweis-univ.hu
CR Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood 133:1071−1085, 2019
   Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. Bosman FT, et al. International Agency for Research on Cancer, Lyon 2017, pp. 587
   Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood 134:960−969, 2019
   Kiraly PA, Kallay K, Marosvari D, et al. Familiaris myelodysplasias szindroma es akut myeloid leukaemia klinikai es genetikai hattere. Orv Hetil 157:283−289, 2016
   Churpek JE. Familial myelodysplastic syndrome/acute myeloid leukemia. Best Pract Res Clin Haematol 30:287−289, 2017
   Katsumura KR, Bresnick EH, Group GFM. The GATA factor revolution in hematology. Blood 129:2092−2102, 2017
   Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood 129:2070−2082, 2017
   Avellino R, Delwel R. Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation. Blood 129:2083−2091, 2017
   Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 373:1136−1152, 2015
   Obrochta E, Godley LA. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol 31:373−378, 2018
   Radomska HS, Huettner CS, Zhang P, et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18:4301−4314, 1998
   Rafei H, DiNardo CD. Hereditary myeloid malignancies. Best Pract Res Clin Haematol 32:163−176, 2019
   Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113:3088−3091, 2009
   Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 117:6673−6680, 2011
   Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 47:180−185, 2015
   West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/ acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 1310:111−118, 2014
   Bodor C, Renneville A, Smith M, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica 97:890−894, 2012
   Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection, MonoMAC, syndrome. Blood 118:2653−2655, 2011
   Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia, Emberger syndrome). Nat Genet 43:929−931, 2011
   Kotmayer L, Kiss R, Kiraly AP, et al. Familiaris myelodysplasias szindromaban szenvedo csalad genomikus kopiaszam-valtozasainak vizsgalata multiplex ligatiofuggo szondaamplifikacioval. Hematologia-Transzfuziologia 51, 2018
   Kiraly AP, Kallay K, Gango A, et al. Familial acute myeloid leukemia and myelodysplasia in Hungary. Pathol Oncol Res 24:83−88, 2018
   Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol 28:55−68, 2015
   Galera P, Hsu AP, Wang W, et al. Donor-derived MDS/AML in families with germline GATA2 mutation. Blood 132:1994−1998, 2018
   Greaves M. Leukaemia ‚firsts’ in cancer research and treatment. Nat Rev Cancer 16:163−172, 2016
   Passamonti F, Maffioli M, Caramazza D, et al. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget 2:485−490, 2011
   Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861−1869, 2013
   Langabeer SE, Haslam K, Linders J, et al. Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Fam Cancer 13:659−663, 2014
   Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia 28:1357−1360, 2014
   Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 25:5630−5635, 2007
   Malak S, Labopin M, Saint-Martin C, et al. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 49:170−176, 2012
   Meza-Espinoza JP, Vasquez-Jimenez EA, Barajas-Torres RL, et al. BCR/ ABL1 transcripts in healthy individuals: a comparative analysis between first-degree relatives of patients with chronic myelogenous leukemia and subjects without antecedents of the disease. Ann Clin Lab Sci 49:703−709, 2019
   Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 96:367−374, 2011
   Lundberg P, Nienhold R, Ambrosetti A, et al. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood 123:2744−2745, 2014
   Law PJ, Sud A, Mitchell JS, et al. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep 7:41071, 2017
   Vijayakrishnan J, Kumar R, Henrion MY, et al. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 31:573−579, 2017
   Skibola CF, Berndt SI, Vijai J, et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet 95:462−471, 2014
   Sud A, Thomsen H, Law PJ, et al. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun 8:1892, 2017
   Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 9:15−27, 2009
   Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459:712−716, 2009
   Steidl C, Telenius A, Shah SP, et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116:418−427, 2010
   Bandapalli OR, Paramasivam N, Giangiobbe S, et al. Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma. Int J Cancer 143:2076−2078, 2018
   Saarinen S, Aavikko M, Aittomaki K, et al. Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood 118:493−498, 2011
   Ristolainen H, Kilpivaara O, Kamper P, et al. Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing. Br J Haematol 170:428−431, 2015
   Rotunno M, McMaster ML, Boland J, et al. Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene. Haematologica 101:853−860, 2016
   Borchmann S, Engert A. The genetics of Hodgkin lymphoma: an overview and clinical implications. Curr Opin Oncol 29:307−314, 2017
   Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265−2273, 2015
   Egyed B, Kovacs G, Kutszegi N, et al. Uj es hagyomanyos iranyok a gyermekkori akut lymphoblastos leukaemia biologiajaban es ellatasaban. Orv Hetil 159:786−797, 2019
   Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 60:4−12, 2018
   Enciso-Mora V, Hosking FJ, Sheridan E, et al. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 26:2212−2215, 2012
   Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 41:1006−1010, 2009
   Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42:492−494, 2010
   Al-Absi B, Razif MFM, Noor SM, et al. Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 gene polymorphisms to acute lymphoblastic leukemia in a Yemeni population. Genet Test Mol Biomarkers 21:592−599, 2017
   Vijayakrishnan J, Qian M, Studd JB, et al. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nat Commun 10:5348, 2019
   Beuten J, Gelfond JA, Piwkham D, et al. Candidate gene association analysis of acute lymphoblastic leukemia identifies new susceptibility locus at 11p15, LMO1). Carcinogenesis 32:1349−1353, 2011
   Qian M, Xu H, Perez-Andreu V, et al. Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood 133:724−729, 2019
   Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 41:1001−1005, 2009
   Churchman ML, Qian M, Te Kronnie G, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 33:937−948, 2018
   Moriyama T, Metzger ML, Wu G, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol 16:1659−1666, 2015
   Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45:1226−1231, 2013
   Kiss R, Papp G, Krizsan S, et al. Genomikus kopiaszam-elteresek szurese kronikus limfoid leukemiaban multiplex ligaciofuggo szomdaamplifikacioval. Hematologia-Transzfuziologia 51, 2018
   Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910−1916, 2000
   Goldin LR, Slager SL. Familial CLL: genes and environment. Hematology Am Soc Hematol Educ Program 339−345, 2007
   Speedy HE, Kinnersley B, Chubb D, et al. Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood 128:2319−2326, 2016
   Goldin LR, Bjorkholm M, Kristinsson SY, et al. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 94:647−653, 2009
   Babushok DV, Bessler M, Olson TS. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma 57:520−536, 2016
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 43
EP 55
PG 13
ER

PT J
AU Ecker, N
   Papai, Zs
AF Ecker, Nora
   Papai, Zsuzsanna
TI Hereditary cancer predisposition syndromes associated with sarcomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer predisposition syndrome; sarcoma; Li-Fraumeni; Recklinghausen
ID cancer predisposition syndrome; sarcoma; Li-Fraumeni; Recklinghausen
AB Based on our current knowledge, 5-10% of all malignancies are part of hereditary cancer syndromes. Although the increasing diagnostic role of molecular genetic testing makes us able to recognize more hereditary cancer patients, the careful exploration of family and clinical history by physicians is still the most important step for the diagnosis. In our review we deal with mesenchymal tumours associated with hereditary syndromes. Sarcomas comprise only 1% of all malignancies, but they often associate with familiar diseases so they can serve as an indicator of these syndromes. The diagnosis of hereditary cancer predisposition syndromes is essential to ensure appropriate therapy and follow-up for our patients.
C1 [Ecker, Nora] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111., 1062 Budapest, Hungary.
RP Papai, Zs (reprint author), Honved Korhaz, Onkologiai Osztaly, 1062 Budapest, Hungary.
EM zspapai@gmail.com
CR Farid M, Ngeow J. Sarcomas associated with genetic cancer predisposition syndromes: a review. Oncologist 21:1002−1013, 2016
   Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49:684−695, 2013
   Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv268−iv269, 2018
   Poyhonen M, Kytola S, Leisti J. Epidemiology of neurofibromatosis type 1, NF1, in northern Finland. J Med Genet 37:632−636, 2000
   Nagy P, Lahm E, Papai Z. Ritka orokletes daganatok. Magy Onkol 58:94−97, 2014
   Guiraud M, Bouroubi A, Beauchamp R, et al. Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey. Orphanet J Rare Dis 14:286, 2019
   Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44:81−88, 2007
   Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 109:1406−1412, 2007
   Dodd RD, Mito JK, Eward WC, et al. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther 12:1906−1917, 2013
   Hwang IK, Hahn SM, Kim HS, et al. Outcomes of treatment for malignant peripheral nerve sheath tumors: different clinical features associated with neurofibromatosis type 1. Cancer Res Treat 49:717−726, 2017
   Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni syndrome. In: GeneReviews, eds. Adam MP, Ardinger HH, Pagon RA, et al, 1993
   Lohmann DR, Gallie BL. Retinoblastoma. In: GeneReviews, eds. Adam MP, Ardinger HH, Pagon RA, et al, 1993
   Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res 2:15, 2012
   Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771−1779, 2008
   http://sarcomahelp.org/articles/sarcoma-predisposition-syndromes. html
   Righetti AE, Jacomini C, Parra RS, et al. Familial adenomatous polyposis and desmoid tumors. Clinics, Sao Paulo, 66:1839−1842, 2011
   Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res 2:16, 2012
   Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol 27(Suppl 1):S1−16, 2014
   Hameed M, Mandelker D. Tumor syndromes predisposing to osteosarcoma. Adv Anat Pathol 25:217−222, 2018
   Larizza L, Roversi G, Volpi L. Rothmund-Thomson syndrome. Orphanet J Rare Dis 5:2, 2010
   Ishikawa Y, Miller RW, Machinami R, et al. Atypical osteosarcomas in Werner Syndrome, adult progeria). Jpn J Cancer Res 91:1345−1349, 2000
   Flanagan M, Cunniff CM. Bloom Syndrome. In: GeneReviews, eds. Adam MP, Ardinger HH, Pagon RA, et al, 1993
   NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian and Pancreatic, Version 1.2020
   Parshad R, Price FM, Pirollo KF, et al. Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res 136:236−240, 1993
   Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv68−iv78, 2018
   Kays JK, Sohn JD, Kim BJ, et al. Approach to wild-type gastrointestinal stromal tumors. Transl Gastroenterol Hepatol 2018,, DOI  10.21037/ tgh.2018.10.13
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 56
EP 61
PG 6
ER

PT J
AU Vizin, G
   Farkas, K
AF Vizin, Gabriella
   Farkas, Kinga
TI Possibilities of cognitive behavioral therapy in the oncological care
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE oncology; psycho-oncology; behavior therapy; cognitive therapy; mindfulness
ID oncology; psycho-oncology; behavior therapy; cognitive therapy; mindfulness
AB Cancer is a huge psychological difficulty both for the patient and the caregivers. Patients often suffer from hopelessness, helplessness, depression, anxiety or other psychological disturbances. Although the cognitive behavioral interventions (cognitive behavioral therapy, mindfulness) are evidence based, short, time-limited, focused treatments for patients with cancer, in Hungary there are only little evidence and experiences about application of cognitive behavioral methods in the oncological care. The main goal of this review to provide a survey about the cognitive behavioral theories and the international practical experiences in the field of oncological care, furthermore, to propose to apply these structured, directive, problem-focused interventions among patients with cancer to professionals which are able to decrease distress of patients or caregivers and these methods are able to treat the mental disorders, such as anxiety, depression, PTSD, which usually relate with cancer.
C1 [Vizin, Gabriella] Eotvos Lorand Tudomanyegyetem PPK, Klinikai Pszichologia es Addiktologia Tanszek, Izabella utca 46., 1064 Budapest, Hungary.
   [Farkas, Kinga] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Vizin, G (reprint author), Eotvos Lorand Tudomanyegyetem PPK, Klinikai Pszichologia es Addiktologia Tanszek, 1064 Budapest, Hungary.
EM vizin.gabriella@ppk.elte.hu
CR Degi Cs. Pszichoonkologia. Orvoskepzes 89:374−380, 2014
   Risko A. Az onkopszichológia első 25 éve az Országos Onkológiai Intézetben: előzmények és események, 1988–2013). Magy Onkol 59:241−250, 2015
   Kovacs P, Koncz Zs, Peti J, et al. Az onkopszichológiai rehabilitáció terü- letei és kihívásai. Magy Onkol 61:284−291, 2017
   Holland JC, Weiss TR. History of psycho-oncology. In: Psycho-oncology. 2nd ed. Eds. Holland J, Breitbart W, Jacobsen P, et al. Oxford University Press, New York 2010, pp. 3−12
   Edelman S, Craig A, Kidman AD. Can psychotherapy increase the survival time of cancer patients? J Psychosom Res 49:149−156, 2000
   Risko A, Tari A. Egyeni pszichoterapia. In: Onkopszichologia a gyakorlatban 2. online kiadas II./II. kötet. Eds. Horti J, Risko A. 2017, pp. 438-444 http://mek.oszk.hu/16600/16625/pdf/16625_2.pdf
   Raingruber B. The effectiveness of psychosocial interventions with cancer patients: an integrative review of the literature, 2006–2011). ISRN Nurs 2011:638218, 2011
   Rohanszky M, Berenyi K, Fridrik D, et al. Eber, tudatos figyelemre epulo, a rakbetegseggel valo megkuzdest segito program, MBCR, hatasvizsgalata magyar rakbetegek koreben. Orv Hetil 158:1293−1301, 2017
   Beck AT, Rush AJ, Shaw BF, Emery G. A depresszio kognitiv terapiaja. Animula Kiado, Budapest 2001
   Perczel-Forintos D. A kognitiv terapia standard modszerei es hatotenyezoi. In: Kognitiv viselkedesterapia. Eds. Perczel-Forintos D, Morotz K. Medicina Kiado, Budapest 2019
   DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62:409−416, 2005
   Hunot V, Churchill R, Silva de Lima M, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 1:CD001848, 2007
   Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 1:368−376, 2014
   Hawton KE, Salkovskis PM, Kirk JE, et al. Cognitive behaviour therapy for psychiatric problems: A practical guide. Oxford University Press, New York 1989
   Morotz K. A viselkedesterapia modszerei. In: Kognitiv viselkedesterapia. Eds. Perczel-Forintos D, Morotz K. Medicina Kiado, Budapest 2019
   Padesky C, Mooney K. Clinical tip: presenting the cognitive model to clients. International Cognitive Therapy Newsletter 6:13−14, 1990
   Antal-Uram D, Harsanyi L, Perczel-Forintos D. Az alacsony intenzitasu, bizonyitottan hatekony kognitiv viselkedesterapia Crohn-betegsegben. Orv Hetil 159:363−369, 2018
   Young JE, Klosko JS, Weishaar ME. Schema therapy: A practitioner’s guide. Guilford Press, New York 2003., Magyarul: Sematerapia, VIKOTE, 2010)
   Kabat-Zinn J. Mindfulness-based interventions in context: past, present, and future. Clin Psychol 10:144−156, 2003
   National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults, updated edition). British Psychological Society, 2010
   Moorey S. Cognitive therapy. In: Psycho-oncology. 2nd ed. Eds. Holland J, Breitbart W, Jacobsen P, et al. Oxford University Press, New York 2010, pp. 402−407
   Purebl Gy. Alacsony intenzitasu pszichologiai intervenciok a mindennapi orvosi gyakorlatban. Oriold es tarsai Kiado, Budapest 2018
   Moorey S, Greer S. Oxford guide to CBT for people with cancer. Oxford University Press, New York 2012
   Greer S, Watson M. Mental adjustment to cancer: its measurement and prognostic importance. Cancer Surv 6:439−453, 1987
   Watson M, Greer S, Young J, et al. Development of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol Med 18:203−209, 1988
   Schnoll RA, Harlow LL, Stolbach LL, et al. A structural model of the relationships among stage of disease, age, coping, and psychological adjustment in women with breast cancer. Psychooncology 7:69−77, 1998
   Link L, Robbins L, Mancuso C, et al. How do cancer patients who try to take control of their disease differ from those who do not? Eur J Cancer Care 13:219−226, 2004
   Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 28:396−402, 2006
   Menyhart O, Fekete JT, Gyorffy B. Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030. Clin Epidemiol 10:1093−1108, 2018
   Eurostat regional yearbook 2018. European Union, 2018
   Urban R. Az egeszsegpszichologia alapjai. ELTE Eotvos Kiado, Budapest 2017
   van’t Spijker A, Trijsburg RW, Duivenvoorden HJ. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med 59:280−293, 1997
   Degi Cs. Pszichoszocialis kockazati tenyezok szerepe a daganatos megbetegedesekben. In: Magyar lelkiallapot. Ed. Kopp M. Semmelweis Kiado, Budapest 2008, pp. 557−568
   Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284:2907−2911, 2000
   DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101−2107, 2000
   Valente SM, Saunders JM, Cohen MZ. Evaluating depression among patients with cancer. Cancer Pract 2:65−71, 1994
   Goodwin JS, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc 52:106−111, 2004
   Rodin GM, Nolan RP, Katz MR. Depression. In: Textbook of Psychosomatic Medicine. Ed. Levenson JL. American Psychiatric Publishing, Washington, D.C., 2005, pp. 193−218
   Jassim GA, Whitford DL, Hickey A, et al. Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev 5:CD008729, 2015
   Safren SA, Gonzalez J, Soroudi N. Coping with Chronic Illness: A Cognitive- Behavioral Therapy Approach for Adherence and Depression: Therapist Guide. Oxford University Press, New York 2008
   Safren SA, O’Cleirigh CM, Bullis JR, et al. Cognitive behavioral therapy for adherence and depression, CBT-AD, in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol 80:404, 2012
   Loscalzo MJ, Clark KL. The psychosocial context of cancer-related infertility. Cancer Treat Res 138:180−190, 2007
   Rohanszky M, Katonai R, Konkoly Thege B. Magyar daganatos betegek pszichoszocialis allapota. Orv Hetil 155:1024−1032, 2014
   Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin 58:214−230, 2008
   National Collaborating Centre for Mental Health. Depression in adults with a chronic physical health problem. British Psychological Society, 2010
   Coleman N, Hession N, Connolly A. Psycho-oncology best practice guidelines and a service perspective: conceptualizing the fit and towards bridging the gap. Irish J Psychol 32:72−89, 2011
   Piet J, Wurtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: A systematic review and meta-analysis. J Consult Clin Psychol 80:1007−1020, 2012
   Compen F, Bisseling E, Schellekens M, et al. Face-to-face and internet- based mindfulness-based cognitive therapy compared with treatment as usual in reducing psychological distress in patients with cancer: a multicenter randomized controlled trial. J Clin Oncol 36:2413−2421, 2018
   Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 385:1206−1218, 2015
   Susánszky É, Riskó Á. „Élet a betegség után.” Sikeresen kezelt rosszindulatú daganatos betegek életminőségének vizsgálata. In: A magyar népesség életminősége az ezredfordulón. Eds. Kopp M, Kovács ME. Semmelweis Kiadó, Budapest 2006, pp. 477−485
   Smith MY, Redd WH, Peyser C, et al. Post-traumatic stress disorder in cancer: a review. Psychooncology 8:521−537, 1999
   Cordova MJ, Riba MB, Spiegel D. Post-traumatic stress disorder and cancer. Lancet Psychiatry 4:330−338, 2017
   Mihalopoulos C, Magnus A, Lal A, et al. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs. Aust N Z J Psychiatry 49:360−376, 2015
   Maslach C, Jackson SE, Leiter MP. MBI: Maslach burnout inventory. Palo Alto, Consulting Psychologists Press, 1996
   Kuerer HM, Eberlein TJ, Pollock RE, et al. Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol 14:3043−3053, 2007
   Elit L, Trim K, Mand-Bains I, et al. Job satisfaction, stress, and burnout among Canadian gynecologic oncologists. Gynecol Oncol 94:134−139, 2004
   Eelen S, Bauwens S, Baillon C, et al. The prevalence of burnout among oncology professionals: oncologists are at risk of developing burnout. Psychooncology 23:1415−1422, 2014
   Dorz S, Novara C, Sica C, et al. Predicting burnout among HIV/AIDS and oncology health care workers. Psychol Health 18:677−684, 2003
   Bálint M. Az orvos, a betege és a betegség. Magyar Pszichiátriai Társaság, Budapest 1990
   Szenyei GA, Adam S, Gyorffy Z, et al. A kiegesi szindroma megelozese – A hagyomanyoktol a modern informacios technologiakig. Magyar Pszichologiai Szemle 70:847−862, 2015
   Korczak D, Wastian M, Schneider M. Therapy of the burnout syndrome. GMS Health Technol Assess 8:Doc05, 2012
   Irving JA, Dobkin PL, Park J. Cultivating mindfulness in health care professionals: A review of empirical studies of mindfulness-based stress reduction, MBSR). Complement Ther Clin Pract 15:61−66, 2009
   Moody K, Kramer D, Santizo RO, et al. Helping the helpers: mindfulness training for burnout in pediatric oncology—a pilot program. J Pediatr Oncol Nurs 30:275−284, 2013
   Haas LJ, Leiser JP, Magill MK, et al. Management of the difficult patient. Am Fam Physician 72:2063−2068, 2005
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 62
EP 69
PG 8
ER

PT J
AU Molnar, BK
AF Molnar, Barbara Kinga
TI Analysis of DNA methylation alterations in cellfree DNA fraction during colorectal cancer development
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE colorectal cancer; colorectal adenoma; DNA methylation; cell-free DNA; epigenetic marker panel
ID colorectal cancer; colorectal adenoma; DNA methylation; cell-free DNA; epigenetic marker panel
AB During colorectal cancer (CRC) development, in addition to genetic alterations, several epigenetic changes, including DNA methylation in the promoter regions accumulate in tumor cells. Cell-free DNA (cfDNA) in the circulatory system can originate also from tumor tissue; therefore the evaluation of methylated cfDNA in the plasma can be a promising method for early cancer screening. In my Ph.D., I have investigated the rate of cfDNA’s release and stability using animal models. I aimed to compile an epigenetic marker panel, which contains genes with altered DNA methylation patterns in the healthy-colorectal adenoma-cancer sequence. I have found that the methylation level of SFRP1, SFRP2, SDC2, and PRIMA1 gene promoters has already increased in adenoma stages in both tissue and plasma samples. Immunohistochemistry analyses indicated decreasing protein expression in parallel with elevated methylation. According to our results, cfDNA amount and the methylation have been influenced by DNA isolation and blood collection methods.
C1 [Molnar, Barbara Kinga] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Molnar, BK (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM bartak.barbara@gmail.com
CR Bartak BK, Kalmar A, Galamb O, et al. Blood collection and cell-free DNA isolation methods influence the sensitivity of liquid biopsy analysis for colorectal cancer detection. Pathol Oncol Res 25:915−923, 2019
   Bartak BK, Nagy ZB, Spisak S, et al. A sejten kivuli szabad DNS felszabadulasanak es degradaciojanak in vivo elemzese. Orv Hetil 159:228–238, 2018
   Bartak BK, Kalmar A, Peterfia B, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751−763, 2017
   Toth K, Bartak BK, Tulassay Z, Molnar B. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. Expert Rev Mol Diagn 16:239−252, 2016
   Galamb O, Kalmar A, Peterfia B, et al. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Epigenetics 11:588−602, 2016
   Molnar B, Toth K, Bartak BK, Tulassay Z. Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn 15:171−184, 2015
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 70
EP 72
PG 3
ER

PT J
AU Szabo, V
AF Szabo, Vanessza
TI Mechanism of tumour vascularisation in experimental lung metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE lung metastasis; vascularisation; vessel co-option; tumour cell migration
ID lung metastasis; vascularisation; vessel co-option; tumour cell migration
AB Treatment of patients with lung metastases remains a major challenge. A possible target for therapies is the inhibition of vascularization of metastases. We examined the vascularisation process of lung metastasis in six different preclinical models and found that the tumours incorporated the pre-existing alveolar capillaries (i.e. vessel co-option). During the initial phase of vessel co-option, the incorporated capillaries were still sheathed by pneumocytes, but these incorporated vessels subsequently underwent different fates dependent on the model. In five of the models examined (B16, HT1080, HT25, C26 and MAT-B-III), the tumour cells gradually stripped the pneumocytes from the vessels. These dissected pneumocytes underwent fragmentation, but the incorporated microvessels survived. In the sixth model (C38), the tumour cells failed to invade the alveolar walls. Instead, they induced the development of vascularised desmoplastic tissue columns. In conclusion, our data show that lung metastases can vascularise by co-opting the pulmonary microvasculature.
C1 [Szabo, Vanessza] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Szabo, V (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM nesszy20@gmail.com
CR Szabo V, Bugyik E, Dezso K, et al. Mechanism of tumour vascularization in experimental lung metastases. J Pathol 235:384–396, 2015
   Bugyik E, Renyi-Vamos F, Szabo V, et al. Mechanisms of vascularization in murine models of primary and metastatic tumor growth. Chin J Cancer 35:19, 2016
   Szabo V, Bugyik E, Dezso K, et al. Tumorsejt-invazio/migracio szerepe kiserletes tudometasztazisok erezodeseben. Magy Onkol 59:319–323, 2015
   Bugyik E, Szabo V, Dezso K, et al. Role of, myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice. Cancer Commun 38:46, 2018
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 73
EP 75
PG 3
ER

PT J
AU Molnar, E
AF Molnar, Eszter
TI vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE BRAF mutation; BRAF inhibitor resistance; migration; proliferation; combination therapy
ID BRAF mutation; BRAF inhibitor resistance; migration; proliferation; combination therapy
AB Targeted therapy for V600 BRAF mutant solid tumors already exists but resistance to the treatment is still a serious problem to be solved. Moreover, there are currently no approved targeted therapeutic options against non-V600 BRAF mutant tumors. Here we studied targeted therapy resistance mechanisms of V600 BRAF mutant melanoma and also explored potential alternative solutions for their treatment. In V600 BRAF mutant melanoma cells that did not or slightly express PTEN protein, prenylation inhibitor zoledronic acid inhibited cell proliferation and induced apoptosis more profoundly than in melanoma cells expressing PTEN. We also investigated the proliferation and migration of pre- and posttreatment isogeneic melanoma cell line pairs. Posttreatment V600 BRAF mutant melanoma cells showed more invasive phenotype. We found that migration and proliferation showed a negative correlation with MITF and FRA-1 mRNA levels, respectively. Both transcription factors correlated with EGFR mRNA expression. Finally, in non-V600 BRAF mutant cell lines combined inhibition of pan-RAF and MEK with sorafenib/AZ628 and selumetinib showed significantly stronger cell growth, cell migration and Erk activation inhibition and also increased apoptosis induction compared to single treatments.
C1 [Molnar, Eszter] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Molnar, E (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM molnar.eszter@med.semmelweis-univ.hu
CR Molnar E, Garay T, Donia M, et al. Long-term vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with EGFR expression. Int J Mol Sci 20:4484, 2019
   Molnar E, Rittler D, Baranyi M, et al. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. BMC Cancer 18:542, 2018
   Garay T, Kenessey I, Molnar E, et al. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. PLoS One 10:e0117021, 2015
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 76
EP 78
PG 3
ER

PT J
AU Kocsis, M
AF Kocsis, Marton
TI Progression type and prognosis in metastatic castration-resistant prostate cancer (mCRPC), according to CATS International Patient Registry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Guideline
C1 [Kocsis, Marton] Sanofi-Aventis Zrt.Budapest, Hungary.
RP Kocsis, M (reprint author), Sanofi-Aventis Zrt., Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2020
VL 64
IS 1
BP 79
EP 80
PG 2
ER

PT J
AU Borbely, K
   Garai, I
   Baranyai, T
   Patko, ZsP
AF Borbely, Katalin
   Garai, Ildiko
   Baranyai, Tibor
   Patko, Zsofia Panna
TI PET-based measurements in oncology: PET/CT and PET/MRI applications
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PET/CT; PET/MRI; clinical applications
ID PET/CT; PET/MRI; clinical applications
AB The introduction and clinical application of 2-deoxy-2-[fluorine- 18]fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) dates back more than two decades. The method has resulted in a paradigm shift in many areas of oncology and its acceptance has grown very rapidly. The state-of-the-art PET-based hybrid measurement, PET/Magnetic Resonance Imaging (PET/ MRI), has been available since 2011 and offers additional invaluable opportunities. Various recommendations have been made to provide guidance for the standardization and harmonization of PET/MRI protocols and to support the application of the method in clinical use and research. Hopefully, with well-defined professional indications, similar to PET/CT applications, the PET/MRI technology, still somewhat mystified today, will soon become part of our everyday lives.
C1 [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Garai, Ildiko] Scanomed Kft.Debrecen, Hungary.
   [Baranyai, Tibor] Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Rontgen- es Izotopdiagnosztikai OsztalySopron, Hungary.
   [Patko, Zsofia Panna] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
CR Borbely K. Funkcionalis kepalkotas az onkologiaban. In: Az onkologia alapjai. Egyetemi tankonyv, 2. atdolgozott kiadas. Ed. Kasler M. Medicina Konyvkiado Zrt., Budapest 2018
   Borbely K. Ujdonsagok es uj lehetosegek a nuklearis medicina kepalkotasban. Magy Onkol 58:232−238, 2014
   Lasocki A, Hicks RJ. How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. Cancer Imaging 19:57, 2019
   Salaun PY, Abgral R, Malard O, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging 47:28−50, 2020
   Yoder JS, Kogan F, Gold GE. PET-MRI for the study of metabolic bone disease. Curr Osteoporos Rep 16:665−673, 2018
   Parghane RV, Basu S. PET/computed tomography and PET/MR imaging basic principles, methodology, and imaging protocol for musculoskeletal applications. PET Clin 13:459–476, 2018
   Umutlu L, Beyer T, Grueneisen JS, et al. Whole-body [18F]-FDG-PET/MRI for oncology: a consensus recommendation. Nuklearmedizin 58:68−76, 2019
   Morsing A, Hildebrandt MG, Vilstrup MH, et al. Hybrid PET/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging 46:2138−2151, 2019
   Yeh CH, Chan SC, Lin CY, et al. Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 47:94−104, 2020
   Liao CT, Hsieh CH, Fan WL, et al. A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging 47:84−93, 2020
   Khiewvan B, Torigian DA, Emamzadehfard S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med 19:254−268, 2016
   Lee DH. Whole-body PET/MRI for colorectal cancer staging: is it the way forward? J Magn Reson Imaging 45:21–35, 2017
   Laurens ST, Oyen WJ. Impact of fluorodeoxyglucose PET/computed tomography on the management of patients with colorectal cancer. PET Clin 10:345–360, 2015
   Beyer T, Hacker M, Goh V. PET/MRI-knocking on the doors of the rich and famous. Br J Radiol 90:20170347, 2017
   Cho IH, Kong EJ. Potential clinical applications of, 18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance mammography in breast cancer. Nucl Med Mol Imaging 51:217−226, 2017
   Borbely K. Ujdonsagok es uj lehetosegek az onkologiai betegek terapias vezeteseben: PET/MR klinikai alkalmazasok. Magy Onkol 59:10−16, 2015
   Borbely K. PET/MR technologia jelene es jovoje. Magy Radiol 92:43−52, 2018
   Borbely K, Kasler M. PET/CT es PET/MR kepalkotas a daganatos betegek diagnozisaban es a terapia eredmenyessegenek koveteseben. Haziorvos Tovabbkepzo Szemle XXIII:8, 2018
   Borbely K, Wintermark M, Martos J, et al. The pre-requisite of a second- generation glioma PET biomarker. J Neurol Sci 298:11−16, 2010
   Chan SC, Wang HM, Yen TC, et al., 18)F-FDG PET/CT and 3.0-T wholebody MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study. Eur J Nucl Med Mol Imaging 38:1607–1619, 2011
   Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 49:1215–1222, 2008
   Moy L, Noz ME, Maguire GO Jr, et al. Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J 16:369–376, 2010
   Taneja S, Jena A, Goel R, et al. Simultaneous whole-body 18F-FDG PETMRI in primary staging of breast cancer: a pilot study. Eur J Radiol 83:2231– 2239, 2014
   Lake ES, Wadhwani S, Subar D, et al. The influence of 18F-FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. Ann R Coll Surg Engl 96:211–215, 2014
   Yip VS, Poston GJ, Fenwick SW, et al. 18F-FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases. Eur J Surg Oncol 40:995–999, 2014
   Groheux D, Cochet A, Humbert O, et al., 18)F-18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 57(Suppl 1):17S–26S, 2016
   Paspulati RM, Partovi S, Herrmann KA, et al. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study. Abdom Imaging 40:1415–1425, 2015
   Koh DM, Brown G, Husband JE. Nodal staging in rectal cancer. Abdom Imaging 31:652–659, 2006
   Sotoudeh H, Sharma A, Fowler KJ, et al. Clinical application of PET/MRI in oncology. J Magn Reson Imaging 44:265−276, 2016
   Maas M, Rutten IJ, Nelemans PJ, et al. What is the most accurate wholebody imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 38:1560–1571, 2011
   Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen, CEA, test for monitoring patients with resected colon cancer. JAMA 270:943–947, 1993
   Panagiotidis E, Datseris IE, Rondogianni P, et al. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT? Nucl Med Commun 35:598–605, 2014
   Bu W, Wei R, Li J, et al. Association between carcinoembryonic antigen levels and the applied value of F-fluorodeoxyglucose positron emission tomography/ computed tomography in post-operative recurrent and metastatic colorectal cancer. Oncol Lett 8:2649–2653, 2014
   Zhang Y, Feng B, Zhang GL, et al. Value of 18F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations. World J Gastroenterol 20:6608–6614, 2014
   Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50, Suppl 1):122S–150S, 2009
   Brendle C, Schwenzer NF, Rempp H, et al. Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging 43:123–132, 2016
   Catalano OA, Coutinho AM, Sahani DV, et al. Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol, NY, 42:1141–1151, 2017
   Borbely K, Bakos M, Patko Z. Endokrin onkologia es nuklearis medicina Magy Radiol 11:2/1–13, 2020
   Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol 6:55−62, 2004
   Schwarz JK, Siegel BA, Dehdashti F, et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298:2289−2295, 2007
   Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738−1744, 2007
   Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 14:5236−5241, 2008
   Chung HH, Kim JW, Kang KW, et al. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 81:e817−822, 2012
   Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 18:2040−2047, 2008
   Cerci SS, Yalcin Y, Bozkurt KK, et al. Hypoxia-inducible factor-1α, adrenomedullin and Bcl-2 although expected are not related to increased uptake of fluorine-18-fluorodeoxyglucose in endometrial cancer. Hell J Nucl Med 18:228−232, 2015
   Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F]fluoro-D-glucose, FDG)-positron emission tomography, PET, on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer 23:1642−1646, 2013
   Fuller AF Jr, Elliott N, Kosloff C, et al. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 33:34−39, 1989
   Pan L, Cheng J, Zhou M, et al. The SUVmax, maximum standardized uptake value for F-18 fluorodeoxyglucose, and serum squamous cell carcinoma antigen, SCC-ag, function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol 138:239−246, 2012
   Nakamura K, Joja I, Nagasaka T, et al. Maximum standardized lymph node uptake value could be an important predictor of recurrence and survival in patients with cervical cancer. Eur J Obstet Gynecol Reprod Biol 173:77−82, 2014
   Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 53:353−359, 2002
   Kang S, Park JY, Lim MC, et al. Pelvic lymph node status assessed by 18F-fluorodeoxyglucose positron emission tomography predicts low-risk group for distant recurrence in locally advanced cervical cancer: a prospective study. Int J Radiat Oncol Biol Phys 79:788−793, 2011
   Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19:3745−3749, 2001
   Zhao Q, Feng Y, Mao X, et al. Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. Int J Gynecol Cancer 23:1184−1190, 2013
   Lewis JS, Laforest R, Dehdashti F, et al. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 49:1177−1182, 2008
   Kitajima K, Suenaga Y, Ueno Y, et al. Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced, 18)F-FDG PET/CT and pelvic MRI. Clin Imaging 38:464−469, 2014
   Eiber M, Rauscher I, Souvatzoglou M, et al. Prospective head-to-head comparison of, 11)C-choline-PET/MR and, 11)C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 44:2179−2188, 2017
   Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to bemissed in, 68)Ga- PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging 44:776–787, 2017
   Freitag MT, Radtke JP, Hadaschik BA, et al. Comparison of hybrid, 68)Ga-PSMAPET/MRI and, 68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43:70–83, 2016
   Kobayashi N, Inaba Y, Tateishi U, et al. New application of 18F-fluoride PET for the detection of bone remodeling in early-stage osteoarthritis of the hip. Clin Nucl Med 38:e379–383, 2013
   Huang B, Law MWM, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251:166–174, 2009
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 87
EP 96
PG 10
ER

PT J
AU Barna, S
   Garai, I
   Nagy, G
AF Barna, Sandor
   Garai, Ildiko
   Nagy, Gabor
TI Single photon emitting radiopharmaceuticals in oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE radiopharmaceutical; single-photon emission computed tomography; SPECT; therapy; theranostics
ID radiopharmaceutical; single-photon emission computed tomography; SPECT; therapy; theranostics
AB In this review the isotopes and radiopharmaceuticals used for single-photon techniques will be discussed, covering their current use and possible future trends. SPECT technics have a wide range of diagnostic isotopes and therapeutic isotopes whose diagnostic imaging is possible thanks to new technologies. In the field of nuclear medicine nowadays the parallel use of diagnostic and therapeutic radiopharmaceuticals is becoming more and more important, causing an important role for theranostics.
C1 [Barna, Sandor] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Garai, Ildiko] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Nagy, Gabor] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
RP Garai, I (reprint author), Scanomed Kft., 4032 Debrecen, Hungary.
CR OECD-NEM. A supply and demand update of the molybdenum-99 market. 1–11, 2012. https://www.oecd-nea.org/med-radio/docs/2012-supply-demand- update-molybdenum-99-market.pdf
   Balogh L, Polyak A, Postenyi Z, et al. SPECT-radiofarmakonok, ujdonsagok es uj lehetosegek. Magy Onkol 58:239–244, 2014
   Zeglis BM, Holland JP, Lebedev AY, et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents. In: Nuclear Oncology. Ed. Strauss H, Mariani G, Volterrani D, Larson S. Springer, New York 2013, pp. 35−78
   Izotop Intezet Kft. honlapja. http://www.izotop.hu/?page_id=15
   Medi-Radiopharma Kft. honlapja. https://www.mediradiopharma.com/ products/kit-products
   Orszagos Gyogyszereszeti Intezet honlapja. http://www.ogyi.hu/
   Biersack HJ, Briele B, Hotze AL, et al. The role of nuclear medicine in oncology. Ann Nucl Med 6:131−136, 1992
   Oliveira C, Parafita R, Canudo A, et al. Nuclear medicine in oncology. Comput Methods Biomech Biomed Eng Imaging Vis 6:429−446, 2016
   Denoyer D, Perek N, Le Jeune N, et al. Spectrum of radiopharmaceuticals in nuclear oncology. Curr Cancer Drug Targets 6:181−196, 2006
   IAEA. Technetium-99m radiopharmaceuticals: Manufacture of kits. Technical Reports Series No. 466:64−129, 2008. https://www-pub.iaea.org/ MTCD/publications/PDF/trs466_web.pdf
   Jang SJ, Moon SH, Kim SK, et al. Comparison of the results for sentinel lymph node mapping in the breast cancer patients using 99mTc-antimony trisulfide colloid, 99mTc-tin colloid, and 99mTc-human serum albumin. Nucl Med Mol Imaging 41:546−552, 2007
   Konszenzus a differencialt pajzsmirigyrak magyarorszagi ellatasarol. Orvostovabbkepzo Szemle XXVI. evf. 9. szam
   Vecchio SD, Salvatore M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging 31:S88−96, 2004
   Del Vecchio S, Zannetti A, Aloj L, et al. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging 30:879−887, 2003
   Del Vecchio S, Zannetti A, Aloj L, et al. MIBI as prognostic factor in breast cancer. Q J Nucl Med Mol Imaging 47:46−50, 2003
   Zhang A, Li P, Liu Q, et al. Breast-specific gamma camera imaging with, 99m)Tc-MIBI has better diagnostic performance than magnetic resonance imaging in breast cancer patients. Hell J Nucl Med 20:26−35, 2017
   Mohan HK, Miles KA. Cost-Effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 50:376−381, 2009
   Rager O, Radojewski P, Dumont RA. Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. Gland Surg 8:S118−125, 2019
   Zhang J, Zhang J, Xu X, et al. Evaluation of radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Sci Rep 10:4179, 2020
   Liqiang L, Yue W, Zihua W, et al. Imaging of the novel HER2-targeted peptide probe 99m Tc-HYNIC-H6F in breast cancer mouse models. J Nucl Med 58:821−826, 2017
   Mojarrad P, Zamani S, Seyedhamzeh M, et al. Novel radiopharmaceutical, Technetium-99m)-(DOTA-NHS-ester)-Methionine as a SPECT-CT tumor imaging agent. Eur J Pharm Sci 141:105−112, 2020
   Qaim SM, Scholten B, Neumaier B. New developments in the production of theranostic pairs of radionuclides. J Radioanal Nucl Chem 318:1493–1509, 2018
   Yamamotoa S, Yogoa K, Noguchib Y, et al. Imaging of Ir-192 source using a high energy gamma camera for high-doserate brachytherapy. Radiat Meas 126:106−128, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 98
EP 103
PG 6
ER

PT J
AU Mikecz, P
   Fekete, A
   Toth, Gy
   Kornyei, J
   Bali, T
   Cservenyak, T
   Borbely, K
AF Mikecz, Pal
   Fekete, Aniko
   Toth, Gyula
   Kornyei, Jozsef
   Bali, Tibor
   Cservenyak, Tibor
   Borbely, Katalin
TI Oncology PET radiopharmaceuticals in clinic and research in 2020
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE 18F and 68Ga isotopes; radiopharmaceuticals; metal isotopes; oncological diagnostics
ID 18F and 68Ga isotopes; radiopharmaceuticals; metal isotopes; oncological diagnostics
AB „PET based” molecular imaging has significant role in personalized medicine. New radiopharmaceuticals are continuously introduced into the daily practice of detecting diseases and assessing the effectiveness of therapy. In recent years theragnostic applications have come to the forefront of radiopharmaceutical development. This article discusses, among others, radiopharmaceuticals labelled with 18F and 68Ga isotopes required for the diagnosis of neuroendocrine and prostate tumours, furthermore the inhibitors of the fibroblast activation protein. The increasing variety of metallic radioisotopes (44Sc, 64Cu, 52Mn, 86Y, 89Zr) will help meet the need for new biomarkers and will greatly facilitate the introduction of the new generation of PET radiopharmaceuticals.
C1 [Mikecz, Pal] Chem PET Bt., Szeged utca 18., 4030 Debrecen, Hungary.
   [Fekete, Aniko] University of Debrecen, Medical and Health Science Center, Institute of Nuclear MedicineDebrecen, Hungary.
   [Toth, Gyula] Pozitron Diagnosztika KftBudapest, Hungary.
   [Kornyei, Jozsef] Izotop Intezet Kft.Budapest, Hungary.
   [Bali, Tibor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Cservenyak, Tibor] Kaposi Mor Teaching HospitalKaposvar, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient DepartmentBudapest, Hungary.
RP Mikecz, P (reprint author), Chem PET Bt., 4030 Debrecen, Hungary.
CR Kornyei J, Mikecz P, Toth Gy. PET-radiofarmakonok: Ujdonsagok es uj lehetosegek. Magy Onkol 58:245–250, 2014
   Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga- DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 54:364–3172, 2013
   Barrio M, Czernin J, Fanti S, et al. The impact of somatostatin receptor- directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med 58:756–761, 2017
   Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171, 2016
   Waldmann CM, Stuparu AD, van Dam RM, et al. The search for an alternative to [68Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of 18F-labeled somatostatin analog development. Theranostics 9:1336–1347, 2019
   Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med 51:454–461, 2010
   Niedermoser S, Chin J, Wangler C, et al. In vivo evaluation of 18FSiFAlin- modified TATE: A potential challenge for 68Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med 56:1100–1105, 2015
   Pauwels E, Cleeren F, Tshibangu T, et al. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging 46:2398–2339, 2019
   Ilhan H, Todica A, Lindner S, et al. First-in-human 18F-SiFAlin-TATE PET/ CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging 46:2400– 2401, 2019
   Lisova K, Sergeev M, Evans-Axelsson S, et al. Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36–44, 2018
   Jansen K, Heirbaut L, Verkerk R, et al. Extended structure–activity relationship and pharmacokinetic investigation of, 4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein, FAP). J Med Chem 57:3053–3074, 2014
   Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59:1415–1422, 2018
   Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805, 2019
   Lindner T, Loktev A, Giesel F, et al. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem 4:16–30, 2019
   Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med 60:1421–1429, 2019
   Lindner T, Altmann A, Giesel FL, et al. Fluorine-18 labeled FAPI-tracers for PET imaging. Eur J Nucl Med Mol Imaging 46(Suppl 1):S168, 2019
   Nanni C, Zanoni L, Bach-Gansmo T, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging– version 1.0. Eur J Nucl Med Mol Imaging 2019,, DOI  10.1007/s00259-019- 04614-y
   Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–935, 1987
   Ristau BT, O‘Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 32:272–279, 2014
   Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288, 2011
   Wester H-J, Schottelius M. PSMA-targeted radiopharmaceuticals for imaging and therapy. Semin Nucl Med 49:302–312, 2019
   Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem 23:688–697, 2012
   Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176, 2015
   Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914– 920, 2015
   Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F] DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645–7653, 2011
   Cardinale J, Schafer M, Benesova M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med 58:425–431, 2017
   Giesel FL, Knorr K, Spohn F, et al. Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60:362–368, 2019
   Behr SC, Aggarwal R, VanBrocklin HF, et al. Phase I study of CTT1057, an 18F-labeled Imaging agent with phosphoramidate core targeting prostate- specific membrane antigen in prostate cancer. J Nucl Med 60:910–916, 2019
   Harada N, Kimura H, Onoe S, et al. Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer. J Nucl Med 57:1978–1984, 2016
   Dietlein F, Hohberg M, Kobe C, et al. A novel 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application. J Nucl Med 61:202–209, 2020
   Lutje S, Franssen MG, Herrmann K, et al. In vitro and in vivo characterization of a 18F-AlF-labeled PSMA ligand for imaging of PSMA-expressing xenografts. J Nucl Med 60:1017–1022, 2019
   Liu T, Liu C, Xu X, et al. Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer imaging. J Nucl Med 60:1284–1292, 2019
   Wurzer A, DiCarlo D, Schmidt A, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA-inhibitors. J Nucl Med 2019,, DOI  10.2967/jnumed.119.234922
   Eiber M, Kroenke M, Wurzer A, et al. 18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy. J Nucl Med 2019,, DOI  10.2967/jnumed. 119.234914
   Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics 10:1–16, 2020
   Derlin T, Grunwald V, Steinbach J, et al. Molecular imaging in oncology using positron emission tomography. Dtsch Arztebl Int 115:175–181, 2018
   Treglia G, Pereira Mestre R, Ferrari M, et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging 9:127–139, 2019
   Albert NL, Weller M, Suchorska B, et al. Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199–208, 2016
   Domanska UM, Kruizinga RC, Nagengastet WB, et al. A review on CXCR4/ CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–30, 2013
   Herrmann K, Schottelius M, Lapa C, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57:248–251, 2016
   Hoilund-Carlsen PF, Sturek M, Alavi A, et al. Atherosclerosis imaging with 18F-sodium fluoride PET: state-of-the-art review. Eur J Nucl Med Mol Imaging 2019,, DOI 10.1007/s00259-019-04603-1
   Tachibana I, Nishimura Y, Hanaoka K, et al. Tumor hypoxia detected by 18F-fluoromisonidazole positron emission tomography, FMISO PET, as a prognostic indicator of radiotherapy, RT). Anticancer Res 38:1775–1781, 2018
   Lopci E, Grassi I, Chiti A, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 4:365– 384, 2014
   Watanabe S, Shiga T, Hirata K, et al. Biodistribution and radiation dosimetry of the novel hypoxia PET probe [18F]DiFA and comparison with [18F] FMISO. EJNMMI Res 9:60, 2019
   Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25:1212–1221, 1984
   Mankoff DA, Clark AS. PET oestrogen receptor imaging: ready for the clinic? Lancet Oncol 20:467–469, 2019
   Qaim SM, Scholten B, Spahn I, et al. Positron-emitting radionuclides for applications, with special emphasis on their production methodologies for medical use. Radiochimica Acta 107:1011–1026, 2019
   De Silva RA, Kumar D, Lisok A, et al., Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer. Mol Pharmaceutics 15:3946– 3952, 2018
   Mate G, Kertesz I, Enyedi KN, et al. In vivo imaging of aminopeptidase N, CD13, receptors in experimental renal tumors using the novel radiotracer 68Ga-NOTA-c(NGR). Eur J Pharm Sci 69:61–71, 2015
   Domnanich KA, Muller C, Farkas R, et al. 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharm Chem 1:8–19, 2016
   Nagy G, Denes N, Kis A, et al. Preclinical evaluation of melanocortin-1 receptor, MC1-R, specific 68Ga- and 44Sc-labeled DOTA-NAPamide in melanoma imaging. Eur J Pharm Sci 106:336–344, 2017
   Nagy G, Szikra D, Trencsenyi G, et al. AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents. Angew Chem Int Ed Engl 56:2118–2122, 2017
   Tang Y, Hu Y, Liu W, et al. A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nucl Med Biol 70:23–31, 2019
   Caserta E, Chea J, Minnix M, et al. Copper-64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131:741–745, 2018
   Koi L, Bergmann R, Bruchner K, et al. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol 110:362–369, 2014
   Graves SA, Hernandez R, Fonslet J, et al. Novel preparation methods of 52Mn for immunoPET imaging. Bioconjugate Chem 26:2118–2124, 2015
   Zhang J, Mao F, Niu G, et al. 68Ga-BBN-RGD PET/CT for GRPR and integrin αvβ3 imaging in patients with breast cancer. Theranostics 8:1121–1130, 2018
   Farkas R, Siwowska K, Ametamey SM, et al. 64Cu- and 68Ga-based PET imaging of folate receptor-positive tumors: development and evaluation of an albumin-binding NODAGA-folate. Mol Pharm 13:1979–1987, 2016
   Zeglis BM, Brand C, Abdel-Atti D, et al. Optimization of a pretargeted strategy for the PET imaging of colorectal carcinoma via the modulation of radioligand pharmacokinetics. Mol Pharm 12:3575–3587, 2015
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 104
EP 111
PG 8
ER

PT J
AU Mezosi, E
AF Mezosi, Emese
TI Theranostics and differentiated thyroid cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE theranostic agent; precision medicine; personalized therapy; differentiated thyroid cancer; radioiodine
ID theranostic agent; precision medicine; personalized therapy; differentiated thyroid cancer; radioiodine
AB The first classic theranostic agent, radioactive iodine was used in the treatment of differentitated thyroid cancer (DTC) and it has an important role in the good prognosis of DTC even nowadays. I-131 provides a specific, molecular targeted therapy through the active uptake of iodide by sodium iodide symporter. The development of other theranostics also aimed the personalized therapy with minimal side effects and optimal therapeutic efficacy. The incidence of DTC which basically has good prognosis is increasing rapidly worldwide. This required the modification of guidelines to avoid the overtreatment of the disease, in the direction of less radical therapy. Currently, new pathological classification and staging systems were reported. The present work summarizes the new recommendations in the management of DTC, focusing on the indications of radioiodine therapy and reviewing the proposal of the Hungarian consensus conference.
C1 [Mezosi, Emese] University of Pecs, I. Department of Internal Medicine, Ifjusag u. 13., 7624 Pecs, Hungary.
RP Mezosi, E (reprint author), University of Pecs, I. Department of Internal Medicine, 7624 Pecs, Hungary.
EM mezosi.emese@pte.hu
CR Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol 91:8, 2018
   Jadvar H. Targeted radionuclide therapy: an evolution toward precision cancer treatment. Am J Roentgenol 209:277−288, 2017
   Ahn BC. Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer. Biomed Res Int 2016:1680464, 2016
   Jadvar H, Chen XY, Cai WB, et al. Radiotheranostics in cancer diagnosis and management. Radiology 286:388−400, 2018
   Sheikh A, Polack B, Rodriguez Y, et al. Nuclear molecular and theranostic imaging for differentiated thyroid cancer. Mol Imaging Radionuclid Ther 26:50−65, 2017
   Verburg FA, Heinzel A, Hanscheid H, et al. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine. Eur J Nucl Med Mol Imaging 41:199−201, 2014
   Santhanam P, Solnes LB, Rowe SB. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Med Oncol 34:7, 2017
   Spanu A, Solinas ME, Chessa F, et al. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med 50:184−190, 2009
   Xue YL, Qiu ZL, Song HJ, Luo QY. Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature. Eur J Nucl Med Mol Imaging 40:768−778, 2013
   Szujo S, Sira L, Bajnok L, et al. The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. Oncotarget 8:79825−79834, 2017
   Morris LGT, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg 142:709−711, 2016
   Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1−133, 2016
   Verburg FA, Aktolun C, Chiti A, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 43:1001−1005, 2016
   Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer, Eighth Edition): What changed and why? Thyroid 27:751−756, 2017
   Mezosi E, Altorjai A, Deak PA, et al. Konszenzus a differencialt pajzsmirigyrak magyarorszagi ellatasarol. OTSZ 26:31−40, 2019
   Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787−803, 2006
   Gillanders SL, O’Neill JP. Prognostic markers in well differentiated papillary and follicular thyroid cancer, WDTC). Eur J Surg Oncol 44:286−296, 2018
   Shi RL, Qu N, Liao T, et al. The trend of age-group effect on prognosis in differentiated thyroid cancer. Sci Rep 6:27086, 2016
   Hay ID, Grant CS, Vanheerden JA, et al. Papillary thyroid microcarcinoma − a study of 535 cases observed in a 50-year period. Surgery 112:1139−1147, 1992
   Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052−1059, 2011
   Wang LY, Palmer FL, Nixon IJ, et al. Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24:1594−1599, 2014
   Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191−197, 2003
   Hughes CJ, Shaha AR, Shah JP, et al. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched-pair analysis. Head Neck 18:127−132, 1996
   Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades, 1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879−885, 2002
   Ito Y, Tomoda C, Uruno T, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: Massive but not minimal extension affects the relapse-free survival. World J Surg 30:780−786, 2006
   Glikson E, Alon E, Bedrin L, et al. Prognostic factors in differentiated thyroid cancer revisited. Isr Med Assoc J 19:114−118, 2017
   Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99:E754−E765, 2014
   Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:1167−1214, 2009
   Foldes I, Lakatos P, Konrady A. Az Emberi Eroforrasok Miniszteriuma szakmai iranyelve a pajzsmirigybetegsegek radiojod kezeleserol. Egeszsegugyi Kozlony 2:473−499, 2017
   Lassmann M, Haenscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405−1412, 2008
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 112
EP 117
PG 6
ER

PT J
AU Sipka, G
   Besenyi, Zs
   Farkas, I
   Pavics, L
AF Sipka, Gabor
   Besenyi, Zsuzsanna
   Farkas, Istvan
   Pavics, Laszlo
TI Theranostics in 2020: Neuroendocrine tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuroendocrine tumor; radionuclide imaging; radionuclide therapy
ID neuroendocrine tumor; radionuclide imaging; radionuclide therapy
AB This article presents the diagnostic and therapeutic nuclear medicine methods for neuroendocrine tumors in accordance with current guidelines. The paper begins with a general characterization of neuroendocrine tumors, followed by a broad introduction to laboratory and imaging diagnostic techniques, and a detailed discussion of peptide receptor radionuclide therapy and meta-iodobenzylguanidine treatment. Finally, the article provides an insight into current research and future developments.
C1 [Sipka, Gabor] University of Szeged, Department of Nuclear Medicine, Koranyi fasor 6., 6720 Szeged, Hungary.
   [Besenyi, Zsuzsanna] University of Szeged, Department of Nuclear Medicine, Koranyi fasor 6., 6720 Szeged, Hungary.
   [Farkas, Istvan] University of Szeged, Department of Nuclear Medicine, Koranyi fasor 6., 6720 Szeged, Hungary.
   [Pavics, Laszlo] University of Szeged, Department of Nuclear Medicine, Koranyi fasor 6., 6720 Szeged, Hungary.
RP Sipka, G (reprint author), University of Szeged, Department of Nuclear Medicine, 6720 Szeged, Hungary.
EM sipka.gabor@med.u-szeged.hu
CR Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335−1342, 2017
   Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy, PRRNT, in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800– 816, 2013
   Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology 105:295–309, 2017
   Oberg K, Knigge U, Kwekkeboom DJ, et al. Neuroendocrine gastro-entero- pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:124−130, 2012
   NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, R), Neuroendocrine tumors. 2017. http://www.nccn.org/professionals/physician_ gls/pdf/neuroendocrine.pdf
   Teijeiro R, Rios R, Costoya JA, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 12:31–38, 2002
   Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846, 2001
   Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma, WHO G3): the NORDIC NEC study. Ann Oncol 24:152−160, 2013
   Reubi JC, Schaer JC, Waser B, et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455–3459, 1994
   Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev Cent East Eur 19:111−117, 2016
   Toth M. A gasztroenteropankreatikus neuroendokrin daganatok kezelese. Magy Onkol 52:99−106, 2018
   Yao JC, Hassan M, Phan A, et al. One hundred years after „carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063−3072, 2008
   Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 758 reported cases. J Exp Clin Cancer Res 18:133−141, 1999
   Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors. Pancreas 38:876−889, 2009
   Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med 70:501−508, 1997
   Stridsberg M, Eriksson B, Fellstrom B, et al. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 139:80−83, 2007
   Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 90:167–183, 2009
   Borbely K. Ujdonsagok es uj lehetosegek a nuklearis medicina kepalkotasban. Magy Onkol 58:232−238, 2014
   Bombardieri E, Ambrosini V, Aktolun C, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37:1441–1448, 2010
   Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor- positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318–1325, 2000
   Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/ HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor–expressing tumors. J Nucl Med 44:708–716, 2003
   Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 51:704–712, 2010
   Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol 2:159–168, 2015
   Even-Sapir E, Keidar Z, Bar-Shalom R. Hybrid imaging, SPECT/CT and PET/CT)--improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med 39:264−275, 2009
   Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/ CT tumor imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004– 2010, 2010
   Binderup T, Knigge U, Mellon Mogensen A, et al. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 87:223–232, 2008
   Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518, 2007
   Treglia G, Cocciolillo F, de Waure C, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging 39:1144–1153, 2012
   Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 94:3922–3930, 2009
   Taieb D, Hicks RJ, Hindie E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46:2112–2137, 2019
   Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE. Eur J Nucl Med Mol Imaging 44:490–499, 2017
   Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu- DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35:1847–1856, 2008
   de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617–620, 2002
   Jamar F, Barone R, Mathieu I, et al., 86YDOTA0)-DPhe1-Tyr3-octreotide, SMT487, – a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30:510–518, 2003
   Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3- octreotide, 90Y-DOTATOC, in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 31:1038–1046, 2004
   Bodei L, Cremonesi M, Grana CM, et al. Yttrium labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging 39:93–102, 2012
   Kunikowska J, Krolicki L, Hubalewska-Dydejczyk, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38:1788–1797, 2011
   Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. J Nucl Med 60:937−943, 2019
   Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42:5–19, 2015
   Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog 177Lu-DOTA0, Tyr3 octreotate in patients with endocrine gastroenteropancreatic tumours. J Clin Oncol 23:2754−2762, 2005
   Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46:83−91, 2005
   Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 4:62S–66S, 2005
   Imhof A, Brunner P, Marincek N, et al. Response, survival, and longterm toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423, 2011
   Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin receptor- based imaging and therapy of gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 17:53−73, 2010
   Iten F, Muller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696– 6702, 2007
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 119
EP 130
PG 12
ER

PT J
AU Garai, I
   Nagy, G
   Batyi, F
   Hascsi, Zs
AF Garai, Ildiko
   Nagy, Gabor
   Batyi, Ferenc
   Hascsi, Zsolt
TI Theranostics in prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE theranostics; PSMA; prostate cancer
ID theranostics; PSMA; prostate cancer
AB Development of radiochemistry and hybrid technology resulted in a new era in the management of prostate cancer. Choline PET provides more sensitive and accurate diagnosis, and it can support the personalized, metastases-directed therapies. PSMA radioligands are used as theranostics worldwide but are not available in Hungary. 68Ga- or 18F-labelled molecules are excellent diagnostic agents which can detect the primary process and its metastases more sensitively than choline, especially at lower PSA levels. 177Lu-labelled PSMA ligand as a therapeutic pair of the diagnostic molecules can provide an effective therapeutic option in metastatic castration resistant prostate cancer. In this publication we review PSMA radioligand therapy (PRLT) in management of prostate cancer based on the recently published European guideline.
C1 [Garai, Ildiko] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Nagy, Gabor] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Batyi, Ferenc] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Hascsi, Zsolt] Scanomed Kft., Nagyerdei korut 98., 4032 Debrecen, Hungary.
RP Garai, I (reprint author), Scanomed Kft., 4032 Debrecen, Hungary.
EM garai@belklinika.com
CR Kasler M, Otto S, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Kuronya Zs, Biro K, Geczi L, Maraz A. Metasztatikus hormonerzekeny prosztatadaganat korszeru kezelese. Orv Hetil 159:1664–1671, 2018
   Morigi JJ, Stricker PD, Van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56:1185–1190, 2015
   Emmett L, Willowson K, Violet J, et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 64:52−60, 2017
   Lutje S, Heskamp S, Cornelissen AS, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: Clinical status. Theranostics 5:1388−1401, 2015
   Farkas I, Besenyi Z, Maraz A, et al. Kezdeti tapasztalatok a 99m Tc-PSMASPECT/ CT-vel prosztatarakos betegekben. Orv Hetil 159:1434−1441, 2018
   Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44:941–949, 2017
   Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of 68Gallium- PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1442−1443, 2016
   Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70:553−557, 2016
   Evangelista L, Briganti A, Fanti S, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70:161−175, 2016
   Borbely K, Szilagyi I, Kasler M. IV. PET/CT multidiszciplinaris nemzeti konszenzus konferencia allasfoglalasa. Magy Onkol 55:117−127, 2011
   Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/ CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209, 2015
   Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11, HBED-CC, PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 44:1258–1268, 2017
   Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 45:471–495, 2018
   Cuccurullo V, Di Stasio GD, Mansi L. Nuclear medicine in prostate cancer: a new era for radiotracers. World J Nucl Med 17:70−78, 2018
   O’Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443:113−127, 1998
   Derks YHW, Lowik DWPM, Sedelaar JPM, et al. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics 9:6824−6839, 2019
   Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands, 177Lu-PSMARLT). Eur J Nucl Med Mol Imaging 46:2536−2544, 2019
   Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38:200–217, 2018
   Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration- resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402−1418, 2016
   Kulkarni HR, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The Bad Berka experience since 2013. J Nucl Med 57:97S−104S, 2016
   Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90, 2017
   Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 7:12477−12488, 2016
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 133
EP 137
PG 5
ER

PT J
AU Baranyai, T
   Martos, J
   Geszler, J
   Blazsevacz, P
   Varga, K
AF Baranyai, Tibor
   Martos, Janos
   Geszler, Jozsef
   Blazsevacz, Peter
   Varga, Karoly
TI Trends of development in CT and MRI doagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE CT and MRI diagnostics; trends; development; cost-efficient; artificial intelligence
ID CT and MRI diagnostics; trends; development; cost-efficient; artificial intelligence
AB Modern imaging processes, with CT and MRI diagnostics among them, play an increasingly important role in the early diagnosis and determination of the extent and nature of illnesses and the evaluation of their response to therapy. The authors review the technical and technological improvements that have recently been realised in CT and MRI diagnostics and are being adopted in clinical practice. Relying on the results achieved so far, they are analysing the potential for further development. In both modalities, the primary aim is incessant hardware and software upgrades, the implementation of cost-efficient solutions by increasing efficiency and cutting back maintenance and operational costs. The reduction in examination time, the ever-improving image quality and the increased comfort level of the examination environment are of outstanding significance to both the patient and the staff. The interpretation of the generated data is highly dependent on the level of expertise and experience and the knowledge of clinical data and technical opportunities of the person issuing the findings. This process is going to be assisted by artificial intelligence (AI) that the authors also discuss in terms of CT and MRI diagnostics.
C1 [Baranyai, Tibor] Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Gyori u. 15., 9400 Sopron, Hungary.
   [Martos, Janos] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Geszler, Jozsef] Fresenius Magyarorszag Kft.Budapest, Hungary.
   [Blazsevacz, Peter] Bluemed Plusz Kft.Budapest, Hungary.
   [Varga, Karoly] Siemens Healthcare Kft.Budapest, Hungary.
RP Baranyai, T (reprint author), Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, 9400 Sopron, Hungary.
EM baranyait44@gmail.com
CR Smart Subscription. https://www.gehealthcare.co.uk/products/smartsubscription
   Real time CT and CT fluoroscopy. http://www.impactscan.org/ctfluoro.htm
   Philips introduces IQon, world’s first spectral detector CT. https://www. medgadget.com/2013/12/philips-introduces-iqon-worlds-first-spectral-detector- ct.html
   IQon Spectral CT. https://www.philips.hu/healthcare/resources/landing/ iqon-spectral-ct
   Baranyai T. Ujdonsagok es uj lehetosegek a vese- es ureterdaganatok radiologiai diagnosztikajaban. Magy Onkol 58:281–289, 2014
   Balkay L, Emri M, Krizsan AK, et al. Ujdonsagok es uj lehetosegek a funkcionalis kepalkotasban: lekepezestechnikai ujdonsagok. Magy Onkol 59:4–9, 2015
   Jaray A, Levai A, Csete M, et al. Dual energias kepalkotas a klinikai gyakorlatban. https://www.imeonline.hu/article.php?article=2008._VII./5/dual_ energias_kepalkotas_aklinikai_gyakorlatban
   Assessing the AI revolution. https://european-hospital.com/media/epaper/ 2/2019_4/#14
   AI opens up boundaries between medical disciplines. https://european- hospital.com/media/epaper/2/2019_4/#8
   Kann BH, Thompson R, Thomas CR, et al. Artificial intelligence in oncology: current applications and future directions. Oncology, Williston Park, 33:46–53, 2019
   Pinto dos Santos D, Baeßler B. Big data, artificial intelligence, and structured reporting. Eur Radiol Exp 2:42, 2018
   BioMatrix Technology. https://www.siemens-healthineers.com/en-us/ magnetic-resonance-imaging/mri-technologies/biomatrix-technology/biomatrix- technology/biomatrix-sensors
   Fellah S, Caudal D, De Paula AM, et al. Multimodal MR imaging, diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am J Neuroradiol 34:1326−1333, 2013
   Borbely K. Ujdonsagok es uj lehetosegek az onkologiai betegek terapias vezeteseben: PET/MR klinikai alkalmazasok. Magy Onkol 59:10–16, 2015
   Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 251:398−407, 2009
   Varallyai P. Ujdonsagok es uj lehetosegek az agydaganatok radiologiai diagnosztikajaban. Magy Onkol 58:261−268, 2014
   Godeny M, Lerant G. Uj lehetosegek, MRI-biomarkerek a fej-nyaki daganatok ertekeleseben. Magy Onkol 58:269−280, 2014
   Federau C, Meuli R, O’Brien K, et al. Perfusion measurement in brain gliomas with intravoxel incoherent motion MRI. Am J Neuroradiol 35:256−262, 2014
   MRI shows cardiac diagnostic value. https://european-hospital.com/ media/epaper/2/2019_4/#6
   Lee, Kim YH, Kim N, Kang DW. Deep into the brain: artificial intelligence in stroke imaging. J Stroke 19:277−285, 2017
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 139
EP 144
PG 6
ER

PT J
AU Emri, M
AF Emri, Miklos
TI Methods of artificial intelligence and their application in imaging diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE artificial intelligence; Big Data technology; oncology; nuclear medicine; radiology
ID artificial intelligence; Big Data technology; oncology; nuclear medicine; radiology
AB Artificial intelligence is a dynamically evolving methodology and, due to its large number of methods, its appearance becomes more important not only in industry but also in all disciplines. Diagnostic instrument manufacturers have realized relatively quickly that these types of algorithms can achieve quality improvements and reduce measurement time, which can provide them with a market advantage and more efficient patient care. In this summary, following a methodological overview, we show examples of new applications in the field of medical imaging and image processing. The analysis of the publications also confirmed the often-stated assumption made by experts that machine learning can only be applied and developed with sufficient quantity and quality of data. Such data can only be aggregated with projects that provide data warehouses that meet the technological needs of the 21st century. With this kind of integration of artificial intelligence in Big Data’s methodology, regularly hidden clinical data can become accessible to advanced data science tools. This opportunity, together with relevant clinical issues, will be the basis for new R&D projects.
C1 [Emri, Miklos] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
RP Emri, M (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4032 Debrecen, Hungary.
EM emri.miklos@med.unideb.hu
CR Cirillo D, Valencia A. Big data analytics for personalized medicine. Curr Opin Biotechnol 58:161–167, 2019
   Tractica: Artificial intelligence market forecast. https://www.tractica. com/research/artificial-intelligence-market-forecasts/
   Noorbakhsh-Sabet N, Zand R, Zhang Y, et al. Artificial intelligence transforms the future of health care. Am J Med 132:795–801, 2019
   Golstein B. A brief taxonomy of AI. https://www.sharper.ai/taxonomy-ai/
   Dickson B. Why the difference between AI and machine learning matters. https://bdtechtalks.com/2018/10/08/artificial-intelligence-vs-machinelearning/
   Browniee J. A tour of machine learning algorithms. 2019. https://machinelearningmastery. com/a-tour-of-machine-learning-algorithms
   Regresszioszamitas. https://hu.wikipedia.org/wiki/Regresszi%C3%B3sz %C3%A1m%C3%ADt%C3%A1s
   Osztalyfelbontas. https://hu.wikipedia.org/wiki/Oszt%C3%A1lyfelbont% C3%A1s
   Kan A. Machine learning applications in cell image analysis. Immunol Cell Biol 95:525–530, 2017
   Linkova D. Top 10 machine learning algorithms: Why are they so important in 2019? https://techjury.net/blog/machine-learning-algorithms/#gref
   Strachnyi K. Brief history of neural networks. https://medium.com/analytics- vidhya/brief-history-of-neural-networks-44c2bf72eec
   Kojuharov S. Cheat sheets for AI, neural networks, machine learning, deep learning & big data. https://becominghuman.ai/cheat-sheets-for-aineural- networks-machine-learning-deep-learning-big-data-678c51b4b463
   Sierra-Sosa D, Garcia-Zapirain B, Castillo C, et al. Scalable healthcare assessment for diabetic patients using deep learning on multiple GPUs, IEEE transactions on industrial informatics. 15:5682−5689, 2019
   Browniee J. A gentle introduction to generative adversarial networks, GANs). https://machinelearningmastery.com/what-are-generative-adversarial- networks-gans/
   Nicholson C. A beginner’s guide to generative adversarial networks, GANs). https://pathmind.com/wiki/generative-adversarial-network-gan
   Korkinof D, Rijken T, O’Neill M, et al. High-resolution mammogram synthesis using progressive generative adversarial networks. https://arxiv.org/ abs/1807.03401
   Blumfield E, Swenson DW, Iyer RS, at al. Gadolinium-based contrast agents – review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. Pediatr Radiol 49:448–457, 2019
   Gong E, Pauly JM, Wintermark M, Zaharchuk G. Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI. J Magn Reson Imaging 48:330–340, 2018
   Mardani M, Gong E, Cheng JY, et al. Deep generative adversarial neural networks for compressive sensing MRI. IEEE Trans Med Imaging 38:167–179, 2019
   Kustner T, Armanious K, Yang J, Y, et al. Retrospective correction of motion- affected MR images using deep learning frameworks. Magn Reson Med 82:1527–1540, 2019
   Kim KH, Do WJ, Park SH. Improving resolution of MR images with an adversarial network incorporating images with different contrast. Med Phys 45:3120–3131, 2018
   Huo D, Kiehn M, Scherzinger A. Investigation of low-dose CT lung cancer screening scan „over-range” issue using machine learning methods. J Digit Imaging 32:931–938, 2019
   Große Hokamp N, Lennartz S, Salem J, et al. Dose independent characterization of renal stones by means of dual energy computed tomography and machine learning: an ex-vivo study. Eur Radiol 2019,, DOI  10.1007/ s00330-019-06455-7
   Liu F, Jang H, Kijowski R, et al. A deep learning approach for 18F-FDG PET attenuation correction. EJNMMI Phys 5:24, 2018
   Ladefoged CN, Marner L, Hindsholm A, et al. Deep learning based attenuation correction of PET/MRI in pediatric brain tumor patients: evaluation in a clinical setting. Front Neurosci 12:1005, 2019
   Arabi H, Zeng G, Zheng G, et al. Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI. Eur J Nucl Med Mol Imaging 46:2746–2759, 2019
   Leynes AP, Yang J, Wiesinger F, et al. Zero-echo-time and Dixon deep pseudo-CT, ZeDD CT): Direct generation of pseudo-CT images for pelvic PET/MRI attenuation correction using deep convolutional neural networks with multiparametric MRI. J Nucl Med 59:852–858, 2018
   Hwang D, Kang SK, Kim KY, et al. Generation of PET attenuation map for whole-body time-of-flight 18F-FDG PET/MRI using a deep neural network trained with simultaneously reconstructed activity and attenuation maps. J Nucl Med 60:1183–1189, 2019
   Shiri I, Ghafarian P, Geramifar P, et al. Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder- decoder, Deep-DAC). Eur Radiol 29:6867–6879, 2019
   Liu CC, Qi J. Higher SNR PET image prediction using a deep learning model and MRI image. Phys Med Biol 64:115004, 2019
   Zaharchuk G. Next generation research applications for hybrid PET/ MR and PET/CT imaging using deep learning. Eur J Nucl Med Mol Imaging 46:2700–2707, 2019
   Munir K, Elahi H, Ayub A, et al. Cancer diagnosis using deep learning: a bibliographic review. Cancers, Basel, 11:1235, 2019
   Trebeschi S, van Griethuysen JJM, Lambregts DMJ, et al. Deep learning for fully-automated localization and segmentation of rectal cancer on multiparametric MR. Sci Rep 7:5301, 2017
   Laukamp KR, Thiele F, Shakirin G, et al. Fully automated detection and segmentation of meningiomas using deep learning on routine multiparametric MRI. Eur Radiol 29:124–132, 2019
   Hu LS, Ning S, Eschbacher JM, et al. Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLoS One 10:e0141506, 2015
   Blackledge MD, Winfield JM, Miah A, et al. Supervised machine-learning enables segmentation and evaluation of heterogeneous post-treatment changes in multi-parametric MRI of soft-tissue sarcoma. Front Oncol 9:941, 2019
   Wu M, Krishna S, Thornhill RE, et al. Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis. J Magn Reson Imaging 50:940–950, 2019
   Huang B, Chen Z, Wu PM, et al. Fully automated delineation of gross tumor volume for head and neck cancer on PET-CT using deep learning: a dual-center study. Contrast Media Mol Imaging 2018:8923028, 2018
   Lindgren Belal S, Sadik M, Kaboteh R, et al. Deep learning for segmentation of 49 selected bones in CT scans: First step in automated PET/CT-based 3D quantification of skeletal metastases. Eur J Radiol 113:89–95, 2019
   Polymeri E, Sadik M, Kaboteh R, et al. Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival. Clin Physiol Funct Imaging 40:106–113, 2020
   Kebir S, Weber M, Lazaridis L, et al. Hybrid 11C-MET PET/MRI combined with „machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220, 2019
   Haubold J, Demircioglu A, Gratz M, et al. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PETMRI and MR Fingerprinting. Eur J Nucl Med Mol Imaging 2019,, DOI  10.1007/ s00259-019-04602-2
   Vogl WD, Pinker K, Helbich TH, et al. Automatic segmentation and classification of breast lesions through identification of informative multiparametric PET/MRI features. Eur Radiol Exp 3:18, 2019
   Gatidis S, Scharpf M, Martirosian P, et al. Combined unsupervised-supervised classification of multiparametric PET/MRI data: application to prostate cancer. NMR Biomed 28:914–922, 2015
   Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol 61:150–166, 2016
   Mirestean CC, Pagute O, Buzea C, et al. Radiomic machine learning and texture analysis - new horizons for head and neck oncology. Maedica, Buchar, 14:126–130, 2019
   Toivonen J, Montoya PI, Movahedi P, et al. Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. PLoS One 14:e0217702, 2019
   Yin Q, Hung SC, Wang L, et al. Associations between tumor vascularity, vascular endothelial growth factor expression and PET/MRI radiomic signatures in primary clear-cell-renal-cell-carcinoma: proof-of-concept study. Sci Rep 7:43356, 2017
   Lucia F, Visvikis D, Vallieres M, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 46:864–877, 2019
   Klinikai kutatas betegadatokbol. Medical Online http://medicalonline. hu/informatika/cikk/klinikai_kutatas_betegadatokbol
   McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. Nature 577:89–94, 2020
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 145
EP 152
PG 8
ER

PT J
AU Kovacs, �
   Legradi, G
   Wirth, A
   Nagy, F
   Forgacs, A
   Barna, S
   Garai, I
   Bukki, T
AF Kovacs, Akos
   Legradi, Gabor
   Wirth, Andras
   Nagy, Ferenc
   Forgacs, Attila
   Barna, Sandor
   Garai, Ildiko
   Bukki, Tamas
TI The value of artificial and human intelligence – the example of bone scintigraphy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE artificial intelligence; bone scintigraphy; clinical validation; noise reduction; signal-to-noise improvement
ID artificial intelligence; bone scintigraphy; clinical validation; noise reduction; signal-to-noise improvement
AB We present a possible method of Artificial Intelligence (AI) based applications that can effectively filter noise-sensitive bone scintigraphy images. The use of special AI, based on preliminary examinations, allows us to significantly reduce study time or activity administered to the patient, thus reducing the patient, assistant, and physician radiation. We present the features of the AI filtering application, its teaching process, which is important to understand, so that the physician can safely take the processed image of the AI as a „secondary reliable opinion” to help them make a more accurate diagnosis. We also examine the robustness of the algorithm, the specificities and challenges of complex clinical control.
C1 [Kovacs, Akos] Mediso Medical Imaging Systems Kft., Laborc. u. 3., 1037 Budapest, Hungary.
   [Legradi, Gabor] Mediso Medical Imaging Systems Kft., Laborc. u. 3., 1037 Budapest, Hungary.
   [Wirth, Andras] Mediso Medical Imaging Systems Kft., Laborc. u. 3., 1037 Budapest, Hungary.
   [Nagy, Ferenc] Scanomed Kft.Debrecen, Hungary.
   [Forgacs, Attila] Scanomed Kft.Debrecen, Hungary.
   [Barna, Sandor] Scanomed Kft.Debrecen, Hungary.
   [Garai, Ildiko] Scanomed Kft.Debrecen, Hungary.
   [Bukki, Tamas] Mediso Medical Imaging Systems Kft., Laborc. u. 3., 1037 Budapest, Hungary.
RP Bukki, T (reprint author), Mediso Medical Imaging Systems Kft., 1037 Budapest, Hungary.
EM tamas.bukki@mediso.com
CR Borbely K. Ujdonsagok es uj lehetosegek az onkologiai betegek terapias vezeteseben: PET/MR klinikai alkalmazasok. Magy Onkol 59:10–16, 2015
   Quantitative Imaging with Tera-Tomo Suit. http://www.openhdx.de/media/ Broschre%20Mediso%20TeraTomo%20Englisch%2001.01_2014.pdf
   InterVeiw Fusion, multimodalitasu kepek feldolgozasat lehetove tevo munkaallomas: http://www.mediso.hu/uploaded/INTF_1014_web.pdf
   Doi K. Computer-aided diagnosis in medical imaging: Historical review, current status and future potential. Comput Med Imaging Graph 31:198−211, 2007
   Razzak MI, Naz S, Zaib A. Deep learning for medical image processing: overview, challenges and the future. In: Classification in BioApps. Lecture Notes in Computational Vision and Biomechanics, vol. 26. Eds. Dey N, Ashour A, Borra S. Springer, 2018
   Han C, Rundo L, Murao K, et al. Bridging the gap between AI and healthcare sides: towards developing clinically relevant AI-powered diagnosis systems. Int J Comput Assist Radiol Surg, 2020 https://arxiv.org/abs/2001.03923v1
   FDA: Artificial Intelligence and Machine Learning in Software as a Medical Device. https://www.fda.gov/medical-devices/software-medical-device-samd/ artificial-intelligence-and-machine-learning-software-medical-device
   Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 43:1723–1738, 2016
   Russo F. Validation of denoising algorithms for medical imaging. In: Advances in Biomedical Sensing, Measurements, Instrumentation and Systems. Lecture Notes in Computational Vision and Biomechanics, vol. 26. Eds. Mukhopadhyay SC, Lay-Ekuakille A. Springer, 2010, pp. 93–105
   Neural Networks and Deep Learning. http://neuralnetworksanddeeplearning. com/index.html
   Convolutional autoencoders for image noise reduction. https://towardsdatascience. com/convolutional-autoencoders-for-image-noise-reduction- 32fce9fc1763
   Park SH, Han K. Methodologic guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction. Radiology 286:800–809, 2018
   Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol 14:109–121, 1979
   Tilbury JB, Van Eetvelt PW, Garibaldi JM, et al. Receiver operating characteristic analysis for intelligent medical systems–a new approach for finding confidence intervals. IEEE Trans Biomed Eng 47:952–963, 2000
   Van den Brink N, Holbrechts B, Brand PLP, et al. Role of intuitive knowledge in the diagnostic reasoning of hospital specialists: a focus group study. BMJ Open 9:e022724, 2019
   Capra F, Luisi PL. Az elet rendszerszemlelete, egyetemi tankonyv, 15.1 fejezet: Az egeszsegugyi ellatas valsaga. Harmonia Halo, 2018, eredeti mu: The Systems View of Life – A Unifying Vison, Cambridge Univ. Press, 2014)
   Zwingmann J, Baile WF, Schmier JW, et al. Effects of patient-centered communication on anxiety, negative affect, and trust in the physician in delivering a cancer diagnosis: A randomized, experimental study. Cancer 123:3167–3175, 2017
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 153
EP 158
PG 6
ER

PT J
AU Balkay, L
   Beresova, M
   Vas, NF
   Kallos-Balogh, P
   Forgacs, A
AF Balkay, Laszlo
   Beresova, Monika
   Vas, Norman Felix
   Kallos-Balogh, Piroska
   Forgacs, Attila
TI Methods and feasibilities of texture analysis in PET diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PET/CT; quantification; image analysis; heterogeneity; texture parameter
ID PET/CT; quantification; image analysis; heterogeneity; texture parameter
AB One of the current research objectives of medical imaging is to determine the prognostic value of tumor textures and related numerical values. In PET/CT studies the diagnostic and prognostic values of specific texture parameters were confirmed at several tumor types (lung, prostate, cervix, colon, head and neck). However, the results are often contradictory, various publications find different texture parameters useful for the same tumor type. The reason for the contradictions is partly methodological, since the definition and the calculation of texture data is a multi-step process. Such steps include scan protocol, image reconstruction, tumor segmentation, re-sampling the voxel values and the form of texture algorithms. Recent publications show that by harmonizing these steps, the prognostic power and reliability of the texture features can be improved. The most optimal way of harmonization would be a special phantom application that could simulate inhomogeneous distributions typical for tumor tissues, with high reproducibility.
C1 [Balkay, Laszlo] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Beresova, Monika] Debreceni Egyetem, AOK, Orvosi Kepalkoto Intezet, Radiologia nem onallo TanszekDebrecen, Hungary.
   [Vas, Norman Felix] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Kallos-Balogh, Piroska] University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, Nagyerdei krt. 98., 4012 Debrecen, Hungary.
   [Forgacs, Attila] Scanomed Kft.Debrecen, Hungary.
RP Balkay, L (reprint author), University of Debrecen, Medical and Health Science Center, Institute of Nuclear Medicine, 4012 Debrecen, Hungary.
EM balkay.laszlo@med.unideb.hu
CR Hatt M, Tixier F, Pierce L, et al. Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur J Nucl Med Mol Imaging 44:151–165, 2017
   Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: Where do we stand? J Nucl Med 56:1624–1644, 2015
   Larue RT, Defraene G, De Ruysscher D, et al. Quantitative radiomics studies for tissue characterization: A review of technology and methodological procedures. Br J Radiol 90:20160665, 2017
   Sanduleanu S, Woodruff HC, de Jong EEC, et al. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score. Radiother Oncol 127:349–360, 2018
   Cook GJR, Azad G, Owczarczyk K, et al. Challenges and promises of PET radiomics. Int J Radiat Oncol Biol Phys 102:1083–1089, 2018
   Nougaret S, Tibermacine H, Tardieu M, et al. Radiomics: an introductory guide to what it may foretell. Curr Oncol Rep 21:70, 2019
   Thawani R, McLane M, Beig N, et al. Radiomics and radiogenomics in lung cancer: A review for the clinician. Lung Cancer 115:34–41, 2018
   Zwanenburg A, Leger S, Vallieres M, et al. Image biomarker standardisation initiative. ArXiv Preprint, 2016. https://arxiv.org/pdf/1612.07003v11. pdf
   El Naqa I, Grigsby PW, Apte A, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 42:1162–1171, 2009
   Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378, 2011
   Lovinfosse P, Hatt M, Visvikis D, et al. Heterogeneity analysis of 18F-FDG PET imaging in oncology: clinical indications and perspectives. Clin Transl Imaging 6:393–410, 2018
   Lovinfosse P, Visvikis D, Hustinx R, et al. FDG PET radiomics: a review of the methodological aspects. Clin Transl Imaging 6:379–391, 2018
   Castiglioni I, Gallivanone F, Soda P, et al. AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics. Eur J Nucl Med Mol Imaging 46:2673–2699, 2019
   Beresova M, Forgacs A, Bujdoso B, et al. Comparing the reliability of biomedical texture analysis tools on different image types. Acta Polytechn Hung 15:29–48, 2018
   Beresova M, Larroza A, Arana E, et al. 2D and 3D texture analysis to differentiate brain metastases on MR images: proceed with caution. MAGMA 31:285–294, 2018
   Reuze S, Orlhac F, Chargari C, et al. Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget 8:43169–43179, 2017
   Bailly C, Bodet-Milin C, Couespel S, et al. Revisiting the robustness of PET-based textural features in the context of multi-centric trials. PLoS One 11:e0159984, 2016
   Forgacs A, Beresova M, Garai I, et al. Impact of intensity discretization on textural indices of [18F]FDG-PET tumour heterogeneity in lung cancer patients. Phys Med Biol 64:125016, 2019
   Forgacs A, Pall Jonsson H, Dahlbom M, et al. A study on the basic criteria for selecting heterogeneity parameters of F18-FDG PET images. PLoS One 11:e0164113, 2016
   Forgacs A, Kallos-Balogh P, Nagy F, et al. Activity painting: PET images of freely defined activity distributions applying a novel phantom technique. PLoS One 14:e0207658, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2020
VL 64
IS 2
BP 159
EP 167
PG 9
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI Foreword
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Ostoros, Gyula] Magyar Tudogyogyasz TarsasagBudapest, Hungary.
RP Ostoros, Gy (reprint author), Magyar Tudogyogyasz Tarsasag, Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 173
EP 173
PG 1
ER

PT J
AU Bogos, K
   Kiss, Z
   Galffy, G
   Tamasi, L
   Ostoros, Gy
   Muller, V
   Urban, L
   Bittner, N
   Sarosi, V
   Vastag, A
   Polanyi, Z
   Nagy-Erdei, Zs
   Voko, Z
   Nagy, B
   Rokszin, Gy
   Abonyi-Toth, Zs
   Moldvay, J
AF Bogos, Krisztina
   Kiss, Zoltan
   Galffy, Gabriella
   Tamasi, Lilla
   Ostoros, Gyula
   Muller, Veronika
   Urban, Laszlo
   Bittner, Nora
   Sarosi, Veronika
   Vastag, Aladar
   Polanyi, Zoltan
   Nagy-Erdei, Zsofia
   Voko, Zoltan
   Nagy, Balazs
   Rokszin, Gyorgy
   Abonyi-Toth, Zsolt
   Moldvay, Judit
TI Novel approaches to the epidemiology of lung cancer in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; epidemiology; incidence; mortality; Hungary
ID lung cancer; epidemiology; incidence; mortality; Hungary
AB In the international publications, in the last decades, incidence and mortality of lung cancer was the highest in Hungary in the ranking of European countries and even worldwide, despite the fact that no lung cancer incidence data were reported from Hungary until 2019. In the studies published by our working group at the end of 2019 and in the first half of 2020, we were the first to publish Hungarian lung cancer incidence and mortality data based on research on the NEAK database. The results of this study showed a significant, 25-30% lower incidence of lung cancer in Hungary than the previously reported data. Based on these findings, it was determined that the previously reported Hungarian lung cancer incidence and mortality data can be compiled due to different methodological applications of inadequately calculated results, and Hungarian lung cancer incidence and mortality are equally high, but not higher than the average in Central European countries. In addition, a decrease in the incidence and mortality of male lung cancer was measured between 2011 and 2016, while increasing values were found for women.
C1 [Bogos, Krisztina] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Kiss, Zoltan] MSD Pharma Hungary Kft.Budapest, Hungary.
   [Galffy, Gabriella] County Hospital of PulmonologyTorokbalint, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Urban, Laszlo] Matrai GyogyintezetMatrahaza, Hungary.
   [Bittner, Nora] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Sarosi, Veronika] University of Pecs, Faculty of Medicine, Department of PulmonologyPecs, Hungary.
   [Vastag, Aladar] MSD Pharma Hungary Kft.Budapest, Hungary.
   [Polanyi, Zoltan] MSD Pharma Hungary Kft.Budapest, Hungary.
   [Nagy-Erdei, Zsofia] MSD Pharma Hungary Kft.Budapest, Hungary.
   [Voko, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Nagy, Balazs] Semmelweis UniversityBudapest, Hungary.
   [Rokszin, Gyorgy] RxTarget LtdSzolnok, Hungary.
   [Abonyi-Toth, Zsolt] RxTarget LtdSzolnok, Hungary.
   [Moldvay, Judit] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
RP Bogos, K (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
CR Bray F, Ferlay J, Soerjomataram ME I, et al. Cancer today − Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403, 2013
   Ferlay J, Colombet M, Soerjomataram I. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356−387, 2018
   European Commission. Revision of the European Standard Population — Report of Eurostat’s task force. Luxembourg: Publications Office of the European Union, 2013. https://ec.europa.eu/eurostat/ documents/3859598/5926869/KS-RA-13-028-EN.PDF/e713fa79-1add- 44e8-b23d-5e8fa09b3f8f
   Bogos K, Kiss Z, Galffy G, et al. Revising incidence and mortality of lung cancer in Central Europe: an epidemiology review from Hungary. Front Oncol 9:1051, 2019
   Fu JB, Kau TY, Severson RK. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 127:768−777, 2005
   Malvezzi M, Bertuccio P, Rosso T. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 26:779−786, 2015
   McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7:418–419, 2016
   Jemal A, Thun MJ, Ries LA. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694, 2008
   Rivera MP. Lung cancer in women: differences in epidemiology, biology, histology, and treatment outcomes. Semin Respir Crit Care Med 34:792−801, 2013
   Tombor I, Paksi B, Urban R, et al. Epidemiology of smoking in the Hungarian population, based on national representative data. Clin Exp Med J 4:1–11, 2010
   Cselko Z, Kovacs G. Dohanyzasi szokasok Magyarorszagon: az utobbi evtized felmereseinek eredmenye. Orv Hetil 154:1454−1468, 2013
   Marel M, Koubkova L, Kovarikova Z. Lung cancer, pulmonary emphysema and pleural effusion: An autopsy study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:642−647, 2015
   McFarlane MJ, Feinstein AR, Wells CK. Clinical features of lung cancers discovered as a postmortem „surprise”. Chest 90:520−523, 1986
   Karwinski B, Svendsen E, Hartveit F. Clinically undiagnosed malignant tumours found at autopsy. APMIS 98:496−500, 1990
   European Health Information Gateway. WHO Europe. Report on autopsy rate of for hospital deaths. https://gateway.euro.who.int/en/indicators/ hfa_544-6400-autopsy-rate-for-hospital-deaths/visualizations/# id=19639&tab=table
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 175
EP 181
PG 7
ER

PT J
AU Timar, J
   Mehes, G
   Vass, L
AF Timar, Jozsef
   Mehes, Gabor
   Vass, Laszlo
TI Molecular diagnostics of lung cancer and its clinical relevance
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; molecular classification; predictive diagnostics
ID lung cancer; molecular classification; predictive diagnostics
AB Molecular classification of lung cancer developed in the past decades to the level where even the rare genetic alterations are included. Unfortunately, adenocarcinoma benefited from this development almost exclusively. Furthermore, the tumor-agnostic novel therapy indications influence the molecular diagnostics of lung cancer including microsatellite status, tumor mutation burden or NTRK fusion gene determinations. On the other hand, the still low resection rate of lung cancer and limited availability of tumor tissue for diagnosis opened the way of routine use of liquid biopsy technologies. The routine use of target therapies triggered the development of various genetic resistance mechanisms, the monitoring of which gradually became a standard of monitoring of the disease. Beside the „targeted” diagnostics, multigene panel testing or whole exome sequencing are more frequent, resulting in a more complex genetic picture of lung cancer. This requires the categorization of genetic alterations into predictive levels for standard, investigational or hypothetic target therapies in the molecular pathology reports.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Vass, Laszlo] Flor Ferenc University Hospital of Pest County, Department. of Pathology/CytopathologyKistarcsa, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
CR The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancer. Nature 489:519−525, 2012
   The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543−550, 2014
   Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutant human cancers. Cancer Metastasis Rev, 2020,, DOI  10.1007/s10555- 020-09915-5
   George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiling of small cell lung cancer. Nature 524:47−53, 2015
   Chakravarty D, Gao J, Phillips SM, et al. OncoKB: A precision oncology knowledge base. J Clin Oncol Prec Oncol 20.1200, 2017
   Mateo J, Chakravarty D, Diensmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets, ESCAT). Ann Oncol 29:1895−1902, 2018
   Domchek SM, Mardis E, Carlisle JW, Owonikoko TK. Integrating genetic and genomic testing into oncology practice. ASCO Educational Book, e259-e263, 2020
   Sisson BA, Uvalic J, Kelly K, et al. Technical and regulatory considerations for taking liquid biopsy to the clinic. Biomarker Insights 14:1−11, 2019
   www.foundationmedicine.com
   www.natera.com
   Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446−454, 2017
   Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815, 2016
   Blakeley CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693−1704, 2017
   Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121:727−737, 2019
   Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118−1133, 2016
   Timar J, Lotz G, Raso E, Moldvay J. Az ALK-pozitiv tudorak korszeru diagnosztikaja. Magy Onkol 61:301−311, 2017
   Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res 25:6662−6670, 2019
   Bubendorf L., Buttner R, Al-Dayel F, et al. Testing for ROS1 in nonsmall cell lung cancer: a review with recommendations. Virchows Arch 469:489−503, 2016
   Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small cell lung cancer. JCO Precis Oncol 2017:10.1200/PO.17.00063, 2017
   Dagogo-Jack I, Stevenson SE, Lin JJ, et al. Emergence of RET V804M gatekeeper mutation during treatment with vandetanib in RET-rearranged NSCLC. J Thorac Oncol 13:e226−e227, 2018
   Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol 30(suppl. 8):viii16−viii22, 2019
   Ladanyi A, Timar J. Immunologic and immunogenomic aspects of tumor progression. Semin Cancer Biol 60:249−261, 2020
   Timar J, Ladanyi A. A daganatok immunterapiajanak prediktiv markerei, a PD-L1-meghatarozas gyakorlati kerdesei. Magy Onkol 61:158−166, 2017
   Tafe LJ. Non-small cell lung cancer as a precision oncology paradigm: emerging targets and tumor mutation burden, TMB). Adv Anat Pathol 27:3−10, 2020
   https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves- pembrolizumab-adults-and-children-tmb-h-solid-tumors
   McKean WB, Moser JC, Rimm D, et al. Biomarkers in precision cancer immunotherapy: promise and challenges. ASCO Educational Book, e275− e287, 2020
   Lagos GG, Izar B, Rizvi NA. Beyond tumor PD-L1: emerging genomic biomarkers for checkpoint inhibitor immunotherapy. ASCO Educational Book, e47−e57, 2020
   Calles A, Riess JW, Brahmer JR. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. ASCO Educational Book, 372−382, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 183
EP 189
PG 7
ER

PT J
AU Agocs, L
   Renyi-Vamos, F
AF Agocs, Laszlo
   Renyi-Vamos, Ferenc
TI What’s new in the surgical treatment of lung cancer?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; thoracic surgery; minimal invasive surgery; salvage surgery; oligometastasis
ID lung cancer; thoracic surgery; minimal invasive surgery; salvage surgery; oligometastasis
AB The incidence of lung cancer in Hungary remains among the highest in Europe. Despite its high mortality rate, surgical treatment of early stage disease may lead to full recovery. In the past two decades, the field of thoracic surgery has seen significant technological advances, as well as a major paradigm shift. Our article aims to summarize these recent improvements. Prediction of survival rates improved significantly due to the 8th revision of the TNM system, but there are other new predictive models too. The growing number of minimally invasive surgical procedures shortened and eased the pre- and postoperative periods. Perioperative risks can be reduced and quality of life will improve with sub-lobar resections. A range of newly developed equipment enables gas exchange leaving free access to airways thus ensuring patient safety during extended procedures. Finally, the development of novel biological drugs brought on the need to reconsider the operability of oligometastatic patients and those requiring so-called salvage procedures.
C1 [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Agocs, L (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, 1122 Budapest, Hungary.
EM agocs.laszlo.dr@gmail.com
CR Bogos K, Kiss Z, Galffy G, et al. Revising incidence and mortality of lung cancer in Central Europe: An epidemiology review from Hungary. Front Oncol 9:1051, 2019
   Bogos K, Ostoros Gy. Tudorak. Koranyi Bulletin 1:32−41, 2019
   Rami-Porta R. Staging Manual in Thoracic Oncology. IASLC, 2016
   Baliko Z, Kerpel-Fronius A, Sarosi V. A tudorak TNM beosztasanak 8. verzioja. Med Thorac 70:94–99, 2017
   Robold T, Neumeier J, Ried M, et al. Ergeben sich durch die Einfuhrung der 8. Auflage der TNM-Klassifikation Anderungen fur eine leitliniengerechte, chirurgische Therapiestrategie des Lungenkarzinoms? Zentralbl Chir, 2020,, DOI  10.1055/a-1164-7058
   Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675−1684, 2015
   Shang X, Yu H, Lin J, et al. A novel nomogram including AJCC stages could better predict survival for NSCLC patients who underwent surgery: a large population-based study. J Oncol 2020:7863984, 2020
   Ng CS, Lee TW, Wan S, et al. Thoracotomy is associated with significantly more profound suppression in lymphocytes and natural killer cells than video- assisted thoracic surgery following major lung resections for cancer. J Invest Surg 18:81−88, 2005
   Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e278S−e313S, 2013
   Yang CFJ, Yendamuri S, Mayne NR, et al. The role of thoracoscopic pneumonectomy in the management of non-small cell lung cancer: A multicenter study. J Thorac Cardiovasc Surg 158:252−264, 2019
   Soultanis KM, Chen-Chao M, Chen J, et al. Technique and outcomes of 79 consecutive uniportal video-assisted sleeve lobectomies. Eur J Cardiothorac Surg 56:876−882, 2019
   Gonzalez-Rivas D, Garcia A, Chen C, et al. Technical aspects of uniportal video-assisted thoracoscopic double sleeve bronchovascular resections. Eur J Cardiothorac Surg, 2020,, DOI  10.1093/ejcts/ezaa037
   Andrade R. Commentary: Why do uniportal video-assisted thoracoscopic lobectomy? J Thorac Cardiovasc Surg 159:2496−2497, 2020
   Sihoe ADL. Video-assisted thoracoscopic surgery as the gold standard for lung cancer surgery. Respirology, 2020,, DOI  10.1111/resp.13920
   Horita K, Itoh T, Furukawa K, et al. Carinal reconstruction under veno- venous bypass using a percutaneous cardiopulmonary bypass system. Thorac Cardiovasc Surg 44:46−49, 1996
   Spaggiari L, Rusca M, Carbognani P, et al. Segmentectomy on a single lung by femorofemoral cardiopulmonary bypass. Ann Thorac Surg 64:1519, 1997
   Rinieri P, Peillon C, Bessou JP, et al. National review of use of extracorporeal membrane oxygenation as respiratory support in thoracic surgery excluding lung transplantation. Eur J Cardiothorac Surg 47:87−94, 2015
   Madurka I, Elek J, Kocsis A, et al. Venovenosus extrakorporalis membranoxigenizacioval, ECMO, vegzett mellkassebeszeti mutetek tapasztalatai Magyarorszagon. Retrospektiv klinikai tanulmany. Orv Hetil 160:1655−1662, 2019
   Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615−622, 1995
   Keenan RJ, Landreneau RJ, Maley RH, Jr, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 78:228−233, 2004
   Kodama K, Higashiyama M, Okami J, et al. Oncologic outcomes of segmentectomy versus lobectomy for clinical T1a N0 M0 non-small cell lung cancer. Ann Thorac Surg 101:504−511, 2016
   Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial, CALGB/Alliance 140503). Lancet Respir Med 6:915−924, 2018
   Ijsseldijk MA, Shoni M, Siegert C, et al. Oncological outcomes of lobar resection, segmentectomy, and wedge resection for T1a non–small-cell lung carcinoma: a systematic review and meta-analysis. Semin Thorac Cardiovasc Surg, 2019,, DOI  10.1053/j.semtcvs.2019.08.004
   Zheng YZ, Zhai WY, Zhao J, et al. Oncologic outcomes of lobectomy vs. segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis. J Thorac Dis 12:3178−3187, 2020
   Winckelmans T, Decaluwe H, De Leyn P, et al. Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg 57:1051−1060, 2020
   Wen Z, Zhao Y, Fu F, et al. Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter. J Cancer Res Clin Oncol 146:1603−1613, 2020
   Kamigaichi A, Tsutani Y, Kagimoto A, et al. Comparing segmentectomy and lobectomy for clinical stage IA solid-dominant lung cancer measuring 2.1 to 3 cm. Clin Lung Cancer, 2020,, DOI  10.1016/j.cllc.2020.04.015
   Nakamura K, Saji H, Nakajima R, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer, JCOG0802/WJOG4607L). Jpn J Clin Oncol 40:271−274, 2010
   Uramoto H. Current topics on salvage thoracic surgery in patients with primary lung cancer. Ann Thorac Cardiovasc Surg 22:65−68, 2016
   Takamochi K, Suzuki K, Sugimura H, et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 58:149−155, 2007
   Hishida T, Nagai K, Mitsudomi T, et al. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg 140:e69−71, 2010
   Bauman JE, Mulligan MS, Martins RG, et al. Salvage lung resection after definitive radiation, >59 Gy, for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg 86:1632−1638, 2008
   Kaba E, Ozyurtkan MO, Ayalp K, et al. Salvage thoracic surgery in patients with lung cancer: potential indications and benefits. J Cardiothorac Surg 13:13, 2018
   Bograd AJ, Mann C, Gorden JA, et al. et al. Salvage lung resections after definitive chemoradiotherapy: a safe and effective oncologic option. Ann Thorac Surg, 2020,, DOI  10.1016/j.athoracsur.2020.04.035
   Hamaji M, Ozasa H, Yoshizawa A, et al. Salvage thoracoscopic resection after nivolumab for stage IV. Asian Cardiovasc Thorac Ann 28:216−218, 2020
   Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1−24, 2020
   Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 13:8−10, 1995
   Niibe Y, Chang JY, Onishi H et al. Oligometastases/oligo-recurrence of lung cancer. Pulm Med 2013:438236, 2013
   Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 15:346−355, 2014
   Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:346−351, 2013
   Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-smallcell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558−1565, 2019
   Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501, 2018
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 190
EP 195
PG 6
ER

PT J
AU Galffy, G
AF Galffy, Gabriella
TI From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; target therapy; EGFR mutation; EGFR T790M mutation; ALK mutation
ID lung cancer; target therapy; EGFR mutation; EGFR T790M mutation; ALK mutation
AB Lung cancer is the leading cause of cancer deaths not only in Hungary but also in the world. Within this, women’s lung cancer morbidity and mortality have increased significantly in recent years. For many years, we only had a chemotherapy option to treat lung cancer. The year 2005 was a major breakthrough in the treatment of non-small cell lung cancer with the advent of a new treatment strategy, targeted treatments, EGFR-TKI treatments. Since then, we have several years of experience with first-, second-, and even third-generation TKI treatments in lung adenocarcinoma. The second major step in targeted therapy for lung cancer was to learn about ALK mutant lung cancer and the emergence of ALK inhibitor therapies on the therapeutic palette with the advent of first, second and third generation formulations. In recent years, the range of options for targeted therapeutic targets has expanded to include personalized therapeutic options. By recognizing and targeting the ROS1, BRAF, MET, RET, NTRK, HER2 mutations, we can tailor the most optimal treatment to more and more patients.
C1 [Galffy, Gabriella] County Hospital of Pulmonology, Munkacsy Mihaly u. 70., 2045 Torokbalint, Hungary.
RP Galffy, G (reprint author), County Hospital of Pulmonology, 2045 Torokbalint, Hungary.
EM ggalffy@hotmail.com
CR Moldvay J, Bogos K. Molekularis celzott terapia tudorakban − Nemzetkozi elmelet, hazai gyakorlat. Med Thorac 71:355−365, 2018
   Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129−2139, 2004
   Harrison PT, Vyse S, Huang PH, et al. Rare epidermal growth factor receptor, EGFR, mutations in non-small cell lung cancer. Semin Cancer Biol 61:167−179, 2020
   Mok TS, Wu YL, Thonprasert S, et al. Gefitinib or paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947−957, 2009
   Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer, OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742, 2011
   Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation- positive non-small-cell lung cancer, EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246, 2012
   Urata Y, Katakami N, Morita S, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol 34:3248−3257, 2016
   Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334, 2013
   Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations, LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222, 2014
   Yang JC, Wu YL.. Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma, LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2:141−151, 2015
   Haaland B, Tan PS, de Castro G, et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol 6:805−811, 2014
   Liang W, Wu X, Fang W. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 9:e85245, 2014
   Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer, LUXLung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 5:577−589, 2016
   Paz-Ares L, Tan EH, O’Byrne K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28:270−277, 2017
   Takeda M, Nakagawa K. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Mol Clin Oncol 1:3−6, 2017
   Mok TS, Cheng Y, Zhou X. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 36:2244−2250, 2018
   Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5), 2016
   Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFRT790M-positive lung cancer. N Engl J Med 376:629−640, 2017
   Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786−792, 2005
   Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 9:1046−1061, 2014
   Goss G, Tsai CM, Shepherd FA. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer, AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 12:1643−1652, 2016
   Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113−125, 2018
   Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4- ALK fusion gene in non-small-cell lung cancer. Nature 448:561−566, 2007
   Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190−1203, 2007
   Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004–1012, 2011
   Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25:415–422, 2014
   Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394, 2011
   Solomon BJ, Kim DW, Nakagawa K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177, 2014
   Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res 21:2745–2752, 2015
   Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473–481, 2014
   Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472–1482, 2012
   Choi YL, Soda M, Yamashita Y, et al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739, 2010
   Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer, AF-002JG): results from the dose-finding portion of a Phase 1/2 study. Lancet Oncol 15:1119–1128, 2014
   Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679–690, 2011
   Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-smallcell lung cancer. N Engl J Med 370:1189–1197, 2014
   Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028, 2014
   Zykadia alkalmazasi eloras., www.ogyei.gov.hu/gyogyszeradatbazis
   Alecensa alkalmazasi eloras., www.ogyei.gov.hu/gyogyszeradatbazis
   Seto T, Kiura K, Nishio M, et al. CH5424802, RO5424802, for patients with ALK-rearranged advanced non-small-cell lung cancer, AF-001JP study): a single- arm, open-label, Phase 1–2 study. Lancet Oncol 14:590–598, 2016
   Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 34:4079–4085, 2016
   Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661– 668, 2016
   Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838, 2017
   Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer, NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35(18_suppl):LBA9008, 2017
   Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 19:1654–1667, 2018
   Kazandjian D, Blumenthal GM, Luo L, et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic nonsmall cell lung cancer. Oncologist 21:974−980, 2016
   Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:261−270, 2020
   Rozlytrek, entrektinib, alkalmazasi eloiras
   Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol 10:1670−1674, 2015
   Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271−282, 2020
   Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience. J Thorac Oncol 10:768−777, 2015
   Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17:642−560, 2016
   Li GG, Somwar R, Joseph J, et al. Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations. Clin Cancer Res 23:2981−2990, 2017
   Drilon AE, Subbiah V, Oxnard GR, et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET altered cancers. J Clin Oncol 36(15_suppl):102, 2018
   Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 11:1493−1502, 2016
   Engstrom LD, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res 23:6661−6672, 2017
   Lohinai Z, Klikovits T, Moldvay J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep 7:39721, 2017
   Yu HA, Sima CS, Shen R, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol 10:431−437, 2015
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 196
EP 204
PG 9
ER

PT J
AU Petak, I
AF Petak, Istvan
TI The application of target-based tissue-agnostic therapy in the treatment of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE precision medicine; targeted molecular therapy; immunotherapy; computational intelligence; diagnostic molecular pathology
ID precision medicine; targeted molecular therapy; immunotherapy; computational intelligence; diagnostic molecular pathology
AB More than 6 million mutations of more than 600 cancer genes can occur in over 200 tumor types according to the COSMIC (Catalogue of Somatic Mutations in Cancer) database. The theoretical combination of all „driver” alterations and tumor types adds up to an enormous number. Therefore, there is a legitimate need to use the same targeted therapy in the presence of its target and mechanism of action in multiple tumor types. The first tissue-agnostic drugs that are registered solely based on molecular biomarkers are the NTRK inhibitors (larotrectinib and entrectinib) and the PD-1 inhibitor pembrolizumab in microsatellite instable (MSI) and tumor mutation burden (TMB) high tumors. These targets are also present in lung cancer, and we have clinical proof of the activity of treatments. In addition, the molecular targets of many targeted therapies registered in other tumor types occur in lung cancer for target-based tissue-agnostic therapy planning in lung cancer.
C1 [Petak, Istvan] Oncompass Medicine Kft., Retek utca 34., 1024 Budapest, Hungary.
RP Petak, I (reprint author), Oncompass Medicine Kft., 1024 Budapest, Hungary.
EM istvan.petak.dr@gmail.com
CR ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578:82−93, 2020
   Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 47:D941−D947, 2019
   Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 339:1546−1558, 2013
   Hess JM, Bernards A, Kim J, et al. Passenger hotspot mutations in cancer. Cancer Cell 36:288−301, 2019
   Berger AH, Brooks AN, Wu X, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 32:214−228, 2017
   Tihanyi D, Kispeter E, Vidermann M, et al. AI oncology algorithm-based prioritisation of EGFR inhibitors in case of rare EGFR mutations. Ann Oncol 30(Suppl_7):vii30, 2019
   Zsakai L, Sipos A, Dobos J, et al. Targeted drug combination therapy design based on driver genes. Oncotarget 10:5255−5266, 2019
   Collisson E, Campbell J, Brooks A, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543–550, 2014
   Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321−1328, 2019
   Wheler JJ, Janku F, Naing A, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 76:3690−3701, 2016
   Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25:744−750, 2019
   Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877–4882, 2010
   Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer, SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324−1334, 2015
   Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets, ESCAT). Ann Oncol 29:1895−1902, 2018
   Moreira A, Masliah-Planchon J, Callens C, et al. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. Eur J Cancer 121:202−209, 2019
   Dirner A, Doczi R, Filotas P, et al. Evaluation of a computational decision support system for molecularly targeted treatment planning by the clinical outcome data of the randomized trial SHIVA01. J Clin Oncol 38(15_suppl): abstr. 3642, 2020
   Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017:10.1200/ PO.17.00073, 2017
   Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731−747, 2018
   Hyman DM, Tan DS, van Tilburg CM, et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 30(Suppl 9):ix123, 2019
   Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol 2018:10.1200, 2018
   Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469−1472, 2013
   Xia H, Xue X, Ding H, et al. Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: Results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer. Clin Lung Cancer 21:247−254, 2020
   Laetsch TW, Hawkins DS. Larotrectinib for the treatment of TRK fusion solid tumors. Expert Rev Anticancer Ther 19:1−10, 2019
   Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs 24:1493−1500, 2015
   Rolfo C, Dziadziuszko R, Doebele RC, et al. Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 30(Suppl 5):v180, 2019
   Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731−739, 2018
   Hyman D, Kummar S, Farago A, et al. Phase I and expanded access experience of LOXO-195, BAY 2731954), a selective next-generation TRK inhibitor, TRKi). Cancer Res 79(13 Suppl):Abstr. CT127, 2019
   Doebele RC, Dziadziuszko R, Drilon A, et al. Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2. Ann Oncol 30(Suppl 5):v865, 2019
   Cocco E, Schram AM, Kulick A, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med 25:1422−1427, 2019
   Doczi R, Tihanyi D, Filotas P, et al. Analysis of molecular profile complexities for immunotherapy decision support. Ann Oncol 30(Suppl 5):v512, 2019
   Schwaederle M, Daniels GA, Piccioni DE, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 14:1488–1494, 2015
   Wheler J, Tsimberidou AM, Hong D, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 18:2922–2929, 2012
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 206
EP 215
PG 10
ER

PT J
AU Ostoros, Gy
AF Ostoros, Gyula
TI Immunotherapy of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immune checkpoint inhibitors; non-small cell lung cancer; small cell lung cancer
ID immune checkpoint inhibitors; non-small cell lung cancer; small cell lung cancer
AB Immune checkpoint inhibitor therapy in lung cancer is a new effective treatment as part of a complex treatment strategy. In the advanced stage of non-small cell non-squamous lung cancer, without actionable mutation, the immune monotherapy or combination treatment with platinum based chemotherapy is a new standard of care depending on PD-L1 status. In case of advanced squamous cell lung cancer the situation is similar. The exact role of combination PD-1 axis and CTLA-4 inhibitor treatment with or without chemotherapy is not exactly defined. Immune checkpoint inhibitor therapy can be used in second or more line treatment as well. After exhaustion of targeted treatment the efficacy of the combination of immunotherapy with angiogenesis inhibitor and platinum based chemotherapy is promising. In locally advanced non-small cell lung cancer after radiochemotherapy the consolidation PD-L1 inhibitor treatment is a new standard of care in case of PD-L1 positivity. There are Phase III trials in neoadjuvant and adjuvant setting as well. In extensive stage small cell lung cancer the platinum-etoposide treatment with PD-L1 inhibitor is a new standard, but we do not have any effective biomarkers yet.
C1 [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Rakoczi u. 13., 2092 Budapest, Hungary.
RP Ostoros, Gy (reprint author), National Koranyi Institute of Pulmonology, 2092 Budapest, Hungary.
EM drostorosgyula@gmail.com
CR Groen HJM, Akerley WL, Souquet PJ, et al. Capmatinib in patients with high level MET amplified advanced NSCLC: Results from the phase 2 GEOMETRY mono-1 study. J Clin Oncol 38(15_suppl):Abstr. 9509, 2020
   Besse B, Felip E, Clifford C, et al. AcceleRet Lung: A phase III study of first line pralsetinib in patients with RET-fusion+ advanced/metastatic NSCLC. J Clin Oncol 38(15_suppl):Abstr. 9515, 2020
   Moldvay J, Ostoros Gy. Tamadas helyett onvedelem − immunterapia tudorakban. Magy Onkol 60:28−33, 2016
   Li Q, Yuan D, Ma C, et al. A new hope: the immunotherapy in small cell lung cancer. Neoplasma 63:342−350, 2016
   Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med 375:1823−1833, 2016
   Alguilar EJ, Gainor J, Kravets S, et al. Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%. J Thorac Oncol 13(10S):367–368, 2018
   Socinski M, Creelan B, Horm L, et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice, IC, of platinum-based doublet chemotherapy, PT-DC, as first-line therapy for stage iv/recurrent programmed death ligand 1, PD-L1)−positive NSCLC. Ann Oncol 27, suppl_6):LBA7, 2016
   Jassem J, Herbst RJ, Marinis F, et al. IMpower110: Clinical safety in a phase III study of atezolizumab, atezo, monotherapy, mono, vs platinum- based chemotherapy, chemo, in first-line non-small cell lung cancer, NSCLC). J Clin Oncol 38(15_suppl):Abstr. e21623, 2020
   Abreau D, Powell SF, Hochmair, et al. Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy with or without pembrolizumab in patients with previously untreated metastatic nonsqamous NSCLC. J Clin Oncol 38(15_suppl):Abstr. 9582, 2020
   Papadimitrakopoulou V, Cobo M, Bordoni R, et al. IMpower132: PFS and safety results with 1L atezolizumab+carboplatin/cisplatin+pemetrexed in stage IV non-squamous NSCLC. J Thorac Oncol 13(10S):S332–S333, 2018
   Pacheco JM. KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. Transl Lung Cancer Res 9:148–153, 2020
   Jotte R, Cappuzzo F, Vynnychenko I, et al. IMpower131: Final OS results of carboplatin+nab-paclitaxel +/- atezolizumab in advanced squamous NSCLC. J Thorac Oncol 14(10S):S243–S244, 2019
   Ramaligman SS, Ciuelanu TE, Pluzanski, et al. Nivolumab+ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Oncol 38(15_suppl):Abstr. 9500, 2020
   Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab, tira, plus atezolizumab, atezo, versus placebo plus atezo as first-line, 1L, treatment in patients with PD-L1-selected NSCLC, CITYSCAPE). J Clin Oncol 38(15_suppl):Abstr. 9503, 2020
   Reck M, Ciuelanu TE, Dols MC, et al. Nivolumab, NIVO)+ipilimumab, IPI)+2 cycles of platinum-doublet chemotherapy, chemo, vs 4 cycles chemo as first line, 1L, treatment, tx, for stage IV recurrent non-small cell lung cancer, NSCLC): CheckMate 9LA. J Clin Oncol 38(15_suppl):Abstr. 9501, 2020
   Reck M, Mok TS, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer, IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7:387–401, 2019
   Gettinger S, Borghaei H, Vokes E, et al. Five year outcomes from the randomized, phase 3 trials CheckMate 017/057: Nivolumab versus docetaxel in previously treated advanced NSCLC. J Thorac Oncol 14(10S):S244–S245, 2019
   Horn L, Spiegel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with non-small-cell lung cancer: two year outcomes from two randomized, open-label, phase III trials. J Clin Oncol 35:3924–3933, 2017
   Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer, KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550, 2016
   Rittmeier A, Barlesi F, Watercamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer, OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255−265, 2017
   Mederos N, Peters S. Upfront immunotherapy in metastatic NSCLC. Schweizer Zeitschrift fur Onkologie 2:14−19, 2020
   Passiglia F, Galvano PF, Rizzo S, et al. Looking for the best immune- checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab, atezolizumab. Int J Cancer 142:1277−1284, 2018
   Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919−1929, 2017
   Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342−2350, 2018
   Reck M, Liu SV, Mansfield AS, et al. IMpower133: updated overall survival, OS, analysis of first-line, 1L, atezolizumab, atezo)+carboplatin+ etoposide in extensive-stage SCLC, ES-SCLC). Ann Oncol 30(suppl. 5):V710−V711, 2019
   Paz-Ares LG, Dvorkin M, Chen, et al. Durvalumab+tremelimumab+platinum- etoposid in first-line extensive-stage SCLC: Updated results from the phase III CASPIAN study. J Clin Oncol 38(15_suppl):Abstr. 9002, 2020
   Rudin CM, Awad MM, Navarro A, et al. KEYNOTE 604: Pembrolizumab, pembro, or placebo plus etoposide and platinum, EP, as first line therapy for extensive-stage, ES, small-cell lung cancer, SCLC). J Clin Oncol 38(15_ suppl):Abstr. 9001, 2020
   Leal T, Wang Y, Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin+ etoposide alone or in combination with nivolumab as front line therapy for extensive stage small cell lung cancer. J Clin Oncol 38(15_suppl):Abstr. 9000, 2020
   Gadgeel M, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer, SCLC). J Thorac Oncol 13:1393–1399, 2018
   Horn L, Whisenant JG, Tom V, et al. Thoracic Cancers International Covid-19 Collaboration, TERAVOLT): Impact of type of cancer therapy and Covid therapy on survival. J Clin Oncol 38(18_suppl):Abstr. LBA 111, 202
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 217
EP 223
PG 7
ER

PT J
AU Moldvay, J
AF Moldvay, Judit
TI Genomic studies to better understand the biological behavior of lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; genomic testing; prognostic factors; predictive factors; molecular targeted therapy
ID lung cancer; genomic testing; prognostic factors; predictive factors; molecular targeted therapy
AB Over the past 15 years, it has become evident that molecular genetic testing has a place in the management of lung cancer patients in routine clinical practice. Initial monogenic examinations are increasingly being replaced by genomic investigations that analyze multiple genes, or even hundreds of genes. In the present paper, the author briefly summarizes the main therapeutic targets for genomic study of non-small cell and small cell lung cancers. In addition, two exciting areas of genomic research through the results of international research with domestic participation are also presented: gene expression pattern analysis predicting lung cancer prognosis, and study on tumor evolution and genetic effect of oncotherapies.
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Piheno ut 1., 1121 Budapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Bogos K, Kiss Z, Galffy G, et al. Revising incidence and mortality of lung cancer in Central Europe: an epidemiology review from Hungary. Front Oncol 9:1051, 2019
   Moldvay J, Bogos K. Molekularis celzott terapia tudorakban – Nemzetkozi elmelet, hazai gyakorlat. Med Thor 71:355−365, 2018
   Timar J, Lotz G, Raso E, et al. Az ALK-pozitiv tudorak korszeru diagnosztikaja. Magy Onkol 61:301−311, 2017
   Moldvay J, Ostoros Gy. Tamadas helyett onvedelem – Immunterapia tudorakban. Magy Onkol 60:28−33, 2016
   Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692−699, 2020
   Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer, INFORM; C-TONG 0804). J Thorac Oncol 10:655−664, 2015
   Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385−2394, 2013
   Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged nonsmall- cell lung cancer. N Engl J Med 371:1963−1971, 2014
   Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984−993, 2016
   Remon J, Swalduz A, Planchard D, et al. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS One 15:e0234302, 2020
   Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5:842−849, 2015
   Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630−635, 2013
   Mazieres J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 27:281−286, 2016
   Normanno N, Barberis M, De Marinis F, et al. Molecular and genomic profiling of lung cancer in the era of precision medicine: a position paper from the Italian Association of Thoracic Oncology, AIOT). Cancers, Basel, 12:1627, 2020
   Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947−957, 2009
   Rajurkar S, Mambetsariev I, Pharaon R, et al. Non-small cell lung cancer from genomics to therapeutics: a framework for community practice integration to arrive at personalized therapy strategies. J Clin Med 9:E1870, 2020
   Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 26:1415−1421, 2015
   Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753−2762, 2015
   William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 8:611−619, 2011
   Nickolich M, Babakoohi S, Fu P, Dowlati A. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. Clin Lung Cancer 15:207–212, 2014
   Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104–1110, 2012
   Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44:1111–1116, 2012
   Umemura S, Mimaki S, Makinoshima H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 9:1324–1331, 2014
   Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184–190, 2010
   Kopper L. A DNS-hibajavitas hibai. Klin Onkol 3:279−285, 2016
   Arriola E, Canadas I, Arumi M, et al. Genetic changes in small cell lung carcinoma. Clin Transl Oncol 10:189−197, 2008
   Ross JS, Wang K, Elkadi OR, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67:772–776, 2014
   Pietanza MC, Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet 44:1074–1075, 2012
   Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer, NSCLC). Thorac Cancer 11:511−518, 2020
   Udagawa H, Umemura S, Murakami I, et al. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis. Lung Cancer 126:182−188, 2018
   Wakuda K, Kenmotsu H, Serizawa M, et al. Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer 84:139–144, 2014
   Clinical Lung Cancer Genome Project. A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153, 2013
   Lu HY, Sun WY, Chen B, et al. Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. Neoplasma 59:100–104, 2012
   Lohinai Z, Megyesfalvi Z, Suda K, et al. Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. Transl Lung Cancer Res 8:938−950, 2019
   Krzystanek M, Moldvay J, Szuts D, et al. A robust prognostic gene expression signature for early stage lung adenocarcinoma. Biomark Res 4:4, 2016
   Biswas D, Birkbak NJ, Rosenthal R, et al. A clonal expression biomarker associates with lung cancer mortality. Nat Med 25:1540−1548, 2019
   Nemeth E, Krzystanek M, Reiniger L, et al. The genomic imprint of cancer therapies helps timing the formation of metastases. Int J Cancer 145:694−704, 2019
   Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354:618−622, 2016
   Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520:353−357, 2015
   Hoadley KA, Siegel MB, Kanchi KL, et al. Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med 13:e1002174, 2016
   Cheung KJ, Padmanaban V, Silvestri V, et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A 113:E854−863, 2016
   Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106−2111, 2008
   Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. Cell Syst 1:210−223, 2015
   Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 10:e1003665, 2014
   Deshwar AG, Vembu S, Yung CK, et al. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol 16:35, 2015
   Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489−494, 2015
   Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 8:1095−1111, 2014
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 225
EP 230
PG 6
ER

PT J
AU Radeczky, P
   Ghimessy, �
   Berta, J
   Laszlo, V
   Hegedus, B
   Renyi-Vamos, F
   Fillinger, J
   Megyesfalvi, Zs
   Dome, B
AF Radeczky, Peter
   Ghimessy, Aron
   Berta, Judit
   Laszlo, Viktoria
   Hegedus, Balazs
   Renyi-Vamos, Ferenc
   Fillinger, Janos
   Megyesfalvi, Zsolt
   Dome, Balazs
TI Therapeutic possibilities in KRAS-mutant lung adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE KRAS mutation; lung cancer; targeted therapy; predictive factor; prognostic factor
ID KRAS mutation; lung cancer; targeted therapy; predictive factor; prognostic factor
AB KRAS mutations are the most common gain-of-function alterations in lung adenocarcinoma (LADC) in the western countries. Although the different mutations of the KRAS gene have been identified decades ago, the development of drugs targeting the KRAS protein directly have not been successful due to the lack of small molecule binding sites and the extremely high affinity to cellular GTP. Indirect strategies to inhibit KRAS (e.g. inhibitors of farnesyltransferase, prenylation, synthetic lethal partners and KRAS downstream signaling) have so far also failed. In recent times, however several compounds have been developed that target subtype- specific KRAS mutations. Covalent KRAS G12C-specific inhibitors showed the most promising preclinical results. Below, we summarize the predictive and prognostic value of KRAS mutations in LADC as well as the current targeting strategies.
C1 [Radeczky, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Ghimessy, Aron] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Berta, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Laszlo, Viktoria] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Hegedus, Balazs] University Duisburg-Essen, Ruhrlandklinik, Department of Thoracic SurgeryEssen, Germany.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Fillinger, Janos] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Megyesfalvi, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Dome, Balazs] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Megyesfalvi, Zs (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
EM megyesfalvi.zsolt@semmelweis-univ.hu
CR Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 553:446–454, 2018
   Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology, mut- Map). Ann Oncol 24:2371–2376, 2013
   Yang H, Liang SQ, Schmid RA, et al. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol 9:953, 2019
   Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2:344–258, 2011
   Timar J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr Opin Oncol 26:138–144, 2014
   O’Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res 139:503–511, 2019
   Matikas A, Mistriotis D, Georgoulias V, et al. Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. Crit Rev Oncol Hematol 110:1–12, 2017
   Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31:2173–2181, 2013
   Redig AJ, Chambers ES, Lydon CA, et al. Genomic complexity in KRAS mutant non-small cell lung cancer, NSCLC, from never/light-smokers v smokers. J Clin Oncol 34(15_suppl):9087, 2016
   Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731–5734, 2008
   Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 124:53–64, 2018
   Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18:6169–6177, 2012
   Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65:5076–5083, 2005
   Vachtenheim J, Horakova I, Novotna H, et al. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clin Cancer Res 1:359–365, 1995
   Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167–1176, 2012
   Renaud S, Seitlinger J, Falcoz P-E, et al. Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery. Br J Cancer 115:346–353, 2016
   Wiesweg M, Kasper S, Worm K, et al. Impact of RAS mutation subtype on clinical outcome – a cross-entity comparison of patients with advanced nonsmall cell lung cancer and colorectal cancer. Oncogene 38:2953–2966, 2019
   Li S, Liu S, Deng J, et al. Assessing therapeutic efficacy of MEK inhibition in a KRAS(G12C)-driven mouse model of lung cancer. Clin Cancer Res 24:4854–4864, 2018
   Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-smallcell lung cancer. Ann Oncol 22:235–237, 2011
   Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107– 1120, 2012
   Lee B, Lee T, Lee SH, et al. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget 7:23874–23884, 2016
   Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 110:2812–2820, 2014
   Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin Cancer Res 24:334–340, 2018
   Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15:285–291, 1997
   Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19:448–457, 2001
   Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909, 2005
   Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5240–5247, 2007
   Zalcman G, Beau-Faller M, Creveuil C, et al. Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity, LOH, to predict progression-free survival, PFS, in perioperative chemotherapy, CT, phase III trial IFCT-0002 in resectable non-small cell lung cancer. J Clin Oncol 26(15_suppl):7500, 2008
   Hames ML, Chen H, Iams W, et al. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer. Lung Cancer 92:29–34, 2016
   Shepherd FA, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 35:2018–2027, 2017
   Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890–2896, 2007
   Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972, 2008
   Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta- analysis of 22 studies. Lung Cancer 69:272–278, 2010
   Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours, TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988, 2013
   Sun JM, Hwang DW, Ahn JS, et al. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. PLoS One 8:e64816, 2013
   Metro G, Chiari R, Duranti S, et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 78:81–86, 2012
   Zer A, Ding K, Lee SM, et al. Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 11:312–323, 2016
   Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400:468–472, 1999
   Fiala O, Buchler T, Mohelnikova-Duchonova B, et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 37:6823–6830, 2016
   Bruera G, Cannita K, Tessitore A, et al. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Crit Rev Oncol Hematol 93:190–202, 2015
   Chaft JE, Rusch V, Ginsberg MS, et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol 8:1084–1090, 2013
   Ghimessy AK, Gellert A, Schlegl E, et al. KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy. Cancers, Basel, 11:1514, 2019
   D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112:95–102, 2015
   Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23:3012–3024, 2017
   Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36:1675–1684, 2018
   Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929–935, 1987
   Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561– 565, 1990
   Guan JL, Zhong WZ, An SJ, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 20:1381–1388, 2013
   Izar B, Zhou H, Heist RS, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol 9:1363–1369, 2014
   Kern JA, Slebos RJ, Top B, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516–520, 1994
   Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutations in nonsmall cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999–5002, 1991
   Ohtaki Y, Shimizu K, Kakegawa S, et al. Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status. Mol Clin Oncol 2:187–196, 2014
   Cserepes M, Ostoros G, Lohinai Z, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer 50:1819–1828, 2014
   Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104:228–239, 2012
   Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92:131–139, 2005
   Villaruz LC, Socinski MA, Cunningham DE, et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer 119:2268–2274, 2013
   Fan G, Zhang K, Ding J, et al. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 8:33922–33932, 2017
   Meng D, Yuan M, Li X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 81:1–10, 2013
   Zhang SM, Zhu QG, Ding XX, et al. Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis. Cancer Manag Res 10:3393–3404, 2018
   Svaton M, Fiala O, Pesek M, et al. The Prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third-line chemotherapy. Anticancer Res 36:1077–1082, 2016
   Lindsay CR, Jamal-Hanjani M, Forster M, et al. KRAS: Reasons for optimism in lung cancer. Eur J Cancer 99:20–27, 2018
   Roman M, Baraibar I, Lopez I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 17:33, 2018
   Friedlaender A, Drilon A, Weiss GJ, et al. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treat Rev 85:101978, 2020
   Gysin S, Salt M, Young A, et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2:359–372, 2011
   Nagasaka M, Li Y, Sukari A, et al. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev 84:101974, 2020
   Dang CV, Reddy EP, Shokat KM, et al. Drugging the ‚undruggable’ cancer targets. Nat Rev Cancer 17:502–508, 2017
   Lohinai Z, Klikovits T, Moldvay J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep 7:39721, 2017
   Dingemans AMC, Mellema WW, Groen HJM, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced, stage IIIb or IV, non–small cell lung cancer with a KRAS mutation. Clin Cancer Res 19:743– 751, 2013
   Papadimitrakopoulou V, Lee JJ, Wistuba, II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 34:3638–3647, 2016
   Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer, MISSION, trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol 10:1745–1753, 2015
   Blumenschein GR Jr, Smit EF, Planchard D, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib, GSK1120212, compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer, NSCLC). Ann Oncol 26:894–901, 2015
   Carter CA, Rajan A, Keen C, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol 27:693–699, 2016
   Riely GJ, Brahmer JR, Planchard D, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer, NSCLC, patients with KRAS mutations. J Clin Oncol 30(15_suppl):7531, 2012
   Manchado E, Weissmueller S, Morris JPt, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534:647–651, 2016
   Hunter JC, Gurbani D, Ficarro SB, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A 111:8895–8900, 2014
   Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351:604–608, 2016
   Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 6:316–329, 2016
   Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 53:199–204, 2014
   Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C, inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548–551, 2013
   Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172:578–589, 2018
   Molina-Arcas M, Moore C, Rana S, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med 11:eaaw7999, 2019
   Spencer-Smith R, O’Bryan JP. Direct inhibition of RAS: Quest for the Holy Grail? Semin Cancer Biol 54:138–148, 2019
   AMG 510 first to inhibit „undruggable” KRAS. Cancer Discov 9:988–989, 2019
   Fakih M, O’Neil B, Price TJ, et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics, PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. J Clin Oncol 37(15_ suppl):3003, 2019
   Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C, inhibitor AMG 510 drives anti-tumour immunity. Nature 575:217–223, 2019
   Saiki AY, Gaida K, Rex K, et al. Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C. Cancer Res 79(13 Suppl):Abstr. 4484, 2019
   Papadopoulos KP, Ou SHI, Johnson ML, et al. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. J Clin Oncol 37(15_suppl):TPS3161, 2019
   Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov 10:54–71, 2020
   Aguirre AJ, Hahn WC. Synthetic lethal vulnerabilities in KRAS-mutant cancers. Cold Spring Harb Perspect Med 8:a031518, 2018
   Downward J. RAS synthetic lethal screens revisited: Still seeking the elusive prize? Clin Cancer Res 21:1802–1809, 2015
   Litvak AM, Drilon AE, Rekhtman N, et al. Phase II trial of bortezomib in KRAS G12D mutant lung cancers. J Clin Oncol 33(15_suppl):e19002, 2015
   Goldman JW, Mazieres J, Barlesi F, et al. A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER. J Clin Oncol 36(15_suppl):9025, 2018
   Goldman JW, Shi P, Reck M, et al. Treatment rationale and study design for the JUNIPER study: a randomized phase III study of abemaciclib with best supportive care versus erlotinib with best supportive care in patients with stage IV non-small-cell lung cancer with a detectable KRAS mutation whose disease has progressed after platinum-based chemotherapy. Clin Lung Cancer 17:80–84, 2016
   Ambrogio C, Nadal E, Villanueva A, et al. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open 1:e000076, 2016
   Bagchi S, Rathee P, Jayaprakash V, et al. Farnesyl transferase inhibitors as potential anticancer agents. Mini Rev Med Chem 18:1611–1623, 2018
   End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131–137, 2001
   Riely GJ, Johnson ML, Medina C, et al. A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 6:1435–1437, 2011
   Kazi A, Xiang S, Yang H, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res 25:5984–5996, 2019
   Tanaka A, Radwan MO, Hamasaki A, et al. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorg Med Chem Lett 27:3862–3866, 2017
   Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: Back to the future for anti-RAS drug discovery? Clin Cancer Res 21:1819– 1827, 2015
   Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 13:828–851, 2014
   Baranyi M, Molnar E, Rittler D, et al. Prenilaciogatlas hatasa RASmutans daganatokra kiserleti rendszerekben. Magy Onkol 63:320–329, 2019
   Kenessey I, Koi K, Horvath O, et al. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget 7:79503–79514, 2016
   Baranyi M, Buday L, Hegedus B. K-Ras prenylation as a potential anticancer target. Cancer Metastasis Rev, 2020,, DOI  10.1007/s10555-020- 09902-w
   Ross SJ, Revenko AS, Hanson LL, et al. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med 9:eaal5253, 2017
   Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535–546, 2009
   Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:1387–1390, 2015
   Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 41:711–716, 2019
   Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation- specific KRAS(G12C, inhibition. Nature 577:421–425, 2020
   Fiala O, Pesek M, Finek J, et al. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet 206:26–31, 2013
   Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918–927, 2010
   Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:707– 715, 2011
   Blumenschein GR Jr, Saintigny P, Liu S, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 19:6967–6975, 2013
   Chenard-Poirier M, Kaiser M, Boyd K, et al. Results from the biomarker- driven basket trial of RO5126766, CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. J Clin Oncol 35(15_suppl):2506, 2017
   Gerber DE, Camidge DR, Morgensztern D, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib, VS-6063, in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer 139:60–67, 2020
   Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244, ARRY- 142886, versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 5:1630–1636, 2010
   Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16:2450–2457, 2010
   Honda K, Yamamoto N, Nokihara H, et al. Phase I and pharmacokinetic/ pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 72:577–584, 2013
   Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38–47, 2013
   Janne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial. JAMA 317:1844–1853, 2017
   Martinez-Garcia M, Banerji U, Albanell J, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 18:4806–4819, 2012
   Smit EF, Dingemans AM, Thunnissen FB, et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 5:719–720, 2010
   Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760–1766, 2003
   Bradbury PA, Morris DG, Nicholas G, et al. Canadian Cancer Trials Group, CCTG, IND211: A randomized trial of pelareorep, Reolysin, in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer 120:142–148, 2018
   Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 39:311–335, 1967
   Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–465, 2003
   Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer, GALAXY-1). Ann Oncol 26:1741–1748, 2015
   Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456–4462, 2004
   Santos E, Martin-Zanca D, Reddy EP, et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223:661–664, 1984
   Scolnick EM, Rands E, Williams D, et al. Studies on the nucleic acid sequences of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma virus. J Virol 12:458–463, 1973
   Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307–3315, 2011
   Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068–3077, 2013
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 231
EP 244
PG 14
ER

PT J
AU Megyesfalvi, Zs
   Barany, N
   Valko, Zs
   Bugyik, E
   Paku, S
   Berta, J
   Lantos, A
   Fillinger, J
   Moldvay, J
   Bogos, K
   Rezeli, M
   Galffy, G
   Lang, Ch
   Lohinai, Z
   Hecz, R
   Lovas, T
   Renyi-Vamos, F
   Laszlo, V
   Dome, B
AF Megyesfalvi, Zsolt
   Barany, Nandor
   Valko, Zsuzsanna
   Bugyik, Edina
   Paku, Sandor
   Berta, Judit
   Lantos, Andras
   Fillinger, Janos
   Moldvay, Judit
   Bogos, Krisztina
   Rezeli, Melinda
   Galffy, Gabriella
   Lang, Christian
   Lohinai, Zoltan
   Hecz, Reka
   Lovas, Timea
   Renyi-Vamos, Ferenc
   Laszlo, Viktoria
   Dome, Balazs
TI Heterogeneity of small cell lung cancer: biological and clinicopathological implications
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE small cell lung cancer; SCLC; heterogeneity; clinical relevance
ID small cell lung cancer; SCLC; heterogeneity; clinical relevance
AB Small cell lung cancer (SCLC; comprising approximately 14% of all lung cancer cases in Hungary) is an aggressive tumor type characterized by rapid growth and early metastasis. Although SCLC is a particularly malignant form of cancer, targeted therapies in its treatment have remained largely unsuccessful and thus there were no major therapeutic advances in the last three decades. SCLC was once considered a molecularly homogeneous malignancy. However, recent analyses led to the classification of neuroendocrine and molecular subtypes, based on the dominant expression of one of the following four transcriptional regulator genes: ASCL1, NEUROD1, YAP1 and POU2F3. Because these genetically and biologically distinct subtypes might contribute to therapeutic resistance, the better understanding of their biological and clinicopathological characteristics may help in the development of more effective SCLC therapies.
C1 [Megyesfalvi, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Barany, Nandor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Valko, Zsuzsanna] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Bugyik, Edina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Berta, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lantos, Andras] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Fillinger, Janos] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Rezeli, Melinda] Lund University, Department of Biomedical Engineering, Division of Clinical Protein Science and ImagingLund, Sweden.
   [Galffy, Gabriella] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Lang, Christian] Medical University of Vienna, Department of Thoracic SurgeryVienna, Austria.
   [Lohinai, Zoltan] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Hecz, Reka] County Hospital of PulmonologyTorokbalint, Hungary.
   [Lovas, Timea] County Hospital of PulmonologyTorokbalint, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Laszlo, Viktoria] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Dome, Balazs] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Megyesfalvi, Zs (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
EM megyesfalvi.zsolt@semmelweis-univ.hu
CR Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692−699, 2020
   Rudin CM, Poirier JT. Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nat Rev Clin Oncol 14:75−76, 2017
   Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17:725−737, 2017
   Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354:618−622, 2016
   Tamasi L, Muller V. A tudo neuroendokrin daganatainak tunetei es diagnosztikaja. Orv Hetil 152:366−370, 2011
   Bunn PA Jr, Minna JD, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol 11:453−474, 2016
   Timar J, Patocs A. A tudo es a gasztrointesztinum neuroendokrin daganatainak genetikaja: hasonlosagok es kulonbsegek. Magy Onkol 62:77−82, 2018
   George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524:47−53, 2015
   Kalemkerian GP, Loo BW, Akerley W, et al. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw 16:1171−1182, 2018
   Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19:289−297, 2019
   Barnard WG. The nature of the “oat-celled sarcoma” of the mediastinum. J Pathol Bacteriol 29:241−244, 1926
   Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol 78:513−519, 1959
   Matthews MJ, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3 4:63−67, 1973
   Oboshi S, Tsugawa S, Seido T, et al. A new floating cell line derived from human pulmonary carcinoma of oat cell type. Gan 62:505−514, 1971
   Pettengill OS, Sorenson GD, Wurster-Hill DH, et al. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45:906−918, 1980
   Drapkin BJ, Rudin CM. Advances in small-cell lung cancer, SCLC, translational research. Cold Spring Harb Perspect Med, 2020,, DOI  10.1101/cshperspect. a038240
   Polley E, Kunkel M, Evans D, et al. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. J Natl Cancer Inst 108:djw122, 2016
   Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913−2923, 1985
   Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 45:2924−2930, 1985
   Doyle LA, Borges M, Hussain A, et al. An adherent subline of a unique small-cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule. J Clin Invest 86:1848−1854, 1990
   Calbo J, van Montfort E, Proost N, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19:244−256, 2011
   Mollaoglu G, Guthrie MR, Bohm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell 31:270−285, 2017
   Gazdar AF. Molecular phenotypes of SCLC. J Thorac Oncol 13(10S):S309, 2018
   Dora D, Rivard C, Yu H, et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. Mol Oncol, 2020,, DOI  10.1002/1878-0261.12741
   Borromeo MD, Savage TK, Kollipara RK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep 16:1259−1272, 2016
   Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer 1:423−436, 2020
   Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915−928, 2018
   Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44:1111−1116, 2012
   Zhang W, Girard L, Zhang YA, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32−49, 2018
   Chalishazar MD, Wait SJ, Huang F, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res 25:5107−5121, 2019
   Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody- drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136, 2015
   Jia D, Augert A, Kim DW, et al. Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition. Cancer Discov 8:1422−1437, 2018
   Timar J, Mehes G, Vass L. A tudorak molekularis diagnosztikajanak modern szemlelete es klinikai jelentosege. Magy Onkol 64,183–189, 2020
   Thomas A, Pattanayak P, Szabo E, et al. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest 154:1284−1290, 2018
   Tata PR, Rajagopal J. Plasticity in the lung: making and breaking cell identity. Development 144:755−766, 2017
   Tata PR, Mou H, Pardo-Saganta A, et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 503:218−223, 2013
   Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240−2247, 2013
   Bordi P, Del Re M, Minari R, et al. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer 131:78−85, 2019
   Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 37:278−285, 2019
   Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol 35:3065−3074, 2017
   Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298−305, 2016
   Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18:666−677, 2012
   Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543−3551, 2008
   Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 30:1692−1698, 2012
   Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive- stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 37:222−229, 2019
   Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7:866−872, 2012
   Zoppoli G, Regairaz M, Leo E, et al. Putative DNA/RNA helicase Schlafen-11, SLFN11, sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 109:15030−15035, 2012
   Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603−607, 2012
   Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570−575, 2012
   Tang SW, Thomas A, Murai J, et al. Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11, SLFN11, expression with class I histone deacetylase inhibitors. Clin Cancer Res 24:1944−1953, 2018
   Murai J, Feng Y, Yu GK, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7:76534−76550, 2016
   Lok BH, Gardner EE, Schneeberger VE, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 23:523−535, 2017
   Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 36:2386−2394, 2018
   Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497−1508, 2016
   Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078−2092, 2018
   Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040−2051, 2018
   Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 131:1210−1219, 2012
   Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34, 2017
   Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585−4593, 2016
   Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 13:1138−1145, 2018
   Hastings K, Yu HA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol 30:1311−1320, 2019
   Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology 85:235−239, 2015
   Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353:117−118, 1999
   Maddison P, Gozzard P, Grainge MJ, et al. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 88:1334−1339, 2017
   Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220−2229, 2018
   Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer, CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929−1939, 2019
   Schultheis AM, Scheel AH, Ozretic L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51:421−426, 2015
   Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer, CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883−895, 2016
   Yamazaki K, Spruill G, Rhoderick J, et al. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res 59:4642−4650, 1999
   Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 12:47, 2019
   Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2:798−811, 2012
   Owonikoko TK, Zhang G, Deng X, et al. Poly, ADP, ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 3:1579−1594, 2014
   Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 18:42−51, 2017
   Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res 25:6958−6966, 2019
   AbbVie: Phase 3 trial of Rova-T as second-line therapy for advanced small-cell lung cancer, TAHOE study, halted. North Chicago, IL, 2018
   Owonikoko TK, Niu H, Nackaerts K, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thorac Oncol 15:274−287, 2020
   Cheng Y, Wang Q, Li K, et al. Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial. J Thorac Oncol 13(10S):S351−S352, 2018
   Poirier JT, Gardner EE, Connis N, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 34:5869−5878, 2015
   Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 131:1704-1711, 2018
   Lochmann TL, Bouck YM, Faber AC. BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer. Oncoscience 5:218−219, 2018
   Takagi S, Ishikawa Y, Mizutani A, et al. LSD1 inhibitor T-3775440 inhibits SCLC cell proliferation by disrupting LSD1 interactions with SNAG domain proteins INSM1 and GFI1B. Cancer Res 77:4652−4662, 2017
   Augert A, Eastwood E, Ibrahim AH, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal 12:eaau2922, 2019
   Poirier JT, Dobromilskaya I, Moriarty WF, et al. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 105:1059−1065, 2013
   Gay CM, Diao L, Stewart CA, et al. Inter- and intra-tumoral variations in ASCL1, NEUROD1, and POU2F3 transcriptional programs underlie three distinct molecular subtypes of small cell lung cancers. Cancer Res 79(13 Suppl):Abstr. 3772, 2019
   Horie M, Saito A, Ohshima M, et al. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer Sci 107:1755−1766, 2016
   Furuta M, Sakakibara-Konishi J, Kikuchi H, et al. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer, HOT1702). Oncologist 24:e1172-e1179, 2019
   Denny SK, Yang D, Chuang C-H, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 166:328−342, 2016
   Udyavar AR, Wooten DJ, Hoeksema M, et al. Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res 77:1063−1074, 2017
   Gay C, Diao L, Stewart C, et al. OA03.06 ASCL1, NEUROD1, and POU2F3 drive distinct subtypes of small cell lung cancer with unique therapeutic vulnerabilities. J Thorac Oncol 14:S213, 2019
   Lohinai Z, Megyesfalvi Z, Suda K, et al. Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. Transl Lung Cancer Res 8:938−950, 2020
   Pearse AG. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones, the APUD series, and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proc R Soc Lond B Biol Sci 170:71−80, 1968
   Bensch KG, Corrin B, Pariente R, et al. Oat-cell carcinoma of the lung. Its origin and relationship to bronchial carcinoid. Cancer 22:1163−1172, 1968
   Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 46:516−525, 1969
   Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471−1477, 1985
   Evans WK, Shepherd FA, Feld R, et al. First-line therapy with VP-16 and cisplatin for small-cell lung cancer. Semin Oncol 13:17−23, 1986
   Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353−357, 1988
   Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 246:491−494, 1989
   Borges M, Linnoila RI, van de Velde HJ, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386:852−855, 1997
   Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4:181−189, 2003
   Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104−1110, 2012
   McColl K, Wildey G, Sakre N, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget 8:73745−73756, 2017
   Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell 31:286−299, 2017
   Allison Stewart C, Tong P, Cardnell RJ, et al. Dynamic variations in epithelial-to-mesenchymal transition, EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget 8:28575−28587, 2017
   Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19:754−764, 2011
   Atrafi F, Groen HJM, Byers LA, et al. Phase 1/2 study of veliparib, V, combined with carboplatin, Cb, and etoposide, E, in patients, pts, with extensive- stage disease, ED, small cell lung cancer, SCLC, and other solid tumors: Phase 1 results. J Clin Oncol 35(15_suppl):8530, 2017
   Wainberg ZA, de Bono JS, Mina L, et al. Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. Mol Cancer Ther 12(11 Suppl):C295, 2013
   Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 41(Suppl 1):S49−53, 2003
   Chiappori AA, Otterson GA, Dowlati A, et al. A randomized phase II study of linsitinib, OSI-906, versus topotecan in patients with relapsed small-cell lung cancer. Oncologist 21:1163−1164, 2016
   Ellis PM, Shepherd FA, Laurie SA, et al. NCIC CTG IND.190 phase I trial of dalotuzumab, MK-0646, in combination with cisplatin and etoposide in extensive- stage small-cell lung cancer. J Thorac Oncol 9:410−413, 2014
   Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29:2215−2222, 2011
   Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21:645−654, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 243
EP 255
PG 13
ER

PT J
AU Bajcsay, A
   Janvary, ZsL
   Ladanyi, K
   Pocza, T
   Major, T
   Polgar, Cs
AF Bajcsay, Andras
   Janvary, Zsolt Levente
   Ladanyi, Katalin
   Pocza, Tamas
   Major, Tibor
   Polgar, Csaba
TI Application of modern radiotherapy in lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; radiotherapy; modern techniques; SABRT; IMRT; IGRT
ID lung cancer; radiotherapy; modern techniques; SABRT; IMRT; IGRT
AB Lung cancer is known for its outstanding incidence and mortality rates. One of the cornerstones of the treatment of this disease is radiation therapy. A remarkable development was observed in this field through the latest decades. Intensity-modulated and image-guided radiotherapy (IMRT and IGRT) are now widely accessible in Hungarian centers, and should be increasingly applied in case of thoracic irradiations as well. Application of modern radiotherapy techniques in the treatment of lung cancer allows better clinical results and lower rates of side effects. In this work the authors give an overview of this above mentioned development regarding different clinical stages.
C1 [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Janvary, Zsolt Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Ladanyi, Katalin] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
CR Polgar Cs, szerk). Onkologia es sugarterapia. Semmelweis Kiado, 2019
   Cheng M, Jolly S, Quarshie WO, et al. Modern radiation further improves survival in non-small cell lung cancer: an analysis of 288,670 patients. J Cancer 10:168−177, 2019
   Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol 11:115, 2016
   Davis JN, Medbery C 3rd, Sharma S, et al. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol 4:55−63, 2015
   Wegner RE, Ahmed N, Hasan S, et al. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag 7:LMT01, 2018
   Schanne DH, Nestle U, Allgauer M, et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125−132, 2015
   Bahig H, Filion E, Vu T, et al. Excellent cancer outcomes following patient- adapted robotic lung SBRT but a case for caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat 14:667−676, 2015
   Janvary ZL, Jansen N, Baart V, et al. Clinical outcomes of 130 patients with primary and secondary lung tumors treated with cyberknife robotic stereotactic body radiotherapy. Radiol Oncol 51:178−186, 2017
   Lanni TB Jr, Grills IS, Kestin L, et al. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 34:494–498, 2011
   von Reibnitz D, Shaikh F, Wu AJ, et al. Stereotactic body radiation therapy, SBRT, improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer, NSCLC). Acta Oncol 57:1567−1573, 2018
   Bajcsay A, Janvary ZsL, Lovey J, et al. Korai stadiumu tudorak legzomozgast kompenzalo sugarkezelese a 3 fazisu ITV-tervezestol a 4D/ CT-alapu ITV koncepcios Linac-SABRT-n at a CyberKnife legzeskoveto besugarzasig – a technikai es klinikai adatok tukreben. Magy Onkol 63:142, 2019
   Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced nonsmall cell lung cancer, NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 17:473–483, 2006
   Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol 28:2181−2190, 2010
   De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 20:98−102, 2009
   Sanders KJC, Hendriks LE, Troost EG, et al. Early weight loss during chemoradiotherapy has a detrimental impact on outcome in NSCLC. J Thorac Oncol 6:873−879, 2016
   van Diessen JNA, Kwint M, Sonke JJ, et al. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients. Radiother Oncol 143:66−72, 2020
   Pocza T, Pesznyak Cs, Lovey J, et al. Legzomozgast figyelembe vevo kepalkoto protokollok alkalmazasa korai stadiumu tudodaganatos betegek besugarzastervezesenel. Magy Onkol 59:133–138, 2015
   Szilagyi A, Pocza T, Polgar Cs, et al. Korai stadiumu tudodaganatok kurativ sugarkezelese legzomozgast figyelembe vevo technikaval. Magy Onkol 60:314–319, 2016
   Fleming C, Cagney DN, O’Keeffe S, et al. Normal tissue considerations and dose–volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer. Radiother Oncol 119:423–431, 2016
   Kisivan K, Miovecz A, Gugyeras D, et al. Multimodalis kepalkotas tudoes hasi sztereotaxias ablativ radioterapia soran: a cine MRI-meresektol a 3D/4D CBCT-n at a kezeles alatti kV-os kepi verifikacioig. Magy Onkol 63:116–124, 2019
   Shrimali RK, Chakraborty S, Prasath S, et al. Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer. Br J Radiol 92:20180928, 2019
   Bitterman DS, Rawal B, Atkins KM, et al. Predictors of radiation esophagitis in locally advanced non-small cell lung cancer with modern radiation therapy planning. Int J Radiat Oncol Biol Phys 102(3 Suppl.):E674–E675, 2018
   Maraz A, Furak J, Varga Z, et al. Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer. Anticancer Res 33:1737–1741, 2013
   Maraz A, Furak J, Palfoldi R, et al. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res 31:1431–1436, 2011
   De Ruysscher D, Faivre-Finn C, Moeller D, et al. European Organization for Research and Treatment of Cancer, EORTC, recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 124;1–10, 2017
   Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379−386, 2009
   Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687– 695, 2014
   Csada E, Bajcsay A. A III-as stadiumu tudorak kemo-radioterapiaja. Med Thorac 5:321−324, 2018
   Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced nonsmall- cell lung cancer, NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl. 4):iv1–iv21, 2017
   NCCN Guidelines Version 7. 2020 Non-Small Cell Lung Cancer. https:// www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non–small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 33:2660−2666, 2015
   Varol Y, Komurcuoglu B, Yilmaz U, et al. The effect of consolidation chemotherapy for LA-NSCLC patients receiving concurrent chemoradiotherapy. J Clin Anal Med 8:142−146, 2017
   Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919−1928, 2017
   Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342−2350, 2018
   Rode I. Klinikai onkoradiologia. Medicina Konyvkiado, Budapest 1984
   Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925−931, 2012
   Wirsdorfer F, de Leve S, Jendrossek V. Combining radiotherapy and immunotherapy in lung cancer: Can we expect limitations due to altered normal tissue toxicity? Int J Mol Sci 20:24, 2019
   Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol 8:612, 2018
   Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer, NSCLC). J Immunother Cancer 6:75, 2018
   Meng X, Feng R, Yang L, et al. The role of radiation oncology in immuno- oncology. Oncologist 24(Special Issue):S42–S52, 2019
   Yang H, Jin T, Li M, et al. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precis Clin Med 2:57–70, 2019
   Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol 30:1244–1253, 2019
   Dobi A, Fodor E, Maraz A, et al. Boost irradiation integrated to whole brain radiotherapy in the management of brain metastases. Pathol Oncol Res 26:149–157, 2020
   Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during wholebrain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol 38:1019−1029, 2020
   Santini Blasco AE, Cortes CV, Arcuch VS, et al. Radiation therapy for nonsmall cell lung cancer in the twenty-first century. Cancer Manag Ther 2018. http://dx.doi.org/10.5772/intechopen.76513
   Tumelty K, McAleese J, Rooney C, et al. Modern radiotherapy increases patient access to curative intent radiotherapy in non-small cell lung cancer. J Thorac Oncol 13(10S):S1009−S1010, 2018
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 255
EP 261
PG 7
ER

PT J
AU Maraz, A
   Geczi, L
   Biro, K
   Varga, L
   Kuronya, Zs
AF Maraz, Aniko
   Geczi, Lajos
   Biro, Krisztina
   Varga, Linda
   Kuronya, Zsofia
TI Therapeutic sequences in the treatment of advanced/metastatic prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE metastatic hormone-sensitive prostate tumor; metastatic castration-resistant prostate tumor; castration- resistant non-metastatic prostate tumor; therapeutic sequence
ID metastatic hormone-sensitive prostate tumor; metastatic castration-resistant prostate tumor; castration- resistant non-metastatic prostate tumor; therapeutic sequence
AB The unprecedented development of prostate cancer therapy is a challenge for the proper sequential use of modern medicines. Patients’ life expectancies improve when we use treatment lines, one after the other. There is no evidence- based guideline regarding the optimal sequence, but a number of data are available to help the physician selecting the best individualized therapeutic option. The basic treatment for advanced prostate cancer is still androgenic deprivation (ADT), to which we can add additional therapeutic agents. New types of hormonal (androgen receptor targeted, ARTA) agents are being used in an increasingly early line. Chemotherapy (CT) is the first choice in case of metastatic, hormone-sensitive disease especially in high volume cases that are causing symptoms or visceral crisis. CT is otherwise applied after ARTA. We have little but encouraging data about the early, sequential use of ARTAs with different mechanisms of action. In later lines, cross-resistance may develop between ARTA treatments, in which cases CT is the right decision. In this paper, we summarize the results of clinical trials that may help in therapeutic decision making, maximizing the benefits for patients.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Varga, Linda] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
CR Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Patrikidou A, Loriot Y, Eymard JC, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis 17:348–352, 2014
   Huggins C, Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297, 1941
   Parker C, Castro E, Fizazi K, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119–1134, 2020
   Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/
   NCCN Guideline. https://www.nccn.org/professionals/physician_gls/pdf/prostate. pdf
   Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer, GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158, 2013
   Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy, ADT, plus docetaxel, D, versus ADT alone in metastatic non-castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70:256–262, 2016
   Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746, 2015
   Maráz A, Géczi L, Küronya Zs. Hormonerzekeny prosztatadaganatok kezelesenek uj iranyai. Magy Onkol 63:33–39, 2019
   James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to firstline long-term hormone therapy in prostate cancer, STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177, 2016
   Fizazi K, Namphuong T, Luis F, et al. abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360, 2017
   Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer, LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet 20:686–700, 2019
   James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351, 2017
   Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974– 2986, 2019
   Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131, 2019
   Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration- sensitive prostate cancer. N Engl J Med 381:13–24, 2019
   Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer, STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366, 2018
   Sydes M, Spears M, Mason M, et al. Adding abiraterone or docetaxel to longterm hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multiarm, multi-stage platform protocol. Ann Oncol 29:1235–1248, 2018
   Küronya Zs, Bíró K, Gyergyay F, Géczi L. Androgenreceptor medialta folyamatok metasztatikus krasztraciorezisztens prosztatadaganatban. Orv Hetil 158:42– 49, 2017
   Küronya Zs, Biró K, Maráz A, Géczi L. Metasztatikus kasztraciorezisztens prosztatadaganat korszeru kezelese. Magy Onkol 63:41–50, 2019
   Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate- specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918–2925, 2005
   Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis- free survival in prostate cancer. N Engl J Med 378:1408–1418, 2018
   Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465–2474, 2018
   Fizazi K, Shore N, Tammela TL, et al. Darolutamid in nonmetastatic, castration- resistant prostate cancer. N Engl J Med 380:1235–1246, 2019
   Small EJ, Saad F, Chowdhury S, et al. Final survival results from SPARTAN, a phase III study of apalutamide, APA, versus placebo, PBO, in patients, pts, with nonmetastatic castration-resistant prostate cancer, nmCRPC). https://meetinglibrary.asco.org/record/187437/abstract
   Fizazi K, Shore ND, Tammela T, et al. Overall survival, OS, results of phase III ARAMIS study of darolutamide, DARO, added to androgen deprivation therapy, ADT, for nonmetastatic castration-resistant prostate cancer, nmCRPC). https:// meetinglibrary.asco.org/record/187482/abstract
   Sternberg CN, Fizazi K, Saad F, et al. Final overall survival, OS, from PROSPER: A phase III, randomized, double-blind, placebo, PBO)-controlled study of enzalutamide, ENZA, in men with nonmetastatic castration-resistant prostate cancer, nmCRPC). https://meetinglibrary.asco.org/record/187453/abstract
   Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512, 2004
   de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: randomised open-label trial. Lancet 376:1147–1154, 2010
   de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005, 2011
   Ryan CJ, Smith MR, deBono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148, 2013
   Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197, 2012
   Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433, 2014
   Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med 363:411–422, 2010
   Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223, 2013
   Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from TRITON2: a phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer, mCRPC, associated with homologous recombination repair, HRR, gene alterations. Ann Oncol 29(suppl_8): viii271–viii302, 2018
   de Bono JS, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091–2102, 2020
   Maráz A, Boér K, Dankovics Z, et al. Hazai tapasztalatok kasztraciorezisztens metasztatikus prosztatadaganatos betegek kabazitaxelterapiajaval. Magy Onkol 61:353–360, 2017
   de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381:2506–2518, 2019
   Oh WK, Miao R, Vekeman F, et al. Real-world characteristics and outcomes of patients with metastatic castration-resistant prostate cancer receiving chemotherapy versus androgen receptor targeted therapy after failure of first-line androgen receptor-targeted therapy in the community setting. Clin Genitourin Cancer 16:50–57, 2018
   Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicenter, randomized, open-label, phase 2, crossover trial. Lancet 20:1730–1739, 2019
   de Bono JS, Smith MR, Saad F, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol 71:656–664, 2017
   Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases, ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 20:408–419, 2019
   Agarwal N, Chowdhury S, Bjartell A, et al. Time to second progression, PFS2, in patients from TITAN with metastatic castration-sensitive prostate cancer by first subsequent therapy, hormonal vs. taxane). J Clin Oncol 38(6_suppl): abstr. 82, 2020
   Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum- sensitive metastatic castration-resistant prostate cancer. Eur Urol 69: 992– 995, 2016
   Adashek JJ, Jain RK, Zhang J, et al. Clinical development of PARP inhibitors in treating metastatic castration-resistant prostate cancer. Cells 8:860, 2019
   Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5:471–478, 2019
   Sharma P, Pachynski RK, Narayan V, et al. Initial results from a phase II study of nivolumab, NIVO, plus ipilimumab, IPI, for the treatment of metastatic castration- resistant prostate cancer, mCRPC; CheckMate 650). J Clin Oncol 37(suppl 7S):abstr. 142, 2019
   Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment- refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 Study. J Clin Oncol 38:395–405, 2020
   https://www.onclive.com/web-exclusives/pembrolizumab-plus-enzalutamide- shows-moderate-activity-in-mcrpc
   https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu- 2020-prostate-cancer/119129-asco-gu-2020-keynote-100-pembrolizumab-plusenzalutamide- for-enzalutamide-resistant-mcrpc-cohorts-4-5.html
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2020
VL 64
IS 3
BP 263
EP 272
PG 10
ER

PT J
AU Forrai, G
   Kovacs, E
   Ambrozay, �
   Barta, M
   Borbely, K
   Lengyel, Zs
   Ormandi, K
   Pentek, Z
   Tasnadi, T
   Sebo, �
AF Forrai, Gabor
   Kovacs, Eszter
   Ambrozay, Eva
   Barta, Miklos
   Borbely, Katalin
   Lengyel, Zsolt
   Ormandi, Katalin
   Pentek, Zoltan
   Tasnadi, Tunde
   Sebo, Eva
TI Radiology/Nuclear Medicine Group. Use of imaging methods in the current screening, diagnostics and treatment of breast cancer – Professional guidelines. 4th Breast Cancer Consensus Conference
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE mammography; 3D tomosynthesis; breast ultrasound; breast screening; breast MRI; conventional nuclear medicine; PET/CT; biopsy
ID mammography; 3D tomosynthesis; breast ultrasound; breast screening; breast MRI; conventional nuclear medicine; PET/CT; biopsy
AB Breast radiologists and nuclear medicine specialists have updated their previous recommendation/guidance at the 4th Hungarian Breast Cancer Consensus Conference. They suggest to adopt this actual protocol for the screening, diagnostics and treatment of breast tumors from now on. This recommendation includes the description of the newest technologies, the recent results of scientific research, as well as the role of imaging methods in the therapeutic processes and the followup. Suggestions for improvement of the current Hungarian practice and other related issues as forensic medicine, media connections, regulations, and reimbursement are also detailed. The guidance has been in agreement with the related medical disciplines.
C1 [Forrai, Gabor] GE-RAD Kft., DMC, Vorosbegy u. 6., 2096 Urom, Hungary.
   [Kovacs, Eszter] GE-RAD Kft., DMC, Vorosbegy u. 6., 2096 Urom, Hungary.
   [Ambrozay, Eva] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Barta, Miklos] Royal Cornwall HospitalTruro, UK.
   [Borbely, Katalin] National Institute of OncologyBudapest, Hungary.
   [Lengyel, Zsolt] Hamad Medical CorporationDoha, Qatar.
   [Ormandi, Katalin] University of SzegedSzeged, Hungary.
   [Pentek, Zoltan] MaMMa Egeszsegugyi RtBudapest, Hungary.
   [Tasnadi, Tunde] Rethy Pal HospitalBekescsaba, Hungary.
   [Sebo, Eva] Kenezy Teaching HospitalDebrecen, Hungary.
RP Forrai, G (reprint author), GE-RAD Kft., DMC, 2096 Urom, Hungary.
EM forrai.gabor@t-online.hu
CR European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edition, European Commission, 2006
   Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20 year follow-up before and after introduction of screening. Lancet 361:1405–1410, 2003
   Yang WT, Lai CJ, Whitman GJ, et al. Comparison of full-field digital mammography and screen-film mammography for detection and characterization of simulated small masses. Am J Roentgenol 187:W576–581, 2006
   Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271:655–663, 2014
   McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of digital breast tomosynthesis compared with digital mammography outcomes analysis from 3 years of breast cancer screening. JAMA Oncol 2:737−743, 2016
   Dromain C, Balleyguier C, Adler G, et al. Contrast-enhanced digital mammography. Eur J Radiol 69:34−42, 2009
   Kim EY, Youn I, Lee KH, et al. Diagnostic value of contrast-enhanced digital mammography versus contrast-enhanced magnetic resonance imaging for the preoperative evaluation of breast cancer. J Breast Cancer 21:453−462, 2018
   Perry H, Phillips J, Dialani V, et al. Contrast-enhanced mammography: a systematic guide to interpretation and reporting. Am J Roentgenol 212:222−231, 2019
   Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol 24:256–264, 2014
   Chou CP, Lewin JM, Chiang CL. Clinical evaluation of contrast-enhanced digital mammography and contrast enhanced tomosynthesis--Comparison to contrast-enhanced breast MRI. Eur J Radiol 84:2501–2508, 2015
   Magyar Radiologusok Tarsasaga Emlodiagnosztikai Szekcio es Ultrahang Szekcio: Kozos allasfoglalas az emlo ultrahangvizsgalatarol. Magy Radiol 75:80, 2001
   Berg WA, Blume JD, Boparai K, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151−2163, 2008
   Lander MR, Tabar L. Automated 3-D breast ultrasound as a promising adjunctive screening tool for examining dense breast tissue. Semin Roentgenol 46:302–308, 2011
   Brem RF, Tabar L, Duffy SW, et al. Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the SomoInsight Study. Radiol 274:663– 673, 2015
   Karst I, Henley C, Gottschalk N, et al. Three-dimensional automated breast US: Facts and artifacts. RadioGraphics 39:913−931, 2019
   Nazari S, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer 25:259−267, 2018
   Emons J, Wunderle M, Hartmann A. Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. Acta Radiol 59:1406−1413, 2018
   Schaefgen B, Heil J, Barr RG. Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis. Eur Radiol 28:2499−2506, 2018
   Berg WA, Leung JWT. Diagnostic Imaging: Breast 3nd Edition, Elsevier Science Health Science, 2019
   Barr RG, Nakashima K, Amy D, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2: breast. Ultrasound Med Biol 41:1148−1160, 2015
   Borbola Gy, Kardos K, Tasnadi T. Az emlo betegsegeinek vizsgalata szonoelasztografiaval. Kezdeti tapasztalatok. Magy Radiol 82:27–33, 2008
   Sidh P, Cantisani V, Dietrich C. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound, CEUS, in Non-Hepatic Applications: Update 2017, Long Version). Ultraschall Med 39:2–44, 2018
   ACR BI-RADS Atlas, 5th Edition, 2013
   Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316, 2010
   Biglia N, Bounous VE, Martincich L, et al. Role of MRI, magnetic resonance imaging, versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol 37:199–204, 2011
   Kuhl CK. High-risk screening: multi-modality surveillance of women at high risk for breast cancer, proven or suspected carriers of a breast cancer susceptibility gene). J Exp Clin Cancer Res 21:103–106, 2002
   Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information for the European Society of Breast Imaging, EUSOBI), with language review by Europa Donna – The European Breast Cancer Coalition. Eur Radiol 25:3669–3678, 2015
   Berger N, Luparia A, Di Leo G et al. Diagnostic performance of MRI versus galactography in women with pathologic nipple discharge: a systematic review and meta-analysis. Am J Roentgenol 209:465−471, 2017
   Lee JH, Rosen E, Mankoff DA, et al. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 1-Overview, detection and staging. J Nucl Med 50:569–581, 2009
   Lee JH, Rosen E, Mankoff DA, et al. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 2-Response to therapy, other indications, and future directions. J Nucl Med 50:738–748, 2009
   Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography, PET)/computed tomography, CT, scanning in cancer. JNCCN 5(Suppl 1):S1–S22, 2007
   Lavayssiere R, Cabee AE, Filmont JE, et al. Positron emission tomography, PET, and breast cancer in clinical practice. Eur J Radiol 69:50–58, 2009
   Poeppel DT, Krause BJ, Heusner TA, et al. PET/CT for staging and follow- up of patients with malignancies. Eur J Radiol 70:382–392, 2009
   Borbely K, Szilagyi I, Kasler M. IV. PET/CT Multidiszciplinaris Nemzeti Konszenzus Konferencia Allasfoglalasa. Magy Onkol 55:117–127, 2011
   National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis Guidelines, Breast Cancer Version 3.2019
   Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836– 1846, 2017
   Borbely K. Ujdonsagok es uj lehetosegek a nuklearis medicina kepalkotasban. Magy Onkol 58:232–238, 2014
   Forrai G, Ambrozay E, Bidlek M, et al. A kepalkoto vizsgalomodszerek alkalmazasa az emlodaganatok korszeru szureseben, diagnosztikajaban es ellatasaban – Szakmai utmutato a III. Emlorak Konszenzus Konferencia alapjan. Magy Onkol 60:181–193, 2016
   Glass SB, Shah ZA. Clinical utility of positron emission mammography. Proc, Bayl Univ Med Cent, 26:314–319, 2013
   Borbely K. Ujdonsagok es uj lehetosegek az onkologiai betegek terapias vezeteseben: PET/MR klinikai alkalmazasok. Magy Onkol 59:10–16, 2015
   Borbely K. A PET/MR technologia jelene es jovoje. Magy Radiol 92:43−52, 2018
   Bhole S, Neuschler E. MRI-guided breast interventions. Appl Radiol 44:7–13, 2015
   Teh W, Michell MJ, Wilson ARM, et al. UK MammotomeTrial Group UK National Health Service Breast Screening Programme, NHSBSP, multicentre image guided biopsy trial: an update. Breast Cancer Res 4:15, 2002
   Dobrossy L. Szervezett szures az onkologiaban. Egeszsegugyi Miniszterium, 2000
   Dobrossy L. Nepegeszsegugyi onkologiai szuresek. ANTSZ, 2005
   Dobrossy L. Daganatok szűrése minőségbiztosítási kézikönyv és módszertani útmutató, Budapest: Országos Tisztifőorvosi Hivatal, 2013
   A mammografias emloszures es a korai emlorak diagnosztikajara es terapiajara vonatkozo protokollok gyujtemenye, OTH Mammografias Emloszuresi Albizottsag 2004, 02. verzio)
   Smith RA, Cokkinides V, Brawley OW, et al. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59:27–41, 2009
   Saslow D, Boetes C, Burke W, et al. For the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89, 2007
   Sauven P, Bishop H, Patnick J, et al. The National Health Service Breast Screening Programme and British Association of Surgical Oncology audit of quality assurance in breast screening 1996–2001. Br J Surg 90:82–87, 2003
   Moss SM, Wale C, Smith R, et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol 16:1123–1132, 2015
   Sardanelli F, Fallenberg EM, Clauser P, et al. Mammography: an update of the EUSOBI recommendations on information for women. Insights Imaging 8:11–18, 2017
   Adany R. Megelozo orvostan es nepegeszsegtan, Debreceni Egyetem, 2011
   Schneerg T, Mitchell G, Taylor D, et al. MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer? J Med Radiat 62:212–225, 2015
   Liort G, Chirivella I, Morales R, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer. On behalf of the Hereditary Cancer Working Group. Clin Transl Oncol 17:956–961, 2015
   Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 21:115–124, 2002
   Lech MO, Eeles RA, Turnbull LW, et al. The UK national study of magnetic resonance imaging as a method of screening for breast cancer, MARIBS). J Exp Clin Cancer Res 21:107–114, 2002
   CG41 Familial Breast Cancer Guideline, NICE), 2013. http://www.nice. org.uk/guidance/cg164
   Sardanelli F, Podo F, D’Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer, HIBCRIT study): interim results. Radiology 242:698–715, 2007
   Olah E. Herediter emlo- es petefeszekrak-szindroma, a gyanutol a rizikocsokkentesig. In: Az emlorak korszeru sebeszete. Szerk. Matrai Z, Gulyas G, Kasler M, Medicina Kiado, Budapest 2015, pp. 389–409
   Olah E. Molekularis onkogenetika. In: Az onkologia alapjai. Szerk. Kasler M, Medicina Kiado, Budapest 2011, pp. 49−69
   Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer: updates and extensions. Br J Cancer 98:1457–1466, 2008
   Momenimovahed Z, Taheri, Tiznobaik A, Salehiniya H. Do the fertility drugs increase the risk of cancer? A review study. Front Endocrinol 10:313, 2019
   Senkus E, Kyriakides S, Ohno S, et al. Primary Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–30, 2015
   Cardoso F, Kyriakides S, Senkus E, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220, 2019
   Slanetz PJ, Freer PE, Birdwell RL. Breast-density legislation—practical considerations. N Engl J Med 372:593–595, 2015
   Artificial Intelligence for Europe a bizottság közleménye az Európai Parlamentnek, a tanácsnak, az Európai Gazdasági És Szociális Bizottságnak és a régiók bizottságanak. https://eur-lex.europa.eu/legal-content/HU/TXT/ PDF/?uri=CELEX:52018DC0237&from=EN, 2018
   Lehman CD, Buist DSM, Kerlikowske K, et al. Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med 175:1828−1837, 2015
   Gilbert FJ, Astley SM, Gillan MG, et al. Single reading with computer-aided detection for screening mammography. N Engl J Med 359:1675−1684, 2008
   Kim EK, Kim HE, Han K, et al. Applying data-driven imaging biomarker in mammography for breast cancer screening: preliminary study. Sci Rep 8:2762, 2018
   Chougrad H, Zouaki H, Alheyane O. Deep Convolutional Neural Networks for breast cancer screening. Comput Methods Programs Biomed 157:19−30, 2018
   Dhungel N, Carneiro G, Bradley AP. A deep learning approach for the analysis of masses in mammograms with minimal user intervention. Med Image Anal 37:114−128, 2017
   Lee HN, Sohn YM, Han KH. Comparison of mammographic density estimation by Volpara software with radiologists’ visual assessment: analysis of clinical-radiologic factors affecting discrepancy between them. Acta Radiol 56:1061−1068, 2015
   U.S. Food & Drug Administration. https://www.accessdata.fda.gov/cdrh_ docs/pdf16/K163623.pdf
   U.S. Food & Drug Administration. DM-Density, 21 CFR 892.2050), Picture archiving and communications system. ttps://www.accessdata.fda.gov/ cdrh_docs/pdf17/K170540.pdf
   Artificial intelligence to improve breast cancer screening. https://www. tees.ac.uk/sections/news/pressreleases_story.cfm?story_id=6784, 2018
   Mendelson EB. Artificial intelligence in breast imaging: Potentials and limitations. Am J Roentgenol 212:293−299, 2018
   Le EPV, Wang Y, Huang Y, et al. Artificial intelligence in breast imaging. Clin Radiol 74:357−366, 2019
   Bahl M, Barzilay R, Yedidia AB, et al. High-risk breast lesions: a machine learning model to predict pathologic upgrade and reduce unnecessary surgical excision. Radiology 286:810−818, 2018
   Sanders LM, Sharma P, El Madany M et al. Clinical breast concerns in low-risk pediatric patients: practice review with proposed recommendations. Pediat Radiol 48:186−195, 2018
   National Institute for Health and Clinical Excellence. Image-guided vacuum- assisted excision biopsy of benign breast lesions. http://www.nice. org. uk/nicemedia/pdf/ip/IPG156guidance.pdf, 2006
   Smith GE, Burrows P. Ultrasound diagnosis of fibroadenoma – is biopsy always necessary? Clin Radiol 63:511−515, 2008
   Taylor K, Lowes S, Stanley E. Evidence for avoiding the biopsy of typical fibroadenomas in women aged 25-29 years. Clin Radiol 74:676−681, 2019
   NICE. https://www.nice.org.uk/guidance/ipg592, 2017
   Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast fibroadenomas. Radiol 234:63−72, 2005
   Zhang BN, Cao XC, Chen JY, et al. Guidelines on the diagnosis and treatment of breast cancer, 2011 edition). Gland Surg 1:39−61, 2012
   BCGuidelines.ca. https://www2.gov.bc.ca/assets/gov/health/practitionerpro/ bc-guidelines/brdisease.pdf, 2013
   Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer. https://www.uhb.nhs.uk/Downloads/pdf/CancerPbImagingBreastCancer. pdf
   Evans A, Pinder S, Wilson R. Breast Calcification − A Diagnostic Manual. Greenwich Medical Media, London 2002
   Forrai G, Toth Zs, Sebo E, et al. Emlodiagnosztikai asszisztensek elmeleti es gyakorlati kezikonyve, OKI 2017, Saxum, 2019
   Lehman C. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010:150−151, 2010
   Lim H, Jeong S, Lee J. Paget disease of the breast: mammographic, US, and MR imaging findings with pathologic correlation. RadioGraphics 31:1973−2011, 2011
   Van der Ploeg IM, Hobbelink M, van den Bosch MA, et al. Radioguided occult lesion localisation, ROLL, for non-palpable breast lesions: a review of the relevant literature. Eur J Surg Oncol 34:1–5, 2008
   Borbely K, Sinkovics I, Madaras B, et al. Az emlorak korszeru kepalkoto diagnosztikaja: nuklearis medicina-technikak. Orv Hetil 153:15–22, 2012
   McCormick JT, Keleher AJ, Tikhomirov VB, et al. Analysis of the use of specimen mammography in breast conservation therapy. Am J Surg 188:433–436, 2004
   Kim T, Giuliano AE, Lyman GH, et al. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. A metaanalysis. Cancer 106:4–16, 2006
   Postma EL, Verkooijen HM, van Esser S, et al. Efficacy of ‘radioguided occult lesion localisation’, ROLL, versus ‘wire-guided localisation’, WGL, in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer Res Treat 136: 469−478, 2012
   Takács T, Paszt A, Simonka Z, et al. Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions. Pathol Oncol Res 19:267–273, 2013
   Harvey J, Lim Y, Murphy J. Safety and feasibility of breast lesion localization using magnetic seeds, Magseed): a multi-centre, open-label cohort study. Breast Cancer Res Treat 169:531−536, 2018
   Kapoor M, Patel M, Scoggins M. The wire and beyond: recent advances in breast imaging preoperative needle localization. RadioGraphics 39:1886−1906, 2019
   McGuire KP, Toro-Burguete J, Dang H, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18:3149–3154, 2011
   Schmitz AC, Gianfelice D, Daniel BL, et al. Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions. Eur Radiol 18:1431–1441, 2008
   Edwards MJ, Broadwater R, Tafra L, et al. Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice. Am J Surg 188:221−224, 2004
   Kaufman CS, Littrup PJ, Freeman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas with long-term follow-up. Breast J 11:344−350, 2005
   Lakoma A, Kim ES. Minimally invasive surgical management of benign breast lesions. Gland Surg 3:142–148, 2014
   Cryoablation therapy in treating patients with invasive ductal breast cancer. https://clinicaltrials.gov/ct2/show/NCT00723294?term=z1072&rank=1, 2017
   Littrup PJ, Jallad B, Chandiwala-Mody P, et al. Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol 20:1329−1341, 2009
   Manenti G, Perreta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol 21:2344−2353, 2011
   Manenti G, Bolacchi F, Perretta T, et al. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology 251:339–346, 2009
   Palussiere J, Henriques C, Mauriac L, et al. Radiofrequency ablation as a substitute for surgery in elderly patients with non resected breast cancer: pilot study with long-term outcomes. Radiology 264:597–605, 2012
   Nguyen T, Hattery E, Khatri VP, et al. Radiofrequency ablation and breast cancer: a review. Gland Surg 3:128–135, 2014
   Linda A, Zuiani C, Furian A, et al. Nonsurgical management of high-risk lesions diagnosed at core needle biopsy: can malignancy be ruled out safely with breast MRI? AJR Am J Roentgenol 198:272–280, 2012
   Pediconi F, Padula S, Dominelli V, et al. Role of breast MR imaging for predicting malignancy of histologically borderline lesions diagnosed at core needle biopsy: prospective evaluation. Radiology 257:653–661, 2010
   Rageth CJ, O’Flynn EAM, Comstock C, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast, B3 lesions). Breast Cancer Res Treat 159:203−213, 2016
   Rageth CJ, O’Flynn EAM, Pinker K, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast, B3 lesions). Breast Cancer Res Treat 174:279–296, 2019
   NHS Breast Screening Programme Clinical guidance for breast cancer screening assessment. https://associationofbreastsurgery.org.uk/media/ 1414/nhs-bsp-clinical-guidance-for-breast-cancer-screening-assessment. pdf, 2016
   Clemens MW, Jacobsen ED, Horwitz SM, et al. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma, BIA-ALCL). Aesthet Surg J 39(S1): S3–S13, 2019
   Taber KJ, Morisy L, Osbahr A. Male breast cancer: risk factors, diagnosis, and management, Review). Oncol Rep 24: 1115−1120, 2010
   Gao Y, Goldberg J, Young T. Breast cancer screening in high-risk men: a 12-year longitudinal observational study of male breast imaging utilization and outcomes. Radiology 293:282−291, 2019
   Marino M, Gucalp A, Leithner D. Mammographic screening in male patients at high risk for breast cancer: is it worth it? Breast Cancer Res Treat 177:705−711, 2019
   Mitchell KB, Johnson HM, Eglash A, et al. ABM Clinical Protocol #30: Breast Masses, Breast Complaints, and Diagnostic Breast Imaging in the Lactating Woman. Breastfeed Med 14:208-214, 2019
   Az Egeszsegugyi Miniszterium Szakmai Protokollja a mammografias emloszuresrol es a korai emlorak diagnosztikajarol. Egeszsegugyi Kozlony 10:2990–3012, 2008
   Brierley JD, Gospodarowicz MK, Wittekind C, et al. A rosszindulatu daganatok TNM-klasszifikacioja es stadiumbesorolasa, Oriold es Tarsai Kiado Kft., 2017
   Kasler M. Ajanlas az emlorak korszeru diagnosztikajara, kezelesere es gondozasara. Elso Magyar Nemzeti Emlorak Konszenzus Konferencia iranyelvei. Magy Onkol 44:11–38, 2000
   Kasler M. A komplex onkodiagnosztika es onkoterapia iranyelvei. Semmelweis Kiado, 2008, pp. 329–368
   Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 26:1533–1546, 2015
   Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer, ABC2). Ann Oncol 25:1871– 1888, 2014
   Tasnadi T, Forrai G. Emlo-MR-vizsgalatok leletezesi protokollja a BIRADS lexikon alapjan I. A leletezes elvei es alapfogalmai. Magy Radiol 8(2):1−16, 2017
   Tasnadi T, Forrai G. Emlo-MR-vizsgalatok leletezesi protokollja a BIRADS lexikon alapjan II. Leletsablonok. Magy Radiol 8(3):1−6, 2017
   23/2012., IX. 14., EMMI-rendelet
   60/2003., X. 20., EszCsM-rendelet
   Bordas P, Jonsson H, Nystrom L, et al. Interval cancer incidence and episode sensitivity in the Norrbotten Mammography Screening Programme, Sweden. J Med Screen 16:39–45, 2009
   Oeffinger KO, Fontham ETH, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk 2015 Guideline Update From the American Cancer Society. JAMA 314:1599–1614, 2015
   Bluekens AMJ, Holland R, Karssemeijer N, et al. Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology 265:707– 714, 2012
   Seradour B, Heid P, Esteve J, et al. Comparison of direct digital mammography, computed radiography, and film-screen in the French national breast cancer screening program. Am J Roentgenol 202:229–236, 2014
   Pinker K, Perry N, Vinnicombe S, et al. Conspicuity of breast cancer according to histopathological type and breast density when imaged by full field digital mammography compared with screen-film mammography. Eur Radiol 21:18–25, 2011
   Yamada T, Ishibashi T, Sato A, et al. Comparison of screen-film and fullfield digital mammography: image contrast and lesion characterization. Radiat Med 21:166–171, 2003
   Fischer U, Baum F, Obenauer S, et al. Comparative study in patients with microcalcifications: full-field digital mammography vs screen-film mammography. Eur Radiol 12:2679–2683, 2002
   Pisano ED, Hendrick RE, Yaffe MJ, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 246:376–383, 2008
   Juel IM, Skaane P, Hoff SR, et al. Screen-film mammography versus fullfield digital mammography in a population-based screening program: The Sogn and Fjordane study. Acta Radiol 51:962–968, 2010
   Ranger NT, Lo JY, Samei E, et al. A technique optimization protocol and the potential for dose reduction in digital mammography. Med Phys 37:962– 969, 2010
   Schueller G, Riedl CC, Mallek R, et al. Image quality, lesion detection, and diagnostic efficacy in digital mammography: full-field digital mammography versus computed radiography-based mammography using digital storage phosphor plates. Eur J Radiol 67:487–496, 2008
   Tabar L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 125:515−523, 2019
   Lakossági szűrővizsgálatok. https://www.antsz.hu/data/cms41690/lakossagi_ szurovizsgalatok.pdf
   A Radiologiai Szakmai Kollegium allasfoglalasa a radiologia digitalizalasaval kapcsolatos kerdesekrol, A digitalis radiologia, a PACS es a teleradiologia fejlodesi iranyai szakmai technikai jogi feltetelrendszere). Radiologiai Szakmai Kollegium. www.radiologia.hu, 2007
   Gennaro G, Avramova-Cholakova S, Azzalini A, et al. Quality controls in digital mammography protocol of the EFOMP Mammo Working group. Phys Med 48:55−64, 2018
   Gresz M. Az emlo rosszindulatu daganata es az emloszures viszonya Magyarorszagon az Orszagos Egeszsegbiztositasi Penztar adatainak tukreben. Orv Hetil 153:1745−1751, 2012
   Laubs-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening– viewpoint of the IARC Working Group. N Engl J Med 372:2353−2358, 2015
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 278
EP 299
PG 22
ER

PT J
AU Cserni, G
   Francz, M
   Jaray, B
   Kalman, E
   Kovacs, I
   Krenacs, T
   Toth, E
   Udvarhelyi, N
   Vass, L
   Voros, A
   Kulka, J
AF Cserni, Gabor
   Francz, Monika
   Jaray, Balazs
   Kalman, Endre
   Kovacs, Ilona
   Krenacs, Tibor
   Toth, Erika
   Udvarhelyi, Nora
   Vass, Laszlo
   Voros, Andras
   Kulka, Janina
TI Pathological diagnosis, work-up and reporting of breast cancer. Recommendations from the 4th Breast Cancer Consensus Conference
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; consensus conference; pathology; recommendations; diagnostics
ID breast cancer; consensus conference; pathology; recommendations; diagnostics
AB There have been some relevant changes in the diagnosis and treatment of breast cancer to implement the updating of the 2016 recommendations made during the 3rd national consensus conference on the disease. Following a wide interdisciplinary consultation, the present recommendations have been finalized after their public discussion at the 4th Hungarian Breast Cancer Consensus Conference. The recommendations cover non-operative, intraoperative and postoperative diagnostics, the determination of prognostic and predictive markers and the content of the cytology and histology reports. Furthermore, it touches some special issues such as the current status of multigene molecular markers, the role of pathologists in clinical trials and prerequisites for their involvement, some relevant points about the future. The most important changes include the integration of the TNM 8th edition, the WHO classification of breast tumors 5th edition, the ASCO/CAP HER2 assessment guidelines from 2018, and the Yokohama terminology for cytology reporting; a more detailed text on tumor-infiltrating lymphocytes and size determination after neoadjuvant therapy and a broader discussion of molecular tests.
C1 [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of Pathology, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Francz, Monika] Josa Andras Teaching Hospital, Department of PathologyNyiregyhaza, Hungary.
   [Jaray, Balazs] Medserv KftBudapest, Hungary.
   [Kalman, Endre] University of Pecs, Department of PathologyPecs, Hungary.
   [Kovacs, Ilona] Kenezy Teaching Hospital, Department of PathologyDebrecen, Hungary.
   [Krenacs, Tibor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Toth, Erika] National Institute of OncologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of OncologyBudapest, Hungary.
   [Vass, Laszlo] Flor Ferenc University Hospital of Pest County, Department. of Pathology/CytopathologyKistarcsa, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Cserni, G (reprint author), Bacs-Kiskun County Hospital, Department of Pathology, 6000 Kecskemet, Hungary.
EM cserni@freemail.hu
CR Cserni G, Francz M, Jaray B, et al. Az emlorak patologiai diagnosztikaja, feldolgozasa es korszovettani leletezese. Szakmai utmutatas a III. Emlorak Konszenzus Konferencia alapjan. Magy Onkol 60:209−228, 2016
   Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489−492, 1987
   Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474−1481, 1999
   Toth J, Cserni G, Kalman E, et al. Az emlorak patologiai feldolgozasa es korszovettani leletezese. Magy Onkol 44:14−16, 2000
   Amendoeira I, Apostolikas N, Bellocq JP, et al. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition. Eds. Perry N, Broeders M, de Wolf C, et al. European Comission, Luxembourg 2006, pp. 219−311
   Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990- 1999. Eur J Cancer 43:1548−1555, 2007
   Jaray B, Szekely E, Istok R, et al. A citopatologus es a radiologus egyuttmukodese a citopatologiaban. LAM 17:233−237, 2007
   Cserni G, Francz M, Jaray B, et al. Az emlorak patologiai diagnosztikaja, feldolgozasa es korszovettani leletezese. Magy Onkol 54:217−226, 2010
   Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:e48−72, 2010
   Cserni G, Amendoeira I, Bianchi S, et al. Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis, TNM, definitions. Eur J Cancer 47:887−894, 2011
   Wells CA, Amendoeira I, Bellocq JP, et al. S2: Pathology update. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition, Supplements. Eds. Perry N, Broeders M, de Wolf C, et al. European Commission, Office for Official Publications of the European Union, Luxembourg 2012, pp. 73–120
   Ellis IO, Al-Sam S, Anderson N, et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. https://www.rcpath.org/uploads/assets/ 7763be1c-d330-40e8-95d08f955752792a/g148_breastdataset-hires-jun16. pdf
   Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364−1382, 2018
   Field AS, Schmitt F, Vielh P. IAC standardized reporting of breast fine-needle aspiration biopsy cytology. Acta Cytol 61:3−6, 2017
   Field AS, Raymond WA, Rickard M, et al. The International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology. Acta Cytol 63:257−273, 2019
   Hoda S, Brachtel EF. Intarnational Academy of Cytology Yokohama System for reporting breast fine-needle aspiration biopsy cytopathology: A review of predictive values and risks of malignancy. Acta Cytologica 63:291– 301, 2019
   Acs B, Szekely N, Szasz AM, et al. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study. Diagn Cytopathol 44:466−471, 2016
   Rageth CJ, O’Flynn EAM, Pinker K, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast, B3 lesions). Breast Cancer Res Treat 174:279−296, 2019
   Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194−1220, 2019
   Cataliotti L, De Wolf C, Holland R, et al. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer 43:660−675, 2007
   Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic 14-gauge breast biopsy: how many core biopsy specimens are needed? Radiology 192:793−795, 1994
   Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40−50, 2018
   Gertych A, Mohan S, Maclary S, et al. Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis. Diagn Pathol 9:213, 2014
   Tot T. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections. Cancer 110:2551−2560, 2007
   Tot T, Gere M, Pekar G, et al. Breast cancer multifocality, disease extent, and survival. Hum Pathol 42:1761−1769, 2011
   Tot T. The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases. Int J Breast Cancer 2012:395415, 2012
   Kaufmann M, Morrow M, von Minckwitz G, et al. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 116:1184−1191, 2010
   Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology- American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507−1515, 2014
   Foschini MP, Miglio R, Fiore R, et al. Pre-operative management of pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. Eur J Surg Oncol 45:2279−2286, 2019
   Decker T, Ruhnke M, Schneider W. Standardisierte pathologische Untersuchung von Mamma-Excisionspraparaten. [Standardized pathologic examination of breast excision specimen. Relevance within an interdisciplinary practice protocol for quality management of breast saving therapy]. Pathologe 18:53−59, 1997
   Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422, 2007
   Provenzano E, Bossuyt V, Viale G, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 25:1185−1201, 2015
   Hortobagyi G, Connolly JL, D’Orsi CJ, et al. Breast. In: AJCC Cancer staging manual, 8th edn. Eds. Amin MB, Edge SB, Greene FL et al, Springer, New York 2017, pp. 587–628
   Brierley JD, Gospodarowicz MK, Wittekind Ch, eds). TNM classification of malignant tumours, 8th ed. John Wiley and Sons, Chichester 2017
   Schnitt SJ, Connolly JL. Pathologic prediction of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 53:1049−1057, 1984
   WHO Classification of Tumours Editorial Board. WHO classification of tumours of the breast, 5th ed. International Agency for Research on Cancer, Lyon 2019
   Cserni G, Sejben A. Grading ductal carcinoma in situ, DCIS, of the breast – what’s wrong with it?” Pathol Oncol Res 26:665−671, 2020
   Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in situ. Cancer 80:1798−1802, 1997
   Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186:337−343, 2003
   Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes, TILs, in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259−271, 2015
   Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes, TILs, in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 52:16−25, 2018
   Dushyanthen S, Beavis PA, Savas, P et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med 13:202, 2015
   Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37:559−569, 2019
   Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927−933, 2010
   Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis. Ann Surg 252:426−433, 2010
   Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases, IBCSG 23- 01): a phase 3 randomised controlled trial. Lancet Oncol 14:297−305, 2013
   Cserni G. Orszemnyirokcsomo-status es honalji blokkdissectio az emlorak sebeszi ellatasaban. Orv Hetil 155:203−215, 2014
   Cserni G. Orszemnyirokcsomo-biopszia es axillaris blokkdisszekcio korai emlorakban – Algoritmus magyarazatokkal, nyitott kerdesekkel. Magy Seb 69:4−13, 2016
   AGO, DGS, SGS, OGS, Panelists, Executive Board Members; Hoffmann J, Souchon R, Lebeau A, et al. German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer. Eur J Cancer 49:2277−2283, 2013
   Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365−1383, 2014
   Tew K, Irwig L, Matthews A, et al. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg 92:1068−1080, 2005
   Liu LC, Lang JE, Lu Y, et al Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. Cancer 117:250−258, 2011
   Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med 138:241−256, 2014
   Bussolati G, Annaratone L, Medico E, et al. Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One 6:e21043, 2011
   Gundisch S, Annaratone L, Beese C, et al. Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Lab Invest 95:561−571, 2015
   Di Novi C, Minniti D, Barbaro S, et al. Vacuum-based preservation of surgical specimens: an environmentally-safe step towards a formalin-free hospital. Sci Total Environ 408:3092−3095, 2010
   Rakha EA, Pinder SE, Bartlett JM, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68:93−99, 2015
   Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17:1414–1420, 2004
   Williams SL, Birdsong GG, Cohen C, et al. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol 2:476−480, 2009
   Hanna W, Barnes P, Berendt R, et al. Testing for her2 in breast cancer: current pathology challenges faced in Canada. Curr Oncol 19:315−323, 2012
   Schmitt F, Vielh P. Fine-needle aspiration cytology samples: a good source of material for evaluating biomarkers in breast cancer. Histopathology 66:314–315, 2015
   Vohra P, Buelow B, Chen YY, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study. Cancer Cytopathol 124:828–835, 2016
   Matsui A, Murata Y, Masuda N, et al. Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study. Oncotarget 10:5680−5689, 2019
   Evidence-Based Series 22-1 EDUCATION AND INFORMATION 2017 A Quality Initiative of the Program in Evidence-Based Care, PEBC), Cancer Care Ontario, CCO, Guideline on Hormone Receptor Testing in Breast Cancer. https://www.cancercareontario.ca › file › download
   Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533−1546, 2015
   Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38:1346−1366, 2020
   Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115:44−58, 2001
   Farshid G, Bilous M, Morey, A, et al. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology 51:345−348, 2019
   Page DB, Wen H, Brogi E, et al. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. Breast Cancer Res Treat 167:547−544, 2018
   Rakha EA, Pinder SE, Bartlett JM, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68:93−99, 2015
   Pekar G, Kasselaki I, Pekar-Lukacs A, et al. Equivocal, HER2 IHC 2+, breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits. Histopathology 74:300−310, 2019
   Krystel-Whittemore M, Xu J, Brogi E, et al. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat 177:61−66, 2019
   Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108−2121, 2018
   Martinez-Morilla S, McGuire J, Gaule P, et al. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Lab Invest 100:4−15, 2020
   Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380:2395−2405, 2019
   Sestak I, Martin M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat 377−386, 2019
   Cardoso F, van’t Veer LJ, Bogaerts J, et al; MINDACT Investigators. 70- Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 717−729, 2016
   Hagemann IS. Molecular testing in breast cancer: A guide to current practices. Arch Pathol Lab Med 140:815−824, 2016
   Vieira AF, Schmitt F. An update on breast cancer multigene prognostic tests–mergent clinical biomarkers. Front Med 5:248, 2018
   Kodahl AR, Ehmsen S, Pallisgaard N, et al. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol Oncol 12:925−935, 2018
   Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30:1437−1447, 2019
   Loibl S, Treue D, Budczies J, et al. Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant GeparSepto trial. Clin Cancer Res 25:3986−3995, 2019
   Krenacs T, Fonyad L, Glasz T, et al. Patologiai mintaelokeszites es -feldolgozas. In: Patologiai es molekularis onkodiagnosztikai modszerek. Szerk. Krenacs T, Bodor Cs, Matolcsy A. Medicina Kiado, 2020, pp. 85−121
   Schneider F, Maurer C, Friedberg RC. International Organization for Standardization, ISO, 15189. Ann Lab Med 37:365−370, 2017
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 301
EP 328
PG 28
ER

PT J
AU Lazar, Gy
   Kelemen, P
   Kosa, Cs
   Maraz, R
   Paszt, A
   Pavlovics, G
   Savolt, �
   Simonka, Zs
   Toth, D
   Matrai, Z
AF Lazar, Gyorgy
   Kelemen, Peter
   Kosa, Csaba
   Maraz, Robert
   Paszt, Attila
   Pavlovics, Gabor
   Savolt, Akos
   Simonka, Zsolt
   Toth, Dezso
   Matrai, Zoltan
TI Modern surgical treatment of breast cancer. 4th Breast Cancer Consensus Conference
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE surgical therapy of breast cancer; sentinel lymph node; oncoplastic principles
ID surgical therapy of breast cancer; sentinel lymph node; oncoplastic principles
AB The surgical treatment is still the most effective method in curing of early breast cancer. Breast preservation and the application of oncoplastic principles became generally accepted, the sentinel lymph node biopsy in the surgical treatment of the axilla is primary, and the indication for axillary block dissection (ABD) is narrowing further. The neoadjuvant oncological treatment that is applied more and more widely presented surgery with new challenges. Hereunder we summarise our recommendations on the surgical treatment of breast cancer based on the content of the 3rd Breast Cancer Consensus Conference and considering the latest international studies and professional recommendations.
C1 [Lazar, Gyorgy] University of Szeged, Department of Surgery, Semmelweis u. 8., 6725 Szeged, Hungary.
   [Kelemen, Peter] National Institute of OncologyBudapest, Hungary.
   [Kosa, Csaba] University of Debrecen, Department of Surgery and Operative TechniquesDebrecen, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Paszt, Attila] University of Szeged, Department of Surgery, Semmelweis u. 8., 6725 Szeged, Hungary.
   [Pavlovics, Gabor] University of Pecs, Department of SurgeryPecs, Hungary.
   [Savolt, Akos] National Institute of OncologyBudapest, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of Surgery, Semmelweis u. 8., 6725 Szeged, Hungary.
   [Toth, Dezso] Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz, Sebeszeti OsztalyMiskolc, Hungary.
   [Matrai, Zoltan] National Institute of OncologyBudapest, Hungary.
RP Lazar, Gy (reprint author), University of Szeged, Department of Surgery, 6725 Szeged, Hungary.
EM gylazar@gmail.com
CR Lazar Gy, Bursics A, Farsang Z, et al. III. Emlorak Konszenzus Konferencia – Az emlorak korszeru sebeszi kezelese. Magy Onkol 60:194–207, 2016
   Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 26:1533–1546, 2015
   Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–30, 2015
   National Comprehensive Cancer Network, NCCN, Guidelines. Breast Cancer. www.nccn.org Version 3.2020
   Zagouri F, Liakou P, Bartsch R, et al. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Breast 24:513–523, 2015
   Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1674, 2019
   Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30:1541–1557, 2019
   Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220, 2019
   Balic M, Thomssen C, Wurstlein R, et al. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 14:103–110, 2019
   Pukancsik D, Kelemen P, Ujhelyi M, et al. Objective decision making between conventional and oncoplastic breast-conserving surgery or mastectomy: An aesthetic and functional prospective cohort study. Eur J Surg Oncol 43:303–310, 2017
   Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 24:2206–2223, 2013
   Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 128:581–583, 2011
   Nijenhuis MV, Rutgers EJ. Conservative surgery for multifocal/multicentric breast cancer. Breast 24(Suppl 2):S96–99, 2015
   Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat 113:577–583, 2009
   Rubio IT, Wyld L, Esgueva A, et al. Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey. Eur J Surg Oncol 45:567–572, 2019
   Hennigs A, Hartmann B, Rauch G, et al. Long-term objective esthetic outcome after breast-conserving therapy. Breast Cancer Res Treat 153:345– 351, 2015
   Losken A, Dugal CS, Styblo TM, et al. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. Ann Plast Surg 72:145–149, 2014
   Kelemen P, Pukancsik D, Ujhelyi M, et al. Comparison of clinicopathologic, cosmetic and quality of life outcomes in 700 oncoplastic and conventional breast-conserving surgery cases: A single-centre retrospective study. Eur J Surg Oncol 45:118–124, 2019
   Association of Breast Surgery at BASO; Association of Breast Surgery at BAPRAS; Training Interface Group in Breast Surgery, Baildam A, Bishop H, Boland G, et al. Oncoplastic breast surgery – a guide to good practice. Eur J Surg Oncol 33(Suppl 1):S1–23, 2007
   Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329, 2009
   Matrai Z, Gulyas G, Kasler M. Az emlorak korszeru sebeszete. Medicina, 2015
   Rezai M, Knispel S, Kellersmann S, et al. Systematization of oncoplastic surgery: Selection of surgical techniques and patient-reported outcome in a cohort of 1,035 patients. Ann Surg Oncol 22:3730–3737, 2015
   Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology – American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507–1515, 2014
   Masannat YA, Bains SK, Pinder SE, et al. Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast 22:194–196, 2013
   Flanagan MR, Rendi MH, Calhoun KE, et al. Pleomorphic lobular carcinoma in situ: Radiologic-pathologic features and clinical management. Ann Surg Oncol 22:4263–4269, 2015
   Takacs T, Paszt A, Simonka Z, et al. Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions. Pathol Oncol Res 19:267–273, 2013
   Chan BK, Wiseberg-Firtell JA, Jois RH, et al. Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database Syst Rev 12:CD009206, 2015
   Mallon P, Feron JG, Couturaud B, et al. The role of nipple-sparing mastectomy in breast cancer: a comprehensive review of the literature. Plast Reconstr Surg 131:969–984, 2013
   Maraz R, Boross G, Pap-Szekeres J, et al. Internal mammary sentinel node biopsy in breast cancer. Is it indicated? Pathol Oncol Res 20:169–177, 2014
   Houssami N, Morrow M. Margins in breast conservation: a clinician’s perspective and what the literature tells us. J Surg Oncol 110:2–7, 2014
   Kodama H, Nio Y, Iguchi C, Kan N. Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer. Br J Cancer 95:811–816, 2006
   Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg 91:38–43, 2004
   Cserni G. Orszemnyirokcsomo-biopszia es axillaris blokkdissectio korai emlorakban – Algoritmus magyarazatokkal, nyitott kerdesekkel. Magy Seb 69:3–12, 2016
   Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43:672–679, 2017
   Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer, EORTC 10981-22023 AMAROS): a randomised, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310, 2014
   Horvath Z, Paszt A, Simonka Z, et al. Is intraoperative touch imprint cytology indicated in the surgical treatment of early breast cancers? Eur J Surg Oncol 43:1252–1257, 2017
   Sabel MS. The need for axillary lymph node dissection in T1/T2 breast cancer surgery–counterpoint. Cancer Res 73:7156–7160, 2013
   Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 167:787–795, 2018
   Kuerer HM, Smith BD, Chavez-MacGregor M, et al. DCIS margins and breast conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8:2653–2662, 2017
   Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 370:485–492, 2007
   Weber WP, Haug M, Kurzeder C, et al. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Res Treat 172:523–537, 2018
   Rageth CJ, O’Flynn EAM, Pinker K, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast, B3 lesions). Breast Cancer Res Treat 174:279–296, 2019
   van Uden DJ, van Laarhoven HW, Westenberg AH, et al. Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol 93:116–126, 2015
   Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer. J Surg Oncol 103:337–340, 2011
   Matrai Z, Banhidy F, Teglas M, et al. Orszemnyirokcsomo-biopszia terhessegi emlorakban. Orv Hetil 154:1991–1997, 2013
   Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol 21:2506–2511, 2014
   Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 17:301–307, 2014
   Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693, 2004
   Szollar A, Ujhelyi M, Polgar C, et al. A long-term retrospective comparative study of the oncological outcomes of 598 very young, ≤35 years, and young, 36-45 years, breast cancer patients. Eur J Surg Oncol 45:2009–2015, 2019
   Fancellu A, Sanna V. High mastectomy rates in young and very young patients with breast cancer. Are they justified? Eur J Surg Oncol 46:1391–1392, 2020
   Patten DK, Sharifi LK, Fazel M. New approaches in the management of male breast cancer. Clin Breast Cancer 13:309–314, 2013
   Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130, 2003
   Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27(suppl 5):v103–v110, 2016
   Kurian AW, Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 312:902–914, 2014
   Guth U, Myrick ME, Viehl CT, et al. Increasing rates of contralateral prophylactic mastectomy – a trend made in USA? Eur J Surg Oncol 38:296–301, 2012
   Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998– 2002. Breast Cancer Res Treat 142:465–476, 2013
   Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 119:1402–1411, 2013
   Kronowitz SJ. State of the art and science in postmastectomy breast reconstruction. Plast Reconstr Surg 135:755–771, 2015
   Potter S, Conroy EJ, Cutress RI, et al. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh, iBRA): a multicentre, prospective cohort study. Lancet Oncol 20:254–266, 2019
   Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493, 1997
   van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 115:101– 113, 2009
   Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516, 2012
   Early Breast Cancer Trialists’ Collaborative Group, EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39, 2018
   Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 22:1118–1127, 2015
   Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy, SENTI- NA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618, 2013
   Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol 33:258–264, 2015
   Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071, Alliance). Ann Surg 261:547–552, 2015
   Galimberti V. Feasibility of sentinel node biopsy in breast cancer after neoadjuvant treatment. Breast 24(Suppl 1):PG 9.02, 2015
   Simons JM, van Nijnatten TJA, van der Pol CC et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant therapy in node-positive breast cancer: A systematic review and meta-analysis. Ann Surg 269:432–442, 2019
   Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer, ABC 4). Ann Oncol 29:1634– 1657, 2018
   Walstra CJEF, Schipper RJ, Poodt IGM, et al. Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review. Eur J Surg Oncol 45:1317–1327, 2019
   Ishitobi M, Fukui R, Hashimoto Y, et al. pTis and pT1a ipsilateral breast tumor recurrence is associated with good prognosis after salvage surgery. Oncology 94:12–18, 2018
   Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36:1073–1079, 2018
   Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: decade report, 2005–2015). Breast 39:131–138, 2018
   Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985–2016. Breast 31:46–50, 2017
   Kwapisz D. Oligometastatic breast cancer. Breast Cancer 26:138–146, 2019
   Ruiz A, Wicherts DA, Sebagh M, et al. Predictive profile-nomogram for liver resection for breast cancer metastases: An aggressive approach with promising results. Ann Surg Oncol 24:535–545, 2017
   Motomura K, Inaji H, Komoike Y, et al. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol 29:604–607, 1999
   Lin J, Lin LS, Chen DR, et al. Indocyanine green fluorescence method for sentinel lymph node biopsy in breast cancer. Asian J Surg 2020,, DOI  10.1016/j.asjsur.2020.02.003
   Thill M, Kurylcio A, Blechmann R, et al. The SentiMag Study: sentinel node biopsy with superparamagnetic iron oxide, SPIO, vs. radioisotope. Eur J Cancer 49:S260–S261, 2013
   Mok CW, Tan SM, Zheng Q, Shi L. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open 3:445–452, 2019
   Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis. Am J Surg 220:665– 676, 2020
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 329
EP 346
PG 18
ER

PT J
AU Horvath, Zs
   Boer, K
   Dank, M
   Kahan, Zs
   Kocsis, J
   Kover, E
   Mahr, K
   Piko, B
   Rubovszky, G
AF Horvath, Zsolt
   Boer, Katalin
   Dank, Magdolna
   Kahan, Zsuzsanna
   Kocsis, Judit
   Kover, Erika
   Mahr, Karoly
   Piko, Bela
   Rubovszky, Gabor
TI Systemic treatment of breast cancer: professional guideline
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE early breast cancer; locally advanced breast cancer; adjuvant treatment; neoadjuvant treatment; metastatic breast cancer; inflammatory breast cancer; guideline
ID early breast cancer; locally advanced breast cancer; adjuvant treatment; neoadjuvant treatment; metastatic breast cancer; inflammatory breast cancer; guideline
AB Since the III. Breast Cancer Consensus Conference, a number of new evidence based on clinical trial results have been published which justified updating the 2016 recommendation. In addition to classical prognostic factors, some multigenic tests, which we have incorporated into the recommendation, will play an important role in therapeutic decision-making. The professional guide primarily reflects the resolutions and recommendations of the current ESMO, NCCN, ABC4, as well as the St. Gallen Consensus Conference. From a didactic point of view, the text follows first the line of early and then locally advanced breast cancer, locoregionally recurrent and metastatic breast cancer. Within these, we discuss each group according to therapeutic options.
C1 [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Boer, Katalin] Szent Margit Hospital, V. Department of Internal Medicine - OncologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri ut 38., 6000 Kecskemet, Hungary.
   [Kover, Erika] University of Pecs, Department of OncologyPecs, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Piko, Bela] Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Klinikai Onkologiai es Sugartherapias OsztalyGyula, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Horvath, Zs (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, 6000 Kecskemet, Hungary.
EM zsodicsom@gmail.com
CR Horvath Zs, Boer K, Dank M, et al. Az emlorak szisztemas kezelese: szakmai utmutatas. Magy Onkol 60:241−257, 2016
   Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194−1220, 2019
   NCCN: NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines): Breast Cancer, ed 1/2020), NCCN.org, 2020
   Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer, ABC 4). Ann Oncol 29:1634−1657, 2018
   Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30:1541−1557, 2019
   Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784−2795, 2010
   Yi M, Huo L, Koenig KB, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25:1004−1011, 2014
   Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 25:1783−1785, 2018
   Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy, NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849−856, 2016
   Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:888−896, 2015
   Phung MT, Tin Tin S, Elwood JM. Prognostic models for breast cancer: a systematic review. BMC Cancer 19:230, 2019
   Gray E, Donten A, Payne K, et al. Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies. Syst Rev 7:142, 2018
   Hearne BJ, Teare MD, Butt M, et al. Comparison of Nottingham Prognostic Index and Adjuvant Online prognostic tools in young women with breast cancer: review of a single-institution experience. BMJ Open 5:e005576, 2015
   Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 14:113−115, 2008
   Harnan S, Tappenden P, Cooper K, et al. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technol Assess 23:1−328, 2019
   Candido Dos Reis FJ, Wishart GC, Dicks EM, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res 19:58, 2017
   Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800−807, 2012
   Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12:R1, 2010
   Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206−2223, 2013
   Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111−121, 2018
   Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726−3734, 2006
   Massarweh SA, Sledge GW, Miller DP, et al. Molecular characterization and mortality from breast cancer in men. J Clin Oncol 36:1396−1404, 2018
   Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4:1700−1706, 2018
   Hibler EA, Kauderer J, Greene MH, et al. Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 23:1228−1232, 2016
   Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379:122−137, 2018
   Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009:CD003370, 2009
   Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol 38:1293−1303, 2020
   Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 34:2221−2231, 2016
   Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107−118, 2014
   Pagani O, Regan MM, Francis PA, et al. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:1358−1359, 2014
   Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225−2232, 2017
   van Hellemond IEG, Geurts SME, Tjan-Heijnen VCG. Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol 19:26, 2018
   Ribnikar D, Sousa B, Cufer T, et al. Extended adjuvant endocrine therapy - A standard to all or some? Breast 32:112−118, 2017
   Clement Z, Kollias J, Bingham J, et al. Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. Gland Surg 7:449−457, 2018
   Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37:423−438, 2019
   Gray R. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. Cancer Res 79(4 Suppl): Abstr. GS3−03, 2019
   Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177−1183, 2009
   Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001:62−66, 2001
   Early Breast Cancer Trialists’ Collaborative Group, EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687−1717, 2005
   Bines J, Earl H, Buzaid AC, et al. Anthracyclines and taxanes in the neo/ adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol 25:1079−1085, 2014
   Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431−1439, 2003
   Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663−1671, 2008
   Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow- up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72−80, 2013
   Swain SM, Tang G, Geyer CE, Jr., et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197−3204, 2013
   Chen H, Xiao L, Li J, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 3:CD008018, 2019
   Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334:1356−1361, 1996
   Hickey BE, Francis DP, Lehman M. Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev 2013:CD005212, 2013
   Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147−2159, 2017
   Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27−35, 2018
   Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline- free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study, TRYPHAENA). Ann Oncol 24:2278−2284, 2013
   von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122−131, 2017
   von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617−628, 2019
   Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer, NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633−640, 2012
   Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer, NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17:791−800, 2016
   Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer, NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25−32, 2012
   Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 37:1868−1875, 2019
   De Cock E, Pivot X, Hauser N, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med 5:389−397, 2016
   Tjalma WAA, Van den Mooter T, Mertens T, et al. Subcutaneous trastuzumab, Herceptin, versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol 221:46−51, 2018
   Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of, neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer, HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869−878, 2012
   Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab- based adjuvant therapy in HER2-positive breast cancer, ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:1688−1700, 2017
   Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor- positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380−1388, 2008
   Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515−523, 2011
   Ueno NT, Espinosa Fernandez JR, Cristofanilli M, et al. International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer 9:1437−1447, 2018
   Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer, CALOR): a randomised trial. Lancet Oncol 15:156−163, 2014
   Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925−1936, 2016
   Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738−1748, 2016
   Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 30:1842, 2019
   Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer, MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19:904−915, 2018
   Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638−3646, 2017
   O’Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 168:127−134, 2018
   Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209−219, 2015
   Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465−2472, 2018
   Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520−529, 2012
   Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307−316, 2019
   Sledge GW, Jr., Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:116−124, 2019
   Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 21:25, 2019
   Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor- 2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25:2357−2362, 2014
   Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor- positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718−2724, 2012
   Massarweh S, Romond E, Black EP, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor, ER)-positive breast cancer after aromatase inhibitor, AI, failure. Breast Cancer Res Treat 143:325−332, 2014
   Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435−444, 2012
   Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(-, metastatic breast cancer. Clin Cancer Res 23:5218−5224, 2017
   Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929−1940, 2019
   Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor- positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529−5537, 2009
   Johnston S, Pippen J, Jr., Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538−5546, 2009
   Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15:122−129, 2010
   Liu Y, Gu F, Liang J, et al. The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLoS One 12:e0173693, 2017
   Cazzaniga ME, Cortesi L, Ferzi A, et al. Metronomic chemotherapy with oral vinorelbine, mVNR, and capecitabine, mCAPE, in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat 160:501−509, 2016
   Li Q, Yan H, Zhao P, et al. Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: a meta-analysis of randomized controlled trials. Sci Rep 5:15746, 2015
   Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24:628−637, 2018
   Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724−734, 2015
   Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642−1649, 2008
   Smyth LM, Iyengar NM, Chen MF, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat 158:91−97, 2016
   Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786−2792, 2006
   Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab, weekly or every-3-week schedule, as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6:425−432, 2005
   Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110:965−972, 2007
   Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246−3250, 2007
   Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853−3858, 2007
   Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as firstline treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 21:27−33, 2012
   Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2, HER2, blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol 36:741−748, 2018
   Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer, EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18:732−742, 2017
   Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783−1791, 2012
   Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer, TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18:743−754, 2017
   Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer, TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689−699, 2014
   Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924−934, 2010
   Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733−2743, 2006
   Baez-Vallecillo L, Raghavendra AS, Hess KR, et al. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine, T-DM1). Breast Cancer Res Treat 176:227−234, 2019
   Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30:2585−2592, 2012
   Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124−1130, 2010
   Cortes J, Lipatov O, Im S, et al. KEYNOTE-119: Phase III study of pembrolizumab, pembro, versus single-agent chemotherapy, chemo, for metastatic triple negative breast cancer, mTNBC). Ann Oncol 30(Suppl 5):v859− v860, 2019
   Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple- negative breast cancer, IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:44−59, 2020
   Early Breast Cancer Trialists’ Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353−1361, 2015
   Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor- associated bone loss, AIBL, in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1−12, 2017
   Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer, D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60−72, 2020
   Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401−415, 2014
   Zimmer AS, Gillard M, Lipkowitz S, et al. Update on PARP inhibitors in breast cancer. Curr Treat Options Oncol 19:21, 2018
   Sonnenblick A, de Azambuja E, Azim HA, Jr., et al. An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol 12:27−41, 2015
   Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol 27:1013−1019, 2016
   Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852−861, 2011
   Deb S, Lakhani SR, Ottini L, et al. The cancer genetics and pathology of male breast cancer. Histopathology 68:110−118, 2016
   Johansson I, Ringner M, Hedenfalk I. The landscape of candidate driver genes differs between male and female breast cancer. PLoS One 8:e78299, 2013
   Ottini L, Palli D, Rizzo S, et al. Male breast cancer. Crit Rev Oncol Hematol 73:141−155, 2010
   Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465−470, 2013
   Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114−2122, 2010
   Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 717:71−83, 2013
   Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 29:405-417, 2018
   Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 173:37−48, 2019
   Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805−816, 2013
   Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133−1144, 2007
   Phipps AI, Ichikawa L, Bowles EJ, et al. Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67:60−66, 2010
   Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97:1159−1168, 2012
   Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer 71:25−33, 2017
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 348
EP 368
PG 21
ER

PT J
AU Polgar, Cs
   Kahan, Zs
   Csejtei, A
   Gabor, G
   Landherr, L
   Mangel, L
   Mayer, �
   Fodor, J
AF Polgar, Csaba
   Kahan, Zsuzsanna
   Csejtei, Andras
   Gabor, Gabriella
   Landherr, Laszlo
   Mangel, Laszlo
   Mayer, Arpad
   Fodor, Janos
TI 4th Hungarian Breast Cancer Consensus Conference – Radiotherapy guidelines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE breast cancer; radiotherapy; guidelines
ID breast cancer; radiotherapy; guidelines
AB The radiotherapy (RT) expert panel revised and updated the RT guidelines accepted in 2016 at the 3rd Hungarian Breast Cancer Consensus Conference based on new scientific evidence. Radiotherapy after breast-conserving surgery (BCS) is indicated in ductal carcinoma in situ (St. 0), as RT decreases the risk of local recurrence (LR) by 50-60%. In early stage (St. I-II) invasive breast cancer RT remains a standard treatment following BCS. However, in elderly (≥70 years) patients with stage I, hormone receptor positive tumour hormonal therapy without RT can be considered. Hypofractionated whole breast irradiation (WBI) and for selected cases accelerated partial breast irradiation are validated treatment alternatives of conventional WBI. Following mastectomy RT significantly decreases the risk of LR and improves overall survival of patients having 1 to 3 or ≥4 positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be substituted with axillary RT. After neoadjuvant chemotherapy (NAC) followed by BCS WBI is mandatory, while after NAC followed by mastectomy locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csejtei, Andras] Vas Megyei Markusovszky Korhaz, OnkoradiologiaSzombathely, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Mayer, Arpad] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM polgar@oncol.hu
CR Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized Phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:1–8, 2006
   Cutulli B, Bernier J, Poortmans P. Radiotherapy in DCIS, an underestimated benefit? Radiother Oncol 112:1–8, 2014
   Cuzick J. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21–29, 2011
   Early Breast Cancer Trialists’ Collaborative Group. Overview of randomised trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41:162–177, 2010
   Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45:536–543, 2006
   Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project, NSABP, eight-year update of protocol B-17. Cancer 86:429–438, 1999
   Meattini I, Livi L, Franceschini D, et al. Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. Eur J Surg Oncol 39:613–618, 2013
   Polgar C, Kahan Z, Orosz Z, et al. The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast. Pathol Oncol Res 14:179–192, 2008
   Stuart KE, Houssami N, Taylor R, et al. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta- regression analysis. BMC Cancer 15:890, 2015
   Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet 378:1707–1716, 2011
   Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347:1233–1241, 2002
   Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387, 2013
   Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer, PRIME II): a randomised controlled trial. Lancet Oncol 16:266–273, 2015
   Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13:412–419, 2012
   NCCN Practice Guidelines in Oncology, Breast Cancer 2019. www.nccn. org
   Polgar Cs, Major T, Fodor J. Korszeru sugarkezeles emlomegtarto mutet utan. Orv Hetil 153:45–55, 2012
   Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232, 2002
   Guenzi M, Blandino G, Vidili MG, et al. Hypofractionated irradiation of infra-supraclavicular lymph nodes after axillary dissection in patients with breast cancer post-conservative surgery: impact on late toxicity. Radiat Oncol 10:177, 2015
   Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy, START, trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086–1094, 2013
   Valle LF, Agarwal S, Bickel KE, et al. Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 162:409–417, 2017
   Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 20:352–360, 2019
   Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. New Engl J Med 513–520, 2010
   Yarnold J, Somaiah N, Bliss JM. Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radiogenomic issues. Breast 24:S108–S113, 2015
   Coles CE, Griffin CI, Kirby AM, et al. Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer, UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060, 2017
   Hannoun-Levi JM, Lam Cham Kee D, Gal J, et al. Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation, SiFEBI, phase I/II trial. Brachytherapy 19:90–96, 2020
   Khan AJ, Chen PY, Yashar C, et al. Three-fraction accelerated partial breast irradiation, APBI, delivered with brachytherapy applicators is feasible and safe: First results from the TRIUMPH-T trial. Int J Radiat Oncol Biol Phys 104:67–74, 2019
   Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 51:451–463, 2015
   Meszaros N, Major T, Stelczer G, et al. Implementation of image-guided intensity-modulated accelerated partial breast irradiation: Three-year results of a phase II clinical study. Strahlenther Onkol 193:70–79, 2017
   Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial. Radiother Oncol 108:197–202, 2013
   Polgar C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 18:259–268, 2017
   Polgar C, van Limbergen E, Potter R, et al. Patient selection for accelerated partial breast irradiation, APBI, after breast-conserving surgery: Recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology, GEC-ESTRO, Breast Cancer Working Group. Radiother Oncol 94:264–273, 2009
   Schafer R, Strnad V, Polgar C, et al. Quality of life in patients treated with accelerated partial breast irradiation using multicatheter interstitial brachytherapy versus whole-breast irradiation: 5-year results from the randomized, phase 3, non-inferiority GEC-ESTRO trial. Lancet Oncol 19:834– 844, 2018
   Strnad V, Ott OJ, Hildebrandt G, et al. Accelerated partial breast irradiation, APBI, using sole interstitial multicatheter brachytherapy versus whole breast irradiation with boost after breast conserving surgery for low risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised phase 3 non-inferiority trial. Lancet 387:229–238, 2016
   Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394:2155–2164, 2019
   Wilkinson JB, Chen PY, Wallace MF, et al. Six-year results from a phase I/II trial for hypofractionated accelerated partial breast irradiation using a 2-day dose schedule. Am J Clin Oncol 41:986–991, 2018
   Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer, RAPID): a randomised controlled trial. Lancet 394:2165– 2172, 2019
   Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135, 2014
   Fodor J, Major T, Polgar Cs. Sugarkezeles mastectomia utan: Evidenciak es nyitott kerdesek. Onkologia 2:35–39, 2014
   Fodor J, Polgar C, Major T, et al. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation: The significance of tumour size. Strahlenther Onkol 179:197–202, 2003
   Krug D, Baumann R, Budach W, et al. Current controversies in radiotherapy for breast cancer. Radiat Oncol 12:25, 2017
   Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24:2268–2275, 2006
   Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New Engl J Med 337:949–955, 1997
   Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641–1648, 1999
   Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c trials. Radiother Oncol 82:247–253, 2007
   Poortmans P. Postmastectomy radiation in patients with one to three involved lymph nodes: ending the debate. Lancet 383:2104–2105, 2014
   Poortmans P, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. New Engl J Med 373:317–327, 2015
   Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. New Engl J Med 373:307–316, 2015
   Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer, EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310, 2014
   Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609, 2006
   Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43:672–679, 2017
   Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 16:383–388, 2005
   Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 22:97–101, 2004
   Speers C, Pierce LJ. Molecular signatures of radiation response in breast cancer: towards personalized decision-making in radiation treatment. Int J Breast Cancer 2017:427972453, 2017
   Akay CL, Meric-Bernstam F, Hunt KK, et al. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19:901–907, 2012
   Chapman CH, Jagsi R. Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. Oncology, Williston Park, 29:657– 666, 2015
   Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22:2303–2312, 2004
   Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172, 2014
   Fowble BL, Einck JP, Kim DN, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys 83:494–503, 2012
   Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol 22:1434–1440, 2015
   Garg AK, Strom EA, McNeese MD, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59:138– 145, 2004
   Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care, Basel, 10:124–130, 2015
   Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22:4691–4699, 2004
   Huang EH, Tucker SL, Strom EA, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62:351–357, 2005
   Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960–3966, 2012
   McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68:1004–1009, 2007
   Bukovszky B, Fodor J, Zongor Z, et al. Az axillaris nyirokcsomok dozisa kulonfele besugarzasi mezoelrendezesekbol emlomegtarto mutet utan. Magy Onkol 63:102–109, 2019
   Major T, Gutierrez C, Guix B, et al. Recommendations from GEC ESTRO Breast Cancer Working Group, II): Target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving open cavity surgery. Radiother Oncol 118:199–204, 2016
   Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New Engl J Med 368:987–988, 2013
   Kahan Z, Csenki M, Varga Z, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 68:673–681, 2007
   Kahan Zs, Varga Z, Csenki M, et al. Torekves a sugarterapia individualizalasara emlorakban: egyeni rizikobecsles es egyenileg alkalmazott technikak. Orv Hetil 148:833–841, 2007
   Kahan Zs, Janvary L. Az emlorak sugarkezelese: a normalis szovetek karosodasanak kockazata. In: Magyar Sugarterapias Tarsasag Technikai Fejlesztes es Klinikai Gyakorlat Szakbizottsaga – A normalis szovetek karosodasa sugarkezeles alatt: tolerancia es kockazatcsokkentes – Tudomanyos bizonyitekokra alapozott iranyelvek. Szerk. Kahan Zs. 2007, pp. 16–26
   Taylor CW, Wang Z, Macaulay E, et al. Exposure of the heart in breast cancer radiation therapy: A systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys 93:845–853, 2015
   Nissen HD, Appelt AE. Improved heart, lung and target dose with deep inspiration breast hold in a large clinical series of breast cancer patients. Radiother Oncol 106:28–32, 2013
   Varga Z, Cserhati A, Rarosi F, et al. Individualized positioning for maximum heart protection during breast irradiation. Acta Oncol 53:58–64, 2014
   Varga Z, Hideghety K, Mezo T, et al. Individual positioning: a comparative study of adjuvant breast radiotherapy in the prone versus supine position. Int J Radiat Oncol Biol Phys 75:94–100, 2009
   Piroth MD, Baumann R, Budach W, et al. Heart toxicity from breast cancer radiotherapy: Current findings, assessment, and prevention. Strahlenther Onkol 195:1–12, 2019
   Ranger A, Dunlop A, Hutchinson K, et al. A dosimetric comparison of breast radiotherapy techniques to treat locoregional lymph nodes including the internal mammary chain. Clin Oncol, R Coll Radiol, 30:346–353, 2018
   Moiseenko V, Einck J, Murphy J, et al. Clinical evaluation of QUANTEC guidelines to predict the risk of cardiac mortality in breast cancer patients. Acta Oncol 55:1506–1510, 2016
   Taylor CW, Kirby AM. Cardiac side-effects from breast cancer radiotherapy. Clin Oncol, R Coll Radiol, 27:621–629, 2015
   Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 31:4488–4495, 2013
   Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47–56, 2015
   Kindts I, Laenen A, Depuydt T, et al. Tumor bed boost radiotherapy for women after breast-conserving surgery, Review). Cochrane Database Syst Rev 11: CD011987, 2017
   Polo A, Polgar C, Hannoun-Levi JM, et al. Risk factors and state-of-theart indications for boost irradiation in invasive breast carcinoma. Brachytherapy 16:552–564, 2017
   Major T, Gutierrez C, Guix B, et al. Interobserver variations of target volume delineation in multi-catheter partial breast brachytherapy after open cavity surgery. Brachytherapy 14:925–932, 2015
   Petersen RP, Truong PT, Kader HA, et al. Target volume delineation for partial breast radiotherapy planning: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys 69:41–48, 2007
   Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 31:4038–4045, 2013
   Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383:603–613, 2014
   Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer, ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14:1269–1277, 2013
   Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother Oncol 118:205–208, 2016
   Csenki M, Ujhidy D, Cserhati A, et al. Radiation dose to the nodal regions during prone versus supine breast irradiation. Ther Clin Risk Manag 10:367–372, 2014
   Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114:3–10, 2015
   Nielsen MH, Berg M, Pedersen AN, et al. Danish Breast Cancer Cooperative Group Radiotherapy Committee. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncol 52:703–710, 2013
   Verhoeven K, Weltens C, Remouchamps V, et al. Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy – PROCAB guidelines. Radiother Oncol 114:11–16, 2015
   Li XA, Tai A, Arthur DW, et al. Radiation Therapy Oncology Group Multi-Institutional and Multiobserver Study. Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys 73:944–951, 2009
   Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 7:652–656, 2006
   Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks, FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395:1613-1626, 2020
   Polgar C, Major T. Current status and perspective of brachytherapy for breast cancer. Int J Clin Oncol 14:7–24, 2009
   Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963–968, 1997
   Zhu L, Jin L, Li S, et al. Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. Breast Cancer Res Treat 137:783–795, 2013
   Budach W, Bolke E, Kammers K, et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized trials – an update. Radiat Oncol 10:258, 2015
   Thorsen LBJ, Offersen BV, Dano H, et al. DBCG-IMN: A population- based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 34:314–320, 2016
   Kantor O, Pesce C, Singh P, et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol 115:668– 676, 2017
   Currey A, Patten CR, Bergom C et al. Management of the axilla after neo-adjuvant chemotherapy for breast cancer: Sentinel node biopsy and radioherapy considerations. Breast J 24:902–910, 2018
   Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 72:474–484, 2008
   Brito RA, Valero VV, Buzdar AU, et al. Long-term results of combined- modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628–633, 2001
   Chia S, Swain SM, Byrd DR, et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786–790, 2008
   Montagna E, Bagnardi V, Rotmensz N, et al. Factors that predict early treatment failure for patients with locally advanced, T4, breast cancer. Br J Cancer 98:1745–1752, 2008
   Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 35:78–86, 2008
   Fodor J, Gulyas G, Polgar Cs, et al. Sugarterapia es halasztott emlohelyreallito mutet implantatummal: az osszeferhetoseg vizsgalata. Magy Onkol 46:323–326, 2002
   Fodor J, Gulyas G, Polgar Cs, et al. Sugarterapia es emlohelyreallito mutet: az osszeferhetoseg kerdese. Orv Hetil 144:549–555, 2003
   Adamovicz K, Marczewska M, Jassem J. Combining systemic therapies with radiation in breast cancer. Cancer Treat Rev 35:409–416, 2009
   Varga Z, Cserhati A, Kelemen G, et al. Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 80:1109–1116, 2011
   Marinko T, Dolenc J, Biban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 48:105– 112, 2014
   Cecchini MJ, Yu E, Potvin K, et al. Concurrent or sequential hormonal and radiation therapy in breast cancer: A literature review. Cureus 7:e364, 2015
   Azria D, Gourgou S, Sozzi WJ, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91:1251–1260, 2004
   Masinghe SP, Faluyi OO, Kerr GR, et al. Breast radiotherapy for occult breast cancer with axillary nodal metastases – does it reduce the local recurrence rate and increase overall survival? Clin Oncol, R Coll Radiol, 23:95–100, 2011
   Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology 68:5–21, 2016
   Lahat G, Lev D, Gerstenhaber F, et al. Sarcoma of the breast. Expert Rev Anticancer Ther 12:1045–1051, 2012
   Depla AL, Scharloo-Karels CH, de Jong MA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma, RAAS, after primary breast cancer: a systematic review. Eur J Cancer 50:1779–1788, 2014
   Fodor J, Orosz Z, Szabo E, et al. Angiosarcoma after conservation treatment for breast carcinoma: Our experience and a review of the literature. J Am Acad Dermatol 54:499-504, 2006
   Shickman R, Leibman AJ, Handa P, et al. Mesenchymal breast lesions. Clin Radiol 70:567–575, 2015
   Fodor J, Major T, Polgar C, et al. Prognosis of patients with local recurrence after mastectomy or conservative surgery for early-stage invasive breast cancer. Breast 17:302–308, 2008
   Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: The NRG Oncology/ RTOG 1014 phase 2 clinical trial. JAMA Oncol 6:75–82, 2019
   Hannoun-Levi JM, Resch A, Kauer-Dorner D, et al. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: Multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol 108:226–231, 2013
   Kuerer HM, Arthur DW, Haffty BG. Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 100:2269–2280, 2004
   Polgar Cs, Major T, Sulyok Z, et al. Masodik emlomegtarto mutet es ismetelt besugarzas szovetkozi nagy dozisteljesitmenyu brachyterapiaval az emlorak lokalis kiujulasanak kezelesere – 5 eves eredmenyek. Magy Onkol 56:68–74, 2012
   Mayer A, Naszaly A, Patyanik M, et al. Perioperative brachytherapy for pretreated chest wall recurrence of breast cancer. Strahlenther Onkol 178:633–636, 2002
   Smanyko V, Meszaros N, Ujhelyi M, et al. Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results. Brachytherapy 18:411–419, 2019
   Polgar Cs. A palliativ sugarkezeles indikacioi. LAM 13:373–378, 2003
   Sahgal A, Aoyama A, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710–717, 2015
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 371
EP 383
PG 13
ER

PT J
AU Kahan, Zs
   Szanto, I
   Dudas, R
   Kapitany, Zs
   Molnar, M
   Koncz, Zs
   Mailath, M
AF Kahan, Zsuzsanna
   Szanto, Istvan
   Dudas, Rita
   Kapitany, Zsuzsanna
   Molnar, Maria
   Koncz, Zsuzsa
   Mailath, Monika
TI Breast cancer: follow-up, rehabilitation, psycho- oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE follow-up; healthy life-style; physical rehabilitation; psychological rehabilitation; social rehabilitation
ID follow-up; healthy life-style; physical rehabilitation; psychological rehabilitation; social rehabilitation
AB Follow-up includes the permanent contact with and health education of the patient, the surveillance and control of the adverse effects of surgery, oncological therapies or radiotherapy, the screening of metachronous cancers, and the comprehensive (physical, psychological and social) rehabilitation of the patient which may be enhanced by healthy life-style. The early detection and curative management if necessary, of local/regional tumor relapse is still a priority but the routine screening of distant metastases by means of imaging studies or tumor marker tests is not justified. Supportive therapy means to endocrine therapy, available social support in Hungary, and the key issues and managing tools of physical and psychooncological care are provided. Individual solution of special issues (breast cancer risk/genetic mutation, pregnancy) may be served by widening options. Ideally, follow-up is practised by a cooperative team of oncologists, surgeons, breast radiologists, social workers, physiotherapists, psychiatrists. The follow-up approach should be comprehensive and holistic.
C1 [Kahan, Zsuzsanna] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Szanto, Istvan] Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Onkologiai OsztalySzekesfehervar, Hungary.
   [Dudas, Rita] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Kapitany, Zsuzsanna] Semmelweis Egyetem ETK, Fizioterapia TanszekBudapest, Hungary.
   [Molnar, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Koncz, Zsuzsa] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Mailath, Monika] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Kahan, Zs (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM kahan.zsuzsanna@med.u-szeged.hu
CR Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34:611−635, 2016
   Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw 16(5S):605−610, 2018
   Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1674, 2019
   Gilligan T, Coyle N, Frankel RM, et al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 35:3618−3632, 2017
   Heitz AE, Baumgartner RN, Baumgartner KB, Boone SD. Healthy lifestyle impact on breast cancer-specific and all-cause mortality. Breast Cancer Res Treat 167:171−181, 2018
   Zeinomar N, Knight JA, Genkinger JM, et al. Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort, ProF-SC). Breast Cancer Res 21:128, 2019
   Hattori M, Iwata H. Advances in treatment and care in metastatic breast cancer, MBC): are there MBC patients who are curable? Chin Clin Oncol 7:23, 2018
   deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer 144:422−430, 2019
   deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 91:153−163, 2019
   Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol 37:2916−2946, 2019
   Paice JA, Portenoy R, Lacchetti C, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:3325−3345, 2019
   Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605−1619, 2014
   Jakes AD, Twelves C. Breast cancer-related lymphoedema and venepuncture: a review and evidence-based recommendations. Breast Cancer Res Treat 154:455−461, 2015
   Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology, ESC). Eur Heart J 37:2768–2801, 2016
   Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35:893−911, 2017
   Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 32:1840−1850, 2014
   Holland JC, Greenberg DB, Hughes MD, et al. NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, Distress Management Version 2.2015. 2015 National Comprehensive Cancer Network, Inc. NCCN.org
   Cascella M, Di Napoli R, Carbone D, et al. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives. Recenti Prog Med 109:523−530, 2018
   Szentmartoni G, Makkos Z, Dank M. Chemobrain. Neuropsychopharmacol Hung 20:112−116, 2018
   Biro E, Kahan Z, Kalman J, et al. Cognitive functioning and psychological well-being in breast cancer patients on endocrine therapy. In Vivo 33:1381−1392, 2019
   Carter J, Lacchetti C, Andersen BL, et al. Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol 36:492−511, 2018
   Mazzarello S, Hutton B, Ibrahim MF, et al. Management of urogenital atrophy in breast cancer patients: A systematic review of available evidence from randomized trials. Breast Cancer Res Treat 152:1−8, 2015
   Areas F, Valadares ALR, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause 26:1052−1058, 2019
   Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 11:2321−2337, 2019
   Singer CF, Balmana J, Burki N, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Eur J Cancer 106:54−60, 2019
   Paluch-Shimon S, Cardoso F, Sessa C et al; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27(suppl 5):v103−v110, 2016
   Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 36:1994−2000, 2018
   Snowden A, Young J, White C, et al. Evaluating holistic needs assessment in outpatient cancer care–a randomised controlled trial: the study protocol. BMJ Open 5:e006840, 2015
   Johnston L, Young J, Campbell K. The implementation and impact of Holistic Needs Assessments for people affected by cancer: A systematic review and thematic synthesis of the literature. Eur J Cancer Care, Engl, 28:e13087, 2019
   Kozma J, szerk.). Kezikonyv a szocialis munka gyakorlatahoz. Szocialis Szakmai Szovetseg, Budapest, 2001
   Mewes JC, Steuten LM, Groeneveld IF, et al. Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. BMC Cancer 15:899, 2015
   de Boer AG, Taskila TK, Tamminga SJ, et al. Interventions to enhance return- to-work for cancer patients. Cochrane Database Syst Rev 9:CD007569, 2015
   Rokkantsagi ellatas es rehabilitacios ellatas Magyarorszagon. http:// emmiugyfelszolgalat.gov.hu/szocialis/megvaltozott
   Rokkantsagi ellatas es rehabilitacios ellatas Magyarorszagon. http:// www.kormanyhivatal.hu/download
   Kozgyogyellatas Magyarorszagon. http://emmiugyfelszolgalat.gov.hu/ szocialis/szocialis-raszorultsag
   Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 62:242−274, 2012
   Jung AY, Behrens S, Schmidt M, et al. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors. Breast Cancer Res 21:117, 2019
   Fukushima KF, Carmo LA, Borinelli AC, Ferreira CW. Frequency and associated factors of axillary web syndrome in women who had undergone breast cancer surgery: a transversaland retrospective study. Springer Plus 4:112, 2015
   Neil-Sztramko SE, Kirkham AA, Hung SH, at al. Aerobic capacity and upper limb strength are reduced in women diagnosed with breast cancer: a systematic review. J Physiother 60:189–200, 2014
   Johansen S, Fossa K, Nesvold IL, et al. Arm and shoulder morbidity following surgery and radiotherapy for breast cancer. Acta Oncol 53:521−529, 2014
   Luz CMD, Deitos J, Siqueira TC, et al. Management of axillary web syndrome after breast cancer: Evidence-based practice. Rev Bras GinecoObstet 39:632−639, 2017
   Bruce J, Williamson E, Lait C, at al; PROSPER Study Group. Randomised controlled trial of exercise to prevent shoulder problems in women undergoing breast cancer treatment: study protocol for the prevention of shoulder problems trial, UK PROSPER). BMJ Open 8:e019078, 2018
   Harrington S, Michener LA, Kendig T, et al. Patient-reported upper extremity outcome measures used in breast cancer survivors systematic review. Arch Physical Med Rehab 95:153−162, 2014
   Binkley JM, Stratford P, Kirkpatrick S, et al. Estimating the reliability and validity of the upper extremity functional index in women after breast cancer surgery. Clin Breast Cancer 18:e1261−e1267, 2018
   Campbell KL, Pusic AL, Zucker DS, et al. A prospective model of care for breast cancer rehabilitation: function. Cancer 118:2300−2311, 2012
   Andrade Ortega JA, Millan Gomez AP, Ribeiro Gonzalez M, et al. Validation of the FACT-B+4-UL questionnaire and exploration of its predictive value in women submitted to surgery for breast cancer Med Clin, Barc, 148:555−558, 2017
   Lacomba MT. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ 340:b5396, 2010
   Mobarakeh ZS, Mokhtari-Hesari P, Lotfi-Tokaldany M, et al. Combined decongestive therapy and reduction of pain and heaviness in patients with breast cancer-related lymphedema. Support Care Cancer 27:3805−3811, 2019
   Holland J, Watson M, Dunn J. The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psycho-Oncology 20:677–680, 2011
   Risko A. Az onkopszichologia szakmai protokollja. In: A klinikai es mentalhigieniai szakpszichologia szakmai protokollja, masodik, atdolgozott valtozat). Szerk. Bagdy E, Tury F. Animula Kiado, Budapest, 2005
   Gradishar WJ, Anderson BO, Blair SL, et al. NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, Breast Cancer Version 2.2015. 2015 National Comprehensive Cancer Network, Inc. NCCN.org
   Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:961−965, 2013
   Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941−1967, 2014
   Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605−1619, 2014
   Janelsins MC, Kohli S, Mohile SG, et al. An update on cancer- and chemotherapy- related cognitive dysfunction: Current status. Semin Oncol 38:431−438, 2011
   Reid-Arndt SA, YeeA, Perry MC, et al. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol 27:415−434, 2009
   Holland J, Watson M, Dunn J. The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psycho-Oncology 20:677–680 1978, 2011
   Bultz BD, Carlson LE. Emotional distress: the sixth vital sign–future directions in cancer care. Psycho-Oncology 15:93–95, 2006
   https://ipos-society.org/endorsements/organizations
   Harju E, Michel G, Roser K. A systematic review on the use of the emotion thermometer in individuals diagnosed with cancer. Psycho-Oncology 28:1803–1818, 2019
   Hinz A, Mitchell AJ, Degi CL, et al. Normative values for the distress thermometer, DT, and the emotion thermometers, ET), derived from a German general population sample. Qual Life Res 28:277–282, 2019
   Muszbek K, Szekely A, Balogh E, et al. Validation of the Hungarian translation of Hospital Anxiety and Depression Scale. Qual Life Res 15:761−766, 2006
   Millar K, Jelicic M, Bonke B, et al. Assessment of preoperative anxiety: comparison of measures in patients awaiting surgery for breast cancer. Br J Anaesth 74:180−183, 1995
   Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale An updated Literature review. J Psychosom Res 52:69−77, 2002
   NCCN Guidelines Version 1.2020 Distress Management, National Comprehensive Cancer Network, 2020
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2020
VL 64
IS 4
BP 384
EP 393
PG 15
ER

PT J
AU Bajcsay, A
AF Bajcsay, Andras
TI Dr. Horvath Akos (1944–2021)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Bajcsay, Andras] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Bajcsay, A (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM Dr.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 4
EP 4
PG 1
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI LECTORIS SALUTEM!
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Lovey, Jozsef] National Institute of Oncology, Rathy Gyorgy u. 7-9, 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM Dr.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 5
EP 5
PG 1
ER

PT J
AU Kisivan, K
   Erdelyesi, D
   Gutyina, D
   Sajti, P
   Gugyeras, D
   Farkas, A
   Glavak, Cs
   Laszlo, Z
   Somogyine Ezer, �
   Mahr, K
   Szabo, Zs
   Szabo, H
   Cselik, Zs
   Gulyban, �
   Petone Csima, M
   Kaposztas, Zs
   Lakosi, F
AF Kisivan, Katalin
   Erdelyesi, Dora
   Gutyina, David
   Sajti, Peter
   Gugyeras, Daniel
   Farkas, Andrea
   Glavak, Csaba
   Laszlo, Zoltan
   Somogyine Ezer, Eva
   Mahr, Karoly
   Szabo, Zsolt
   Szabo, Helga
   Cselik, Zsolt
   Gulyban, Akos
   Petone Csima, Melinda
   Kaposztas, Zsolt
   Lakosi, Ferenc
TI Linac-based stereotactic ablative radiotherapy for pancreatic cancer with intrafractional triggered imaging
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE DIBH; stereotactic ablative radiotherapy; pancreatic cancer; real-time tumor tracking
ID DIBH; stereotactic ablative radiotherapy; pancreatic cancer; real-time tumor tracking
AB Our aim was to present different treatment strategies (non-gated [NG], respiratory-gated [RG] and deep inspiration breath-hold [DIBH] technique) of linac-based stereotaxic ablative radiotherapy (SABR) for pancreatic cancer in terms of use of marker, abdominal compression, image quality, and time efficiency. From October 2016 to October 2020 14 patients were treated with VMAT-based SABR (NG: 6/14, 8/14 RG RT including 3/8 DIBH SABR). Treatment verification consisted of 3D/4D CBCTs. For intrafractional tumor visualization (11/14) different type of fiducials were used. The average treatment time was the shortest with NG RT, followed by DIBH and RG RT. However, the best image quality was achieved with DIBH technique. The Krippendorff’s agreement test among three independent RTTs showed that DIBH CBCT (Cone Beam CT) can produce sufficient image quality for OARs and can be used to reliably determine OARs position related to safety zone (PRV). Overall, marker-based DIBH SABR with intrafractional tumor visualization appears to be the best technique on linac at present.
C1 [Kisivan, Katalin] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Erdelyesi, Dora] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Gutyina, David] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Sajti, Peter] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Gugyeras, Daniel] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Farkas, Andrea] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Glavak, Csaba] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Laszlo, Zoltan] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
   [Somogyine Ezer, Eva] Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai OnkologiaKaposvar, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Zsolt] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Szabo, Helga] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Cselik, Zsolt] Csolnoky Ferenc Korhaz, Regionalis Onkologiai Centrum, Sugarterapias OsztalyVeszprem, Hungary.
   [Gulyban, Akos] Institut Jules Bordet, Medical Physics DepartmentBrusszel, Belgium.
   [Petone Csima, Melinda] Kaposvari Egyetem, Pedagogiai KarKaposvar, Hungary.
   [Kaposztas, Zsolt] Somogy Megyei Kaposi Mor Oktato Korhaz, Sebeszeti OsztalyKaposvar, Hungary.
   [Lakosi, Ferenc] Kaposvar University, Department of Radiation Oncology, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
RP Lakosi, F (reprint author), Kaposvar University, Department of Radiation Oncology, 7400 Kaposvar, Hungary.
EM lakosiferenc@yahoo.com
CR Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer, CRiSP): An international systematic review and meta-analysis. Cancer 126:2120–2131, 2020
   Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys 97:313–322, 2017
   Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol 9:322–332, 2019
   Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121:1128–1137, 2015
   Comito T, Cozzi L, Clerici E, et al. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat 2016:1533034616650778, 2016
   Suker M, Nuyttens JJ, Eskens FA, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer, LAPC-1 trial). EClinicalMedicine 2019:17, 2019
   Koay EJ, Hanania AN, Hall WA, et al. Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach. Pract Radiat Oncol 10:e495–507, 2020
   Rudra S, Jiang N, Rosenberg SA, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med 8:123–132, 2019
   Zhu X, Ju X, Cao Y, et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys 104:101–110, 2019
   Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: Techniques and results. Radiat Oncol 14:1–8, 2019
   Colbert LE, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol 2:403–415, 2017
   Tyran M, Jiang N, Cao M, et al. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiother Oncol 129:319–325, 2018
   Loi M, Magallon-Baro A, Suker M, et al. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol 134:67–73, 2019
   Panje C, Andratschke N, Brunner TB, et al. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer: Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 192:875–885, 2016
   Zaorsky NG, Lehrer EJ, Handorf E, Meyer JE. Dose escalation in stereotactic body radiation therapy for pancreatic cancer. Am J Clin Oncol Cancer Clin Trials 42:46–55, 2019
   Kisivan K, Miovecz A, Gugyeras D, et al. Multimodalis kepalkotas tudo- es hasi sztereotaxias ablativ radioterapia soran: a cine MRI-meresektol a 3D/4D CBCT-n at a kezeles alatti kV-os kepi verifikacioig. Magy Onkol 63:116–124, 2019
   Oar A, Lee M, Le H, et al. Australasian Gastrointestinal Trials Group, AGITG, and Trans-Tasman Radiation Oncology Group, TROG, Guidelines for Pancreatic Stereotactic Body Radiation Therapy, SBRT). Pract Radiat Oncol 10:e136–146, 2020
   Krippendorff K. Agreement and information in the reliability of coding. Commun Methods Meas 5:93–112, 2011
   Zeng C, Xiong W, Li X, et al. Intrafraction tumor motion during deep inspiration breath hold pancreatic cancer treatment. J Appl Clin Med Phys 20:37−43, 2019
   Vinogradskiy Y, Goodman KA, Schefter T, et al. The clinical and dosimetric impact of real-time target tracking in pancreatic SBRT. Int J Radiat Oncol Biol Phys 103:268–275, 2019
   Song Y, Yuan Z, Li F, et al. Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer. Onco Targets Ther 8:1427– 1431, 2015
   Luterstein E, Cao M, Lamb J, et al. Stereotactic MRI-guided adaptive radiation therapy, SMART, for locally advanced pancreatic cancer: a promising approach. Cureus 10:e2324, 2018
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 6
EP 13
PG 8
ER

PT J
AU Gerdan, M
   Pocza, T
   Polgar, Cs
   Major, T
AF Gerdan, Mercedesz
   Pocza, Tamas
   Polgar, Csaba
   Major, Tibor
TI The effects of normal tissue objective parameters on lung stereotactic body radiotherapy dose distributions
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung; SBRT; dose calculation algorithm; dose gradient; optimization criteria
ID lung; SBRT; dose calculation algorithm; dose gradient; optimization criteria
AB In treatment planning of small-sized lung tumors treated with stereotactic body radiotherapy (SBRT) in Eclipse treatment planning system with the Normal tissue objective (NTO) tool sharp dose gradients beyond the target volume can be achived. NTO has 5 variable parameters, so it is difficult to know which settings are optimal. The purpose of this study was to characterize the effects of changing NTO parameters on lung SBRT dose distributions. Ten lung SBRT cases were replanned using different NTO parameters. Dose calculation was performed using AAA and AXB algorithms as well. Differences between AAA and AXB plans were statistically significant. Plans were evaluated based on plan quality metrics. According to this analysis the fall-off of 0.15 and the priority of 500 have satisfied our institutional criteria best. Using NTO during planning is recommended in clinical practice.
C1 [Gerdan, Mercedesz] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
RP Gerdan, M (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM merciagape@gmail.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldvide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356−387, 2018
   Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy, HypoFXSRT, for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94−100, 2007
   Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: Relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47−54, 2009
   Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070−1076, 2010
   Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 106:276−282, 2013
   Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: fouryear results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677−682, 2009
   Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 82:967−973, 2012
   Navarria P, Ascolese AM, Mancosu P, et al. Volumetric modulated arc therapy with flattening filter free, FFF, beams for stereotactic body radiation therapy, SBRT, in patients with medically inoperable early stage non small cell lung cancer, NSCLC). Radiother Oncol 107:414−418, 2013
   Tillikainen L, Helminen H, Torsti T, et al. A 3D pencil-beam-based superposition algorithm for photon dose calculation in heterogeneous media. Phys Med Biol 53:3821−3839, 2008 11 Knoos T, Wieslander E, Cozzi L, et al. Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations. Phys Med Biol 51:5785−5807, 2006 12. Ojala JJ, Kapanen M. Quantification of dose differences between two versions of Acuros XB algorithm compared to Monte Carlo simulations – the effect on clinical patient treatment planning. J Appl Clin Med Phys 16:213−225, 2015 13. Spezi E, Lewis G. An overview of Monte Carlo treatment planning for radiotherapy. Radiat Prot Dosimetry 131:123−129, 2008 14. Sievinen J, Ulmer W, Kaissl W. AAA photon dose calculation model in Eclipse. Varian Medical Systems, Palo Alto, CA, 2005, RAD 7170B, 15. Failla GA, Wareing T, Archambault Y, Thompson S. Acuros XB advanced dose calculation for the Eclipse treatment planning system. Varian Medical Systems, Palo Alto, CA, 2015 16. Vassiliev ON, Wareing TA, McGhee J, et al. Validation of a new grid-based Boltzmann equation solver for dose calculation in radiotherapy with photon beams. Phys Med Biol 55:581−598, 2010 17. Fogliata A, Nicolini G, Clivio A, et al. Critical appraisal of Acuros XB and Anisotropic Analytic Algorithm dose calculation in advanced non-small-cell lung cancer treatments. Int J Radiat Oncol Biol Phys 83:1587−1595, 2012 18. Zhou C, Bennion N, Ma R, et al. A comprehensive dosimetric study on switching from a Type-B to a Type-C dose algorithm for modern lung SBRT. Radiat Oncol 12:80, 2017 19. Eclipse photon and electron algorithms reference guide. P1020505- 001-A. Varian Medical Systems, Palo Alto, CA, 2017 20. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 64:333−342, 2006 21. Van’t Riet A, Mak AC, Marinus A, et al. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: Application to the prostate. Int J Radiat Oncol Biol Phys 37:731−736, 1997 22. Rana S, Rogers K, Pokharel S, Cheng C. Evaluation of Acuros XB algorithm based on RTOG 0813 dosimetric criteria for SBRT lung treatment with RapidArc. J Appl Clin Med Phys 15:4474, 2014 23. Rana S, Rogers, K, Lee T, et al. Verification and dosimetric impact of Acuros XB algorithm for stereotactic body radiation therapy, SBRT, and RapidArc planning for non-small-cell lung cancer, NSCLC, patients. Int J Med Phys Clin Eng Radiat Oncol 2:6−14, 2013 24. Bell JP, Patel P, Higgins K, et al. Fine-tuning the normal tissue objective in eclipse for lung stereotactic body radiation therapy. Med Dosim 43:344−350, 2018
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 14
EP 22
PG 9
ER

PT J
AU Mihaly, D
   Melles-Bencsik, B
   Pocza, T
   Kontra, G
   Major, T
   Bajcsay, A
   Polgar, Cs
   Pesznyak, Cs
AF Mihaly, Dalma
   Melles-Bencsik, Barbara
   Pocza, Tamas
   Kontra, Gabor
   Major, Tibor
   Bajcsay, Andras
   Polgar, Csaba
   Pesznyak, Csilla
TI Dosimetric analysis of LINAC based stereotactic irradiation of brain tumours in CIRS SHANE phantom
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE brain tumour; stereotaxic; film dosimetry; VMAT
ID brain tumour; stereotaxic; film dosimetry; VMAT
AB The aim of the study was to compare the different stereotactic treatment plans and dose calculation algorithms for small targets with film dosimetry in anthropomorphic phantom. Treatment plans were prepared for multiple targets with single setup isocenter. Plans for three different irradiation techniques were generated using conformal arc with four non-coplanar arcs, RapidArc with two coplanar full arcs and RapidArc with four non-coplanar arcs in the Varian Eclipse v13.7.16 TPS. Conformal arc and RapidArc plans were calculated using AAA, Acuros XBDm and XBDw algorithms. Conformity index, gradient index and dose maximum were calculated for all PTVs. All measurements were made on the Varian TrueBeam linear accelerator. Comparison between computed and measured dose distributions was performed with gamma evaluation criteria of 3%, 3 mm; 3%, 1 mm and 2%, 2 mm. According to our results, the Eclipse AAA and AXB algorithms provide accurate dose distributions for homogeneous cranial irradiation.
C1 [Mihaly, Dalma] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Melles-Bencsik, Barbara] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy utca 7−9., 1122 Budapest, Hungary.
RP Mihaly, D (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
CR Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291−298, 2000
   Molinier J, Kerr C, Simeon S, et al. Comparison of volumetric-modulated arc therapy and dynamic conformal arc treatment planning for cranial stereotactic radiosurgery. J Appl Clin Med Phys 17:92−101, 2016
   Clark GM, Popple RA, Prendergast BM, et al. Plan quality and treatment planning technique for single isocenter cranial radiosurgery with volumetric modulated arc therapy. Pract Radiat Oncol 2:306−313, 2012
   Huang Y, Chin K, Robbins JR, et al. Radiosurgery of multiple brain metastases with single-isocenter dynamic conformal arcs, SIDCA). Radiother Oncol 112:128−132, 2014
   Nath SK, Lawson JD, Simpson DR, et al. Single-isocenter frameless intensity- modulated stereotactic radiosurgery for simultaneous treatment of multiple brain metastases: clinical experience. Int J Radiat Oncol Biol Phys 78:91−97, 2010
   Palmans H, Andreo P, Huq MS, et al. Dosimetry of small static fields used in external photon beam radiotherapy: Summary of TRS-483, the IAEAAAPM international Code of Practice for reference and relative dose determination. Med Phys 45:e1123−e1145, 2018
   Zongor Z, Bela D, Kiraly R, et al. Az EBT2 onhivo filmek sugarterapias klinikai alkalmazhatosaganak vizsgalata. Magy Onkol 60:299−304, 2016
   https://www.cirsinc.com/products/radiation-therapy/phantom-patientfor- vmat-imrt/
   Shaw E, Kline R, Gillin M, et al. Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 27:1231−1239, 1993
   Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 93(Suppl 3):219−222, 2000
   Feuvret L, Noel G, Mazeron JJ, et al. Conformity index: a review. Int J Radiat Oncol Biol Phys 64:333−342, 2006
   Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index. J Neurosurg 105:194−201, 2006
   Micke A, Lewis FD, Yu X, et al. Multichannel film dosimetry with nonuniformity correction. Med Phys 38:2523–2534, 2011
   Low DA, Harms WB, Mutic S, et al. A technique for the quantitative evaluation of dose distributions. Med Phys 25:656−661, 1998
   Miften M, Olch A, Mihailidis D, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218. Med Phys 45:e53–e83, 2018
   Salkeld AL, Unicomb K, Hayden AJ, et al. Dosimetric comparison of volumetric modulated arc therapy and linear accelerator-based radiosurgery for the treatment of one to four brain metastases. J Med Imaging Radiat Oncol 58:722−728, 2014
   Wang JZ, Pawlicki T, Rice R, et al. Intensity-modulated radiosurgery with rapidarc for multiple brain metastases and comparison with static approach. Med Dosim 37:31−36, 2012
   Clark GM, Popple RA, Young PE, et al. Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases. Int J Radiat Oncol Biol Phys 76:296−302, 2010
   Calvo Ortega JF, Moragues S, Pozo M, et al. A dosimetric evaluation of the Eclipse AAA algorithm and Millennium 120 MLC for cranial intensity- modulated radiosurgery. Med Dosim 39:129−133, 2014
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 23
EP 29
PG 7
ER

PT J
AU Farkas, Gy
   Szekely, G
   Pocza, T
   Kocsis, Zs
   Mihaly, D
   Kun-gazda, M
   Pesznyak, Cs
   Major, T
   Polgar, Cs
   Juranyi, Zs
AF Farkas, Gyongyi
   Szekely, Gabor
   Pocza, Tamas
   Kocsis, S. Zsuzsa
   Mihaly, Dalma
   Kun-gazda, Marta
   Pesznyak, Csilla
   Major, Tibor
   Polgar, Csaba
   Juranyi, Zsolt
TI Biological dose estimation for photons of different qualities in radiation therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE linear accelerator; flattening filter free mode; biological dosimetry; dicentric and ring chromosome; linear- quadratic model
ID linear accelerator; flattening filter free mode; biological dosimetry; dicentric and ring chromosome; linear- quadratic model
AB Flattening filter free mode (FFF) has been introduced in radiotherapy during the past decades, however, not much has been reported on its radiobiological effect. The purpose of our study was to compare the radiobiological effects of flattening filter and flattening filter free photon beams on chromosomal aberrations in peripheral blood lymphocytes. In our study the blood of the same healthy donor was irradiated with linear accelerator using both conventional flattening filter (FF) and FFF photon beams at dose rate of 3.57–23.08 Gy/min, using 6 or 10 MV. The dose-response calibration curves for dicentric + ring chromosomes induced by irradiation were fitted with linear-quadratic model. CABAS (Chromosomal Aberration Calculation Software) was used to prepare the curves. The coefficients and equations of the curves were calculated and compared with the results of other authors. We found significant differences in the number of aberrations at different irradiation parameters. Based on our results, FFF mode has a 10-20% higher biological effect than FF mode. These results can be used during radiotherapy or to estimate the biological doses in case of an accidental exposure to radiation.
C1 [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Farkas, Gy (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, 1122 Budapest, Hungary.
EM farkas.gyongyi@oncol.hu
CR Georg D, Knoos T, McClean B. Current status and future perspective of flattening filter free photon beams. Med Phys 38:1280–1293, 2011
   Xiao Y, Kry SF, Popple R, et al. Flattening filter-free accelerators: a report from the AAPM Therapy Emerging Technology Assessment Work Group. J Appl Clin Med Phys 16:5219, 2015
   Tillman C, Grafstrom G, Jonsson AC, et al. Survival of mammalian cells exposed to ultrahigh dose rates from a laser-produced plasma x-ray source. Radiology 213:860–865, 1999
   Ling CC, Spiro IJ, Mitchell J, et al. The variation of OER with dose rate. Int J Radiat Oncol Biol Phys 11:1367–1373, 1985
   Michaels HB, Epp ER, Ling CC, et al. Oxygen sensitization of CHO cells at ultrahigh dose rates: prelude to oxygen diffusion studies. Radiat Res 76:510– 521, 1978
   Ling CC, Gerweck LE, Zaider M, et al. Dose-rate effects in external beam radiotherapy redux. Radiother Oncol 95:261–268, 2010
   Sorensen BS, Vestergaard A, Overgaard J, et al. Dependence of cell survival on instantaneous dose rate of a linear accelerator. Radiother Oncol 101:223–225, 2011
   Lohse I, Lang S, Hrbacek J, et al. Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol 101:226–232, 2011
   Nakano H, Minami K, Yagi M, et al. Radiobiological effects of flattening filter-free photon beams on A549 non-small-cell lung cancer cells. J Radiat Res 59:442–445, 2018
   Savage JR. Classification and relationships of induced chromosomal structual changes. J Med Genet 13:103–122, 1976
   Edwards AA. The use of chromosomal aberrations in human lymphocytes for biological dosimetry. Radiat Res 148(5 Suppl):S39–44, 1997
   Albertini RJ, Anderson D, Douglas GR, et al. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. Mutat Res 463:111–172, 2000
   IAEA-International Atomic Energy Agency. Cytogenetic Dosimetry: Applications in Preparedness for and Response to Radiation Emergencies. In: EPR Biodosimetry. Vienna 2011
   Deperas J, Szluinska M, Deperas-Kaminska M, et al. CABAS: a freely available PC program for fitting calibration curves in chromosome aberration dosimetry. Radiat Prot Dosimetry 124:115–123, 2007
   Lemos-Pinto MM, Cadena M, Santos N, et al. A dose-response curve for biodosimetry from a 6 MV electron linear accelerator. Braz J Med Biol Res 48:908–914, 2015
   Martins V, Antunes AC, Monteiro Gil O. Implementation of a dose-response curve for gamma-radiation in the Portuguese population by use of the chromosomal aberration assay. Mutat Res 750:50–54, 2013
   Schroder H, Heimers A. Chromosome aberrations induced in human lymphocytes by in vitro and in vivo X-rays. Mutat Res 517:167–172, 2002
   Barquinero JF, Barrios L, Caballin MR, et al. Establishment and validation of a dose-effect curve for gamma-rays by cytogenetic analysis. Mutat Res 326:65–69, 1995
   Beinke C, Braselmann H, Meineke V. Establishment of an x-ray standard calibration curve by conventional dicentric analysis as prerequisite for accurate radiation dose assessment. Health Phys 98:261–268, 2010
   Prasanna PG, Moroni M, Pellmar TC. Triage dose assessment for partial- body exposure: dicentric analysis. Health Phys 98:244–251, 2010
   Vinnikov VA, Ainsbury EA, Maznyk NA, et al. Limitations associated with analysis of cytogenetic data for biological dosimetry. Radiat Res 174:403– 414, 2010
   Lindholm C, Luomahaara S, Koivistoinen A, et al. Comparison of dose-response curves for chromosomal aberrations established by chromosome painting and conventional analysis. Int J Radiat Biol 74:27–34, 1998
   Romm H, Oestreicher U, Kulka U. Cytogenetic damage analysed by the dicentric assay. Ann Ist Super Sanita 45:251–259, 2009
   Bauchinger M. Microdosimetric aspects of the induction of chromosome aberrations. In: Radiation induced chromosome damage in man. Ed. Ishihara T, Alan R.Liss, Inc, New York 1983, pp. 1−22
   Wilkins RC, Romm H, Kao TC, et al. Interlaboratory comparison of the dicentric chromosome assay for radiation biodosimetry in mass casualty events. Radiat Res 169:551–560, 2008
   Lloyd D, Edwards AA, Prosser JS. Chromosome aberrations induced in human lymphocytes by in vitro acute X and gamma radiation. Radiat Prot Dosimetry 15:83–88, 1986
   Vinnikov VA, Maznyk NA. Cytogenetic dose-response in vitro for biological dosimetry after exposure to high doses of gamma-rays. Radiat Prot Dosimetry 154:186–197, 2013
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 30
EP 37
PG 8
ER

PT J
AU Bukovszky, B
   Fodor, J
   Szekely, G
   Kocsis, Zs
   Oberna, F
   Major, T
   Takacsi-Nagy, Z
   Polgar, Cs
   Juranyi, Zs
AF Bukovszky, Botond
   Fodor, Janos
   Szekely, Gabor
   Kocsis, S. Zsuzsa
   Oberna, Ferenc
   Major, Tibor
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
   Juranyi, Zsolt
TI Mutagen sensitivity and risk of second cancer in young patients with head and neck squamous cell cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE mutagen sensitivity; head and neck cancer; second primary cancer
ID mutagen sensitivity; head and neck cancer; second primary cancer
AB Head and neck cancer patients are at high risk for secondary primary cancer (SPC) development. Mutagen hypersensitivity may be associated with elevated risk of SPC. A survey was made of SPC among 124 young (≤50 years) patients with squamous cell carcinoma of the head and neck who were enrolled in a pretreatment mutagen sensitivity investigation during 1996–2006. Mutagen sensitivity was assessed by exposing lymphocytes to bleomycin in vitro and quantitating the bleomycin-induced chromatid breaks per cell (b/c). Patients were classified as hypersensitive (>1 b/c) or not hypersensitive (≤1 b/c). The mean follow-up time was 64 months (range: 5–244 months). Eighteen patients (15%) developed a SPC. The 10-year estimated rate of SPC for hypersensitive (n=65) or not hypersensitive (n=59) patients were 17% and 30%, respectively (p=0.4272). Thirty-nine percent of SPC was developed after 10-year follow-up. The 5-year cancer-specific survival was 17% following the development of SPC. According to our findings, mutagen hypersensitivity does not increase the risk of developing SPC.
C1 [Bukovszky, Botond] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9, 1122 Budapest, Hungary.
RP Bukovszky, B (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM bukovszkybotond@gmail.com
CR Takacsi-Nagy Z, Oberna F. Fej-nyaki daganatok kezelese. In: Onkologia es sugarterapia, szerk. Polgar Csaba, Semmelweis Kiado, Budapest 2018, pp. 105−115
   Takacsi-Nagy Z. Valtozo tendenciak a human papillomavirus okozta szajgaratdaganatok kezeleseben. Magy Onkol 62:145−152, 2018
   Li FP, Montesano R. Interactions of cancer susceptibility genes and environmental carcinogens. American Association for Cancer Research, AACR), International Agency for Research on Cancer, IARC, Joint Conference. Cancer Res 54:4243−4247, 1994
   Hsu TC. Genetic instability in the human population: a working hypothesis. Hereditas 98:1−9, 1983
   Spitz MR, Hsu TC, Wu X, et al. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4:99−103, 1995
   Kosti O, Byrne C, Meeker KL, et al. Mutagen sensitivity, tobacco smoking and breast cancer risk: a case-control study. Carcinogenesis 31:654−659, 2010
   Schottenfeld D, Gantt RC, Wynder EL. The role of alcohol and tobacco in multiple primary cancers of the upper digestive system, larynx, and lung: a prospective study. Prev Med 3:277−293, 1974
   Silverman S, Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 106:33–35, 1983
   Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 86:131−137, 1994
   Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biological marker for risk of multiple primary malignancies. J Natl Cancer Inst 82:1773−1775, 1990
   Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 86:1681−1684, 1994
   Cloos J, Braakhuis BJM, Steen I, et al. Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56:816−819, 1994
   Szekely G, Remenar E, Kasler M, Gundy S. Expozicio vagy rakhajlam? Fej-nyaki laphamrakos betegek citogenetikai szurese. Magy Onkol 45:152− 157, 2001
   Szekely G, Remenar E, Kasler M, Gundy S. Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis 20:381−385, 2005
   Gundy S, Szekely G, Farkas G, et al. Biomarkerek alkalmazasa soran felmerulo problemak malignus es nem malignus betegsegben szenvedo alkoholistak eseteben. Magy Onkol 52:153−161, 2008
   Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457−481, 1958
   Adjei Boakye E, Buchanan P, Hinyard L, et al. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 144:727−737, 2018
   Suton P, Prpic M, Tarle M, et al. Outcomes for patients with second primary malignancy after primary surgical treatment for early-stage squamous cell carcinoma of the oral cavity. Head Neck 40:2347−2352, 2018
   Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 43:403−409, 1989
   Wu X, Gu J, Dong Q, et al. Joint effect of mutagen sensitivity and insulin- like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194−7201, 2006
   Cloos J, Leemans CR, van der Sterre ML, et al. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 9:713−717, 2000
   Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10:823−829, 2001
   Yamamoto E, Shibuya H, Yoshimura R, Miura M. Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer 94:2007−2014, 2002
   Morris LG, Sikora AG, Patel SG, et al. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus- associated oropharyngeal cancer. J Clin Oncol 29:739−746, 2011
   Diaz DA, Reis IM, Weed DT, et al. Head and neck second primary cancer rates in the human papillomavirus era: A population-based analysis. Head Neck 38(Suppl 1):E873−883, 2016
   Gan SJ, Dahlstrom KR, Peck BW, et al. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index non oropharyngeal head and neck cancers. Cancer 119:2593−2601, 2013
   Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449−456, 1989
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 39
EP 45
PG 7
ER

PT J
AU Nagykalnai, T
   Landherr, L
AF Nagykalnai, Tamas
   Landherr, Laszlo
TI Secondary lung cancer risk after breast cancer radiation therapy. The benefits substantially overweight the minimal disadvantages
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE postoperative radiotherapy; risk of recurrence; secondary malignancies; benefits
ID postoperative radiotherapy; risk of recurrence; secondary malignancies; benefits
AB Considerable evidence supports the rationale for postoperative radiotherapy after breast cancer surgery. Moreover, local tumour control affects survival too. High-dose irradiation is inherently associated with an increased risk of secondary malignancies in the long run. This radiobiological phenomenon raises the question whether it is worth taking this hazard, and the exact level of the risk of a secondary malignancy should be clarified. Answering these questions is important, regarding the large population size of breast cancer survivors, as well as patients’ improving survival rates and time. The postoperative radiation load to the ipsilateral lung tissue can be reduced, but it is still significant. The current literature review aims to evaluate the risk of secondary lung cancer associated with breast cancer- specific radiotherapy. Published evidence suggests that the benefits of postoperative radiotherapy following breast cancer surgery are much higher than the minimal risk of secondary lung cancer associated with this management strategy.
C1 [Nagykalnai, Tamas] Budapest, XV. ker. Onkormanyzat Egeszsegugyi IntezmenyeBudapest, Hungary.
   [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Uzsoki utca 29−41, 1145 Budapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, 1145 Budapest, Hungary.
EM landherr@uzsoki.hu
CR EBCTCG. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet 383:2127−35, 2014
   Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456−1461, 1995
   Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer, PRIME II): a randomized controlled trial. Lancet Oncol 16:266−273, 2015
   EBCTCG. Effect of radiotherapy after breast-conserving surgery on 10- year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 378:1707– 1716, 2011
   Schafer R, Strnad V, Polgar C, et al for the Groupe Europeen de Curietherapie of European Society for Radiotherapy and Oncology, GEC-ESTRO). Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery, GEC-ESTRO): 5-year results of a randomized, phase 3 trial. Lancet Oncol 19:834−844, 2018
   Polgar C, Kahan Z, Csejtei A, et al. IV. Emlorak Konszenzus Konferencia – Sugarterapias iranyelvek. Magy Onkol 64:371−383, 2020
   Aznar MC, Duane FK, Darby SC, et al. Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015. Radiother Oncol 125:148−154, 2018
   Taylor C, Correa C, Duane FK, et al for the Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35:1641−1649, 2017
   Shaitelman SF, Howell RM, Smith BD. Effects of smoking on late toxicity from breasts radiation. J Clin Oncol 35:1633−1635, 2017
   Fodor J, Orosz Z, Szabo E, et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. Ann Acad Dermatol 54:499−504, 2006
   Hayat MJ, Howlander N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results, SEER, program. Oncologist 12:20−37, 2007
   Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 15:2020−2026, 2006
   Land CE, Boice JD, Shore RE, et al. Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women. J Natl Cancer Inst 65:353−376, 1980
   Ewertz M, Mourisden HT. Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 68:325−329, 1985
   Inskip PD, Stowall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 86:983−988, 1994
   Neugut AI, Murray T, Santos, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73:1615−1620, 1994
   Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8:764–770, 1997
   Neugut AI, Weinberg MD, Ahsan H, Rescigno J. Carcinogenic effects of radiotherapy for breast cancer. Oncology, Williston Park, 13:1245−1256, 1999
   Rubino C, de Vathaire F, Diallo I, et al. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61:183−195, 2000
   Rubino C, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 89:840−846, 2003
   Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project, NSABP, clinical trials B-04 and B-06. Cancer 98:1362−1368, 2003
   Das IJ, Cheng EC, Freedman G, et al. Lung and heart dose volume analyses with CT simulator in radiation treatment of breast cancer. Int J Radiat Oncol Biol Phys 42:11−19, 1998
   Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97:1404−1411, 2003
   Woodward WA, Strom EA, McNeese MD, et al. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys 57:327−335, 2003
   Ford M, Sigurdson AJ, Petrulis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 98:1457−1464, 2003
   Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91:868−872, 2004
   Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol 23:7467−7474, 2005
   Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 6:557–565, 2005
   Kaufman EL, Jacobson JS, Hershman D, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26:392−398, 2008
   De Giorgi U, Perkins GH, Cristofallini M. Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual? J Clin Oncol 26:4044−4045, 2008
   Andersson M, Jensen MB, Engholm G, Storm H. Risk of second primary cancer among patients with early operable breast cancer registered or randomized in Danish Breast Cancer Cooperative Group, DBCG, protocols of the 77, 82 and 89 programmes during 1977–2001. Acta Oncol 47:755– 764, 2008
   Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26:1239–1246, 2008
   Kirova YM, Dr Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different modalities. Br J Cancer 98:870−874, 2008
   Berrington de Gonzales A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 102:220−226, 2010
   Clough-Gorr KM, Thwin SS, Bosco JLF, et al. Incident malignancies among older long-term breast cancer survivors and the age-matched and site-matched nonbreast cancer comparison group over 10 years of follow- up. Cancer 119:1478−1485, 2013
   Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 108:179−182, 2013
   Hamilton SN, Tyldesley S, Li D, et al. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation? Int J Radiat Oncol Biol Phys 91:977−985, 2015
   Molina-Montes E, Requena M, Sanchez-Cantalejo E, et al. Risk of second cancers after a first primary breast cancer: a systematic review and meta- analysis. Gynecol Oncol 136:158−171, 2015
   Lin CY, Chen SH, Huang CC, et al. Risk of secondary cancers in women with breast cancer and the influence of radiotherapy. Medicine, Baltimore, 95:e5556, 2016
   Bazire L, De Rycke Y, Asselain B, et al. Risk of second malignancies after breast cancer treatment: long-term results. Cancer Radiother 21:10−15, 2017
   Morton LM, Onel K, Curtis RE, et al. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. ASCO Educ Book 34:e57−67, 2014
   Ng J, Shuryak I. Minimizing second cancer risk following radiotherapy: current perspectives. Cancer Manag Res 7:1−11, 2015
   EBCTCG. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355:1757−1770, 2000
   Buchholz TA. Lung carcinoma development after radiotherapy for breast carcinoma. Cancer 98:1362−1368, 2003
   Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 114:56−65, 2015
   Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol 121:402−413, 2016
   Burt LM, Ying J, Poppe MM, et al. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 35:122−129, 2017
   Wang C, Kishan AU, Yu JB, et al. Association between long-term second malignancy risk and radiation: a comprehensive analysis of the entire Surveillance, Epidemiology, and End Results database, 1973-2014). Adv Radiat Oncol 4:738−747, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 46
EP 52
PG 7
ER

PT J
AU Martin, T
   Dank, M
   Biro, K
   Kuronya, Zs
   Gyergyay, F
   Nagyivanyi, K
   Budai, B
   Furesz, K
   Geczi, L
AF Martin, Tamas
   Dank, Magdolna
   Biro, Krisztina
   Kuronya, Zsofia
   Gyergyay, Fruzsina
   Nagyivanyi, Krisztian
   Budai, Barna
   Furesz, Katinka
   Geczi, Lajos
TI Fertility preservation in testicular cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE testicular tumor; spermiogenesis; sperm conservation; fertility
ID testicular tumor; spermiogenesis; sperm conservation; fertility
AB Germ cell tumors of the testicle account for 1% of all tumors. Testicular cancer (TC) is the most common malignancy in men aged 15–35 years. Patients with TC have an excellent survival rate but often have not yet attempted to father children, and fertility is one of the main concerns of survivors, therefore it is important to preserve it. The most commonly used method is sperm banking. Retrospective analysis of the Hungarian data showed that in case of testicular cancer spermatogenesis is more impaired in the more advanced disease. No correlation was found among the histological types and the proportion of azoo- and oligozoospermia. The parameters of testicular cancer and non-Hodgkin lymphoma patients were worse compared to the normal population. Sperm cryopreservation prior to initiating life-saving cancer treatment offers men the best chance to father children and should be offered to all men with testicular cancer before chemotherapy, since cytostatic therapy may lead to infertility.
C1 [Martin, Tamas] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Gyergyay, Fruzsina] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
   [Furesz, Katinka] KRIO IntezetBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Rath Gy. u. 7–9, 1122 Budapest, Hungary.
RP Martin, T (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM dr.martin.tamas@gmail.com
CR Magyar Nemzeti Rakregiszter
   Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol 17:327–331, 2010
   Van Der Kaaij MAE, Van Echten-Arends J, Simons AHM. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 28:168–179, 2010
   Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials. J Clin Oncol 31:231–239, 2013
   Romerius P, Stahl O, Moell C, et al. High risk of azoospermia in men treated for childhood cancer. Int J Androl 34:69–76, 2011
   Hintze J. NCSS and PASS. Number Cruncher Statistical System. 2001 Kaysville, UT, www.ncss.com
   Kelleher S, Wishart SM, Liu PY, et al. Long-term outcomes of elective human sperm cryostorage. Hum Reprod 16:2632–2639, 2001
   Gandini L, Sgro P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 21:2882–2889, 2006
   van Casteren NJ, Boellaard WPA, Romijn JC, Dohle GR. Gonadal dysfunction in male cancer patients before cytotoxic treatment. Int J Androl 33:73– 79, 2010
   Rives N, Perdrix A, Hennebicq S, et al. The semen quality of 1158 men with testicular cancer at the time of cryopreservation: Results of the French National CECOS Network. J Androl 33:1394–1401, 2012
   Depalo R, Falagario D, Masciandaro P, et al. Fertility preservation in males with cancer: 16-year monocentric experience of sperm banking and post-thaw reproductive outcomes. Ther Adv Med Oncol 8:412–420, 2016
   Meseguer M, Molina N, Garcia-Velasco JA, et al. Sperm cryopreservation in oncological patients: A 14-year follow-up study. Fertil Steril 85:640–645, 2006
   Bizet P, Saias-Magnan J, Jouve E, et al. Sperm cryopreservation before cancer treatment: A 15-year monocentric experience. Reprod Biomed Online 24:321–330, 2012
   Crha I, Ventruba P, Zakova J, et al. Survival and infertility treatment in male cancer patients after sperm banking. Fertil Steril 91:2344–2348, 2009
   Lass A, Akagbosu F, Brinsden P. Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner. Hum Reprod Update 7:370–377, 2001
   Agarwal A, Ranganathan P, Kattal N, et al. Fertility after cancer: A prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 81:342–348, 2004
   Magelssen H, Haugen TB, Von During V, et al. Twenty years experience with semen cryopreservation in testicular cancer patients: Who needs it? Eur Urol 48:779–785, 2005
   Ragni G, Somigliana E, Restelli L, et al. Sperm banking and rate of assisted reproduction treatment: Insights from a 15-year cryopreservation program for male cancer patients. Cancer 97:1624–1629, 2003
   van Casteren NJ, van Santbrink EJP, van Inzen W, et al. Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil Steril 90:2245–2250, 2008
   Muller I, Oude Ophuis RJ, Broekmans FJ, Lock TM. Semen cryopreservation and usage rate for assisted reproductive technology in 898 men with cancer. Reprod Biomed Online 32:147–153, 2016
   Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510, 2013
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 53
EP 57
PG 5
ER

PT J
AU Szivos, L
   Virga, J
   Klekner, �
   Arkosy, P
AF Szivos, Laszlo
   Virga, Jozsef
   Klekner, Almos
   Arkosy, Peter
TI The role of low grade glioma prognostic factors in therapeutic choices – summary of international literature and recommendations with conclusions
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE malignant glioma; astrocytoma; oligodendroglioma; prognosis; molecular biology
ID malignant glioma; astrocytoma; oligodendroglioma; prognosis; molecular biology
AB Our knowledge on low grade gliomas has grown extensively recently. Both molecular alterations and clinical trials unraveling their clinical significance are difficult to get familiar with. Thus, efforts made to reach any consensus are of upmost importance, so that multidisciplinary teams involved in patient management can make up-to-date, individually-tailored therapeutic plans. Our aims were to synthesize all the molecular and clinical investigations, recommendations and guidelines related to low grade gliomas in Hungarian language, and to define low and high risk prognostic groups with different therapeutic strategies. The roles of 21 molecular pathological markers and their significance levels in low grade gliomas are summarized in this paper. Data from relevant literature, as well as recommendations of neuro-oncological organizations were included. This summary could help to integrate diverse therapeutic plans of the past decades in low grade gliomas. Moreover, this paper may serve as a source for future revisions when updating low and high risk groups in low grade gliomas.
C1 [Szivos, Laszlo] University of Debrecen, Clinical Center, Department of Neurosurgery, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Virga, Jozsef] University of Debrecen, Clinical Center, Department of Neurosurgery, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of Neurosurgery, Moricz Zsigmond krt. 22., 4032 Debrecen, Hungary.
   [Arkosy, Peter] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
RP Klekner, � (reprint author), University of Debrecen, Clinical Center, Department of Neurosurgery, 4032 Debrecen, Hungary.
EM neurosurgery.debrecen@freemail.hu
CR Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803−820, 2016
   Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010−2014. Neuro Oncol 19(suppl_5):v1−v88, 2017
   Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152−2165, 1988
   Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist 19:403−413, 2014
   Schiff D, Van den Bent M, Vogelbaum MA, et al. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology, SNO, and European Association of Neuro-Oncology, EANO, consensus. Neuro Oncol 21:837−853, 2019
   Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129:585−596, 2015
   Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867−873, 2015
   Picca A, Berzero G, Sanson M. Current therapeutic approaches to diffuse grade II and III gliomas. Ther Adv Neurol Disord 11:1756285617752039, 2018
   Le Rhun E, Taillibert S, Chamberlain MC. Current management of adult diffuse infiltrative low grade gliomas. Curr Neurol Neurosci Rep 16:15, 2016
   Oberheim Bush NA, Chang S. Treatment strategies for low-grade glioma in adults. J Oncol Pract 12:1235−1241, 2016
   van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 19:5513−5522, 2013
   Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 118:1157−1168, 2013
   Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility- weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 238:658−667, 2006
   Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923−929, 1999
   Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076−2084, 2002
   Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499−2508, 2015
   Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481−2498, 2015
   Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s, for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153−166, 2018
   Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805−810, 2018
   Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol 130:269−282, 2016
   Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20:103−112, 2018
   van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344−350, 2013
   Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344−1355, 2016
   Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon- determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835−841, 2008
   Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide- based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 91:497−504, 2015
   Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/ RTOG 0424 Trial. JAMA Oncol 4:1405−1409, 2018
   Wu J, Kim C, Bai HX, et al. Comparison of radiation therapy alone and chemotherapy alone for low-grade gliomas without surgical resection. World Neurosurg 122:e108−e120, 2019
   Roelz R, Strohmaier D, Jabbarli R, et al. Residual tumor volume as best outcome predictor in low grade glioma − a nine-years near-randomized survey of surgery vs. biopsy. Sci Rep 6:32286, 2016
   Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308:1881−1888, 2012
   Bower M, Waxman J. NCCN Guidelines, Central Nervous System Cancers. Natl Compr Cancer Netw, 2018
   Sepulveda-Sanchez JM, Munoz Langa J, Arraez MA, et al. SEOM clinical guideline of diagnosis and management of low-grade glioma, 2017). Clin Transl Oncol 20:3−15, 2018
   Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro- Oncology, EANO, guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315−e329, 2017
   Addison J, Whitcombe J, William Glover S. How doctors make use of online, point-of-care clinical decision support systems: a case study of UpTo- Date©. Health Info Libr J 30:13−22, 2013
   Thiele RH, Poiro NC, Scalzo DC, Nemergut EC. Speed, accuracy, and confidence in Google, Ovid, PubMed, and UpToDate: results of a randomised trial. Postgrad Med J 86:459−465, 2010
   Lucas BP, Evans AT, Reilly BM, et al. The impact of evidence on physicians’ inpatient treatment decisions. J Gen Intern Med 19:402−409, 2004
   Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863−8869, 2005
   Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469−474, 2009
   Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765−773, 2009
   Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10, mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852−9861, 2006
   Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337−343, 2013
   Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma, EORTC 22033- 26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521−1532, 2016
   Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol 134:97−120, 2016
   Aquilanti E, Miller J, Santagata S, et al. Updates in prognostic markers for gliomas. Neuro Oncol 20:vii17−vii26, 2018
   Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194−1203, 2012
   Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133−146, 2015
   Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443−451, 2013
   Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 6:30295−30305, 2015
   Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135:639−642, 2018
   Horbinski C. To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 72:2−7, 2013
   Chi AS, Batchelor TT, Yang D, et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 31:e233−e236, 2013
   Vuong HG, Altibi AMA, Duong UNP, et al. BRAF mutation is associated with an improved survival in glioma − a systematic review and meta-analysis. Mol Neurobiol 55:3718−3724, 2018
   Brandner S, Jaunmuktane Z. Neurological update: gliomas and other primary brain tumours in adults. J Neurol 265:717−727, 2018
   Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 22:841−847, 2012
   Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol 75:4−18, 2016
   Saadeh FS, Mahfouz R, Assi HI. EGFR as a clinical marker in glioblastomas and other gliomas. Int J Biol Markers 33:22−32, 2018
   Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615−625, 2012
   Jaiswal S. Role of immunohistochemistry in the diagnosis of central nervous system tumors. Neurol India 64:502−512, 2016
   Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117−1124, 2002
   Zhi F, Chen X, Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46:1640−1649, 2010
   Rasheed BK, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187−4190, 1997
   Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350−1354, 2000
   Wang L, Zhang C, Zhang Z, et al. Specific clinical and immune features of CD68 in glioma via 1,024 samples. Cancer Manag Res 10:6409−6419, 2018
   Riemenschneider MJ, Koy TH, Reifenberger G. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol 107:277−282, 2004
   Suzuki A, Nobusawa S, Natsume A, et al. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. J Neurooncol 120:283−291, 2014
   Majchrzak K, Kaspera W, Szymas J, et al. Markers of angiogenesis, CD31, CD34, rCBV, and their prognostic value in low-grade gliomas. Neurol Neurochir Pol 47:325−331, 2013
   Kong X, Guan J, Ma W, et al. CD34 over-expression is associated with gliomas’ higher WHO grade. Medicine, Baltimore, 95:e2830, 2016
   Hatanpaa KJ, Hu T, Vemireddy V, et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. J Neurooncol 117:183−189, 2014
   Ma YH, Mentlein R, Knerlich F, et al. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86:31−45, 2008
   Ducray F, Mokhtari K, Criniere E, et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802−808, 2011
   Durand K, Guillaudeau A, Pommepuy I, et al. Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status. J Clin Pathol 64:793−801, 2011
   Dehghani F, Schachenmayr W, Laun A, Korf HW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493−504, 1998
   Lin L, Wang G, Ming J, et al. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. Tumour Biol 37:15333−15339, 2016
   Preusser M, Laggner U, Haberler C, et al. Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology. Histopathology 48:438−444, 2006
   Paw I, Carpenter RC, Watabe K, et al. Mechanisms regulating glioma invasion. Cancer Lett 362:1−7, 2015
   Virga J, Bognar L, Hortobagyi T, et al. Tumor grade versus expression of invasion-related molecules in astrocytoma. Pathol Oncol Res 24:35−43, 2018
   Virga J, Bognar L, Hortobagyi T, et al. The expressional pattern of invasion- related extracellular matrix molecules in CNS tumors. Cancer Invest 36:492−503, 2018
   Virga J, Szemcsak CD, Remenyi-Puskar J, et al. Differences in extracellular matrix composition and its role in invasion in primary and secondary intracerebral malignancies. Anticancer Res 37:4119−4126, 2017
   Virga J, Bognar L, Hortobagyi T, et al. Prognostic role of the expression of invasion-related molecules in glioblastoma. J Neurol Surg A Cent Eur Neurosurg 78:12−19, 2017
   Robinson PD, Kalkanis SN, Linskey ME, Santaguida PL. Methodology used to develop the AANS/CNS management of brain metastases evidence- based clinical practice parameter guidelines. J Neurooncol 96:11−16, 2010
   Grading guide: UpToDate Inc. https://www.uptodate.com
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 59
EP 70
PG 12
ER

PT J
AU Major, E
   Benedek, A
   Szasz, M
   Benyo, Z
   Balogh, A
AF Major, Eniko
   Benedek, Anett
   Szasz, A. Marcell
   Benyo, Zoltan
   Balogh, Andrea
TI The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE melanoma; modulated electro-hyperthermia (mEHT); cell culture; chemotherapy; apoptosis
ID melanoma; modulated electro-hyperthermia (mEHT); cell culture; chemotherapy; apoptosis
AB Our aim was to detect the effect of modulated electro-hyperthermia (mEHT) on cell viability and to examine if hyperthermia can augment the cell killing effect of various chemotherapeutic agents. B16F10 melanoma cells were treated for 30, 60, 90 and 120 minutes with mEHT using LabEHY100 (OncothermTM). Cell viability was measured using MTT assay and apoptosis by annexin V/7-AAD staining using flow cytometry 24 hours post-treatment. For analyzing gene expression with qPCR cells were harvested after 60 minutes treatment. In combined protocols, cells were treated with paclitaxel (40 nM), dacarbazine (40 μM) or nutlin-3a (10 μM) after mEHT. mEHT induced nuclear translocation of p53 which in turn regulates pro- and anti-apoptotic gene expression accounting for decreased cell viability. In combination with chemotherapy, mEHT augmented the cell killing effect of dacarbazine or nutlin-3a but not that of paclitaxel determined 48 hours post-treatment. The sensitizing effect on chemotherapeutics demonstrate the efficiency of mEHT as an adjuvant modality in cancer treatment.
C1 [Major, Eniko] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37–47., 1094 Budapest, Hungary.
   [Benedek, Anett] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37–47., 1094 Budapest, Hungary.
   [Szasz, A. Marcell] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37–47., 1094 Budapest, Hungary.
   [Balogh, Andrea] Semmelweis University, Department of Immunology-Haematology-Transfusiology, Tuzolto u. 37–47., 1094 Budapest, Hungary.
RP Benyo, Z (reprint author), Semmelweis University, Department of Immunology-Haematology-Transfusiology, 1094 Budapest, Hungary.
EM benyo.zoltan@med.semmelweis-univ.hu
CR Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941−1953, 2019
   Apalla Z, Lallas A, Sotiriou E, et al. Epidemiological trends in skin cancer. Dermatol Pract Concept 7:1−6, 2017
   Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239−271, 2014
   Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 417:949−954, 2002
   Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol, Pozn, 22:61−67, 2018
   Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372−8377, 2003
   Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968−8977, 2005
   Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712−4717, 2003
   Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252−264, 2012
   Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543−9553, 2005
   Roussakow SV. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect- to-treatment analysis. BMJ Open 7:e017387, 2017
   Andocs G, Szasz O, Szasz A. Oncothermia treatment of cancer: from the laboratory to clinic. Electromagn Biol Med 28:148−165, 2009
   Kim W, Kim MS, Kim HJ, et al. Role of HIF-1alpha in response of tumors to a combination of hyperthermia and radiation in vivo. Int J Hyperthermia 34:276−283, 2018
   Kleef R, Moss R, Szasz AM, et al. Complete clinical remission of stage IV triple-negative breast cancer lung metastasis administering low-dose immune checkpoint blockade in combination with hyperthermia and interleukin- 2. Integr Cancer Ther 17:1297−1303, 2018
   Lee SY, Lee NR, Cho DH, et al. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett 14:73−78, 2017
   Morimoto T, Kimura S, Konishi Y, et al. A study of the electrical bio-impedance of tumors. J Invest Surg 6:25−32, 1993
   Szasz A, Szasz N, Szasz O. Oncothermia: Principles and Practices. 2011
   Khramtsov VV, Gillies RJ. Janus-faced tumor microenvironment and redox. Antioxid Redox Signal 21:723−729, 2014
   Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, et al. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52, 2016
   Zou Y, Guo Z. A review of electrical impedance techniques for breast cancer detection. Med Eng Phys 25:79−90, 2003
   Meggyeshazi N, Andocs G, Balogh L, et al. DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia. Strahlenther Onkol 190:815−822, 2014
   Vancsik T, Kovago C, Kiss E, et al. Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts. J Cancer 9:41−53, 2018
   Vancsik T, Forika G, Balogh A, et al. Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro. Cancer Med 8:4292−4303, 2019
   Cha J, Jeon TW, Lee CG, et al. Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis. Int J Hyperthermia 31:784−792, 2015
   Tsang YW, Huang CC, Yang KL, et al. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy. BMC Cancer 15:708, 2015
   Besztercei B, Vancsik T, Benedek A, et al. Stress-induced, p53-mediated tumor growth inhibition of melanoma by modulated electrohyperthermia in mouse models without major immunogenic effects. Int J Mol Sci 20: pii: E4019, 2019
   Oei AL, van Leeuwen CM, ten Cate R, et al. Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis. Cancer Res 75:5120−5129, 2015
   Tsang YW, Chi KH, Huang CC, et al. Modulated electro-hyperthermia- enhanced liposomal drug uptake by cancer cells. Int J Nanomedicine 14:1269−1279, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 71
EP 77
PG 7
ER

PT J
AU Kovacs, P
   Esperger, Zs
   Horvath, D
   Lacsan, K
   Patyi, D
   Stefanovits, N
   Zsoldos, L
   Horvath, O
AF Kovacs, Peter
   Esperger, Zsofia
   Horvath, Dora
   Lacsan, Katalin
   Patyi, Daniel
   Stefanovits, Nora
   Zsoldos, Lili
   Horvath, Orsolya
TI Psychological phenomena and symptoms in active and complex oncology care: challenges of interventions and rehabilitation opportunities.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE psycho-oncology; rehabilitation; psychotherapy; trauma; crisis; distress; burnout; compliance; telemedicine
ID psycho-oncology; rehabilitation; psychotherapy; trauma; crisis; distress; burnout; compliance; telemedicine
AB According to research, almost every second oncology patient experiences intense distress during their oncology treatment. The development of new medical treatment options in cancer care allows longer survival for cancer patients. Because of this, quality of life becomes an increasingly important factor during treatments. Psycho-oncological interventions include all psychosocial interventions that are designed to positively influence the patient’s psychosocial adaptation and adjustment to diagnosis, treatment, and survivorship. Interventions also promote rehabilitation progress and help the emotional integration of disease-related crisis and trauma. Psycho-oncological therapies are supposed to manage cancer-related distress and other psychosocial problems by specific types of treatments or interventions. It is crucial for the medical system to deal with the psychosocial aspects of cancer care in order to identify and deal with patients’ needs for better compliance and adherence to treatment. The key of personalized holistic rehabilitation is multidisciplinary teamwork during the whole healing process: sharing the emotional experience also helps to prevent healthcare workers’ burnout.
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Esperger, Zsofia] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Horvath, Dora] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Lacsan, Katalin] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Patyi, Daniel] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Stefanovits, Nora] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Zsoldos, Lili] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Horvath, Orsolya] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, 1122 Budapest, Hungary.
EM kope.kope@gmail.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Kozponti Statisztikai Hivatal. Halalozasok a gyakoribb halalokok szerint, 1990-), 2019 https://www.ksh.hu/docs/hun/xstadat/xstadat_eves/i_ wnh001.html
   Kasler M, Otto S, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84−89, 2017
   Khan FA, Akhtar SS, Sheikh MK. Cancer treatment − objectives and quality of life issues. Malays J Med Sci 12:3−5, 2005
   Shrestha A, Martin C, Burton M, et al. Quality of life versus length of life considerations in cancer patients: A systematic literature review. Psychooncology 28:1367–1380, 2019
   Mehnert A, Hartung TJ, Friedrich M, et al. One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Psychooncology 27:75–82, 2018
   Riba MB, Donovan KA, Andersen B, et al. Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:1229−1249, 2019
   Watts S, Prescott P, Mason J, et al. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 5:e007618, 2015
   Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 7:300−322, 2013
   Rohanszky M, Konkoly-Thege B, Bodoky Gy. „Akik tuleltek a betegseget” – Daganatos betegek eletminosege egy retrospektiv vizsgalat tukreben. Magy Onkol 55:193−198, 2011
   Kovacs P, Panczel G, Balatoni T, et al. Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients. J Psychosom Res 78:579−584, 2015
   Pitman A, Suleman S, Hyde N, Hodgkiss A. Exploring low mood in a person with cancer. BMJ 361:k1488, 2018
   Walker J, Holm HC, Martin P, et al. Prevalence of depression in adults with cancer: a systematic review. Ann Oncol 24:895−900, 2013
   Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 23:121−130, 2014
   Halliwell E, Main L, Richardson C. The fundamental facts: The latest facts and figures on mental health. Mental Health Foundation, London 2007
   Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 4:e003901, 2014
   Mitchell AJ, Meader N, Davies E, et al. Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group. J Affect Disord 140:149−160, 2012
   Degi LCs. Pszichoszocialis kockazati tenyezok szerepe a daganatos megbetegedesekben. In: Magyar lelkiallapot. Ed. Kopp M. Semmelweis Kiado, Budapest 2008, pp. 557−568
   Niedzwiedz CL, Knifton L, Robb KA, et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer 19:1−8, 2019
   Schwartz LA, DeRosa BW, Kazak AE. Adult survivors of childhood cancer. In: Psycho-Oncology, 2nd edition). Eds. Holland JC et al. Oxford University Press, New York 2010, pp. 562−568
   Caplan G. Principles of preventive psychiatry. Basic Books, New York 1964
   Kovacs P, Konz Zs, Peti J, et al. Az onkopszichologiai rehabilitacio teruletei es kihivasai. Magy Onkol 61:284−291, 2017
   Chaturvedi SK. Psychiatric oncology: Cancer in mind. Indian J Psychiatry 54:111, 2012
   McFarland DC, Walsh L, Napolitano S, et al. Suicide in patients with cancer: identifying the risk factors. Oncology, Williston Park, 33:221−226, 2019
   Kovacs P, Panczel G, Melegh K, et al. Immunterapiak pszichologiai vonatkozasai a melanoma komplex es multidiszciplinaris kezeleseben. Magy Onkol 60:22−27, 2016
   Izci F, Ilgun AS, Findikli E, et al. Psychiatric symptoms and psychosocial problems in patients with breast cancer. J Breast Health 12:94, 2016
   Sharpe L, Curran L, Butow P, et al. Fear of cancer recurrence and death anxiety. Psychooncology 27:2559−2565, 2018
   Sun H, Yang Y, Zhang J. Fear of cancer recurrence, anxiety and depressive symptoms in adolescent and young adult cancer patients. Neuropsychiatr Dis Treat 15:857, 2019
   Van Bruggen V, Vos J, Westerhof G, et al. Systematic review of existential anxiety instruments. J Humanist Psychol 55:173−201, 2015
   Henderson FM, Cross AJ, Baraniak AR. ‘A new normal with chemobrain’: Experiences of the impact of chemotherapy-related cognitive deficits in longterm breast cancer survivors. Health Psychol Open 6:2055102919832234, 2019
   Ma L, Poulin P, Feldstain A, et al. The association between malnutrition and psychological distress in patients with advanced head-and-neck cancer. Curr Oncol 20:e554, 2013
   Fiorentino L, Ancoli-Israel S. Sleep dysfunction in patients with cancer. Curr Treat Options Neurol 9:337−346, 2007
   Kroenke K, Zhong X, Theobald D, et al. Somatic symptoms in patients with cancer experiencing pain or depression: prevalence, disability, and health care use. Arch Intern Med 170:1686−1694, 2010
   Peti J. Nogyogyaszati daganatos betegek psziches vezetese. In: Nogyogyaszati onkologia – gyakorlati kezikonyv. Eds. Pete I, Kasler M. Zafir Press, Budapest 2012, pp. 3–10
   Arpawong TE, Oland A, Milam JE, et al. Post-traumatic growth among an ethnically diverse sample of adolescent and young adult cancer survivors. Psychooncology 22:2235−2244, 2013
   Cordova MJ, Riba MB, Spiegel D. Post-traumatic stress disorder and cancer. Lancet Psychiatry 4:330−338, 2017
   American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Washington, DC 2013
   Thompson SB, Eccleston L, Hickish T. Post-traumatic stress disorder in cancer survivors: recognising and acknowledging the symptoms. Webmed- Central ONCOLOGY 2:WMC002062, 2011
   Marziliano A, Tuman M, Moyer A. The relationship between post-traumatic stress and post-traumatic growth in cancer patients and survivors: A systematic review and meta-analysis. Psychooncology 29:604−616, 2020
   Recklitis CJ, Syrjala KL. Provision of integrated psychosocial services for cancer survivors post-treatment. Lancet Oncol 18:e39−e50, 2017
   Van Marle S, Holmes J. Supportive psychotherapy as an integrative psychotherapy. In: Integration in psychotherapy: Models and methods. Eds. Holmes J, Bateman A. Oxford University Press, New York 2002, pp. 175−205
   Singer S, Kojima E, Beckerle J, et al. Practice requirements for psychotherapeutic treatment of cancer patients in the outpatient setting–A survey among certified psychotherapists in Germany. Psychooncology 26:1093−1098, 2017
   Teo I, Krishnan A, Lee GL. Psychosocial interventions for advanced cancer patients: A systematic review. Psychooncology 28:1394−1407, 2019
   Purebl Gy. Alacsony intenzitasu pszichologiai intervenciok a mindennapi orvosi gyakorlatban. Oriold es Tarsai Kiado, Budapest 2018
   Vizin G, Farkas K. A kognitiv viselkedesterapia lehetosegei az onkologiai ellatasban. Magy Onkol 64:62−69, 2020
   Moorey S, Greer S. Oxford guide to CBT for people with cancer. Oxford University Press, New York 2011
   Koncz Zs. Emlorakban megbetegedett nok lelektani jellemzoi es a mutetre valo felkeszites lehetosegei. In: Egy hajoban… Eds. Gerlinger L, Kovacs P. Medicina Kiado, Budapest 2018, pp. 85−102
   Godeny A, Horvath D. A pszichoedukacio jelentosege sugarterapiaban reszesulo betegek ellatasaban. In: Egy hajoban… Eds. Gerlinger L, Kovacs P. Medicina Kiado, Budapest 2018, pp. 123−136
   Koncz Zs. Onkopszichológia. A klinikai szakpszichológus szerepe az onkológián. In: Klinikai szakpszichologia a gyakorlatban – Utiranyok. Eds. Kapitany-Foveny M, Koncz Zs, Varga SK. Medicina Kiado, Budapest 2019, pp. 124−186
   Hong YA, Hossain MM, Chou WYS. Digital interventions to facilitate patient-provider communication in cancer care: A systematic review. Psychooncology 29:591−603, 2020
   Kircher SM, Mulcahy M, Kalyan A, et al. Telemedicine in oncology and reimbursement policy during COVID-19 and beyond. J Natl Compr Canc Netw 1:1−7, 2020
   Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA Intern Med 178:745−746, 2018
   van Der Lee ML, Schellekens MP. Bridging the distance: Continuing psycho- oncological care via video-consults during the COVID-19 pandemic. Psychooncology 29:1421−1423, 2020
   Hegedus K. A palliativ ellatas alapjai. Semmelweis Kiado, Budapest 2009
   Yennurajalingam S, Zhang T, Bruera E. The impact of the palliative care mobile team on symptom assessment and medication profiles in patients admitted to a comprehensive cancer center. Support Care Cancer 15:471−475, 2007
   Benyo G, Lukacs M, Busa Cs, et al. A magyarorszagi palliativ-hospice ellatas helyzete, kihivasai, kitoresi pontjai. Magy Onkol 61:292−299, 2017
   Salsman JM, Pustejovsky JE, Schueller SM, et al. Psychosocial interventions for cancer survivors: A meta-analysis of effects on positive affect. J Cancer Surviv 13:943−955, 2019
   Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull 130:601−630, 2004
   Seiler A, Jenewein J. Resilience in cancer patients. Front Psychiatry 10:208, 2019
   Piko B. Magatartas-tudomany es prevencio: a preventiv magatartas-orvoslas jelentosege. Magy Tud 11:1381−1390, 2003
   Kahan Zs, Szanto I, Molnar MJ, et al. Emlorak: gondozas, rehabilitacio, pszichoonkologia. Magy Onkol 60:258−268, 2016
   Mailath M, Laczkone MR, Horvath Zs, Szabo GS. A psziches morbiditasok korai felismerese a pszichoonkologiai ellatas soran. Magy Onkol 61:276−283, 2017
   Arving C, Thormodsen I, Brekke G, et al. Early rehabilitation of cancer patients – a randomized controlled intervention study. BMC Cancer 13:9, 2013
   Risko A. A test, a lelek es a daganat: bevezetes az onkopszichologiaba. Animula Kiado, Budapest 1999
   Tari A. Pszichoszocialis folyamatok az onkologiai teamben. In: Onkopszichologia a gyakorlatban. Eds. Horti J, Risko A. Medicina Kiado, Budapest 2006
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 78
EP 88
PG 11
ER

PT J
AU Szabo, A
   Csikosne Macsok, E
   Piko, B
AF Szabo, Anita
   Csikosne Macsok, Erzsebet
   Piko, Bela
TI “The phlebotomist” − venous punction and venous access obtaining in the department of oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE blood taking; obtaining peripheral venous access; peripheral vein cannulation; phlebotomist nurse; principle of administration
ID blood taking; obtaining peripheral venous access; peripheral vein cannulation; phlebotomist nurse; principle of administration
AB The protection of the veins in patients with malignancies is of high importance (regarding both blood taking and the drug administration). In order to prevent any unnecessary injury, every phlebotomy needs to have a sophisticated indication and requires skilled hands and adequate mentality. For the administration of cytostatic treatment, insertion of cannula is necessary, in most of the cases through a peripheral vein. Recently with more successful treatment possibilities, patients undergo many subsequent types of treatment. Thus, more examinations and diagnostic procedures (e.g. blood taking, radiologic examinations) are needed. Therefore, the need for central venous catheter or Porth-a-Cath device is increasing. Our report demonstrates general guidelines of blood taking and our everyday practice.
C1 [Szabo, Anita] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Csikosne Macsok, Erzsebet] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, 5700 Gyula, Hungary.
CR Polgar Cs. A daganatok kezelesenek modszerei – sebeszet, sugarterapia es gyogyszeres kezeles. In: Onkologia es sugarterapia. Szerk. Polgar Cs. Semmelweis Kiado, Budapest 2018, pp. 33−39
   60/2003., X. 20., ESzCsM rendelet az egeszsegugyi szolgaltatasok nyujtasahoz szukseges szakmai minimumfeltetelekrol. https://net.jogtar.hu/ jogszabaly?docid=a0300060.esc
   Dank M. Az onkologiai szakbizottsagok. In: Az onkologia tankonyve. Szerk. Tulassay Zs, Matolcsy A. Semmelweis Kiado, Budapest 2011, pp. 146−147
   Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1 – update and clarification: from the RECIST Committee. Eur J Cancer 62:132−137, 2016
   Benyo G, Lukacs M, Busa Cs, et al. A magyarorszagi palliativ-hospice ellatas helyzete, kihivasai, kitoresi pontjai. Magy Onkol 61:292−299, 2017
   Lovey J, Mersich T, Nagykalnai T, et al. Surgossegi betegellatas az onkologiaban. In: Az onkologiai alapjai. Egyetemi tankonyv. Szerk. Kasler M. Medicina Konyvkiado Zrt, Budapest 2018, pp. 1283−1300
   Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease. NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines®). Version 1. 2020 – April 16, 2020 https://www.nccn.org/ professionals/physician_gls/pdf/vte.pdf
   Dank M. A kemoterapia alapjai, mellekhatasok kezelese. In: Onkologia es sugarterapia. Szerk. Polgar Cs. Semmelweis Kiado, Budapest 2018, pp. 68−75
   Piko B, Puskasne SZK, Bassam A, et al. Citosztatikumok paravazacioja. Magy Onkol 55:4−13, 2011
   Tordai A. Laboratoriumi mintaveteli szabalyzat. Orszagos Klinikai Idegtudomanyi Intezet, 2019. https://okiti.hu/uploads/content/Szabalyzatok/ SZ-13%20Laborat%C3%B3riumi%20mintav%C3%A9teli%20szab%C3%A- 1lyzat.pdf
   Papai T. A venas vervetel mintaveteli specialitasai. 2018. https://tankorterem. wordpress.com/2018/10/03/a-venas-vervetel-mintaveteli-specialitasai/
   Periferias venabol vervetel: felso vegtagi phlebotomia, vena femoralis phlebotomia. TAMOP-4.1.2.A/1-11/1-2011-0084 2011. http://demo.medsim. med.unideb.hu/sites/default/files/belgy_13_magyar_student_0.pdf
   Lee H, Bang J, Kim S, et al. The axillary vein and its tributaries are not in the mirror image of the axillary artery and its branches. PLoS ONE 14:e0210464, 2019
   Toldt K. A tetembontas atlasza, II. kotet. Atnezte es gondozta: Hoschstetter F. A magyar kiadast sajto ala rendezte: Tellyesniczky K. Universitas Konyvkiado Tarsasag, Budapest 1912, p. 697
   Timar J. A terapiahoz kapcsolodo molekularis patologiai diagnosztika helyzete es finanszirozasa hazankban. IME 12:47−51, 2019
   Kosa J, Balla B, Kocsis-Deak B, et al. Tumordiagnosztika verbol – a folyadekbiopszia. Magy Tud 180:679−685, 2019
   Wadan H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation, DIC, according to four DIC guidelines. J Intensive Care 2:15, 2014
   Baroti-Toth K, Csernus Z, Hoffer I, et al., szerk., Transzfuzios Szabalyzat, az OVSZ modszertani levele). OVSZ, Budapest 2016 https://www.ovsz.hu/ sites/default/files/Transzfuziologia/Transzfuzios_szabalyzat/ovsz_trnszf_ szab_20161201_beliv.pdf
   Sousa B, Furlanetto J, Hutka M, et al. Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol 26(Suppl 5):v152−v168, 2015
   Kollar G, Alizadeh H, Gulyas E. „Centralis vena – nover modra?” Periferiarol bevezetett centralis venas kanulokkel szerzett tapasztalataink. Orv Hetil 158:856−863, 2017
   Matey L, Camp‑Sorrell D. Venous access devices: clinical rounds. Asia Pacific J Oncol Nurs 3:357−364, 2016
   Papai T. A centralis vena kanulalas es gondozas apoloi feladatai. 2018. https://tankorterem.wordpress.com/2018/10/25/a-centralis-vena-kanulalas- es-gondozas-apoloi-feladatai/
   Yin L, Li J. Central venous catheter insertion in colorectal cancer patients, PICC or PC? Cancer Manag Res 12:5813–5818, 2020
   Schiffer CA, Mangu PM, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 31:1357−1370, 2013
   Goossens GA. Flushing and locking of venous catheters: available evidence and evidence deficit. Nursing Res Pract 2015:985686, 2015
   Dalton KA, Aucoin J, Meyer B. Obtaining coagulation blood samples from central venous access devices: a review of the literature. Clin J Oncol Nurs 19:418−423, 2015
   Cummings-Winfield C, Mushani T. Restoring patency to central venous access devices. Clin J Oncol Nurs 12:925−934, 2008
   Dimak S, Szolics A, Piko B, Szabo Zs. Tartos centralis venas port szerepe az onkologiaban. Erbetegsegek 1:3−9, 2015
   Sugarterapias es Onkologiai Szakmai Kollegium, az Anaesthesiologiai es Intenzivterapias, valamint a Sebeszeti Szakmai Kollegiumok egyetertesevel. Venabiztositas az onkologiaban. Szakmai-modszertani level. Magy Onkol 48:193−196, 2004
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2021
VL 65
IS 1
BP 89
EP 95
PG 7
ER

PT J
AU Kasler, M
   Oberna, F
AF Kasler, Miklos
   Oberna, Ferenc
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
C1 [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Kasler, M (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 99
EP 100
PG 2
ER

PT J
AU Tovari, J
AF Tovari, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
C1 [Tovari, Jozsef] Orszagos Onkologiai Intezet, Kiserletes Farmakologiai Osztaly, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Tovari, J (reprint author), Orszagos Onkologiai Intezet, Kiserletes Farmakologiai Osztaly, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 101
EP 101
PG 1
ER

PT J
AU Radeczky, P
   Megyesfalvi, Zs
   Fillinger, J
   Laszlo, V
   Raso, E
   Moldvay, J
   Schlegl, E
   Barbai, T
   Bogos, K
   Timar, J
   Renyi-Vamos, F
   Hegedus, B
   Dome, B
AF Radeczky, Peter
   Megyesfalvi, Zsolt
   Fillinger, Janos
   Laszlo, Viktoria
   Raso, Erzsebet
   Moldvay, Judit
   Schlegl, Erzsebet
   Barbai, Tamas
   Bogos, Krisztina
   Timar, Jozsef
   Renyi-Vamos, Ferenc
   Hegedus, Balazs
   Dome, Balazs
TI Predictive relevance of KRAS mutational status in bone metastatic lung adenocarcinoma treated with bisphosphonate therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE KRAS mutational status; lung adenocarcinoma; bone metastasis
ID KRAS mutational status; lung adenocarcinoma; bone metastasis
AB The therapeutic impact of KRAS mutations remains controversial in bone metastatic lung adenocarcinoma (LADC). Therefore, our aim was to investigate the effects of KRAS mutational status on overall survival (OS) in these patients according to bisphosphonate therapy (BTx) and radiation therapy (RTx). In total, 134 LADC patients diagnosed with simultaneous bone metastasis were included in this study. The results of the univariate (p=0.008) and multivariate (p=0.004) survival analyses indicated that KRAS mutation is a negative prognostic factor. Both BTx and RTx can increase the OS with a pronounced benefit for patients with KRAS wild-type tumors. Importantly, the concomitant use of BTx and RTx might increase the OS irrespective of KRAS status compared to BTx or RTx alone. In summary, our results might contribute to the development of new therapeutic approaches with regards to KRAS mutational status in bone metastatic LADC.
C1 [Radeczky, Peter] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Megyesfalvi, Zsolt] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Fillinger, Janos] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Laszlo, Viktoria] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti Klinika, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Schlegl, Erzsebet] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Hegedus, Balazs] University Duisburg-Essen, Ruhrlandklinik, Department of Thoracic SurgeryEssen, Germany.
   [Dome, Balazs] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Megyesfalvi, Zs (reprint author), National Institute of Oncology, Department of Surgery, Budapest, Hungary.
EM megyesfalvi.zsolt@semmelweis-univ.hu
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288−300, 2016
   Rinaldi S, Berardi R. Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients? Ann Transl Med 5:353−353, 2017
   Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692−699, 2020
   Bogos K, Kiss Z, Galffy G, et al. Revising incidence and mortality of lung cancer in Central Europe: an epidemiology review from Hungary. Front Oncol 9:1051−1051, 2019
   Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med 18:s41–s46, 2018
   Zhou Y, Yu QF, Peng AF, et al. The risk factors of bone metastases in patients with lung cancer. Sci Rep 7:8970−8970, 2017
   Klikovits T, Lohinai Z, Fabian K, et al. New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer 126:139−148, 2018
   D’Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 6:101−114, 2014
   Al Husaini H, Wheatley-Price P, Clemons M, et al. Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251−259, 2009
   Green JR. Antitumor effects of bisphosphonates. Cancer 97:840−847, 2003
   Fairchild A. Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine? World J Clin Oncol 5:845−857, 2014
   Timar J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr Opin Oncol 26:138−144, 2014
   Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 124:53−64, 2018
   Yang H, Liang SQ, Schmid RA, et al. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol 9:953, 2019
   Ghimessy A, Radeczky P, Laszlo V, et al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev 39:1159−1177, 2020
   Radeczky P, Ghimessy A, Berta J, et al. A KRAS-mutans tudo-adenokarcinoma kezelesi lehetosegei. Magy Onkol 64:231−244, 2020
   Kern JA, Slebos RJ, Top B, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516−520, 1994
   Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutations in nonsmall cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999−5002, 1991
   Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561−565, 1990
   Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20:1507−1510, 1999
   Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92:131−1319, 2005
   Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31:2173−2181, 2013
   Lohinai Z, Klikovits T, Moldvay J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep 7:39721, 2017
   Kenessey I, Koi K, Horvath O, et al. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget 7:79503−79514, 2016
   Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 4:128−134, 2012
   Cserepes M, Ostoros G, Lohinai Z, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer 50:1819−1828, 2014
   Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw 17:1464−1472, 2019
   Kang EJ, Lee SY, Kim HJ, et al. Prognostic factors and skeletal-related events in patients with small cell lung cancer with bone metastases at the time of diagnosis. Oncology 90:103−111, 2016
   Niu Y, Lin Y, Pang H, et al. Risk factors for bone metastasis in patients with primary lung cancer: A systematic review. Medicine 98:e14084-e14084, 2019
   Cho YJ, Cho YM, Kim SH, et al. Clinical analysis of patients with skeletal metastasis of lung cancer. BMC Cancer 19:303, 2019
   Confavreux CB, Girard N, Pialat JB, et al. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study, POUMOS- TEC). Bonekey Rep 3:580, 2014
   Bittner N, Baliko Z, Sarosi V, et al. Bone metastases and the EGFR and KRAS mutation status in lung adenocarcinoma--the results of three year retrospective analysis. Pathol Oncol Res 21:1217−1221, 2015
   Zhao J, Han Y, Li J, et al. Prognostic value of KRAS/TP53/PIK3CA in nonsmall cell lung cancer. Oncol Lett 17:3233−3240, 2019
   Dormieux A, Mezquita L, Cournede PH, et al. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. 30:5021–5028, 2020
   Bittner N, Baliko Z, Sarosi V, et al. The EGFR and KRAS mutation status and correlations with the prevalence of bone metastases − the results of three year retrospective analysis. J Carcinog Mutagen 5:5, 2014
   Kuijpers C, Hendriks LEL, Derks JL, et al. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer. Lung Cancer 121:76−81, 2018
   Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31:1112−1121, 2013
   Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321−327, 2003
   Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459−1468, 2000
   Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88:1971−1978, 2003
   Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602−2608, 2001
   Di Salvatore M, Orlandi A, Bagala C, et al. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44:139−146, 2011
   Kubota H, Soejima T, Sulaiman NS, et al. Predicting the survival of patients with bone metastases treated with radiation therapy: a validation study of the Katagiri scoring system. Radiat Oncol 14:13, 2019
   De Felice F, Piccioli A, Musio D, et al. The role of radiation therapy in bone metastases management. Oncotarget 8:25691−25699, 2017
   Lopez-Olivo MA, Shah NA, Pratt G, et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20:2985−2998, 2012
   Ural AU, Avcu F, Candir M, et al. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52−R52, 2006
   Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61:535−542, 2005
   Ural AU, Avcu F. Radiosensitizing effect of zoledronic acid in small cell lung cancer. Lung Cancer 50:271−272, 2005
   Steel GG. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol 11:31−53, 1988
   Ryu K, Murata H, Koto K, et al. Combined effects of bisphosphonate and radiation on osteosarcoma cells. Anticancer Res 30:2713−2270, 2010
   Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125−129, 2008
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 103
EP 111
PG 9
ER

PT J
AU Mezo, G
   Andrea, APT
   Randelovic, I
   Enyedi, KN
   Biri-Kovacs, B
   Tovari, J
AF Mezo, Gabor
   Andrea, Angelo Pierluigi Tripodi
   Randelovic, Ivan
   Enyedi, Kata Nora
   Biri-Kovacs, Beata
   Tovari, Jozsef
TI Application of Asn-Gly-Arg sequence based cyclic peptides for targeted tumor therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE targeted tumor therapy; NGR peptides; daunomycin; CD13 receptor; integrins; Kaposi’s sarcoma; HT-29 colon cancer
ID targeted tumor therapy; NGR peptides; daunomycin; CD13 receptor; integrins; Kaposi’s sarcoma; HT-29 colon cancer
AB The in vivo antitumor effect of two NGR sequence containing peptide-daunomycin conjugates was studied on CD13+ Kaposi’s sarcoma s.c. tumor model on SCID mice, and on orthotopically developed CD13- HT-29 colon adenocarcinoma SCID mouse model. Both tumor types were positive for integrins. Significant tumor growth inhibition was observed on both tumor types by the treatment with the conjugates (Dau=Aoa-GFLGK(cyclo[KNGRE]-GG)-NH2 (1) and Dau=Aoa-GFLGK(cyclo[NleNGRE]-GG)-NH2 (2)). KS conjugate 1 with rather stable construct was more potent in tumor growth inhibition that might be explained by the CD13 receptor recognition of NGR sequence. In contrast, conjugate 2 that has propensity to rearrange isoAsp derivative showed significantly higher inhibition on CD13- HT-29 tumor model that is related to the integrin binding of isoDGR sequence. Next to the low toxic side effect of the conjugates in comparison with the free daunomycin, the positive efficiency of the conjugates was detected by the lower proliferation index and lower neovascularization of the tumor tissue.
C1 [Mezo, Gabor] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Andrea, Angelo Pierluigi Tripodi] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Randelovic, Ivan] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Enyedi, Kata Nora] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Biri-Kovacs, Beata] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Pazmany Peter setany 1/A, 1117 Budapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
RP Mezo, G (reprint author), Eotvos Lorand University, Faculty of Science, Institute of Chemistry, 1117 Budapest, Hungary.
EM gabor.mezo@ttk.elte.hu
CR Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol 12:3−20, 2015
   Parakh S, King D, Gan HK, Scott AM. Current development of monoclonal antibodies in cancer therapy. Recent Results Cancer Res 214:1−70, 2020
   Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res 18:3−19, 2020
   Gilad Y, Firer M, Gellerman G. Recent innovations in peptide based targeted drug delivery to cancer cells. Biomedicines 4:pii:E11, 2016
   Vrettos E, Mezo G, Tzakos AG. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem 14:930−954, 2018
   Schuster S, Biri-Kovacs B, Szeder B, et al. Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification. Pharmaceutics 10:223, 2018
   Kiss K, Biri-Kovacs B, Szabo R, et al. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. Eur J Med Chem 176:105−116, 2019.
   Enyedi KN, Toth S, Szakacs G, Mezo G. NGR-peptide-drug conjugates with dual targeting properties. PLoS One 12:e0178632, 2017
   Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 268:20205−20210, 1993
   Healy JM, Murayama O, Maeda T, et al. Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 34:3948−3955, 1995
   Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867−874, 2002
   Curnis F, Longhi R, Crippa L, et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281:36466−36476, 2006
   Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722−727, 2000
   Corti A, Curnis F, Rossoni G, et al. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs Clin Immunother Biopharm Gene Ther 27:591−603, 2013
   Enyedi KN, Czajlik A, Knapp K, et al. Development of cyclic NGR peptides with thioether linkage: structure and dynamics determining deamidation and bioactivity. J Med Chem 58:1806−1817, 2015
   Negussie AH, Miller JL, Reddy G, et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 143:265–273, 2010
   Tripodi AAP, Toth S, Enyedi KN, et al. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property. Beilstein J Org Chem 14:911−918, 2018
   Tripodi AAP, Randelovic I, Biri-Kovacs B, et al. In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunorubicin conjugates developed for targeted drug delivery. Pathol Oncol Res 26:1879−1892, 2020
   Kapuvari B, Schulcz A, Hegedus R, et al. Modositott GnRH-III-antraciklin biokonjugatumok daganatnovekedest gatlo hatasanak tanulmanyozasa in vivo szubkutan vs. ortotopikus rendszerekben Magy Onkol 59:310−318, 2015
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 113
EP 120
PG 8
ER

PT J
AU Uhlyarik, A
   Piurko, V
   Papai, Zs
   Raso, E
   Lahm, E
   Kiss, E
   Sikter, M
   Vachaja, J
   Vizkeleti, L
   Kenessey, I
   Timar, J
AF Uhlyarik, Andrea
   Piurko, Violetta
   Papai, Zsuzsanna
   Raso, Erzsebet
   Lahm, Erika
   Kiss, Edina
   Sikter, Marta
   Vachaja, Jozsef
   Vizkeleti, Laura
   Kenessey, Istvan
   Timar, Jozsef
TI EGFR protein is a negative prognostic and predictive factor in wild-type RAS colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE colorectal cancer; wild type RAS; EGFR protein expression; anti-EGFR antibody therapy
ID colorectal cancer; wild type RAS; EGFR protein expression; anti-EGFR antibody therapy
AB Negative predictive markers of the anti-EGFR antibody therapies are RAS or BRAF mutations, while left sidedness can be considered as a positive predictor. Here we analyzed 97 wild type RAS metastatic colorectal cancers looking for the prognostic and predictive roles of EGFR protein expression. We found that right-sided colorectal cancers are characterized by significantly higher EGFR protein expression as compared to left-sided ones, irrespective of the primary or metastatic tissue analysis. Furthermore, tumors with multiple organ involvement are characterized by significantly higher EGFR protein expression as compared to single organ ones. In the homogenous cetuximab treated cohort (n=90) we have found that lower than the applied EGFR protein expression cut-off was associated with favorable survival. In the multivariate analysis only sidedness proved to be a strong independent predictor, however sidedness is an EGFR-dependent predictor of anti-EGFR therapy.
C1 [Uhlyarik, Andrea] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Piurko, Violetta] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Lahm, Erika] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Sikter, Marta] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vachaja, Jozsef] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Vizkeleti, Laura] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Field K, Lipton L. Metastatic colorectal cancer − past, progress and future. World J Gastroenterol 13:3806−3815, 2007
   Modest DP, Pont S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 109:70−83, 2019
   Bokemeyer C, Van Cutsem E, Rougiuer P, et al. Addition of cetuximab to chemotherapy as first line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466–1475, 2012
   Bokemeyer C, Kohne CH, Ciardiello F, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51:1243– 1252, 2015
   Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: Prognosis, treatment and new perspectives. Ann Oncol 28:2648– 2657, 2017
   Montagut C, Dalmases A, Bellosillo B, et al. Identification of mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18:221–223, 2012
   Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526:263–267, 2015
   Algars A, Sundstrom J, Lintunen M, et al. EGFR copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PI3CA wild type metastatic colorectal cancer. Int J Cancer 40:922–929, 2017
   Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15, 2001
   Van Krieken JHJM, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal for an European quality assurance program. Virchows Arch 453:417–431, 2008
   Erbitux alkalmazasi eloiras. https://www.ema.europa.eu/en/documents/ product-information/erbitux-epar-product-information_hu.pdf
   Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16:2205–2213, 2010
   Licitra L, Storkel S, Kerr KM, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49:1161–1168, 2013
   Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810, 2005
   Lievre A, Ouine B, Canet J, et al. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. Br J Cancer 117:1819–1827, 2017
   Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46:1997–2009, 2010
   Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408– 1417, 2009
   Li D, Fu Q, Li M, et al. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: A meta-analysis. Future Oncol 13:1115–1127, 2017
   Cao DD, Xu HL, Xu XM, Ge W. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different KRAS status: A systematic review and meta-analysis. Oncotarget 8:53631– 53641, 2017
   Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon and rectal cancers. Oncotarget 8:86356– 86368, 2017
   Heinemann V, von Weikerstahl LF, Decker T, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer 124:587−594, 2021
   Uhlyarik A, Piurko V, Papai Z, et al. EGFR protein expression in KRAS wild type metastatic colorectal cancer is another negative predictive factor of the cetuximab therapy. Cancers 12:614, 2020
   Uhlyarik A, Piurko V, Vizkeleti L, et al. EGFR protein expression of KRAS wild type colorectal cancer: Predictive value of the sidedness for efficacy of anti-EGFR therapy. Pathol Oncol Res 26:1429−1434, 2020
   Derecskei K, Moldvay J, Bogos K, Timar J. Protocol modifications influence the result of EGFR receptor immunodetection by EGFR pharmDX in paraffin-embedded cancer tissues. Pathol Oncol Res 12:243–245, 2006
   Baran B, Ozupek NM, Tetik YN, et al. Difference between left sided and right sided colorectal cancer: a focused review of literature. Gastroenterol Res 11:264−273, 2018
   Loree JM, Pereira AL, Lam M, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 24:1062−1072, 2018
   Khelwatty S, Essapen S, Bagwan I, et al. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget 8:7666–7677, 2017
   Gao L, Xu J, He G, et al. CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. Am J Cancer Res 9:2531–2543, 2019
   Martini G, Cardone C, Vitiello PP, et al. EPHA2 is a predictive biomarker of resistance and potential therapeutic target for improving anti-epidermal growth factor receptor therapy of colorectal cancer. Mol Cancer Ther 18:845– 855, 2019
   Woolston A, Khan K, Spain G, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti- EGFR treatment in colorectal cancer. Cancer Cell 36:35–50, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 121
EP 127
PG 7
ER

PT J
AU Neuperger, P
   Szebeni, GJ
AF Neuperger, Patricia
   Szebeni, Gabor Janos
TI Single cell mass cytometric comparison of human H1975 lung and MDA-MD-231 breast adenocarcinoma cellular models
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE single-cell analysis; adenocarcinoma; PD-L1; epidermal growth factor receptor; epithelial cell adhesion molecule
ID single-cell analysis; adenocarcinoma; PD-L1; epidermal growth factor receptor; epithelial cell adhesion molecule
AB The most frequent cancer types are lung and breast cancer in the Western world. However, the prognosis of breast cancer patients shows an improved tendency, while lung cancer types remained with high mortality. Intratumor heterogeneity (ITH) frequently leads to the failure of treatments, so there is an unmet need revealing ITH at single cell resolution. Our aim was to study female-derived human H1975 lung and MDA-MB-231 triple-negative breast cancer adenocarcinoma cell line models using single cell mass cytometry. Nine of thirteen carcinoma markers showed significant differences in the percentage of cells. Our current work shed light on the intra- and inter cell line heterogeneity still preserved in the studied, widely-used adenocarcinoma laboratory models.
C1 [Neuperger, Patricia] Eotvos Lorand Kutatasi Halozat, Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika Laboratorium, Temesvari krt. 62., 6726 Szeged, Hungary.
   [Szebeni, Gabor Janos] Eotvos Lorand Kutatasi Halozat, Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika Laboratorium, Temesvari krt. 62., 6726 Szeged, Hungary.
RP Szebeni, GJ (reprint author), Eotvos Lorand Kutatasi Halozat, Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika Laboratorium, 6726 Szeged, Hungary.
EM szebeni.gabor@brc.hu
CR Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356−387, 2018
   Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692−699, 2020
   Remenyi Kissne D, Gede N, Szakacs Z, Kiss I. Breast cancer screening knowledge among Hungarian women: a cross-sectional study. BMC Womens Health 21:69, 2021
   Kelly RT. Single-cell proteomics: progress and prospects. Mol Cell Proteomics 19:1739−1748, 2020
   Vistain LF, Tay S. Single-cell proteomics. Trends Biochem Sci 2021,, DOI  10.1016/j.tibs.2021.01.013
   Alfoldi R, Balog JA, Farago N, et al. Single cell mass cytometry of nonsmall cell lung cancer cells reveals complexity of in vivo and three-dimensional models over the Petri-dish. Cells 8:1093, 2019
   Kotogany E, Balog JA, Nagy LI, et al. Imidazo[1,2-b]pyrazole-7-carboxamide derivative induces differentiation-coupled apoptosis of immature myeloid cells such as acute myeloid leukemia and myeloid-derived suppressor cells. Int J Mol Sci 21:5135, 2020
   Balog JA, Hackler L, Jr., Kovacs AK, et al. Single cell mass cytometry revealed the immunomodulatory effect of cisplatin via downregulation of splenic CD44+, IL-17A+ MDSCs and promotion of circulating IFN-gamma+ myeloid cells in the 4T1 metastatic breast cancer model. Int J Mol Sci 21:170, 2019
   Balog JA, Honti V, Kurucz E, et al. Immunoprofiling of Drosophila hemocytes by single-cell mass cytometry. Genomics Proteomics Bioinformatics 2021,, DOI  10.1016/j.gpb.2020.06.022
   Nassar AF, Ogura H, Wisnewski AV. Impact of recent innovations in the use of mass cytometry in support of drug development. Drug Discov Today 20:1169−1175, 2015
   Keller L, Werner S, Pantel K. Biology and clinical relevance of EpCAM. Cell Stress 3:165−180, 2019
   Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol 12:3-20, 2018
   Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727−742, 2020
   Kovacs-Solyom F, Blasko A, Fajka-Boja R, et al. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett 127:108−118, 2010
   Cousin JM, Cloninger MJ. The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1. Int J Mol Sci 17:1566, 2016
   Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta 1863:427−437, 2016
   Altevogt P, Sammar M, Huser L, et al. Novel insights into the function of CD24: A driving force in cancer. Int J Cancer 148:546−559, 2021
   Han ZW, Lyv ZW, Cui B, et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs 38:1888−1898, 2020
   Schmit K, Michiels C. TMEM proteins in cancer: a review. Front Pharmacol 9:1345, 2018
   Ancey PB, Contat C, Meylan E. Glucose transporters in cancer − from tumor cells to the tumor microenvironment. FEBS J 285:2926−2943, 2018
   Payen VL, Mina E, Van Hee VF, et al. Monocarboxylate transporters in cancer. Mol Metab 33:48−66, 2020
   Sharma P, Alsharif S, Fallatah A, et al. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells 8:497, 2019
   Snyder KA, Hughes MR, Hedberg B, et al. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res 17:46, 2015
   Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 38:65−77, 2019
   Amir el AD, Davis KL, Tadmor MD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 31:545−552, 2013
   Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87:636−645, 2015
   Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169:750−765, 2017
   Jackson HW, Fischer JR, Zanotelli VRT, et al. The single-cell pathology landscape of breast cancer. Nature 578:615−620, 2020
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 129
EP 138
PG 10
ER

PT J
AU Farkas, Gy
   Kocsis, Zs
   Szekely, G
   Dobozi, M
   Polgar, Cs
   Juranyi, Zs
AF Farkas, Gyongyi
   Kocsis, S. Zsuzsa
   Szekely, Gabor
   Dobozi, Maria
   Polgar, Csaba
   Juranyi, Zsolt
TI And what about doctors? Associations between spontaneous chromosomal aberrations and cancer morbidity in healthcare workers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE healthcare workers; chromosome aberrations; cancer risk; ionizing radiation; cytostatic drugs
ID healthcare workers; chromosome aberrations; cancer risk; ionizing radiation; cytostatic drugs
AB Healthcare workers may be occupationally exposed to low dose rate radiation or different chemicals during their work. There are strong associations between the increased frequency of spontaneous chromosomal aberrations in blood lymphocytes and the risk of cancer. Cytogenetic tests were conducted on 1240 healthy medical workers and cancer incidence was followed up between 1997–2018. Both structural and numerical chromosome aberrations were evaluated and the results were compared taking into account gender, age, and smoking. The frequency of aberrant cells was significantly higher in smoker males than in non-smokers (p=0.009). Within the same study period, there was no significant difference in chromosome aberrations between the potentially exposed group of workers and the control group. Among 82 cancer cases (6.6%) the most common tumors were breast (16), colon (12), lung (7) and thyroid gland cancers (7). Our analysis showed 7.3% cancer occurrence among smokers compared to 6.2% among non-smokers. These results suggest that in our cases cytogenetic effects of smoking are more deleterious than occupational exposures.
C1 [Farkas, Gyongyi] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Szekely, Gabor] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Dobozi, Maria] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Farkas, Gy (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM farkas.gyongyi@oncol.hu
CR Kasuba V, Rozgaj R, Jazbec A. Chromosome aberrations in peripheral blood lymphocytes of Croatian hospital staff occupationally exposed to low levels of ionising radiation. Arh Hig Rada Toksikol 594:251−259, 2008
   Muller WU, Streffer C. Biological indicators for radiation damage. Int J Radiat Biol 594:863−873, 1991
   Paz-y-Mino C, Leone PE, Chavez M, et al. Follow up study of chromosome aberrations in lymphocytes in hospital workers occupationally exposed to low levels of ionizing radiation. Mutat Res 3353:245−251, 1995
   Jha AN, Sharma T. Enhanced frequency of chromosome aberrations in workers occupationally exposed to diagnostic X-rays. Mutat Res 2604:343−348, 1991
   Rozgaj R, Kasuba V, Sentija K, et al. Radiation-induced chromosomal aberrations and haematological alterations in hospital workers. Occup Med, Lond, 496:353−360, 1999
   Carrano AV, Natarajan AT. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. Mutat Res 2043:379−406, 1988
   Grummt T, Grummt HJ, Schott G. Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 3021:19−24, 1993
   Albertini RJ, Sullivan LM, Berman JK, et al. Mutagenicity monitoring in humans by autoradiographic assay for mutant T lymphocytes. Mutat Res 2043:481−492, 1988
   Sorsa M, Pyy L, Salomaa S, et al. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 2043:465−479, 1988
   Roussel C, Witt KL, Shaw PB, Connor T. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat Res 781:207−217, 2019
   Perera FP, Whyatt RM. Biomarkers and molecular epidemiology in mutation/ cancer research. Mutat Res 3132-3:117−129, 1994
   Maffei F, Angelini S, Forti GC, et al. Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation. Mutat Res 5471-2:91−99, 2004
   Tompa A, Biro A, Jakab M. Genotoxic monitoring of nurses handling cytotoxic drugs. Asia Pac J Oncol Nurs 34:365−369, 2016
   Perera FP, Hemminki K, Gryzbowska E, et al. Molecular and genetic damage in humans from environmental pollution in Poland. Nature 3606401:256−258, 1992
   DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 5672-3:447−474, 2004
   Bofetta P, van der Hel O, Norppa H, et al. Chromosomal aberrations and cancer risk: Results of a cohort study from Central Europe. Am J Epidemiol 165:36-43, 2006
   Bonassi, S, Norppa, H, Ceppi, M, et al. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis 29:1178−1183, 2008
   Farkas G, Juranyi Z, Szekely G, et al. Relationship between spontaneous frequency of aneuploidy and cancer risk in 2145 healthy Hungarian subjects. Mutagenesis 315:583−588, 2016
   Waksvik H, Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 657-8:607−610, 1981
   Huttner E, Mergner U, Braun R, et al. Increased frequency of 6-thioguanine- resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutat Res 2432:101−107, 1990
   Stucker I, Hirsch A, Doloy T, et al. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 573:195−205, 1986
   Balasem AN, Ali AS, Mosa HS, et al. Chromosomal aberration analysis in peripheral lymphocytes of radiation workers. Mutat Res 2713:209−211, 1992
   Barquinero JF, Barrios L, Caballin MR, et al. Cytogenetic analysis of lymphocytes from hospital workers occupationally exposed to low levels of ionizing radiation. Mutat Res 2862:275−279, 1993
   Cardoso RS, Takahashi-Hyodo S, Peitl P, Jr, et al. Evaluation of chromosomal aberrations, micronuclei, and sister chromatid exchanges in hospital workers chronically exposed to ionizing radiation. Teratog Carcinog Mutagen 216:431−439, 2001
   Bonassi S, Forni A, Bigatti P, et al. Chromosome aberrations in hospital workers: evidence from surveillance studies in Italy, 1963-1993). Am J Ind Med 313:353−360, 1997
   Garaj-Vrhovac V, Kopjar N, Poropat M. Evaluation of cytogenetic damage in nuclear medicine personnel occupationally exposed to low-level ionising radiation. Arh Hig Rada Toksikol 571:31−38, 2006
   Anderson D, Jenkinson PC, Dewdney RS, et al. Chromosome aberrations, mitogen-induced blastogenesis and proliferative rate index in peripheral lymphocytes from 106 control individuals of the U.K. population. Mutat Res 2043:407−420, 1988
   Bender MA, Preston RJ, Leonard RC, et al. Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. II. Extension of age range. Mutat Res 2122:149−154, 1989
   Carbonell E, Peris F, Xamena N, et al. Chromosomal aberration analysis in 85 control individuals. Mutat Res 3701:29−37, 1996
   Bolognesi C, Abbondandolo A, Barale R, et al. Age-related increase of baseline frequencies of sister chromatid exchanges, chromosome aberrations, and micronuclei in human lymphocytes. Cancer Epidemiol Biomarkers Prev 64:249−256, 1997
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 141
EP 148
PG 8
ER

PT J
AU Szasz, I
   Koroknai, V
   Vizkeleti, L
   Balazs, M
AF Szasz, Istvan
   Koroknai, Viktoria
   Vizkeleti, Laura
   Balazs, Margit
TI Molecular background of BRAF inhibitor induced resistance in BRAFV600E mutant melanoma cell lines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE BRAFV600E mutation; malignant melanoma; vemurafenib analogue; gene expression; proteome profiler
ID BRAFV600E mutation; malignant melanoma; vemurafenib analogue; gene expression; proteome profiler
AB Target-specific inhibition of the BRAFV600E mutant protein has been a major breakthrough in the treatment of metastatic cutaneous melanoma. However, the success of therapies is significantly overshadowed by the development of resistance. Understanding the molecular mechanisms associated with acquired resistance is an important step to increase the effectiveness of melanoma treatment. Our aim was to elucidate the molecular differences underlying the development of drug resistance using a mutant BRAF protein inhibitor (vemurafenib analogue: PLX4720) in BRAFV600E mutant melanoma cell lines. We developed four BRAF inhibitor-resistant cell lines and examined the effect of BRAF inhibitor “withdrawal” on cell division. ArrayCGH was used to define genetic, and Affymetrix HumanGene 1.0 microarray to monitor gene expression alterations between the sensitive and resistant cell lines. Protein expression was determined using Proteome Profiler Human XL Oncology Array. We found that withdrawal of the inhibitor reduces cell proliferation in the resistant cells. The invasive potential of the resistant cells increased. Using genomic and proteomic methods we described new molecular alterations associated with acquired resistance.
C1 [Szasz, Istvan] University of Debrecen, MTA-DE Public Health Research GroupDebrecen, Hungary.
   [Koroknai, Viktoria] University of Debrecen, MTA-DE Public Health Research GroupDebrecen, Hungary.
   [Vizkeleti, Laura] University of Debrecen, MTA-DE Public Health Research GroupDebrecen, Hungary.
   [Balazs, Margit] University of Debrecen, MTA-DE Public Health Research GroupDebrecen, Hungary.
RP Szasz, I (reprint author), University of Debrecen, MTA-DE Public Health Research Group, Debrecen, Hungary.
EM szasz.istvan@med.unideb.hu
CR Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: Update 2019. Adv Exp Med Biol 1268:123−139, 2020
   Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol 4:383, 2014
   Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 150:251−263, 2012
   Iwei Y, Eric J, Ling S, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst 111:1068–1077, 2019
   Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855−867, 2004
   Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 28:2581−2587, 2017
   Patel H, Yacoub N, Mishra R, et al. Current advances in the treatment of BRAF-mutant melanoma. Cancers, Basel, 12:482, 2020
   Smiech M, Leszczynski P, Kono H, et al. Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes, Basel, 11:1342, 2020
   Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507−2516, 2011
   Ascierto PA, Minor D, Ribas A, et al. Phase II trial, BREAK-2, of the BRAF inhibitor dabrafenib, GSK2118436, in patients with metastatic melanoma. J Clin Oncol 31:3205−3211, 2013
   Shirley M. Encorafenib and binimetinib: first global approvals. Drugs 78:1277−1284, 2018
   Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer 126:33−44, 2020
   Patel M, Eckburg A, Gantiwala S, et al. Resistance to molecularly targeted therapies in melanoma. Cancers, Basel, 13:1115, 2021
   Szasz I, Koroknai V, Kiss T, et al. Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells. Melanoma Res 29:390−400, 2019
   Garber K. Cancer research. Melanoma drug vindicates targeted approach. Science 326:1619, 2009
   Proietti I, Skroza N, Bernardini N, et al. Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review. Cancers, Basel, 12:2801, 2020
   Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11:873−886, 2012
   Yeon M, Kim Y, Jung HS, Jeoung D. Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol 8:486, 2020
   Koroknai V, Szasz I, Hernandez-Vargas H, et al. DNA hypermethylation is associated with invasive phenotype of malignant melanoma. Exp Dermatol 29:39−50, 2020
   Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494:251−255, 2013
   Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF(V600E, inhibition in melanoma. Nature 508:118−122, 2014
   Manandhar S, Kim CG, Lee SH, et al. Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells. Oncotarget 8:70521−70537, 2017
   Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies, V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012
   Krepler C, Xiao M, Sproesser K, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second- line combination therapies. Clin Cancer Res 22:1592−1602, 2016
   Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E, inhibition by RTK or N-RAS upregulation. Nature 468:973−977, 2010
   Webster MR, Weeraratna AT. A Wnt-er migration: the confusing role of beta-catenin in melanoma metastasis. Sci Signal 6:pe11, 2013
   Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546:431−435, 2017
   Jenkins MH, Steinberg SM, Alexander MP, et al. Multiple murine BRaf(V600E, melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res 27:495−501, 2014
   Liao YH, Chiang KH, Shieh JM, et al. Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma. Oncogene 36:2228−2242, 2017
   Izraely S, Ben-Menachem S, Sagi-Assif O, et al. ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. Oncotarget 8:75778−75796, 2017
   Molnar E, Garay T, Donia M, et al. Long-term vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with EGFR expression. Int J Mol Sci 20:4484, 2019
   Szasz I, Koroknai V, Patel V, et al. Cell proliferation is strongly associated with the treatment conditions of an ER stress inducer new anti-melanoma drug in melanoma cell lines. Biomedicines 9:96, 2021
   Cerezo M, Lehraiki A, Millet A, et al. Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell 29:805−819, 2016
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 149
EP 156
PG 8
ER

PT J
AU Matolay, O
   Badon, ES
   Balazs, L
   Juhasz, P
   Csonka, T
   Mehes, G
AF Matolay, Orsolya
   Badon, Emese Sarolta
   Balazs, Lidia
   Juhasz, Peter
   Csonka, Tamas
   Mehes, Gabor
TI The role of carbonic anhydrase IX in the progression of malignant tumors – a potential therapeutic target?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tumor metabolism; metabolic profile; CAIX; carboanhydrase; pH
ID tumor metabolism; metabolic profile; CAIX; carboanhydrase; pH
AB Insufficient tissue perfusion in malignancies results in hypoxic areas, favoring neoplastic progression. Tumor cells under hypoxia undergo an adaptive program by activating alternative metabolic pathways, which is regulated by hypoxia inducible factor-1 (HIF1) in order to overcome microenvironmental changes. The expression of carbonic anhydrase IX (CAIX) is a prominent protective mechanism against intracellular acidosis occurring in cancer cells suffering from hypoxia. Due to the activity of CAIX, the restored intracellular pH (pHi) supports tumor cell proliferation and migration, while the compensatory extracellular acidosis contributes to immunoprotection and to chemo- and radioresistance. In vitro and animal model experiments showed that the chemotherapeutic efficiency could be significantly improved by the selective inhibition of CAIX, thus, its adjuvant therapeutic potential is under active investigation.
C1 [Matolay, Orsolya] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Badon, Emese Sarolta] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Balazs, Lidia] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Juhasz, Peter] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Csonka, Tamas] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of Pathology, Nagyerdei korut 98., 4032 Debrecen, Hungary.
RP Mehes, G (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, 4032 Debrecen, Hungary.
CR Vaupel P, Multhoff G. Fatal alliance of hypoxia-/HIF-1α-driven microenvironmental traits promoting cancer progression. Adv Exp Med Biol 1232:169– 176, 2020
   Sedlakova O. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol 4:400, 2014
   Mboge M, Mahon B, McKenna R, Frost S. Carbonic anhydrases: role in pH control and cancer. Metabolites 8:19, 2018
   Thiry A, Dogne JM, Supuran C, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 7:855–864, 2007
   Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168–181, 2008
   Tafreshi NK, Lloyd MC, Bui MM, et al. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem 75:221–254, 2014
   Kuo WH, Yang SF, Hsieh YS, et al. Differential expression of carbonic anhydrase isoenzymes in various types of anemia. Clin Chim Acta 351:79–86, 2005
   Barker H, Aaltonen M, Pan P, et al. Role of carbonic anhydrases in skin wound healing. Exp Mol Med 49:e334–e334, 2017
   Shatzman AR, Henkin RI. Gustin concentration changes relative to salivary zinc and taste in humans. Proc Natl Acad Sci USA 78:3867–3871, 1981
   Thatcher BJ, Doherty AE, Orvisky E, et al. Gustin from human parotid saliva is carbonic anhydrase VI. Biochem Biophys Res Commun 250:635–641, 1998
   Becker HM. Carbonic anhydrase IX and acid transport in cancer. Br J Cancer 122:157–167, 2020
   McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3:84– 97, 2012
   McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites 8:20, 2018
   Raghunand N, He X, van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80:1005–1011, 1999
   Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. Biochem Pharmacol 66:1207–1218, 2003
   Ward C, Meehan J, Gray M, et al. Carbonic anhydrase IX, CAIX), cancer, and radiation responsiveness. Metabolites 8:13, 2018
   Ilardi G, Zambrano N, Merolla F, et al. Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr Med Chem 21:1569–1582, 2014
   van Kuijk SJA, Yaromina A, Houben R, et al. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front Oncol 6:69, 2016
   Haapasalo J, Nordfors K, Haapasalo H, Parkkila S. The expression of carbonic anhydrases II, IX and XII in brain tumors. Cancers 12:1723, 2020
   Nordfors K, Haapasalo J, Haapasalo H, Parkkil S. Carbonic anhydrase IX in adult and pediatric brain tumors. In: Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications Ed: Lichtor T. IntechOpen, 2013
   Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. Carbonic anhydrase- 9 expression in head and neck cancer: a meta-analysis. Eur Arch Otorhinolaryngol 268:661–670, 2011
   Eckert AW, Horter S, Bethmann D, et al. Investigation of the prognostic role of carbonic anhydrase 9, CAIX, of the cellular mRNA/protein level or soluble CAIX protein in patients with oral squamous cell carcinoma. Int J Mol Sci 20:375, 2019
   Adams A, van Brussel AS, Vermeulen JF, et al. The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression. BMC Cancer 13:538, 2013
   Chen Z, Ai L, Mboge MY, et al. Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells. PLoS One 13:e0199476, 2018
   Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 102:1627–1635, 2010
   Koh YW, Lee SJ, Han JH, et al. PD-L1 protein expression in non-smallcell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. Lung Cancer 129:41–47, 2019
   Nakamura H, Ichikawa T, Nakasone S, et al. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions. Lung Cancer 115:56–63, 2018
   Mayer A, Schmidt M, Seeger A, et al. GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. BMC Cancer 14:760, 2014
   Zhu Y, Zhou XY, Yao XD, et al. Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study. Urol Oncol Semin Orig Investig 31:706–711, 2013
   Ambrosio MR, Di Serio C, Danza G, et al. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol 11:45, 2016
   Fraga A, Ribeiro R, Coelho A, et al. Genetic polymorphisms in key hypoxia- regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol 17:12, 2017
   Smith AD, Truong M, Bristow R, et al. The utility of serum CA9 for prognostication in prostate cancer. Anticancer Res 36:4489–4492, 2016
   Liao SY, Darcy KM, Randall LM, et al. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 116:452–458, 2010
   Hernandez-Caballero AI, Vierkoetter KR, Ahn HJ, et al. Novel immunohistochemical markers in the differential diagnosis of endocervical and endometrial adenocarcinoma: The added benefit of CAIX and PAX8. Gynecol Oncol Rep 33:100614, 2020
   Choschzick M, Oosterwijk E, Muller V, et al. Overexpression of carbonic anhydrase IX, CAIX, is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459:193–200, 2011
   de Martino M, Lucca I, Mbeutcha A, et al. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. Eur Urol 68:552–554, 2015
   Klatte T, Seligson DB, Rao JY, et al. Carbonic anhydrase IX in bladder cancer: A diagnostic, prognostic, and therapeutic molecular marker. Cancer 115:1448–1458, 2009
   Katsila T, Liontos M, Patrinos GP, et al. The new age of -omics in urothelial cancer – re-wording its diagnosis and treatment. EBioMedicine 28:43–50, 2018
   Kivela AJ. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol 11:155, 2005
   Drenckhan A, Freytag M, Supuran CT, et al. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. J Enzyme Inhib Med Chem 33:1024– 1033, 2018
   Nortunen M, Huhta H, Helminen O, et al. Carbonic anhydrases II, IX, and XII in Barrett’s esophagus and adenocarcinoma. Virchows Arch Int J Pathol 473:567–575, 2018
   Senol S, Aydin A, Kosemetin D, et al. Gastric adenocarcinoma biomarker expression profiles and their prognostic value. J Environ Pathol Toxicol Oncol 35:207–222, 2016
   Yang L, Yang Z, Li D, et al. Overexpression of FZD1 and CAIX are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma. Pathol Oncol Res 24:899–906, 2018
   Strapcova S, Takacova M, Csaderova L, et al. Clinical and pre-clinical evidence of carbonic anhydrase IX in pancreatic cancer and its high expression in pre-cancerous lesions. Cancers 12:2005, 2020
   Viikila P, Kivela AJ, Mustonen H, et al. Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas. World J Gastroenterol 22:8168, 2016
   Deynoux M, Sunter N, Herault O, Mazurier F. Hypoxia and hypoxia-inducible factors in leukemias. Front Oncol 6:41, 2016
   Borsi E, Terragna C, Brioli A, et al. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res 165:641– 650, 2015
   Filippi I, Saltarella I, Aldinucci C, et al. Different adaptive responses to hypoxia in normal and multiple myeloma endothelial cells. Cell Physiol Biochem 46:203–212, 2018
   Matolay O, Mehes G. Sustain, adapt, and overcome—hypoxia associated changes in the progression of lymphatic neoplasia. Front Oncol 9:1277, 2019
   Mehes G. A primer kozponti idegrendszeri limfomak patologiaja. Magy Onkol 61:81–87, 2017
   Mehes G, Matolay O, Beke L, et al. Carbonic anhydrase inhibitor acetazolamide enhances CHOP treatment response and stimulates effector T-cell infiltration in A20/BalbC murine B-cell lymphoma. Int J Mol Sci 21:5001, 2020
   Mehes G, Matolay O, Beke L, et al. Hypoxia-related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin’s lymphoma. Histopathology 74:699–708, 2019
   Matolay O, Beke L, Gyurkovics A, et al. Quantitative analysis of carbonic anhydrase IX uncovers hypoxia-related functional differences in classical Hodgkin lymphoma subtypes. Int J Mol Sci 20:3463, 2019
   Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 8:2, 2017
   Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 12:423–431, 2016
   Williams KJ, Gieling RG. Preclinical evaluation of ureidosulfamate carbonic anhydrase IX/XII inhibitors in the treatment of cancers. Int J Mol Sci 20:6080, 2019
   Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250, RENCAREX®, and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29:121–126, 2011
   Nocentini A, Moi D, Balboni G, et al. Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy. Bioorganic Chem 77:633–639, 2018
   Ibrahim HS, Abou-Seri SM, Tanc M, et al. Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. Eur J Med Chem 103:583–593, 2015
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 157
EP 166
PG 10
ER

PT J
AU Kiss, D
   Lovrics, A
   Szakacs, G
   Furedi, A
   Kovacs, L
   Drexler, D
AF Kiss, Daniel
   Lovrics, Anna
   Szakacs, Gergely
   Furedi, Andras
   Kovacs, Levente
   Drexler, Daniel
TI Mathematical and computational methods to model chemotherapy- induced resistance
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE multidrug resistance; chemotherapy; in silico; precision medicine
ID multidrug resistance; chemotherapy; in silico; precision medicine
AB Chemotherapy plays an important role in the treatment of cancer. While clinical chemotherapy protocols can lead to remission in some patients, in many cases tumor progression occurs despite continued treatment. In the present study we summarize mathematical approaches to model tumor growth and response to treatment, focusing on anticancer therapy resistance. We present results obtained at the recently founded Cybermedical Competence Center at Obuda University, focusing on the development of a new therapy optimization concept that aims to optimize traditional chemotherapy.
C1 [Kiss, Daniel] Obudai Egyetem, Alkalmazott Informatikai es Alkalmazott Matematikai Doktori IskolaBudapest, Hungary.
   [Lovrics, Anna] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Szakacs, Gergely] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Furedi, Andras] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Kovacs, Levente] Obudai Egyetem, Egyetemi Kutato es Innovacios Kozpont, Elettani Szabalyozasok Kutatokozpont, Becsi ut 96/B, 1034 Budapest, Hungary.
   [Drexler, Daniel] Obudai Egyetem, Egyetemi Kutato es Innovacios Kozpont, Elettani Szabalyozasok Kutatokozpont, Becsi ut 96/B, 1034 Budapest, Hungary.
RP Drexler, D (reprint author), Obudai Egyetem, Egyetemi Kutato es Innovacios Kozpont, Elettani Szabalyozasok Kutatokozpont, 1034 Budapest, Hungary.
EM drexler.daniel@nik.uni-obuda.hu
CR Yu HA, Sima C, Feldman D, et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278−284, 2017
   Zhang J, Cunningham JJ, Brown JS, et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun 8:1−9, 2017
   Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nat Rev Cancer 15:730−745, 2015
   Metzcar J, Wang Y, Heiland R, et al. A review of cell-based computational modeling in cancer biology. JCO Clin Cancer Inform 3:1−13, 2019
   Yin A, Moes DJAR, van Hasselt JGC, et al. A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacometrics Syst Pharmacol 8:720−737, 2019
   Lowengrub JS, Frieboes HB, Jin F, et al. Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity 23:1−9, 2010
   Mahlbacher G, Curtis LT Lowengrub J, et al. Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6:10, 2018
   Karsch-Bluman A, Feiglin A, Arbib E, et al. Tissue necrosis and its role in cancer progression. Oncogene 38:1920–1935, 2019
   Dagogo-Jack I, Shaw A. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81–94, 2018
   Smalley I, Kim E, Li J, et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine 48:178−190, 2019
   Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis 9:115, 2018
   Csercsik D, Kovacs L. Dynamic modeling of the angiogenic switch and its inhibition by bevacizumab. Complexity 2019:079104, 2019
   Hahnfeldt P, Panigrahy D, Folkman J, et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59:4770−4775, 1999
   Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic, PK/PD, modelling. Int J Clin Pharmacol Ther 35:401−413, 1997
   Drexler D, Sapi J, Kovacs L. Modeling of tumor growth incorporating the effects of necrosis and the effect of bevacizumab. Complexity 2017:5985031, 2017
   Drexler D, Ferenci T, Lovrics A, et al. Tumor dynamics modeling based on formal reaction kinetics. Acta Polytech Hung 16:31−44, 2019
   Drexler DA, Ferenci T, Furedi A, et al. Experimental data-driven tumor modeling for chemotherapy. In: Proceedings of the 21st International World Congress of the International Federation of Automatic Control, Berlin 2020
   Furedi A, Toth S, Hamori L, et al. Allatmodellek szerepe a multidrogrezisztens tumorokat celzo kemoterapia fejleszteseben. Magy Onkol 59: 338−345, 2015
   Vajda F, Bajtai E, Gombos B, et al. Uj strategiak fejlesztese a gyogyszerrezisztens daganatok kezelesehez. Magy Onkol 65:176−187, 2021
   Furedi A, Szebenyi K, Toth S, et al. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release 261:287−296, 2017
   Poleszczuk J, Macklin P, Enderling H. Agent-based modeling of cancer stem cell driven solid tumor growth. Methods Mol Biol 1516:335−346, 2016
   Antonopoulos M, Dionysiou D, Stamatakos G, et al. Three-dimensional tumor growth in time-varying chemical fields: a modeling framework and theoretical study. BMC Bioinformatics 20:442, 2019
   Waclaw B, Bozic I, Pittman M, et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525:261–264, 2015
   Graner F, Glazier J. Simulation of biological cell sorting using a two-dimensional extended Potts model. Phys Rev Lett 69:2013–2017, 1992
   Szabo A, Merks RMH. Cellular Potts modeling of tumor growth, tumor invasion, and tumor evolution. Front Oncol 3:87, 2013
   Drasdo D, Kree R, McCaskill JS. Monte Carlo approach to tissue-cell populations. Phys Rev E 52:6635, 1995
   Drain AP, Zahir N, Northey JJ, et al. Matrix compliance permits NF- κB activation to drive therapy resistance in breast cancer. J Exp Med 218: e20191360, 2021
   Drasdo D, Hoehme S, Block M. On the role of physics in the growth and pattern formation of multicellular systems: What can we learn from individual- cell based models? J Stat Phys 128:287−345, 2007
   Anderson AR, Rejniak KA, Gerlee P, et al. Microenvironment driven invasion: A multiscale multimodel investigation. J Math Biol 58:579−624, 2009
   Ghaffarizadeh A, Heiland R, Friedman SH, et al. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. PLOS Comput Biol 14:e1005991, 2018
   Kiss D, Lovrics A. Simulating solid tumors with a microenvironment-coupled agent-based computational model. Acta Univ Sapientiae Electr Mech Eng 10:90−101, 2018
   McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategies. J Theor Biol 241:564−589, 2006
   Yoon H, Tang CM, Banerjee S, et al. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene 40:1957–1973, 2021
   Macklin P, Edgerton ME, Thompson AM, et al. Patient-calibrated agentbased modelling of ductal carcinoma in situ, DCIS): From microscopic measurements to macroscopic predictions of clinical progression. J Theor Biol 301:122−140, 2012
   Szabo A, Merks RMH. Blood vessel tortuosity selects against evolution of aggressive tumor cells in confined tissue environments: A modeling approach. PLOS Comput Biol 13:e1005635, 2017
   Leedale J, Herrmann A, Bagnall J, et al. Modeling the dynamics of hypoxia inducible factor-1α, HIF-1α, within single cells and 3D cell culture systems. Math Biosci 258:33−43, 2014
   Chisholm RH, Lorenzi T, Lorz A, et al. Emergence of drug tolerance in cancer cell populations: An evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. Cancer Res 75:930−939, 2015
   Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol 5:e1000557, 2009
   Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol 263:179−188, 2010
   Liu LL, Li F, Pao W, et al. Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients. PLoS One 10:e0141665, 2015
   Chmielecki J, Foo J, Oxnard G, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59, 2011
   Emmink B, Van Houdt WJ, Vries RG, et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 141:269−278, 2011
   Silva AS, Gatenby RA. A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct 5:1−17, 2010
   Enderling H, Anderson ARA, Chaplain MAJ, et al. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res 69:8814−8821, 2009
   Greene JM, Gevertz JL, Sontag ED. Mathematical approach to differentiate spontaneous and induced evolution to drug resistance during cancer treatment. JCO Clin Cancer Inform 3:1−20, 2019
   Akhmetzhanov AR, Kim JW, Sullivan R, et al. Modelling bistable tumour population dynamics to design effective treatment strategies. J Theor Biol 474:88−102, 2019
   Vakil V, Trappe W. Dosage strategies for delaying resistance emergence in heterogeneous tumors. FEBS Open Bio 11:1322−1331, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 167
EP 175
PG 9
ER

PT J
AU Vajda, F
   Bajtai, E
   Gombos, B
   Karai, E
   Hamori, L
   Szakacs, G
   Furedi, A
AF Vajda, Flora
   Bajtai, Eszter
   Gombos, Balazs
   Karai, Edina
   Hamori, Lilla
   Szakacs, Gergely
   Furedi, Andras
TI Development of novel treatment strategies for drug resistant cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neoplasms; drug resistance; tumor microenvironment; drug therapy; animal models
ID neoplasms; drug resistance; tumor microenvironment; drug therapy; animal models
AB There are about 14 million new cancer cases and 8 million deaths every year. Every second man and one in every three women will get cancer during their lifetimes. Following decades of steady increase, death rates have stabilized due to increased awareness and prevention, early detection, and the emergence of more effective therapy. Yet despite all the advances cancer remains a major killer. Despite improved therapies, nearly all current treatments face the same problem: for many patients, they ultimately stop working. Therapy resistance is the ultimate challenge facing cancer researchers and patients today. In this review we present an overview of the most important resistance mechanisms, discussing progress in therapies designed to prevent or overcome anticancer therapy resistance. Finally, we present recent findings from our own laboratory on the development of new experimental models and new therapeutic approaches to combat multidrug resistant cancer.
C1 [Vajda, Flora] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Bajtai, Eszter] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Gombos, Balazs] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Karai, Edina] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Hamori, Lilla] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Szakacs, Gergely] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
   [Furedi, Andras] Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Magyar tudosok korutja 2., 1117 Budapest, Hungary.
RP Furedi, A (reprint author), Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, 1117 Budapest, Hungary.
EM furedi.andras@ttk.hu
CR Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014, ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493−1505, 2019
   Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 205:275−292, 2005
   Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 53:615−627, 2002
   Fiedler EC, Hemann MT. Aiding and abetting: How the tumor microenvironment protects cancer from chemotherapy. Annu Rev Cancer Biol 3:409−428, 2019
   Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19:39−56, 2020
   Noll EM, Eisen C, Stenzinger A, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 22:278−287, 2016
   Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193−204, 2008
   Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib- induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103:14907−14912, 2006
   Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7:2168−2181, 2001
   Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5:1876−1883, 1999
   Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925−6930, 1990
   Eijdems EW, de Haas M, Timmerman AJ, et al. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer 71:40−47, 1995
   Christie EL, Pattnaik S, Beach J, et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun 10:1295, 2019
   Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219−234, 2006
   Furedi A, Toth Sz, Hamori L, et al. Allatmodellek szerepe a multidrogrezisztens tumorokat celzo kemoterapia fejleszteseben. Magy Onkol 59:338−345, 2015
   Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174−1184, 1970
   Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129−137, 2004
   Furedi A, Toth S, Szebenyi K, et al. Identification and validation of compounds selectively killing resistant cancer: delineating cell line-specific effects from P-glycoprotein-induced toxicity. Mol Cancer Ther 16:45−56, 2017
   Cserepes M, Turk D, Toth S, et al. Unshielding multidrug resistant cancer through selective iron depletion of P-glycoprotein-expressing cells. Cancer Res 80:663−674, 2020
   Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116−1120, 2008
   Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535:382−387, 2016
   Wojtaszek JL, Chatterjee N, Najeeb J, et al. A small molecule targeting mutagenic translesion synthesis improves chemotherapy. Cell 178:152−159, 2019
   Veeck J, Ropero S, Setien F, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 28:e563−e564, 2010
   Ter Brugge P, Kristel P, van der Burg E, et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J Natl Cancer Inst 108:djw148, 2016
   Furedi A, Szebenyi K, Toth S, et al. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release 261:287−296, 2017
   Liu X, Holstege H, van der Gulden H, et al. Somatic loss of Brca1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 104:12111−12116, 2007
   Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105:17079−17084, 2008
   Hamori L, Kudlik G, Szebenyi K, et al. Establishment and characterization of a Brca1(-/-), p53(-/-, mouse mammary tumor cell line. Int J Mol Sci 21:1185, 2020
   Lau AN, Heiden MGV. Metabolism in the tumor microenvironment. Annu Rev Cancer Biol 4:17−40, 2020
   Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20:840, 2019
   Luraghi P, Reato G, Cipriano E, et al. MET signaling in colon cancer stemlike cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 74:1857−1869, 2014
   Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18:1359−1368, 2012
   Zhang D, Li L, Jiang H, et al. Tumor-stroma IL1beta-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res 78:1700−1712, 2018
   Louault K, Bonneaud TL, Seveno C, et al. Interactions between cancer- associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene 38:3261−3273, 2019
   Wang Y, Liu J, Ma X, et al. Real-time imaging of senescence in tumors with DNA damage. Sci Rep 9:2102, 2019
   Zhang HR, Wang XD, Yang X, et al. An FGFR inhibitor converts the tumor promoting effect of TGF-beta by the induction of fibroblast-associated genes of hepatoma cells. Oncogene 36:3831−3841, 2017
   Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105−113, 2010
   Chen PH, Lipschitz M, Weirather JL, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5:e134612, 2020
   Durand RE. Intermittent blood flow in solid tumours--an under-appreciated source of ‚drug resistance’. Cancer Metastasis Rev 20:57−61, 2001
   Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37:2317−2328, 2019
   Drain AP, Zahir N, Northey JJ, et al. Matrix compliance permits NF-kappaB activation to drive therapy resistance in breast cancer. J Exp Med 218:e20191360, 2021
   Eikenes L, Tari M, Tufto I, et al. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin, Caelyx, in human osteosarcoma xenografts. Br J Cancer 93:81−88, 2005
   Ramirez M, Rajaram S, Steininger RJ, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 7:10690, 2016
   Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drugtolerant state in cancer cell subpopulations. Cell 141:69−80, 2010
   Vinogradova M, Gehling VS, Gustafson A, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol 12:531−538, 2016
   Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551:247−250, 2017
   Shen S, Faouzi S, Souquere S, et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep 33:108421, 2020
   Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 46:364−370, 2014
   Rothe K, Babaian A, Nakamichi N, et al. Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors. Cell Stem Cell 27:110−124, 2020
   Goldman A, Khiste S, Freinkman E, et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci Signal 12: eaas8779, 2019
   Karai E, Szebenyi K, Windt T, et al. Celecoxib prevents doxorubicin-induced multidrug resistance in canine and mouse lymphoma cell lines. Cancers, Basel, 12:1117, 2020
   Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release 160:117−134, 2012
   Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med 4:e10143, 2019
   Meng J, Guo F, Xu H, et al. Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 6:22390, 2016
   Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 7:834−840, 2011
   Chan MS, Liu LS, Leung HM, et al. Cancer-cell-specific mitochondria- targeted drug delivery by dual-ligand-functionalized nanodiamonds circumvent drug resistance. ACS Appl Mater Interfaces 9:11780−11789, 2017
   Zhu Y, Li J, Li W, et al. The biocompatibility of nanodiamonds and their application in drug delivery systems. Theranostics 2:302−312, 2012
   Ali MK, Liu Q, Liang K, et al. Bacteria-derived minicells for cancer therapy. Cancer Lett 491:11−21, 2020
   MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11:431−445, 2007
   MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27:643−651, 2009
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 176
EP 187
PG 12
ER

PT J
AU Cserepes, M
   Nelhubel, Gy
   Meilinger-Dobra, M
   Surguta, SE
   Raso, E
   Ladanyi, A
   Kenessey, I
   Szoor, �
   Vereb, Gy
   Remenar, �
   Tovari, J
AF Cserepes, Mihaly
   Nelhubel, A. Gyorgyi
   Meilinger-Dobra, Monika
   Surguta, Sara Eszter
   Raso, Erzsebet
   Ladanyi, Andrea
   Kenessey, Istvan
   Szoor, Arpad
   Vereb, Gyorgy
   Remenar, Eva
   Tovari, Jozsef
TI Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE head and neck cancer; EGFR; c-Met; targeted therapy; cetuximab; SU11274; resistance
ID head and neck cancer; EGFR; c-Met; targeted therapy; cetuximab; SU11274; resistance
AB Head and neck squamous cell carcinomas (HNSCC) take many lifes worldwide. Patients with recurrent/metastatic disease receive combination chemotherapy containing anti-EGFR antibody cetuximab. However, resistance often hurdles therapy. The mechanism is yet to unveil, although EGFR extracellular alterations and activity of c-Met signaling were accused. We investigated the effects of EGFR-vIII and EGFR-R521K on cetuximab efficacy in HNSCC in cellular, xenograft, and clinical setup. Furthermore, we investigated the efficacy of c-Met inhibition in HNSCC in vitro and in vivo. We showed that EGFR-vIII is very rare in HNSCC, while the common R521K polymorphism abolishes antibody-dependent cellular cytotoxicity and in vivo antitumor effect of cetuximab. This selectivity was not reflected in immunophenotype or survival data of HNSCC patients, suggesting a more complex mechanism behind. Interestingly, c-Met inhibitor SU11274 was more effective in cetuximab-resistant, EGFR R521K heterozygous cells and xenografts, raising the possible importance of simultaneous targeting of the two receptors.
C1 [Cserepes, Mihaly] National Institute of Oncology, Department of Clinical Research, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Nelhubel, A. Gyorgyi] National Institute of Oncology, Department of Clinical Research, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Meilinger-Dobra, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Surguta, Sara Eszter] National Institute of Oncology, Department of Clinical Research, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Szoor, Arpad] University Medical School of Debrecen, Department of Biophysics and Cell BiologyDebrecen, Hungary.
   [Vereb, Gyorgy] University Medical School of Debrecen, Department of Biophysics and Cell BiologyDebrecen, Hungary.
   [Remenar, Eva] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical Research, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Tovari, J (reprint author), National Institute of Oncology, Department of Clinical Research, 1122 Budapest, Hungary.
EM jtovari@yahoo.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Oosting SF, Haddad RI. Best practice in systemic therapy for head and neck squamous cell carcinoma. Front Oncol 9:815, 2019
   Ho WJ, Mehra R. Pembrolizumab for the treatment of head and neck squamous cell cancer. Expert Opin Biol Ther 19:879–885, 2019
   Nivolumab doubles survival for patients with HNSCC. Cancer Discov 6:OF3, 2016
   Keytruda. European Medicines Agency, 2018. https://www.ema.europa.eu/en/ medicines/human/EPAR/keytruda
   Opdivo. European Medicines Agency, 2018 https://www.ema.europa.eu/en/ medicines/human/EPAR/opdivo
   Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127, 2008
   Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. New Engl J Med 357:1695–1704, 2007
   Specenier PM, Remenar E, Buter J, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol 28:2219– 2224, 2017
   Alsahafi E, Begg K, Amelio I, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10:1–17, 2019
   Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417, 2009
   Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther 18:483–493, 2018
   Wiechec E, Hansson KT, Alexandersson L, et al. Hypoxia mediates differential response to anti-EGFR therapy in HNSCC cells. Int J Mol Sci 18:943, 2017
   Rebucci M, Peixoto P, Dewitte A, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 38:189–200, 2011
   Swick AD, Prabakaran PJ, Miller MC, et al. Cotargeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC. Mol Cancer Ther 16:1257–1268, 2017
   Trivedi S, Concha-Benavente F, Srivastava RM, et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol 26:40–47, 2015
   Bagchi A, Haidar JN, Eastman SW, et al. Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance. Mol Cancer Ther 17:521–531, 2018
   Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor, EGFRvIII, contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073, 2006
   Su NW, Leu YS, Lee JC, et al. EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. Onco Targets Ther 7:2197–2204, 2014
   Braig F, Kriegs M, Voigtlaender M, et al. Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. Cancer Res 77:1188– 1199, 2017
   Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E. Polymorphisms of the epidermal growth factor receptor, EGFR, and survival in patients with advanced cancer of the head and neck, HNSCC). Anticancer Res 32:421–425, 2012
   Klinghammer K, Knodler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 16:304–310, 2010
   Cortesina G, Martone T, Galeazzi E, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 89:286–292, 2000
   Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031, 2009
   Ladanyi A, Kapuvari B, Papp E, et al. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. Head Neck 41:1237–1245, 2019
   Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor, EGFRvIII, contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073, 2006
   Melchers LJ, Clausen MJAM, Mastik MF, et al. Head and neck squamous cell carcinomas do not express EGFRvIII. Int J Radiat Oncol Biol Phys 90:454–462, 2014
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2021
VL 65
IS 2
BP 188
EP 195
PG 8
ER

PT J
AU Timar, J
AF Timar, Jozsef
TI Molecular classification of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic cancer; KRAS; molecular classification
ID pancreatic cancer; KRAS; molecular classification
AB Pancreatic cancer is a malignancy with outstandingly poor prognosis caused by several factors among which one is that it is predominated by mutant KRAS oncogene. Genomic studies revealed that clinically useful therapy targets are present only in the DNA repair deficient subgroup and in the minor wild type KRAS-carrying group. However, phylogenetic studies defined four molecular subgroups of pancreatic cancer among which the immunogenic progenitor form could well be the target of immunotherapies. Furthermore, this group may well be the one characterized by DNA repair deficiency and high tumor mutational burden. Furthermore, the majority of familiar pancreatic cancers could also be found in this latter subgroup. Unfortunately, the G12C mutation of KRAS in pancreatic cancer is rare, therefore pancreatic cancer patients could not benefit from the recent revolution of KRAS target therapies.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutation in human cancer. Cancer Metastasis Rev 39:1029–1038, 2020
   Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–500, 2015
   Mas J, Lupinacci RM, Cros J, et al. Intraductal papillary mucinous carcinoma versus conventional ductal adenocarcinoma. Int J Mol Sci 22:6756, 2021
   Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16:207–218, 2019
   Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156:2242–2253, 2019
   Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut 70:148–156, 2021
   Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase-II KEYNOTE-158 study. J Clin Oncol 38:1–10, 2020
   Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res 27:1236–1241, 2021
   Bailey P, Chnag DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52, 2016
   Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet 52:231–240, 2020
   Liu Y, Zhu D, Xing H, et al. A 6-gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients. Oncol Rep 41:1521–1530, 2019
   Petersen GM. Familiar pancreatic cancer. Semin Oncol 43:548–553, 2016
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 201
EP 205
PG 5
ER

PT J
AU Borka, K
AF Borka, Katalin
TI Pathology of pancreatic tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic cancers; histomorphological variants; pancreatic ductal adenocarcinoma; precursor lesions
ID pancreatic cancers; histomorphological variants; pancreatic ductal adenocarcinoma; precursor lesions
AB Pancreatic cancer in the narrower sense is defined as pancreatic ductal adenocarcinoma (PDAC), which accounts for 95% of malignancies of the pancreas. The tumor has a very poor prognosis, one of the reasons being that it is often only recognized at an advanced, already metastatic stage. Another reason is that although oncotherapy has developed rapidly in recent decades, there has been no significant improvement in the treatment of these tumors. Based on Hungarian and international analyses, we can expect an increase in the number of patients in the coming decades, so research in any field of medicine is of paramount importance for early diagnosis and the development of more effective treatment strategies. However, it is important to know the other benign and malignant exocrine and neuroendocrine tumors, the precursor lesions, as the basic condition for proper treatment is an accurate pathological diagnosis. The summary presents the pathological diversity of tumors, detailing their macroscopic, microscopic, and immunohistochemical characteristics.
C1 [Borka, Katalin] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Borka, K (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM borka.katalin@med.semmelweis-univ.hu
CR Hackeng WM, Hruban RH, Offerhaus GJA, et al. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol 11:472, 2016
   Menyhart O, Fekete JT, Gyorffy B. Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030. Clin Epidemiol 10:1093−1108, 2018
   Gill AJ, Klimstra DS, Lam AK, Washington MK. Digestive System Tumours. International Agency for Research on Cancer. WHO Classification of Tumours series, 5th ed., vol. 1. Lyon 2019
   Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol 4:50, 2019
   Munding J, Luttges J, Esposito I, Tannapfel A. [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?] Pathologe 35:509−518, 2014
   Verbeke C, Haberle L, Lenggenhager D, Esposito I. Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Pancreatology 18:467−476, 2018
   WHO Classification of Tumours of Endocrine Organs, WHO/IARC Classification of Tumours, 4th Edition, Ed. Lloyd RV, Osamura RY, Kloppel G, Rosai J, vol. 10, WHO Press 2017
   Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer, IARC, and World Health Organization, WHO, expert consensus proposal. Mod Pathol 31:1770–1786, 2018
   Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173−184, 2012
   Panzuto F, Cicchese N, Partelli S, et al. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS One 12:e0179445, 2017
   UICC TNM classification of Malignant Tumors, 8th Edition, Ed. Brierley J, Gospodarowicz M, Wittekind C, Wiley Blackwell, 2016
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 206
EP 213
PG 8
ER

PT J
AU Strausz, T
AF Strausz, Tamas
TI Pathology of pancreatic ductal adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic ductal adenocarcinoma; intraductal papillary mucinous neoplasm; mucinous cystic neoplasm
ID pancreatic ductal adenocarcinoma; intraductal papillary mucinous neoplasm; mucinous cystic neoplasm
AB Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. At the time of diagnosis, the cancer is usually at an advanced stage and only a minority of the cases are eligible for surgical resection. To improve prognosis, it is crucial to diagnose and treat the disease at an early stage. This article reviews the cytopathology and histopathology of PDAC and its precursors. The three main aspects of PDAC pathology are the primary confirmation of cancer, the macroscopic and microscopic evaluation of pancreatic resection specimens and molecular testing. It is beneficial to run the diagnostics and to treat the patients at specialized pancreatic cancer centers, where every member of the team is confronted with many cases.
C1 [Strausz, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7−9.Budapest, 1122, Hungary.
RP Strausz, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
EM drstrausz@gmail.com
CR Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 68:7−302, 2018
   Zhang S, Defrias DV, Alasadi R, Nayar R. Endoscopic ultrasound-guided fine needle aspiration, EUS-FNA): experience of an academic centre in the USA. Cytopathology 21:35−43, 2010
   Lin F, Staerkel G. Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer 99:44−50, 2003
   Pitman MB, Centeno BA, Ali SZ, et al. Standardized terminology and nomenclature for pancreatobiliary cytology: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol 42:338−350, 2014
   Peixoto RD, Speers C, McGahan CE, et al. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med 4:1171−1177, 2015
   Verbeke CS, Gladhaug IP. Dissection of pancreatic resection specimens. Surg Pathol Clin 9:523−538, 2016
   Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 93:1232−1237, 2006
   Kim KS, Kwon J, Kim K, et al. Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat 49:824−833, 2017
   Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15:165−174, 2008
   Schlitter AM, Segler A, Steiger K, et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas, PDACs): Identification of prognostic subtypes. Sci Rep 7:41064, 2017
   Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System, WHO/IARC Classification of Tumours. 4th edition. IARC Press, Lyon 2019, pp. 307−332
   Hruban RH, Klimstra DS. Adenocarcinoma of the pancreas. Semin Diagn Pathol 31:443−451, 2014
   Klimstra DS, Adsay NV. Tumors of the pancreas. In: Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 3rd edition, ed. Odze RD, Goldblum JR. Saunders, Philadelphia 2015, pp. 1081−1119
   Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 156:37−43, 2000
   Haeberle L, Kapp AC, Esposito I, et al. Morphologic characterization of pancreatic ductal adenocarcinoma after neoadjuvant therapy. Pancreatology 17:S20, 2017
   Nagaria TS, Wang H, Chatterjee D, Wang H. Pathology of treated pancreatic ductal adenocarcinoma and its clinical implications. Arch Pathol Lab Med 144:838−845, 2020
   Komatsu H, Egawa S, Motoi F, et al. Clinicopathological features and surgical outcomes of adenosquamous carcinoma of the pancreas: a retrospective analysis of patients with resectable stage tumors. Surg Today 45:297−304, 2015
   Clark CJ, Graham RP, Arun JS, et al. Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg 215:627−634, 2012
   Agaimy A, Haller F, Frohnauer J, et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod Pathol 28:248−260, 2015
   Muraki T, Reid MD, Basturk O, et al. Undifferentiated carcinoma with osteoclastic giant cells of the pancreas: clinicopathologic analysis of 38 cases highlights a more protracted clinical course than currently appreciated. Am J Surg Pathol 40:1203−1216, 2016
   Tan MC, Basturk O, Brannon AR, et al. GNAS and KRAS mutations define separate progression pathways in intraductal papillary mucinous neoplasm- associated carcinoma. J Am Coll Surg 220:845−854, 2015
   Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 156:1641−1651, 2000
   Theisen BK, DiCianno R, Singhi AD. Pancreatic frozen section nightmares. Diagn Histopathol 22:236−242, 2016
   Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th edition. Wiley-Blackwell, 2016
   Schlitter AM, Jesinghaus M, Jager C. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Eur J Cancer 84:121−129, 2017
   Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 16:996−1006, 2003
   Basturk O, Chung SM, Hruban RH, et al. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch 469:523−532, 2016
   Noe M, Brosens LA. Pathology of pancreatic cancer precursor lesions. Surg Pathol Clin 9:561−580, 2016
   Yamada S, Fujii T, Shimoyama Y, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol 21:2444−2452, 2014
   Hirono S, Kawai M, Okada K, et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery 160:306−317, 2016
   Jang KT, Park SM, Basturk O, et al. Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis. Am J Surg Pathol 39:179−187, 2015
   Rooney SL, Shi J. Intraductal tubulopapillary neoplasm of the pancreas: an update from a pathologist’s perspective. Arch Pathol Lab Med 140:1068−1073, 2016
   Kloppel G, Basturk O, Schlitter AM, et al. Intraductal neoplasms of the pancreas. Semin Diagn Pathol 31:452−466, 2014
   Pitman MB, Centeno BA, Daglilar ES. Cytological criteria of high-grade epithelial atypia in the cyst fluid of pancreatic intraductal papillary mucinous neoplasms. Cancer Cytopathol 122:40−47, 2014
   Pitman MB, Centeno BA, Genevay M, et al. Grading epithelial atypia in endoscopic ultrasound-guided fine-needle aspiration of intraductal papillary mucinous neoplasms: an international interobserver concordance study. Cancer Cytopathol 121:729−736, 2013
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 214
EP 221
PG 8
ER

PT J
AU Nemeth, K
   Budai, A
AF Nemeth, Kristof
   Budai, Andras
TI All you should know about intraductal papillary mucinous neoplasm (IPMN)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic intraductal neoplasms; precancerous conditions; pancreatic cancer; IPMN
ID pancreatic intraductal neoplasms; precancerous conditions; pancreatic cancer; IPMN
AB In an increasingly aging Western society, the treatment of the malignant diseases became the greatest challenge of medicine in the 21st century. Among these, pancreatic ductal adenocarcinoma (PDAC) is of particular interest which, in spite of modern oncology treatments, is a malignancy with an unfavorable prognosis. Underlying the poor survival rates, relatively late-stage recognition, limitations of surgical removal, and ineffective oncological treatments can be mentioned. Its importance is further enhanced by its growing incidence. As a consequence of these reasons, there is an increasing effort for the early detection of invasive tumors, the central part of which is the detection and clinical addressing of precancerous conditions in the pancreas. Of these, intraductal papillary mucinous neoplasia (IPMN) has a paramount importance. In this review, we present the latest evidence-based knowledge of the etiological factors, epidemiological features, pathomorphological manifestations, most up-to-date diagnosis and treatment of IPMN.
C1 [Nemeth, Kristof] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Budai, Andras] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Budai, A (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM budai.andras@med.semmelweis-univ.hu
CR Buscail E, Cauvin T, Fernandez B, et al. Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process. BMC Surg 19:115, 2019
   Dominguez-Comesana E, Gonzalez-Rodriguez FJ, Ulla-Rocha JL, et al. Morbidity and mortality in pancreatic resection. Cirugia Espanola, English Edition, 91:651–658, 2013
   Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. World J Gastrointest Surg 2:314–318, 2010
   Del Chiaro M, Haas SL, Schulick RD, ed., Cystic Tumors of the Pancreas: Diagnosis and Treatment. Springer, 2016
   Del Chiaro M, Ateeb Z, Hansson MR, et al. Survival analysis and risk for progression of intraductal papillary mucinous neoplasia of the pancreas, IPMN, under surveillance: a single-institution experience. Ann Surg Oncol 24:1120–1126, 2017
   Reid-Lombardo KM, St Sauver J, Li Z, et al. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984−2005: a population study. Pancreas 37:139–144, 2008
   Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee, American Gastroenterology Association, American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148:819–22, 2015
   Chang YR, Park JK, Jang J-Y, et al. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: Largescale, single-center cohort study. Medicine 95:e5535, 2016
   Cancer today. https://gco.iarc.fr/today
   Capurso G, Boccia S, Salvia R, et al. Risk factors for intraductal papillary mucinous neoplasm, IPMN, of the pancreas: a multicentre case-control study. Am J Gastroenterol 108:1003–1009, 2013
   Raimondi S, Lowenfels AB, Morselli-Labate AM, et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24:349–358, 2010
   Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083, 2005
   Kamata K, Takenaka M, Nakai A, et al. Association between the risk factors for pancreatic ductal adenocarcinoma and those for malignant intraductal papillary mucinous neoplasm. Oncology 93(Suppl 1):102–106, 2017
   Rezaee N, Khalifian S, Cameron JL, et al. Smoking is not associated with severe dysplasia or invasive carcinoma in resected intraductal papillary mucinous neoplasms. J Gastrointest Surg 19:656–665, 2015
   Carr RA, Roch AM, Shaffer K, et al. Smoking and IPMN malignant progression. Am J Surg 213:494–497, 2017
   Maire F, Hammel P, Terris B, et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 51:446–449, 2002
   Sparr JA, Bandipalliam P, Redston MS, Syngal S. Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol 33:309–312, 2009
   Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3:92ra66, 2011
   Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol 6:58, 2017
   Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 159:2017–2022, 2001
   Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239:678–685, 2004
   Ngamruengphong S, Lennon AM. Analysis of pancreatic cyst fluid. Surg Pathol Clin 9:677–684, 2016
   Singhi AD, Nikiforova MN, Fasanella KE, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res 20:4381–4389, 2014
   Navez J, Hubert C, Gigot JF, et al. Impact of intraoperative pancreatoscopy with intraductal biopsies on surgical management of intraductal papillary mucinous neoplasm of the pancreas. J Am Coll Surg 221:982–987, 2015
   Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17:738–753, 2017
   Wang W, Zhang L, Chen L, et al. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Biomed Rep 3:43–50, 2015
   The European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67:789–804, 2018
   Crippa S, Pergolini I, Rubini C, et al. Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. Surgery 159:1041–1049, 2016
   Baiocchi GL, Portolani N, Missale G, et al. Intraductal papillary mucinous neoplasm of the pancreas, IPMN): clinico-pathological correlations and surgical indications. World J Surg Oncol 8:25, 2010
   Hipp J, Mohamed S, Pott J, et al. Management and outcomes of intraductal papillary mucinous neoplasms. BJS Open 3:490–499, 2019
   Suzuki S, Kajiyama H, Takemura A, et al. The clinical outcomes after total pancreatectomy. Dig Surg 34:142–150, 2017
   Lee SY, Allen PJ, Sadot E, et al. Distal pancreatectomy: a single institution’s experience in open, laparoscopic, and robotic approaches. J Am Coll Surg 220:18–27, 2015
   Chen K, Pan Y, Huang CJ, et al. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy. BMC Cancer 21:382, 2021
   Falconi M, Mantovani W, Crippa S, et al. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 95:85–91, 2008
   Sauvanet A, Gaujoux S, Blanc B, et al. Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 260:364–371, 2014
   Mizuta Y, Akazawa Y, Shiozawa K, et al. Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 5:470–474, 2005
   Gan SI, Thompson CC, Lauwers GY, et al. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc 61:746–752, 2005
   Oh HC, Seo DW, Lee TY, et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc 67:636–642, 2008
   Oh HC, Seo DW, Song TJ, et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology 140:172–179, 2011
   DeWitt JM, Al-Haddad M, Sherman S, et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy 46:457–464, 2014
   Sawai Y, Yamao K, Bhatia V, et al. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy 42:1077–1084, 2010
   Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 76:839–844, 2010
   Alexander BM, Fernandez-Del Castillo C, Ryan DP, et al. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res 4:116–121, 2011
   Castellano-Megias VM, Andres CI, Lopez-Alonso G, Colina-Ruizdelgado F. Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas. World J Gastrointest Oncol 6:311–324, 2014
   Kloppel G. Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepatogastroenterology 45:1981–1985, 1998
   Carroll NZ, Reyes B, Vazquez L. Intraductal papillary mucinous neoplasms of the pancreas: challenges and new insights. In: Challenges in Pancreatic Pathology, 71, 2017
   Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 24:1372–1377, 2000
   Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branchduct intraductal papillary mucinous neoplasms. Gastroenterology 158:226– 237, 2020
   Okabayashi T, Shima Y, Kosaki T, et al. Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN. Oncol Lett 5:1819–1825, 2013
   Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 262:875–880, 2015
   Roch AM, Ceppa EP, Al-Haddad MA, et al. The natural history of main duct–involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Ann Surg 260:680, 2014
   Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60:509–516, 2011
   WHO Classification of Tumours Editorial, Digestive System Tumours: WHO Classification of Tumours. World Health Organization, 2019
   Corfield AP. Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 1850:236–252, 2015
   Birchenough GMH, Johansson MEV, Gustafsson JK, et al. New developments in goblet cell mucus secretion and function. Mucosal Immunol 8:712– 719, 2015
   Nagtegaal ID, Odze RD, Klimstra D, et al. WHO Classification of Tumours Editorial Board, The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188, 2020
   Ban S, Naitoh Y, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasm, IPMN, of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol 30:1561–1569, 2006
   Xiao SY. Intraductal papillary mucinous neoplasm of the pancreas: an update. Scientifica 2012:893632, 2012
   Nasca V, Chiaravalli M, Piro G, et al. Intraductal pancreatic mucinous neoplasms: a tumor-biology based approach for risk stratification. Int J Mol Sci 21:6286, 2020
   Mohri D, Asaoka Y, Ijichi H, et al. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol 47:203–213, 2012
   Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60:1712–1720, 2011
   Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447:794–799, 2005
   Shimizu T, Akita M, Sofue K, et al. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features. Hum Pathol 91:26–35, 2019
   Potjer TP, Schot I, Langer P, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 19:442–449, 2013
   Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 96:507–509, 2007
   Wolpin BM, Chan AT, Hartge P, Chanock SJ, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 101:424–431, 2009
   Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium, Panc4). Ann Oncol 23:1880–1888, 2012
   American Institute for Cancer Research-World Cancer Research Fund, Diet, nutrition, physical activity and pancreatic cancer. https://www.wcrf.org/ sites/default/files/Pancreatic-cancer-report.pdf., 2018
   Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol 27:299–322, 2013
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 223
EP 230
PG 8
ER

PT J
AU Kepes, Z
   Garai, I
   Borbely, K
AF Kepes, Zita
   Garai, Ildiko
   Borbely, Katalin
TI Nuclear medicine techniques in the diagnosis of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic tumors; SPECT; PET based hybrid imaging techniques
ID pancreatic tumors; SPECT; PET based hybrid imaging techniques
AB The prognosis of pancreatic cancer is closely related to the histological origin of the tumors and the stage of the disease. As recognition is advanced in most cases, treatment options are limited. The development of nuclear medicine hybrid techniques (SPECT/CT, PET/CT, PET/MRI) and new therapies plays an important role in the recognition and treatment of pancreatic tumors. These measurements are useful in characterizing biological behavior, based on which tumors can be recognized at an early stage, promote the treatment, the selection of optimal therapies (e.g., targeted therapies). The authors discuss the role of nuclear medicine techniques in the management of patients suffering from pancreatic tumors.
C1 [Kepes, Zita] Orvosi Kepalkoto Klinika, Nuklearis Medicina TanszekBudapest, Hungary.
   [Garai, Ildiko] Orvosi Kepalkoto Klinika, Nuklearis Medicina TanszekBudapest, Hungary.
   [Borbely, Katalin] National Institute of Oncology, PET/CT Outpatient Department, Rath Gyorgy 7–9., 1122 Budapest, Hungary.
RP Borbely, K (reprint author), National Institute of Oncology, PET/CT Outpatient Department, 1122 Budapest, Hungary.
EM katalin.borbely@oncol.hu
CR Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–594, 2004
   Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342, 2017
   Chi W, Warner RRP, Chan DL, et al. Long-term outcomes of gastroenteropancreatic neuroendocrine tumors. Pancreas 47:321–325, 2018
   Duan H, Baratto L, Iagaru A. The role of PET/CT in the imaging of pancreatic neoplasms. Semin Ultrasound CT MR 40:500–508, 2019
   Dromain C, Deandreis D, Scoazec JY, et al. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging 97:1241–1257, 2016
   Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch 440:461–475, 2002
   Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80:51–56, 2004
   Scott AT, Howe JR. Evaluation and management of neuroendocrine tumors of the pancreas. Surg Clin North Am 99:793–814, 2019
   Oksuz MO, Winter L, Pfannenberg C, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interv Imaging 95:289–300, 2014
   Chiti A, Fanti S, Savelli G, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med Mol Imaging 25:1396–1403, 1998
   Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228:228–238, 1998
   Farchione A, Rufini V, Brizi MG, et al. Evaluation of the added value of diffusion- weighted imaging to conventional magnetic resonance imaging in pancreatic neuroendocrine tumors and comparison with 68Ga-DOTANOC positron emission tomography/computed tomography. Pancreas 45:345–354, 2016
   Johnbeck CB, Knigge U, Loft A, et al. Head-to-head comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58:451–457, 2017
   Berzaczy D, Giraudo C, Haug AR, et al. Whole-body 68Ga-DOTANOC PET/ MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors. Clin Nucl Med 42:669–674, 2017
   Abgral R, Leboulleux S, Deandreis D, et al. Performance of 18fluorodeoxyglucose- positron emission tomography and somatostatin receptor scintigraphy for high Ki67, ≥10%, well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96:665–671, 2011
   Naswa N, Sharma P, Gupta SK, et al. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clin Nucl Med 39:27–34, 2014
   Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93S, 2001
   Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923–929, 2006
   Warburg O. On the origin of cancer cells. Science 123:309–314, 1956
   Wang XY, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 20:15580–15589, 2014
   Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235–243, 2005
   Strobel O, Buchler MW. FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol 10:203–205, 2013
   Zimny M, Bares R, Faß J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24:678–682, 1997
   Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150S, 2009
   Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol 77:1420–1425, 2010
   Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7:953–960, 2003
   Topkan E, Parlak C, Kotek A, et al. Predictive value of metabolic 18FDGPET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 11:1–9, 2011
   Sperti C, Pasquali C, Bissoli S, et al. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 14:131–140, 2010
   Daamen LA, Groot VP, Goense L, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol 106:128–136, 2018
   Serrano OK, Chaudhry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv Surg 44:313–325, 2010
   Borbely K, Bakos M, Patko ZsP. Endokrin onkologia es nuklearis medicina. Magy Radiol 94:43–55, 2020
   Tessonnier L, Sebag F, Ghander C, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 95:303–307, 2010
   Ribeiro MJ, Boddaert N, Delzescaux T, et al. Functional imaging of the pancreas: the role of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Dev Pancreas Neonatal Diabetes 12:55–66, 2007
   Rufini V, Baum RP, Castaldi P, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37:1004–1020, 2012
   Ahlstrom H, Eriksson B, Bergstrom M, et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195:333–337, 1995
   Minn H, Kauhanen S, Seppanen M, et al. 18F-FDOPA: a multiple-target molecule. J Nucl Med 50:1915–1918, 2009
   Jager PL, Chirakal R, Marriott CJ, et al. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 49:573–586, 2008
   Herrmann K, Eckel F, Schmidt S, et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med 49:1437–1444, 2008
   Cheng MF, Huang YY, Ho BY, et al. Prospective comparison of, 4S)-4-, 3-18F-fluoropropyl)-l-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-ofconcept study. Eur J Nucl Med Mol Imaging 46:810–820, 2019
   Baek S, Choi CM, Ahn SH, et al. Exploratory clinical trial of, 4S)-4-, 3-[18F]fluoropropyl)-l-glutamate forimaging xC−transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 18:5427–5437, 2012
   Rohrich M, Naumann P, Giesel FL, et al. Impact of 68 Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med 62:779–786, 2021
   Kryza T, Khan T, Puttick S, et al. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics 10:4116–4133, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 231
EP 235
PG 5
ER

PT J
AU Jederan, �
AF Jederan, Eva
TI Importance of conventional pancreas imaging: ultrasound, CT, and MRI. Facts and possibilities
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic tumor; abdominal and contrast ultrasound; CT and MR diagnostics; artificial intelligence
ID pancreatic tumor; abdominal and contrast ultrasound; CT and MR diagnostics; artificial intelligence
AB Modern imaging procedures, including CT and MR diagnostics, play a significant role in recognizing, characterizing, determining the extent of pancreatic tumor lesions, assessing their operability, and evaluating response to treatment and patient follow-up. This article reviews the conventional imaging modalities used in the modern diagnosis of pancreatic tumors, conventional and contrast-enhanced abdominal ultrasound, standard protocols using the latest research results from CT and MRI scans, and their location and diagnostic value in the treatment of solid and cystic neoplasia. In addition, it briefly discusses the additional possibilities of artificial intelligence-based processing of digital imaging data, which is under strong development and is expected to be incorporated into clinical practice in the future.
C1 [Jederan, Eva] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Jederan, � (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM eva.jederan@gmail.com
CR Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 3:209–249, 2021
   Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors affiliations expand. Review World J Oncol 1:10–27, 2019
   NCCN Guidelines for Pancreatic Adenocarcinoma V.2.2021
   Babiker HM, Hoilat GJ, Recio-Boiles A. Mucinous Cystic Pancreatic Neoplasms. StatPearls Publishing, Treasure Island, FL), 2017
   Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg. 5:651–657, 2004
   Stamatakos M, Sargedi C, Angelousi A, et al. Management of the rare entity of primary pancreatic cystic neoplasms. Review J Gastroenterol Hepatol 7:1203–1210, 2009
   Postlewait LM, Ethun CG, McInnis MR, et al. Association of preoperative risk factors with malignancy in pancreatic mucinous cystic neoplasms: a multicenter study. JAMA Surg 1:19–25, 2017
   Murphy KM, Hughes LS, Conway P. A path to sustain rural hospitals. JAMA 12:1193–1194, 2018
   Rhee H, Park MS. The role of imaging in current treatment strategies for pancreatic adenocarcinoma. Korean J Radiol 1:23–40, 2021
   Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-theart review. Review World J Gastroenterol 24:7864–7877, 2014
   Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. Review World J Gastroenterol 19:2047–2060, 2018
   Morana G, Fusaro M, Dorigo A. Imaging of the pancreas: state of the art. Cancer Imaging 15:O5, 2015
   Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Suppl 5:v56–68, 2015
   Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 4:438–445, 2005
   Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 1:87–96, 2010
   Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 1:248–260, 2014
   Loizou L, Albiin N, Leidner B, et al. Multidetector CT of pancreatic ductal adenocarcinoma: Effect of tube voltage and iodine load on tumour conspicuity and image quality. Randomized Controlled Trial Eur Radiol 11:4021–4029, 2016
   Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 1:32–61, 2010
   Lin XZ, Wu ZY, Tao R, et al. Dual energy spectral CT imaging of insulinoma – Value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol 10:2487–2494, 2012
   Svensson A, Thor D, Fischer MA, et al. Dual source abdominal computed tomography: the effect of reduced X-ray tube voltage and intravenous contrast media dosage in patients with reduced renal function. Acta Radiol 3:293–300, 2019
   Matos C, Bali MA, Delhaye M, Deviere J. Magnetic resonance imaging in the detection of pancreatitis and pancreatic neoplasms. Best Pract Res Clin Gastroenterol 1:157–178, 2006
   Patel BN. Routine MR imaging for pancreas. Magn Reson Imaging Clin N Am 3:315–322, 2018
   De Robertis R, Tinazzi Martini P, Demozzi E, et al. Diffusion-weighted imaging of pancreatic cancer. World J Radiol 10:319–328, 2015
   Niu X, Das SK, Bhetuwal A, et al. Value of diffusion-weighted imaging in distinguishing pancreatic carcinoma from mass-forming chronic pancreatitis: a meta-analysis. Chin Med J, Engl, 19:3477–3482, 2014
   Barral M, Taouli B, Guiu B, et al. Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology 1:45–63, 2015
   Islim F, Salik AE, Bayramoglu S, et al. Non-invasive detection of infection in acute pancreatic and acute necrotic collections with diffusion-weighted magnetic resonance imaging: preliminary findings. Abdom Imaging 3:472– 481, 2014
   Jang KM, Kim SH, Min JH, et al. Value of diffusion-weighted MRI for differentiating malignant from benign intraductal papillary mucinous neoplasms of the pancreas. AJR Am J Roentgenol 5:992–1000, 2014
   Park MJ, Hong N, Han K, et al. Use of imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging. Radiology 2F:423–431, 2017
   Jeon SK, Lee JM, Joo I, et al. Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT. Eur Radiol 8:3484–3493, 2018
   Kim HW, Lee JC, Paik KH, et al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery 6:1579–1587, 2017
   Godeny M. Modern kepalkotok szerepe a daganatok diagnosztikajaban. HTSZ 1:10–12, 1996
   Borbely K, Garai I, Baranyai T, Patko PZ. PET-alapu meresek az onkologiaban: PET/CT es PET/MR alkalmazasok. Magy Onkol 2:87–96, 2020
   Elbanna KY, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging 1:58, 2020
   Haj-Mirzaian A, Kawamoto S, Zaheer A, et al. Pitfalls in the MDCT of pancreatic cancer: strategies for minimizing errors. Abdom Radiol 45:457–478, 2020
   Tamada T, Ito K, Kanomata N, et al. Pancreatic adenocarcinomas without secondary signs on multiphasic multidetector CT: association with clinical and histopathologic features. Eur Radiol 3:646–655, 2016
   Kim JH, Lee JM, Yoon JH, et al. Portal vein thrombosis in patients with hepatocellular carcinoma: diagnostic accuracy of gadoxetic acid-enhanced MR imaging. Radiology 3:773–783, 2016
   Wu LM, Xu JR, Hua J, et al. Value of diffusion-weighted imaging for the discrimination of pancreatic lesions: a meta-analysis. Eur J Gastroenterol Hepatol 2:134–142, 2012
   Treadwell JR, Zafar HM, Mitchell MD, et al. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma: a meta-analysis. Pancreas 6:789–795, 2016
   Prokesch RW, Chow LC, Beaulieu CF, et al. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 3:764–768, 2002
   Toft J, Hadden WJ, Laurence JM, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 92:17–23, 2017
   Amin MB, Edge S, et al., Eds.). AJCC Cancer Staging Manual, 8th edition). Springer International Publishing: American Joint Commission on Cancer, 2017
   Rozenblum L, Mokrane FZ, Yeh R, et al. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. Abdom Radiol, NY, 7:2474–2493, 2019
   European Study Group on Cystic Tumours of the Pancreas. European evidence- based guidelines on pancreatic cystic neoplasms. Gut 5:789–804, 2018
   Saleh M, Bhosale PR, Yano M, et al. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol, NY, 2020, DOI  10.1007/s00261-020-02833-8
   Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 7:863– 881, 2020
   Tamm EP, Bhosale P, Lee JH, et al. State-of-the-art imaging of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2:375–400, 2016
   Kim JH, Eun HW, Kim YJ, et al. Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade. Abdom Imaging 5:1106–1114, 2013
   De Robertis R, Cingarlini S, Tinazzi Martini P, et al. Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. World J Gastroenterol 2:275–285, 2017
   Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club, European Study Group on Cystic Tumors of the Pancreas). Gut 2:305–312, 2016
   Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Ann Surg 1:72-81, 2014
   Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 5:738–753, 2017
   Yoon JG, Smith D, Ojili V, et al. Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management. Abdom Radiol, NY, 46:3946–3962, 2021
   Megibow AJ, Baker ME, Morgan DE, et al. Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol 7:911–923, 2017
   Machicado JD, Koay EJ, Krishna SG. Radiomics for the diagnosis and differentiation of pancreatic cystic lesions. Diagnostics, Basel, 7:505, 2020
   Bartoli M, Barat M, Dohan A, et al. CT and MRI of pancreatic tumors: an update in the era of radiomics. Jpn J Radiol 12:1111–1124, 2020
   Okusaka T, Nakamura M, Yoshida M, et al. Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 3:326–335, 2020
   Tirkes T, Shah ZK, Takahashi N, et al. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Reporting standards for chronic pancreatitis by using CT, MRI, and MR cholangiopancreatography: The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Radiology 1:207–215, 2019
   Yeh R, Steinman J, Luk L, et al. Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging 42:203–217, 2017
   Hewitt MJ, McPhail MJ, Possamai L, et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc 2:319–331, 2012
   Cassinotto C, Cortade J, Belleannee G, et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 4:589–593, 2013
   Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 7:3104–3116, 2017
   Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 1:12–17, 2015
   Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 23:5749–5756, 2012
   Kim YE, Park MS, Hong HS, et al. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Radiology 3:758–765, 2009
   Morgan DE, Waggoner CN, Canon CL, et al. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR Am J Roentgenol 3:615– 622, 2010
   Tamm EP, Loyer EM, Faria S, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 5:568–574, 2006
   Cassinotto C, Cortade J, Belleannee G, et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 4:589–593, 2013
   Cassinotto C, Mouries A, Lafourcade JP, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 1:108–116, 2014
   Noda Y, Goshima S, Miyoshi T, et al. Assessing chemotherapeutic response in pancreatic ductal adenocarcinoma: histogram analysis of iodine concentration and CT number in single-source dual-energy CT. AJR Am J Roentgenol 6:1221–1226, 2018
   Bali MA, Pullini S, Metens T, et al. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion- weighted MR quantitative parameters and RECIST. Eur J Radiol 104:49– 57, 2018
   Wang ZJ, Behr S, Consunji MV, et al. Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI. AJR Am J Roentgenol 5:1010–1019, 2018
   Borhani AA, Dewan R, Furlan A, et al. Assessment of response to neoadjuvant therapy using CT texture analysis in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 2:362–369, 2020
   Nasief H, Zheng C, Schott D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ Precis Oncol 3:25, 2019
   Khalvati F, Zhang Y, Baig S, et al. Prognostic value of CT radiomic features in resectable pancreatic ductal adenocarcinoma. Sci Rep 1:5449, 2019
   Zins M, Matos C, Cassinotto C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology 2:374– 390, 2018
   Khanna L, Prasad SR, Sunnapwar A, et al. Pancreatic neuroendocrine neoplasms: 2020 update on pathologic and imaging findings and classification. Radiographics 40:1240–1262, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 237
EP 249
PG 14
ER

PT J
AU Gyokeres, T
AF Gyokeres, Tibor
TI Endoscopy of pancreatic tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; palliative therapy; pancreatic neoplasms; self-expandable metallic stents
ID endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; palliative therapy; pancreatic neoplasms; self-expandable metallic stents
AB This review provides an overview about the role of endoscopy in the care of patients suffering from pancreatic cancer. In the field of diagnostics the role of endoscopic ultrasound is highlighted in both solid and cystous pancreatic tumors. The decreasing diagnostic relevance of endoscopic retrograde cholangiopancreatography (ERCP) is also discussed. The issue of preoperative biliary drainage in case of obstruction is negotiated in detail, while palliative settings are appointed thoroughly. Besides conventional enteral stenting in case of gastric outlet syndrome caused by local spreading of pancreatic tumor, some new innovative endoscopic solutions are summarized. Several endoscopic ultrasound-guided antitumor interventions that are mainly in clinical trial phase are referred in the article. The diagnostics and treatment of pancreatic neuroendocrine tumors are discussed separately due to their different biological behavior. The review emphasizes the need for multidisciplinary approach of the patients suffering from malignant pancreatic tumors.
C1 [Gyokeres, Tibor] Magyar Honvedseg Egeszsegugyi Kozpont, Gasztroenterologia, Podmaniczky u. 111., 1062 Budapest, Hungary.
RP Gyokeres, T (reprint author), Magyar Honvedseg Egeszsegugyi Kozpont, Gasztroenterologia, 1062 Budapest, Hungary.
EM tiborgyokeres65@gmail.com
CR Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine plus capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer, ESPAC-4): a multicentre, open-label, randomised, Phase 3 trial. Lancet 389:1011−1024, 2017
   Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694−9705, 2016
   Loosen SH, Neumann UP, Trautwein C, et al. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 39:1010428317692231, 2017
   Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105−119, 2012
   Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142:318−321, 2012
   Kubiliun N, Ribeiro A, Fan YS, et al. EUS-FNA with rescue fluorescence in situ hybridization, FISH, for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc 74:541−547, 2011
   Zerboni G, Signoretti M, Crippa S, et al. Systematic review and meta‑analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology 19:2−9, 2019
   Pusateri AJ, Krishna SG. Pancreatic cystic lesions: Pathogenesis and malignant potential. Diseases 6:50, 2018
   Jones MJ, Buchanan AS, Neal CP, et al. Imaging of indeterminate pancreatic cystic lesions: A systematic review. Pancreatology 13:436−442, 2013
   European Study Group on Cystic Tumours of the Pancreas. European evidence‑based guidelines on pancreatic cystic neoplasms. Gut 67:789−804, 2018
   Napoleon B, Lemaistre AI, Pujol B, et al. In vivo characterization of pancreatic cystic lesions by needle‑based confocal laserendomicroscopy, nCLE): Proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. Surg Endosc 30:2603−2612, 2016
   van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: A pooled analysis. Gastrointest Endosc 62:383−389, 2005
   Khamaysi I, Abu Ammar A, Vasilyev G, et al. Differentiation of pancreatic cyst types by analysis of rheological behavior of pancreatic cyst fluid. Sci Rep 7:45589, 2017
   Ribaldone DG, Bruno M, Gaia S, et al. Differential diagnosis of pancreatic cysts: A prospective study on the role of intra‑cystic glucose concentration. Dig Liver Dis 52:1026−1032, 2020
   Domagk D, Oppong KW, Aabakken L, et al. Performance measures for ERCP and endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy, ESGE, Quality Improvement Initiative. Endoscopy 50:1116−1127, 2018
   Navaneethan U, Njei B, Lourdusamy V, et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 81:168−176, 2015
   Elek G, Gyokeres T, Schafer E, et al. Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy. Pathol Oncol Res 11:145−155, 2005
   Caillol F, Bories E, Autret A, et al. Evaluation of pCLE in the bile duct: final results of EMID study. Surg Endosc 29:2661−2668, 2015
   Dumonceau JM, Tringali A, Papanikolau IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy, ESGE, clinical guideline – updated October 2017. Endoscopy 50:910−930, 2018
   de Pastena M, Marchegiani G, Paiella S, et al. Impact of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy: An analysis of 1500 consecutive cases. Dig Endosc 30:777−784, 2018
   Dumonceau JM, Tringali A, Blero D, et al. Biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy, ESGE, clinical guideline. Endoscopy 44:277−298, 2012
   Dumonceau JM, Heresbach D, Deviere J, et al. Biliary stents: models and methods for endoscopic stenting. Endoscopy 43:617−626, 2011
   Wang J, Wang Y, Zhao Y, et al. Endoscopic ultrasound-guided radiofrequency ablation of unresectable pancreatic cancer with low ablation power and multiple applications: a preliminary study of 11 patients. Ann Palliat Med 10:1842−1850, 2021
   Lohse I, Brothers SP. Pathogenesis and treatment of pancreatic cancer related pain. Anticancer Res 40:1789−1796, 2020
   Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 291:1092–1099, 2004
   Pezzilli R, Partelli S, Cannizzaro R, et al. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms, PNENs): A systematic review. Adv Med Sci 61:147–153, 2016
   Polkowski M, Jenssen CC, Kaye PV, et al. Technical aspects of endoscopic ultrasound, EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy, ESGE, Technical Guideline–March 2017. Endoscopy 49:989–1006, 2017
   Yamashita Y, Shimokawa T, Napoleon B, et al. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A meta-analysis. Dig Endosc 31:125–133, 2019
   Takada S, Kato H, Saragai Y, et al. Contrast-enhanced harmonic endoscopic ultrasound using time–intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm. J Med Ultrason 46:449–458, 2019
   Melita G, Pallio S, Tortora A, et al. Diagnostic and interventional role of endoscopic ultrasonography for the management of pancreatic neuroendocrine neoplasms. J Clin Med 10: 2638, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 250
EP 256
PG 7
ER

PT J
AU Bursics, A
AF Bursics, Attila
TI Surgery of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE ductal carcinoma of the pancreas; pancreaticoduodenectomy; surgery; minimally invasive surgery; neoadjuvant therapy
ID ductal carcinoma of the pancreas; pancreaticoduodenectomy; surgery; minimally invasive surgery; neoadjuvant therapy
AB The pancreatic ductal adenocarcinoma (PDAC) is responsible for 95% of pancreatic malignancies. It is the 12th most common cancer and is the 7th leading cause of cancer deaths worldwide. The incidence of PDAC is increasing in the USA and in Europe (including Hungary), while mortality rate is not changing too much. The only curative therapeutic possibility is R0 surgical resection. The mortality of pancreatic resections has been decreasing in recent years and can be kept below 5% in HPB centers. The limits of surgical radicality have been extended and the en bloc resection of greater veins around the pancreas is now accepted. The survival could be improved by R0 resection of early cancers without lymph node spread and results can be augmented by combined oncologic therapies.
C1 [Bursics, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, Rona u. 196−212., 1145 Budapest, Hungary.
RP Bursics, A (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Sebeszeti-Onkosebeszeti Osztaly, 1145 Budapest, Hungary.
EM bursics@uzsoki.hu
CR Globocan International Agency for Research on Cancer. Data Visualization Tools for Exploring the Global Cancer Burden in 2020. https:// gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&- mode_population=countries&population=900&populations=900&key=- total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_ group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_ items=15&group_cancer=1&include_nmsc=0&include_nmsc_other=1&- type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%252 2%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal& type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue% 252C%2522bottom%2522%253Afalse%257D
   Kenner BJ, Chari ST, Maitra A, et al. Early detection of pancreatic cancer: A defined future using lessons from other cancers: A white paper. Pancreas 45:1073–1079, 2016
   Wong MCS, Jiang JY, Liang M, et al. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci Rep 7:3165, 2017
   Ushio J, Kanno A, Ikeda E, et al. Pancreatic ductal adenocarcinoma: epidemiology and risk factors. Diagnostics 11:562, 2021
   Lewis R, Drebin JA, Callery MP, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB 15:49−60, 2013
   Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg 105:1171–1181, 2018
   Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg 265:565–573, 2017
   https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455
   Chawla A, Ferrone CR. Neoadjuvant therapy for resectable pancreatic cancer: an evolving paradigm shift. Front Oncol 9:1085, 2019
   O’Reilly EM, Ferrone C. Neoadjuvant or adjuvant therapy for resectable or borderline resectable pancreatic cancer: which is preferred? J Clin Oncol 38:1757−1759, 2020
   Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer, Prep-02/JSAP-05). J Clin Oncol 37(4_ suppl):189, 2019
   Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38:1763−1773, 2020
   Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 102:763–779, 1935
   Flautner L, Tihanyi T, Szecseny A. Pancreatogastrostomy: an ideal complement to pancreatic head resection with preservation of the pylorus in the treatment of chronic pancreatitis. Am J Surg 150:608−611, 1985
   Traverso LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 146:959−962, 1978
   Klaiber U, Probst P, Buchler MW, et al. Pylorus preservation pancreatectomy or not. Transl Gastroenterol Hepatol 2:100−107, 2017
   Hayashibe A, Kameyama M, Shinbo M, et al. The surgical procedure and clinical results of subtotal stomach preserving pancreaticoduodenectomy, SSPPD, in comparison with pylorus preserving pancreaticoduodenectomy, PPPD). J Surg Oncol 95:106−109, 2007
   Nakao A. Selection and outcome of portal vein resection in pancreatic cancer. Cancers 2:1990−2000, 2010
   Delpero JR, Sauvanet A. Vascular resection for pancreatic cancer: 2019 French recommendations based on a literature review from 2008 to 6-2019. Front Oncol 10:40, 2020
   Orci LA, Meyer J, Combescure C, et al. A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB 17:565–572, 2015
   Hackert T, Strobel O, Michalski CW, et al. The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB 19:1001–1007, 2017
   Sanjay P, Takaori K, Govil S, et al. ‘Artery-first’ approaches to pancreatoduodenectomy. Br J Surg 99:1027−1035, 2012
   Strasberg SM, Drebin JA, Linehan D, et al. Radical antegrade modular pancreatosplenectomy. Surgery 133:521−527, 2003
   Murakawa M, Aoyama T, Asari M, et al. The short- and long-term outcomes of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. BMC Surgery 15:120, 2015
   Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International Evidence- Based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg 271:1−14, 2020
   Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group, ISGPS, definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 161:584−591, 2017
   Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying, DGE, after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery, ISGPS). Surgery 142:761−768, 2007
   Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage, PPH)–An International Study Group of Pancreatic Surgery, ISGPS, definition. Surgery 142:20−25, 2007
   Kuroda T, Kumagi T, Yokota T, el al. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients. BMC Gastroenterology 13:134−142, 2013
   Niesen W, Hank T, Buchler MW, et al. Local radicality and survival outcome of pancreatic cancer surgery. Ann Gastroenterol Surg 3:464−475, 2019
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 257
EP 264
PG 8
ER

PT J
AU Janvary, ZsL
   Lovey, J
AF Janvary, Zsolt Levente
   Lovey, Jozsef
TI Radiotherapy of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic cancer; radiotherapy; stereotactic body radiotherapy
ID pancreatic cancer; radiotherapy; stereotactic body radiotherapy
AB The therapy of pancreatic cancer is fundamentally based on surgical removal and chemotherapy. The available evidence and results of publications concerning the application of radiotherapy are controversial. Accordingly, the international guidelines formulated by radiation oncology organizations have paramount interest in this particular pathology. Answers are eagerly awaited in several unclear questions from ongoing, or recently closed, yet unpublished trials. Modern radiotherapy techniques, like stereotactic radiotherapy, or actually less available modalities, like particle therapy or magnetic resonance imaging guided radiotherapy show promising results, as well as combination of radiation with immunotherapy.
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM janvarylevente@yahoo.com
CR https://onkol.hu/nemzeti-rakregiszter/
   Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol 9:322−332, 2019
   Brunner TB, Haustermans K, Huguet F, et al. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiother Oncol 154:60–69, 2021
   National Comprehensive Cancer Network Guidelines: Pancreatic Adenocarcinoma. https://www.nccn.org/guidelines/guidelines-detail?category= 1&id=1455
   Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):56−68, 2015
   Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899−903, 1985
   Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776−782, 1999
   Smeenk HG, van Eijck CHJ, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246:734−740, 2007
   Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200−1210, 2004
   Abrams RA, Winter KA, Safran H, et al. Results of the NRG Oncology/ RTOG 0848 adjuvant chemotherapy question – erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase II randomized clinical trial. Am J Clin Oncol 43:173−179, 2020
   Passoni P, Reni, M, Cattaneo GM, et al. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: A phase I study. Int J Radiat Oncol Biol Phys 87:1000–1006, 2013
   Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer, ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011−1024, 2017
   Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105:946–958, 2018
   Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 38:1763−1773, 2020
   Mellon EA, Hoe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 54:979–985, 2015
   Barhoumi M, Mornex F, Bonnetain F, et al. Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000- 2001 FFCD/SFRO phase III trial. Cancer Radiother 15:182−191, 2011
   Loehrer Sr PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105−4112, 2011
   Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326−331, 2007
   Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib − The LAP07 Randomized Clinical Trial. JAMA 315:1844−1853, 2016
   Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58:1017–1021, 2004
   Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72:678–686, 2008
   Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81:181–188, 2011
   Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121:1128–1137, 2015
   Arcelli A, Guido A, Buwenge M, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis PAULA- 1. Anticancer Res 40:465–472, 2020
   Jung J, Yoon SM, Park JH, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS One 14:e0214970, 2019
   Chapman BC, Gleisner A, Rigg D, et al. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy, SBRT, versus intensity-modulated radiation therapy, IMRT, in pancreatic adenocarcinoma. J Surg Oncol 117:1073–1083, 2018
   Ryan JF, Rosati LM, Groot VP, et al. Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Oncotarget 9:16427–16436, 2018
   Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys 97:313–322, 2017
   Brunner TB, Nestle U, Grosu AL, et al. SBRT in pancreatic cancer: What is the therapeutic window? Radiother Oncol 114:109–116, 2015
   Zhong J, Patel K, Switchenko J, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123:3486−3493, 2017
   Zhu X, Cao Y, Liu W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 22:1093−1102, 2021
   Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine- based chemoradiation for locally advanced pancreatic cancer. Br J Cancer 116:1264−1270, 2017
   Arscott WT, Nead KT, Bear A, et al. Concurrent nab-paclitaxel and radiotherapy: novel radiosensitization for borderline resectable or unresectable pancreatic cancer. Am J Clin Oncol 2021,, DOI  10.1097/COC.0000000000000854
   Kisivan K, Erdelyesi D, Gutyina D, et al. Hasnyalmirigyrak linearis gyorsito alapu sztereotaxias sugarterapiaja kezeles alatti tumorkovetessel. Magy Onkol 65:6−13, 2021
   Heerkens HD, van Vulpen M, Erickson B, et al. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Br J Radiol 91:20170563, 2018
   Oar A, Lee M, Le H, et al. Australasian Gastrointestinal Trials Group, AGITG, and Trans-Tasman Radiation Oncology Group, TROG, Guidelines for Pancreatic Stereotactic Body Radiation Therapy, SBRT). Pract Radiat Oncol 10:e136−e146, 2020
   Bouchard M, Amos RA, Briere TM, et al. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol 92:238– 243, 2009
   Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabine- concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol 103:25–31, 2012
   Nichols RC, George TJ, Zaiden RA, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol 52:498–505, 2013
   Sachsman S, Nichols RS, Morris CG, et al. Proton therapy and concomitant capecitabine for non-metastatic unresectable pancreatic adenocarcinoma. Int J Particle Ther 1:692–701, 2014
   Hiroshima Y, Fukumitsu N, Saito T, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol 136:37–43, 2019
   Shinoto M, Yamada S, Yasuda S, et al. Working Group for Pancreas, C. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 119:45–51, 2013
   Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan Carbon- ion Radiation Oncology Study Group, J-CROS, Study 1403 Pancreas. Int J Radiat Oncol Biol Phys 101:1212−1221, 2018
   Valentini V, Calvo F, Reni M, et al. Intra-operative radiotherapy, IORT, in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol 91:54–59, 2009
   Ogawa K, Karasawa K, Ito Y, et al. Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients. Int J Radiat Oncol Biol Phys 77:734–742, 2010
   Palta M, Willett C, Czito B. The role of intraoperative radiation therapy in patients with pancreatic cancer. Semin Radiat Oncol 24:126–131, 2014
   Scott JG, Sedor G, Ellsworth P, et al. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose, GARD): a cohort-based pooled analysis. Lancet Oncol S1470−2045, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 265
EP 271
PG 7
ER

PT J
AU Lakatos, G
AF Lakatos, Gabor
TI Systemic treatment of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pancreatic cancer; chemotherapy; precision oncology
ID pancreatic cancer; chemotherapy; precision oncology
AB Pancreatic cancer is a devastating disease, survival rates did not improve during the last decades. At the same time new drugs and chemotherapy regimens have been approved for systemic use lately, the results of targeted therapy and the precision medicine approach are also encouraging. Further progress is needed covering all treatment modalities (surgery, radiotherapy, systemic treatment) in order to improve outcome of patients suffering from pancreatic cancer.
C1 [Lakatos, Gabor] Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, Albert Florian ut 5–7., 1097 Budapest, Hungary.
RP Lakatos, G (reprint author), Egyesitett Szent Istvan es Szent Laszlo Korhaz, Onkologiai Osztaly, 1097 Budapest, Hungary.
EM lakagab@yahoo.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, 2020 Lyon, France. https://gco. iarc.fr/today
   Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 385:1206−1218, 2015
   NCCN Clinical Picture Guidelines in Oncology, Pancreatic adenocarcinoma, Version 2.2021-February 25, 2021
   Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727−1733, 2009
   Oba A, Ho F, Bao QR, et al. Neoadjuvant treatment in pancreatic cancer. Front Oncol 10:245, 2020
   Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104−3116, 2017
   Tee MC, Krajewski AC, Groeschl RT, et al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J Am Coll Surg 227:255−269, 2018
   Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg 273:579−586, 2021
   Hammel P, Lacy J, Portales F, et al. Phase II LAPACT trial of nab-paclitaxel, nab-P, plus gemcitabine, G, for patients with locally advanced pancreatic cancer, LAPC). J Clin Oncol 36(4_suppl):204, 2018
   Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 13:497−501, 2012
   Tinchon C, Hubmann E, Pichler A, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 52:1231−1233, 2013
   Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 30:361, 2013
   Nitsche U, Wenzel P, Siveke JT, et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single- center experience. Ann Surg Oncol 22(Suppl 3):S1212−1220, 2015
   Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with Folfirinox results in resectability in 60% of the patients. Ann Surg 264:457−463, 2016
   Yoo C, Kang J, Kim KP, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget 8:46337−46347, 2017
   Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol 44:1619−1623, 2018
   Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 26:416−425, 2019
   Kunzmann V, Hartlapp I, Scheurlen M, et al. Sequential neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer, LAPC): A PILOT study. J Clin Oncol 31(15_suppl): e15193, 2013
   Reni M, Balzano G, Zanon S, et al. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin, PAXG regimen, in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer 115:290−296, 2016
   Takahashi H, Akita H, Ioka et al. Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas 47:1135−1141, 2018
   Reni M, Zanon S, Balzano G, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer 102:95−102, 2018
   Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776−782, 1999
   Neoptolemos JP, Stocken DD, Friess H, et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200−1210, 2004
   Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504−512, 2014
   Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267−277, 2007
   Neoptolemos JP, Buchler M, Stocken DD, et al. A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/ folinic acid, 5-FU/FA, versus gemcitabine, GEM, in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27:LBA4505, 2009
   Uesaka K, Boku N, Fukutomi A, et al; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial, JASPAC 01). Lancet 388:248−257, 2016
   Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer, ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011−1024, 2017
   Conroy T, Hammel P, Hebbar M et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395−2406, 2018
   Tempero MA, Reni M, Riess H, et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine, nab -P/G, vs. gemcitabine, G, for surgically resected pancreatic adenocarcinoma. J Clin Oncol 37:4000, 2019
   Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol 30:1472−1478, 2019
   Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403−2413, 1997
   Herrmann R, Bodoky G, Ruhstaller T, et al; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212−2217, 2007
   Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817−1825, 2011
   Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691−1703, 2013
   Ducreux M, Cuhna AS, Caramella C, et al; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56−68, 2015
   Perera S, Jang GH, Zhang A, et al. hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer. J Clin Oncol 39(suppl 15):A4011, 2021
   Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial, PRODIGE 35-PANOPTIMOX). J Clin Oncol 36:4000, 2018
   Wang-Gillam A, Li CP, Bodoky G, et al; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy, NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545−557, 2016
   Moore MJ, Goldstein D, Hamm J, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960−1966, 2007
   Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov 8:1096−1111, 2018
   Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124−3129, 2015
   Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132−1138, 2014
   Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523−533, 2017
   Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495−2505, 2018
   Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317−327, 2019
   Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site – When a biomarker defines the indication. N Engl J Med 377:1409−1412, 2017
   Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 8:2536−2540, 2002
   Ghidini M, Lampis A, Mirchev MB, et al. Immune-based therapies and the role of microsatellite instability in pancreatic cancer. Genes, Basel, 12:33, 2020
   Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731−739, 2018
   Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271−282, 2020
   Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21:508−518, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 273
EP 281
PG 9
ER

PT J
AU Simonfalvi, I
AF Simonfalvi, Ildiko
TI Role of nanoliposomal irinotecan in the treatment of pancreatic cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Guideline
AB The article reflects the opinion of the author.
C1 [Simonfalvi, Ildiko] Servier, Vaci ut 1-3., 1062 Budapest, Hungary.
RP Simonfalvi, I (reprint author), Servier, 1062 Budapest, Hungary.
CR Ozer M, Yu KH. Further defining the role of nanoliposomal irinotecan in pancreatic cancer. Dig Med Res 3:92, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2021
VL 65
IS 3
BP 283
EP 284
PG 2
ER

PT J
AU Szekely, E
   Sukosd, F
AF Szekely, Eszter
   Sukosd, Farkas
TI Pathology of tumors of the urinary bladder, aspects and expectations of the histological report (TUR, cystectomy)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bladder cancer; histology; classification; reporting
ID bladder cancer; histology; classification; reporting
AB Urothelial tumors are among the most frequently occurring malignancies. The patients’ clinical outcome can be diverse after recognition of the presence of the tumor. The result of the histology report (grade, histologic subtype, stage) makes remarkable impact on treatment strategies. There are innumerable papers (debates) in the literature concerning the best methods in classification, stage determination, application of immunohistochemical markers (to possibly avoid false negative, false positive results) and the use of molecular biological examinations. The authors attempt to draw attention on the everyday diagnostic difficulties of the „general pathologist”, through their own experience and the latest reports of the literature.
C1 [Szekely, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
RP Szekely, E (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM szeszter@gmail.com
CR Babjuk M, Burger M, Comperat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer, TaT1 and Carcinoma In Situ, − 2019 Update. V. Eur Urol 76:639−657, 2019
   van Rhijn BWG, Hentschel AE, Brundl J, et al. Prognostic value of the WHO1973 and WHO2004/2016 classification systems for grade in primary Ta/ T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 4:182−191, 2021
   Raspollini MR, Montironi R, Mazzucchelli R, et al. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. Virchows Arch 477:3−16, 2020
   Amin MB, Comperat E, Epstein JI, et al. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol 28:179−195, 2021
   Soukup V, Capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol 72:801−813, 2017
   Bosschieter J, Hentschel A, Savci-Heijink CD, et al. Reproducibility and prognostic performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A multicenter study in 328 bladder tumors. Clin Genitourin Cancer 16:e985-e992, 2018 7 Varma M, Delahunt B, van der Kwast T. Grading noninvasive bladder cancer: World Health Organisation 1973 or 2004 may be the wrong question. Eur Urol 76:413−415, 2019 8. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133:788−795, 2010 9. Schubert T, Danzig MR, Kotamarti S, et al. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome. World J Urol 33:847−852, 2015 10. Pan CC, Chang YH, Chen KK, et al. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol 63:910−915, 2010 11. Toll AD, Epstein JI. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases. Am J Surg Pathol 36:1081−1086, 2012 12. Lawless M, Gulati R, Tretiakova M. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology 71:406−414, 2017 13. Lopez-Beltran A, Cheng L. Stage T1 bladder cancer: diagnostic criteria and pitfalls. Pathology 53:67−85, 2021 14. Turan T, Efiloglu O, Gunaydin B, et al. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder. Int Braz J Urol 44:267−272, 2018 15. Magers MJ, Lopez-Beltran A, Montironi R, et al. Staging of bladder cancer. Histopathology 74:112−134, 2019 16. Patriarca C, Hurle R, Moschini M, et al. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagn Pathol 11:6, 2016 17. Bosschieter J, Hentschel AE, Savci-Heijink CD, et al. Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. Urol Oncol 37:530.e1−530.e8, 2019 18. Seisen T, Comperat E, Leon P, et al. Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr Opin Urol 24:524−531, 2014 19. Rebola J, Agular P, Blanca A, et al. Predicting outcomes in non-muscle invasive, Ta/T1, bladder cancer: the role of molecular grade based on luminal/ basal phenotype Virchows Arch 475:445−455, 2019 20. https://documents.cap.org/protocols/cp-urinary-bladder-17protocol- 4010.pdf 21. https://www.rcpath.org/uploads/assets/e2c11ff6-780a-471e-a21a4dc48788d35b/ Dataset-for-tumours-of-the-urinary-collecting-system.pdf
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 291
EP 300
PG 10
ER

PT J
AU Lotz, G
   Kocsmar, I
   Timar, J
AF Lotz, Gabor
   Kocsmar, Ildiko
   Timar, Jozsef
TI Molecular classification of bladder cancer in 2021
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bladder cancer; mutational profile; prognostic and predictive markers
ID bladder cancer; mutational profile; prognostic and predictive markers
AB Bladder cancer belongs to the high mutation burden cancers due to the genetic alterations in non-conventional DNA repair systems such as ERCC2. Bladder cancer is characterized by mutations of FGFR3, HER-2 and HRAS and translocations of FGFR3 and PPARG. The papillary luminal form is the FGFR3 mutant, the unstable luminal version is the HER-2 mutant, while in the basal form EGFR amplification can be detected. Prognosis of bladder cancer is also defined by molecular features such as the claudin and MMP expressions and chromosomal alterations detected by UroVysion test. Last but not least, molecular aberrations are strong predictive factors: high mutation burden defines sensitivity toward immunotherapies, ERCC2 and HER-2 mutations define sensitivity toward chemotherapy, BRCA1/2 mutations define sensitivity to PARP inhibitors, tumors with FGFR3 mutation are prone to FGFR inhibitors while HRAS mutations define sensitivity to farnesyltransferase inhibitors.
C1 [Lotz, Gabor] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kocsmar, Ildiko] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Tanaka T, Miyazawa K, Tsukamoto T, et al. Pathobiology and chemoprevention of bladder cancer. J Oncol 2011:528353, 2011
   Kiss A, Fillinger J, Mehes G, et al. A tumormutacios terheles, TMB, mint tumoragnosztikus prediktiv marker. Klin Onkol 31:247−253, 2021
   Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol 5:2, 2005
   Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540−556, 2017
   McConkey DJ. Molecular biology of bladder cancer. Potential implications for therapy. Hematol Oncol Clin N Am 35:457−468, 2021
   Nassar AH, Alawi SA, AlDubayan SH, et al. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med 22:709−718, 2020
   Kamoun A, deReynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 27:420−433, 2020
   Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27−42, 2016
   Tran L, Xiao JF, Agarwal N, et al. Advances in bladder cancer biology and therapy. Nat Rev Cancer 21:104−121, 2021
   Kim SK, Park SH, Kim YU, et al. A molecular signature determines the prognostic and therapeutic subtype of non-muscle-invasive bladder cancer responsive to intravesical Bacillus Calmette-Guerin therapy. Int J Mol Sci 22:1450, 2021
   Lerner SP, McConkey DJ, Hoadley KA, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2:37−47, 2016
   Torzsok P, Riesz P, Kenessey I, et al. Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder. J Histochem Cytochem 59:1022−1030, 2011
   Kardos J, Chai S, Mose LE, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 1:e85902, 2016
   Miao C, Liang C, Zhu J, et al. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis. Oncotarget 8:32309−32321, 2017
   Szarvas T, Becker M, von Dorp F, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 101:1300−1308, 2010
   Szarvas T, Hoffmann MJ, Olah C, et al. MMP-7 serum and tissue levels are associated with poor survival in platinum-treated bladder cancer patients. Diagnostics, Basel, 11:48, 2020
   Kocsmar I, Pajor G, Gyongyosi B, et al. Development and initial testing of a modified UroVysion-based fluorescence in situ hybridization score for prediction of prognosis in bladder cancer. Am J Clin Pathol 153:274−284, 2020
   Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140−1153, 2014
   Lotz G, Smuk G, Kocsmar E, et al. A programozott sejthalal feherje 1, PD-1, – programozott sejthalal ligandum 1, PD-L1, gatlas prediktiv diagnosztikaja. Magy Onkol 63:183−191, 2019
   Garje R, An J, Obeidat M, et al. Fibroblast growth factor receptor, FGFR, inhibitors in urothelial cancer. Oncologist 25:e1711−e1719, 2020
   Kiss B, Wyatt AW, Douglas J, et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep 7:42713, 2017
   Moore AR, Rosenberg SC, McCormick F, Malek J. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 19:533−552, 2020
   Beukers W, Hercegovac A, Zwarthoff EC. HRAS mutations in bladder cancer. Eur J Human Genet 22:837−839, 2014
   Lee HW, Sa JK, Gualberto A, et al. A phase II trial of tipifarnib for patients with previously treated metastatic urothelial carcinoma harboring HRAS mutations. Clin Cancer Res 26:5113−5119, 2020
   Dhillon S. Lonafarnib: first approval. Drugs 81:283−289, 2021
   Garje R, Vaddepally RK, Zakharia Y. PARP inhibitors in prostate and urothelial cancers. Front Oncol 10:114, 2020
   Borcsok J, Diossy M, Sztupinszki Z, et al. Detection of molecular signatures of homologous recombination deficiency in bladder cancer. Clin Cancer Res 27:3734−3743, 2021
   Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol 18:93−103, 2021
   Cubas RC, Zhang S, Chen C, Yao Q. Trop-2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. BMC Mol Cancer 9:253, 2010
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 301
EP 306
PG 6
ER

PT J
AU Tenke, P
   Fabian, N
   Nemeth, Z
AF Tenke, Peter
   Fabian, Norbert
   Nemeth, Zalan
TI Modern surgical treatment of urothelial tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bladder tumor; urothelial cell tumor; transurethral tumor resection; cystectomy; reccurence rate; NBI
ID bladder tumor; urothelial cell tumor; transurethral tumor resection; cystectomy; reccurence rate; NBI
AB Urothelial cell tumors are the most common malignant urinary tract lesions, affecting the bladder in the majority of cases, however, 5% of the tumors occur in the upper urinary tract (urethra, renal pelvis). About 2,000 new diseases occur in Hungary every year and due to this tumor, almost 1,000 deaths occur in every year. The purpose of this paper is to summarize the results of radical surgery indicated in patients with non-invasive and muscle-invasive urothelial cancer, as well as its international recommendations. Based on the AUA and EAU guidelines, the latest and standard treatment options are described. Transurethral resection (TUR) is still a gold standard in the initial diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). The indication for radical cystectomy in addition to muscle invasive tumors (T2-T4a, N0-Nx, M0) is BCG resistant in T1G3 (evidence level: 3, recommendation level: B). Risk stratification is of paramount importance for the future treatment and follow-up of patients with bladder urothelial cell tumors. Although the proportions of changes in surgical care lag behind the novelties of urooncological treatments, advances in surgical technique, urinary tract reconstruction, and multimodal therapy may continue to improve the prognosis and quality of life of patients with bladder urothelial cell tumors. Tenke P, Fabian N, Nemeth Z. Modern surgical treatment of urothelial tumors.
C1 [Tenke, Peter] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
   [Fabian, Norbert] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
   [Nemeth, Zalan] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
RP Tenke, P (reprint author), Jahn Ferenc Korhaz, Urologia, 1204 Budapest, Hungary.
EM tenke.peter@gmail.com
CR IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021. https://gco.iarc.fr/today/online-analysis-table
   Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234−234, 2013
   Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of tumours, 3 Ed., vol. 7, Eds. Eble JN, Sauter G, Epstein J, Sesterhenn I, IARCC Press, Lyon 2004
   May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57:850−858, 2010
   Soukup V, Capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol 72:801−813, 2017
   Choyke PL. Radiologic evaluation of hematuria: guidelines from the American College of Radiology’s appropriateness criteria. Am Fam Physician 78:347−352, 2008
   Yafi AF, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 66:25−31, 2015
   Ibarrola S, Soria F, Abufaraj M, et al. Surgical checklist impact on recurrence- free survival of patients with nonmuscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. BJU Int 123:646−650, 2019
   Anderson C, Weber R, Patel D, et al. A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor. J Urol 196:1014−1020, 2016
   Cumberbatch MGK, Foerster B, Catto JW F, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73:925−933, 2018
   Naselli A, Hurle R, Paparella S, et al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:558−567, 2018
   Brant A, Daniels M, Chappid MR, et al. Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World J Urol 37:2683−2689, 2019
   Zhangqun Y, Jia H, Xiaodong S, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. Sci Rep 5:10905, 2015
   Mosonyi P, Szepesvary Zs, Kerenyi G, et al. Ígeretes kepalkoto technika a nem-izominvaziv holyagdaganatok diagnosztikajaban: az NBI, narrow band imaging, alkalmazasa az urologiaban. Magy Urol XXIX(2):57−63, 2017
   Witjes JA, Bruins HM, Cathomas R, et al. Muscle-invasive and metastatic bladder cancer. European Association of Urology guidelines 7:26−43, 2021
   Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552, 2017
   Gotsadze DT, Chakvetadze VT, Danelia VT. [Why and how to modify standard cystectomy.] Urologia 2008:22−26, 2008
   Bai S, Yao Z, Zhu X, et al. The feasibility and safety of reproductive organ preserving radical cystectomy for elderly female patients with muscle-invasive bladder cancer: a retrospective propensity score-matched study. J Urology 125:138−145, 2019
   Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365−376, 1993
   Nuhn P, May M, Sun M, et al. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol 61:58−64, 2012
   Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19:89–93, 2001
   Giacalone NJ, Shipley WU, Clayman RB, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 71:952−960, 2017
   Pieretti A, Krasnow R, Drumm M, et al. Complications and outcomes of salvage cystectomy after trimodality therapy. J Urol 206:29−36, 2021
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 307
EP 311
PG 5
ER

PT J
AU Riesz, P
   Juhasz, D
   Kovacs, PT
   Vargha, J
   Szarvas, T
AF Riesz, Peter
   Juhasz, Daniel
   Kovacs, Petra Terezia
   Vargha, Judit
   Szarvas, Tibor
TI Local care and systemic drug treatment of non-muscle invasive bladder tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE transitional cell carcinoma; non-muscle invasive bladder cancer; transurethral resection; local chemoinstillation
ID transitional cell carcinoma; non-muscle invasive bladder cancer; transurethral resection; local chemoinstillation
AB Bladder cancer is the most common malignancy of the urinary tract. It can be divided into non-muscle invasive and muscle-invasive groups according to depth of tumor invasion. Based on the significant differences regarding their biological behavior, propensity to progress, and therapy responsiveness these two groups are discussed seperately. Treatment of non-muscle invasive bladder cancers has traditionally been performed by urologists, but recent advances in the field predict that clinical oncologists may have a more intense role in high-risk non-muscle invasive cases. In the present study, we summarize the current surgical and pharmacological treatment options for non-muscle invasive bladder cancer.
C1 [Riesz, Peter] Semmelweis University, Department of Urology, Ulloi ut 78/B., 1082 Budapest, Hungary.
   [Juhasz, Daniel] Semmelweis University, Department of Urology, Ulloi ut 78/B., 1082 Budapest, Hungary.
   [Kovacs, Petra Terezia] Semmelweis University, Department of Urology, Ulloi ut 78/B., 1082 Budapest, Hungary.
   [Vargha, Judit] Semmelweis University, Department of Urology, Ulloi ut 78/B., 1082 Budapest, Hungary.
   [Szarvas, Tibor] Semmelweis University, Department of Urology, Ulloi ut 78/B., 1082 Budapest, Hungary.
RP Riesz, P (reprint author), Semmelweis University, Department of Urology, 1082 Budapest, Hungary.
EM rieszp@gmail.com
CR Witjes JA, Comperat E, Cowan NC, et al. European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778−792, 2014
   Pajor L, Bajory Z. A noninvaziv holyagdaganat kezelese. A Magyar Urologia Iranyelvei, Szeged 1−7, 2009
   Riesz P, Mavrogenis S, Szucs M, et al. Hugyholyagrak. Orv Hetil 149:613−615, 2008
   Richterstetter M, Wullich B, Amann K, et al. The value of extended transurethral resection of bladder tumour, TURBT, in the treatment of bladder cancer. BJU Int 110:E76−E79, 2012
   Brausi M, Laurence C, Karlheinz K, et al. and EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41:523−531, 2002
   Paramananthan M, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843−849, 2010
   Gerhard J, Algaba F, Malmstrom PU, et al. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45:539−546, 2004
   Giacomo N, Ficarra V. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 58:193−194, 2010
   Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997−1008, 2011
   Abern M R, Owusu RA, Anderson MR, et al. Perioperative intravesical chemotherapy in non–muscle-invasive bladder cancer: a systematic review and metaanalysis. J Natl Compr Cancer Netw 11:477−484, 2013
   Pawinski A, Sylvester R, Kurth KH, et al and The Medical Research Council Working Party. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156:1934−1941, 1996
   Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer 34:1532−1540, 1974
   Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88:209−216, 2001
   Zlotta AR, Van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? Eur Urol 37:470−477, 2000
   Ganesh RV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283−1286, 2007
   Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG, KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22:919−930, 2021
   Powles T, Csoszi T, Ozguroglu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma, KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931−945, 2021
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 313
EP 317
PG 5
ER

PT J
AU Agoston, P
   Jorgo, K
   Kocsis, Zs
   Varga, L
   Gesztesi, L
   Takacsi-Nagy, Z
   Polgar, Cs
AF Agoston, Peter
   Jorgo, Kliton
   Kocsis, S. Zsuzsa
   Varga, Levente
   Gesztesi, Laszlo
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
TI Trimodal, organ-preserving treatment of organ-confined, muscle-invasive bladder cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE urinary bladder neoplasms; muscle-invasive; organ preservation; trimodal
ID urinary bladder neoplasms; muscle-invasive; organ preservation; trimodal
AB Radical cystectomy is the gold standard treatment in localized muscle-invasive bladder cancer according to today’s guidelines. However, in many cases, surgery is not possible due to the patient’s general condition, or the patient refuses bladder removal. In such cases, as well as in some selected patients suitable for surgery, trimodal organ preservation therapy is an alternative, which provides the patient with similar survival, local tumor control, so that 80% of patients retain their bladder. In some cases, due to complications or a muscle-invasive local recurrence in the bladder, the bladder may not be retained. At this point, a salvage cystectomy can still save the patient’s quality of life and life. Adequate patient selection is a prerequisite for effective trimodal therapy. We summarize the components of organ-preserving treatment, including radiation therapy, its state-of-the-art technology, results and side effects. The results and toxicity of trimodal treatment are compared with those of radical cystectomy.
C1 [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Varga, Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM agoston.peter@oncol.hu
CR Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7:325−334, 2000
   Kogevinas M, Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14:907− 914, 2003
   Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25−41, 2015
   Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle- invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 6:708−715, 2016
   Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55:164−174, 2009
   Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO guidelines committees. Eur Urol 77:223−250, 2020
   Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 120:639−650, 2017
   Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 71:952−960, 2017
   Kanady KE, Shipley WU, Zietman AL, et al. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. Semin Surg Oncol 13:359−364, 1997
   Premo C, Apolo AB, Agarwal PK, et al. Trimodality therapy in bladder cancer: Who, what and when? Urol Clin North Am 42:169−180, 2015
   Kim LHC, Patel MI. Transurethral resection of bladder tumour, TURBT). Transl Androl Urol 9:3056−3072, 2020
   Suer E, Hamidi N, Gokce MI, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J Urol 34:847−851, 2016
   Kliton J, Polgar C, Tenke P, et al. Izominvaziv holyagrak kepvezerelt sugarkezelese intravesicalisan befecskendezett lipiodolos jelolessel. A holyagmegtarto kezeles uj lehetosege. Orv Hetil 158:2041−2047, 2017
   Mangar S, Thompson A, Miles E, et al. A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. Br J Radiol 80:279−283, 2007
   Liu W, Tian J, Zhang S et al. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta- analysis. Minerva Urol Nephrol 73:144−153, 2021
   Martinez-Pineiro JA, Martin MG, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153:964−973, 1995
   Malmstom, PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155:1903−1906, 1996
   International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171−2177, 2011
   Audenet F, Waingankar N, Ferket BS, et al. Effectiveness of transurethral resection plus systemic chemotherapy as definitive treatment for muscle invasive bladder cancer in population level data. J Urol 200:996−1004, 2018
   Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2901−2907, 1996
   Dinh TKT, Mitin T, Bagshaw H, et al. Executive summary of the American Radium Society appropriate use criteria for radiation treatment of node-negative muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys 109:953−963, 2021
   International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171−2177, 2011
   Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576−3583, 1998
   Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol 22:246−255, 2021
   Amestoya F, Roubaudb G, Antoinec M, et al. Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit Rev Oncol Hematol 142:76−85, 2019
   Goldsmith B, Baumann BC, He J, et al. Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 88:603−610, 2014
   Gschwend JE, Heck MM, Lehmann J, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 75:604−611, 2019
   Tan MP, Harris V, Warren-Oseni K, et al. The Intensity-Modulated Pelvic Node and Bladder Radiotherapy, IMPART, trial: A phase II single-centre prospective study. Clin Oncol, R Coll Radiol, 32:93−100, 2020
   Fackrell DG, Ford D, Chetiyawardana S, et al. The delivery of radical radiotherapy to the bladder and pelvis in node-positive, N1, bladder cancer: a five patient case series. BJR Case Rep 3:160−164, 2016
   Haque W, Verma V, Butler EB, Teh BS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer 27:283−291, 2017
   Kong V, Hansen VN, Hafeez S. Image-guided adaptive radiotherapy for bladder cancer. Clin Oncol, R Coll Radiol, 33:350−368, 2021
   Canlas R, McVicar N, Nakano S, et al. Assessment of adaptive margins using a single planning computed tomography scan for bladder radiotherapy. J Med Imaging Radiat Sci 47:227−234, 2016
   Huddart R, Hafeez S, Lewis R, et al. Clinical outcomes of a randomized trial of adaptive plan-of-the-day treatment in patients receiving ultra-hypofractionated weekly radiation therapy for bladder cancer. Int J Radiat Oncol Biol Phys 110:412−424, 2021
   Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061−3071, 2002
   Mannion L, Bosco C, Nair R, et al. Overall survival, disease-specific survival and local recurrence outcomes in patients with muscle-invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review. BJU Int 125:780−791, 2020
   Caffo O, Thompson C, De Santis M, et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol 121:193−198, 2016
   Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072−1080, 2007
   Mak KS, Smith AB, Eidelman A, et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96:1028−1036, 2016
   Schuettfort VM, Pradere B, Quhal F, et al. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World J Urol 39:1757−1768, 2021
   Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 57:1058−1063, 2010
   James ND, Hussain SA, Hall E, et al. BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477−1488, 2012
   Polo-Alonso E, Kuk C, Guruli G, et al. Trimodal therapy in muscle invasive bladder cancer management. Minerva Urol Nephrol 72:650−662, 2020
   Krause FS, Walter B, Ott OJ, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 31:985−990, 2011
   Baxter E, Dennis K, Kollmannsberger C, et al. Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. Urol Oncol 33:13−19, 2015
   Hara T, Nishijima J, Miyachika Y, et al. Primary cT2 bladder cancer: a good candidate for radiotherapy combined with cisplatin for bladder preservation. Jpn J Clin Oncol 41:902−907, 2011
   Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32:3801−3809, 2014
   Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039−1047, 2012
   Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666−675, 2001
   Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35:2299−2305, 2017
   Ritch CR, Balise R, Prakash NS, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle- invasive bladder cancer. BJU Int 121:745−751, 2018
   Cahn DB, Handorf EA, Ghiraldi EM, et al. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder- preservation therapy for muscle-invasive bladder cancer. Cancer 123:4337−4345, 2017
   Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ- sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol 95:387−396, 2015
   Fahmy O, Khairul-Asri MG, Schubert T, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol 36:43−53, 2018
   Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79:82−104, 2021
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 319
EP 328
PG 10
ER

PT J
AU Maraz, A
   Varga, L
   Posfai, B
   Geczi, L
   Kuronya, Zs
AF Maraz, Aniko
   Varga, Linda
   Posfai, Boglarka
   Geczi, Lajos
   Kuronya, Zsofia
TI New aspects of chemotherapy and indications for maintenance immunotherapy in urothelial cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bladder cancer; chemotherapy; cisplatin; avelumab; antibody-drug conjugates
ID bladder cancer; chemotherapy; cisplatin; avelumab; antibody-drug conjugates
AB Chemotherapy for the treatment of urothelial and bladder cancers has focused on renewed indications in light of clinical trials of modern therapies, which are described in our review. In stage T2-T4a N0-1 M0 cases, that are suitable for cisplatin, surgery is performed after neoadjuvant cisplatin- based chemotherapy. Less significant result is observed with adjuvant chemotherapy, especially in pT3-4 and/or N+ stage, if no neoadjuvant chemotherapy was administered. Cisplatin-based chemotherapy is the first-line treatment of cisplatin-eligible metastatic patients. First-line choice in chemo-fit cases with cisplatin ineligibility can be carboplatin- based chemotherapy. 4-6 cycles of cisplatin or carboplatin cause stable disease or regression, maintenance avelumab immunotherapy improves patient’s survival. For those patients who progress during or after platinum-based chemotherapy, the effectiveness of chemotherapy in the second/multiple lines is less favourable in comparison with immunotherapy and targeted therapy. Modern antibody – cytotoxic drug conjugates have been discovered in the form of enfortumab vedotin and sacituzumab govitecan, and currently they seem to be effective in the third line after chemotherapy and immunotherapy.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Varga, Linda] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Posfai, Boglarka] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
CR Horwich A, Babjuk M, J Bellmunt J, et al. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Ann Oncol 30:1697–1727, 2019
   Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii40–48, 2014
   Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer, Ta, T1, and Carcinoma in Situ). Eur Urol 2021,, DOI  10.1016/j.eururo.2021.08.010
   Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol Oncol 3:131–144, 2020
   NCCN Guideline Bladder Cancer – https://www.nccn.org/professionals/ physician_gls/pdf/bladder_blocks.pdf
   Kessel KE, Zuiverloon TC, Alberts AR, et al. Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol 12:681–694, 2015
   Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381:338–348, 2019
   Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135, 2021
   Tagawa ST, Balar VA, Petrylak PD, et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 39:2474–2485, 2021
   Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866, 2003
   David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 178:451–454, 2007
   Advanced Bladder Cancer, ABC, Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer, ABC, meta-analysis collaboration. Eur Urol 48:202–205, 2005
   International Collaboration of Trialists, on behalf of the Medical Research Council Advanced Bladder Cancer Working Party the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177, 2011
   Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle- invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21:708–715, 2016
   Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297–303, 2004
   Pfister C, Gravis G, Flechon A, et al. Randomized phase III trial of dosedense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79:214–221, 2021
   Galsky MD, Hahn NM, Rosenberg JE, et al. Defining „cisplatin ineligible” patients with metastatic bladder cancer. J Clin Oncol 29(7 suppl):abstr 238, 2011
   Lee CT, Madii R, Daignault S. et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 175:1262–1267, 2006
   Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61:1229–1238, 2012
   Culp SH, Dickstein RJ, Grossman HB, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40–47, 2014
   Powles T, Meeks JJ, Galsky MD, et al. A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer, NIAGARA). J Clin Oncol 39(6_suppl):TPS505, 2021
   Sonpavde G, Necchi A, Gupta S, et al. ENERGIZE: a phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol 16:4359–4368, 2020
   Siefker-Radtke AO, Steinberg GD, Bedke J, et al. Phase III study of perioperative pembrolizumab, pembro, plus neoadjuvant chemotherapy, chemo, versus placebo plus neoadjuvant chemo in cisplatin-eligible patients, pts, with muscle-invasive bladder cancer, MIBC): KEYNOTE-866. J Clin Oncol 38(6_suppl):TPS599, 2020
   Advanced Bladder Cancer, ABC, Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta- analysis of individual patient data Advanced Bladder Cancer, ABC, Meta- analysis Collaboration. Eur Urol 48:189–199, 2005
   Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta- analysis of randomized trials. Eur Urol 66:42–54, 2014
   Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin, PGC, to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group, SOGUG, 99/01 study. J Clin Oncol 28:LBA4518, 2010
   Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder, EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76–86, 2015
   NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/ dictionaries/cancer-terms?cdrid=45587
   von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608, 2005
   Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54, 2006
   Bellmunt J, Van der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30:1107– 1113, 2012
   De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191–199, 2012
   von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077, 2000
   De Santis M, Wiechno PJ, Bellmunt J, et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial, JASINT1). Ann Oncol 27:449–454, 2016
   Park I, Kim BS, Lim HY, et al. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study, COACH, KCSG GU10-16). Eur J Cancer 127:183–190, 2020
   Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218–1230, 2020
   Grivas P, Park SH, Voog E, et al. Avelumab 1L maintenance + best supportive care, BSC, vs BSC alone with 1L chemotherapy for advanced urothelial carcinoma: subgroup analyses from JAVELIN Bladder 100. Ann Oncol 31(suppl_4):S550, 2020
   Grivas P, Park SH, Eric Voog, et al. Avelumab first-line, 1L, maintenance plus best supportive care, BSC, versus BSC alone for advanced urothelial carcinoma, UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100. J Clin Oncol 39(15_suppl):4525, 2021
   Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27:49–61, 2016
   Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody- drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003–3013, 2016
   Goldenberg DM, Stein R, Sharkey RM, et al. The emergence of trophoblast cell-surface antigen 2, TROP-2, as a novel cancer target. Oncotarget 9:28989–29006, 2018
   O’Donnel PH, Balar AV, Vuky J, et al. KEYNOTE-052: phase 2 study evaluating first-line pembrolizumab, pembro, in cisplatin-ineligible advanced urothelial cancer, UC)— Updated response and survival results. J Clin Oncol 37(15_suppl):4546, 2019
   Bellmunt J, Balar A, Galsky MD, et al. IMvigor210: updated analyses of first-line, 1L, atezolizumab, atezo, in cisplatin, cis)-ineligible locally advanced/metastatic urothelial carcinoma, mUC). Ann Oncol 27(Suppl 6):782PD, 2016
   Sharma P, Rezt M, Siefker-Radtke, A et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy, CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312–322, 2017
   Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma, IMvigor 211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748–757, 2018
   Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026, 2017
   Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381:338–348, 2019
   Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11:400–410, 2014
   Kamoun A, de Reynies A, Yves Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420–433, 2020
   Maraz A, Varga L, Kuronya Zs. Az immunkezeles eredmenyesseget javito lehetosegek, fokuszban a celzott terapiak. Magy Onkol 63:209–216, 2019
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 329
EP 337
PG 9
ER

PT J
AU Geczi, L
   Dienes, T
   Kuronya, Zs
   Maraz, A
   Nagyivanyi, K
AF Geczi, Lajos
   Dienes, Tamas
   Kuronya, Zsofia
   Maraz, Aniko
   Nagyivanyi, Krisztian
TI Immunotherapy in advanced urothelial cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE bladder cancer; immunotherapy; pembrolizumab; nivolumab; atezolizumab
ID bladder cancer; immunotherapy; pembrolizumab; nivolumab; atezolizumab
AB Cisplatin containing chemotherapy has proven benefit for muscle-invasive locally advanced and metastatic urothelial cancer. The carboplatin based combinations are less effective in these settings. In most cases for the platinum based chemotherapy ineligible patients only the best supportive care could be given. The treatment options have expanded in the past few years with the introduction of systemic immunotherapy with checkpoint inhibitors. We review the relevant clinical trials’ data which can completely transform the treatment landscape of locally advanced or metastatic urothelial cancer.
C1 [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. 7–9., 1122 Budapest, Hungary.
   [Dienes, Tamas] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. 7–9., 1122 Budapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. 7–9., 1122 Budapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. 7–9., 1122 Budapest, Hungary.
RP Geczi, L (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM geczi.lajos@oncol.hu
CR Nemzeti Rakregiszter 2018. – https://onkol.hu/nemzeti-rakregiszter/
   Geczi L. Az invaziv hugyholyagdaganatok korszeru kemoterapias kezelese. Magy Onkol 51:133−138, 2007
   Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211−214, 2011
   Galsky MD, Hahn NM, Rosenberg J. Treatment of patients with metastatic urothelial cancer „unfit” for cisplatin-based chemotherapy. J Clin Oncol 29:2432−2438, 2011
   von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068−3077, 2000
   Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure, JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19:51−64, 2018
   Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum- containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454−4461, 2009
   Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer, KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483–1492, 2017
   O’Donnell PH, Balar AV, Vuky J, et al. First-line pembrolizumab, pembro, in cisplatin-ineligible patients with advanced urothelial cancer, UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol 39(15_suppl):4508, 2021
   Galsky MD, Arija JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer, IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. IMvigor130 Study Group. Lancet395:1547−1557, 2020
   Powles T, Csoszi T, Ozguroglu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy foradvanced urothelial carcinoma, KEYNOTE-361): a randomised, open-label,phase 3 trial. Lancet Oncol 22:931−945, 2021
   Powles T, van der Heijden MS, Castellano D, et al. Durvalumab aloneand durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma, DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21:1574−1588, 2020
   Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218−1230, 2020
   Galsky MD, Necchi A, Sridhar SS, et al. A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care, SoC, chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer, NILE). J Clin Oncol 39(6_suppl):TPS504, 2021
   Galsky MD, Powles T, Li S, et al. A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care, SOC, versus SOC alone in patients, pts, with previously untreated unresectable or metastatic urothelial carcinoma, mUC; CheckMate 901). J Clin Oncol 36(6_suppl):TPS539, 2018
   van der Heijden MS, Gupta S, Galsky MD, et al. Study EV-302: A 3-arm,open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer. Ann Oncol 31(Suppl 4):S605−S606
   Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30:970−976, 2019
   Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma, IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748−757, 2018
   Galsky MD, Saci A, Szabo PM, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarkeranalyses with extended follow-up from CheckMate 275. Clin Cancer Res26:5120−5128, 2020
   Lopez-Beltran A, Cimadamore A, Blanca et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers, Basel, 13:131, 2021
   Aurilio G, Cimadamore A, Lopez-Beltran A, et al. Narrative review: update on immunotherapy and pathological features in patients with bladdercancer. Transl Androl Urol 10:1521−1529, 2021
   Rhea LP, Mendez-Marti S, Kim D, et al. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun 26:100296, 2021
   https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-bladder-cancer/132175-esmo-2021-invited-discussant-the-phase-2-norse-trial.html
   Rey-Cardenas M, Guerrero-Ramos F, Gomez de Liano Lista A, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat Rev 93:102142, 2021
   Gartrell BA, He T, Sharma J, Sonpavde G. Update of systemic immunotherapy for advanced urothelial carcinoma. Urol Oncol 35:678−686, 2017
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 339
EP 346
PG 8
ER

PT J
AU Kuronya, Zs
   Biro, K
   Geczi, L
   Maraz, A
AF Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
   Maraz, Aniko
TI Forward directions for targeted treatment of urothelial tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE metastatic urothelial tumor; targeted treatment; erdafitinib; enfortumab vedotin; sacituzumab govitecan
ID metastatic urothelial tumor; targeted treatment; erdafitinib; enfortumab vedotin; sacituzumab govitecan
AB Platinum-based chemotherapy is the standard therapy for inoperable, locally advanced, or metastatic urothelial tumors. Although the initial response rate with combination chemotherapy is very high, the median survival is approximately 15 months. Secondary chemotherapy has had modest clinical benefit and toxicity, with the breakthrough coming from the introduction of checkpoint inhibitory immunotherapies. After chemotherapy and immunotherapy, there is currently no accepted standard of care in the third line. Based on the results of the two phase II and one phase III studies available so far, the use of targeted treatments in tertiary treatment may be a new direction. The purpose of our review is to present these clinical trials, and we would also like to draw attention to promising targeted therapies in the future.
C1 [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM kuronyaz@gmail.com
CR Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/ cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 120: 2684–2693, 2014
   Powles T, Huddart RA, Elliott T, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J Clin Oncol 35:48–55, 2017
   Oudard S, Culine S, Vano Y, et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer 51:45–54, 2015
   Rosenberg JE, Ballmann KA, Halabi S, et al. Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: Results of CALGB 90601, Alliance). J Clin Oncol 39:2486– 2496, 2021
   Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy, RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 21:105–120, 2020
   Kamoun A, De Reynies AK, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420–433, 2020
   Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib, JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res 25:4888–4897, 2019
   Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381:338–348, 2019
   Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003−3013, 2016
   Thomas P, Jonathan ER, Guru PS, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125−1135, 2021
   Bishoy F, David M, Goldenberg AJ, et al. Sacituzumab govitecan, a novel antibody drug-conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer 14:e75−79, 2016
   Goldenberg DM, Stein R, Sharkey RM, et al. The emergence of trophoblast cell-surface antigen 2, TROP-2, as a novel cancer target. Oncotarget 9:28989−29006, 2018
   Tagawa ST, Balar VA, Petrylak PD, et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 39:2474−2485, 2021
   Scholtes M, Akbarzadeh M, Zwarthoff E, et al. Targeted therapy in metastatic bladder cancer: Present status and future directions. Appl Sci 10:7102, 2020
   Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 8:812– 821, 2018
   Pal SK, Bajorin D, Dizman N, et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer 126:2597– 2606, 2020
   Maraz A, Varga L, Kuronya Zs. Az immunkezeles eredmenyesseget javito lehetosegek, fokuszban a celzott terapiak. Magy Onkol 63:209−216, 2019
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 348
EP 353
PG 6
ER

PT J
AU Piko, B
   Kis, A
   Laczo, I
   Meszaros, T
   Bassam, A
AF Piko, Bela
   Kis, Anita
   Laczo, Ibolya
   Meszaros, Tibor
   Bassam, Ali
TI Rare, but existing clinical entity – the neuroendocrine cancer of the bladder
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuroendocrine tumor of the bladder; operation; radiotherapy and cytostatic therapy; tumor agnostic therapy; palliative treatment
ID neuroendocrine tumor of the bladder; operation; radiotherapy and cytostatic therapy; tumor agnostic therapy; palliative treatment
AB The neuoroendocrine cancer of the bladder is a rare tumor, and from this entity the well-differentiated tumors with favorable prognosis, the paraganglioma with unfavorable prognosis, small and large cell types of tumors should be emphasized. From the methods of the anticancer therapies operation can be eligible by itself in the first group but in the second group should form only the part of the multimodal treatment. Radiotherapy plays a role only in the treatment of the small and large cell tumors and during the treatment of these tumors the administration of the cytostatic drugs is also essential (mainly platina derivates). Somatostatin analogs, immune checkpoint inhibitors could be beneficial in special cases and some tumor agnostic treatment can be useful as well. Moreover, the palliative treatment should represent an important modality even in the early treatment period but it should also be provided when no other treatment options are left.
C1 [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Kis, Anita] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Laczo, Ibolya] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
   [Meszaros, Tibor] Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Urologiai OsztalyGyula, Hungary.
   [Bassam, Ali] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Semmelweis u. 1., 5700 Gyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, 5700 Gyula, Hungary.
EM dr.piko.bela@gmail.com
CR Batista da Costa J, Gibb EA, Bivalacqua TJ, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clin Cancer Res 25:3908−3920, 2019
   Xia K, Zhong W, Chen J, et al. Clinical characteristics, treatment strategy, and outcomes of primary large cell neuroendocrine carcinoma of the bladder: a case report and systematic review of the literature. Front Oncol 10:1291, 2020
   Niu Q, Lu Y, Xu S, et al. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res 10:4479−4489, 2018
   Fotopoulos G, Pentheroudakis G, Ioachim E, et al. A patient with neuroendocrine carcinoma of the urinary bladder and paraneoplastic degenerative parencephalitis: A case report and review of the literature. Cancer Treat Comm 2:8−11, 2014
   Csikosne ME, Szabo A, Piko B. Online onkoteam kialakitasa a Bekes Megyei Kozponti Korhazban. IME 19:17−20, 2020
   Masood B, Iqbal N, Iqbal W, et al. Small-cell neuroendocrine carcinoma of the urinary bladder: A case report. Int J Health Sci 14:53−55, 2020
   Moretto P, Wood L, Emmenegger U, et al. Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists, CAGMO). Can Urol Assoc J 7:E44−56, 2013
   Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer. NCCN Clinical Practice in Oncology. Version 3.2021 – April 22, 2021. https://www.nccn.org/ professionals/physician_gls/pdf/bladder.pdf
   Posfai B, Kuthi L, Varga L, et al. The colorful palette of neuroendocrine neoplasms in the genitourinary tract. Anticancer Res 38:3243−3254, 2018
   Mascolo M, Altieri V, Mignogna C. et al. Calcitonin-producing well-differentiated neuroendocrine carcinoma, carcinoid tumor, of the urinary bladder: case report. BMC Cancer 5:88, 2005
   Li H, Xie J, Chen Z, et al. Diagnosis and treatment of a rare tumor-bladder paraganglioma. Mol Clin Oncol 13:40, 2020
   Hermi A, Ichaoui H, Kacem A, et al. Functional bladder paraganglioma treated by partial cystectomy. Case Rep Urol 2019:4549790, 2019
   Ranaweera M, Chung E. Bladder paraganglioma: A report of case series and critical review of current literature. World J Clin Cases 2:591−595, 2014
   Lamberti G, Brizzi MP, Pusceddu S, et al. Perioperative chemotherapy in poorly differentiated neuroendocrine neoplasia of the bladder: a multicenter analysis. J Clin Med 9:1351, 2020
   Oronsky B, Ma PC, Morgensztern D, et al. Nothing but NET: A review of neuroendocrine tumors and carcinomas. Neoplasia 19:991−1002, 2017
   Tsoli M, Chatzellis E, Koumarianou A, et al. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab 10:2042018818804698, 2018
   Orszagos Gyogyszereszeti es Elelmezes-egeszsegugyi Intezet. Somatuline Autogel 60 mg oldatos injekcio eloretoltott fecskendoben, Somatuline Autogel 90 mg oldatos injekcio eloretoltott fecskendoben, Somatuline Autogel 120 mg oldatos injekcio eloretoltott fecskendoben. Summary of Product Characteristics, SPC). https://www.ogyei.gov.hu/gyogyszeradatbazis& action=show_details&item=21749
   Liu XJ, Liu C, Liu D, Yao DW. Primary small cell carcinoma of the urinary bladder: a 10-year retrospective review of treatment and survival at a single institution. Biomed Res 29:1815−1821, 2018
   Pini GM, Uccella S, Corinti M, et al. Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior: Description of a case and review of the pertinent literature. Virchows Arch 479:69−78, 2021
   Prelaj A, Rebuzzi SE, Magliocca FM, et al. Neoadjuvant chemotherapy in neuroendocrine bladder cancer: a case report. Am J Case Rep 17:248−253, 2016
   Tiong J. Long surviving patient with metastatic neuroendocrine bladder cancer: about a case report. Clin Case Rep 5:9, 2015
   Wilde L, Ali SM, Solomides CC, et al. Response to pembrolizumab in a patient with chemotherapy refractory bladder cancer with small cell variant histology: a case report and review of the literature. Clin Genitourin Cancer 15:e521–e524, 2017
   Philip EJ, Wright F, Kim DM, et al. Efficacy of immune checkpoint inhibitors, ICIs, in rare histological variants of bladder cancer. J Clin Oncol 38(6suppl):502, 2020
   Hatayama T, Hayashi T, Matsuzaki S, et al. Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab. IJU Case Rep 3:252−256, 2020
   Nguyen OTD, Sundstrom SH, Westvik GS, et al. Major durable response of pembrolizumab in chemotherapy refractory small cell bladder cancer: a case report. Case Rep Oncol 13:1059−1066, 2020
   Petak I. Celpontalapu, szovettanitipus-agnosztikus daganatterapia es a tudorak. Magy Onkol 64:206−215, 2020
   Uhlyarik A. Agnosztikus terapia onkologiai alkalmazasa. Klin Onkol 7:315−322, 2020
   Looney AM, Nawaz K, Webster RM. Tumour-agnostic therapies. Nat Rev Drug Discov 19:383−384, 2020
   Csikos A., szerk.). Palliativ ellatas. Egyetemi jegyzet. Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, 2015. https://hospice.hu/docu/Palliativ- ellatas_egyetemi-jegyzet.pdf
   Benyo G, Lukacs M, Busa Cs, et al. A magyarorszagi palliativ-hospice ellatas helyzete, kihivasai, kitoresi pontjai. Magy Onkol 61:292−299, 2017
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2021
VL 65
IS 4
BP 355
EP 358
PG 4
ER

PT J
TI The Hungarian Society of Oncologists XXXIV. Congress
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 1
EP 66
PG 66
ER

PT J
AU Agocs, L
   Kocsis, �
   Radeczky, P
   Ghimessy, �
   Gieszer, B
   Torok, K
   Bogyo, L
   Meszaros, L
   Tallosy, B
   Csende, K
   Tihanyi, H
   Tarsoly, G
   Ferencz, B
   Megyesfalvi, Zs
   Dome, B
   Renyi-Vamos, F
AF Agocs, Laszlo
   Kocsis, Akos
   Radeczky, Peter
   Ghimessy, Aron
   Gieszer, Balazs
   Torok, Klara
   Bogyo, Levente
   Meszaros, Laszlo
   Tallosy, Bernadett
   Csende, Kristof
   Tihanyi, Hanna
   Tarsoly, Gabor
   Ferencz, Bence
   Megyesfalvi, Zsolt
   Dome, Balazs
   Renyi-Vamos, Ferenc
TI Effects of VATS and open thoracotomy on postoperative period and survival
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Video-assisted thoracoscopic surgeries (VATS) play a prominent role in the surgical treatment of early-stage non-small cell lung cancer. Nevertheless, the benefits of the method are still partly controversial. Therefore, we aimed to investigate the perioperative variables and long-term survival of lung cancer patients treated with VATS or open thoracotomy according to the surgical approach. MATERIAL AND METHOD: In our study, we analyzed data from patients diagnosed with early-stage lung cancer who underwent VATS or open anatomical resection at the Department of Thoracic Surgery of the National Institute of Oncology between 2015 and 2021. Estimated probability score matching (PSM) was used to reduce biases due to selection errors. For comparative statistical analyzes, Mann – Whitney U- and chi-square tests were used, while overall survival (OS) was analyzed by Kaplan-Meier method and log-rank test. RESULTS: A total of 1707 patients met the inclusion criteria. Data from 339/1217 patients operated on with VATS during the PSM were associated with variables from 335/490 individuals undergoing open thoracotomy. The mean duration of the surgical procedure was significantly shorter in the VATS subgroup (vs. open thoracotomy, p <0.001), and the postoperative probability of both arrhythmia (p = 0.008) and prolonged air permeability (p = 0.007) was also significantly lower in VATS surgery. as after open thoracotomy. Accordingly, the duration of hospital stay after surgery was also shorter in VATS-treated patients (p <0.001), and the mean drainage length was also significantly shorter after VATS surgery (vs. open thoracotomy, p <0.001). It should be emphasized, however, that no significant difference was observed between the two surgical approaches in terms of OS (p = 0.679). DISCUSSION: VATS anatomical resection is associated with a shorter surgical time, fewer postoperative complications, and shorter hospital stays and drainage time than open thoracotomy. However, the surgical approach used does not affect long-term survival chances. Given the one-center nature of our studies, our results should be handled with due care and further prospective studies are required to assess accurate clinical relevance.
C1 [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Tallosy, Bernadett] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Csende, Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Tihanyi, Hanna] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Tarsoly, Gabor] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Ferencz, Bence] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Megyesfalvi, Zsolt] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Agocs, L (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Agoston, P
   Jorgo, K
   Gesztesi, L
   Stelczer, G
   Kontra, G
   Major, T
   Takacsi-Nagy, Z
   Polgar, Cs
AF Agoston, Peter
   Jorgo, Kliton
   Gesztesi, Laszlo
   Stelczer, Gabor
   Kontra, Gabor
   Major, Tibor
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
TI Stereotaxic radiotherapy of patients with low to moderate risk of organ-localized prostate cancer with CyberKnife. Results of the first 100 patients treated
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To describe the results and side effects of the first 100 patients treated with extreme hypofractionated CyberKnife (CK) for stereotactic primary and low-risk primary prostate cancer (PCA). MATERIALS AND METHODS: Between February 2, 2018 and May 5, 2019, 102 patients with low and moderate risk of organ-localized PCA were treated on the CK device. Two patients were lost for follow-up, and data from 100 patients were evaluated. The mean age of the patients was 72.3 years (range, 54–82 years). Seventeen patients were treated with low-risk PCA and 83 patients with moderate-risk PCA. Forty patients also received hormone therapy for up to 6 months before and during radiotherapy. Radiation capture markers were implanted in the prostate for image-guided radiotherapy. The clinical target volume was the prostate at low risk, for which 40 Gy was administered in 5 fractions the next day. Sperm bladder bases were also treated with 32.5 Gy in medium risk using a simultaneous boost technique. Due to their elderly age, the fraction dose was reduced by 0.5 Gy in four patients. A safety zone of 3 mm was used between the clinical and design target volumes. During the treatment, the position of the markers was checked by X-ray every 30–40 seconds, and the irradiation was adjusted automatically by the CK. Patients were monitored every three months and their PSA and side effects were recorded. Biochemical relapse was determined at a PSA value greater than 2 ng / ml nadir. Additional imaging studies were performed with increasing PSA. Patient survival data were analyzed according to Kaplan-Meier, and Mann-Whitney U-test was used to compare patient groups. RESULTS: The median follow-up of patients was 24 months (duration: 6-36 months). For the overall population, the estimated 3-year overall and prostate tumor-specific survival were 97.7% and 100%, and the survival without biochemical and clinical relapse was 96.5% and 99%, respectively. Estimated 3-year biochemical relapse-free survival in hormone-treated vs. in the untreated group 100% vs. 94.2% (p = 0.146), the small vs. in moderate risk patients 100% vs. Was 95.7% (p = 0.379), respectively. Acute grade 2 gastrointestinal and urological toxicity occurred in 7% and 53%, respectively. There was no Grade 3-4 acute toxicity. Late, cumulative grade 1, 2, and 3 gastrointestinal and urological toxicity were recorded at 7%, 0%, 2%, and 16%, 17%, and 4%, respectively. DISCUSSION: In our study, the early results of irradiation of low- and medium-risk prostate tumors with CK in 5 fractions at a total dose of 37.5–40 Gy are encouraging. Although the rate of grade 2 urological adverse events was significant, no serious early adverse events occurred. The rate of late, cumulative grade 3 adverse events is less than 5%. Additional follow-up time is required to confirm the results.
C1 [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Agoston, P (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 7
EP 7
PG 1
ER

PT J
AU Badon, ES
   Andras, Cs
   Monus, A
   Mokanszki, A
   Mehes, G
AF Badon, Emese Sarolta
   Andras, Csilla
   Monus, Aniko
   Mokanszki, Attila
   Mehes, Gabor
TI Tracking of gene variants of MAP kinase signaling (KRAS, NRAS, BRAF) in histological and liquid biopsy specimens of metastatic colorectal adenocarcinoma with new generation sequencing
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Investigation of targeted gene variants is essential to assess the appropriate therapy for metastatic colorectal adenocarcinoma (mCRC). Metastatic foci may have different molecular profiles, which affects tumor progression and the effectiveness of therapy. Sequential analysis of genes makes it possible to analyze genetic modifications and variants simultaneously with high resolution, more recently from circulating free DNA extracted from peripheral blood. MATERIALS AND METHODS: At the Institute of Pathology of the Clinical Center of the University of Debrecen, molecular analysis of KRAS, NRAS and BRAF genes was performed on the histological and liquid biopsy (LB) samples of 596 CRC cases between 2019 and 2021 using reverse hybridization (Stripassay). In 259 (43%) cases, the KRAS mutant genotype was confirmed. In cases where primary and metastatic tumors, respectively. a different KRAS genotype was confirmed during LB tracking, and a new generation sequencing (NGS) of 15 gene panels (TruSight Tumor 15 Solid Tumor kit, Illumina MiSeq platform) was performed. For variant tracking, we sought an association between primary tumors, metastases, and pathogenic abnormalities detected in LB samples. RESULTS: A detailed processing of 39 histological and 41 LB samples from a total of 20 mCRC cases was performed by NGS. In 12 cases, the sample from the metastasis belonged to the primary tumor. In 14 cases, a pathogenic KRAS variant was confirmed in the primary histological specimen, but genotyping occurred in histological and LB specimens from a later time point. In six cases, the primary tumor started with a wild type and later KRAS, NRAS, or BRAF variants appeared in the LB samples. In one case, the lung metastases showed a triple variant, the liver metastases a double variant, and the LB sample showed a variant of the primary tumor, which was also present in the metastases. In another case, there is a double variant in ovarian metastasis, one of which also appeared in the primary tumor and LB sample. A further four cases confirmed double variants during sample processing. DISCUSSION: The genetic heterogeneity of malignant processes and the dynamics of variants greatly influence tumor progression and therapeutic efficacy. In mCRC cases, the molecular genetic profile may change significantly as a result of the treatments. A huge opportunity for precision oncology is to track current molecular status with LB sampling, which ideally reflects the genetic characteristics of the entire tumor mass.
C1 [Badon, Emese Sarolta] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Andras, Csilla] Debreceni Egyetem, Onkologiai Klinika, Onkologia OsztalyDebrecen, Hungary.
   [Monus, Aniko] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mokanszki, Attila] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Badon, ES (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 7
EP 9
PG 1
ER

PT J
AU Bajtai, E
   Szakacs, G
   Tovari, J
   Furedi, A
AF Bajtai, Eszter
   Szakacs, Gergely
   Tovari, Jozsef
   Furedi, Andras
TI Characterization of tumor cells surviving chemotherapy and understanding their role in the development of relapse
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Successful treatment of cancer is one of the greatest clinical challenges of our time. Although the new therapeutic approaches developed in recent decades have achieved significant success, they are not a sure way to prolong survival, one of the main reasons for which is the development of resistance in tumor cells as a result of treatment. Based on the observation that treatments are not able to completely kill even drug-sensitive tumors, it can be concluded that some of the tumor cells in the treatment are able to adapt after the first exposure to the toxic compounds and survive the treatment in a previously unknown manner. These transient, therapy-tolerant cells may ensure complete tumor survival at the start of therapy, may lead to relapse, and may allow time for the emergence of resistance mechanisms that may ultimately result in loss of treatment efficacy. MATERIAL AND METHOD: For our experiments, we have developed an in vitro technique to efficiently model the behavior of tumor cells surviving high-dose chemotherapy. In our studies, breast tumor cell lines with different molecular backgrounds and morphologies (MCF-7, T47D, MDA-MB-231, Hs578T) were treated with high-dose doxorubicin, and cultures were monitored for several weeks to examine the morphological and molecular changes in surviving cells. RESULTS: Surviving cells typically showed altered morphology: increased nucleus and cytoplasmic volume, and a large, flattened cell body. In addition, extensive DNA damage and significantly increased mitochondrial lysosome levels were detected in surviving cells. These properties are called characteristic of cellular senescence. To the best of our knowledge, cellular senescence is an irreversible cell cycle closure due to DNA damage, however, our results show that these surviving tumor cells are still able to exit this condition and begin to divide again after a long time. These observations may explain the onset of relapses, which often recur long after chemotherapy. DISCUSSION: The state of cellular senescence raises the so-called the use of senolytic (in combination with senescent cells) in combination with chemotherapy. By destroying the critical subpopulation of tumor cells that survive chemotherapy, it would be possible to eliminate or reduce the likelihood of relapse.
C1 [Bajtai, Eszter] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Szakacs, Gergely] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Furedi, Andras] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
RP Bajtai, E (reprint author), Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balatoni, T
   Panczel, G
   Madurka, I
   Szilagyi, R
   Kertai, P
   Kende, HR
   Liszkay, G
AF Balatoni, Timea
   Panczel, Gitta
   Madurka, Ildiko
   Szilagyi, Ruth
   Kertai, Petra
   Kende, Hanna Rebekka
   Liszkay, Gabriella
TI Covid-19 and melanoma: 1 year of experience at the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The Covid-19 pandemic, in addition to causing millions of deaths worldwide in just over 1 year, has a number of other indirect negative consequences, of particular importance for those at risk of underlying disease and drug therapies. problem. MATERIAL AND METHOD: In our study, March 2020 - 2021. We analyzed the course of patients with advanced melanoma treated at our center between March and 2007 based on our institutional database. Covid-19 infection and vaccination data were recorded. RESULTS: During the above period, 382 patients received systemic treatment for melanoma at our center, 181 received immunotherapy, 141 received targeted biological therapy, and 60 received chemotherapy. Twenty-four of our treated patients became infected with the SARSCoV-2 virus during therapy. The “1. only one of our treated patients, 6 patients in November – December 2020, and then 18 patients in therapy in February – April 2021, were affected by coronavirus infection. The median age of our patients was 60 years, six of whom received stage III, 18 of whom received stage IV, 14 patients received immunotherapy, 5 and 4 patients received targeted therapy and chemotherapy, respectively, and we were unable to start treatment with fulminant therapy. due to coronavirus infection. In 7 of our patients with Covid infection (29%), the patient was killed by a viral infection, with an average of 11.8 days. 1 patient has post-Covid syndrome and 2 patients have persistent PCR positivity. No patient was able to complete the vaccination before infection, 3 of our patients received a single vaccination, and the course of the infection was asymptomatic or mild in all three cases. DISCUSSION: Among our patients with advanced cancer, the lethality of SARS-CoV-2 virus infection was significantly higher than the mortality observed in the age-proportioned population. Although only a small group of our patients were vaccinated during the study period, there were no deaths or severe infections among them. The above also draws attention to the importance of vaccination, which is of particular importance in cancer patients.
C1 [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Madurka, Ildiko] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Szilagyi, Ruth] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kertai, Petra] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kende, Hanna Rebekka] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 9
EP 9
PG 1
ER

PT J
AU Balazs, K
   Juranyi, Zs
   Kocsis, Zs
   Agoston, P
   Jorgo, K
   Polgar, Cs
   Safrany, G
   Lumniczky, K
AF Balazs, Katalin
   Juranyi, Zsolt
   Kocsis, S. Zsuzsa
   Agoston, Peter
   Jorgo, Kliton
   Polgar, Csaba
   Safrany, Geza
   Lumniczky, Katalin
TI Effect of low and high dose brachytherapy on systemic immunological parameters in prostate cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Early detection and personalized treatment of prostate cancer is still a major challenge today due to the lack of reliable prognostic / predictive markers. The aim of our study is to provide long-term monitoring of tumor-associated ionizing radiation-induced systemic immune processes in groups of patients with prostate cancer treated with different radiotherapy protocols, the knowledge of which may contribute to more accurate prediction of therapeutic response and side effects. MATERIAL AND METHOD: Peripheral blood samples were collected at 8 time points before and after treatment for four years. To date, immunophenotyping of peripheral mononuclear cells from low-dose (LDR) and high-dose (HDR) brachytherapy patients has been achieved. RESULTS: In the HDR patient group, the levels of naive and activated CD8 T cells decreased significantly due to the tumor, however, the levels of early senescent CD8 and CD4 T cells showed a strong significant increase in the post-therapy time points up to 36 months. The level of effector memory cells migrating to the site of inflammation was also elevated in the HDR group 3 months after therapy compared to the control group and pre-treatment values. Changes in several functional cell populations in the two patient groups were compared, such as different maturation subpopulations of natural killer (NK) cells. The levels of mature cytotoxic NK cells decreased in the HDR group compared to the control group, while their level in the LDR group showed a strong increase from 3 months, which can be detected 36 months later. The levels of degranulated NK cells performing their function were elevated prior to therapy in both groups and then further increased in the HDR group, while they dropped below 3 months in the LDR group throughout the follow-up period. The proportion of lymphoid dendritic cells (DCs) varied similarly in the two patient groups; before and after therapy increased for 3 months compared to the control and then returned to normal. DISCUSSION: We found significant differences and changes in the immune parameters of prostate cancer patients receiving two types of brachytherapy, which may be related to the different kinetic ionizing radiation release underlying different therapeutic protocols, which may significantly affect the immune process in patients. Support: National Office for Research, Development and Innovation (ID: NKFI-124879)
C1 [Balazs, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Juranyi, Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kocsis, S. Zsuzsa] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Balazs, K (reprint author), Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 9
EP 10
PG 1
ER

PT J
AU Baranyai, F
   Balatoni, T
   Czirbesz, K
   Panczel, G
   Kispal, M
   Danyi, T
   Frohlich, G
   Liszkay, G
AF Baranyai, Fanni
   Balatoni, Timea
   Czirbesz, Kata
   Panczel, Gitta
   Kispal, Mihaly
   Danyi, Timea
   Frohlich, Georgina
   Liszkay, Gabriella
TI Comparison of side effects of BRAF-MEK inhibitor therapies in 118 patients with metastatic melanoma at the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In BRAF-mutant melanoma, BRAF-MEK inhibitor therapy provides a significant survival advantage over prior chemotherapy and BRAF inhibitor monotherapy. There is no statistically significant difference in their effectiveness, but their side effect profile is different. In our study, we summarized our clinical experience with BRAF-MEK inhibitor therapy (38 patients vemurafenib-cobimetinib, 80 patients dabrafenib-trametinib) in a total of 118 patients with disseminated melanoma between 2015 and 2018. The aim of our study was to compare the side effect profile of combination therapies based on real-life data. MATERIAL AND METHOD: There were 58 women (49%) and 61 men (51%) in the patient population studied. The mean age was 58.8 years in the dabrafenib-trametinib group and 60.7 years in the vemurafenib-cobimetinib group. The median follow-up was 12 months (3-43) for dabrafenib-trametinib and 18 months (3-43) for vemurafenib-cobimetinib. Adverse reactions were classified according to CTCAE 4.03 terminology. RESULTS: Elevated liver enzymes (50%), rash (34%), diarrhea (39%), elevated CPK (32%), and photosensitivity (29%) were most commonly observed with vemurafenib-cobimetinib therapy. Serous retinopathy occurred in 13% of patients. Grade 3-4 adverse events were detected in 34%. Dose modification was required in 11 patients. 6 patients were forced to discontinue cobimetinib therapy (16%) and 2 patients were permanently discontinued from vemurafenib therapy (5%). Elevated CPK (24%), hepatic enzyme function (13%), fever (13%), diarrhea (8%), papulopustular rash (9%) and leukocytopenia (6%) were most commonly observed with dabrafenib-trametinib therapy. Serous rethinopathy occurred in 2% of patients. Grade 3-4 side effects were detected in only 10%. A dose modification of 20% was required. None of the patients had to discontinue dabrafenib-trametinib permanently. DISCUSSION: Both BRAF-MEK inhibitor therapies can be used with similar efficacy in BRAF-positive metastatic melanoma, prolonging both progression-free survival and overall survival compared to previously used DTIC chemotherapy or BRAF inhibitor monotherapy. However, their side effect profile is slightly different based on our clinical experience and international literature. In summary, due to the different spectrum of side effects, it is recommended that patients' comorbidities be considered in the choice of therapy.
C1 [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Baranyai, F (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 10
EP 10
PG 1
ER

PT J
AU Bartha, �
   Munkacsy, Gy
   Klement, �
   Darula, Zs
   Nyirady, P
   Gyorffy, B
AF Bartha, Aron
   Munkacsy, Gyongyi
   Klement, Eva
   Darula, Zsuzsanna
   Nyirady, Peter
   Gyorffy, Balazs
TI Targeted analysis of clear cell kidney and normal kidney transcriptome and proteome levels
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Clear cell kidney cancer is the most common kidney cancer, accounting for roughly 80% of all cases. Although the survival rate in low-stage patients is relatively favorable (93% of patients exceed five-year survival), the prognosis in patients with distant metastases is significantly worse. Therefore, the identification of key genes and proteins involved in the development and progression of renal cell carcinoma may provide valuable information to prolong patient survival. The aim of our research was to identify new potential prognostic and predictive biomarkers for clear cell kidney cancer. MATERIALS AND METHODS Using our online gene chip and RNA sequencing databases, we identified genes that show different expression in patients with kidney cancer and normal tissue samples. In the next step, RNA sequencing was performed on tissue samples from patients treated at the Department of Urology, Semmelweis University. Proteins from genes with different gene expressions were also evaluated by targeted mass spectrometry to obtain protein-level expression data. RESULTS: In the course of our research, we created a database containing a total of 558 tumor and normal tissues, of which 414 gene chip and 144 RNA sequencing data. Based on the created database, we identified the top 30 genes that may play an important role in the pathogenesis of renal cell carcinoma. Among the identified genes, IGFBP3 (p = 2.17E-12), PLIN2 (p = 1.10E-11) and PFKP (p = 3.24E-12) showed the most significant differences. The determined gene panel was also validated on samples containing 162 renal tumors and associated normal tissues using RNA-Seq and mass spectrometry. In the analysis of the independent data set, IGFBP3 (p = 2.75E-11), PLIN2 (p = 4.79E-11), and PFKP (p = 4.76E-05) showed significant differences in RNA expression levels. Proteomic analysis also confirmed the differential expression of IGFBP3 (p = 2.64E-19), PLIN2 (p = 1.11E-33), and PFKP (p = 8.66E-35) in normal and tumor tissues. DISCUSSION: Nowadays, a limited number of therapeutic options are available for the molecularly targeted therapy of clear cell kidney cancer, and our results will help us explore new therapeutic options. Furthermore, the specific gene panel may be suitable to support diagnostic and prognostic decision making.
C1 [Bartha, Aron] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Munkacsy, Gyongyi] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Klement, Eva] HCEMM, Single Cell Omics Advanced Core FacilitySzeged, Hungary.
   [Darula, Zsuzsanna] HCEMM, Single Cell Omics Advanced Core FacilitySzeged, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
RP Bartha, � (reprint author), Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 10
EP 11
PG 1
ER

PT J
AU Bellyei, Sz
   Nagy, B
   Mangel, L
AF Bellyei, Szabolcs
   Nagy, Bettina
   Mangel, Laszlo
TI Special indications for the use of cetuximab in the treatment of head and neck tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The standard treatment for locally advanced head and neck tumors is radiochemistry using high doses of cisplatin. In cases where the use of cisplatin is high risk or contraindicated, radiotherapy may be treated with cetuximab. MATERIAL AND METHOD: We present the cases of 2 patients. A 65-year-old male patient has been receiving hemodialysis for years due to chronic renal failure. T4N2-stage mesopharynx occupancy was diagnosed. Cisplatin is contraindicated in patients with renal insufficiency. A 66-year-old male patient who has undergone liver transplantation due to liver failure and has since been receiving immunosuppressive therapy. Supraglottic squamous cell carcinoma of stage T3N0 was found. Cisplatin is not possible due to immunosuppressive therapy. In both cases, radiotherapy (70 / 2Gy total dose + weekly cetuximab) was used. RESULTS: The treatment was well tolerated by a male patient on hemodialysis. He received a weekly dose of cetuximab for 7 cycles, with a 4-day rest period due to Grade II-III skin and mucosal reactions in the last weeks of treatment. She completed treatment 3 years ago and has been cancer-free ever since. The male liver transplant patient underwent treatment with almost no complaints, received 7 cycles of cetuximab, and did not require treatment interruption. It has been tumor free for 1 year. In both cases, supportive care was used (in consultation with peers) to prevent side effects (doxycycline, NSAID, topical steroid, topical anesthetic, caphasol). DISCUSSION: Cetuximab is recommended when cisplatin is contraindicated. After transplantation, cetuximab can be safely administered in patients with renal insufficiency, even during dialysis.
C1 [Bellyei, Szabolcs] University of Pecs, Department of OncologyPecs, Hungary.
   [Nagy, Bettina] University of Pecs, Department of OncologyPecs, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
RP Bellyei, Sz (reprint author), University of Pecs, Department of Oncology, Pecs, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Biro, A
   Koch, L
   Matics, Zs
   Erdelyi, T
   Muller, V
   Tamasi, L
AF Biro, Andrea
   Koch, Lilla
   Matics, Zsombor
   Erdelyi, Tamas
   Muller, Veronika
   Tamasi, Lilla
TI Epidemiology of real-life oncopulmonary patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: There are few real-life data analyzes available for the Central European oncopulmonary patient population. The aim of our study was to identify areas for further development through a systematic survey of oncology care in our institution. MATERIAL AND METHOD: June 1, 2019 - 2020. In the interval between 05. and 31, the data of the patients presented to the Oncology Committee of our institution during one year were subjected to a cross-sectional examination. Age, gender, history of smoking, incidence of chronic obstructive pulmonary disease (COPD), diagnosis supported by histology or cytology, presence of frequent driver mutations, rate of programmed cell death ligand-1 expression, stage of diagnosis, perform therapeutic modalities (surgery, irradiation, systemic oncotherapy). RESULTS: Of the 613 patients presented to the Oncology Committee, 443 were diagnosed with primary lung cancer by histological or cytological examination. No pathological verification was performed in 110 patients, and mesothelioma, lymphoma, solid tumor lung metastases, or benign disease were confirmed in 60 patients. The median age of patients diagnosed with lung cancer was 68 years (range 38-91 years), with 51% female. The histological types are distributed as follows: adenocarcinoma 54%, squamous cell carcinoma 28%, small cell lung cancer 14%. COPD is reported as comorbidity in 51% of lung cancer cohorts, with the highest proportion among patients with squamous cell carcinoma (64%). 40% of patients with non-small cell lung cancer were in the early stage (IA-IIIA) at the time of diagnosis. Eighty-seven percent of patients with early-stage adenocarcinoma and only 51% of patients with early-stage squamous cell carcinoma received curative surgical care. In locally advanced and metastatic adenocarcinoma, driver mutations were seen with EGFR 8%, ALK 2%, BRAF 3% (determined in 89, 81, and 56 percent of patients, respectively). 11% of non-small cell lung carcinoma patients receiving systemic oncotherapy received immunotherapy in the first line and 43% in the second or third line. DISCUSSION: Pathological verification should not be performed due to poor performance status, low compliance, or severe COPD in a significant number of patients tested for pulmonary volume. The treatment of early-stage planocellular carcinoma remains a challenge due to the frequent severe comorbidities. Immunotherapy is gaining ground in real-life oncopulmonology care.
C1 [Biro, Andrea] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Koch, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Matics, Zsombor] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Erdelyi, Tamas] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Biro, A (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 11
EP 11
PG 1
ER

PT J
AU Biro, K
   Budai, B
   Geczi, L
   Petri, K
AF Biro, Krisztina
   Budai, Barna
   Geczi, Lajos
   Petri, Klara
TI Our experience in the primary stage of testicular cancer with repeated early imaging
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Testicular cancer, although a relatively rare disease, is the most common organ-derived tumor in young men. When treated in the center, an excellent recovery of up to 95% can be achieved. In recent years, one of the main goals has been to reduce the side effects of treatment while maintaining excellent results. The first step in this direction is to avoid unnecessary treatments. In case of only moderately elevated marker levels (AFP <20 ng / ml and / or HCG <20 mU / l), recommendations are recommended to repeat the laboratory test. If lymph nodes <2 cm or small insecure foci are found in the retroperitoneum, “early restaging” is recommended. This means repeating the CT scan in seminoma (S) 8 weeks and in non-seminoma (NS) 6 weeks after stage-determining CT. MATERIALS AND METHODS: Between January 1, 2017 and May 1, 2021, onceam recommended early restaging (18 S and 12 NS) in our ward. Mean age of seminoma: 35 years, non-seminoma: 42 years. In 27 of the 30 patients, the initial CT showed enlarged or enlarged lymph nodes at a typical site (stage II / A), and in 3, insecure lung foci (stage III / A) were found. RESULTS: On the control CT scan, regression was observed in 11 patients, stable disease in 10 patients, and progression in 9 patients (7 NS, 2 S). 8 patients had baseline stage II / A and one had stage III / A. Elevation of the marker before castratio did not predict progression. Based on control CT, 1 patient remained stage III / A (growing lung nodule), 4 patients became stage II / B (> 2 cm lymph node), and 4 patients remained stage II / A. After confirmation of progression, patients received 3 BEPs. Eight patients developed CR as a result of chemotherapy, but one patient required retroperitoneal lymphadenectomy for teratoma. Although the timing of control CTs did not meet the international recommendation (mean 3.1 months in seminoma and 3.6 months in non-seminoma), all 30 patients were tumor-free and well. DISCUSSION: “Early restaging” is a safe procedure in testicular cancer. In 21 (70%) of the 30 patients we examined, unnecessary chemotherapy could be avoided. In the future, however, efforts should be made to schedule CT scans appropriately.
C1 [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Petri, Klara] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Biro, K (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 11
EP 13
PG 1
ER

PT J
AU Bittner, N
   Szanto, E
   Der, �
   Csiki, E
   Besenyoi, M
   Barta, Zs
   Simon, M
   Orosz, Zs
   Lieber, A
   Kovacs, �
AF Bittner, Nora
   Szanto, Erika
   Der, Adam
   Csiki, Emese
   Besenyoi, Maria
   Barta, Zsuzsanna
   Simon, Mihaly
   Orosz, Zsuzsanna
   Lieber, Attila
   Kovacs, Arpad
TI A III. Our initial experience with the treatment of patients with stage NSCLC supplemented with chemotherapy after duroumab (durvalumab)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To evaluate the experience with chemo-radiotherapy and subsequent durvalumab treatment in patients with non-small cell lung cancer. MATERIALS AND METHODS: From June 2019 to May 2021, chemo-radiotherapy was administered to 16 patients at the DEKK Oncoradiology and Pulmonary Medicine Clinics, followed by immunotherapy. stage, non-small cell, PD-L1-positive lung cancer. Irradiation was performed by VMAT technique at a total dose of 60–70 Gy in competitive or sequential chemo-radiotherapy. If there was no evidence of progression on control CT after radiotherapy, patients received durvalumab. Respiratory function parameters were also examined in patients before and after treatment. RESULTS: The mean age of the patients was 61 years (53–74 years), 56% were male and 44% were female. Based on diagnostic imaging, the largest tumor diameter was 44 (15–80) mm on average. 9 patients received competing, 7 patients received sequential chemo-radiotherapy and were well tolerated. All 16 patients are currently being monitored, with a median survival of 11.6 months from baseline and an average of 11.3 cycles of durvalumab treatment to date. Immunotherapy was discontinued in 2 patients after 1 year of treatment in 2 patients, and is still ongoing in 12 patients based on stable disease. DISCUSSION: In our experience, combination therapy with subsequent immunotherapy is well tolerated in patients with adequate patient selection. Our results with chemo-radiotherapy followed by durvalumab immunotherapy in non-small cell lung cancer patients are encouraging and are being followed up.
C1 [Bittner, Nora] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Szanto, Erika] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Der, Adam] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Csiki, Emese] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Besenyoi, Maria] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Barta, Zsuzsanna] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Simon, Mihaly] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Orosz, Zsuzsanna] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Lieber, Attila] University of Debrecen Medical and Health Science Center, Department of Pulmonary MedicineDebrecen, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
RP Bittner, N (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Bozsik, A
   Grolmusz, VK
   Papp, J
   Butz, H
   Patocs, A
   Olah, E
AF Bozsik, Aniko
   Grolmusz, Vince Kornel
   Papp, Janos
   Butz, Henriett
   Patocs, Attila
   Olah, Edit
TI Clarification of the pathogenetic role of BRCA1 / 2 variants (VUS) with unknown effects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our department, genetic testing for hereditary breast cancer will also detect rare BRCA1 / 2 variants whose pathological role is unclear based on clinical databases. These are called unknown effect variants (VUS). These are mandatory on the genetic finding, but their clinical interpretation is difficult. RNA-level functional studies and further analysis of tumor tissues are required to assess their pathogenicity. MATERIAL AND METHOD: We performed RNA-level studies of six rare variants that were likely to cause defective splicing (intron excision) with in silico predictions. RNA was recovered from peripheral blood cells, from which RT-PCR was performed with primers designed for exons surrounding the variant. In addition to the control, the presence of aberrant product of different sizes was examined by agarose gel electrophoresis. Bidirectional Sanger sequencing confirmed the exact nucleotide level change and RNA expression as well as the structure of the protein encoded by it. Where possible, a heterozygosity loss test was also performed on the tumor tissue of the probands carrying the variants. RESULTS: The presence of aberrant splice product was confirmed for four variants. One of these (BRCA1 c.4484 + 4dupA) destroyed a physiological splice donor site. BRCA1 c.4358-31A> C altered a nucleotide with a branchpoint role, but the extent of the splicing caused by this was incomplete. At the transcript level, both variants resulted in the omission of exon 14 of BRCA1, which caused an early termination codon and degradation of the defective RNA. In the third case (BRCA1 c.5407-10G> A), the formation of a de novo splice acceptor site and an 8 base intron inclusion was observed. Loss of heterozygosity was also detected in the tumor in this variant. The fourth variant (BRCA2 c.8487G> T) altered the last nucleotide of the exon, rendering the normal splice donor site inoperable. This was associated with complete deletion and loss of function of the BRCA2 exon 19. DISCUSSION: For three variants (BRCA1 c.4484 + 4dupA, BRCA1 c.5407-10G> A, BRCA2 c.8487G> T), clear evidence from RNA-level functional assays and tumor tissue assays from the “unknown effect” reclassification to the “likely pathogenic” category was allowed. For the fourth variant (BRCA1 c.4358-3A> C), the presence of partial aberrant splicing suggested its likely pathogenic role, but further evidence is needed for a clear reclassification.
C1 [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Grolmusz, Vince Kornel] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Butz, Henriett] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Bozsik, A (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 13
EP 13
PG 1
ER

PT J
AU Butz, H
   Papp, J
   Bozsik, A
   Grolmusz, V
   Olah, E
   Patocs, A
AF Butz, Henriett
   Papp, Janos
   Bozsik, Aniko
   Grolmusz, Vince
   Olah, Edit
   Patocs, Attila
TI Investigation of breast cancer risk genes beyond BRCA1 / 2
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Genetic studies to determine the risk of breast cancer have been widely used, although the relationship between these genes and the risk of breast cancer, with the exception of BRCA1 / 2 genes, is weak and their exact clinical relevance is uncertain. Given that BRCA1 / 2 pathogenic variants cannot be identified in the background of many familial cases, it is important to clarify the role of other candidate genes in addition to BRCA1 / 2 genes. MATERIALS AND METHODS: Of the patients sent for genetic testing between 2015 and 2020, we performed exome sequencing in 48 BRCA1 / 2 negative cases where either a suggestive family history or young age suggested heredity. RESULTS: Analysis of 20 genes other than BRCA1 / 2 previously associated with breast cancer risk in the literature identified a pathogenic variant (PV) in 8% (4/48) of the BARD1, PTEN, TP53 and CHEK2 genes, 33% ( 16/48) and a variant of unknown significance (VUS) in 9 genes. Of the variants identified, 9 are new, previously unknown deviations. In the case of PV carriers, the disease occurred at an average age of 7 years younger (p = 0.03). No significant differences were found between the tumor tissue characteristics (hormone receptor and HER2 status, proliferation index) of PV carriers and non-carriers, and tumors of PV carriers typically had hormone receptor-positive histology. Further categorization of VUSs in silico may lead to a more pathogenic effect in 4 cases and a more benign effect in 8 cases, however, further characterization of VUSs is warranted. DISCUSSION: Examination of breast cancer risk genes beyond the BRCA1 / 2 genes may identify additional patients at risk for heredity and increased risk of breast cancer. The so-called high-risk genes (TP53, PTEN, STK11, CDH1) may present with poor clinical abnormalities due to reduced penetrance, and these can only be identified by extended testing. The inclusion of carriers in the early screening protocol is also recommended for genes with a medium risk for breast cancer, so extended gene panel testing should be used in clinical practice for these genes.
C1 [Butz, Henriett] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Grolmusz, Vince] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Olah, Edit] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Molekularis Genetika OsztalyBudapest, Hungary.
RP Butz, H (reprint author), Orszagos Onkologiai Intezet, Molekularis Genetika Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 13
EP 14
PG 1
ER

PT J
AU Budi, L
   Tamasi, L
   Sutto, Z
   Dombai, B
   Seres, �
   Polivka, L
   Muller, V
AF Budi, Lilla
   Tamasi, Lilla
   Sutto, Zoltan
   Dombai, Brigitta
   Seres, Eva
   Polivka, Lorinc
   Muller, Veronika
TI Covid-19 in Malignancies - Experiences from the Covid Departments of the Department of Pulmonology, Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The Covid-19 pandemic has a significant direct and indirect impact on the care of oncology patients. Epidemiological rules may delay diagnosis (bronchoscopy, respiratory function, isolation, etc.), make it more difficult to arrange oncology treatments (infectious controls in connection with treatments), and those with malignancies are at risk for infections. No domestic data are available to date on Covid-19 disease in cancer patients. MATERIALS AND METHODS: SARS-Cov-2 infection confirmed by RT-PCR (real time polymerase chain reaction assay) or Panbio-Covid-19 antigen rapid test at the Covid Departments of the Department of Pulmonology, Semmelweis University data from patients with solid or haematopoietic malignancies within 5 years were pooled. RESULTS: A total of 52 patients were analyzed for clinical, radiological, and laboratory data (mean age 69.5 years [47−92], 65% male). The majority of patients were diagnosed with solid tumors (n = 43; 82%) and 32 (61.5%) were undergoing active oncology at admission. The most common tumor was lung cancer (n = 17; 33%). Half of the patients were enrolled in ECOG-PS> 2. Covid-19 pulmonary parenchyma involvement was seen on chest CT scans in 38 (73%) patients during the treatment period. In addition to steroid prophylaxis, ulcer and thrombosis prophylaxis according to the protocol, 44 (84.5%) patients required oxygen supplementation, 9 (17%) patients received reconvalent plasma, 10 (19%) patients received favipiravir, and 10 (19%) patients received remdesivirt. Mortality was found to be 50%, with the majority dying in active treatment and those receiving palliative drug oncotherapy. DISCUSSION: Covid-19, caused by the SARS-CoV-2 virus, has one of the highest mortality rates in cancer patients.
C1 [Budi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Sutto, Zoltan] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Dombai, Brigitta] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Seres, Eva] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Polivka, Lorinc] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Budi, L (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Czikora, �
   Erdelyi, K
   Szanyi, Sz
   Balog, N
   Toth, AM
   Ditroi, T
   Tovari, J
   Nagy, P
AF Czikora, Agnes
   Erdelyi, Katalin
   Szanyi, Szilard
   Balog, Noemi
   Toth, Anna Maria
   Ditroi, Tamas
   Tovari, Jozsef
   Nagy, Peter
TI Investigation of the role of cystathionine β-synthase overexpression in pancreatic ductal adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our previous measurements, we observed a significant increase in the expression of one of the key enzymes in the transulfuration pathway, cystathionine β-synthase (CBS), in pancreatic ductal adenocarcinoma. The aim of our study was to explore the role of redox metabolomic and signaling changes induced by CBS overexpression in PDAC progression and metastasis. MATERIAL AND METHOD: In vitro experiments used immortalized cell lines from lymph node metastasis (T3M4) and primary tumor (BxPC3). Molecular biology (RNA-based gene silencing, qPCR), biochemical (Western blot) and cell biology (wound closure and colony formation assays) measurements were performed on the cells. In our in vivo measurements, we used NOD SCID male mice to study metastasis. Mice were inoculated directly into the pancreas with T3M4 cells and tumor formation was monitored, and liver tissues isolated from the mice were subjected to immunohistochemistry. RESULTS: For our measurements, we generated the CBS-deficient T3M4 cell line by RNA-based gene silencing, in which we found reduced WNT5a gene expression compared to the control during our qPCR measurements. A similar result was obtained for primary tumor cells. We also confirmed this observation at the protein level using Western blot. The WNT5a molecule plays an important role in the major steps of the metastasis cascade. Wound closure and colony formation assays also showed that genetically CBS-deficient and primary tumor cells migrate more slowly compared to control T3M4 cells. In our experiments, we tried to find an explanation for what may be behind the decrease in WNT5a protein. Under normal conditions, a decrease in STAT3 phosphorylation was observed in CBS-deficient cells, which was further reduced by cystine withdrawal. We hypothesize that this may be due to the formation of intra- and intermolecular disulfide bridges due to the oxidative oxidation of STAT3, which leads to a decrease in the transcriptional activity of STAT3. Our in vitro results were also confirmed by in vivo mouse experiments. The genetically CBS-deficient cell line inoculated into the pancreas resulted in fewer liver metastases compared to the control. DISCUSSION: In summary, CBS overexpression through the regulation of epithelial-mesenchymal transition also plays an important role in the aggression and metastasis of ductal adenocarcinoma.
C1 [Czikora, Agnes] National Institute of OncologyBudapest, Hungary.
   [Erdelyi, Katalin] National Institute of OncologyBudapest, Hungary.
   [Szanyi, Szilard] National Institute of OncologyBudapest, Hungary.
   [Balog, Noemi] National Institute of OncologyBudapest, Hungary.
   [Toth, Anna Maria] National Institute of OncologyBudapest, Hungary.
   [Ditroi, Tamas] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
RP Czikora, � (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 14
EP 14
PG 1
ER

PT J
AU Csanyi, I
   Houshmand, N
   Szucs, M
   Ocsai, H
   Kemeny, L
   Olah, J
   Baltas, E
AF Csanyi, Ildiko
   Houshmand, Nazanin
   Szucs, Monika
   Ocsai, Henriette
   Kemeny, Lajos
   Olah, Judit
   Baltas, Eszter
TI Clinicopathological characterization and prognostic factors of acrolentiginosus melanoma: a single-center, four-decade retrospective study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Acrolentiginosus melanoma (ALM) is a rare prognostic subtype of cutaneous melanoma (CM) in Caucasian skin types that originates from the skin under the palms, soles, and nails. It is rare in Caucasian skin types. In our study, we aimed to summarize and evaluate the experience of ALM over the past nearly 40 years in the light of literature data. MATERIALS AND METHODS: Within the framework of a retrospective study, we reviewed the demographic data of our patients diagnosed with ALM at the Department of Dermatology and Allergology of the University of Szeged between 1976 and 2016, the conditions of diagnosis, the main characteristics of cancer and diagnostics. Our data were analyzed by statistical methods, survival by Kaplan-Meier analysis, and prognostic factors by Cox regression model. RESULTS: A total of 4593 cases of cutaneous melanoma were diagnosed over 40 years, of which 176 (3.83%) were ALM. The mean age of the patients was 66.2 years, and it took an average of 18 months from the time the skin lesion was detected to the time of seeing a doctor. A significant proportion of tumors (88.63%) occurred in the lower limb. The mean Breslow tumor thickness was 3.861 mm, 37.5% of tumors were thicker than 4.00 mm, and microscopic ulceration was present in 71.6%. Nearly one-third of the patients underwent sentinel lymph node (SLN) biopsy, of which 60.3% were positive. In SLN-positive cases, we encountered significantly thicker tumors and poorer survival. The overall survival of our patients at 5 and 10 years was 60.5 and 41.6%, respectively. In a multivariate Cox regression analysis, patient age, tumor thickness, and the presence of distant metastases were shown to be independent prognostic factors for survival. DISCUSSION: We found that the clinicopathological features and prognostic factors of ALM in our region were similar to those previously seen in Caucasian skin type. It should be noted that Breslow's tumor thickness, which influenced the prognosis of the disease, was found to be higher in our case, and the survival of our patients was less favorable. The importance of our study is underlined by the fact that we were the first to summarize data on ALM in Central and Eastern Europe.
C1 [Csanyi, Ildiko] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Houshmand, Nazanin] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Szucs, Monika] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Ocsai, Henriette] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kemeny, Lajos] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Baltas, Eszter] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Csanyi, I (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 14
EP 15
PG 1
ER

PT J
AU Cserepes, M
   Turk, D
   Toth, Sz
   Pape, V
   Gaal, A
   Gera, M
   Szabo, JE
   Kucsma, N
   Varady, Gy
   Vertessy, B
   Streli, Ch
   Szabo, P
   Tovari, J
   Szoboszlai, N
   Szakacs, G
AF Cserepes, Mihaly
   Turk, Dora
   Toth, Szilard
   Pape, Veronika
   Gaal, Aniko
   Gera, Melinda
   Szabo, Judit Eszter
   Kucsma, Nora
   Varady, Gyorgy
   Vertessy, G. Beata
   Streli, Christina
   Szabo, T. Pal
   Tovari, Jozsef
   Szoboszlai, Norbert
   Szakacs, Gergely
TI Targeted killing of multidrug-resistant tumors by selective iron depletion of P-glycoprotein-expressing cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Modern chemotherapy for the treatment of cancer is initially effective, but over time it is often impossible in the clinic, leading to disease progression and ultimately inadequate treatment. Expression of the multidrug transporter P-glycoprotein (Pgp) is responsible for the removal of many drugs from the cell and thus for resistance to a number of substrates (multidrug resistance, MDR). However, in the group of 8-hydroxyquinoline derivatives we studied, many compounds show the opposite effect: in the case of increased Pgp function, the cells are more sensitive and the compounds are more toxic (MDR-selective toxicity). In our work, we investigated the mechanism of action of the potent MDR-selective 8-hydroxyquinoline derivative, NSC297366, capable of metal chelation activity. RESULTS: The effects measured in tumor cells were comparable to those of other iron chelators, both at the molecular level by altering the expression of transferrin receptor (TfR) and hypoxia-inducible factor (Hif-1a), and by altering ribonucleotide reductase and p53 activity in cell cycle regulation. for cell death (apoptosis). Direct measurement of cellular iron levels and chelator levels showed that export of the chelator-iron complex via Pgp may lead to selective iron deficiency in tumor cells. DISCUSSION: Our results identify iron homeostasis as a novel therapeutic strategy to target the destruction of Pgp-expressing multidrug-resistant tumor cells, preventing or reversing the development of chemotherapy resistance.
C1 [Cserepes, Mihaly] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Turk, Dora] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Toth, Szilard] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Pape, Veronika] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Gaal, Aniko] Eotvos Lorand University, Faculty of Science, Institute of ChemistryBudapest, Hungary.
   [Gera, Melinda] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Szabo, Judit Eszter] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Kucsma, Nora] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Varady, Gyorgy] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Vertessy, G. Beata] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Streli, Christina] Technische Universitaet Wien, AtominstitutVienna, Austria.
   [Szabo, T. Pal] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Szoboszlai, Norbert] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
   [Szakacs, Gergely] Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi KutatokozpontBudapest, Hungary.
RP Cserepes, M (reprint author), Eotvos Lorand Kutatasi Halozat, Termeszettudomanyi Kutatokozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Csernak, E
   Bencze, E
   Fulop, L
   Toth, E
AF Csernak, Erzsebet
   Bencze, Eszter
   Fulop, Laszlo
   Toth, Erika
TI Experiences of Liquid Biopsy Examinations at the Department of Surgery and Molecular Pathology of the National Institute of Oncology between 2019−2021
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The most common resistance mutation in the treatment of epidermal growth factor receptor gene (EGFR) mutant lung adenocarcinomas with low molecular weight tyrosine kinase inhibitors (TKIs) is the T790M mutation in EGFR exon 20. Identifying this is essential for patients, as the third-generation EGFR TKI (osimertinib) is a highly effective therapeutic option. Detection of the T790M variation is challenging both in terms of the low presence of the mutation, the type of sample available (re-biopsy, liquid biopsy, cytological smear) and the detection method used. The aim of this presentation is to investigate the applicability of the different sample types received by our institute for resistance mutation testing and the suitability of the available methods for the detection of the T790M mutation. MATERIAL AND METHOD: In our study, we processed data from patients with EGFR mutant lung adenocarcinoma showing clinical progression between 2019 and 2021 and examined the association between sample type, DNA concentration, EGFR primary mutation, and the presence of T790M. A CE-IVD kit based on allele-specific PCR was used for the assays. RESULTS: Plasma samples (92%), a small percentage of re-biopsies (4%) and chest fluid and cytological smears (2-2%) were available for the studies. EGFR mutations were detected in 36% of cases submitted (305). Of the 110 positive cases, 66 had a T790M mutation with a 60% incidence. In the case of re-biopsy, the hit rate was 88%. Among EGFR mutant cases, T790M positivity was most common with EGFR exon 19 deletion (49%). The distribution of DNA concentration between the mutant and wild-type cases and between the different sample types showed a similar trend. DISCUSSION: Based on our results, it can be said that the frequency of T790M positive cases in our laboratory is the same as in the literature. DNA concentration did not correlate with the presence of the EGFR mutation, it is likely that detectability is more related to sample purity and method sensitivity. Re-biopsy occurred in a very low number in our material (4%), however, the hit rate of the T790M mutation was the highest in these cases (88%).
C1 [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bencze, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Fulop, Laszlo] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Csernak, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 15
EP 15
PG 1
ER

PT J
AU Cserni, G
   Ambrozay, �
   Serenyi, P
   Bori, R
   Sejben, I
   Serfozo, O
   Lorand, K
   Venczel, L
   Maraz, R
   Sinko, M
   Szeleczki, N
   Nyari, T
   Zombori, T
AF Cserni, Gabor
   Ambrozay, Eva
   Serenyi, Peter
   Bori, Rita
   Sejben, Istvan
   Serfozo, Orsolya
   Lorand, Katalin
   Venczel, Laszlo
   Maraz, Robert
   Sinko, Maria
   Szeleczki, Nora
   Nyari, Tibor
   Zombori, Tamas
TI Investigation of preoperative axillary staging of invasive lobular breast cancer (ILC) by routine axillary aspiration cytology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: At present, axillary surgery for early breast cancer is differentiated between patients with clinically negative axillary status according to whether they have> 2 or ≤2 metastatic lymph nodes. In ILC, preoperative axillary staging is more inaccurate than in other types of breast cancer. MATERIAL AND METHOD: In our retrospective study, we analyzed the preoperative (tactile, axillary ultrasound [AXUS]) staging study of 153 ILC patients who underwent axillary surgery (sentinel lymph node biopsy or axillary block dissection) in two stages between January 2013 and June 2018. aspiration cytology (FNAC) sampling; Between July 2018 and December 2020, FNAC-based staging was attempted for preferably all patients with ILC (n = 47). RESULTS: Based on data from the first period, only AXUS / FNAC-based staging was found to be independent (for all patients) and extracapsular proliferation and lymphatic invasion (for non-clinically metastatic cases) were found to be independent of logistic regression based on logistic regression. The sensitivity, specificity, and false negative rate of AXUS were the same in the two periods, but the sensitivity, specificity, and false negative rate of AXUS-controlled FNAC were significantly different (90% vs. 50%; 60% vs. 95%; 10% vs. 50%). %, all p <0.001, binomial test). DISCUSSION: AXUS-guided FNAC did not improve detection of patients with> 2 metastatic lymph nodes in all patients with ILC, but increased the false-negative rate of the study by including patients who would not otherwise have been negative for AXUS.
C1 [Cserni, Gabor] University of Szeged, Department of PathologySzeged, Hungary.
   [Ambrozay, Eva] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Serenyi, Peter] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Bori, Rita] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Sejben, Istvan] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Serfozo, Orsolya] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Lorand, Katalin] Bacs-Kiskun County Teaching Hospital, Breast Diagnostic UnitKecskemet, Hungary.
   [Venczel, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Sinko, Maria] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szeleczki, Nora] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Nyari, Tibor] University of Szeged, Department of Medical InformaticsSzeged, Hungary.
   [Zombori, Tamas] University of Szeged, Department of PathologySzeged, Hungary.
RP Cserni, G (reprint author), University of Szeged, Department of Pathology, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 15
EP 17
PG 1
ER

PT J
AU Csikosne Macsok, E
   Piko, B
   Banhegyi, RJ
AF Csikosne Macsok, Erzsebet
   Piko, Bela
   Banhegyi, Robert Janos
TI Online onkoteam
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB At the Bekes County Central Hospital, an oncopy appointment (with the exception of emergency care to be reported) is mandatory for all cancer patients. Because oncology and oncoradiology care worked throughout, we also had to ensure continuity of consultations during the Covid-19 pandemic, adherence to epidemiological measures, the availability of data to provide opinions, and the opportunity for discussions between physicians. This was achieved by uploading patient records to the institutional IT system, using the Skype program, and displaying the proposal in the EESC. In our presentation, we highlight the importance of the role of the onkoteam organizer and the special tasks that occur during online (virtual) onkoteam discussions. Based on the analysis of the data, despite the limitations, the number of patients discussed at oncohemic meetings did not decrease and even showed a slow increase. The method proved to be such a lucky solution that the molecular oncopeam teams from another site, another health care institution and ONCOMPASS Kft. Have been taking place in the form of telemedicine ever since.
C1 [Csikosne Macsok, Erzsebet] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Banhegyi, Robert Janos] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Csikosne Macsok, E (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Csordas, IB
   Kis, D
   Szatmari, T
   Persa, E
   Safrany, G
   Lumniczky, K
AF Csordas, Ilona Barbara
   Kis, David
   Szatmari, Tunde
   Persa, Eszter
   Safrany, Geza
   Lumniczky, Katalin
TI Effect of ionizing radiation on miRNA composition of bone marrow extracellular vesicles
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our previous work we have shown that the content of extracellular vesicles (EVs) emitted by cells changes under the influence of low and high doses of ionizing radiation. This phenomenon plays an important role in the generation of non-targeted effects caused by radiation, especially in the formation of the bystander effect. In the present work, we examined and compared changes in the miRNA content of bone marrow cells and the EVs they release and the amount of proteins that package the miRNAs into EV. MATERIALS AND METHODS: Male CBA mice irradiated with different doses (0 Gy, 0.1 Gy, 3 Gy) at 10–12 weeks of age were used for the experiments. Twenty-four hours after irradiation, the miRNA content of EVs isolated from bone marrow cells and bone marrow cell supernatants was examined by RT-qPCR. Quantitative changes in miRNA-packaging hnRNP proteins were detected by Western blotting. RESULTS: Out of the 12 miRNAs examined, the amount of 6 miRNAs in the bone marrow and 10 in the EV changed significantly. The miRNA composition measured in EV is not a simple reflection of the content of bone marrow cells: in 2 cases, the amount of miRNAs with elevated concentrations in bone marrow was significantly reduced in EV. Furthermore, miRNA levels in the bone marrow, which were not significantly altered in the EV, were significantly elevated by both low- and high-dose irradiation. For EVs, a miRNA was detected whose relative concentration showed the opposite change from low and high dose irradiation compared to the control 0 Gy sample. Significantly variable miRNAs play a role in the regulation of signaling pathways associated with cancer, particularly leukemias. The hnRNPa2b1 protein showed a strong dose-dependent change in both bone marrow cells and EV: it increased in bone marrow but decreased in EV 24 hours after irradiation. The level of hnRNPQ protein in EV was increased by ionizing radiation. Changes in the levels of miRNAs potentially recognized by hnRNP proteins and transported to EV followed the measurable level of protein in EV. DISCUSSION: Differences in the miRNA and protein content of EVs and bone marrow cells demonstrate that miRNAs can enter the EV in a passive manner that depends not only on their intracellular concentration. Their packaging may be based on an active transport process following a sorting mechanism.
C1 [Csordas, Ilona Barbara] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Kis, David] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Szatmari, Tunde] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Persa, Eszter] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Safrany, Geza] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
   [Lumniczky, Katalin] Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani OsztalyBudapest, Hungary.
RP Csordas, IB (reprint author), Orszagos Kozegeszsegugyi Intezet, Sugarbiologiai es Sugaregeszsegugyi Foosztaly, Sugarorvostani Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Deme, D
   Jamool, N
AF Deme, Daniel
   Jamool, Nizar
TI Our own experience with the use of OncotypeDX in early-stage breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The OncotypeDX assay as a method for predicting adjuvant chemotherapeutic benefit in ER / PR positive HER2 normal breast cancer (pT1b-pT3, pN0) was validated in the 2018 TAILORx clinical trial. The recurrence score (RS) can be used to determine who is exempt from adjuvant chemotherapy (> 50 years RS <26 and <50 years RS <16). Based on study SWOG8814, chemotherapy should be given for pN1 and RS> = 31 (> = 18 should be considered). In the RxPONDER study, which will end in 2022, a threshold in the RS0-25 range below which chemotherapy may be omitted is sought. MATERIALS AND METHODS: We processed the data of 56 patients operated on in our institution for early breast cancer who underwent an OncotypeDX study in the last three years (August 13, 2018 - July 30, 2021). RESULTS: The mean age of the 56 patients was 62.09 years (range 46.15–76.1). The median time between surgery and histological findings was 15.63 days (range 0-33). The median time between histology and OncotypeDX results was 27.68 days (duration 13-77). One patient <50 years of age was treated in another institution. Thus, the data of 55 subjects were indicated as chemotherapy in stage IA for 4/29 subjects, in stage IIB for 4/8 subjects, and in stage IIIA for 1/4 subjects. In stages IB (2 subjects) and IIA (12 subjects), RS became low. It should be noted that the highest RS36 value was found in the case of relatively good pathological characteristics (pT1c, pN0, Gr. III lumA, p53 10%, Ki67 15%), while the lowest RS0 value was found in a higher stage disease (pT3, pN1a, Gr. III, lumA, p53 neg., Ki67 2-3%). The highest proliferation rate (Ki67 35%) in our case> 50 years (pT1c, pN0, Gr. III, lumB1, p53 70%) was RS21, while the low proliferation rate (Ki67 5%) in a case> 50 years (pT1c, pN0 , Gr. II-III, lumB1, p53-neg.) RS28. Furthermore, in our two p53-negative cases (pT3, pN1a, Gr. II-III., LumB1, Ki67 25%) and (pT1c, pN0, Gr. III., LumB1, PR-neg., Ki67 15%) became RS35 and RS32 . In lymph node micrometastasis (3 subjects), one patient (pT3, pN1mi, cc. Lob., LumB1, p53-neg., Ki67 1%) had the highest RS17, while the lowest RS3 was in a lower stage disease (pT1c, pN1mi, cc. lob., Gr. II., lumA, p53-neg., Ki67 2-3%) was confirmed. DISCUSSION: 16% of our patients required chemotherapy. With the introduction of OncotypeDX studies, the number of unjustified chemotherapies was significantly reduced, however, we also found high RS values ​​among cases with relatively good pathological characteristics.
C1 [Deme, Daniel] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
   [Jamool, Nizar] Szent Lazar Megyei Korhaz, Onkologiai OsztalySalgotarjan, Hungary.
RP Deme, D (reprint author), Szent Lazar Megyei Korhaz, Onkologiai Osztaly, Salgotarjan, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 17
EP 17
PG 1
ER

PT J
AU Erdelyi, K
   Ditroi, T
   Johansson, H
   Czikora, �
   Balog, N
   Silwal-Pandit, L
   Ida, T
   Olasz, J
   Matrai, Z
   Csuka, O
   Tovari, J
   Engebraten, O
   Akaike, T
   Borresen, DAL
   Kasler, M
   Lehtio, J
   Nagy, P
AF Erdelyi, Katalin
   Ditroi, Tamas
   Johansson, J. Henrik
   Czikora, Agnes
   Balog, Noemi
   Silwal-Pandit, Laxmi
   Ida, Tomoaki
   Olasz, Judit
   Matrai, Zoltan
   Csuka, Orsolya
   Tovari, Jozsef
   Engebraten, Olav
   Akaike, Takaaki
   Borresen, Dale Anne-Lise
   Kasler, Miklos
   Lehtio, Janne
   Nagy, Peter
TI The role of reprogramming of transulfurization pathways in the progression of basal subtype breast tumors by controlling protein functions by persulfation modifications
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The basal subtype of breast tumors (BLBC) is a highly aggressive group of tumors with poor prognosis. One reason for this is the lack of targeted therapies available. Exploratory research into innovative, targeted therapies is therefore essential to cure those suffering from such diseases. The design of new drugs requires a more detailed understanding of the regulation of BLBC biology. The present work is based on the fundamental observation in a large number of patient samples that the levels of several enzymes in this tumor that are key players in oxidative-mediated signaling of cells and affect tumor growth have changed significantly. We aimed to use our prior knowledge and new discoveries to interpret the role of these enzymatic pathways in basal breast tumor, thereby exploring alternative targets for overcoming this deadly disease. MATERIAL AND METHOD: Our studies were performed on human breast tumors, xenograft models, and gene-silenced cell model systems. In addition to gene silencing, we investigated the role of differential expression proteins in BLBC in tumor progression by several methods. Quantitative mass spectrometric methods were used for metabolomic analysis of transulfurization pathways in living cells and mouse tissue samples. RESULTS: Although cysteine ​​is not an essential amino acid for normal cells (it can be produced by transulfurization pathways), in this study we have shown that adequate cysteine ​​replenishment is essential for the progression of BLBC tumors. In many directions, we have been able to support that by modifying the expression levels and functions of enzymes involved in transulfurization pathways, BLBCs control the functions of other key proteins for tumor progression. We provide evidence that these processes are likely to be so-called achieved by the dynamic generation and degradation of persulfidation protein modifications that promote angiogenesis and tumor cell proliferation, stimulate the hypoxic response, and inhibit oxidative cell death. DISCUSSION: The results of our study pave the way for the treatment of patients with BLBC breast cancer before new therapeutic procedures are developed.
C1 [Erdelyi, Katalin] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ditroi, Tamas] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Johansson, J. Henrik] Karolinska InstituteSolna, Sweden.
   [Czikora, Agnes] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Balog, Noemi] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Silwal-Pandit, Laxmi] Oslo University Hospital HFOslo, Norway.
   [Ida, Tomoaki] Tohoku University, Graduate School of MedicineSendai, Japan.
   [Olasz, Judit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
   [Csuka, Orsolya] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Engebraten, Olav] University of OsloOslo, Norway.
   [Akaike, Takaaki] Tohoku University, Graduate School of MedicineSendai, Japan.
   [Borresen, Dale Anne-Lise] Oslo University Hospital HFOslo, Norway.
   [Kasler, Miklos] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Lehtio, Janne] Karolinska InstituteSolna, Sweden.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Erdelyi, K (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Erdelyi, K
   Galambos, K
   Balog, N
   Szoke, J
   Bathory-Fulop, L
   Tovari, J
   Nagy, P
AF Erdelyi, Katalin
   Galambos, Klaudia
   Balog, Noemi
   Szoke, Janos
   Bathory-Fulop, Laszlo
   Tovari, Jozsef
   Nagy, Peter
TI Potential role of peroxydroxin-2 in lung adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Some isoforms of the peroxiredoxin (Prx) family of enzymes are antioxidant enzymes present in high concentrations in cells that efficiently degrade intracellular hydrogen peroxide. In addition to their protective role, they also play an important role in hydrogen peroxide-related redox signaling processes. We found that the level of Prx2 in the A549 cell line, which is of human lung adenocarcinoma origin, is exceptionally low. In order to understand the potential role of low Prx2 levels in tumor progression, we established stable Prx2 overexpression in A549 cells. Numerous in vitro and xenograft experiments were performed with the genetically modified cell lines. Our main findings were also examined in human lung adenocarcinoma samples. MATERIAL AND METHOD: Stable transfection was established with the Sleeping Beauty transposon system, and individual clones overexpressing Prx2 were isolated and grown. Enzyme levels were assayed by RT-qPCR and Western blot. Proliferation was measured by Sulforhodamine B method, and tumor growth was examined in an in vivo xenograft mouse model. Tumor and non-tumor areas of xenograft tissue and lung tissue from human adenocarcinoma were examined by immunohistochemistry. RESULTS: Human patient samples confirmed that Prx2 expression is significantly reduced in lung adenocarcinoma patients compared to non-tumor tissue, consistent with our in vitro observation. Decreased proliferation was observed in vitro due to Prx2 overexpression, while decreased tumor growth was observed in vivo in a xenograft mouse model. In our in vitro experiments, we found a correlation between STAT3 transcription factor activity and Prx2 levels. In our in vitro and xenograft experiments, we found an association between the levels of the transcription factor Prx2 and STAT5α, which, however, could not be supported by measurements from human samples. Furthermore, in our in vitro experiments, we detected significant differences in the level of the transcription factor Egr1. DISCUSSION: Based on our in vitro, xenograft mouse model, and human patient samples, Prx2 plays an important role in tumor growth in lung adenocarcinoma, and the underlying molecular mechanisms are being mapped.
C1 [Erdelyi, Katalin] National Institute of OncologyBudapest, Hungary.
   [Galambos, Klaudia] National Institute of OncologyBudapest, Hungary.
   [Balog, Noemi] National Institute of OncologyBudapest, Hungary.
   [Szoke, Janos] National Institute of OncologyBudapest, Hungary.
   [Bathory-Fulop, Laszlo] National Institute of OncologyBudapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
RP Erdelyi, K (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 18
EP 18
PG 1
ER

PT J
AU Esperger, Zs
   Kovari, RL
   Novak, Z
   Mersich, T
   Matrai, Z
   Kovacs, P
AF Esperger, Zsofia
   Kovari, Reka Luca
   Novak, Zoltan
   Mersich, Tamas
   Matrai, Zoltan
   Kovacs, Peter
TI Pre-rehabilitation approach in oncology surgery 1: non-specific factors of psychological preparation
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Multimodal (psychological and somatic) preparation prior to oncology treatments can bring important gains for later stages of treatment. Studies on the subject focus mainly on surgical interventions. The perioperative psychological preparation methods described and presented on the basis of research requiring significant investment have a well-defined influence on the postoperative period. In addition to presenting effective methods, our aim is to highlight the non-specific factors of psychological preparation. MATERIAL AND METHOD: A qualitative analysis of the effects of psychological preparation prior to oncology surgery was performed. RESULTS: Effective methods of psychic preparation include psychoeducation, development of stress management (eg relaxation, adaptive coping strategies, problem solving), psychotherapy. The effect of psychiatric preparation in the postoperative period is reflected in the immune function, subjective mental state and quality of life of patients, however, in the case of traditional surgical variables (eg pain relief, number of days in hospital, complications) there was not always a measurable positive change. DISCUSSION: Non-specific factors of psychological preparation include the fact that patients become partners in the preparation, that the experience is better structured as a result of the intervention, and that they receive increased personalized attention during the interventions. It is an important objective, but further efforts are needed to further assess the impact of psychological preparation methods. However, beyond the methods, we should not forget the role of non-specific factors that emphasize the importance of the prehabilitation approach in oncopsychological care.
C1 [Esperger, Zsofia] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovari, Reka Luca] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Esperger, Zs (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 18
EP 19
PG 1
ER

PT J
AU Fekete, JT
   Gyorffy, B
AF Fekete, Janos Tibor
   Gyorffy, Balazs
TI Predictive biomarkers of FOLFOX therapy in colorectal tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Colorectal cancer (CRC) is the second most commonly diagnosed tumor type worldwide. The most commonly used adjuvant chemotherapy in the treatment of CRC patients is the combination of 5-fluorouracil (5FU) / leucovorin / oxaliplatin (FOLFOX). MATERIALS AND METHODS: Data from 10 gene expression studies were downloaded from the Gene Expression Omnibus (GEO) repository and then organized into a single database. Therapeutic response was categorized based on RECIST criteria. The database includes the following treatments: 5-fluorouracil (n = 355), capecitabine (n = 67), oxaliplatin (n = 226), irinotecan (n = 129), and bevacizumab (n = 54). ROC analysis and Mann-Whitney test were used to analyze the relationship between gene expression and therapeutic response. Ontological analysis was also performed for significant genes. RESULTS: A total of 59 genes were found whose expression was significantly associated with the outcome of FOLFOX treatment. The top three genes upregulated in the resistant group were LTHA4 (p = 1.12E-05, AUC = 0.712), SMURF2 (p = 1.41E-05, AUC = 0.710) and TIMM22 (p = 2.43E- 05, AUC = 0.704), while the upregulated genes in the sensitive group were CARM1 (p = 8.02 E-06, AUC = 0.716), IRF7 (p = 1.19E-05, AUC = 0.712) and NFKBIB (p = 2.24E-05, AUC = 0.705). Ontological analysis of genes with significant results according to the Mann-Whitney analysis showed an enrichment of the transcriptional activity of the SMAD2 / SMAD3 / SMAD4 heterotrimer. The full database application is available at www.rocplot.org/crc/index. DISCUSSION: Analysis of the web application database identified genes and pathways potentially involved in the outcome of FOLFOX treatment. The ROC Plotter web application provides the opportunity to study gene validation-based predictive biomarkers and validate results for the most commonly used drug therapies in the treatment of colorectal tumors.
C1 [Fekete, Janos Tibor] Semmelweis UniversityBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis UniversityBudapest, Hungary.
RP Fekete, JT (reprint author), Semmelweis University, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Fodor, P
   Molnar-Fodor, K
   Zsebik, B
   Szabo, Zs
   Dobos, N
   Schally, AV
   Halmos, G
AF Fodor, Petra
   Molnar-Fodor, Klara
   Zsebik, Barbara
   Szabo, Zsuzsanna
   Dobos, Nikoletta
   Schally, Andrew Victor
   Halmos, Gabor
TI Investigation of the combined use of an angiogenesis-targeted therapeutic VEGF inhibitor and a cytotoxic peptide hormone analogue in ueal melanoma in vitro
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Although there is a growing need in clinical practice for the combined use of targeted cancer therapy molecules, little is known about the potential drug interactions. We investigated whether VEGF inhibitor therapies had a synergistic or antagonistic effect when used in combination with free doxorubicin or a doxorubicin-containing targeted therapeutic peptide hormone analog. The antitumor activity of the investigated tumor therapeutic molecules was investigated by in vitro modeling of various therapeutic protocols, followed by molecular pharmacological studies to elucidate the molecular background of the drug resistance experienced. MATERIAL AND METHOD: Ranibizumab (anti-VEGF, Lucentis®), doxorubicin (DOX), and DOHR-conjugated LHRH analog (AEZS-108) were used to treat OCM3 human uveal melanoma cells in vitro. During the treatments, the cells were pretreated with a VEGF inhibitor or co-administered with free DOX or its targeted therapeutic form, and the monotherapy use of the drugs was modeled. The cytotoxicity of the molecules and their combined use was examined by MTS assay. Following mRNA and protein isolation, changes in the expression of genes involved in angiogenesis, metastasis, and drug resistance pumps were examined using RTqPCR and Protein Profiler Human XL Oncology Array. RESULTS: Based on the MTS assay, pretreatment with ranibizumab reduced the cytotoxicity of free DOX and AEZS-108 in OCM3 cells. Co-administration of ranibizumab with cytotoxic therapeutic molecules increased the expression of genes involved in angiogenesis and cell proliferation. Combination therapies resulted in decreased expression of MRP1, MRP2, and MRP4, while increased expression of MRP5 compared to controls. VEGF inhibitor pretreatment resulted in a different expression pattern based on the protein array for genes that play a key role in metastasis. DISCUSSION: Based on our results, VEGF inhibitors are able to influence the response of OCM3 tumor cells to DOX-containing targeted or classical DOX therapy, depending on the order of administration of the drugs used. The results may contribute to more effective therapy for the most common malignancies in the eye.
C1 [Fodor, Petra] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Molnar-Fodor, Klara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Zsebik, Barbara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dobos, Nikoletta] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Schally, Andrew Victor] Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and EducationMiami, USA.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Fodor, P (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 19
EP 19
PG 1
ER

PT J
AU Gaal, Sz
   Kahan, Zs
   Koszo, R
   Egyud, Zs
   Paczona, V
   Deak, B
   Nikolenyi, A
   Hideghety, K
   Varga, Z
AF Gaal, Szilvia
   Kahan, Zsuzsanna
   Koszo, Renata
   Egyud, Zsofia
   Paczona, Viktor
   Deak, Bence
   Nikolenyi, Aliz
   Hideghety, Katalin
   Varga, Zoltan
TI Individual irradiation techniques to reduce the risk of radiogenic heart damage in left breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The risk of heart damage increases with irradiation of the left breast / chest wall in proportion to the radiation exposure of the heart. A number of irradiation techniques are available to prevent radiogenic cardiac damage, including the practical introduction of the Deep Inspirational Breath Hold (DIBH) technique. MATERIAL AND METHOD: In our prospective clinical trial, in cases requiring left breast or chest wall irradiation, we prepared irradiation plans using DIBH and traditional methods (back and abdomen with normal breathing). Patients' breathing was assessed by a physiotherapist and prepared for DIBH technique. We examined the dose variation of the heart and left anterior descending coronary artery (LAD) compared to conventional techniques, and the cardiac risk status of our patients based on risk factors (hypertension, known coronary artery disease, chemotherapy, trastuzumab treatment). by aggregation. RESULTS: 130 patients requiring postoperative irradiation were included in our study. Of these, 26 were unsuitable for the DIBH technique for a variety of reasons, and in 16 cases, the heart or LAD dose did not meet expectations, so a different technique had to be used. Finally, the DIBH technique resulted in a significant improvement in cardiac load in 88/130 cases (54 complete breast populations, 34 thoracic +/− lymphatic regions). The mean dose to the heart (MHD) was reduced by more than 50%, the volume of the heart receiving at least 25 Gy (V25 Gy) by more than 80%, the mean dose of LAD by more than 70%, and the maximum dose was reduced by about half. About half of the patients had some known cardiac risk factor. Oncardiological follow-up of patients according to risk status is performed according to international recommendations. DISCUSSION: In our experience, the DIBH irradiation technique can be used in approximately two-thirds of patients with good results in left breast or chest wall irradiation. We plan to further analyze our data to predict the individual benefit of the DIBH technique.
C1 [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paczona, Viktor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Deak, Bence] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Gaal, Sz (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 19
EP 21
PG 1
ER

PT J
AU Galambos, K
   Erdelyi, K
   Balog, N
   Ditroi, T
   Liszkay, G
   Nagy, P
AF Galambos, Klaudia
   Erdelyi, Katalin
   Balog, Noemi
   Ditroi, Tamas
   Liszkay, Gabriella
   Nagy, Peter
TI Investigation of redox systems in melanoma cells resistant to dabrafenib-trametinib targeted therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: BRAF and MEK inhibitor therapy has been shown to be effective in the treatment of melanoma patients with the BRAF V600E mutation, however, the development of resistance is unavoidable in most cases. Interestingly, resistant cells are characterized by higher levels of reactive oxygen species (Wang et al., 2018, Cell). Our goal is to understand the redox changes underlying resistance. MATERIAL AND METHOD: Our experiments were performed with the BRAF V600E mutant A375 cell line and the resistant line we generated. Enzyme levels were measured by Western blot. Cell viability was assessed by the Sulforhodamine B method. Sulfur-containing metabolites were measured by mass spectrometry. RESULTS: Treatment of control cells with drugs was found to increase the levels of enzymes (catalase, superoxide dismutase 2) responsible for the degradation of oxidation-inducing peroxide and superoxide by approximately two to three times. In resistant cells, their levels are about one and a half to two times higher than in untreated control cells, or they are reduced by withdrawing the drug from the resistant cells. A similar trend was seen in the levels of the enzymes responsible for the reduction after oxidation (thioredoxin reductase 1, TRP14, glutathione peroxidase 1,4) and in the level of the enzyme responsible for the production of NADPH, which provides reduction equivalents for these enzymes, glucose-6-phosphate dehydrogenase. The reducing enzyme cascade consists of a number of proteins containing selenocysteine. Selenium depletion resulted in a significant decrease in selenium-dependent enzyme levels, and selenium depletion resulted in a 2-fold increase in susceptibility of resistant cells to cystin depletion-induced cell death. Furthermore, a 1.5-fold increase in cystine uptake and intracellular glutathione levels was observed in resistant cells compared to the untreated control, and intracellular cysteine ​​levels were halved. In addition, the level of pi, the enzyme responsible for neutralizing xenobiotics, glutathione S-transferase, was increased 1.5-fold. DISCUSSION: We were able to identify changes in redoxenzyme levels associated with the development of resistance. Our results suggest that melanoma cells resistant to BRAF and MEK inhibitor therapy have significantly increased selenium and cysteine ​​requirements to counteract oxidative stress.
C1 [Galambos, Klaudia] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Erdelyi, Katalin] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Balog, Noemi] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Ditroi, Tamas] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
RP Galambos, K (reprint author), Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Ganofszky, E
   Hitre, E
   Nemeth, Zs
   Rubovszky, G
AF Ganofszky, Erna
   Hitre, Erika
   Nemeth, Zsuzsanna
   Rubovszky, Gabor
TI Our first experience with immunotherapy for metastatic breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: A new therapeutic agent for triple-negative breast cancer is PD-L1 inhibitor therapy. It is currently the first line, in combination with nab-paclitaxel, to be given an individual fairness license. We share our experiences with our first patients. MATERIAL AND METHOD: Retrospective analysis of data from patients treated with atezolizumab in combination with nab-paclitaxel. RESULTS: The mean age of the 7 patients treated was 56.3 years (49-68 years). By histological type: invasive ductal type in 6 patients, spindle cell metaplastic carcinoma in 1 patient. In six cases, 1–10% of the tumor cells and more than 50% of one patient expressed PD-L1 protein. ECOG status was better than 2 in all cases. Six patients had received prior chemotherapy (neoadjuvant, adjuvant, or first-line). Efficacy and side effects data will be presented to Congress. DISCUSSION: The combination of atezolizumab + nab-paclitaxel is an effective first-line treatment for triple-negative breast cancer.
C1 [Ganofszky, Erna] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hitre, Erika] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Nemeth, Zsuzsanna] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Ganofszky, E (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 21
EP 21
PG 1
ER

PT J
AU Ghimessy, �
   Gellert, �
   Csende, K
   Gieszer, B
   Bogyo, L
   Radeczky, P
   Kocsis, �
   Agocs, L
   Fillinger, J
   Alexis, S
   Megyesfalvi, Zs
   Renyi-Vamos, F
   Madurka, I
   Dome, B
AF Ghimessy, Aron
   Gellert, Aron
   Csende, Kristof
   Gieszer, Balazs
   Bogyo, Levente
   Radeczky, Peter
   Kocsis, Akos
   Agocs, Laszlo
   Fillinger, Janos
   Alexis, Slama
   Megyesfalvi, Zsolt
   Renyi-Vamos, Ferenc
   Madurka, Ildiko
   Dome, Balazs
TI Use of an isolated lung perfusion experimental model in surgically removed tumor lungs with pharmacological agents
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Pulmonary physiology and the effects of therapeutic interventions can be well studied in isolated lung perfusion (ILP) models. The essence of the technique is to connect a removed half-lung or lung lobe to an extracorporeal perfusion circuit and keep it artificially close under physiological conditions. The ex vivo pulmonary perfusion (EVLP) procedure was used for the first time in lung transplantation in 2001 to assess the function of the lung to be implanted. The aim of the present work is to make the experimental lung perfusion model applicable to pharmacological studies of surgically removed tumor lung lobes or unilateral lungs. MATERIALS AND METHODS: Surgery should be performed in an open or minimally invasive manner in accordance with general clinical practice. The removed lungs were immediately cooled with cold physiological saline and then perfused with a preservative solution to remove blood and thrombi. Cannulas are sutured to the venous and arterial mouths, and a tube is attached to the bronchus. The lungs are packaged in ice and transported refrigerated to the experimental operating room, where they are connected to an ECMO (extracorporeal membrane oxygenator) circuit through which they are perfused with a special perfusion solution, ventilated, and the oxygen taken up by the lungs is removed from the system using a membrane oxygenator. Physiological parameters were monitored by arterial blood gas (pO2 and pCO2, pH, glucose intake, lactate production), while clinical data (temperature, ventilation parameters, pulmonary pressure, edema production) were measured. If the pH drops below 7 permanently or edema production limits gas exchange, terminate the experiment. The goal is to perfuse and ventilate the lungs for a minimum of 4 hours, allowing time for the perfused or inhaled agents to distribute within the organ. At the end of the experiment, the lungs are transferred to the pathology department, where, in addition to standard diagnosis and molecular examinations, a representative section is taken from a representative area to examine the distribution and penetration of drugs by MALDI-MS (matrix assisted laser desorption / ionization) technique. RESULTS AND DISCUSSION: This is the first time that we have used the EVLP model on tumor organs in Hungary. The experimental model was implemented, we performed the first successful experiments. During the conference, we will present the early results and the series of experiments based on them.
C1 [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gellert, Aron] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Csende, Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of Pulmonology, Department of Tumor BiologyBudapest, Hungary.
   [Alexis, Slama] University Duisburg-Essen, Ruhrlandklinik, Department of Thoracic SurgeryEssen, Germany.
   [Megyesfalvi, Zsolt] Semmelweis Egyetem-Orszagos Onkologiai Intezet, Mellkassebeszeti KlinikaBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Madurka, Ildiko] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Ghimessy, � (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 21
EP 22
PG 1
ER

PT J
AU Ghimessy, �
   Tallosy, B
   Pipek, O
   Fillinger, J
   Moldvay, J
   Laszlo, V
   Rezeli, M
   Renyi-Vamos, F
   Megyesfalvi, Zs
   Dome, B
AF Ghimessy, Aron
   Tallosy, Bernadett
   Pipek, Orsolya
   Fillinger, Janos
   Moldvay, Judit
   Laszlo, Viktoria
   Rezeli, Melinda
   Renyi-Vamos, Ferenc
   Megyesfalvi, Zsolt
   Dome, Balazs
TI Investigation of the organ-specific metastasis pattern of small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Although small cell lung cancer (SCLC) is an aggressive, fast-growing, and prone metastatic tumor type, the exact pattern of organ-specific metastasis is currently unknown. The aim of our study was to examine the pattern of metastasis as a function of the time course of distant metastases and the organs involved. MATERIAL AND METHOD: A total of 1009 patients with advanced stage SCLC were retrospectively analyzed in our studies. The temporal and organ-specific appearance of distant metastases was examined according to the location of the primary tumor. Tumors visible bronchoscopically were considered central, while tumors not visible were considered peripheral lesions. RESULTS: The organs most commonly affected by metastases were the liver, brain, and bones. In terms of time course, bone (p <0.001), cerebral (p <0.001) and pericardial (p = 0.02) metastases were found to be late, while adrenal (p = 0.005) and hepatic (p <0.001) metastases occur early. The localization of the primary tumor did not significantly affect the time course of organ metastases. Regarding co-occurring metastases, bone metastases occurred simultaneously with liver metastases, while cerebral metastases occurred mainly with adrenal metastases. However, we found that contralateral lung, pleural, and pericardial metastases also occur frequently simultaneously. Although overall survival (OS) was lower in patients with central primary tumors than in peripheral locations, this association was not found to be statistically significant (p = 0.078). As expected, the number of organs involved significantly affected the OS (p <0.0001). DISCUSSION: Our study provides information on the metastasis pattern of SCLC depending on the location and time course of distant metastases. The mapping of co-occurring organ metastases may help to develop new - metastasis-specific - diagnostic algorithms, thus contributing to the early detection of specific metastases.
C1 [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Tallosy, Bernadett] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Pipek, Orsolya] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Moldvay, Judit] Eotvos Lorand UniversityBudapest, Hungary.
   [Laszlo, Viktoria] Medical University of ViennaVienna, Austria.
   [Rezeli, Melinda] Lund UniversityLund, Sweden.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Megyesfalvi, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Ghimessy, � (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Gieszer, B
   Brcic, L
   Klikovits, Th
   Fillinger, J
   Kern, I
   Laszlo, V
   Jakopovic, M
   Skarda, J
   Hegedus, B
   Renyi-Vamos, F
   Megyesfalvi, Zs
   Dome, B
AF Gieszer, Balazs
   Brcic, Luka
   Klikovits, Thomas
   Fillinger, Janos
   Kern, Izidor
   Laszlo, Viktoria
   Jakopovic, Marko
   Skarda, Jozef
   Hegedus, Balazs
   Renyi-Vamos, Ferenc
   Megyesfalvi, Zsolt
   Dome, Balazs
TI Investigation of the prognostic role of PD-1 and PD-L1 in malignant pleural mesothelioma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The role of PD-1 / PD-L1 proteins and their inhibitory antibodies in oncology practice has significantly increased in recent years. However, the prognostic role of these proteins in chest tumors is currently largely unknown. The aim of our study was to investigate the prognostic significance of PD-1 and PD-L1 expression in malignant pleural mesothelioma (MPM), respectively. MATERIAL AND METHOD: In our study, we analyzed data and histological specimens from a total of 203 MPM patients in five Central European centers. The expression of PD-1 / PD-L1 in tumor cells (TC) and tumor-infiltrating lymphocytes (TIL) was examined by immunohistochemistry, and expression levels were analyzed as a function of clinicopathological parameters and overall survival (OS). RESULTS: High (> 10%) TC PD-L1 expression was observed in 8% of cases, while high TIL PD-1 expression was observed in 24% of cases. It should be noted that PD-L1 expression levels were extremely low for TIL [≥1%, n = 13 (8%)]. No significant association was found between PD-1 / PD-L1 expression of TCs or TILs and clinicopathological parameters (stage and histological subtype). However, it should be emphasized that high (> 10%) TC PD-L1 expression was associated with significantly lower OS compared to tumors with low TC PD-L1 expression (median OS 6.3 vs. 15.1 months; p <0.001 ). Based on our multivariate Cox regression model, we found that high TC PD-L1 expression (> 10%) was an independent negative prognostic factor in MPM (p = 0.005). Expression of TIL PD-1 / PD-L1 did not significantly affect survival. DISCUSSION: In our multicenter study, we showed that high (> 10%) TC PD-L1 expression is an independent negative prognostic factor in MPM. In this way, our results can contribute to the development of new follow-up and treatment strategies.
C1 [Gieszer, Balazs] National Institute of OncologyBudapest, Hungary.
   [Brcic, Luka] Medical University of GrazGraz, Austria.
   [Klikovits, Thomas] Medical University of ViennaVienna, Austria.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Kern, Izidor] University Clinic of Respiratory and Allergic DiseasesGolnik, Slovenia.
   [Laszlo, Viktoria] Medical University of ViennaVienna, Austria.
   [Jakopovic, Marko] University of Zagreb, School of MedicineZagreb, Croatia.
   [Skarda, Jozef] Palacky EgyetemAlamoc, Czech Republic.
   [Hegedus, Balazs] University of Duisburg-EssenEssen, Germany.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
   [Megyesfalvi, Zsolt] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
RP Gieszer, B (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 22
EP 22
PG 1
ER

PT J
AU Grolmusz, VK
   Nagy, P
   Butz, H
   Bozsik, A
   Papp, J
   Olah, E
   Patocs, A
AF Grolmusz, Vince Kornel
   Nagy, Petra
   Butz, Henriett
   Bozsik, Aniko
   Papp, Janos
   Olah, Edit
   Patocs, Attila
TI The role of immunogenetic modifiers in Lynch syndrome
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Lynch's syndrome (LS) is one of the most common inherited cancers, most commonly caused by colon and uterine tumors. The predisposition is due to germ cell mutations in key enzymes of mismatch error correction (MMR), resulting in high tumors, which allow the immune system to activate due to increased expression of neoantigens. The PD-1 / PD-L1 immune checkpoint plays a prominent role in silencing the immune response and its inhibition is one of the major targets of modern immunotherapies. We aimed to investigate common single-point nucleotide polymorphisms (SNPs) of the PDCD1 and CD274 genes encoding PD-1 and PD-L1 in patients with LS. MATERIAL AND METHOD: We enrolled 85 patients with index LS from an independent family who had pathogenic mutations in the MLH1 or MSH2 genes on their DNA samples isolated from peripheral blood. Based on in silico analysis, we selected 8 SNPs (rs2227981 and rs7421861 from the PDCD1 gene, rs822338, rs35744625, rs7341737, rs7042084, rs10481593 and rs10975124 from the field of the CD274 gene) time on a PCR instrument. In a statistical analysis, we examined the effect of SNPs on the time to onset and survival of the first colorectal carcinoma (CRC) using log-rank and Gehan − Breslow – Wilcoxon tests. RESULTS: There was no significant correlation between genotype and time to CRC in any of the SNPs studied. Carriers of the rs7042084 polymorphism tended to develop CRC later (dominant model, p = 0.0784). For the rs822338 and rs10481593 polymorphisms, the overall survival of the less common allele carriers was shorter compared to the more common allele carriers (recessive model, p = 0.0307 and p = 0.0239). DISCUSSION: Two SNPs of CD274 may have an effect on the prognosis of LS-associated CRCs. Characterization of the relationships requires validation and functional studies on an independent sample.
C1 [Grolmusz, Vince Kornel] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Nagy, Petra] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Butz, Henriett] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bozsik, Aniko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Patocs, Attila] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Grolmusz, VK (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 22
EP 23
PG 1
ER

PT J
AU Gurgolne Marcsa, K
AF Gurgolne Marcsa, Krisztina
TI Side effect management in radiotherapy for the head and neck region from the nurse's point of view
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Patients with tumors located in the head and neck region, who require special care, are often admitted to our radiotherapy department. Their provision requires a holistic approach that views man as a whole, presupposing the unity of his body, mind, and emotions. MATERIAL AND METHOD: Their treatment requires multimodal oncotherapy. The surgical solution is primary, followed by chemotherapy or radio-chemotherapy. In radiotherapy, it is key to treat acute side effects to avoid therapeutic breaks. The nurse plays an extremely important role in effective and successful side effect management. It performs preventive tasks, as its monitoring activity, it is possible to quickly recognize the side effects and, in cooperation with the doctor, participates effectively in their prevention. In addition, it supports the patient mentally and emotionally. RESULTS: Early-discovered side effects are easier and more effective to treat, making the patient more successful in the long run. The patient's quality of life improves and so does compliance and adherence. DISCUSSION: In our ward, we provide the highest possible level of care to our patients so that we can deliver them to their homes in the most optimal state of health possible under the circumstances by effectively reducing side effects.
C1 [Gurgolne Marcsa, Krisztina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Gurgolne Marcsa, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Hajdu, A
   Juhasz, �
   Kerek, B
   Dank, M
AF Hajdu, Anett
   Juhasz, Agnes
   Kerek, Barbara
   Dank, Magdolna
TI Treatment of sarcopenic obesity in oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Sarcopenia, defined as loss of muscle mass, muscle strength, and physical performance, is common in cancer patients and may be associated with obesity. Sarcopenic obesity negatively affects anticancer treatments, contributes to the development of postoperative complications, increased chemotherapeutic toxicity, and adversely affects survival. The fact of cancer itself is mentally stressful, and if it is accompanied by obesity, you are more likely to develop a negative body image, self-esteem problems, a deterioration in your health-related quality of life, or even depression. A patient with sarcopenia obese has a high body weight, total body fat, and a BMI, all of which hides sarcopenia, misleading physicians. Nutritional therapy is also warranted in obese patients. In addition to a personalized diet, this pathological nutritional condition can be improved with psychotherapy as well as movement therapy, which improves aerobic fitness, body composition, and quality of life.
C1 [Hajdu, Anett] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Juhasz, Agnes] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Kerek, Barbara] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Hajdu, A (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Harisi, R
   Sebestyen, A
   Jeney, A
AF Harisi, Revekka
   Sebestyen, Anna
   Jeney, Andras
TI Efforts to limit the progression of therapy-resistant tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Research aimed at halting drug resistance has focused on modifying the way drugs work on the one hand and eliminating the defense mechanism of tumors in recent decades. Meanwhile, based on the results of complex molecular biological studies of tumors, resistance has been classified as a consequence of tumor progression. It has been found that proliferating tumor cells acquire the ability to resist in addition to migration during transdifferentiation to be resistant to the expected damaging factors during metastasis. Immune cells, especially modified macrophages (M2), as well as several signaling pathways that activate epithelial-mesenchymal transformation (EMT) play an important role in the process that can be interpreted as the first step in tumor progression. This event is attributed to the transient and reversible uptake of tumor cell stem cell properties that may function under both physiological and pathological conditions. Taking all these new findings into account, we studied the role of proteoglycans in initiating tumor progression and the differential effects of drugs on proliferation as well as migration. Our group found that the invasive growth-inducing effect of heparan sulfate on proteoglycan may be related to a decrease in the quotient of topoisomerase-1 and topoisomerase-2 activity and to the function of the Wnt signaling pathway. Based on this, it has been found that the migration of tumor cells containing high heparan sulfate proteoglycan can be inhibited by hexyl deoxyuridine, which inhibits heparan sulfate proteoglycan biosynthesis. Similarly, rapamycin, ribavirin, and borrelidin, which are classified as mTOR-directed translational inhibitors, significantly inhibit tumor cell migration. Consistent with the position adopted in recent years, inhibition of tumor migration can be considered a promising therapeutic target for the progression of resistant tumors. However, given the diversity of regulatory mechanisms involved in tumor preparation for migration, individual identification of biomarkers that predict the effectiveness of therapy is necessary.
C1 [Harisi, Revekka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Harisi, R (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 23
EP 23
PG 1
ER

PT J
AU Horvath, A
   Redling, M
AF Horvath, Anna
   Redling, Mariann
TI Causes, diagnostic and therapeutic options in the background of lymphatic stenosis during breast cancer therapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB In Hungary, as in the rest of the world, the most common cause of acquired, ie secondary, lymphedema is oncological treatment after breast cancer. After the interventions, not only limb lymphedema but also breast edema can be a quality-disrupting disorder. According to the literature, its incidence was 13–43% in various oncology centers, but its incidence decreased with the introduction of new professional guidelines. In oncology therapy, finding out the cause of limb and breast swelling often causes practical difficulty. Impairment of lymphedema as a result of deterioration in the patient's quality of life, the severity of the possibility of progression, and a reduction in life expectancy with discontinuation or modification of therapy also call for an investigation as soon as possible. After complete axillary lymph node removal surgery, the likelihood of developing remains high. This is why the view that led to surgical treatment of the lymphatic system may have been common, but it is now clear that some radiotherapy, chemotherapy, and oral medications alone can cause circulatory disturbances and abnormal fluid retention between tissues. - reproduction. Targeted physiotherapy after surgery helps to develop proper lymph flow, but early manual therapy does not prevent lymphatic stagnation. Due to the slowly progressing condition, the significance of the problem has often been underestimated by both oncologists and patients. When the early start of lymphedema treatment is delayed due to a delay in diagnosis, it can lead to late complications. It is recommended that in patients undergoing oncology treatment for breast cancer, the circumference of both arms and the edema of the breast tissue be described prior to initiating treatment, and that the current status be re-documented during each follow-up examination. Thus, the development of the disease can be detected earlier and the effectiveness of the therapy can be monitored. Among the therapeutic options, conservative therapies are available in Hungary, currently there is no possibility of lymph reconstruction surgery requiring supermicrosurgical techniques in the treatment range. Complex lymphatic drainage treatment is the primary treatment option of choice, the main elements of which are compression, manual lymphatic drainage, movement therapy and skin care. In addition to complex therapy, the choice of oral drugs may increase efficacy (benzopyrines, hyaluronidase, somatostatin analogs) and a new therapeutic option is the indication of VEGF-C expression by transgenic therapy.
C1 [Horvath, Anna] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Redling, Mariann] Del-pesti Centrumkorhaz, Belgyogyaszati, Angiologiai es Nefrologiai Osztaly, Borgyogyaszat SzakrendeloBudapest, Hungary.
RP Horvath, A (reprint author), Semmelweis University, Department of Internal Medicine and Haematology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 23
EP 25
PG 1
ER

PT J
AU Horvath, A
   Toth, �K
   Graf, L
   Lohinszky, J
   Rumaszauer, �
   Tegze, B
   Szabo, �
   Barabas, L
   Turcsanyi, G
   Novak, A
   Toth, E
   Pollner, P
   Fonyad, L
   Istvan, G
   Redling, M
AF Horvath, Anna
   Toth, Eva Katalin
   Graf, Laszlo
   Lohinszky, Julia
   Rumaszauer, Agnes
   Tegze, Balint
   Szabo, Akos
   Barabas, Lorand
   Turcsanyi, Gabor
   Novak, Andras
   Toth, Eniko
   Pollner, Peter
   Fonyad, Laszlo
   Istvan, Gabor
   Redling, Mariann
TI Frequency of upper limb lymphedema diagnosed in a population of those admitted to an oncology outpatient clinic at the Department of Internal Medicine and Hematology between 2020 and 2021
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The most common cause of acquired, ie secondary, lymphedema is oncological treatment after breast cancer. Based on the data in the literature, the incidence of lymphedema due to breast cancer was 13–43% in different oncology centers. Edema can be attributed to several factors. Surgical removal of regional lymph nodes, radiotherapy, and chemotherapy may all play a role in its development, and the genetic role of hereditary predisposition is also being investigated. Chronic lymphedema is a condition that significantly affects quality of life and requires lifelong treatment. In our experience, its incidence has decreased in recent years with the introduction of new professional guidelines. MATERIAL AND METHOD: At the Oncology Outpatient Clinic of the Department of Internal Medicine and Hematology, between January 2020 and May 2021, we reviewed the findings of 100 patients treated for breast cancer. RESULTS: Between 99 women and 1 man with breast cancer, lymphedema of the upper extremity occurred in 15% of the time. Lymphatic circulatory disorders were detected in one third of them at the time of diagnosis of breast cancer, so only a maximum incidence of 10% was observed as a result of the treatments. According to our survey, a total of 5 patients out of 38 patients who underwent axillary lymph node block removal (ABD) developed lymphatic circulation disorders after surgery. The other five patients received other treatments (eg SLN). There was only one therapy-resistant lymphedema among the patients treated. According to previous international data, the probability of developing after surgery to remove axillary lymph nodes (ABD) is 33–69%. The current rate of 13% is particularly good, as in this working group, surgeons did not have the opportunity to reconstruct the lymphatics during surgery. Surgical techniques that sparingly protect the lymphatics, radiation therapy according to strict professional criteria, and personalized chemotherapy according to the new guidelines can be very good results at the international level. DISCUSSION: The small number of cases can be criticized, as well as the inclusion of patients in care in the patient population during the pandemic, making the study incomplete. Due to the above, we plan to supplement the data. In the meantime, we would like to provide feedback to the profession by presenting the declining incidence of limb dysfunction caused by lymphatic circulation disorders in daily care.
C1 [Horvath, Anna] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Toth, Eva Katalin] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Graf, Laszlo] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Lohinszky, Julia] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Rumaszauer, Agnes] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Tegze, Balint] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Szabo, Akos] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Barabas, Lorand] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Turcsanyi, Gabor] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Novak, Andras] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Toth, Eniko] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Pollner, Peter] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Fonyad, Laszlo] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Istvan, Gabor] Semmelweis University, 2nd Department of SurgeryBudapest, Hungary.
   [Redling, Mariann] Del-pesti Centrumkorhaz, Belgyogyaszati, Angiologiai es Nefrologiai Osztaly, Borgyogyaszat SzakrendeloBudapest, Hungary.
RP Horvath, A (reprint author), Semmelweis University, Department of Internal Medicine and Haematology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Horvath, O
   Budai, B
   Hegedus, K
AF Horvath, Orsolya
   Budai, Barna
   Hegedus, Katalin
TI Who is responsible for end-of-life care for cancer patients? - Results of a survey of oncologists and general practitioners in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The pathway of patients with cancer requires the coordinated work of several professions, from diagnosis through active oncology treatment to follow-up of patients who have recovered and end-of-life therapy. It is a sensitive point in care, both professionally and emotionally, when the management of a patient’s treatment needs to be taken over by another doctor. This is especially true for end-of-life therapy. MATERIAL AND METHOD: We assessed the attitudes of 104 oncologists and 99 GPs regarding hospice care with an internationally validated questionnaire. With the help of the mail system of the Hungarian Society of Oncologists, we received the answers of 20.4% of the clinical oncology specialists registered in Hungary. GPs were accessed through a closed medical portal. We analyzed which issues were most agreed upon and where the biggest differences were. RESULTS: GPs and oncologists agree that cancer patients require special care in the last stages of their lives. Representatives of both professions agreed with the following statements: 1. All patients with advanced cancer should receive advanced palliative care, even at the same time as anti-tumor therapy (p = 0.96); 2. The dying patient is not in the active oncology ward (p = 0.88). However, there is no consensus on who is responsible for managing this special palliative care. Oncologists feel it is their own job, while those in primary care say it should be part of GP work. It may be that the answers to this question were the most divergent: 1. The management of the care of cancer patients at all stages is the responsibility of the oncologist, from the onset of the disease to end-of-life care (p = 0.00004). DISCUSSION: Close co-operation between an oncologist, a GP and a palliative doctor is required in the end-of-life care of cancer patients. It is an important goal that the right patient receives the right quality palliative care at the right time. In order to clarify the tasks and competencies, it is necessary to create easy-to-use, efficient referral models and protocols. During professional training, the protocols should be made known to the widest possible audience in the medical community, building on the recommendations.
C1 [Horvath, Orsolya] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Budai, Barna] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Hegedus, Katalin] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Horvath, O (reprint author), Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 25
EP 25
PG 1
ER

PT J
AU Horvath, Sz
AF Horvath, Szimonetta
TI What you need to know about patient education
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Patient education is the process by which a patient acquires the practice, knowledge and attitude required by his or her state of health, and by contacting the patient we can relieve anxiety, alleviate fear and promote recovery. Therapeutic education enables the patient to lead an optimal life. Patient education is achieved through continuous communication. It includes educational activities for all patients. Patient education can be done by any healthcare professional, so it is always an integral part of the healing process. The aim is to provide patients with quality data and information on treatment, prevention and how to cope with chronic illness. It is important that education builds a good relationship between patients and healthcare professionals so that care decisions are made jointly. Education should always be planned, and re-evaluated with the patient from time to time. As a result of well-designed and executed education, the patient feels more responsible for their own health, becomes more cooperative and committed to healing.
C1 [Horvath, Szimonetta] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
RP Horvath, Sz (reprint author), Zala Megyei Szent Rafael Korhaz, Onkologia, Zalaegerszeg, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 25
EP 26
PG 1
ER

PT J
AU Jakus, N
   Horvath, O
AF Jakus, Nikoletta
   Horvath, Orsolya
TI Introduction of the Palliative Mobile Team of the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The Palliative Mobile Team of the National Institute of Oncology started its operation in September 2019 with the aim of ensuring that patients undergoing palliative care in the institution and in need of palliative care have timely access to palliative care outside their institution. The reception of the team among the staff was higher than we expected, the number of patients in our care is increasing. The aim of our poster is to present our results so far and to present the benefits of close cooperation with oncology care and the possibilities of future development directions to a wider professional circle. MATERIALS AND METHODS: In 2020, we cared for 77 patients, while by June 30, 2021, 134 patients were asked to help arrange palliative care. By processing the data of these patients, we present, among other things: - how patients have survived since the start of special palliative care - the reasons for requesting the assistance of the Palliative Mobile Team - the number of unplanned hospital admissions for patients cared for by the Team has changed - change in the number of patients who died on the active beds of the Institute of Oncology after starting the work of the Team DISCUSSION: Palliative care is an approach that aims to improve the quality of life of a patient with a life-threatening illness and their family members. It prevents or reduces suffering by integrating palliative care as the disease progresses over time. The Palliative Mobile Team, which operates as a hospital consultative group and is not yet widespread in Hungary, helps to put this approach into practice, but we hope that over time this care will be available in more and more oncology.
C1 [Jakus, Nikoletta] Orszagos Onkologiai Intezet, Palliativ Mobil TeamBudapest, Hungary.
   [Horvath, Orsolya] Orszagos Onkologiai Intezet, Palliativ Mobil TeamBudapest, Hungary.
RP Jakus, N (reprint author), Orszagos Onkologiai Intezet, Palliativ Mobil Team, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Jorgo, K
   Polgar, Cs
   Takacsi-Nagy, Z
   Kocsis, Zs
   Nallbani, M
   Tenke, P
   Major, T
   Stelczer, G
   Agoston, P
AF Jorgo, Kliton
   Polgar, Csaba
   Takacsi-Nagy, Zoltan
   Kocsis, Zsuzsanna
   Nallbani, Marsel
   Tenke, Peter
   Major, Tibor
   Stelczer, Gabor
   Agoston, Peter
TI Trimodal treatment of muscle invasive bladder cancer with image-guided hypofractional radiotherapy using intravesically injected lipiodol tumor bed marking: a 3-year clinical outcome of a prospective study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To investigate the side effects and clinical outcomes of radiochemotherapy of muscle invasive bladder tumors with intravascular lipiodol injection-labeled tumor bed-based imaging (IGRT) and simultaneous integrated boost (SIB) techniques. MATERIALS AND METHODS: Between April 4, 2016 and April 20, 2021, 22 patients with isoinvasive, transient cellular carcinoma were included in our prospective study. Tumor bed resection (maximal TURBT) was performed on all of them before starting radiochemotherapy. During TURBT, 10 ml of a solution of lipiodol (Lipiodol® Ultra-Fluide, Guerbet LLC, Bloomington, IN) was injected subcutaneously into the tumor bed to mark the tumor site for elevated dose irradiation. During radiochemotherapy, 51 Gy (1.7 Gy per day) was applied to the pelvis, 57 Gy (1.9 Gy daily) to the entire bladder, and 63 Gy (2.1 Gy daily) to the lipiodol-labeled tumor bed in 30 fractions. ) was given as a SIB using a rotary intensity-modulated (RapidArc) technique. Irradiation accuracy was ensured by IGRT with kilovolt cone CT with daily online correction. Early and late radiogenic urogenital (GU) and gastrointestinal (GI) adverse events were classified according to the RTOG schedule. RESULTS: No significant perioperative side effects or toxicity were observed during and after lipiodol administration. The duration of radiotherapy was 6 weeks (5 fractions per week). During kilovolt CT examinations, the lipiodol-labeled tumor bed was clearly visible in all cases. The median follow-up was 38 months. Early grade ≥2 GI and UG adverse events occurred in 32% and 41%, respectively. The incidence of late grade ≥2 GI and UG adverse events was 9-9%. Local recurrence was observed in 23% of cases. 80% of local recurrences were found to be “in situ” carcinoma. 95% of treated patients retained their bladder, with only 1 patient requiring radical cystectomy for recurrence. Kaplan-Meier 3-year tumor-specific and overall survival were 81.6% and 81.6%, respectively. DISCUSSION: Radiation therapy based on a lipiodol-labeled tumor bed is safe and well tolerated in the trimodal treatment of patients with isoinvasive bladder cancer. The total treatment time was shortened by 4 days with increasing the total biological dose delivered to the tumor bed. Early and late radiogenic adverse events were moderate, with grade 4 adverse events observed in a single patient. The vast majority of patients retained their own bladder with adequate local tumor control and disease-specific survival.
C1 [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kocsis, Zsuzsanna] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Nallbani, Marsel] Allami Egeszsegugyi Kozpont – Honvedkorhaz, UrologiaBudapest, Hungary.
   [Tenke, Peter] Jahn Ferenc Korhaz, UrologiaBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Jorgo, K (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 26
EP 26
PG 1
ER

PT J
AU Juhasz, P
   Hasulyo, D
   Beke, L
   Bedekovics, J
   Mehes, G
AF Juhasz, Peter
   Hasulyo, Dora
   Beke, Livia
   Bedekovics, Judit
   Mehes, Gabor
TI Carbonic anhydrase IX (CAIX) induced by hypoxic microenvironment is negatively associated with immune cell infiltrate in breast carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Hypoxia as well as necrosis at the tissue level can be interpreted as a new prognostic marker in the diagnosis of breast cancer. This is because hypoxia makes it more difficult to treat breast cancer because tumor cells adapt to a lack of oxygen and change their metabolic processes, thereby creating resistance to standard therapies. At low oxygen levels, tumor cells activate specific genes under the influence of hypoxia-induced factor-1 α (HIF-1α) that enhance tumor vascularization and the minimum supply of oxygen and nutrients required for survival. Thus, the enzyme carbonic anhydrase IX (CAIX) is activated, which plays an important role in maintaining the acid-base balance of tumor cells under hypoxic conditions. Metabolic differences also cause significant heterogeneity in stromal and immune cell interactions in the environment of tumor cells. MATERIAL AND METHOD: In our work, we developed a histological method based on image analysis to investigate the distribution of the immune infiltrate of breast cancers. Using this, we studied the effect of CAIX expression on the occurrence of immune cells in a total of 36 cases of invasive breast cancer. RESULTS: CAIX positivity was detected in 19 samples, while 17 cases were used as negative controls. In our study, we found a significant difference between the number of CD8-positive T lymphocytes identifiable in CAIX-positive and CAIX-negative areas within the same tumor (23 ± 23 vs. 165 ± 105, p <0.005). On average, 7-fold more lymphocytes were detected in CAIX-negative areas. DISCUSSION: Our results suggest that CAIX expression locally indicates a change in the microenvironment in breast carcinoma, and that tissue acidosis of hypoxia is well related to the influx of immune cells. The efficacy of immunotherapies, which are becoming more widely available today, may be adversely affected by hypoxia.
C1 [Juhasz, Peter] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Hasulyo, Dora] Debreceni Egyetem, TDK-hallgatoDebrecen, Hungary.
   [Beke, Livia] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Bedekovics, Judit] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Mehes, Gabor] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
RP Juhasz, P (reprint author), University of Debrecen, Faculty of Medicine, Department of Pathology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 26
EP 27
PG 1
ER

PT J
AU Kelemen, Gy
   Hetenyi, A
   Dobi, �
   Uhercsak, G
   Santha, D
   Valicsek, E
   Koszo, R
   Voros, A
   Olah-Nemeth, O
   Hamar, S
   Lazar, Gy
   Simonka, Zs
   Paszt, A
   Ormandi, K
   Hoffmann, Cs
   Telek, A
   Kahan, Zs
   Olah, J
   Nikolenyi, A
AF Kelemen, Gyongyi
   Hetenyi, Alexandra
   Dobi, Agnes
   Uhercsak, Gabriella
   Santha, Dora
   Valicsek, Erzsebet
   Koszo, Renata
   Voros, Andras
   Olah-Nemeth, Orsolya
   Hamar, Sandor
   Lazar, Gyorgy
   Simonka, Zsolt
   Paszt, Attila
   Ormandi, Katalin
   Hoffmann, Csilla
   Telek, Anna
   Kahan, Zsuzsanna
   Olah, Judit
   Nikolenyi, Aliz
TI Is male breast cancer different from female? - 15 years of experience
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Male breast cancer is a rare disease, accounting for only 1% of breast cancers, but its incidence is steadily increasing. Because scientific life focuses primarily on female breast cancer, the diagnosis and treatment of male breast cancer to date is largely based on clinical trials and therapeutic considerations for female breast cancer. Our goal was to emphasize the unique characteristics of male breast cancer and to characterize the therapy used to provide a broader understanding of the disease and to treat it more effectively in the future. MATERIAL AND METHOD: In our retrospective study, we processed data from histologically confirmed male breast cancer patients treated at our clinic between 2006 and 2020. The number of the ethics permit is 151/2020-SZTE. RESULTS: Data from 30 patients were evaluated. The median age of the patients was 64 years. The majority of tumors were histologically invasive ductal carcinoma. Based on imaging studies, 63.3% of patients were diagnosed in stage I-II, 5 patients were de novo metastatic. Estrogen receptor (ER) was positive in 96.6%, progesterone receptor (PR) in 82.8%, and HER-2 in 6.9%. The most common clinicopathological subtype was Luminalis B, HER-2-negative. Breast surgery was performed in 27 cases and lymph node surgery in 26 cases. Breast-conserving surgery was performed in 1 case. Fifteen patients received postoperative radiotherapy and 12 patients received adjuvant chemotherapy, 58.3% of which were anthracycline and taxane-based. Adjuvant hormone therapy was initiated in 89.3% of ER-positive cases, compared to 88% with tamoxifen. In HER-2-positive cases, adjuvant trastuzumab therapy was initiated. DISCUSSION: Male breast cancer is typically diagnosed at a later age and at more advanced stages than female breast cancer. The proportion of hormone receptor-positive cases was higher, with HER-2 positivity and the incidence of triple-negative tumors being lower. Mastectomy was significantly more common than in women with breast cancer. Therapy did not follow a uniform protocol. In order to optimize care, it would be important to involve male breast cancer patients in clinical trials and to develop international guidelines.
C1 [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hetenyi, Alexandra] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Voros, Andras] University of Szeged, Department of PathologySzeged, Hungary.
   [Olah-Nemeth, Orsolya] University of Szeged, Department of PathologySzeged, Hungary.
   [Hamar, Sandor] University of Szeged, Department of PathologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of SurgerySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Ormandi, Katalin] University of Szeged, Department of RadiologySzeged, Hungary.
   [Hoffmann, Csilla] University of Szeged, Department of RadiologySzeged, Hungary.
   [Telek, Anna] University of Szeged, Department of RadiologySzeged, Hungary.
   [Kahan, Zsuzsanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kelemen, Gy (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Kenessey, I
   Szoke, G
   Dobozi, M
   Szatmari, I
   Weber, A
   Fogarassy, Gy
   Nagy, P
   Kasler, M
   Polgar, Cs
   Fogarassyne Vathy, �
AF Kenessey, Istvan
   Szoke, Georgina
   Dobozi, Maria
   Szatmari, Istvan
   Weber, Andras
   Fogarassy, Gyorgy
   Nagy, Peter
   Kasler, Miklos
   Polgar, Csaba
   Fogarassyne Vathy, Agnes
TI Comparison of survival patterns of cancer patients in the period 2001–2005 to 2011–2015 based on the database of the National Cancer Registry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Population-based registration of cancer survival may well demonstrate the effectiveness of oncology treatments and provide valuable data for the development and organization of the oncology care system. The most accurate quality assurance feedback may be from survival analysis, however, the vast majority of studies available in the literature use estimation-based models. In our work, we analyzed much more accurate, population-based data. MATERIALS AND METHODS: Cases of colorectal cancer, lung cancer, breast cancer, prostate cancer and cervical cancer reported to the National Cancer Registry between 2001 and 2015 were analyzed. The incidence was standardized according to the 2013 European Standard Population and compared with mortality data from the Central Statistical Office. We performed a statistical analysis of patient survival on a cleansed database. The comparison was made between two different periods (2001–2005 and 2011–2015) and the stage of the tumor. RESULTS: The standardized incidence of colorectal, breast, and prostate cancers increased during the study period, while there was a decrease in lung and cervical cancers. In addition, the survival of patients with colorectal, breast and prostate carcinomas improved between 2011 and 2015 compared to 2001–2005. In contrast, there was a slight deterioration in lung cancer, while there was no significant change in cervical cancer. Examination of the survival pattern based on the tumor stage revealed that at a low stage, the outcome was more favorable for almost all tumor types, however, at a more advanced stage, survival benefit is no longer expected from oncology treatment. Analysis of the distribution of each stage showed that while colorectal, breast and prostate cancer were generally detected at a lower stage between 2011 and 2015, a higher proportion of lung and cervical cancers were in the higher stage. DISCUSSION: Our results support that new types of oncology therapies are more effective in early-stage patients, and greater progress is expected from the development of a screening network. Nevertheless, the rising cost of oncology and the longer survival of patients is an ever-increasing burden on society.
C1 [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Szoke, Georgina] Pannon Egyetem, Rendszer- es Szamitastudomanyi TanszekVeszprem, Hungary.
   [Dobozi, Maria] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Szatmari, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Weber, Andras] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Fogarassy, Gyorgy] Allami Szivkorhaz, 1. Sz. Kardiologiai OsztalyBalatonfured, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Molekularis Immunologia es Toxikologia OsztalyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fogarassyne Vathy, Agnes] Pannon Egyetem, Rendszer- es Szamitastudomanyi TanszekVeszprem, Hungary.
RP Kenessey, I (reprint author), National Institute of Oncology, National Cancer Registry, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 27
EP 27
PG 1
ER

PT J
AU Keresztes, T
   Kocsis, J
   Rimai, J
   Szocs, A
   Kovacs, V
   Horvath, Zs
AF Keresztes, Tamas
   Kocsis, Judit
   Rimai, Judith
   Szocs, Aniko
   Kovacs, Viktorne
   Horvath, Zsolt
TI Long-term central venous insurance in oncology practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our center it is possible to provide a permanent vein in the form of a port-acath and a picc-line catheter. Despite the most careful port-a-cath implantation and care, there are complications that are constantly documented. This summary compares the results of 311 implantations performed between January 2017 and June 2019 (30 months) with the experience of 294 implantations between 1 July 2019 and 31 December 2020 (28 months). During this period, we changed the patient selection and implantation methodology. Our goal was to reduce the rate of early and late complications. MATERIAL AND METHOD: Based on the practice developed in our center, the port-a-cath implantation is performed by cannulation of the subclavian vein, fixed to the pectoralis fascia. The following modifications were made: we preferred the implantation of smaller-headed anthers, the insertion into the subdominant side, and the introduction of intraoperative Doppler ultrasound in the case of technically difficult cannulation. RESULTS: Powder implantation in 294 patients, 65.3% in gastrointestinal cancer patients (56.3% in the previous study period), 17.7% in breast cancer (previously: 28.9%) and 17% in other tumors. (previously: 17.5%). Puncture of the subclavian artery (2.4% vs. 1.29% in the previous period) and the development of pneumothorax (2.4% vs. 0.64% in the previous period) were observed as perioperative complications. As a complication beyond 7 days, powder reversal was observed in 0.68% (previously studied period: 0.94%) and powder cannula-associated thrombosis in 1.7% (previously studied period: 0.64%). Earlier-than-planned portextraction was required for skin decubitation in 10.2% (previously studied period: 3.86%), port-associated infection or cannula sepsis in 0.34% (previously studied period: 1.6%), pain 0, 68% (previously studied period: 0.96%). The differences are not significant. DISCUSSION: Analyzing the data from the 28 months studied and comparing the data from the previous 30 months, it can be concluded that the proportion of early and late complications did not change significantly with the modification of the implantation technique. However, intraoperative use of doppler ultrasound improves the success of the intervention. Further analyzes are planned to more accurately detect and prevent early and late complications of the portal application, with a particular focus on portassociated thrombotic events.
C1 [Keresztes, Tamas] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Rimai, Judith] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Szocs, Aniko] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kovacs, Viktorne] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Keresztes, T (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 27
EP 29
PG 1
ER

PT J
AU Kiraly, J
   Halmos, G
   Szabo, Zs
AF Kiraly, Jozsef
   Halmos, Gabor
   Szabo, Zsuzsanna
TI Investigation of oncogenic miRNA expression of plant-based shikonin in human kidney tumor cell lines by Nanostring technology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Worldwide, kidney cancer and its therapy continue to be a serious problem. The disease has a poor prognosis and is difficult to treat, and its therapy is an increasing challenge today. Sunitinib treatment in patients with metastatic renal cancer has not been shown to be effective in recent years. Therefore, research into newer therapeutic options and the molecular mechanisms behind them is of great importance. Our aim was to investigate the cytotoxic effect of an extract from a Chinese plant, shikonin, on human clear cell renal carcinoma cell lines CAKI-2 and A-498 after 2, 4, 6, and 24 h of treatment. To investigate the inhibitory effect of shikonin on cell proliferation in vitro on cell lines and the expression of certain miRNA groups using Nanostring technology, and to analyze target genes specific for these miRs in control and treated CAKI-2 and A-498 cell lines. MATERIALS AND METHODS: For cell proliferation experiments, shikonin was used at a concentration of 1-40 μM, and the cytotoxic effect after the treatment was measured by a clonogenicity assay. Total RNA isolated using the Macherey− Nagel kit was used to profile miRNA with the Nanostring nCounter® microRNA platform according to the manufacturer's instructions. Samples were normalized using BRB arraytools software. The change in expression of the proteins encoded by each target gene was measured by Western blot (WB). RESULTS AND DISCUSSION: Shikonin exerts a dose-dependent effect on both cell lines tested and results in significant inhibition of cell proliferation in vitro even at very low concentrations of 2.5 μM. Following nanostric analysis, we found that for both CAKI-2 and A-498 cell lines, a group of miRs (hsa-miR-99b-5p, hsa-miR-365a-3p, miR-29a-3p, miR-15b-3p) showed significant downregulation compared to control cells. In contrast, some miRs (hsa-miR-873-3p, hsa-miR-6721-5p, hsa-miR-612, hsa-miR-582, hsa-miR-3144-3p, hsa-miR-221 -3p) showed upregulation only in the A-498 cell line after shiconin treatment compared to the control cell, whereas in the case of the CAKI-2 cell line there was no difference after said shikonin treatment. In the WB study of the target proteins, a decrease in the expression of PTEN and NF-κB proteins was observed in both cell lines after 24 h of treatment.
C1 [Kiraly, Jozsef] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi KarDebrecen, Hungary.
RP Kiraly, J (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Kiraly, Zs
   Halmos, G
   Szabo, Zs
AF Kiraly, Zsolt
   Halmos, Gabor
   Szabo, Zsuzsanna
TI Physician referral habits, diagnostic delay factors in patients with lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Lung cancer is a serious public health problem worldwide in terms of morbidity and mortality. The aim of our research was to determine how long it takes for patients to see a doctor with their complaints (delayed illness). Subsequently, in addition to the time spent examining the patient, the time required to start treatment was determined. Socio-demographic and tumor-specific parameters of the patients were also analyzed in connection with the survey. The effects of the Covid pandemic were also examined along these criteria. MATERIALS AND METHODS: A quantitative cross-sectional study was performed between 1 January 2020 and 31 December 2020 in all primary lung cancer patients presented at the Veszprem County Lung Hospital. In addition to descriptive statistical analysis, chi-square test, ANOVA, and correlation analysis were performed at 95% probability using the SPSS 26 statistical program (p <0.05). RESULTS: Data from 171 patients were analyzed in this study. The mean age was 66.95 ± 8.2 years. 109 men and 62 women. The patient delay was 37.32 days, the diagnostic delay was 48.58 days, and the therapeutic delay was 17.58 days. In connection with the pandemic, the number of patients showed a decreasing trend. Patient delays decreased in the second and third quarters, but increased to the fourth quarter. There was also evidence of a reduction in diagnostic delay. DISCUSSION: Patients are shorter than the time required to make a diagnosis and start therapy until they see their doctor.
C1 [Kiraly, Zsolt] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
   [Halmos, Gabor] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
   [Szabo, Zsuzsanna] Veszprem Megyei Onkormanyzat TudogyogyintezeteFarkasgyepu, Hungary.
RP Kiraly, Zs (reprint author), Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 29
EP 29
PG 1
ER

PT J
AU Kis, D
   Hargitai, R
   Persa, E
   Szatmari, T
   Kis, E
   Safrany, G
   Lumniczky, K
AF Kis, David
   Hargitai, Rita
   Persa, Eszter
   Szatmari, Tunde
   Kis, Eniko
   Safrany, Geza
   Lumniczky, Katalin
TI The role of extracellular vesicles in radiation-induced leukemias
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The bone marrow is a particularly radiosensitive organ and radiation exposure to the bone marrow increases the incidence of leukemias. Radiation damages bone marrow stem and progenitor cells and interferes with communication between the stem cell population and bone marrow stromal cells. The main aim of our work was to study the effect of bone marrow-derived extracellular vesicles (EVs) on the incidence of developing leukemias and their role in the mechanism of leukemia development. MATERIAL AND METHOD: Radiation-induced leukemia was studied in CBA mice because this mouse strain is more prone to radiation after acute myeloid leukemia. The mice were irradiated. We tracked some of them for the rest of their lives. EVs were isolated from the bone marrow of another part of them and inoculated into either untreated or previously irradiated mice. We examined the frequency and type of leukemia onset, the time of onset of the disease, and the cellular and molecular lesions affected by EVs and characteristic of leukemias. RESULTS: Compared to the incidence of spontaneous leukemias (1-2%), high-dose whole-body irradiation increased the incidence of leukemia to 19%. The incidence of leukemias following EV treatment ranged from 4.5 to 6% and there was no significant difference between the effects of EVs from irradiated or control animals. Combined radiation and EV treatment additively increased the incidence of leukemia to 25%. EVs significantly influenced the phenotype of developing leukemias. While the rate of immature myeloblastic leukemias within all leukemias was 25% due to radiation alone, this rate increased to 60–80% with combined radiation and EV treatment, depending on whether it was performed with an irradiated or control EV. the treatment. EVs also had a significant and type-dependent effect on the time to onset of leukemias. DISCUSSION: Bone marrow-derived EVs have been shown to influence the incidence and phenotype of radiation-induced leukemias independently of irradiation. Our results call attention to the importance of intercellular communication in the development of radiation-induced leukemias in the bone marrow.
C1 [Kis, David] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Hargitai, Rita] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Persa, Eszter] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Szatmari, Tunde] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Kis, Eniko] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Safrany, Geza] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
   [Lumniczky, Katalin] Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato IntezetBudapest, Hungary.
RP Kis, D (reprint author), Fodor Jozsef Orszagos Kozegeszsegugyi Kozpont, Orszagos Frederic Joliot-Curie Sugarbiologiai es Sugaregeszsegugyi Kutato Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 29
EP 30
PG 1
ER

PT J
AU Kis, E
AF Kis, Erika
TI Electro-chemotherapeutic treatment of advanced cutaneous angiosarcomas: a European registry-based prospective cohort study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Cutaneous angiosarcomas (CAS) are rare, aggressively growing tumors that challenge the surgeon in terms of radical removal. Electrochemotherapy (ECT) based on a combination of a cytotoxic agent and electrical impulses is an effective procedure for the treatment of solid tumors as a new option in the treatment of CAS as an intraoperative adjuvant treatment. Through the results of an international cohort study, we present the experience gained with ECT in the treatment of advanced CAS. MATERIALS AND METHODS: Between October 2013 and October 2018, we processed the data of prospectively collected data of locally advanced / metastatic CAS patients treated with ECT in 8 European centers in the InspECT (International network for sharing practices of ECT) database. ECT treatments were performed in all centers according to the ESOPE protocol. Tumor response to treatment was assessed according to Recist 1.1, side effects were assessed according to CTCAEv5.0, post-treatment pain according to the VAS scale, and quality of life according to the EQ-5D questionnaire. RESULTS: Twenty patients with advanced CAS in the scalp / face (n = 7), chest / torso (n = 10), or limbs (n = 3) were included in the study. Tumors (n = 51) were 2.3 cm (1–20) in size. ECT treatment was performed 24 times with a safety zone of 1–4 cm, in 5 cases electro-chemotherapy was combined with surgical treatment. Tissue current was 3 A (1.5–10 A) and tumor edge coverage was 75% (15/20 patients). Complete remission was achieved in 40%, and the objective tumor response was 80%. Ulceration was observed in 15% and pain after treatment in 10%. In ulcerative bleeding tumors, control of bleeding was achieved in 13/14 patients. Median overall survival was 12.5 months, while survival without local recurrence was 10.9 months. DISCUSSION: In advanced CAS, a prolonged tumor response can be achieved with ECT treatment with few side effects and should be considered as a new therapeutic option. Treatment is well tolerated by patients, with additional beneficial effects of long-term local tumor and bleeding control. Determining the exact timing of the intervention, the safety zone used, and the combination with surgical treatment will require further investigation.
C1 [Kis, Erika] Szegedi Tudomanyegyetem, Plasztikai Sebeszeti OsztalySzeged, Hungary.
RP Kis, E (reprint author), Szegedi Tudomanyegyetem, Plasztikai Sebeszeti Osztaly, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Kispal, MT
   Janvary, LZs
   Baranyai, F
   Czirbesz, K
   Danyi, T
   Vattay, D
   Stelczer, G
   Panczel, G
   Bocs, K
   Kontra, G
   Bajcsay, A
   Balatoni, T
   Liszkay, G
AF Kispal, Mihaly Tamas
   Janvary, Levente Zsolt
   Baranyai, Fanni
   Czirbesz, Kata
   Danyi, Timea
   Vattay, Dorottya
   Stelczer, Gabor
   Panczel, Gitta
   Bocs, Katalin
   Kontra, Gabor
   Bajcsay, Andras
   Balatoni, Timea
   Liszkay, Gabriella
TI Stereotaxic radiotherapy in stage IV melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Radiosurgery in the appropriate indication may also contribute to the results of drug therapy in disseminated melanoma. The CyberKnife technique, which is the state-of-the-art in stereotaxic radiotherapy, has been the only one available in Hungary since 2018. MATERIALS AND METHODS: Between January 2018 and October 2020, 30 patients with disseminated melanoma were treated with medication based on the decision of a multidisciplinary oncosteam. In 22 cases (73%) intracranial, in 4 cases (13%) pulmonary, in one case (3%) the foci in the epipharynx, retrobulbar, in the kidney and adrenal glands were treated, in the case of foci causing a small number of complaints, according to the institutional protocol. RESULTS: In 15 (50%) of our 30 patients we achieved partial remission, in 4 (13%) cases complete remission, in 4 (13%) cases stable disease was observed, in 7 (24%) cases the treated foci progressed. Of the 30 patients treated, at the end of the study period, with a median follow-up of 9.5 months, 14 patients (47%) were still receiving systemic therapy or observation, and 16 patients (53%) were progressing despite systemic therapy and stereotaxic irradiation. Gr 1-2 side effects and Gr 3 side effects were observed in 16 patients (53%), the most common being dizziness and headache in 12 patients (40%) due to irradiation of cerebral metastases. During pulmonary irradiation, the most common adverse reaction was mild bronchitis following treatment (2%). Prior to stereotaxic therapy, 8 patients (27%) received targeted Braf-MEK inhibitor therapy, 8 patients (27%) received systemic therapy, 4 patients (13%) received chemotherapy, and 10 patients (33%) received no prophylactic systemic therapy. After irradiation, 16 (53%) patients were able to continue their treatment before treatment. DISCUSSION: Our initial results suggest that stereotaxic radiosurgery, including CyberKnife technology, may contribute to the effectiveness of systemic therapy. Further clinical experience with a larger number of patients is needed to determine the exact indication and to achieve further results in melanoma.
C1 [Kispal, Mihaly Tamas] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Janvary, Levente Zsolt] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Vattay, Dorottya] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Bocs, Katalin] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Kontra, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Kispal, MT (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 30
EP 30
PG 1
ER

PT J
AU Kiss, E
   Szabo, �
   Szendroi, M
   Agoston, P
   Papai, Zs
AF Kiss, Edina
   Szabo, Adam
   Szendroi, Miklos
   Agoston, Peter
   Papai, Zsuzsanna
TI Tumoragnostic targeted therapy - TRK inhibition in practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Oncology based on personalized molecular diagnostic tests may signal a new shift in approach to cancer therapy. NTRK (neurotrophic tropomyosin receptor tyrosine kinase) gene fusions are important driver gene targets in both pediatric and adult tumors, with frequencies varying by tumor type and more commonly associated with rare tumors. Gene fusion can be detected by various molecular diagnostic methods. Selective inhibition of TRK (tropomyosin receptor-tyrosine kinase) fusion proteins involves personalized so-called precision oncology therapy in many tumor types. Its significance is that, in contrast to previous treatments based on tissue subtype or localization, it is independent of them, i.e., tumor agnostic, and the indication for therapy is based on the molecular target. A breakthrough in the history of targeted therapies was the registration by the FDA of the first-generation TRK inhibitor larotrectinib on 26 November 2018 and entrustinib on 15 August 2019 with molecular diagnostic methods. In the case of NTRK gene fusion, regardless of tumor type, localization, and patient age. During the presentation, we would like to present the case of our young patient with soft tissue sarcoma, for whom the systemic treatments applied due to the disseminated disease did not show a meaningful therapeutic response. Molecular diagnostic testing has confirmed a very rare driver oncology target, the NTRK gene fusion. The TRK inhibitor larotrectinib therapy available under the OGYEI early access program was used with high efficacy and a low side effect profile. It was an oral, well-tolerated, convenient treatment for a limb deficient patient. This was the first and only systemic therapy to which the disease responded. The new generation of targeted therapies against driver oncogenes will fundamentally change and individualize the treatment of tumors.
C1 [Kiss, Edina] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szabo, Adam] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Szendroi, Miklos] Semmelweis University, Department of OrthopedicsBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Klarik, Z
   Oberna, F
AF Klarik, Zoltan
   Oberna, Ferenc
TI Complex surgical treatment of large lip tumors with free forearm flap
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The treatment of lip tumors with a good prognosis is primarily surgical. Despite their easy recognition, to date, patients are too late to seek treatment and, due to their large size, develop significant tissue deficiency after tumor removal. The most important task of lip reconstruction is to restore anatomical conditions and function similar to the original condition. In our presentation, the m. our cases of lip reconstruction with free fasciocutaneous forearm combined with palmaris longus tendon are presented and the evaluation of the achieved results is presented. MATERIALS AND METHODS: Between 2017 and 2021, we performed a combined immediate reconstruction of the fasciocutaneous forearm and palmaris longus tendon in our center at a total of 6 male patients (mean age: 65 years) at our center. In one case, recurrence following radiochemotherapy, in four cases with primary removal of the tumor, and in one patient to eliminate microsomy secundaer after tumor surgery. The localization of neoplasms affected the lower lip in four patients, the total upper lip in one patient, the entire lower lip in one of our patients, and 1/3 of the upper lip. RESULTS: In their case study, no complete lobe death was observed, in one case we underwent repeated surgery on the fourth postoperative day due to partial venous insufficiency. Restoration of oral function was successful in all 6 patients, as evidenced by the postoperative results of the internationally accepted, validated functional lip reconstruction questionnaire (FLiGS). DISCUSSION: Surgical reconstruction of complete or near complete absence of the lower lip and upper lip can be accomplished with a large bilateral trained local or distal lobe. Tissue replacement with a free lobe microvascular technique used in head and neck surgery also provides an opportunity for functional repair of defects. However, after the removal of lip tumors, care should always be taken to adhere to the principles of reconstruction: preserving the closure of the oral cavity and the sphincter function of the lip, restoring anatomical boundaries and units, opening the mouth to eat .
C1 [Klarik, Zoltan] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Klarik, Z (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Kocsis, J
   Radeczky, �
   Vizhanyo, R
   Fajth, B
   Kelemen, Zs
   Cserni, G
   Horvath, Zs
AF Kocsis, Judit
   Radeczky, Agota
   Vizhanyo, Rita
   Fajth, Bence
   Kelemen, Zsuzsa
   Cserni, Gabor
   Horvath, Zsolt
TI Our experience with pembrolizumab treatment of microsatellite-unstable tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Tumors due to mismatch repair deficiency (dMMR) belong to a specific biological group. The genome is characterized by microsatellite instability (MSI-H), a high rate of tumor mutation, and these tumors respond well to immunotoxin point inhibition. In May 2017, the first tumor agnostic therapy, the PD-1 inhibitor pembrolizumab, was registered by the FDA in solid tumors with the MSI-H phenotype. Our aim was to analyze the results of patients treated with pembrolizumab for advanced MSI-H solid tumors at Bacs-Kiskun County Teaching Hospital. MATERIALS AND METHODS: Over the past 1.5 years, we have applied for and received funding for pembrolizumab treatment in 9 patients with advanced colorectal cancer and 3 patients with endometrial cancer at our center. RESULTS: In the endometrial indication, patient 1 developed severe immune-mediated adverse reactions (myasthenia gravis, myositis, carditis) after the second cycle of line 2 pembrolizumab treatment, requiring discontinuation, and restaging CT confirmed partial regression. Our 2nd patient has so far received 24 cycles of metastatic first-line treatment and is in complete remission. Our 3rd patient has received 4 cycles in the second line so far, his illness is stable, he is waiting for an extension of the permit. In metastatic colorectal indication, patient 1 did not initiate treatment (fifth line) due to further progression. Our 2nd patient developed an ischemic stroke after 1 cycle, so we could not continue treatment. Second-line pembrolizumab was discontinued in 4 patients due to progression after 4 cycles; DISCUSSION: In cases of microsatellite instability in patients with advanced colorectal cancer and endometrial cancer, immunosuppressive therapy is an effective therapy. Investigation of microsatellite instability is of paramount importance in these tumors, thus enabling the administration of effective, chemotherapy-free therapy in the early treatment line.
C1 [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Radeczky, Agota] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vizhanyo, Rita] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Fajth, Bence] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kelemen, Zsuzsa] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Kocsis, J (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 31
EP 31
PG 1
ER

PT J
AU Kocsis, Zs
   Agoston, P
   Farkas, Gy
   Kun-gazda, M
   Szekely, G
   Major, T
   Mihaly, D
   Pesznyak, Cs
   Stelczer, G
   Jorgo, K
   Gesztesi, L
   Polgar, Cs
   Juranyi, Zs
AF Kocsis, Zsuzsa
   Agoston, Peter
   Farkas, Gyongyi
   Kun-gazda, Marta
   Szekely, Gabor
   Major, Tibor
   Mihaly, Dalma
   Pesznyak, Csilla
   Stelczer, Gabor
   Jorgo, Kliton
   Gesztesi, Laszlo
   Polgar, Csaba
   Juranyi, Zsolt
TI Radiological methods for predicting radiotherapeutic side effects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The development of biomarkers that predict outcome and side effects is vital in all types of tumor therapy, but there are very few such markers. In the case of radiotherapy, this is especially important because late side effects can occur years after treatment, when it is no longer possible to change the therapy. MATERIALS AND METHODS: For four types of radiotherapy used to treat prostate cancer in our institute (high dose rate and seed brachytherapy, CyberKnife and LINAC based telotherapy), we examined the performance of chromosome aberration and RILA (Radiation Induced Lymphocyte Apoptosis) methods. Blood taken prior to therapy was irradiated with 8 Gy and the RILA obtained from the apoptotic ratio of CD8 + lymphocytes as determined by flow cytometry (propidium iodide DNA staining, DNA volume and size-reduced cells) was compared to therapeutic side effects. Blood was taken every three months after therapy (annually after the first year) and lymphocyte chromosome aberrations were determined microscopically. RESULTS: Irradiation resulted in an increase in the number of radiation-specific dicentric and ring chromosomes in all arms, with the largest change observed with LINAC-based therapy (LINAC: 0.6 ± 0.1 to 8.3 ± 1.0, CyberKnife : 0.4 ± 0.1 to 5.0 ± 0.6, seed: 0.5 ± 0.1 to 2.1 ± 0.2, HDR: 0.4 ± 0.1 to 1.2 ± 0.2) (at 3 months, relative to 100 cells). The quantitative order of dicentric + ring aberrations at each time point was as follows: LINAC> CyberKnife> seed> HDR. The number of total aberrations increased similarly to that of the dicentric chromosomes after irradiation and later decreased, but first reached the baseline value used in our laboratory only at the four-year follow-up point (5%). In accordance with international recommendations, we have determined the limit of the RILA method to be used in our laboratory and that the incubation times used during the preparation are set correctly. Furthermore, we found a relationship between chromosome aberrations and the results provided by the RILA method: the Spearman correlation coefficient between the chromosome breaks measured nine months after radiotherapy and the RILA value = 0.56. This correlation was also significant in regression analysis (R2 = 20.0%, p = 0.032). DISCUSSION: Our results suggest that radiological values ​​may be predictive markers of radiotherapeutic toxicities.
C1 [Kocsis, Zsuzsa] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Farkas, Gyongyi] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Kun-gazda, Marta] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Szekely, Gabor] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Mihaly, Dalma] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Stelczer, Gabor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Jorgo, Kliton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Gesztesi, Laszlo] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Juranyi, Zsolt] Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai OsztalyBudapest, Hungary.
RP Kocsis, Zs (reprint author), Orszagos Onkologiai Intezet, Sugarterapias Kozpont, Klinikai Sugarbiologiai es Diagnosztikus Onkocitogenetikai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Koncz, Zs
AF Koncz, Zsuzsa
TI Association of Oncologists and Psychologists: Special Framework, Limits and Challenges of Psychological Work in Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB BACKGROUND AND OBJECTIVE: The mysterious, complex process of the pathogenesis of cancer has occupied humanity for centuries. The emotional life, which seemed similarly mysterious, was associated with a causal relationship by many. Such assumptions have been replaced by scientific research since the ’50s, along which psychology may have entered into a dialogue with oncology. Decades of hard work by dedicated professionals have led to an alliance between the two disciplines that gave birth to oncopsychology. Today, psychological interventions are an essential part of oncology care, but developing frameworks and boundaries is a major challenge for professionals in everyday practice. One reason for this is that the specifics of psychological work performed in an oncology setting are different from traditional psychotherapeutic frameworks. Furthermore, due to the lack of vocational training in oncopsychology in Hungary, orientation and learning in this field require significant personal commitment, respect, patience, attention and continuous, mutual communication between professionals. In addition to overloading the health care system, this can cause significant difficulties in everyday life, but learning the language of oncology, getting to know colleagues and regular supervision are essential to practicing the profession. On the other hand, the emotional pressure on the psychologist is also very special in this field. The purpose of this presentation is to review the specifics of oncopsychological work to support and develop oncologist-patient-psychologist collaboration. MATERIAL AND METHOD: Based on a review of international recommendations and research results, as well as the processing of clinical experience, I provide a summary of the history, specifics, and current situation of the oncopsychological profession. RESULTS AND DISCUSSION: In my presentation, I provide an insight into the history of oncopsychology, from the theories of the psychological effects that are misapplied in the development of cancer to scientifically grounded multidisciplinary teamwork. I raise the common psychological difficulties associated with oncological illness and treatment and the possibilities of their psychological treatment, with special regard to the peculiarities of the psychologist-patient relationship, the possibilities of oncologist-psychologist cooperation, and the delicate issues related to competence boundaries.
C1 [Koncz, Zsuzsa] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
RP Koncz, Zs (reprint author), Semmelweis University, Institute of Behavioural Sciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 33
EP 33
PG 1
ER

PT J
AU Koncz, Zs
   Gyorffy, Zs
   Matrai, Z
AF Koncz, Zsuzsa
   Gyorffy, Zsuzsa
   Matrai, Zoltan
TI Investigation of the use of complementary and alternative medicine in women with breast cancer in the perioperative period
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The popularity of complementary and alternative medicine (CVD) among cancer patients is increasing worldwide. 51% of cancer patients and 45% of breast cancer women use KAM, compared to 62.5% of younger breast cancer women. There is little data available on this topic in Hungary. The use of KAM agents during oncology treatments can be risky due to drug interactions, so it is extremely important to know the patients' treatment choice practices and motivations. Our goal is the systematic collection of data to increase the safety of patient care. MATERIALS AND METHODS: Our questionnaire was performed at the Department of Breast and Soft Surgery of the National Institute of Oncology among the women in the department. In addition to sociodemographic questions, we used validated measures in our questionnaire to assess psychological factors (distress, depression, anxiety, coping, health control) and KAM use, and supplemented our database with clinical data. Our questionnaire was completed by 146 women. RESULTS: At the time of completing the questionnaire, 58% of the respondents were still before surgery, 41% had already undergone at least one surgery, 51% had already received chemotherapy, and 21% had gone beyond radiation therapy. 70.5% of the respondents use some form of KAM preparation and 63.7% use some form of self-help practice. Most patients chose KAM based on the advice of a healthcare professional (24%) or family member (14.4%). The majority of fillers (56.8%) want to strengthen their immune system with the product used. A holistic approach to health and internal and social external health control are dominant in the sample. Patients who visit KAM providers are more sympathetic to naturopathy, preferring internal control and judging their own health to be better. Users of KAM formulations are also characterized by internal control. Levels of depression and anxiety were elevated in the sample. DISCUSSION: The results of our study show that in addition to wanting to take an active role in their treatment, patients trust their caregivers the most and want to receive information from them. The high rate of KAM use makes it absolutely necessary to discuss the topic during medical consultations, and clarifying the motivational background underpins the development of oncopsychological interventions that allow for adequate and safe distress reduction.
C1 [Koncz, Zsuzsa] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Gyorffy, Zsuzsa] Semmelweis University, Institute of Behavioural SciencesBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of SurgeryBudapest, Hungary.
RP Koncz, Zs (reprint author), Semmelweis University, Institute of Behavioural Sciences, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 33
EP 34
PG 1
ER

PT J
AU Konya, G
   Kiraly, J
   Dobos, N
   Szegedi, K
   Zsebik, B
   Fodor, P
   Szabo, Zs
   Halmos, G
AF Konya, Gabor
   Kiraly, Jozsef
   Dobos, Nikoletta
   Szegedi, Krisztian
   Zsebik, Barbara
   Fodor, Petra
   Szabo, Zsuzsanna
   Halmos, Gabor
TI Investigation of indolamine 2,3-dioxygenase (IDO) and PTEN expression in renal tumors and human renal tumor cell lines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The immunological processes of tumor cells are significantly different from those of normal cells. Therefore, immune processes affecting the development of tumors may form the basis of immunotherapy as well as chemotherapy that can be combined with it. Inhibition of the IDO molecule produced during immune processes could provide a promising therapeutic option in the treatment of cancer, including renal tumors. Tumor suppressors involved in tumor growth, e.g. PTEN may also affect disease prognosis and immunotherapy. We aimed to explore the processes in kidney tumors that can block the functioning of the immune system. Related to this, we examined the presence of IDO and PTEN in human kidney tumor and intact tissue samples as well as in human kidney tumor (CAKI-2 and A-498) cell lines. MATERIALS AND METHODS: For our studies we had 20 pairs of tumor and intact kidney tissue samples surgically removed from the Urology Clinic of the University of Debrecen. Total RNA and protein were isolated from the samples and human kidney tumor cell lines. Following reverse transcription, the expression of IDO and PTEN genes was examined by real-time qRT-PCR (specific CFR-96, BIORAD) using specific oligonucleotide primers. The presence of the tested proteins was confirmed by Western blotting. RESULTS AND DISCUSSION: Our results show that PTEN and IDO genes are more significantly expressed in the examined tumor kidney samples compared to the intact samples, which was confirmed by our Western blot studies. The age group and gender distribution of the cases did not show a correlation with the expression of the studied genes. Expression of PTEN was also observed in the A-498 and CAKI-2 cell lines, whereas IDO was not expressed in any of the human kidney tumor cell lines tested.
C1 [Konya, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Kiraly, Jozsef] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Dobos, Nikoletta] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szegedi, Krisztian] University of Debrecen, Medical and Health Science Center, Department of UrologyDebrecen, Hungary.
   [Zsebik, Barbara] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Fodor, Petra] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Szabo, Zsuzsanna] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
   [Halmos, Gabor] Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszekDebrecen, Hungary.
RP Konya, G (reprint author), Debreceni Egyetem, Gyogyszeresztudomanyi Kar, Biofarmacia tanszek, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kovacs, P
   Horvath, O
AF Kovacs, Peter
   Horvath, Orsolya
TI The practice of complex oncopsychological care at the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The activities of the Oncopsychology Team, which operates as an independent working group in the Rehabilitation Department of the National Institute of Oncology, intertwine all areas of complex active and palliative medical care. According to research, approximately one in two oncology patients experience distress during their oncology treatments. The recurrence of psychological and psychiatric symptoms, as well as physical and physical symptoms, often of psychogenic origin, along with increasingly effective modern oncomedical treatments, can significantly impair patients' quality of life and impede cooperation with treatments. In addition to permanent anxiety, it is often necessary to take into account the development of acute stressful situations as well as crisis conditions, depressive symptoms, and intensifying character pathological functions during care. Current and manifest, and often the same, hidden but hidden psychological processes as a result of the crisis make it difficult for physician-patient communication and hinder collaboration. The toolkit of psychological interventions can be adapted to the multifaceted challenges of somatic healing, including oncology care. Psychodiagnostic tools, psychosocial assessment, targeted mental preparation for medical treatments and interventions, stress relief techniques, and various psychotherapeutic options are all available to provide the necessary psychosocial support during the healing process. Psychosocial interventions that promote spiritual integration during the healing and care process in multidisciplinary teamwork are the key to rehabilitation with a holistic approach.
C1 [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Horvath, Orsolya] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 34
EP 34
PG 1
ER

PT J
AU Kovacs, SzA
   Balajti, M
   Gyorffy, B
AF Kovacs, Szonja Anna
   Balajti, Mate
   Gyorffy, Balazs
TI Predictive role of MLH1 (MutL Homolog 1) in immunotherapy-treated malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: MLH1 (MutL Homolog 1) is involved in DNA repair and mutations are common in MSI-H / dMMR tumors. Low expression (lack) of MLH1 may be associated with resistance to chemotherapy / targeted therapies in some tumor types and susceptibility in others. However, its role in the response to immunotherapies has been even less studied. Our aim is to investigate the role of MLH1 in predicting the response to immunotherapy by processing gene expression and survival data from patients with malignant tumors. MATERIAL AND METHOD: Using the NCBI GEO and CRI iAtlas databases, we collected transcriptomic and clinical data from patients who underwent anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatment. After removal of duplicate results, samples from single cell RNA sequencing, cell line, mouse, immune cells, or non-tumor tissue were excluded. Crude expression data from RNA sequencing, NanoString platform, and RT-qPCR were quantitatively normalized. The gene-by-gene expression data for the samples were combined into a single data table with the R program environment. Significant gene expression differences were calculated by Mann-Whitney test. RESULTS: 3006 clinical samples from 154 studies were processed, 1806 samples from 1323 patients were included in the final database. Changes in MLH1 gene expression were examined in anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atesolizumab) and anti-CTLA-4 (ipilimumab, tremelimumab) treatments in esophageal cancer, melanoma, urothelial and head and neck tumors. Samples from esophageal and urothelial tumors also received chemotherapy. Out of a total of 722 melanoma patients, 177 responded to the immunotherapy treatments tested and 545 were resistant. MLH1 was lower in melanoma patients who did not respond to anti-PD1 (p = 1.25E-07, FC = 0.69) and anti-CTLA-4 (p = 0.002, FC = 0.82). no significant association was found in other tumor types. Furthermore, decreased expression of MSH3 (p = 4.13E-08, FC = 0.54) and MSH6 (p = 0.0001, FC = 0.68) was observed in pembrolizumab- and nivolumabab-resistant melanoma samples. DISCUSSION: Differential expression of MLH1 was observed in melanoma in 722 patients with resistance to pembrolizumab, nivolumab, ipilimumab, and tremelimumab. In addition to MLH1, the MSH3 and MSH6 genes may also play a role in the resistance of anti-PD-1 inhibitors.
C1 [Kovacs, Szonja Anna] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Balajti, Mate] MTA TTK, Lendulet Cancer Biomarker Research GroupBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Kovacs, SzA (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 34
EP 35
PG 1
ER

PT J
AU Kovari, RL
   Esperger, Zs
   Novak, Z
   Mersich, T
   Matrai, ZT
   Kovacs, P
AF Kovari, Reka Luca
   Esperger, Zsofia
   Novak, Zoltan
   Mersich, Tamas
   Matrai, Zoltan Tamas
   Kovacs, Peter
TI Pre-rehabilitation approach in oncology surgery 2 .: Possibilities of relaxation techniques
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB According to domestic and international research, one-third of cancer patients experience significant and nearly half have moderate levels of distress during their oncology treatments. Increased anxiety associated with surgery is an emotional state that significantly strains mental well-being, which is critical for both current quality of life and subsequent adherence due to increased suffering pressure. In addition to the use of anxiolytic pharmacotherapy, the level of distress in acute anxiety can also be reduced by stress-reducing psychological interventions. Various psychological therapies use a wide range of tools: skills-related stress reduction techniques, low-intensity psychological interventions, interventions to help with oncotherapy and psychoeducation, autogenic training, progressive muscle relaxation, Numerous studies have examined and demonstrated that psychological interventions applied in the preoperative phase have a beneficial effect on the postoperative period and recovery, respectively. Prior to surgery, learning and practicing relaxation techniques has been associated with lower postoperative distress levels and pain, resulting in increased adherence and improved compliance. Reducing psychological strain is also beneficial in terms of the doctor-patient relationship. The lecture will present the practices used at the National Institute of Oncology to support mental preparation for surgery, with special regard to customizable relaxation techniques.
C1 [Kovari, Reka Luca] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Esperger, Zsofia] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Matrai, Zoltan Tamas] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Kovari, RL (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Kullmann, T
   Kocsis, K
   Ambrus, A
   Szepesvary, Zs
AF Kullmann, Tamas
   Kocsis, Karoly
   Ambrus, Adel
   Szepesvary, Zsolt
TI One-center experience with second-line hormone therapy in castration-resistant metastatic prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The prognosis of castration-resistant metastatic prostate tumors has been significantly improved by several recently introduced treatments, including second-line hormone inhibitors. However, there are still a number of open questions regarding the optimal use of treatment. Among other things, is hydrocortisone a disadvantage in the substitution treatment of abiraterone? Or, is there a disadvantage to continuing second-line hormone therapy only until biological and non-radiological progression? MATERIAL AND METHOD: As part of the home self-assessment, we analyzed the results of our database of 62 patients who started treatment at our outpatient clinic by 31 December 2019. RESULTS: 36 patients received abiraterone with prednisone substitution, 11 patients received abiraterone with hydrocortisone substitution, and 15 patients received enzalutamide. The median survival of hydrocortisone-substituted patients was not worse than the median survival of prednisone-substituted patients. The median survival of patients treated until biological progression was not worse than the median survival of patients treated until clinical or radiological progression. Tumor marker kinetics in patients receiving abiraterone and enzalutamide were consistent with those expected from PFS values ​​in the registration studies. DISCUSSION: If our results are confirmed by higher case studies, prednisone could be replaced by hydrocortisone in the steroid substitution required in addition to abiraterone treatment, and second-line hormone therapy would be sufficient until biological progression. An alternative route of administration could provide a better spectrum of side effects and lower costs.
C1 [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kocsis, Karoly] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Ambrus, Adel] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Szepesvary, Zsolt] Petz Aladar Hospital, Department of UrologyGyor, Hungary.
RP Kullmann, T (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Lacsan, K
   Kovacs, P
AF Lacsan, Katalin
   Kovacs, Peter
TI Psychosocial support for relatives of patients in palliative care and end-stage patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Facing an oncological diagnosis has not only a drastic, psychologically critical period in a patient’s life, but also a significant impact on his or her relatives. The emotional involvement of family members varies, so the psychologically stressful events of the treatment process or the end of life may be different for them. Critical life situations elicit extreme emotional reactions from both the patient and the relative. There is a possibility of vicarial trauma from the beginning of the treatment. Ambivalent or conflicting relationships can make it difficult for relatives to help their loved one emotionally well enough to support them during difficult times. A particularly strenuous and psychologically stressful period of the disease is palliative care and the end of life. Maintaining and developing quality relationships with relatives, through the impact of social support, makes a significant contribution to maintaining a patient’s quality of life. However, this psychologically challenging process can also place an additional burden on the patient's family, with saturation inducing clinical psychiatric complaints. In addition to the literature review, the presentation presents the possibilities of relative-supportive psychological interventions to be applied together with the palliative working group of the National Institute of Oncology.
C1 [Lacsan, Katalin] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Rehabilitacios ReszlegBudapest, Hungary.
RP Lacsan, K (reprint author), Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 35
EP 35
PG 1
ER

PT J
AU Ladanyi, A
   Hegyi, B
   Balatoni, T
   Liszkay, G
   Dudas, J
AF Ladanyi, Andrea
   Hegyi, Barbara
   Balatoni, Timea
   Liszkay, Gabriella
   Dudas, Jozsef
TI Decreased HLA-I expression in progressive metastases in melanoma patients treated with ipilimumab
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Antibodies targeting immune checkpoints elicit a sustained clinical response in a subset of treated advanced cancer patients, but the majority of patients do not respond to treatment or develop resistance after an initial favorable response. The mechanisms responsible for the development of primary and acquired resistance are still poorly understood. Because HLA-I molecules play a key role in antigen recognition of cytotoxic T lymphocytes, our study aimed to investigate the longitudinal expression of HLA-I expression in tumor cells in patients with metastatic melanoma treated with ipilimumab by comparing metastases operated before and after treatment. MATERIAL AND METHOD: The percentage of HLA-I expression in melanoma cells was examined by immunohistochemistry using three antibodies specific for different HLA-I chains (HC10, HCA2, anti-beta2-microglobulin). There were 29 metastases in six patients (18 before treatment and 11 after treatment). RESULTS: Significantly lower HLA-I expression levels were detected in postoperative metastases compared to metastases operated prior to initiating ipilimumab treatment. Examining the differences on a patient-by-patient basis, a reduction was observed in the progressive metastases of unresponsive patients. Although the limited number of cases did not allow for statistical analysis by patient, it should be noted that the decrease in HLA-I expression was most pronounced in the two patients with the worst prognosis. The intensity of infiltration of CD8 + T lymphocytes and NK cells was also examined, but no consistent difference was found between pre- and post-treatment tumor samples. DISCUSSION: Although our results need to be confirmed in larger studies, our attention is drawn to the role of decreased HLA-I expression as a possible mechanism for resistance in immunoprotection inhibitors and other T cell-based immunotherapies.
C1 [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Hegyi, Barbara] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Dudas, Jozsef] Medical University Innsbruck, Department of OtorhinolaryngologyInnsbruck, Austria.
RP Ladanyi, A (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 35
EP 37
PG 1
ER

PT J
AU Lakosi, F
   Glavak, Cs
   Kisivan, K
   Farkas, A
   Laszlo, Z
AF Lakosi, Ferenc
   Glavak, Csaba
   Kisivan, Katalin
   Farkas, Andrea
   Laszlo, Zoltan
TI Linear accelerator-based prostate stereotaxic ablative radiotherapy for low- and medium-risk prostate tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To demonstrate clinical experience with linear accelerator-based prostate stereotaxic ablative radiotherapy (ProSABR) MATERIAL AND METHOD: Between October 2017 and January 2021, 28 low (8) and moderate-risk (20) patients received 5 × 7.25 Gy SABR treatment with VMAT technique with dose escalation for intraprostatic lesions if seen on mpMRI. ProSABR treatments were performed on a Varian TrueBeam (version 2.7, ± Advanced IGRT & Motion Package) linear accelerator with pre- and post-treatment CBCT with continuous gold marker monitoring during treatment. Patients' quality of life and urinary side effects were measured using the EPIC and IPSS questionnaire packages. Adverse reactions were recorded based on RTOG and CTCAE v4.0. RESULTS: After a median follow-up of twenty-four months (3–45), no biochemical relapse was detected, with a median PSA of 0.13 ng / ml (0.006–1.5) at the time of the last follow-up. PSA nadir has not yet been achieved in 70% of patients. One patient died of heart failure following limb amputation. Acute urinary adverse events were observed in all patients with the following distribution: LUTS (Lower Urinary Tract Symptoms) Gr. 1: 7/28, Gr. 2: 20/28; Retention requiring TURP Gr. 3: 1/28; haematuria, cystitis Gr. 2: 1/28. Acute GI side effects were observed in only 7 patients, including 7 Gr. 1 urgency and 2 Gr. 2 anal pain. Late side effects (10/28) were exclusively urinary without Gr. 3 side effects: LUTS: Gr. 2: 6, Gr. 1: 4; cystitis Gr. 2: 1 (post-TURP, transient); incontinence Gr. 1 2/28. The need for alpha-blockers decreased over time, with only 3 patients taking more medication than at baseline at the time of the last follow-up, including 2 in combination with an anticholinergic. Approaching baseline for IPSS semi-annual follow-up. Erectile dysfunction that responded well to medication occurred in two of 10 patients with intact sexual function prior to treatment. DISCUSSION: Two years of clinical experience with linear accelerator-based ProSABR is positive, with an excellent PSA response with a favorable side effect rate. Additional patient admission and follow-up are required to measure long-term clinical outcomes.
C1 [Lakosi, Ferenc] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Glavak, Csaba] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Kisivan, Katalin] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Farkas, Andrea] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Laszlo, Zoltan] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
RP Lakosi, F (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi Kozpont, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Lang, O
   Takacs, A
   Dorman, Gy
   Magyar, Cs
   Lajko, E
   Bertok, B
   Kohidai, L
AF Lang, Orsolya
   Takacs, Angela
   Dorman, Gyorgy
   Magyar, Csaba
   Lajko, Eszter
   Bertok, Bela
   Kohidai, Laszlo
TI Design and impedance-based screening of new apoptosis-inducing heterocyclic molecules
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Ductal adenocarcinoma of the pancreas (PDAC) is one of the most aggressive tumor types, with a five-year survival of less than 5%. One of the main reasons for poor mortality data is the lack of effective oncology treatment. Resistance of pancreatic carcinoma cells to apoptosis may contribute to the failure of chemotherapy. The aim of our research was to design and generate new heterocyclic molecules that induce apoptosis on PDAC cells. To this end, we investigated (i) the cytotoxic effect of new heterocyclic compounds on different tumor cell lines by HTS impedimetry; (ii) possible molecular targets for the new molecules; and (iii) their effect on induction of apoptosis. MATERIALS AND METHODS: The drug library was designed using the Target Oriented Library Platform, from which low molecular weight molecules with more favorable physicochemical properties and higher sp3 / sp2 atomic ratios were synthesized. Biological screening assays were performed on different tumor cell lines, PANC-1 (pancreatic adenocarcinoma), COLO205 (colon cancer), A2058 (melanoma), EBC-1 (lung cancer) cells. Cytotoxicity was detected by impedimetric measurement (xCELLigence SP; ACEA) and AlamarBlue assay. Induction of apoptosis was confirmed by flow cytometry measuring caspase 3 or 7 activity with BD FACSCalibur ™. RESULTS: A total of 231 relatively low molecular weight (<600 Daltons) heterocyclic molecules with conjugated functional groups were synthesized in high purity (> 95%). Of the compounds tested, 43 were found to be significantly cytotoxic on pancreatic tumor cells (PANC-1), which were also able to reduce the viability of other tumor cell lines (COLO205, A2058, and EBC-1). Database screening based on structural similarities showed that XIAP (X-linked apoptosis inhibitor) is a potential target for several components. Apoptosis studies have demonstrated that some of the new molecules are capable of inducing activation of caspase 3 and 7 in model cells. DISCUSSION: Although XIAP is not expressed in healthy ductal cells, recent clinical studies have shown that it is overexpressed and associated with poor prognosis in pancreatic carcinoma cells, so selective inhibition of XIAP may have a beneficial therapeutic effect.
C1 [Lang, Orsolya] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Takacs, Angela] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Dorman, Gyorgy] ComInnex Zrt.Budapest, Hungary.
   [Magyar, Csaba] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Lajko, Eszter] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
   [Bertok, Bela] ComInnex Zrt.Budapest, Hungary.
   [Kohidai, Laszlo] Semmelweis University, Department of Genetics, Cell and ImmunobiologyBudapest, Hungary.
RP Lang, O (reprint author), Semmelweis University, Department of Genetics, Cell and Immunobiology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 37
EP 37
PG 1
ER

PT J
AU Lengyel, D
   Novak, Z
AF Lengyel, Daniel
   Novak, Zoltan
TI Transvaginal ultrasound-guided biopsies in oncology patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: For the first time in Hungary, transvaginal ultrasound-guided thick-needle biopsy has become commonplace in our department. We would like to present our experiences and results with our presentation. MATERIAL AND METHOD: One of the useful and reliable options for histological elucidation of lesions of uncertain dignity is a thick needle biopsy. The procedure can be performed in a short time within the framework of outpatient care, without special preparation. In addition to the Department of Radiology at the National Institute of Oncology, ultrasound-guided transvaginal thick-needle biopsies have been performed at the Department of Gynecological Oncology since October 2018. RESULTS: Under ultrasound control, tumors were detected from a variety of localizations, such as the endometrium, rectovaginal spatium, Douglas peritonum, bladder, parailiac lymph node, or ovarian formula. During the presentation, we will present our experiences, visual and video materials, our achievements and their effects. Transvaginal core biopsy of patients referred to our department on suspicion of a gynecological tumor was approximately confirmed tumors of non-gynecological origin, so gastrointestinal, urological, soft tissue and dermatological tumors were also recognized. Without vaginal disinfection, an infectious complication was detected in three cases, and such a complication did not recur after the introduction of the disinfection. In collaboration with the Department of Pathology of our institute, biopsy specimens are automatically processed in a short time. Patients who already have an extremely painful vaginal examination, such as after irradiation, will also be sampled under anesthesia. DISCUSSION: Since the introduction of the procedure, the patient pathways of our patients have been shortened, especially in the case of patients with disseminated ovarian tumors, it is possible to start neoadjuvant chemotherapy in a significantly shorter time. Among our patients, the procedure is well tolerated, with only low pain.
C1 [Lengyel, Daniel] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
RP Lengyel, D (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 37
EP 38
PG 1
ER

PT J
AU Lengyel, M
   Uray, IP
AF Lengyel, Mate
   Uray, Ivan Peter
TI Effect of soluble rexinoid-regulated factor ZG16B on breast epithelial cell proliferation and migration
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Pharmacological prevention of the development of breast tumors is possible, but it depends on a targeted chemopreventive effect. Most of the estrogen receptor-independent gene regulatory functions of rexinoids are based on induced expression, and in our present work we have searched for targets whose suppression may be part of an antiproliferative and potentially chemopreventive mechanism. RNA sequencing of immortalized normal mammary epithelial cells confirmed suppression of the ZG16B gene by bexarotene, which can be enhanced by low-dose synergistic drug combinations. The ZG16B gene is less expressed in healthy breast tissue than in primary and metastatic breast tumors. We hypothesize that the ZG16B protein may play a role in regulating mammalian cell proliferation and migration, as well as promoting malignant transformation of mammalian cells. MATERIAL AND METHOD: To examine the function of the protein, the ZG16B gene was cloned into plasmid pEGFP-C3 and expressed in HEK293 cells. Expression of the ZG16B gene was confirmed by RT-qPCR assay, Western blot, and mass spectrometry. Premalignant and malignant, ER-positive and -negative cells (‘normal’ HMEC-hTert, MCF7, T47D, MDA-MB-231, HCC38, HCC1143) cultured in vitro with the supernatant containing ZG16B protein were treated. Cell proliferation was examined by microscopic analysis and migration by wound healing assay. Activation of signaling pathways responsible for increased proliferation and migration (MAPK / Erk1 / 2, PI3K / Akt, Src) was examined by Western blot after ZG16B treatment. The transforming effect of ZG16B was examined using a soft agar assay. RESULTS: The ZG16B protein increased the migration capacity of all cell lines we examined, but only the proliferation of HMEC-hTert, MCF7, T47D cell lines. After ZG16B treatment, activation of Akt and Src kinases occurred regardless of receptor status and transformation, but phosphorylation of Erk1 / 2 proteins was only detectable in HMEC-hTert cells. ZG16B also significantly increased the number of spheroids T47D and MDA-MB-231. DISCUSSION: The activation of the signaling pathways we examined is consistent with the results obtained with the proliferation and migration assay. Biological processes influenced by the ZG16B protein favor the development and progression of breast tumors, making the protein a potential target for preventive and antitumor therapies. Given that protein expression can be determined from serum samples, a biomarker can be raised to predict the invasiveness of early tumors.
C1 [Lengyel, Mate] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Uray, Ivan Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Lengyel, M (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Levai, T
   Krajinovic, E
   Lazar, Gy
   Latos, M
AF Levai, Tunde
   Krajinovic, Erna
   Lazar, Gyorgy
   Latos, Melinda
TI Hungarian adaptation of the emotional graph among patients who have undergone surgery - the results we have achieved so far in the group of patients with cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The aim of our research is to assess the change in emotional state between the diagnosis of the disease and the surgical procedure in chronic patients, and to explore the relationships between the emotions experienced during the disease process and the mental state after the operation. MATERIAL AND METHOD: The set goal is achieved by using a qualitative graphic technique (Thygesen et al., 2011), which has not been used in Hungary so far, which allows the patient to experience significant events during the entire disease process, the associated affective condition and its assessment of the change using a graph drawn by the patient. The adaptation of the emotional graph to the Hungarian sample is the basis for the realization of our goal. To date, our study sample of 93 patients has undergone surgery for chronic disease, of whom 63 have undergone cancer and have a mean age of 55.05 years (standard deviation: 9.76). The test is taken 1–5 days after the operation. takes place within days, during which, in addition to creating an emotional graph, we assess disease perception, trait and condition anxiety, depression, quality of life, and perceived stress. RESULTS: Based on the charge of the emotion shown in the graph, the sample of cancer patients can be divided into two groups: the group of 42 people with negative emotions and the group of 21 people with positive emotions. In the group of those with a negative charge emotion, the intensity of the emotion depicted during the plot of the graph shows a significant, positive, moderate correlation with the levels of postoperative depression (p = 0.009), trait anxiety (p = 0.020) and disease perception (p = 0.004). DISCUSSION: Based on our results so far, the procedure we have adapted proves to be an effective research and intervention tool in several respects: the use of visual technique can reveal connections between the valence and intensity of emotions experienced during the disease process and postoperative psychological status. Using the method, it is possible for patients to structure outstanding experiences and events during their illness, to record their emotional reactions, and to evaluate their intensity and development, which is essential for successful psychological intervention, both preoperatively and postoperatively.
C1 [Levai, Tunde] University of Szeged, Department of SurgerySzeged, Hungary.
   [Krajinovic, Erna] University of Szeged, Department of SurgerySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Latos, Melinda] University of Szeged, Department of SurgerySzeged, Hungary.
RP Levai, T (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 38
EP 38
PG 1
ER

PT J
AU Levay, B
   Revesz, M
   Oberna, F
AF Levay, Bernadett
   Revesz, Monika
   Oberna, Ferenc
TI TOETVA - scar-free thyroid surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB INTRODUCTION: Thyroid surgery produces a visible scar on the neck that is difficult to cover and can affect the quality of life of patients in the long run. Over the past two decades, numerous minimally invasive surgical penetrations have been developed that have reduced the scars of thyroid surgeries in size or placed them in a less visible region. The variety of methods indicates that none of the procedures were able to adequately deliver the expected clinical and cosmetic results. Surgery through natural body openings results in a healing without a visible scar. Of the surgeries developed from oral penetration, oral thyroidectomy (TOETVA) proved to be the safest and most effective surgical procedure. It is indicated for smaller cystic thyroid lobes, nodular lobes, smaller papillary carcinoma, and parathyroid adenoma. MATERIAL AND METHOD: In the Multidisciplinary Center for Head and Neck Tumors of the National Institute of Oncology, June 12, 2018 - 2020. Between 02 and 18, we performed thyroid surgery by oral endoscopic technique in 7 patients. Histological examination revealed papillary carcinoma in 5 cases, follicular adenoma and benign colloidal nodule in 1 case. The 10–30 mm formulas were removed by isthmectomy in 1 case and lobectomy in 6 cases. RESULTS: During surgery, we were forced to convert due to bleeding in 2 cases. No drain was inserted at the end of the 5 endoscopic surgeries, and our patients were discharged on the 1st postoperative day. The two converted surgical patients were emitted on postoperative day 2 after removal of the cervical drain. Removal of tumors based on histology complied with oncological principles, n. no recurrent injury or other complication was observed. The mean surgical time was 127 minutes. DISCUSSION: TOETVA is the only surgical method of thyroid removal that does not involve an external scar and does not result in keloid formation. The learning phase is given in 15–20 surgeries, after which the surgical time is reduced. However, its safe and effective performance requires a large number of specialists who have performed open thyroid surgery and are also experienced in endoscopic surgery.
C1 [Levay, Bernadett] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Revesz, Monika] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck OncologyBudapest, Hungary.
RP Levay, B (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Liszkay, G
   Matrai, Z
   Czirbesz, K
   Jani, N
   Bencze, E
   Kenessey, I
AF Liszkay, Gabriella
   Matrai, Zoltan
   Czirbesz, Kata
   Jani, Nora
   Bencze, Eszter
   Kenessey, Istvan
TI Predictive and prognostic value of primary tumor BRAF and NRAS mutations in relation to sentinel lymph node status; Retrospective study of 159 patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Sentinel lymph node (SLN) status is one of the most important prognostic factors in melanoma. In our study, we analyze the value of BRAF and NRAS mutations in the primary tumor in addition to known prognostic factors in relation to sentinel lymph node status and survival. MATERIALS AND METHODS: In our retrospective study, 159 patients were age, sex, primary tumor localization, Breslow, exulceration, histological type, number of mitosis observed in the tumor, lymphovascular and perineural invasion, and tumor infiltrating lymphocytes, presence of lymphocytes NRAS mutation was compared with sentinel lymph node status as well as different survival parameters. RESULTS: Among the clinicopathological factors examined, tumor thickness alone increased the risk of SLN positivity by multivariate analysis (p = 0.0025). BRAF and NRAS mutations in the primary tumor did not prove to be predictors of SLN status. While progression-free and distant metastasis-free survival of the NRAS mutant subgroup was the most unfavorable compared with BRAF-positive and dual wild-type tumors. In NRAS-mutant melanomas, sentinel lymph node positivity was less frequent than in the other two groups. In addition to sentinel lymph node status, the NRAS mutation in the primary tumor was shown to be an independent prognostic factor for progression. DISCUSSION: Based on our analysis, we conclude that the NRAS mutant subgroup, despite negative SLN status, requires closer observation for early detection of higher rates of progression.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Matrai, Zoltan] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Jani, Nora] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bencze, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kenessey, Istvan] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Maraz, AG
   Kovacs, P
AF Maraz, Andras Gabor
   Kovacs, Peter
TI Relationships between anxiety and depression and types of oncology treatments
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The aim of the research is to get a more accurate picture of the psychological condition of Hungarian oncology patients, their psychosocial characteristics, and the mental and physical aspects of living with cancer. MATERIAL AND METHOD: The study processes the data of oncopsychological screening packages used at the National Institute of Oncology. In the retrospective study, psychological questionnaire data from 893 cancer patients were pooled (559 women, 334 men). The study included the Beck Depression Questionnaire (BDI), the Spielberger Condition and Trait Anxiety Questionnaire (STAI), and the Caldwell Social Support Questionnaire. The obtained results were compared in connection with the typical oncomedic treatments of active oncology care (chemotherapy, adjuvant therapy, radiotherapy, surgical interventions). RESULTS: The research showed a relationship between social support and patients' anxiety (r = −0.241 p <0.00) and depression scores (r = −0.209 p <0.001). The correlation is negative: the more extensive the patient’s network of contacts, the less they are characterized by anxiety and clinical-level depression. A further result of the research was that patients treated with different oncotherapy had anxiety (F (3,882) = 7.82, p <0.001); There is a significant difference between (F (3,879) = 9.13, p <0.001) and depression values ​​(F (3,886) = 40.87, p <0.001). The group with the highest anxiety score was the chemotherapy subsample (STAI I mean: 44.96 standard deviation: 12.70; STAI II mean: 45.57 standard deviation: 10.58), while the surgical group had the highest depression rates (mean: 12.92, standard deviation: 9.26). DISCUSSION: Based on our research, social support is a protective factor as it has a moderating effect on the onset and extent of anxiety and depression. Different types of treatment face specific side effects and challenges for patients. Patients show high levels of anxiety during chemotherapy, and surgery can contribute to the development or worsening of patients' depression. Depression and anxiety scores in patients treated with radiotherapy are also higher than the mean in the sine morbo population. Taking these factors into account during oncomedic care can help improve the physical and mental health of patients.
C1 [Maraz, Andras Gabor] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
RP Maraz, AG (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 39
EP 39
PG 1
ER

PT J
AU Marko, L
   Sikorszki, L
   Horvath, Zs
   Vajda, K
   Bartok, �
   Kocsis, J
   Gabor, G
AF Marko, Laszlo
   Sikorszki, Laszlo
   Horvath, Zsolt
   Vajda, Kornel
   Bartok, Adam
   Kocsis, Judit
   Gabor, Gabriella
TI Rectum tumors. Preoperative oncology treatment, surgery, pathological complete remission
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The radiotherapy machine park in Hungary at the 13 Oncology Centers has been renewed. A new drug is also used in the preoperative radiochemical treatments of rectal tumors. The treatment plan for all patients with rectal cancer is determined by Onkoteam in our hospital. The number of laparoscopic surgeries increased significantly. MATERIAL AND METHOD: In the last four years, we performed 616 colorectal tumor surgeries, of which 268 were rectal tumors. In the postoperative oncoteam, pathological complete remission of the rectum was observed in 23 patients (8.6%). This ratio has increased compared to previous years. RESULTS: We would consider it worth reviewing this patient material nationwide. We believe that due to individualized, better, more effective preoperative radiochemotherapy, the trend may be similar in other Hungarian surgical / oncology departments. DISCUSSION: The next congress of the Surgical-Oncology Section of the Hungarian Society of Surgeons could discuss the possibility of minor on-radical rectal surgeries or close oncology follow-up in the presence of preoperative complete staging examinations in cCR cases (Angelita Habr-Gama).
C1 [Marko, Laszlo] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Vajda, Kornel] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Bartok, Adam] Bacs-Kiskun County Hospital, Department of SurgeryKecskemet, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Gabor, Gabriella] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Marko, L (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Marosi, E
   Polgar, Cs
   Takacsi-Nagy, Z
   Oberna, F
   Zambo, O
   Ungor, B
   Kenessey, I
   Weber, A
   Kis-Gyorgy, R
   Bertokne Tamas, R
   Arvane Egri, Cs
   Nagy, K
   Nagy, P
   Muller, C
   Surjan, O
   Kasler, M
AF Marosi, Edit
   Polgar, Csaba
   Takacsi-Nagy, Zoltan
   Oberna, Ferenc
   Zambo, Orsolya
   Ungor, Beata
   Kenessey, Istvan
   Weber, Andras
   Kis-Gyorgy, Rita
   Bertokne Tamas, Renata
   Arvane Egri, Csilla
   Nagy, Katalin
   Nagy, Peter
   Muller, Cecilia
   Surjan, Orsolya
   Kasler, Miklos
TI iPAAC WP5 - Pilot Program for Early Detection of Oral Tumors in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB INTRODUCTION AND OBJECTIVE: The iPAAC JA (Innovative Partnership on Action Against Cancer) is a joint action co-financed by the European Union (2018-2021) with the primary objective of facilitating and harmonizing the development of innovative cancer control programs. Hungary is represented in the project by the National Institute of Oncology (OOI). The OOI is actively involved in the work packages WP5 (Prevention) and WP10 (Management of Integrated Comprehensive Oncology Care). The WP5 work package, in which the OOI co-leader focuses, inter alia, on “Developing Strategies for Early Detection of Cancer”. To this end, a pilot program for the early detection of oral tumors will be implemented in Hungary in cooperation with the National Center for Public Health (NNK), the University of Szeged (SZTE) and the OOI. Tumors of the lips, mouth and throat are a significant burden among the Hungarian population, according to the National Cancer Registry, this is the 9th most common type of malignancy in Hungary. Based on GLOBOCAN data, focusing on oral tumors (BNO C00-06), Hungary ranks 8th in the world and 1st in Europe in terms of age-standardized, estimated incidence and mortality for both sexes. The NNK survey confirmed differences within the country in the incidence of malignancies of the lips, mouth and pharynx by gender: the most unfavorable disease rates were measured in Borsod-Abauj-Zemplen county for men and in Heves county for women. The aim of the pilot program is to screen 5,000 people living in catching-up small settlements on screening buses, to develop related patient pathways and to educate the public about the prevention of oral malignancies and the importance of early detection. MATERIAL AND METHOD: The institutions participating in the pilot program jointly defined the methodology of the program (eg development of protocols, test sheets, patient pathways). The screenings are carried out with the involvement of the dental hygiene students of the University of Szeged and the specialists who have already graduated. The infrastructure will be provided by filter buses operated by NNK, which will stop in 62 catching-up small settlements in 15 counties between 21 June and 7 October 2021. RESULTS: The expected result of the research is an oral screening of 5,000 people. Referral and care of persons with lesions to specialists, and processing of statistical data obtained during screening with the help of the National Cancer Registry.
C1 [Marosi, Edit] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of OncologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of OncologyBudapest, Hungary.
   [Zambo, Orsolya] National Institute of OncologyBudapest, Hungary.
   [Ungor, Beata] National Institute of OncologyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of OncologyBudapest, Hungary.
   [Weber, Andras] National Institute of OncologyBudapest, Hungary.
   [Kis-Gyorgy, Rita] University of SzegedSzeged, Hungary.
   [Bertokne Tamas, Renata] Nemzeti Nepegeszsegugyi KozpontBudapest, Hungary.
   [Arvane Egri, Csilla] Nemzeti Nepegeszsegugyi KozpontBudapest, Hungary.
   [Nagy, Katalin] University of SzegedSzeged, Hungary.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
   [Muller, Cecilia] Nemzeti Nepegeszsegugyi KozpontBudapest, Hungary.
   [Surjan, Orsolya] Nemzeti Nepegeszsegugyi KozpontBudapest, Hungary.
   [Kasler, Miklos] Emberi Eroforrasok MiniszteriumaBudapest, Hungary.
RP Marosi, E (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Martin, T
   Szonyi, M
   Kuronya, Zs
   Biro, K
AF Martin, Tamas
   Szonyi, Marta
   Kuronya, Zsofia
   Biro, Krisztina
TI Novelties and practical experiences in the prevention of chemotherapy-induced nausea and vomiting
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Newer drugs have been included in the protocol for the prevention of chemotherapy-induced nausea and vomiting (CINV), and these combinations have significantly reduced the incidence of this feared side effect. However, both delayed and breakthrough CINV pose a serious challenge in everyday practice and we need to introduce new treatment strategies. Recent randomized trials indicate that olanzapine, an atypical antipsychotic, also plays a role in the prevention and treatment of CINV induced by chemotherapy with high and moderate emetogenic potential. The combination of olanzapine with routine 5-HT antagonists (ondansetron, granisetron) and low-dose steroids (dexamethasone) significantly improved the prevention of CINV. For breakthrough vomiting, olanzapine alone was more effective than all other standard antiemetic agents. In our experience, olanzapine at a daily dose of 5 mg significantly reduced the incidence of nausea and vomiting in patients receiving high emetogenic chemotherapy with standard ondansetron and dexamethasone.
C1 [Martin, Tamas] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Szonyi, Marta] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Biro, Krisztina] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Martin, T (reprint author), Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 40
EP 40
PG 1
ER

PT J
AU Matics, Zs
   Biro, A
   Erdelyi, T
   Tamasi, L
   Muller, V
AF Matics, Zsombor
   Biro, Andrea
   Erdelyi, Tamas
   Tamasi, Lilla
   Muller, Veronika
TI Small cell lung cancer (SCLC): therapeutic outcome - based on data from the Department of Pulmonology, Semmelweis University
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Treatment options for lung cancer have a poor prognosis and high mortality, including small cell lung cancer (SCLC), and its outcome is one of the worst types of lung cancer. Our aim was to investigate the characteristics, treatment, and outcome of patients with SCLC treated at the Department of Pulmonology, Semmelweis University. MATERIAL AND METHOD: In our prospective data analysis, 01.12.2018–2020. Data from prevalent cases presented at clinical oncopeam in the period up to 31 May were processed (N = 1012). SCLC (12%) was confirmed in 121 cases during the study period. In patients, staging, therapy, and response to therapy were recorded until March 31, 2021. RESULTS: The mean age of the patients was 66 ± 8 years (male: female ratio 57:64), and the majority (83.5%) were diagnosed in good general condition (PS: 0−1) in terms of Performance Status (PS). Concomitant COPD was detected in 51% of cases and 95% of patients were smokers or ex-smokers. SCLC was diagnosed as advanced (IIIB-IV) (80%). The distribution of metastases among those with metastasis during oncoteam presentation showed predominant localization in the pleural and hepatic (22% –22%) and adrenal and cerebral (19% –19%). In terms of therapy, 88% received first-line treatment, 12% of patients no longer allowed PS first-line treatment, or the patient refused treatment. First-line therapy consisted of 95% platinum-etoposide combination, with a therapeutic effect in 39% of cases (CR / PR / SD). The median time to initiation of second-line therapy was nearly 9 months. 41% of patients were eligible for second-line treatment. Mortality was high during the study period, with a 6-month survival of 51% and a one-year survival of 23%. DISCUSSION: SCLC is usually discovered in Hungary at an advanced stage. 88% of patients are eligible for first-line treatment, with a therapeutic response rate of 39%. Mortality is high during the 10-17 month follow-up period, so new and more effective treatment protocols are needed.
C1 [Matics, Zsombor] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Biro, Andrea] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Erdelyi, Tamas] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Tamasi, Lilla] Semmelweis University, Department of PulmonologyBudapest, Hungary.
   [Muller, Veronika] Semmelweis University, Department of PulmonologyBudapest, Hungary.
RP Matics, Zs (reprint author), Semmelweis University, Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 40
EP 41
PG 1
ER

PT J
AU Megyesfalvi, Zs
   Barany, N
   Lantos, A
   Valko, Zs
   Pipek, O
   Lang, Ch
   Schwendenwein, A
   Bugyik, E
   Paku, S
   Ferencz, B
   Fillinger, J
   Lohinai, Z
   Schlegl, E
   Nagy, E
   Moldvay, J
   Galffy, G
   Luka, B
   Helmut, P
   Izidor, K
   Mile, K
   Rezeli, M
   Marko-Varga, Gy
   Bogos, K
   Renyi-Vamos, F
   Schelch, K
   Laszlo, V
   Dome, B
AF Megyesfalvi, Zsolt
   Barany, Nandor
   Lantos, Andras
   Valko, Zsuzsanna
   Pipek, Orsolya
   Lang, Christian
   Schwendenwein, Anna
   Bugyik, Edina
   Paku, Sandor
   Ferencz, Bence
   Fillinger, Janos
   Lohinai, Zoltan
   Schlegl, Erzsebet
   Nagy, Erzsebet
   Moldvay, Judit
   Galffy, Gabriella
   Luka, Brcic
   Helmut, Popper
   Izidor, Kern
   Mile, Kovacevic
   Rezeli, Melinda
   Marko-Varga, Gyorgy
   Bogos, Krisztina
   Renyi-Vamos, Ferenc
   Schelch, Karin
   Laszlo, Viktoria
   Dome, Balazs
TI Prognostic and clinicopathological significance of molecular subtypes of small cell lung cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Clinically, small cell lung cancer (SCLC) is still treated as a homogeneous tumor type. However, recent data suggest that SCLC can be further subdivided depending on neuroendocrine differentiation and the expression profile of four genes associated with it (ASCL1, NEUROD1, POU2F3, YAP1). Exploring and understanding these subgroups may provide an opportunity to develop new therapeutic agents and treatment strategies. The aim of our study was to investigate the clinical significance of molecular subtypes in human clinical specimens. MATERIAL AND METHOD: To investigate the clinical relevance and prognostic value of the molecular subgroups, a total of 388 surgically treated SCLC patients and histological specimens were analyzed. Patients included were grouped by study and validation cohort depending on the type of histological specimen available (FFPE vs. TMA). Histological specimens were analyzed by immunohistochemistry to determine the expression of subtype-specific proteins. RESULTS: We confirmed the presence of the SCLC-A, SCLC-N and SCLC-P subgroups in human surgical specimens, as well as the presence of a fourth - SCLC-AN - and a fifth - triple-negative - subgroup. It should be noted that the presence of a stand-alone YAP1 subtype could not be demonstrated. Regarding the prognostic relevance of subtype-specific proteins, high ASCL1 expression is poor, while high POU2F3 expression is associated with good prognosis. Based on the multivariate Cox regression model, high ASCL1 expression was found to be an independent negative prognostic factor (p = 0.03). DISCUSSION: In the present study, we were the first in the international literature to investigate the clinical relevance of SCLC molecular subtypes in a large number of surgical patients. Our results demonstrate that SCLC, as a clinicopathological entity, can be classified into different subtypes depending on the expression profile of ASCL1, NEUROD1, and POU2F3, and that some of these subtype-specific markers have different prognostic values. Overall, our study may provide an opportunity to develop new SCLC biomarkers and treatment strategies by molecular subgroups.
C1 [Megyesfalvi, Zsolt] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
   [Barany, Nandor] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lantos, Andras] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Valko, Zsuzsanna] Medical University of ViennaVienna, Austria.
   [Pipek, Orsolya] Eotvos Lorand UniversityBudapest, Hungary.
   [Lang, Christian] Medical University of ViennaVienna, Austria.
   [Schwendenwein, Anna] Medical University of ViennaVienna, Austria.
   [Bugyik, Edina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Paku, Sandor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Ferencz, Bence] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Lohinai, Zoltan] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Schlegl, Erzsebet] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Nagy, Erzsebet] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Galffy, Gabriella] County Hospital of PulmonologyTorokbalint, Hungary.
   [Luka, Brcic] Medical University of GrazGraz, Austria.
   [Helmut, Popper] Medical University of GrazGraz, Austria.
   [Izidor, Kern] University Clinic of Respiratory and Allergic DiseasesGolnik, Slovenia.
   [Mile, Kovacevic] University Clinic of Respiratory and Allergic DiseasesGolnik, Slovenia.
   [Rezeli, Melinda] Lund UniversityLund, Sweden.
   [Marko-Varga, Gyorgy] Lund UniversityLund, Sweden.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
   [Schelch, Karin] Medical University of ViennaVienna, Austria.
   [Laszlo, Viktoria] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet - Semmelweis EgyetemBudapest, Hungary.
RP Megyesfalvi, Zs (reprint author), Orszagos Onkologiai Intezet - Semmelweis Egyetem, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Menyhart, O
   Fekete, JT
   Gyorffy, B
AF Menyhart, Otilia
   Fekete, Janos Tibor
   Gyorffy, Balazs
TI Biomarkers of therapeutic resistance in glioblastoma multiforme
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Despite knowledge of the molecular background of glioblastoma multiforme, a predictive biomarker with little and limited clinical relevance is currently available in medicine. Our goal was therefore to explore a gene expression pattern that can be related to the outcome of treatment. In patients responding to temozolomide- and nitrosourea-based and refractory to therapy, the gene expression pattern separating the two groups was determined by examining pre-treatment tumor samples. MATERIAL AND METHOD: Gene expression data were collected from several independent data sets. Patients who were alive 16 months after surgery were considered responders to therapy, otherwise they were classified as resistant. For each gene, we compared the expression level as a function of therapeutic response using the Mann-Whitney U-test. AUC values ​​were calculated using the “roc” package. RESULTS: Expression data for a total of 10103 genes from 454 patients are included in the database we collected. In combination with temozolomide nitrosourea therapy, 68% of patients responded to therapy with the highest predictive value of FCGR2B gene overexpression (AUC = 0.72, p <0.001). Increased expression of CSTA and MRPS17 genes was associated with resistance to multiple therapeutic treatments. In contrast, patients with high DLL3 expression responded well to any temozolomide-containing therapeutic protocol. In a cohort of young patients with generally better prospects, high expression of PLSCR1, MX1, and MDM2 was associated with poor prognosis. DISCUSSION: The biomarkers we have identified provide a basis for further preclinical studies, may be useful in predicting therapeutic response, and may provide a guide for the therapeutic grouping of patients diagnosed with glioblastoma.
C1 [Menyhart, Otilia] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Fekete, Janos Tibor] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Menyhart, O (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 41
EP 41
PG 1
ER

PT J
AU Mersich, T
   Sztipits, T
   Wettstein, D
AF Mersich, Tamas
   Sztipits, Tamas
   Wettstein, Daniel
TI CovidSURG Week study results, surgical care and pandemic
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The purpose of the CovidSURG Week prospective cross-sectional study was to explore the morbidity and mortality data of the Covid-19 pandemic for surgery. MATERIAL AND METHOD: At the time of vaccination introduction, the study collected data on all patients undergoing surgery for 1 week in terms of demographics, Covid status, and surgical morbidity and mortality in all surgical professions. The study involved 143,000 patients from 114 countries, including 8 departments from 6 institutions in Hungary. RESULTS: Analysis of the results suggests that patients awaiting elective surgery should receive Covid-19 vaccinations in the majority of the population to reduce postoperative viral deaths. Between 0.6% and 1.6% of patients enrolled in the study develop Covid-19 infection after elective surgery. Patients who develop a Covid-19 infection have a 4 to 8-fold increased risk of dying within 30 days of surgery. For example, the mortality rate for patients 70 years of age or older who have had surgery for a tumor is usually 2.8%, and it increases to 18.6% for Covid-19 infection. The risk of surgical death can be significantly reduced or restored to baseline levels by inoculating patients preoperatively. DISCUSSION: Based on the above results, the following recommendations can be made: 1. It is recommended that the patient be vaccinated prior to elective surgery to avoid complications from Covid. This is also recommended if the patient is undergoing PCR screening. 2. In the case of a patient undergoing surgery for a tumor: 2a. It is advisable to encourage the patient to take the vaccine during neoadjuvant therapy. 2b. In the case of primary surgical care, the relative urgency of the surgical treatment and the expected benefit of vaccination should be considered. Given that the preparation for surgery is rarely shorter than 2-4 weeks, it is recommended that a vaccine be given. After surgery, the vaccination line can be completed. 3. In the case of emergency surgery, there is, of course, no way to postpone surgery on the basis of vaccination.
C1 [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Sztipits, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
   [Wettstein, Daniel] Orszagos Onkologiai Intezet, Hasi Sebeszeti OsztalyBudapest, Hungary.
RP Mersich, T (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 41
EP 42
PG 1
ER

PT J
AU Mezei, T
   Meszaros, D
   Pollner, P
   Bago, AGy
   Fedorcsak, I
   Banczerowski, P
   Sipos, L
AF Mezei, Tamas
   Meszaros, David
   Pollner, Peter
   Bago, Attila Gyorgy
   Fedorcsak, Imre
   Banczerowski, Peter
   Sipos, Laszlo
TI Effect of valproate therapy on survival in patients with supratentorial glioma - a supportive option for radiochemotherapy?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The treatment of malignant gliomas remains an unresolved oncological problem. The onset of epilepsy is a positive prognostic factor due to early diagnosis and the potential antitumor effects of antiepileptic drugs. The survival-prolonging effect of valproate has been the subject of basic and clinical research for more than 20 years. The mechanism of action of cytotoxic, proapoptotic, antiangiogenic and histone deacetylase inhibitors is now known. The aim of our study was to investigate the survival-prolonging effect of valproate. MATERIAL AND METHOD: A single-center, retrospective clinical study was performed. The study included 80 adult patients who underwent surgery for supratentorial glioma between 2000 and January 2018, took antiepileptic drugs for seizure activity, and received at least radiotherapy during the course of their disease. At the same time, a drug-free control group was established. Descriptive-statistical, Kaplan-Meier and log-rank analysis were performed. RESULTS: There was a significant difference in progression-free (p = 0.031) and overall (p = 0.027) survival between the different antiepileptic groups, which became even more pronounced when comparing the survival of patients taking valproate and other antiepileptics (p = 0.006). , p = 0.015). DISCUSSION: In our study, valproate resulted in a prolongation of progression-free and overall survival in our patients. Based on the data in the literature and our research, we consider the first-line use of valproate in patients with epilepsy and glioma receiving oncotherapy to be considered.
C1 [Mezei, Tamas] National Institute of NeurosurgeryBudapest, Hungary.
   [Meszaros, David] Semmelweis Egyetem, Idegsebeszeti TanszekBudapest, Hungary.
   [Pollner, Peter] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Bago, Attila Gyorgy] National Institute of NeurosurgeryBudapest, Hungary.
   [Fedorcsak, Imre] National Institute of NeurosurgeryBudapest, Hungary.
   [Banczerowski, Peter] National Institute of NeurosurgeryBudapest, Hungary.
   [Sipos, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
RP Mezei, T (reprint author), National Institute of Neurosurgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Mezei, T
   Pollner, P
   Nagy, Z
   Czigleczki, G
   Banczerowski, P
   Horvath, A
AF Mezei, Tamas
   Pollner, Peter
   Nagy, Zoltan
   Czigleczki, Gabor
   Banczerowski, Peter
   Horvath, Anna
TI Development of a prediction system for patients with spinal metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our medical work, we strive to implement personalized medicine in which risk assessment systems can help us. Systems for predicting prognosis and recommending a therapeutic option in patients with spinal metastases have long been known in the literature, but still do not have sufficient predictive accuracy. The aim of our research was to examine the known systems and to develop a reliable system by eliminating their inaccuracies. MATERIALS AND METHODS: A single-center, retrospective clinical trial was performed on 454 patients who underwent surgery for spinal metastases. To select the prognostic factors, we performed classical survival studies (Kaplan-Meier analysis, log-rank test, Cox analysis), performed network science-based correlation studies in the design of the system, and then Uno's C-statistics and D-statistics for internal validation of our system. and the IDI (integrated discrimination index) calculation was used. RESULTS: As a result of network analysis and multivariate Cox analysis, we found 5 independent prognostic factors suitable for integration into our system, namely, subcategories of “primary tumor type,” “age,” “presence of intestinal metastases,” and “serum protein level”. The new system showed significantly better predictive power based on the results of D-statistics, with an average AUC of 0.706. DISCUSSION: The ability to estimate survival in cancer patients is essential when planning therapy. Our system is designed for patients with spinal metastases, however, our methodology may provide a good basis for developing risk calculators for other patient populations. Our prediction system can provide reliable support for clinicians in selecting patients for neurosurgical care.
C1 [Mezei, Tamas] National Institute of NeurosurgeryBudapest, Hungary.
   [Pollner, Peter] ELTE, Biologiai Fizika TanszekBudapest, Hungary.
   [Nagy, Zoltan] National Institute of NeurosurgeryBudapest, Hungary.
   [Czigleczki, Gabor] National Institute of NeurosurgeryBudapest, Hungary.
   [Banczerowski, Peter] National Institute of NeurosurgeryBudapest, Hungary.
   [Horvath, Anna] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
RP Mezei, T (reprint author), National Institute of Neurosurgery, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 42
EP 42
PG 1
ER

PT J
AU Moldvai, D
   Krencz, I
   Vetlenyi, E
   Danko, T
   Petovari, G
   Sztankovics, D
   Raffay, R
   Szaloki, G
   Meszaros, K
   Sebestyen, E
   Papay, J
   Vegso, Gy
   Sebestyen, A
AF Moldvai, Dorottya
   Krencz, Ildiko
   Vetlenyi, Eniko
   Danko, Titanilla
   Petovari, Gabor
   Sztankovics, Daniel
   Raffay, Regina
   Szaloki, Gabor
   Meszaros, Katalin
   Sebestyen, Endre
   Papay, Judit
   Vegso, Gyula
   Sebestyen, Anna
TI Investigation of the therapeutic sensitivity of clear cell renal tumors in model systems
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The treatment of clear cell renal tumors (ccRCC) today is primarily a surgical therapy, and if discovered at the right time, it can even be curative. However, the treatment of recurrent tumors in advanced cases or after surgery is still a major challenge today. This is due to heterogeneous primary and rapidly developing secondary resistance. The latter may also be due to changes in activity or metabolic adaptation mechanisms in the signaling network. In our previous work, we also characterized the differences in in situ mTOR activity and metabolic enzyme expression of ccRCCs in immunohistochemical studies. Tissue heterogeneity has highlighted that differences in therapeutic responses may be due to individual metabolic changes. In our work, we aim to model these in vitro and to elucidate the resistance mechanisms associated with metabolic abnormalities. MATERIALS AND METHODS: In our in vitro studies, two renal carcinoma cell lines (A498, 786-O) were treated with some conventional chemotherapeutic (cisplatin, vindesine), targeted therapy (pazopanib, sorafenib) and other metabolic (BPTES, CB839, chloroquin, etc.) and mT Differences in susceptibility to inhibitory (PP242) treatments were characterized using cell proliferation assays (Alamar Blue and Sulforhodamine B). The function of Pgp, which is known in the background of multidrug resistance, was checked by FACS. The basic metabolic characteristics of the cell lines, the expression of metabolic enzymes (WES Simple, Western blot) and the metabolite concentration ratios (LC-MS) were also examined. RESULTS: The two cell lines showed a significant difference in drug sensitivity. The ED50 of the multi-tyrosine kinase inhibitor (pazopanib) used in first-line therapy in the A498 cell line is one hundred times that of 786-O cells, but the MDR mechanism has no role in this difference. Further differences in the two cell lines were confirmed by LC-MS and Wes Simple analytical methods: elevated mTORC1 activity was detected in the two carcinoma cell lines, and high mTORC2 and glycolytic activity was detected in the 786-O cell line. DISCUSSION: Characterization of the relationships between differences in sensitivity, metabolite concentration, and protein expression for the two cell lines may help to understand the mechanisms of resistance. Further, by characterizing the combined effects of metabolic inhibitors and current treatments, as well as the mechanisms of resistance in vitro and in vivo, we can select new targets and more effective, personalized treatments.
C1 [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vetlenyi, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Raffay, Regina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Szaloki, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Meszaros, Katalin] Hungarian Academy of Sciences and Semmelweis University, Hereditary Endocrine Tumors Research GroupBudapest, Hungary.
   [Sebestyen, Endre] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Moldvai, D (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 42
EP 43
PG 1
ER

PT J
AU Moldvay, J
   Megyesfalvi, Zs
   Dulai, V
   Papay, J
   Kovalszky, I
   Timar, J
   Fillinger, J
   Harko, T
   Pipek, O
   Teglasi, V
   Regos, E
   Papp, G
   Szallasi, Z
   Galffy, G
   Bodor, Cs
   Dome, B
   Gieszer, B
AF Moldvay, Judit
   Megyesfalvi, Zsolt
   Dulai, Viktoria
   Papay, Judit
   Kovalszky, Ilona
   Timar, Jozsef
   Fillinger, Janos
   Harko, Tunde
   Pipek, Orsolya
   Teglasi, Vanda
   Regos, Eszter
   Papp, Gergo
   Szallasi, Zoltan
   Galffy, Gabriella
   Bodor, Csaba
   Dome, Balazs
   Gieszer, Balazs
TI Frequency of EGFR mutant allele predicts therapeutic efficacy of EGFR-TKI in lung adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Although a sensitizing mutation in the EGFR gene in lung adenocarcinoma (ADC) is a beneficial predictor of EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) therapy, disease progression will sooner or later occur. The aim of our study was to determine the predictive role of the EGFR mutant allele frequency (MAF) in the EGFR-TKI treatment of lung ADCs. MATERIALS AND METHODS: 89 patients with advanced EGFR status and EGFR-TKI therapy with advanced pulmonary ADC were included in the study. EGFR-MAF values ​​and some clinicopathological parameters, e.g. the correlation between PFS (progression-free survival) and OS (overall survival). RESULTS: Of the 89 EGFR mutant ADC patients, 46 had exon 19 deletions (51.7%), 41 had exon 21 point mutations (46.1%), and 2 had exon 18 point mutations (2.2%). . Tumor EGFR-MAF was significantly higher in exon 19 deletion cases than in exon 21 point mutations (p <0.001). It is noteworthy that exon 19 mutation positive patients showed more favorable PFS (p = 0.003) and OS (p = 0.02) values ​​compared to exon 21 mutation positive patients. Regardless of the exon subtype of the EGFR mutation, a significant positive linear correlation was observed between tumor EGFR-MAF and PFS (r = 0.319; p = 0.002). High (≥70%) EGFR-MAF was found to be an independent predictor of longer PFS compared with low (<70%) EGFR-MAF cases (median PFS 52 weeks vs. 26 weeks; p <0.001). However, high EGFR-MAF was associated with better overall survival (p = 0.011). DISCUSSION: Our results suggest that high EGFR-MAF (≥70%) in tumor tissue predicts the therapeutic efficacy of EGFR-TKI in advanced lung ADC. However, exon 19 deletion is associated with high EGFR-MAF and better patient survival.
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Semmelweis University, Ist Department of PulmonologyBudapest, Hungary.
   [Megyesfalvi, Zsolt] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dulai, Viktoria] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Papay, Judit] Semmelweis UniversityBudapest, Hungary.
   [Kovalszky, Ilona] Semmelweis UniversityBudapest, Hungary.
   [Timar, Jozsef] Semmelweis UniversityBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Harko, Tunde] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Pipek, Orsolya] Eotvos Lorand UniversityBudapest, Hungary.
   [Teglasi, Vanda] Semmelweis UniversityBudapest, Hungary.
   [Regos, Eszter] Semmelweis UniversityBudapest, Hungary.
   [Papp, Gergo] Semmelweis UniversityBudapest, Hungary.
   [Szallasi, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Galffy, Gabriella] County Hospital of PulmonologyTorokbalint, Hungary.
   [Bodor, Csaba] Semmelweis UniversityBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Gieszer, Balazs] National Institute of OncologyBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Semmelweis University, Ist Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Moldvay, J
   Teglasi, V
   Pipek, O
   Harko, T
   Vadasz, P
   Rojko, L
   Dome, B
   Bago, A
   Timar, J
   Szallasi, Z
   Reiniger, L
AF Moldvay, Judit
   Teglasi, Vanda
   Pipek, Orsolya
   Harko, Tunde
   Vadasz, Pal
   Rojko, Livia
   Dome, Balazs
   Bago, Attila
   Timar, Jozsef
   Szallasi, Zoltan
   Reiniger, Lilla
TI PD-L1 expression of tumor cells in lung adenocarcinoma is not significantly altered during cerebral metastasis
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In lung cancer, a comprehensive comparison of PD-1 and PD-L1 expression in primary tumors and their brain metastases and in tumor-associated immune cells (IC) has not been performed, and little is known about the effects of chemo-, radio- and steroid therapy on these tissues. biomarkers. MATERIAL AND METHOD: Tumor cell (TC) PD-L1 and IC PD-1 / PD-L1 expression and immune cell density. RESULTS: We found a significant correlation between the number of PD-L1-positive tumor cells (TC) in primary lung cancers and their brain metastases (p <0.001). Chemotherapy or steroid therapies prior to cerebral metastasectomy had no effect on PD-L1 TC expression. There was no or very limited correlation in the number of PD-1 / PD-L1 positive ICs between primary and metastatic samples. Similarly, there was no association regarding the change in density of tumor-associated ICs between primary and metastatic tumors in the presence or absence of chemo-, radiotherapy, or steroid therapies. DISCUSSION: Based on the above, a strong correlation can be observed in PD-L1 TC expression in lung adenocarcinoma between primary lung tumors and their brain metastases, which was not significantly affected by chemo-, radiotherapy, and steroid therapy.
C1 [Moldvay, Judit] National Koranyi Institute of Pulmonology, Semmelweis University, Ist Department of PulmonologyBudapest, Hungary.
   [Teglasi, Vanda] Semmelweis UniversityBudapest, Hungary.
   [Pipek, Orsolya] Eotvos Lorand UniversityBudapest, Hungary.
   [Harko, Tunde] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Vadasz, Pal] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Rojko, Livia] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Bago, Attila] Orszagos Pszichiatriai es Neurologiai IntezetBudapest, Hungary.
   [Timar, Jozsef] Semmelweis UniversityBudapest, Hungary.
   [Szallasi, Zoltan] Semmelweis UniversityBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis UniversityBudapest, Hungary.
RP Moldvay, J (reprint author), National Koranyi Institute of Pulmonology, Semmelweis University, Ist Department of Pulmonology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 43
EP 43
PG 1
ER

PT J
AU Molnar, Zs
   Csikosne Macsok, E
   Piko, B
AF Molnar, Zsanett
   Csikosne Macsok, Erzsebet
   Piko, Bela
TI The importance of nursing work in patient education and follow-up
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The aim of our presentation is to demonstrate the importance and benefits of nurse patient education for some oncology products; based on the experience and documented cases gained at the County Oncology Center of the Kalman Pandy County Hospital of the Bekes County Hospital. The side effect profile of some drugs used in oncology is different from that of “classical” cytostatics. In most cases, the side effects are not serious, but in the absence of adequate information, they are frightening and, without treatment, can impair the patient's quality of life and 'loyalty' to treatment (therapeutic adherence). By discontinuation of medication due to side effects, the antitumor effect of the drug is usually also interrupted, thus impairing the patient's life expectancy. The vast majority of side effects occur during the first few months of therapy. Close contact with proper “proactive” side effect management is not always possible within normal patient care and requires extra time and energy. We are currently monitoring and assisting patients with the use of six formulations. These include sunitinib, palbocyclib, cabozantinib, pazopanib, abiraterone acetate and ribocyclib. We can talk about the largest number of cases using sunitinib, so we would like to present our experience and results with this preparation, which clearly prove that the nurse can play a significant role in patient education. In our opinion, involving nurses in patient support programs in as many care settings and using as many products as possible would greatly improve patients' quality of life, the effectiveness of treatments - and specialist communication would also help the physician.
C1 [Molnar, Zsanett] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Csikosne Macsok, Erzsebet] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Molnar, Zs (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 43
EP 44
PG 1
ER

PT J
AU Munkacsy, Gy
   Fekete, J
   Gyorffy, B
AF Munkacsy, Gyongyi
   Fekete, Janos
   Gyorffy, Balazs
TI Predictive role of MKI-67 and PCNA cell proliferation markers in the pharmacological treatment of breast malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Ki-67 is the most widely used marker of cell proliferation, while the PCNA protein has long been identified as an important participant in DNA replication. In the present study, we sought to determine whether these two genes encoding proteins may be predictive markers of drugs currently used in breast cancer therapy. MATERIAL AND METHOD: We downloaded breast tumor data from the GEO database using the keywords “breast,” “cancer,” and “therapy”. For both markers, the microarray probe most representative of the gene was selected using the JetSet algorithm. Gene expressions in the endocrine, anti-HER2, and chemotherapy-responsive and non-chemotherapy groups were compared by Receiver Operating Characteristic (ROC-) analysis and Mann-Whitney test. The significance level threshold was set at p = 0.05. RESULTS: In the final database, a total of n = 1775 patients had a pathological complete response and n = 1329 patients had relapse-free survival data within 5 years. For the MKI-67 gene, a significant difference was found between the gene expressions of two groups responding to chemotherapy and those not responding to chemotherapy: fluorouracil adriamycin cytoxan (FAC treatment) (n = 248; AUC = 0.604; ROC p-value: 6.2e-03) and fluorouracil epirubicin cyclophosphamide (FEC) (n = 303; AUC = 0.708; ROC p-2.5e-11). PCNA gene expressions differ significantly between anthracycline-responsive and non-responders (n = 1626; AUC = 0.606; ROC p-value: 4.6e-13). DISCUSSION: The predictive role of MKI-67 and PCNA genes in the chemotherapy of breast cancer patients has been demonstrated. The MKI-67 gene was shown to be predictive in combination with FEC and FAC treatment and PCNA in anthracycline therapy. The genes were not associated with a therapeutic response in patients treated with anti-HER2 and endocrine therapy.
C1 [Munkacsy, Gyongyi] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Fekete, Janos] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Munkacsy, Gy (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Muller, D
   Gyorffy, B
AF Muller, Dalma
   Gyorffy, Balazs
TI Investigation of DNA methylation in colon cancer using 1559 samples
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Of the platforms that study DNA methylation at the full genome level, Illumina HumanMethylation450k is the most popular platform for large sample studies. Our goal was to integrate the data available from the studies using the platform into a database and to identify the genes with the largest methylation difference. MATERIAL AND METHOD: Raw signal intensity and clinical data from a systematic search in the GEO (Gene Expression Omnibus) database and the GDC database were used to create the database. The raw data were reprocessed in the R program environment using the minfi program package for all samples. The difference in methylation within the genes was examined for different regions of the genes (promoter, 5’UTR, first exon, gene body, 3’UTR). Gene comparisons were performed using the Mann-Whitney test, and significant differences were ranked according to the difference in beta values ​​expressing the degree of methylation. RESULTS: Based on GEO and GDC data, we created a database of data from 1559 samples containing data from 791 healthy adenoma and 637 adenocarcinoma tissues. When comparing healthy and adenocarcinoma samples, ZNF264 (p <0.001, fold change = 10.02), ZNF354C (p <0.001, fold change = 7) were among the genes with the most significant methylation increase in the gene promoter, first exon and 5'UTR regions. , 79) and ZNF256 (p <0.001, fold change = 5.95) genes encoding zinc finger proteins, as well as DTX3 (p <0.001, fold change = 6.47) involved in the Notch signaling pathway and Rho GTPase. activator ARHGAP20 (p <0.001, fold change = 10.27) gene. The three most significant genes in the gene body were ZNF788 (p <0.001, fold change = 5.47), ZNF85 (p <0.001, fold change = 5.41) and LOX (p <0.001, fold change = 5.2). . FDA-approved markers were significant in the promoter region (BMP3, p <0.001, fold change = 5.2; SEPT9, p <0.001, fold change = 1.16). DISCUSSION: Using a large number of colon tumor methylation data, we created a database and identified the genes with the largest methylation differences in these samples. In the next step of the work, we plan to develop AI systems that can be used to identify tumor cells based on normal / tumor methylation abnormalities. Our research may be the starting point for the identification of new clinically useful DNA methylation biomarkers in colon cancer.
C1 [Muller, Dalma] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Gyorffy, Balazs] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
RP Muller, D (reprint author), Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 44
EP 44
PG 1
ER

PT J
AU Nagy, �
   Gyorffy, B
AF Nagy, Adam
   Gyorffy, Balazs
TI Linking mutation and gene expression in colon adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To investigate the relationship between gene mutations and gene expression, it will be possible to identify new therapeutic targets in colon cancer. In the present study, we aimed to identify genes whose alterations in gene expression are associated with somatic mutations affecting the most common APC gene in colon adenocarcinoma. MATERIAL AND METHOD: Data processing and statistical calculation were performed in R statistical program environment. Mutation and RNA sequencing data were used from the TCGA (The Cancer Genome Atlas) database. Mutation data identified by the MuTect2 algorithm were processed using the MAFtools R Bioconductor software package. The DESeq2 algorithm was used to normalize RNA sequencing data and the BioMart R Bioconductor program was used for gene annotation. RESULTS: A total of 396 patients with colon adenocarcinoma with both mutational and RNA sequencing data were identified in the TCGA database. According to the database, APC is the most frequently mutated gene among patients with colon adenocarcinoma, with a total of 291 patients carrying this mutation. In the case of the APC mutation, the genes with the five most significant changes in gene expression were RNF43 (p = 3.22E-17, FC = 1.91), AXIN2 (p = 1.93E-14, FC = 1.97), and TDGF1. (p = 8.98E-13, FC = 1.85), ENGASE (p = 1.22E-12, FC = 1.76), and LRRC2 (p = 3.13E-12, FC = 1, 99) were. Among the results, it is worth highlighting the upregulated RNF43 protein with ubiquitin ligase function, which plays a significant role in the development of colon and uterine tumors by disrupting the WNT signaling pathway. The RNF43 protein is one of the key targets of the tegafur chemotherapeutic agent used in gastric, colon, liver and pancreatic tumors. We also supplemented our system for linking mutation and gene expression (https://mutarget.com/) with colon adenocarcinoma data. DISCUSSION: In colon adenocarcinoma tumors, we identified genes with the highest correlation at the gene expression level with the APC mutation that could serve as biomarkers or new therapeutic targets.
C1 [Nagy, Adam] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Nagy, � (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 44
EP 45
PG 1
ER

PT J
AU Neuperger, P
   Balog, J�
   Furak, J
   Tiszlavicz, L
   Szalontai, K
   Man, I
   Kotogany, E
   Puskas, L
   Szebeni, G
AF Neuperger, Patricia
   Balog, Jozsef Agoston
   Furak, Jozsef
   Tiszlavicz, Laszlo
   Szalontai, Klara
   Man, Imola
   Kotogany, Edit
   Puskas, Laszlo
   Szebeni, Gabor
TI Intratumor heterogeneity assay identified TMEM45A as a protein in lung adenocarcinoma by single cell mass cytometry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: One of the leading causes of death in the world is cancer, especially lung cancer, due to its high mortality rate. The treatment of tumors is greatly complicated by the fact of heterogeneity, as subpopulations of cells within the tumor show a different phenotype. As a result, single-cell-level studies that take into account multiplex and heterogeneity are becoming increasingly important. MATERIALS AND METHODS: 3 human non-small cell lung adenocarcinomas were used in our experiments: cell lines A549, H1975 and H1650 were used, and human surgical lung tumor samples were also examined. Central to our methods is the single-cell mass cytometer, which uses antibodies conjugated to metal isotopes, allowing the multiparametric analysis of up to 44 proteins from a single cell level. In our work, the expression of the following proteins was measured by mass cytometry from a sample: GLUT1, MCT4, CA9, TMEM45A, CD66, CD274, CD24, CD326, pankeratin, TRA-1-60, galectin-3, galectin-1 and EGFR. The cell cycle of the cell lines was synchronized with hydroxyurea and then synchronized with a flow cytometer. TMEM45A expression and HIF1-α colocalization were examined on histopathological samples. RESULTS: Heterogeneity between and within cell lines was illustrated by viSNE and FlowSOM figures based on common marker expression by reducing a multidimensional space. The phenotype of the cell lines shows a different pattern, and populations that weakly and strongly express each marker can also be distinguished within the cell line. In contrast to healthy human primary lung tissue, the markers with the strongest change in human primary invasive acinar adenocarcinoma tumor were MCT4, GLUT1, CA9, and TMEM45A, whose expression was increased 10-fold. In immunohistochemical lung tumor sections, TMEM45A (n = 17) was strongly expressed compared to non-tumor emphysema control samples (n = 3). TMEM45A and HIF1-α show partial colocalization in tumor sections. DISCUSSION: We have shown that despite cell cycle synchronization, intracellular heterogeneity persists, adequate models of cell lines where heterogeneity does not result from different phases of the cell cycle. We were the first to identify the TMEM45A protein on the cell surface in a primary human lung adenocarcinoma sample, the expression of which was confirmed by immunohistochemistry.
C1 [Neuperger, Patricia] Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika LaboratoriumSzeged, Hungary.
   [Balog, Jozsef Agoston] Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika LaboratoriumSzeged, Hungary.
   [Furak, Jozsef] Szegedi Tudomanyegyetem, AOK, Mellkassebeszeti TanszekSzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Szalontai, Klara] Csongrad County Hospital of Chest DiseasesDeszk, Hungary.
   [Man, Imola] Avikor Kft.Szeged, Hungary.
   [Kotogany, Edit] Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika LaboratoriumSzeged, Hungary.
   [Puskas, Laszlo] Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika LaboratoriumSzeged, Hungary.
   [Szebeni, Gabor] Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika LaboratoriumSzeged, Hungary.
RP Neuperger, P (reprint author), Szegedi Biologiai Kutatokozpont, Funkcionalis Genomika Laboratorium, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 45
EP 45
PG 1
ER

PT J
TI Retrospective study of definitive radiochemotherapy in patients with cervical cancer: Analysis of late gastrointestinal and urogenital side effects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: We retrospectively analyzed the survival data and late gastrointestinal (GI) and urogenital (GU) side effects of our cervical cancer patients treated with definite radiochemotherapy in a retrospective manner. MATERIAL AND METHOD: In the 481 patients treated between October 2002 and March 2017, we processed the available medical documentation and data obtained during a telephone interview. Radiation treatment was performed with 45 or 50.4 Gy external pelvic irradiation (EBRT), boxing technique, and 3 or 4 × 7 Gy brachytherapy (BT), dosed to point A. Factors influencing disease outcome were examined by Cox regression, while predictors of the severity of GI and GU side effects were examined by logistic regression. RESULTS: The mean age of the patients studied was 54 years (22-77). Median follow-up: 57 months. 10-year overall survival (OS): 40.1%, disease-free survival (DFS): 60.6%, locoregional relapse-free survival (LRFS): 70.3%, metastatic-free survival (MFS): 72.7% . In the group of patients treated with 50.4 Gy EBRT for bulky tumor (> 4 cm) and positive lymph node status, 4 × 7 Gy BT improved LRFS (p = 0.037), DFS (p = 0.003), CSS (p = 0.01) and OS (p = 0.01) in the 3 × 7 Gy BT group. For non-bulky tumors, no significant survival benefit was found at the higher BT dose. Out of all patients, 329 patients have data on GI and 322 patients have data on GU side effects. Grade 0: 61.1%, grade 1: 15.5%, grade 2: 13.1%, grade 3: 8.2% and grade 4: 2.1% in patients with GI side effect, grade 0: 76.4% , grade 1: 8.4%, grade 2: 12.7%, grade 3: 2.5%, and grade 4: 0% were reported to have GU side effects. 23 patients underwent intestinal surgery for grade 3-4 GI complications and 17 underwent final stoma. The dose of EBRT and BT and the dose of EQD2 had no effect on the severity of side effects. DISCUSSION: No predictor factor influencing the severity of late side effects was found in our patient population. In large tumors and lymph node-positive patients, treatment with a higher dose of BT has been shown to be more beneficial. Due to the frequency and severity of side effects, further analysis is considered important.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 45
EP 45
PG 1
ER

PT J
AU Novak, Z
   Nanassy, L
   Teglas, Gy
   Vesztergom, D
AF Novak, Zoltan
   Nanassy, Laszlo
   Teglas, Gyongyver
   Vesztergom, Dora
TI New possibilities related to the preservation of fertility and the treatment of tumors during pregnancy in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our presentation, we would like to show what progress has been made in the last 2 years in maintaining the fertility of young female cancer patients, and how this can help the clinician in practice. As a first step, we present a study that aims to assess the knowledge of Hungarian oncologists and their information habits about fertility conservation technologies in order to reach patients more effectively. MATERIAL AND METHOD: Based on literature data, we prepared a questionnaire on fertility conservation, which was sent to the members of the Hungarian Society of Oncology (MOT) twice. The survey was started by 154 oncology professionals, of whom 94 were completed in full. The results were evaluated on the basis of 94 completed questionnaires. The questionnaire survey was carried out with the support of the Central and Eastern European Academy of Oncology (CEEAO). RESULTS: The majority of respondents ask patients under the age of 40 if they would like another child (77%), often consider the gonadotoxicity of treatment in patients of childbearing age (79%) and usually discuss this with the patient (85%). Nevertheless, 42 respondents (45%) stated that they do not or rarely refer their patients to an infertility center, and 13% do not mention any fertility-preserving methods to the patient undergoing oncology treatment. The main aspects that prevent patients from referring to a fertility procedure are inadequate collaboration between professionals, urgent treatment of the tumor, priority for oncology therapy, lack of information from both the patient and the doctor, and a lack of a fertility maintenance network. they were. DISCUSSION: At the end of our presentation, we report on the new possibilities that are already available in Hungary for the preservation of the fertility of Hungarian cancer patients of fertile age. We try to provide help on how the treatment oncologist can quickly ask for help from the Hungarian oncofertility network. In addition, we present the international initiative that is already available from Hungary (ABCIP). An international team of medical experts in the treatment of cancer during pregnancy provides free treatment to the treating physician and, of course, to the patient.
C1 [Novak, Zoltan] National Institute of Oncology, Center of GynaecologyBudapest, Hungary.
   [Nanassy, Laszlo] Universitares Kinderwunschzentrum LubeckLubeck, Germany.
   [Teglas, Gyongyver] Semmelweis Egyetem, Asszisztalt Reprodukcios CentrumBudapest, Hungary.
   [Vesztergom, Dora] Semmelweis Egyetem, Asszisztalt Reprodukcios CentrumBudapest, Hungary.
RP Novak, Z (reprint author), National Institute of Oncology, Center of Gynaecology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 45
EP 47
PG 1
ER

PT J
AU Ottlakan, A
   Lazar, Gy
   Olah, J
   Hideghety, K
   Koszo, R
   Deak, B
   Nagy, A
   Bottyan, K
   Vass, G
   Kis, E
AF Ottlakan, Aurel
   Lazar, Gyorgy
   Olah, Judit
   Hideghety, Katalin
   Koszo, Renata
   Deak, Bence
   Nagy, Andras
   Bottyan, Krisztina
   Vass, Gabor
   Kis, Erika
TI Bleomycin-based electrochemotherapy for soft tissue sarcomas using Variable Electrode Geometry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In our study, we evaluated the efficacy of bleomycin-based electrochemotherapy for soft tissue sarcomas using VEG (Variable Electrode Geometry) electrodes. MATERIALS AND METHODS: During a two-year period (January 2019 - March 2021), we performed the electrochemotherapy of 6 surgically inoperable soft tissue sarcomas at the Clinic of Surgery of the University of Szeged. Electrode placement was performed following software design and preoperative imaging (CT / MRI) and intraoperative ultrasound. Eight minutes before the onset of electric waves with intravenous bleomycin (15,000 IU / m2), the procedure was continued for a maximum of 40 minutes. RESULTS: Four male and 2 female patients were treated with fibromyxoid (n = 2), epitheloid (n = 3), and liposarcoma (n = 1), with a mean age of 60.5 years (39–87). The median tumor size, tumor volume, and tumor depth were 5.9 cm (3.7–22.5), 165.75 cm3 (35.6–2456.22), and 6.18 cm (3.74–18.18), respectively. . The interventions lasted an average of 90 minutes (35–110), with a median stay of 1.5 days (1–3). Based on RECIST v1.1, 2-month radiological follow-up confirmed 4 partial responses (66.66%), 1 stable disease (16.66%), and 1 progressive disease (16.66%). Grade 2 ulceration occurred in four cases and no severe adverse event occurred. DISCUSSION: Based on our results, bleomycin-based VEG electrochemotherapy can be used successfully and safely in the local control of advanced, surgically inoperable soft tissue sarcomas.
C1 [Ottlakan, Aurel] University of Szeged, Department of SurgerySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of SurgerySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of SurgerySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Deak, Bence] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy, Andras] University of Szeged, Department of RadiologySzeged, Hungary.
   [Bottyan, Krisztina] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Vass, Gabor] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kis, Erika] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Ottlakan, A (reprint author), University of Szeged, Department of Surgery, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Panczel, G
   Balatoni, T
   Kende, H
   Kertai, P
AF Panczel, Gitta
   Balatoni, Timea
   Kende, Hanna
   Kertai, Petra
TI Survival outcomes of 21 patients with metastatic ocular melanoma treated with anti-PD-1 immunotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In adults, uveal melanoma is the most common intraocular tumor, but accounts for only 3-5% of all melanoma. The most common site of metastasis is hepar. The molecular pathological properties of uveal melanomas and the course of the disease are fundamentally different from those of cutaneous melanomas. The results of innovative therapies for uveal melanoma are unclear. Median PFS with 2.6-4.5 months was the best outcome in clinical trials with anti-PD-1 immunotherapy. MATERIAL AND METHOD: Data from 21 patients with metastatic ocular melanoma treated with anti-PD-1 (Keytruda and Opdivo) immunotherapy were processed at the National Institute of Oncology between 2015 and 2021 in a retrospective study. Response rates, progression-free survival, and overall survival were determined. The analysis was performed using Microsoft Office Excel. Therapeutic response was assessed using the iRECIST criteria system. RESULTS: 9 female (43%) and 12 male (57%) patients were treated. Patients had a mean age of 62 years (range, 49–79 years) and an ECOG status of 0–1. Only 10 patients had liver metastases and 11 patients had extrahepatic dissemination at the start of immunotherapy. Six patients received therapy in the first line, 13 patients in the second line, and 2 patients in the multiple line. 19 patients received pembrolizumab and 2 patients received nivolumab immunotherapy. One patient treated with nivolumab had previously received ipilimumab. Previously, 10 patients (48%) received prophylactic intraarterial liver chemotherapy. The median follow-up was 13 months. At the time of analysis, 2 patients (10%) were alive. Only 1 of the patients had partial remission, 5 had stable disease, and 15 had progressive disease. Complete remission did not occur in any patient. The median PFS was 3 months (1–15 months) and the median OS was 11 months (2–34 months). The side effects were as previously described. DISCUSSION: The group of patients studied is small, the PFS and OS values ​​correspond to the data reported in the literature. The PFS value does not reach the result of intra-arterial chemotherapy in our previous study (3 months vs. 7 months) or the PFS value of cutaneous melanoma (CheckMate 067: 6.9 months). Further immunological and molecular pathology research is needed to improve the therapeutic efficacy of uveal melanoma.
C1 [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kende, Hanna] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kertai, Petra] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Panczel, G (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 47
EP 47
PG 1
ER

PT J
AU Papp, J
   Bozsik, A
   Pocza, T
   Patocs, A
   Butz, H
   Grolmusz, VK
   Olah, E
AF Papp, Janos
   Bozsik, Aniko
   Pocza, Timea
   Patocs, Attila
   Butz, Henriett
   Grolmusz, Vince Kornel
   Olah, Edit
TI Hereditary pathogenic variants in male breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Male breast cancer is a rare disease, with an average of 100-200 new cases diagnosed in Hungary each year. Among the genetic risk factors for this disease, the presence of germline pathogenic variants of the BRCA2 (and to a lesser extent BRCA1) gene is of paramount importance, but these explain a smaller proportion of cases. In order to better understand the hereditary predisposition to male breast cancer, we aimed to assess the role of genes already known for model breast cancer in this disease as well. MATERIALS AND METHODS: In our studies, DNA was obtained from the peripheral blood samples of 140 male patients diagnosed with breast cancer, and mutation studies were performed using NGS methods using various gene panels. Bioinformatics evaluation of the sequencing results was performed with open access software and self-developed algorithms. RESULTS: The BRCA1 / 2 genes were examined in all samples, and 25 pathogenic abnormalities (17.9%) were identified, most of them in the BRCA2 gene. At the next level, 115 BRCA-negative samples were further examined for additional known genes in breast cancer, and the analysis of the first 60 evaluated samples revealed the presence of a clear pathogenic abnormality in 5 more cases (3 CHEK2 and 2 ATM pathogen variants). The evaluation of the remaining 55 samples is ongoing. DISCUSSION: The genetics of male breast cancer are little known, mainly due to its rare occurrence, so its prognosis and therapeutic approaches are not well developed. Our results suggest that studies with extended gene panels may contribute significantly to a better understanding of the increased hereditary predisposition to the disease and thus to a more accurate identification of risk factors and potential therapeutic targets.
C1 [Papp, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Bozsik, Aniko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pocza, Timea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Patocs, Attila] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Butz, Henriett] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Grolmusz, Vince Kornel] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Olah, Edit] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Papp, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 47
EP 48
PG 1
ER

PT J
AU Pentek, I
   Dank, M
   Juhasz, �
   Desfalvi, J
   Hajdu, A
AF Pentek, Iren
   Dank, Magdolna
   Juhasz, Agnes
   Desfalvi, Judit
   Hajdu, Anett
TI Rehabilitation at the Semmelweis University Oncology Center
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Presentation of the department dealing with the rehabilitation of oncology patients, our results and plans. The Department of Oncology operated as part of the 1st Department of Internal Medicine on March 1, 2013, and on January 1, 2016, the Oncology Center of Semmelweis University was established under the leadership of Prof. Dr. Magdolna Dank, and the rehabilitation department started in April 2017. Rehabilitation should be an integral part of anti-cancer treatments. Interventions in the treatment of cancer can in some cases lead to the loss of the affected organ or its function, as well as to the development of physical and mental damage. The task of rehabilitation is to alleviate and eliminate these consequences. Rehabilitation must begin after the diagnosis has been made, accompanied by treatment (restorative, supportive, maintenance) and then post-treatment; but always tailored to the individual. Our rehabilitation program is a comprehensive interdisciplinary program developed to rehabilitate all cancer patients, regardless of whether the patient is newly diagnosed or has been treated for a long time. Oncological rehabilitation differs from the rehabilitation work plan for other diseases. The oncology rehabilitation plan should be treated in a more flexible and differentiated way, always taking into account the changes resulting from the disease and the treatments. Our goal is to improve the physical activity and quality of life of our patients. We have created customized programs. Our experienced team works with an oncologist, rehabilitation specialist, physiotherapist, physiotherapist, physiotherapist, dietitian and psychologist to alleviate the various symptoms of the patients.
C1 [Pentek, Iren] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Juhasz, Agnes] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Desfalvi, Judit] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Hajdu, Anett] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Pentek, I (reprint author), Semmelweis University, Department of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Petovari, G
   Danko, T
   Raffay, R
   Moldvai, D
   Sztankovics, D
   Krencz, I
   Vetlenyi, E
   Kulka, J
   Tokes, AM
   Hajdu, M
   Sebestyen, A
AF Petovari, Gabor
   Danko, Titanilla
   Raffay, Regina
   Moldvai, Dorottya
   Sztankovics, Daniel
   Krencz, Ildiko
   Vetlenyi, Eniko
   Kulka, Janina
   Tokes, Anna Maria
   Hajdu, Melinda
   Sebestyen, Anna
TI Prognostic significance of differences in mTORC1 / C2 and metabolic enzyme expression in breast tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The early detection and effectiveness of the treatment of breast tumors has improved significantly in recent years, but the number of patients is still increasing; the chances of long-term survival are poor in some types. Preventing the occurrence of relapses and preventing the development of therapeutic resistance is an important task that is difficult to solve without understanding and mapping the mechanisms of resistance. The role of changes in the activity of metabolic pathways between tumor tissue heterogeneity and multiple adaptation pathways may also suggest a number of drug target mechanisms. MATERIAL AND METHOD: In our study we studied the in situ expression pattern of proteins characterizing the mTOR and metabolic pathways of ten human breast carcinoma cell lines and biopsy tissue samples (Western blot, immunohistochemistry). The effects of metabolic (3BP, BPTES, etomoxir, BMS) and mTOR inhibitors (rapamycin, PP242, GDC) were studied in vitro, following the quantitative changes of metabolic enzymes and proteins characterizing mTOR activity. RESULTS: Based on our results, different breast tumor cell lines can be characterized by subtype-independent unique mTORC1, mTORC2, and metabolic activity. SKBR3, MDA-MB453 and HS578T cells are mainly mTORC1-; T47D, ZR75.1 and BT474 are mTORC2-; however, the other cell lines have balanced mTOR activity. Associated mTOR inhibitory susceptibility was observed in vitro, and two cell lines were resistant to mTOR and Akt inhibitors. The effects of glycolysis and glutamolysis inhibitors were also associated with the expression of enzymes characterizing these processes, with glycolysis inhibitors proving to be the most effective. Treatment with etomoxir, an inhibitor of lipid metabolism, showed significant inhibition of proliferation in only two cell lines. Based on mTOR and metabolic enzyme expression profiling of human tissue samples, the Warburg phenotype is characteristic of HER2 + and triple-negative subtypes. However, a subtype-independent association was found between high mTOR activity and concomitant expression of proteins characteristic of alternative metabolic pathways with increased expression and poor prognosis in breast tumors. DISCUSSION: Our results suggest that differences and heterogeneity in mTORC1 / C2 and metabolic enzyme expression may play an important role in the development of therapy resistance. By mapping these, we can learn about new therapeutic targets in the future that complement current treatments.
C1 [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Raffay, Regina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vetlenyi, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Tokes, Anna Maria] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Hajdu, Melinda] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Petovari, G (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 48
EP 48
PG 1
ER

PT J
AU Piko, B
   Csikosne Macsok, E
   Balogh, Cs�
   Ali, B
AF Piko, Bela
   Csikosne Macsok, Erzsebet
   Balogh, Csaba Adam
   Ali, Bassam
TI During a pandemic ...
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Oncology and oncoradiology continued to operate in our hospital during the Covid-19 pandemic. As the Paly Kalman Member Hospital of the Bekes County Central Hospital is an institution designated for the care of the infected, we have taken measures to protect the patients and staff: , nursing and medical history, examination), and in suspected cases an immunological rapid test was performed. Patients at risk for mask wear and care conditions (head and neck tumors, agranulocytosis, etc.) were screened regardless of their condition. The construction of the oncology center made it possible to separate the access and treatment rooms with the door closed, only the patients could go to the inpatient ward on the floor, saying goodbye to the relatives who had been helping until then. Patients admitted during the radiotherapy were not allowed to go home, and patients with a serious condition under the CLIV Act 1997 who were eligible to receive visitors were transferred to the Adult Hospice-Palliative Care Unit of the center as soon as possible. Mask wear and hand disinfection were also rigorously and regularly inspected, and although not always easy, we provided the necessary protective equipment (mask, gloves, goggles, face mask, protective clothing) and the required amount of hand and surface disinfectants. In 12 of the patients admitted to the hospital, based on our own control, we found those infected before hospitalization or the start of the curative care, and a total of 5 patients and 16 contacts had to be referred for infection due to the later symptoms of the patients already admitted.
C1 [Piko, Bela] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Csikosne Macsok, Erzsebet] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Balogh, Csaba Adam] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Ali, Bassam] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
RP Piko, B (reprint author), Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Centrum, Gyula, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 48
EP 49
PG 1
ER

PT J
AU Puskas, G
AF Puskas, Gabriella
TI Difficult track
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB It is not an easy task for those health professionals who have chosen to care for oncology patients. 32 years have taught me a lot in oncology, I have learned a lot from patients and colleagues. We went through countless stories together; healings, struggles and tragedies. I didn’t think there was much more to show me, but I have re-evaluated this opinion over the past year. We and our patients drifted with the events. In my presentation, I would like to tell you how we struggled with workers and patients in the chemotherapy outpatient clinic during different periods of Covid. I would like to demonstrate all this with stories, examples and case studies.
C1 [Puskas, Gabriella] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
RP Puskas, G (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Polgar, Cs
   Major, T
   Takacsi-Nagy, Z
   Fodor, J
AF Polgar, Csaba
   Major, Tibor
   Takacsi-Nagy, Zoltan
   Fodor, Janos
TI Partial or full breast irradiation after breast-conserving surgery: 20-year results of a prospective, randomized study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To analyze the results of a 20-year prospective, randomized study comparing partial and whole mammalian irradiation. MATERIAL AND METHOD: Between 1998 and 2004, 258 patients undergoing breast-conserving surgery for low-risk (pT1 pN0-1mi, HG 1-2, EIC negative, non-lobular, negative surgical edge) breast cancer were randomized: 130 in 50 Gy standard full breast radiotherapy (TERT), 128 received partial breast radiotherapy (PERT). In the PERT arm, radiation treatment was performed in 88 patients with 7 × 5.2 Gy HDR brachytherapy (HDR-BT) and in 40 patients with 50 Gy electron irradiation (ELE). During follow-up, breast cancer-related events, cosmetic findings, and late side effects were recorded. RESULTS: After a median follow-up of 17 years (range: 1.5–21.2 years), the 20-year probability of local tumor recurrence was 9.6% and 7.9% in the PERT and TERT faculties, respectively (p = 0.59). There was also no significant difference in 20-year overall survival (59.5% vs. 59.7%), tumor-specific survival (92.6% vs. 88.1%), and tumor-free survival (79.7% vs. 78.3%). %). The excellent / good cosmetic score was 79.2% after PERT (82.4% after HDR-BT; 72.5% after ELE) compared to 59.5% in the control group (p = 0.0007). The incidence of grade 3 fibrosis was 2.4% after HDR-BT and 0.9% after TERT (p = NS). The rates of grade 3 late skin adverse events were 0% and 2.5%, respectively (p = NS). DISCUSSION: Partial breast irradiation with HDR-BT or telotherapy provides the same 20-year local tumor-free status in conventional patients as conventional whole breast irradiation. Accelerated partial breast radiotherapy with appropriate technique and dosing provides significantly better cosmetic results than 5 weeks of external irradiation of the whole breast. The risk of severe (grade 3) late side effects is not significantly increased by partial breast irradiation.
C1 [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Fodor, Janos] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Poosz, M
   Herczeg, B
   Ferenczi, �
   Tolvaj, E
   Polgar, Cs
   Takacsi-Nagy, Z
AF Poosz, Marton
   Herczeg, Brigitta
   Ferenczi, Ors
   Tolvaj, Eniko
   Polgar, Csaba
   Takacsi-Nagy, Zoltan
TI Tumor volume reduction during radiotherapy of head and neck tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Radiation therapy is one of the most important tools for the treatment of locally advanced head and neck tumors. However, this method can have significant side effects in both the short and long term. Severe acute side effects may force the clinician to discontinue or reduce the dose, thereby impairing local control, while long-term side effects may cause a significant deterioration in the patient's quality of life. It is important to point out that patients with head and neck can undergo significant anatomical changes during treatment, which can lead to an increase in side effects. Adaptive radiation therapy is a method that attempts to improve the side effect profile while maintaining local control by continuing the treatment with a new irradiation plan based on a recent imaging one or more times during treatment. With this procedure, the treatment can be adapted to changes in the size and position of the target volumes, improving the protection of the risk organs. With proper nutritional therapy and side effect management, the reduction in Gross Tumor Volume (GTV) due to treatment, especially in the case of boost, is the most important factor that can affect the effectiveness of therapy and the success of treatment. MATERIALS AND METHODS: In 2021, 27 patients with definitive 70 Gy receiving head and neck radiotherapy or radiochemotherapy from the National Institute of Oncology examined the extent of GTV reduction relative to the onset of irradiation at a dose of 50 Gy using native planning CT. before. In 6 patients the tumor was p16-negative, in 9 cases the histology was p16-positive, in 11 cases the HPV status was unknown, and in one case EBV-positive tumor was confirmed. RESULTS: As expected, we found that the rate of GTV reduction in p16-positive cases was on average more than 70% at the onset of the boost, compared to 55% in p16-negative cases. In p16-positive cases, the mean GTV volume decreased from 54.5 cm3 to 13.3 cm3 after the delivery of an elective dose of 50 Gy, compared to p16-negative cases, where from 27.2 cm3 to 10.1 cm3. a reduction in size was seen. Surprisingly, there was also a volume reduction of more than 70% in the case of unknown HPV status. Here, the mean pre-treatment volume fell from 30.1 cm3 to 9 cm3. The reduction in volume for the whole group was 67% with an initial mean volume of 37.9 cm3, which shrank to 10.8 cm3 at a dose of 50 Gy. DISCUSSION: Despite the small number of cases and the limitations of native CT resolution, the present study also seems to confirm the known phenomenon that HPV-positive head and neck squamous cell carcinomas respond very well to radiation therapy, but p16-negative cases may show sufficient regression to do so. that adaptive radiotherapy should be used in patients to reduce side effects, especially long-term xerostomia. It may be worthwhile to further investigate the topic and adaptive radiotherapy schemes by increasing the number of cases and improving the imaging resolution in addition to the use of design MR.
C1 [Poosz, Marton] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Herczeg, Brigitta] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Ferenczi, Ors] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Tolvaj, Eniko] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Poosz, M (reprint author), National Institute of Oncology, Center of Radiotherapy, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 49
EP 49
PG 1
ER

PT J
AU Radeczky, P
   Moldvay, J
   Fillinger, J
   Szeitz, B
   Ferencz, B
   Kristiina, B
   Rezeli, M
   Bogos, K
   Renyi-Vamos, F
   Hegedus, B
   Megyesfalvi, Zs
   Dome, B
AF Radeczky, Peter
   Moldvay, Judit
   Fillinger, Janos
   Szeitz, Beata
   Ferencz, Bence
   Kristiina, Boettiger
   Rezeli, Melinda
   Bogos, Krisztina
   Renyi-Vamos, Ferenc
   Hegedus, Balazs
   Megyesfalvi, Zsolt
   Dome, Balazs
TI Bone-specific pattern of metastasis in lung adenocarcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: In advanced lung adenocarcinoma (LADC), one of the most commonly diagnosed distant organ metastases is bone metastases, which can be diagnosed in 25-40% of cases during the course of the disease. Although the development of bone metastases is a significant oncological problem, the bone-specific metastasis pattern is currently unknown in these patients. The aim of our study was to map the bone-specific metastasis pattern in LADC with advanced stage as a function of primary tumor location. MATERIALS AND METHODS: A total of 209 clinopathological parameters of LADC patients diagnosed with bone metastases were analyzed retrospectively. The metastasis pattern was examined according to the location and type of affected bones and the location of the primary tumor. In addition to their location in the lobe, primary tumors were grouped according to their bronchoscopic visibility (i.e., central or peripheral). RESULTS: The bones most commonly affected by metastases were the spine (n = 103), ribs (n = 60), pelvis (n = 36), and femur (n = 22). Regarding the localization of the primary tumor, we found that peripheral tumors were associated with femoral (p = 0.022) and rib (p = 0.012) metastases, while central tumors were associated with maxillary metastases (p = 0.018). Skull metastases were most common in left tumors (vs. right tumors; p = 0.018). It should be noted that the localization of the primary tumor did not significantly affect the type of bones involved. In a multivariate Cox regression analysis adjusted for clinical parameters, central localization of the primary tumor was shown to be an independent negative prognostic factor for overall survival. DISCUSSION: Our studies provide information on the bone-specific metastasis pattern as a function of primary tumor location. The localization of the primary tumor significantly influences the site of onset of bone metastases, however, no association was found between the type of bones involved and the location of the primary tumor. Overall, knowledge of the metastasis pattern can facilitate rapid diagnosis and serve as a basis for developing a personalized treatment plan.
C1 [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Szeitz, Beata] Semmelweis University, Department of OncologyBudapest, Hungary.
   [Ferencz, Bence] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Kristiina, Boettiger] Medical University of ViennaVienna, Austria.
   [Rezeli, Melinda] Lund UniversityLund, Sweden.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Hegedus, Balazs] University Duisburg-Essen, Ruhrlandklinik, Department of Thoracic SurgeryEssen, Germany.
   [Megyesfalvi, Zsolt] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
   [Dome, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti OsztalyBudapest, Hungary.
RP Radeczky, P (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 49
EP 51
PG 1
ER

PT J
AU Rozsa, P
   Varga, A
   Ocsai, H
   Kemeny, L
   Olah, J
   Baltas, E
AF Rozsa, Petra
   Varga, Anita
   Ocsai, Henriette
   Kemeny, Lajos
   Olah, Judit
   Baltas, Eszter
TI Differential diagnosis of respiratory symptoms in patients with melanoma treated with immunotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Immune checkpoint inhibitors have made a major breakthrough in the treatment of metastatic melanoma. In addition to the survival benefit experienced by patients, the so-called immune-linked inverse reactions (irAE). Recognition and effective management of these in a timely manner is of paramount importance. As the symptoms are often not specific, the presence of other underlying conditions should be ruled out. MATERIALS AND METHODS: Between 04/02/2020 and 04/04/2020, six patients with melanoma treated with immunotherapy (46–74 years, mean: 61 years) reported respiratory complaints at our clinic. Two received combination immunotherapy (CTLA-4 inhibitor + PD-1 inhibitor) and four received PD-1 inhibitor monotherapy. It took 2 to 27 months (mean: 11 months) from the start of treatment to the onset of symptoms. Based on clinical symptoms, the directional diagnosis was immune-associated pneumonitis. RESULTS: In addition to the general symptoms (weakness, fever, chills), we have seen various respiratory symptoms (dyspnoea, exertional dyspnoea, sputum, cough). Laboratory and imaging studies performed after the physical examination, as well as consultation with associates, helped to establish an accurate diagnosis. Respiratory symptoms were diagnosed with pneumonitis (Grade 2), pulmonary embolism, infectious disease, and progression of the underlying disease. DISCUSSION: Respiratory symptoms in patients with melanoma treated with immunotherapy may be due to a number of conditions. In addition to physical examination, other examination methods and interdisciplinary collaboration are important in making an accurate diagnosis. For early diagnosis, it is important to draw the patient’s attention to the symptoms of possible immune-related side effects. If irAE occurs, patients should be examined as soon as possible at their oncology center. It is important to rule out SARS-CoV-2 virus infection in patients with respiratory symptoms.
C1 [Rozsa, Petra] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Varga, Anita] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Ocsai, Henriette] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Kemeny, Lajos] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
   [Baltas, Eszter] University of Szeged, Department of Dermatology and AllergologySzeged, Hungary.
RP Rozsa, P (reprint author), University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Rubovszky, G
AF Rubovszky, Gabor
TI Role of perioperative capecitabine in the treatment of early triple-negative breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB There is no potential for either endocrine or anti-Her2 treatment of triple-negative breast cancer (TNBC). The backbone of medication is chemotherapy. Standard treatments also include anthracyclines, taxanes, and alkylating agents, which are increasingly used before surgery. In this group of patients, the recurrence rate is around 30%. Complementary chemotherapy may have added value. In this regard, data are available with capecitabine to support the addition of capecitabine in certain situations. By reviewing the relevant studies, a clearer wording of the indication is of practical importance. The structure of the studies is not uniform, so their evaluation is a complex task. Although several studies have been positive, the only currently accepted perioperative indication is limited to cases of residual tumor (non-pCR) following standard neoadjuvant anthracycline and taxane treatment. Meta-analyzes also suggest that capecitabine should be administered primarily as a substitute for TNBCs and as an adjunct.
C1 [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Rubovszky, G (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 51
EP 51
PG 1
ER

PT J
AU Schvarcz, Cs
   Danics, L
   Viana, P
   Vancsik, T
   Benyo, Z
   Kaucsar, T
   Hamar, P
AF Schvarcz, Csaba
   Danics, Lea
   Viana, Pedro
   Vancsik, Tamas
   Benyo, Zoltan
   Kaucsar, Tamas
   Hamar, Peter
TI Investigation of the effect of modulated electro-hyperthermia treatment on local stress response and tumor growth in a three-fold negative mouse cancer model
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The treatment of triple negative breast cancer (TNBC) is problematic due to the lack of cell surface receptors. Modulated electrohyperthermia (mEHT) treatment is a new potential adjunctive therapy. In doing so, selective energy transfer and local heating in the tumors can be achieved using an electromagnetic field. Our aim was to use repeated mEHT treatment in a TNBC mouse model and to investigate the effect of treatment on tumor progression and molecular changes. MATERIAL AND METHOD: 4T1 and 4T07 cells were inoculated into the nipples of female Balb / c mice. Tumor growth was monitored by ultrasound and mice were divided into sham (sham, n = 9−10) and mEHT (n = 8−11) treated groups. The animals were treated every 48 hours with a Labehy 200 device (Oncotherm Kft.). Twenty-four hours after the last treatment, the tumors were removed and weighed and then histologically and molecularly processed. Tumor Destruction Ratio (TDR%) was determined on H&E sections. The expression of cC3, HSP70 and Ki67 was determined by immunohistochemical staining. Tumor samples were subjected to RNA isolation, qPCR, NGS, Nanostring, and MS assays. KRIBB11 (Sigma Aldrich) was used to inhibit the heat shock response to treatment and its effect on cell viability was examined in vitro. RESULTS: mEHT treatment reduced tumor growth and weight (sham: 2883 ± 58.1 mg vs. mEHT: 85.3 ± 21.3 mg, p <0.05). HSP70 expression was 6.1 × and cC3 + dead tumor area was 6.3 × higher in the mEHT group (p <0.05 and p <0.001). The number of Ki67 + nuclei was significantly lower in mEHT-treated than in sham-treated tumors (sham: 2874 ± 193.6 pcs / mm2 vs. mEHT: 1737 ± 315.3 pcs / mm2, p <0.05). The most activated pathway identified by the NGS assay is ‘Response to Stimulus’ (GO: 0050896). KRIBB11 treatment was effective in reducing HSP70 and C4b complement expression and cell viability, potentiating the efficacy of mEHT in vitro. DISCUSSION: mEHT treatment is effective in reducing tumor growth, proliferative activity, and cC3-mediated tumor death in TNBC isografts. Inhibition of the heat-induced heat shock response significantly enhances the efficacy of mEHT.
C1 [Schvarcz, Csaba] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Danics, Lea] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Viana, Pedro] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Vancsik, Tamas] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Benyo, Zoltan] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Kaucsar, Tamas] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
   [Hamar, Peter] Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina IntezetBudapest, Hungary.
RP Schvarcz, Cs (reprint author), Semmelweis Egyetem, Elmeleti Orvostudomanyi Kozpont, Transzlacios Medicina Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 51
EP 52
PG 1
ER

PT J
AU Sebestyen, A
   Petovari, G
   Krencz, I
   Felkai, L
   Mohas, A
   Raffay, R
   Danko, T
   Sztankovics, D
   Moldvai, D
   Vetlenyi, E
   Jeney, A
   Csoka, M
   Papay, J
AF Sebestyen, Anna
   Petovari, Gabor
   Krencz, Ildiko
   Felkai, Luca
   Mohas, Anna
   Raffay, Regina
   Danko, Titanilla
   Sztankovics, Daniel
   Moldvai, Dorottya
   Vetlenyi, Eniko
   Jeney, Andras
   Csoka, Monika
   Papay, Judit
TI In situ heterogeneity of metabolic processes, the role of metabolic plasticity of tumor cells in the progression of solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Tumor tissue heterogeneity is an important factor in the development of therapeutic resistance due to tumor evolution; it is characterized by a rearrangement of the metabolic pathways of tumor cells, which aids in the dynamic change of tumor cells and the microenvironment during tumor growth during the therapeutic response. In our work, we investigate the metabolic heterogeneity of human tumors, the metabolic plasticity of tumor cells, and the potential for inhibition in in vitro and in vivo models. MATERIAL AND METHOD: The metabolic heterogeneity of human tumors is characterized by mTOR activity markers and metabolic enzymes (IHC staining), which are compared with clinical data. In vitro 2D, 3D bioprinted and in vivo models of co-administered tumor types were also examined for changes in cellular metabolism by quantification of intracellular metabolites and metabolic proteins (LC-MS, WES Simple, Western blot, immunocytochemistry); and the sensitizing effects of various metabolic inhibitors to conventional chemotherapeutic agents and other combinations. In vivo and in vitro results are compared to monitor the activation of cell death and survival mechanisms (caspase activation, necrosis, autophagy-mediated cell death by confocal TEM microscopy and flow cytometry). RESULTS: In the case of various solid tumors (breast, lung, kidney tumors, some sarcomas) we have confirmed the correlation between metabolic heterogeneity and, consequently, metabolic plasticity in tumor tissue and in vitro with the success of current treatments. Examination of model systems of some tumor types has identified combinations of metabolic inhibitors (glycolysis, glutaminolysis, and other mitochondrial, autophagy, lipid metabolism inhibitors) that significantly inhibit metabolic uptake following transient activation of autophagy, resulting in prolonged cell death. DISCUSSION: New methods have been established for the metabolic characterization of tumors. The association between potent combinations of metabolic inhibitors and basal metabolic features, and the significance of basal tissue metabolic plasticity in the case of multiple inhibition of multiple pathways, was observed. Based on our studies, the characterization of these may receive increasing emphasis in the validation of future metabolic targets and in the therapeutic combination of therapeutic agents with old-new metabolic effects.
C1 [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Felkai, Luca] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Mohas, Anna] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Raffay, Regina] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vetlenyi, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jeney, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of PediatricsBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Sebestyen, E
   Arkosy, PF
   Szekanecz, �
AF Sebestyen, Eniko
   Arkosy, Peter Ferenc
   Szekanecz, Eva
TI Side effects with PD-1 inhibitor treatment in our own patient population
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The known differences in the mechanism of action of agents used as systemic oncotherapy result in a different side effect profile, which is significantly different from the side effects experienced with classical cytotoxic agents. In addition to immunoassay therapies, it is not organically specific manifestations that occur, but rather immunological or endocrine abnormalities. MATERIALS AND METHODS: Data from 70 patients with predominantly renal cancer treated with PD-1 inhibitor nivolumab or pembrolizumab at the DEKK Oncology Clinic between 2017 and 2021 were retrospectively followed and analyzed based on documentation. RESULTS: Adverse reactions observed in the patient population treated in our clinic and their frequency correlate with the distribution data available in the literature. Immunotherapy-related adverse events of G1 or greater were observed in 51% of patients, the most common being endocrine abnormalities and untreated skin symptoms. The majority of complications were untreated with a G1 grade. Of course, the events in question were handled in accordance with the professional guidelines and guidelines available and accepted in Europe (ESMO, NCCN, SITC, and ASCO). DISCUSSION: Overall, immuncheckpoint inhibitory therapies with outstanding efficacy have a tolerable side effect profile. In the event of an undesirable complication that may occur during these treatments, our goal is to take care of the patient's life as soon as possible so that the patient's life is not endangered by the degree of treatment. Accurate knowledge, early detection, and appropriate treatment of adverse events with immunopathogenesis require proficiency and, in many cases, multidisciplinary care involving multiple professions. Our institution also has the necessary conditions for communication and collaboration with experts in other professions, ensuring adequate care for patients.
C1 [Sebestyen, Eniko] University of DebrecenDebrecen, Hungary.
   [Arkosy, Peter Ferenc] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Sebestyen, E (reprint author), University of Debrecen, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 52
EP 52
PG 1
ER

PT J
AU Sipos, D
   Kunstar, O
   Jenei, T
   Kovesdi, OL
   Kovacs, �
   Petone Csima, M
   Danko, T
   Sztankovics, D
   Moldvai, D
   Vetlenyi, E
   Jeney, A
   Csoka, M
   Papay, J
AF Sipos, David
   Kunstar, Oliver
   Jenei, Timea
   Kovesdi, Orsolya Liza
   Kovacs, Arpad
   Petone Csima, Melinda
   Danko, Titanilla
   Sztankovics, Daniel
   Moldvai, Dorottya
   Vetlenyi, Eniko
   Jeney, Andras
   Csoka, Monika
   Papay, Judit
TI Assessing burnout rates among workers in oncology patient care
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Those working in oncology patient care may be physically, emotionally, and intellectually overwhelmed compared to those working in other areas of patient care, which can lead to burnout. The aim of our survey was to assess the burnout rate of nurses, radiographers, and oncologists working in oncology patient care. MATERIAL AND METHOD: With the help of the Hungarian Society of Oncologists (MOT), we sent our self-edited and internationally validated Maslach Burnout Inventory questionnaire to the electronic contacts registered in the MOT administration system. Our questionnaire is from November 2020 to 2021. was available in the February interval. RESULTS: A total of 205 people completed our questionnaire, in which women were overrepresented (n = 158; 77.1%). Regarding the job, the proportion of nurses and oncologists was almost the same (n = 78; 38.0%; n = 75; 36.6%), and 52 radiographers also completed our questionnaire (25.4%). Oncologists had significantly higher values ​​of depersonalization (p = 0.008) and emotional exhaustion (p = 0.008) compared to nurses and radiographers. The number of years spent at work did not significantly affect any of the dimensions of burnout. Regarding the number of hours worked per week, the value of emotional exhaustion was significantly higher for colleagues who worked more than 50 hours and took 3–5 hours per month (p = 0.040; p = 0.041). DISCUSSION: The value of depersonalization and emotional exhaustion in oncologists was significantly increased compared to the values ​​of nurses and radiographers involved in oncology patient care. The results obtained correlate well with those described in the international literature, and coping techniques will play a key role in reducing burnout in the future.
C1 [Sipos, David] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Kunstar, Oliver] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Jenei, Timea] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Kovesdi, Orsolya Liza] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Kovacs, Arpad] Debreceni Egyetem, Onkologiai Klinika, Sugarterapia OsztalyDebrecen, Hungary.
   [Petone Csima, Melinda] MATE, Nevelestudomanyi IntezetKaposvar, Hungary.
   [Danko, Titanilla] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Sztankovics, Daniel] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Moldvai, Dorottya] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Vetlenyi, Eniko] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Jeney, Andras] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
   [Csoka, Monika] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Papay, Judit] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi KozpontKaposvar, Hungary.
RP Sipos, D (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi Kozpont, Kaposvar, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 52
EP 53
PG 1
ER

PT J
AU Surguta, SE
   Cserepes, M
   Tatrai, E
   Garay, T
   Tovari, J
AF Surguta, Sara Eszter
   Cserepes, Mihaly
   Tatrai, Eniko
   Garay, Tamas
   Tovari, Jozsef
TI Effect of hypoxia on motility and metastasis of tumor cell lines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The hypoxic condition and the consequent lack of oxygen cause a number of changes in the behavior of tumor cells that may contribute to tumor progression. Tumor hypoxia promotes neoangiogenesis and contributes to the development of an aggressive phenotype resistant to radiation and chemotherapy of tumor cells. One of the major regulatory proteins in cellular responses to tissue hypoxia is hypoxia inducible factor 1 (HIF-1), which regulates the expression of several molecules (VEGF, VEGFR, EGFR, EPO, EPOR, NOS2, glucose metabolism genes, etc.) as a transcription factor. Tumor cell motility and epithelial-mesenchymal transition (EMT) play an important role in metastasis, in the regulation of which small G proteins of the Rho family (Rac1, CDC42, and RhoA) play an important role. Our aim was to better understand how the hypoxic environment affects the motility and metastatic potential of different tumor cells and what molecular events play a prominent role in these processes. MATERIALS AND METHODS: In vitro gene and protein expression of hypoxia-induced factor-1 (HIF-1α), Rac1, CDC42, and RhoA was measured in proliferation and migration experiments under normoxic and hypoxic conditions. The ability of tumor cells to metastasize in vivo in mucosal hypoxia following tail-vein inoculation was investigated. In addition, the expression of these genes in human clinical specimens was examined for correlation with tumor progression. RESULTS AND DISCUSSION: The partial results so far show that we found an association between basal motility and metastatic potential, as well as gene expression and clinical course in the tumor cell lines studied. In addition, we have also shown that hypoxia enhances the ability of cells with higher basal motility to migrate and metastasize compared to the normoxic environment. Consistent with our own observations previously described, the hypoxic environment induced cell type-dependent changes in the level and activation of small GTPases and resulted in variable migration and metastatic potential in different human tumor cell lines.
C1 [Surguta, Sara Eszter] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Cserepes, Mihaly] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Tatrai, Eniko] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
   [Garay, Tamas] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical ResearchBudapest, Hungary.
RP Surguta, SE (reprint author), National Institute of Oncology, Department of Clinical Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Szabo, �
   Ecker, N
   Aranyi, M
   Papai, Zs
AF Szabo, Adam
   Ecker, Nora
   Aranyi, Marietta
   Papai, Zsuzsanna
TI Experience with trabectedin treatment in the Department of Oncology of the Hungarian Army Center in patients with locally advanced recurrent or metastatic liposarcoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The survival prognosis of locally advanced and metastatic soft tissue sarcomas is relatively low - average survival 15 months - and treatment options are limited in this group of diseases. Trabectedin is a cytostatic with a complex mechanism of action that has shown significant efficacy in patients with liposarcoma based on preliminary clinical trials. We performed a retrospective analysis of data from patients treated with trabectedin in our ward. Our aim was to compare our results with trabectedin treatment with those obtained in the trabectedin registration clinical trial, with particular reference to the best therapeutic response and progression-free survival. MATERIALS AND METHODS: Between November 1, 2011 and January 1, 2020, we treated a total of 33 liposarcoma patients in our ward with trabectedin. 39.39% (n = 13) of patients were female and 60.61% (n = 20) were male. The median age of our treated patients was 60.5 years (range, 26–77 years). Primary tumors were most common in retroperitonium (69.69%, n = 23). Limb soft tissue tumors were observed in 24.24% of cases (n = 8). Trabectedin was administered at a dose of 1.5 mg / m2 via a central venous port every 21 days according to the prescribing information. RESULTS: Survival results of 31 patients were evaluable during processing, and our efficacy results are based on these data. Complete remission occurred in 1 patient (3.23%) and partial remission was observed in 2 patients (6.45%). Stable disease was observed in 32.26% of cases (n = 10) as the best therapeutic response. Progression was observed in 17 patients (54.84%). Based on this, the overall response rate (ORR) was found to be 9.68%. The disease control rate (DCR) was 41.94%. Median progression-free survival was 3 months (0.5-18 months), which is consistent with the trabectedin study in liposarcoma patients. The most common adverse reactions were hepatic enzyme abnormalities and haematological adverse reactions. Grade 1-2 elevations in liver enzymes and grade 3-4 elevations in liver enzymes were observed in 7 patients. Grade 1-2 anemia occurred in 23 patients, grade 3 anemia occurred in 2 patients. Grade 1-2 neutropenia occurred in 1 patient and grade 3 neutropenia occurred in 2 patients. Grade 1-2 thrombocytopenia was observed in 4, grade 3 thrombocytopenia in 3 patients. DISCUSSION: Based on our studies, we observed results and toxicity profiles similar to those observed in the trabectedin registration study in our patients treated for liposarcoma.
C1 [Szabo, Adam] Honved KorhazBudapest, Hungary.
   [Ecker, Nora] Honved KorhazBudapest, Hungary.
   [Aranyi, Marietta] Honved KorhazBudapest, Hungary.
   [Papai, Zsuzsanna] Honved KorhazBudapest, Hungary.
RP Szabo, � (reprint author), Honved Korhaz, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 53
EP 53
PG 1
ER

PT J
AU Szabo, P
AF Szabo, Peter
TI Neurooncological examinations with FET PET-CT
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB The aim of the presentation is to present the PET-CT examinations performed with the radiopharmaceutical, 18F-fluoroethyl tyrosine (FET), which is considered a novelty in Hungary, for neurooncological purposes, and to present some interesting cases. PETCT studies started in Hungary more than 15 years ago, which for many years were performed exclusively with 18F-fluoro-deoxyglucose (FDG) as a radiopharmaceutical. As a glucose analog molecule, FDG is an excellent agent for detecting areas of high metabolic activity within the body, which in most cases are identical to lesions containing uncontrolled fast-dividing cells, i.e., malignancies and their metastases. Therefore, to date, FDG has become an indispensable tool in PET-CT in the staging of most cancers (primarily N and M staging). However, brain tumors cannot be examined with this procedure. The brain has an absolutely high glucose uptake, so it accumulates FDG intensively under physiological conditions, within which it is often not possible to isolate an area with a pathologically increased metabolism. Since 2019, the FET radiopharmaceutical has been available in Hungary, which is used as an amino acid analog for the examination of tumors in the brain with PET-CT. This radiopharmaceutical has a low level of so-called background activity, however, accumulates significantly in tissues with highly intense protein synthesis, which are also mostly tumors. This tracer can also be used to detect malignancies (primary, metastatic and eg lymphomas) in the brain with high sensitivity. For the time being, we are the only user in Hungary to have performed more than 200 FET PET-CT scans at the Budapest Center of ScanoMed Kft. In the last 2 years. The main indications for the studies were to isolate the benign-malignant lesion, to locate the biopsy, to plan for irradiation, to detect relapse, and to assess the therapeutic response. Based on feedback from neurooncologists, FET PET-CT has been shown to be an effective method for examining a wide range of tumors in the brain, in many cases supplementing or resolving an ambiguous image with MRI.
C1 [Szabo, Peter] Scanomed Kft., Budapesti PET-CT KozpontBudapest, Hungary.
RP Szabo, P (reprint author), Scanomed Kft., Budapesti PET-CT Kozpont, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 53
EP 54
PG 1
ER

PT J
AU Szekely, B
   Papp, E
   Somoracz-Kiss, D
   Hegyi, B
   Udvarhelyi, N
   Szentkereszty, M
   Toth, E
   Rubovszky, G
AF Szekely, Borbala
   Papp, Eszter
   Somoracz-Kiss, Dora
   Hegyi, Barbara
   Udvarhelyi, Nora
   Szentkereszty, Marton
   Toth, Erika
   Rubovszky, Gabor
TI Chest SMARCA4-deficient undifferentiated tumor - case report
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: To review the undifferentiated tumor of the breast SMARCA4-deficient and its latest treatment options through a case study. The occurrence of SMARCA4-deficient undifferentiated tumors in the thorax is very rare, characterized by specific genetic abnormalities of the BAF chromatin remodeling complex, resulting in a growing tumor and an aggressive clinical course of the disease. Patients are characterized by young age and a history of smoking. CASE STUDY: Our presented patient is 41 years old and has been examined for severe bone pain. Multiple bone involvement, significant amounts of pleural fluid and mediastinal volume and pleural soft tissue abnormalities dislocating both sides of the breast and esophagus were confirmed. A histological specimen from the breast identified infiltration of a poorly differentiated tumor with a high grade morphology that was diagnosed as a breast SMARCA4-deficient undifferentiated tumor based on tissue image and immunohistochemical phenotype. Following adjustment of thoracic hydration and analgesia, chemotherapy in the form of paclitaxel + carboplatin was initiated with an emergency indication, with a transient reduction in complaints as the best response. Based on literature data, these tumors generally respond well to immunoprotection inhibitors, but the predictive value for high TMB or PD-L1 positivity is still conflicting. An individual fairness request was submitted to initiate pembrolizumab treatment.
C1 [Szekely, Borbala] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Papp, Eszter] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Somoracz-Kiss, Dora] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Hegyi, Barbara] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Szentkereszty, Marton] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
RP Szekely, B (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Szekeres, T
   Vizin, G
   Virag, M
   Perczel-Forintos, D
AF Szekeres, Tamas
   Vizin, Gabriella
   Virag, Marta
   Perczel-Forintos, Dora
TI Complex, modern oncopsychological care
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Methods widely used in oncopsychological care include psychoeducation, preparation for surgery, individual and group forms of various relaxation methods, and support for relatives. Although cognitive behavioral therapy (CBT) is a short, time-limited, well-focused psychological intervention and toolkit that has been shown to be effective in improving the quality of life of cancer patients, the use of these methods in oncology care is still underrepresented in Hungary. It is of paramount importance that psychological interventions be performed using evidence-based methods in patients diagnosed with cancer, and that interventions should always be tailored to the patient's current condition. This is also highlighted in the NICE (The National Institute for Health and Care Excellence) oncopsychological guidelines, which state that cognitive behavioral therapy procedures have been shown to be effective in oncopsychological care. International protocols recommend the introduction of a tiered model of mental health assessment and assistance. The tiered care model describes the range of psychological skills and expertise that can be relied upon by people with cancer at different stages of the patient’s journey. It also includes the psychological skills covered by the different disciplines, as well as the competency limits of each professional, which also ensures that the patient can receive care targeted at specific complaints. During our presentation, we would like to briefly present the application proposals and possible areas of these interventions.
C1 [Szekeres, Tamas] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Vizin, Gabriella] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Virag, Marta] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Perczel-Forintos, Dora] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
RP Szekeres, T (reprint author), Semmelweis Egyetem, AOK, Klinikai Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 54
EP 54
PG 1
ER

PT J
AU Szigeti, A
   Kocsis, K
   Ambrus, A
   Szepesvary, Zs
   Kullmann, T
AF Szigeti, Andras
   Kocsis, Karoly
   Ambrus, Adel
   Szepesvary, Zsolt
   Kullmann, Tamas
TI Experience of a center using PSMA in the staging of PET-CT prostate tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The sensitivity and specificity of bone isotope and thoracic-abdominal CT scans traditionally used in the staging of prostate tumors fall short of clinical expectations. In 2020, the use of PSMA PET-CT in clinical diagnostics became available at our institution. MATERIAL AND METHOD: As part of the home self-assessment, we analyzed the results of patients who underwent PSMA PET-CT examination at our outpatient clinic until 31 December 2020. RESULTS: 24 patients were asked for PSMA PET-CT. The indication was primary staging in 7 patients, chemical relapse in 16 patients, and 1 patient was considered oligometastatic by conventional CT and bone isotope examinations. In the primary staging study, the lowest PSA associated with metastatic disease was 5 ng / ml and the highest PSA associated with organ-localized disease was 70 ng / ml. The study used for chemical relapse showed distant metastasis only for PSA values ​​above 1 ng / ml. The disease, which was considered oligometastatic by conventional staging studies, proved to be multimetastatic. The PSMA PET-CT result completely changed our treatment strategy in 7 cases compared to the choice imagined without the result of the study. DISCUSSION: The diagnostic value of PSMA PET-CT is considered clinically relevant in the staging of prostate tumors. Based on the results of our pilot study, definitive / salvage radiotherapy to the prostate bed and pelvic lymph regions below 1 ng / ml without imaging may be an acceptable strategy for chemical relapse following prostatectomy.
C1 [Szigeti, Andras] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Kocsis, Karoly] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Ambrus, Adel] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Szepesvary, Zsolt] Petz Aladar Hospital, Department of UrologyGyor, Hungary.
   [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
RP Szigeti, A (reprint author), Petz Aladar Hospital, Department of Oncoradiology, Gyor, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 54
EP 55
PG 1
ER

PT J
AU Sztankovics, D
   Krencz, I
   Danko, T
   Nagy, N
   Petovari, G
   Papay, J
   Khoor, A
   Sebestyen, A
AF Sztankovics, Daniel
   Krencz, Ildiko
   Danko, Titanilla
   Nagy, Noemi
   Petovari, Gabor
   Papay, Judit
   Khoor, Andras
   Sebestyen, Anna
TI Investigation of RICTOR amplification and mTOR inhibitor susceptibility in small cell lung carcinoma cell lines
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Small cell lung carcinomas (SCLC) are neuroendocrine tumors, accounting for 15-20% of newly diagnosed lung cancers. The disease is characterized by early dissemination and poor prognosis. In the vast majority of cases, therapeutic resistance develops during chemotherapy. Targeted therapeutic options are limited, but recently amplification of the RICTOR gene has been identified as the most common targeting genetic abnormality in SCLCs. The aim of our study was to determine the RICTOR amplification status and mTOR activity of human SCLC cell lines and to investigate the susceptibility of the characterized cell lines to cisplatin and various mTOR inhibitors. MATERIAL AND METHOD: RICTOR amplification status of SCLC cell lines was determined by fluorescent in situ hybridization and Droplet Digital PCR. The expression of mTOR signaling proteins was also examined by immunohistochemistry and Western blot. The susceptibility of cell lines to cisplatin and various mTOR inhibitors was determined using proliferation assays (Alamar Blue, sulforhodamine B). RESULTS: The presence of RICTOR amplification was identified in two SCLC cell lines. Expression of mTOR signaling proteins and mTOR activity correlated well with RICTOR amplification and other genetic abnormalities described in the cells examined. MTOR inhibitors significantly inhibited cell proliferation. In cell lines with RICTOR gene amplification or other genetic differences in the mTOR signaling pathway, mTORC1 and C2 kinase inhibitors have been shown to be most effective. DISCUSSION: In cisplatin-resistant SCLCs, mTOR inhibitors (primarily mTORC1 and C2 kinase inhibitors) may be an effective therapeutic option. MTOR inhibitors may increase the effectiveness of chemotherapeutic agents (eg cisplatin) in combination therapies. This may be of significant significance in the presence of RICTOR amplification and high mTOR and mTORC2 activity.
C1 [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Khoor, Andras] Mayo Clinic, Department of Laboratory Medicine and PathologyJacksonville, USA.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Sztankovics, D (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Todorov, JI
   Gombkoto, A
   Gecsene Biro, �
AF Todorov, Jozsef Illesne
   Gombkoto, Anna
   Gecsene Biro, Agnes
TI Covid-19 the way we lived
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Some of my colleagues and I worked in the Covid department at several locations. Through our own experiences, we want to show that we have lived for the past year and a half. Multiple redirections have put us all to the test, both physically and mentally. Meanwhile, our original workplace, our departments, also worked with superhuman force, as the supply did not stop, it only had to be solved with far fewer workers. Based on our experience, we compare work organization and preparedness in different Covid departments. Let’s tell you what we were afraid of, what caused tension, how we faced the unknown and struggled with the awareness that we could get infected at any time and take it home to our loved ones. We feared each other and the patients as well. Our lives will never be the same before Covid, we have to be constantly on the lookout. Despite the difficulties, we loved working in the Covid department. We parted on the last day when it was needed again, in the same place, together as a team, we face the ordeals again. Why is that? Because that's our business. We met great people, professionals, we worked well together as a team, as everyone was fighting for the same. It worked even though we weren’t a familiar team, we didn’t know each other and the place, yet everyone knew it.
C1 [Todorov, Jozsef Illesne] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Gombkoto, Anna] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Gecsene Biro, Agnes] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
RP Todorov, JI (reprint author), Semmelweis University, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Torday, L
   Csenki-Lalia, M
   Pepo, J
   Nagy-Laszlo, R
   Toth, D
   Vasas, B
   Sukosd, F
   Tiszlavicz, L
   Toth, LB
   Olah, J
AF Torday, Laszlo
   Csenki-Lalia, Melinda
   Pepo, Judit
   Nagy-Laszlo, Roland
   Toth, David
   Vasas, Bela
   Sukosd, Farkas
   Tiszlavicz, Laszlo
   Toth, Lajos Barna
   Olah, Judit
TI Our first experience with pembrolizumab in patients with MSI-H / dMMR irresectable colon carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Based on recent studies, the standard first- and multi-line therapy for MSI-H / dMMR irresectable colorectal tumors (uCRC) has been the PD-1 inhibitor pembrolizumab (pembro). The drug is also available in Hungary, we report on our first experiences gained under real treatment conditions. MATERIALS AND METHODS: Retrospective processing of treatment data from patients with MSI-H / dMMR uCRC who received pembrane at the Oncotherapy Clinic of the University of Szeged was performed. RESULTS: 5 patients (MSI-H / dMMR uCRC) treated with pembrane (February 21, 2019 - July 14, 2021) (median age: 68.4 years) were found. In 3 cases the primary tumor was located in the coecum and in 2 cases in the ascending colon, in 4 cases with T4b and in 3 cases with ≥N1 stage. All tumors were RAS wild and one was BRAF mutant. The dMMR status was confirmed by immunohistochemistry in all cases, MLH1 / PMS2 in 3 cases, and MLH1- and PMS2 in 1-1 cases. PMS2 deficiency was confirmed. 2 patients received prophylactic adjuvant therapy and all patients received prophylactic first-line (1L) therapy. The best tumor response with 1L treatment was progression in 2 cases and stable disease in 3 cases. Of the latter, 2 had already progressed according to the second staging study, and in one case they had switched to pembrane. At the start of pembro, 4 patients were metastatic and 1 case showed local spread. A total of 72 cycles of pembro were administered (per patient: 38, 18, 6, 6, 4). Toxicity was Gr I diarrhea in two patients and Gr I weakness in one patient. There was no cycle delay, no steroid use. Treatments were initiated in two patients who had fallen due to rapid progression and in two patients with severe tumor complaints. In two patients, all tumor-induced symptoms resolved after the 2nd, one in the 3rd, and one in the 7th pembrocycle. The tumor responses achieved are known in 2 patients. In one of them, the extremely enlarged paraaortic and left inguinal lymph nodes almost completely disappeared, and the lymphatic circulation in the lower extremities was restored. In the other, the locally advanced process had already destroyed the bladder, uterus, vaginal vault, and rectum prior to treatment. In the absence of metastasis, pelvic exenteration was performed after treatment 18 to improve quality of life. Pathological processing confirmed pCR, so the patient's treatment was terminated. DISCUSSION: Our initial experience has shown that pembrolizumab has promising activity in the treatment of patients with MSI-H / dMMR uCRC.
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki-Lalia, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Toth, David] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vasas, Bela] University of Szeged, Department of PathologySzeged, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Toth, Lajos Barna] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Altalanos SebeszetNyiregyhaza, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 55
EP 55
PG 1
ER

PT J
AU Torday, L
   Tigyi, D
   Nagy-Laszlo, R
   Toth, D
   Uhercsak, G
   Pepo, J
   Maraz, A
   Santha, D
   Csenki, M
   Dobi, �
   Valicsek, E
   Szilagyi, �
   Vasas, B
   Erdos, M
   Paszt, A
   Szepes, Z
   Tiszlavicz, L
   Lazar, Gy
   Olah, J
AF Torday, Laszlo
   Tigyi, Dora
   Nagy-Laszlo, Roland
   Toth, David
   Uhercsak, Gabriella
   Pepo, Judit
   Maraz, Aniko
   Santha, Dora
   Csenki, Melinda
   Dobi, Agnes
   Valicsek, Erzsebet
   Szilagyi, Eva
   Vasas, Bela
   Erdos, Marton
   Paszt, Attila
   Szepes, Zoltan
   Tiszlavicz, Laszlo
   Lazar, Gyorgy
   Olah, Judit
TI Perioperative FLOT in the treatment of resectable gastric / GEJ tumors: results of real clinical practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The first step in standard therapy for resectable gastric / GEJ carcinomas (rGC / GEJC) is perioperative FLOT treatment, however, additional data are required for proper evaluation under real treatment conditions. MATERIAL AND METHOD: Data from a retrospective observational study of patients with rGC / GEJC treated with perioperative FLOT at the Oncotherapy Clinic of the University of Szeged are reported. RESULTS: 46 patients with rGC / GEJC treated with FLOT (December 20, 2017 - January 17, 2017) were found (median age: 65.5 years). 87% were ECOG 0. 33% were GEJC and 67% GC. Based on pre-treatment CT and EUS studies, 68% (30/46) of tumors were ≥cT3 and 61% (28/46) were ≥cN1. A preop. 86% of patients completed the treatment phase. Treatment was discontinued due to toxicity (2 out of 3 cases in cardiac) and deterioration in general condition (2 cases). 8.7% of the preop. after phase, progression was confirmed. 76% of cases underwent surgery with a 100% resection rate, of which 89% were R0 and 74% were D2 resections. 46% of patients were postoperative. treatment, but for tolerability reasons only 33% completed it. Peripheral neuropathy (33%), diarrhea (28%), nausea (22%) and fatigue (22%) were the most common toxicities. Neutropenia was observed in 2%. Cardiac events were identified as a new signal of toxicity. A preop. post-phase imaging showed a 7.1%, 9.5% and 18.6% improvement in dowstaging for T, N and TNM, 4.7%, 4.7% and 16.2% upstaging, and no change was observed in 88%, 85.7% and 65.1% of cases. Pathological processing of surgical preparations for pathological stages T, N and TNM indicated a pathological reduction in the pathological stage (downstaging) in 38.8%, 53.3% and 34.2%, respectively. % and 21% upstaging, and no change in 33.3%, 23.3% and 44.7% of cases. Based on tumor regression grades (Mandard-score), 96% of tumors showed pathological regression and 30% showed a major tumor response. DISCUSSION: Regarding the course of treatments, toxicity (excluding cardiac events) and results, our data are consistent with the literature, preop. phase with a high rate of induced pathological T, N and TNM stage reduction. However, the differences observed in the stage changes detected by pathological and imaging studies question the usefulness of imaging in preop. in the evaluation of post-phase T and N stages.
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Tigyi, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Toth, David] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vasas, Bela] University of Szeged, Department of PathologySzeged, Hungary.
   [Erdos, Marton] University of Szeged, Department of SurgerySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Szepes, Zoltan] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Torday, L
   Varga, E
   Nagy-Laszlo, R
   Toth, D
   Uhercsak, G
   Pepo, J
   Maraz, A
   Santha, D
   Csenki, M
   Nikolenyi, A
   Dobi, �
   Valicsek, E
   Szilagyi, �
   Farkas, Gy
   Vasas, B
   Szepes, Z
   Tiszlavicz, L
   Lazar, Gy
   Olah, J
AF Torday, Laszlo
   Varga, Eszter
   Nagy-Laszlo, Roland
   Toth, David
   Uhercsak, Gabriella
   Pepo, Judit
   Maraz, Aniko
   Santha, Dora
   Csenki, Melinda
   Nikolenyi, Aliz
   Dobi, Agnes
   Valicsek, Erzsebet
   Szilagyi, Eva
   Farkas, Gyula
   Vasas, Bela
   Szepes, Zoltan
   Tiszlavicz, Laszlo
   Lazar, Gyorgy
   Olah, Judit
TI MFOLFIRINOX in the treatment of pancreatic carcinoma: results of real clinical practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: FOLFIRINOX is an accepted chemotherapy for pancreatic carcinoma (PC), but additional data are required to evaluate it under real treatment conditions. MATERIAL AND METHOD: Data from a retrospective observational study of PC patients treated with mFOLFIRINOX at the Oncotherapy Clinic of the University of Szeged are provided. RESULTS: We found 98 mFOLFIRINOX-treated (01/06/2015 - 12/12/2020) PC patients with a median age of 63 years. The disease was M1 in 49%, locally advanced in 45.9%, and already resected in 5.1%. 45.9% had stent implantation. CA19-9 levels were elevated to 68.3% (median 254 U / ml) and 25.5% above 1000 U / ml. Dose reduction was due to the onset of toxicity in 35.7% at baseline and in 24.5%. The most common toxicities were diarrhea (37.8%), nausea (25.5%), vomiting (22.4%), and peripheral neuropathy (22.4%). Neutropenia was observed in 7.1% and thrombocytopenia in 4%. In 5.1%, treatment was initiated with an adjuvant, in 30.6% with a conversion, and in 64.2% with a palliative purpose. 70% of the patients receiving conversion treatment underwent surgery, with 36.6% having a successful resection (R0: 100%). In R0 cases, the median time to treatment (ToT) was 183 days. Of the palliative treatments, 76.1% were first-line, 22.2% were second-line, and 1.5% were third-line, and 17.4% of patients received only one cycle of treatment. ToT (211 days) was longer for palliative conversion treatments (n = 17) than for first-line treatments (72 days) or second-line treatments (55 days) (HR1: 0.4572, HR2: 0.4213, p = 0.0152). In M0 (n = 31), ToT was significantly longer than in M1 (n = 37) (191 vs. 96 days, HR: 0.4933, p = 0.003). M0 patients showed better ToT compared to patients with “liver metastases only” (n = 14) (191 vs. 56 days, HR: 0.3609, p = 0.0077), with no difference in ToT in the presence of extrahepatic involvement. significant. ToT differences were also found between the groups of patients without liver metastases (n = 27) and those with (n = 41) patients (181 vs. 93 days, HR: 0.4790, p = 0.0024). Neither the initial CA19-9 levels (limit values ​​at 200 and 1000 U / ml, respectively) nor age (limit values ​​at 65, 70, and 75 years) significantly affected the ToT values ​​in the resulting patient groups. DISCUSSION: With appropriate patient selection, mFOLFIRINOX is an effective treatment standard for “borderline” resectable and nonresectable PCs with a well-tolerated toxicity profile under appropriate management.
C1 [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Varga, Eszter] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Toth, David] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nikolenyi, Aliz] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Valicsek, Erzsebet] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Szilagyi, Eva] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Farkas, Gyula] University of Szeged, Department of SurgerySzeged, Hungary.
   [Vasas, Bela] University of Szeged, Department of PathologySzeged, Hungary.
   [Szepes, Zoltan] University of Szeged, 1st Department of MedicineSzeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Torday, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 57
EP 57
PG 1
ER

PT J
AU Toth, E
   Kohanka, A
   Rubovszkyne Gallai, M
   Fulop, L
   Csernak, E
AF Toth, Erika
   Kohanka, Andrea
   Rubovszkyne Gallai, Monika
   Fulop, Laszlo
   Csernak, Erzsebet
TI First experience with NGS-based multigenic examination of lung adenocarcinomas in the laboratory of the Department of Surgery and Molecular Pathology of the National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Due to the ever-increasing number of targeted therapeutic options in the treatment of tumors, NGS-based multigenic studies are gaining prominence in more and more tumor types in molecular pathology diagnostics. Among solid tumors, lung adenocarcinomas currently have the most options, so in these cases, international guidelines now basically recommend multigenic studies. Since 2020, we have been conducting a multigenic study for lung adenocarcinomas in our institute. We present our experience and results in the presentation. MATERIAL AND METHOD: The molecular profile of 274 lung adenocarcinoma tumor samples was analyzed. The most common mutations in tumors were examined on the ION S5plus next-generation sequencer running on the IonTorrent platform. The tests were run with the Oncomine Focus Assay kit, which allows analysis of 52 genes. The application allows the detection of SNVs (single nucleotide variation), Indels (insertions, deletions), CNVs (copy number variation), fusion genes and splice site variants for RNA. Mutations were identified from the sequence data using the Torrent Variant Caller algorithm running on Ion Reporter software. The results were evaluated with Ion Reporter software, on which various statistical analyzes were performed. RESULTS: In 83 of the 274 cases, no differences were identified with the 52 gene panels used. In 112 cases, mutations significant for targeted therapy were identified in 41% of cases (EGFR - 24 cases, BRAF - 4 cases, MET - 6 cases, KRAS - 54 cases, 26 cases G12C) or fusion (ALK - 6 cases, ROS1 - 2 cases, RET - 5 cases, MET exon 14 skipping - 11 cases). Other mutations not currently clinically relevant were found in 79 cases. Smoking status was known in 71 cases, of which 46 patients were smokers. DISCUSSION: In the case of lung adenocarcinomas, the number of patients eligible for targeted therapy is also significantly increased by targeted smaller gene panel studies. These panels also provide an opportunity for multigenic examination of usually small biopsies or cytological smears where samples with low DNA and RNA concentrations are available due to the relatively low tumor cell ratio.
C1 [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Kohanka, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Rubovszkyne Gallai, Monika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Fulop, Laszlo] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 57
EP 58
PG 1
ER

PT J
AU Ujhelyi, M
   Jozsef, Zs
   Ping, O
   Domjan, Sz
   Fulop, R
   Ivady, G
   Tisler, R
   Rubovszky, G
   Meszaros, N
   Kenessey, I
   Matrai, Z
AF Ujhelyi, Mihaly
   Jozsef, Zsofia
   Ping, Orsolya
   Domjan, Szilard
   Fulop, Rita
   Ivady, Gabriella
   Tisler, Rahel
   Rubovszky, Gabor
   Meszaros, Norbert
   Kenessey, Istvan
   Matrai, Zoltan
TI Analysis of dynamic changes in surgeries with or without internal Ultrapro mesh fixation for implant-based breast reconstruction and contralateral breast symmetrization
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The cosmetic results of the bilateral breasts obtained by immediate post-mastectomy reconstruction techniques and the applied symmetrization surgeries and the associated patient satisfaction have been extensively studied in the international literature, at least in the early postoperative. However, the long-term results of the hugely popular and widespread state-of-the-art mastectomies, immediate reconstructions and symmetrization interventions, and related patient satisfaction indicators have so far become little or no focus in clinical trials, so the available scientific data are severely limited. The 10-year overall survival of patients with early breast cancer is 84%, and consequently, breast reconstruction should provide long-term symmetry and acceptable patient satisfaction. The study hypothesized that the results of modern postmastectomy-based implant-based breast reconstruction and symmetrization surgeries would decrease significantly over time and later result in limited patient satisfaction. MATERIAL AND METHOD: In the present, one-center comparative study, symmetrization breast suturing was performed with internal ULTRAPRO mesh fixation (MG) and non-mesh group (NMG), which is a long-term clinical, patient satisfaction, and aesthetic comparison. the results are presented. RESULTS: Data from 59 patients in the MG group and 58 patients in the NMG group were analyzed. There was no significant difference (p = 0.521; chi-square) between the two groups in terms of complications. At the end of the study, the median difference between the jugulum and the nipple was 1 cm in the MG group and 3.5 cm in the NMG group. The median distance between the nipple and the lower fold fold was 0.5 cm and 0.75 cm. Net implantation did not interfere with either oncology follow-up or imaging studies. Based on the BREAST.Q patient satisfaction questionnaire, we found significant differences in breast-related satisfaction (p = 0.0004), physical (p = 0.012), and sexual (p = 0.047) well-being. DISCUSSION: Symmetrization supplemented with ULTRAPRO mesh has been effective in reducing the development of ptosis and pseudoptosis, providing a safe alternative for maintaining long-term symmetry and patient satisfaction.
C1 [Ujhelyi, Mihaly] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Jozsef, Zsofia] Szent Imre Egyetemi Oktatokorhaz, Plasztikai Sebeszeti ProfilBudapest, Hungary.
   [Ping, Orsolya] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Domjan, Szilard] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
   [Fulop, Rita] National Institute of Oncology, Center of RadiologyBudapest, Hungary.
   [Ivady, Gabriella] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Tisler, Rahel] Semmelweis University, Faculty of MedicineBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Meszaros, Norbert] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Kenessey, Istvan] National Institute of Oncology, National Cancer RegistryBudapest, Hungary.
   [Matrai, Zoltan] Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti OsztalyBudapest, Hungary.
RP Ujhelyi, M (reprint author), Orszagos Onkologiai Intezet, Emlo- es Lagyreszsebeszeti Osztaly, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Vajda, F
   Nemet, K
   Erdei, Zs
   Furedi, A
   Szakacs, G
AF Vajda, Flora
   Nemet, Katalin
   Erdei, Zsuzsa
   Furedi, Andras
   Szakacs, Gergely
TI The role of tumor microenvironment cells in chemotherapy resistance
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Successful treatment of malignancies remains one of the major challenges in clinical oncology. The response of tumors to chemotherapy is often only transient due to the development of drug resistance. Tumor microenvironment (TME) plays a key role in tumor progression, metastasis, and activation of various resistance mechanisms. In addition to tumor cells, TME consists of immune cells, vascular endothelial cells, and extracellular matrix, among others; one of the most abundant cell types in this complex network of cellular and non-cellular elements is the mesenchymal stem cell (MSC). MSCs are multipotent cells that are able to differentiate into osteoblast, adipocyte, and chondrocyte and migrate into the tumor microenvironment. MSCs can affect the local immune response, support angiogenesis, and induce drug resistance. Despite our growing knowledge of TME, little is known about the sensitivity of MSCs to chemotherapy. MATERIALS AND METHODS: The effects of a group of clinically used antitumor agents (bendamustine, cisplatin, methotrexate, irinotecan, doxorubicin, mitoxantrone, vinblastine, temozolomide, TPEN, nutlin-3) were investigated in several MSC cell lines isolated from patients. The sensitivity of the cells to the compounds was compared to that of known tumor cell lines. RESULTS: A group of drugs tested has been shown to be significantly more effective on tumor cells, according to the position adopted today, but surprisingly, some compounds have killed both cell types to the same extent. Given that the rate of division of MSCs is significantly lower compared to tumor cells, our results call into question views on chemotherapy treatments. We have shown that MSCs are not killed by apoptosis against tumor cells, in which apoptotic pathways are presumably better regulated, or are killed by some other mechanism. DISCUSSION: Our results thus call into question the widely accepted position of the MSC on drug resistance. Our goal is to optimize therapeutic protocols by combining drugs that target both cancer and stromal cells.
C1 [Vajda, Flora] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Nemet, Katalin] Creative Cell Kft.Budapest, Hungary.
   [Erdei, Zsuzsa] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Furedi, Andras] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Szakacs, Gergely] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
RP Vajda, F (reprint author), Eotvos Lorand Kutatasi Halozat, Enzimologiai Intezet, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 58
EP 58
PG 1
ER

PT J
AU Varga, �
   Kovacs, SzA
   Gyorffy, B
AF Varga, Agnes
   Kovacs, Szonja Anna
   Gyorffy, Balazs
TI Founding of Semmelweis Onkobank: a collection of oncological tissue samples
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB With the establishment of Semmelweis Onkobank, we aimed to collect and store biological samples (tumor, normal tissue, blood) of patients with malignant neoplasms treated in outpatient and inpatient departments of Semmelweis University clinics, as well as long-term follow-up of clinical data. By analyzing the data obtained from the genomic, transcriptomic, and proteomic analysis of the samples, mutational, gene expression, and protein expression profiles associated with tumor formation can be established to identify diagnostic, predictive, and prognostic biomarkers. Once patients have been properly informed and consent has been signed, tissue sampling will always be performed for tumor removal only, and Semmelweis Onkobank will receive these samples in formalinfixed, paraffin-embedded (FFPE) or cryopreserved form. Plasma, serum and buffy coat can be separated from blood samples. DNA, RNA and protein are isolated from the samples received by Onkobank, which are used in subsequent genomic, transcriptomic and proteomic studies. Samples may be stored at room temperature, 4 ° C, −20 ° C, −80 ° C or −196 ° C, depending on their stability, sensitivity and shelf life. Collected personal and health data, sample data, and data from studies performed in a research laboratory are recorded in an online REDCap (Research Electronic Data Capture) database specifically designed for long-term, secure clinical data collection. The appropriate infrastructure and personal conditions are provided by Semmelweis Onkobank: vapor phase liquid nitrogen storage, ultra-deep freezer at −80 ° C, barcode scanner, centrifuges, etc. The biological samples of the patients are provided to us by the authorized doctors and section assistants of the partner institutions. 13 Hungarian and one German institution participates in the activities of Semmelweis Onkobank. By obtaining a research license and setting up the infrastructure, Semmelweis Onkobank is ready to operate a new-generation oncology unit that uniquely processes and stores blood and tissue samples and data from individuals with malignant neoplasms.
C1 [Varga, Agnes] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Kovacs, Szonja Anna] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Varga, � (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 58
EP 59
PG 1
ER

PT J
AU Varga, L
   Burian, H
   Posfai, B
   Olah, J
   Maraz, A
AF Varga, Linda
   Burian, Hanna
   Posfai, Boglarka
   Olah, Judit
   Maraz, Aniko
TI Our initial results with enzalutamide treatment of high-risk, non-metastatic, castration-resistant prostate cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Radiation therapy, radical prostatectomy and androgen deprivation therapy may be used to treat localized prostate carcinoma. Subsequent biological progression to castration testosterone levels is expected to result in metastases in non-metastatic disease at high risk within two years. A novel option is the introduction of androgen receptor blocker therapy, which prolongs patients' metastasis-free survival. Our aim was to evaluate our early experience with enzalutamide therapy in high-risk, non-metastatic, castration-resistant prostate carcinoma, to analyze the PSA response and side effects. MATERIALS AND METHODS: Patients with high-risk, non-metastatic, castration-resistant prostate carcinoma who received enzalutamide therapy at the Clinic of Oncotherapy of the University of Szeged in the field of androgen therapy were included in our study. The dose of enzalutamide treatment was 160 mg daily. PSA, laboratory, and physical examinations were performed every three months during therapy. Conventional imaging was performed first after three months and then every six months thereafter. RESULTS: Treatment is ongoing in 9 patients (81.8%) and therapy has been temporarily discontinued in two patients (18.2%). Patients ranged in age from 69 to 88 years and had a median Gleason score of 8 (± 1.38). Previously, radical prostatectomy was performed in 3 patients (18.2%), while all patients underwent radiotherapy. At enrollment, the median PSA doubling time (± SD) was 4.4 (± 2.22) months and the median baseline PSA (± SD) was 6.35 (± 3.37) ng / ml. In 9 cases (81.8%), a reduction in PSA levels of more than 50% was detected during treatment. The last median PSA measured (± SD) was 0.36 (± 1.95) ng / ml. Radiological progression was not confirmed during the still relatively short follow-up. As a side effect, fatigue occurred in 4 patients (36.4%) and cardiovascular toxicity in 2 cases (18.2%). DISCUSSION: Based on our study, treatment with enzalutamide in patients at high risk for non-metastatic, castration-resistant prostate cancer results in a favorable PSA response and is a potentially effective therapeutic option. We plan to follow our patients for a longer period of time and confirm the results with a larger number of patients.
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Burian, Hanna] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Posfai, Boglarka] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Varga, L
   Maraz, A
   Hideghety, K
   Borzasi, E
   Csenki, M
   Cserhati, A
   Dobi, �
   Egyud, Zs
   Gaal, Sz
   Kelemen, Gy
   Koszo, R
   Nagy-Laszlo, R
   Paczona, V
   Pepo, J
   Santha, D
   Uhercsak, G
   Vegvary, Z
   Vasas, B
   Berenyi, Zs
   Lazar, Gy
   Abraham, Sz
   Paszt, A
   Simonka, Zs
   Olah, J
   Torday, L
AF Varga, Linda
   Maraz, Aniko
   Hideghety, Katalin
   Borzasi, Emoke
   Csenki, Melinda
   Cserhati, Adrienn
   Dobi, Agnes
   Egyud, Zsofia
   Gaal, Szilvia
   Kelemen, Gyongyi
   Koszo, Renata
   Nagy-Laszlo, Roland
   Paczona, Viktor
   Pepo, Judit
   Santha, Dora
   Uhercsak, Gabriella
   Vegvary, Zoltan
   Vasas, Bela
   Berenyi, Zsolt
   Lazar, Gyorgy
   Abraham, Szabolcs
   Paszt, Attila
   Simonka, Zsolt
   Olah, Judit
   Torday, Laszlo
TI Our initial experience with total neoadjuvant therapy (TNT) in patients with locally advanced, high-risk rectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: A new direction in the preoperative oncology treatment of locally advanced rectal tumors (LARCs) is the so-called total neoadjuvant (NA) therapy (TNT), which is the sequential combination of radiotherapy (RT) or chemo-radiotherapy (KRT) and chemotherapy (CT). The exact order, dosing and timing of the treatment elements are not fully understood, therefore TNT is not yet considered a clear new standard. Our aim was to evaluate our early experience with TNT in the preoperative oncology treatment of high-risk LARC. MATERIAL AND METHOD: At the Oncotherapy Clinic of the University of Szeged, January 1, 20, 2020. Data from 36 patients with histologically verified rectal adenocarcinoma were analyzed and NA treatment was performed. Selection criteria included the exclusion of distant metastasis from thoracic abdominal CT and the diagnosis of potentially resectable LARC with at least one risk factor (cT4 a-b, cN2, EMVI +, CRM +) as determined by rectal MR. All patients received NA short-term RT or long-term KRT as well as oxaliplatin-based CT scheduled for 3 months prior to surgery, based on an oncote decision. RESULTS: 36 patients (72% male, 28% female) were included in our study. Their mean age was 60 (28–78, SD ± 13) years. Based on rectal MR, stage ≥T3 was described in all cases, lymph node positivity in 25 patients, MRF involvement in 20 patients, and EMVI in 7 patients. Prior to oncology treatment, 10 patients required passage safety surgery for critical lumen narrowing. TNT was started in RT in 26 patients and in KT in 10 patients. The RTs were 50-50% short-term RTs and long-term KRTs, which could be completed except for 1 case. During RTs, adverse reactions were reported in 21 (58%) patients, most commonly grade 1/2 radioproctitis, dermatitis, and rectal pain. KT was FOLFOX-4 in one case and CAPOX in 35 cases. The most common side effects of CTs were peripheral neuropathy, hand-foot syndrome, and nausea. Postoperative TNT surgery was performed in 24 patients by the end of data collection, successful definitive surgery in 22 cases, and only exploration in 2 cases due to irresectable tumor. Pathological results and surgical complications will be reported in our presentation. DISCUSSION: Based on our results, TNT can be performed safely and successfully in everyday clinical practice without compromising surgical care. Based on the increasing number of high-evidence studies, TNT may become the standard treatment for high-risk LARC in the future.
C1 [Varga, Linda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Hideghety, Katalin] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Borzasi, Emoke] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Csenki, Melinda] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Cserhati, Adrienn] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dobi, Agnes] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Egyud, Zsofia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Gaal, Szilvia] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Kelemen, Gyongyi] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Koszo, Renata] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Nagy-Laszlo, Roland] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Paczona, Viktor] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Pepo, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Santha, Dora] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Uhercsak, Gabriella] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vegvary, Zoltan] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Vasas, Bela] University of Szeged, Department of PathologySzeged, Hungary.
   [Berenyi, Zsolt] University of Szeged, Department of RadiologySzeged, Hungary.
   [Lazar, Gyorgy] University of Szeged, Department of SurgerySzeged, Hungary.
   [Abraham, Szabolcs] University of Szeged, Department of SurgerySzeged, Hungary.
   [Paszt, Attila] University of Szeged, Department of SurgerySzeged, Hungary.
   [Simonka, Zsolt] University of Szeged, Department of SurgerySzeged, Hungary.
   [Olah, Judit] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Varga, L (reprint author), University of Szeged, Department of Oncotherapy, Szeged, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 59
EP 59
PG 1
ER

PT J
AU Vas, N
   Gyorffy, B
AF Vas, Nikoletta
   Gyorffy, Balazs
TI Predicting individual survival and therapeutic responsiveness using artificial intelligence algorithms in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Individual prediction of the expected benefits of systemic cytotoxic therapy may be a tool to support therapeutic decision-making, however, a study to support the selection of personalized therapy for all patients is not currently available. Our goal is to create a validated model that predicts individual survival and therapeutic responsiveness and is widely applicable in clinical practice. MATERIALS AND METHODS: Data from various international registries (TCGA - The Cancer Genome Atlas, Pan-Cancer Clinical Data Resource, SEER - Surveillance, Epidemiology, and End Results Program), published in a large number of clinical studies (METABRIC, IMPACT) and recorded data set was used. The distribution pattern of clinical parameters was examined by k-means cluster analysis and optimized for survival of adjuvant chemotherapy. Individual survival prediction is performed using a model based on multi-task logistic regression taught in the most clinically similar cases to the case under study. Similar cases are selected using the machine learning SVM classifier. Group-level survival analysis was performed using the Kaplan-Meier method, and significance was calculated using a log-rank test. The discriminative ability of the individual survival prediction model was validated by calculating the C-index and its calibration by 1-calibration, in the latter case the significance was calculated by the Hosmer − Lemeshow test. RESULTS: Clinical data from 354,172 breast cancer cases were pooled and used in the cluster analysis across the entire database. All follow-up and therapeutic data required for survival analysis were available in 51,206 cases. Twelve groups with characteristic outcomes and therapeutic responses were identified. New cases are classified into one of these with an accuracy of at least 97.73%. The C-index values ​​are 0.7688 and 0.7570 for five- and ten-year overall survival, respectively. The model is well calibrated for 2–6 years from diagnosis based on the calculated p-values, and overestimates 5-year overall survival by 1.81%. Based on the results of our validation studies, the performance of the model is even in the subgroups for which the accuracy of the currently available bioinformatics predictions is unreliable. DISCUSSION: The model we created can be used to predict the expected survival of breast cancer patients. Based on the prediction made for the different therapeutic options, the expected benefits of the treatments can be deduced.
C1 [Vas, Nikoletta] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika TanszekBudapest, Hungary.
RP Vas, N (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Vattay, D
   Balatoni, T
   Panczel, G
   Czirbesz, K
   Baranyai, F
   Kispal, MT
   Danyi, T
   Kende, HR
   Kertai, P
   Liszkay, G
AF Vattay, Dorottya
   Balatoni, Timea
   Panczel, Gitta
   Czirbesz, Kata
   Baranyai, Fanni
   Kispal, Mihaly Tamas
   Danyi, Timea
   Kende, Hanna Rebeka
   Kertai, Petra
   Liszkay, Gabriella
TI Cemiplimab treatment in metastatic and locally advanced cutaneous squamous cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The inhibitor PD-1 (programmed cell death protein-1) cemiplimab has recently become available in Hungary as a systemic therapy for metastatic and locally advanced cutaneous squamous cell carcinoma. In our case report, we summarize our clinical experience with 7 patients diagnosed with advanced cutaneous squamous cell carcinoma receiving cemiplimab therapy in our department between October 2019 and June 2021. CASE DESCRIPTION: 71.4% of the patients studied were male, with a mean age of 69.7 years. Our patients received therapy in 3-week cycles at a fixed dose of 350 mg. They received an average of 4 (1-8) cycles of cemiplimab immunotherapy. The median follow-up was 5.1 (0.4–10.2) months. We evaluated the side effects during the therapy and the effectiveness of the therapy. Adverse reactions were evaluated according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). One case of grade 2 thyroiditis and grade 1 dermatitis developed during the treatments. No serious (grade 3-4) side effects were observed. Regarding the therapeutic response, partial remission was observed in 2 (28.6%) patients as early as week 12, and in 2 (28.6%) patients the previous staging examinations confirmed stationary status. Due to significant progression, 1 patient (14.3%) was discontinued at week 13. Treatment was discontinued in 2 (28.6%) patients due to poor general condition or worsening of comorbidities. DISCUSSION: The therapy was well tolerated by our treated patients. Our experience to date suggests that cemiplimab immunotherapy may be more effective than chemotherapy and may represent an advance in the treatment of advanced cutaneous squamous cell carcinoma.
C1 [Vattay, Dorottya] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Czirbesz, Kata] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kispal, Mihaly Tamas] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Danyi, Timea] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kende, Hanna Rebeka] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Kertai, Petra] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Vattay, D (reprint author), National Institute of Oncology, Department of Dermatology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Venczel, L
   Maraz, R
   Albert, E
   Cserni, G
   Sikorszki, L
AF Venczel, Laszlo
   Maraz, Robert
   Albert, Emoke
   Cserni, Gabor
   Sikorszki, Laszlo
TI Role of indocyan green fluorescence in sentinel lymph node biopsy for breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The most common method of sentinel lymph node biopsy for breast cancer is radioisotope and blue dye double labeling. In recent years, a number of newer labeling methods have appeared, most of which the authors recommend the indocyan green fluorescence method. Based on the data in the literature, the hit ratio of indocyan green fluorescence can be compared with the radioisotope method. MATERIALS AND METHODS: In our department, we used indocyan green fluorescence to visit the sentinel lymph node, as part of a triple label, in addition to radioisotope and blue dye, in 79 of our patients who underwent breast cancer between 06/05/2020 and 13/07/2021. RESULTS: A total of 135 sentinel lymph nodes were identified and removed from our 79 operated patients. 114 sentinel lymph nodes stained well with indocyan green (hit rate: 0.84; 95% confidence interval: 0.77-0.90), 77 stained with blue (hit rate: 0.57; 95% confidence interval: 0.49-0) , 65), while 131 sentinel lymph nodes were radiolabeled (hit rate: 0.97; 95% confidence interval: 0.93–0.99). DISCUSSION: Based on our experience with the method, we can say that indocyan green fluorescence can be used as a supplement to other labeling methods, it greatly helps to visit the sentinel lymph node. Based on literature data, the method increases the hit rate of sentinel lymph node identification and can be used as part of a double or triple labeling method.
C1 [Venczel, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Maraz, Robert] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Albert, Emoke] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Cserni, Gabor] Bacs-Kiskun County HospitalKecskemet, Hungary.
   [Sikorszki, Laszlo] Bacs-Kiskun County HospitalKecskemet, Hungary.
RP Venczel, L (reprint author), Bacs-Kiskun County Hospital, Kecskemet, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 61
EP 61
PG 1
ER

PT J
AU Vetlenyi, E
   Krencz, I
   Moldvai, D
   Danko, T
   Sztankovics, D
   Petovari, G
   Sebestyen, E
   Papay, J
   Vegso, Gy
   Sebestyen, A
AF Vetlenyi, Eniko
   Krencz, Ildiko
   Moldvai, Dorottya
   Danko, Titanilla
   Sztankovics, Daniel
   Petovari, Gabor
   Sebestyen, Endre
   Papay, Judit
   Vegso, Gyula
   Sebestyen, Anna
TI Investigation of clear cell and papillary kidney tumors in vitro / in vivo in tumor models and human samples
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Kidney tumors account for 3-5% of adult malignancies. The most common are clear cell and papillary kidney tumors, the former accounting for 80% of diagnosed kidney tumors and the latter for 15%, and tumors with very poor prognosis for late detection. A better understanding of the rearrangement of metabolic pathways and the energy use of the tumor may help in the discovery of new therapeutic targets. Studies to date have focused primarily on the metabolic characteristics of clear cell renal tumors. Our aim is to characterize and compare the metabolic changes of clear cell and papillary kidney tumors and to identify possible metabolic therapeutic targets. MATERIAL AND METHOD: The main markers of different metabolic pathways (mTOR, glycolysis, alternative metabolic pathways) (p-S6, GLUT1, GLS, etc.) were examined in human biopsy specimens by evaluating immunohistochemical staining and the results were compared from the mRNA database (The Cancer Genome Atlas). also by statistical analysis of the data collected. In our in vitro experiments, we examined the metabolic characteristics of human normal renal proximal tubular epithelial (HK2) and human clear cell (786-O, A498) and papillary (ACHN) renal tumor cell lines, as well as their sensitivity to mTOR and metabolic inhibitors (WES Simple, LC-MS , in vitro proliferation tests). RESULTS: Increased expression of glycolytic and mTORC1 markers was observed in clear cell kidney tumors, while the amount of enzymes of alternative metabolic pathways, glutaminolysis, and acetate utilization was increased in papillary kidney tumors. Increased mTOR activity and metabolic enzyme expression in renal tumor cell lines were observed compared to the “normal” tubular epithelial cell line, and the glycolytic and TCA metabolic ratios indicated increased glycolytic capacity and glutamine consumption. Metabolic inhibitors potentiate the antiproliferative effect of rapamycin. DISCUSSION: Based on our studies, it can be concluded that glycolytic pathways are prominent in clear cell renal tumors, while alternative metabolic pathways are prominent in papillary kidney tumors.
C1 [Vetlenyi, Eniko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Sebestyen, Endre] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Vegso, Gyula] Semmelweis University, Department of Transplantation and SurgeryBudapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
RP Vetlenyi, E (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 61
EP 62
PG 1
ER

PT J
AU Virga, �
   Toth, J
   Arkosy, PF
   Virga, J
AF Virga, Akos
   Toth, Judit
   Arkosy, Peter Ferenc
   Virga, Jozsef
TI Investigation of neoadjuvant treatment of triple-negative and Her2-overexpressed breast cancer in own patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Breast cancer is the most common cancer among women, making it the most common type of cancer leading to death. It is very often recognized in Hungary at an advanced or metastatic stage, impairing the chances of survival. Of these, triple-negative breast cancer (TNBC) and tumors with Her2 overexpression have the worst survival, rapid growth, and more frequent recurrence compared to other histological subtypes, so early detection and effective treatment are paramount. MATERIAL AND METHOD: At the Department of Oncology of the University of Debrecen, we processed the complete documentation of 24 female patients receiving neoadjuvant chemotherapy (NAC) for triple negative and Her2-overexpressed breast cancer between 2016 and 2020. The mean age of the patients was 53.38 years. We examined the effect of NAC on tumor size, the rate of complete pathological response, and the incidence of lymph node downstaging, and analyzed the effect of NAC on Mib-1 expression. RESULTS: Comparing the size of the tumor before and after treatment, we found a significant difference when measured by ultrasound and determined by a pathologist in both TNBC (p = 0.0047) and Her2-overexpressed (p = 0.0259) cases. Complete pathological response occurred in 50% of cases in TNBC and in 33% of cases expressed in Her2 overexpressed cases. There was no significant difference between the two histological subgroups. Examined in the TNBC subtype, the proportion of dividing cells (Mib-1 staining) showed a significant difference when comparing pre- and post-treatment samples (p = 0.0053). Using the 10% cut-off value recommended by the international literature for the Mib-1 staining index, the number of tumors with a high division rate also showed a significant reduction for TNBC. DISCUSSION: Overall, neoadjuvant chemotherapy has significantly reduced tumor size, regardless of histological type. The proportion of proliferating cells in the TNBC subtype tumor decreased as a result of treatment. Neoadjuvant treatment may also bring certain advanced tumors to a resectable state and reduce surgical morbidity through lymph node downstaging.
C1 [Virga, Akos] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Arkosy, Peter Ferenc] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Virga, Jozsef] University of Debrecen, Department of OncologyDebrecen, Hungary.
RP Virga, � (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Virga, J
   Demeter, Zs
   Szivos, L
   Rostas, M
   Toth, J
   Arkosy, P
   Klekner, �
AF Virga, Jozsef
   Demeter, Zsofia
   Szivos, Laszlo
   Rostas, Melinda
   Toth, Judit
   Arkosy, Peter
   Klekner, Almos
TI The role of the invasion spectrum in the prognosis of lower-grade gliomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: Astrocytomas and oligodendrogliomas of glial origin are the most common primary tumors of the EMS. Gliomas are characterized by peritumoral invasion, which inhibits complete surgical resection. At present, even with knowledge of genetic abnormalities (e.g., IDH mutation, 1p / 19q coding), it is not possible to accurately estimate the prognosis of the disease, although clinical experience suggests that the progression of astrocytomas is faster in the two tumors. It is known that invasive ability significantly influences prognosis and that the extracellular matrix (ECM) plays a key role in invasion, so we aimed to identify additional prognostic markers by examining invasive ECM molecules in glial tumors. MATERIALS AND METHODS: mRNA expression of 23 ECM molecules was analyzed on 90 quick-frozen glioma samples using RT-qPCR. The ECM composition of the same grade samples was compared to look for individual differences in the molecules, and then the total invasion spectra of the samples were compared using linear discriminant analysis (LDA). RESULTS: Mann-Whitney test for mRNA expression among grade II tumors in 14 molecules (BCAN, CD44, CSPG5, GFAP, IDH1, ITGA3, NCAN, ITGAV, ITGB5, EGFR, LAMA4, VCAN, MMP2, MDM2) , while it confirmed a statistical difference between grade III samples in 3 cases (LAMB1, MMP2, NCAN). The LDA groups the samples based on the invasion spectrum and identifies the most important molecules that most influence the decision. VGB, LAMA4, CD44 and MMP2 play an important role in the identification of grade II samples, while ITGB1, CD44, VCAN and LAMB1 molecules play an important role in grade III samples. The LDA isolated 100 and 96.2% of the grade III samples from each other. DISCUSSION: Based on these, there is a demonstrable difference in the ECM composition of astrocytomas and oligodendrogliomas with different invasiveness. Because the type of tumor can be determined with such high accuracy based on the invasion spectrum, it can be concluded that the combined pattern of invasive molecules plays a role in the degree of invasiveness and thus in the prognosis of the tumor. Based on the LDA study, the invasion spectrum may be used as a prognostic factor, while the highlighted molecules may be used as a personalized oncotherapy target in the future.
C1 [Virga, Jozsef] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Demeter, Zsofia] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Szivos, Laszlo] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Rostas, Melinda] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Toth, Judit] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
   [Arkosy, Peter] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Klekner, Almos] University of Debrecen, Clinical Center, Department of NeurosurgeryDebrecen, Hungary.
RP Virga, J (reprint author), University of Debrecen, Department of Oncology, Debrecen, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 62
EP 62
PG 1
ER

PT J
AU Vizin, G
   Juhasz, A
AF Vizin, Gabriella
   Juhasz, Anita
TI Proven Effective Psychooncological Intervention: Presentation of the KLOE Program
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The incidence of cancer is quite high. Despite the fact that the survival rate of cancer is increasing as a result of increasingly effective anti-cancer treatments, Hungary still has the highest mortality from cancer in the European Union. Psychologically, devastating mortality outcomes may be due to unrecognized or inadequately treated psychiatric disorders and the associated weaker adherence. Our present research is translational research, the primary purpose of which is to assess the extent of adherence and various psychological factors (mental well-being, shame) and to explore their relationship among people with breast cancer and controls. Based on our results, another goal is to develop a cognitive behavioral therapy program, which is also reported in our presentation. MATERIAL AND METHOD: Our research was performed in breast cancer subjects (N = 70), clinical controls (N = 200) and healthy controls (N = 102). Our study was conducted in the form of a questionnaire, with convenience sampling, online. For statistical analysis, analysis of variance, correlation analysis and moderation analysis were performed using SPSS 22.0. RESULTS: Our results show a significant difference in the symptoms of physical health, mental well-being, stigmatization, and post-traumatic stress disorder between the three groups we examined. The results of the correlation study showed positive, significant relationships between mental well-being and adherence, and negative, significant relationships between factors of mental well-being and shame. The relationship between adherence and spiritual well-being is moderated by shame. DISCUSSION: Our results draw attention to the effect of shame and spiritual well-being on adherence. Based on our results, we have developed a cognitive therapeutic, shame-focused, self-empathy program (KLOE Program = Cognitive Therapeutic Spiritual Assistance for Improving the Quality of Life of Oncology Patients), the structure and plans of which will be reviewed in our presentation.
C1 [Vizin, Gabriella] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Juhasz, Anita] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
RP Vizin, G (reprint author), Semmelweis Egyetem, AOK, Klinikai Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 62
EP 63
PG 1
ER

PT J
AU Vizin, G
   Juhasz, A
   Dezso, F
   Szocs, H
   Koncz, Zs
AF Vizin, Gabriella
   Juhasz, Anita
   Dezso, Flora
   Szocs, Henrietta
   Koncz, Zsuzsa
TI The needs and requirements of doctors and nurses in relation to psychology in the field of oncology care
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The use of psychologists in oncology care is part of modern, evidence-based clinical practice. Although the use of clinical psychologists in oncology care is becoming more common, their responsibilities can be very different. In addition to assessing the mental status of people with oncology, there is a wide range of psychological interventions available to reduce patients ’distress, improve their state of mind, and improve their quality of life, which also affects adherence. In addition, mental health responsibilities among medical and professional staff may appear as part of clinical psychological work. The main purpose of our present presentation is to draw attention to the legitimate psychological needs and requirements of health care personnel by presenting the background and steps of a planned research. MATERIAL AND METHOD: In our presentation, we review the needs and potential needs of physicians and nurses in the field of psychology based on international recommendations and research findings. We have very little domestic data on what kind of psychological presence doctors see as justified in oncology care, for example in patient care, treatment of communication difficulties, or prevention of burnout. As a first step, we conducted interviews with oncology surgeons, the content analysis of which provides a good background for our planned research. RESULTS: According to the opinion of oncology surgeons, in addition to patient care, it can be an important task of psychological care to hold various skills development trainings and to maintain and improve the mental health of professionals in the field of oncology care. DISCUSSION: The latest international oncology manuals, similarly to the Hungarian literature, hardly mention the importance and possibilities of psychological interventions in the care of oncology patients. All of this may raise the possibility that the platforms and opportunities of psychology may not be sufficiently transparent for physicians working in oncology care. We seek to explore the psychological needs of oncology professionals through a quantitative study. In our presentation, we would like to present the background, goals and methods of this research, as well as its expected practical usefulness.
C1 [Vizin, Gabriella] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Juhasz, Anita] Semmelweis Egyetem, AOK, Klinikai Pszichologia TanszekBudapest, Hungary.
   [Dezso, Flora] Honved KorhazBudapest, Hungary.
   [Szocs, Henrietta] ELTE PPK, Pszichologiai Doktori IskolaBudapest, Hungary.
   [Koncz, Zsuzsa] Semmelweis Egyetem, AOK, Mentalis Egeszsegtudomanyok Doktori IskolaBudapest, Hungary.
RP Vizin, G (reprint author), Semmelweis Egyetem, AOK, Klinikai Pszichologia Tanszek, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 63
EP 63
PG 1
ER

PT J
AU Weber, A
   Mery, L
   Nagy, P
   Kasler, M
   Polgar, Cs
   Bray, F
   Kenessey, I
AF Weber, Andras
   Mery, Les
   Nagy, Peter
   Kasler, Miklos
   Polgar, Csaba
   Bray, Freddie
   Kenessey, Istvan
TI Quality assurance feedback of cancer reports by analyzing the National Cancer Registry database
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: The National Cancer Registry (NRR) at the National Institute of Oncology publishes the number of patients with different malignancies and in situ tumors discovered in a year, broken down by gender, age group and geography, in accordance with international guidelines. In this way, the population-based disease registry can contribute to the design and development of the Hungarian oncology network. In addition, the strength of the database is fundamentally determined by the quality and completeness of the data reported. In collaboration with the WHO International Agency for Research on Cancer, we analyzed the Cancer Registry database based on international standards. MATERIALS AND METHODS: We calculated the standardized detection rates per tumor, confirmed by the pathological examination, derived from the dead examination certificate only, coded for uncertain primary localization, respectively. the proportion of completed cases for tumor extent and the average number of reports per diagnosis, including per metropolitan and rural institution. Markers were compared with WHO GLOBOCAN international estimates and cancer registries in other countries. RESULTS: Based on the NRR database, WHO estimates showed varying directions and degrees of variation from tumor to tumor. 62 percent of reported tumors were verified using a morphological examination, which is a low value by international comparison and raises the high number of false tumors in the database. The proportion of cases derived only from a dead examination certificate - included in the CSO, not in the NRR - is 5.2 per cent, and the proportion of tumors coded for uncertain primary localization is 3.2 per cent. In international comparison, both values ​​are favorable. In contrast to other registers, in Hungary the average number of reports per case is 14.8 - extremely high, ie the NRR is suitable for the follow-up of patients and the determination of individual patient pathways. However, the content of the report often falls short of the requirements set by the oncology profession and falls short of the mandatory data content in the health records. DISCUSSION: Well-functioning disease registries are essential for the health organization of developed societies. Improving the functioning of the NRR requires broad social cohesion. This requires the modernization of available medical codebooks, the development of hardware and software for IT tools, and the targeted training of medical and healthcare staff involved in oncology care.
C1 [Weber, Andras] National Institute of OncologyBudapest, Hungary.
   [Mery, Les] World Health Organization (WHO), International Agency for Research on Cancer (IARC)Lyon, France.
   [Nagy, Peter] National Institute of OncologyBudapest, Hungary.
   [Kasler, Miklos] National Institute of OncologyBudapest, Hungary.
   [Polgar, Csaba] National Institute of OncologyBudapest, Hungary.
   [Bray, Freddie] World Health Organization (WHO), International Agency for Research on Cancer (IARC)Lyon, France.
   [Kenessey, Istvan] National Institute of OncologyBudapest, Hungary.
RP Weber, A (reprint author), National Institute of Oncology, Budapest, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 63
EP 64
PG 1
ER

PT J
AU Zollei, I
   Matyas, L
   Gyori, A
   Cifra, J
   Al-Farhat, Y
AF Zollei, Istvan
   Matyas, Laura
   Gyori, Attila
   Cifra, Janos
   Al-Farhat, Yousuf
TI Demonstration of the case of a rare patient with dual gastric cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB OBJECTIVE: A wide range of pharmacological and surgical treatments are available for the treatment of gastric tumors. The most accurate examination possible is needed to plan treatment. The authors present a medical history of a patient in whom not only the originally detected intestinal adenocarcinoma but also a smaller neuroendocrine tumor was present in the surgically removed stomach. The latter provided a lymph node metastasis. CASE REPORT: A 60-year-old woman underwent a gastroscopic examination at Szekszard Hospital due to uncertain abdominal complaints. A “ulcer” of 15–20 mm was found on the small curvature side of the stomach. Chronic gastritis with intestinal metaplasia was detected in the biopsy material, and the presence of adenocarcinoma in a superficial area was even suggested. Following the oncology discussion, repeated sampling was performed at the University of Szeged using endoscopic ultrasound: T3N2 adenocc. ventriculite was commented. The next step was 4 cycles of FLOT treatment. This was followed by a total gastrectomy. The patient recovered without complications. He was referred for further oncology treatment. HISTOLOGICAL FINDING: Intestinal-type adenocci detected before surgery. ventricular findings: low grade, ypT2 ypN0 (0/10), partial response to treatment, R0 resection. An unexpected tumor was also detected: farther from the previous tumor, a 6 mm tumor was found to be a clear neuroendocrine tumor by chromogranin A immunohistochemistry and showed a proliferation activity of 2-3% in grade Ki67 immunohistochemistry (grade II). One of the lymph nodes examined was a metastasis of this tumor. pT2 pN1 (1/10) R0 resection. DISCUSSION: Oncology treatment of the examined patient was performed as planned. He received chemotherapy before surgery. The surgery was scheduled for complete gastric removal. Histological examination of the surgical specimen yielded unexpected results. The intestinal type of adenocc. neuroendocrine tumors (with a lymph node metastasis) have also been reported. Further treatment was determined with this in mind. Additional FLOT treatment was recommended by oncoteam, but was discontinued after consultation with the patient. The authors point out that the presence of a rare double gastric tumor was revealed only after surgery.
C1 [Zollei, Istvan] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Matyas, Laura] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Gyori, Attila] Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti OsztalySzekszard, Hungary.
   [Cifra, Janos] Balassa Janos County Hospital, Department of PathologySzekszard, Hungary.
   [Al-Farhat, Yousuf] Tolna Megyei Balassa Janos Korhaz, Onkologiai OsztalySzekszard, Hungary.
RP Zollei, I (reprint author), Tolna megyei Onkormanyzat Balassa Janos Korhaza, Sebeszeti Osztaly, Szekszard, Hungary.
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2021
VL 65
IS 5
BP 64
EP 64
PG 1
ER

PT J
AU Kenessey, I
   Weber, A
   Szilagyi, I
   Nagy, P
   Polgar, Cs
   Kasler, M
AF Kenessey, Istvan
   Weber, Andras
   Szilagyi, Istvan
   Nagy, Peter
   Polgar, Csaba
   Kasler, Miklos
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oncology; coding systems; ICD10; SNOMED
ID oncology; coding systems; ICD10; SNOMED
AB The incidence and mortality of malignant diseases show constant increase worldwide. Proper epidemiological data may establish the planning and development of oncological network, which is provided by population-based registries (in Hungary: National Cancer Registry). The quality of the reported data determines the reliability of the Registry. Recorded medical codes during everyday physician-patient encounters are part of the official documentation as well as a permanent imprint of the medical activity in the Registry’s database. Uncritical coding degrades the quality of epidemiological data, moreover, leads to unnecessary patient stigmatization, which may be the base of legal procedure against the physician who authenticated the false code. However, neither graduate nor postgraduate medical training focus on coding. In addition, hospitals apply obsolete versions of coding systems which does not follow developments in medicine. The aim of the present review is presentation of proper coding in oncology, which may contribute to avoid that kind of basic professional pitfalls, and improve quality of medical activity.
C1 [Kenessey, Istvan] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Weber, Andras] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Szilagyi, Istvan] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Nagy, Peter] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kasler, Miklos] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Kenessey, I (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM kenessey.istvan@oncol.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209−249, 2021
   Parkin DM. The role of cancer registries in cancer control. Int J Clin Oncol 13:102−111, 2008
   https://nrr.hu/
   http://stat.nrr.hu/
   WHO. A betegsegek es az egeszseggel kapcsolatos problemak nemzetkozi statisztikai osztalyozasa, 10. revizio. Nepjoleti Miniszterium, 1995
   Brierley JD, Gospodarowicz MK, Wittekind C, szerk.). A rosszindulatu daganatok TNM-klasszifikacioja es stadiumbesorolasa. 8. kiadas, Oriold es Tarsai Kiado es Szolgaltato Kft., Budapest 2017
   Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline, version 1.1). Eur J Cancer 45:228−247, 2009
   http://finanszirozas.neak.gov.hu/szabalykonyv/index.asp?mid=1
   Binder H, Blettner M. Big data in medical science--a biostatistical view. Dtsch Arztebl Int 112:137−142, 2015
   2019. EuK. 2. szam EMMI kozlemeny. h t t p s : / /www. h b c s . h u / uploads/jogszabaly/2839/fajlok/EMMI_modszertani_levele_betegs% C3%A9gregiszterek.pdf. Az Emberi Eroforrasok Miniszteriuma modszertani levele a betegsegregiszterek adattartalmarol.
   Cornet R, de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inform Decis Mak 8(Suppl 1):S2, 2008
   IARC. http://www.iacr.com.fr/index.php?Itemid=577
   http://www.neak.gov.hu/data/cms1001070/BNOX_3_4.zip
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 4
EP 10
PG 7
ER

PT J
AU Landherr, L
   Pinter, T
   Hornyak, L
   Revesz, J
   Mahr, K
   Torday, L
   Andras, Cs
   Erfan, J
   Arkosy, P
   Bodoky, Gy
AF Landherr, Laszlo
   Pinter, Tamas
   Hornyak, Lajos
   Revesz, Janos
   Mahr, Karoly
   Torday, Laszlo
   Andras, Csilla
   Erfan, Jozsef
   Arkosy, Peter
   Bodoky, Gyorgy
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE bevacizumab; median progression-free survival; metastatic colorectal carcinoma; observational study; prognostic factors
ID bevacizumab; median progression-free survival; metastatic colorectal carcinoma; observational study; prognostic factors
AB The primary aim of AVACONT was to collect data in the course of routine oncological care from patients with metastatic colorectal cancer (mCRC) treated with bevacizumab supplemented fluoropyrimidine-based chemotherapy doublet in an open, multicentre, observational study in Hungary. Primary endpoint of the study was to determine progression-free survival (PFS). The Full Analysis Set (FAS) comprised 280 patients. Median PFS calculated from enrolment was 270 days in the FAS population. The metastatic involvement of the liver or more than one organ significantly decreased (250 and 245 days), while a clinical response achieved significantly increased (partial response: 404, complete response: 623 days) the mPFS calculated from enrolment. PFS calculated from the start of the first-line treatment was significantly decreased by the presence of mutant RAS gene (481 vs. 395 days). The results confirm the efficacy, known prognostic factors and safety profile of bevacizumab in combination with chemotherapy dosed during standard oncology care in Hungarian centres.
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Uzsoki utca 29., 1145 Budapest, Hungary.
   [Pinter, Tamas] Petz Aladar County HospitalGyor, Hungary.
   [Hornyak, Lajos] Veszprem County Csolnoky Ferenc HospitalVeszprem, Hungary.
   [Revesz, Janos] County Hospital of Borsod-Abauj-ZemplenMiskolc, Hungary.
   [Mahr, Karoly] County Hospital of ZalaZalaegerszeg, Hungary.
   [Torday, Laszlo] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Andras, Csilla] University of DebrecenDebrecen, Hungary.
   [Erfan, Jozsef] Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi OktatokorhazDebrecen, Hungary.
   [Arkosy, Peter] Kenezy Teaching HospitalDebrecen, Hungary.
   [Bodoky, Gyorgy] Del-Pesti CentrumkorhazBudapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, 1145 Budapest, Hungary.
EM landherr@uzsoki.hu
CR Ferlay J, Steliarova-Foucher E, Lortet-Tieulentet J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403, 2013
   Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84−89, 2017
   Strickler HJ, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17:513–524, 2012
   Avastin SmPC. https://www.ema.europa.eu/en/documents/product-information/ avastin-epar-product-information_en.pdf
   Saltz LB, Sirzen, F, Cassidy J, et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013−2019, 2008
   Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin, FOLFOX4, for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539−1544, 2007
   Koopman M, Simkens LHJ, Ten Tije AJ, et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer, mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group, DCCG). J Clin Oncol 31(suppl):abstr 3502, 2013
   Koopman M, Simkens L, May A, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer, mCRC). J Clin Oncol 32(suppl):abstr LBA388, 2014
   Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III ‘Stop and Go’ Study results – A Turkish Oncology Group Trial. Oncology 85:328–335, 2013
   Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer, CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385:1843, 2015
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 11
EP 19
PG 9
ER

PT J
AU Marki, I
AF Marki, Istvan
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast cancer; positive lymph node; radiotherapy planning; computer-assisted; intensity-modulated; volumetric modulated arc therapy
ID breast cancer; positive lymph node; radiotherapy planning; computer-assisted; intensity-modulated; volumetric modulated arc therapy
AB Volumetric modulated arc therapy (VMAT) irradiation plans are a potentially improved version to the now widespread intensity-modulated radiotherapy (IMRT) irradiation techniques, which in turn are gradually replacing traditional conformal breast irradiation techniques. The aim of this study was to dosimetrically compare VMAT and IMRT radiotherapy plans for lymph node positive breast cancer irradiations. Patients over the age of 18, with lymph node positivity and stage II or stage III classification (according to the AJCC/ UICC), were selected for our study. Several IMRT and VMAT plans were prepared and compared for all the investigated patients. According to our results the VMAT technique leads to equal results in terms of the target area, while providing comparable outcomes for the organs at risk (OAR). We also noted that the treatment times and monitor units are considerably lower for VMAT plans.
C1 [Marki, Istvan] Bacs-Kiskun County Hospital, Department of Oncoradiology, Nyiri ut 38., 6000 Kecskemet, Hungary.
RP Marki, I (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, 6000 Kecskemet, Hungary.
EM markii@kmk.hu
CR Beckham WA, Popescu CC, Patenaude VV, et al. Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Med Phys Clin Eng Radiat Oncol 69:918–924, 2007
   Pirzkall A, Lohr F, Hoss A, et al. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 48:1371−1380, 2000
   Nithya L, Vineeta G, Deepti S, et al. Dosimetric comparison of different planning techniques in left-sided whole-breast irradiation: A planning study. J Med Phys 45:148−155, 2020
   Chiavassa S, Bessieres I, Edouard M, et al. Complexity metrics for IMRT and VMAT plans: a review of current literature and applications. Br J Radiol Suppl 92:20190270, 2019
   Su HF, Zhao M, Zhang J, Dai, ZT. Dosimetric effects related to collimator angle optimization in intensity-modulated radiotherapy planning for gastric cancer. Prec Radiat Oncol 2021:25–33, 2021
   Ghulam M, Shahid M, Shahid R, et al. Dosimetric effect of limited aperture multileaf collimator on VMAT plan quality: A study of prostate and head-and-neck cancers. Rep Pract Oncol Radiother 23:189–198, 2018
   Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys 37:207–213, 2012
   Alongi F, Giaj-Levra N, Fiorentino A, et al. Low-dose bath with volumetric modulated arc therapy in breast cancer: „Much ado about nothing?” Tumori 102:335−336, 2016
   Zhang Q, Yu XY, Hu GW, et al. Dosimetric comparison for volumetric modulated arc therapy and intensity modulated radiotherapy on the left-sided chestwall and internal mammary nodes irradiation in treating post-mastectomy breast cancer. Radiol Onco 49:91−98, 2015
   Pasler M, Georg D, Bartelt S, Lutterbach J. Node-positive left-sided breast cancer: does VMAT improve treatment plan quality with respect to IMRT? Strahlenther Onkol 189:380–386, 2013
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 21
EP 27
PG 7
ER

PT J
AU Kiss, E
   Papai, Zs
AF Kiss, Edina
   Papai, Zsuzsanna
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE umor-agnostic; targeted therapy; TRK inhibitors; larotrectinib
ID umor-agnostic; targeted therapy; TRK inhibitors; larotrectinib
AB Tumor agnostic therapies target specific genomic alterations regardless of tumor localization and histological subtype. Neurotrophic tropomyosin receptor tyrosine kinase (NTRK) gene fusions are important driver gene targets in both pediatric and adult tumors. The first generation TRK inhibitors provide a rapid, effective, and long-lasting antitumor effect with a favorable side effect profile through selective inhibition of TRK fusion proteins. In the case report, we present a case of a young adult female patient with soft tissue sarcoma, in whom the multiple recurrent lower limb tumor disseminated after 3 years, but the systemic treatments used did not show a meaningful therapeutic response. Molecular diagnostic method confirmed the translocation of a very rare driver oncology target, the neurotrophic tropomyosin receptor tyrosine kinase 3 gene. We used convenient and safe inhibitor of tropomyosin receptor tyrosine kinase larotrectinib therapy with good efficacy and excellent quality of life. Larotrectinib was the first and only systemic therapy to which this metastatic soft tissue tumor responded.
C1 [Kiss, Edina] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111−113., 1062 Budapest, Hungary.
   [Papai, Zsuzsanna] Honved Korhaz, Onkologiai Osztaly, Podmaniczky u. 111−113., 1062 Budapest, Hungary.
RP Kiss, E (reprint author), Honved Korhaz, Onkologiai Osztaly, 1062 Budapest, Hungary.
EM edina.kiss.dobos@gmail.com
CR Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:e000023, 2016
   Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731−747, 2018
   Kiss E, Papai Zs. Uj celzott terapias lehetoseg az onkologiaban: tropomiozin receptor-tirozin-kinaz gatlok. Orv Hetil 162:1362–1369, 2021
   Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460–467, 2019
   Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731−739, 2018
   Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25−34, 2015
   Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460–467, 2019
   Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancers. Nat Commun 5:4846, 2014
   Marchio C, Scaltriti M, Ladanyi M, et al. ESMO recommendation on standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30:1417−1427, 2019
   Vitrakvi. https://ema.europa.eu/en/medicines/human/EPAR/vitrakvi
   Rozlytek. https://ema.europa/en/medicines/human/EPAR/rozlytek
   Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov 7:963–972, 2017
   Zhai D, Deng W, Huang J, et al. TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling. Cancer Res 77(Suppl 13):3161, 2017
   Selitrectinib. pubchem.ncbi.nlm.nih.gov/compound/Selitrectinib
   Repotrectinib. pubchem.ncbi.nlm.nih.gov/compound/Repotrectinib
   Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 5:1049–1057, 2015
   Vitrakvi alkalmazasi eloiras. https://europa.eu/documents/product-information/ vitrakvi-epar-product-information_hu.pdf
   Szendroi M, Rahoty P, Papai Zs, et al. Felnottkori lagyresz-sarcomak. In: Az onkologia alapjai. Szerk. Kasler M. Medicina Konyvkiado, Budapest 2018, pp. 1151−1175
   Fletcher CD. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification. Histopathology 64:2−11, 2014
   Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur J Cancer 49:684−695, 2013
   NCCN Clinical Practice Guidelines in Oncology, “Soft Tissue Sarcoma. Version 2.2021,” National Comprehensive Cancer Network, Inc., 2021
   Gronchi A, Miah AB, Dei Tois AP, et al. Soft tissue and visceral sarcoma: ESMO-EURACAN-GENTURIS Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:1348−1365, 2021
   Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15:415−423, 2014
   www.cancaertherapyadvisor.com/wp-content/uploads/sites/12/2018/ soft-tissue-sarcoma_0418_65641.pdf
   Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 29:2528–2533, 2011
   FDA approves larotrectinib for solid tumors with NTRK gene fusions. https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrkgene- fusions
   Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 30(Suppl 8):viii23−viii30, 2019
   van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma, PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886, 2012
   Steins MB, Serve H, Zuhlsdorf M, et al. Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours, malignant schwannoma, refractory to first-line therapy. Oncol Rep 9:627–630, 2002
   https://www.nbci.nlm.nih.gov/pmc/articles/PMC4489850/
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 29
EP 33
PG 5
ER

PT J
AU Szekely, B
   Halmos, B
AF Szekely, Borbala
   Halmos, Balazs
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE COVID-19; coronavirus; oncology; pandemic; epidemic
ID COVID-19; coronavirus; oncology; pandemic; epidemic
AB The COVID-19 pandemic has had tremendous impact worldwide but possibly no other patient subset has been impacted as much as patients with a cancer diagnosis. Significantly increased morbidity and mortality was defined amongst identifiable subsets of cancer patients, such as the elderly, patients with co-morbid illnesses and certain malignancy types and therapies. In addition, major compromises in cancer care and drastic drop-offs in cancer screening rates have led to significant further setbacks in recent advances in cancer care. Emerging information as to the benefit of COVID-19 vaccinations, including booster vaccines that can benefit even the most immune suppressed along with novel anti-COVID antibodies preemptively reduce the risk of infection. Antiviral and other therapeutics mitigating the severity of COVID-19 infections now offer major insights, new and effective options and hope for being able to optimize cancer care even in the face of the ongoing pandemic.
C1 [Szekely, Borbala] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Halmos, Balazs] Montefiore Medical Center/Albert Einstein College of Medicine, Department of Oncology, 1300 Morris Park AveBronx, NY, USA.
RP Halmos, B (reprint author), Montefiore Medical Center/Albert Einstein College of Medicine, Department of Oncology, Bronx, USA.
EM bahalmos@montefiore.org
CR Elkrief A, Wu JT, Jani C, et al. Learning through a pandemic: the current state of knowledge on COVID-19 and cancer. Cancer Discov 12:303−330, 2021
   Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer, CCC19): a cohort study. Lancet 395:1907−1918, 2020
   Alom S, Chiu CM, Jha A, et al. The effects of COVID-19 on cancer care provision: a systematic review. Cancer Control 28:1073274821997425, 2021
   van Dam PA, Huizing M, Mestach G, et al. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev 89:102068, 2020
   Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46:1089−1098, 2020
   Zhou X, Ye Q. Cellular immune response to COVID-19 and potential immune modulators. Front Immunol 12:646333, 2021
   Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 75:1564−1581, 2020
   Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 26:1623−1635, 2020
   Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta- analysis. Clin Oncol, R Coll Radiol, 33:e180−e191, 2021
   Fendler A, Au L, Shepherd S, et al. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer 2:1321−1337, 2021
   Bange EM, Han NA, Wileyto P, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 27:1280−1289, 2021
   Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 383:2586−2588, 2020
   Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood 122:1712−1723, 2013
   Li A, Kuderer NM, Hsu CY, et al. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost 19:2522−2532, 2021
   Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18:1859−1865, 2020
   Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 10:935−941, 2020
   Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 32:787−800, 2021
   Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov 10:1465−1474, 2020
   Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies, TERAVOLT): first results of an international, registry- based, cohort study. Lancet Oncol 21:914−922, 2020
   Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21:893−903, 2020
   Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 21:1309−1316, 2020
   Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm, QCOVID, for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 371:m3731, 2020
   Qian W, Ye Y, Zuo L, et al. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. Immunotherapy 13:1271−1282, 2021
   Yekeduz E, Utkan G, Urun Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer 141:92−104, 2020
   Naidoo J, Reuss JE, Suresh K, et al. Immune-related, IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. J Immunother Cancer 8:e000984, 2020
   COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 396:27−38, 2020
   LaPlant Q, Thor M, Shaverdian N, et al. Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiother Oncol 161:115−117, 2021
   Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 386:305−315, 2022
   Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602:664−670, 2022
   Helsper CW, Campbell C, Emery J, et al. Cancer has not gone away: A primary care perspective to support a balanced approach for timely cancer diagnosis during COVID-19. Eur J Cancer Care, Engl, 29:e13290, 2020
   London JW, Fazio-Eynullayeva E, Palchuk MB, et al. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform 4:657−665, 2020
   Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 4:1059−1071, 2020
   Kaufman HW, Chen Z, Niles J, et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019, COVID-19, pandemic. JAMA Netw Open 3:e2017267, 2020
   Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 21:1023−1034, 2020
   Wilkinson E. How cancer services are fighting to counter covid-19’s impact. BMJ 370:m2747, 2020
   Civantos AM, Carey RM, Lichtenstein GR, et al. Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases. Head Neck 42:1131−1136, 2020
   Chiang J, Yang VS, Han S, et al. Minimizing transmission of COVID-19 while delivering optimal cancer care in a National Cancer Centre. J Cancer Policy 25:100241, 2020
   van de Haar J, Hoes LR, Coles CE, et al. Author correction: Caring for patients with cancer in the COVID-19 era. Nat Med 26:1146, 2020
   Sud A, Jones ME, Broggio J, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 31:1065−1074, 2020
   Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 371:m4087, 2020
   Elkrief A, Kazandjian S, Bouganim N. Changes in lung cancer treatment as a result of the coronavirus disease 2019 pandemic. JAMA Oncol 6:1805−1806, 2020
   Mulvey TM, Jacobson JO. COVID-19 and cancer care: ensuring safety while transforming care delivery. J Clin Oncol 38:3248−3251, 2020
   Rodler S, Apfelbeck M, Stief C, et al. Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany? Eur J Cancer 132:136−140, 2020
   Gupta S, Cantor J, Simon KI, et al. Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States. Health Aff, Millwood, 40:1465−1472, 2021
   Bartsch SM, Wedlock PT, O’Shea KJ, et al. Lives and costs saved by expanding and expediting coronavirus disease 2019 vaccination. J Infect Dis 224:938−948, 2021
   Corti C, Curigliano G. Commentary: SARS-CoV-2 vaccines and cancer patients. Ann Oncol 32:569−571, 2021
   Thakkar A, Pradhan K, Jindal S, et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer 2:392−399, 2021
   Houot R, Levy R, Cartron G, et al. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer 136:4−6, 2020
   Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell 39:1091−1098, 2021
   Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol 7:1133−1140, 2021
   Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 31:565−569,2020
   Wurm H, Attfield K, Iversen AK, et al. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler 26:1261−1264, 2020
   Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584:457−462, 2020
   Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. Clin Infect Dis 2021:ciab687, 2021
   Mittelman M, Magen O, Barda N, et al. Effectiveness of the BNT162b- 2mRNA COVID-19 vaccine in patients with hematological neoplasms. Blood 2021:blood.2021013768, 2021
   Shapiro LC, Thakkar A, Campbell ST, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell 40:3−5, 2022
   Greenberger LM, Saltzman LA, Senefeld JW, et al. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell 39:1297−1299, 2021
   Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 385:1244−1246, 2021
   Hill JA, Ujjani CS, Greninger AL, et al. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell 39:1037−1038, 2021
   Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 385:1393−1400, 2021
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 35
EP 41
PG 7
ER

PT J
AU Bogos, K
   Torok, Sz
   Pucsok, M
   Cselko, Zs
   Renyi-Vamos, F
   Ostoros, Gy
   Dome, B
   Megyesfalvi, Zs
AF Bogos, Krisztina
   Torok, Szilvia
   Pucsok, Mariann
   Cselko, Zsuzsanna
   Renyi-Vamos, Ferenc
   Ostoros, Gyula
   Dome, Balazs
   Megyesfalvi, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE COVID-19 infection; lung cancer; thoracic tumors
ID COVID-19 infection; lung cancer; thoracic tumors
AB The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide. Patients with cancer, and particularly those with lung malignancies, represent a highrisk group for COVID-19 since they are more susceptible to infection and have a higher risk of severe outcomes. However, the restructuration of the healthcare environment, the development of guidelines for treatment and surveillance, and the improvement of vaccination coverage allowed adequate patient shielding and continuity of oncological care of cancer patients. By shedding light on the characteristics of COVID-19 patients with thoracic malignancies, recent studies also contributed to the development of personalized therapeutic strategies. Accordingly, several determinants were identified to predict disease outcomes. These include the ECOG performance status, the levels of C-reactive protein, neutrophils and procalcitonin, the disease stage, and the presence of pneumonia. COVID-19 vaccines are safe in patients with lung cancer. In order to obtain adequate immunization, the booster dose is recommended in these patients
C1 [Bogos, Krisztina] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Torok, Szilvia] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Pucsok, Mariann] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Cselko, Zsuzsanna] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Ostoros, Gyula] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
   [Megyesfalvi, Zsolt] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1122 Budapest, Hungary.
RP Bogos, K (reprint author), National Koranyi Institute of Pulmonology, 1122 Budapest, Hungary.
EM bogos@koranyi.hu
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394−424, 2018
   Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692−699, 2020
   Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol 45:100618, 2020
   https://ourworldindata.org/
   Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 10:783−791, 2020
   Lemos AEG, Silva GR, Gimba ERP, et al. Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities. Thorac Cancer 12:2637−2647, 2021
   Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol 31:1386−1396, 2020
   Whisenant JG, Baena J, Cortellini A, et al. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol, 2022,, DOI  10.1016/j. jtho.2021.12.015
   Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23:3−20, 2022
   Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25:2045−2052, 2004
   Wang S, Qiu Z, Hou Y, et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res 31:126−140, 2021
   Ren P, Gong C, Ma S. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients. Open Med, Wars, 15:613−622, 2020
   Zhang H, Quek K, Chen R, et al. Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. J Cancer 11:5289−5292, 2020
   Kong Q, Xiang Z, Wu Y, et al. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Mol Cancer 19:80, 2020
   Zhang Y, Fan L, Yao R, et al. ACEs family genes: Important molecular links between lung cancer and COVID-19. Clin Transl Med 11:e615, 2021
   Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 3: e202000786, 2020
   Basak A, Chen A, Scamuffa N, et al. Blockade of furin activity and furin-induced tumor cells malignant phenotypes by the chemically synthesized human furin prodomain. Curr Med Chem 17:2214−2221, 2010
   Scamuffa N, Sfaxi F, Ma J, et al. Prodomain of the proprotein convertase subtilisin/kexin furin, ppFurin, protects from tumor progression and metastasis. Carcinogenesis 35:528−536, 2014
   Mbikay M, Sirois F, Yao J, et al. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 75:1509−1514, 1997
   Liu X, Liu B, Shang Y, et al. Decreased TMPRSS2 expression by SARSCoV- 2 predicts the poor prognosis of lung cancer patients through metabolic pathways and immune infiltration. Aging, Albany NY, 14:73−108, 2022
   Martinez-Hernandez NJ, Caballero Silva U, Cabanero Sanchez A, et al. Effect of COVID-19 on thoracic oncology surgery in Spain: A Spanish Thoracic Surgery Society, SECT, survey. Cancers, Basel, 13:2897, 2021
   Park JY, Lee YJ, Kim T, et al. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea. BMC Cancer 20:1040, 2020
   Van Haren RM, Delman AM, Turner KM, et al. Impact of the COVID-19 pandemic on lung cancer screening program and subsequent lung cancer. J Am Coll Surg 232:600−605, 2021
   Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 21:1023−1034, 2020
   Gorospe L, Ayala-Carbonero AM, Paredes-Rodriguez P, et al. Challenges in management of patients with lung cancer in times of COVID-19: An imaging perspective. Clin Lung Cancer 21:568−570, 2020
   EMMI Egeszsegugyi Szakmai Kollegium Onkologiai es sugarterapia Tagozatanak ajanlasa a COVID-19 ellatasrenddel kapcsolatban. 2020
   Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 31:1320−1335, 2020
   Waissengrin B, Agbarya A, Safadi E, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol 22:581−583, 2021
   Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol 7:1133−1140, 2021
   Waldhorn I, Holland R, Goshen-Lago T, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov 11:2430−2435, 2021
   Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 39:1081−1090, 2021
   Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell 39:1091−1098, 2021
   Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol 22:1681−1691, 2021
   Gounant V, Ferre VM, Soussi G, et al. Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol 17:239−251, 2022
   Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2, delta, variant. N Engl J Med 385:585−594, 2021
   Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov 12:31-46, 2022
   Yuan X, Yao Z, Wu J, et al. G1 phase cell cycle arrest induced by SARSCoV 3a protein via the cyclin D3/pRb pathway. Am J Respir Cell Mol Biol 37:9−19, 2007
   Xu LH, Huang M, Fang SG, et al. Coronavirus infection induces DNA replication stress partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA polymerase delta. J Biol Chem 286:39546−39559, 2011
   Mullen PJ, Garcia G, Jr., Purkayastha A, et al. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat Commun 12:1876, 2021
   Shirvaliloo M. Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection. Epigenomics 13:745- 750, 2021
   Bos LDJ. COVID-19-related acute respiratory distress syndrome: not so atypical. Am J Respir Crit Care Med 202:622−624, 2020 42 . Francescangeli F, De Angelis ML, Baiocchi M, et al. COVID-19-induced modifications in the tumor microenvironment: Do they affect cancer reawakening and metastatic relapse? Front Oncol 10:592891, 2020 43. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 383:120−128, 2020 44. Meini S, Giani T, Tascini C. Intussusceptive angiogenesis in COVID-19: hypothesis on the significance and focus on the possible role of FGF2. Mol Biol Rep 47:8301−8304, 2020 45. Tutuncuoglu B, Cakir M, Batra J, et al. The landscape of human cancer proteins targeted by SARS-CoV-2. Cancer Discov 10:916−921, 2020 46. El Bairi K, Trapani D, Petrillo A, et al. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 141:40−61, 2020 47. Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 23:941−948, 2010 48. Zhang Q, Lu S, Li T, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res 38:173, 2019 49. Bradley BT, Maioli H, Johnston R, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 396:320−332, 2020 50. Burel-Vandenbos F, Cardot-Leccia N, Passeron T. Apoptosis and pericyte loss in alveolar capillaries in COVID-19 infection: choice of markers matters. Author’s reply. Intensive Care Med 46:1967−1968, 2020 51. Jain A, Doyle DJ. Apoptosis and pericyte loss in alveolar capillaries in COVID-19 infection: choice of markers matters. Intensive Care Med 46:1965−1966, 2020 52. Som A, Lang M, Little B. Pulmonary vascular pathology in COVID-19. N Engl J Med 383:887, 2020 53. Tsoukalas N, Aravantinou-Fatorou E, Tolia M, et al. Epithelial-mesenchymal transition in non small-cell lung cancer. Anticancer Res 37:1773−1778, 2017 54. Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun 11:5859, 2020
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 43
EP 49
PG 7
ER

PT J
AU Hunyadi, K
   Nadudvari, N
   Kispal, M
   Balatoni, T
   Madurka, I
   Liszkay, G
AF Hunyadi, Karen
   Nadudvari, Nora
   Kispal, Mihaly
   Balatoni, Timea
   Madurka, Ildiko
   Liszkay, Gabriella
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE melanoma; COVID-19; immunotherapy; coronavirus infection; vaccination
ID melanoma; COVID-19; immunotherapy; coronavirus infection; vaccination
AB The COVID-19 pandemic has created significant barriers to the treatment of cancer patients requiring regular hospitalisation, as coronavirus infection significantly increases the risk of serious and even fatal complications. In our case report, a middle-aged patient with advanced melanoma has developed immune-mediated pancreatitis after more than a year of pembrolizumab treatment. After changing the therapy, the patient was diagnosed with coronavirus infection, which led to nearly a month of hospitalisation and rehabilitation, thus suspending active oncotherapeutical treatment. Thanks to professional medical care, our patient successfully recovered from the severe COVID-19 pneumonia caused by the infection, even in the absence of a coronavirus vaccine. After recovery, he received two Pfizer- BioNTech vaccines in August and September 2021, and a follow-up CT scan showed almost complete remission. Given the patient’s lack of complaints and the absence of tumours other than two residual pulmonary nodules, he was observed afterwards. Our patient was in a serious condition before the vaccines were introduced, but has recovered thanks to professional medical care.
C1 [Hunyadi, Karen] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Nadudvari, Nora] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Madurka, Ildiko] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Hunyadi, K (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM hunyadi.karen@oncol.hu
CR https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_ guidance_v5-0.pdf?sfvrsn=b483da2b_76
   http://otszonline.hu/cikk/a_covid_19_hez_tarsulo_citokin_vihar_kezelese
   https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma. pdf
   Martellucci CA, Flacco MA, Cappadona R, et al. SARS-CoV-2 pandemic: An overview. Adv Biol Regul 77:1−11, 2020
   https://www.economist.com/graphic-detail/tracking-coronavirusacross- europe
   https://www.ecdc.europa.eu/en/covid-19/variants-concern
   https://www.uptodate.com/contents/toxicities-associated-with-checkpoint- inhibitor-immunotherapy
   Wu Q, Chu Q, Zhang H, et al. Clinical outcomes of coronavirus disease 2019, COVID-19, in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Commun 40:374−379, 2020
   https://www.who.int/publications/m/item/weekly-epidemiological-update- on-covid-19---25-january-2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 51
EP 54
PG 4
ER

PT J
AU Galffy, G
   Molnar, A
   Blasszauer, C
   Komka, I
   Reibl, D
   Lovey, J
AF Galffy, Gabriella
   Molnar, Andrea
   Blasszauer, Celia
   Komka, Ida
   Reibl, Daniel
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung cancer; BMI; weight loss; survival
ID lung cancer; BMI; weight loss; survival
AB During oncological treatments, body mass index (BMI) and weight loss (WL) are important prognostic factors, but can be influenced by nutrition therapy. The aim of the study was to collect data on BMI and WL of patients with lung cancer and on the nutritional therapy influencing malnutrition. In our multicenter, retrospective study involving 1616 patients, data were collected using a questionnaire with 51 questions, and statistical analysis was performed with descriptive, and multivariate analysis methods with IBM SPSS 20 software. According to the method of Martin, based on BMI and WL, patients were ranked on a scale of 0 to 4 (grade 0 24.9%; grade 1 20.7%; grade 2 14.9%; grade 3 22.4%; grade 4 17.0%). Based on this data low BMI and WL may affect survival in 75.1%. In contrast, only 37.6% of patients received nutritional therapy, based on 47 different strategies. The data substituted into the prognostic matrix highlights that weight loss may shorten patients’ survival. The 47 strategies indicate that the use of nutritional therapy is inconsistent throughout this patient cohort.
C1 [Galffy, Gabriella] County Hospital of PulmonologyTorokbalint, Hungary.
   [Molnar, Andrea] Magyar Dietetikusok Orszagos SzovetsegeBudapest, Hungary.
   [Blasszauer, Celia] MedicalScan Kft.Budapest, Hungary.
   [Komka, Ida] MedicalScan Kft.Budapest, Hungary.
   [Reibl, Daniel] MedicalScan Kft.Budapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM lovey.jozsef@oncol.hu
CR Bogos K, Kiss Z, Galffy G, et al. Lung cancer in Hungary. J Thorac Oncol 15:692–929, 2020
   Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 6:100092, 2021
   Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical nutrition in cancer. Clin Nutr 40:2898–2913, 2021
   Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr 40:4745–4761, 2021
   Gomes F, Schuetz P, Bounoure L, et al. ESPEN guidelines on nutritional support for polymorbid internal medicine patients. Clin Nutr 37:336–353, 2018
   Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition − A consensus report from the global clinical nutrition community. Clin Nutr 38:1–9, 2019
   Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 36:49–64, 2017
   Az Emberi Eroforrasok Miniszteriuma szakmai iranyelve a korhazi, az egeszsegugyi apolasi otthonokban es az otthoni ellatasra szorulo felnott betegek taplaltsagi allapotanak felmerese es a taplaltsagi zavarok taplalasterapiaval torteno kezeleserol. Egeszsegugyi Kozlony 65:3772–3791, 2016
   Az Emberi Eroforrasok Miniszteriuma szakmai iranyelve a multimorbid geriatriai betegek ellatasarol es kezeleserol. Egeszsegugyi Kozlony 71:1887–1955, 2021
   Sobotka L. Basics in clinical nutrition. 5 ed. Gallen, Praga 2019
   Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33:90–99, 2015
   Lovey J. A daganatos betegek taplalasterapiaja. Magy Onkol 61:229–237, 2017
   Belak B. A taplaltsagi allapot, mint prediktiv es prognosztikus tenyezo a daganatos betegek betegsegenek kimenetele szempontjabol. Szakdolgozat 2020; SE-ETK Taplalkozastudomanyi mesterkepzesi szak
   A felnott betegek dagantos cachexiaja: az ESMO klinikai gyakorlati iranyelve. Klin Onkol 8(S1):1–24, 2021
   Specialis gyogyaszati celra szant tapszerek, elelmiszerek). https://ogyei. gov.hu/specialis_gyogyaszati_celra_szant_tapszerek_elelmiszerek
   Pressoir M, Desne S, Berchery D, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 102:966–971, 2010.
   Mele MC, Rinninella E, Cintoni M, et al. Nutritional support in lung cancer patients: the state of the art. Clin Lung Cancer 22:e584–e594, 2021
   Hebuterne X, Lemarie E, Michallet M, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr 38:196–204, 2014.
   Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck 29:893–900, 2007
   Ji X, Ding H. The efficacy of enteral nutrition combined with accelerated rehabilitation in non-small cell lung cancer surgery: A randomized controlled trial protocol. Medicine, Baltimore, 99:e23382, 2020
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 55
EP 63
PG 9
ER

PT J
AU Magyar Sugarterapias, T
AF Magyar Sugarterapias, Tarsasag
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB Tihany, 23–25 september, 2021
C1 [Magyar Sugarterapias, Tarsasag] Magyar Sugarterapias Tarsasag, 1122 Budapest, Hungary.
RP Magyar Sugarterapias, T (reprint author), Magyar Sugarterapias Tarsasag, 1122 Budapest, Hungary.
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2022
VL 66
IS 1
BP 65
EP 88
PG 24
ER

PT J
AU Parrag, P
   Weber, A
   Liszkay, G
   Nagy, P
   Kasler, M
   Polgar, Cs
   Kenessey, I
AF Parrag, Petra
   Weber, Andras
   Liszkay, Gabriella
   Nagy, Peter
   Kasler, Miklos
   Polgar, Csaba
   Kenessey, Istvan
TI Hungarian situation of melanoma incidence and mortality in the first two decades of 21st century
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE melanoma; epidemiology; incidence; mortality; survival
ID melanoma; epidemiology; incidence; mortality; survival
AB Skin melanoma is not among malignancies with the highest incidences and mortalities worldwide; however, the observed constant increase in newly diagnosed cases is troublesome. According to the database of the Hungarian Cancer Registry, the number of newly reported cases doubled between 2001 and 2019, which is consistent with international data. Notwithstanding, within the same interval, Hungarian mortality did not change significantly according to the database of the Hungarian Statistical Office, which is in contrast to international trends. The increasing incidence together with unchanging mortality resulted in better survival rates and hence more favorable follow-up data in our country. Advancements in secondary prevention programs and better efficacy of modern therapeutic interventions in the last decade may have contributed to the observed improvement in the survival rates of Hungarian melanoma patients.
C1 [Parrag, Petra] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Weber, Andras] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Liszkay, Gabriella] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kasler, Miklos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kenessey, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Kenessey, I (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM kenessey.istvan@oncol.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209−249, 2021
   Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 55:74−108, 2005
   Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84−89, 2017
   http://stat.nrr.hu/, Orszagos Onkologiai Intezet, Nemzeti Rakregiszter es Biostatisztikai Kozpont, 2021
   https://www.ksh.hu/, Kozponti Statisztikai Hivatal, 2021
   https://gco.iarc.fr/today/home. Cancer Today, International Agency for Research on Cancer, 2021
   Pace M, Lanzieri G, Glickman M, et al. Revision of the European Standard Population - Report of Eurostat’s task force, Eurostat, 2013
   Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 45:756−764, 2009
   https://www.r-project.org/, „R: The R Project for Statistical Computing”, 2021
   Hammer O, Harper DAT, Ryan PD. PAST: Paleontological Statistics software package for education and data analysis. 4:9, 2001
   Timar J, Ladanyi A. A daganatok immunterapiajanak prediktiv markerei, a PD-L1-meghatarozas gyakorlati kerdesei. Magy Onkol 61:158−166, 2017
   Liszkay G, Kiss Z, Gyulai R, et al. Changing trends in melanoma incidence and decreasing melanoma mortality in Hungary between 2011 and 2019: A nationwide epidemiological study. Front Oncol 10:612459, 2020
   Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41:45−60, 2005
   Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28−44, 2005
   Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040−2059, 2005
   Balatoni T, Liszkay G, Miklos Z, et al. A melanoma malignum epidemiologiaja. Klinikai tapasztalatok az Orszagos Onkologiai Intezetben. Orv Hetil 152:1000−1006, 2011
   Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902−908, 1970
   Doma V, Karpati S, Raso E, et al. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer 19:786, 2019
   Doma V, Barbai T, Beleaua MA, et al. KIT mutation incidence and pattern of melanoma in Central Europe. Pathol Oncol Res 26:17–22, 2020
   Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507−2516, 2011
   Czirbesz K, Gorka E, Balatoni T, et al. Efficacy of vemurafenib treatment in 43 metastatic melanoma patients with BRAF mutation. Single-institute retrospective analysis, early real-life survival data. Pathol Oncol Res 25:45−50, 2019
   Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867−1876, 2014
   Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30−39, 2015
   Liszkay G, Matrai Z, Czirbesz K, et al. Predictive and prognostic value of BRAF and NRAS mutation of 159 sentinel lymph node cases in melanoma − A retrospective single-institute study. Cancers, Basel, 13:3302, 2021
   Raedler LA. Keytruda, pembrolizumab): First PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits 8:96−100, 2015
   Raedler LA. Opdivo, nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 8:180−183, 2015
   Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535−1546, 2019
   Gorka E, Fabo D, Gezsi A, et al. Dabrafenib therapy in 30 patients with melanoma metastatic to the brain: a single-centre controlled retrospective study in Hungary. Pathol Oncol Res 24:401−406, 2018
   Balatoni T, Ladanyi A, Frohlich G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Pathol Oncol Res 26:317−325, 2020
   Vukadin S, Khaznadar F, Kizivat T, et al. Molecular mechanisms of resistance to immune checkpoint inhibitors in melanoma treatment: an update. Biomedicines 9:835, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 94
EP 99
PG 6
ER

PT J
AU Timar, J
   Ladanyi, A
AF Timar, Jozsef
   Ladanyi, Andrea
TI Molecular pathology of skin melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; BRAF; NRAS; KIT mutations; target therapy; immune checkpoint inhibitors; diagnostics
ID melanoma; BRAF; NRAS; KIT mutations; target therapy; immune checkpoint inhibitors; diagnostics
AB Skin melanoma became one of the most frequent malignancies of the skin mainly due to the increased exposure to environmental UV irradiation. However, this did not lead to the increase of mortality, mainly due to the efficient early diagnostics as well as to the development of new therapies which were based on the identification of the mutation patterns and understanding of the immunobiology. Molecular markers are important to differentiate malignant tumors from precancerous ones but also routinely available to define prognosis. Immunotherapy can be used in any molecular class of melanoma, while target therapy is only available in case of BRAF mutant form. Meanwhile these novel therapies induce new resistance mechanisms based on the development of acquired genetic alterations. Due to these facts the initial molecular profiling of the resected primary tumors must gradually be replaced by continuous monitoring.
C1 [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Timar J, Barbai T, Gyorffy B, Raso E. Chapter 2. Understanding melanoma progression by gene expression signatures. In: Cancer Genomics, Ed. Pfeffer U., Springer, Dordrecht 2013, pp. 47–79
   Timar J. A daganatok oroklodesenek molekularis alapjai. Magy Onkol 64: 7–12, 2020
   Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers 6:24, 2020
   The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161:1681–1696, 2015
   Doma V, Barbai T, Beleaua MA, et al. KIT mutation incidence and pattern of melanoma in central-east Europe. Pathol Oncol Res 26:17–22, 2020
   Timar J, Vizkeleti L, Doma V, et al. Genetic progression of malignant melanoma. Cancer Metastasis Rev 35:93–107, 2016
   Plotar V, Orosz Zs, Toth E, Szentirmay Z. A melanoma malignum hisztopatologiai prognosztikus faktorai. Magy Onkol 51:39–46, 2007
   Ordonez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma. Hum Pathol 45:191–205, 2014
   Deacon DC, Smith EA, Judson-Torres RI. Molecular biomarkers for melanoma screening, diagnosis and prognosis. Front Med 8:642380, 2021
   Uguen A, Talagas M, Costa S, et al. A p16-Ki-67-HMB45 immunohistochemistry score system as an ancillary diagnostic tool in the diagnosis of melanoma. Diagn Pathol 10:195, 2015
   Reimann JDR, Salim S, Velazquez EF, et al. Comparison of melanoma gene expression score with histopathology, FISH and SNP array for the classification of melanocytic neoplasms. Mod Pathol 31:1733–1743, 2018
   Clarke LE, Flake DD, Busam K, et al. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. Cancer 123:617–628, 2017
   Elmore JG, Elder DE, Barnhill RL, et al. Concordance and reproducibility of melanoma staging according to the 7th and 8th edition of the AJCC cancer staging manual. JAMA Netw Open 1:e180083, 2018
   Imredi E, Liszkay G, Kenessey I, et al. Aquaporin-1 protein expression of the primary tumor may predict cerebral progression of cutaneous melanoma. Pathol Oncol Res 26:405–410, 2020
   Hsueh EC, DeBloom JR, Lee JH, et al. Long-term outcomes in a multicenter prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol 5:589–601, 2021
   Ladanyi A, Timar J. Immunologic and immunogenomic aspects of tumor progression. Semin Cancer Biol 60:249–261, 2020
   Ladanyi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res 28:490–500, 2015
   Doma V, Karpati S, Raso E, et al. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer 19:786, 2019
   Seth R, Messerschmith H, Kaur V, et al. Systemic therapy of melanoma: ASCO guideline. J Clin Oncol 38:3947–3970, 2020
   Timar J, Hegedus B, Raso E. The role of lipid signaling in the progression of malignant melanoma. Cancer Metastasis Rev 37:245–255, 2018
   Spain L, Larkin J, Turajlic S. New survival standards for advanced melanoma. Br J Cancer 122:1275–1276, 2020
   Larkin JL, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipili- mumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34, 2015
   Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199, 2014
   Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment – a review from the melanoma perspective. Front Immunol 9:1474, 2018
   Ladanyi A. Immunologiai biomarkerek a rakellenes kezeles hatasanak megjoslasaban. Magy Onkol 60:4–10, 2016
   Balatoni T, Ladanyi A, Frohlich G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Pathol Oncol Res 26:317–325, 2020
   Balatoni T, Mohos A, Papp E et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother 67:141–151, 2018
   Ladanyi A, Papp E, Mohos A, et al. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in melanoma patients. J Immunother Cancer 8:e000209, 2020
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 101
EP 108
PG 8
ER

PT J
AU Czirbesz, K
   Panczel, G
   Baranyai, F
   Kispal, M
   Toth, E
   Bocs, K
   Balatoni, T
   Frohlich, G
   Liszkay, G
AF Czirbesz, Kata
   Panczel, Gitta
   Baranyai, Fanni
   Kispal, Mihaly
   Toth, Erika
   Bocs, Katalin
   Balatoni, Timea
   Frohlich, Georgina
   Liszkay, Gabriella
TI BRAF-MEK inhibitor therapy in melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE BRAF mutation; melanoma therapy; BRAF-MEK inhibitor; survival
ID BRAF mutation; melanoma therapy; BRAF-MEK inhibitor; survival
AB We investigated the efficacy and safety of vemurafenib+cobimetinib (V+C) and dabrafenib+trametinib (D+T) based on real-life data. From 2015 and 2018 we have selected 118 BRAF-mutated metastatic melanoma patients, treated with V+C and D+T in our institute. We retrospectively analyzed the overall response rate (ORR), the progression-free survival (PFS), the overall survival (OS) and the adverse events of the therapies. The median follow-up time was 18 months (3–43) with V+C and 12 months (3–43) with D+T. The median PFS was 8 months in the V+C and 8.5 months in the D+T group. Median OS was 18 months in V+C group and 12 months with D+T. The ORR was revealed to be 82% in D+T group and 76% in V+C group. Each combination displayed a slightly different safety profile. In our retrospective analysis both BRAF-MEK inhibitor combination therapies showed favorable efficacy with a slightly different spectrum of toxicity profile.
C1 [Czirbesz, Kata] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Panczel, Gitta] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Baranyai, Fanni] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Toth, Erika] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Bocs, Katalin] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Frohlich, Georgina] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
RP Czirbesz, K (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM czirbikatu@gmail.com
CR Magyar Nemzeti Rakregiszter
   Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline − Update 2016. Eur J Cancer 63:201−217, 2016
   Liszkay G, Kiss Z, Gyulai R, et al. Changing trends in melanoma incidence and decreasing melanoma mortality in Hungary between 2011 and 2019: a nationwide epidemiological study. Front Oncol 10:612459, 2020
   Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313−319, 2004
   Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855−867, 2004
   Loo E, Khalili P, Beuhler K, et al. BRAF V600E mutation across multiple tumor types: Correlation between DNA-based sequencing and mutation- specific immunohistochemistry. Appl Immunohistochem Mol Morphol AIMM 26(10):709−713, 2018
   Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 10:85, 2012
   Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline, version 1.1). Eur J Cancer 45:228−247, 2009
   Common Terminology Criteria for Adverse Events, CTCAE)
   Vaz-Carneiro A, Luz R, Borges M, Costa J. [Primary and secondary outcomes in oncology clinical trials: definitions and uses]. Acta Med Port 27:498−502, 2014
   Curry JL, Torres-Cabala CA, Tetzlaff MT, et al. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 31:267−273, 2012
   Janku F, Claes B, Huang HJ, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6:26886−26894, 2015
   Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358−365, 2012
   Manzano JL, Layos L, Buges C, et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med 4:237, 2016
   Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma, coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248−1260, 2016
   Lewis KD, Larkin J, Ribas A, et al. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer 121:522−528, 2019
   Ribas A, Daud A, Pavlick AC, et al. Extended 5-year follow-up results of a phase Ib study, BRIM7, of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res 26:46−53, 2020
   Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381:626−636, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 110
EP 117
PG 8
ER

PT J
AU Olah, J
AF Olah, Judit
TI mmunotherapy of cutaneous melanoma – update 2022
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; CTLA-4-inhibitor; PD-1-inhibitor; LAG-3 inhibitor; combined immunotherapy
ID melanoma; CTLA-4-inhibitor; PD-1-inhibitor; LAG-3 inhibitor; combined immunotherapy
AB Melanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.
C1 [Olah, Judit] University of Szeged, Department of Dermatology and Allergology, Koranyi fasor 6., 6720 Szeged, Hungary.
RP Olah, J (reprint author), University of Szeged, Department of Dermatology and Allergology, 6720 Szeged, Hungary.
EM lazarne.olah.judit@med.u-szeged.hu
CR Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 30:1884–1901, 2019
   Hayward NK, Wilmott JS, Waddel N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 545:175–180, 2017
   Moser JC, Chen D, Hu-Lieskovan S, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/ MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med 18:7637–7643, 2019
   Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma, IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395:1835–1844, 2020
   Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546, 2019
   Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137, 2021
   Atkins MB, Kirkwood JM, Wolchok JD, et al. Long-term follow-up of CA209-004, a phase I dose-escalation study of combined nivolumab and ipilimumab in patients with advanced melanoma. J Clin Oncol 37(15_suppl): 9533, 2019
   Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30:582–588, 2019
   Tawbi H, Forsyth A, Hodi FS, et al. Efficacy and safety of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases, CheckMate 204). J Clin Oncol 37(15_suppl): 9501, 2019
   Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:118–142, 2017
   Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24–34, 2022
   Larocca CA, LeBoeuf NR, Silk AW, et al. An update on the role of talimogene laherparepvec, T-VEC, in the treatment of melanoma: best practices and future directions. Am J Clin Dermatol 21:821–832, 2020
   Pfannenstiel LW, McNeilly C, Xiang C, et al. Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 8:e1507669, 2018
   Quaresmini D, Di Lauro A, Fucci L, et al. Electrochemotherapy as a trigger to overcome primary resistance to anti-PD-1 treatment: a case report of melanoma of the scalp. Front Oncol 11:742666, 2021
   Longo F, Perri F, Caponigro F, et al. Boosting the immune response with combination of electrochemotherapy and immunotherapy. A new weapon for squamous cell carcinoma of the head and neck? Cancers 12:2781, 2020
   Theurich S, Rotchschild SI, Hoffmann M, et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 9:744–754, 2016
   Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823, 2017
   Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824–1835, 2017
   Eggermont AM, Blank UC, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 116:148–157, 2019
   Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium, INMC). Nat Med 27:301– 309, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 119
EP 124
PG 6
ER

PT J
AU Janvary, ZsL
   Kispal, M
AF Janvary, Zsolt Levente
   Kispal, Mihaly
TI Stereotactic radiotherapy with CyberKnife and linear accelerator in the management of malignant melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; oligometastases; stereotactic radiotherapy; CyberKnife; linear accelerator
ID melanoma; oligometastases; stereotactic radiotherapy; CyberKnife; linear accelerator
AB Stereotactic radiotherapy gains more and more importance in the management of malignant melanoma, owing to technical developments of recent years. This approach might be applied with success in solitary or oligometastatic cases, since the deliverable biological dose is far higher than that of conventional radiotherapy. Beyond chemotherapy of decreasing importance, there is a widening range of new targeted and immunotherapy agents, leading to longer survival times even in disseminated stages. This latter underlines that it is worth to treat metastatic lesions locally, making this strategy part of present clinical routine. The authors summarize relevant literature of strereotactic radiotherapy in malignant melanoma, and describe related concepts such as oligometastases, abscopal effect or the combination of radiosurgery with modern systemic therapies.
C1 [Janvary, Zsolt Levente] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of DermatologyBudapest, Hungary.
RP Janvary, ZsL (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM janvary.levente@oncol.hu
CR Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab, anti-PD-1, in melanoma. N Engl J Med 369:134−144, 2013
   Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020−1030, 2014
   Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23−34, 2015
   Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006−2017, 2015
   Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment, CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375−384, 2015
   Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193−201, 1995
   Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139:961−966, 2004
   Feun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma, stage IVA melanoma). Cancer 50:1656−1663, 1982
   Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev 34:614−620, 2008
   Ollila DW, Hsueh EC, Stern SL, et al. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 71:209−213, 1999
   Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 16:155−160, 2004
   Gibbs IC. Frameless image-guided intracranial and extracranial radiosurgery using the Cyberknife robotic system. Cancer Radiother 10:283–287, 2006
   Kilby W, Dooley JR, Kuduvalli G, et al. The CyberKnife robotic radiosurgery system in 2010. Technol Cancer Res Treat 9:433–452, 2010
   https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma. pdf
   Harrison BE, Johnson JL, Clough RW, et al. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol 26:354–357, 2003
   Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300, 2004
   Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044, 2009
   Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J Neurosurg 114:769–779, 2011
   Lesueur P, Lequesne J, Barraux V, et al. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries, melanoma and renal cancer). Radiat Oncol 13:138, 2018
   Hara W, Tran P, Li G, et al. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery 64(2 Suppl):A26−32, 2009
   Christ SM, Mahadevan A, Floyd SR, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg Neurol Int 6(Suppl 12):S355−365, 2015
   Rades D, Sehmisch L, Huttenlocher S, et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Res 34:5079−5082, 2014
   Kessel KA, Deichl A, Gempt J, et al. Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA. Clin Transl Oncol 23:2020−2029, 2021
   Frakes JM, Figura NB , Ahmed KA et al. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg 123:1261−1267, 2015
   Bauer-Nilsen K, Trifiletti DM, Chatrath A, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases. J Neurooncol 140:83−88, 2018
   Franceschini D, Franzese C, De Rose F, et al. Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. Br J Radiol 90:20170257, 2017
   Youland RS, Blanchard ML, Dronca R, et al. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clin Transl Radiat Oncol 6:25−30, 2017
   Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 6:34, 2011
   Muacevic A, Nentwich M, Wowra B, et al. Development of a streamlined, non-invasive robotic radiosurgery method for treatment of uveal melanoma. Technol Cancer Res Treat 7:369–374, 2008
   Krema H, Somani S, Sahgal A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up. Br J Ophthalmol 93:1172–1176, 2009
   Muller K, Nowak PJ, de Pan C, et al. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 63:116–122, 2005
   Dunavoelgyi R, Dieckmann K, Gleiss A, et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 81:199−205, 2011
   Ozyigit G, Cengiz M, Yazici G, et al. Robotic stereotactic body radiotherapy in the treatment of sinonasal mucosal melanoma: report of four cases. Head Neck 35:E69−73, 2013
   Bourgeois DJ, Singh AK. Single-fraction stereotactic body radiation therapy for sinonasal malignant melanoma. Head Neck 37:E34−37, 2015
   Abe T, Ebara T, Miyaura K, et al. Malignant melanoma of the nasal cavity treated with stereotactic radiotherapy using CyberKnife: report of 2 cases. Am J Otolaryngol 36:306−309, 2015
   Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy: A synergistic combination. J Clin Invest 123:2756−2763, 2013
   Jiang W, Chan CK, Weissman IL, et al. Immune priming of the tumor microenvironment by radiation. Trends Cancer 2:638−645, 2016
   Sharma S, DeOliveira RB, Kalantari P, et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35:194−207, 2011
   Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259−1271, 2006
   Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions. Front Pharmacol 9:185, 2018
   Anvari A, Sasanpour P, Kheradmardi MR. Radiotherapy and immunotherapy in melanoma brain metastases. Hematol Oncol Stem Cell Ther S1658-3876(21)00110-2, 2021
   Gabani P, Fischer-Valuck BW, Johanns TM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Radiother Oncol 128:266−273, 2018
   Liermann J, Winkler JK, Syed M, et al. Stereotactic radiosurgery with concurrent immunotherapy in melanoma brain metastases is feasible and effective. Front Oncol 10:592796, 2020
   Feng R, Oermann EK, Shrivastava R, et al. Stereotactic radiosurgery for melanoma brain metastases: a comprehensive clinical case series. World Neurosurg 100:297−304, 2017
   Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: Consensus guidelines from the Eastern Cooperative Oncology Group, ECOG). Int J Radiat Oncol Biol Phys 95:632−646, 2016
   Forschner A, Zips D, Schraml C, et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 24:512−516, 2014
   Baroudjian B, Boussemart L, Routier E, et al. Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? Eur J Dermatol 24:265−267, 2014
   Hecht M, Zimmer L, Loquai C, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26:1238−1244, 2015
   Hall EJ. The bystander effect. Health Phys 85:31−35, 2003
   Trommer M, Yeo SY, Persigehl T, et al. Abscopal effects in radio-immunotherapy– response analysis of metastatic cancer patients with progressive disease under anti-PD-1 immune checkpoint inhibition. Front Pharmacol 10:511, 2019
   Liu Y, Dong Y, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11:104, 2018
   Xing D, Siva S, Hanna GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool’s gold or El Dorado? Clin Oncol, R Coll Radiol, 31:432−443, 2019
   Watanabe T, Firat E, Scholber J, et al. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother 69:1823−1832, 2020
   Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology 3:e28780,2014
   Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925−931, 2012
   Kodet O, Nemejcova K, Strnadova K, et al. The abscopal effect in the era of checkpoint inhibitors. Int J Mol Sci 22:7204, 2021
   Dagoglu N, Karaman S, Caglar HB, et al. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus 11:e4103, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 127
EP 133
PG 7
ER

PT J
AU Liszkay, G
   Balatoni, T
AF Liszkay, Gabriella
   Balatoni, Timea
TI Actual points of melanoma management
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE melanoma; BRAF; PD-L1; SLNB; oligoprogression
ID melanoma; BRAF; PD-L1; SLNB; oligoprogression
AB The development of the therapy of advanced melanoma resulted in significant improvement of disease outcome; over 6 years of median survival was reached in the CheckMate 067 study. The new therapeutic modalities are already implemented in the clinical practice according to the current guidelines, however some diagnostic and therapeutic questions are still unresolved. We aimed to highlight the topic of therapeutic options for BRAF mutated melanomas, the role of PD-L1 ligand examination, the adequate therapy of oligoprogression, and the current indication of sentinel lymph node biopsy.
C1 [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
   [Balatoni, Timea] National Institute of Oncology, Department of Dermatology, Rath Gy. u. 7−9., 1122 Budapest, Hungary.
RP Liszkay, G (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM gabriella.liszkay@oncol.hu
CR Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 26:2507−2516, 2011
   Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 9839:358−365, 2012
   Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 20:1867−1876, 2014
   Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 1:30−39, 2015
   Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib, D, and trametinib, T, with vemurafenib, Vem, as first-line therapy in patients, pts, with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 51(Suppl 3):3301, 2015
   Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 9992:444−451, 2015
   Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma, COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 5:603−615, 2018
   Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer 126:33−44, 2020
   Galambos K, Erdelyi K, Balog N, et al. Redox rendszerek vizsgalata a dabrafenib- trametinib celzott terapiara rezisztens melanomasejtekben. Magy Onkol 65(Szuppl):21, 2021
   Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 8:711−723, 2010
   Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 14:1345−1356, 2017
   Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma, Check- Mate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480−1492, 2018
   van Bussel MTJ, Beijnen JH, Brandsma D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC Cancer 19:519, 2019
   Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma, IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395:1835−1844, 2020
   Lotz G, Smuk G, Kocsmar E, et al. A programozott sejthalal feherje 1, PD-1, − programozott sejthalal ligandum 1, PD-L1, gatlas prediktiv diagnosztikaja. Magy Onkol 63:183−191, 2019
   Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275−287, 2016
   Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors, imRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 36:850−858, 2018
   Spagnolo F, Boutros A, Cecchi F, et al. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer 21:425, 2021
   Comito F, Leslie I, Boos L, et al. Oligoprogression after checkpoint inhibition in metastatic melanoma treated with locoregional therapy: a single- center retrospective analysis. J Immunother 43:250−255, 2020
   Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381:626−636, 2019
   Chua TC, Scolyer RA, Kennedy CW, et al. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol 19:1774−1781, 2012
   Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res 23:307−311, 2013
   Dueck GS, Chua N, Prasad A, et al. Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol 27(15_ suppl):8524, 2009
   Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence- based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472−492, 2017
   Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211−2222, 2017
   Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma, DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757−767, 2016
   Plotar V, Liszkay G, Ladanyi A, et al. A malignus melanoma uj TNM-klas�- szifikacioja, AJCC, 2009, es az orszemnyirokcsomo-biopszia patologiai jelentosege. Magy Onkol 57:68−72, 2013
   Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110−2121, 2001
   Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824−1835, 2017
   Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789−1801, 2018
   Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813−1823, 2017
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 134
EP 139
PG 6
ER

PT J
AU Balatoni, T
   Kispal, M
   Madurka, I
   Liszkay, G
AF Balatoni, Timea
   Kispal, Mihaly
   Madurka, Ildiko
   Liszkay, Gabriella
TI COVID-19 and melanoma: a single center retrospective cohort study from Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE melanoma; COVID-19
ID melanoma; COVID-19
AB COVID-19 pandemic affected the diagnosis and management of many diseases, including the most vulnerable group of patients with cancer. In this retrospective survey we evaluated the course of disease of patients treated for melanoma, who got infected with COVID-19 virus between March 2020 and April 2021. 382 patients had been treated for advanced melanoma in our center in this time period. 24 of them had been infected with coronavirus. Six of them suffered in stage III melanoma, the remaining 18 patients had stage IV disease. 14, 5 and 4 of the infected patients had been administered with checkpoint inhibitor, targeted therapy and chemotherapy, respectively. Seven (29%) patients died in COVID-19 infection, in a median of 12 days. None of our patients who had been vaccinated at least one time, had severe symptoms. As a conclusion, the mortality of COVID-19 infection was significantly higher among our melanoma patients compared to the age-standardized mortality rate in Hungary.
C1 [Balatoni, Timea] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Kispal, Mihaly] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
   [Madurka, Ildiko] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Liszkay, Gabriella] National Institute of Oncology, Department of Dermatology, Rath Gyorgy u. 7−9., 1122 Budapest, Hungary.
RP Balatoni, T (reprint author), National Institute of Oncology, Department of Dermatology, 1122 Budapest, Hungary.
EM balatoni.timea@oncol.hu
CR Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775−1776, 2020
   Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019, COVID-19, outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239−1242, 2020
   Quaglino P, Fava P, Brizio M. Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. Future Oncol 17:759−761, 2021
   D’Ippolito S, Ambrosini E, Shams M, et al. The effect of loneliness on cancer mortality. Ann Oncol 28:vi82, 2017
   Hill EM, Hamm A. Intolerance of uncertainty, social support, and loneliness in relation to anxiety and depressive symptoms among women diagnosed with ovarian cancer. Psychooncology 28:553–560, 2019
   National Comprehensive Cancer Network. Short-Term Recommendations for Cutaneous Melanoma Management During COVID-19 Pandemic, Version 3.2020)
   European Society for Medical Oncology. ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Melanoma. https:// www.esmo.org/guidelines/cancer-patient-management-during-thecovid- 19-pandemic/melanoma-in-the-covid-19-era, accessed February 10, 2021)
   Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 384:72–79, 2021
   Conforti C, Lallas A, Argenziano G, et al. Impact of the COVID-19 pandemic on dermatology practice worldwide: results of a survey promoted by the International Dermoscopy Society, IDS). Dermatol Pract Concept 11:e2021153, 2021
   Indini A, Costa S, Lerardi AM. COVID-19 vaccination mimicking lymphnode progression in a patient with melanoma: a case report. Melanoma Res 31:490−493, 2021
   Prieto PA, Mannava K, Sahasrabudhe DM. COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma. Lancet Oncol 22:e281, 2021
   McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol 147:48–54, 2002
   Basnet A, Wang D, Sinha S, et al. Effect of a delay in definitive surgery in melanoma on overall survival: a NCDB analysis. J Clin Oncol 36(15_Suppl): e21586, 2018
   Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. J Am Acad Dermatol 78:40–46, 2018
   Teuscher M, Diehl K, Schaarschmidt ML. Effects of the COVID-19 pandemic on care of melanoma patients in Berlin, Germany: the Mela-COVID survey. Eur J Dermatol 31:521–529, 2021
   British Association of Dermatologists and British Society for Dermatological Surgery. Clinical Guidance for the Management of Skin Cancer Patients During the Coronavirus Pandemic, Version 3.2020)
   Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823, 2017
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 141
EP 145
PG 5
ER

PT J
AU Kozma, A
   Meggyesi, N
   Hardi, A
   Cegledi, A
   Toman, �
   Kapocs, K
   Mikala, G
AF Kozma, Andras
   Meggyesi, Nora
   Hardi, Apor
   Cegledi, Andrea
   Toman, Agnes
   Kapocs, Katalin
   Mikala, Gabor
TI Calreticulin: Pathophysiology of an unusual gain-of-function and its clinical consequences
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE calreticulin; frameshift mutation; myelofibrosis; essential thrombocytosis; misfolded protein
ID calreticulin; frameshift mutation; myelofibrosis; essential thrombocytosis; misfolded protein
AB One characteristic type of the common somatic mutations causing myeloproliferative neoplasias is the frameshift mutation of the calreticulin gene that leads to proteins of abnormal structure. The pathologic protein induces novel cell biological processes that are fundamental to the onset and maintenance of myeloproliferative diseases. In this review, an insight is provided into these processes, aiding better understanding of the underlining pathobiological processes and eventually to more effective therapy in the future.
C1 [Kozma, Andras] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai LaboratoriumBudapest, Hungary.
   [Meggyesi, Nora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai LaboratoriumBudapest, Hungary.
   [Hardi, Apor] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, Albert Florian ut 5−7., 1097 Budapest, Hungary.
   [Cegledi, Andrea] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, Albert Florian ut 5−7., 1097 Budapest, Hungary.
   [Toman, Agnes] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai LaboratoriumBudapest, Hungary.
   [Kapocs, Katalin] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai LaboratoriumBudapest, Hungary.
   [Mikala, Gabor] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, Albert Florian ut 5−7., 1097 Budapest, Hungary.
RP Mikala, G (reprint author), Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios Osztaly, 1097 Budapest, Hungary.
EM gmikala@dpckorhaz.hu
CR Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol 105:743−747, 2017
   Michalak M, Groenendyk J, Szabo E, et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 417:651−666, 2009
   Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379−2390, 2013
   Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369: 2391−2405, 2013
   Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129:667−679, 2017
   Li J, Prins D, Park HJ, et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood 131:649−661, 2018
   Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 127:1317−1324, 2016
   Shide K, Kameda T, Yamaji T, et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia 31:1136−1144, 2017
   Elf S, Abdelfattah NS, Baral AJ, et al. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood 131:782−786, 2018
   Elf S, Abdelfattah NS, Chen E, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov 6:368−381, 2016
   Han L, Schubert C, Kohler J, et al. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol 9:45, 2016
   Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 127:1307−1316, 2016
   Araki M, Komatsu N. Mutant molecular chaperone activates cytokine receptor as a homomultimer. Oncotarget 9:35201−35202, 2018
   Araki M, Yang Y, Imai M, et al. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia 33:122−131, 2019
   Pecquet C, Chachoua I, Roy A, et al. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood 133:2669−2681, 2019
   Masubuchi N, Araki M, Yang Y, et al. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia 34:499−509, 2020
   Liu P, Zhao L, Loos F, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell 77:748−760 e9, 2020
   Daitoku S, Takenaka K, Yamauchi T, et al. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis. Exp Hematol 44:817−825, 2016
   Cimen Bozkus C, Roudko V, Finnigan JP, et al. Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov 9:1192−1207, 2019
   Arshad N, Cresswell P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem 293:9555−9569, 2018
   Di Buduo CA, Abbonante V, Marty C, et al. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood 135:133−144, 2020
   Salati S, Genovese E, Carretta C, et al. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Sci Rep 9:10558, 2019
   Pronier E, Cifani P, Merlinsky TR, et al. Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:e122703, 2018
   Lau WW, Hannah R, Green AR, et al. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood 125:1679−1681, 2015
   Nam AS, Kim KT, Chaligne R, et al. Somatic mutations and cell identity linked by genotyping of transcriptomes. Nature 571:355−360, 2019
   Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391−2405, 2016
   Langabeer SE, Andrikovics H, Asp J, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 95:270−279, 2015
   Egyed M, Illes A. Aktualitasok az essentialis thrombocythaemia diagnosztikajaban es terapiajaban. Hematologia–Transzfuziologia 51:5–14, 2018
   Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 99:1184−1190, 2014
   Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29:249−252, 2015
   Cottin L, Riou J, Orvain C, et al. Sequential mutational evaluation of CALR-mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol 188:935−944, 2020
   Gango A, Mozes R, Boha Z, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res 65:42−48, 2018
   Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431−438, 2016
   Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552−1555, 2014
   Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544−1551, 2014
   Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124:1062−1069, 2014
   Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28:1568−1570, 2014
   Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121−124, 2014
   Perez Encinas MM, Sobas M, Gomez-Casares MT, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. Eur J Haematol 106:371−379, 2021
   Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5:e360, 2015
   Li B, Xu Z, Li Y, et al. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. Am J Hematol 91:E320−321, 2016
   Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472−1477, 2014
   Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36:310−318, 2018
   Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127:1325−1335, 2016
   Mansier O, Prouzet-Mauleon V, Jegou G, et al. The expression of myeloproliferative neoplasm-associated calreticulin variants depends on the functionality of ER-associated degradation. Cancers, Basel, 11:1921, 2019
   Holmstrom MO, Martinenaite E, Ahmad SM, et al. The calreticulin, CALR, exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32:429−437, 2018
   Handlos Grauslund J, Holmstrom MO, Jorgensen NG, et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms. Front Oncol 11:637420, 2021
   Jia R, Balligand T, Atamanyuk V, et al. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. Blood 137:1920−1931, 2021
   Vainchenker W, Plo I, Marty C, et al. The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Expert Rev Hematol 12:437−448, 2019
   Achyutuni S, Nivarthi H, Majoros A, et al. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti- CALR antibody immunotherapies in vivo. Am J Hematol 96:698−707, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 147
EP 152
PG 6
ER

PT J
AU Kremzer, T
   Pete, I
   Stari, O
   Loderer, Z
AF Kremzer, Tamas
   Pete, Imre
   Stari, Oliver
   Loderer, Zoltan
TI The primary surgical therapy of a synchronous sigmoid, rectal and vulvar cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE multiple primary neoplasms; synchronous neoplasms; vulvar cancer
ID multiple primary neoplasms; synchronous neoplasms; vulvar cancer
AB Malignant tumors were the leading cause of death in Hungary between 1990 and 2018 according to the central statistical office (www.ksh.hu). While the mortality of cerebrovascular diseases is decreasing, cancer-related mortality is getting worse, despite the improvement of both diagnostic and therapeutic opportunities. The exact number of synchronous double and triple cancers in Hungary is unknown, and their therapeutic pathways are unclear. Currently there is no data available regarding these questions in the National Cancer Registry. In this case report we present the diagnostic and therapeutic algorithm of a patient with a triple malignancy.
C1 [Kremzer, Tamas] Markusovszky Egyetemi Oktatokorhaz, Altalanos Er- es Plasztikai Sebeszeti Osztaly, Markusovszky Lajos u. 5., 9700 Szombathely, Hungary.
   [Pete, Imre] Markusovszky Egyetemi Oktatokorhaz, Szuleszet-Nogyogyaszati OsztalySzombathely, Hungary.
   [Stari, Oliver] Markusovszky Egyetemi Oktatokorhaz, Altalanos Er- es Plasztikai Sebeszeti Osztaly, Markusovszky Lajos u. 5., 9700 Szombathely, Hungary.
   [Loderer, Zoltan] Markusovszky Egyetemi Oktatokorhaz, Altalanos Er- es Plasztikai Sebeszeti Osztaly, Markusovszky Lajos u. 5., 9700 Szombathely, Hungary.
RP Loderer, Z (reprint author), Markusovszky Egyetemi Oktatokorhaz, Altalanos Er- es Plasztikai Sebeszeti Osztaly, 9700 Szombathely, Hungary.
EM medloderer@yahoo.com
CR Abu-Musa A, Khalil A, Ghaziri G, et al. Synchronous vulvar and breast cancer. Eur J Obstet Gynecol Reprod Biol 100:92–93, 2001
   Vahidfar M, Abdolahi AH, Karimi Zarchi M. Colorectal and vulvar synchronous cancer a case. Iran J Blood Cancer 5:151–152, 2013
   Deppe G, Dolan TE, Zbella EA, Heredia R. Synchronous multiple primary malignant neoplasms of the breast, colon and vulva. A case report. J Reprod Med 29:878–880, 1984
   Bisof V, Basic-Koretic M, Juretic A, et al. [Multiple primary malignancies.] Lijec Vjesn 133;384–388, 2011
   Salem A, Abu-Hijlih R, Abdelrahman F, et al. Multiple primary malignancies: analysis of 23 patients with at least three tumors. J Gastrointest Cancer 43:437–443, 2012
   Buchler DA. Multiple primaries and gynecologic malignancies. Am J Obstet Gynecol 123:376–381, 1975
   Shinohara M, Matsuura Y, Baba S, Kashimura M. [Multiple primary cancers associated with gynecologic malignancies.] Nihon Sanka Fujinka Gakkai Zasshi 42:561–566, 1990
   Kamata H, Koide Y, Miyagawa N, et al. [Report on 15 cases of multiple primary cancers in our department.] Gan No Rinsho 29:A-21, 321–324, 1983
   Dudnyikova A, Vereczkey I, Pete I. Szinkron jelentkezo harom malignus es egy benignus nogyogyaszati daganat esetismertetese. Magy Onkol 56:55–59, 2012
   Yang L, Zhang D, Li F, Ma X. Simultaneous laparoscopic distal gastrectomy, uncut Roux-en-Y anastomosis), right hemi-colectomy and radical rectectomy, Dixon, in a synchronous triple primary stomach, colon and rectal cancers patient. J Vis Surg 2:101–101, 2016
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 153
EP 156
PG 4
ER

PT J
AU Toth, G
   Hecz, R
   Toth, J
   Pencz, B
   Szabo, A
   Lukats, O
   Szucs, M
   Dank, M
   Nagy, ZZs
   Csakany, B
AF Toth, Gabor
   Hecz, Reka
   Toth, Jeannette
   Pencz, Bianka
   Szabo, Antal
   Lukats, Olga
   Szucs, Miklos
   Dank, Magdolna
   Nagy, Zoltan Zsolt
   Csakany, Bela
TI Metastatic clear cell renal cell carcinoma: a potential mimicker of choroidal melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE ocular metastasis; choroidal metastasis; ultrasonography; renal cell carcinoma
ID ocular metastasis; choroidal metastasis; ultrasonography; renal cell carcinoma
AB While metastases are the most common intraocular malignancies, ocular metastases of renal cell carcinoma are rare. The most frequent primary malignancy of the eye is uveal melanoma. The common ocular localization is the choroid in both cases. The clinical differentiation of choroidal metastasis from renal cell carcinoma and choroidal melanoma malignum is a diagnostic challenge for the ophthalmologist. We present two cases where renal cell carcinoma had metastasized to the choroid. Enucleation was performed in a 61- and a 71-year-old male patient with suspected advanced choroidal malignant melanoma following biomicroscopic and B-scan ultrasonography examination. Histopathological examination confirmed clear-cell renal cell carcinoma in both cases. The clinical and ultrasonographic appearance of clear-cell renal cell carcinoma metastasis may mimic choroidal malignant melanoma, and may only be suspected if a primary renal cell carcinoma is already established.
C1 [Toth, Gabor] Semmelweis University, Department of Ophthalmology, Maria utca 39., 1085 Budapest, Hungary.
   [Hecz, Reka] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Toth, Jeannette] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Pencz, Bianka] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Szabo, Antal] Semmelweis University, Department of Ophthalmology, Maria utca 39., 1085 Budapest, Hungary.
   [Lukats, Olga] Semmelweis University, Department of Ophthalmology, Maria utca 39., 1085 Budapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Dank, Magdolna] Semmelweis University, 1st Department of Internal MedicineBudapest, Hungary.
   [Nagy, Zoltan Zsolt] Semmelweis University, Department of Ophthalmology, Maria utca 39., 1085 Budapest, Hungary.
   [Csakany, Bela] Semmelweis University, Department of Ophthalmology, Maria utca 39., 1085 Budapest, Hungary.
RP Toth, G (reprint author), Semmelweis University, Department of Ophthalmology, 1085 Budapest, Hungary.
EM gabortothgabor@gmail.com
CR Shields CL, Shields JA, Gross NE, et al. Survey of 520 eyes with uveal metastases. Ophthalmology 104:1265–1276, 1997
   Welch RJ, Malik K, Considine SP, et al. Uveal metastasis based on patient sex in 2214 tumours of 1111 patients. A comparison of female versus male clinical features and outcomes. Asia Pac J Ophthalmol, Phila, 8:298–303, 2019
   Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 55:74–108, 2005
   Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 349:g4797, 2014
   Biro K, Kuronya Zs. Az elorehaladott vesedaganat kezelesenek ujabb lehetosegei a nemzetkozi ajanlasok tukreben. Magy Onkol 54:369–376, 2010
   Thomas JS, Kabbinavar F. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. Crit Rev Oncol Hematol 96:527–533, 2015
   Komanski CB, Rubino SM, Meyer JC, et al. Choroideal melanoma mimicker: A case of metastatic clear-cell renal cell carcinoma. Ocul Oncol Pathol 3:279–282, 2017
   Gong J, Maia MC, Dizman N, et al. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol 3:286-292, 2016
   Haimovici R, Gragoudas ES, Gregor Z, et al. Choroideal metastases from renal cell carcinoma. Ophthalmology 104:1152–1158, 1997
   Wyzinski P, Rootman J, Wood W. Simultaneous bilateral iris metastases from renal cell carcinoma. Am J Ophthalmol 92:206–209, 1981
   Slamovits TL, Burde RM. Bumpy muscles. Surv Ophthalmol 33:189–199, 1988
   Nelson CC, Hertzberg BS, Klintworth GK. A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. Am J Ophthalmol 95:788–793, 1983
   Cohen VML. Ocular metastases. Eye 27:137–141, 2013
   Damjanovich J, Suranyi E, Berta A. Az uvea melanomak kezelesenek alapelvei. Szemeszet 149:1–5, 2012
   Selby LD, Stiefel HC, Skalet AH, et al. Vision loss from choroideal and pituitary metastases secondary to renal cell carcinoma: A case report. Neuroophthalmology 42:391–398, 2018
   Shome D, Honavar SG, Gupta P, et al. Metastasis to the eye and orbit from renal cell carcinoma – A report of three cases and review of literature. Surv Ophthalmol 52:213–223, 2007
   Toth G, Szalai E, Csakany B, et al. Pigmentsejt-eredetu szemfelszini elvaltozasok differencialdiagnozisa es kezelese. Orv Hetil 161:563–574, 2020
   Toth G, Sandor GL, Gyenes A, et al. Szemfelszini lapham-neoplasia. Orv Hetil 158:2011–2022, 2017
   Toth G, Szentmary N, Sandor GL, et al. Clinicopathological review of 547 bulbar enucleations in Hungary, 2006-2017). J Ophthalmol 2019:2042459, 2019
   Arepalli S, Kaliki S, Shields CL. Choroideal metastases: Origin, features, and therapy. Indian J Ophthalmol 63:122–127, 2015
   Mourad WF, Dutcher J, Ennis RD. State-of-the-art management of renal cell carcinoma. Am J Clin Oncol 37:498–505, 2014
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 157
EP 161
PG 5
ER

PT J
AU Maraczi, A
   Kajtar, B
   Nagy, �
   Gyorke, E
   Gorog, P
   Kurucz, J
   Kalman, B
   Garzuly, F
AF Maraczi, Alexandra
   Kajtar, Bela
   Nagy, Adam
   Gyorke, Eszter
   Gorog, Petra
   Kurucz, Jozsefne
   Kalman, Bernadette
   Garzuly, Ferenc
TI Case report: molecular analysis of congenital glioblastoma in a newborn
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE congenital glioblastoma; immunohistochemistry; molecular testing; targeted therapy
ID congenital glioblastoma; immunohistochemistry; molecular testing; targeted therapy
AB Background: Congenital glioblastoma (cGBM) is a brain tumor very rarely observed in newborns and young infants, and differs in several respects from glioblastoma (GBM) of childhood and adulthood. Our aim was the presentation of a cGBM case with 14 days of postnatal survival at the Pediatric Oncology Center of the Markusovszky University Teaching Hospital in 2004. We investigated formalin-fixed, paraffin-embedded autoptic tumor samples of the newborn by immunohistochemical and molecular genetic (FISH and pyrosequencing) methods. We found polysomy of chromosome 2 and 5’ deletion of the ALK gene in the glioma cells by ALK FISH. This result indicates the importance of molecular analyses in the diagnostic evaluation of cGBM, and raises the possibility of a personalized, targeted therapy (crizotinib, alectinib).
C1 [Maraczi, Alexandra] Markusovszky Egyetemi Oktatokorhaz, Molekularis Patologia, Markusovszky L. u. 5., 9700 Szombathely, Hungary.
   [Kajtar, Bela] University of Pecs, Department of PathologyPecs, Hungary.
   [Nagy, Adam] Markusovszky Egyetemi Oktatokorhaz, Molekularis Patologia, Markusovszky L. u. 5., 9700 Szombathely, Hungary.
   [Gyorke, Eszter] Markusovszky Egyetemi Oktatokorhaz, Gyermekonkologiai CentrumSzombathely, Hungary.
   [Gorog, Petra] Markusovszky Hospital, Department of PathologySzombathely, Hungary.
   [Kurucz, Jozsefne] Markusovszky Hospital, Department of PathologySzombathely, Hungary.
   [Kalman, Bernadette] Markusovszky Egyetemi Oktatokorhaz, Molekularis Patologia, Markusovszky L. u. 5., 9700 Szombathely, Hungary.
   [Garzuly, Ferenc] Markusovszky Hospital, Department of PathologySzombathely, Hungary.
RP Maraczi, A (reprint author), Markusovszky Egyetemi Oktatokorhaz, Molekularis Patologia, 9700 Szombathely, Hungary.
EM maraczi.alexandra@gmail.com
CR Jakobovits A. A magzat daganatos betegsegei, Oncologia foetalis, = Fetal oncology. Orv Hetil 148:2377−2384, 2007
   Isaaks HJ. I. Perinatal brain tumors. A review of 250 cases. Pediatr Neurol 27:243–261, 2002
   Solitare GB, Krigman MR. Congenital intracranial neoplasm. A case report and review of the literature. J Neuropathol Exp Neurol 23:280–292, 1964
   Isaaks HJ. II. Perinatal brain tumors. A review of 250 cases. Pediatr Neurol 27:333–342, 2002
   Balint EK, Julow J. A kozponti idegrendszer daganatainak patologiaja. Melania Kiado, Budapest, 2010
   Kameda M, Otani Y, Ichikawa T, et al. Congenital glioblastoma with distinct clinical and molecular characteristics: case reports and a literature review. World Neurosurg 101:817, 2017
   Macy ME, Birks DK, Barton VN, et al. Clinical and molecular characteristics of congenital glioblastoma. Neuro Oncol 14:931–941, 2012
   Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820, 2016
   Verhaak RGW, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98, 2010
   Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510−522, 2010
   Guerreiro SAS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/ MET drive a group of infantile hemispheric gliomas. Nat Commun 10:4343, 2019
   Moore SW, Sasco AJ, Dechelotte P, et al. In vitro fertilization and brain tumors. J Neurosurg 106:418, 2007
   Das A, Simmons C, Danielpour M. A congenital brain tumor associated with assisted in vitro fertilization. Case report. J Neurosurg 103:451−453, 2005
   Tompa M, Nagy A, Komoly S, et al. Wnt pathway markers in molecular subgroups of glioblastoma. Brain Res 1718:114−125, 2019
   Maraczi A, Nagy A, Eder K, et al. Daganatos betegek molekularis vizsgalatai a Nyugat-dunantuli regioban 2015 es 2018 kozott. Egeszseg Akademia 9:150−162, 2018
   Holt L. Gliosarcoma in an infant of several weeks resembling hydrocephalus. Am J Dis Child 39:219−221, 1917
   Winters JL, Wilson D, Davis DG. Congenital glioblastoma multiforme. A report of three cases and a review of the literature. J Neurol Sci 188:13−19, 2001
   Ben Nsir A, Darmoul M, Hadhri R, et al. Congenital glioblastoma: Lessons learned from a rare case with unusual presentation. Turk Neurosurg 27:464−467, 2017
   Jung WH, Choi S, Oh KK, et al. Congenital glioblastoma multiforme – report of an autopsy case. J Korean Med Sci 5:225−231, 1990
   Brat DJ, Shehata BM, Castellano-Sanchez AA, et al. Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol 17:276−281, 2007
   Seker A, Ozek MM. Congenital glioblastoma multiforme. Case report and review of the literature. J Neurosurg 105:473−479, 2006
   Mazzone D, Magro G, Lucenti A, et al. Report of a case of congenital glioblastoma multiforme: an immunohistochemical study. Childs Nerv Syst 11:311−313, 1995
   Zhong Y, Lin F, Xu F, et al. Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma. Cancer Genet 252−253:37−42, 2021
   Prasad VB, Rajesh A, Purohit AK, et al. A rare case of congenital glioblastoma with atypical presentation in an eleven month-old infant: Case report with review of literature. Asian J Neurosurg 12:72−74, 2017
   Franceschi E, Biase DD, Nunno DV, et al. The clinical and prognostic role of ALK in glioblastoma. Pathol Res Pract 221:153447, 2021
   Elsers D, Temerik DF, Attia AM, et al. Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations. J Pathol Transl Med 55:212−224, 2021
   Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 31:1105–1111, 2013
   Bagchi A, Orr BA, Campagne O, et al. Lorlatinib in a child with ALK-fusion- positive high-grade glioma. N Engl J Med 385:761−763, 2021
   Kettner LO, Henriksen TB, Bay B, et al. Assisted reproductive technology and somatic morbidity in childhood: a systematic review. Fertil Steril 103:707−719, 2015
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2022
VL 66
IS 2
BP 162
EP 167
PG 6
ER

PT J
AU Boncz, I
   Bodis, J
AF Boncz, Imre
   Bodis, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
DE preface; prevention; screening
ID preface; prevention; screening
C1 [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Bodis, Jozsef] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Pecs, Hungary.
CR 51/1997., XII. 18., NM-rendelet a kotelezo egeszsegbiztositas kereteben igenybe veheto betegsegek megelozeset es korai felismereset szolgalo egeszsegugyi szolgaltatasokrol es a szurovizsgalatok igazolasarol
   Boncz I, Sebestyen A, Dobrossy L, et al. The organization and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol 18:795–799, 2007
   Kovacs A, Dobrossy L, Budai A, et al. A nepegeszsegugyi mehnyakszures helyzete Magyarorszagon 2006-ban. Orv Hetil 148:535–540, 2007
   Bosze P, Gocze P, Hernadi Z, et al. A mehnyakrak szuresenek szempontjai: hazai iranyelvek. Nogyogyaszati Onkologia 14:11–17, 2009
   Boncz I, Sebestyen A, Gulacsi L, et al. Az emlorakszuresek egeszseg-gazdasagtani elemzese. Magy Onkol 47:149–154, 2003
   Boncz I, Sebestyen A, Pal M, et al. A mehnyakrakszuresek egeszseg-gazdasagtani elemzese. Orv Hetil 144:713–717, 2003
   19/2009., VI. 18., EuM-rendelet a tizenhat eveseknek szervezett ingyenes orvosi vizsgalat megvalositasaval es az uj Egeszsegugyi Konyv bevezetesevel osszefuggo egyes miniszteri rendeletek modositasarol
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 173
EP 173
PG 1
ER

PT J
AU Kenessey, I
   Nagy, P
   Polgar, Cs
AF Kenessey, Istvan
   Nagy, Peter
   Polgar, Csaba
TI The Hungarian situation of cancer epidemiology in the second decade of the 21st century
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE oncology; cancer; epidemiology; incidence; mortality
ID oncology; cancer; epidemiology; incidence; mortality
AB Evaluation of cancer incidence and mortality is essential for the design and development of oncology networks. In Hungary the population-based epidemiological data collection in oncology is executed by the Hungarian National Cancer Registry, whilst, mortality statistics are compiled by the Hungarian Central Statistical Office. In this review, Hungarian cancer epidemiology of 2010s was presented, using population- based morbidity and mortality data, and positioning the country in European cancer statistics. According to GLOBOCAN estimations, Hungary suffers from the highest cancer incidence and mortality rates in Europe. We have reported a steady increase in the number of new cases, while mortality stagnated. Lung and colorectal cancers showed the highest incidence, which was followed by breast cancer. These three malignancies are responsible for almost half of the cancer-related deaths. Improving the quality of population- based disease registries, such as the Hungarian Cancer Registry, requires wide and extensive multidisciplinary collaborative work from many stakeholders.
C1 [Kenessey, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Kenessey, I (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM kenessey.istvan@oncol.hu
CR Kenessey I, Weber A, Szilagyi I, et al. Az orvosi kodtarak gyakorlati alkalmazasa az onkologiaban – szakmai utmutato a Nemzeti Rakregiszter tapasztalatai alapjan. Magy Onkol 66:4–10, 2022
   Kasler M, Otto Sz, Solyom O. Nemzeti Rakregiszter. A hiteles adatok gyujtesenek jelentosege a hazai onkologiai ellatas szuksegszeru szerkezetvaltasaban. Orv Hetil 155:1415–1420, 2014
   Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   https://gco.iarc.fr/today/home. Cancer Today, International Agency for Research on Cancer, 2021
   Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387, 2018
   Ellis L, Belot A, Rachet B, et al. The mortality-to-incidence ratio is not a valid proxy for cancer survival. J Glob Oncol 5:1–9, 2019
   Sunkara V, Hebert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer 121:1563–1569, 2015
   Varnai M, Kiss Z, Gyulai R, et al. Improving quality indicator of melanoma management – change of melanoma mortality-to-incidence rate ratio based on a Hungarian nationwide retrospective study. Front Oncol 11:745550, 2021
   Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45:747–755, 2009
   Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 45:756–764, 2009
   Tusnady G, Gaudi I, Rejto L, et al. A magyar daganatos betegek tulelesi eselye a Nemzeti Rakregiszter adatai alapjan. Magy Onkol 52:339–349, 2008
   Otto Sz, Kasler M. Rakmortalitas es -incidencia hazankban az europai adatok tukreben. Magy Onkol 46:111–117, 2002
   Otto Sz, Kasler M. A hazai es nemzetkozi daganatos halalozasi es megbetegedesi mutatok alakulasa. A nepegeszsegugyi programok jellegzetessegei es varhato eredmenyei. Magy Onkol 49:99–107, 2005
   Kasler M, Otto Sz. Europai es hazai kihivasok az onkologiaban. Magy Onkol 52:21–33, 2008
   http://stat.nrr.hu/, Nemzeti Rakregiszter, 2022
   https://www.ksh.hu/, Kozponti Statisztikai Hivatal, 2021
   Melczer M. Krompecher Odon alapi sejtes rakja a szazadfordulon es ma. Orv Hetil 100:382–387, 1959
   Parrag P, Weber A, Liszkay G, et al. A melanoma hazai morbiditasi es mortalitasi helyzete a XXI. szazad elso ket evtizedeben. Magy Onkol 66:94–99, 2022
   Binder H, Blettner M. Big data in medical science – a biostatistical view. Dtsch Arztebl Int 112:137–142, 2015
   Bogos K, Kiss Z, Galffy G, et al. A tudorak hazai epidemiologiai adatai uj megkozelitesben. Magy Onkol 64:175–181, 2020
   Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014, ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493–1505, 2019
   Morris EJA, Goldacre R, Spata E, et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population- based study. Lancet Gastroenterol Hepatol 6:199–208, 2021
   Kaufman HW, Chen Z, Niles J, et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019, COVID-19, pandemic. JAMA Netw Open 3:e2017267, 2020
   Gathani T, Clayton G, MacInnes E, et al. The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020. Br J Cancer 124:710–712, 2021
   Johansson ALV, Laronningen S, Skovlund CW, et al. The impact of the COVID-19 pandemic on cancer diagnosis based on pathology notifications: A comparison across the Nordic countries during 2020. Int J Cancer 151:381–395, 2022
   Raymond E, Thieblemont C, Alran S, et al. Impact of the COVID-19 outbreak on the management of patients with cancer. Target Oncol 15:249–259, 2020
   Lai AG, Pasea L, Banerjee A, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open 10:e043828, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 175
EP 184
PG 10
ER

PT J
AU Vajda, R
   Bodis, J
   Ponusz-Kovacs, D
   Elmer, D
   Kajos, LF
   Csakvari, T
   Kives, Zs
   Boncz, I
AF Vajda, Reka
   Bodis, Jozsef
   Ponusz-Kovacs, Dalma
   Elmer, Diana
   Kajos, Luca Fanni
   Csakvari, Timea
   Kives, Zsuzsanna
   Boncz, Imre
TI Participation indicators of organized cervical cancer screening in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cervical cancer screening; cervical cancer; organized screening; HPV; participation rate
ID cervical cancer screening; cervical cancer; organized screening; HPV; participation rate
AB The aim of this study was to determine the percentage of women in Hungary who underwent gynecological cytological examinations either as part of a screening test or diagnostic examinations. Data derived from the nationwide financing database of the Hungarian National Health Insurance Fund Management and covered the period 2008–2021. We analyzed both diagnostic and screening cytological tests. The number of diagnostic tests has decreased. The number of patients per 10,000 female inhabitants in 2021 was a national average of 840. The highest rate was observed in the counties of Hajdu-Bihar (1464/10,000 female inhabitants), Tolna (1443) and Baranya (1254). In screening, the number of cytological tests is lower compared to smearing. The annual participation rate decreased from 28% to 17%. The number of patients and the participation rate of diagnostic cytology examinations decreased during the examined period. The added value of screening cytology is moderate, the willingness to participate is low, falling short of the expected value.
C1 [Vajda, Reka] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Bodis, Jozsef] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Ponusz-Kovacs, Dalma] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Elmer, Diana] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Kajos, Luca Fanni] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Csakvari, Timea] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Kives, Zsuzsanna] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Pecs, Hungary.
EM imre.boncz@etk.pte.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175–184, 2022
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 90:1–636, 2007
   Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395:575–590, 2020
   Boersma P, Black LI. Human papillomavirus vaccination among adults aged 18–26, 2013–2018. NCHS Data Brief 354:1–8, 2020
   Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin 70:274–280, 2020
   Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 132:854–867, 2013
   Depuydt CE, Criel AM, Benoy IH, et al. Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 16:3096–3104, 2012
   Burger EA, de Kok I, Groene E, et al. Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis. J Natl Cancer Inst 112:955–963, 2020
   Schmidt E, Bozsa Sz, Gocze P, et al. Szentinel nyirokcsomo-szcintigrafia korai stadiumu mehnyak- es mehtestdaganatok kezeleseben. IME: Interdiszciplinaris Magyar Egeszsegugy / Informatika es menedzsment az egeszsegugyben 12:18–21, 2013
   Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and metaanalysis. Obstet Gynecol 111:167–177, 2008
   Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:88–99, 2012
   Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99, 2009
   Dobrossy L, Lapis K. Screening for oral cancer 2018. J Cancer Ther 9:465-479, 2018
   Boncz I, Sebestyen A, Dobrossy L, et al. The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol 18:795–799, 2007
   Boncz I, Sebestyen A, Dobrossy L, et al. The role of immunochemical testing for colorectal cancer. Lancet Oncol 7:363–364, 2006
   Banerjee D, Mittal S, Mandal R, et al. Screening technologies for cervical cancer: Overview. Cytojournal 19:23, 2022
   US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 320:674–686, 2018
   Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 70:321–346, 2020
   Dobrossy L. Daganatok szurese – Minosegbiztositasi kezikonyv es modszertani utmutato. Orszagos Tisztifoorvosi Hivatal, 2013, Budapest
   Orszagos Tisztifoorvosi Hivatal Mehnyakszuresi Munkacsoport. Lakossagi mehnyakszures az „Egeszseg evtizede” program kereteben: torekvesek a nogyogyaszati rakszures korszerusitesere Magyarorszagon. Orv Hetil 145:35–40, 2004
   Bosze P. A mehnyakrak szurese es megelozese: hagyomanyok es uj iranyzatok. Nogyogyaszati Onkologia 13:10–30, 2008
   Boncz I, Sebestyen A, Dobrossy L, et al. A mehnyakszures reszveteli mutatoi Magyarorszagon. Orv Hetil 148:2177–2182, 2007
   Kovacs A, Dobrossy L, Budai A, et al. A nepegeszsegugyi mehnyakszures helyzete Magyarorszagon 2006-ban. Orv Hetil 148:535–540, 2007
   Elfstrom KM, Arnheim-Dahlstrom L, Karsa LV, et al. Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur J Cancer 51:950–968, 2015
   Bosze P, Gocze P, Hernadi Z, et al. A mehnyakrak szuresenek szempontjai: hazai iranyelvek. Nogyogyaszati Onkologia 14:11–17, 2009
   Koiss R, Boncz I, Hernadi Z, et al. Javaslat a hazai mehnyakszuresi eljarasrend korszerusitesere. Orv Hetil 158:2062–2067, 2017
   Boncz I, Sebestyen A, Ember I. Organized, nationwide cervical cancer screening programme in Hungary. Gynecol Oncol 106:272–273, 2007
   Boncz I. Prevention of cervical cancer in low-resource settings. JAMA 295:1248, 2006
   Pakai A, Der A, Kriszbacher I, et al. Why don’t Hungarian women take part in organized cervical screening? New Medicine 14:25–28, 2010
   Millei K, Vajda R, Kives Zs, et al. HPV-fertozessel kapcsolatos ismeretek vizsgalata edesanyak es leanyaik koreben. Egeszsegfejlesztes 56:9–16, 2015
   Pakai A, Brantmuller E, Vajda R, et al. Reasons for non-appearance on organized cervical screening in Hungary. Pract Theory Systems Educ 11:142–154, 2017
   Vajda R, Karamanne PA, Elias Zs, et al. A mehnyakrakkal kapcsolatos ismeretek es szurovizsgalaton valo reszveteli mutatok vizsgalata. Lege Artis Med 24:118–125, 2014
   Karamanne PA, Nemeth K, Meszaros L, et al. A mehnyakrakszures hatekonysaganak vizsgalata Zala megyeben. Egeszsegugyi Gazdasagi Szemle 46:43–48, 2008
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 186
EP 193
PG 8
ER

PT J
AU Laczo, A
   Bodis, J
   Bogner, P
   Molnar, K
   Vajda, R
   Ponusz-Kovacs, D
   Elmer, D
   Kajos, LF
   Csakvari, T
   Kives, Zs
   Boncz, I
AF Laczo, Andrea
   Bodis, Jozsef
   Bogner, Peter
   Molnar, Krisztian
   Vajda, Reka
   Ponusz-Kovacs, Dalma
   Elmer, Diana
   Kajos, Luca Fanni
   Csakvari, Timea
   Kives, Zsuzsanna
   Boncz, Imre
TI Participation indicators of organized mammography screening in Hungary between 2012–2021
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast screening; breast cancer; organized screening; mammography; participation rate
ID breast screening; breast cancer; organized screening; mammography; participation rate
AB The aim of our study is to analyze the participation indicators of screening rounds Nr. 6–10 (2012–2021) of the organized nationwide mammography screening program. Data derived from the nationwide financing database of the Hungarian National Health Insurance Fund Management and covered the period 2012–2021. We analyzed both diagnostic and screening mammography examinations. Between 2012 and 2019 the coverage (screening and diagnostic mammography) varied between 48.1–51.5, which decreased to 31.8% in 2020–2021. Within total coverage, the organized screening rate declined from 30.3–31.2 to 20.0, while the diagnostic mammography rate decreased from 17.7–20.7% to 11.8%. We can conclude that the number of both the diagnostic and screening mammography declined. In order to reduce the mortality of breast cancer, participation rate of mammography screening program should be increased.
C1 [Laczo, Andrea] Orszagos Korhazi Foigazgatosag, Del-dunantuli Teruleti Koordinacios OsztalyPecs, Hungary.
   [Bodis, Jozsef] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Bogner, Peter] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Molnar, Krisztian] PTE KK, Radiologiai KlinikaPecs, Hungary.
   [Vajda, Reka] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Ponusz-Kovacs, Dalma] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Elmer, Diana] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Kajos, Luca Fanni] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Csakvari, Timea] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Kives, Zsuzsanna] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Pecs, Hungary.
EM boncz.imre@etk.pte.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26:444–457, 2017
   DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin 69:438451, 2019
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175-184, 2022
   Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69:349–355, 1982
   Shapiro S, Venet W, Strax P, et al. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr 67:65–74, 1985
   Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish National Board of Health and Welfare. Lancet 8433:829–832, 1985
   Egeszseges Nemzetert Nepegeszsegugyi Program 2001–2010. Egeszsegugyi Kozlony 16:2237–2324, 2001
   Boncz I, Sebestyen A, Pinter I, et al. The effect of an organized, nationwide breast cancer screening programme on non-organized mammography activities. J Med Screen 15:14–17, 2008
   OGY hatarozat az Egeszseg Evtizedenek Johan Bela Nemzeti Programjarol. Magyar Kozlony 38:2766–2829, 2003
   Boncz I, Sebestyen A, Dobrossy L, et al. The organization and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol 18:795–799, 2007
   Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380:1778–1786, 2012
   Dobrossy L, Lapis K. Screening for oral cancer 2018. J Cancer Ther 9:465–479, 2018
   Boncz I, Sebestyen A, Dobrossy L, et al. The role of immunochemical testing for colorectal cancer. Lancet Oncol 7:363–364, 2006
   Boncz I, Sebestyen A, Pinter I, et al. Age-group specific gap between treatment cost of and mortality due to breast and colorectal cancer. J Clin Oncol 25:4501–4502, 2007
   Boncz I, Sebestyen A, Ember I. Organized, nationwide cervical cancer screening programme in Hungary. Gynecol Oncol 106:272–273, 2007
   Boncz I. Prevention of cervical cancer in low-resource settings. JAMA 295:1248, 2006
   Pakai A, Der A, Kriszbacher I, et al. Why don’t Hungarian women take part in organized cervical screening? New Medicine 14:25–28, 2010
   Kovacs A, Dobrossy L, Budai A, et al. Cervical screening in Hungary: why does the “English model” work but the “Hungarian model” does not? Eur J Gynaecol Oncol 29:5–9, 2008
   World Health Organization, WHO). WHO Position Paper on Mammography Screening. WHO; 2014. paho.org/hq/dmdocuments/2015/WHO-ENG-Mammography- Factsheet.pdf
   Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164:279–296, 2016
   Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314:1599–1614, 2015
   Boncz I, Sebestyen A, Dobrossy L, et al. A szervezett emloszuresi program masodik ciklusanak, 2004–2005, reszveteli aranyai. Orv Hetil 149:1491– 1498, 2008
   Boncz I, Dobrossy L, Pentek Z, et al. A szervezett emloszuresi program harmadik, 2006–2007, szuresi ciklusanak reszveteli aranyai. Magy Onkol 57:140–146, 2013
   Boncz I, Sebestyen A, Dobrossy L, et al. A szervezett emloszuresi program 2002–2003. evi reszveteli aranyai, es a program hatasa a diagnosztikus es szuresi celu mammografiak szamara. Orv Hetil 146:1963–1970, 2005
   Boncz I, Dobrossy L, Pentek Z, et al. A szervezett orszagos emloszuresi program negyedik, 2008–2009, szuresi korenek reszveteli aranyai. Orv Hetil 154:1975–1983, 2013
   Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis. European Communities, 2006
   Zielecka-Debska D, Maciejczyk A, Lichon K, et al. The effect of population- based screening on the incidence and detection on breast cancer in woman in Lower Silesia over the period 2005–2014. Przegl Epidemiol 76:37– 50, 2022
   Jarm K, Kadivec M, Sval C, et al. Quality assured implementation of the Slovenian breast cancer screening programme. PLoS One 16:e0258343, 2021
   Ding L, Jidkova S, Greuter MJW, et al. Coverage determinants of breast cancer screening in Flanders: an evaluation of the past decade. Int J Equity Health 19:212, 2020
   Malek D, Kaab-Sanyal V. Implementation of the German Mammography Screening Program, German MSP, and first results for initial examinations, 2005–2009. Breast Care 11:5, 2016
   Screening & Immunisations Team. Breast Screening Programme England, 2019–20, UK. NHS Digital
   Lagerlund M, Akesson A, Zackrisson S. Change in mammography screening attendance after removing the out-of-pocket fee: a population- based study in Sweden, 2014–2018). Cancer Causes Control 32:1257– 1268, 2021
   Jacobsen KK, von Euler-Chelpin M. Performance indicators for participation in organized mammography screening. J Public Health, Oxf, 34:272– 278, 2012
   Epstein MM, Sundaresan D, Fair M, et al. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts. Cancer Causes Control 33:1313–1323, 2022
   Toss A, Callegari V, Cortesi G, et al. COVID-related disruption in mammographic screening: a year later. ESMO Open 7:100539, 2022
   Grimm LJ, Lee C, Rosenberg RD, et al. Impact of the COVID-19 pandemic on breast imaging: an analysis of the National Mammography Database. J Am Coll Radiol 19:919–934, 2022
   Tabar L, Dean PB, Chen THH, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 125:515–523, 2019
   Boncz I, Sebestyen A, Gulacsi L, et al. Az emlorakszuresek egeszseg- gazdasagtani elemzese. Magy Onkol 47:149–154, 2003
   Boncz I, Sebestyen A, Pal M, et al. A mehnyakrakszuresek egeszseg-gazdasagtani elemzese. Orv Hetil 144:713–717, 2003
   Boncz I, Sebestyen A, Dozsa Cs, et al. A colorectalis szuresek egeszseg- gazdasagtani elemzese. Magy Onkol 48:111–115, 2004
   Day NE, Williams DDR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59:954– 958, 1989
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 195
EP 200
PG 6
ER

PT J
AU Kerpel-Fronius, A
AF Kerpel-Fronius, Anna
TI Low-dose lung cancer screening programs – European outlook
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE lung cancer; low-dose CT; screening; cost-efficiency; risk assessment
ID lung cancer; low-dose CT; screening; cost-efficiency; risk assessment
AB Lung cancer has a high incidence and mortality throughout the world. For a long time no screening methods were available that could detect early, operable lung cancers, and could significantly lower mortality. The NLST trial, published in 2013, and the NELSON trial in 2019 both proved that low-dose CT lung cancer screening in a targeted group of at-risk people lowers long-term mortality significantly. In parallel to, or following these studies pilot programs were started in several European countries, including Hungary. In this article different European approaches are presented, when available including the results thereof.
C1 [Kerpel-Fronius, Anna] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
RP Kerpel-Fronius, A (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
EM kerpel.anna@koranyi.hu
CR https://www.wcrf.org/cancer-trends/lung-cancer-statistics
   The International Early Lung Cancer Action Program Investigators, IELCAP). Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355:1763–1771, 2006
   National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409, 2011
   Clinical Summary: Lung Cancer: Screening. U.S. Preventive Services Task Force. October14. https://www.uspreventiveservicestaskforce.org/Page/Document/ ClinicalSummaryFinal/lung-cancer-screening
   De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382:503–513, 2020
   Kauczor HU, Bonomo L, Gaga M, et al. European Society of Radiology, ESR); European Respiratory Society, ERS). ESR/ERS white paper on lung cancer screening. Eur Radiol 25:2519–2531, 2015
   Oudkerk M, Devaraj A, Vliegenthart R, et al European position statement on lung cancer screening. Lancet Oncol 18:e754–e766, 2017
   Laisaar T. Thoracic surgery in Estonia. J Thorac Dis 14:1719–1724, 2022
   https://aihta.at/page/lungenkarzinomscreening-in-risikogruppen-systematische- review-s-zu-wirksamkeit-und-nutzen-teil-1-kosten-und-budgetfolgen- teil-2/en
   Vasakova M. What is currently ongoing in Europe? Break-out session 1 @ ERS seminar June 23, 2022 Lisbon, szobeli kozles)
   Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess 20:1–146, 2016
   Crosbie, PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. Thorax 74:405–409, 2019
   Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta- analysis. Lancet Reg Health Eur 10:100179, 2021
   https://www.england.nhs.uk/2022/04/hundreds-of-people-diagnosedwith- cancer-early-through-life-saving-nhs-lung-checks/
   Baldwin DR. What is currently ongoing in Europe? Break-out session 1 @ ERS seminar June 23, 2022 Lisbon, szobeli kozles)
   https://www.aphp.fr/actualite/depistage-du-cancer-du-poumon-parscanner- faible-dose-lap-hp-lance-letude-pilote-cascade
   https://cordis.europa.eu/project/id/848294
   Wait S, Alvarez-Rosete A, Osama T, et al Implementing lung cancer screening in Europe: Taking a systems approach. JTO Clin Res Rep 3:100329, 2022
   Rzyman W, Szurowska E, Adamek M. Implementation of lung cancer screening at the national level: Polish example. Transl Lung Cancer Res, Suppl 1):S95–S105, 2019
   Moizs M, Bajzik G, Lelovics Z, et al. Characterization of individuals taking part in low dose computed tomography, LDCT, screening program. Pathol Oncol Res 21:1167–1173, 2015
   Kerpel-Fronius A, Monostori Z, Kovacs G, et al. Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. Eur Radiol 32:4457–4467, 2022
   Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening – Results from the randomized German LUSI trial. Int J Cancer 146:1503–1513, 2020
   Vogel-Claussen J, Lasch F, Bollmann BA, et al. Design and rationale of the HANSE study: A holistic German lung cancer screening trial using low-dose computed tomography. Rofo 2022,, DOI  10.1055/a-1853–8291
   Paci E, Puliti D, Lopes Pegna A, ITALUNG Working Group. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 72:825–831, 2017
   Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 30:1162–1169, 2019
   Pastorino U, Boeri M, Sestini S, et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol 33:395–405, 2022
   Seijo LM. What is currently ongoing in Europe? Break-out session 1 @ ERS seminar June 23, 2022 Lisbon, szobeli kozles)
   Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 32:768–773, 2014
   Baldwin BD, Callister ME, Crosbie PA, et al. Biomarkers in lung cancer screening: the importance of study design. Eur Respir J 57:2004367, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 202
EP 206
PG 5
ER

PT J
AU Kives, Zs
   Bodis, J
   Hunyady, B
   Ponusz-Kovacs, D
   Elmer, D
   Kajos, LF
   Csakvari, T
   Vajda, R
   Boncz, I
AF Kives, Zsuzsanna
   Bodis, Jozsef
   Hunyady, Bela
   Ponusz-Kovacs, Dalma
   Elmer, Diana
   Kajos, Luca Fanni
   Csakvari, Timea
   Vajda, Reka
   Boncz, Imre
TI Participation indicators of colorectal screenings in Hungary between 2008–2021
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE colon cancer; screening; stool blood; participation rate; coding
ID colon cancer; screening; stool blood; participation rate; coding
AB The aim of our study is to analyse the participation indicators of colorectal cancer screening between 2008–2021. Data derived from the nationwide financing database of the Hungarian National Health Insurance Fund Management. We analysed both diagnostic and screening examinations. According to our results, the screening rate was low, varying between 5.1–6.8% in the years examined. Between 2008 and 2019, the number of participating patients increased slightly. The highest number of patients can be observed in 2019 (178,568 people). In 2020 and 2021, we see a significant decrease, which is a consequence of the COVID-19 pandemic. In the number of patients of the entire examined period (2,233,963 people, 938,223 men, 1,295,740 women), the largest proportion was fecal blood detection by immunochemical method (OENO code: 22631). In 2021, at the county level, the highest number of patients can be seen in Csongrad-Csanad county (994 patients/10,000 people), and the least in Bekes county (218 patients/10,000 people). The participation rate of women is higher than that of men in all counties. Participation in colorectal screening is very low. In order to prevent colorectal cancer death, it is necessary to increase the participation rate.
C1 [Kives, Zsuzsanna] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Bodis, Jozsef] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Hunyady, Bela] University of Pecs, Medical School, First Department of Medicine, Division of GastroenterologyPecs, Hungary.
   [Ponusz-Kovacs, Dalma] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Elmer, Diana] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Kajos, Luca Fanni] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Csakvari, Timea] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Vajda, Reka] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
   [Boncz, Imre] Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi IntezetPecs, Hungary.
RP Boncz, I (reprint author), Pecsi Tudomanyegyetem, Egeszsegtudomanyi Kar, Egeszsegbiztositasi Intezet, Pecs, Hungary.
EM boncz.imre@etk.pte.hu
CR Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon, France, 2018. https:// gco.iarc.fr/today
   Országos Onkológiai Intézet, Nemzeti Rákregiszter. https://onkol.hu/ nemzeti-rakregiszter
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175-184, 2022
   Gatta G, Trama A, Capocaccia R. Variation in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. JNCI Monographs 46:79–87, 2013
   Allemani C, Rachet B, Weir HK, et al. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open 3:e003055, 2013
   Tusnády G, Gaudi I, Rejtő L, et al. A magyar daganatos betegek túlélési esélye a Nemzeti Rákregiszter adatai alapján. Magy Onkol 52:339–349, 2008
   Inotai A, Abonyi-Tóth Z, Rokszin G, et al. Prognosis, cost, and occurrence of colorectal, lung, breast, and prostate cancer in Hungary. Health Regional Issues 7:1–8, 2015
   American Cancer Society. Survival rates for colorectal cancer. American Cancer Society, 2020
   Schütze M, Boeing H, Pischon T, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 342:d1584, 2011
   Botteri E, Iodice S, Raimondi S, et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134:388–395, 2008
   Boyle T, Fritcshi L, Platell C, Heyworth J. Lifestyle factors associated with survival after colorectal cancer diagnosis. Br J Cancer 109:814–822, 2013
   Song M, Garrett WS, Chan AT. Nutrients, food, and colorectal cancer prevention. Gastroenterology 158:1244–1260.e16, 2015
   Nolte E, McKee M. Does healthcare save lives? Avoidable mortality revisited. The Nuffield Trust, London, 2004
   Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126:1674–1680, 2004
   Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471, 1996
   Nakajima M, Saito H, Soma Y, et al. Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study. Br J Cancer 89:23–28, 2003
   Segnan N, Patnick J, von Karsa L, European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition. Publications Office of the European Union, Luxembourg, 2010
   World Gastroenterology Organisation/International Digestive Cancer Alliance Practice Guidelines: Colorectal cancer screening, 2007. https://www. worldgastroenterology.org/UserFiles/file/guidelines/colorectal-cancerscreening- english-2007.pdf
   State of Health in the EU Magyarország: Egészségügyi országprofil 2017. OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels. http://dx.doi.org/10.1787/9789264285231-hu
   Kívés Zs, Kovács A, Budai A, et al. A Csongrád megyei vastagbélszű- rési pilotprogram minőségi indikátorai és teljesítménymutatói. Magy Onkol 63:125–132, 2019
   Boncz I, Sebestyen A, Dobrossy L, et al. The role of immunochemical testing for colorectal cancer. Lancet Oncol 7:363–364, 2006
   Boncz I, Sebestyen A, Pinter I, et al. Age-group specific gap between treatment cost of and mortality due to breast and colorectal cancer. J Clin Oncol 25:4501–4502, 2007
   Dobrossy L, Lapis K. Screening for oral cancer 2018. J Cancer Ther 9: 465–479, 2018
   Boncz I, Sebestyen A, Dobrossy L, et al. The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol 18:795–799, 2007
   Boncz I, Sebestyen A, Ember I. Organized, nationwide cervical cancer screening programme in Hungary. Gynecol Oncol 106:272–273, 2007
   Boncz I. Prevention of cervical cancer in low-resource settings. JAMA 295: 1248, 2006
   Pakai A, Der A, Kriszbacher I, et al. Why don’t Hungarian women take part in organized cervical screening? New Medicine 14:25–28, 2010
   Nemzeti Népegészségügyi Központ Komplex Népegészségügyi Szűrések. https://www.nnk.gov.hu/index.php/nnk-projektek/komplex-nepegeszseg- ugyi-szuresek
   Eljárásrend a népegészségügyi célú, célzott vastagbélszűrésen résztvevő háziorvosok számára – EFOP 1.8.1-VEKOP-15-2016-00001 „Komplex Nepegeszsegugyi Szuresek” cimu projekt, 2021
   Katičić M, Antoljak N, Kujundžić M, et al. Results of national colorectal cancer screening program in Croatia, 2007–2011). World J Gastroenterol 18:4300–4307, 2012
   Leuraud K, Jezewski-Serra D, Viguier J, et al. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol 37:959–967, 2013
   Blom J, Kilpelainen S, Hultcrantz R, et al. Five-year experience of organized colorectal cancer screening in a Swedish population – increased compliance with age, female gender, and subsequent screening round. J Med Screen 21:144–150, 2014
   Novak Mlakar D, Kofol Bric T, Skrjanec AL. Colorectal cancer screening in Slovenia. National Institute of Public Health Lubljana, 2018
   National Institution for Public Health and Environment Bowel Cancer screening program. Dutch Minister of Health. https://www.rivm.nl/en/Topics/ B/Bowel_cancer_screening_programme
   Malila N, Oivanen T, Malminiemi O, et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 337:a2261, 2008
   Logan RF, Patnick J, Nickerson C, et al. English Bowel Cancer Screening Evaluation Committee. Outcomes of the Bowel Cancer Screening Programme, BCSP, in England after the first 1 million tests. Gut 61:1439–1446, 2012
   Kívés Zs, Endrei D, Elmer D, et al. A vastag- és végbéldaganat okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon. Orv Hetil 162(Suppl 1):14–21, 2021
   Ran T, Cheng CY, Misselwitz B, et al. Cost-effectiveness of colorectal cancer screening strategies – a systematic review. Clin Gastroenterol Hepatol 17:1969–1981.e15, 2019
   Boncz I, Sebestyen A, Gulacsi L, et al. Az emlorakszuresek egeszseg- gazdasagtani elemzese. Magy Onkol 47:149–154, 2003
   Boncz I, Sebestyen A, Pal M, et al. A mehnyakrakszuresek egeszseg-gazdasagtani elemzese. Orv Hetil 144:713–717, 2003
   Boncz I, Sebestyen A, Dozsa Cs, et al. A colorectalis szuresek egeszseggazdasagtani elemzese. Magy Onkol 48:111–115, 2004
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 209
EP 217
PG 9
ER

PT J
AU Szalontai, J
   Horvath, A
   Szucs, M
   Nyirady, P
AF Szalontai, Janos
   Horvath, Andras
   Szucs, Miklos
   Nyirady, Peter
TI Prostate cancer screening – past, present, future
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostate; screening; cancer; prostate specific antigen; early detection
ID prostate; screening; cancer; prostate specific antigen; early detection
AB Prostate cancer is one of the most significant cancers among men. In addition to epidemiological and etiological data, this summary provides a description of the most important features of prostate specific antigen, used most, and other markers that can make easier to diagnose the disease. It presents the major international and Hungarian studies dealing with prostate cancer screening, including the economic aspects. Genetic tests, DNA- and RNAbased biomarkers are gaining more and more space, they can even help us in screening and avoiding overdiagnosis. The main goal of the future researches should be to develop methods that can be used to detect prostate cancer at an early, curable stage.
C1 [Szalontai, Janos] Semmelweis University, Department of Urology, Ulloi ut 78., 1082 Budapest, Hungary.
   [Horvath, Andras] Semmelweis University, Department of Urology, Ulloi ut 78., 1082 Budapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of Urology, Ulloi ut 78., 1082 Budapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of Urology, Ulloi ut 78., 1082 Budapest, Hungary.
RP Szalontai, J (reprint author), Semmelweis University, Department of Urology, 1082 Budapest, Hungary.
EM szajanos@outlook.com
CR https://uroweb.org/guidelines/prostate-cancer
   Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Schroder F, Roobol M. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 58:46–52, 2010
   Eckersberger E, Finkelstein J, Sadri H, et al. Screening for pros- tate cancer: a review of the ERSPC and PLCO trials. Rev Urol 11:127–133, 2009
   Lane J, Hamdy F, Martin R, et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies. Eur J Cancer 46:3095–3101, 2010
   Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101:809–816, 2008
   Rencz F, Brodszky V, Varga P, et al. A prosztatarak gazdasagi terhe nagy betegregiszterek alapjan. Orv Hetil 155:509–520, 2014
   Van Poppel H, Hogenhout R, Albers P, et al. A European model for an organised risk-stratified early detection programme for prostate cancer. Eur Urol Oncol 4:731–739, 2021
   Goldberg H. The future of prostate cancer screening is here, the 21st Annual Meeting of the Society of Urologic Oncology, SUO), 2020
   Ilic D, Djulbegovic M, Hung Jung J, et al. Prostate cancer screening with prostate-specific antigen, PSA, test: a systematic review and meta-analysis. BMJ 362:k3519, 2018
   Kramer B, Brown M, Prorok P, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119:914–923, 1993
   Benafif S, Kote-Jarai Z, Eeles R, et al. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU Int 129:325–336, 2022
   Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119– 1134, 2020
   NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection Version 1, 2022. https://www.nccn.org/professionals/physician_ gls/pdf/prostate_detection.pdf
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 219
EP 222
PG 4
ER

PT J
AU Novak, Z
   Bagameri, A
   Mate, Sz
   Vereczkey, I
   Toth, E
   Toth, I
   Papp, Sz
   Krasznai, Z
AF Novak, Zoltan
   Bagameri, Andrea
   Mate, Szabolcs
   Vereczkey, Ildiko
   Toth, Erika
   Toth, Ico
   Papp, Szilard
   Krasznai, Zoard
TI The treatment of ovarian cancer. Recommendation of the Hungarian Society of Gynaecologic Oncologists
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE ovarian cancer; surgery; chemotherapy; guideline; pathology
ID ovarian cancer; surgery; chemotherapy; guideline; pathology
AB In Hungary, there is no actual ovarian cancer guideline, despite this disease being the most lethal gynaecologic cancer. An expert panel was created by the Hungarian Society of Gynaecologic Oncologists to prepare a recommendation for the reatment of ovarian cancer patients. This multidisciplinary expert group worked together during the first trimester of 2022 using the guidelines and recommendations of the European Society of Gynaecologic Oncologists (ESGO) and the European Society for Medical Oncology (ESMO) and created the updated recommendations. This paper presents the recommended surgical and medical treatment of early, advanced stage and recurrent ovarian cancer.
C1 [Novak, Zoltan] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Bagameri, Andrea] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Mate, Szabolcs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati KlinikaBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Toth, Ico] Malyvavirag AlapitvanyDunaharaszti, Hungary.
   [Papp, Szilard] Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, Szuleszeti es Nogyogyaszati KlinikaPecs, Hungary.
   [Krasznai, Zoard] Debreceni Egyetem OEC, Szuleszeti es Nogyogyaszati Klinika, Nogyogyaszati Onkologiai TanszekDebrecen, Hungary.
RP Novak, Z (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM novak.zoltan@oncol.hu
CR Updated recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. https://www.esmo. org/guidelines/guidelines-by-topic/gynaecological-cancers/newly-diagnosed- and-relapsed-epithelial-ovarian-carcinoma/eupdate-newly-diagnosed- epithelial-ovarian-carcinoma-treatment-recommendations
   Colombo N, Sessa C, du Bois A, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30:672–705, 2019
   NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3.2022. https:// www.nccn.org/professionals/physician_gls/pdf/
   Female Genital Tumours, WHO Classification of Tumours, 5th Edition, Volume 4
   Shih KK, Garg K, Soslow RA, et al. Accuracy of frozen section diagnosis of ovarian borderline tumor. Gynecol Oncol 123:517–521, 2011
   Park HJ, Kim DW, Yim GW, et al. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol 209:58. e1–8, 2013
   Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–182, 2001
   Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197:198–205, 2003
   Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol 122:536–540, 2011
   Gouy S, Saidani M, Maulard A, et al. Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep 22:21–25, 2017
   Bentivegna E, Gouy S, Maulard A, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol 27:1994–2004, 2016
   Bentivegna E, Fruscio R, Roussin S, et al. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril 104:1319–1324, 2015
   Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95:125–132, 2003
   Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95:105–112, 2003
   Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 116:301–306, 2010
   Darai E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 19:151–166, 2013
   du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie, AGO, Study Group. Eur J Cancer 49:1905–1914, 2013
   Uzan C, Nikpayam M, Ribassin-Majed L, et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol 25:1312–1319, 2014
   Cheng A, Li M, Kanis MJ, et al. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta- analysis. Gynecol Oncol 144:215–222, 2017
   Dewilde K, Moerman P, Leunen K, et al. Staging with unilateral salpingo- oophorectomy and expert pathological review result in no recurrences in a series of 81 intestinal-type mucinous borderline ovarian tumors. Gynecol Obstet Invest 83:65–69, 2018
   Vasconcelos I, Olschewski J, Braicu I, Sehouli J. A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants. Oncologist 20:151–158, 2015
   Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom, AGO-OVAR, and the Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire, GINECO). Cancer 115:1234–1244, 2009
   Vergote IB, Van Nieuwenhuysen E, Vanderstichele A. How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol 34:3827–3828, 2016
   Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer Inter- Group, GCIG, consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750–755, 2011
   Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953, 2010
   Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer, CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249– 257, 2015
   Michielsen K, Dresen R, Vanslembrouck R, et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98, 2017
   Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13:1156–1161, 2006
   Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology, ESGO, Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 27:1534–1542, 2017
   Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 26:1354–1363, 2016
   Fotopoulou C, Concin N, Planchamp F, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology, ESGO): 2020 update. Int J Gynecol Cancer 30:436–440, 2020
   Burger V, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483, 2011
   Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496, 2011
   Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab- containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 70:133–142, 2017
   Garcia YGD, Juan A, Mendiola C, et al. Phase II randomized trial of neoadjuvant, NA, chemotherapy, CT, with or without bevacizumab, Bev, in advanced epithelial ovarian cancer, EOC,, GEICO 1205/NOVA TRIAL). J Clin Oncol 35(15_suppl):5508, 2017
   Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495–2505, 2018
   Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402, 2019
   Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416–2428, 2019
   Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dosedense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020–1026, 2013
   Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer, MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396–405, 2014
   van der Burg ME, Onstenk W, Boere IA, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/ platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer 50:2592–2601, 2014
   Clamp AR, McNeish IA, Dean A, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma, EOC, treatment: results of primary progression-free survival, PFS, analysis. Ann Oncol 28(Suppl 5):627, 2017
   Crane EK, Sun CC, Ramirez PT, et al. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 136:25–29, 2015
   Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125:661–666, 2012
   Geurts SM, de Vegt F, van Altena AM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer 21:837–845, 2011
   Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology, SGO, recommendations. Gynecol Oncol 146:3–10, 2017
   Baert T, Ferrero A, Sehouli J, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol 32:710–725, 2021
   Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The Multicenter Intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289– 295, 2011
   Harter P, Sehouli J, Vergote I, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385:2123–2131, 2021
   Straubhar AM, Filippova OT, Cowan RA, et al. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecol Oncol 158:608–613, 2020
   Lee CK, Simes RJ, Brown C, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol 24:937–943, 2013
   Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta- analysis using individual patient data. Ann Oncol 24:3028–3034, 2013
   Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308, 2014
   Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel- carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer, NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779–791, 2017
   Pignata S, Lorusso D, Joly F, et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 36(15_suppl):5506, 2018
   Pujade-lauraine E, Colombo N, Glasspool R, et al. OREO/ENGOT OV-38: a phase IIIB trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer. Ann Oncol 28(Suppl 5):2242, 2017
   Liu JF, Brady MF, Matulonis UA, et al. A phase III study comparing single- agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J Clin Oncol 38(15_suppl):6003, 2020
   Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323–3329, 2010
   Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707, 2006
   Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum- based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106, 2003
   Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139:10–16, 2015
   Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation, SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274–1284, 2017
   Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392, 2012
   Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 21:771–775, 2011
   Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol 37:2437–2448, 2019
   Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive, platinum-free interval 6–12 months, subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22:39–48, 2011
   Fincham L, Copp G, Caldwell K, et al. Supportive care: experiences of cancer patients. Eur J Oncol Nurs 9:258–268, 2005
   Lo SS, Buss MK. What is the difference between supportive and palliative care? Asco Daily News, July 3, 2019
   Ovarian Cancers: Evolving Paradigms in Research and Care. 5. Supportive Care Along the Survivorship Trajectory. Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Washington, DC): National Academies Press, US), 2016
   https://malyvavirag.hu/sites/default/files/images/inlineimages/ malyvatukor_mehnyakrak_es_petefeszekrak_betegut_kutatas_ 2019_tanulmany.pdf
   https://engage.esgo.org/discover/projects/
   Pilling J. Orvosi kommunikacio a gyakorlatban. Medicina Konyvkiado Zrt., 2018
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 223
EP 238
PG 16
ER

PT J
AU Petovari, G
AF Petovari, Gabor
TI mTOR complex activity and metabolic changes as potential targets in solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
DE breast cancer; tissue heterogeneity; metabolism; mTOR
ID breast cancer; tissue heterogeneity; metabolism; mTOR
AB We investigated the activity and inhibition of mTOR and other metabolic pathways with their clinical significance in human breast tumors (using ten cell lines and nearly a hundred biopsy samples).Based on our results, the metabolic and mTOR inhibitor treatments showed a moderate tumor growth inhibitory effect in the cell lines subtype independently, which indicates tumor cell and tissue adaptation. Providing human tissue samples, we found a subtype independent correlation between high mTOR activity and protein expression characterizing alternative metabolic pathways with increased expression and the poor prognosis of breast tumors. Breast tumors are characterized by metabolic heterogeneity and significant metabolic plasticity, which can be targeted by combining anti-metabolic treatments and new therapies. Concerning these, an immunohistochemical evaluation (IHC panel) can be recommended, which is suitable for both metabolic plasticity evaluation and recognition of cases that may require stricter follow-up or metabolic targeted therapy due to the expected poor prognosis.
C1 [Petovari, Gabor] Semmelweis University, School of PhD Studies, Ulloi ut 26., 1085 Budapest, Hungary.
RP Petovari, G (reprint author), Semmelweis University, School of PhD Studies, 1085 Budapest, Hungary.
EM gaborpetovari@gmail.com
CR  Petovari G, Danko T, Tokes AM, et al. In situ metabolic characterisation of breast cancer and its potential impact on therapy. Cancers, Basel, 12:2492, 2020 Petovari G, Hujber Z, Krencz I, et al. Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. Cancer Cell Int 18:211, 2018 Petovari G, Danko T, Krencz I, et al. Inhibition of metabolic shift can decrease therapy resistance in human high-grade glioma cells. Pathol Oncol Res 26:23– 33, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 239
EP 241
PG 3
ER

PT J
AU Koroknai, V
AF Koroknai, Viktoria
TI Genomic alterations of invasive melanoma cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
DE malignant melanoma; tumor cell invasion; metastasis; DNA methylation
ID malignant melanoma; tumor cell invasion; metastasis; DNA methylation
AB Tumour cell invasion is the first step in metastasis, during which cells are able to infiltrate surrounding tissues. We aimed to investigate genetic and epigenetic differences associated with the invasiveness in melanoma. To determine the invasiveness of cells, we used Matrigel invasion chamber. Genetic analyses were performed by array CGH, DNA methylation was assessed by Illumina array, gene expression changes were determined by Affymetrix array. Our results showed significantly higher copy numbers of GDNF, GPAA1, PLEC and SHARPIN genes in invasive cells compared to non-invasive ones. We observed that the invasive cells were characterized by a hypermethylated pattern. Most of the hypermethylated genes were associated with decreased expression, however, increased gene expression was observed for EGFR and RBP4 genes with hypermethylation extending into the gene body. Hypermethylation of the ARHGAP22 and NAV2 genes characterized invasive cells and melanoma metastasis samples. Our results point to the hypermethylation pattern of invasive cells, which may be related to the invasive property.
C1 [Koroknai, Viktoria] Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Nepegeszseg- es Jarvanytani Intezet, ELKH-DE Nepegeszsegugyi Kutatocsoportja, Kassai ut 26., 4028 Debrecen, Hungary.
RP Koroknai, V (reprint author), Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Nepegeszseg- es Jarvanytani Intezet, ELKH-DE Nepegeszsegugyi Kutatocsoportja, 4028 Debrecen, Hungary.
EM koroknai.viktoria@med.unideb.hu
CR  Koroknai V, Szasz I, Hernandez-Vargas H, et al. DNA hypermethylation is associated with invasive phenotype of malignant melanoma. Exp Dermatol 29:39–50, 2020 Koroknai V, Ecsedi S, Vizkeleti L, et al. Genomic profiling of invasive melanoma cell lines by array comparative genomic hybridization. Melanoma Res 26:100–107, 2016
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 243
EP 245
PG 3
ER

PT J
TI Summaries of the 2022 conference of the Young Oncologists Section of the Hungarian Society of Oncologists
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD OCT
PY 2022
VL 66
IS 3
BP 247
EP 256
PG 10
ER

PT J
AU Acs, N
AF Acs, Nandor
TI Introduction
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Acs, Nandor] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/A., 1082 Budapest, Hungary.
RP Acs, N (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, 1082 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 261
EP 261
PG 1
ER

PT J
AU Krasznai, Z
   Molnar, Sz
AF Krasznai, Zoard
   Molnar, Szabolcs
TI Epidemiology of cervical cancer in Hungary and the world
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE epidemiology; cervical cancer; human papilloma virus; prevention; vaccination
ID epidemiology; cervical cancer; human papilloma virus; prevention; vaccination
AB Cervical cancer is one of the most common cancers among women and one of those completely preventable according to the current state of medical science. The pathogenesis of the disease is known, the human papillomavirus plays an essential role in the development in 99.9% of cases. With the available vaccines against the virus and the use of effective screening methods, the complete elimination of the disease can be achieved within a few decades, according to WHO estimates. Despite all these facts, the current state of the fight against the disease is still very controversial, which can be characterized by the epidemiological indicators of the disease. We would like to present these data in our publication, highlighting the challenges that not only developing but also developed countries face every day in relation to the prevention of cervical cancer.
C1 [Krasznai, Zoard] University Medical School of Debrecen, Department of Gynecology and Obstetrics, Egyetem ter 1., 4032 Debrecen, Hungary.
   [Molnar, Szabolcs] University Medical School of Debrecen, Department of Gynecology and Obstetrics, Egyetem ter 1., 4032 Debrecen, Hungary.
RP Krasznai, Z (reprint author), University Medical School of Debrecen, Department of Gynecology and Obstetrics, 4032 Debrecen, Hungary.
EM krasznai.zoard@med.unideb.hu
CR Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):28–44, 2021
   Global Cancer Observatory. Incidence of Cervical Cancer, Europe, https:// gco.iarc.fr/today/
   Zur Hausen H, De Villiers EM, Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 12(Suppl):124–128, 1981
   Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41:660–664, 2014
   Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 23:87–101, 2019
   ARC. Cervix cancer screening – IARC handbooks of cancer prevention. IARC Press, Lyon 2005
   Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. Lancet 382:889–899, 2013
   Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524–532, 2014
   Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 69:184–210, 2019
   Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol 16:e56, 2015
   Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711–723, 2015
   Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138, 2012
   Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet 393:169– 182, 2019
   WHO. Cervical cancer. World Health Organization, Geneva 2018. http:// www.who.int/
   Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42:193–206, 1941
   Patnick J. Méhnyakrákszűrés: a minőségbiztosítás fejlődése Európában. Nőgyógy Onkol 1-2:39–41, 1999
   Dobrossy L. A méhnyakrákszûrés öt évtizede Magyarországon. Nőgyógy Onkol 12:5–9, 2007
   51/1997., XII. 18., NM rendelet a kotelezo egeszsegbiztositas kereteben igenybe veheto betegsegek megelozeset es korai felismereset szolgalo egeszsegugyi szolgaltatasokrol es a szurovizsgalatok igazolasarol.
   Pangarkar MA. The Bethesda System for reporting cervical cytology. Cytojournal 19:28, 2022
   Klinkhamer PJ, Meerding WJ, Rosier PF, et al. Liquid-based cervical cytology. Cancer 99:263–271, 2003
   Louvanto K, Chevarie-Davis M, Ramanakumar AV, et al. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol 210:474e1–7, 2014
   Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:e191–e203, 2020
   Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda, MD, USA, 2007
   Small W, Jr., Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis. Cancer 123:2404–2412, 2017
   Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 65:87–108, 2015
   Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675–2686, 2011
   Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14, CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population- based registries in 71 countries. Lancet 391:1023–1075, 2018
   Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 109:418–424, 2004
   Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4–66, 2001
   Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395:575– 590, 2020
   Global Cancer Observatory – Mortality of Cervical Cancer, Europe). https://gco.iarc.fr/today/
   Wojtyla C, Ciebiera M, Kowalczyk D, Panek G. Cervical cancer mortality in East-Central European countries. Int J Environ Res Public Health 17:4639, 2020
   Nemzeti Rakregiszter. http://stat.nrr.hu/
   Kozponti Statisztikai Hivatal. https://www.ksh.hu/stadat_files/nep/hu/ nep0003.html
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175– 184, 2022
   Langmar Z, Nemeth M, Kornya L. Mehnyakszures Magyarorszagon – epidemiologiai, torteneti es modszertani vonatkozasok. Orv Hetil 152:2063– 2066, 2011
   Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust 205:359–364, 2016
   Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 4:e19–e27, 2019
   Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14:80514, 2003
   Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 185:32431, 2002
   UNAIDS. The gap report. https://www.unaids.org/en/resources/campaigns/ 2014/2014gapreport/gapreport
   Olorunfemi G, Ndlovu N, Masukume G, et al. Temporal trends in the epidemiology of cervical cancer in South Africa, 1994-2012). Int J Cancer 143:2238–2249, 2018
   Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer J Clin 71:505–526, 2021
   Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 190:37–45, 2004
   Ghebre RG, Grover S, Xu MJ, et al. Cervical cancer control in HIV-infected women: Past, present and future. Gynecol Oncol Rep 21:101–108, 2017
   Wendland EM, Villa LL, Unger ER, et al. Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study. Sci Rep 10:4920, 2020
   Shew ML, Fortenberry JD. HPV infection in adolescents: natural history, complications, and indicators for viral typing. Semin Pediatr Infect Dis 16:168–174, 2005
   Moscicki AB. HPV infections in adolescents. Dis Markers 23:229–234, 2007
   Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 24:102–131, 2020.
   US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 320:674– 686, 2018
   Marcus JZ, Cason P, Downs LS, et al. The ASCCP Cervical Cancer Screening Task Force Endorsement and Opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. J Low Genit Tract Dis 25:187–191, 2021
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 262
EP 269
PG 8
ER

PT J
AU Jaray, B
   Schaff, Zs
AF Jaray, Balazs
   Schaff, Zsuzsa
TI The pathology of cervical cancer – molecular tests
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cervical cancer; precancerous lesions; histology; cytology; human papillomavirus
ID cervical cancer; precancerous lesions; histology; cytology; human papillomavirus
AB Cervical cancer is the 4th in incidence and mortality rate among women worldwide. Histologically the majority of cervical cancers are squamous cell carcinomas, with a minor proportion of adenocarcinomas. Cervical carcinogenesis can be followed through different steps of precancerous lesions, previously named dysplasias (mild, moderate and severe), by recently used terminology of the Bethesda classification as LSIL (low-grade squamous epithelial lesion) and HSIL (high-grade squamous epithelial lesion) before progression to invasive cancer by cytological screening together and controlled by histology. Introduction of several newly developed viral and cellular molecular biomarkers are extendedly applied as diagnostic tests for detection of human papillomavirus (HPV) and other markers as signs of cellular transformation, which increased both the sensitivity and specificity of the testing. Cytology, histology, HPV detection in combination with novel molecular tests are incorporated into the modern screening and diagnostic guidelines in several countries which is strongly suggested in Hungary too.
C1 [Jaray, Balazs] Medserv Kft, Lehel ut 59., 1135 Budapest, Hungary.
   [Schaff, Zsuzsa] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
RP Jaray, B (reprint author), Medserv Kft, 1135 Budapest, Hungary.
EM jaraybalazs@gmail.com
CR Bray F, J Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Ferlay J, Ervik M, Lam F, et al. F. B. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2020. https://gco.iarc.fr/today, elerheto: 2021)
   Bosse T, Lax S, Abu-Rustum N, et al. The role of predictive biomarkers in endocervical adenocarcinoma: Recommendation from International Society of Gynecological Pathologists. Int J Gynecol Pathol 40:S102–S110, 2021
   Safaeinan M, Sherman ME. From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination. J Natl Cancer Inst 105:1524–1526, 2013
   Solomon D, Davey D, Kurman R, et al. The Bethesda System 2001: terminology for reporting the results of cervical cytology. JAMA 287:2114–2119, 2002
   Benczik M, Galamb A, Zinner B, et al. Uj molekularis biologiai modszerek es biologiai jelzok a mehnyak szureseben. Nogyogy Onkol 18:61–65, 2013
   Crosbie EJ, Einstein MH, Franceschi, et al. Human papillomavirus and cervical cancer. Lancet 382:889–899, 2013
   WHO Classification of Tumours, 5th ed., Female Genital Tumours. Vol. 4. WHO Press, Geneva, Switzerland, 2020
   Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch 475:537–549, 2019
   Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet 383:493–494, 2014
   Tornesello MJ, Buonaguro L, Giorgi-Rossi P, et al. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int 2013:519619, 2013
   Volkova LV, Pashov AI, Omelchuk NN. Cervical carcinoma: Oncobiology and biomarkers. Int J Mol Sci 22:1271, 2021
   Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543:378–384, 2017
   Fleischmann M, Chatzikonstantinou G, Fokas E, et al. Molecular markers to predict prognosis and treatment response in uterine cervical cancer. Cancers 13:5748, 2021
   Lin M, Ye M, Zhou J, et al. Recent advances on the molecular mechanism of cervical carcinogenesis based on systems biology technologies. Comput Struct Biotech J 17:241–250, 1919
   Marino FZ, Ronchi A, Stilo M, et al. Multiplex HPV RNA in situ hybridization/ p16 immunohistochemistry: a novel approach to detect papillomavirus in HPV-related cancers. A novel multiplex ISH/IHC assay to detect HPV. Infect Agent Cancer 15:46, 2020
   Arbyn M, Simon M, Peeters E, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect 27:1383–1405, 2021
   Martin CM, O’Leary JJ. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 25:605–615, 2011
   Varga N, Mozes J, Keegan H, et al. The value of a novel panel of cervical biomarkers for triage of HPV positive patients and for detecting disease progression. Pathol Oncol Res 23:295–305, 2017
   Fogarasi AI, Benczik M, Moravcsik-Kornyicki A, et al. The prevalence of high risk human papillomavirus in Hungary – A geographically representative cross-sectional study. Pathol Oncol Res 28:1610424, 2022
   Poka R. Mehnyakszures. Nemzetkozi korkep es javaslat a hazai iranyelvek fejlesztesere. Magy Noorv Lapja 81:38–46, 2018
   Koiss R, Boncz I, Hernadi Z, et al. Javaslat a hazai mehnyakszuresi eljarasrend korszerusitesere. Orv Hetil 15:2062–2067, 2017
   Bishop JA, Wang XJ, Luo Y, et al. Detection of transcriptionally active high risk HPV in patients with head and neck squamous cell carcinoma as visualized by novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 36:1874–1882, 2012
   Kelly H, Benavente Y, Pavon MA, et al. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia, CIN2+): A systematic review and meta-analysis. Br J Cancer 121:954–965, 2021
   Li Z, Chen J, Zhao S, et al. Discovery and validation of novel biomarkers for detection of cervical cancer. Cancer Med 10:2063–2074, 2021
   Galamb A, Benczik M, Zinner B. Dysregulation of microRNA expression in human cervical preneoplastic amd neoplastic lesion. Pathol Oncol Res 21:503–508, 2015
   Szekerczes T, Galamb A, Varga N, et al. Increased miR-20b level in high grade cervical intraepithelial neoplasia. Pathol Oncol Res 26:2633–2640, 2020
   Benczik M, Galamb A, Koiss R, et al. Claudin-1 as biomarker of cervical cytology and histology. Pathol Oncol Res 22:179–188, 2016
   Verlaat W, Snoek BC, Heideman DAM, et al. Identification and validation of a 3-gene methylation classifier for HPV-based cervical screening on self-samples. Clin Cancer Res 24:3556–3464, 2018
   Xu W, Xu M, Wang L, et al. Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transd Target Ther 4:55, 2019
   Sobel G, Paska C, Szabo I, et al. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169, 2005
   Szekerczes T, Galamb A, Kocsis A, et al. Dual-stained cervical cytology and histology with claudin-1 and Ki67. Pathol Oncol Res 25:477–486, 2019
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 271
EP 278
PG 8
ER

PT J
AU Sobel, G
AF Sobel, Gabor
TI Precancerous lesions of the cervix and their treatment
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cervical cancer; premalignant lesion; human papillomavirus; cytology; screening
ID cervical cancer; premalignant lesion; human papillomavirus; cytology; screening
AB Global cervical cancer incidence and mortality rank fourth in women with malignant tumors, which have been reduced by population-based cervical cancer screening. The previously used Papanicolaou cytological testing of cervical smears was replaced by the Bethesda classification, which facilitated the early detection of the pre-cancerous lesions, used together with other methods such as colposcopy, testing of high-risk genotypes of human papillomavirus (hrHPV) and molecular techniques. The recently introduced terminology as ASC (atypical squamous cells), ASC-US (ASC, undetermined significance), ASC-H (ASC, cannot exclude HSIL), as well LSIL and HSIL (low- and high-grade squamous intraepithelial lesions) is widely used in Hungary, which guides the treatments of the patients by the clinicians. The detection of HPV is incorporated into the management of the patients as well. It is, however, highly important to update the domestic cervical cancer screening, especially with the introduction of the first-line, primary HPV screening in Hungary, in agreement with the opinions of other groups.
C1 [Sobel, Gabor] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/A, 1082 Budapest, Hungary.
RP Sobel, G (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, 1082 Budapest, Hungary.
EM sobelg@gmail.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424, 2018
   IARC. https://hpvcentre.net/statistics/reports/HUN_FS.pdf
   WHO Classification of Tumors, 5th ed., Female Genital Tumours. Vol. 4. WHO Press, Geneva, Switzerland, 2020
   Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350, 2002
   Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology or reporting results of cervical cytology. JAMA 287:2114–2119, 2002
   Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: result from a histological review of population based cervical sample. Int J Gynecol Pathol 26:441–446, 2007
   Bosze P. A mehnyaklapham rakelozo allapota, cervicalis intraepithelialis neoplasia, CIN). 1. resz. Nogyogy Onkol 15:133–139, 2010
   Papp Z. A szuleszet-nogyogyaszat tankonyve. Semmelweis Kiado, Budapest, 2021
   Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epid 141:680–689, 1995
   Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet 383:493–494, 2014
   Bodo M. Bethesda-szisztema: uj klasszifikacio, a klinikus szemszogebol. Magy Noorv Lapja 54:55–57, 1991
   Nayar R, Wilbur DC. The Pap Test and Bethesda 2014. Acta Cytologica 59:121–132, 2015
   Khan MJ, Castle PE, Lorincz A, et al. The elevated 10 year risk of cervical precancer and cancer in women with human papillomavirus, HPV, type 16 or 18 and the possible utility of HPV testing in clinical practice. J Natl Cancer Inst 97:1072–1079, 2005
   Cox JT, Schiffman M, Solomon D, et al. Triage Study, ALTS, Group. Prospective follow-up suggest similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188:1406–1412, 2003
   Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchow Arch 475:537–549, 2019
   Zinner B, Gyongyosi B, Babarczi E, et al. Claudin 1 expression characterizes human uterine cervical reserve cells. J Histochem Cytochem 61:880– 888, 2013
   Lambert APF, Anschau F, Schmitt VM. p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 80:192–196, 2006
   Meyer JL, Hanlon DW, Andersen BT, et al. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtecp16INK4a assay. Cancer Cytopathol 111:83–92, 2007
   Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 105:1550–1557, 2013
   Benczik M, Galamb A, Zinner B, et al. Uj molekularis biologiai modszerek es biologiai jelzok a mehnyakrak szureseben. Nogyogy Onkol 18:63–67, 2013
   Bosze P. A mehnyakrak szurese es megelozese: hagyomany es uj iranyzatok. Nogyogy Onkol 13:10–30, 2008
   Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 108:264–272, 2006
   Stuebs FA, Schulmeyer CE, Mehlhorn G, et al. Accuracy of colposcopy- directed biopsy in detecting early cervical neoplasia: a retrospective study. Arch Gynecol Obstet 299:525–532, 2019
   Duesing N, Schwarz J, Choschzick M, et al. Assessment of cervical intraepithelial neoplasia, CIN, with colposcopic biopsy and efficacy of loop electrosurgical excision procedure, LEEP). Arch Gynecol Obstet 286:1549–1554, 2012
   Bosze P. A mehnyaklapham rakelozo allapota, cervicalis intraepithelialis neoplasia, CIN). 2. resz. Nogyogy Onkol 16:56–64, 2011
   Chanen W, Rome RM. Electrocoagulation diathermy for cervical dysplasia and adenocarcinoma in situ: a 15-year survey. Obstet Gynecol 61:673–679, 1983
   Paraskevaidis E, Davidson EJ, Koliopoulos G, et al. Bleeding after loop electrosurgical excision procedure performed in either the follicular or the luteal phase of the menstrual cycle: a randomized trial. Obstet Gynecol 99:997–1000, 2002
   Garcia F, Hatch KD, Berek JS. Intraepithelial disease of the cervix, vagina, and vulva. In: Berek & Novak’s Gynecology. Eds. Berek JS, Novak E, 15th ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2012, pp. 592–604
   Varras M, Akrivis C, Anastasiadis A, et al. Peritonitis due to iatrogenic colpotomy after large loop excision of the transformation zone, LLETZ, in a patient with cervical intraepithelial neoplasia III: our experience of a rare case with review of the literature. Eur J Gynaecol Oncol 33:214–216, 2012
   Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetrical and fertility outcomes after conservative treatment for intra-epithelial or early invasive cervical lesions: a systemic review and meta-analysis of the literature. Lancet 367:489–498, 2006
   Conner SN, Frey HA, Cahill AG, et al. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. Obstet Gynecol 123:752–761, 2014
   Soutter WP, Sasieni P, Panaskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 118:2048–2055, 2006
   van Hamont D, van Ham MA, Zanden PH, et al. Long-term follow-up after large-loop excision of the transformation zone: evaluation of 22 years treatment of high-grade cervical intraepithelial neoplasia. Int J Gynecol Cancer 16:615–619, 2006
   Falcaro M, Castanin A, Ndlela B et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 398:2084–2092, 2021
   Cody P, Tobe K, Abe M, Elbasha EH. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis 21:11, 2021
   Tjalma WAA, Van Heerden J, Van den Wyngaart T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? Eur J Obstet Gynecol Reprod Biol 269:98–101, 2022
   Jentschke M, Kampers J, Becker J, et al. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis. Vaccine 38:6402– 6409, 2020
   A mehnyakrak szuresenek szempontjai: hazai iranyelvek. A Szuleszeti es Nogyogyaszati Szakmai Kollegium utmutatoja. Osszeallitotta: Bosze P, Gocze P, Hernadi Z, Papp K, Ungar L. Az Egeszsegugyi Miniszterium szakmai iranyelve a mehnyakrak szuresenek szempontjairol
   Safaeian M, Solomon D, Wacholder S, et al. Risk of precancer and follow- up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 109:1325–1331, 2007
   Jone BA, Novis DA. Follow-up of abnormal gynecologic cytology: a College of American Pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 124:665–671, 2000
   Jone BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 124:672–681, 2000
   Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnosis in Northern New England. Pediatrics 103:539–545, 1999
   Dunn TS, Burke M, Shwayder J. A ’see and treat’ management for highgrade squamous intraepithelial lesion Pap smears. J Low Genit Tract Dis 7:104–106, 2003
   Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 102:765–782, 2003
   Koiss R, Boncz I, Hernadi Z, et al. Javaslat a hazai mehnyakszuresi eljarasrend korszerusitesere. Orv Hetil 158:2062–2067, 2017
   Poka R. Mehnyakszures. Nemzetkozi korkep es javaslat a hazai iranyelvek fejlesztesere. Magy Noorv Lapja 81:38–46, 2018
   Fogarasi AI, Benczik M, Moravcsik-Kornyicki A, et al. The prevalence of high risk human papillomavirus in Hungary – A geographically representative cross-sectional study. Pathol Oncol Res 28:1610424, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 280
EP 287
PG 8
ER

PT J
AU Lintner, B
AF Lintner, Balazs
TI Different radical surgical treatment of cervical cancer based on the histopathological characteristics of the tumour
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE radical surgery; sentinel node; lymphadenectomy; nerve sparing
ID radical surgery; sentinel node; lymphadenectomy; nerve sparing
AB The surgical treatment of cervical tumours is a complex problem that often puzzles the gynaecological surgeon. The operation was previously named after Ernst Wertheim, who performed the first radical hysterectomy more than a century ago, and has since undergone many modifications. Today, almost 50% of patients are diagnosed at an early stage, when the disease is still localised to the cervix, with a 5-year survival rate of more than 90%. Surgical treatment is the first-line treatment for this group of patients, which offers a good solution in terms of long-term quality of life through ovarian preservation and surgical technique. In the majority of cases where fertility preservation is not an option, radical removal of the uterus and removal of lymph nodes is the basis for surgery. For both interventions, there have been many changes in the last decades and a detailed description of these changes and treatment planning is the main aim of this study.
C1 [Lintner, Balazs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/ABudapest, Hungary.
RP Lintner, B (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Budapest, Hungary.
EM lintnerster@gmail.com
CR Cibula D, Abu-Rustum NR, Dusek L, et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 124:496–501, 2012
   Cibula D, Oonk MH, Abu-Rustum NR. Sentinel lymph node biopsy in the management of gynecologic cancer. Curr Opin Obstet Gynecol 27:66–72, 2015
   Mathevet P, Lecuru F, Uzan C, et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial, SENTICOL-2). Eur J Cancer 148:307–315, 2021
   Cibula D, Dostalek L, Hillemanns P, et al. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. Eur J Cancer 143:88–100, 2021
   Cibula D, McCluggage WG. Sentinel lymph node, SLN, concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol 152:202–207, 2019
   Lecuru FR, McCormack M, Hillemanns P, et al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. Int J Gynecol Cancer 29:829– 834, 2019
   Nemejcova K, Kocian R, Kohler C, et al. Central pathology review in SENTIX, a prospective observational international study on sentinel lymph node biopsy in patients with early-stage cervical cancer, ENGOT-CX2). Cancers 12:1115, 2020
   Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379:1895– 1904, 2018
   Querleu D, Morow P. Classification of radical hysterectomy. Lancet Oncol 9:297–303, 2008
   Querleu D, Cibula D, Abu-Rustum NR. 2017 Update on the Querleu-Morrow classification of radical hysterectomy. Ann Surg Oncol 24:3406–3412, 2017
   Palfalvi L, Ungar L. Laterally extended parametrectomy, LEP), the technique for radical pelvic sidewall dissection: feasibility, technique, and results. Int J Gynecol Cancer 13:914–917, 2003
   Hockel M. Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecologic malignancies. Am J Obstet Gynecol 180:306–312, 1999
   Fujii S, Takakura K, Matsumura N, et al. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol 107:4–13, 2007
   Melamed A, Rauh-Hain JA, Ramirez PT. Minimally invasive radical hysterectomy for cervical cancer: when adoption of a novel treatment precedes prospective, randomized evidence. J Clin Oncol 37:3069–3074, 2019
   Covens A. GOG Protocol 278. https://www.nrgoncology.org/Clinical-Trials/ Protocol/gog-0278?filter=gog-0278
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 289
EP 293
PG 5
ER

PT J
AU Banhidi, A
   Novak, Z
AF Banhidi, Andor
   Novak, Zoltan
TI Robotic surgery in gynecologic cancer, especially in cervical cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE robotic surgery; surgery; laparoscopy; cervical cancer; uterine cancer
ID robotic surgery; surgery; laparoscopy; cervical cancer; uterine cancer
AB The development of robotic surgery is another step in the evolution of modern surgery. Robot-assisted minimally invasive procedures undoubtedly have many advantages compared to traditional laparotomy, which is why they have also been introduced in the treatment of gynecological cancers. Numerous studies have confirmed the advantages of robotic surgery in terms of quicker recovery, reduced blood loss, and shorter hospitalization. The technique provides a significant advantage in the minimally invasive treatment of overweight patients. However, in the treatment of cervical cancer, the use of minimally invasive procedures have declined in recent years due to worse oncological results. It is necessary to carry out further clinical trials in this indication using surgical solutions that prevent the spread of the tumor, in order to find out whether minimally invasive surgery regains its important role in the surgical treatment of early cervical cancer.
C1 [Banhidi, Andor] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of Gynaecology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Novak, Z (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM novak.zoltan@oncol.hu
CR Falcone T, Goldberg J, Garcia-Ruiz A, et al. Full robotic assistance for laparoscopic tubal anastomosis: a case report. J Laparoendosc Adv Surg Tech A 9:107–113, 1999
   Himpens J, Leman G, Cadiere G. Telesurgical laparoscopic cholecystectomy. Surg Endosc 12:1091, 1998
   Intuitive.com
   Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 10:CD006655, 2018
   Netter A, Jauffret C, Brun C, et al. Choosing the most appropriate minimally invasive approach to treat gynecologic cancers in the context of an enhanced recovery program: Insights from a comprehensive cancer center. PLoS One15:e0231793, 2020
   Brandt B, Sioulas V, Basaran D, et al. Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: survival outcomes. Gynecol Oncol 156:591–597, 2020
   Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med 379:1905–1914, 2018
   Nezhat CR, Burrell MO, Nezhat FR, et al. Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection. Am J Obstet Gynecol 166:864–865, 1992
   Sert BM, Abeler VM. Robotic-assisted laparoscopic radical hysterectomy, Piver type III, with pelvic node dissection: case report. Eur J Gynaecol Oncol 27:531–533, 2006
   Sert BM, Kristensen GB, Kleppe A, Dorum A. Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience. Gynecol Oncol 162:284–291, 1992
   Nam JH, Park JY, Kim DY, et al. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. Ann Oncol 23:903–911, 2012
   Geetha, P, Nair MK. Laparoscopic, robotic and open method of radical hysterectomy for cervical cancer: A systematic review. J Minimal Access Surg 8:67–73, 2012
   Cao T, Feng Y, Huang Q, et al. Prognostic and safety roles in laparoscopic versus abdominal radical hysterectomy in cervical cancer: A meta-analysis. J Laparoendosc Adv Surg Tech A 25:990–998, 2015
   Wang YZ, Deng L, Xu HC, et al. Laparoscopy versus laparotomy for the management of early stage cervical cancer. BMC Cancer 15:928, 2015
   Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379:1895– 1904, 2018
   Nitecki R, Ramirez PT, Frumovitz M, et al. Survival after minimally invasive vs. open radical hysterectomy for early-stage cervical cancer: a systematic review and meta-analysis. JAMA Oncol 6: 1019–1027, 2020
   National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Cervical Cancer. https://www.nccn.org/professionals/ physician_gls/pdf/cervical.pdf
   Querleu D, Cibula D, Concin N, et al. Laparoscopic radical hysterectomy: A European Society of Gynaecological Oncology, ESGO, statement. Int J Gynecol Cancer 30:15, 2020
   Matsuo K, Mandelbaum RS, Klar M, et al. Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. Gynecol Oncol 162:43–49, 2021
   Frumovitz M, Obermai A, Coleman RL, et al. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy, LACC): A secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 21:851–860, 2020
   Obermair A, Asher R, Pareja R, et al. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: Results of a randomized controlled trial. Am J Obstet Gynecol 222:249.e1–249.e10, 2020
   Touhami O, Plante M. Minimally invasive surgery for cervical cancer in light of the LACC trial: What have we learned? Curr Oncol 29:1093–1106, 2022
   Chen CH, Chiu LH, Chang CW, et al. Comparing robotic surgery with conventional laparoscopy and laparotomy for cervical cancer management. Int J Gynecol Cancer 24:1105–1111, 2014
   Kato T, Takashima A, Kasamatsu T, et al. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer, JCOG0806-A). Gynecol Oncol 137:34–39, 2015
   Chiva L, Zanagnolo V, Querleu D, et al. SUCCOR study: An international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. Int J Gynecol Cancer 30:1269–1277, 2020
   A randomized phase III trial comparing radical hysterectomy and pelvic node dissection vs. simple hysterectomy and pelvic node dissection in patients with low-risk early stage cervical cancer, SHAPE). https://clinicaltrials. gov/ct2 /show/NCT01658930
   Bhatla N, Aoki D, Sharma DN, Sankaranarayanan B. Cancer of the cervix uteri. Int J Gynaecol Obstet 143:22–36, 2018
   Wenze HHB, Smolders RGV, Beltman JJ, et al. Survival of patients with early- stage cervical cancer after abdominal or laparoscopic radical hysterectomy: A nationwide cohort study and literature review. Eur J Cancer 133:14–21, 2020
   Chen C, Liu P, Ni Y, et al. Laparoscopic versus abdominal radical hysterectomy for stage IB1 cervical cancer patients with tumor size ≤ 2 cm: A casematched control study. Int J Clin Oncol 25:937–947, 2020
   Kim SI, Lee M, Lee S, et al. Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea. Gynecol Oncol 155:75–82, 2019
   Yang J, Mead-Harvey C, Polen-De C, et al. Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: Our surgical pathology interrogation. Gynecol Oncol 159:373–380, 2020
   Falconer H, Palsdottir K, Stalberg K, et al. Robot-assisted approach to cervical cancer, RACC): An international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer 29:1072–1076, 2019
   A trial of Robotic Versus Open Hysterectomy in Cervix Cancer, ROCC). https://clinicaltrials.gov/ct2/show/ NCT04831580
   Kohler C, Hertel H, Herrmann J, et al. Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff – A multicenter analysis. Int J Gynecol Cancer 29:845–850, 2019
   Padilla-Iserte P, Lago V, Tauste C, et al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol 224:65.e1–65.e11, 2021
   Kim S, Min KJ, Lee S, et al. Learning curve could affect oncologic outcome of minimally invasive radical hysterectomy for cervical cancer. Asian J Surg 44:174–180, 2021
   Casarin J, Bogani G, Papadia A, et al. Preoperative conization and risk of recurrence in patients undergoing laparoscopic radical hysterectomy for early-stage cervical cancer: A multicenter study. J Minim Invasive Gynecol 28:117–123, 2021
   Uppal S, Gehrig PA, Peng K, et al. Recurrence rates in patients with cervical cancer treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional retrospective review study. J Clin Oncol 38:1030–1040, 2020
   Jensen T, Schnack TH, Froding LP, et al. Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer – a population-based study. Eur J Cancer 128:47–56, 2020
   Alfonzo E, Wallin E, Ekdahl L, et al. No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study. Eur J Cancer 116:169–177, 2019
   Zhang SS, Ding T, Cui ZH, et al. Efficacy of robotic radical hysterectomy for cervical cancer compared with that of open and laparoscopic surgery: A separate meta-analysis of high-quality studies. Medicine, Baltimore, 98:e14171, 2019
   Cibula D, Planchamp F, Fischerova D, et al. European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. Int J Gynecol Cancer 30:3–14, 2020
   Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. Cancer J Clin 71:7–33, 2021
   Nobre SP, Mueller JJ, Ginger J, et al. Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. Int J Gynecol Cancer 30:1162–1168, 2020
   Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 27:5331–5336, 2009
   Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700, 2012
   Eoh KJ, Nam EJ, Kim SW, et al. Nationwide comparison of surgical and oncologic outcomes in endometrial cancer patients undergoing robotic, laparoscopic, and open surgery: a population-based cohort study. Cancer Res Treat 53:549–557, 2020
   Peter AA, Jordan M, Rivard CL, et al. Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer. Gynecol Oncol 165:347–352, 2022
   Song TL, Hopkins L, Fung-Kee-Fung M, et al. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer. Int J Gynecol Cancer 30:160–166, 2020
   Maenpaa MM, Nieminen K, Tomas EI, et al. Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: a randomized controlled trial. Am J Obstet Gynecol 215:588.e1–588.e7, 2016
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 295
EP 301
PG 7
ER

PT J
AU Ungar, L
   Lintner, B
AF Ungar, Laszlo
   Lintner, Balazs
TI The need, potential and unresolved issues of fertility preservation in the early stages of cervical cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE conisation; radical trachelectomy; parametrium
ID conisation; radical trachelectomy; parametrium
AB In the choice of a planned fertility preservation procedure for stage IA1 and IB1 cervical cancer, optimal oncological safety is the main focus of virtually all protocols. The surgeon should remove the appropriate proportion of the cervix for oncological safety, ensuring an adequate tumour-free surgical margin. However, some of the literature on fertility preservation, referring to histological parameters, still considers conisation with excellent fertility results to be optimal for the treatment of tumours with a diameter of 2 cm. With regard to fertility preservation in the case of radical trachelectomy versus simple conisation, we are aware of several ongoing studies, the results of which may provide an answer as to whether a more conservative surgical therapy for smaller tumours (less than 2 cm in diameter) represents an acceptable oncological safety.
C1 [Ungar, Laszlo] Duna Medical CenterBudapest, Hungary.
   [Lintner, Balazs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/a, 1082 Budapest, Hungary.
RP Lintner, B (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, 1082 Budapest, Hungary.
EM lintnerster@gmail.com
CR Smith ES, Moon AS, O’Hanlon R, et al. Radical trachelectomy for the treatment of early-stage cervical cancer: a systematic review. Obstet Gynecol 136:533–542, 2020
   Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 121:290–297, 2011
   Hauspy J, Beiner M, Harley I, et al. Sentinel lymph nodes in early stage cervical cancer. Gynecol Oncol 105:285–290, 2007
   Kokka F, Bryant A, Brockbank E, Jeyarajah A. Surgical treatment of stage IA2 cervical cancer. Cochrane Database Syst Rev 2014:CD010870, 2014
   Mota F. Microinvasive squamous carcinoma of the cervix: treatment modalities. Acta Obstet Gynecol Scand 82:505–509, 2003
   Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility- sparing surgery for cervical cancer: a systematic review. Lancet Oncol 17:e240–e253, 2016
   Zusterzeel PL, Pol FJ, Van Ham M, et al. Vaginal radical trachelectomy for early-stage cervical cancer: increased recurrence risk for adenocarcinoma. Int J Gynecol Cancer 26:1293–1299, 2016
   Spoozak L, Lewin SN, Burke WM, et al. Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 206:80.e1–6, 2012
   Machida H, Iwata T, Okugawa K, et al. Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate. Gynecol Oncol 156:341–348, 2020
   Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility- sparing surgery for cervical cancer: a systematic review. Lancet Oncol 17:e240–e253, 2016
   Falcetta FS, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 11:CD005342, 2016
   Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 73:177–183, 1999
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 302
EP 305
PG 4
ER

PT J
AU Polgar, Cs
   Major, T
   Varga, Sz
AF Polgar, Csaba
   Major, Tibor
   Varga, Szilvia
TI Radiotherapy and radio-chemotherapy of cervical cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cervical cancer; radiotherapy; radio-chemotherapy; brachytherapy
ID cervical cancer; radiotherapy; radio-chemotherapy; brachytherapy
AB Radiotherapy has a significant role in the management of cervical cancer. Radiotherapy is indicated in two-thirds of all cervical cancer patients. Indications of radiotherapy are based on level I-II evidences in the vast majority of cases, although in some cases the use of radiotherapy is supported by the results of retrospective clinical trials. In this review, indications of curative and palliative irradiation and radio-chemotherapy are summarized and technological advances of contemporary external beam radiotherapy and brachytherapy are presented.
C1 [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Varga, Szilvia] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
CR Usmani N, Farshad F, Du J, et al. An evidence-based estimate of the appropriate rate of utilization of radiotherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys 63:812–827, 2005
   Varga Sz, Polgar Cs. Nogyogyaszati daganatok sugarkezelese. In: Nogyogyaszati onkologia. Szerk. Pete I, Kasler M. Zafir Press, Budapest 2013, pp. 269–279
   Demeter A, Varga Sz. Nogyogyaszati daganatok kezelese – Mehnyakrak. In: Onkologia es sugarterapia. Szerk. Polgar Cs. Semmelweis Kiado, Budapest 2018, pp. 145–151
   Polgar Cs. A palliativ sugarkezeles indikacioi. LAM 13:373–378, 2003
   Atlan D, Touboul E, Deniaud-Alexandre E, et al. Operable stages IB and II cervical carcinomas: A retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:780–793, 2002
   Bataille B, Escande A, Le Tinier F, et al. Outcomes of pre-operative brachytherapy followed by hysterectomy for early cervical cancer. Int J Gynecol Cancer 30:181–186, 2020
   Beskow C, Agren-Cronqvist AK, Granath F, et al. Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage IB and IIA is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989–1991. Int J Gynecol Cancer 12:158–170, 2002
   Gauci PA, Kee DLC, Thamphya B, et al. Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis. Brachytherapy 21:273–282, 2022
   Kellas-Sleczka S, Wojcieszek P, Szlag M, et al. Pre-operative high-doserate brachytherapy in early-stage cervical cancer: long-term single-center results. J Contemp Brachytherapy 14:43–51, 2022
   Mundt AJ, Waggoner S, Herbst A, et al. Preoperative intracavitary brachytherapy in early-stage cervical carcinoma. Am J Clin Oncol 22:73–77, 1999
   Muschitz S, Petrow P, Briot E, et al. Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma. Radiother Oncol 73:187–194, 2004
   Poka R, Szluha K, Hernadi Z, et al. Analysis of survival in stage IB and IIA cervical cancer treated with and without preoperative local radiotherapy. Eur J Gynaecol Oncol 16:208–211, 1995
   Resbeut MR, Alzieu C, Gonzague-Casabianca L, et al. Combined brachytherapy and surgery for early carcinoma of the uterine cervix: Analysis of extent of surgery on outcome. Int J Radiat Oncol Biol Phys 50:873–881, 2001
   Varela Cagetti L, Gonzague-Casabianca L, Zemmour C, et al. The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. Gynecol Oncol 161:166–172, 2021
   Vizkeleti J, Pete I, Vereczkey I, et al. Patologiai komplett remisszio preoperativ, nagy dozisteljesitmenyu brachyterapiat kovetoen operabilis mehnyakdaganatos betegeknel: egy prospektiv, randomizalt vizsgalat elozetes eredmenyei. Magy Onkol 56:171–177, 2012
   Vizkeleti J, Vereczkey I, Frohlich G, et al. Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: Preliminary results of a prospective randomized multicentric study. Pathol Oncol Res 21:247–256, 2015
   Perez CA, Kavanagh BD. Uterine cervix. In: Principles and practice of radiation oncology. Eds. Perez CA, Brady LW, Halperin EC, et al. Lippincott Williams & Wilkins, Philadelphia, USA, 2004, pp. 1800–1915
   Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73:177–183, 1999
   Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 65:169–176, 2006
   Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613, 2000
   Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 96:721–728, 2005
   Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 350:535– 540, 1997
   Sundfor K, Trope CG, Kjorstad KE. Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B – long-term results from a randomized study 1968–1980. Acta Oncol 35:99–107, 1996
   Cibula D, Potter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol 127:404–416, 2018
   Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143, 1999
   Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial, RTOG, 90-01. J Clin Oncol 22:872–880, 2004
   Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–1348, 1999
   Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153, 1999
   Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical cancer. N Engl J Med 340:1154–1161, 1999
   Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 3:CD002225, 2005
   Dunst J, Haensgen G. Simultaneous radiochemotherapy in cervical cancer: Recommendations for chemotherapy. Strahlenther Onkol 177:635–640, 2001
   Rojas-Espaillat LA, Rose PG. Management of locally advanced cervical cancer. Curr Opin Oncol 17:485–492, 2005
   Faye MD, Alfieri J. Advances in radiation oncology for the treatment of cervical cancer. Curr Oncol 29:928–944, 2022
   Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer. Semin Radiat Oncol 30:273–280, 2020
   Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer. Recent data and ongoing trials. Cancer Treat Rev 106:102385, 2022
   Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis. Radiat Oncol 13:177, 2018
   Klopp AH, Moughan J, Portelance L, et al. Hematologic in RTOG 0418: A phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 86:83–90, 2013
   Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol 36:2538–2544, 2018
   Jayatilakebanda I, Tsang YM, Hoskin P. High dose simultaneous integrated boost for node positive cervical cancer. Radiat Oncol 16:92, 2021
   Locsei Z, Sebestyen K, Sebestyen Z, et al. IMAT-IGRT treatment with simultaneous integrated boost as dose escalation for patients with cervical cancer: A single institution, prospective pilot study. Pathol Oncol Res 27:608446, 2021
   Jadon R, Pembroke CA, Hanna CL. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clin Oncol, R Coll Radiol, 26:185–196, 2014
   Shelley CE, Barraclough LH, Nelder CL, et al. Adaptive radiotherapy in the management of cervical cancer: Review of strategies and clinical implementation. Clin Oncol 33:579–590, 2021
   de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al. The MOMENTUM study: An international registry for the evidence-based introduction of MR-guided adaptive therapy. Front Oncol 10:1328, 2020
   Tanderup K, Nielsen SK, Nyvang GB, et al. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer. Radiother Oncol 94:173– 180, 2010
   Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary versus intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis of the retroEMBRACE study. Radiother Oncol 120:434–440, 2016
   Sturdza A, Potter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in Retro EMBRACE, a multicenter cohort study. Radiother Oncol 120:428–433, 2016
   Potter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer, EMBRACE-I): A multicentre prospective cohort study. Lancet Oncol 22:538–547, 2021.
   Frohlich G, Vizkeleti J, Nhung NA, et al. Mehnyakdaganatok kepvezerelt adaptiv intersticialis-intrakavitalis brahiterapiajanak dozimetriai elemzese es a hagyomanyos kezelesi technikakkal valo osszehasonlitasa. Magy Onkol 62:242–248, 2018
   Vizkeleti J, Frohlich G, Nhung NA, et al. Elorehaladott mehnyakdaganatok kepvezerelt adaptiv kombinalt intrakavitalis-intersticialis brahiterapiajanak bevezetese Magyarorszagon. Magy Onkol 62:249–257, 2018
   Frohlich G, Geszti G, Vizkeleti J, et al. Dosimetric comparison of inverse optimisation methods versus forward optimisation in HDR brachytherapy of breast, cervical and prostate cancer. Strahlenther Onkol 195:991–1000, 2019
   Major T, Frohlich G, Agoston P, et al. The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. Strahlenther Onkol 198:93–109, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 307
EP 314
PG 8
ER

PT J
AU Mate, Sz
AF Mate, Szabolcs
TI Medical therapy of cervical cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cervical cancer; chemotherapy; immunotherapy; targeted therapy
ID cervical cancer; chemotherapy; immunotherapy; targeted therapy
AB Early stage cervical cancer can be successfully treated with either surgery or radiotherapy, but medical therapy is inevitably necessary for the treatment of locally advanced and metastatic cases. Chemotherapy is routinely used to increase the efficacy of radiation therapy (chemoradiation) and in the palliative setting, but it has also been investigated as neoadjuvant and adjuvant therapy. Due to the limited efficacy of chemotherapies in cervical cancer and to the development of the oncological therapies, in the last decade many studies have been performed with novel agents. First the anti-VEGF antibody bevacizumab, later immunotherapeutic agents, lately an antibody drug conjugate have proven their efficiency and gained approval from the federal and European medical agencies. The aim of this paper is to give an overview of the medical therapies of cervical cancer (excluding chemoradiation), focusing on currently available modern treatment options and future possibilities.
C1 [Mate, Szabolcs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/A, 1082 Budapest, Hungary.
RP Mate, Sz (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, 1082 Budapest, Hungary.
EM mate.szabolcs@med.semmelweis-univ.hu
CR Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48:899–903, 1981
   Kumar L, Harish P, Malik PS, et al. Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer 42:120–128, 2018
   Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119, 2004
   Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633, 2005
   Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655, 2009
   Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129–2135, 2015
   https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
   Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial, Gynecologic Oncology Group 240). Lancet 390:1654–1663, 2017
   Neoadjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis of individual patient data from 21 randomised trials. Neoadjuvant Chemotherapy for Cervix Cancer Meta-analysis Collaboration, NACCCMA Collaboration). Eur J Cancer 39:2470–2486, 2003
   McCormack M, Kadalayil L, Hackshaw A, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 108:2464–2469, 2013
   Vale CL, Tierney JF, Davidson SE, et al. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists’ audit. Clin Oncol 22:590–601, 2010
   Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res 40:4819–4828, 2020
   Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36:1548–1555, 2018
   Kenter G, Greggi S, Vergote I, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer: EORTC55994. J Clin Oncol 37(15_suppl):5503, 2019
   Cibula D, Potter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer 28:641–655, 2018
   Salihi R, Leunen K, Moerman P, et al. Neoadjuvant weekly paclitaxel- carboplatin is effective in stage I-II cervical cancer. Int J Gynecol Cancer 27:1256–1260, 2017
   Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol 30:1601–1612, 2019
   Mandic A, Maricic S, Malenkovic G, et al. Neoadjuvant chemotherapy in locally advanced cervical cancer in pregnancy – Review of the literature. J BUON 25:597–604, 2020
   Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer 19(Suppl 1):S1–12, 2009
   Li M, Zhao Y, Qie M, et al. Management of cervical cancer in pregnant women: a multi-center retrospective study in China. Front Med 7:538815, 2020
   Rosa DD, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 6:CD005342, 2012
   Chung HC, Ros W, Delord JP et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37:1470–1478, 2019
   Tewari KS, Monk BJ, Vergote I, et al Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 386:544–555, 2022
   Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 385:1856–1867, 2021
   Tewari KS, Colombo N, Monk BL, et al. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: subgroup analysis of KEYNOTE-826. J Clin Oncol 40(16_suppl):5506, 2022
   Zhao X, Cheng C, Gou J, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med 16:4075–4081, 2018
   de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours, InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol 20:383–393, 2019
   Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer, innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single- arm, phase 2 study. Lancet Oncol 22:609–619, 2021
   https://www.clinicaltrials.gov/ct2/show/NCT04697628
   Vergote I, Mirza M. R, Sehouli J, et al. Trial in progress update on ENGOT- cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line, 1L, tisotumab vedotin, TV, + pembrolizumab, pembro, + carboplatin, carbo, ± bevacizumab, bev, in recurrent/metastatic cervical cancer, r/mCC). J Clin Oncol 40(16_suppl):TPS5603, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 315
EP 323
PG 9
ER

PT J
AU Landherr, L
   Naszaly, A
AF Landherr, Laszlo
   Naszaly, Attila
TI Dr. Nagykalnai Tamas (1942–2022)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
DE necrolog
ID necrolog
C1 [Landherr, Laszlo] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Uzsoki utca 29-41., 1145 Budapest, Hungary.
   [Naszaly, Attila] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Uzsoki utca 29-41., 1145 Budapest, Hungary.
RP Landherr, L (reprint author), Fovarosi Onkormanyzat Uzsoki utcai Korhaza, 1145 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 324
EP 324
PG 1
ER

PT J
AU Schaff, Zs
   Jaray, B
AF Schaff, Zsuzsa
   Jaray, Balazs
TI Screening for cervical cancer, human papillomavirus (HPV) vaccination
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cervical cancer screening; vaccination; cytology; human papillomavirus; premalignant lesions
ID cervical cancer screening; vaccination; cytology; human papillomavirus; premalignant lesions
AB Cervical cancer screening is widely used worldwide, which led to a significant decrease both in incidence and mortality of the disease in several countries. Cervical cancer screening was introduced in the 1950s as opportunistic method for secondary prevention of cervical cancer in Hungary, later, however, became a part of National Immunization Program. Detection of human papillomavirus (HPV) is the first-line method of screening in several countries before cytology, which has been proposed to be introduced in Hungary by several groups. The incidence and mortality of cervical cancer can be reduced further or even completely eliminated by the application of HPV vaccines first by 2- , followed by 4- and recently by 9- valent HPV vaccines. Nationwide vaccination program for 12-year-old girls was introduced in 2014 which was extended for boys of the same age in 2020 involving 60-80% of the target population in Hungary. The next step would be to extend the vaccination program as catch up and pre- or postconization vaccination to approach the WHO goal for elimination of HPV infection and cervical cancer.
C1 [Schaff, Zsuzsa] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Jaray, Balazs] Medserv KftBudapest, Hungary.
RP Schaff, Zs (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM schaff.zsuzsa@med.semmelweis-univ.hu
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon 2020. https://gco.iarc.fr/ today
   Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer 149:778–789, 2021
   Koiss R, Boncz I, Hernadi Z, et al. Javaslat a hazai mehnyakszuresi eljarasrend korszerusitesere. Orv Hetil 15:2062–2067, 2017
   Papp Z. Az onkocitologia mint szuromodszer. A szuleszet-nogyogyaszat tankonyve. 6., atdolgozott kiadas. Semmelweis Kiado, Budapest 2012, pp. 568–573
   Poka R. Mehnyakszures. Nemzetkozi korkep es javaslat a hazai iranyelvek fejlesztesere. Magy Noorv Lapja 81:38–46, 2018
   Dobrossy L, Koiss R. „Gynecological cancer screening” or „cervical scrrening”? The case of Hungary. Eur J Gynaecol Oncol 37:445–450, 2016
   Fogarasi AI, Benczik M, Moravcsik-Kornyicki A, et al. The prevalence of high-risk human papillomavirus in Hungary – A geographically representative cross-sectional study. Pathol Oncol Res 28:1610424, 2022
   Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812–3815, 1983
   Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350, 2002
   National Cancer Institute Workshop: The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. JAMA 262:931–934, 1989
   Solomon D, Davey D, Kurman R, et al. The Bethesda System 2001: terminology for reporting the results of cervical cytology. JAMA 287:2114–2119, 2002
   Bodo M. Bethesda-szisztema: uj klasszifikacio, a klinikus szemszogebol. Magy Noorv Lapja 54:55–57, 1991
   Jaray B, Schaff Zs. A mehnyakrak szovettana – Molekularis vizsgalatok. Magy Onkol 66:271–278, 2022
   Papanicolaou GN, Traut HP. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42:193–205, 1941
   Sobel G. A mehnyak rakelozo allapotai es azok kezelese. Magy Onkol 66:280–287, 2022
   World Health Organization, WHO). Fact sheet. Human papillomavirus, HPV, and cervical cancer. January 24, 2019
   European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. 2020 Stockholm ECDC. www.ecdc. europa.eu
   European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries: ECDC, 2008
   CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book. 13th ed., 2015
   Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus, HPV, vaccination in Australia: what additional disease burden will a nanovalent vaccine prevent? Euro Surveill 23:30–40, 2018
   Lei J, Ploner A, Lehtinen M, et al. Impact of HPV vaccination on cervical screening performance: a population-based cohort study. Br J Cancer 123:155–160, 2020
   Cody P, Tobe K, Abe M, et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Inf Dis 21:1–13, 2021
   Tjalma WAA, van Heerden J, van den Wyngaart T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? Eur J Obstet Gynecol Reprod Biol 269:98–101, 2022
   Ayesha N, Aboulghras S, Jahangeer M, et al. Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus. Environ Sci Pull Res 28:47752–47772, 2021
   Bruni L, Saura-Lazaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med 144:106399, 2021
   World Health Organization, WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://apps.who. int/iris/handle/10665/336583
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2022
VL 66
IS 4
BP 325
EP 330
PG 6
ER

PT J
AU Santa, F
   Posfai, B
   Sejben, A
   Kuthi, L
AF Santa, Fanni
   Posfai, Boglarka
   Sejben, Anita
   Kuthi, Levente
TI Pathological characteristics and genetic background of renal cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kidney cancer; RCC; renal cell carcinoma
ID kidney cancer; RCC; renal cell carcinoma
AB Renal cell carcinoma (RCC) is the most common malignant kidney tumor. It is not a single entity but an umbrella term for several distinct tumor types. The most prevalent and clinically significant subtype of RCC is clear cell carcinoma, which consists of cells with empty cytoplasm. These tumor cells harbor biallelic loss of the VHL gene, resulting in a pseudohypoxic state that promotes angiogenesis and cellular proliferation. Papillary RCC and chromophobe carcinoma are also common subtypes, with the former displaying a papillary appearance and cMET mutation. The latter is characterized by eosinophilic tumor cells and multiple chromosomal losses. These subtypes are responsible for 90-95% of all kidney cancers in adults. Additionally, rare tumor subtypes with unique immunohistochemical features, genetic abnormalities, or a specific clinical course may be identified. Currently, the RCC subtype only holds prognostic significance, and no treatment is associated with any subtype. However, therapies associated with histological subtypes may emerge in the future, and thus, the diagnosis of RCCs should be made following current recommendations.
C1 [Santa, Fanni] University of Szeged, Department of Pathology, Allomas u. 2., 6725 Szeged, Hungary.
   [Posfai, Boglarka] University of Szeged, Department of Pathology, Allomas u. 2., 6725 Szeged, Hungary.
   [Sejben, Anita] University of Szeged, Department of Pathology, Allomas u. 2., 6725 Szeged, Hungary.
   [Kuthi, Levente] University of Szeged, Department of Pathology, Allomas u. 2., 6725 Szeged, Hungary.
RP Kuthi, L (reprint author), University of Szeged, Department of Pathology, 6725 Szeged, Hungary.
EM kuthi.levente@med.u-szeged.hu
CR Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 75:74–84, 2019
   Tarabeia J, Kaluski DN, Barchana M, et al. Renal cell cancer in Israel: sex and ethnic differences in incidence and mortality, 1980–2004. Cancer Epidemiol 34:226–231, 2010
   Santa F, Semjen D, Kuthi L. Orokletes vesetumor-szindromak. Patologiai es genetikai attekintes. Orv Hetil 164:363–375, 2023
   Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis 9:45–52, 2016
   Semjen D, Denes B, Somoracz A, et al. Renal cell carcinoma in end-stage renal disease: A retrospective study in patients from Hungary. Pathobiology 2023,, DOI  10.1159/000529276
   Kovacs G, Akhtar M, Beckwith JB, et al. The Heidelberg classification of renal cell tumours. J Pathol 183:131–133, 1997
   Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Ed. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. International Agency for Research on Cancer, Lyon 2004
   Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology, ISUP, Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 37:1469–1489, 2013
   WHO Classification of Tumours of the Urinary System and Male Genital Organs. Ed. Moch H, Humphrey PA, Ulbright TM, Reuter V. International Agency for Research on Cancer, Lyon 2016
   Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology, ISUP, Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. Am J Surg Pathol 37:1490–1540, 2013
   Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663, 1982
   WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. International Agency for Research on Cancer, Lyon 2022
   Kuthi L, Jenei A, Hajdu A, et al. Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res 23:689–698, 2017
   Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260:1317–1320, 1993
   Hemmerlein B, Kugler A, Ozisik R, et al. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 439:645–652, 2001
   de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma. A study of 101 cases. Am J Surg Pathol 25:275–284, 2001
   Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol 73:311–315, 2018
   Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N Engl J Med 385:2036–2046, 2021
   Macher-Goeppinger S, Keith M, Endris V, et al. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget 8:1046–1057, 2017
   Sankin A, Cohen J, Wang H, et al. Rate of renal cell carcinoma subtypes in different races. Int Braz J Urol 37:29–34, 2011
   Saleeb RM, Brimo F, Farag M, et al. Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis. Am J Surg Pathol 41:1618– 1629, 2017
   Zhu B, Poeta ML, Costantini M, et al. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas. Nat Commun 11:3096, 2020
   Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 18:161– 169, 2005
   Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822– 1834, 2008
   Tickoo SK, Lee MW, Eble JN, et al. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional, clear cell, renal cell carcinoma. Am J Surg Pathol 24:1247–1256, 2000
   Rogala J, Kojima F, Alaghehbandan R, et al. Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases. Bosn J Basic Med Sci 22:531–539, 2022
   Massari F, Ciccarese C, Hes O, et al. The tumor entity denominated „clear cell-papillary renal cell carcinoma” according to the WHO 2016 new classification, have the clinical characters of a renal cell adenoma as does harbor a benign outcome. Pathol Oncol Res 24:447–456, 2018
   Hes O, Comperat EM, Rioux-Leclercq N. Clear cell papillary renal cell carcinoma, renal angiomyoadenomatous tumor, and renal cell carcinoma with leiomyomatous stroma relationship of 3 types of renal tumors: a review. Ann Diagn Pathol 21:59–64, 2016
   Somoracz A, Kuthi L, Micsik T, et al. Renal cell carcinoma with clear cell papillary features: perspectives of a differential diagnosis. Pathol Oncol Res 26:1767–1776, 2020
   Peckova K, Martinek P, Sperga M, et al. Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of lowgrade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma. Ann Diagn Pathol 19:226–231, 2015
   Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol 27:875–886, 2014
   Kuthi L, Somoracz A, Micsik T, et al. Clinicopathological findings on 28 cases with XP11.2 renal cell carcinoma. Pathol Oncol Res 26:2123–2133, 2020
   Argani P, Ladanyi M. Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of the paediatric renal carcinomas. Pathology 35:492–498, 2003
   Akgul M, Saeed O, Levy D, et al. Morphologic and immunohistochemical characteristics of fluorescent in situ hybridization confirmed TFE3-gene fusion associated renal cell carcinoma: a single institutional cohort. Am J Surg Pathol 44:1450–1458, 2020
   Argani P. Translocation carcinomas of the kidney. Genes Chromosomes Cancer 61:219–227, 2022
   Argani P, Reuter VE, Zhang L, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 40:1484–1495, 2016
   Akgul M, Williamson SR. Immunohistochemistry for the diagnosis of renal epithelial neoplasms. Semin Diagn Pathol 39:1–16, 2022
   Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol 40:865–875, 2016
   Pivovarcikova K, Martinek P, Grossmann P, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases. Ann Diagn Pathol 39:63–68, 2019
   Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 38:627–637, 2014
   Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase, SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 38:1588–1602, 2014
   Yoo A, Tang C, Zucker M, et al. Genomic and metabolic hallmarks of SDHand FH-deficient renal cell carcinomas. Eur Urol Focus 8:1278–1288, 2022
   Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase- deficient renal cell carcinoma with focus on clinical and pathobiological aspects. Pol J Pathol 67:3–7, 2016
   Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic solid and cystic renal cell carcinoma, ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol 41:1299–1308, 2017
   Jenei A, Hes O, Kuthi L. Provizorikus veserakaltipusok a 2016. evi WHO-klasszifikaciot kovetoen. Orv Hetil 161:83–94, 2020
   Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol 40:60–71, 2016
   Xie Z, Yadav S, Lohse CM, et al. Collecting duct carcinoma: A single-institution retrospective study. Urol Oncol 40:13.e9–13.e18, 2022
   Cimadamore A, Cheng L, Scarpelli M, et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know – a narrative review. Transl Androl Urol 10:1506–1520, 2021
   Perrino CM, Grignon DJ, Williamson SR, et al. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology 72:305–319, 2018
   Farcas M, Gatalica Z, Trpkov K, et al. Eosinophilic vacuolated tumor, EVT, of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol 35:344–351, 2022
   Williamson SR, Hes O, Trpkov K, et al. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology 82:296–304, 2023
   Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney, CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 75:174–184, 2019
   Vujanic GM, Gessler M, Ooms AHAG, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol 15:693–701, 2018
   Vujanic GM, Parsons LN, D’Hooghe E, et al. Pathology of Wilms’ tumour in International Society of Paediatric Oncology, SIOP, and Children’s Oncology Group, COG, renal tumour studies: Similarities and differences. Histopathology 80:1026–1037, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 7
EP 17
PG 16
ER

PT J
AU Nagy, A
AF Nagy, Andras
TI Role of interventional radiology in the treatment of primary and metastatic renal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kidney biopsy; thermal ablation; embolization
ID kidney biopsy; thermal ablation; embolization
AB More and more asymptomatic renal lesions are diagnosed as a result of the growing number of routine imaging examinations. Lesion characterization is often only possible with percutaneous biopsy. Stage T1 renal cell carcinoma is potentially curable not only by partial nephrectomy, but also with thermoablations. The most common ones used in renal cell carcinoma are radiofrequency (RFA), microwave (MWA) and cryoablation (CA). All of them have different physical background with different advantages. They have excellent oncological results, though only a few prospective trials compare their results to surgery. Apart from local renal cell carcinoma, metastatized renal cell carcinomas are also possible to treat with interventional radiological procedures. Renal artery embolization may be done prior to nephrectomy or as a palliative step. Furthermore, hypervascularized renal cell carcinoma metastases can also be embolized preoperatively. Interventional radiological tools may be used for the diagnosis, curative and palliative treatment and also as an aid to surgical procedures of renal cell carcinoma.
C1 [Nagy, Andras] University of Szeged, Department of Radiology, Semmelweis u. 6., 6725 Szeged, Hungary.
RP Nagy, A (reprint author), University of Szeged, Department of Radiology, 6725 Szeged, Hungary.
EM nagy.andras@szte.hu
CR Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 66:7– 30, 2016
   Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass. Radiology 249:16–31, 2008
   Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:706–720, 2019
   Walker PD. The renal biopsy. Arch Pathol Lab Med 133:181–188, 2009
   Whittier WL. Complications of the percutaneous kidney biopsy. Adv Chronic Kidney Dis 19:179–187, 2012
   Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology 60:40–49, 2002
   Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol 247:C125–C142, 1984
   MacLennan S, Imamura M, Lapitan MC, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 61:972–993, 2012
   Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol 198:520–529, 2017
   Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75:799–810, 2019
   Park BK, Kim CK, Park SY, et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 54:418–427, 2013
   Xiaobing W, Wentao G, Guangxiang L, et al. Comparison of radiofrequency ablation and partial nephrectomy for tumor in a solitary kidney. BMC Urol 17:79, 2017
   Bhindi B, Mason RJ, Haddad MM, et al. Outcomes after cryoablation versus partial nephrectomy for sporadic renal tumors in a solitary kidney: a propensity score analysis. Eur Urol 73:254–259, 2018
   Lin Y, Liang P, Yu XL, et al. Percutaneous microwave ablation of renal cell carcinoma is safe in patients with a solitary kidney. Urology 83:357–363, 2014
   Rosenberg MD, Kim CY, Tsivian M, et al. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol 196:935–939, 2011
   Hudspeth TN, Abdelsalam ME, Sabir SH, et al. Minimally invasive image guided thermal ablation for recurrent renal cell carcinoma, RCC, after ipsilateral partial nephrectomy. J Clin Oncol 36:e16557, 2018
   Krokidis ME, Orsi F, Katsanos K, et al. CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol 40:177– 191, 2017
   Wah TM, Koenig P, Irving HC, et al. Radiofrequency ablation of a central renal tumor: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol 16:1551–1555, 2005
   Park BK, Kim SH, Byun JY, et al. CT-guided instillation of 5% dextrose in water into the anterior pararenal space before renal radiofrequency ablation in a porcine model: positive and negative effects. J Vasc Interv Radiol 18:1561–1569, 2007
   Laeseke PF, Lee FT Jr, Sampson LA, et al. Microwave ablation versus radiofrequency ablation in the kidney: high-power triaxial antennas create larger ablation zones than similarly sized internally cooled electrodes. J Vasc Interv Radiol 20:1224–1229, 2009
   Rosenberg MD, Kim CY, Tsivian M, et al. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol 196:935–939, 2011
   Janzen NK, Perry KT, Han KR, et al. The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. J Urol 173:1368–1374, 2005
   Park BK, Shen SH, Fujimori M, et al. Thermal ablation for renal cell carcinoma: expert consensus from the Asian Conference on Tumor Ablation. Korean J Radiol 22:1490–1496, 2021
   Okhunov Z, Juncal S, Ordon M, et al. Comparison of outcomes in patients undergoing percutaneous renal cryoablation with sedation vs general anesthesia. Urology 85:130–134, 2015
   Park BK, Kim CK, Choi HY, et al. Limitation for performing ultrasound- guided radiofrequency ablation of small renal masses. Eur J Radiol 75:248–252, 2010
   Andrews JR, Atwell T, Schmit G, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 76:244–251, 2019
   Iannuccilli JD, Dupuy DE, Beland MD, et al. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14- year single institution experience in 203 patients. Eur Radiol 26:1656–1664, 2016
   Uhlig J, Strauss A, Rucker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta- analysis. Eur Radiol 29:1293–1307, 2019
   Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 67:252–259, 2015
   Zhou W, Arellano RS. Thermal ablation of T1c renal cell carcinoma: a comparative assessment of technical performance, procedural outcome, and safety of microwave ablation, radiofrequency ablation, and cryoablation. J Vasc Interv Radiol 29:943–951, 2018
   Atwell TD, Carter RE, Schmit GD, et al. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol 23:48–54, 2012
   Dai Y, Covarrubias D, Uppot R, et al. Image-guided percutaneous radiofrequency ablation of central renal cell carcinoma: assessment of clinical efficacy and safety in 31 tumors. J Vasc Interv Radiol 28:1643–1650, 2017
   Georgiades CS, Hong K, Bizzell C, et al. Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol 19:1302–1310, 2008
   Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 200:461–466, 2013
   Garnon J, Van Strijen MJ, Nielsen TK, et al. Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective percutaneous database. Eur Radiol 29:6293–6299, 2019
   Schmit GD, Schenck LA, Thompson RH, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology 272:903–910, 2014
   Zargar H, Atwell TD, Cadeddu JA, et al. Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol 69:116–128, 2016
   Li D, Pua BB, Madoff DC. Role of embolization in the treatment of renal masses. Semin Intervent Radiol 31:70–81, 2014
   Sauk S, Zuckerman DA. Renal artery embolization. Semin Intervent Radiol 28:396–406, 2011
   Ginat DT, Saad WE, Turba UC. Transcatheter renal artery embolization: clinical applications and techniques. Tech Vasc Interv Radiol 12:224–239, 2009
   Loffroy R, Rao P, Kwak BK, et al. Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol 11:257–268, 2010
   Loffroy R, Rao P, Ota S, et al. Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol 83:630, 2010
   Schwartz MJ, Smith EB, Trost DW, et al. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int 99:881–886, 2007
   May M, Brookman-Amissah S, Pflanz S, et al. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol 82:724–731, 2009
   Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 23:6–12, 2000
   Subramanian VS, Stephenson AJ, Goldfarb DA, et al. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology 74:154–159, 2009
   Wallace S, Chuang VP, Swanson D, et al. Embolization of renal carcinoma. Radiology 138:563–570, 1981
   Maxwell NJ, Saleem Amer N, Rogers E, et al. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol 80:96–102, 2007
   Mukund A, Gamanagatti S. Ethanol ablation of renal cell carcinoma for palliation of symptoms in advanced disease. J Palliat Med 13:117–120, 2010
   Munro NP, Woodhams S, Nawrocki JD, et al. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 92:240–244, 2003
   Onishi T, Oishi Y, Suzuki Y, et al. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int 87: 312–315, 2001
   Tigrani VS, Reese DM, Small EJ, et al. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology 55:36–40, 2000
   Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432, 2013
   Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262: 689–700, 2012
   Feldman F, Casarella WJ, Dick HM, et al. Selective intra-arterial embolization of bone tumors. A useful adjunct in the management of selected lesions. Am J Roentgenol Radium Ther Nucl Med 123:130–139, 1975
   Cernoch P, Hechelhammer L, von Hessling A, et al. Pre-operative embolisation of spinal metastasis: technique, complication rate and outcome- clinical experience. Int Orthop 39:1399–1404, 2015
   Pazionis TJ, Papanastassiou ID, Maybody M, et al. Embolization of hypervascular bone metastases reduces intraoperative blood loss: a case-control study. Clin Orthop Relat Res 472:3179–3187, 2014
   Manke C, Bretschneider T, Lenhart M, et al. Spinal metastases from renal cell carcinoma: effect of preoperative particle embolization on intraoperative blood loss. AJNR Am J Neuroradiol 22:997–1003, 2001
   Clausen C, Dahl B, Frevert SC, et al. Preoperative embolization in surgical treatment of spinal metastases: single-blind, randomized controlled clinical trial of efficacy in decreasing intraoperative blood loss. J Vasc Interv Radiol 26:402–412e1, 2015
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 19
EP 25
PG 7
ER

PT J
AU Fabian, N
   Nemeth, Z
   Tenke, P
AF Fabian, Norbert
   Nemeth, Zalan
   Tenke, Peter
TI Could robotic surgery really be a revolutionary change in the treatment of kidney cancer in Hungary?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kidney tumor; robot-assisted kidney surgery; partial nephrectomy; Da Vinci robot system
ID kidney tumor; robot-assisted kidney surgery; partial nephrectomy; Da Vinci robot system
AB Robotic-assisted partial nephrectomy (RAPN) was first described in 2004 and, since its introduction in clinical practice, has progressively gained increasing popularity. Over the years, the indications have also expanded, enabling robot-assisted surgical removal of complex kidney tumors. Important considerations for clinicians when choosing a minimally invasive technique are complete resection of the tumor, maximum protection of kidney function, and avoidance of complications. The first Da Vinci robotic surgery system was installed in Hungary at the Jahn Ferenc Del- Pest Hospital and the National Institute of Oncology. The first robotic surgery took place at the National Institute of Oncology, and then at the Jahn Ferenc Del-Pest hospital. In addition to open surgeries, only the laparoscopic procedure was available to perform kidney tumor surgeries in Hungary. The short one-year robotic surgery experience in our country supports the results of the international literature. Due to the introduction of robotics, a higher level of precision and freedom of movement creates new opportunities compared to open or laparoscopic kidney tumor surgeries.
C1 [Fabian, Norbert] Jahn Ferenc Korhaz, Urologia, Koves utca 1., 1204 Budapest, Hungary.
   [Nemeth, Zalan] Jahn Ferenc Korhaz, Urologia, Koves utca 1., 1204 Budapest, Hungary.
   [Tenke, Peter] Jahn Ferenc Korhaz, Urologia, Koves utca 1., 1204 Budapest, Hungary.
RP Fabian, N (reprint author), Jahn Ferenc Korhaz, Urologia, 1204 Budapest, Hungary.
EM fabiannorbert.dr@gmail.com
CR Az onkologia alapjai. Szerk. Kasler M. Masodik, javitott, bovitett kiadas, Medicina, 2017
   Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. CA Cancer J Clin 72:7–33, 2022
   Renal Cancer: Contemporary Management. Ed. Libertino JA, Gee JR. Second edition, Springer, 2019, pp. 1–3, 49–68
   Ni Y, Yang X. A systematic review and meta-analysis of comparison of outcomes of robot-assisted versus open partial nephrectomy in clinical T1 renal cell carcinoma patients. Urol Int 106:757–767, 2022
   Sun M, Abdollah F, Shariat SF, et al. Propensity-score matched comparison of blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series. Eur J Surg Oncol 38:80–87, 2012
   Socarras MR, Elbers JR, Rivas JG, et al. Retroperitoneal robot-assisted partial nephrectomy, RRAPN): Surgical technique and review. Curr Urol Rep 22:33, 2021
   Rogers CG, Metwalli A, Blatt AM, et al. Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J Urol 180:2353–2356, 2008
   Horstmann M, Horton K, Kurz M, et al. Prospective comparison between the AirSeal System valve-less Trocar and a standard VersaportTM Plus V2 Trocar in robotic-assisted radical prostatectomy. J Endourol 27:579–582, 2013
   Hughes-Hallett A, Pratt P, Mayer E, et al. Image guidance for all–TilePro display of 3-dimensionally reconstructed images in robotic partial nephrectomy. Urology 84:237–242, 2014
   McClintock TR, Bjurlin MA, Wysock JS, et al. Can selective arterial clamping with fluorescence imaging preserve kidney function during robotic partial nephrectomy? Urology 84:327–332, 2014
   Pavan N, Derweesh IH, Mir CM, et al. Outcomes of laparoscopic and robotic partial nephrectomy for large, >4 cm, kidney tumors: systematic review and meta-analysis. Ann Surg Oncol 24:2420–2428, 2017
   Buffi NM, Saita A, Lughezzani G, et al. Robot-assisted partial nephrectomy for complex, PADUA score ≥10, tumors: techniques and results from a multicenter experience at four high-volume centers. Eur Urol 77:95–100, 2020
   Peyronnet B, Seisen T, Oger E, et al. Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol 23:4277–4283, 2016
   Minervini A, Vittori G, Antonelli A, et al. Open versus robotic-assisted partial nephrectomy: a multicenter comparison study of perioperative results and complications. World J Urol 32:287– 293, 2014
   Long, JA, Yakoubi R, Lee B, et al. Robotic versus laparoscopic partial nephrectomy for complex tumors: Comparison of perioperative outcomes. Eur Urol 61:1257–1262, 2012
   Bray G, Bahadori A, Mao D, et al. Benefits of robotic assisted vs. traditional laparoscopic partial nephrectomy: A single surgeon comparative study. J Clin Med 11:6974, 2012
   Benway BM, Bhayani SB. Surgical outcomes of robot-assisted partial nephrectomy. BJU Int 108:955–961, 2011
   Choi SY, Jung H, You D, et al. Robot-assisted partial nephrectomy is associated with early recovery of renal function: comparison of open, laparoscopic, and robot-assisted partial nephrectomy using DTPA renal scintigraphy. J Surg Oncol 119:1016–1023, 2019
   Liu W, Li Y, Chen M, et al. Off-clamp versus complete hilar control partial nephrectomy for renal cell carcinoma: a systematic review and meta-analysis. J Endourol 28:567–576, 2014
   Deng W, Liu X, Hu J, et al. Off-clamp partial nephrectomy has a positive impact on short- and long-term renal function: a systematic review and meta- analysis. BMC Nephrol 19:188, 2018
   Simone G, Gill IS, Mottrie A, et al. Indications, techniques, outcomes, and limitations for minimally ischemic and off-clamp partial nephrectomy: a systematic review of the literature. Eur Urol 68:632–640, 2015
   Chang KD, Abdel R, Kim A, et al. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: A multicentre comparative matched-pair analyses with a median of 5 years’ follow-up. BJU Int 122:618–626, 2018
   Gill IS, Eisenberg MS, Aron M, et al. “Zero ischemia” partial nephrectomy: novel laparoscopic and robotic technique. Eur Urol 59:128–134, 2014
   Mattevi D, Luciani LG, Mantovani W, et al. Fluorescence-guided selective arterial clamping during RAPN provides better early functional outcomes based on renal scan compared to standard clamping. J Robot Surg 13:391– 396, 2019
   Larcher A, Muttin F, Baiamonte G, et al. The learning curve for robot-assisted partial nephrectomy: Impact of surgical experience on perioperative outcomes. Eur Urol 75:259–260, 2019
   Beauval JB, Peyronnet B, Benoit T, et al. Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study. World J Urol 36:897–904, 2018
   Otaola-Arca H, Krebs A, Bermudez H, et al. Long-term oncological and functional outcomes after robot-assisted partial nephrectomy for clinically localized renal cell carcinoma. Ann Surg Oncol 29:2484–2494, 2022
   Vartolomei MD, Remzi M, Fajkovic H, et al. Robot-assisted partial nephrectomy mid-term oncologic outcomes: A systematic review. J Clin Med 11:6165, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 27
EP 31
PG 5
ER

PT J
AU Mencser, Z
   Toth, T
   Kis, D
   Varga, �
   Tiszlavicz, L
   Barzo, P
AF Mencser, Zoltan
   Toth, Tamas
   Kis, David
   Varga, Adam
   Tiszlavicz, Laszlo
   Barzo, Pal
TI Neurosurgical management for metastatic brain tumors in renal cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Case Reports
DE brain metastases; renal cell carcinoma; brain surgery; radiosurgery
ID brain metastases; renal cell carcinoma; brain surgery; radiosurgery
AB The therapeutic approach to brain metastases has changed significantly in the last 30 years. The development of surgical technique, the use of new MRI techniques, preoperative surgical planning and the administration of intraoperative navigation reduced the risks of surgery and improved the results. In the case of aggressive renal cell carcinomas, we detect brain metastases relatively often, which are difficult to treat, but the improved surgical and radiosurgery techniques can also be used with success. In our report, we present the neurosurgical management of metastatic spreading of renal cell carcinoma to the brain. Modern surgical planning and more precise, tailored approach with modern radiosurgery techniques are able to improve the outcome and prolong survival even in aggressive types of renal cell carcinomas that give rise to brain metastases. In more severe cases and even in the case of multiple brain metastases, cranial surgery can be recommended.
C1 [Mencser, Zoltan] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Toth, Tamas] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Kis, David] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Varga, Adam] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Tiszlavicz, Laszlo] University of Szeged, Department of PathologySzeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
RP Mencser, Z (reprint author), University of Szeged, Department of Neurosurgery, 6725 Szeged, Hungary.
EM mencser@hotmail.com
CR Cairncross JG, Posner JB. The management of brain metastases. In: Oncology of the Nervous System. Ed. Walker MD. Martinus Nijhoff, Boston, 1983. Vol. 12, Cancer Treatment and Research. pp. 341–377
   Cairncross JG, Kim JH, Posner JB, et al. Radiation therapy for brain metastases. Ann Neurol 7:529–541, 1980
   Patchell RA, Tibbs PA, Wahls J W, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500, 1990
   Brown PD, Ahluwalia MS, Kahn OH, et al. Whole-brain radiotherapy for brain metastases: evolution or revolution? J Clin Oncol 36:483–491, 2018
   Yoo J, Park HH, Kang SG, et al. Recent update on neurosurgical management of brain metastasis. Brain Tumor Res Treat 10:164–171, 2022
   Derks S, Veldt A, Smits M, et al. Brain metastases: the role of clinical imaging. Br J Radiol 95:20210944, 2022
   Timar J, Ladanyi A. A daganatok immunterapiajanak prediktiv markerei, a PD-L1-meghatarozas gyakorlati kerdesei. Magy Onkol 61:158–166, 2017
   Chevreau, C, Ravaud, A, Escudier B, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 12:50–54, 2014
   Yekeduz E, Arzu YH, Utkan G, et al. A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma. J Oncol Pharm Pract 26:972–981, 2020
   Shuto T, Inomori S, Fujino H, et al. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. J Neurosurg 105:555–560, 2006
   Bates JE, Youn P, Peterson CR, et al. Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: The University of Rochester experience. Am J Clin Oncol 40:439–443, 2017
   Hanzly M, Abbotoy D, Creighton T, et al. Early identification of asymptomatic brain metastases from renal cell carcinoma. Clin Exp Metastasis 32:783–788, 2015
   Sun M, De Velasco G, Brastianos P K, et al. The development of brain metastases in patients with renal cell carcinoma: Epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 5:474–481, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 32
EP 37
PG 6
ER

PT J
AU Toth, T
   Mencser, Z
   Veres, R
   Barzo, P
AF Toth, Tamas
   Mencser, Zoltan
   Veres, Robert
   Barzo, Pal
TI Techniques and indications of neurosurgical treatment of oligometastatic renal cell carcinomas in case of spinal metastases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE spinal metastases; renal cell carcinoma; spine surgery
ID spinal metastases; renal cell carcinoma; spine surgery
AB The treatment of spinal metastases is a huge challenge, but both oncological and surgical treatment have improved significantly. Spine surgeons use the experience of spine surgeries performed for an increased number of degenerative causes during spine surgeries performed for an increased number of tumors. Establishing an indication for surgery is at least as much of a challenge as the surgery itself, for which there are many objective point systems available. Renal cell carcinoma metastases are less sensitive to radiation, which is why careful surgery is even more important. In our short summary, we review the symptoms, the examination, the grading systems used and the surgical options.
C1 [Toth, Tamas] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Mencser, Zoltan] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Veres, Robert] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
   [Barzo, Pal] University of Szeged, Department of Neurosurgery, Semmelweis u. 6., 6725 Szeged, Hungary.
RP Toth, T (reprint author), University of Szeged, Department of Neurosurgery, 6725 Szeged, Hungary.
EM tottom78@gmail.com
CR Vialle LR, Gokaslan ZL, Boriani S. AOSpine Masters Series Vol. 1 Metastatic Spinal Tumors, Thieme 2015, ISBN 978-1-62623-046-0
   Bollen L, Wibmer C, Van der Linden YM, et al. Predictive value of six prognostic scoring systems for spinal bone metastasis. Spine 41:E155–E162, 2016
   Banczerowski P, Lipoth L, Veres R. A cervicothoracalis atmenenetben elhelyezkedo daganatok eltavolitasa ventralis es kombinalt ventrodorsalis megkozelitesbol: sajat tapasztalatok. Ideggy Szle 56:174–178, 2003
   Flynn SC, Eli IM, Ghogawala Z, Yew AY. Minimally invasive surgery for spinal metastasis: a review. World Neurosurg 159:e32–e39, 2022
   Barzilai O, Fisher CG, Bilsky MH. State of the art treatment of spinal metastatic disease. Neurosurgery 82:757–769, 2018
   Davila D, Antoniou A, Chaudhry MA. Evaluation of osseous metastasis in bone scintigraphy. Semin Nucl Med 45:3–15, 2015
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 38
EP 42
PG 5
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI Radiotherapy of kidney cancers: an allegory for changing approach in theory and practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE renal cell carcinoma; radiotherapy; stereotactic; oligometastatic; combination
ID renal cell carcinoma; radiotherapy; stereotactic; oligometastatic; combination
AB The evolution of radiotherapy (RT) technologies in the last two decades has changed the RT treatment attitude, and the routine application of novel stereotactic methods has opened new avenues in the complex cancer care. To prove the clinical consequences of this paradigm shift, a good example is the transformation of the renal cell carcinoma (RCC) treatment strategy. RCC was originally considered as a radioresistant disease, however, the introduction of new RT technologies has provided a risk-free focal dose escalation, so RT in primary or metastatic RCCs has become a more efficient method. Meanwhile, there has also been a spectacular development in the medical treatment of advanced RCC, thus the treatment strategy has radically changed in this field of oncology, resulting in a remarkably increased effectiveness. In the present communication, we summarize the steps of recent RT evolution, the new fields of indications and possibilities of combination therapies in RCC.
C1 [Mangel, Laszlo] University of Pecs, Oncotherapy Institute, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Oncotherapy Institute, 7624 Pecs, Hungary.
EM mangel.laszlo@pte.hu
CR Spyropoulou D, Tsiganos P, Dimitrakopoulos FI, et al. Radiotherapy and renal cell carcinoma: a continuing saga. In Vivo 35:1365–1377, 2021
   Blanco AI, Teh BS, Amato RJ. Role of radiation therapy in the management of renal cell cancer. Cancers, Basel, 3:4010–4023, 2011
   Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 4:549–563, 2017
   Dohopolski M, Hannan R, Wardak Z, et al. The reintroduction of radiotherapy into the integrated management of kidney cancer. Cancer J 26:448–459, 2020
   Heinrich W. [Radiosensitivity of renal carcinoma]. Strahlentherapie 89:397–400, 1952
   Ning S, Trisler K, Wessels BW, et al. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80:2519–2528, 1997
   Sun MR, Brook A, Powell MF, et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. AJR Am J Roentgenol 206:544–553, 2016
   De Felice F, Tombolini V. Radiation therapy in renal cell carcinoma. Crit Rev Oncol Hematol 128:82–87, 2018
   Funayama S, Onishi H, Kuriyama K, et al. Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy. Technol Cancer Res Treat 18:1533033818822329, 2019
   Leksell, L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102:316–319, 1951
   Mangel L. Sztereotaxias extrakranialis radioterapia: uj lehetosegek es indikaciok a daganatok sugarkezeleseben. Onkologia 1:38–42, 2016
   Mangel L, Laszlo Z, Varga Z, et al. Hasuregi daganatattetek stereotaxias sugarkezelese egy ulesben. Beszamolo az elso hazai, koponyan kivuli sugarsebeszeti beavatkozasrol. Orv Hetil 156:1593–1599, 2015
   Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31:1384–1390, 2013
   Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28–37, 2014
   Sosa-Fajardo P, Blanco-Suarez JM, Pineda-Munguia A, et al. Stereotactic body radiation therapy for kidney cancer. Where do we stand? Int J Urol 2023,, DOI  10.1111/iju.15156
   Le Guevelou J, Sargos P, Siva S, et al. The emerging role of extracranial stereotactic ablative radiotherapy for metastatic renal cell carcinoma: a systematic review. Eur Urol Focus 9:114–124, 2023
   Leopold Z, Passarelli R, Mikhail M, et al. Modern management of localized renal cell carcinoma – is ablation part of the equation? J Kidney Cancer VHL 9:5–23, 2022
   Rich BJ, Noy MA, Dal Pra A. Stereotactic body radiotherapy for localized kidney cancer. Curr Urol Rep 23:371–381, 2022
   D’Andrea MA, Reddy GK. Immune system activation in patients with metastatic renal cell carcinoma induced by the systemic abscopal effects of radiation therapy. Oncol Res Treat 46:33–44, 2023
   Correa RJM, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 5:958–969, 2019
   Krengli M, Pisani C, Deantonio L, et al. Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers. Radiat Oncol 12:18, 2017
   Kliucharev BV, Kuz’min VG. [Surgical and combined treatment of kidney cancer]. Vestn Khir Im I I Grek 125:76–79, 1980
   Stein M, Kuten A, Halpern J, et al. The value of postoperative irradiation in renal cell cancer. Radiother Oncol 24:41–44, 1992
   Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13:665–672, 1987
   Makarewicz R, Zarzycka M, Kulinska G, et al. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45:380–383, 1998
   Ulutin HC, Aksu G, Fayda M, et al. The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori 92:202–206, 2006
   Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol 21:1839–1845, 2010
   Buller DM, Antony M, Ristau BT. Adjuvant therapy for high-risk localized renal cell carcinoma: current landscape and future direction. Onco Targets Ther 16:49–64, 2023
   Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther 13:12301–12316, 2020
   Gaas MY, Kaprin AD, Vorobyev NV, et al. Markers of local kidney cancer recurrence: A surgeon’s mistake or a pattern? Review. Urologia 14:3915603221140964, 2022
   Yamamoto T, Kawasaki Y, Umezawa R, et al. Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. J Radiat Res 62:533–539, 2021
   Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 13:8–10, 1995
   Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 8:378–382, 2011
   Milano MT, Biswas T, Simone CB 2nd, et al. Oligometastases: history of a hypothesis. Ann Palliat Med 10:5923–5930, 2021
   Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma, SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol 2:515–523, 2019
   Ali M, Mooi J, Lawrentschuk N, et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 82:613–622, 2022
   Hardcastle N, Cook O, Ray X, et al. Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. Radiat Oncol 16:142, 2021
   Sipos L, Bajcsay A, Kontra G, et al. Korai tapasztalataink CyberKnife-kezelessel suprasellarisan is terjedo hypernephroma-attet eseten. Ideggy Szle 72:427–431, 2019
   Franzese C, Marini B, Baldaccini D, et al. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. J Cancer Res Clin Oncol 2022,, DOI  10.1007/s00432-022-04352-z
   Cheung P, Patel S, North SA, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol 80:693–700, 2021
   Damm R, Streitparth T, Hass P, et al. Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single- arm pilot trial. Strahlenther Onkol 195:982–990, 2019
   Raszewski L, Chyrek AJ, Marciniak M, et al. High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases. J Contemp Brachytherapy 13:331–337, 2021
   Rehailia-Blanchard A, Morel A, Rancoul C, et al. Vaginal metastasis of renal clear-cell cancer. Gulf J Oncolog 1:67–71, 2018
   Aibe N, Ogino H, Teramukai S, et al. Multi-institutional retrospective analysis of the outcomes of proton beam therapy for patients with 1 to 3 pulmonary oligometastases from various primary cancers. Adv Radiat Oncol 6:100690, 2021
   Ingrosso G, Becherini C, Francolini G, et al. Stereotactic body radiotherapy, SBRT, in combination with drugs in metastatic kidney cancer: A systematic review. Crit Rev Oncol Hematol 159:103242, 2021
   Heo JH, Park C, Ghosh S, et al. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. J Clin Pharm Ther 46:35–49, 2021
   Cetin B, Wabl CA, Gumusay O. Reshaping treatment paradigms for advanced renal cell cancer patients and improving patient management: optimal management for renal cell cancer patients. Curr Treat Options Oncol 23:609–629, 2022
   Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract 18:187–196, 2022
   Mazzola R, Jereczek-Fossa BA, Franceschini D, et al. Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiat Oncol 15:92, 2020
   Maraz A, Bodrogi I, Csejtei A, et al. Attetes vesedaganatos betegek pazopanibterapiajaval szerzett elso hazai tapasztalatok. Magy Onkol 57:173–176, 2013
   Maraz A, Bodoky Gy, Dank M, et al. Attetes vesedaganatos betegek everolimusterapiajaval szerzett hazai tapasztalatok. Magy Onkol 58:4–9, 2014
   Geczi L, Nagyivanyi K, Maraz A. Immunterapia a vesedaganatok kezeleseben. Magy Onkol 61:126–131, 2017
   Maraz A, Cserhati A, Uhercsak G, et al. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer 18:296, 2018
   Maraz A, Csejtei A, Kocsis J, et al. Assessment of the role of everolimus therapy in patients with renal cell carcinoma based on daily routine and recent research results. Pathol Oncol Res 25:149–156, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 43
EP 51
PG 9
ER

PT J
AU Kuronya, Zs
   Biro, K
   Geczi, L
   Maraz, A
AF Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
   Maraz, Aniko
TI Immune combination possibilities in the first-line treatment of metastatic renal cell cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kidney tumor; first line; combination treatments; immunotherapy; clear cell renal cell cancer
ID kidney tumor; first line; combination treatments; immunotherapy; clear cell renal cell cancer
AB First-line treatment of metastatic renal cancer can be divided into three main phases. The cytokine era was replaced by targeted therapies in 2006 with the introduction of tyrosine kinase inhibitors. Until 2018, the standard first-line therapy was the use of sunitinib or pazopanib. Over the past decade, numerous attempts have been made to combine these drugs, which are already approved or in development, but these attempts have not been successful, primarily because of intolerable toxicity. In 2018, we reached a new stage in the treatment of metastatic renal tumors. This year, the combination immunotherapy of ipilimumab and nivolumab was approved. Since then, the combination of immunotherapy and targeted therapies has led to success. The main objective of our summary is to present in chronological order the clinical trials of combination therapies already approved in Europe, as well as the most recent phase III clinical trials. It is also intended to provide a brief practical guide on how to decide on first-line therapy based on the results of these trials.
C1 [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
RP Kuronya, Zs (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM kuronya.zsofia@oncol.hu
CR Kasler M, Otto Sz, Kenessey I, et al. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol 11:79–87, 2020
   Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148, 2013
   Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:706–720, 2019
   Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590, 2009
   Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068, 2010
   Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813, 2015
   Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277– 1290, 2018
   Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 380:1116–1127, 2019
   Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103–1115, 2019
   Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829– 841, 2021
   Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300, 2021
   Motzer R, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:67–81, 2022
   Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399–410, 2022
   Motzer JR, McDermott FD, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128:2085–2097, 2022
   Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5:e001079, 2020
   Choueiri T, Powles TB, Albiges L, et al. Phase III study of cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma of IMDC intermediate or poor risk, COSMIC- 313). Ann Oncol 33(suppl_7):Abstr LBA08, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 53
EP 58
PG 6
ER

PT J
AU Nagyivanyi, K
   Geczi, L
AF Nagyivanyi, Krisztian
   Geczi, Lajos
TI Second and further lines treatment options for locally advanced or metastatic renal cell carcinoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE clear cell renal tumor; targeted therapy; TKI; immune checkpoint inhibitor treatment; mTOR inhibitor treatment
ID clear cell renal tumor; targeted therapy; TKI; immune checkpoint inhibitor treatment; mTOR inhibitor treatment
AB The treatment of locally advanced, inoperable or metastatic kidney tumors is a dynamically changing field of oncology. Since the registration of the first targeted therapeutic product (2005), more and more new products have been internationally accepted and registered almost every year. The development of immune checkpoint inhibitors and their inclusion in care algorithms (2015) further expanded the therapeutic possibilities. Despite all this, the optimal selection of medication used in different therapeutic lines poses a significant challenge to clinicians. In this review we have collected the data, aspects, and results of clinical tests necessary for the choice of therapy that can be applied in second and further lines. We also present the domestic treatment options.
C1 [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Nagyivanyi, K (reprint author), National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology Department, 1122 Budapest, Hungary.
EM nagyivanyi.krisztian@oncol.hu
CR Navani V, Wells JC, Boyn DJ, et al. CABOSEQ: The effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, IMDC). Clin Genitourin Cancer S1558–7673, 2022
   Goebell PJ, Ivanyi P, Bedke J, et al. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncol 16:2307–2328, 2020
   Iacovelli R, Ciccarese C, Procopio G, et al. Current evidence for second- line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Cancer Treat Rev 105:102379, 2022
   Guadalupi V, Carteni C, Iacovelli R, et al. Second-line treatment in renal cell carcinoma: clinical experience and decision making. Ther Adv Urol 13:17562872211022870, 2021
   Shaw T, Lee H, Figlin R, et al. Second-line therapies in the changing landscape of first-line therapies for metastatic clear cell renal cell cancer. Oncology, Williston Park, 35:306–310, 2021
   Tannir NM, Pal SK, Atkins MB, et al. Second-line treatment landscape for renal cell carcinoma: a comprehensive review. Oncologist 23:540–555, 2018
   Iacovelli R, Ciccarese C, Facchini, G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Target Oncol 15:495–501, 2020
   McGregor BA, Lalani AKA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer 135:203–210, 2020
   Santoni M, Heng DY, Bracarda S, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers, Basel, 12:84, 2019
   Hirsch L, Chanza NM, Farah S, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 7:1815–1823, 2021
   Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol 36:765–772, 2018
   Maraz A, Csejtei A, Kocsis J, et al. Assessment of the role of everolimus therapy in patients with renal cell carcinoma based on daily routine and recent research results. Pathol Oncol Res 25:149–156, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 61
EP 72
PG 12
ER

PT J
AU Maraz, A
   Nagyivanyi, K
   Balogh, I
   Bodoky, Gy
   Mangel, L
   Kuronya, Zs
   Geczi, L
   Torday, L
   Dudas, Sz
   Szucs, M
   Nagy, Zs
   Hornyak, L
   Zolcsak, Z
   Bassam, A
   Kocsis, J
   Keresztes, T
   Kullmann, T
   Mahr, K
   Solymosi, T
   Papdan, T
   Szabo, I
   Varga, Z
   Biro, K
AF Maraz, Aniko
   Nagyivanyi, Krisztian
   Balogh, Ingrid
   Bodoky, Gyorgy
   Mangel, Laszlo
   Kuronya, Zsofia
   Geczi, Lajos
   Torday, Laszlo
   Dudas, Szilvia
   Szucs, Miklos
   Nagy, Zsofia
   Hornyak, Lajos
   Zolcsak, Zita
   Bassam, Ali
   Kocsis, Judit
   Keresztes, Tamas
   Kullmann, Tamas
   Mahr, Karoly
   Solymosi, Tibor
   Papdan, Timea
   Szabo, Imre
   Varga, Zoltan
   Biro, Krisztina
TI Multicentric Hungarian results of cabozantinib therapy in patients with metastatic kidney cancer based on real-world data
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE metastatic kidney cancer; cabozantinib therapy; overall survival; real-world data; renal cell carcinoma
ID metastatic kidney cancer; cabozantinib therapy; overall survival; real-world data; renal cell carcinoma
AB The aim of our analysis was to evaluate the efficacy of cabozantinib in patients with metastatic renal cell carcinoma. Cabozantinib therapy initiated between 01/01/2019 and 31/12/2022 was evaluated based on a retrospective review of data from 14 renal centers in Hungary. The starting dose was 60 or 40 mg. Physical examinations and laboratory tests were performed every 4 weeks and imaging studies 3-monthly. Tumor response was assessed according to RECIST 1.1, and toxicity according to NCI CTCAE 4.0. A total of 230 patient records were evaluated, 201 (87.4%) of them had clear cell RCC. Cabozantinib was administered as third, second and first-line treatment in 48.7%, 38.3% and <5% of cases, respectively. Dose reductions occurred in 62.6% and treatment interruption in 6.5%. Duration of therapy was 10.03 months, which was independent of dose reduction. Overall tumor response rate was 39.2% and clinical benefit was 82.8%. The duration of first-, second-, third- and fourth-line treatment was 11.47, 8.03, 11.57 and 10.13 months, respectively. Overall survival from the start of therapy was 22.0 months. Cabozantinib therapy in daily practice was more beneficial than according to registry study results. Dose reduction did not affect efficacy.
C1 [Maraz, Aniko] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Nagyivanyi, Krisztian] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Balogh, Ingrid] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Bodoky, Gyorgy] Del-pesti Centrumkorhaz, Onkologiai CentrumBudapest, Hungary.
   [Mangel, Laszlo] University of Pecs, Department of OncologyPecs, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Torday, Laszlo] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Dudas, Szilvia] Del-pesti Centrumkorhaz, Onkologiai CentrumBudapest, Hungary.
   [Szucs, Miklos] Semmelweis University, Department of UrologyBudapest, Hungary.
   [Nagy, Zsofia] Honved Korhaz, Onkologiai OsztalyBudapest, Hungary.
   [Hornyak, Lajos] Ferenc Csolnoky Hospital, Oncological CenterVeszprem, Hungary.
   [Zolcsak, Zita] Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Onkoradiologiai KozpontBudapest, Hungary.
   [Bassam, Ali] Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai CentrumGyula, Hungary.
   [Kocsis, Judit] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Keresztes, Tamas] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
   [Kullmann, Tamas] Petz Aladar Hospital, Department of OncoradiologyGyor, Hungary.
   [Mahr, Karoly] Zala Megyei Szent Rafael Korhaz, OnkologiaZalaegerszeg, Hungary.
   [Solymosi, Tibor] Borsod County Hospital and University Academic Hospital, Institute of Radiotherapy and Clinical OncologyMiskolc, Hungary.
   [Papdan, Timea] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Szabo, Imre] University of Pecs, Department of OncologyPecs, Hungary.
   [Varga, Zoltan] University of Szeged, Department of Oncotherapy, Koranyi fasor 12., 6720 Szeged, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
RP Maraz, A (reprint author), University of Szeged, Department of Oncotherapy, 6720 Szeged, Hungary.
EM dr.aniko.maraz@gmail.com
CR Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:706–720, 2019
   Richter I, Poprach A, Zemankova A, et al. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 166:97–104, 2022
   Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma, METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927, 2016
   Powles T, Motzer RJ, Escudier B, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 119:663–669, 2018
   Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176–1178, 2018
   Powles T, Escudier B, Motzer RJ, et al. Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma, RCC). BJU Int 118(S5):4, 2016
   McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65:577–584, 2014
   Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol 36:765–772, 2018
   Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk, Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94:115–125, 2018
   George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial. Oncologist 24:1497–1501, 2019
   Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. JNCCN J Natl Compr Canc Netw 20:67–81, 2022
   National Cancer Institute. Common Terminology Criteria for Adverse Events, CTCAE, version 4.0. NIH Publication, 2009
   Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 62:138–145, 2016
   Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823, 2015
   Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer, 1989–2005). Cancer 113:2457–2463, 2008
   Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427, 2018
   Petrelli F, Coinu A, Vavassori I, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 14:465–472, 2016
   Choi JD, Cho JM, Yoo TK. Is cytoreductive nephrectomy still beneficial for patients with metastatic renal cell carcinoma in the contemporary immunotherapy era? Korean J Urol Oncol 20:139–150, 2022
   Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799, 2009
   Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2530, 1999
   Fioramonti M, Santini D, Iuliani M, et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Oncotarget 8:20113–20121, 2017
   Bersanelli M, Buti S, Ghidini A, et al. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick? Anticancer Drugs 31:211–215, 2020
   Bodnar L, Kopczynska A, Zolnierek J, et al. Real-world experience of cabozantinib as second- or subsequent line treatment in patients with metastatic renal cell carcinoma: data from the Polish Managed Access Program. Clin Genitourin Cancer 17:e556–e564, 2019
   Hasanov E, Yeboa DN, Tucker MD, et al. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 72:454–489, 2022
   Hirsch L, Martinez Chanza N, Farah S, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 7:1815, 2021
   Maruzzo M, Pierantoni F, Bortolami A, et al. Real-world treatment with nivolumab or cabozantinib for metastatic renal cell carcinoma, mRCC, in the Veneto region of Italy: results of AMOUR study. Target Oncol 17:467–474, 2022
   Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773, 2011
   Maraz A, Cserhati A, Uhercsak G, et al. Sunitinib indukalta “off-target” mellekhatasok terapias jelentosege. Magy Onkol 58:167–172, 2014
   Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277– 1290, 2018
   Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829– 841, 2021
   Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127, 2019
   Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib, CLEAR): a randomised, phase 3 study. Lancet Oncol 23:768–780, 2022
   Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813, 2015
   Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longterm follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126:4156-4167, 2020
   Stukalin I, Wells JC, Graham J, et al. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Curr Oncol 26:175–179, 2019
   Maraz A, Csejtei A, Kocsis J, et al. Assessment of the role of everolimus therapy in patients with renal cell carcinoma based on daily routine and recent research results. Pathol Oncol Res 25:149–156, 2019
   Maraz A, Cserhati A, Uhercsak G, et al. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer 18:296, 2018
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 73
EP 83
PG 10
ER

PT J
AU Szucs, M
   Szalontai, J
   Nyirady, P
AF Szucs, Miklos
   Szalontai, Janos
   Nyirady, Peter
TI Adjuvant treatment of kidney tumors – a more successful future?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE kidney; tumor; adjuvant therapy; tyrosine kinase inhibitors; immunotherapy
ID kidney; tumor; adjuvant therapy; tyrosine kinase inhibitors; immunotherapy
AB Considering the data of the past years, the number of kidney tumor patients grows constantly. These patients are usually found incidentally with the help of common imaging procedures. The classic triad – lower back pain, bloody urine, and palpable flank terime – occurs rarely. Their presence foresees an advanced disease. In our article, in addition to the mentioning of the epidemiological and etiological data, symptoms, surgical therapy and histological types of the kidney tumors, we present the adjuvant treatment options, their types and effectiveness.
C1 [Szucs, Miklos] Semmelweis University, Department of Urology, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Szalontai, Janos] Semmelweis University, Department of Urology, Ulloi ut 78/B, 1082 Budapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of Urology, Ulloi ut 78/B, 1082 Budapest, Hungary.
RP Szucs, M (reprint author), Semmelweis University, Department of Urology, 1082 Budapest, Hungary.
EM szucsmdr@gmail.com
CR EAU Guideline on Renal Cell Carcinoma
   Wallis CJD. Epidemiology and etiology of kidney cancer. Uro Today, November 20th, 2018. https://www.urotoday.com/library-resources/kidney-cancer- today/109190-epidemiology-and-etiology-of-kidney-cancer.html
   Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 75:74–84, 2019
   Ryan CW, Tangen C, Heath EI, et al. EVEREST: Everolimus for renal cancer ensuing surgical therapy – A phase III study, SWOG S0931, NCT01120249). J Clin Oncol 40(17_suppl):LBA4500, 2022
   Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma, ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387: 2008–2016, 2016
   Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35:3916–3923, 2017
   Gross-Goupil M, Kwon TG , Eto M et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 29:2371–2378, 2018
   Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol 38:4064–4075, 2020
   Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246–2254, 2016
   Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection, IMmotion 010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400:1103–1116, 2022
   Allaf M, Kim SE, Harshman LC, et al. Phase III randomized study comparing perioperative nivolumab, nivo, versus observation in patients, Pts, with renal cell carcinoma, RCC, undergoing nephrectomy, PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol 33, suppl_7):LBA67, 2022
   Motzer RJ, Russo P, Gruenwald V, et al. Adjuvant nivolumab plus ipilimumab, NIVO+IPI, vs placebo, PBO, for localized renal cell carcinoma, RCC, at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Ann Oncol 33(suppl_7):LBA4, 2022
   Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma, KEYNOTE-564): 30-month follow up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 23:1133– 1144, 2022
   Oza B, Frangou E, Smith B, et al. RAMPART: A phase III multi-arm multistage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma, RCC, at high or intermediate risk of relapse. Contemp Clin Trials 108:106482, 2021
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 84
EP 89
PG 6
ER

PT J
AU Cserepes, TM
AF Cserepes, Tamas Mihaly
TI Impact, and treatment possibility of chemotherapy resistance in cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
DE chemotherapy resistance; multidrug resistance; Pgp; MDR-selective therapy; iron depletion
ID chemotherapy resistance; multidrug resistance; Pgp; MDR-selective therapy; iron depletion
AB Chemotherapy resistance in tumours is due to complex processes and is responsible for about half of all cancer deaths. In my thesis, I have investigated multiple different resistance mechanisms, most in depth the effect of multidrug resistance (MDR) caused by expression and function of P-glycoprotein (Pgp), and the MDR-selective compounds (such as NSC297366) effectively targeting it. The mechanism was investigated using cell models with different Pgp expression. Seeking the mechanism of action of the MDR-selective NSC297366, we showed that the intracellular iron-binding chelator molecule is able to reduce the amount of free iron available within the cell. Furthermore, by active efflux through Pgp in MDR cells, the compounds can lead to intracellular iron deficiency, upregulation of iron-demanding processes such as cell cycle and apoptosis, and selective death of MDR cancer cells. Our results raise the possibility of targeted killing of MDR phenotypic cancer cells resistant to other therapies, which in combination with conventional chemotherapeutic approaches may form the basis of a strategy of long-term control of the disease.
C1 [Cserepes, Tamas Mihaly] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Cserepes, TM (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM cserepes.tamas@oncol.hu
CR Cserepes M, Turk D, Toth S, et al. Unshielding multidrug resistant cancer through selective iron depletion of P-glycoprotein-expressing cells. Cancer Res 80:663–674, 2020
   Kenessey I, Koi K, Horvath O, et al. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget 7:79503–79514, 2016
   Tatrai E, Bartal A, Gacs A, et al. Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8:44498–44510, 2017
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 90
EP 92
PG 3
ER

PT J
AU Hajdu, T
AF Hajdu, Tibor
TI In vitro examination of N-methyl-D-aspartate type glutamate receptors in non-excitable cells
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
DE N-methyl-D-aspartate receptor; calcium; chondrocyte; melanocyte; melanoma cell
ID N-methyl-D-aspartate receptor; calcium; chondrocyte; melanocyte; melanoma cell
AB Our research was based on studies involving N-methyl- D-aspartate type glutamate receptors in chicken-derived differentiating chondrocytes, as well as in healthy and pathological human pigment cells. Given that NMDARs primarily mediate Ca2+ currents, we focused on the changes of Ca2+ homeostasis. The experiments proved that NMDARs may have roles in the precisely regulated intracellular Ca2+ oscillations of chondroprogenitor cells, and NMDAR-evoked Ca2+ signals are associated with optimal chondrogenesis. NMDAR subunit protein expression profiles in melanoma cells, involving subcellular fractions, revealed major differences between melanocytes and melanoma cells with potentially functional nuclear NMDARs in the latter. In summary we demonstrated in vitro, for the first time, in non-excitable cells from outside the nervous system the presence of functional NMDARs (in differentiating chondrocytes), and the nuclear localisation of NMDARs (in melanoma cells). The former mediate Ca2+-dependent pathways that are indispensable to chondrogenesis, while the latter may have appeared as a result of malignant transformation.
C1 [Hajdu, Tibor] Debreceni Egyetem, Molekularis Orvostudomany Doktori IskolaDebrecen, Hungary.
RP Hajdu, T (reprint author), Debreceni Egyetem, Molekularis Orvostudomany Doktori Iskola, Debrecen, Hungary.
EM hajdu.tibor@med.unideb.hu
CR Hajdu T, Juhasz T, Szucs-Somogyi C, et al. NR1 and NR3B composed intranuclear N-methyl-d-aspartate receptor complexes in human melanoma cells. Int J Mol Sci 19:1929, 2018
   Matta C, Juhasz T, Fodor J, et al. N-methyl-D-aspartate, NMDA, receptor expression and function is required for early chondrogenesis. Cell Commun Signal 17:166, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD APR
PY 2023
VL 67
IS 1
BP 94
EP 96
PG 3
ER

PT J
AU Igaz, P
AF Igaz, Peter
TI Paraneoplastic endocrine syndromes: clinical picture and laboratory diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tumor; hormone; paraneoplastic endocrine syndromes; humoral hypercalcemia of malignancy; SIADH; ectopic ACTH syndrome
ID tumor; hormone; paraneoplastic endocrine syndromes; humoral hypercalcemia of malignancy; SIADH; ectopic ACTH syndrome
AB The term paraneoplastic syndrome refers to the conditions when tumor-related symptoms are not caused by the size, invasion or metastasis of a tumor, but due to soluble mediators produced or an immune reaction induced by a tumor. Paraneoplastic syndromes occur in about 8% of all malignant tumors. Hormone-related paraneoplastic syndromes are termed paraneoplastic endocrine syndromes. In this short synopsis, the main clinical and laboratory characteristics of the most important paraneoplastic endocrine syndromes are presented including humoral hypercalcemia, the syndrome of inappropriate ADH secretion, ectopic ACTH syndrome. Two very rare diseases, paraneoplastic hypoglycemia and tumor-induced osteomalatia are also briefly presented.
C1 [Igaz, Peter] Semmelweis Egyetem AOK, Endokrinologiai TanszekBudapest, Hungary.
RP Igaz, P (reprint author), Semmelweis Egyetem AOK, Endokrinologiai Tanszek, Budapest, Hungary.
EM igaz.peter@med.semmelweis-univ.hu
CR Schutte K, Trautmann-Grill K. Diagnostik und Therapie klinisch relevanter paraneoplastischer Syndrome. Schmerz 36:447–457, 2022
   Jeyabalan A, Trivedi M. Paraneoplastic glomerular diseases. Adv Chronic Kidney Dis 29:116–126, 2022
   Lancaster E. Autoantibody encephalitis: presentation, diagnosis, and management. J Clin Neurol 18:373–390, 2022
   Dimitriadis GK, Angelousi A, Weickert MO, et al. Paraneoplastic endocrine syndromes. Endocr Relat Cancer 24:r173–r190, 2017
   Edwards CM, Johnson RW. From good to bad: the opposing effects of PTHrP on tumor growth, dormancy, and metastasis throughout cancer progression. Front Oncol 11:644303, 2021
   Guise TA, Wysolmerski JJ. Cancer-associated hypercalcemia. New Eng J Med 386:1443–1451, 2022
   Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 85:838–854, 2010
   Young J, Haissaguerre M, Viera-Pinto O, et al. Management of endocrine disease: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 182:R29–R58, 2020
   Szabo A, Igaz P, Kiss R, et al. Ectopias ACTH-termelo neuroendokrin daganat. Esetismertetes. Orv Hetil 152:403–406, 2011
   Ferriere A, Tabarin A. Biochemical testing to differentiate Cushing’s disease from ectopic ACTH syndrome. Pituitary 25:705–708, 2022
   Vassiliadi DA, Mourelatos P, Kratimenos T, et al. Inferior petrosal sinus sampling in Cushing’s syndrome: usefulness and pitfalls. Endocrine 73:530–539, 2021
   Iglesias P, Diez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 170:R147–157, 2014
   Minisola S, Fukumoto S, Xia W, et al. Tumor-induced osteomalacia: a comprehensive review. Endocr Rev 44:323–353, 2022
   Borson-Chazot F, Garby L, Raverot G, et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Ann Endocrinol 73: 497–502, 2012
   Mulatero P, Rabbia F, Veglio F. Paraneoplastic hyperaldosteronism associated with non-Hodgkin’s lymphoma. New Eng J Med 344:1558–1559, 2001
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 102
EP 105
PG 4
ER

PT J
AU Horti-Oravecz, K
   Grolmusz, VK
AF Horti-Oravecz, Klaudia
   Grolmusz, Vince Kornel
TI The expanding possibilities of immuno-oncology treatments
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immune checkpoint inhibition; tumor-infiltrating lymphocyte; CAR-T-cell therapy; cancer vaccines; cytokines
ID immune checkpoint inhibition; tumor-infiltrating lymphocyte; CAR-T-cell therapy; cancer vaccines; cytokines
AB Immuno-oncology treatments have revolutionized the therapeutic options for many types of cancer. The rapid clinical translation of the research results from the past decades has enabled the spread of immune checkpoint inhibitor therapy. In addition to cytokine treatments that modulate anti-tumor immunity, major advances have also been made in adoptive cell therapy, especially regarding the expansion and readministration of tumor-infiltrating lymphocytes. The study of genetically modified T cells is more advanced in hematological malignancies while the applicability in solid tumors is widely investigated. Neoantigens determine antitumor immunity, and neoantigen-based vaccines might contribute to therapy optimization. In this review, we present the diversity of immuno-oncology treatments both that are currently in use and those that are investigated in the research field.
C1 [Horti-Oravecz, Klaudia] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
   [Grolmusz, Vince Kornel] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7-9., 1122 Budapest, Hungary.
RP Grolmusz, VK (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
CR Ahmed S, Rai KR. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol 16:69–81, 2003
   Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 134:860–866, 2019
   Sinha N, Sinha S, Valero C, et al. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer Res 82:2076–2083, 2022
   Pollari M, Bruck O, Pellinen T, et al. PD-L1+ tumor-associated macrophages and PD- 1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica 103:1908–1914, 2018
   Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Front Immunol 13:874589, 2022
   Verdon DJ, Jenkins MR. Identification and targeting of mutant peptide neoantigens in cancer immunotherapy. Cancers, Basel, 13:4245, 2021
   June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7:280ps7, 2015
   Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561, 2017
   Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529, 2018
   Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124– 128, 2015
   Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549:106–110, 2017
   Chan LC, Li CW, Xia W, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 129:3324–3338, 2019
   Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413, 2017
   Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207–2218, 2020
   Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 17:3837–3849, 2021
   Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363–2376, 2022
   Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26:566–576, 2020
   Crisafulli G, Sartore-Bianchi A, Lazzari L, et al. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov 12:1656–1675, 2022
   Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356, 2017
   Lin AY, Schnitter JM, Gordon LI. Immune checkpoint blockade for the treatment of Hodgkin lymphoma. Immunotargets Ther 11:1–10, 2022
   Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217–226, 2022
   Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537–546, 2019
   Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol 16:1872–1882, 2021
   Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 71:3540–3551, 2011
   Curigliano G, Gelderblom H, Mach N, et al. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res 27:3620–3629, 2021
   Zhao L, Cheng S, Fan L, et al. TIM-3: An update on immunotherapy. Int Immunopharmacol 99:107933, 2021
   Maruhashi T, Sugiura D, Okazaki IM, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer 8:e001014, 2020
   Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24–34, 2022
   Logtenberg MEW, Jansen JHM, Raaben M, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy. Nat Med 25:612– 619, 2019
   Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 379:1711–1721, 2018
   Deng J, Zhao S, Zhang X, et al. OX40, CD134, and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther 12:7347–7353, 2019
   Duhen R, Ballesteros-Merino C, Frye AK, et al. Neoadjuvant anti-OX40, MEDI6469, therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun 12:1047, 2021
   Hamid O, Chiappori AA, Thompson JA, et al. First-in-human study of an OX40, ivuxolimab, and 4-1BB, utomilumab, agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer 10:e005471, 2022
   Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29:313–319, 2006
   Bulgarelli J, Piccinini C, Petracci E, et al. Radiotherapy and high-dose interleukin-2: Clinical and immunological results of a proof of principle study in metastatic melanoma and renal cell carcinoma. Front Immunol 12:778459, 2021
   Feng L, Qi Q, Wang P, et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res 46:5228–5236, 2018
   Pachynski RK, Morishima C, Szmulewitz R, et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration- resistant prostate cancer, mCRPC). J Immunother Cancer 9, 2021
   Lian B, Si L, Chi ZH, et al. Toripalimab, anti-PD-1, versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol 33:1061–1070, 2022
   Foltz JA, Hess BT, Bachanova V, et al. Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma. Clin Cancer Res 27:3339–3350, 2021
   Nguyen LT, Saibil SD, Sotov V, et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother 68:773–785, 2019
   Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56–71, 2014
   Linette GP, Carreno BM. Tumor-infiltrating lymphocytes in the checkpoint inhibitor era. Curr Hematol Malig Rep 14:286–291, 2019
   Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821, 2020
   van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes, TIL, therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer 8:e000848, 2020
   Pflugler S, Svinka J, Scharf I, et al. IDO1+ Paneth cells promote immune escape of colorectal cancer. Commun Biol 3:252, 2020
   Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 387:2113–2125, 2022
   Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti- PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27:1410–1418, 2021
   Kverneland AH, Pedersen M, Wulff Westergaard MC, et al. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget 11:2092–2105, 2020
   Borch TH, Andersen R, Ellebaek E, et al. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer 8:000668, 2020
   Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726–1737, 2019
   Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual- targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res 27:2764–2772, 2021
   Adusumilli PS, Zauderer MG, Riviere I, et al. A phase I trial of regional mesothelin- targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov 11:2748–2763, 2021
   Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28:1189–1198, 2022
   Narayan V, Barber-Rotenberg JS, Jung IY, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28:724–734, 2022
   Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907–917, 2018
   Mutant KRAS-Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT05013216
   Brun JL, Rajaonarison J, Nocart N, et al. Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials. Mol Clin Oncol 8:227– 235, 2018
   Roudko V, Bozkus CC, Orfanelli T, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183:1634–1649, 2020
   Leoni G, D’Alise AM, Cotugno G, et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res 80:3972–3982, 2020
   Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol 5:67–73, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 107
EP 114
PG 8
ER

PT J
AU Bartha-Tatar, A
   Kappelmayer, J
   Nagy, B
AF Bartha-Tatar, Anita
   Kappelmayer, Janos
   Nagy, Bela
TI The role of classic serum tumor markers in the diagnosis and treatment monitoring of solid tumors in adults
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tumor marker; prognostic biomarker; treatment monitoring; other body fluid
ID tumor marker; prognostic biomarker; treatment monitoring; other body fluid
AB Malignancies are considered as leading cause of death in parallel to cardio- and cerebrovascular diseases and their incidence is still growing from year to year. Early detection and monitoring of cancers after complex therapeutic interventions are essential for the survival of patients. In these aspects, beside radiological investigations, some lab tests play a key role, namely the tumor markers. These mostly protein-based mediators are produced in a large quantity by either cancer cells or the human body itself in response to the development of tumor. Measurement of tumor markers is usually assessed in serum samples, however, to locally detect an early malignant event, other body fluids, such as ascites, cerebrospinal fluid, or pleural effusion sample can also be analyzed. Due to the potential effects of other non-malignant conditions on the serum level of a tumor marker, the entire clinical status of investigated person needs to be considered for the correct interpretation of these results. In this review article, we summarized some important characteristics of the most widely used tumor markers
C1 [Bartha-Tatar, Anita] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Kappelmayer, Janos] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
   [Nagy, Bela] University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98., 4032 Debrecen, Hungary.
RP Nagy, B (reprint author), University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, 4032 Debrecen, Hungary.
EM nagy.bela@med.unideb.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor- markers-fact-sheet
   Trape J, Filella X, Alsina-Donadeu M, et al. Oncology Section of the Catalan Association of Clinical Laboratory Science. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 49:1605–1620, 2011
   Faria SC, Sagebiel T, Patnana M, et al. Tumor markers: myths and facts unfolded. Abdom Radiol, NY, 44:1575–1600, 2019
   Santotoribio JD, Del Valle-Vazquez L, Garcia-de la Torre A, et al. The diagnostic value of pleural fluid homocysteine in malignant pleural effusion. PLoS One 14:e0222616, 2019
   Yang J, Cao W, Xing E. Levels and significance of tumor markers and cytokines in serum and peritoneal lavage fluid of patients with peritoneal metastasis of gastric cancer. Biomed Res Int 2022:9528444, 2022
   Zhang H, Li C, Hu F, et al. Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion. Respir Res 21:284, 2020
   Oh SH, Lee JK, Lee KT, et al. The combination of cyst fluid carcinoembryonic antigen, cytology and viscosity increases the diagnostic accuracy of mucinous pancreatic cysts. Gut Liver 11:283–289, 2017
   Oh HJ, Park HY, Kim KH, et al. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis 8:2530–2537, 2016
   Liu XM, Liu XH, Mao MJ, et al. The automated processing algorithm to correct the test result of serum neuron-specific enolase affected by specimen hemolysis. J Clin Lab Anal 35:e23895, 2021
   Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol 14:343–357, 2019
   Mazzone PJ, Wang XF, Han X, et al. Evaluation of a serum lung cancer biomarker panel. Biomark Insights 13:1177271917751608, 2018
   Molina R, Marrades RM, Auge JM, et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 193:427–437, 2016
   Nagy B Jr, Bhattoa HP, Steiber Z, et al. Serum human epididymis protein 4, HE4, as a tumor marker in men with lung cancer. Clin Chem Lab Med 52:1639–1648, 2014
   Chen Z, Liu L, Zhu F, et al. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy. Cancer Med 11:3115–3125, 2022
   Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220, 2019
   Youlden DR, Cramb SM, Dunn NA, et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36:237–248, 2012
   de la Pena FA, Ortiz-Munoz B, Quintanar-Verduguez T, et al. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer. Clin Transl Oncol 23:1272–1280, 2021
   Li J, Liu L, Feng Z, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer 27:621– 630, 2020
   Stieber P, Nagel D, Blankenburg I, et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer – A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta 448:228– 231, 2015
   Molina F, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen, CEA, and carbohydrate antigen 15.3, CA 15.3, in patients with primary locoregional breast cancer. Clin Chem 56:1148–1157, 2010
   Nicolini A, Ferrari P, Fulceri F, et al. An individual reference limit for ‘early’ diagnosis of metastatic breast cancer during postoperative follow-up. Biomark Med 9:307–317, 2015
   Argiles G, Tabernero J, Labianca R, et al. ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291–1305, 2020
   Becerra AZ, Probst CP, Tejani MA, et al. Evaluating the prognostic role of elevated preoperative carcinoembryonic antigen levels in colon cancer patients: results from the National Cancer Database. Ann Surg Oncol 23:1554–1561, 2016
   Stojkovic Lalosevic M, Stankovic S, Stojkovic M, et al. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? Hell J Nucl Med 20:41–45, 2017
   Lee T, Jie Teng TZ, Shelat VG. Carbohydrate antigen 19-9 – tumor marker: Past, present, and future. World J Gastrointest Surg 12:468–490, 2020
   Thomsen M, Skovlund E, Sorbye H, et al. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer 118:1609–1616, 2018
   Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380, 2018
   Zong J, Fan Z, Zhang Y. Serum tumor markers for early diagnosis of primary hepatocellular carcinoma. J Hepatocell Carcinoma 7:413–422, 2020
   Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells 9:1370, 2020
   Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63:844–855, 2014
   Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 19:670–681, 2022
   Xu D, Su C, Sun L, et al. Performance of serum glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis. Ann Hepatol 18:58–67, 2019
   Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am 99:315–335, 2019
   Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204–247, 2000
   Macerola E, Poma AM, Vignali P, et al. Predictive biomarkers in thyroid cancer. Front Oncol 12:901004, 2022
   Werner RA, Schmid JS, Muegge DO, et al. Prognostic value of serum tumor markers in medullary thyroid cancer patients undergoing vandetanib treatment. Medicine, Baltimore, 94:e2016, 2015
   Leimbach RD, Hoang TD, Shakir MK. Diagnostic challenges of medullary thyroid carcinoma. Oncology 99:422–432, 2021
   Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133, 2016
   Censi S, Manso J, Mian C. Other markers of medullary thyroid cancer, not only calcitonin. Eur J Endocrinol 188:lvac009, 2023
   Zahra HO, Omran GA, Gewely AG, et al. Prognostic value of serum thyroglobulin and anti-thyroglobulin antibody in thyroid carcinoma patients following thyroidectomy. Diagnostics, Basel, 11:2080, 2021
   Zhang R, Siu MK, Ngan HY, et al. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci 23:12041, 2022
   Colombo N, Sessa C, Bois AD, et al. ESMO–ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer ijgc-2019-000308, 2019
   Carreras-Dieguez N, Glickman A, Munmany M, et al. Comparison of HE4, CA125, ROMA and CPH-I for preoperative assessment of adnexal tumors. Diagnostics, Basel, 12:226, 2022
   Revythis A, Shah S, Kutka M, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics, Basel, 11:1341, 2021
   Ding L, Gosh A, Lee DJ, et al. Prognostic biomarkers of cutaneous melanoma. Photodermatol Photoimmunol Photomed 38:418–434, 2022
   Frauchiger AL, Dummer R, Mangana J. Serum S100B levels in melanoma. Methods Mol Biol 1929:691–700, 2019
   Nagy B Jr, Bhattoa HP, Kappelmayer J. A prosztatarak laboratoriumi diagnosztikaja: honnan hova tartunk? Magy Onkol 63:16–25, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 116
EP 123
PG 8
ER

PT J
AU Engi, H
   Toth, E
AF Engi, Helga
   Toth, Erika
TI The importance of liquid biopsy studies in solid tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE liquid biopsy; circulating tumour DNA (ctDNA); targeted therapy; MRD (minimal residual disease); therapy resistance
ID liquid biopsy; circulating tumour DNA (ctDNA); targeted therapy; MRD (minimal residual disease); therapy resistance
AB The incidence of cancer is rising significantly in Hungary and worldwide. It is one of the leading causes of both morbidity and mortality. In recent years, the advent of personalised treatments and targeted therapies have brought significant advances in the treatment of cancer. Targeted therapies are based on the identification of genetic variations in patients’ tumour tissue. However, tissue or cytological sampling poses a number of difficulties, while non-invasive procedures such as liquid biopsy studies can be a good alternative to overcome these problems. In nucleic acids from liquid biopsy samples, circulating tumour cells or free circulating tumour DNA, RNA present in the plasma the same genetic abnormalities can be detected that are present in tumours and their quantification is suitable for therapy monitoring and prognosis estimation. In our summary, we describe the advantages and difficulties of liquid biopsy specimen analysis and its potential for use in everyday clinical practice for molecular diagnosis of solid tumours.
C1 [Engi, Helga] National Institute of Oncology, National Tumour Biology Laboratory, Department of Surgical and Molecular Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, National Tumour Biology Laboratory, Department of Surgical and Molecular Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Engi, H (reprint author), National Institute of Oncology, National Tumour Biology Laboratory, Department of Surgical and Molecular Pathology, 1122 Budapest, Hungary.
CR Zhang H, Lin X, Huang Y, et al. Detection methods and clinical applications of circulating tumor cells in breast cancer. Front Oncol 11:652253, 2021
   Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol 32:466–477, 2021
   Tivey A, Church M, Rothwell D, et al. Circulating tumour DNA – looking beyond the blood. Nat Rev Clin Oncol 19:600–612, 2022
   Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24, 2014
   Engi H, Szakacs O, Csuka O, et al. A keringo tumor-DNS jelentosege a melanomas betegek terapiajaban. Onkologia es Hematologia 3:23–26, 2022
   Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223–238, 2017
   Szilagyi M, Pos O, Marton E, et al. Circulating cell-free nucleic acids: main characteristics and clinical application. Int J Mol Sci 21:6827, 2020
   Priskin K, Pinter L, Jaksa G, et al. Folyekony biopszia a klinikai onkologiaban – a precizios orvoslas vonalvezetoje. Klinikai Onkologia 6:65–72, 2019
   Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548– 554, 2014
   Bencze E, Bogos K, Kohanka A, et al. EGFR T790M mutation detection in patients with non-small cell lung cancer after first line EGFR TKI therapy: Summary of results in a three-year period and a comparison of commercially available detection kits. Pathol Oncol Res 28:1610607, 2022
   Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595:432–437, 2021
   Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation- based multi-cancer early detection test using an independent validation set. Ann Oncol 32:1167–1177, 2021
   Bartak BK, Markus E, Kalmar A, et al. A plazmaban keringo szabad DNS jellemzoi es diagnosztikai alkalmazasi lehetosegei vastagbelrak eseten. Orv Hetil 160:1167–1177, 2019
   Constantin N, Sina AA, Korbie D, et al. Opportunities for early cancer detection: the rise of ctDNA methylation-based pan-cancer screening technologies. Epigenomes 6:6, 2022
   Chemi F, Pearce SP, Clipson A, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer 3:1260–1270, 2022
   Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 386:2261–2272, 2022
   Frisone D, Friedlaender A, Addeo A. The role and impact of minimal residual disease in NSCLC. Curr Oncol Rep 23:136, 2021
   Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J Clin Oncol 40:2408–2419, 2022
   Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced nonsmall cell lung cancer. Nat Cancer 1:176–183, 2020
   Tay TKY, Tan PH. Liquid biopsy in breast cancer: a focused review. Arch Pathol Lab Med 145:678–686, 2021
   Suppan C, Graf R, Jahn S, et al. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. Br J Cancer 126:456–463, 2022
   O’Leary B. PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. Nat Rev Clin Oncol 20:67–68, 2023
   Cheng ML, Pectasides E, Hanna GJ, et al. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin 71:176–190, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 125
EP 130
PG 6
ER

PT J
AU Kollo, Z
   Vasarhelyi, B
   Karvaly, GB
AF Kollo, Zoltan
   Vasarhelyi, Barna
   Karvaly, Gellert Balazs
TI Therapeutic drug monitoring for supporting oncological treatments: a new era begins
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE therapeutic drug monitoring; precision pharmacotherapy; busulfan; methotrexate; tyrosine kinase inhibitor; mass spectrometry
ID therapeutic drug monitoring; precision pharmacotherapy; busulfan; methotrexate; tyrosine kinase inhibitor; mass spectrometry
AB Recently, oncological pharmacotherapy and the related imaging and laboratory techniques employed for the optimization and monitoring of interventions have undergone revolutionary development. The implementation of personalized treatments based on therapeutic drug monitoring (TDM) is, with a few exceptions, lacking. The key factor limiting the integration of TDM into oncological practice is the need for dedicated central laboratories with resource-intensive, specialized analytical instruments, as well as highly skilled multidisciplinary staff. Unlike in certain other fields, the monitoring of serum trough concentrations often fails to provide clinically relevant information. Instead, the clinical interpretation of the results requires clinical pharmacological and bioinformatics expertise. Our goal is to present the pharmacokinetic-pharmacodynamic considerations of interpreting oncological TDM assay outcomes with the aim of providing direct support for clinical decision making.
C1 [Kollo, Zoltan] Semmelweis University, Department of Laboratory Medicine, Nagyvarad ter 4., 1089 Budapest, Hungary.
   [Vasarhelyi, Barna] Semmelweis University, Department of Laboratory Medicine, Nagyvarad ter 4., 1089 Budapest, Hungary.
   [Karvaly, Gellert Balazs] Semmelweis University, Department of Laboratory Medicine, Nagyvarad ter 4., 1089 Budapest, Hungary.
RP Karvaly, GB (reprint author), Semmelweis University, Department of Laboratory Medicine, 1089 Budapest, Hungary.
EM karvaly.gellert_balazs@med.semmelweis-univ.hu
CR Stojanova J, Carland JE, Murnion B, et al. Therapeutic drug monitoring in oncology – what’s out there: a bibliometric evaluation of the topic. Front Oncol 12:959741, 2022
   Dasgupta A, Krasowski M. Antineoplastic drugs. In: Therapeutic drug monitoring data. A concise guide, 4th edition. Elsevier, Amsterdam 2020, pp. 331–350
   Menz BD, Stocker SL, Verougstraete N, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol 87:227–236, 2021
   Iwamoto T, Hiraku Y, Oikawa S, et al. DNA intrastrand cross-link at the 5’-GA-3’ sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci 95:454–458, 2004
   Marsit H, Philippe M, Neely M, et al. Intra individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell transplanted children. Clin Pharmacokinet 59:1049–1061, 2020
   Fukumoto M, Kumo H, Ogamo A. Quantitative determination of busulfan in serum using gas chromatography – mass spectrometry in negative-ion chemical ionization mode. Anal Lett 34:1795, 2001
   Pablo A, Breaud AR, Clarke W. Analysis of busulfan in plasma by liquid chromatography – tandem mass spectrometry. Curr Protoc Toxicol 84:e93, 2020
   Barnett S, Kong J, Makin G, et al. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. Br J Clin Pharmacol 87:256–262, 2021
   Moeung S, Chevreau C, Poinsignon V, et al. Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoring. Ther Drug Monit 41:66–74, 2019
   Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78:447–464, 2016
   Braal CL, Jager A, Oomen-de Hoop E, et al. Therapeutic drug monitoring of endoxifen for tamoxifen precision dosing: feasible in patients with hormone- sensitive breast cancer. Clin Pharmacokinet 61:527–537, 2022
   Schroth W, Winter S, Murdter T, et al. Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol 8:582, 2017
   Haider MS, Ahmad T, Groll J, et al. The challenging pharmacokinetics of mitotane: an old drug in need of new packaging. Eur J Drug Metab Pharmacokinet 46:575–593, 2021
   Von Slooten H, van Seters AP, Smeenk D, et al. O,p’-DDD, Mitotane, levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol 9:85–88, 1982
   Paragliola M, Torino F, Papi G, et al. Role of mitotane in adrenocortical carcinoma – review and state of the art. Eur Endocrinol 14:62–66, 2018
   Van den Hombergh E, de Rouw N, van den Heuvel M, et al. Simple and rapid quantification of the multi-enzyme targeting antifolate premetrexed in human plasma. Ther Drug Monit 42:146–150, 2020
   Schlichtig K, Durr P, Dorje F, et al. New oral anti-cancer drugs and medication safety. Dtsch Arztebl Int 116:775–782, 2019
   Clarke WA, Chatelut E, Fotoohi AK, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer 157: 428–440, 2021
   Guntner AS, Peyri A, Mayr L, et al. Cerebrodpinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol Comm 8:78, 2020
   Kollo Z, Garami M, Vincze I, et al. Therapeutic monitoring of orally administered, small-molecule anticancer medications with tumor-specific cellular protein targets in peripheral fluid spaces – a review. Pharmaceutics 15:239, 2023
   Barnett S, Holden V, Campbell-Hewson Q, et al. Perspecives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations. Front Oncol 11:815040, 2022
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 131
EP 137
PG 7
ER

PT J
AU Lakatos, K
   Kiss, A
   Varga, Zs
   Butz, H
AF Lakatos, Kinga
   Kiss, Anna
   Varga, Zsuzsanna
   Butz, Henriett
TI Thromboembolic complications associated to malignant diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cancer; venous thromboembolism; mechanism; risk factor; treatment; anticoagulation
ID cancer; venous thromboembolism; mechanism; risk factor; treatment; anticoagulation
AB Cancers are known to increase the tendency for thrombosis, both on the venous and arterial side, which to this day is an important factor in the management of oncology patients. Malignant disease is an independent risk factor for developing venous thromboembolism (VTE). Thromboembolic complications in addition to the disease worsen prognosis and are accompanied by significant morbidity and mortality. VTE is the second most common cause of death in cancer after disease progression. Tumors are characterized by hypercoagulability, in addition to which venous stasis and endothelial damage also occur in cancer patients promoting increased clotting. Treatment of cancer-associated thrombosis is often complex; therefore, it is important to identify patients who benefit from primary thromboprophylaxis. The importance of cancer-associated thrombosis is indisputable in everyday oncology. We briefly summarize the frequency and characteristics of their occurrence, the underlying mechanisms, risk factors, clinical appearance, laboratory diagnostics, and the possibilities of prevention and treatment.
C1 [Lakatos, Kinga] National Institute of Oncology, Central Clinical Laboratory, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kiss, Anna] National Institute of Oncology, Central Clinical Laboratory, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Varga, Zsuzsanna] National Institute of Oncology, Central Clinical Laboratory, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Butz, Henriett] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Lakatos, K (reprint author), National Institute of Oncology, Central Clinical Laboratory, 1122 Budapest, Hungary.
EM lakatos.kinga@oncol.hu
CR Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245–1248, 2002
   Menapace LA, Peterson DR, Berry A, et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 106:371–378, 2011
   Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634, 2007
   Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancer. Arch Intern Med 166:458–464, 2006
   Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850, 2000
   Mulder FI, Horvath-Puho E, Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137:1959–1969, 2021
   Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484–490, 2006
   Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575–579, 2002
   Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17:297–303, 2006
   Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722, 2005
   Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. J Gen Intern Med 8:476–486, 1993
   Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117:219–230, 2017
   Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2:209–215, 1996
   Falanga A, Alessio MG, Donati MB, et al. A new procoagulant in acute leukemia. Blood 71:870–875, 1988
   Yu JL, Rak JW. Shedding of tissue factor, TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2:2065–2067, 2004
   Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 122:1873–1880, 2013
   Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112:853–862, 2003
   Levi M, Van der Poll T, Ten Cate H, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 27:3–9, 1997
   Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 303:1532–1535, 2004
   Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109:13076–13081, 2009
   Rocha E, Paramo JA, Fernandez FJ, et al. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 54:699–707, 1989
   Casslen B, Bossmar T, Lecander I, et al. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer 30:1302–1309, 1994
   Blom JW, Vanderschoot JPM, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4:529–535, 2006
   Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:2339–2346, 2007
   Dicke C, Amirkhosravi A, Spath B, et al. Tissue factor-dependent and – independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol 4:22, 2015
   Razak NBA, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers 10:380, 2018
   Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 160:2021–2024, 1998
   Agnelli G, Bolis G, Capusotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:89–95, 2006
   Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103:994–999, 2005
   Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917–927, 2017
   Ranpura V, Hapani S, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49:287–297, 2010
   Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212, 2008
   Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res 118:1392–1408, 2016
   Li W, Garcia D, Cornell RF, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol 3:980- 988, 2017
   Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727–742, 2020
   Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168, 2018
   Kang JH, Bluestone JA, Young A. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol 42:293– 311, 2021
   Wang TF, Khorana AA, Carrier M. Thrombotic complications associated with immune checkpoint inhibitors. Cancers, Basel, 13:4606, 2021
   Sussman TA, Li H, Hobbs B, et al. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 9:e001719, 2021
   Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907, 2008
   Ramacciotti E, Wolosker N, Puech-Leao P, et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 109:171– 174, 2003
   Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101:558–566, 2004
   Canonico ME, Santoro C, Avvedimento M, et al. Venous thromboembolism and cancer: a comprehensive review from pathophysiology to novel treatment. Biomolecules 12:259, 2022
   Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: the old and the new – an evolving avenue. Circulation 133:1272–1289, 2016
   Brill-Edwards P, Lee A. D-dimer testing in the diagnosis of acute venous thromboembolism. Thromb Haemost 82:688–694, 1999
   Wells PS, Hirsh J, Anderson DR, et al. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med 243:15–23, 1998
   Ten Wolde M, Kraaijenhagen RA, Prins MH, et al. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med 162:1880–1884, 2002
   Moik F, Prager G, Thaler J, et al. Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer. Arterioscler Thromb Vasc Biol 41:2837–2847, 2021
   Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 131:417–423, 1999
   Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study, CATS). Blood 112:2703–2708, 2008
   Cheng M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp, Warsz, 54:75–84, 2006
   Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2189–2204, 2013
   Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023,, DOI  10.1016/j. annonc.2022.12.014
   Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 17:1772–1778, 2019
   Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38:496–520, 2020
   Queiroz Crusoe E, Massarenti M, Almeida M, et al. Venous thromboembolism prophylaxis with aspirin for multiple myeloma patients receiving thalidomide combination as first-line treatment. Blood 124:5764, 2014
   Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 11:CD004318, 2018
   Merlo ABB, Martinez JIA, Luque JDT, et al. Form of presentation, natural history and course of postoperative venous thromboembolism in patients operated on for pelvic and abdominal cancer. Analysis of the RIETE registry. Cir Esp 95:328–334, 2017
   Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134:1214–1219, 2014
   Tsoukalas N, Brito-Dellan N, Font C, et al. Complexity and clinical significance of drug-drug interactions, DDIs, in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis, CAT). Support Care Cancer 30:8559–8573, 2022
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 139
EP 145
PG 7
ER

PT J
AU Nadorvari, ML
   Kiss, A
   Barbai, T
   Kulka, J
   Raso, E
   Timar, J
AF Nadorvari, Maja Lilla
   Kiss, Andras
   Barbai, Tamas
   Kulka, Janina
   Raso, Erzsebet
   Timar, Jozsef
TI Molecular epidemiology of microsatellite instability/mismatch repair deficiency in our institute – methodical aspects
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE mismatch repair deficiency; immunohistochemistry; microsatellite instability; PCR; malignant tumors
ID mismatch repair deficiency; immunohistochemistry; microsatellite instability; PCR; malignant tumors
AB Molecular epidemiology of mismatch repair deficiency (dMMR)/microsatellite instability (MSI) are different in various ethnic groups; accordingly, our aim was to test this in a large single-center Hungarian cancer patient cohort. We have found that dMMR/MSI incidence correlates well with TCGA data in case of colorectal, gastric and endometrial cancers. We have also observed that immunohistochemistry- based dMMR incidences are higher as compared to MSI. We suggest that the testing guidelines must be fine-tuned for immune-oncology indications. Nadorvari ML, Kiss A, Barbai T, Raso E, Timar J. Molecular epidemiology of mismatch repair deficiency, microsatellite instability in a large single diagnostic center cancer cohort.
C1 [Nadorvari, Maja Lilla] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Kulka, Janina] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
CR Szallasi Z, Sztupinszki Zs, Moldvay J. DNS-javito mechanizmusok hianya szolid tumorokban. Klin Onkol 9:375–386, 2022
   Sukosd F. Mikroszatellitak mint a genom szeizmografjai. Klin Onkol 8:143–150, 2021
   Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterisation of microsatellite instability across 18 cancer types. Nat Med 22:1342–1349, 2016
   Szentirmay Z, Gallai M, Serester O, et al. A microsatellita-status es a morfologia osszefuggese vastagbelrakokban. Magy Onkol 54:169–178, 2010
   Regos E, Lotz G. Az immuncheckpoint-gatlok biomarkereinek molekularis diagnosztikai vizsgalata. Orvoskepzes 3:469–477, 2021
   Chen W, Swanson BJ, Frankel W. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol 12:24, 2017
   Abildgaard AB, Nielsen SV, Bernstein I, et al. Lynch syndrome, molecular mechanisms and variant classification. Br J Cancer 128:726–734, 2022
   Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high, TMB-high, and microsatellite instability, MSI, confirms their utility as immunotherapy biomarkers. ESMO Open 7:100336, 2022
   Le DT, Kim WT, Van Cutsem E, et al. Phase-II open label study of pembrolizumab in treatment refractory, microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. KEYNOTE-164. J Clin Oncol 38:11–19, 2020
   Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer, CheckMate 142). Lancet Oncol 18:1182–1191, 2017
   Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer. J Clin Oncol 38:1–10, 2019
   Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer and its relationship with PD-1/PD-L1 expression and tumor mutational burden. Ann Oncol 30:1232–1243, 2019
   Yoshino T, Pentheroudakis G, Mishima S, et al. JSCO-ESMO-ASCOJSMO- TOS: international expert consensus recommendations for tumoragnostic treatments in patients with solid tumors with microsatellite instability or NTRK fusion. Ann Oncol 31:861–871, 2020
   Timar J, Ladanyi A. A danatok immunterapiajanak prediktiv markerei, a PD-L1-meghatarozas gyakorlati kerdesei. Magy Onkol 61:158–166, 2017
   McCarthy AJ, Capo-Chichi J-M, Spence T, et al. Heterogenous loss of mismatch repair, MMR, protein expression: a challenge for immunohistochemical interpretation and microsatellite instability, MSI, evaluation. J Pathol Clin Res 5:115–129, 2019
   Jaffrelot M, Fares N, Brunac AC, et al. An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes. Mod Pathol 35:427–437, 2022
   Lorenzi M, Amonkar M, Zhang J, et al. Epidemiology of microsatellite instability high, MSI-H, and deficient mismatch repair, dMMR, in solid tumors: a structured literature review. J Oncol 2020:1807929, 2020
   Quaas A, Rehkaemper J, Rueschoff J, et al. Occurrence of high microsatellite- instability/mismatch repair deficiency in nearly 200 human adenocarcinomas of the gastrointestinal tract, pancreas and bile duct: a study from a large German Comprehensive Cancer Center. Front Oncol 11:569475, 2021
   Desalins AGD, Tachon G, Cohen R, et al. Discordance between immunohistochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open 3:100120, 2021
   Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability or both? Mod Pathol 35:1515–1528, 2022
   Andre T, Cohen R, Salem ME. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022. ASCO Educational Book, 2022, pp. 1–8
   Chen ML, Chen JY, Hu J, et al. Comparison of microsatellite status detection methods in colorectal carcinoma. Int J Exp Pathol 11:1431–1438, 2018
   Malapelle U, Parente P, Pepe F, et al. Impact of pre-analytical factors on MSI test accuracy in mucinous colorectal adenocarcinoma: a multi-assay concordance study. Cells 9:9092019, 2020
   Dedeurwaerdere F, Claes KBM, Van Dorpe J, et al. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep 11:12880, 2021
   Siemanowski J, Schoming-Markiefka B, Buhl T, et al. Managing difficulties of microsatellite instability testing in endometrial cancer. Limitations and advantages of four different PCR-based approaches. Cancers 13:1268, 2021
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 147
EP 153
PG 7
ER

PT J
AU Der, B
   Fazekas, T
   Csizmarik, A
   Soos, �
   Fekete, B
   Nyirady, P
   Szarvas, T
AF Der, Balint
   Fazekas, Tamas
   Csizmarik, Anita
   Soos, Aron
   Fekete, Balint
   Nyirady, Peter
   Szarvas, Tibor
TI Current therapeutic and familial implications of the genetic background of prostate cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostate cancer; genetic counseling; BRCA; PARP inhibitor; pembrolizumab
ID prostate cancer; genetic counseling; BRCA; PARP inhibitor; pembrolizumab
AB Genetic testing for prostate cancer (PC) is becoming more widely used in the clinical routine, primarily due to the introduction of PARP inhibitors targeting genetically affected patients in their BRCA1/2 and other homologous recombination repair (HRR) genes. Simultaneously, the number of available therapies that are specifically targeting genetically defined PC subgroups is steadily increasing. As a result, the selection of treatment for PC patients is likely to require testing of multiple genes to enable more specific treatment sequences that consider the genetic characteristics of the tumor. Some of the mutations discovered by genetic testing may be hereditary, necessitating the use of germline testing from normal tissue, which is only permitted within the framework of clinical counseling. This change in PC care requires the collaboration by multiple specialists, including experts in molecular pathology, bioinformatics, biology, and genetic counseling. In this review, we aim to provide an overview on the currently relevant genetic alterations in PC for therapeutic purposes and their implications for familial testing.
C1 [Der, Balint] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Fazekas, Tamas] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Csizmarik, Anita] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Soos, Aron] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Fekete, Balint] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Nyirady, Peter] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
   [Szarvas, Tibor] Semmelweis University, Department of Urology, Ulloi ut 78/b, 1082 Budapest, Hungary.
RP Szarvas, T (reprint author), Semmelweis University, Department of Urology, 1082 Budapest, Hungary.
EM szarvas.tibor@semmelweis.hu
CR De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091–2102, 2020
   Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383:2345–2357, 2020
   Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38:3763–3772, 2020
   Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753–3758, 2019
   Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer, IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398:131–142, 2021
   Vietri MT, D’Elia G, Caliendo G, et al. Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci 22:3753, 2021
   Sipeky C, Talala KM, Tammela TLJ, et al. Prostate cancer risk prediction using a polygenic risk score. Sci Rep 10:17075, 2020
   Timar J. Molecular pathology of prostate cancer. Magy Onkol 63:5–9, 2019
   Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 461:1071–1078, 2009
   Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748–1757, 2013
   Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta- analysis. Prostate 79:880–895, 2019
   Rajwa P, Quhal F, Pradere B, et al. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nat Rev Urol 20:205–216, 2023
   Sztupinszki Z, Diossy M, Krzystanek M, et al. Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations. Clin Cancer Res 26:2673–2680, 2020
   Lotan TL, Kaur HB, Salles DC et al. Homologous recombination deficiency, HRD, score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol 34:1185–1193, 2021
   Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995, 2016
   Zafeiriou Z, Bianchini D, Chandler R, et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol 75:184–192, 2019
   Nagy ND, Fazekas T, Baghy K, et al. A karboplatin-kemoterapia hatekonysaga egy attetes, kasztraciorezisztens, BRCA2-mutacio-pozitiv prosztatarakos betegben. Orv Hetil 162:1004–1008, 2021
   Schmid S, Omlin A, Higano C, et al. Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open 3:e2021692, 2020
   Iannantuono GM, Torino F, Rosenfeld R, et al. The role of histology-agnostic drugs in the treatment of metastatic castration-resistant prostate cancer. Int J Mol Sci 23:8535, 2022
   Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413, 2017
   Pecina-Slaus N, Kafka A, Salamon I, et al. Mismatch repair pathway, genome stability and cancer. Front Mol Biosci 7:122, 2020
   Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20:16, 2020
   Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch- repair deficiency. N Engl J Med 372:2509–2520, 2015
   Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 27:4685–4689, 2021
   Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37:286–295, 2019
   Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228, 2015
   Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol 75:378–382, 2019
   Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5:471–478, 2019
   Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS One 15:e0233260, 2020
   Sena LA, Fountain J, Isaacsson Velho P, et al. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncologist 26:e270–e278, 2021
   Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:e000023, 2016
   Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222–234, 2018
   Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4:299–309, 2003
   Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747, 2018
   Ling Q, Li B, Wu X, et al. The landscape of NTRK fusions in Chinese patients with solid tumor. Ann Oncol 29:viii22–viii23, 2018
   Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 5:69, 2019
   Lassen U. How I treat NTRK gene fusion-positive cancers. ESMO Open 4(Suppl 2):e000612, 2019
   Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540, 2020
   Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22, 2010
   Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 67:795–802, 2015
   De Bono JS, De Giorgi U, Nava Rodrigues D, et al. Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res 25:928–936, 2019
   Yang M, Kim JW. Principles of genetic counseling in the era of next-generation sequencing. Ann Lab Med 38:291–295, 2018
   Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol 19:331–343, 2022
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUN
PY 2023
VL 67
IS 2
BP 154
EP 160
PG 7
ER

PT J
AU Szalai, F
   Krencz, I
   Moldvai, D
   Petovari, G
   Danko, T
   Nagy, N
   Papp, G
   Papay, J
   Sebestyen, A
   Sztankovics, D
AF Szalai, Fatime
   Krencz, Ildiko
   Moldvai, Dorottya
   Petovari, Gabor
   Danko, Titanilla
   Nagy, Noemi
   Papp, Gergo
   Papay, Judit
   Sebestyen, Anna
   Sztankovics, Daniel
TI he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE mTOR serine-threonine kinases; Rictor protein; gene amplification; molecular targeted therapy; neoplasms
ID mTOR serine-threonine kinases; Rictor protein; gene amplification; molecular targeted therapy; neoplasms
AB Failures of anti-tumour therapies and drug resistance initiate difficulties in cancer treatments often caused by alterations in signalling network activity, including PI3K/Akt/mTOR hyperactivity due to oncogenic mutations. In this review, we summarise the relevance of mTOR (mechanistic target of rapamycin) dysregulation identified decades ago, which is now known to be characteristic of many tumours. In this context, we present differences in activity, function and testability of mTOR kinase complexes (mTORC1 and mTORC2) differing in structure, regulatory mechanisms and inhibitor sensitivity. We highlight that genetic alterations, including RICTOR amplification and associated mTOR hyperactivity, are relevant in targeted therapy development. It is recommended to investigate mTOR profile activity in patients for whom mTOR inhibitor therapies are considered since the current first-generation mTOR inhibitors (rapamycin and analogues) may be ineffective in case of mTORC2 hyperactivity. Ongoing phase trials of new inhibitors and combination therapies are promising in advanced stage patients selected by molecular markers.
C1 [Szalai, Fatime] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Nagy, Noemi] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Papp, Gergo] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Papay, Judit] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM hsebanna@gmail.com
CR Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 168:960–976, 2017
   Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124:471–484, 2006
   Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 4:183–203, 2020
   Fu W, Hall MN. Regulation of mTORC2 signaling. Genes, Basel, 11:1045, 2020
   Sebestyen A, Danko T, Sztankovics D, et al. The role of metabolic ecosystem in cancer progression – metabolic plasticity and mTOR hyperactivity in tumor tissues. Cancer Metastasis Rev 40:989–1033, 2021
   Yamaguchi H, Kawazu M, Yasuda T, et al. Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer. Cancer Sci 106:1687– 1692, 2015
   Grabiner BC, Nardi V, Birsoy K, ez al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4:554–563, 2014
   Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 371:1426–1433, 2014
   Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2):S43–51, 2008
   Eng CP, Sehgal SN, Vezina C. Activity of rapamycin, AY-22,989, against transplanted tumors. J Antibiot 37:1231–1237, 1984
   Egervari G, Mark A, Hajdu M, et al. Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein. Histochem Cell Biol 135:409–417, 2011
   Sebestyen A, Sticz TB, Mark A, et al. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study. Mod Pathol 25:1623– 1628, 2012
   Mark A, Hajdu M, Varadi Z, et al. Characteristic mTOR activity in Hodgkin- lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study. BMC Cancer 13:250, 2013
   Nemes K, Sebestyen A, Mark A, et al. Mammalian target of rapamycin, mTOR, activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia, ALL). PLoS One 8:e59335, 2013
   Rajnai H, Heyning FH, Koens L, et al. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. Virchows Arch 464:229–239, 2014
   Marosvari D, Nagy N, Kriston C, et al. Discrepancy between low levels of mTOR activity and high levels of P-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation. J Neuropathol Exp Neurol 77:268–273, 2018
   Sticz T, Molnar A, Mark A, et al. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression. J Clin Pathol 70:410–416, 2017
   Sapi Z, Fule T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol 20:22–33, 2011
   Petovari G, Danko T, Tokes AM, et al. In situ metabolic characterisation of breast cancer and its potential impact on therapy. Cancers, Basel, 12:2492, 2020
   Krencz I, Vetlenyi E, Danko T, et al. Metabolic adaptation as potential target in papillary renal cell carcinomas based on their in situ metabolic characteristics. Int J Mol Sci 23:10587, 2022
   Petovari G, Danko T, Krencz I, et al. Inhibition of metabolic shift can decrease therapy resistance in human high-grade glioma cells. Pathol Oncol Res 26:23–33, 2020
   Felkai L, Krencz I, Kiss DJ, et al. Characterization of mTOR activity and metabolic profile in pediatric rhabdomyosarcoma. Cancers, Basel, 12:1947, 2020
   Mohas A, Krencz I, Varadi Z, et al. In situ analysis of mTORC1/C2 and metabolism- related proteins in pediatric osteosarcoma. Pathol Oncol Res 28:1610231, 2022
   Pocza T, Sebestyen A, Turanyi E, et al. mTOR pathway as a potential target in a subset of human medulloblastoma. Pathol Oncol Res 20:893–900, 2014
   Hujber Z, Petovari G, Szoboszlai N, et al. Rapamycin, mTORC1 inhibitor, reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. J Exp Clin Cancer Res 36:74, 2017
   Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424–430, 2006
   Gkountakos A, Pilotto S, Mafficini A, et al. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis 39:971–980, 2018
   Krencz I, Sebestyen A, Khoor A. mTOR in lung neoplasms. Pathol Oncol Res 26:35–48, 2020
   Jiang WJ, Feng RX, Liu JT, et al. RICTOR expression in esophageal squamous cell carcinoma and its clinical significance. Med Oncol 34:32, 2017
   Wazir U, Newbold RF, Jiang WG, et al. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer. Oncol Rep 29:1969–1974, 2013
   Driscoll DR, Karim SA, Sano M, et al. mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Res 76:6911–6923, 2016
   Joechle K, Guenzle J, Hellerbrand C, et al. Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. World J Gastrointest Oncol 13:1632–1647, 2021
   Jebali A, Battistella M, Lebbe C, et al. RICTOR affects melanoma tumorigenesis and its resistance to targeted therapy. Biomedicines 9:1498, 2021
   Bang H, Ahn S, Kim EJ, et al. Correlation between RICTOR overexpression and amplification in advanced solid tumors. Pathol Res Pract 216:152734, 2020
   Krencz I, Sebestyen A, Papay J, et al. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. Hum Pathol 93:74–80, 2019
   Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 20:755 2019
   Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4:476–495, 2011
   Chen B, Tan Z, Gao J, et al. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. J Exp Clin Cancer Res 34:126, 2015
   Ekman S, Wynes MW, Hirsch FR. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 7:947–953, 2012
   Spoerke JM, O’Brien C, Huw L, et al. Phosphoinositide 3-kinase, PI3K, pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 18:6771–6783, 2012
   Krencz I, Sebestyen A, Fabian K, et al. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. Hum Pathol 62:66–73, 2017
   Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol 12:425–436, 2017
   Krencz I, Sztankovics D, Danko T, et al. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations. Cancer Metastasis Rev 40:1141–1157, 2021
   Schmid K, Bago-Horvath Z, Berger W, et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103:622–628, 2010
   Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis, LAM): molecular insights lead to targeted therapies. Respir Med 104:S45– S58, 2010
   Henske EP, McCormack FX. Lymphangioleiomyomatosis – a wolf in sheep’s clothing. J Clin Invest 122:3807–3816, 2012
   Adachi K, Miki Y, Saito R, et al. Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis. Hum Pathol 46:1685–1693, 2015
   Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol 50:34–42, 2016
   Krencz I, Sebestyen A, Papay J, et al. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human lymphangioleiomyomatosis. Hum Pathol 79:199–207, 2018
   Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101, 2005
   Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15:273–291, 2018
   Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book 2013
   Sehgal SN, Baker H, Vezina C. Rapamycin, AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28:727–732, 1975
   Mao B, Zhiang Q, Ma L, et al. Overview of research into mTOR inhibitors. Molecules 27:5295, 2022
   Werfel TA, Wang S, Jackson MA, et al. Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival. Cancer Res 78:1845–1858, 2018
   Benavides-Serrato A, Lee J, Holmes B, et al. Specific blockade of Rictor- mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. PLoS One 12:e0176599, 2017
   Conciatori F, Ciuffreda L, Bazzichetto C, et al. mTOR cross-talk in cancer and potential for combination therapy. Cancers, Basel, 10:23, 2018
   Ali ES, Mitra K, Akter S, et al. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int 22:284, 2022
   Park S, Shim J, Mortimer PGS, et al. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum- based chemotherapy. Cancer 126:4002–4012, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 165
EP 180
PG 16
ER

PT J
AU Berta, J
   Ferencz, B
   Horvath, L
   Fillinger, J
   Lantos, A
   Bogos, K
   Renyi-Vamos, F
   Megyesfalvi, Zs
   Dome, B
AF Berta, Judit
   Ferencz, Bence
   Horvath, Lilla
   Fillinger, Janos
   Lantos, Andras
   Bogos, Krisztina
   Renyi-Vamos, Ferenc
   Megyesfalvi, Zsolt*
   Dome, Balazs
TI Small cell lung cancer heterogeneity and molecular subtypes: biological and clinical relevance
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE small cell lung cancer; heterogeneity; molecular subtypes; proteomics
ID small cell lung cancer; heterogeneity; molecular subtypes; proteomics
AB Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterised by genomic instability and early metastatic spread. Patients are typically diagnosed at advanced disease stage, when platinum-based chemotherapy with immunotherapy represents the standard therapeutic approach. The role of radiotherapy with concomitant systemic therapy is also well established in the management of SCLC patients. Although these therapeutic approaches are initially effective, most patients rapidly develop resistance. This clearly highlights the need to improve therapeutic efficacy and broaden the scope of current therapeutic strategies. Recent advances in the study of this disease, once considered homogeneous, have led to a new model of the SCLC classification scheme based on the relative expression of certain transcriptional regulators and inflammatory characteristics. New biological insights into the molecular subtypes of SCLC could lead to the implementation of subtype-specific therapeutic approaches. Here, we summarise our key findings concerning the biological and clinical relevance of SCLC molecular subtypes.
C1 [Berta, Judit] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Ferencz, Bence] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Horvath, Lilla] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Fillinger, Janos] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Lantos, Andras] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Megyesfalvi, Zsolt*] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
   [Dome, Balazs] National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1., 1121 Budapest, Hungary.
RP Berta, J (reprint author), National Koranyi Institute of Pulmonology, 1121 Budapest, Hungary.
EM berta.judit@koranyi.hu
CR Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17:765, 2017
   Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC – State of the art and what does the future have in store? Clin Lung Cancer 17:325–333, 2016
   Schwendenwein A, Megyesfalvi Z, Barany N, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics 20:470–483, 2021
   Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 7:3, 2021
   Ganti AKP, Loo BW, Bassetti M, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:1441–1464, 2021
   Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 2023,, DOI  10.3322/caac.21785
   Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer. J Oncol Pract 14:359–366, 2018
   Taniguchi H, Sen T, Rudin CM. Targeted therapies and biomarkers in small cell lung cancer. Front Oncol 10:741, 2020
   Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19:289–297, 2019
   Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol 15:1823–1835, 2020
   Borromeo MD, Savage TK, Kollipara RK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep 16:1259–1272, 2016
   Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 45:2924–2930, 1985
   George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524:47–53, 2015
   Mollaoglu G, Guthrie MR, Bohm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell 31:270–285, 2017
   Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915–928, 2018
   Caeser R, Egger JV, Chavan S, et al. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nat Commun 13:2144, 2022
   Megyesfalvi Z, Barany N, Lantos A, et al. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol 257:674–686, 2022
   Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39:346–360, 2021
   Bai R, Lv Z, Xu D, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Res 8:34, 2020
   Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542–e551, 2016
   McColl K, Wildey G, Sakre N, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget 8:73745–73756, 2017
   Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24:70–76, 2006
   Welter S, Aigner C, Roesel C. The role of surgery in high grade neuroendocrine tumours of the lung. J Thorac Dis 9:S1474–S1483, 2017
   Furuta M, Sakakibara-Konishi J, Kikuchi H, et al. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer, HOT1702). Oncologist 24:e1172–e1179, 2019
   Kosari F, Ida CM, Aubry MC, et al. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene 33:3776–3783, 2014
   Dora D, Rivard C, Yu H, et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. Mol Oncol 14:1947–1965, 2020
   Gazdar A. Molecular phenotypes of SCLC, in International Association for the Study of Lung Cancer – 19th World Conference on Lung Cancer. JTO: Toronto, September 23–26, 2018
   Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody- drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7:302ra136, 2015
   Zhang W, Girard L, Zhang YA, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32–49, 2018
   Picard Leblanc G, Blais N, Tehfe M, et al. Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data. J Clin Oncol 37:e20082, 2019
   Ito T, Matsubara D, Tanaka I, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci 107:1527–1538, 2016
   Thng DKH, Toh TB, Chow EK. Capitalizing on synthetic lethality of MYC to treat cancer in the digital age. Trends Pharmacol Sci 42:166–182, 2021
   Szeitz B, Megyesfalvi Z, Woldmar N, et al. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer. Clin Transl Med 12:e1060, 2022
   Denny SK, Yang D, Chuang CH, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 166:328–342, 2016
   Arriola E, Canadas I, Arumi M, et al. Genetic changes in small cell lung carcinoma. Clin Transl Oncol 10:189–197, 2008
   Mori N, Yokota J, Akiyama T, et al. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5:1713–1717, 1990
   Wistuba, II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3–13, 2001
   Ghandi M, Huang FW, Jane-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503–508, 2019
   Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14:549–561, 2017
   Guillemot F, Hassan BA. Beyond proneural: emerging functions and regulations of proneural proteins. Curr Opin Neurobiol 42:93–101, 2017
   Cargill KR, Stewart CA, Park EM, et al. Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer Metab 9:33, 2021
   Sica V, Bravo-San Pedro JM, Stoll G, et al. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int J Cancer 146:10–17, 2020
   Liao Y, Yin G, Wang X, et al. Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis. Oncol Lett 18:3723–3733, 2019
   Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196, 2014
   Hwang JJ, Choi SY, Koh JY. The role of NADPH oxidase, neuronal nitric oxide synthase and poly(ADP ribose, polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin- 4/5. J Neurochem 82:894–902, 2002
   Griffin N, Faulkner S, Jobling P, et al. Targeting neurotrophin signaling in cancer: The renaissance. Pharmacol Res 135:12–17, 2018
   Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature 474:179–183, 2011
   Caeser R, Hulton C, Costa E, et al. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience 24:103224, 2021
   Tlemsani C, Pongor L, Elloumi F, et al. SCLC-CellMiner: A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures. Cell Rep 33:108296, 2020
   Chemi F, Pearce SP, Clipson A, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer 3:1260–1270, 2022
   Horie M, Saito A, Ohshima M, et al. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer Sci 107:1755–1766, 2016
   Paolucci L, Rozengurt E. Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C. Cancer Res 59:572–577, 1999
   Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19:279–290, 2013
   Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5:662–668, 1999
   Zhao P, Sun X, Li H, et al. c-Myc targets HDAC3 to suppress NKG2DL expression and innate immune response in N-type SCLC through histone deacetylation. Cancers, Basel, 14:457, 2022
   Chan JM, Quintanal-Villalonga A, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 39:1479–1496, 2021
   Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer, GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41:D955–961, 2013
   Lochmann TL, Floros KV, Naseri M, et al. Venetoclax is effective in smallcell lung cancers with high BCL-2 expression. Clin Cancer Res 24:360–369, 2018
   Schenk RL, Strasser A, Dewson G. BCL-2: Long and winding path from discovery to therapeutic target. Biochem Biophys Res Commun 482:459– 469, 2017
   Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol 8:180002, 2018
   Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2:798–811, 2012
   Anstee NS, Bilardi RA, Ng AP, et al. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Cell Death Differ 26:1316–1331, 2019
   Pan R, Ruvolo VR, Wei J, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor, -)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood 126:363–372, 2015
   Lochmann TL, Bouck YM, Faber AC. BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer. Oncoscience 5:218–219, 2018
   Juarez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context 8:212574, 2019
   Roberts AW, Stilgenbauer S, Seymour JF, et al. Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin Cancer Res 23:4527–4533, 2017
   Ben-Ezra JM, Kornstein MJ, Grimes MM, et al. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145:1036–1040, 1994
   Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer 17:399, 2017
   Zhang Q, Riley-Gillis B, Han L, et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7:51, 2022
   Valko Z, Megyesfalvi Z, Schwendenwein A, et al. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. Br J Cancer 128:1850–1861, 2023
   Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A 111:14788–14793, 2014
   Costanzo F, Martinez Diez M, Santamaria Nunez G, et al. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells. EMBO Mol Med 14:e14841, 2022
   Knelson EH, Patel SA, Sands JM. PARP inhibitors in small-cell lung cancer: rational combinations to improve responses. Cancers, Basel, 13:727, 2021
   Dutta C, Day T, Kopp N, et al. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res 72:4193–4203, 2012
   Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther 15:1132–1144, 2016
   Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58:1–17, 2017
   Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int 20:524, 2020
   Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123:4111–4119, 2014
   Yasuda Y, Ozasa H, Kim YH, et al. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L, expression. Cell Death Dis 11:177, 2020
   Wang Y, Wang Y, Fan X, et al. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. Biochem Biophys Res Commun 503:1214–1220, 2018
   Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33:905–917, 2019
   Prukova D, Andera L, Nahacka Z, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res 25:4455–4465, 2019
   Algarin EM, Diaz-Tejedor A, Mogollon P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica 105:e116–e120, 2020
   Seiller C, Maiga S, Touzeau C, et al. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. Cell Death Dis 11:316, 2020
   Siu KT, Huang C, Panaroni C, et al. BCL2 blockade overcomes MCL1 resistance in multiple myeloma. Leukemia 33:2098–2102, 2019
   Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538:477–482, 2016
   Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202–208, 2013
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 181
EP 192
PG 12
ER

PT J
AU Dank, M
   Herold, M
   Garay, TM
   Gajdacsi, J
   Herold, Z
   Szasz, AM
AF Dank, Magdolna
   Herold, Magdolna
   Garay, Tamas Marton
   Gajdacsi, Jozsef
   Herold, Zoltan
   Szasz, Attila Marcell
TI Electromagnetic procedures in the treatment of pancreatic cancer: eminent or resentful?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE concomitant therapy; modulated electro-hyperthermia; pancreatic neoplasms; survival analysis
ID concomitant therapy; modulated electro-hyperthermia; pancreatic neoplasms; survival analysis
AB The treatment of advanced-stage pancreatic cancers is limited. Previous studies have found that the use of modulated electro-hyperthermia (mEHT) is beneficial in this patient population. However, there is no data on the optimal treatment number and initiation period. Therefore, a retrospective study was conducted with the inclusion of 96 mEHT-treated and 86 age- and sex-matched control pancreatic cancer patients. 76, 57, 38 and 33 patient pairs were enrolled into propensity score matched cohorts, whether they received at least 10, 20, 30 and 40 mEHT treatments, respectively. The survival of patients with at least 30 (HR: 0.5011; p = 0.0041) and 40 (HR: 0.5048; p = 0.0085) mEHT treatments was significantly longer, median survival was almost twice as long (10 vs. 18 months). The introduction of mEHT had the greatest benefit in the first (HR: 0.5382; p = 0.0056) and second (HR: 0.7861; p = 0.0031) 6 months after diagnosis.
C1 [Dank, Magdolna] Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, Baross u. 23–26., 1085 Budapest, Hungary.
   [Herold, Magdolna] Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, Baross u. 23–26., 1085 Budapest, Hungary.
   [Garay, Tamas Marton] Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, Baross u. 23–26., 1085 Budapest, Hungary.
   [Gajdacsi, Jozsef] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Herold, Zoltan] Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, Baross u. 23–26., 1085 Budapest, Hungary.
   [Szasz, Attila Marcell] Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, Baross u. 23–26., 1085 Budapest, Hungary.
RP Szasz, AM (reprint author), Semmelweis University, 1st Department of Internal Medicine and Oncology, Oncology Profile, 1085 Budapest, Hungary.
EM szasz.attila.marcell@semmelweis.hu
CR Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 395:2008–2020, 2020
   Chin V, Nagrial A, Sjoquist K, et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 3:CD011044, 2018
   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 70:7–30, 2020
   Weniger M, Honselmann KC, Liss AS. The extracellular matrix and pancreatic cancer: a complex relationship. Cancers, Basel, 10:316, 2018
   Fan JQ, Wang MF, Chen HL, et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer 19:32, 2020
   Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–68, 2015
   Szmola R, Farkas G, Hegyi P, et al. Pancreasrak. A Magyar Hasnyalmirigy Munkacsoport bizonyitekon alapulo kezelesi iranyelvei. Orv Hetil 156:326– 339, 2015
   Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol 13:1109–1120, 2021
   Chichel A, Skowronek J, Kubaszewska M, Kanikowski M. Hyperthermia – description of a method and a review of clinical applications. Rep Pract Oncol Radiother 12:267–275, 2007
   Krenacs T, Meggyeshazi N, Forika G, et al. Modulated electro-hyperthermia- induced tumor damage mechanisms revealed in cancer models. Int J Mol Sci 21:6270, 2020
   Alshaibi HF, Al-Shehri B, Hassan B, et al. Modulated electrohyperthermia: a new hope for cancer patients. Biomed Res Int 2020:8814878, 2020
   Szasz AM, Minnaar CA, Szentmartoni G, et al. Review of the clinical evidences of modulated electro-hyperthermia, mEHT, method: an update for the practicing oncologist. Front Oncol 9:1012, 2019
   Fiorentini G, Sarti D, Casadei V, et al. Modulated electro-hyperthermia as palliative treatment for pancreatic cancer: a retrospective observational study on 106 patients. Integr Cancer Ther 18:1534735419878505, 2019
   Fiorentini G, Sarti D, Ranieri G, et al. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients. World J Clin Oncol 12:1064–1071, 2021
   Petenyi FG, Garay T, Muhl D, et al. Modulated electro-hyperthermic, mEHT, treatment in the therapy of inoperable pancreatic cancer patients – a single-center case-control study. Diseases 9:81, 2021
   Dani A, Varkonyi A, Magyar T, et al. Clinical study for advanced pancreas cancer treated by oncothermia. Oncothermia J 6:11–25, 2012
   Volovat C, Volovat S, Scripcaru V, Miron L. Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia, EHY-2000, in patients with refractory metastatic pancreatic cancer – preliminary results of a prospective trial. Romanian Rep Physics 66:166– 174, 2014
   Therneau T, Crowson C, Atkinson E. Using time dependent covariates and time dependent coefficients in the Cox model. https://cran.r-project. org/web/packages/survival/vignettes/timedep.pdf, 2023
   Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70, 1979
   Pang CLK, Zhang X, Wang Z, et al. Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial. Mol Clin Oncol 6:723–732, 2017
   Wismeth C, Dudel C, Pascher C, et al. Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed highgrade gliomas: phase I clinical results. J Neurooncol 98:395–405, 2010
   Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306– 2316, 2017
   Szasz AM, Arrojo Alvarez EE, et al. Meta-analysis of modulated electro- hyperthermia and tumor treating fields in the treatment of glioblastomas. Cancers 15:880, 2023
   Szasz AM, Szentmartoni G, Garay T, et al. Breast cancer series treated with modulated electro-hyperthermia, mEHT, – a single centre experience, Chapter 5). In: Challenges and Solutions of Oncological Hyperthermia, Ed. Szasz A, Cambridge Scholars Publishing 105, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 194
EP 201
PG 12
ER

PT J
AU Menyhart, O
   Fekete, JT
   Gyorffy, B
AF Menyhart, Otilia
   Fekete, Janos Tibor
   Gyorffy, Balazs
TI Increased activity of inflammation-related signaling pathways in anthracycline- paclitaxel resistant breast carcinomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE anthracyclin; paclitaxel; resistance; inflammation; innate immune response
ID anthracyclin; paclitaxel; resistance; inflammation; innate immune response
AB A frequently recommended systemic therapy for breast cancer involves a combination of anthracyclines and taxanes, however, approximately 30% of patients experience recurrence. We aimed to investigate the mechanisms of resistance to anthracycline-paclitaxel based treatment by analyzing gene expression patterns in tumor samples collected during surgery and subsequent therapeutic responses. A database of 187 patients with information about relapse-free survival (RFS) allowed the analysis of 10,017 genes. Patients were divided into responders and nonresponders based on whether relapse occurred within sixty months. The expression of each gene was compared between the two groups using the Mann–Whitney U-test, with a statistical significance set at p <0.05 and fold change (FC) ≥1.44. We identified 51 up-regulated genes among nonresponders, primarily associated with inflammatory processes and the innate immune response. The high expression of SLC7A5, encoding an amino acid transporter, was linked to worse overall survival (p = 2.3E-10), with elevated expression in tumors (p = 2.94E-20), and further increase in metastases (p = 1.33E-10). Our results emphasize the significance of tumor microenvironment and metabolism in therapy resistance. These findings may allow better patient classification and identification of relevant treatment targets.
C1 [Menyhart, Otilia] Semmelweis Egyetem, Bioinformatika Tanszek, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Fekete, Janos Tibor] Semmelweis Egyetem, Bioinformatika Tanszek, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Egyetem, Bioinformatika Tanszek, Tuzolto u. 7–9., 1094 Budapest, Hungary.
RP Gyorffy, B (reprint author), Semmelweis Egyetem, Bioinformatika Tanszek, 1094 Budapest, Hungary.
EM gyorffy.balazs@med.semmelweis-univ.hu
CR Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15–23, 2022
   Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 8:420–444, 2022
   Mesa-Eguiagaray I, Wild SH, Rosenberg PS, et al. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population- based study of Scottish cancer registry data. Br J Cancer 123:852–859, 2020
   Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin 72:524–541, 2022
   Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432– 444, 2012
   Anthracycline-containing and taxane-containing chemotherapy for early- stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet 401:1277–1292, 2023
   Beretta GL, Zunino F. Molecular mechanisms of anthracycline activity. Top Curr Chem 283:1–19, 2008
   Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3:193–203, 2003
   Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22, 2007
   Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9:827–836, 2003
   Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance, MDR1, P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389–398, 1998
   Pasquier J, Magal P, Boulange-Lecomte C, et al. Consequences of cellto- cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct 6:5, 2011
   Harbottle A, Daly AK, Atherton K, et al. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 92:777–783, 2001
   Guo B, Tam A, Santi SA, et al. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer 16:762, 2016
   Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811–814, 1996
   Liu Z, Gao J, Gu R, et al. Comprehensive analysis of transcriptomics and genetic alterations identifies potential mechanisms underlying anthracycline therapy resistance in breast cancer. Biomolecules 12:1834, 2022
   Knappskog S, Leirvaag B, Gansmo LB, et al. Prevalence of the CHEK2 R95* germline mutation. Hered Cancer Clin Pract 14:19, 2016
   Gautier L, Moller M, Friis-Hansen L, et al. Alternative mapping of probes to genes for Affymetrix chips. BMC Bioinformatics 5:111, 2004
   Li Q, Birkbak NJ, Gyorffy B, et al. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 12:474, 2011
   Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods 12:115–121, 2015
   Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists, 2021 update). Nucleic Acids Res 50:W216–w221, 2022
   Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research, KMplot): development and implementation. J Med Internet Res 23:e27633, 2021
   Bartha A, Gyorffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 22:2622, 2021
   van den Ende NS, Nguyen AH, Jager A, et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci 24:2969, 2023
   Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121, 2022
   Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444, 2009
   Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100:926–939, 2008
   Nguyen PH, Fedorchenko O, Rosen N, et al. LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia. Cancer Cell 30:610–622, 2016
   Vom Stein AF, Rebollido-Rios R, Lukas A, et al. LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1. Nat Commun 14:1330, 2023
   Choi YL, Bocanegra M, Kwon MJ, et al. LYN is a mediator of epithelial- mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70:2296–2306, 2010
   Dou T, Fu M, Wang Y, et al. Signatures of positive selection in LY96 gene in vertebrates. J Biosci 38:899–904, 2013
   Bist P, Shu S, Lee H, et al. Annexin-A1 regulates TLR-mediated IFN-β production through an interaction with TANK-binding kinase 1. J Immunol 191:4375–4382, 2013
   Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45:e66, 2013
   Wang Y, Luo W, Han J, et al. MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. Nat Commun 11:2148, 2020
   Yang Y, Sheng Y, Wang J, et al. Aureusidin derivative CNQX inhibits chronic colitis inflammation and mucosal barrier damage by targeting myeloid differentiation 2 protein. J Cell Mol Med 25:7257–7269, 2021
   Rychkov D, Neely J, Oskotsky T, et al. Cross-tissue transcriptomic analysis leveraging machine learning approaches identifies new biomarkers for rheumatoid arthritis. Front Immunol 12:638066, 2021
   Rajamanickam V, Yan T, Xu S, et al. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis. Int J Biol Sci 16:1288–1302, 2020
   Zheng S, Fu W, Ma R, et al. Suppression of MD2 inhibits breast cancer in vitro and in vivo. Clin Transl Oncol 23:1811–1817, 2021
   Dibaba DT, Ogunsina K, Braithwaite D, et al. Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype. Breast Cancer Res Treat 174:209–218, 2019
   Bond P. Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance. J Int Soc Sports Nutr 13:8, 2016
   El Ansari R, Craze ML, Miligy I, et al. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Res 20:21, 2018
   Saito Y, Soga T. Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci 112:2958–2965, 2021
   Sato M, Harada-Shoji N, Toyohara T, et al. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Sci Rep 11:589, 2021
   Liu Y, Ma G, Liu J, et al. SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironment. Heliyon 8:e10866, 2022
   Ciocan-Cartita CA, Jurj A, Zanoaga O, et al. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells. J Exp Clin Cancer Res 39:241, 2020
   Chou CW, Huang YM, Chang YJ, et al. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer. Int J Med Sci 18:2521–2531, 2021
   Christowitz C, Davis T, Isaacs A, et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer 19:757, 2019
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 203
EP 212
PG 10
ER

PT J
AU Vizkeleti, L
   Ladanyi, A
   Papp, O
   Doma, V
   Karpati, S
   Raso, E
   Barbai, T
   Timar, J
AF Vizkeleti, Laura
   Ladanyi, Andrea
   Papp, Orsolya
   Doma, Viktoria
   Karpati, Sarolta
   Raso, Erzsebet
   Barbai, Tamas
   Timar, Jozsef
TI Potential role of type I interferon in the genetic progression of melanoma
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cutaneous melanoma; visceral metastasis; genomics; type I interferon resistance
ID cutaneous melanoma; visceral metastasis; genomics; type I interferon resistance
AB We have followed the genomic progression of cutaneous melanoma in visceral metastases using genome-wide copy number analysis. We have detected an increased chromosomal instability due to the loss of several DNA repair genes. Furthermore, we found co-amplifications of HGF and MET genes in metastases. The most interesting finding was gene amplifications of several, mostly IFN-regulated immune cell genes in lung metastases. Next we have defined a type I IFN resistance gene expression signature (GES) using human cell lines, several elements of which were proved to be stable in vitro and in vivo as well. The components of this GES have been detected in TCGA as well as in publicly available datasets of immunotherapy-treated melanoma cases. In case of samples from previously IFN-treated melanoma cases we have identified treatment-specific genomic alterations (predominantly amplifications) which were most characteristic for brain metastases.
C1 [Vizkeleti, Laura] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Orsolya] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Doma, Viktoria] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Karpati, Sarolta] Semmelweis University, Department of Dermatology, Venereology and DermatooncologyBudapest, Hungary.
   [Raso, Erzsebet] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Barbai, Tamas] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Timar J, Ladanyi A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction. Int J Mol Sci 23:5384, 2022
   Doma V, Karpathy S, Raso E, et al. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer 19:786, 2019
   Timar J, Vizkeleti L, Doma V, et al. Genetic progression of malignant melanoma. Cancer Metastasis Rev 35:93–107, 2016
   Papp O, Doma V, Gil J, et al. Organ specific copy number variations in visceral metastases of human melanoma. Cancers 13:5984, 2021
   Pipek O, Vizkeleti L, Doma V, et al. The driverless triple-wild type, BRAF, RAS, KIT, cutaneous melanoma: whole genome sequencing discoveries. Cancers 15:1712, 2023
   Ladanyi A, Raso E, Barbai T, et al. Identification of a tumor cell associated type I IFN resistance gene expression signature of human melanoma, the components of which have a predictive potential for immunotherapy. Int J Mol Sci 23:2704, 2022
   Grasso CS, Tsol J, Onyschenko M, et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 38:500–515, 2020
   Hargadon K, Gyorffy B, McGee TJ. Genomic and transcriptional chnages in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunothetrapy in melanoma patients. Exp Rev Clin Immunol 16:1099–1103, 2020
   Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analysis from the OpaCIN-neo and OpaCIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27:256–263, 2021
   Diossy M, Reiniger L, Sztupinszki Z, et al. Breast cancer brain metastases show incrased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol 29:1948–1954, 2018
   Kim KB, Soroceanu L, de Semir D, et al. Prevalence of homologous recombination pathway gene mutations in melanoma. J Invest Dermatol 141:2028–2036, 2021
   Timar J, Honn KV, Hendrix MJC, et al. Newly indentified form of phenotypic plasticity of cancer: immunogenic mimicry. Cancer Metastasis Rev 42:323–334, 2023
   Betancourt LH, Gil J, Sanchez A, et al. The human melanoma proteome atlas – complementing the melanoma transcriptome. Clin Transl Med 11:e451, 2021
   Betancourt LH, Gil J, Kim Y, et al. The human melanoma proteome atlas – defining the molecular pathology. Clin Transl Med 11:e473, 2021
   Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450– 461, 2015
   Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 22:1856–1864, 2016
   Di Trolio R, Simeone E, Di Lorenzo G, et al. The use of interferon in melanoma patients. Cytokine Growth Factor Rev 26:203–212, 2015
   Katlinskaya YV, Katlinsky KV, Yu Q, et al. Suppression of type I IFN signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep 15:171–180, 2016
   Hoekstra ME, Bornes L, Dijkfraaf FE, et al. Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFNγ. Nat Cancer 1:291–301, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 215
EP 221
PG 7
ER

PT J
AU Baranyi, M
   Hegedus, B
   Molnar, E
   Tovari, J
   Randelovic, I
   Perczel, A
   Buday, L
   Keseru, Gy
   Timar, J
AF Baranyi, Marcell
   Hegedus, Balazs
   Molnar, Eszter
   Tovari, Jozsef
   Randelovic, Ivan
   Perczel, Andras
   Buday, Laszlo
   Keseru, Gyorgy
   Timar, Jozsef
TI Farnesyltransferase inhibitors have antitumoral effects in mutant KRAS containing cancer cells in preclinical models
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE farnesyltrasferase inhibitor; combination therapy; preclinical tumor models
ID farnesyltrasferase inhibitor; combination therapy; preclinical tumor models
AB In silico studies raised the possibility that farnesyltransferase inhibitors (FTIs) may have antitumoral effects on KRAS mutant cancer cells. Accordingly, we have tested FTIs (tipifarnib and lonafarnib) in G12C mutant human cancer cell lines in vitro and in vivo. We have discovered that the combination of the two drugs has a synergistic antitumoral effect. Next, we have tested FTIs on G12D mutant human cancer cell lines and found that the combination has antitumoral effect in various preclinical cancer models. At last, we have also tested FTIs on G12V mutant human cancer cells and again we have detected antitumoral effects. We suggest that FTIs may have clinical relevance outside the HRAS mutant cancers.
C1 [Baranyi, Marcell] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Hegedus, Balazs] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Molnar, Eszter] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
   [Tovari, Jozsef] National Institute of OncologyBudapest, Hungary.
   [Randelovic, Ivan] National Institute of OncologyBudapest, Hungary.
   [Perczel, Andras] Eotvos Lorand University, Faculty of Science, Institute of Chemistry, Department of Organic ChemistryBudapest, Hungary.
   [Buday, Laszlo] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Keseru, Gyorgy] Eotvos Lorand Kutatasi Halozat, Enzimologiai IntezetBudapest, Hungary.
   [Timar, Jozsef] Semmelweis University, 2nd Department of Pathology, Ulloi ut 93., 1091 Budapest, Hungary.
RP Timar, J (reprint author), Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Hungary.
EM jtimar@gmail.com
CR Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev 39:1029–1033, 2020
   Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 19:533–552, 2020
   Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C, inhibition with sotorasib in advanced solid tumors. N Engl J Med 383:1207–1217, 2020
   Nakajima EC, Drezner N, Li X, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 28:1482–1486, 2022
   Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small cell lung cancer harboring a KRASG12C mutation. N Engl J Med 387:120–131, 2022
   Dunnett-Kane V, Nicola P, Blackhall F, et al. Mechanisms of resistance to KRAS(G12C, inhibitors. Cancers 13:151, 2021
   Nagasaka M, Potugai B, Nguyen A, et al. KRAS inhibitors – yes but what next? Direct targeting of KRAS – vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev 101:102309, 2021
   Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D, inhibitor. J Med Chem 65:3123–3133, 2021
   Hoffmann MH, Galah D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov 12:924–937, 2022
   Tran TH, Alexander P, Dharmaiah S, et al. The small molecule BI-2852 induces a nonfunctional dimer of KRAS. Proc Natl Acad Sci USA 117:3363– 3364, 2020
   Hillig RC, Santier B, Schroeder J, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci USA 116:2551–2560, 2019
   Ho AL, Brana I, Haddad R, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 39:1856–1864, 2021
   Dhillon S. Lonafarnib: first approval. Drugs 82:283–289, 2021
   Lee HW, Sa JK, Gualberto A, et al. A phase II trial for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutation. Clin Cancer Res 26:5113–5119, 2020
   Lietman CD, Johnson ML, McCormick FM, Lindsay CR. More to the RAS story: KRASG12C inhibition, resistance mechanisms and moving beyond KRASG12C. 2022 ASCO Educational Book 351333:1–13, 2022
   Kenessey I, Koi K, Horvath O, et al. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell lung cancer preclinical models. Oncotarget 7:79503–79514, 2016
   Radeczky P, Megyesfalvi Z, Laszlo V, et al. The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. Transl Lung Cancer Res 10:675–684, 2021
   Baranyi M, Buday L, Hegedus B. K-RAS prenylation as a potential anticancer target. Cancer Metastasis Rev 39:127–141, 2020
   Rittler D, Baranyi M, Molnar E, et al. The antitumor effect of lipophylic bisphosphonate BHP1222 in melanoma models: the role of the PI3K/AKT pathway and the small G protein RHEB. Int J Mol Sci 20:4917, 2019
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 223
EP 235
PG 13
ER

PT J
AU Moldvai, D
   Sztankovics, D
   Danko, T
   Szalai, F
   Miyaura, R
   Petovari, G
   Krencz, I
   Gelencser, R
   Sebestyen, A
AF Moldvai, Dorottya
   Sztankovics, Daniel
   Danko, Titanilla
   Szalai, Fatime
   Miyaura, Risa
   Petovari, Gabor
   Krencz, Ildiko
   Gelencser, Rebeka
   Sebestyen, Anna
TI Effects of 3D tissue structure on drug sensitivity – 3D bioprinted tissue mimetic structures in cancer research
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cancer; in vitro test; bioprinting; 3D cell culture; drug development
ID cancer; in vitro test; bioprinting; 3D cell culture; drug development
AB The issues surrounding the cost effectiveness of drug development and the ethical concerns associated with animal testing, emphasise the necessity for innovative in vitro models that allow enhanced pre-selection. Therefore, we aim to create 3D bioprinted tissue mimetic structures (TMS) utilizing various human cancer cell lines. We have generated TMSs from human tumour cell lines (breast, kidney, glioma), with detailed characterisation of the ZR75.1 cell line. In this study, the tissue heterogeneity, the growth rate, and the drug sensitivity of different in vitro and in vivo models were compared. Tissue formation occurs within the TMS after one week, with a tissue heterogeneity similar to in vivo growing tumours. Moreover, TMSs exhibit similar drug sensitivity to that observed in vivo. In summary, the established 3D bioprinted TMSs represent an advanced in vitro model, which can contribute to achieve a more effective and ethical drug development process in the field of oncology.
C1 [Moldvai, Dorottya] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Sztankovics, Daniel] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Danko, Titanilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Szalai, Fatime] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Miyaura, Risa] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Petovari, Gabor] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Krencz, Ildiko] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Gelencser, Rebeka] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Sebestyen, Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Sebestyen, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM hsebanna@gmail.com
CR Deloitte Centre for Health Solutions. Seize the digital momentum. Measuring the return from pharmaceutical innovation 2022. https://www2.deloitte. com/content/dam/Deloitte/uk/Documents/life-sciences-health-care/ deloitte-uk-seize-digital-momentum-rd-roi-2022.pdf
   IQVIA Institute. Global Oncology Trends 2022. https://www.iqvia.com/insights/ the-iqvia-institute/reports/global-oncology-trends-2022
   Roser M, Ritchie H. Cancer. https://ourworldindata.org/cancer
   European Parliament. E. Regulation, EC, No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, recast,, Text with EEA relevance). 2009
   Ritskes-Hoitinga M. Medical regulators: look beyond animal tests. Nature 604:599, 2022
   Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49:1567–1575, 2017
   Rodrigues J, Heinrich MA, Teixeira LM, et al. 3D in vitro model, r)evolution: unveiling tumor-stroma interactions. Trends Cancer 7:249–264, 2021
   Law AMK, Rodriguez de la Fuente L, Grundy TJ, et al. Advancements in 3D cell culture systems for personalizing anti-cancer therapies. Front Oncol 11:782766, 2021
   Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 32:760–772, 2014
   Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 13:4, 2020
   Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 20:273–286, 2019
   Deloitte M. Early Value Assessment 2020. https://www2.deloitte. com/content/dam/Deloitte/be/Documents/life-sciences-health-care/Deloitte% 20Belgium_Early%20Value%20Assessment.pdf
   Pozzi S, Scomparin A, Israeli Dangoor S, et al. Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development? Adv Drug Deliv Rev 175:113760, 2021
   Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer 19:65–81, 2019
   Tang Y, Soroush F, Sheffield JB, et al. A biomimetic microfluidic tumor microenvironment platform mimicking the EPR effect for rapid screening of drug delivery systems. Sci Rep 7:9359, 2017
   Neufeld L, Yeini E, Reisman N, et al. Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment. Sci Adv 7:eabi9119, 2021
   Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat Rev Genet 19:671–687, 2018
   Yi HG, Jeong YH, Kim Y, et al. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat Biomed Eng 3:509–519, 2019
   Rijal G, Li W. A versatile 3D tissue matrix scaffold system for tumor modeling and drug screening. Sci Adv 3:e1700764, 2017
   Utama RH, Tan VTG, Tjandra KC, et al. A covalently crosslinked ink for multimaterials drop-on-demand 3D bioprinting of 3D cell cultures. Macromol Biosci 21:e2100125, 2021
   Danko T, Petovari G, Raffay R, et al. Characterisation of 3D bioprinted human breast cancer model for in vitro drug and metabolic targeting. Int J Mol Sci 23:7444, 2022
   Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81–94, 2018
   Chae S, Ha DH, Lee H. 3D bioprinting strategy for engineering vascularized tissue models. Int J Bioprint 9:748, 2023
   You S, Xiang Y, Hwang HH, et al. High cell density and high-resolution 3D bioprinting for fabricating vascularized tissues. Sci Adv 9:eade7923, 2023
   Gilmore AC, Flaherty SJ, Somasundaram V, et al. An in vitro tumorigenesis model based on live-cell-generated oxygen and nutrient gradients. Commun Biol 4:477, 2021
   Grunewald L, Lam T, Andersch L, et al. A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization. Front Immunol 12:689697, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 237
EP 246
PG 10
ER

PT J
AU Huszty, G
   Bihari, L
   Graf, L
   Szijarto, A
   Mate, Sz
AF Huszty, Gergely
   Bihari, Laszlo
   Graf, Laszlo
   Szijarto, Attila
   Mate, Szabolcs
TI Surgery of peritoneal surface malignancies – surgical cytoreduction and hyperthermic intraperitoneal chemotherapy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE peritoneal carcinosis; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; HIPEC; pseudomyxoma
ID peritoneal carcinosis; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; HIPEC; pseudomyxoma
AB Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers – the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies.
C1 [Huszty, Gergely] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Bihari, Laszlo] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Graf, Laszlo] Semmelweis University, Department of Internal Medicine and HaematologyBudapest, Hungary.
   [Szijarto, Attila] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Mate, Szabolcs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati KlinikaBudapest, Hungary.
RP Huszty, G (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM ghuszty@gmail.com
CR Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 134:247– 264, 2007
   Toth LB, Bartok R, Bogdan Rajcs S, Szigligeti G. A cytoreductiv sebeszet es hyperthermias intraperitonealis chemotherapia szerepe a peritoneum malignus elvaltozasainak kezeleseben. Magy Seb 68:225–230, 2015
   Govaerts K, Lurvink RJ, De Hingh IHJT, et al.; PSOGI. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 47:11–35, 2021
   Bushati M, Rovers KP, Sommariva A, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International, PSOGI). Eur J Surg Oncol 44:1942–1948, 2018
   Zarnescu EC, Zarnescu NO, Costea R. Updates of risk factors for anastomotic leakage after colorectal surgery. Diagnostics, Basel, 11:2382, 2021
   Wiseman JT, Kimbrough C, Beal EW, et al. Predictors of anastomotic failure after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: does technique matter? Ann Surg Oncol 27:783–792, 2020
   Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374, 1996
   Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 199:642.e1–6, 2008
   Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 12:649–671, 2003
   Hobeika C, Sabbagh C, Najah H, Eveno C. Laparoscopic exploration for peritoneal carcinomatosis: Surgical technique. J Visc Surg 154:430–435, 2017
   Rosendahl M, Harter P, Bjorn SF, Hogdall C. Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28:316–322, 2018
   Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 255:348–356, 2012
   Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 156:e206363, 2021
   Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg 272:847–854, 2020
   Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292, 2004
   Mishra M, Singh N, Ghatage P. Past, present, and future of hyperthermic intraperitoneal chemotherapy, HIPEC, in ovarian cancer. Cureus 13:e15563, 2021
   Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 10:550–558, 2009
   https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Sipos N, Szantho A, Mate Sz, et al. A hasuregi kemoterapia helye a petefeszekrak ellatasaban. Nogyogy Onkol 19:3–5, 2014
   Laplace N, Kepenekian V, Friggeri A, et al. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy, HIPEC, with Cisplatin. Int J Hyperthermia 37:897–902, 2020
   McConnell YJ, Mack LA, Francis WP, et al. HIPEC + EPIC versus HIPECalone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 107:591–596, 2013
   Sugarbaker PH, Stuart OA. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study. Surg Oncol 35:441–446, 2020
   Leiting JL, Day CN, Harmsen WS. The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. Int J Hyperthermia 37:1182–1188, 2020
   Fung X, Li IC, Chandrakumaran K. Early postoperative intraperitoneal chemotherapy, EPIC, following cytoreductive surgery, CRS, and hyperthermic intraperitoneal chemotherapy, HIPEC, in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience. Eur J Surg Oncol 48:1614–1618, 2022
   https://gco.iarc.fr/today/home
   https://www.qub.ac.uk/research-centres/nicr/CancerInformation/official- statistics/BySite/Ovariancancer/
   Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104, 1975
   Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom, AGO-OVAR, and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire, GINECO). Cancer 115:1234–1244, 2009
   Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup, GCIG, consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750–755, 2011
   https://seer.cancer.gov/statfacts/html/ovary.html/
   Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953, 2010
   van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240, 2018
   Lim MC, Chang S, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg 157:374–383, 2022
   Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol 29:2617–2625, 2022
   Lei Z, Wang Y, Wang J, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open 3:e2013940, 2020
   Filis P, Mauri D, Markozannes G, et al. Hyperthermic intraperitoneal chemotherapy, HIPEC, for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open 7:100586, 2022
   Souadka A, Essangri H, Majbar MA, et al. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in ovarian cancer: an umbrella review of meta-analyses. Front Oncol 12:809773, 2022
   Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–1575, 2015
   Zivanovic O, Chi DS, Zhou Q, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study. J Clin Oncol 39:2594–2604, 2021
   Koole S, van Stein R, Sikorska K, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy, HIPEC, for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 30:888–892, 2020
   https://clinicaltrials.gov/ct2/show/NCT05659381
   Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg 30:233–280, 1996
   Ye S, Zheng S. Comprehensive understanding and evolutional therapeutic schemes for pseudomyxoma peritonei: a literature review. Am J Clin Oncol 45:223–231, 2022
   Carr NJ, Cecil TD, Mohamed F, et al. A Consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International, PSOGI, modified Delphi process. Am J Surg Pathol 40:14–26, 2016
   Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer 126:2525–2533, 2020
   Vaira M, Robella M, Guaglio M, et al. Diagnostic and therapeutic algorithm for appendiceal tumors and pseudomyxoma peritonei: a consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology, SICO). Cancers, Basel, 15:728, 2023
   Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6:727– 731, 1999
   Guaglio M, Sinukumar S, Kusamura S, et al. Clinical surveillance after macroscopically complete surgery for low-grade appendiceal mucinous neoplasms, LAMN, with or without limited peritoneal spread: long-term results in a prospective series. Ann Surg Oncol 25:878–884, 2018
   Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population- based study. Eur J Surg Oncol 34:196–201, 2008
   Fournier K, Rafeeq S, Taggart M, et al. Low-grade appendiceal mucinous neoplasm of uncertain malignant potential, LAMN-UMP): prognostic factors and implications for treatment and follow-up. Ann Surg Oncol 24:187–193, 2017
   Foster JM, Sleightholm RL, Wahlmeier S, et al. Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. World J Surg Oncol 14:243, 2016
   Esquivel J, Averbach A. Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin. Gastroenterol Res Pract 2012:981245, 2012
   Arjona-Sanchez A, Esquivel J, Glehen O, et al. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy, HIPEC, in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies, ASPSM, multi-institution analysis. Surg Endosc 33:854–860, 2019
   Govaerts K, Chandrakumaran K, Carr NJ, et al. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei. Eur J Surg Oncol 44:1371–1377, 2018
   Moran B, Baratti D, Yan TD, et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination, pseudomyxoma peritonei). J Surg Oncol 98:277–282, 2008
   Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456, 2012
   Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 219:112–119, 1994
   Ahmadi N, Kostadinov D, Sakata S, et al. Managing recurrent pseudomyxoma peritonei in 430 patients after complete cytoreduction and HIPEC: A dilemma for patients and surgeons. Ann Surg Oncol 28:7809–7820, 2021
   Grotz TE, Overman MJ, Eng C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for moderately and poorly differentiated appendiceal adenocarcinoma: survival outcomes and patient selection. Ann Surg Oncol 24:2646–2654, 2017
   Reddy S, Punjala SR, Allan P, et al. First report with medium term follow up of intestinal transplantation for advanced and recurrent non-resectable pseudomyxoma peritonei. Ann Surg 277:835–840, 2022
   Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705, 2012
   Chang GJ, Kaiser AM, Mills S, et al. Practice parameters for the management of colon cancer. Dis Colon Rectum 55: 831–843, 2012
   Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267, 2012
   Verwaal V, Ruth S, Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743, 2003
   Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292, 2004
   Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68, 2010
   Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065– 1071, 2013
   Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy, HIPEC, for peritoneal metastasis from colorectal cancer. J Clin Med 7:567, 2018
   Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis 19:224– 236, 2017
   Leitlinienprogramm Onkologie. S3-Leitlinie Kolorektales Karzinom. Berlin, Krebsgesellschaft, www.awmf.org 2014
   Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516, 2012
   Di Carlo S, Cavallaro G, La Rovere F, et al. Synchronous liver and peritoneal metastases from colorectal cancer: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option? Front Surg 9:1006591, 2022
   Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases, PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:256–266, 2021
   Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685, 2009
   Sommariva A, Tonello M, Coccolini F, et al. Colorectal cancer with peritoneal metastases: the impact of the results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 trials on peritoneal disease management. Cancers, Basel, 15:165, 2022
   Sugarbaker PH, Ghabra S. Protocols versus practice in the management of colorectal peritoneal metastases. J Surg Oncol 125:1200–1201, 2022
   Ghabra S, Desale S, Sugarbaker PH. Clinical and histopathologic features of 35 patients treated for colorectal peritoneal metastases who survived 5 years. Dis Colon Rectum 28:e002448, 2023
   Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer, COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4:761–770, 2019
   Goere D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases, PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol 21:1147–1154, 2020
   Van de Vlasakker VCJ, Lurvink RJ, Cashin PH, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International, PSOGI). Eur J Surg Oncol 47:2888–2892, 2021
   Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10–32, 2023
   Pereira F, Serrano A, Manzanedo I, et al. GECOP‑MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy, HIPEC, with mytomicin‑C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer 22:536, 2022
   Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71:209–249, 2021
   Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 22:1114, 2016
   Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42:1123–1131, 2016
   Newhook TE, Agnes A, Blum M, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol 26:1394– 1400, 2019
   Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol 23:1971–1979, 2016
   Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17:2370–2377, 2010
   Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases, CYTO-CHIP study): A propensity score analysis. J Clin Oncol 37:2028–2040, 2019
   Patel M, Arora A, Mukherjee D, Mukherjee S. Effect of hyperthermic intraperitoneal chemotherapy, HIPEC, on survival and recurrence rates in advanced gastric cancer – a systematic review and meta-analysis. Int J Surg 109:2435–2450, 2023
   Rau B, Lang H, Konigsrainer A, et al. The effect of hyperthermic intraperitoneal chemotherapy, HIPEC, upon cytoreductive surgery, CRS, in gastric cancer, GC, with synchronous peritoneal metastasis, PM): A randomized multicentre phase III trial, GASTRIPEC-I-trial). Ann Oncol 32(Suppl 5):S1040, 2021
   Bonnot PE, Lintis A, Mercier F, et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy, CYTO-CHIP study). Br J Surg 108:1225–1235, 2021
   Khan H, Johnston FM. Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J Surg Oncol 125:1176–1182, 2022
   Lei Z, Wang J, Li Z, et al. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity scorematched cohort study. Chin J Cancer Res 32:794–803, 2020
   Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy, PIPAC, with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 20:367–373, 2016
   Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237, 1988
   Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14:183, 2014
   Brandl A, Yonemura Y, Glehen O, et al. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. Eur J Surg Oncol 47:172–180, 2021
   Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30:19–33, 2019
   Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 47:36–59, 2021
   Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22:1686–1693, 2015
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 247
EP 258
PG 8
ER

PT J
AU Bodor, Cs
   Alpar, D
   Batai, B
   Laszlo, T
AF Bodor, Csaba
   Alpar, Donat
   Batai, Bence
   Laszlo, Tamas
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Letter
C1 [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Alpar, Donat] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Batai, Bence] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Laszlo, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
RP Bodor, Cs (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, 1085 Budapest, Hungary.
EM bodor.csaba1@semmelweis.hu
CR Bodor C, Renneville A, Smith M, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica 97:890–894, 2012
   Tawana K, Wang J, Kiraly PA, et al. Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree. Eur J Hum Genet 25:1020–1024, 2017
   Al Seraihi AF, Rio-Machin A, Tawana K, et al. GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. Leukemia 32:2502–2507, 2018
   Armes H, Rio-Machin A, Krizsan S, et al. Acquired somatic variants in inherited myeloid malignancies. Leukemia 36:1377–1381, 2022
   Tawana K, Wang J, Renneville A, et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126:1214–1223, 2015
   Homan CC, Drazer MW, Yu K, et al. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Adv, 2023,, DOI  10.1182/bloodadvances.2023010045
   Homan CC, King-Smith SL, Lawrence DM, et al. The RUNX1 database, RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica 106:3004–3007, 2021
   Kotmayer L, Romero-Moya D, Marin-Bejar O, et al. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. Br J Haematol 199:482–495, 2022
   Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, et al. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. Haematologica 108:2551–2557, 2023
   Rio-Machin A, Vulliamy T, Hug N, et al. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun 11:1044, 2020
   Gango A, Mozes R, Boha Z, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res 65:42–48, 2018
   Mozes R, Gango A, Sulak A, et al. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. Pathology 51:301–307, 2019
   Batai B, Levai D, Gaal-Weisinger J, et al. A szemelyre szabott terapia uj lehetosege follicularis lymphomaban – Az EZH2 hiszton metil-transzferaz gatlasa. Hematologia–Transzfuziologia 51:61–70, 2018
   Bodor C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122:3165–3168, 2013
   Nagy A, Batai B, Kiss L, et al. Folyadekbiopszia-vizsgalatok alkalmazasi lehetosegei az onkohematologiaban. Hematologia–Transzfuziologia 53:144– 156, 2020
   Bodor C, Alpar D, Marosvari D, et al. Molecular subtypes and genomic profile of primary central nervous system lymphoma. J Neuropathol Exp Neurol 79:176–183, 2020
   Sebestyen E, Nagy A, Marosvari D, et al. Distinct miRNA expression signatures of primary and secondary central nervous system lymphomas. J Mol Diagn 24:224–240, 2022
   Nagy A, Batai B, Balogh A, et al. Quantitative analysis and monitoring of EZH2 mutations using liquid biopsy in follicular lymphoma. Genes 11:785, 2020
   Nagy A, Batai B, Kiss L, et al. Parallel testing of liquid biopsy, ctDNA, and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma. J Int Med 294:295–313, 2023
   Kiss L, Batai B, Bodor Cs, et al. Uj molekularis klasszifikacios rendszerek diffuz nagy B-sejtes limfomaban. Hematologia–Transzfuziologia 54:104– 112, 2021
   Varga L, Bodor Cs, Batai B. A Magyar Diffuz Nagy B-sejtes Lymphoma Molekularis Profilozasi Projekt, HU-LyGen): Ismerteto es elso eredmenyek. Hematologia–Transzfuziologia 2023, Doi: 10.1556/2068.2023.00178
   Marosvari D, Alpar D, Kiraly AP, et al. A kronikus limfocitas leukemia genetikai hattere az ujgeneracios szekvenalas korszakaban. Magy Onkol 60:118–125, 2016
   Kiss R, Alpar D, Gango A, et al. Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Haematologica 104:e38–e41, 2019
   Gango A, Alpar D, Galik B, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer 146:85–93, 2020
   Bodor C, Kotmayer L, Laszlo T, et al. Screening and monitoring of the BTK(C481S, mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol 194:355–364, 2021
   Kotmayer L, Laszlo T, Mikala G, et al. Landscape of BCL2 resistance mutations in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukemia treated with venetoclax. Int J Mol Sci 24:5802, 2023
   Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood 137:1365–1376, 2021
   Bonfiglio S, Sutton LA, Ljungstrom V, et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv 7:2794–2806, 2023
   Mansouri L, Thorvaldsdottir B, Sutton LA, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia 37:339–347, 2023
   Rendeiro AF, Krausgruber T, Fortelny N, et al. Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun 11:577, 2020
   Fesus V, Marosvari D, Kajtar B, et al. A TP53-mutacio-analizis jelentosege kronikus lymphocytas leukaemiaban. Orv Hetil 158:220–228, 2017
   Fesus V, Eyupoglu E, Kiss R, et al. Az IGHV mutacioanalizis jelentosege kronikus lymphocytas leukemiaban. Hematologia–Transzfuziologia 51:22– 29, 2018
   Aczel D, Matrai Z, Kiss R, et al. Ibrutinibrezisztencia kronikus limfocitas leukemiaban. Hematologia–Transzfuziologia 52:136–148, 2019
   Kotmayer L, Balogh A, Grof S, et al. A kronikus limfocitas leukemia genetikai hattere es szemelyre szabott terapiaja. Orvoskepzes:14, 2021
   Laszlo T, Kotmayer L, Alpar D, et al. Venetoclax-rezisztencia kronikus lymphocytas leukemiaban. Hematologia–Transzfuziologia 54:143–151, 2021
   Nagy A, Andrikovics H, Kajtar B, et al. Az IGHV-mutacios statusz vizsgalata a Magyar Hematologiai es Transzfuziologiai Tarsasag Molekularis Diagnosztika Munkacsoportjanak laboratoriumaiban. Hematologia–Transzfuziologia 54:75–80, 2021
   Kiss R, Gango A, Benard-Slagter A, et al. Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia. Mod Pathol 33:812–824, 2020
   Kiss R, Kosztolanyi S, Gango A, et al. Multiplex ligatiofuggo szondaamplifikacio az onkohematologiai kutatasban es diagnosztikaban. Orv Hetil 159:583–592, 2018
   Kosztolanyi S, Horvath B, Hosnyanszki D, et al. Molekularis citogenetikai vizsgalatok Baranya es Tolna megye plazmasejtes myelomaban szenvedo betegein. Orv Hetil 160:944–951, 2019
   Kosztolanyi S, Kiss R, Atanesyan L, et al. High-throughput copy number profiling by digital multiplex ligation-dependent probe amplification in multiple myeloma. J Mol Diagn 20:777–788, 2018
   Bedics G, Egyed B, Kotmayer L, et al. PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia. Br J Cancer 129:455–465, 2023
   Mansur MB, Furness CL, Nakjang S, et al. The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia. Cancer Med 10:4864–4873, 2021
   Krizsan S, Peterffy B, Egyed B, et al. Next-generation sequencing-based genomic profiling of children with acute myeloid leukemia. J Mol Diagn 25:555–568, 2023
   Alpar D, Egyed B, Bodor C, Kovacs GT. Single-cell sequencing: biological insight and potential clinical implications in pediatric leukemia. Cancers, Basel, 13, 2021
   Alpar D, Egyed B, Krizsan S, et al. A gyermekkori akut leukaemiak korszeru molekularis diagnosztikaja es kezelese. Orvoskepzes 13:5658, 2021
   Kotmayer L, Papp G, Baghi K, et al. Daganatos megbetegedesek celzott diagnosztikajat es kezeleset tamogato molekularis diagnosztikai eljarasok a mindennapokban. Orvoskepzes 12:309, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 260
EP 265
PG 6
ER

PT J
AU Horvath, Zs
AF Horvath, Zsolt
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
C1 [Horvath, Zsolt] Bacs-Kiskun County Hospital, Department of OncoradiologyKecskemet, Hungary.
RP Horvath, Zs (reprint author), Bacs-Kiskun County Hospital, Department of Oncoradiology, Kecskemet, Hungary.
CR Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 41:777–783, 2015
   Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12:443–450, 2007
   https://www.drugs.com/monograph/bevacizumab.html
   Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919, 2015
   Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil, TAS-102, versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 90:63–72, 2018
   Pfeiffer P, Yilmaz M, Moller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator- initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412– 420, 2020
   Takahashi T, Yamazaki K, Oki E, et al. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open 6:100093, 2021
   Yoshida Y, Yamada T, Kamiyama H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol 26:111–117, 2021
   Satake H, Kato T, Oba K, et al. Phase Ib/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies, BiTS Study). Oncologist 25:e1855–e1863, 2020
   Bendell JC, Rosen LS, Mayer RJ, et al. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 76:925–932, 2015
   Mayer RJ, Hochster HS, Cohen SJ, et al. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 82:961– 969, 2018
   Prager GW, Taieb JM, Fakih M, et al. Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657– 1667, 2023
   Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet 394:1467–1480, 2019
   Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632– 1643, 2019
   Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treat Rev 76:22–32, 2019
   Bregni G, Sciallero S, Sobrero A. HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer. JAMA Oncol 5:605–606, 2019
   Dasari A, Sobrero A, Yao J, et al. A global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 217:3151–3162, 2021
   Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 29:835–856, 2018
   Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer, CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303– 312, 2013
   Cremolini C, Rossini D, Martinelli E, et al. Trifluridine/tipiracil, TAS-102, in refractory metastatic colorectal cancer: A multicenter register in the frame of the Italian Compassionate Use Program. Oncologist 23:1178–1187, 2018
   Tsai HL, Huang CW, Ma CJ, et al. An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. Transl Cancer Res 8:2357–2370, 2019
   Nakayama G, Uehara K, Ishigure K, et al. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial, CCOG-0801). Cancer Chemother Pharmacol 70:575–581, 2012
   Zhou M, Yu P, Qu J, et al. Efficacy of bevacizumab in the first-line treatment of patients with RAS mutations metastatic colorectal cancer: a systematic review and network meta-analysis. Cell Physiol Biochem 40:361–369, 2016
   https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
   Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10–32, 2023
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2023
VL 67
IS 3
BP 267
EP 268
PG 2
ER

PT J
AU Polgar, Cs
   Kiss, A
   Lovey, J
AF Polgar, Csaba
   Kiss, Andras
   Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Polgar, Csaba] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
   [Kiss, Andras] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Lovey, Jozsef] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 273
EP 273
PG 1
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Polgar, Csaba] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 275
EP 275
PG 1
ER

PT J
AU Lovey, J
AF Lovey, Jozsef
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Lovey, Jozsef] National Institute of Oncology, Rathy Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Lovey, J (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 277
EP 277
PG 1
ER

PT J
AU Kenessey, I
   Patocs, A
   Dobozi, M
   Nagy, P
   Polgar, Cs
AF Kenessey, Istvan
   Patocs, Attila
   Dobozi, Maria
   Nagy, Peter
   Polgar, Csaba
TI The epidemiology of primary brain malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE brain tumor; incidence; mortality; risk factors; hereditary syndromes
ID brain tumor; incidence; mortality; risk factors; hereditary syndromes
AB The occurrence of central nervous system malignancies is relatively low; however, these tumors exhibit poor prognosis and a high mortality rate. On epidemiological grounds, Hungary was placed in the last third among European countries: in the last decade annually 750 to 1000 new cases were diagnosed and the number of deaths was between 550 and 690, without any apparent trends. Age distribution analyses revealed childhood peak and a higher peak at around 65 years of age. Histologically, heterogeneity was apparent, but at least half of the cases were glioblastomas. The exact etiology of adulthood brain tumors is mostly unknown. Among environmental exposures the effect of ionizing radiation was confirmed, the identification of other potential risk factors requires further examinations. 7-10 percent of brain tumors were hereditary tumor syndromes (Li-Fraumeni, neurofibromatosis, sclerosis tuberosa, von Hippel-Lindau, Gorlin- Goltz). Therefore, genetic testing is recommended for families where the diagnosis of brain tumor is suspected.
C1 [Kenessey, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Dobozi, Maria] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Kenessey, I (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM kenessey.istvan@oncol.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of Iincidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 55:74–108, 2005
   Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308–347, 2021
   Pace M, Lanzieri G, Glickman M, et al. Revision of the European standard population – Report of Eurostat’s task force, Eurostat, 2013
   https://gco.iarc.fr/today/home. Cancer Today, International Agency for Research on Cancer, 2021
   WHO: A betegsegek es az egeszseggel kapcsolatos problemak nemzetkozi statisztikai osztalyozasa, 10. revizio. Nepjoleti Miniszterium, 1995
   http://stat.nrr.hu/, Orszagos Onkologiai Intezet, Nemzeti Rakregiszter es Biostatisztikai Kozpont, 2023
   Weber A, Szatmari I, Dobozi M, et al. A Kozponti Statisztikai Hivatal halalozasi adatainak osszevetese a Nemzeti Rakregiszter adatbazisaval. Egy adat-osszekapcsolas tanulsagai. Orv Hetil 163:1481–1489, 2022
   Weber A, Mery L, Nagy P, et al. Evaluation of data quality at the Hungarian National Cancer Registry, 2000–2019. Cancer Epidemiol 82:102306, 2023
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175–184, 2022
   https://www.ksh.hu/, Kozponti Statisztikai Hivatal, 2023
   Parrag P, Weber A, Liszkay G, et al. A melanoma hazai morbiditasi es mortalitasi helyzete a XXI. szazad elso ket evtizedeben. Magy Onkol 66:94–99, 2022
   Soerjomataram I, Bardot A, Aitken J, et al. Impact of the COVID-19 pandemic on population-based cancer registry. Int J Cancer 150:273–278, 2022
   Lawler M, Davies L, Oberst S, et al. European Groundshot-addressing Europe’s cancer research challenges: a Lancet Oncology Commission. Lancet Oncol 24:e11–e56, 2023
   Kenessey I, Weber A, Szilagyi I, et al. Az orvosi kodtarak gyakorlati alkalmazasa az onkologiaban – szakmai utmutato a Nemzeti Rakregiszter tapasztalatai alapjan. Magy Onkol 66:4–10, 2022
   Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 71:381–406, 2021
   WHO’s European Health Information Gateway. WHO, 2023
   Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347:78–81, 2015
   EMMI. Az Emberi Eroforrasok Miniszteriuma egeszsegugyi szakmai iranyelve a genetikai tanacsadasrol. Egeszsegugyi Kozlony LXX:3014, 2020
   Clarke JE, Magoon S, Forghani I, et al. Radiologic screening and surveillance in hereditary cancers. Eur J Radiol Open 9:100422, 2022
   Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17:1295– 1305, 2016
   Cooper-Jones B, Verstraten K. A game-changer for hereditary cancer patients. CMAJ 189:E843–E844, 2017
   Kumamoto T, Yamazaki F, Nakano Y, et al. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol 26:2161–2178, 2021
   Butz H, Bozsik A, Grolmusz V, et al. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre. Sci Rep 13:14259, 2023
   Walker DA, Aquilina K, Spoudeas H, et al. A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences. Front Pediatr 11:1038937, 2023
   Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15:290–301, 2015
   Raju GP, Urion DK, Sahin M. Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol 36:128–131, 2007
   Gergics P, Patocs A, Toth M, et al. Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol 161:495–502, 2009
   Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32:4155–4161, 2014
   Watkins D, Rouleau GA. Genetics, prognosis and therapy of central nervous system tumors. Cancer Detect Prev 18:139–144, 1994
   Rasheed S, Rehman K, Akash MSH. An insight into the risk factors of brain tumors and their therapeutic interventions. Biomed Pharmacother 143:112119, 2021
   Kheirollahi M, Dashti S, Khalaj Z, et al. Brain tumors: Special characters for research and banking. Adv Biomed Res 4:4, 2015
   Kim KR, Kim E, Son EI. Aberrant CpG islands hypermethylation profiles in malignant gliomas. Brain Tumor Res Treat 2:29–35, 2014
   Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 472:323–342, 2009
   Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325:1330–1336, 1991
   Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep 7:208–214, 2007
   Vienne-Jumeau A, Tafani C, Ricard D. Environmental risk factors of primary brain tumors: A review. Rev Neurol, Paris, 175:664–678, 2019
   Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol 21:1357–1375, 2019
   Amirian ES, Zhou R, Wrensch MR, et al. Approaching a scientific consensus on the association between allergies and glioma risk: a report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282–290, 2016
   Pranata R, Feraldho A, Lim MA, et al. Coffee and tea consumption and the risk of glioma: a systematic review and dose-response meta-analysis. Br J Nutr 127:78–86, 2022
   Zhang W, Jiang J, Li X, et al. dietary factors and risk of glioma in adults: a systematic review and dose-response meta-analysis of observational studies. Front Nutr 9:834258, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 279
EP 287
PG 9
ER

PT J
AU Scheich, B
   Rajnai, H
AF Scheich, Balint
   Rajnai, Hajnalka
TI Classical pathology and basic concepts of the current WHO classification (5th edition) of central nervous system tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE central nervous system tumors; WHO classification; histopathology; immunohistochemistry; integrated diagnostics
ID central nervous system tumors; WHO classification; histopathology; immunohistochemistry; integrated diagnostics
AB Considerable changes were introduced into the 5th World Health Organization (WHO) classification of central nervous system (CNS) tumors, published in 2021, including new entities, a clearer classification of previous categories, correlating better with clinical behavior and changes in nomenclature. The number of definitions based on molecular features in addition to histopathology continued to increase. Here, we highlight the basic principles of the 5th CNS WHO classification and discuss glial, glioneuronal, neuronal, choroid plexus, embryonal and pineal tumors, as well as meningiomas in more details. We pay special attention to new entities as well as altered criteria and designations. Our primary goal is to present the „classical” pathological aspects, but the inseparable molecular pathological features are also briefly discussed, to the absolutely necessary extent for comprehension. We aim to provide a guideline to understand the modern classification of CNS tumors for practitioners of neuro-oncology and neuropathology.
C1 [Scheich, Balint] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Rajnai, Hajnalka] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
RP Scheich, B (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM scheich.balint@semmelweis.hu
CR WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. IARC, Lyon, 2021, WHO classification of tumours series, 5th ed.; vol. 6), https://publications.iarc.fr/601
   Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds). WHO Classification of Tumours of the Central Nervous System, Revised 4th edition). IARC, Lyon, 2016
   Koelsche C, von Deimling A. Methylation classifiers: Brain tumors, sarcomas, and what’s next. Genes Chromosomes Cancer 61:346–355, 2022
   Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro Oncol 25(Suppl_4):iv1–iv99, 2023
   Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol 32:e13062, 2022
   Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873, 2015
   DeWitt JC, Jordan JT, Frosch MP, et al. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol 19:1640–1650, 2020
   Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608, 2020
   van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol 35:2394–2401, 2017
   Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474, 2009
   Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10, mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861, 2006
   Ortega A, Nuno M, Walia S, et al. Treatment and survival of patients harboring histological variants of glioblastoma. J Clin Neurosci 21:1709–1713, 2014
   Stichel D, Ebrahimi A, Reuss D, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803, 2018
   Berzero G, Di Stefano AL, Ronchi S, et al. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966, 2021
   Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 19:1127–1134, 2017
   Solomon DA, Wood MD, Tihan T, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569–580, 2016
   Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131:137–146, 2016
   Korshunov A, Schrimpf D, Ryzhova M, et al. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 134:507–516, 2017
   Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 10:4343, 2019
   Bale TA, Rosenblum MK. The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol 32:e13060, 2022
   Jeon YK, Cheon JE, Kim SK, et al. Clinicopathological features and global genomic copy number alterations of pilomyxoid astrocytoma in the hypothalamus/ optic pathway: comparative analysis with pilocytic astrocytoma using array-based comparative genomic hybridization. Mod Pathol 21:1345–1356, 2008
   Gareton A, Tauziede-Espariat A, Dangouloff-Ros V, et al. The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population. Acta Neuropathol 139:287–303, 2020
   Reinhardt A, Stichel D, Schrimpf D, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136:273–291, 2018
   Korshunov A, Chavez L, Sharma T, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol 28:656–662, 2018
   Bongaarts A, Giannikou K, Reinten RJ, et al. Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget 8:95516–95529, 2017
   Goode B, Mondal G, Hyun M, et al. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun 9:810, 2018
   Wood MD, Tihan T, Perry A, et al. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol 28:192–202, 2018
   Pekmezci M, Villanueva-Meyer JE, Goode B, et al. The genetic landscape of ganglioglioma. Acta Neuropathol Commun 6:47, 2018
   Deng MY, Sill M, Chiang J, et al. Molecularly defined diffuse leptomeningeal glioneuronal tumor, DLGNT, comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol 136:239–253, 2018
   Imber BS, Braunstein SE, Wu FY, et al. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol 126:193–200, 2016
   Kresbach C, Neyazi S, Schuller U. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. Brain Pathol 32:e13068, 2022
   Tihan T, Zhou T, Holmes E, et al. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177, 2008
   Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506:451–455, 2014
   Panwalkar P, Clark J, Ramaswamy V, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705–714, 2017
   Ghasemi DR, Sill M, Okonechnikov K, et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 138:1075–1089, 2019
   Lee JC, Sharifai N, Dahiya S, et al. Clinicopathologic features of anaplastic myxopapillary ependymomas. Brain Pathol 29:75–84, 2019
   Rushing EJ, Cooper PB, Quezado M, et al. Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol 85:297–305, 2007
   Jeibmann A, Hasselblatt M, Gerss J, et al. Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol 65:1069–1073, 2006
   Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472, 2012
   Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31:737–754, 2017
   Kaur K, Kakkar A, Kumar A, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: a simplified approach. Brain Pathol 26:334–343, 2016
   Pietsch T, Haberler C. Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline. Clin Neuropathol 35:344–352, 2016
   Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 18:958–971, 2017
   Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus. Neuro Oncol 22:613–624, 2020
   Johann PD, Hovestadt V, Thomas C, et al. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol 27:411–418, 2017
   Lambo S, Grobner SN, Rausch T, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature 576:274–280, 2019
   Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164:1060–1072, 2016
   Jouvet A, Saint-Pierre G, Fauchon F, et al. Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases. Brain Pathol 10:49–60, 2000
   Lee JC, Mazor T, Lao R, et al. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation, PPTID, from pineoblastoma. Acta Neuropathol 137:851–854, 2019
   Li BK, Vasiljevic A, Dufour C, et al. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol 139:223–241, 2020
   Gerkes EH, Fock JM, den Dunnen WFA, et al. A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening. Neurogenetics 17:83–89, 2016
   Goutagny S, Nault JC, Mallet M, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24:184–189, 2014
   Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140:409–413, 2020
   Gauchotte G, Peyre M, Pouget C, et al. Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study. J Neuropathol Exp Neurol 79:754– 762, 2020
   Shankar GM, Abedalthagafi M, Vaubel RA, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19:535– 545, 2017
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 289
EP 303
PG 15
ER

PT J
AU Vida, L
   Horvath, B
   Kajtar, B
AF Vida, Livia
   Horvath, Balint
   Kajtar, Bela
TI Practical approach to molecular pathology of central nervous system tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE CNS tumours; molecular pathology; genetics; FISH; WES
ID CNS tumours; molecular pathology; genetics; FISH; WES
AB Recent advances in molecular diagnostics are transforming the classification of malignant tumours, it has long played a major role in the field of CNS tumours. Examination of 1p/19q codeletion is indispensable in case of diffuse gliomas. Glioblastoma may be diagnosed even in the absence of characteristic morphological features, when EGFR amplification, TERT promoter mutation or +7/-10 copy number abnormalities are present. The number of entities defined by a genetic abnormality is growing. Comprehensive analysis of DNA methylation may be of considerable help in addition to histology and basic molecular studies, especially in case of small samples. Keeping up with the ever-expanding diagnostic repertoire is difficult, however, advantages and disadvantages of these methods and the context in which they may be useful should be understood by those who are involved in the diagnosis of CNS tumours. This summary provides a general overview of the main methods used in molecular diagnostics.
C1 [Vida, Livia] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Horvath, Balint] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Kajtar, Bela] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
RP Kajtar, B (reprint author), University of Pecs, Department of Pathology, 7624 Pecs, Hungary.
EM kajtar.bela@pte.hu
CR WHO Classification of Tumours. Central nervous system tumours. Ed: WHO Classification of Tumours Editorial Board, 5th edition. International Agency for Research on Cancer 2021
   Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231– 1251, 2021
   Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602, 2008
   Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153, 2009
   Banan R, Stichel D, Bleck A, et al. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol 140:569–581, 2020
   Kumar VC, Pai R. Genes of the month: H3.3 histone genes: H3F3A and H3F3B. J Clin Pathol 74:753–758, 2021
   Leske H, Dalgleish R, Lazar AJ, et al. A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. J Pathol 254:109–120, 2021
   Ammendola S, Caldonazzi N, Simbolo M, et al. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Arch 479:987–996, 2021
   Clynes D, Higgs DR, Gibbons RJ. The chromatin remodeller ATRX: a repeat offender in human disease. Trends Biochem Sci 38:461–466, 2013
   Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026, 2013
   Ikemura M, Shibahara J, Mukasa A, et al. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69:260–267, 2016
   Ebrahimi A, Skardelly M, Bonzheim I, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60, 2016
   Tosuner Z, Gecer MO, Hatiboglu MA, et al. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncol Lett 16:2402–2408, 2018
   Dono A, Moosvi AM, Goli PS, et al. TERT immunohistochemistry as a surrogate marker for TERT promoter mutations in infiltrating gliomas. Appl Immunohistochem Mol Morphol 31:288–294, 2023
   Lee M, Kang SY, Suh YL. Genetic alterations of epidermal growth factor receptor in glioblastoma: the usefulness of immunohistochemistry. Appl Immunohistochem Mol Morphol 27:589–598, 2019
   Yu J, Wang Q, Xue P, et al. A model for the impact of FFPE section thickness on gene copy number measurement by FISH. Sci Rep 9:7518, 2019
   Horbinski C, Miller CR, Perry A. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 21:57–73, 2011
   Woehrer A, Sander P, Haberler C, et al. FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice – a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies, Euro-CNS). Clin Neuropathol 30:47–55, 2011
   Pinkham MB, Telford N, Whitfield GA, et al. FISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation. Clin Oncol, R Coll Radiol, 27:445–453, 2015
   Brandner S, McAleenan A, Jones HE, et al. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review. Neuropathol Appl Neurobiol 48:e12790, 2022
   French PJ, Eoli M, Sepulveda JM, et al. Defining EGFR amplification status for clinical trial inclusion. Neuro Oncol 21:1263–1272, 2019
   Kiss R, Kosztolanyi S, Gango A, et al. Multiplex ligatiofuggo szondaamplifikacio az onkohematologiai kutatasban es diagnosztikaban. Orv Hetil 159:583–592, 2018
   Homig-Holzel C, Savola S. Multiplex ligation-dependent probe amplification, MLPA, in tumor diagnostics and prognostics. Diagn Mol Pathol 21:189–206, 2012
   Dyke J, Calapre L, Beasley A, et al. Application of multiplex ligation-dependent probe amplification, MLPA, and low pass whole genome sequencing, LP-WGS, to the classification / characterisation of low grade glioneuronal tumours. Pathol Res Pract 229:153724, 2022
   Arita H, Narita Y, Matsushita Y, et al. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 32:22–30, 2015
   Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016, 2017
   Szivos L, Virga J, Klekner A, et al. Az alacsony gradusu gliomak prognosztikai faktorainak szerepe a terapia megvalasztasaban – a nemzetkozi irodalom es ajanlasok osszefoglalasa konkluziokkal. Magy Onkol 65:59–70, 2021
   Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 21:167–178, 2019
   Turanyi E, Hanzely Z, Balint K, et al. A patologus szerepe a kozponti idegrendszer tumorainak diagnosztikajaban, a terapiatervezesben. Prognosztikus es prediktiv markerek vizsgalata. Magy Onkol 57:215–221, 2013
   Butler M, Pongor L, Su YT, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer 6:380–391, 2020
   Chai R, Li G, Liu Y, et al. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med 18:272–282, 2021
   Sahara N, Hartanto RA, Yoshuantari N, et al. Diagnostic accuracy of immunohistochemistry in detecting MGMT methylation status in patients with glioma. Asian Pac J Cancer Prev 22:3803–3808, 2021
   Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 22:407–419, 2012
   Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature 555:469–474, 2018
   Wenger A, Caren H. Methylation profiling in diffuse gliomas: diagnostic value and considerations. Cancers, Basel, 14:5679, 2022
   Schepke E, Lofgren M, Pietsch T, et al. DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: A prospective population-based study. Neuropathol Appl Neurobiol 48:e12838, 2022
   Jaunmuktane Z, Capper D, Jones DTW, et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol Commun 7:24, 2019
   Ferreyra Vega S, Olsson Bontell T, Corell A, et al. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics 13:102, 2021
   Wenger A, Ferreyra Vega S, Kling T, et al. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol 21:616–627, 2019
   Gempt J, Withake F, Aftahy AK, et al. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: Implications for biopsy targeting, classification and therapy. ESMO Open 7:100566, 2022
   Ji J, Kaneva K, Hiemenz MC, et al. Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. Neurooncol Adv 3:vdab037, 2021
   Tirro E, Massimino M, Broggi G, et al. A custom DNA-based NGS panel for the molecular characterization of patients with diffuse gliomas: diagnostic and therapeutic applications. Front Oncol 12:861078, 2022
   Romanidou O, Apostolou P, Kouvelakis K, et al. Molecular profile and clinical features of patients with gliomas using a broad targeted next generation- sequencing panel. Oncol Lett 25:38, 2022
   Lorenz J, Rothhammer-Hampl T, Zoubaa S, et al. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology. Acta Neuropathol Commun 8:124, 2020
   Khasraw M, Walsh KM, Heimberger AB, et al. What is the burden of proof for tumor mutational burden in gliomas? Neuro Oncol 23:17–22, 2020
   Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517–523, 2020
   Zhao Z, Zhang KN, Sun Z, et al. WES data from 286 diffuse gliomas under the 2021 WHO Classification of Tumors of the Central Nervous System. Sci Data 9:692, 2022
   Vodicska B, Deri J, Tihanyi D, et al. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors. World J Pediatr 12:992–1008, 2023
   Sakthikumar S, Roy A, Haseeb L, et al. Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes. Genome Biol 21:127, 2020
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 304
EP 313
PG 10
ER

PT J
AU Bruckner, E
   Bedics, G
   Reiniger, L
   Rajnai, H
   Jakab, Zs
   Bodor, Cs
   Scheich, B
   Garami, M
AF Bruckner, Edit
   Bedics, Gabor
   Reiniger, Lilla
   Rajnai, Hajnalka
   Jakab, Zsuzsanna
   Bodor, Csaba
   Scheich, Balint
   Garami, Miklos
TI Childhood brain tumors: diagnosis and therapy – comprehensive genomic profiling
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE targeted therapy; childhood brain tumors; signal transduction pathway; kinase inhibition
ID targeted therapy; childhood brain tumors; signal transduction pathway; kinase inhibition
AB With the advancement of molecular oncology, numerous new opportunities are available for the effective and efficient treatment of patients diagnosed with childhood brain tumors. This includes gene panel analysis aiding personalized treatment used in clinical trials, and the application of targeted therapy independent of tissue type (tumor agnostic therapy). Most personalized therapies inhibit certain kinases. In our review, we present the modern pathological diagnosis of childhood brain tumors, as well as the complex intracellular regulation of signal transduction pathways important from the point of view of clinical practice, and we describe their further targets defined on the basis of pharmacological characteristics of the pathway, based on international and our own results. Despite common mutations affecting kinases, personalized therapy is not available in many types of tumors. Through the example of childhood brain tumors, we demonstrate the expected future therapeutic significance of tyrosine kinases.
C1 [Bruckner, Edit] Semmelweis Egyetem, Gyermekgyogyaszati Klinika, Tuzolto utca 7–9., 1094 Budapest, Hungary.
   [Bedics, Gabor] HCEMM-SE Molecular Oncohematology Research GroupBudapest, Hungary.
   [Reiniger, Lilla] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Rajnai, Hajnalka] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Jakab, Zsuzsanna] Semmelweis Egyetem, Gyermekgyogyaszati Klinika, Tuzolto utca 7–9., 1094 Budapest, Hungary.
   [Bodor, Csaba] HCEMM-SE Molecular Oncohematology Research GroupBudapest, Hungary.
   [Scheich, Balint] Semmelweis University, 1st Department of Pathology and Experimental Cancer ResearchBudapest, Hungary.
   [Garami, Miklos] Semmelweis Egyetem, Gyermekgyogyaszati Klinika, Tuzolto utca 7–9., 1094 Budapest, Hungary.
RP Garami, M (reprint author), Semmelweis Egyetem, Gyermekgyogyaszati Klinika, 1094 Budapest, Hungary.
EM garami.miklos@semmelweis.hu
CR Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 72:7–33, 2022
   Zhou H. Treatments associated with all-cause mortality among children with primary brain and central nervous system tumors: a retrospective cohort study from the SEER database. Transl Pediatr 12:1504–1516, 2023
   Lu VM, Elarjani T, Niazi TN. Global, regional and national incidence and mortality trends in pediatric central nervous system tumors over the last two decades. World Neurosurg 2023,, DOI  10.1016/j.wneu.2023.09.003
   Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231– 1251, 2021
   World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. The WHO Classification of Tumours, ed. W.C.o.T.E. Board. 2021, Lyon, France: International Agency for Research on Cancer. 584.
   AlRayahi J, Alwalid O, Mubarak W, et al. Pediatric brain tumors in the molecular era: updates for the radiologist. Semin Roentgenol 58:47–66, 2023
   Alemany M, Velasco R, Simo M, et al. Late effects of cancer treatment: consequences for long-term brain cancer survivors. Neurooncol Pract 8:18– 30, 2021
   Satam H, Joshi K, Mangrolia U, et al. Next-generation sequencing technology: current trends and advancements. Biology, Basel, 12:997, 2023
   Sahm F, Brandner S, Bertero L, et al. Molecular diagnostic tools for the World Health Organization, WHO, 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol 25:1731–1749, 2023
   Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing, NGS, for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491–1505, 2020
   Froyen G, Geerdens E, Berden S, et al. Diagnostic validation of a comprehensive targeted panel for broad mutational and biomarker analysis in solid tumors. Cancers, Basel, 14:2457, 2022
   Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer 18:767–777, 2018
   Forbes SA, Beare D, Boutselakis H, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45:D777–783, 2017
   Targeted options for glioma looking good. Cancer Discov 13:1755, 2023
   Rezaei Adariani S, Buchholzer M, Akbarzadeh M, et al. Structural snapshots of RAF kinase interactions. Biochem Soc Transact 46:1393–1406, 2018
   Kaley T, Touat M, Subbiah V, et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477–3484, 2018
   Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124:1655–1658, 2014
   Yuan J, Ng WH, Tian Z, et al. Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis. Sci Signal 11:eaar6795, 2018
   Bouffet E, Hansford JR, Garre ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389:1108–1120, 2023
   Timar J, Uhlyarik A. A celzott kezelesek „celzott” mellekhatasai. Klin Onkol 9:157–168, 2022
   Szabo S, Bedics G, Bodor Cs, et al. Tumoragnosztikus terapia a gyermekonkologiaban. Klin Onkol 10:127–132, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 315
EP 320
PG 6
ER

PT J
AU Szabo, P
AF Szabo, Peter
TI The role of PET/CT in the central nervous system tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE PET/CT; 18F-FDG; amino acid tracers; PCNSL; glioma
ID PET/CT; 18F-FDG; amino acid tracers; PCNSL; glioma
AB The appearance of hybrid imaging, including PET/CT has been a huge milestone not only in the development of nuclear medicine but of the whole medical imaging. The examination with 18F-FDG, the most frequently used radiopharmaceutical has become for now one of the most important diagnostic tools in oncological patient care, applied with numerous indication goals. However, the depiction of central nervous system malignancies, especially those of the brain, with FDG PET has limitations due to high cerebral background activity, it can be used primarily in lymphoma cases. To evaluate gliomas and brain metastases, amino acid tracers (11C-methionine, 18F-DOPA and 18F-FET) gained ground, which reflect other biological processes compared to that of FDG. Upon multiplying of evidences their usage is becoming more and more diverse, from the primary assessment of brain tumours (benign vs. malignant), through their grading and evaluation of posttherapeutical viability/recurrence, up to the radiotherapy planning. This paper reviews all of these in more details, mentioning shortly the prospects and challenges of the future.
C1 [Szabo, Peter] Scanomed Kft., Budapesti PET-CT Kozpont, Laky Adolf u. 44-46., 1145 Budapest, Hungary.
RP Szabo, P (reprint author), Scanomed Kft., Budapesti PET-CT Kozpont, 1145 Budapest, Hungary.
EM szabo.peter@scanomed.hu
CR Hicks RJ, Lau EWF, Binns DS. Hybrid imaging is the future of molecular imaging. Biomed Imaging Interv J 3:e49, 2007
   Townsend DW. Combined positron emission tomography–computed tomography: the historical perspective. Semin Ultrasound CT MR 29:232–235, 2008
   Fischer BM, Siegel BA, Weber WA, et al. PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. Eur J Nucl Med Mol Imaging 43:1749–1752, 2016
   Giammarile F, Castellucci P, Dierckx R, et al. Non-FDG PET/CT in diagnostic oncology: a pictorial review. Eur J Hybrid Imaging 3:20, 2019
   Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354, 2015
   Chan HP, Liu WS, Liou WS, et al. Comparison of FDG-PET/CT for cancer detection in populations with different risks of underlying malignancy. In Vivo 34:469–478, 2020
   Sureshbabu W, Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol 33:156–161, 2005
   Grootjans W, Rietbergen DDD, van Velden FHP. Added value of respiratory gating in positron emission tomography for the clinical management of lung cancer patients. Semin Nucl Med 52:745–758, 2022
   Haberkorn U, Ziegler SI, Oberdorfe F. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21:827–834, 1994
   Szablewski L. Brain glucose transporters: role in pathogenesis and potential targets for the treatment of Alzheimer’s disease. Int J Mol Sci 22:8142, 2021
   Wehner J, Weissler B, Dueppenbecker P, et al. PET/MRI insert using digital SiPMs: Investigation of MR-compatibility. Nucl Instrum Methods Phys Res A 734:116–121, 2014
   Martin O, Schaarschmidt BM, Kirchner J, et al. PET/MRI versus PET/CT for wholebody staging: results from a single-center observational study on 1,003 sequential examinations. J Nucl Med 61:1131–1136, 2020
   Huang B, Yang F, Yin M, et al. A review of multimodal medical image fusion techniques. Comput Math Methods Med 2020:8279342, 2020
   Pietrzak A, Marszalek A, Kunikowska J, et al. Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies. Sci Rep 11:18293, 2021
   Portnow LH, Vaillancourt DE, Okun MS. The history of cerebral PET scanning: from physiology to cutting-edge technology. Neurology 80:952–956, 2013
   Jung J, Ahn BC. Current radiopharmaceuticals for positron emission tomography of brain tumors. Brain Tumor Res Treat 6:47–53, 2018
   Gromme C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol 35:2410–2418, 2017
   Krebs S, Barasch JG, Young RJ, et al. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. Ann Lymphoma 5:15, 2021
   Purandare NC, Puranik A, Shah S, et al. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation? Nucl Med Commun 38:1109–1116, 2017
   Gupta M, Gupta T, Purandare N, et al. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. CNS Oncol 8:CNS46, 2019
   Quigg M, Kundu B. Dynamic FDG-PET demonstration of functional brain abnormalities. Ann Clin Transl Neurol 9:1487–1497, 2022
   Zou Y, Tong J, Leng H, et al. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis. Oncotarget 8:41518–41528, 2017
   Nanni C, Kobe C, Herrmann K, et al. Defining the role of nuclear medicine in haematological tumours–EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours. Eur J Nucl Med Mol Imaging 50:2925–2926, 2023
   Jo JC, Yoon DH, Kim S, et al. Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. Ann Hematol 96:1509–1515, 2017
   Bhatt G, Li XF, Jain, A, et al. The normal variant 18F FDG uptake in the lower thoracic spinal cord segments in cancer patients without CNS malignancy. Am J Nucl Med Mol Imaging 3:317–325, 2013
   Patel PY, Dalal I, Griffith B. [18F]FDG-PET evaluation of spinal pathology in patients in oncology: pearls and pitfalls for the neuroradiologist. Am J Neuroradiol 43:332–340, 2022
   Zheng F, Wanjun X, Shuaishuai W, et al. Diagnostic value of 18F FDG PET/CT and MRI for intraspinal lesions: A comparative study. Med Int, Lond, 1:23, 2021
   Sun A, Liu X, Tang G. Carbon-11 and fluorine-18 labeled amino acid tracers for positron emission tomography imaging of tumors. Front Chem 5:124, 2017
   Treglia G, Muoio B, Trevisi G, et al. Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta- analyses. Int J Mol Sci 20:4669, 2019
   Deng SM, Zhang W, Zhang B, et al. Correlation between the uptake of 18F-fluorodeoxyglucose, 18F-FDG, and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS One 10:e0129028, 2015
   Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540–557, 2019
   Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 18:426–434, 2016
   Popperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942, 2007
   Furtak J, Rakowska J, Szylberg T, et al. Glioma biopsy based on hybrid dual time-point FET-PET/MRI – a proof of concept study. Front Neurol 12:634609, 2021
   Nagy DG, Fedorcsak I, Bago AG, et al. Therapy defining at initial diagnosis of primary brain tumor – the role of 18F-FET PET/CT and MRI. Biomedicines 11:128, 2023
   Galldiks N, Albert NL, Wollring M, et al. Advances in PET imaging for meningioma patients. Neurooncol Adv 5(Suppl 1):i84–i93, 2023
   Galldiks N, Unterrainer M, Judov N, et al. Photopenic defects on O-(2-[18F]-fluoroethyl)- L-tyrosine PET: clinical relevance in glioma patients. Neuro Oncol 21:1331–1338, 2019
   Li H, Deng L, Bai HX, et al. Diagnostic accuracy of amino acid and FDG-PET in differentiating brain metastasis recurrence from radionecrosis after radiotherapy: a systematic review and meta-analysis. Am J Neuroradiol 39:280–288, 2018
   Akhoundova D, Hiltbrunner S, Mader C, et al. 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer. Clin Nucl Med 45:113–117, 2020
   Zhang-Yin JT, Girard A, Bertaux M. What does PET imaging bring to neuro-oncology in 2022? A Review. Cancers, Basel, 14:879, 2022
   Takahashi Y, Akahane T, Yamamoto D, et al. Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas. Mol Clin Oncol 2:525– 529, 2014
   Ahn SY, Kwon SY, Jung SH, et al. Prognostic significance of interim 11C-methionine PET/CT in primary central nervous system lymphoma. Clin Nucl Med 43:e259–e264, 2018
   Kawase Y, Yamamoto Y, Kameyama R, et al. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol 13:1284–1289, 2011
   Chandekar KR, Prashanth A, Vinjamuri A, et al. FAPI PET/CT imaging–an updated review. Diagnostics, Basel, 13:2018, 2023
   Sidrak MMA, De Feo MS, Corica F, et al. Fibroblast activation protein inhibitor, FAPI)- based theranostics – where we are at and where we are heading: a systematic review. Int J Mol Sci 24:3863, 2023
   Yao Y, Tan X, Yin W, et al. Performance of 18 F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study. BMC Med Imaging 22:226, 2022
   Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer 48:3499–3513, 2012
   Hatakeyama T, Kawai N, Nishiyama Y, et al. 11C-methionine, MET, and 18F-fluorothymidine, FLT, PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009–2017, 2008
   Nikaki A, Angelidis G, Efthimiadou R, et al. 18F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med 31:495–505, 2017
   Kunz WG, Jungblut LM, Kazmierczak PM, et al. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 58:1580–1587, 2017
   Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med 56:347–353, 2015
   Acker G, Kluge A, Lukas AM, et al. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution. Neurosurg Focus 46:E9, 2019
   Annunziata S, Treglia G. Editorial: Radiomics and artificial intelligence in radiology and nuclear medicine. Front Med, Lausanne, 10:1216434, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 321
EP 331
PG 11
ER

PT J
AU Markia, B
   Kiss-Miki, R
   Deri, G
AF Markia, Balazs
   Kiss-Miki, Renata
   Deri, Gabriella
TI Surgical treatment of paediatric brain tumours
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE brain tumour; paediatric population; medulloblastoma
ID brain tumour; paediatric population; medulloblastoma
AB Central nervous system (CNS) tumours are the second most common neoplasm types in children. In most cases the aetiology is unknown, but some genetic syndromes can be related to CNS tumours. The symptoms are not specified, that is why in case of younger ages the tumour can reach extreme sizes. In case of infants the surgical technique is determined by the amount of circulating blood. Precise haemostasis is of utmost importance. In the last years, because of the development of imaging, surgical and anaesthetic techniques, the overall survival rate increased among paediatric brain cancer patients, and with this, the quality of life as well has improved significantly. Between 1975 and 2010 there was a 50% improvement in 5-year survival.
C1 [Markia, Balazs] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Kiss-Miki, Renata] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Deri, Gabriella] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
RP Markia, B (reprint author), National Institute of Neurosurgery, 1145 Budapest, Hungary.
EM markiabalazs@gmail.com
CR Udaka YT, Packer RJ. Pediatric brain tumors. Neurol Clin 36:533–556, 2018
   American Childhood Cancer Organisation, https://www.acco.org
   CancerNet, https://www.cancer.net/cancer-types/central-nervous-system- tumors-brain-and-spinal-cord-childhood/statistics
   Banczerowski P, Vajda J. Az idegsebeszet alapjai. Medicina, Budapest, 2022
   Adel Fahmideh M, Scheurer ME. Pediatric brain tumors: descriptive epidemiology, risk factors, and future directions. Cancer Epidemiol Biomarkers Prev 30:813–821, 2021
   Yang W, Cai Y, Chen J, et al. Epidemiological characteristics, clinical presentations, and prognoses of pediatric brain tumors: Experiences of national center for children’s health. Front Oncol 13:1067858, 2023
   Reulecke BC, Erker CG, Fiedler BJ, et al. Brain tumors in children: initial symptoms and their influence on the time span between symptom onset and diagnosis. J Child Neurol 23:178–183, 2008
   Ismail FY, Fatemi A, Johnston MV. Cerebral plasticity: Windows of opportunity in the developing brain. Eur J Paediatr Neurol 21:23–48, 2017
   Marusak HA, Iadipaolo AS, Harper FW, et al. Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes. Neuropsychol Rev 28:123–175, 2018
   Pancaldi A, Pugliese M, Migliozzi C, et al. Neuropsychological outcomes of children treated for brain tumors. Children 10:472, 2023
   Mu W, Dahmoush H. Classification and neuroimaging of ependymal tumors. Front Pediatr 11:1181211, 2023
   The ISPN Guide to Pediatric Neurosurgery, https://ispn.guide/tumors- of-the-nervous-system-in-children/molecular-biology-of-brain-tumors- in-children-homepage/medulloblastomaprimitive-neuroectodermal- tumors-in-the-brains-of-children/
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 333
EP 339
PG 7
ER

PT J
AU Belak, B
   Molnar, A
   Palfi, E
   Blasszauer, C
   Reibl, D
   Lovey, J
AF Belak, Barbara
   Molnar, Andrea
   Palfi, Erzsebet
   Blasszauer, Celia
   Reibl, Daniel
   Lovey, Jozsef
TI Effect of long-term medical nutrition therapy on the survival of head and neck cancer patients – based on real-world data
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Practice Guideline
DE head and neck cancer; nutrition therapy; persistence; survival
ID head and neck cancer; nutrition therapy; persistence; survival
AB At the 45th Congress of ESPEN (The European Society for Clinical Nutrition and Metabolism), we presented for the first time the initial results of our 2023 oncology research, in which we revealed positive correlations between the persistence of medical nutrition therapy and overall survival, in head and neck cancer patients. Patients who received longterm nutrition therapy (≥7 months) had a significantly longer survival (p<0.0001) than those who received only short-term nutrition therapy intervention, i.e., for 1–3 months. The aim, methodology and results of the Hungarian research aroused the interest of the congress participants; therefore, we also publish it in Hungarian in the form of a short notice.
C1 [Belak, Barbara] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Molnar, Andrea] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Palfi, Erzsebet] Semmelweis University, School of PhD StudiesBudapest, Hungary.
   [Blasszauer, Celia] MedicalScan Kft.Budapest, Hungary.
   [Reibl, Daniel] MedicalScan Kft.Budapest, Hungary.
   [Lovey, Jozsef] Semmelweis University, Department of OncologyBudapest, Hungary.
RP Belak, B (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM dr.belak.barbara@gmail.com
CR Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 6:100092, 2021
   Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr 40:2898–2913, 2021
   Seo Y, Eo W, Kim S, et al. Can nutritional status predict overall survival in patients with advanced non-small cell lung cancer? Nutr Cancer 71:1108– 1117, 2019
   Yu Y, Wu H, Qiu J, et al. A nutrition-related factor-based risk stratification for exploring the clinical benefits in the treatment of patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy: a retrospective cohort study. Front Nutr 9:896847, 2022
   Migita K, Matsumoto S, Wakatsuki K, et al. A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy. Surg Today 47:1018–1026, 2017
   Mardas M, Madry R, Stelmach-Mardas M. Dietary intake variability in the cycle of cytotoxic chemotherapy. Support Care Cancer 24:2619–2625, 2016
   Castillo-Martinez L, Castro-Eguiluz D, Copca-Mendoza ET, et al. Nutritional assessment tools for the identification of malnutrition and nutritional risk associated with cancer treatment. Rev Invest Clin 70:121–125, 2018
   Koyama S, Tabuchi T, Okawa S, et al. Hospital volume and 5-year survival in head and neck cancer patients in Osaka, Japan. Jpn J Clin Oncol 51:1515– 1522, 2021
   Du E, Mazul AL, Farquhar D, et al. Long-term survival in head and neck cancer: impact of site, stage, smoking, and human papillomavirus status. Laryngoscope 129:2506–2513, 2019
   Guo K, Xiao W, Chen X, et al. Epidemiological trends of head and neck cancer: a population-based study. Biomed Res Int 2021:1738932, 2021
   Golusinski P, Corry J, Poorten VV, et al. De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed? Oral Oncol 123:105620, 2021
   Migliaro M, Massuh D, Infante MF, et al. Role of Epstein-Barr virus and human papilloma virus in the development of oropharyngeal cancer: a literature review. Int J Dent 2022:3191569, 2022
   ESMO pocket gudeline Head and neck cancer 2021. https://interactiveguidelines. esmo.org/esmo-web-app/toc/index.php?subjectAreaId=11&- loadPdf=1.
   Cawood AL, Burden ST, Smith T, et al. A systematic review and meta- analysis of the effects of community use of oral nutritional supplements on clinical outcomes. Ageing Res Rev 88:101953, 2023
   Molnar A, Csontos AA, Dako S, et al. A taplalasterapia hatekonysaganak vizsgalata gyulladasos belbetegsegben szenvedok gondozasa soran. Orv Hetil 158:731–239, 2017
   Lovey J, Molnar A, Banky B. Long-term nutrition in patients candidate to neoadjuvant and adjuvant treatments. Eur J Surg Oncol 2023,, DOI  10.1016/j. ejso.2023.02.007
   Saesen R, Kantidakis G, Marinus A, et al. How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer. Front Pharmacol 13:969778, 2022
   Caccialanza R, Goldwasser F, Marschal O, et al. Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. Ther Adv Med Oncol 12:1758835919899852, 2020
   Bossi P, Delrio P, Mascheroni A, et al. The spectrum of malnutrition/ cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients 13:1980, 2021
   Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33:90–99, 2015
   Bischoff SC, Austin P, Boeykens K, et al. ESPEN practical guideline: Home enteral nutrition. Clin Nutr 41:468–488, 2022
   Pironi L, Boeykens K, Bozzetti F, et al. ESPEN practical guideline: Home parenteral nutrition. Clin Nutr 42:411–430, 2023
   Almada-Correia I, Neves PM, et al. Body composition evaluation in head and neck cancer patients: a review. Front Oncol 9:1112, 2019
   Muller-Richter U, Betz C, Hartmann S, et al. Nutrition management for head and neck cancer patients improves clinical outcome and survival. Nutr Res 48:1–8, 2017
   Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck 29:893–900, 2007
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2023
VL 67
IS 4
BP 341
EP 344
PG 4
ER

PT J
TI The Society of Hungarian Oncologists® XXXV. Congress
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
AB With great respect, we welcome you to the Hungarian Oncologists' Society® XXXV. Congress in Budapest at the Congress Center. This year's congress of MOT® awaits all interested parties with outstanding academic programs, exhibitor symposia and unforgettable social programs. MOT® currently has more than 1,100 registered members and works every day to adequately represent doctors, researchers, psychologists, pharmacists and professionals involved in the field of research, diagnostics, therapy and rehabilitation used in the treatment of cancer patients. The purpose of the national congress, organized every two years, is to help the professional development of those working in the various specialties of oncology, to learn together, to create connections, to create new scientific collaborations, and at the same time to provide an opportunity for personal meetings. In accordance with our traditions, at the congress we will also present the Krompecher awards, which are considered the highest recognition of MOT®, and the awards for the best publications of 2021 and 2022 from our official journal, Magyar Onkologia. This year, the scientific program planned for three days will cover a wide range of oncological diseases and present modern methods and procedures from several aspects. The presentation of new domestic epidemiological data related to cancer, the program of the newly established multidisciplinary Robotic Surgery Section of the MOT®, and the plenary lectures of renowned foreign speakers are also of particular interest. A total of 15 foreign (European and overseas) invited speakers, 15 scientific symposia (from the application of artificial intelligence to the accreditation of oncology centers) MOT® sections: the Drug Therapy Section, the Oncopsychology and Rehabilitation Section, the Young Oncologists Section, the Oncodermatology Section, the Through the independent events of the members of the Experimental Oncology and Pathology Section and the Professional Section) provides a comprehensive presentation of the domestic and international situation and new directions of multidisciplinary oncology. The success of our event will be helped by 17 company symposia and the exhibition presented on more than 280 square meters. At the congress, we will hold our next renewal general assembly, where we will elect the future president and full presidency, as well as install the incoming president in his position as president. We look forward to seeing you at the Congress! With friendly and collegial greetings: Prof. Dr. Csaba Polgar (president) Prof. Dr. Attila Patocs (general secretary)
NR 5
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD NOV
PY 2023
VL 67
IS 5
BP 1
EP 68
PG 68
ER

PT J
AU Eross, L
   Halasz, L
   Miklos, G
AF Eross, Lorand
   Halasz, Laszlo
   Miklos, Gabriella
TI Intra- and perioperative imaging options in neurosurgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE neuronavigation; CNS neoplasms; MRI; artificial intelligence; neurosurgery
ID neuronavigation; CNS neoplasms; MRI; artificial intelligence; neurosurgery
AB The treatment of central nervous system tumors is still a major challenge for the oncological and neurosurgical teams. Due to the heterogeneous histological and topological characteristics of these neoplasms, every case requires individual evaluation. In addition to histology and stage, survival is largely determined by the extent of resection, which can be severely limited by the proximity of eloquent brain regions. A key component of current modern neuro-oncological care is the planning and execution of surgical intervention to ensure the longest possible progression-free survival with adequate quality of life. The simultaneous development of several pre- and intra-operative imaging modalities is making optimal therapy more and more accessible and safe. Structural, diffusion and functional MRI offers the possibility to visualize the tumor and the surrounding areas both before and during surgery. For the surgeon, the optimal intra-operative environment, orientation and visual acuity are provided by increasingly sophisticated microscopes, navigation devices, intra-operative imaging equipment, endo- and exoscopes.
C1 [Eross, Lorand] National Institute of NeurosurgeryBudapest, Hungary.
   [Halasz, Laszlo] National Institute of NeurosurgeryBudapest, Hungary.
   [Miklos, Gabriella] National Institute of NeurosurgeryBudapest, Hungary.
RP Eross, L (reprint author), National Institute of Neurosurgery, Budapest, Hungary.
EM l.g.eross@gmail.com
CR Fink JR, Muzi M, Peck M, Krohn KA. Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. Chin J Nucl Med Mol Imaging 37:743–749, 2017
   Gulyas B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 56:173–190, 2012
   Kaifi R. A review of recent advances in brain tumor diagnosis based on AI-based classification. Diagnostics 13:3007, 2023
   Sastry R, Bi WL, Pieper S, et al. Applications of ultrasound in the resection of brain tumors. J Neuroimaging 27:5–15, 2017
   Wang J, Liu X, Hou W, et al. The relationship between intra-operative ultrasonography and pathological grade in cerebral glioma. J Int Med Res 36:1426–1434, 2008
   Unsgaard G, Selbekk T, Muller TB, et al. Ability of navigated 3D ultrasound to delineate gliomas and metastases – comparison of image interpretations with histopathology. Acta Neurochir 147:1259–1269, 2005
   Villanueva-Meyer JE, Mabray MC, Cha S. Current clinical brain tumor imaging. Neurosurgery 81:397–415, 2017
   Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol 23:1231– 1251, 2021
   Patel SH, Poisson LM, Brat DJ, et al. T2–FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: A TCGA/ TCIA project. Clin Cancer Res 23:6078–6085, 2017
   Kleesiek J, Morshuis JN, Isensee F, et al. Can virtual contrast enhancement in brain MRI replace gadolinium?: A feasibility study. Invest Radiol 54:653–660, 2019
   Choi YS, Bae S, Chang JH, et al. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics. Neuro-Oncol 23:304–313, 2020
   Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncol 17(suppl_4):iv1–62, 2015
   Lohmann P, Elahmadawy MA, Gutsche R, et al. FET PET radiomics for differentiating pseudoprogression from early tumor progression in glioma patients post-chemoradiation. Cancers 12:3835, 2020
   Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466, 2009
   Castellano A, Cirillo S, Bello L, et al. Functional MRI for surgery of gliomas. Curr Treat Options Neurol 19:34, 2017
   Giussani C, Roux FE, Ojemann J, et al. Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. Neurosurgery 66:113–120, 2010
   Verburg N, Hamer PC de W. State-of-the-art imaging for glioma surgery. Neurosurg Rev 44:1331–1343, 2021
   Alexander AL, Lee JE, Lazar M, et al. Diffusion tensor imaging of the brain. Neurotherapeutics 4:316–329, 2007
   Zhylka A, Sollmann N, Kofler F, et al. Tracking the corticospinal tract in patients with high-grade glioma: clinical evaluation of multi-level fiber tracking and comparison to conventional deterministic approaches. Front Oncol 11:761169, 2021
   Alexopoulos G, Cikla U, Tecle NE, et al. The value of white matter tractography by diffusion tensor imaging in altering a neurosurgeon’s operative plan. World Neurosurg 132:e305–313, 2019
   Essayed WI, Zhang F, Unadkat P, et al. White matter tractography for neurosurgical planning: A topography-based review of the current state of the art. NeuroImage Clin 15:659–672, 2017
   Soni N, Mehrotra A, Behari S, et al. Diffusion-tensor imaging and tractography application in pre-operative planning of intra-axial brain lesions. Cureus 9:e1739, 2017
   Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery 61:935–949, 2007
   Saliba J, Steven A, Berry JF, et al. Diffusion tensor imaging and tractography utilized in the resection of a midbrain cavernous malformation. Ochsner J 20:303–306, 2020
   Kim JH, Phi JH, Lee JY, et al. Surgical outcomes of thalamic tumors in children: the importance of diffusion tensor imaging, neuro-navigation and intraoperative neurophysiological monitoring. Brain Tumor Res Treat 6:60– 67, 2018
   D’Amico A, Furlanis GM, Baro V, et al. Thalamopeduncular tumors in pediatric age: advanced preoperative imaging to define safe surgical planning: a multicentric experience. J Clin Med 12:5521, 2023
   Xiao X, Kong L, Pan C, et al. The role of diffusion tensor imaging and tractography in the surgical management of brainstem gliomas. Neurosurg Focus 50:E10, 2021
   Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:997–1003, 2011
   Rogers CM, Jones PS, Weinberg JS. Intraoperative MRI for brain tumors. J Neuro-Oncol 151:479–490 2021
   Costabile JD, Alaswad E, D’Souza S, et al. Current applications of diffusion tensor imaging and tractography in intracranial tumor resection. Front Oncol 9:426, 2019
   D’Andrea G, Familiari P, Lauro AD, et al. Safe resection of gliomas of the dominant angular gyrus availing of preoperative FMRI and intraoperative DTI: preliminary series and surgical technique. World Neurosurg 87:627– 639, 2016
   Uluc K, Kujoth GC, Baskaya MK. Operating microscopes: past, present, and future. Neurosurg Focus 27:E4, 2009
   Bin-Alamer O, Abou-Al-Shaar H, Gersey ZC, et al. Intraoperative imaging and optical visualization techniques for brain tumor resection: a narrative review. Cancers 15:4890, 2023
   Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401, 2006
   Zeiss Kinevo [Internet]. https://www.zeiss.com/meditec/en/products/ surgical-microscopes/zeiss-kinevo-900.html
   Mehta GU, Lonser RR, Oldfield EH. The history of pituitary surgery for Cushing disease: Historical vignette. J Neurosurg 116:261–268, 2012
   Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 87:44–51, 1997
   Schroeder HWS. Intraventricular tumors. World Neurosurg 79:S17. e15-S17.e19, 2013
   Bourdillon P, Ferrand-Sorbet S, Apra C, et al. Surgical treatment of hypothalamic hamartomas. Neurosurg Rev 44:753–762, 2021
   Williams S, Horsfall HL, Funnell JP, et al. Artificial intelligence in brain tumour surgery–an emerging paradigm. Cancers 13:5010, 2021
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 5
EP 12
PG 8
ER

PT J
AU Bago, AGy
   Nagy, DG
AF Bago, Attila Gyorgy
   Nagy, David Gergo
TI Brain tumor surgery in adults.
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE brain tumor; surgery; microneurosurgery; neuronavigation; intraoperative neuromonitoring
ID brain tumor; surgery; microneurosurgery; neuronavigation; intraoperative neuromonitoring
AB Despite the advanced medical and radiation therapy, the role of surgical resection of brain neoplasms still remains indisputable. The maximal safe resection of benign brain tumors may result in complete recovery of the patient. Surgery of malignant tumors can resolve mass effect, improve the neurological condition of the patient providing the possibility for further complex oncotherapy based on molecular level histopathology results. The advances in technical and multidisciplinary environment of brain tumor surgery facilitate more radical and safer resection resulting in better outcomes and preservation of quality of life, even in case of tumors which were considered inoperable until recently. In this review we present the recent technical innovations used in brain tumor surgery and discuss the surgical strategy of the most common tumor types (gliomas, meningiomas, cranial nerve tumors and brain metastases). The surgical management of complex skull base tumors, pituitary tumors, as well as neuro-endoscopic surgery and pediatric brain tumors are discussed in other papers of this special issue.
C1 [Bago, Attila Gyorgy] Semmelweis Egyetem, Idegsebeszeti es Neurointervencios Klinika, Neuroonkologiai Osztaly, Amerikai ut 57., 1145 Budapest, Hungary.
   [Nagy, David Gergo] Semmelweis Egyetem, Idegsebeszeti es Neurointervencios Klinika, Neuroonkologiai Osztaly, Amerikai ut 57., 1145 Budapest, Hungary.
RP Bago, AGy (reprint author), Semmelweis Egyetem, Idegsebeszeti es Neurointervencios Klinika, Neuroonkologiai Osztaly, 1145 Budapest, Hungary.
EM bago.attila@semmelweis.hu
CR Fatemi P, Zhang M, Miller KJ, et al. How intraoperative tools and techniques have changed the approach to brain tumor surgery. Curr Oncol Rep 20:89, 2018
   Parney IF, Berger MS. Principles of brain tumor surgery. Handb Clin Neurol 104:187–213, 2012
   Bago AG, Czirjak S, Fedorcsak I, et al. Az agy daganatos megbetegedesei. In: Az idegsebeszet alapjai. Ed. Banczerowski P, Vajda J. Medicina Konyvkiado Zrt., 2022, pp. 113–196
   Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol 130:269–282, 2016
   Bago A, Fedorcsak I, Nyary I. A neuronavigacio es szerepe a modern idegsebeszetben. Uj modszer ismertetese – az elso hazai tapasztalatok. Ideggy Szle/Clin Neurosci 53:1–2, 20–27, 2000
   Hu S, Kang H, Baek Y, et al. Real-time imaging of brain tumor for image- guided surgery. Adv Healthc Mater 7:e1800066, 2018
   Schupper AJ, Rao M, Mohammadi N, et al. Fluorescence-guided surgery: a review on timing and use in brain tumor surgery. Front Neurol 12:682151, 2021
   Potgieser AR, Wagemakers M, van Hulzen AL, et al. The role of diffusion tensor imaging in brain tumor surgery: a review of the literature. Clin Neurol Neurosurg 124:51–58, 2014
   Brown T, Shah AH, Bregy A, et al. Awake craniotomy for brain tumor resection: the rule rather than the exception? J Neurosurg Anesthesiol 25:240–247, 2013
   Dziedzic T, Bernstein M. Awake craniotomy for brain tumor: indications, technique and benefits. Expert Rev Neurother 14:1405–1415, 2014
   Tate MC. Surgery for gliomas. Cancer Treat Res 163:31–47, 2015
   Verburg N, de Witt Hamer PC. State-of-the-art imaging for glioma surgery. Neurosurg Rev 44:1331–1343, 2021
   Sales AHA, Beck J, Schnell O, et al. Surgical treatment of glioblastoma: state-of-the-art and future trends. J Clin Med 11:5354, 2022
   Mut M. Surgical treatment of brain metastasis: a review. Clin Neurol Neurosurg 114:1–8, 2012
   Proescholdt MA, Schodel P, Doenitz C, et al. The management of brain metastases-systematic review of neurosurgical aspects. Cancers 13:1616, 2021
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 13
EP 25
PG 13
ER

PT J
AU Mezei, T
   Baskay, J
   Pollner, P
   Kovacs, V
   Markia, B
   Nagy, G
   Bajcsay, A
   Sipos, L
AF Mezei, Tamas
   Baskay, Janos
   Pollner, Peter
   Kovacs, Viktoria
   Markia, Balazs
   Nagy, Gabor
   Bajcsay, Andras
   Sipos, Laszlo
TI Neurosurgical treatment of tumors of the pineal region – literature review and overview of cases at OMIII
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE pineal region; tumor; endoscopic surgery; radiotherapy
ID pineal region; tumor; endoscopic surgery; radiotherapy
AB Pineal region tumors account for less than 1% of adult supratentorial tumors. Their treatment requires a multimodality approach. Previously, the treatment of choice was direct surgery, which is associated with high surgical risk. Advances in minimally invasive techniques and onco-radiotherapy offer a safe and multimodal personalized therapy. The aim of our study was to describe the practice of our Institute based on combined endoscopic and radiotherapy techniques. We performed a retrospective clinical study. We processed data from 23 adult patients who underwent endoscopic third ventricle fenestration and pineal tumor biopsy between 2014 and 2023. Descriptive statistics, t-test, Fisher’s exact test and Kaplan-Meier analysis were performed. Clinical improvement with endoscopic intervention was achieved in 78.3% of cases. Significant increase in preoperative performance status was observed in the postoperative period (p=2.755e-5), and radiotherapy resulted in regression or stable disease. Our results suggest a safe treatment with good clinical outcome and an excellent alternative to direct surgery.
C1 [Mezei, Tamas] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Baskay, Janos] Semmelweis Egyetem, Egeszsegugyi Menedzserkepzo Kozpont, Adatvezerelt Egeszseg Divizio – Egeszsegbiztonsag Nemzeti LaboratoriumBudapest, Hungary.
   [Pollner, Peter] Semmelweis Egyetem, Egeszsegugyi Menedzserkepzo Kozpont, Adatvezerelt Egeszseg Divizio – Egeszsegbiztonsag Nemzeti LaboratoriumBudapest, Hungary.
   [Kovacs, Viktoria] Semmelweis Egyetem, Idegsebeszeti TanszekBudapest, Hungary.
   [Markia, Balazs] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Nagy, Gabor] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Sipos, Laszlo] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
RP Sipos, L (reprint author), National Institute of Neurosurgery, 1145 Budapest, Hungary.
EM lksipos@gmail.com
CR Vuong HG, Ngo TNM, Dunn IF. Incidence, prognostic factors, and survival trend in pineal gland tumors: a population-based analysis. Front Oncol 11:780173, 2021
   Al-Hussaini M, Sultan I, Abuirmileh N, et al. Pineal gland tumors: experience from the SEER database. J Neurooncol 94:351–358, 2009
   Gaillard F, Jones J. Masses of the pineal region: clinical presentation and radiographic features. Postgrad Med J 86:597–607, 2010
   Lombardi G, Poliani PL, Manara R, et al. Diagnosis and treatment of pineal region tumors in adults: a EURACAN overview. Cancers, Basel, 14:3646, 2022
   Morgenstern PF, Souweidane MM. Pineal region tumors: simultaneous endoscopic third ventriculostomy and tumor biopsy. World Neurosurg 79:S18.e9–13, 2013
   Morgenstern PF, Osbun N, Schwartz TH, et al. Pineal region tumors: an optimal approach for simultaneous endoscopic third ventriculostomy and biopsy. Neurosurg Focus 30:E3, 2011
   Sonabend AM, Bowden S, Bruce JN. Microsurgical resection of pineal region tumors. J Neurooncol 130:351–366, 2016
   Samadian M, Maloumeh EN, Shiravand S, et al. Pineal region tumors: Long-term results of endoscopic third ventriculostomy and concurrent tumor biopsy with a single entry approach in a series of 64 cases. Clin Neurol Neurosurg 184:105418, 2019
   Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231– 1251, 2021
   Lu VM, Luther EM, Eichberg DG, et al. Prognosticating survival of pineal parenchymal tumors of intermediate differentiation, PPTID, by grade. J Neurooncol 155:165–172, 2021
   Palmisciano P, Ogasawara C, Nwagwu CD, et al. Metastases in the pineal region: a systematic review of clinical features, management strategies, and survival outcomes. World Neurosurg 159:156–167, 2022
   Yamini B, Refai D, Rubin CM, et al. Initial endoscopic management of pineal region tumors and associated hydrocephalus: clinical series and literature review. J Neurosurg 100:437–441, 2004
   Cipri S, Gangemi A, Cafarelli F, et al. Neuroendoscopic management of hydrocephalus secondary to midline and pineal lesions. J Neurosurg Sci 49:97–106, 2005
   Fukushima T. Endoscopic biopsy of intraventricular tumors with the use of a ventriculofiberscope. Neurosurgery 2:110–113, 1978
   Oppido PA, Fiorindi A, Benvenuti L, et al. Neuroendoscopic biopsy of ventricular tumors: a multicentric experience. Neurosurg Focus 30:E2, 2011
   Shepard MJ, Haider AS, Prabhu SS, et al. Long term outcomes following surgery for pineal region tumors. J Neurooncol 156:491–498, 2022
   Rogers SJ, Mosleh-Shirazi MA, Saran FH. Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 6:509–519, 2005
   Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOPCNS- GCT-96 trial. Neuro Oncol 19:1661–1672, 2017
   Mynarek M, Pizer B, Dufour C, et al. Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology, SIOP-E, and US Head Start data. Neuro Oncol 19:576–585, 2017
   Mathieu D, Iorio-Morin C. Stereotactic radiosurgery for pineal region tumors. Prog Neurol Surg 34:173–183, 2019
   Zeynal M, Karaaslan B, Dagli O, et al. Stereotactic radiosurgery for tumors of the pineal region: A single-center experience. Medicine, Baltimore, 102:e34005, 2023
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 27
EP 35
PG 9
ER

PT J
AU Kovacs, �
AF Kovacs, Arpad
TI External radiation therapy of primary central nervous system tumors – current trends and practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE central nervous system; primary tumor; EBRT
ID central nervous system; primary tumor; EBRT
AB The family of primary central nervous system (CNS) tumors is a highly heterogeneous group of diseases. In the complex care of CNS tumors, in addition to surgical and systemic treatments, modern external beam radiation therapy (EBRT) plays a prominent role. This summary article provides an overview of the current indications related to EBRT, diagnostic procedures, contouring, planning, and radiation therapy techniques and applications that can be used in daily routine for adults’ most common primary CNS tumors.
C1 [Kovacs, Arpad] Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Onkoradiologiai Tanszek, Nagyerdei Krt. 98., 4032 Debrecen, Hungary.
RP Kovacs, � (reprint author), Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Onkoradiologiai Tanszek, 4032 Debrecen, Hungary.
EM kovacsarpad@med.unideb.hu
CR Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008– 2012. Neuro Oncol 17(Suppl 4):iv1–iv62, 2015
   Papathoma P, Thomopoulos TP, Karalexi MA, et al. Childhood central nervous system tumours: incidence and time trends in 13 Southern and Eastern European cancer registries. Eur J Cancer 51:1444–1455, 2015
   Hemminki K, Tretli S, Olsen JH, et al. Familial risks in nervous system tumours: joint Nordic study. Br J Cancer 102:1786–1790, 2010
   Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113:1953–1968, 2008
   Farooqi A, Li J, de Groot J, et al. Current role of radiation therapy in the management of malignant central nervous system tumors. Hematol Oncol Clin North Am 34:13–28, 2020
   Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820, 2016
   Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s, for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166, 2018
   Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251, 2021
   Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608, 2020
   Louis DN, Wesseling P, Aldape K, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30:844–856, 2020
   Ishkanian A, Laperriere NJ, Xu W, et al. Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer 117:4070–4079, 2011
   Brown PD, Anderson SK, Carrero XW, et al. Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251, Alliance). Neurooncol Pract 2:199–204, 2015
   Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer, EORTC, Study 22844. Int J Radiat Oncol Biol Phys 36:549–556, 1996
   Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267–2276, 2002
   Van Den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990, 2005
   Weller M, Van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186, 2021
   Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329, 1980
   Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial ofthe Scandinavian Glioblastoma Study Group. Cancer 47:649– 652, 1981
   Swennen MH, Bromberg JE, Witkamp TD, et al. Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neurooncol 66:333–339, 2004
   Lorentini S, Amelio D, Giri MG, et al. IMRT or 3DCRT in glioblastoma? A dosimetric criterion for patient selection. Technol Cancer Res Treat 12:411–420, 2013
   Amelio D, Lorentini S, Schwarz M, Amichetti M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol 97:361–369, 2010
   Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996, 2005
   Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466, 2009
   Van Den Bent MJ, Erridge S, Vogelbaum MA, et al. Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. J Clin Oncol 37(15_suppl):2000, 2019
   Van Den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350, 2013
   Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 17:1188–1198, 2015
   Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972, 2010
   Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol 13:279–289, 2017
   Sipos D, Toth Z, Lukacs G, et al. F-Dopa jelzett PET/CT-PET/MR alapu modern 3D besugarzastervezes glioblastoma multiformes, GBM-, betegek komplex kezeleseben: az elso magyarorszagi tapasztalatok. Ideggyogy Szle 72:209–215, 2019
   Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C] methionine. Eur J Nucl Med Mol Imaging 30:1561–1567, 2003
   Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2- [18F]fluoroethyl)-L-tyrosine, FET)- and L-[methyl-11C]methionine, MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 81:1049–1058, 2011
   Gotz I, Grosu AL. [(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients – a review. Front Oncol 3:104, 2013
   Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients – a report of the PET/RANO group. Neuro Oncol 23:881–893, 2021
   Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain J Neurol 128:678–687, 2005
   Jansen NL, Suchorska B, Wenter V, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 55:198–203, 2014
   Ladefoged CN, Law I, Anazodo U, et al. A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. Neuroimage 147:346–359, 2017
   Toth Z, Lukacs G, Cselik Z, et al. A PET/MR kepalkotas magyarorszagi klinikai alkalmazasanak lehetosegei, elso tapasztalatai. Orv Hetil 159:1375–1384, 2018
   Niyazi M, Brada M, Chalmers AJ, et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol 118:35–42, 2016
   Oppitz U, Maessen D, Zunterer H, et al. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57, 1999
   Lukacs G, Toth Z, Sipos D, et al. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients: the importance of MRI information in survival: single-center experience. Ideggyogy Szle 71:95–103, 2018
   Niyazi M, Andratschke N, Bendszus M, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol 184:109663, 2023
   Al-Hallaq HA, Cervino L, Gutierrez AN, et al. AAPM task group report 302: Surface-guided radiotherapy. Med Phys 49:82–112, 2022
   Boda-Heggemann J, Walter C, Rahn A, et al. Repositioning accuracy of two different mask systems-3D revisited: comparison using true 3D/3D matching with cone-beam CT. Int J Radiat Oncol Biol Phys 66:1568–1575, 2006
   Rosenfelder NA, Corsini L, McNair H, et al. Comparison of setup accuracy and intrafraction motion using stereotactic frame versus 3-point thermoplastic mask-based immobilization for fractionated cranial image guided radiation therapy. Pract Radiat Oncol 3:171–179, 2013
   Mir R, Kelly SM, Xiao Y, et al. Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. Radiother Oncol 150:30–39, 2020
   Munck AF, Rosenschold P, Law I, et al. Influence of volumetric modulated arc therapy and FET PET scanning on treatment outcomes for glioblastoma patients. Radiother Oncol 130:149–155, 2019
   Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926, 2012
   Lorentini S, Amelio D, Giri MG, et al. IMRT or 3DCRT in glioblastoma? A dosimetric criterion for patient selection. Technol Cancer Res Treat 12:411–420, 2013
   Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36, 2021
   Ruda R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol 20:445–456, 2018
   Oh MC, Ivan ME, Sun MZ, et al. Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. Neuro Oncol 15:208–215, 2018
   Warren KE, Vezina G, Poussaint TY, et al. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol 20:13–23, 2018
   Franceschi E, Hofer S, Brandes AA, et al. EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol 20:715–728, 2019
   Diamond C, Taylor TH, Im T, et al. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res 4:375–378, 2006
   Dabaja B, Milgrom S, Parikh R, et al. The challenges of applying radiation in primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 107:398– 400, 2020
   Ivanidze J, Roytman M, Lin E, et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging 29:650–656, 2019
   Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncol 23:1821–1834, 2021
   Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35–47, 2018
   Frappaz D, Dhall G, Murray M J, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro Oncol 24:516–527, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 37
EP 50
PG 14
ER

PT J
AU Fedorcsak, I
   Bajcsay, A
   Janvary, L
AF Fedorcsak, Imre
   Bajcsay, Andras
   Janvary, Levente
TI Stereotactic radiosurgery of brain tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE radiosurgery; fractionated stereotactic radiotherapy; brain tumor; brain metastasis; indications
ID radiosurgery; fractionated stereotactic radiotherapy; brain tumor; brain metastasis; indications
AB Stereotactic radiosurgery is today a well-established treatment modality for various intracranial pathologies. The principle of high dose focused intracranial radiation guided by stereotactic technique („Gamma Knife”) was introduced by the Swedish neurosurgeon Prof. Lars Leksell in 1968. After the advent of CT and later MR imaging, stereotactic radiosurgery evolved rapidly regarding indications, and new technical solutions made it possible for linear accelerator systems to perform radiosurgery. A huge number of patients are treated yearly worldwide with this technology. In this article we overview the major indications, advantages and possible complications of stereotactic radiosurgery.
C1 [Fedorcsak, Imre] National Institute of Neurosurgery, Amerikai ut 57., 1145 Budapest, Hungary.
   [Bajcsay, Andras] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Janvary, Levente] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Fedorcsak, I (reprint author), National Institute of Neurosurgery, 1145 Budapest, Hungary.
EM ifedorcsak@gmail.com
CR Lo SS. Stereotactic radiosurgery, Medscape, updated July 17. 2023. https:// emedicine.medscape.com/article/1423298-overview?form=fpf
   Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 102(Suppl): 195–199, 2005
   Hsieh CT, Ju DT. Stereotactic radiosurgery for recurrent glioblastoma multiforme. In: Tumor Progression and Metastasis. Ed. Lasfar A, Cohen-Solal K, 2020
   Lovo EE, Moreira A, Barahona KC, et al. Stereotactic radiosurgery for recurrent glioblastoma multiforme: a retrospective multi-institutional experience. Cureus 13:e18480, 2021
   Trifiletti DM, Chao ST, Sahgal A, Sheehan JP, eds). Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. A Comprehensive Guide. Springer, 2019
   Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492–516, 2021
   Young KH, Siddiqui F, Tanyi JA et al. A retrospective review of SBRT for larger brain metastases or post-resection cavities: preliminary evidence from the Knight Cancer Institute. J Radiat Oncol 3:253–258, 2014
   Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1040–1048, 2017
   Redmond KJ, De Salles A, Fariselli L, et al. Stereotactic radiosurgery for postoperative metastatic surgical cavities: a critical review and International Stereotactic Radiosurgery Society, ISRS, practice guidelines. Int J Radiat Oncol Biol Phys 111:68–80, 2021
   Liermann J, Winkler JK, Syed M, et al. Stereotactic radiosurgery with concurrent immunotherapy in melanoma brain metastases is feasible and effective. Front Oncol 10:592796, 2020
   Tonse R, Tom MC, Mehta MP, et al. Integration of systemic therapy and stereotactic radiosurgery for brain metastases. Cancers 13:3682, 2021
   Palumbo I, Pasqualetti F, Delishaj D, et al. Integrating stereotactic radiotherapy and systemic therapies. Rep Pract Oncol Radiother 27:310–317, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 53
EP 59
PG 7
ER

PT J
AU Lakosi, F
AF Lakosi, Ferenc
TI The role of whole brain irradiation nowadays: more or less or different?
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE whole brain radiotherapy; hippocampal sparing; memantine
ID whole brain radiotherapy; hippocampal sparing; memantine
AB In patients with poor performance status (KPS<50), ineligibility for effective systemic treatment and multiple brain metastases (BM) best supportive care is the preferred treatment over whole brain radiotherapy (WBRT). WBRT should be considered for the treatment of non-limited number (>4) brain metastases, depending on the patient’s life expectancy, neurological symptoms, size, number and location of brain metastases, indication, type and availability of systemic therapy. In these patients if life expectancy is >4 months without small cell histology and without hippocampal lesions, hippocampal sparing WBRT with or without memantine is recommended. Simultaneous integrated boost for the BM is a logical and supportable concept. Prophylactic cranial irradiation (PCI) is still recommended in small cell lung cancer patients with complete remission. Hippocampal sparing WBRT needs further validation in this indication.
C1 [Lakosi, Ferenc] Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi Kozpont, Guba Sandor u. 40., 7400 Kaposvar, Hungary.
RP Lakosi, F (reprint author), Somogy Megyei Kaposi Mor Oktato Korhaz, Baka Jozsef Diagnosztikai, Onkoradiologiai, Kutatasi es Oktatasi Kozpont, 7400 Kaposvar, Hungary.
EM lakosiferenc@yahoo.com
CR Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy, QUARTZ): results from a phase 3, non-inferiority randomized trial. Lancet 388:2004–2014, 2016
   Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 40:492–516, 2022
   Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during wholebrain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001. J Clin Oncol 38:1019–1029, 2020
   Popp I, Rau S, Hintz M, et al. Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer 126:2694–2703, 2020
   Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease, NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049–1060, 2017
   Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. JAMA 316:401–419, 2016
   Laack NN, Pugh SL, Brown PD, et al. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract 6:274–282, 2019
   Yamamoto M, Serizawa T, Higuchi Y, et al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases, JLGK0901 study update): Irradiation-related complications and long-term maintenance of mini-mental state examination scores. Int J Radiat Oncol 99:31–40, 2017
   Lebow ES, Hwang WL, Zieminski S, et al. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. J Neurooncol 148:81–88, 2020
   Dobi A, Fodor E, Maraz A, et al. Boost irradiation integrated to whole brain radiotherapy in the management of brain metastases. Pathol Oncol Res 26:149–157, 2020
   Oehlke O, Wucherpfennig D, Fels F, et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases. Strahlenther Onkol 191:461–469, 2015
   Popp I, Grosu AL, Fennell JT, et al. Optimization of hippocampus sparing during whole brain radiation therapy with simultaneous integrated boost— tutorial and efficacy of complete directional hippocampal blocking. Strahlenther Onkol 198:537–546, 2022
   Popp I, Rau A, Kellner E, et al. Hippocampus-avoidance whole-brain radiation therapy is efficient in the long-term preservation of hippocampal volume. Front Oncol 11:1–11, 2021
   Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol 83:487–493, 2017
   Duman JG, Dinh J, Zhou W, et al. Memantine prevents acute radiation- induced toxicities at hippocampal excitatory synapses. Neuro Oncol 20:655–665, 2018
   Ma TM, Grimm J, McIntyre R, et al. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation. Radiother Oncol 125:234–240, 2017
   Redmond KJ, Grimm J, Robinson CG, et al. Steep dose-response relationship between maximum hippocampal dose and memory deficits following hippocampal avoidance whole brain radiation therapy, HA-WBRT, for brain metastases: a secondary analysis of NRG/RTOG 0933. Int J Radiat Oncol 108:S176, 2020
   Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases, RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 32:3810–3816, 2014
   McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev 3:CD003154, 2019
   Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429–1437, 2013
   Duman JG, Dinh J, Zhou W, et al. Memantine prevents acute radiation induced toxicities at hippocampal excitatory synapses. Neuro Oncol 20:655– 665, 2018
   Wong P, Leppert IR, Roberge D, et al. A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget 7:50986–50996, 2016
   Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during wholebrain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG Oncology CC001. J Clin Oncol 38:1019–1030, 2020
   Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489, 2009
   Pan K, Zhao L, Gu S, et al. Deep learning-based automatic delineation of the hippocampus by MRI: geometric and dosimetric evaluation. Radiat Oncol 16:1–10, 2021
   Liu H, Clark R, Magliari A, et al. RapidPlan hippocampal sparing whole brain model version 2 – how far can we reduce the dose? Med Dosim 47:258– 263, 2022
   Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18:663–667, 2017
   Belderbos JSA, De Ruysscher DKM, De Jaeger K, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC, NCT01780675). J Thorac Oncol 16:840–849, 2021
   De Dios NR, Counago F, Murcia-Mejia M, et al. Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer, PREMER): A GICOR-GOECP-SEOR study. J Clin Oncol 39:3118–3127, 2023
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 60
EP 65
PG 6
ER

PT J
AU Mangel, L
AF Mangel, Laszlo
TI Systemic treatment of adult gliomas: a narrative review
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE glioma; glioblastoma; combined treatment; temozolomide; bevacizumab; immunotherapy
ID glioma; glioblastoma; combined treatment; temozolomide; bevacizumab; immunotherapy
AB Gliomas are considered as locally aggressive diseases, consequently, surgery and radiotherapy are the basic therapies of the glial tumors. Nevertheless, the long-term ineffectiveness of the local treatment modalities and the frequently observed relapses explain the unmet medical need for the elaboration of effective systemic treatment regimes. In the last few decades of the 20th century, the use of different chemotherapeutic agents and their combinations, and the alternative administration of drugs have been in the therapeutic forefront of gliomas, whereas, later, in the first years of this century temozolomide was introduced to the everyday clinical practice as the most effective „anti-glioma” medicine, and it is still widely used both in monotherapy and in different combinations. Nevertheless, in the last two decades, considering the recognition of different predictive molecular markers, different targeted therapies, e.g. VEGFR inhibitor agents were also introduced into the routine clinical practice, and there have been promising results published in immunotherapy trials in the recent years, as well. Besides the promising results with the novel systemic therapies, it should be emphasized that both in the primary and the salvage care of the glial tumors the most effective treatment options are the individualized combinations of local and systemic treatment modalities, with the proper interpretation of brain imaging data and patient-centered clinical management.
C1 [Mangel, Laszlo] University of Pecs, Oncotherapy Institute, Edesanyak utja 17., 7624 Pecs, Hungary.
RP Mangel, L (reprint author), University of Pecs, Oncotherapy Institute, 7624 Pecs, Hungary.
EM mangel.laszlo@pte.hu
CR Wilhelm I, Nyul-Toth A, Suciu M, et al. Heterogeneity of the blood-brain barrier. Tissue Barriers 4:e1143544, 2016
   Ahmed MH, Canney M, Carpentier A, et al. Overcoming the blood brain barrier in glioblastoma: Status and future perspective. Rev Neurol, Paris, 179:430–436, 2023
   Lesniak MS, Langer R, Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 1:210–216, 2001
   Krajcer A, Grzywna E, Lewandowska-Lancucka J. Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy. Biomed Pharmacother 165:115174, 2023
   Mangel L, Najbauer J, Kajtar B, Pongracz JE. A gliomak immunterapiajanak nehezsegei es remenyei. Magy Onkol 63:217–223, 2019
   Hildebrand J, Sahmoud T, Mignolet F, et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44:1479–1483, 1994
   Vitanovics D, Sipos L, Afra D. BCNU-DBD, dibromodulcitol, chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas. Neoplasma 49:342–345, 2002
   Hildebrand J, Gorlia T, Kros JM, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study, EORTC study 26882). Eur J Cancer 44:1210–1216, 2008
   Roux A, Caire F, Guyotat J, et al. Carmustine wafer implantation for highgrade gliomas: Evidence-based safety, efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. Neurochirurgie 63:433–443, 2017
   Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987– 996, 2005
   Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466, 2009
   Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569, 2006
   Sipos L, Vitanovics D, Afra D. Recidiv malignus gliomak kezelese temozolomide- dal. Orv Hetil 143:1201–1204, 2002
   Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29–38, 2008
   Gramatzki D, Kickingereder P, Hentschel B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 88:1422–1430, 2017
   Quan R, Zhang H, Li Z, et al. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. Medicine, Baltimore, 99:e18591, 2020
   Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 19:1119– 1126, 2017
   Alimohammadi E, Bagheri SR, Taheri S, et al. The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta- analysis and systematic review. Oncol Rev 14:461, 2020
   Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter, CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393:678–688, 2019
   van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial, EORTC study 26053–22054, of treatment with concurrent and adjuvant temozolomide for 1p/19q non-codeleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390:1645–1653, 2017
   Van den Bent MJ, Tesileanu CMS, Wick W, et al. Adjuvant and concurrent temozolomide for 1p/19q non-codeleted anaplastic glioma, CATNON; EORTC study 26053–22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813–823, 2021
   Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63–68, 2009
   Marwah R, Xing d, Squire T, et al. Reirradiation versus systemic therapy versus combination therapy for recurrent high grade glioma: a systematic review and meta analysis of survival and toxicity. J Neurooncol 164:505–524, 2023
   Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729, 2007
   Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336, 2009
   Fu M, Zhou Z, Huang X, et al. Use of bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer 23:544, 2023
   Kim MM, Umemura Y, Leung D. Bevacizumab and glioblastoma: past, present, and future directions. Cancer J 24:180–186, 2018
   Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340, 2011
   Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33:2735–2744, 2015
   Nesseler JP, Schaue D, McBride WH, et al. Irradiation to improve the response to immunotherapeutic agents in glioblastomas. Adv Radiat Oncol 4:268–282, 2018
   Wang X, Guo G, Guan H, et al. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 38:87, 2019
   Xu Y, Guan H, Yu K, et al. Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis. Front Pharmacol 14:1191480, 2023
   Lombardi G , De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma, REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110–119, 2019
   Van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 16:1570–1574, 2014
   NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 1.2023. https://www.nccn.org/professionals/physician_ gls/pdf/cns.pdf
   McGranahan T, Therkelsen KE, Ahmad S, et al. Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol 20:24, 2019
   Srivastava S, Jackson C, Kim T, et al. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers, Basel, 11:537, 2019
   Maxwell R, Luksik AS, Garzon-Muvdi T, et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology 7:e1500108, 2018
   Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11:504–514, 2015
   Garant A, Guilbault C, Ekmekjian T. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. Crit Rev Oncol Hematol 120:86–92, 2017
   Abid H, Watthanasuntorn K, Shah O, et al. Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier. Cureus 11:e4446, 2019
   Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003–1010, 2020
   Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, Check- Mate-143: the game is not over yet. Oncotarget 8:91779–91794, 2017
   Omuro A, Reardon DA, Sampson JH, et al. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neurooncol Adv 4:vdac025, 2022
   Reardon DA, Kim TM, Frenel JS, et al. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127:1620–1629, 2021
   Agosti E, Zeppieri M, De Maria L, et al. Glioblastoma immunotherapy: a systematic review of the present strategies and prospects for advancements. Int J Mol Sci 24:15037, 2023
   Yang K, Wu Z, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21:39, 2022
   Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 389:589–601, 2023
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 67
EP 75
PG 9
ER

PT J
AU Horvath, O
   Kovacs, P
AF Horvath, Orsolya
   Kovacs, Peter
TI The importance and areas of modern supportive and early integrated palliative care in the treatment of brain tumor patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE supportive care; palliative care; quality of life; brain tumor; communication; burnout
ID supportive care; palliative care; quality of life; brain tumor; communication; burnout
AB During the care of brain tumor patients, supportive care and palliation are carried out in an individualized manner, accompanied by adequate communication, in a multidisciplinary professional environment. In the case of brain tumor patients, the burden of symptoms resulting from the progression of the disease and the complications of treatments occur in a particularly high proportion. The supportive care of patients in a modern approach covers the targeted treatment of physical and psychosocial problems and also includes integrated palliation. Palliative care is a form of care that can be used in addition to curative therapies, and it is advisable and necessary to introduce it as early as possible among brain tumor patients due to the significant deterioration of the quality of life. Dealing with seriously ill patients on a daily basis is also an emotional burden for the professional staff, and carries the risk of burnout. The support of the staff and family members, as well as the issues of adequate communication, are also part of the scope of the supportive care approach.
C1 [Horvath, Orsolya] Orszagos Onkologiai Intezet, Rehabilitacios Reszleg, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Kovacs, Peter] Orszagos Onkologiai Intezet, Onkopszichologiai ReszlegBudapest, Hungary.
RP Kovacs, P (reprint author), Orszagos Onkologiai Intezet, Onkopszichologiai Reszleg, Budapest, Hungary.
EM kovacs.peter@oncol.hu
CR Janda M, Eakin EG, Bailey L, et al. Supportive care needs of people with brain tumours and their carers. Support Care Cancer 14:1094–1103, 2006
   Zahid N, Martins RS, Brown N, et al. Psychosocial factors influencing quality of life in patients with primary brain tumors in Pakistan: an analytical cross-sectional study. BMC Res Notes 16:1–7, 2023
   Jalali R, Dutta D. Factors influencing quality of life in adult patients with primary brain tumors. Neuro Oncol 14:8–16, 2012
   Pan CJ, Liu HC, Liang SY, et al. Resilience and coping strategies influencing the quality of life in patients with brain tumor. Clin Nurs Res 28:107–124, 2019
   Kohler M, Steinmann E, Maximilian MH, et al. The importance of social relationships for brain tumor patients’ quality of life: A case for the inclusion of the concept of disclosure in psycho-oncological care. J Psychosoc Oncol 38:310–327, 2020
   Zdun-Ryzewska A, Basinski K, Majkowicz M, et al. Association between social support and quality of life in patients with affective disorders. Eur J Psychiatry 32:132–138, 2018
   Liang SY, Liu HC, Lu YY, et al. The influence of resilience on the coping strategies in patients with primary brain tumors. Asian Nurs Res 14:50–55, 2020
   Pace A, Dirven L, Koekkoek JA, et al. European Association for Neuro-Oncology, EANO, guidelines for palliative care in adults with glioma. Lancet Oncol 18:330–340, 2017
   National Comprehensive Cancer Network, NCCN). Guidelines for Patients – Brain Cancer, 2021). https://www.nccn.org/patients/guidelines/content/ PDF/brain-gliomas-patient.pdf
   Magyar Hospice-Palliativ Egyesulet.Vegsokig kiserni – Tanacsado fuzet. https://hospice.hu/docu/Vegsokig-kiserni.pdf
   Tarsasag a Szabadsagjogokert. Meltosaggal meghalni, 2018. https:// hospice.hu/docu/Meltosaggal-meghalni.pdf
   Young JS, Al-Adli N, Sibih YE, et al. Recognizing the psychological impact of a glioma diagnosis on mental and behavioral health: a systematic review of what neurosurgeons need to know. J Neurosurg 1:1–9, 2022
   Rooney AG, McNamara S, Mackinnon M, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol 29:4307–4312, 2011
   Belugyminiszterium, Egeszsegugyi Allamtitkarsag. Egeszsegugyi szakmai iranyelv az onkopszichologiai ellatasrol. Egeszsegugyi Kozlony, LXXI:1955–2007, 2021. http://www.kozlonyok.hu/kozlonyok/Kozlonyok/6/PDF/2021/19.pdf
   National Comprehensive Cancer Network, NCCN). Guidelines for Central Nervous System Cancers, 2023). https://www.nccn.org/guidelines/ guidelines-detail?category=1&id=1425
   Ownsworth T, Chambers S, Damborg E, et al. Evaluation of the making sense of brain tumor program: a randomized controlled trial of a homebased psychosocial intervention. Psychooncology 24:540–547, 2015
   Palfine KA, Zana A. Pszichoszocialis tamogatas. In: Palliativ ellatas. Ed. Csikos A. Medicina, Budapest, 2022, pp. 496–511
   Halkett GK, Lobb EA, Rogers MM, et al. Predictors of distress and poorer quality of life in high grade glioma patients. Patient Educ Couns 98:525–532, 2015
   Goebel S, Stark AM, Kaup L, et al. Distress in patients with newly diagnosed brain tumours. Psychooncology 20:623–630, 2011
   Randazzo D, Peters KB. Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. CNS Oncol 5:241–249, 2016
   Halkett GK, Lobb E, Spilsbury K, et al. Brain cancer patients’ levels of distress and supportive care needs over time. Psychooncology 31:2074– 2085, 2022
   Rohanszky M, Kegye A, Molnar M, et al. Pszichoszocialis onkologia. Zafir Press 2014, pp. 192–193
   Riba MB, Donovan KA, Andersen B, et al. Distress management, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:1229–1249, 2019
   Ford E, Catt S, Chalmers A, et al. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro Oncol 14:392– 404, 2012
   Walbert T, Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat Res 163:171–184, 2015
   Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. J Clin Oncol 30:1187–1196, 2012
   Pidani AS, Siddiqui AR, Azar I, et al. Depression among adult patients with primary brain tumour: a cross-sectional study of risk factors in a low– middle-income country. BMJ Open 10:327–348, 2020
   Newton HB, Ray L. Supportive care of brain tumor patients. In: Epilepsy and Brain Tumors. Ed. Newton HB, Maschio M. Academic Press 2015, pp. 45–63
   Stark D, Kiely M, Smith A, et al. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20:3137–3148, 2002
   Eaton KD, Frieze DA. Cancer pain: Perspectives of a medical oncologist. Curr Pain Headache Rep 12:270–276, 2008
   Belugyminiszterium, Egeszsegugyi Allamtitkarsag. Egeszsegugyi szakmai iranyelv a daganatos felnott betegek teljes koru hospice es palliativ ellatasarol. Egeszsegugyi Kozlony LXXIII:476–526, 2023. http://www.kozlonyok. hu/kozlonyok/index.php?m=0&p=kozltart&ev=2023&szam=4&k=6 [cited 2023.08.16.], https://hospice.hu/jogszabalyok-rendeletek/2023-03-24_A_ Belugyminiszterium_ egeszsegugyi_szakmai
   Csikos A. Palliativ szedacio. In: Palliativ ellatas. Ed. Csikos A. Medicina, Budapest, 2022, pp. 452–462
   Lovey J. A daganatos betegek taplalasterapiaja. Magy Onkol 61:229–237, 2017
   McGovern J, Dolan RD, Skipworth RJ, et al. Cancer cachexia: a nutritional or a systemic inflammatory syndrome? Br J Cancer 127:379–382, 2022
   Law ML. Cancer cachexia: Pathophysiology and association with cancer- related pain. Front Pain Res 3:971295, 2022
   Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547, 2013
   Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489–495, 2011
   Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608, 2007
   Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89–95, 2007
   Berger AM, Mooney K, Alvarez-Perez A, et al. Cancer-related fatigue, version 2.2015. J Natl Compr Canc Netw 13:1012–1039, 2015
   Grant R, Brown PD. Fatigue randomized controlled trials—how tired is “too tired” in patients undergoing glioma treatment? Neuro Oncol 18:759– 760, 2016
   Walbert T. Palliative care, end-of-life care, and advance care planning in neuro-oncology. Continuum 23:1709–1726, 2017
   World Health Organization Definition of Palliative Care. https://www. who.int/health-topics/palliative-care
   World Health Organization. National cancer control programmes: policies and managerial guidelines. 2002. https://apps.who.int/iris/bitstream/ handle/10665/42494/9241545577.pdf?sequence=1&isAllowed=y
   Agarwal R, Epstein AS. The role of palliative care in oncology. Semin Intervent Radiol 34:307–312, 2017
   Csikos A. A palliativ ellatas alapjai, jelenlegi helyzete es kihivasai. In: Palliativ ellatas. Ed. Csikos A. Medicina, Budapest, 2022, pp. 35–50
   Horvath O, Racz K, Jakus N, et al. A hospice-palliativ ellatas hatekony integralasa a hazai onkologiai es csaladorvosi gyakorlatba. Orv Hetil 163:1520–1527, 2022
   Horvath O, Foldesi E, Hegedus K. Mikor es hogyan integraljuk az onkologiai es a palliativ ellatast? Orv Hetil 162:1769–1775, 2021
   Hawley PH. The bow tie model of 21st century palliative care. J Pain Symptom Manag 47:2–5, 2014
   Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33:1438–1445, 2015
   Busa C, Zeller J, Csikos A. Ki dontson az elet vegen? Az ellatas elozetes tervezesenek nemzetkozi gyakorlata es hazai lehetosegei. Orv Hetil 159:131–140, 2018
   Magyar Hospice Alapitvany. Segedlet elozetes egeszsegugyi rendelkezes elokeszitesehez, 2017. https://hospicehaz.hu/wp-content/uploads/2022/07/ Nyilatkozatminta-Elozetes-eu-rendelkezes-MHA.pdf
   Applebaum AJ, Kryza-Lacombe M, Buthorn J, et al. Existential distress among caregivers of patients with brain tumors: a review of the literature. Neurooncol Pract 3:232–244, 2016
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 77
EP 85
PG 9
ER

PT J
AU Smanyko, V
AF Smanyko, Viktor
TI Local treatment of ipsilateral breast cancer recurrences: comparison of alternative therapeutic options
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
DE breast cancer; local recurrence; second breast conserving therapy; salvage mastectomy; brachytherapy
ID breast cancer; local recurrence; second breast conserving therapy; salvage mastectomy; brachytherapy
AB We compared the clinical outcomes of second breast conserving therapy (2ndBCT) versus salvage mastectomy (sMT) for the treatment of ipsilateral breast tumour recurrences (IBTR). 195 patients who presented with an IBTR after previous breast conserving treatment were salvaged either with re-excision and perioperative interstitial brachytherapy (n=39) or sMT (n=156). A total dose of 5×4.4Gy was delivered to the tumour bed, on 3 consecutive days. The median follow-up time was 59 and 56 months. During follow-up 4 (10.2%) and 28 (17.9%) second local recurrences occurred after 2ndBCT and sMT, respectively. There were no significant differences between treatments in 5-year oncological outcomes (local and regional recurrence-free survival, disease- and metastasis-free survival, cancer-specific and overall survival). After 2ndBCT, the rate of good to excellent cosmesis was 70%. 2ndBCT is a safe and feasible option for the management of IBTR, resulting similar 5-year oncological outcomes and better cosmetic results compared to sMT.
C1 [Smanyko, Viktor] Semmelweis University, School of PhD StudiesBudapest, Hungary.
RP Smanyko, V (reprint author), Semmelweis University, School of PhD Studies, Budapest, Hungary.
EM smanyko.viktor@oncol.hu
CR Smanyko V, Meszaros N, Ujhelyi M, et al. Masodik emlomegtarto mutet es szovetkozi sugarkezeles az emlodaganat lokalis kiujulasanak kezelesere. Orv Hetil 159:430–438, 2018
   Smanyko V, Meszaros N, Ujhelyi M, et al. Second breast-conserving surgery and interstitial brachytherapy vs. salvage mastectomy for the treatment of local recurrences: 5-year results. Brachytherapy 18:411–419, 2019
   Hannoun-Levi JM, Gal J, Van Limbergen E, Smanyko V, et al. Salvage mastectomy versus second conservative treatment for second ipsilateral breast tumor event: a propensity score-matched cohort analysis of the GEC-ESTRO Breast Cancer Working Group Database. Int J Radiat Oncol Biol Phys 110:452–461, 2021
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2024
VL 68
IS 1
BP 86
EP 88
PG 0
ER

PT J
AU Polgar, Cs
AF Polgar, Csaba
TI Preface
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Polgar, Csaba] National Institute of Oncology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Polgar, Cs (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 93
EP 93
PG 1
ER

PT J
AU Weber, A
   Szatmari, I
   Dobozi, M
   Keki, Zs
   Hilbert, L
   Branyiczkine, GG
   Nagy, P
   Polgar, Cs
   Kenessey, I
AF Weber, Andras
   Szatmari, Istvan
   Dobozi, Maria
   Keki, Zsuzsanna
   Hilbert, Laszlone
   Branyiczkine, Geczy Gabriella
   Nagy, Peter
   Polgar, Csaba
   Kenessey, Istvan
TI County differences in incidence and mortality of malignant neoplasms in Hungary between 2005 and 2019
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cancer incidence; mortality; county regional differences
ID cancer incidence; mortality; county regional differences
AB The objective of our study was to map county differences in incidence and mortality by cancers and examine their changes over time. Based on the database of National Cancer Registry and Central Statistical Office, age-standardized incidence and mortality rates per 100,000 person-years were calculated for each county for 15 cancer types and 3 time periods. East-West divide was apparent in incidence and mortality of lung cancer, with larger weight in East (Borsod-Abauj-Zemplen, Heves, Jasz-Nagykun-Szolnok, Bekes counties). Concentration of lip and oral cavity malignancies was identified in the northeastern periphery (Borsod-Abauj-Zemplen, Szabolcs-Szatmar-Bereg counties). Breast cancer incidence was the highest in Budapest. As a conclusion, changes in cancer incidence and mortality over time were similar to developed countries; however, values were higher. Differences in spatial distribution follow territorial pattern of social deprivation, which correspond to higher prevalence of health risk factors. Our study contributes to planning of public health programs by pinpointing regional inequalities in different cancer types.
C1 [Weber, Andras] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Szatmari, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Dobozi, Maria] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Keki, Zsuzsanna] Kozponti Statisztikai HivatalBudapest, Hungary.
   [Hilbert, Laszlone] Kozponti Statisztikai HivatalBudapest, Hungary.
   [Branyiczkine, Geczy Gabriella] Kozponti Statisztikai HivatalBudapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kenessey, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Weber, A (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM weber.andras@oncol.hu
CR WHO The Global Health Observatory. Global health estimates: Leading causes of death. Cause-specific mortality, 2000–2019, https://www.who.int/ data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading- causes-of-death
   Cancer today, International Agency for Research on Cancer, 2023, http:// gco.iarc.fr/today/home
   Statistics, Eurostat, 2023, https://ec.europa.eu/eurostat/databrowser/ view/hlth_cd_asdr2/default/table?lang=en
   Regulation, EC, No 1059/2003 of the European Parliament and of the Council of 26 May 2003 on the establishment of a common classification of territorial units for statistics, NUTS), https://eur-lex.europa.eu/legal-content/ EN/ALL/?uri=CELEX%3A32003R1059
   Kasler M, Otto Sz, Kenessey I. A rakmorbiditas es -mortalitas jelenlegi helyzete a Nemzeti Rakregiszter tukreben. Orv Hetil 158:84–89, 2017
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175–184, 2022
   Orszagos Onkologiai Intezet, Nemzeti Rakregiszter es Biostatisztikai Kozpont, 2023, http://stat.nrr.hu/
   Weber A, Mery L, Nagy P, et al. Evaluation of data quality at the Hungarian National Cancer Registry, 2000–2019. Cancer Epidemiol 82:102306, 2023
   Weber A, Szatmari I, Dobozi M, et al. A Kozponti Statisztikai Hivatal halalozasi adatainak osszevetese a Nemzeti Rakregiszter adatbazisaval – Egy adat-osszekapcsolas tanulsagai. Orv Hetil 163:1481–1489, 2022
   Kozponti Statisztikai Hivatal, 2023, https://www.ksh.hu/
   WHO: A betegsegek es az egeszseggel kapcsolatos problemak nemzetkozi statisztikai osztalyozasa, 10. revizio. Nepjoleti Miniszterium, 1995
   Magyarorszag helysegnevtara, 2023, https://www.ksh.hu/apps/hntr.main
   KSH Statinfo v39, Temakorvalaszto, 2023, https://statinfo.ksh.hu/Statinfo/ themeSelector.jsp?lang=hu
   Pace M, Lanzieri G, Glickman M, et al. Revision of the European Standard Population: report of Eurostat’s task force, Eurostat, 2013
   Parkin D, Whelan S, Ferlay J, et al. Cancer incidence in five continents. Vol. VIII. IARC scientific publications, 2002
   R: The R Project for Statistical Computing, 2023, https://www.r-project. org/
   Lovelace R, Nowosad J, Muenchow J. Geocomputation with R. Chapman and Hall/CRC, 2019
   Vaccarella S, Georges D, Bray F, et al. Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study. Lancet Reg Health Eur 25:100551, 2022
   European Cancer Information System, 2023, https://ecis.jrc.ec.europa. eu/
   Cancer Over Time, International Agency for Research on Cancer, 2023, https://gco.iarc.fr/overtime
   Vajda R, Bodis J, Ponusz-Kovacs D, et al. A szervezett lakossagi mehnyakszures reszveteli mutatoi Magyarorszagon. Magy Onkol 66:186–193, 2022
   Laczo A, Bodis J, Bogner P, et al. A szervezett lakossagi mammografias emloszures reszveteli mutatoi 2012–2021 kozott Magyarorszagon. Magy Onkol 66:195–200, 2022
   Kives Z, Bodis J, Hunyady B, et al. A kolorektalis szuresek reszveteli mutatoi Magyarorszagon 2008–2021 kozott. Magy Onkol 66:209–217, 2022
   Population and social conditions, Health, Health Care, Preventive Services, Statistics, Eurostat, 2023, https://ec.europa.eu/eurostat/web/main/ data/database
   Kenessey I, Szoke G, Dobozi M, et al. Comparison of cancer survival trends in Hungary in the periods 2001–2005 and 2011–2015 according to a population-based cancer registry. Pathol Oncol Res 28:1610668, 2022
   Gyulai A, Nagy A, Pataki V, et al. General practitioners can increase participation in cervical cancer screening – a model program in Hungary. BMC Fam Pract 19:67, 2018
   Adany R, Juhasz A, Nagy C. A rosszindulatu daganatos betegsegek es morbiditasi es mortalitasi kockazatanak eloszlasa hazankban a deprivacioval osszefuggesben. Magy Bel Arch 71:244–256, 2018
   Vincze I, Nador G, Paldy A, et al. Fontosabb betegsegek miatti halandosag teruleti eloszlasa Magyarorszagon 1986–1997. Nemzeti Kornyezet- egeszsegugyi Akcioprogram, 2000
   Galffy G, Vastag A, Bogos K, et al. Significant regional differences in lung cancer incidence in Hungary: Epidemiological study between 2011 and 2016. Pathol Oncol Res 27:1609916, 2021
   Kiss I, Sandor J, Nagymajtenyi L, Ember I. A daganatos halalozasok regionalis es megyei megoszlasa Magyarorszagon. In: A magyar lakossag egeszsegi allapota az ezredfordulon. Medicina Konyvkiado, Budapest 2003, 121–128
   Balint L. A teruleti halandosagi kulonbsegek alakulasa Magyarorszagon 1980–2006. KSH Nepessegtudomanyi Kutato Intezet, Budapest, 2010
   Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control 3:242, 1994
   Voko Z, Barra M, Molnar A, et al. Az alacsony dozisu CT-vel vegzett tudorakszures magyarorszagi egeszseg-gazdasagtani elemzesenek koncepcionalis terve. Orv Hetil 158:963–975, 2017
   De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382:503–513, 2020
   National Center for Chronic Disease Prevention and Health Promotion, US, Office on Smoking and Health. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention, US), Atlanta, GA), 2014
   Rumgay H, Murphy N, Ferrari P, et al. Alcohol and cancer: Epidemiology and biological mechanisms. Nutr J 13:3173, 2021
   Paldy A, Nador G, Vincze I, et al. Az ajak, szajureg es garat rosszindulatu daganatos betegsege miatti halalozas valamint a morbiditas teruleti kulonbsegei Magyarorszagon. Magy Onkol 45:106–114, 2001
   Marosi E, Polgar Cs, Takacsi-Nagy Z, et al. iPAAC WP5 – Szajuregi daganatok korai felismeresere iranyulo pilotprogram Magyarorszagon. Magy Onkol 65(1. Szuppl.):40, 2021
   Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308–347, 2021
   Stordal B. Breastfeeding reduces the risk of breast cancer: A call for action in high-income countries with low rates of breastfeeding. Cancer Med 12:4616–4625, 2022
   Steponavicienė L, Vanseviciutė R, Zabulienė L, et al. Reproductive factors and breast cancer risk in Lithuanian women: A population-based cohort study. AML 27:70–75, 2020
   Jozan P. Rakepidemiologiai viszonyok Magyarorszagon. Magy Tud 2005:931, 2005
   Kovacs K. Tarsadalmi egyenlotlensegek a mortalitasban Magyarorszagon, 1971–2008, es az epidemiologiai atmenet elmelete. KSH Nepessegtudomanyi Kutato Intezet, Budapest, 2011
   Siller G, Paldy A, Nador G, et al. A prosztata rosszindulatu daganata, BNO-10: C61, miatti mortalitas es morbiditas teruleti megoszlasa Magyarorszagon. Magy Onkol 45:131–137, 2002
   Szalontai J, Horvath A, Szucs M, et al. A prosztatarak szurese – mult, jelen, jovo. Magy Onkol 66:219–222, 2022
   Lissowska J, Bardin-Mikolajczak A, Fletcher T, et al. Lung cancer and indoor pollution from heating and cooking with solid fuels: The IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol 162(:326–333, 2005
   Sandor J, Szerencse P, Szucs M, et al. Kornyezeti eredetu daganatos megbetegedesek teruleti halmozodasainak vizsgalata. Magy Onkol 47:177– 183, 2003
   Lynge E, Holmsgaard HA, Holmager TLF, et al. Cancer incidence in Thyboron- Harboore, Denmark: a cohort study from an industrially contaminated site. Sci Rep 11:13006, 2021
   Liszkay G, Benedek A, Polgar C, et al. Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019. J Eur Acad Dermatol Venereol 37:932–940, 2023
   Parrag P, Weber A, Liszkay G, et al. A melanoma hazai morbiditasi es mortalitasi helyzete a XXI. szazad elso ket evtizedeben. Magy Onkol 66:94– 99, 2022
   Kenessey I, Weber A, Szilagyi I, et al. Az orvosi kodtarak gyakorlati alkalmazasa az onkologiaban – szakmai utmutato a Nemzeti Rakregiszter tapasztalatai alapjan. Magy Onkol 66:4–10, 2022
   Flanders WD. Inaccuracies of death certificate information. J Epidemiol 3:3–5, 1992
   Kiss Z, Bogos K, Tamasi L, et al. Underlying reasons for post-mortem diagnosed lung cancer cases – A robust retrospective comparative study from Hungary, HULC study). Front Oncol 12:1032366, 2022
   Kendrey G, Szende B, Lapis K, et al. Misdiagnosis of lung cancer in a 2000 consecutive autopsy study in Budapest. Gen Diagn Pathol 141:169– 178, 1996
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 95
EP 112
PG 10
ER

PT J
AU Parrag, P
   Dobozi, M
   Szatmari, I
   Weber, A
   Nagy, P
   Polgar, Cs
   Kenessey, I
AF Parrag, Petra
   Dobozi, Maria
   Szatmari, Istvan
   Weber, Andras
   Nagy, Peter
   Polgar, Csaba
   Kenessey, Istvan
TI The pitfalls of lung cancer coding practices based on the evaluation of the National Cancer Registry
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cancer registry; data collection; epidemiology; public health; validity
ID cancer registry; data collection; epidemiology; public health; validity
AB The quality of input data determines the reliability of epidemiological assessments. Thus, the verification of cases reported to the National Cancer Registry is required. The objective of our study was evaluating the reliability of cases diagnosed by lung cancer, exploring the patterns of erroneous reports. The validation of the 11,750 lung cancer cases reported to the Cancer Registry in 2018 was performed with the involvement of the recording hospitals, analyzing the characteristics of reports by gender, age and attributes of the reporting institutions. 81.3 percent of the reported cases was confirmed, in 40.4 percent of the false reports, malignancy was not present at all. Among the erroneous cases women and the elderly age group were overrepresented. The highest deleted rate occurred in Borsod- Abauj-Zemplen county. As a conclusion, there is a strong need for the improvement of the efficiency in encoding lung cancer. The most common errors: confusion of malignant-benign, cancerous-non-cancerous and primary-metastatic lesions. The reliability is not affected by the role of individual institutions in the hierarchy of health care. The availability of reliable epidemiological data is crucial in the fight against cancer, which requires broad professional cooperation.
C1 [Parrag, Petra] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Dobozi, Maria] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Szatmari, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Weber, Andras] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Nagy, Peter] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kenessey, Istvan] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Kenessey, I (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM kenessey.istvan@oncol.hu
CR International Agency for Reserach on Cancer, IARC). Cancer over time. Available from: https://gco.iarc.fr/overtime/en
   Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387, 2018
   1997. evi CLIV. torveny az egeszsegugyrol. https://net.jogtar.hu/jogszabaly? docid=99700154.TV
   WHO. A betegsegek es az egeszseggel kapcsolatos problemak nemzetkozi statisztikai osztalyozasa, 10. revizio. Nepjoleti Miniszterium, 1995
   Weber A, Mery L, Nagy P, et al. Evaluation of data quality at the Hungarian National Cancer Registry, 2000–2019. Cancer Epidemiol 82:102306, 2023
   Kenessey I. Egyesitett nemzeti adatbazisok a regiszterfejlesztes szolgalataban – A Nemzeti Rakregiszter mukodesi gyakorlata, az adatok felhasznalasa. IME – Interdiszciplinaris Magyar Egeszsegugy XVIII:59–63, 2019
   49/2018., XII. 28., EMMI-rendelet a nepegeszsegugyi szempontbol kiemelt jelentosegu vagy egyebkent jelentos koltsegteherrel jaro megbetegedesek korerol, a megbetegedeseket nyilvantarto betegsegregisztert vezeto szerv kijeloleserol, valamint ezen megbetegedesek bejelentesere es nyilvantartasara vonatkozo reszletes szabalyokrol. https://net.jogtar.hu/ jogszabaly?docid=a1800049.emm
   Az Emberi Eroforrasok Miniszteriuma modszertani levele a betegsegregiszterek adattartalmarol. 2019;2. http://www.kormany.hu/download/b/ ea/81000/ML.pdf
   O’Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours – towards common understanding and reasonable expectations. Lancet Oncol 18:849–851, 2017
   https://www.ksh.hu/
   The R project for statistical computing. https://www.r-project.org/
   Binder H, Blettner M. Big data in medical science – a biostatistical view. Dtsch Arztebl Int 112:137–142, 2015
   Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45:747–755, 2009
   Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 45:756–764, 2009
   Dimitrova N, Parkin DM. Data quality at the Bulgarian National Cancer Registry: An overview of comparability, completeness, validity and timeliness. Cancer Epidemiol 39:405–413, 2015
   Ryzhov A, Bray F, Ferlay J, et al. Evaluation of data quality at the National Cancer Registry of Ukraine. Cancer Epidemiol 53:156–165, 2018
   Barchuk A, Tursun-Zade R, Nazarova E, et al. Completeness of regional cancer registry data in Northwest Russia 2008-2017. BMC Cancer 23:994, 2023
   Maret-Ouda J, Tao W, Wahlin K, Lagergren J. Nordic registry-based cohort studies: Possibilities and pitfalls when combining Nordic registry data. Scand J Public Health 45:14–19, 2017
   Kenessey I, Weber A, Szilagyi I, et al. Az orvosi kodtarak gyakorlati alkalmazasa az onkologiaban – szakmai utmutato a Nemzeti Rakregiszter tapasztalatai alapjan. Magy Onkol 66:4–10, 2022
   Kenessey I, Patocs A, Dobozi M, et al. A kozponti idegrendszer primer rosszindulatu daganatainak epidemiologiaja es etiologiaja. Magy Onkol 67:279–287, 2023
   Kendrey G, Szende B, Lapis K, et al. Misdiagnosis of lung cancer in a 2000 consecutive autopsy study in Budapest. Gen Diagn Pathol 141:169–178, 1996
   Maudsley G, Williams EM. What lessons can be learned for cancer registration quality assurance from data users? Skin cancer as an example. Int J Epidemiol 28:809–815, 1999
   Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490, 2015
   Molina-Ortiz EI, Vega AC, Calman NS. Patient registries in primary care: essential element for quality improvement. Mt Sinai J Med 79:475–480, 2012
   Hoeijmakers F, Beck N, Wouters M, et al. National quality registries: how to improve the quality of data? J Thorac Dis 10:S3490–S3499, 2018
   Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308–347, 2021
   Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol 1:505–527, 2015
   Bogos K, Kiss Z, Galffy G, et al. A tudorak hazai epidemiologiai adatai uj megkozelitesben. Magy Onkol 64:175–181, 2020
   Nahvijou A, Esmaeeli E, Kalaghchi B, et al. Using electronic health record system to establish a national patient’s registry – Lessons learned from the Cancer Registry in Iran. Int J Med Inform 180:105245, 2023
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 115
EP 123
PG 9
ER

PT J
AU Svajda, L
   Cserepes, M
   Hegyi, B
   Niczky, Th
   Tovari, J
AF Svajda, Laura
   Cserepes, Mihaly
   Hegyi, Barbara
   Niczky, Theodora
   Tovari, Jozsef
TI Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE tumor hypoxia; immune checkpoint inhibitor; HIF-1 transcription factor; combination therapy
ID tumor hypoxia; immune checkpoint inhibitor; HIF-1 transcription factor; combination therapy
AB Tumor hypoxia plays an important role in controlling tumor progression through signaling pathways related to the transcription factor HIF-1. In addition to enhancing migration, promoting angiogenesis and regulating metabolism, the hypoxic environment also affects immune function. In this hypoxic microenvironment an immunosuppressive milieu is established, where HIF-1 upregulates the expression of PD-L1, a key regulator of the immune response. We have found that elevated expression of PD-L1 correlates with increased HIF-1 levels in cancer cell lines and clinical samples. Thus, the co-inhibition of HIF-1 and PD-1/PD-L1 offers promising therapeutic possibilities. In this review we have examined the limitations of HIF-1 and PD-1/PD-L1 inhibition as monotherapy, explored their combined benefits and evaluated the feasibility of targeting PD-L1 with HIF-1 inhibitors.
C1 [Svajda, Laura] National Institute of Oncology, Department of Clinical Research, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Cserepes, Mihaly] National Institute of Oncology, Department of Clinical Research, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Hegyi, Barbara] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Niczky, Theodora] National Institute of Oncology, Department of Clinical Research, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Tovari, Jozsef] National Institute of Oncology, Department of Clinical Research, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Svajda, L (reprint author), National Institute of Oncology, Department of Clinical Research, 1122 Budapest, Hungary.
EM svajda.laura@ext.oncol.hu
CR Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8:70, 2023
   Schito L, Rey-Keim S. Hypoxia signaling and metastatic progression. Semin Cancer Biol 97:42–49, 2023
   Kenessey I, Nagy P, Polgar Cs. A rosszindulatu daganatok hazai epidemiologiai helyzete a XXI. szazad masodik evtizedeben. Magy Onkol 66:175–184, 2022
   Joshi V, Lakhani SR, McCart Reed AE. NDRG1 in cancer: A suppressor, promoter, or both? Cancers 14:5739, 2022
   Nguyen TVH, Bergmann U, Kietzmann T, et al. Protein kinase B/AKT phosphorylates hypoxia-inducible factor-3α1 in response to insulin, promoting cell growth and migration. Front Cell Dev Biol 11:1250000, 2023
   Zhao Y, Xing C, Deng Y, et al. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis 11:234–251, 2024
   Qannita RA, Alalami AI, Harb AA, et al. Targeting hypoxia-inducible factor- 1, HIF-1, in cancer: Emerging therapeutic strategies and pathway regulation. Pharmaceuticals 17:195, 2024
   Ghosh R, Samanta P, Sarkar R, et al. Targeting HIF-1α by natural and synthetic compounds: A promising approach for anti-cancer therapeutics development. Molecules 27:5192, 2022
   Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol 18:573–587, 2022
   Xie H, Simon MC. Oxygen availability and metabolic reprogramming in cancer. J Biol Chem 292:16825–16832, 2017
   Katopodi T, Petanidis S, Anestakis D, et al. Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization. Front Immunol 14:1325360, 2024
   Abou Khouzam R, Janji B, Thiery J, et al. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy. Semin Cancer Biol 97:104–123, 2023
   Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 13:964442, 2022
   Shurin MR, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest 132:e159473, 2022
   Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781–790, 2014
   Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416, 2017
   Zhao T, Li Y, Zhang J, et al. PD‑L1 expression increased by IFN‑γ via JAK2‑STAT1 signaling and predicts a poor survival in colorectal cancer. Oncol Lett 20:1127–1134, 2020
   Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27:409–416, 2016
   Zheng H, Ning Y, Zhan Y, et al. Co-expression of PD-L1 and HIF-1α predicts poor prognosis in patients with non-small cell lung cancer after surgery. J Cancer 12:2065–2072, 2021
   Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 38:675–678, 2020
   Li Y, Zhang MZ, Zhang SJ, et al. HIF-1α inhibitor YC-1 suppresses triplenegative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1- induced macrophage polarization. Biomed Pharmacother 161:114423, 2023
   Yao ZG, Li WH, Hua F, et al. LBH589 inhibits glioblastoma growth and angiogenesis through suppression of HIF-1α expression. J Neuropathol Exp Neurol 76:1000–1007, 2017
   Lee CJ, Yue CH, Lin YY, et al. Antitumor activity of acriflavine in human hepatocellular carcinoma cells. Anticancer Res 34:3549–3556, 2014
   Lee A, Jin HO, Masudul Haque M, et al. Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax, ABT‑263, in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme. Int J Oncol 60:2, 2021
   Friedland JC, Smith DL, Sang J, et al. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs 32:14–24, 2014
   Goldberg RM, Garrett CR, Berkowitz NC, et al. Phase II study of EZN- 2208, PEG-SN38, with or without cetuximab in patients with metastatic colorectal cancer, CRC). J Clin Oncol 30(4_suppl):448, 2012
   Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino- 17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14:7940–7946, 2008
   Yang CH, Kies MS, Glisson B, et al. A phase II study of lonafarnib, SCH66336, in patients with chemo-refractory advanced head and neck squamous cell carcinoma, HNSCC). J Clin Oncol 23(16_suppl):5565, 2005
   Bui BP, Nguyen PL, Lee K, et al. Hypoxia-inducible factor-1: A novel therapeutic target for the management of cancer, drug resistance, and cancer- related pain. Cancers 14:6054, 2022
   https://www.fda.gov/drugs/resources-information-approved-drugs/ fda-approves-belzutifan-advanced-renal-cell-carcinoma
   Kao TW, Bai GH, Wang TL, et al. Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. J Exp Clin Cancer Res 42:171, 2023
   Riccardi F, Colantuoni G, Diana A, et al. Exemestane and everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region, Southern Italy, focused on activity, efficacy and safety. Mol Clin Oncol 9:255–263, 2018
   Krasner C, Birrer M, Peters C, et al. Phase II trial of the NDC CRLX101 in combination with bevacizumab in patients with platinum-resistant ovarian cancer, PROC). Cancer Res 76(14_Suppl): Abstr. CT090, 2016
   Aquino-Galvez A, Gonzalez-Avila G, Delgado-Tello J, et al. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep 35:577–583, 2016
   Marti-Diaz R, Montenegro MF, Cabezas-Herrera J, et al. Acriflavine, a potent inhibitor of HIF-1α, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions. Cancers 13:102, 2020
   Terzuoli E, Puppo M, Rapisarda A, et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion. Cancer Res 70:6837–6848, 2010
   Fu J, Zeng W, Chen M, et al. Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma. Chem Biol Interact 361:109966, 2022
   Shirai Y, Chow CCT, Kambe G, et al. An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor. Cancers 13:2813, 2021
   Viziteu E, Grandmougin C, Goldschmidt H, et al. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer 114:519–523, 2016
   Tanaka T, Yamaguchi J, Shoji K, et al. Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. J Biol Chem 287:34866– 34882, 2012
   Xu R, Wang F, Yang H, et al. Action sites and clinical application of HIF-1α inhibitors. Molecules 27:3426, 2022
   Ban HS, Kim BK, Lee H, et al. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth. Cell Death Dis 8: e2843–e2843, 2017
   Xu H, Chen Y, Li Z, et al. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo. Eur J Pharmacol 930:175154, 2022
   Weldon Gilcrease G, Stenehjem DD, Wade ML, et al. Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Invest New Drugs 37:482–489, 2019
   Zhou X, Chen J, Yi G, et al. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 7:873–884, 2016
   Gao W, Zhang X, Yang W, et al. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. J Immunother Cancer 7:231, 2019
   Pili R, Quinn DI, Albany C, et al. Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients. J Clin Oncol 37(15_suppl):2572, 2019
   Saxena R, Wang Y, Mier JW. CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. Melanoma Res 30:14–25, 2020
   https://ogyei.gov.hu/gyogyszeradatbazis/
   Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 15:24, 2022
   Lai S, Xu L, Zhang L, et al. Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study. Front Pharmacol 14:1141075, 2023
   Shen Z, Pei Q, Zhang H, et al. Hypoxia-inducible factor-1α inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models. Anticancer Drugs 33:587–594, 2022
   Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 139:396–403, 2016
   Rini BI, Appleman LJ, Figlin RA, et al. Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. J Clin Oncol 37(7_suppl):558, 2019
   https://classic.clinicaltrials.gov/ct2/show/NCT03994744
   Khedri M, Kooshki H, Taheri R. Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain. Res Pharm Sci 16:165, 2021
   Lastwika KJ, Wilson W, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT–mTOR Pathway in non–small cell lung cancer. Cancer Res 76:227–238, 2016
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 126
EP 135
PG 10
ER

PT J
AU Melegh, Zs
   Csernak, E
   Kohanka, A
   Rubovszkyne Gallai, M
   Bencze, E
   Szoke, M
   Pap, L
   Simon, A
   Kuronya, Zs
   Biro, K
   Geczi, L
   Toth, E
AF Melegh, Zsombor
   Csernak, Erzsebet
   Kohanka, Andrea
   Rubovszkyne Gallai, Monika
   Bencze, Eszter
   Szoke, Melinda
   Pap, Luca
   Simon, Andrea
   Kuronya, Zsofia
   Biro, Krisztina
   Geczi, Lajos
   Toth, Erika
TI Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE prostate adenocarcinoma; homologous recombination repair system; PARP inhibitor therapy
ID prostate adenocarcinoma; homologous recombination repair system; PARP inhibitor therapy
AB The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology diagnostics. Among 281 patients with prostate adenocarcinoma, somatic pathogenic mutations in one of these genes were identified in 21.4% of patients. In 28.5% of the patients, the test was unsuccessful; the main limitation of successful testing was the age of the paraffin blocks and low DNA concentration. In the case of BRCA1/2 testing, the success rate was significantly reduced for samples older than 5 years, while in tests involving a broader set of homologous recombination repair genes, the success rate was significantly reduced for samples older than 2 years. Therefore, it is very important to test high-risk prostate cancers at the time of primary diagnosis, and probably also liquid biopsy testing of circulating tumor DNA will play an important role in safe diagnosis in the near future.
C1 [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kohanka, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Rubovszkyne Gallai, Monika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Bencze, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Szoke, Melinda] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Pap, Luca] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Simon, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kuronya, Zsofia] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Biro, Krisztina] National Institute of Oncology, Urogenital Tumors and Clinical Pharmacology DepartmentBudapest, Hungary.
   [Geczi, Lajos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM dr.toth.erika@oncol.hu
CR Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther 6:254, 2021
   Congregado B, Rivero I, Osman I, et al. PARP inhibitors: A new horizon for patients with prostate cancer. Biomedicines 10:1416, 2022
   Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 14:51, 2021
   de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091–2102, 2020
   Mateo J, de Bono JS, Fizazi K, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial. J Clin Oncol 42:571–583, 2024
   von Werdt A, Brandt L, Scharer OD, et al. PARP inhibition in prostate cancer with homologous recombination repair alterations. JCO Precis Oncol 5:PO.21.00152, 2021
   Hussain M, Corcoran C, Sibilla C, et al. Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound, Olaparib). Clin Cancer Res 28:1518–1530, 2022
   Skotheim RI, Bogaard M, Carm KT, et al. Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature. Biochim Biophys Acta Rev Cancer 1879:189080, 2024
   Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw 22:140–150, 2024
   Mandel P, Hoeh B, Humke C, et al. Feasibility of next-generation sequencing of liquid biopsy, circulating tumor DNA, samples and tumor tissue from patients with metastatic prostate cancer in a real-world clinical setting in Germany. Eur Urol Focus 15:S2405-4569(24)00043-9, 2024
   Shah S, Rachmat R, Enyioma S, et al. BRCA mutations in prostate cancer: Assessment, implications and treatment considerations. Int J Mol Sci 22:12628, 2021
   Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 162:454, 2015
   Selvarajah S, Schrader KA, Kolinsky MP, et al. Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada. Can Urol Assoc J 16:321–332, 2022
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 137
EP 141
PG 5
ER

PT J
AU Melegh, Zs
   Nemeth, K
   Szekely, E
   Borka, K
   Bori, R
   Semjen, D
   Posfai, B
   Sukosd, F
   Salamon, F
   Bidiga, L
   Kuthi, L
AF Melegh, Zsombor
   Nemeth, Kamilla
   Szekely, Eszter
   Borka, Katalin
   Bori, Rita
   Semjen, David
   Posfai, Boglarka
   Sukosd, Farkas
   Salamon, Ferenc
   Bidiga, Laszlo
   Kuthi, Levente
TI The pathological processing of prostate biopsy and resection specimens
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE prostaste cancer; adenocarcinoma; pathology; reporting
ID prostaste cancer; adenocarcinoma; pathology; reporting
AB Prostate cancer stands as the most prevalent malignant tumor among men; with its incidence increasing with advancing age. The spectrum of patient care options for this disease is broad, encompassing approaches such as „active surveillance,” definitive radiation therapy, robot-assisted surgery, among others. These diverse modalities afford opportunities for cure or successful management in the majority of cases. It is paramount to underscore that optimal treatment hinges upon a multidisciplinary framework, wherein the coordinated efforts of allied healthcare professionals yield the highest standard of patient care. Hence, it is imperative for pathologists to keep abreast of contemporary processing and specimen collection protocols, as well as the potential necessity of supplementary investigations and their clinical significance. The latest Hungarian guideline on prostate cancer care features a dedicated chapter delineating the pivotal role and responsibilities of pathologists. Through this discourse, we aim to consolidate and disseminate pertinent insights, thereby fostering the continuing enhancement of pathologists’ knowledge and elucidating the intricacies of histological processing to our clinical counterparts.
C1 [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Nemeth, Kamilla] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Szekely, Eszter] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Borka, Katalin] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Bori, Rita] Bacs-Kiskun County Hospital, Department of PathologyKecskemet, Hungary.
   [Semjen, David] University of Pecs, Department of PathologyPecs, Hungary.
   [Posfai, Boglarka] University of Szeged, Department of PathologySzeged, Hungary.
   [Sukosd, Farkas] University of Szeged, Department of PathologySzeged, Hungary.
   [Salamon, Ferenc] Fovarosi Uzsoki utcai Korhaz, PathologiaBudapest, Hungary.
   [Bidiga, Laszlo] University of Debrecen, Faculty of Medicine, Department of PathologyDebrecen, Hungary.
   [Kuthi, Levente] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Kuthi, L (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM kuthi.levente@oncol.hu
CR Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105:1050–1058, 2013
   Epstein JI, Srigley J, Grignon D, et al. Recommendations for the reporting of prostate carcinoma. Hum Pathol 38:1305–1309, 2007
   Stone NN, Crawford ED, Skouteris VM, et al. The ratio of the number of biopsy specimens to prostate volume, biopsy density, greater than 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate. J Urol 202:264-271, 2019
   Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology, ISUP, consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228-1242, 2005
   Hilscher M, Roder A, Helgstrand JT, et al. Risk of prostate cancer and death after benign transurethral resection of the prostate – A 20-year population- based analysis. Cancer 128:3674-3680, 2022
   Maraz A, Geczi L, Biro K, et al. Terapias szekvenciak az elorehaladott/ attetes prosztatadaganatok gyogyszeres kezeleseben. Magy Onkol 64:263– 272, 2020
   Samaratunga H, Montironi R, True L, et al. International Society of Urological Pathology, ISUP, consensus conference on handling and staging of radical prostatectomy specimens: working group 1: specimen handling. Mod Pathol 24:6–15, 2011
   Egeszsegugyi szakmai iranyelv – A prosztatarak komplex diagnosztikajarol es ellatasarol. Egeszsegugyi Kozlony, 2024. https://kollegium.aeek.hu/ Iranyelvek/Index
   Dash A, Maine IP, Varambally S, et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol 161:1743–1748, 2002
   Best S, Sawers Y, Fu VX, et al. Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology 70:328–332, 2007
   Bong GW, Ritenour CW, Osunkoya AO, et al. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int 103:327–331, 2009
   Montironi R, Cheng L, Mazzucchelli R, et al. Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique. Eur Urol 55:1305– 1309, 2008
   Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society, GUPS, white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med 145:461–493, 2021
   Borhan W, Epstein JI. Significance of Gleason score 7 with tertiary pattern 5 at radical prostatectomy. Urology 100:175–179, 2017
   Baras AS, Nelson JB, Han M, et al. The effect of limited, tertiary, Gleason pattern 5 on the new prostate cancer grade groups. Hum Pathol 63:27–32, 2017
   Van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology, ISUP, consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87–e99, 2020
   Dong F, Yang P, Wang C, et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 37:1855–1861, 2013
   Srigley JR. Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med 130:303–317, 2006
   Magi-Galluzzi C, Evans AJ, Delahunt B, et al. International Society of Urological Pathology, ISUP, consensus conference on handling and staging of radical prostatectomy specimens. working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 24:26–38, 2011
   Rodriguez-Covarrubias F, Larre S, Dahan M, et al. Invasion of bladder neck after radical prostatectomy: one definition for different outcomes. Prostate Cancer Prostatic Dis 11:294–297, 2008
   van Veggel BA, van Oort IM, Witjes JA, et al. Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. Histopathology 59:692– 702, 2011
   Kim JK, Lee HJ, Hwang SI, et al. Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer. Sci Rep 10:5693, 2020
   John A, Lim A, Catterwell R, et al. Length of positive surgical margins after radical prostatectomy: Does size matter? – A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 26:673–680, 2023
   Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 179:S47–51, 2008
   Kurose H, Ueda K, Ogasawara N, et al. Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor. Mol Clin Oncol 16:82, 2022
   Grypari IM, Zolota V, Tzelepi V. Radical or not-so-radical prostatectomy: Do surgical margins matter? Cancers, Basel, 14:13, 2021
   Salomon L, Levrel O, Anastasiadis AG, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43:3944, 2003
   Epstein JI. Pathologic assessment of the surgical specimen. Urol Clin North Am 28:567–594, 2001
   Cheng L, Jones TD, Lin H, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol 174:2181–2185, 2005
   Villers A, McNeal JE, Redwine EA, et al. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 142:763–768, 1989
   van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology, ISUP, consensus conference on handling and staging of radical prostatectomy specimens. working group 2: T2 substaging and prostate cancer volume. Mod Pathol 24:16–25, 2011
   Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:245–253, 2017
   Chopra S, Alemozaffar M, Gill I, et. Extended lymph node dissection in robotic radical prostatectomy: Current status. Indian J Urol 32:109–114, 2016
   Zhang X, Zhang G, Wang J, et al. Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis. World J Surg Oncol 21:80, 2023
   Bidot S, Monsrud A, Kline M,et al. Risk stratification of prostatic adenocarcinoma metastatic to the lymph nodes. Arch Pathol Lab Med 146:1345–1352, 2022
   Toth E, Salamon F. A prosztatarak prognosztikai patologiai leletenek tartalmi kovetelmenye – tubiopszias es radikalis prosztatektomias specimen. Magy Onkol 63:10–15, 2019
   Kweldam CF, Kummerlin IP, Nieboer D, et al. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Mod Pathol 30:1126–1132, 2017
   Yang DD, Muralidhar V, Mahal BA, et al. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol 38:735.e9–735.e15, 2020
   Verhoef EI, Kweldam CF, Kummerlin IP, et al. Comparison of tumor volume parameters on prostate cancer biopsies. Arch Pathol Lab Med 2020,, DOI  10.5858/arpa.2019-0361-OA
   Arias-Stella JA 3rd, Varma KR, Montoya-Cerrillo D, et al. Does discontinuous involvement of a prostatic needle biopsy core by adenocarcinoma correlate with a large tumor focus at radical prostatectomy? Am J Surg Pathol 39:281–286, 2015
   de la Calle CM, Mamawala MM, Landis P, et al. Clinical significance of perineural invasion in men with grade group 1 prostate cancer on active surveillance. J Urol 209:180–186, 2023
   Tollefson MK, Karnes RJ, Kwon ED, et al. Prostate cancer Ki-67, MIB-1, expression, perineural invasion, and Gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc 89:308–318, 2014
   van der Kwast TH, Lopes C, Santonja C, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 56:336–340, 2003
   Morote J, Schwartzmann I, Celma A, et al. The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia. BJU Int 129:627–633, 2022
   Leone A, Gershman B, Rotker K, et al. Atypical small acinar proliferation, ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer Prostatic Dis 19:68–71, 2016
   O’Connor E, Dowling C, Casey M, et al. Implications of a diagnosis of atypical small acinar proliferation, ASAP, and high-grade prostatic intraepithelial neoplasia, HGPIN, on prostate biopsy: a 5-year follow-up study. Ir J Med Sci 191:2035–2040, 2022
   Trpkov K, Thompson J, Kulaga A, et al. How much tissue sampling is required when unsuspected minimal prostate carcinoma is identified on transurethral resection? Arch Pathol Lab Med 132:1313–1316, 2008
   McDowell PR, Fox WM, Epstein JI. Is submission of remaining tissue necessary when incidental carcinoma of the prostate is found on transurethral resection? Hum Pathol 25:493–497, 1994
   Carneiro A, Barbosa ARG, Takemura LS, et al. The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: A systematic review of the literature. Front Oncol 8:377, 2018
   Epstein JI, Egevad L, Humphrey PA, et al. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e6–e19, 2014
   Tan HL, Haffner MC, Esopi DM, et al. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol 28:446–456, 2015
   Inamura K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget 9:14723–14737, 2018
   Robinson D, Van Allen EM, Wu YM, et. al Integrative clinical genomics of advanced prostate cancer. Cell 162:454, 2015
   Guedes LB, Antonarakis ES, Schweizer MT, et al. MSH2 loss in primary prostate cancer. Clin Cancer Res 23:6863–6874, 2017
   Mohler JL, Antonarakis ES. NCCN guidelines updates: management of prostate cancer. J Natl Compr Canc Netw 17:583–586, 2019
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 143
EP 153
PG 16
ER

PT J
AU Major, T
   Vizkeleti, J
   Agoston, P
   Takacsi-Nagy, Z
   Polgar, Cs
AF Major, Tibor
   Vizkeleti, Julia
   Agoston, Peter
   Takacsi-Nagy, Zoltan
   Polgar, Csaba
TI Application of new imaging modalities for brachytherapy of cancer patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE low magnetic field MR; brachytherapy treatment planning; image distortion; cone beam CT; position check of radiation source
ID low magnetic field MR; brachytherapy treatment planning; image distortion; cone beam CT; position check of radiation source
AB In the Radiotherapy Centre of the National Institute of Oncology, Budapest, a 0.55 T MR scanner (MAGNETOM Free. Max) and a ring-like X-ray machine (ImagingRing) have been in operation since 2022. The MR scanner has a tunnel diameter of 80 cm, the X-ray machine has a ring diameter of 121 cm. The latter can also be used for cone-beam CT (CBCT) imaging. The MR scanner is mainly used for planning gynaecological brachytherapy (BT) treatments. Image distortions in MR imaging were investigated with a special grid phantom. After head and neck and breast implant, image quality of ImagingRing CBCT and planning CT was compared. The position of the radiation source was verified by radiographs taken during treatment. Despite the lower field strength, the image quality of the MR scanner was found to be adequate for treatment planning of gynaecological BT. Image distortions were found to be clinically negligible. On CBCT images obtained with ImagingRing, catheters could always be well identified, and anatomical organs were adequately visualized for head and neck treatments, but not for breast implants. The MR scanner is suitable for treatment planning for gynaecological BT due to its good image quality and low image distortion. The image quality of the ImagingRing is suitable for treatment planning for small body sizes, but not for larger sizes. The device can be used to in vivo check of the radiation source position during treatment.
C1 [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Vizkeleti, Julia] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Agoston, Peter] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Takacsi-Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Major, T (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM major.tibor@oncol.hu
CR Major T, Frohlich G, Agoston P, et al. The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. Strahlenther Onkol 198:93–109, 2022
   Major T, Polgar Cs, Mangel L, et al. CT-kepeken alapulo konformalis brachyterapias besugarzastervezes. Magy Onkol 44:109–115, 2000
   Karius A, Karolczak M, Strnad V, Bert C. Technical evaluation of the conebeam computed tomography imaging performance of a novel, mobile, gantry- based X-ray system for brachytherapy. J Appl Clin Med Phys 23:e13501, 2021
   Dimopoulos J, Schard G, Berger D, et al. Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: Potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. Int J Radiat Oncol Biol Phys 64:1380–1388, 2006
   Zolciak-Siwinska A, Kowalczyk A, Sikorska K, et al. Comparison of computed tomography with magnetic resonance imaging for imaging-based clinical target volume contours in cervical cancer brachytherapy. Brachytherapy 17:667–672, 2018
   Tanderup K, Lindegaard JC, Kirisits C, et al. Image guided adaptive brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome. Radiother Oncol 120:365–369, 2016
   Vojtisek R, Hosek P, Sukovska E, et al. Treatment outcomes of MRI-guided adaptive brachytherapy in patients with locally advanced cervical cancer: institutional experiences. Strahlenther Onkol 198:783–791, 2022
   Potter R, Federico M, Sturdza A, et al. Value of magnetic resonance imaging without or with applicator in place for target definition in cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 94:588–597, 2016
   Rogowski P, Rottler M, Walter F, et al. Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer. Gynecol Oncol 166:576–581, 2022
   Grigo J, Masitho S, Fautz HP et al. Usability of magnetic resonance images acquired at a novel low-field 0.55 T scanner for brain radiotherapy treatment planning. Phys Imag Radiat Oncol 25:100412, 2023
   Potter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol based image, MRI, guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123, 2011
   Kim Y, Muruganandham M, Modrick JM, et al. Evaluation of artefacts and distortions of titanium applicators on 3.0-Tesla MRI: feasibility of titanium applicators in MRI-guided brachytherapy for gynecological cancer. Int J Radiat Oncol Biol Phys 80:947–955, 2011
   Dimopoulos JC, Petrow P, Tanderup K, et al. Recommendations from Gynaecological, GYN, GEC-ESTRO Working Group, IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 103:113–122, 2012
   Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological, GYN, GEC-ESTRO Working Group, I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235–245, 2005
   Aubry JF, Cheung J, Morin O, et al. Investigation of geometric distortions on magnetic resonance and cone beam computed tomography images used for planning and verification of high-dose rate brachytherapy cervical cancer treatment. Brachytherapy 9:266–273, 2010
   Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43, Med Phys 22:209–234, 1995
   Berger D, Dimopoulos J, Potter R, et al. Direct reconstruction of the Vienna applicator on MR images. Radiother Oncol 93:347–351, 2009
   Karius A, Strnad V, Lotter M, et al. First clinical experience with a novel, mobile cone-beam CT system for treatment quality assurance in brachytherapy. Strahlenther Onkol 198:573–581, 2022
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 155
EP 162
PG 8
ER

PT J
AU Gazdag-Hegyesi, Sz
   Galdi, �
   Pocza, T
   Major, T
   Takacsi Nagy, Z
   Pesznyak, Cs
AF Gazdag-Hegyesi, Szilvia
   Galdi, Adam
   Pocza, Tamas
   Major, Tibor
   Takacsi Nagy, Zoltan
   Pesznyak, Csilla
TI Photon field junction for external beam radiotherapy of breast cancer involving axillary and supraclavicular lymph nodes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE field junction; IMRT; 3D-CRT; portal dosimetry; dose-volume histogram
ID field junction; IMRT; 3D-CRT; portal dosimetry; dose-volume histogram
AB We present evaluation of junction of coplanar external beam photon fields and its portal dosimetric analysis for breast cancer with positive lymph nodes. In our work, we compared twelve patients affected by breast cancer with axillary and supraclavicular lymph nodes, using conformal external beam plans from a dosimetric point of view. 3-3 plans were prepared per patient. Three methods were used for the conformal technique to investigate the potential of lymph nodes treatment field’s collimations. During the evaluation of the portal dosimetry images, it was concluded that the junction plane at isocenter appeared as a discrete coldline, when fitted the regional field with or without collimation manually and by the software. However, the coverage of the isocenter plane is strongly influenced by the linear accelerator and the fitted field edges. Based on our results, in order to avoid uncertainties arising from field junctions and the overdosed areas of the target volume, it is more appropriate to choose another advanced irradiation technique such as intensity-modulated radiation therapy.
C1 [Gazdag-Hegyesi, Szilvia] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Galdi, Adam] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Pocza, Tamas] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Major, Tibor] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Takacsi Nagy, Zoltan] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Pesznyak, Csilla] National Institute of Oncology, Center of Radiotherapy, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Gazdag-Hegyesi, Sz (reprint author), National Institute of Oncology, Center of Radiotherapy, 1122 Budapest, Hungary.
EM hegyesi.szilvia@oncol.hu
CR Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4(Suppl 1):S1–S26, 2006
   Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edition, 2010
   Stelczer G, Meszaros N, Pesznyak C, et al. External beam accelerated partial breast irradiation: dosimetric assessment of conformal and three different intensity modulated techniques. Radiol Oncol 53:123–130, 2019
   Varga Sz, Takacsi Nagy Z, Polgar Cs. Mezoillesztes emlobesugarzasnal. Magy Onkol 45:343–346, 2001
   Dogan N, Cuttino L, Lloyd R, et al. Optimized dose coverage of regional lymph nodes in breast cancer: the role of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:1238–1250, 2007
   Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:8–30, 2015
   Pocza T, Szegedi D, Major T, Pesznyak C. Verification of an optimizer algorithm by the beam delivery evaluation of intensity-modulated arc therapy plans. Radiol Oncol 55:508–515, 2021
   Podgorsak EB. Radiation Oncology Physics A Handbook for Teachers and Students. IAEA, Vienna 2005, p. 194
   Khan FM. The Physics of Radiation Therapy. 3rd edition, 2003
   Stelczer G, Tatai-Szabo D, Major T, et al. Measurement of dose exposure of image guidance in external beam accelerated partial breast irradiation: Evaluation of different techniques and linear accelerators. Phys Medica 63:70–78, 2019
   Nailon WH, Welsh D, McDonald K, et al. EPID-based in vivo dosimetry using Dosimetry Check. J Appl Clin Med Phys 20:6–16, 2018
   Kwok CB, Lam G, El-Sayed S. Suitability of using multileaf collimator, MLC, for photon field matching. Med Dosimetry 29:184–195, 2004
   Miles EA, Venables K, Hoskin KJ, et al. Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa. Radiother Oncol 91:42–48, 2009
   Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J 36:71–78, 2018
   Aras S, Ikizceli T, Aktan M. Dosimetric comparsion of three-dimensional conformal radiotherapy, 3D-CRT, and intensity modulated radiotherapy techniques, IMRT, with radiotherapy dose simulations for left-sided mastectomy patients. Eur J Breast Health 15:85–89, 2019
   ICRU REPORT 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy, IMRT). Journal of the ICRU 10, 2010
   van’t Riet A, Mak AC, Moerland MA, et al. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: Application to the prostate. Int J Radiat Oncol Biol Phys 37:731–736, 1997
   Pesznyak Cs, Safrany G. Sugarbiologia. Tipotex, 2017
   Low DA. Gamma dose distribution evaluation tool. J Phys Conf Ser 250: 349–359, 2010
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 163
EP 168
PG 6
ER

PT J
AU Veres, Sz
   Martinovszky, F
   Di Giovanni, M
   Budai, B
   Beszedics, B
   Szabo, I
   Butz, H
   Patocs, A
   Torok, B
   Ujlaki, M
   Tarnoki, DL
   Tarnoki, �D
AF Veres, Szilard
   Martinovszky, Fruzsina
   Di Giovanni, Mark
   Budai, Bettina
   Beszedics, Beatrix
   Szabo, Istvan
   Butz, Henriett
   Patocs, Attila
   Torok, Balint
   Ujlaki, Matyas
   Tarnoki, David Laszlo
   Tarnoki, Adam Domonkos
TI Examination of breast density in breast cancer discordant twin pairs
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE mammography; breast cancer; genetics; heritability; risk factor
ID mammography; breast cancer; genetics; heritability; risk factor
AB Previous twin studies show that genetic factors are responsible for 63% of the variability in breast density. We analyzed the mammographic images of 9 discordant twin pairs for breast cancer from the population-based Hungarian Twin Registry. We measured breast density using 3D Slicer software. Genetic variants predisposing to breast cancer were also examined. One of the examined twin pairs had a BRCA2 mutation in both members. There was no significant difference between the mean values of breast density in the tumor and non-tumor groups (p=0.323). In terms of parity and the presence of menopause, we found mostly no significant difference between the members of the twin pair. In our cohort of identical twins discordant for breast cancer, the average breast density showed no significant difference, which can be explained by the common genetic basis of breast cancer and breast density.
C1 [Veres, Szilard] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Martinovszky, Fruzsina] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Di Giovanni, Mark] Semmelweis University, Medical Imaging CenterBudapest, Hungary.
   [Budai, Bettina] Semmelweis University, Medical Imaging CenterBudapest, Hungary.
   [Beszedics, Beatrix] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Szabo, Istvan] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Butz, Henriett] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Torok, Balint] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Ujlaki, Matyas] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Tarnoki, David Laszlo] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Tarnoki, Adam Domonkos] National Institute of Oncology, Center of Radiology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Tarnoki, �D (reprint author), National Institute of Oncology, Center of Radiology, 1122 Budapest, Hungary.
EM tarnoki.adam@oncol.hu
CR Kozponti Statisztikai Hivatal. Bejelentett uj rosszindulatu daganatos megbetegedesek. 2023, https://www.ksh.hu/stadat_files/ege/hu/ege0025.html
   American Cancer Society. Breast Cancer Facts and Figures 2022–2024, https://www.cancer.org/research/cancer-facts-statistics/breast-cancerfacts-figures.html
   Lian J, Li K. A review of breast density implications and breast cancer screening. Clin Breast Cancer 20:283–290, 2020
   McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169, 2006
   Edmonds CE, O’Brien SR, Conant EF. Mammographic breast density: current assessment methods, clinical implications, and future directions. Semin Ultrasound CT MR 44:35–45, 2023
   Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347:886–894, 2002
   Castillo-Fernandez JE, Spector TD, Bell JT. Epigenetics of discordant monozygotic twins: implications for disease. Genome Med 6:60, 2014
   Tarnoki AD, Tarnoki DL, Forgo B, et al. The Hungarian Twin Registry update: turning from a voluntary to a population-based registry. Twin Res Hum Genet 22:561–566, 2019
   Heath AC, Nyholt DR, Neuman R, et al. Zygosity diagnosis in the absence of genotypic data: an approach using latent class analysis. Twin Res 6:22–26, 2003
   Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 9:217, 2007
   Sieh W, Rothstein JH, Klein RJ, et al. Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk. Nat Commun 11:5116, 2020
   Chaudhuri O, Koshy ST, Branco da Cunha C, et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat Mater 13:970–978, 2014
   Boyd N, Berman H, Zhu J, et al. The origins of breast cancer associated with mammographic density: a testable biological hypothesis. Breast Cancer Res 20:17, 2018
   Becker S, Kaaks R. Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results Cancer Res 181:135–157, 2009
   Ye Z, Nguyen TL, Dite GS, et al. Causal relationships between breast cancer risk factors based on mammographic features. Breast Cancer Res 25:127, 2023
   Tarnoki DL, Piroska M, Forgo B, et al. The population-based Hungarian Twin Registry: An update. Twin Res Hum Genet 27:115-119, 2024
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 171
EP 176
PG 6
ER

PT J
AU Levay, B
   Peter, I
   Frohlich, G
   Koltai, P
   Ivady, G
   Jaray, B
   Pogany, P
   Szoke, J
   Toth, E
   Udvarhelyi, N
   Oberna, F
AF Levay, Bernadett
   Peter, Ilona
   Frohlich, Georgina
   Koltai, Pal
   Ivady, Gabriella
   Jaray, Balazs
   Pogany, Peter
   Szoke, Janos
   Toth, Erika
   Udvarhelyi, Nora
   Oberna, Ferenc
TI Incidentally discovered ectopic tissue in the central neck region (level VI) of the neck – A case series, retrospective analysis and literature review
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE thyroid cancer; lymph node dissection; ectopic residual tissues
ID thyroid cancer; lymph node dissection; ectopic residual tissues
AB The thymus derives from the third branchial pouch, which migrates to the mediastinum through the central region of the neck. During the migration, particles split off and develop separately. The prevalence of ectopic thymus is 20–40%. The purpose of this retrospective case series study was to investigate the prevalence of embryological tissue remnants in the central region, in patients treated for thyroid lesions. Between January 1 2018 and September 1 2020, 84 patients who underwent central neck dissection were selected. Clinicopathological data as age, gender, histopathological result and TNM stage were analyzed. Ectopic tissue in the central neck region was discovered in 28 cases. The prevalence of ectopic lesions showed increase in Stage I thyroid carcinomas. There was no significant correlation with patients’ age, gender, or with the stage. We emphasize the clinicopathological role of ectopic tissues, which can occur in the central region of the neck.
C1 [Levay, Bernadett] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Peter, Ilona] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Frohlich, Georgina] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
   [Koltai, Pal] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Ivady, Gabriella] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Jaray, Balazs] Medserv KftBudapest, Hungary.
   [Pogany, Peter] Medserv KftBudapest, Hungary.
   [Szoke, Janos] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Udvarhelyi, Nora] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
RP Levay, B (reprint author), National Institute of Oncology, Multidisciplinary Center of Head and Neck Oncology, 1122 Budapest, Hungary.
EM drlevayb@hotmail.com
CR Sung H, Ferlay J, Siege RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2020
   Egeszsegugyi szakmai iranyelv. A differencialt pajzsmirigyrak diagnosztikaja es kezelese. Emberi Eroforrasok Miniszteriuma. Egeszsegugyi Szakmai Kollegium. Egeszsegugyi Kozlony 2021/24:1–75, 2021
   Mazzaferri EL, Harmer C, Mallick UK, et al. Practical management of thyroid cancer. A multidisciplinary approach. Springer-Verlag London Limited, 2006
   Rosai J. Thyroid gland. In: Surgical Pathology. Ed. Rosai J, 10th edition, volume I, chapter 9. Elsevier, Mosby, 2011, pp. 488–491; 533–535
   Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133, 2016
   Haddad RI, Bischoff L, Ball D. Thyroid carcinoma. Version 2 2022. NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:925– 951, 2022
   Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1856–1883, 2019
   Boer A, Peter I, Sinkovics I, et al. Pajzsmirigydaganatok. In: Az onkologia alapjai, Egyetemi tankonyv, masodik, javitott, bovitett kiadas. Szerk. Kasler M. Medicina Konyvkiado, Budapest, 2018, pp. 1213–1228
   Lakatos P, Takacs I. Pajzsmirigybetegsegek az orvosi gyakorlatban. SpringMed Kiado, Budapest, 2017
   Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. The American Thyroid Association Surgery Working Group with participation from the American Association of Endocrine Surgeons, American Academy of Otolaryngology–Head and Neck Surgery, and American Head and Neck Society. Thyroid 19:1153–1158, 2009
   Ritchie AC. Boyd’s Textbook of Pathology, 9th edition. Lea and Febiger, Philadelphia, 1991
   Bale M, Sotelo-Avila C. Maldescent of the thymus: 34 necropsy and 10 surgical cases, including 7 thymuses medial to the mandible. Pediatr Pathol 13:181–190, 1993
   Taterra D, Wong LM, Vikse J, et al. The prevalence and anatomy of parathyroid glands: a meta–analysis with implications for parathyroid surgery. Langenbecks Arch Surg 404:63–70, 2019
   Noussios G. Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp Clin Endocrinol Diabetes 120:604–610, 2012
   De Felice M, Di Lauro RR. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 25:722–746, 2004
   Noussios G, Anagnostis P, Goulis DG, et al. Ectopic thyroid tissue: anatomical, clinical, and surgical implications of a rare entity. Eur J Endocrinol 65:375–382, 2011
   Biddinger PW. Embryology and developmental lesions. In: Diagnostic Pathology and Molecular Genetics of the Thyroid. Ed. Nikiforov YE, Biddinger PW, Thompson LDR. Lippincott Williams and Wilkins, Philadelphia, 2009, Chapter 2, pp. 11–28
   Mete O, Seethala RR, Asa SL, et al. Protocol for the examination of specimens from patients with carcinoma of the thyroid gland. College of American Pathologists, CAP, 2019
   Lloyd RV, Osamura RY, Kloppel G, Rosai J. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs, 4th ed.). IARC Press, Lyon, 2017
   Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27–63, 2022
   Ramieri MT, Gallo E, Marino M. Immunohistochemistry of normal thymus. In: Atlas of Thymic Pathology. Ed. Jain D, Bishop JA, Wick MR. Springer Nature Singapore Pte. Ltd., 2020, pp. 11–21
   Cameselle-Teijeiro JM, Eloy C, Sobrinho-Simous M. Pitfalls in challenging thyroid tumors: Emphases on differential diagnosis and ancillary biomarkers. Endocr Pathol 31:197–217, 2020
   Alzumaili B, Xu B, Spanheimer PM, et al. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Mod Pathol 33:1690–1701, 2022
   Brierly JD, Gosporadowicz MK, Wittekind Chr. UICC TNM Classification of Malignant Tumours, 8th Edition. Wiley Blackwell, John Wiley and Sons Ltd., UK, 2017
   Meilinger-Dobra M, Remenar E, Frohlich G, et al. Pajzsmirigy-mikrokarcinomas eseteink retrospektiv attekintese a 2001–2010 kozotti idoszakban. Magy Onkol 62:153–158, 2018
   Bongiovanni M, Trimboli P, Rossi ED, et al. Diagnosis of endocrine disease: High-yield thyroid fine-needle aspiration cytology: an update focused on ancillary techniques improving its accuracy. Eur J Endocrinol 174:R53–R63, 2016
   Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid cytopathology. J Am Soc Cytopathol 6:217–222, 2017
   Bak M, Peter I, Nyari T, et al. Pajzsmirigygobok vekonytu-aspiracios vizsgalata. A Bethesda-rendszer, 2006, minosegbiztositasa. Orv Hetil 156:1661– 1666, 2015
   Jaray B. Vekonytu-biopszia. In: Pajzsmirigybetegsegek az orvosi gyakorlatban. Szerk. Lakatos P, Takacs I. SpringMed Kiado, Budapest, 2017, pp. 51–58
   Varga I, Galfiova P, Jablonska-Mestanova V, et al. Some aspects of early development of the thymus: embryological basis for ectopic thymus and thymopharyngeal duct cyst. Rev Arg Anat Clin 3:22–33, 2011
   Prabhu AV, Kale HA Bransletter BF 4th. Residual cervical thymus: A normal CT finding that may be present throughout patients’ lives. AJNR Am J Neuroradiol 36:1525–1528, 2015
   Escobar FA, Pantanowitz L, Picarsic JL, et al. Cytomorphology and sonographic features of ectopic thymic tissue diagnosed in paediatric FNA biopsies. Cytopathology 29:241–246, 2018
   Ravikanth R. Ectopic cervical thymus in an adult: A rare presentation. J Med Ultrasound 30:45–46, 2022
   Talmon GA, Lewis JE. Lymphocyte-depleted thymic remnants. A potential diagnostic pitfall in the evaluation of central neck dissections. Am J Clin Pathol 132:707–712, 2009
   Mushtaque M, Naqash SH, Malik AA, et al. Papillary carcinoma thyroid with metastasis to ectopic cervical thymus. World J Surg Oncol 9:22, 2011
   Marx A. The normal thymus. In: Atlas of Thymic Pathology. Ed. Jain D, Bishop JA, Wick MR. Springer Nature Singapore Pte. Ltd., 2020, pp. 1–10
   Bodi IH, Minko K, Prodan Zs, et al. A thymus szerkezete a XXI. szazad elejen. Orv Hetil 161:163–171, 2019
   A fej-nyaki terulet szervei. In: Langman orvosi embriologia. 13. kiadas. Szerk. Sadler TW. Medicina Konyvkiado, Budapest, 2018, 17. fejezet, pp. 315–342
   Li F, Tao Y, Bauer G, et al. Unraveling the role of ectopic thymic tissue in patients undergoig thymectomy for myasthenia gravis. J Thorac Dis 11:4039–4048, 2019
   Parilla M, Cipriani N. Cervical remnant thymus and intermixed ectopic thyroid tissue TTF-1. ASH Image Bank, Category: Lymph Node and Spleen: Reactive/infectious # 00062250, American Society of Hematology
   Volante M, Hunt JL, Komminoth P, et al. Mixed medullary and follicular thyroid carcinoma. In: World Health Organization, WHO, Classification of Tumours of Endocrine Organs. Ed. Lloyd RV, Osamura RY, Kloppe G, Rosai J, et al. 4th ed. WHO International Agency for Research on Cancer, IARC, Lyon, 2017, pp. 114–116
   Thomas A, Mittal N, Rane SU, et al. Papillary and medullary thyroid carcinomas presenting as collision tumors: a case series of 21 cases at a tertiary care cancer center. Head Neck Pathol 15:1137–1146, 2021
   Fagman H, Nilsson M. Morphogenetics of early thyroid development. J Mol Endocrinol 46:R33–R42, 2011
   Nilsson M, Williams D. On the origin of cells and derivation of thyroid cancer: C cell story revisited. Eur Thyroid J 5:79–93, 2016
   Bychkov A. Ectopic thyroid tissue. https://www.pathologyoutlines.com/ topic/thyroidheterotopic.html
   LiVolsi VA, Perzin KH, Savetsky L. Carcinoma arising in median ectopic thyroid, including thyroglossal duct tissue). Cancer 4:1303–1315, 1974
   Iftikhar H, Ikram M, Nathan KR, et al. Papillary thyroid carcinoma within thyroglossal duct cyst: case series and literature review. Int Arch Otolaryngeol 22:253–255, 2018
   Thompson LDR, Herrera HB, Lau SK. A clinicopathologic series of 685 thyroglossal duct remnant cysts. Head Neck Pathol 10:465–474, 2016
   Triantafyllou A, Williams DM, Angelos P, et al. Incidental findings of thyroid tissue in cervical lymph nodes: old controversy not yet resolved? Eur Arch Otorhinolaryngol 273:2867–2875, 2016
NR 2
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD JUL
PY 2024
VL 68
IS 2
BP 177
EP 190
PG 9
ER

PT J
AU Bartfai, R
   Herczeg, A
   Ladanyi, A
AF Bartfai, Reka
   Herczeg, Adrienn
   Ladanyi, Andrea
TI We say goodbye to Dr. Eva Remenar
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
AB On July 15, 2024, at the age of 75, Dr. Eva Remenar, an outstanding figure in otolaryngology/head and neck surgery, died unexpectedly.
C1 [Bartfai, Reka] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Herczeg, Adrienn] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Ladanyi, Andrea] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Ladanyi, A (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM ladanyi.andrea@oncol.hu
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 196
EP 197
PG 2
ER

PT J
AU Tenke, P
AF Tenke, Peter
TI The introduction of robotic surgery in Hungary
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Tenke, Peter] National Institute of Oncology, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Tenke, P (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 199
EP 199
PG 1
ER

PT J
AU Szijarto, A
   Levay, K
   Pekli, D
AF Szijarto, Attila
   Levay, Klara
   Pekli, Damjan
TI The path leading to robotic surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE surgery; robotic surgery; da Vinci; progression; future
ID surgery; robotic surgery; da Vinci; progression; future
AB Robotic surgery, as a type of minimally invasive surgery, is applied in the medical care, and offers numerous benefits for patients. In this article, the development and changes in robotics, and the aim of robot manufacturing will be reviewed. Furthermore, by summarizing the history of the surgical field, we are going to describe the main paradigm shifts, which show the human acceptance and usage of novel ideas in Europe and in the USA. As a summary, the complex structure, place in surgery and the advantages of the surgical robots and some state-of-the-art research projects will be described, to let us forecast the surgical field of the future.
C1 [Szijarto, Attila] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Levay, Klara] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
   [Pekli, Damjan] Semmelweis University, Department of Transplantation and Surgery, Ulloi ut 78., 1082 Budapest, Hungary.
RP Szijarto, A (reprint author), Semmelweis University, Department of Transplantation and Surgery, 1082 Budapest, Hungary.
EM szijarto.attila@semmelweis.hu
CR Tondini T, Isidro A, Camaros E. Case report: Boundaries of oncological and traumatological medical care in ancient Egypt: new palaeopathological insights from two human skulls. Front Med 11:1371645, 2024
   Moran ME. Evolution of robotic arms. J Robot Surg 1:103–111, 2007
   Leal Ghezzi T, Campos Corleta O. 30 years of robotic surgery. World J Surg 40:2550–2557, 2016
   Kodate N, Maeda Y, Hauray B, et al. Hopes and fears regarding care robots: Content analysis of newspapers in East Asia and Western Europe, 2001–2020. Front Rehabil Sci 3:1019089, 2022
   Tanioka T. Nursing and rehabilitative care of the elderly using humanoid robots. J Med Invest 66:19–23, 2019
   Moawad GN, Rahman S, Martino MA, et al. Robotic surgery during the COVID pandemic: why now and why for the future. J Robot Surg 14:917–920, 2020
   Fleming CA, Fullard A, Croghan S, et al. Robotic abdominal surgery and COVID-19: a systematic review of published literature and peer-reviewed guidelines during the SARS-CoV-2 pandemic. J Clin Med 11:2957, 2022
   Acidi B, Ghallab M, Cotin S, et al. Augmented reality in liver surgery. J Visc Surg 160:118–126, 2023
   Giannone F, Felli E, Cherkaoui Z, et al. Augmented reality and image-guided robotic liver surgery. Cancers, Basel, 13:6268, 2021
   Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 78:606–617, 1997
   Guerrini GP, Esposito G, Magistri P, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis. Int J Surg 82:210–228, 2020
   Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma. Ann Surg 277:e103–e111, 2023
   Saqib SU, Bajwa AA. The role of Da Vinci Xi robotic simulation curriculum in enhancing skills in robotic colorectal surgery. Ann Med Surg, Lond, 85:6001–6007, 2023
   Moglia A, Ferrari V, Melfi F, et al. Performances on simulator and da Vinci robot on subjects with and without surgical background. Minim Invasive Ther Allied Technol 27:309–314, 2018
   Van’t Hullenaar CDP, Hermans B, Broeders I. Ergonomic assessment of the da Vinci console in robot-assisted surgery. Innov Surg Sci 2:97–104, 2017
   Pandav K, Te AG, Tomer N, et al. Leveraging 5G technology for robotic surgery and cancer care. Cancer Rep, Hoboken, 5:e1595, 2022
   Zheng J, Wang Y, Zhang J, et al. 5G ultra-remote robot-assisted laparoscopic surgery in China. Surg Endosc 34:5172–5180, 2020
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 201
EP 205
PG 5
ER

PT J
AU Somogyvari, K
   Haromi, I
   Jakab-Peter, K
   Szanyi, I
AF Somogyvari, Krisztina
   Haromi, Istvan
   Jakab-Peter, Kinga
   Szanyi, Istvan
TI Indications and early experience with transoral robotic surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE cancer of unknown primary (CUP); HPV associated oropharyngeal tumor; oropharyngeal tumor; p16-positivity; transoral robotic surgery (TORS)
ID cancer of unknown primary (CUP); HPV associated oropharyngeal tumor; oropharyngeal tumor; p16-positivity; transoral robotic surgery (TORS)
AB Recently, organ preservation has gained importance for head and neck malignancies. The negative consequences of the therapies can be reduced without compromising the survival and the quality of life. Accordingly, transoral robotic surgery (TORS) is gaining ground internationally. We have been performing TORS procedures at the University of Pecs since January 2023. We operated on 27 patients until July 2024, including fifteen p16-positive tumors. Neck dissections were performed in 19 cases. The use of TORS is helpful in oropharyngeal cases, where inaccessible structures can be reached minimally invasively, compared to other transoral approaches. This is important for young patients with human papillomavirus-associated tumors, which have a better prognosis and longer life expectancy. TORS also has advantages over the previously used approaches for cancer of unknown primary (CUP). Compared to the standardly used FDG-PET/CT and „blindly” taken biopsies, TORS offers a higher detection rate of the primary tumor, by performing tonsillectomy and complete mucosectomy of the tongue base.
C1 [Somogyvari, Krisztina] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti Klinika, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Haromi, Istvan] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti Klinika, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Jakab-Peter, Kinga] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti Klinika, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Szanyi, Istvan] PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti Klinika, Munkacsy M. u. 2., 7621 Pecs, Hungary.
RP Somogyvari, K (reprint author), PTE KK, Ful-Orr-Gegeszeti es Fej-Nyaksebeszeti Klinika, 7621 Pecs, Hungary.
EM somogyvari.krisztina@pte.hu
CR Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Somogyvari K, Haromi I, Jakab-Peter K, et al. Beszamolo az elso hazai fej-nyaksebeszeti robotmutetekrol. Ful-Orr-Gegegyogyaszat 69:14–16, 2023
   Ramchandani JP, Brunet A, Skalidi N, et al. Neck dissection timing in transoral robotic or laser microsurgery in oropharyngeal cancer: a systematic review. OTO Open 6:2473974X221131513, 2022
   Mockelmann N, Busch CJ, Munscher A, et al. Timing of neck dissection in patients undergoing transoral robotic surgery for head and neck cancer. Eur J Surg Oncol 41:773–778, 2015
   Mehanna H, Kong A, Ahmed S. Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130:S181– 190, 2016
   Mandapathil M, Roessler M, Werner JA, et al. Salvage surgery for head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 271:1845–1850, 2014
   Lorincz BB, Jowett N, Knecht R. Decision management in transoral robotic surgery: Indications, individual patient selection, and role in the multidisciplinary treatment for head and neck cancer from a European perspective. Head Neck 38(Suppl 1):2190–2196, 2016
   Hussain T. Patient benefit and quality of life after robot-assisted head and neck surgery. Laryngorhinootologie 101(S 01):160–185, 2022
   Golusinski W. Functional organ preservation surgery in head and neck cancer: transoral robotic surgery and beyond. Front Oncol 9:293, 2020
   Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting. Head Neck 31:1393–1422, 2009
   Adelstein DJ, Ismaila N, Ku JA, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol 37:1578–1589, 2019
   Nichols AC, Theurer J, Prisman E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma, ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 20:1349–1359, 2019
   Palma DA, Prisman E, Berthelet E, et al. Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial. JAMA Oncol 8:1–7, 2022
   Geltzeiler M, Bertolet M, Albergotti W, et al. Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort. Oral Oncol 84:82–87, 2018
   Kang JJ, Yu Y, Chen L, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin 73:164–197, 2023
   White H, Ford S, Bush B, et al. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA Otolaryngol Head Neck Surg 139:773–778, 2013
   Stolzel K, Bottcher A. Das zervikale CUP-Syndrom: Wie vorzugehen ist bei Malignomen im Kopf-Hals-Bereich mit unbekanntem Ursprung. HNO Nachrichten 153:44–51, 2023
   Halmos R, Czifra J, Kalman E, et al. Az ismeretlen kiindulasu primer daganat, Cancer of Unknown Primary, CUP; Occult Primary, szindroma: az uj fej-nyaki kivizsgalasi iranyelvek ismertetese es ket esetunk bemutatasa. Ful-Orr-Gegegyogyaszat 36:17–22, 2023
   Szalenko-Tokes A, van der Laan W, Rovo L, et al. A DaVinci operacios robot szerepe az ismeretlen primer fej-nyaki tumorok diagnosztikajaban – a Groningeni Egyetem tapasztalatai. Ful-Orr-Gegegyogyaszat 69:140–145, 2023
   Zhu L, Wang N. 18F-fluorodeoxyglucose positron emission tomography- computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a metaanalysis. Surg Oncol 22:190–194, 2013
   Cianchetti M, Mancuso AA, Amdur RJ, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 119:2348–2354, 2009
   Farooq S, Khandavilli S, Dretzke J. et al. Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. Oral Oncol 91:97– 106, 2019
   Mehta V, Johnson P, Tassler A, et al. A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery. Laryngoscope 123:146–151, 2013
   de Almeida JR. Role of transoral robotic surgery in the work-up of the unknown primary. Otolaryngol Clin North Am 53:965–980, 2020
   Geltzeiler M, Doerfler S, Turner M. et al. Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status. Oral Oncol 66:9–13, 2017
   Meccariello G, Cammaroto G, Ofo E, et al. The emerging role of transoral robotic surgery for the detection of the primary tumour site in patients with head-neck unknown primary cancers: A meta-analysis. Auris Nasus Larynx 46:663–671, 2019
   Asik MB, Satar B, Serdar M. Meta-analytic comparison of robotic and transoral laser surgical procedures in supraglottic carcinoma. J Laryngol Otol 133:404–412, 2019
   Lai KWK, Lai R, Lorincz BB, et al. Oncological and functional outcomes of transoral robotic surgery and endoscopic laryngopharyngeal surgery for hypopharyngeal cancer: a systematic review. Front Surg 8:810581, 2022
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 207
EP 213
PG 7
ER

PT J
AU Papp, A
   Duboczki, Zs
AF Papp, Andras
   Duboczki, Zsolt
TI Robot-assisted esophageal surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE Esophageal cancer; minimal invasive surgery; robot-assisted esophageal resection
ID Esophageal cancer; minimal invasive surgery; robot-assisted esophageal resection
AB The introduction of robot-assisted minimally invasive esophageal surgery (RAMIE) represents a significant advancement in minimally invasive surgery. The robot system typically includes a high-resolution 3D camera and specially maneuverable instruments that are controlled by the surgeon from a console. By reducing the trauma caused by the intervention, this method allows for faster recovery compared to traditional open surgeries. Furthermore, the increased range of motion provided by the robot instruments enables more precise manipulations in the area of the esophagus and surrounding tissues, thereby improving the effectiveness of tumor resections and reconstructions. The results of clinical trials are promising: there is a decrease in postoperative pain, a lower risk of complications, and a shorter hospital stay, while the oncological outcomes are at least equivalent to open surgeries. As technology advances, robot-assisted esophageal surgery is expected to spread more widely, providing better patient care and surgical outcomes for both benign and malignant esophageal diseases.
C1 [Papp, Andras] University of Pecs, Department of Surgery, Ifjusag ut 13., 7624 Pecs, Hungary.
   [Duboczki, Zsolt] National Institute of OncologyBudapest, Hungary.
RP Papp, A (reprint author), University of Pecs, Department of Surgery, 7624 Pecs, Hungary.
EM papp.andras@pte.hu
CR Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 109:djx030, 2017
   Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 381:400–412, 2013
   Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379:1887–1892, 2012
   Luketich JD, Pennathur A, Awais O, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg 256:95–103, 2012
   Okusanya OT, Sarkaria IS, Hess NR, et al. Robotic assisted minimally invasive esophagectomy, RAMIE): the University of Pittsburgh Medical Center initial experience. Ann Cardiothorac Surg 6:179–185, 2017
   van derHorst S, Weijs TJ, Ruurda JP, et al. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. J Thorac Dis 9:834–842, 2017
   Grimminger PP, Hadzijusufovic E, Lang H. Robotic-assisted Ivor Lewis esophagectomy, RAMIE, with a standardized intrathoracic circular end-toside stapled anastomosis and a team of two, surgeon and assistant only). Thorac Cardiovasc Surg 66:404–406, 2018
   van der Sluis PC, Ruurda JP, Verhage RJ, et al. Oncologic long-term results of robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with two field lymphadenectomy for esophageal cancer. Ann Surg Oncol 22(Suppl 3):1350–1356, 2015
   Weksler B, Sullivan JL. Survival after esophagectomy: a propensitymatched study of different surgical approaches. Ann Thorac Surg 104:1138– 1146, 2017
   Li XK Xu Y, Zhou H, et al. Does robot-assisted minimally invasive oesophagectomy have superiority over thoraco-laparoscopic minimally invasive oesophagectomy in lymph node dissection? Dis Esophagus 34:1–12, 2021
   Papp A, Palkovics A, Sindler DL, et al. Achalasia miatt vegzett robotasszisztalt laparoszkopos cardiomyotomia es fundoplicatio, Heller–Dormutet). Orv Hetil 164:542–547, 2023
   Szijarto A, Fulop A. Filozofia es technika a robotsebeszet mindennapjaiban. Magy Seb 76:103–110, 2023
   Takacs K, Lukacs E, Levendovics R, et al. Assessment of surgeons’ stress levels with digital sensors during robot-assisted surgery: an experimental study. Sensors, Basel, 24:2915, 2024
   Sagawa H, Saito M, Ito S, et al. Near infrared ray-guided surgery using Firefly technology of the daVinci Xi system and intraoperative upper gastrointestinal endoscopy for subtotal gastrectomy and surgery for cancer of the gastroesophageal junction. BMC Surg 22:174, 2022
   https://isrg.intuitive.com/news-releases/news-release-details/intuitive- announces-fda-clearance-fifth-generation-robotic
   Asadizeidabadi A, Hosseini S, Vetshev F, et al. Comparison of da Vinci 5 with previous versions of da Vinci and Sina: A review. Lapar Endosc Robot Surg 7:60–65, 2024
   Mederos MA, de Virgilio MJ, Shenoy R, et al. Comparison of clinical outcomes of robot-assisted, video-assisted, and open esophagectomy for esophageal cancer: a systematic review and meta-analysis. JAMA Netw Open 4:e2129228, 2021
   van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial. Ann Surg 269:621–630, 2019
   de Groot EM, van der Horst S, Kingma BF, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open esophagectomy: long-term follow-up of a randomized clinical trial. Dis Esophagus 33(Supplement_2): doaa079, 2020
   Goense L, van der Sluis PC, van der Horst S, et al. Cost analysis of robot- assisted versus open transthoracic esophagectomy for resectable esophageal cancer. Results of the ROBOT randomized clinical trial. Eur J Surg Oncol 49:106968, 2023
   Tagkalos E, van der Sluis PC, Berlth F, et al. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial, ROBOT-2 trial). BMC Cancer 21:1060, 2021
   Yang Y, Li B, Yi J, et al. Robot-assisted versus conventional minimally invasive esophagectomy for resectable esophageal squamous cell carcinoma: early results of a multicenter randomized controlled trial: the RAMIE trial. Ann Surg 275:646–653, 2022
   Jin D, Yao L, Yu J, et al. Robotic-assisted minimally invasive esophagectomy versus the conventional minimally invasive one: A meta-analysis and systematic review. Int J Med Robot 15:e1988, 2019
   van der Sluis PC, Ruurda JP, van der Horst S, et al. Learning curve for robot- assisted minimally invasive thoracoscopic esophagectomy: results from 312 cases. Ann Thorac Surg 106:264–271, 2018
   Vimolratana M, Sarkaria IS, Goldman DA, et al. Two-year quality of life outcomes after robotic-assisted minimally invasive and open esophagectomy. Ann Thorac Surg 112:880–889, 2021
   Neuschutz KJ, Fourie L, Germann N, et al. Long-term quality of life after hybrid robot-assisted and open Ivor Lewis esophagectomy for esophageal cancer in a single center: a comparative analysis. Langenbecks Arch Surg 409:118, 2024
   Nishigori T, Miyata H, Okabe H, et al. Impact of hospital volume on risk-adjusted mortality following oesophagectomy in Japan. Br J Surg 103:1880–1886, 2016
   Parise P, Elmore U, Fumagalli U, et al. Esophageal surgery in Italy. Criteria to identify the hospital units and the tertiary referral centers entitled to perform it. Updates Surg 68:129–133, 2016
   Henneman D, Dikken JL, Putter H, et al. Centralization of esophagectomy: how far should we go? Ann Surg Oncol 21:4068–4074, 2014
   Nimptsch U, Haist T, Krautz C, et al. Hospital volume, in-hospital mortality, and failure to rescue in esophageal surgery. Dtsch Arztebl Int 115:793– 800, 2018
   Lang H, Grimminger PP, Meyer HJ. Mindestmengenregelungen in der Chirurgie aus Sicht der Fachgesellschaft, DGCH): Spagat zwischen Wissenschaft, Politik, Versorgungsrealitat und einer Reihe weiterer Aspekte. Chirurg 93:342–348, 2022
   Papp A. Nyelocsodaganatok sebeszete – Elvarhato standardok. Magy Seb 76:7–13, 2023
   Sindler DL, Matrai P, Szako L, et al. Faster recovery and bowel movement after early oral feeding compared to late oral feeding after upper GI tumor resections: a meta-analysis. Front Surg 10:1092303, 2023
   Sindler DL, Papp C, Csontos A, et al. A korai, szajon keresztuli taplalas nem jelent veszelyt a felso tapcsatornai mutetek utan. Orv Hetil 165:24–29, 2024
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 215
EP 220
PG 6
ER

PT J
AU Ghimessy, �
   Radeczky, P
   Torok, K
   Bogyo, L
   Csende, K
   Meszaros, L
   Gieszer, B
   Tihanyi, H
   Tarsoly, G
   Csaba, M
   Lality, S
   Hartyanszky, IK
   Kocsis, �
   Madurka, I
   Agocs, L
   Renyi-Vamos, F
AF Ghimessy, Aron
   Radeczky, Peter
   Torok, Klara
   Bogyo, Levente
   Csende, Kristof
   Meszaros, Laszlo
   Gieszer, Balazs
   Tihanyi, Hanna
   Tarsoly, Gabor
   Csaba, Marton
   Lality, Sara
   Hartyanszky, Istvan Kazmer
   Kocsis, Akos
   Madurka, Ildiko
   Agocs, Laszlo
   Renyi-Vamos, Ferenc
TI Robot-assisted thoracic surgery. Our first experiences
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE robotic surgery; thoracic surgery; lung cancer; learning curve; lymph node dissection
ID robotic surgery; thoracic surgery; lung cancer; learning curve; lymph node dissection
AB Our goal was to examine the postoperative indicators after the first 300 thoracic robotic cases in the National Institute of Oncology. We retrospectively analyzed the clinicopathological and postoperative indicators of the first 300 patients. We also compared the first 30 cases performed by one surgeon to his 30 VATS (video-assisted thoracic surgery) and open cases. The average hospital stay was 5.2 days, the chest tube was removed on the second day. Conversion, need for reoperation and morbidity was low (1.8%, 2% and 10.6%, respectively). The change in operating time slows down after 20 cases. The hospital stay and complications were slightly favorable with RATS (robotic-assisted thoracic surgery) than with VATS. The intensive care stay, however, was significantly shorter while the amount of removed lymph nodes was significantly higher in RATS procedures. As a conclusion, RATS is a safe technique in thoracic surgery. Moreover, more lymph nodes are removed with RATS which can lead to better staging.
C1 [Ghimessy, Aron] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Radeczky, Peter] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Torok, Klara] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Bogyo, Levente] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Csende, Kristof] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Meszaros, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Gieszer, Balazs] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Tihanyi, Hanna] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Tarsoly, Gabor] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Csaba, Marton] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Lality, Sara] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Hartyanszky, Istvan Kazmer] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Kocsis, Akos] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Madurka, Ildiko] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Agocs, Laszlo] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
   [Renyi-Vamos, Ferenc] Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, Rath Gyorgy utca 7-9., 1122 Budapest, Hungary.
RP Ghimessy, � (reprint author), Orszagos Onkologiai Intezet, Mellkassebeszeti Osztaly, 1122 Budapest, Hungary.
CR Melfi FM, Ambrogi MC, Lucchi M, Mussi A. Video robotic lobectomy. Multimed Man Cardiothorac Surg 2005:mmcts 2004 000448, 2005
   Melfi FM, Menconi GF, Mariani AM, Angeletti CA. Early experience with robotic technology for thoracoscopic surgery. Eur J Cardiothorac Surg 21:864– 868, 2002
   Morgan JA, Ginsburg ME, Sonett JR, et al. Advanced thoracoscopic procedures are facilitated by computer-aided robotic technology. Eur J Cardiothorac Surg 23:883–887, 2003
   Shugaba A, Lambert JE, Bampouras TM, et al. Should all minimal access surgery be robot-assisted? A systematic review into the musculoskeletal and cognitive demands of laparoscopic and robot-assisted laparoscopic surgery. J Gastrointest Surg 26:1520–1530, 2022
   Cerfolio RJ. Total port approach for robotic lobectomy. Thorac Surg Clin 24:151–156, 2014
   Ramadan OI, Cerfolio RJ, Wei B. Tips and tricks to decrease the duration of operation in robotic surgery for lung cancer. J Vis Surg 3:11, 2017
   Cerfolio RJ, Bryant AS. How to teach robotic pulmonary resection. Semin Thorac Cardiovasc Surg 25:76–82, 2013
   Novellis P, Bottoni E, Voulaz E, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute. J Thorac Dis 10:790–798, 2018
   Veronesi G, Novellis P, Voulaz E, Alloisio M. Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer 101:28–34, 2016
   Cerfolio RJ, Ghanim AF, Dylewski M, et al. The long-term survival of robotic lobectomy for non-small cell lung cancer: A multi-institutional study. J Thorac Cardiovasc Surg 155:778–786, 2018
   Terra RM, Araujo P, Lauricella LL, et al. A Brazilian randomized study: Robotic-Assisted vs. Video-assisted lung lobectomy Outcomes, BRAVO trial). J Bras Pneumol 48:e20210464, 2022
   Williams AM, Zhao L, Grenda TR, et al. Higher long-term quality of life metrics after video-assisted thoracoscopic surgery lobectomy compared with robotic-assisted lobectomy. Ann Thorac Surg 113:1591–1597, 2022
   O’Connor LA, Dua A, Orhurhu V, et al. Opioid requirements after intercostal cryoanalgesia in thoracic surgery. J Surg Res 274:232–241, 2022
   Finnerty DT, McMahon A, McNamara JR, et al. Comparing erector spinae plane block with serratus anterior plane block for minimally invasive thoracic surgery: a randomised clinical trial. Br J Anaesth 125:802–810, 2020
   Rincavage M, Hammond L, Reddy S, et al. Pain control using liposomal bupivacaine versus bupivacaine for robotic assisted thoracic surgery. Int J Clin Pharm 41:258–263, 2019
   Qsous G, Downes A, Carroll B, et al. A comparison of the differences in postoperative chronic pain between video-assisted and robotic-assisted approaches in thoracic surgery. Cureus 14:e31688, 2022
   Ma J, Li X, Zhao S, et al. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis. BMC Cancer 21:498, 2021
   Jin R, Zhang Z, Zheng Y, et al. Health-related quality of life following robotic-assisted or video-assisted lobectomy in patients with non-small cell lung cancer: results from the RVlob randomized clinical trial. Chest 163:1576–1588, 2023
   Veronesi G, Abbas AE, Muriana P, et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study, ROMAN study). Front Oncol 11:726408, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 223
EP 228
PG 6
ER

PT J
AU Lintner, B
AF Lintner, Balazs
TI Endometrial cancer: our experience with roboticassisted technique
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE endometrial carcinoma; obesity; sentinel lymph node; robot-assisted technique
ID endometrial carcinoma; obesity; sentinel lymph node; robot-assisted technique
AB Endometrial carcinoma is the most common type of gynaecological cancer. Its primary incidence is highest around the age of 60. The majority of cases are detected at an early stage and therefore have a good prognosis. The majority of patients suffer from obesity, which makes primary surgical treatment difficult. Minimally invasive surgery, as recommended by international protocols, is the first choice for appropriate surgical treatment and significantly reduces the incidence of complications for patients. Robotic techniques are particularly important in the care of patients with often abnormal obesity. In this article, we summarise our knowledge of endometrial carcinoma and our experience with da Vinci robot-assisted surgery, which started almost 2 years ago at Semmelweis University.
C1 [Lintner, Balazs] Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, Ulloi ut 78/A, 1082 Budapest, Hungary.
RP Lintner, B (reprint author), Semmelweis Egyetem, Szuleszeti es Nogyogyaszati Klinika, 1082 Budapest, Hungary.
EM lintnerster@gmail.com
CR Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018
   Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105:575–580, 2005
   Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol Oncol 161:573–580, 2021
   National Collaborating Centre for Cancer, UK). Suspected Cancer: Recognition and Referral. London: National Institute for Health and Care Excellence, NICE), 2015
   Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol 214:1–17, 2016
   Long B, Clarke MA, Morillo ADM, et al. Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis. Gynecol Oncol 157:624–633, 2020
   van Hanegem N, Prins MM, Bongers MY, et al. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 197:147–155, 2016
   Crosbie EJ, Zwahlen M, Kitchener HC, et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19:3119–3130, 2010
   Kitson S, Crosbie EJ. Endometrial cancer and obesity. Obstet Gynaecol 21:237–245, 2019
   Ryan NAJ, McMahon R, Tobi S, et al. The proportion of endometrial tumours associated with Lynch syndrome, PETALS): A prospective cross-sectional study. PLoS Med 17:e1003263, 2020
   Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 1:105–143, 2006
   Hohn AK, Brambs CE, Hiller GGR, et al. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd 8:1145–1153, 2021
   Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular- based classification for endometrial cancers. Br J Cancer 113:299–310, 2015
   Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700, 2012
   Mourits MJ, Bijen CB, Arts HJ et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 11:763–71, 2010
   Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1016, 2008
   ASTEC study group; Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer, MRC ASTEC trial): a randomised study. Lancet 10:125–136, 2009
   Frost JA, Webster KE, Bryant A, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 10:CD007585, 2017
   Leitao MM Jr, Khoury-Collado F, Gardner G, et al. Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecol Oncol 129:38–41, 2013
   Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146:234–239, 2017
   Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging, FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392, 2017
   Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 3:12–39, 2021
   Bernardini MQ, Gien LT, Tipping H, et al. Surgical outcome of robotic surgery in morbidly obese patient with endometrial cancer compared to laparotomy. Int J Gynecol Cancer 22:76–81, 2012
   Tang KY, Gardiner SK, Gould C, et al. Robotic surgical staging for obese patients with endometrial cancer. Am J Obstet Gynecol 206:513.e1–6, 2012
   Gehrig PA, Cantrell LA, Shafer A, et al. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? Gynecol Oncol 111:41–45, 2008
   Geppert B, Lonnerfors C, Persson J. Robot-assisted laparoscopic hysterectomy in obese and morbidly obese women: surgical technique and comparison with open surgery. Acta Obstet Gynecol Scand 90:1210–1217, 2011
   Perrone E, Capasso I, Pasciuto T, et al. Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study. J Gynecol Oncol 32:45, 2021
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 232
EP 238
PG 7
ER

PT J
AU Kerepesi, J
   Korosi, J
   Kiarash, B
   Novak, Z
AF Kerepesi, Judit
   Korosi, Julia
   Kiarash, Bahrehmand
   Novak, Zoltan
TI Trends of minimally invasive surgical techniques in endometrial carcinoma at the National Institute of Oncology (2016–2024)
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE endometrial cancer; minimally invasive surgery; robotic-assisted surgery; hysterectomy
ID endometrial cancer; minimally invasive surgery; robotic-assisted surgery; hysterectomy
AB The aim of this study was to analyze the trends and clinical outcomes of minimally invasive surgical techniques in the treatment of endometrial carcinoma at the National Institute of Oncology, Department of Gynecology, from 2016 to 2023. This retrospective study included patients with endometrial carcinoma stages I-IV who underwent primary surgical treatment between 2016 and 2023. The techniques analyzed were total laparoscopic hysterectomy (TLH), robotic- assisted hysterectomy (RAH), and total abdominal hysterectomy (TAH). A total of 1127 patients were included. The number of minimally invasive surgeries increased significantly: in 2016, there were 69 laparotomies and 1 TLH, while in 2023, there were 57 laparotomies, 19 TLHs and 123 robotic-assisted hysterectomies. As a conclusion, the use of minimally invasive techniques significantly increased in the treatment of endometrial carcinoma. The entire team, including anesthesiologists, gained experience in managing morbidly obese patients, enabling safe minimally invasive surgeries.
C1 [Kerepesi, Judit] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Korosi, Julia] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Kiarash, Bahrehmand] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Novak, Zoltan] National Institute of Oncology, Center of Gynaecology, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
RP Kerepesi, J (reprint author), National Institute of Oncology, Center of Gynaecology, 1122 Budapest, Hungary.
EM kerepesi.judit@oncol.hu
CR Collins A, Jacob A, Moss E. Robotic-assisted surgery in high-risk surgical patients with endometrial cancer. Best Pract Res Clin Obstet Gynaecol 92:102421, 2024
   Janda M, Gebski V, Forder P, et al. Total laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized controlled trial. Contemp Clin Trials 27:353–363, 2006
   Janda M, Gebski V, Brand A, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer, LACE): a randomised trial. Lancet Oncol 11:772–780, 2010
   Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 27:5331–5336, 2009
   Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700, 2012
   Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39, 2021
   Raffone A, Travaglino A, Raimondo D, et al. Laparotomic versus robotic surgery in elderly patients with endometrial cancer: A systematic review and meta-analysis. Int J Gynaecol Obstet 157:1–10, 2022
   Janda M, Gebski V, Davies LC, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317:1224– 1233, 2017
   Abel MK, Chan JK, Chow S, et al. Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. Int J Gynecol Cancer 30:1347–1355, 2020
   Eklind S, Lindfors A, Sjoli P, et al. A prospective, comparative study on robotic versus open-surgery hysterectomy and pelvic lymphadenectomy for endometrial carcinoma. Int J Gynecol Cancer 25:250–256, 2015
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 239
EP 242
PG 4
ER

PT J
AU Banyai, D
   Sarlos, DP
   Belak, M
   Czetany, P
   Szanto, �
AF Banyai, Daniel
   Sarlos, Donat Peter
   Belak, Matyas
   Czetany, Peter
   Szanto, Arpad
TI Our initial experience with robot-assisted partial nephrectomy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE kidney cancer; robotic-assisted surgery; partial nephrectomy; learning curve
ID kidney cancer; robotic-assisted surgery; partial nephrectomy; learning curve
AB The aim of our study was to summarize our initial experience with robot-assisted partial nephrectomy (RAPN) surgeries. Our data were obtained retrospectively by analyzing the data from the first RAPN surgeries performed at University of Pecs Clinical Centre. Between October 2022 and April 2024, we performed 53 robot-assisted partial nephrectomies. Due to our specific circumstances, including the lack of funding from the National Health Insurance Fund (OEP), we performed only 16 surgeries in the first eight months and 37 in the subsequent nine months. According to the PADUA score, 55% of the surgeries were categorized as simple, 36% as moderate, and 9% as highly complex. The average console time was 134 minutes, showing a decreasing trend with increased practice. The average warm ischemia time was 12 minutes. There were no conversions to open surgery, but one radical nephrectomy was performed due to peritoneal tumor infiltration. Our patients were discharged on the third postoperative day. The introduction of RAPN in our clinic, as the first provincial centre, was successful. The transition from laparoscopic partial nephrectomy quickly yielded good results despite performing only a few surgeries in the first eight months due to the lack of OEP funding. Nevertheless, our results clearly show that performing 20-30 robot-assisted surgeries per year per surgeon, as described in the literature, is minimally necessary.
C1 [Banyai, Daniel] University of Pecs, Department of Urology, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Sarlos, Donat Peter] University of Pecs, Department of Urology, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Belak, Matyas] University of Pecs, Department of Urology, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Czetany, Peter] University of Pecs, Department of Urology, Munkacsy M. u. 2., 7621 Pecs, Hungary.
   [Szanto, Arpad] University of Pecs, Department of Urology, Munkacsy M. u. 2., 7621 Pecs, Hungary.
RP Banyai, D (reprint author), University of Pecs, Department of Urology, 7621 Pecs, Hungary.
EM banyai.daniel@pte.hu
CR Lee SW, Hyung JK, Sayada ZK, et al. Familial risk of renal cell cancer and interaction with obesity and hyperglycemia: a population-based study. J Urol 208:251–258, 2022
   Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 75:74–84, 2019
   Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387, 2018
   Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors – is there a difference in mortality and cardiovascular outcomes? J Urol 181:55–61, 2009
   Dursun F, Elshabrawy A, Wang H, et al. Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma. Int J Clin Oncol 27:1068–1076, 2022
   Van Poppel H, Luigi DP, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 51:1606–1616, 2007
   Masson-Lecomte A, Yates DR, Hupertan V, et al. A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urol Oncol 31:924–929, 2011
   Boszormenyi-Nagy G, Molnar PJ. Beszamolo az urologiai fekvobeteg-ellatasrol a 2021-es adatok alapjan. Magy Urol 1:11–33, 2023
   Territo A, Baboudjian M, Diana P, et al. To drain or not to drain in uro-oncological robotic surgery? A systematic review and meta-analysis. Minerva Urol Nephrol 75:144–153, 2023
   Pusztai Cs, Bagheri F, Banyai D, et al. Laparoszkopos parcialis nephrectomia – A pecsi modszer. Magy Urol 2:60–64, 2018
   Bertolo R, Antonelli A, Minervini A, et al. Off-clamp versus on-clamp partial nephrectomy: re-envision of a dilemma. Eur Urol Oncol 2:173–176, 2024
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 243
EP 247
PG 5
ER

PT J
AU Meszaros, P
   Duboczki, Zs
   Mezo, K
   Budai, B
   Mersich, T
AF Meszaros, Peter
   Duboczki, Zsolt
   Mezo, Kornel
   Budai, Barna
   Mersich, Tamas
TI First experience with robotic-assisted colorectal surgery
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE robotic-assisted rectal surgery; robotic-assisted oncological surgery; robotic-assisted colorectal procedures; minimally invasive rectal surgery; quality control in rectal surgery
ID robotic-assisted rectal surgery; robotic-assisted oncological surgery; robotic-assisted colorectal procedures; minimally invasive rectal surgery; quality control in rectal surgery
AB Robot-assisted surgery has been available at the National Institute of Oncology since 2022. We report on the most important parameters of the colorectal robot-assisted surgery of the first 191 patients. Robotically assisted rectal surgery was compared with our previous laparoscopic and open surgical activities. Perioperative indicators of rectal cancer patients operated laparoscopically (n=225) and open (n=213) were retrospectively compared with patients operated robotically assisted (n=140). In comparison of the three groups (laparoscopic, open, robot-assisted), robotic surgery shows a significant advantage in quality of mesorectal excision (complete TME rate 77%, 72.7% and 90%, respectively), in the days of care (median 7, 9 and 5 days, respectively), hospital readmissions (8%, 16%, 6.4%), and the rate of sphincter preservation (68%, 60% and 89.5%). As a conclusion, robotic surgery is sufficiently safe from oncological point of view. It has a significant advantage in quality of lymph node dissection, shorter care, fewer hospital readmissions, partially lower morbidity rate and a higher sphincter preservation rate compared to laparoscopic and open surgeries.
C1 [Meszaros, Peter] Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Duboczki, Zsolt] Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Mezo, Kornel] Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Budai, Barna] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Mersich, Tamas] Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
RP Mersich, T (reprint author), Orszagos Onkologiai Intezet, Hasi Sebeszeti Osztaly, 1122 Budapest, Hungary.
EM mersich.tamas@oncol.hu
CR Herrando AI, Azevedo J, Fernandez LM, et al. Intraoperative complications in laparoscopic colorectal surgery and how to avoid them – a video vignette. Colorectal Dis 25:821–822, 2023
   Jayne D, Pigazzi A, Marshall H, et al. Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT. Southampton, UK): NIHR Journals Library, 2019
   Feng Q, Yuan W, Li T, et al. Robotic versus laparoscopic surgery for middle and low rectal cancer, REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 7:991–1004, 2022
   Flynn J, Larach JT, Kong JCH, et al. Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta-analysis. ANZ J Surg 93:510–521, 2023
   Miskovic D, Ahmed J, Bissett-Amess R, et al. European consensus on the standardization of robotic total mesorectal excision for rectal cancer. Colorectal Dis 21:270–276, 2019
   Watanabe J, Takemasa I, Kotake M, et al. Blood perfusion assessment by indocyanine green fluorescence imaging for minimally invasive rectal cancer surgery, EssentiAL trial): a randomized clinical trial. Ann Surg 278:e688– e694, 2023
   Panteleimonitis S, Miskovic D, Bissett-Amess R, et al. Short-term clinical outcomes of a European training programme for robotic colorectal surgery. Surg Endosc 35:6796–6806, 2021
   Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 318:1569–1580, 2017
   Liu G, Zhang S, Zhang Y, et al. Robotic surgery in rectal cancer: potential, challenges, and opportunities. Curr Treat Options Oncol 23:961–979, 2022
   Park JS, Lee SM, Choi GS, et al. Comparison of laparoscopic versus robot- assisted surgery for rectal cancers: the COLRAR randomized controlled trial. Ann Surg 278:31–38, 2023
   Ravindra C, Igweonu-Nwakile EO, Ali S, et al. Comparison of non-oncological postoperative outcomes following robotic and laparoscopic colorectal resection for colorectal malignancy: a systematic review and meta-analysis. Cureus 14:e27015, 2022
   Rouanet P, Bertrand MM, Jarlier M, et al. Robotic versus laparoscopic total mesorectal excision for sphincter-saving surgery: results of a single- center series of 400 consecutive patients and perspectives. Ann Surg Oncol 25:3572-3579, 2018
   Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv263, 2018
   Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006:CD005033, 2006
   Clancy C, O’Leary DP, Burke JP, et al. A meta-analysis to determine the oncological implications of conversion in laparoscopic colorectal cancer surgery. Colorectal Dis 17:482–490, 2015
   Tschann P, Szeverinski P, Weigl MP, et al. Short- and long-term outcome of laparoscopic- versus robotic-assisted right colectomy: a systematic review and meta-analysis. J Clin Med 11:2387, 2022
   Wang J, Johnson NW, Casey L, et al. Robotic colon surgery in obese patients: a systematic review and meta-analysis. ANZ J Surg 93:35–41, 2023
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 248
EP 253
PG 6
ER

PT J
AU Nemeth, M
   Szepesvary, ZsJ
   Torzsok, P
AF Nemeth, Mate
   Szepesvary, Zsolt Jeno
   Torzsok, Peter
TI Robot-assisted radical prostatectomy
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE robot-assisted; prostatectomy; minimal invasive; prostate cancer; nerve-sparing
ID robot-assisted; prostatectomy; minimal invasive; prostate cancer; nerve-sparing
AB Prostate cancer is one of the most commonly seen malignancies. Radical prostatectomy - open, laparoscopic or robot-assisted – is considered the first-line treatment for intermediate and high-risk prostate cancer, along with radiotherapy, if the expected survival is greater than 10 years. Radical prostatectomy is also considered in case of low-risk patients alongside active follow-up. Today, robot-assisted radical prostatectomy is the most common surgical treatment for localised prostate cancer. It is associated with shorter hospitalisation times and lower transfusion requirements compared to open surgery. Satisfactory long-term biochemical recurrence-free survival and tumour-specific survival can be achieved with robot-assisted radical prostatectomy in the treatment of low-, intermediate- and highrisk prostate cancer. It has the advantage of rapid postoperative continence recovery and high potency recovery rates. The cost of the minimal invasive approach is higher compared to open radical prostatectomy, and the benefits of faster postoperative recovery should be further investigated to quantify cost-effectiveness. The robot-assisted approach has enabled a number of new surgical techniques and further rapid advances in this field are expected.
C1 [Nemeth, Mate] Petz Aladar Hospital, Department of Urology, Magyar u. 8., 9023 Gyor, Hungary.
   [Szepesvary, Zsolt Jeno] Petz Aladar Hospital, Department of Urology, Magyar u. 8., 9023 Gyor, Hungary.
   [Torzsok, Peter] Petz Aladar Hospital, Department of Urology, Magyar u. 8., 9023 Gyor, Hungary.
RP Nemeth, M (reprint author), Petz Aladar Hospital, Department of Urology, 9023 Gyor, Hungary.
EM nemeth9mate@gmail.com
CR Wang L, Wang B, Ai Q, et al. Long-term cancer control outcomes of robot- assisted radical prostatectomy for prostate cancer treatment: a meta- analysis. Int Urol Nephrol 49:995–1005, 2017
   Gandaglia G, Montorsi F, Karakiewicz PI, Sun M. Robot-assisted radical prostatectomy in prostate cancer. Future Oncol 11:2767–2773, 2015
   Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESURSIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243–262, 2021
   Young HH. VIII. Conservative perineal prostatectomy: the results of two years’ experience and report of seventy-five cases. Ann Surg 41:549–557, 1905
   Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128:492–497, 1982
   Pasticier G, Rietbergen JB, Guillonneau B, et al. Robotically assisted laparoscopic radical prostatectomy: feasibility study in men. Eur Urol 40:70–74, 2001
   Arenas-Gallo C, Shoag JE, Hu JC. Optimizing surgical techniques in robot- assisted radical prostatectomy. Urol Clin North Am 48:1–9, 2021
   Novara G, Ficarra V, Rosen RC, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 62:431–52, 2012
   Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol 61:679–685, 2012
   Chung SD, Kelle JJ, Huang CY, et al. Comparison of 90-day re-admission rates between open retropubic radical prostatectomy, RRP), laparoscopic RP, LRP, and robot-assisted laparoscopic prostatectomy, RALP). BJU Int 110:E966–971, 2012
   Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302:1557–1564, 2009
   Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 62:1–15, 2012
   Yuh B, Artibani W, Heidenreich A, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of highrisk prostate cancer: a systematic review. Eur Urol 65:918–927, 2014
   Menon M, Bhandari M, Gupta N, et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol 58:838–846, 2010
   Zorn KC, Wille MA, Thong AE, et.al. Continued improvement of perioperative, pathological and continence outcomes during 700 robot-assisted radical prostatectomies. Can J Urol 16:4742–4749, 2009
   Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62:405–417, 2012
   Scales CD Jr, Jones PJ, Eisenstein EL, et al. Local cost structures and the economics of robot assisted radical prostatectomy. J Urol 174:2323–2329, 2005
   Szabo JF, de la Taille A. Robotsebeszet, a prosztatarak modern sebeszi kezelese. Magy Onkol 58:173–181, 2014
   Potdevin L, Ercolani M, Jeong J, Kim IY. Functional and oncologic outcomes comparing interfascial and intrafascial nerve sparing in robot-assisted laparoscopic radical prostatectomies. J Endourol 23:1479–1484, 2009
   Weng H, Zeng XT, Li S, et al. Intrafascial versus interfascial nerve sparing in radical prostatectomy for localized prostate cancer: a systematic review and meta-analysis. Sci Rep 7:11454, 2017
   Menon M, Shrivastava A, Kaul S, et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 51:648–657, 2007
   Galfano A, Ascione A, Grimaldi S, et al. A new anatomic approach for robot-assisted laparoscopic prostatectomy: a feasibility study for completely intrafascial surgery. Eur Urol 58:457–461, 2010
   Ferretti S, Dell’Oglio P, Ciavarella D, et al. Retzius-sparing robotic-assisted prostatectomy: technical challenges for surgeons and key prospective refinements. Res Rep Urol 15:541–552, 2023
   Lim SK, Kim KH, Shin TY, et al. Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retropubic and perineal approaches. BJU Int 114:236–244, 2014
   Menon M, Dalela D, Jamil M, et al. Functional recovery, oncologic outcomes and postoperative complications after robot-assisted radical prostatectomy: an evidence-based analysis comparing the Retzius sparing and standard approaches. J Urol 199:1210–1217, 2018
   Checcucci E, Veccia A, Fiori C, et al. Retzius-sparing robot-assisted radical prostatectomy vs the standard approach: a systematic review and analysis of comparative outcomes. BJU Int 125:8–16, 2020
   Asimakopoulos AD, Annino F, D’Orazio A, et al. Complete periprostatic anatomy preservation during robot-assisted laparoscopic radical prostatectomy, RALP): the new pubovesical complex-sparing technique. Eur Urol 58:407–417, 2010
   Rodriguez Socarras M, Gomez Rivas J, Reinoso Elbers J, et al. Robot-assisted radical prostatectomy by lateral approach: technique, reproducibility and outcomes. Cancers, Basel, 15:5442, 2023
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 255
EP 261
PG 7
ER

PT J
AU Voko, B
   Mayer, T
   Szegedi, �
   Tenke, P
AF Voko, Boldizsar
   Mayer, Tamas
   Szegedi, Akos
   Tenke, Peter
TI Uro-oncological robotic procedures performed in our department
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE uro-oncology; robotic surgery; prostatectomy
ID uro-oncology; robotic surgery; prostatectomy
AB Our objective was to present the perioperative and oncological results of robot-assisted surgery performed in our department. In our publication, we retrospectively reviewed the data of 658 robot-assisted procedures performed between 01/02/2022 and 31/03/2024. The average operative time for radical prostatectomy with bilateral lymph node block dissection was 229 minutes, mean blood loss was 305 ml. Without lymphadenectomy, mean blood loss was 233 ml, operative time was 185 minutes. Biochemical relapse- free rate was 81.6% one year after the procedures. 165 patients underwent robot-assisted partial nephrectomy, and 48 patients underwent radical nephrectomy. We performed the first robot-assisted cystectomy with intracorporeal „neobladder” technique in Hungary. In terms of urinary diversion, we performed orthotopic bladder formation in 10 cases, Bricker bladder formation in 20 cases, and uretherocutaneostomia in 4 cases. We also performed the first robot- assisted retroperitoneal lymphadenectomy in the country. As a conclusion, using robot-assisted technology, the full spectrum of radical uro-oncological surgical procedures can be safely performed in a minimally invasive manner. Our experience and results are encouraging so far, validating the increasing domestic distribution of robotic surgery.
C1 [Voko, Boldizsar] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
   [Mayer, Tamas] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
   [Szegedi, Akos] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
   [Tenke, Peter] Jahn Ferenc Korhaz, Urologia, Koves ut 1., 1204 Budapest, Hungary.
RP Voko, B (reprint author), Jahn Ferenc Korhaz, Urologia, 1204 Budapest, Hungary.
EM vokob1@gmail.com
CR Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESURSIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243–262, 2021
   Cao L, Yang Z, Qi L, et al. Robot-assisted and laparoscopic vs open radical prostatectomy in clinically localized prostate cancer: perioperative, functional, and oncological outcomes: A systematic review and meta-analysis. Medicine, Baltimore, 98:e15770, 2019
   Koukourikis P, Rha KH. Robotic surgical systems in urology: What is currently available? Investig Clin Urol 62:14–22, 2021
   Peters BS, Armijo PR, Krause C, et al. Review of emerging surgical robotic technology. Surg Endosc 32:1636–1655, 2018
   https://ales.amegroups.org/article/view/5499/pdf
   Mayer T, Voko B, Magyar A, et al. A Jahn Ferenc Del-pesti Korhaz Urologiai Osztalyan 2022. februar es oktober kozott elvegzett robotasszisztalt mutetek osszegzese. Magy Urol 2023:128–132, 2023
   Milonas D, Venclovas Z, Muilwijk T, et al. External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. Cent European J Urol 73:19–25, 2020
   Murphy DG, Kerger M, Crowe H, et al. Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur Urol 55:1358– 1366
   Bouchier-Hayes DM, Clancy KX, Canavan K, et al. Initial consecutive 125 cases of robotic assisted laparoscopic radical prostatectomy performed in Ireland’s first robotic radical prostatectomy centre. Ir J Med Sci 181:21–25, 2012
   Asimakopoulos AD, Annino F, Mugnier C, et al. Robotic radical prostatectomy: analysis of midterm pathologic and oncologic outcomes: A historical series from a high-volume center. Surg Endosc 35:6731–6745, 2021
   Peyronnet B, Seisen T, Oger E, et al. French Comittee of Urologic Oncology, CCAFU). Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol 23:4277–4283, 2016
   Choi JE, You JH, Kim DK, et al. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol 67:891–901, 2015
   Chang KD, Abdel Raheem A, Kim KH, et al. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years’ follow-up. BJU Int 122:618–626, 2018
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 263
EP 266
PG 4
ER

PT J
AU Kolossvary, K
   Nagy, R
   Papp, E
   Savolt, �
   Toth, E
   Rubovszky, G
AF Kolossvary, Kinga
   Nagy, Reka
   Papp, Eszter
   Savolt, Akos
   Toth, Erika
   Rubovszky, Gabor
TI Retrospective analysis of metaplastic breast cancer cases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast neoplasms; chemotherapy; metaplastic; rare
ID breast neoplasms; chemotherapy; metaplastic; rare
AB Metaplastic breast tumour is a rare, aggressive, mostly triple- negative, dedifferentiated malignancy, which poorly responds to chemotherapy compared to other invasive breast tumours. Since 2000, the WHO has considered it as a separate entity among breast tumours. Given the extremely poor prognosis of the tumour, more studies are needed to establish the most effective treatment strategy supported by data to increase overall survival. The objective of our research was a retrospective analysis of 77 patients with metaplastic breast cancer treated between 01.01.2012 and 28.02.2023 at our institute. Following the descriptive statistics of the patients, the pathological or clinical response was examined in cases of 15 patients treated with neoadjuvant and 14 patients with palliative chemotherapy. Finally, we compared the overall and progression-free survival of metaplastic breast cancer patients treated at our institute with those described in the international literature. The research results, both at our institute and in the literature, are limited by the small number of cases. In our research, with similar numbers of cases as many other investigations, we obtained results close to international data, thereby supporting the collection of data and further research necessary for the most effective treatment strategy for this rare tumour.
C1 [Kolossvary, Kinga] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Nagy, Reka] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Papp, Eszter] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Savolt, Akos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Department of Diagnostic PathologyBudapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Kolossvary, K (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, 1122 Budapest, Hungary.
EM kolossvary.kinga@oncol.hu
CR Gonzalez-Martinez S, Perez-Mies B, Carretero-Barrio I, et al. Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma. Cancers, Basel, 12:1832, 2020
   Nelson RA, Guye ML, Luu T, et al. Survival outcomes of metaplastic breast cancer patients: Results from a US population-based analysis. Ann Surg Oncol 22:24−31, 2015
   Huvos AG, Lucas JC|Jr, Foote FW|Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 73:1078−1082, 1973
   Organization WH: WHO Classification of Tumours: Breast Tumours, 5th ed.), 2019
   Avigdor BE, Beierl K, Gocke CD, et al. Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. Clin Cancer Res 23:4875−4884, 2017
   Thomas HR, Hu B, Boyraz B, et al. Metaplastic breast cancer: A review. Crit Rev Oncol Hematol 182:103924, 2023
   Polamraju P, Haque W, Cao K, et al. Comparison of outcomes between metaplastic and triple-negative breast cancer patients. Breast 49:8−16, 2020
   Esbah O, Turkoz FP, Turker I, et al. Metaplastic breast carcinoma: case series and review of the literature. Asian Pac J Cancer Prev 13:4645−4649, 2012
   Lester TR, Hunt KK, Nayeemuddin KM, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor- negative breast cancers. Breast Cancer Res Treat 131:41−48, 2012
   Abada E, Daaboul F, Ebare K, et al. Clinicopathologic characteristics and outcome descriptors of metaplastic breast carcinoma. Arch Pathol Lab Med 146:341−350, 2022
   McMullen ER, Zoumberos NA, Kleer CG. Metaplastic breast carcinoma: Update on histopathology and molecular alterations. Arch Pathol Lab Med 143:1492−1496, 2019
   Murphy BL, Fazzio RT, Hoskin TL, et al. Management of the axilla in metaplastic breast carcinoma. Gland Surg 7:200−206, 2018
   Paul Wright G, Davis AT, Koehler TJ, et al. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol 21:3497−3503, 2014
   He X, Ji J, Dong R, et al. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Res Treat 173:329−341, 2019
   Wang J, Zhang WW, Lian CL, et al. The effect of post-mastectomy radiotherapy in patients with metaplastic breast cancer: an analysis of SEER database. Front Oncol 9:747, 2019
   Haque W, Verma V, Naik N, et al. Metaplastic breast cancer: Practice patterns, outcomes, and the role of radiotherapy. Ann Surg Oncol 25:928−936, 2018
   Daly MB, Pal T, Berry MP, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:77−102, 2021
   Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 10:413−419, 1999
   Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res 24:5820−5829, 2018
   Ng CKY, Piscuoglio S, Geyer FC, et al. The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res 23:3859−3870, 2017
   Moulder S, Helgason T, Janku F, et al. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol 26:1346−1352, 2015
   Coussy F, El Botty R, Lavigne M, et al. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. J Hematol Oncol 13:13, 2020
   Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: Evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3:509−515, 2017
   Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810−821, 2020
   Leyrer CM, Berriochoa CA, Agrawal S, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat 165:499−504, 2017
   Tadros AB, Sevilimedu V, Giri DD, et al. Survival outcomes for metaplastic breast cancer differ by histologic subtype. Ann Surg Oncol 28:4245−4253, 2021
   Erjan A, Almasri H, Abdel-Razeq H, et al. Metaplastic breast carcinoma: Experience of a tertiary cancer center in the Middle East. Cancer Control 28:10732748211004889, 2021
   Patil Okaly GV, Akshatha C, Sandhya N, et al. Revisiting metaplastic carcinoma of breast: an emphasis on the clinico-pathological and immunohistochemical variables analyzed at a tertiary cancer centre in South India. Iran J Pathol 17:268−274, 2022
   Cimino-Mathews A, Verma S, Figueroa-Magalhaes MC, et al. A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. Am J Clin Pathol 145:365−372, 2016
   Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17:605−613, 2006
   Takuwa H, Ueno T, Ishiguro H, et al. A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy. Breast Cancer 21:504−507, 2014
   Al-Hilli Z, Choong G, Keeney MG, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat 176:709−716, 2019
   Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev 79:101888, 2019
   Takala S, Heikkila P, Nevanlinna H, et al. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. Breast J 25:418−424, 2019
   Moreno AC, Lin YH, Bedrosian I, et al. Outcomes after treatment of metaplastic versus other breast cancer subtypes. J Cancer 11:1341−1350, 2020
   Yan Q, Deng Y, Zhang Q. A comprehensive overview of metaplastic breast cancer: Features and treatments. Cancer Sci, 2024,, DOI  10.1111/cas.16208
   Thomas A, Douglas E, Reis-Filho JS, et al. Metaplastic breast cancer: Current understanding and future directions. Clin Breast Cancer 23:775−783, 2023
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 269
EP 275
PG 7
ER

PT J
AU Pinter, T
AF Pinter, Tamas
TI Trifluridine/tipiracil and bevacizumab combination in refractory metastatic colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
AB The treatment of metastatic colorectal cancer - especially in the case of refractory disease - is a serious clinical challenge. The trifluridine/tipiracil+bevacizumab combination has been shown to be effective in refractory disease in previous clinical trials, however, data reflecting real conditions are scarce. A Chinese research group investigated the efficacy of trifluridine/tipiracil in combination with or without bevacizumab in a Chinese center, while a Spanish group recently reported the "real world" results of the combination treatment. The results of these two announcements are presented below.
C1 [Pinter, Tamas] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Pinter, T (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
CR Li RR, Zhou HJ, Zeng DY, et al. Efficacy and safety of trifluridine/ tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. J Gastrointest Oncol 15:612–629, 2024
   Lago NM, Borja Gonzalez B, Martin EG, et al. Real-world effectiveness and safety of trifluridine-tipiracil, FTD/TPI, and bevacizumab, BEV, in refractory metastatic colorectal cancer, mCRC): The BeTAS trial. J Clin Oncol 42(3_suppl):51, 2024
NR 3
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD SEP
PY 2024
VL 68
IS 3
BP 277
EP 278
PG 2
ER

PT J
AU Kapuvari, B
AF Kapuvari, Bence
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Kapuvari, Bence] National Institute of Oncology, Rath Gyorgy u. 7., 1122 Budapest, Hungary.
RP Kapuvari, B (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 285
EP 285
PG 1
ER

PT J
AU Patocs, A
AF Patocs, Attila
TI 
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Personal Narrative
C1 [Patocs, Attila] National Institute of Oncology, Rath Gyorgy u. 7-9., 1122 Budapest, Hungary.
RP Patocs, A (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 287
EP 287
PG 1
ER

PT J
AU Rokusz, A
   Melegh, Zs
   Vereczkey, I
   Papp, E
   Madaras, L
   Toth, E
AF Rokusz, Andras
   Melegh, Zsombor
   Vereczkey, Ildiko
   Papp, Eszter
   Madaras, Lilla
   Toth, Erika
TI Predictive markers in gynaecological, prostate, and breast cancers
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE molecular pathology; predictive biomarker; gynecological cancers; prostate cancer; breast cancer
ID molecular pathology; predictive biomarker; gynecological cancers; prostate cancer; breast cancer
AB The implementation of targeted therapies in oncology has brought significant improvement in the treatment of many solid tumours. At the same time, pathological and molecular pathological diagnostics became more important. Today, there are hardly any solid tumours that do not require predictive biomarker testing. In recent years, a number of new targeted therapies have emerged for gynaecological tumours, prostate and breast cancer. In this article, we summarise the molecular pathology tests required in these tumours based on current clinical and pathological guidelines.
C1 [Rokusz, Andras] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Ulloi ut 26., 1085 Budapest, Hungary.
   [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Vereczkey, Ildiko] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Papp, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Madaras, Lilla] Semmelweis University, 2nd Department of PathologyBudapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
RP Rokusz, A (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, 1085 Budapest, Hungary.
EM rokusz.andras@semmelweis.hu
CR Min HY, Lee HY: Molecular targeted therapy for anticancer treatment. Exp Mol Med 54:1670-1694, 2022
   Tjota MY, Segal JP, Wang P: Clinical utility and benefits of comprehensive genomic profiling in cancer. J Appl Lab Med 9:76-91, 2024
   Cibula D, Raspollini MR, Planchamp F, et al: ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023. Int J Gynecol Cancer 33:649-666, 2023
   Chuang LT, Temin S, Berek JS: Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. JCO Glob Oncol 8:e2200027, 2022
   Marletta S, Fusco N, Munari E, et al: Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems. J Pers Med 12:1073, 2022
   WHO Classification of Tumours, Female Genital Tumours. 5th ed. IARC Press, 2020
   Buza N: Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Semin Diagn Pathol 39:58-77, 2022
   Kortekaas KE, Bastiaannet E, Van Doorn HC, et al: Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol 159:649-656, 2020
   Shapira-Frommer R, Mileshkin L, Manzyuk L, et al: Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. Gynecol Oncol 166:211-218, 2022
   Oonk MHM, Planchamp F, Baldwin P, et al: European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer – Update 2023. Int J Gynecol Cancer 33:1023-1043, 2023
   Mosele F, Remon J, Mateo J, et al: Recommendations for the use of next-generation sequencing, NGS, for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491-1505, 2020
   The Cancer Genome Atlas Research Network, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73, 2013
   Kommoss S, McConechy MK, Kommoss F, et al: Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population- based case series. Ann Oncol 29:1180-1188, 2018
   Wang Y, Shi C, Eisenberg R, Vnencak-Jones CL: Differences in microsatellite instability profiles between endometrioid and colorectal cancers. J Mol Diagn 19:57-64, 2017
   Kobel M, Piskorz AM, Lee S, et al: Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247-258, 2016
   Leon–Castillo A, Britton H, McConechy MK, et al: Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250:323-335, 2020
   Concin N, Matias-Guiu X, Vergote I, et al: ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12-39, 2021
   Oaknin A, Bosse TJ, Creutzberg CL, et al: Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:860-877, 2022
   Berek JS, Matias–Guiu X, Creutzberg C, et al: FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet 162:383-394, 2023
   Buza N, Euscher ED, Matias-Guiu X, et al: Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multiinstitutional interobserver agreement study. Mod Pathol 34:1194- 1202, 2021
   Talia KL, Banet N, Buza N: The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 55:8-18, 2023
   Kuroki L, Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ 371:m3773, 2020
   Dinneen K, Arora R: Molecular testing in ovarian tumours: challenges from the pathologist’s perspective. Diagnostics 13:2072, 2023
   Ledermann JA, Matias-Guiu X, Amant F, et al: ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 35:248-266, 2024
   Peng Z, Li M, Li H, Gao Q: PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities. Drug Discov Today 28:103666, 2023
   Novak Z, Bagameri A, Mate Sz, et al: A petefeszekrak kezelese. A Magyar Nogyogyasz Onkologusok Tarsasaganak, MNOT, ajanlasa az ESMO es ESMO- ESGO ajanlasok felhasznalasaval. Magy Onkol 66:223-238, 2022
   Bell S, McKeeve C, Roxburgh P, et al: An overview of the molecular pathology of ovarian carcinomas. Diagn Histopathol 30: P477-486, 2024
   Carroll PH, Mohler JL: NCCN Guidelines Updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw 16(5S):620-623, 2018
   Barata PC, Assayag J, Li B, et al: Genetic testing in men with metastatic castration-resistant prostate cancer. JAMA Oncol 10:975, 2024
   Melegh Zs, Csernak E, Kohanka A, et al: A homolog rekombinacios hibajavito rendszer szomatikus genmutacioinak vizsgalata prosztata-adenokarcinomaban, ujgeneracios szekvenalassal. Magy Onkol 68:137-141, 2024
   Daly GR, AlRawashdeh MM, McGrath J, et al: PARP inhibitors in breast cancer: a short communication. Curr Oncol Rep 26:103-113, 2024
   Shah M, Osgood CL, Amatya AK, et al: FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early- stage triple-negative breast cancer. Clin Cancer Res 28:5249-5253, 2022
   McVeigh TP, Kerin MJ: Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer, Dove Med Press, 9:393-400, 2017
   Litton JK, Burstein HJ, Turner NC: Molecular testing in breast cancer. Published online 2019 ASCO Educational Book
   Turner NC, Oliveira M, Howell SJ, et al: Capivasertib in hormone receptor– positive advanced breast cancer. N Engl J Med 388:2058-2070, 2023
   Burstein HJ, DeMichele A, Somerfield MR, et al: Testing for ESR1 mutations to guide therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 41:3423-3425, 2023
   Engi H, Toth E: Folyadekbiopsziabol vegzett vizsgalatok jelentosege szolid tumorok eseten. Magy Onkol 67:125-130, 2023
   Armstrong N, Ryder S, Forbes C, et al: A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543-561, 2019
   Morganti S, Bychkovsky BL, Poorvu PD, et al: Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: evidence and controversies. Oncologist 28:565-574, 2023
   Desai NV, Zakalik D, Somerfield MR, et al: A new standard of care for germline BRCA1 and/or BRCA2 mutation carriers with early-stage breast cancer. JCO Oncol Pract 18:427-429, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 289
EP 289
PG 9
ER

PT J
AU Vida, L
   Kereskai, L
   Kovacs, LK
   Kajtar, B
AF Vida, Livia
   Kereskai, Laszlo
   Kovacs, Laura Kitti
   Kajtar, Bela
TI Diagnostic challenges of pediatric gliomas; the role of molecular profiling in everyday diagnostics
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pediatric gliomas; diagnostic challenges; molecular profiling; brain tumors; personalized treatment
ID pediatric gliomas; diagnostic challenges; molecular profiling; brain tumors; personalized treatment
AB Aim: This study aims to evaluate the diagnostic challenges and molecular aspects of pediatric gliomas, among the most common brain tumors in children, focusing on improving early detection and personalized treatment strategies.  Methods: We conducted a comprehensive review of recent literature, examining current diagnostic techniques, including imaging and histopathological analysis, alongside molecular profiling methods such as next-generation sequencing (NGS) and methylation profiling.  Results: The findings highlight significant diagnostic challenges due to the heterogeneity of pediatric gliomas. Molecular profiling has proven essential in identifying key genetic alterations, such as those in the H3F3A and MAPK pathway genes, offering insights into tumor behavior and therapeutic targets.  Conclusions: Early and accurate diagnosis of pediatric gliomas is hampered by their molecular diversity. Integrating molecular diagnostics with traditional methods is crucial for enhancing diagnostic accuracy and guiding personalized treatment approaches.
C1 [Vida, Livia] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Kereskai, Laszlo] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Kovacs, Laura Kitti] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
   [Kajtar, Bela] University of Pecs, Department of Pathology, Szigeti ut 12., 7624 Pecs, Hungary.
RP Vida, L (reprint author), University of Pecs, Department of Pathology, 7624 Pecs, Hungary.
EM vidalivia@gmail.com
CR Ostrom QT, Cioffi G, Gittleman H, et al: CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 21(Suppl 5):1-100, 2019
   Diwanji TP, Engelman A, Snider JW, et al: Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Heal Med Ther 8:99-113, 2017
   Siegel RL, Miller KD, Fuchs HE, et al: Cancer statistics, 2021. CA Cancer J Clin 71:7-33, 2021
   Ostrom QT, de Blank PM, Kruchko C, et al: Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 10):x1-x36, 2015
   Louis DN, Perry A, Wesseling P, et al: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231- 1251, 2021
   Hosseini A, Minucci S: Alterations of histone modifications in cancer. In: Epigenetics in Human Disease, 2nd edition). Ed. Tollefsbol TO. 2018, pp. 6:141-217
   Cai Y, Zhang Y, Loh YP, et al: H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions. Nat Commun 12:719, 2021
   Lewis PW, Muller MM, Koletsky MS, et al: Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857-861, 2013
   Larson JD, Kasper LH, Paugh BS, et al: Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression. Cancer Cell 35:140-155, 2019
   Lim KY, Won K, Park, CK, et al: H3 G34-mutant high-grade glioma. Brain Tumor Pathol 38:4-13, 2021
   Nguyen AV, Soto JM, Gonzalez SM, et al: H3G34-mutant gliomas – a review of molecular pathogenesis and therapeutic options. Biomedicines 11:2002, 2023
   Braicu C, Buse M, Busuioc C, et al: A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers 11:1618, 2022
   Plotnikov A, Zehorai E, Procaccia S, et al: The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 1813:1619-1633, 2011
   Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al: Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma, DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol 36:1963-1972, 2018
   Zheng L, Gong J, Yu T, et al: Diffuse midline gliomas with histone H3 K27M mutation in adults and children: a retrospective series of 164 cases. Am J Surg Pathol 46:863-871, 2022
   Panwalkar P, Clark J, Ramaswamy V, et al: Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705-714, 2017
   Buczkowicz P, Hoeman C, Rakopoulos P, et al: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451-456, 2014
   Yoshimoto K, Hatae R, Sangatsuda Y, et al: Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34:103-112, 2017
   Gianno F, Giovannoni I, Cafferata B, et al: Paediatric-type diffuse highgrade gliomas in the 5th CNS WHO Classification. Pathologica 114:422-435, 2022
   Korshunov A, Schrimpf D, Ryzhova M, et al: H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 134:507-516, 2017
   Tauziede-Espariat A, Beccaria K, Dangouloff-Ros V, et al: A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant-type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma. Brain Pathol 33:13182, 2023
   Torre M, Vasudevaraja V, Serrano J, et al: Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun 8:107, 2020
   Giannini C, Scheithauer BW, Lopes MB, et al: Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 26:479-485, 2022
   Phillips JJ, Gong H, Chen K, et al: The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol 29:85-96, 2019
   Lassaletta A, Zapotocky M, Mistry M, et al: Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35:2934-2941, 2017
   Wang S, He Q, Zhang Q, Guan B, et al: Clinicopathologic features and prognosis of epithelioid glioblastoma. Int J Clin Exp Pathol 13:1529-1539, 2020
   Bonnin JM, Rubinstein LJ: Astroblastomas: a pathological study of 23 tumors, with a postoperative follow-up in 13 patients. Neurosurgery 25:6-13, 1989
   Sturm D, Orr BA, Toprak UH, et al: New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164:1060-1072, 2016
   Wefers AK, Stichel D, Schrimpf D, et al: Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol 139:193-209, 2020
   Tatevossian RG, Tang B, Dalton J, et al: MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol 120:731-743, 2010
   Lake JA, Donson AM, Prince E, et al: Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. Pediatr Blood Cancer 67:28028, 2020
   Shakur SF, McGirt MJ, Johnson MW, et al: Angiocentric glioma: a case series. J Neurosurg Pediatr 3:197-202, 2009
   Suh YY, Lee K, Shim YM, et al: MYB/MYBL1: QKI fusion-positive diffuse glioma. J Neuropathol Exp Neurol 82:250-260, 2023
   Huse JT, Snuderl M, Jones DT, et al: Polymorphous low-grade neuroepithelial tumor of the young, PLNTY): an epileptogenic neoplasm with oligodendroglioma- like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133:417-429, 2017
   Benson JC, Summerfield D, Carr C, et al: Polymorphous low-grade neuroepithelial tumor of the young as a partially calcified intra-axial mass in an adult. AJNR Am J Neuroradiol 41:573-578, 2020
   Capper D, Jones DTW, Sill M, et al: DNA methylation-based classification of central nervous system tumours. Nature 555:469-474, 2018
   Ryall S, Zapotocky M, Fukuoka K, et al: Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37:569-583, 2020
   Coakley KJ, Huston J 3rd, Scheithauer BW, et al: Pilocytic astrocytomas: well-demarcated magnetic resonance appearance despite frequent infiltration histologically. Mayo Clin Proc 70:747-751, 1995
   Krishnatry R, Zhukova N, Guerreiro Stucklin AS, et al: Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Cancer 122:1261-1269, 2016
   Phillips JJ, Gong H, Chen K, et al: The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol 29:85-96, 2019
   Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:243-254, 2013
   Sharma MC, Ralte AM, Gaekwad S, et al: Subependymal giant cell astrocytoma – a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 10:219-224, 2004
   Franz DN, Belousova E, Sparagana S, et al: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex, EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132, 20133
   Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: Glioblastoma. Ed. De Vleeschouwer S. Brisbane Codon Publications, 2017, pp. 54-72
   Lassaletta A, Zapotocky M, Bouffet E, et al: An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. Childs Nerv Syst 32:1789-1797, 2016
   Bruckner E, Bedics G, Reiniger L, et al: Gyermekkori agydaganatok: diagnosis es terapia – komprehenziv genomikai profilozas. Magy Onkol 67:315-320, 2023
   Kanherkar RR, Bhatia-Dey N, Csoka AB: Epigenetics across the human lifespan. Front Cell Dev Biol 2:49, 2014
   Targeted options for glioma looking good. Cancer Discov 13:1755, 2023
   Hargrave DR, Bouffet E, Tabori U, et al: Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: Results from a phase I/IIa study. Clin Cancer Res 25:7303-7311, 2019
   Timar J, Uhlyarik A. A celzott kezelesek „celzott” mellekhatasai. Magy Onkol 9:157-168, 2022
   Kattner P, Strobel H, Khoshnevis N, et al: Compare and contrast: pediatric cancer versus adult malignancies. Cancer Metastasis Rev 38:673-682, 2019
   Fletcher JI, Ziegler DS, Trahair TN, et al: Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nat Rev Cancer 18:389- 400, 2018
   Szabo S, Bedics G, Bodor Cs, et al: Tumoragnosztikus terapia a gyermekonkologiaban. Magy Onkol 10:127-132, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 299
EP 299
PG 12
ER

PT J
AU Botos, PB
   Erhardt, J
   Jenei, S
   Li, LK
   Kovacs, SD
   Egyed, B
   Beniczky, NJ
   Erdelyi, D
   Muller, J
   Bruckner, E
   Csoka, M
   Szabo, A
   Kornyei, L
   Bertalan, R
   Kovacs, G
   Vilmanyi, Cs
   Garami, M
   Bodor, Cs
   Kovacs, �F
AF Botos, Peter Barnabas
   Erhardt, Julia
   Jenei, Samuel
   Li, Luca Kamilla
   Kovacs, Sandor David
   Egyed, Balint
   Beniczky, Nikolett Jusztina
   Erdelyi, Daniel
   Muller, Judit
   Bruckner, Edit
   Csoka, Monika
   Szabo, Andrea
   Kornyei, Laszlo
   Bertalan, Rita
   Kovacs, Gabor
   Vilmanyi, Csaba
   Garami, Miklos
   Bodor, Csaba
   Kovacs, Arpad Ferenc
TI Diagnostic and therapeutic perspectives in RASopathies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE RASopathy; molecular diagnostics; genetic counselling; targeted therapy
ID RASopathy; molecular diagnostics; genetic counselling; targeted therapy
AB RASopathies are congenital diseases that manifest in childhood with symptoms and potential complications, typically associated with an elevated tumour predisposition risk. The heterogeneous symptoms involve mostly central nervous, cardiovascular, musculoskeletal systems and skin, and modified growth pattern. From molecular perspective, the function of a key protein involved in Ras signalling is impaired, leading to disrupted regulation of cell growth and division. It is crucial to uncover genetic history, analyse tumour and cardiac involvement pattern along four generation pedigree and depict minor anomaly pattern. Upon clinical suspicion a stepwise approach to molecular testing is recommended to confirm or rule out the specific RASopathy. Post-test genetic counselling should address potential complications, developmental and follow-up strategies in line with current guidelines. Cascade pedigree segregation analysis according to the inheritance pattern should be offered to family planning parents and potentially affected family members. In case of certain specific organ involvement or complications, targeted therapeutics are available, highlighting the importance of early diagnosis.
C1 [Botos, Peter Barnabas] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Erhardt, Julia] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Jenei, Samuel] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Li, Luca Kamilla] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Kovacs, Sandor David] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Egyed, Balint] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Beniczky, Nikolett Jusztina] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Erdelyi, Daniel] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Muller, Judit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Bruckner, Edit] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Csoka, Monika] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Szabo, Andrea] Gottsegen Gyorgy Orszagos Kardiovaszkularis IntezetBudapest, Hungary.
   [Kornyei, Laszlo] Gottsegen Gyorgy Orszagos Kardiovaszkularis IntezetBudapest, Hungary.
   [Bertalan, Rita] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Kovacs, Gabor] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Vilmanyi, Csaba] Gottsegen Gyorgy Orszagos Kardiovaszkularis IntezetBudapest, Hungary.
   [Garami, Miklos] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research GroupBudapest, Hungary.
   [Kovacs, Arpad Ferenc] Semmelweis University, 2nd Department of Pediatrics, Tuzolto u. 7–9., 1094 Budapest, Hungary.
RP Kovacs, �F (reprint author), Semmelweis University, 2nd Department of Pediatrics, 1094 Budapest, Hungary.
CR Padhiyar J, Mahajan R, Panda M: RASopathies: evolving concepts in pathogenetics, clinical features, and management. Indian Dermatol Online J 15:392-404, 2024
   Lioncino M, Monda E, Verrillo F, et al: Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin 18:19, 2022
   Saint-Laurent C, Mazeyrie L, Yart A, Edouard T: Novel therapeutic perspectives in Noonan syndrome and RASopathies. Eur J Pediatr 183:1011- 1019, 2024
   Lee TSJ, Chopra M, Kim RH, et al: Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis 18:292, 2023
   Torales LDG, Sempowski BA, Krikorian GL, et al: Central conducting lymphatic anomaly: from bench to bedside. J Clin Invest 134:e172839, 2024
   Evans DG, Mostaccioli S, Pang D, et al: ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. Eur J Hum Genet 30:812-817, 2022
   Hirbe AC, Gutmann DH: Neurofibromatosis type 1: A multidisciplinary approach to care. Lancet Neurol 13:834-843, 2014
   Leoni C, Viscogliosi G, Tartaglia M, et al: Multidisciplinary management of Costello syndrome: current perspectives. J Multidiscip Healthc 15:1277- 1296, 2022
   Spurlock G, Bennett E, Chuzhanova N, et al: SPRED1 mutations, Legius syndrome): Another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J Med Genet 46:431-437, 2009
   Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN: The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet 136:129- 148, 2017
   Zenker M, Edouard T, Blair JC, Cappa M: Noonan syndrome: improving recognition and diagnosis. Arch Dis Child 107:1073-1078, 2022
   Eerola I, Boon LM, Mulliken JB, et al: Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73:1240-1249, 2003
   Alfurayh N, Alsaif F, Alballa N, et al: LEOPARD syndrome with PTPN11 gene mutation in three family members presenting with different phenotypes. J Pediatr Genet 09:246-251, 2020
   Scorrano G, David E, Cali E, et al: The cardiofaciocutaneous syndrome: from genetics to prognostic-therapeutic implications. Genes, Basel, 14:2111, 2023
   Tartaglia M, Kalidas K, Shaw A, et al: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563, 2002
   Hebron KE, Hernandez ER, Yohe ME: The RASopathies: from pathogenetics to therapeutics. Dis Model Mech 15:2, 2022
   Thomas S, Bikeyeva V, Abdullah A, et al: Systematic review of pediatric brain tumors in neurofibromatosis type 1: status of gene therapy. Cureus 14:e27963, 2022
   Legius E, Messiaen L, Wolkenstein P, et al: Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23:1506-1513, 2021
   Ney G, Gross A, Livinski A, et al: Cancer incidence and surveillance strategies in individuals with RASopathies. Am J Med Genet C Semin Med Genet 190:530-540, 2022
   Schraepen C, Donkersloot P, Duyvendak W, et al: What to know about schwannomatosis: a literature review. Br J Neurosurg 36:171-174, 2022
   Sarkozy A, Digilio MC, Dallapiccola B: Leopard syndrome. Orphanet J Rare Dis 3:13, 2008
   Palit A, Inamadar AC: RASopathies: Dermatologists’ viewpoints. Indian J Dermatol Venereol Leprol 88:452-463, 2022
   Siano MA, Pivonello R, Salerno M, et al: Endocrine system involvement in patients with RASopathies: A case series. Front Endocrinol, Lausanne, 13:1030398, 2022
   Gripp KW, Lin AE: Costello syndrome: A Ras/mitogen activated protein kinase pathway syndrome, rasopathy, resulting from HRAS germline mutations. Genet Med 14:285-292, 2012
   Kehrer-Sawatzki H, Mautner VF, Cooper DN: Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet 136:349-376, 2017
   Tamburrino F, Scarano E, Schiavariello C, et al: Endocrinological manifestations in RASopathies. Am J Med Genet C Semin Med Genet 190:471-477, 2022
   Otten BJ, Noordam C: Growth in Noonan syndrome. Horm Res 72(Suppl 2):31-35, 2009
   Dahlgren J, Noordam C: Growth, endocrine features, and growth hormone treatment in noonan syndrome. J Clin Med 11:2034, 2022
   Delogu AB, Limongelli G, Versacci P, et al: The heart in RASopathies. Am J Med Genet C Semin Med Genet 190:440-451, 2022
   Faienza MF, Meliota G, Mentino D, et al: Cardiac phenotype and gene mutations in RASopathies. Genes, Basel, 15:1015, 2024
   Padhiyar J, Mahajan R, Panda M: RASopathies: evolving concepts in pathogenetics, clinical features, and management. Indian Dermatol Online J 15:392, 2024
   Lioncino M, Monda E, Verrillo F, et al: Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin 18:19-29, 2022
   Hilal N, Chen Z, Chen MH, Choudhury S: RASopathies and cardiac manifestations. Front Cardiovasc Med 10:1176828, 2023
   Zenker M: Clinical overview on RASopathies. Am J Med Genet C Semin Med Genet 190:414-424, 2022
   Gripp KW, Zand DJ, Demmer L, et al: Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis. Am J Med Genet A 161:2420-2430, 2013
   Kim YE, Baek ST: Neurodevelopmental aspects of rasopathies. Mol Cells 42:441-447, 2019
   Montanaro FAM, Alfieri P, Caciolo C, et al: Neuropsychological features in RASopathies: A pilot study on parent training program involving families of children with Noonan syndrome. Am J Med Genet C Semin Med Genet 190:510-519, 2022
   Papadopoulou A, Bountouvi E: Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes. Front Endocrinol, Lausanne, 14:1231828, 2023
   Wong Ramsey KN, Loichinger MH, Slavin TP, et al: The perinatal presentation of cardiofaciocutaneous syndrome. Am J Med Genet A 164:2036-2042, 2014
   Cao H, Alrejaye N, Klein OD, et al: A review of craniofacial and dental findings of the RASopathies. Orthod Craniofac Res 20:32-38, 2017
   Myers A, Bernstein JA, Brennan ML, et al: Perinatal features of the RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome. Am J Med Genet A 164:2814-2821, 2014
   Cave H, Caye A, Strullu M, et al: Acute lymphoblastic leukemia in the context of RASopathies. Eur J Med Genet 59:173-178, 2016
   Pierpont MEM, Magoulas PL, Adi S, et al: Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 134:e1149-e1162, 2014
   Sleutjes J, Kleimeier L, Leenders E, et al: Lymphatic abnormalities in noonan syndrome spectrum disorders: a systematic review. Mol Syndromol 13:1-11, 2022
   Kratz CP, Franke L, Peters H, et al: Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 112:1392-1397, 2015
   Digilio MC, Lepri F, Baban A, et al: RASopathies: Clinical diagnosis in the first year of life. Mol Syndromol 1:282-289, 2011
   Perrino MR, Das A, Scollon SR, et al: Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, Noonan syndrome, CBL syndrome, Costello syndrome, and related RASopathies. Clin Cancer Res 30:4834-4843, 2024
   Carli D, Resta N, Ferrero GB, et al: Mosaic RASopathies: A review of disorders caused by somatic pathogenic variants in the genes of the RAS/MAPK pathway. Am J Med Genet C Semin Med Genet 190:520-529, 2022
   Kovacs AF, Nemethi Z, Abonyi T, et al: Enhancing molecular testing for effective delivery of actionable gene diagnostics. Bioengineering 9:745, 2022
   Koster R, Schipper LJ, Giesbertz NAA, et al: Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics. Genet Med 26:101032, 2024
   Pandit B, Sarkozy A, Pennacchio LA, et al: Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007-1012, 2007
   Pierpont EI, Bennett AM, Schoyer L, et al: The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy. Am J Med Genet A 194:e63477, 2024
   Wang S, Yu WM, Zhang W, et al: Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase, PTPN11, enhance cell migration and angiogenesis. J Biol Chem 284:913-920, 2009
   Rohrer TR, Abuzzahab J, Backeljauw P, et al: Long-term effectiveness and safety of childhood growth hormone treatment in Noonan syndrome. Horm Res Paediatr 93:380-395, 2021
   Triantafyllou P, Christoforidis A, Vargiami E, Zafeiriou DI: Growth hormone replacement therapy in Costello syndrome. Growth Horm IGF Res 24:271-275, 2014
   Horikawa R, Ogata T, Matsubara Y, et al: Long-term efficacy and safety of two doses of Norditropin®, somatropin, in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J 67:803-818, 2020
   Noonan JA, Kappelgaard AM: The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 83:157-166, 2015
   Orraca-Castillo M, Estevez-Perez N, Reigosa-Crespo V: Neurocognitive profiles of learning disabled children with neurofibromatosis type 1. Front Hum Neurosci 8:386, 2014
   Hyman SL, Arthur E, North KN: Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficithyperactivity disorder. Dev Med Child Neurol 48:973-977, 2006
   Granstrom S, Friedrich RE, Langenbruch AK, et al: Influence of learning disabilities on the tumour predisposition syndrome NF1—Survey from adult patients’ perspective. Anticancer Res 34:3675-3681, 2014
   Payne JM, Barton B, Ullrich NJ, et al: Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology 87:2575-2584, 2016
   Jung NH, Egert-Schwender S, Schossow B, et al: Improvement of synaptic plasticity and cognitive function in RASopathies – a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial, SynCoRAS). Trials 24:383, 2023
   Johnson B, Goldberg-Strassler D, Gripp K, et al: Function and disability in children with Costello syndrome and cardiofaciocutaneous syndrome. Am J Med Genet A 167:40-44, 2015
   De Blank PMK, Gross AM, Akshintala S, et al: MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro Oncol 24:1845-1856, 2022
   Andelfinger G, Marquis C, Raboisson MJ, et al: Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. J Am Coll Cardiol 73:2237-2239, 2019
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 313
EP 313
PG 11
ER

PT J
AU Strausz, T
   Bathory-Fulop, L
   Papp, E
   Toth, E
AF Strausz, Tamas
   Bathory-Fulop, Laszlo
   Papp, Eszter
   Toth, Erika
TI Molecular pathology of gastrointestinal neoplasms
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE molecular pathology; predictive biomarker; colorectal cancer; gastric cancer; pancreatic cancer
ID molecular pathology; predictive biomarker; colorectal cancer; gastric cancer; pancreatic cancer
AB The molecular pathological examination of solid tumors is essential not only for supporting histological diagnosis but also for detecting hereditary variations and predictive biomarkers. Analyzing predictive markers is fundamental to personalized cancer therapy, directly affecting patient care through pathological testing. These analyses employ both traditional immunohistochemical staining methods and molecular genetic techniques. In both approaches, preanalytics is of critical importance, necessitating the adoption of standardized and reproducible processes. Molecular diagnostics in colorectal cancer focuses on detecting activating mutations in the MAPK pathway (KRAS, NRAS, BRAF), as well as evaluating microsatellite instability and HER2 amplification. Immunohistochemical methods can effectively identify biomarkers for gastric cancers, including the novel claudin18.2. The responsiveness of gastrointestinal stromal tumors to imatinib requires validation via molecular testing. Patients diagnosed with pancreatic cancer may see enhanced survival rates by targeted therapy addressing microsatellite instability and BRCA mutations. In bile duct malignancies, especially intrahepatic cholangiocarcinoma of the small duct variant, the analysis of IDH1 mutations and FGFR2 fusions presents new treatment prospects.
C1 [Strausz, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Bathory-Fulop, Laszlo] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Papp, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Strausz, T (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM drstrausz@gmail.com
CR World Health Organization. Digestive System Tumours: WHO Classification of Tumours. 5th ed., International Agency for Research on Cancer, 2019
   Guinney J, Dienstmann R, Wang X, et al: The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350-1356, 2015
   Argiles G, Tabernero J, Labianca R, et al: Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291-1305, 2020
   Chen W, Frankel WL: A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol 32(Suppl 1):1-15, 2019
   Loria A, Ammann AM, Olowokure OO, et al: Systematic review of neoadjuvant immunotherapy for mismatch repair deficient locally advanced colon cancer: an emerging strategy. Dis Colon Rectum 67:762-771, 2024
   Shin AE, Giancotti FG, Rustgi AK: Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 44:222-236, 2023
   Yaeger R, Weiss J, Pelster MS, et al: Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 388:44-54, 2023
   Ratti M, Grizzi G, Passalacqua R, et al: NTRK fusions in colorectal cancer: clinical meaning and future perspective. Expert Opin Ther Targets 25:677- 683, 2021
   Chia NY, Tan P: Molecular classification of gastric cancer. Ann Oncol 27:763-769, 2016
   Rocken C: Predictive biomarkers in gastric cancer. J Cancer Res Clin Oncol 149:467-481, 2023
   Pietrantonio F, Miceli R, Raimondi A, et al: Individual patient data meta- analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 37:3392-3400, 2019
   Bartley AN, Washington MK, Ventura CB, et al: HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 140:1345-1363, 2016
   Ajani JA, D’Amico TA, Bentrem DJ, et al: Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:167-192, 2022
   Mathias-Machado MC, de Jesus VHF, Jacome A, et al: Claudin 18.2 as a new biomarker in gastric cancer-what should we know? Cancers, Basel, 16:679, 2024
   Shah MA, Shitara K, Ajani JA, et al: Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133-2141, 2023
   Wainberg ZA, Enzinger PC, Kang YK, et al: Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma, FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 23:1430-1440, 2022
   Sato Y, Okamoto K, Kawano Y, et al: Novel biomarkers of gastric cancer: current research and future perspectives. J Clin Med 12:4646, 2023
   Stickler S, Rath B, Hamilton G: Targeting KRAS in pancreatic cancer. Oncol Res 32:799-805, 2024
   Aung KL, Fischer SE, Denroche RE, et al: Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS Trial. Clin Cancer Res 24:1344-1354, 2018
   Golan T, Hammel P: Management of BRCA mutation carriers with pancreatic adenocarcinoma. J Natl Compr Canc Netw 19:469-473, 2021
   Conroy T, Pfeiffer P, Vilgrain V, et al: Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:987-1002, 2023
   Wattenberg MM, Reiss KA: Determinants of homologous recombination deficiency in pancreatic cancer. Cancers, Basel, 13:4716, 2021
   Brozos-Vazquez E, Toledano-Fonseca M, Costa-Fraga N, et al: Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treat Rev 125:102719, 2024
   Zhen DB, Safyan RA, Konick EQ, et al: The role of molecular testing in pancreatic cancer. Therap Adv Gastroenterol 16:17562848231171456, 2023
   Guedj N: Pathology of cholangiocarcinomas. Curr Oncol 30:370-380, 2022
   Merath K, Tiwari A, Parikh AA, et al: Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol 19:2607-2621, 2023
   Zhu AX, Macarulla T, Javle MM, et al: Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 7:1669-1677, 2021
   Frampton JE: Pemigatinib: a review in advanced cholangiocarcinoma. Target Oncol 19:107-114, 2024
   Li Y, Yu J, Zhang Y, Peng C, et al: Advances in targeted therapy of cholangiocarcinoma. Ann Med 56:2310196, 2024
   Martin-Broto J, Rubio L, Alemany R, et al: Clinical implications of KIT and PDGFRA genotyping in GIST. Clin Transl Oncol 12:670-676, 2010
   Ibrahim A, Chopra S: Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med 144:655-660, 2020
   Wada R, Arai H, Kure S, et al: „Wild type” GIST: Clinicopathological features and clinical practice. Pathol Int 66:431-437,2016
   Serrano C, Martin-Broto J, Asencio-Pascual JM, et al: 2023 GEIS guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol 15:17588359231192388, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 325
EP 325
PG 7
ER

PT J
AU Kohanka, A
   Bathory-Fulop, L
   Tanacs-Bencze, E
   Engi, H
   Bogos, K
   Moldvay, J
   Papai, SzZs
   Szalai, Zs
   Szoke, J
   Toth, E
AF Kohanka, Andrea
   Bathory-Fulop, Laszlo
   Tanacs-Bencze, Eszter
   Engi, Helga
   Bogos, Krisztina
   Moldvay, Judit
   Papai, Szekely Zsolt
   Szalai, Zsuzsanna
   Szoke, Janos
   Toth, Erika
TI Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE lung adenocarcinoma; EGFR T790M mutation; cfDNA
ID lung adenocarcinoma; EGFR T790M mutation; cfDNA
AB Aim: In our institute, we have been testing EGFR T790M resistance mutations since 2019, which is the most common resistance mutation that develops during first-line, second- line EGFR TKI treatment of EGFR mutant lung adenocarcinomas. The importance of this study is that the identification of this mutation will allow the use of an effective third-generation TKI. In this article, we report on studies from January 2022 to August 2024, compared with our results from the 2019–2021 period.  Methods: 380, predominantly blood samples from 222 patients were tested during the present period using Super- ARMS EGFR Mutation Detection Kit (AmoyDx).  Results: EGFR mutations were identified in 57% of all samples in the primary tumours, with a 38.3% frequency of T790M mutation.  Conclusions: Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019–2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.
C1 [Kohanka, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Bathory-Fulop, Laszlo] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Tanacs-Bencze, Eszter] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Engi, Helga] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Bogos, Krisztina] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Moldvay, Judit] National Koranyi Institute of PulmonologyBudapest, Hungary.
   [Papai, Szekely Zsolt] Szent Gyorgy University Teaching Hospital of Fejer County, Department of PulmonologySzekesfehervar, Hungary.
   [Szalai, Zsuzsanna] Petz Aladar Megyei Oktato Korhaz, PulmonologiaGyor, Hungary.
   [Szoke, Janos] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Szoke, J (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
CR Min HY, Lee HY: Molecular targeted therapy for anticancer treatment. Exp Mol Med 54:1670-1694, 2022
   Shuel SL: Targeted cancer therapies: Clinical pearls for primary care. Can Fam Physician 68:515-518, 2022
   Sabnis AJ, Bivona TG: Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med 25:185- 197, 2019
   Graham RP, Treece AL, Lindeman NI, et al: Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med 142:163-167, 2018
   Oxnard GR, Hu Y, Mileham KF, et al: Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib. JAMA Oncol 4:1527, 2018
   Tan CS, Cho BC, Soo RA: Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. Lung Cancer 93:59-68, 2016
   Engi H, Toth E: Folyadekbiopsziabol vegzett vizsgalatok jelentosege szolid tumorok eseten. Magy Onkol 67:125-130, 2023
   Bencze E, Bogos K, Kohanka A, et al: EGFR T790M mutation detection in patients with non-small cell lung cancer after first line EGFR TKI therapy: summary of results in a three-year period and a comparison of commercially available detection kits. Pathol Oncol Res 28:1610607, 2022
   Li X, Zhou C: Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget 8:100801- 100818, 2017
   Daly ME, Singh N, Ismaila N, et al: Management of stage III non–small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol 42:3058-3060, 2024
   Gosney JR, Paz-Ares L, Janne P, et al: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open 8:101587, 2023
   Hendriks LE, Kerr KM, Menis J, et al: Oncogene-addicted metastatic nonsmall-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339-357, 2023
   Pei G, Li M, Min X, et al: Molecular identification and genetic characterization of early-stage multiple primary lung cancer by large-panel next-generation sequencing analysis. Front Oncol 11:653988, 2021
   Hofman P: EGFR status assessment for better care of early stage nonsmall cell lung carcinoma: what is changing in the daily practice of pathologists? Cells 10:2157, 2021
   Hondelink LM, Ernst SM, Atmodimedjo P, et al: Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a reallife West-European cohort: Implications for adjuvant therapy. Eur J Cancer 181:53-61, 2023
   Pereira I, Gaspar C, Pina M, et al: Real-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer. Cureus 12:e12128, 2020
   Wang ZF, Ren SX, Li W, Gao GH: Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19 Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer 18:148, 2018
   Sundaresan TK, Sequist LV, Heymach JV, et al: Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22:1103-1110, 2016
   Jenkins S, Yang JCH, Ramalingam SS, et al: Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer. J Thorac Oncol 12:1061-1070, 2017
   Seto T, Nogami N, Yamamoto N, et al: Real-world EGFR T790M testing in advanced non-small cell lung cancer: a prospective observational study in Japan. Oncol Ther 6:203-215, 2018
   Filipits M, Kainz V, Sebek V, Zach H, on behalf of the Liquid Biopsy Collaborative Study Group: Epidermal growth factor receptor T790M mutation testing in non-small cell lung cancer: an international collaborative study to assess molecular EGFR T790M testing in liquid biopsy. Cancers 15:3528, 2023
   Testa U, Castelli G, Pelosi E: Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori 110:88-95, 2024
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 334
EP 334
PG 5
ER

PT J
AU Ujfalusi, A
AF Ujfalusi, Aniko
TI The role of cytogenetic tests in the diagnosis of malignant hematologic diseases
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE cytogenetics; FISH; clonal; chromosome
ID cytogenetics; FISH; clonal; chromosome
AB In malignant hematological diseases, clonal genetic alterations, such as chromosomal aberrations and gene mutations, are responsible for the uncontrolled division of abnormal hemopoietic cells. The detection of clonal variants has not only diagnostic, but also prognostic and therapeutic significance. They enable risk-based differentiated treatment of patients and the use of targeted (genotype-specific) therapies. Chromosomal abnormalities can be identified with cytogenomic testing (karyotyping, fluorescent in situ hybridization – FISH, microarray). In chronic myeloid leukemia, myelodysplastic neoplasia and acute leukemias, chromosome analysis is a mandatory test at the time of diagnosis. In some lymphoid malignancies (chronic lymphocytic leukemia, multiple myeloma), instead of karyotyping, submicroscopic abnormalities and translocations are detected by FISH method. Despite the rapid spread of high-sensitivity new-generation sequencing techniques, cytogenetic studies are still essential in the routine diagnosis of malignant hematological diseases.
C1 [Ujfalusi, Aniko] Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Laboratoriumi Medicina Intezet, Klinikai Genetikai Tanszek, Egyetem ter 1., 4032 Debrecen, Hungary.
RP Ujfalusi, A (reprint author), Debreceni Egyetem, Altalanos Orvostudomanyi Kar, Laboratoriumi Medicina Intezet, Klinikai Genetikai Tanszek, 4032 Debrecen, Hungary.
EM ujfalusi.aniko@med.unideb.hu
CR Khoury JD, Solary E, Abla O, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours. Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36:1703-1719, 2022
   Alaggio R, Amador C, Anagnostopoulos I, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours. Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022
   Rack KA, van den Berg E, Haferlach C, et al: European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia 3:1851-1867, 2019
   McGowan-Jordan J, Hastings R, Moore S., ed): An International System for Human Cytogenomic Nomenclature. Karger, Basel, 2020
   Gonzales PR, Mikhail FM: Diagnostic and prognostic utility of fluorescence in situ hybridization, FISH, analysis in acute myeloid leukemia. Curr Hematol Malig Rep 12:568-573, 2017
   Mukherjee S, Sathanoori M, Ma Z, et al: Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer Genet 216-217:128-141, 2017
   Hochhaus A, Baccarani M, Silver RT, et al: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966-984, 2020
   Cross NCP, Ernst T, Branford S, et al: European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia 37:2150-2167, 2023
   Hehlmann R, Lauseker M, Voskanyan A, et al: Impact of emerging ACA on survival in chronic myeloid leukemia, CML). Leukemia 36:2544-2547, 2022
   Deininger MW, Cortes J, Paquette R, et al: The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110:1509-1519, 2007
   Kuykendall AT, Talati C, Padron E, et al: Genetically inspired prognostic scoring system, GIPSS, outperforms dynamic international prognostic scoring system, DIPSS, in myelofibrosis patients. Am J Hematol 94:87-92, 2019
   Tefferi A: Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:801-821, 2023
   Rippel N, Kremyanskaya M: Recent advances in JAK2 inhibition for the treatment of myelofibrosis. Expert Opin Pharmacother 25:1175-1186, 2024
   Shomali W, Gotlib J: World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol 99:946-968, 2024
   Ning Y, Zhang Y, Kallen MA, et al: Cytogenetics and molecular genetics of myelodysplastic neoplasms. Best Pract Res Clin Haematol 36:101512, 2023
   Malcovati L, Hellstrom-Lindberg E, Bowen D, et al: Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943-2964, 2013
   Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
   Bernard E, Tuechler H, Greenberg PL, et al: Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 1:EVIDoa2200008, 2022
   Schanz J, Steidl C, Fonatsch C, et al: Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 29:1963-1970, 2011
   Tang G, Zhang L, Fu B, et al: Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 89:813- 818, 2014
   Hunter A, Padron E: Genomic landscape and risk stratification in chronic myelomonocytic leukemia. Curr Hematol Malig Rep 16:247-255, 2021
   Patnaik MM, Tefferi A: Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol 99:1142-1165, 2024
   Snaith O, Poveda-Rogers C, Laczko D, et al: Cytogenetics and genomics of acute myeloid leukemia. Best Pract Res Clin Haematol 37:101533, 2024
   Shimony S, Stahl M, Stone RM: Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:502-526, 2023
   Dohner H, Wei AH, Appelbaum FR, et al: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345-1377, 2022
   Malard F, Mohty M: Acute lymphoblastic leukaemia. Lancet 395:1146-1162, 2020
   Secker-Walker LM: Prognostic and biological importance of chromosome findings in acute lymphoblastic leukemia. Cancer Genet Cytogenet 49:1-13, 1990
   Stary J, Zimmermann M, Campbell M, et al: Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 32:174–184, 2014
   Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764, 2007
   Pagliaro L, Chen SJ, Herranz D, et al: Acute lymphoblastic leukaemia. Nat Rev Dis Primers 10:41, 2024
   Homfeldt L, Wei L, Diaz-Flores E, et al: The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242–252, 2013
   Hunger SP, Mullighan CG: Acute lymphoblastic leukemia in children. N Engl J Med 373:1541-1552, 2015
   Brady SW, Roberts KG, Gu Z, et al: The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet 54:1376-1389, 2022
   Graux C, Cools J, Michaux L, et al: Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 20:1496-1510, 2006
   Duffield AS, Mullighan CG, Borowitz MJ: International Consensus Classification of acute lymphoblastic leukemia/lymphoma. Virchows Arch 482:11-26, 2023
   Ljungstrom V, Baliakas P: Prognostic and predictive implications of cytogenetics and genomics. Hematol Oncol Clin North Am 35:703-713, 2021
   Braish J, Cerchione C, Ferrajoli A: An overview of prognostic markers in patients with CLL. Front Oncol 14:1371057, 2024
   Hallek M, Cheson BD, Catovsky D, et al: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745-2760, 2018
   de Leval L, Alizadeh AA, Bergsagel PL, et al: Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 140:2193-2227, 2022
   Baliakas P, Espinet B, Mellink C, et al: Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. Hemasphere 6:e707, 2022
   Wierda WG, Brown J, Abramson JS, et al: Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22:175-204, 2024
   Marosvari D, Alpar D, Kiraly AP, et al: A kronikus limfocitas leukemia genetikai hattere az uj generacios szekvenalas korszakaban. Magy Onkol 60:118-125, 2016
   Malcikova J, Pavlova S, Baliakas P, et al: ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. Leukemia 38:1455- 1468, 2024
   Kumar SK, Rajkumar SV: The multiple myelomas – current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 15:409-421, 2018
   Fernandez de Larrea C, Kyle RA, Durie BG, et al: Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780-791, 2013
   Palumbo A, Avet-Loiseau H, Oliva S, et al: Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33:2863-2869, 2015
   Sonneveld P, Avet-Loiseau H, Lonial S, et al: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2955-2962, 2016
   Sanchez-Beato M, Mendez M, Guirado M, et al: A genetic profiling guideline to support diagnosis and clinical management of lymphomas. Clin Transl Oncol 26:1043-1062, 2024
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 341
EP 341
PG 9
ER

PT J
AU Orfi, Z
   Kallai, A
   Csaban, D
   Meggyesi, N
   Nagy-Schwendtner, M
   Harasztdombi, J
   Kajtar, B
   Cegledi, A
   Batai, �
   Tordai, A
   Remenyi, P
   Mikala, G
   Ungvari, Z
   Andrikovics, H
AF Orfi, Zoltan
   Kallai, Attila
   Csaban, Dora
   Meggyesi, Nora
   Nagy-Schwendtner, Mariann
   Harasztdombi, Jozsef
   Kajtar, Bela
   Cegledi, Andrea
   Batai, Arpad
   Tordai, Attila
   Remenyi, Peter
   Mikala, Gabor
   Ungvari, Zoltan
   Andrikovics, Hajnalka
TI The role of clonal hematopoiesis in the molecular diagnostics of solid tumors
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE clonal hematopoiesis; clonal hematopoiesis of indeterminate potential; molecular diagnostics; cell-free DNA; TP53
ID clonal hematopoiesis; clonal hematopoiesis of indeterminate potential; molecular diagnostics; cell-free DNA; TP53
AB This review presents the latest molecular genetic diagnostic and clinical aspects related to clonal hematopoiesis of indeterminate potential (CHIP). CHIP belongs to the continuously expanding group of pre-cancerous conditions, increasingly recognized in routine patient care due to the development of molecular diagnostic tools and the increase in life expectancy. The incidence of CHIP mutations increases with age (1–2% in individuals aged 50 years, 15–45% in those aged 80 years). According to international studies, 5–8% of examinations performed on solid tumors may contain erroneous results due to the presence of leukocytes. This rate increases to 10–15% in case of liquid biopsy samples. To avoid misleading diagnostic results, it is recommended to perform comparative analysis of samples from different tissue origins, blood/tumor sample pairs. The authors illustrate CHIP-related alterations affecting targeted therapies for solid tumors (e.g. KRAS, ATM, IDH1, TP53). The impact of CHIP on the detection of germline genetic alterations is also discussed.
C1 [Orfi, Zoltan] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Kallai, Attila] Semmelweis Egyetem, Megelozo Orvostani es Nepegeszsegtani IntezetBudapest, Hungary.
   [Csaban, Dora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Meggyesi, Nora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Nagy-Schwendtner, Mariann] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Harasztdombi, Jozsef] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Kajtar, Bela] University of Pecs, Department of PathologyPecs, Hungary.
   [Cegledi, Andrea] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Batai, Arpad] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Tordai, Attila] Semmelweis Egyetem, Transzfuziologiai TanszekBudapest, Hungary.
   [Remenyi, Peter] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Mikala, Gabor] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Ungvari, Zoltan] Semmelweis Egyetem, Megelozo Orvostani es Nepegeszsegtani IntezetBudapest, Hungary.
   [Andrikovics, Hajnalka] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
RP Andrikovics, H (reprint author), Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, 1097 Budapest, Hungary.
EM andrikovics.hajnalka@dpckorhaz.hu
CR Osorio FG, Rosendahl Huber A, Oka R, et al: Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep 25:2308-2316.e4, 2018
   Alaggio R, Amador C, Anagnostopoulos I, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022
   Khoury JD, Solary E, Abla O, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/ Dendritic Neoplasms. Leukemia 36:1703-1719, 2022
   Mitchell E, Spencer Chapman M, Williams N, et al: Clonal dynamics of haematopoiesis across the human lifespan. Nature 606:343-350, 2022
   Hormaechea-Agulla D, Matatall KA, Le DT, et al: Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell Stem Cell 28:1428-1442.e6, 2021
   Fuster JJ, Zuriaga MA, Zorita V, et al: TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep 33:108326, 2020
   Tobias DK, Manning AK, Wessel J, et al: Clonal hematopoiesis of indeterminate potential, CHIP, and incident type 2 diabetes risk. Diabetes Care 46:1978-1985, 2023
   Kar SP, Quiros PM, Gu M, et al: Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat Genet 54:1155-1166, 2022
   Schwartz JR, Ma J, Kamens J, et al: The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nat Commun 12:985, 2021
   Coombs CC, Zehir A, Devlin SM, et al: Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21:374-382 e4, 2017
   Swisher EM, Harrell MI, Norquist BM, et al: Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol 2:370-272, 2016
   Dudgeon C, Shreeram S, Tanoue K, et al: Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle 12:2656-2664, 2013
   Jensen K, Konnick EQ, Schweizer MT, et al: Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol 7:107-110, 2021
   Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hematopoiesis associated with adverse outcomes. New Engl J Med 371:2488-2498, 2014
   Genovese G, Kahler AK, Handsaker RE, et al: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New Engl J Med 371:2477-2487, 2014
   Niroula A, Sekar A, Murakami MA, et al: Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med 27:1921-1927, 2021
   Ptashkin RN, Mandelker DL, Coombs CC, et al: Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol 4:1589-1593, 2018
   Olszewski AJ, Chorzalska AD, Kim AS, et al: Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. Br J Haematol 186:e31-e35, 2019
   Bolton KL, Ptashkin RN, Gao T, et al: Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52:1219-1226, 2020
   Razavi P, Li BT, Brown DN, et al: High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med 25:1928-1937, 2019
   Bobin C, Iddir Y, Butterworth C, et al: Sequential analysis of cfDNA reveals clonal evolution in patients with neuroblastoma receiving ALK-targeted therapy. Clin Cancer Res 30:3316-3328, 2024
   Coombs CC, Gillis NK, Tan X, et al: Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res 24:5918-5924, 2018
   Arisi MF, Dotan E, Fernandez SV: Circulating tumor DNA in precision oncology and its applications in colorectal cancer. Int J Mol Sci 23:4441, 2022
   Moss J, Magenheim J, Neiman D, et al: Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 9:5068, 2018
   Snyder MW, Kircher M, Hill AJ, et al: Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57- 68, 2016
   Lui YY, Chik KW, Chiu RW, et al: Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48:421-427, 2002
   Gimeno-Valiente F, Martin-Arana J, Tebar-Martinez R, et al: Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. ESMO Open 8:102051, 2023
   Young AL, Challen GA, Birmann BM, et al: Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 7:12484, 2016
   Hu Y, Ulrich BC, Supplee J, et al: False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 24:4437-4443, 2018
   Mayrhofer M, De Laere B, Whitington T, et al: Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med 10:85, 2018
   Pascual J, Attard G, Bidard FC, et al: ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33:750-768, 2022
   Mosele MF, Westphalen CB, Stenzinger A, et al: Recommendations for the use of next-generation sequencing, NGS, for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 35:588-606, 2024
   Krebs MG, Malapelle U, Andre F, et al: Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol 8:1830-1839, 2022
   Fairchild L, Whalen J, D’Aco K, et al: Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Sci Transl Med 15:eabm8729, 2023
   Huang F, Yang Y, Chen X, et al: Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/ NRAS/BRAF genotyping for metastatic colorectal cancer. Clin Biochem 92:46- 53, 2021
   Siravegna G, Mussolin B, Buscarino M, et al: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795-801, 2015
   Hayman TJ: Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity. JNCI Cancer Spectrum 8:pkae045, 2024
   Service RF: Rescuing the guardian of the genome. Science 354:26-28, 2016
   Munir T, Brown JR, O’Brien S, et al: Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94:1353-1363, 2019
   Mandelker D, Donoghue M, Talukdar S, et al: Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol 30:1221-1231, 2019
   Coffee B, Cox HC, Kidd J, et al: Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genet 211:5-8, 2017
   Slavin TP, Coffee B, Bernhisel R, et al: Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genet 235-236:31-38, 2019
   Bernard E, Tuechler H, Greenberg PL, et al: Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 1: EVIDoa2200008, 2022
   Butz H, Bozsik A, Grolmusz V, et al: Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre. Sci Rep 13:14259, 2023
   Renaux-Petel M, Charbonnier F, Thery JC, et al: Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet 55:173- 180, 2018
   Weitzel JN, Chao EC, Nehoray B, et al: Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816, 2018
   Brunet T, Berutti R, Dill V, et al: Clonal hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders. Hum Mol Genet 31:2386-2395, 2022
   Singh J, Li N, Ashrafi E, et al: Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis. Blood Adv 8:3771-3784, 2024
   Yun JK, Kim S, An H, et al: Pre-operative clonal hematopoiesis is related to adverse outcome in lung cancer after adjuvant therapy. Genome Med 15:111, 2023
   Gillis NK, Ball M, Zhang Q, et al: Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol 18:112-121, 2017
   Weeks LD, Niroula A, Neuberg D, et al: Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid 2: 10.1056/evidoa2200310, 2023
   Arends CM, Kopp K, Hablesreiter R, et al: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer. Leukemia 38:1378-1389, 2024
   Shah MV, Mangaonkar AA, Begna KH, et al: Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J 12:106, 2022
   Zekavat SM, Viana-Huete V, Matesanz N, et al: TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nat Cardiovasc Res 2:144-158, 2023
   Mammadova J, Colin-Leitzinger C, Nguyen D, et al: Clonal hematopoiesis as a molecular risk factor for doxorubicin-induced cardiotoxicity: a proofof- concept study. JCO Precis Oncol 7:e2300208, 2023
   Sano S, Wang Y, Ogawa H, et al: TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight 6:e146076, 2021
   Mangaonkar AA, Patnaik MM: Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. Am J Hematol 98:951-964, 2023
   Bottomly D, Long N, Schultz AR, et al: Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40:850- 864.e9, 2022
   Knisbacher BA, Lin Z, Hahn CK, et al: Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet 54:1664-1674, 2022
   Miller DT, Lee K, Abul-Husn NS, et al: ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics, ACMG). Genet Med 25:100866, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 351
EP 351
PG 12
ER

PT J
AU Laszlo, T
   Kenez, LA
   Szepesi, G
   Matuz, M
   Barna, G
   Bodor, Cs
AF Laszlo, Tamas
   Kenez, Lili Anna
   Szepesi, Gabriella
   Matuz, Marcell
   Barna, Gabor
   Bodor, Csaba
TI The clinical potential of measurable residual disease in hematological malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE MRD; liquid biopsy; next generation sequencing
ID MRD; liquid biopsy; next generation sequencing
AB In recent years, there have been remarkable improvements in the treatment of hematological malignancies with the introduction of novel therapeutic modalities. The advent of these therapies has made it feasible to significantly and permanently decrease (possibly eradicate) tumor cells in the body. Evaluating the effectiveness of these treatments required the development of a new diagnostic method. Currently, the most appropriate approach for assessing the objective response is through the measurement of „measurable residual disease” (MRD). MRD refers to the presence of malignant cells in a patient’s body after receiving treatment, even in the absence of apparent signs or symptoms. Several techniques can be employed to detect MRD, including multiparametric flow cytometry, RQ-PCR as well as more recent approaches including digital PCR or next generation sequencing. This review offers an in-depth overview of the different techniques used to estimate measurable residual disease and their current applications in hematological malignancies.
C1 [Laszlo, Tamas] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Kenez, Lili Anna] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Szepesi, Gabriella] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Matuz, Marcell] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
   [Barna, Gabor] Semmelweis Egyetem, Patologiai es Kiserleti Rakkutato Intezet, Aramlasi Citometriai LaboratoriumBudapest, Hungary.
   [Bodor, Csaba] Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Ulloi ut 26., 1085 Budapest, Hungary.
RP Laszlo, T (reprint author), Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, 1085 Budapest, Hungary.
EM laszlo.tamas@stud.semmelweis.hu
CR Kiraly AP, Alpar D, Fesus V, et al: Az onkokematologia molekularis diagnosztikai vizsgalomodszereinek alapjai. Magy Onkol 60:88-98, 2016
   Chen X, Wood BL: Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev 31:63-75, 2017
   Kriegsmann K, Manta C, Schwab R, et al: Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM. Blood Adv 7:379-383, 2023
   Saygin C, Cannova J, Stock W, et al: Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica 107:2783-2793, 2022
   Pierce E, Mautner B, Mort J, et al: MRD in ALL: optimization and innovations. Curr Hematol Malig Rep 17:69-81, 2022
   Falini B, Dillon R: Criteria for diagnosis and molecular monitoring of NPM1-mutated AML. Blood Cancer Discov 5:8-20, 2024
   Urushihara R, Takezako N, Yoroidaka T, et al: Eight-color multiparameter flow cytometry, EuroFlow-NGF, is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. EJHaem 4:184-191, 2023
   van Dongen JJ, Lhermitte L, Bottcher S, et al: EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908-1975, 2012
   Wood BL, Arroz M, Barnett D, et al: 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 72B:S14-S22, 2007
   Rawstron AC, Bottcher S, Letestu R, et al: Improving efficiency and sensitivity: European Research Initiative in CLL, ERIC, update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27:142-149, 2013
   Soverini S, De Benedittis C, Mancini M, et al: Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21:626-633, 2016
   van der Velden VHJ, Dombrink I, Alten J, et al: Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia 38:1315-1322, 2024
   Alikian M, Gale RP, Apperley JF, et al: Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif 11:4-20, 2017
   Kiss R, Jenei A, Demeter J, Bodor Cs: Molekularis genetikai vizsgalatok jelentosege kronikus myeloid leukaemiaban. Orvoskepzes 3:535-550, 2021
   Nunes V, Cazzaniga G, Biondi A: An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn 17:953- 963, 2017
   Svaton M, Skotnicova A, Reznickova L, et al: NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 141:529-533, 2023
   Quan PL, Sauzade M, Brouzes E: dPCR: a technology review. Sensors, Basel, 18:1271, 2018
   Galimberti S, Balducci S, Guerrini F, et al: Digital droplet PCR in hematologic malignancies: a new useful molecular tool. Diagnostics 12:1305, 2022
   Della Starza I, Nunes V, Cavalli M, et al: Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. Br J Haematol 174:541-549, 2016
   Drandi D, Kubiczkova-Besse L, Ferrero S, et al: Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn 17:652-660, 2015
   Monter A, Nomdedeu JF: ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diagn 19:571-578, 2019
   Ching T, Duncan ME, Newman-Eerkes T, et al: Analytical evaluation of the clonoSEQ assay for establishing measurable, minimal, residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 20:612, 2020
   Newman AM, Bratman SV, To J, et al: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548-554, 2014
   Kurtz DM, Soo J, Co Ting Keh L, et al: Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39:1537-1547, 2021
   Cortes J, Rea D, Lipton JH: Treatment-free remission with first- and second- generation tyrosine kinase inhibitors. Am J Hematol 94:346-357, 2019
   Batar P: Kronikus myeloid leukemia: Mult, jelen, jovo. Hematol Transzfuziol 56:17-23, 2023
   Hochhaus A, Saussele S, Rosti G, et al: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv41- iv51, 2017
   Hochhaus A, Baccarani M, Silver RT, et al: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966-984, 2020
   Shah NP, Bhatia R, Altman JK, et al: Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22:43-69, 2024
   Kiss R, Kiraly AP, Gaal-Weisinger J, et al: A kronikus mieloid leukemia molekularis monitorozasanak aktualis kerdesei. Magy Onkol 61:57-66, 2017
   Rollig C, Bornhauser M, Thiede C, et al: Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 29:2758-2765, 2011
   Tiong IS, Loo S: Targeting measurable residual disease, MRD, in acute myeloid leukemia, AML): moving beyond prognostication. Int J Mol Sci 24:4790, 2023
   Buckley SA, Wood BL, Othus M, et al: Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102:865-873, 2017
   Short NJ, Fu C, Berry DA, et al: Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia 36:2817-2826, 2022
   Kayser S, Levis MJ: Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol 196:316-328, 2022
   Schuurhuis GJ, Heuser M, Freeman S, et al: Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275-1291, 2018
   Heuser M, Freeman SD, Ossenkoppele GJ, et al: 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753-2767, 2021
   Dohner H, Wei AH, Appelbaum FR, et al: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345-1377, 2022
   Kovy P, Orfi Z, Bors A, et al: Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS One 16:e0253386, 2021
   Pui CH, Evans WE: A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50:185-196, 2013
   Alpar D, Egyed B, Krizsan Sz, et al: A gyermekkori akut leukaemiak korszeru molekularis diagnosztikaja es kezelese. Orvoskepzes 3:507-522, 2021
   Stock W, Luger SM, Advani AS, et al: A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood 133:1548-1559, 2019
   Wieduwilt MJ, Stock W, Advani A, et al: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia 35:2076-2085, 2021
   Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111:5477-5485, 2008
   Vora A, Goulden N, Wade R, et al: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease, UKALL 2003): a randomised controlled trial. Lancet Oncol 14:199-209, 2013
   Bartram J, Wade R, Vora A, et al: Excellent outcome of minimal residual disease- defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003. Arch Dis Child 101:449-454, 2016
   Bassan R, Bruggemann M, Radcliffe HS, et al: A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 104:2028-2039, 2019
   van Dongen JJM, van der Velden VHJ, Bruggemann M, et al: Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125:3996-4009, 2015
   Zhang J, Oak J: Challenges of detecting measurable/minimal disease in acute leukemia. Semin Diagn Pathol 40:216-220, 2023
   Wood B, Wu D, Crossley B, et al: Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 131:1350-1359, 2018
   Short NJ, Kantarjian H, Ravandi F, et al: High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6:4006-4014, 2022
   Flohr T, Schrauder A, Cazzaniga G, et al: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771-782, 2008
   Fronkova E, Mejstrikova E, Avigad S, et al: Minimal residual disease, MRD, analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 22:989-997, 2008
   Pieters R, de Groot-Kruseman H, Van der Velden V, et al: Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 34:2591-2601, 2016
   Kenez LA: Beszamolo a EuroMRD halozat eves konferenciajarol. Hematol Transzfuziol 56:199-200, 2023
   Kwok M, Rawstron AC, Varghese A, et al: Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood 128:2770-2773, 2016
   Thompson PA, Srivastava J, Peterson C, et al: Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134:1951-1959, 2019
   Al-Sawaf O, Robrecht S, Zhang C, et al: S145: Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized Cll14 study. HemaSphere 7:e064430a, 2023
   Kater A, Harrup R, Kipps TJ, et al: S201: Final 7-year follow up and retreatment substudy analysis of Murano: venetoclax-rituximab, Venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia, R/R CLL). HemaSphere 7:e492813f, 2023
   Furstenau M, De Silva N, Eichhorst B, et al: Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere 3:e287, 2019
   Seymour JF, Kipps TJ, Eichhorst BF, et al: Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140:839-850, 2022
   Al-Sawaf O, Zhang C, Tandon M, et al: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia, CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21:1188-1200, 2020
   Al-Sawaf O, Zhang C, Lu T, et al: Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 39:4049-4060, 2021
   Rawstron AC, Fazi C, Agathangelidis A, et al: A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 30:929-936, 2016
   Rawstron AC, Kreuzer KA, Soosapilla A, et al: Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL, ERIC, & European Society for Clinical Cell Analysis, ESCCA, harmonisation project. Cytometry B Clin Cytom 94:121-128, 2018
   Rawstron AC, Villamor N, Ritgen M, et al: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956-964, 2007
   Takacs F, Kardos I, Czeti A, et al: A minimalis rezidualis betegseg vizsgalata kronikus limfoid leukemiaban. Hematol Transzfuziol 53:17-22, 2020
   Niemann CU, Munir T, Moreno C, et al: Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax, Ibr+Ven, versus chlorambucil plus obinutuzumab, Clb+O): The Glow study. Blood 140:228-230, 2022
   Laszlo T, Csacsovszky O, Bodor Cs: Uj megkozelitesek a B-sejtes lymphomak kezeleseben. Klin Onkol 11:139-148, 2024
   Bratman SV, Newman AM, Alizadeh AA, et al: Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn 15:715-719, 2015
   Nagy A, Batai B, Kiss L, et al: Folyadekbiopszia-vizsgalatok alkalmazasi lehetosegei az onkohematologiaban. Hematol Transzfuziol 53:144-156, 2020
   Diehl F, Schmidt K, Choti MA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990, 2008
   Scherer F, Kurtz DM, Newman AM, et al: Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364ra155, 2016
   Nagy A, Batai B, Hogan G, et al: Phased variants allow robust profiling of circulating tumor DNA in untreated follicular lymphomas. Blood 142:1626, 2023
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 364
EP 364
PG 10
ER

PT J
AU Nemeth, Zs
   Rubovszky, G
AF Nemeth, Zsuzsanna
   Rubovszky, Gabor
TI Advances in immunotherapy of colorectal cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE colon neoplasms; rectal neoplasms; immunotherapy; pembrolizumab; nivolumab
ID colon neoplasms; rectal neoplasms; immunotherapy; pembrolizumab; nivolumab
AB Treatment of locally advanced rectal cancer involves neoadjuvant chemoradiotherapy (CRT), including induction or consolidation chemotherapy. Introduction of immunotherapy has brought success in several solid tumors and hematological diseases. In colorectal tumors, it was only introduced later. A general predictive biomarker is the deficient mismach repair (dMMR) status and consequent microsatellite instability (MSI-H). In these tumors, immune checkpoint inhibitor (ICI) therapy is the first-choice therapy in metastatic colorectal cancer. ICIs have been used in earlier, non-metastatic stages in several studies, with breakthrough results in the microsatellite-unstable patient group and recently in combination with neoadjuvant CRT in rectal tumor patients with pMMR/MSI-L status. In our report we focused on the recent immune checkpoint inhibitor treatment of metastatic and locally advanced colorectal cancer, as a monotherapy, or combined with chemo- or radiotherapy. We summarize the studies with the most promising results.
C1 [Nemeth, Zsuzsanna] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Rubovszky, Gabor] Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Nemeth, Zs (reprint author), Orszagos Onkologiai Intezet, Mellkasi es Hasuregi Daganatok es Klinikai Farmakologiai Osztaly, 1122 Budapest, Hungary.
EM zsnemethzsuzsanna@gmail.com
CR Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249, 2021
   Qwaider YZ, Goldstone RN, Cauley CE, et al. Ten-year survival after pathologic complete response in rectal adenocarcinoma. J Surg Oncol 123:293– 298, 2021
   National Comprehensive Cancer Network. Rectal Cancer, version 1.2024). www.nccn.org/Rectal Cacner V.1.2024. https://www.nccn.org/guidelines/ guidelines-dhetail?category=1&id=1461
   Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 19:2212–2223, 2012
   National Comprehensive Cancer Network, NCCN). NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/ pdf/gist.pdf
   Temmink SJD, Martling A, Angenete E, et al. Complete response rates in rectal cancer: Temporal changes over a decade in a population-based nationwide cohort. Eur J Surg Oncol 49:106991, 2023
   van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database, IWWD): an international multicentre registry study. Lancet 2537–2545, 2018
   Giunta EF, Bregni G, Pretta A, et al. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev 96:102177, 2021
   Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision, TME, versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer, RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29–42, 2021
   Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow- up of the RAPIDO trial. Ann Surg 278:e766–e772, 2023
   Rejali L, Seifollahi Asl R, Sanjabi F, et al. Principles of molecular utility for CMS classification in colorectal cancer management. Cancers, Basel, 15:2746, 2023
   Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291–1305, 2020
   Papke DJ Jr, Yurgelun MB, Noffsinger AE, et al. Prevalence of mismatch- repair deficiency in rectal adenocarcinomas. N Engl J Med 387:1714– 1716, 2022
   Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer, CRC, with high-level microsatellite instability, MSI-H). Ann Oncol 25:1032–1038, 2014
   Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability- high advanced colorectal cancer. N Engl J Med 383:2207–2218, 2020
   Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23:659–670, 2022
   Somarouthu B, Lee SI, Urban T, et al. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol 91:20170457, 2018
   Lenz HJ, Van Custem E, Limon ML, et al. First-line nivolumab plus lowdose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 40:161–170, 2022
   Andre T, Elez E, Van Cutsem E, et al. Nivolumab, NIVO, plus ipilimumab, IPI, vs chemotherapy, chemo, as first-line, 1L, treatment for microsatellite instability-high/mismatch repair-deficient, MSI-H/dMMR, metastatic colorectal cancer, mCRC): First results of the CheckMate 8HW study. J Clin Oncol 42(suppl):LBA768, 2024
   Lenz HJ, Parikh A, Spiegel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer 12:e008409, 2024
   Lenz HJ, Parikh A, R Spigel D, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer, AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 23: 876–887, 2022
   Tabernero J, Grothey A, Arnold D, et al. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. ESMO Open 7:100559, 2022
   Cohen R, Raeisi M, Chibaudel B, et al. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer 199:113537, 2024
   Pan QZ, Zhao JJ, Liu L, et al. XELOX, capecitabine plus oxaliplatin, plus bevacizumab, anti-VEGF-A antibody, with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal Transduct Target Ther 9:79, 2024
   Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer, CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–91, 2017
   Veen T, Kanani A, Lea D, Soreide K. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer. Cancer Immunol Immunother 72:3135–3147, 2023
   Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early- stage colon cancers. Nat Med 26:566–576, 2020
   Verschoor YL, van den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. J Clin Oncol 40(16 suppl): abstr. 3511, 2022
   Chalabi M, Verschoor Y, van den Berg J, et al. Neoadjuvant immune checkpoint inhibition in locally advanced in MMR-deficient colon cancer: The Niche-2 study. Ann Oncol 33(suppl.7):S1389, 2022
   Verschoor Y, van den Berg J, Balduzzi S, et al. Neoadjuvant nivolumab plus relatlimab, anti-LAG3, in locally advanced MMR-deficient colon cancers: The NICHE-3 study. Ann Oncol 34(suppl 2): S1270, 2023
   Avallone A, De Stefano A, Tatangelo U, et al. Neoadjuvant nivolumab in early stage colorectal cancer. Ann Oncol 31(suppl 4):S449, 2020
   Yuki S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 38(15_suppl): 4100, 2020
   Salvatore L, Bensi M, Corallo S, et al. Phase II study of preoperative, PREOP, chemoradiotherapy, CTRT, plus avelumab, AVE, in patients, PTS, with locally advanced rectal cancer, LARC): The AVANA study. J Clin Oncol 39(15_suppl): A3511, 2021
   Yaqi W, Lijun S, Juefeng W, et al. Short-course radiotherapy combined with CAPOX and toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial, TORCH). BMC Cancer 22:274, 2022
   George TJ, Yothers G, Rahma OE, et al. Long-term results from NRGGI002: A phase II clinical trial platform using total neoadjuvant therapy, TNT, in locally advanced rectal cancer, LARC). J Clin Oncol 41(4_suppl):A7, 2023
   Zhang T, Tao K, Lin Z, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial, UNION). Ann Oncol 34(suppl 2): S1266–S1267, 2023
   Cerek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair- deficient, locally advanced rectal cancer. N Engl J Med 386:2363–2376, 2022
   Keane C, Fearnhead NS, Bordeianou LG, et al. International consensus definition of low anterior resection syndrome. Dis Colon Rectum 63:274–284, 2020
   McKenna NP, Bews KA, Yost KJ, et al. Bowel dysfunction after low anterior resection for colorectal cancer: a frequent late effect of surgery infrequently treated. J Am Coll Surg 234:529–537, 2022
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 375
EP 375
PG 6
ER

PT J
TI Summaries of the 2024 conference of the Young Oncologists Section of the Hungarian Society of Oncologists
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Congress
NR 4
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD DEC
PY 2024
VL 68
IS 4
BP 387
EP 387
PG 11
ER

PT J
AU Patocs, A
AF Patocs, Attila
TI Foreword
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Editorial
C1 [Patocs, Attila] National Institute of Oncology, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Patocs, A (reprint author), National Institute of Oncology, 1122 Budapest, Hungary.
EM patocs.attila@oncol.hu
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 5
EP 5
PG 1
ER

PT J
AU Patocs, A
   Toth, E
   Butz, H
   Grolmusz, VK
   Bathory-Fulop, L
   Kovacs, G�
   Heczei, J
   Polgar, Cs
AF Patocs, Attila
   Toth, Erika
   Butz, Henriett
   Grolmusz, Vince Kornel
   Bathory-Fulop, Laszlo
   Kovacs, Gabor Adam
   Heczei, Janos
   Polgar, Csaba
TI The status of precision medicine in Hungary in the light of European practice
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE genomic data; precision oncology
ID genomic data; precision oncology
AB Background and aim: Molecular genetic diagnostics is a complex process, most modern laboratory technologies, IT procedures, data management, medical decision support systems, databases and algorithms are used together. Oncological treatments are expensive procedures and the effectiveness of individual therapies varies in different subtypes of cancer. Nowadays, agnostic approach is increasingly emerging in oncological treatments, i.e. the unique characteristics of the tumors determines the therapeutic direction for each patient. With the development of diagnostic technologies, more and more data are being collected about the biology and genetic characteristics of tumors. Our current work summarizes the milestones of precision oncology and presents those European projects which focus on elimination of inequalities between countries.  Results: Milestones of domestic precision medicine oncology program have been closely linked to European initiatives.  Conclusion: The developed and introduced procedures in Hungary are unique among European countries and resulted in a significant improvement of patient care.
C1 [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Toth, Erika] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Butz, Henriett] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Grolmusz, Vince Kornel] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Bathory-Fulop, Laszlo] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Kovacs, Gabor Adam] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Heczei, Janos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai LaboratoriumBudapest, Hungary.
   [Polgar, Csaba] National Institute of Oncology, Center of RadiotherapyBudapest, Hungary.
RP Patocs, A (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM patocs.attila@oncol.hu
CR Butz H, Patocs A: Brief summary of the most important molecular genetic methods, PCR, qPCR, microarray, next-generation sequencing, etc.). Exp Suppl 111:33-52, 2019
   Edsjo A, Gisselsson D, Staaf J, et al: Current and emerging sequencing- based tools for precision cancer medicine. Mol Aspects Med 96:101250, 2024
   Toth E, Kuronya Z, Soos E, et al: Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Acta Oncol 16:433-440, 2024
   Edsjo A, Russnes HG, Lehtio J, et al: High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond. J Intern Med 295:785-803, 2024
   Van Der Velden DL, Hoes LR, Van Der Wijngaart H, et al: The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574:127-131, 2019
   https://b1mg-project.eu/
   https://gdi.onemilliongenomes.eu
   Riba M, Sala C, Culhane AC, et al: The 1+Million Genomes minimal dataset for cancer. Nat Genet 56:733-736, 2024
   Patocs A, Nagy P, Papp J, et al: Cost-effectiveness of genetic testing of endocrine tumor patients using a comprehensive hereditary cancer gene panel. J Clin Endocrinol Metab 109:3220-3233, 2024
   Palla S, Toke J, Bozsik A, et al: Whole genome sequencing resolves 10 years diagnostic odyssey in familiar myxoma. Sci Rep 13:14658, 2023
   Bozsik A, Butz H, Grolmusz VK, et al: Genome sequencing-based discovery of a novel deep intronic APC pathogenic variant causing exonization. Eur J Hum Genet 31:841-845, 2023
   Horti-Oravecz K, Bozsik A, Pocza T, et al: Whole genome sequencing completes the molecular genetic testing workflow of patients with Lynch syndrome. NPJ Genom Med 10:5, 2025
   https://digital-strategy.ec.europa.eu/en/news/genome-europe-project- launched-first-step-towards-european-reference-genome
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 7
EP 12
PG 6
ER

PT J
AU Toth, E
   Csernak, E
   Kohanka, A
   Bathory-Fulop, L
   Butz, H
   Patocs, A
   Pinter, T
   Horvath, Zs
   Kuronya, Zs
   Strausz, T
   Adamik, I
   Melegh, Zs
AF Toth, Erika
   Csernak, Erzsebet
   Kohanka, Andrea
   Bathory-Fulop, Laszlo
   Butz, Henriett
   Patocs, Attila
   Pinter, Tamas
   Horvath, Zsolt
   Kuronya, Zsofia
   Strausz, Tamas
   Adamik, Imola
   Melegh, Zsombor
TI First results of comprehensive genomic studies on solid tumours in National Institute of Oncology
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE comprehensive genomic profiling; solid tumours; therapeutic targets
ID comprehensive genomic profiling; solid tumours; therapeutic targets
AB Aims: The Molecular Pathology Laboratory of the National Institute of Oncology has been performing comprehensive genomic studies (500-gene panel) since 2021. This paper summarizes our results obtained between 2022 and 2024, focusing on clinical requests, the histological type of cases studied and the potential therapeutic benefit of identified variants.  Methods: Comprehensive genomic profiling was performed using next generation sequencing on an Ion S5 Plus system (Thermo Fisher Scientific) with Oncomine Comprehensive Assay Plus kit. DNA and RNA were extracted from formalin- fixed, paraffin-embedded samples.  Results: 402 analyses were performed. We identified mutations with therapeutic significance in 37.3% (150/402) of cases, including 26.4% (106/402) of cases with on label therapies. The most frequently investigated cases were soft tissue sarcomas and gynaecological tumours.  Conclusions: Genetic alterations with therapeutic relevance primarily include high TMB and high GIS. Previously unknown mutations suitable for targeted therapy were rarely identified, as almost all cases had previously undergone small targeted panel testing.
C1 [Toth, Erika] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Csernak, Erzsebet] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Kohanka, Andrea] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Bathory-Fulop, Laszlo] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Butz, Henriett] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Patocs, Attila] National Institute of Oncology, Center of Surgical and Molecular Tumor PathologyBudapest, Hungary.
   [Pinter, Tamas] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Horvath, Zsolt] Orszagos Onkologiai Intezet, „B” Belgyogyaszati-Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Kuronya, Zsofia] Orszagos Onkologiai Intezet, Kemoterapia „C” Belgyogyaszati- Onkologiai es Klinikai Farmakologiai OsztalyBudapest, Hungary.
   [Strausz, Tamas] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Adamik, Imola] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
   [Melegh, Zsombor] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. utca 7–9., 1122 Budapest, Hungary.
RP Toth, E (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM dr.toth.erika@oncol.hu
CR Zhao XF: The role of pathologist in precision medicine. Hematopath 5:1-5, 2020
   Vranic S, Gatalica Z: The role of pathology in the era of personalized, precision, medicine: a brief review. Acta Medica Acad 50:47, 2021
   Tjota MY, Segal JP, Wang P: Clinical utility and benefits of comprehensive genomic profiling in cancer. J Appl Lab Med 9:76-91, 2024
   Mosele MF, Westphalen CB, Stenzinger A, et al: Recommendations for the use of next-generation sequencing, NGS, for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 35:588-606, 2024
   Westphalen CB, Martins-Branco D, Beal JR, et al: The ESMO Tumour-Agnostic Classifier and Screener, ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ann Oncol 35:936-953, 2024
   Yorio J, Lofgren KT, Lee JK, et al: Association of timely comprehensive genomic profiling with precision oncology treatment use and patient outcomes in advanced non–small-cell lung cancer. JCO Precis Oncol e2300292, 2024
   Matsubara J, Mukai K, Kondo T, et al: First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open 6:e2323336, 2023
   Teuwen L-A, Roets E, D’Hoore P, et al: Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital. Diagnostics 13:1619, 2023
   Hung LJ, Huang CY, Tung KC, et al: Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohorts. J Formos Med Assoc S0929664624004054, 2024
   Toth E, Kuronya Z, Soos E, et al: Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Acta Oncol 63:433-440, 2024
   Vikas P, Messersmith H, Compton C, et al: Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol 41:1943-1948, 2023
   Aggarwal C, Ben-Shachar R, Gao Y, et al: Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw Open 6:e2311181, 2023
   Strickler JH, Hanks BA, Khasraw M: Tumor mutational burden as a predictor of immunotherapy response: Is more always better? Clin Cancer Res 27:1236-1241, 2021
   Miller RE, Leary A, Scott CL, et al: ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 31:1606-1622, 2020
   Tew WP, Lacchetti C, Ellis A, et al: PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38:3468-3493, 2020
   Eid M, Trizuljak J, Taslerova R, et al: Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single- centre, molecular tumour board experience. Mutagenesis geae014, 2024
   Van De Haar J, Roepman P, Andre F, et al: ESMO recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol 35:954-967, 2024
   Mathew A, Joseph S, Boby J, et al: Clinical benefit of comprehensive genomic profiling for advanced cancers in India. JCO Glob Oncol 8:e2100421, 2022
   Limaye S, Deshmukh J, Rohatagi N, et al: Usefulness of comprehensive genomic profiling in clinical decision-making in oncology: a systematic review. J Immunother Precis Oncol 8:55-63, 2025
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 15
EP 22
PG 8
ER

PT J
AU Horti-Oravecz, K
   Kelemen, I
   Grolmusz, VK
AF Horti-Oravecz, Klaudia
   Kelemen, Istvan
   Grolmusz, Vince Kornel
TI The role of immunosurveillance and immunoediting in hereditary cancer predisposition syndromes
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE immunosurveillance; immunoediting; immunophenotyping; Lynch syndrome; hereditary breast and ovarian cancer syndrome
ID immunosurveillance; immunoediting; immunophenotyping; Lynch syndrome; hereditary breast and ovarian cancer syndrome
AB Immunosurveillance is the ability of the immune system to detect preneoplastic lesions as well as primary tumors. Immunoediting, on the other hand, includes all tumor-immune interactions and can be subdivided into three steps according to the outcome. During elimination, which can correspond to immunosurveillance, the immune system is able to eradicate immunogenic preneoplastic lesions or tumors. During the second step, the so-called equilibrium, tumors start to leverage mechanisms for immune evasion, however their growth is still controlled by the immune system. The ability of cancers to master their immune evasion efforts leads to the third step, called escape, when tumors are no longer successfully controlled by anti-tumor immunity. Hereditary cancer predisposition syndromes elevate cancer risk in a gene- and organ-specific manner. Lately, new results were uncovered regarding carcinogenic steps and pre-cancer immunity in the case of Lynch syndrome and hereditary breast and ovarian cancer syndrome, the two most frequently diagnosed cancer perdisposition syndromes. Our current review aims to summarize these novel results.
C1 [Horti-Oravecz, Klaudia] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Kelemen, Istvan] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
   [Grolmusz, Vince Kornel] National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, Rath Gy. u. 7–9., 1122 Budapest, Hungary.
RP Grolmusz, VK (reprint author), National Institute of Oncology, Center of Surgical and Molecular Tumor Pathology, 1122 Budapest, Hungary.
EM grolmusz.vince@oncol.hu
CR Horti-Oravecz K, Grolmusz KV: Az immunonkologiai kezelesek bovulo lehetosegei. Magy Onkol 67:107-114, 2023
   Ehrlich P: Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273, 1909
   Burnet M: Cancer; a biological approach. I. The processes of control. Br Med J 1:779-786, 1957
   Thomas L: On immunosurveillance in human cancer. Yale J Biol Med 55:329-333, 1982
   Yang YL, Yang F, Huang ZQ, et al: T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. Front Immunol 14:1199173, 2023
   Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109, 2002
   Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002
   Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1-14, 2007
   Aoki H, Tsunoda M, Ogiwara H, et al: Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses. Cancer Immunol Res 11:847-862, 2023
   Kitsou M, Ayiomamitis GD, Zaravinos A: High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. Int J Oncol 57:237-248, 2020
   Guo Z, Zhang R, Yang AG, et al: Diversity of immune checkpoints in cancer immunotherapy. Front Immunol 14:1121285, 2023
   Ariyan CE, Brady MS, Siegelbaum RH, et al: Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6:189-200, 2018
   Zhou J, Mahoney KM, Giobbie-Hurder A, et al: Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res 5:480-492, 2017
   Willsmore ZN, Coumbe BGT, Crescioli S, et al: Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol 51:544-556, 2021
   Jiang T, Shi T, Zhang H, et al: Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol 12:93, 2019
   Jurtz V, Paul S, Andreatta M, et al: NetMHCpan-4.0: improved peptide- MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol 199:3360-3368, 2017
   Wang C, Wang Z, Yao T, et al: The immune-related role of beta-2-microglobulin in melanoma. Front Oncol 12:944722, 2022
   Liu F, Zhong F, Wu H, et al: Prevalence and associations of beta2-microglobulin mutations in MSI-H/dMMR cancers. Oncologist 28:e136-144, 2023
   Germano G, Lu S, Rospo G, et al: CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors. Cancer Discov 11:1844-1859, 2021
   de Vries NL, van de Haar J, Veninga V, et al: γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613:743-750, 2023
   Perea F, Sanchez-Palencia A, Gomez-Morales M, et al: HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 9:4120-4133, 2018
   Kawase K, Taguchi A, Ishizaka A, et al: Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia. HLA 103:e15509, 2024
   Crisafulli G, Sartore-Bianchi A, Lazzari L, et al: Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov 12:1656-1675, 2022
   Germano G, Lamba S, Rospo G, et al: Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552:116-120, 2017
   Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148, 2004
   Abu-Ghazaleh N, Kaushik V, Gorelik A, et al: Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: Systematic review and meta-analysis. Genet Med 24:971-985, 2022
   Dedeurwaerdere F, Claes KB, Van Dorpe J, et al: Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep 11:12880, 2021
   Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823, 1971
   Luzi E, Marini F, Giusti F, et al: The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the “Knudson’s second hit”. PLoS One 7:e39767, 2012
   Ahadova A, Gallon R, Gebert J, et al: Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer 143:139-150, 2018
   Shia J, Stadler ZK, Weiser MR, et al: Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. Fam Cancer 14:61-68, 2015
   Kloor M, Huth C, Voigt AY, et al: Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol 13:598-606, 2012
   De Jong AE, Morreau H, Van Puijenbroek M, et al: The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 126:42-48, 2004
   Wong S, Hui P, Buza N: Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. Mod Pathol 33:1172-1181, 2020
   Hegazy S, Brand RE, Dudley B, et al: DNA mismatch repair-deficient non-neoplastic endometrial glands are common in Lynch syndrome patients and are present at a higher density than in the colon. Histopathology 79:573- 583, 2021
   Bohaumilitzky L, Kluck K, Huneburg R, et al: The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients. Gastroenterology 162:907-919, 2022
   Roudko V, Bozkus CC, Orfanelli T, et al: Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183:1634- 1649, 2020
   Bolivar AM, Duzagac F, Deng N, et al: Genomic landscape of Lynch syndrome colorectal neoplasia identifies shared mutated neoantigens for immunoprevention. Gastroenterology 166:787-801, 2024
   Ballhausen A, Przybilla MJ, Jendrusch M, et al: The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nat Commun 11:4740, 2020
   Schwitalle Y, Kloor M, Eiermann S, et al: Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988-997, 2008
   Roudko V, Cimen Bozkus C, Greenbaum B, et al: Lynch syndrome and MSI-H cancers: from mechanisms to “off-the-shelf” cancer vaccines. Front Immunol 12:757804, 2021
   Westdorp H, Gorris MAJ, Boudewijns S, et al: Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. Ann Oncol 27:vi362, 2016
   Michael JO, Joan M, Paul E, et al: Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer. JCO 41(16_suppl):e14665, 2023
   Ahadova A, Witt J, Haupt S, et al: Is HLA type a possible cancer risk modifier in Lynch syndrome? Int J Cancer 152:2024-2031, 2023
   Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987-3991, 2006
   Petrucelli N, Daly MB, Pal T: BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: GeneReviews®, ed. Pagon RA, Adam MP, Ardinger HH, et al. University of Washington, Seattle, 1993
   Godet I, Gilkes DM: BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Therap 4:10.15761/ICST.1000228, 2017
   Yoshida R. Hereditary breast and ovarian cancer, HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 28:1167-1180, 2021
   Schmid P, Cortes J, Pusztai L, et al: Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810-821, 2020
   Lim E, Vaillant F, Wu D, et al: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913, 2009
   Nee K, Ma D, Nguyen QH, et al: Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis. Nat Genet 55:595-606, 2023
   Goff SL, Danforth DN: The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer. Clin Breast Cancer 21:e63-e73, 2021
   Ogony J, Hoskin TL, Stallings-Mann M, et al: Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers. Breast Cancer Res Treat 197:277-285, 2023
   Balog JA, Horti-Oravecz K, Kovesdi D, et al: Peripheral immunophenotyping reveals lymphocyte stimulation in healthy women living with hereditary breast and ovarian cancer syndrome. iScience 27:109882, 2024
   Ruangapirom L, Sutivijit N, Teerapakpinyo C, et al: Identification of shared neoantigens in BRCA1-related breast cancer. Vaccines, Basel, 10:1597, 2022
   Samstein RM, Krishna C, Ma X, et al: Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer 1:1188-1203, 2021
   Church JM: Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition. Dis Colon Rectum 57:396-397, 2014
   Ma X, Riaz N, Samstein RM, Lee M, et al: Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet 54:996-1012, 2022
   Villy M-C, Masliah-Planchon J, Schnitzler A, et al: MSH3: a confirmed predisposing gene for adenomatous polyposis. J Med Genet 60:1198-1205, 2023
   Wimmer K, Kratz CP, Vasen HFA, et al: Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD”, C4CMMRD). J Med Genet 51:355-365, 2014
   Das A, Sudhaman S, Morgenstern D, et al: Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med 28:125-135, 2022
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 25
EP 33
PG 9
ER

PT J
AU Nagy, P
   Papp, J
   Grolmusz, VK
   Bozsik, A
   Pocza, T
   Patocs, A
   Butz, H
AF Nagy, Petra
   Papp, Janos
   Grolmusz, Vince Kornel
   Bozsik, Aniko
   Pocza, Timea
   Patocs, Attila
   Butz, Henriett
TI Pathogenic role of CHEK2 variants in Hungarian cancer patients: implications for breast cancer risk and genetic counselling
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE breast cancer; CHEK2; cancer risk; hereditary tumour syndrome
ID breast cancer; CHEK2; cancer risk; hereditary tumour syndrome
AB Aim: Our study assessed the prevalence of CHEK2 gene variants, including low-penetrance variants (lp-CHEK2: p.I157T, p.S428F, p.T476M) and their association with clinicopathological parameters in cancer patients and controls.  Methods: Germline genetic analysis of 1,280 breast and ovarian cancer (BOC), 191 young breast (<33 years, yBr), 568 nonbreast (non-BOC) and 96 endocrine cancer patients was performed using the Illumina TruSight Hereditary Cancer Panel.  Results: CHEK2 disease-causing (pathogenic/likely pathogenic) variants were more frequent in the BOC and yBr groups (2 and 2.6%) compared to non-BOC and endocrine tumour patients (0.5% and 0%, p=0.049). Lp-CHEK2 variants were detected in 4% of all groups and associated with other disease-causing genetic abnormalities more often than pathogenic/likely pathogenic CHEK2 variants (16% vs. 1%, p<0.0001).  Conclusions: Despite their frequent occurrence, lp-CHEK2 variants confer a negligible risk of breast cancer and show no association with other tumour types. Disease-causing CHEK2 variants, however, have implications for the clinical management of breast cancer patients according to current guidelines.
C1 [Nagy, Petra] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Grolmusz, Vince Kornel] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
   [Butz, Henriett] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u 7–9., 1122 Budapest, Hungary.
RP Butz, H (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM butz.henriett@oncol.hu
CR Sung H, Ferlay J, Siegel RL, et al: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021
   Arzanova E, Mayrovitz HN: The epidemiology of breast cancer. In: Breast Cancer, ed. Mayrovitz HN. Exon Publications, Brisbane, 2022. http://www. ncbi.nlm.nih.gov/books/NBK583819/
   Wendt C, Margolin S: Identifying breast cancer susceptibility genes – a review of the genetic background in familial breast cancer. Acta Oncol Stockh Swed 58:135-146, 2019
   Emberi Eroforrasok Miniszteriuma: 2020. EuK. 20. szam EMMI szakmai iranyelv 2 a genetikai tanacsadasrol [Internet], 2020. https://www.hbcs. hu/uploads/jogszabaly/3278/fajlok/2020_EuK_20_szam_EMMI_szakmai_ iranyelv_2.pdf
   National Comprehensive Cancer Network: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. https://www.nccn.org/guidelines/ guidelines-detail?category=2&id=1503
   Hu C, Hart SN, Gnanaolivu R, et al: A population-based study of genes previously implicated in breast cancer. N Engl J Med 384:440–451, 2021
   Neben CL, Zimmer AD, Stedden W, et al: Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn 21:646-657, 2019
   Mustofa MK, Tanoue Y, Tateishi C, et al: Roles of Chk2/CHEK2 in guarding against environmentally induced DNA damage and replication-stress. Environ Mol Mutagen 61:730-735, 2020
   Toss A, Tenedini E, Piombino C, et al: Clinicopathologic profile of breast cancer in germline ATM and CHEK2 mutation carriers. Genes 12: 616, 2021
   Bychkovsky BL, Agaoglu NB, Horton C, et al: Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2. JAMA Oncol 8:1598-1606, 2022
   Cybulski C, Gorski B, Huzarski T, et al: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135, 2004
   Wang Y, Dai B, Ye D: CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8:15708-15715, 2015
   Cybulski C, Wokolorczyk D, Kladny J, et al: Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 15:237-241, 2007
   Truong H, Sheikh R, Kotecha R, et al: Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing. Eur Urol Oncol 4:993-1000, 2021
   Breast Cancer Association Consortium, Dorling L, Carvalho S, et al: Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med 384:428-439, 2021
   Boonen RACM, Vreeswijk MPG, van Attikum H: CHEK2 variants: linking functional impact to cancer risk. Trends Cancer 8:759-770, 2022
   Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424, 2015
   Bilyalov A, Nikolaev S, Shigapova L, et al: Application of multigene panels testing for hereditary cancer syndromes. Biology 11:1461, 2022
   Lerner-Ellis J, Khalouei S, Sopik V, et al: Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther 15:1315-1326, 2015
   National Comprehensive Cancer Network: Genetic/Familial High-Risk Assessment: Colorectal. https://www.nccn.org/guidelines/guidelines-detail? category=2&id=1436
   Tung N, Domchek SM, Stadler Z, et al: Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13:581-588, 2016
   Mundt E, Mabey B, Rainville I, et al: Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants. Cancer Genet 278-279:84-90, 2023
   Breast Cancer Association Consortium, Mavaddat N, Dorling L, et al: Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol 8:e216744, 2022
   Schmidt MK, Hogervorst F, van Hien R, et al: Age- and tumor subtype- specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol 34:2750-2760, 2016
   Agaoglu NB, Unal B, Akgun Dogan O, et al: Consistency of variant interpretations among bioinformaticians and clinical geneticists in hereditary cancer panels. Eur J Hum Genet 30:378-383, 2022
   Hanson H, Astiazaran-Symonds E, Amendola LM, et al: Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics, ACMG). Genet Med 25:100870, 2023
   Tambets K, Yunusbayev B, Hudjashov G, et al: Genes reveal traces of common recent demographic history for most of the Uralic-speaking populations. Genome Biol 19:139, 2018
   Santos P, Gonzalez-Fortes G, Trucchi E, et al: More rule than exception: parallel evidence of ancient migrations in grammars and genomes of Finno- Ugric speakers. Genes 11:1491, 2020
   Singer CF, Balmana J, Burki N, et al: Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. Eur J Cancer 106:54-60, 2019
   Macklin S, Durand N, Atwal P, et al: Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genet Med 20:346- 350, 2018
   Mighton C, Charames GS, Wang M, et al: Variant classification changes over time in BRCA1 and BRCA2. Genet Med 21:2248-2254, 2019
   Singer J, Irmisch A, Ruscheweyh HJ, et al: Bioinformatics for precision oncology. Brief Bioinform 20:778-788, 2019
   Turner SA, Rao SK, Morgan RH, et al: The impact of variant classification on the clinical management of hereditary cancer syndromes. Genet Med 21:426-430, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 35
EP 41
PG 7
ER

PT J
AU Kovacs, V
   Butz, H
   Papp, J
   Pocza, T
   Grolmusz, VK
   Nagy, P
   Patocs, A
   Bozsik, A
AF Kovacs, Viktoria
   Butz, Henriett-
   Papp, Janos
   Pocza, Timea
   Grolmusz, Vince Kornel
   Nagy, Petra
   Patocs, Attila
   Bozsik, Aniko
TI Pathogenic large duplication in TP53 as a hereditary predisposing factor in breast cancer
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE HBOC syndrome; germline TP53 mutation; duplication; aberrant transcript
ID HBOC syndrome; germline TP53 mutation; duplication; aberrant transcript
AB Aim: Germline pathogenic variants of TP53 are associated with Li-Fraumeni syndrome and represent a high risk for hereditary breast and ovarian cancer. We identified a germline, multi-exon heterozygous duplication variant in TP53, NM_000546.6:dup(ex2-5), in a young triple-negative breast cancer patient. We aimed to assign its pathogenicity.  Methods: DNA and RNA (cDNA) level specific amplification tests and sequencings were performed to identify the genomic duplication breakpoint and to detect the presence of defective transcripts.  Results: cDNA tests revealed aberrant transcript, which causes a shift in the reading frame. Allelic imbalance was also observed, indicating degradation of the defective RNA product. By locating the breakpoints at the DNA level, we determined that 6975 bp was repeated in tandem and in the same orientation. We also revealed the possible mechanism of the structural rearrangement.  Conclusions: We established that the duplication identified at DNA level manifested in the mRNA and coded for a non-functional protein. Based on these data, we were able to classify this duplication variant as pathogenic, which affects the patient’s therapeutic options and justifies genetic screening of family members.
C1 [Kovacs, Viktoria] Nemzeti Tudoskepzo AkademiaBudapest, Hungary.
   [Butz, Henriett-] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Papp, Janos] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Pocza, Timea] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Grolmusz, Vince Kornel] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Nagy, Petra] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
   [Bozsik, Aniko] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy utca 7–9., 1122 Budapest, Hungary.
RP Bozsik, A (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM bozsik.aniko@oncol.hu
CR de Andrade KC, Khincha PP, Hatton JN, et al: Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline variants: an observational cohort study. Lancet Oncol 22:1787-1798, 2021
   Kratz CP, Freycon C, Maxwell KN, et al: Analysis of the Li-Fraumeni spectrum based on an international germline variant data set: an International Agency for Research on Cancer database analysis. JAMA Oncol 7:1800-1805, 2021
   Slavin TP, Maxwell KN, Lilyquist J, et al: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3:22, 2017
   Barth MJ: NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines ®). J Natl Compr Cancer Netw 18:1105, 2020
   Petry V, Bonadio RC, Cagnacci AQC, et al: Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants, Li-Fraumeni syndrome). Fam Cancer 19:47-53, 2020
   Butz H, Bozsik A, Grolmusz V, et al: Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre. Sci Rep 13:14259, 2023
   Fostira F, Kostantopoulou I, Apostolou P, et al: One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet 57:53-61, 2020
   Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424, 2015
   Bozsik A, Papp J, Grolmusz VK, et al: Reclassification of five BRCA1/2 variants with unknown significance using complex functional study. Cancer Res Treat 54:970-984, 2022
   Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, et al: Overview of hereditary breast and ovarian cancer, HBOC, guidelines across Europe. Eur J Med Genet 64:104350, 2021
   Butz H, Nagy P, Papp J, et al: PALB2 variants extend the mutational profile of Hungarian patients with breast and ovarian cancer. Cancers, Basel, 15:4350, 2023
   Walker LC, Hoya M, Wiggins GAR, et al: ClinGen Sequence Variant Interpretation Working Group. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. Am J Hum Genet 7:1046-1067, 2023
   Kratz CP, Achatz MI, Brugieres L, et al: Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23:e38-e45, 2017
   Schmidlen TJ, Bristow SL, Hatchell KE, et al: The impact of proband indication for genetic testing on the uptake of cascade testing among relatives. Front Genet 13:867226, 2022.
   Xu F, Aref-Eshghi E, Wu J, et al: A novel TP53 tandem duplication in a child with Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 8:a006181, 2022
   Houdayer C, Caux-Moncoutier V, Krieger S, et al: Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/ in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 33:1228-1238, 2012
   Easton DF, Deffenbaugh AM, Pruss D, et al: A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873-883, 2007
   Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al: Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 28:1379-1386, 2020
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 43
EP 49
PG 7
ER

PT J
AU Sarkadi, B
   Patocs, A
AF Sarkadi, Balazs
   Patocs, Attila
TI Germline mutations define the prognosis and therapy of pheochromocytomas and paragangliomas
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE pheochromocytoma; paraganglioma; hereditary tumor; personalized medicine
ID pheochromocytoma; paraganglioma; hereditary tumor; personalized medicine
AB Pheochromocytomas and paragangliomas are rare neuroendocrine tumors, where the genetic background is of particular importance in terms of the diagnosis, follow-up, treatment and prognosis of the disease. Although the prognosis in benign cases is encouraging, in the case of malignant disease the mortality rates are dramatically worse due to the high tumor burden and possible cardiovascular complications caused by catecholamine oversecretion. In recent years, significant progress has been made both in the functional imaging of the disease and in the therapy of malignant diseases, which in many cases are also related to the underlying genetic background. The aim of our brief summary is to place the diverse genetic background and tumor biology of the disease in the context of diagnostics and therapy, thus highlighting the importance of our understanding of the disease at the individual patient level.
C1 [Sarkadi, Balazs] Fejer County Szent Gyorgy HospitalSzekesfehervar, Hungary.
   [Patocs, Attila] Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Patocs, A (reprint author), Orszagos Onkologiai Intezet, Nemzeti Tumorbiologiai Laboratorium, 1122 Budapest, Hungary.
EM patocs.attila@oncol.hu
CR Maluchenko A, Maksimov D, Antysheva Z, et al: Molecular basis of pancreatic neuroendocrine tumors. Int J Mol Sci 25:11017, 2024
   Lamarca A, Bartsch DK, Caplin M, et al: European Neuroendocrine Tumor Society, ENETS, 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol 36:e13423, 2024
   Mete O, Asa SL, Gill AJ, et al: Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol 33:90-114, 2022
   Crona J, Taieb D, Pacak K: New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev 38:489-515, 2017
   Nolting S, Bechmann N, Taieb D, et al: Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43:199-239, 2022
   Bracigliano A, Marretta AL, Guerrera LP, et al: The management of phaeochromocytomas and paragangliomas in the era of precision medicine: Where are we now? Evidence-based systemic treatment options and future cluster oriented perspectives. Pharmaceuticals, Basel, 17:354, 2024
   Lenders JWM, Kerstens MN, Amar L, et al: Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 38:1443-1456, 2020
   Lenders JW, Duh QY, Eisenhofer G, et al: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915-1942, 2014
   Hescot S, Curras-Freixes M, Deutschbein T, et al: Prognosis of Malignant Pheochromocytoma and Paraganglioma, MAPP-Prono Study): A European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab 104:2367-2374, 2019
   Gimenez-Roqueplo AP, Robledo M, Dahia PLM: Update on the genetics of paragangliomas. Endocr Relat Cancer 30:e220373, 2023
   Gaal J, Burnichon N, Korpershoek E, et al: Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95:1274-1278, 2010
   Neumann HPH, Young WF, Jr., Eng C: Pheochromocytoma and paraganglioma. N Engl J Med 381:552-565, 2019
   Neumann HP, Young WF, Krauss T, et al: 65 years of the double helix: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocr Relat Cancer 25:T201-T219, 2018
   Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308, 2012
   Xiao M, Yang H, Xu W, et al: Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26:1326-1338, 2012
   Baysal BE, Maher ER: 15 years of paraganglioma: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. Endocr Relat Cancer 22:T71-82, 2015
   Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004, 2004
   Toledo RA, Qin Y, Srikantan S, et al: In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 20:349-59, 2013
   Gaal J, van Nederveen FH, Erlic Z, et al: Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 94:4367-4371, 2009
   Kavinga Gunawardane PT, Grossman A: The clinical genetics of phaeochromocytoma and paraganglioma. Arch Endocrinol Metab 61:490-500, 2017
   Santoro M, Carlomagno F, Romano A, et al: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383, 1995
   Califano D, Rizzo C, D’Alessio A, et al: Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem 275:19297-19305, 2000
   Brandi ML, Gagel RF, Angeli A, et al: Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658- 5671, 2001
   Moline J, Eng C: Multiple endocrine neoplasia type 2: an overview. Genet Med 13:755-764, 2011
   Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, et al: Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene 35:1080-1089, 2016
   Toledo RA, Qin Y, Cheng ZM, et al: Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res 22:2301-2310, 2016
   Wallace MR, Marchuk DA, Andersen LB, et al: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186, 1990
   Bausch B, Schiavi F, Ni Y, et al: Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol 3:1204-1212, 2017
   Eisenhofer G, Huynh TT, Pacak K, et al: Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11:897-911, 2004
   Deng Y, Qin Y, Srikantan S, et al: The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808, 2018
   Castro-Vega LJ, Letouze E, Burnichon N, et al: Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun 6:6044, 2015
   Toledo R: Genetics of pheochromocytomas and paragangliomas: an overview on the recently implicated genes MERTK, MET, fibroblast growth factor receptor 1, and H3F3A. Endocr Metab Clin North Am 46:459-489, 2017
   Fishbein L, Leshchiner I, Walter V, et al: Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181- 193, 2017
   Fishbein L, Del Rivero J, Else T, et al: The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma. Pancreas 50:469-493, 2021
   Fishbein L, Khare S, Wubbenhorst B, et al: Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 6:6140, 2015
   Pang Y, Liu Y, Pacak K, et al: Pheochromocytomas and paragangliomas: From genetic diversity to targeted therapies. Cancers, Basel, 11:436, 2019
   Wilzen A, Rehammar A, Muth A, et al: Malignant pheochromocytomas/ paragangliomas harbor mutations in transport and cell adhesion genes. Int J Cancer 138:2201-2211, 2016
   Meskytė EM, Keskas S, Ciribilli Y: MYC as a multifaceted regulator of tumor microenvironment leading to metastasis. Int J Mol Sci 21:7710, 2020
   Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al: Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol 23:1995-2019, 2021
   Ben Aim L, Pigny P, Castro-Vega LJ, et al: Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet 56:513-520, 2019
   Buffet A, Smati S, Mansuy L, et al: Mosaicism in HIF2A-related polycythemia- paraganglioma syndrome. J Clin Endocrinol Metab 99:E369-373, 2014
   Lorenzo FR, Yang C, Ng Tang Fui M, et al: A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med, Berl, 91:507-512, 2013
   Lenders JWM, Duh QY, Eisenhofer G, et al: Pheochromocytoma and paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99:1915-1942, 2014
   Flores SK, Estrada-Zuniga CM, Thallapureddy K, et al: Insights into mechanisms of pheochromocytomas and paragangliomas driven by known or new genetic drivers. Cancers 13:4602, 2021
   Ryder SJ, Love AJ, Duncan EL, et al: PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clin Endocrinol, Oxf, 95:13-28, 2021
   Taieb D, Hicks RJ, Hindie E, et al: European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46:2112-2137, 2019
   Taieb D, Fargette C, Jha A, et al: Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine. Endocr Relat Cancer 30:e220375, 2023
   Taieb D, Timmers HJ, Hindie E, et al: EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1977-1995, 2012
   Jha A, de Luna K, Balili CA, et al: Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol 9:53, 2019
   Janssen I, Chen CC, Taieb D, et al: 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 57:186-191, 2016
   Amar L, Pacak K, Steichen O, et al: International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 17:435-444, 2021
   Janssen I, Chen CC, Zhuang Z, et al: Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes. J Nucl Med 58:1236-1242, 2017
   van Berkel A, Rao JU, Lenders JW, et al: Semiquantitative 123I-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. J Nucl Med 56:839-846, 2015
   Maurice JB, Troke R, Win Z, et al: A comparison of the performance of 68Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1266-1270, 2012
   Fassnacht M, Assie G, Baudin E, et al: Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1476-1490, 2020
   Niemeijer ND, Alblas G, van Hulsteijn LT, et al: Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol, Oxf, 81:642-651, 2014
   Fischer A, Kloos S, Remde H, et al: Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. Eur J Endocrinol 189:546-565, 2023
   Gonias S, Goldsby R, Matthay KK, et al: Phase II study of high-dose, 131I, metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27:4162-4168, 2009
   Pryma DA, Chin BB, Noto RB, et al: Efficacy and safety of high-specific- activity, 131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 60:623-630, 2019
   Jimenez C, Chin BB, Noto RB, et al: Biomarker response to high-specific- activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer 30:e220236, 2023
   Jimenez C, Baudrand R, Uslar T, et al: Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas. Ther Adv Med Oncol 16:17588359241301359, 2024
   Al-Ward R, Brondani VB, Sawani S, et al: High-specific-activity 131 I-MIBG for the treatment of advanced pheochromocytoma and paraganglioma. Clin Nucl Med 49:610-620, 2024
   Lin EP, Chin BB, Fishbein L, et al: Head and neck paragangliomas: an update on the molecular classification, state-of-the-art imaging, and management recommendations. Radiol Imaging Cancer 4:e210088, 2022
   Fischer A, Kloos S, Maccio U, et al: Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses. J Clin Endocrinol Metab 108:2676-2685, 2023
   Deeks ED: Belzutifan: first approval. Drugs 81:1921-1927, 2021
   Liu Y, Pang Y, Zhu B, et al: Therapeutic targeting of SDHB-mutated pheochromocytoma/ paraganglioma with pharmacologic ascorbic acid. Clin Cancer Res 26:3868-3880, 2020
   Rao JU, Engelke UFH, Sweep FCGJ, et al: Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics. J Clin Endocrinol Metab 100:E214-E222, 2015
   Lussey-Lepoutre C, Hollinshead KER, Ludwig C, et al: Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun 6:8784-8784, 2015
   Sarkadi B, Meszaros K, Krencz I, et al: Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas. Cancers, Basel, 12:599, 2020
   Kim HM, Koo JS: Expression of glutamine metabolism-related and amino acid transporter proteins in adrenal cortical neoplasms and pheochromocytomas. Dis Markers 2021:8850990, 2021
   Lorendeau D, Rinaldi G, Boon R, et al: Dual loss of succinate dehydrogenase, SDH, and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng 43:187-197, 2017
   Jimenez C, Subbiah V, Stephen B, et al: Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas. Cancers, Basel, 12:2307, 2020
   Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006
   Hadoux J, Favier J, Scoazec JY, et al: SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135:2711-2720, 2014
   Tong A, Li M, Cui Y, et al: Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma/paraganglioma - Case report and review of the literature. Front Endocrinol, Lausanne, 11:61, 2020
   Baudin E, Goichot B, Berruti A, et al: Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double- blind, phase 2 trial. Lancet 403:1061-1070, 2024
   Jimenez C, Fazeli S, Roman-Gonzalez A: Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer 27:R239-254, 2020
   Choy E, Cote GM, Michaelson MD, et al: Phase II study of cabozantinib in patients with bone metastasis. Oncologist 27:600-606, 2022
   Jimenez C, Habra MA, Campbell MT, et al: Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma, the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol 25:658- 667, 2024
   Liu Y, Liu L, Zhu F: Therapies targeting the signal pathways of pheochromocytoma and paraganglioma. Onco Targets Ther 12:7227-7241, 2019
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 50
EP 59
PG 10
ER

PT J
AU Csaban, D
   Borsy, A�
   Varga, L
   Tanko, L
   Orfi, Z
   Bors, A
   Harasztdombi, J
   Fabian, J
   Varkonyi, A
   Lakatos, V
   Kallay, K
   Krivan, G
   Gopcsa, L
   Remenyi, P
   Andrikovics, H
AF Csaban, Dora
   Borsy, Adrienn Eva
   Varga, Livia
   Tanko, Lenke
   Orfi, Zoltan
   Bors, Andras
   Harasztdombi, Jozsef
   Fabian, Janos
   Varkonyi, Andrea
   Lakatos, Viktor
   Kallay, Krisztian
   Krivan, Gergely
   Gopcsa, Laszlo
   Remenyi, Peter
   Andrikovics, Hajnalka
TI Diagnostic approaches and clinical relevance of hereditary hematological malignancies
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE hematologic neoplasms; genetic predisposition; penetrance; allogeneic transplantation; genetic counseling
ID hematologic neoplasms; genetic predisposition; penetrance; allogeneic transplantation; genetic counseling
AB Hereditary hematological malignancies (HHM) are characterized by genetic heterogeneity, variable penetrance, and expressivity. Although individual gene involvement is rare, germline pathogenic variants are estimated to be present in at least 5-10% of hematological malignancies. In cases diagnosed at young age, with positive family history, or with multiple malignancies (including myeloid neoplasms after cytotoxic treatments), the prevalence rises, reaching 13–21%. Germline-focused tumor analysis may suggest genetic predisposition even without clinical suspicion. Using larger gene panels or whole-exome sequencing can further increase the detection rate of pathogenic germline variants to over 20%. In HHM, peripheral blood/bone marrow samples may contain somatic and germline variants. Germline confirmation requires non-hematopoietic samples, such as hair follicles or fibroblast cultures. Identifying HHM has clinical implications, especially in the timing of allogeneic stem cell transplantation, donor selection, conditioning, and follow-up. Genetic screening and counseling are essential for predisposed patients and family members to provide interdisciplinary care.
C1 [Csaban, Dora] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Borsy, Adrienn Eva] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Varga, Livia] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Tanko, Lenke] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Orfi, Zoltan] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Bors, Andras] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
   [Harasztdombi, Jozsef] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Fabian, Janos] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Varkonyi, Andrea] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Lakatos, Viktor] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Kallay, Krisztian] Del-pesti Centrumkorhaz, Orszagos Hematologiai es Infektologiai Intezet, Gyermekhematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Krivan, Gergely] Del-pesti Centrumkorhaz, Orszagos Hematologiai es Infektologiai Intezet, Gyermekhematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Gopcsa, Laszlo] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Remenyi, Peter] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Hematologiai es Ossejt-transzplantacios OsztalyBudapest, Hungary.
   [Andrikovics, Hajnalka] Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, Albert Florian u. 5–7., 1097 Budapest, Hungary.
RP Andrikovics, H (reprint author), Del-pesti Centrumkorhaz – Orszagos Hematologiai es Infektologiai Intezet, Molekularis Genetikai Laboratorium, 1097 Budapest, Hungary.
EM andrikovics.hajnalka@dpckorhaz.hu
CR Cazzola M: Introduction to a review series on germ line predisposition to hematologic malignancies: time to consider germ line testing. Blood 141:1509-1512, 2023
   Ansar S, Malcolmson J, Farncombe KM, et al: Clinical implementation of genetic testing in adults for hereditary hematologic malignancy syndromes. Genet Med 24:2367-2379, 2022
   Alaggio R, Amador C, Anagnostopoulos I, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022
   Khoury JD, Solary E, Abla O, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/ Dendritic Neoplasms. Leukemia 36:1703-1719, 2022
   Dohner H, Wei AH, Appelbaum FR, et al: Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood 140:1345-1377, 2022
   Arber DA, Orazi A, Hasserjian RP, et al: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200-1228, 2022
   Feurstein S, Churpek JE, Walsh T, et al: Germline variants drive myelodysplastic syndrome in young adults. Leukemia 35:2439-2444, 2021
   Feurstein S, Trottier AM, Estrada-Merly N, et al: Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood 140:2533-2548, 2022
   Makishima H, Saiki R, Nannya Y, et al: Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141:534-549, 2023
   Godley LA, DiNardo CD, Bolton K: Germline predisposition in hematologic malignancies: testing, management, and implications. Am Soc Clin Oncol Educ Book 44:e432218, 2024
   Kotmayer L, Kallay K, Bodor C: Orokletes hematologiai malignitasok. Magy Onkol 64:43-55, 2020
   Trottier AM, Bannon S, Bashir Q, et al: When should transplant physicians think about familial blood cancers? Adv Cell Gene Ther 2:e68, 2019
   Huang KL, Mashl RJ, Wu Y, et al: Pathogenic germline variants in 10,389 adult cancers. Cell 173:355-370, 2018
   Godley LA, Shimamura A: Genetic predisposition to hematologic malignancies: management and surveillance. Blood 130:424-432, 2017
   Tawana K, Drazer MW, Churpek JE: Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet? Leukemia 32:1482-1492, 2018
   Zhang B, He L, Zhou C, et al: A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers. Sci Rep 14:2367, 2024
   Churpek JE, Marquez R, Neistadt B, et al: Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122:304-311, 2016
   Oh J, Kim YR, Kim Y, et al: Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer. J Cancer 12:4288-4294, 2021
   Schulz E, Valentin A, Ulz P, et al: Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet 49:422-428, 2012
   Shih AJ, Jun T, Skol AD, et al: Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol 200:489-493, 2023
   Singhal D, Hahn CN, Feurstein S, et al: Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia 35:3245-3256, 2021
   Voso MT, Fabiani E, Zang Z, et al: Fanconi anemia gene variants in therapy- related myeloid neoplasms. Blood Cancer J 5:e323-e323, 2015
   Yun J, Song H, Kim SM, et al: Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea. Hum Genomics 17:13, 2023
   Franco S, Godley LA: Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants. Gynecol Oncol 187:235-240, 2024
   Molteni E, Bono E, Galli A, et al: Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. Blood 142:643-657, 2023
   Guijarro F, Lopez-Guerra M, Morata J, et al: Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome. Blood Adv 7:5799-5811, 2023
   Hwang SM: Genomic testing for germline predisposition to hematologic malignancies. Blood Res 59:12, 2024
   Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256, 2009
   Rana HQ, Gelman R, LaDuca H, et al: Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. J Natl Cancer Inst 110:863-870, 2018
   Butz H, Bozsik A, Grolmusz V, et al: Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre. Sci Rep 13:14259, 2023
   Palomo L, Ibanez M, Abaigar M, et al: Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 188:605-622, 2020
   Mandelker D, Zhang L, Kemel Y, et al: Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 318:825-835, 2017
   Kuzbari Z, Bandlamudi C, Loveday C, et al: Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol 34:215-227, 2023
   Arai H, Matsui H, Chi S, et al: Germline variants and characteristic features of hereditary hematological malignancy syndrome. Int J Mol Sci 25:652, 2024
   Baliakas P, Tesi B, Wartiovaara-Kautto U, et al: Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up. Hemasphere 3:e321, 2019
   Cobaleda C, Godley LA, Nichols KE, et al: Insights into the molecular mechanisms of genetic predisposition to hematopoietic malignancies: the importance of gene-environment interactions. Cancer Discov 14:396-405, 2024
   Speight B, Hanson H, Turnbull C, et al: Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group, UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. Br J Haematol 201:25-34, 2023
   Mandelker D, Donoghue M, Talukdar S, et al: Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol 30:1221-1231, 2019
   Desai AV, Perpich M, Godley LA: Clinical assessment and diagnosis of germline predisposition to hematopoietic malignancies: the University of Chicago experience. Front Pediatr 5:252, 2017
   Roloff GW, Godley LA, Drazer MW: Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genet Med 23:211-214, 2021
   Roloff GW, Shaw R, O’Connor TE, et al: Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. J Genet Couns 32:744-749, 2023
   Reinig EF, Rubinstein JD, Patil AT, et al: Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis. Leukemia 37:1589-1599, 2023
   Schlegelberger B, Mecucci C, Wlodarski M: Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies. Fam Cancer 20:295-303, 2021
   Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424, 2015
   Abou Dalle I, Kantarjian H, Bannon SA, et al: Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol 95:227-229, 2020
   Cunningham L, Merguerian M, Calvo KR, et al: Natural history study of patients with familial platelet disorder with associated myeloid malignancy. Blood 142:2146-2158, 2023
   Su L, Shi YY, Liu ZY, et al: Acute myeloid leukemia with CEBPA mutations: current progress and future directions. Front Oncol 12:806137, 2022
   Trottier AM: Hereditary hematologic malignancies: a Canadian perspective. Canadian Hematology Today 1:13–17, 2022
   Trottier AM, Feurstein S, Godley LA: Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders. Best Pract Res Clin Haematol 37:101537, 2024
   Porter CC, Druley TE, Erez A, et al: Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res 23:e14-e22, 2017
   Kiraly PA, Kallay K, Marosvari D, et al: Familiaris myelodysplasias szindroma es akut myeloid leukaemia klinikai es genetikai hattere. Orv Hetil 157:283- 289, 2016
   Szmyd B, Mlynarski W, Pastorczak A: Genetic predisposition to lymphomas: Overview of rare syndromes and inherited familial variants. Mutat Res Rev Mutat Res 788:108386, 2021
   Keel SB, Scott A, Sanchez-Bonilla M, et al: Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica 101:1343-1350, 2016
   Gupta S, Weis JM, Axell L, et al: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. NCCN Clinical Practice Guidelines in Oncology, 2024
   Miller DT, Lee K, Abul-Husn NS, et al: ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics, ACMG). Genet Med 25:100866, 2023
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 61
EP 72
PG 12
ER

PT J
AU Levay, B
   Santha, B
   Kiss, A
   Revesz, M
   Kovacs, B
   Both, �
   Zelenai, F
   Oberna, F
AF Levay, Bernadett
   Santha, Beata
   Kiss, Alexandra
   Revesz, Monika
   Kovacs, Balazs
   Both, Akos
   Zelenai, Ferenc
   Oberna, Ferenc
TI Thyroid surgery in local anesthesia: renewal of an old method
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE regional anesthesia; thyroid surgery
ID regional anesthesia; thyroid surgery
AB Aim: Before the introduction of general anesthesia, thyroid operations were performed under local anesthesia. With the development of anesthesia, surgeons preferred to operate in narcosis. Nowadays regional anesthesia has become popular leading to faster recovery.  Methods: At the Multidisciplinary Head and Neck Cancer Center of our institute, between May 2019 and October 2024, 11 patients were treated in regional anesthesia with the blockage of the superficial branches of the cervical plexus, followed by an ultrasound-guided thyroid capsule sheath space block. Patients were previously given 2 mg of i.v. midazolam, in case of need 50 μg of i.v. fentanyl under hemodynamic monitoring.  Results: One patient had transient Horner’s syndrome, one patient suffered from transient left shoulder numbness. The average operating time was 42.7 minutes (25–80 minutes). The incidence of postoperative pain, nausea and vomiting were reduced.  Conclusions: Regional nerve block anesthesia as an alternative of narcosis can be used in thyroid surgery, offering several advantages.
C1 [Levay, Bernadett] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Santha, Beata] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Kiss, Alexandra] Kaposi Mor Oktato Korhaz, Ful- Orr- Gegeszeti OsztalyKaposvar, Hungary.
   [Revesz, Monika] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Kovacs, Balazs] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
   [Both, Akos] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Zelenai, Ferenc] National Institute of Oncology, Department of Anesthesiology and Intensive TherapyBudapest, Hungary.
   [Oberna, Ferenc] National Institute of Oncology, Department of Head and Neck Surgery, Rath Gyorgy u. 7–9., 1122 Budapest, Hungary.
RP Levay, B (reprint author), National Institute of Oncology, Department of Head and Neck Surgery, 1122 Budapest, Hungary.
EM drlevaybernadett@gmail.com
CR Parry Z, Macnab R: Thyroid disease and thyroid surgery. Anaesth Intensive Care Med 18:488-495, 2017
   Rogers-Stevane J, Kauffman GL: A historical perspective on surgery of the thyroid and parathyroid glands. Otolaryngol Clin North Am 41:1059-1067, 2008
   Taylor S: Sir Thomas Peel Dunhill 1876-1957. World J Surg 21:660-662, 1997
   Hannan SA: The magnificent seven: a history of modern thyroid surgery. Int J Surg 4:187-191, 2006
   Lo Gerfo P: Local/regional anesthesia for thyroidectomy: Evaluation as an outpatient procedure. Surgery 124:975-979, 1998
   Hisham AN, Aina EN: A reappraisal of thyroid surgery under local anaesthesia: Back to the future? ANZ J Surg 72:287-289, 2002
   Arora N, Dhar P, Fahey TJ: Seminars: Local and regional anesthesia for thyroid surgery. J Surg Oncol 94:708-713, 2006
   Snyder SK: Local anesthesia with monitored anesthesia care vs general anesthesia in thyroidectomy. Arch Surg 141:167, 2006
   Spanknebel K, Chabot JA, DiGiorgi M, et al: Thyroidectomy using local anesthesia: A report of 1,025 cases over 16 years. J Am Coll Surg 201:375-385, 2005
   Williams M, Lo Gerfo P: Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: A review and description of the technique. Thyroid 12:523-525, 2002
   Sessler CN, Gosnell MS, Grap MJ, et al: The Richmond Agitation–Sedation Scale. Am J Respir Crit Care Med 166:1338-1344, 2002
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 73
EP 76
PG 4
ER

PT J
AU Belak, B
   Palfi, E
   Mokanszki, B
   Molnar, A
AF Belak, Barbara
   Palfi, Erzsebet
   Mokanszki, Bela
   Molnar, Andrea
TI Results of malnutrition risk self-screening in Hungarian oncology patients
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Journal Article
DE malnutrition; self-screening questionnaire; nutritional status; MUST; PG-SGA
ID malnutrition; self-screening questionnaire; nutritional status; MUST; PG-SGA
AB Aim: Our aim was to introduce self-screening for the risk of malnutrition in cancer patients using the PG-SGA questionnaire, and to compare the results of the new method with the abnormal values of the previously used BMI and MUST method.  Methods: We performed self-screening using the PGSGA questionnaire, MUST risk screening, and nutritional status classification based on BMI in parallel with 101 oncology patients.  Results: A high risk of malnutrition was diagnosed in 73 subjects (72%) using the PG-SGA method, 58 subjects (57%) using the MUST method, and 8 subjects (8%) using the BMI method.  Conclusions: The PG-SGA method can be easily implemented in the Hungarian practice, which effectively screens the risk of malnutrition in cancer patients. The sensitivity of the questionnaire is increased by the disease-specific questions, which ask about symptoms affecting nutrition and stress factors that determine metabolic demand. Early detection of malnutrition and the initiation of nutritional therapy in cancer are key factors in terms of improving quality of life and increasing survival.
C1 [Belak, Barbara] Semmelweis University, Doctoral School, Health Sciences DivisionBudapest, Hungary.
   [Palfi, Erzsebet] Semmelweis Egyetem, Egeszsegtudomanyi Kar, Dietetikai es Taplalkozastudomanyi TanszekBudapest, Hungary.
   [Mokanszki, Bela] Semmelweis University, Karoly Racz Doctoral School of Clinical MedicineBudapest, Hungary.
   [Molnar, Andrea] Semmelweis University, Doctoral School, Health Sciences DivisionBudapest, Hungary.
RP Belak, B (reprint author), Semmelweis University, Doctoral School, Health Sciences Division, Budapest, Hungary.
EM dr.belak.barbara@gmail.com
CR Kozponti Statisztikai Hivatal, KSH): Halalozasok a gyakoribb halalokok es nem szerint [Internet]. https://www.ksh.hu/stadat_files/nep/hu/nep0010. html, eleres: 2024.10.08.)
   Arends J, Strasser F, Gonella S, et al: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 6:100092, 2021
   Muscaritoli M, Arends J, Bachmann P, et al: ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr 40:2898-2913, 2021
   A Belugyminiszterium egeszsegugyi szakmai iranyelve – ujabb szempontok a korhazi, az egeszsegugyi apolasi otthonokban elo es az otthoni ellatasra szorulo felnott betegek taplaltsagi allapotanak felmereserol es a taplaltsagi zavarok taplalasterapiaval torteno kezeleserol. Egeszsegugyi Kozlony 73:1346-1381, 2023
   Abbott J, Teleni L, McKavanagh D, et al: Patient-Generated Subjective Global Assessment Short Form, PG-SGA SF, is a valid screening tool in chemotherapy outpatients. Support Care Cancer 24:3883-3887, 2016
   Nitichai N, Angkatavanich J, Somlaw N, et al: Validation of the Scored Patient-Generated Subjective Global Assessment, PG-SGA, in Thai setting and association with nutritional parameters in cancer patients. Asian Pac J Cancer Prev 20:1249-1255, 2019
   Burden ST, Bibby N, Donald K, et al: Nutritional screening in a cancer prehabilitation programme: A cohort study. J Hum Nutr Diet 36:384-394, 2023
   Furka A: Onkologiai prehabilitacio. Orv Hetil 163:1975-1981, 2022
   Belak B, Mokanszki B, Acs F, et al: Dysphagia elofordulasa es taplalasterapiaja a fej-nyak daganatos betegeknel. Magy Belorv Arch 77: 83-86, 2024
   Ruan X, Nakyeyune R, Shao Y, et al: Nutritional screening tools for adult cancer patients: A hierarchical Bayesian latent-class meta-analysis. Clin Nutr 40:1733-1743, 2021
   Lovey J, Molnar A, Banky B: Long-term nutrition in patients candidate to neoadjuvant and adjuvant treatments. Eur J Surg Oncol 50:106850, 2024
   Molnar A, Palfi E, Belak B, et al: Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer. Pathol Oncol Res 30:1611664, 2024
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 77
EP 79
PG 3
ER

PT J
AU Bender, T
   Szekanecz, �
   Gomez, I
   Pentek, I
   Maraz, A
   Dank, M
   Szekanecz, Z
AF Bender, Tamas
   Szekanecz, Eva
   Gomez, Izabella
   Pentek, Iren
   Maraz, Aniko
   Dank, Magdolna
   Szekanecz, Zoltan
TI Physical therapy of cancer patients – narrative review and expert opinion
SO MAGYAR ONKOLOGIA
LA Hungarian
DT Review
DE malignancy; physical therapy; exercise; massage; expert opinion
ID malignancy; physical therapy; exercise; massage; expert opinion
AB Aim: The issue of physical therapy for people with malignancies has been very controversial. In the past, physical therapy was completely contraindicated in cancer patients. Many doctors are still conservative regarding this issue. Therefore, based on a narrative summary of literature data, we compiled a consensus-based expert opinion.  Methods: The narrative summary was prepared based on publications of the last 5 years. Then the expert group created an expert opinion based on a common consensus.  Results: We created a concise expert opinion consisting of 10 points and a practical algorithm. The use of physical therapy is established jointly by the patient, doctors and health professionals. Exercise is essentially recommended for everyone. We formulated specific recommendations regarding massage, ultrasound, laser, shockwave, TENS and balneotherapy. These methods can be used with appropriate precautions in cancer patients. On the other hand, most electrotherapy modalities are not recommended, while the evaluation of massage in patients with osteosarcoma is not clear, so we prefer not to recommend it.  Conclusions: Exercise, certain modalities of physical therapy and balneotherapy can be useful additions to the rehabilitation of cancer patients.
C1 [Bender, Tamas] Betegapolo Irgalmasrend, Budai Irgalmasrendi Korhaz, Reumatologiai Osztaly, Frankel Leo u. 31., 1023 Budapest, Hungary.
   [Szekanecz, Eva] University of Debrecen, Department of OncologyDebrecen, Hungary.
   [Gomez, Izabella] Orszagos Mozgasszervi IntezetBudapest, Hungary.
   [Pentek, Iren] Semmelweis University, Department of Internal Medicine and OncologyBudapest, Hungary.
   [Maraz, Aniko] University of Szeged, Department of OncotherapySzeged, Hungary.
   [Dank, Magdolna] Semmelweis University, Department of Internal Medicine and OncologyBudapest, Hungary.
   [Szekanecz, Zoltan] University of Debrecen, Medical and Health Science Center, Department of RheumatologyDebrecen, Hungary.
RP Bender, T (reprint author), Betegapolo Irgalmasrend, Budai Irgalmasrendi Korhaz, Reumatologiai Osztaly, 1023 Budapest, Hungary.
EM bender.tamas@t-online.hu
CR Bender T, Szekanecz Z, Szekanecz E, et al: Onko-fizioterapia kerekasztal. Magyar Balneologiai Egyesulet 2023 evi Nagygyulese, Debrecen, 2023
   Bender T: Tumoros anamnezisu betegek fizioterapiaja. Magy Reumatol 50:114-115, 2009
   Gomez I, Szekanecz E, Szekanecz Z, Bender T: Daganatos betegek fizioterapiaja. Orv Hetil 157:1224-1231, 2016
   Pentek I, Dank M, Hajdu A, et al: Onkologiai rehabilitacio. Orvostovabbkepzo Szemle 28:55-59, 2021
   Dank M, Pentek I, Juhasz A, et al: Daganatos betegek rehabilitacioja. Klin Onkol 8:64-69, 2021
   Courneya KS: The emerging role of exercise as a cancer treatment. J Sport Health Sci 13:443-444, 2024
   Fiuza-Luces C, Valenzuela PL, Galvez BG, et al: The effect of physical exercise on anticancer immunity. Nat Rev Immunol 24:282-293, 2024
   Brummer C, Pukrop T, Wiskemann J, et al: Can exercise enhance the efficacy of checkpoint inhibition by modulating anti-tumor immunity? Cancers, Basel, 15:4668, 2023
   Fernandez-Sanchez J, Trujillo-Colmena D, Rodriguez-Castano A, et al: Effects of exercise on life satisfaction of people diagnosed with cancer: a systematic review and meta-analysis. Support Care Cancer 32:297, 2024
   Buffart LM, Kalter J, Sweegers MG, et al: Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev 52:91-104, 2017
   Isanejad A, Nazari S, Gharib B, et al: Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients. J Sport Health Sci 12:674-689, 2023
   Lin HP, Kuo YH, Tai WY, et al: Exercise effects on fatigue in breast cancer survivors after treatments: A systematic review and meta-analysis. Int J Nurs Pract 28:e12989, 2022
   Maric D, Ficarra S, Di Bartolo L, et al: Effects of resistance training on sleep quality and disorders among individuals diagnosed with cancer: A systematic review and meta-analysis of randomized controlled trials. Cancer Med 13:e7179, 2024
   Engle J, Marshall G, Lefkowitz T, et al: Fractured knowledge: Making sense of exercise in patients with bone metastases. Am J Phys Med Rehabil 103:S58-S61, 2024
   Crevenna R, Hasenoehrl T, Wiltschke C, et al: Prescribing exercise to cancer patients suffering from increased bone fracture risk due to metastatic bone disease or multiple myeloma in Austria – An inter- and multidisciplinary evaluation measure. Cancers, Basel, 15:1245, 2023
   Avancini A, Borsati A, Baldo E, et al: A feasibility study investigating an exercise program in metastatic cancer based on the patient-preferred delivery mode. Oncologist 29:e828-e836, 2024
   Weller S, Hart NH, Bolam KA, et al: Exercise for individuals with bone metastases: A systematic review. Crit Rev Oncol Hematol 166:103433, 2021
   Herranz-Gomez A, Suso-Marti L, Varangot-Reille C, et al: The benefit of exercise in patients with cancer who are receiving chemotherapy: A systematic review and network meta-analysis. Phys Ther 104:pzad132, 2024
   Zaorsky NG, Allenby T, Lin J, et al: Exercise therapy and radiation therapy for cancer: A systematic review. Int J Radiat Oncol Biol Phys 110:973-983, 2021
   Mur-Gimeno E, Coll M, Yuguero-Ortiz A, et al: Comparison of water- vs. land-based exercise for improving functional capacity and quality of life in patients living with and beyond breast cancer, the AQUA-FiT study): a randomized controlled trial. Breast Cancer 31:815-824, 2024
   Papadopoulou M, Stamou M, Bakalidou D, et al: Non-pharmacological interventions on pain and quality of life in chemotherapy induced polyneuropathy: Systematic review and meta-analysis. In Vivo 37:47-56, 2023
   Zhang Y, Wang S, Ma X, et al: Massage therapy can effectively relieve cancer pain: A meta-analysis. Medicine, Baltimore, 102:e33939, 2023
   Epstein AS, Liou KT, Romero SAD, et al: Acupuncture vs massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial. JAMA Netw Open 6:e2342482, 2023
   Lopez G, Eng C, Overman M, et al: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep 12:19023, 2022
   Shan S, Lin L, Fang Q, et al: Massage therapy significantly improves cancer- related fatigue in cancer patients: a meta-analysis of randomized controlled trials. Support Care Cancer 31:464, 2023
   Karda I, Wan Ismail WF, Kamal AF: Massage manipulation and progression of osteosarcoma, does it really correlate: a combination of prospective and retrospective cohort study. Sci Rep 13:18541, 2023
   Galvao DA, Taaffe DR, Spry N, et al: Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc 50:393-399, 2018
   Al Onazi MM, Yurick JL, Harris C, et al: Therapeutic ultrasound for chemotherapy- related pain and sensory disturbance in the hands and feet in patients with colorectal cancer: A pilot randomized controlled trial. J Pain Symptom Manage 61:1127-1138, 2021
   Kilmartin L, Denham T, Fu MR, et al: Complementary low-level laser therapy for breast cancer-related lymphedema: a pilot, double-blind, randomized, placebo-controlled study. Lasers Med Sci 35:95-105, 2020
   Kozanoglu E, Gokcen N, Basaran S, et al: Long-term effectiveness of combined intermittent pneumatic compression plus low-level laser therapy in patients with postmastectomy lymphedema: a randomized controlled trial. Lymphat Res Biol 20:175-184, 2022
   Lee JH, Kim SB, Lee KW, Ha WW: Long-term effects of extracorporeal shock wave therapy on breast cancer-related lymphedema. J Clin Med 11:6747, 2022
   Mathias OD, Pattanshetty RB: Effect of TENS and stabilization exercises on pelvic pain in pelvic cancer survivors following multimodal treatment: A clinical trial. J Cancer Res Ther 18:1124-1128, 2022
   Nakano J, Ishii K, Fukushima T, et al: Effects of transcutaneous electrical nerve stimulation on physical symptoms in advanced cancer patients receiving palliative care. Int J Rehabil Res 43:62-68, 2020
   Tai JB, Hong L, Ma ME, et al: Evaluation of therapeutic effect of transcutaneous electrical acupoint stimulation on bone metastasis pain and its influence on immune function of patients. Ann Palliat Med 9:2538-2544, 2020
   Sudek EW, Mach S, Huh B, et al: Use of temporary percutaneous peripheral nerve stimulation in an oncologic population: a retrospective review. Neuromodulation 27:118-125, 2024
   Reger M, Kutschan S, Freuding M, et al: Water therapies, hydrotherapy, balneotherapy or aqua therapy, for patients with cancer: a systematic review. J Cancer Res Clin Oncol 148:1277-1297, 2022
   Munoz-Gomez E, Arnal-Gomez A, Lopez Cascon A, et al: Systematic review of aquatic therapeutic exercise efficacy in breast cancer survivors. Support Care Cancer 31:44, 2022
   Fujimoto S, Iwawaki Y, Takishita Y, et al: Effects and safety of mechanical bathing as a complementary therapy for terminal stage cancer patients from the physiological and psychological perspective: a pilot study. Jpn J Clin Oncol 47:1066-1072, 2017
   Vasson MP, Kwiatkowski F, Rossary A, et al: Effectiveness of a global multidisciplinary supportive and educational intervention in thermal resort on anthropometric and biological parameters, and the disease-free survival after breast cancer treatment completion, PACThe). J Oncol 2020:4181850, 2020
NR 1
PU Hungarian Cancer Society
PI Budapest
PA 7-9 Rath Gyorgy, Budapest H-1122, Hungary
SN 0025-0244
J9 MagyOnkol
JI Magy Onkol
PD MAR
PY 2025
VL 69
IS 1
BP 80
EP 88
PG 9
ER

EF